<SEC-DOCUMENT>0001356090-21-000003.txt : 20210301
<SEC-HEADER>0001356090-21-000003.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301161553
ACCESSION NUMBER:		0001356090-21-000003
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		156
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECIGEN, INC.
		CENTRAL INDEX KEY:			0001356090
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36042
		FILM NUMBER:		21697937

	BUSINESS ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876
		BUSINESS PHONE:		301-556-9900

	MAIL ADDRESS:	
		STREET 1:		20374 SENECA MEADOWS PARKWAY
		CITY:			GERMANTOWN
		STATE:			MD
		ZIP:			20876

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTREXON CORP
		DATE OF NAME CHANGE:	20060313
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pgen-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309,d:e210b0c7fc84429f915eaf73d0946948--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:pgen="http://www.dna.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pgen-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl8zLTEtMS0xLTA_cd4aee4c-e29a-4e38-8085-a57ce1cce2ef">false</ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl80LTEtMS0xLTA_ad637d8c-2b1e-4eb4-b9b7-c47954e3967d">2020</ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl81LTEtMS0xLTA_bcea5a34-20fd-4d8d-a43e-4bfb2620e002">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl82LTEtMS0xLTA_dea48d14-3b21-44a9-b5c7-277138da5892">0001356090</ix:nonNumeric><ix:nonNumeric contextRef="iba5ee3e148774f35bb26b15071f0a9c9_D20170101-20171231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMC0xLTEtMTAyOTE_98b5dcf3-d951-4783-922d-2c0ea94a8c36">us-gaap:AccountingStandardsUpdate201409Member</ix:nonNumeric><ix:nonNumeric contextRef="ic649546dedd34f7e81b3041baaf93e20_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i321fedbbadb34d4087e52ceb65be7798_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i5155424e1c244be3a4c16ac6cae35737_D20180701-20180731" name="pgen:ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzY1OTcwNjk3NzUxMzU_d9e7d0e6-80ed-4f13-b999-56a720a01b9a">P5D</ix:nonNumeric><ix:nonNumeric contextRef="id45a0b9d2a934bb4b5153625e67c9998_I20201231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM0NA_ddde4444-f884-4ed7-beb8-9b358f73343e">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pgen-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i61afe01c77bd4075ac870cbeb744df69_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4338078300e342f196795af559ba89f6_I20210215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d32b7d02bc4077abe174a0c01bf2da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4535941e16234d449e24cbb104b312eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90df5438bc447dc89f799623be8dd72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d688646c4e54b0b9ff3d9d869a84f8d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49fe028d6f84a65a5e7dc2e03d52395_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa378b75eb8240abb90e3c3a90199627_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63f92b55b3047a6985c52240063ce82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2563c9235194a59932361f4fd160992_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c945d017804d08b6055d50caecddfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1416fdd04854b98b98cc981399bba77_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f67f091705d4ed88119185ea9668127_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17726fa9a8714d378f70b578726ea61b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf2a0142d19421f844e564b6e81c75e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53867cd3f9c14cdebf63cdf61a3ccdc6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867e347749054e8a8f0790f939874f83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia53c6ab11e9c492084aefb26999ce44a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c80061711f435bbcfbfe956b9bc43c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d62e92e6fa4e01ac83a1dcdafa12a1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c47c15a0a441909e132dd1581ceaec_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee3c718a7f048cfb2836108df24bc3d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e53100af51f408a935d99fdc04896b2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e07b0b288a443e6a8678c87bf210341_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba5ee3e148774f35bb26b15071f0a9c9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b48ec0589f54ea18ed709e5622f1f36_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58e0c90d812453b961a416919b494e7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edb27434f8c42f4b2dafbfd636c960d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ac13fe6c894e4d8bb963cd6fcd7ba1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7328bdd74884f999183a972e9e74902_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526adef7e72140d5b11b92f77958580e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dafd01f416a4fecabcd3625798ec85e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d775ca87aa45c7b569ef0164d07e18_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62afd0579ab049588695814b856db8fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00106458d554c29aab7306c704ec827_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e57cab296f149399d486ae6ead87efa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190b69f516da44baba7e77735b9083e9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f4056c01d04eeb92c3e2110de99905_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a7a2917a5840d1828b5b69ba7afea7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0df81f9c8d4e7097109272f7381494_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1053dfe438874cc9b2cd88769aca7327_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c7b560b46b448dab6e990b87500645_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75596e499ae443c3adaaf6abf5854f90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce876c2b26448c6b08a1b65b0889bf7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f5c113267a4a07b0fd84856590b114_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fae6176c89149ef8b0e8046c310748e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762149a5fcb747d7b935b70a375b135b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5035cb92632a453d81e2f99ab37a6a4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife91272387c04b268c5f208e51e80445_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0677b8b8ac4e0194068bb8d9fa9a09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f6c337649843ef9b6c799eb5e89d84_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:ProductsandServicesRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8cb877d0184774ae2285744aa4fce4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4041a8bb484da3b179334191b0137d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8952cdcb9a6e414eb3558452807047c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ad6258403540099941f2a068f4043d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba88e8a7dd14e0e90467b7df8a754de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie518adbaa2914c83a75398892dc33f68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027d6d87c78e4317a791117a2393e261_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d3ba94d22bb43898d8e8b5658bd229f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91fece37ad5247789405374ea393337a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a4580dd157421b961abbc9269d361d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36032ed843b643ee8327a678783a2ac2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486b675333cb4c5b91c24f42597dc946_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BreedingAndProductionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0750ead12ac4214b42916e3ed24bdfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BreedingAndProductionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5e98f13a3a461ca2c7fbf143a0e4cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pgen:ComputerHardwareandSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab8005306a844bda35c05aa23ceb1a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pgen:ComputerHardwareandSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic649546dedd34f7e81b3041baaf93e20_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id068240ac9514712ac2777d3f353304d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321fedbbadb34d4087e52ceb65be7798_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11e11947645549f79ae1c1b067e15412_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea8840b9e7545d180e072548e790580_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a99bff0ee894d4ebc0529513dfabc6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b61e5b1fd0b43908fdd386d73838549_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71c2fc0f42a444597ac62521827f72b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1657211515ac4efba0ceb6486e26a0fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a892879d07044f58213c5a70dccecdb_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5536916a8c741d08eecaed7c735bd94_I20200102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pgen:OkanaganOxitecFineChemicalsAndAgBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b81adc30c64968b22a72162d34e9c2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1656e2b95eb4e86b30c7f13bec36e35_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b06f8ff3659402fb91abb688b2698ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3da9f131522486b89e80d1abf10d1c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85eefc0df3064556bd575eced34b22d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ea4810310f41c692ba79c0e33d366e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf18b6a46ee942b59306c66d27119d0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie008c068818d4427824c7865a4533062_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6652a9a128043e1991ddf1ffe2cf37e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ddb7daeedd421691d65e569834db38_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pgen:OxitecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyAndEnviroFlightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib745c0a5e3374688a77e7b600fc20292_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000d1fd7f4c64d64832e5ec0e8209d77_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab86611cff54ee49aacd99b0b4f6651_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0d69f64390425490a158f5ad474449_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c882e708e9042fab6cf9bdb465e7487_I20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ad8e1a4d324efba50a474ce9400787_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9baf13b1f64feeacf1476a168dca43_I20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417eb3d3304845829b5d8b4c5c5ba767_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="board_seat"><xbrli:measure>pgen:board_seat</xbrli:measure></xbrli:unit><xbrli:context id="i9405291ea07342cfb48d39ff6203c28c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f4ceddf2d74e208b2f43425f7a604c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcde56c84e2945f99d5ff518fcea780f_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02736ce52d7d455880b3764529cb4205_D20151201-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed29543f11f4730be40ffd5240b7e9d_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af9e206e25f49e585e8fac9b7a42c1f_D20151201-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AllInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-12-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd86fd0107044a1afd4581beb90db93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bc12535b5845a98af2708db090b1cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b676559c5894899a277cab47b7d3686_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b58e935da8149088da93a6187e4101f_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08141bec58644c55a3f1a64ad4aba2ca_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37eae9042f0b4b7991fad96ce5cd70f8_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38614b5cdd4748fe900bdb143da08bc2_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18b9f13ca97407987783276b9377121_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac2f1a572c141fc8915df3c7e0d761b_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04474b4f60340a5bfef5669908aca1b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea41f0f9f8340a5ac240c128def61b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbb27ff74fa4587a1663d2f6c036f55_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3fe0767e9cf4dcd85529165525f8758_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2655f8d02da8422ba8e92858830a2d09_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9caeeb9311142fcad4dc58cba84fe45_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a58ef1f100e41ec83f7fadf1f120f61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3225f360239c4da99ac5a0f30e582367_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b7ccf82abb46088675f71ca095ea7d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c5e81e3c27464cb9bb433ba78dd8ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0a5d57f00774002911cf03b4ecb5d06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6a3055772b4276a974fbd3f46d80af_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657bccd941e9476e84df5f1bb47c01ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd6ae11540d4a89bdea2402ffd96b43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271b77f3585b428ab9b387bac0632795_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5465b8e9f47c478a9888a2bf4f068315_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a7a75f53fb43bd8a86301d20bd199f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615893ff388945289ba1d816cb0d5415_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826d35e5de9342c1ac0b82187aa61817_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0b6fb6681044eeb9ccb81e27858225_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3047a704254986b92408ff7382d63c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia38b8c82221e4b158e81089d5dec6cc4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc53c28fbc7455ea6911f3515a2093c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2da118b80dc492fa5a08a890cbbb15a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb26c32900c24b22b16c104fc410013d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a7cf1aab2104d78877dc52205013114_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89a9eb5dec3401bb6b1302d72d9b091_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d02ad8dbd04496a07bb96530bd6fe0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbcf7e50ae94bdb84158a09d5e84357_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802c849fe1f7499fa51a352c7c1b630c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75a4228d5b9446f82180329f657e205_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf2e5287fca469988ba7db1017cc983_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d624d8cf2ba4c258b6200df93fe4dff_D20110101-20110131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c23dc33d54d41fbb6d5de96a2aa6645_D20120101-20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df2f4bdfd5a4853b136cd50ea2e2827_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="quarterly_installment"><xbrli:measure>pgen:quarterly_installment</xbrli:measure></xbrli:unit><xbrli:context id="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>pgen:product</xbrli:measure></xbrli:unit><xbrli:context id="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edf0818b0a147da90be9143a66128d0_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b584f29328e4ebf97207baf9e676a54_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:ReacquiredInProcessResearchDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6a0b31f0c84cbea171358d7cdb8c59_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390dbfc7bee54d449d2489dfabeb4caa_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:TransitionServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife505a4aa67447108ab17810720818e9_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac36b06d9ed4949b460f25d930f6824_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>pgen:target</xbrli:measure></xbrli:unit><xbrli:context id="ib33d19e6739641da9b757a245fd3ec93_I20150301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia684f990dec54beeb358abe6adf669ab_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507644cf395a4e4eb490f23ed7a3fb54_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9c931963d5454d95e8956328330cee_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659785a3f54a436ebb55a8cdf1f7716e_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7fde582b25949f282255f9473749cb4_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:GentenTherapeuticsCRSBioAndRelieveGeneticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife64afba6e6c4c7f9966578282bdffdf_D20150101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59907113dd1d4344981247aabca5ca34_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c97ac54869431f9460b1de625fdd9c_D20121001-20121031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-10-01</xbrli:startDate><xbrli:endDate>2012-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1461c02f7c1144288c060625dfec3d80_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07cadd8e29a94d468d706d75d4fa4499_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8dfaf8751c2466e8b7d83681e50ce63_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119157bf1fca4e4597d6d2074e4b318c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i768914f9023446359debd6de8db387bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0886f93ed7be4cb289c37677075c1648_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:PrepaidProductAndServiceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24eba9045a464d27b051cf73783cbc93_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:PrepaidProductAndServiceRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f077edbb924395b6f3b5746a7091b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:DeferredRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4b2e1046db40339eccf1d387df8274_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:DeferredRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762e74716595460bbc13425c76eaa2db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a8f257af9be4b51bb429c76d609121d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4a4131130d462a9487459be4d56bd7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb44801a44b4a62ad0fdbd70e99dccd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4820c653de64b4b8753948eb803072b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb4353ff9fff4974bf8fc31f026182f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8484095ee2884725be04bc8135beae81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dece6850a884e9aaa7eb9648a40bb74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34fe2362ff8a42598a97fb6bdba06548_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066d432119f04600ad1a8035bcb6cf5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6512fb771f0b42ee964e35ec040d3d77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87b208d51a248b49c170094f36869ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd853c6b5c544c1a4eb81cd5293cada_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d34d40eae14e879388b762c83dc166_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65a1530d1d0476ca8be03ad2268129a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f70a5b8fd749b8b7137c61cfab72a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5561d3f0a6bc49eabcffabca3089383f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98da80d8ac14d7791e297eacb592f73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6774b04fc34844d7bb0f5cabaee47b02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559d7af0e8444c759749c165c72c4dd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d7c23fc413485dac1d297dad0adfd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d533c22a81455786266a631fcc3c93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efc7bf936b3476083f68d4965ac2088_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625594ecb5a643c1be9c45946c3fe6bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05375e0f8b94091a3e217e403a5e204_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5f8179595b4e5ba09bd4c1c6d600b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd472d7ad35f4a15b21d2195d5808bb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcfedad06ddd479bba91d37f6def04da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1c801fb36143c49fd0b608bcfa5b48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia61312b716ae4e47b5211d08c39bc9a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897525fafdb1444eb6402bf2a7754355_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida01d18612bb4a56b451ba944d2f4a9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6fff13a081c481cb9e48baa81cacfaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7aae1a7de0b42298d4467fd3ec004af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia72f10ede16740f6939170db24c97f9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id33a83c66e5e4d04930c270f49fcf9fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9143d9e97c0c469295ecf8f8e86bf4b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a32497816a24b0e98bfe2b91cdb5f5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f0abd7a34b402a805fc120d404fcab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2add7e1ec07f40dbb767635c38522992_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2add8a116b4448d19d15dd64d77975a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9829035a8a2f448e9920c55d9173e8fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27aebe7d32b349b39eabbc338188b25c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400855cb5a3d4e6582b7e57125c949fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided6796ecfc64dfd806da8fc7d8e889f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaff95dd2e5e6493cab06cdbfe40f221f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88fed49ad0634fc1978b61d0cad74161_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:SuppliesEmbryosAndOtherProductionMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1e8bcd17ae4fc0b556dc1a59ce8c5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:SuppliesEmbryosAndOtherProductionMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e13e1046d1a4e8d8a5d3ce4b8599cde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:WorkInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148174464dab4df3b6cc16ca4f94f20c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:WorkInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cbec292daaf4a33adb6add3983c2aca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id66643537bcc4586b5c8295486ad53db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:LivestockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917953d1a25e429ca029530f8e586cc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:FeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8e97e073a840e3a917dd25f9403665_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:FeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>pgen:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827c577308054c018d5e48fada14ff8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6fc55d839644cba90653e38f783a62e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3d42982abc4d50a68c8e28b6a8c52b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59cb5726db6446eb9557596ccf3c7f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e33c160a5e4e85abbb9e977904ab51_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if23ada0abe5047e9816a9b05e4ac3a06_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2462eb080f5476ba12592a72425bb0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:FirstNationalBankofOmahaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe34c2e16ef4ced904a0a453bb78be8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:FirstNationalBankofOmahaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7417cafe9a0140cdb536d3070b429916_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ExemplarGeneticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20ccfa747e64113890f0974c9cb925e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1adbe486ee94be59a3ea92894502ff4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933e7cc3ab3e474b9117c918400f0682_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b7410140b740b2845853aabed50d7d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792bcba573ad43159c20ae7da25f6f15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pgen:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac99bde42eb4b6eba9f0cd1ac7f2e1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pgen:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>pgen:day</xbrli:measure></xbrli:unit><xbrli:context id="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf57ef00bf69495496f71af763419a23_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea183b22e6204e749452fefc61666933_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300109a3973b48cfaf6c87f24830c1e8_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dcdccfde7b24e57841cf202a0c22c5e_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf7a9ed58fa4c19bfac3158a4004562_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:ActoBioNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc2b6cdd3fa4b82a31d23fe1ca4681d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfb43cef36f48d58869fc13628164ec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1c0bfc1a8642e5b23938f795103bcb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09db21ffd978403fb95c9f969486cebe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:MerckConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i998ab898facc4cc6929d5d5803057739_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:MerckConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f9a8543e394b0089b989601e44377b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33041383733943a0bdbb0c01bba1ae14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbd89e79742463bb7bb2c8072e4d28d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fa0174f15049ad925a5c7467f8806f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7249ffe7fdf04fc58a2bebc05c00ac77_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b9331a29684594bdc6ff0bcff164e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib75f9587ce8b496db2609e0682fcb9b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd35f7da52004f518b3b73faaa279403_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2e86fa379664890bce6f8505ae63863_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94e6997c4484c4fb71d5424d9a823e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6024ac23c341aab2161aee0517820f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2140f32269b445a7a78f85b8ded04f8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c2f36dc30c4039a45bf45425bd3b3c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846cd2227b1f4f05943d3faf0edb56d7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc0ff9076414c038f13048e82021a34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pgen:GeneratedAfter2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0274c8f694d3486099220e08fbba1fc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc450189ce644024ba68868dd2551779_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ForeignSubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-31</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db2284265074c3289f29fb1232d187f_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae95dbfa1fb42c993e1fed2a97942b1_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AffiliatesOfThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938616e63e9046f9b8b561f8f75cd7c5_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5155424e1c244be3a4c16ac6cae35737_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3792a1ad213496a8d41cfdce5e38535_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184114ce7b3f42b58ddf4c429939454e_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79bf4a7c0c64ef68087d0bb20da73a2_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pgen:AquaBountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7bc616c8ee45679cdc730430d0f09a_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf169456400e4ce8aeed85e7ca335ce6_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pgen:AquaBountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d40ed18f6934798ba07115922d698e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb78e848d959475a8e60240fef86d616_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258e6ee1096c48f3bafa2a89b56d3570_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7408085271934977bcbe87b303ee566b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507bf64ce91c4dbe855ace68943a9ff1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0809b9c1122b4425b82973aa53316a00_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if630c00264644a5f934f6c52739e171f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b4d072e6db4429be9358d98ef2695d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6fd3bf62174baf8ea4e643cd5ee2a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bc9ff4a3e6143fe87ea8e2e89c9f0d2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1be10c992143819d5ff797b4bdd3b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb66d1f63fcb401b899173c39dea5ef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie12981139b134339950cececc0d8cefd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793cc475e5a349a38e9012cbdf287644_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db0821a8b444dd48ee9d160de991bf8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b44220e572445a7aaaedaab0fba9599_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33202a64c764d2294be298ec498bf0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd4e1dad5ab4578a892678be6523d79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04130b19133407c8ffb14a7cdb84896_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2008PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db41e22786f4f8e803bd5da7ae7655b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2013PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dfda69a28ff4552bd02d489a6714039_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ec59376227463da776d509a74f26c7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59afefa3805d493fad5e5f44d615e29c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i523c931240534675a00b833db69b7b7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b3bd75c2af44de39219feee8729308e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c5460f623b41c18486f8f337c91484_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7451bc6286184839ac5a35196b93e9b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10990e5b1d6d46afa61c13573d2718f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a89d08d41a54d1186a979123197a002_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02779a4a24e94615abd773c870dd6261_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd402c659aa49ba8a4130d86b580fa0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f91c9052bd04dc58720b0900b461cbd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i371617dbee39477bb1cb5742a03f41fe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a9238cdda843cd8e2b1cdc9a3927be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39bd16d2b0240b687313c2d206093e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42f0609642c4f08b491b5e9e5e122cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10782278c1794d1c8b675aaa49765ed4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc52713e7d8949749938bc75522e6d98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87018f1bd95f4a4f8cd3775dc1bdc558_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4889fe27e2cc4966b4f58c1e494a13ed_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53aa5fac20ac403b9bce2f3bbe67a3a5_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27caa5d0d3674cb8873fa0e6c545b8cc_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3e7401f5244362a8da8bdd6081990c_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45a0b9d2a934bb4b5153625e67c9998_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0854d2b69b794445a113081a1772158a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>pgen:claim</xbrli:measure></xbrli:unit><xbrli:context id="idf63e5924ca540d89aef4d0830021e64_D20201201-20201201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590473c574a14f01bc57d3d29295299d_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e90193768804ac2897e65914b465074_D20190320-20190320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-20</xbrli:startDate><xbrli:endDate>2019-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53067c947c6445b99c0734630919c2f_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162c6a00ebd8403087aaba03e9e7257d_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:MethaneBioconversionPlatformDisclosuresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:SecuritiesAndExchangeCommissionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163004d1571347a9896c92d4b1ec572f_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2615524a66c943229cbd226d85d96e2a_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb40c1f06726442485a1ee1321b1baa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib672478b9e8e43829ba3dd9807ad3e12_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555d23957e82412498d8f685f322401f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87f8cebc3d94d3a9961d37fd3d97771_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AffiliatesOfThirdSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pgen:SeriesAPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i599bfce00a9945d9b726ceb46d1b4829_D20171001-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pgen:SeriesAPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0670171b99994e70abea87f63ac354ea_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ZiopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70be85e7d3844aaca71c406b666d60d6_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a435ac6ca244c79163f5df75db8e16_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic063de9522b3438b84804a067d67c361_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e54f6e16a9443f0a47fc8c8084f977e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="relatedparty"><xbrli:measure>pgen:relatedParty</xbrli:measure></xbrli:unit><xbrli:context id="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:VariousECCAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:CollaborationandlicensingagreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3e239ae20c45c7b7aaf57a9b6cf875_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b50be6f05c0474e83a58face9d3645c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c1e80d080904677b59656be2a1b40b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f71aeaa143c4b289ab59dfbe54174aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib379ad98b2cb45daaf83b5b7a21cc98e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adb4d0947454afaa177f45a75cc9d60_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fb0d7ad0b6498ea08417bed7233684_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2017226d1f364332a399d4d0f2c037e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0ee46d4ad6348e8955c1243244ba4e8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7c17ddfd9e4cfe8f7cfcc1d3d89d94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1d30c65b074157a537d57ad73c2775_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c9e1d13159420db631b851192aed69_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8404b30334554a8282ddc4963025afb9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11002969f3e4f0b9cad7acc95c9688d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816e511c14e944e784ccf02ef49dcfc1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6adeb8393ffb4cd9af54545b7f666403_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416c63b209e448e4a1691314a0e720fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de8331b876d4b82921c05eee138928f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f84542b3ea54137a7e7be5308c1f271_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49361cac902b4125a327a91917c78be8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87036dbc7d542818b7d1e05ad396f7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3efccfc60d644e148ff53a1aea8fb101_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65e43c5c8a9408d98dae73506aec312_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142de93e903443e4ab31cfa896a0f6c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb84bd71d814449b98a10354224cd024_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05ba222657c4da3a7946904d64b7cda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45928d9759c446fd8135abd8ae21531c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4c851ce2bf04d2d8ee0ae2363c3095c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6efc76794cd4f70892c233dfb405b21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec754f7c8fe345e9a691b4617bc583a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1856a6ee6ec445a2a3d19b2ec22d5c69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6153d68f9fcc4906bd9e9cd50a4813d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab2a93de6ee44cf97247286fbd7e13b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04441decbc7f413abc71cd43fc461da1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4ba24eafed49019e6ec63aabe7a182_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1adcf1f7e2814c5a98b167b18ede27d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57be64036b41497caa88c720697751d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c2727e865d423586be763a463a4aeb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadd9097495e4bc7a7045a8c4457de90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafa1b4c69804dfd96a439a35168dfc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d3a6d84abe14c848540902462585373_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b2a762b98949cc80b92e79db724b1c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7bed861874412b9f1e982a3d5b7883_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b5d19dccb34749ad0bdd8bddb68e52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62d85ceb878414ab0381b19dae2d6e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50dbf2c0e31425c97e6391b41ca69ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163a14083d2840e7b31ad5dfcf65b399_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736231a7920a4f7da29a6de5b917aa57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdd8a57941e4059a00f31f76dafd79e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie213b50bea4c453b9fc821145579a6d8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eda440ff9e84b8aab723bc6229cafb9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa651b05eb6d42d7956529f80d128fb4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ada1cfca67342dbb51b59cb99e04067_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if943aa72ff3a4b8ba9787819a93ee378_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4927248b8114f8fa633cd593f9b134d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ad89a96f44459196c39386869a91e4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b87aa4811c44854b9ddc4b70159d6f6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f203cb6a2c84a37a5bda3f93b68e7a3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d70b9845a5b44eb94cdadc203be4f74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fd320c35794ded9d690fc67a61ee36_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6609bfdc1f48b586a5b70a92a8e8ff_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4962cdf48204222844e9ce74fd74c3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93fa25606544244a088b1c2b2a76bc8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9dcf0952c04e27a75572dcc547c1e7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2c484ec2494489bb341fdba607cadb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71de56fffeb14a6988696974ced53186_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i714a0770b5544bb98754740acc834259_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133129ec5f3246d683d35411173d33aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c8be8caa2f46178129d4ec229adbb2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b2874d2bdd4deb9104cb8ea4baf8de_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8166ea8ff5b14ea1a56f75013f866d68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6c9fa8b50d4640b4010be6ab64cc36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a62b5534d74990aab59d86bee4c7e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1a0c4bdf624f5a9be5028ebfc27876_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7a12392b3748ccb33c84786aaae792_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564e1936099a4468b2f386769723ec16_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356090</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie210b0c7fc84429f915eaf73d0946948_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.403%"><tr><td style="width:1.0%"></td><td style="width:19.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YzcyMDNiYmZjNzc3NDFlYjhkOTc2NmQ0MDcwNzU1NTQvdGFibGVyYW5nZTpjNzIwM2JiZmM3Nzc0MWViOGQ5NzY2ZDQwNzA3NTU1NF8wLTItMS0xLTA_9e7196c8-189d-4040-8015-7f4a2b3a3501">10-K</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODE2NWY3NzBjZGFkNDBlNDhiNDhiOGY1YTE3MzlmYzEvdGFibGVyYW5nZTo4MTY1Zjc3MGNkYWQ0MGU0OGI0OGI4ZjVhMTczOWZjMV8wLTAtMS0xLTA_2fc8709c-be72-4a92-a889-4ff86336b081">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8xMTM_f0cd3672-8cc1-4dc7-9b44-dada0b3abb80"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8xMTM_23df9167-e62d-4437-a176-b9e645245f16">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6OWU2Y2QxZDA5NjNkNGZlMDk2ODZjZGNkZTU5MjJjOGQvdGFibGVyYW5nZTo5ZTZjZDFkMDk2M2Q0ZmUwOTY4NmNkY2RlNTkyMmM4ZF8wLTAtMS0xLTA_5c90e610-0ba4-44a4-a097-c247ffb453ac">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc5_d39e7210-f35d-42df-9381-c8bc1d125e00">001-36042</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgw_0439e67f-2386-41e1-8e6b-678d0a9d4618">PRECIGEN, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:8.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8wLTEtMS0xLTA_a2eaea02-6fb8-4565-8680-f75823b224e8">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8wLTQtMS0xLTA_77806bf8-4b33-481e-ba46-ef14c4334616">26-0084895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8zLTEtMS0xLTA_683108f1-010e-4add-843b-95358491f930">20374 Seneca Meadows Parkway</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTEtMS0xLTA_f6945d02-d572-4c18-bf48-899ea611a6e1">Germantown,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTItMS0xLTA_e62d086f-c6d4-411f-8767-d08f1f01b3c8">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTQtMS0xLTA_1f3dce2a-2a70-452d-99f4-c5a79ec999ce">20876</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant's telephone number, including area code: (<ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgx_9c5108fe-8009-49e7-8852-b93c982c5476">301</ix:nonNumeric>) <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc1_5b3dc564-3466-4ef5-ac41-40d8aaa0b861">556-9900</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTAtMS0xLTA_c79c43dc-2e37-4d75-88dc-ed3f6b4978cc">Common Stock, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTItMS0xLTA_c31289d0-6ad2-43c4-afac-f67ded6056e8">PGEN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTQtMS0xLTA_59831f58-460b-459e-8331-bbe92b98c1e3">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:288.75pt"><tr><td style="width:1.0pt"></td><td style="width:286.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgy_7d66eefe-86c2-40ea-b612-56792aa0de2d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgz_25a51a63-5208-46e8-9346-a3784b7f8161">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc3_090701b1-6114-42ff-ad3c-c1c2410a9e70">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc4_b52f5e9b-9d1a-4e51-a1d0-e40a7e917e38">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl8wLTQtMS0xLTMzNTU_0a18a5e2-72d8-40a2-a777-679736979e2a">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl8yLTYtMS0xLTA_981178fc-a9ce-4953-9fb7-1db835b76a39">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl80LTYtMS0xLTEwMzk3_ac0d0583-ad64-468f-9a35-529f6514b4e5">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF82NTk3MDY5NzcwNjEy_1a5a823f-1fb7-4ac6-be93-c457b60f05b0">&#9746;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTg0_0b7179c1-6445-450f-ae9f-e31fe16e6bf7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2020, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant's common stock held by non-affiliates based upon the closing price of such shares on the Nasdaq Global Select Market on such date was approximately $<ix:nonFraction unitRef="usd" contextRef="i61afe01c77bd4075ac870cbeb744df69_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yNTEz_a539b7c1-6f83-4c9b-a540-359483f766d6">435.1</ix:nonFraction> million. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;15, 2021, <ix:nonFraction unitRef="shares" contextRef="i4338078300e342f196795af559ba89f6_I20210215" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yNTI4_2300f6ba-689a-4f4a-a4fb-fe3d625aff0a">205,661,239</ix:nonFraction> shares of common stock, no par value per share, were issued and outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc2_63672a67-fdea-4d17-a40c-44bff77d0bad" escape="true">Portions of the registrant's Definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2020.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents </a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_10">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_13">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_16">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_19">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_22">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_25">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_28">66</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_31">PART II</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_34">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_34">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_37">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_40">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_40">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_43">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_43">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_46">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_49">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_49">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_52">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_52">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_55">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_55">89</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_58">PART III</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_61">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_61">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_64">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_64">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_67">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_67">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_70">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_70">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_73">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_73">90</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_76">PART IV</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_79">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_79">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_82">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_82">94</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intrexon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trans Ova Genetics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ActoBiotics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Progentus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UltraCAR-T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RheoSwitch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, UltraVector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and RheoSwitch Therapeutic System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are our and/or our affiliates' registered trademarks in the United States and GenVec&#8482;, Precigen&#8482;, AdenoVerse&#8482;, ActoBio Therapeutics&#8482;, UltraPorator&#8482;, AttSite&#8482;, and Precigen Therapeutics&#8482; are our and/or our affiliates' common law trademarks in the United States. This Annual Report on Form 10-K, or Annual Report, and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned by us or other companies. Solely for convenience, trademarks, service marks, and trade names referred to in this Annual Report and the information incorporated herein, including logos, artwork, and other visual displays, may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks, and trade names. We do not intend our use or display of other companies' trade names, service marks, or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Other trademarks, trade names, and service marks appearing in this Annual Report are the property of their respective owners. Unless the context requires otherwise, references in this Annual Report to "Precigen", "we", "us", and "our" refer to Precigen, Inc.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents </a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Annual Report, including statements regarding our strategy; future events, including their outcome or timing; future operations; future financial position; future revenue; projected costs; prospects; plans; objectives of management; and expected market growth, are forward-looking statements. The words "aim", "anticipate", "assume", "believe", "continue", "could", "due", "estimate", "expect", "intend", "may", "plan", "potential", "positioned", "predict", "project", "seek", "should", "target", "will", "would", and the negatives of these terms or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements may relate to, among other things: (i) the impact of the COVID-19 pandemic on our clinical trials, businesses, operating results, cash flows, and/or financial condition; (ii) the timeliness of regulatory approvals; (iii) our strategy and overall approach to our business model, our recent efforts to realign our business, and our ability to exercise more control and ownership over the development process and commercialization path; (iv) our ability to successfully enter new markets or develop additional product candidates, including the expected timing and results of investigational studies and preclinical and clinical trials, including any delays or potential delays as a result of the COVID-19 pandemic, whether with our collaborators or independently; (v) our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers; (vi) our ability to successfully enter into optimal strategic relationships with our subsidiaries and operating companies that we may form in the future; (vii) our ability to hold or generate significant operating capital, including through partnering, asset sales, and operating cost reductions; (viii) actual or anticipated variations in our operating results; (ix) actual or anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (x) our cash position; (xi) market conditions in our industry; (xii) the volatility of our stock price; (xiii) the ability, and the ability of our collaborators, to protect our intellectual property and other proprietary rights and technologies; (xiv) our ability, and the ability of our collaborators, to adapt to changes in laws or regulations or policies, including federal, state, and local government responses to the COVID-19 pandemic; (xv) outcomes of pending and future litigation; (xvi) the rate and degree of market acceptance of any products developed by us, our subsidiaries, collaborations, or joint ventures, or JVs, and competition from existing technologies and products or new technologies and products that may emerge; (xvii) our ability to retain and recruit key personnel; (xviii) expectations related to the use of proceeds from public offerings and other financing efforts; (xix) estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; (xx) the challenges inherent in leadership transitions; and (xxi) the effects, duration, and severity of the ongoing COVID-19 pandemic and the actions we and others have taken or may take in response.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, assumptions, and expectations of our future performance, and may also concern our expectations relating to our subsidiaries and other affiliates. We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report, particularly in "Summary of Risk Factors" set forth below and Item&#160;1A, "Risk Factors," that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, JVs, or investments that we may make.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report, the documents that we reference in this Annual Report, the audited consolidated financial statements and related notes thereto included in this Annual Report, the other reports we have filed with the Securities and Exchange Commission, or SEC, and the documents that we have filed as exhibits to our filings with the SEC completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents </a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of risks and uncertainties, including risks that could have a material adverse effect on our business, financial condition, results of operations, and cash flows. The following summary of the principal factors that make an investment in our securities speculative or risky should not be relied upon as an exhaustive summary of the material risks facing us. You should read the following summary together with the more detailed description of the risks that we deem material described under "Risk Factors" in Item 1A of this Annual Report and the other information contained in this Annual Report before investing in our securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Capital Needs</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, we may not achieve or maintain profitability, and we will need substantial additional capital in the future in order to fund our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Servicing our debt may require a significant amount of cash, and we may not have sufficient cash flows from our business, or otherwise have available cash, to pay our substantial debts when due.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Despite our current debt levels, we may still incur substantially more debt or take other actions that would intensify the risks discussed above.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption that could have an adverse effect on our access to capital on favorable terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Product Candidates</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval, and ultimately commercialize them.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory process of the U.S. Food and Drug Administration, or FDA, and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and we may be unable to obtain FDA approval of our product candidates. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business, and our results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As an organization, we have limited experience designing and implementing clinical trials and failure to adequately design a trial, conduct a trial in accordance with regulatory requirements, or enroll patients in clinical trials, could result in adverse effects, including but not limited to increased or unexpected costs and delayed timelines.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell and gene therapies are novel, complex, and difficult to manufacture.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change, which could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may cause undesirable side effects or have other properties that could delay or halt their clinical development, limit their commercial potential, or result in significant negative consequences.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have chosen to prioritize certain of our product candidates and, as a result, may expend our limited resources on product candidates that do not yield a successful product, or fail to capitalize on opportunities that may be more profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing COVID-19 pandemic could cause a disruption of the development of our product candidates and adversely impact our healthcare business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur significant costs complying with environmental, health, and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if a product candidate receives marketing approval, it may fail to achieve the degree of market acceptance necessary for commercial success.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents </a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing processes may delay or disrupt our commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The successful commercialization of our product candidates will depend in part on the extent to which third-party payers provide coverage and adequate reimbursement levels.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations and Strategy</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to develop and commercialize some of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have previously entered into strategic collaborations, that we cannot operate solely for our benefit, and which we may fail to successfully manage, or from which disputes may arise.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our subsidiaries, our collaborators, and other third parties to deliver timely and accurate information.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be sued for product liability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The livestock products of our operating subsidiaries are subject to disease outbreaks.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitors and potential competitors may develop products and technologies that make ours obsolete or garner greater market share than ours.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience a significant breach of data security or disruption in our information systems, our business could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The effects of the COVID-19 pandemic have disrupted, and will likely continue to disrupt, our business operations, which could have a material adverse effect on our results of operations, cash flows, and financial position.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may pursue strategic acquisitions and investments that could have an adverse impact on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to compete may decline if we do not adequately protect our proprietary technologies or intellectual property rights.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from commercializing our technologies or impact our stock price.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain additional protection under United States or foreign legislation by extending the patent terms and obtaining regulatory exclusivity for our technologies, our business may be materially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enforcing our intellectual property rights may be difficult and unpredictable, within the United States and elsewhere.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not anticipate paying cash dividends, and accordingly, shareholders will have to rely on any stock appreciation for return on their investment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The issuance of our common stock pursuant to a share lending agreement, including sales of the shares that we lend, and other market activity related to the share lending agreement may lower the market price of our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31, 2020, Randal J. Kirk controlled approximately 44 percent of our common stock and may be able to control or significantly influence shareholder votes and other corporate actions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART I</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_13"></div><div style="margin-top:9pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We have developed an extensive pipeline of therapies across multiple indications within these core focus areas.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively advancing our lead clinical programs, including: PRGN-3005 and PRGN-3006, which are built on our UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on our AdenoVerse immunotherapy platform; and AG019, which is built on our ActoBiotics platform. In addition, we recently completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on our UltraVector platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies. Our UltraPorator device received FDA clearance for manufacturing UltraCAR-T cells in clinical trials in October 2020, and we began dosing patients with UltraCAR-T cells manufactured with UltraPorator in our PRGN-3005 and PRGN-3006 clinical trials in November 2020. We also have a robust pipeline of preclinical programs that we are pursuing in order to drive long-term value creation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exercise discipline in our portfolio management by systematically evaluating data from our preclinical programs in order to make rapid "go" and "no go" decisions. Through this process, we believe we can more effectively allocate resources to programs that we believe show the most promise and advance such programs to clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To guide our decision-making and operations, we have adopted the following tenets, which form the core of our operating ideology: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Financial Discipline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Responsibly allocate capital in an effort to ensure maximum value creation.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Active Portfolio Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Continuously evaluate our portfolio and strictly adhere to data-driven "go" and "no go" decisions to advance programs with the highest probability of success. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid Execution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advance priority programs quickly to value inflection points.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Strategic Partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Seek strategic partnerships to maximize value generation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><img src="pgen-20201231_g1.jpg" alt="pgen-20201231_g1.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:560px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to use our discovery and clinical development infrastructure to continue advancement of our clinical programs with the goal of improving outcomes for patients with significant unmet medical needs. The key elements of our strategy include: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Advancing our lead clinical stage programs and seeking opportunities to maximize their value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are actively advancing our lead programs that we believe have significant potential value. We intend to efficiently pursue these programs toward clinical proof-of-concept and commercialization, whether independently or with collaborators.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Strategically pursuing our preclinical programs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a robust pipeline of preclinical programs that we are pursuing in order to drive long-term value creation. We exercise discipline in our portfolio management by systematically evaluating data from our preclinical programs in order to make rapid "go" and "no go" decisions. Through this process, we believe we can more effectively allocate resources to programs that we believe show the most promise and advance such programs to clinical trials.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging our technology and therapeutic platforms across indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Through the application of our suite of proprietary and complementary synthetic biology technologies, we believe we can create optimized biological processes and overcome the limitations of traditional techniques, leading to precision medicines that are manufactured more efficiently and cost-effectively with superior performance. We continually assess the application of these technologies across therapeutic areas to determine where we can develop and provide unique solutions to challenges facing existing therapies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strategically focused our efforts on developing an innovative pipeline of therapies in immuno-oncology, infectious diseases, and autoimmune disorders based on our transformative UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics therapeutic platforms. A core focus of our research and development programs has been an effort to address the drawbacks associated with conventional cell and gene therapy manufacturing approaches. To this end, we are developing therapeutic candidates that reduce manufacturing risk by eliminating the need for centralized manufacturing and have invested in internal manufacturing capabilities to de-risk our clinical production.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g2.jpg" alt="pgen-20201231_g2.jpg" style="height:303px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical Pipeline</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g3.jpg" alt="pgen-20201231_g3.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Healthcare Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our healthcare business is operated by our wholly owned subsidiaries PGEN Therapeutics, Inc., or PGEN Therapeutics, Precigen ActoBio, Inc., or ActoBio, and Exemplar Genetics, LLC, doing business as Precigen Exemplar, or Exemplar, and also includes our majority ownership interest in Triple-Gene LLC, doing business as Precigen Triple-Gene, or Triple-Gene, as well as equity and royalty interests in therapeutics and therapeutic platforms from companies not controlled by us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PGEN Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGEN Therapeutics is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. PGEN Therapeutics operates as an innovation engine, progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PGEN Therapeutics' Technology Platforms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage a diverse portfolio of proprietary technology platforms to accelerate research and development efforts to deliver the promise of precision medicine. Precigen's innovative technology platforms enable us to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">construct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> powerful, multigenic programs that we believe will drive efficacy, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">deliver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multigenic constructs using viral and non-viral approaches that we believe will drive lower costs, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expression of genes and performance of therapeutics </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for precise targeting of complex malignancies. The following discussion describes the technology platforms that we use for our approach to precision medicine.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g4.jpg" alt="pgen-20201231_g4.jpg" style="height:210px;margin-bottom:5pt;vertical-align:text-bottom;width:475px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the development of innovative biological products requires a deep understanding of the complexity of cellular processes and the construction of improved gene programs developed in conditions reflective of the natural environment. We accomplish the design of optimized gene programs for our therapeutic approaches via our UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs. UltraVector-enabled matrices facilitate rapid identification of components that yield desired gene expression. Our library of characterized genetic components and associated functional characterization data enable construction of gene programs for optimized expression of multiple effector genes. Expression of our membrane-bound interleukin-15, or mbIL15, gene improves functional characteristics of certain immune cells, including T cells, by enhancing their potential for expansion and persistence.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deliver gene programs via viral, non-viral, and microbe-based approaches, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AttSite recombinases, and gorilla adenoviral vectors, from our AdenoVerse library. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a non-viral transposon/transposase system licensed from the University of Texas MD Anderson Cancer Center that stably reprograms immune cells by inserting specific DNA sequences into the genome. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system has been shown to promote random integration in the genome without insertion bias, which contrasts with the predilection of lentiviral vectors for integration at transcriptionally active sites. We believe that this non-viral system may confer benefits including a reduction of the risk of genotoxicity. Precigen has made significant improvements to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system by optimizing gene elements, genetic payload capacity, and efficiency of delivery, which provides a system tailored to our multigenic UltraCAR-T platform. Our AttSite recombinases, which break and rejoin DNA at specific sequences in a unidirectional, irreversible fashion to direct integration of a transgene into the host cell genome, allow for stable, site-specific gene integration. Genetically engineered adenoviruses (a common group of viruses) called adenovectors that are designed to insert genes into cells are an important part of our technology platforms. Our AdenoVerse technology platform is composed of a library of engineered adenovector serotypes that yield greater tissue specificity and target selection as compared to known human Ad5 adenovectors. This includes our gorilla adenovectors, which provide a potential competitive advantage in their large payload capacity, ability for repeat administrations and generation of robust antigen-specific immune responses. The UltraPorator system includes proprietary hardware and software solutions and potentially represents major advancements over current electroporation devices by significantly reducing the processing time and contamination risk. UltraPorator is designed for rapid and cost-effective manufacturing of UltraCAR-T therapies and has the potential to enable rapid manufacturing of a range of gene and cell therapies beyond UltraCAR-T.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final component of our approach to precision medicine is our ability to control gene expression and regulation using the RheoSwitch, kill switches, and tissue-specific promoters. The RheoSwitch Therapeutic System, our inducible gene switch system, we believe is the most clinically advanced gene switch system and provides quantitative dose-proportionate regulation of the amount and timing of target protein expression in response to an orally available activator ligand, veledimex. In addition, we have developed a suite of kill switches, which allow us to selectively eliminate cell therapies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> after their administration, to improve their safety profile. We are developing tissue-specific promoters to only induce gene expression locally in cells or tissues of therapeutic interest.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have leveraged our proprietary and complementary technology platforms discussed above and our expertise in immunology to develop key therapeutic platforms, including UltraCAR-T and AdenoVerse, to address multiple pathways of complex disorders with significant unmet medical needs and to realize our core promise of precision medicine.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PGEN Therapeutics' Therapeutic Platforms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UltraCAR-T</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent technological advances have revolutionized the field of immunotherapy for the treatment of cancer. Of the many immunotherapy approaches, chimeric antigen receptor T, or CAR-T, cell therapies in particular have shown remarkable responses in cancer patients with hematological malignancies. These therapies rely on the modification of T cells with chimeric antigen receptors to enable those T cells to bind to specific antigens on the patient's tumor cells and kill the tumor cells. Concerns remain, however, regarding complex and lengthy manufacturing processes and the safety profile of CAR-T cell therapies. Furthermore, current autologous and allogeneic CAR-T cell therapies face challenges in the treatment of solid tumors due to rapid exhaustion and limited persistence of CAR-T cells. Current approaches to CAR-T manufacturing require extensive </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion following viral vector transduction to achieve clinically relevant cell numbers. We believe such an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion process can result in the exhaustion of CAR-T cells prior to their administration, limiting their potential for persistence in patients after administration. Furthermore, lengthy and complex manufacturing of current CAR-T approaches results in high manufacturing costs and long delays in providing the CAR-T treatment to cancer patients. Time is of the essence for advanced cancer patients and even modest delays in treatment can adversely affect outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our UltraCAR-T platform is differentiated from the competition, and we believe it has the potential to address the shortcomings of current technologies and disrupt the CAR-T treatment landscape by increasing patient access through shortening manufacturing time from weeks to days, decreasing manufacturing-related costs, and improving outcomes.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g5.jpg" alt="pgen-20201231_g5.jpg" style="height:207px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently introduced our vision for a new UltraCAR-T library approach, which is intended to transform the personalized cell therapy landscape for cancer patients. Our goal is to develop and validate a library of non-viral plasmids to target tumor-associated antigens. Enabled by what we believe to be design and manufacturing advantages of UltraCAR-T, coupled with the capabilities of the UltraPorator system, we are working to empower cancer centers to deliver personalized, autologous UltraCAR-T treatment with overnight manufacturing to any cancer patient. If our goal is realized, one or more non-viral plasmids could be selected based on the patient's cancer indication and biomarker profile from the library to build a personalized UltraCAR-T treatment. After initial treatment, this approach has the potential to allow for redosing of UltraCAR-T targeting the same or new tumor-associated antigens based on the treatment response and the changes in antigen expression of the patient's tumor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g6.jpg" alt="pgen-20201231_g6.jpg" style="height:209px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key advantages of UltraCAR-T versus the traditional CAR-T approaches include:</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced non-viral multigenic delivery system</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have optimized and advanced the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system using our UltraVector DNA construction platform to produce multigenic UltraCAR-T cells. As a result of this optimization, our UltraCAR-T cells are precision-engineered to produce a homogeneous cell product that simultaneously co-expresses antigen-specific CAR, kill switch, and mbIL15 genes in any genetically modified UltraCAR-T cell. This design differentiates our UltraCAR-T platform from the approaches used by our competitors and, we believe, reduces the developmental risk as compared to those approaches because product homogeneity is a critical consideration for later stages of clinical development and subsequent commercialization. We utilize our protein engineering and immunology expertise to optimize antigen binding, hinge, and signaling domains of each CAR based on the target antigen expression profile and cancer indication. We have also included our proprietary kill switch technology in our UltraCAR-T cells to improve the safety profile.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enhanced persistence and elimination of ex vivo expansion step due to expression of mbIL15</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key driver of improved UltraCAR-T cell performance is mbIL15. The expression of mbIL15 has been shown to enhance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion of UltraCAR-T cells in the presence of tumor antigens and prevent T cell exhaustion to maintain a less differentiated, stem-cell like memory phenotype leading to longer persistence of UltraCAR-T cells. This yields an enduring anti-tumor response that has been shown to outlast conventional CAR-T cells in preclinical studies, which we believe is essential to successfully targeting solid tumors. This design allows us to eliminate the need for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion prior to administration, a requirement that is a major limitation of current CAR-T treatments. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scalable, rapid, decentralized manufacturing process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another key differentiator of the UltraCAR-T therapeutic platform is our rapid and decentralized proprietary manufacturing process, which allows us to manufacture UltraCAR-T cells overnight at a medical center's current good manufacturing practices, or cGMP, facility and reinfuse the patient the following day after gene transfer. This process improves upon current approaches to CAR-T manufacturing, which require extensive </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion following viral vector transduction to achieve clinically relevant cell numbers that we believe can result in the exhaustion of CAR-T cells prior to their administration, limiting their potential for persistence in patients. The decentralized nature of the manufacturing process allows us to scale beyond the confines of a dedicated facility. We are the first company to implement non-viral, rapid, decentralized manufacturing of CAR-T cells in the clinic and have validated our proprietary UltraCAR-T manufacturing process in practice by infusing patients one day after gene transfer at two different sites in our ongoing clinical trials. We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies. The UltraPorator system, intended to be a viable scale-up and commercialization solution for decentralized UltraCAR-T manufacturing, includes proprietary hardware and software solutions and potentially represents major advancements over current electroporation devices by significantly reducing the processing time and contamination risk.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="pgen-20201231_g7.jpg" alt="pgen-20201231_g7.jpg" style="height:165px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our UltraCAR-T manufacturing process will provide a significant potential competitive advantage in the timeline and cost required to manufacture and deliver CAR-T therapies to patients as compared to current treatment approaches that require large, centralized facilities to support manufacturing of a relatively small number of treatments. We believe development of rapid and successful overnight manufacturing of UltraCAR-T therapies at medical centers signifies a paradigm shift in CAR-T therapy by eliminating manufacturing and timing risks associated with conventional CAR-T therapies, and our intent is for it to take place directly in numerous treatment centers, which can improve the accessibility of our therapies for patients.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g8.jpg" alt="pgen-20201231_g8.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGEN Therapeutics' most advanced programs based on the UltraCAR-T platform include PRGN-3005, which is in a Phase 1/1b clinical trial for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, and PRGN-3006, which is in a Phase 1/1b clinical trial for patients with relapsed or refractory acute myeloid leukemia, or AML, high-risk myelodysplastic syndromes, or MDS, and chronic myelomonocytic leukemia, or CMML.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRGN-3005</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-3005 is a first-in-class, investigational autologous CAR-T therapy that utilizes our UltraCAR-T platform to simultaneously express a CAR targeting the unshed portion of the Mucin 16 antigen, or MUC16, mbIL15, and kill switch genes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="pgen-20201231_g9.jpg" alt="pgen-20201231_g9.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MUC16 is an extremely large, type I transmembrane cell surface glycoprotein that plays a key role in the pathogenesis of ovarian cancer by promoting an increase in cell proliferation, metastasis, resistance to chemotherapy and immune system evasion by cancer cells. MUC16 is overexpressed on more than 80 percent of ovarian tumors but has limited expression in healthy tissues, making it an attractive CAR-T target for ovarian cancer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other cancers with known overexpression of MUC16 include pancreatic, breast, endometrial, lung, and bladder cancers. MUC16 undergoes proteolytic cleavage in the extracellular domain resulting in shedding of a large portion of extracellular domain, termed CA125, from the cell surface and leaving only a short, unshed extracellular domain tethered to the cell surface. Therapies that target the region of MUC16 that is shed from the cell surface may have limited effectiveness due to their binding to CA125 in circulation which is not associated with tumor cells. In order to eliminate binding to circulating CA125, we have designed our MUC16 CAR using an antigen binding domain that specifically binds the unshed portion of MUC16 and optimized its affinity to preferentially target PRGN-3005 to tumor cells.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g10.jpg" alt="pgen-20201231_g10.jpg" style="height:332px;margin-bottom:5pt;vertical-align:text-bottom;width:425px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-3005 is being evaluated for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancers. Advanced ovarian cancer is often fatal, with Stage IV survival rates as low as 20 percent, and has limited treatment options. Patients with ovarian cancer represent a large population, with approximately 300,000 patients diagnosed worldwide annually, including 22,000 in the United States alone.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies, PRGN-3005 UltraCAR-T cells have shown robust MUC16-specific cytotoxicity of ovarian cancer cell lines, a stem-cell like memory phenotype and significant improvement in their longevity even in the absence of exogenous cytokines as compared to conventional CAR-T cells. PRGN-3005 UltraCAR-T cells have shown significantly superior anti-tumor response in mouse models of ovarian cancer compared to mice treated with a saline solution or conventional MUC16 CAR-T cells lacking mbIL15 expression. Specifically, a single administration of PRGN-3005 one day after non-viral gene transfer showed significantly superior expansion and preferred memory phenotype of UltraCAR-T </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and significantly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">superior efficacy compared to traditional CAR-T resulting in all PRGN-3005 treated mice becoming tumor-free. Furthermore, rechallenging these tumor-free mice three months later with ovarian tumors for a second time (to simulate tumor relapse) led to the elimination of tumor burden without additional PRGN-3005 UltraCAR-T treatment. These data demonstrated the potential of UltraCAR-T cells to persist long-term </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, prevent CAR-T cell exhaustion, and mount a durable anti-tumor response with the ability to continue to respond upon tumor rechallenge.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-3005 is currently being evaluated in a Phase 1/1b clinical trial. The Phase 1 portion of the study is a dual-arm, non-randomized, open-label clinical trial in patients with advanced, recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Patients in this investigator-initiated Phase 1 dose escalation trial receive either intraperitoneal, or IP (Arm A), or intravenous, or IV (Arm B), administration of PRGN-3005 without prior lymphodepletion. The primary objectives of the Phase 1 trial are to assess the safety and maximum tolerated dose, or MTD, of PRGN-3005. For both routes of administration, PRGN-3005 will follow a 3+3 dose escalation pattern. We are conducting this trial in collaboration with The University of Washington and The Fred Hutchinson Cancer Research Center, leaders in immunotherapy and CAR-T treatments. We expect to enroll up to 71 patients total in this study.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g11.jpg" alt="pgen-20201231_g11.jpg" style="height:225px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced the FDA clearance of our UltraPorator system, a proprietary electroporation device and software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T therapies, as a manufacturing device for clinical trials of our investigational UltraCAR-T therapies in compliance with cGMP. In November 2020, we announced that we have successfully dosed the first patient in the PRGN-3005 Phase 1 trial using UltraCAR-T cells manufactured using the UltraPorator system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we presented preliminary data from the first six patients treated with PRGN-3005, who were treated at the two lowest dose levels in the IP arm without prior lymphodepletion. The six patients were treated at either Dose Level 1 (&gt;3x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - &#8804; 1 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> UltraCAR-T cells/kg; N=3) or Dose Level 2 (&gt;1x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - &#8804; 3 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> UltraCAR-T cells/kg; N=3). Patients had received between 6 and 9 prior therapies before enrolling in the PRGN-3005 study. Preliminary data from these patients showed that PRGN-3005 was well-tolerated, with no dose-limiting toxicities, or DLTs, neurotoxicities, or cytokine release syndromes reported. PRGN-3005 UltraCAR-T cells showed encouraging expansion and persistence after low dose IP infusion without lymphodepletion across both dose levels. In addition, 50 percent (3 out of 6) of the patients experienced regression in total target tumor burden and 33 percent (2 out of 6) patients achieved stable disease according to RECIST v1.1 criteria at their restaging evaluation. In addition, we believe that our consistent ability to successfully manufacture UltraCAR-T cells at a medical center confirms the validity of our rapid, decentralized approach to manufacturing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment is ongoing in the IP arm of the trial, and an expansion phase is planned at the MTD. We have received clearance from the FDA to initiate dosing in the IV arm of the trial concurrently with the IP arm.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRGN-3006</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-3006 is a first-in-class, investigational autologous CAR-T therapy that utilizes our UltraCAR-T platform to express a CAR to target CD33, mbIL15 and a kill switch for better precision and control.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="pgen-20201231_g12.jpg" alt="pgen-20201231_g12.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD33, also known as Siglec-3, is a single pass transmembrane glycoprotein and a member of the sialic acid-binding immunoglobulin-like lectin super-family. CD33 is an attractive target for immunotherapy because it is over-expressed on AML blasts and leukemic stem cells, or LSCs, but is not expressed on normal blood stem cells, also known as hematopoietic stem cells. Approximately 85-90 percent of AML patients express CD33 on their tumor cells. In addition to broad expression on AML blasts, CD33 is expressed on LSCs underlying AML.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSCs are thought to be more resistant to chemotherapy treatment and to be capable of reinitiating the disease resulting in high relapse rates for AML. In healthy subjects, CD33 is primarily expressed on normal myeloid precursors, colony-forming cells, monocytes, and maturing granulocytes. Because CD33 is not expressed outside the hematopoietic system or on normal hematopoietic stem cells, it is an attractive target for treatment of AML.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AML is among the most common types of leukemia in adults with approximately 20,000 AML patients diagnosed in the United States annually. AML is a heterogeneous disease with 50-70 percent relapse rates and rapid progression. The prognosis for patients with AML is poor, with an average five-year survival rate of approximately 25 percent. More than 10,000 cases of higher-risk MDS are diagnosed annually in the United States. Due to the aggressive nature of AML progression, rapid availability of treatment is of even greater importance in this patient population, and our non-viral UltraCAR-T manufacturing process would represent a significant potential advantage over current approaches that require long lead times for manufacturing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, PRGN-3006 demonstrated robust expansion in the presence of CD33 antigen, lack of autonomous expansion in the absence of CD33 and prolonged persistence in the absence of exogenous cytokines. PRGN-3006 exhibited target-specific killing of CD33</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor cells as well as a significant release of inflammatory cytokines such as IFN&#947;, upon co-culture with AML tumor cells. PRGN-3006 cells were specifically eliminated by kill switch activator treatment, displaying functionality of the kill switch, which is intended to improve the safety profile of PRGN-3006. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a single administration of PRGN-3006 UltraCAR-T cells only one day after gene transfer effectively eliminated the tumor burden and significantly improved overall survival of tumor bearing mice compared to CAR-T cells lacking mbIL15 expression (conventional CAR-T) in an aggressive xenograft model of AML. PRGN-3006 demonstrated engraftment and significantly higher expansion and persistence in mice compared to conventional CAR-T cells, which lack mbIL15 expression.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-3006 is currently being evaluated in an investigator-initiated Phase 1/1b trial. The Phase 1 portion of this study is a dual-arm, non-randomized, dose-escalation clinical trial where PRGN-3006 is delivered via intravenous infusion. The patient population includes relapsed or refractory AML, higher-risk MDS, and CMML.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 3+3 dose escalation phase, patients will be treated in one of the two arms: patients in Arm 1, or No Lymphodepletion arm, will receive UltraCAR-T cell infusion without prior lymphodepletion, and patients in Arm 2, or Lymphodepletion arm, will receive lymphodepleting chemotherapy prior to UltraCAR-T infusion. Because our UltraCAR-T cells have the potential for enhanced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion and persistence due to expression of mbIL15, we are evaluating the administration of PRGN-3006 in patients without prior lymphodepletion. The primary objective of this trial is to assess the safety of PRGN-3006 and determine the MTD. The Phase 1 trial is being conducted in collaboration with Moffitt Cancer Center, a pioneer in CAR-T clinical development.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g13.jpg" alt="pgen-20201231_g13.jpg" style="height:213px;margin-bottom:5pt;vertical-align:text-bottom;width:446px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced the FDA clearance of our UltraPorator system as a manufacturing device for clinical trials of our investigational UltraCAR-T therapies in compliance with cGMP. In November 2020, we announced that we have successfully dosed the first patient in the PRGN-3006 Phase 1 trial using UltraCAR-T cells manufactured using the UltraPorator system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Principal Investigator of the PRGN-3006 clinical trial presented clinical progress and preliminary data from the ongoing Phase 1 trial, including a case study of a patient treated at Dose Level 2 of the No Lymphodepletion arm at the 62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASH Annual Meeting and Exposition. Later in December, we presented additional data to expand upon the preliminary data presented at the ASH Annual Meeting and Exposition. As of November 10, 2020, the cutoff date for the results, a total of nine patients had been treated in either the No Lymphodepletion arm or the Lymphodepletion arm of the trial. Of the nine patients treated, six were treated at either the Dose Level 1 (&gt;3x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - &#8804; 1 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> UltraCAR-T cells/kg; N=3) or the Dose Level 2 (&gt;1x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - &#8804; 3 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> UltraCAR-T cells/kg; N=3) of the No Lymphodepletion arm, and three were treated at the Dose Level 1 (&gt;3x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - &#8804; 1 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> UltraCAR-T cells/kg; N=3) of the Lymphodepletion arm. Preliminary data from these patients showed that PRGN-3006 was well-tolerated, with no DLTs and no neurotoxicity. Transient grade 1 to 3 cytokine release syndrome was reported in two patients, which was resolved without intervention. There was low incidence of treatment-related adverse events and serious adverse events, and Grade 3 or greater treatment-emergent adverse events included hematologic events, decreased electrolytes, and infections. PRGN-3006 UltraCAR-T showed encouraging expansion and persistence in peripheral blood of patients in both No Lymphodepletion and Lymphodepletion arms and across all dose levels. Furthermore, PRGN-3006 UltraCAR-T cells showed the ability to traffic, expand, and persist in bone marrow. In addition, we believe that our consistent ability to successfully manufacture UltraCAR-T cells at a medical center confirms the validity of our rapid, decentralized approach to manufacturing. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A case study of the patient with the longest follow-up as of the data cutoff was also presented at the ASH Annual Meeting and Exposition. The case study patient was a 69 year old female with secondary AML and four prior lines of therapy, including induction chemotherapy, or IC, allogenic hematopoietic stem cell transplantation, or allo-HSCT, hypomethylating agent plus venetoclax, or HMA+VEN. The patient was refractory to all therapy post allo-HSCT. The patient had approximately 40 percent peripheral blasts and 47 percent bone marrow blasts at baseline. The patient was treated at Dose Level 2 in No Lymphodepletion arm with a total of only 24 million UltraCAR-T cells via IV infusion. Case study findings presented showed that, after a low dose infusion without prior lymphodepletion, PRGN-3006 UltraCAR-T cells demonstrated robust expansion and persistence in blood at seven months post-infusion. PRGN-3006 UltraCAR-T cells demonstrated trafficking to bone marrow and the ability to expand and persist in bone marrow. The patient showed a decline in AML blast levels in blood and bone marrow concomitant with UltraCAR-T expansion and persistence and had durable stable disease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment is ongoing simultaneously in both the No Lymphodepletion and the Lymphodepletion arms of this Phase 1 trial. The dose escalation phase of each arm will be followed by a dose expansion phase at the MTD. PRGN-3006 was granted Orphan Drug designation for the treatment of AML by the FDA.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">"Off-the-shelf" AdenoVerse Immunotherapy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AdenoVerse immunotherapy platform utilizes a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens. We have established proprietary manufacturing cell lines and production methodologies from our AdenoVerse immunotherapy platform, which we believe are easily scalable for commercial supply. We believe that our proprietary gorilla adenovectors, which are part of the AdenoVerse technology, have superior performance characteristics as compared to current competition, including standard human adenovirus serotype 5, or Ad5, rare </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human adenovirus types and other non-human primate adenovirus types.</span></div><div style="margin-top:6pt;text-align:center"><img src="pgen-20201231_g14.jpg" alt="pgen-20201231_g14.jpg" style="height:168px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key advantages of AdenoVerse immunotherapy platform include:</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Large genetic payload capacity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gorilla adenovectors have a larger genetic payload capacity than other viral vectors that currently dominate the gene therapy field, allowing us to engineer multigenic therapeutic candidates to treat complex diseases. Currently, we are able to engineer up to a 12kb genetic payload using our gorilla adenovectors, providing us with a significant advantage to express multiple genes in a controlled manner.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repeat administration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike most competing approaches, our gorilla adenovectors are suitable for repeat administration, which can lead to boosted antibody and T cell responses. This suitability for repeat administration stems from the very low to non-existent seroprevalence of and limited immunity to gorilla adenoviruses in the human population. For example, our gorilla adenovector variant GC46 has been shown to have a seroprevalence of less than 6 percent in the United States, with low seropositive titers. In comparison, the seroprevalence of Ad5 in the United States is estimated to be 58 percent, with most of seropositive individuals having high titers. This high Ad5 seroprevalence limits the effectiveness of Ad5-based adenovectors in clinical studies. The rare and weak pre-existing immunity against gorilla adenovectors may therefore provide an advantage in clinical applications as compared to existing competition.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inability to replicate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gorilla adenovectors are engineered and manufactured using a process that ensures the production of replication incompetent adenoviral therapeutic candidates with no cytopathic or cytotoxic effect in normal human cells. This has been achieved by engineering deletions of two regions essential for replication of the adenoviral genome. The use of a proprietary complementing cell line provides the necessary genetic elements for manufacture of AdenoVerse immunotherapy candidates. We believe our AdenoVerse immunotherapy candidates have reduced regulatory and commercialization risk due to their design, which renders them incapable of replicating and therefore less susceptible to manufacturing failures. Furthermore, our gorilla adenovector manufacturing process has yielded therapeutic candidates at a very high titer and has reduced the complexity of manufacturing.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Durable antigen-specific immune response</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gorilla adenovectors have been shown in preclinical studies to generate high-level and durable antigen-specific neutralizing antibodies and effector T cell immune responses, as well as an ability to boost these antibody and T cell responses via repeat administration.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">cGMP Manufacturing Facility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our central differentiating factors and competitive gene therapy advantages is our investment in internal cGMP manufacturing capabilities in Germantown, Maryland, with the aim to reduce a myriad of risks that can impact manufacturing of viral vectors. These include technology transfer risks when outsourcing to contract manufacturing organizations as well as process and timing risks. Our modular cGMP facility with a small footprint was designed with agility and control in mind, focusing on rapid manufacturing and the ability to scale production appropriately to meet early-stage clinical trial needs of gene therapy vectors, especially our AdenoVerse-based therapeutics. We are able to generate greater than 1,000 doses of early phase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial material at this facility at an expedited timeline and reduced cost compared to contract manufacturing organizations. As a result, we feel we are in a position to be in control of meeting our gene therapy manufacturing needs for our early-phase clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGEN Therapeutics' most advanced programs based on the AdenoVerse immunotherapy platform include: (i) PRGN-2009, a first-in-class, "off-the-shelf" investigational immunotherapy utilizing the AdenoVerse platform, is designed to activate the immune system to recognize and target human papillomavirus-positive, or HPV+, solid tumors, which is in a Phase 1/2 clinical trial for patients with HPV-associated cancers in collaboration with the National Cancer Institute, or NCI, pursuant to a cooperative research and development arrangement, or CRADA; and (ii) PRGN-2012, a first-in-class, investigational "off-the-shelf" AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV type 6, or HPV6, or HPV type 11, or HPV11, which recently received investigational new drug application, or IND, approval from the FDA to initiate a Phase 1 trial in patients with recurrent respiratory papillomatosis, or RRP.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRGN-2009</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-2009, a first-in-class, "off-the-shelf" investigational immunotherapy, is designed to activate the immune system to recognize and target HPV+ solid tumors. PRGN-2009 leverages our UltraVector and AdenoVerse platforms to optimize HPV type 16, or HPV16, and HPV type 18, or HPV18, antigen design for delivery via a proprietary gorilla adenovector with a large genetic payload capacity and the ability for repeat administrations. Guided by our bioinformatics analysis and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein engineering, PRGN-2009 encodes for a novel, multi-epitope antigen design to target HPV16 and HPV18 infected cells and potentially differentiates from the competition. PRGN-2009 has been engineered using our AdenoVerse platform to be replication deficient </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV infections account for 5 percent of all cancers globally, and 690,000 new cancer cases are attributable to HPV infections per year. HPV infects the squamous cell carcinoma. Some cervical cancers come from HPV infection of gland cells in the cervix and are referred to as adenocarcinomas. HPV-related cancers include cervical, oropharyngeal, anal, penile, vaginal, and vulvar. Nearly 44,000 HPV-associated cancers occur in the United States each year. Of these, approximately 25,000 occur in women and 19,000 occur in men. HPV is considered responsible for more than 90 percent of anal and cervical cancers, about 70 percent of vaginal and vulvar cancers, and more than 60 percent of penile cancers. Recent studies indicate that about 70 percent of cancers of the oropharynx also may be related to HPV.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, PRGN-2009 treatment induced strong HPV-specific immune response and effectively controlled solid tumors in a murine model of HPV+ head and neck cancer. In a humanized mouse model of HPV+ cancer, PRGN-2009 treatment led to an increase in CD8 and CD4 T cells in the tumor microenvironment and a reduction in the tumor. In a syngeneic mouse model of HPV+ cancer, repeated injections of PRGN-2009 monotherapy resulted in generation of high levels of HPV-specific T cells, and reduction in tumor burden. The combination of PRGN-2009 with bintrafusp alfa, or M7824, an investigational bifunctional fusion protein, further reduced tumor growth, increased HPV-specific T cells, and increased T-cell infiltration into the tumor microenvironment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-2009 is in a Phase 1/2 clinical trial for patients with HPV-associated cancers in collaboration with NCI pursuant to a CRADA. The Phase 1 portion of the study will follow 3+3 dose escalation to evaluate the safety of PRGN-2009 administered as a monotherapy, Arm A, to determine the recommended Phase 2 dose, or R2PD, followed by an evaluation of the safety of the combination of PRGN-2009 at the R2PD and M7824, Arm B. The Phase 1 study population includes patients with recurrent or metastatic HPV-associated cancers. PRGN-2009 will be administered via sub cutaneous injection once every 2 weeks for three administrations and may be continued every 4 weeks for up to one year, as clinically appropriate. M7824 will be administered on Day 1 and then every 2 weeks. The Phase 2 portion of the study will evaluate PRGN-2009 as a monotherapy or in combination with M7824 as a neoadjuvant or induction therapy in patients with newly-diagnosed stage II/III HPV16-positive oropharyngeal cancer and patients with newly diagnosed operable stage II/III/IVA/IVB HPV+ sinonasal squamous cell cancer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g15.jpg" alt="pgen-20201231_g15.jpg" style="height:228px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced preliminary data from the ongoing Phase 1/2 clinical trial of PRGN-2009 in patients with HPV-associated cancers. Enrollment in the Phase 1 monotherapy dose escalation arm, Arm A, of this trial is complete, and enrollment in the Phase 1 combination arm, Arm B, has been initiated. A total of six patients were treated in the monotherapy arm. All patients in the monotherapy arm have received multiple PRGN-2009 administrations to date. Preliminary data showed that repeated administrations of PRGN-2009 was well-tolerated by these patients with no DLTs. In addition, preliminary correlative analysis by the NCI of peripheral blood mononuclear cells from three patients treated at the initial dose level showed an increase in HPV16 and/or HPV18-specific T-cell response in 100 percent (3 out of 3) patients. Furthermore, an increase in the magnitude and breadth of immune response was seen after repeat administration of PRGN-2009.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRGN-2012</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRGN-2012, a first-in-class, investigational "off-the-shelf" AdenoVerse immunotherapy for the treatment of RRP. PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses our gorilla adenovector technology, part of our proprietary AdenoVerse platform, to elicit immune responses directed against cells infected with HPV6 and HPV11. Gorilla adenovectors have numerous advantages, including the ability for repeat administration, the inability to replicate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which may improve safety, and the ability to deliver large payload capacity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a rare, difficult-to-treat, and sometime fatal neoplastic disease of the respiratory tract caused by infection with HPV6 or HPV11. RRP is classified based on age of onset as juvenile or adult. Juvenile-onset disease has an incidence of 4 per 100,000 and adult-onset RRP has an incidence of 2 to 3 per 100,000. There is no cure for RRP, and the current standard-of-care is repeated endoscopic debulking with ablation or excision of papillomatous lesions. Recurrence of papilloma after surgical removal is very common, and repeated procedures are required to debulk and monitor the disease, which exposes patients to anesthetic and surgical risks and emotional distress. Some patients require a tracheotomy and need a trach tube indefinitely to keep the breathing passage open. RRP morbidity and mortality results from the effects of papilloma mass on the vocal cords, trachea, and lungs, which may cause voice changes, stridor, airway occlusion, loss of lung volume, and/or post-obstructive pneumonia. Although rare, one to three percent of RRP cases can transform into invasive squamous cell carcinoma. In addition, more than 90 percent of genital warts are related to HPV6 and HPV11 infection.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g16.jpg" alt="pgen-20201231_g16.jpg" style="height:189px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical models, PRGN-2012 has demonstrated strong HPV6 and HPV11-specific T-cell response in RRP patient samples </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced that the FDA had cleared the IND to initiate the Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in adult patients with RRP. The Phase 1 study will follow 3+3 dose escalation of PRGN-2012 as an adjuvant immunotherapy following standard-of-care surgical removal of visible papillomatosis disease. Patients will receive up to four injections of PRGN-2012. The primary objective of the study is to determine safety and tolerability and the recommended Phase 2 dose of PRGN-2012. The study will enroll 3 to 6 subjects at each dose level, and 12 patients will be treated at the MTD. PRGN-2012 is being developed in collaboration with the Center for Cancer Research at the NCI through a CRADA.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a robust pipeline of preclinical programs that we are pursuing in order to drive long-term value creation. Our pipeline includes a number of product candidates, including UltraCAR-T therapeutics for various cancers, an "off-the-shelf" AdenoVerse immunotherapy for infectious disease, and a multifunctional therapeutic for solid tumors. We expect to continue development of various preclinical programs to identify product candidates for evaluation in clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating multiple UltraCAR-T candidates for treatment of hematological and solid tumors in preclinical testing. We recently introduced our vision for a new UltraCAR-T library approach aimed at transforming the personalized cell therapy landscape for cancer patients. Our goal is to develop and validate a library of non-viral plasmids to target tumor-associated antigens.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing PRGN-2013, a preclinical stage asset based on our "off-the-shelf" AdenoVerse immunotherapy platform, to treat chronic hepatitis B virus, or HBV, infection. HBV can cause serious health problems, including liver damage, cirrhosis, liver cancer, and death. Preclinical studies of PRGN-2013 showed that mice treated with PRGN-2013 saw (i) a more significant cytotoxic T-cell response against more HBV epitopes and (ii) decreased plasma levels of HBsAg, the key marker of chronic HBV infection in mice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing immuno-oncology product candidates based on our Multifunctional Therapeutic platform to target solid tumors. Additional preclinical programs under development include an AdenoVerse cytokine therapy candidate for solid tumors and candidates to target autoimmune disorders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a number of other potential product candidates in our preclinical pipeline and, consistent with our commitment to actively manage our portfolio programs, we exercise discipline in our portfolio management by systematically evaluating data from our preclinical programs in order to make rapid "go" and "no go" decisions. Through this process, we believe we can more effectively allocate resources to programs that we believe show the most promise and advance such programs to clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Precigen ActoBio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ActoBio is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. We refer to these microbe-based biopharmaceuticals as ActoBiotics.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Precigen ActoBio's Therapeutic Platforms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ActoBiotics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ActoBiotics platform is a unique therapeutic platform precisely tailored for specific disease modification with the potential for superior efficacy and safety. ActoBiotics combine the advantages of highly selective protein-based therapeutic agents with local delivery by the well-characterized and food-grade bacterium </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lactococcus lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L. lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ActoBiotics can be delivered orally in a capsule, through an oral rinse or in a topical solution. We believe ActoBiotics have the potential to provide superior safety and efficacy via the sustained release of appropriate quantities of select therapeutic agents as compared to injectable biologics, while reducing the side effects commonly attributed to systemic delivery and corresponding peaks in concentration. ActoBiotics work via genetically modified bacteria that deliver proteins and peptides at mucosal sites, rather than the insertion of one or more genes into a human cell by means of a virus or other delivery mechanism. By foregoing this insertion, ActoBiotics allow "gene therapy" without the need for cell transformation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key advantages of ActoBiotics include:</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Food-grade bacterium with easy genetic manipulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ActoBiotics combine the advantages of highly selective protein-based therapeutic agents with local delivery by the well-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characterized and food-grade bacterium with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L. lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which has a long history of safe use. ActoBiotics are generated by genetically modifying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L. lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> via chromosomal integration through targeted double homologous recombination to express and release a variety of highly versatile biological moieties. Multiple therapeutic agents, such as proteins, peptides, and antibodies, can be incorporated into a single ActoBiotics therapeutic, enabling the simultaneous targeting of multiple pathways in one disease. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L. lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> host is also engineered for environmental containment, thus preventing the spread of bacteria outside the human body.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost-effective and scalable manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established an efficient and reliable cGMP manufacturing process for the production of ActoBiotics that we believe is easily scalable for commercial supply. The manufacturing process involves fermentation of genetically modified </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">L. lactis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to generate significant quantities of the therapeutic agent, followed by concentration and freeze-drying. The process does not require the costly purification required to produce conventional biologics.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convenient delivery method</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ActoBiotics can be delivered to the oral cavity through a mouthwash, intestinally via a capsule, or through a topical formula. Physiological dosing is low, and our ActoBiotics product candidates have been well-tolerated in preclinical and clinical studies. As compared to conventional biologics, we believe ActoBiotics have the potential to provide superior safety and efficacy via the sustained release of appropriate quantities of select therapeutic agents while reducing the side-effects commonly attributed to systemic delivery and corresponding peaks in concentration of conventional biologics.</span></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g17.jpg" alt="pgen-20201231_g17.jpg" style="height:209px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ActoBio's most advanced internal pipeline candidate, AG019, is a first-in-class disease modifying antigen-specific, investigational immunotherapy for the prevention, delay, or reversal of type 1 diabetes mellitus, or T1D. AG019 is an easy-to-take capsule formulation of ActoBiotics engineered to deliver the autoantigen human proinsulin, or PINS, and the tolerance-enhancing cytokine human interleukin-10 to the mucosal lining of gastro-intestinal tissues in patients with T1D. We believe this design can reduce T1D pathology by reestablishing immunological tolerance to islet antigens via the production of regulatory T, or Treg, cells.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T1D represents a highly unmet medical need, with approximately 132,000 patients, most commonly children and young adults, diagnosed each year. In T1D, the immune system destroys insulin-producing beta cells in the pancreas, creating a blood glucose imbalance and numerous symptoms, including polyuria, polydipsia, polyphagia, weight loss, lassitude, nausea and blurred vision. The current treatment standard for T1D consists of exogenous insulin along with diet and lifestyle modification, but no disease-modifying treatment is available. We believe that AG019 has the potential to address the unmet medical need for disease modifying treatment in T1D.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies in mice have shown that AG019, in association with a short-term treatment with a low-dose anti-CD3 monoclonal antibody, induced stable reversion to normal blood sugar levels and reversed the disease in diabetic mice treated at an early stage. Furthermore, AG019 treatment induced accumulation and proliferation of PINS-specific FoxP3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Treg cells in the pancreas and peripheral lymph nodes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG019 is currently in a Phase 1b/2a clinical trial for the treatment of early-onset T1D. The Phase 1b portion of the study evaluates the safety and tolerability of AG019 monotherapy administered as a single dose and repeated daily doses in adult and adolescent patients. Enrollment and dosing in the Phase 1b and Phase 2a portions of the study are complete. The Phase 2a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portion of the study investigates the safety and tolerability of AG019 in combination with teplizumab, or PRV-031. In August 2020, we announced that the primary endpoint of assessing safety and tolerability in the Phase 1b monotherapy portion of the study was met and that preliminary results at six months after AG019 monotherapy treatment initiation showed an encouraging trend in the insulin C-peptide levels, a biomarker for T1D disease progression. In December 2020, we announced additional data from our ongoing Phase 1b portion and initial preliminary data from the Phase 2a portion of our ongoing Phase 1b/2a clinical trial. The additional data from the Phase 1b monotherapy portion of the trial showed that AG019 continued to be well-tolerated, with no discontinuations due to treatment-emergent adverse events. From the perspective of clinical activity, this data showed that 58 percent (7 of 12) of patients aged 17 or older receiving the AG019 monotherapy showed stabilization of C-peptide levels during the first six months of treatment and slower decline in C-peptide levels after being treated for 12 months as compared to treatment with placebo. In addition, a mechanistic analysis performed by an independent research group found the induction of antigen-specific tolerance in conjunction with the reduction of disease-specific T cell responses for adult patients after three months of treatment with AG019. We believe these results indicate the potential of AG019 to preserve insulin production in early-onset T1D through AG019's capacity to induce antigen-specific immune modulation. Data from the Phase 2a combination portion with teplizumab showed that the combination was well-tolerated. This data showed that 70 percent of adult patients (7 of 10) experienced stabilization of C-peptide levels after six months of treatment with a trend toward higher C-peptide levels as compared to baseline levels. Mechanistic data were consistent with the data shown in the monotherapy trial, which we believe indicates the effect may be attributed to AG019. We believe preliminary results in the combination trial point to the potential to boost or prolong teplizumab-induced metabolic effects. No dose-related adverse events or serious adverse events were reported in either portion of this trial.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Precigen Triple-Gene</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triple-Gene is a clinical stage gene therapy company focused on developing advanced treatments for complex cardiovascular diseases. Triple-Gene's approach is to develop a holistic treatment for heart failure through improvements in angiogenesis, calcium homeostasis-associated cellular energetics, reductions in inflammatory signals, and the activation/recruitment of stem cells to support heart remodeling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Triple-Gene's most advanced candidate, INXN-4001, a non-viral triple effector plasmid based on our UltraVector platform designed for the constitutive expression of human S100A1, SDF-1a, and VEGF-165, is engineered to address multiple pathways of heart failure. Utilizing a single plasmid comprising all three genes, instead of each individual gene on separately delivered plasmids, INXN-4001 can control for delivery and ensure expression of three genes in all transfected cells.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heart failure represents a significant unmet medical need and a major economic burden worldwide. There are approximately 25 million heart failure patients worldwide, of whom 6 million are in the United States. Heart failure is the number one cause of hospitalization in patients aged 65 years and older, and 50 percent of heart failure patients die within five years after diagnosis. Heart failure is a complex and multifaceted disease most often resulting from the intersection of multiple genetic predispositions with negative environmental factors. Existing treatments improve quality of life in the short-term and offer some improvement in long-term survival at high cost and with associated complications. We believe that developing a holistic and clinically relevant treatment for heart failure will require improvements in numerous areas, including angiogenesis, calcium homeostasis-associated cellular energetics, reductions in inflammatory signals, and the activation or recruitment of stem cells to support heart remodeling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies of INXN-4001 showed significant improvement in beat rate, contractile duration and contraction rate of human induced pluripotent stem cell-derived cardiomyocytes in a dilated cardiomyopathy model to the levels demonstrated by control cells and did not result in increased cell death compared to controls. Coronary sinus delivery of INXN-4001 in a large animal ischemic heart failure model showed decreased left ventricular end systolic volume and increased absolute mean ejection fraction, which are indicators of myocardial function, as well as no increase in arrhythmias compared to controls.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently completed our Phase 1 clinical trial of INXN-4001, which was a first-in-human, open label study designed to evaluate the safety of retrograde coronary sinus infusion, or RCSI, of INXN-4001 in outpatient left ventricular assist device, or LVAD, recipients. Twelve stable patients with implanted LVAD for mechanical support of end stage heart failure were allocated into two cohorts of six subjects for infusion of the same amount of INXN-4001 (80mg) in either 40mL or 80mL via RCSI at a rate of 20mL per minute. The primary objectives of the Phase 1 study are to evaluate the safety of INXN-4001 infusion into the myocardium of LVAD patients and to demonstrate safety and feasibility of RCSI. Secondary endpoints include improvements in the six minute walk test, or 6MWT, duration and distance and quality of life, as assessed by Kansas City Cardiomyopathy Questionnaire, or KCCQ, responses. We have completed dosing and follow-up of patients in this trial.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we provided six-month follow-up data from the Phase 1 study of INXN-4001. Twelve chronic heart failure patients were treated with INXN-4001 in either Cohort 1 (80 mg/40 mL; n=6) or Cohort 2 (80 mg/80 mL; n=6), and ten were </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluated for six-month follow-up. The study has met the primary endpoints to evaluate safety and feasibility for INXN-4001. The infusions of INXN-4001 were overall well tolerated, with no adverse events attributed to INXN-4001, whereas one serious adverse event was considered related to the infusion procedure. Furthermore, preliminary assessment of the secondary endpoints show improvement by at least five points in total KCCQ score, a validated tool qualified by the FDA for Clinical Outcome Assessment, was observed in 50 percent of patients evaluable (5 out of 10) at the six-month follow-up visit, These included four patients treated in Cohort 1 and one patient treated in Cohort 2. Of the evaluable patients, 50 percent (4 out of 8) had an improvement in the 6MWT (&gt; 50 meters in distance walked) at six months post-infusion compared to pre-treatment baseline. The Phase 1 trial has now been completed, and analysis of final results is ongoing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Precigen Exemplar</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exemplar is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. Historically, researchers have lacked animal models that faithfully represent human diseases. As a result, a sizeable barrier has blocked progress in the discovery of human disease mechanisms; novel diagnostics, procedures, devices, prevention strategies and therapeutics; and the ability to predict in humans the efficacy of those next-generation procedures, devices, and therapeutics. Exemplar's MiniSwine models are genetically engineered to exhibit a wide variety of human disease states, which provides a more accurate platform to test the efficacy of new medications and devices.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Program</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have partnered with Castle Creek Biosciences, Inc. (formerly Fibrocell Science, Inc.), or Castle Creek, to advance product candidates D-Fi (debcoemagene autoficel), formerly designated FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB, and FCX-013 for the treatment of localized scleroderma. In October 2020, Castle Creek announced the dosing of the first patient in the ongoing Phase 3 trial of D-Fi and the dosing of the first patient in the ongoing Phase 1/2 trial of FCX-013. The FDA has granted Orphan Drug designation to D-Fi for the treatment of Dystrophic Epidermolysis Bullosa, which includes RDEB. In addition, D-Fi has been granted Rare Pediatric Disease designation, Fast Track designation, and Regenerative Medicine Advanced Therapy designation by the FDA for treatment of RDEB. The FDA has granted Orphan Drug designation to FCX-013 for the treatment of localized scleroderma. In addition, FCX-013 has been granted Rare Pediatric Disease designation and Fast Track designation for the treatment of moderate to severe localized scleroderma. Pursuant to the collaboration, we licensed our technology platforms to Castle Creek for use in certain specified fields, and in exchange, we received and were entitled to certain access fees, milestone payments, royalties, and sublicensing fees related to the development and commercialization of product candidates. In March 2020, we and Castle Creek terminated the original collaboration agreement by mutual agreement, with the parties agreeing that FCX-007 and FCX-013 would be treated as "Retained Products" under the terms of the original agreement. Castle Creek retains a license to continue to develop and commercialize the Retained Products within the field of use for so long as Castle Creek continues to pursue such development and commercialization, and we are also entitled to certain royalties with respect to the Retained Products. We are also required to perform certain drug product manufacturing activities related to the Retained Products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition: Healthcare Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our novel approach to developing the next generation of gene and cell therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases provides us with competitive advantages, our industry is highly competitive and subject to rapid and significant technological change. Many of our competitors have significantly greater financial, technical, and human resource capabilities than we do, and certain of our competitors may also benefit from local government subsidies and other incentives that are not available to us. In addition, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of the resources available to our competitors, our competitors may be able to develop competing and/or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we can. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates that we successfully develop and commercialize will compete with a range of therapies that are currently approved and any new therapies that may become available in the future. Our ability to compete successfully will depend on our ability to develop proprietary technologies that can be used to produce products that reach the market in a timely manner and are technologically superior to and/or are less expensive than other products on the market. The availability of reimbursement from government and other third-party payers will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the market. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products, as well as the availability of intellectual property protection.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-oncology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidates include PRGN-3005 for the treatment of ovarian cancer and PRGN-3006 for the treatment of AML, which are built on our UltraCAR-T platform, and PRGN-2009, which is based on our AdenoVerse immunotherapy platform. While we are employing a novel approach, there are a number of competitors pursuing CAR-T cell therapies for the treatment of cancer. We believe that, among others, Bristol-Myers Squibb, Tmunity Therapeutics, and MaxCyte are developing CAR-T based treatments for ovarian cancer and TCR2 Therapeutics is developing TCR-T based treatment for ovarian cancer. We believe that Celyad, Mustang Bio, Amgen, Cellectis S.A., and Allogene Therapeutics are also using CAR-T technology to develop product candidates for the treatment of AML. We believe that INOVIO Pharmaceuticals, AstraZeneca, Transgene SA, and Advaxis Immunotherapies are developing immunotherapies against HPV-associated cancers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bristol-Myers Squibb's product candidate, JCAR020, is a MUC16-IL-12 armored T-cell therapy being developed to treat ovarian cancer. Similar to our UltraCAR-T platform, this product candidate targets MUC16 on ovarian tumors. JCAR020 is engineered with "armored CAR" technology to co-express CAR and IL-12, a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity. Tmunity Therapeutics is developing Tm Tn-MUC 01 CAR-T for various solid tumors including ovarian cancer. This candidate targets TnMUC-1 antigen on tumor cells. Tmunity Therapeutics is also developing TmFR&#945;01 CAR-T targeting folate receptor alpha for ovarian cancer. MaxCyte's MCY-M11 is a mesothelin-specific human mRNA CAR-T cell therapy being developed to treat ovarian cancer. MCY-M11 is a non-viral approach that uses repeated infusions of mesothelin-specific messenger RNA (mRNA) transfected T cells transiently expressing CAR to permit prospective control of 'on-target/off-tumor' toxicity. TCR2 Therapeutics' TC-210 targets mesothelin and is based on TCR Fusion Construct T cells, or TRuC-T cells, technology and is manufactured using lentiviral transduction of autologous T cells.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the treatment of AML using CAR-T therapies, we believe that Celyad and Mustang Bio have product candidates in the most advanced clinical trials. Celyad's product candidate, CYAD-02, is an NKG2D-based CAR-T with co-expression of a single shRNA targeting NKG2DL, MICA and MICB, that uses the OptimAb manufacturing process, which generates a higher frequency of less differentiated CAR-T cells. CYAD-02 is in clinical trials for r/r AML or MDS patients. Mustang Bio's product candidate, MB-102, is an autologous CAR-T cell therapy that is produced by engineering patient T cells to recognize and eliminate CD123-expressing tumors. Amgen is developing AMG 553, an FMS-like tyrosine kinase 3, or FLT3, CAR-T cell therapy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing autologous T cells genetically modified </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to express a transmembrane CAR to target FLT3 protein on the surface of AML cells irrespective of FLT3 mutational status. Cellectis S.A. is also developing UCART123, an allogeneic anti-CD123 CAR-T cell therapy, which utilizes lentivector transduction followed by TALEN-mediated gene editing to eliminate expression of TCR&#945;&#946; from donor T cells. Finally, Allogene Therapeutics' allogeneic CAR-T therapies ALLO-316 and ALLO-819, targeting FLT3 and CD70, respectively, which we believe are in preclinical development for AML, are manufactured using healthy donor T-cells that are engineered using lentiviral transduction to express CAR followed by gene editing to eliminate expression of TCR to reduce the potential of rejection of therapy by a patient's immune system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our direct competitors that are using CAR-T therapies specifically for the treatment of ovarian cancer and AML, the CAR-T technology space has significant other competition including from multiple companies and their collaborators, such as Novartis and University of Pennsylvania, Kite and Gilead, Adaptimmune and GSK, Autolus Therapeutics, Poseida Therapeutics, and Bellicum Pharmaceuticals. We also face competition from non-cell based cancer treatments offered by other companies such as Amgen, AstraZeneca, Incyte, Merck, Abbvie, and Roche.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Our Therapeutic Platforms - UltraCAR-T," "Our Product Pipeline - PRGN-3005" and "Our Product Pipeline - PRGN-3006" for a discussion of the features that we believe differentiate UltraCAR-T treatments in general and PRGN-3005 and PRGN-3006 specifically from our competitors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the treatment of HPV-associated cancers, we believe that INOVIO Pharmaceuticals, AstraZeneca, and Transgene S.A. are developing immunotherapies that are in clinical testing. TG4001 is an investigational therapeutic cancer vaccine candidate using an attenuated and modified poxvirus, or MVA, as a vector expressing the HPV16 E6 and E7 proteins and interleukin-2. We believe TG4001 is in a clinical trial in combination with anti-PD-L1 antibody avelumab for recurrent HPV+ cancers. INOVIO's lead investigational candidate VGX-3100 is a plasmid DNA based vaccine designed to increase T cell immune responses against the E6 and E7 antigens of HPV16 and HPV18. VGX-3100 is in clinical trials for precancerous cervical dysplasia. We believe AstraZeneca's MEDI0457, an investigational DNA vacine designed by INOVIO, is in clinical trials for various HPV-associated cancers. MEDI0457 is a multi-component DNA vaccine that uses different DNA plasmids to express modified sequences for E6 and E7 antigens of HPV16 and HPV18 and immune activator interleukin-12, or IL-12. Cellid is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing BVAC-C, which is based on CeliVax technology that uses patient-derived B cells and monocytes transfected with E6/E7 recombination gene of HPV16 and HPV18 and loaded with an adjuvant for HPV-associated cancers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our direct competitors developing vaccines for treatment of HPV-associated cancers, various development-stage companies are involved in different vaccine and immunotherapy technologies, including Advaxis Immunotherapies, Bavarian Nordic, and Altimmune. We also face competition from non-vaccine based approaches being developed by companies such as Kite, Iovance, Bristol-Myers Squibb, and Merck.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infectious Diseases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate is PRGN-2012, which is based on our AdenoVerse immunotherapy platform, for the treatment of RRP. While we believe our approach for PRGN-2012 is novel based on the design of antigen targeting HPV6 and HPV11 and use of our gorilla adenovector, we face competition in the treatment of RRP. We believe our main competitor in the field is INOVIO Pharmaceuticals with their investigational DNA vaccine INO-3107 targeting HPV6 and HPV11 antigens.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Autoimmune Disorders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also using our suite of proprietary and complementary synthetic biology technologies for the preclinical and clinical development of product candidates for the treatment of autoimmune disorders, including T1D. While we believe AG019 is the first disease-modifying treatment for T1D, there are a number of competitors pursuing immunotherapy product candidates to treat T1D. We believe that our primary competitors with respect to the development of immunotherapies for T1D are Provention Bio, Midatech Pharma, and MerciaPharma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply a multilayered approach for protecting intellectual property relating to the inventions we have developed internally, as well as those we have acquired from third parties, such as by assignment or by in-license. As we advance technologies, we evaluate and determine under the circumstances what type or types of intellectual property is appropriate for the technology, including patents, trademarks, know-how and trade secret protections. We seek patent protection in the United States and in other countries for our inventions, and we develop and protect our know-how and trade secrets relating to our platform technologies, as well as to our pipeline products including those of our subsidiaries and collaborators.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, we pursue protection to switch technologies,&#160;gene delivery technologies, and genetic componentry related to our pipeline products. In addition, we seek patents covering specific collaborator's products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our intellectual property on aspects of our platforms and technologies that provide for the design and creation of cells, vectors and components for our pipeline and the pipelines of our collaborators, as well as technologies directed to improve delivery and expression of our pipeline products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, upon our ability to obtain patents and maintain adequate protection for our intellectual property relating to our technologies and product pipeline. We have adopted a strategy of seeking patent protection in the United States and in other jurisdictions globally as we deem appropriate under the circumstances, with respect to certain of the technologies used in or relating to our technologies and product pipeline. For instance, where we believe appropriate, we have counterpart patents and patent applications in other jurisdictions, such as Australia, Brazil, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Korea, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and Taiwan. In the future, we may file in these or additional jurisdictions as deemed appropriate for the protection of our technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we owned or in-licensed at least 55 issued United States patents and 40 pending United States patent applications relating to various aspects of our platforms and technologies, and we have pursued counterpart patents and patent applications in other jurisdictions around the world, as we have deemed appropriate. We continue to actively develop our portfolio through the filing of new patent applications, provisional and continuations or divisionals relating to our advancing technologies, methods and products as we and our collaborators deem appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work to maintain protection for our key technologies including: our various switch technologies, with a last to expire patent currently in 2038; our portfolio around various gene delivery technologies and their use, with a last to expire patent in 2040; and our portfolio around various genetic componentry such as specialized vectors containing these genetic componentry and their use, with a last to expire patent in 2042. Although we have no certainty that these patents will not be subject to challenge in the future, as of this filing, there are currently no material contested proceedings and/or third-party claims with respect to any of these patent portfolios.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we complement our intellectual property portfolio with exclusive and non-exclusive patent licenses and options for licenses to third-party technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We further solidify our intellectual property protection through a combination of trade secrets, know-how, confidentiality, nondisclosure and other contractual provisions, and security measures to protect our confidential and proprietary information related to each platform and collaborator program. We regularly assess and review the risks and benefits of protecting our developments through various aspects of intellectual property available to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on trade secrets, know-how, and continuing technological advances to protect various aspects of our technology, we require our employees, consultants and scientific collaborators to execute confidentiality and invention assignment agreements with us to maintain the confidentiality of our trade secrets and proprietary information. Our confidentiality agreements generally provide that the employee, consultant or scientific collaborator will not disclose our confidential information to third parties. These agreements also provide that inventions conceived by the employee, consultant or scientific collaborator in the course of working for us will be our exclusive property. Additionally, our employees agree to take certain steps to facilitate our assertion of ownership over such intellectual property. These measures may not adequately protect our trade secrets or other proprietary information. If they do not adequately protect our rights, third parties could use our technologies, and we could lose any competitive advantage we may have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access to our trade secrets, which could impair any competitive advantage we may have.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our diverse portfolio of proprietary technologies and novel therapeutic candidates, we are subject to significant and diverse regulations governing, among other things, research, operations and product approval. Regulatory compliance is critical to our ability to operate, our management of potential liabilities, and ultimately, our freedom to sell our products. Moreover, the products we are pursuing or are produced by us are subject to extensive regulation. We also rely on our collaborators' compliance with laws and regulations applicable to the products they produce. We do not independently monitor whether our collaborators comply with applicable laws and regulations. Please see the risk factor entitled "We rely on third parties, including through collaborations, to develop and commercialize some of our product candidates. Markets in which our collaborators are developing product candidates using our technologies are subject to extensive regulation, and we rely on our collaborators to comply with all applicable laws and regulations."</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental regulations affecting us and our collaborators</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground; the generation, storage, handling, use, transportation and disposal of hazardous materials; and the health and safety of employees with respect to laboratory activities required for the development of products and technologies. These laws and regulations require us and our collaborators to obtain environmental permits and comply with numerous environmental restrictions. These laws and regulations also may require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory activities and those of our collaborators inherently involve the use of potentially hazardous materials, which are subject to health, safety and environmental regulations. We design our infrastructure, procedures, and equipment to meet our obligations under these regulations. We perform recurring internal and third-party audits and provide employees ongoing training and support, as required. All of our employees must comply with safety instructions and procedures, which are codified in our employment policies. Federal and state laws and regulations impose requirements on the production, importation, use, and disposal of chemicals and genetically-modified microorganisms which impact us and our collaborators. Our and our collaborators' processes may contain genetically engineered organisms which, when used in industrial processes, are considered new chemicals under the Toxic Substances Control Act program of the United States Environmental Protection Agency, or EPA. These laws and regulations would require us and our collaborators to obtain and comply with the EPA's Microbial Commercial Activity Notice process to operate. In the European Union, we and our collaborators may be subject to a chemical regulatory program known as REACH (Registration, Evaluation, Authorization and Restriction of Chemical Substances). Under REACH, companies are required to register their products with the European Commission, and the registration process could result in significant costs or delay the manufacture or sale of products in the European Union.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations affecting us and our collaborators</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human therapeutics regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, sale, marketing, import and export of therapeutic products such as those being developed by us and our collaborators. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes, regulations, and requirements imposed by regulatory agencies, require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceuticals and biological products must receive approval from the FDA before being marketed. The FDA approves drug products other than biological products through its authority under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The FDA licenses biological products, or biologics, through its authority under the Public Health Service Act, or PHSA, and implementing regulations. The development processes for obtaining FDA approval for a non-biological drug product under the FDCA and for biologic licensure under the PHSA are generally similar but have product-related differences reflected in regulations and in FDA guidance documents.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States pharmaceutical development process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a pharmaceutical product candidate may be marketed generally involves the following:</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;studies in accordance with applicable regulatory requirements, which may include the FDA's current Good Laboratory Practice regulations and the Animal Welfare Act;</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials commence;</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials according to the FDA's Good Clinical Practices, or GCP, regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed product candidate for each intended use;</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of an application for marketing approval that includes substantial evidence of safety, purity and potency for a biologic, or of safety and efficacy for a non-biologic drug, including from results of nonclinical testing and clinical trials;</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product candidate is produced to assess compliance with cGMP and that the methods and controls are adequate to assure the product candidate's identity, safety, strength, quality, potency and purity;</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA inspection of the nonclinical and clinical trial sites that generated the data in support of the application; and</span></div><div style="margin-top:12pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the application.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical testing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any product candidate in humans in the United States, a company must develop preclinical data, generally including laboratory evaluation of the product candidate's chemistry and formulation, as well as toxicological and pharmacological studies in animal species to assess safety and quality. Certain types of animal studies must be conducted in compliance with the FDA's Good Laboratory Practice regulations and the Animal Welfare Act, which is enforced by the Department of Agriculture.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IND application</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A person or entity sponsoring clinical trials in the United States to evaluate a product candidate's safety and effectiveness must submit to the FDA, prior to commencing such trials, an IND application, which contains preclinical testing results and other data and information that allow the FDA to evaluate whether there is an adequate basis for testing the drug in humans. If the FDA does not object to the IND application within 30 days of submission, the clinical testing proposed in the IND may begin. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after the IND has gone into effect and clinical testing has begun, the FDA may put clinical trials on "clinical hold," suspending or, in some cases, ending them because of safety concerns or for other reasons.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human clinical trials under an IND</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve administering the product candidate to healthy volunteers or patients under the supervision of qualified investigators. Clinical trials must be conducted and monitored in accordance with the FDA's regulations, such as GCP requirements. Each clinical trial must also be conducted under a protocol that details, among other things, the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. The protocol is submitted to the FDA as part of the IND and reviewed by the agency. Further, each clinical trial must be reviewed and approved by an Institutional Review Board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers, among other things, whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The sponsor of a clinical trial, the investigators, and IRBs each must comply with requirements and restrictions that govern, among other things, obtaining informed consent from each study subject, complying with the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting adverse events. Clinical trials involving recombinant or synthetic nucleic acid molecules, such as DNA, conducted at institutions that receive any funding from the National Institutes of Health also must be reviewed by an institutional biosafety committee, an institutional committee that reviews and oversees basic and clinical research that utilizes recombinant DNA at that institution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsor of a clinical trial or the sponsor's designated responsible party may be required to register certain information about the trial and disclose certain results on government or independent registry websites, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">clinicaltrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The product candidate is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain early understanding of its effectiveness. For some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the targeted disease.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The product candidate is administered and evaluated in a limited patient population to identify possible adverse effects and safety risks, to evaluate preliminary efficacy evidence for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The product candidate is administered to an expanded patient population with the target disease or disorder, often at geographically dispersed clinical trial sites, in adequate and well-controlled clinical trials to generate sufficient data to evaluate the safety and efficacy of the non-biologic drug, or the safety, purity, and potency of the biologic. These clinical trials are intended to establish the overall risk/benefit profile of the product candidate and provide an adequate basis for product labeling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted, or may be required to be conducted, after initial approval to further assess the risk/benefit profile of the product and to gain additional experience from treatment of patients in the intended indication, including for long-term safety follow-up.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional regulation for gene therapy clinical trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional standards apply to clinical trials involving gene therapy. The FDA has issued guidance documents regarding gene therapies, which relate to, among other things: preclinical assessments; chemistry, manufacturing and controls, or CMC, information that should be included in an IND application; the proper design of tests to measure product potency in support of an application; and long-term follow-up measures to observe delayed adverse effects in subjects exposed to investigational gene therapies when the risk of such effects is not low or when the gene therapy utilizes genome-editing technology, shows signs of persistence, has the potential for latency and reactivation, or genetically alters the human genome.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States review and approval processes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical tests and clinical trials, together with detailed information relating to the product's CMC and proposed labeling, among other things, are submitted to the FDA as part of an application requesting approval to market the product for one or more uses, or indications. When an application is submitted, the FDA makes an initial determination as to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether the application is sufficiently complete to be accepted for review. If the application is not, the FDA may refuse to accept the application for filing and request additional information. A refusal to file, which requires resubmission of the application with the requested additional information, delays review of the application. For gene therapies, selecting patients with applicable genetic defects is often a necessary condition to effective treatment and may require diagnostic devices that the FDA has cleared or approved prior to or contemporaneously with approval of the gene therapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, or PREA, certain marketing applications generally must contain data to assess the safety and effectiveness of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product candidate is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any product candidate for an indication for which orphan designation has been granted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the marketing application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the application, the FDA may issue an approval letter.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a Risk Evaluation and Mitigation Strategy, or REMS, or otherwise limit the scope of any approval. In addition, the FDA may require postmarketing clinical trials designed to further assess the risk/benefit profile of the product and to gain additional experience from treatment of patients in the intended indication, including for long-term safety follow-up.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with cGMP requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug and biologics manufacturers must comply with applicable cGMP regulations. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing of drugs. Establishments may be subject to periodic, unannounced inspections by the FDA and other government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved product application and may extend to requiring withdrawal of the product from the market.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation in the United States</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs and biological products intended to treat a "rare disease or condition," which generally is a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a marketing application or supplement seeking approval for the orphan indication. After the FDA grants orphan drug designation, the common identity of the therapeutic agent and its potential orphan use are publicly disclosed by the FDA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation does not&#8212;by itself&#8212;convey any advantage in, or shorten the duration of, the regulatory review and approval process. If a product that has an orphan drug designation subsequently receives the first FDA approval for that drug or biologic for the indication for which it has been designated, the product is entitled to an orphan exclusivity period in which the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to the seven-year exclusivity period may apply in limited circumstances, such as where the sponsor of a different version of the product is able to demonstrate that its product is clinically superior to the approved orphan drug product. This exclusivity does not prevent a competitor from obtaining approval to market a different product that treats the same disease or condition, or the same product to treat a different disease or condition. The FDA can revoke a product's orphan drug exclusivity under certain circumstances, including when the holder of the approved orphan drug application is unable to assure the availability of sufficient quantities of the drug to meet patient needs. Orphan exclusivity operates independently from other regulatory exclusivities and other protections against generic or biosimilar competition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor of a product application that has received an orphan drug designation is also granted tax incentives for clinical research undertaken to support the application. In addition, the FDA may coordinate with the sponsor on research study design for an orphan drug and may exercise its discretion to grant marketing approval on the basis of more limited product safety and efficacy data than would ordinarily be required, based on the limited size of the applicable patient population. Orphan drug designation does not, however, change the legal standard required for a product candidate to obtain FDA approval.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has a number of expedited review programs for drugs that are intended for the treatment of a serious or life-threatening condition. As one example, under the agency's Fast Track program, the sponsor of a new drug candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND for the product candidate, if nonclinical and clinical data demonstrate the product's potential to address unmet medical needs and the product is intended to treat a serious condition. The FDA must determine if the product candidate qualifies for Fast Track designation within 60 days after receipt of the sponsor's request.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other benefits, such as the ability to have more frequent interactions with the FDA, the agency may initiate review of sections of a Fast Track product's marketing application before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's review period for a Fast Track application does not begin until the last section of the marketing application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regenerative Medicine Advanced Therapy Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant regenerative medicine advanced therapy, or RMAT, designation to regenerative medicine therapies, which may include cell therapies, human gene therapies, therapeutic tissue engineering products, and human cell and tissue products, if certain criteria are met. In particular, a drug may be eligible for RMAT designation if the drug is a regenerative medicine therapy as defined in Section 506(g)(8) of the FDCA; the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease and condition. The FDA must determine if the product candidate qualifies for RMAT designation within 60 days after receipt of the sponsor's request.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A grant of RMAT designation includes all of the benefits of Fast Track designation, intensive guidance on efficient drug development beginning as early as Phase 1, and organizational commitment involving senior managers. The RMAT designation may be withdrawn by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous and extensive FDA regulation of drugs and biologics continues after approval, including requirements relating to recordkeeping, periodic reporting, product sampling and distribution, adverse experiences with the product, cGMP, and advertising and promotion. Changes to the product, manufacturing process, or facility often require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. Additionally, the FDA may require postmarketing studies or clinical trials, changes to a product's approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution restrictions, if new safety information emerges. Failure to comply with the applicable requirements may result in administrative, judicial, civil or criminal actions and adverse publicity. These actions may include FDA's refusal to approve or delay in approving pending applications or supplemental applications, withdrawal of approval, clinical hold, suspension or termination of clinical trial, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Exclusivity and Biosimilar Competition in the United States</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the federal Biologics Price Competition and Innovation Act, or BPCIA, was enacted, creating a statutory pathway for licensure, or approval, of biological products that are biosimilar to, and possibly interchangeable with, reference biological products licensed under the Public Health Service Act.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, innovator manufacturers of original biological products are granted 12 years of marketing exclusivity after first licensure before biosimilar versions of such products can be licensed for marketing in the United States. This means that the FDA may not approve an application for a biosimilar product that references data in an innovator's Biologics License Application, or BLA, until 12 years after the date of approval of the reference biological product, with a potential six-month extension of exclusivity if certain pediatric studies are conducted and the results are reported to the FDA. A biosimilar application may be submitted four years after the date of licensure of the reference biological product, but the FDA cannot approve the application until the full exclusivity period has expired. This 12-year exclusivity period operates independently from other protections that may apply to biosimilar competitors, including patents that are held for those products. Additionally, the BPCIA establishes procedures by which the biosimilar applicant must provide information about its application and product to the reference product sponsor and by which information about potentially relevant patents may be shared and litigation over patents may proceed in advance of approval. The BPCIA also provides a period of exclusivity for the first biosimilar to be determined by the FDA to be interchangeable with the reference product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, which was subsequently made applicable to biological products by the BPCIA, the FDA may also issue a Written Request asking a sponsor to conduct pediatric studies related to a particular active moiety; if the sponsor agrees and meets certain requirements, the sponsor may be eligible to receive an additional six months of marketing exclusivity for its drug product containing such active moiety.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other regulatory exclusivity may be granted to drugs, including, but not limited to, three-year and five-year exclusivity granted to non-biologic drugs under the Drug Price Competition and Patent Term Restoration Act of 1984, also referred to as the Hatch-Waxman Amendments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and specifics of FDA approval of a product candidate, some of a sponsor's United States patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product's approval date. The United States Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Only one patent applicable to an approved drug product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign regulation of human therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, our subsidiaries, such as PGEN Therapeutics and ActoBio, and our collaborators that are focused on the development of human therapeutic products will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the products enabled by our technologies. Whether or not the developer obtains FDA approval for a product, they must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before they may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Kickback, False Claims, and Other Marketing and Fraud and Abuse Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with healthcare providers, patients and third-party payers will expose us to broadly applicable United States fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and collaborative partners through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations are discussed in the "Risk Factors" section below.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privacy Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we may be subject to data privacy and security laws and regulations by both the federal government and the states in which we conduct our business. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state data breach notification laws, state health information and/or genetic privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission, or FTC, Act and the California Consumer Privacy Act, or CCPA), govern the collection, use, disclosure, and protection of health-related and other personal information. Many of these laws differ from each other in significant ways and may not have the same </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming. Federal regulators, state attorneys general, and plaintiffs' attorneys, including class action attorneys, have been and will likely continue to be active in this space.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the CCPA became effective on January 1, 2020 and establishes certain requirements for data use and sharing transparency, and provides California residents certain rights concerning the use, disclosure, and retention of their personal data. The CCPA and its implementing regulations have already been amended multiple times since their enactment. Similarly, there are a number of legislative proposals in the United States, at both the federal and state level that could impose new obligations or limitations in areas affecting our business. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. The CCPA and evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of any collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, has substantially changed the way healthcare is financed by both governmental and commercial payers and significantly impacts the pharmaceutical industry. Certain provisions of the Affordable Care Act have been subject to judicial challenges, as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act, or Tax Act, enacted on December 22, 2017 eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, commonly referred to as the "individual mandate," effective January 1, 2019. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. It is unclear how the Affordable Care Act and its implementation, as well as efforts to repeal, replace, or otherwise modify, or invalidate, the Affordable Care Act, or portions thereof, will affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, as amended, among other things led to aggregate reductions in Medicare payments for all items and services, including prescription drugs and biologics, to service providers of, on average, 2 percent per fiscal year beginning April 1, 2013, and, due to subsequent legislation, continuing until 2030 (with the exception of a temporary suspension from May 1, 2020, through March 31, 2021) unless Congress takes additional action.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Affordable Care Act, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, and their implementation may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from commercial payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transition to Our Core Healthcare Business Model</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we developed technology platforms for application across a variety of diverse end markets, including health, food, energy, and environment. In January&#160;2020, we announced that we were increasing our focus on our healthcare opportunities, which reflected our most advanced platforms, and in connection therewith, we divested a number of our non-healthcare assets and changed our name to Precigen, Inc. These transactions included the sale of a number of our non-healthcare assets, or the TS </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology Sale, to TS Biotechnology Holdings, LLC, or TS Biotechnology, an entity formed by Third Security, LLC, or Third Security. Randal J. Kirk, who is the former CEO of Precigen and is currently the Executive Chairman and a member of our board of directors, serves as the Senior Managing Director and Chairman of Third Security and owns 100 percent of the equity interests of Third Security. In addition, in January 2020, in a separate transaction, we sold our interest in EnviroFlight, LLC, or EnviroFlight, to Darling Ingredients, Inc., or Darling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, LLC, or MBP Titan, our methane bioconversion business, beginning in the second quarter of 2020 and throughout the remainder of 2020, we suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially complete by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. This discontinuation of operations represented the continuation of a strategic shift that we commenced in early 2020 to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. After the wind down of MBP Titan, certain assets and contractual obligations which were originally related to MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include our equity interests in and collaboration agreements with Intrexon Energy Partners, LLC, or Intrexon Energy Partners, and Intrexon Energy Partners II, LLC, or Intrexon Energy Partners II, including the associated deferred revenue remaining under each collaboration agreement, as well as the associated intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report for additional discussion of our discontinued operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Notes to the Consolidated Financial Statements - Note 5" appearing elsewhere in this Annual Report for a discussion of Intrexon Energy Partners and Intrexon Energy Partners II.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Healthcare Business </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, our only non-healthcare business is our established bovine genetics company, Trans Ova Genetics, L.C., or Trans Ova.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trans Ova</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova is internationally recognized as a provider of industry-leading bovine reproductive technologies. Trans Ova offers bovine embryo transfer technologies, in addition to other advanced reproductive technologies, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fertilization, or IVF, sexed-semen, genetic preservation, and cloning. Through extensive research programs and applied science, Trans Ova has developed and implemented new technologies that, we believe, have helped to move the science of bovine genetic improvement forward. We continue to evaluate the optimal means to utilize these technology assets and Trans Ova's broad customer base and deep industry knowledge to maximize the value of the business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, Trans Ova had 183 production employees. Trans Ova's primary domestic production facilities, including approximately 360 acres of land, are located in Sioux Center, Iowa. The land and facilities are primarily used for our embryo transfer and IVF processes, as well as housing livestock used in such processes. As of December 31, 2020, Trans Ova also leased or owned regional production facilities and land in California, Maryland, Missouri, South Dakota, Texas, Washington, and Wisconsin for these purposes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition: Non-Healthcare Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Animal Genetics Market</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Trans Ova's focus on continuous research and use of applied science allows Trans Ova to develop and implement new technologies that will help move the science of bovine genetic improvement forward rapidly and differentiate it from its competitors. However, there are a number of companies that compete with Trans Ova, including traditional breeding companies and other companies that use advanced reproductive technologies. These competitors may be larger and have better funding than Trans Ova. In addition, Trans Ova's competitors may be companies that have a predominant focus on developing the newest technologies in animal breeding whereas Trans Ova is one part of our overall strategy. Finally, Trans Ova's competitors that operate using more traditional breeding techniques may enjoy greater market acceptance over Trans Ova, and other companies, that utilize genetic manipulation, semen sorting and cloning techniques.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has had and continues to have an extensive impact on the global health and economic environments. The health and safety of our employees is of the utmost importance. Our essential employees are practicing appropriate safety measures, including social distancing and use of personal protective equipment. These efforts have permitted us to continue to advance our programs, with the ultimate goal of benefiting patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second half of March 2020, our healthcare business began to experience delays to certain of our clinical trials as a result of COVID-19. For example, starting in March 2020, ActoBio temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, our employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and the study is recruiting patients again. Additionally, from April to May 2020, enrollment of new patients in our PRGN-3005 Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. Recruitment resumed in the PRGN-3005 trial in May 2020. At this time, we do not expect that these suspensions will result in significant overall delay. Furthermore, uncertainty regarding the duration and severity of the ongoing pandemic may adversely impact our clinical as well as preclinical pipeline candidates in the future. Notwithstanding the foregoing, as the COVID-19 pandemic continues to evolve, we may experience additional delays to our clinical trials, including related to enrollment, site closures, reduced availability of key personnel, or our ability to receive the necessary approvals from the FDA or other regulatory agencies to advance our programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also closely monitoring the impact of COVID-19 on other aspects of our business. While Trans Ova and Exemplar have not experienced any significant impacts as a result of COVID-19 at this time, we are unable to reliably quantify or estimate what future impacts may be. In addition, we have taken certain steps with respect to our operations of MBP Titan as a result of the impacts of the COVID-19 pandemic and other factors. See "Transition to Our Core Healthcare Business Model" above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on our ongoing business, results of operations, and overall financial performance cannot be reasonably estimated at this time. For more information regarding the risks associated with COVID-19 and its impact on our business, see "Risk Factors - Risks Related to Our Business."</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, our reportable segments are (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December 31, 2020. See "Notes to the Consolidated Financial Statements - Note 20" appearing elsewhere in this Annual Report for a discussion of our reportable segments and Segment Adjusted EBITDA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 140 employees supporting our research and development functions of our healthcare operations, including operational and facility activities. We incurred expenses of $41.6 million, $66.7 million and $333.0 million in 2020, 2019, and 2018, respectively, on research and development activities for continuing operations. We anticipate that our research and development expenditures could increase as we advance our healthcare programs and platforms. As of December&#160;31, 2020, our primary domestic research and development operations were located in laboratory facilities in Germantown, Maryland, and our primary international research and development operations were located in a laboratory facility in Ghent, Belgium.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues, product revenues, service revenues and other revenues and operating loss for each of the last three fiscal years, along with assets as of December&#160;31, 2020 and 2019, are set forth in the consolidated financial statements, which are included in Item&#160;8 of this Annual Report. Financial information about geographic areas is set forth in "Notes to the Consolidated Financial Statements - Note 20" appearing elsewhere in this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 194 employees in support of our healthcare operations, of which 140 support our research and development functions including operational and facility activities. Of these research and development employees, 59 have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advanced degrees, of which 35 are PhDs. Our corporate employees provide support to all of our operating subsidiaries and are responsible for the execution of all corporate functions, including executive, operational, finance, information technology, legal, and corporate communications. In addition to our healthcare operations, Trans Ova employs 229 full-time employees and 54 part-time employees. None of our employees are represented by a collective bargaining agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We structure our compensation packages to compete for the best scientific talent. Our compensation packages include a competitive base salary and bonus, the issuance of equity incentives, and health and wellness benefits, including a health insurance plan with a Platinum actuarial value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are proud of the fact that our domestic healthcare operations and corporate functions include 40 percent of employees in ethnic and racial minority groups and also the fact that 46 percent of the same population of employees are women.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recent employee development initiatives included employee training targeting specific areas of interest, executive and manager coaching, and performance management which encompass performance goals and competency evaluations. We implemented safety protocols in response to the COVID-19 pandemic including increased cleaning protocols, employee preventative measures, contract tracing, and bi-weekly virus testing. These measures enabled us to have the majority of our research and development employees return to their workplaces by early June 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precigen.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information on, or that can be accessed through, our website does not constitute part of, and is not deemed to be incorporated by reference into, this Annual Report. We post regulatory filings on this website as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings include annual reports on Form 10-K; quarterly reports on Form 10-Q; current reports on Form 8-K; Section&#160;16 reports on Forms 3, 4, and 5; and any amendments to those reports filed with or furnished to the SEC. We also post our press releases on our website. Access to these filings or any of our press releases on our website is available free of charge. Copies are also available, without charge, from Precigen Investor Relations, 20374 Seneca Meadows Parkway, Germantown, Maryland 20876. Reports filed with the SEC may be viewed at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Corporate Governance Guidelines, Code of Business Conduct and Ethics, and charters for the Audit Committee, the Compensation Committee and the Nominating and Governance Committee are available free of charge to shareholders and the public through the "Corporate Governance" section of our website. Printed copies of the foregoing are available to any shareholder upon written request to our Communications Department at the address set forth on the cover of this Annual Report or may be requested through our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precigen.com.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_16"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this Annual Report, including our consolidated financial statements and the related notes appearing at the end of this Annual Report, before making your decision to invest in shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition, or prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by us described below and elsewhere in this Annual Report. See "Special Note Regarding Forward-Looking Statements" for information relating to these forward-looking statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position and Capital Needs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we may not achieve or maintain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception, including net losses attributable to Precigen of $170.5 million, $322.3 million and $509.3 million in 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $1.8 billion. We may incur losses and negative cash flow from operating activities for the foreseeable future. Historically, we have derived a significant portion of our revenues from collaborations and license agreements, but revenues of these types for existing collaborations will continue to decrease as we complete our transition to a discovery and clinical stage biopharmaceutical company. We no longer expect to receive reimbursement of costs incurred by us for new research and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development services other than through existing collaborations or future strategic transactions, nor will we recognize deferred revenues associated with previously terminated collaborations. In addition, certain of our collaborations and license agreements provide for milestone payments, future royalties, and other forms of contingent consideration, the payment of which are uncertain as they are dependent on our collaborators' abilities and willingness to successfully develop and commercialize product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially as we continue to advance the preclinical and clinical development of our existing product candidates and our research programs, and there is a significant risk that our product candidates will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain regulatory approval, or become commercially viable. We expect a significant period of time could pass before commercialization of our various product candidates or before the achievement of contractual milestones and the realization of royalties on product candidates commercialized under our collaborations and revenues sufficient to achieve profitability. As a result, our expenses may exceed revenues for the foreseeable future, and we may not achieve profitability. If we fail to achieve profitability, or if the time required to achieve profitability is longer than we anticipate, we may not be able to continue our business. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital in the future in order to fund our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. We are and will continue to be dependent on public or private financings, new collaborations or licensing arrangements with strategic partners, or additional debt financing sources to fund continuing operations. We expect our future capital requirements will be substantial and will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress in our research and development programs, as well as the magnitude of these programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of potential regulatory approval of products of our collaborations and operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of any payments received in connection with strategic transactions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of sales and royalties, if any, from our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and capital requirements to scale up our various product candidates and service offerings and customer acceptance thereof;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and establish additional collaborative arrangements and/or new strategic initiatives;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources, time, and cost required for the preparation, filing, prosecution, maintenance, and enforcement of our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic mergers and acquisitions, if any, including both the upfront acquisition cost as well as the cost to integrate, maintain, and expand the strategic target; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future financings involve the issuance of equity securities, our existing shareholders would suffer further dilution. If we raise additional debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop product candidates or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of product candidates resulting from our technologies, curtail or cease operations or obtain funds through strategic transactions or other collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our debt may require a significant amount of cash, and we may not have sufficient cash flows from our business, or otherwise have available cash, to pay our substantial debt when due.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the 3.50 percent convertible senior notes due 2023, or Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flows from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flows, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are our exclusive obligations and are not guaranteed by any of our operating subsidiaries. We believe that a substantial portion of our intrinsic value is represented by assets that are held by our subsidiaries. Accordingly, our ability to service our debt, including the Convertible Notes, depends on the results of operations of our subsidiaries and upon the ability of such subsidiaries to provide us with cash, whether in the form of dividends, loans, or otherwise, to pay amounts due on our obligations, including the Convertible Notes. Our subsidiaries are separate and distinct legal entities and have no obligation, contingent or otherwise, to make payments on the Convertible Notes or to make any funds available for that purpose. In addition, dividends, loans or other distributions to us from such subsidiaries may be subject to contractual and other restrictions and are subject to other business considerations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite our current debt levels, we may still incur substantially more debt or take other actions that would intensify the risks discussed above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our current consolidated debt levels, we and our subsidiaries may incur substantial additional debt in the future, subject to the restrictions contained in our debt instruments, some of which may be secured debt. We are not restricted under the terms of the indenture governing the Convertible Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that are not limited by the terms of the indenture governing the Convertible Notes that could have the effect of diminishing our ability to make payments on the Convertible Notes when due.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption that could have an adverse effect on the Company's access to capital on favorable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. We are and will continue to be dependent on public or private financings, new collaborations or licensing arrangements with strategic partners, or additional debt financing sources to fund continuing operations. As the COVID-19 pandemic continues to negatively impact the economy, our future access to capital on favorable terms may be materially impacted. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. Given the rapid evolution of the COVID-19 pandemic and the uncertainty surrounding it, its impact to our financial condition, including but not limited to, possible impairment, restructuring, and other changes, cannot be reliably quantified or estimated.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval, and ultimately commercialize them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts. We initiated our first clinical trial for our lead programs, PRGN-3005 in April 2019, PRGN-3006 in May 2019, PRGN-2009 in August 2020, AG019 in October 2018, and INXN-4001 in May 2018, and currently have a pipeline of preclinical programs. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of some or all of these product candidates, and any future product candidates we develop, which may never occur. Our current and future product candidates will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, coverage from pricing and reimbursement authorities, sufficient cGMP manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment, and significant marketing efforts before we generate any revenues from product sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and commercial success of our current and future product candidates will depend on several factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely and successful completion of preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of INDs for future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers that can do so;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful launch of commercial sales of our product candidates, if approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations to further the development of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patent and other intellectual property protection or regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community, and third-party payers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance of a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our compliance with any post-approval requirements imposed on our products, such as postmarketing studies, a REMS, or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost prohibitive;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete effectively with other therapies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain healthcare coverage and adequate reimbursement from third-party payers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that any of our current or future product candidates will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. There can be no assurance that we will not experience problems or delays in developing new product candidates and that such problems or delays will not cause unanticipated costs, or that any such development problems can be solved. We also may experience unanticipated problems or delays in expanding our manufacturing capacity, which may delay or prevent the completion of clinical trials and the commercializing of product candidates on a timely or profitable basis, if at all. For example, we, a collaborator, or another group may uncover a previously unknown risk with any of our product candidates, which may prolong the period of observation required for obtaining regulatory approval, may necessitate additional clinical testing, or may otherwise result in a change in the requirements for approval of any of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, European Medicines Agency, or EMA, and other regulatory authorities and the criteria these regulators use when evaluating product candidates vary substantially according to the type, complexity, novelty, and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied product candidates. Even if we are successful in developing product candidates, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals in either the United States or jurisdictions outside the United States or how long it will take to commercialize these product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. For example, the FDA has established the Office of Tissues and Advanced Therapies and the Division of Cellular and Gene Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its marketing application review process.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain FDA approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business, and our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To gain approval to market our product candidates in the United States, we must provide the FDA with clinical data that adequately demonstrate the safety, purity, and potency, including efficacy, of the product candidate for the proposed indication or indications in a BLA submission. Product development is a long, expensive, and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of gene therapy is still early in development. The FDA first approved a gene therapy for use in humans in 2017, and to date has only approved a limited number. Clinical trials with gene therapies have encountered a multitude of significant technical problems in the past, including unintended integration with host DNA leading to serious adverse events, poor levels of protein expression, transient protein expression, viral overload, immune reactions to either viral capsids utilized to deliver DNA, DNA itself, proteins expressed or cells transfected with DNA. There can be no assurance that our development efforts will be timely or successful, that we or our collaborators will receive the regulatory approvals necessary to initiate clinical trials, where applicable, or that we will ever be able to successfully commercialize a product candidate enabled by our technologies. To the extent that we utilize viral constructs or other systems to deliver gene therapies and the same or similar delivery systems demonstrate unanticipated and/or unacceptable side effects in preclinical or clinical trials conducted by ourselves or others, we may be forced to, or elect to, discontinue development of such product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are pursuing the development and commercialization of adoptive cell therapies based on CAR T-cell therapies targeting a variety of cancer malignancies. Because this is a newer approach to cancer immunotherapy and cancer treatment generally, developing and commercializing such product candidates subjects us to a number of challenges, including: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and deploying consistent and reliable processes for engineering a patient's T-cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and infusing the engineered T-cells back into the patient;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possibly conditioning patients with chemotherapy in conjunction with delivering each of the potential product candidates, which may increase the risk of adverse side effects of the potential products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating medical personnel regarding the potential side effect profile of each of the potential products, such as the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential adverse side effects related to cytokine release;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing processes for the safe administration of these potential products, including long-term follow-up for all patients who receive the potential products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process the potential products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing a manufacturing process and distribution network with a cost of goods that allows for an attractive return on investment;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales and marketing capabilities after obtaining any regulatory approval required to gain market access and acceptance;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing therapies for types of cancers beyond those addressed by the current potential products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not infringing the intellectual property rights, in particular, the patent rights, of third parties, including competitors developing alternative CAR T-cell therapies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoiding any applicable regulatory barriers to market, such as data and marketing exclusivities held by third parties, including competitors with approved CAR T-cell therapies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that T-cell immunotherapy technologies that we may develop will yield satisfactory products that are safe and effective, scalable, or profitable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development involves a lengthy and expensive process with uncertain outcomes. Results from preclinical studies or previous clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired results in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high failure rate for drugs and biologics proceeding through clinical trials and failure may occur at any stage due to a multitude of factors both within and outside our control. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects. If clinical trials result in negative or inconclusive results, we may decide, or regulators may require us, to discontinue trials of the product candidates or conduct additional clinical trials or preclinical studies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect our ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and delayed timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payers. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in clinical trials, which could delay or prevent us from proceeding with clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to success. The timing of clinical trials depends on the ability to recruit patients to participate as well as completion of required follow-up periods. If patients are unwilling to participate in our clinical studies for any number of reasons, such as because of negative publicity from adverse events related to the biotechnology or gene therapy fields, the timeline for recruiting patients, conducting clinical trials and obtaining regulatory approval may be delayed. Additionally, any shelter-in-place orders from local, state, or federal governments or clinical trial site policies resulting from the COVID-19 pandemic may impact our ability to enroll patients in clinical trials. These delays could result in increased costs, delays in advancing product candidates, or termination of the clinical trials altogether.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to suspend, repeat, or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, or the trials are not well designed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the FDA's current good clinical practices requirements or analogous requirements of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs, or ethical committees at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or study protocols;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the clinical trial operations or trial sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen adverse side effects or the emergence of undue risks to study subjects;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the trial design necessary to demonstrate efficacy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not appear to offer benefits over current therapies; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality or stability of the product candidate may fall below acceptable standards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or the termination of, any clinical trial of any of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition, results of operations, cash flows, and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell and gene therapies are novel, complex, and difficult to manufacture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes that we use to produce our product candidates for human therapeutics are complex, novel and have not been validated for commercial use. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error, or disruptions in the operations of our suppliers. Our synthetic biology product candidates require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic often cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, it is necessary to employ multiple steps to control our manufacturing process to assure that the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, or insufficient inventory. We have developed our proprietary electroporation device, UltraPorator, to permit the rapid and cost-effective manufacturing of our UltraCAR-T therapies, but we may face challenges in the production and implementation of this device, which may, in turn, adversely impact the therapeutic candidates. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA, or other applicable standards or specifications with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consistent and acceptable production yields and costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation, and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit, validation, and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials. While new approaches have been developed to reduce these side effects, gene therapy and synthetic biology therapy in general is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to these product candidates due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other possible adverse side effects that could occur with treatment using cell and gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient's health, could substantially limit the effectiveness of the treatment. In previous clinical trials involving adeno-associated virus, vectors for gene therapy, some subjects experienced the development of a T-cell response, whereby after the vector is within the target cell, the cellular immune response system triggers the removal of transduced cells by activated T-cells. If a similar effect occurs with our product candidates, we may decide or be required to halt or delay further clinical development of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any of our product candidates receive marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to healthcare practitioners, and provider certification. Such requirements could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition, and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even where product candidates meet their endpoints in clinical trials, the clinical trial results may not support approval of our product candidates if they fail to demonstrate that our product candidates are both safe and effective for their intended uses. Similarly, the regulatory authorities may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require precautions or contraindications with respect to conditions of use or they may grant approval subject to the performance of costly postmarketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have chosen to prioritize development of certain of our product candidates, including PRGN-3005 and PRGN-3006. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on other opportunities for which there may be a greater likelihood of success or may be more profitable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited resources, we are required to strategically prioritize our application of resources to particular development efforts. Any resources we expend on one or more of these efforts could be at the expense of other potentially profitable opportunities. If we focus our efforts and resources on one or more of these opportunities or markets and they do not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lead to commercially viable products, our revenues, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic could cause a disruption of the development of our product candidates, which could adversely impact our healthcare business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, ActoBio took the initiative to temporarily suspend the last remaining cohort of the Phase1b/2a trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, and our employees and contractors. This voluntary suspension was lifted in June 2020, and the study is recruiting patients again. Further, from April to May 2020, enrollment of new patients in our PRGN-3005 Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. As the COVID-19 pandemic continues to evolve, we may experience delays in the development of our product candidates, including as a result of declines in new patient enrollment for new and existing trials, ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography, site closures, reduced availability of other key personnel, availability of supplies, or for other reasons that may be difficult to anticipate. For example, we received IND clearance earlier this year to initiate, and initiated, a Phase 1/2 trial to study PRGN-2009 in participants with HPV+ cancers, but our ability to complete such a trial may be delayed or impeded by any of the foregoing factors as a result of the COVID-19 pandemic. In addition, the FDA or other regulatory authorities may have their resources diverted to responding to, or otherwise may be disrupted by, the COVID-19 pandemic, which could result in delays of reviews, approvals, and communications with regulatory authorities related to our clinical trials and product candidates. As the focus of our business is on healthcare, disruptions to our clinical trials could result in increased costs, delays in advancing product candidates, or ultimately, termination of clinical trials altogether resulting in a material adverse impact to our overall business. Furthermore, a failure to achieve meaningful clinical trial results, or even progress toward those results, could have a material adverse effect on the value of our securities and our ability to secure needed additional capital.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Product Candidates and Other Legal Compliance Matters </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payers, and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethical, social, and legal concerns about gene and cell therapies could result in additional regulations restricting or prohibiting our product candidates. Even with the requisite approvals from the FDA in the United States, the EMA in the European Union, and other regulatory authorities internationally, the commercial success of our product candidates will depend, in part, on their acceptance by physicians, patients, and healthcare payers as medically necessary, cost-effective, and safe. Public perception may be influenced by claims that gene and cell therapies are unsafe, and any product candidate that we commercialize may not gain acceptance by physicians, patients, healthcare payers, and others in the medical community. In particular, our success will depend upon appropriate physicians prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue to make the products profitable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in obtaining regulatory approval of manufacturing processes and facilities or disruptions in manufacturing processes may delay or disrupt our commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can begin to commercially manufacture our product candidates for human therapeutics, we must obtain regulatory approval from the FDA for the applicable manufacturing process and facility. This likely will require the manufacturing facility to pass a pre-approval inspection by the FDA. A manufacturing authorization must also be obtained from the appropriate European Union regulatory authorities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain FDA approval, we will need to ensure that all of the processes, methods, and equipment are compliant with cGMP and perform extensive audits of vendors, contract laboratories, and suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation(s) or while we work to identify suitable replacement vendors. The cGMP requirements govern, among other things, quality control of the manufacturing process, raw materials, containers/closures, buildings and facilities, equipment, storage and shipment, labeling, laboratory activities, data integrity, documentation policies and procedures, and returns. In complying with cGMP, we will be obligated to expend time, money, and effort in production, record keeping, and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action that could adversely affect our business, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations, financial condition, and cash flows, including the inability to sell any products that we may develop.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, these candidates will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, and submission of safety and other postmarket information. Regulatory approvals also may be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly postmarketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA guidance advises that patients treated with some types of gene therapy undergo follow-up observations for potential adverse events for as long as 15 years. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and other government agencies to ensure compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers' compliance with these regulations and standards, but we may ultimately be responsible for any of their failures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may take a range of adverse actions, including, among other things, issuing a warning letter, imposing monetary penalties, restricting or suspending manufacturing, or causing us to withdraw the product from the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA's policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of our current and future product candidates in other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which third-party payers, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of coverage and adequacy of reimbursement by third-party payers, including managed care plans, governmental healthcare programs, such as Medicare and Medicaid and private health insurers is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our product candidates or procedures using our product candidates by third-party payers will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product candidate is used may not be available. A decision by a third-party payer not to cover or not to separately reimburse for our product candidates or procedures using our product candidates could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates by a third-party payer, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union, or elsewhere will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. The Medicare and Medicaid programs are increasingly used as models in the United States for how private third-party payers and other governmental payers develop their coverage and reimbursement policies for drugs and biologics. Some third-party payers may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payers will decide with respect to the coverage and reimbursement for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No uniform policy for coverage and reimbursement for products exist among third-party payers in the United States. Therefore, coverage and reimbursement for products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our product candidates to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by third-party payers in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal and state legislatures, health agencies and third-party payers continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our product candidates, if approved, are prescribed and purchased. For example, the Affordable Care Act has changed the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. In addition, the Tax Act eliminated the tax-based shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Code, commonly referred to as the "individual mandate," effective January 1, 2019. Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most Medicare drug plans, commonly known as the "donut hole," by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January 1, 2019. Further legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for certain drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the United States and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our product candidates, if approved. In addition, under the Affordable Care Act, as states implement their health care marketplaces or operate under the federal exchange, the impact on drug manufacturers will depend in part on the formulary and benefit design decisions made by insurance sponsors or plans participating in these programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States. It is possible that we may need to provide discounts or rebates to such plans in order to maintain favorable formulary access for our future product candidates, if approved, which could have an adverse impact on our sales and results of operations. In addition, if we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, third-party payers, and others may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians, and third-party payers will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for the furnishing or arranging for the furnishing, or the purchase, lease or order, or arranging for or recommending the purchase, lease or order, of any good or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil False Claims Act, which imposes liability, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment of governmental funds that are false or fraudulent, making a false statement material to an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA's fraud provisions, which impose criminal liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a health care offense, or knowingly and willfully making false statements relating to healthcare matters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by non-governmental third-party payers, including private insurers; state and foreign </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers in those jurisdictions; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some states also prohibit certain marketing-related activities including the provision of gifts, meals, or other items to certain health care providers, and others restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; other states and cities require identification or licensing of sales representatives; and state and foreign laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Although compliance programs can help mitigate the risk of investigations and prosecution for violations of these laws, the risks cannot be eliminated entirely. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defending against actions or investigations for violations of these laws and regulations, even if ultimately successful, will incur significant legal expenses and divert management's attention from the operation of our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable United States privacy and data protection laws and regulation, we may be subject to liabilities that adversely affect our business, operations and financial performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we may be subject to data privacy and security laws and regulations by both the federal government and the states in which we conduct our business. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state data breach notification laws, state health information and/or genetic privacy laws and federal and state consumer protection laws (e.g., Section 5 of the FTC Act and the CCPA), govern the collection, use, disclosure, and protection of health-related and other personal information. Many of these laws differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, and time consuming. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes requirements relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the CCPA became effective on January 1, 2020 and establishes certain requirements for data use and sharing transparency, and provides California residents certain rights concerning the use, disclosure, and retention of their personal data. The CCPA and its implementing regulations have already been amended multiple times since their enactment. Similarly, there are a number of legislative proposals in the United States, at both the federal and state level, that could impose new obligations or limitations in areas affecting our business. These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. The CCPA and evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our agents, or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and privacy laws and regulations, or if we were to experience a data breach involving personal information, we could be subject to government enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other remedies that harm our business, including orders that we modify or cease existing business practices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur significant costs complying with environmental, health, and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use hazardous chemicals and radioactive and biological materials in our business, including in Trans Ova, and are subject to a variety of federal, state, local and international laws and regulations governing, among other matters, the use, generation, manufacture, transportation, storage, handling, disposal of, and human exposure to these materials both in the United States and overseas, including regulation by governmental regulatory agencies, such as the Occupational Safety and Health Administration and the EPA. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations. Although we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain United States and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, United States and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is heavily regulated and therefore involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-United States activities to increase in time. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the United States Foreign Corrupt Practices Act of 1977, as amended, or FCPA. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. In particular, our operations will be subject to FCPA, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws and regulations could result in fines, criminal sanctions, including imprisonment, against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, debarment, reputational harm, prohibitions on the conduct of our business, and other consequences. Any such violations could also result in prohibitions on our ability to offer our product candidates in one or more countries as well as difficulties in manufacturing or continuing to develop our product candidates, and could materially damage our reputation, our brand, our ability to attract and retain employees and our business, prospects, operating results, and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations and Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our efforts to realign our business and divest assets may not be successful and could increase our capital requirements, increase our costs, or otherwise harm our operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy has evolved, and continues to evolve, toward relationships and structures that provide us with more control and ownership over the development process and commercialization path. This approach entails risks in implementation and operations and there is no guarantee that it will be successful. Furthermore, our focus on a healthcare-oriented business strategy will require additional capital beyond what we have available, and we may incur costs associated with the implementation and execution of our changing business strategy. In addition, as we perform our annual impairment tests, we will evaluate the impact of changes in our business strategy and, as a result, may incur impairment charges and write-offs and other related expenses, any of which, if material, could harm our operating results and financial condition. Market changes and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in judgments, assumptions, and estimates that we have made in assessing the fair value of goodwill could cause us to consider some portion or all of certain assets to become impaired, which could adversely impact our financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we announced and completed a sale of the majority of our non-healthcare assets to TS Biotechnology. We simultaneously announced that Intrexon EF Holdings, Inc., our wholly owned subsidiary, sold its 50 percent membership interest in EnviroFlight. As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, we suspended MBP Titan's operations, preserved MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its assets and obligations. We cannot provide any assurances that these recent, or any future, divestitures will achieve the business goals we expect. In addition, any future divestiture activities may present financial and operational risks, including the (1) diversion of management attention from existing core businesses, (2) the challenges associated with separating personnel and financial and other systems, including impaired employee relations, and (3) inefficiencies or increased costs, any of which could adversely affect our business, financial condition, results of operations and cash flows. Finally, as we continue our efforts to focus our business and generate additional capital, we may be willing to enter into transactions involving one or more of our remaining operating segments and reporting units for which we record impairment charges related to the write off of goodwill and intangible assets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties, including through collaborations, to develop and commercialize some of our product candidates. Markets in which our collaborators are developing product candidates using our technologies are subject to extensive regulation, and we rely on our collaborators to comply with all applicable laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered, and may in the future enter into collaboration arrangements to develop product candidates enabled by our technologies. There can be no guarantee that we can successfully manage these relationships. If our collaborators are not able to successfully develop the product candidates enabled by our technologies, none of these enabled product candidates will become commercially available, and we will receive no back-end payments under these arrangements. Some of our existing collaborators do not themselves have the resources necessary to commercialize product candidates, and they in turn will need to rely on additional sources of financing or third-party collaborations. We may be asked to, or choose to, invest additional funds in these collaborators so that they can execute on their business plans. If we fail to invest such additional funds, the collaborator may not have sufficient capital to continue operations. In addition, we typically have limited or no control over the amount or timing of resources that any collaborator is able or willing to devote to developing product candidates or collaborative efforts. Any of our collaborators may fail to perform its obligations. Our collaborators may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely manner. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technologies are used in product candidates that are subject to extensive regulation by governmental authorities. We depend on our collaborators to comply with these laws and regulations with respect to product candidates they produce using our technologies, and we do not independently monitor whether our collaborators comply with applicable laws and regulations. If our collaborators fail to comply with applicable laws and regulations, we are subject to substantial financial and operating risks because, in addition to our own compliance, we also depend on our collaborators to produce the end products enabled by our technologies for sale. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have previously entered into strategic collaborations, which we may fail to successfully manage, or from which disputes may arise. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously entered into strategic collaborations to develop products enabled by our technologies. There can be no guarantee that we can successfully manage these relationships, as they involve complex interests and our interests and our collaborators' interests may diverge, including as we transition away from, or terminate, strategic collaborations.&#160;In some cases, our strategic collaborations have resulted in disagreements and disputes with our current and former collaborators, including the Harvest Intrexon Enterprise Fund I, LP, or Harvest, the investors of Intrexon Energy Partners, and the investors of Intrexon Energy Partners II, regarding the relative rights, obligations, and revenues of us and our collaboration partners. In addition, we remain susceptible to future additional disagreements and disputes with any of our current or future collaborators. Disagreements and disputes may result in litigation, unfavorable settlements or concessions by us, or management distraction, that could harm our business operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our subsidiaries, our collaborators, and other third parties to deliver timely and accurate information in order to accurately report our financial results in the time frame and manner required by law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need to receive timely, accurate, and complete information from a number of third parties in order to accurately report our financial results on a timely basis. We rely on our subsidiaries and certain collaborators to provide us with complete and accurate information regarding revenues, expenses, and payments owed to or by us on a timely basis. In addition, we intend to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rely on current and future collaborators under our collaboration agreements and JVs to provide us with product sales and cost saving information in connection with royalties, if any, owed to us. If the information that we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement, and we may not receive the full amount of consideration to which we are entitled under our collaboration agreements or JVs. Although we have audit rights with these parties, performing such an audit could be expensive and time consuming and may not be adequate to reveal any discrepancies in a timeframe consistent with our reporting requirements. In the future, we may need to consolidate the financial statements of one or more other collaborators into our consolidated financial statements. Although we have contractual rights to receive information and certifications allowing us to do this, such provisions may not ensure that we receive information that is accurate or timely. As a result, we may have difficulty completing accurate and timely financial disclosures, which could have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A portion of our business is conducted by JVs that we cannot operate solely for our benefit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In JVs, we share ownership and management of a company with one or more parties who may not have the same goals, strategies, priorities, or resources as we do and may compete with us outside the JV. JVs are intended to be operated for the benefit of all JV partners, rather than for our exclusive benefit. Operating a business as a JV often requires additional organizational formalities as well as time-consuming procedures for sharing information and making decisions. In JVs we are required to foster our relationships with our JV partners as well as promote the overall success of the JV, and if a JV partner changes or relationships deteriorate, our success in the JV may be materially adversely affected. The benefits from a successful JV are shared among the JV partners, so we do not receive all the benefits from our successful JVs. Moreover, as a partial owner of a JV, we are exposed to potential risks and liabilities that we do not face when we enter into collaboration with an independent third party. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be sued for product liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering, or selling our products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, each of our collaborations requires the collaborator to indemnify us for liability related to products produced pursuant to the collaboration and to obtain insurance coverage related to product liability in amounts considered standard for the industry. We believe that these industry-standard coverage amounts range from $10 million to $40 million in the aggregate. Even so, we may be named in product liability suits relating to products that are produced by our collaborators using our technologies. These claims could be brought by various parties, including other companies who purchase products from us or our collaborators or by the end users of the products. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that our collaborators will not breach the indemnity and insurance coverage provisions of the collaboration. Further, insurance coverage is expensive and may be difficult to obtain, and may not be available to us or to our collaborators in the future on acceptable terms, or at all. We cannot assure you that we or our collaborators will have adequate insurance coverage against potential claims. In addition, although we currently maintain product liability insurance for our technologies in amounts we believe to be commercially reasonable. If the coverage limits of these insurance policies are not adequate, a claim brought against us, whether covered by insurance or not, could have a material adverse effect on our business, results of operations, financial condition, and cash flows or even cause us to go out of business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for products enabled by our technologies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our or our collaborators' reputations and significant negative media attention;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend resulting litigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products using our technologies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The livestock products of our operating subsidiaries are subject to disease outbreaks that can increase the cost of production and/or reduce production harvests, and the loss of existing livestock would result in the loss of commercial technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of the products of our operating subsidiaries, including Trans Ova and Exemplar, are subject to periodic outbreaks of a variety of diseases. Although these companies take measures to protect their stock, there can be no assurance that a disease will not damage or destroy existing livestock. The economic impact of disease to our subsidiaries' production systems can be significant, as farmers must incur the cost of preventive measures, such as vaccines and antibiotics, and then if infected, the cost of lost or reduced production.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The markets in which we are developing candidate products using our technologies are highly competitive. Competitors and potential competitors may develop products and technologies that make ours obsolete or garner greater market share than ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our novel approach to developing the next generation of gene and cell therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases provides us with competitive advantages, our industry is highly competitive and subject to rapid and significant technological change. Many of our competitors have significantly greater financial, technical, and human resource capabilities than we do, and certain of our competitors may also benefit from local government subsidies and other incentives that are not available to us. In addition, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of the resources available to our competitors, our competitors may be able to develop competing and/or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we can. The availability of reimbursement from government and other third-party payers will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidates include PRGN-3005 for the treatment of ovarian cancer and PRGN-3006 for the treatment of AML, which are built on our UltraCAR-T platform, and PRGN-2009, which is based on our AdenoVerse platform. While we are employing a novel approach, there are a number of competitors pursuing CAR-T cell therapies for the treatment of cancer. We believe that, among others, Bristol-Myers Squibb, Tmunity Therapeutics, and MaxCyte are developing CAR-T based treatments for ovarian cancer and TCR2 Therapeutics is developing TCR-T based treatment for ovarian cancer. We believe that Celyad, Mustang Bio, Amgen, Cellectis S.A., and Allogene Therapeutics are also using CAR-T technology to develop product candidates for the treatment of AML. The CAR-T technology space also has significant other competition including from multiple companies and their collaborators, such as Novartis and University of Pennsylvania, Kite and Gilead, Adaptimmune and GSK, Autolus Therapeutics, Poseida Therapeutics, and Bellicum Pharmaceuticals. We also face competition from non-cell based cancer treatments offered by other companies such as Amgen, AstraZeneca, Incyte, Merck, Abbvie, and Roche.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the area of infectious diseases, our lead product candidate is PRGN-2012, which is based on our AdenoVerse immunotherapy platform, for the treatment of RRP. We believe there are competitors in this area, including INOVIO </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals with their investigational DNA vaccine INO-3107 targeting HPV6 and HPV11 antigens.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also using our suite of proprietary and complementary technologies for the preclinical and clinical development of product candidates for the treatment of autoimmune disorders, including T1D. We believe that our primary competitors with respect to the development of immunotherapies for T1D are Provention Bio, Midatech Pharma, and MerciaPharma.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies that compete with our subsidiary Trans Ova, including traditional breeding companies and other companies that use advanced reproductive technologies. These competitors may be larger and have better funding than Trans Ova. Trans Ova's competitors may also be companies that have a predominant focus on developing the newest technologies in animal breeding whereas Trans Ova is one part to our overall strategy. Trans Ova's competitors that operate using more traditional breeding techniques may enjoy greater market acceptance over Trans Ova, and other companies, that utilize genetic manipulation, semen sorting and cloning techniques.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete successfully will depend on our ability to develop proprietary technologies that can be used to produce products that reach the market in a timely manner and are technologically superior to and/or are less expensive than other products on the market. As more companies develop new intellectual property in our markets, a competitor could acquire patent or other rights that may limit products using our technologies, which could lead to litigation. To the extent that any of our competitors are more successful with respect to any key competitive factor or we are forced to reduce, or are unable to raise, the price of any products enabled by our technologies in order to remain competitive, our operating results and financial condition could be materially adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key personnel, including key management personnel, or are unable to attract and retain additional personnel, it could delay our product development programs, harm our research and development efforts, and we may be unable to continue to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves complex operations and requires a management team and employee workforce that is knowledgeable in the many areas in which we operate. The loss of any key members of our management, including our Chief Executive Officer, Helen Sabzevari Ph.D., or the failure to attract or retain other key employees who possess the requisite expertise for the conduct of our business, could prevent us from developing and commercializing our product candidates for our target markets and entering into collaborations or licensing arrangements to execute on our business strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of any key scientific staff, or the failure to attract or retain other key scientific employees, could prevent us from developing our technologies for our target markets or from further developing and commercializing our products and services offerings to execute on our business strategy. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among biotechnology, synthetic biology and other technology-based businesses, or due to the unavailability of personnel with the qualifications or experience necessary for our business. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience staffing constraints that will adversely affect our ability to support our internal research and development programs or meet other demands.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had a number of executive officers depart from our Company over the last several years and we continually evaluate our leadership structure. For instance, effective January 1, 2020, our Board appointed Dr. Sabzevari, to the position of President and Chief Executive Officer. Mr. Kirk, our previous Chief Executive Officer, now serves as our Executive Chairman and continues to serve as Chairman of the Board. As with any leadership changes, our past or future changes could lead to strategic and operational challenges and uncertainties, distractions of management from other key initiatives, inefficiencies or increased costs, any of which could adversely affect our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on sophisticated information technology and infrastructure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on various information systems to manage our operations. These systems are complex and include software that is internally developed, software licensed from third parties, and hardware purchased from third parties. These products may contain internal errors or defects, particularly when first introduced or when new versions or enhancements are released. Failure of these systems could have an adverse effect on our business, which in turn may materially adversely affect our operating results and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience a significant breach of data security or disruption in our information systems, our business could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on various information systems to manage our operations and to store information, including sensitive data such as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidential business information and personally identifiable information. These systems have been and continue to be vulnerable to interruption or malfunction, including due to events beyond our control, and to unauthorized access, computer hackers, ransomware, viruses, and other security problems. Failure of these systems or any significant breach of our data security could have an adverse effect on our business and may materially adversely affect our operating results and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data security breaches could result in loss or misuse of information, which could, in turn, result in potential regulatory actions or litigation, including material claims for damages, compelled compliance with breach notification laws, interruption to our operations, damage to our reputation or could otherwise have a material adverse effect on our business, financial condition and operating results. Companies throughout our industry have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access to networks or sensitive information. While we have implemented and continue to implement cybersecurity safeguards and procedures, these safeguards have been vulnerable to attack. As cyber threats continue to evolve, we may be required to expend additional resources to enhance our cybersecurity measures or to investigate or remediate any vulnerabilities or breaches.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain insurance to protect ourselves in the event of a breach or disruption of certain of our information systems, we cannot ensure that the coverage is adequate to compensate for any damages that may be incurred.</span></div><div style="margin-top:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The effects of the COVID-19 pandemic have disrupted, and will likely continue to disrupt, our business operations, which could have a material adverse effect on our results of operations, cash flows, and financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring the impacts of COVID-19 on all aspects of our business. The operations of our businesses may continue to be adversely impacted by COVID-19, including, for example, if we are unable to secure necessary supplies, including personal protection equipment for our employees. We also rely on third parties for various aspects of our business, including developing some of our product candidates. These third parties may experience similar disruptions or negative impacts to their businesses due to COVID-19, which may result in additional delays or otherwise adversely impact our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova, our established bovine genetics company, has not been significantly impacted by disruptions from COVID-19 to date. However, ongoing disruptions from COVID-19 and its cascading effects could mean that the business may be materially adversely affected in the future, including by a decrease in sales or overall demand for our products, the inability of our customers to pay for our services and products, similar negative effects on our suppliers, and disruptions to the global supply chain generally. There have already been a number of initial reports regarding such disruptions to the beef and dairy industry as a result of the COVID-19 pandemic, which impact both Trans Ova's potential customers and its sources of certain resources, such as embryos. While Exemplar, our subsidiary that develops MiniSwine models to enable the study of life-threatening diseases, has not been significantly impacted by disruptions from COVID-19 to date, it could face similar types of challenges, including its customers delaying or refusing shipments because of delays in their research and development operations similar to, or more severe than, the challenges and risks we face with our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential impacts to our operations, we have initiated several precautions to mitigate the spread of the illness across our businesses, which may impact our ability to carry out our business as usual, including additional sanitation and cleaning procedures in our laboratories and other facilities, instituting remote working when possible, and implementing social distancing and staggered worktime requirements for our employees that must work on-site. The increase in remote working may also result in elevated susceptibility to cyber security risks. We have incurred additional costs as a result of these measures and will likely continue to do so as a result of these and any future measures necessary to ensure the safety of our employees and the continuity of our operations. These measures could also lead to reduced efficiency in our operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our subsidiaries are leanly staffed and rely on key personnel to manage operations. The loss of our key scientific staff, personnel, or other key employees, as a result of illness or otherwise, could negatively impact our business and operations, particularly if we are unable to adequately find or train replacements. Certain of our subsidiaries, such as Trans Ova and Exemplar, that operate in industries in which remote working is not possible may be particularly at risk. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on our ongoing business, results of operations, and overall financial performance cannot be reasonably estimated at this time, and it could have a material adverse effect on our results of operations, cash flows, and financial position, including resulting in impairments to goodwill and long-lived assets and additional credit losses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have international operations and assets and may have additional international operations and assets in the future. Our international operations and assets may be subject to various economic, social, and governmental risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations and any future international operations may expose us to risks that could negatively impact our future results. Our operations may not develop in the same way or at the same rate as might be expected in a country with an economy similar to the United States. The additional risks that we may be exposed to in these cases include, but are not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs and trade barriers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">currency fluctuations, which could decrease our revenues or increase our costs in United States dollars;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations related to customs and import/export matters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax issues, such as tax law changes and variations in tax laws;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited access to qualified staff;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate infrastructure;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural and language differences;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate banking systems;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different and/or more stringent environmental laws and regulations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the repatriation of profits or payment of dividends;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disease outbreaks, environmental catastrophes, crime, strikes, riots, civil disturbances, terrorist attacks or wars;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nationalization or expropriation of property;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">law enforcement authorities and courts that are weak or inexperienced in commercial matters; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deterioration of political relations among countries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are exposed to risks associated with changes in foreign currency exchange rates. We present our consolidated financial statements in United States dollars. Our international subsidiaries have assets and liabilities denominated in currencies other than the United States dollar. Future expenses and revenues of our international subsidiaries are expected to be denominated in currencies other than in United States dollars. Therefore, movements in exchange rates to translate from foreign currencies may have an impact on our reported results of operations, financial position, and cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may pursue strategic acquisitions and investments that could have an adverse impact on our business if they are unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made acquisitions in the past and, if appropriate opportunities become available, we may acquire additional businesses, assets, technologies, or products to enhance our business in the future. In connection with any future acquisitions, we could:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue additional equity securities, which would dilute our current shareholders;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur substantial debt to fund the acquisitions; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assume significant liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we conduct due diligence reviews of our acquisition targets, such processes may fail to reveal significant liabilities. Acquisitions involve numerous risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems integrating the purchased operations, facilities, technologies, or products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs and other liabilities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential disruption of our ongoing business and diversion of management resources;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse effects on existing business relationships with current and/or prospective collaborators, customers and/or suppliers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenses related to the acquired operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with entering markets in which we have no or limited prior experience;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unknown liabilities associated with the acquired business and technology;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liabilities related to litigation involving the acquired companies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential periodic impairment of goodwill and intangible assets acquired; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential loss of key employees or potential inability to retain, integrate, and motivate key personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that any acquisition will be successful or that we will realize the anticipated benefits of the acquisition. In particular, we may not be able to realize the strategic and operational benefits and objectives we had anticipated. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions also may require us to record goodwill and non-amortizable intangible assets that will be subject to impairment testing on a regular basis and potential periodic impairment charges, incur amortization expenses related to certain intangible assets, and incur large and immediate write-offs and restructuring and other related expenses, all of which could harm our operating results and financial condition. In addition, we may acquire companies that have insufficient internal financial controls, which could impair our ability to integrate the acquired company and adversely impact our financial reporting. If we fail in our integration efforts with respect to any of our acquisitions and are unable to efficiently operate as a combined organization, our business, and financial condition may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trans Ova operates in an industry that is not a part of our core business, and may require additional resources and capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate advancing opportunities through Trans Ova. Trans Ova may never generate revenue that is significant or large enough to achieve or maintain profitability and may require us to divert the necessary capital and resources away from our core healthcare business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Alternatively, we may choose to divert the necessary capital and resources from further developing Trans Ova in order to focus on our core healthcare business. The failure of our subsidiaries, including Trans Ova, to become and remain profitable may decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Convertible Notes in cash or to repurchase the Convertible Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Convertible Notes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Convertible Notes have the right to require us to repurchase their Convertible Notes upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100 percent of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the Convertible Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Convertible Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Convertible Notes surrendered therefor or Convertible Notes being converted. In addition, our ability to repurchase the Convertible Notes or to pay cash upon conversions of the Convertible Notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase Convertible Notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the Convertible Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Convertible Notes or make cash payments upon conversions thereof.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Convertible Notes is triggered, holders of Convertible Notes will be entitled to convert the Convertible Notes at any time during specified periods at their option. If one or more holders elect to convert their Convertible Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Convertible Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accounting for convertible debt securities that may be settled in cash, such as the Convertible Notes, could have a material effect on our reported financial results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2008, the Financial Accounting Standards Board, or FASB, issued FASB Staff Position No. APB&#160;14-1,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which has subsequently been codified as Accounting Standards Codification, or ASC,&#160;Subtopic 470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC&#160;470-20. Under&#160;ASC&#160;470-20, an entity must separately account for the liability and equity components of the convertible debt instruments (such as the Convertible Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer's economic interest cost. The effect of&#160;ASC&#160;470-20&#160;on the accounting for the Convertible Notes is that the equity component is required to be included in the additional&#160;paid-in&#160;capital section of shareholders' equity on our consolidated balance sheet, and the value of the equity component would be treated as original issue discount for purposes of accounting for the debt component of the Convertible Notes. As a result, we record a greater amount of&#160;noncash&#160;interest expense in current periods presented as a result of the amortization of the discounted carrying value of the Convertible Notes to their face amount over the term of the Convertible Notes. We report lower net income in our financial results because ASC 470-20 requires interest to include both the current period's amortization of the debt discount and the instrument's coupon interest, which could adversely affect our reported or future financial results, the trading price of our common stock and the trading price of the Convertible Notes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under certain circumstances, convertible debt instruments (such as the Convertible Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Convertible Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Convertible Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess, if we elected to settle such excess in shares, are issued.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which will require us to use the "if-converted" method when calculating diluted earnings per share for convertible instruments. As the treasury stock method will no longer be permitted beginning in our fiscal year 2022, our diluted earnings per share could be adversely affected. Additionally, we cannot be sure whether other changes may be made to the current accounting standards related to the Convertible Notes, or otherwise, that could have an adverse impact on our financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use estimates in determining the fair value of certain assets and liabilities. If new information or changes in circumstances negatively impact our estimates, we may be required to write down the value of these assets or write up the value of these liabilities, which could adversely affect our financial position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to measure and report our financial position and operating results is influenced by the need to estimate the impact or outcome of future events on the basis of information available at the time of the financial statements. An accounting estimate is considered critical if it requires that management make assumptions about matters that were highly uncertain at the time the accounting estimate was made. If actual results differ from management's judgments and assumptions, then they may have an adverse impact on our results of operations and cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is estimated based on a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset or liability developed based on the best information available in the circumstances. The fair value hierarchy prioritizes the inputs to valuation techniques into three broad levels whereby the highest priority is given to Level 1 inputs and the lowest to Level 3 inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuations are highly dependent upon the reasonableness of management's assumptions and the predictability of the relationships that drive the results of our valuation methodologies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had net operating loss carryforwards of approximately $756.2 million for United States federal income tax purposes available to offset future taxable income, including $503.5 million generated after 2017, United States capital loss carryforwards of $211.5 million, and United States federal and state research and development tax credits of $10.2 million, prior to consideration of annual limitations that may be imposed under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382. Net operating loss carryforwards generated prior to 2018 begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. As a result of our past issuances of stock, as well as due to prior mergers and acquisitions, certain of our net operating losses have been subject to limitations pursuant to Section 382. As of December&#160;31, 2020, we had utilized all net operating losses subject to Section 382 limitations, other than those losses inherited via acquisitions. As of December&#160;31, 2020, approximately $42.1 million of domestic net operating losses were acquired via acquisition and are limited based on the value of the target at the time of the transaction. Future changes in stock ownership may also trigger an ownership change and, consequently, a Section&#160;382 limitation. As of December&#160;31, 2020, our direct foreign subsidiaries included in continuing operations had foreign loss carryforwards of approximately $82.3 million, most of which do not expire.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Act introduced certain limitations on utilization of losses that are generated after 2017, generally limiting utilization of those losses to 80 percent of future annual taxable income. However, net operating losses generated after 2017 will generally have an indefinite carryforward period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to compete may decline if we do not adequately protect our proprietary technologies or if we lose some of our intellectual property rights through costly litigation or administrative proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain patents and maintain adequate protection of our intellectual property in the United States and abroad for our suite of technologies and product candidates. We have adopted a strategy of seeking patent protection in the United States and abroad with respect to certain of the technologies used in or relating to our technologies and product pipeline. We have also in-licensed rights to additional patents and pending patent applications in the United States and abroad. We intend to continue to apply for patents relating to our technologies, methods, and products as we deem appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, we pursue protection to switch technologies, gene delivery technologies, and genetic componentry related to our pipeline products. In addition, we seek patents covering specific collaborator's products. We have also filed patents and patent applications in other jurisdictions, such as Australia, Brazil, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Korea, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and Taiwan. In the future we may file in these or additional jurisdictions as deemed appropriate for the protection of our technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enforceability of patents, as well as the actual patent term and expiration thereof, involves complex legal and factual questions and, therefore, the extent of enforceability cannot be guaranteed. Issued patents and patents issuing from pending applications may be challenged, invalidated, or circumvented. Moreover, the United States Leahy-Smith America Invents Act, enacted in September 2011, brought significant changes to the United States patent system, which include a change to a "first to file" system from a "first to invent" system and changes to the procedures for challenging issued patents and disputing patent applications during the examination process, among other things. These changes could increase the costs and uncertainties surrounding the prosecution of our patent applications and the enforcement or defense of our patent rights. Additional uncertainty may result from legal precedent handed down by the United States Court of Appeals for the Federal Circuit and United States Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies' patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that&#160;we were the first to invent the inventions covered by our pending patent applications; we were the first to file patent applications for these inventions; the patents we have obtained, particularly certain patents claiming nucleic acids, proteins, or methods, are valid and enforceable; and the proprietary technologies we develop will be patentable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unauthorized parties may attempt to copy or otherwise obtain and use our products or technology. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technologies, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import into the United States or other territories products, or information leading to potentially competing products, made using our inventions in countries where we do not have patent protection for those inventions. If competitors are able to use our technologies, our ability to compete effectively could be harmed. Moreover, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect our technologies, especially in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. While we require our employees, academic collaborators, collaborators, consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary or licensed information. If we cannot maintain the confidentiality of our proprietary and licensed technologies and other confidential information, our ability and that of our licensor to receive patent protection and our ability to protect valuable information owned or licensed by us may be imperiled. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods, and know-how.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from commercializing our technologies or impact our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success also depends in part on not infringing patents and proprietary rights of third parties and not breaching any licenses or other agreements that we have entered into with regard to our technologies, products, and business. We cannot ensure that patents have not been issued to third parties that could block our or our collaborators' ability to obtain patents or to operate as we would like. There may be patents in some countries that, if valid, may block our ability to make, use or sell our products in those countries, or import our products into those countries, if we are unsuccessful in circumventing or acquiring the rights to these patents. There also may be claims in patent applications filed in some countries that, if granted and valid, also may block our ability to commercialize products or processes in these countries if we are unable to circumvent or license them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry is characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many companies have employed intellectual property litigation as a way to gain a competitive advantage. Our involvement in litigation, interferences, opposition proceedings or other intellectual property proceedings inside and outside of the United States, to defend our intellectual property rights or as a result of alleged infringement of the rights of others, may divert management's time from focusing on business operations and could cause us to spend significant amounts of money. Some of our competitors may have significantly greater resources and, therefore, they are likely to be better able to sustain the cost of complex patent or intellectual property litigation than we could. The uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our business or to enter into additional collaborations with others. Furthermore, any potential intellectual property litigation also could force us or our collaborators to do one or more of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop selling, incorporating or using products that use the intellectual property at issue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain from the third party asserting its intellectual property rights a license to sell or use the relevant technology, which license may not be available on reasonable terms, if at all; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesign those products or processes that use any allegedly infringing technology, or relocate the operations relating to the allegedly infringing technology to another jurisdiction, which may result in significant cost or delay to us, or that could be technically infeasible.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent landscape in the field of biotechnology is particularly complex. We are aware of United States and foreign patents and pending patent applications of third parties that cover various aspects of cell and gene biology including patents that some may view as covering aspects of our technologies. In addition, there may be patents and patent applications in the field of which we are not aware. In many cases, the technologies we develop are early-stage technologies, and we are just beginning the process of designing and developing products using these technologies. Although we will seek to avoid pursuing the development of products that may infringe any patent claims that we believe to be valid and enforceable, we and our collaborators may fail to do so. Moreover, given the breadth and number of claims in patents and pending patent applications in the field of synthetic biology and the complexities and uncertainties associated with them, third parties may allege that we are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringing upon patent claims even if we do not believe such claims to be valid and enforceable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for claims we believe will not be material to our financial results, no third party has asserted a claim of infringement against us. Others may hold proprietary rights that could prevent products using our technologies from being marketed. Any patent-related legal action against persons who license our technologies or us claiming damages and seeking to enjoin commercial activities relating to products using our technologies or our processes could subject us to potential liability for damages and require our licensee or us to obtain a license to continue to manufacture or market such products or any future product candidates that use our technologies. We cannot predict whether we or our licensor would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that any such products or any future product candidates or processes could be redesigned to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us or our licensees from developing and commercializing products using our technologies, which could harm our business, financial condition, and operating results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors have filed patent applications or obtained patents that claim inventions also claimed by us, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention and, thus, the right to the patents for these inventions in the United States. These proceedings could result in substantial cost to us even if the outcome is favorable. Even if successful, an interference may result in loss of certain of our important claims.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any litigation or proceedings could divert our management's time and efforts. Even unsuccessful claims could result in significant legal fees and other expenses, diversion of management's time, and disruption in our business. Uncertainties resulting from initiation and continuation of any patent or related litigation could harm our ability to compete.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent process. Given the size of our intellectual property portfolio, compliance with these provisions involves significant time and expense. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain additional protection under the Hatch-Waxman Amendments, other United States legislation, and similar foreign legislation by extending the patent terms and obtaining regulatory exclusivity for our technologies, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and specifics of FDA marketing approval of products using our technologies, one or more of the United States patents we own or license may be eligible for limited patent term restoration under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues could be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our products may not have patent protection and, as a result, potential competitors face fewer barriers in introducing competing products. We may rely on trade secrets and other unpatented proprietary information to protect our commercial position with respect to such products, which we may be unable to do. In some instances, we may also rely on regulatory exclusivity, including orphan drug exclusivity, to protect our products from competition. Some of our or our collaborators' products may be subject to the BPCIA, which may provide those products exclusivity that prevents approval of a biosimilar product that references the data in one of our BLAs in the United States for 12 years after approval. However, the BPCIA and other regulatory exclusivity frameworks may evolve over time based on statutory changes, FDA issuance of new regulations, and judicial decisions. In addition, the BPCIA exclusivity period does not prevent another company from independently developing a product that is highly similar to an approved product, generating all the data necessary for a full BLA and seeking approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcing our intellectual property rights may be difficult and unpredictable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent claiming one of our technologies, the defendant could counterclaim that our patent is invalid and/or unenforceable or assert that the patent does not cover its manufacturing processes, manufacturing components or products. Proving patent infringement may be difficult, especially where it is possible to manufacture a product by multiple processes. Furthermore, in patent litigation in the United States, defendant counterclaims alleging both invalidity and unenforceability are commonplace. Although we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of our patent rights, we cannot be certain, for example, that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would not be able to exclude others from practicing the inventions claimed therein. Such a loss of patent protection could have a material adverse impact on our business. Even if our patent rights are found to be valid and enforceable, patent claims that survive litigation may not cover commercially valuable products or prevent competitors from importing or marketing products similar to our own, or using manufacturing processes or manufacturing components similar to those used to produce the products using our technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe we have obtained assignments of patent rights from all inventors, if an inventor did not adequately assign their patent rights to us, a third party could obtain a license to the patent from such inventor. This could preclude us from enforcing the patent against such third party.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to synthetic biology. This could make it difficult for us to stop the infringement of our patents or misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our technologies or products using our technologies are stolen, misappropriated, or reverse engineered, others could use the technologies to produce competing technologies or products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our collaborators, contract manufacturers, contractors and others involved in our business, often have access to our technologies. If our technologies, or products using our technologies, were stolen, misappropriated, or reverse engineered, they could be used by other parties that may be able to reproduce our technologies or products using our technologies, for their own commercial gain. If this were to occur, it would be difficult for us to challenge this type of use, especially in countries with limited intellectual property protection.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require our new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our technologies or products using our technologies, and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results have varied significantly in the past and may continue to fluctuate from quarter to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as other factors described elsewhere in this Annual Report: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve or maintain profitability;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our research programs, clinical trials, or other product development and approval processes;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and successfully commercialize our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of any payments received in connection with upfront, milestone, and sale and royalty payments, if any; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully scale up production of our commercial products and customer acceptance thereof;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into strategic transactions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain our technologies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the international aspects of our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately report our financial results in a timely manner;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on, and the need to attract and retain, key management, and other personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, protect and enforce our intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages that our competitors and potential competitors may have in securing funding or developing competing technologies or products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional capital that may be necessary to expand our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions such as power outages and other natural disasters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate any businesses or technologies we may acquire with our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative public opinion and increased regulatory scrutiny of gene and cell therapies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of new accounting pronouncements on our current and future operating results;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to use our net operating loss carryforwards to offset future taxable income; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our consolidated subsidiaries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of our future operating performance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is volatile, and purchasers of our common stock could incur&#160;substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this "Risk Factors" section, or for reasons unrelated to our operations, such as reports by media or industry analysts, investor perceptions or negative announcements by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our collaborators regarding their own performance, as well as industry conditions and general financial, economic and political instability. From January&#160;1, 2019 through February&#160;15, 2021, our common stock has traded as high as $11.10 per share and as low as $1.26 per share. The stock market in general, as well as the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of acquisitions, collaborations, financings, divestitures, or other transactions by us;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or delay of a development program;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this "Risk Factors" section.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there has been and may continue to be substantial off-market transactions in derivatives of our stock, including short selling activity or related similar activities, which are beyond our control and which may be beyond the full control of the SEC and Financial Institutions Regulatory Authority, or FINRA. While SEC and FINRA rules prohibit some forms of short selling and other activities that may result in stock price manipulation, such activity may nonetheless occur without detection or enforcement. Significant short selling or other types of market manipulation could cause our stock trading price to decline, to become more volatile, or both.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have historically, and may from time to time in the future, own equity interests in our collaborators. Owning equity in our collaborators increases our exposure to the risks of our collaborators' businesses beyond the products of those collaborations. Any equity ownership in our collaborators exposes us to volatility and the potential for negative returns. We may have restrictions on resale and/or limited markets to sell our equity ownership. If our equity position is a minority position, we are exposed to further risk as we will not be able to exert control over the companies in which we hold securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying cash dividends, and accordingly, shareholders will have to rely on any stock appreciation for return on their investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We do not anticipate paying cash dividends in the future and intend to retain all of our future earnings, if any, to finance the operations, development, and growth of our business. As a result, appreciation of the price of our common stock, which may never occur, will provide a return to shareholders. Investors seeking cash dividends should not invest in our common stock. We have twice distributed equity securities of affiliated entities to our shareholders as a special stock dividend, most recently in 2017, but it is possible that we may never declare a special dividend again, and shareholders should not rely upon potential future special dividends as a source of return on their investment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports, or publish inaccurate or unfavorable research or reports about our business, our share price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our shares of common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If securities or industry analysts do not continue to cover us, the trading price for our shares of common stock may be negatively impacted. If one or more of the analysts who covers us downgrades our shares of common stock, changes their opinion of our shares or publishes inaccurate or unfavorable research about our business, our share price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our shares of common stock could decrease and we could lose visibility in the financial markets, which could cause our share price and trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of our common stock pursuant to a share lending agreement, including sales of the shares that we lend, and other market activity related to the share lending agreement may lower the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our offering of the Convertible Notes in July 2018, we entered into a share lending agreement with J.P. Morgan Securities LLC (that we refer to when acting in this capacity as the "share borrower"), the underwriter for our offering, pursuant to which we agreed to lend up to 7,479,431 shares of our common stock to the share borrower.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were informed by the share borrower that it or one of its affiliates intended to use the short position created by the share </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan and the concurrent short sales of the borrowed shares to facilitate transactions by which investors in the Convertible Notes, or the Convertible Notes Investors, hedge their investments through short sales or privately negotiated derivatives transactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence of the share lending agreement in connection with the offering of the borrowed shares, the short sales of our common stock effected in connection with the sale of the Convertible Notes and the related derivatives transactions, or any unwind of such short sales or derivatives transactions, could cause the market price of our common stock to be lower over the term of the share lending agreement than it would have been had we not entered into that agreement, due to the effect of the increase in the number of outstanding shares of our common stock or otherwise. For example, in connection with any cash settlement of any such derivative transaction, the share borrower or its affiliates may purchase shares of our common stock and the Convertible Notes Investors may sell shares of our common stock, which could temporarily increase, temporarily delay a decline in, or temporarily decrease, the market price of our common stock. The market price of our common stock could be further negatively affected by these or other short sales of our common stock, including other sales by the Convertible Notes Investors hedging their investment therein.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjustments by the Convertible Notes Investors of their hedging positions in our common stock and the expectation thereof may have a negative effect on the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The borrowed shares are used by the Convertible Notes Investors to establish hedged positions with respect to our common stock through short sale transactions or privately negotiated derivative transactions. The number of borrowed shares may be more or less than the number of shares that will be needed in such hedging transactions. Any buying or selling of shares of our common stock by those Convertible Notes Investors to adjust their hedging positions may affect the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the existence of the Convertible Notes may also encourage short selling by market participants because the conversion of the Convertible Notes could depress our common stock price. The price of our common stock could be affected by possible sales of our common stock by the Convertible Notes Investors who view the Convertible Notes as a more attractive means of equity participation in us and by hedging or arbitrage trading activity that we expect to occur involving our common stock. This hedging or arbitrage trading activity could, in turn, affect the market price of the Convertible Notes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the accounting guidelines relating to the borrowed shares or our inability to classify the borrowed shares as equity could decrease our reported earnings per share and potentially our common stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the borrowed shares (or identical shares) must be returned to us when the share lending agreement terminates pursuant to its terms (or earlier in certain circumstances), we believe that under generally accepted accounting principles in the United States, or U.S. GAAP, as presently in effect, assuming the borrowed shares issued pursuant to the share lending agreement are classified as equity under U.S. GAAP, the borrowed shares will not be considered outstanding for the purpose of computing and reporting our earnings per share. If accounting guidelines were to change in the future or we are unable to classify the borrowed shares issued pursuant to the share lending agreement as equity, we may be required to treat the borrowed shares as outstanding for purposes of computing earnings per share, our reported earnings per share would be reduced and our common stock price could decrease, possibly significantly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As of December&#160;31, 2020, Randal J. Kirk controlled approximately 44 percent of our common stock. If our executive officers and directors choose to act together, they may be able to significantly influence our management and operations, acting in their own best interests and not necessarily those of other shareholders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically been controlled, managed, and principally funded by Randal J. Kirk, our former Chief Executive Officer and current Executive Chairman, and affiliates of Mr. Kirk, including Third Security. As of December&#160;31, 2020, Mr. Kirk and shareholders affiliated with him beneficially owned approximately 44 percent of our voting stock, and our executive officers and directors, as a group, owned approximately 46 percent of our voting common stock. Mr. Kirk may be able to control or significantly influence all matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions, and he may be able to exert significant influence on other corporate actions as a result of his role as our Executive Chairman and status as a significant shareholder. Further, our executive officers and directors, acting together as shareholders, would be able to significantly influence all matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions, as well as our management and affairs. The interests of this group of shareholders may not always coincide with the interests of other shareholders, and they may act in a manner that advances their best interests and not necessarily those of other shareholders. This concentration of ownership control may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, defer, or prevent a change in control;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entrench our management and/or the board of directors; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impede a merger, consolidation, takeover, or other business combination involving us that other shareholders may desire.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have engaged in transactions with companies in which Randal J. Kirk, our Executive Chairman, and his affiliates have an interest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in a variety of transactions, including collaborations and our sale of our non-healthcare assets to TS Biotechnology, with companies in which Mr. Kirk and affiliates of Mr. Kirk have a direct or indirect interest. See "Notes to the Consolidated Financial Statements - Notes 1, 3, 4, 5, 6, 14, 15, 17, and 18" appearing elsewhere in this Annual Report for a discussion of such transactions. Mr. Kirk serves as the Senior Managing Director and Chairman of Third Security and owns 100 percent of the equity interests of Third Security. We believe that each of these transactions was on terms no less favorable to us than terms we could have obtained from unaffiliated third parties, and each of these transactions was approved by at least a majority of the disinterested members of the audit committee of our board of directors. Furthermore, as we execute on these transactions going forward, a conflict may arise between our interests and those of Mr. Kirk and his affiliates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. If Mr. Kirk or any of his affiliates were to sell a substantial portion of the shares they hold, it could cause our stock price to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2020, there were 11,255,896 shares subject to outstanding options that will become eligible for sale in the public market to the extent permitted by any applicable vesting requirements, lock-up agreements and Rules 144 and 701 under the Securities Act of 1933, as amended. As of December&#160;31, 2020, there were 1,727,712 Restricted Stock Units, or RSUs, outstanding. Shares issuable upon the exercise of such options and upon vesting of the RSUs can be freely sold in the public market upon issuance and once vested. Additionally, as of December&#160;31, 2020, we had 7,055,010 of shares available for grant under the 2013 Omnibus Incentive Plan and 2,432,624 shares available for grant under the 2019 Incentive Plan for Non-Employee Service Providers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our articles of incorporation authorize us to issue preferred stock with terms that are preferential to those of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles of incorporation authorize us to issue, without the approval of our shareholders, one or more classes or series of preferred stock having such designations, preferences, limitations and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors may determine. For example, in connection with the formation of a Preferred Stock Equity Facility, which was subsequently terminated in June 2018, we filed an amendment to our articles of incorporation to set the designations of our Series A Preferred Stock. Effective February 1, 2020, the Series A Preferred Stock designations was terminated. In the future, we may enter into similar facilities or issue preferred stock that has greater rights, preferences, and privileges than our common stock. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-takeover provisions in our articles of incorporation and bylaws and under Virginia law that could delay or prevent an acquisition of our Company, even if the acquisition would be beneficial to our shareholders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of Virginia law, the commonwealth in which we are incorporated, and our articles of incorporation and bylaws could hamper a third party's acquisition of us, or discourage a third party from attempting to acquire control of us. These provisions:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">include a provision allowing our board of directors to issue preferred stock with rights senior to those of the common stock without any vote or action by the holders of our common stock. The issuance of preferred stock could adversely affect the rights and powers, including voting rights, of the holders of common stock;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at shareholder meetings;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for the inability of shareholders to convene a shareholders' meeting without the support of shareholders </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owning together 25 percent of our common stock;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for the application of Virginia law prohibiting us from entering into a business combination with the beneficial owner of 10 percent or more of our outstanding voting stock for a period of three years after the 10 percent or greater owner first reached that level of stock ownership, unless we meet certain criteria;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which shareholders can remove directors from the board;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that shareholder actions must be effected at a duly called shareholder meeting and prohibit actions by our shareholders by written consent; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call a special meeting of shareholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions also could limit the price that certain investors might be willing to pay in the future for shares of our common stock. In addition, these provisions make it more difficult for our shareholders, should they choose to do so, to remove our board of directors or management.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_19"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_22"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish the geographic locations of our research and development operations based on proximity to the relevant market expertise and access to available talent pools. The following table shows information about our primary lab operations used in our healthcare operations as of December&#160;31, 2020:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.184%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Square&#160;Footage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germantown, Maryland (PGEN Therapeutics segment)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ghent, Belgium (ActoBio segment)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary domestic production facilities, for our Trans Ova segment, are located in Sioux Center, Iowa, and include approximately 275,000 square feet of production and office facilities and approximately 360 acres of land. The land and production facilities are primarily used for embryo transfer and IVF processes, as well as housing livestock used in such processes. We also lease or own regional production facilities and land in California, Maryland, Missouri, South Dakota, Texas, Washington, and Wisconsin for these purposes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary administrative offices are in Germantown, Maryland, and Blacksburg, Virginia. See also "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8212; Contractual Obligations and Commitments" appearing elsewhere in this Annual Report.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_25"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of our business, we are involved in litigation and legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. We do not believe that any such matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, results of operations, or cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Notes to the Consolidated Financial Statements - Note 17" appearing elsewhere in this Annual Report for further discussion of ongoing legal matters.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_28"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART II</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_34"></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market, or Nasdaq, under the symbol "PGEN". </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;15, 2021, we had 287 holders of record of our common stock. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include shareholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain earnings, if any, to finance the growth and development of our business and do not expect to pay any cash dividends on our common stock in the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_67">Item 12 of Part III</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This performance graph shall not be deemed "soliciting material" or to be "filed" with the SEC for purposes of Section&#160;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Precigen, Inc. under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows a comparison from December&#160;31, 2015 through December&#160;31, 2020 of the cumulative total return for our common stock; the Standard&#160;&amp; Poor's 500 Stock Index, or the S&amp;P 500 Index; and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested at the market close on December&#160;31, 2015 in the common stock of Precigen, Inc., the S&amp;P 500 Index, and the Nasdaq Biotechnology Index, and data for the S&amp;P 500 Index and the Nasdaq Biotechnology Index assumes reinvestments of dividends. The stock price performance of the following graph is not necessarily indicative of future stock price performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="pgen-20201231_g18.jpg" alt="pgen-20201231_g18.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company / Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Base Period 12/31/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Precigen, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">asdaq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> Biotechnology Index</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company / Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Precigen, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">S&amp;P 500 Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company / Index</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Precigen, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">S&amp;P 500 Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities and Use of Proceeds from Registered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Use of Proceeds</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_37"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Selected Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our selected consolidated financial data for the periods and as of the dates indicated. You should read the following selected consolidated financial data in conjunction with our audited consolidated financial statements and the related notes thereto included elsewhere in this Annual Report and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selected consolidated financial data set forth below as of December&#160;31, 2020 and 2019, and for the years ended December&#160;31, 2020, 2019 and 2018, are derived from our audited consolidated financial statements included elsewhere in this Annual Report. The selected consolidated financial data set forth below as of December&#160;31, 2018, 2017, and 2016, and for the years ended December&#160;31, 2017 and 2016, are derived from our audited consolidated financial statements contained in reports previously filed with the SEC, not included herein. Our audited consolidated financial statements have been prepared in United States dollars in accordance with U.S. GAAP. The selected consolidated financial data in the below tables have been adjusted to reflect the effects of discontinued operations. See "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,065,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,138,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,998,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,983,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current and non-current (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Precigen shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues and deferred revenue in 2020, 2019, and 2018 are accounted for under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, and revenues and deferred revenue prior to 2018 are accounted for under ASC 605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 605. We adopted ASC 606 on January 1, 2018 using the modified retrospective method, which applies the changes in accounting prospectively and does not restate prior periods. See "Notes to the Consolidated Financial Statements - Notes 4, 6, and 18" for discussions of transactions in 2018 resulting in a decrease in the balances of deferred revenue.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total assets include $191, $161,225, and $129,545 of investments in preferred stock as of December&#160;31, 2018, 2017, and 2016, respectively. In conjunction with the ZIOPHARM License Agreement in 2018, all of our ZIOPHARM preferred shares were returned to ZIOPHARM. See "Notes to the Consolidated Financial Statements - Notes 10 and 11" for discussions of impairment losses on goodwill and other noncurrent assets recognized in 2020 and 2019.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In 2018, we completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Other liabilities include $8,801 of deferred consideration as of December 31, 2016.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_40"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with, Part I, Item&#160;1, "Business" and Item&#160;8, "Financial Statements and Supplementary Data." For information on risks and uncertainties related to our business that may make past performance not indicative of future results, or cause actual results to differ materially from any forward-looking statements, see "Special Note Regarding Forward-Looking Statements," and Part I, Item&#160;1A, "Risk Factors."</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. We anticipate that we may continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. Our historical collaboration and licensing revenues were generated under a business model from which we have gradually transitioned, and we do not expect to expend significant resources servicing our historical collaborations in the future. We may enter into strategic transactions for individual platforms or programs in the future from which we may generate new collaboration and licensing revenues. We continue to generate product and service revenues through our Trans Ova and Exemplar subsidiaries, and in 2020, both of these subsidiaries generated positive Segment Adjusted EBITDA. Products currently in our clinical pipeline will require regulatory approval and/or commercial scale-up before they may commence significant product sales and operating profits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, as part of our efforts to focus our business on the healthcare industry, we sold a number of our non-healthcare assets to TS Biotechnology and separately sold our interest in EnviroFlight to Darling, referred to collectively as the Transactions. We determined that the assets, liabilities and operations sold in the Transactions collectively met the criteria for discontinued operations and have been reclassified and presented as such for all periods. As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, we suspended MBP </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially complete by December 31, 2020, with the final disposition of certain property and equipment and the facility operating lease occurring in January 2021. As of December 31, 2020, we determined that the assets, liabilities, and expenses related to the discontinued operations of MBP Titan met the criteria for discontinued operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report for further discussion of discontinued operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we continue our efforts to focus our business and generate additional capital, we may be willing to enter into transactions involving one or more of our operating segments and reporting units for which we have goodwill and intangible assets. These efforts could result in us identifying impairment indicators or recording impairment charges in future periods. In addition, market changes and changes in judgments, assumptions and estimates that we have made in assessing the fair value of goodwill could cause us to consider some portion or all of certain assets to become impaired.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have derived our collaboration and licensing revenues through agreements with counterparties for the development and commercialization of products enabled by our technologies. Generally, the terms of these collaborations provide that we receive some or all of the following: (i) technology access fees upon signing; (ii) reimbursements of costs incurred by us for our research and development and/or manufacturing efforts related to specific applications provided for in the collaboration; (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv) royalties on sales of products arising from the collaboration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology access fees and milestone payments may be in the form of cash or securities of the collaborator. Our collaborations contain multiple arrangements, and we typically defer revenues from the technology access fees and milestone payments received and recognize such revenues in the future over the anticipated performance period. We are also entitled to sublicensing revenues in those situations where our collaborators choose to license our technologies to other parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to shift our focus on our healthcare business, we have and may continue to mutually terminate collaboration agreements or repurchase rights to the exclusive fields from collaborators, relieving us of any further performance obligations under the agreement. Upon such circumstances or when we determine no further performance obligations are required of us under an agreement, we may recognize any remaining deferred revenue as either collaboration revenue or as a reduction of operating expense, depending on the circumstances. See "Notes to the Consolidated Financial Statements - Note 6" appearing elsewhere in this Annual Report for a discussion of changes to our significant collaborations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product and service revenues primarily through sales of products or services that are created from technologies developed or owned by us. Our primary current offerings arise from Trans Ova and include sales of advanced reproductive technologies, including our bovine embryo transfer and IVF processes and from genetic preservation and sexed semen processes, and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production.&#160;Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. We recognize revenue when control of the promised product is transferred to the customer or when the promised service is completed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, in connection with our focus on healthcare, our revenues will primarily depend on our ability to advance and create our own programs and the extent to which we bring products enabled by our technologies to market. Other than for collaboration revenues recognized upon cancellation or modification of an existing collaboration or for revenues generated pursuant to future strategic transactions for any of our existing platforms or programs, we expect our collaboration revenues will continue to decrease in the near term. Our revenues will also depend upon our ability to maintain or improve the volume and pricing of Trans Ova's and Exemplar's current product and service offerings and to develop and scale up production of new offerings from the various technologies of our subsidiaries. As we focus on our healthcare business, we anticipate that our expenses will increase substantially if, and as, we continue to advance the preclinical and clinical development of our existing product candidates and our research programs. We expect a significant period of time could pass before commercialization of our various product candidates or before the achievement of contractual milestones and the realization of royalties on product candidates commercialized under our collaborations and revenues sufficient to achieve profitability. Accordingly, there can be no assurance as to the timing, magnitude, and predictability of revenues to which we might be entitled.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of products and services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products and services includes primarily labor and related costs, drugs and supplies used primarily in Trans Ova's embryo transfer and IVF processes, livestock and feed used in production, and facility charges, including rent and depreciation. Fluctuations in the price of livestock and feed have not had a significant impact on our operating margins and no derivative financial instruments are used to mitigate the price risk.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries and benefits, including stock-based compensation expense, for personnel in research and development functions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants and contract research organizations who perform research on our behalf and under our direction;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to laboratory supplies used in our research and development efforts and acquiring, developing, and manufacturing preclinical study and clinical trial materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to certain in-licensed technology rights or reacquired in-process research and development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amortization of patents and related technologies acquired in mergers and acquisitions; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include direct depreciation costs and unallocated expenses for rent and maintenance of facilities and other operating costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses are generally incurred by our operating segments and primarily relate to either costs incurred to expand or otherwise improve our technologies or the costs incurred to develop our own products and services. PGEN Therapeutics is progressing preclinical and clinical programs in immuno-oncology, autoimmune disorders and infectious diseases, including PRGN-3005 and PRGN-3006 which are both in Phase 1/1b clinical trials. ActoBio has a portfolio of candidates available for clinical development across a number of potential indications using our ActoBiotics platform, including its most advanced candidate, AG019, that is currently in a Phase 1b/2a clinical trial. Trans Ova's research and development activities support new and improved product and service offerings for its customers. The Human Biotherapeutics division supports our INXN-4001 product candidate with Triple-Gene and our partnered program with Castle Creek. Other operating segment research and development primarily relates to Exemplar's research and development activities related to new and improved pig research models. The following table summarizes our research and development expenses incurred by reportable segment for the years ended December 31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Biotherapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses from reportable segments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses from operating segments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,641&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles research and development expenses by reportable segments to research and development expenses on the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses from reportable segments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development expenses, including from other operating segments (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,644&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes corporate research and development expenses not allocated to operating segments, as well as certain expenses incurred to reacquire previously licensed technology rights in the year ended December 31, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of research and development expenses may be impacted by, among other things, the number and nature of our own proprietary programs, and the number and size of programs we may support on behalf of an ECC. We expect that our research and development expenses will increase as we continue to develop our own proprietary programs, including progression of these programs into preclinical and clinical stages. We believe these increases will likely include increased costs paid to consultants and contract research organizations, and increased costs related to laboratory supplies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses may also increase as a result of ongoing research and development operations that we might assume through mergers and acquisitions or in-licensing of technologies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative, or SG&amp;A, expenses consist primarily of salaries and related costs, including stock-based compensation expense, for employees in executive, operational, finance, information technology, legal, and corporate communications functions. Other significant SG&amp;A expenses include rent and utilities, insurance, accounting, and legal services (including the cost of settling any claims and lawsuits), and expenses associated with obtaining and maintaining our intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses may fluctuate in the future depending on the scaling of our corporate functions required to support our corporate initiatives, and the outcomes of legal claims and assessments against us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically held equity securities and preferred stock of private and publicly traded companies, including investments received and/or purchased from certain collaborators. These equity securities and preferred stock were recorded at fair value at each reporting date. Unrealized appreciation (depreciation) resulting from fair value adjustments were reported as other income (expense) in the consolidated statements of operations. In January 2020, as part of the TS Biotechnology Sale, we sold our remaining equity securities and investment in preferred stock, and therefore, no future gains (losses) will be incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is expected to increase in future periods due to the noncash amortization of the long-term debt discount and debt issuance costs related to the Convertible Notes due July 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash and cash equivalents and short-term investments and may fluctuate based on amounts invested and current interest rates. Dividend income historically consisted of the monthly preferred stock dividends received from our investments in preferred stock, all of which have been liquidated as of December 31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity in net income (loss) of affiliates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in net income or loss of affiliates is our pro-rata share of our equity method investments' operating results, adjusted for accretion of basis difference. We account for investments in our JVs using the equity method of accounting since we have the ability to exercise significant influence, but not control, over the operating activities of these entities. We previously accounted for our investments in start-up entities backed by Harvest using the equity method of accounting. In December 2020, we entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and our remaining equity interests in start-up entities backed by Harvest were terminated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment performance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Segment Adjusted EBITDA as our primary measure of segment performance. We define Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. Corporate expenses are not allocated to the segments and are managed at a consolidated level. See "Notes to the Consolidated Financial Statements - Note 20" appearing elsewhere in this Annual Report for further discussion of Segment Adjusted EBITDA.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the year ended December 31, 2020 to the year ended December 31, 2019</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2020 and 2019, together with the changes in those items in dollars and as a percentage:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing revenues (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,603)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;200%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income tax benefit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323,916)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,324)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Including $3,053 and $11,832 from related parties for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">See "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the collaboration and licensing revenue recognized for the years ended December 31, 2020 and 2019, together with the changes in those items.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics,&#160;Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the year ended December 31, 2019, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and licensing revenues increased $7.1 million, or 51 percent, over the year ended December 31, 2019 primarily due to the accelerated recognition of previously deferred revenue upon the mutual terminations of collaborations with Castle Creek and Oragenics in 2020. This increase was partially offset by a decrease in collaboration revenues related to programs that have been paused since the second half of 2019 while the other parties evaluate the status of the projects and their desired future development activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product revenues and gross margin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues increased $0.6 million, or 2 percent, over the year ended December 31, 2019. The increase in product revenue was primarily due to higher customer demand for animal products. Gross margin on products improved in the current period as a result of operational efficiencies gained through reductions in workforce and improved inventory management and a decrease in the cost of cows used in production.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service revenues and gross margin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenues increased $5.1 million, or 10 percent, over the year ended December 31, 2019. Trans Ova's service revenues and gross margins thereon increased due to an increase in services performed for new and existing customers and the expansion of its commercial dairy business. Gross margin also increased due to a reduction in third-party royalty rate obligations for certain licensed technologies and reductions in workforce. Additionally, Exemplar's service revenues increased in the current period due to an increase in services performed resulting from higher demand from existing customers, which also improved gross margin on services performed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $25.0 million, or 38 percent, from the year December 31, 2019. Salaries, benefits, and other personnel costs decreased $7.3 million and contract research organization costs and lab supplies decreased $13.9 million in 2020 as we deprioritized certain programs at ActoBio and closed two of our operating divisions in 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $6.9 million, or 7 percent, from the year ended December 31, 2019, and include a decrease in professional fees payable to certain third-party vendors and reduced personnel costs as we scaled down our corporate functions to support a more streamlined organization. Other corporate expenses decreased $2.6 million as part of the streamlined organization and the impact of the COVID-19 pandemic on travel. These decreases were partially offset by increased share-based compensation expense attributable to equity grants made in the first quarter of 2020, one-time severance costs for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminated employees, and increased legal fees associated with litigation matters, including our settlements with Harvest and the SEC.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of goodwill and other noncurrent assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses for the year ended December 31, 2020 of $0.9 million were due to the impairment of the right-of-use assets for certain of our leased facilities. Impairment losses for the year ended December 31, 2019 of $30.8 million arose primarily from a goodwill impairment charge related to Trans Ova.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total other expense, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net, which primarily includes interest expense, increased $14.1 million, or over 200 percent, over the year ended December 31, 2019. In 2019, our equity securities and investments in preferred stock, which were fully liquidated by early 2020, had net unrealized and realized appreciation of $8.3 million that partially offset interest expense of $17.7 million. As these investments were fully liquidated by early 2020, there was no such appreciation to offset interest expense of $18.4 million in 2020. Additionally, interest income earned on our short-term investments decreased in 2020 due to lower interest rates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment performance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Segment Adjusted EBITDA, which is our primary measure of segment performance, for the years ended December&#160;31, 2020 and 2019, for each of our reportable segments and for All Other segments combined, as well as unallocated corporate costs.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,861)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Biotherapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a reconciliation of Segment Adjusted EBITDA to net loss from continuing operations before income taxes, see "Notes to the Consolidated Financial Statements - Note 20" appearing elsewhere in this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from external customers for the years ended December&#160;31, 2020 and 2019, for each of our reportable segments and for All Other segments combined.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;200%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Biotherapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;200%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PGEN Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for PGEN Therapeutics declined from 2019 to 2020 because we had no significant collaborations requiring services in 2020. Segment Adjusted EBITDA improved due to higher costs for contract research organizations incurred in 2019 for preclinical activities on certain programs prior to moving to clinical trials and the manufacturing of clinical trial materials in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advance of initiation of the trials. Additionally, fewer costs related to the PRGN-3005 Phase 1 trials were incurred in the second quarter of 2020 as enrollment of new patients in this trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. Costs related to PGEN Therapeutics' clinical trials are expected to increase in 2021 as the trials progress and as we initiate new clinical trials for new clinical programs. Finally, capital expenditures decreased in the current period as PGEN Therapeutics completed an expansion of its lab facilities in 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ActoBio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for ActoBio increased primarily due to accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Oragenics in July 2020. Segment Adjusted EBITDA has improved as ActoBio incurred fewer costs with contract research organizations due to deprioritizing certain programs in late 2019 and fewer AG019 trial costs in the second quarter of 2020 due to the temporary suspension of the last cohort of the Phase 1b/2a clinical trial.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trans Ova</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for Trans Ova increased primarily as a result of more procedures performed for new and existing customers and the expansion of its commercial dairy business. The improvement in Segment Adjusted EBITDA was primarily due to operational efficiencies gained through reductions in workforce and improved inventory management, a decrease in the cost of cows used in production, and a reduction in third-party royalty rate obligations for certain licensed technologies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Human Biotherapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Human Biotherapeutics' revenues was due to the accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. Segment Adjusted EBITDA declined due to one-time severance costs associated with workforce reductions in the first quarter of 2020 and increased costs for contract research organizations related to our INXN-4001 program.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">All Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Revenues in All Other decreased in 2020 as our partnered programs with Harvest start-up entities were paused since the third quarter of 2019. These decreases were partially offset by an increase in Exemplar's revenues as a result of higher demand from its existing customers. Segment Adjusted EBITDA improved period over period as a result of improved Segment Adjusted EBITDA at Exemplar due to its higher revenues and reduced costs, as well as the closure of two operating segments in 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Unallocated Corporate Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Unallocated corporate costs decreased primarily due to a reduction of corporate employees as well as a decrease in certain professional fees as we scaled down our corporate functions to support our more streamlined organization. These decreases were partially offset by an increase in legal fees associated with litigation matters, including our settlement with the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:110%">Comparison of the year ended December 31, 2019 to the year ended December 31, 2018</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2019 and 2018, together with the changes in those items in dollars and as a percentage:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing revenues (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,722&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,178&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,456)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520,845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,789)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395,912)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,648&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380,487)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income tax benefit (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323,916)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514,706)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,324)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Including $11,832 and $55,573 from related parties for the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">See "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the collaboration and licensing revenue recognized for the years ended December 31, 2019 and 2018, together with the changes in those items.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology, Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ares Trading S.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics,&#160;Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon T1D Partners, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,585)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,481)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the years ended December 31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December 31, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration and licensing revenues decreased $55.5 million, or 80 percent, from the year ended December 31, 2018 primarily due to the reacquisition of rights previously licensed to certain collaborators, including ZIOPHARM, Ares Trading, and certain of the Harvest start-up entities, the result of which eliminated or substantially reduced revenues generated from those collaborations. Additionally, in 2018, we recognized additional revenues which arose from the acceleration of previously deferred revenue upon mutual termination of certain collaborations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product revenues and gross margin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues decreased $4.7 million, or 17 percent, from the year ended December 31, 2018. The decrease in product revenues was primarily due to lower customer demand in the beef and dairy industries resulting in fewer sales of pregnant cows and calf products. Gross margin on products declined in the current period as a result of fewer products sold.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service revenues and gross margin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenues decreased $0.6 million, or 1 percent, from the year ended December 31, 2018. Trans Ova's service revenues and gross margin thereon declined slightly due to fewer services performed and underutilized capacity as a result of lower customer demand.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $266.3 million, or 80 percent, from the year ended December 31, 2018. The 2018 research and development expenses include $236.7 million of expenses related to in-process research and development reacquired from former collaborators.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses decreased $26.5 million, or 21 percent, from the year ended December 31, 2018. Salaries, benefits and other personnel costs decreased $16.4 million primarily due to decreased share-based compensation expense as a result of the reversal of previously recognized expense for unvested options granted to former employees as well as the conclusion of the vesting period for other previously granted stock options. Legal and professional fees decreased $7.0 million primarily due to fewer legal fees associated with Trans Ova.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of goodwill and other noncurrent assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses for the year ended December 31, 2019 of $30.8 million arose primarily from a goodwill impairment charge related to Trans Ova following an annual goodwill impairment test where we determined that it was more-likely-than-not that the fair value of Trans Ova was less than its carrying value</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total other expense, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net, decreased $15.2 million, or 88 percent, over the year ended December 31, 2018. This decrease was primarily attributable to an improvement in unrealized and realized appreciation (depreciation) on our securities portfolio of $36.6 million primarily due to unrealized losses on our ZIOPHARM preferred stock in 2018 and a realized gain on the sale of our common shares held in AquaBounty Technologies, Inc., or AquaBounty, in October 2019, net of a decrease in dividend income of $15.1 million following the return of our investment in ZIOPHARM preferred stock to ZIOPHARM in October 2018. Additionally, these decreases were partially offset by an increase in interest expense of $8.6 million associated with our Convertible Notes issued in July 2018.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment performance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Segment Adjusted EBITDA, which is our primary measure of segment performance, for the years ended December&#160;31, 2019 and 2018, for each of our reportable segments and for All Other segments combined, as well as unallocated corporate costs.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(865)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Biotherapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a reconciliation of Segment Adjusted EBITDA to net loss from continuing operations before income taxes, see "Notes to the Consolidated Financial Statements - Note 20" appearing elsewhere in this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from external customers for the years ended December&#160;31, 2019 and 2018, for each of our reportable segments and for All Other segments combined.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended&#160;<br/>&#160;December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar<br/>Change</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent<br/>Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Biotherapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PGEN Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for PGEN Therapeutics declined from 2018 to 2019 primarily due to the reacquisition of rights previously licensed to certain collaborators, which eliminated or significantly reduced collaboration revenues from research and development services provided and recognition of previously deferred revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ActoBio</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ActoBio reacquired rights previously licensed to certain collaborators, including Intrexon T1D Partners, Inc., resulting in the elimination of collaboration revenues from research and development services performed in 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trans Ova</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Trans Ova's Segment revenues was primarily attributable to lower product revenues due to lower customer demand.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Human Biotherapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human Biotherapeutics was a new segment in 2019 and the revenue is associated with our collaboration with Castle Creek. Segment Adjusted EBITDA includes the costs associated with our collaboration with Castle Creek as well as our INXN-4001 program.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">All Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Segment Adjusted EBITDA of All Other improved period over period due our closure of two reporting units in 2019 and write-downs of certain long-lived assets in 2018. Revenues in All Other declined in 2019 as result of fewer research and development services performed for collaborations with Harvest start-up entities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Unallocated Corporate Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Unallocated corporate costs decreased primarily due to an improvement in unrealized and realized appreciation (depreciation) on our securities portfolio of $36.6 million primarily due to unrealized losses on our ZIOPHARM preferred stock in 2018 and a realized gain on the sale of our common shares held in AquaBounty in October 2019, net of a decrease in dividend income of $15.1 million following the return of our investment in ZIOPHARM preferred stock to ZIOPHARM in October 2018. Additionally, consolidated costs from AquaBounty decreased in 2019 due to our deconsolidation in April 2019. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses from operations since our inception, and as of December&#160;31, 2020, we had an accumulated deficit of $1.8 billion. From our inception through December&#160;31, 2020, we have funded our operations principally with proceeds received from private and public equity and debt offerings, cash received from our collaborators, and through product and service sales made directly to customers. As of December&#160;31, 2020, we had cash and cash equivalents of $51.8 million and short-term investments of $48.3 million. In January 2021, we closed an underwritten public offering of our common stock, resulting in net proceeds of approximately $121.2 million, after deducting underwriting discounts and estimated offering expenses. Cash in excess of immediate requirements is typically invested primarily in money market funds and United States government debt securities in order to maintain liquidity and preserve capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate cash receipts primarily from sales of products and services and from strategic transactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Trans Ova was in compliance with the debt covenants associated with its line of credit as discussed in "Notes to the Consolidated Financial Statements - Note 12" appearing elsewhere in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant sources and uses of cash for the periods set forth below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,021)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,927)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,795&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,184)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,748)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,637&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from operating activities:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our net loss was $170.5 million, which includes the following significant noncash expenses totaling $107.9 million from both continuing and discontinued operations: (i) $27.0 million of accumulated foreign currency translation losses that were realized upon the closing of the Transactions, (ii) $23.0 million of impairment losses related to goodwill and long-lived assets, (iii) $18.4 million of stock-based compensation expense, (iv) $17.5 million of depreciation and amortization expense, (v) $11.4 million loss on settlement agreement with Harvest, and (vi) $10.6 million accretion of debt discount and amortization of deferred financing costs. These expenses were partially offset by the recognition of $12.8 million of previously deferred revenue upon the mutual terminations of collaboration agreements with Castle Creek and Oragenics in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, our net loss was $323.9 million, which includes the following significant noncash expenses totaling $191.0 million from both continuing and discontinued operations: (i) $120.5 million of impairment loss, (ii) $24.9 million of depreciation and amortization expense, (iii) $19.0 million of stock-based compensation expense, (iv) $10.4 million of shares issued for payment of services, (v) $9.5 million accretion of debt discount and amortization of deferred financing costs, and (vi) $6.7 million of equity in net loss of affiliates. These expenses were partially offset by $7.8 million of unrealized and realized appreciation on equity securities and preferred stock, net. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, our net loss was $514.7 million, which includes the following significant noncash expenses totaling $440.0 million from both continuing and discontinued operations: (i) $236.7 million of expense related to reacquired in-process research and development previously licensed to certain of our collaborators, (ii) $60.5 million of impairment loss, (iii) $36.3 million of stock-based compensation expense, (iv) $33.1 million of depreciation and amortization expense, (v) $30.2 million of net unrealized and realized losses on our equity securities and preferred stock, (vi) $20.9 million of loss on disposal of assets, (vii) $11.6 million of equity in net loss of affiliates, and (viii) $10.7 million of shares issued as payment for services. These expenses were partially offset by (i) $21.3 million of net changes in deferred income taxes and (ii) $14.8 million of noncash dividend income. Additionally, we had a $20.0 million net increase in our operating assets and liabilities primarily as a result of the recognition of previously deferred revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 cash outflows from operations decreased $58.9 million from the year ended December 31, 2019 primarily due to (i) the reduction in cash required to fund the businesses sold in the TS Biotechnology Sale, (ii) the reduction in cash requirements for MBP Titan as we wound down those operations starting in the second quarter of 2020, and (iii) reductions in operating expenses for our ActoBio and corporate operations as we streamlined both in order to further prioritize the use of our capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2019 cash outflows from operations increased $11.7 million over the year ended December 31, 2018 due to increased expenses primarily for our clinical programs combined with the lack of reimbursement for research and development services we used to receive under certain key collaborations which we reacquired in 2018.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from investing activities:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we purchased $171.4 million of investments, primarily using the $64.2 million of proceeds received from the Transactions, net of cash sold, and the private placement discussed below. We also reinvested a portion of the $133.0 million proceeds we received during the year from the maturities of investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we received proceeds of $111.4 million from the maturities and sales of investments, net of purchases; $21.6 million proceeds from the sale of our AquaBounty securities, and we used $37.9 million for purchases of property, plant and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we used $112.7 million for purchases of short-term investments, net of maturities; $41.6 million for purchases of property, plant and equipment; and $16.6 million for investments in our JVs, and we received $15.5 million in an asset acquisition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from financing activities:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received $35.0 million proceeds from the sale of our common stock in a private placement to TS Biotechnology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we received $6.6 million in net proceeds from underwritten public offerings completed by AquaBounty. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we received $219.9 million net proceeds from the issuance of long-term debt and $88.0 million net proceeds from public financings.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future capital requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing liquid assets, including the net proceeds from our underwritten public offering in January 2021, will enable us to fund our operating expenses and capital requirements for at least the next 12 months. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress in our research and development programs, as well as the magnitude of these programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays or potential delays to our clinical trials as a result of the COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory approval of our product candidates and those of our collaborations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any payments received in connection with strategic transactions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of upfront, milestone, and other payments, if any, from present and future collaborators, if any;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of sales and royalties, if any, from our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and capital requirements to scale up our various product candidates and service offerings and customer acceptance thereof;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and establish additional collaborative arrangements and/or new strategic initiatives;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources, time, and cost required for the preparation, filing, prosecution, maintenance, and enforcement of our intellectual property portfolio;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic mergers and acquisitions, if any, including both the upfront acquisition cost as well as the cost to integrate, maintain, and expand the strategic target;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any such legal disputes; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects, duration, and severity of the ongoing COVID-19 pandemic and the actions we have taken or may take in response, any of which could significantly impact our business, operations, and financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can regularly generate positive operating cash flows, we plan to finance our cash needs through a combination of equity offerings, debt financings, government, or other third-party funding, strategic alliances, sales of assets, and licensing arrangements. As the COVID-19 pandemic continues to negatively impact the economy, our future access to capital on favorable terms may be materially impacted. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ownership interests of our common shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Our current stock price may make it more difficult to pursue equity financings and lead to substantial dilution if the price of our common stock does not increase. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through strategic transactions, collaborations, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or to grant licenses on terms that may not be favorable to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development, and clinical manufacturing of its product candidates. Our success is dependent upon our ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of our products, successfully commercialize our products, generate revenue, meet our obligations and, ultimately, attain profitable operations. Our ability to achieve what is necessary for our success may be negatively impacted by the uncertainty caused by the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section entitled "Risk Factors" for additional risks associated with our substantial capital requirements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations and commitments from continuing operations as of December&#160;31, 2020 and the effects such obligations are expected to have on our liquidity and cash flows in future periods:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less&#160;Than 1&#160;Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1-3&#160;Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3-5&#160;Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More Than 5&#160;Years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest payable on convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">See "Notes to the Consolidated Financial Statements - Notes 3 and 23" appearing elsewhere in this Annual Report for further discussion of our operating lease related to MBP Titan which is included in discontinued operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">See "Notes to the Consolidated Financial Statements - Note 12" appearing elsewhere in this Annual Report for further discussion of our convertible debt.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the obligations in the table above, as of December&#160;31, 2020 we also have the following significant contractual obligations described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the formation of our JVs, we committed to making future capital contributions subject to certain conditions and limitations. As of December&#160;31, 2020, our remaining capital contribution commitments to our JVs were $14.2 million. These future capital contributions are not included in the table above due to the uncertainty of the timing and amounts of such contributions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to in-licensed research and development agreements with various academic and commercial institutions where we could be required to make future payments for annual maintenance fees as well as for milestones and royalties we might receive upon commercial sales of products that incorporate their technologies. These agreements are generally subject to termination by us and therefore no amounts are included in the tables above. As of December&#160;31, 2020, we also had research and development commitments with third parties totaling $12.1 million that had not yet been incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net operating losses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had net operating loss carryforwards of approximately $756.2 million for United States federal income tax purposes available to offset future taxable income, including $503.5 million generated after 2017, United States </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital loss carryforwards of $211.5 million, and United States federal and state research and development tax credits of approximately $10.2 million, prior to consideration of annual limitations that may be imposed under Section&#160;382. Net operating loss carryforwards generated prior to 2018 begin to expire in 2022 and capital loss carryforwards will expire if unutilized beginning in 2024. Our foreign subsidiaries included in continuing operations have foreign loss carryforwards of approximately $82.3 million, most of which do not expire. Excluding certain deferred tax liabilities totaling $2.9 million, our remaining net deferred tax assets, which primarily relate to these loss carryforwards, are offset by a valuation allowance due to our history of net losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our past issuances of stock, as well as due to prior mergers and acquisitions, certain of our net operating losses have been subject to limitations pursuant to Section 382. As of December&#160;31, 2020, Precigen has utilized all net operating losses subject to Section 382 limitations, other than those losses inherited via acquisitions. As of December&#160;31, 2020, approximately $42.1 million of domestic net operating losses were inherited via acquisitions and are limited based on the value of the target at the time of the transaction. Future changes in stock ownership may also trigger an ownership change and, consequently, a Section&#160;382 limitation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Act introduced certain limitations on utilization of net operating losses that are generated after 2017, generally limiting utilization of those losses to 80 percent of future annual taxable income. However, net operating losses generated after 2017 will generally have an indefinite carryforward period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance sheet arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in "Notes to the Consolidated Financial Statements - Note 2" appearing elsewhere in this Annual Report, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when our customer obtains control of the promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically generated collaboration and licensing revenues through agreements with collaborators, known as ECCs, and licensing agreements whereby the collaborators or the licensee obtain exclusive access to our proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that we receive some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by us for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborators retains a right to terminate the agreement upon providing us written notice a certain period of time prior to such termination, generally 90 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. We determine whether each of the promises is a distinct performance obligation. As the nature of the promises in our collaboration and licensing agreements are highly integrated and interrelated, we typically combine most of our promises into a single performance obligation. Because we are performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, we have determined that the technology license and research and development services are typically inseparable from each other during the performance period of our collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of our agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we determine the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by us for research and development efforts; milestone payments upon the achievement of certain development, regulatory and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. We determine the initial transaction price and exclude variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. We typically group the promises in our collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as we provide interrelated research and development services along with other obligations over an estimated period of performance. We utilize judgment to determine the most appropriate method to measure our progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. We evaluate our measure of progress to recognize revenue each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Our measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete our performance obligations. We evaluate modifications and amendments to our contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to our efforts to provide services and the reimbursements are consistent with what we would typically charge other collaborators for similar services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. We then assess whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because we apply the sales- or usage-based royalties recognition exception provided for under ASC 606. We determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we receive upfront payments in our collaboration and licensing agreements, we evaluate whether any significant financing components exist in our collaboration and licensing agreements. Based on the nature of our collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that we will complete our obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain collaborators may cancel our agreements, relieving us of any further performance obligations under the agreement. Upon such cancellation or when we have determined no further performance obligations are required of us under an agreement, we recognize any remaining deferred revenue as revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $21.2 million, $14.1 million, and $69.5 million of collaboration and licensing revenues in the years ended December&#160;31, 2020, 2019, and 2018, respectively. As of December&#160;31, 2020 and 2019, we have $23.4 million and $50.6 million, respectively, of deferred revenue related to our receipt of upfront and milestone payments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product and service revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including our bovine embryo transfer and IVF processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, we recognize the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized. We recognized $81.2 million, $75.6 million, and $80.9 million of product and service revenues for the years ended December&#160;31, 2020, 2019, and 2018, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of goodwill and long-lived assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate long-lived assets to be held and used, which include property, plant and equipment and intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the assets may be impaired. We perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required. If the quantitative goodwill impairment test is required or elected to be performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). Impairment losses on goodwill are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in our estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, we compare the sum of the reporting units' fair values to our market capitalization (per share stock price times the number of shares outstanding) and calculate an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assess the reasonableness of our implied control premium.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, we recorded $0.9 million and $30.8 million, respectively, of impairment charges from continuing operations to write down the values of goodwill and other long-lived assets. See additional discussion regarding these impairments in "Notes to the Consolidated Financial Statements - Notes 10 and 11" appearing elsewhere in this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Notes to the Consolidated Financial Statements - Note 2" appearing elsewhere in this Annual Report for a description of recent accounting pronouncements applicable to our business, which is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sections provide quantitative information on our exposure to interest rate risk and foreign currency exchange risk. We make use of sensitivity analyses that are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $100.1 million and $75.1 million as of December&#160;31, 2020 and 2019, respectively. Our cash and cash equivalents and short-term investments consist of cash, money market funds, United States government debt securities, and certificates of deposit. The primary objectives of our investment activities are to preserve principal, maintain liquidity, and maximize income without significantly increasing risk. Our investments consist of United States government debt securities and certificates of deposit, which may be subject to market risk due to changes in prevailing interest rates that may cause the fair values of our investments to fluctuate. We believe that a hypothetical 100 basis point increase in interest rates would not materially affect the fair value of our interest-sensitive financial instruments and any such losses would only be realized if we sold the investments prior to maturity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency exchange risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have international subsidiaries in Belgium and Germany. These subsidiaries' assets, liabilities, and current revenues and expenses are denominated in their respective foreign currency. We do not hedge our foreign currency exchange rate risk. The effect of a hypothetical 10 percent change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_46"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is contained on pages F-1 through F-61 of this Annual Report and is incorporated herein by reference.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_49"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_52"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of our chief executive officer, our executive chairman, and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on their evaluation of our disclosure controls and procedures as of December&#160;31, 2020, our chief executive officer, executive chairman, and chief financial officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(f) and Rule 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deloitte &amp; Touche LLP, an independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting as of December&#160;31, 2020, as stated in their report, which is included in Part II Item 8 of this Annual Report. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_55"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART III</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_61"></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is hereby incorporated by reference to our Definitive Proxy Statement relating to our 2021 Annual Meeting of Shareholders to be filed with the SEC within 120 days of the fiscal year ended December&#160;31, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees, which is available on our website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">investors.precigen.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under "Corporate Governance." We will provide a copy of this document, without charge, upon request, by writing to us at Precigen, Inc., 20374 Seneca Meadows Parkway, Germantown, Maryland 20876, Attention: Investor Relations. We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on our website at the address and location specified above.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_64"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is hereby incorporated by reference to our Definitive Proxy Statement relating to our 2021 Annual Meeting of Shareholders to be filed with the SEC within 120 days of the fiscal year ended December&#160;31, 2020.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_67"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is hereby incorporated by reference to our Definitive Proxy Statement relating to our 2021 Annual Meeting of Shareholders to be filed with the SEC within 120 days of the fiscal year ended December&#160;31, 2020.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_70"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is hereby incorporated by reference to our Definitive Proxy Statement relating to our 2021 Annual Meeting of Shareholders to be filed with the SEC within 120 days of the fiscal year ended December&#160;31, 2020.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_73"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is hereby incorporated by reference to our Definitive Proxy Statement relating to our 2021 Annual Meeting of Shareholders to be filed with the SEC within 120 days of the fiscal year ended December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART IV</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_79"></div><div style="-sec-extract:summary;margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following consolidated financial statements of Precigen, Inc. and its subsidiaries, and the independent registered public accounting firm reports thereon, are included in Part II, Item 8 of this Annual Report:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Financial Statements of Precigen, Inc. and Subsidiaries</span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reports of Independent Registered Public Accounting Firm for the Years Ended December&#160;31, 2020 and 2019</span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report of Independent Registered Public Accounting Firm for the Year Ended December 31, 2018</span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019 </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations for the Years Ended December&#160;31, 2020, 2019, and 2018 </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2020, 2019, and 2018 </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Shareholders' and Total Equity for the Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020, 2019, and 2018 </span></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because either the required information is not applicable or the information required is included in the consolidated financial statements and notes thereto included in this Annual Report.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;text-decoration:underline">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits are listed in Item 15(b) below.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed with this Annual Report or incorporated by reference:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520023400/d876809dex31.htm">Amended and Restated Articles of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (17)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520160727/d932829dex31.htm">Amended and Restated Bylaws</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (20)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520175730/d933596dex41.htm">Specimen certificate evidencing shares of common stock</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (22)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312513307597/d551077dex42.htm">Form of Second Amended and Restated Warrant to Purchase Shares of Common Stock</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (1)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312518212457/d662928dex41.htm">Base Indenture, dated July 3, 2018, by and between the Company and The Bank of New York Mellon Trust Company, N.A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (10)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312518212457/d662928dex42.htm">First Supplemental Indenture (including the form of 3.50% convertible senior notes due 2023), dated July 3, 2018, by and between the Company and The Bank of New York Mellon Trust Company, N.A.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (10)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000162828020002699/pgen-20191231exx45.htm">Description of Securities</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (18)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312513307597/d551077dex101.htm">Amended and Restated 2008 Equity Incentive Plan of the Company</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (1)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514236419/d742603dex101.htm">Amended and Restated 2013 Omnibus Incentive Plan of the Company, effective as of June 9, 2014</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (4)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2A&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514236419/d742603dex102.htm">Amended and Restated 2013 Omnibus Incentive Plan of the Company, Form of Restricted Stock Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (4)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2B&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514236419/d742603dex103.htm">Amended and Restated 2013 Omnibus Incentive Plan of the Company, Form of Incentive Stock Option Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (4)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2C&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514236419/d742603dex104.htm">Amended and Restated 2013 Omnibus Incentive Plan of the Company, Form of Nonqualified Stock Option Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (4)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2D&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312515225910/d944797dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, effective as of June 11, 2015</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (5)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2E&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312516620186/d207755dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, effective as of June 9, 2016</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (6)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2F&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312517220231/d419065dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, effective as of June 28, 2017</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (7)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2G&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312518187136/d602751dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective as of June 7, 2018</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (9)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2H&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312519171376/d756142dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective as of June 12, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (14)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2I&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609020000005/pgen-20200331xexx101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective January 5, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (19)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2J&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520174055/d949411dex101.htm">Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective as of June 19, 2020</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (21)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2K&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609018000002/xon-20171231exx102k.htm">2013 Amended and Restated Omnibus Incentive Plan of the Company, as amended, Form of Restricted Stock Unit Agreement for Officers</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (8)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2L&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609018000002/xon-20171231exx102l.htm">2013 Amended and Restated Omnibus Incentive Plan of the Company, as amended, Form of Restricted Stock Unit Agreement for Directors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (8)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609019000011/xon-20190630xexx105.htm">2019 Incentive Plan of the Company for Non-Employee Service Providers, effective as of June 12, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (14)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609019000007/xon-20190331xexx102.htm">Form of Continuing Employment Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (13)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520003100/d863704dex101.htm">Employment Agreement, dated January 1, 2020, by and between the Company and Helen Sabzevari, Ph.D.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (16)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609020000012/pgen-20200930xexx101.htm">Executive Chairman Compensation Arrangement, by and between the Company and Randal J. Kirk</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (23)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514131808/d703295dex101.htm">Exclusive Channel Collaboration Agreement, dated as of March 26, 2014, by and between the Company and Intrexon Energy Partners, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (2)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312514131808/d703295dex102.htm">Amended and Restated Limited Liability Company Agreement of Intrexon Energy Partners, LLC, dated as of March 26, 2014, by and among the Company and the parties thereto</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (2)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312515009734/d851675dex102.htm">Securities Issuance Agreement by and among the Company, The University of Texas System Board of Regents on behalf of The University of Texas MD Anderson Cancer Center dated as of January 13, 2015</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (3)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609018000015/xon-20180930xexx101.htm">Exclusive License Agreement, dated October 5, 2018, by and between Precigen, Inc. and ZIOPHARM Oncology, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (11)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312515225910/d944797dex102.htm">Annual Executive Incentive Plan of the Company, adopted as of April 29, 2015</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (5)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312518212457/d662928dex101.htm">Share Lending Agreement, dated June 28, 2018, by and between the Company, J.P. Morgan Securities LLC and JPMorgan Chase Bank, National Association, New York Branch</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (10)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000135609019000004/xon-20181231exx1022.htm">Securities Purchase, Assignment and Assumption Agreement, dated December 19, 2018, by and between the Company, ARES TRADING S.A. and Precigen, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (12)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520000698/d860802dex101.htm">Stock and Asset Purchase Agreement, dated January 1, 2020, by and between the Company and TS Biotechnology Holdings, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (15)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1356090/000119312520000698/d860802dex102.htm">Subscription Agreement, dated January 1, 2020, by and between the Company and TS Biotechnology Holdings, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (15)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx211.htm">List of Subsidiaries of Precigen, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx231.htm">Consent of Deloitte &amp; Touche LLP</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx232.htm">Consent of PricewaterhouseCoopers LLP</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.359%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx311.htm">Certification of Helen Sabzevari, Chief Executive Officer (Principal Executive Officer) of Precigen, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx312.htm">Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Precigen, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx321.htm">Certification of Helen Sabzevari, Chief Executive Officer (Principal Executive Officer) of Precigen, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pgen-20201231xexx322.htm">Certification of Rick L. Sterling, Chief Financial Officer (Principal Financial Officer) of Precigen, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File (Precigen, Inc. and Subsidiaries Consolidated Financial Statements for the years ended December 31, 2020, 2019, and 2018, formatted in Inline XBRL (eXtensible Business Reporting Language)).</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attached as Exhibit 101 are the following documents formatted in XBRL: (i) the Consolidated Balance Sheets as of December 31, 2020 and 2019, (ii) the Consolidated Statements of Operations for the years ended December 31, 2020, 2019, and 2018, (iii) the Consolidated Statements of Shareholders' and Total Equity for the years ended December 31, 2020, 2019, and 2018, (iv) the Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019, and 2018 and (v) the Notes to the Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Previously filed and incorporated by reference to the exhibit indicated in the following filings by the Company:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:7.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No.&#160;1 to Registration Statement on Form S-1, filed with the Securities and Exchange Commission on July&#160;29, 2013.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on April 4, 2014.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on January&#160;14, 2015.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 13, 2014.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 17, 2015.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 13, 2016.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 30, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2018.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 8, 2018.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 3, 2018.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 8, 2018.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2019.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 9, 2019.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 9, 2019.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 2, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 7, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 4, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 2, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 11, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 4, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 19, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:7.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statement on Form S-3, filed with the Securities and Exchange Commission on June 22, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2020.</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Portions of the exhibit (indicated by asterisks) have been omitted in compliance with Item 601 of Regulation S-K.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to Item 15(a)2 is incorporated herein by reference.</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_82"></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: March&#160;1, 2021 </span></div><div style="margin-top:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.152%"><tr><td style="width:0.1%"></td><td style="width:1.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRECIGEN, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;HELEN SABZEVARI</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Sabzevari</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;HELEN SABZEVARI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Sabzevari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RICK L. STERLING</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Accounting and Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rick L. Sterling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RANDAL J. KIRK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randal J. Kirk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/    CESAR L. ALVAREZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cesar L. Alvarez</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;STEVEN FRANK</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Frank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;VINITA D. GUPTA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vinita D. Gupta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;FRED HASSAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fred Hassan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;JEFFREY B. KINDLER</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey B. Kindler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;DEAN J. MITCHELL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dean J. Mitchell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;ROBERT B. SHAPIRO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert B. Shapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;JAMES S. TURLEY</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James S. Turley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to the Financial Statements and Schedules</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:91.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_91">Consolidated Financial Statements of Precigen, Inc. and Subsidiaries</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_91">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_94">Reports of Independent Registered Public Accounting Firm for the Years Ended December 31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_94">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_97">Report of Independent Registered Public Accounting Firm for the Year Ended December 31, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_97">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_100">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_100">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_106">Consolidated Statements of Operations for the Years Ended December&#160;31, 2020, 2019, and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_106">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_112">Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2020, 2019, and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_112">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_115">Consolidated Statements of Shareholders' and Total Equity for the Years Ended December&#160;31, 2020, 2019, and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_115">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_118">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020, 2019, and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_118">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_121">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_121">17</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020, 2019 and 2018 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Precigen, Inc. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Precigen, Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, shareholders' and total equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1, 2021, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill - Trans Ova Reporting Unit - Refer to Notes 2 and 11 to the financial statements </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's goodwill balance was $54.4 million as of December 31, 2020, of which $16.6 million is allocated to the Trans Ova reporting unit. The Company's evaluation of goodwill for impairment involves the comparison of the fair value of the reporting unit to its carrying amount. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. Given the significant estimates and assumptions management makes to estimate the fair value of the Trans Ova reporting unit and the sensitivity of Trans Ova's valuation to changes in these estimates, performing audit procedures to evaluate the reasonableness of management's estimates and assumptions required a high degree of auditor judgment and an increased extent of effort, including the need to involve our fair value specialists. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the forecasts of future revenues, operating margins, and cash flow ("forecasts"), and the selection of the discount rate for the Trans Ova reporting unit included the following, among others: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the operating effectiveness of controls over management's goodwill impairment evaluation, including those over the determination of the Trans Ova reporting unit fair value, such as controls related to management's forecasts and selection of the discount rate.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated management's ability to accurately forecast revenues and operating margins by comparing actual results to management's historical forecasts, as well as external information. </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We evaluated the reasonableness of management&#8217;s forecasts by comparing the forecasts to (1) historical results, (2) internal communications to management and the Board of Directors, (3) industry growth projections, and (4) forecasted information prepared in the prior year.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the assistance of our fair value specialists, we evaluated the discount rate, including testing the underlying source information and the mathematical accuracy of the calculations, and developing a range of independent estimates and comparing those to the discount rate selected by management.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 1, 2021</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Precigen, Inc. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Precigen, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2020, of the Company and our report dated March 1, 2021 expressed an unqualified opinion on those financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 1, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Board of Directors and Shareholders of Precigen, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the consolidated statements of operations, comprehensive loss, shareholders&#8217; and total equity and cash flows of Precigen, Inc. (formerly known as Intrexon Corporation) and its subsidiaries (the &#8220;Company&#8221;) for the year ended December 31, 2018, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).  In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations and cash flows of the Company for the year ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Substantial Doubt About the Company's Ability to Continue as a Going Concern</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses, cash outflows from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1.  The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.  Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.  We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PricewaterhouseCoopers LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Atlanta, Georgia</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 1, 2019, except for the effects of discontinued operations discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. section within Note 3 and the change in composition of reportable segments discussed in Note 20, as to which the date is March 2, 2020, and the effects of discontinued operations discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MBP Titan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section within Note 3, as to which the date is March 1, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We served as the Company's auditor from 2006 to 2019.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020 and 2019 </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Amounts in thousands, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzMtMS0xLTEtMA_9bc925aa-3bea-479b-a607-22dd4159dd12">51,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzMtMy0xLTEtMA_300f002f-c2fd-4ec7-9f0f-49095dd44984">65,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzUtMS0xLTEtMA_ece3fc47-2a27-4570-9ff8-8ff86c657190">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzUtMy0xLTEtMA_2645f9fb-726f-4df4-b339-71f4ca83001a">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade, less allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjE1YzdhODkwNjYyODQxZTRhNzRiYzM1NDY3MmMyNWU3XzQzOTgwNDY1MTExODg_7b80dcb5-1d98-4382-9421-72e459f64728">4,825</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjE1YzdhODkwNjYyODQxZTRhNzRiYzM1NDY3MmMyNWU3XzQzOTgwNDY1MTExOTE_766bb8ba-2f89-4264-b2a1-666e50afbca9">5,201</ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMS0xLTEtMA_f6cba48a-2f99-49a4-8fe8-ed4beb18989c">16,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMy0xLTEtMA_884c2b7c-93bf-436a-a665-7beccb13ea6b">20,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related parties, less allowance for credit losses of $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMC0xLTEtMC90ZXh0cmVnaW9uOjQwZjljYTkwNWVlNTQwMzI5MTYwZDA4NWMxMTc1MTEzXzQzOTgwNDY1MTExODM_fc0e7a17-d8b5-4443-a85a-6a75665b89d2">1,509</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMC0xLTEtMC90ZXh0cmVnaW9uOjQwZjljYTkwNWVlNTQwMzI5MTYwZDA4NWMxMTc1MTEzXzQzOTgwNDY1MTExOTA_9d84e3a8-5d3e-4a40-a602-01c1f9abb68a">2,312</ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMS0xLTEtMA_08738b18-102c-4438-8270-4df754be3ee2">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMy0xLTEtMA_3c5af274-cc51-4f22-bba1-bcb207c023e4">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEwLTEtMS0xLTA_a5fbe770-3ccc-44de-bfae-65bd6bb4d530">3,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEwLTMtMS0xLTA_3b488125-2373-42cf-b6e3-b6ae2c53d0c8">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzExLTEtMS0xLTA_531e2aa0-cb1a-4988-b0c3-d0ab738afbef">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzExLTMtMS0xLTA_124e4ab0-ea4d-499d-aac3-a180afe392ac">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEyLTEtMS0xLTA_d98c7546-ab3a-4b74-b3ae-b66a28d52a13">11,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEyLTMtMS0xLTA_13abc31d-62b4-4e4e-9b5b-37631da03838">16,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEzLTEtMS0xLTA_36592e16-6c38-412a-a9f4-7f3228a16cb7">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEzLTMtMS0xLTA_6af24414-69b5-457c-9457-248f38f8b1b7">5,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets held for sale or abandonment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE0LTEtMS0xLTA_9f21ec58-a4b4-4954-a48a-7468ea9d42bc">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE0LTMtMS0xLTA_538f57c8-8441-4d49-82b1-f811ab8ad261">111,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE1LTEtMS0xLTA_62002a39-cefc-4b59-9663-5451bb1fac53">148,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE1LTMtMS0xLTA_0e6189d2-f37e-48b4-a3bf-44c34b7d4e57">234,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE4LTEtMS0xLTA_e2a6ac94-9a17-4d3b-b87b-cea84417f368">34,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE4LTMtMS0xLTA_2911289a-bbf4-4e35-98c4-83210e9f0cd5">43,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE5LTEtMS0xLTA_601a5416-364f-4e56-85ab-6c7f593a6b24">65,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE5LTMtMS0xLTA_5bdd5813-6389-4448-aa5e-61959153801b">68,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIwLTEtMS0xLTA_bb7cba7c-74c6-49aa-8aeb-384fd071a7b8">54,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIwLTMtMS0xLTA_7e9e3a3a-b73e-4b3b-9287-3c6dea76cf39">54,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIxLTEtMS0xLTA_454ab537-eeab-4b02-9b36-2b13cae6c528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIxLTMtMS0xLTA_5647282a-03a4-4aa9-b4e4-919024f09627">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIyLTEtMS0xLTA_d377ae82-18c2-42ed-84fd-38c9460a0441">9,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIyLTMtMS0xLTA_fdeccf00-8153-4926-9fc1-27bee92e6b54">11,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIzLTEtMS0xLTA_68694fbe-bf3b-43c7-b68b-da4b05bb8d0e">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIzLTMtMS0xLTA_965445b4-a3f2-42f6-a3c1-7508696bbb36">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets held for sale or abandonment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI0LTEtMS0xLTA_07320d0e-247b-41ce-b15c-15845388275e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI0LTMtMS0xLTA_7e497a0a-eaf3-471e-998c-6d6e3512a7db">40,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI1LTEtMS0xLTA_4db5ba68-bfcb-4bfd-bc96-f0efabc83342">314,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI1LTMtMS0xLTA_5bdc533f-926b-4e0f-b409-630dd502f9cd">455,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2020 and 2019 </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Amounts in thousands, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMtMS0xLTEtMA_9c0a30ba-450a-4b48-82f0-be8c91966b52">4,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMtMy0xLTEtMA_07efa1e6-5cc0-475d-9f5d-7b972b133c2f">5,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzQtMS0xLTEtMA_3e69f1f0-e3b0-411a-8664-118bf3538fec">8,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzQtMy0xLTEtMA_ee7eb570-6703-4b5c-b7aa-142403dfad46">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzUtMS0xLTEtMA_6f8d8269-0f7b-4975-8562-0d4c694293bb">9,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzUtMy0xLTEtMA_198f6fd6-dc99-44d0-ae3b-11fa91c08aa1">11,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, including $<ix:nonFraction unitRef="usd" contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI5N2Q5NzUxODljNjQ2YzZiZjczOGY0M2YwMDFmNTIzXzQzOTgwNDY1MTEyNDg_425a350c-c8d9-49e9-8a2f-b8762152f9f9">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4535941e16234d449e24cbb104b312eb_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI5N2Q5NzUxODljNjQ2YzZiZjczOGY0M2YwMDFmNTIzXzQzOTgwNDY1MTEyNTc_b2acff20-a50a-43db-8bbc-a62e5925fb85">877</ix:nonFraction> from related parties as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMS0xLTEtMA_a1227f38-04e8-4e41-a2be-f4cbb417e66d">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMy0xLTEtMA_ac40d7a7-515f-4b88-a437-5ace1b5ef444">5,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lines of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzctMS0xLTEtMA_07ec0c6a-75cd-41d3-8326-b256b64e0d2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzctMy0xLTEtMA_1a2c96e5-ee46-4f86-989d-952aa52700e2">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, including $<ix:nonFraction unitRef="usd" contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmE3ZDg4ZDJjM2U5NzQ0MjRhZjA2YzZhYzM5ZTA3MmVhXzQzOTgwNDY1MTEyNjU_629c12a5-7539-4b1d-b3a8-054b8c1280d5">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4535941e16234d449e24cbb104b312eb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmE3ZDg4ZDJjM2U5NzQ0MjRhZjA2YzZhYzM5ZTA3MmVhXzQzOTgwNDY1MTEyNjk_a9ddea4a-e95d-4321-96a9-e4d5a2d627cb">31,211</ix:nonFraction> to related parties as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMS0xLTEtMA_b911815b-282b-4ede-a940-955d5fe52edb">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMy0xLTEtMA_56b24d3b-bc52-45a8-9f6e-01ade336dad3">31,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEwLTEtMS0xLTA_56b408f6-d92a-4764-bb34-95a4d54bf6ee">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEwLTMtMS0xLTA_419547ba-ccd2-485e-86c5-59ebe8829ee8">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzExLTEtMS0xLTA_ce561204-cc1c-418f-841c-a00ebe0d57f6">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzExLTMtMS0xLTA_a3dc0318-e86b-41de-8db0-a8dedc98b92d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities held for sale or abandonment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEyLTEtMS0xLTA_8ef4d4c4-96f0-4a5b-ab60-abebb6c0e9bc">14,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEyLTMtMS0xLTA_e16d94cf-3d8f-46b8-8585-dd59ab49850f">50,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEzLTEtMS0xLTA_bfa5b578-96d0-4e42-b34b-764cdfb39078">42,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEzLTMtMS0xLTA_5bdc7626-ce01-4fca-ae55-18751fcbd410">122,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion, including $<ix:nonFraction unitRef="usd" contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDZiOTlhZGMxYzM0ZDBlOWMxNjRmYjVmNjJmN2FmZF80Mzk4MDQ2NTExMzE0_6a874d18-67c8-44f8-aa17-6bc26aa708d0">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4535941e16234d449e24cbb104b312eb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDZiOTlhZGMxYzM0ZDBlOWMxNjRmYjVmNjJmN2FmZF80Mzk4MDQ2NTExMzIz_5267f2a3-3205-4e7e-93a5-a888218139f1">25,000</ix:nonFraction> to related parties as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTEtMS0xLTA_3538e522-480c-41bd-89ae-a124d2cf1541">171,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTMtMS0xLTA_4b4ed052-574f-4750-bd53-ec9464abb29d">186,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion, including $<ix:nonFraction unitRef="usd" contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZmE5ZWY2NWZjN2M0MWJkODVhOTAyNGMyY2QxNDA2ZF80Mzk4MDQ2NTExMjc5_6c962a0c-e327-4e68-9cab-390556574928">21,205</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4535941e16234d449e24cbb104b312eb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZmE5ZWY2NWZjN2M0MWJkODVhOTAyNGMyY2QxNDA2ZF80Mzk4MDQ2NTExMjg4_664b55e8-bcc2-41c0-af92-8155dd1e8f1e">30,182</ix:nonFraction> from related parties as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTEtMS0xLTA_9f699316-76b3-4eb5-8f55-64b7713bc5a3">23,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTMtMS0xLTA_52b4bd80-ebd0-4041-bc10-2311ec9d2e5d">48,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE3LTEtMS0xLTA_5cb415c4-406d-46c0-bf0b-80369a199088">7,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE3LTMtMS0xLTA_50b0f981-7b73-4eec-b28d-82027cd76164">10,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE4LTEtMS0xLTA_44ac06df-b7de-49ee-ab7f-cdb4395d4b8d">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE4LTMtMS0xLTA_d1a3beb3-3717-43bb-9bcc-dc565c567978">2,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE5LTEtMS0xLTA_5634eb7d-025d-404f-8e38-3f0480c693bf">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE5LTMtMS0xLTA_0b6f5386-e07a-4c35-b6a2-2f06e617318b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities held for sale or abandonment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIwLTEtMS0xLTA_9f213629-21fb-4c82-888d-2f48bba71b72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIwLTMtMS0xLTA_b05184cb-5e97-48a4-81c9-bb19685367e9">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIxLTEtMS0xLTA_bb76f7e6-a840-444c-bea6-bc7ed5410562">247,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIxLTMtMS0xLTA_73e86458-4a32-4d49-b4cf-9639dc56d7a2">384,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 17)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIyLTEtMS0xLTA_976ea59b-dde1-4879-8efa-435d77e29d24"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIyLTMtMS0xLTA_05048050-8627-441c-bf8a-2052b3931940"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, no par value, <ix:nonFraction unitRef="shares" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDM2_5b6f68a9-7148-4a19-a6bf-cb4243ffd87e"><ix:nonFraction unitRef="shares" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDM2_cf6df0cc-4781-41e1-babb-857c3e94aace">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2020 and 2019; and <ix:nonFraction unitRef="shares" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDYz_1a016d14-2893-418f-ab4a-8116b549b6c3"><ix:nonFraction unitRef="shares" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDYz_f796ec2a-1dfc-4e0d-9385-1fa3b72f8387">187,663,207</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDc4_97aeb52f-8fec-46f3-8342-5a0823aaffe4"><ix:nonFraction unitRef="shares" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDc4_adfaaa25-9a00-47fe-9c6a-8300684c67e3">163,274,880</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTEtMS0xLTA_350d3254-d381-418b-9a52-ff359fd6830a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTMtMS0xLTA_df00da76-534a-4e40-b66d-ab2c06fbc061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI1LTEtMS0xLTA_51cdf9e0-cb11-4b53-b6d5-7de1045c611a">1,886,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI1LTMtMS0xLTA_584dd2de-732d-4b3b-9adb-00dc9c15c310">1,752,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI2LTEtMS0xLTA_717b0803-b483-4a2b-8a1a-161c564645de">1,823,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI2LTMtMS0xLTA_0cbafbb3-328b-464b-ab11-973208b7bdf9">1,652,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI3LTEtMS0xLTA_b3054236-80ac-49fb-9bbf-28bbdea7e4fa">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI3LTMtMS0xLTA_cc3955bc-cc00-4662-859d-f1b43ddb62ef">27,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI4LTEtMS0xLTA_87c10b6b-fc74-48d5-8ff3-d31be065a78b">67,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI4LTMtMS0xLTA_7806294f-04f2-4328-93db-ed74a21d1a33">71,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMxLTEtMS0xLTA_e8d756c5-5f30-47e2-a0f0-2b5bedd992fa">314,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMxLTMtMS0xLTA_d48cba7b-fb11-49ef-8ccf-b658bf3ff823">455,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Amounts in thousands, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing revenues, including $<ix:nonFraction unitRef="usd" contextRef="if90df5438bc447dc89f799623be8dd72_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyNzA_bcee0023-0e8b-4a53-8ceb-dc461ad0d9d0">3,053</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4d688646c4e54b0b9ff3d9d869a84f8d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyNzk_2161fa36-5797-4159-8a17-fdb069c8ac27">11,832</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="ia49fe028d6f84a65a5e7dc2e03d52395_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyODk_a5701fb6-5038-400d-95f9-9db572cbd632">55,573</ix:nonFraction> from related parties in 2020, 2019, and 2018, respectively</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa378b75eb8240abb90e3c3a90199627_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMS0xLTEtMA_9102896b-4ced-4a24-be29-8c3301cb1048">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63f92b55b3047a6985c52240063ce82_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMy0xLTEtMA_7ff6ece3-3f3d-4dee-886c-58dda9a17faa">14,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2563c9235194a59932361f4fd160992_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItNS0xLTEtMA_0477a057-ff6c-4c3d-8da3-0b9d52c52873">69,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c945d017804d08b6055d50caecddfc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtMS0xLTEtMA_c9dd6065-1c79-4e09-800d-7c074e74f262">24,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtMy0xLTEtMA_475eee3c-04d7-4c3e-9912-b2e4593c9274">23,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1416fdd04854b98b98cc981399bba77_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtNS0xLTEtMA_806509ba-e6fa-45f4-857c-aafa2a8f1eb8">28,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtMS0xLTEtMA_509675ca-272e-43ab-b308-eae40e345267">56,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtMy0xLTEtMA_0408a9f7-2957-4a6d-8731-f20ee74ac6c3">51,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f67f091705d4ed88119185ea9668127_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtNS0xLTEtMA_69f6a5d5-af9b-469e-92f2-b57ace7ca965">52,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17726fa9a8714d378f70b578726ea61b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtMS0xLTEtMA_0607ee0e-8be1-420f-bbee-01a2a3231cd9">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf2a0142d19421f844e564b6e81c75e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtMy0xLTEtMA_098c82a8-a5ef-4dda-b79b-29e184620cbf">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53867cd3f9c14cdebf63cdf61a3ccdc6_D20180101-20181231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtNS0xLTEtMA_b5657232-bf74-4bcc-9321-0cad0e6e3822">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtMS0xLTEtMA_19b99410-92ce-464d-86df-a7a02e786734">103,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtMy0xLTEtMA_eba8edf2-6172-42a9-8cd1-0e8760c23689">90,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtNS0xLTEtMA_68d231a2-ae0d-4ae4-82c3-5fd27d1f07ab">151,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c945d017804d08b6055d50caecddfc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtMS0xLTEtMA_fc406c0c-63fe-4945-9bb1-d23dc0fac9e7">28,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtMy0xLTEtMA_f6838e0f-27dd-4a84-8e9a-ad94644371ce">31,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1416fdd04854b98b98cc981399bba77_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtNS0xLTEtMA_ec1d33a0-934a-48a7-9e9b-bcedc12105c8">35,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktMS0xLTEtMA_567ff732-a96b-48f9-95d8-d4674d888692">26,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktMy0xLTEtMA_97cad642-ce4f-4026-8c82-784a405f79ec">29,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f67f091705d4ed88119185ea9668127_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktNS0xLTEtMA_03426578-70ed-44e7-815f-9dca90c6f7a1">27,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTEtMS0xLTA_4ee8d78d-5104-4db4-85a9-30a957feaa7b">41,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTMtMS0xLTA_82d55c9c-4f0f-4e79-b5da-9eba352f961f">66,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTUtMS0xLTA_d8bc8107-1977-44b4-a848-e53711519c1b">333,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTEtMS0xLTA_3b445914-c897-42d0-8e08-5ef3dbfe1af0">91,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTMtMS0xLTA_b7833d00-c159-489a-85fb-5b861c8d6c3c">98,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTUtMS0xLTA_80992873-3f48-4775-a34b-0854103caf46">125,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTEtMS0xLTA_1861d83c-1690-469f-955b-22821d0d29bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTMtMS0xLTA_baf162c0-c474-47c6-9527-2cf8cfa5a41c">29,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTUtMS0xLTA_692f8e5e-4ba0-42a6-80e8-9ecd8989ae46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTEtMS0xLTY0NA_70ce0585-792d-48fb-96be-c73d330a91af">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTMtMS0xLTY0NA_0eb04f47-bddd-47ff-9aeb-b1bce1398a0e">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTUtMS0xLTY0NA_1ab14c2d-4e10-4ee1-bcd6-2425c0227c24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTEtMS0xLTA_76e9a80d-a39b-4bf9-8e7f-38034aca52af">189,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTMtMS0xLTA_f85a7595-83d3-4eb5-96f1-243dc1c881ec">257,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTUtMS0xLTA_0b4336d5-a9a0-4930-ac95-6d4709e1018e">520,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTEtMS0xLTA_9f6bfbf5-b5dc-4c0a-8e52-a57b29cd5509">86,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTMtMS0xLTA_a7851457-e1d1-489b-babf-0ce15272f961">166,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTUtMS0xLTA_eb8ccd04-fd06-4a81-9b6b-cb93361c8824">369,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTEtMS0xLTA_b9c27c35-d306-4ad6-ae7d-682bb5b69463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTMtMS0xLTA_05fccedf-68ec-4515-9896-9bb0b17f7681">8,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTUtMS0xLTA_74dfc3f8-b90b-4505-9a7b-845d9f19c3c4">28,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTEtMS0xLTA_fa24aa64-db33-4941-b1a0-7a3a58bd96c6">18,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTMtMS0xLTA_97664556-6491-4ddb-b8df-ae1c7e1515fb">17,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTUtMS0xLTA_bc6905f3-061a-442d-9f2e-513f71c0fba6">8,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and dividend income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTEtMS0xLTA_2e032ecd-31d6-4d9a-be44-398c83a2f911">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTMtMS0xLTA_0d821615-1862-4488-bc89-beff0e4bc9fb">3,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTUtMS0xLTA_d7abdf6b-5c9e-4231-aa58-ed67a171e49f">19,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTEtMS0xLTA_b0b7294d-573a-4974-a5ba-82ab72a51ccf">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTMtMS0xLTA_58f9642f-f5ab-46f7-a40a-f192df945c75">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTUtMS0xLTA_6805b18e-8b46-46b8-b4ca-ab150912f6da">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTEtMS0xLTA_5be7ac78-efeb-43f1-ab2e-7a80d449ab20">16,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTMtMS0xLTA_aaeed121-a5a6-4bf0-bf97-7626715e2d0d">2,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTUtMS0xLTA_2a291d57-6548-4d68-b005-a9935deffdce">17,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTEtMS0xLTA_2f7b6728-07d2-4fed-bab4-800a4656383f">1,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTMtMS0xLTA_5d16426c-e105-4a21-ac08-4cb5d446ebcf">2,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTUtMS0xLTA_51c4a3cf-3a98-4141-a6c6-516829b248f8">8,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTEtMS0xLTA_3d57007e-f00f-449a-98f1-0c869aef4cc3">103,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTMtMS0xLTA_98716638-719a-423c-bc4f-ccb253ef1699">171,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTUtMS0xLTA_834c11bc-a0f0-45d6-9332-bbcaab27c495">395,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTEtMS0xLTA_b081cc0f-b408-4d2b-ac9b-1563ad848286">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTMtMS0xLTA_43a82ae0-4754-4568-8629-be2bc01ee8ef">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTUtMS0xLTA_827a539c-fb6c-4387-a499-c5087f355482">15,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTEtMS0xLTA_898363e8-f6cc-43a5-bccc-b602b1e964f4">103,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTMtMS0xLTA_141bb8db-ba21-4813-b54a-98b06e83142f">170,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTUtMS0xLTA_eb665e04-d562-4f78-9869-cf7219ee0304">380,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTEtMS0xLTA_e323b9a1-27e1-405f-8322-f7a9914c67fc">66,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTMtMS0xLTA_7537f139-eaf3-4779-8d14-7372633017d4">153,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTUtMS0xLTA_c163ff95-67d6-4246-8221-abe5add31e0c">134,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTEtMS0xLTA_85e33e47-77fb-4c79-9a16-57d355a9d298">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTMtMS0xLTA_1a82963d-fb8b-4fa7-864f-f0793f927f6c">323,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTUtMS0xLTA_68f04d59-bec6-4c96-9724-1d7d27dbfe36">514,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to the noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTEtMS0xLTA_5a157744-a737-451e-a62c-5d358bb2c423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTMtMS0xLTA_2c56e110-5ea5-4ca3-a6f5-543fae01ecb9">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTUtMS0xLTA_17d72d8a-3e30-4fa8-9f1c-aabf9b8e4869">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTEtMS0xLTA_35556c4c-3f78-4da9-91dd-9d98b4c68968">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTMtMS0xLTA_76670388-60ec-4047-b095-78d515b3776e">322,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTUtMS0xLTA_bb869e6c-d8cd-4792-bdb9-0b2e38d22833">509,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Attributable to Precigen</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTEtMS0xLTA_b206a290-1f7a-4683-bb0d-72a8f98d0989">103,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTMtMS0xLTA_ed30d60e-efec-42fa-a93b-efc7daa8d8ac">168,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTUtMS0xLTA_6f7d3951-86ba-4058-baa6-bdf3510cb8d5">375,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTEtMS0xLTA_42d45cd8-9487-4809-959a-dc864a992b1c">66,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTMtMS0xLTA_7a2563fe-09ce-4da1-b6fa-88eb7e64e468">153,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTUtMS0xLTA_e07d3bb8-1f2d-4230-9d70-307c92ac22c0">134,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTEtMS0xLTA_396b4a22-6ad4-47df-8d5d-b637b2546ab3">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTMtMS0xLTA_45bab461-b07e-4425-ba0b-5ccef2dfee41">322,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTUtMS0xLTA_60038c1a-2dbb-471c-b906-40e0d2c71ca3">509,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss per Share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTEtMS0xLTA_27de82f7-ad1b-4bf9-abf0-364c5a89d819">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTMtMS0xLTA_bf106a81-3521-413d-a1d2-6319985192fb">1.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTUtMS0xLTA_58dc8483-1e43-40db-9615-f26fcd80910d">2.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTEtMS0xLTA_59076b00-2366-41f7-9356-525feac6e7c9">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTMtMS0xLTA_c571a521-2a9d-4b84-b1ba-0dd23a152dee">1.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTUtMS0xLTA_62d1ea4c-bae7-40bf-ae04-9909b37fb3dd">1.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTEtMS0xLTA_a4d8b2a2-a385-4df5-b437-28965c0663fb">1.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTMtMS0xLTA_b076eedc-e909-44f6-9a5f-d08d9ef2c976">2.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTUtMS0xLTA_290ff555-eda5-40eb-a9b2-1949657093f5">3.93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTEtMS0xLTA_092e4812-fa90-4e07-a790-6faa19328968">167,065,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTMtMS0xLTA_0b80049e-f2c5-45cb-83cf-52e26f311170">154,138,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTUtMS0xLTA_8a184fef-458d-4ef8-b0d4-031348c49256">129,521,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtMS0xLTEtMA_bb75a0af-abab-4789-9541-2678b7f268ab">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtMy0xLTEtMA_9b4bcff3-f390-43c2-90c5-764cf44cb6e5">323,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtNS0xLTEtMA_03160038-27fd-4e42-84d7-3d4396d1f66f">514,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtMS0xLTEtMA_8dab26a1-bee1-4589-9c05-857dc028f432">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtMy0xLTEtMA_e0e39d48-d3e1-4d47-ac94-0f0d6d38b128">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtNS0xLTEtMA_a7f0b39b-98f4-4308-bdae-3f21e454f055">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtMS0xLTEtMA_6af7e283-b139-4c75-ad10-e47a1023d058">4,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtMy0xLTEtMA_2d140392-8b86-45b2-9df1-0e413a341241">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtNS0xLTEtMA_9aaa260a-e834-466c-ae2c-efc5bf688f19">13,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of cumulative foreign currency translation adjustments to net loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMS0xLTEtNjU2_7eaa80ef-bbda-46d2-a902-ed135433f653">26,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMy0xLTEtNjU2_eb0ccb00-5e68-4cbd-aaba-0d61fb761b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtNS0xLTEtNjU2_32d17a32-6386-4165-94d8-d7b2079e738c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMS0xLTEtMA_04714076-e27e-45b6-9f40-a7be2fcad3e1">139,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMy0xLTEtMA_08438683-0278-4190-abf2-7e593defe2c0">322,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtNS0xLTEtMA_991cc544-9ff4-4cfa-b423-a8109b977c1e">527,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to the noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtMS0xLTEtMA_6d7fccbc-7e03-4e72-838c-383df7d70244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtMy0xLTEtMA_d049a804-0b5f-456f-8092-3d59e5e0614a">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtNS0xLTEtMA_924f4633-fd25-477e-82b9-d9644c4690ee">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Precigen</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctMS0xLTEtMA_6235efb5-4043-4184-ac2b-02a9fc104afd">139,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctMy0xLTEtMA_96b28480-caee-49e9-8649-6b4fe950a00d">321,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctNS0xLTEtMA_30c0c1c6-2b98-4d3f-880f-824947225fc5">522,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_115"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' and Total Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:28.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.704%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Precigen<br/>Shareholders'<br/>Equity</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia53c6ab11e9c492084aefb26999ce44a_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMS0xLTEtMA_fe1d885e-2217-440c-bf29-0dd8833ee738">122,087,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53c6ab11e9c492084aefb26999ce44a_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMy0xLTEtMA_7af36ddf-6020-4eb6-8da3-5adc217f87a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c80061711f435bbcfbfe956b9bc43c_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItNS0xLTEtMA_6a74913f-1008-4bac-8a0c-2cae528067e9">1,397,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2d62e92e6fa4e01ac83a1dcdafa12a1_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItNy0xLTEtMA_5c25a292-2dc2-48c1-b170-995399241b5a">15,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44c47c15a0a441909e132dd1581ceaec_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItOS0xLTEtMA_d94dc0d8-582e-4e77-be2f-a5c7b2b79a37">847,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee3c718a7f048cfb2836108df24bc3d_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTEtMS0xLTA_b0477d6d-c162-4d6c-9626-586b76844f26">533,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e53100af51f408a935d99fdc04896b2_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTMtMS0xLTA_ed7ed26d-75f9-455a-8b1f-b86d6bcb3d23">12,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTUtMS0xLTA_9ae8abf0-9c49-431b-b8a4-533a87d3b872">546,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMC0xLTEtMTAyOTE_98b5dcf3-d951-4783-922d-2c0ea94a8c36">Cumulative effect of adoption of ASC 606</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b48ec0589f54ea18ed709e5622f1f36_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtNy0xLTEtMA_9b668684-6c06-4459-be1f-0ab4f880445c">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58e0c90d812453b961a416919b494e7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtOS0xLTEtMA_49b078f1-ed5f-4014-800a-f3478421d761">26,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edb27434f8c42f4b2dafbfd636c960d_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMTEtMS0xLTA_548fafe0-22d6-4017-8d38-68cbfca210fa">26,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ac13fe6c894e4d8bb963cd6fcd7ba1_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMTUtMS0xLTA_5cafb66a-9849-4146-a45a-2fed1491fd91">26,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtNS0xLTEtMA_9cfd0b83-f8be-4728-b6fc-64a83af24fbe">36,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTEtMS0xLTA_be236414-6b83-4b83-b6d7-c11ce885116f">36,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTMtMS0xLTA_b8f12678-d101-4aa0-ae14-e38f1645c8cf">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTUtMS0xLTA_abae2ac7-b271-4b70-b722-c44779985608">36,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMS0xLTEtMA_07a51e26-aac1-40ed-b152-91a56d5fb383">70,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtNS0xLTEtMA_5a6af045-666f-4a36-bd26-d78e1f44979d">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTEtMS0xLTA_727cdb5f-0a3d-499b-82d5-036296cdf334">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTMtMS0xLTA_5635b339-4595-4f58-8b52-4f6a1a3f1b8a">2,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTUtMS0xLTA_6b4c8bcc-bb8d-423e-a6aa-c1fe9a6862f3">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued as payment for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMS0xLTEtMA_d22863c4-5a2c-4e3c-a84f-e1db91d9ab03">909,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtNS0xLTEtMA_ba729e93-d657-42fa-8cf7-8398ea4061de">10,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTEtMS0xLTA_2d7dd8cf-9559-4ab4-8fbb-b25a72005617">10,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTMtMS0xLTA_98ea265d-a081-4c6d-9466-4ffcf931a2c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTUtMS0xLTA_7a5e4b52-96b8-4969-8e3f-45daecee40d5">10,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares and warrants issued in public offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMS0xLTEtMA_7f8f0ffd-10e8-4bb3-8c00-5ef1bc2e221c">6,900,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctNS0xLTEtMA_931a0085-bbb1-4fd4-bb74-684869e893b2">82,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTEtMS0xLTA_211c9869-5e19-4afa-ab75-592bcc06aa03">82,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTMtMS0xLTA_aee39b4c-42d4-4012-8ef6-76142d6d1aca">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTUtMS0xLTA_84480e96-84ca-4950-97a4-f1cc4340208e">87,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt, net of issuance costs and deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtNS0xLTEtMA_0610a1d8-f5d3-4a71-82b3-b24077de314e">36,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTEtMS0xLTA_5e0fddde-bd37-4180-8a71-248000fc8c3b">36,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTMtMS0xLTA_3c4f5309-269c-4c55-9d86-e8ec0508899b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTUtMS0xLTA_7870e5fc-bc17-4d2d-92b9-bc5cba813ce1">36,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued pursuant to share lending agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="pgen:OwnshareLendingArrangementSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzktMS0xLTEtMA_cb036f51-cba6-4848-b5a6-aeb13ffc5081">7,479,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for reacquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTEtMS0xLTA_02a38483-64c8-46de-b5d0-de152c1cbc7c">22,573,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTUtMS0xLTA_fadaa66a-2a83-4e62-a3ec-01b3a594a624">159,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTExLTEtMS0w_58ad1efe-527f-441d-8bf4-212e1af5cd8e">159,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTEzLTEtMS0w_e550afb2-f992-4fa5-a330-97c513d0abdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTE1LTEtMS0w_9cfb494f-d27f-4b2f-9f7e-8e3614e02d5e">159,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231" decimals="-3" sign="-" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTUtMS0xLTA_743cab46-0d62-4c34-8675-9175f0e8c7bb">724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" sign="-" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTExLTEtMS0w_609f0b43-ac43-40b2-8a5f-50205e6cbe5c">724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTEzLTEtMS0w_c9b09048-5f30-40a9-9e3c-f301c3a6521c">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTE1LTEtMS0w_f46eb72f-500c-4424-942d-96fac7754e20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7328bdd74884f999183a972e9e74902_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTktMS0xLTA_7e96abbe-b641-4d98-812a-2ace3e0b35b5">509,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTExLTEtMS0w_3408f308-86dc-4d7d-b113-750fc91b799b">509,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTEzLTEtMS0w_9c483546-d83e-48e0-aa79-2de24739efbc">5,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTE1LTEtMS0w_78a55a1c-3cf9-475e-af68-ee4b2f2b373b">514,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i526adef7e72140d5b11b92f77958580e_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTctMS0xLTA_5c28705f-37e5-431b-b9c4-98b96b2eae28">12,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTExLTEtMS0w_24ccfd24-65ca-4c6d-b922-81c2e6e487ae">12,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTEzLTEtMS0w_67e40284-f75e-485f-9d54-79222a96db4c">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTE1LTEtMS0w_405d2852-ad7a-40c7-af36-f351b3e87405">13,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTEtMS0xLTA_5223ad68-d0b8-4fea-8ac2-6ffbd72bf5aa">160,020,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTMtMS0xLTA_3a3311e9-18d2-4941-ae24-e61841619e1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d775ca87aa45c7b569ef0164d07e18_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTUtMS0xLTA_d242ee72-ae6e-4347-a387-8c005edfc022">1,722,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62afd0579ab049588695814b856db8fb_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTctMS0xLTA_6d3e356d-8247-49c8-9daf-ab3202213753">28,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00106458d554c29aab7306c704ec827_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTktMS0xLTA_7af6b318-83ff-4af3-bcc5-8cdc173f346a">1,330,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e57cab296f149399d486ae6ead87efa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTExLTEtMS0w_adb6c75f-1416-4c8b-a20b-e687752263e4">362,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTEzLTEtMS0w_c7958b4b-5b5a-49e7-8164-506a27a4ec2c">15,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTE1LTEtMS0w_fdb7efdb-22e6-40a2-baf4-86cfc43fbea8">378,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' and Total Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:28.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.704%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Precigen<br/>Shareholders'<br/>Equity</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMS0xLTEtMA_5223ad68-d0b8-4fea-8ac2-6ffbd72bf5aa">160,020,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMy0xLTEtMA_3a3311e9-18d2-4941-ae24-e61841619e1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d775ca87aa45c7b569ef0164d07e18_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItNS0xLTEtMA_d242ee72-ae6e-4347-a387-8c005edfc022">1,722,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62afd0579ab049588695814b856db8fb_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItNy0xLTEtMA_6d3e356d-8247-49c8-9daf-ab3202213753">28,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00106458d554c29aab7306c704ec827_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItOS0xLTEtMA_7af6b318-83ff-4af3-bcc5-8cdc173f346a">1,330,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e57cab296f149399d486ae6ead87efa_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTEtMS0xLTA_adb6c75f-1416-4c8b-a20b-e687752263e4">362,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTMtMS0xLTA_c7958b4b-5b5a-49e7-8164-506a27a4ec2c">15,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTUtMS0xLTA_fdb7efdb-22e6-40a2-baf4-86cfc43fbea8">378,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtNS0xLTEtMA_3aec5cb6-2a7a-4a28-9b5f-75768b0e9c1f">18,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTEtMS0xLTA_1efcc494-befd-485a-9c7a-f15c132f34ef">18,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTMtMS0xLTA_5b9208f7-660b-4d21-a7b7-36ad9a632718">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTUtMS0xLTA_75eb29fb-afdc-46b2-b030-16a66bc7ea17">18,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMS0xLTEtMA_bd4232f8-e3f1-4322-af28-3223eedf6c72">1,028,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtNS0xLTEtMA_b9f8fe20-60d6-4381-933d-7bbdb566a31d">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTEtMS0xLTA_e8f3814b-8c9f-4a7f-ac82-0bd9a0bc8018">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTMtMS0xLTA_5a433f48-7341-4991-b6b6-69ef2564fced">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTUtMS0xLTA_84fd22e0-d402-4cf3-af42-b07deb6d58d5">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodSharesAccruedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMS0xLTEtMA_36d6cba8-6bdf-4fd4-901d-56fad81e064e">150,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodValueAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtNS0xLTEtMA_137c4261-505d-44ad-8d38-f9fe866cb7de">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodValueAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMTEtMS0xLTA_9bd62362-2ed9-4c9c-95d9-a077b9f0944d">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodValueAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMTUtMS0xLTA_e2105326-3358-4588-be80-381d76fda2b7">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued as payment for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMS0xLTEtMA_438e8540-ffb2-4480-953a-4207b548a3ef">2,075,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtNS0xLTEtMA_8ebd929b-73e3-43dc-a167-220779049fc2">10,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMTEtMS0xLTA_b3b86656-f3d4-4a24-a330-29c0c818960a">10,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMTUtMS0xLTA_009b51c3-d54e-482e-9f19-778b525d6b87">10,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares and warrants issued in public offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzctMTMtMS0xLTA_f07fc04f-b8bd-49e2-a5fb-1ff0f8b29d75">6,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzctMTUtMS0xLTA_5aea7780-6939-4db8-8e9e-0f1623352a1e">6,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231" decimals="-3" sign="-" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtNS0xLTEtMA_99e163d1-553b-4be6-9e05-6504488de3ca">456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" sign="-" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTEtMS0xLTA_4b1aa850-67c5-49a4-aa8a-2b53ddb5f00f">456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTMtMS0xLTA_af34d568-f0df-4f83-87d1-0afcc6300089">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:Adjustmentsfornoncontrollinginterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTUtMS0xLTA_67211ce1-d797-4ff1-8c5e-bdaa3d332086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzktMTMtMS0xLTA_af3bcd03-8f02-45e0-809e-12fe0c8bac7b">21,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzktMTUtMS0xLTA_27e0c0c2-8bbc-418f-af96-b2419e323104">21,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46f4056c01d04eeb92c3e2110de99905_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTktMS0xLTA_010c9c07-0fcf-48c2-a937-e7cd74e8c044">322,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTExLTEtMS0w_94f27f17-f2ac-4341-9bdd-ebc715692d8b">322,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTEzLTEtMS0w_0ef17039-6d16-4993-9855-0076a1eb889e">1,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTE1LTEtMS0w_5268a78d-0f39-4120-b7ca-07b05afb0e2c">323,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a7a2917a5840d1828b5b69ba7afea7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTctMS0xLTA_c03199aa-91ff-4984-9195-404c8acdf003">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTExLTEtMS0w_b830b7e7-83f1-4f31-80e8-b0415cb7634d">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTEzLTEtMS0w_9a25b663-b571-4e57-9a3c-7a1ce93b160b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTE1LTEtMS0w_c1db7540-1ba4-4c8e-90aa-45af3442c8ed">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTEtMS0xLTA_75c99fba-eaaa-4f32-99f8-37d2bac4ad44">163,274,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTMtMS0xLTA_9508c173-c367-412e-a85a-d202623435fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1053dfe438874cc9b2cd88769aca7327_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTUtMS0xLTA_8ea268a2-b328-42e7-8c91-946d43231e82">1,752,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c7b560b46b448dab6e990b87500645_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTctMS0xLTA_e69d3a8d-0a74-405e-a704-e40d4e724781">27,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75596e499ae443c3adaaf6abf5854f90_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTktMS0xLTA_59dee6e8-1610-4a51-bbfc-2bbaa38f5b59">1,652,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTExLTEtMS0w_e29ac137-62e6-40cb-9689-f16eb5236a5c">71,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce876c2b26448c6b08a1b65b0889bf7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTEzLTEtMS0w_4da91bea-f740-431d-9f59-f67ac44d1c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTE1LTEtMS0w_3a984046-0f79-4540-a787-d5aedcc58474">71,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' and Total Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders'<br/>Equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMS0xLTEtNjgx_75c99fba-eaaa-4f32-99f8-37d2bac4ad44">163,274,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMy0xLTEtNjgx_9508c173-c367-412e-a85a-d202623435fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1053dfe438874cc9b2cd88769aca7327_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItNS0xLTEtNjgx_8ea268a2-b328-42e7-8c91-946d43231e82">1,752,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c7b560b46b448dab6e990b87500645_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItNy0xLTEtNjgx_e69d3a8d-0a74-405e-a704-e40d4e724781">27,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75596e499ae443c3adaaf6abf5854f90_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItOS0xLTEtNjgx_59dee6e8-1610-4a51-bbfc-2bbaa38f5b59">1,652,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMTEtMS0xLTY4MQ_e29ac137-62e6-40cb-9689-f16eb5236a5c">71,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzMtNS0xLTEtNjgx_ad1409c6-4892-4bcd-a0d9-123d0b3574a9">18,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzMtMTEtMS0xLTY4MQ_3b6c44f0-1299-40b6-bcab-3a9d54ffa5ff">18,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon vesting of restricted stock units and for exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtMS0xLTEtNjgx_1d18e814-0d23-47e9-a296-05075e90cf6e">877,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtNS0xLTEtNjgx_de55d652-85cc-4b50-81cd-76880d05f8fd">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtMTEtMS0xLTY4MQ_0bd07244-1b34-43d0-a16a-d642481e0729">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodSharesAccruedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtMS0xLTEtNjgx_f3adc0e9-1cf2-4726-acf4-be2ce404bfee">1,955,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodValueAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtNS0xLTEtNjgx_69b2da99-c527-463f-a3dd-4f134da3b708">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringThePeriodValueAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtMTEtMS0xLTY4MQ_4231aa37-14a4-4998-81bb-87bdc6b731cd">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued as payment for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtMS0xLTEtNjgx_6276dcae-d31c-4301-9b1c-c17646c564d5">413,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtNS0xLTEtNjgx_32030566-eb2d-4f79-a7d6-578c28f5092b">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtMTEtMS0xLTY4MQ_a8703fc1-f10b-499a-bc65-bb714ebfbc4c">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued in private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctMS0xLTEtNjgx_a76e5d57-6536-4d89-98df-f7576edc4d19">5,972,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctNS0xLTEtNjgx_f37fe3f6-3130-4292-a969-f60f03fd37d7">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctMTEtMS0xLTY4MQ_e1544346-1916-4b7b-a8b8-5bfc647a2ab2">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued upon conversion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtMS0xLTEtMjQ2MQ_43299bb6-8808-4c0a-9a3a-6db6840b22a6">13,051,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtNS0xLTEtMjQ2MQ_fd026b24-d585-4295-877b-f6b931be1540">56,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtMTEtMS0xLTI0NjE_6a8d76f6-5cf6-4dd9-944c-d0eec432ec17">56,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued in conjunction with settlement agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMS0xLTEtMzc2Mw_43a26baa-ae6d-4218-9422-2103b0137fa3">2,117,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktNS0xLTEtMzc2Mw_60c8ba36-d5cb-4a75-a7d7-edfb8516b4f6">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMTEtMS0xLTM3NjM_c299aff2-794b-429a-a1ab-f15b738565bc">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5f5c113267a4a07b0fd84856590b114_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEwLTktMS0xLTY4MQ_2fb9966b-470f-4331-906d-b6ec29c800b9">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEwLTExLTEtMS02ODE_1133f9d5-0aa7-496a-917d-a1b4b45374be">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of cumulative translation adjustment to loss from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktNy0xLTEtNjk1_a5a8f32f-bf27-4969-bf7e-69d95e11b9e9">26,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMTEtMS0xLTY5NQ_eeee55a8-ef6a-4253-a9ee-d4fef8ff78c1">26,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzExLTctMS0xLTY4MQ_00ac8df9-93ff-47e0-a336-f963b6f6d054">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzExLTExLTEtMS02ODE_a7f65673-a0a3-4fce-8554-14518d035dda">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fae6176c89149ef8b0e8046c310748e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTEtMS0xLTY4MQ_83c7c163-1834-4afd-bd84-b58d5664d1bf">187,663,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fae6176c89149ef8b0e8046c310748e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTMtMS0xLTY4MQ_92233e14-5d8c-44de-bffe-ec74bec93f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i762149a5fcb747d7b935b70a375b135b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTUtMS0xLTY4MQ_7836bbb6-170d-48e6-996e-4d94e3d6f58b">1,886,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5035cb92632a453d81e2f99ab37a6a4d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTctMS0xLTY4MQ_3242a1ef-b9bb-436c-b549-635e2903a2a7">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife91272387c04b268c5f208e51e80445_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTktMS0xLTY4MQ_4ef69ebc-3540-4b85-b5e6-499bbd717b9a">1,823,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0677b8b8ac4e0194068bb8d9fa9a09_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTExLTEtMS02ODE_ea390b9c-02dc-4b56-8270-fe14af1a4a30">67,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItMS0xLTEtMA_ca84e3ce-a184-4c8c-8a6d-2ff2c3e370a2">170,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItMy0xLTEtMA_5aa1988d-6286-4582-8bbe-35e283ce7cc7">323,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItNS0xLTEtMA_6c68c640-1450-492c-8162-55f1f9350a8a">514,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtMS0xLTEtMA_738735b1-15ac-461f-89ee-9005947b2c9e">17,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtMy0xLTEtMA_f99a6b1a-6b14-492f-af6c-b27e0e9d33dd">24,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtNS0xLTEtMA_749c11ef-7abd-47d5-89fd-f84e07644aff">33,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on abandonment and disposals of assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtMS0xLTEtMA_1eda414d-b034-4d2e-9f42-71d00ba6b899">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtMy0xLTEtMA_7abaed70-f83d-44c5-926b-075ca397e351">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtNS0xLTEtMA_adc7d188-8fd1-4aac-88b5-a2a4918c433c">20,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtMS0xLTEtMA_7787acfa-d5d1-42d2-ae79-166c76c04d1e">9,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtMy0xLTEtMA_564dc141-9a90-42a0-bc88-a5479710ea94">87,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtNS0xLTEtMA_4ebe229d-1761-4a49-bdbe-224e673a9b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMS0xLTEtNzIx_76cbe2ff-c59b-42b0-b0e8-8bba881d6841">13,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMy0xLTEtNzIx_9b28b803-0acb-4607-bf1e-ee9c78449ac1">32,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctNS0xLTEtNzIx_23f3d7eb-c60b-41fc-b4ad-8fd253bda068">60,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMS0xLTEtNzIx_756e1614-9461-4891-ab94-aad7aa3c3297">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMy0xLTEtNzIx_5baeeff0-17e5-44ee-a792-17a4f9780d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtNS0xLTEtNzIx_547a03e7-28ed-4015-aad4-5e219563eac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustments to loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMS0xLTEtNzIx_c6cc5b82-2c4f-4bc1-8928-b15cc4bcca2e">26,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMy0xLTEtNzIx_102dff72-fef3-401d-9752-265720cefc34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktNS0xLTEtNzIx_a951ad51-efae-45c9-ba30-90e8485159b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reacquisition of in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMS0xLTEtMA_a68ab8ca-3ad2-44e5-bd21-b86f76a3203d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMy0xLTEtMA_54cc3553-d4b1-42b6-979c-05087464240f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctNS0xLTEtMA_638d9978-577c-4098-95d5-c405420ea01a">236,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on settlement agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTEtMS0xLTM3NzU_6261a33b-e1aa-4ba8-a57e-abaf46255c12">11,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTMtMS0xLTM3NzU_d2436c2f-32b8-40b3-99ea-ee1058d172fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTUtMS0xLTM3NzU_383cf479-9eff-4902-a495-56499b7a0bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMS0xLTEtMA_14e3ad15-bae7-443b-860d-918ecb3c0c0d">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMy0xLTEtMA_ab9a7ba8-4292-49ee-9676-defbd2fa7fc7">7,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtNS0xLTEtMA_7cd6ca45-6f2d-4e01-b3f2-e94fe36002aa">30,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash dividend income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:NoncashDividendIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMS0xLTEtMA_2686f84f-9bb7-4658-9ddf-2f2552e0c2ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="pgen:NoncashDividendIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMy0xLTEtMA_6aa5ea4d-40ef-4ac9-b08c-fb7386beb7a5">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:NoncashDividendIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktNS0xLTEtMA_61557047-5442-462f-8ae6-9eca8f7a86c3">14,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of discounts on investments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTEtMS0xLTA_82b71461-9ea2-4e99-a41b-9b97eb00dd5a">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTMtMS0xLTA_c8f4f293-c113-4c29-9e13-e0a910a311de">1,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTUtMS0xLTA_102060ca-18af-4c27-92ff-8b878b609107">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTEtMS0xLTA_0722e750-f6d7-4163-a1ef-c0ff61070b6d">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTMtMS0xLTA_a1d365b1-f27d-44c9-9677-2ce83efbd4e1">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTUtMS0xLTA_7f630503-6806-4d7d-9135-ff56e06e7cee">11,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTEtMS0xLTA_3f75c36b-6515-40af-8c1c-1aec1fdc3207">18,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTMtMS0xLTA_6966ca76-b907-43be-8b25-b725ef8e9fb8">18,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTUtMS0xLTA_acdf7ae5-e3ef-4479-9a1f-e318c2eb6ded">36,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued as payment for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTEtMS0xLTA_408bf1e4-ccf3-4845-aaa8-bb979dc51bac">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTMtMS0xLTA_c03c3d9d-d1b3-4872-9f6c-632214b3cda0">10,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTUtMS0xLTA_a63b1b84-4952-4cf4-b0c9-a1fdfb4f026f">10,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTEtMS0xLTA_95259375-2e69-44e0-ac34-01974451956f">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTMtMS0xLTA_af40236f-c6b5-47c4-bea6-37efa351d7f1">3,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTUtMS0xLTA_281008f9-6986-49c9-8b2c-9f851cffb0de">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of debt discount and amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTEtMS0xLTA_8ba3ab2c-efbb-4272-b5b3-e27328042689">10,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTMtMS0xLTA_19cdfd4e-a9c3-48cf-b1e3-8733c20bd71f">9,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTUtMS0xLTA_4fc84b43-dc42-464b-8240-96dcdaa09705">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTEtMS0xLTA_4f979a02-8e30-4d35-b88c-39f1b6a11c00">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTMtMS0xLTA_1d1ce9dd-cfe1-4823-a0a6-2ce15ed798cb">3,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTUtMS0xLTA_14ffe700-eed3-4975-8ca8-a6e2c2eda0db">21,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTEtMS0xLTA_32998071-d709-4a5d-927d-ad9bc0716387">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTMtMS0xLTA_06704ef0-f43a-488a-8f20-172ad3800742">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTUtMS0xLTA_fd07cbb8-8a51-479a-87b4-3ef43f874831">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTEtMS0xLTA_7a2779ad-69c5-4204-87dc-18e575e0ceaa">2,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTMtMS0xLTA_d8d8a62c-bcc2-48bb-adab-20faef552e40">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTUtMS0xLTA_3c0734fe-6820-40db-8cdb-f93fd7ad41ef">2,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTEtMS0xLTA_92b92d97-a7f8-4acc-8a3f-96b95e9ff1d6">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTMtMS0xLTA_34369bb2-aba2-4d20-868b-37638925c357">967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTUtMS0xLTA_36a52b53-2c8b-4f2c-b365-d5eac3214f9b">11,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTEtMS0xLTA_c69736a7-5f55-45a7-8ee8-d95245afcb13">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTMtMS0xLTA_4f4005f5-17d6-474f-b858-5f6f9a8cc357">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTUtMS0xLTA_c1309498-9a9b-496d-9740-68009dfd8d94">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTEtMS0xLTA_71f3c917-04a9-4e4c-b4cd-50dea06d1684">2,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTMtMS0xLTA_c52a7dd0-b84f-4c26-b98b-9a1b3d0a1349">4,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTUtMS0xLTA_683b679c-4b35-4f85-b430-babde58689a8">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTEtMS0xLTA_98e70a7e-3e25-4ad6-a7f1-c6e40fc8c2d5">812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTMtMS0xLTA_a6db5edb-5afd-44bf-9d33-61e84660efd3">2,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTUtMS0xLTA_d5b5697f-66c3-4246-9c1a-935e8938d084">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTEtMS0xLTA_e9e8151e-86b7-458d-9d9a-dcaf46862c5b">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTMtMS0xLTA_b799bc29-82dd-4a14-89c7-85d02fa008b8">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTUtMS0xLTA_c5d34ba3-3031-4b5b-90fa-e40f5e81850f">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTEtMS0xLTA_1e4393f0-f809-4258-ba48-fa2b031fa805">1,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTMtMS0xLTA_fc0c0512-7a31-44bf-be3a-46df0c205184">5,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTUtMS0xLTA_96491556-6c7f-4140-9949-8fe5e1a84ef7">4,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTEtMS0xLTA_b4e1a9b0-53da-4733-91ad-d34446bd7fd6">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTMtMS0xLTA_22f114c3-6b90-4c9b-9434-239f69697882">5,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTUtMS0xLTA_d6a51073-639c-43fb-8618-4f89968407bc">4,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTEtMS0xLTA_99b7f831-d2f8-4666-bce6-dd100fea85af">2,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTMtMS0xLTA_a5f94e0f-32ae-44e4-a536-1c623b91c223">5,516</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTUtMS0xLTA_26ead79f-be6f-4ad8-9bb0-4f393dc1daf6">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTEtMS0xLTA_374d5892-f5a1-4fa6-8021-cc59cce2d05a">21,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTMtMS0xLTA_fee981ac-5f00-4a9c-a5ee-d4dfcc770384">7,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTUtMS0xLTA_63d8d517-561e-443f-b662-77805914fc1b">38,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="pgen:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTEtMS0xLTA_b66ebad7-af6e-4cf9-9943-dd8aaff76241">887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="pgen:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTMtMS0xLTA_6c9e69ce-0550-4897-9801-8e9a1da9719f">995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTUtMS0xLTA_e29e95b0-8889-40d4-9e91-d2c4273360f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTEtMS0xLTA_fe841cb4-89ec-46e0-bce0-d5ccb4f53eb2">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTMtMS0xLTA_c26c78c4-58ec-4061-856e-1db815d34e4a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTUtMS0xLTA_7e401375-0649-4c95-9df7-9110dd6461b1">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTEtMS0xLTA_f5dc836d-7342-4bb7-a8e2-9f0a1f2f9112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTMtMS0xLTA_027661da-57bd-49c2-8557-a5b5f0258b87">585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTUtMS0xLTA_872146c0-dbc6-4854-aa6b-cd1ccd397177">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTEtMS0xLTA_efd7f07e-0097-495d-8f36-40901566475e">77,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTMtMS0xLTA_a9493389-4223-4973-aeb9-8dff20e4f015">135,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTUtMS0xLTA_ef6e1279-5b3d-4351-ba9c-eb9aa4bcb7ce">124,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItMS0xLTEtMA_1ab2ab96-96b4-46bb-8696-a310aee4fc10">171,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItMy0xLTEtMA_1369ddfd-2e96-43ce-8976-2fb70e93a081">55,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItNS0xLTEtMA_61882b83-f132-4b4e-8523-6bf2d6812560">178,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtMS0xLTEtMA_9d19f202-7a84-43c1-a3e1-8c746b57aff5">133,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtMy0xLTEtMA_3d2b47c0-eef4-4655-ae82-58163fd96403">166,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtNS0xLTEtMA_98e4e451-b601-43e9-8320-339dd554d13e">65,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtMS0xLTEtMA_9ca54d85-dc6d-4983-8086-125f208f9fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtMy0xLTEtMA_37992cd0-f7be-4110-884b-61e76de1f0a0">23,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtNS0xLTEtMA_88c3a11e-0f17-4984-920c-690c8ada5e6e">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtMS0xLTEtMA_78aba40c-e2e3-420d-a133-c0c89f346ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtMy0xLTEtMA_e8a69a6b-bad6-4626-b8ff-99c57abe316c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtNS0xLTEtMA_d8ad73dc-a174-41de-8a1c-6e93f12a1c8d">920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctMS0xLTEtMA_fb5b5bfe-1c2f-4c09-a43e-ac1d1380508d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctMy0xLTEtMA_95bb1228-74ef-4a21-b9e1-8df33c3b496e">3,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctNS0xLTEtMA_5a1f91c3-1d20-4bc2-a704-98c5427f72b8">16,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in cash from deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtMS0xLTEtMA_f350f4a8-ef14-4a60-99a3-71f7027dfa52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtMy0xLTEtMA_722014ed-dea1-4f98-b73b-5d17ffac538f">7,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtNS0xLTEtMA_e7969c7e-5251-47ec-9b3c-5362985d54b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Return of investment in affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktMS0xLTEtMA_ea0b6329-fd79-44a2-8012-de625a8f9d51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktMy0xLTEtMA_63b4da53-4f61-4e9b-ae39-e2a12220c47e">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktNS0xLTEtMA_032f06af-7cce-46be-aca4-40c0053e3220">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received in asset acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:CashInflowsOutflowsInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTEtMS0xLTA_6f6951e7-a20a-40ee-b420-d1a7bc4898ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:CashInflowsOutflowsInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTMtMS0xLTA_05f22a87-c9cd-4be0-9674-388195796648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CashInflowsOutflowsInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTUtMS0xLTA_0f0b3c18-ffc7-4177-98dc-39433aadb099">15,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTEtMS0xLTA_0da44c02-a245-4d13-b528-c1a597d5c1b5">7,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTMtMS0xLTA_13ccfd82-7ede-4e59-adf1-b7f213fe87bf">37,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTUtMS0xLTA_934eb80f-5078-4c6a-89c4-1f18a111d1c6">41,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTEtMS0xLTA_810b56e1-c744-408d-ac47-bd91d59eceff">6,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTMtMS0xLTA_bafd4fd6-41d5-4973-8fdf-12eef6d00a5d">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTUtMS0xLTA_59e7027e-1175-4e04-aa10-df7df2846deb">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of discontinued operations, net of cash sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTEtMS0xLTczMA_6a51fc70-9c33-4930-89de-1df22dc1b450">64,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTMtMS0xLTczMA_f8ff5269-a029-4d66-9812-50230f9684ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTUtMS0xLTczMA_bcb88c0d-5afa-404e-ba8e-94f180526776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from repayment of notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTEtMS0xLTA_7e6084f6-c4b8-4031-bb0a-1cff71a83cff">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTMtMS0xLTA_9256ef47-5813-43b1-b804-207961bf44be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTUtMS0xLTA_7d050d7a-ac08-4586-907d-b54a23dc2191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTEtMS0xLTA_2c3fc4fe-5bea-418a-90c4-ea16dafc3c21">27,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTMtMS0xLTA_d78b680e-4053-46a5-8d51-d121734845bd">86,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTUtMS0xLTA_1b9e07af-dcda-40d6-b0b7-4c418edddf3a">151,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of shares in a private placement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTEtMS0xLTA_6e40247b-a29e-4962-9636-34b8c485dedd">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTMtMS0xLTA_2e86b0f5-fb4c-4040-ab24-30255db4d7d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTUtMS0xLTA_2fc10fba-39ab-47f7-96ed-ff5a8b81b61d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of shares and warrants in public offerings, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTEtMS0xLTA_b2002f17-39e4-4abf-a0c5-59e629d2e006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTMtMS0xLTA_791298ed-61b3-4115-96bc-7888c4c7b1a2">6,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTUtMS0xLTA_20d7ea15-1b67-494a-838a-895deea536de">87,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advances from lines of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTEtMS0xLTA_e497d4c6-1e07-4189-9e18-29f668b26ebd">10,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTMtMS0xLTA_213b9e19-b4f3-451c-9bae-ab0b975a960a">11,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTUtMS0xLTA_1c43bf81-cc61-4041-81c1-0fe5fe4c6b79">4,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of advances from lines of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTEtMS0xLTA_1a1f2857-b466-4214-a9bc-b08ec4fff057">11,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTMtMS0xLTA_937c13d1-4cb4-4a1e-a8e2-7a225bc5348d">10,301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTUtMS0xLTA_7a1a39ec-65ad-4a41-8c26-9e4e22729e2a">4,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTEtMS0xLTA_18c86698-fcd3-4d44-841f-cc717c80f96e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTMtMS0xLTA_ccd3d7d3-2548-41c4-a290-cda45c974000">376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTUtMS0xLTA_704c2b09-085b-422b-893f-b61beebe0c23">219,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTEtMS0xLTA_835223a2-dbc7-40e6-90cc-4e47986d5f62">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTMtMS0xLTA_9b9b1f8d-e6ff-432e-81e6-818010229cae">618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTUtMS0xLTA_56e62d3a-61ea-4aec-aa07-cba5ac49d1dd">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock option and warrant exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="pgen:ProceedsfromStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTEtMS0xLTA_eba9fd2e-1c83-4b6f-adad-bbefc7cab190">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="pgen:ProceedsfromStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTMtMS0xLTA_e319bf25-5af3-45f2-af0b-dab25b1bcf33">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ProceedsfromStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTUtMS0xLTA_8ece16ab-d689-4a52-b390-ed488fb3bc4b">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTEtMS0xLTA_24f48b5f-e91d-4b08-b630-4ad4124f1c3e">32,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTMtMS0xLTA_cbcaaaf5-4d99-42b5-b6b2-2bca2a02635f">8,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTUtMS0xLTA_1809f371-06ae-4f3c-96b6-5174bbbd98f5">309,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTEtMS0xLTA_b58ddf14-636a-4a32-93ee-7ad7b0dd8dde">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTMtMS0xLTA_0dd66e14-608d-47f9-abe0-46a40f9c6655">810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTUtMS0xLTA_61a1f37a-e9db-447c-8b23-3aa9860c3024">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTEtMS0xLTA_1b6860cc-7626-4159-9fb7-49995e311cb9">16,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTMtMS0xLTA_7d42ca14-d08d-48ff-9562-d48380904243">41,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTUtMS0xLTA_04779040-d04d-414c-96e0-2ac48f308df2">34,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTEtMS0xLTA_7c7e7c44-3dcc-47ed-bbcb-dba2cc525e75">68,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTMtMS0xLTA_40ca2e43-007c-44cc-b83d-fcc7d77eba1f">110,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTUtMS0xLTA_ac819100-d7e1-42f8-8266-851c34e3b2bb">75,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTEtMS0xLTA_4d194d61-4dc8-4d28-91cc-ef103be30397">52,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTMtMS0xLTA_68a918a3-634d-4c23-bb76-c8942bae6f87">68,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTUtMS0xLTA_88a3117a-8711-44a6-b144-75bc8a2c2f8e">110,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Amounts in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItMS0xLTEtMA_02dbfc9c-4fbd-4f01-918a-051e4620f35f">7,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItMy0xLTEtMA_8721155e-dca8-4d16-9a8c-95638622a1cf">3,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItNS0xLTEtMA_c3222a34-ef77-498b-9700-f65b74b71dc1">3,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtMS0xLTEtMA_a5417225-37b0-42ce-9521-00f17efeb383">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtMy0xLTEtMA_c80ae8e0-a5b3-46a7-9682-491aeeffe692">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtNS0xLTEtMA_e78137ec-35f1-4fb2-9814-ca882e1065f6">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant noncash activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock received as consideration for collaboration agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:StockReceivedAsConsiderationForCollaborationAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtMS0xLTEtMA_5108f355-b8d3-48a9-9ecf-050475d388ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockReceivedAsConsiderationForCollaborationAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtMy0xLTEtMA_3137fc98-a30a-419a-93b1-db8a175363f3">4,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:StockReceivedAsConsiderationForCollaborationAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtNS0xLTEtMA_9f11115e-4fd7-4ba2-b47f-9d6e3e73e391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock issued for reacquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:StockIssuedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTEtMS0xLTA_e82bb58a-a92e-44c3-ab44-cdd452fc36ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:StockIssuedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTMtMS0xLTA_adc6ef49-2651-4b02-9f69-8c3b44230b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTUtMS0xLTA_d68f560e-2868-4a60-9fca-b198698bc149">159,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock issued upon conversion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTEtMS0xLTI0NzE_b18580a3-71b5-4dfb-b04e-b87414f7031c">56,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTMtMS0xLTI0NzE_78c73979-3197-4893-b54d-393ce8584a50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTUtMS0xLTI0NzE_ae4e03f8-b946-42bf-8f85-a3064b9c19b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock issued in conjunction with settlement agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedSettlementAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTEtMS0xLTM3ODI_bc9e85ec-ac59-47bf-b688-73b849548d29">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:StockIssuedSettlementAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTMtMS0xLTM3ODI_8718eb54-39d6-4e2e-bc37-4b2604a5b9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:StockIssuedSettlementAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTUtMS0xLTM3ODI_36dda342-33d4-4a51-ab5c-401fdde66fb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt issued to a related party in an asset acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTEtMS0xLTA_1adf077b-466c-4cf2-b6b3-715c8d94dde8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTMtMS0xLTA_23e77173-2cb5-4328-84f4-1e00f5af5980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTUtMS0xLTA_181df834-557f-42fc-87fd-b7855f4a0a3a">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation paid in equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:AccruedCompensationPaidinEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTEtMS0xLTc0Mg_8ce5966b-089f-47e8-ac39-31b4d16d54d1">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:AccruedCompensationPaidinEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTMtMS0xLTc0Mg_8d11f795-613a-4819-a8ae-2c5155a0a908">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:AccruedCompensationPaidinEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTUtMS0xLTc0Mg_8ee896d7-5c11-4ddd-813e-0e4991f43bef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTEtMS0xLTA_0a775eb7-3a59-4574-a95b-8d83bca69ae0">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTMtMS0xLTA_afc733ca-d0a3-48d0-9ec7-188fe51f1858">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTUtMS0xLTA_4545b030-f23d-43b7-b7ef-4c4c5e9706f4">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equipment financed through debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTEtMS0xLTA_15d15a9d-8307-4481-ac4c-e2a5fd855f1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTMtMS0xLTA_1df90459-e462-4525-a75f-a1d540ae0e22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTUtMS0xLTA_cc1c6af8-1ed3-42d1-829a-d68b8b3548fb">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of assets included in receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SaleOfAssetsIncludedInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTEtMS0xLTM3ODg_954347c6-82db-453e-8be4-2fc5ef372d98">4,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:SaleOfAssetsIncludedInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTMtMS0xLTM3ODg_e29de67a-3041-4d0b-9f79-34b2092ef0c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:SaleOfAssetsIncludedInReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTUtMS0xLTM3ODg_29225496-2d47-41b5-a25e-83987a2c2313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of December&#160;31, 2020 and 2019 as shown above:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzEtMS0xLTEtMA_7a4a7c05-6d00-466d-b421-365cd0be6c99">51,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzEtMy0xLTEtMA_32d7cc98-28fa-4963-ac82-29567a1ea141">65,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents included in current assets held for sale or abandonment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzMtMS0xLTEtMA_89266eb8-8942-4ab2-b22b-75eec23f0f8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzMtMy0xLTEtMA_7ab31f8c-1a77-4469-9f9f-1e281cff87c2">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzQtMS0xLTEtMA_122d22bc-278e-468d-8775-980f7c04b91b">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzQtMy0xLTEtMA_dc774d6c-2a24-4f80-a656-334b4f060fde">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzUtMS0xLTEtMA_6030dfa0-ad1b-4489-af45-42813c6fbf05">52,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzUtMy0xLTEtMA_fc1ae7cd-6261-4f63-89df-3663c5ab423e">68,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Precigen, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div id="ie210b0c7fc84429f915eaf73d0946948_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzk0NDQ_4b616906-c39b-467b-895a-3dde72c18a7d" continuedAt="if145773083434e13b0584189a6be62cb" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="if145773083434e13b0584189a6be62cb" continuedAt="i3d90a5a616ab4d31b04ca26f181ad7ae"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova Genetics, L.C. ("Trans Ova") and Progentus, L.C. ("Progentus"), providers of reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and has substantially completed the wind down by December 31, 2020. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty resulting in a loss on deconsolidation of $<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzMzNzE_ba90c4d3-cf6e-455e-8104-7d81c58ff7f8">2,648</ix:nonFraction>, which is included in other income, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. After deconsolidating the entity in April 2019, Precigen held its AquaBounty equity securities, which was an equity method investment that the Company accounted for using the fair value option, until October 2019 when the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party, for $<ix:nonFraction unitRef="usd" contextRef="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzQyNzc_da1c9b75-0e6e-4531-b4dd-881cf196456e">21,587</ix:nonFraction>, resulting in the recognition of a realized gain of $<ix:nonFraction unitRef="usd" contextRef="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031" decimals="-3" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzQzMzI_c00f3c48-54a5-4489-a8d2-f827416c8295">7,348</ix:nonFraction> which is included in unrealized and realized appreciation in fair value of equity securities and preferred stock, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 14 for further discussion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company." </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i3d90a5a616ab4d31b04ca26f181ad7ae"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that existing liquid assets as of December&#160;31, 2020, along with the net proceeds from the underwritten public offering in January 2021 (Note 23), will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators' product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December&#160;31, 2020, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzYxNTU_35556c4c-3f78-4da9-91dd-9d98b4c68968">170,521</ix:nonFraction> and, as of December&#160;31, 2020, had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzYyMDM_717b0803-b483-4a2b-8a1a-161c564645de">1,823,390</ix:nonFraction>. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, reduce uses of cash for operating and investing activities for non-healthcare functions, obtain regulatory approval of its product candidates, successfully commercialize its product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the original issuance of the Company's financial statements for the year ended December 31, 2018, the Company's resources of cash, cash equivalents, and short-term investments were not sufficient to fund the Company's planned operations through one year after the date the 2018 consolidated financial statements were originally issued and accordingly, there was substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern did not include cash sources outside of the Company's direct control that management expected to be available within the twelve months following the original issuance of the 2018 consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of the original issuance of the 2018 consolidated financial statements, the Company could not ensure that it would be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it was able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, was dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that were favorable to the Company. Should the Company not have been able to secure additional funding through these means, the Company could have had to engage in any or all of the following activities: (i) shift internal investments from subsidiaries and platforms whose potential for value creation was longer-term to near-term opportunities; (ii) sell certain of its operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. The 2018 consolidated financial statements were prepared on a going concern basis and did not include any adjustments to the amounts and classification of assets and liabilities that may have been necessary in the event the Company could no longer continue as a going concern.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjQ0_c4e98b72-d59d-4792-81a3-dfb75619b53f" continuedAt="if392f41344bd4e0797ad32634959830b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if392f41344bd4e0797ad32634959830b" continuedAt="i0ee6ff40724b4b928f57619dd2315443"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzA1_79f78e73-c0be-4a15-bb6b-bbd7463c4fa6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has had and continues to have an extensive impact on the global health and economic environments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second half of March 2020, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March 2020, ActoBio temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and the study is recruiting patients again. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i0ee6ff40724b4b928f57619dd2315443" continuedAt="ic4badf1a294444c3b107f92943b55617"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. The temporary suspension of the PRGN-3005 trial was not related to safety issues in the studies, and in May 2020, recruitment resumed in the PRGN-3005 Phase 1 trial. Furthermore, uncertainty regarding the duration and severity of the ongoing pandemic may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for further discussion of the impact of COVID-19 on MBP Titan.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzEx_200108a3-a2db-4d5d-b8c6-73d8ce6f4693" continuedAt="i60f7a6ac57df4736981070fd11215aea" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:durday" name="pgen:CollaborationAgreementTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MDA_0de35b66-3913-436b-be1d-fc8432b9dc1d">90</ix:nonNumeric> days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ic4badf1a294444c3b107f92943b55617" continuedAt="i168bba7022bf4cebaf1541f64eddd372"><ix:continuation id="i60f7a6ac57df4736981070fd11215aea"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product and service revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within <ix:nonNumeric contextRef="i17f6c337649843ef9b6c799eb5e89d84_D20200101-20201231" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzkw_103ed3e5-6ed0-4dc1-8070-f245992e2d44">30 days</ix:nonNumeric> of invoicing, which occurs prior to or when revenue is recognized.</span></div></ix:continuation><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDAz_9036b768-83a4-4079-b5a1-b77420d7ac7e" continuedAt="i57d270154adf41398f4d6c2cf19ff7c3" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i168bba7022bf4cebaf1541f64eddd372" continuedAt="i403aa94cafd24013b1666c28cf93e1cc"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57d270154adf41398f4d6c2cf19ff7c3">research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.</ix:continuation></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December&#160;31, 2020 and 2019, the Company had research and development commitments with third parties that had not yet been incurred totaling $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE2ODQx_a025ca0a-ebf1-429c-ad95-5c021b81fb7b">12,054</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE2ODQ4_c8f4dde2-fc2e-47f0-a343-e92aa5555099">14,664</ix:nonFraction>, respectively. The commitments are generally cancellable by the Company at any time upon written notice.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc3_59a2e9a4-8ed2-485f-a10e-b3b2ada243cc" continuedAt="ia1259187546f4b1a81622d3c4ba35425" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1259187546f4b1a81622d3c4ba35425">All highly liquid investments with an original maturity of <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:durwordsen" name="pgen:HighlyLiquidInvestmentMaximumMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3MDQx_0c241872-c3c1-4a42-ae28-3df629e6dab2">three months</ix:nonNumeric> or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.</ix:continuation> As of December&#160;31, 2020 and 2019, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3NTIw_0fd4d58e-48d3-4e5e-ab09-ed1f5d11eb83">30,164</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3NTI3_a3120486-a9c3-417d-bf30-e87acc9275e9">47,238</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzc3_f593718d-7044-40d9-a12c-9ec55dcc54f3" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard&#160;&amp; Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="pgen:EquitySecuritiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjYw_46bf401a-40ed-4d45-9deb-411c830951fb" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 18 for additional discussion of certain equity securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjUw_7189e78f-f34e-462e-8428-6bf878717231" continuedAt="i4b83948845d34dfe8017e70f5ff69d24" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets and liabilities;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i403aa94cafd24013b1666c28cf93e1cc" continuedAt="i7b51c8da771247a09391674b4d12bb71"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><ix:continuation id="i4b83948845d34dfe8017e70f5ff69d24"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQ2_b457f886-5b32-4a77-af89-4313f892c782" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December&#160;31, 2020, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc5_4e043626-f4a4-489d-936e-334b6b2023f2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its investments in each of its joint ventures ("JVs") and in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Notes 4 and 17 and to certain of the Company's JVs in Note 5.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDA4_41427a8e-e997-47fc-afb7-6ca9bc3fb326" continuedAt="ie70ee783f13b4896955fbd05fa958419" escape="true">Variable Interest Entities</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie70ee783f13b4896955fbd05fa958419">The Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company determined that certain of its collaborators and JVs were VIEs. It also determined Harvest was a VIE as of December 31, 2019. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December&#160;31, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MjM4_9b189323-0ee7-428d-8bff-d338248fae71">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MjQ1_091c0bc5-a1e9-437a-ab58-5dce979e32c7">1,461</ix:nonFraction>, respectively, which represents the Company's maximum risk of loss related to the identified VIEs. See Note 5 for discussion of the Company's future funding commitments for its significant JVs.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQw_5cda666c-4b3e-4b07-8640-29553be1efaa" continuedAt="if04e80ff683c4e569a5e1337a7cace99" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company applies FASB Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including accounts receivable. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i7b51c8da771247a09391674b4d12bb71" continuedAt="i5fa77b92b8a74674a22911b9407e9778"><ix:continuation id="if04e80ff683c4e569a5e1337a7cace99"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.</span></div></ix:continuation><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjY4_6410bf32-ecf7-44a3-8a84-8a82c34ba1af" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity in the allowance for credit losses for the years ended December&#160;31, 2020, 2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtMS0xLTEtMA_c6d05399-fe8c-4609-b7bc-6eeb50b32da0">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtMy0xLTEtMA_66e838ea-b7e2-46a5-8c87-5a543c5d1429">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4041a8bb484da3b179334191b0137d_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtNS0xLTEtMA_09e09e5f-b272-4ee7-b32a-7d0f3024cc11">4,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItMS0xLTEtMA_9725deff-551b-4f15-bdd8-2e97fa4f6785">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItMy0xLTEtMA_38251d48-95f7-4e6c-9dfc-ee441b77af3b">3,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItNS0xLTEtMA_65d87677-25ec-474b-ba88-5a7895b70453">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtMS0xLTEtMA_3497d1bb-6a74-41b8-9ff3-16791634f7a1">2,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtMy0xLTEtMA_86074990-4d35-4730-ad9f-ce93bd932470">862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtNS0xLTEtMA_517c9d77-a162-4209-b9d1-8600b438482a">1,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8952cdcb9a6e414eb3558452807047c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtMS0xLTEtMA_217623f5-a2cc-4326-b9d2-ec7d8322bdf3">6,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtMy0xLTEtMA_9104b2d0-e126-4fa9-9256-96e91a776c2e">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtNS0xLTEtMA_32df0423-f218-4c61-9ad9-b3d502963415">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQx_3c4e209b-e26c-4f81-9047-183c554e0ee0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzAx_9576fc40-259e-40e2-bc61-cf274b590356" continuedAt="i3f29d7d301f043f09fddbe5f07a9c071" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="pgen:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjMx_6876822c-0e99-4984-9739-f0c6ebaa350a" continuedAt="i085bcc632c9b45d185de927cd5d9e71b" escape="true">The estimated useful lives of these assets from continuing operations are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i085bcc632c9b45d185de927cd5d9e71b" continuedAt="i08baf43d47be4168b56753ce1f19ffca"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3ad6258403540099941f2a068f4043d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliODNlNjk0YTlmNTRkYjk4ODhkNWY2MjFiMTI0YzMxXzQzOTgwNDY1MTExMTM_77ffa09b-6457-4bea-9d72-30f4a016bd61">4</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i6ba88e8a7dd14e0e90467b7df8a754de_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliODNlNjk0YTlmNTRkYjk4ODhkNWY2MjFiMTI0YzMxXzQzOTgwNDY1MTExMTg_dfc79ff4-534a-4d28-a195-ed44793930f2">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie518adbaa2914c83a75398892dc33f68_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzItMS0xLTEtMC90ZXh0cmVnaW9uOjU1NTBmMWU3NWFlNzQ4YWRiOTdlYjNlZDVhMTk0NmM5XzQzOTgwNDY1MTExMjE_59e6dd39-4dfa-4bb8-9bc4-743d79f94d94">3</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i027d6d87c78e4317a791117a2393e261_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzItMS0xLTEtMC90ZXh0cmVnaW9uOjU1NTBmMWU3NWFlNzQ4YWRiOTdlYjNlZDVhMTk0NmM5XzQzOTgwNDY1MTExMjY_b8192658-2305-4445-9b0d-3cc340430649">23</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d3ba94d22bb43898d8e8b5658bd229f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmE1ODZjODFhODNmNzQ2YmNhYTcxN2U1MjQ4YzU5ZjQ0XzQzOTgwNDY1MTExMTI_9a3d5bf3-2ba4-4b17-841e-19a51675d840">1</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i91fece37ad5247789405374ea393337a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmE1ODZjODFhODNmNzQ2YmNhYTcxN2U1MjQ4YzU5ZjQ0XzQzOTgwNDY1MTExMTY_5b335309-87db-47e6-9f0c-4c62b1eacb37">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i84a4580dd157421b961abbc9269d361d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJjZTE3OTJiMjIyNDQ5Mjg4OTJmNWU3NmUxOGIzMTdlXzQzOTgwNDY1MTExMTI_3e3c06dd-6923-4087-8224-f41837a68673">1</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i36032ed843b643ee8327a678783a2ac2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJjZTE3OTJiMjIyNDQ5Mjg4OTJmNWU3NmUxOGIzMTdlXzQzOTgwNDY1MTExMTY_77fe126b-44dd-4906-a074-49e91b1cf852">9</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i486b675333cb4c5b91c24f42597dc946_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJjYzdmODU1MjgwMTQ2NzQ4MjM3NzA3ZDk4MGQwMDQ3XzQzOTgwNDY1MTExMTI_6315b056-e52f-48e5-b010-c1220dce88e9">2</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="ie0750ead12ac4214b42916e3ed24bdfe_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJjYzdmODU1MjgwMTQ2NzQ4MjM3NzA3ZDk4MGQwMDQ3XzQzOTgwNDY1MTExMTY_5671e4ee-6af5-4cf0-9eb0-98fa36d2d708">4</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a5e98f13a3a461ca2c7fbf143a0e4cb_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmM2NjZlYmNjZTY2ZTQ2N2NiMzRhY2RhYzVmMDY0NzU3XzQzOTgwNDY1MTExMTI_970b40d3-4bf9-4db6-9ac6-e2b8a6bf76e8">1</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i3ab8005306a844bda35c05aa23ceb1a6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmM2NjZlYmNjZTY2ZTQ2N2NiMzRhY2RhYzVmMDY0NzU3XzQzOTgwNDY1MTExMTY_b134dbec-af49-46e0-a1c0-316d7cc2bca1">7</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08baf43d47be4168b56753ce1f19ffca"><ix:continuation id="i3f29d7d301f043f09fddbe5f07a9c071">Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">one</span> to <ix:nonNumeric contextRef="id068240ac9514712ac2777d3f353304d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjEy_5968307d-5f67-4df8-82b9-a1123e7d833c">fourteen years</ix:nonNumeric></ix:continuation>.</ix:continuation></span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjkx_ed87f4b1-4898-4083-b495-fa1379b85ea1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets.&#160;The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i5fa77b92b8a74674a22911b9407e9778" continuedAt="ic2db4146abe849f0b14c761e522dbaa1"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjg2_5cd7f939-ce38-4cdf-87b4-1ad82d196b0a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 11 for additional discussion regarding goodwill impairment charges recorded in the years ended December 31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzMw_e4f49f07-f28e-4ffe-aa3b-425010607434" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e">three</span> to <ix:nonNumeric contextRef="i11e11947645549f79ae1c1b067e15412_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjE4_949335dc-8b5e-4ca6-b501-6da4e4e791d0">eighteen years</ix:nonNumeric> for the patents, developed technologies, and know-how; customer relationships; and trademarks.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzMx_03281ae7-3e46-4d13-93de-0aa8c3b7de08" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 10 for additional discussion of impairment of long-lived assets for the three years ended December 31, 2020.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDMy_1d37d6a8-02e3-4ad4-820a-b5a51c6613f0" continuedAt="id5c1c595089f4174ad00909a0222909f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the proceeds received in July 2018 from the issuance of Precigen's <ix:nonFraction unitRef="number" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzM0Nzc2_99b5b2fc-d809-4717-9302-53ce58d51f0e">3.50</ix:nonFraction>% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ic2db4146abe849f0b14c761e522dbaa1" continuedAt="i349e727781914126a3d81435611545cc"><ix:continuation id="id5c1c595089f4174ad00909a0222909f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for the further discussion of the Convertible Notes.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzI4_3deca997-d840-4159-969b-89edafeaede1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzkz_2957d5dc-f6f6-4049-92a0-1ba41a1e13a5" continuedAt="i2689c947a78e4513a8933d4139b123b2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2689c947a78e4513a8933d4139b123b2">The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises.</ix:continuation> There was no impact from GILTI to the accompanying consolidated financial statements.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDE3_127f4db8-98ba-4b0c-8bb0-ef2c545c944c" continuedAt="if32b89b1e69e4002b4f459d07aa948f2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzQxMjE4_e1dd957f-47ed-433f-b063-3ac27aaf0fb8">0</ix:nonFraction>% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQ5_d41ffca3-79bb-4788-96fe-a0d4388ff2ee" continuedAt="i758b4c60af7e4b429592412c33073a94" escape="true">The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:</ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i349e727781914126a3d81435611545cc" continuedAt="i24fe5a13137b475db4567cc2b2f51db8"><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="if32b89b1e69e4002b4f459d07aa948f2" continuedAt="ia72c5650cc6a46d4a9a9e85080973539"><ix:continuation id="i758b4c60af7e4b429592412c33073a94"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItMS0xLTEtMA_17a7d72a-e0ae-43a3-a496-4b57449473ed">0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItMy0xLTEtMA_51745177-a930-476e-acc2-d87835d85119">0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItNS0xLTEtMA_5d2233eb-fadb-4c08-956d-13f52c470e78">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjdjN2E4MzllM2NiNTQ2Mzk5Nzg5ZjMxNTRjYTIzOTZjXzQzOTgwNDY1MTExMzI_b3b4199f-00da-4841-bbb4-641add517a41">59</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjdjN2E4MzllM2NiNTQ2Mzk5Nzg5ZjMxNTRjYTIzOTZjXzQzOTgwNDY1MTExMzg_7c464798-a8fc-49d8-9f01-3ba207bf6106">90</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjMzMjFkMzBiZGU2ZDRkODhiMzYzMzZjODc2NjVhOWExXzQzOTgwNDY1MTExMzI_194b1e43-58ce-4d4f-840e-440f12921511">58</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjMzMjFkMzBiZGU2ZDRkODhiMzYzMzZjODc2NjVhOWExXzQzOTgwNDY1MTExMzg_6dfd8684-d19b-453e-b4a1-0a2a2339cc7a">64</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjJhYTU0MmUxOTExNzRhYzE5MDQ3ZWFiMzJmZjMzNzI0XzQzOTgwNDY1MTExMzI_44714a02-c80a-494a-9d4a-cc535e341c55">55</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjJhYTU0MmUxOTExNzRhYzE5MDQ3ZWFiMzJmZjMzNzI0XzQzOTgwNDY1MTExMzg_6a020b7e-8172-4ced-8d3e-8517eb4e21fd">59</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a99bff0ee894d4ebc0529513dfabc6f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjI2M2JkNGYyM2YyMTQ5M2NhZmUzYzQ1NDJlMjg1NzAzXzQzOTgwNDY1MTExNDI_e2104200-0549-4423-81b1-aea05db30950">6.00</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i5b61e5b1fd0b43908fdd386d73838549_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjI2M2JkNGYyM2YyMTQ5M2NhZmUzYzQ1NDJlMjg1NzAzXzQzOTgwNDY1MTExNTA_47d81402-e6fc-4c5e-9217-e1dcee4d4dc3">10.00</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMy0xLTEtMA_b3111627-b476-4474-8a0c-e2ae75a7f180">6.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtNS0xLTEtMA_9ca3324a-49a7-403c-a031-cb6ca1767454">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNGUyNDdlZmI3YTQwMjY4N2Y0NDE4NTY0ODg0NThjXzQzOTgwNDY1MTExNDY_a4657105-d00b-4333-8c08-5c3686b675f2">0.36</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNGUyNDdlZmI3YTQwMjY4N2Y0NDE4NTY0ODg0NThjXzQzOTgwNDY1MTExNTQ_82f9b230-257b-482c-b2dc-db098a3952f1">1.80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjY3YTBiMWZjNjljYjQ2NTZhZDAzYmU5MmY5ZTZkOTAyXzQzOTgwNDY1MTExNDY_e75690be-113e-4afe-b492-d65e89272dd9">1.53</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjY3YTBiMWZjNjljYjQ2NTZhZDAzYmU5MmY5ZTZkOTAyXzQzOTgwNDY1MTExNTQ_27142f14-5d8c-489c-8749-02213cff8a98">2.58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtNS0xLTEtMC90ZXh0cmVnaW9uOjU5YjhiNmJlYmVlNTQ1MTNhMDQwMDhhMmMxNDVmYTU0XzQzOTgwNDY1MTExNDY_10db9821-646b-42c2-9ff6-3dfd5c599aed">2.33</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtNS0xLTEtMC90ZXh0cmVnaW9uOjU5YjhiNmJlYmVlNTQ1MTNhMDQwMDhhMmMxNDVmYTU0XzQzOTgwNDY1MTExNTQ_22188a77-96eb-468e-bd82-aa47a9ec3138">3.06</ix:nonFraction>%</span></div></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia72c5650cc6a46d4a9a9e85080973539">Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjU2_9cb0ee4e-8366-4708-ae15-df4103840b9a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzM1_30f68441-3dbf-4157-b7f7-4d038bea41fc" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. As of December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) Trans Ova; and (iv) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. See Note 20 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 20 for further discussion of the Company's segments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc0_a90f448b-b26b-44b3-8741-cde3acb3c4fa" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDA1_4f7ca151-6223-41ae-869e-426bc8f4e3d5" continuedAt="iad4ae0d1f1ba46b8836a6c48e3603e70" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i24fe5a13137b475db4567cc2b2f51db8"><ix:continuation id="iad4ae0d1f1ba46b8836a6c48e3603e70"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model for receivables to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2020-06"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021. Early adoption is permitted but no earlier than annual periods beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_133"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzUzNjg_1cc9d764-6a74-4398-aee5-d76736ba2a81" continuedAt="ia3f70db3cbf34b72b47dffdee824dedd" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="ia3f70db3cbf34b72b47dffdee824dedd" continuedAt="i9133a015a47243e282c9b3c201089aeb"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MBP Titan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially complete by December 31, 2020, with the final disposition of certain property and equipment </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i9133a015a47243e282c9b3c201089aeb" continuedAt="if66891cea1974103bf884b0efcc1f4a5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the facility operating lease occurring in January 2021. See Note 23 for further discussion of the facility operating lease. This discontinuation of operations represented the continuation of a strategic shift, that the Company commenced as part of the Transactions defined and discussed below, to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners and Intrexon Energy Partners II, including the associated deferred revenue remaining under each collaboration agreement (Notes 5 and 6), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying consolidated financial statements for all periods presented as a result of the Company's continuing involvement.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzY1OTcwNjk3ODg3MDc_c0d5e9f2-91ec-4b4d-a38a-c466cb5ec6b9" continuedAt="id18c8e18a01a446cb20cc391bb6da141" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzUtMS0xLTEtNjQ2OQ_b5522f36-67d8-415b-aedf-4e1afa8fa16b">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzUtMy0xLTEtNjQ2OQ_1a03aa64-8fe4-4a64-a022-70b517490e83">17,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzctMS0xLTEtNjQ2OQ_79db8a84-ef01-49fd-9668-b460bebfeecd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzctMy0xLTEtNjQ2OQ_f6ee2f34-b7e8-48fd-a859-c70bb39bb5d6">9,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzktMS0xLTEtNjQ2OQ_efaf5011-7ed1-4a98-ad75-71bde048c671">9,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzktMy0xLTEtNjQ2OQ_fd6497b2-96cc-4722-b69f-239c3a142043">13,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzEwLTEtMS0xLTExNTcw_825caff5-08ab-4c9d-8aa6-74b476c68fd6">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzEwLTMtMS0xLTExNTcw_43ceae79-0de7-4e58-aa1f-e0fd67395216">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale or abandonment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzExLTEtMS0xLTY0Njk_b69b42ac-df87-48ce-aea4-960536e168c2">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzExLTMtMS0xLTY0Njk_a28dbd53-78bb-4b6b-9268-e920c86d74be">40,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE0LTEtMS0xLTY0Njk_62950e8d-471e-48ce-b1ab-8d85d891ed8c">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE0LTMtMS0xLTY0Njk_a4a51bcc-7e21-4745-81fc-9f2fd1d464f2">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE1LTEtMS0xLTY0Njk_e669065a-798b-4d34-8d70-072d2cd5a677">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE1LTMtMS0xLTY0Njk_a4024b39-65a2-415d-8b17-806611b410e1">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE3LTEtMS0xLTY0Njk_c7702df6-93be-44bc-87e8-471b496d1b2d">11,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE3LTMtMS0xLTY0Njk_c9c29774-0e8c-44bc-a2cd-cafbcca0e72a">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale or abandonment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE5LTEtMS0xLTY0Njk_dd679729-4caf-4c47-996b-6d4374caf486">14,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE5LTMtMS0xLTY0Njk_25b17b52-edf2-495f-a3b4-c754bec0dcf1">16,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of discontinued operations of MBP Titan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtMS0xLTEtNjUwNg_e670922d-8991-45b6-a313-9c2788c85917">40,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtMy0xLTEtNjUwNg_f0e9b1f5-c662-4c7c-9591-d19200473026">37,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtNS0xLTEtNjUwNg_691d1d95-9232-4de4-88c5-1240df691649">33,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtMS0xLTEtNjUwNg_2f147fd2-9c29-40dd-8174-3b46eda05bb1">40,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtMy0xLTEtNjUwNg_b5ec775e-b911-4584-ac7e-ad70a7ee2fa8">37,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtNS0xLTEtNjUwNg_253b2a03-7328-481d-97e6-2118b3d5cf88">33,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktMS0xLTEtNjUwNg_c5d7e8ed-6ed0-4785-a988-f58d40faa54f">40,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktMy0xLTEtNjUwNg_10afd061-3ba8-4ccb-b2ee-902100441791">37,423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktNS0xLTEtNjUwNg_c3cc51ed-2744-4987-b13b-59dfba825e89">33,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTEtMS0xLTY1MDY_35464bd9-4dca-49e3-b1c9-2d5d3f1aa024">40,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTMtMS0xLTY1MDY_858902f8-c911-4d39-b981-a792e98c3963">37,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTUtMS0xLTY1MDY_30dcd668-bc81-4ec5-bef8-608dde3d56c9">33,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MzExNDg_113e89d0-8fc4-4127-a0f2-edef17650bc2">9,635</ix:nonFraction> and an impairment charge on property, plant and equipment and ROU Assets of $<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MzExNTg_4b236ea2-63de-470a-9a6b-09e4888be3c1">12,406</ix:nonFraction> recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="if66891cea1974103bf884b0efcc1f4a5" continuedAt="i07ba98b01cfe43df85b864420b3299b4"><ix:continuation id="id18c8e18a01a446cb20cc391bb6da141" continuedAt="i6495c31963234885b6912e6e3f93d740"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtMS0xLTEtMTAwODA_a68d3c87-312b-4826-bf59-c1e1ec43f763">2,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtMy0xLTEtMTAwODA_73658f77-ffc0-40be-8dbb-8c7183f5b595">3,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtNS0xLTEtMTAwODA_edc3e045-8d6c-4b6e-8ac8-7c96d339ee35">3,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtMS0xLTEtMTAwODA_83f1fd4f-ff14-433b-a41c-4602ddc7a37e">9,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtMy0xLTEtMTAwODA_d0a6b7f1-b85c-442a-b0a7-8c146a13298f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtNS0xLTEtMTAwODA_075b83d0-2e8a-42f3-bb85-8c21c45a7b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtMS0xLTEtMTAwODA_74dd5a83-5b79-42bf-a678-6f1de5fbacb0">12,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtMy0xLTEtMTAwODA_02636f38-4617-40d6-9d57-f788663af3f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtNS0xLTEtMTAwODA_68ebd66b-d49f-4825-a5e8-cb5943d99bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTEtMS0xLTEwMDgw_45dbdff0-35cd-45ef-bd85-268950b3bb91">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTMtMS0xLTEwMDgw_93a6615b-3bae-495c-9102-65c48a7e7871">1,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTUtMS0xLTEwMDgw_542aa32a-c343-44a7-9dac-741fec5052c2">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTEtMS0xLTEwMDgw_e2805fbb-5d84-4f5a-af99-04e621b4e5fa">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTMtMS0xLTEwMDgw_5dbce272-4022-42d3-982d-8c7cefd28ff8">2,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTUtMS0xLTEwMDgw_8a2587f9-c23c-4746-8fcf-f4b0d65ae183">3,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $<ix:nonFraction unitRef="usd" contextRef="i8a892879d07044f58213c5a70dccecdb_I20200131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM2Mw_9d47d207-7827-407f-9a5a-ea5379999c8b">53,000</ix:nonFraction> and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $<ix:nonFraction unitRef="usd" contextRef="ie5536916a8c741d08eecaed7c735bd94_I20200102" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzE3MTE_50e437ed-f9dc-4ca3-a9d4-1a392f972f73">12,200</ix:nonFraction> (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions".</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. Immediately prior to the reclassification, the Company evaluated goodwill, long-lived assets, and the equity method investment included in the Transactions for impairment. The Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MDE_9e3be7d2-b7bc-4786-a05c-e1f17c499451">79,396</ix:nonFraction>, including $<ix:nonFraction unitRef="usd" contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MTU_46b5aad5-e99f-4472-a8f6-20579df61092">58,042</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MjI_d6ae38c6-8139-4126-8c65-50da54fb2394">21,354</ix:nonFraction> related to goodwill and other long-lived assets, respectively, at the Okanagan, Oxitec, Fine Chemicals, and AgBio reporting units. Additionally, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i87b81adc30c64968b22a72162d34e9c2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI3OTM_1222abdd-e0b9-4db4-8b36-d46b0a9894f9">10,283</ix:nonFraction> impairment charge for the write down of the equity method investment and related intangible assets included in the EnviroFlight Sale. These impairment charges are included in loss from discontinued operations in the accompanying consolidated statement of operations for the year ended December, 31, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i07ba98b01cfe43df85b864420b3299b4" continuedAt="i53dd7d25f63847ad9c201133fa1ddf4e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $<ix:nonFraction unitRef="usd" contextRef="ib1656e2b95eb4e86b30c7f13bec36e35_D20200101-20200131" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTk0NDY_3dd433e8-8395-442f-9b23-fa2c8a01cee6">26,957</ix:nonFraction> were released to earnings and included in loss from discontinued operations. See further discussion below.</span></div><ix:continuation id="i6495c31963234885b6912e6e3f93d740" continuedAt="i2e4a03acc530489cbcddd267b9155356"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtMS0xLTEtMA_1069d7ee-8477-4ba0-98a7-1d8143c25f33">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtMy0xLTEtMA_268171ad-b799-4725-93ab-808eb2257bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtNS0xLTEtMA_d585c3f4-129c-4768-8f3c-5b552932ab0c">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtMS0xLTEtMA_0cfbe85a-939a-48a3-85cb-80a2daeeb009">9,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtMy0xLTEtMA_680ec9a9-fefb-43a1-991f-539f64761cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtNS0xLTEtMA_2f16da96-e780-4ba1-98d3-51bc6f053451">9,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtMS0xLTEtMA_88802fe6-7a6b-4cae-9243-2dbdd0331474">51,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtMy0xLTEtMA_4bd6abbf-7706-404b-bccf-cfcb55751967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtNS0xLTEtMA_2b8dd491-29f6-41db-b7f6-70089e15bbd3">51,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtMS0xLTEtMA_5ad6aa66-286a-4dbe-8ecb-2b743cf17e00">20,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtMy0xLTEtMA_7adcc202-93bd-4408-a6c4-9bf1f250d39a">4,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtNS0xLTEtMA_af3ded6c-984f-4f7a-96a3-d5ed0c1eb247">25,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzctMy0xLTEtMA_e4778527-7fcb-4268-8936-cbab018fc014">7,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzctNS0xLTEtMA_9d1d1b50-6bdb-413a-8743-3ed732660bfd">7,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktMS0xLTEtMA_284cf8e3-91e8-4026-80ed-0cb720413b8e">13,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktMy0xLTEtMA_b35c9daa-5220-495e-91b9-01325d27ec85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktNS0xLTEtMA_33a819d3-a140-4cc1-903e-fcc84dc55ad8">13,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTEtMS0xLTA_fcecb608-e465-4fd0-81d8-0714624c4fb1">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTMtMS0xLTA_3e6654a4-6537-4a35-b897-6f8895cd6069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTUtMS0xLTA_a406107e-2786-48ec-8776-f6b650940b42">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTEtMS0xLTA_ddac7efe-c713-4d60-ac41-1f7b05907659">98,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTMtMS0xLTA_8cc62a56-c1f8-4f1f-9789-1ed54bf95643">12,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTUtMS0xLTA_53284801-6aa7-4a57-bc9d-646ceedb6d83">110,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTEtMS0xLTA_b1bf8083-753c-4ba4-9369-0c1448365db8">8,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTMtMS0xLTA_2d6ea7e5-f0ac-402f-af1c-3b6d50591b82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTUtMS0xLTA_78eeab4f-f944-402f-82d6-0d36fbd77008">8,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTEtMS0xLTA_b1081731-98a0-410d-baf7-1bad67dd1028">2,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTMtMS0xLTA_e5833bcd-a834-47c9-9b22-463e7b4e9823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTUtMS0xLTA_6d56927c-bf65-4f04-a11f-61743026fccd">2,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTEtMS0xLTA_7f100272-fe4f-4d6e-9b93-dc6d3f36faef">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTMtMS0xLTA_46e78319-ece6-4098-a67d-ef8e501d9b77">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTUtMS0xLTA_34799c58-33c0-48f3-94be-6d301de4aa7e">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTEtMS0xLTA_66d432c0-37be-4db3-bc0c-9fad2cc0cc56">19,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTMtMS0xLTA_c55b00a2-75c6-4ff4-b1f2-893eee4b7af2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTUtMS0xLTA_24f6f171-18df-4cd3-80fa-79599b5114a3">19,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTEtMS0xLTA_654587c2-ca40-4a85-81fc-51ef5aed3360">12,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTMtMS0xLTA_3f6df299-aeac-46cf-87a2-1b23eea585c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTUtMS0xLTA_ce455bcc-7f1c-47db-a665-14046d78e28c">12,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTEtMS0xLTA_928f319c-1b1c-4ff8-a899-20d041666eb4">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTMtMS0xLTA_e0afa688-cda8-40a8-a09d-e7b0309f5707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTUtMS0xLTA_47962867-e2f8-4410-a15d-85467e1aec18">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTEtMS0xLTA_fa731729-12a0-46d9-84c8-0ae9d7ae573a">47,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTMtMS0xLTA_1a13b36c-1b9c-43c4-ac12-499070e542c7">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTUtMS0xLTA_051393b8-0a25-4b9a-baa6-cf252a2b7781">47,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, current, from related parties of $<ix:nonFraction unitRef="usd" contextRef="i85eefc0df3064556bd575eced34b22d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM1NjM_b568a260-1f25-4667-b83b-e73c47ea3ed0">1,243</ix:nonFraction>.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, net of current portion, from related parties of $<ix:nonFraction unitRef="usd" contextRef="i85eefc0df3064556bd575eced34b22d9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM2NDI_ccecf7de-77e4-4537-b5d2-1adeaf333591">6,836</ix:nonFraction>.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i53dd7d25f63847ad9c201133fa1ddf4e" continuedAt="i80d50acf614d487ca8ba86d3fbb28bb9"><ix:continuation id="i2e4a03acc530489cbcddd267b9155356" continuedAt="ifbf846a8eb864a168f0c6a11d6b20379"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial results of discontinued operations related to the Transactions:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItMS0xLTEtMA_46c31076-ba39-42b0-b769-afddd707086c">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItMy0xLTEtMA_a68ca088-f47d-471e-ad84-669100d1a4f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItNS0xLTEtMA_45493750-8b5c-4733-a3d5-587197b73260">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtMS0xLTEtMA_41bd62bd-7ab0-4a25-8330-191e9a4c9e97">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtMy0xLTEtMA_38fe144e-6dd0-4b16-ad2c-cf677a1c58a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtNS0xLTEtMA_453a1c5b-124f-4a08-b8f0-f41a9ba0e3a2">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtMS0xLTEtMA_eede913a-bb73-4298-83b9-7956118652b1">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtMy0xLTEtMA_10f49833-c0db-4572-aa26-f0efc91ca5b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtNS0xLTEtMA_f59cdfb0-d469-4890-b592-afa8d22bc51d">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMS0xLTEtMTAzNg_6c2b9cf1-71b4-46f7-9bb8-4f7885f84182">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMy0xLTEtMTAzNg_59d67b04-bd8f-4b6d-a9df-732124dc7af9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtNS0xLTEtMTAzNg_ecc90129-b73b-44a9-9e3c-f98fc822d5fa">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMS0xLTEtMTAzNg_fbe79ab6-df6e-4820-986d-69a0a4133ab1">26,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMy0xLTEtMTAzNg_14de6909-1e14-47d5-8fe6-a0a1048c7e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtNS0xLTEtMTAzNg_93c35bc5-68f8-4f6f-81c5-b31ef6391dc1">26,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMS0xLTEtMA_afa71fbe-a097-4bc5-9cc2-78e5513b735f">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMy0xLTEtMA_d53ff244-036f-4f48-9fc0-e3ae6b53955f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtNS0xLTEtMA_95ce8ac5-1972-4b2b-9442-c52be33cd7bc">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" sign="-" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMy0xLTEtMA_28a6c60c-c110-4a22-8902-a61e502c44e8">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" sign="-" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtNS0xLTEtMA_06f996da-4250-4b76-9ab2-790362d8f178">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctMS0xLTEtMA_ee1cdf3e-cb7a-486d-aac5-86450c047d16">26,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctMy0xLTEtMA_509571cc-7735-4544-9efd-e433bc7665e6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctNS0xLTEtMA_7a4c9e72-42b2-46c6-9b39-f943664687f2">26,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtMS0xLTEtMA_00045c1b-c082-4e11-aa9c-4ef4996ce565">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtMy0xLTEtMA_c27a7d1b-c94e-41d9-b835-a8b3052e39fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtNS0xLTEtMA_0185db6e-cfb3-4e6d-9382-a28eb5f35b28">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktMS0xLTEtMA_ab8c23cc-5b57-49e9-8881-401a4c80b508">26,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktMy0xLTEtMA_e195f0c8-b0f2-45c3-b750-5513e4d68c41">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktNS0xLTEtMA_bf03e4cc-74e3-41bd-b7ed-97a6de345c77">26,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenues recognized from related parties of $<ix:nonFraction unitRef="usd" contextRef="if3ea4810310f41c692ba79c0e33d366e_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM3ODA_9629c1cd-0518-4a0e-a1e5-c8d5b71312a4">436</ix:nonFraction>.</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItMS0xLTEtMA_bf28db07-5a06-45c8-951b-d7b06d2f0a8b">12,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItMy0xLTEtMA_fb459ae7-9a15-49d3-a07f-9069b301e357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItNS0xLTEtMA_d896ba19-26ff-46f9-a9dc-098464ca7f6f">12,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtMS0xLTEtMA_c1e9b226-eb7d-49da-96f5-e049fb11299b">116,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtMy0xLTEtMA_e9bf3684-d664-46c0-a362-1c98815e6b43">10,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtNS0xLTEtMA_b0dd2e60-7d76-4a44-a7d6-b1a3398a76b1">126,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtMS0xLTEtMA_c89eb886-91a4-4b11-b27c-5bd0f21bc932">103,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtMy0xLTEtMA_dae736de-ce08-4fad-b51c-e1c032320ab9">10,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtNS0xLTEtMA_56584439-a8ab-467f-b1df-78e20d4e5cd0">114,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtMS0xLTEtMA_96e47cdd-933b-4019-99d5-eb77f1fb38bc">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtMy0xLTEtMA_735460b6-1710-41fd-9360-66e72cfe8c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtNS0xLTEtMA_34b133ab-88b1-4753-890f-21bd610c56c1">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzYtMy0xLTEtMA_605a1539-7e2c-4d95-ab34-9ba7f5ea1b53">4,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzYtNS0xLTEtMA_6c1cede6-ada4-4f1a-8ab5-f0b03ef4941c">4,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctMS0xLTEtMA_2c62f679-59e3-4b9a-a82d-cc1db21de911">104,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctMy0xLTEtMA_b75146cb-cea2-48f3-97f1-886782939a1a">15,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctNS0xLTEtMA_2fcad9f2-2fc9-4eae-b146-d02d51471197">119,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtMS0xLTEtMA_ef4e5bf3-e625-4aad-ba4d-205501e0588e">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtMy0xLTEtMA_3b9b8aa3-adae-451d-a884-2c4c5619c4da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtNS0xLTEtMA_e1c1464b-5e93-412a-ad74-c7ea193d487c">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktMS0xLTEtMA_b79c00a3-f585-49ec-8e7c-41f2a2b90e0a">101,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktMy0xLTEtMA_2de219b0-e4c9-47e0-b3fe-7b078cce3a14">15,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktNS0xLTEtMA_aac5f600-14af-4fae-a07c-a0909c9de78f">116,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $<ix:nonFraction unitRef="usd" contextRef="idf18b6a46ee942b59306c66d27119d0e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM5MjE_4eb87f3b-32ff-4ae8-b07c-abc6e721ea32">3,042</ix:nonFraction>.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes the impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTcxNzM_010869da-6462-48b2-bd24-b5499d465960">89,679</ix:nonFraction> related to the Transactions discussed above.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItMS0xLTEtMA_b5fefc2a-f5af-44fe-b8ff-39e2b2072826">9,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItMy0xLTEtMA_6d9a3071-278c-4d92-8794-d85bdec2e67a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItNS0xLTEtMA_d791f6ed-ce7c-4e35-b9b2-1ca5f5473615">9,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtMS0xLTEtMA_c99a5111-0fd9-4233-bff8-ce36af0dcd59">111,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtMy0xLTEtMA_0cf54347-7b58-4de0-9f1c-eccae90b64f6">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtNS0xLTEtMA_6419cb81-ff82-4ae7-8a79-8775e71a29ef">111,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtMS0xLTEtMA_f51b8b4c-70e3-4310-8540-bd948995f7c1">101,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtMy0xLTEtMA_292988bb-c4c0-4e1b-b68f-1bac1353962d">470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtNS0xLTEtMA_0ae1fb2e-331c-4422-b4e0-b3dd3261a990">102,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtMS0xLTEtMA_559f3846-8539-4c2c-951b-aa0163fe28c5">1,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtMy0xLTEtMA_6382f130-0502-4415-b9ad-008ce5c06a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtNS0xLTEtMA_b9cd8750-18fa-46a4-bdb8-96ba3f01fd49">1,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzYtMy0xLTEtMA_cf837f95-6807-43d2-a11b-0ea79477d151">2,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzYtNS0xLTEtMA_f54613d9-f219-438d-9ca2-efab7065ea65">2,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctMS0xLTEtMA_77d19c2d-0753-418a-b4d2-6f0aeea9e328">103,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctMy0xLTEtMA_40e28cef-f2ef-43b8-aafa-1d679a5e8890">3,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctNS0xLTEtMA_230cd18f-ca51-415f-a434-a38481dace72">106,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtMS0xLTEtMA_4d112e48-811d-4785-9906-e7d63c79295f">6,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtMy0xLTEtMA_757a111e-d657-4487-8683-39572c1ca383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtNS0xLTEtMA_9ebd977e-4d44-4021-a025-a0cd7a431b12">6,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktMS0xLTEtMA_f767298f-ea61-4e67-8afa-98e3c8d600ac">97,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktMy0xLTEtMA_15ea213e-8713-43cd-8b75-8493a1cf99ba">3,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktNS0xLTEtMA_a6ed9fc4-ec46-4968-a389-5a67b7da4cc9">100,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $<ix:nonFraction unitRef="usd" contextRef="ib6652a9a128043e1991ddf1ffe2cf37e_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzMDM_3934cf93-2b24-4989-ac28-9ee1602afac4">4,665</ix:nonFraction>.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i54ddb7daeedd421691d65e569834db38_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzNDA_f873c505-9547-43a6-a82d-de63a4023409">60,504</ix:nonFraction> recorded in 2018 related to Oxitec's developed technology targeting the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aedes Aegypti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mosquito and a $<ix:nonFraction unitRef="usd" contextRef="i54ddb7daeedd421691d65e569834db38_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTc2OTg_d802672f-9f8b-4197-8b7e-40541730e877">5,057</ix:nonFraction> loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i80d50acf614d487ca8ba86d3fbb28bb9" continuedAt="id6d3e0d15d78434ba931ebfb9d5d1351"><ix:continuation id="ifbf846a8eb864a168f0c6a11d6b20379" continuedAt="i870cace3c2dc408e866ae156e2d93930"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtMS0xLTEtMA_c977994e-e388-49d7-9b08-4de0f1f67246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtMy0xLTEtMA_26dc27e0-7273-495c-8bf3-ec58b23ece07">5,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtNS0xLTEtMA_5f2ddb3f-c303-4522-ac10-e8a2297178b2">9,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtMS0xLTEtMA_a3082e75-75ad-4e02-9bb5-9bee4d822ae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtMy0xLTEtMA_aa92d677-8dba-418f-ae5b-51e9fbef4024">58,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtNS0xLTEtMA_8e08ce6b-c1c1-4ff8-be8a-048e842da9a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMS0xLTEtMTEwMQ_65e6dc51-9d3d-4669-abb5-e125178e2c16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMy0xLTEtMTEwMQ_29b7264d-df62-4ade-9732-7211be294764">31,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtNS0xLTEtMTEwMQ_229af8f1-b4fe-4fa9-9ed7-82a23234f984">60,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMS0xLTEtMTEwMQ_bf04e295-db32-4428-991c-cc092eb535ee">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMy0xLTEtMTEwMQ_1558e3bd-9eca-42a3-8ade-b41c3ea668e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtNS0xLTEtMTEwMQ_7b67f99d-61d4-4351-bcfb-532e55c2f30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMS0xLTEtMTEwMQ_d0b1806f-21ea-4182-b54f-5a1518640866">26,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMy0xLTEtMTEwMQ_263a70ec-aa1f-4e7c-9bf0-9ac166918ad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctNS0xLTEtMTEwMQ_93cf1e73-8498-49fd-9c62-0b8fa8e755ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized and realized depreciation on equity securities and preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" sign="-" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMS0xLTEtMA_b2b5a89b-ea24-4bfd-97d3-41e34282856e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" sign="-" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMy0xLTEtMA_28584e9c-5b33-490f-ae78-2612ba6ef15a">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtNS0xLTEtMA_ae9ba72e-8db1-4a2d-9032-05d7db66f045">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMS0xLTEtMA_c7ee251b-2acf-4399-aa01-4d91ef4d309e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMy0xLTEtMA_ab304029-2df6-4044-b61f-073ad57059e4">4,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtNS0xLTEtMA_9b370ed2-9314-4822-a5b8-f708a12fcf4c">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMS0xLTEtMA_1f69d442-6c0b-4194-9e53-3d6736063f30">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMy0xLTEtMA_e6e373b6-3a78-48b1-a170-46d5e095a0ae">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctNS0xLTEtMA_0a8ec396-1f64-4762-bba9-ca250d24ec95">3,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtMS0xLTEtMA_7fb5f144-400f-4eaf-bb0a-936e20dec647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtMy0xLTEtMA_387714dd-358d-474c-9f7d-2af4ccac69a0">2,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtNS0xLTEtMA_de5802f9-8969-49e5-9180-88045f0194e0">5,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTEtMS0xLTA_d0cf9a54-e530-4eaf-b588-f6fa0843a083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTMtMS0xLTA_4e3b664a-8975-47bc-a159-bea8de145d19">2,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTUtMS0xLTA_318dbdb3-b6ee-4159-b864-5277df739fe2">12,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTEtMS0xLTA_c596ea2c-1e56-4693-87a4-deb9ede802ef">382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTMtMS0xLTA_2649de86-f75b-4434-a417-1a95538da24c">23,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTUtMS0xLTA_60b97d27-3469-4c9e-9849-a3d694c95485">21,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also see Note 14 below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its investment in EnviroFlight using the equity method of accounting. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for certain equity securities held in one of its collaborators using the fair value option, and the collaborator was considered an equity method investment through September 30, 2018.</span></div><ix:continuation id="i870cace3c2dc408e866ae156e2d93930"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzItMy0xLTEtMA_26062af7-b09a-4766-ba34-375ec6c63570">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzMtMy0xLTEtMA_c0f6e587-5355-4a01-aa8b-5c85906b30d3">30,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzQtMy0xLTEtMA_149445f8-e5d0-4b64-b2b4-d9f277452c32">31,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzUtMy0xLTEtMA_befcd584-4352-443b-b308-5b7ab3f5772c">2,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzYtMy0xLTEtMA_51e4efca-a6ec-4c3b-aab5-41a07e93ccc4">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzctMy0xLTEtMA_177e6c55-ce39-4025-b7f4-26e864893ba5">2,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzgtMy0xLTEtMA_4f41886b-42f5-4a86-a128-cdc8756e60c5">28,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItMS0xLTEtMA_75f63c57-70f0-46c2-9ae8-65ebc40a3755">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItMy0xLTEtMA_c366c5b3-a0c7-45e5-adb6-b9e8a7b330da">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItNS0xLTEtMA_345e4e7d-f2b2-4636-9e94-be46076ae71a">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtMS0xLTEtMA_7cacd978-1004-4800-95ad-21db27d78053">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtMy0xLTEtMA_ac9f4ad8-c9f2-4b58-98ca-1750668a98f7">9,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtNS0xLTEtMA_462b6fac-5c31-4657-8866-0cc4ce3b2673">12,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtMS0xLTEtMA_db6ecfd0-b186-4e9f-8560-c1ed7efa2ed7">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtMy0xLTEtMA_f04d1713-8489-4f99-a0ab-b4a8268074ed">8,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtNS0xLTEtMA_1e904c10-952d-4812-9f8c-35716cee46a2">12,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtMS0xLTEtMA_b70495f1-cf2f-4820-92dc-7d1b32f6ab72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtMy0xLTEtMA_a204d9c2-17ec-45e9-a1d9-c7d784e489dc">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtNS0xLTEtMA_08b9ef06-1372-498c-a2b3-ce70543ea4d4">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtMS0xLTEtMA_a2402c2d-8d94-4fdb-8a36-3dfd5a623839">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtMy0xLTEtMA_264249a9-b72a-4232-bdd8-70034e1da718">8,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtNS0xLTEtMA_b9c27439-609b-44f7-89da-b939dc4ac42e">12,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="id6d3e0d15d78434ba931ebfb9d5d1351"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where applicable, the notes to the accompanying consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Out-of-Period Adjustment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recorded an out-of-period adjustment of $<ix:nonFraction unitRef="usd" contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTkxMjI_efe7c57f-7807-4b73-ab1d-3877fce3a6a9">26,572</ix:nonFraction> to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's financial position or results of operations for the years ended December 31, 2020 and 2019.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzQzMDY_da7c2a2f-48cd-419d-a662-71f00d931457" continuedAt="iaf6f2687eec541a0b757b91047a671ef" escape="true">Mergers and Acquisitions</ix:nonNumeric></span></div><ix:continuation id="iaf6f2687eec541a0b757b91047a671ef"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition of Certain Harvest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $<ix:nonFraction unitRef="usd" contextRef="ib745c0a5e3374688a77e7b600fc20292_D20180901-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzE2NA_820dab3d-86a3-4581-9bbf-fdbacc401c50">30,000</ix:nonFraction> of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc. ("CRS Bio"); Genten Therapeutics, Inc. ("Genten Therapeutics"); and Relieve Genetics, Inc. ("Relieve Genetics") (collectively the "Harvest entities"). The Company also received $<ix:nonFraction unitRef="usd" contextRef="i000d1fd7f4c64d64832e5ec0e8209d77_D20180901-20180930" decimals="-3" format="ixt:numdotdecimal" name="pgen:CashInflowsOutflowsInAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzQ1Mw_68ffe9f5-2a1f-4685-aa6e-41db89f9bb93">15,500</ix:nonFraction> cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $<ix:nonFraction unitRef="usd" contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzY3MQ_220d3e16-4da5-4d7b-801f-fe72bc319888">4,303</ix:nonFraction>, and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns <ix:nonFraction unitRef="number" contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930" decimals="INF" name="pgen:RelatedPartyOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0Xzc5MA_9aa64fd8-3970-48c6-8726-e56f29823884">100</ix:nonFraction>% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original ECCs and therefore wrote off deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzEyNjA_2090ed29-1566-40d6-a3d8-64b418d413c2">10,078</ix:nonFraction> in September 2018 as part of the transaction. The remaining value acquired of $<ix:nonFraction unitRef="usd" contextRef="i6a0d69f64390425490a158f5ad474449_D20180901-20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzEzNDE_9bc9f998-48c6-456d-86f7-2626ddff131b">8,721</ix:nonFraction> was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for additional discussion of the convertible promissory notes.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY5MTc_0242447e-4cfc-4310-ad4c-17b0bfbe2446" continuedAt="id257e2660ff940c69597a402ffc3f3b9" escape="true">Investments in Joint Ventures</ix:nonNumeric></span></div><ix:continuation id="id257e2660ff940c69597a402ffc3f3b9" continuedAt="ic8b2b0b7727b42549ee49cfa875ac41c"><div style="margin-bottom:11pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a JV formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3Xzc3NQ_f47f13fe-67a0-48ba-bef6-00a937653e8c">25,000</ix:nonFraction> while retaining a <ix:nonFraction unitRef="number" contextRef="i1c882e708e9042fab6cf9bdb465e7487_I20140331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3Xzc5Ng_e35b90be-fb3a-4a30-95bf-b75a7a1e02eb">50</ix:nonFraction>% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $<ix:nonFraction unitRef="usd" contextRef="id6ad8e1a4d324efba50a474ce9400787_D20140301-20140331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzkxMQ_125798c8-38cb-418a-bd58-57052e6f778a">25,000</ix:nonFraction> in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling <ix:nonFraction unitRef="number" contextRef="i9a9baf13b1f64feeacf1476a168dca43_I20140331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEwMTU_7c90be19-38b8-421d-9773-313bed59299f">50</ix:nonFraction>%. In addition, Precigen has committed to make capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="i1c882e708e9042fab6cf9bdb465e7487_I20140331" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEwOTQ_2834e348-1607-4672-b97a-d95f800d874e">25,000</ix:nonFraction>, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="i9a9baf13b1f64feeacf1476a168dca43_I20140331" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEyOTY_f88b7b0e-747d-4604-bc52-c2adf478c76d">25,000</ix:nonFraction>, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $<ix:nonFraction unitRef="usd" contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE0ODY_a7619b0a-7951-4869-8171-729610a1a921">4,225</ix:nonFraction>. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has <ix:nonFraction unitRef="board_seat" contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoard" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE1NzY_d536c9b3-b908-4a31-98f4-649234a8eff6">five</ix:nonFraction> members. <ix:nonFraction unitRef="board_seat" contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardInternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE1ODg_c7a57313-b622-4755-af91-f18867602e4d">Two</ix:nonFraction> members of the Intrexon Energy Partners Board are designated by the Company and <ix:nonFraction unitRef="board_seat" contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardExternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE2NzE_a101bc80-9cf0-4d75-aefd-752a5f4f0390">three</ix:nonFraction> members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ic8b2b0b7727b42549ee49cfa875ac41c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Intrexon Energy Partners was $(<ix:nonFraction unitRef="usd" contextRef="i9405291ea07342cfb48d39ff6203c28c_I20201231" decimals="-3" sign="-" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE5OTE_150d89af-63d7-4c53-926d-9a7eb8c7f147">425</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="i84f4ceddf2d74e208b2f43425f7a604c_I20191231" decimals="-3" sign="-" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE5OTg_b3197267-ece1-4c9a-a67d-4822852161f1">423</ix:nonFraction>) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for additional discussion regarding the Company's investment in Intrexon Energy Partners.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners II</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a JV formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231" decimals="INF" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzI5NjY_4b12f32d-421d-4120-9542-524174f67364">18,000</ix:nonFraction> while retaining a <ix:nonFraction unitRef="number" contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzI5ODc_a556e5ea-2f5e-4e12-8e6e-a4bad0c9bd2b">50</ix:nonFraction>% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $<ix:nonFraction unitRef="usd" contextRef="i02736ce52d7d455880b3764529cb4205_D20151201-20151231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMxMDc_7b4096db-baa2-49f5-964a-8e3a39ed169a">18,000</ix:nonFraction> in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling <ix:nonFraction unitRef="number" contextRef="i6ed29543f11f4730be40ffd5240b7e9d_I20151231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMyMTQ_fcf57029-b314-43c5-a0b2-26c485653c57">50</ix:nonFraction>%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $<ix:nonFraction unitRef="usd" contextRef="i2af9e206e25f49e585e8fac9b7a42c1f_D20151201-20151231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMzMDk_cc5ea3e2-51f7-417f-8ede-8de289305e55">4,000</ix:nonFraction>, half of which was paid by the Company. Precigen has committed to make additional capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM0MjU_bfb1f899-ada1-4518-8887-1ef0e254615b">10,000</ix:nonFraction>, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="i6ed29543f11f4730be40ffd5240b7e9d_I20151231" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM2MzI_5d65a812-d70a-4412-ad96-01c195890ddb">10,000</ix:nonFraction>, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $<ix:nonFraction unitRef="usd" contextRef="i3dd86fd0107044a1afd4581beb90db93_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM4Mjk_5c0689ff-0d76-4db3-b444-5c3f38a678fa">10,000</ix:nonFraction>. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has <ix:nonFraction unitRef="board_seat" contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoard" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM5MjU_a9d7213a-b15a-43f8-951e-adcd756f9c3f">five</ix:nonFraction> members. <ix:nonFraction unitRef="board_seat" contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardInternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM5Mzc_df54a692-0024-4727-9d41-e5c3831c918b">One</ix:nonFraction> member of the Intrexon Energy Partners II Board is designated by the Company and <ix:nonFraction unitRef="board_seat" contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardExternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQwMjE_ac97a734-d3e9-4152-83bd-81aa208d9cb1">four</ix:nonFraction> members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Intrexon Energy Partners II was $(<ix:nonFraction unitRef="usd" contextRef="i22bc12535b5845a98af2708db090b1cd_I20201231" decimals="-3" sign="-" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQzNTE_5849ad1e-28c9-4836-afd4-7887c39e633d">435</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="i0b676559c5894899a277cab47b7d3686_I20191231" decimals="-3" sign="-" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQzNTg_233fa4d3-8d7a-47ae-a3e9-615f572a258b">435</ix:nonFraction>) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 17 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon T1D Partners</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a JV formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provided the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="i8b58e935da8149088da93a6187e4101f_D20160301-20160331" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUyNTE_2164ce54-9e89-4264-8410-a3131c108f40">10,000</ix:nonFraction> while retaining a <ix:nonFraction unitRef="number" contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUyNzI_084bcf65-a136-46fc-9dcc-403df802645f">50</ix:nonFraction>% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $<ix:nonFraction unitRef="usd" contextRef="i37eae9042f0b4b7991fad96ce5cd70f8_D20160301-20160331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUzODQ_7764deb7-d6eb-4c9b-af21-69f9fccbcf41">10,000</ix:nonFraction> in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling <ix:nonFraction unitRef="number" contextRef="i38614b5cdd4748fe900bdb143da08bc2_I20160331" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU0ODU_453f0c06-2829-41ae-958b-64bb2e71901c">50</ix:nonFraction>%. Precigen committed to make capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU1NDc_68a008a2-2cf5-4450-9e62-b0ad3f3c685c">5,000</ix:nonFraction>, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $<ix:nonFraction unitRef="usd" contextRef="i38614b5cdd4748fe900bdb143da08bc2_I20160331" decimals="INF" format="ixt:numdotdecimal" name="pgen:JointVentureAdditionalCapitalContributionsCommitted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU3NDE_ecef400d-db4d-45e6-8061-06a18c690680">5,000</ix:nonFraction>, at the request of Intrexon T1D Partners' board of managers, which consisted of <ix:nonFraction unitRef="board_seat" contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardInternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU4MjQ_b229a7f2-7eec-4735-b4cc-3db9d2b08fdd">two</ix:nonFraction> members appointed by the Company and <ix:nonFraction unitRef="board_seat" contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberofSeatsonGoverningBoardExternallySelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU4NjQ_3183fdca-6d80-45fb-a5cb-0a485ee2eece">three</ix:nonFraction> members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued <ix:nonFraction unitRef="shares" contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYwNTY_c69eac3f-825a-46f5-b970-5f0528ab4c69">1,933,737</ix:nonFraction> shares of Precigen common stock valued at $<ix:nonFraction unitRef="usd" contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYxMDE_8ab74f19-ca9d-4d6e-856e-73f55e5d91cc">18,970</ix:nonFraction> to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns <ix:nonFraction unitRef="number" contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYyMzE_29c2ee40-4de0-4176-9bab-b6ea7f21d7a1">100</ix:nonFraction>% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $<ix:nonFraction unitRef="usd" contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY3MDE_f7c6fd6b-4e16-463d-addc-9014eeadc7e8">8,517</ix:nonFraction> of deferred revenue in November 2018 as part of the transaction. The remaining value of $<ix:nonFraction unitRef="usd" contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY3OTI_7ee043a2-6158-499f-a026-81a62e0a19e0">10,453</ix:nonFraction> was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzY1OTcwNjk4NTEwMTA_b21dfbe5-c616-4db2-9f3e-a1c15fb54cde" continuedAt="ic102708e8aaa4a7da4d0f88745f69c55" escape="true">Collaboration and Licensing Revenue</ix:nonNumeric></span></div><ix:continuation id="ic102708e8aaa4a7da4d0f88745f69c55" continuedAt="ibabfd9a56c944c12a655ff171fb80559"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTg1_928eb972-73bc-4249-94eb-fb568b76d342" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04474b4f60340a5bfef5669908aca1b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItMS0xLTEtMA_1ef031fd-0b86-450a-8a17-a984bf8da236">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea41f0f9f8340a5ac240c128def61b7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItMy0xLTEtMA_039192a6-20cd-47d4-9dce-0b761ceb3895">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbb27ff74fa4587a1663d2f6c036f55_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItNS0xLTEtMA_cb1f5582-46f6-40c7-9915-3a276bafb459">16,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ares Trading S.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3fe0767e9cf4dcd85529165525f8758_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtMS0xLTEtMA_98a33017-2be5-4832-aa9d-7d5efe374d15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2655f8d02da8422ba8e92858830a2d09_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtMy0xLTEtMA_32ebc089-7215-4f9c-9f62-e7725bec6ad3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9caeeb9311142fcad4dc58cba84fe45_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtNS0xLTEtMA_45a25464-326c-4ee3-87bf-f58850a748ae">11,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a58ef1f100e41ec83f7fadf1f120f61_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtMS0xLTEtMA_7d0f6bac-d449-48bf-9a71-be0038ed4b71">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3225f360239c4da99ac5a0f30e582367_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtMy0xLTEtMA_11495355-2ed3-44a6-a5f9-e11f170a7e99">564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b7ccf82abb46088675f71ca095ea7d_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtNS0xLTEtMA_b7e9c21d-d284-467f-b743-e0e92223732e">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon T1D Partners, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c5e81e3c27464cb9bb433ba78dd8ac_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtMS0xLTEtMA_ad22d417-a419-44fa-98fa-8904412881fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a5d57f00774002911cf03b4ecb5d06_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtMy0xLTEtMA_4e2e6d2e-061c-4f0f-9dae-0405126c7fde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6a3055772b4276a974fbd3f46d80af_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtNS0xLTEtMA_5c56ac74-d848-43ef-95ea-a851500cf6cf">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657bccd941e9476e84df5f1bb47c01ed_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtMS0xLTEtMA_75fb64c0-043d-4df4-8720-e0c6cb71644f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd6ae11540d4a89bdea2402ffd96b43_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtMy0xLTEtMA_482c5726-4786-4dbc-a8b4-a03984ac1069">2,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271b77f3585b428ab9b387bac0632795_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtNS0xLTEtMA_dde240aa-ff46-413e-9dfc-f009686eb8a8">6,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5465b8e9f47c478a9888a2bf4f068315_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctMS0xLTEtMA_85d3a45f-8802-4889-8b9f-c2a1e32e6f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a7a75f53fb43bd8a86301d20bd199f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctMy0xLTEtMA_08f49d71-9a48-4c57-bb51-4d5d51a9c152">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615893ff388945289ba1d816cb0d5415_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctNS0xLTEtMA_af21dd89-9bf2-4b20-a82c-f5169d8f0eba">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826d35e5de9342c1ac0b82187aa61817_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtMS0xLTEtMA_333c9f97-e7cf-419b-9db9-f80469e74797">17,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtMy0xLTEtMA_9c80c8c2-72c8-4349-9536-78ffbdebc65c">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0b6fb6681044eeb9ccb81e27858225_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtNS0xLTEtMA_25d08b17-87f3-4102-8c7f-df8f162b9ebf">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3047a704254986b92408ff7382d63c_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTEtMS0xLTA_bc16644b-8c90-4507-a3fe-030f91e263b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38b8c82221e4b158e81089d5dec6cc4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTMtMS0xLTA_cf59ea7d-204d-4b1b-b72c-8125aeabb5e0">4,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc53c28fbc7455ea6911f3515a2093c_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTUtMS0xLTA_f784fdb4-cee7-43ce-b24f-368be3914dd6">14,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2da118b80dc492fa5a08a890cbbb15a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTEtMS0xLTA_ac343ae6-5f20-47a8-a3c9-48526cc5ad63">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb26c32900c24b22b16c104fc410013d_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTMtMS0xLTA_b08eaefb-503b-4a48-931e-e854f7ac869c">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7cf1aab2104d78877dc52205013114_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTUtMS0xLTA_fee6833f-b4df-44fc-a959-4ae802c99a0c">12,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89a9eb5dec3401bb6b1302d72d9b091_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTEtMS0xLTA_52722686-2110-4041-9d34-ff949f5f4175">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d02ad8dbd04496a07bb96530bd6fe0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTMtMS0xLTA_09e0a436-f827-44e9-a499-5c8eab7d9763">14,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fbcf7e50ae94bdb84158a09d5e84357_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTUtMS0xLTA_6609a6f3-7a76-4f60-9175-d592e33e9a7c">69,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the years ended December&#160;31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December&#160;31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Collaboration and licensing revenues recognized for the years ended December&#160;31, 2020, 2019 and 2018, include the recognition of $<ix:nonFraction unitRef="usd" contextRef="i802c849fe1f7499fa51a352c7c1b630c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MTI_e3baaa79-204f-43e7-b6b1-c2fed00e488c">20,205</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia75a4228d5b9446f82180329f657e205_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MTc_ed761bf8-47e2-4a02-8db6-4223d0588199">7,505</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="iebf2e5287fca469988ba7db1017cc983_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MjI_896b3f03-0b39-4c82-9a71-b1a91eff4b15">39,446</ix:nonFraction>, respectively, associated with upfront and milestone payments which were previously deferred.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZIOPHARM Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January&#160;2011, the Company entered into an ECC with ZIOPHARM Oncology, Inc. ("ZIOPHARM"), a related party at the time. Pursuant to the&#160;ECC,&#160;ZIOPHARM received a license to the Company's technology platform within the field&#160;of&#160;oncology as defined more specifically in the agreement. The Company received upfront consideration upon execution of the ECC in the form of ZIOPHARM common shares valued at $<ix:nonFraction unitRef="usd" contextRef="i3d624d8cf2ba4c258b6200df93fe4dff_D20110101-20110131" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI5ODk_6e6b9fa4-3f95-4cee-a176-64e48eba9c85">17,457</ix:nonFraction>, shares of ZIOPHARM common stock valued at $<ix:nonFraction unitRef="usd" contextRef="i4c23dc33d54d41fbb6d5de96a2aa6645_D20120101-20121231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM3MzE_af5e08bf-83bd-4f92-a55f-52b7711353c0">18,330</ix:nonFraction> as consideration upon achievement of a milestone in 2012, and reimbursements for research and development services performed during the ECC. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a wholly owned subsidiary of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modified the scope of the ECC </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ibabfd9a56c944c12a655ff171fb80559" continuedAt="i35e7da317b3c427d8e453fd4df37f41c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the Merck Agreement and provided that the Company would pay to ZIOPHARM <ix:nonFraction unitRef="number" contextRef="i8df2f4bdfd5a4853b136cd50ea2e2827_D20150301-20150331" decimals="INF" name="pgen:CollaborationArrangementPercentOfCollaborationPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQ2MTI_a440ea02-2a67-43f0-b933-25878a7e2b53">50</ix:nonFraction>% of all payments received for upfront fees, milestones and royalties under the Merck Agreement. See discussion of the Merck Agreement below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company amended the ECC and a prior ECC that was mutually terminated in December 2017 to reduce the rate of royalty that the Company was entitled to receive on certain products commercialized pursuant to the agreements. As consideration for execution of the amendments, ZIOPHARM issued the Company shares of ZIOPHARM's Series 1 Preferred Stock. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. See Note 18 for additional discussion of the terms of the preferred stock and the accounting treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license agreement (the "ZIOPHARM License Agreement") with ZIOPHARM, which terminated and replaced the terms of the original ZIOPHARM ECC, including the amendments thereto.&#160;Pursuant to the terms of the ZIOPHARM License Agreement, the Company granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i)&#160;products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii)&#160;chimeric antigen receptor ("CAR") products directed to (a)&#160;CD19 for the treatment of cancer (the "CD19 Products"), and (b)&#160;a second target, subject to the rights of the Company to pursue such target under the Merck Agreement, and (iii)&#160;T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. ZIOPHARM will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. ZIOPHARM is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products, and after a two-year period, the TCR Products. The Company also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. ZIOPHARM is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. ZIOPHARM and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with ZIOPHARM responsible for <ix:nonFraction unitRef="number" contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031" decimals="INF" name="pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzg4Njc_9d248c86-cd92-4e1d-8a21-2392b3dd9537">80</ix:nonFraction>% of the development costs and receiving <ix:nonFraction unitRef="number" contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031" decimals="INF" name="pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzg5MDk_ec6a4d57-6354-4156-ba2c-db245e264d9a">80</ix:nonFraction>% of the operating profits, as defined in the ZIOPHARM License Agreement, and the Company responsible for the remaining <ix:nonFraction unitRef="number" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="INF" name="pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzkwMzA_2a202ed2-4970-4e3a-add8-487ce8374aa2">20</ix:nonFraction>% of the development costs and receiving <ix:nonFraction unitRef="number" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="INF" name="pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzkwNzI_b9b8761c-71f8-42d9-b554-4935da097602">20</ix:nonFraction>% of the operating profits, except that ZIOPHARM will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the licenses and other rights granted by the Company, ZIOPHARM will pay the Company an annual license fee of $<ix:nonFraction unitRef="usd" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="-3" name="pgen:LicenseAgreementAnnualFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0MDg_34eec396-4d97-44bd-8380-819db4c15759">100</ix:nonFraction> and agreed to reimburse the Company $<ix:nonFraction unitRef="usd" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:LicensingAgreementReimbursementofHistoricalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0NDc_8d93c6e7-0fbc-4278-b89a-4f6187a97b2c">1,000</ix:nonFraction>, paid in <ix:nonFraction unitRef="quarterly_installment" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0NTk_28a0110e-e885-4bf3-be63-b6dfe3d53087">four</ix:nonFraction> quarterly installments, with respect to historical Gorilla IL-12 Products (the "historical Gorilla reimbursements"). ZIOPHARM will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed programs in various jurisdictions, totaling up to an additional $<ix:nonFraction unitRef="usd" contextRef="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk3ODc_0bb312e0-c6f4-4460-a1d9-32820acbbadc">52,500</ix:nonFraction> for each of <ix:nonFraction unitRef="product" contextRef="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LicenseAgreementNumberofExclusivelyLicensedProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk4MDI_2483eb7c-6c34-4e27-8986-c3eb41de11ec">four</ix:nonFraction> exclusively licensed programs, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk4NTg_d3d4bfea-1916-4d2e-a42e-8018d4f2b1fb">210,000</ix:nonFraction>. In addition, ZIOPHARM will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. ZIOPHARM will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $<ix:nonFraction unitRef="usd" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:LicenseAgreementRoyaltyDueAggregated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwMjYz_8f7e6815-4f47-422c-8df1-8bff5a113e5b">100,000</ix:nonFraction> in the aggregate. ZIOPHARM will also pay the Company <ix:nonFraction unitRef="number" contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" decimals="INF" name="pgen:LicenseAgreementPercentageofSublicensingIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwMzE5_c4385d17-f15a-4fd0-b72e-5c2d3f21eb52">20</ix:nonFraction>% of any sublicensing income received by ZIOPHARM relating to the licensed products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reacquired rights to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to ZIOPHARM. The Company will pay ZIOPHARM royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $<ix:nonFraction unitRef="usd" contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:LicenseAgreementRoyaltyDueAggregated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwODQw_c1446f5a-f98b-45ea-9043-293b58e75e6e">50,000</ix:nonFraction>. The Company also received from ZIOPHARM reimbursement of costs incurred to transition the necessary knowledge and materials for ZIOPHARM programs for a period of <ix:nonNumeric contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" format="ixt-sec:durwordsen" name="pgen:TransitionPeriodDuringWhichCostsWillBeReimbursed" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzExMDA2_b45da37f-8f38-4d79-ac20-67675a779275">one year</ix:nonNumeric> from the effective date (the "Transition Services").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As between the parties, the Company agreed to perform all of the obligations of ZIOPHARM under the Merck Agreement, other than an obligation of exclusivity thereunder and ZIOPHARM will remain responsible for all payments owed under the Merck Agreement</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to CD19 and the other target under the Merck Agreement as a result of ZIOPHARM's, its affiliates' or its sublicensees' exploitation of CAR products. Further, the Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to ZIOPHARM for such products. The ZIOPHARM License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i35e7da317b3c427d8e453fd4df37f41c" continuedAt="i8010128cad0944ac9f018208b7509cf4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the later to occur of (i)&#160;the expiration of the last to expire patent claim for a licensed product, or (ii) <ix:nonNumeric contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031" format="ixt-sec:duryear" name="pgen:LicenseAgreementTerminationPeriodFollowingTriggeringEvent" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzExODk3_7fb0c568-ffb6-471a-aa0f-89267281b26c">12</ix:nonNumeric> years after the first commercial sale of a licensed product in such country. In addition, ZIOPHARM may terminate the ZIOPHARM License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the ZIOPHARM License Agreement following notice of a material breach.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the ZIOPHARM License Agreement, the 2016 Securities Issuance Agreement between the Company and ZIOPHARM was terminated as of the effective date of the ZIOPHARM License Agreement, all of the benefits, rights, obligations and liabilities thereunder immediately ceased and terminated and the Company returned to ZIOPHARM all of the preferred stock owned by the Company as of the Effective Date, which was valued at $<ix:nonFraction unitRef="usd" contextRef="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEyNjU2_14daef21-d09d-4826-b7e0-52d987d1f0d3">158,376</ix:nonFraction>. See Note 18 for additional discussion of the preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the execution of the ZIOPHARM License Agreement, the Company had $<ix:nonFraction unitRef="usd" contextRef="i9edf0818b0a147da90be9143a66128d0_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEyNzk2_c3686f26-0f09-4287-bdf7-695e98728d61">51,084</ix:nonFraction> of deferred revenue remaining from the original ECC, which was related to the Company's obligations to perform under that agreement. Replacement of the original ECC with the ZIOPHARM License Agreement was a contract modification under ASC 606 that represented the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which were limited to the Transition Services, were distinct from those under the ECC. Therefore, the Company reviewed the various forms of consideration in the ZIOPHARM License Agreement to determine the transaction price. As the Company's obligations under the ZIOPHARM License Agreement were only related to the Transition Services and no other obligations under the ECC remained, a portion of the previously deferred revenue from the ECC was relieved, which the Company determined to be $<ix:nonFraction unitRef="usd" contextRef="i2b584f29328e4ebf97207baf9e676a54_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNjk1_707add9d-d53a-4891-8bd1-9c85558d1e9b">49,329</ix:nonFraction>, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i3e6a0b31f0c84cbea171358d7cdb8c59_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNzE3_9d823a85-03c7-4dd9-af58-ae0516868fb4">1,755</ix:nonFraction> was included in the transaction price. The initial annual license payment of $<ix:nonFraction unitRef="usd" contextRef="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031" decimals="-3" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNzk3_5c2b24c5-04d6-4dcb-9a0c-099313643cbd">100</ix:nonFraction> was also included in the transaction price. The remaining annual license payments and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of ZIOPHARM products developed pursuant to the ZIOPHARM License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price of $<ix:nonFraction unitRef="usd" contextRef="i390dbfc7bee54d449d2489dfabeb4caa_I20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE0MzEx_0d3b48fa-5d7f-41c8-9649-639616001307">1,855</ix:nonFraction> as it performed the Transition Services required under the ZIOPHARM License Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reviewed the consideration paid and potential consideration to be paid to ZIOPHARM as part of the ZIOPHARM License Agreement, which included the $<ix:nonFraction unitRef="usd" contextRef="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE0NTYz_14daef21-d09d-4826-b7e0-52d987d1f0d3">158,376</ix:nonFraction> of ZIOPHARM preferred stock returned by the Company and potential royalty payments to ZIOPHARM from sales of the Company's CAR products. The Company determined the exchange of its investment in ZIOPHARM preferred stock for certain CAR rights previously licensed under the ECC (i.e., in-process research and development) and the relief of performance obligations to ZIOPHARM under the ECC constituted an exchange for distinct goods and services. Therefore, the Company wrote off the $<ix:nonFraction unitRef="usd" contextRef="i2b584f29328e4ebf97207baf9e676a54_I20180930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1MDQ4_707add9d-d53a-4891-8bd1-9c85558d1e9b">49,329</ix:nonFraction> of relieved deferred revenue and recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="ife505a4aa67447108ab17810720818e9_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1MTA3_191b4128-d736-457d-afe3-5fc0723fdb8c">109,047</ix:nonFraction> for the reacquired in-process research and development. Potential royalty payments to ZIOPHARM will be expensed as incurred as they relate to distinct goods or services. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Gorilla Program represented a separate collaboration agreement under the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 808") and was not included in the accounting for the ZIOPHARM License Agreement under ASC 606. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1NTU5_f28e936a-2711-4c35-be0d-f04e41cfa9c5">500</ix:nonFraction> of the historical Gorilla reimbursements on the contract modification date and recognized the remaining amounts when receipt became probable. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck Licensing Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MjI3_87f9274f-ce24-406e-b478-fa459f336060">115,000</ix:nonFraction> as upfront consideration, of which $<ix:nonFraction unitRef="usd" contextRef="i6ac36b06d9ed4949b460f25d930f6824_D20150301-20150331" decimals="-3" format="ixt:numdotdecimal" name="pgen:PaymentsToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MjY1_a9f976e3-ddfc-41a4-b820-5a5a394edf4b">57,500</ix:nonFraction> was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first <ix:nonFraction unitRef="target" contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331" decimals="INF" format="ixt-sec:numwordsen" name="pgen:CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MzY4_5e1acff5-bd34-4372-b396-768a1a49f11e">two</ix:nonFraction> targets by Ares Trading, the Company received $<ix:nonFraction unitRef="usd" contextRef="ib33d19e6739641da9b757a245fd3ec93_I20150301" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2NDE3_6cc91bf7-87c5-47dc-a91d-55feef0681ba">10,000</ix:nonFraction> in equal quarterly installments over <ix:nonNumeric contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331" format="ixt-sec:durwordsen" name="pgen:CollaborativeArrangementConsiderationReceivableCollectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2NDU3_eedecd1c-3ed5-4970-ac4b-6dd1ab1ee420">two years</ix:nonNumeric>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a Securities Purchase, Assignment and Assumption Agreement (the "Merck Purchase Agreement") with Ares Trading pursuant to which the Company reacquired Ares Trading's development and commercialization rights under the Merck Agreement. As consideration for the reacquisition of the Merck Agreement, the Company issued Ares Trading <ix:nonFraction unitRef="shares" contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2ODMz_19c1b713-6553-467d-9b8d-2b610a124f69">20,640,119</ix:nonFraction> shares of Precigen common stock valued at $<ix:nonFraction unitRef="usd" contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2ODc4_002efc34-6cd5-4e83-9c17-6a26a32712ed">140,353</ix:nonFraction> and agreed to pay Ares Trading a royalty of <ix:nonFraction unitRef="number" contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231" decimals="INF" name="pgen:RoyaltyPercentageToBePaidtoOtherParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2OTI1_20a30c5f-ea0b-4513-82b6-363cf547482f">10</ix:nonFraction>% of the net sales derived from two CAR products specified in the Merck Purchase Agreement. By reacquiring the rights previously licensed to Ares Trading, the Company is relieved of its obligations under the Merck Agreement and therefore wrote off deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ia684f990dec54beeb358abe6adf669ab_I20181130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE3MTk0_4ad6b819-9eaa-4342-8b5e-27447f126a0a">31,826</ix:nonFraction>. The remaining value acquired of $<ix:nonFraction unitRef="usd" contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE3MjMw_ae8d8af4-36e9-40b1-bcee-266c8d401f7c">108,527</ix:nonFraction> was considered in-process research and development related to the reacquired rights under the Merck Agreement and expensed immediately. The </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i8010128cad0944ac9f018208b7509cf4" continuedAt="i043feb04fcaf477cb09961ed2ff9ab49"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential future royalty payments to Ares Trading do not represent consideration paid to a customer and will be recorded when the payments are probable. See Note 12 for additional discussion of this transaction.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oragenics Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, the Company entered into an ECC with Oragenics, a related party at the time. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $<ix:nonFraction unitRef="usd" contextRef="i507644cf395a4e4eb490f23ed7a3fb54_D20150601-20150630" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE4MDMy_943009ba-1cd5-4f55-83ff-db5f70b81147">5,000</ix:nonFraction> convertible promissory note, which was subsequently converted to shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale (Note 3). The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. In July 2020, the Company and Oragenics mutually agreed to terminate the ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the ECC totaling $<ix:nonFraction unitRef="usd" contextRef="ibc9c931963d5454d95e8956328330cee_D20200701-20200731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NDcxMjA_6a38d4d0-5f28-4fab-a094-c336fba0a298">2,823</ix:nonFraction>. Following the termination of the ECC, Oragenics is no longer a related party.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon T1D Partners Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="i8b58e935da8149088da93a6187e4101f_D20160301-20160331" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE5OTY2_c96f0348-8cf0-4948-bb1d-d8425e5ecbba">10,000</ix:nonFraction>. The Company received reimbursement of research and development services provided pursuant to the ECC agreement. In November 2018, the Company completed an asset acquisition with the T1D Investors, resulting in the Company owning <ix:nonFraction unitRef="number" contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130" decimals="INF" name="pgen:RelatedPartyOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIwMTk5_eb62f3de-06da-4f37-b080-0a2d47429b7f">100</ix:nonFraction>% of the membership interest of Intrexon T1D Partners including all rights under the ECC (Note 5).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genten Therapeutics, CRS Bio, and Relieve Genetics Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into three separate ECCs with Genten Therapeutics, CRS Bio, and Relieve Genetics, all affiliates of Harvest and related parties. The total upfront consideration received for the three collaborations was $<ix:nonFraction unitRef="usd" contextRef="i659785a3f54a436ebb55a8cdf1f7716e_D20160101-20161231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NzA3NTE_32b24d38-4c2a-457c-9d61-4d6ed6abc4be">10,933</ix:nonFraction>, which mostly consisted of equity interests in these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning <ix:nonFraction unitRef="number" contextRef="ib7fde582b25949f282255f9473749cb4_I20180930" decimals="INF" name="pgen:RelatedPartyOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIxMTU5_a6ce38ef-5189-4764-ac75-1db09f0ec4f8">100</ix:nonFraction>% of the equity interests in these entities, including all rights under the ECCs (Note 4).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a JV between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIzNTIz_3b2b539b-7744-4b6f-9df5-8c5b85e696fe">25,000</ix:nonFraction> as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March&#160;2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon <ix:nonNumeric contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331" format="ixt-sec:durday" name="pgen:CollaborationAgreementTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIzOTM0_8cca5c03-8399-4b48-9bf7-908749316dba">90</ix:nonNumeric> days written notice to the Company. The ECC is not active while the IEP Investors evaluate the status of the project and their desired future development activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners II Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $<ix:nonFraction unitRef="usd" contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI0NTcx_ac32fcf5-79d5-4dcc-91ad-1ad534dd4c6e">18,000</ix:nonFraction> and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon <ix:nonNumeric contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231" format="ixt-sec:durday" name="pgen:CollaborationAgreementTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI0OTcz_c1d48c44-344c-43cc-962f-2cf35dd08367">90</ix:nonNumeric> days written notice to the Company. The ECC is not active while the IEPII Investors evaluate the status of the project and their desired future development activities.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i043feb04fcaf477cb09961ed2ff9ab49" continuedAt="i650abd258b5946a98331fd1beaed3c46"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exotech Bio, AD Skincare, and Thrive Agrobiotics Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 and 2016, the Company entered into three separate ECCs with Exotech Bio, Inc. ("Exotech Bio"), AD Skincare, Inc. ("AD Skincare"), and Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), all affiliates of Harvest and related parties at the time. The total upfront consideration received for the three collaborations was $<ix:nonFraction unitRef="usd" contextRef="ife64afba6e6c4c7f9966578282bdffdf_D20150101-20161231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1ODgwMzU_246084f8-09db-42fc-b67c-3a433272fb6b">11,000</ix:nonFraction>, which consisted of equity interests in each of these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In conjunction with a settlement agreement with Harvest (Note 17), these ECCs were terminated in December 2020, and the previously licensed technology rights reverted to the Company pursuant to the ECCs. The Company wrote off the remaining balance of deferred revenue associated with these ECCs totaling $<ix:nonFraction unitRef="usd" contextRef="i59907113dd1d4344981247aabca5ca34_I20201130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1ODg5MTA_824783d9-6016-4645-8ad1-a535d113ba41">6,993</ix:nonFraction> as an offset to the loss recognized on the settlement agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Castle Creek Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2012, the Company entered into an ECC (the "2012 Castle Creek ECC") with Castle Creek Biosciences, Inc. ("Castle Creek", formerly known as Fibrocell Science, Inc.). Castle Creek was a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until it was acquired in December 2019 by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical"), a privately held company focused on developing medicine for rare genetic disorders. Pursuant to the 2012 Castle Creek ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The Company received (i) upfront consideration upon execution of the ECC in the form of Castle Creek common stock valued at $<ix:nonFraction unitRef="usd" contextRef="ib7c97ac54869431f9460b1de625fdd9c_D20121001-20121031" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI4MzUw_67e59eac-6215-465c-9867-590d86f439ee">7,576</ix:nonFraction>, (ii) shares of Castle Creek common stock valued at $<ix:nonFraction unitRef="usd" contextRef="i1461c02f7c1144288c060625dfec3d80_D20130101-20131231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NDc0MjQ_c35cf329-abc7-40ef-b7e8-d519d4d85863">7,612</ix:nonFraction> as consideration for a 2013 amendment which expanded the field of use defined in the agreement, (iii) sublicensing fees totaling $<ix:nonFraction unitRef="usd" contextRef="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementConsiderationReceivedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzMwMjg0_2c8c9c87-0b46-4ae3-819a-435b55afa567">3,750</ix:nonFraction> in the form of cash in 2019, and (iv) reimbursements for research and development services performed during the ECC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company and Castle Creek terminated the 2012 Castle Creek ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates, FCX-007 and FCX-013, pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Castle Creek ECC. As Retained Products, Castle Creek retains a license under the 2012 Castle Creek ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Castle Creek ECC for so long as Castle Creek continues to pursue such development and commercialization. No further licenses to the Company's technology within the field of use are provided to Castle Creek. On a quarterly basis, Castle Creek will pay the Company royalties of <ix:nonFraction unitRef="number" contextRef="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331" decimals="INF" name="pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5NTQ_81f0c524-084c-4df7-9487-2057e75e1c2f">7</ix:nonFraction>% of net sales up to $<ix:nonFraction unitRef="usd" contextRef="i07cadd8e29a94d468d706d75d4fa4499_I20200331" decimals="INF" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5Nzc_6cd784f1-ed04-4db3-b6c2-1695fe086f67">25,000</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331" decimals="INF" name="pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5ODU_e0829782-9855-4d5e-8206-3d1db9069d99">14</ix:nonFraction>% of net sales above $<ix:nonFraction unitRef="usd" contextRef="i07cadd8e29a94d468d706d75d4fa4499_I20200331" decimals="INF" format="ixt:numdotdecimal" name="pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NzgwMDg_545b3ad3-ed9c-4c2b-a1b9-0bb1f0f7f4d7">25,000</ix:nonFraction> on each Retained Product from the 2012 Castle Creek ECC, as defined in the agreement. Additionally, the Termination Agreement provides for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract, and the remaining deferred revenue from the 2012 Castle Creek ECC is being recognized prospectively as the manufacturing activities are performed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2015, the Company entered into a second ECC with Castle Creek (the "2015 Castle Creek ECC"). Pursuant to the ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Castle Creek mutually agreed to terminate the 2015 Castle Creek ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Castle Creek ECC totaling $<ix:nonFraction unitRef="usd" contextRef="ib8dfaf8751c2466e8b7d83681e50ce63_D20200201-20200229" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Njk1OTc_68c7740c-bfc5-4092-a3a1-c8dc06f630b5">10,000</ix:nonFraction>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i650abd258b5946a98331fd1beaed3c46"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTc1_5f4204c4-c51c-4481-a87b-561a3c78c1db" continuedAt="ief33b40396b14e5498f181ef49e19ac6" escape="true">Deferred revenue consisted of the following:</ix:nonNumeric></span></div><div style="margin-bottom:11pt;margin-top:11pt"><ix:continuation id="ief33b40396b14e5498f181ef49e19ac6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119157bf1fca4e4597d6d2074e4b318c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzItMS0xLTEtMA_ee1adc54-373d-44f7-8f6e-da8e0920c5c2">23,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768914f9023446359debd6de8db387bc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzItMy0xLTEtMA_9982d9cf-74c3-4724-a75c-3987cb41d7af">50,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid product and service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0886f93ed7be4cb289c37677075c1648_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzMtMS0xLTEtMA_34c2f83d-24b7-4cb1-8167-a1fc200c1aaa">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24eba9045a464d27b051cf73783cbc93_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzMtMy0xLTEtMA_44511e5f-80e9-4207-8321-914b104ff232">2,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f077edbb924395b6f3b5746a7091b7_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzQtMS0xLTEtMA_84e25c50-81bc-4cdf-9407-bf40ae53ffab">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4b2e1046db40339eccf1d387df8274_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzQtMy0xLTEtMA_7df5fc39-f634-4656-8c35-333ab8532cfb">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzUtMS0xLTEtMA_000bc118-7fc4-4070-85e7-69c72639dde1">25,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzUtMy0xLTEtMA_ec40e4b0-56bf-4fe6-b77d-03d9eee24db3">53,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzYtMS0xLTEtMA_449a5fb0-15cf-41dd-ad70-1a4eb8509566">2,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzYtMy0xLTEtMA_2d84556c-f18a-4097-abc5-429c98678657">5,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzctMS0xLTEtMA_7a7dfa08-0a35-4a8b-bcfe-fb2c737651ba">23,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzctMy0xLTEtMA_66810b74-8d8d-4a70-ada2-71fc00af475a">48,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzgtMS0xLTEtMA_2418ed7a-b9ea-4f43-b448-8d50d41af5c0">25,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzgtMy0xLTEtMA_52196f5e-0480-4102-9c02-6c72185fd009">53,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTg3_2627eb42-01f6-43d3-81b5-11aecd03265e" continuedAt="ifdbe09ab55ac4a05960192cc2eb87d5d" escape="true">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December&#160;31, 2020 and 2019, as well as the estimated remaining performance period as of December&#160;31, 2020.</ix:nonNumeric></span></div><ix:continuation id="ifdbe09ab55ac4a05960192cc2eb87d5d"><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Performance Period (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i762e74716595460bbc13425c76eaa2db_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtMS0xLTEtMA_686369ca-66ae-4b08-a336-077845d616ab">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a8f257af9be4b51bb429c76d609121d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtMy0xLTEtMA_f8decd20-dc67-4660-bc43-0c50eb8603b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4a4131130d462a9487459be4d56bd7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtNS0xLTEtMA_25eb0053-531b-4802-81c7-c3468f758609">2,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9eb44801a44b4a62ad0fdbd70e99dccd_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtMS0xLTEtMA_d4487ac5-0f5b-4e72-bc80-1f3b0c2172d5">3.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4820c653de64b4b8753948eb803072b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtMy0xLTEtMA_4c8a7a63-59a3-4934-a154-e9f036ab48c4">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4353ff9fff4974bf8fc31f026182f0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtNS0xLTEtMA_45b3045a-3444-415a-86e4-a4f1441cd9d7">8,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8484095ee2884725be04bc8135beae81_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtMS0xLTEtMA_a91facc7-f39a-4fb5-bd9f-96fdfb1c5a8c">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dece6850a884e9aaa7eb9648a40bb74_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtMy0xLTEtMA_6e85761b-3e6b-4a0c-a18d-e4a06c95201c">12,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fe2362ff8a42598a97fb6bdba06548_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtNS0xLTEtMA_6f9266e9-687e-478f-ada9-79b7301d7fa5">12,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i066d432119f04600ad1a8035bcb6cf5e_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtMS0xLTEtMA_358ec8af-e65b-4bc2-b622-d130d425622f">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6512fb771f0b42ee964e35ec040d3d77_I20201231" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtMy0xLTEtMA_cb86d1cd-e11a-470b-95ea-2c5ff8f29545">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87b208d51a248b49c170094f36869ec_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtNS0xLTEtMA_86dd6b49-1d1f-4d4f-a0ef-765ce3d50d6b">17,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dd853c6b5c544c1a4eb81cd5293cada_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctMS0xLTEtMA_b92e4ab0-73d7-4af6-8278-8ff05891f1ee">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d34d40eae14e879388b762c83dc166_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctMy0xLTEtMA_500bcf70-a43e-4415-838b-a842f868a7bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65a1530d1d0476ca8be03ad2268129a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctNS0xLTEtMA_b84ebfcd-6343-4361-9d81-faed63f29a13">6,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23f70a5b8fd749b8b7137c61cfab72a9_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtMS0xLTEtMA_552a47d1-09e3-433b-bfae-c9a82079f63e">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5561d3f0a6bc49eabcffabca3089383f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtMy0xLTEtMA_a2a7b271-d3ea-414b-8447-c628273d432c">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98da80d8ac14d7791e297eacb592f73_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtNS0xLTEtMA_6ba77858-fbee-481c-a559-593d5af7030f">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6774b04fc34844d7bb0f5cabaee47b02_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzktMy0xLTEtMA_0152d8f6-8f08-406c-8255-23d3feb3f6d4">23,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559d7af0e8444c759749c165c72c4dd3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzktNS0xLTEtMA_62faf5ea-43ac-4cfd-a1bf-76190142599d">50,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.</span></div></ix:continuation></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90ZXh0cmVnaW9uOmNiZmFhYmMxMTg5MTRmNzQ5NmZjODQ1Yzg2NzdkMTc5XzE1MTg_f328fefa-15fd-4914-8084-28e95f5a258c" continuedAt="ieb518ad4bfa34050b94d59bd6968d333" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="ieb518ad4bfa34050b94d59bd6968d333" continuedAt="ic76990ea3ab04694851e972181e87908"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investments are classified as available-for-sale. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90ZXh0cmVnaW9uOmNiZmFhYmMxMTg5MTRmNzQ5NmZjODQ1Yzg2NzdkMTc5XzE1MTU_63acb84d-4dfd-4870-a44e-150d6fe5c967" continuedAt="i9ac4c9b91a524b07ae63a14ef8dd45ce" escape="true">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2020:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i9ac4c9b91a524b07ae63a14ef8dd45ce" continuedAt="i24f0a05a264f4b0ab12083f0aad5365c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtMS0xLTEtMA_345a1738-f952-439b-a5a9-a70a02252441">48,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtMy0xLTEtMA_d40a1124-c65c-4cc2-a5a0-83879380468c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtNS0xLTEtMA_7c332f63-2369-4513-ad0b-9c0494f21a80">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtNy0xLTEtMA_20ed3f9c-61ad-4c2f-a517-1a9bfe1341be">48,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItMS0xLTEtMA_ee7fdf81-9064-4f67-9bb3-7d1405067a4c">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItMy0xLTEtMA_eaf9038e-6cc7-4744-b878-a6ffeee28d62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItNS0xLTEtMA_334bffc9-041a-415c-ae5f-8657c58a47f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItNy0xLTEtMA_50ffc2bb-8b26-487b-a310-e85780572b5e">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtMS0xLTEtMA_d3f2edde-9240-4fb7-8946-0499d085714d">48,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtMy0xLTEtMA_32bff181-20ec-46e1-9031-4feefc9d3b75">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtNS0xLTEtMA_6a33ed3b-7a88-479e-a187-f4ad7d0520d8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtNy0xLTEtMA_c926ca82-6954-43c2-836f-e6e057ce69cd">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ic76990ea3ab04694851e972181e87908"><ix:continuation id="i24f0a05a264f4b0ab12083f0aad5365c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtMS0xLTEtMA_86c7662a-72c3-4b4a-9c07-b853f693346f">8,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtMy0xLTEtMA_dd0c85b5-41bc-44a9-b413-7a39547bdad1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtNS0xLTEtMA_582b8594-918d-4e7c-8191-c040939461ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtNy0xLTEtMA_590fa3eb-4c97-442f-bde5-36dd0ba91667">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItMS0xLTEtMA_c1f3fa51-2e95-448b-8294-9555ba21f0b6">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItMy0xLTEtMA_5a7957c8-562d-49bf-8260-142a18dfb2f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItNS0xLTEtMA_7002684e-1983-49a9-b944-d685c22ecacc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItNy0xLTEtMA_93d831a6-11b2-48c4-bd64-bf0313c7b37d">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtMS0xLTEtMA_a0cbd669-7e8e-4b17-aa96-04d07d22312c">9,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtMy0xLTEtMA_dcca9203-7116-4930-ab27-e74f81cc8f1e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtNS0xLTEtMA_6fe5065f-8393-4020-b112-70dfce25f74a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtNy0xLTEtMA_6cfae6a9-60b5-4299-a305-efc20e1a240b">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 2 and 8 for further discussion on the Company's method for determining the fair value of its assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, all of the available-for-sale investments were due within one year based on their contractual maturities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and are not significant as of December&#160;31, 2020.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MDk_99bbf5ff-1eb3-41b6-983a-5ac6cd530acb" continuedAt="icc591b377cf2473a9dc5bdb84c5af103" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="icc591b377cf2473a9dc5bdb84c5af103" continuedAt="i7eea9f5025a8407bb54ba2743fe77240"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MDM_44245595-b218-4dca-9a74-7d18a3102a02" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05375e0f8b94091a3e217e403a5e204_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItMS0xLTEtMA_1617313b-cb9c-4afd-b96a-a2486a7db120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5f8179595b4e5ba09bd4c1c6d600b7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItMy0xLTEtMA_ddec1fd6-2592-44a8-a9dd-89529dae22d5">48,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd472d7ad35f4a15b21d2195d5808bb5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItNS0xLTEtMA_e4f4a42e-3446-43b2-a088-5051fe54b2b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItNy0xLTEtMA_e90f7486-d505-4b8a-8c26-d9294c465cf2">48,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfedad06ddd479bba91d37f6def04da_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtMS0xLTEtMA_ce8f38ff-b3f6-4e8f-b607-b20c6f91f236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1c801fb36143c49fd0b608bcfa5b48_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtMy0xLTEtMA_957a3e9f-48de-4ce1-a9a7-de8ef7572288">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61312b716ae4e47b5211d08c39bc9a4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtNS0xLTEtMA_16dcd630-4f71-430c-aea0-f96c8c228c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897525fafdb1444eb6402bf2a7754355_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtNy0xLTEtMA_148a6eb4-57a4-48a5-b0bd-c5869004d750">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida01d18612bb4a56b451ba944d2f4a9e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtMS0xLTEtMA_f8ecee8b-047c-47bd-b141-093c411098c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fff13a081c481cb9e48baa81cacfaa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtMy0xLTEtMA_af9f07a8-d6fc-483f-97f8-03fb914f84dc">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtNS0xLTEtMA_2943bc94-0bea-44c4-8a1e-4b3342d0b8ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtNy0xLTEtMA_1f549760-aa32-4e69-af6b-00c0acc5ec7d">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7aae1a7de0b42298d4467fd3ec004af_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItMS0xLTEtMA_29c497e4-6b24-4c18-ae4f-2e7b7e160072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72f10ede16740f6939170db24c97f9d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItMy0xLTEtMA_954dfd2f-387b-4abd-8157-c52adf938366">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33a83c66e5e4d04930c270f49fcf9fd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItNS0xLTEtMA_d886f178-96a1-4db1-9345-816e40a3a2d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItNy0xLTEtMA_a559aa06-7fd9-4b97-ac4b-40f694edbf1a">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9143d9e97c0c469295ecf8f8e86bf4b2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtMS0xLTEtMA_b31a3a0c-25b8-4c6f-9074-4d2ba80ef3e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a32497816a24b0e98bfe2b91cdb5f5b_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtMy0xLTEtMA_9a0b8533-3b76-4f9f-8163-0ae84d003e44">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f0abd7a34b402a805fc120d404fcab_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtNS0xLTEtMA_0f7cf90c-787c-4467-953e-d8780740c125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2add7e1ec07f40dbb767635c38522992_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtNy0xLTEtMA_fd9fb7fa-fa82-4e7d-9cd9-393da3796710">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2add8a116b4448d19d15dd64d77975a5_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtMS0xLTEtMA_0f12a3f0-abb3-41e3-aa10-74584602d75e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9829035a8a2f448e9920c55d9173e8fa_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtMy0xLTEtMA_62ff97fa-3a9d-4cd5-8fe8-1cef182971ff">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtNS0xLTEtMA_82cc5aea-ddfe-43ea-a9b5-caca587f6382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtNy0xLTEtMA_66399f1c-7963-42b9-95b6-4bc52ca38652">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. During 2019, the Company's equity securities of AquaBounty (Note 1) and preferred stock owned in one of its collaborators (Note 18) were classified as Level 3 within the fair value hierarchy prior to disposition.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i7eea9f5025a8407bb54ba2743fe77240"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MTE_7cb1f302-363c-4c14-b36b-f4d0ad6b5a2a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Level 3 investments during the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27aebe7d32b349b39eabbc338188b25c_I20181231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzEtMy0xLTEtMA_dd3790ef-b287-4721-9c65-595e5f87f25a">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained interest in deconsolidated subsidiary</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzUtMy0xLTEtMA_790d7c3d-fd2c-476c-8118-486a7930f748">14,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend income from investments in preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" name="pgen:NoncashDividendIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzYtMy0xLTEtMA_541c44fc-9519-48a0-a7b3-75d5e3fccdad">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzctMy0xLTEtMA_6eb534fe-a28b-4333-a301-e7fc754cee06">7,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzktMy0xLTEtMA_b9900648-9f99-4ec6-b106-776051bd561b">21,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds to be received from preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" name="pgen:PreferredStockReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzEwLTMtMS0xLTA_ec8e0c16-b21d-4b50-a566-5d3230b404b3">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzExLTMtMS0xLTA_d39ad3a3-86e6-4feb-8469-de321617e736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculated fair value of the Convertible Notes (Note 12) was approximately $<ix:nonFraction unitRef="usd" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzIxNjQ_899d763e-8c26-4025-af4a-e255a1b11f2d">165,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ided6796ecfc64dfd806da8fc7d8e889f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzIxNzE_ead318d3-4887-461f-824f-f2725218d599">126,000</ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $<ix:nonFraction unitRef="usd" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI2NTA_49dc7cfd-7243-4ca4-ab35-f54ab5558d2f">168,147</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ided6796ecfc64dfd806da8fc7d8e889f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI2NTc_a3a14832-a04f-4585-984f-eeefe9ca0bdf">157,560</ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company's contingent consideration liability, which was $<ix:nonFraction unitRef="usd" contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzQzOTgwNDY1MTUxMDA_19167995-9590-41e1-8dbc-959b7087d173">585</ix:nonFraction> as of December&#160;31, 2019, was reduced to $<ix:nonFraction unitRef="usd" contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI3OTU_4d4ae252-a16e-4b0d-a410-a978023bf0c4">0</ix:nonFraction> as the period for potential payment of this contingent consideration expired without payment in June 2020. The contingent consideration liability was remeasured to fair value at each reporting date until the contingency was resolved, and those changes in fair value were recognized in earnings. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzY1OTcwNjk3NzMzMjQ_ef8f9ffe-c897-4716-aaa7-25d19636f30c" continuedAt="i426af64ad7cc4c3e84bcb0700a7aa278" escape="true">The changes in the fair value of the Level 3 liability during the years ended December&#160;31, 2020 and 2019 were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i426af64ad7cc4c3e84bcb0700a7aa278"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzEtMS0xLTEtMTM5NQ_1169f95d-7613-45be-8457-eef02a8e653b">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27aebe7d32b349b39eabbc338188b25c_I20181231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzEtMy0xLTEtMTM5NQ_20f5ffaa-34cb-4c66-924c-ca40c5b114f8">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration recognized in selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaff95dd2e5e6493cab06cdbfe40f221f_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzUtMS0xLTEtMTM5NQ_1ef905fa-0d4a-47c3-a3d6-9dd2675fb51b">585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzUtMy0xLTEtMTM5NQ_28613fae-4af0-4bec-8250-19993cac2ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzExLTEtMS0xLTEzOTU_478e87ce-9b2a-42d2-b8b3-28f5edeef84b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzExLTMtMS0xLTEzOTU_deb726f8-29a7-4098-80a8-333157324a54">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 10 and 11 for discussion of non-recurring fair value estimates used in calculating impairment charges recorded during the year ended December&#160;31, 2020.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90ZXh0cmVnaW9uOjk3OTI2NTFkZjBjODQ3MzQ4ODRkNzY5NTRlN2FhOTJmXzk0_0c240aec-cf4e-4a95-832a-25b7f180d22c" continuedAt="ifbf11e1081c648a0a4da478dbbf2e696" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ifbf11e1081c648a0a4da478dbbf2e696"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90ZXh0cmVnaW9uOjk3OTI2NTFkZjBjODQ3MzQ4ODRkNzY5NTRlN2FhOTJmXzg0_a5cacfc3-a054-4c4d-b43a-4c62c600c9e2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies, embryos and other production materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fed49ad0634fc1978b61d0cad74161_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzItMS0xLTEtMA_2d3868a1-f077-4d7d-abc7-9dc8f509f8d6">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1e8bcd17ae4fc0b556dc1a59ce8c5d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzItMy0xLTEtMA_f450b133-7a52-4c59-a1ff-28731a76533d">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e13e1046d1a4e8d8a5d3ce4b8599cde_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzMtMS0xLTEtMA_9442e998-9b87-4ec2-97ed-4802d5d36049">2,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148174464dab4df3b6cc16ca4f94f20c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzMtMy0xLTEtMA_227ff454-3e47-4326-b477-f82e9d70f57d">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cbec292daaf4a33adb6add3983c2aca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzQtMS0xLTEtMA_a2500011-3f50-48cb-a8cd-2960b1af7921">5,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66643537bcc4586b5c8295486ad53db_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzQtMy0xLTEtMA_55630679-d376-4351-85d1-9804757c9bcb">7,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917953d1a25e429ca029530f8e586cc9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzUtMS0xLTEtMA_b2dcf670-1d76-43c0-bb4b-8cba9501bd65">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8e97e073a840e3a917dd25f9403665_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzUtMy0xLTEtMA_18eb6a5a-aba6-4799-add1-d4722decb570">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzYtMS0xLTEtMA_83650940-c7cf-4e0f-bbef-fb8ea4ae9fc6">11,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzYtMy0xLTEtMA_56340b23-2f3c-4ea2-be15-33133b14be6f">16,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzYyMg_896adc31-e7bb-448b-89ac-aed2e586d106" continuedAt="i8a7f0a2c7f1d463c881e8e598b23f52a" escape="true">Property, Plant and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i8a7f0a2c7f1d463c881e8e598b23f52a"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzYxOA_6c8d9e7a-54e8-40d5-bbf7-5bceb752d625" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LandAndLandImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzItMS0xLTEtMA_eabd4650-0977-4011-90f2-f06f55f231f3">9,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LandAndLandImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzItMy0xLTEtMA_5c28011a-b7b7-4288-8ff1-9c6edc6b4f59">9,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzMtMS0xLTEtMA_84b8c064-723b-4b72-87d9-7d80d8ab9a89">12,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzMtMy0xLTEtMA_e4f3d7c6-1f6b-4bfe-b716-2af20953269f">11,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzQtMS0xLTEtMA_3f864806-0a6c-49bc-bd34-9e612269c74b">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FurnitureAndFixturesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzQtMy0xLTEtMA_7cb7d87f-7d23-4e73-b1f0-a61be663170b">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzUtMS0xLTEtMA_24ff058d-35c6-41b6-8306-e6ea6de01df9">31,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzUtMy0xLTEtMA_e15a6e4c-71e9-4db9-a182-2065218a876f">33,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzYtMS0xLTEtMA_55f76c56-5f9f-426c-b28e-8f10f855224b">6,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzYtMy0xLTEtMA_9a4318ea-fa2b-42de-84ff-2ceee594c995">6,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="pgen:BreedingandProductionAnimalsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzctMS0xLTEtMA_128e7bd8-36b9-447e-8de1-5e28c22ce6bd">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:BreedingandProductionAnimalsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzctMy0xLTEtMA_146fb098-bfbe-4ee0-bc5b-0df802c26a04">5,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ComputerHardwareandSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzgtMS0xLTEtMA_07f0e2ba-b12a-498a-a42b-59b0ec8b3a81">5,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ComputerHardwareandSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzgtMy0xLTEtMA_f9adbdf6-72f3-4022-8f6f-d7dedcbb2073">6,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction and other assets in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEwLTEtMS0xLTA_5352eb34-70b7-4e5d-8b2b-c83f9173856e">2,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEwLTMtMS0xLTA_9724eb60-7269-4656-b8f1-18ab8f7c5ecb">5,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzExLTEtMS0xLTA_8d1339cb-b3f7-4456-9bbb-d7268a6ba7de">69,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzExLTMtMS0xLTA_d7519be1-f5ff-46fe-b2af-eb58d4749978">80,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEyLTEtMS0xLTA_9a6a3862-e907-46ea-9254-c8e0b43760b0">34,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEyLTMtMS0xLTA_b0a5f9ef-ed86-4797-95a0-9fb6288d1ac1">36,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEzLTEtMS0xLTA_2d4eb57d-2230-46ab-874d-67ddd36049ea">34,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEzLTMtMS0xLTA_be8eeabc-5e01-44f6-9dfb-4db57965b648">43,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5NzY_5e7d3748-92a2-40e3-9b12-5869f5e772d0">7,449</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5ODE_1e2a657f-1557-46dd-8547-7320e25aab9e">8,222</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5ODk_7fc415bb-0bc8-4c14-b4df-519829c6f296">8,946</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzc2OTY1ODEzOTY3NDI_929668f5-d28d-46b7-8868-3a5e1678ca20">920</ix:nonFraction>, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, primarily related to right-of-use assets at certain of the Company's leased locations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recorded impairment losses of $<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTIyMzQ_15c2be63-7411-430b-8daa-5c01774713c4">448</ix:nonFraction>, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, related to the impairment of property, plant and equipment in conjunction with the closing of <ix:nonFraction unitRef="reporting_unit" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberOfReportingUnitsClosed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQ2OQ_4db7ad21-282c-4c5e-a364-d56a7d88f69c">two</ix:nonFraction> of its operating units during the third quarter of 2019.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDM_31535fcd-ee06-4a38-bf35-5158589fd597" continuedAt="ia521b381c29f4247accaf7c8b8b672ce" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="ia521b381c29f4247accaf7c8b8b672ce" continuedAt="iaf03976b1e404918a1d76a9542ffbcb4"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDU_bebf475d-53a9-4fab-a86e-c519e1194367" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzEtMS0xLTEtMA_599250d8-880c-4349-9511-f21cc43d4195">54,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzEtMy0xLTEtMA_1506750b-676a-47dd-b1e8-90a65daed31f">83,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzMtMS0xLTEtMA_a48a6503-d8ff-4626-ae26-4143fc215c3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzMtMy0xLTEtMA_bf62d2d4-06ef-4c62-814d-36d9ccce307e">29,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzQtMS0xLTEtMA_cdb1840a-3ff5-4903-bf0c-c8cbfe232ac2">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzQtMy0xLTEtMA_20c852d7-7f4c-48eb-a295-2aa644d50317">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8952cdcb9a6e414eb3558452807047c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzUtMS0xLTEtMA_9a0b7bdf-6907-4c3b-a188-dec5278799b1">54,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzUtMy0xLTEtMA_1e78b675-4a71-4e85-a55d-5d6d448affc6">54,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE1Nw_91dfa908-9d30-4476-bf35-3af17410ba36"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE1Nw_9ea69d35-c99e-4faa-b674-42bc6cc03b78">43,643</ix:nonFraction></ix:nonFraction> of cumulative impairment losses as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2019, during the Company's annual goodwill impairment test, the Company determined it was more-likely-than-not that the fair value of the Trans Ova reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the Trans Ova reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $<ix:nonFraction unitRef="usd" contextRef="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzQzOTgwNDY1MTMyNjc_080de05b-a154-4165-a925-98f3362db10f">29,642</ix:nonFraction> goodwill impairment charge for the excess carrying value. Additionally, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzQzOTgwNDY1MTMyNzE_e6a96ee1-1056-471a-96bb-d4050b0104b1">178</ix:nonFraction> of goodwill impairment in conjunction with the closing of <ix:nonFraction unitRef="reporting_unit" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberOfReportingUnitsClosed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzg1OQ_b428303e-46aa-4cfb-9606-5a987fd11514">two</ix:nonFraction> of its reporting units during the third quarter of 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="iaf03976b1e404918a1d76a9542ffbcb4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20 for information regarding goodwill by reportable segment.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxMzQ_0283b9b2-30c5-4239-8423-e7e7c865eb4a" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i827c577308054c018d5e48fada14ff8b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtMS0xLTEtMA_71c97422-4459-468f-a9af-9f37b19231b6">16.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtMy0xLTEtMA_def113cd-58e0-4740-9f81-7d797095ee8d">96,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtNS0xLTEtMA_150992f6-3762-40f5-a829-d3ac216e30f2">34,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtNy0xLTEtMA_05063f03-ea5e-46ed-8aa7-4bee0476792a">62,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6fc55d839644cba90653e38f783a62e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItMS0xLTEtMA_bbe4abb7-badd-4d3e-a18a-04815efb7564">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItMy0xLTEtMA_2b6b3635-778e-4bf9-aabe-2030ce36a475">10,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItNS0xLTEtMA_3f505d48-b95a-4cde-be13-f86f1a4670f3">9,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItNy0xLTEtMA_2c732b08-997b-453a-9e50-047fd2855f0d">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f3d42982abc4d50a68c8e28b6a8c52b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtMS0xLTEtMA_81ee7adc-7630-499a-8241-d1ee0a8feac3">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtMy0xLTEtMA_380cc879-9c29-406b-81db-75db1f048d30">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtNS0xLTEtMA_de8f334d-ee41-40f3-a7a6-49fde9810627">4,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtNy0xLTEtMA_cf8352b8-b91e-4f43-b984-991a7a3a3e53">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtMy0xLTEtMA_69d400dc-260d-4fd0-be53-f2243392bd16">113,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtNS0xLTEtMA_aee79093-8664-4be0-a7df-de971c88bb4b">48,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtNy0xLTEtMA_cba2bcdf-4029-40ea-9405-69f62863aaaa">65,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2019:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtMS0xLTEtMA_e8804e6b-4174-4ed4-8b00-0faece147aea">90,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtMy0xLTEtMA_4f95fc26-7e55-4b60-a9ab-b766fdb1d379">26,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtNS0xLTEtMA_5442f952-f773-47a6-9687-53d4e4733700">64,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItMS0xLTEtMA_ebc96679-c702-43d9-af7e-bf178c8e1cbf">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItMy0xLTEtMA_7fd3f94f-1f1b-499d-aade-91dc18dae349">8,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItNS0xLTEtMA_a301b727-32af-4510-931a-62b9ee76826c">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtMS0xLTEtMA_759c88f3-1cfa-46c2-8465-96cf33c853cc">5,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtMy0xLTEtMA_1900da34-4de1-4276-b234-b9a429494177">3,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtNS0xLTEtMA_87a3d364-2dea-4b8b-911e-44c58a4988b6">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtMS0xLTEtMA_86f1d5bc-dbef-4fc4-a807-a3fe5097736a">107,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtMy0xLTEtMA_d27ead5a-c65c-4965-a0a2-c518f7492124">38,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtNS0xLTEtMA_d5b28d1b-e110-463a-9f8b-51e0b7b7f3a7">68,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="if23ada0abe5047e9816a9b05e4ac3a06_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzExNTE_8537c3fa-f2ce-4b8d-a5e7-c54ae3db478a">16,027</ix:nonFraction> loss related to the abandonment of certain developed technologies that the Company ceased using in the fourth quarter of 2018. The Company does not expect to use these technologies as a defensive asset or market them for sale in the future. Because these technologies were used in combination with other technologies, the identifiable cash flows did not result in an impairment loss; however, because the Company made a decision to abandon the assets, it recorded the charge to research and development expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5NTg_e8b49f10-b769-4d85-9371-9dc5f4a0fe0a">7,593</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5NjI_3a609555-f07a-4241-8c1e-8d07bd7ff1fd">7,920</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5Njk_d6962e64-2949-4d9f-b91f-38ee851b7e77">11,666</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDY_627c13d9-f2be-4813-8f0b-f5b9c5200263" continuedAt="i81892accbc454ae1b86871bd4ac24c38" escape="true">Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:</ix:nonNumeric></span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><ix:continuation id="i81892accbc454ae1b86871bd4ac24c38"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzAtMS0xLTEtMA_9533809b-e658-41e3-b24d-fb2a4af139bc">7,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzEtMS0xLTEtMA_32417b44-e867-4faf-b93b-716b1b8c3847">6,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzItMS0xLTEtMA_30b302d0-03bb-4b12-9706-608beda551d3">5,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzMtMS0xLTEtMA_705763b4-2afa-4f84-a361-fe5430b82316">5,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzQtMS0xLTEtMA_c7b8f16c-1b0c-4a92-b2c3-6b762ac23b5c">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzUtMS0xLTEtMA_f1ef4644-a851-4652-865a-a66f3f8af712">34,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzYtMS0xLTEtMA_13520983-caab-41fb-975c-e09647338919">65,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODY_6f0fdfd2-6f16-46dd-98f8-52c948ac18cd" continuedAt="i3f6f8a35b6d34f1abebb075b57201e42" escape="true">Lines of Credit and Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="i3f6f8a35b6d34f1abebb075b57201e42" continuedAt="i652f10776ec14688a7b3efcd077f67ba"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova has a $<ix:nonFraction unitRef="usd" contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc2_f57678f2-d9fd-48db-84e1-e63ee41c05b8">5,000</ix:nonFraction> revolving line of credit with First National Bank of Omaha that matures on April 1, 2021. The line of credit bears interest at the greater of the U.S. Prime Rate or <ix:nonFraction unitRef="number" contextRef="iebe34c2e16ef4ced904a0a453bb78be8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI2Nw_f8ff3655-f557-41d7-bb21-2d524f03a242">3.00</ix:nonFraction>%, and the actual rate was <ix:nonFraction unitRef="number" contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI5NQ_03dc1fb3-9444-4dad-bbd4-57df4d680cce">3.25</ix:nonFraction>% as of December&#160;31, 2020. As of December&#160;31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM1NA_ddc16188-7d06-45f0-9e49-1b88507b6f61">no</ix:nonFraction> outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $<ix:nonFraction unitRef="usd" contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzUwMw_c66f18d5-4e03-4dc8-9da5-14a8b9b6a398">5,000</ix:nonFraction> as of December&#160;31, 2020. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exemplar has a $<ix:nonFraction unitRef="usd" contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzgyNQ_80480286-00b3-4ef0-8529-843ef5b251cf">700</ix:nonFraction> revolving line of credit with American State Bank that matures on October 31, 2021. The line of credit bears interest at <ix:nonFraction unitRef="number" contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0OQ_7026d556-2315-4ef1-adfa-2c1d6378e059">4.00</ix:nonFraction>% per annum. As of December&#160;31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzEwMDk_7a8e7672-e99a-4b07-82a1-da46bf052637">no</ix:nonFraction> outstanding balance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i652f10776ec14688a7b3efcd077f67ba" continuedAt="ib61f076aa98444c49441c00f51da13a5"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODg_1b9bec01-f097-445c-8fb2-8702877d4be8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20ccfa747e64113890f0974c9cb925e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzItMS0xLTEtMA_bb72a31c-0d6e-470b-8ee5-a87a74bcaea1">168,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1adbe486ee94be59a3ea92894502ff4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzItMy0xLTEtMA_b2f975cf-0dcb-43f0-8944-4af3462b3e69">213,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i933e7cc3ab3e474b9117c918400f0682_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzMtMS0xLTEtMA_c974279a-7532-48cc-9795-ac9aba16dbb2">3,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b7410140b740b2845853aabed50d7d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzMtMy0xLTEtMA_957283b7-6923-4798-aeac-c8828655b229">4,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792bcba573ad43159c20ae7da25f6f15_I20201231" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzQtMS0xLTEtMA_ee6577d3-984c-4077-a2c4-0e01c0786c25">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac99bde42eb4b6eba9f0cd1ac7f2e1b_I20191231" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzQtMy0xLTEtMA_9a9d3da0-2660-4d88-a7ae-3ef524ad22d6">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzUtMS0xLTEtMA_c01e9f6c-e0da-4020-8c11-70222846b5c6">171,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzUtMy0xLTEtMA_fa26016a-094e-4cde-81cf-0a0eb45790b9">217,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzYtMS0xLTEtMA_981ac02c-aa1c-42bc-9c17-de489506686e">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzYtMy0xLTEtMA_cdf87677-d0f2-4686-a5f8-bf1ae7371e6d">31,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzctMS0xLTEtMA_c9b9d2ad-cf30-4792-aa89-33d964611430">171,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzctMy0xLTEtMA_d4706b88-5f56-4990-811b-43783b14daeb">186,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Precigen Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, Precigen completed a registered underwritten public offering of $<ix:nonFraction unitRef="usd" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzEzOTA_2019a9a2-01f1-42a2-ae6c-99b657fbf454">200,000</ix:nonFraction> aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE3Mzc_e986a6ad-5e6c-45f5-a655-b060e1719221">193,958</ix:nonFraction> after deducting underwriting discounts and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE4MDQ_8df972cb-ebb0-48e1-97e0-9caa7039fd95">6,042</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE5MDY_db9b9db5-95e4-4bfc-aa36-bfb0bb246cc3">3.50</ix:nonFraction>% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is <ix:nonFraction unitRef="number" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzIzMDU_e161b96a-0c59-4486-a0e2-59127a0c00d6">58.6622</ix:nonFraction> shares of Precigen common stock per $<ix:nonFraction unitRef="usd" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="INF" format="ixt:numdotdecimal" name="pgen:ConvertibleDebtPrincipalAmountInitialConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzIzNDQ_4f5de2c1-b891-40b8-b364-3aad6c6fa637">1,000</ix:nonFraction> principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI0NDU_ab43cf98-17a0-4102-9b07-33fc01eda153">17.05</ix:nonFraction> per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least <ix:nonFraction unitRef="day" contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMyMTk_f0cb27e0-1e15-447f-b225-3de627d9f62c">20</ix:nonFraction> trading days (whether or not consecutive) during the last <ix:nonFraction unitRef="day" contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMyODA_7e80859c-43df-4e88-a874-84e23b761762">30</ix:nonFraction> consecutive trading days of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMzODI_708fe7bb-ef2b-4fe5-a041-cd2a7139b1ad">130</ix:nonFraction>% of the conversion price on each applicable trading day;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the <ix:nonFraction unitRef="day" contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM0NTI_f5061769-dcc9-4265-acaf-aff308bf67a2">five</ix:nonFraction> business day period after any <ix:nonFraction unitRef="day" contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM0ODU_6cd11aed-2eac-4d51-8313-d4dca01251c8">five</ix:nonFraction> consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than <ix:nonFraction unitRef="number" contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM2MTU_27a3125a-a9d0-4e4e-8748-702a82ea923c">98</ix:nonFraction>% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon the occurrence of specified corporate events as defined in the Indenture.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December&#160;31, 2020. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzODI_051c3e21-a0ee-4252-9beb-4b998761cd07">100</ix:nonFraction>% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ib61f076aa98444c49441c00f51da13a5" continuedAt="i404bc4dbbf324a36b6ce14fc8d59a947"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU0NTg_516a7575-b449-4b7a-98c3-5d20531acb10">143,723</ix:nonFraction>, and additional paid-in capital, the equity component, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU1MzM_80c2154b-d131-422d-8fa6-b282e8b31a03">50,235</ix:nonFraction>. Additional paid-in capital was further reduced by $<ix:nonFraction unitRef="usd" contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU1ODc_af0602c3-27ee-48fa-943b-5212a8b3bc36">13,367</ix:nonFraction> of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount (Note 13). As of December&#160;31, 2020, the outstanding principal balance on the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYwMDE_cfe20fd8-cb75-4425-aaf6-7b198541a78f">200,000</ix:nonFraction> and the carrying value of long-term debt was $<ix:nonFraction unitRef="usd" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYwNDk_49dc7cfd-7243-4ca4-ab35-f54ab5558d2f">168,147</ix:nonFraction>. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is <ix:nonFraction unitRef="number" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYxODk_50ac8a04-33e8-4831-a5d7-fb96553b4e75">11.02</ix:nonFraction>%. As of December&#160;31, 2020, the unamortized long-term debt discount and debt issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYyNzU_10853c45-9f33-45ed-9b20-cbfd98ecf6e9">31,853</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODE_bfb28e09-8ad4-4d6d-9b5b-fbabaaa77c9e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of interest expense related to the Convertible Notes were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItMS0xLTEtMA_f92a03b4-0d24-4bd6-9eec-4f32c8c42302">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItMy0xLTEtMA_2338e7e1-67af-4d1e-ba94-f1c8cfa14320">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItNS0xLTEtMA_c322df41-2827-49c3-a2c0-3273bf9f1c0d">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtMS0xLTEtMA_1841017d-11b0-4562-8549-30b88fe46da3">10,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtMy0xLTEtMA_a9b95906-6ce3-45ea-95b7-b42d4ad4bdf2">9,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtNS0xLTEtMA_79579241-102e-4eb3-8b3f-9cfe11c8b7c1">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtMS0xLTEtMA_ed2efd14-05d7-46dc-aa13-dfe4afe7713e">17,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtMy0xLTEtMA_d80784ee-37ff-46c4-8c09-ab2d11ba6f6f">16,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtNS0xLTEtMA_c0294868-bac6-4f43-a9a8-65f415d0bd49">7,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest of $<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYzODY_a8d69c5e-b2fe-4a7b-9c49-dc83b52a863a">3,500</ix:nonFraction> is included in other accrued liabilities on the accompanying consolidated balance sheet as of December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ActoBio Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, ActoBio issued $<ix:nonFraction unitRef="usd" contextRef="i300109a3973b48cfaf6c87f24830c1e8_I20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzY1NDc_deb5d86b-5193-4bba-ae66-1612abb254f0">30,000</ix:nonFraction> of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 4). The ActoBio Notes, which accrued interest at <ix:nonFraction unitRef="number" contextRef="i5dcdccfde7b24e57841cf202a0c22c5e_I20180930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzY3Njg_4220ce2f-82d0-4ce1-8853-c7ccb8733ab2">3.0</ix:nonFraction>% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued <ix:nonFraction unitRef="shares" contextRef="ifbf7a9ed58fa4c19bfac3158a4004562_D20200901-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MTU_94aee9c0-3523-47b9-94e1-295929b0f1b3">6,293,402</ix:nonFraction> shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $<ix:nonFraction unitRef="usd" contextRef="ibcc2b6cdd3fa4b82a31d23fe1ca4681d_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc0MzA_01b8b472-d365-4872-bf24-61d0f4d616f4">616</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="iddfb43cef36f48d58869fc13628164ec_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc0Mzc_32ba2a60-992b-404b-9dd9-25da6d5ef03e">921</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i7c1c0bfc1a8642e5b23938f795103bcb_D20180101-20181231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjUzMjY_75e6bbb7-c250-4a03-b5d4-39fd979dc059">290</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Precigen and PGEN Therapeutics Convertible Note</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, in conjunction with the Merck Purchase Agreement (Note 6), Precigen and PGEN Therapeutics jointly and severally issued a $<ix:nonFraction unitRef="usd" contextRef="i09db21ffd978403fb95c9f969486cebe_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc3NjA_f06d22aa-9a71-4dcd-a27d-b74d04d54782">25,000</ix:nonFraction> convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note had a maturity date of June 28, 2021 although it automatically converted to Precigen common stock on the first trading day following the second anniversary of issuance, which is December 2020, if not otherwise converted prior to that date. In October 2020, pursuant to the terms of the Merck Note, Ares Trading voluntarily elected to convert the entire $<ix:nonFraction unitRef="usd" contextRef="i09db21ffd978403fb95c9f969486cebe_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MjY_0f0e93e0-ed1f-4a2f-a1e7-7eac87d5afca">25,000</ix:nonFraction> outstanding into <ix:nonFraction unitRef="shares" contextRef="i998ab898facc4cc6929d5d5803057739_D20201001-20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MzU_1d025269-08c1-448f-9e4b-761b34ea4625">6,758,400</ix:nonFraction> shares of Precigen common stock. The shares are restricted from resale by Ares Trading for a period of <ix:nonNumeric contextRef="i998ab898facc4cc6929d5d5803057739_D20201001-20201031" format="ixt-sec:durday" name="pgen:DebtInstrumentResaleRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4NTM_d47998af-987c-45e8-bfc7-3ab0579e7f7e">180</ix:nonNumeric> days from the date of issuance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Payable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="id1f9a8543e394b0089b989601e44377b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkyMjE_8cb7bcc2-9668-49d8-a430-d65437a291ad">3,655</ix:nonFraction> as of December&#160;31, 2020. Trans Ova pays monthly installments of $<ix:nonFraction unitRef="usd" contextRef="i33041383733943a0bdbb0c01bba1ae14_D20200101-20201231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkyNzM_3d85d756-9f8a-4053-94dd-817fb9df2741">39</ix:nonFraction>, which includes interest at <ix:nonFraction unitRef="number" contextRef="id1f9a8543e394b0089b989601e44377b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkzMDQ_075cca64-3f9f-4b83-ba10-fe15151c41b4">3.95</ix:nonFraction>%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i404bc4dbbf324a36b6ce14fc8d59a947"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Maturities</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0OTY_89cd6991-2271-4011-b258-b978b17e4058" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of long-term debt as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzAtMS0xLTEtMA_8faaea40-d676-41b6-b659-33ea1b0f7dfc">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzEtMS0xLTEtMA_86b78876-1dfb-432b-9267-7955bd92d067">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzItMS0xLTEtMA_f3d35aad-fd53-4a4d-a8c4-1eeba4793755">200,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzMtMS0xLTEtMA_9b45eb64-36b5-4c89-92c4-933d88d4535c">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzQtMS0xLTEtMA_28e3f082-0c1f-4f14-a52a-fb715fb22cdf">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzUtMS0xLTEtMA_71c18a67-7dc2-4ef4-8b9c-8247cf7be5e9">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzYtMS0xLTEtMA_4ff40e50-a95d-4ccf-938b-e40ef0f11898">203,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU3OTQ_0a050296-7489-450b-9892-f5ac1b5514d0" continuedAt="i6bbd26a60b6c4b2b91fc5b430901708f" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i6bbd26a60b6c4b2b91fc5b430901708f" continuedAt="i2f58b09c12a64372acaa1a1498ee2227"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MjM_0193e5c4-1379-46e1-bd7f-34fd3b2d400a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from continuing operations before income taxes are presented below:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebbd89e79742463bb7bb2c8072e4d28d_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItMS0xLTEtMA_5a459034-4c9b-4b35-bdee-d90ba4447475">97,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fa0174f15049ad925a5c7467f8806f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItMy0xLTEtMA_c96f0de9-3822-4da5-9f27-b2e3dae7e316">167,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7249ffe7fdf04fc58a2bebc05c00ac77_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItNS0xLTEtMA_a50548ff-9409-43c5-aaab-abd9026f5a17">394,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86b9331a29684594bdc6ff0bcff164e6_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtMS0xLTEtMA_362d9279-1275-470c-80ec-bd51d8742d7e">6,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib75f9587ce8b496db2609e0682fcb9b5_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtMy0xLTEtMA_e1455b5c-67c9-4dd9-9c88-2dd4eb043c83">3,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd35f7da52004f518b3b73faaa279403_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtNS0xLTEtMA_50e4ea91-2c6b-4f7b-8691-c23324c6caf2">1,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtMS0xLTEtMA_71376b21-ab61-4f4d-befb-f181eaf9450a">103,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtMy0xLTEtMA_3961ec10-4b4d-4f8b-be63-e220d1cb3ca7">171,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtNS0xLTEtMA_6969727e-89ef-4521-9efd-a1eed58fdb73">395,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU3OTg_945143f9-6f3a-4331-bf03-1b73f65249c4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax benefit from continuing operations are presented below:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtMS0xLTEtMA_a913fe56-f690-473c-88e7-e3f3803b2a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtMy0xLTEtMA_9935fc62-80be-4c96-b135-ad9c12132043">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtNS0xLTEtMA_41f82a44-3a55-488a-a49f-3a10b893c4c9">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtMS0xLTEtMA_b2c3e85f-91b5-4d08-ae55-80f6a6acf333">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtMy0xLTEtMA_b2a7f9e6-8b86-4429-93c4-f0344492a3d4">561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtNS0xLTEtMA_f8efd96f-c4af-4680-8615-3bd345c76ce7">11,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtMS0xLTEtMA_fa4fb136-1032-4307-9f15-214c3d81fc9a">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtMy0xLTEtMA_175002a8-55a9-40f4-a4bf-a2a462709b7e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtNS0xLTEtMA_5c1dc206-fe0f-40a2-b002-3ef61777d0e9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctMS0xLTEtMA_578621d8-eae1-4d01-bc48-b76fbdd36d32">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctMy0xLTEtMA_4b34ad3e-8ca1-4450-bf14-5bf3588c75ee">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctNS0xLTEtMA_e3b2d59a-1f76-4ded-afcb-52823f9018d2">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktMS0xLTEtMA_fba5009a-5812-464e-839a-8f932d637c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktMy0xLTEtMA_632b2fca-c3a7-4003-94f9-ada636a55282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktNS0xLTEtMA_f066df36-b605-4083-9084-6e3a44790c26">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTEtMS0xLTA_6f5b7cee-4c44-4c0a-93dd-0ddabb378836">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTMtMS0xLTA_3fd216a0-49e9-4183-9b1f-c18f2f71fc94">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTUtMS0xLTA_8bcbe859-5e88-4509-a54a-9f4166549d9b">4,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTEtMS0xLTA_242e0590-a5e1-4c1d-8861-11220bba0563">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTMtMS0xLTA_597e105b-f76a-44a6-947a-6079935fe39c">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTUtMS0xLTA_6c9e5d2d-2a4b-4001-a50b-eee0ecc94923">15,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i2f58b09c12a64372acaa1a1498ee2227" continuedAt="i81733d33b3db4a77a2468a6ffda4d61b"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MTc_b1f661bc-bcc5-4a12-9cb6-9a6ed6f9781d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit from continuing operations for the years ended December&#160;31, 2020, 2019 and 2018 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed statutory income tax benefit from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtMS0xLTEtMA_0caf630f-b2d8-461f-80b1-feb100d1ca11">21,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtMy0xLTEtMA_bb310613-e5e5-4ae8-a5d2-e86e5c6f361f">35,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtNS0xLTEtMA_29d62a35-45d0-4c78-8c0c-f97b59464d81">83,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and provincial income tax benefit, net of federal income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItMS0xLTEtMA_424d0f10-f43c-46a3-a971-be5394ed0411">5,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItMy0xLTEtMA_0864fbf4-88ac-421d-85e8-f74ab536e1b6">5,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItNS0xLTEtMA_07b524ba-eebf-488e-8118-474eaa0d2342">21,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtMS0xLTEtMA_545594a6-68d7-47f4-a3c9-012fe50d61ff">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtMy0xLTEtMA_3ad4ac48-086e-4389-adb6-fc6b456aa391">10,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtNS0xLTEtMA_1d730c51-7fd1-4ace-830d-c905a0c91917">4,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtMS0xLTEtMA_b903692b-32ff-4655-a7c6-4d82b3f00b45">728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtMy0xLTEtMA_84300b45-e1e1-4bd9-b556-fb43cc6a89db">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtNS0xLTEtMA_63388795-7e30-4011-8b6f-530a5999f610">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtMS0xLTEtMA_23491dfe-0ac6-4816-b664-7b76e308d840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtMy0xLTEtMA_489d497d-4cd0-40d3-8238-c9b9ef3d6303">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtNS0xLTEtMA_ea924e65-8424-43e9-aa6e-16eacadf5c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctMS0xLTEtMA_8449d7ee-165e-4109-9696-05c2cec4a6c6">524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctMy0xLTEtMA_e1f2bce4-6da7-4bf5-a8e2-e2dad24409b6">1,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctNS0xLTEtMA_ea7a2962-e863-4c37-87fc-780bba598bce">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and internal restructuring transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtMS0xLTEtMA_32af91aa-5936-4b8c-8b6d-ff724bc0cfee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtMy0xLTEtMA_143887bb-e60c-4890-98f6-49d924468bb2">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtNS0xLTEtMA_1024f096-f617-4777-9133-259d9031dc57">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTEtMS0xLTA_2dc851e3-f343-4594-aaba-1701962f2429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTMtMS0xLTA_9b6b203c-b4f3-4eb8-a637-8976e66be6d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTUtMS0xLTA_38fdd769-b96b-4f57-ba7c-95c355c32640">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTEtMS0xLTA_e4722f34-c3eb-4752-8f21-d1e7b5ccf1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTMtMS0xLTA_8898af44-31bf-48be-ad86-7d7f37c40208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTUtMS0xLTA_4cce247f-98fd-4825-b8d5-2de82c238479">8,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States-foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTEtMS0xLTA_fab8f4da-413d-46d1-8792-a06c867ca41b">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTMtMS0xLTA_69d49fc8-08b8-409a-9357-93616cee3bcc">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTUtMS0xLTA_98b6e65e-e7d9-44cb-85ce-8323fb52738a">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTEtMS0xLTA_66491972-f38d-4d7e-af2a-9aef9dfe8ddc">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTMtMS0xLTA_eac65a08-d5fb-4b7a-96dd-ef145a14c76e">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTUtMS0xLTA_af4bad47-7511-4907-842f-58b8dd9d2f4e">3,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTEtMS0xLTA_98f70e76-9d9a-432a-bf2e-6dd289cb508c">21,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTMtMS0xLTA_df8b88b3-e188-4a47-bc2e-34d2ec0f857c">31,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTUtMS0xLTA_7b0236a9-2f49-4103-a5a9-b7c6e9880f50">91,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTEtMS0xLTA_1f90910e-d8a3-4f62-a409-ca3788c3d106">21,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTMtMS0xLTA_07d3230d-d3d5-4f94-83f6-266e9a3ba894">31,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTUtMS0xLTA_b9195b7c-6454-460b-88a4-1ee2d65cfd9e">76,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTEtMS0xLTA_3921ea67-1cd6-4564-8a3c-d8d1df05cff6">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTMtMS0xLTA_c5d51f6f-bdf0-44dd-a935-2b30c88a68bc">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTUtMS0xLTA_8c876023-ec6c-491b-b494-9cf18e87a9cf">15,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MTU_f2f86172-5312-48c7-ac56-aea9ec53c8f4" escape="true"><div style="margin-bottom:11pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzItMS0xLTEtMA_5b3d4253-6641-4760-877f-3084f61ba996">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzItMy0xLTEtMA_a3f16896-6d76-44b2-a7b2-eeaee147ca96">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzMtMS0xLTEtMA_25b58700-83ad-407e-9c53-4a1c58c4fa6c">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzMtMy0xLTEtMA_d3edfe43-544d-4899-b65d-7c76d26f3cbb">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities and investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzQtMS0xLTEtMA_ca4d6f75-431a-4ab6-a464-90213ebc1927">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzQtMy0xLTEtMA_013e2e9c-854a-4b11-83f8-edc45f3b36b8">11,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzUtMS0xLTEtMA_eddf1b06-4e5c-4fe5-8fc8-940f36905cb0">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzUtMy0xLTEtMA_1a4d21c6-17be-4667-be07-be64b19d8f13">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzYtMS0xLTEtMA_fef933bd-d72b-462c-9b94-20974186d333">74,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzYtMy0xLTEtMA_15222a33-fd76-4124-9635-ebae648863e6">85,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzctMS0xLTEtMA_dd243756-2953-448d-981b-30db0ba50ed4">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzctMy0xLTEtMA_4c2c3584-595c-4d06-aa88-0e53f5f0e8d0">3,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzgtMS0xLTEtMA_6e83e7c5-7a98-498a-9cdb-a473a94fe5ef">6,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzgtMy0xLTEtMA_41ce0cc8-00a4-4b69-bf2d-2c7e8605cd93">10,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzktMS0xLTEtMA_284e70f3-1c92-410f-97cc-d7948ff1017d">16,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzktMy0xLTEtMA_1834385d-09bc-4905-b1a9-2b8c3ded4e37">19,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEwLTEtMS0xLTA_eff5ad04-e291-4a9d-9ff8-a0c33df10cda">7,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEwLTMtMS0xLTA_dce2f97b-20c0-45e2-9ca7-a2ac7fe091b8">14,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzExLTEtMS0xLTA_a6720e63-ba66-4173-a331-72151f1dfd34">10,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzExLTMtMS0xLTA_ad2343c4-c37a-4a9b-92d5-69a9ca181102">9,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEyLTEtMS0xLTA_6b91054f-c70f-4699-aa69-ccfd270b945e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEyLTMtMS0xLTA_d7f3e0cd-6fae-451e-9651-ae368eeb1fc5">8,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating, capital loss, and interest expense carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEzLTEtMS0xLTA_229ee362-8af9-41a5-bffd-3cd9bfe8dde7">275,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEzLTMtMS0xLTA_1963c657-f72f-40b2-9a75-ea496a5f8696">196,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE0LTEtMS0xLTA_57001b41-e313-41ed-86c1-7a443987b165">397,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE0LTMtMS0xLTA_e5b18e3f-02e3-464b-8a48-b7f557fa6ebb">364,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE1LTEtMS0xLTA_20ed4a2d-d961-47c4-81b7-60e8197e20c6">387,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE1LTMtMS0xLTA_4f5f52b6-5a1b-4b96-97c5-f8d892d7ccea">349,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE2LTEtMS0xLTA_0e531a61-416d-4df0-8a60-aec69d47ce62">9,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE2LTMtMS0xLTA_3effbaa1-11f1-455d-beac-bf87bd7fb304">15,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE5LTEtMS0xLTA_46d89263-0887-4154-bf45-60c338dda704">5,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE5LTMtMS0xLTA_87c4f449-3a06-44e7-b7fc-e11b71375e47">8,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIxLTEtMS0xLTA_2d412ae0-8830-4455-887b-7ec78cab9198">7,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIxLTMtMS0xLTA_52a4870e-7011-4e1f-9b8c-5d5732880bd6">9,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIyLTEtMS0xLTA_ba783f5b-d8b4-48ee-89ca-7c80144cb6a1">12,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIyLTMtMS0xLTA_faf6e88a-c0b7-45c6-910a-62a11ec39ac1">18,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities included in continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIzLTEtMS0xLTA_52080663-a049-4133-ab74-2dcd81fa4ba1">2,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIzLTMtMS0xLTA_bd7d8d6b-20fe-4634-aeb9-200a64b335d1">2,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i81733d33b3db4a77a2468a6ffda4d61b"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MDQ_2f2417eb-4bce-4f73-907e-da6f3e8d87d1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December&#160;31, 2020, 2019 and 2018 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtMS0xLTEtMA_993d59d5-3d45-4b2f-98b4-0d3cc84c0d58">349,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtMy0xLTEtMA_16166d60-5400-444c-8706-169d7e57981d">292,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtNS0xLTEtMA_3f9d48c6-7827-4b00-931a-429b95d48881">211,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance as a result of</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtMS0xLTEtMA_6dd1ffaf-5f85-4c84-9f79-54d785634414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtMy0xLTEtMA_763bcced-2997-44b5-b38e-6d8223de0c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtNS0xLTEtMA_7666c15b-68d3-4fac-bf10-4c99a6d383af">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of AquaBounty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtMS0xLTEtMA_558790ff-cf60-4190-8ee9-751c0a2cd22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtMy0xLTEtMA_d55090c5-7894-430c-9981-c9e972805c4e">3,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtNS0xLTEtMA_c18d63fa-7c2b-4513-8e58-cff869405f77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of deferred taxes for subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtMS0xLTEtMA_142c15de-262a-4e10-a916-ded4c47d909c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtMy0xLTEtMA_1c0b8d28-6c91-467d-b3c4-effb76ae64da">8,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtNS0xLTEtMA_b2885b19-a5b0-404e-931f-6cbefad08afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtMS0xLTEtMA_63229744-43a1-4980-aa84-944f3638925a">21,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtMy0xLTEtMA_a62dafc9-57c9-461b-8e1c-6bfa6dae02ab">31,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtNS0xLTEtMA_7ccdfdca-a429-45f8-af82-cef264b4ee7f">98,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations treated as asset sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctMS0xLTEtMA_8c97a03d-3818-4c7d-a2f5-48a5df669a75">7,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctMy0xLTEtMA_01af1545-6be7-4ef0-b721-d47b0a0de263">10,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctNS0xLTEtMA_a8e53641-b0ed-4cec-a319-184354e03d57">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations related to MBP Titan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMS0xLTEtMTIxNDE_711ffbca-34c5-41d7-a2a3-9583e4b90e12">8,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMy0xLTEtMTIxNDE_c8e12696-b186-4734-8ae8-38fcd2e6e6b8">9,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtNS0xLTEtMTIxNDE_b4382c15-6b8d-4393-9afb-87bbe263519d">8,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 842</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2e86fa379664890bce6f8505ae63863_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMS0xLTEtMA_863f97ca-7f02-45d4-b64f-a9982c6fc102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94e6997c4484c4fb71d5424d9a823e7_D20190101-20191231" decimals="-3" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMy0xLTEtMA_1604bd68-3bbe-4196-a36c-6b2db0d56983">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6024ac23c341aab2161aee0517820f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtNS0xLTEtMA_571e430d-decb-40cf-8732-73b762320cc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 606</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2140f32269b445a7a78f85b8ded04f8f_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktMS0xLTEtMA_63d0f720-71d4-4d8a-bcc5-0c2b0689c003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c2f36dc30c4039a45bf45425bd3b3c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktMy0xLTEtMA_1c0ed883-d5f0-45b5-be45-bdfc88ef2317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i846cd2227b1f4f05943d3faf0edb56d7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktNS0xLTEtMA_d148899a-a2c9-4f5d-a833-558131b826d7">7,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTEtMS0xLTA_be852aff-3ae5-4828-ae77-9398fc924241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTMtMS0xLTA_62caf22c-0850-477e-994a-4d37ad7511a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTUtMS0xLTA_6f75166c-467a-4e5b-b72d-427b5c41695a">13,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTEtMS0xLTA_6ca4d4f0-7849-46a3-a0b4-ebb1e948e60b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTMtMS0xLTA_9572db7a-fa92-483a-a5a6-383902961ea6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTUtMS0xLTA_7745f52d-cbe8-4e99-afc4-47b2f0ed0142">8,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTEtMS0xLTA_a577fa8a-adb1-482e-9008-5c93c82eba81">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTMtMS0xLTA_6d7442e2-7809-4138-a92b-8976d08de732">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" name="pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTUtMS0xLTA_4e208476-70ea-4fe8-9053-2bc7d234c6c7">885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTEtMS0xLTA_e7d82f3f-1f6b-41fc-a1c8-9a4b849a3c23">387,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTMtMS0xLTA_b60fbbe4-be2f-4d6e-9fdc-a911bf948c3e">349,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190b69f516da44baba7e77735b9083e9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTUtMS0xLTA_f06968b6-47f5-4005-8b3b-c6fc58ee492d">292,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section&#160;382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December&#160;31, 2020, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December&#160;31, 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzIzNjQ_106ea097-cee7-4a61-a015-51c3946fd506">42,100</ix:nonFraction> of the Company's domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI3MDI_508ea15c-2a5c-49e3-9bcc-82b7f72c1253">756,200</ix:nonFraction> available to offset future taxable income, including approximately $<ix:nonFraction unitRef="usd" contextRef="i0dc0ff9076414c038f13048e82021a34_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI3NzI_3cc908b0-3d33-4b42-94b0-e4ca4841d28a">503,500</ix:nonFraction> generated after 2017, United States capital loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI4NTU_c1068d61-3361-4c3d-b200-c76866e9f755">211,500</ix:nonFraction>, and federal and state research and development tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI5MzU_6cc46dab-f812-4eb8-b90b-f280e4533f90">10,200</ix:nonFraction>, prior to consideration of annual limitations that may be imposed under Section&#160;382. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. The Company's foreign subsidiaries included in continuing operations have foreign loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i0274c8f694d3486099220e08fbba1fc1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzMyOTI_3c9fa2cc-1bd4-4859-90b9-fc0ba81f780e">82,300</ix:nonFraction>, most of which do not expire.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $<ix:nonFraction unitRef="usd" contextRef="icc450189ce644024ba68868dd2551779_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzM0NTM_52cced54-c778-48a1-98da-d0411e55cb74">21,200</ix:nonFraction>. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries do not have material unrecognized tax benefits as of December&#160;31, 2020. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQ0MzI_a407d3ed-4d63-42ca-9310-9df1f4d70b5b" continuedAt="ie3ea2bc9f61d4f6e900c09c8e58eed13" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ie3ea2bc9f61d4f6e900c09c8e58eed13"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Precigen Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased <ix:nonFraction unitRef="shares" contextRef="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQzOTgwNDY1MTU4NTI_f7529ae2-9f1a-4980-a488-8476481d1753">5,972,696</ix:nonFraction> shares of the Company's common stock for $<ix:nonFraction unitRef="usd" contextRef="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQzOTgwNDY1MTU4NjM_4e4c957e-3404-4274-9195-c7dd4d952e04">35,000</ix:nonFraction> on January 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Precigen closed a public offering of <ix:nonFraction unitRef="shares" contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzExOQ_e8d63711-5d85-4df9-8015-53a3e7d03d74">6,900,000</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i9ae95dbfa1fb42c993e1fed2a97942b1_D20180101-20180131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzE2MA_987dd5e0-f411-4963-8c8b-a5550a0d41d1">1,000,000</ix:nonFraction> shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $<ix:nonFraction unitRef="usd" contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI2Nw_56967a15-a120-4ac9-961e-6aa99cd39c4c">82,374</ix:nonFraction>, after deducting underwriting discounts of $<ix:nonFraction unitRef="usd" contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMxMw_069cf137-99bc-4688-aa96-d2e5a0d8f09b">3,688</ix:nonFraction> and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzM0MQ_4a587558-d7ff-4545-8848-fb38811be21a">188</ix:nonFraction>, all of which were capitalized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 12, 17, and 23 for discussion regarding additional issuances of Precigen common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Lending Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the offering of the Convertible Notes (Note 12), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered <ix:nonFraction unitRef="shares" contextRef="i938616e63e9046f9b8b561f8f75cd7c5_I20180731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:OwnshareLendingArrangementSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzg1Ng_639f2c7f-6d56-43f6-a397-4391bc08df05">7,479,431</ix:nonFraction> shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzY1OTcwNjk3NzUxMzU_d9e7d0e6-80ed-4f13-b999-56a720a01b9a">five</span> business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i938616e63e9046f9b8b561f8f75cd7c5_I20180731" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzE2OTQ_309caafe-5069-4b68-bf94-0a5ee8358df2">13.37</ix:nonFraction> per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of AquaBounty Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic3792a1ad213496a8d41cfdce5e38535_D20190301-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI2ODI_8e60d74a-66cb-428b-a3f1-8a35a0867fa3">6,611</ix:nonFraction> after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i184114ce7b3f42b58ddf4c429939454e_D20180101-20180131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI5ODE_8306f168-3477-4611-beee-c8c4298c29a6">10,616</ix:nonFraction> after deducting discounts, fees and expenses. As part of this offering, Precigen purchased $<ix:nonFraction unitRef="usd" contextRef="ie79bf4a7c0c64ef68087d0bb20da73a2_D20180101-20180131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMwNzU_1cf05bd5-4301-4ea4-b1e4-f02c699c10fa">5,000</ix:nonFraction> of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="icf7bc616c8ee45679cdc730430d0f09a_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMyNTI_1064190b-763e-4028-a225-32656872e348">4,316</ix:nonFraction>, including $<ix:nonFraction unitRef="usd" contextRef="icf169456400e4ce8aeed85e7ca335ce6_D20181001-20181031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMyNjY_a32491b3-bbc3-45e7-8dde-cd671acdf99d">3,077</ix:nonFraction> from Precigen.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQ0MjA_671d76fd-1a14-4409-86d6-5caa91348da8" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d40ed18f6934798ba07115922d698e0_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzItMS0xLTEtMA_2bff1576-c62c-4061-b275-0fe0a63d4427">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb78e848d959475a8e60240fef86d616_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzItMy0xLTEtMA_2f25f975-2a67-4827-9669-43d188586bf4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) on foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258e6ee1096c48f3bafa2a89b56d3570_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzMtMS0xLTEtMA_461f5ef0-7eb4-4c65-afb4-f6001aace1c5">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7408085271934977bcbe87b303ee566b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzMtMy0xLTEtMA_56c20b6b-13ab-4967-b35f-d8e93dc826e2">27,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5035cb92632a453d81e2f99ab37a6a4d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzQtMS0xLTEtMA_0c050b4e-d75d-4af9-973f-8eb39ee4b13a">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c7b560b46b448dab6e990b87500645_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzQtMy0xLTEtMA_087a0064-8cf7-4bf8-93bb-9a3fd6b7ad66">27,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMjA_e1929a82-e39f-4941-91f9-5f0097700d6d" continuedAt="i651b030c508449ab87766376d50d76ea" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i651b030c508449ab87766376d50d76ea" continuedAt="ie5d5c87b81f9459d8fc77bb94971060e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTY_853a3d63-35ae-4746-8e06-d2a04561c5b7" continuedAt="i59f024928b2f4e18b43b023232626f98" escape="true">Stock-based compensation costs included in the consolidated statements of operations are presented below:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><ix:continuation id="i59f024928b2f4e18b43b023232626f98"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507bf64ce91c4dbe855ace68943a9ff1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItMS0xLTEtMA_044d83c5-3796-4ecc-a8d7-767727b8fb85">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0809b9c1122b4425b82973aa53316a00_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItMy0xLTEtMA_4e592c2e-ab5f-4098-b650-290ceeb9057f">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if630c00264644a5f934f6c52739e171f_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItNS0xLTEtMA_958ba80d-f776-4315-a303-5570b43912a9">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b4d072e6db4429be9358d98ef2695d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtMS0xLTEtMA_897f3b82-adb8-4c0b-a233-425457956a34">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6fd3bf62174baf8ea4e643cd5ee2a8_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtMy0xLTEtMA_8a348c6a-20c4-462a-a4af-5e2b256c5a72">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc9ff4a3e6143fe87ea8e2e89c9f0d2_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtNS0xLTEtMA_e3c17f2f-a1d3-4d4a-b70a-eaa4d2ed709c">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1be10c992143819d5ff797b4bdd3b5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtMS0xLTEtMA_2ec5c74e-f101-4f65-9875-5fa896b5f9c6">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb66d1f63fcb401b899173c39dea5ef6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtMy0xLTEtMA_49c9c123-9b6e-4711-9a7c-10a6e86ba0e1">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12981139b134339950cececc0d8cefd_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtNS0xLTEtMA_f43bb2df-48e4-4349-8174-1338f1db3c76">5,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793cc475e5a349a38e9012cbdf287644_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtMS0xLTEtMA_5781753e-5f52-4296-a6be-83b08be97c50">17,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db0821a8b444dd48ee9d160de991bf8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtMy0xLTEtMA_6ec97d86-490f-43f0-a004-9822edd60a59">11,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b44220e572445a7aaaedaab0fba9599_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtNS0xLTEtMA_1b5125bb-29cb-45be-a487-f638ea865f36">25,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib33202a64c764d2294be298ec498bf0e_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtMS0xLTEtMA_5b2af002-1b56-4d68-9867-e79fb3ae03ad">1,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd4e1dad5ab4578a892678be6523d79_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtMy0xLTEtMA_f3df47e8-bb18-415d-a7b0-38319a11a316">3,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04130b19133407c8ffb14a7cdb84896_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtNS0xLTEtMA_3d016b3e-3b86-477f-84e9-d2497948e180">5,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctMS0xLTEtMA_b366b899-4893-4dc2-a366-b1d702242dba">18,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctMy0xLTEtMA_ed784d5b-d9d0-4ec7-9e14-b6af7bcbd79e">18,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctNS0xLTEtMA_67d93494-7f48-44ca-a0a8-fa8debcd82c6">36,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Precigen Stock Option Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), <ix:nonFraction unitRef="shares" contextRef="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzgyNg_413902ea-9e8b-46ed-a869-caa41a0a521d">no</ix:nonFraction> new awards may be granted under the 2008 Plan. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1Xzg5Nw_79469737-ca9a-42e4-99d5-83f05c8bcac3">185,078</ix:nonFraction> stock options outstanding under the 2008 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxODI_f87719f3-4fb2-41ff-8501-b214ba0847b2">27,000,000</ix:nonFraction> shares authorized for issuance under the 2013 Plan, of which <ix:nonFraction unitRef="shares" contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzEzNTA_cd2d3f63-2b0f-4c94-8983-6dcd7f019388">10,225,570</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzEzNzE_40fdac22-ce34-4c9d-b9f8-9424cf1c6f69">1,176,629</ix:nonFraction> RSUs were outstanding and <ix:nonFraction unitRef="shares" contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE0MDA_d967f5d9-beb5-4cc7-a567-60257e6680f2">7,055,010</ix:nonFraction> shares were available for grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE4MDU_2f320281-7872-43ef-a171-29b5daabde37">5,000,000</ix:nonFraction> shares authorized for issuance under the 2019 Plan, of which <ix:nonFraction unitRef="shares" contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxNDE_ca2a8f29-cdd0-4220-a3ec-1f4bb86c87a9">845,248</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxNjU_0c2fa17a-29fd-468a-9350-fc5856144558">551,083</ix:nonFraction> RSUs were outstanding and <ix:nonFraction unitRef="shares" contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE5MDA_b2229464-c5fe-4beb-a504-63a9119ea1f4">2,432,624</ix:nonFraction> shares were available for grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have <ix:nonNumeric contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzY1OTcwNjk3NzU0MDk_08a9cb76-cabd-4924-a4b6-55bbfdb07620"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzIzMTI_4cc47823-fc59-4c2e-9a60-e59fdaca78a8">ten</ix:nonNumeric>-year</ix:nonNumeric> terms and vest <ix:nonNumeric contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzIzMzU_bf3d5161-b148-4d1d-96e5-be50c5b72c9a">four years</ix:nonNumeric> from the date of grant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ie5d5c87b81f9459d8fc77bb94971060e" continuedAt="i05529d28f5644ddcb158088d48c8b4be"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMDk_0d899db7-a49b-4737-8b16-b2c80dad5ab0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3ec59376227463da776d509a74f26c7_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtMS0xLTEtMA_ad071af7-3d83-4281-98e5-46f37dab76d3">11,382,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3ec59376227463da776d509a74f26c7_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtMy0xLTEtMA_0eab2524-5f5e-4aba-bc49-7d63f9aba421">28.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtNS0xLTEtMA_e4282566-2bd9-4052-a6c2-9e25d128bdbc">7.32</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzItMS0xLTEtMA_a05b5191-5e72-4751-bd3f-aac7144ee34a">1,470,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzItMy0xLTEtMA_456be612-1941-4b18-9d4f-35aa69acced6">14.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzQtMS0xLTEtMA_3a14f26d-07f7-4285-840e-9a0f105955ce">45,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzQtMy0xLTEtMA_8e24db03-00f8-4d4d-abc9-24343845ce24">6.59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzUtMS0xLTEtMA_4722c311-70e0-4d96-9b68-b9671efe9de4">929,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzUtMy0xLTEtMA_ef0348b9-1dcb-4876-afc6-da928e8134ea">21.48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzYtMS0xLTEtMA_54a1d435-d8bf-4180-b49b-bbab2dfd35c8">785,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzYtMy0xLTEtMA_09c8bffa-64d5-4348-a1b8-316c8a2e9440">26.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctMS0xLTEtMA_1796de51-e71d-49e4-a2ad-3a4cd3adb86f">11,093,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctMy0xLTEtMA_fc04f34b-cd3b-4e2b-93ff-c0d528bb2d86">27.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctNS0xLTEtMA_ea905e48-f1b7-42f2-86f2-03af1235e4f8">6.81</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzgtMS0xLTEtMA_86a38a9d-9e97-4d84-b102-fb19e3342b74">1,556,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzgtMy0xLTEtMA_9d948b85-e886-4d20-9a12-affe6466b6e3">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzktMS0xLTEtMA_5bcef2b8-7483-44d2-9806-80ffd69672d0">19,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzktMy0xLTEtMA_f8713253-615d-4d42-abc1-ca113df8c644">3.17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEwLTEtMS0xLTA_88464658-292f-41a9-9943-1517f2a8b799">1,236,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEwLTMtMS0xLTA_93601681-3faf-4938-a08f-533bee7fafa5">24.92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzExLTEtMS0xLTA_d3829b25-6881-46db-aa3d-1c9effb02a47">2,371,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzExLTMtMS0xLTA_c6721ffd-331d-45a3-b85c-87eb8434c20a">38.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTEtMS0xLTA_3c1fa560-87cf-426b-89b6-d2862904dcd5">9,022,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTMtMS0xLTA_10a8cb7e-5533-4da8-b42b-e1af56318c74">21.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTUtMS0xLTA_9ae62756-e609-4e33-ab4f-21ffce6f4761">6.10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEzLTEtMS0xLTA_e3fbed7c-3698-459a-91e6-363073a27704">5,693,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEzLTMtMS0xLTA_e5b4f4ca-e2fd-4833-8959-80dd5dc3374c">10.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE0LTEtMS0xLTA_983e660e-2678-4c46-a2c1-be5571a0975f">30,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE0LTMtMS0xLTA_6d165e7a-9c52-453e-9501-4de4a56ccd93">3.88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE1LTEtMS0xLTA_a7085b9a-f0a9-46e8-a881-605452700dc1">976,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE1LTMtMS0xLTA_53934c61-b4c0-4ac4-9370-baa5a2ba6ec8">15.47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE2LTEtMS0xLTA_d181f0ab-bb0a-4f9d-bb42-52cd535703b8">2,453,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE2LTMtMS0xLTA_c70ee6a9-5ddd-4d30-a4d7-b5a0135be19b">26.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTEtMS0xLTA_0c97482e-17a4-433f-a15e-239c730c9d7a">11,255,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTMtMS0xLTA_902010b4-3342-4468-abc0-482980a41de9">15.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTUtMS0xLTA_78f2efeb-1777-4862-a030-f31fa5105496">7.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTEtMS0xLTA_307bec45-d59a-42ed-8115-54c27cc68eb6">5,437,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTMtMS0xLTA_a01b1deb-c7bc-4125-8b7d-5e72beffb684">19.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTUtMS0xLTA_d5dec43f-e4a4-4ef1-88bf-7827fab53157">5.61</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation costs related to unvested awards as of December&#160;31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI0ODE_ad964341-e0a7-4325-ab91-67d1e16d9c1a">13,842</ix:nonFraction>, and are expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI1Njc_4cdaa388-3e27-4ec9-b890-c7ab0911461d">2.75</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2NTg_340a0560-64df-4fb3-b433-2dc328fabc8a">2.98</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2NjI_2a256675-f3f7-414d-9fd3-b4306af27d2b">3.79</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2Njk_1ac874b3-6540-4bdb-805d-e8ac6d0f5700">7.94</ix:nonFraction>, respectively. The aggregate intrinsic value of options exercised during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3NjM_fd8cc3e6-7aa1-453c-9094-6e088d39f1f7">51</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3Njc_72a27a96-5df4-4875-8646-f752cc1b7dd0">66</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3NzQ_16a6df2b-04ad-4b54-9353-4d053a77c4cb">356</ix:nonFraction>, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTM_ff1620d5-fc6f-4687-a530-7cd541734b19" continuedAt="i99ed4c2a33144443b27d034724b8253d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMC0xLTEtMA_64581347-98e0-438d-9c56-62ab144559f5">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMi0xLTEtMA_f77acc18-95de-4106-b1c6-3c1e6e3c80fa">5.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItNC0xLTEtMA_321961d8-9ced-4bec-b342-f3d0fde7d655">3,259,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItNi0xLTEtMA_9270202c-a9b1-4936-875d-a32c68aba692">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItOC0xLTEtMA_1def582a-2349-4b9f-b6d2-4a1205fe6afc">8.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTAtMS0xLTA_bc6b55b8-c23f-4cec-a134-e428dd876c3d">18,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTItMS0xLTA_2cd000d1-bafa-4253-8e21-cab897ef24db">1,271,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTQtMS0xLTA_0c450353-146e-4da8-ac87-e9c0d9a1af1e">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTYtMS0xLTA_bd29fc97-362f-4560-9b68-fbbfeeb115f3">8.73</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTgtMS0xLTA_37acbbf2-9548-4c9a-89d3-f4078a8aca7f">9,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMC0xLTEtMA_7be89c09-4472-4c34-9f48-f61ca4a51609">6.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMi0xLTEtMA_15b267bf-e0ae-4c82-a33a-4c637a6d9db7">15.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtNC0xLTEtMA_bfd1ac66-050d-4cfa-aeff-c6b4c0345ee9">2,261,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtNi0xLTEtMA_19993252-d674-44f7-93d8-428b2cc2097a">11.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtOC0xLTEtMA_aaa8c596-b101-403a-8b71-0c5dfc79f08c">8.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTAtMS0xLTA_2358c55c-f40f-43f7-abc3-c790ffc5024b">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTItMS0xLTA_2a700251-bb92-49b9-8c47-dc9b95831e01">345,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTQtMS0xLTA_5af7f639-301d-4f55-872f-f4d6e0bd7551">9.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTYtMS0xLTA_51061ebc-5d83-462f-822c-31e220a33833">4.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTgtMS0xLTA_92de3d05-739a-4bb4-b386-9b9bae2a8600">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMC0xLTEtMA_70be1292-ff1d-41b5-b7a4-008eb04f373c">15.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMi0xLTEtMTcwMA_ff7df371-11b9-4e31-b0de-1a5bb6ebf824">20.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtNC0xLTEtMA_f8cc158c-626b-4f20-9a03-516e1ba46dbb">3,028,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtNi0xLTEtMA_53a83f37-3404-4f91-a521-c1043bfc7207">18.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtOC0xLTEtMA_7b150a62-e420-4dee-b55b-db30722e6f2f">7.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTAtMS0xLTA_2af1e4e9-099d-4752-a53f-bbf030c6df2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTItMS0xLTA_a8743b2b-19a2-406c-bf9a-01adc92d3dbc">1,216,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTQtMS0xLTA_9816e64c-ff46-40c6-bd11-b9d912925357">19.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTYtMS0xLTA_c7f1f92e-6591-4e28-ad00-db73d29b12ba">5.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTgtMS0xLTA_4cea8974-6511-4d4f-9c7d-626e867b0e5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMC0xLTEtMA_458661e9-78f4-47cb-8a90-e6819674183f">21.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMi0xLTEtMA_438ad919-68c4-4245-bf3b-c160f1597f45">36.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtNC0xLTEtMA_1715dc16-01c8-464f-bd58-71a93d876894">2,303,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtNi0xLTEtMA_f66294b4-3927-4bc8-96e7-b1406b4e2665">26.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtOC0xLTEtMA_54e659ba-c627-4504-8d0b-0c848a1df81c">4.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTAtMS0xLTA_66ad208e-cd03-4eba-9d40-7d1f69d0da05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTItMS0xLTA_9d300989-c83c-41a4-b053-4dc0a39114de">2,200,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTQtMS0xLTA_ca5c0005-187f-48a0-a16d-1122388d9aab">26.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTYtMS0xLTA_28e8cfc6-8f56-474e-a000-4195a2341c57">4.22</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTgtMS0xLTA_6e29f2db-d79b-4c36-a6a2-ef33e96c5290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMC0xLTEtMA_2ea02c56-693a-4271-b5fd-b4c47cdc3ca3">37.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMi0xLTEtMA_a0b74e2f-9f2a-4b8d-ae23-8a915879ddd1">47.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtNC0xLTEtMA_70b1cf8d-efe9-4f58-9cc9-b44775ff12b6">403,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtNi0xLTEtMA_65430317-d1d7-4472-be47-1f26e72cb774">42.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtOC0xLTEtMA_38c05950-8dca-411b-9ff0-4e6d5ab86265">4.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTAtMS0xLTA_a1a5f32a-0479-405d-96f9-f25dcb74603c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTItMS0xLTA_ff40702b-8a41-4020-bbf9-fa054ebc278a">403,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTQtMS0xLTA_93ecc817-edda-465e-9449-8ab37f4ee0a9">42.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTYtMS0xLTA_0442accb-072a-4113-a04d-395b0bd61f42">4.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTgtMS0xLTA_0ae5674f-2827-40e7-a2ad-63a1b0f7ea28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctNC0xLTEtMA_b9675b11-e063-4425-b967-6accb3a4bd5e">11,255,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctNi0xLTEtMA_6e5fc448-8efb-46b4-bec3-eae24380228d">15.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctOC0xLTEtMA_c1f03ad3-72f0-4774-91cb-85498345b393">7.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTAtMS0xLTA_463bd404-d76d-4bd8-82f5-0fb78e488fb9">19,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTItMS0xLTA_42992251-3800-4d19-957d-7a54202e7c2f">5,437,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTQtMS0xLTA_88687913-cb8b-410a-a093-175ca3080402">19.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTYtMS0xLTA_353671dc-d4a0-4f58-9e4a-b416776ccdc5">5.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTgtMS0xLTA_0ba23820-0451-407f-9783-479421136f9b">9,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i05529d28f5644ddcb158088d48c8b4be" continuedAt="ibffc1c4e314d4d6c8e4b1f42acc12fdd"><ix:continuation id="i99ed4c2a33144443b27d034724b8253d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMC0xLTEtMA_077869b0-2b96-49a5-8174-38641573368b">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMi0xLTEtMA_cd936058-70a1-4e38-a724-380fb1b1abc9">8.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItNC0xLTEtMA_87dd945b-b239-49c0-9b11-4db812da91ed">1,612,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItNi0xLTEtMA_77bf6e5d-b42e-4b36-b777-c70d35424436">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItOC0xLTEtMA_c0462ce6-9f84-417a-af2c-512df306c520">8.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTAtMS0xLTA_ac8d004a-bb20-4dd0-a451-2ee070749abe">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTItMS0xLTA_bed6c5db-a38e-4269-ada8-9f3a36461eb7">585,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTQtMS0xLTA_24fee8d1-b926-4a5b-8c14-277f54632e3a">5.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTYtMS0xLTA_2f26cd09-3064-4dca-ab43-58b4c9267f0c">5.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTgtMS0xLTA_98dbd3ce-7999-4fbb-979c-8dfadbe25b00">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMC0xLTEtMA_1661c376-151d-42d4-8503-8b3bb1f725a9">8.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMi0xLTEtMA_fb681298-14ba-4c60-a267-63ebd64b5fdb">20.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtNC0xLTEtMA_4209b15e-5b94-4edf-9f34-ac8c84e76fec">1,278,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtNi0xLTEtMA_8627ad12-8bcb-40dc-9273-3867afa24863">15.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtOC0xLTEtMA_15876988-5dd4-4bc4-a103-eef50523f624">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTAtMS0xLTA_3be24d5e-fd94-4ed6-b226-7fded2956550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTItMS0xLTA_845facb4-8326-4f12-ab03-c89b1874ba0b">753,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTQtMS0xLTA_a22287fa-4e6c-4396-8bce-824b64e4abfc">15.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTYtMS0xLTA_9b8e9ff4-86df-4a45-9971-d13b9dd53153">5.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTgtMS0xLTA_68b5c107-ef11-4cb2-80d4-368354e040c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMC0xLTEtMA_5dcc6399-e8fb-436c-b809-9198a70db3e8"><ix:nonFraction unitRef="usdPerShare" contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMC0xLTEtMA_9f9588c0-3ddc-41c6-bce0-5dc9519dd81e">20.94</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtNC0xLTEtMA_31f73026-cba0-4066-bb48-37840d498319">1,646,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtNi0xLTEtMA_ac67eb54-01e5-4531-acf8-bc2dabb1c371">20.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtOC0xLTEtMA_be1337c0-6a44-4f89-9dfe-1c4e7c4a86ae">6.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTAtMS0xLTA_56adab87-1e8e-4d32-8c17-175001b79595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTItMS0xLTA_fa3f5030-89ec-4840-9a48-946e4b2d46a1">892,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTQtMS0xLTA_539fcdd7-6d79-435b-9a83-31632be7e126">20.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTYtMS0xLTA_abaafafc-6749-4d88-9abb-375b4ae757b5">6.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTgtMS0xLTA_8daba2e9-cbd7-4047-bc52-9e29412f643e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMC0xLTEtMA_aebf93d5-eece-4214-bb11-20c98fdf5ac9">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMi0xLTEtMA_97f175c6-be5c-427d-a140-b1ebd45e9f24">29.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtNC0xLTEtMA_5a8b13af-9851-4033-92fd-41dc4bc7c6e8">1,976,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtNi0xLTEtMA_6dd1886e-a658-41a6-82d4-7b49da392529">23.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtOC0xLTEtMA_ca937bdd-13bf-4e08-a389-b163e82270d5">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTAtMS0xLTA_42c80521-07b4-4bd8-afd8-e6d3bbd5a02b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTItMS0xLTA_dc7aae06-bb8c-4397-9802-f1fb40d4f21e">1,585,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTQtMS0xLTA_a98346e2-5475-4e0e-826f-8bdd4d0c4660">23.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTYtMS0xLTA_1e4a1937-bc5a-42ec-976d-c5f0a91bda81">5.79</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTgtMS0xLTA_2959d08a-1f00-4c58-b0f3-cc9563c0e324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMC0xLTEtMA_a360695d-1fc0-44be-ab6a-14ddbf2b7dab">29.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMi0xLTEtMA_2575b6d8-c2f0-4828-8b53-ea8c0d547b1c">65.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtNC0xLTEtMA_33b858ff-d934-48bf-8e36-320366cb65d2">2,508,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtNi0xLTEtMA_67756dcd-43e4-4b08-bd2b-648eb0c73280">34.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtOC0xLTEtMA_bd2809d1-ee7a-4e8d-9263-9a6f4216f63a">4.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTAtMS0xLTA_4d9e8566-ed9f-43df-b091-64f3c8925bc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTItMS0xLTA_ee8b5ae6-89c4-4fa0-8bea-616549cad969">2,448,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTQtMS0xLTA_1b0b6c49-39e2-4c87-893d-d01451fbc3a3">34.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTYtMS0xLTA_8a5474cb-0d1f-4e3c-a0d1-661337f77d98">4.33</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTgtMS0xLTA_d5523d4b-fbfe-4fdc-a866-a3171eb53810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctNC0xLTEtMA_e609655b-80d1-44ab-a87e-d4ccbaf5a33b">9,022,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctNi0xLTEtMA_0695cfe2-1ea7-43b1-96bd-35327153f05d">21.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctOC0xLTEtMA_096baac3-3631-4ee1-b9ef-4830b3124811">6.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTAtMS0xLTA_d7c9486d-9a79-450e-882f-ea7c8a57b95c">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTItMS0xLTA_2bc24dc6-bca0-41ba-a474-8e03294b5d4b">6,264,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTQtMS0xLTA_ff4129dc-48d1-40eb-952f-99f95a75c640">24.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTYtMS0xLTA_6f9c0e90-1b89-4493-9a93-08d309b7ab36">5.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTgtMS0xLTA_0b9b3f30-ca1c-4269-acbe-d69deaf0d3b5">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTg_7f896e78-9d5e-4cb5-92dc-f68b9b322299" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3ec59376227463da776d509a74f26c7_I20171231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMS0xLTEtMTcxMw_3f2ceed3-2e69-4fe4-8465-a6c169e38dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3ec59376227463da776d509a74f26c7_I20171231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMy0xLTEtMTcxMw_b3d69197-ef41-4d46-be1d-162f93c18322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtNS0xLTEtMTcxMw_8f4cf2b7-5d0f-4c19-b7f0-371595bb3486">0.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMS0xLTEtMTcxMw_74935450-afff-400d-b8c7-d7a58558aa5b">1,069,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMy0xLTEtMTcxMw_a7740db7-bb58-40ab-88e2-8c64a9d1acae">13.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMS0xLTEtMTcxMw_6873f230-ad4c-4b3b-8d1a-57365a7c925c">25,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMy0xLTEtMTcxMw_844fe9cb-8ce7-42fc-9999-ce65af980003">15.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMS0xLTEtMTcxMw_f20f50e1-c213-42c8-a420-db9f5f71123d">73,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMy0xLTEtMTcxMw_7001d795-88a2-4d0d-a50b-725866ebbfb1">13.47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMS0xLTEtMA_24ab316a-9b95-4bb5-a481-dde757a82d92">970,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMy0xLTEtMA_a2cc4a15-b16c-4087-8d26-c41c9684c5f5">13.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtNS0xLTEtMA_0143bb34-775a-431e-9126-a556487ec5c2">1.43</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMS0xLTEtMA_85ac3dbc-7eed-4b85-b027-32649796d523">2,278,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMy0xLTEtMA_70dd1986-c60f-49d2-ab57-c4f542bb7cfd">6.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMS0xLTEtMA_5ec425aa-0313-4717-9a4e-c9d30f847c32">1,159,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMy0xLTEtMA_0a737018-3078-4bc1-b2e0-c712bb312841">8.74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMS0xLTEtMA_d978a58f-9101-4444-815e-7a8ceec7d90e">307,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMy0xLTEtMA_2adff320-3dfe-4ccd-89f0-4c2f2ddd12b4">8.99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtMS0xLTEtMA_1b321767-5bd1-4c09-bb24-0a48edd774d3">1,781,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtMy0xLTEtMA_c5df6fc6-502e-474e-a84d-777f3bbccb56">8.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtNS0xLTEtMA_9932a4f4-5672-4740-9b3c-ceb1fafeec02">1.24</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzYtMS0xLTEtMA_5d18a009-5f82-4bab-9826-c211e3a887c0">3,157,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzYtMy0xLTEtMA_5439cfdd-74ce-44db-8d42-3632bebab1bb">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzctMS0xLTEtMA_36f3b477-23eb-430c-96d5-7f2d14db6088">2,802,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzctMy0xLTEtMA_cefa6dcb-4c4f-46fc-b28b-f6c011580c00">3.99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzgtMS0xLTEtMA_a0f2baf6-164e-42a8-a884-5a25cf0ea1f6">409,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzgtMy0xLTEtMA_8bcb00ca-1f25-483f-b243-bcef0ad0023f">8.59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktMS0xLTEtMA_f48aa38c-8013-4afd-a8a1-a03fadb25f5a">1,727,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i523c931240534675a00b833db69b7b7f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktMy0xLTEtMA_444b4840-4141-433e-bd8e-e076bb1a2099">6.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktNS0xLTEtMA_e2b92e21-0d15-4486-a423-16d22e165f6c">0.42</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation costs related to unvested RSU awards as of December&#160;31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="id3a9238cdda843cd8e2b1cdc9a3927be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzMzOTc_20d82d72-d09e-4108-a4bd-d1b17dd0af88">4,188</ix:nonFraction> and are expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="id39bd16d2b0240b687313c2d206093e5_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzM0ODI_6c044122-5f75-4e2e-a6d1-3fea99e35661">0.75</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen currently uses authorized and unissued shares to satisfy share award exercises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Executive Chairman ("Executive Chairman"), who previously served as the Company's Chief Executive Officer ("CEO") until January 1, 2020, and as an employee and executive officer until September 24, 2020, received a base salary of $<ix:nonFraction unitRef="usd" contextRef="ic42f0609642c4f08b491b5e9e5e122cc_D20200101-20201231" decimals="-3" name="pgen:CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzM3NTI_0aa29dc4-e5ae-40c2-a7f8-91360cdc4447">200</ix:nonFraction> per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a <ix:nonNumeric contextRef="i10782278c1794d1c8b675aaa49765ed4_D20200101-20201231" format="ixt-sec:durwordsen" name="pgen:LockupPeriodOnRestrictedStockUnitShares" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzY1OTcwNjk3NzU0MTA_f6e1709e-5a40-49bf-b335-8156146248dd">three-year</ix:nonNumeric> lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month through March 2019 and based on the volume weighted average of the price of Precigen common stock over the 30 day period ending on the last calendar day of each month thereafter, and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Precigen and the Executive Chairman pursuant to the terms of the 2013 Plan. The RSU Agreement expired March 31, 2020. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="icc52713e7d8949749938bc75522e6d98_D20200101-20201231" decimals="-3" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NDA_ac334b75-b0b9-447a-97bb-172829b656cf">454</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i87018f1bd95f4a4f8cd3775dc1bdc558_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NDQ_7b10d31b-aa58-4fac-8dcd-0950aa998d6a">1,868</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i4889fe27e2cc4966b4f58c1e494a13ed_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NTI_aceb5c65-e532-4f58-a10a-c3e2cf1a68d6">1,956</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman. The new arrangement consists of (i) an annual retainer of $<ix:nonFraction unitRef="usd" contextRef="i53aa5fac20ac403b9bce2f3bbe67a3a5_D20200901-20200930" decimals="-3" name="pgen:CompensationArrangementWithIndividualAnnualCashRetainer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgwODk_7c009ff6-cef7-4995-a9ab-427e17975510">100</ix:nonFraction> payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibffc1c4e314d4d6c8e4b1f42acc12fdd">vested stock options having a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="i27caa5d0d3674cb8873fa0e6c545b8cc_D20200901-20200930" decimals="-3" name="pgen:CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgwOTg_4c6113dc-5ea8-45f0-bee4-22d19b4663c2">250</ix:nonFraction>; and (iii) an annual grant of RSUs having a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="i1a3e7401f5244362a8da8bdd6081990c_D20200901-20200930" decimals="-3" name="pgen:CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgxMDc_3f6cb14a-cfe2-481d-bf2f-2f83f26ff815">250</ix:nonFraction>. The compensation arrangement begins in calendar year 2021, and the foregoing elements were prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. The terms of the equity awards granted to the Executive Chairman are pursuant to the 2019 Plan.</ix:continuation></span></div><div id="ie210b0c7fc84429f915eaf73d0946948_181"></div><div style="margin-bottom:11pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODA_ad3e6dd6-64da-4222-9761-354bde7c6160" continuedAt="icb3f662e6eba4379848b8615333ccd34" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="icb3f662e6eba4379848b8615333ccd34"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM0NA_ddde4444-f884-4ed7-beb8-9b358f73343e">one</span> to <ix:nonNumeric contextRef="i0854d2b69b794445a113081a1772158a_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM1MA_c78bf1b4-57fa-41b8-ae26-e72d8fd61bea">nine years</ix:nonNumeric>, some of which may include options to extend the lease and some of which may include options to terminate the lease within <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" format="ixt-sec:durwordsen" name="pgen:LesseeOperatingLeaseTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzQ3Ng_4c1a8450-4254-4164-a9f4-959f458d5cd3">one year</ix:nonNumeric>. The Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions.</span></div><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODE_c9b79972-f08d-4b9c-ae1b-aee4edfea29f" continuedAt="if51560edfdb7492cb282f388e9ad6d43" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzItMS0xLTEtMA_9e3dc14c-79ae-42d4-ad10-0ea75027a9b1">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzItMy0xLTEtMA_039131d9-4e1b-42e1-92dc-c71385cbb0c5">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzMtMS0xLTEtMA_38c82878-3b0a-4a01-a760-d0dc3c459b85">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzMtMy0xLTEtMTAwMTA_e2fe4a3b-010b-48dc-9282-a46651bd6b85">2,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzQtMS0xLTEtMA_6e4d1bb4-94cb-4742-91c6-55bb9bec18ea">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzQtMy0xLTEtMA_508ea5f7-d928-41c9-b321-8fe6d3759fcb">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzUtMS0xLTEtMA_bacbe7bb-8d67-4678-a539-488e3a075410">6,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzUtMy0xLTEtMA_184dd92e-36aa-4f25-b035-05c36abd0731">6,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODI_3ff32045-4dc0-4fa0-9518-2e0d9eb50ef2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzAtMS0xLTEtMA_eb071ebc-1972-49c9-b104-034ec967289a">3,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzEtMS0xLTEtMA_cb5b86a5-af13-4f0a-ba91-25135cb1e67b">3,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzItMS0xLTEtMA_d09c79d7-bae9-4a14-a8d9-115b98206fd7">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzMtMS0xLTEtMA_b3180856-edc1-4996-85f4-9068424a447c">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzQtMS0xLTEtMA_dc22fc5f-84f4-4f11-aa1d-27a151a5734e">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzUtMS0xLTEtMA_2fee591c-28c9-49fd-8657-81ce4fcbc6ca">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzYtMS0xLTEtMA_865a40c9-a2c8-4c99-935c-00f007358625">12,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzctMS0xLTEtMA_cdc43fcb-1218-4435-9ae6-a3a2f84af445">2,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzgtMS0xLTEtMA_e32a4472-a957-4e37-b150-6d8a66af19e5">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzktMS0xLTEtMA_e3733666-ec63-4554-a89d-f2d8621cb2f6">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzEwLTEtMS0xLTA_56ba858e-c455-4c83-8e41-8b97f37dd3c5">7,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzExLTEtMS0xLTA_f1561b3b-782c-420a-aeba-e8e0af255cc2">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="if51560edfdb7492cb282f388e9ad6d43"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases in continuing operations was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzItMS0xLTEtMA_8f14fde6-b984-459c-bbda-ad3136032d59">4.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzItMy0xLTEtMA_9331d247-d1ab-4757-8313-533d9c770440">4.81</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzMtMS0xLTEtMA_b29a4ec8-8ef9-4d2d-943d-47357d8785d9">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzMtMy0xLTEtMA_b37da50e-8b23-4963-b60f-18eb0d8187f9">10.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzMtMS0xLTEtMA_2f9cf619-a75d-455c-b118-f2140d294d3c">4,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzMtMy0xLTEtMA_35a6d447-e068-40be-a867-2bf3c5a7c6d6">3,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets added in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzQtMS0xLTEtMA_2aa33b23-0eed-40ec-8080-8cf47bb08747">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzQtMy0xLTEtMA_0ba62d4a-8180-44aa-89be-158633452d72">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><div id="ie210b0c7fc84429f915eaf73d0946948_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzEwMDc3_458f2f78-3743-4a12-8b44-8e1dd2eccdac" continuedAt="iff9f352a31f143cea20cb01011630631" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="iff9f352a31f143cea20cb01011630631" continuedAt="i109ebbe88cfb426f8e603d8592fc7420"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2020, Trans Ova settled <ix:nonFraction unitRef="claim" contextRef="idf63e5924ca540d89aef4d0830021e64_D20201201-20201201" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxNzM_21a35cb8-7163-496a-af18-9997b1a0ed54">one</ix:nonFraction> of <ix:nonFraction unitRef="claim" contextRef="i590473c574a14f01bc57d3d29295299d_I20201130" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxODI_8a76ca23-8944-4ef9-a2b3-be6d1b6241ef">two</ix:nonFraction> patent infringement lawsuits brought by XY, LLC ("XY"). The lawsuit, originally filed in 2012, was tried and appealed between 2016 and 2020. On December 1, 2020, the parties reached a settlement resolving all remaining disputes. As part of that settlement, Trans Ova remitted to XY a settlement payment, which, in addition to all the other monies Trans Ova had previously paid XY, constituted full payment and satisfaction of the judgment, including pre-judgment interest, post-judgment interest, costs, and all past, current and future royalty obligations under the judgment. In exchange, XY released and forever discharged Trans Ova from all obligations arising out of the judgment. In addition, XY dismissed with prejudice its pending appeal. On January 8, 2021, the parties filed a stipulation of case termination with the district court.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second patent infringement lawsuit brought on by XY was filed in December 2016. On March 20, 2019, the United States District Court for the District of Colorado entered judgment under Rule 54(b) as to <ix:nonFraction unitRef="claim" contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzYxMTY_0fd916a1-0ede-4afe-95d9-b5219ff9dc13">ten</ix:nonFraction> of the <ix:nonFraction unitRef="claim" contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LossContingenciesTotalClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzYxMzg_4178017b-6ebf-4d09-baef-74e6af514d01">twelve</ix:nonFraction> counts of the operative complaint, dismissed those patent counts from the case, and stayed the remaining <ix:nonFraction unitRef="claim" contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgwOTc_0988d278-5a05-46e6-a032-ed1b33d26c08">two</ix:nonFraction> counts of patent infringement pending XY's appeal of the Rule 54(b) judgment. While XY's appeal was pending, <ix:nonFraction unitRef="claim" contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LossContingencyClaimsInvalidatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMDU_a2f5ca20-6bee-43dd-9170-41f297dcf1a7">one</ix:nonFraction> of the <ix:nonFraction unitRef="claim" contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMTM_50fba674-af6e-49f9-859d-bca935c7be27">two</ix:nonFraction> patents remaining in the case was separately invalidated in a different district court proceeding, which XY did not appeal. As to the <ix:nonFraction unitRef="claim" contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgwODM_262f9538-a65f-4aa9-9fe3-be9cbf777670">ten</ix:nonFraction> dismissed counts in the suit XY brought against Trans Ova, XY appealed dismissal of only <ix:nonFraction unitRef="claim" contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LossContingencyAppealedClaimsDismissed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMjE_0d2b556d-026f-4afe-8716-b4565305a6cf">four</ix:nonFraction> of them, each alleging patent infringement. On July 31, 2020, the United States Court of Appeals for the Federal Circuit reversed the district court's dismissal of those <ix:nonFraction unitRef="claim" contextRef="if53067c947c6445b99c0734630919c2f_I20200731" decimals="INF" format="ixt-sec:numwordsen" name="pgen:LossContingencyReversedClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMzE_9c3b350b-34e9-43ac-a4e3-6de20b0854bb">four</ix:nonFraction> patent counts and remanded the case for further proceedings. The Court is assessing next steps of the case, including an amended scheduling order.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While this patent infringement lawsuit is pending, Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of district court and appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company's disclosures regarding its methane bioconversion platform. The Company produced documents to, and met with, the staff of the SEC and voluntarily cooperated with the SEC investigation. In September 2020, the Company reached a final settlement with the SEC regarding the matter. Under the terms of the settlement, the Company, without admitting or denying the allegations of the SEC, consented to the entry of an administrative order requiring that the Company: (i) cease and desist from committing or causing any violations and future violations under Section 13(a) of the Securities Exchange Act of 1934, as amended, and Rules 13a-11 and 12b-20 promulgated thereunder; and (ii) pay a $<ix:nonFraction unitRef="usd" contextRef="i162c6a00ebd8403087aaba03e9e7257d_D20200901-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1MjY4MTk_e79a7be9-e61a-4dc6-8892-d543895c2598">2,500</ix:nonFraction> civil money penalty to the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, <ix:nonFraction unitRef="claim" contextRef="i163004d1571347a9896c92d4b1ec572f_D20201001-20201031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1MjY5MTU_407f6376-1ab6-4380-9d76-93b040d9bf53">three</ix:nonFraction> purported shareholder class action lawsuits, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abadilla v. Precigen, Inc., F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chen v. Precigen, Inc. F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seppen v. Precigen, Inc. F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, were filed in the U.S. District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims track the allegations in the SEC's administrative order described above. The plaintiffs seek compensatory damages, interest, and an award of reasonable attorneys' fees and costs and have filed motions to consolidate these claims. In December 2020, a derivative shareholder action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. The complaint names as defendants current directors and certain officers. The plaintiff's claims track the allegations in the SEC's administrative order described above. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 10, 2020, the Company received a notice of arbitration from Harvest pursuant to the Collaboration Investment Opportunity Agreement dated March 13, 2015. In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231" decimals="INF" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI0NjA_b592c1dc-cb32-47d0-9889-d3ae8adc45a7">2,117,264</ix:nonFraction> shares of its common stock to Harvest valued at $<ix:nonFraction unitRef="usd" contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI0OTI_f4f778ff-0b37-48a6-b983-abbc908079b9">18,103</ix:nonFraction> in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Exotech Bio, and AD Skincare, which the Company had $<ix:nonFraction unitRef="usd" contextRef="i59907113dd1d4344981247aabca5ca34_I20201130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI1OTQ_824783d9-6016-4645-8ad1-a535d113ba41">6,993</ix:nonFraction> of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $<ix:nonFraction unitRef="usd" contextRef="i2615524a66c943229cbd226d85d96e2a_I20201130" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI3MzE_42bd017a-57e3-4e7d-87cb-0b10bd85ff03">326</ix:nonFraction> prior to the settlement agreement; (iii) the commitment of Harvest to take reasonable commercial efforts to transfer its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i109ebbe88cfb426f8e603d8592fc7420"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid, resulting in a loss on the settlement agreement of $<ix:nonFraction unitRef="usd" contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI4NTk_40e4f89d-a1d1-41cc-a061-be4cfa74cb74">11,436</ix:nonFraction> which is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2020. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including the IEP Investors and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of December 31, 2020 and 2019. These disagreements and disputes result in management distraction and may result in litigation, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company's business or operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December&#160;31, 2020, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzY1OTcwNjk3OTI5ODU_87c1d258-503e-43e5-8e66-72920f3cc17c" continuedAt="ide7da8e55cbf441791359f539fbf4398" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ide7da8e55cbf441791359f539fbf4398" continuedAt="i80d4fcf664c746f9bbbbfd296d68f97c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Security and Affiliates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns <ix:nonFraction unitRef="number" contextRef="ifb40c1f06726442485a1ee1321b1baa6_I20201231" decimals="INF" name="pgen:RelatedPartyOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIxMA_76dca096-0fb5-43b7-a8c8-7bc8e3ba1781">100</ix:nonFraction>% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximated $<ix:nonFraction unitRef="usd" contextRef="ib672478b9e8e43829ba3dd9807ad3e12_D20190101-20191231" decimals="-3" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzE0MDM_75497651-63ad-40fc-b79c-988265bcbc33">800</ix:nonFraction> per month. In 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month and issued to Third Security at the end of the month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the <ix:nonNumeric contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231" format="ixt-sec:durwordsen" name="pgen:CommonStockCalculationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzY1OTcwNjk3OTI5NTI_cf867d39-d44b-4f11-8c61-140036c2330e">30-day</ix:nonNumeric> period ending on the 15th day of the calendar month when the applicable services were provided. For the years ended December&#160;31, 2019 and 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIzODA_9e139204-8d1d-48f8-8a25-a16a5e47c1c2">1,606,062</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIzOTU_48d2ffdf-e44b-4d45-b781-4e3ee99e0758">696,033</ix:nonFraction> shares, respectively, with values of $<ix:nonFraction unitRef="usd" contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI0Mzk_6cc99970-ae4d-441c-b2e8-f0bba0981ecd">8,233</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI0NDc_d21b3671-8607-4d04-a1cf-c67b9c1d54ad">8,324</ix:nonFraction>, respectively, to Third Security as payment for services rendered pursuant to the Services Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf prior to and after the expiration of the Services Agreement under a separate agreement. The total expenses incurred by the Company under these arrangements were $<ix:nonFraction unitRef="usd" contextRef="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231" decimals="-3" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NTk_6c3a20ff-4e04-4139-b67b-921b76cb2789">159</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231" decimals="-3" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NjM_6999262b-3106-415f-9833-0d16bd68c269">26</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231" decimals="-3" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NzE_e080e86b-3943-4c76-a771-eace3e6611ed">47</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $<ix:nonFraction unitRef="usd" contextRef="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MDM_4f8d8987-974b-4606-b4d2-7f204431e5b5">83</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MDg_025eef88-b1ac-43dd-ac75-a467df392cbd">89</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231" decimals="-3" name="us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MTc_84d5d37f-97c4-49cd-871f-72f8c9548a7c">89</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 15 regarding compensation arrangements between the Company and its Executive Chairman.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Equity Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Equity Facility, the Company could, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $<ix:nonFraction unitRef="usd" contextRef="ib87f8cebc3d94d3a9961d37fd3d97771_I20171031" decimals="INF" format="ixt:numdotdecimal" name="pgen:ConvertiblePreferredStockAmountAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzMzNzA_3941684e-e733-4f1f-ae55-31d20694804b">100,000</ix:nonFraction> of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). In conjunction with the Company's July 2018 registered underwritten public offering of Convertible Notes (Note 12), the Preferred Stock Equity Facility was terminated. <ix:nonFraction unitRef="shares" contextRef="i599bfce00a9945d9b726ceb46d1b4829_D20171001-20180731" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzM2MjM_7dc0838f-3793-41eb-82bd-90858aed07d5">No</ix:nonFraction> shares of Series A Preferred Stock had been issued under the Preferred Stock Equity Facility.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i80d4fcf664c746f9bbbbfd296d68f97c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 1, 3, and 14 regarding additional transactions with affiliates of Third Security.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with ECC Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM previously acquired through collaborations. In conjunction with the ZIOPHARM License Agreement in October 2018 (Note 6), the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the year ended December 31, 2018, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0670171b99994e70abea87f63ac354ea_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:NoncashDividendIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzU0MTg_23233ef6-4289-4db9-bca0-979d6e649754">14,793</ix:nonFraction> of dividend income in the accompanying consolidated statement of operations. Following the transaction in October 2018, ZIOPHARM is no longer a related party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Castle Creek, and warrants to purchase shares of Castle Creek common stock previously acquired through collaborations and other transactions. As a result of the acquisition of Castle Creek by Castle Creek Pharmaceutical in December 2019, the Company received $<ix:nonFraction unitRef="usd" contextRef="i70be85e7d3844aaca71c406b666d60d6_D20191201-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzcxNzI_30426a5b-baf4-4bc2-b45f-d46d05299841">1,280</ix:nonFraction> in December 2019 for its shares of Castle Creek common stock and received a total of $<ix:nonFraction unitRef="usd" contextRef="i89a435ac6ca244c79163f5df75db8e16_D20200101-20200131" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzcyMzg_0624c9b6-23f6-4281-a134-264848e894b2">3,311</ix:nonFraction> in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The $<ix:nonFraction unitRef="usd" contextRef="ic063de9522b3438b84804a067d67c361_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1Mzc0MjE_d10daa8a-8f05-492c-8661-1ad4749c5a6f">3,311</ix:nonFraction> is included in receivables on the accompanying consolidated balance sheet as of December&#160;31, 2019. The Company recognized a total gain of $<ix:nonFraction unitRef="usd" contextRef="i1e54f6e16a9443f0a47fc8c8084f977e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzc1MDc_bcfce0c4-5903-4658-8bf2-bac4112d9bcd">3,222</ix:nonFraction> on the change in fair value of these instruments, which is included in total other expense, net, in the accompanying consolidated statement of operations for the year ended December 31, 2019. Subsequent to the acquisition by Castle Creek Pharmaceutical, Castle Creek is no longer a related party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company mutually terminated ECC agreements with <ix:nonFraction unitRef="relatedparty" contextRef="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="pgen:NumberOfRelatedPartiesWithTerminatedAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1Mzc3MTY_be50a0c3-0a44-4d5b-9ca2-f4250123df5e">three</ix:nonFraction> separate related parties which resulted in the recognition of the remaining deferred revenue associated with these ECCs totaling $<ix:nonFraction unitRef="usd" contextRef="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzgwODQ_1f0fe52f-af5d-4078-bf37-db5d74f25320">11,877</ix:nonFraction>.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_193"></div><div style="margin-top:40pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM0Ng_82d7cc53-93d2-4d13-a6b9-4806ddabda87" continuedAt="if54a36428c9543caa684930b21fe68f4" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="if54a36428c9543caa684930b21fe68f4" continuedAt="i030b827a0c0749f58ae10ec61ef32ac8"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM0OA_08e90cd4-2b94-4b48-9f54-7a2543a79884" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtMS0xLTEtMA_b1400f56-e09b-41e7-8770-dacc69fd6003">103,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtMy0xLTEtMA_9dd64c9e-4aa8-4e6c-8db2-4b394eb7a802">168,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtNS0xLTEtMA_3fce35f9-5d9d-4ed8-b60f-77b855d3514b">375,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtMS0xLTEtMA_cdc12911-e812-456e-8fc9-be02a9f5a509">66,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtMy0xLTEtMA_8ec48dd0-7024-4dc7-9011-d9f32e4e0b7b">153,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtNS0xLTEtMA_fb7ace54-bdf6-4920-ab72-72dabca9127e">134,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtMS0xLTEtMA_0ab1be1e-50ae-48ee-bf0e-5da5f27d2620">170,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtMy0xLTEtMA_77db2edd-2ebd-4d02-a68f-ff1de72109a5">322,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtNS0xLTEtMA_c062ff8a-1b0c-42ff-aa5a-10a11ca6d134">509,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctMS0xLTEtMA_df60ff1e-2c01-4bd2-92d0-ed302bed3ae6">167,065,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctMy0xLTEtMA_b60169f8-e34b-46b2-8ff1-fd7fac0ceb04">154,138,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctNS0xLTEtMA_25002fea-aa4a-44b2-a54b-6222b4bdae33">129,521,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktMS0xLTEtMA_4569b10c-1d67-4976-b20b-d84667da1f25">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktMy0xLTEtMA_53c4a1a9-e3fa-48aa-ad9c-5e556203fc0a">1.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktNS0xLTEtMA_f44ff83e-1398-4b0f-b39d-c5d3fc8ec0d2">2.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen per share, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTEtMS0xLTA_f6ed29ef-633d-46d1-ab2c-d99d0c7da69e">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTMtMS0xLTA_c4a5b6a7-f4e0-4f32-8f0b-34a0450fd99d">1.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTUtMS0xLTA_ed638410-162f-4f7a-bfe7-448569e06ad7">1.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTEtMS0xLTA_0a6a0710-bf46-4eac-ba05-4117f8f841d1">1.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTMtMS0xLTA_fee5bcc3-e979-4473-8251-b48a5ecd956c">2.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTUtMS0xLTA_a404e5eb-c566-4f36-9269-94531a897100">3.93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i030b827a0c0749f58ae10ec61ef32ac8"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM2NA_2ce05e3c-65b9-4f2a-b79e-013a3b3d0ae4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities as of December&#160;31, 2020, 2019, and 2018, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f3e239ae20c45c7b7aaf57a9b6cf875_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItMS0xLTEtMA_e2567761-d4ae-4209-a809-cd37e605839a">11,732,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b50be6f05c0474e83a58face9d3645c_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItMy0xLTEtMA_3befa157-0a21-4a8f-a5cf-87d279267646">21,323,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c1e80d080904677b59656be2a1b40b2_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItNS0xLTEtMA_7ab311a4-3565-4462-9ebc-265317b862ca">18,955,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f71aeaa143c4b289ab59dfbe54174aa_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtMS0xLTEtMA_308df600-4ded-4432-9038-37894077a762">11,255,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib379ad98b2cb45daaf83b5b7a21cc98e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtMy0xLTEtMA_0f3cc204-ddec-41db-a25d-412011b07a96">9,022,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7adb4d0947454afaa177f45a75cc9d60_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtNS0xLTEtMA_55382cc5-9208-4f3c-a3d0-890bd0197253">11,093,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27fb0d7ad0b6498ea08417bed7233684_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtMS0xLTEtMA_c6dd9b65-7b7a-42cf-9030-a6772db46d64">1,727,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2017226d1f364332a399d4d0f2c037e2_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtMy0xLTEtMA_88a80284-501a-474d-b804-c6d59491bb4f">1,781,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ee46d4ad6348e8955c1243244ba4e8_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtNS0xLTEtMA_be1589d0-1ca6-43e7-b79a-20c307d8e120">970,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife7c17ddfd9e4cfe8f7cfcc1d3d89d94_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtMS0xLTEtMA_0c5b0a49-a0f3-42a9-9f6a-8470854ad8a1">133,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc1d30c65b074157a537d57ad73c2775_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtMy0xLTEtMA_48c1f48b-74cb-493c-ba7c-5b94914763a7">133,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2c9e1d13159420db631b851192aed69_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtNS0xLTEtMA_eb8f8d2a-0a15-4e19-b06d-3eafca3076e3">133,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtMS0xLTEtMA_427196c7-fd52-45a7-9e82-2227a70a6b51">24,849,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtMy0xLTEtMA_6ccc89f6-face-45a3-8b6d-b4e804973ab1">32,260,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtNS0xLTEtMA_1403d502-a7e2-4c08-8387-ae29dc9e2127">31,152,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_196"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTY_84ffd0d2-3e2d-4506-87ec-5e9413096606" continuedAt="i5c1cb342432e4788a84d4ebe8bef75cb" escape="true">Segments</ix:nonNumeric></span></div><ix:continuation id="i5c1cb342432e4788a84d4ebe8bef75cb" continuedAt="ia650efe0b4e44a09987b796f6d83ba9b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realigned its business in April 2019, and as a result, its CODM began regularly reviewing disaggregated financial information for various operating segments. The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise.&#160;The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the year ended December 31, 2020, the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. The Company also excluded noncash losses associated with settlement agreements. Segment Adjusted EBITDA for the years ended December 31, 2019 and 2018, were not impacted by these changes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results.&#160;The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment.&#160;Corporate expenses are not allocated to the segments and are managed at a consolidated level.&#160;The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed.&#160;The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December&#160;31, 2020. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which in 2020 and 2019 included the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Castle Creek (Note 6). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ia650efe0b4e44a09987b796f6d83ba9b" continuedAt="i9c6e7f55ce144527961341033f8d1146"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTQ_82e675f9-ec37-45c9-8875-d084a09cfed6" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information by reportable segment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8404b30334554a8282ddc4963025afb9_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMS0xLTEtMA_876a4e0b-4761-441b-be6c-87b8949050ae">15,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11002969f3e4f0b9cad7acc95c9688d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMy0xLTEtMA_e6aa2ca0-5b56-4d6a-a48c-6d4afa67b0f4">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816e511c14e944e784ccf02ef49dcfc1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItNy0xLTEtMA_182d20a1-dfd3-4bb4-92f3-28438aea252d">46,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6adeb8393ffb4cd9af54545b7f666403_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItOS0xLTEtMjExNA_f0f7bf32-1024-44a2-8a66-50dfc5293041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416c63b209e448e4a1691314a0e720fc_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItOS0xLTEtMA_2e2299e1-8749-4e7f-91f6-85b89df00fcb">20,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de8331b876d4b82921c05eee138928f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMTEtMS0xLTA_8eb70488-373d-46b5-a675-6e469df30d0f">83,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reallocations from changes to reporting units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMS0xLTEtMA_1d4f7cff-d727-466e-b47e-c6dc932fabd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMy0xLTEtMA_77a37129-4c62-4211-b42f-99fb00dd7de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtNy0xLTEtMA_a3717ad2-da7c-43ab-82fc-b970b0201957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtOS0xLTEtMjExNA_746a0dc9-eab5-4078-bff1-af48ac8edf68">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtOS0xLTEtMA_0025137f-20fe-4c85-bf62-8de8537ffdcc">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillTransfers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMTEtMS0xLTA_969aed6b-6c2c-4702-b781-f6d89bbe287c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMS0xLTEtMA_6cc370f3-087d-4705-bc51-c903d0d15fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMy0xLTEtMA_68e4c07f-7b34-4917-89dc-7621fae9aec8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtNy0xLTEtMA_06c18b64-f4fd-4893-8335-96247c81d106">29,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtOS0xLTEtMjExNA_5f452505-1dcc-47db-a022-a1f80a79c103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtOS0xLTEtMA_a852a676-b17a-426f-a80e-968eaeb632e8">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMTEtMS0xLTA_530fce25-691c-4f55-8f8d-08a58347b8bf">29,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMS0xLTEtMA_5ad1bfc2-8456-461c-a6c1-6e1dc661dffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMy0xLTEtMA_139b5a68-660c-467d-8f04-f517a91d8894">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtNy0xLTEtMA_38597be2-8627-448f-9197-4c35934dcf5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtOS0xLTEtMjExNA_ddf175a0-4f11-4d64-8c9a-31989008c5b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtOS0xLTEtMA_d9ed2c0f-aef4-46d6-b56c-6ff9c4c8db6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMTEtMS0xLTA_8b55caa3-ae3c-4cf7-906b-39815afb3229">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f84542b3ea54137a7e7be5308c1f271_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMS0xLTEtMA_ffa7b89c-a730-40eb-9982-3cae30a44b3c">15,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49361cac902b4125a327a91917c78be8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMy0xLTEtMA_5e466d5d-0569-4223-a881-bdba3e319034">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87036dbc7d542818b7d1e05ad396f7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtNy0xLTEtMA_f5f07d0c-b19c-43d3-9b48-a810e0d55be5">16,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efccfc60d644e148ff53a1aea8fb101_I20191231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtOS0xLTEtMjExNA_a58402a3-0859-4333-b972-c2f551d710bc">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65e43c5c8a9408d98dae73506aec312_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtOS0xLTEtMA_6ee71cbb-786f-4441-a1d0-8668b6af3982">20,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142de93e903443e4ab31cfa896a0f6c4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMTEtMS0xLTA_aec6ccda-5031-40ca-a531-357759ba0e00">54,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMS0xLTEtMA_460c5568-d043-4671-91a7-fbbfbf641431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMy0xLTEtMA_b49ecfbb-7289-4f25-8639-093befbc521b">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktNy0xLTEtMA_629a2740-e98a-4792-8e49-760333afa5a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktOS0xLTEtMjExNA_82366c4e-2225-4a71-98a8-b4cccf641d8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktOS0xLTEtMA_b3f0c704-ba5c-40c6-922a-e3d3f975270f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMTEtMS0xLTA_8b9a6788-d168-419a-86d4-9eb0a71bdcfc">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05ba222657c4da3a7946904d64b7cda_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTEtMS0xLTA_aab2c48d-523a-4a37-a7c1-85a4628e2d26">15,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45928d9759c446fd8135abd8ae21531c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTMtMS0xLTA_9e1bb648-f445-4a89-8f53-4a4f63024b2b">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c851ce2bf04d2d8ee0ae2363c3095c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTctMS0xLTA_c6d0c973-d6c4-4cc6-90df-f5e76da99bbd">16,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6efc76794cd4f70892c233dfb405b21_I20201231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTktMS0xLTIxMTQ_e95e7867-1476-482b-98e9-9e02559a94f8">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec754f7c8fe345e9a691b4617bc583a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTktMS0xLTA_cb08bb9e-b8ad-4ff8-b209-e65e147fc6a5">20,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1856a6ee6ec445a2a3d19b2ec22d5c69_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTExLTEtMS0w_902ffa46-7a8d-4382-a9d0-8e8dde38d08a">54,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMS0xLTEtMA_db7749d9-6ce5-4d30-a957-90813c3dee7e">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMy0xLTEtMA_9b5220db-2bf6-4ff4-aebb-54ecb8911169">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItNy0xLTEtMA_0c610d13-2385-4a2e-8118-27d1c2230db9">71,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItOS0xLTEtMjEzMQ_208b88c3-cb7b-48c1-bf47-0661568aecfc">17,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItOS0xLTEtMA_8ab3617f-bedd-446f-a531-119a71eb4410">10,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMTEtMS0xLTA_4b25f295-843a-4297-a68f-1f425004a237">103,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6153d68f9fcc4906bd9e9cd50a4813d6_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMS0xLTEtMA_87df99a6-17a0-4e62-ba66-680a0b580446">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ab2a93de6ee44cf97247286fbd7e13b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMy0xLTEtMA_82721c36-e4d7-4aa5-a617-f48076e32409">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04441decbc7f413abc71cd43fc461da1_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtNy0xLTEtMA_141fae14-b366-436b-bab9-2d6dcbe10d3b">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4ba24eafed49019e6ec63aabe7a182_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtOS0xLTEtMjEzMQ_31b66241-f2a5-4659-9156-198e82b0f058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1adcf1f7e2814c5a98b167b18ede27d8_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtOS0xLTEtMA_3025143a-27b5-42c6-874d-5c2974723b33">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57be64036b41497caa88c720697751d4_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMTEtMS0xLTA_377a902d-70f5-45af-bd81-30c3968e9b34">5,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMS0xLTEtMA_817521dd-d2a4-469a-9370-2e579b617984">5,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMy0xLTEtMA_162755cd-778f-47bf-8dca-1dc7e3375e4d">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtNy0xLTEtMA_8a155fef-b3e4-415b-beb4-aed18c577bbe">71,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtOS0xLTEtMjEzMQ_6f156b0c-decf-4561-b5d1-fd0dae92c65f">17,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtOS0xLTEtMA_4b0e7cc2-caad-48bd-90fd-6269ef4bc02f">10,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMTEtMS0xLTA_926bd9a5-8338-4039-a3fd-2679f384df1f">108,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c2727e865d423586be763a463a4aeb_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMS0xLTEtMA_c9c686ac-3f05-4a32-bce2-d9793c4d63ff">25,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idadd9097495e4bc7a7045a8c4457de90_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMy0xLTEtMA_65fad4e5-2429-4404-82d0-4e17b89f891c">7,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafa1b4c69804dfd96a439a35168dfc0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtNy0xLTEtMA_4cdca778-07f0-4aa5-bbe8-d9d8c8b84909">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d3a6d84abe14c848540902462585373_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtOS0xLTEtMjEzMQ_24657508-632a-45df-a653-cef3f453a51e">2,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtOS0xLTEtMA_891033cb-7a33-4ceb-8678-541da5e3b4cb">4,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMTEtMS0xLTA_6c6d1b29-46e4-4182-acdb-8f907ad109eb">28,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMS0xLTEtMA_b8c0b7aa-d9ec-4c0e-9e3d-1d1d29fb2fdd">2,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMy0xLTEtMA_9a6c683b-68a5-46b5-8f28-0c47d0a6c89f">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItNy0xLTEtMA_00f0e0ec-0440-481c-b7c6-bfc0aa0cbb24">68,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItOS0xLTEtMjE0Ng_4f922186-ea81-429c-b326-eff607c86730">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItOS0xLTEtMA_082eb1ee-8ed8-419a-af8f-3dced4a0a3df">12,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMTEtMS0xLTA_46553483-a2f3-4720-81c7-6916aa0828e7">86,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b2a762b98949cc80b92e79db724b1c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMS0xLTEtMA_17bdbdee-81f7-4347-a62d-43ca9ceb6658">11,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bed861874412b9f1e982a3d5b7883_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMy0xLTEtMA_4322c66e-377d-4ced-a778-61653e307299">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b5d19dccb34749ad0bdd8bddb68e52_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtNy0xLTEtMA_bf4334b9-2ce5-41bc-ad5c-49150e2c1acb">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62d85ceb878414ab0381b19dae2d6e9_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtOS0xLTEtMjE0Ng_c0cdd07b-0eb3-4fb6-b335-f0c23923259e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50dbf2c0e31425c97e6391b41ca69ab_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtOS0xLTEtMA_0d2ef95e-0f52-49fe-b2a0-f151afd96422">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMTEtMS0xLTA_c23d1f9a-992e-4663-81c6-c91cf16adc7a">14,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMS0xLTEtMA_b621e97a-5b2e-4e82-8d7e-1953a2bed513">13,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMy0xLTEtMA_9f3b8a81-7e94-43bf-921f-afe8e8d1b7f6">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtNy0xLTEtMA_dbb0fef1-df28-4f24-9a43-0aebfacf87c9">70,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtOS0xLTEtMjE0Ng_8a6d25d8-869b-497f-a5a2-babbd0db8678">3,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtOS0xLTEtMA_676344af-6179-4c28-be6e-96c4b55027a8">13,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMTEtMS0xLTA_563dbfe6-1c80-4aa4-b446-03a8ec678cf8">101,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i163a14083d2840e7b31ad5dfcf65b399_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMS0xLTEtMA_1892aadb-42a5-4008-9e19-99272a561982">30,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736231a7920a4f7da29a6de5b917aa57_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMy0xLTEtMA_44260a92-2899-42f6-af91-f171068aba67">13,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtNy0xLTEtMA_35ae4a4e-c6c7-48e6-a65d-39ff280b60b4">6,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfdd8a57941e4059a00f31f76dafd79e_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtOS0xLTEtMjE0Ng_d5853d92-0aa9-410e-8187-2682c01d4bab">1,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtOS0xLTEtMA_3eaf5bdf-3165-4aef-b628-e3cceaad68b7">4,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMTEtMS0xLTA_fa9c8ff8-b6c9-4c96-822b-d7d77d4c6f3a">56,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMS0xLTEtMA_75ace042-1636-4827-a412-96b8b533abdd">29,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMy0xLTEtMA_892d9cb7-4929-445f-be4c-f8cfe1f4310a">6,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItNy0xLTEtMA_6b42d826-fb84-465e-89fa-8015c9ee5900">75,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItOS0xLTEtMjE2MQ_57a001b2-a883-43e4-899e-d871f4790221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItOS0xLTEtMA_438c0527-94a6-4b73-b88c-3439dbe2a262">30,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMTEtMS0xLTA_4a4f7b9d-f5c6-43de-8d20-5b54578bf212">141,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie213b50bea4c453b9fc821145579a6d8_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMS0xLTEtMA_a6c97f61-55d5-4ae6-9a9f-b4fe20167ad6">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eda440ff9e84b8aab723bc6229cafb9_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMy0xLTEtMA_097fb054-50b4-4d24-9057-0c20116a274a">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa651b05eb6d42d7956529f80d128fb4_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtNy0xLTEtMA_f4d8f10b-95b0-4cd9-8cb9-7ac10f608370">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ada1cfca67342dbb51b59cb99e04067_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtOS0xLTEtMjE2MQ_61114d2d-dc25-4dcb-9b85-2d0c48922621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if943aa72ff3a4b8ba9787819a93ee378_D20180101-20181231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtOS0xLTEtMA_4c7e3b88-7895-4a13-9009-6592430afc28">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMTEtMS0xLTA_0027dfc7-3559-4968-a9ab-17756f9f8839">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMS0xLTEtMA_c3352b14-468e-4c32-a4b3-8687a827a654">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMy0xLTEtMA_c9844665-f622-4d8f-ad9d-a6607482895f">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtNy0xLTEtMA_246d1864-60d4-4652-83ae-53cb02fbdd5f">75,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtOS0xLTEtMjE2MQ_3b1be7f1-fb7a-4e5a-bb73-00aa9977ea92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtOS0xLTEtMA_b3158340-6731-4aa5-b7b0-184a7724b68d">30,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMTEtMS0xLTA_8da398f4-8bf2-4dce-9579-9fe413fe081a">143,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4927248b8114f8fa633cd593f9b134d_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMS0xLTEtMA_1779f91a-0539-4b9c-b321-bcf6176abb8d">32,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ad89a96f44459196c39386869a91e4_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMy0xLTEtMA_650521fe-4246-4166-9732-2bab415b93f0">12,797</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b87aa4811c44854b9ddc4b70159d6f6_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtNy0xLTEtMA_50d0f094-e7c4-4b67-a49e-2382d8859cd7">5,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f203cb6a2c84a37a5bda3f93b68e7a3_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtOS0xLTEtMjE2MQ_cd92a4c5-6c51-4be7-a622-53c40395d37b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtOS0xLTEtMA_9f3bf82c-d6da-4060-a540-2797df00ffa1">10,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMTEtMS0xLTA_23c9135c-6808-499c-9173-c29bd31a5375">62,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTU_c0a0b9fd-5d7e-42c3-84a1-f46550ec5751" continuedAt="iaf710ef940d749c685319edb6fafab19" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles total segment revenues from reportable segments to total consolidated revenues:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues from reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItMS0xLTEtMA_5d546549-87cb-4b78-a011-ee29ce46af64">98,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItMy0xLTEtMA_ae8fb1d3-3843-4c22-a93b-cb7d5cedb0de">87,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItNS0xLTEtMA_9a385f0b-3866-45f2-8efb-59d2485740b1">112,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues, including from other operating segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d70b9845a5b44eb94cdadc203be4f74_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtMS0xLTEtMA_af301417-5180-4f2e-b136-20b40be43864">10,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fd320c35794ded9d690fc67a61ee36_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtMy0xLTEtMA_dfd539f1-3caa-4c18-955f-c34f086ebd08">17,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6609bfdc1f48b586a5b70a92a8e8ff_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtNS0xLTEtMA_91da869f-c10d-4c5b-91df-f1b02e597c30">40,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4962cdf48204222844e9ce74fd74c3a_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtMS0xLTEtMA_c0ac12ff-8f15-467b-a3bd-f68715312459">5,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic93fa25606544244a088b1c2b2a76bc8_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtMy0xLTEtMA_70495894-9e2a-4de2-8e89-01dc02fdd329">14,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f9dcf0952c04e27a75572dcc547c1e7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtNS0xLTEtMA_539704c7-255a-4e01-8cd6-73b37918b13b">2,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtMS0xLTEtMA_5c071077-5eaf-4538-998f-6059f3ffa956">103,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtMy0xLTEtMA_9cda1038-940c-47cd-bf16-3d86ab5be427">90,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtNS0xLTEtMA_e389f3bb-8f3f-4e2a-95b7-91d668dcb742">151,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="i9c6e7f55ce144527961341033f8d1146"><ix:continuation id="iaf710ef940d749c685319edb6fafab19"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItMS0xLTEtMA_832cdc3a-d8dc-4f68-a3e5-dd9e547004bb">32,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItMy0xLTEtMA_11db10a5-b545-4131-9899-38bb39138b36">51,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItNS0xLTEtMA_003390eb-5805-465c-8797-69a6d23d46ed">51,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Segment Adjusted EBITDA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtMS0xLTEtMA_25e63e31-06c4-42e8-9f86-e34841849df5">4,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtMy0xLTEtMA_fdb7ba83-d40f-4929-b0a0-730e2aff00b4">4,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtNS0xLTEtMA_a8337878-cd84-4a05-87cc-2f3daad03d36">10,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remove cash paid for capital expenditures and investments in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CapitalExpendituresAndInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtMS0xLTEtMA_72ca49f4-5529-4875-a8ff-0369c33075e4">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CapitalExpendituresAndInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtMy0xLTEtMA_fdcd9574-7181-4c3d-87b6-8b3cc0c26880">12,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="pgen:CapitalExpendituresAndInvestmentsinAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtNS0xLTEtMA_05470cbb-7353-4f61-8c26-7feeafccdec3">15,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add recognition of previously deferred revenue associated with upfront and milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e2c484ec2494489bb341fdba607cadb_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtMS0xLTEtMA_55b8ae6b-5477-4e77-915b-91ac72689877">25,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71de56fffeb14a6988696974ced53186_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtMy0xLTEtMA_48ba4145-9d0b-43e8-94f4-ab347c9f1f59">14,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i714a0770b5544bb98754740acc834259_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtNS0xLTEtMA_239554be-4a65-4f7d-9954-985fbe046b26">33,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctMS0xLTEtMA_ae069b32-f5eb-4f82-974d-aaefdfdfa0f0">18,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctMy0xLTEtMA_c5134473-7c3e-4fd1-9ce2-d19122f56fb5">17,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctNS0xLTEtMA_48783402-f47c-41d0-a9eb-c107ad6dcc8b">8,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtMS0xLTEtMA_e88e7d33-18ce-4994-8fa7-22bdc6d5d76e">15,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtMy0xLTEtMA_7375de71-4f1e-4100-869d-5806be7deb87">16,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtNS0xLTEtMA_d02c146b-9559-4951-8c80-9916317b52ea">20,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktMS0xLTEtMA_81fb0f98-4d04-4303-a788-3c739f76d3ce">920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktMy0xLTEtMA_b37342de-80b8-4f0c-a1d5-963b6a9d3c01">30,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktNS0xLTEtMA_2deacb4a-e5bf-48d1-9197-0c3a2ad346fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquisition of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTEtMS0xLTA_2c08456e-16d4-493b-babd-ee6c4b17eb44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTMtMS0xLTA_d46cdf9e-5671-48ec-8bd1-342157d6a1c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTUtMS0xLTA_2825e40a-7d1b-4e0b-8e98-76ea79a343b6">236,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTEtMS0xLTM4NDk_e2f89ab3-500e-4827-b3a1-5c37bcb746ad">11,436</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTMtMS0xLTM4NDk_523ef463-4aef-47f4-bf19-56b7407ebd55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:GainLossRelatedToNoncashLitigationSettlement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTUtMS0xLTM4NDk_d918dbc1-2a66-485f-91fb-19ab5e3095d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTEtMS0xLTA_4d068fb5-c98a-4907-8e1b-55f9fdd3ae6e">19,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTMtMS0xLTA_9d19546d-3aaf-470d-9933-7a32f3b5ce74">15,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTUtMS0xLTA_80f4a2e9-4a64-40d6-992e-7d425d604236">30,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment related to accrued bonuses paid in equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:AdjustmentForBonusesPaidInEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTEtMS0xLTIxNzA_687c5e63-8283-4167-ada6-a06b580a3e8b">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="pgen:AdjustmentForBonusesPaidInEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTMtMS0xLTIxNzA_8244a322-3ff5-4cbc-a7a0-485c0958033f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="pgen:AdjustmentForBonusesPaidInEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTUtMS0xLTIxNzA_355a7664-5373-4cd6-b17c-8c6f111a8cf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTEtMS0xLTA_30d35d67-cebb-4515-a715-5af5f18a1c47">1,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTMtMS0xLTA_092c7c6e-45b8-4458-9bc2-09474cea5fc5">2,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTUtMS0xLTA_09a7c49a-4ae0-44f4-84be-54eb10412619">8,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTEtMS0xLTA_d9c7925e-34f9-4ca4-887b-6b44c3db3ec5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTMtMS0xLTA_4076a635-b4f1-4cb5-b353-b851dc0de576">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTUtMS0xLTA_99913ad7-f8dd-42b3-aa4c-8e0eb040cbb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i133129ec5f3246d683d35411173d33aa_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTEtMS0xLTA_6a63e3cc-1801-4ddf-b4f4-811ab9019323">37,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13c8be8caa2f46178129d4ec229adbb2_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTMtMS0xLTA_6b068164-f27a-4fd4-9f3d-f719b270cc26">46,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9b2874d2bdd4deb9104cb8ea4baf8de_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTUtMS0xLTA_6977f0a5-67fe-401a-9d68-ae82d327db66">74,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57be64036b41497caa88c720697751d4_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTEtMS0xLTA_995098ab-524c-4989-95c8-23c0f24f9b7b">5,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTMtMS0xLTA_9068db8c-49d9-4b1c-b6a3-5d925feac087">14,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTUtMS0xLTA_c29f486b-518e-4246-8a45-1d7dac22eeb5">2,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTEtMS0xLTA_fa4dd1f8-99fe-4fdc-aef5-62ac305ff197">103,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTMtMS0xLTA_9eb105a7-a5e1-4f6a-9401-eed93d67b1fd">171,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTUtMS0xLTA_f038644e-4f21-47c7-8f3f-d56c8c22feb8">395,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8166ea8ff5b14ea1a56f75013f866d68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMxNjA_f6c2bd85-d368-4fc8-ba37-49da05b9674f">5,908</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibb6c9fa8b50d4640b4010be6ab64cc36_I20191231" decimals="-3" format="ixt:numdotdecimal" name="pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMxNjc_a8eb3934-34cd-409d-87b9-f01102c35308">6,724</ix:nonFraction>, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $<ix:nonFraction unitRef="usd" contextRef="id4a62b5534d74990aab59d86bee4c7e1_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNTI_dcf5c392-e415-4474-a013-9b5ef3991f5f">595</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i8d1a0c4bdf624f5a9be5028ebfc27876_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNTY_613613b9-ac29-4da7-8b3d-e3a0316d493e">1,401</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i8e7a12392b3748ccb33c84786aaae792_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNjQ_aaccf619-29fc-488d-805e-cff98266be76">6,255</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_199"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90ZXh0cmVnaW9uOmFmNDIyZDcxYTEwYzQ4MDU5ZTM1OTdkNDlkODVlZDk5XzEwODY_6a0e2f27-7900-4e89-b80f-eb5b0bb5ef0e" continuedAt="ia7eba25db6984a8690cbde9097b1f879" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ia7eba25db6984a8690cbde9097b1f879" continuedAt="ib701ad3dec2e445cb9dd812e79c96f44"><ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90ZXh0cmVnaW9uOmFmNDIyZDcxYTEwYzQ4MDU5ZTM1OTdkNDlkODVlZDk5XzEwOTc_710baea1-5068-430d-ba98-dba751eec8de" continuedAt="i854aecdd6ce04dd1a559a47fffceff1d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItMS0xLTEtMA_863c5d58-13b0-439a-8f25-a9b73f7eec12">29,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItMy0xLTEtMA_b6f2c6b1-ba99-4113-9c85-6c2ae8d0cc2f">30,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItNS0xLTEtMA_f37b20fb-3cf1-430f-9adb-2c09a4ae5a13">23,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItNy0xLTEtMA_217a241a-a419-488e-9ce8-2d11f85ce23f">19,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtMS0xLTEtMA_712577b0-289b-4308-bd52-c215a044e603">16,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtMy0xLTEtMA_fe8516c2-b57d-4fb1-bd7b-a90723e231da">11,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtNS0xLTEtMA_073e7f2a-8180-4920-ad41-11f7a024a4ec">23,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtNy0xLTEtMA_d6200738-635d-456d-af6d-af7758d13ee4">35,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtMS0xLTEtMA_f6c9d01e-59dc-4df1-91a4-843ce10f03f0">20,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtMy0xLTEtMA_48c49972-163c-475d-8294-51366c3b6b08">15,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtNS0xLTEtMA_a68de76d-d241-4aea-9668-aeba318b3bfb">27,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtNy0xLTEtMA_2b367a15-7534-4a00-a529-50cd67630879">39,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtMS0xLTEtMA_ca97d6c4-143e-4ea1-a15d-e4813b3ad2fe">55,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtMy0xLTEtMA_0bddbab4-cfa8-4465-a418-f15559e2fc6d">43,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtNS0xLTEtMA_7b223c98-a02a-455d-a065-95a431b252fd">29,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtNy0xLTEtMA_bec5c6e8-1b52-43af-ae27-d6dc08277690">41,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtMS0xLTEtMA_f99efede-65c6-4109-8b3d-2228f5f123aa">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtMy0xLTEtMA_5db781f3-d4c4-4a27-9970-11e07c4a85df">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtNS0xLTEtMA_08bc89d5-5a85-4f74-8d0b-b389731105e4">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtNy0xLTEtMA_e20e173c-2c3c-4bf1-bd49-a30dc6099eb1">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctMS0xLTEtMA_82245c8b-0517-44a3-80ad-ebdef8943e7e">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctMy0xLTEtMA_a0c17ca1-a53e-49b4-8835-b4e0623b2424">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctNS0xLTEtMA_3b3b6fd6-266e-48bd-b295-237f034a4f36">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctNy0xLTEtMA_6171f7d2-a388-4103-95e5-d81169308e5a">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:20pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7">Contents</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie210b0c7fc84429f915eaf73d0946948_7"> </a></span></div></div><ix:continuation id="ib701ad3dec2e445cb9dd812e79c96f44"><ix:continuation id="i854aecdd6ce04dd1a559a47fffceff1d"><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItMS0xLTEtMA_6e135b59-99c5-4f51-a759-78150e5a70b6">22,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItMy0xLTEtMA_08a4f570-c567-4db7-8de5-d49aebf3c11a">32,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItNS0xLTEtMA_72c946c6-91ca-47d2-b952-513fdf44d889">18,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItNy0xLTEtMA_ec4ddac4-f403-474a-8c85-e331bc6d1703">17,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtMS0xLTEtMA_9966c64b-e1b6-40f0-912a-d2a640591431">41,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtMy0xLTEtMA_6b4adced-3d79-4164-af5a-f50e376c35d7">21,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtNS0xLTEtMA_d6b49e6b-572c-4303-b611-fb62b932712d">34,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtNy0xLTEtMA_9f9b93a0-6eb6-4b91-9e4e-f40b9d07cb63">68,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtMS0xLTEtMA_2635eae6-cb50-4e19-a221-db03b8872301">44,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtMy0xLTEtMA_1708b554-0ea6-45cf-9a4a-fb47cf71a46c">22,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtNS0xLTEtMA_45257e0e-c089-46c8-937b-1888606db3b9">39,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtNy0xLTEtMA_14905d32-0417-421d-bdbf-531931261cb8">64,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtMS0xLTEtMA_0b2086aa-77c3-41e3-b04a-e71ee2f1b52c">60,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtMy0xLTEtMA_18ec40c3-ef01-45b2-87b9-1e27d07edcce">38,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtNS0xLTEtMA_5f47fc9a-c0cd-4eb1-8dff-07579e1ecd15">53,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtNy0xLTEtMA_0c616586-bd82-4ff4-a600-b2adfb0828f5">169,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtMS0xLTEtMA_99515707-922f-4231-8b87-275e3d886dc6">0.28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtMy0xLTEtMA_c4deb10f-d7ed-451f-a4a5-56ee8e7a2637">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtNS0xLTEtMA_c361bb69-83fc-4b84-afaa-579ac9020237">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtNy0xLTEtMA_76df87df-be4b-44af-b774-95d863199641">0.41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctMS0xLTEtMA_6c091756-3a35-4b80-8d0c-6cacd77fb475">0.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctMy0xLTEtMA_a08b0b56-1cf7-4871-9809-786e82ed8f40">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctNS0xLTEtMA_3d33914a-018d-4ebf-8de0-f39a0684dc12">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctNy0xLTEtMA_9b768b1c-98dd-41de-97b2-e0d05e1d2855">1.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).</span></div></ix:continuation></ix:continuation><div id="ie210b0c7fc84429f915eaf73d0946948_202"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzM3MA_2869fcdc-d388-4986-82c4-d153bf7543e7" continuedAt="ia9e14d5ddf2e4064883b28a715121c46" escape="true">Defined Contribution Plans</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia9e14d5ddf2e4064883b28a715121c46">The Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $<ix:nonFraction unitRef="usd" contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMyMQ_e56dbd49-6e29-46f7-ac73-bc817cf05a18">873</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMyNQ_860af679-8745-4f70-80bb-46b1c62a89a1">1,186</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMzMg_99423a6e-6836-4195-b7f5-3f12e6cda670">1,392</ix:nonFraction> for the years ended December 31, 2020, 2019 and 2018, respectively.</ix:continuation></span></div><div id="ie210b0c7fc84429f915eaf73d0946948_205"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23. <ix:nonNumeric contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzU0OA_a7177bc7-62c5-44a3-9f0e-c829b69b492b" continuedAt="iccc71863bb0e4abc97b0df6aec2dbc63" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="iccc71863bb0e4abc97b0df6aec2dbc63"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed a public offering of <ix:nonFraction unitRef="shares" contextRef="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQ4MTk_d10889dc-2f7d-48ed-972a-7f7eead1010e">17,250,000</ix:nonFraction> shares of its common stock, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQ4MzE_9ecda68e-e355-4282-8628-34732bd4c7ff">121,200</ix:nonFraction>, after deducting underwriting discounts and estimated capitalizable offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility which were originally due to expire in July 2025. The Company will record the impact of this termination as discontinued operations in the Company's consolidated financial statements during the first quarter of 2021. As of December 31, 2020, the right-of-use asset related to the lease was $<ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQzNzM_71772ee5-d75b-4d4c-989a-cba256541b80">9,131</ix:nonFraction> and the lease liability was $<ix:nonFraction unitRef="usd" contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="pgen:DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQzODQ_6632db69-fd4b-4d86-90f1-74e59bbdfda5">13,428</ix:nonFraction>, which are included in current assets held for sale or abandonment and current liabilities held for sale or abandonment, respectively, in the consolidated balance sheet. Following January 2021, the Company has no further payment obligations under the lease.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>pgen-20201231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2883582dc9ea447c85e66997462b1b37_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">List of Subsidiaries of Precigen, Inc.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Domestic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exemplar Genetics, LLC</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genomatix, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GenVec LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon AB, Co.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon CEU, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MabLogix, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MBP Titan LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PGEN Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen ActoBio, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen ActoBio CED, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen ActoBio CRS, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen ActoBio Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen ActoBio T1D, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ProGentus, L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova Genetics, L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Triple-Gene LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unicell Bio International, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ViaGen, L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XON Cells, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ActoBio Laboratories Belgium BVBA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(besloten vennootschap met beperkte aansprakelijkheid)</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ER Cell LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon ActoBiotics NV </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(naamloze vennootschap)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Precigen BioInformatics Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trans Ova Laboratories India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>pgen-20201231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iba3eaf7986b64e3889bbf639f8561610_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in Registration Statement Nos. 333-239366 and 333-249172 on Form S-3 and Registration Statement Nos. 333-190614, 333-196840, 333-205642, 333-213065, 333-219874, 333-226821, 333-233209, 333-233211, and 333-239367 on Form S-8 of our reports dated March&#160;1, 2021, relating to the financial statements of Precigen, Inc. and the effectiveness of Precigen, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baltimore, Maryland</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2021 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>pgen-20201231xexx232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib3898a48364b492db21336716fd5ddd1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-190614, 333-196840, 333-205642, 333-213065, 333-219874, 333-226821, 333-239367) and Form S-3 (Nos. 333-220326, 333-239366, 333-239366) of Precigen, Inc. (formerly known as Intrexon Corporation) of our report dated March 1, 2019, except for the effects of discontinued operations discussed in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section within Note 3 and the change in composition of reportable segments discussed in Note 20, as to which the date is March 2, 2020, and the effects of discontinued operations discussed in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MBP Titan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section within Note 3, as to which the date is March 1, 2021, relating to the financial statements which appears in this Form 10-K.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atlanta, Georgia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2021 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>pgen-20201231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if867d2f75f6a41369b3aa98358b6b6f9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen Sabzevari, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Precigen, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;HELEN SABZEVARI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Sabzevari</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>pgen-20201231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia1ca01bb49dd4c618d2849ee1e278201_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Rick L. Sterling, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Precigen, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;RICK L. STERLING&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rick L. Sterling</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>pgen-20201231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if8abb23f87e3434580486d15ac5c6076_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen Sabzevari, Chief Executive Officer of Precigen, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;HELEN SABZEVARI&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen Sabzevari</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>pgen-20201231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1b4d3be9f9b04f3280a48b9bd219b8c5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Rick L. Sterling, Chief Financial Officer of Precigen, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;RICK L. STERLING&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rick L. Sterling</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section&#160;906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>pgen-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pgen="http://www.dna.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dna.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pgen-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pgen-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pgen-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pgen-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.dna.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.dna.com/role/ConsolidatedBalanceSheets">
        <link:definition>100010002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations">
        <link:definition>100030004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations_1" roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations_1">
        <link:definition>100030004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsParenthetical" roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical">
        <link:definition>100040005 - Statement - Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>100050006 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersandTotalEquity" roleURI="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity">
        <link:definition>100060007 - Statement - Consolidated Statements of Shareholders' and Total Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100070008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsReconciliationofCash" roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash">
        <link:definition>100080009 - Statement - Consolidated Statements of Cash Flows (Reconciliation of Cash)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.dna.com/role/OrganizationandBasisofPresentation">
        <link:definition>210011001 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationAdditionalInformationDetails" roleURI="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails">
        <link:definition>240024001 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>210031002 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>220042001 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>230053001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>240064002 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails">
        <link:definition>240074003 - Disclosure - Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>240084004 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails">
        <link:definition>240094005 - Disclosure - Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.dna.com/role/DiscontinuedOperations">
        <link:definition>210101003 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.dna.com/role/DiscontinuedOperationsTables">
        <link:definition>230113002 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails">
        <link:definition>240124006 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails">
        <link:definition>240134007 - Disclosure - Discontinued Operations - Summary of Financial Results for MBP Titan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails">
        <link:definition>240144008 - Disclosure - Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsNarrativeDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails">
        <link:definition>240154009 - Disclosure - Discontinued Operations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails">
        <link:definition>240164010 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails">
        <link:definition>240174011 - Disclosure - Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails">
        <link:definition>240184012 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails">
        <link:definition>240194013 - Disclosure - Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersandAcquisitions" roleURI="http://www.dna.com/role/MergersandAcquisitions">
        <link:definition>210201004 - Disclosure - Mergers and Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" roleURI="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails">
        <link:definition>240214014 - Disclosure - Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinJointVentures" roleURI="http://www.dna.com/role/InvestmentsinJointVentures">
        <link:definition>210221005 - Disclosure - Investments in Joint Ventures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails">
        <link:definition>240234015 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails">
        <link:definition>240244016 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails">
        <link:definition>240254017 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenue" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenue">
        <link:definition>210261006 - Disclosure - Collaboration and Licensing Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueTables" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueTables">
        <link:definition>230273003 - Disclosure - Collaboration and Licensing Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails">
        <link:definition>240284018 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueAdditionalInformationDetails" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails">
        <link:definition>240294019 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails">
        <link:definition>240304020 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails">
        <link:definition>240314021 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1">
        <link:definition>240314021 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails">
        <link:definition>240324022 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.dna.com/role/ShorttermInvestments">
        <link:definition>210331007 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.dna.com/role/ShorttermInvestmentsTables">
        <link:definition>230343004 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" roleURI="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails">
        <link:definition>240354023 - Disclosure - Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.dna.com/role/FairValueMeasurements">
        <link:definition>210361008 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.dna.com/role/FairValueMeasurementsTables">
        <link:definition>230373005 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>240384024 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofLevel3InvestmentsDetails" roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails">
        <link:definition>240394025 - Disclosure - Fair Value Measurements - Summary of Level 3 Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>240404026 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" roleURI="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails">
        <link:definition>240414027 - Disclosure - Fair Value Measurements - Change in Fair Value Level 3 Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.dna.com/role/Inventory">
        <link:definition>210421009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.dna.com/role/InventoryTables">
        <link:definition>230433006 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://www.dna.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>240444028 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNet">
        <link:definition>210451010 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>230463007 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>240474029 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetAdditionalInformationDetails" roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails">
        <link:definition>240484030 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>210491011 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>230503008 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails">
        <link:definition>240514031 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>240524032 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>240534033 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails">
        <link:definition>240544034 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebt" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebt">
        <link:definition>210551012 - Disclosure - Lines of Credit and Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtTables" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtTables">
        <link:definition>230563009 - Disclosure - Lines of Credit and Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails">
        <link:definition>240574035 - Disclosure - Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails">
        <link:definition>240584036 - Disclosure - Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails">
        <link:definition>240594037 - Disclosure - Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails">
        <link:definition>240604038 - Disclosure - Lines of Credit and Long-Term Debt - Components of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails">
        <link:definition>240614039 - Disclosure - Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.dna.com/role/IncomeTaxes">
        <link:definition>210621013 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.dna.com/role/IncomeTaxesTables">
        <link:definition>230633010 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>240644040 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxBenefitDetails" roleURI="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails">
        <link:definition>240654041 - Disclosure - Income Taxes - Components of Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>240664042 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>240674043 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofValuationAllowanceDetails" roleURI="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails">
        <link:definition>240684044 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>240694045 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.dna.com/role/ShareholdersEquity">
        <link:definition>210701014 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.dna.com/role/ShareholdersEquityTables">
        <link:definition>230713011 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityAdditionalInformationDetails" roleURI="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails">
        <link:definition>240724046 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>240734047 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.dna.com/role/ShareBasedPayments">
        <link:definition>210741015 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.dna.com/role/ShareBasedPaymentsTables">
        <link:definition>230753012 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>240764048 - Disclosure - Share-Based Payments - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>240774049 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockOptionActivityDetails" roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails">
        <link:definition>240784050 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" roleURI="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails">
        <link:definition>240794051 - Disclosure - Share-Based Payments - Summary of Information About Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails">
        <link:definition>240804052 - Disclosure - Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.dna.com/role/OperatingLeases">
        <link:definition>210811016 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.dna.com/role/OperatingLeasesTables">
        <link:definition>230823013 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesAdditionalInformationDetails" roleURI="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails">
        <link:definition>240834053 - Disclosure - Operating Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesComponentsofLeaseCostsDetails" roleURI="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails">
        <link:definition>240844054 - Disclosure - Operating Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>240854055 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>240854055 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesLeaseTermsandDiscountRatesDetails" roleURI="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails">
        <link:definition>240864056 - Disclosure - Operating Leases - Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOtherInformationDetails" roleURI="http://www.dna.com/role/OperatingLeasesOtherInformationDetails">
        <link:definition>240874057 - Disclosure - Operating Leases - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.dna.com/role/CommitmentsandContingencies">
        <link:definition>210881017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesContingenciesAdditionalInformationDetails" roleURI="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails">
        <link:definition>240894058 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.dna.com/role/RelatedPartyTransactions">
        <link:definition>210901018 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>240914059 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.dna.com/role/NetLossperShare">
        <link:definition>210921019 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.dna.com/role/NetLossperShareTables">
        <link:definition>230933014 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>240944060 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" roleURI="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails">
        <link:definition>240954061 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.dna.com/role/Segments">
        <link:definition>210961020 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.dna.com/role/SegmentsTables">
        <link:definition>230973015 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsInformationbyReportableSegmentDetails" roleURI="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails">
        <link:definition>240984062 - Disclosure - Segments - Information by Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" roleURI="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails">
        <link:definition>240994063 - Disclosure - Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" roleURI="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails">
        <link:definition>241004064 - Disclosure - Segments - Reconciliation of Net Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsAdditionalInformationDetails" roleURI="http://www.dna.com/role/SegmentsAdditionalInformationDetails">
        <link:definition>241014065 - Disclosure - Segments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>211021021 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>231033016 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails">
        <link:definition>241044066 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlans" roleURI="http://www.dna.com/role/DefinedContributionPlans">
        <link:definition>211051022 - Disclosure - Defined Contribution Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlansAdditionalInformationDetails" roleURI="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails">
        <link:definition>241064067 - Disclosure - Defined Contribution Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.dna.com/role/SubsequentEvents">
        <link:definition>211071023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.dna.com/role/SubsequentEventsDetails">
        <link:definition>241084068 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" abstract="false" name="DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_SeriesAPreferredSharesMember" abstract="true" name="SeriesAPreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LicensingAndPatentInfringementSuitMember" abstract="true" name="LicensingAndPatentInfringementSuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OragenicsMember" abstract="true" name="OragenicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_JointVentureAdditionalCapitalContributionsCommitted" abstract="false" name="JointVentureAdditionalCapitalContributionsCommitted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_GeneratedAfter2017Member" abstract="true" name="GeneratedAfter2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_A3.5ConvertibleNotesDue2023Member" abstract="true" name="A3.5ConvertibleNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LossContingencyReversedClaimsDismissedNumber" abstract="false" name="LossContingencyReversedClaimsDismissedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" abstract="true" name="SummaryofDeferredRevenuebyCollaboratorLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_ExecutiveChairmanMember" abstract="true" name="ExecutiveChairmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedIntangibleAssets" abstract="false" name="StockIssuedIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_NumberofSeatsonGoverningBoard" abstract="false" name="NumberofSeatsonGoverningBoard" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_IntrexonEnergyPartnersIILLCMember" abstract="true" name="IntrexonEnergyPartnersIILLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_EliminationsAndReconcilingItemsMember" abstract="true" name="EliminationsAndReconcilingItemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" abstract="true" name="TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_AccountsReceivableAllowanceForCreditLossTable" abstract="true" name="AccountsReceivableAllowanceForCreditLossTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_NumberOfReportingUnitsClosed" abstract="false" name="NumberOfReportingUnitsClosed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" abstract="false" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" abstract="false" name="DeferredTaxLiabilitiesEquityComponentofLongTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" abstract="false" name="DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_AdjustmentForBonusesPaidInEquityAwards" abstract="false" name="AdjustmentForBonusesPaidInEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" abstract="true" name="LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" abstract="false" name="LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_PreferredStockReceivables" abstract="false" name="PreferredStockReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_RelatedPartyOwnershipInterest" abstract="false" name="RelatedPartyOwnershipInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_HarvestIntrexonEnterpriseFundILPMember" abstract="true" name="HarvestIntrexonEnterpriseFundILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" abstract="false" name="SharesIssuedDuringPeriodValueIssuedForServicesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" abstract="false" name="CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_ActoBioNotesMember" abstract="true" name="ActoBioNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CashInflowsOutflowsInAssetAcquisition" abstract="false" name="CashInflowsOutflowsInAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LockupPeriodOnRestrictedStockUnitShares" abstract="false" name="LockupPeriodOnRestrictedStockUnitShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_EnviroFlightLLCMember" abstract="true" name="EnviroFlightLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" abstract="false" name="StockIssuedDuringThePeriodSharesAccruedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pgen_DebtInstrumentResaleRestrictionPeriod" abstract="false" name="DebtInstrumentResaleRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_CapitalExpendituresAndInvestmentsinAffiliates" abstract="false" name="CapitalExpendituresAndInvestmentsinAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ThirdSecurityMember" abstract="true" name="ThirdSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_VariousECCAgreementsMember" abstract="true" name="VariousECCAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_NumberofSeatsonGoverningBoardInternallySelected" abstract="false" name="NumberofSeatsonGoverningBoardInternallySelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_StockReceivedAsConsiderationForCollaborationAgreements" abstract="false" name="StockReceivedAsConsiderationForCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CollaborationandlicensingagreementsMember" abstract="true" name="CollaborationandlicensingagreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OxitecMember" abstract="true" name="OxitecMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" abstract="true" name="CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" abstract="false" name="CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" abstract="false" name="LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_ProductsandServicesRevenuesMember" abstract="true" name="ProductsandServicesRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OkanaganOxitecFineChemicalsAndAgBioMember" abstract="true" name="OkanaganOxitecFineChemicalsAndAgBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" abstract="false" name="LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CommonStockCalculationPeriod" abstract="false" name="CommonStockCalculationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" abstract="false" name="ResearchAndDevelopmentCommitmentsNotYetIncurred" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_RelatedPartiesAggregatedMember" abstract="true" name="RelatedPartiesAggregatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LicensingAgreementReimbursementofHistoricalCosts" abstract="false" name="LicensingAgreementReimbursementofHistoricalCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_MergersandAcquisitionsAbstract" abstract="true" name="MergersandAcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_CostOfServicesMember" abstract="true" name="CostOfServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" abstract="false" name="InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" abstract="false" name="ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PrecigenStockOptionPlan2013PlanMember" abstract="true" name="PrecigenStockOptionPlan2013PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" abstract="false" name="LicenseAgreementTerminationPeriodFollowingTriggeringEvent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_IntrexonEnergyPartnersMember" abstract="true" name="IntrexonEnergyPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LossContingenciesTotalClaimsNumber" abstract="false" name="LossContingenciesTotalClaimsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_LicenseAgreementRoyaltyDueAggregated" abstract="false" name="LicenseAgreementRoyaltyDueAggregated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_AllInvestorsMember" abstract="true" name="AllInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_MethaneBioconversionPlatformDisclosuresMember" abstract="true" name="MethaneBioconversionPlatformDisclosuresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" abstract="false" name="MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" abstract="false" name="NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_AquaBountyMember" abstract="true" name="AquaBountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedDuringThePeriodValueAccruedCompensation" abstract="false" name="StockIssuedDuringThePeriodValueAccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ScheduleOfInvestmentsInJointVentureTable" abstract="true" name="ScheduleOfInvestmentsInJointVentureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_AmericanStateBankMember" abstract="true" name="AmericanStateBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" abstract="false" name="StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" abstract="false" name="ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" abstract="false" name="EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_OtherCollaborationsMember" abstract="true" name="OtherCollaborationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_AccountsReceivableAllowanceForCreditLossLineItems" abstract="true" name="AccountsReceivableAllowanceForCreditLossLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_AccruedCompensationPaidinEquityAwards" abstract="false" name="AccruedCompensationPaidinEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_FeedMember" abstract="true" name="FeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_WorkInProcessMember" abstract="true" name="WorkInProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_SecuritiesAndExchangeCommissionMember" abstract="true" name="SecuritiesAndExchangeCommissionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OwnshareLendingArrangementSharesIssued1" abstract="false" name="OwnshareLendingArrangementSharesIssued1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pgen_IntrexonT1DPartnersLLCMember" abstract="true" name="IntrexonT1DPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_SaleOfAssetsIncludedInReceivables" abstract="false" name="SaleOfAssetsIncludedInReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PrecigenActioBioIncMember" abstract="true" name="PrecigenActioBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CollaborationAgreementTerminationNoticePeriod" abstract="false" name="CollaborationAgreementTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_ZiopharmMember" abstract="true" name="ZiopharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" abstract="false" name="CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_CollaborativeArrangementConsiderationReceivedCash" abstract="false" name="CollaborativeArrangementConsiderationReceivedCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" abstract="false" name="JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" abstract="false" name="CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_BreedingandProductionAnimalsGross" abstract="false" name="BreedingandProductionAnimalsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_GainLossRelatedToNoncashLitigationSettlement" abstract="false" name="GainLossRelatedToNoncashLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" abstract="false" name="CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_NumberOfRelatedPartiesWithTerminatedAgreements" abstract="false" name="NumberOfRelatedPartiesWithTerminatedAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_Adjustmentsfornoncontrollinginterests" abstract="false" name="Adjustmentsfornoncontrollinginterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_TSBiotechnologyHoldingsLLCMember" abstract="true" name="TSBiotechnologyHoldingsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_RoyaltyPercentageToBePaidtoOtherParty" abstract="false" name="RoyaltyPercentageToBePaidtoOtherParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" abstract="false" name="ProceedsfromIssuanceofCommonStockandWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_PGENTherapeuticsSegmentMember" abstract="true" name="PGENTherapeuticsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CorporateAndReconcilingItemsMember" abstract="true" name="CorporateAndReconcilingItemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" abstract="false" name="OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_AffiliatesOfThirdSecurityMember" abstract="true" name="AffiliatesOfThirdSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CompensationArrangementWithIndividualAnnualCashRetainer" abstract="false" name="CompensationArrangementWithIndividualAnnualCashRetainer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ScheduleOfInvestmentsInJointVentureLineItems" abstract="true" name="ScheduleOfInvestmentsInJointVentureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_ActoBioMember" abstract="true" name="ActoBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_PrepaidProductAndServiceRevenuesMember" abstract="true" name="PrepaidProductAndServiceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_TransOvaGeneticsLcMember" abstract="true" name="TransOvaGeneticsLcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_HumanBiotherapeuticsSegmentMember" abstract="true" name="HumanBiotherapeuticsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CastleCreekBiosciencesIncMember" abstract="true" name="CastleCreekBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LossContingencyAppealedClaimsDismissed" abstract="false" name="LossContingencyAppealedClaimsDismissed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_UpfrontAndMilestonePaymentsMember" abstract="true" name="UpfrontAndMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" abstract="false" name="CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pgen_AresTradingS.A.Member" abstract="true" name="AresTradingS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExercisePriceDomain" abstract="true" name="ExercisePriceDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LesseeOperatingLeaseTerminationPeriod" abstract="false" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_StockIssuedSettlementAgreement" abstract="false" name="StockIssuedSettlementAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CollaborationAgreementsLineItems" abstract="true" name="CollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pgen_ReacquiredInProcessResearchDevelopmentMember" abstract="true" name="ReacquiredInProcessResearchDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_LicenseAgreementPercentageofSublicensingIncome" abstract="false" name="LicenseAgreementPercentageofSublicensingIncome" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_XYLLCMember" abstract="true" name="XYLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PaymentsToRelatedParties" abstract="false" name="PaymentsToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_NoncashDividendIncome" abstract="false" name="NoncashDividendIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ExercisePriceThreeMember" abstract="true" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" abstract="false" name="TransitionPeriodDuringWhichCostsWillBeReimbursed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_FirstNationalBankofOmahaMember" abstract="true" name="FirstNationalBankofOmahaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" abstract="false" name="LicenseAgreementNumberofExclusivelyLicensedProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_EquitySecuritiesPolicyTextBlock" abstract="false" name="EquitySecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" abstract="false" name="MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ReportableSegmentsMember" abstract="true" name="ReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" abstract="false" name="CollaborativeArrangementConsiderationReceivableCollectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pgen_TransOvaSegmentMember" abstract="true" name="TransOvaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ComputerHardwareandSoftwareMember" abstract="true" name="ComputerHardwareandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ProceedsfromStockOptionsandWarrantsExercised" abstract="false" name="ProceedsfromStockOptionsandWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" abstract="false" name="ValuationAllowanceDeferredTaxAssetDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_MBPTitanMember" abstract="true" name="MBPTitanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExotechADSkincareAndThriveAgrobioticsMember" abstract="true" name="ExotechADSkincareAndThriveAgrobioticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExemplarGeneticsLLCMember" abstract="true" name="ExemplarGeneticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_TSBiotechnologyAndEnviroFlightMember" abstract="true" name="TSBiotechnologyAndEnviroFlightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExercisePriceAxis" abstract="true" name="ExercisePriceAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_OperatingSegmentsAndCorporateNonSegmentMember" abstract="true" name="OperatingSegmentsAndCorporateNonSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExercisePriceFiveMember" abstract="true" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_LossContingencyClaimsInvalidatedNumber" abstract="false" name="LossContingencyClaimsInvalidatedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" abstract="false" name="CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_OtherAccruedLiabilitiesMember" abstract="true" name="OtherAccruedLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" abstract="false" name="EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PrecigenStockOptionPlan2019PlanMember" abstract="true" name="PrecigenStockOptionPlan2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" abstract="false" name="DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ConvertiblePreferredStockAmountAuthorized" abstract="false" name="ConvertiblePreferredStockAmountAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_OtherFinancialAssetsMember" abstract="true" name="OtherFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" abstract="false" name="EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_TransitionServicesMember" abstract="true" name="TransitionServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ExercisePriceTwoMember" abstract="true" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pgen_CostOfProductsMember" abstract="true" name="CostOfProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DeferredRevenueOtherMember" abstract="true" name="DeferredRevenueOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_CollaborationAgreementsTable" abstract="true" name="CollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" abstract="false" name="LicensingAgreementPercentageofOperatingProfitstoBeReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" abstract="false" name="CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_CollaborationArrangementPercentOfCollaborationPayments" abstract="false" name="CollaborationArrangementPercentOfCollaborationPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="pgen_ExercisePriceOneMember" abstract="true" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" abstract="false" name="StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" abstract="false" name="RelatedPartyReceivableAllowanceforCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_LicenseAgreementAnnualFee" abstract="false" name="LicenseAgreementAnnualFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" abstract="false" name="ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PrecigenStockOptionPlan2008PlanMember" abstract="true" name="PrecigenStockOptionPlan2008PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ComputerHardwareandSoftware" abstract="false" name="ComputerHardwareandSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_MerckConvertibleNoteMember" abstract="true" name="MerckConvertibleNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" abstract="false" name="ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_PrecigenStockOptionPlansMember" abstract="true" name="PrecigenStockOptionPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_SummaryofDeferredRevenuebyCollaboratorTable" abstract="true" name="SummaryofDeferredRevenuebyCollaboratorTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pgen_HarvestStartUpEntitiesAggregatedMember" abstract="true" name="HarvestStartUpEntitiesAggregatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" abstract="true" name="GentenTherapeuticsCRSBioAndRelieveGeneticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ExercisePriceFourMember" abstract="true" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ForeignSubsidiariesMember" abstract="true" name="ForeignSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="pgen_CollaborativeArrangementConsiderationReceivedValue" abstract="false" name="CollaborativeArrangementConsiderationReceivedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" abstract="false" name="ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" abstract="false" name="ConvertibleDebtPrincipalAmountInitialConversionRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" abstract="true" name="SuppliesEmbryosAndOtherProductionMaterialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="pgen_NumberofSeatsonGoverningBoardExternallySelected" abstract="false" name="NumberofSeatsonGoverningBoardExternallySelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>pgen-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dna.com/role/CoverPage" xlink:type="simple" xlink:href="pgen-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93f5cc2c-092d-4e99-abef-5ff86f1b9b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_904b37e7-8151-4932-90f1-7d83a36bc873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f5cc2c-092d-4e99-abef-5ff86f1b9b3a" xlink:to="loc_us-gaap_CommonStockValueOutstanding_904b37e7-8151-4932-90f1-7d83a36bc873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_387fa09b-b85e-46dd-95ca-3621f624a906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f5cc2c-092d-4e99-abef-5ff86f1b9b3a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_387fa09b-b85e-46dd-95ca-3621f624a906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5072a0e-2802-4c6d-b6b4-b32f433811b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f5cc2c-092d-4e99-abef-5ff86f1b9b3a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5072a0e-2802-4c6d-b6b4-b32f433811b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20f59c35-3d3b-4705-94ad-cfbaea2aa68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_93f5cc2c-092d-4e99-abef-5ff86f1b9b3a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20f59c35-3d3b-4705-94ad-cfbaea2aa68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4713c14c-9a7e-44e0-88a2-4e7ed7c652ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_AssetsCurrent_4713c14c-9a7e-44e0-88a2-4e7ed7c652ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5ee240c-fffe-4f30-ad12-4d3e1477793e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5ee240c-fffe-4f30-ad12-4d3e1477793e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e3a2f549-4b56-475f-b1ec-bebe41c280ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e3a2f549-4b56-475f-b1ec-bebe41c280ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1c2bd1b7-5ce3-4cfb-a7eb-94d51716de0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_Goodwill_1c2bd1b7-5ce3-4cfb-a7eb-94d51716de0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1b33cb0a-401f-4a4a-9f7c-2e2e47bbd05d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_EquityMethodInvestments_1b33cb0a-401f-4a4a-9f7c-2e2e47bbd05d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_76b4d401-907f-47ac-968d-f4645a4efe67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_76b4d401-907f-47ac-968d-f4645a4efe67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_32669b41-1373-46c4-9712-e0083afbba2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_32669b41-1373-46c4-9712-e0083afbba2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_3988c259-6ea4-4f01-ba81-30115e33608c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0bdb8fc7-a3c5-4a8e-92a1-a30066560591" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_3988c259-6ea4-4f01-ba81-30115e33608c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_409179b9-a7f0-43bb-b191-220d4bdd6770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3bfaa4ed-f077-4283-a4dd-5173ba1e17e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_409179b9-a7f0-43bb-b191-220d4bdd6770" xlink:to="loc_us-gaap_Liabilities_3bfaa4ed-f077-4283-a4dd-5173ba1e17e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b9a9a0f2-e432-4140-874a-d4e7daf559bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_409179b9-a7f0-43bb-b191-220d4bdd6770" xlink:to="loc_us-gaap_StockholdersEquity_b9a9a0f2-e432-4140-874a-d4e7daf559bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_355ca561-7916-48f2-a5b2-e18147f95b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_409179b9-a7f0-43bb-b191-220d4bdd6770" xlink:to="loc_us-gaap_CommitmentsAndContingencies_355ca561-7916-48f2-a5b2-e18147f95b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_af1c9188-5040-445d-8f59-740fe61cc583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_AccountsPayableCurrent_af1c9188-5040-445d-8f59-740fe61cc583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0935cb95-dd2d-4e14-b031-4679342b451f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0935cb95-dd2d-4e14-b031-4679342b451f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f2fe28fc-7f85-4e30-b69c-dc4114dea21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f2fe28fc-7f85-4e30-b69c-dc4114dea21d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9755dd13-174c-425f-952d-2807b0828be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9755dd13-174c-425f-952d-2807b0828be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_97c0bf03-2f12-4959-bc01-b68462177947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_97c0bf03-2f12-4959-bc01-b68462177947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_8e1017bf-9701-4483-b465-694f01bf8f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_LinesOfCreditCurrent_8e1017bf-9701-4483-b465-694f01bf8f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e2f96fce-9b68-4837-82e7-34c65bc9f0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_LongTermDebtCurrent_e2f96fce-9b68-4837-82e7-34c65bc9f0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2a8ccc2-b31d-4fc9-941c-d2e7fefc005b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f2a8ccc2-b31d-4fc9-941c-d2e7fefc005b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f4ea73b6-b067-4190-808f-4b4f10f39463" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63f707ba-0207-40ad-a4f4-a4cea068a567" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f4ea73b6-b067-4190-808f-4b4f10f39463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b1043b1b-c019-445b-a25c-752347b34f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_LiabilitiesCurrent_b1043b1b-c019-445b-a25c-752347b34f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_063b7bfb-b092-49d9-8d17-1728a98cc5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_063b7bfb-b092-49d9-8d17-1728a98cc5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80f24917-074d-454e-b67c-10a394cd6693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_80f24917-074d-454e-b67c-10a394cd6693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c7d736e1-6398-4447-8a91-5d56b03752d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c7d736e1-6398-4447-8a91-5d56b03752d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a8edab5c-beb6-4e2a-afe5-4958738dc030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a8edab5c-beb6-4e2a-afe5-4958738dc030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ff9228c-cfe4-4f93-ac2c-2a9b766f3179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ff9228c-cfe4-4f93-ac2c-2a9b766f3179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_16e71502-739f-4426-b6d7-53f972203fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d4ff5ee-d18f-45bb-a280-222171b5156c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_16e71502-739f-4426-b6d7-53f972203fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e193530f-1111-46bd-9570-d48f6ec20406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_InventoryGross_e193530f-1111-46bd-9570-d48f6ec20406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_35875abd-b2d6-4612-8bc7-21c34fe7869e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_35875abd-b2d6-4612-8bc7-21c34fe7869e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3984b781-fde2-4422-8404-5b05161f133f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3984b781-fde2-4422-8404-5b05161f133f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f9fd6c0d-2a80-401e-b7b5-60d3a9b97890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f9fd6c0d-2a80-401e-b7b5-60d3a9b97890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554ceab3-0266-4b41-b75d-d67a874eabb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554ceab3-0266-4b41-b75d-d67a874eabb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_dbb9b880-ebdc-4e29-87e4-674805b4f89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_dbb9b880-ebdc-4e29-87e4-674805b4f89d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_14fc8e89-b5fc-458e-bede-62fef1fa3c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_14fc8e89-b5fc-458e-bede-62fef1fa3c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_376a0261-a381-4f25-b95f-332d91c6f573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_ShortTermInvestments_376a0261-a381-4f25-b95f-332d91c6f573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd970d2e-4d41-4a0e-9510-963d64cf262e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d37538d2-af19-4e45-922f-2086f04c67f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cd970d2e-4d41-4a0e-9510-963d64cf262e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_be165e51-a557-41d5-b685-7c0aa6c57053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_be165e51-a557-41d5-b685-7c0aa6c57053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7e232cd9-81d8-4205-ad66-a6af1a233e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7e232cd9-81d8-4205-ad66-a6af1a233e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32423d81-ba86-4dd8-8a35-efab5f30a1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32423d81-ba86-4dd8-8a35-efab5f30a1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b308accb-eaee-40a5-ae88-0626e7c96b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b308accb-eaee-40a5-ae88-0626e7c96b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5e297665-bdce-428b-86d2-4a38f0c2956c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4c6aa783-5d55-4817-8d9f-efef14b56738" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5e297665-bdce-428b-86d2-4a38f0c2956c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5d885b48-ff41-4e4b-aa4d-1dad6cee27e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c8871814-28b9-41be-86e5-dd6da4b01a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d885b48-ff41-4e4b-aa4d-1dad6cee27e5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c8871814-28b9-41be-86e5-dd6da4b01a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_946a403c-fd7c-4785-a0ed-07009dfff9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d885b48-ff41-4e4b-aa4d-1dad6cee27e5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_946a403c-fd7c-4785-a0ed-07009dfff9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68ad2f60-a939-45f1-a336-7a846797023c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a2bb3c73-1638-4b4f-b952-b05e7020053a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68ad2f60-a939-45f1-a336-7a846797023c" xlink:to="loc_us-gaap_OperatingIncomeLoss_a2bb3c73-1638-4b4f-b952-b05e7020053a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_acf54e8f-bba4-4aa5-97a6-63759a90c578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68ad2f60-a939-45f1-a336-7a846797023c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_acf54e8f-bba4-4aa5-97a6-63759a90c578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8c4e721-5bbb-4866-a9db-cbb2b2f590ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_68ad2f60-a939-45f1-a336-7a846797023c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8c4e721-5bbb-4866-a9db-cbb2b2f590ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d98d24ef-4484-49f5-bcfb-14c1017f6b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_722f4bfa-4234-4707-9f11-c459a10ae8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d98d24ef-4484-49f5-bcfb-14c1017f6b00" xlink:to="loc_us-gaap_ProfitLoss_722f4bfa-4234-4707-9f11-c459a10ae8bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cad4fd81-2fe9-4233-b6e2-09221fe7740d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d98d24ef-4484-49f5-bcfb-14c1017f6b00" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_cad4fd81-2fe9-4233-b6e2-09221fe7740d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_137bf89c-b46d-49f3-9f5c-82e6dcafa57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_ba8cbfe7-f561-40c3-8eb8-e999ad271823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_137bf89c-b46d-49f3-9f5c-82e6dcafa57d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_ba8cbfe7-f561-40c3-8eb8-e999ad271823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_48b542d7-3b76-4d42-b74c-52ef23ae3ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_137bf89c-b46d-49f3-9f5c-82e6dcafa57d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_48b542d7-3b76-4d42-b74c-52ef23ae3ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a570977-69bb-4faa-89c2-0c548ab5d21c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_9b191ef9-a880-4dfc-aaa6-1ac558badeb5" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a570977-69bb-4faa-89c2-0c548ab5d21c" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_9b191ef9-a880-4dfc-aaa6-1ac558badeb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8b875444-4f58-4851-87cd-816602e35710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a570977-69bb-4faa-89c2-0c548ab5d21c" xlink:to="loc_us-gaap_InterestExpense_8b875444-4f58-4851-87cd-816602e35710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_8ae1b105-d549-4ac8-b93e-dfd08869abbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a570977-69bb-4faa-89c2-0c548ab5d21c" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_8ae1b105-d549-4ac8-b93e-dfd08869abbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e2bf5b91-e91b-435e-8463-aa0655c6a4f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9a570977-69bb-4faa-89c2-0c548ab5d21c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e2bf5b91-e91b-435e-8463-aa0655c6a4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8cb7656d-b1e3-4d06-b0a0-a9aa3816ca8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d87605a7-2adb-4cda-802c-dce672b08742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8cb7656d-b1e3-4d06-b0a0-a9aa3816ca8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d87605a7-2adb-4cda-802c-dce672b08742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_df9d80cd-d366-41e8-a001-e925007dc913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8cb7656d-b1e3-4d06-b0a0-a9aa3816ca8b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_df9d80cd-d366-41e8-a001-e925007dc913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c259337c-631d-4d59-bd26-2dc23eb3c0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_abcd0bf3-7a5f-4f1e-8683-9d77e4dd3fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c259337c-631d-4d59-bd26-2dc23eb3c0ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_abcd0bf3-7a5f-4f1e-8683-9d77e4dd3fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_02f7decf-225c-4f84-8788-e99f05f111e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c259337c-631d-4d59-bd26-2dc23eb3c0ad" xlink:to="loc_us-gaap_OperatingExpenses_02f7decf-225c-4f84-8788-e99f05f111e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperations_1"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperations_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_755378f5-a0ec-4344-9483-63b5d8611252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_37f3d6bd-5411-449f-9539-090eae945707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_755378f5-a0ec-4344-9483-63b5d8611252" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_37f3d6bd-5411-449f-9539-090eae945707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e8def870-1295-4478-a22f-50b15269745d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_755378f5-a0ec-4344-9483-63b5d8611252" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e8def870-1295-4478-a22f-50b15269745d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperationsParenthetical"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="pgen-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bcabd22f-da6d-455c-a847-56aba1bccb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_590f2575-a81b-4918-84cf-39015db4be34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bcabd22f-da6d-455c-a847-56aba1bccb39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_590f2575-a81b-4918-84cf-39015db4be34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5110a192-1a52-4174-96aa-ff3103909923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bcabd22f-da6d-455c-a847-56aba1bccb39" xlink:to="loc_us-gaap_ProfitLoss_5110a192-1a52-4174-96aa-ff3103909923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_92edfd8c-e5fb-46ae-a9f0-60ddb6f15397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bcabd22f-da6d-455c-a847-56aba1bccb39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_92edfd8c-e5fb-46ae-a9f0-60ddb6f15397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a54aed1d-baad-4ec6-8440-01aa794683a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bcabd22f-da6d-455c-a847-56aba1bccb39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a54aed1d-baad-4ec6-8440-01aa794683a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a359c1-5e2a-4e82-b186-baff75843565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_44e513bc-0622-4e8f-af57-4b279b4c4967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a359c1-5e2a-4e82-b186-baff75843565" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_44e513bc-0622-4e8f-af57-4b279b4c4967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5dddfffe-4165-4c3e-8a6a-d3f785fd3cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a359c1-5e2a-4e82-b186-baff75843565" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_5dddfffe-4165-4c3e-8a6a-d3f785fd3cc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofShareholdersandTotalEquity"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_517de8e1-7a0b-4865-a33e-105132844eac" xlink:href="pgen-20201231.xsd#pgen_GainLossRelatedToNoncashLitigationSettlement"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_517de8e1-7a0b-4865-a33e-105132844eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_b46adeb1-4a88-46a8-a5c9-c1159ad30338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_b46adeb1-4a88-46a8-a5c9-c1159ad30338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2a29e34b-f204-4677-8ba2-d6ef0936f191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2a29e34b-f204-4677-8ba2-d6ef0936f191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7b5b946f-1ad9-48bb-84f3-a7f0ca509e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7b5b946f-1ad9-48bb-84f3-a7f0ca509e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_2934a614-d702-49eb-b8c6-2896b6dca6c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_2934a614-d702-49eb-b8c6-2896b6dca6c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e4f0d16f-6344-402c-bbb0-7a8bed5fa3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e4f0d16f-6344-402c-bbb0-7a8bed5fa3e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_705942d1-223a-42ab-b7ab-955d22351691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_705942d1-223a-42ab-b7ab-955d22351691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_c33689a9-08e4-47c3-b807-b321c7357fe8" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_c33689a9-08e4-47c3-b807-b321c7357fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c9dcde5f-f9e8-4733-b061-128702a9512a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c9dcde5f-f9e8-4733-b061-128702a9512a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_fc980ddc-f574-47c9-b375-2c72d5b6bfb4" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_fc980ddc-f574-47c9-b375-2c72d5b6bfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_80e6e0c8-dc6b-4586-b1f9-47368623191e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_80e6e0c8-dc6b-4586-b1f9-47368623191e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_df351c51-a6e2-4567-90a0-02964728734a" xlink:href="pgen-20201231.xsd#pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_df351c51-a6e2-4567-90a0-02964728734a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_fbc99b96-d5cd-413c-83b5-e7fa401efb6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_fbc99b96-d5cd-413c-83b5-e7fa401efb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7c2efcff-6d1b-414c-8c74-d132df4a6d3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7c2efcff-6d1b-414c-8c74-d132df4a6d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_c0551657-7d04-4b40-894d-4de791f81766" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_NoncashDividendIncome_c0551657-7d04-4b40-894d-4de791f81766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_91d9e045-5b1b-46c7-8bc7-5055cf423108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_91d9e045-5b1b-46c7-8bc7-5055cf423108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f25737fd-b36e-4a7e-953a-2b34e74306fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f25737fd-b36e-4a7e-953a-2b34e74306fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8b972143-abdd-43fd-a79c-2250a254678b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8b972143-abdd-43fd-a79c-2250a254678b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a13a271-536a-4ad0-a44d-0823d7b2d2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0a13a271-536a-4ad0-a44d-0823d7b2d2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f4aea3b-a06e-4519-b141-a74b9cb50b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f4aea3b-a06e-4519-b141-a74b9cb50b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81621e3b-753e-413c-98f9-a8adcd997190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81621e3b-753e-413c-98f9-a8adcd997190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e587f1c5-4898-40e9-a2bf-f73ec2440fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_e587f1c5-4898-40e9-a2bf-f73ec2440fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2bd1d769-62ff-4fcc-8559-8a13c31e43c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2bd1d769-62ff-4fcc-8559-8a13c31e43c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_07137fd0-e0e7-4f36-856f-aceb7909a76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_07137fd0-e0e7-4f36-856f-aceb7909a76e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_292089c0-8179-49e1-be88-032699f232fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_292089c0-8179-49e1-be88-032699f232fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncreaseDecreaseInLeaseLiabilities_a51769a1-0453-499f-8646-cf225ec72936" xlink:href="pgen-20201231.xsd#pgen_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_pgen_IncreaseDecreaseInLeaseLiabilities_a51769a1-0453-499f-8646-cf225ec72936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c039b0b1-60a7-4916-8569-25162fc233f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_ShareBasedCompensation_c039b0b1-60a7-4916-8569-25162fc233f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c487c495-1dc9-4df6-bde9-26212066990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="28" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_ProfitLoss_c487c495-1dc9-4df6-bde9-26212066990b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_d3862ee8-14c7-4348-92e5-cf7f64ecfb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="29" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_d3862ee8-14c7-4348-92e5-cf7f64ecfb9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bd897dde-8c11-4301-b3d9-84b3fbe32e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="30" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bd897dde-8c11-4301-b3d9-84b3fbe32e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_3a410982-86fd-46d9-a771-6773a9f45475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:calculationArc order="31" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_3a410982-86fd-46d9-a771-6773a9f45475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aa3284ba-ea86-44af-884e-ddbe58377573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="32" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_33121ac6-d9a1-4391-be51-cadf131532f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aa3284ba-ea86-44af-884e-ddbe58377573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ff43907-30af-4b89-afb6-e358273d72fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b947076-98fd-489c-8eff-47bc11a8e2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ff43907-30af-4b89-afb6-e358273d72fa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b947076-98fd-489c-8eff-47bc11a8e2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06ed0b74-6d90-432c-861f-edafc421de6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ff43907-30af-4b89-afb6-e358273d72fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06ed0b74-6d90-432c-861f-edafc421de6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec7760b6-7cb3-4735-9e28-ac6e41328e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ff43907-30af-4b89-afb6-e358273d72fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec7760b6-7cb3-4735-9e28-ac6e41328e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3a7d798-d493-439a-b42e-729e91cbdbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3ff43907-30af-4b89-afb6-e358273d72fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3a7d798-d493-439a-b42e-729e91cbdbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_14423ccf-6ca2-462c-a9a6-40cfd3591735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_14423ccf-6ca2-462c-a9a6-40cfd3591735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c3f61919-b446-4dc6-8dd7-59be7e9c393d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_c3f61919-b446-4dc6-8dd7-59be7e9c393d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_db721fad-7ea8-46d6-ae33-dbc68b738ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_db721fad-7ea8-46d6-ae33-dbc68b738ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_ccd32fbe-ed5c-4eb5-bd84-9fb1f1f4fb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_ccd32fbe-ed5c-4eb5-bd84-9fb1f1f4fb77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a23c2713-d759-44f0-9212-57b0a3b3ac1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a23c2713-d759-44f0-9212-57b0a3b3ac1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_6171e271-00bb-4d11-ab91-9d4607006344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_6171e271-00bb-4d11-ab91-9d4607006344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b6654aa1-703e-4d1f-9d17-b86f4c2d1015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b6654aa1-703e-4d1f-9d17-b86f4c2d1015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_c756104a-02e9-4648-91fc-05ff6c15b760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_c756104a-02e9-4648-91fc-05ff6c15b760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_aeabddeb-71cc-4e57-83af-b1847438a3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_aeabddeb-71cc-4e57-83af-b1847438a3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7931dcb3-c2df-4b9e-b5de-768dc9c8a315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_7931dcb3-c2df-4b9e-b5de-768dc9c8a315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_07d222a9-2d46-434c-92ff-f14ffaf13c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_07d222a9-2d46-434c-92ff-f14ffaf13c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CashInflowsOutflowsInAssetAcquisition_cb41550d-5dee-4ff8-b537-102af82353dd" xlink:href="pgen-20201231.xsd#pgen_CashInflowsOutflowsInAssetAcquisition"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4631b566-6e47-4024-b7e6-eb87d8fdf89a" xlink:to="loc_pgen_CashInflowsOutflowsInAssetAcquisition_cb41550d-5dee-4ff8-b537-102af82353dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6684e15e-737c-4701-8c4e-fda1118af1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6684e15e-737c-4701-8c4e-fda1118af1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_32fd8993-db04-48e0-86fb-9d26c5b88c55" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_32fd8993-db04-48e0-86fb-9d26c5b88c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_416b6a79-58a7-4d87-bbdc-07d0d51b98ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_416b6a79-58a7-4d87-bbdc-07d0d51b98ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_bcc05c49-e5bf-42c9-ba15-6634c796f37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_bcc05c49-e5bf-42c9-ba15-6634c796f37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1b4c78f-285f-4931-a397-c86756abc013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c1b4c78f-285f-4931-a397-c86756abc013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_22960d4a-60d0-47df-82b1-35fbb7ae22ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_22960d4a-60d0-47df-82b1-35fbb7ae22ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised_9e968620-4787-4407-af24-55a9bac133a0" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromStockOptionsandWarrantsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_673a6c88-01cb-455a-9a66-05d6e2968af7" xlink:to="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised_9e968620-4787-4407-af24-55a9bac133a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlowsReconciliationofCash"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84431914-00c6-460b-9dfb-a9d9e7b62937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b620763e-1780-4de6-baba-5f33c5444f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84431914-00c6-460b-9dfb-a9d9e7b62937" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b620763e-1780-4de6-baba-5f33c5444f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ec210e39-cc2b-4dfb-ad15-ebc26f065ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84431914-00c6-460b-9dfb-a9d9e7b62937" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ec210e39-cc2b-4dfb-ad15-ebc26f065ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ae2be3f0-49dd-4336-af6e-07dea9f83ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84431914-00c6-460b-9dfb-a9d9e7b62937" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ae2be3f0-49dd-4336-af6e-07dea9f83ece" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperations"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7183f2f7-e1d6-40b6-bff8-e8287b024944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7183f2f7-e1d6-40b6-bff8-e8287b024944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_5330ad7b-12eb-4bee-a51a-a4c16faaa22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_5330ad7b-12eb-4bee-a51a-a4c16faaa22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_4d417b57-1ee7-4f1c-9f25-8219e2031a18" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_4d417b57-1ee7-4f1c-9f25-8219e2031a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_f1ae1833-6c05-475d-80a3-465ae1bd7f70" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_f1ae1833-6c05-475d-80a3-465ae1bd7f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_14e9e882-3c1e-45ad-a889-0f57a4c48fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_14e9e882-3c1e-45ad-a889-0f57a4c48fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_10104977-4556-45fc-9938-3d9617ceb566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c1223742-fd4d-4de6-abeb-430eafce5cf0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_10104977-4556-45fc-9938-3d9617ceb566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76d2969a-5616-49e3-9c2c-67a810c1f81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_da946aa1-0f5a-4a56-880f-e904e12def70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76d2969a-5616-49e3-9c2c-67a810c1f81f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_da946aa1-0f5a-4a56-880f-e904e12def70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_1b80bcaa-aea7-4143-b132-7eb93d49b43a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76d2969a-5616-49e3-9c2c-67a810c1f81f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_1b80bcaa-aea7-4143-b132-7eb93d49b43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_47667bd2-9720-4537-9f02-08dbe1874803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76d2969a-5616-49e3-9c2c-67a810c1f81f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_47667bd2-9720-4537-9f02-08dbe1874803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_8f65d6a8-7fe5-4303-8c7f-95d6e27d04de" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_76d2969a-5616-49e3-9c2c-67a810c1f81f" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_8f65d6a8-7fe5-4303-8c7f-95d6e27d04de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_346e18d8-819b-43db-892b-64cb8dc76285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a3b35665-3f44-4088-ba32-8f87419c444f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_346e18d8-819b-43db-892b-64cb8dc76285" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a3b35665-3f44-4088-ba32-8f87419c444f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_869b9939-9bb8-4e5a-92c6-d00308c515c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_346e18d8-819b-43db-892b-64cb8dc76285" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_869b9939-9bb8-4e5a-92c6-d00308c515c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c98f290b-d0fe-46aa-bad3-c580e5506faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c98f290b-d0fe-46aa-bad3-c580e5506faa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_97eda67c-c750-4036-9ce4-a9c90f4e023c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_97eda67c-c750-4036-9ce4-a9c90f4e023c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_fd24bd58-1005-41f9-8479-fed55541c0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_fd24bd58-1005-41f9-8479-fed55541c0c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_3848791f-30ff-4a41-8521-6303f36b88ae" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_3848791f-30ff-4a41-8521-6303f36b88ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_79f78364-417c-40fe-ab09-ff2379d7dbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bf92c28-3292-4bf8-9272-f263a0262617" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_79f78364-417c-40fe-ab09-ff2379d7dbf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b32b117e-1729-4273-ba61-ae4f381e3383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_28ac3b93-532b-460b-818d-78faf4efd731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b32b117e-1729-4273-ba61-ae4f381e3383" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_28ac3b93-532b-460b-818d-78faf4efd731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_f8acd015-c9a9-41ac-a3ac-1dadcebb1033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b32b117e-1729-4273-ba61-ae4f381e3383" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_f8acd015-c9a9-41ac-a3ac-1dadcebb1033" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ed8a647-855c-493f-8dc7-a621e8ddf6db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e98f5295-cab7-400c-816c-ebd35b47df95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ed8a647-855c-493f-8dc7-a621e8ddf6db" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e98f5295-cab7-400c-816c-ebd35b47df95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0c308631-4e4f-4543-941c-665601e304fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ed8a647-855c-493f-8dc7-a621e8ddf6db" xlink:to="loc_us-gaap_LiabilitiesCurrent_0c308631-4e4f-4543-941c-665601e304fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f5f0bfea-7699-4bcb-8bd8-26ab3bcd7797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a8d9c12c-50a3-46e4-8221-e8182b8e23c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5f0bfea-7699-4bcb-8bd8-26ab3bcd7797" xlink:to="loc_us-gaap_AssetsCurrent_a8d9c12c-50a3-46e4-8221-e8182b8e23c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3050fbf1-4f77-4a09-8725-2e619d512dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f5f0bfea-7699-4bcb-8bd8-26ab3bcd7797" xlink:to="loc_us-gaap_AssetsNoncurrent_3050fbf1-4f77-4a09-8725-2e619d512dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_5c52e259-9dd2-436e-9bf8-cf9de570bea1" xlink:href="pgen-20201231.xsd#pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ab9e4c1d-6aa4-4b4c-9ed6-dd01969535d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_5c52e259-9dd2-436e-9bf8-cf9de570bea1" xlink:to="loc_us-gaap_Assets_ab9e4c1d-6aa4-4b4c-9ed6-dd01969535d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a0bd33d3-6cde-4870-a2f7-7f8cbac0f7a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_5c52e259-9dd2-436e-9bf8-cf9de570bea1" xlink:to="loc_us-gaap_Liabilities_a0bd33d3-6cde-4870-a2f7-7f8cbac0f7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b0513caf-0eb1-4143-9195-4f8f2751f0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e7fa4a4b-22b7-4825-b5d9-cbef06e2cdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b0513caf-0eb1-4143-9195-4f8f2751f0e4" xlink:to="loc_us-gaap_Revenues_e7fa4a4b-22b7-4825-b5d9-cbef06e2cdd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_69d423fd-fdf2-4bc4-87b5-9d38e0ba877b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b0513caf-0eb1-4143-9195-4f8f2751f0e4" xlink:to="loc_us-gaap_OperatingExpenses_69d423fd-fdf2-4bc4-87b5-9d38e0ba877b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3b867eb6-4ef4-4236-9e46-0d2355e24f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b4b8616-8b61-4f42-8769-f7a12270560b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3b867eb6-4ef4-4236-9e46-0d2355e24f0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b4b8616-8b61-4f42-8769-f7a12270560b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6926ac01-8e99-449c-80cc-10330f7fc7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_3b867eb6-4ef4-4236-9e46-0d2355e24f0b" xlink:to="loc_us-gaap_GrossProfit_6926ac01-8e99-449c-80cc-10330f7fc7fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitions" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitions"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/MergersandAcquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVentures"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenue"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8f8ca041-5409-4b57-8e78-9d347023a6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07894de4-c9a4-4122-a4d6-977475121683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_8f8ca041-5409-4b57-8e78-9d347023a6c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_07894de4-c9a4-4122-a4d6-977475121683" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f3835a11-f776-43db-81c4-96798ff7a7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_8f8ca041-5409-4b57-8e78-9d347023a6c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f3835a11-f776-43db-81c4-96798ff7a7d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestments"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShorttermInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d94119a6-2af7-4149-8d0d-7c751b5274fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e089d0f-9cc5-4135-b29c-b231b86958a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d94119a6-2af7-4149-8d0d-7c751b5274fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e089d0f-9cc5-4135-b29c-b231b86958a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575189e9-c7e4-44db-8c4c-56d2aab6d1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d94119a6-2af7-4149-8d0d-7c751b5274fb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575189e9-c7e4-44db-8c4c-56d2aab6d1dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a667015b-4843-4085-acc9-183e2d4d6ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d94119a6-2af7-4149-8d0d-7c751b5274fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a667015b-4843-4085-acc9-183e2d4d6ac8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofLevel3InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/Inventory" xlink:type="simple" xlink:href="pgen-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNet"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a4c83f27-fa57-4a3f-bb15-112c1f01f5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8ca84bd9-54cd-4fa7-a3f1-3afcb73129bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a4c83f27-fa57-4a3f-bb15-112c1f01f5b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8ca84bd9-54cd-4fa7-a3f1-3afcb73129bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b93f021-eb58-4c60-9981-c2dc729c026b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a4c83f27-fa57-4a3f-bb15-112c1f01f5b9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b93f021-eb58-4c60-9981-c2dc729c026b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements_bfd7f1b6-8339-4f29-88bc-d0bc2c847dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_LandAndLandImprovements_bfd7f1b6-8339-4f29-88bc-d0bc2c847dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_39a2c98d-265a-4196-826d-ff8f7d9165b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_39a2c98d-265a-4196-826d-ff8f7d9165b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_eb9e44e0-5a0a-4f30-a254-880d651d642f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_eb9e44e0-5a0a-4f30-a254-880d651d642f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_b05288a6-5bfe-4a10-843a-da82abd0ce0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_b05288a6-5bfe-4a10-843a-da82abd0ce0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_50b92d41-f62b-4846-b25f-a55db98ab2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_50b92d41-f62b-4846-b25f-a55db98ab2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_BreedingandProductionAnimalsGross_e9a0e84f-e4ca-4758-862d-a0a28a058d51" xlink:href="pgen-20201231.xsd#pgen_BreedingandProductionAnimalsGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_pgen_BreedingandProductionAnimalsGross_e9a0e84f-e4ca-4758-862d-a0a28a058d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftware_3d52b8e7-ac9b-4681-b5c8-d86b16fd157d" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftware"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_pgen_ComputerHardwareandSoftware_3d52b8e7-ac9b-4681-b5c8-d86b16fd157d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_2383b2af-47ea-4910-8e6c-d5966755e3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_41b5db08-2484-4b9a-9858-8cc3e00e264a" xlink:to="loc_us-gaap_ConstructionInProgressGross_2383b2af-47ea-4910-8e6c-d5966755e3e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2db0ef3-0f4e-4aa0-a70d-15d0b9555c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3feb1fd-5632-43a7-b96f-2f02c240cdee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2db0ef3-0f4e-4aa0-a70d-15d0b9555c76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f3feb1fd-5632-43a7-b96f-2f02c240cdee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ab72141c-52a3-4323-8645-f4abd813340e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2db0ef3-0f4e-4aa0-a70d-15d0b9555c76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ab72141c-52a3-4323-8645-f4abd813340e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1ad5b1c5-81d7-4b14-ae97-bf577d20ce00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1ad5b1c5-81d7-4b14-ae97-bf577d20ce00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_169cb686-efd7-44fc-9b41-b9bcb57aea79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_169cb686-efd7-44fc-9b41-b9bcb57aea79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b6b54f71-5b54-4734-9b2a-f5eb50a84640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b6b54f71-5b54-4734-9b2a-f5eb50a84640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0dd2302e-5d31-4b27-b680-6a4e3be3c851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0dd2302e-5d31-4b27-b680-6a4e3be3c851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f1ce2da4-8e84-4c52-a8a5-5636506f816b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f1ce2da4-8e84-4c52-a8a5-5636506f816b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_cf082949-cda0-4f1f-a4fc-d5d33df6110f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_086efb63-339c-4b15-87a0-d387444fd5dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_cf082949-cda0-4f1f-a4fc-d5d33df6110f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebt"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5d42d376-83c3-4c14-8fce-40441b351a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b201748c-20c2-4cb0-b5ee-a84e3bbd37a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5d42d376-83c3-4c14-8fce-40441b351a86" xlink:to="loc_us-gaap_LongTermDebtCurrent_b201748c-20c2-4cb0-b5ee-a84e3bbd37a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b9df5886-312b-4036-9847-e97fe1eceec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5d42d376-83c3-4c14-8fce-40441b351a86" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b9df5886-312b-4036-9847-e97fe1eceec6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_29468dcd-ea26-41f2-96a5-5d8d24964384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c25a5ff5-06fc-42f5-9f75-1f4ce614846d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_29468dcd-ea26-41f2-96a5-5d8d24964384" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c25a5ff5-06fc-42f5-9f75-1f4ce614846d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_f3cea078-5b75-42a8-9d04-fd62dc0ccbe4" xlink:href="pgen-20201231.xsd#pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_29468dcd-ea26-41f2-96a5-5d8d24964384" xlink:to="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_f3cea078-5b75-42a8-9d04-fd62dc0ccbe4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3b114c8b-e6ae-4a7e-aa5e-6ace0e5a2012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3b114c8b-e6ae-4a7e-aa5e-6ace0e5a2012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47382286-baf5-45f9-9995-f1cbf3785338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47382286-baf5-45f9-9995-f1cbf3785338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0f037aea-53de-4eae-a795-410a73899159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0f037aea-53de-4eae-a795-410a73899159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b3edfaa2-4a4e-429f-bc85-505dd3d2f146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b3edfaa2-4a4e-429f-bc85-505dd3d2f146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_00ddbd3b-ec2b-4b07-9767-f2901cdcb66b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_00ddbd3b-ec2b-4b07-9767-f2901cdcb66b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ffdabc72-a628-4e05-97ea-11a61c75d1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_74e15f06-91fa-47e0-858a-931ee29459dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_ffdabc72-a628-4e05-97ea-11a61c75d1cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b16ed65d-2d6e-4df4-aa90-b171fe55063b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b16ed65d-2d6e-4df4-aa90-b171fe55063b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_23ed549b-bb4d-4ae5-a5f3-d60c243a060f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_23ed549b-bb4d-4ae5-a5f3-d60c243a060f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c2788d06-653b-4057-8339-b455c4128af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c2788d06-653b-4057-8339-b455c4128af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc83ee16-68ad-46e4-9d6e-cf812d12dd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc83ee16-68ad-46e4-9d6e-cf812d12dd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6118ab65-8b27-48ac-9db5-89ed95a80670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6118ab65-8b27-48ac-9db5-89ed95a80670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e05edc3c-30a3-4aad-b6db-e5de38adcae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3ec6f48e-498e-420c-8c44-b95db3941c7d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e05edc3c-30a3-4aad-b6db-e5de38adcae5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b7902ca4-20d2-4680-88e4-a0e7e92d2171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b7902ca4-20d2-4680-88e4-a0e7e92d2171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e9d401eb-81c1-452e-97f4-4ec2e33cd0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e9d401eb-81c1-452e-97f4-4ec2e33cd0fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_77f9c4d2-1c89-4d78-a412-c3f3179826f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_77f9c4d2-1c89-4d78-a412-c3f3179826f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_08f88811-bd08-42b0-bad6-32b89369d64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_08f88811-bd08-42b0-bad6-32b89369d64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_600d9ec8-d2e2-44b5-a1b1-61ead96aafad" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_600d9ec8-d2e2-44b5-a1b1-61ead96aafad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a5c66328-ab76-4ac6-ab31-dac1d81dfabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a5c66328-ab76-4ac6-ab31-dac1d81dfabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_d55535b6-f42e-4e7c-92f5-5c46ece11d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_d55535b6-f42e-4e7c-92f5-5c46ece11d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_90480381-003e-4c36-af97-08f87880d19c" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_90480381-003e-4c36-af97-08f87880d19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8986420d-2906-4595-875e-9699efff0fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8986420d-2906-4595-875e-9699efff0fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_2a8a7e24-8843-4347-966f-74edad1560dc" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_2a8a7e24-8843-4347-966f-74edad1560dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_9b20e43d-3ef9-456c-a2fe-f39447b71853" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_912c7dfd-bd56-4a34-9999-221c7df83366" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_9b20e43d-3ef9-456c-a2fe-f39447b71853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cdb3e3f3-1eb5-40c7-a465-888a2735c752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_22167305-8a90-47d4-8e34-39174a75e1f7" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cdb3e3f3-1eb5-40c7-a465-888a2735c752" xlink:to="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_22167305-8a90-47d4-8e34-39174a75e1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_91c35ff7-ff4d-4a33-9e19-19c1dd6acc69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cdb3e3f3-1eb5-40c7-a465-888a2735c752" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_91c35ff7-ff4d-4a33-9e19-19c1dd6acc69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_58a073bb-f660-4e00-87ed-0841e0570d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_aee61264-9dc7-4b9a-b463-96af6bd8bff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_58a073bb-f660-4e00-87ed-0841e0570d5b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_aee61264-9dc7-4b9a-b463-96af6bd8bff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_456dce9f-8f77-4ce4-b1d3-0f01d694bc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_58a073bb-f660-4e00-87ed-0841e0570d5b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_456dce9f-8f77-4ce4-b1d3-0f01d694bc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_044b55e1-92e4-417f-9bc0-7748b4f8d7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_044b55e1-92e4-417f-9bc0-7748b4f8d7ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_957626f5-4bdf-4c65-81ec-47c6ac9ee7d4" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_957626f5-4bdf-4c65-81ec-47c6ac9ee7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6b2de8fe-2373-4c76-a8b6-bb8569cb5ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6b2de8fe-2373-4c76-a8b6-bb8569cb5ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b8d560c0-dae4-4310-a507-2cab7f5966ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b8d560c0-dae4-4310-a507-2cab7f5966ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_44ae8d37-1265-4269-b31c-5722887e55fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_44ae8d37-1265-4269-b31c-5722887e55fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f1a26eb9-3370-4c75-934f-41aeb54efcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_f1a26eb9-3370-4c75-934f-41aeb54efcb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_180fd943-4e99-4791-a005-a329ef811dee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_180fd943-4e99-4791-a005-a329ef811dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_144ae9c5-72ed-45a1-bf80-929420b1f89c" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_144ae9c5-72ed-45a1-bf80-929420b1f89c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_fa080507-65a5-4170-b07d-f783e4dc0ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_fa080507-65a5-4170-b07d-f783e4dc0ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsLeaseLiabilities_99378806-c317-4d36-ad2f-605c798b3b04" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_pgen_DeferredTaxAssetsLeaseLiabilities_99378806-c317-4d36-ad2f-605c798b3b04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_ab383434-09c1-433b-8f94-00e0427bd704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_ab383434-09c1-433b-8f94-00e0427bd704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_cbff9f99-cad7-4b35-8856-66d6953256a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0041f1d4-b8d6-4d7c-9485-13e74ac0cc49" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_cbff9f99-cad7-4b35-8856-66d6953256a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_91868701-99d6-445a-8373-ffdc7d85275e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_2eb15056-0949-4582-921e-2b2b957008ec" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91868701-99d6-445a-8373-ffdc7d85275e" xlink:to="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_2eb15056-0949-4582-921e-2b2b957008ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b82d301d-d2fa-4860-b4cb-54db301d380d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91868701-99d6-445a-8373-ffdc7d85275e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b82d301d-d2fa-4860-b4cb-54db301d380d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_709c5c55-24b0-4610-9ec2-b10e5b2e637c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_997778ea-d43d-4788-a3ad-672b86ee7318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_709c5c55-24b0-4610-9ec2-b10e5b2e637c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_997778ea-d43d-4788-a3ad-672b86ee7318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_caa17551-f38e-422f-bd5c-189ee052b18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_709c5c55-24b0-4610-9ec2-b10e5b2e637c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_caa17551-f38e-422f-bd5c-189ee052b18f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeases" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeases"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ead22a9f-27af-4db3-a35a-c41b393c31a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cdbf1446-806f-4730-bf3a-75caf1c0ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ead22a9f-27af-4db3-a35a-c41b393c31a9" xlink:to="loc_us-gaap_OperatingLeaseCost_cdbf1446-806f-4730-bf3a-75caf1c0ad3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_b1933ac2-eb41-47e5-9eb1-b13816bc446f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ead22a9f-27af-4db3-a35a-c41b393c31a9" xlink:to="loc_us-gaap_ShortTermLeaseCost_b1933ac2-eb41-47e5-9eb1-b13816bc446f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_51cbc7f0-b2a6-45f7-8c46-5f8e5ea41254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ead22a9f-27af-4db3-a35a-c41b393c31a9" xlink:to="loc_us-gaap_VariableLeaseCost_51cbc7f0-b2a6-45f7-8c46-5f8e5ea41254" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_396944d8-cacf-4f9b-96fc-e340498229d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4859c097-6a50-4210-ac8c-36898d991e26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_396944d8-cacf-4f9b-96fc-e340498229d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4859c097-6a50-4210-ac8c-36898d991e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97df4f6e-3af6-4ab6-a000-5a2b67202aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_396944d8-cacf-4f9b-96fc-e340498229d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97df4f6e-3af6-4ab6-a000-5a2b67202aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2e25d41-0d6b-4070-8f8e-af452c72018b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_50b07904-7961-4936-81dc-18c547e396e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2e25d41-0d6b-4070-8f8e-af452c72018b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_50b07904-7961-4936-81dc-18c547e396e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ebb8349b-4e1e-497e-963d-a2c9f9e123c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2e25d41-0d6b-4070-8f8e-af452c72018b" xlink:to="loc_us-gaap_OperatingLeaseLiability_ebb8349b-4e1e-497e-963d-a2c9f9e123c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ae7883cd-b48d-417a-b19d-d347c9198dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ae7883cd-b48d-417a-b19d-d347c9198dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18baae7-8b45-4d52-8d5e-1dfea6a3178d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b18baae7-8b45-4d52-8d5e-1dfea6a3178d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1541e0d0-939a-4287-b6a5-ccb8fac7bd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1541e0d0-939a-4287-b6a5-ccb8fac7bd39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_504de439-38cf-419d-882d-2c8b57705193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_504de439-38cf-419d-882d-2c8b57705193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0b606ce-b69d-4771-a1b2-544d2ab08b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0b606ce-b69d-4771-a1b2-544d2ab08b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4753de16-307c-4dc1-9ad0-00c227f46001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50c12717-41cd-4abc-bbec-3ea5385ceed4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4753de16-307c-4dc1-9ad0-00c227f46001" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesLeaseTermsandDiscountRatesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesOtherInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingenciesContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShare" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShare"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/NetLossperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/NetLossperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/Segments" xlink:type="simple" xlink:href="pgen-20201231.xsd#Segments"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/Segments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SegmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsInformationbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlans" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlans"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DefinedContributionPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlansAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>pgen-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.dna.com/role/CoverPage" xlink:type="simple" xlink:href="pgen-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CoverPage" xlink:type="extended" id="i97e30985defb4736b467c131cd6b1440_CoverPage"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="if11122c73f8b4df7a57f8a5e4cee26e6_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ic042b044329e449f85cf7d6d0ed47580_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_18712066-036f-4c44-ba7b-c950bc1b7dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_18712066-036f-4c44-ba7b-c950bc1b7dfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_df8d894c-184a-4b39-a43d-ad27f3d797a1" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_df8d894c-184a-4b39-a43d-ad27f3d797a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a45de100-073f-41ea-9c18-c06396740636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a45de100-073f-41ea-9c18-c06396740636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d39e7963-8eb2-4a9b-9fec-8a8cf3411b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_LongTermDebtCurrent_d39e7963-8eb2-4a9b-9fec-8a8cf3411b1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dc92e7d9-f1a4-43c6-bec8-5ef410cc0458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dc92e7d9-f1a4-43c6-bec8-5ef410cc0458" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f887f93-f124-4b6a-bea8-d4a8e8e04787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f887f93-f124-4b6a-bea8-d4a8e8e04787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1b754b80-2f99-404d-bcef-a9fa7063d8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1b754b80-2f99-404d-bcef-a9fa7063d8b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e61b0694-02b4-4e87-857d-7f987bf3c967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesIssued_e61b0694-02b4-4e87-857d-7f987bf3c967" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1cbe9674-d356-46aa-9aeb-7d7e46d18467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1cbe9674-d356-46aa-9aeb-7d7e46d18467" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0c1e9ff5-e947-403a-bb7a-1650647b4823_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:to="loc_us-gaap_RelatedPartyDomain_0c1e9ff5-e947-403a-bb7a-1650647b4823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:to="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_6d4ba452-bf6d-4f8f-a1fe-a532aade794d" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_6d4ba452-bf6d-4f8f-a1fe-a532aade794d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i959ef8879bb54a689c1e096cba37b7f4_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c6c6be5-c8ee-4780-a744-ae01124fd7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c6c6be5-c8ee-4780-a744-ae01124fd7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5c71cfcd-97d1-4579-a43f-ebb28268af26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5c71cfcd-97d1-4579-a43f-ebb28268af26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b92b148f-4c05-4b5c-aa5a-c01e3fea8c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b92b148f-4c05-4b5c-aa5a-c01e3fea8c6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dcf9e771-068f-4ed5-a393-519c694a7b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dcf9e771-068f-4ed5-a393-519c694a7b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2ce7834f-cfdb-417c-86e0-894c4fda82f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2ce7834f-cfdb-417c-86e0-894c4fda82f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_7491dee8-2031-4a18-b94c-6fdb178175dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_7491dee8-2031-4a18-b94c-6fdb178175dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_196e57ca-2c90-43df-9db7-d29d83dcd115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_OperatingExpenses_196e57ca-2c90-43df-9db7-d29d83dcd115" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_04b0dd97-0773-463f-a364-143278b9ea73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_OperatingIncomeLoss_04b0dd97-0773-463f-a364-143278b9ea73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cd31d639-4aee-423d-89eb-dd34edbcbf06" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cd31d639-4aee-423d-89eb-dd34edbcbf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_49e7f062-6e7e-433c-b527-e097d07db228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_InterestExpense_49e7f062-6e7e-433c-b527-e097d07db228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9d571cea-cc93-4fcb-a398-7f0680f1a386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9d571cea-cc93-4fcb-a398-7f0680f1a386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3b1beaf0-3d51-422d-9dd8-a8d16de2f742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3b1beaf0-3d51-422d-9dd8-a8d16de2f742" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0c72782d-6737-4b17-9b43-cb5ad8a7f202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0c72782d-6737-4b17-9b43-cb5ad8a7f202" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_783dd99e-6c6c-4f7a-9c51-6a958530e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_783dd99e-6c6c-4f7a-9c51-6a958530e922" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a43737f9-bd0d-4cca-8b44-38f2be82e231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a43737f9-bd0d-4cca-8b44-38f2be82e231" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_90bf1748-fe7e-485e-93ef-d9049800249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_90bf1748-fe7e-485e-93ef-d9049800249f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dae8c117-8288-4029-ab16-588b66afbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dae8c117-8288-4029-ab16-588b66afbce0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_945680d8-6ecd-433e-b951-0a2045561f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_945680d8-6ecd-433e-b951-0a2045561f9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ec043867-3f8e-488b-a109-9c810fbf6b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_ProfitLoss_ec043867-3f8e-488b-a109-9c810fbf6b75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dcf63e3b-8878-4adf-9eb2-328b817d97ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dcf63e3b-8878-4adf-9eb2-328b817d97ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ffa62f2-81c0-4e1c-8295-731a7dfabcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NetIncomeLoss_3ffa62f2-81c0-4e1c-8295-731a7dfabcd4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_6b3b1e93-c31d-48c3-9642-39b6604e6829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_6b3b1e93-c31d-48c3-9642-39b6604e6829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_654364aa-5e0e-4d9a-ada2-099c3fa3810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_654364aa-5e0e-4d9a-ada2-099c3fa3810b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f842451-571a-433c-aea0-5b62160b2197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8c5b38e9-7c88-4d70-ac08-0cfbdb2e99db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8c5b38e9-7c88-4d70-ac08-0cfbdb2e99db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_cb793589-4838-4eb8-8670-2bc2b256871e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_cb793589-4838-4eb8-8670-2bc2b256871e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_67b9ee70-5de5-4411-91d9-ea76f402f743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_67b9ee70-5de5-4411-91d9-ea76f402f743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_124365e2-a973-47c2-896b-90e526ed4a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_124365e2-a973-47c2-896b-90e526ed4a1c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_831eca24-cc3b-4993-b6f5-9f28e181ea85_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_831eca24-cc3b-4993-b6f5-9f28e181ea85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_825e71c7-c6bd-4d66-a492-815175bea4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_825e71c7-c6bd-4d66-a492-815175bea4d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e66d6650-229f-42d0-8af9-a3a8aecce35f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:to="loc_srt_ProductsAndServicesDomain_e66d6650-229f-42d0-8af9-a3a8aecce35f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:to="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c43ff0be-0384-4591-898f-0530a6ad0ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_us-gaap_ProductMember_c43ff0be-0384-4591-898f-0530a6ad0ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6b5aa0b6-3c1b-4fa0-983e-542cb74e0dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_us-gaap_ServiceMember_6b5aa0b6-3c1b-4fa0-983e-542cb74e0dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherMember_481275c9-5a7b-43ec-bfa2-9c7f0f54db00" xlink:href="pgen-20201231.xsd#pgen_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_pgen_OtherMember_481275c9-5a7b-43ec-bfa2-9c7f0f54db00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e9039be-5c76-4a42-b35c-6cf8ffe09553_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e9039be-5c76-4a42-b35c-6cf8ffe09553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_59ca5168-9fb3-4e95-98f3-4a003b8c6208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_59ca5168-9fb3-4e95-98f3-4a003b8c6208" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperationsParenthetical"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="extended" id="i20f0a26cbeda47d4a6c0ecdc8cedc663_ConsolidatedStatementsofOperationsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177a1eb9-2533-4e19-a0d8-8ed8ebfde312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177a1eb9-2533-4e19-a0d8-8ed8ebfde312" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_2788c35e-90f8-4a55-8535-26e6aefd0907_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_2788c35e-90f8-4a55-8535-26e6aefd0907_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_4445e4b6-0aa7-4294-ae51-c9a2e54f6ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_4445e4b6-0aa7-4294-ae51-c9a2e54f6ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c2c4bd2-cb4c-4694-84b9-c469b748d52c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c2c4bd2-cb4c-4694-84b9-c469b748d52c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_10a6c2ee-d17d-48a7-be9a-99e4137f5d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:to="loc_us-gaap_CollaborativeArrangementMember_10a6c2ee-d17d-48a7-be9a-99e4137f5d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f8247135-2562-4841-b666-6d0868ad86c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:to="loc_us-gaap_RelatedPartyDomain_f8247135-2562-4841-b666-6d0868ad86c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:to="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_6ffdf392-f54e-4953-982a-da3e304866a1" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_6ffdf392-f54e-4953-982a-da3e304866a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="pgen-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i05df55c764e6484cb95c9ece5428654f_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofShareholdersandTotalEquity"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="extended" id="id13e7f33177a42ff9eb71f8c6df42cbf_ConsolidatedStatementsofShareholdersandTotalEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32121acd-d9db-4615-a5a6-811bd275cff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32121acd-d9db-4615-a5a6-811bd275cff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc40ddf5-65d7-4d1e-95aa-7fe72e0a7fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc40ddf5-65d7-4d1e-95aa-7fe72e0a7fa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_983516f7-3605-46c0-b95e-2a0bd04bff2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_983516f7-3605-46c0-b95e-2a0bd04bff2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_591868a7-f69c-4ea9-b322-c2dfbf74f9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_591868a7-f69c-4ea9-b322-c2dfbf74f9f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_ee364fd5-9a13-4f2f-b97d-5ba4b78cb3e0" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_ee364fd5-9a13-4f2f-b97d-5ba4b78cb3e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_c988f865-564f-482b-9bcc-217031d1b416" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_c988f865-564f-482b-9bcc-217031d1b416" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_d852f1a1-3c97-45ff-a4ff-9794315006af" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_d852f1a1-3c97-45ff-a4ff-9794315006af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_576371fe-5889-41e7-9635-b08744d759b7" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_576371fe-5889-41e7-9635-b08744d759b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_3d449c84-c038-40e4-b021-517728f975ad" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodValueAccruedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_3d449c84-c038-40e4-b021-517728f975ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_fec6cbc9-e674-4581-9f4a-18c27ee952cf" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodSharesAccruedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_fec6cbc9-e674-4581-9f4a-18c27ee952cf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_da26e143-5af3-4480-b42b-a1ae47e47fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_da26e143-5af3-4480-b42b-a1ae47e47fc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_129561c3-c190-4160-864e-bcfcba88b706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_129561c3-c190-4160-864e-bcfcba88b706" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d99e9a4-43a3-4791-bbb8-5ec06a7613a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d99e9a4-43a3-4791-bbb8-5ec06a7613a6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ea68390-9327-4c77-ba2d-b7045b9c9b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ea68390-9327-4c77-ba2d-b7045b9c9b84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3ed19391-901c-454b-a177-548bfcc288b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3ed19391-901c-454b-a177-548bfcc288b0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_85f3f842-976a-4b38-a344-1588a276c92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_85f3f842-976a-4b38-a344-1588a276c92f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3d39c258-58d1-4288-96da-05017c8827c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3d39c258-58d1-4288-96da-05017c8827c2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_e63ef13f-97f5-4e47-936a-57a29eebac49" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_e63ef13f-97f5-4e47-936a-57a29eebac49" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_558e607e-ee16-4937-a9c8-09e0972771dc" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_558e607e-ee16-4937-a9c8-09e0972771dc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OwnshareLendingArrangementSharesIssued1_012257c0-3e67-47bc-ae2e-5e52840db60e" xlink:href="pgen-20201231.xsd#pgen_OwnshareLendingArrangementSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_OwnshareLendingArrangementSharesIssued1_012257c0-3e67-47bc-ae2e-5e52840db60e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_86fcad6c-b591-469f-9d44-f6769cec3d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_86fcad6c-b591-469f-9d44-f6769cec3d21" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_dd96d145-6cad-4f11-8cab-32829280264d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_dd96d145-6cad-4f11-8cab-32829280264d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_Adjustmentsfornoncontrollinginterests_6825001a-fe2a-46d4-8fbe-23d61d973e52" xlink:href="pgen-20201231.xsd#pgen_Adjustmentsfornoncontrollinginterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_Adjustmentsfornoncontrollinginterests_6825001a-fe2a-46d4-8fbe-23d61d973e52" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_b136c131-31e5-4f49-8fe8-98119c0d07d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_b136c131-31e5-4f49-8fe8-98119c0d07d9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b51069f2-2143-42ee-bbc6-7f494d8cec98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_ProfitLoss_b51069f2-2143-42ee-bbc6-7f494d8cec98" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_ae780ddc-1e3f-4932-8f66-6712a32d42fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_ae780ddc-1e3f-4932-8f66-6712a32d42fa" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bdcfb7d9-6177-44cc-a26e-999b99754fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bdcfb7d9-6177-44cc-a26e-999b99754fd2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43f72e68-ea42-48cd-9261-4b1467e1380f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a68d11ed-685c-47af-99ca-8d430ad5e009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:to="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:to="loc_us-gaap_EquityComponentDomain_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:to="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:to="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_126d63da-cd78-486a-a8a4-c106b13130c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_CommonStockMember_126d63da-cd78-486a-a8a4-c106b13130c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ea9e4c5-1b7d-4f88-a8f2-b46cb59c848d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ea9e4c5-1b7d-4f88-a8f2-b46cb59c848d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_777dceeb-7484-474c-a6ce-f743e6b63c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_777dceeb-7484-474c-a6ce-f743e6b63c75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a9e9534c-8829-49a3-ab5b-8cde68414662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_RetainedEarningsMember_a9e9534c-8829-49a3-ab5b-8cde68414662" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_da7270c9-db5e-4586-8291-bf7a74a04a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_da7270c9-db5e-4586-8291-bf7a74a04a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af47f082-ba0b-4b15-aa67-8d972181752a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af47f082-ba0b-4b15-aa67-8d972181752a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i9921e5cb4cc441ec9a0c2e3b683c4a1d_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlowsReconciliationofCash"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="extended" id="id6ed57f6de5b4547a23a2b5e2d28398a_ConsolidatedStatementsofCashFlowsReconciliationofCash"/>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i7863fde9e50e47ad81b224ddd236875c_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="extended" id="id694c34f9562467988ad875760dce313_OrganizationandBasisofPresentationAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i5af86130d186411590570b4a8f4b5386_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic61c0e1bcd904125b3f0f0eff4b4f0ae_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i045ae0c0f1e049c3866b8fa879c51ca3_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="iecea4fb80e9b441d9838703db62ce192_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:href="pgen-20201231.xsd#pgen_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementTerminationNoticePeriod_a316057e-f578-4ee2-8903-46fd08f7363c" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_CollaborationAgreementTerminationNoticePeriod_a316057e-f578-4ee2-8903-46fd08f7363c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_996a9d6a-eea4-41dc-a8b2-fac927d92330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_996a9d6a-eea4-41dc-a8b2-fac927d92330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_8a30942e-4040-4b0b-965b-da2f47bae07a" xlink:href="pgen-20201231.xsd#pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_8a30942e-4040-4b0b-965b-da2f47bae07a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_171cc394-11b7-4401-82ca-2eedeef25b2f" xlink:href="pgen-20201231.xsd#pgen_HighlyLiquidInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_171cc394-11b7-4401-82ca-2eedeef25b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c120f161-dfd5-4514-8441-9093fc19f89c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c120f161-dfd5-4514-8441-9093fc19f89c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_5b1a1eab-018f-4c39-bd7a-ec02a085b20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_5b1a1eab-018f-4c39-bd7a-ec02a085b20b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5a9e4b1c-583d-4274-8052-76ede146966b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5a9e4b1c-583d-4274-8052-76ede146966b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e75c2004-d628-47cd-90c8-535f7c327598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e75c2004-d628-47cd-90c8-535f7c327598" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a15c03db-a3f9-41de-a7f5-6cfc2a9a86b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a15c03db-a3f9-41de-a7f5-6cfc2a9a86b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:href="pgen-20201231.xsd#pgen_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ff8e968-9e4b-47c0-990a-506f02bb27d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ff8e968-9e4b-47c0-990a-506f02bb27d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_302b3a22-2e4f-4179-93e9-03a51630e4c4" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_302b3a22-2e4f-4179-93e9-03a51630e4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51644b5c-c9b0-42fb-856b-5e633fb6e1d7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:to="loc_srt_ProductsAndServicesDomain_51644b5c-c9b0-42fb-856b-5e633fb6e1d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:to="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationandlicensingagreementsMember_c28aa82f-893f-4ed0-a814-30f648ec2fa6" xlink:href="pgen-20201231.xsd#pgen_CollaborationandlicensingagreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:to="loc_pgen_CollaborationandlicensingagreementsMember_c28aa82f-893f-4ed0-a814-30f648ec2fa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProductsandServicesRevenuesMember_a7fbae9f-91ed-45c3-b0db-a9030fa103cd" xlink:href="pgen-20201231.xsd#pgen_ProductsandServicesRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:to="loc_pgen_ProductsandServicesRevenuesMember_a7fbae9f-91ed-45c3-b0db-a9030fa103cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80ecd6c4-abf9-4058-8dfe-744f9b01ab63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:to="loc_us-gaap_PlanNameDomain_80ecd6c4-abf9-4058-8dfe-744f9b01ab63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:to="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_78ee8e26-783c-430c-9e85-9c0bd8a5d7c6" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_78ee8e26-783c-430c-9e85-9c0bd8a5d7c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:to="loc_srt_RangeMember_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:to="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50176dba-0681-486b-927a-fe485d9e4a51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:to="loc_srt_MinimumMember_50176dba-0681-486b-927a-fe485d9e4a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aee7cef7-fce8-4881-b084-3e3acbff8ebe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:to="loc_srt_MaximumMember_aee7cef7-fce8-4881-b084-3e3acbff8ebe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="extended" id="id2e6e73acaef486eb3d162c1155bd65c_SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_98fe53df-06d1-413d-8abd-df65f14b65ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_98fe53df-06d1-413d-8abd-df65f14b65ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5b2e419e-5197-406e-a95d-30e427d2c58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5b2e419e-5197-406e-a95d-30e427d2c58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2d79f1bb-ad77-498e-bc8e-20e4927b4181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2d79f1bb-ad77-498e-bc8e-20e4927b4181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0087afdd-398a-4668-883c-0e0fb9296d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_6d1ec04c-f6af-4667-9e05-24ade63468ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_6d1ec04c-f6af-4667-9e05-24ade63468ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended" id="ifef0b374df5547b0acc9ad802245dbe6_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cbdb529d-f5b4-460f-ad33-ed50ae255d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cbdb529d-f5b4-460f-ad33-ed50ae255d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:to="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c1be996-bbd0-4418-9577-9ae94f02c097_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:to="loc_srt_RangeMember_7c1be996-bbd0-4418-9577-9ae94f02c097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:to="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7b3f0e1-26b7-490f-8423-d540b7f21f0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:to="loc_srt_MinimumMember_c7b3f0e1-26b7-490f-8423-d540b7f21f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c50466f6-2db1-4e22-9b35-1905bac76c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:to="loc_srt_MaximumMember_c50466f6-2db1-4e22-9b35-1905bac76c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_981abee4-4b2e-4ff0-90b3-d1f9063444db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_981abee4-4b2e-4ff0-90b3-d1f9063444db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_f1b99418-0d57-47ab-b9a6-40c69cce89c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_LandImprovementsMember_f1b99418-0d57-47ab-b9a6-40c69cce89c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_be28a3a0-810a-4d77-a8e9-83f577c59818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_be28a3a0-810a-4d77-a8e9-83f577c59818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0e17c9c3-07f9-46fb-9e49-5d1418f4f657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0e17c9c3-07f9-46fb-9e49-5d1418f4f657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_dcf44379-8ce5-427e-841f-6223f6a51ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_EquipmentMember_dcf44379-8ce5-427e-841f-6223f6a51ad3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BreedingAndProductionAnimalsMember_c4c057c4-beda-42b9-a7eb-f2470ce0adf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BreedingAndProductionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_BreedingAndProductionAnimalsMember_c4c057c4-beda-42b9-a7eb-f2470ce0adf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftwareMember_8d730932-0bff-424e-a700-5f117dd85c80" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_pgen_ComputerHardwareandSoftwareMember_8d730932-0bff-424e-a700-5f117dd85c80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3e26b2b2-33a1-4116-9f7a-b3de706350fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3e26b2b2-33a1-4116-9f7a-b3de706350fc" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="extended" id="i7a3fff7bf7f943b9b2c1c04f9070bf37_SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7bb497a-750b-46f6-8f98-0b24d85a0881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7bb497a-750b-46f6-8f98-0b24d85a0881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_297acc04-9e53-4b23-baf0-0239c03a5b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_297acc04-9e53-4b23-baf0-0239c03a5b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_567aff32-5e84-43f8-b2aa-41ccf30e61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_567aff32-5e84-43f8-b2aa-41ccf30e61ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4101fdb6-bbe3-406f-ab9f-8ec76801a632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4101fdb6-bbe3-406f-ab9f-8ec76801a632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ea44905c-2d3a-4594-9283-0c67272b297b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ea44905c-2d3a-4594-9283-0c67272b297b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86a59c12-3a81-446f-a505-5ce49f484ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86a59c12-3a81-446f-a505-5ce49f484ded" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:to="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5ede9366-70a4-4e57-be83-d70dd9b953f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:to="loc_us-gaap_PlanNameDomain_5ede9366-70a4-4e57-be83-d70dd9b953f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:to="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_08ee7c05-0d3c-41f0-8168-8974d8801f6e" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_08ee7c05-0d3c-41f0-8168-8974d8801f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:to="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a06ba27-0d85-4e35-80cc-d2227134ecb7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:to="loc_srt_RangeMember_5a06ba27-0d85-4e35-80cc-d2227134ecb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:to="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65a88ab6-d762-4c90-a30d-60c399d3e7ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:to="loc_srt_MinimumMember_65a88ab6-d762-4c90-a30d-60c399d3e7ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9840fe6-7373-4c26-9e82-e8c7ddf037fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:to="loc_srt_MaximumMember_e9840fe6-7373-4c26-9e82-e8c7ddf037fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperations"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperations" xlink:type="extended" id="ieae944415dd94b6a91f097c7ee951acb_DiscontinuedOperations"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="extended" id="i4e8bb6ea94804a5ea25c08c38c3e6e2f_DiscontinuedOperationsTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="extended" id="i7fd4522b06144633bca70e45ca1c497d_DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c461f8d0-16fe-425a-b68f-76125caa09b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c461f8d0-16fe-425a-b68f-76125caa09b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c3f5d8b5-49f0-4fbf-92c8-c94fb4615fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c3f5d8b5-49f0-4fbf-92c8-c94fb4615fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_99f34ca9-26a8-4ef1-acf5-7e36fe80d563" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_99f34ca9-26a8-4ef1-acf5-7e36fe80d563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2f9be42f-b436-46bf-abf5-92bafa064ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2f9be42f-b436-46bf-abf5-92bafa064ff6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e0aba335-074c-4c68-9098-d715a74397e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e0aba335-074c-4c68-9098-d715a74397e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_dd3c57aa-1404-4d14-b938-6ba7b5c6fc59" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_dd3c57aa-1404-4d14-b938-6ba7b5c6fc59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_99ce6e06-0043-418c-8b0c-93be5dd42f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_99ce6e06-0043-418c-8b0c-93be5dd42f76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_37588f4c-4d6f-4640-adf8-2b25b53bd54c" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_37588f4c-4d6f-4640-adf8-2b25b53bd54c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4c306086-7195-41ee-8dec-c2879e248d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4c306086-7195-41ee-8dec-c2879e248d2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_66ca78b5-0593-4863-8819-f3bb2265831d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_66ca78b5-0593-4863-8819-f3bb2265831d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_00045082-6529-4ce8-9d0e-c07d6f509697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_00045082-6529-4ce8-9d0e-c07d6f509697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2af8c617-f6ce-4048-8021-daeff856b90a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2af8c617-f6ce-4048-8021-daeff856b90a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_95ce8bfb-2f7e-4e60-83b4-ce1fb86e738d" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:to="loc_pgen_MBPTitanMember_95ce8bfb-2f7e-4e60-83b4-ce1fb86e738d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="extended" id="i117c797ba06b4af39207d45abd5d941b_DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_c725df85-66eb-4514-a53f-16e1466b2dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_c725df85-66eb-4514-a53f-16e1466b2dfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d6243ecb-0f31-4ff7-a7ff-f75e437ca1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d6243ecb-0f31-4ff7-a7ff-f75e437ca1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_3d95ff6e-ee69-48af-af33-27047ad6c2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_3d95ff6e-ee69-48af-af33-27047ad6c2c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_48df57d0-c966-46c8-928d-f4dfc9d8ef09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_48df57d0-c966-46c8-928d-f4dfc9d8ef09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1885b18a-71fe-4818-8f5c-372621ece321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1885b18a-71fe-4818-8f5c-372621ece321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_25f3ab1c-4687-4d9f-87ad-0301cda37c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_25f3ab1c-4687-4d9f-87ad-0301cda37c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10f16171-3945-49c8-be7c-d42c77903d7c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_10f16171-3945-49c8-be7c-d42c77903d7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_0d2bbbb2-4831-496b-9fa6-4d65474c9d0b" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:to="loc_pgen_MBPTitanMember_0d2bbbb2-4831-496b-9fa6-4d65474c9d0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_69155bdb-d9bb-4e97-986f-2fe9001b3941_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_69155bdb-d9bb-4e97-986f-2fe9001b3941_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_cd089b48-c158-4974-9599-ed5790dddb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_cd089b48-c158-4974-9599-ed5790dddb65" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="extended" id="ia3f91542d48e4b3fb115b4351a000492_DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b437006-4951-4b82-9039-884923d8a055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b437006-4951-4b82-9039-884923d8a055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ecfca031-8c62-4976-9d4f-066a70f22363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ecfca031-8c62-4976-9d4f-066a70f22363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d4e24f1c-350e-4259-9260-12c25f8642cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d4e24f1c-350e-4259-9260-12c25f8642cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f4d0d9de-24c7-464a-90c0-b8227bcd181e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_ShareBasedCompensation_f4d0d9de-24c7-464a-90c0-b8227bcd181e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c01ed41-ff1a-4f61-91fe-d711a51a1ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c01ed41-ff1a-4f61-91fe-d711a51a1ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b6fdf9ce-641f-4514-80c4-13f7000f501d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b6fdf9ce-641f-4514-80c4-13f7000f501d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_a3a55065-8fb9-4a4b-ab14-2eb80f388714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_a3a55065-8fb9-4a4b-ab14-2eb80f388714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6232db8-c43e-4d0d-b014-fca599a15e78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c6232db8-c43e-4d0d-b014-fca599a15e78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_4e016fa8-093c-4a72-ac56-4bc2a37cb5c8" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:to="loc_pgen_MBPTitanMember_4e016fa8-093c-4a72-ac56-4bc2a37cb5c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended" id="ie35a4298a4e74442a49250631ad5e4a3_DiscontinuedOperationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_620ab3c4-d7bf-485d-ad47-5fc1e8c90474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_620ab3c4-d7bf-485d-ad47-5fc1e8c90474" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3244524f-e443-4d48-9347-3248353202f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_AssetImpairmentCharges_3244524f-e443-4d48-9347-3248353202f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_31a31436-ba7b-4807-b885-4c674b316940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_31a31436-ba7b-4807-b885-4c674b316940" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_fe00ca4c-ac52-4324-bc53-8a2be5700021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_fe00ca4c-ac52-4324-bc53-8a2be5700021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_aef0562b-7280-4448-868b-2045ff1eeb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_aef0562b-7280-4448-868b-2045ff1eeb17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4677263f-4b30-4f0f-841e-4c6d9de34629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4677263f-4b30-4f0f-841e-4c6d9de34629" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_f9e7678f-4c5a-4608-bf44-98deaaea3305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_f9e7678f-4c5a-4608-bf44-98deaaea3305" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_47d44a70-9607-403c-b593-f1d920697650_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:to="loc_us-gaap_ReportingUnitDomain_47d44a70-9607-403c-b593-f1d920697650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:to="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_d8c88fad-864d-4cd7-80d9-bede1edf545f" xlink:href="pgen-20201231.xsd#pgen_OkanaganOxitecFineChemicalsAndAgBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:to="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_d8c88fad-864d-4cd7-80d9-bede1edf545f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0ccba8f8-6662-416b-8f1e-b14620020de3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0ccba8f8-6662-416b-8f1e-b14620020de3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_a0613c7e-7d8d-4fc2-b2ec-cde9a992889c" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_a0613c7e-7d8d-4fc2-b2ec-cde9a992889c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_438df4d9-2627-47aa-a29e-3163ef8ba268" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_EnviroFlightLLCMember_438df4d9-2627-47aa-a29e-3163ef8ba268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_abbce8a5-e3d7-46bc-a890-19e8be6e91fc" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_abbce8a5-e3d7-46bc-a890-19e8be6e91fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5c90d604-fcd8-4621-90eb-cfa3cd959060_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5c90d604-fcd8-4621-90eb-cfa3cd959060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ffaefe0b-e5de-485a-b6d7-a8af79b9bf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ffaefe0b-e5de-485a-b6d7-a8af79b9bf5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_f37de2c5-df19-4cc8-b254-b48c0618038c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_f37de2c5-df19-4cc8-b254-b48c0618038c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended" id="ie393b2fb529147fe9465cb7cda0a1d92_DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_785da446-d2ff-49a5-9143-756016eaaf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_785da446-d2ff-49a5-9143-756016eaaf5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f3737d65-69c5-4ed2-a450-3e8feb1dbb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f3737d65-69c5-4ed2-a450-3e8feb1dbb31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5f7e1fd8-3b2a-49e9-8f83-789666de927d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5f7e1fd8-3b2a-49e9-8f83-789666de927d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_69e405e1-cb1a-4e39-9d63-d7d16368f853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_69e405e1-cb1a-4e39-9d63-d7d16368f853" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_b5cea2b8-bb2f-48ec-8f48-7fd218a9e73e" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_b5cea2b8-bb2f-48ec-8f48-7fd218a9e73e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_ce9000e3-b907-4683-b67b-ebe82adfd7d1" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_ce9000e3-b907-4683-b67b-ebe82adfd7d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_964f270e-2bde-409a-abd1-b76560d75ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_964f270e-2bde-409a-abd1-b76560d75ed4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_a799f016-e12e-4a65-bfbb-e12df45a8fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_a799f016-e12e-4a65-bfbb-e12df45a8fce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_b099d6c8-5cac-489f-aeb9-a8cac762c919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_b099d6c8-5cac-489f-aeb9-a8cac762c919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_247de821-9e1a-42d8-abd2-39836fef269c" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_247de821-9e1a-42d8-abd2-39836fef269c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3349ff1f-4dcc-4e32-9995-5b0f796233fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3349ff1f-4dcc-4e32-9995-5b0f796233fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_9c0d6529-6f2f-40c7-8c7a-06d6a6d822f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_9c0d6529-6f2f-40c7-8c7a-06d6a6d822f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_161ed772-7b6e-4058-9f5e-9e03a0abcd95" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_161ed772-7b6e-4058-9f5e-9e03a0abcd95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5a0b7c09-d906-4fc2-8ba4-f4260443bbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5a0b7c09-d906-4fc2-8ba4-f4260443bbd1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1ea2f860-5012-4b43-9894-b0901be0ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1ea2f860-5012-4b43-9894-b0901be0ac06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_add4bed8-1632-4834-955e-e9310312b3e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_add4bed8-1632-4834-955e-e9310312b3e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_541b47c4-5323-4124-8c0f-a85f62bd650c" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_541b47c4-5323-4124-8c0f-a85f62bd650c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_35d718ea-2370-4da8-a587-506618c47354" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:to="loc_pgen_EnviroFlightLLCMember_35d718ea-2370-4da8-a587-506618c47354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_efeb4ed7-86ac-487e-86f3-08c8d8764715_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_efeb4ed7-86ac-487e-86f3-08c8d8764715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7df3ed0a-bd0a-4a15-8604-1376beb86056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7df3ed0a-bd0a-4a15-8604-1376beb86056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_724ba564-9a1f-4451-b9ad-e9cdc24bc04b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:to="loc_us-gaap_RelatedPartyDomain_724ba564-9a1f-4451-b9ad-e9cdc24bc04b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:to="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_d2dfee0d-3ca3-4c9c-9459-6cb16b7f135a" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_d2dfee0d-3ca3-4c9c-9459-6cb16b7f135a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended" id="i7f3296a8c8614bf2ad4814b11c15b446_DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_61dff281-321c-4fb8-adad-4784feae7969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_61dff281-321c-4fb8-adad-4784feae7969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f153d8f2-5797-4f28-947f-d69e39818330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f153d8f2-5797-4f28-947f-d69e39818330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_9bfd9cc4-8f98-4844-bb6f-4342a8b3dc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_9bfd9cc4-8f98-4844-bb6f-4342a8b3dc5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7d643bcf-fb35-4780-906d-298a7ee08fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7d643bcf-fb35-4780-906d-298a7ee08fb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_00ee10eb-666d-49dd-adcb-4302c60d4655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_00ee10eb-666d-49dd-adcb-4302c60d4655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_90e646a6-34d8-4f13-add2-3a5fbb1a72a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_90e646a6-34d8-4f13-add2-3a5fbb1a72a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_62b97909-6137-4f59-bdae-9ab279239cb0" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_62b97909-6137-4f59-bdae-9ab279239cb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_711c2cda-f679-4040-802b-ab379e561005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_711c2cda-f679-4040-802b-ab379e561005" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_310b7ec0-979f-44cc-9cda-9d0892e966e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_310b7ec0-979f-44cc-9cda-9d0892e966e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_562590fb-b010-4e67-b632-1d506c59dbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_562590fb-b010-4e67-b632-1d506c59dbb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_40a5f41c-6270-4152-95a1-32835c30c101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_AssetImpairmentCharges_40a5f41c-6270-4152-95a1-32835c30c101" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5c2098c1-7d1b-45e7-a709-b6fd9d882db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5c2098c1-7d1b-45e7-a709-b6fd9d882db8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_965bf17b-fd08-4604-b657-939df2253375_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:to="loc_us-gaap_RelatedPartyDomain_965bf17b-fd08-4604-b657-939df2253375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:to="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_25c05b81-eda9-445c-b6fa-9bf78387e61c" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_25c05b81-eda9-445c-b6fa-9bf78387e61c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_cd8601ae-f856-4d01-9eea-e070c27b7620" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_cd8601ae-f856-4d01-9eea-e070c27b7620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_3f9dfdfd-4a05-4f00-a39d-41c2d3da7eb9" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_EnviroFlightLLCMember_3f9dfdfd-4a05-4f00-a39d-41c2d3da7eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_1ded4bea-1e31-4f73-9dd2-591b3f4dce2e" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_1ded4bea-1e31-4f73-9dd2-591b3f4dce2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9041ac0b-26ce-42f2-85c7-f1f59713f149_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9041ac0b-26ce-42f2-85c7-f1f59713f149_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6720f77a-2d74-4ae2-9210-40fc84195e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6720f77a-2d74-4ae2-9210-40fc84195e27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:to="loc_us-gaap_ReportingUnitDomain_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:to="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OxitecMember_d78a5d02-d29c-48f7-a3b4-45e05d91a82b" xlink:href="pgen-20201231.xsd#pgen_OxitecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:to="loc_pgen_OxitecMember_d78a5d02-d29c-48f7-a3b4-45e05d91a82b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="extended" id="i38c032ef7ec547ada4fd264fbb2c4a71_DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_677773c2-d8e6-4fce-918b-51c9cb91047e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_677773c2-d8e6-4fce-918b-51c9cb91047e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e38c9416-bebd-47ab-a0f7-c64e74efb076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e38c9416-bebd-47ab-a0f7-c64e74efb076" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_bac43223-27f5-4af0-bdbb-8fdde0ad78a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_bac43223-27f5-4af0-bdbb-8fdde0ad78a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_42ab40c0-06bd-4d88-abaa-1b819d296107" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_42ab40c0-06bd-4d88-abaa-1b819d296107" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4e04ccad-a4d5-4b69-915b-91ffb084f558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4e04ccad-a4d5-4b69-915b-91ffb084f558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cfde6d02-bc87-49a0-ace1-654dd80e97ed" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cfde6d02-bc87-49a0-ace1-654dd80e97ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_053daa4c-d632-4e12-bc40-e3f94732f0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_053daa4c-d632-4e12-bc40-e3f94732f0dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e61cb924-8a45-487b-baf9-30ff46d726d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_ShareBasedCompensation_e61cb924-8a45-487b-baf9-30ff46d726d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71199c4f-9a25-4dd8-9954-e471d77dfcd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71199c4f-9a25-4dd8-9954-e471d77dfcd8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8bef4dd2-a399-44aa-b81c-6202c0bf46dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8bef4dd2-a399-44aa-b81c-6202c0bf46dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a0fe57f-4329-408e-b3d4-1f48095440cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a0fe57f-4329-408e-b3d4-1f48095440cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_956b6850-14ba-4f3e-afc0-ec053e9c4d48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_956b6850-14ba-4f3e-afc0-ec053e9c4d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_ee42e845-4479-488f-927d-67f05afe553d" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_ee42e845-4479-488f-927d-67f05afe553d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_c351e0fa-e64b-4c9c-96e5-4b3323391e18" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:to="loc_pgen_EnviroFlightLLCMember_c351e0fa-e64b-4c9c-96e5-4b3323391e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_684dd452-9c6a-48fc-9e61-38a90e5ebf09_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_684dd452-9c6a-48fc-9e61-38a90e5ebf09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f8b7085a-b2d6-4f6b-8a03-3fff47b491a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f8b7085a-b2d6-4f6b-8a03-3fff47b491a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="extended" id="i07e58d5abcdc4ad991a8e50079600f10_DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_69b1f6da-461d-475f-9198-73575b388090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_AssetsCurrent_69b1f6da-461d-475f-9198-73575b388090" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_84b2c3e4-3df2-4893-a70f-ee2781991a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_AssetsNoncurrent_84b2c3e4-3df2-4893-a70f-ee2781991a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a0c3d082-8664-4133-b081-10ca51081a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Assets_a0c3d082-8664-4133-b081-10ca51081a20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a34954a2-8a6b-455c-b708-503693543445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_a34954a2-8a6b-455c-b708-503693543445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a3e3037d-d6a0-40df-840b-6205c60e0840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a3e3037d-d6a0-40df-840b-6205c60e0840" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a6f1bd3-53c4-4246-bb46-61bcdf3d19d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Liabilities_5a6f1bd3-53c4-4246-bb46-61bcdf3d19d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_6e274269-dc0f-4500-acc1-38185a113c67" xlink:href="pgen-20201231.xsd#pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_6e274269-dc0f-4500-acc1-38185a113c67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92a27da9-0b6c-44ad-a348-63f26ca3a564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Revenues_92a27da9-0b6c-44ad-a348-63f26ca3a564" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8d3c822f-15ba-4dad-93df-3ed5e4e4ab41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_OperatingExpenses_8d3c822f-15ba-4dad-93df-3ed5e4e4ab41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_112d62fd-0f17-4e54-b6d8-ca87a5dbc4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_GrossProfit_112d62fd-0f17-4e54-b6d8-ca87a5dbc4b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31192232-7ec0-4730-a86c-60c5ef054e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31192232-7ec0-4730-a86c-60c5ef054e03" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d6524074-2e06-4c2d-b41c-abac062aa5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_ProfitLoss_d6524074-2e06-4c2d-b41c-abac062aa5ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_6bf4d376-58d0-4820-88af-27a57543e9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_6bf4d376-58d0-4820-88af-27a57543e9b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_2af9263f-2224-4266-959c-d338f7a7cbc9" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:to="loc_pgen_EnviroFlightLLCMember_2af9263f-2224-4266-959c-d338f7a7cbc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyAndEnviroFlightMember_7ec93801-71c1-4363-8921-97ef3ffec2a4" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyAndEnviroFlightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:to="loc_pgen_TSBiotechnologyAndEnviroFlightMember_7ec93801-71c1-4363-8921-97ef3ffec2a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_ba9db28a-4165-4913-b609-fa4bcb5d9fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_ba9db28a-4165-4913-b609-fa4bcb5d9fac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_bb5d6994-a311-4b47-b58e-0dfcc3d9eda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_bb5d6994-a311-4b47-b58e-0dfcc3d9eda0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitions" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitions"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/MergersandAcquisitions" xlink:type="extended" id="ifbbc2d8c0c0142638119556370abca34_MergersandAcquisitions"/>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="extended" id="i5b20972c9634408296a0cabe17d577fd_MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_3d2809e5-bd18-4378-bfb1-76559174c4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_3d2809e5-bd18-4378-bfb1-76559174c4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CashInflowsOutflowsInAssetAcquisition_ef90fc71-a670-44ac-8b31-1f7ca13ebeaf" xlink:href="pgen-20201231.xsd#pgen_CashInflowsOutflowsInAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_pgen_CashInflowsOutflowsInAssetAcquisition_ef90fc71-a670-44ac-8b31-1f7ca13ebeaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_79d9cac7-8c73-4863-80aa-0c29f34f9f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_EquityMethodInvestments_79d9cac7-8c73-4863-80aa-0c29f34f9f5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_7c4426d8-e3a6-402e-b396-7d02c19ec2e8" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_7c4426d8-e3a6-402e-b396-7d02c19ec2e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2f5b14a1-aed8-4480-9333-6b601d80c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2f5b14a1-aed8-4480-9333-6b601d80c52e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_87e6a533-c77b-41ee-9e56-e07589087135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_87e6a533-c77b-41ee-9e56-e07589087135" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f94e8f7f-378c-4d64-be2f-358067392f27_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f94e8f7f-378c-4d64-be2f-358067392f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_cc34275b-61f0-4c84-b812-40f47ffa7d14" xlink:href="pgen-20201231.xsd#pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:to="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_cc34275b-61f0-4c84-b812-40f47ffa7d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fba131cc-47ca-4bd8-8125-4957ae4bca21_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:to="loc_dei_EntityDomain_fba131cc-47ca-4bd8-8125-4957ae4bca21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:to="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenActioBioIncMember_eb4dbb35-318a-49af-81b4-1620d8421225" xlink:href="pgen-20201231.xsd#pgen_PrecigenActioBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:to="loc_pgen_PrecigenActioBioIncMember_eb4dbb35-318a-49af-81b4-1620d8421225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4050fc03-2684-445a-aa92-b846060806a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:to="loc_us-gaap_RelatedPartyDomain_4050fc03-2684-445a-aa92-b846060806a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:to="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4932d912-e35d-4fc7-8a44-8185bade9f13" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4932d912-e35d-4fc7-8a44-8185bade9f13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVentures"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="extended" id="i372ce652232146f6a093a2eb61375b1d_InvestmentsinJointVentures"/>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="extended" id="ie9850dac300d496cbc4e68d42baaa023_InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_9605e1e5-1354-475a-a541-a5618107c9fa" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_9605e1e5-1354-475a-a541-a5618107c9fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b7650d2-feaf-4b0c-9588-6685259eb3cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b7650d2-feaf-4b0c-9588-6685259eb3cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_acf6f38d-3cff-4abc-84cd-037df032d8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_acf6f38d-3cff-4abc-84cd-037df032d8df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_9d932ae7-58a7-421d-b3f3-99e29ab12f15" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_9d932ae7-58a7-421d-b3f3-99e29ab12f15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_31481568-bbe3-446d-945c-d4e4684f9190" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_31481568-bbe3-446d-945c-d4e4684f9190" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoard_72c6d5f6-d870-4a06-9cb2-ba48d99204c4" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoard_72c6d5f6-d870-4a06-9cb2-ba48d99204c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_17845d2e-30e3-4acc-b1fb-abcc25a99c56" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_17845d2e-30e3-4acc-b1fb-abcc25a99c56" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_f814c7d7-1e70-4cdf-9aba-e772cea9aa50" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_f814c7d7-1e70-4cdf-9aba-e772cea9aa50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b2bd27c-56d8-4540-897f-c95f4b8a03d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_EquityMethodInvestments_2b2bd27c-56d8-4540-897f-c95f4b8a03d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb479db5-951c-4f1b-acd8-b46cecf6e6c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cb479db5-951c-4f1b-acd8-b46cecf6e6c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_fd831a27-e980-4624-82a8-d25e0fcafab3" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_fd831a27-e980-4624-82a8-d25e0fcafab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0a0fdfbd-054e-462c-b8b3-654c5def58f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0a0fdfbd-054e-462c-b8b3-654c5def58f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherAccruedLiabilitiesMember_a5fa7b11-5f69-4992-8a17-798e2a75cc6b" xlink:href="pgen-20201231.xsd#pgen_OtherAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:to="loc_pgen_OtherAccruedLiabilitiesMember_a5fa7b11-5f69-4992-8a17-798e2a75cc6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_41310591-a5c1-41df-974e-69cab1931abf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:to="loc_us-gaap_RelatedPartyDomain_41310591-a5c1-41df-974e-69cab1931abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:to="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_45850696-6be7-4369-b7cf-a3f27f4aa6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:to="loc_us-gaap_InvestorMember_45850696-6be7-4369-b7cf-a3f27f4aa6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_79ffde6c-7689-4e13-9925-460852070f15_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_79ffde6c-7689-4e13-9925-460852070f15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_77ff1d8c-9164-4c2e-9245-758d9fa8dacb" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_77ff1d8c-9164-4c2e-9245-758d9fa8dacb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89f70e19-5e84-4981-a106-4bf53f12672b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89f70e19-5e84-4981-a106-4bf53f12672b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_13cd80a0-9594-43dd-93e8-15a6fe36a065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:to="loc_us-gaap_CollaborativeArrangementMember_13cd80a0-9594-43dd-93e8-15a6fe36a065" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="extended" id="ic3cbf4ff30b946d480052cfc81f51e44_InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_bf06ee6a-5ea2-48cc-9f4a-cb1490cc1c79" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_bf06ee6a-5ea2-48cc-9f4a-cb1490cc1c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc6af343-c49c-4308-8f84-0a54b4490cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc6af343-c49c-4308-8f84-0a54b4490cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_92d3015d-1b12-4444-a627-6b308aa32ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_92d3015d-1b12-4444-a627-6b308aa32ec7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_ec3d2d50-a843-47c7-910f-ef73d2986bea" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_ec3d2d50-a843-47c7-910f-ef73d2986bea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_29d7a2fb-e123-4024-9f79-4c49dc8eb515" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_29d7a2fb-e123-4024-9f79-4c49dc8eb515" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoard_bc04316c-fda1-4262-909c-7c0b3472a8d0" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoard_bc04316c-fda1-4262-909c-7c0b3472a8d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_1552525c-f3bd-4480-a1cb-c30c744ae097" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_1552525c-f3bd-4480-a1cb-c30c744ae097" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_1d2af16a-34e2-44f7-ad5a-ad06f74357a6" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_1d2af16a-34e2-44f7-ad5a-ad06f74357a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_273dfe64-a638-47ca-b264-74e8eb2fb6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_EquityMethodInvestments_273dfe64-a638-47ca-b264-74e8eb2fb6bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_a157744b-9c86-477e-afa2-bd188d1b9b12" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_a157744b-9c86-477e-afa2-bd188d1b9b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_67d7f036-4195-4289-ba2c-082ef4dbd252_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_67d7f036-4195-4289-ba2c-082ef4dbd252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherAccruedLiabilitiesMember_eb98b13a-5f6a-4682-9e30-2ba76e16364e" xlink:href="pgen-20201231.xsd#pgen_OtherAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:to="loc_pgen_OtherAccruedLiabilitiesMember_eb98b13a-5f6a-4682-9e30-2ba76e16364e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:to="loc_us-gaap_RelatedPartyDomain_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:to="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_f68496c8-4da6-43f2-9945-e84c3e0df9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:to="loc_us-gaap_InvestorMember_f68496c8-4da6-43f2-9945-e84c3e0df9bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AllInvestorsMember_12eab386-f57f-43d4-aa46-ad985f54b602" xlink:href="pgen-20201231.xsd#pgen_AllInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:to="loc_pgen_AllInvestorsMember_12eab386-f57f-43d4-aa46-ad985f54b602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_da61eb1c-c249-43a9-852d-733e34877254_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_da61eb1c-c249-43a9-852d-733e34877254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_2df64aec-d6b9-42be-8444-a143f398c043" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_2df64aec-d6b9-42be-8444-a143f398c043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cbe78882-db74-4edd-9bfb-7928655d8d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cbe78882-db74-4edd-9bfb-7928655d8d28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="extended" id="i8bab9583a5fe485891769a8e29d04043_InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_8b5bbe90-17dd-4500-9181-a4393ae39fe5" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_8b5bbe90-17dd-4500-9181-a4393ae39fe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_25c07368-bf62-431e-be1d-55b779bcf9c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_25c07368-bf62-431e-be1d-55b779bcf9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_129ee348-4728-4c18-a86c-a4a88b8269a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_129ee348-4728-4c18-a86c-a4a88b8269a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_7c843fd1-de39-4c0e-942d-613c3db87101" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_7c843fd1-de39-4c0e-942d-613c3db87101" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_eed9f7e6-aa5f-4839-8517-63d238d37c73" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_eed9f7e6-aa5f-4839-8517-63d238d37c73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_816f9b2b-5d71-42c0-9da7-9bf3698a2cd3" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_816f9b2b-5d71-42c0-9da7-9bf3698a2cd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bffcdc0b-ee1d-4ae1-b4c6-ae2ff155d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bffcdc0b-ee1d-4ae1-b4c6-ae2ff155d057" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_48127831-2bbb-4a5e-875f-b644c248aeb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_48127831-2bbb-4a5e-875f-b644c248aeb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8efa84d2-eb81-4515-b55e-3155be780c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8efa84d2-eb81-4515-b55e-3155be780c6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe21624b-9e9d-43c8-ac72-f586e20e9b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe21624b-9e9d-43c8-ac72-f586e20e9b05" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e7a8dd5-e593-4845-891f-a4f4f9649112_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e7a8dd5-e593-4845-891f-a4f4f9649112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_9774a1d0-9daf-4c0f-bb76-97b1e2dd7fca" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_9774a1d0-9daf-4c0f-bb76-97b1e2dd7fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3ff2544e-ae3b-4d91-aa03-3e9b01967634_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:to="loc_us-gaap_RelatedPartyDomain_3ff2544e-ae3b-4d91-aa03-3e9b01967634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:to="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_60dde377-38c2-4b6d-9041-ecb743a5bb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:to="loc_us-gaap_InvestorMember_60dde377-38c2-4b6d-9041-ecb743a5bb79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1b4fcdb0-206b-450a-8120-48c6a4325ec9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1b4fcdb0-206b-450a-8120-48c6a4325ec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_0fb0b49b-3166-44c7-b8c4-77e0ae3dc297" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_0fb0b49b-3166-44c7-b8c4-77e0ae3dc297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52904676-eea6-4e08-ac95-cf2df329d151_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52904676-eea6-4e08-ac95-cf2df329d151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e2b97ff2-23b2-4258-8041-e92224dc22a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e2b97ff2-23b2-4258-8041-e92224dc22a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenue"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="extended" id="i53c73acc91d047728c00891cefc83235_CollaborationandLicensingRevenue"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="extended" id="i96b20e1b02f947e08baf9e66dd8c762e_CollaborationandLicensingRevenueTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="extended" id="i34b7dc8a272348cfb6922a8e315fdcb3_CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb04f2eb-e43c-485d-a14d-3eb2dcd30651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb04f2eb-e43c-485d-a14d-3eb2dcd30651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb50fe46-8090-4843-9a1f-ffbcf8b0788c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb50fe46-8090-4843-9a1f-ffbcf8b0788c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:to="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_507f45c0-77ea-4ea5-ab15-a9df4b45bc3a" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_ZiopharmMember_507f45c0-77ea-4ea5-ab15-a9df4b45bc3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AresTradingS.A.Member_c178de98-1785-4412-b8ca-cf2334488cf8" xlink:href="pgen-20201231.xsd#pgen_AresTradingS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_AresTradingS.A.Member_c178de98-1785-4412-b8ca-cf2334488cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_46d5c431-c2ed-4ff1-bcff-e724d3ca81ec" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_OragenicsMember_46d5c431-c2ed-4ff1-bcff-e724d3ca81ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_bdd5c211-6800-4d24-9af2-a81234fdd48a" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_bdd5c211-6800-4d24-9af2-a81234fdd48a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_ebcf68c1-a815-4f2e-9cd0-80b4539da43b" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_ebcf68c1-a815-4f2e-9cd0-80b4539da43b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_48f09e6f-5b6f-4fd1-8d4c-090805cbceec" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_48f09e6f-5b6f-4fd1-8d4c-090805cbceec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_fc451994-abff-44d8-bf34-dfcd7ac94df1" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_fc451994-abff-44d8-bf34-dfcd7ac94df1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_f7049b77-1159-4ee3-a65d-cd91f11a7c67" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_f7049b77-1159-4ee3-a65d-cd91f11a7c67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherMember_2302bce1-bdfb-4221-8c58-a01d6cdb557a" xlink:href="pgen-20201231.xsd#pgen_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_OtherMember_2302bce1-bdfb-4221-8c58-a01d6cdb557a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_60c005d3-372d-4a71-8f79-07eb3b593968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_60c005d3-372d-4a71-8f79-07eb3b593968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_9ae42e5e-5a0e-41d3-8be7-57a4c84ce43e" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_9ae42e5e-5a0e-41d3-8be7-57a4c84ce43e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="extended" id="i85e064e3de5a467f97d68211ba6877cd_CollaborationandLicensingRevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_21be23fd-3fb8-4a82-98d3-49472b641fd3" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_21be23fd-3fb8-4a82-98d3-49472b641fd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments_204a3819-f1c7-4f51-807c-f9830fce511c" xlink:href="pgen-20201231.xsd#pgen_CollaborationArrangementPercentOfCollaborationPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments_204a3819-f1c7-4f51-807c-f9830fce511c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_051ed9f1-d10d-4be9-b9ba-675511094f4a" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_051ed9f1-d10d-4be9-b9ba-675511094f4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_9f4187a0-6dbb-4088-a6fa-57e90194509e" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_9f4187a0-6dbb-4088-a6fa-57e90194509e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementAnnualFee_dc71531c-58ad-46c7-a60f-5147d4835969" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementAnnualFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementAnnualFee_dc71531c-58ad-46c7-a60f-5147d4835969" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts_a4e0e726-ae0f-46ca-93ab-7ea120b9e706" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementReimbursementofHistoricalCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts_a4e0e726-ae0f-46ca-93ab-7ea120b9e706" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_c0121614-648f-41bf-be7c-ae7b81f414f3" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_c0121614-648f-41bf-be7c-ae7b81f414f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_f5c90f43-254b-44e0-ab3d-56759dee3990" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_f5c90f43-254b-44e0-ab3d-56759dee3990" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_d93b4500-10db-4334-b578-b8e3731daa16" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementNumberofExclusivelyLicensedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_d93b4500-10db-4334-b578-b8e3731daa16" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_02ef5302-e370-4e8f-b9bc-5e54d00b1d29" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_02ef5302-e370-4e8f-b9bc-5e54d00b1d29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementRoyaltyDueAggregated_49098d58-8f2e-47ec-8c9c-99bf548351d4" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementRoyaltyDueAggregated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementRoyaltyDueAggregated_49098d58-8f2e-47ec-8c9c-99bf548351d4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofSublicensingIncome_f5f1e14f-34cf-4570-84c1-5e90fb34af08" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofSublicensingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementPercentageofSublicensingIncome_f5f1e14f-34cf-4570-84c1-5e90fb34af08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_e1de32a7-512a-4f01-945c-f371fe2e27b3" xlink:href="pgen-20201231.xsd#pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_e1de32a7-512a-4f01-945c-f371fe2e27b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_4b067935-8a36-40de-910f-2496ba0375d9" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_4b067935-8a36-40de-910f-2496ba0375d9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_714c4220-2a9a-44c4-ab49-612657f539c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_714c4220-2a9a-44c4-ab49-612657f539c7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b32179d4-6ec3-4cf9-b179-957dd08359da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b32179d4-6ec3-4cf9-b179-957dd08359da" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0b841072-e376-484b-91e5-0015c8879ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0b841072-e376-484b-91e5-0015c8879ac0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bd904da-9a03-4682-b992-41fbebcf92c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bd904da-9a03-4682-b992-41fbebcf92c0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PaymentsToRelatedParties_601dc791-8d17-4d4d-b1a9-3edf72e52a47" xlink:href="pgen-20201231.xsd#pgen_PaymentsToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_PaymentsToRelatedParties_601dc791-8d17-4d4d-b1a9-3edf72e52a47" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_4f4ec3eb-1e30-44dc-89a8-7cacf0e4b785" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_4f4ec3eb-1e30-44dc-89a8-7cacf0e4b785" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_12609c47-df29-4a03-9aac-45c6056e507e" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_12609c47-df29-4a03-9aac-45c6056e507e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_85f706da-971b-4ce7-9002-7054bfa7d572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_85f706da-971b-4ce7-9002-7054bfa7d572" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_7845b226-624b-43b2-a4cc-13ff02b67835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_7845b226-624b-43b2-a4cc-13ff02b67835" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty_280fdac5-a03f-4dbc-be16-2df1ee2918c7" xlink:href="pgen-20201231.xsd#pgen_RoyaltyPercentageToBePaidtoOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty_280fdac5-a03f-4dbc-be16-2df1ee2918c7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_ea09be70-6401-415c-b7a6-f831d810046a" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_ea09be70-6401-415c-b7a6-f831d810046a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_4b9e843a-270e-4e0b-bea3-cc0c34f33135" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_4b9e843a-270e-4e0b-bea3-cc0c34f33135" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementTerminationNoticePeriod_e9c60b07-3570-4255-9a02-60c173472e30" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborationAgreementTerminationNoticePeriod_e9c60b07-3570-4255-9a02-60c173472e30" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedCash_ba2986c0-da2d-4b31-8ea9-4d6c7faba30a" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedCash_ba2986c0-da2d-4b31-8ea9-4d6c7faba30a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_fe7c46c9-ba61-469e-9e58-62fbde79b971" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_fe7c46c9-ba61-469e-9e58-62fbde79b971" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_7e436ee5-7524-4566-b331-35c6c83d36e2" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_7e436ee5-7524-4566-b331-35c6c83d36e2" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_0fa4cd70-aa3e-4ea8-9bdd-37029f2b1128" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_0fa4cd70-aa3e-4ea8-9bdd-37029f2b1128" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e12dfa06-2d28-488c-ae44-bf3b902a0511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e12dfa06-2d28-488c-ae44-bf3b902a0511" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bd7446a9-c0c4-4936-b045-1c98418d5b67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bd7446a9-c0c4-4936-b045-1c98418d5b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_acadbf8b-3ad2-4c04-96be-99ab1968a023" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:to="loc_pgen_ZiopharmMember_acadbf8b-3ad2-4c04-96be-99ab1968a023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_d9c21a5d-ad70-4de2-b9c5-a8280a99f515" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:to="loc_pgen_OragenicsMember_d9c21a5d-ad70-4de2-b9c5-a8280a99f515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c18b14a2-872c-47ac-a587-f74537326062_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c18b14a2-872c-47ac-a587-f74537326062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_730c50be-5cdc-41b9-a62b-fe576f1ec424" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_730c50be-5cdc-41b9-a62b-fe576f1ec424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_07720cc6-c90d-4e17-b34b-f5172b8a7db5" xlink:href="pgen-20201231.xsd#pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:to="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_07720cc6-c90d-4e17-b34b-f5172b8a7db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0ce7d97a-26fa-47db-b67e-384f94bd3553_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0ce7d97a-26fa-47db-b67e-384f94bd3553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c81e53d1-ac68-47d0-a2f3-9a9d846eb653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:to="loc_us-gaap_PreferredStockMember_c81e53d1-ac68-47d0-a2f3-9a9d846eb653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b369bd2-0235-4a1d-b8db-f519c150d5ec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b369bd2-0235-4a1d-b8db-f519c150d5ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_904192d8-db96-4ad4-af94-6731109efbeb" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_ZiopharmMember_904192d8-db96-4ad4-af94-6731109efbeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AresTradingS.A.Member_1d6356e3-d58a-4128-9ea0-1be9b082820d" xlink:href="pgen-20201231.xsd#pgen_AresTradingS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_AresTradingS.A.Member_1d6356e3-d58a-4128-9ea0-1be9b082820d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_c5b26f3a-535d-4450-8964-c48511f518a2" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_OragenicsMember_c5b26f3a-535d-4450-8964-c48511f518a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_856e162a-5e6e-4dab-8560-dac4ddd3d004" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_856e162a-5e6e-4dab-8560-dac4ddd3d004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_d58d41ee-5989-4c87-b7ae-ba81d130839e" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_d58d41ee-5989-4c87-b7ae-ba81d130839e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_9f6704ba-7b6d-4354-a346-056501b65dd7" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_9f6704ba-7b6d-4354-a346-056501b65dd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_e8ec80e0-d01a-4db5-984a-c09c68840dde" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_e8ec80e0-d01a-4db5-984a-c09c68840dde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_9aa89e5e-df75-471d-8054-0b9f65bcf8ab" xlink:href="pgen-20201231.xsd#pgen_ExotechADSkincareAndThriveAgrobioticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_9aa89e5e-df75-471d-8054-0b9f65bcf8ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_1e22cb24-75d7-499b-a411-b1c92c406ecb" xlink:href="pgen-20201231.xsd#pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_1e22cb24-75d7-499b-a411-b1c92c406ecb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e84f5781-0129-402b-8c65-e7253dcdf717_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:to="loc_dei_EntityDomain_e84f5781-0129-402b-8c65-e7253dcdf717_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:to="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_3f2f494f-f692-4d7e-8875-2d5343f0a68c" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:to="loc_pgen_ZiopharmMember_3f2f494f-f692-4d7e-8875-2d5343f0a68c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b849c65-1487-4c19-b2d6-8e6ce88ada63_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:to="loc_srt_RangeMember_0b849c65-1487-4c19-b2d6-8e6ce88ada63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:to="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f02f643a-de4b-4a36-be45-8ea785aba784" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:to="loc_srt_MaximumMember_f02f643a-de4b-4a36-be45-8ea785aba784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1c71b5f8-a50f-45ac-b609-7fc3cd032229_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:to="loc_us-gaap_RelatedPartyDomain_1c71b5f8-a50f-45ac-b609-7fc3cd032229_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:to="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_5081e176-5969-413a-9e3e-b51da4e579c1" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:to="loc_pgen_ZiopharmMember_5081e176-5969-413a-9e3e-b51da4e579c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b04d0603-1b12-40b0-9e39-dd83c3ef1a50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b04d0603-1b12-40b0-9e39-dd83c3ef1a50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_ef72eea0-450f-4e42-9741-9a6f8ca83d95" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_ef72eea0-450f-4e42-9741-9a6f8ca83d95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_edd77297-3b85-40fb-a49e-87a7d87fc875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_edd77297-3b85-40fb-a49e-87a7d87fc875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_1590f856-8033-4b1b-a7c8-fae40a95d086" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_1590f856-8033-4b1b-a7c8-fae40a95d086" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReacquiredInProcessResearchDevelopmentMember_444cd871-39ca-4bfa-80ad-bb3b40f7a2dd" xlink:href="pgen-20201231.xsd#pgen_ReacquiredInProcessResearchDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:to="loc_pgen_ReacquiredInProcessResearchDevelopmentMember_444cd871-39ca-4bfa-80ad-bb3b40f7a2dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionServicesMember_d8fc7957-586c-4ede-862d-b08b6c1d1d3e" xlink:href="pgen-20201231.xsd#pgen_TransitionServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:to="loc_pgen_TransitionServicesMember_d8fc7957-586c-4ede-862d-b08b6c1d1d3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="extended" id="i617a5014d5e149aebad7b8772962f1e7_CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a16835a7-712e-4832-9523-60549382796d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a16835a7-712e-4832-9523-60549382796d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4a559c41-a077-4f06-879a-ff8d9ff00c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4a559c41-a077-4f06-879a-ff8d9ff00c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ce196b3a-ed13-4aca-8c98-962c49639c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ce196b3a-ed13-4aca-8c98-962c49639c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc10d1c9-2677-44ae-9914-3a5702979d0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc10d1c9-2677-44ae-9914-3a5702979d0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_404572ff-e2d0-4222-85da-a5d5400d8b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_404572ff-e2d0-4222-85da-a5d5400d8b0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:to="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd788bdb-188e-4956-bfcf-0981487606d1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:to="loc_srt_ProductsAndServicesDomain_dd788bdb-188e-4956-bfcf-0981487606d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:to="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrepaidProductAndServiceRevenuesMember_83712b5d-c876-4126-892f-4fa18b14be54" xlink:href="pgen-20201231.xsd#pgen_PrepaidProductAndServiceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:to="loc_pgen_PrepaidProductAndServiceRevenuesMember_83712b5d-c876-4126-892f-4fa18b14be54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredRevenueOtherMember_77829199-ba1e-4171-81a8-9820d3e09fe1" xlink:href="pgen-20201231.xsd#pgen_DeferredRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:to="loc_pgen_DeferredRevenueOtherMember_77829199-ba1e-4171-81a8-9820d3e09fe1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="extended" id="i8e29c3019200475798cd47bcfb0cd479_CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890dd37a-ae58-4332-a8d5-b086b2c3ad3d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890dd37a-ae58-4332-a8d5-b086b2c3ad3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c552414b-7e17-411e-a041-3ba4811d8961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c552414b-7e17-411e-a041-3ba4811d8961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="extended" id="ib455d1ced85643b087c6cdbaf5692b0d_CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890dd37a-ae58-4332-a8d5-b086b2c3ad3d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890dd37a-ae58-4332-a8d5-b086b2c3ad3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="extended" id="i2eb7429e7b47412f9c58897050f508e0_CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_349e9073-2356-4422-b1e8-3f4f9f0a55ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_349e9073-2356-4422-b1e8-3f4f9f0a55ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:to="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5982c1a-a2cd-404d-a14b-65ec3a32a993_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5982c1a-a2cd-404d-a14b-65ec3a32a993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_da363596-e6d4-4691-8910-0a722e19f5d9" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_OragenicsMember_da363596-e6d4-4691-8910-0a722e19f5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_8e866f51-4107-43c1-99a4-224c9d5ab3db" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_8e866f51-4107-43c1-99a4-224c9d5ab3db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_248bf721-0ae4-43e6-b5db-7e538604da1e" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_248bf721-0ae4-43e6-b5db-7e538604da1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_73bc2483-52b3-462b-a4e7-21c21fe46de2" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_73bc2483-52b3-462b-a4e7-21c21fe46de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_35bace31-83a5-4823-8da3-545cfcca2332" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_35bace31-83a5-4823-8da3-545cfcca2332" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember_45719ef2-2294-4842-990b-e5c7e2d381b2" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_OtherCollaborationsMember_45719ef2-2294-4842-990b-e5c7e2d381b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_7db7b088-5bd2-401d-9c9e-21d37c941917" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_7db7b088-5bd2-401d-9c9e-21d37c941917" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestments"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShorttermInvestments" xlink:type="extended" id="ib9b797e9f48e4a3fab0d2c94da967e2b_ShorttermInvestments"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="extended" id="ia0704a866ea04a20a976a9d44a67d8cb_ShorttermInvestmentsTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended" id="idf70704845894ae98883cb0c15fa07fc_ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0b56e986-2cb2-4fd7-a4d6-6340f6f9ff7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0b56e986-2cb2-4fd7-a4d6-6340f6f9ff7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1399cf18-f480-44c7-a35b-4ab616b9fcd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1399cf18-f480-44c7-a35b-4ab616b9fcd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe69d0ec-6ec7-4c4a-8a93-bcfed1f9838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe69d0ec-6ec7-4c4a-8a93-bcfed1f9838a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bdda23a-b87e-4ee8-b50b-e57374f334ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bdda23a-b87e-4ee8-b50b-e57374f334ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_291608c6-f230-4bd0-a95a-ec26785cdc6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_291608c6-f230-4bd0-a95a-ec26785cdc6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7528a4b6-67a0-4a75-a2db-751114b6e8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7528a4b6-67a0-4a75-a2db-751114b6e8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_10deaa14-9978-4378-8c63-5cb7ea54cf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:to="loc_us-gaap_CertificatesOfDepositMember_10deaa14-9978-4378-8c63-5cb7ea54cf89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurements" xlink:type="extended" id="ic97aa60197fc4c2b8abded7051807eb3_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i34c79306bf3d49cc8efc0fe4abf4ae8c_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i0ebae70152e340f8817350562eb562da_FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_04626c9f-900b-4f8a-af2c-8bb03d2f172e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_04626c9f-900b-4f8a-af2c-8bb03d2f172e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f858079-8a73-42be-96a3-d23b0aba413e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f858079-8a73-42be-96a3-d23b0aba413e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bf65d2d4-6fdc-4899-9cc6-f2fe3b9b2c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bf65d2d4-6fdc-4899-9cc6-f2fe3b9b2c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_40f045b0-c950-42d8-9c2e-d1ea03bb6a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_40f045b0-c950-42d8-9c2e-d1ea03bb6a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_56518859-caa6-4f47-bb69-83acfc29e9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_56518859-caa6-4f47-bb69-83acfc29e9fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_42cec1b7-7639-4da1-87e3-e6a18041773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_42cec1b7-7639-4da1-87e3-e6a18041773b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherFinancialAssetsMember_1f3c628b-5ff7-49ee-b4c8-6a17cc845d47" xlink:href="pgen-20201231.xsd#pgen_OtherFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:to="loc_pgen_OtherFinancialAssetsMember_1f3c628b-5ff7-49ee-b4c8-6a17cc845d47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofLevel3InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="extended" id="ie56de5bd43f44db9909a2ea97ba3e01d_FairValueMeasurementsSummaryofLevel3InvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_347c4f5d-8138-4f2e-b59d-a14cf3207e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_347c4f5d-8138-4f2e-b59d-a14cf3207e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_bc8b1762-1e90-47c5-b350-1a0a368417a8" xlink:href="pgen-20201231.xsd#pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_bc8b1762-1e90-47c5-b350-1a0a368417a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_355fb19d-1fa2-4a12-91b4-8733d002d556" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_NoncashDividendIncome_355fb19d-1fa2-4a12-91b4-8733d002d556" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_c5b905e8-8b89-4f57-9ccb-b69d75a4bef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_c5b905e8-8b89-4f57-9ccb-b69d75a4bef5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1bba86cc-9248-42d3-8eb6-7bccf9f116a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1bba86cc-9248-42d3-8eb6-7bccf9f116a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PreferredStockReceivables_b8601118-9c7d-4d19-920d-ad0081b0ca93" xlink:href="pgen-20201231.xsd#pgen_PreferredStockReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_PreferredStockReceivables_b8601118-9c7d-4d19-920d-ad0081b0ca93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fbf199a9-7ef6-4af6-8edb-3b77c735c61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7b5c97d-4532-4e83-a78c-693f86915498_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7b5c97d-4532-4e83-a78c-693f86915498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c19f4396-7fdc-449c-b98f-7940bd69b3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c19f4396-7fdc-449c-b98f-7940bd69b3ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="ib58f78edbe59498db7a28fa49550121f_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0cc18040-208b-45fd-ab8a-05dfda0e385a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0cc18040-208b-45fd-ab8a-05dfda0e385a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5b9a0475-8986-4503-a01b-9e2ab7b214bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_ConvertibleDebt_5b9a0475-8986-4503-a01b-9e2ab7b214bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb416e85-5468-4796-8b6e-0ab01ae5e6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb416e85-5468-4796-8b6e-0ab01ae5e6a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:to="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_45f837a1-cdbc-49c8-a585-35b5532d7b25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_45f837a1-cdbc-49c8-a585-35b5532d7b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_8a582af9-093f-4a5d-a82b-582523a30c35" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_8a582af9-093f-4a5d-a82b-582523a30c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d94a0edb-a850-42f3-9b34-a0a9797aff5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d94a0edb-a850-42f3-9b34-a0a9797aff5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6bde63f-c1a7-4c9b-b371-b343797d3955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6bde63f-c1a7-4c9b-b371-b343797d3955" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="extended" id="ie1a3612d721e4db4a363bf97b641f839_FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c710c76-50c0-4394-8a62-09fb5f2c4622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c710c76-50c0-4394-8a62-09fb5f2c4622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8328206-dd3e-4be8-b7ac-406fc1761313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8328206-dd3e-4be8-b7ac-406fc1761313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d3e7e801-4285-483a-a19c-f17a033ea0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3cfd284-4a21-433d-833e-fbbc0c85d970_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b3cfd284-4a21-433d-833e-fbbc0c85d970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_83b9a933-4d24-47aa-b367-d34cc0838e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_83b9a933-4d24-47aa-b367-d34cc0838e0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/Inventory" xlink:type="simple" xlink:href="pgen-20201231.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/Inventory" xlink:type="extended" id="i1295c5f61ff04c4b87c0939c71d339f1_Inventory"/>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InventoryTables" xlink:type="extended" id="i9a34ac665d8d42a886c8216337d9f3d8_InventoryTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended" id="idef5630d66ba430a83aa6defe22e1369_InventoryScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_80ac62bf-97ec-4d59-a38c-802fa7e05a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:to="loc_us-gaap_InventoryGross_80ac62bf-97ec-4d59-a38c-802fa7e05a6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:to="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_d9fdd98f-9516-40ae-9e73-a5eb7fce6961_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_d9fdd98f-9516-40ae-9e73-a5eb7fce6961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_eff41bd0-b209-4c57-b75f-5c4b79bdfc89" xlink:href="pgen-20201231.xsd#pgen_SuppliesEmbryosAndOtherProductionMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_eff41bd0-b209-4c57-b75f-5c4b79bdfc89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_WorkInProcessMember_aca04f50-6ab7-45a1-9afd-6d3036b43b30" xlink:href="pgen-20201231.xsd#pgen_WorkInProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_WorkInProcessMember_aca04f50-6ab7-45a1-9afd-6d3036b43b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LivestockMember_edf79cc1-e633-4fb3-94c0-b1c737413e72" xlink:href="pgen-20201231.xsd#pgen_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_LivestockMember_edf79cc1-e633-4fb3-94c0-b1c737413e72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FeedMember_bf557bed-174e-413b-8100-73efb7b1638d" xlink:href="pgen-20201231.xsd#pgen_FeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_FeedMember_bf557bed-174e-413b-8100-73efb7b1638d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNet"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="extended" id="ia000ed3967954369bf1e217f4b3f172c_PropertyPlantandEquipmentNet"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended" id="i340fa9e6a75b4791892547a30740a26f_PropertyPlantandEquipmentNetTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i1261763a741c474bb9fbd0354d4c6dbe_PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="extended" id="ie0879856e45b470fbef4d709366dadd0_PropertyPlantandEquipmentNetAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended" id="i94f99c23b5344864b87005256afb8be3_GoodwillandIntangibleAssetsNet"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended" id="i2c8481f904394edb863f079d97ca97d7_GoodwillandIntangibleAssetsNetTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="ie515b25cb0f74065826284ace78e3eee_GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:to="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_62959b47-b7ed-44a4-a7d6-928ac3be31df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_Goodwill_62959b47-b7ed-44a4-a7d6-928ac3be31df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_dec5a96e-32b8-48d4-a478-6d44200c9cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_dec5a96e-32b8-48d4-a478-6d44200c9cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_710eb27a-57f6-4b17-be6d-6b02ad954555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_710eb27a-57f6-4b17-be6d-6b02ad954555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8998d5e1-8772-4165-92c6-5abdf6bb5aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_c5168ccd-7dc5-479f-981c-842e52df6fd1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_c5168ccd-7dc5-479f-981c-842e52df6fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_05dfd585-c71d-4564-b447-c7a4850af1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_05dfd585-c71d-4564-b447-c7a4850af1a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended" id="i13703cd33bf94374bcd7f841539018e1_GoodwillandIntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_bc087c1a-87b2-4fa0-a683-9b53dcb011cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_bc087c1a-87b2-4fa0-a683-9b53dcb011cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_de1bb945-8e30-44ad-8740-8690926afacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_de1bb945-8e30-44ad-8740-8690926afacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfReportingUnitsClosed_9f7a75eb-8db5-4ad3-8f92-b5ac9bec8a38" xlink:href="pgen-20201231.xsd#pgen_NumberOfReportingUnitsClosed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_pgen_NumberOfReportingUnitsClosed_9f7a75eb-8db5-4ad3-8f92-b5ac9bec8a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cbfe4af4-8c7f-4651-8b5d-dc6311274e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cbfe4af4-8c7f-4651-8b5d-dc6311274e15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_caef4584-9e71-4519-91dc-578349ea2a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_caef4584-9e71-4519-91dc-578349ea2a0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d715f40c-af5b-4aba-84da-b86a17c7401c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d715f40c-af5b-4aba-84da-b86a17c7401c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_935e6aaf-d546-4d61-9d5c-38496de22f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:to="loc_us-gaap_IntellectualPropertyMember_935e6aaf-d546-4d61-9d5c-38496de22f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:to="loc_us-gaap_SegmentDomain_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:to="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaSegmentMember_43769bbc-0df1-41d7-8a59-03a7e5f62119" xlink:href="pgen-20201231.xsd#pgen_TransOvaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:to="loc_pgen_TransOvaSegmentMember_43769bbc-0df1-41d7-8a59-03a7e5f62119" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i849e153efa1145ef981842d32f29cc70_GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0bac35f8-eefc-4902-b456-46406e6d5595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0bac35f8-eefc-4902-b456-46406e6d5595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e03074c0-2ec4-4fa9-99b4-5fecdec642f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e03074c0-2ec4-4fa9-99b4-5fecdec642f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7d051952-8be9-413b-9659-8d32c0947d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7d051952-8be9-413b-9659-8d32c0947d67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5a56bb3-bfc1-44ce-9187-0036382e21fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5a56bb3-bfc1-44ce-9187-0036382e21fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:to="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4fda159-bf5b-4c0e-8c7a-493200043192_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:to="loc_srt_RangeMember_c4fda159-bf5b-4c0e-8c7a-493200043192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:to="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_386f3805-00a0-4ce0-b05b-29fd3092dc30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:to="loc_srt_WeightedAverageMember_386f3805-00a0-4ce0-b05b-29fd3092dc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_133bd074-0955-4b3a-9a03-7c03c1765ad0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_133bd074-0955-4b3a-9a03-7c03c1765ad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_903f13bb-4c18-48c3-829e-b7d202e530c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_IntellectualPropertyMember_903f13bb-4c18-48c3-829e-b7d202e530c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e824b0b-5642-42e9-a107-e23b505b55a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e824b0b-5642-42e9-a107-e23b505b55a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9bd832d0-81e6-4878-a122-b81a0d6103c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_TrademarksMember_9bd832d0-81e6-4878-a122-b81a0d6103c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended" id="ia9c41f921fed4159bc63e8fb7d66e3aa_GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebt"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="extended" id="i5da9baac401d44d0a6a8d114f73dba2f_LinesofCreditandLongTermDebt"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="extended" id="i7dd2b056c860452c906ae4e98756a533_LinesofCreditandLongTermDebtTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="i78fb8cb4be4744beb47d5cabf38b1d20_LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a58876a1-f613-439d-947a-9845cb57cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a58876a1-f613-439d-947a-9845cb57cc79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa11984-2d5d-4bb0-ac7d-78ad114c91d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa11984-2d5d-4bb0-ac7d-78ad114c91d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8e422589-ffaa-4fba-9de9-454a3189b1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8e422589-ffaa-4fba-9de9-454a3189b1b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3542adbf-497b-4ea7-a47b-09050e2002dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCredit_3542adbf-497b-4ea7-a47b-09050e2002dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_e9d4322d-4f45-407b-9beb-5f3639e53d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_e9d4322d-4f45-407b-9beb-5f3639e53d37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75996776-2cb5-46b9-8e46-6f36c23c32c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:to="loc_srt_RangeMember_75996776-2cb5-46b9-8e46-6f36c23c32c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:to="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf05c01-70f7-4dc6-9ad5-55f3513bc395" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:to="loc_srt_MinimumMember_7cf05c01-70f7-4dc6-9ad5-55f3513bc395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8f0ae1da-837a-4fb7-966c-f209f1d65313_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:to="loc_us-gaap_CreditFacilityDomain_8f0ae1da-837a-4fb7-966c-f209f1d65313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:to="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_65e1170e-b999-446c-9605-aec0c94ffc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_65e1170e-b999-446c-9605-aec0c94ffc08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9f2e24bc-c294-407e-b114-2972d10fa102_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:to="loc_dei_EntityDomain_9f2e24bc-c294-407e-b114-2972d10fa102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:to="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaGeneticsLcMember_d029b6e4-1e4a-4731-ba10-c1e052396863" xlink:href="pgen-20201231.xsd#pgen_TransOvaGeneticsLcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:to="loc_pgen_TransOvaGeneticsLcMember_d029b6e4-1e4a-4731-ba10-c1e052396863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExemplarGeneticsLLCMember_e1091f5c-2832-4025-b5fb-11d80a63720a" xlink:href="pgen-20201231.xsd#pgen_ExemplarGeneticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:to="loc_pgen_ExemplarGeneticsLLCMember_e1091f5c-2832-4025-b5fb-11d80a63720a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_efa855a0-787f-41bf-8874-e05cedb6785f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_efa855a0-787f-41bf-8874-e05cedb6785f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FirstNationalBankofOmahaMember_a85cd19e-56c0-41fb-bd84-b19d90c121ce" xlink:href="pgen-20201231.xsd#pgen_FirstNationalBankofOmahaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:to="loc_pgen_FirstNationalBankofOmahaMember_a85cd19e-56c0-41fb-bd84-b19d90c121ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AmericanStateBankMember_7fe32a74-dc6f-4ea7-9cc1-be6604313653" xlink:href="pgen-20201231.xsd#pgen_AmericanStateBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:to="loc_pgen_AmericanStateBankMember_7fe32a74-dc6f-4ea7-9cc1-be6604313653" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="extended" id="i7e8cc4daa4cf4d18b30ab7fb5d1d7702_LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c01bf28-0edb-4df3-9f1d-23538286b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebt_4c01bf28-0edb-4df3-9f1d-23538286b9f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ef9a60ea-f470-45d2-aa3b-1f2f1c407e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebtCurrent_ef9a60ea-f470-45d2-aa3b-1f2f1c407e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4918e6e9-7439-4e65-9c3c-c2e466e5aead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4918e6e9-7439-4e65-9c3c-c2e466e5aead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b604eadd-0df1-4172-bfe4-4cfe1cc7875e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_us-gaap_ConvertibleDebtMember_b604eadd-0df1-4172-bfe4-4cfe1cc7875e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_13f758ed-32da-42f2-a430-1c45b3e63eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_13f758ed-32da-42f2-a430-1c45b3e63eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherLongTermDebtMember_23b37cae-efbd-4e19-bb43-58ebb05876ec" xlink:href="pgen-20201231.xsd#pgen_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_pgen_OtherLongTermDebtMember_23b37cae-efbd-4e19-bb43-58ebb05876ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i90cb34b22c2248608b4a9830b9a384a0_LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_89e303f2-6951-49c0-9d52-df173686849b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_89e303f2-6951-49c0-9d52-df173686849b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c438e374-3e6d-43e9-aed0-e0f7179effda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c438e374-3e6d-43e9-aed0-e0f7179effda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_ddfecca7-55e6-46a2-9259-a8b46876458a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_ddfecca7-55e6-46a2-9259-a8b46876458a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b74b975a-58c0-49ad-8c30-e8d2907ecd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b74b975a-58c0-49ad-8c30-e8d2907ecd1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9e2b1841-020b-499c-861b-674d87bc02ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9e2b1841-020b-499c-861b-674d87bc02ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_0faefa03-0245-4e85-aa5a-94cc8a92f6bb" xlink:href="pgen-20201231.xsd#pgen_ConvertibleDebtPrincipalAmountInitialConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_0faefa03-0245-4e85-aa5a-94cc8a92f6bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_eca382b3-98ce-4649-8786-18514d448c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_eca382b3-98ce-4649-8786-18514d448c68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5c5ada24-b772-4aee-a106-1b23e0e5951d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5c5ada24-b772-4aee-a106-1b23e0e5951d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70a823b1-ea51-46a9-b0b5-a8ac36cc48c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70a823b1-ea51-46a9-b0b5-a8ac36cc48c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_82690ab4-0fad-4db5-9ebf-03f8c668ba64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_82690ab4-0fad-4db5-9ebf-03f8c668ba64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_e8e4905d-3e99-436b-8b8f-866987de8ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_e8e4905d-3e99-436b-8b8f-866987de8ad6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4aa7d991-dafe-4908-9b3c-8086ecce347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_ConvertibleDebt_4aa7d991-dafe-4908-9b3c-8086ecce347e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6022c7c3-38dd-44fc-bd67-bcb3d1012f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6022c7c3-38dd-44fc-bd67-bcb3d1012f15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9fba3cfd-aa89-4c1a-87b2-ff010d93eee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9fba3cfd-aa89-4c1a-87b2-ff010d93eee2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7b46e148-5789-465c-87f7-018535c08298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7b46e148-5789-465c-87f7-018535c08298" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_10de0bc1-8e20-4aad-b1f8-9baf7b119c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_10de0bc1-8e20-4aad-b1f8-9baf7b119c56" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_aa9a0b88-7362-4520-90f5-73f5261a423b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_aa9a0b88-7362-4520-90f5-73f5261a423b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_7195f135-f75f-4024-9174-932b405bb095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_7195f135-f75f-4024-9174-932b405bb095" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_96ad8830-0cac-45c5-b208-e8aef3cae374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_InterestExpense_96ad8830-0cac-45c5-b208-e8aef3cae374" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DebtInstrumentResaleRestrictionPeriod_c2e9d9a8-0c87-4324-b79e-a26f05ff3099" xlink:href="pgen-20201231.xsd#pgen_DebtInstrumentResaleRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_pgen_DebtInstrumentResaleRestrictionPeriod_c2e9d9a8-0c87-4324-b79e-a26f05ff3099" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c215fabd-55ac-4e83-8a24-89b88b695074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_LongTermDebt_c215fabd-55ac-4e83-8a24-89b88b695074" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_8f144de0-8aad-4f6c-872c-fcae808411b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_8f144de0-8aad-4f6c-872c-fcae808411b1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6009ad1f-ac7b-47b0-b8ff-096ee5d29509_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:to="loc_us-gaap_RelatedPartyDomain_6009ad1f-ac7b-47b0-b8ff-096ee5d29509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:to="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_0be0f3c0-eead-4371-9e10-74a4edce20ff" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_0be0f3c0-eead-4371-9e10-74a4edce20ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0846944-570b-48a2-b5a6-f44ab232fbff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0846944-570b-48a2-b5a6-f44ab232fbff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_02d866c1-2b93-4b05-8599-6c81144538f1" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_02d866c1-2b93-4b05-8599-6c81144538f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MerckConvertibleNoteMember_53391107-fbb0-46f1-aa11-9bd44ccf5214" xlink:href="pgen-20201231.xsd#pgen_MerckConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_MerckConvertibleNoteMember_53391107-fbb0-46f1-aa11-9bd44ccf5214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioNotesMember_9851965c-bc75-40a5-bbc3-2b5ba5fa3f43" xlink:href="pgen-20201231.xsd#pgen_ActoBioNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_ActoBioNotesMember_9851965c-bc75-40a5-bbc3-2b5ba5fa3f43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6660b3f9-f074-4e0b-8fc3-1998c21c20a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6660b3f9-f074-4e0b-8fc3-1998c21c20a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e172a5d8-6e0b-4918-a68a-359f63f3b7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:to="loc_us-gaap_ConvertibleDebtMember_e172a5d8-6e0b-4918-a68a-359f63f3b7f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_e91f9447-82b2-44c5-8ef7-4006b4b49921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:to="loc_us-gaap_NotesPayableToBanksMember_e91f9447-82b2-44c5-8ef7-4006b4b49921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5c62871c-5afe-4a46-85b4-37806ccfd098_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:to="loc_dei_EntityDomain_5c62871c-5afe-4a46-85b4-37806ccfd098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:to="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaGeneticsLcMember_38407e0c-d178-4069-8666-b8d1a800b9fb" xlink:href="pgen-20201231.xsd#pgen_TransOvaGeneticsLcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:to="loc_pgen_TransOvaGeneticsLcMember_38407e0c-d178-4069-8666-b8d1a800b9fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenActioBioIncMember_e1d9a1ea-1959-4449-bcef-ccb0ad51be47" xlink:href="pgen-20201231.xsd#pgen_PrecigenActioBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:to="loc_pgen_PrecigenActioBioIncMember_e1d9a1ea-1959-4449-bcef-ccb0ad51be47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_506faa20-21e7-4689-8fdb-535181b6aaac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_506faa20-21e7-4689-8fdb-535181b6aaac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AmericanStateBankMember_3a46a37d-2981-4bd6-94df-39d36693c989" xlink:href="pgen-20201231.xsd#pgen_AmericanStateBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:to="loc_pgen_AmericanStateBankMember_3a46a37d-2981-4bd6-94df-39d36693c989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4ba4ada9-3382-47c2-853c-92bc15eff0db" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4ba4ada9-3382-47c2-853c-92bc15eff0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83e27c21-a4ff-4c98-a00b-9c5e269c4471_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:to="loc_srt_RangeMember_83e27c21-a4ff-4c98-a00b-9c5e269c4471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:to="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_423266ee-9ea3-43d7-b0b7-56174ad14534" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:to="loc_srt_MinimumMember_423266ee-9ea3-43d7-b0b7-56174ad14534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cacd9429-444e-43c5-8acb-a7ca49eec020" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:to="loc_srt_MaximumMember_cacd9429-444e-43c5-8acb-a7ca49eec020" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="extended" id="i5f18d9d0509a4b3cbbe4178f824c4225_LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_36210e31-d136-40ab-a255-f14131fae964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_36210e31-d136-40ab-a255-f14131fae964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_44aea45e-033b-484b-af78-8096497c49ba" xlink:href="pgen-20201231.xsd#pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_44aea45e-033b-484b-af78-8096497c49ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_83c88ee6-8fde-4cb3-a2eb-f1446d51c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_us-gaap_InterestExpenseDebt_83c88ee6-8fde-4cb3-a2eb-f1446d51c0e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:to="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_0622aa94-543f-4ea8-be48-1cdaff26acd8" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_0622aa94-543f-4ea8-be48-1cdaff26acd8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="extended" id="i8ddbd27f2e6a43bc8c75893f0337f81c_LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxes" xlink:type="extended" id="iee15350e366a4651b4bc0c62b717bc5a_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesTables" xlink:type="extended" id="i3ba5f51fc7704b4387a60e95f84ddd4a_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended" id="iba8325a687534b208462cbdd619a9be7_IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23c433d5-8481-46a7-8451-eccac7e477d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23c433d5-8481-46a7-8451-eccac7e477d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:to="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_521b617d-a934-4390-89ff-c2c4be4e61e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:to="loc_us-gaap_DomesticCountryMember_521b617d-a934-4390-89ff-c2c4be4e61e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0444898f-8724-461e-9fa9-71782bfa17e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:to="loc_us-gaap_ForeignCountryMember_0444898f-8724-461e-9fa9-71782bfa17e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="extended" id="i23f23751449747ee9905eec41eba610d_IncomeTaxesComponentsofIncomeTaxBenefitDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" id="idc7add70cae94a74ab5466c56e4f605d_IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i1961e7e0c7654b738f0e5723998f5647_IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended" id="i2142b21878204f5187c2d23e6637d204_IncomeTaxesSummaryofValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1934c2d5-1efd-43f6-9cea-7d7cc874bbfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1934c2d5-1efd-43f6-9cea-7d7cc874bbfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_5bba1907-50d5-4baa-bcfb-c46b2f59e5f9" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_5bba1907-50d5-4baa-bcfb-c46b2f59e5f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_9426fba2-b2fd-4bd1-89c3-6197aad35847" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_9426fba2-b2fd-4bd1-89c3-6197aad35847" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_a6b5918c-6a9f-4d3b-b876-c1e4c186b13c" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_a6b5918c-6a9f-4d3b-b876-c1e4c186b13c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_52d0933b-e58d-4209-96be-7f741045a042" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_52d0933b-e58d-4209-96be-7f741045a042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_c246c98f-f0d1-47bc-b13a-417f1e0b63ba" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_c246c98f-f0d1-47bc-b13a-417f1e0b63ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_3f68682f-9b2a-4056-86db-612c9cc181f1" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_3f68682f-9b2a-4056-86db-612c9cc181f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_2dc65335-3abd-4d6b-8fd8-621129ae7e0a" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_2dc65335-3abd-4d6b-8fd8-621129ae7e0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_cc7bb67f-b0d7-42b2-b6cd-da7e5111a3da" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_cc7bb67f-b0d7-42b2-b6cd-da7e5111a3da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_df562a6e-8600-4689-b70c-34f68fa46365" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_df562a6e-8600-4689-b70c-34f68fa46365" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_9fa317e7-605b-4e87-be1d-339847cb9fe1" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_9fa317e7-605b-4e87-be1d-339847cb9fe1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_60fb1405-9c95-4b00-8c2b-fca3448bc7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4a547fc6-8e41-4c30-9b5a-ba87e53b430f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4a547fc6-8e41-4c30-9b5a-ba87e53b430f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_81605cab-e374-48eb-a91c-4c4ba19bfb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_81605cab-e374-48eb-a91c-4c4ba19bfb4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_da61fc47-0479-4e03-b528-314b14da8146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_da61fc47-0479-4e03-b528-314b14da8146" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i555d8daefeda4c348c8d16d39187a1de_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_b2d3d9df-4193-4f02-9831-66a87f49a13a" xlink:href="pgen-20201231.xsd#pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_b2d3d9df-4193-4f02-9831-66a87f49a13a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6aa6092f-1c62-4ca5-914d-680ccd94001f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6aa6092f-1c62-4ca5-914d-680ccd94001f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_aa6489c5-2a1c-4e01-ba83-29bb56dc256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_aa6489c5-2a1c-4e01-ba83-29bb56dc256a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84ad2d3d-e4c8-4cd4-8b6d-e00042779cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84ad2d3d-e4c8-4cd4-8b6d-e00042779cb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e980365e-a4a0-4164-848d-3819e9437767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e980365e-a4a0-4164-848d-3819e9437767" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2d21695e-59ac-438b-a2cc-49e225503dfc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2d21695e-59ac-438b-a2cc-49e225503dfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GeneratedAfter2017Member_36ac1e41-830c-446c-a440-d2742a364b44" xlink:href="pgen-20201231.xsd#pgen_GeneratedAfter2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:to="loc_pgen_GeneratedAfter2017Member_36ac1e41-830c-446c-a440-d2742a364b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_de9f3f31-a1f2-4db4-8b0f-3575b118e341_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_de9f3f31-a1f2-4db4-8b0f-3575b118e341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db2da65f-3eaa-486f-b9dc-b9e5e8bd501b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:to="loc_us-gaap_DomesticCountryMember_db2da65f-3eaa-486f-b9dc-b9e5e8bd501b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f7e4278e-41bf-45d0-a98a-abc2ccb56f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:to="loc_us-gaap_ForeignCountryMember_f7e4278e-41bf-45d0-a98a-abc2ccb56f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5d4cf244-8593-4fcd-925d-87b7c2f83e01_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:to="loc_dei_EntityDomain_5d4cf244-8593-4fcd-925d-87b7c2f83e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:to="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ForeignSubsidiariesMember_cb78c948-cdc3-4b56-902f-a3304cd2fd02" xlink:href="pgen-20201231.xsd#pgen_ForeignSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:to="loc_pgen_ForeignSubsidiariesMember_cb78c948-cdc3-4b56-902f-a3304cd2fd02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareholdersEquity" xlink:type="extended" id="ic5b0688a931649d6a0f362ab5314403b_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="extended" id="i42abe52a24de45f1a558e3743aa4a9a7_ShareholdersEquityTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="extended" id="if91867d1f3484642a8f929fc7f502f1a_ShareholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49271ef4-7412-462c-b2d4-d6ad5b21523a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49271ef4-7412-462c-b2d4-d6ad5b21523a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_043049a9-c615-456c-a15a-13da4122ad83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_043049a9-c615-456c-a15a-13da4122ad83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e5a7ded2-8c5d-4c11-8de0-e15993f4469e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e5a7ded2-8c5d-4c11-8de0-e15993f4469e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c381cd53-4500-4999-a568-6c90ad6ffcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c381cd53-4500-4999-a568-6c90ad6ffcaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OwnshareLendingArrangementSharesIssued_a503971b-b907-46cf-b6e6-acd14f10b811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_OwnshareLendingArrangementSharesIssued_a503971b-b907-46cf-b6e6-acd14f10b811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_b57c3cc8-3d47-41a2-9d86-5f65226ecc43" xlink:href="pgen-20201231.xsd#pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_b57c3cc8-3d47-41a2-9d86-5f65226ecc43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6d606512-0306-495a-b7d7-8cd7f15511f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6d606512-0306-495a-b7d7-8cd7f15511f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_0f3e6c1e-8028-4f9b-a239-f5b30a2dbc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_0f3e6c1e-8028-4f9b-a239-f5b30a2dbc83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_8817b0af-d605-40f0-81db-bf56c9276bea" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_8817b0af-d605-40f0-81db-bf56c9276bea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:to="loc_srt_OwnershipDomain_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:to="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AquaBountyMember_711ee122-16c9-42d1-9d77-9a849b4f9494" xlink:href="pgen-20201231.xsd#pgen_AquaBountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:to="loc_pgen_AquaBountyMember_711ee122-16c9-42d1-9d77-9a849b4f9494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_711b4270-6dab-450b-bf3d-3aefdca0a942_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:to="loc_dei_EntityDomain_711b4270-6dab-450b-bf3d-3aefdca0a942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:to="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AquaBountyMember_2d54d594-b5fd-4f54-90af-a28bc1f6a5bc" xlink:href="pgen-20201231.xsd#pgen_AquaBountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:to="loc_pgen_AquaBountyMember_2d54d594-b5fd-4f54-90af-a28bc1f6a5bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:to="loc_us-gaap_RelatedPartyDomain_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:to="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_b1f617a2-2d0f-438e-a215-31069593638f" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_b1f617a2-2d0f-438e-a215-31069593638f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AffiliatesOfThirdSecurityMember_7caf80e9-197f-4265-aef9-60cadeac71a9" xlink:href="pgen-20201231.xsd#pgen_AffiliatesOfThirdSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:to="loc_pgen_AffiliatesOfThirdSecurityMember_7caf80e9-197f-4265-aef9-60cadeac71a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i7027b9b3151d4bc0a2a97b09ea3d04b5_ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8472b1a-27bb-4ef8-b390-3b29f0ce8f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8472b1a-27bb-4ef8-b390-3b29f0ce8f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_648b9cd6-5df0-41a8-93d4-8f25a2122978_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:to="loc_us-gaap_EquityComponentDomain_648b9cd6-5df0-41a8-93d4-8f25a2122978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:to="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_824053d1-67ff-4a48-b76e-a764518546ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_824053d1-67ff-4a48-b76e-a764518546ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_618d3e3c-b53e-43f8-9d8b-36591d49fe09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_618d3e3c-b53e-43f8-9d8b-36591d49fe09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c4e7aee-c9fe-420b-a658-b9c6c87df5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c4e7aee-c9fe-420b-a658-b9c6c87df5bb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPayments" xlink:type="extended" id="i28a398343ecf43a3a85ffbb3462e73dd_ShareBasedPayments"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i4e80cce659614adc91c620cf759c264e_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i83796c9e2bbb4fcea2e41ae2ba6577b2_ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_56ebc148-c22b-4286-8fb4-623a22972502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_56ebc148-c22b-4286-8fb4-623a22972502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80f99dbc-f1e0-4229-8d17-9973b4fd32c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80f99dbc-f1e0-4229-8d17-9973b4fd32c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfProductsMember_52f791c2-16fd-4506-a226-8392f92fb05a" xlink:href="pgen-20201231.xsd#pgen_CostOfProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_pgen_CostOfProductsMember_52f791c2-16fd-4506-a226-8392f92fb05a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfServicesMember_177d0e63-976a-41e7-b8f1-9aed756ba345" xlink:href="pgen-20201231.xsd#pgen_CostOfServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_pgen_CostOfServicesMember_177d0e63-976a-41e7-b8f1-9aed756ba345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3c7836ca-9bc1-4696-83c1-e9091401940e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3c7836ca-9bc1-4696-83c1-e9091401940e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c6f25c9d-5fed-408f-b64e-8a0855fb8ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c6f25c9d-5fed-408f-b64e-8a0855fb8ff4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b2ab22ca-ebef-47e0-9758-7617332ac3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b2ab22ca-ebef-47e0-9758-7617332ac3b5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended" id="ief0470b651b3461da35edd5a78af87d4_ShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6832cc78-f66e-4170-84c4-1dbdebdc2b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6832cc78-f66e-4170-84c4-1dbdebdc2b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d3a521-902d-4cd0-8149-e6646cf98f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d3a521-902d-4cd0-8149-e6646cf98f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a8047af0-4a21-47e3-b303-e339b1f45d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a8047af0-4a21-47e3-b303-e339b1f45d4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ced10cc9-594f-4290-8b04-0a853e669b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ced10cc9-594f-4290-8b04-0a853e669b2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_423fea61-6519-44e9-b0f5-e7f170b16ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_423fea61-6519-44e9-b0f5-e7f170b16ed5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f3ec3f8-ef45-48d0-a130-b0b4b215c080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f3ec3f8-ef45-48d0-a130-b0b4b215c080" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bd6f773a-0930-41dc-88cc-55ca2d8d4e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bd6f773a-0930-41dc-88cc-55ca2d8d4e14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e3bad5b-143a-4308-a8ad-cdc33b8a0f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e3bad5b-143a-4308-a8ad-cdc33b8a0f39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0affcc44-0358-4d70-9daf-c31a11f16450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0affcc44-0358-4d70-9daf-c31a11f16450" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aa28b37e-d761-48be-a7ea-7704c8825cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aa28b37e-d761-48be-a7ea-7704c8825cf7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d3e6c29-9bd2-4bc7-b588-b1291ad6cb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d3e6c29-9bd2-4bc7-b588-b1291ad6cb58" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_d1d2b746-f130-453b-a1e8-e798c93a795f" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_d1d2b746-f130-453b-a1e8-e798c93a795f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LockupPeriodOnRestrictedStockUnitShares_12f69cb6-cd2b-4d66-904a-aa82b0af1a60" xlink:href="pgen-20201231.xsd#pgen_LockupPeriodOnRestrictedStockUnitShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_LockupPeriodOnRestrictedStockUnitShares_12f69cb6-cd2b-4d66-904a-aa82b0af1a60" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_7e208329-3e99-4fb4-ad00-7f1d09037633" xlink:href="pgen-20201231.xsd#pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_7e208329-3e99-4fb4-ad00-7f1d09037633" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_5c970cbb-1fae-4485-8219-f4bbacb2473b" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualCashRetainer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_5c970cbb-1fae-4485-8219-f4bbacb2473b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_e1e9d936-ae77-47bb-bfd5-ac01736f5827" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_e1e9d936-ae77-47bb-bfd5-ac01736f5827" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_ccd7329a-9d08-411a-8e9e-eaa7b710941e" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_ccd7329a-9d08-411a-8e9e-eaa7b710941e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce6402b3-4c2c-49e5-b036-ccf20914a65c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce6402b3-4c2c-49e5-b036-ccf20914a65c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_828618ec-0fcf-46b3-9a13-25730bbf5cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_828618ec-0fcf-46b3-9a13-25730bbf5cec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_020ef829-b07f-408e-a476-3ed04e91ce65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_020ef829-b07f-408e-a476-3ed04e91ce65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6dc5dbda-0322-4bb1-b899-5ec1869d61aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6dc5dbda-0322-4bb1-b899-5ec1869d61aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0938f054-3038-4911-b421-702d08ece5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0938f054-3038-4911-b421-702d08ece5b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3a56be59-338b-4356-92bc-e51d3aa2a7ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:to="loc_us-gaap_RelatedPartyDomain_3a56be59-338b-4356-92bc-e51d3aa2a7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:to="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_3ac796c9-0fe3-4b71-b2ba-5bb0199e120e" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:to="loc_pgen_ExecutiveChairmanMember_3ac796c9-0fe3-4b71-b2ba-5bb0199e120e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e9f5324c-d6d6-41f3-8a03-c646023e6553_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:to="loc_us-gaap_PlanNameDomain_e9f5324c-d6d6-41f3-8a03-c646023e6553_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:to="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2008PlanMember_9b07e56f-1620-4c00-bf08-105da767e2dd" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2008PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2008PlanMember_9b07e56f-1620-4c00-bf08-105da767e2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2013PlanMember_f202fb18-1bc6-44cb-8a85-6570f4aa0ed8" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2013PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2013PlanMember_f202fb18-1bc6-44cb-8a85-6570f4aa0ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2019PlanMember_ce3c4f2d-5be8-4e3a-a8e6-e316ca1f795d" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2019PlanMember_ce3c4f2d-5be8-4e3a-a8e6-e316ca1f795d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_26f6e4ef-7161-415f-b04d-19b2bc30af55_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_26f6e4ef-7161-415f-b04d-19b2bc30af55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_4c8cbe1f-749a-473e-8405-988617f7b9af" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:to="loc_pgen_ExecutiveChairmanMember_4c8cbe1f-749a-473e-8405-988617f7b9af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="extended" id="i098667d526ca4f598dae89f827b6f493_ShareBasedPaymentsScheduleofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_567aff58-94d0-4f2f-90b7-ebaa4a4e8f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_567aff58-94d0-4f2f-90b7-ebaa4a4e8f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_45c46716-85f1-4ba5-aef0-bb87cd0d0956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_45c46716-85f1-4ba5-aef0-bb87cd0d0956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9b803d2-7f18-4741-96f0-f4f2d481b977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9b803d2-7f18-4741-96f0-f4f2d481b977" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5f1ec19b-5a2b-4303-88c8-5d062eb9167d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5f1ec19b-5a2b-4303-88c8-5d062eb9167d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_39c112c6-15d7-4a0f-a10b-599785d2f2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_39c112c6-15d7-4a0f-a10b-599785d2f2a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0deafca8-ec43-4326-a512-a0e840f7a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34dc5889-b5ef-4fbe-96db-f77edffbab93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34dc5889-b5ef-4fbe-96db-f77edffbab93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8746c7ae-3995-491c-b13a-945a3f40bde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8746c7ae-3995-491c-b13a-945a3f40bde7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44f658cc-abda-4f46-ad96-3c9ede0818ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44f658cc-abda-4f46-ad96-3c9ede0818ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80061675-769e-42ea-bd32-432ff53ce608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80061675-769e-42ea-bd32-432ff53ce608" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47fed912-176e-4980-990f-a3b8949fa2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47fed912-176e-4980-990f-a3b8949fa2b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8825d607-553a-4712-a22f-2d1547fdefb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42e3c275-2b9c-438f-8db0-0b42a95afcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42e3c275-2b9c-438f-8db0-0b42a95afcb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7f33df0a-ed50-40a1-ac8c-57a23720e86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7f33df0a-ed50-40a1-ac8c-57a23720e86b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4baf6054-45f9-4870-9679-906aea230a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4baf6054-45f9-4870-9679-906aea230a08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9fbc19c3-b8bd-4fdb-9ad3-cda2e468a283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9fbc19c3-b8bd-4fdb-9ad3-cda2e468a283" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:to="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_787ece7d-9196-484d-8f18-c60d61f5984e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:to="loc_us-gaap_PlanNameDomain_787ece7d-9196-484d-8f18-c60d61f5984e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:to="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_77b778bf-e96d-4024-b951-4dadd808756b" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_77b778bf-e96d-4024-b951-4dadd808756b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="extended" id="if0ae8aa92d3b4b45853b3febf62207c6_ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_07770d7a-1d66-423d-9328-d43394d94f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_07770d7a-1d66-423d-9328-d43394d94f23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_cdedff26-5afe-47be-8272-538999e26263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_cdedff26-5afe-47be-8272-538999e26263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ff3778e7-9b78-4efc-b535-7c1e119588c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ff3778e7-9b78-4efc-b535-7c1e119588c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627e4f41-f192-425b-ba58-66bbff760b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627e4f41-f192-425b-ba58-66bbff760b8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c794c05b-33fb-4d6c-a246-ffffa2654e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c794c05b-33fb-4d6c-a246-ffffa2654e6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d1e2b4d-3bdf-459d-92be-a165c17e97e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d1e2b4d-3bdf-459d-92be-a165c17e97e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_56976288-ca61-4f07-a623-6935496ddd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_56976288-ca61-4f07-a623-6935496ddd7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d8f20e81-ad64-4220-a4f9-db47924a7ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d8f20e81-ad64-4220-a4f9-db47924a7ecb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2e2a2823-df77-4c03-b720-d6e96a87786b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2e2a2823-df77-4c03-b720-d6e96a87786b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ac7a51f2-18f5-49c5-a035-690517fc14a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ac7a51f2-18f5-49c5-a035-690517fc14a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:to="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_eba3766e-50b9-4832-af50-6c661aef7957_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:to="loc_us-gaap_PlanNameDomain_eba3766e-50b9-4832-af50-6c661aef7957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:to="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_8aef5ab0-f7af-4bdb-8a2f-52be1c44fd17" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_8aef5ab0-f7af-4bdb-8a2f-52be1c44fd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:to="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceDomain_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee_default" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:to="loc_pgen_ExercisePriceDomain_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:to="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceOneMember_b1e688b7-bc37-4a4a-9826-112f8c7f9e0c" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceOneMember_b1e688b7-bc37-4a4a-9826-112f8c7f9e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceTwoMember_4a26366a-5fb1-4bce-ba7d-7820af47e00b" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceTwoMember_4a26366a-5fb1-4bce-ba7d-7820af47e00b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceThreeMember_48f551f4-a6e6-4057-b27f-6ea4935c0c78" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceThreeMember_48f551f4-a6e6-4057-b27f-6ea4935c0c78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFourMember_91e72265-e3f8-455c-8e33-ee0088b45493" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceFourMember_91e72265-e3f8-455c-8e33-ee0088b45493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFiveMember_8b2b8108-f81a-4798-aafb-4284d4a53d7b" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceFiveMember_8b2b8108-f81a-4798-aafb-4284d4a53d7b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended" id="iabb956c1cdd741419ea9cf6e172e1491_ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce99ed36-29f2-477d-9f66-7f1db011bbbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce99ed36-29f2-477d-9f66-7f1db011bbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04ca699b-92fb-4741-b397-71f1074ac460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04ca699b-92fb-4741-b397-71f1074ac460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_486d78b6-df1f-4560-abc3-93da3278f17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_486d78b6-df1f-4560-abc3-93da3278f17f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ce4dee4-d9c9-4f4a-bc7a-a7c9fed14943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ce4dee4-d9c9-4f4a-bc7a-a7c9fed14943" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6eb2e91-e084-4263-b032-59a56632daf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5018e812-89f7-4e00-b8b6-a68ead46f795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5018e812-89f7-4e00-b8b6-a68ead46f795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cacda8fa-371a-46b3-abc1-bd2d61cbac59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cacda8fa-371a-46b3-abc1-bd2d61cbac59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53bb633b-3ff2-44c8-8c49-ad52ed39c5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53bb633b-3ff2-44c8-8c49-ad52ed39c5d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bcfeb1d7-8243-4870-85fe-a6af253fee47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bcfeb1d7-8243-4870-85fe-a6af253fee47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26b508b4-78e9-4229-bea7-a5b11d46c9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40a58f3c-a49f-4765-955a-9451d78788ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40a58f3c-a49f-4765-955a-9451d78788ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:to="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_12a07daa-ed25-4193-9949-336390788139_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:to="loc_us-gaap_PlanNameDomain_12a07daa-ed25-4193-9949-336390788139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:to="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_cc58996a-63d6-4580-b042-f832971d0c9b" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_cc58996a-63d6-4580-b042-f832971d0c9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeases" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeases"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeases" xlink:type="extended" id="i0e1e4f3ca13146dcbec65be2ed4b51f5_OperatingLeases"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesTables" xlink:type="extended" id="i428ed10e1f3b4171be341fe22b606553_OperatingLeasesTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended" id="if20c713ca92a402ebf33d2f8aa91dd80_OperatingLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b99ec50e-cad5-4759-821f-f9412df16cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b99ec50e-cad5-4759-821f-f9412df16cf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LesseeOperatingLeaseTerminationPeriod_7ef7c452-970b-4633-98e6-d7bd7a31352a" xlink:href="pgen-20201231.xsd#pgen_LesseeOperatingLeaseTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:to="loc_pgen_LesseeOperatingLeaseTerminationPeriod_7ef7c452-970b-4633-98e6-d7bd7a31352a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:to="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf6857a7-6371-476c-9e9a-16938e5ca727_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:to="loc_srt_RangeMember_bf6857a7-6371-476c-9e9a-16938e5ca727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:to="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60b9a13d-943c-4a8a-a734-842ce0ecf791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:to="loc_srt_MinimumMember_60b9a13d-943c-4a8a-a734-842ce0ecf791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f647e8e1-e0b6-4e8b-93da-3370ab99ad33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:to="loc_srt_MaximumMember_f647e8e1-e0b6-4e8b-93da-3370ab99ad33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesComponentsofLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="extended" id="i08eedf1a15d94eaeaf2b4649efd317c9_OperatingLeasesComponentsofLeaseCostsDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i8bbeed56d0b142b6af0a2672f9d75153_OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesLeaseTermsandDiscountRatesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="extended" id="ic21f14ff546e453a932ca9de2a404a6a_OperatingLeasesLeaseTermsandDiscountRatesDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="extended" id="i88957dd8f3604c6abb0933cf018d1312_OperatingLeasesOtherInformationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="extended" id="if788d5409bd14506a51231eec57460c5_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingenciesContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="extended" id="ic4aabdc5bd0f4cf48ad529a7e43e5414_CommitmentsandContingenciesContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_c3732d77-f66a-4168-b037-fe828b129d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_c3732d77-f66a-4168-b037-fe828b129d8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingenciesTotalClaimsNumber_7e8544a6-66df-44b9-bfc5-cf93140b9680" xlink:href="pgen-20201231.xsd#pgen_LossContingenciesTotalClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingenciesTotalClaimsNumber_7e8544a6-66df-44b9-bfc5-cf93140b9680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_bda60d99-401c-4c4c-aa7e-3cba69661aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_bda60d99-401c-4c4c-aa7e-3cba69661aa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4e877512-6b65-4bd3-aeb0-42ab0d443323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4e877512-6b65-4bd3-aeb0-42ab0d443323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyClaimsInvalidatedNumber_7a7715a0-bcef-48b3-b23e-e034e40a9b77" xlink:href="pgen-20201231.xsd#pgen_LossContingencyClaimsInvalidatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyClaimsInvalidatedNumber_7a7715a0-bcef-48b3-b23e-e034e40a9b77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyAppealedClaimsDismissed_fcca40cf-23b7-402b-99e3-d9508240d8b6" xlink:href="pgen-20201231.xsd#pgen_LossContingencyAppealedClaimsDismissed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyAppealedClaimsDismissed_fcca40cf-23b7-402b-99e3-d9508240d8b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyReversedClaimsDismissedNumber_ec3bcbdb-a948-49d5-9593-dc23ed6e0568" xlink:href="pgen-20201231.xsd#pgen_LossContingencyReversedClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyReversedClaimsDismissedNumber_ec3bcbdb-a948-49d5-9593-dc23ed6e0568" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_da7726c8-8327-4e3a-b247-811248014ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_da7726c8-8327-4e3a-b247-811248014ef5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c07ffc1b-4a63-4be3-9871-826f7a083ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c07ffc1b-4a63-4be3-9871-826f7a083ca1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_deac6879-8d11-407d-9b8d-474c20b67301" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_deac6879-8d11-407d-9b8d-474c20b67301" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_8477edc6-101b-4665-93e1-98093fd39112" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_8477edc6-101b-4665-93e1-98093fd39112" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6642f50a-37fc-4f74-8fda-a13de276fc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6642f50a-37fc-4f74-8fda-a13de276fc10" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3e9b6e8f-0cb0-4ec4-a363-6e13845e8924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_EquityMethodInvestments_3e9b6e8f-0cb0-4ec4-a363-6e13845e8924" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8026e90f-ee15-4928-a345-940486b98b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8026e90f-ee15-4928-a345-940486b98b89" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_XYLLCMember_27316cc2-bfd0-4452-8ec6-6607381f61f4" xlink:href="pgen-20201231.xsd#pgen_XYLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_XYLLCMember_27316cc2-bfd0-4452-8ec6-6607381f61f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SecuritiesAndExchangeCommissionMember_1c183188-6088-4a6b-9396-93229d10baac" xlink:href="pgen-20201231.xsd#pgen_SecuritiesAndExchangeCommissionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_SecuritiesAndExchangeCommissionMember_1c183188-6088-4a6b-9396-93229d10baac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_66dbabc8-e113-4213-9007-848e6ad6e6cc" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_66dbabc8-e113-4213-9007-848e6ad6e6cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_86ca8345-832e-4617-a409-656e1fb719ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:to="loc_srt_LitigationCaseTypeDomain_86ca8345-832e-4617-a409-656e1fb719ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:to="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAndPatentInfringementSuitMember_e99ee5bd-6541-4b27-8f19-95a7fe7027a1" xlink:href="pgen-20201231.xsd#pgen_LicensingAndPatentInfringementSuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:to="loc_pgen_LicensingAndPatentInfringementSuitMember_e99ee5bd-6541-4b27-8f19-95a7fe7027a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MethaneBioconversionPlatformDisclosuresMember_61c1bdee-679f-4751-867a-cd4bfc362a1b" xlink:href="pgen-20201231.xsd#pgen_MethaneBioconversionPlatformDisclosuresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:to="loc_pgen_MethaneBioconversionPlatformDisclosuresMember_61c1bdee-679f-4751-867a-cd4bfc362a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_40832777-9043-429d-977a-71a3630bc62e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_40832777-9043-429d-977a-71a3630bc62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_cfd2da8c-0c0b-4ead-949c-26f87dee2adf" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_cfd2da8c-0c0b-4ead-949c-26f87dee2adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_4fe5528a-9f2d-4582-98b2-c9f4e696c1c4" xlink:href="pgen-20201231.xsd#pgen_ExotechADSkincareAndThriveAgrobioticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:to="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_4fe5528a-9f2d-4582-98b2-c9f4e696c1c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="extended" id="ia78efbe764024b5ebf8799740086df40_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i3c5e4091fc0a4bee872d8e1b75bc10c8_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_de62660a-c96c-460b-b863-49d9d8d1fce6" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_de62660a-c96c-460b-b863-49d9d8d1fce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_bd36a897-4166-4d7a-81e9-fbad5aa34ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_bd36a897-4166-4d7a-81e9-fbad5aa34ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CommonStockCalculationPeriod_93fa4da7-8166-4b68-a7ed-cbc769f1f270" xlink:href="pgen-20201231.xsd#pgen_CommonStockCalculationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_CommonStockCalculationPeriod_93fa4da7-8166-4b68-a7ed-cbc769f1f270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2e54d421-3332-4a88-ade3-6747dac936e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2e54d421-3332-4a88-ade3-6747dac936e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_db4c3735-4dc6-468e-9cc3-8cfef1effe9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_db4c3735-4dc6-468e-9cc3-8cfef1effe9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_49c8a63d-b3f0-4837-a9ef-61c955e6c8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_SubleaseIncome_49c8a63d-b3f0-4837-a9ef-61c955e6c8b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_e1ff7873-b823-4a33-8b00-785df4e81809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_e1ff7873-b823-4a33-8b00-785df4e81809" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertiblePreferredStockAmountAuthorized_6f09383c-e8e4-4022-a520-d55c90253bd7" xlink:href="pgen-20201231.xsd#pgen_ConvertiblePreferredStockAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_ConvertiblePreferredStockAmountAuthorized_6f09383c-e8e4-4022-a520-d55c90253bd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db4d0fc7-eddf-4d92-aab1-d0472e711ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db4d0fc7-eddf-4d92-aab1-d0472e711ab8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_ca65bca6-ca40-43ab-907c-e8327b2febcc" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_NoncashDividendIncome_ca65bca6-ca40-43ab-907c-e8327b2febcc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fb24c727-2b32-4691-8a51-41c3f56461a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fb24c727-2b32-4691-8a51-41c3f56461a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be25e168-c1fd-4854-bbe5-8e569a764426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be25e168-c1fd-4854-bbe5-8e569a764426" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea762a51-6f27-414e-9579-13791bee7357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea762a51-6f27-414e-9579-13791bee7357" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4ceb01da-7477-4947-8373-fab9dc6a19bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4ceb01da-7477-4947-8373-fab9dc6a19bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_c0e45d45-9989-4def-b205-548c323f92f4" xlink:href="pgen-20201231.xsd#pgen_NumberOfRelatedPartiesWithTerminatedAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_c0e45d45-9989-4def-b205-548c323f92f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_da30f431-4848-418f-8e39-598fd9ba2868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_da30f431-4848-418f-8e39-598fd9ba2868" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_b58f4476-5a58-40e7-8afd-768789168060" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:to="loc_pgen_ZiopharmMember_b58f4476-5a58-40e7-8afd-768789168060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7188c7b6-da2d-4db8-8ad6-d8e53062a438_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:to="loc_srt_ProductsAndServicesDomain_7188c7b6-da2d-4db8-8ad6-d8e53062a438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:to="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationandlicensingagreementsMember_146a911d-57da-4693-9d42-f0ef61436922" xlink:href="pgen-20201231.xsd#pgen_CollaborationandlicensingagreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:to="loc_pgen_CollaborationandlicensingagreementsMember_146a911d-57da-4693-9d42-f0ef61436922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:to="loc_dei_EntityDomain_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:to="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ThirdSecurityMember_1c2a0d7d-cc6b-4ed9-9a12-9faff1a5c442" xlink:href="pgen-20201231.xsd#pgen_ThirdSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:to="loc_pgen_ThirdSecurityMember_1c2a0d7d-cc6b-4ed9-9a12-9faff1a5c442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_0f83d5da-95ae-4714-bbb3-7f6a655971c7" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:to="loc_pgen_ZiopharmMember_0f83d5da-95ae-4714-bbb3-7f6a655971c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c71b1daa-0179-4634-896a-403a75140627_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:to="loc_us-gaap_ClassOfStockDomain_c71b1daa-0179-4634-896a-403a75140627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:to="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ada6f55f-bee3-435d-89c8-0495980d9a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:to="loc_us-gaap_CommonStockMember_ada6f55f-bee3-435d-89c8-0495980d9a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SeriesAPreferredSharesMember_282f9838-f07b-4248-868c-038045c90a3c" xlink:href="pgen-20201231.xsd#pgen_SeriesAPreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:to="loc_pgen_SeriesAPreferredSharesMember_282f9838-f07b-4248-868c-038045c90a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ca768692-b32b-4e60-993c-1c1fe60e254d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:to="loc_us-gaap_RelatedPartyDomain_ca768692-b32b-4e60-993c-1c1fe60e254d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:to="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_fac035a5-68bb-4ed2-ae2a-a4fc7e09d046" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_ExecutiveChairmanMember_fac035a5-68bb-4ed2-ae2a-a4fc7e09d046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ThirdSecurityMember_6de03076-7f8c-4c9a-b41b-f829c2c44925" xlink:href="pgen-20201231.xsd#pgen_ThirdSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_ThirdSecurityMember_6de03076-7f8c-4c9a-b41b-f829c2c44925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AffiliatesOfThirdSecurityMember_788e04a3-2609-43a1-ba7c-d9f0d1cda0d7" xlink:href="pgen-20201231.xsd#pgen_AffiliatesOfThirdSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_AffiliatesOfThirdSecurityMember_788e04a3-2609-43a1-ba7c-d9f0d1cda0d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_802a970b-4a21-45f9-928c-8c598d5f5cad" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_802a970b-4a21-45f9-928c-8c598d5f5cad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_VariousECCAgreementsMember_406d4890-38e3-422d-98df-ea5f4e470154" xlink:href="pgen-20201231.xsd#pgen_VariousECCAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_VariousECCAgreementsMember_406d4890-38e3-422d-98df-ea5f4e470154" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShare" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShare"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/NetLossperShare" xlink:type="extended" id="i7bdfe45ccef94879a75baeed372d45cc_NetLossperShare"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/NetLossperShareTables" xlink:type="extended" id="ib149a925006c4c47b8b95b7d27950168_NetLossperShareTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended" id="id335369dd2984ab0b78ebc6e766c38ac_NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="extended" id="i7c24f9df6f444d25abb1af8a0dcf9200_NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76f59408-2943-4ad2-b480-1b736adb7f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76f59408-2943-4ad2-b480-1b736adb7f94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c90d7717-ae5f-4edf-9e48-21215a8a21e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c90d7717-ae5f-4edf-9e48-21215a8a21e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_735dbe44-f048-488e-b77c-587225441c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_ConvertibleDebtMember_735dbe44-f048-488e-b77c-587225441c7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6e64f293-5711-4826-a0c7-bbc5d6afb70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_StockOptionMember_6e64f293-5711-4826-a0c7-bbc5d6afb70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ef8cbc96-244f-4ce3-bc22-a1ec32a4ce8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ef8cbc96-244f-4ce3-bc22-a1ec32a4ce8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9da98252-24c7-49c0-afb8-d8d217376d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_WarrantMember_9da98252-24c7-49c0-afb8-d8d217376d29" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/Segments" xlink:type="simple" xlink:href="pgen-20201231.xsd#Segments"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/Segments" xlink:type="extended" id="i66f5ef5d9aa041919c8206f417230984_Segments"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SegmentsTables" xlink:type="extended" id="icc3c8368cb7c44d89024be6b408ed1c1_SegmentsTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsInformationbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="extended" id="i0bf6345ebe2742539d1e93b2231a9ae0_SegmentsInformationbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2087df5-aae4-4ba5-894e-eb40d3724235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_Goodwill_b2087df5-aae4-4ba5-894e-eb40d3724235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_6b47fa41-2896-4a0f-b66f-20cfdd9d13b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillTransfers_6b47fa41-2896-4a0f-b66f-20cfdd9d13b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_23c99c81-0325-4c83-96e0-ce1c8794a85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_23c99c81-0325-4c83-96e0-ce1c8794a85e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6b8cda17-256b-4904-aeed-23179255e629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6b8cda17-256b-4904-aeed-23179255e629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7bfb2828-f3f6-4922-aefb-60821f30ab47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7bfb2828-f3f6-4922-aefb-60821f30ab47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7703facf-1cc5-4989-97d8-d37854e484be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_Revenues_7703facf-1cc5-4989-97d8-d37854e484be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_af2fb840-a7ed-4c5a-a6f3-9f79ad169389" xlink:href="pgen-20201231.xsd#pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_af2fb840-a7ed-4c5a-a6f3-9f79ad169389" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:to="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:to="loc_srt_ConsolidationItemsDomain_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:to="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e2139369-9dc9-4fb6-8e5d-006cf1b39259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:to="loc_us-gaap_OperatingSegmentsMember_e2139369-9dc9-4fb6-8e5d-006cf1b39259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_389f6c3c-4ac8-4816-a1e2-f0835244849a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_389f6c3c-4ac8-4816-a1e2-f0835244849a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f241a608-4494-4f28-81ae-333a87c3a151_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:to="loc_us-gaap_SegmentDomain_f241a608-4494-4f28-81ae-333a87c3a151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:to="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PGENTherapeuticsSegmentMember_9defa1e7-ae66-4fad-9c6a-a64b3e0c714c" xlink:href="pgen-20201231.xsd#pgen_PGENTherapeuticsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_PGENTherapeuticsSegmentMember_9defa1e7-ae66-4fad-9c6a-a64b3e0c714c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioMember_f2a03b77-254b-4843-bf0f-de5375223c4c" xlink:href="pgen-20201231.xsd#pgen_ActoBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_ActoBioMember_f2a03b77-254b-4843-bf0f-de5375223c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaSegmentMember_6eb3ada0-d6af-47cc-a71b-c3a018a766da" xlink:href="pgen-20201231.xsd#pgen_TransOvaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_TransOvaSegmentMember_6eb3ada0-d6af-47cc-a71b-c3a018a766da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HumanBiotherapeuticsSegmentMember_66e260b0-f4c3-47ed-a0c2-ff8ec186a04f" xlink:href="pgen-20201231.xsd#pgen_HumanBiotherapeuticsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_HumanBiotherapeuticsSegmentMember_66e260b0-f4c3-47ed-a0c2-ff8ec186a04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8ace9f52-7679-4431-9a6c-273eba873052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8ace9f52-7679-4431-9a6c-273eba873052" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="extended" id="if4f8f053ca374222a1ecde168ed044f6_SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8a511f60-8338-450d-9275-1ca405f1676e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:to="loc_us-gaap_Revenues_8a511f60-8338-450d-9275-1ca405f1676e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_784a659e-4052-47b2-8bdc-51131dfea84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_784a659e-4052-47b2-8bdc-51131dfea84b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e4ff3daf-9569-4597-abce-c00fdf5e9dc4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:to="loc_us-gaap_SegmentDomain_e4ff3daf-9569-4597-abce-c00fdf5e9dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:to="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReportableSegmentsMember_8469ab22-388c-4c96-871b-1d96b58d4b69" xlink:href="pgen-20201231.xsd#pgen_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:to="loc_pgen_ReportableSegmentsMember_8469ab22-388c-4c96-871b-1d96b58d4b69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:to="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b2ce0841-7747-4dee-9a50-5d150e84382e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:to="loc_srt_ConsolidationItemsDomain_b2ce0841-7747-4dee-9a50-5d150e84382e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:to="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember_4cb96787-4f1f-4c61-ba5a-63e7613aab27" xlink:href="pgen-20201231.xsd#pgen_OperatingSegmentsAndCorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:to="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember_4cb96787-4f1f-4c61-ba5a-63e7613aab27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EliminationsAndReconcilingItemsMember_7bfb073c-2fc7-49c8-8939-77f6513e1736" xlink:href="pgen-20201231.xsd#pgen_EliminationsAndReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:to="loc_pgen_EliminationsAndReconcilingItemsMember_7bfb073c-2fc7-49c8-8939-77f6513e1736" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="extended" id="i9dbd136cd6bd40bc8f45718149e264d1_SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_8b771309-95b3-4472-a95a-3bd971d238e6" xlink:href="pgen-20201231.xsd#pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_8b771309-95b3-4472-a95a-3bd971d238e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates_6a5e12b7-9d94-4db8-8763-ac51d73121d3" xlink:href="pgen-20201231.xsd#pgen_CapitalExpendituresAndInvestmentsinAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates_6a5e12b7-9d94-4db8-8763-ac51d73121d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f577d853-893e-4ebc-8564-c4e6b38b98e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f577d853-893e-4ebc-8564-c4e6b38b98e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_71f7caa6-2e7e-44a8-9774-b2c6b4c85a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_InterestExpense_71f7caa6-2e7e-44a8-9774-b2c6b4c85a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_40c200bf-71f7-44b7-9732-4db43c306154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_40c200bf-71f7-44b7-9732-4db43c306154" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c72bbb75-313c-4f43-844e-92dc9fff2e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_AssetImpairmentCharges_c72bbb75-313c-4f43-844e-92dc9fff2e3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_589f8542-46d4-49fb-b943-7da86dcf4d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_589f8542-46d4-49fb-b943-7da86dcf4d08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_b841c9a3-b8db-44a6-a760-75a726a4c18f" xlink:href="pgen-20201231.xsd#pgen_GainLossRelatedToNoncashLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_b841c9a3-b8db-44a6-a760-75a726a4c18f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47f65548-a46a-46e1-a503-673e97e0a35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47f65548-a46a-46e1-a503-673e97e0a35d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AdjustmentForBonusesPaidInEquityAwards_f09681e1-73b4-428a-b954-5ac753c518cc" xlink:href="pgen-20201231.xsd#pgen_AdjustmentForBonusesPaidInEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_pgen_AdjustmentForBonusesPaidInEquityAwards_f09681e1-73b4-428a-b954-5ac753c518cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_df43e1e8-7ca0-4ce9-9542-385813725b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_df43e1e8-7ca0-4ce9-9542-385813725b81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4e0a794e-7e81-4f98-9269-840e629cf2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4e0a794e-7e81-4f98-9269-840e629cf2c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51bdb8e8-2d6c-43ce-b4d8-cb3f8f4990c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51bdb8e8-2d6c-43ce-b4d8-cb3f8f4990c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9311e84-1728-48ad-9388-34b462f6d598_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:to="loc_srt_ProductsAndServicesDomain_f9311e84-1728-48ad-9388-34b462f6d598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:to="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_25bf924f-9dee-443e-a5bb-dc9366fa2d23" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_25bf924f-9dee-443e-a5bb-dc9366fa2d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:to="loc_us-gaap_SegmentDomain_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:to="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReportableSegmentsMember_3982a8db-5b6e-4a53-87ba-f00bbb20a472" xlink:href="pgen-20201231.xsd#pgen_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:to="loc_pgen_ReportableSegmentsMember_3982a8db-5b6e-4a53-87ba-f00bbb20a472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8a645714-b0d6-40a6-abad-5ad83d5b6a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8a645714-b0d6-40a6-abad-5ad83d5b6a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_728803f9-21b9-4ce6-b2db-3251f5f930fd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:to="loc_srt_ConsolidationItemsDomain_728803f9-21b9-4ce6-b2db-3251f5f930fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:to="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5e8f2924-b9a6-41b9-8dd4-92e37e85b43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_OperatingSegmentsMember_5e8f2924-b9a6-41b9-8dd4-92e37e85b43f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CorporateAndReconcilingItemsMember_46a761f3-d5f9-4555-b4ed-c641771834c0" xlink:href="pgen-20201231.xsd#pgen_CorporateAndReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_pgen_CorporateAndReconcilingItemsMember_46a761f3-d5f9-4555-b4ed-c641771834c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3b078708-6642-4f62-a13c-b8ff15b7ba56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3b078708-6642-4f62-a13c-b8ff15b7ba56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_10d41b35-41b4-4e9e-9125-7bc4ec717850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_IntersegmentEliminationMember_10d41b35-41b4-4e9e-9125-7bc4ec717850" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="extended" id="i9e29c13b60fb4981998c37e7c0963e37_SegmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_b7d8fd22-9bac-405b-90cf-2e14ec2ca221" xlink:href="pgen-20201231.xsd#pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:to="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_b7d8fd22-9bac-405b-90cf-2e14ec2ca221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2ed2d97e-82d4-45e5-8d8f-51a1a4c36acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:to="loc_us-gaap_Revenues_2ed2d97e-82d4-45e5-8d8f-51a1a4c36acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:to="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98a93298-bf5d-46a9-ab98-506ad4119ef3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:to="loc_srt_SegmentGeographicalDomain_98a93298-bf5d-46a9-ab98-506ad4119ef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:to="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b7b4106b-60e5-442c-98db-f482231953bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:to="loc_us-gaap_NonUsMember_b7b4106b-60e5-442c-98db-f482231953bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" id="i7be94a82e83942e4b81cae02030a6692_QuarterlyFinancialInformationUnaudited"/>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="i89fde765082e422b9a0abb0a9070a6ae_QuarterlyFinancialInformationUnauditedTables"/>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="extended" id="ifd26095aa0d84ff3a8f65378c382d08a_QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlans" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlans"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DefinedContributionPlans" xlink:type="extended" id="i8c97149c17ac4a1eb9ad06ccdfc96c75_DefinedContributionPlans"/>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="extended" id="id4a486c797ce45b48001f45f4a18ef5d_DefinedContributionPlansAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SubsequentEvents" xlink:type="extended" id="ie66cc0a6eac24eb6a6daa2d27adc889e_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="extended" id="if3896155b2b943afb8dd068e482e41c4_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5c08ab2-66bb-4186-867f-65e98d4df1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5c08ab2-66bb-4186-867f-65e98d4df1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7177653-e8e1-49d9-a609-b3f1009a148a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7177653-e8e1-49d9-a609-b3f1009a148a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_4e1d09b7-1e07-446e-8767-ee84feff67ae" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_4e1d09b7-1e07-446e-8767-ee84feff67ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_5b7886f1-cb16-4f56-a869-296d97855728" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_5b7886f1-cb16-4f56-a869-296d97855728" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_07f25567-6874-4c52-b626-6c03030036b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_07f25567-6874-4c52-b626-6c03030036b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2bfd76e7-eb2b-490d-aec6-9ad2b1e20d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:to="loc_us-gaap_SubsequentEventMember_2bfd76e7-eb2b-490d-aec6-9ad2b1e20d91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_ecd5df6d-cece-40aa-b64d-700ed5b88642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_ecd5df6d-cece-40aa-b64d-700ed5b88642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4376e703-f25f-46df-883a-9fd5143ae8aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4376e703-f25f-46df-883a-9fd5143ae8aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_5e40e1df-46d9-47bc-a4d6-0bbdc8653d83" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:to="loc_pgen_MBPTitanMember_5e40e1df-46d9-47bc-a4d6-0bbdc8653d83" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>pgen-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6d69765-e77a-4051-8de4-87764b92915a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_9612b097-f91a-4f02-92ab-7b626972893c_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lines of credit</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7c98aa60-c400-43a4-910e-97a5c91d7c97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_770ad7af-a599-48ff-9f27-632b7b7bacba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_005abf25-536f-4e89-9210-43d208042ce6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ed97dab6-7706-4c4e-9f85-f683b546c7cf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PaymentsToRelatedParties_ed91740d-3120-4287-9160-cf1a77098100_terseLabel_en-US" xlink:label="lab_pgen_PaymentsToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_pgen_PaymentsToRelatedParties_label_en-US" xlink:label="lab_pgen_PaymentsToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Related Parties</link:label>
    <link:label id="lab_pgen_PaymentsToRelatedParties_documentation_en-US" xlink:label="lab_pgen_PaymentsToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflows for payments made to related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PaymentsToRelatedParties" xlink:href="pgen-20201231.xsd#pgen_PaymentsToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PaymentsToRelatedParties" xlink:to="lab_pgen_PaymentsToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_GainLossRelatedToNoncashLitigationSettlement_698c12aa-9f8b-49fb-9a4f-b49e1367f878_negatedTerseLabel_en-US" xlink:label="lab_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement agreement</link:label>
    <link:label id="lab_pgen_GainLossRelatedToNoncashLitigationSettlement_6860f02c-03c3-42e9-9204-2afa86c73a79_terseLabel_en-US" xlink:label="lab_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement agreement</link:label>
    <link:label id="lab_pgen_GainLossRelatedToNoncashLitigationSettlement_label_en-US" xlink:label="lab_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Noncash Litigation Settlement</link:label>
    <link:label id="lab_pgen_GainLossRelatedToNoncashLitigationSettlement_documentation_en-US" xlink:label="lab_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Noncash Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:href="pgen-20201231.xsd#pgen_GainLossRelatedToNoncashLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:to="lab_pgen_GainLossRelatedToNoncashLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_a5ddc5dc-c9b1-4eb0-ad82-767db9556f7b_terseLabel_en-US" xlink:label="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating, capital loss, and interest expense carryforwards</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_label_en-US" xlink:label="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating, Capital Loss, And Interest Expense Carryforwards</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_documentation_en-US" xlink:label="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax assets attributable to deductible operating loss carryforwards, capital loss carryforwards, and interest expense carryforwards, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:to="lab_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_416136f0-ef18-431e-8aa5-4eab00ae51ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_acd4657a-c9c2-4b41-a8b4-e3e6208255fc_terseLabel_en-US" xlink:label="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_label_en-US" xlink:label="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Amortization of Debt Discount (Premium) and Debt Issuance Costs</link:label>
    <link:label id="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_documentation_en-US" xlink:label="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments and amortization expense attributable to debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:href="pgen-20201231.xsd#pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:to="lab_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f8815edd-ee28-4042-ba47-a64b680d3bbb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a02b969-ad3a-492c-8a28-08ab0c63830b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fcec390-dd94-4071-a565-504f41f97e13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_29785dbf-4ac1-4fe3-85fe-621af8fdcb2b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8e39d11f-b0d7-4745-95cf-525745a4b699_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in EnviroFlight</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_6f2c4a81-f408-460b-bbb3-3f126bf6dac1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_f01adf6f-ad89-4e02-b828-bf7c1b332a0c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_612dbff4-7353-46b4-b476-ab2117777850_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt, net of issuance costs and deferred taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_39403e68-be6c-487e-9855-3123bc885462_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_a7a318a5-3b63-400f-9ae5-b77ebc3ea953_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, consideration receivable, collection period</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Receivable, Collection Period</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period over which the consideration is owed to the entity under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:to="lab_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9d6b8793-5dbe-4f32-9545-92043143154d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e490aae3-81f1-4a75-8b15-ccaf004f701e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6ac27000-9a4f-47b5-a202-51b0c9e3e3f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e891246-701c-416a-9ae7-bed2a9ac92e9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8ad1ea98-f38b-4bc0-b9e4-dfe7956679b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74a99dd0-70c6-423b-818d-5a7ff11d8f72_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_96128f10-3319-43f1-85ab-37a34abfe27c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4f11e1d3-e37f-4c5b-aec6-2895f849e850_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1139359f-0716-4501-bf46-561865f6ed0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ee5aa99b-15ba-4c18-93e4-c83a1c133540_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_82f7fbf7-1ebc-483f-a5fa-c09311118de7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_c37c5e0f-3b27-47a4-8b3a-b272f1c045e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DeferredTaxAssetsLeaseLiabilities_165ade9e-fb5f-4399-bcb2-cd5749b3f82f_terseLabel_en-US" xlink:label="lab_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_pgen_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_79040bb4-a299-4ee4-996b-e981a0c7534b_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party payables</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e0dba502-1d0d-40b6-9479-1742385c4d2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0e8d6e00-f53d-486a-bde9-96db77b360bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_b1de88a1-c21f-4132-b79c-3a7435ba2e69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_0197d615-8380-47a5-b521-54912bf2943e_terseLabel_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred state tax rate</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_label_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred State Tax Rate, Amount</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_documentation_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic deferred state income tax rates, attributable to increase (decrease) in the income tax rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:to="lab_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_27960a27-65a0-4cbe-b21b-c3aa6c62c46f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OtherCollaborationsMember_68a2b7af-5df4-4543-8d61-e248d03ef601_terseLabel_en-US" xlink:label="lab_pgen_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pgen_OtherCollaborationsMember_label_en-US" xlink:label="lab_pgen_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaborations [Member]</link:label>
    <link:label id="lab_pgen_OtherCollaborationsMember_documentation_en-US" xlink:label="lab_pgen_OtherCollaborationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate of other collaborations not separately disclosed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OtherCollaborationsMember" xlink:to="lab_pgen_OtherCollaborationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a0c79468-865d-45dd-aa5f-be7a0560df54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_1742bd5d-495e-4e57-8a91-4f58a4a8f041_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa503412-3d1b-40ce-bd77-a45df6676d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54cee9c3-daa2-48b6-b101-16b5b79e613f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ea107a79-0b40-434a-9ec3-02331f4652bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_124397da-1889-49b3-8152-b8edec3ad350_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_9a4bc06c-56b3-4eb8-b39b-2d2908df07f9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Abandonment</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b7e7560e-2e92-4cca-a762-1e3dca6060e9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d23bcb3b-ca90-4b9a-8531-26507e78139d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_42cb0acb-6305-401a-93e2-f3ecac8a37a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, exercise price range, lower limit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LockupPeriodOnRestrictedStockUnitShares_502c1ee2-8c42-4180-b37a-6d4a29a6194c_terseLabel_en-US" xlink:label="lab_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up period</link:label>
    <link:label id="lab_pgen_LockupPeriodOnRestrictedStockUnitShares_label_en-US" xlink:label="lab_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lockup Period On Restricted Stock Unit Shares</link:label>
    <link:label id="lab_pgen_LockupPeriodOnRestrictedStockUnitShares_documentation_en-US" xlink:label="lab_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time during which issued shares are subject to a lock-up on resale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:href="pgen-20201231.xsd#pgen_LockupPeriodOnRestrictedStockUnitShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:to="lab_pgen_LockupPeriodOnRestrictedStockUnitShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_520d34c6-e1c1-4827-b477-dacb238eae14_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_b1a5c6a5-42a0-4b9b-b47c-119c9ff4ab10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_36c790c1-45cf-443f-888b-62b49bf71d52_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d3878c84-2ad6-4a8b-9d78-46c4464fbd4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_bdd023fa-a74d-4502-bcea-2a949b8730fb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_89e900ef-228e-4650-bb2d-9714e0f91d1e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8364577a-5142-416b-a0c5-00e84f3e3273_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_49e91b5d-976a-42ef-8a00-42299916d7b8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_843de8aa-7a34-47c6-a7a0-7914de78d6a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_8d24d5bf-a47b-4472-832e-7e2f9b1b62ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment financed through debt</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LivestockMember_4650a4ce-6c62-4c6f-928a-6b1a522394b1_terseLabel_en-US" xlink:label="lab_pgen_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_pgen_LivestockMember_label_en-US" xlink:label="lab_pgen_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_pgen_LivestockMember_documentation_en-US" xlink:label="lab_pgen_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LivestockMember" xlink:href="pgen-20201231.xsd#pgen_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LivestockMember" xlink:to="lab_pgen_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_FeedMember_583d7b62-9c0e-4c24-bacc-14f19da62e56_terseLabel_en-US" xlink:label="lab_pgen_FeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feed</link:label>
    <link:label id="lab_pgen_FeedMember_label_en-US" xlink:label="lab_pgen_FeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feed [Member]</link:label>
    <link:label id="lab_pgen_FeedMember_documentation_en-US" xlink:label="lab_pgen_FeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FeedMember" xlink:href="pgen-20201231.xsd#pgen_FeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_FeedMember" xlink:to="lab_pgen_FeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_73b54fc6-7db2-45d3-b500-4fd6e195e364_terseLabel_en-US" xlink:label="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.</link:label>
    <link:label id="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_label_en-US" xlink:label="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. [Member]</link:label>
    <link:label id="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_documentation_en-US" xlink:label="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:href="pgen-20201231.xsd#pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:to="lab_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ProductsandServicesRevenuesMember_ea11061d-0844-41e1-8f59-e285277771bf_terseLabel_en-US" xlink:label="lab_pgen_ProductsandServicesRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services revenues</link:label>
    <link:label id="lab_pgen_ProductsandServicesRevenuesMember_label_en-US" xlink:label="lab_pgen_ProductsandServicesRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services Revenues [Member]</link:label>
    <link:label id="lab_pgen_ProductsandServicesRevenuesMember_documentation_en-US" xlink:label="lab_pgen_ProductsandServicesRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from products and services sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProductsandServicesRevenuesMember" xlink:href="pgen-20201231.xsd#pgen_ProductsandServicesRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ProductsandServicesRevenuesMember" xlink:to="lab_pgen_ProductsandServicesRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_70b6a476-792a-4c34-98bb-f3818cdf7a96_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_392e67fa-bdbc-4eaa-8d61-8b5f522a3645_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6214ab80-6766-4e0e-b288-c5cde39f5b60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_484e3d11-e1cb-419c-ae2e-0f0310e46b66_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f638b206-04ec-490f-a614-2ef577548b43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fcae8ae6-7ee0-4484-bdf0-6e906bb9058f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8670700c-8a3b-4cc1-a540-2d531995ffe0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write offs of accounts receivable, net of recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_804a8c77-3155-4fe8-bb7f-df21471ed901_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ComputerHardwareandSoftware_3b2c751a-373e-4183-9cc0-13d14b2b209b_terseLabel_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_pgen_ComputerHardwareandSoftware_label_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware and Software</link:label>
    <link:label id="lab_pgen_ComputerHardwareandSoftware_documentation_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before accumulated depreciation and amortization of computer hardware and purchased software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftware" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ComputerHardwareandSoftware" xlink:to="lab_pgen_ComputerHardwareandSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_de1da9d6-cd87-4dc2-bae5-7fe5f4e2e1ae_terseLabel_en-US" xlink:label="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_label_en-US" xlink:label="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Equity Component of Long-Term Debt</link:label>
    <link:label id="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_documentation_en-US" xlink:label="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from equity component of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:to="lab_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_fa41f021-72a4-422f-ba94-b37274b9ea06_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Years)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_96735688-4397-4df1-b55d-e0783bc22ea9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0e0ef61b-2aef-45c0-849a-8de958f32c68_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e09baec6-1f8b-49f9-b86a-fbc45b8681c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_RelatedPartiesAggregatedMember_bc7414d6-0f94-451c-bb76-5041ffdba5a2_terseLabel_en-US" xlink:label="lab_pgen_RelatedPartiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties, Aggregated</link:label>
    <link:label id="lab_pgen_RelatedPartiesAggregatedMember_label_en-US" xlink:label="lab_pgen_RelatedPartiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties, Aggregated [Member]</link:label>
    <link:label id="lab_pgen_RelatedPartiesAggregatedMember_documentation_en-US" xlink:label="lab_pgen_RelatedPartiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties, Aggregated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_RelatedPartiesAggregatedMember" xlink:to="lab_pgen_RelatedPartiesAggregatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_11618444-4478-48c4-a43d-9b51093d1411_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lines of Credit and Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ed59902-09bb-4827-b5c4-6daeb4166c60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_256140ae-66e4-47b6-bf9b-467a6de99a68_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_561a1862-ae35-4c1e-a811-eac15c75bee0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and licensing agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems_33021eba-6bd3-427d-8965-288bf32de7bc_terseLabel_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Line Items]</link:label>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems_label_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Line Items]</link:label>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems_documentation_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:to="lab_pgen_ScheduleOfInvestmentsInJointVentureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AmericanStateBankMember_797662a3-3610-4747-94b9-f586598973d8_terseLabel_en-US" xlink:label="lab_pgen_AmericanStateBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American State Bank</link:label>
    <link:label id="lab_pgen_AmericanStateBankMember_label_en-US" xlink:label="lab_pgen_AmericanStateBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American State Bank [Member]</link:label>
    <link:label id="lab_pgen_AmericanStateBankMember_documentation_en-US" xlink:label="lab_pgen_AmericanStateBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American State Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AmericanStateBankMember" xlink:href="pgen-20201231.xsd#pgen_AmericanStateBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AmericanStateBankMember" xlink:to="lab_pgen_AmericanStateBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7d6d13a8-f4a2-4433-9ab9-561d1b622c16_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MerckConvertibleNoteMember_1f9515d6-f87b-49aa-9eca-0f020bcef020_terseLabel_en-US" xlink:label="lab_pgen_MerckConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Convertible Note</link:label>
    <link:label id="lab_pgen_MerckConvertibleNoteMember_label_en-US" xlink:label="lab_pgen_MerckConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Convertible Note [Member]</link:label>
    <link:label id="lab_pgen_MerckConvertibleNoteMember_documentation_en-US" xlink:label="lab_pgen_MerckConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Convertible Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MerckConvertibleNoteMember" xlink:href="pgen-20201231.xsd#pgen_MerckConvertibleNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MerckConvertibleNoteMember" xlink:to="lab_pgen_MerckConvertibleNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6829145c-8220-4dd9-908d-841d6ac3a551_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66114552-07c0-481c-9a22-62eafa0a8707_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_776f1ef5-8293-4214-9fb5-9ac8d73a5311_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3a4aeda6-7e5c-4dde-bfd8-3390ffb4db1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTransfers_f647f5d6-dd7a-4985-a52d-ddb63382b853_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reallocations from changes to reporting units</link:label>
    <link:label id="lab_us-gaap_GoodwillTransfers_label_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTransfers" xlink:to="lab_us-gaap_GoodwillTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2b84dc55-0faa-49f5-a99a-3a97827801b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of authorized awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_cf0f0861-dbe2-4448-b97c-df78ffbb9240_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated corporate costs</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f090381c-1c9c-4c76-a74a-a3b40ac8a8dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining shares available to grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_fdaa6917-434d-4d81-8cf8-b21dd49faba6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_d7c782ff-7ced-4f15-a22c-059cba264787_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of shares in a private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CashInflowsOutflowsInAssetAcquisition_2cc3f802-f6f5-4436-9346-f5d824ff8b05_terseLabel_en-US" xlink:label="lab_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in asset acquisitions</link:label>
    <link:label id="lab_pgen_CashInflowsOutflowsInAssetAcquisition_cfc1f88d-1e4c-463c-ae60-cc8e7eda57ce_verboseLabel_en-US" xlink:label="lab_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in asset acquisition</link:label>
    <link:label id="lab_pgen_CashInflowsOutflowsInAssetAcquisition_label_en-US" xlink:label="lab_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Inflows (Outflows) In Asset Acquisition</link:label>
    <link:label id="lab_pgen_CashInflowsOutflowsInAssetAcquisition_documentation_en-US" xlink:label="lab_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of cash inflows (outflows) related to an asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:href="pgen-20201231.xsd#pgen_CashInflowsOutflowsInAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:to="lab_pgen_CashInflowsOutflowsInAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_98ac3192-15aa-4c4b-949c-73993c1cb01f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_3b843924-1660-4e75-b999-1f35d09b425f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and service revenues, standard payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2019PlanMember_d3adb3b6-f249-40f4-8d40-7d2fc69b2301_terseLabel_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2019 Plan</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2019PlanMember_label_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2019 Plan [Member]</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2019PlanMember_documentation_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2019 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:to="lab_pgen_PrecigenStockOptionPlan2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3ca71a0-262a-45e7-a1b5-ec54088f1fdd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_b580ed41-3188-4d04-a0fe-c2ecabe9696b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum risk of loss related to the identified VIEs</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:to="lab_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_90f9c7f9-6b35-4c08-b67d-13bd44595a3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_08b236c3-1514-4339-974d-d0d86b9fa1ac_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7972a91a-6753-4de1-86b4-5145e5f38755_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_576faaa5-de0c-4478-ba14-318ca013f3b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IntrexonEnergyPartnersMember_fe12bb78-91f1-426b-8d0d-89c097bb573e_terseLabel_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners, LLC</link:label>
    <link:label id="lab_pgen_IntrexonEnergyPartnersMember_label_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners [Member]</link:label>
    <link:label id="lab_pgen_IntrexonEnergyPartnersMember_documentation_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IntrexonEnergyPartnersMember" xlink:to="lab_pgen_IntrexonEnergyPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9ebfcb95-5bdc-41f6-b07f-18a43c51b4b7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to unvested stock option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_901c211a-c56c-4960-a372-67cf290f88f5_terseLabel_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation arrangement with individual, annual RSU grant, grant date fair value</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_label_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual RSU Grant, Grant Date Fair Value</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_documentation_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual RSU Grant, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:to="lab_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a573580-fb29-4129-b882-feac04ed165c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_HarvestStartUpEntitiesAggregatedMember_9751572c-749d-4397-becd-6393bd83b270_verboseLabel_en-US" xlink:label="lab_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Start-Up Entities</link:label>
    <link:label id="lab_pgen_HarvestStartUpEntitiesAggregatedMember_label_en-US" xlink:label="lab_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Start-Up Entities, Aggregated [Member]</link:label>
    <link:label id="lab_pgen_HarvestStartUpEntitiesAggregatedMember_documentation_en-US" xlink:label="lab_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Start-Up Entities, Aggregated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:to="lab_pgen_HarvestStartUpEntitiesAggregatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_2c80ea9c-bf95-4564-9242-34cd34b149ea_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised and Restricted Stock Awards</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:to="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_41443d9e-4fe0-4df3-8f6f-f2c185d0aabb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e2e87234-3828-46b4-a04a-5591a85540b3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70b9e79d-744c-4cf7-85be-1b7c86cd1d37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of cumulative foreign currency translation adjustments to net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8a1eb2e5-a03b-4528-8629-b23805b41d7c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of cumulative translation adjustment to loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_64b8169f-1abb-46b5-ab4b-a352d84ce5eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d5fce682-3b23-4db5-b052-f51fb1ee0d28_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax incentives</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IntrexonEnergyPartnersIILLCMember_b03641d9-df04-4fff-91af-e8b2c0608f4f_terseLabel_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersIILLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners II, LLC</link:label>
    <link:label id="lab_pgen_IntrexonEnergyPartnersIILLCMember_label_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersIILLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners II, LLC [Member]</link:label>
    <link:label id="lab_pgen_IntrexonEnergyPartnersIILLCMember_documentation_en-US" xlink:label="lab_pgen_IntrexonEnergyPartnersIILLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon Energy Partners II, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IntrexonEnergyPartnersIILLCMember" xlink:to="lab_pgen_IntrexonEnergyPartnersIILLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0de6ddf2-99cc-45a9-8a4f-6096e2203129_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_78d444fc-e7cd-445e-b66f-b0e753c89900_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_eb425cf7-d376-489c-bd03-aa7ad10cca40_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_83632672-0a8a-4f81-acc4-212401c21ffb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross" xlink:to="lab_us-gaap_FurnitureAndFixturesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4f68e756-588b-4e55-b06a-5bb9b50bffcf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_27217405-008d-48a2-884e-a4cf6cae0427_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a18f6b5b-1841-499f-be8a-6f8742ecc1cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e1b88079-dd50-4db3-b28e-81e7d027f401_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as payment for services, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_322a834e-2d20-46b9-94b3-3200a9e39c81_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_a8f3d7d7-7ec0-45e6-85c8-c8989f4fe17b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_343eb8c6-d016-44b2-9390-f68d4953ba6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_8aecb8ef-6e88-4177-af7a-b8f7ec25de9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in subsidiaries included in discontinued operations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investment in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_3d26b9a4-de4a-4bf6-9915-97aa05cfc62c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_ee15efd1-b8fe-49c5-ad2a-e29e976dce5e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_273db6b2-7cf9-4023-8b20-bec3beb82900_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1f2e2b16-849d-4420-996d-e3e7c3ac66ad_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CorporateAndReconcilingItemsMember_c8b3dde1-e5b0-4117-b4c4-dde6b768bd1c_terseLabel_en-US" xlink:label="lab_pgen_CorporateAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses:</link:label>
    <link:label id="lab_pgen_CorporateAndReconcilingItemsMember_label_en-US" xlink:label="lab_pgen_CorporateAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Reconciling Items [Member]</link:label>
    <link:label id="lab_pgen_CorporateAndReconcilingItemsMember_documentation_en-US" xlink:label="lab_pgen_CorporateAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CorporateAndReconcilingItemsMember" xlink:href="pgen-20201231.xsd#pgen_CorporateAndReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CorporateAndReconcilingItemsMember" xlink:to="lab_pgen_CorporateAndReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4781eb77-2961-48e1-abe3-ee38666442e2_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da9df73f-8d7e-4417-ab1b-e2a15bd525f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da932bdf-62ff-4870-bbea-a7efdc55dac9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c2d68a5-c790-44f8-b0e7-bca6aef734e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_4e3b31a5-cf2e-4d87-8e7a-b817a5d338b9_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DeferredRevenueOtherMember_66216b3b-76bb-4516-9fe1-405ec60ad040_terseLabel_en-US" xlink:label="lab_pgen_DeferredRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pgen_DeferredRevenueOtherMember_label_en-US" xlink:label="lab_pgen_DeferredRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Other [Member]</link:label>
    <link:label id="lab_pgen_DeferredRevenueOtherMember_documentation_en-US" xlink:label="lab_pgen_DeferredRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredRevenueOtherMember" xlink:href="pgen-20201231.xsd#pgen_DeferredRevenueOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DeferredRevenueOtherMember" xlink:to="lab_pgen_DeferredRevenueOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_96413501-16bd-4cfb-ac40-2e9d274c0f41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon conversion of long-term debt (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_dfbd3e1f-ae9e-4813-873c-0e15c548fec6_terseLabel_en-US" xlink:label="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as payment for services</link:label>
    <link:label id="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_label_en-US" xlink:label="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued During Period Value Issued For Services Expense</link:label>
    <link:label id="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_documentation_en-US" xlink:label="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized for consideration of services paid in the form of stock. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:href="pgen-20201231.xsd#pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:to="lab_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ac42cdc3-d6b1-4496-9c1f-7f00b28317e0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6da58da1-f830-4d09-92af-b07854d5c50a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d0f76103-7a4a-42b3-9330-796de4c03441_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_ba841454-f87f-4ac6-a352-d82ac25cb893_terseLabel_en-US" xlink:label="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition period during which costs will be reimbursed</link:label>
    <link:label id="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_label_en-US" xlink:label="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Period During Which Costs Will Be Reimbursed</link:label>
    <link:label id="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_documentation_en-US" xlink:label="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period following the effective date of the licensing agreement during which costs incurred to transition knowledge and materials will be reimbursed by third party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:href="pgen-20201231.xsd#pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:to="lab_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75813879-2e29-4439-be80-f6933d67e911_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_b5b22fba-04ac-4089-86d5-3f3d4b3a358e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_dbd5c162-c1b3-4321-a324-30d7bf38e1c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_08efa40f-5a9e-4ead-8edf-3aa5bfe58d09_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_ef2dcf7b-d0a9-405c-93f4-7b559af145bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible stock based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborationandlicensingagreementsMember_931b79ca-f7df-4c69-a70f-e3d9c000fcae_terseLabel_en-US" xlink:label="lab_pgen_CollaborationandlicensingagreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and licensing agreements</link:label>
    <link:label id="lab_pgen_CollaborationandlicensingagreementsMember_label_en-US" xlink:label="lab_pgen_CollaborationandlicensingagreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and licensing agreements [Member]</link:label>
    <link:label id="lab_pgen_CollaborationandlicensingagreementsMember_documentation_en-US" xlink:label="lab_pgen_CollaborationandlicensingagreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees, milestone payments, and research services related to collaboration and licensing agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationandlicensingagreementsMember" xlink:href="pgen-20201231.xsd#pgen_CollaborationandlicensingagreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborationandlicensingagreementsMember" xlink:to="lab_pgen_CollaborationandlicensingagreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dcf380ff-0269-40da-ab6c-28644f40b863_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_6b347067-5f43-4567-a557-3b0164fa628d_terseLabel_en-US" xlink:label="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="pgen-20201231.xsd#pgen_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_pgen_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_0793b410-722c-474a-ba2b-ad6011b66314_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d3d9725a-aed1-469d-b9f5-df7538f9f320_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember_f1b1da49-8bc4-4860-9200-dbbf292c024a_terseLabel_en-US" xlink:label="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues, including from other operating segments</link:label>
    <link:label id="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember_label_en-US" xlink:label="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments And Corporate Non-Segment [Member]</link:label>
    <link:label id="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember_documentation_en-US" xlink:label="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments And Corporate Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:href="pgen-20201231.xsd#pgen_OperatingSegmentsAndCorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:to="lab_pgen_OperatingSegmentsAndCorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_69c12c87-a36c-43fa-bd6c-7d19b83720ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_804f558b-6dc8-4c18-bcf2-19cb6bd686e7_terseLabel_en-US" xlink:label="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing agreement between ZIOPHARM and Precigen 2018</link:label>
    <link:label id="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_label_en-US" xlink:label="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement Between ZIOPHARM and Precigen 2018 [Member]</link:label>
    <link:label id="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_documentation_en-US" xlink:label="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement Between ZIOPHARM Oncology, Inc. and Precigen, Inc. in 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:to="lab_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2e8ee406-007f-49fb-bb7e-4733902f4321_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9feaacc4-81de-48f4-8a68-84b122bc51b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in&#160;Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_83c396ea-0bb3-4b79-935d-33a25228ac42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember_8e70aa67-f866-40eb-8ac6-27a12633a596_terseLabel_en-US" xlink:label="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc.</link:label>
    <link:label id="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember_label_en-US" xlink:label="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exotech, AD Skincare, and Thrive Agrobiotics [Member]</link:label>
    <link:label id="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember_documentation_en-US" xlink:label="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exotech, AD Skincare, and Thrive Agrobiotics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:href="pgen-20201231.xsd#pgen_ExotechADSkincareAndThriveAgrobioticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:to="lab_pgen_ExotechADSkincareAndThriveAgrobioticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_cda85621-3d4d-4a02-b03c-aabe19ee2321_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e33ca55-90e4-4ff1-8d31-ce3f0aa6b0b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9be5c4e8-b1d7-4bc7-9223-9fa4409037f0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ac588096-98f9-4000-a342-3d541e89a8cd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_f911e009-6598-4f7e-93f8-6cf8fc43f5b8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TransOvaGeneticsLcMember_a6ad42c8-0e4e-4072-802a-5c3d7255947d_terseLabel_en-US" xlink:label="lab_pgen_TransOvaGeneticsLcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova Genetics, LC</link:label>
    <link:label id="lab_pgen_TransOvaGeneticsLcMember_label_en-US" xlink:label="lab_pgen_TransOvaGeneticsLcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova Genetics Lc [Member]</link:label>
    <link:label id="lab_pgen_TransOvaGeneticsLcMember_documentation_en-US" xlink:label="lab_pgen_TransOvaGeneticsLcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova Genetics LC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaGeneticsLcMember" xlink:href="pgen-20201231.xsd#pgen_TransOvaGeneticsLcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TransOvaGeneticsLcMember" xlink:to="lab_pgen_TransOvaGeneticsLcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_c283b58b-6fec-4904-a75d-7e95049788a7_terseLabel_en-US" xlink:label="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses inherited via acquisition</link:label>
    <link:label id="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_label_en-US" xlink:label="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Acquired In Acquisition Of Business</link:label>
    <link:label id="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_documentation_en-US" xlink:label="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, acquired in acquisition of a business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:href="pgen-20201231.xsd#pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:to="lab_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_baecea88-f841-4d69-b94c-744fe7f624a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_693a7e77-219c-40fd-9969-1cc017a5a925_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_443e7aa2-8e44-4941-a023-6a922bc4ef11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IntrexonT1DPartnersLLCMember_69eb42da-21af-4b7f-be9d-bab058762211_terseLabel_en-US" xlink:label="lab_pgen_IntrexonT1DPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon T1D Partners, LLC</link:label>
    <link:label id="lab_pgen_IntrexonT1DPartnersLLCMember_label_en-US" xlink:label="lab_pgen_IntrexonT1DPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon T1D Partners, LLC [Member]</link:label>
    <link:label id="lab_pgen_IntrexonT1DPartnersLLCMember_documentation_en-US" xlink:label="lab_pgen_IntrexonT1DPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrexon T1D Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IntrexonT1DPartnersLLCMember" xlink:to="lab_pgen_IntrexonT1DPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7a6cc7f0-3254-4dce-b580-df628a1d0972_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a82e8d36-0915-4d77-83f6-172e92dc484e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_14e42e8f-4ccc-4ebc-a9f1-c31ee5159025_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fe85f22d-817a-44e0-bdd4-529d5bbad917_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5bec520a-39a5-4be3-9f63-925d3b63f09c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e4f49510-14fa-46c3-ab65-305bde6afec1_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_fa0996fb-353c-4780-ab7f-c337c1fd2acf_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense for services</link:label>
    <link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_label_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_4f59e118-97c5-4260-9eae-67ba09a296cc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b0f0d21b-58f9-41b1-86ff-14199216dfe3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_5b5f099e-f117-46fe-9872-89a53d81c842_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ca53f164-0b50-47e8-9d08-4159db680063_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_367cf324-8a78-46bb-b03f-75bb719d2568_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_9658d8b9-9518-401d-9a08-339221252d29_terseLabel_en-US" xlink:label="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net</link:label>
    <link:label id="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_70766b06-2a37-4b3f-938f-a7ae08845db2_negatedLabel_en-US" xlink:label="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net</link:label>
    <link:label id="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_41146e7b-01eb-47be-836e-78bdabe3bea1_negatedTerseLabel_en-US" xlink:label="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized and realized depreciation on equity securities and preferred stock, net</link:label>
    <link:label id="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_label_en-US" xlink:label="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities and Preferred Stock, Unrealized and Realized Appreciation (Depreciation)</link:label>
    <link:label id="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_documentation_en-US" xlink:label="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:to="lab_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EnviroFlightLLCMember_54d77286-8436-42e6-b6d5-89d0bbce3f8e_terseLabel_en-US" xlink:label="lab_pgen_EnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EnviroFlight Sale</link:label>
    <link:label id="lab_pgen_EnviroFlightLLCMember_label_en-US" xlink:label="lab_pgen_EnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EnviroFlight, LLC [Member]</link:label>
    <link:label id="lab_pgen_EnviroFlightLLCMember_documentation_en-US" xlink:label="lab_pgen_EnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EnviroFlight, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EnviroFlightLLCMember" xlink:to="lab_pgen_EnviroFlightLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0a40953-6047-48ce-a7db-56a79f89ce9e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ebe9e3a5-fa98-47cd-8089-e2f425b365fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d756f019-9868-4591-979f-214fea234436_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f3f8d029-a236-4a6a-85d8-ee8f7d8ba2e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7dafb1ee-5e40-487f-81f6-9732525507d2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_31c8ffb7-285b-4e1d-8f1b-05edb840d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable to banks</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_dda5aeec-6858-498f-bce9-5b7c222973a7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_55991845-1bc5-4bde-9252-ada90a680cb1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c0557f54-f279-4b52-8a6a-e8ad5456ae59_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c5d48260-bed0-4b29-a905-804c914468f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementPercentageofSublicensingIncome_99015f5f-a93f-4b2d-8d51-80c297f15785_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, percentage of sublicensing income</link:label>
    <link:label id="lab_pgen_LicenseAgreementPercentageofSublicensingIncome_label_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Sublicensing Income</link:label>
    <link:label id="lab_pgen_LicenseAgreementPercentageofSublicensingIncome_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Sublicensing Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofSublicensingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:to="lab_pgen_LicenseAgreementPercentageofSublicensingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_b40cb56a-86d6-4676-915f-db6d29953420_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes:</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b1db7bcb-9445-438a-a5f3-df005bff706e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty_2fafa3d3-3b09-4f47-8f49-b48412c73e1c_terseLabel_en-US" xlink:label="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be paid to other party</link:label>
    <link:label id="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty_label_en-US" xlink:label="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Paid to Other Party</link:label>
    <link:label id="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty_documentation_en-US" xlink:label="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage royalty payable to another party as defined in applicable agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:href="pgen-20201231.xsd#pgen_RoyaltyPercentageToBePaidtoOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:to="lab_pgen_RoyaltyPercentageToBePaidtoOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c770788a-a3c6-4892-b9ca-1879bbc19ae2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b61a791f-7604-4114-80a9-d0328c25ea50_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_830ecfc5-1973-47c2-bc39-e8819f497b9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5ada7ed1-88f4-446e-9f76-32ae8feedecf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dabca15b-25d0-48c0-81a5-e55d44267f92_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_963ba5c6-817e-4c20-96a1-aac8c91925c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_98742661-5a47-46b9-94e1-a3f084952a9c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_7e78ba6e-5cfe-4504-ab75-8e7b144a0122_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for reacquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5b0266ed-a4c1-47c3-8a9f-3895d2c930e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fa268ed7-d04c-495d-aeab-5f42e1c7e7cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4eafaa65-0ecb-45c9-a2df-6eb6f5db4d73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, unamortized discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5160f388-bf79-4804-a062-e3bad5dd3067_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_6e5c98b8-0a36-458a-922f-35d6e92825fb_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year continuing operations</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Change In Amount Current Year Operations</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the valuation allowance for deferred tax assets as a result of current year operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_db68ee0c-08ea-49eb-a196-36969d7fe1f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c74260c8-3345-4281-9e70-739b5fff981f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_169de9cb-5a14-4db6-a022-915e7d203ad1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2f11ee7d-1029-4fab-9f84-8e283d18bbac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_de07b11b-6602-46c7-8cfe-6d70276cd5ff_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dd2c223c-fcd2-42de-832e-fe96df1865a8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b3637397-9d74-4cd9-ab82-b0a60b213e66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0f0a6ba3-4a23-4563-b0a1-5c3494bcaac3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_51e807dc-e858-40d4-9a3b-796c4528d29b_terseLabel_en-US" xlink:label="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies, embryos and other production materials</link:label>
    <link:label id="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_label_en-US" xlink:label="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies, Embryos And Other Production Materials [Member]</link:label>
    <link:label id="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_documentation_en-US" xlink:label="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies, Embryos And Other Production Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:href="pgen-20201231.xsd#pgen_SuppliesEmbryosAndOtherProductionMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:to="lab_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d42fa949-3118-47e6-9788-a995babf84c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_456b9560-e389-45e5-aa82-ba55ce5c9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_b26d921d-12e1-4a72-a881-f40913523f35_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties, less allowance for credit losses of $1,509 and $2,312 as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_935979a5-03fc-480c-b0f8-cba078d8ac6d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_45a5f2a2-7e0e-42e5-b7ee-559177ed2e4e_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:to="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_984ceffe-67da-4a0c-adfc-94ff7a61f72d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net loss of affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ee5258e6-fa64-4d37-9ab7-4d94672aa8c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net loss of affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_639fc9ed-71fb-4825-ad5e-d1e985d50fb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net loss of EnviroFlight</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8d1ccc94-d778-4bdb-b34d-215179a8ba49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_946a027f-8b40-4269-a30c-14dd95749f3f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_43f38d2a-dfd9-4b58-9a78-c18e7f1d43de_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9c344bda-f15f-4a7c-bb93-3367c3952ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OragenicsMember_df2f0431-c239-43fc-87d6-17a7cc545f1e_terseLabel_en-US" xlink:label="lab_pgen_OragenicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oragenics, Inc.</link:label>
    <link:label id="lab_pgen_OragenicsMember_label_en-US" xlink:label="lab_pgen_OragenicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oragenics [Member]</link:label>
    <link:label id="lab_pgen_OragenicsMember_documentation_en-US" xlink:label="lab_pgen_OragenicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oragenics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OragenicsMember" xlink:to="lab_pgen_OragenicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_A3.5ConvertibleNotesDue2023Member_9f3b247d-84bc-4f9e-b3f9-81a35feeaf6a_terseLabel_en-US" xlink:label="lab_pgen_A3.5ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.5% Convertible Notes Due 2023</link:label>
    <link:label id="lab_pgen_A3.5ConvertibleNotesDue2023Member_label_en-US" xlink:label="lab_pgen_A3.5ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.5% Convertible Notes Due 2023 [Member]</link:label>
    <link:label id="lab_pgen_A3.5ConvertibleNotesDue2023Member_documentation_en-US" xlink:label="lab_pgen_A3.5ConvertibleNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.5% Convertible Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_A3.5ConvertibleNotesDue2023Member" xlink:to="lab_pgen_A3.5ConvertibleNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_36cdc0cb-d7fc-4c90-b478-49a7ab08e147_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LossContingencyClaimsInvalidatedNumber_df500ace-a923-499d-80a9-3297fdade252_terseLabel_en-US" xlink:label="lab_pgen_LossContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims invalidated number</link:label>
    <link:label id="lab_pgen_LossContingencyClaimsInvalidatedNumber_label_en-US" xlink:label="lab_pgen_LossContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalidated Number</link:label>
    <link:label id="lab_pgen_LossContingencyClaimsInvalidatedNumber_documentation_en-US" xlink:label="lab_pgen_LossContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalidated Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyClaimsInvalidatedNumber" xlink:href="pgen-20201231.xsd#pgen_LossContingencyClaimsInvalidatedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LossContingencyClaimsInvalidatedNumber" xlink:to="lab_pgen_LossContingencyClaimsInvalidatedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0a85b380-f4a9-4887-9ce2-14775eccb21f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_8ad9f938-bf65-4745-882e-bce6b40ea712_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CastleCreekBiosciencesIncMember_fabe8306-6237-46d4-ab29-12429852a187_terseLabel_en-US" xlink:label="lab_pgen_CastleCreekBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Castle Creek Biosciences, Inc.</link:label>
    <link:label id="lab_pgen_CastleCreekBiosciencesIncMember_label_en-US" xlink:label="lab_pgen_CastleCreekBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Castle Creek Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_pgen_CastleCreekBiosciencesIncMember_documentation_en-US" xlink:label="lab_pgen_CastleCreekBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Castle Creek Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CastleCreekBiosciencesIncMember" xlink:to="lab_pgen_CastleCreekBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2f49cda3-5545-48d1-b527-527d1a926ddc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_0ea28724-779c-4abb-a336-45995368b617_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3858aacf-c85c-4097-a242-c88af731c6c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cf7686db-8803-4ac7-a0df-f87d4adbf26c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_a6f5bae5-093c-4f4b-93fc-92c816bfdf87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, terms of award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_dcf8040e-de3d-45bd-9145-e2c92a8b7a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_e55a4c26-50cf-4171-9c6f-d048d83c3ddf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on release of cumulative foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4f5ee40a-a099-4022-b7fd-45e60d46fd17_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on release of cumulative foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected_aae9f223-c94e-4289-aa7e-be84cdb3052f_terseLabel_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of seats on the joint venture's governing board, internally selected</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected_label_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Seats on Governing Board, Internally Selected</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected_documentation_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of seats on the governing board selected internally.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:to="lab_pgen_NumberofSeatsonGoverningBoardInternallySelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a850c4a8-c26b-481a-acae-79c0dd451d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e3d82da-70db-4edf-969b-aab67c3219fa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_21aa14d8-2b32-45d6-9025-dd068c115931_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_229844cb-5f27-4cbb-a7c6-754b90831135_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_009d9bea-19ee-4719-a71a-15b4a0316650_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_5d825ff9-ae49-4f07-bcc3-4f64321ab1e7_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations treated as asset sales</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Discontinued Operations Treated As Asset Sales</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Discontinued Operations Treated As Asset Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_98df8781-1e69-48b4-85bb-768a74528540_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e202343a-bc3a-4dd8-bd21-cb7baca24225_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3f1ba7b9-63a5-4e45-8f4f-c29772bcb96a_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States federal income taxes:</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_f41c2e62-f19f-4f42-8801-9b7827065201_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_15eb97a5-e908-414b-8a76-dba4deda7f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71387bfc-58da-4902-9125-6451b491c5ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_054d2a1a-4dab-4f3b-97f3-6f35cbed9fca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used in Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9490beab-f752-4575-be66-a96af00c2b42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoard_dcec26e2-fe74-49d4-84d3-b22bf8819a8b_terseLabel_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of seats on the joint venture's governing board</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoard_label_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Seats on Governing Board</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoard_documentation_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of seats on the governing board.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoard" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NumberofSeatsonGoverningBoard" xlink:to="lab_pgen_NumberofSeatsonGoverningBoard" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ReportableSegmentsMember_e2f1b444-27ff-4340-9944-782d33651c99_terseLabel_en-US" xlink:label="lab_pgen_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total segment revenues from reportable segments</link:label>
    <link:label id="lab_pgen_ReportableSegmentsMember_f6b490eb-6beb-4b13-afc3-a6301592e487_verboseLabel_en-US" xlink:label="lab_pgen_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_pgen_ReportableSegmentsMember_label_en-US" xlink:label="lab_pgen_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments [Member]</link:label>
    <link:label id="lab_pgen_ReportableSegmentsMember_documentation_en-US" xlink:label="lab_pgen_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReportableSegmentsMember" xlink:href="pgen-20201231.xsd#pgen_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ReportableSegmentsMember" xlink:to="lab_pgen_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_64c2284d-e11a-49cf-8863-c9761e3c199f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_89ebefdb-ef3f-46d6-aaef-604c37ec8e7b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_308fb1d6-63b9-4f74-b4b3-fec8cbf33a12_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of adoption of ASC 606</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandImprovementsMember_abfbeb2d-a615-4761-8443-d3b65e454dff_terseLabel_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land improvements</link:label>
    <link:label id="lab_us-gaap_LandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovementsMember" xlink:to="lab_us-gaap_LandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_9acdfad7-6ea1-4f7b-b3f1-397073221d54_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AccruedCompensationPaidinEquityAwards_a3b96a2a-0c19-4553-8eb0-5f9699793471_terseLabel_en-US" xlink:label="lab_pgen_AccruedCompensationPaidinEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation paid in equity awards</link:label>
    <link:label id="lab_pgen_AccruedCompensationPaidinEquityAwards_label_en-US" xlink:label="lab_pgen_AccruedCompensationPaidinEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation Paid in Equity Awards</link:label>
    <link:label id="lab_pgen_AccruedCompensationPaidinEquityAwards_documentation_en-US" xlink:label="lab_pgen_AccruedCompensationPaidinEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation Paid in Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccruedCompensationPaidinEquityAwards" xlink:href="pgen-20201231.xsd#pgen_AccruedCompensationPaidinEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AccruedCompensationPaidinEquityAwards" xlink:to="lab_pgen_AccruedCompensationPaidinEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3169925b-3a6b-4f53-89d2-85165656856b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_88cf7361-89ce-47fb-a047-638a217749dd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_f3ce69bd-9860-4270-8215-52403030d390_totalLabel_en-US" xlink:label="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_label_en-US" xlink:label="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets Liabilities, Net</link:label>
    <link:label id="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:href="pgen-20201231.xsd#pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:to="lab_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e4087937-89c0-4e5f-8f05-f62e64831248_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_80b82d4e-73e9-4a87-94be-df71ffc7e785_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_77ebc87d-0a0e-44f3-99ff-181a16273543_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b2a8e71b-6748-4426-91e1-898e0b9a03e2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_eae5879f-9b01-40cb-99ba-df47196246fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements_0f4630a6-cfb4-49a0-8899-f744e7d1c17e_terseLabel_en-US" xlink:label="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock received as consideration for collaboration agreements</link:label>
    <link:label id="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements_label_en-US" xlink:label="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Received As Consideration For Collaboration Agreements</link:label>
    <link:label id="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements_documentation_en-US" xlink:label="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock received from collaborative partners as consideration for collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:href="pgen-20201231.xsd#pgen_StockReceivedAsConsiderationForCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:to="lab_pgen_StockReceivedAsConsiderationForCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_962be690-add8-48f1-b17e-aaad2845b523_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment revenues</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_cf6f4075-e9d0-47dc-a7d1-77c10c1b1ce1_verboseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f527a695-4330-40ff-92b0-ec28028942d7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquisition of in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_d2295521-301f-4559-94a6-ca7f1fc39a11_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_535af736-38d7-404b-b448-f6a0a807a2ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrecigenStockOptionPlansMember_081fc39a-89aa-4f95-b3b8-3493a308cdb3_terseLabel_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plans</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlansMember_label_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plans [Member]</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlansMember_documentation_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrecigenStockOptionPlansMember" xlink:to="lab_pgen_PrecigenStockOptionPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_586dc1eb-289a-44b0-bba4-59f45db21214_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of long-term debt</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_37696e0f-e80d-457a-8a48-1fbbb3f68fc6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_65be81f5-3f24-4dfa-9506-16b76fc67ed8_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_36103ac0-fc5f-4feb-bf4d-55a637e248e2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_da5a77fd-4e7a-41df-9511-fdbb9e287bd5_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate as a percentage of net sales, tier 2</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Royalties As Percentage Of Net Sales Tier Two</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:to="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2950a95a-1c6a-4b97-a3b7-0032b9e3c53a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_17235c3a-d50a-4041-a85b-cf7bdc6b2451_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_80655d17-39ab-4ba4-98d8-1762cbb95dda_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_2b6aeed2-f91f-4254-a752-1cc9beb7d8bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4428359f-5b46-495e-a7c0-d22aec10aa27_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_474c3449-a404-430d-a7ee-007a77145493_terseLabel_en-US" xlink:label="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genten Therapeutics, CRS Bio, and Relieve Genetics</link:label>
    <link:label id="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_label_en-US" xlink:label="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genten Therapeutics, CRS Bio, and Relieve Genetics [Member]</link:label>
    <link:label id="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_documentation_en-US" xlink:label="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genten Therapeutics, CRS Bio, and Relieve Genetics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:href="pgen-20201231.xsd#pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:to="lab_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LesseeOperatingLeaseTerminationPeriod_cfb07b5e-59d6-41a6-ac16-6c61c66afaf4_terseLabel_en-US" xlink:label="lab_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_pgen_LesseeOperatingLeaseTerminationPeriod_label_en-US" xlink:label="lab_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_pgen_LesseeOperatingLeaseTerminationPeriod_documentation_en-US" xlink:label="lab_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:href="pgen-20201231.xsd#pgen_LesseeOperatingLeaseTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:to="lab_pgen_LesseeOperatingLeaseTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_416ad8f5-ddb9-4aa3-a506-94820818c3a2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_138ba226-4429-4066-a88e-b1fa448d7cba_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_e581aa9f-7c6f-47be-b0c4-90a012c7e52f_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_5b1f5f68-efad-4bcd-b43f-b23170e35c38_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4060ea7d-dc91-4cc5-bdc5-76525a299171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted_f1c4fc07-2ad1-4d6b-b54c-abfb8ceb859b_terseLabel_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional capital contributions committed</link:label>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted_label_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Additional Capital Contributions Committed</link:label>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted_documentation_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional capital contributions to the joint venture for which the entity is committed, maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:to="lab_pgen_JointVentureAdditionalCapitalContributionsCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cfb0cca-a0ac-47cb-acdd-876fd9be07df_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_78252be0-38f5-4c70-bea4-6aa69e0bc032_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4707615f-a122-4c75-ac20-512624a70204_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_117d194e-d054-4b0f-9678-6ff46f466936_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of AquaBounty</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Deconsolidation</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a2a7611b-773b-442d-af0d-670bd0fed254_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value, gain</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ed56c649-3049-4e9e-9251-101cf67a0419_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_f5e492c6-8217-4abb-80c2-970cc4a7855c_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, reimbursement of historical costs, number of quarterly installments</link:label>
    <link:label id="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_label_en-US" xlink:label="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Reimbursement of Historical Costs, Number of Quarterly Installments</link:label>
    <link:label id="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installments in which historical costs will be reimbursed under licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:to="lab_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_4060a856-ad1c-4963-9006-f5c4f5c7a7af_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f50721f5-d5bc-4def-a13e-a4935112bcf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6a401082-c8af-4a08-9aed-6d9c33a6e528_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0b6cfc2e-441a-4279-8d59-12321b37748c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0dc03824-eddc-4d35-aea2-b6b85b24a1bd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4643ad5a-1062-4ee0-86e6-29ab5818a7a0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_bf0ee02f-2cf1-4dd1-81f2-c3d13b59595e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1b7fae05-787e-478d-bf1c-aa3ab5da7c45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_3f24d5c7-f6ed-4d61-bc7f-afcadf10afba_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2b6407d8-0818-4326-9152-c2b01028794f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant noncash activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_64e0342e-c9c3-4421-b026-33c2cb70e168_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, including $0 and $877 from related parties as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_94325ad5-ba0d-4b1e-a77a-165113c90641_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_ccd80f3d-d285-4830-87cf-3592874f0a5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of adoption of ASC 606 [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_29793333-4459-4a78-8dfa-4d475c1f3018_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_89cbaae7-8801-4657-9433-dca243751a18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LossContingenciesTotalClaimsNumber_aa4217bb-a8f5-4952-a526-e27582432ead_terseLabel_en-US" xlink:label="lab_pgen_LossContingenciesTotalClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims</link:label>
    <link:label id="lab_pgen_LossContingenciesTotalClaimsNumber_label_en-US" xlink:label="lab_pgen_LossContingenciesTotalClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies, Total Claims, Number</link:label>
    <link:label id="lab_pgen_LossContingenciesTotalClaimsNumber_documentation_en-US" xlink:label="lab_pgen_LossContingenciesTotalClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingenciesTotalClaimsNumber" xlink:href="pgen-20201231.xsd#pgen_LossContingenciesTotalClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LossContingenciesTotalClaimsNumber" xlink:to="lab_pgen_LossContingenciesTotalClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_51fdb578-aaa6-4d4c-85e8-2e795095b85e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6f50d75e-3d60-4cac-9a03-935121c2ab42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_BreedingandProductionAnimalsGross_58b24336-0df9-48bc-b9e6-a8ca44b915ec_terseLabel_en-US" xlink:label="lab_pgen_BreedingandProductionAnimalsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breeding stock</link:label>
    <link:label id="lab_pgen_BreedingandProductionAnimalsGross_label_en-US" xlink:label="lab_pgen_BreedingandProductionAnimalsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breeding and Production Animals, Gross</link:label>
    <link:label id="lab_pgen_BreedingandProductionAnimalsGross_documentation_en-US" xlink:label="lab_pgen_BreedingandProductionAnimalsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before accumulated depreciation of animals maintained to create offspring or to produce goods to be sold for profit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_BreedingandProductionAnimalsGross" xlink:href="pgen-20201231.xsd#pgen_BreedingandProductionAnimalsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_BreedingandProductionAnimalsGross" xlink:to="lab_pgen_BreedingandProductionAnimalsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_91df9757-30ec-4719-911b-5fcae5cce265_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_e6a0b1ef-1890-4bc8-b58b-8248de953005_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_0438d3d2-98eb-49fa-8003-f5e7ec221df2_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_label_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_documentation_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:to="lab_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_089db13d-2098-46fe-b00a-8a09a1ac0ea4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount and amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_47402c7b-4169-4644-ae6a-64f39e2ddd09_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_1ab94c58-d21d-4af9-b8d9-6260a50c2b8d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_61c22d30-0155-44c3-b4d4-700300ec5a18_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_df253f9e-afae-4b14-b748-729386542aea_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_f312c35a-a094-480a-9cc6-46e4af524c0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Information About Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_c20bc8c5-3ab8-4ce2-b785-e0ca801f1fb9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_09e85d2c-0e02-4cc4-aa5e-2272b85f5d80_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_030413c6-364f-4fcf-8164-d2c98fc26792_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a076af89-fa7e-4571-83ac-1f3252139621_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_77b46a2e-de8a-4546-9a68-6066fe7c2b2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_096321be-1c16-4d87-84fc-cac14b69898c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e126a6f0-dd0b-4e7f-b518-0f6edf26cba1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_90269753-eefb-4f01-bcd4-b5818972c5c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, including $0 and $31,211 to related parties as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3036c8c7-015c-4800-8df3-cf1596279935_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ad416ffd-6e7b-4a27-94de-a23809cfc5c0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_09ee6d18-b7f0-409e-bc76-3af162a80a87_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration recognized in selling, general, and administrative expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_880ccdb9-1b69-4cb3-a00d-8266eec4fc44_verboseLabel_en-US" xlink:label="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Adjusted EBITDA</link:label>
    <link:label id="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_label_en-US" xlink:label="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Adjusted EBITDA, Including Cash Paid for Capital Expenditures and Investments in Affiliates</link:label>
    <link:label id="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_documentation_en-US" xlink:label="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Adjusted EBITDA defined as net income (loss) before (i) interest expense, (ii) income tax expense/benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) write-off of reacquired in-process research and development, (vii) equity in net income (loss) of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:href="pgen-20201231.xsd#pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:to="lab_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f5261a9f-36f8-4482-8552-4c0ea93030a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_15352bda-2bca-4806-afbb-4aa2e8b6d91f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4d9476ad-30f6-4519-bfb6-7018f1956cdd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_4ccf6666-36af-4d75-93c0-94bbac03ac2f_terseLabel_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation arrangement with individual, annual cash retainer</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_label_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual Cash Retainer</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_documentation_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual Cash Retainer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualCashRetainer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:to="lab_pgen_CompensationArrangementWithIndividualAnnualCashRetainer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6b6992c2-5ef8-4463-93f8-a6260b37ccd7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OtherFinancialAssetsMember_7d63c0c9-401d-46b9-9909-57d3e7cd7b7a_terseLabel_en-US" xlink:label="lab_pgen_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pgen_OtherFinancialAssetsMember_label_en-US" xlink:label="lab_pgen_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Assets [Member]</link:label>
    <link:label id="lab_pgen_OtherFinancialAssetsMember_documentation_en-US" xlink:label="lab_pgen_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherFinancialAssetsMember" xlink:href="pgen-20201231.xsd#pgen_OtherFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OtherFinancialAssetsMember" xlink:to="lab_pgen_OtherFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_79e97fc5-4e24-43da-b3fb-f21df1a922fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4d517772-6170-435c-a5a1-c490593966a4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised_53e28cb6-9e45-491d-9412-eec58989d7d1_terseLabel_en-US" xlink:label="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option and warrant exercises</link:label>
    <link:label id="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised_label_en-US" xlink:label="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised_documentation_en-US" xlink:label="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow associated with the amount received (i) from exercise of stock options granted under share-based compensation arrangement and (ii) from holders exercising their stock warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromStockOptionsandWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:to="lab_pgen_ProceedsfromStockOptionsandWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_3aa95041-1790-4aaf-ba59-8c1454242027_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e12347eb-ee59-42b2-89c9-6adbe5f6542b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_081f1b7e-f483-4c33-be9f-8a75d91657fb_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities included in continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d061f7d9-8a3c-44b4-b942-b1ef6debe5c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued as payment for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_131e3315-150e-46d9-8053-92d7ca2906c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion, including $0 and $25,000 to related parties as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_2f01326b-84f9-4341-a51a-e3f829c971f8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_47bde621-e400-4535-918e-d3498492b57e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f222806a-a13f-4cbb-ba22-9fb9c1087bde_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_869ba378-3625-4762-9a8b-b8bef95ac00c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9928111e-2d6d-4a36-b1a8-42928cffbdaf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States-foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4af5f9c8-0822-4528-8231-45d87c7496c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivablesAbstract_e44cd666-379b-4f04-82c3-d82280dae0cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c612e15e-0e58-4b60-b8c9-3cfdb1915ba6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_5e1571cc-a076-4fb1-ba16-6ec2a230c56c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_26b720dd-8e31-44ec-aaf4-40ce8446b3de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_15c7c633-4e5a-40d5-a46d-7381c82fa3cf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_454f9365-92e0-4f91-8a0e-77ac3aff640d_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Precigen Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bc14ae51-eba0-49e8-9a5d-e9e27d7e0ed6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d88e83d1-4fc2-4057-b656-76aaa6b248cc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_f1967502-551d-4d3e-b894-21e8ebeb50a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_d64322eb-11fb-4dd1-8179-9cf51630c50e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_438bf79a-fafb-467a-9c8e-1869996eacf8_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents, developed technologies and know-how</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_203f6972-33f3-4318-904c-815ca06cec02_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_53a90006-b903-4d96-8884-96079b4a0208_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_eea84279-0ebc-4135-8dd6-b11085defba9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, interest rate at period end</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_943b1767-f348-4f53-b1bc-b7abdd5c757e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_601bb91e-603b-467b-a5e8-f5ae02d21e3c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_77cbcde0-9cf4-4a79-9650-a2b65b03a5a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cd9146a2-6646-47e6-b19c-93e2e82e171b_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at end of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_3a10895e-7494-436f-a7ab-6970e5df47cd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_88d2759b-1b33-42e3-b849-551bb473b356_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f6882a15-d7e0-40c8-b054-9126a755cd4e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_f1a8ba26-b6d7-4031-b32d-8820c562255f_totalLabel_en-US" xlink:label="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation income tax benefit before valuation allowance, total</link:label>
    <link:label id="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_label_en-US" xlink:label="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance</link:label>
    <link:label id="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_documentation_en-US" xlink:label="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:to="lab_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_cbff7a82-ccf6-4088-ae03-9434a8a2d1fd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_f41eaa75-71e7-4159-a924-d660cd40ec41_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_1c8edd99-4183-4d7f-9c88-aecbf0dab3f2_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_52ca5ba9-03b9-4617-9b3c-3dfc72eb37d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IncomeTaxTable_06c67066-0782-49fa-be4f-95d12c58d000_terseLabel_en-US" xlink:label="lab_pgen_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_pgen_IncomeTaxTable_label_en-US" xlink:label="lab_pgen_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_pgen_IncomeTaxTable_documentation_en-US" xlink:label="lab_pgen_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxTable" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IncomeTaxTable" xlink:to="lab_pgen_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a531d0a6-5cea-47df-86ed-75c3a1b70dab_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_f8243d36-8651-4054-aba4-bdf464792ec7_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, number of exclusively licensed products</link:label>
    <link:label id="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_label_en-US" xlink:label="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Number of Exclusively Licensed Products</link:label>
    <link:label id="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exclusively licensed products under a licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementNumberofExclusivelyLicensedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:to="lab_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f4fe31f5-187a-49a4-8849-676a88fe8035_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8c6ed66a-bdb3-49ff-856a-22f2ce931e8e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8994c7bb-7c31-402b-a6e2-177d964c7c4d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e18bef6c-0936-4859-9129-18abbfc73a7d_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to the noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9e13776f-2114-4184-be7b-fbc27531b358_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c6313f16-8dd9-4a4f-9542-b6ee0dc304ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f92254f1-19ad-4dae-a10c-6d21f391728d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_74a547fd-0e6b-40a5-a155-5a602a4113b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrepaidProductAndServiceRevenuesMember_2a756183-cf62-4f0e-a5af-046672e3266d_terseLabel_en-US" xlink:label="lab_pgen_PrepaidProductAndServiceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product and service revenues</link:label>
    <link:label id="lab_pgen_PrepaidProductAndServiceRevenuesMember_label_en-US" xlink:label="lab_pgen_PrepaidProductAndServiceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Product And Service Revenues [Member]</link:label>
    <link:label id="lab_pgen_PrepaidProductAndServiceRevenuesMember_documentation_en-US" xlink:label="lab_pgen_PrepaidProductAndServiceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Product And Service Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrepaidProductAndServiceRevenuesMember" xlink:href="pgen-20201231.xsd#pgen_PrepaidProductAndServiceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrepaidProductAndServiceRevenuesMember" xlink:to="lab_pgen_PrepaidProductAndServiceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_475655aa-a969-4a9f-a402-8b231f066682_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a5319f2b-8392-48bc-9766-f6f1c17510ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e3a57cf8-8c61-434c-b9ae-c66a04c43a86_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4db933ad-ef12-411a-833b-f11682fe029b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for reacquired in-process research and development, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_692640f7-b0ce-46c1-90cc-9a7002c79f22_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_899c0862-b382-47fa-a39a-8d0df0cbe049_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on settlement agreement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_e86d45dd-af18-49d0-a4fb-5fc87266bcd0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems_9a48188a-38b1-4c2e-b445-d4a7bfbedf7d_terseLabel_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss [Line Items]</link:label>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems_label_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss [Line Items]</link:label>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems_documentation_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:to="lab_pgen_AccountsReceivableAllowanceForCreditLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected_028acf43-b155-44e8-b507-fd7dc96eba8f_terseLabel_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of seats on the joint venture's governing board, externally selected</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected_label_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Seats on Governing Board, Externally Selected</link:label>
    <link:label id="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected_documentation_en-US" xlink:label="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of seats on the governing board, externally selected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:to="lab_pgen_NumberofSeatsonGoverningBoardExternallySelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_b17e03af-a102-4677-bc78-eb97f828dae7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e2d7627d-2013-4489-89fc-4fcb4f0fc50e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_97958b20-91b8-4a7b-a96a-c35776e3cdb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_422d9290-fbd6-4661-9ae0-a0e0bee245c9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_f774fc99-f9cd-4510-9360-58428f30d6a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) on foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6309d210-fea0-4c55-9ac2-fbfbfe3ea9e5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_198a4f01-7a27-486a-a52c-6469cfb29b2b_terseLabel_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation arrangement with individual, annual stock option grant, grant date fair value</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_label_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual Stock Option Grant, Grant Date Fair Value</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_documentation_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Annual Stock Option Grant, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:to="lab_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_49174607-8b54-48ce-97e0-37fa208011d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of investment in affiliate</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_bad2d51f-719d-46fe-82c6-a30b593c70c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plans, cost recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ZiopharmMember_7e850db5-c92f-4168-a01a-bd086b07c07f_terseLabel_en-US" xlink:label="lab_pgen_ZiopharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZIOPHARM Oncology, Inc.</link:label>
    <link:label id="lab_pgen_ZiopharmMember_label_en-US" xlink:label="lab_pgen_ZiopharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ziopharm [Member]</link:label>
    <link:label id="lab_pgen_ZiopharmMember_documentation_en-US" xlink:label="lab_pgen_ZiopharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZIOPHARM Oncology, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ZiopharmMember" xlink:to="lab_pgen_ZiopharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementRoyaltyDueAggregated_805da66c-589f-44ed-9711-f726c01d638a_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty due, aggregated</link:label>
    <link:label id="lab_pgen_LicenseAgreementRoyaltyDueAggregated_label_en-US" xlink:label="lab_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Due, Aggregated</link:label>
    <link:label id="lab_pgen_LicenseAgreementRoyaltyDueAggregated_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty amount due under licensing agreement, aggregated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementRoyaltyDueAggregated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:to="lab_pgen_LicenseAgreementRoyaltyDueAggregated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9e1c591c-b876-4c0b-86f8-141932624b44_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_e7cc8529-9219-4916-bbf5-57871294a358_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SummaryOfSignificantAccountingPoliciesTable_4aaa8dfc-4965-4b26-9e66-92e437f7c54b_terseLabel_en-US" xlink:label="lab_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pgen_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pgen_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:href="pgen-20201231.xsd#pgen_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pgen_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ad60adbc-ec54-4282-bf69-e901f9dd9f2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8203ee98-506c-47ff-a562-eaf1b34991ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Performance Period (Years)</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3ba137db-c0f8-42e6-b615-ad6fbe71143c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_c0d09df7-5d13-494e-83f7-b0d4e1d04558_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0e9b80a7-3a25-403a-8979-a7f9c9c4bccc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25cb354d-07ac-4af0-93fc-533a387f5e99_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7d72a82e-67ad-4fa7-a31f-2ddc8ead977b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ComputerHardwareandSoftwareMember_52232dd7-a307-4783-bd75-736dc7f88342_terseLabel_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_pgen_ComputerHardwareandSoftwareMember_label_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware and Software [Member]</link:label>
    <link:label id="lab_pgen_ComputerHardwareandSoftwareMember_documentation_en-US" xlink:label="lab_pgen_ComputerHardwareandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftwareMember" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ComputerHardwareandSoftwareMember" xlink:to="lab_pgen_ComputerHardwareandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3847d3ab-10f2-40f2-883d-570d2089bfbf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_b4e376fc-b8b6-4b6c-a1ed-da6a9f6c8f3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_f43230d4-1bf9-49a3-8235-9992c05322b7_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of restricted stock units and for exercises of stock options, shares</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options Exercised and Restricted Stock Awards</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:to="lab_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_92e91bde-b9b1-49ad-a4db-0ddd27b59f81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_118e9f3b-5acb-4710-9ac2-228398193aee_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of long-term debt</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Equity Component of Long-Term Debt</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance for deferred tax assets as a result of the equity component of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_VariousECCAgreementsMember_7157fc91-4c9a-4965-8daf-ba5430c1c67f_terseLabel_en-US" xlink:label="lab_pgen_VariousECCAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various ECC Agreements</link:label>
    <link:label id="lab_pgen_VariousECCAgreementsMember_label_en-US" xlink:label="lab_pgen_VariousECCAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various ECC Agreements [Member]</link:label>
    <link:label id="lab_pgen_VariousECCAgreementsMember_documentation_en-US" xlink:label="lab_pgen_VariousECCAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various ECC Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_VariousECCAgreementsMember" xlink:href="pgen-20201231.xsd#pgen_VariousECCAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_VariousECCAgreementsMember" xlink:to="lab_pgen_VariousECCAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f5be9d44-dd10-4889-88a7-e1252373c7f2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_4e6a17d8-d74c-43c6-9394-752f2a6a21aa_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e7865f90-ee22-4536-bf0e-5e22cc534d12_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_a29c14db-8b42-462c-99b1-888bb8394948_terseLabel_en-US" xlink:label="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount used in conversion</link:label>
    <link:label id="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_label_en-US" xlink:label="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Principal Amount Initial Conversion Rate</link:label>
    <link:label id="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_documentation_en-US" xlink:label="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount in principal used in the initial conversion rate of the Convertible Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:href="pgen-20201231.xsd#pgen_ConvertibleDebtPrincipalAmountInitialConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:to="lab_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1cdf103a-c9f4-40a3-a2ee-db8789c8aeda_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_0dfd20e1-f695-46c6-88ae-a37eaa967aea_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_661d26a8-c865-4f45-b141-da6d1bf3d9c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_411f5562-07e0-46b4-8e39-20112151fe9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1dfe26bc-7b61-46e1-b911-b37cde5b9b07_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ecaeeb36-887b-42ee-9634-804e9ce5ab8d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8bf11f9f-16ab-4909-963c-3d9d21b3291f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1ec0fc41-afba-4cef-af51-5ebbee3f1460_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c3cbf777-94d6-4a1d-b7cf-c83c7d0730eb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f8c7435c-0d42-41f2-afca-7f405e6cf288_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9b8c63fe-7cd4-42df-8b35-13bb3b3bdb07_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_4c092bc8-80b6-485f-b6ae-2f9315a48578_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Change In Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the valuation allowance for deferred tax assets as a result of foreign currency translation adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_5cb8ff03-97cd-4d82-aa1c-3e9b75a85d6f_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level of net sales at which royalty rate changes to tier 2</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Net Sales At Which Royalty Rate Changes To Tier Two</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:to="lab_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_d01be2aa-96d9-44fb-971f-f4b7a4488600_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of discontinued operations, net of cash sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7d5c5969-8035-460e-a92d-8ddc14ba003d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedCash_712a07a7-69b9-404f-88b2-3f2b815e6c63_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, consideration received, cash</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedCash_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Consideration Received Cash</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedCash_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Consideration Received Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:to="lab_pgen_CollaborativeArrangementConsiderationReceivedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_1be9579a-39da-43a1-a1fc-7048f66df87d_terseLabel_en-US" xlink:label="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Okanagan, Oxitec, Fine Chemicals, And AgBio</link:label>
    <link:label id="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_label_en-US" xlink:label="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Okanagan, Oxitec, Fine Chemicals, And AgBio [Member]</link:label>
    <link:label id="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_documentation_en-US" xlink:label="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Okanagan, Oxitec, Fine Chemicals, And AgBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:href="pgen-20201231.xsd#pgen_OkanaganOxitecFineChemicalsAndAgBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:to="lab_pgen_OkanaganOxitecFineChemicalsAndAgBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6412c72a-0673-4258-92a9-187c6c1f76b3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8d874105-e36b-4627-ae47-c335f07fdb92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_f3212288-c8de-43e4-86f7-8ad3b96ea54d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1e4a001b-3bba-49be-9d1b-6004b2929322_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_25e3134d-dc51-458d-8b32-3fb37965c457_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable_59832e37-2df7-4f48-b01d-89d3d171477a_terseLabel_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue by Collaborator [Table]</link:label>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable_label_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue by Collaborator [Table]</link:label>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable_documentation_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred revenue disclosure which includes the collaborator and the corresponding amount that comprise the balance of deferred revenue as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:to="lab_pgen_SummaryofDeferredRevenuebyCollaboratorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e7614fd0-1099-4fb3-958e-9d861be6fa7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0397ff79-bbcf-4e29-86f3-a09244fc5a1a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_ccd50219-e906-4ff1-b6cf-288dc7bae3d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_97d34f5b-0008-4d18-8fcd-ab519e0886af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceThreeMember_097f66de-b1f1-4629-ae26-8ea856107868_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price range 3</link:label>
    <link:label id="lab_pgen_ExercisePriceThreeMember_label_en-US" xlink:label="lab_pgen_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Three [Member]</link:label>
    <link:label id="lab_pgen_ExercisePriceThreeMember_documentation_en-US" xlink:label="lab_pgen_ExercisePriceThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceThreeMember" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceThreeMember" xlink:to="lab_pgen_ExercisePriceThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_634a4741-2bd4-45d1-8549-bcd7a063b6ac_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ForeignSubsidiariesMember_8e0b7976-063b-42e9-a42b-daff80f8e15e_terseLabel_en-US" xlink:label="lab_pgen_ForeignSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Subsidiaries</link:label>
    <link:label id="lab_pgen_ForeignSubsidiariesMember_label_en-US" xlink:label="lab_pgen_ForeignSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Subsidiaries [Member]</link:label>
    <link:label id="lab_pgen_ForeignSubsidiariesMember_documentation_en-US" xlink:label="lab_pgen_ForeignSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ForeignSubsidiariesMember" xlink:href="pgen-20201231.xsd#pgen_ForeignSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ForeignSubsidiariesMember" xlink:to="lab_pgen_ForeignSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0dc8d64-2033-4323-be87-dbc714935092_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_272c4a15-7c79-4f40-93ba-162a7964cc83_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e662ef39-fe7a-4443-a545-75dd9256694b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_96dd8849-775f-452b-be2c-8a12eb1e2ad2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_53591197-5966-4eb8-bcf2-a0ddc68778d8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_6dd25c19-b746-4d29-93b8-ed92ffb86cc3_terseLabel_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue by Collaborator [Line Items]</link:label>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_label_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue by Collaborator [Line Items]</link:label>
    <link:label id="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_documentation_en-US" xlink:label="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of deferred revenue disclosure which includes the collaborator and the corresponding amount that comprise the balance of deferred revenue as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:to="lab_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8f6560a3-3328-4955-8428-e28852b895fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_be95494d-1784-4e5c-90a8-d98ab7a37740_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, current</link:label>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Discontinued Operations, Operating Lease, Liability, Current</link:label>
    <link:label id="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Discontinued Operations, Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:to="lab_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_950be9c8-4016-45ff-9527-e222c4c57d13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_6b1d8461-5897-4090-a796-b97906eb62cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_07081a8c-a20d-4a49-9448-8fb78d7274de_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_400aa1e2-7efb-4796-82a8-7913369f5de9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8e919303-c76a-452e-9f30-cfae82d11d6f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fb199232-2968-4449-ae03-c1b0a06c6272_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_7e42794e-4e7d-4fc0-9c0e-1b2a26746662_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_583b1d6a-7bcf-4901-b9a9-f6115aab5b97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end, weighted average remaining contractual period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AresTradingS.A.Member_b3445796-41c1-47a6-9b23-c7a20d8b819e_terseLabel_en-US" xlink:label="lab_pgen_AresTradingS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ares Trading S.A.</link:label>
    <link:label id="lab_pgen_AresTradingS.A.Member_label_en-US" xlink:label="lab_pgen_AresTradingS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ares Trading S.A. [Member]</link:label>
    <link:label id="lab_pgen_AresTradingS.A.Member_documentation_en-US" xlink:label="lab_pgen_AresTradingS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ares Trading S.A., a subsidiary of Merck Serono S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AresTradingS.A.Member" xlink:href="pgen-20201231.xsd#pgen_AresTradingS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AresTradingS.A.Member" xlink:to="lab_pgen_AresTradingS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CostOfProductsMember_9defe12b-837a-4fd3-bb69-aa5e7239fc87_terseLabel_en-US" xlink:label="lab_pgen_CostOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products</link:label>
    <link:label id="lab_pgen_CostOfProductsMember_label_en-US" xlink:label="lab_pgen_CostOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Products [Member]</link:label>
    <link:label id="lab_pgen_CostOfProductsMember_documentation_en-US" xlink:label="lab_pgen_CostOfProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfProductsMember" xlink:href="pgen-20201231.xsd#pgen_CostOfProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CostOfProductsMember" xlink:to="lab_pgen_CostOfProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_8696cb38-964b-49e5-a146-b2f2ffa4a258_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_591802e6-1560-4ad6-858a-5c623faa0ab6_negatedLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_4012eb18-1c3e-4a15-bb32-e247d947bd7c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue by Collaborator</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b59e3b2-62b4-4646-becc-e3862e6df5e7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_3a31d172-54c3-4a8b-9922-f4f75709a48e_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cbf45a46-e972-4ca0-9dda-d3b8bbfa0764_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b88e891c-eff1-4f43-a7ab-4f188b82f6e1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f47973e9-61c3-41e6-8069-07fc1df5e509_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_23e5feac-ad39-4153-874b-b87572b3a774_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_019a54c0-13b8-4211-bab1-d2b53fe1f714_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7c369826-63f1-4eb3-9c02-cb125b360afe_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2fafae14-924a-44ab-82b3-379e635dbdf8_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f1ee20ea-52f0-4d6b-8772-0cdcf1517fe2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1ec52755-aa9b-49ff-a7d3-0b80ef0be7e0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_75b11876-5877-4fb9-9436-c49f5726e795_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21a1844b-e05d-40ea-97dc-b3f38521325a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_69657ed5-e4ad-46d2-8551-0ea4e71485f1_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_e7ce04ef-45ae-46f8-8380-4788ade6fe8b_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0d4d88c0-63dc-433d-a9c7-03f34b4e499e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_HarvestIntrexonEnterpriseFundILPMember_0c2741a0-1f24-4ad1-ba8c-4b10e5099ee0_terseLabel_en-US" xlink:label="lab_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Intrexon Enterprise Fund I, LP</link:label>
    <link:label id="lab_pgen_HarvestIntrexonEnterpriseFundILPMember_label_en-US" xlink:label="lab_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Intrexon Enterprise Fund I, LP [Member]</link:label>
    <link:label id="lab_pgen_HarvestIntrexonEnterpriseFundILPMember_documentation_en-US" xlink:label="lab_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harvest Intrexon Enterprise Fund I, LP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:to="lab_pgen_HarvestIntrexonEnterpriseFundILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_556bfd89-ada4-4a24-8ccf-7be8de418a43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4732615f-d898-4a7e-a2a6-0e2a47e37419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1bfdd833-fbbb-4e7d-a524-4c991072cdd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LossContingencyReversedClaimsDismissedNumber_81be3043-ecd7-4a46-98ff-9be24835fc01_terseLabel_en-US" xlink:label="lab_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, reversed claims dismissed number</link:label>
    <link:label id="lab_pgen_LossContingencyReversedClaimsDismissedNumber_label_en-US" xlink:label="lab_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reversed Claims Dismissed Number</link:label>
    <link:label id="lab_pgen_LossContingencyReversedClaimsDismissedNumber_documentation_en-US" xlink:label="lab_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reversed Claims Dismissed Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:href="pgen-20201231.xsd#pgen_LossContingencyReversedClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:to="lab_pgen_LossContingencyReversedClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ec6fafad-b8a9-4e7d-9a85-66f0995283a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bdce9cec-f738-434f-ba7e-02fa623c732b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_e73a8079-ad5c-459d-9513-9092bb2a5964_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceDomain_faf7d4e8-4715-4b77-b773-1e7dbe6caf7c_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Domain]</link:label>
    <link:label id="lab_pgen_ExercisePriceDomain_label_en-US" xlink:label="lab_pgen_ExercisePriceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Domain]</link:label>
    <link:label id="lab_pgen_ExercisePriceDomain_documentation_en-US" xlink:label="lab_pgen_ExercisePriceDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceDomain" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceDomain" xlink:to="lab_pgen_ExercisePriceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_00d8dbb3-b0ed-45f2-8e7d-16dc23c4ea7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_08e80f27-55c0-4550-9ca9-3a680fe5af45_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_ReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cebdc377-93a0-47b9-8b2b-b7b3a09087ee_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2008PlanMember_ba2f3f47-1ae0-426a-aadd-13597c7156aa_terseLabel_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2008 Plan</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2008PlanMember_label_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2008 Plan [Member]</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2008PlanMember_documentation_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2008 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2008PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:to="lab_pgen_PrecigenStockOptionPlan2008PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_60ecd492-e91d-4407-a4ef-7a95c91685d4_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_label_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Equity Method Investments</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_documentation_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:to="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_30a321b9-4165-4042-b102-cf78c7fe0cff_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_933642b1-3ce1-49c8-ba64-b852361bf8dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborationAgreementsTable_3606b27b-98a4-4322-b682-c00566b8cac7_terseLabel_en-US" xlink:label="lab_pgen_CollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Table]</link:label>
    <link:label id="lab_pgen_CollaborationAgreementsTable_label_en-US" xlink:label="lab_pgen_CollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Table]</link:label>
    <link:label id="lab_pgen_CollaborationAgreementsTable_documentation_en-US" xlink:label="lab_pgen_CollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsTable" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborationAgreementsTable" xlink:to="lab_pgen_CollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0affdf2c-9c04-4922-b339-7ecc37d02937_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_452c6645-8c14-4de1-9409-fdd6d4a79a5d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt issued to a related party in an asset acquisition</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Debt Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d33f63f0-bb38-4744-8ab6-1d309d0469f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_414c522d-1feb-480f-8998-762f9bd68810_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fc9fafb5-3eb2-4a35-b587-1d49551d0297_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of equity grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_933b4484-8aae-4261-a9b1-b40780f70656_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_180d71f4-cb0d-4711-aa14-2f745c577b4d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e23b0d7b-6b94-4db4-92d0-7182a3753f05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_10bfbf9d-1fa4-4931-bee2-73c6fabae9e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_77b86da3-4656-41e2-bdc4-791e47e570ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computed statutory income tax benefit from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_548c3b1c-2594-4138-8e62-cdd0c1def655_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_dd39e3e6-07de-4c32-bb4b-e4da731c8998_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_9bce142f-5f3c-492c-a29a-9ea0b7cac78b_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1ab272c3-b2f7-45e9-81f2-c515d6060090_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_f902e19c-0333-4e8e-be21-5d68c0403374_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of advances from lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ec37d6ba-2805-42cb-90a6-63d0de1729d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicensingAndPatentInfringementSuitMember_a713d154-16f8-45a4-896c-f138c7e34237_terseLabel_en-US" xlink:label="lab_pgen_LicensingAndPatentInfringementSuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing and patent infringement suit</link:label>
    <link:label id="lab_pgen_LicensingAndPatentInfringementSuitMember_label_en-US" xlink:label="lab_pgen_LicensingAndPatentInfringementSuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing And Patent Infringement Suit [Member]</link:label>
    <link:label id="lab_pgen_LicensingAndPatentInfringementSuitMember_documentation_en-US" xlink:label="lab_pgen_LicensingAndPatentInfringementSuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing And Patent Infringement Suit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAndPatentInfringementSuitMember" xlink:href="pgen-20201231.xsd#pgen_LicensingAndPatentInfringementSuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicensingAndPatentInfringementSuitMember" xlink:to="lab_pgen_LicensingAndPatentInfringementSuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_36ff2668-2c87-46d6-9541-9a3bbcc084da_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalent investments in highly liquid money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_d5f2f8cc-4158-4b9a-9944-87b601901372_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_848c488e-8574-4e27-91fc-a575040b7de0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_4b803265-fa46-442d-b837-a7b1a9eed424_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, consideration received, value of convertible promissory note</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Consideration Received Value Of Convertible Promissory Note</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:to="lab_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_117d7f4e-325f-4e59-9a02-5276f3b6b357_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, consideration receivable, minimum targets required</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Consideration Receivable, Minimum Targets Required</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:to="lab_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5ffc2ce0-dac5-4f21-8d2e-af95850f6e1e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_66d33a76-3161-4717-8114-70452009d242_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_851468e1-9638-4918-b03e-a062e533af08_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MBPTitanMember_ef40f431-ea96-4a99-8da7-926eb2e9728c_terseLabel_en-US" xlink:label="lab_pgen_MBPTitanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBP Titan</link:label>
    <link:label id="lab_pgen_MBPTitanMember_label_en-US" xlink:label="lab_pgen_MBPTitanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBP Titan [Member]</link:label>
    <link:label id="lab_pgen_MBPTitanMember_documentation_en-US" xlink:label="lab_pgen_MBPTitanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MBP Titan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MBPTitanMember" xlink:to="lab_pgen_MBPTitanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_bea07285-4e89-4c5c-8c31-9061ce9cc603_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Operating Lease, Liability, Current</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:to="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_31388571-8a08-4154-8194-06bd548eae98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_9885ec6b-71d5-4dc7-a898-4a84f4918bb7_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_872f7fca-69d7-40ff-9919-2de785559731_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4b2c549-d18f-42e3-a47f-06c8f3681410_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Preferred Shares and convertible note</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_4ec1998b-4309-49a8-8198-4f30339d72ad_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TransitionServicesMember_2dfa70ed-29fa-4a76-9ff8-2dbffcce5b9a_terseLabel_en-US" xlink:label="lab_pgen_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services</link:label>
    <link:label id="lab_pgen_TransitionServicesMember_label_en-US" xlink:label="lab_pgen_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services [Member]</link:label>
    <link:label id="lab_pgen_TransitionServicesMember_documentation_en-US" xlink:label="lab_pgen_TransitionServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionServicesMember" xlink:href="pgen-20201231.xsd#pgen_TransitionServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TransitionServicesMember" xlink:to="lab_pgen_TransitionServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceTwoMember_4dc3027e-e6d8-4e1d-a1df-ee8ed1d3c7a0_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price range 2</link:label>
    <link:label id="lab_pgen_ExercisePriceTwoMember_label_en-US" xlink:label="lab_pgen_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Two [Member]</link:label>
    <link:label id="lab_pgen_ExercisePriceTwoMember_documentation_en-US" xlink:label="lab_pgen_ExercisePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceTwoMember" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceTwoMember" xlink:to="lab_pgen_ExercisePriceTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_0482e546-fbac-4997-8cf0-63b623d3a821_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and acquisitions, net</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Change In Amount Mergers And Acquisitions Net</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the valuation allowance for deferred tax assets as a result of mergers and acquisitions, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_HumanBiotherapeuticsSegmentMember_4b9b722d-8cd9-45d0-b0c0-be83728d3f8b_terseLabel_en-US" xlink:label="lab_pgen_HumanBiotherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Human Biotherapeutics</link:label>
    <link:label id="lab_pgen_HumanBiotherapeuticsSegmentMember_label_en-US" xlink:label="lab_pgen_HumanBiotherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Human Biotherapeutics Segment [Member]</link:label>
    <link:label id="lab_pgen_HumanBiotherapeuticsSegmentMember_documentation_en-US" xlink:label="lab_pgen_HumanBiotherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Human Biotherapeutics Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HumanBiotherapeuticsSegmentMember" xlink:href="pgen-20201231.xsd#pgen_HumanBiotherapeuticsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_HumanBiotherapeuticsSegmentMember" xlink:to="lab_pgen_HumanBiotherapeuticsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_397b1d9e-03e8-45b6-b3cd-321bcb0bc270_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_720c912b-adbd-48b2-9eb4-8ed6236c8ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction and other assets in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_dd2495d7-3714-4ac1-811b-c0997fc8add4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_97adda74-4e85-4f63-83d2-786e9fad2bc8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac58bf6d-33d3-44d0-a163-13e336428126_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from external customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_2112fdaf-0674-436d-aec1-4ec4e22aaa25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_aa0187d0-3f65-4194-a812-5357d191dedf_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4b8322da-7f65-46a5-8904-56bf3f9035e0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_5f33d740-d602-4457-85f6-ece0b6fa4b1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ActoBioMember_17a2e57e-a9f1-4f8b-8f8e-f978f68b337e_terseLabel_en-US" xlink:label="lab_pgen_ActoBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio</link:label>
    <link:label id="lab_pgen_ActoBioMember_label_en-US" xlink:label="lab_pgen_ActoBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio [Member]</link:label>
    <link:label id="lab_pgen_ActoBioMember_documentation_en-US" xlink:label="lab_pgen_ActoBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioMember" xlink:href="pgen-20201231.xsd#pgen_ActoBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ActoBioMember" xlink:to="lab_pgen_ActoBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bad5223f-2cf9-4ac6-b2e7-02a88b3912a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BreedingAndProductionAnimalsMember_3f8bff30-a616-4bd7-be0b-5a2f7d39c673_terseLabel_en-US" xlink:label="lab_us-gaap_BreedingAndProductionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breeding stock</link:label>
    <link:label id="lab_us-gaap_BreedingAndProductionAnimalsMember_label_en-US" xlink:label="lab_us-gaap_BreedingAndProductionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breeding and Production Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BreedingAndProductionAnimalsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BreedingAndProductionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BreedingAndProductionAnimalsMember" xlink:to="lab_us-gaap_BreedingAndProductionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0015b12b-5c94-466e-ad14-074e3ede8c36_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_022d2f45-b5ff-4c5a-9ffd-73e53f075d5f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8c00939b-8617-4458-a7d4-d171b9b197dd_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_baa776a0-87e9-4b91-8ce2-f112244b1ac4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_76605729-0b1d-4c48-bbe8-38dfb7bcda1b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_bd504c51-51d2-4c95-b42e-dfe08b721752_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c11e54d3-a55f-4eaf-8059-6072e9b5ad2e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossTable_0a71a1ab-47d7-48ec-9acb-6bcbbfa46afb_terseLabel_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss [Table]</link:label>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossTable_label_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss [Table]</link:label>
    <link:label id="lab_pgen_AccountsReceivableAllowanceForCreditLossTable_documentation_en-US" xlink:label="lab_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:to="lab_pgen_AccountsReceivableAllowanceForCreditLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ThirdSecurityMember_c77fd4de-dbe1-4cc1-b6be-bdc767a1bb70_terseLabel_en-US" xlink:label="lab_pgen_ThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Security</link:label>
    <link:label id="lab_pgen_ThirdSecurityMember_label_en-US" xlink:label="lab_pgen_ThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Security [Member]</link:label>
    <link:label id="lab_pgen_ThirdSecurityMember_documentation_en-US" xlink:label="lab_pgen_ThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Security, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ThirdSecurityMember" xlink:href="pgen-20201231.xsd#pgen_ThirdSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ThirdSecurityMember" xlink:to="lab_pgen_ThirdSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_619ca67f-a441-4171-b0b5-02e682c36e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7b003b19-bebe-44a2-94b8-8a4068811c93_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_80575773-39c4-4468-aefb-897fd4a369e0_terseLabel_en-US" xlink:label="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development commitments with third parties not incurred</link:label>
    <link:label id="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_label_en-US" xlink:label="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Commitments Not Yet Incurred</link:label>
    <link:label id="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_documentation_en-US" xlink:label="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of commitments related to research and development arrangements with third parties which has not yet been incurred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:href="pgen-20201231.xsd#pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:to="lab_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3254b536-deba-4fc3-8305-6fe9e5f5aab6_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Precigen per share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_6177829b-68ca-4195-a2fc-39ac5db87adb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Precigen per share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_36133a0d-cf2d-4b23-abd1-ace77ed95bc4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_63e041c4-fd43-455f-a1f8-45f98d148952_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a3ca6daf-f920-4df5-a8cb-3424c2c77720_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at period end, weighted average remaining contractual period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_a2a50025-686a-4a86-a6ad-acceb400e3bc_terseLabel_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments required upon successful achievement, per product</link:label>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_label_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Required Upon Successful Achievement, Per Product</link:label>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_documentation_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of potential future milestone payments to be received under agreement per product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:to="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8a0e29c-0d9b-4c91-adf6-9a0c6f376702_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e98dac46-338f-460c-b5cc-9f8b915162c5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_041a0e6a-5e05-465d-a1b5-92d4fc47573a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cd2d0edb-7122-49fd-a20f-81404b8023ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_37d398c4-3097-485b-a8d5-863f98c352bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_68c5e211-2c51-4af3-b9a6-7a1f1f823aa3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_78a141e6-ffab-44f7-993c-d77b4317b6e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_56e47e49-a976-4b16-8d92-ceaa1fee585f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_d4899168-19e7-4e19-920e-0515c4e97748_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureTable_215dc420-0887-41f3-a364-36e8d19883e4_terseLabel_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Table]</link:label>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureTable_label_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Table]</link:label>
    <link:label id="lab_pgen_ScheduleOfInvestmentsInJointVentureTable_documentation_en-US" xlink:label="lab_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments In Joint Venture [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:to="lab_pgen_ScheduleOfInvestmentsInJointVentureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c589ae25-b7cf-41c9-a493-9babf3baed98_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2013PlanMember_cdecf4c0-4129-40b0-8390-8912f03f4152_terseLabel_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2013 Plan</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2013PlanMember_label_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2013 Plan [Member]</link:label>
    <link:label id="lab_pgen_PrecigenStockOptionPlan2013PlanMember_documentation_en-US" xlink:label="lab_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen Stock Option Plan 2013 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2013PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:to="lab_pgen_PrecigenStockOptionPlan2013PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f8138c9f-fa1b-4417-bfa9-0605f8b81ff3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9ff16804-4a2a-4a4f-a52a-f96dd56bc7f8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_dcd541ce-a560-4d1b-951d-30d6dba398d9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LossContingencyAppealedClaimsDismissed_a454842f-fb34-497f-bc6a-975fcd3409a2_terseLabel_en-US" xlink:label="lab_pgen_LossContingencyAppealedClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, appealed claims dismissed</link:label>
    <link:label id="lab_pgen_LossContingencyAppealedClaimsDismissed_label_en-US" xlink:label="lab_pgen_LossContingencyAppealedClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Appealed Claims Dismissed</link:label>
    <link:label id="lab_pgen_LossContingencyAppealedClaimsDismissed_documentation_en-US" xlink:label="lab_pgen_LossContingencyAppealedClaimsDismissed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Appealed Claims Dismissed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyAppealedClaimsDismissed" xlink:href="pgen-20201231.xsd#pgen_LossContingencyAppealedClaimsDismissed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LossContingencyAppealedClaimsDismissed" xlink:to="lab_pgen_LossContingencyAppealedClaimsDismissed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_116ef472-c202-4cd5-adb4-0cc80c0be15b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c6f8bd38-3e6b-4d90-8103-0cacc6a9e595_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9f51771f-c822-4b0a-a6d5-f9cce3d222cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ec3dd7b6-e9f9-4596-9db5-616712dbafae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_73af1841-7d3e-4080-864b-52742ba34026_terseLabel_en-US" xlink:label="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, percentage of operating profits to be received</link:label>
    <link:label id="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_label_en-US" xlink:label="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Percentage of Operating Profits to Be Received</link:label>
    <link:label id="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_documentation_en-US" xlink:label="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of operating profits to be received by an entity under a licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:to="lab_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OtherAccruedLiabilitiesMember_f7cfa619-5eeb-4fb3-a14d-d773965b86a5_terseLabel_en-US" xlink:label="lab_pgen_OtherAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_pgen_OtherAccruedLiabilitiesMember_label_en-US" xlink:label="lab_pgen_OtherAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities [Member]</link:label>
    <link:label id="lab_pgen_OtherAccruedLiabilitiesMember_documentation_en-US" xlink:label="lab_pgen_OtherAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherAccruedLiabilitiesMember" xlink:href="pgen-20201231.xsd#pgen_OtherAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OtherAccruedLiabilitiesMember" xlink:to="lab_pgen_OtherAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_fdeac7e5-8984-44ac-a980-25a5a6197d74_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_28c4f808-78d9-45dd-b168-299097a9c931_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a6b7254f-1079-4c8f-85a3-fbed19b4e657_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94f6f3e3-1cf6-4472-a2b6-dc1de229353b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e9929089-a0d4-447c-be75-f487aeadec66_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9cb45002-3f59-4877-b867-56453a2c28fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f08df8e9-321d-4e21-8495-aeda58648f9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2e43f5c1-1704-4b0a-8482-6a6dc08d4c91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ec6e41f8-97fd-472d-8b8a-7ace84b0810b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_60457ff0-ddd6-4f45-abea-4866ba4e00a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NoncashDividendIncome_e1d5efd6-bf65-4c6d-a574-d7c837b83af8_negatedTerseLabel_en-US" xlink:label="lab_pgen_NoncashDividendIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash dividend income</link:label>
    <link:label id="lab_pgen_NoncashDividendIncome_78647dbb-793e-4eb0-bdae-7ff20c68dd3c_verboseLabel_en-US" xlink:label="lab_pgen_NoncashDividendIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income from investments in preferred stock</link:label>
    <link:label id="lab_pgen_NoncashDividendIncome_label_en-US" xlink:label="lab_pgen_NoncashDividendIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Dividend Income</link:label>
    <link:label id="lab_pgen_NoncashDividendIncome_documentation_en-US" xlink:label="lab_pgen_NoncashDividendIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of dividend income included in net income that results in no cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NoncashDividendIncome" xlink:to="lab_pgen_NoncashDividendIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_80241b68-6233-459d-a727-31b60283f8a3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f38dec2c-aac9-4be8-a3cf-92c4fed17461_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_03b5dfac-67ed-4e54-b261-c5362b32483a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_e253c655-f282-4f65-b8bb-05e92f65c1ee_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_b4009574-ce2b-4ab1-813b-8c32aa3dc57e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovements_255e6c07-995d-4892-a3cc-ecca934254b6_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovements_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovements" xlink:to="lab_us-gaap_LandAndLandImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d58eeb42-7ef9-40c6-9ea7-790ddf7e3521_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_bd9f51d3-e0f3-4373-8077-ce6bebb553b6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_d5e3416a-923d-4074-ad97-e37fdbe198cb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Joint Ventures</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5b4e75f4-f1d7-4874-badf-807d7b8d4bb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common share price over conversion price for conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_260ed093-bdda-48c8-8bb9-54ffd9f595c7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d83656-3628-4a29-be2d-1a22398f5fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares and warrants issued in public or private offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0195c449-1371-4079-9596-1f4b9297bd0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued in public or private offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_91035b68-aa63-4b55-af81-d6556484fe79_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued in public or private offering (estimated)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SaleOfAssetsIncludedInReceivables_a8f386d1-96be-420e-8635-86009e3b445c_terseLabel_en-US" xlink:label="lab_pgen_SaleOfAssetsIncludedInReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of assets included in receivables</link:label>
    <link:label id="lab_pgen_SaleOfAssetsIncludedInReceivables_label_en-US" xlink:label="lab_pgen_SaleOfAssetsIncludedInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Assets Included In Receivables</link:label>
    <link:label id="lab_pgen_SaleOfAssetsIncludedInReceivables_documentation_en-US" xlink:label="lab_pgen_SaleOfAssetsIncludedInReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Assets Included In Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SaleOfAssetsIncludedInReceivables" xlink:href="pgen-20201231.xsd#pgen_SaleOfAssetsIncludedInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SaleOfAssetsIncludedInReceivables" xlink:to="lab_pgen_SaleOfAssetsIncludedInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1f1cef50-4dfa-4ecc-a6ee-cad8e4a11229_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_fe9b975e-8eb7-4a15-95cf-3582300766b4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_c7e4a4cd-4bb1-4796-8a70-f9c19ce41be3_terseLabel_en-US" xlink:label="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Property, Plant and Equipment</link:label>
    <link:label id="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of property plant and equipment used in the normal conduct of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="lab_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_28c885a9-ded8-40ba-867c-75367727e05c_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_64afe8ec-eb73-48de-83ee-e7da5091b1a3_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, net, total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20716d8d-99a7-459a-b8b1-3827a8b9a3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PGENTherapeuticsSegmentMember_259bce9e-3ce4-46b6-8bf0-5b5e086f112d_terseLabel_en-US" xlink:label="lab_pgen_PGENTherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGEN Therapeutics</link:label>
    <link:label id="lab_pgen_PGENTherapeuticsSegmentMember_label_en-US" xlink:label="lab_pgen_PGENTherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGEN Therapeutics Segment [Member]</link:label>
    <link:label id="lab_pgen_PGENTherapeuticsSegmentMember_documentation_en-US" xlink:label="lab_pgen_PGENTherapeuticsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGEN Therapeutics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PGENTherapeuticsSegmentMember" xlink:href="pgen-20201231.xsd#pgen_PGENTherapeuticsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PGENTherapeuticsSegmentMember" xlink:to="lab_pgen_PGENTherapeuticsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_75bc5cd8-9a64-4a75-b7b6-a0523054bb9d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9ecc2826-62a3-46ab-9b1d-96c738a1b27f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_53237cd9-bdb2-474c-84d7-85f8a3473df2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_82076d04-ca9d-41a0-bdc9-04e99ea064f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8d8afba7-c385-44bf-b4ad-5e8d11f66241_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_665222a1-978f-4ca6-8daf-e68b6841a83d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_408a3544-be6d-42a9-8b97-cd3f5523d723_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1b7f7621-4466-49ca-809e-04be8c428dde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_77721c90-09f4-4995-9923-9dd369f97985_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_56e34c0e-237c-4284-81d9-8277d5106a95_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_e86a7a5d-e025-43bc-8dd5-adf372f0bd75_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents included in current assets held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_1a3aadfe-cfcf-4541-b9f2-8ee045d746b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_0425d28f-176e-4099-ba79-50ef3d35948f_terseLabel_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Holdings LLC and Enviro Flight LLC</link:label>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_label_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Holdings LLC And Enviro Flight LLC [Member]</link:label>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_documentation_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Holdings LLC And Enviro Flight LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:to="lab_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_26e150e8-64f2-4528-8016-d024bf66f76c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized over weighted-average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3bced24b-13ec-4bca-9b01-0361e933b48b_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceAxis_8ae8653b-7dad-4fbb-905d-2849227d3bfd_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Axis]</link:label>
    <link:label id="lab_pgen_ExercisePriceAxis_label_en-US" xlink:label="lab_pgen_ExercisePriceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Axis]</link:label>
    <link:label id="lab_pgen_ExercisePriceAxis_documentation_en-US" xlink:label="lab_pgen_ExercisePriceAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceAxis" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceAxis" xlink:to="lab_pgen_ExercisePriceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_1c832eb7-5454-4972-abad-7284d4c26ec0_terseLabel_en-US" xlink:label="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share lending agreement, length of time for shares to be returned upon termination</link:label>
    <link:label id="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_label_en-US" xlink:label="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Lending Agreement, Length Of Time For Shares To Be Returned Upon Termination</link:label>
    <link:label id="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_documentation_en-US" xlink:label="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Lending Agreement, Length Of Time For Shares To Be Returned Upon Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:href="pgen-20201231.xsd#pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:to="lab_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_866582c8-62b2-477f-84b3-12e81ce0708a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts_9ca93886-e30e-4484-abdf-a6290b336e4a_terseLabel_en-US" xlink:label="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, reimbursement of historical costs</link:label>
    <link:label id="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts_label_en-US" xlink:label="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreement, Reimbursement of Historical Costs</link:label>
    <link:label id="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts_documentation_en-US" xlink:label="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of historical costs to which an entity is entitled under a licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementReimbursementofHistoricalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:to="lab_pgen_LicensingAgreementReimbursementofHistoricalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d070ffb-9bfa-4aa8-ac94-08ab04d1d6ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from previously deferred balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2a76df2e-87b3-4383-896d-fc7cc795e67e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add recognition of previously deferred revenue associated with upfront and milestone payments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_1bb54424-55c1-48ff-9fff-816f6bbc5a98_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for accrued compensation</link:label>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_label_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During The Period, Value, Accrued Compensation</link:label>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued in lieu of cash for accrued compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodValueAccruedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:to="lab_pgen_StockIssuedDuringThePeriodValueAccruedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PrecigenActioBioIncMember_803664db-8eda-4050-ae5f-b141547fb7b4_terseLabel_en-US" xlink:label="lab_pgen_PrecigenActioBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen ActoBio, Inc.</link:label>
    <link:label id="lab_pgen_PrecigenActioBioIncMember_label_en-US" xlink:label="lab_pgen_PrecigenActioBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen ActioBio Inc. [Member]</link:label>
    <link:label id="lab_pgen_PrecigenActioBioIncMember_documentation_en-US" xlink:label="lab_pgen_PrecigenActioBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precigen ActioBio Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenActioBioIncMember" xlink:href="pgen-20201231.xsd#pgen_PrecigenActioBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PrecigenActioBioIncMember" xlink:to="lab_pgen_PrecigenActioBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b15bc4e0-6403-4863-8e23-3a272ca55292_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1572caa5-a87f-4e41-98e8-49a15447036f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceFourMember_b86b2848-b2c3-4a0b-ab39-bb182dae22d8_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price range 4</link:label>
    <link:label id="lab_pgen_ExercisePriceFourMember_label_en-US" xlink:label="lab_pgen_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Four [Member]</link:label>
    <link:label id="lab_pgen_ExercisePriceFourMember_documentation_en-US" xlink:label="lab_pgen_ExercisePriceFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFourMember" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceFourMember" xlink:to="lab_pgen_ExercisePriceFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b6c47f64-44ef-4c23-99d5-d45c5a86a380_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_0cce9c02-2b84-4326-b6cb-e544d60c6097_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_de1c6d81-1043-4935-9de7-dad5730a0d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8fdcb09d-b11c-4559-a917-c0dbd84e536e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb18387d-a69b-4fc3-b1c3-97bccc19fa59_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ef5fa0e-b236-4c2e-be54-a9f1af9feaae_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_636052ef-8baa-41ce-a41e-eb9088334e8f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_PreferredStockReceivables_35359cd0-48d4-4c35-bfea-6d86b8382093_negatedTerseLabel_en-US" xlink:label="lab_pgen_PreferredStockReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds to be received from preferred stock</link:label>
    <link:label id="lab_pgen_PreferredStockReceivables_label_en-US" xlink:label="lab_pgen_PreferredStockReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Receivables</link:label>
    <link:label id="lab_pgen_PreferredStockReceivables_documentation_en-US" xlink:label="lab_pgen_PreferredStockReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from conversion of preferred stock to cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PreferredStockReceivables" xlink:href="pgen-20201231.xsd#pgen_PreferredStockReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_PreferredStockReceivables" xlink:to="lab_pgen_PreferredStockReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_99bbf57a-1e70-4b11-a8cf-9743ceae1737_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_f6cae59e-dbbd-4b20-9929-648c851c9191_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_eb002693-9b31-43c0-9cf5-dbe9e6bc22bf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_43ec0eb4-3664-4c4e-9602-d12f5d5eec3e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_5fd2ea63-74c3-45f1-8659-7393aa7d911a_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred state tax rate</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Deferred State Tax Rate</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance for deferred tax assets as a result of the change in deferred state tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_869974f4-9580-45fb-9d84-db48a25ab314_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and provincial income tax benefit, net of federal income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TSBiotechnologyAndEnviroFlightMember_8afde887-311b-4c8e-b21c-7c92eba63648_terseLabel_en-US" xlink:label="lab_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology and EnviroFlight</link:label>
    <link:label id="lab_pgen_TSBiotechnologyAndEnviroFlightMember_label_en-US" xlink:label="lab_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology and EnviroFlight [Member]</link:label>
    <link:label id="lab_pgen_TSBiotechnologyAndEnviroFlightMember_documentation_en-US" xlink:label="lab_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology and EnviroFlight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyAndEnviroFlightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:to="lab_pgen_TSBiotechnologyAndEnviroFlightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_28a04cbb-af14-4cae-88be-a319aebec376_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2006ca4c-20b1-4f54-bb69-3c35f3115e28_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_be7c2511-2688-43ec-86d1-be831c5dea3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_311fa040-63f3-4c91-a35d-8ea8c9826f36_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_UpfrontAndMilestonePaymentsMember_2ae42824-3c19-4c28-8e14-9484c5fd9f3f_verboseLabel_en-US" xlink:label="lab_pgen_UpfrontAndMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Milestone Payments</link:label>
    <link:label id="lab_pgen_UpfrontAndMilestonePaymentsMember_label_en-US" xlink:label="lab_pgen_UpfrontAndMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments [Member]</link:label>
    <link:label id="lab_pgen_UpfrontAndMilestonePaymentsMember_documentation_en-US" xlink:label="lab_pgen_UpfrontAndMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received as collaboration for the entity's collaborations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_UpfrontAndMilestonePaymentsMember" xlink:to="lab_pgen_UpfrontAndMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_28fe57cb-6cce-4aee-b9df-cf3c33ca3ed9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_803aedb2-cd77-480f-83d6-2bb224e06415_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceFiveMember_fb400b75-1ccc-4b6c-9e37-6b5540241ffe_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price range 5</link:label>
    <link:label id="lab_pgen_ExercisePriceFiveMember_label_en-US" xlink:label="lab_pgen_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Five [Member]</link:label>
    <link:label id="lab_pgen_ExercisePriceFiveMember_documentation_en-US" xlink:label="lab_pgen_ExercisePriceFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFiveMember" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceFiveMember" xlink:to="lab_pgen_ExercisePriceFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OwnshareLendingArrangementSharesIssued_7f2520b4-f7b9-4e0d-b36f-4a23729c2f76_terseLabel_en-US" xlink:label="lab_us-gaap_OwnshareLendingArrangementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in share lending agreement, shares</link:label>
    <link:label id="lab_us-gaap_OwnshareLendingArrangementSharesIssued_label_en-US" xlink:label="lab_us-gaap_OwnshareLendingArrangementSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Own-share Lending Arrangement, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OwnshareLendingArrangementSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OwnshareLendingArrangementSharesIssued" xlink:to="lab_us-gaap_OwnshareLendingArrangementSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_55c8ae5b-9467-4896-aebb-e06802662d85_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_FirstNationalBankofOmahaMember_49707b59-4116-46a4-8f74-282285c325ef_terseLabel_en-US" xlink:label="lab_pgen_FirstNationalBankofOmahaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First National Bank of Omaha</link:label>
    <link:label id="lab_pgen_FirstNationalBankofOmahaMember_label_en-US" xlink:label="lab_pgen_FirstNationalBankofOmahaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First National Bank of Omaha [Member]</link:label>
    <link:label id="lab_pgen_FirstNationalBankofOmahaMember_documentation_en-US" xlink:label="lab_pgen_FirstNationalBankofOmahaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First National Bank of Omaha [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FirstNationalBankofOmahaMember" xlink:href="pgen-20201231.xsd#pgen_FirstNationalBankofOmahaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_FirstNationalBankofOmahaMember" xlink:to="lab_pgen_FirstNationalBankofOmahaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cf213fb7-8b6c-47f2-843a-a07fc0fa40ce_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets held-for-use</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_174b60b4-a217-46f9-8821-a6148fa6f1db_terseLabel_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquired in-process research and development</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_label_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Reacquired In-process Research and Development, Amount</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_documentation_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible reacquired in-process research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:to="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_c8882a0a-d576-414b-b870-e7ab41e2b48e_terseLabel_en-US" xlink:label="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities and investments in affiliates</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_label_en-US" xlink:label="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset Equity Method Investments and Investments Accounted For Under The Fair Value Option</link:label>
    <link:label id="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_documentation_en-US" xlink:label="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments and investments accounted for under the fair value option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:to="lab_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_9060a958-ded7-4cfd-8721-86949b38ada1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OxitecMember_35fb9228-e169-4f70-a4e0-001708e04ead_terseLabel_en-US" xlink:label="lab_pgen_OxitecMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxitec</link:label>
    <link:label id="lab_pgen_OxitecMember_label_en-US" xlink:label="lab_pgen_OxitecMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxitec [Member]</link:label>
    <link:label id="lab_pgen_OxitecMember_documentation_en-US" xlink:label="lab_pgen_OxitecMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxitec</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OxitecMember" xlink:href="pgen-20201231.xsd#pgen_OxitecMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OxitecMember" xlink:to="lab_pgen_OxitecMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_50abf4f9-1f40-42b1-86b5-f4069395465a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on abandonment and disposals of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_f65d322a-8b21-489c-80c4-6a9d7ed6c4ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on abandonment of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8e60c2bd-0d26-4235-aa38-a30c5bebce16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_66c496b8-15b4-4c46-abda-c8b1d83d73aa_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d98e8ef5-3166-496a-ab09-8db12dd2ce39_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f9e9c077-07b2-4544-b177-2293e80c00bf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OwnshareLendingArrangementSharesIssued1_e3909693-954e-4ab1-a418-6759b837c302_terseLabel_en-US" xlink:label="lab_pgen_OwnshareLendingArrangementSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued pursuant to share lending agreement, shares</link:label>
    <link:label id="lab_pgen_OwnshareLendingArrangementSharesIssued1_label_en-US" xlink:label="lab_pgen_OwnshareLendingArrangementSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Own-share Lending Arrangement, Shares, Issued1</link:label>
    <link:label id="lab_pgen_OwnshareLendingArrangementSharesIssued1_documentation_en-US" xlink:label="lab_pgen_OwnshareLendingArrangementSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares issued during the period in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OwnshareLendingArrangementSharesIssued1" xlink:href="pgen-20201231.xsd#pgen_OwnshareLendingArrangementSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OwnshareLendingArrangementSharesIssued1" xlink:to="lab_pgen_OwnshareLendingArrangementSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_419dc02a-a3a1-4cdb-a52f-8727cdcac76c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_WorkInProcessMember_84a32fbf-27a7-45ea-ae04-56b8f0d299d1_terseLabel_en-US" xlink:label="lab_pgen_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_pgen_WorkInProcessMember_label_en-US" xlink:label="lab_pgen_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work In Process [Member]</link:label>
    <link:label id="lab_pgen_WorkInProcessMember_documentation_en-US" xlink:label="lab_pgen_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work In Process [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_WorkInProcessMember" xlink:href="pgen-20201231.xsd#pgen_WorkInProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_WorkInProcessMember" xlink:to="lab_pgen_WorkInProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_048a4819-43a1-4583-929a-d55a897a2b3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_9d0d2ed4-9f8a-492b-9b86-d01bc424566f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f498747d-6c3c-4c07-b19b-86087fb738e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f2043baa-611d-4b32-aa58-9d085d5cf686_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d0773c15-5153-458b-a39f-b668b3245055_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4e6b7284-fe4c-46c5-9f70-73878b7c0a3d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b9b9a760-1a1f-44f0-bb75-b03620cce010_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f595ef65-f4a7-40a3-8dbc-8a8817a0008b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0641ebba-a6a2-4b94-b79b-c415cc9e6c44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_e78feb68-bd4f-4f38-a763-7f389ad0d0cd_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of restricted stock units and for exercises of stock options</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Awards Vested and Stock Options Exercised</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:to="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_a30d7ad7-556a-4f53-86b6-104d98980405_terseLabel_en-US" xlink:label="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_label_en-US" xlink:label="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_documentation_en-US" xlink:label="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:to="lab_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValue_ad915b78-3b6c-4d68-bced-07b80faa5276_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, consideration received, value</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValue_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Consideration Received Value</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementConsiderationReceivedValue_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of consideration received by the entity for collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:to="lab_pgen_CollaborativeArrangementConsiderationReceivedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_83d9a7f3-5e76-407c-ba51-1c2345d21a42_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_62f9c9c7-2835-4492-87db-775aa50ea187_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CostOfServicesMember_c59a824c-741d-436d-bc95-1a72acba6dc7_terseLabel_en-US" xlink:label="lab_pgen_CostOfServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_pgen_CostOfServicesMember_label_en-US" xlink:label="lab_pgen_CostOfServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Services [Member]</link:label>
    <link:label id="lab_pgen_CostOfServicesMember_documentation_en-US" xlink:label="lab_pgen_CostOfServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfServicesMember" xlink:href="pgen-20201231.xsd#pgen_CostOfServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CostOfServicesMember" xlink:to="lab_pgen_CostOfServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_233f9d86-ae01-4150-b994-fae49d2ea642_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Collaboration and Licensing Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f1dfb645-d5d4-4fa3-850d-66f5a3afaaee_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9a3ee9a9-a273-4b98-846a-d09b492873e6_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IncreaseDecreaseInLeaseLiabilities_9edbec92-b915-4076-be4c-f5ba0a56ecbd_terseLabel_en-US" xlink:label="lab_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_pgen_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities</link:label>
    <link:label id="lab_pgen_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:href="pgen-20201231.xsd#pgen_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_pgen_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_Adjustmentsfornoncontrollinginterests_e1467ca9-21c3-4855-82a1-cb94acc5f071_terseLabel_en-US" xlink:label="lab_pgen_Adjustmentsfornoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for noncontrolling interests</link:label>
    <link:label id="lab_pgen_Adjustmentsfornoncontrollinginterests_label_en-US" xlink:label="lab_pgen_Adjustmentsfornoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for noncontrolling interests</link:label>
    <link:label id="lab_pgen_Adjustmentsfornoncontrollinginterests_documentation_en-US" xlink:label="lab_pgen_Adjustmentsfornoncontrollinginterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in noncontrolling interest balance because of current period activity, including business combinations and subsidiary equity issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_Adjustmentsfornoncontrollinginterests" xlink:href="pgen-20201231.xsd#pgen_Adjustmentsfornoncontrollinginterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_Adjustmentsfornoncontrollinginterests" xlink:to="lab_pgen_Adjustmentsfornoncontrollinginterests" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_RelatedPartyOwnershipInterest_546314d8-6a5a-44c2-9cb2-ac39f9b6c52c_terseLabel_en-US" xlink:label="lab_pgen_RelatedPartyOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_pgen_RelatedPartyOwnershipInterest_label_en-US" xlink:label="lab_pgen_RelatedPartyOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Ownership Interest</link:label>
    <link:label id="lab_pgen_RelatedPartyOwnershipInterest_documentation_en-US" xlink:label="lab_pgen_RelatedPartyOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of ownership of common stock or equity participation in a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_RelatedPartyOwnershipInterest" xlink:to="lab_pgen_RelatedPartyOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1fe00ebf-a107-4a06-a9ee-2651fce714b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_58259901-3df4-4de2-b60d-ef7f591c69ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_f6f770fc-303e-4c06-a85f-882ee2ab3349_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_64820c99-462d-4895-aaf6-649c1347172e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_GeneratedAfter2017Member_de515c1f-4080-4b7c-8a13-1180caba311f_terseLabel_en-US" xlink:label="lab_pgen_GeneratedAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated after 2017</link:label>
    <link:label id="lab_pgen_GeneratedAfter2017Member_label_en-US" xlink:label="lab_pgen_GeneratedAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated After 2017 [Member]</link:label>
    <link:label id="lab_pgen_GeneratedAfter2017Member_documentation_en-US" xlink:label="lab_pgen_GeneratedAfter2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generated After 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GeneratedAfter2017Member" xlink:href="pgen-20201231.xsd#pgen_GeneratedAfter2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_GeneratedAfter2017Member" xlink:to="lab_pgen_GeneratedAfter2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_81a40c82-415e-47a4-8496-adc13addfed2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExemplarGeneticsLLCMember_91102a30-a941-4fe8-ba68-84d77fa983a0_terseLabel_en-US" xlink:label="lab_pgen_ExemplarGeneticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exemplar Genetics, LLC</link:label>
    <link:label id="lab_pgen_ExemplarGeneticsLLCMember_label_en-US" xlink:label="lab_pgen_ExemplarGeneticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exemplar Genetics, LLC [Member]</link:label>
    <link:label id="lab_pgen_ExemplarGeneticsLLCMember_documentation_en-US" xlink:label="lab_pgen_ExemplarGeneticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exemplar Genetics, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExemplarGeneticsLLCMember" xlink:href="pgen-20201231.xsd#pgen_ExemplarGeneticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExemplarGeneticsLLCMember" xlink:to="lab_pgen_ExemplarGeneticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MethaneBioconversionPlatformDisclosuresMember_6081fc64-ad07-4420-9c58-f2c9efcf6f2a_terseLabel_en-US" xlink:label="lab_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methane Bioconversion Platform Disclosures</link:label>
    <link:label id="lab_pgen_MethaneBioconversionPlatformDisclosuresMember_label_en-US" xlink:label="lab_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methane Bioconversion Platform Disclosures [Member]</link:label>
    <link:label id="lab_pgen_MethaneBioconversionPlatformDisclosuresMember_documentation_en-US" xlink:label="lab_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methane Bioconversion Platform Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:href="pgen-20201231.xsd#pgen_MethaneBioconversionPlatformDisclosuresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:to="lab_pgen_MethaneBioconversionPlatformDisclosuresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e07233d1-79c7-473d-bcbe-8b2b14299e44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d289b0ec-044f-4808-9eff-d69884773748_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_78e5eb93-a4b5-4ade-85a9-bf7f624e89f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_9019d015-e58c-4c67-9665-9ac36d28417b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_48c1a86e-e5e8-47f6-a5cb-d765983238b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_5512974c-2daf-485f-a75b-a241e2421490_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AffiliatesOfThirdSecurityMember_a2a1a284-cad7-402a-9f9f-a91597b4b111_terseLabel_en-US" xlink:label="lab_pgen_AffiliatesOfThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Third Security</link:label>
    <link:label id="lab_pgen_AffiliatesOfThirdSecurityMember_label_en-US" xlink:label="lab_pgen_AffiliatesOfThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Third Security [Member]</link:label>
    <link:label id="lab_pgen_AffiliatesOfThirdSecurityMember_documentation_en-US" xlink:label="lab_pgen_AffiliatesOfThirdSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Third Security, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AffiliatesOfThirdSecurityMember" xlink:href="pgen-20201231.xsd#pgen_AffiliatesOfThirdSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AffiliatesOfThirdSecurityMember" xlink:to="lab_pgen_AffiliatesOfThirdSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e9e497d4-efc5-426c-958d-2484eece184a_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discounts on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TransOvaSegmentMember_33bb0ce3-009f-490b-abfe-ae0b37782608_terseLabel_en-US" xlink:label="lab_pgen_TransOvaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova</link:label>
    <link:label id="lab_pgen_TransOvaSegmentMember_label_en-US" xlink:label="lab_pgen_TransOvaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova Segment [Member]</link:label>
    <link:label id="lab_pgen_TransOvaSegmentMember_documentation_en-US" xlink:label="lab_pgen_TransOvaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trans Ova Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaSegmentMember" xlink:href="pgen-20201231.xsd#pgen_TransOvaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TransOvaSegmentMember" xlink:to="lab_pgen_TransOvaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_0b9392ce-3696-43d6-bf14-9b12857bc956_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_d60f98d7-bb26-48a4-9020-6cbac812aafa_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7b2a1595-977d-4cf1-8af5-eb7407eab838_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3bc01330-7816-4396-8e1d-e0c246667f4d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product and services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b52c1273-9e9f-4db5-ad5b-59415a52d8ef_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d0effd80-c240-4a34-bb5f-04a14befcaa2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_bc8f8187-79d5-41fa-b369-eb99ff6b4af6_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from discontinued operations attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_5e4dd240-c0c4-4ee4-a3f7-9022058831d3_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, percentage of development costs for which responsible</link:label>
    <link:label id="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_label_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Development Costs For Which Responsible</link:label>
    <link:label id="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of development costs for which an entity is responsible under a licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:to="lab_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_60a8f10c-8b3e-45a5-a666-f1c5895c8f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Assets, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fa2163cb-cb46-43dc-bf5c-1d4a1c23b7be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_bb56fabc-7182-4876-8a48-e95e093c9877_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims pending resolution</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_365ed7ce-e409-44a6-98da-87206415bca0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9a996a8d-c887-4f7b-81ac-61f0113407f8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b3017980-d7d8-4c25-bb19-f8f29c9c9a51_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1fed35e5-1f13-4a5b-8493-d8714227cb30_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_e857fa45-e166-4be2-a45e-41de3ebaae44_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge on write down of investment in affiliate</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborationAgreementTerminationNoticePeriod_1b7fd747-2959-4ed4-88ce-b3f90999ec1c_terseLabel_en-US" xlink:label="lab_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required notice period for voluntary termination of collaborative agreement</link:label>
    <link:label id="lab_pgen_CollaborationAgreementTerminationNoticePeriod_label_en-US" xlink:label="lab_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Termination Notice Period</link:label>
    <link:label id="lab_pgen_CollaborationAgreementTerminationNoticePeriod_documentation_en-US" xlink:label="lab_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Termination Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:to="lab_pgen_CollaborationAgreementTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExercisePriceOneMember_3ffa9a27-b367-427b-a720-1288c892a8ac_terseLabel_en-US" xlink:label="lab_pgen_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price range 1</link:label>
    <link:label id="lab_pgen_ExercisePriceOneMember_label_en-US" xlink:label="lab_pgen_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price One [Member]</link:label>
    <link:label id="lab_pgen_ExercisePriceOneMember_documentation_en-US" xlink:label="lab_pgen_ExercisePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceOneMember" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExercisePriceOneMember" xlink:to="lab_pgen_ExercisePriceOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_31ea6f3e-0820-46e4-b2c7-f5bff7b8eec6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to restricted stock unit awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_2c89f2f8-7d61-43a1-9076-e32af5facc99_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations related to MBP Titan</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Discontinued Operations</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6d7ba1a8-3525-46ad-891e-71c1050cff72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to the noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e94ef4ad-d48e-461e-82b2-87388e12f8ab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_17a21a08-600d-497a-ad12-aaae2348dd60_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in conjunction with settlement agreement</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:to="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bd4c634a-8ca0-4840-96f1-7cf080282ec8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38c5faf3-a5e9-4393-8c81-4e1476f881bf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8a745645-417e-4522-af67-e3aa9282d43f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1b7c7030-87a6-4e08-b4ac-912025048dd1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1ee74523-41cf-454e-8c38-feacbe94ed94_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_044e729e-b8fe-4900-b74f-2002410798c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6096629e-74e2-499a-817b-f5fedd060387_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_02016c85-5bf9-4972-b7c3-6846bc2337a1_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_712401e1-6f71-4277-aac5-b1fdce739dec_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments_60ce8551-b9a0-4a35-920b-8533005ca0b2_terseLabel_en-US" xlink:label="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, percent of collaboration payments</link:label>
    <link:label id="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments_label_en-US" xlink:label="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Collaboration Payments</link:label>
    <link:label id="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments_documentation_en-US" xlink:label="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:href="pgen-20201231.xsd#pgen_CollaborationArrangementPercentOfCollaborationPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:to="lab_pgen_CollaborationArrangementPercentOfCollaborationPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_34b7a830-63d9-4675-84f7-b5bb9b27afcd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_083046f3-ed16-4e56-8211-f1fe54ec349a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3ce54a4c-f42d-40fe-bd99-d7604e5d5299_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_cae65301-a199-4738-ab44-eb4080214717_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_6fb76de9-cc68-49d5-8d5d-fa07870a99ec_terseLabel_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate as a percentage of net sales, tier 1</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_label_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Royalties As Percentage Of Net Sales Tier One</link:label>
    <link:label id="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_documentation_en-US" xlink:label="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:to="lab_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_052d22f8-e476-40db-bb4e-638373b22816_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate on convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_73be6024-ce9b-4904-abe8-15776ef9850d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4aa9847a-c5d9-401e-91ed-cc80539a2603_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_04da9a35-fcbe-4ce7-9202-22e36bb76bae_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_13fbc391-375b-41f5-9a42-4834db5ed422_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1d35e702-38c1-4b21-b840-130d35eb8b84_negatedNetLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d47cba55-056f-4b62-84af-f6cfbce9c70c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade, less allowance for credit losses of $4,825 and $5,201 as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2733772c-af07-4771-84c7-d783c3d5fcfa_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_e8920702-24dd-48ce-aab0-03d7f55ea687_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_eeab43c4-8298-4c39-9ec7-313b1a9a0f5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCMember_eabfc1db-afb5-4cc1-b4b6-33bb937e9345_terseLabel_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Sale</link:label>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCMember_label_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Holdings, LLC [Member]</link:label>
    <link:label id="lab_pgen_TSBiotechnologyHoldingsLLCMember_documentation_en-US" xlink:label="lab_pgen_TSBiotechnologyHoldingsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TS Biotechnology Holdings, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_TSBiotechnologyHoldingsLLCMember" xlink:to="lab_pgen_TSBiotechnologyHoldingsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_88341933-96c7-446e-a46f-c142afc896cd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_8c35cafb-fbdf-4e0d-9d0e-ccd67abae959_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d6550571-d2bb-4770-b180-dde2bbe11fc5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AdjustmentForBonusesPaidInEquityAwards_648bfc5b-122b-4e36-818f-79ebb4baef4c_terseLabel_en-US" xlink:label="lab_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment related to accrued bonuses paid in equity awards</link:label>
    <link:label id="lab_pgen_AdjustmentForBonusesPaidInEquityAwards_label_en-US" xlink:label="lab_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment For Bonuses Paid In Equity Awards</link:label>
    <link:label id="lab_pgen_AdjustmentForBonusesPaidInEquityAwards_documentation_en-US" xlink:label="lab_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment For Bonuses Paid In Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:href="pgen-20201231.xsd#pgen_AdjustmentForBonusesPaidInEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:to="lab_pgen_AdjustmentForBonusesPaidInEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_82008292-6c35-4e95-b5c0-7863a7eb5dfa_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_16d670a9-a58e-4244-b47c-b99ebe8ca0cd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementAnnualFee_256ad941-ca51-4f1b-b115-63f5687a7e9b_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementAnnualFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, annual fee</link:label>
    <link:label id="lab_pgen_LicenseAgreementAnnualFee_label_en-US" xlink:label="lab_pgen_LicenseAgreementAnnualFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Annual Fee</link:label>
    <link:label id="lab_pgen_LicenseAgreementAnnualFee_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementAnnualFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual licensing fee due under licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementAnnualFee" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementAnnualFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementAnnualFee" xlink:to="lab_pgen_LicenseAgreementAnnualFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_dfbf1219-3e04-4229-b3f3-780aa504341e_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense, Net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9f760431-03a1-4df3-bc83-b5d25d3fbe7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_d3d9e9d5-4507-4d6c-ba4b-8084476c27aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_2b43eee6-b421-4194-8f32-d92846d2f752_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income taxes:</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_74d34f18-94d8-44ee-8e4a-dc43afe3d057_terseLabel_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional capital contributions committed, remaining commitment</link:label>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_label_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Additional Capital Contributions Committed, Remaining Commitment</link:label>
    <link:label id="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_documentation_en-US" xlink:label="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount of additional capital contributions to the joint venture for which the entity is committed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:to="lab_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_b19a64f6-6c04-4d79-9437-d987e7c54885_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_47560ccf-ac29-4218-9cc3-1945dff35284_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NumberOfReportingUnitsClosed_520ce7bd-fd3b-4dce-813c-c3f5841c4a7b_terseLabel_en-US" xlink:label="lab_pgen_NumberOfReportingUnitsClosed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units closed</link:label>
    <link:label id="lab_pgen_NumberOfReportingUnitsClosed_label_en-US" xlink:label="lab_pgen_NumberOfReportingUnitsClosed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units Closed</link:label>
    <link:label id="lab_pgen_NumberOfReportingUnitsClosed_documentation_en-US" xlink:label="lab_pgen_NumberOfReportingUnitsClosed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units Closed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfReportingUnitsClosed" xlink:href="pgen-20201231.xsd#pgen_NumberOfReportingUnitsClosed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NumberOfReportingUnitsClosed" xlink:to="lab_pgen_NumberOfReportingUnitsClosed" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_14b564f6-2ef5-4c50-9997-ac06492738a1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0d29bb38-b902-4ef9-87cc-f4cc9419b743_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_f2519f71-a374-489e-ac8e-a32a2b708d32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8af43d3a-5401-42d5-a9e4-324e01fda9c5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32457eb7-5fcb-4eef-b395-6e54f1a4dd3b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_02b69cd3-7a4c-4f9e-b5e1-f2d61a189a0f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d2c83be6-b70c-405e-90ec-e407a6a48782_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7304afac-cd29-423f-b0ba-c95c15a5dfc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_9a835c5f-9a24-4e29-84fe-04c296c6d139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_54a13e85-42e8-43f0-a754-810028f69034_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from discontinued operations, net of income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_3d875892-ddef-43e3-abd1-5907f7ce9325_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, no par value, 400,000,000 shares authorized as of December&#160;31, 2020 and 2019; and 187,663,207 shares and 163,274,880 shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_042c6b38-53be-4228-9af4-f18673465686_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_68fcf18f-668c-45de-b6e7-fb72a9849af7_terseLabel_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and internal restructuring transaction costs</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_label_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Acquisition-related Transaction Costs</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_documentation_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to adjustments for acquisition-related transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:to="lab_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b8cc716-95d8-4956-96bc-f770921811eb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_15bf883a-a0f9-4865-9510-821f5d08ae29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c090960f-967d-4edc-b302-4b994c03ca59_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ebbfd5f1-6325-476b-84d6-51c563f8a1eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CollaborationAgreementsLineItems_9c8f9c6d-9e48-4c21-8eb0-2d1707838268_terseLabel_en-US" xlink:label="lab_pgen_CollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_pgen_CollaborationAgreementsLineItems_label_en-US" xlink:label="lab_pgen_CollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_pgen_CollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_pgen_CollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsLineItems" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CollaborationAgreementsLineItems" xlink:to="lab_pgen_CollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_35379fb7-b9b0-47fa-b3cc-a212ed5ce403_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedIntangibleAssets_2c3dfeed-a5c9-4d43-9658-18192a302c1c_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock issued for reacquired in-process research and development</link:label>
    <link:label id="lab_pgen_StockIssuedIntangibleAssets_label_en-US" xlink:label="lab_pgen_StockIssuedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Intangible Assets</link:label>
    <link:label id="lab_pgen_StockIssuedIntangibleAssets_documentation_en-US" xlink:label="lab_pgen_StockIssuedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of stock issued to acquired intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedIntangibleAssets" xlink:href="pgen-20201231.xsd#pgen_StockIssuedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedIntangibleAssets" xlink:to="lab_pgen_StockIssuedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AllInvestorsMember_5464a9c3-9eec-4032-9421-7eeb397f9143_terseLabel_en-US" xlink:label="lab_pgen_AllInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Investors</link:label>
    <link:label id="lab_pgen_AllInvestorsMember_label_en-US" xlink:label="lab_pgen_AllInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Investors [Member]</link:label>
    <link:label id="lab_pgen_AllInvestorsMember_documentation_en-US" xlink:label="lab_pgen_AllInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Investors of Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AllInvestorsMember" xlink:href="pgen-20201231.xsd#pgen_AllInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AllInvestorsMember" xlink:to="lab_pgen_AllInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a202f1e6-d9d9-400b-828a-f1d1a9c72b7b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b7f09c0f-429d-4a55-bff8-e3f710cd105d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b45758d3-563a-40f8-9fd5-f508ac6288a7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_fc6ac8aa-3b2a-44b8-8146-7970eccffd76_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_XYLLCMember_1c5d434d-ef70-4b6d-817b-8d3da5e62245_terseLabel_en-US" xlink:label="lab_pgen_XYLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XY, LLC</link:label>
    <link:label id="lab_pgen_XYLLCMember_label_en-US" xlink:label="lab_pgen_XYLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XY, LLC [Member]</link:label>
    <link:label id="lab_pgen_XYLLCMember_documentation_en-US" xlink:label="lab_pgen_XYLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XY, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_XYLLCMember" xlink:href="pgen-20201231.xsd#pgen_XYLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_XYLLCMember" xlink:to="lab_pgen_XYLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f368e408-2c45-4c16-bd0f-ca1ede8cf896_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_5506915f-b177-45c4-b4e4-e792032595bd_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_75ca5621-57d3-4a29-9d65-00623f51a219_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Income Statement, Sublease Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:to="lab_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_c801ea86-fd8a-4a2c-8981-4a42f593b0e4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_cc2f0ef0-ba8e-4b95-a9dc-e00e48571641_verboseLabel_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_label_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Monthly Expense</link:label>
    <link:label id="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_documentation_en-US" xlink:label="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of monthly expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:to="lab_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f4b12bc7-cf35-498c-8597-65b6b606aa6a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_0197de59-3a73-48ef-b991-2a29f170ea4d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7b61f980-bb51-456b-aa9a-3f2661942da1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SeriesAPreferredSharesMember_537027e2-d947-4c5e-a05b-ac084348ba4e_terseLabel_en-US" xlink:label="lab_pgen_SeriesAPreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Shares</link:label>
    <link:label id="lab_pgen_SeriesAPreferredSharesMember_label_en-US" xlink:label="lab_pgen_SeriesAPreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Shares [Member]</link:label>
    <link:label id="lab_pgen_SeriesAPreferredSharesMember_documentation_en-US" xlink:label="lab_pgen_SeriesAPreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A redeemable preferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SeriesAPreferredSharesMember" xlink:href="pgen-20201231.xsd#pgen_SeriesAPreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SeriesAPreferredSharesMember" xlink:to="lab_pgen_SeriesAPreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_9689cdce-5fa9-48d4-b120-25c59bed141b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13c60c23-3731-42ca-93bf-1604bed0a733_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_71578db9-241d-4869-bb12-cb2825c26149_terseLabel_en-US" xlink:label="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, termination, period following triggering event</link:label>
    <link:label id="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_label_en-US" xlink:label="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination, Period Following Triggering Event</link:label>
    <link:label id="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_documentation_en-US" xlink:label="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period following a triggering event after which a licensing agreement will be terminated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:to="lab_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ActoBioNotesMember_8d5d51cf-ab54-4d43-96e9-7d2a3d2aa0e7_terseLabel_en-US" xlink:label="lab_pgen_ActoBioNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio Notes</link:label>
    <link:label id="lab_pgen_ActoBioNotesMember_label_en-US" xlink:label="lab_pgen_ActoBioNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio Notes [Member]</link:label>
    <link:label id="lab_pgen_ActoBioNotesMember_documentation_en-US" xlink:label="lab_pgen_ActoBioNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ActoBio Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioNotesMember" xlink:href="pgen-20201231.xsd#pgen_ActoBioNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ActoBioNotesMember" xlink:to="lab_pgen_ActoBioNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0859931d-259b-41f6-9e4b-c564f8b07bb6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_53db1f0e-b4e5-4688-b6fc-a83d2ca09750_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_7f28464d-35f5-4757-a699-ab9068efaaa7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, loss, amount</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DebtInstrumentResaleRestrictionPeriod_1e479bf8-a56b-4ce1-905f-3ad796bab7ed_terseLabel_en-US" xlink:label="lab_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, resale restriction days</link:label>
    <link:label id="lab_pgen_DebtInstrumentResaleRestrictionPeriod_label_en-US" xlink:label="lab_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Resale Restriction Period</link:label>
    <link:label id="lab_pgen_DebtInstrumentResaleRestrictionPeriod_documentation_en-US" xlink:label="lab_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Resale Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:href="pgen-20201231.xsd#pgen_DebtInstrumentResaleRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:to="lab_pgen_DebtInstrumentResaleRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8f02fc0e-dfac-4a58-86ca-39f6f52b3e70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ExecutiveChairmanMember_d9758593-99e0-47e3-a1d1-0cb2d20d4bee_terseLabel_en-US" xlink:label="lab_pgen_ExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman</link:label>
    <link:label id="lab_pgen_ExecutiveChairmanMember_label_en-US" xlink:label="lab_pgen_ExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman [Member]</link:label>
    <link:label id="lab_pgen_ExecutiveChairmanMember_documentation_en-US" xlink:label="lab_pgen_ExecutiveChairmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ExecutiveChairmanMember" xlink:to="lab_pgen_ExecutiveChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_145624c4-1d65-44a8-8d8b-cf25bb4dda47_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3cd435de-ce4f-42ef-ad71-6f15c6af6920_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedSettlementAgreement_cce4fe62-3981-4629-be25-0e3db609f6d3_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock issued in conjunction with settlement agreement</link:label>
    <link:label id="lab_pgen_StockIssuedSettlementAgreement_label_en-US" xlink:label="lab_pgen_StockIssuedSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Settlement Agreement</link:label>
    <link:label id="lab_pgen_StockIssuedSettlementAgreement_documentation_en-US" xlink:label="lab_pgen_StockIssuedSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedSettlementAgreement" xlink:href="pgen-20201231.xsd#pgen_StockIssuedSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedSettlementAgreement" xlink:to="lab_pgen_StockIssuedSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2e063890-fcf2-49eb-848a-b11a2a940638_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2736706b-a8fd-4e61-ac4f-fee27c1161fc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CommonStockCalculationPeriod_c05d4a12-bbae-42d6-af95-da70216df689_terseLabel_en-US" xlink:label="lab_pgen_CommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock calculation period</link:label>
    <link:label id="lab_pgen_CommonStockCalculationPeriod_label_en-US" xlink:label="lab_pgen_CommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Calculation Period</link:label>
    <link:label id="lab_pgen_CommonStockCalculationPeriod_documentation_en-US" xlink:label="lab_pgen_CommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Calculation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CommonStockCalculationPeriod" xlink:href="pgen-20201231.xsd#pgen_CommonStockCalculationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CommonStockCalculationPeriod" xlink:to="lab_pgen_CommonStockCalculationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_f9ea1cc1-46ed-414c-8550-f079b8b4c0f0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_ec7d0140-4bc1-4dec-b22d-b436c67b22e7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_c718f363-6e05-46c7-b706-3306143dba20_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of ASC 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_174f9995-f409-4550-8bcc-43c8bf603d3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_cd6cb4ae-2670-4e51-be5d-562aa9754f2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_491b1b79-92ad-4381-ac3e-8aab875007b5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_52169b8d-d406-446f-b0c8-f0d3dc0949c4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_8b678e78-3683-42e3-b4d4-a77a70fbaf4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_87ce78b3-361a-44fb-878b-d4eb126fd748_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eea044cf-e77e-4e5b-883e-feaec0a32e6d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_59a1be6f-bcc4-40c0-8bb3-536c562fea62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_IncomeTaxLineItems_e344ea76-57ca-474d-a30d-845e4c72c68a_terseLabel_en-US" xlink:label="lab_pgen_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_pgen_IncomeTaxLineItems_label_en-US" xlink:label="lab_pgen_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_pgen_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_pgen_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxLineItems" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_IncomeTaxLineItems" xlink:to="lab_pgen_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_62c0e8d4-f710-41df-b8ec-c8d8ee778590_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_2aa8b450-fb37-4c05-848f-d12f701d99fb_terseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Establishment of deferred taxes for subsidiaries included in discontinued operations</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Establishment Of Deferred Taxes For Subsidiaries Included In Discontinued Operations</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Assets, Establishment Of Deferred Taxes For Subsidiaries Included In Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ff6866fe-2a76-4ba2-9e2e-f6da09b11666_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_01abdb10-beab-485a-81b2-199ed41ff747_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_ac9eec4b-2615-43b3-b94d-cf7977cb7d0a_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued in conjunction with settlement agreement, shares</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:to="lab_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_15a650c5-bd8f-4052-ab34-b20be3f40508_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected useful life of intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_923a1450-ef99-45db-9f0d-c107a224eb47_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_61753123-08aa-4345-a7fa-60e83112cec8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_e9a3b7cb-5e88-4c29-8171-973e80609799_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquisition of in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_514c7da9-6caf-4410-b63e-1f12dc8a33f5_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_375d2054-a5a7-4a9d-a6b0-1e4f37dd62b1_verboseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued for exercises of warrants</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_label_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Awards Vested and Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:to="lab_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a9030b25-070e-45a3-9586-c682763a481b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_f02bc86a-b7f3-40fb-ba69-1d1ebcc92790_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_0d0e548b-5e08-48d4-9d8a-4d0f5cf24b4f_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8995b86a-df6b-4653-8962-4c0bd5cb2b5a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_14a3e1a8-e352-48ca-8162-718c1ec8fab8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OtherLongTermDebtMember_4e02542d-b578-4b5a-92dc-dd48c15e114b_terseLabel_en-US" xlink:label="lab_pgen_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pgen_OtherLongTermDebtMember_label_en-US" xlink:label="lab_pgen_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt [Member]</link:label>
    <link:label id="lab_pgen_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_pgen_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherLongTermDebtMember" xlink:href="pgen-20201231.xsd#pgen_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OtherLongTermDebtMember" xlink:to="lab_pgen_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e33933a0-77d0-42ed-adba-6738340891be_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_3a4ef7f0-2ffd-4843-b62c-8cc5aa782bab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e7f4e37f-a9b4-414e-af6c-cb290cdbee64_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cbf5bee3-2bd6-4f4e-961c-118c1523029b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_29ec459f-613b-472f-8474-ea65e1d896b5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Precigen</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_651162e5-1189-4ecd-b346-010fcdb1af82_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_ff340b2e-fec0-4a72-8b9e-a2500801c6f0_terseLabel_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net loss of affiliates</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_label_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_documentation_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:to="lab_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ed3ae963-d2b9-41c0-bdab-4c3eb06d68de_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_afed324c-fbad-4732-88b6-84d330937923_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_c65c9320-6f6c-4ea1-8228-b14a7010f1e8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional investment in subsidiary</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_16e19746-bc01-45de-b239-9307bc649462_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ded1c4e2-dc3b-41b4-9777-b345369b0a39_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_AquaBountyMember_adff2a12-32de-413c-bee0-2c0bc1d03831_terseLabel_en-US" xlink:label="lab_pgen_AquaBountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AquaBounty Technologies, Inc.</link:label>
    <link:label id="lab_pgen_AquaBountyMember_label_en-US" xlink:label="lab_pgen_AquaBountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aqua Bounty [Member]</link:label>
    <link:label id="lab_pgen_AquaBountyMember_documentation_en-US" xlink:label="lab_pgen_AquaBountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aqua Bounty Technologies, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AquaBountyMember" xlink:href="pgen-20201231.xsd#pgen_AquaBountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_AquaBountyMember" xlink:to="lab_pgen_AquaBountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_0bde1982-e43f-4069-9f32-a15259c4b3d4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_SecuritiesAndExchangeCommissionMember_faa53d52-98d4-4e8c-a1c4-336ffe14985f_terseLabel_en-US" xlink:label="lab_pgen_SecuritiesAndExchangeCommissionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities And Exchange Commission</link:label>
    <link:label id="lab_pgen_SecuritiesAndExchangeCommissionMember_label_en-US" xlink:label="lab_pgen_SecuritiesAndExchangeCommissionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities And Exchange Commission [Member]</link:label>
    <link:label id="lab_pgen_SecuritiesAndExchangeCommissionMember_documentation_en-US" xlink:label="lab_pgen_SecuritiesAndExchangeCommissionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities And Exchange Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SecuritiesAndExchangeCommissionMember" xlink:href="pgen-20201231.xsd#pgen_SecuritiesAndExchangeCommissionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_SecuritiesAndExchangeCommissionMember" xlink:to="lab_pgen_SecuritiesAndExchangeCommissionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MergersandAcquisitionsAbstract_1650a8d9-be80-495a-8071-17de0bb55d7a_terseLabel_en-US" xlink:label="lab_pgen_MergersandAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions [Abstract]</link:label>
    <link:label id="lab_pgen_MergersandAcquisitionsAbstract_label_en-US" xlink:label="lab_pgen_MergersandAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions [Abstract]</link:label>
    <link:label id="lab_pgen_MergersandAcquisitionsAbstract_documentation_en-US" xlink:label="lab_pgen_MergersandAcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers and Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MergersandAcquisitionsAbstract" xlink:href="pgen-20201231.xsd#pgen_MergersandAcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MergersandAcquisitionsAbstract" xlink:to="lab_pgen_MergersandAcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_bb0bab64-3418-4600-89ce-2360a37f1dbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_1ec66600-6692-471f-a4c3-9bec00ff4271_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_83fb970f-ead3-491c-96bc-7ca46783b3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_1cbeee54-b5ef-4462-809c-8bb4e9340be7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_cee3254c-67bd-4fe0-8966-eabbbc4ae91b_terseLabel_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for accrued compensation, shares</link:label>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_label_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During The Period, Shares, Accrued Compensation</link:label>
    <link:label id="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_documentation_en-US" xlink:label="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in lieu of cash for accrued compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodSharesAccruedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:to="lab_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_94ef5490-0409-4f91-ac3f-c7348966b6a6_terseLabel_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible officer compensation</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_label_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation</link:label>
    <link:label id="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_documentation_en-US" xlink:label="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible officers' compensation costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:to="lab_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8c7387eb-6323-4541-8f69-31c28f24e676_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion, including $21,205 and $30,182 from related parties as of December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2f38b016-3074-43e2-996d-5e4d21466bef_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_b21cd687-46af-45c2-a4c5-145a1ee877a2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_9550b1a6-aaba-4d32-a752-2891e0020ddc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_357d6e2c-59fa-46c9-b13d-f51db07d6967_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9561b288-3abf-4841-a350-6be0ab3df1ae_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ab2b5296-87b0-4ced-981a-c8f003bd4b81_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flows Information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_c6f23768-70ca-4804-afe8-67a95e407e18_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_889cccf2-f106-432c-8c19-0c8af034a14e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_67bf5b8b-d7a3-40c7-afcc-0e1200421c6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_22f9388c-8695-43d4-8ca8-f5cd45eb68db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_aad8e8e1-bd77-4b0a-a089-b96f7ea9ad8d_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_faaa8999-a2e2-4bea-8371-dc48f2b53dd4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8d4abde9-3145-48f7-b8b3-242587a82e0e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ReacquiredInProcessResearchDevelopmentMember_b5f7eca2-4eaf-483b-81ad-b9bc34178cd0_terseLabel_en-US" xlink:label="lab_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquired in-process research &amp; development</link:label>
    <link:label id="lab_pgen_ReacquiredInProcessResearchDevelopmentMember_label_en-US" xlink:label="lab_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquired In-Process Research &amp; Development [Member]</link:label>
    <link:label id="lab_pgen_ReacquiredInProcessResearchDevelopmentMember_documentation_en-US" xlink:label="lab_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reacquired In-Process Research &amp; Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:href="pgen-20201231.xsd#pgen_ReacquiredInProcessResearchDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:to="lab_pgen_ReacquiredInProcessResearchDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6d296482-1a05-47ca-a66e-1d64c6939dbd_netLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares and warrants issued in public or private offerings, net of issuance costs, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_50e1280c-cd3e-4678-a8ec-c890bc365586_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public or private offerings, net of issuance costs, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9b6ffdb8-5792-4040-b5e6-d4bb3f63a36f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_fcaa1657-6294-45a5-9297-81f1964f3d31_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ConvertiblePreferredStockAmountAuthorized_2e136298-fe07-47f6-906a-07083cc31932_terseLabel_en-US" xlink:label="lab_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, amount authorized</link:label>
    <link:label id="lab_pgen_ConvertiblePreferredStockAmountAuthorized_label_en-US" xlink:label="lab_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Amount Authorized</link:label>
    <link:label id="lab_pgen_ConvertiblePreferredStockAmountAuthorized_documentation_en-US" xlink:label="lab_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum value of preferred shares permitted to be issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:href="pgen-20201231.xsd#pgen_ConvertiblePreferredStockAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:to="lab_pgen_ConvertiblePreferredStockAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_466b2635-986d-4f95-bdbe-f3c8b41d4088_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a2887b1e-b616-4f3c-a013-c68c4767c8f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6e95a84e-b80f-49ce-8b06-61034e08e857_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of long-term debt, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_141059b4-97de-4a09-848a-5b9a2f4618d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_bd2a8d3c-5add-4eb5-95b5-2c7d8b3ec492_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to operating expenses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_82796e53-e7c1-404c-bd1c-96493b31189f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EliminationsAndReconcilingItemsMember_c6b7dd92-879c-4fa8-98da-657e0e930490_terseLabel_en-US" xlink:label="lab_pgen_EliminationsAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of intersegment revenues</link:label>
    <link:label id="lab_pgen_EliminationsAndReconcilingItemsMember_label_en-US" xlink:label="lab_pgen_EliminationsAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliminations And Reconciling Items [Member]</link:label>
    <link:label id="lab_pgen_EliminationsAndReconcilingItemsMember_documentation_en-US" xlink:label="lab_pgen_EliminationsAndReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliminations And Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EliminationsAndReconcilingItemsMember" xlink:href="pgen-20201231.xsd#pgen_EliminationsAndReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EliminationsAndReconcilingItemsMember" xlink:to="lab_pgen_EliminationsAndReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_009a0f84-59e1-4c12-ab05-9acfe617c5e9_terseLabel_en-US" xlink:label="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of related parties with terminated agreements</link:label>
    <link:label id="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_label_en-US" xlink:label="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Related Parties With Terminated Agreements</link:label>
    <link:label id="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_documentation_en-US" xlink:label="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Related Parties With Terminated Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:href="pgen-20201231.xsd#pgen_NumberOfRelatedPartiesWithTerminatedAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:to="lab_pgen_NumberOfRelatedPartiesWithTerminatedAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3e7cf24b-d0d8-47e8-b8fd-35e9465e9de8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_b2dfde09-eb32-432e-930c-a11ca885ee03_terseLabel_en-US" xlink:label="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of shares and warrants in public offerings, net of issuance costs</link:label>
    <link:label id="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_label_en-US" xlink:label="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock and Warrants, Net</link:label>
    <link:label id="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_documentation_en-US" xlink:label="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity (in exchange for shares of common stock) and from issuance of rights to purchase common shares at a predetermined price (usually issued together with corporate debt), net of capitalized issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:to="lab_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3cd88073-d801-42f1-ac49-af0de82629ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_d57653b0-8526-4f69-b601-25831b7b1874_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_c39ebe08-99dc-4856-a8de-8eb576df3b5a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock issued upon conversion of long-term debt</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30097c2e-fe3c-4190-92f3-8f20dd12c28e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_884f784b-6de0-44aa-aa76-add8961f2c80_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_80fb93e6-fa8f-4c88-aeb0-32d4c9aa7b0b_verboseLabel_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of new accounting pronouncements</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_label_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change in Amount due to Adoption of Accounting Principle</link:label>
    <link:label id="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_documentation_en-US" xlink:label="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the valuation allowance for deferred tax assets resulting from the adoption of a recently issued accounting pronouncement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:to="lab_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_2a869042-8d27-42c3-88c9-08afa1f1c5b5_negatedTerseLabel_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of discontinued operations</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_label_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:label id="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_documentation_en-US" xlink:label="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:to="lab_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_bcdca7b2-5bde-4e01-af06-58a2f7fadbb0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_8378632b-08a1-4487-b0c2-25bb0d55b95f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets held for sale or abandonment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_de1c6186-d7aa-453a-a65a-ee9e76ac0b70_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_28b53fff-6bad-45d8-a918-498854bf6d8b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3ec70a23-1375-4698-90f9-de6769523914_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b3f58ae3-c1f7-4c01-b27f-3a889db00b36_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_09c18e69-fe55-424d-a3d0-3ca424748881_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_ec4541b2-f1cf-4811-b8d9-093c15b3b13f_terseLabel_en-US" xlink:label="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period of highly liquid investment</link:label>
    <link:label id="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investment Maximum Maturity Period</link:label>
    <link:label id="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original maturity period for highly liquid investments to be considered cash equivalent, maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:href="pgen-20201231.xsd#pgen_HighlyLiquidInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:to="lab_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_97cc5390-1117-4dc6-844e-7477c23fb5cc_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets added in exchange for new lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates_09a94b39-404f-4518-be55-d76ec8825de8_terseLabel_en-US" xlink:label="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remove cash paid for capital expenditures and investments in affiliates</link:label>
    <link:label id="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates_label_en-US" xlink:label="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures And Investments in Affiliates</link:label>
    <link:label id="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates_documentation_en-US" xlink:label="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures and Investments in Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:href="pgen-20201231.xsd#pgen_CapitalExpendituresAndInvestmentsinAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:to="lab_pgen_CapitalExpendituresAndInvestmentsinAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_05235db7-8d2e-4de0-b7c2-48e20bc3bafa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ca1f438f-e8ef-411d-80e7-3f2561cc1f99_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_36719f70-3ab5-4fcd-a663-23c1cda29724_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_de650737-3d75-4da4-ad84-fce3e03dac4f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_EquitySecuritiesPolicyTextBlock_5f86927c-6f74-4bc4-9786-2464a073dd63_terseLabel_en-US" xlink:label="lab_pgen_EquitySecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_pgen_EquitySecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_pgen_EquitySecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Policy Text Block]</link:label>
    <link:label id="lab_pgen_EquitySecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_pgen_EquitySecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesPolicyTextBlock" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_EquitySecuritiesPolicyTextBlock" xlink:to="lab_pgen_EquitySecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_664cc494-1308-48b4-bb27-f80d1bfddcac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c23d05b8-f1c7-4cb1-accc-7a900494e5c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42ac94b6-20f6-400f-b997-edcf9c305e26_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_adda19c8-78b5-4ae2-b78d-cb729228b6e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5ec8a9c1-392b-42f5-8317-62d6a6c31ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_35036a58-ee4c-4552-a0b2-15e0834071c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_25f4c242-931f-44e3-a81f-89edc30249dd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_814922a4-d82f-436a-a98b-3be38029295f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_35b1eed5-99c9-4c3f-a919-29928dba39fb_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_fdabd6a8-fda9-413a-b835-6ddedc8d2a14_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d2cec41-46b1-40f7-bff7-f1f8974e0dd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_8adef098-632d-4ea4-bcfa-8dce3fc1ca85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e3cd6d23-b758-4292-b904-c0c631e763c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_29492a4e-ed5f-41d9-901f-b1a1a2d2c588_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, exercise price range, upper limit (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_aaf97e51-1e45-42b8-ab01-bfe782f08bdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c98925ad-0c9f-46da-ae6f-5252ce1b3ae0_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_0ca6c021-4f14-41df-bffb-901c40e59a96_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_08627185-91de-407e-851b-0754542d1e2d_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8dd9281a-f75f-4eb1-8ddb-96ccfe511a92_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c0d672fd-9d48-434f-a37b-33f352ec0d90_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_778728bf-22f1-415c-8e4c-60894e47fd9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2736e1ae-b437-466b-80fe-631dc01fe5a8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fe945a3d-2d00-405e-a4e5-8d0d27bec119_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_103d9ff6-6a83-4568-9a7e-5586a8ecdb14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_e8020117-75e9-4dd6-ba16-a3f0c4bbc0a6_verboseLabel_en-US" xlink:label="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_label_en-US" xlink:label="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets, Including Property, Plant, and Equipment and Right Of Use Assets</link:label>
    <link:label id="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_documentation_en-US" xlink:label="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets, Including Property, Plant, and Equipment and Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:href="pgen-20201231.xsd#pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:to="lab_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cb516b5d-fac7-4da1-98cd-56898e8331a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_1cc395df-67b6-4e1f-988a-36f5188ba0dd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_107213e6-5d1d-4622-aa30-e104f410652d_terseLabel_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments required upon successful achievement, aggregated</link:label>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_label_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Required Upon Successful Achievement Aggregated</link:label>
    <link:label id="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_documentation_en-US" xlink:label="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Required Upon Successful Achievement Aggregated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:to="lab_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_719bece0-846d-44c7-bcc9-cd2a24a06b89_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5845ecfe-4e72-4605-b9ee-5d2a175fe6c8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_25b3af10-49f9-4dcb-807a-237f83341f08_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b5948f24-c9a5-446a-b558-fe6ea202ae3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_352ebaca-aeb1-437d-87ac-1c57d35b67f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances at period end, weighted average remaining contractual period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f6ee6da-d1a9-45a6-9e2c-df8727fa8edf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_db582571-8602-4d4b-838c-074b16fdecce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash from deconsolidation of subsidiary</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6b21ca9-ffdf-4a60-9e74-deea9a0bc4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_780945ff-9ae0-49b1-b673-d987edc2aea4_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4d988fef-e205-4dfc-8089-147d3d1f7d3d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_10990830-47e5-4383-91a6-09549ee81127_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party payables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_96e35177-35ef-4bdc-923c-4c542e2763d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e978962d-5d18-45c1-acf7-ead3717b4d84_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ae0a2b6e-8895-4610-9a7f-096f31dd6f69_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_58cfd637-a2e7-44a9-9bca-d440cedc27f5_terseLabel_en-US" xlink:label="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained interest in deconsolidated subsidiary</link:label>
    <link:label id="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_label_en-US" xlink:label="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Increase Due to Deconsolidation of Subsidiary</link:label>
    <link:label id="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_documentation_en-US" xlink:label="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Increase Due to Deconsolidation of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:href="pgen-20201231.xsd#pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:to="lab_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_pgen_OtherMember_f33511f6-cb60-4c8c-9ed7-bf94151ae5fe_terseLabel_en-US" xlink:label="lab_pgen_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_pgen_OtherMember_label_en-US" xlink:label="lab_pgen_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_pgen_OtherMember_documentation_en-US" xlink:label="lab_pgen_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherMember" xlink:href="pgen-20201231.xsd#pgen_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pgen_OtherMember" xlink:to="lab_pgen_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d0260a95-59a6-4851-94d0-ba0894abe07c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_6c5bae70-e450-4a59-995d-c948f1e188ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances from lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2beed96a-a905-4cb4-91dc-22233d791a30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_0c345367-8fef-4660-b0cb-678609c02a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>pgen-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:351c53fb-de17-40de-a388-e121b20a34d3,g:d3c1937a-9363-4bc4-8d01-c2c87872d309-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.dna.com/role/CoverPage" xlink:type="simple" xlink:href="pgen-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_31a3020a-eabd-4f46-91de-37f0b470ed81" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentType_31a3020a-eabd-4f46-91de-37f0b470ed81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_8b09befb-cb7d-45af-ba03-bd9a833f4d84" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentAnnualReport_8b09befb-cb7d-45af-ba03-bd9a833f4d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c00c5988-3501-4ab7-aa24-3175839157ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentPeriodEndDate_c00c5988-3501-4ab7-aa24-3175839157ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_28c4f19e-5175-4a8c-a900-2405772dc283" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_CurrentFiscalYearEndDate_28c4f19e-5175-4a8c-a900-2405772dc283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1d65ff70-7384-4843-8319-e7e89348240d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentTransitionReport_1d65ff70-7384-4843-8319-e7e89348240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0ccb53d8-3957-4fc9-a830-4ea155a230df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityFileNumber_0ccb53d8-3957-4fc9-a830-4ea155a230df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31b86246-649f-412b-8cbe-0260fac5e95b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityRegistrantName_31b86246-649f-412b-8cbe-0260fac5e95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e6a3b6ce-e26a-44c2-8988-14ad2b4fe8de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e6a3b6ce-e26a-44c2-8988-14ad2b4fe8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3f7dfc9a-ad1c-4978-b641-9501a1dec1e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityTaxIdentificationNumber_3f7dfc9a-ad1c-4978-b641-9501a1dec1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6b0d2e2b-d5d4-413d-bbe0-17ba88a1e5d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityAddressAddressLine1_6b0d2e2b-d5d4-413d-bbe0-17ba88a1e5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a4c6ffba-fc0f-4592-8e1e-062e8fc7a810" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityAddressCityOrTown_a4c6ffba-fc0f-4592-8e1e-062e8fc7a810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7ff2056b-8a83-494f-90da-77c315a8a5cb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityAddressStateOrProvince_7ff2056b-8a83-494f-90da-77c315a8a5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_421a153a-7c7a-41c4-8c44-52216f4efc1d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityAddressPostalZipCode_421a153a-7c7a-41c4-8c44-52216f4efc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1a66a481-caf6-4014-918b-ab8979068d32" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_CityAreaCode_1a66a481-caf6-4014-918b-ab8979068d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9a8edd4d-e95a-4462-aa24-d86ea5acff16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_LocalPhoneNumber_9a8edd4d-e95a-4462-aa24-d86ea5acff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_317e1402-e4d8-4085-8742-6ead8182573a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_Security12bTitle_317e1402-e4d8-4085-8742-6ead8182573a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_54b512f4-b048-4566-aec2-0cda0ce61ffb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_TradingSymbol_54b512f4-b048-4566-aec2-0cda0ce61ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_96c2f775-7dfa-4eed-8ae7-aadea11b1559" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_SecurityExchangeName_96c2f775-7dfa-4eed-8ae7-aadea11b1559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_35458bb9-522d-4578-939e-f736df186786" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_35458bb9-522d-4578-939e-f736df186786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ce98174f-c5db-482a-b864-e5fb58ece972" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityVoluntaryFilers_ce98174f-c5db-482a-b864-e5fb58ece972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_05d2c3ee-40e8-4094-bdde-a1fbbf01b1f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityCurrentReportingStatus_05d2c3ee-40e8-4094-bdde-a1fbbf01b1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_284a5af3-1c34-4357-a9c7-960124d08183" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityInteractiveDataCurrent_284a5af3-1c34-4357-a9c7-960124d08183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_393e0019-e7a6-419f-8d74-e2d9170e9f08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityFilerCategory_393e0019-e7a6-419f-8d74-e2d9170e9f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4c0667fe-9e31-445f-b95f-39bbc4e0e40c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntitySmallBusiness_4c0667fe-9e31-445f-b95f-39bbc4e0e40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a9dbad66-627d-42ee-beb9-a0c3d8888b3f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityEmergingGrowthCompany_a9dbad66-627d-42ee-beb9-a0c3d8888b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_7b44e32d-6755-4c59-b582-7d0a5801ed9d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_7b44e32d-6755-4c59-b582-7d0a5801ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d98ee229-21fc-4a96-bced-791361fd037e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityShellCompany_d98ee229-21fc-4a96-bced-791361fd037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_509ed561-d32b-4321-8833-2c830a426326" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityPublicFloat_509ed561-d32b-4321-8833-2c830a426326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4752b6ff-b0e1-4ace-990e-f2602a7c6adf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4752b6ff-b0e1-4ace-990e-f2602a7c6adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_868e2b3e-d5b0-43c6-8b35-ff914e134f83" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_868e2b3e-d5b0-43c6-8b35-ff914e134f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_28858123-9b71-4766-98c8-71d4858686ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_AmendmentFlag_28858123-9b71-4766-98c8-71d4858686ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f34b2d0-5d78-4ea9-8e18-3c310168274c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentFiscalYearFocus_4f34b2d0-5d78-4ea9-8e18-3c310168274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_62b62abe-5566-47bf-b6ef-63b83c8b713d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_62b62abe-5566-47bf-b6ef-63b83c8b713d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0957dd16-0a9e-4617-baa6-875824718a22" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_35d1d067-c32e-487b-931e-266c172ec3c1" xlink:to="loc_dei_EntityCentralIndexKey_0957dd16-0a9e-4617-baa6-875824718a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_55f6caab-9745-4dd7-b809-4083f991dd26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55f6caab-9745-4dd7-b809-4083f991dd26" xlink:to="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76980860-58c6-450e-819f-bbf4ff9cbaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76980860-58c6-450e-819f-bbf4ff9cbaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d452da71-363b-4e47-8d87-28856446b742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_ShortTermInvestments_d452da71-363b-4e47-8d87-28856446b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4debd8cc-ebd9-4454-8767-620bbd56608c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4debd8cc-ebd9-4454-8767-620bbd56608c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_11428532-0bf5-4012-8b34-c08d571d74ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_11428532-0bf5-4012-8b34-c08d571d74ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_e857fc7a-33ca-4fd1-94ed-b6b132a8491b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_e857fc7a-33ca-4fd1-94ed-b6b132a8491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ed71ea0c-bea9-4af5-a934-66c9d74f882b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesNetCurrentAbstract_3ed62585-4c58-436b-bcf8-f7f1b889ea95" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ed71ea0c-bea9-4af5-a934-66c9d74f882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_76fe7b51-be92-4644-8ee9-18994b6c2e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_InventoryGross_76fe7b51-be92-4644-8ee9-18994b6c2e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ddc6d55c-c4ff-450c-9091-bbfb7cb321f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ddc6d55c-c4ff-450c-9091-bbfb7cb321f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_db81e343-5d79-4a31-8281-01e7c579ba1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_db81e343-5d79-4a31-8281-01e7c579ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f50d65a8-47c7-42fc-b798-b5840e11484c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_22dc1c61-9c36-41f3-b044-4c5ce0b7364a" xlink:to="loc_us-gaap_AssetsCurrent_f50d65a8-47c7-42fc-b798-b5840e11484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2011603d-7151-437f-89a6-97a5b708bd18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2011603d-7151-437f-89a6-97a5b708bd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52182354-f430-4922-b8b8-48a381076149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52182354-f430-4922-b8b8-48a381076149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e120af35-b37e-4a54-9f7c-6a328d176b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_Goodwill_e120af35-b37e-4a54-9f7c-6a328d176b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3c015473-40ce-4fe3-b438-c67a1b70ce63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_EquityMethodInvestments_3c015473-40ce-4fe3-b438-c67a1b70ce63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_81f4497f-ab28-43a4-b5b2-083612e74d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_81f4497f-ab28-43a4-b5b2-083612e74d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ba59842b-bc86-48b1-927c-3c52379e37b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ba59842b-bc86-48b1-927c-3c52379e37b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_84dd0f53-6e87-4108-bd6d-4556957681cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_84dd0f53-6e87-4108-bd6d-4556957681cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8ff1b56f-0fbd-4f5b-abd0-b7ec1c97158f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ab24870b-a40a-4458-89a9-0ef8dc355b71" xlink:to="loc_us-gaap_Assets_8ff1b56f-0fbd-4f5b-abd0-b7ec1c97158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55f6caab-9745-4dd7-b809-4083f991dd26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dd4d8ad4-25de-4f72-b5ee-75eae77dbf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_AccountsPayableCurrent_dd4d8ad4-25de-4f72-b5ee-75eae77dbf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48f7488f-08a4-4239-9b95-51d341451911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_48f7488f-08a4-4239-9b95-51d341451911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c6dc06a0-5854-4f49-9c4a-ffa6ae8df19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c6dc06a0-5854-4f49-9c4a-ffa6ae8df19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a76390-b102-4c69-81dd-3f5ac5fb89bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a76390-b102-4c69-81dd-3f5ac5fb89bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_5f2ef92e-bbef-4511-a964-5cc2aff36503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_LinesOfCreditCurrent_5f2ef92e-bbef-4511-a964-5cc2aff36503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b455353e-69f2-4352-a697-ebf74195c948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_LongTermDebtCurrent_b455353e-69f2-4352-a697-ebf74195c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_65bd8f5c-b62d-44cd-af8c-058afdce20ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_65bd8f5c-b62d-44cd-af8c-058afdce20ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e6940472-7b5f-4959-9e90-0172d03fc345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e6940472-7b5f-4959-9e90-0172d03fc345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a116a4aa-bc1b-4420-a100-d558c355c1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_a116a4aa-bc1b-4420-a100-d558c355c1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_08876970-09db-4cec-b803-3d5517e81e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b7464f1e-7ccf-4b87-83f3-3d9f7cb3ad78" xlink:to="loc_us-gaap_LiabilitiesCurrent_08876970-09db-4cec-b803-3d5517e81e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f450e1a1-30dc-4a7e-8073-6c174ffeb2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f450e1a1-30dc-4a7e-8073-6c174ffeb2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_beb59992-7688-45c8-8a62-51e45491957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_beb59992-7688-45c8-8a62-51e45491957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_067cbb90-7e51-4e8e-bdc3-742d826d5749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_067cbb90-7e51-4e8e-bdc3-742d826d5749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5697ea4-eb1c-43eb-bf86-6e886df22517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5697ea4-eb1c-43eb-bf86-6e886df22517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_87f1b099-e324-4748-92d2-874db66883ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_87f1b099-e324-4748-92d2-874db66883ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d346c4e5-6d89-4abf-b6ed-090b744ebcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_d346c4e5-6d89-4abf-b6ed-090b744ebcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7576d867-5344-42f0-861e-192798b6cf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_Liabilities_7576d867-5344-42f0-861e-192798b6cf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_956fb5cd-6b9d-4a1b-b3c0-4b7d6838c150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_956fb5cd-6b9d-4a1b-b3c0-4b7d6838c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_130f1395-0472-4d8c-8318-8c8f7ff83350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:to="loc_us-gaap_CommonStockValueOutstanding_130f1395-0472-4d8c-8318-8c8f7ff83350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8e213a61-369f-4755-ab4d-863d3c2beeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8e213a61-369f-4755-ab4d-863d3c2beeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01aa3fed-78c4-4412-998d-55d6c41f488a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_01aa3fed-78c4-4412-998d-55d6c41f488a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_235c43c4-6b44-43eb-9d0d-3cf1e006d711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_235c43c4-6b44-43eb-9d0d-3cf1e006d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ba14cea-2453-48b6-aa29-a5c1638749c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9522bbae-2473-4edb-9c16-b2ba4072d577" xlink:to="loc_us-gaap_StockholdersEquity_2ba14cea-2453-48b6-aa29-a5c1638749c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fdbff242-03c8-4869-a404-7164b084a5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26856ed0-5ecb-4e17-acf7-4ed77f5ece8c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fdbff242-03c8-4869-a404-7164b084a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d8a6b64f-ee10-49c3-a05a-5ce735ed4c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d8a6b64f-ee10-49c3-a05a-5ce735ed4c43" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0c1e9ff5-e947-403a-bb7a-1650647b4823" xlink:to="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_6d4ba452-bf6d-4f8f-a1fe-a532aade794d" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d71a6e8c-b126-44bb-8d36-e3775dbbd842" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_6d4ba452-bf6d-4f8f-a1fe-a532aade794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8158af61-da97-4ee8-a525-08ed2ed9dbca" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_18712066-036f-4c44-ba7b-c950bc1b7dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_18712066-036f-4c44-ba7b-c950bc1b7dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_df8d894c-184a-4b39-a43d-ad27f3d797a1" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent_df8d894c-184a-4b39-a43d-ad27f3d797a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a45de100-073f-41ea-9c18-c06396740636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a45de100-073f-41ea-9c18-c06396740636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d39e7963-8eb2-4a9b-9fec-8a8cf3411b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_LongTermDebtCurrent_d39e7963-8eb2-4a9b-9fec-8a8cf3411b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dc92e7d9-f1a4-43c6-bec8-5ef410cc0458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dc92e7d9-f1a4-43c6-bec8-5ef410cc0458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f887f93-f124-4b6a-bea8-d4a8e8e04787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1f887f93-f124-4b6a-bea8-d4a8e8e04787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1b754b80-2f99-404d-bcef-a9fa7063d8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1b754b80-2f99-404d-bcef-a9fa7063d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e61b0694-02b4-4e87-857d-7f987bf3c967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesIssued_e61b0694-02b4-4e87-857d-7f987bf3c967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1cbe9674-d356-46aa-9aeb-7d7e46d18467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_651119fa-6888-4c92-8010-cc7e374690c9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1cbe9674-d356-46aa-9aeb-7d7e46d18467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0e97ac7e-30e4-4fa2-9ffe-cd04058fc441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0e97ac7e-30e4-4fa2-9ffe-cd04058fc441" xlink:to="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_831eca24-cc3b-4993-b6f5-9f28e181ea85" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_825e71c7-c6bd-4d66-a492-815175bea4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_4509d4d7-33eb-44f7-95e6-5662440bd925" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_825e71c7-c6bd-4d66-a492-815175bea4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e66d6650-229f-42d0-8af9-a3a8aecce35f" xlink:to="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c43ff0be-0384-4591-898f-0530a6ad0ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_us-gaap_ProductMember_c43ff0be-0384-4591-898f-0530a6ad0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6b5aa0b6-3c1b-4fa0-983e-542cb74e0dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_us-gaap_ServiceMember_6b5aa0b6-3c1b-4fa0-983e-542cb74e0dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherMember_481275c9-5a7b-43ec-bfa2-9c7f0f54db00" xlink:href="pgen-20201231.xsd#pgen_OtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feeeafc2-e1fd-4709-bfd6-bb08dc6a9292" xlink:to="loc_pgen_OtherMember_481275c9-5a7b-43ec-bfa2-9c7f0f54db00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9e9039be-5c76-4a42-b35c-6cf8ffe09553" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_59ca5168-9fb3-4e95-98f3-4a003b8c6208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a946e39d-838c-4a9e-b493-8a5c5578e37d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_59ca5168-9fb3-4e95-98f3-4a003b8c6208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ba0f9e0c-9be5-49a8-af3f-226e7826efb6" xlink:to="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c6c6be5-c8ee-4780-a744-ae01124fd7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_92692df4-d197-499b-b53b-bcf0600230b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c6c6be5-c8ee-4780-a744-ae01124fd7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5c71cfcd-97d1-4579-a43f-ebb28268af26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5c71cfcd-97d1-4579-a43f-ebb28268af26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b92b148f-4c05-4b5c-aa5a-c01e3fea8c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b92b148f-4c05-4b5c-aa5a-c01e3fea8c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dcf9e771-068f-4ed5-a393-519c694a7b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dcf9e771-068f-4ed5-a393-519c694a7b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2ce7834f-cfdb-417c-86e0-894c4fda82f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2ce7834f-cfdb-417c-86e0-894c4fda82f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_7491dee8-2031-4a18-b94c-6fdb178175dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_7491dee8-2031-4a18-b94c-6fdb178175dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_196e57ca-2c90-43df-9db7-d29d83dcd115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b55ce6a8-f848-4ea0-9a0f-4b7bb997cf73" xlink:to="loc_us-gaap_OperatingExpenses_196e57ca-2c90-43df-9db7-d29d83dcd115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_04b0dd97-0773-463f-a364-143278b9ea73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_OperatingIncomeLoss_04b0dd97-0773-463f-a364-143278b9ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cd31d639-4aee-423d-89eb-dd34edbcbf06" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cd31d639-4aee-423d-89eb-dd34edbcbf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_49e7f062-6e7e-433c-b527-e097d07db228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_InterestExpense_49e7f062-6e7e-433c-b527-e097d07db228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9d571cea-cc93-4fcb-a398-7f0680f1a386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9d571cea-cc93-4fcb-a398-7f0680f1a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3b1beaf0-3d51-422d-9dd8-a8d16de2f742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3b1beaf0-3d51-422d-9dd8-a8d16de2f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0c72782d-6737-4b17-9b43-cb5ad8a7f202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e354376c-fb14-404b-b07f-2ce29e532805" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0c72782d-6737-4b17-9b43-cb5ad8a7f202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_783dd99e-6c6c-4f7a-9c51-6a958530e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_783dd99e-6c6c-4f7a-9c51-6a958530e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a43737f9-bd0d-4cca-8b44-38f2be82e231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a43737f9-bd0d-4cca-8b44-38f2be82e231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_90bf1748-fe7e-485e-93ef-d9049800249f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_90bf1748-fe7e-485e-93ef-d9049800249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dae8c117-8288-4029-ab16-588b66afbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dae8c117-8288-4029-ab16-588b66afbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_945680d8-6ecd-433e-b951-0a2045561f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_945680d8-6ecd-433e-b951-0a2045561f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ec043867-3f8e-488b-a109-9c810fbf6b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_ProfitLoss_ec043867-3f8e-488b-a109-9c810fbf6b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dcf63e3b-8878-4adf-9eb2-328b817d97ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dcf63e3b-8878-4adf-9eb2-328b817d97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ffa62f2-81c0-4e1c-8295-731a7dfabcd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_NetIncomeLoss_3ffa62f2-81c0-4e1c-8295-731a7dfabcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_6b3b1e93-c31d-48c3-9642-39b6604e6829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_6b3b1e93-c31d-48c3-9642-39b6604e6829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_654364aa-5e0e-4d9a-ada2-099c3fa3810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_654364aa-5e0e-4d9a-ada2-099c3fa3810b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f842451-571a-433c-aea0-5b62160b2197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_384698b5-eeae-4dda-8ac3-dddd485c1924" xlink:to="loc_us-gaap_NetIncomeLoss_8f842451-571a-433c-aea0-5b62160b2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8c5b38e9-7c88-4d70-ac08-0cfbdb2e99db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_8c5b38e9-7c88-4d70-ac08-0cfbdb2e99db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_cb793589-4838-4eb8-8670-2bc2b256871e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_cb793589-4838-4eb8-8670-2bc2b256871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_67b9ee70-5de5-4411-91d9-ea76f402f743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_d0237acd-9752-495c-b7e3-a6b342fd0663" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_67b9ee70-5de5-4411-91d9-ea76f402f743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_124365e2-a973-47c2-896b-90e526ed4a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f87d8fb-9e0e-4522-b917-8271cccfb82b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_124365e2-a973-47c2-896b-90e526ed4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperations_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperations_1"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperations_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7c244ac2-6bb6-4709-aed1-b8e5cb8b3604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7c244ac2-6bb6-4709-aed1-b8e5cb8b3604" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_2788c35e-90f8-4a55-8535-26e6aefd0907" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_4445e4b6-0aa7-4294-ae51-c9a2e54f6ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_f67d1afe-32b8-4952-9d70-79cbd07c909c" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_4445e4b6-0aa7-4294-ae51-c9a2e54f6ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9c2c4bd2-cb4c-4694-84b9-c469b748d52c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_10a6c2ee-d17d-48a7-be9a-99e4137f5d25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5de61e34-739d-44f6-8bd3-74352c152636" xlink:to="loc_us-gaap_CollaborativeArrangementMember_10a6c2ee-d17d-48a7-be9a-99e4137f5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f8247135-2562-4841-b666-6d0868ad86c8" xlink:to="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_6ffdf392-f54e-4953-982a-da3e304866a1" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_00988e38-c2f2-49f2-87b4-6fa8131991c1" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_6ffdf392-f54e-4953-982a-da3e304866a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b43a007-c6e2-481b-b7b1-638463fc78fc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177a1eb9-2533-4e19-a0d8-8ed8ebfde312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dd4d6962-22a7-4285-baeb-d45c34ed566b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177a1eb9-2533-4e19-a0d8-8ed8ebfde312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="pgen-20201231.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e422192-4ae4-4b58-b6f7-8c82712b0223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:to="loc_us-gaap_ProfitLoss_5e422192-4ae4-4b58-b6f7-8c82712b0223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_16cb61d4-5c65-4317-a0f3-3cbbb2cce2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_16cb61d4-5c65-4317-a0f3-3cbbb2cce2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74afa67d-ee1a-4ad3-a5ae-33582345523d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_16cb61d4-5c65-4317-a0f3-3cbbb2cce2d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74afa67d-ee1a-4ad3-a5ae-33582345523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f58fd61e-1231-45d5-898d-6231c16bf3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_16cb61d4-5c65-4317-a0f3-3cbbb2cce2d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_f58fd61e-1231-45d5-898d-6231c16bf3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1c3dedc3-6f8b-445c-8cb9-4730e4a123f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_16cb61d4-5c65-4317-a0f3-3cbbb2cce2d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1c3dedc3-6f8b-445c-8cb9-4730e4a123f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e0d1364-ba75-4cb1-a9d8-338e3a0fe802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7e0d1364-ba75-4cb1-a9d8-338e3a0fe802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_58a6c794-bab2-4e84-8bed-706ef6abe453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_58a6c794-bab2-4e84-8bed-706ef6abe453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9fa9f04-595c-4830-a03b-a85c8161b56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_42b52eeb-3272-4885-b4af-5e81ff5919c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b9fa9f04-595c-4830-a03b-a85c8161b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofShareholdersandTotalEquity"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8e90e20e-948f-4794-8ba4-3e7d99c2c0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8e90e20e-948f-4794-8ba4-3e7d99c2c0de" xlink:to="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648ede39-45d4-43b2-8e8f-6bfb30d1fbc9" xlink:to="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:to="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_126d63da-cd78-486a-a8a4-c106b13130c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_CommonStockMember_126d63da-cd78-486a-a8a4-c106b13130c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ea9e4c5-1b7d-4f88-a8f2-b46cb59c848d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ea9e4c5-1b7d-4f88-a8f2-b46cb59c848d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_777dceeb-7484-474c-a6ce-f743e6b63c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_777dceeb-7484-474c-a6ce-f743e6b63c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a9e9534c-8829-49a3-ab5b-8cde68414662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_caeb23fe-b300-4bf6-b5de-cbbe18cf8dc2" xlink:to="loc_us-gaap_RetainedEarningsMember_a9e9534c-8829-49a3-ab5b-8cde68414662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_da7270c9-db5e-4586-8291-bf7a74a04a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad99ef79-7d68-4c8b-baec-d8e86c6ef2ac" xlink:to="loc_us-gaap_NoncontrollingInterestMember_da7270c9-db5e-4586-8291-bf7a74a04a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_18b68c14-ddb9-4aaa-996a-e21e8cd2d15d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af47f082-ba0b-4b15-aa67-8d972181752a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c0b12ed5-fbc7-417f-bd06-79c9b87c06c4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_af47f082-ba0b-4b15-aa67-8d972181752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09b46ab5-fcbe-46b4-9788-bd57bddc0624" xlink:to="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f21db2fe-7daf-4a4d-b46f-819904410b58" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32121acd-d9db-4615-a5a6-811bd275cff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32121acd-d9db-4615-a5a6-811bd275cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc40ddf5-65d7-4d1e-95aa-7fe72e0a7fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc40ddf5-65d7-4d1e-95aa-7fe72e0a7fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_983516f7-3605-46c0-b95e-2a0bd04bff2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_983516f7-3605-46c0-b95e-2a0bd04bff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_591868a7-f69c-4ea9-b322-c2dfbf74f9f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_591868a7-f69c-4ea9-b322-c2dfbf74f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_ee364fd5-9a13-4f2f-b97d-5ba4b78cb3e0" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_ee364fd5-9a13-4f2f-b97d-5ba4b78cb3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_c988f865-564f-482b-9bcc-217031d1b416" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards_c988f865-564f-482b-9bcc-217031d1b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_d852f1a1-3c97-45ff-a4ff-9794315006af" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised_d852f1a1-3c97-45ff-a4ff-9794315006af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_576371fe-5889-41e7-9635-b08744d759b7" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards_576371fe-5889-41e7-9635-b08744d759b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_3d449c84-c038-40e4-b021-517728f975ad" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodValueAccruedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringThePeriodValueAccruedCompensation_3d449c84-c038-40e4-b021-517728f975ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_fec6cbc9-e674-4581-9f4a-18c27ee952cf" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringThePeriodSharesAccruedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation_fec6cbc9-e674-4581-9f4a-18c27ee952cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_da26e143-5af3-4480-b42b-a1ae47e47fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_da26e143-5af3-4480-b42b-a1ae47e47fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_129561c3-c190-4160-864e-bcfcba88b706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_129561c3-c190-4160-864e-bcfcba88b706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d99e9a4-43a3-4791-bbb8-5ec06a7613a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d99e9a4-43a3-4791-bbb8-5ec06a7613a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ea68390-9327-4c77-ba2d-b7045b9c9b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ea68390-9327-4c77-ba2d-b7045b9c9b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3ed19391-901c-454b-a177-548bfcc288b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_3ed19391-901c-454b-a177-548bfcc288b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_85f3f842-976a-4b38-a344-1588a276c92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_85f3f842-976a-4b38-a344-1588a276c92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3d39c258-58d1-4288-96da-05017c8827c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3d39c258-58d1-4288-96da-05017c8827c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_e63ef13f-97f5-4e47-936a-57a29eebac49" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_e63ef13f-97f5-4e47-936a-57a29eebac49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_558e607e-ee16-4937-a9c8-09e0972771dc" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_558e607e-ee16-4937-a9c8-09e0972771dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OwnshareLendingArrangementSharesIssued1_012257c0-3e67-47bc-ae2e-5e52840db60e" xlink:href="pgen-20201231.xsd#pgen_OwnshareLendingArrangementSharesIssued1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_OwnshareLendingArrangementSharesIssued1_012257c0-3e67-47bc-ae2e-5e52840db60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_86fcad6c-b591-469f-9d44-f6769cec3d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_86fcad6c-b591-469f-9d44-f6769cec3d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_dd96d145-6cad-4f11-8cab-32829280264d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_dd96d145-6cad-4f11-8cab-32829280264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_Adjustmentsfornoncontrollinginterests_6825001a-fe2a-46d4-8fbe-23d61d973e52" xlink:href="pgen-20201231.xsd#pgen_Adjustmentsfornoncontrollinginterests"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_pgen_Adjustmentsfornoncontrollinginterests_6825001a-fe2a-46d4-8fbe-23d61d973e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_b136c131-31e5-4f49-8fe8-98119c0d07d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_b136c131-31e5-4f49-8fe8-98119c0d07d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b51069f2-2143-42ee-bbc6-7f494d8cec98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_ProfitLoss_b51069f2-2143-42ee-bbc6-7f494d8cec98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_ae780ddc-1e3f-4932-8f66-6712a32d42fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_ae780ddc-1e3f-4932-8f66-6712a32d42fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bdcfb7d9-6177-44cc-a26e-999b99754fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bdcfb7d9-6177-44cc-a26e-999b99754fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43f72e68-ea42-48cd-9261-4b1467e1380f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43f72e68-ea42-48cd-9261-4b1467e1380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a68d11ed-685c-47af-99ca-8d430ad5e009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8190ad93-5e60-432a-a81b-71fb2b835132" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a68d11ed-685c-47af-99ca-8d430ad5e009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_87fa96d0-8d27-4aa7-80c3-ed8fe6088911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:to="loc_us-gaap_ProfitLoss_87fa96d0-8d27-4aa7-80c3-ed8fe6088911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f7e4c135-4804-4856-8c8c-7cf7a1e3c8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f7e4c135-4804-4856-8c8c-7cf7a1e3c8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_72f85eb3-a8a1-4bd6-8122-3dffcfa2ab65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_72f85eb3-a8a1-4bd6-8122-3dffcfa2ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cb73e999-ca50-4e3a-ab0a-4db71cdc9f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cb73e999-ca50-4e3a-ab0a-4db71cdc9f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_09864c1b-1871-4118-90e2-627044e95c0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_09864c1b-1871-4118-90e2-627044e95c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_79365fad-72b0-4523-ac2f-152b03e26672" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_79365fad-72b0-4523-ac2f-152b03e26672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_b7fdb857-523a-45b3-b662-c7165607a389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_b7fdb857-523a-45b3-b662-c7165607a389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_27af6a0c-4ee9-4a73-bfe7-50264e7dffe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_27af6a0c-4ee9-4a73-bfe7-50264e7dffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_f3de521a-5e47-401a-9540-fa8ceda519bb" xlink:href="pgen-20201231.xsd#pgen_GainLossRelatedToNoncashLitigationSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_f3de521a-5e47-401a-9540-fa8ceda519bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_ef7cd48b-e052-4aaf-a8dc-ab3ca26e1979" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_ef7cd48b-e052-4aaf-a8dc-ab3ca26e1979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_ef69d71a-edc1-4b7a-ad3c-889507ee966b" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_pgen_NoncashDividendIncome_ef69d71a-edc1-4b7a-ad3c-889507ee966b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8cd04b17-5c84-4099-9d8a-b4d08656db52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8cd04b17-5c84-4099-9d8a-b4d08656db52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a9e13a2a-736e-47c8-ba3e-1e39685afb74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a9e13a2a-736e-47c8-ba3e-1e39685afb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0b4e3283-4a89-4a48-918e-7ce0177a1aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_ShareBasedCompensation_0b4e3283-4a89-4a48-918e-7ce0177a1aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_85236b62-258b-45f7-9036-bb368fd392c6" xlink:href="pgen-20201231.xsd#pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_85236b62-258b-45f7-9036-bb368fd392c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_57bdc1e3-b1f4-4a11-af88-fd28183118c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_57bdc1e3-b1f4-4a11-af88-fd28183118c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_18fe3a4d-70ca-4f5d-abb9-aaa10b248c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_18fe3a4d-70ca-4f5d-abb9-aaa10b248c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af093b4b-4d80-42dd-85d7-50beb883a5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af093b4b-4d80-42dd-85d7-50beb883a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_571436a2-dba4-4554-93cd-68609ef826a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16734cc2-e41d-4684-8706-78b00cc2f487" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_571436a2-dba4-4554-93cd-68609ef826a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract_e70b278a-8cdf-4212-bf07-5ad21d2f7d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivablesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract_e70b278a-8cdf-4212-bf07-5ad21d2f7d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1749c7f2-d996-4341-901b-c7820ae5bccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract_e70b278a-8cdf-4212-bf07-5ad21d2f7d78" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1749c7f2-d996-4341-901b-c7820ae5bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_a9c84cfb-56bc-4352-a208-65294c217eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract_e70b278a-8cdf-4212-bf07-5ad21d2f7d78" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_a9c84cfb-56bc-4352-a208-65294c217eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48af9af9-4e03-4fbe-a515-3f76c8e00e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivablesAbstract_e70b278a-8cdf-4212-bf07-5ad21d2f7d78" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_48af9af9-4e03-4fbe-a515-3f76c8e00e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5ff5a35e-a75c-4178-8d4a-0f27a0eeed82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5ff5a35e-a75c-4178-8d4a-0f27a0eeed82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78a00359-09f3-48e3-8b28-d23c13d561f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78a00359-09f3-48e3-8b28-d23c13d561f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bf4b79dc-88fa-40c0-894f-96bcd4907ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bf4b79dc-88fa-40c0-894f-96bcd4907ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_4b16fb1a-2f26-4eb2-85f3-40401594237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_4b16fb1a-2f26-4eb2-85f3-40401594237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b0f906-a397-47aa-bb55-80def6d930bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_f8b0f906-a397-47aa-bb55-80def6d930bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a8e4e72d-918c-403e-a3ab-e74079577aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a8e4e72d-918c-403e-a3ab-e74079577aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a3f71fa9-35ee-46eb-9c70-5648e8b8f866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a3f71fa9-35ee-46eb-9c70-5648e8b8f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncreaseDecreaseInLeaseLiabilities_536dab56-1554-41e2-9e33-639ad0f8df4a" xlink:href="pgen-20201231.xsd#pgen_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_pgen_IncreaseDecreaseInLeaseLiabilities_536dab56-1554-41e2-9e33-639ad0f8df4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_81339297-b1cc-418e-9c03-74a1a168ca68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_81339297-b1cc-418e-9c03-74a1a168ca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6093dc4e-82df-422d-847b-f8fb488c2daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ed65a0e-5b2f-4218-bd85-610455f5966a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_6093dc4e-82df-422d-847b-f8fb488c2daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee5cdeee-61e2-4083-8cb6-5dd547dfb982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c7c16d1b-76a4-4251-8e1a-583fb3160a82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ee5cdeee-61e2-4083-8cb6-5dd547dfb982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_31d34afd-3b8c-438c-93ea-176680110e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_31d34afd-3b8c-438c-93ea-176680110e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_556087f7-6081-4a63-a758-7ba13e2b70f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_556087f7-6081-4a63-a758-7ba13e2b70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_eb0b0e39-7f20-4cb9-94e6-194d76431be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_eb0b0e39-7f20-4cb9-94e6-194d76431be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_828b6725-23c6-4c3c-9710-b45de9a4d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_828b6725-23c6-4c3c-9710-b45de9a4d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_88965b54-28c0-4123-b8d6-3bdd1c432c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_88965b54-28c0-4123-b8d6-3bdd1c432c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_b0a04dd0-40f2-40e8-8119-3271a893fc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_b0a04dd0-40f2-40e8-8119-3271a893fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_fc79523a-48d1-4577-9ed8-f610f67a4e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_fc79523a-48d1-4577-9ed8-f610f67a4e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CashInflowsOutflowsInAssetAcquisition_594c9b15-f0b0-4137-8af6-3a57593c4167" xlink:href="pgen-20201231.xsd#pgen_CashInflowsOutflowsInAssetAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_pgen_CashInflowsOutflowsInAssetAcquisition_594c9b15-f0b0-4137-8af6-3a57593c4167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11da63a4-4a78-41bf-84e7-6f0e86508928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11da63a4-4a78-41bf-84e7-6f0e86508928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_6a443415-b6c3-4362-b397-0c87aa8941f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_6a443415-b6c3-4362-b397-0c87aa8941f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5da52182-5821-46ac-87f4-0acb775c9e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5da52182-5821-46ac-87f4-0acb775c9e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_958cb931-4c7b-4c2b-80ac-c1efa08d7431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_958cb931-4c7b-4c2b-80ac-c1efa08d7431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_431df9e2-96df-468d-ac0a-3ca015d98feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcda0bc9-aa6d-4917-86d8-9904207888ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_431df9e2-96df-468d-ac0a-3ca015d98feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_80cd5846-e81f-4706-8ff5-92571966ed08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_80cd5846-e81f-4706-8ff5-92571966ed08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_a9799b21-5c52-43f8-bf70-e78a6c32abc7" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet_a9799b21-5c52-43f8-bf70-e78a6c32abc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_76ade5e8-ae8f-411c-8ae7-09b405ded30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_76ade5e8-ae8f-411c-8ae7-09b405ded30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2c999641-2ff3-4e0d-8bbe-7c5c7c651a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2c999641-2ff3-4e0d-8bbe-7c5c7c651a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3adbffc2-988e-48c4-bf1d-f7e7b80bb950" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3adbffc2-988e-48c4-bf1d-f7e7b80bb950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c054be1a-2454-4018-84f1-244e11544d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c054be1a-2454-4018-84f1-244e11544d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised_95e44a68-556d-4242-affe-b376a6283897" xlink:href="pgen-20201231.xsd#pgen_ProceedsfromStockOptionsandWarrantsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_pgen_ProceedsfromStockOptionsandWarrantsExercised_95e44a68-556d-4242-affe-b376a6283897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72539a61-e7b1-4349-9e14-2b13bb42e157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ae1901e3-92f8-4060-b899-f348579f2c0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72539a61-e7b1-4349-9e14-2b13bb42e157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d4d9ea2-f8c0-4d11-9243-1727b38655c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d4d9ea2-f8c0-4d11-9243-1727b38655c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e8d6a14b-b44b-435c-ad29-b9fa6f6df4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e8d6a14b-b44b-435c-ad29-b9fa6f6df4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d1f09854-88f6-4d45-8676-4e33e4be8a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_d1f09854-88f6-4d45-8676-4e33e4be8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2118c7b8-218a-4f89-aa92-6332b7f93c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d1f09854-88f6-4d45-8676-4e33e4be8a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2118c7b8-218a-4f89-aa92-6332b7f93c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55790df5-130a-41f8-9b33-ad4be409bd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d1f09854-88f6-4d45-8676-4e33e4be8a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55790df5-130a-41f8-9b33-ad4be409bd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f3d5bffe-53d7-4d72-bf22-a0c3f9793b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f3d5bffe-53d7-4d72-bf22-a0c3f9793b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_98ae23f9-d8e4-45d4-9100-291516744a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f3d5bffe-53d7-4d72-bf22-a0c3f9793b0b" xlink:to="loc_us-gaap_InterestPaidNet_98ae23f9-d8e4-45d4-9100-291516744a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_05859cc8-39e0-4914-b025-3505ba310581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f3d5bffe-53d7-4d72-bf22-a0c3f9793b0b" xlink:to="loc_us-gaap_IncomeTaxesPaid_05859cc8-39e0-4914-b025-3505ba310581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3d6140b-4770-41e4-87dd-5000f99d25cd" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockReceivedAsConsiderationForCollaborationAgreements_29a98683-c9a0-497a-9ff0-e6dfe3057352" xlink:href="pgen-20201231.xsd#pgen_StockReceivedAsConsiderationForCollaborationAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_pgen_StockReceivedAsConsiderationForCollaborationAgreements_29a98683-c9a0-497a-9ff0-e6dfe3057352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedIntangibleAssets_6e332255-50c4-44c7-8f3c-5d544eddbf13" xlink:href="pgen-20201231.xsd#pgen_StockIssuedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_pgen_StockIssuedIntangibleAssets_6e332255-50c4-44c7-8f3c-5d544eddbf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_c2086891-e858-46a6-95e4-0bf0b3e4964c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_us-gaap_StockIssued1_c2086891-e858-46a6-95e4-0bf0b3e4964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedSettlementAgreement_d5af8a45-2ec3-40b4-bb8a-274d1678fe96" xlink:href="pgen-20201231.xsd#pgen_StockIssuedSettlementAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_pgen_StockIssuedSettlementAgreement_d5af8a45-2ec3-40b4-bb8a-274d1678fe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_9b4cb80c-1ac3-468e-ab58-edc3f275d43c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_9b4cb80c-1ac3-468e-ab58-edc3f275d43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccruedCompensationPaidinEquityAwards_5f6d30bc-35b7-4ddf-9ece-7c75237c5032" xlink:href="pgen-20201231.xsd#pgen_AccruedCompensationPaidinEquityAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_pgen_AccruedCompensationPaidinEquityAwards_5f6d30bc-35b7-4ddf-9ece-7c75237c5032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96a10239-ed50-4573-91b3-f3bfa2024147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96a10239-ed50-4573-91b3-f3bfa2024147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_602f016b-5fa4-4bdc-8963-8d2220d4514d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_us-gaap_LiabilitiesAssumed1_602f016b-5fa4-4bdc-8963-8d2220d4514d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SaleOfAssetsIncludedInReceivables_40f42d22-b01c-4601-8b4a-4206595f44f1" xlink:href="pgen-20201231.xsd#pgen_SaleOfAssetsIncludedInReceivables"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_83f927b8-b530-4773-b915-cfa9bf22e45f" xlink:to="loc_pgen_SaleOfAssetsIncludedInReceivables_40f42d22-b01c-4601-8b4a-4206595f44f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="simple" xlink:href="pgen-20201231.xsd#ConsolidatedStatementsofCashFlowsReconciliationofCash"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_387acb5f-4aba-47df-83d8-1efa27abfe58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43bdc025-865d-4881-ad51-e5f4e9d07ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387acb5f-4aba-47df-83d8-1efa27abfe58" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43bdc025-865d-4881-ad51-e5f4e9d07ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_f880dc26-3cef-4719-b74f-5c383dc5a619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387acb5f-4aba-47df-83d8-1efa27abfe58" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_f880dc26-3cef-4719-b74f-5c383dc5a619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7481d4e8-776e-43c1-9b63-d2c5c962b7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387acb5f-4aba-47df-83d8-1efa27abfe58" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7481d4e8-776e-43c1-9b63-d2c5c962b7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a057654a-01a9-46a9-a40e-cf4ccdb0adfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_387acb5f-4aba-47df-83d8-1efa27abfe58" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a057654a-01a9-46a9-a40e-cf4ccdb0adfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db10b858-dae5-401b-92d5-47fa40a681bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0fe9d4aa-6128-484b-979b-c549944d2102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_db10b858-dae5-401b-92d5-47fa40a681bb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0fe9d4aa-6128-484b-979b-c549944d2102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OrganizationandBasisofPresentationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_9578ebf3-3715-4bf4-a9b6-102dcf66c92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_9578ebf3-3715-4bf4-a9b6-102dcf66c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_d3d2b260-b554-4d17-8ada-f61be84ae973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_d3d2b260-b554-4d17-8ada-f61be84ae973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_92169be6-4b15-42f8-84c7-47c8ade742c7" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_92169be6-4b15-42f8-84c7-47c8ade742c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad0b5362-8e0c-437c-b228-dbfdee00f141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:to="loc_us-gaap_NetIncomeLoss_ad0b5362-8e0c-437c-b228-dbfdee00f141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b927eee-cb1f-492f-8404-7baaad2dde8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a0ea17fc-78fd-40a5-a731-660c9932f60f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b927eee-cb1f-492f-8404-7baaad2dde8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7238553d-f060-40b2-9faf-f8a96d391cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f0418a88-248e-4487-a5f4-b38d041c6a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7238553d-f060-40b2-9faf-f8a96d391cc5" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f0418a88-248e-4487-a5f4-b38d041c6a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_794221d1-f6d3-4505-80fe-4877b5c221a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_794221d1-f6d3-4505-80fe-4877b5c221a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_940562ad-bc2b-4ee5-b919-1a9125137430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_940562ad-bc2b-4ee5-b919-1a9125137430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7cb6f9d9-f8f5-446f-be08-639b13265ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7cb6f9d9-f8f5-446f-be08-639b13265ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0d0a1fe4-058a-4536-9c98-383e2a2775b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0d0a1fe4-058a-4536-9c98-383e2a2775b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_11b50d1b-d4e9-463b-a14a-1a56a6ea020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_11b50d1b-d4e9-463b-a14a-1a56a6ea020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesPolicyTextBlock_cd076b70-e7ec-42ed-885d-316c7fe5f471" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_pgen_EquitySecuritiesPolicyTextBlock_cd076b70-e7ec-42ed-885d-316c7fe5f471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_87c00b6b-41bc-48f2-bda7-c003b5a61c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_87c00b6b-41bc-48f2-bda7-c003b5a61c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c4f7e8b8-ad26-4dac-8788-6596f554cdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c4f7e8b8-ad26-4dac-8788-6596f554cdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_c5eeedf3-d937-4510-a8da-612439f9dd9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_c5eeedf3-d937-4510-a8da-612439f9dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_26bad276-4030-44ec-bdab-964d239eb928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_26bad276-4030-44ec-bdab-964d239eb928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_64e452c3-d2fe-46fe-b12c-4b0d23d1eb5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_64e452c3-d2fe-46fe-b12c-4b0d23d1eb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_49b2fb65-79c0-4b61-b5a7-7e087b2bd6cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_49b2fb65-79c0-4b61-b5a7-7e087b2bd6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e800ddea-453d-453f-883b-720d75d39609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e800ddea-453d-453f-883b-720d75d39609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8f4dea93-d244-47dc-962c-13af7c46abd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8f4dea93-d244-47dc-962c-13af7c46abd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fa020a8f-90e1-43c3-a383-a5dc6cd96cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_fa020a8f-90e1-43c3-a383-a5dc6cd96cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4e230a4b-f1e4-439a-86c5-ca56d239cde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_4e230a4b-f1e4-439a-86c5-ca56d239cde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_26866207-b1e4-4fac-9220-0fed0fa55172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_26866207-b1e4-4fac-9220-0fed0fa55172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_e4f72f76-9129-459f-a5d2-e2d4cb434fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_DebtPolicyTextBlock_e4f72f76-9129-459f-a5d2-e2d4cb434fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_efbf43e0-954f-4ea9-9304-45e7a7e29fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_efbf43e0-954f-4ea9-9304-45e7a7e29fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5bb27d7d-42a5-4f41-b38b-44a2cda6c85b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5bb27d7d-42a5-4f41-b38b-44a2cda6c85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cccfbbe5-7055-4bdf-872f-846a4f629c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cccfbbe5-7055-4bdf-872f-846a4f629c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_cddaa5e3-cac0-432f-9b6c-5fee9a612144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_cddaa5e3-cac0-432f-9b6c-5fee9a612144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b00a9791-5e1e-4188-b481-58fd2eceb642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b00a9791-5e1e-4188-b481-58fd2eceb642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3cd3a045-2186-4e01-bfc8-6f42cdc23516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_UseOfEstimates_3cd3a045-2186-4e01-bfc8-6f42cdc23516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_53bfc458-1cbe-4ca5-b1e8-5d1f4d190b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f948e99-1769-4c7c-bfa5-7ead30c94fd1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_53bfc458-1cbe-4ca5-b1e8-5d1f4d190b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48740aa3-5542-4cb6-bb41-1df3d24e8a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_c478d0f2-e25d-4384-8932-9aaa3e5bd12b" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48740aa3-5542-4cb6-bb41-1df3d24e8a29" xlink:to="loc_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_c478d0f2-e25d-4384-8932-9aaa3e5bd12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1f8fa7ae-c437-4f2b-96d9-d78c6b50848b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48740aa3-5542-4cb6-bb41-1df3d24e8a29" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1f8fa7ae-c437-4f2b-96d9-d78c6b50848b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_6508123d-393a-40bd-99aa-411d01c6b851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48740aa3-5542-4cb6-bb41-1df3d24e8a29" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_6508123d-393a-40bd-99aa-411d01c6b851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db18b326-a392-4ec4-8874-e269b94b1ba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:href="pgen-20201231.xsd#pgen_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db18b326-a392-4ec4-8874-e269b94b1ba9" xlink:to="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ff8e968-9e4b-47c0-990a-506f02bb27d7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_302b3a22-2e4f-4179-93e9-03a51630e4c4" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2430238a-cae0-4c1a-b826-23953239f484" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_302b3a22-2e4f-4179-93e9-03a51630e4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_51644b5c-c9b0-42fb-856b-5e633fb6e1d7" xlink:to="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationandlicensingagreementsMember_c28aa82f-893f-4ed0-a814-30f648ec2fa6" xlink:href="pgen-20201231.xsd#pgen_CollaborationandlicensingagreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:to="loc_pgen_CollaborationandlicensingagreementsMember_c28aa82f-893f-4ed0-a814-30f648ec2fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ProductsandServicesRevenuesMember_a7fbae9f-91ed-45c3-b0db-a9030fa103cd" xlink:href="pgen-20201231.xsd#pgen_ProductsandServicesRevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_06be8eaf-3f20-490e-8861-e1e83a0df7a1" xlink:to="loc_pgen_ProductsandServicesRevenuesMember_a7fbae9f-91ed-45c3-b0db-a9030fa103cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_80ecd6c4-abf9-4058-8dfe-744f9b01ab63" xlink:to="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_78ee8e26-783c-430c-9e85-9c0bd8a5d7c6" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a18beff7-d64d-4b54-9814-a4525ccec45f" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_78ee8e26-783c-430c-9e85-9c0bd8a5d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99cfca5e-55e8-48a7-9696-ffd1bbcdfd69" xlink:to="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50176dba-0681-486b-927a-fe485d9e4a51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:to="loc_srt_MinimumMember_50176dba-0681-486b-927a-fe485d9e4a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aee7cef7-fce8-4881-b084-3e3acbff8ebe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bcd9291b-1c21-4c17-9745-38a2a253c642" xlink:to="loc_srt_MaximumMember_aee7cef7-fce8-4881-b084-3e3acbff8ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:href="pgen-20201231.xsd#pgen_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryOfSignificantAccountingPoliciesTable_83c0be79-5627-40d4-b6c1-aa3e54b83a7d" xlink:to="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementTerminationNoticePeriod_a316057e-f578-4ee2-8903-46fd08f7363c" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementTerminationNoticePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_CollaborationAgreementTerminationNoticePeriod_a316057e-f578-4ee2-8903-46fd08f7363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_996a9d6a-eea4-41dc-a8b2-fac927d92330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_996a9d6a-eea4-41dc-a8b2-fac927d92330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_8a30942e-4040-4b0b-965b-da2f47bae07a" xlink:href="pgen-20201231.xsd#pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred_8a30942e-4040-4b0b-965b-da2f47bae07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_171cc394-11b7-4401-82ca-2eedeef25b2f" xlink:href="pgen-20201231.xsd#pgen_HighlyLiquidInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod_171cc394-11b7-4401-82ca-2eedeef25b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c120f161-dfd5-4514-8441-9093fc19f89c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_c120f161-dfd5-4514-8441-9093fc19f89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_5b1a1eab-018f-4c39-bd7a-ec02a085b20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount_5b1a1eab-018f-4c39-bd7a-ec02a085b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5a9e4b1c-583d-4274-8052-76ede146966b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5a9e4b1c-583d-4274-8052-76ede146966b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e75c2004-d628-47cd-90c8-535f7c327598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e75c2004-d628-47cd-90c8-535f7c327598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a15c03db-a3f9-41de-a7f5-6cfc2a9a86b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_OrganizationAndSignificantAccountingPoliciesLineItems_e977ef8f-67a0-4fb9-8d4f-d1f9369bd33d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a15c03db-a3f9-41de-a7f5-6cfc2a9a86b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8531a79e-03f1-47a6-80c3-2e44ca96652f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_b26eb6e1-ea6d-42d3-9c61-606fa1dbd98a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8531a79e-03f1-47a6-80c3-2e44ca96652f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_b26eb6e1-ea6d-42d3-9c61-606fa1dbd98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_b26eb6e1-ea6d-42d3-9c61-606fa1dbd98a" xlink:to="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1b0e8c-24cb-4d95-901e-7e6e826fa2b8" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_6d1ec04c-f6af-4667-9e05-24ade63468ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_40ab7231-b082-4754-a8f3-877f9cfc73a1" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_6d1ec04c-f6af-4667-9e05-24ade63468ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:href="pgen-20201231.xsd#pgen_AccountsReceivableAllowanceForCreditLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossTable_0cc2324b-4cc4-4fc9-96e1-d0e80019a7c7" xlink:to="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_98fe53df-06d1-413d-8abd-df65f14b65ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_98fe53df-06d1-413d-8abd-df65f14b65ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5b2e419e-5197-406e-a95d-30e427d2c58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5b2e419e-5197-406e-a95d-30e427d2c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2d79f1bb-ad77-498e-bc8e-20e4927b4181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2d79f1bb-ad77-498e-bc8e-20e4927b4181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0087afdd-398a-4668-883c-0e0fb9296d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_AccountsReceivableAllowanceForCreditLossLineItems_3f084be3-6de5-4a76-8715-83826857ff22" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_0087afdd-398a-4668-883c-0e0fb9296d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a743e147-77cb-428e-b88c-7061e3c757dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a743e147-77cb-428e-b88c-7061e3c757dc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:to="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c1be996-bbd0-4418-9577-9ae94f02c097" xlink:to="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c7b3f0e1-26b7-490f-8423-d540b7f21f0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:to="loc_srt_MinimumMember_c7b3f0e1-26b7-490f-8423-d540b7f21f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c50466f6-2db1-4e22-9b35-1905bac76c19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98f72202-c1f4-4ffa-b865-c37b274b29eb" xlink:to="loc_srt_MaximumMember_c50466f6-2db1-4e22-9b35-1905bac76c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_981abee4-4b2e-4ff0-90b3-d1f9063444db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_f1b99418-0d57-47ab-b9a6-40c69cce89c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_LandImprovementsMember_f1b99418-0d57-47ab-b9a6-40c69cce89c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_be28a3a0-810a-4d77-a8e9-83f577c59818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_be28a3a0-810a-4d77-a8e9-83f577c59818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0e17c9c3-07f9-46fb-9e49-5d1418f4f657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0e17c9c3-07f9-46fb-9e49-5d1418f4f657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_dcf44379-8ce5-427e-841f-6223f6a51ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_EquipmentMember_dcf44379-8ce5-427e-841f-6223f6a51ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BreedingAndProductionAnimalsMember_c4c057c4-beda-42b9-a7eb-f2470ce0adf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BreedingAndProductionAnimalsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_BreedingAndProductionAnimalsMember_c4c057c4-beda-42b9-a7eb-f2470ce0adf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftwareMember_8d730932-0bff-424e-a700-5f117dd85c80" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftwareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_pgen_ComputerHardwareandSoftwareMember_8d730932-0bff-424e-a700-5f117dd85c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3e26b2b2-33a1-4116-9f7a-b3de706350fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65aba4f9-e9e6-4079-a1b3-30e792a9ea75" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3e26b2b2-33a1-4116-9f7a-b3de706350fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_164e047d-d751-4a5f-b509-376642368c9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cbdb529d-f5b4-460f-ad33-ed50ae255d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c8e1f01-7c15-4570-8355-4d77782c37fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_cbdb529d-f5b4-460f-ad33-ed50ae255d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_293f8a18-3a88-4a97-8585-2fea5aa58da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_293f8a18-3a88-4a97-8585-2fea5aa58da1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:to="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5ede9366-70a4-4e57-be83-d70dd9b953f6" xlink:to="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_08ee7c05-0d3c-41f0-8168-8974d8801f6e" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_88b3b32e-f09a-4fbf-9a11-2c9fc6c3de07" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_08ee7c05-0d3c-41f0-8168-8974d8801f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:to="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a06ba27-0d85-4e35-80cc-d2227134ecb7" xlink:to="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65a88ab6-d762-4c90-a30d-60c399d3e7ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:to="loc_srt_MinimumMember_65a88ab6-d762-4c90-a30d-60c399d3e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9840fe6-7373-4c26-9e82-e8c7ddf037fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c112d6e-b563-43fa-9dce-0fdbabe42781" xlink:to="loc_srt_MaximumMember_e9840fe6-7373-4c26-9e82-e8c7ddf037fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_95e72aec-fa35-44c7-84ba-06f0f65487c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7bb497a-750b-46f6-8f98-0b24d85a0881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f7bb497a-750b-46f6-8f98-0b24d85a0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_297acc04-9e53-4b23-baf0-0239c03a5b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_297acc04-9e53-4b23-baf0-0239c03a5b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_567aff32-5e84-43f8-b2aa-41ccf30e61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_567aff32-5e84-43f8-b2aa-41ccf30e61ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4101fdb6-bbe3-406f-ab9f-8ec76801a632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4101fdb6-bbe3-406f-ab9f-8ec76801a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ea44905c-2d3a-4594-9283-0c67272b297b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ea44905c-2d3a-4594-9283-0c67272b297b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86a59c12-3a81-446f-a505-5ce49f484ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e671ae0a-f429-4392-9f03-7af0a3c91d1f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_86a59c12-3a81-446f-a505-5ce49f484ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4401deb1-7acf-40f0-bfe7-4648ca046514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_907c3ad9-4c27-4445-9330-9864ba4bd5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4401deb1-7acf-40f0-bfe7-4648ca046514" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_907c3ad9-4c27-4445-9330-9864ba4bd5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0125acc4-fa30-433a-8d9d-b718bdb2bcc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_68a36e32-c7f0-4315-9e0c-3fe914f1bf1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0125acc4-fa30-433a-8d9d-b718bdb2bcc0" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_68a36e32-c7f0-4315-9e0c-3fe914f1bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_af2589ce-0579-4a1f-b878-9ab7ea693787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_af2589ce-0579-4a1f-b878-9ab7ea693787" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66ca78b5-0593-4863-8819-f3bb2265831d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_00045082-6529-4ce8-9d0e-c07d6f509697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_944fadb9-2154-4357-aa2a-1073eb6e94c6" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_00045082-6529-4ce8-9d0e-c07d6f509697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2af8c617-f6ce-4048-8021-daeff856b90a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_95ce8bfb-2f7e-4e60-83b4-ce1fb86e738d" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a86c45e2-d23d-4107-a530-9b31ee182096" xlink:to="loc_pgen_MBPTitanMember_95ce8bfb-2f7e-4e60-83b4-ce1fb86e738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bc64ba16-b911-4b4a-96e7-c0844e5c75ba" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c461f8d0-16fe-425a-b68f-76125caa09b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_c461f8d0-16fe-425a-b68f-76125caa09b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c3f5d8b5-49f0-4fbf-92c8-c94fb4615fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c3f5d8b5-49f0-4fbf-92c8-c94fb4615fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_99f34ca9-26a8-4ef1-acf5-7e36fe80d563" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_99f34ca9-26a8-4ef1-acf5-7e36fe80d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2f9be42f-b436-46bf-abf5-92bafa064ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_2f9be42f-b436-46bf-abf5-92bafa064ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e0aba335-074c-4c68-9098-d715a74397e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5ed7e5fa-e263-4886-a4cd-6a7e585a58f2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e0aba335-074c-4c68-9098-d715a74397e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d92ceec5-4b44-41d7-b428-c011b5e3fad4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_dd3c57aa-1404-4d14-b938-6ba7b5c6fc59" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_dd3c57aa-1404-4d14-b938-6ba7b5c6fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_99ce6e06-0043-418c-8b0c-93be5dd42f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_99ce6e06-0043-418c-8b0c-93be5dd42f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_37588f4c-4d6f-4640-adf8-2b25b53bd54c" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_37588f4c-4d6f-4640-adf8-2b25b53bd54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4c306086-7195-41ee-8dec-c2879e248d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc4e847c-8560-419e-8010-38cd6d6687bb" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_4c306086-7195-41ee-8dec-c2879e248d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_53a4c79d-7878-4615-ad95-bf4ddb50a818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_53a4c79d-7878-4615-ad95-bf4ddb50a818" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10f16171-3945-49c8-be7c-d42c77903d7c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_0d2bbbb2-4831-496b-9fa6-4d65474c9d0b" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_544d2d2a-8f8b-4275-9b5d-266eea9eecbe" xlink:to="loc_pgen_MBPTitanMember_0d2bbbb2-4831-496b-9fa6-4d65474c9d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_69155bdb-d9bb-4e97-986f-2fe9001b3941" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_cd089b48-c158-4974-9599-ed5790dddb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_60180fd3-de12-4511-be80-53124acacc18" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_cd089b48-c158-4974-9599-ed5790dddb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_89b0de3b-8c19-4c92-94f2-8d2de86f63ff" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_c725df85-66eb-4514-a53f-16e1466b2dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_c725df85-66eb-4514-a53f-16e1466b2dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d6243ecb-0f31-4ff7-a7ff-f75e437ca1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_d6243ecb-0f31-4ff7-a7ff-f75e437ca1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_3d95ff6e-ee69-48af-af33-27047ad6c2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_3d95ff6e-ee69-48af-af33-27047ad6c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_48df57d0-c966-46c8-928d-f4dfc9d8ef09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_48df57d0-c966-46c8-928d-f4dfc9d8ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1885b18a-71fe-4818-8f5c-372621ece321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1885b18a-71fe-4818-8f5c-372621ece321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_25f3ab1c-4687-4d9f-87ad-0301cda37c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fd9a6d3-786f-4739-8196-4660d5e7d587" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_25f3ab1c-4687-4d9f-87ad-0301cda37c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_62eacd1b-66a8-476d-a975-eaa2c327dcc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_62eacd1b-66a8-476d-a975-eaa2c327dcc7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b6fdf9ce-641f-4514-80c4-13f7000f501d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_a3a55065-8fb9-4a4b-ab14-2eb80f388714" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_69ab98d8-b48e-4024-a8f0-a1587a754d81" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_a3a55065-8fb9-4a4b-ab14-2eb80f388714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c6232db8-c43e-4d0d-b014-fca599a15e78" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_4e016fa8-093c-4a72-ac56-4bc2a37cb5c8" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a0516dd7-afc7-4665-aa98-ceb27fe7033e" xlink:to="loc_pgen_MBPTitanMember_4e016fa8-093c-4a72-ac56-4bc2a37cb5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6a8170a6-801e-42c4-8d0f-42e02c7e3c32" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b437006-4951-4b82-9039-884923d8a055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b437006-4951-4b82-9039-884923d8a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ecfca031-8c62-4976-9d4f-066a70f22363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ecfca031-8c62-4976-9d4f-066a70f22363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d4e24f1c-350e-4259-9260-12c25f8642cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d4e24f1c-350e-4259-9260-12c25f8642cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f4d0d9de-24c7-464a-90c0-b8227bcd181e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42eec4c3-1fae-43c0-9dc0-a2d5f66ed1d9" xlink:to="loc_us-gaap_ShareBasedCompensation_f4d0d9de-24c7-464a-90c0-b8227bcd181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac05c681-1f1d-4ccd-8cdc-34e62791c9ed" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c01ed41-ff1a-4f61-91fe-d711a51a1ce8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_deab4837-ee9c-40e8-886d-8b308d9d6cff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c01ed41-ff1a-4f61-91fe-d711a51a1ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_60160a36-79f4-47b0-82e7-1d95a5123e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_60160a36-79f4-47b0-82e7-1d95a5123e15" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_47d44a70-9607-403c-b593-f1d920697650" xlink:to="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_d8c88fad-864d-4cd7-80d9-bede1edf545f" xlink:href="pgen-20201231.xsd#pgen_OkanaganOxitecFineChemicalsAndAgBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_1e23c92a-8e2d-4336-9cb0-22ec018480bb" xlink:to="loc_pgen_OkanaganOxitecFineChemicalsAndAgBioMember_d8c88fad-864d-4cd7-80d9-bede1edf545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0ccba8f8-6662-416b-8f1e-b14620020de3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_a0613c7e-7d8d-4fc2-b2ec-cde9a992889c" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_a0613c7e-7d8d-4fc2-b2ec-cde9a992889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_438df4d9-2627-47aa-a29e-3163ef8ba268" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_EnviroFlightLLCMember_438df4d9-2627-47aa-a29e-3163ef8ba268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_abbce8a5-e3d7-46bc-a890-19e8be6e91fc" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1814efcb-10c9-4ad1-a5c0-3c7afa8aa487" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_abbce8a5-e3d7-46bc-a890-19e8be6e91fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5c90d604-fcd8-4621-90eb-cfa3cd959060" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ffaefe0b-e5de-485a-b6d7-a8af79b9bf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ffaefe0b-e5de-485a-b6d7-a8af79b9bf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_f37de2c5-df19-4cc8-b254-b48c0618038c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3ed34e4e-84ba-4a1c-9905-685da3a7a4b1" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_f37de2c5-df19-4cc8-b254-b48c0618038c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_27de949e-efb0-40b7-a4d7-0d8718a86814" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_620ab3c4-d7bf-485d-ad47-5fc1e8c90474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_620ab3c4-d7bf-485d-ad47-5fc1e8c90474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3244524f-e443-4d48-9347-3248353202f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_AssetImpairmentCharges_3244524f-e443-4d48-9347-3248353202f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_31a31436-ba7b-4807-b885-4c674b316940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_31a31436-ba7b-4807-b885-4c674b316940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_fe00ca4c-ac52-4324-bc53-8a2be5700021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_fe00ca4c-ac52-4324-bc53-8a2be5700021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_aef0562b-7280-4448-868b-2045ff1eeb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_aef0562b-7280-4448-868b-2045ff1eeb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4677263f-4b30-4f0f-841e-4c6d9de34629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4677263f-4b30-4f0f-841e-4c6d9de34629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_f9e7678f-4c5a-4608-bf44-98deaaea3305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_69839659-c9a3-4c95-b726-ccd0eedfe6f7" xlink:to="loc_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax_f9e7678f-4c5a-4608-bf44-98deaaea3305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b92d2dd4-8257-4435-933b-448e8a3502e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b92d2dd4-8257-4435-933b-448e8a3502e9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_add4bed8-1632-4834-955e-e9310312b3e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_541b47c4-5323-4124-8c0f-a85f62bd650c" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_541b47c4-5323-4124-8c0f-a85f62bd650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_35d718ea-2370-4da8-a587-506618c47354" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5518a398-bb32-4a7d-8fa4-07dff335c94f" xlink:to="loc_pgen_EnviroFlightLLCMember_35d718ea-2370-4da8-a587-506618c47354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_efeb4ed7-86ac-487e-86f3-08c8d8764715" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7df3ed0a-bd0a-4a15-8604-1376beb86056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_26fbfc6c-fa2d-47cb-b467-a4c492a889c7" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_7df3ed0a-bd0a-4a15-8604-1376beb86056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_724ba564-9a1f-4451-b9ad-e9cdc24bc04b" xlink:to="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_d2dfee0d-3ca3-4c9c-9459-6cb16b7f135a" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_49ad59dd-3690-43f7-995a-7e4ba4eb3eae" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_d2dfee0d-3ca3-4c9c-9459-6cb16b7f135a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e4d8680c-59a2-455b-8792-778855bf1ee9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_785da446-d2ff-49a5-9143-756016eaaf5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_785da446-d2ff-49a5-9143-756016eaaf5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f3737d65-69c5-4ed2-a450-3e8feb1dbb31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f3737d65-69c5-4ed2-a450-3e8feb1dbb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5f7e1fd8-3b2a-49e9-8f83-789666de927d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_5f7e1fd8-3b2a-49e9-8f83-789666de927d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_69e405e1-cb1a-4e39-9d63-d7d16368f853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_69e405e1-cb1a-4e39-9d63-d7d16368f853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_b5cea2b8-bb2f-48ec-8f48-7fd218a9e73e" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments_b5cea2b8-bb2f-48ec-8f48-7fd218a9e73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_ce9000e3-b907-4683-b67b-ebe82adfd7d1" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_ce9000e3-b907-4683-b67b-ebe82adfd7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_964f270e-2bde-409a-abd1-b76560d75ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_964f270e-2bde-409a-abd1-b76560d75ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_a799f016-e12e-4a65-bfbb-e12df45a8fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_5436fb64-d551-4b80-8efb-a073fdef25ce" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_a799f016-e12e-4a65-bfbb-e12df45a8fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_18181305-a90a-496d-bde9-2c6b6ee4deed" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_b099d6c8-5cac-489f-aeb9-a8cac762c919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_b099d6c8-5cac-489f-aeb9-a8cac762c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_247de821-9e1a-42d8-abd2-39836fef269c" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent_247de821-9e1a-42d8-abd2-39836fef269c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3349ff1f-4dcc-4e32-9995-5b0f796233fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_3349ff1f-4dcc-4e32-9995-5b0f796233fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_9c0d6529-6f2f-40c7-8c7a-06d6a6d822f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent_9c0d6529-6f2f-40c7-8c7a-06d6a6d822f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_161ed772-7b6e-4058-9f5e-9e03a0abcd95" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent_161ed772-7b6e-4058-9f5e-9e03a0abcd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5a0b7c09-d906-4fc2-8ba4-f4260443bbd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5a0b7c09-d906-4fc2-8ba4-f4260443bbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1ea2f860-5012-4b43-9894-b0901be0ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_540036ec-c8d4-4ab4-96cf-ed42f39926b2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1ea2f860-5012-4b43-9894-b0901be0ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec70cb48-3b97-47cd-8d85-8988d54b9bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec70cb48-3b97-47cd-8d85-8988d54b9bea" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_965bf17b-fd08-4604-b657-939df2253375" xlink:to="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartiesAggregatedMember_25c05b81-eda9-445c-b6fa-9bf78387e61c" xlink:href="pgen-20201231.xsd#pgen_RelatedPartiesAggregatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_05026f2f-b6f8-4c50-b914-46cd178b2237" xlink:to="loc_pgen_RelatedPartiesAggregatedMember_25c05b81-eda9-445c-b6fa-9bf78387e61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638a4dff-9b12-4a9d-a093-da4e1a6e5d6e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_cd8601ae-f856-4d01-9eea-e070c27b7620" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_cd8601ae-f856-4d01-9eea-e070c27b7620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_3f9dfdfd-4a05-4f00-a39d-41c2d3da7eb9" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_EnviroFlightLLCMember_3f9dfdfd-4a05-4f00-a39d-41c2d3da7eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_1ded4bea-1e31-4f73-9dd2-591b3f4dce2e" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3e669d8-3323-45de-9faa-ff944d141f1d" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_1ded4bea-1e31-4f73-9dd2-591b3f4dce2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9041ac0b-26ce-42f2-85c7-f1f59713f149" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6720f77a-2d74-4ae2-9210-40fc84195e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ef9b5955-1430-496f-8994-5c493389d895" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6720f77a-2d74-4ae2-9210-40fc84195e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_d8b38b02-afa1-4f7a-af6d-f72b24bf2f89" xlink:to="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OxitecMember_d78a5d02-d29c-48f7-a3b4-45e05d91a82b" xlink:href="pgen-20201231.xsd#pgen_OxitecMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_f6d2b13d-a42a-4c3c-bde2-728b29a7911d" xlink:to="loc_pgen_OxitecMember_d78a5d02-d29c-48f7-a3b4-45e05d91a82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d50c9f26-9597-4fe4-a710-34fb58bf0f39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_61dff281-321c-4fb8-adad-4784feae7969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_61dff281-321c-4fb8-adad-4784feae7969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f153d8f2-5797-4f28-947f-d69e39818330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f153d8f2-5797-4f28-947f-d69e39818330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_9bfd9cc4-8f98-4844-bb6f-4342a8b3dc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_9bfd9cc4-8f98-4844-bb6f-4342a8b3dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7d643bcf-fb35-4780-906d-298a7ee08fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7d643bcf-fb35-4780-906d-298a7ee08fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_00ee10eb-666d-49dd-adcb-4302c60d4655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_00ee10eb-666d-49dd-adcb-4302c60d4655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_90e646a6-34d8-4f13-add2-3a5fbb1a72a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_90e646a6-34d8-4f13-add2-3a5fbb1a72a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_62b97909-6137-4f59-bdae-9ab279239cb0" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments_62b97909-6137-4f59-bdae-9ab279239cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_711c2cda-f679-4040-802b-ab379e561005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_711c2cda-f679-4040-802b-ab379e561005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_310b7ec0-979f-44cc-9cda-9d0892e966e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_310b7ec0-979f-44cc-9cda-9d0892e966e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_562590fb-b010-4e67-b632-1d506c59dbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_562590fb-b010-4e67-b632-1d506c59dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_40a5f41c-6270-4152-95a1-32835c30c101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_AssetImpairmentCharges_40a5f41c-6270-4152-95a1-32835c30c101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5c2098c1-7d1b-45e7-a709-b6fd9d882db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b723a202-4740-448b-a818-1431b7f5a3fa" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5c2098c1-7d1b-45e7-a709-b6fd9d882db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c0f1e197-8602-4daf-a7ec-28d946d1c03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c0f1e197-8602-4daf-a7ec-28d946d1c03a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_956b6850-14ba-4f3e-afc0-ec053e9c4d48" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_ee42e845-4479-488f-927d-67f05afe553d" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember_ee42e845-4479-488f-927d-67f05afe553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_c351e0fa-e64b-4c9c-96e5-4b3323391e18" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dffa15cb-6dee-4dd0-adfa-0cdda025de76" xlink:to="loc_pgen_EnviroFlightLLCMember_c351e0fa-e64b-4c9c-96e5-4b3323391e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_684dd452-9c6a-48fc-9e61-38a90e5ebf09" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f8b7085a-b2d6-4f6b-8a03-3fff47b491a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_d5ae5edd-51d6-4e67-950b-7150b0ccacbd" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f8b7085a-b2d6-4f6b-8a03-3fff47b491a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_adabec2a-7c01-4814-815f-c91352aa229b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_677773c2-d8e6-4fce-918b-51c9cb91047e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_677773c2-d8e6-4fce-918b-51c9cb91047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e38c9416-bebd-47ab-a0f7-c64e74efb076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e38c9416-bebd-47ab-a0f7-c64e74efb076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_bac43223-27f5-4af0-bdbb-8fdde0ad78a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_bac43223-27f5-4af0-bdbb-8fdde0ad78a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_42ab40c0-06bd-4d88-abaa-1b819d296107" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal_42ab40c0-06bd-4d88-abaa-1b819d296107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4e04ccad-a4d5-4b69-915b-91ffb084f558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4e04ccad-a4d5-4b69-915b-91ffb084f558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cfde6d02-bc87-49a0-ace1-654dd80e97ed" xlink:href="pgen-20201231.xsd#pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation_cfde6d02-bc87-49a0-ace1-654dd80e97ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_053daa4c-d632-4e12-bc40-e3f94732f0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_053daa4c-d632-4e12-bc40-e3f94732f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e61cb924-8a45-487b-baf9-30ff46d726d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_ShareBasedCompensation_e61cb924-8a45-487b-baf9-30ff46d726d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71199c4f-9a25-4dd8-9954-e471d77dfcd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_17561ee5-adba-4538-a759-46d7f4d56b61" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71199c4f-9a25-4dd8-9954-e471d77dfcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8bef4dd2-a399-44aa-b81c-6202c0bf46dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_8bef4dd2-a399-44aa-b81c-6202c0bf46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a0fe57f-4329-408e-b3d4-1f48095440cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_908c4db2-c149-44f0-aee0-d5713f3e443b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a0fe57f-4329-408e-b3d4-1f48095440cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d0b8ed72-7b5a-478c-95a2-ea3d5fccbb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d0b8ed72-7b5a-478c-95a2-ea3d5fccbb86" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_0f7db378-e46b-4cc8-a01f-0cb0c050fcb4" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_6bf4d376-58d0-4820-88af-27a57543e9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_f5f3a874-792d-4663-80cd-8f57b3fb9811" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_6bf4d376-58d0-4820-88af-27a57543e9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ff44a67a-e642-47a9-8d85-6b0ca85ee7d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EnviroFlightLLCMember_2af9263f-2224-4266-959c-d338f7a7cbc9" xlink:href="pgen-20201231.xsd#pgen_EnviroFlightLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:to="loc_pgen_EnviroFlightLLCMember_2af9263f-2224-4266-959c-d338f7a7cbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyAndEnviroFlightMember_7ec93801-71c1-4363-8921-97ef3ffec2a4" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyAndEnviroFlightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f0e021ab-f95d-4fc5-a2d0-7e68f32ccca9" xlink:to="loc_pgen_TSBiotechnologyAndEnviroFlightMember_7ec93801-71c1-4363-8921-97ef3ffec2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2048dfd6-bb2b-42b9-bf21-2ed1b42c834e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_ba9db28a-4165-4913-b609-fa4bcb5d9fac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_ba9db28a-4165-4913-b609-fa4bcb5d9fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_bb5d6994-a311-4b47-b58e-0dfcc3d9eda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_db0e9421-9a21-4353-b35c-a366a234cd0e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_bb5d6994-a311-4b47-b58e-0dfcc3d9eda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7beb3ae1-d0bd-4d55-9c98-07e1890e1d97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_69b1f6da-461d-475f-9198-73575b388090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_AssetsCurrent_69b1f6da-461d-475f-9198-73575b388090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_84b2c3e4-3df2-4893-a70f-ee2781991a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_AssetsNoncurrent_84b2c3e4-3df2-4893-a70f-ee2781991a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a0c3d082-8664-4133-b081-10ca51081a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Assets_a0c3d082-8664-4133-b081-10ca51081a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a34954a2-8a6b-455c-b708-503693543445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_LiabilitiesCurrent_a34954a2-8a6b-455c-b708-503693543445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a3e3037d-d6a0-40df-840b-6205c60e0840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a3e3037d-d6a0-40df-840b-6205c60e0840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a6f1bd3-53c4-4246-bb46-61bcdf3d19d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Liabilities_5a6f1bd3-53c4-4246-bb46-61bcdf3d19d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_6e274269-dc0f-4500-acc1-38185a113c67" xlink:href="pgen-20201231.xsd#pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet_6e274269-dc0f-4500-acc1-38185a113c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_92a27da9-0b6c-44ad-a348-63f26ca3a564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_Revenues_92a27da9-0b6c-44ad-a348-63f26ca3a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8d3c822f-15ba-4dad-93df-3ed5e4e4ab41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_OperatingExpenses_8d3c822f-15ba-4dad-93df-3ed5e4e4ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_112d62fd-0f17-4e54-b6d8-ca87a5dbc4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_GrossProfit_112d62fd-0f17-4e54-b6d8-ca87a5dbc4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31192232-7ec0-4730-a86c-60c5ef054e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31192232-7ec0-4730-a86c-60c5ef054e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d6524074-2e06-4c2d-b41c-abac062aa5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2374e227-5834-4e88-878d-5e7eb40a46f0" xlink:to="loc_us-gaap_ProfitLoss_d6524074-2e06-4c2d-b41c-abac062aa5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitions" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitions"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/MergersandAcquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MergersandAcquisitionsAbstract_5501c5db-81cc-4875-8fc2-388fb2c6a7e9" xlink:href="pgen-20201231.xsd#pgen_MergersandAcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e959ac29-68e5-45cf-8dd5-4d9b7f9dad07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_MergersandAcquisitionsAbstract_5501c5db-81cc-4875-8fc2-388fb2c6a7e9" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e959ac29-68e5-45cf-8dd5-4d9b7f9dad07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MergersandAcquisitionsAbstract_14ab8441-f147-43cb-8971-ab4a98d06956" xlink:href="pgen-20201231.xsd#pgen_MergersandAcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_MergersandAcquisitionsAbstract_14ab8441-f147-43cb-8971-ab4a98d06956" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f94e8f7f-378c-4d64-be2f-358067392f27" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_cc34275b-61f0-4c84-b812-40f47ffa7d14" xlink:href="pgen-20201231.xsd#pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fab59667-bb64-4ec7-9631-c4f58e7711ab" xlink:to="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_cc34275b-61f0-4c84-b812-40f47ffa7d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fba131cc-47ca-4bd8-8125-4957ae4bca21" xlink:to="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenActioBioIncMember_eb4dbb35-318a-49af-81b4-1620d8421225" xlink:href="pgen-20201231.xsd#pgen_PrecigenActioBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_51362cdb-a225-4d5f-a10f-7445498f4df4" xlink:to="loc_pgen_PrecigenActioBioIncMember_eb4dbb35-318a-49af-81b4-1620d8421225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4050fc03-2684-445a-aa92-b846060806a2" xlink:to="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4932d912-e35d-4fc7-8a44-8185bade9f13" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3c3ee174-759e-46b3-ac7b-504459862a54" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4932d912-e35d-4fc7-8a44-8185bade9f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d657ae7b-ed24-4c4c-8819-377851ec1040" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_3d2809e5-bd18-4378-bfb1-76559174c4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_3d2809e5-bd18-4378-bfb1-76559174c4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CashInflowsOutflowsInAssetAcquisition_ef90fc71-a670-44ac-8b31-1f7ca13ebeaf" xlink:href="pgen-20201231.xsd#pgen_CashInflowsOutflowsInAssetAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_pgen_CashInflowsOutflowsInAssetAcquisition_ef90fc71-a670-44ac-8b31-1f7ca13ebeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_79d9cac7-8c73-4863-80aa-0c29f34f9f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_EquityMethodInvestments_79d9cac7-8c73-4863-80aa-0c29f34f9f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_7c4426d8-e3a6-402e-b396-7d02c19ec2e8" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_7c4426d8-e3a6-402e-b396-7d02c19ec2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2f5b14a1-aed8-4480-9333-6b601d80c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2f5b14a1-aed8-4480-9333-6b601d80c52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_87e6a533-c77b-41ee-9e56-e07589087135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_061f7394-ff37-4718-8fc4-d057d6db751c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_87e6a533-c77b-41ee-9e56-e07589087135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVentures"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVentures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a9717a40-8c8f-47e3-a3c3-59bd083a8f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_23d800af-ecbe-421a-8fda-2f68022721b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a9717a40-8c8f-47e3-a3c3-59bd083a8f3c" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_23d800af-ecbe-421a-8fda-2f68022721b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_445e0f53-3418-4748-9226-0ea52e0ad4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_445e0f53-3418-4748-9226-0ea52e0ad4fe" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cb479db5-951c-4f1b-acd8-b46cecf6e6c2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_fd831a27-e980-4624-82a8-d25e0fcafab3" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d461d26-ef3d-467c-8d6d-e2df63a6090b" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_fd831a27-e980-4624-82a8-d25e0fcafab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a0fdfbd-054e-462c-b8b3-654c5def58f4" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherAccruedLiabilitiesMember_a5fa7b11-5f69-4992-8a17-798e2a75cc6b" xlink:href="pgen-20201231.xsd#pgen_OtherAccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6ceecf39-4191-493b-aaf6-c642e4ac9d34" xlink:to="loc_pgen_OtherAccruedLiabilitiesMember_a5fa7b11-5f69-4992-8a17-798e2a75cc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_41310591-a5c1-41df-974e-69cab1931abf" xlink:to="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_45850696-6be7-4369-b7cf-a3f27f4aa6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b84ce3cd-9443-4308-89c0-30fbc87c579f" xlink:to="loc_us-gaap_InvestorMember_45850696-6be7-4369-b7cf-a3f27f4aa6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_79ffde6c-7689-4e13-9925-460852070f15" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_77ff1d8c-9164-4c2e-9245-758d9fa8dacb" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_959cf76f-5e94-466d-a752-ee98eb132436" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_77ff1d8c-9164-4c2e-9245-758d9fa8dacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89f70e19-5e84-4981-a106-4bf53f12672b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_13cd80a0-9594-43dd-93e8-15a6fe36a065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_513c4e08-9629-49d3-a577-81347caf7087" xlink:to="loc_us-gaap_CollaborativeArrangementMember_13cd80a0-9594-43dd-93e8-15a6fe36a065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_c450c827-34e1-49e1-91e9-700dd1e22823" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_9605e1e5-1354-475a-a541-a5618107c9fa" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_9605e1e5-1354-475a-a541-a5618107c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b7650d2-feaf-4b0c-9588-6685259eb3cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1b7650d2-feaf-4b0c-9588-6685259eb3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_acf6f38d-3cff-4abc-84cd-037df032d8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_acf6f38d-3cff-4abc-84cd-037df032d8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_9d932ae7-58a7-421d-b3f3-99e29ab12f15" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_9d932ae7-58a7-421d-b3f3-99e29ab12f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_31481568-bbe3-446d-945c-d4e4684f9190" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_31481568-bbe3-446d-945c-d4e4684f9190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoard_72c6d5f6-d870-4a06-9cb2-ba48d99204c4" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoard"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoard_72c6d5f6-d870-4a06-9cb2-ba48d99204c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_17845d2e-30e3-4acc-b1fb-abcc25a99c56" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_17845d2e-30e3-4acc-b1fb-abcc25a99c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_f814c7d7-1e70-4cdf-9aba-e772cea9aa50" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_f814c7d7-1e70-4cdf-9aba-e772cea9aa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2b2bd27c-56d8-4540-897f-c95f4b8a03d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_09073b49-ab3d-4c75-a0ff-ea6f9f81ca9f" xlink:to="loc_us-gaap_EquityMethodInvestments_2b2bd27c-56d8-4540-897f-c95f4b8a03d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2e04706-6d92-4fb4-a66c-c3d6e3dc06dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d2e04706-6d92-4fb4-a66c-c3d6e3dc06dc" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0dcb5a66-59cc-4bbd-aee4-18b05a9acce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_a157744b-9c86-477e-afa2-bd188d1b9b12" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3843d40b-1f7a-40d4-b972-a63528f289d3" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_a157744b-9c86-477e-afa2-bd188d1b9b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_67d7f036-4195-4289-ba2c-082ef4dbd252" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherAccruedLiabilitiesMember_eb98b13a-5f6a-4682-9e30-2ba76e16364e" xlink:href="pgen-20201231.xsd#pgen_OtherAccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_af99ddef-8dc5-48e1-850c-9b9af7c2f242" xlink:to="loc_pgen_OtherAccruedLiabilitiesMember_eb98b13a-5f6a-4682-9e30-2ba76e16364e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c4eb0ad5-9fea-4f3b-b26e-2c03da6b18ee" xlink:to="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_f68496c8-4da6-43f2-9945-e84c3e0df9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:to="loc_us-gaap_InvestorMember_f68496c8-4da6-43f2-9945-e84c3e0df9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AllInvestorsMember_12eab386-f57f-43d4-aa46-ad985f54b602" xlink:href="pgen-20201231.xsd#pgen_AllInvestorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4a114716-e68a-498a-8b69-7e9fa9c0a757" xlink:to="loc_pgen_AllInvestorsMember_12eab386-f57f-43d4-aa46-ad985f54b602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_da61eb1c-c249-43a9-852d-733e34877254" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_2df64aec-d6b9-42be-8444-a143f398c043" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ccc1df28-fdd4-414d-af33-e21710415337" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_2df64aec-d6b9-42be-8444-a143f398c043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_09e1ba9b-e91a-4cc3-8216-1f3b5fe7ffca" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cbe78882-db74-4edd-9bfb-7928655d8d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a3dfb16d-7c2d-4d5e-a7ea-41a4ab591de8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cbe78882-db74-4edd-9bfb-7928655d8d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_84335ae1-ab65-4bab-99d0-0b3ba6426933" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_bf06ee6a-5ea2-48cc-9f4a-cb1490cc1c79" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_bf06ee6a-5ea2-48cc-9f4a-cb1490cc1c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc6af343-c49c-4308-8f84-0a54b4490cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fc6af343-c49c-4308-8f84-0a54b4490cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_92d3015d-1b12-4444-a627-6b308aa32ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_92d3015d-1b12-4444-a627-6b308aa32ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_ec3d2d50-a843-47c7-910f-ef73d2986bea" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_ec3d2d50-a843-47c7-910f-ef73d2986bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_29d7a2fb-e123-4024-9f79-4c49dc8eb515" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment_29d7a2fb-e123-4024-9f79-4c49dc8eb515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoard_bc04316c-fda1-4262-909c-7c0b3472a8d0" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoard"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoard_bc04316c-fda1-4262-909c-7c0b3472a8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_1552525c-f3bd-4480-a1cb-c30c744ae097" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_1552525c-f3bd-4480-a1cb-c30c744ae097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_1d2af16a-34e2-44f7-ad5a-ad06f74357a6" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_1d2af16a-34e2-44f7-ad5a-ad06f74357a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_273dfe64-a638-47ca-b264-74e8eb2fb6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dc04f11f-d1d4-4e59-b1bd-013a11423ed9" xlink:to="loc_us-gaap_EquityMethodInvestments_273dfe64-a638-47ca-b264-74e8eb2fb6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3181f038-a350-4d89-a1c0-27265a3fcb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3181f038-a350-4d89-a1c0-27265a3fcb58" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5e7a8dd5-e593-4845-891f-a4f4f9649112" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_9774a1d0-9daf-4c0f-bb76-97b1e2dd7fca" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a366684-820c-4602-9402-6a12e21e9d50" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_9774a1d0-9daf-4c0f-bb76-97b1e2dd7fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3ff2544e-ae3b-4d91-aa03-3e9b01967634" xlink:to="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_60dde377-38c2-4b6d-9041-ecb743a5bb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_62635e9d-b573-4691-8d51-f45eb7696349" xlink:to="loc_us-gaap_InvestorMember_60dde377-38c2-4b6d-9041-ecb743a5bb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1b4fcdb0-206b-450a-8120-48c6a4325ec9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_0fb0b49b-3166-44c7-b8c4-77e0ae3dc297" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8aef301c-eb2d-47cb-b4cf-df0bbff1f2b5" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_0fb0b49b-3166-44c7-b8c4-77e0ae3dc297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52904676-eea6-4e08-ac95-cf2df329d151" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e2b97ff2-23b2-4258-8041-e92224dc22a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_929e0b49-fa8b-42ed-8795-103150dc6c56" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e2b97ff2-23b2-4258-8041-e92224dc22a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:href="pgen-20201231.xsd#pgen_ScheduleOfInvestmentsInJointVentureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureTable_b5196501-c9b4-4b27-b037-cd5d90d3de3e" xlink:to="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_8b5bbe90-17dd-4500-9181-a4393ae39fe5" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_8b5bbe90-17dd-4500-9181-a4393ae39fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_25c07368-bf62-431e-be1d-55b779bcf9c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_25c07368-bf62-431e-be1d-55b779bcf9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_129ee348-4728-4c18-a86c-a4a88b8269a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_129ee348-4728-4c18-a86c-a4a88b8269a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_7c843fd1-de39-4c0e-942d-613c3db87101" xlink:href="pgen-20201231.xsd#pgen_JointVentureAdditionalCapitalContributionsCommitted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_JointVentureAdditionalCapitalContributionsCommitted_7c843fd1-de39-4c0e-942d-613c3db87101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_eed9f7e6-aa5f-4839-8517-63d238d37c73" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardInternallySelected"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardInternallySelected_eed9f7e6-aa5f-4839-8517-63d238d37c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_816f9b2b-5d71-42c0-9da7-9bf3698a2cd3" xlink:href="pgen-20201231.xsd#pgen_NumberofSeatsonGoverningBoardExternallySelected"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_pgen_NumberofSeatsonGoverningBoardExternallySelected_816f9b2b-5d71-42c0-9da7-9bf3698a2cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bffcdc0b-ee1d-4ae1-b4c6-ae2ff155d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bffcdc0b-ee1d-4ae1-b4c6-ae2ff155d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_48127831-2bbb-4a5e-875f-b644c248aeb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_48127831-2bbb-4a5e-875f-b644c248aeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8efa84d2-eb81-4515-b55e-3155be780c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8efa84d2-eb81-4515-b55e-3155be780c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe21624b-9e9d-43c8-ac72-f586e20e9b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ScheduleOfInvestmentsInJointVentureLineItems_dacc3a58-4fab-433a-8948-b8417eb79681" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_fe21624b-9e9d-43c8-ac72-f586e20e9b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenue"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e942de4-5326-46e1-9729-bd5cfec59d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a8da403b-453e-4359-9cd3-5e0f55b217d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e942de4-5326-46e1-9729-bd5cfec59d58" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a8da403b-453e-4359-9cd3-5e0f55b217d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f83c4f6f-7886-4033-8907-38081afba6b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_770d8bdf-1b92-4985-8ffa-d325d33fc693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f83c4f6f-7886-4033-8907-38081afba6b2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_770d8bdf-1b92-4985-8ffa-d325d33fc693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad9cf7ac-c9cd-4bc2-ab51-dca02018931c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f83c4f6f-7886-4033-8907-38081afba6b2" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ad9cf7ac-c9cd-4bc2-ab51-dca02018931c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_8f753f95-fb59-433b-935d-1c22b518a8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f83c4f6f-7886-4033-8907-38081afba6b2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_8f753f95-fb59-433b-935d-1c22b518a8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53d7c4ff-10dd-4a01-b6d4-3e7fa6eadf5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53d7c4ff-10dd-4a01-b6d4-3e7fa6eadf5c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:to="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3c58b7d4-9488-4f65-b0bb-902bfe85d9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_507f45c0-77ea-4ea5-ab15-a9df4b45bc3a" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_ZiopharmMember_507f45c0-77ea-4ea5-ab15-a9df4b45bc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AresTradingS.A.Member_c178de98-1785-4412-b8ca-cf2334488cf8" xlink:href="pgen-20201231.xsd#pgen_AresTradingS.A.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_AresTradingS.A.Member_c178de98-1785-4412-b8ca-cf2334488cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_46d5c431-c2ed-4ff1-bcff-e724d3ca81ec" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_OragenicsMember_46d5c431-c2ed-4ff1-bcff-e724d3ca81ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_bdd5c211-6800-4d24-9af2-a81234fdd48a" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_bdd5c211-6800-4d24-9af2-a81234fdd48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_ebcf68c1-a815-4f2e-9cd0-80b4539da43b" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_ebcf68c1-a815-4f2e-9cd0-80b4539da43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_48f09e6f-5b6f-4fd1-8d4c-090805cbceec" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_48f09e6f-5b6f-4fd1-8d4c-090805cbceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_fc451994-abff-44d8-bf34-dfcd7ac94df1" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_fc451994-abff-44d8-bf34-dfcd7ac94df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_f7049b77-1159-4ee3-a65d-cd91f11a7c67" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_f7049b77-1159-4ee3-a65d-cd91f11a7c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherMember_2302bce1-bdfb-4221-8c58-a01d6cdb557a" xlink:href="pgen-20201231.xsd#pgen_OtherMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_625ced90-eebd-4959-bc6a-65f146370725" xlink:to="loc_pgen_OtherMember_2302bce1-bdfb-4221-8c58-a01d6cdb557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecb1c6ff-be03-4a95-8b2b-0977394a9f3f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_60c005d3-372d-4a71-8f79-07eb3b593968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_60c005d3-372d-4a71-8f79-07eb3b593968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_9ae42e5e-5a0e-41d3-8be7-57a4c84ce43e" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2e3d025-1e2a-4cc4-b85e-870139d6aec1" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_9ae42e5e-5a0e-41d3-8be7-57a4c84ce43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_44fe21c4-b588-4eed-bd4e-6095304569ba" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb04f2eb-e43c-485d-a14d-3eb2dcd30651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb04f2eb-e43c-485d-a14d-3eb2dcd30651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb50fe46-8090-4843-9a1f-ffbcf8b0788c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_00f71f2e-9db5-4052-a097-23da46369926" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fb50fe46-8090-4843-9a1f-ffbcf8b0788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6cf64148-6ac4-4ca0-8257-b23e742188ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6cf64148-6ac4-4ca0-8257-b23e742188ed" xlink:to="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd7446a9-c0c4-4936-b045-1c98418d5b67" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_acadbf8b-3ad2-4c04-96be-99ab1968a023" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:to="loc_pgen_ZiopharmMember_acadbf8b-3ad2-4c04-96be-99ab1968a023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_d9c21a5d-ad70-4de2-b9c5-a8280a99f515" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_06a81dda-ac95-4ac1-bb87-ab0469b5c0cd" xlink:to="loc_pgen_OragenicsMember_d9c21a5d-ad70-4de2-b9c5-a8280a99f515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c18b14a2-872c-47ac-a587-f74537326062" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_730c50be-5cdc-41b9-a62b-fe576f1ec424" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_730c50be-5cdc-41b9-a62b-fe576f1ec424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_07720cc6-c90d-4e17-b34b-f5172b8a7db5" xlink:href="pgen-20201231.xsd#pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b7ddd1f4-017b-4fed-9cc2-03940f7e4d5e" xlink:to="loc_pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember_07720cc6-c90d-4e17-b34b-f5172b8a7db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0ce7d97a-26fa-47db-b67e-384f94bd3553" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_c81e53d1-ac68-47d0-a2f3-9a9d846eb653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_486ed7f6-4d52-4e38-885d-5a43fdeece34" xlink:to="loc_us-gaap_PreferredStockMember_c81e53d1-ac68-47d0-a2f3-9a9d846eb653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4b369bd2-0235-4a1d-b8db-f519c150d5ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_904192d8-db96-4ad4-af94-6731109efbeb" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_ZiopharmMember_904192d8-db96-4ad4-af94-6731109efbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AresTradingS.A.Member_1d6356e3-d58a-4128-9ea0-1be9b082820d" xlink:href="pgen-20201231.xsd#pgen_AresTradingS.A.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_AresTradingS.A.Member_1d6356e3-d58a-4128-9ea0-1be9b082820d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_c5b26f3a-535d-4450-8964-c48511f518a2" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_OragenicsMember_c5b26f3a-535d-4450-8964-c48511f518a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonT1DPartnersLLCMember_856e162a-5e6e-4dab-8560-dac4ddd3d004" xlink:href="pgen-20201231.xsd#pgen_IntrexonT1DPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonT1DPartnersLLCMember_856e162a-5e6e-4dab-8560-dac4ddd3d004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_d58d41ee-5989-4c87-b7ae-ba81d130839e" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_d58d41ee-5989-4c87-b7ae-ba81d130839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_9f6704ba-7b6d-4354-a346-056501b65dd7" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_9f6704ba-7b6d-4354-a346-056501b65dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_e8ec80e0-d01a-4db5-984a-c09c68840dde" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_e8ec80e0-d01a-4db5-984a-c09c68840dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_9aa89e5e-df75-471d-8054-0b9f65bcf8ab" xlink:href="pgen-20201231.xsd#pgen_ExotechADSkincareAndThriveAgrobioticsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_9aa89e5e-df75-471d-8054-0b9f65bcf8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_1e22cb24-75d7-499b-a411-b1c92c406ecb" xlink:href="pgen-20201231.xsd#pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f771314d-609e-43ab-90c0-0956a080d05a" xlink:to="loc_pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member_1e22cb24-75d7-499b-a411-b1c92c406ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e84f5781-0129-402b-8c65-e7253dcdf717" xlink:to="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_3f2f494f-f692-4d7e-8875-2d5343f0a68c" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ef7baea1-393a-48d9-bcb0-454bcde72da4" xlink:to="loc_pgen_ZiopharmMember_3f2f494f-f692-4d7e-8875-2d5343f0a68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b849c65-1487-4c19-b2d6-8e6ce88ada63" xlink:to="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f02f643a-de4b-4a36-be45-8ea785aba784" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e137d3b-a5fc-4d98-9d8b-5c6b322c3d79" xlink:to="loc_srt_MaximumMember_f02f643a-de4b-4a36-be45-8ea785aba784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1c71b5f8-a50f-45ac-b609-7fc3cd032229" xlink:to="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_5081e176-5969-413a-9e3e-b51da4e579c1" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_347164a8-1b59-45da-9ebc-2bf3b4fc8f50" xlink:to="loc_pgen_ZiopharmMember_5081e176-5969-413a-9e3e-b51da4e579c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b04d0603-1b12-40b0-9e39-dd83c3ef1a50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_ef72eea0-450f-4e42-9741-9a6f8ca83d95" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member_ef72eea0-450f-4e42-9741-9a6f8ca83d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_edd77297-3b85-40fb-a49e-87a7d87fc875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_edd77297-3b85-40fb-a49e-87a7d87fc875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_1590f856-8033-4b1b-a7c8-fae40a95d086" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fd859c3-7a00-4ae7-8bbb-fa06632a47e1" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_1590f856-8033-4b1b-a7c8-fae40a95d086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_bc3b337f-07ce-40bc-8c55-5f99bdd1f63e" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReacquiredInProcessResearchDevelopmentMember_444cd871-39ca-4bfa-80ad-bb3b40f7a2dd" xlink:href="pgen-20201231.xsd#pgen_ReacquiredInProcessResearchDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:to="loc_pgen_ReacquiredInProcessResearchDevelopmentMember_444cd871-39ca-4bfa-80ad-bb3b40f7a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionServicesMember_d8fc7957-586c-4ede-862d-b08b6c1d1d3e" xlink:href="pgen-20201231.xsd#pgen_TransitionServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_090a448d-c97b-46f5-bafb-dddf2af787da" xlink:to="loc_pgen_TransitionServicesMember_d8fc7957-586c-4ede-862d-b08b6c1d1d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementsLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsTable_8bcbd6f4-d944-4af7-a638-57f8c0c8c070" xlink:to="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_21be23fd-3fb8-4a82-98d3-49472b641fd3" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValue_21be23fd-3fb8-4a82-98d3-49472b641fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments_204a3819-f1c7-4f51-807c-f9830fce511c" xlink:href="pgen-20201231.xsd#pgen_CollaborationArrangementPercentOfCollaborationPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborationArrangementPercentOfCollaborationPayments_204a3819-f1c7-4f51-807c-f9830fce511c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_051ed9f1-d10d-4be9-b9ba-675511094f4a" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible_051ed9f1-d10d-4be9-b9ba-675511094f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_9f4187a0-6dbb-4088-a6fa-57e90194509e" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived_9f4187a0-6dbb-4088-a6fa-57e90194509e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementAnnualFee_dc71531c-58ad-46c7-a60f-5147d4835969" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementAnnualFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementAnnualFee_dc71531c-58ad-46c7-a60f-5147d4835969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts_a4e0e726-ae0f-46ca-93ab-7ea120b9e706" xlink:href="pgen-20201231.xsd#pgen_LicensingAgreementReimbursementofHistoricalCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicensingAgreementReimbursementofHistoricalCosts_a4e0e726-ae0f-46ca-93ab-7ea120b9e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_c0121614-648f-41bf-be7c-ae7b81f414f3" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments_c0121614-648f-41bf-be7c-ae7b81f414f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_f5c90f43-254b-44e0-ab3d-56759dee3990" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct_f5c90f43-254b-44e0-ab3d-56759dee3990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_d93b4500-10db-4334-b578-b8e3731daa16" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementNumberofExclusivelyLicensedProducts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts_d93b4500-10db-4334-b578-b8e3731daa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_02ef5302-e370-4e8f-b9bc-5e54d00b1d29" xlink:href="pgen-20201231.xsd#pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated_02ef5302-e370-4e8f-b9bc-5e54d00b1d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementRoyaltyDueAggregated_49098d58-8f2e-47ec-8c9c-99bf548351d4" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementRoyaltyDueAggregated"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementRoyaltyDueAggregated_49098d58-8f2e-47ec-8c9c-99bf548351d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementPercentageofSublicensingIncome_f5f1e14f-34cf-4570-84c1-5e90fb34af08" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementPercentageofSublicensingIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementPercentageofSublicensingIncome_f5f1e14f-34cf-4570-84c1-5e90fb34af08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_e1de32a7-512a-4f01-945c-f371fe2e27b3" xlink:href="pgen-20201231.xsd#pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed_e1de32a7-512a-4f01-945c-f371fe2e27b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_4b067935-8a36-40de-910f-2496ba0375d9" xlink:href="pgen-20201231.xsd#pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent_4b067935-8a36-40de-910f-2496ba0375d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_714c4220-2a9a-44c4-ab49-612657f539c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_714c4220-2a9a-44c4-ab49-612657f539c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b32179d4-6ec3-4cf9-b179-957dd08359da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b32179d4-6ec3-4cf9-b179-957dd08359da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0b841072-e376-484b-91e5-0015c8879ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0b841072-e376-484b-91e5-0015c8879ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bd904da-9a03-4682-b992-41fbebcf92c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2bd904da-9a03-4682-b992-41fbebcf92c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PaymentsToRelatedParties_601dc791-8d17-4d4d-b1a9-3edf72e52a47" xlink:href="pgen-20201231.xsd#pgen_PaymentsToRelatedParties"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_PaymentsToRelatedParties_601dc791-8d17-4d4d-b1a9-3edf72e52a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_4f4ec3eb-1e30-44dc-89a8-7cacf0e4b785" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired_4f4ec3eb-1e30-44dc-89a8-7cacf0e4b785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_12609c47-df29-4a03-9aac-45c6056e507e" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod_12609c47-df29-4a03-9aac-45c6056e507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_85f706da-971b-4ce7-9002-7054bfa7d572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_85f706da-971b-4ce7-9002-7054bfa7d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_7845b226-624b-43b2-a4cc-13ff02b67835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_7845b226-624b-43b2-a4cc-13ff02b67835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty_280fdac5-a03f-4dbc-be16-2df1ee2918c7" xlink:href="pgen-20201231.xsd#pgen_RoyaltyPercentageToBePaidtoOtherParty"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_RoyaltyPercentageToBePaidtoOtherParty_280fdac5-a03f-4dbc-be16-2df1ee2918c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_ea09be70-6401-415c-b7a6-f831d810046a" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote_ea09be70-6401-415c-b7a6-f831d810046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_4b9e843a-270e-4e0b-bea3-cc0c34f33135" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_4b9e843a-270e-4e0b-bea3-cc0c34f33135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationAgreementTerminationNoticePeriod_e9c60b07-3570-4255-9a02-60c173472e30" xlink:href="pgen-20201231.xsd#pgen_CollaborationAgreementTerminationNoticePeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborationAgreementTerminationNoticePeriod_e9c60b07-3570-4255-9a02-60c173472e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementConsiderationReceivedCash_ba2986c0-da2d-4b31-8ea9-4d6c7faba30a" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementConsiderationReceivedCash"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementConsiderationReceivedCash_ba2986c0-da2d-4b31-8ea9-4d6c7faba30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_fe7c46c9-ba61-469e-9e58-62fbde79b971" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne_fe7c46c9-ba61-469e-9e58-62fbde79b971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_7e436ee5-7524-4566-b331-35c6c83d36e2" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo_7e436ee5-7524-4566-b331-35c6c83d36e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_0fa4cd70-aa3e-4ea8-9bdd-37029f2b1128" xlink:href="pgen-20201231.xsd#pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo_0fa4cd70-aa3e-4ea8-9bdd-37029f2b1128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e12dfa06-2d28-488c-ae44-bf3b902a0511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_CollaborationAgreementsLineItems_0cd22e57-0dfe-42d1-9b43-ab463ff5c238" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e12dfa06-2d28-488c-ae44-bf3b902a0511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08df45aa-0610-410a-a0ea-c2de65218286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08df45aa-0610-410a-a0ea-c2de65218286" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc10d1c9-2677-44ae-9914-3a5702979d0d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_404572ff-e2d0-4222-85da-a5d5400d8b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0fbbb5e-c43e-4a68-8b9b-74c005040c4c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_404572ff-e2d0-4222-85da-a5d5400d8b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:to="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dd788bdb-188e-4956-bfcf-0981487606d1" xlink:to="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrepaidProductAndServiceRevenuesMember_83712b5d-c876-4126-892f-4fa18b14be54" xlink:href="pgen-20201231.xsd#pgen_PrepaidProductAndServiceRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:to="loc_pgen_PrepaidProductAndServiceRevenuesMember_83712b5d-c876-4126-892f-4fa18b14be54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredRevenueOtherMember_77829199-ba1e-4171-81a8-9820d3e09fe1" xlink:href="pgen-20201231.xsd#pgen_DeferredRevenueOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_971c22c6-7dc5-4c3d-b97f-334216271061" xlink:to="loc_pgen_DeferredRevenueOtherMember_77829199-ba1e-4171-81a8-9820d3e09fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_fb806a1c-e239-4605-80cc-8eb0c2424ff7" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a16835a7-712e-4832-9523-60549382796d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a16835a7-712e-4832-9523-60549382796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4a559c41-a077-4f06-879a-ff8d9ff00c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4a559c41-a077-4f06-879a-ff8d9ff00c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ce196b3a-ed13-4aca-8c98-962c49639c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_6de5e1cf-8977-427e-bf38-8a093348021f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ce196b3a-ed13-4aca-8c98-962c49639c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0bd0cfb8-8e2f-4b9a-8124-df9d8bee0469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0bd0cfb8-8e2f-4b9a-8124-df9d8bee0469" xlink:to="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_890dd37a-ae58-4332-a8d5-b086b2c3ad3d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OragenicsMember_c29ebcca-f86e-4d86-ab6c-227d993c112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_3e82cd76-b349-4627-8c71-b5f4e2f03161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_45089eb8-5122-4f32-9944-be91280da0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_73ddb193-92d0-4053-9c55-2632065ed859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_a4842bdf-8394-4723-a50c-767e2bdda78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92aa783a-2f67-4078-b3ee-0e9e672b772d" xlink:to="loc_pgen_OtherCollaborationsMember_ea46d284-7d19-40c8-8bb8-f2df4f444b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c552414b-7e17-411e-a041-3ba4811d8961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_c552414b-7e17-411e-a041-3ba4811d8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c9bdf27d-9b8c-43b0-8e92-e23d2bc6584e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38fa3858-a2a9-4fce-b23d-3554510ff42b" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_4a6b5f09-7e30-4ece-ab39-4b598953c15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:href="pgen-20201231.xsd#pgen_SummaryofDeferredRevenuebyCollaboratorLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorTable_ffdd0a22-0ef3-491a-85fb-c5d59cafebd8" xlink:to="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7243c7b9-ca6e-4002-8f23-5e2fdab2cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems_35ca6916-28fa-4fae-bf5e-44bdccc94f44" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d7423b2d-1f47-4840-944e-bd4c49095c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cca9bd79-600e-4b4f-a6d8-13ccab449fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cca9bd79-600e-4b4f-a6d8-13ccab449fbf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:to="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a5982c1a-a2cd-404d-a14b-65ec3a32a993" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OragenicsMember_da363596-e6d4-4691-8910-0a722e19f5d9" xlink:href="pgen-20201231.xsd#pgen_OragenicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_OragenicsMember_da363596-e6d4-4691-8910-0a722e19f5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersMember_8e866f51-4107-43c1-99a4-224c9d5ab3db" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_IntrexonEnergyPartnersMember_8e866f51-4107-43c1-99a4-224c9d5ab3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IntrexonEnergyPartnersIILLCMember_248bf721-0ae4-43e6-b5db-7e538604da1e" xlink:href="pgen-20201231.xsd#pgen_IntrexonEnergyPartnersIILLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_IntrexonEnergyPartnersIILLCMember_248bf721-0ae4-43e6-b5db-7e538604da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_73bc2483-52b3-462b-a4e7-21c21fe46de2" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_73bc2483-52b3-462b-a4e7-21c21fe46de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_35bace31-83a5-4823-8da3-545cfcca2332" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_35bace31-83a5-4823-8da3-545cfcca2332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherCollaborationsMember_45719ef2-2294-4842-990b-e5c7e2d381b2" xlink:href="pgen-20201231.xsd#pgen_OtherCollaborationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af52b784-91d5-40b7-a4d4-d24ac2f6bc5e" xlink:to="loc_pgen_OtherCollaborationsMember_45719ef2-2294-4842-990b-e5c7e2d381b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44fe18f7-7bd5-46b3-8dae-216ac6c0cb52" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_7db7b088-5bd2-401d-9c9e-21d37c941917" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_920530e0-2a42-4c15-abfe-478944226559" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_7db7b088-5bd2-401d-9c9e-21d37c941917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_c30e6339-1a3d-411e-8792-41bef0976100" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_349e9073-2356-4422-b1e8-3f4f9f0a55ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dbfc0a50-a23e-49a4-b6f1-0ef827113f96" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_349e9073-2356-4422-b1e8-3f4f9f0a55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ba5e59b-5144-4fa0-b0e1-219cfb58fbd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_abdaf91b-f579-4b3d-bc1f-3137341d7214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5ba5e59b-5144-4fa0-b0e1-219cfb58fbd7" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_abdaf91b-f579-4b3d-bc1f-3137341d7214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4e5be7de-fe63-4fa9-b9a2-a09cc76edb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eac3d597-afd3-4d83-b81d-ed72d7c23f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4e5be7de-fe63-4fa9-b9a2-a09cc76edb2f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eac3d597-afd3-4d83-b81d-ed72d7c23f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_339c706e-10a3-4599-a7c9-597cc2c15092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_339c706e-10a3-4599-a7c9-597cc2c15092" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_291608c6-f230-4bd0-a95a-ec26785cdc6d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7528a4b6-67a0-4a75-a2db-751114b6e8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7528a4b6-67a0-4a75-a2db-751114b6e8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_10deaa14-9978-4378-8c63-5cb7ea54cf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f0f1a0b-bdb1-4083-884d-90357f8a0080" xlink:to="loc_us-gaap_CertificatesOfDepositMember_10deaa14-9978-4378-8c63-5cb7ea54cf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1f44a2d5-9d5c-4e37-928c-aaa6c502dfc3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0b56e986-2cb2-4fd7-a4d6-6340f6f9ff7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0b56e986-2cb2-4fd7-a4d6-6340f6f9ff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1399cf18-f480-44c7-a35b-4ab616b9fcd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1399cf18-f480-44c7-a35b-4ab616b9fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe69d0ec-6ec7-4c4a-8a93-bcfed1f9838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fe69d0ec-6ec7-4c4a-8a93-bcfed1f9838a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bdda23a-b87e-4ee8-b50b-e57374f334ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cbc6e83-16ad-4608-afdc-025b7b875993" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bdda23a-b87e-4ee8-b50b-e57374f334ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_db15c934-3827-44c6-8c7b-44552d2cc625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d0c42f00-c158-4058-bef2-e9c76baa890a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_db15c934-3827-44c6-8c7b-44552d2cc625" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d0c42f00-c158-4058-bef2-e9c76baa890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a28e6cf0-fbdf-451b-bb3d-2eb22353cee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4c9426ab-dc64-46fe-955a-83b141da32d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a28e6cf0-fbdf-451b-bb3d-2eb22353cee3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4c9426ab-dc64-46fe-955a-83b141da32d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_dbb43c5c-0309-4349-b376-a9d280ad19be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a28e6cf0-fbdf-451b-bb3d-2eb22353cee3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_dbb43c5c-0309-4349-b376-a9d280ad19be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8e441919-f8d1-424c-ada4-34b88b32589e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a28e6cf0-fbdf-451b-bb3d-2eb22353cee3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8e441919-f8d1-424c-ada4-34b88b32589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_57c7fd29-ed1e-4194-804d-93e78af4b932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_57c7fd29-ed1e-4194-804d-93e78af4b932" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2f858079-8a73-42be-96a3-d23b0aba413e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bf65d2d4-6fdc-4899-9cc6-f2fe3b9b2c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bf65d2d4-6fdc-4899-9cc6-f2fe3b9b2c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_40f045b0-c950-42d8-9c2e-d1ea03bb6a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_40f045b0-c950-42d8-9c2e-d1ea03bb6a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_56518859-caa6-4f47-bb69-83acfc29e9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84e33cfb-14a9-4d02-8e39-44cb40976b1c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_56518859-caa6-4f47-bb69-83acfc29e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37eea4a7-aabc-4c3b-b55a-7cbf4eb61b00" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_42cec1b7-7639-4da1-87e3-e6a18041773b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_42cec1b7-7639-4da1-87e3-e6a18041773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherFinancialAssetsMember_1f3c628b-5ff7-49ee-b4c8-6a17cc845d47" xlink:href="pgen-20201231.xsd#pgen_OtherFinancialAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a34ea5f-8a20-4a86-af17-b9898e59d976" xlink:to="loc_pgen_OtherFinancialAssetsMember_1f3c628b-5ff7-49ee-b4c8-6a17cc845d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8407978c-fe81-4a7e-8779-dfeaaaea1924" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_04626c9f-900b-4f8a-af2c-8bb03d2f172e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ad4155f1-8ac6-44e2-9c20-17114a998099" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_04626c9f-900b-4f8a-af2c-8bb03d2f172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsSummaryofLevel3InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a2e76232-461c-436e-bbd5-5f6494d2af4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2e76232-461c-436e-bbd5-5f6494d2af4c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c7b5c97d-4532-4e83-a78c-693f86915498" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c19f4396-7fdc-449c-b98f-7940bd69b3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4b18a97-512c-4454-b08e-b8016f462f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c19f4396-7fdc-449c-b98f-7940bd69b3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ace0d854-075d-4163-b3f7-ecf70be5398e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6e57ec4-1f30-4630-8efa-fbd387e976c5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_13cfe4eb-eec0-4863-9c1d-56c96b766557" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_347c4f5d-8138-4f2e-b59d-a14cf3207e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_347c4f5d-8138-4f2e-b59d-a14cf3207e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_bc8b1762-1e90-47c5-b350-1a0a368417a8" xlink:href="pgen-20201231.xsd#pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary_bc8b1762-1e90-47c5-b350-1a0a368417a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_355fb19d-1fa2-4a12-91b4-8733d002d556" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_NoncashDividendIncome_355fb19d-1fa2-4a12-91b4-8733d002d556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_c5b905e8-8b89-4f57-9ccb-b69d75a4bef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_c5b905e8-8b89-4f57-9ccb-b69d75a4bef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1bba86cc-9248-42d3-8eb6-7bccf9f116a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1bba86cc-9248-42d3-8eb6-7bccf9f116a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PreferredStockReceivables_b8601118-9c7d-4d19-920d-ad0081b0ca93" xlink:href="pgen-20201231.xsd#pgen_PreferredStockReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_pgen_PreferredStockReceivables_b8601118-9c7d-4d19-920d-ad0081b0ca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fbf199a9-7ef6-4af6-8edb-3b77c735c61a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dc3342be-0747-4fbb-a75a-7c0865fc2253" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fbf199a9-7ef6-4af6-8edb-3b77c735c61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_12f6bc68-aeef-4c3b-ad47-d7711b1b3469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_12f6bc68-aeef-4c3b-ad47-d7711b1b3469" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:to="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_45f837a1-cdbc-49c8-a585-35b5532d7b25" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_8a582af9-093f-4a5d-a82b-582523a30c35" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d433eb3d-fdf1-441f-a3ed-a23f527659a4" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_8a582af9-093f-4a5d-a82b-582523a30c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d94a0edb-a850-42f3-9b34-a0a9797aff5b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6bde63f-c1a7-4c9b-b371-b343797d3955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8cd929fb-1bb6-483c-b102-43fe18053ba3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6bde63f-c1a7-4c9b-b371-b343797d3955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6928e2fd-e29b-4c21-bcb8-c11c0cc41d1d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0cc18040-208b-45fd-ab8a-05dfda0e385a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0cc18040-208b-45fd-ab8a-05dfda0e385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5b9a0475-8986-4503-a01b-9e2ab7b214bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_ConvertibleDebt_5b9a0475-8986-4503-a01b-9e2ab7b214bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb416e85-5468-4796-8b6e-0ab01ae5e6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522afaec-bab5-4b15-8984-b3e9b03f46a7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eb416e85-5468-4796-8b6e-0ab01ae5e6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c91b7f57-2aad-415e-882d-cdcf30b8d37a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c91b7f57-2aad-415e-882d-cdcf30b8d37a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3cfd284-4a21-433d-833e-fbbc0c85d970" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_83b9a933-4d24-47aa-b367-d34cc0838e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_73357a1f-1556-4498-9dcd-4caab8d50f58" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_83b9a933-4d24-47aa-b367-d34cc0838e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cf323c4-618e-4d55-a857-a7c335f5e2f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2f3acfe-6807-4fd3-a232-3d903f651335" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c710c76-50c0-4394-8a62-09fb5f2c4622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9c710c76-50c0-4394-8a62-09fb5f2c4622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8328206-dd3e-4be8-b7ac-406fc1761313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8328206-dd3e-4be8-b7ac-406fc1761313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d3e7e801-4285-483a-a19c-f17a033ea0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73b450d6-c1da-4f01-90a8-de9b3f3b5f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d3e7e801-4285-483a-a19c-f17a033ea0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/Inventory" xlink:type="simple" xlink:href="pgen-20201231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_54837557-8e1b-4ed0-940f-9161abd84e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2b22c43c-55a2-4021-854a-5e19a3803a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_54837557-8e1b-4ed0-940f-9161abd84e14" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2b22c43c-55a2-4021-854a-5e19a3803a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d17d6e0b-4e24-4944-982d-6e8d3f095db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_134d2010-85d9-4e7c-8b39-b5c7704b06f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d17d6e0b-4e24-4944-982d-6e8d3f095db9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_134d2010-85d9-4e7c-8b39-b5c7704b06f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5aeb97fa-affd-4e8d-9fde-a8b683ec90ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5aeb97fa-affd-4e8d-9fde-a8b683ec90ea" xlink:to="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_d9fdd98f-9516-40ae-9e73-a5eb7fce6961" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_eff41bd0-b209-4c57-b75f-5c4b79bdfc89" xlink:href="pgen-20201231.xsd#pgen_SuppliesEmbryosAndOtherProductionMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_SuppliesEmbryosAndOtherProductionMaterialsMember_eff41bd0-b209-4c57-b75f-5c4b79bdfc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_WorkInProcessMember_aca04f50-6ab7-45a1-9afd-6d3036b43b30" xlink:href="pgen-20201231.xsd#pgen_WorkInProcessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_WorkInProcessMember_aca04f50-6ab7-45a1-9afd-6d3036b43b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LivestockMember_edf79cc1-e633-4fb3-94c0-b1c737413e72" xlink:href="pgen-20201231.xsd#pgen_LivestockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_LivestockMember_edf79cc1-e633-4fb3-94c0-b1c737413e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FeedMember_bf557bed-174e-413b-8100-73efb7b1638d" xlink:href="pgen-20201231.xsd#pgen_FeedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_40134c5a-9c3e-4372-9b6b-53ec49cf5096" xlink:to="loc_pgen_FeedMember_bf557bed-174e-413b-8100-73efb7b1638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_731cbc31-6da3-48d2-9841-fdecc99d96c8" xlink:to="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_80ac62bf-97ec-4d59-a38c-802fa7e05a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_02de5023-7fbb-409d-9728-9ca21f514b09" xlink:to="loc_us-gaap_InventoryGross_80ac62bf-97ec-4d59-a38c-802fa7e05a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe1ff8a3-731d-4b8a-b3fa-01056b9ea73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4d7927ea-b4a9-47c7-858e-85c92dc67df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe1ff8a3-731d-4b8a-b3fa-01056b9ea73a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4d7927ea-b4a9-47c7-858e-85c92dc67df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_08852290-7cf7-448e-98ae-53e475de4453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c8a87821-8cad-47dc-bb21-6c52f40cbfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_08852290-7cf7-448e-98ae-53e475de4453" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c8a87821-8cad-47dc-bb21-6c52f40cbfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovements_6205b7a6-ed35-4094-890b-ca3019cb7407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndLandImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_LandAndLandImprovements_6205b7a6-ed35-4094-890b-ca3019cb7407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_9c303632-e32b-498f-8b78-af10b3655965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_9c303632-e32b-498f-8b78-af10b3655965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_8095c511-5d8b-41b7-8b21-1c8bf5dc2c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_8095c511-5d8b-41b7-8b21-1c8bf5dc2c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_f9b21e4e-29d8-416c-8173-13dc329cdd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_f9b21e4e-29d8-416c-8173-13dc329cdd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_f0a1dbc9-e5bc-485a-a385-9dc99e633455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_f0a1dbc9-e5bc-485a-a385-9dc99e633455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_BreedingandProductionAnimalsGross_53624096-a976-44e5-a16f-7b8b31ef9dff" xlink:href="pgen-20201231.xsd#pgen_BreedingandProductionAnimalsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_pgen_BreedingandProductionAnimalsGross_53624096-a976-44e5-a16f-7b8b31ef9dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ComputerHardwareandSoftware_322e3673-5bb2-4853-9f01-91024c83a85b" xlink:href="pgen-20201231.xsd#pgen_ComputerHardwareandSoftware"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_pgen_ComputerHardwareandSoftware_322e3673-5bb2-4853-9f01-91024c83a85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a4f314ab-3030-4230-99ff-fe9ac55a20c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_ConstructionInProgressGross_a4f314ab-3030-4230-99ff-fe9ac55a20c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8568919d-9b62-4032-9b24-ef8f53ad56f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8568919d-9b62-4032-9b24-ef8f53ad56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79b00abd-e370-4693-9730-e2fe1befd893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79b00abd-e370-4693-9730-e2fe1befd893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7fd4a36-bddb-41bb-90e4-3491f4d4090d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9343f7a0-fd3d-4f52-b44a-6359fc603a61" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7fd4a36-bddb-41bb-90e4-3491f4d4090d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#PropertyPlantandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de42e3a6-32f2-4c2e-a610-86cdc61f1210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_77baf165-32ad-41f8-b0eb-c5c79ea0941a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de42e3a6-32f2-4c2e-a610-86cdc61f1210" xlink:to="loc_us-gaap_Depreciation_77baf165-32ad-41f8-b0eb-c5c79ea0941a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_517dd968-493d-4dc3-8245-36010bac86a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de42e3a6-32f2-4c2e-a610-86cdc61f1210" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_517dd968-493d-4dc3-8245-36010bac86a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfReportingUnitsClosed_0c2d64e9-a21f-40bd-afc8-ad35600c9275" xlink:href="pgen-20201231.xsd#pgen_NumberOfReportingUnitsClosed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_de42e3a6-32f2-4c2e-a610-86cdc61f1210" xlink:to="loc_pgen_NumberOfReportingUnitsClosed_0c2d64e9-a21f-40bd-afc8-ad35600c9275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1679ae5e-46bd-4924-85dc-445585d7eb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7f50ea3d-b4d6-48ec-a98e-b5ae270bc41f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1679ae5e-46bd-4924-85dc-445585d7eb49" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7f50ea3d-b4d6-48ec-a98e-b5ae270bc41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1452b5e4-2d4b-4ecd-a2c1-d63c9bfad87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_5825f3af-50b9-4695-8c32-3bd819d073e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1452b5e4-2d4b-4ecd-a2c1-d63c9bfad87a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_5825f3af-50b9-4695-8c32-3bd819d073e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d5c2a3a9-4343-476c-8185-697bcc82f936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1452b5e4-2d4b-4ecd-a2c1-d63c9bfad87a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d5c2a3a9-4343-476c-8185-697bcc82f936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2b2d0a78-3f03-4a4c-a1a1-99f678603fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1452b5e4-2d4b-4ecd-a2c1-d63c9bfad87a" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2b2d0a78-3f03-4a4c-a1a1-99f678603fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008913d5-f83c-4842-b26d-3f41ce51c599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_008913d5-f83c-4842-b26d-3f41ce51c599" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_c5168ccd-7dc5-479f-981c-842e52df6fd1" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_05dfd585-c71d-4564-b447-c7a4850af1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_e56034a5-4c0c-4127-9dad-fa5403b30c72" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_05dfd585-c71d-4564-b447-c7a4850af1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_32783b63-2eb5-480a-a50f-ef7b61945a0c" xlink:to="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_54289a02-6374-43f4-8a1b-85a34c5e2127" xlink:to="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_62959b47-b7ed-44a4-a7d6-928ac3be31df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_Goodwill_62959b47-b7ed-44a4-a7d6-928ac3be31df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_dec5a96e-32b8-48d4-a478-6d44200c9cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_dec5a96e-32b8-48d4-a478-6d44200c9cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_710eb27a-57f6-4b17-be6d-6b02ad954555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_710eb27a-57f6-4b17-be6d-6b02ad954555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8998d5e1-8772-4165-92c6-5abdf6bb5aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5cb25a-bbeb-4a0e-a23e-f016f646068b" xlink:to="loc_us-gaap_Goodwill_8998d5e1-8772-4165-92c6-5abdf6bb5aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7c145e4f-9ee5-4534-abc4-7035bc2c04de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7c145e4f-9ee5-4534-abc4-7035bc2c04de" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d715f40c-af5b-4aba-84da-b86a17c7401c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_935e6aaf-d546-4d61-9d5c-38496de22f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c5f07d28-cf79-417a-9f6d-7fae099ce0f0" xlink:to="loc_us-gaap_IntellectualPropertyMember_935e6aaf-d546-4d61-9d5c-38496de22f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_cc27d4b7-ba96-4e19-ae8c-f42b89e91baa" xlink:to="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaSegmentMember_43769bbc-0df1-41d7-8a59-03a7e5f62119" xlink:href="pgen-20201231.xsd#pgen_TransOvaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eb3e26a7-3a07-474a-9631-79e988dd1975" xlink:to="loc_pgen_TransOvaSegmentMember_43769bbc-0df1-41d7-8a59-03a7e5f62119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_05651ab0-24b8-4098-a81c-533752b117f6" xlink:to="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_bc087c1a-87b2-4fa0-a683-9b53dcb011cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_bc087c1a-87b2-4fa0-a683-9b53dcb011cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_de1bb945-8e30-44ad-8740-8690926afacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_de1bb945-8e30-44ad-8740-8690926afacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfReportingUnitsClosed_9f7a75eb-8db5-4ad3-8f92-b5ac9bec8a38" xlink:href="pgen-20201231.xsd#pgen_NumberOfReportingUnitsClosed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_pgen_NumberOfReportingUnitsClosed_9f7a75eb-8db5-4ad3-8f92-b5ac9bec8a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cbfe4af4-8c7f-4651-8b5d-dc6311274e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cbfe4af4-8c7f-4651-8b5d-dc6311274e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_caef4584-9e71-4519-91dc-578349ea2a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_d4aad269-1a1e-42f3-8d35-59c5a8aeaeeb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_caef4584-9e71-4519-91dc-578349ea2a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_efa7dedc-4093-46d0-97d9-3eda0191aad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_efa7dedc-4093-46d0-97d9-3eda0191aad9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:to="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c4fda159-bf5b-4c0e-8c7a-493200043192" xlink:to="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_386f3805-00a0-4ce0-b05b-29fd3092dc30" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_150ed4e8-8688-4186-ae2c-d8fa2d35d125" xlink:to="loc_srt_WeightedAverageMember_386f3805-00a0-4ce0-b05b-29fd3092dc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_133bd074-0955-4b3a-9a03-7c03c1765ad0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_903f13bb-4c18-48c3-829e-b7d202e530c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_IntellectualPropertyMember_903f13bb-4c18-48c3-829e-b7d202e530c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e824b0b-5642-42e9-a107-e23b505b55a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e824b0b-5642-42e9-a107-e23b505b55a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_9bd832d0-81e6-4878-a122-b81a0d6103c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ae5881ae-23e4-4d21-9c09-98bd92bcf8f1" xlink:to="loc_us-gaap_TrademarksMember_9bd832d0-81e6-4878-a122-b81a0d6103c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d2bfc0ba-9967-4db8-9f74-06df496609c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0bac35f8-eefc-4902-b456-46406e6d5595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0bac35f8-eefc-4902-b456-46406e6d5595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52f77f2a-25ef-4553-9c07-bfb3c229a6ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e03074c0-2ec4-4fa9-99b4-5fecdec642f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e03074c0-2ec4-4fa9-99b4-5fecdec642f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7d051952-8be9-413b-9659-8d32c0947d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7d051952-8be9-413b-9659-8d32c0947d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5a56bb3-bfc1-44ce-9187-0036382e21fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7f399d08-5162-4589-a0a6-5dffac7f9e4a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e5a56bb3-bfc1-44ce-9187-0036382e21fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3304245-035c-40e2-b8fc-5ae809c0d2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3304245-035c-40e2-b8fc-5ae809c0d2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_83910067-06d2-4f5e-bab2-b98272737d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_83910067-06d2-4f5e-bab2-b98272737d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f05285af-429b-49b1-8922-9e4de57148bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f05285af-429b-49b1-8922-9e4de57148bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2bc86ce-739b-4e84-8bd8-d150ceb43efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2bc86ce-739b-4e84-8bd8-d150ceb43efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_070ba55d-b005-4739-9219-4b16e165bf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_070ba55d-b005-4739-9219-4b16e165bf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa0d5d4f-7286-4803-99bc-98119d925460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa0d5d4f-7286-4803-99bc-98119d925460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b935c319-b8bb-447c-8ff3-c0aed58578c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7efddc2b-7d86-4f38-9683-172a033c4d2b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b935c319-b8bb-447c-8ff3-c0aed58578c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebt"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_de256e35-3537-474f-a398-96bf288cebf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3a6710a6-e29c-4b4e-abb6-548d69ef4117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_de256e35-3537-474f-a398-96bf288cebf3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3a6710a6-e29c-4b4e-abb6-548d69ef4117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b0229789-fe72-4f60-972d-c97f37b1d1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5c0a1802-6184-45d9-9729-e2073504f6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b0229789-fe72-4f60-972d-c97f37b1d1bd" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5c0a1802-6184-45d9-9729-e2073504f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_8490a533-184c-4b9e-9707-abcbe6010be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b0229789-fe72-4f60-972d-c97f37b1d1bd" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_8490a533-184c-4b9e-9707-abcbe6010be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dd6f0cec-41c3-471d-9dff-a1b290043858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b0229789-fe72-4f60-972d-c97f37b1d1bd" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_dd6f0cec-41c3-471d-9dff-a1b290043858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f8a84990-825a-4e08-933f-36a3210c58ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f8a84990-825a-4e08-933f-36a3210c58ee" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_75996776-2cb5-46b9-8e46-6f36c23c32c1" xlink:to="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7cf05c01-70f7-4dc6-9ad5-55f3513bc395" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37dea5ce-10bd-4ff9-a541-9ed8cd0da067" xlink:to="loc_srt_MinimumMember_7cf05c01-70f7-4dc6-9ad5-55f3513bc395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8f0ae1da-837a-4fb7-966c-f209f1d65313" xlink:to="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_65e1170e-b999-446c-9605-aec0c94ffc08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_345d0ae8-2891-4c17-90b6-76fe8c6e7aa1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_65e1170e-b999-446c-9605-aec0c94ffc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9f2e24bc-c294-407e-b114-2972d10fa102" xlink:to="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaGeneticsLcMember_d029b6e4-1e4a-4731-ba10-c1e052396863" xlink:href="pgen-20201231.xsd#pgen_TransOvaGeneticsLcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:to="loc_pgen_TransOvaGeneticsLcMember_d029b6e4-1e4a-4731-ba10-c1e052396863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExemplarGeneticsLLCMember_e1091f5c-2832-4025-b5fb-11d80a63720a" xlink:href="pgen-20201231.xsd#pgen_ExemplarGeneticsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bd4992fa-13eb-4333-8698-ce8a753eff4e" xlink:to="loc_pgen_ExemplarGeneticsLLCMember_e1091f5c-2832-4025-b5fb-11d80a63720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_efa855a0-787f-41bf-8874-e05cedb6785f" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_FirstNationalBankofOmahaMember_a85cd19e-56c0-41fb-bd84-b19d90c121ce" xlink:href="pgen-20201231.xsd#pgen_FirstNationalBankofOmahaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:to="loc_pgen_FirstNationalBankofOmahaMember_a85cd19e-56c0-41fb-bd84-b19d90c121ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AmericanStateBankMember_7fe32a74-dc6f-4ea7-9cc1-be6604313653" xlink:href="pgen-20201231.xsd#pgen_AmericanStateBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1429f08a-f910-45b3-bd91-b14d59127d1d" xlink:to="loc_pgen_AmericanStateBankMember_7fe32a74-dc6f-4ea7-9cc1-be6604313653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_dedc7c37-6f1c-46b6-baa8-1f142787d649" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a58876a1-f613-439d-947a-9845cb57cc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a58876a1-f613-439d-947a-9845cb57cc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa11984-2d5d-4bb0-ac7d-78ad114c91d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa11984-2d5d-4bb0-ac7d-78ad114c91d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8e422589-ffaa-4fba-9de9-454a3189b1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8e422589-ffaa-4fba-9de9-454a3189b1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3542adbf-497b-4ea7-a47b-09050e2002dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCredit_3542adbf-497b-4ea7-a47b-09050e2002dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_e9d4322d-4f45-407b-9beb-5f3639e53d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2e06d345-4924-4734-986c-2c2c759ef8c8" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_e9d4322d-4f45-407b-9beb-5f3639e53d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cc20c47a-000f-4aab-9592-a511749d478e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cc20c47a-000f-4aab-9592-a511749d478e" xlink:to="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa30f8bf-7de9-498a-9d8a-9c8c891fd91b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b604eadd-0df1-4172-bfe4-4cfe1cc7875e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_us-gaap_ConvertibleDebtMember_b604eadd-0df1-4172-bfe4-4cfe1cc7875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_13f758ed-32da-42f2-a430-1c45b3e63eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_13f758ed-32da-42f2-a430-1c45b3e63eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OtherLongTermDebtMember_23b37cae-efbd-4e19-bb43-58ebb05876ec" xlink:href="pgen-20201231.xsd#pgen_OtherLongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ccf4b34e-74ca-444f-ba3d-424ff981321b" xlink:to="loc_pgen_OtherLongTermDebtMember_23b37cae-efbd-4e19-bb43-58ebb05876ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_183b6363-9427-4d8e-8ffa-88406ddb776d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c01bf28-0edb-4df3-9f1d-23538286b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebt_4c01bf28-0edb-4df3-9f1d-23538286b9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ef9a60ea-f470-45d2-aa3b-1f2f1c407e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebtCurrent_ef9a60ea-f470-45d2-aa3b-1f2f1c407e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4918e6e9-7439-4e65-9c3c-c2e466e5aead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e1e38085-f63c-40c8-9e2f-cfa02a0bed2e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4918e6e9-7439-4e65-9c3c-c2e466e5aead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4aee302d-1f84-405a-b1d2-631272c4d56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4aee302d-1f84-405a-b1d2-631272c4d56a" xlink:to="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6009ad1f-ac7b-47b0-b8ff-096ee5d29509" xlink:to="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_0be0f3c0-eead-4371-9e10-74a4edce20ff" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8c390434-a985-444d-9c72-37ad291f3a2d" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_0be0f3c0-eead-4371-9e10-74a4edce20ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0846944-570b-48a2-b5a6-f44ab232fbff" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_02d866c1-2b93-4b05-8599-6c81144538f1" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_02d866c1-2b93-4b05-8599-6c81144538f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MerckConvertibleNoteMember_53391107-fbb0-46f1-aa11-9bd44ccf5214" xlink:href="pgen-20201231.xsd#pgen_MerckConvertibleNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_MerckConvertibleNoteMember_53391107-fbb0-46f1-aa11-9bd44ccf5214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioNotesMember_9851965c-bc75-40a5-bbc3-2b5ba5fa3f43" xlink:href="pgen-20201231.xsd#pgen_ActoBioNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64279e90-18c7-4473-a650-d23ac7000cd0" xlink:to="loc_pgen_ActoBioNotesMember_9851965c-bc75-40a5-bbc3-2b5ba5fa3f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6660b3f9-f074-4e0b-8fc3-1998c21c20a9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_e172a5d8-6e0b-4918-a68a-359f63f3b7f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:to="loc_us-gaap_ConvertibleDebtMember_e172a5d8-6e0b-4918-a68a-359f63f3b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_e91f9447-82b2-44c5-8ef7-4006b4b49921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6fa451c5-0710-4f33-ae78-892303243f5a" xlink:to="loc_us-gaap_NotesPayableToBanksMember_e91f9447-82b2-44c5-8ef7-4006b4b49921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5c62871c-5afe-4a46-85b4-37806ccfd098" xlink:to="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaGeneticsLcMember_38407e0c-d178-4069-8666-b8d1a800b9fb" xlink:href="pgen-20201231.xsd#pgen_TransOvaGeneticsLcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:to="loc_pgen_TransOvaGeneticsLcMember_38407e0c-d178-4069-8666-b8d1a800b9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenActioBioIncMember_e1d9a1ea-1959-4449-bcef-ccb0ad51be47" xlink:href="pgen-20201231.xsd#pgen_PrecigenActioBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1d2c27c3-cb30-45fb-a9bd-2bdbadc1f69d" xlink:to="loc_pgen_PrecigenActioBioIncMember_e1d9a1ea-1959-4449-bcef-ccb0ad51be47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_506faa20-21e7-4689-8fdb-535181b6aaac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AmericanStateBankMember_3a46a37d-2981-4bd6-94df-39d36693c989" xlink:href="pgen-20201231.xsd#pgen_AmericanStateBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:to="loc_pgen_AmericanStateBankMember_3a46a37d-2981-4bd6-94df-39d36693c989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4ba4ada9-3382-47c2-853c-92bc15eff0db" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_07dbb573-e496-45ac-bd93-4813b598dba8" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_4ba4ada9-3382-47c2-853c-92bc15eff0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83e27c21-a4ff-4c98-a00b-9c5e269c4471" xlink:to="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_423266ee-9ea3-43d7-b0b7-56174ad14534" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:to="loc_srt_MinimumMember_423266ee-9ea3-43d7-b0b7-56174ad14534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cacd9429-444e-43c5-8acb-a7ca49eec020" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5cc29f9f-7adb-4df8-9173-a06e71d08bf0" xlink:to="loc_srt_MaximumMember_cacd9429-444e-43c5-8acb-a7ca49eec020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dd3821c4-cea1-4c80-9eae-2743eae74059" xlink:to="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_89e303f2-6951-49c0-9d52-df173686849b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_89e303f2-6951-49c0-9d52-df173686849b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c438e374-3e6d-43e9-aed0-e0f7179effda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c438e374-3e6d-43e9-aed0-e0f7179effda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_ddfecca7-55e6-46a2-9259-a8b46876458a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_ddfecca7-55e6-46a2-9259-a8b46876458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b74b975a-58c0-49ad-8c30-e8d2907ecd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b74b975a-58c0-49ad-8c30-e8d2907ecd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9e2b1841-020b-499c-861b-674d87bc02ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9e2b1841-020b-499c-861b-674d87bc02ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_0faefa03-0245-4e85-aa5a-94cc8a92f6bb" xlink:href="pgen-20201231.xsd#pgen_ConvertibleDebtPrincipalAmountInitialConversionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate_0faefa03-0245-4e85-aa5a-94cc8a92f6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_eca382b3-98ce-4649-8786-18514d448c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_eca382b3-98ce-4649-8786-18514d448c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5c5ada24-b772-4aee-a106-1b23e0e5951d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_5c5ada24-b772-4aee-a106-1b23e0e5951d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70a823b1-ea51-46a9-b0b5-a8ac36cc48c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70a823b1-ea51-46a9-b0b5-a8ac36cc48c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_82690ab4-0fad-4db5-9ebf-03f8c668ba64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_82690ab4-0fad-4db5-9ebf-03f8c668ba64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_e8e4905d-3e99-436b-8b8f-866987de8ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_e8e4905d-3e99-436b-8b8f-866987de8ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_4aa7d991-dafe-4908-9b3c-8086ecce347e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_ConvertibleDebt_4aa7d991-dafe-4908-9b3c-8086ecce347e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6022c7c3-38dd-44fc-bd67-bcb3d1012f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_6022c7c3-38dd-44fc-bd67-bcb3d1012f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9fba3cfd-aa89-4c1a-87b2-ff010d93eee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9fba3cfd-aa89-4c1a-87b2-ff010d93eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7b46e148-5789-465c-87f7-018535c08298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7b46e148-5789-465c-87f7-018535c08298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_10de0bc1-8e20-4aad-b1f8-9baf7b119c56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_10de0bc1-8e20-4aad-b1f8-9baf7b119c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_aa9a0b88-7362-4520-90f5-73f5261a423b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_aa9a0b88-7362-4520-90f5-73f5261a423b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_7195f135-f75f-4024-9174-932b405bb095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_7195f135-f75f-4024-9174-932b405bb095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_96ad8830-0cac-45c5-b208-e8aef3cae374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_InterestExpense_96ad8830-0cac-45c5-b208-e8aef3cae374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DebtInstrumentResaleRestrictionPeriod_c2e9d9a8-0c87-4324-b79e-a26f05ff3099" xlink:href="pgen-20201231.xsd#pgen_DebtInstrumentResaleRestrictionPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_pgen_DebtInstrumentResaleRestrictionPeriod_c2e9d9a8-0c87-4324-b79e-a26f05ff3099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c215fabd-55ac-4e83-8a24-89b88b695074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_LongTermDebt_c215fabd-55ac-4e83-8a24-89b88b695074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_8f144de0-8aad-4f6c-872c-fcae808411b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_129c55b0-7482-45d0-aef4-0acd80687adb" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_8f144de0-8aad-4f6c-872c-fcae808411b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_07f5a35d-403f-4522-8621-680fbe274c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_07f5a35d-403f-4522-8621-680fbe274c94" xlink:to="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:to="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1dcd976f-78aa-4a1d-bb65-b1cf1f7a8d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_A3.5ConvertibleNotesDue2023Member_0622aa94-543f-4ea8-be48-1cdaff26acd8" xlink:href="pgen-20201231.xsd#pgen_A3.5ConvertibleNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0af037f6-581e-400f-b006-f01dbc0bce9c" xlink:to="loc_pgen_A3.5ConvertibleNotesDue2023Member_0622aa94-543f-4ea8-be48-1cdaff26acd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2a9fba32-a871-485c-9eed-27ddcca7778a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_36210e31-d136-40ab-a255-f14131fae964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_36210e31-d136-40ab-a255-f14131fae964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_44aea45e-033b-484b-af78-8096497c49ba" xlink:href="pgen-20201231.xsd#pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts_44aea45e-033b-484b-af78-8096497c49ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_83c88ee6-8fde-4cb3-a2eb-f1446d51c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b95c20a5-8b78-4298-91e3-b5c23d437eee" xlink:to="loc_us-gaap_InterestExpenseDebt_83c88ee6-8fde-4cb3-a2eb-f1446d51c0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_67af2cf0-be35-4b1c-997f-80377f7cb07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_67af2cf0-be35-4b1c-997f-80377f7cb07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eeb1811a-8486-40db-92c1-f5825339185e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eeb1811a-8486-40db-92c1-f5825339185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ec9730bd-a4ea-4e9e-9393-cbd8ae1e3511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ec9730bd-a4ea-4e9e-9393-cbd8ae1e3511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9b4614bd-45ab-4077-88d7-88d58285b392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9b4614bd-45ab-4077-88d7-88d58285b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e914060d-2e70-4611-9168-7c79025bd500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e914060d-2e70-4611-9168-7c79025bd500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_15854065-ec06-486e-8af2-dc489cb13489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_15854065-ec06-486e-8af2-dc489cb13489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_24746e67-67da-4c34-a0a5-faa2359f8923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd6cc882-cd45-4022-b80b-a2a4c9e44920" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_24746e67-67da-4c34-a0a5-faa2359f8923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_192e545c-f04f-46f4-a895-2728a2d5071d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4de840cb-4865-45c3-8b23-04fb45f2b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_192e545c-f04f-46f4-a895-2728a2d5071d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4de840cb-4865-45c3-8b23-04fb45f2b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5e99403d-1352-4032-b4cd-de56b50e86d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5e99403d-1352-4032-b4cd-de56b50e86d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e750551f-df97-4354-9ab6-8582999965d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e750551f-df97-4354-9ab6-8582999965d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d2b19834-9ebf-49ee-80a4-b1cc08f5cd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d2b19834-9ebf-49ee-80a4-b1cc08f5cd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55d18da2-6807-420e-989a-e3d808f90090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_55d18da2-6807-420e-989a-e3d808f90090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_756b369b-2161-4e33-b493-2507e169d7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_283359bc-882f-42d8-80f3-119cf887fe8e" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_756b369b-2161-4e33-b493-2507e169d7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c28a7461-09d0-480c-af20-2b54e2df2184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c28a7461-09d0-480c-af20-2b54e2df2184" xlink:to="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c57a8c2-c6a2-4555-bcb5-badb8e2fd610" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_521b617d-a934-4390-89ff-c2c4be4e61e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:to="loc_us-gaap_DomesticCountryMember_521b617d-a934-4390-89ff-c2c4be4e61e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0444898f-8724-461e-9fa9-71782bfa17e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_bc4ea106-dfad-4a98-96c0-931a64fd6cd0" xlink:to="loc_us-gaap_ForeignCountryMember_0444898f-8724-461e-9fa9-71782bfa17e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_IncomeTaxTable_ac92b12d-6f66-4a45-98d8-1ab6e431fc4f" xlink:to="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23c433d5-8481-46a7-8451-eccac7e477d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_IncomeTaxLineItems_36e23231-3465-47f3-8821-ae7678547a54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23c433d5-8481-46a7-8451-eccac7e477d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3eef6c-df7b-4558-ad32-7d28f95f1f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_799ae5d4-7c00-4eb1-ac5e-935b9bba3884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3eef6c-df7b-4558-ad32-7d28f95f1f44" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_799ae5d4-7c00-4eb1-ac5e-935b9bba3884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c89c6ee1-8de0-435a-a4fc-ba2928375c57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_799ae5d4-7c00-4eb1-ac5e-935b9bba3884" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_c89c6ee1-8de0-435a-a4fc-ba2928375c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fffb5147-684c-4fc4-8af3-e3de9e6e3125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_799ae5d4-7c00-4eb1-ac5e-935b9bba3884" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fffb5147-684c-4fc4-8af3-e3de9e6e3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_9206ff79-97b7-4055-8968-f685b20c082f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3eef6c-df7b-4558-ad32-7d28f95f1f44" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_9206ff79-97b7-4055-8968-f685b20c082f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bdf1c05e-e865-42ab-9203-8b4f732e3d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_9206ff79-97b7-4055-8968-f685b20c082f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bdf1c05e-e865-42ab-9203-8b4f732e3d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b21e5549-29bd-4260-9441-b773c41d2ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_9206ff79-97b7-4055-8968-f685b20c082f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b21e5549-29bd-4260-9441-b773c41d2ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d5febd58-827a-44fd-809b-8fc2177c57bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3eef6c-df7b-4558-ad32-7d28f95f1f44" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d5febd58-827a-44fd-809b-8fc2177c57bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ff247bc-d7c9-4139-9e2a-3cb73a84c730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d5febd58-827a-44fd-809b-8fc2177c57bd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2ff247bc-d7c9-4139-9e2a-3cb73a84c730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f2359336-b357-44e8-9f81-ca57c140e26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_d5febd58-827a-44fd-809b-8fc2177c57bd" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f2359336-b357-44e8-9f81-ca57c140e26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e9aa953e-9cbb-4dbb-a2a7-5ff590cb1f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dd3eef6c-df7b-4558-ad32-7d28f95f1f44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e9aa953e-9cbb-4dbb-a2a7-5ff590cb1f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3de3b0f7-f811-4a52-adec-91769426a503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3de3b0f7-f811-4a52-adec-91769426a503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0fb18b7b-63ec-47ff-b001-d59158d13e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0fb18b7b-63ec-47ff-b001-d59158d13e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fe9046a7-0e08-435c-af5d-3d30912b42e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fe9046a7-0e08-435c-af5d-3d30912b42e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_a166e6ea-39bd-4d22-b076-aae02f40b624" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation_a166e6ea-39bd-4d22-b076-aae02f40b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c813d6f1-939c-4d64-b583-1ac0903da087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_c813d6f1-939c-4d64-b583-1ac0903da087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8e31687e-f60d-40de-92c2-56356a58db3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8e31687e-f60d-40de-92c2-56356a58db3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_e0e825f3-574b-4c34-b22e-a4d4b641ba57" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts_e0e825f3-574b-4c34-b22e-a4d4b641ba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_ef5065c0-20ac-4095-a623-88737e30698b" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount_ef5065c0-20ac-4095-a623-88737e30698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_700967f5-00b2-4718-8dcb-21f64057f3e2" xlink:href="pgen-20201231.xsd#pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount_700967f5-00b2-4718-8dcb-21f64057f3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f6b008a1-0ccd-452e-a004-01ae2e7bd1eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f6b008a1-0ccd-452e-a004-01ae2e7bd1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_08e43c7f-07c6-4361-a584-d0083fe80ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_08e43c7f-07c6-4361-a584-d0083fe80ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_690d75c1-7309-409d-b681-5b4574c80a7d" xlink:href="pgen-20201231.xsd#pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance_690d75c1-7309-409d-b681-5b4574c80a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7c240f5-961f-4441-a1d1-01d16ee96821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7c240f5-961f-4441-a1d1-01d16ee96821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9acd13c5-d21d-4fd1-af5d-34c33dd7c898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd6ffc80-6f12-422f-a546-f040f0a914b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9acd13c5-d21d-4fd1-af5d-34c33dd7c898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c9ff931-dd8c-4dc9-86a2-7432a71c8758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c9ff931-dd8c-4dc9-86a2-7432a71c8758" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1255cb99-4419-4ff1-aaa3-e059c7c190d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1255cb99-4419-4ff1-aaa3-e059c7c190d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_7c80b666-b3e9-476f-9523-d33214240659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_7c80b666-b3e9-476f-9523-d33214240659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_e8dda3c2-fb06-4276-9f98-6ea17cea983a" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption_e8dda3c2-fb06-4276-9f98-6ea17cea983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_74c60b36-2f5c-4835-bcf9-5ba5adf428f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_74c60b36-2f5c-4835-bcf9-5ba5adf428f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5469a545-36be-4008-aa5e-89506103d491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5469a545-36be-4008-aa5e-89506103d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_daedfa35-0300-4026-918c-cfc40917e19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_daedfa35-0300-4026-918c-cfc40917e19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsLeaseLiabilities_7adf7305-8ebf-497b-8da0-ccc6af4a057e" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_pgen_DeferredTaxAssetsLeaseLiabilities_7adf7305-8ebf-497b-8da0-ccc6af4a057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2f43e3da-d94b-4892-b4af-546030832fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2f43e3da-d94b-4892-b4af-546030832fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_083e890c-c72c-49ff-9376-d86c8a719e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_083e890c-c72c-49ff-9376-d86c8a719e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_beb50214-cd16-410e-90a4-7e4be25e2d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_beb50214-cd16-410e-90a4-7e4be25e2d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_991605dd-81d5-4c75-b1cd-e5dcd4e1ebca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries_991605dd-81d5-4c75-b1cd-e5dcd4e1ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_528c36ad-9c70-4f92-96e4-a55e7d860efa" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards_528c36ad-9c70-4f92-96e4-a55e7d860efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6366fe94-761a-4f45-bd34-5c1945681990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6366fe94-761a-4f45-bd34-5c1945681990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_86733179-e665-4857-9e73-3723add1a2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_86733179-e665-4857-9e73-3723add1a2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d880d3ed-96d2-434a-bde5-323fa402ea6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e048969-19df-4871-9a03-76b77752f9f4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d880d3ed-96d2-434a-bde5-323fa402ea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ec9b06f-35c3-4f25-93b1-8bbae58534a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c9ff931-dd8c-4dc9-86a2-7432a71c8758" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ec9b06f-35c3-4f25-93b1-8bbae58534a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_17373302-7ddf-4a71-9fe6-aacd3c4bea8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ec9b06f-35c3-4f25-93b1-8bbae58534a7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_17373302-7ddf-4a71-9fe6-aacd3c4bea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_bb6129d8-84d3-4a46-b8e2-94fe2736baa9" xlink:href="pgen-20201231.xsd#pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ec9b06f-35c3-4f25-93b1-8bbae58534a7" xlink:to="loc_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt_bb6129d8-84d3-4a46-b8e2-94fe2736baa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_313f2b51-99fd-438c-8739-909894a40460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6ec9b06f-35c3-4f25-93b1-8bbae58534a7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_313f2b51-99fd-438c-8739-909894a40460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_14b3fa65-6deb-44dd-ae72-4a3399594dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c9ff931-dd8c-4dc9-86a2-7432a71c8758" xlink:to="loc_us-gaap_DeferredTaxLiabilities_14b3fa65-6deb-44dd-ae72-4a3399594dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesSummaryofValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f9e99df5-82c5-436a-b7ff-473ec5bf96c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9e99df5-82c5-436a-b7ff-473ec5bf96c8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4a547fc6-8e41-4c30-9b5a-ba87e53b430f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_81605cab-e374-48eb-a91c-4c4ba19bfb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_81605cab-e374-48eb-a91c-4c4ba19bfb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_da61fc47-0479-4e03-b528-314b14da8146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_be8a1ba0-da68-4991-9fa2-862a52ecc586" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_da61fc47-0479-4e03-b528-314b14da8146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_50000c96-d513-4aac-aca2-9fa0801b6d68" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e17b9d96-0787-4028-b355-435254304be3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1934c2d5-1efd-43f6-9cea-7d7cc874bbfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1934c2d5-1efd-43f6-9cea-7d7cc874bbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_5bba1907-50d5-4baa-bcfb-c46b2f59e5f9" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet_5bba1907-50d5-4baa-bcfb-c46b2f59e5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_9426fba2-b2fd-4bd1-89c3-6197aad35847" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation_9426fba2-b2fd-4bd1-89c3-6197aad35847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_a6b5918c-6a9f-4d3b-b876-c1e4c186b13c" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations_a6b5918c-6a9f-4d3b-b876-c1e4c186b13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_52d0933b-e58d-4209-96be-7f741045a042" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations_52d0933b-e58d-4209-96be-7f741045a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_c246c98f-f0d1-47bc-b13a-417f1e0b63ba" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales_c246c98f-f0d1-47bc-b13a-417f1e0b63ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_3f68682f-9b2a-4056-86db-612c9cc181f1" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations_3f68682f-9b2a-4056-86db-612c9cc181f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_2dc65335-3abd-4d6b-8fd8-621129ae7e0a" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple_2dc65335-3abd-4d6b-8fd8-621129ae7e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_cc7bb67f-b0d7-42b2-b6cd-da7e5111a3da" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt_cc7bb67f-b0d7-42b2-b6cd-da7e5111a3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_df562a6e-8600-4689-b70c-34f68fa46365" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate_df562a6e-8600-4689-b70c-34f68fa46365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_9fa317e7-605b-4e87-be1d-339847cb9fe1" xlink:href="pgen-20201231.xsd#pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment_9fa317e7-605b-4e87-be1d-339847cb9fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_60fb1405-9c95-4b00-8c2b-fca3448bc7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7a419ce7-18ee-469b-b16f-389d157999fb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_60fb1405-9c95-4b00-8c2b-fca3448bc7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_62febea8-5be7-4f8a-8a7f-74ea688f0125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_62febea8-5be7-4f8a-8a7f-74ea688f0125" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2d21695e-59ac-438b-a2cc-49e225503dfc" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GeneratedAfter2017Member_36ac1e41-830c-446c-a440-d2742a364b44" xlink:href="pgen-20201231.xsd#pgen_GeneratedAfter2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_4b4351eb-a4af-4b26-8acb-52cd38e2c9d4" xlink:to="loc_pgen_GeneratedAfter2017Member_36ac1e41-830c-446c-a440-d2742a364b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_de9f3f31-a1f2-4db4-8b0f-3575b118e341" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_db2da65f-3eaa-486f-b9dc-b9e5e8bd501b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:to="loc_us-gaap_DomesticCountryMember_db2da65f-3eaa-486f-b9dc-b9e5e8bd501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_f7e4278e-41bf-45d0-a98a-abc2ccb56f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_990c0b6d-6bf2-4d49-bbc3-9fdcf71cd232" xlink:to="loc_us-gaap_ForeignCountryMember_f7e4278e-41bf-45d0-a98a-abc2ccb56f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5d4cf244-8593-4fcd-925d-87b7c2f83e01" xlink:to="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ForeignSubsidiariesMember_cb78c948-cdc3-4b56-902f-a3304cd2fd02" xlink:href="pgen-20201231.xsd#pgen_ForeignSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5d8a15f5-847d-41f2-93b4-d02af70f3764" xlink:to="loc_pgen_ForeignSubsidiariesMember_cb78c948-cdc3-4b56-902f-a3304cd2fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_0d1e091e-71fd-4495-bae1-3a7d36215af2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_b2d3d9df-4193-4f02-9831-66a87f49a13a" xlink:href="pgen-20201231.xsd#pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness_b2d3d9df-4193-4f02-9831-66a87f49a13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6aa6092f-1c62-4ca5-914d-680ccd94001f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6aa6092f-1c62-4ca5-914d-680ccd94001f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_aa6489c5-2a1c-4e01-ba83-29bb56dc256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_aa6489c5-2a1c-4e01-ba83-29bb56dc256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84ad2d3d-e4c8-4cd4-8b6d-e00042779cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_84ad2d3d-e4c8-4cd4-8b6d-e00042779cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e980365e-a4a0-4164-848d-3819e9437767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_42df50f7-51a3-4a4e-9109-89def858275c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e980365e-a4a0-4164-848d-3819e9437767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fea90041-fd4a-4b9a-9d20-1ab09c73b02e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6846a9a4-0932-4f7a-b0c8-db0ab1b8236f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fea90041-fd4a-4b9a-9d20-1ab09c73b02e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6846a9a4-0932-4f7a-b0c8-db0ab1b8236f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b61cae5d-bb97-4662-9b01-2142ab29bc43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0dc2cf22-7a7a-4fc2-b059-b6814c3bc3e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b61cae5d-bb97-4662-9b01-2142ab29bc43" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_0dc2cf22-7a7a-4fc2-b059-b6814c3bc3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_da8874b1-3395-4799-80aa-cf687d64af75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_da8874b1-3395-4799-80aa-cf687d64af75" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_d8b99ad4-a2ea-4384-8b9c-d8fd136810c9" xlink:to="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AquaBountyMember_711ee122-16c9-42d1-9d77-9a849b4f9494" xlink:href="pgen-20201231.xsd#pgen_AquaBountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_493b91d3-6c5a-4b6c-ad51-4474764c3e43" xlink:to="loc_pgen_AquaBountyMember_711ee122-16c9-42d1-9d77-9a849b4f9494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_711b4270-6dab-450b-bf3d-3aefdca0a942" xlink:to="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AquaBountyMember_2d54d594-b5fd-4f54-90af-a28bc1f6a5bc" xlink:href="pgen-20201231.xsd#pgen_AquaBountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a7d35029-f7fb-445f-ac53-cd6ccf3cd9c8" xlink:to="loc_pgen_AquaBountyMember_2d54d594-b5fd-4f54-90af-a28bc1f6a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9d3100ea-5eff-4eb4-824d-5a0a7c7a4ec7" xlink:to="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TSBiotechnologyHoldingsLLCMember_b1f617a2-2d0f-438e-a215-31069593638f" xlink:href="pgen-20201231.xsd#pgen_TSBiotechnologyHoldingsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:to="loc_pgen_TSBiotechnologyHoldingsLLCMember_b1f617a2-2d0f-438e-a215-31069593638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AffiliatesOfThirdSecurityMember_7caf80e9-197f-4265-aef9-60cadeac71a9" xlink:href="pgen-20201231.xsd#pgen_AffiliatesOfThirdSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_011aa0ed-c10b-4f0f-90f0-3f6f783ba435" xlink:to="loc_pgen_AffiliatesOfThirdSecurityMember_7caf80e9-197f-4265-aef9-60cadeac71a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a50a5b1a-7572-4137-a070-78ca02c4a90b" xlink:to="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49271ef4-7412-462c-b2d4-d6ad5b21523a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_49271ef4-7412-462c-b2d4-d6ad5b21523a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_043049a9-c615-456c-a15a-13da4122ad83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_043049a9-c615-456c-a15a-13da4122ad83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e5a7ded2-8c5d-4c11-8de0-e15993f4469e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e5a7ded2-8c5d-4c11-8de0-e15993f4469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c381cd53-4500-4999-a568-6c90ad6ffcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c381cd53-4500-4999-a568-6c90ad6ffcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OwnshareLendingArrangementSharesIssued_a503971b-b907-46cf-b6e6-acd14f10b811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OwnshareLendingArrangementSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_OwnshareLendingArrangementSharesIssued_a503971b-b907-46cf-b6e6-acd14f10b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_b57c3cc8-3d47-41a2-9d86-5f65226ecc43" xlink:href="pgen-20201231.xsd#pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination_b57c3cc8-3d47-41a2-9d86-5f65226ecc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_6d606512-0306-495a-b7d7-8cd7f15511f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_6d606512-0306-495a-b7d7-8cd7f15511f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_0f3e6c1e-8028-4f9b-a239-f5b30a2dbc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent_0f3e6c1e-8028-4f9b-a239-f5b30a2dbc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_8817b0af-d605-40f0-81db-bf56c9276bea" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18546225-c829-4822-b6f3-1cc7a986c40b" xlink:to="loc_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised_8817b0af-d605-40f0-81db-bf56c9276bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_70491398-2f31-4ef3-bc08-df0957d63df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_70491398-2f31-4ef3-bc08-df0957d63df9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_648b9cd6-5df0-41a8-93d4-8f25a2122978" xlink:to="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_824053d1-67ff-4a48-b76e-a764518546ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_824053d1-67ff-4a48-b76e-a764518546ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_618d3e3c-b53e-43f8-9d8b-36591d49fe09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_618d3e3c-b53e-43f8-9d8b-36591d49fe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c4e7aee-c9fe-420b-a658-b9c6c87df5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ddc92b-6c06-4588-a96f-685866542593" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0c4e7aee-c9fe-420b-a658-b9c6c87df5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3db23793-118b-490a-bee2-258b38989a32" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8472b1a-27bb-4ef8-b390-3b29f0ce8f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_31efd08d-8107-4e5b-a672-90d5f7c324ca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b8472b1a-27bb-4ef8-b390-3b29f0ce8f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_407634db-ee66-49a8-98d1-793be8b8f444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2d012a5e-e6e8-4d60-8a2b-b203669a812b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_407634db-ee66-49a8-98d1-793be8b8f444" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2d012a5e-e6e8-4d60-8a2b-b203669a812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2237ccc6-6e4e-47b1-b438-4a72f890a81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_01f16252-e2d2-4bbe-afba-fa84f221a1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2237ccc6-6e4e-47b1-b438-4a72f890a81e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_01f16252-e2d2-4bbe-afba-fa84f221a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_35018ff3-7698-4300-985a-dc57c053465c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2237ccc6-6e4e-47b1-b438-4a72f890a81e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_35018ff3-7698-4300-985a-dc57c053465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fb08ebe6-d907-46fe-98c5-64f2d25af6ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2237ccc6-6e4e-47b1-b438-4a72f890a81e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fb08ebe6-d907-46fe-98c5-64f2d25af6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ff87e76b-6253-48d6-8c8a-9c80e56ccec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2237ccc6-6e4e-47b1-b438-4a72f890a81e" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ff87e76b-6253-48d6-8c8a-9c80e56ccec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_649ae24d-bf9f-4ad7-aee8-e620fe5c1412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_649ae24d-bf9f-4ad7-aee8-e620fe5c1412" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_80f99dbc-f1e0-4229-8d17-9973b4fd32c7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfProductsMember_52f791c2-16fd-4506-a226-8392f92fb05a" xlink:href="pgen-20201231.xsd#pgen_CostOfProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_pgen_CostOfProductsMember_52f791c2-16fd-4506-a226-8392f92fb05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CostOfServicesMember_177d0e63-976a-41e7-b8f1-9aed756ba345" xlink:href="pgen-20201231.xsd#pgen_CostOfServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_pgen_CostOfServicesMember_177d0e63-976a-41e7-b8f1-9aed756ba345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3c7836ca-9bc1-4696-83c1-e9091401940e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3c7836ca-9bc1-4696-83c1-e9091401940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c6f25c9d-5fed-408f-b64e-8a0855fb8ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c6f25c9d-5fed-408f-b64e-8a0855fb8ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_b2ab22ca-ebef-47e0-9758-7617332ac3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e6d7df4b-3d8e-4c8d-8f09-1476f5d76217" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_b2ab22ca-ebef-47e0-9758-7617332ac3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dd62094a-91e3-44b6-9cbf-7caa299490b5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_56ebc148-c22b-4286-8fb4-623a22972502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4cb23b8d-f4f2-4fce-88ad-9fa85bb00649" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_56ebc148-c22b-4286-8fb4-623a22972502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20191ad0-3333-42b2-9a8f-ed6ded0504a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20191ad0-3333-42b2-9a8f-ed6ded0504a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ce6402b3-4c2c-49e5-b036-ccf20914a65c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_828618ec-0fcf-46b3-9a13-25730bbf5cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_828618ec-0fcf-46b3-9a13-25730bbf5cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_020ef829-b07f-408e-a476-3ed04e91ce65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bcd306b-c1c2-4625-be5e-3091adbbbd23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_020ef829-b07f-408e-a476-3ed04e91ce65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dc5dbda-0322-4bb1-b899-5ec1869d61aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0938f054-3038-4911-b421-702d08ece5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cc1c9a58-07c6-4767-84c7-c44d4d51623f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0938f054-3038-4911-b421-702d08ece5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a56be59-338b-4356-92bc-e51d3aa2a7ba" xlink:to="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_3ac796c9-0fe3-4b71-b2ba-5bb0199e120e" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a7a3b40c-6358-4043-a5c3-3cc231669afd" xlink:to="loc_pgen_ExecutiveChairmanMember_3ac796c9-0fe3-4b71-b2ba-5bb0199e120e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e9f5324c-d6d6-41f3-8a03-c646023e6553" xlink:to="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9dc1b03b-2915-4f27-991d-1a5bf79b7618" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2008PlanMember_9b07e56f-1620-4c00-bf08-105da767e2dd" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2008PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2008PlanMember_9b07e56f-1620-4c00-bf08-105da767e2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2013PlanMember_f202fb18-1bc6-44cb-8a85-6570f4aa0ed8" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2013PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2013PlanMember_f202fb18-1bc6-44cb-8a85-6570f4aa0ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlan2019PlanMember_ce3c4f2d-5be8-4e3a-a8e6-e316ca1f795d" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlan2019PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_PrecigenStockOptionPlansMember_af35f76e-d327-4a42-b6e2-ea3484b4fa8f" xlink:to="loc_pgen_PrecigenStockOptionPlan2019PlanMember_ce3c4f2d-5be8-4e3a-a8e6-e316ca1f795d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_26f6e4ef-7161-415f-b04d-19b2bc30af55" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_4c8cbe1f-749a-473e-8405-988617f7b9af" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08c1b01f-8ed5-4534-af10-451030e58f13" xlink:to="loc_pgen_ExecutiveChairmanMember_4c8cbe1f-749a-473e-8405-988617f7b9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_138cfaab-5a72-4ddf-a7be-df313520560b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6832cc78-f66e-4170-84c4-1dbdebdc2b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6832cc78-f66e-4170-84c4-1dbdebdc2b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d3a521-902d-4cd0-8149-e6646cf98f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d3a521-902d-4cd0-8149-e6646cf98f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a8047af0-4a21-47e3-b303-e339b1f45d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a8047af0-4a21-47e3-b303-e339b1f45d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ced10cc9-594f-4290-8b04-0a853e669b2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ced10cc9-594f-4290-8b04-0a853e669b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_423fea61-6519-44e9-b0f5-e7f170b16ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_423fea61-6519-44e9-b0f5-e7f170b16ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f3ec3f8-ef45-48d0-a130-b0b4b215c080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f3ec3f8-ef45-48d0-a130-b0b4b215c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bd6f773a-0930-41dc-88cc-55ca2d8d4e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bd6f773a-0930-41dc-88cc-55ca2d8d4e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e3bad5b-143a-4308-a8ad-cdc33b8a0f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e3bad5b-143a-4308-a8ad-cdc33b8a0f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0affcc44-0358-4d70-9daf-c31a11f16450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0affcc44-0358-4d70-9daf-c31a11f16450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aa28b37e-d761-48be-a7ea-7704c8825cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aa28b37e-d761-48be-a7ea-7704c8825cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d3e6c29-9bd2-4bc7-b588-b1291ad6cb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d3e6c29-9bd2-4bc7-b588-b1291ad6cb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_d1d2b746-f130-453b-a1e8-e798c93a795f" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense_d1d2b746-f130-453b-a1e8-e798c93a795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LockupPeriodOnRestrictedStockUnitShares_12f69cb6-cd2b-4d66-904a-aa82b0af1a60" xlink:href="pgen-20201231.xsd#pgen_LockupPeriodOnRestrictedStockUnitShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_LockupPeriodOnRestrictedStockUnitShares_12f69cb6-cd2b-4d66-904a-aa82b0af1a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_7e208329-3e99-4fb4-ad00-7f1d09037633" xlink:href="pgen-20201231.xsd#pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense_7e208329-3e99-4fb4-ad00-7f1d09037633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_5c970cbb-1fae-4485-8219-f4bbacb2473b" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualCashRetainer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualCashRetainer_5c970cbb-1fae-4485-8219-f4bbacb2473b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_e1e9d936-ae77-47bb-bfd5-ac01736f5827" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue_e1e9d936-ae77-47bb-bfd5-ac01736f5827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_ccd7329a-9d08-411a-8e9e-eaa7b710941e" xlink:href="pgen-20201231.xsd#pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfe180c8-c252-4fbe-83b8-ef454a73db31" xlink:to="loc_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue_ccd7329a-9d08-411a-8e9e-eaa7b710941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e41858-fa31-46f4-8d5f-0d52a902da83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e41858-fa31-46f4-8d5f-0d52a902da83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:to="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_787ece7d-9196-484d-8f18-c60d61f5984e" xlink:to="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_77b778bf-e96d-4024-b951-4dadd808756b" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_22dd034f-cb70-4d7a-819f-a8dcabe3be05" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_77b778bf-e96d-4024-b951-4dadd808756b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cb9d512d-5ee9-478a-be47-9b722f9cecae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_567aff58-94d0-4f2f-90b7-ebaa4a4e8f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_567aff58-94d0-4f2f-90b7-ebaa4a4e8f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_45c46716-85f1-4ba5-aef0-bb87cd0d0956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_45c46716-85f1-4ba5-aef0-bb87cd0d0956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9b803d2-7f18-4741-96f0-f4f2d481b977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9b803d2-7f18-4741-96f0-f4f2d481b977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5f1ec19b-5a2b-4303-88c8-5d062eb9167d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5f1ec19b-5a2b-4303-88c8-5d062eb9167d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_39c112c6-15d7-4a0f-a10b-599785d2f2a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_39c112c6-15d7-4a0f-a10b-599785d2f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0deafca8-ec43-4326-a512-a0e840f7a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db057fca-7214-4ab1-997b-0f26f2995984" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0deafca8-ec43-4326-a512-a0e840f7a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34dc5889-b5ef-4fbe-96db-f77edffbab93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34dc5889-b5ef-4fbe-96db-f77edffbab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8746c7ae-3995-491c-b13a-945a3f40bde7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8746c7ae-3995-491c-b13a-945a3f40bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44f658cc-abda-4f46-ad96-3c9ede0818ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44f658cc-abda-4f46-ad96-3c9ede0818ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80061675-769e-42ea-bd32-432ff53ce608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80061675-769e-42ea-bd32-432ff53ce608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47fed912-176e-4980-990f-a3b8949fa2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_47fed912-176e-4980-990f-a3b8949fa2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8825d607-553a-4712-a22f-2d1547fdefb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_51026f32-299c-4f38-901d-4cc7c6c17b93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8825d607-553a-4712-a22f-2d1547fdefb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b815603-cb1f-4409-9121-2b24837af6ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42e3c275-2b9c-438f-8db0-0b42a95afcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42e3c275-2b9c-438f-8db0-0b42a95afcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7f33df0a-ed50-40a1-ac8c-57a23720e86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7f33df0a-ed50-40a1-ac8c-57a23720e86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4baf6054-45f9-4870-9679-906aea230a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4baf6054-45f9-4870-9679-906aea230a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9fbc19c3-b8bd-4fdb-9ad3-cda2e468a283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4abf741b-95ee-4835-9e5c-0e0f5a87c862" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9fbc19c3-b8bd-4fdb-9ad3-cda2e468a283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3706e7f0-777e-4565-9621-79b104c4327c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3706e7f0-777e-4565-9621-79b104c4327c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:to="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_eba3766e-50b9-4832-af50-6c661aef7957" xlink:to="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_8aef5ab0-f7af-4bdb-8a2f-52be1c44fd17" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bc6f31da-0bcb-4acf-8d35-9e96a727076c" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_8aef5ab0-f7af-4bdb-8a2f-52be1c44fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:to="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceAxis_3e3498d9-4aaa-4db6-9b19-171ca5c8b5ee" xlink:to="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceOneMember_b1e688b7-bc37-4a4a-9826-112f8c7f9e0c" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceOneMember_b1e688b7-bc37-4a4a-9826-112f8c7f9e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceTwoMember_4a26366a-5fb1-4bce-ba7d-7820af47e00b" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceTwoMember_4a26366a-5fb1-4bce-ba7d-7820af47e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceThreeMember_48f551f4-a6e6-4057-b27f-6ea4935c0c78" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceThreeMember_48f551f4-a6e6-4057-b27f-6ea4935c0c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFourMember_91e72265-e3f8-455c-8e33-ee0088b45493" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceFourMember_91e72265-e3f8-455c-8e33-ee0088b45493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExercisePriceFiveMember_8b2b8108-f81a-4798-aafb-4284d4a53d7b" xlink:href="pgen-20201231.xsd#pgen_ExercisePriceFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pgen_ExercisePriceDomain_d444c1f4-1877-4c07-9275-2772948193a3" xlink:to="loc_pgen_ExercisePriceFiveMember_8b2b8108-f81a-4798-aafb-4284d4a53d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1d817d36-20fa-4786-bf40-2dade291200d" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_07770d7a-1d66-423d-9328-d43394d94f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_07770d7a-1d66-423d-9328-d43394d94f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_cdedff26-5afe-47be-8272-538999e26263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_cdedff26-5afe-47be-8272-538999e26263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ff3778e7-9b78-4efc-b535-7c1e119588c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_ff3778e7-9b78-4efc-b535-7c1e119588c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627e4f41-f192-425b-ba58-66bbff760b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627e4f41-f192-425b-ba58-66bbff760b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c794c05b-33fb-4d6c-a246-ffffa2654e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c794c05b-33fb-4d6c-a246-ffffa2654e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d1e2b4d-3bdf-459d-92be-a165c17e97e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d1e2b4d-3bdf-459d-92be-a165c17e97e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_56976288-ca61-4f07-a623-6935496ddd7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_56976288-ca61-4f07-a623-6935496ddd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d8f20e81-ad64-4220-a4f9-db47924a7ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d8f20e81-ad64-4220-a4f9-db47924a7ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2e2a2823-df77-4c03-b720-d6e96a87786b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2e2a2823-df77-4c03-b720-d6e96a87786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ac7a51f2-18f5-49c5-a035-690517fc14a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_56501c18-4ecc-4f16-a372-fbe5ae778a12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ac7a51f2-18f5-49c5-a035-690517fc14a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fc767a5-03ff-4611-abde-c3d4c204ea77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fc767a5-03ff-4611-abde-c3d4c204ea77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:to="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_12a07daa-ed25-4193-9949-336390788139" xlink:to="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PrecigenStockOptionPlansMember_cc58996a-63d6-4580-b042-f832971d0c9b" xlink:href="pgen-20201231.xsd#pgen_PrecigenStockOptionPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8c22649d-7db5-4a10-8591-551d5212f5a6" xlink:to="loc_pgen_PrecigenStockOptionPlansMember_cc58996a-63d6-4580-b042-f832971d0c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_458bb661-0c6a-4fb9-bb2e-55b12414c762" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce99ed36-29f2-477d-9f66-7f1db011bbbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce99ed36-29f2-477d-9f66-7f1db011bbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04ca699b-92fb-4741-b397-71f1074ac460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_04ca699b-92fb-4741-b397-71f1074ac460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_486d78b6-df1f-4560-abc3-93da3278f17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_486d78b6-df1f-4560-abc3-93da3278f17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ce4dee4-d9c9-4f4a-bc7a-a7c9fed14943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4ce4dee4-d9c9-4f4a-bc7a-a7c9fed14943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6eb2e91-e084-4263-b032-59a56632daf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ff0b36a-8195-4900-91e2-dfcc04719d7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b6eb2e91-e084-4263-b032-59a56632daf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5018e812-89f7-4e00-b8b6-a68ead46f795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5018e812-89f7-4e00-b8b6-a68ead46f795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cacda8fa-371a-46b3-abc1-bd2d61cbac59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cacda8fa-371a-46b3-abc1-bd2d61cbac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53bb633b-3ff2-44c8-8c49-ad52ed39c5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_53bb633b-3ff2-44c8-8c49-ad52ed39c5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bcfeb1d7-8243-4870-85fe-a6af253fee47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bcfeb1d7-8243-4870-85fe-a6af253fee47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26b508b4-78e9-4229-bea7-a5b11d46c9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ee8cb069-7709-455f-aec1-ea53c8b1058a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26b508b4-78e9-4229-bea7-a5b11d46c9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8271d09d-bca1-4799-8253-34fbd65a25a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40a58f3c-a49f-4765-955a-9451d78788ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8e4e8d5-f015-4605-8ba5-30fbc4f1afd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40a58f3c-a49f-4765-955a-9451d78788ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeases" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e0fa41a2-8bbc-493e-940a-f76b0923ba59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a46a7ccf-2273-47c5-b5bc-c339732a91b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e0fa41a2-8bbc-493e-940a-f76b0923ba59" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a46a7ccf-2273-47c5-b5bc-c339732a91b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f9254e25-c9d9-4a09-a6e0-1dc4f87a5275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cf4697a4-e66a-4ec8-8611-155044b4f046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9254e25-c9d9-4a09-a6e0-1dc4f87a5275" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cf4697a4-e66a-4ec8-8611-155044b4f046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2344b80f-90a8-4afc-8c67-eebb33a4b190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f9254e25-c9d9-4a09-a6e0-1dc4f87a5275" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2344b80f-90a8-4afc-8c67-eebb33a4b190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f80385c-e32d-4cdb-9603-1547c47f26e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f80385c-e32d-4cdb-9603-1547c47f26e3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:to="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bf6857a7-6371-476c-9e9a-16938e5ca727" xlink:to="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60b9a13d-943c-4a8a-a734-842ce0ecf791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:to="loc_srt_MinimumMember_60b9a13d-943c-4a8a-a734-842ce0ecf791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f647e8e1-e0b6-4e8b-93da-3370ab99ad33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_600af3bb-2ac4-4d64-8cdc-59818841a353" xlink:to="loc_srt_MaximumMember_f647e8e1-e0b6-4e8b-93da-3370ab99ad33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_b1418041-c9cb-448e-b578-87153b8e006f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b99ec50e-cad5-4759-821f-f9412df16cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b99ec50e-cad5-4759-821f-f9412df16cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LesseeOperatingLeaseTerminationPeriod_7ef7c452-970b-4633-98e6-d7bd7a31352a" xlink:href="pgen-20201231.xsd#pgen_LesseeOperatingLeaseTerminationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5ffa0432-afe5-44fe-ad46-4e14f2e4cea0" xlink:to="loc_pgen_LesseeOperatingLeaseTerminationPeriod_7ef7c452-970b-4633-98e6-d7bd7a31352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bcc5118f-e974-4a0f-8ada-03cbf12f2e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_26a1e9d9-e96b-4cc3-a669-0dfbc5e6dbba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcc5118f-e974-4a0f-8ada-03cbf12f2e2f" xlink:to="loc_us-gaap_OperatingLeaseCost_26a1e9d9-e96b-4cc3-a669-0dfbc5e6dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_db172c3c-5087-4634-ac39-293d5da1f3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcc5118f-e974-4a0f-8ada-03cbf12f2e2f" xlink:to="loc_us-gaap_ShortTermLeaseCost_db172c3c-5087-4634-ac39-293d5da1f3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_1ca1c945-43c1-4a1e-b911-2bafeba0d60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcc5118f-e974-4a0f-8ada-03cbf12f2e2f" xlink:to="loc_us-gaap_VariableLeaseCost_1ca1c945-43c1-4a1e-b911-2bafeba0d60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c94bf33a-4632-4290-bedb-652c3be801d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcc5118f-e974-4a0f-8ada-03cbf12f2e2f" xlink:to="loc_us-gaap_LeaseCost_c94bf33a-4632-4290-bedb-652c3be801d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a4d90fd8-cf65-4b87-82ea-92b129a85186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d90fd8-cf65-4b87-82ea-92b129a85186" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_030aa225-ef28-475d-9893-f5c89a5eab0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_030aa225-ef28-475d-9893-f5c89a5eab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fe77ca0-7dc9-4364-b688-de31333092e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8fe77ca0-7dc9-4364-b688-de31333092e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b22b9288-2e68-4b1d-b1a3-897a7ca97953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b22b9288-2e68-4b1d-b1a3-897a7ca97953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d160d53-7b12-45a2-a6b0-2ea0c8350910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d160d53-7b12-45a2-a6b0-2ea0c8350910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8772311d-ef96-490d-9cbe-66e690a723fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8772311d-ef96-490d-9cbe-66e690a723fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b0460b6c-a204-41e4-abf8-ccd00b0ea2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b0460b6c-a204-41e4-abf8-ccd00b0ea2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_501b5742-b6e5-4e66-ad55-ac0346a89722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_501b5742-b6e5-4e66-ad55-ac0346a89722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24070848-1512-4d2c-bfad-86d00cbf1140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_24070848-1512-4d2c-bfad-86d00cbf1140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_adf87661-23d9-4211-92f1-6ad5875a1a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_217b2600-05d1-4b8e-b749-c902473d565e" xlink:to="loc_us-gaap_OperatingLeaseLiability_adf87661-23d9-4211-92f1-6ad5875a1a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_92527c7d-6b95-4351-9172-d3877cd1998c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d90fd8-cf65-4b87-82ea-92b129a85186" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_92527c7d-6b95-4351-9172-d3877cd1998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5effa481-0ccb-4a03-afa2-c84e26c7a0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4d90fd8-cf65-4b87-82ea-92b129a85186" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5effa481-0ccb-4a03-afa2-c84e26c7a0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesLeaseTermsandDiscountRatesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4650a5e0-8863-4d15-abdd-3afdf7bc967f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4b68bbc3-b3c6-40a0-bf9e-fe3c4fca1485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4650a5e0-8863-4d15-abdd-3afdf7bc967f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4b68bbc3-b3c6-40a0-bf9e-fe3c4fca1485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_539b1f94-9ba5-499f-8121-1d633f57b392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4650a5e0-8863-4d15-abdd-3afdf7bc967f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_539b1f94-9ba5-499f-8121-1d633f57b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#OperatingLeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/OperatingLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6af945b3-e168-49a5-96f5-f14f63a1744c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_684087e1-fc87-46ff-bfcc-feb10d0bdad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6af945b3-e168-49a5-96f5-f14f63a1744c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_684087e1-fc87-46ff-bfcc-feb10d0bdad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5b24ec44-1855-4576-99c0-546c01c7cc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_684087e1-fc87-46ff-bfcc-feb10d0bdad9" xlink:to="loc_us-gaap_OperatingLeasePayments_5b24ec44-1855-4576-99c0-546c01c7cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_211be488-17b2-42ce-889f-823dad91044f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_684087e1-fc87-46ff-bfcc-feb10d0bdad9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_211be488-17b2-42ce-889f-823dad91044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_020d8577-cf5b-4823-bdf2-5ce83add9d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf926393-481e-4bd3-ae56-a5cfd3762083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_020d8577-cf5b-4823-bdf2-5ce83add9d1d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf926393-481e-4bd3-ae56-a5cfd3762083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#CommitmentsandContingenciesContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0862a90-cd00-49eb-b9d5-dad9a425804d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0862a90-cd00-49eb-b9d5-dad9a425804d" xlink:to="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0c6fb3f0-69bc-42ed-9ca7-a652aaddc6fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_XYLLCMember_27316cc2-bfd0-4452-8ec6-6607381f61f4" xlink:href="pgen-20201231.xsd#pgen_XYLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_XYLLCMember_27316cc2-bfd0-4452-8ec6-6607381f61f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SecuritiesAndExchangeCommissionMember_1c183188-6088-4a6b-9396-93229d10baac" xlink:href="pgen-20201231.xsd#pgen_SecuritiesAndExchangeCommissionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_SecuritiesAndExchangeCommissionMember_1c183188-6088-4a6b-9396-93229d10baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_66dbabc8-e113-4213-9007-848e6ad6e6cc" xlink:href="pgen-20201231.xsd#pgen_HarvestIntrexonEnterpriseFundILPMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7fb5d1bb-057b-4be0-9344-5508b2f26a40" xlink:to="loc_pgen_HarvestIntrexonEnterpriseFundILPMember_66dbabc8-e113-4213-9007-848e6ad6e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_86ca8345-832e-4617-a409-656e1fb719ce" xlink:to="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LicensingAndPatentInfringementSuitMember_e99ee5bd-6541-4b27-8f19-95a7fe7027a1" xlink:href="pgen-20201231.xsd#pgen_LicensingAndPatentInfringementSuitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:to="loc_pgen_LicensingAndPatentInfringementSuitMember_e99ee5bd-6541-4b27-8f19-95a7fe7027a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MethaneBioconversionPlatformDisclosuresMember_61c1bdee-679f-4751-867a-cd4bfc362a1b" xlink:href="pgen-20201231.xsd#pgen_MethaneBioconversionPlatformDisclosuresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0680376a-d60d-4297-8ae6-b4c77beaeaea" xlink:to="loc_pgen_MethaneBioconversionPlatformDisclosuresMember_61c1bdee-679f-4751-867a-cd4bfc362a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_40832777-9043-429d-977a-71a3630bc62e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HarvestStartUpEntitiesAggregatedMember_cfd2da8c-0c0b-4ead-949c-26f87dee2adf" xlink:href="pgen-20201231.xsd#pgen_HarvestStartUpEntitiesAggregatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:to="loc_pgen_HarvestStartUpEntitiesAggregatedMember_cfd2da8c-0c0b-4ead-949c-26f87dee2adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_4fe5528a-9f2d-4582-98b2-c9f4e696c1c4" xlink:href="pgen-20201231.xsd#pgen_ExotechADSkincareAndThriveAgrobioticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ee212090-7356-429b-a997-5600b879e164" xlink:to="loc_pgen_ExotechADSkincareAndThriveAgrobioticsMember_4fe5528a-9f2d-4582-98b2-c9f4e696c1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9a7c3c99-3275-4144-81b5-80772b43430c" xlink:to="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_c3732d77-f66a-4168-b037-fe828b129d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_c3732d77-f66a-4168-b037-fe828b129d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingenciesTotalClaimsNumber_7e8544a6-66df-44b9-bfc5-cf93140b9680" xlink:href="pgen-20201231.xsd#pgen_LossContingenciesTotalClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingenciesTotalClaimsNumber_7e8544a6-66df-44b9-bfc5-cf93140b9680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_bda60d99-401c-4c4c-aa7e-3cba69661aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_bda60d99-401c-4c4c-aa7e-3cba69661aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_4e877512-6b65-4bd3-aeb0-42ab0d443323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_4e877512-6b65-4bd3-aeb0-42ab0d443323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyClaimsInvalidatedNumber_7a7715a0-bcef-48b3-b23e-e034e40a9b77" xlink:href="pgen-20201231.xsd#pgen_LossContingencyClaimsInvalidatedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyClaimsInvalidatedNumber_7a7715a0-bcef-48b3-b23e-e034e40a9b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyAppealedClaimsDismissed_fcca40cf-23b7-402b-99e3-d9508240d8b6" xlink:href="pgen-20201231.xsd#pgen_LossContingencyAppealedClaimsDismissed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyAppealedClaimsDismissed_fcca40cf-23b7-402b-99e3-d9508240d8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LossContingencyReversedClaimsDismissedNumber_ec3bcbdb-a948-49d5-9593-dc23ed6e0568" xlink:href="pgen-20201231.xsd#pgen_LossContingencyReversedClaimsDismissedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_LossContingencyReversedClaimsDismissedNumber_ec3bcbdb-a948-49d5-9593-dc23ed6e0568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_da7726c8-8327-4e3a-b247-811248014ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_da7726c8-8327-4e3a-b247-811248014ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c07ffc1b-4a63-4be3-9871-826f7a083ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_c07ffc1b-4a63-4be3-9871-826f7a083ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_deac6879-8d11-407d-9b8d-474c20b67301" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues_deac6879-8d11-407d-9b8d-474c20b67301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_8477edc6-101b-4665-93e1-98093fd39112" xlink:href="pgen-20201231.xsd#pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues_8477edc6-101b-4665-93e1-98093fd39112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6642f50a-37fc-4f74-8fda-a13de276fc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6642f50a-37fc-4f74-8fda-a13de276fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3e9b6e8f-0cb0-4ec4-a363-6e13845e8924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_EquityMethodInvestments_3e9b6e8f-0cb0-4ec4-a363-6e13845e8924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8026e90f-ee15-4928-a345-940486b98b89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_304e5454-372d-4363-a9ea-a0fa9904571b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8026e90f-ee15-4928-a345-940486b98b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ac4ef097-f467-4d55-9b69-6434f0144aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0f9aa943-ba03-4103-aabc-8c92a84a286e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ac4ef097-f467-4d55-9b69-6434f0144aaf" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0f9aa943-ba03-4103-aabc-8c92a84a286e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_457645fa-2a2b-4605-898c-5869aeac42c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_457645fa-2a2b-4605-898c-5869aeac42c3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d1596e87-1c2a-4f9d-9e9c-8f29ca59f933" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_b58f4476-5a58-40e7-8afd-768789168060" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_50e39d4e-7545-4a6c-9a14-cbe971a88dc9" xlink:to="loc_pgen_ZiopharmMember_b58f4476-5a58-40e7-8afd-768789168060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7188c7b6-da2d-4db8-8ad6-d8e53062a438" xlink:to="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CollaborationandlicensingagreementsMember_146a911d-57da-4693-9d42-f0ef61436922" xlink:href="pgen-20201231.xsd#pgen_CollaborationandlicensingagreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cefc70a8-fe8b-4125-b423-63136f92ae87" xlink:to="loc_pgen_CollaborationandlicensingagreementsMember_146a911d-57da-4693-9d42-f0ef61436922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c1be41f4-5009-4324-a8f2-3bbfc3a12ac2" xlink:to="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ThirdSecurityMember_1c2a0d7d-cc6b-4ed9-9a12-9faff1a5c442" xlink:href="pgen-20201231.xsd#pgen_ThirdSecurityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:to="loc_pgen_ThirdSecurityMember_1c2a0d7d-cc6b-4ed9-9a12-9faff1a5c442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ZiopharmMember_0f83d5da-95ae-4714-bbb3-7f6a655971c7" xlink:href="pgen-20201231.xsd#pgen_ZiopharmMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cc2b3f92-7919-4e04-95b2-41e3206fb0b2" xlink:to="loc_pgen_ZiopharmMember_0f83d5da-95ae-4714-bbb3-7f6a655971c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c71b1daa-0179-4634-896a-403a75140627" xlink:to="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ada6f55f-bee3-435d-89c8-0495980d9a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:to="loc_us-gaap_CommonStockMember_ada6f55f-bee3-435d-89c8-0495980d9a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_SeriesAPreferredSharesMember_282f9838-f07b-4248-868c-038045c90a3c" xlink:href="pgen-20201231.xsd#pgen_SeriesAPreferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8519a15-596c-4bd6-bdd8-a3608e7e7b0b" xlink:to="loc_pgen_SeriesAPreferredSharesMember_282f9838-f07b-4248-868c-038045c90a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ca768692-b32b-4e60-993c-1c1fe60e254d" xlink:to="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ExecutiveChairmanMember_fac035a5-68bb-4ed2-ae2a-a4fc7e09d046" xlink:href="pgen-20201231.xsd#pgen_ExecutiveChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_ExecutiveChairmanMember_fac035a5-68bb-4ed2-ae2a-a4fc7e09d046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ThirdSecurityMember_6de03076-7f8c-4c9a-b41b-f829c2c44925" xlink:href="pgen-20201231.xsd#pgen_ThirdSecurityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_ThirdSecurityMember_6de03076-7f8c-4c9a-b41b-f829c2c44925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AffiliatesOfThirdSecurityMember_788e04a3-2609-43a1-ba7c-d9f0d1cda0d7" xlink:href="pgen-20201231.xsd#pgen_AffiliatesOfThirdSecurityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_AffiliatesOfThirdSecurityMember_788e04a3-2609-43a1-ba7c-d9f0d1cda0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CastleCreekBiosciencesIncMember_802a970b-4a21-45f9-928c-8c598d5f5cad" xlink:href="pgen-20201231.xsd#pgen_CastleCreekBiosciencesIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_CastleCreekBiosciencesIncMember_802a970b-4a21-45f9-928c-8c598d5f5cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_VariousECCAgreementsMember_406d4890-38e3-422d-98df-ea5f4e470154" xlink:href="pgen-20201231.xsd#pgen_VariousECCAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_edda6d63-f17d-4daf-a1a4-faabceebc937" xlink:to="loc_pgen_VariousECCAgreementsMember_406d4890-38e3-422d-98df-ea5f4e470154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68746c21-19a1-438b-ac87-62a1c89e5296" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_RelatedPartyOwnershipInterest_de62660a-c96c-460b-b863-49d9d8d1fce6" xlink:href="pgen-20201231.xsd#pgen_RelatedPartyOwnershipInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_RelatedPartyOwnershipInterest_de62660a-c96c-460b-b863-49d9d8d1fce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_bd36a897-4166-4d7a-81e9-fbad5aa34ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_bd36a897-4166-4d7a-81e9-fbad5aa34ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CommonStockCalculationPeriod_93fa4da7-8166-4b68-a7ed-cbc769f1f270" xlink:href="pgen-20201231.xsd#pgen_CommonStockCalculationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_CommonStockCalculationPeriod_93fa4da7-8166-4b68-a7ed-cbc769f1f270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2e54d421-3332-4a88-ade3-6747dac936e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2e54d421-3332-4a88-ade3-6747dac936e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_db4c3735-4dc6-468e-9cc3-8cfef1effe9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_db4c3735-4dc6-468e-9cc3-8cfef1effe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_49c8a63d-b3f0-4837-a9ef-61c955e6c8b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_SubleaseIncome_49c8a63d-b3f0-4837-a9ef-61c955e6c8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_e1ff7873-b823-4a33-8b00-785df4e81809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue_e1ff7873-b823-4a33-8b00-785df4e81809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ConvertiblePreferredStockAmountAuthorized_6f09383c-e8e4-4022-a520-d55c90253bd7" xlink:href="pgen-20201231.xsd#pgen_ConvertiblePreferredStockAmountAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_ConvertiblePreferredStockAmountAuthorized_6f09383c-e8e4-4022-a520-d55c90253bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db4d0fc7-eddf-4d92-aab1-d0472e711ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_db4d0fc7-eddf-4d92-aab1-d0472e711ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NoncashDividendIncome_ca65bca6-ca40-43ab-907c-e8327b2febcc" xlink:href="pgen-20201231.xsd#pgen_NoncashDividendIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_NoncashDividendIncome_ca65bca6-ca40-43ab-907c-e8327b2febcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fb24c727-2b32-4691-8a51-41c3f56461a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_fb24c727-2b32-4691-8a51-41c3f56461a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be25e168-c1fd-4854-bbe5-8e569a764426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_be25e168-c1fd-4854-bbe5-8e569a764426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea762a51-6f27-414e-9579-13791bee7357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea762a51-6f27-414e-9579-13791bee7357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4ceb01da-7477-4947-8373-fab9dc6a19bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_4ceb01da-7477-4947-8373-fab9dc6a19bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_c0e45d45-9989-4def-b205-548c323f92f4" xlink:href="pgen-20201231.xsd#pgen_NumberOfRelatedPartiesWithTerminatedAgreements"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_pgen_NumberOfRelatedPartiesWithTerminatedAgreements_c0e45d45-9989-4def-b205-548c323f92f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_da30f431-4848-418f-8e39-598fd9ba2868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_468bd7b9-6eba-4bd4-8005-7196ac361e50" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_da30f431-4848-418f-8e39-598fd9ba2868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShare" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64fe2730-e209-411c-b286-8d42e8b08af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_fc8c70e9-f18c-46e6-8af8-81b3b722f66b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64fe2730-e209-411c-b286-8d42e8b08af7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_fc8c70e9-f18c-46e6-8af8-81b3b722f66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ac2b9c3d-17d2-4ae7-9f32-1ee530e61806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0e0988a0-0780-43f4-937c-deb289661fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac2b9c3d-17d2-4ae7-9f32-1ee530e61806" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0e0988a0-0780-43f4-937c-deb289661fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_67d106c0-f0a2-432a-b430-57a53cee9a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac2b9c3d-17d2-4ae7-9f32-1ee530e61806" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_67d106c0-f0a2-432a-b430-57a53cee9a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_05a9ed82-a1f1-4ba9-bb7e-6e218165e533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_05a9ed82-a1f1-4ba9-bb7e-6e218165e533" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d28822fe-ef7e-4909-9d0f-0ae2f5cf99a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d28822fe-ef7e-4909-9d0f-0ae2f5cf99a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_95fe3ba0-7ea1-4f12-9ffc-0148da56a59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d28822fe-ef7e-4909-9d0f-0ae2f5cf99a9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_95fe3ba0-7ea1-4f12-9ffc-0148da56a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_03216528-ba47-44d8-863b-09e0026dcb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d28822fe-ef7e-4909-9d0f-0ae2f5cf99a9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_03216528-ba47-44d8-863b-09e0026dcb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_026abfbd-3051-4339-94d5-5dafc16ad46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d28822fe-ef7e-4909-9d0f-0ae2f5cf99a9" xlink:to="loc_us-gaap_NetIncomeLoss_026abfbd-3051-4339-94d5-5dafc16ad46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6251a8ce-f048-4532-ba4a-7555de750482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6251a8ce-f048-4532-ba4a-7555de750482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4ef3ae53-a8c6-457c-b639-8b2011144cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6251a8ce-f048-4532-ba4a-7555de750482" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4ef3ae53-a8c6-457c-b639-8b2011144cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_a509b81b-cb0c-4312-ac63-0f39c3e9ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_a509b81b-cb0c-4312-ac63-0f39c3e9ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_f0362cfb-ff43-4da7-af17-a050ed286da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_f0362cfb-ff43-4da7-af17-a050ed286da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_59a9dc89-be8e-4caf-9552-2dd351ee3aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_9dd0bffe-0c1f-4d38-b2a2-9629c451c470" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_59a9dc89-be8e-4caf-9552-2dd351ee3aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64b723a4-5710-4780-a166-64644495ded8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64b723a4-5710-4780-a166-64644495ded8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c90d7717-ae5f-4edf-9e48-21215a8a21e3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_735dbe44-f048-488e-b77c-587225441c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_ConvertibleDebtMember_735dbe44-f048-488e-b77c-587225441c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_6e64f293-5711-4826-a0c7-bbc5d6afb70e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_StockOptionMember_6e64f293-5711-4826-a0c7-bbc5d6afb70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ef8cbc96-244f-4ce3-bc22-a1ec32a4ce8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ef8cbc96-244f-4ce3-bc22-a1ec32a4ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9da98252-24c7-49c0-afb8-d8d217376d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_75ce30af-7ac9-4000-81a8-83e609284d2c" xlink:to="loc_us-gaap_WarrantMember_9da98252-24c7-49c0-afb8-d8d217376d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_176f0879-131a-4269-a686-bbc831691444" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76f59408-2943-4ad2-b480-1b736adb7f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b46b43a6-1389-471d-bf28-1e78ed5e4f80" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_76f59408-2943-4ad2-b480-1b736adb7f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/Segments" xlink:type="simple" xlink:href="pgen-20201231.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8f56d4cc-2e84-41df-8f06-3607289a4e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_176f846e-3de1-49d5-916a-fc3296b5aa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8f56d4cc-2e84-41df-8f06-3607289a4e1c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_176f846e-3de1-49d5-916a-fc3296b5aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ebe539ae-fb3e-4545-9f17-d315fbe13731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d2f7eb07-9f3c-4116-b543-7b461488461d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ebe539ae-fb3e-4545-9f17-d315fbe13731" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d2f7eb07-9f3c-4116-b543-7b461488461d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fa3ab97b-09df-4215-80a0-248fd67c6438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ebe539ae-fb3e-4545-9f17-d315fbe13731" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fa3ab97b-09df-4215-80a0-248fd67c6438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsInformationbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_12817aa7-5a5c-4df4-b70d-64a8ef104666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_12817aa7-5a5c-4df4-b70d-64a8ef104666" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:to="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9d84cf59-64a8-4e70-bf4f-cb4f6f0c2f75" xlink:to="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e2139369-9dc9-4fb6-8e5d-006cf1b39259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:to="loc_us-gaap_OperatingSegmentsMember_e2139369-9dc9-4fb6-8e5d-006cf1b39259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_389f6c3c-4ac8-4816-a1e2-f0835244849a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_4639ff20-191a-416f-bb9c-baba9068397e" xlink:to="loc_us-gaap_IntersegmentEliminationMember_389f6c3c-4ac8-4816-a1e2-f0835244849a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f241a608-4494-4f28-81ae-333a87c3a151" xlink:to="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_PGENTherapeuticsSegmentMember_9defa1e7-ae66-4fad-9c6a-a64b3e0c714c" xlink:href="pgen-20201231.xsd#pgen_PGENTherapeuticsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_PGENTherapeuticsSegmentMember_9defa1e7-ae66-4fad-9c6a-a64b3e0c714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ActoBioMember_f2a03b77-254b-4843-bf0f-de5375223c4c" xlink:href="pgen-20201231.xsd#pgen_ActoBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_ActoBioMember_f2a03b77-254b-4843-bf0f-de5375223c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_TransOvaSegmentMember_6eb3ada0-d6af-47cc-a71b-c3a018a766da" xlink:href="pgen-20201231.xsd#pgen_TransOvaSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_TransOvaSegmentMember_6eb3ada0-d6af-47cc-a71b-c3a018a766da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_HumanBiotherapeuticsSegmentMember_66e260b0-f4c3-47ed-a0c2-ff8ec186a04f" xlink:href="pgen-20201231.xsd#pgen_HumanBiotherapeuticsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_pgen_HumanBiotherapeuticsSegmentMember_66e260b0-f4c3-47ed-a0c2-ff8ec186a04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8ace9f52-7679-4431-9a6c-273eba873052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2de052f7-db6d-4c23-8b1b-61ca651dd26e" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8ace9f52-7679-4431-9a6c-273eba873052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2d7e54bf-a4e6-47cb-9756-80063f451a2b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2087df5-aae4-4ba5-894e-eb40d3724235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_Goodwill_b2087df5-aae4-4ba5-894e-eb40d3724235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_6b47fa41-2896-4a0f-b66f-20cfdd9d13b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillTransfers_6b47fa41-2896-4a0f-b66f-20cfdd9d13b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_23c99c81-0325-4c83-96e0-ce1c8794a85e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_23c99c81-0325-4c83-96e0-ce1c8794a85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6b8cda17-256b-4904-aeed-23179255e629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e050682a-a453-40f8-beff-e06a6569ad22" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6b8cda17-256b-4904-aeed-23179255e629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7bfb2828-f3f6-4922-aefb-60821f30ab47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7bfb2828-f3f6-4922-aefb-60821f30ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7703facf-1cc5-4989-97d8-d37854e484be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_us-gaap_Revenues_7703facf-1cc5-4989-97d8-d37854e484be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_af2fb840-a7ed-4c5a-a6f3-9f79ad169389" xlink:href="pgen-20201231.xsd#pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d75d141f-2d37-4c56-8087-cf811c277889" xlink:to="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_af2fb840-a7ed-4c5a-a6f3-9f79ad169389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2bcbbb76-9f09-4d94-b772-901ad70a749e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2bcbbb76-9f09-4d94-b772-901ad70a749e" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e4ff3daf-9569-4597-abce-c00fdf5e9dc4" xlink:to="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReportableSegmentsMember_8469ab22-388c-4c96-871b-1d96b58d4b69" xlink:href="pgen-20201231.xsd#pgen_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b987231c-faae-4841-be18-cb3f2a97f23c" xlink:to="loc_pgen_ReportableSegmentsMember_8469ab22-388c-4c96-871b-1d96b58d4b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:to="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b2ce0841-7747-4dee-9a50-5d150e84382e" xlink:to="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember_4cb96787-4f1f-4c61-ba5a-63e7613aab27" xlink:href="pgen-20201231.xsd#pgen_OperatingSegmentsAndCorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:to="loc_pgen_OperatingSegmentsAndCorporateNonSegmentMember_4cb96787-4f1f-4c61-ba5a-63e7613aab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_EliminationsAndReconcilingItemsMember_7bfb073c-2fc7-49c8-8939-77f6513e1736" xlink:href="pgen-20201231.xsd#pgen_EliminationsAndReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e1695de4-5ca3-4482-b345-260f18dd13e1" xlink:to="loc_pgen_EliminationsAndReconcilingItemsMember_7bfb073c-2fc7-49c8-8939-77f6513e1736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_ebf62825-6647-483c-a2d6-f8d3e391ecd1" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8a511f60-8338-450d-9275-1ca405f1676e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:to="loc_us-gaap_Revenues_8a511f60-8338-450d-9275-1ca405f1676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_784a659e-4052-47b2-8bdc-51131dfea84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_052809dd-c397-4f23-9da7-a54676919969" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_784a659e-4052-47b2-8bdc-51131dfea84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_14f9a726-2e6d-47f5-8fa6-13afce168dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_14f9a726-2e6d-47f5-8fa6-13afce168dc9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f9311e84-1728-48ad-9388-34b462f6d598" xlink:to="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_UpfrontAndMilestonePaymentsMember_25bf924f-9dee-443e-a5bb-dc9366fa2d23" xlink:href="pgen-20201231.xsd#pgen_UpfrontAndMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_05fcccd9-5f1b-48b4-a0fb-20f6e7ce6e81" xlink:to="loc_pgen_UpfrontAndMilestonePaymentsMember_25bf924f-9dee-443e-a5bb-dc9366fa2d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9b813b48-2a4b-461f-8a3c-9c6bb3118fd8" xlink:to="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_ReportableSegmentsMember_3982a8db-5b6e-4a53-87ba-f00bbb20a472" xlink:href="pgen-20201231.xsd#pgen_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:to="loc_pgen_ReportableSegmentsMember_3982a8db-5b6e-4a53-87ba-f00bbb20a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_8a645714-b0d6-40a6-abad-5ad83d5b6a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b5485243-1fee-43ea-8754-51c04125d36d" xlink:to="loc_us-gaap_AllOtherSegmentsMember_8a645714-b0d6-40a6-abad-5ad83d5b6a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_728803f9-21b9-4ce6-b2db-3251f5f930fd" xlink:to="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5e8f2924-b9a6-41b9-8dd4-92e37e85b43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_OperatingSegmentsMember_5e8f2924-b9a6-41b9-8dd4-92e37e85b43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CorporateAndReconcilingItemsMember_46a761f3-d5f9-4555-b4ed-c641771834c0" xlink:href="pgen-20201231.xsd#pgen_CorporateAndReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_pgen_CorporateAndReconcilingItemsMember_46a761f3-d5f9-4555-b4ed-c641771834c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3b078708-6642-4f62-a13c-b8ff15b7ba56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3b078708-6642-4f62-a13c-b8ff15b7ba56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_10d41b35-41b4-4e9e-9125-7bc4ec717850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b2f7c2c-ad3f-494a-9c6a-32a7b9a78f65" xlink:to="loc_us-gaap_IntersegmentEliminationMember_10d41b35-41b4-4e9e-9125-7bc4ec717850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1176aedc-e655-4963-bcd7-6c0196083779" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_8b771309-95b3-4472-a95a-3bd971d238e6" xlink:href="pgen-20201231.xsd#pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates_8b771309-95b3-4472-a95a-3bd971d238e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates_6a5e12b7-9d94-4db8-8763-ac51d73121d3" xlink:href="pgen-20201231.xsd#pgen_CapitalExpendituresAndInvestmentsinAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_pgen_CapitalExpendituresAndInvestmentsinAffiliates_6a5e12b7-9d94-4db8-8763-ac51d73121d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f577d853-893e-4ebc-8564-c4e6b38b98e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f577d853-893e-4ebc-8564-c4e6b38b98e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_71f7caa6-2e7e-44a8-9774-b2c6b4c85a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_InterestExpense_71f7caa6-2e7e-44a8-9774-b2c6b4c85a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_40c200bf-71f7-44b7-9732-4db43c306154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_40c200bf-71f7-44b7-9732-4db43c306154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c72bbb75-313c-4f43-844e-92dc9fff2e3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_AssetImpairmentCharges_c72bbb75-313c-4f43-844e-92dc9fff2e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_589f8542-46d4-49fb-b943-7da86dcf4d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_589f8542-46d4-49fb-b943-7da86dcf4d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_b841c9a3-b8db-44a6-a760-75a726a4c18f" xlink:href="pgen-20201231.xsd#pgen_GainLossRelatedToNoncashLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_pgen_GainLossRelatedToNoncashLitigationSettlement_b841c9a3-b8db-44a6-a760-75a726a4c18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47f65548-a46a-46e1-a503-673e97e0a35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47f65548-a46a-46e1-a503-673e97e0a35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_AdjustmentForBonusesPaidInEquityAwards_f09681e1-73b4-428a-b954-5ac753c518cc" xlink:href="pgen-20201231.xsd#pgen_AdjustmentForBonusesPaidInEquityAwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_pgen_AdjustmentForBonusesPaidInEquityAwards_f09681e1-73b4-428a-b954-5ac753c518cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_df43e1e8-7ca0-4ce9-9542-385813725b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_df43e1e8-7ca0-4ce9-9542-385813725b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4e0a794e-7e81-4f98-9269-840e629cf2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_70e6853e-cd6b-45bb-a757-823584a6d7d5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4e0a794e-7e81-4f98-9269-840e629cf2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51bdb8e8-2d6c-43ce-b4d8-cb3f8f4990c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d89e008-a345-4cb5-99e4-00a6d03679f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_51bdb8e8-2d6c-43ce-b4d8-cb3f8f4990c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SegmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SegmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bebe6722-68a5-4492-b26e-175b4252e002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bebe6722-68a5-4492-b26e-175b4252e002" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:to="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_98a93298-bf5d-46a9-ab98-506ad4119ef3" xlink:to="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b7b4106b-60e5-442c-98db-f482231953bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_90c23d17-f51b-4480-af3a-66267508c6ec" xlink:to="loc_us-gaap_NonUsMember_b7b4106b-60e5-442c-98db-f482231953bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_13c92822-c782-4408-b179-bdc9e7452d18" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_b7d8fd22-9bac-405b-90cf-2e14ec2ca221" xlink:href="pgen-20201231.xsd#pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:to="loc_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets_b7d8fd22-9bac-405b-90cf-2e14ec2ca221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2ed2d97e-82d4-45e5-8d8f-51a1a4c36acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e61aaa2d-bedd-4630-babf-62338bd2c6f0" xlink:to="loc_us-gaap_Revenues_2ed2d97e-82d4-45e5-8d8f-51a1a4c36acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d647d730-2bfd-42a2-a3f7-a9f873ee758e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_6cb29c27-ff08-4644-a215-34aac7ad57aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d647d730-2bfd-42a2-a3f7-a9f873ee758e" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_6cb29c27-ff08-4644-a215-34aac7ad57aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7fbaa275-5fef-46f8-a325-918bf8453b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a7c0c15e-99e6-4ff5-9774-36f3d72d70fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_7fbaa275-5fef-46f8-a325-918bf8453b6b" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_a7c0c15e-99e6-4ff5-9774-36f3d72d70fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_913bef91-29d1-4b6d-8008-4ec03d2d7f58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_913bef91-29d1-4b6d-8008-4ec03d2d7f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3ecc1aa0-cc3a-4a50-b192-102a242dbeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_OperatingIncomeLoss_3ecc1aa0-cc3a-4a50-b192-102a242dbeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9d455173-69e0-41cc-9e09-7c7c62e7170f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9d455173-69e0-41cc-9e09-7c7c62e7170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_969788af-73fd-4353-8a02-f730b38d0d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_NetIncomeLoss_969788af-73fd-4353-8a02-f730b38d0d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_19100ddd-5bcf-4eb6-9812-55a37f543495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_19100ddd-5bcf-4eb6-9812-55a37f543495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9f4b184c-05bc-430b-ac22-0dc7f6d47b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6d030f87-19a1-45cb-9739-1011fe67208a" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9f4b184c-05bc-430b-ac22-0dc7f6d47b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlans" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlans"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DefinedContributionPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cad9c0fc-0983-482d-bac9-cc7d4376ac93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_c5f8a21b-b31a-4ef1-b813-f6a2790f7296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cad9c0fc-0983-482d-bac9-cc7d4376ac93" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_c5f8a21b-b31a-4ef1-b813-f6a2790f7296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#DefinedContributionPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_23dd968e-5600-4c74-bfbb-346b9e533997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_5712e4b6-8c93-4a9b-9e06-855923457592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_23dd968e-5600-4c74-bfbb-346b9e533997" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_5712e4b6-8c93-4a9b-9e06-855923457592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEvents" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_117b87cb-a3a6-48aa-b9d2-210420dcff74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_dfaf3974-dfba-4df6-95d3-aeb91a833377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_117b87cb-a3a6-48aa-b9d2-210420dcff74" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_dfaf3974-dfba-4df6-95d3-aeb91a833377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="pgen-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.dna.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_cfd571fe-b7d5-4a27-8a1b-1ad3e1dd8f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_cfd571fe-b7d5-4a27-8a1b-1ad3e1dd8f1d" xlink:to="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07f25567-6874-4c52-b626-6c03030036b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2bfd76e7-eb2b-490d-aec6-9ad2b1e20d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a7acddfc-8a14-499c-9c36-6406be31c16b" xlink:to="loc_us-gaap_SubsequentEventMember_2bfd76e7-eb2b-490d-aec6-9ad2b1e20d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8ec4c2a-e016-4c2e-bbd5-20f203e3d5ba" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_ecd5df6d-cece-40aa-b64d-700ed5b88642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_13c6b942-9944-4d63-86d2-2fcfdffe1cb1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember_ecd5df6d-cece-40aa-b64d-700ed5b88642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4376e703-f25f-46df-883a-9fd5143ae8aa" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_MBPTitanMember_5e40e1df-46d9-47bc-a4d6-0bbdc8653d83" xlink:href="pgen-20201231.xsd#pgen_MBPTitanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af4fe648-a2b7-437e-a903-ac3fab21af2a" xlink:to="loc_pgen_MBPTitanMember_5e40e1df-46d9-47bc-a4d6-0bbdc8653d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2e20e686-c6aa-4ccf-9a3e-0cf88348c309" xlink:to="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5c08ab2-66bb-4186-867f-65e98d4df1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d5c08ab2-66bb-4186-867f-65e98d4df1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7177653-e8e1-49d9-a609-b3f1009a148a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f7177653-e8e1-49d9-a609-b3f1009a148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_4e1d09b7-1e07-446e-8767-ee84feff67ae" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset_4e1d09b7-1e07-446e-8767-ee84feff67ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_5b7886f1-cb16-4f56-a869-296d97855728" xlink:href="pgen-20201231.xsd#pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1f26d995-fdcf-4a7e-a5da-181960d5ec59" xlink:to="loc_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent_5b7886f1-cb16-4f56-a869-296d97855728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pgen-20201231_g1.jpg
<TEXT>
begin 644 pgen-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,I!Q,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK%]NMB0I9D7Y0ZL5SM !#C@8.=JF!E",I1DI<N]MT3./)%3WB^I]G45^6/\
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M>N:A+='3I\XCE5I&)5"3M<#C!#?PUAAL+/%1FX;QZ=QRIM4O;=+_ )6_S/V
MHI%8, 0<@\@BOR2^"?QM^(FK?\%!H?#E[X]\3WGAX^+-2MCI-QK-R]IY2M/M
MC\HOLVC:N%Q@8'I48>@\1/D3MI?\O\R>7]U.K_+_ ,'_ "/UNHHHKF("BOP\
MU/XH?'KXA_M :]X+\&?$+QI=:I=:W?6]AIL/B>>W3:DDC;%+S*B@(AP"0.,"
MO8_!_P  _P!MZS\7:)/JFI^-6TR*^@>Z$OCN*1#")%+Y7[8=PVYXP<UZL,"I
M1A*=11YDGJ;U:7LN97NUT/U@HKCOBY\5M ^"GP^U?QAXEN3;Z7IT>XJ@S),Y
M.$B0=W9B /KDX )K\I?$'[0'[0_[>'CR[T'P(-0TG0D^;^R=&N3:VUO"20&N
M[G*[R1V8X)'RIFN.AAYXAOEV6[>R%&G>//)V1^Q=%?D#=_\ !,']H#P3;MX@
MT36=#N]8@'FI#HNL3PWI;_9>2*-=W_ Q77_LI_\ !0GQG\,/'$?P\^-\UY=:
M<MP+(ZIJR%;_ $J7(7%P6PTD>>I?+KG.2!BNOZDJEU0J*3704Z;C'GCJC]3Z
M*C,BR6YDC8,K+N5E.01C@@U^%/P_^(W[1/QB\??\(KX,^(?CC5M;G,TD-F/%
M<\ *("S'=).JC ![URX;#O$2E%.W*K_G_D5"ESTW4O9)I??<_=JBOQJO/V@/
MVJ/V._&&EP^/-2UJXAN/WPT[Q+=+J5M>QK@,JSAW((R,['!!()Z\_K1\)?B1
MIWQ>^&OASQEI2M'8ZS9I=+$Y!:)B,/&2.ZL&4^XK2MA94H*JI*47I=&4XNG)
M1EUV.MHHK\W_ /@JU\5O&WP[\8_#^'PIXPU_PQ#=6%T\\>C:G/:+*PD0 L(V
M&X@$]?6N:E!U:L:2^U_DW^A=.FZC:70_2"BOQGL/#?[9^E^!;3XA6NN>.KWP
MW+91ZI#=+XG%[NMV02+(;;SW<C:02"F0.HKZS_X)W?MM:]\>KO4_ WCR:*\\
M46-L;VSU2.)8C>0!E5UD10%#J64@J!D'IE23W5,!**DXR4G'==43./+%36J?
M4^Y:**_+'_@IC^U5XKTGXT6/@OP/XMUCPW;^'[0'4)-$U&:T::YF ?8YC9=P
M1!'C/0NU<5&FZU54H]?Z_P"!\RZ=)U+VZ'ZG45\=?\$R_P!H+4?C%\'=1T3Q
M'J]UK/BCPY=E);O4+AI[B>VE)>)W=B68@B1.2>$6OHOXZ:7XDUSX-^--/\'/
M<Q^*KG2;B+2WL[H6TPN"A$924LH1MV,-N&/6GB*,L/4=.70R@N:7*]-;?U^9
MW5%?A]\9;G]JG]GY-);Q]XV\<:"NJF46?_%8O<^;Y>W?_J;E]N-Z]<9SQWKU
M;]F;P/\ M:>.?$WP[\;'Q!XRU;X?7.JVEW<W%SXQ#12V:7"B;? ]SO9=JN"I
M3)'&#FO167IQ4_:KEO:_0UJ4_9QYF^EUYV['ZUT5^2O_  4<^-GQ$\#_ +45
M_I7ASQ[XG\/Z6NG6;K8Z7K%Q;0!F3+$(CA<GN<<U^CO[0NKWVB_LY^/]3TZ]
MN+#4;7PY>3P7EK*T<T4BP,5=74@JP/((.:\^I1=/#QQ#>DK_ (#]B_:PI7^*
MWZ?YGIM%?AG\'=>_:?\ C]J6H:?X#\=^.-=N]/A6>YC_ .$OEM_+1FV@YFN$
M!Y[#)KWKX8_ C]M73?B1X4N_$.I^,WT&WU6UEU!;CQQ%-&;=9E,H:,79WKL#
M97!R.,&O0>7J,E&=5+U)E!13=[M=#]4J*^%O^"K'Q%\5_#OP)X#N/"GB?6?#
M$]SJ5Q'/+H^H2VC2J(@0K&-@6 /8U@?\$S_VQM0\?&Y^&7CS6[G5/$*;[O1]
M4U*X::>[CY:2!Y')9G7EER22NX=%%<=+"SK4958_9Z"J4W3A&IT?X:M'Z$45
MYQ^TCJM[H7[/WQ&U'3;RXT_4+70+V:WN[65HI89%A8JZ.I!5@1D$'(KX=_X)
M4_%CQQ\1/'_CNV\5>,O$'B:"WTN&2"+6-4GNTB8RX+*)'(4XXR*SI475A.:^
MRK_G_D$H<M+VO2]OR_S/TIHK\:?C;X5_:[^#^F:OXL\3>*/&VC>%X[TQK=)X
MT\U5$DA$8$<5TS '(_AX]JPO@_IW[6OQZT*\UGP)XP\<:[IMG<_9)YO^$T:W
MV2[5;;MFN4)^5E.0,<UVPP*J0]HJBLM_+U^\VG04'\2M^9^V=%?!_P#P4"_:
M8\8? 7X/^!_!VBWMQIGB_P 06 &HZLLNZXMXXHXUE"2 G]X[L1Y@)("L0<D$
M?(&E_L6?'JX^&MC\:=&OOMMS=VXU6-=/U28ZUY+#<)L@#)*_-M60O@_=SQ65
M/"J4'4G-1BG:_?\ X'^1$*7-&+;LY:I'[7T5\V?L'^*OB_XL^#<%W\6+'RWR
MO]DZA=,4O[RVQ]^>/'';:Y(9QR5_B?Z3KFK4G1J.FW>W8YD[A1116!04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS'@  $DFO"=K:F$;W5MR#0/#^F^%=%LM(T>PM],TNRB6&VL[6,1Q1(.BJHX
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MK^:+C14M(ROI_7XG[T>)/^1=U3_KUE_] -?@Y^RE^T1_PS%\5/\ A,_^$?\
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M?F%?K5^QY^U!#^TE\ []]1G0>,]$LVM-7AR 93Y;;+@#^[( <^C!ATQ7E_\
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M\._%S_A1/[7FI^.O[*_MS^Q_$&I2?8/M/V?SMS31X\S8^W&_/W3TK[-\,?\
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MGV^[\CXQ_P""R?\ QZ?"C_?U/^5K7U3^P3_R:'\-?^O"3_THEKY6_P""R?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS!1'+N8I&I. 2,G&!D5];T55;$QJ<G+!1Y7?3KJG^GXCC5Y:BFELFOO/D/\
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MRXU+1Y)*Z/Q^O/\ @J%\?O&=J= T;2="M-7F'E)<:/I$\M[NZ?*CRR+N_P"
M5UO[*W_!/KQM\5_'4?Q#^-T%[::6UQ]LDTW6&9M0U:3.1YRL=T<>>H?#$#&
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MQ)^(&I:7XZ\'76K^)-*L(E2X\-VLCN]E(IXN;>$'YMW ;:-X*@\C.WYEU/\
M;\^/OB[P#<?"V:""\U"[@;39[R+2Y3K$R,-C1D!MNXJ=I(CW<YSGFOVDHK6C
MB5"G[&I!2BM4;>V^&5O>6S/AO_@F?^R?X@^"NBZSXV\9V+Z5K^NPI;6FESKB
M:UM0V\F4?PN[;?D/*A!G!) ^Y***RQ%>6(J<\CEZN3W84445S#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ+?8U**^//\ @I7X^\,6_P "[KPS+XCTF+Q(=3TZY&CO?1"\,(G!,GDEM^W
M)W8QP:](^.$'@3]IG]GGQ1HVG?%/1M*T+$2WWB/3-2@N;:S*,C[)V64+M/ *
MLZY!'-:*FW357IS6^7NZ_C^!IR^_&,M$T>]T5\2_M0>%;?P/\(/V:= M-9?Q
M%::=XTT*WAU:1PYNT5'VR@@D$,,$8)XQR>M>I_&KX'Z'XX_:0^%'C&_^))\,
MZMHK2?8/#)FC5]5V'>_D@R*P.#B3:K[D !V]:U]C&Z][1RDKV[).]M];[=";
M>XI/=QYOQ:M?Y;GT/17 ZW^T!\+_  SJUUI>L?$CPCI6IVK^7<65]KMK#-"P
MZJZ-(&4^Q%/T'X[?#3QEJT&CZ%\1?"NLZK=;E@LM-URVGN)"%).Q$<L2 ">!
MT!-<_)-JZ5Q6:W.[HKYX_9 ^"F@_!/2_'<>B_$H?$.*^UR26\F\^-Q83H/GA
ME*R/^^^8&0G:3\N5%>O#XJ>"CX47Q0/&&@GPTSF-=9_M.#[&6!*E1-NV9!!&
M,]0:J<5%VB[K3\5_2\QM:M+NU_7^1U-%87A'QYX9\?V,E[X8\1:3XDLXVV/<
M:1?174:MZ%HV(!]JW:AIQ=F2%%<3J7QO^'.CZ\=$O_'_ (7L=:#B,Z;<ZS;1
MW 8]%\LN&S[8KH9/%FB0Z[9Z))K&GIK-Y US;:<UT@N)X5^](D>=S*.[ 8%/
ME=D[;C>FYJT44E2(6BN(;XY?#A=>_L1OB!X6&M>9Y7]G'6K;[1OSC;Y>_=G/
M;%=O3LTKM ]'9A163H?BS0_$TVHPZ/K.GZM-IMRUG?1V-TDS6LZ_>BE"D[''
M=6P1Z5/KFO:9X7TFZU76=1M-)TNU3S+B]OIUAAA7.-SNQ"J.1R32V'9WL7Z*
MQ=8\;>'?#^GZ??ZIKVEZ;8ZC-';V5S>7D<4=S+(,QI&S, [, 2H7)/:JUK\2
M/"-]XKE\+VWBG1;CQ+$"TFC1:A"UX@ R280V\8'M5<K["Z7.CHHJIJNK6.A:
M?-?:E>V^GV,*[I;FZE6*.,>K,Q  ^M2!;HKD/"OQB\!>.K]K'PUXW\.>(;U1
MEK;2M6M[F0#U*QN36_X@\1:5X3T>YU;6]3L]&TJV4-/?:A<)!!$"0 6=R%49
M(')[TW%QW0[.]NIH45%:W4-];0W-M+'<6\R"2.:)@R.I&0RD<$$<Y%4+KQ1H
MUCKUEH=SJ]C;ZW?1O-:Z;+<HMS<(GWVCC)W,%[D @=Z+.]A=+FI17QE_P4-^
M)'A*+2_AYH3^*-%36]-\=Z3>7VFMJ$(N;6 +(QEECW;D0!E.Y@!A@<\U]+GX
MV?#MO"K^)!X]\,'PZL_V0ZN-9MOL@GQGRO.W[-^.=N<XJW3DJ7M4NK7X+\[V
M-)0<7%=U?\7^BN=M17QK_P $X?B7X0'PC/A@^*]$'B2Z\0:G-;Z/_:,/VR5#
M(7#I#NWL-H+9 Q@$]*]#_95^!^A_"'Q'\4;S1_B2?'LNLZT9+ZV\Z-SI<Z%R
MT4NV1_WW[S#%@A(5?E&*UG1]FVI.UE?;?;_/?RMU%*/+S+JI6]5=J_X;?Y'T
M/17,Q_%#P;-X;F\1)XMT-_#\,K0RZLNI0FUCD4X9&EW;0P/!!.14WA#XA>%?
MB%:S7/A;Q-H_B6WA;9+-H]_%=HC>C&-B ?K6'*^Q.VYT%%%<7K7QL^'?AO6S
MHVK^/?#&EZN&"G3[W6;:&X!/0>6SAL_A22<G9!9G:45D3^+M"M=7TS2IM:TZ
M'5-4C>6PL9+N-9[M$ 9VB0G=(%!!)4' /-:]%F(***Y/Q;\6_ W@&\CM/$_C
M/P]X<NI!N2#5M5@M7<>H61P2*$FW9#LWL=915/2=8L-?T^"_TN^MM2L9UW17
M5I*LL4@]59201]*N4;;B"BN*7XV_#M_$ T%?'WAAM<,GE?V8-9MOM._IM\K?
MNS[8KPBX_P"4F-I_V3EO_2TUK3IN<DGI=-_<F_T+Y?=DWTM^+2_4^K**9+*D
M,;R2.L<: LS,<  =23Z5QNC?&[X=>(M:&CZ3X^\+ZIJY;8+"SUFVFG+#MY:N
M6S^%9).6R(Z7.UHK+T_Q5HNK:UJ>CV.L6%[JVE^7]OL+>Y22>T\P%H_-C!W)
MN )&X#('%2:]XBTKPKI<VI:UJ=GI&G0\R7E_<)!"G^\[$ ?B:6P[.]C0HKE_
M!_Q2\&?$*29/"WB[0?$KPC,JZ/J<-V4'JWEL<?C744W%QT:$%%-DD2&-Y)&6
M.- 69F.  .I)KFE^*7@QO"<?BD>+M"/AF0LJ:T-2A^Q,0Q4@3;MAP58'GJ".
MU [,Z>BN;\'_ !*\(?$)9F\*^*M$\2K!_K6T?48;L1YZ;O+8X_&O"/\ @I%_
MR9]XT_ZZV/\ Z60U48MSC!Z7:7WM(TI0]I-0N?3=%9WAW_D7]+_Z]8O_ $ 5
MS_B;XS?#_P $ZH-,\0^.O#6@ZD0"+/4]7M[:8@]#L=P?THE%J;@M3"FW4BI)
M;G8T5A77COPU9?V-]H\0Z5!_;4@ATSS;V)?MTA&0D&6_>-CLN37S)_P4L\=^
M&K+]FGQ7X8N/$.E0>);K[%/;Z-+>Q+>31B[C)=(2V]EPC<@8^4^AHC!RG&'=
MI?>[?AN;TH>UFHWW/KBBO-_#/QP^'5QX!&LP>/O"\VDZ;#!#>W\>LVS06LCJ
M B2R!]J,QX 8@D]*^1?V$M%^%/Q(N-/^(?B3Q+::A\<;[6;ZY1+CQ&WVYHU9
MPJ"T\T!H_*!/,9X&00 ,;QH-RFG>T?+^O5^1E'6C[5_UHW^EO4_0*BJFJ:M9
M:'I\]]J-Y;Z?8P+OEN;J58XXU]69B !]:YWPG\7? OCZ^DL_#'C3P[XCO(UW
M/;Z3JL%U(H]2L;D@5S)-[!TN=;15+6M;T[PWI-UJFK7]KI>F6J&6XO+V9888
M4'5G=B H]R:P+SXM>!M/O=)L[KQGX?MKO5TCETZWFU2!)+U'^XT*E\R!LC!7
M.>U"3EHD'F=917/-\1/"J2:VC>)M'5]#*C55-_%G3RPRHG^;]UD<C?C-1>#_
M (G>#OB$UPOA7Q9H?B5K?'G#1]2ANS%GIN\MCC\:?*][ =-17+>*OBKX*\"W
MUO9>)?&&@^'KRX&8;?5=3@MI)1G'RJ[ GGTKIH9DN(DEB=9(W 970Y# ]"#W
M%*SM?H&VX^BBOB;]HWXO>!/^&Q/@%<_\)KX=^SZ#<ZQ%JTW]JP;-.<P*@6X.
M_$1+ KA\<@BM*--UJD::ZW_!-_I;YEQBY1E+LF_NZ'VS16?H/B'2_%6CVVK:
M)J5GK&EW2[X+ZPG2>"502"4="589!'![5SGB#XU?#SPGK!TG7/'GAG1M5! ^
MPZAK%O!/ST^1W#?I4<KORVU(6NJ.SHJ*VNH;RWCGMY4G@D4.DL;!E93T((X(
MI[NL:,[L%51DLQP /6IV#<=17#VOQU^&U]K@T:W^(7A6XUC?Y7]GQ:U;-<;_
M .[Y8?=GVQ7;-]P_2B5XJ[0^MF.HKY,_X)]:YIOAO]F;4M1U;4+72]/@\1:H
MTUW>S+#%&/.ZL[$ #ZFOI/PA\0O"OQ"M9KGPMXET?Q+;PMLEFT>_BNT1O1C&
MQ /UK6=-P=EKM^*N.2Y92CV;7W-HZ"BLK6_%FB>&;C3H-7UG3]*GU*X%I8QW
MUTD+74QZ11!B-[G^ZN36)K_QC\ ^%-:71];\<>&]'U=B MAJ&K6\$Y)Z8C=P
MW/TK-1;V0M3L**;'(LL:NC!T895E.00>XJCKWB+2O"NES:EK6IV>D:=#S)>7
M]PD$*?[SL0!^)I"6NQH45S'@_P"*/@SXA-,OA7Q=H7B5H!F5='U*&[,8]6\M
MCC\:\D_;[_Y-"^)'_7G%_P"E$5.2<6DT:TH>TJ1IWW=CZ"HKF?AC_P DU\)_
M]@BT_P#1*56\5?&#P%X%U!+#Q+XV\.>'KYP&6UU75K>VE8'H0KN":N<'&;@M
M;,YZ<G4@I);JYU]%5M.U*TUBQ@O;"ZAO;.=0\5Q;R"2.13T*L#@CW%6"<<G@
M5F]-RQ:*XB#XX_#BZU[^Q(?B!X6EUKS/*_LV/6K9KC?TV^6'W9]L5T</BC1K
MCQ%/H$6KV,FNV\"W4VEI<H;J.%CA9&BSN"$\!B,$U7*^P/3<U**^>?V?_@?H
MGPX^.'Q<\2:;\2#XNU+7;Q)+_0S,CR:2S,SJDVV1B6P2$W*F$&,'K7N/B3Q7
MHG@W2WU+Q!K&GZ%IR'#7FI726\*D]B[D ?G3E%+EL]TOO?3_ (/4IKWW&.MO
MQ-6BN<\(?$CPE\0HYI/"WBG1?$L</$C:/J$-V$_WC&QQ^-=#)(D,;22,J(H+
M,S'  '4DU+3CN2.HKG/"GQ)\(^/)KN'PSXIT7Q%+9G;<QZ3J,-TT!SC#B-CM
M_&NCH::W#R"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!\I_\$_O^01\:O^RE:Q_*&OJR
MOB7]BWXP> _A[#\9M/\ %/C;PYX:OY?B+J\\=KK&K6]I*\9,:APLC@E<JPST
MR#Z5Z[\0_P!N7X/>!=-9[+Q?8^,=8E_=V6C>%Y1J%Q=S'A8U\K<JDGC+$#TS
MP#V5H2E*/*F_=A_Z2C:<9.K/3[4OS9RGP35-!_;E^/VE6*F/3[RPTG5+B-3\
MBW)BPS8[%@Q)]:^<]"_:)^ _Q@^*WBCQI\=_%*WL>GZC+8>%O"-UI]Y=6%G9
MH0!<.D4+1R22GD[B<8Y'W=OU9^R-\+_$VCP^,?B1X_M%L/'/C^]6^N=-ZG3K
M1%*VUL?]I5)S]0#R#7G7P-^(6D?L<^*O$/P@^(URGAK0;C5+G5?"7B*\&RPN
M[29M[0/+]V.2,GG=@<]LKNVIVC/D>LHP2T[JU[/75+16Z)C<HR52<;N[6W9*
MS>VS:3^>O4\Q^*GQ3_8YU[1WU+P'XFL?AUX]TU&GT77/#'AV_P!/>&X ^42+
M%;*DB,?E8,#\K'&*^A_#\H_;=_8IM)[X1V>L:[IK%9XP56WU*WD95F3NH$T6
MX8/0XJ;XN?MM^!_#.FKI/P\U2Q^)OQ!U/]QHVA>'9A?++,1PTTD1*I&OWF^8
M' ..Y'OOAV;4[G0--EUJV@LM7DMXVO+:UE,L44Q4;U1R 64-D XYK.HW['9K
M56;>UK[:+RN]KI=12DXRA);J_P!WGY=OF>8_LX?&4?$KX&Z?XCUYUT_6=)CE
ML/$,<WRFUO+;*7&\?P_=W_1A7FW[&>GW'Q.\1>/OCWJ\+I/XOO6L-!CF&#;Z
M1;-LCP#]TNRDL.A* ]Z\G_:D\(>-/!?Q<UGP!X(@9/#WQUEMXI[A,[=.NXV
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MO4HP32<W9KH]K/R2U\M7K>QPQN\/&_2+?DUU^>EK^B['I'Q\O-5^.G[0&B?
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M/B3_ -@C_P!G2N+F?U2U_M2_])@=%-MXBC\O_2CQC]I/_DAO[+'_ &-'AO\
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M?X\?#WPS^S3\8/@_\0/ &D6GA%]7\20>%]:T_1XA;6E]:7(;!>% $W(R[@0
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MZY8^.O&WC)XK""#09UO(;6'S4:6>>6,LB(J*<\YYSC )&4Z<ZWL^17O&*_\
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MD\$RPZ$=0B,4MW9K<IBYVGD*\AD*_P"R!54/;^TESWM:5[_X7WZ_C:_2Y/\
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M_P#@GO\ %%?%*I'XM\16NH>(-8AC(*PW%P0QCR"1E5"@X.,YP2.:^F/V>?\
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MRN0?KQ6\[_O/9[\SOWMI;Y7O\]^AP4N;V-+EVM^/_#6M\[=3RZ\\(Q?L7_M
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M!A5    X %6**0&5I?A/1-#U35-3TW1M/T_4M4=9+^\M;5(IKME&%:5U ,A
M) +$XS2^(O"^C>+]._L_7M(L=;L/,2;[+J-LEQ%O4Y1MK@C((!!Z@UJ44[O1
M]@"LK2?"FB>']0U._P!+T?3]-OM4E$]_<VEJD4MW(!@/*R@&1@">6R>:U:*0
M!63J7A/0]8UK3-8O]&T^^U;2RYL+^YM8Y)[3>,/Y4A!9-PX.TC(ZUK44]G=
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ME<*W(&/E/I7DOAS]H#X)_"_X^>"[KX$^*'.A^*M532?$G@Z&QO8;+]\0L5[
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M?8RP)4J)MVS(((QGJ#5SPCX\\,^/[&2]\,>(M)\26<;;'N-(OHKJ-6]"T;$
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M[FUCDGM-XP_E2$%DW#@[2,CK4OB#PYI/BS2IM,UO2[/6=-F&);/4+=)X9/\
M>1P0?Q%/G3IPIM?#>_S;?ZFLI*4E)]$E]U_\SXQ^&A\$_P##=EM+\#9[.;PS
M<:#/+XS_ .$?D#Z1YN3]F*[#Y0E+8^Y_M=R]?;]8GA/P/X<\!:>UAX9\/Z7X
M<L&?S&M=)LH[6(M_>*QJ!GWK;IU*BDHQ7V5;7?=O\+V7DD1)\TW+O;\$E^AX
M+^V;X/U#6/A*GBS0(]WBCP)?0^)]-VY!?[.<S19'.'B\P8[D"LC]BVTNO&6A
M^+OC%J]HUKJOQ#U1KRVBF'SP:;"/)M(CS_=5FXX._-?1TT*7$3Q2HLD;J59'
M&0P/!!'<5!I>E66AZ;:Z=IMG;Z?I]K$L-O:6L2Q10QJ,*B(H 50   !@4H5.
M6G*'?];7^_EC^/<<I<T8Q[?ET7R;;];=C\^+KP#KLG[1#?LVBSD_X5[-XF_X
M3]IA]P:9CS3:8_YY_:QM^M?3O[<?'[)?Q- X']E'_P!&)7M']CV']K?VK]AM
MO[4\C[-]M\I?.\G=N\O?C=MW<[<XSS3-<T'3/%&DW6E:SIUIJVEW2>7<65]
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M_L5]-_\ 2:.O4*JZ7I=EH>FVNG:;9V^GZ?:1+!;VEK$L44,:@!41% "J
M, "K517J*K5E475M_><T(\L5'L%%%%8EA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS$LS'))ZDU\'Q3CG3IQPD'K+5^G3[W^1];D.%4YRQ$EMHO7^OS$HHHK\S/N
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MBBBN@Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)]?5]CBIXJK[51K1Y5+;U\S[)HHHKX<]4]9^%OB,ZAI[Z;.V9K49C)ZF/T_
M\?0BNZKP#PSK#:'KEI> X1'Q(/5#PP_*O?E8,H93D$9!%?KO#F.>*PGLYOWH
M:?+I_E\C\ZSK"K#XCGBM):_/K_F+1117U9\^%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!YY\7]0V6EA9*?]8[2L/8# _F?RKR^NS^*UQYWB98^T,"K^))/]17&
M5^*Y[6=;,*K[.WW:'Z?E-/V>#IKOK]X4445X)ZP4444 ! 8$$9%?EQXQT?6?
MV-_VDXK^P@>;3;>X-U8;VPMY8R9#1%L'Y@I:,G'#*& Z5^H]<!\:/@GX<^.7
MA0Z-KT+)+"QEL]0@P)K20C&Y3W!Z,IX.!W"D?5\/9O3RNO.GB8\U&JN6:\N_
MRN_DWU//QN&>(BG!VE'5&5<3>"_VM/@S=VEGJ+S:-JJ(LI@95N;.9&60*ZG.
MUU95R#P1T)5@3^=/B[]G#Q!X7^.MM\-$D-[<W=S!':ZDMNZQ20R!3Y^WDA4!
M;=@D HW)QFNS\0?L^_&K]FKQ))JGA8ZC>6HSMU7PX'E62,'=B>$ D   D.I3
M/0G&:DMOV]_BYI]J;2XFTNYN -IGN-."RY]<*57/_ :_2\HP.+R_VDLEK0K4
M)W:3=G&3V;T>UK-:7[(\+$U:=:RQ47&:\MT?<7P4^#OA_P#9O^'<UA'?QN%+
M7NJ:Q>;81(P7EVR<)&JC@9P!DYR23\-_M4?&NX_:2^)FE>'/",,]]HUE*;33
M8T7#7UQ(0&EV\8!PJJ&Z $G&X@9\_P#POO\ :LGMK>>/6-5TEW^1FA%GIB8.
M=S$!8V9<]]S]AGI7V%^S/^R/I/P,4:UJDT6M>,9(RANT!\BT4C#+ " <D<%R
M 2. %!8'QE'#\.59YCF-95L6[VBNC>EWV[;*RT2?3I]_'15"C'EIKJST_P"#
M/PYB^$OPQ\/^%(Y1.VGV^)IEZ23.Q>5AD9VEV;&>@Q7:445^45JT\14E6J.\
MI-M^KU9]%&*A%1CL@HHHK$H56*L"#@CD$5]"Z+?C5-(L[OO-$KGZD<C\\U\\
MU[5\-+C[1X1ME/)B=T_\>)_K7W'"E9QQ-2ET:O\ <_\ @L^6X@I\U"%3L_S_
M .&.IHHHK]0/@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK5^-+TB\
MN^\,3./J!P/SQ5VN6^)=Q]G\(W*C@RNB?^/ _P!*X\;6>'PU2JMXIO\  Z<+
M3]M7A3?5H\69BS$DY)Y)-)117X&?K@5\L_MM?LVZG\6-/M/%GATO=:WI%J8)
M=-&2;F ,7S&/[ZEF^7JP.!R #]345Z679A6RO$QQ5!^]'[FNJ?J85Z,<13=.
M>S/R.^ OPK\,_%CQ4WAO7?%4WA359F"V6^S66*X?H8BQ==K^@Z-TZX!^E)_^
M"9L#8\GXB21^OF:,&_E.*V_VO/V1#XF:[\>>!+4QZ\A,^H:7;C'VO')FB _Y
M:]RH^_U'S??N_LB_M<KXXCM?!7C6Z$7B6,"*RU"8X^W8X".3_P M?0_Q_P"]
M][]9Q^<9CC<)_:>3UGRKXX6BW!]]5=K_ (?NE\[1PM"E4]AB8ZO9ZZ_B<C_P
M[+_ZJ1_Y0O\ [IH_X=E_]5(_\H7_ -TU]QT5\-_KAGG_ #__ /)8?_(GK?V;
MA/Y/Q?\ F?#G_#LO_JI'_E"_^Z:/^'9?_52/_*%_]TU]QT4?ZX9Y_P __P#R
M6'_R(?V;A/Y/Q?\ F?#G_#LO_JI'_E"_^Z:S/$W_  3QTOP;H-[K6M?%6+3]
M,LXS+/<3:'A5'_@3DDG  ')) &2:^Y?$7B+3?">B7FL:Q>1:?IMG&99[B8X5
M%'\R3@ #DD@#DU^=?Q.^)?C+]M+XFVWA/PG;30>&X)2UO;.2J*@X:ZN2,@<'
MISMR%7+,=WTF2YMG^:U)3GB>2C#6<G&%DNR]W?\ +<X<5AL'ATDH7D]E=_YG
MC?@'X2ZC\6OB%_PC7@X3:C"TA(OKJ(0B. '!FE +!!TX!;D@#<2,_J]\*_A_
M:_"OX>Z)X5L[B2[ATV#R_M$O!D8L7=L9. 69B!DX&!VK$^!OP-T'X$^$4TC2
M$^T7LVU[_4I% ENI .I_NJ,G:O0 GJ22?1J\'B;B*6<5%1I?P8/2^\GMS/\
M1?TNS 8)86//+XG^'D%%%%?#GJGJ'P@U#?:7]DQ_U;K*H]B,'^0_.O0Z\?\
MA3<>3XF:/M- R_B"#_0U[!7[%P[6=7+X)_9;7Z_J?FV=4_9XR376S"BBBOIC
MPPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[4M7\&ZQ8WGBZ_\ /_T.*\\P0Y.Z7RH_X>ASUP,@8'%?05?FG^QS_P G:?\
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M_ UZ'"]9T\<Z?22?X:GD9]3Y\+S_ ,K7^1WE%%%?K)^>A1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (<ZL5BHX>*2UD]D,^*GQ6\8?MF?$BU\'^#[6:#P[%*6@MG)5=HX:ZN6&0
M>!SC(499OF^V_@3\#-"^!/@^/2=+07.H3!7U#4W3$EU(._\ LH,D*N< $]22
M2WX$? C0?@/X172]+476HSA7U#5)$ DNI /_ !U!D[5[9[DDGTJNW.LYIXBF
MLOR]<F&ALNLG_,_T^]Z[987"R@W6K.\W^'D@HHHKX\](**** .G^&S%?&-D!
MW$@/_?#5[97C'POA,GBR%@/]7$['\L?UKV>OU?A9-8&5_P"9_DC\^S]_[6O\
M*_-A1117V)\V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.U)$ME)G<9XL<[,\D#[O4?+]WUW]D_\ :PM?C!I\7ASQ'-':>,K=,*W"IJ"
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ME>\U^G\)I_5ZC_O?H?"\0O\ ?07E^H4445]R?*!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!Y+\76/\ PD%HO86H/_C[5PU=_P#&"$KJEA+CAH2O
MY-G^M<!7XGG::S&M?O\ HC]1RMWP5.W;]3YT_;:^-O\ PJ_X9OHFFS[/$/B%
M6MH=A^:&WQB63V)!V#IRQ(^[6C^QS\$?^%0_"^*ZU"#R_$FNA;R]WCYHDQ^Z
MA/IM!)(/(9V'85Q_[5G[)>N_%;Q%_P )IX6UMGUVW@2--*O'"IA 2H@D_@.<
MG#<%F)W#I7 ^$_VX_%_PQ6_\-?%/PS<SZY9PN+>Z$8@F>0 ^6)DP%96./WB=
MN<-G-?6T<'+&Y)#"93)3FWS55>TO)6>\5Z[ZKJ<\JBI8MU,2K+:+Z?\ #FQ^
MW+\3K_Q9KVB_!SPMNNM1OYX7U&.(C+.Q'D0'GCJ)#G_IF<]:^F_@Y\,;#X/_
M  [TCPQ8[7-K'NN;A1CSYVYDD/?D],]%"CM7YX?L]_&C2O!?QPD\=?$2RO+R
M;5UEDAU0+N%L\CE6G5,991AT^4_*-P ) %?IKH>O:=XFTFVU32;V#4=.N4WP
MW-NX=''L1[\>Q&*PXDPU;*L+A\MA%JFO><NDIO?[MDGK^!>!J1Q%2==OWGI;
MLO\ @E^N:^('Q&\/?"[P[-K?B74HM.L8_E7><O*^,A(U'+,?0>Y. ":\R_:$
M_:O\-? ^VDT^$KKGBQEQ'I<+\0DC(:=A]T8P=OWCD= =P^</"/P3\:_M+:F?
MB+\7]:?0/"$2-/&L["#]QUQ$K?+#%CG>W)X/S9+5Y679'[2DL;F$O94.G\T_
M*"ZW[_F=%;%\LO945S3_  7J;+?\%&-4'C&2\3P@DG@?S! H+,MX.3\YDR4W
M$9/EX[8W?Q5]$Z#XY^%O[5W@^?2Q):ZS!(F^;2KT>7>6S8^\%SN4C=C>A(YQ
MGK78>&_A_P""8_A]::!H^CZ7<^$)X%>*V2-9[>X1@")"3GS"1@[R23US7SE\
M2O\ @GOHVI:G_:G@+79O"UQNW_8KC=+"K=C&X.]/QW=>W2O1]OD6,GRPC+"S
MC\,E>6W\RW3]/FS#DQ=-7;51/=;?=Y'D'Q,\)^)?V&_']IJO@WQ5#>:3J9)7
M3;N0&5T4YV7$(QN7D@2+@YW8VGK]W?"?QM<_$?X=:%XEN])ET2?4K?SS93-N
M*#) 8'NK !E/HPKYS^%_[ 6GZ1X@CUOQ]K[>+;B-A(MBBL(7<=Y78EI!T^7
MZ<Y'%?7"J$4*H"JHP !@"LN(LPP>,ITJ=.7M:L?BJ\O+?LK=?5]M-V5@J-2G
M*4I+EB]HWO8\?_:F^"J?&OX6WEC;1*VOZ?F\TR3')D ^:+/HZ_+UQG:3TKSK
M]A'XTOXP\%3>!]8E(UWPXNV!9>'EM,[5&.N8SA#TP"GO7T1XV\=:#\.O#]QK
M?B/4H=+TV'K+,>6;!(55'+,<'"@$G%?F3J_QP@TG]H>Z^*7@C1KO3-'%^KSV
M\Q 6?S%(E5]H(0RA9&VY;!R0>..W(L'7SG+*^ E!\L?>A+HI_P M_P"]^&_5
M&>+J0PM>%9/5Z->7?Y'U+^WC\&IO$/A>T^(6AHZ:YX> ^U-!D.]KNR'!'.8V
M.[C'RLQ)^45ZS^S/\9HOC9\+=/U>1U_MJU_T34XEXQ.H'S@>CC##' R1_":^
M9/'O[5'C[]HO4+GP9\)O#MW;:=<QM%<73HK7$D3 @EV/R0(<D9R3T^89Q7MG
M[*?[,%Y\ X=0U'5->:^U;5(5CN+&TXM(]IRIR1EW'(#?* &88/6C,,-]6R2&
M&S.2C7@[TXWO+E>ZE;9=5]PJ-3VF*=2@KP>[Z7\CZ%KTSX.L?+U9>P,1_P#0
MZ\SKU'X/PE;#49<<-*J_D"?ZU\[PZF\RIV\_R89T[8*?R_-'H5%%%?LA^:A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >7_ !@L2M[I]X!P\;1$_P"Z<C_T(_E7
MD'CCP?8_$#P?K'AS4C*MCJ=L]M*T#;9%##&Y3@C(.",@CCD$<5]$?$;23JGA
MB=E&9;8^>OT'WOT)_*O$Z_(N(*4\)F+K0TYK23\U_P %7/T;)JJK8-0?V;IG
MRUX%_P"">?P_\.S"?Q#>ZCXKE!.(9'^RV^.V5C._(_W\>U?1GA7P7H'@?3_L
M/A[1;#1+0X+16-ND(<@8W-M W''<Y-;-%>3C<UQV8N^*JN7E?3[EI^!Z]+#T
MJ/\ #BD%%%%>4=!X5\:_VP/!_P $?%2^'=1LM3U75/)2>5=/2,I"K9VJQ9P=
MQ !P!T8<UY[_ ,/(O W_ $+/B#_OF#_XY7N7Q&_9Y^'OQ:U>#5/%?AR/5-0A
MA$"7"W,\#>6"2%/E.N[!)QG.,UQE[^P]\&KJSGAB\*R6<LD;(MQ#J=V7B)&
MZAI64D=1N!''((XK[;!5^&HT(1Q=*HZG5IJU_+WEI\CRJL,<YMTY1MT_JQP'
M_#R+P-_T+/B#_OF#_P".55U'_@H=\.M8M7M;_P ':U>VS?>AN(;:1#]5,F*^
M3OC)\"/$7[/WC!(-;TY-7T3S@UIJ!21;2^0'.QBC!D; (9 P8<D$C#'7O/BE
M\(&T$I:_!*&/6S'M$TWB6^>V63'WM@<,5S_#N![;N]?H<>&LEG"G7PE&=6,M
MG&:T]>:47_D>-]>Q2;A4DHM=&O\ ),Z3X^?&CX._$SP@\'ACX=S>&_$L<BO;
MZA;V]O:QX+#S!*L1_>94'&1D'!!'(/D'A7Q!XVUC17\ >'+K5+K3]4NOM#Z)
MIX9OM,NP EE498;4!(/R_("?NY'6? O]F_Q/\?M:=M,@72?#\4NVZU:9&,,/
M<I&"<R. ?NYXR-Q&0:^]K/2?A3^Q;X$:Y<I9RS*0US*%FU+4W 'R+T)&=ORC
M:BYR<9)/7C,SP61PCEV$@Z]5NZ@VY6?2[=[=TEKUTO<RI4*N+;KU'R1ZO:YX
M=\&_V![+1;$^(_BUJ$,%M;QM/)H\-R$AB0 $M<7 (  ^;(0@# .\C(KEOVA?
MVP(-0TO_ (0'X36ZZ)X8C!MY+ZQA^SM<*3_JX$ 'EQDDY. S9QP,[N,^+/Q\
M\?\ [6'BBW\,:!IUS#I,T@%KH%@2S2D'/F7#\!L=<G"(!GL6/U?^S/\ L<Z1
M\'XX-?\ $8@UOQB0&1\;K>P]H@?O/ZR$>R@<EO&Q=59?RYAQ!/VE;>%)?#'S
MMM\W?_MYV.JG'VUZ.#7+'K+J_P"OZL<!^R'^QS<^&[[3O'?CJW,&I0D3Z;HL
MJ_-;MU6:8=G'4)U4X)PPP/M&BBORO-,TQ.;XAXC$O7HNB79'T&'P\,-#D@%>
M]>#;$Z?X7TZ$C#>4'(]"WS'^=>+>'M+.M:U9V0'$L@#8[*.6/Y U] JH50 ,
M < 5]7PGAWS5<0_\*_-_H?+\0UE:%%>OZ+]1:***_1CXL**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCY4L<5OIJS^2UY(Q_P!6'VMM^4,Q.#@*3@]*[B>>.UADFFD6*&-2[R2,%55
MR22>@ K\M/VNOC]_PN[X@"+3)6_X1;1]T%@.0)V)^><C_:P ,_PJ.A)KZWAG
M)99QC5&2_=PUEZ=OG^5V>=C\4L-2=OB>W]>1]9K_ ,%E1&H5?@\%51@ >)N
M/_ .G?\ #YC_ *I!_P"7-_\ <=?FG17]%_V?AOY/Q?\ F?GOL8=C]+/^'S'_
M %2#_P N;_[CH_X?,?\ 5(/_ "YO_N.OS3HI_P!GX;^7\7_F'L8=C]+/^'S'
M_5(/_+F_^XZ/^'S'_5(/_+F_^XZ_-.BC^S\-_+^+_P P]C#L?I9_P^8_ZI!_
MY<W_ -QT?\/F/^J0?^7-_P#<=?FG11_9^&_E_%_YA[&'8_2S_A\Q_P!4@_\
M+F_^XZ/^'S'_ %2#_P N;_[CK\TZ*/[/PW\OXO\ S#V,.Q^EG_#YC_JD'_ES
M?_<='_#YC_JD'_ES?_<=?FG11_9^&_E_%_YA[&'8_2S_ (?,?]4@_P#+F_\
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M>.=6\3ZL^;J^E+B('*PQCA(U]E4 >^,]37+U_3&2\/T,MP4*-2-Y[R=WN_\
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MMHVT!J-HIVVC;0&HVBG;:-M :C:_<#_@G!_R9A\//^XC_P"G&ZK\0=M?M_\
M\$X?^3,?AY_W$?\ TXW5>-FO\!>OZ,Y<1\"/I6BBBOE3SPHHHH **** /A__
M (*[_P#)MOAO_L;;;_TCO*_(FOUV_P""NW_)MOAO_L;;;_TCO*_(O;7UV6_[
MO\V>E0^ ;13MM&VO5.C4;13MM&V@-1M%.VT;: U&T4[;1MH#4;13MM&V@-1M
M%.VT;: U&T4[;1MH#4;13MM&V@-1M%.VT;: U&T^.1X9$DC9HY$(964X((Z$
M'UI-M&VD&I],_!_]O#QKX!2WT_Q(@\8:/& @:Y?9>1K[2X.__@8)/]X5]?\
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ML>).<ZDN:;NQM%.VT;:Z2-1M%.VT;: U&T4[;1MH#4;13MM&V@-1M%.VT;:
MU&T4[;1MH#4;13MM&V@-1M%.VT;: U&T4[;1MH#4;7W!_P $B/\ DY+Q)_V*
M5S_Z66=?$.VOM_\ X)$C_C)+Q)_V*5S_ .EEG7%C/]WGZ&56_(S]=:***^)/
M*"BBB@ HHHH *_(G_@KO_P G)>&_^Q2MO_2R\K]=J_(K_@KL/^,DO#?_ &*5
MM_Z67E>KEO\ O'R9T4/C/AZBG;:-M?7'I:C:*=MHVT!J-HIVVC;0&HVBG;:-
MM :C:*=MHVT!J-HIVVC;0&HVBG;:-M :C:*=MHVT!J-HIVVC;0&HVBG;:-M
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M"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"OM_P#X)$_\G)>)/^Q2N?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJK4.=1V>O2VE_G_P3X*HK]KOVTOVT/\ AE>Y\/Z7_P (=_PD_P#;]K<MYO\
M:GV3R-A1>GDR;L[\]1TKS7]@W_E'WXO_ .XS_P"B!7&LQE]6GB73]U;:[ZV?
M32P>U?-3BU\<K?>F[_@?DW17Z0?\$B_BJDDWC3X8W[AXKA!K-E$_(/W8KA>?
M4&$X]FKXL_:6^%;_  5^.GC'PAY?EVEC?.UGUYM9,20\GK^[=0?<&O0]O_M#
MP[72Z??O]S_4TIR]ISJUG%_T_P OO/,J*_6OX+QK^Q[_ ,$Z;_Q7,OV7Q#JM
ME)JR[@=WVJZ"QVBD=?E4PDCMAJ\^_P"".+-(_P 6F8EF8Z62Q.23_I=9O%:5
MVHZ4K?-W2:^5_,Q]O^Y]M;1NR].Y^:M%?J)XX_X*X?\ "&^--?\ #_\ PJG[
M9_96H7%C]H_X2/9YOE2,F_;]E.W.W.,G&>IK\Y?BMXY_X6=\3/%/B[[%_9O]
MN:G<:C]C\WS?)\V0OLW[5W8SC.!G'04\/7JUK.5.T6KWO<Z8WL^=6:_X/Y?J
M<K17K?[(_P#R<[\+_P#L8+3_ -&"OU:_:V_;:L_V5O%GA;1]0\'R^(['6H)+
MB:Y@OUA>W5'"D+&T9$AYSRZT8G$2H2IPC'F<[I:VV5_R.=U9>T=.,;V2?WMH
M_$JBOTF_X*D? _P?:_#_ ,,?%;P]I,.B:K?WT=G>I;0K"+M)87E221!QYBE,
M;NI#8).!C%_8E_8U\%V7PPE^-OQE6WET!(7O+#3+\'[+';H>;F=?^6FX@A(\
M$$8)#%@%B&-@Z$JTU:SLUY]BW57)"4=>;;SZ'YYT5^H&I?\ !6KP-X9U>/1O
M"WPPNKGPG 1"MQ]JBLF" XS';+&R[<= 77W K;^(G[/_ ,(?V]OA'>?$#X3V
MUOH'C6$,66.!;9I+@+N-M>1+\NYL\2KD\@[F48K*6-G37/5I-0[[V]4)5+24
M:BM?[OO/RDHKZ:_X)X6<^G_MI^![6YB>WN8)-0BEBD4JR,ME< J1V(((K]#O
MCU^W3IWP/^/VB_#/5O!DVK6.IPVLDFK07J[X_/D:,#[.8\/@K_ST&<]/7HQ&
M(E2J4Z5*/,YJZUMU:_0FI6=.4DU\*NS\5Z*_2K]NKP-X7_98^.WPO^,WACP[
M;1^9?R2:AH=FXM(;F:$*RR+A&$98.P8A3D@'&22?K']G']J+_AH#X(ZS\0_^
M$9_L'^SIKJ'^S?M_VGS/)B63/F>4F,[L?=.,=ZY)9C;#_68PO%7OKM;\QSJ2
MC**4;J5K/N]=/E8_"2BOL+XI?M>?\-9_M!?!:\_X1/\ X17^Q=;MH=G]I?;/
M.\R[@.<^5'MQL]\YK[\_;(_;*_X9+_X17_BD/^$J_MS[3_S$_L?D>5Y?_3&3
M=GS/;&.^:UGBZM-4U*G[TKZ7[>?FM1^TDY^SC&[M?\_\C\0:*^AOVB_C=J7[
M;_QM\,W.C^$SH>JW-M;Z':Z<+_[7YLAF<JQ?RX]HS+@\<!<YK[CMO ?P+_X)
MN_#W2-8\5V$?BOQ_>C]U<?9DFO+B4 ;_ +,KG;!$F[!;()! )8D"M9XITJ<9
M5(VE+1):CG4Y9*$5=M7]#\EJ*_4;PS_P50^&_P 3M1;PY\1OANVD^&[P^2;B
M>:/5;<*3C,T+1(0N.NT.?:O'_P!OS]BO0OA;HMK\4?AKM/@K4)(Q>:?#)YL5
MH90#%-"W.87) P2=I9<?*P"Q'%RC.,:\.7FT3O=7[#A4YI<CTD?#-%?J]_P2
MX_Y-)\=_]AN^_P#2*VK\H:Z(UN;$5*%OA47?_$K_ (#ISYTWV;7W!17ZO_M!
M?\HI/#__ & = _\ 1MM7S9_P3^_8OT[X_75_XT\;>8/ ^D3>0EFKF/\ M"<*
M&96<$%8T!7)&"2V,C!K..*C:K*>BIR:^ZVOXF/MU[*-1K?H?&=%?J5XN_P""
MFGPJ^"-^?"GPM^'<>M:+8R-"]S82Q:79-CJT(6)S(,Y^9E7)Y!(.3TNGVOP'
M_P""EG@S519Z5_PBWQ!L80[W'D1QZA:D\*Y9>+F#=P0W3/1&*FL/KE11]HZ3
MY._6WH5[5P:]JK7^?WGY(45TWQ,^'FL?"?Q]KGA#7HEBU;2+EK:;824?'*NI
M/564JP/HPKF:]*,HSBIQ=TSI::=F%%%%4(**** "OV^_X)P_\F8_#S_N(_\
MIQNJ_$&OV^_X)P_\F8_#S_N(_P#IQNJ\7-OX"]?T9RXCX$?2M%%%?*'G!111
M0 4444 ?$'_!7;_DVWPW_P!C;;?^D=Y7Y%U^NG_!7;_DVWPW_P!C;;?^D=Y7
MY%U]AEG^[KU9Z6'^ ****]4Z0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BOTI_P""-W_-6?\ N%_^W=>X?"O]LKPW^TA\:?%'P:\0_#N...U>
M]MUFNKA+^VNUMY"C^9&T2[,@9 ^;GC/>O/Q&*G1K2HPAS<J4M[:63?W7.26(
MY7)M:)I??L?C-17N'[:7P>TKX&_M%>)_#&A IH@,5Y9P,Q8P1RQA_+R>H5BP
M&<G:!DDYKZ#_ ."3/P=_X27XHZY\0KV#=9>'+;[)9.PX-W.""0?58@X/_75:
MWCB(2P_UCI:__ ^_0VKS]C&^^UO._P#P-3X,HK]0_P#@K)\)X/$W@/PI\4](
M$=T-.<:?>7$&&62UF.Z&3<.JK)E1_P!=J_-KP!_R/GAO_L)6W_HU:6"Q"QD4
M[6=[/R_I68JM3V=%UEK9-_=T_ P:*_<[]L#]K6/]E'1_#-_+X6;Q1%K5U+;N
MBWXM3"$56+#,3[\[NG'3K7SW^WM\-? _Q@_95TWXY:)H::'KGD66H+,(4BGN
M+>Y9$,4^WAV7S%(;)(VD X)KSZ>9.:C)T[1;Y;WZOR"$W*48R5N;;Y'Y:T5^
MKWPC_P"42NI_]B_K/_I5<US?_!'/_D7?B=_U]6/_ *!-794Q7(\0N7^$_O\
M>M\N_4QEB.6"G;[37W'YBT5^JLW_  52\&R^.-7\*>./AS<VNBVU[+I\E]!=
MQZ@K!9"A=X'BC^7C) +''0&O-?\ @H!^R)X-L/A[9_&GX506=GH$PA?4+'3
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M!]F^Q_VK+;WWV??O\KS9[E]F[ W8W8S@9QT%>T>"?VU_#WQE_:*U_P"!NO\
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MCBOJ7QE_P3*^%GQLU ^*OA?\0(]#T>_D,S6^GQ1:I9#/40%94,8SGY2S 9P
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M:6B@!-M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@#])_\
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M.6=XX:O1>Z3DO1_TON9]U?MA?&7X5?!O1?#5Y\4O!'_":VUW<RII\8TJTO\
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M[:-M+17TQL)MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;2T4
M)MHVTM% ";:-M+10 FVOM[_@D6/^,DO$G_8IW/\ Z66=?$5?;W_!(O\ Y.1\
M2?\ 8IW/_I99UQ8W_=Y^AE5^!GZY4445\,>2%%%% !1110 5^1G_  5T'_&2
M7AO_ +%.V_\ 2R\K]<Z_(W_@KI_R<CX;_P"Q3MO_ $LO*];*_P#>%Z,Z,/\
M&?$&VC;2T5]@>F)MHVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVC;
M2T4 >L_LS_M'>(?V9?B-#XDT0"\LIE%OJ>E2N5CO8,Y*Y_A<=5?'![$$@_I?
M\0OAC\)O^"D?PIC\5>%KR.P\76D/E0:@4"75G+@D6MX@^\F<X/.,ED)!.[Y*
M_P"">OASX!^/%\1>&/B386Y\9Z@C6^GW&K7(2WD@D4*5MLX5+A6Y!.6Y!0C#
M"OL#X$_LN^"/V#KSQ=X[UCXD2/HMY;>1&NI*EK%#"'WJ&PQ\^;( 4JJGYF 7
MYJ\+,)TN:SO&<5[K77R_K_@/SY3:J<U)>]>UNZ[_ -?\-^2DWA/4_ OQ.'A[
M6;9K35M+U5;.Z@)SLD24*P![C(X(X(YK])_^"OW_ "2KX?\ _88E_P#1!KX$
M^+7Q(M_B]^TAKGC"S@:VLM6UQ9[>.3[PBWJJ%O1BJ@D>I-???_!7W_DE7P__
M .PQ+_Z(-&,E.5/"2J*TG+5>?N7.BR6.LMN5_P#MQPO_  1S&/$GQ0_Z]+#_
M -#GK[5_M3P9X<\&>.OB3\// >D:GXEL'U".]CT^SAL[V^NK>5Q/%),D98LS
M(S<[BV0<<U\5?\$=?^1D^*'_ %Z6'_H<]=+^R#\?!X1_;,^+_P ,M5GVZ3XE
M\2:E<Z>)#\J7R32;EZ?\M(UQSWB4#K7/C:,JU>HH/51OZVW7W?D<LHI.I5>J
M4HW7E;^O17/S_P#C=\8=<^/7Q*U?QIXA*+?7[@);PY\JWB4;8XDSV4#\3DGD
MU^HO[./@S6OV:/V";K6-#T+4-7\<ZS92:Q'8:?9RW-P]S<*J6P\I 6PB>46&
M.,.:^6_B;^Q/)9_MXZ/X'LK)D\&^)+S^VH61"(XK$$R7,.0,+M*N@] \?K7T
MO^W%^W9KO[,GC;0/!_@?2]#U"\-A]KU :M!+(D"LVV%$$4L>#A')SG@IBM*]
M2%;#4L/05N?IY+=???7NCIJ\U3$)1U4?>\O+\.GFBS^Q+X?\5?$3]EOQ7\*?
MBCX6\0:&T(N+*&?7=.GMFN+:Y#N&1I5&]XY"YXZ?NZ_)OQCX3O\ P-XLUGP[
MJD?DZEI5Y+97">DD;E6Q[9''M7Z"_ 3_ (*E>./''QA\*^'?&>C>%[#P]JUZ
MMC/=:;:W,<T3296)@SW#J!YA3.5Z9Z5Y]_P56^#O_"%_&S3_ !K9P;-.\5VN
M9F4' O(0J/GL-R&(^Y#&M*;J4<9>I&RJ+IW7^>M_5#P]TYTGO\7W[_UT2/H?
MPK_RB7N?^Q<N_P#TJDKXG_X)YC_C,/X>?]=;O_TCGK[8\*_\HE[G_L7+O_TJ
MDKXH_P"">?\ R>%\//\ KK=_^D<]:T?][QO_ &]_[><M/_D7O_M[\D?H+^UG
M^T9\ OA/\3K71OB=\+_^$R\12:9%<QZA_P (_I]]MMVDD58_,GD5QAE<[<8&
M[W-?*5C\7O@]\6OVU/@KJ'P^\%Q^"M"M+R."ZMI-*M+!9KHR,87VV[LK'<8P
M"3G(%?5W[6?_  3[_P"&HOB=:^+_ /A/?^$9\G3(M.^Q_P!C_:\[))'W[_/C
MZ^9C&.W7FOST_:L_9GNOV.?'WA>TL?%[Z_>W-N-3@OH[#[$UM(DN%P/-DR05
M!SD?2N++WAKTTY/GUTU\_EMJ;<D:M*<*;U<;/\/U/=?^"O\ 'JW_  M;P,\Y
MD_L,Z-(+3^X)_.;SL>^TP9]L5YO^R)^P1_PU5X!U7Q-_PG7_  B_V'4FT[[+
M_9'VO?B*.3?N\^/'^LQC!Z=>:^L/ ?Q[^#?[?7PELO!'Q1N;70/&D04&.6=;
M60W(7:+BRE;Y26R?W1R>H*LH!/,6_P#P2'\)Z=K#ZAJOQ1OG\,(2YMTT^*"8
M)[W+2,GU/E_@*THU?J=%X:J^22O9VNM[_P# _'R'*OS1BOADK)JW96_X)QOC
MS_@DK#X$\#^(/$EQ\6Q+!H^GW%^\9\.;-ZQ1LY7/VHXSMQG!Z]#7J7_!*'_D
MVKQQ_P!AVX_])(*\Y_;4_:T\"^#OA##\"_@U<VMUI:VZV5_J&GR>9;06PP3!
M'+D^:\A^^X)&"PR68[?1_P#@E%_R;7XX_P"P[<?^DD%95I5ZF Q$ZKO&RM=)
M:76MO/UZ?>2YN6ES_%S?I_PYPW_!');+SOBF?^8AMTX<X_U6;CIWZ]?PKX8_
M: _M)OCI\0CK'F?VG_;]]Y_F9SN\]_7MC&/;%=7^R7^TA>_LQ_%BV\2I;R:A
MHUS$;/5=/C8!IK=B#E,\;T8!AGK@C(#$U^A'Q'_9Q^!7[?3#QOX+\:1:5XIG
MA475QI^QY&( 5?M=FY5PX"[0<H2 .6 6N_$-T,6L3)>ZXVTZ-6_RO\PA-49S
MC/:333]$?D=MHVU^K'@?_@G_ /!3]F*1/&'Q6\;6OB);(EX8M:CCLK L.1_H
MY=VF?CA-Q!S]P\5^>7[1FM?#WQ%\7M>U#X8:7=:1X1FEW06]SA5+_P ;Q)C,
M<3'E4)) _N\*O32QE.O4Y*2;7?H;PE[2[2T7XGFFVC;2T5W&@FVC;2T4 )MH
MVTM% ";:-M+10 FVC;2T4 )MHVTM% ";:-M+10 FVBEHH **=15 -HIU% #:
M*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=1
M0 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 V
MBG44 -HIU% #:*=10 VBG44 >D?LR_\ )R/PH_[&S2?_ $LBK^@:OY^_V9?^
M3D/A1_V-FD_^ED5?T"5\OG'QP]#@Q.Z"BBBOGSC"BBB@ HHHH _$/_@HY_R>
M;\0_^X=_Z;K:OFNOI7_@HY_R>9\0O^X=_P"FZVKYLK[_  W\"GZ+\CUZ?P(;
M13J*Z30;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%
M.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH
M ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M?MY_P3C_Y,R^'G_<1_].-S7XBU
M^W7_  3C_P"3,_A[_P!Q'_TXW->)FW\!>OZ,Y<1\"/I2BBBODCS@HHHH ***
M* /B'_@KI_R;=X;_ .QLMO\ TCO*_(VOUS_X*Y?\FW^&_P#L;+;_ -([ROR.
MK['*_P#=UZL]+#_ -HIU%>N=(VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=
M10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10
MVBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:^WO^"1?_
M "<CXD_[%.Y_]++.OB.OMW_@D;_R<AXD_P"Q3N?_ $LLZX<=_NT_0RJ_ S]<
M:***^%/)"BBB@ HHHH *_(W_ (*Z?\G(^&_^Q3MO_2R\K]<J_([_ (*Y?\G(
M>&_^Q3MO_2R\KU\K_P!X7HSHP_QGQ!13J*^Q/3&T4ZB@!M%.HH ;13J* &T4
MZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@
M!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%
M.HH ;13J* &T4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_;OQ9
M\>O^&;?V.?!7C;^PO^$B\C2=)MOL/VO[+N\R%%W;_+?&/3;S7XB5^L/[9G_*
M.'PK_P!>>A_^BTKR,T5Z5.+ZS@ODW9G%4BIXFG&6UI?H:?PL_:@^"?[=MPW@
M3QGX'AT[Q#<PNUM:ZH(YO,.#N^RW2A764+EN AQG&<''P=\=/V>[G]FK]IW3
M/"IN'O=)EOK2^TN\D #RVKS *'QQO5E9#CJ5S@ XKA/V;9;Z']H3X:OII<7H
M\16&SR\YQ]H0,..VW.?;-?=7_!4I+<?&#X&NH7[49YA(1][8+BVVY]LE_P!:
MJE26#QM"-+2,VTUZ*]T8UFX4JU+=<C:\NAH_\%A/^1(^''_81NO_ $4E>A_#
M6S\._L8_L9:1\0/#'@@^+]8NM+L]1U2XLF"3W'G*KO(\VQV6&,.< *0 ,XY9
MJ\\_X+"?\B1\./\ L(W7_HI*\S_8/_;XMOASI]G\-/B5-N\*9\G3-:D&_P"P
M!B?W,X[PY/#?P9P?D^YY6&I5*V E&GOS7MW2W7]?G8Z*L?W=&;5XI.Z_[>>O
MR.7_ &UOVF/@M^T+X%T'4O#GA"ZL_B/,P>[OVC6W-G&#AHIF48N=P *'^$'.
M5.Y"W]@/]BO3OC])?^-/&_FKX(TR8V\=G'(T1U"<*&<,X(*Q(",E2"2< C!K
MM/V_?V'M%\%>'Y_BQ\-(XHO#DC)+J>DVI#00+(0%N+?'2,LPR@X7<"N%X'L/
MP/\ .7_@E7JA\.B3[>="U@R>7_K-_GS^;C;WV9QWQBNGV\*.!G4PUT[VL]XM
MZ_=9?C?<<_?5*$)>[)VOY?Y_IMI8QO&'_!2GX4? G4)?"GPL^'D.M:78RM#)
M<:=+%I=BY'5H2L3F09S\Q5<]06!!,FI?'O\ 98_;#\"ZY<>/M.M_!6OZ?:&:
M2YO4CAU%0%X:UGC!-Q@GB(@DG_EF17Y945V?V;2Y=WS?S7U+]C&+3AH?HG_P
M2/CLXOB9\4DTZ::YL%L[<6\UQ$(I)(Q-)M9D#,%8C!(#'!XR>M>;> ?^4I=Q
M_P!CMJ/_ *%-7H'_  1[_P"1Z^(__8-M?_1KUY_X!_Y2EW'_ &.VH_\ H4U9
MVMC6O[GZHYYZX?&/S7_I#/MO]J;]NK3_ -F3XGZ#X2U7P;/K^G:G8)?SW]M?
M*DD*M+)&56!HR'(\O/+KG..V:^;O^"J7P%\)^%=)\+_$;P[I=OHE]J=Z=/U"
M"TA6*.Y9HVE24H, .-C@G&6W#/2OH[]JO]ICX,_ GXEZ'%X^^'TWB?Q6-/2]
MT_5;?1[*YDMHO-D556::170AU=L*,#=GJ37YU_MC?MD:K^U5KFFPQZ9_8'A7
M26D:RT\S>9++(V 9I6  W;0 % PN6&3G->9@Z,Y>RG2@TTW>5]&NUOP_JYTT
MXN,TTN6/*OF[;_K_ %K]G?M!?\HI_#__ & M _\ 1MM7YM? W_DMGP^_[&'3
M_P#TICK])?V@O^44_A__ + 6@?\ HVVK\VO@;_R6SX??]C#I_P#Z4QU[6!_B
M8C_KY+\D<T?]T^3_ %/O#_@L7_S2O_N)?^VU?5?PG^&^B_%[]BSP1X0\0V_V
MC2M4\)V,,F -T;>0A21">C*P# ]BHKY4_P""Q?\ S2O_ +B7_MM7L7BKXF:S
M\'?^"=?@/QCH$HCU/2=)\/S(K?=D4R6ZO&W^RZ%E/LQQ7B1CSY=3AM>HE][D
MC2KS6HN&ZB[?>?F'\1OA!K?P*^.+^#==C/VJPU"+RK@*52ZA+@QS)_LLN#['
M(/(-?H#_ ,%>_P#DE7P__P"PQ+_Z(-=-^T1\,]"_;>^!OA'XL^!8UD\2:6$N
MHX@!YTD*N#<6;X_C1@Q7W! X?-<S_P %?/\ DE7P_P#^PQ+_ .B#6U:O*JL/
M"I\<9V?WPU^?YW"E.-7$QJ1V<7\G9W1Z1^S9\2/^%/\ _!._0?&G]G?VM_8N
MD7-W]A\_R?.VW,GR[]K;>O7::^:_B9_P5>_X6+\._$_A7_A5O]G_ -M:;<:?
M]K_X2'S?)\V-DW[/LHW8W9QD9QU%?2G[-GB?PYX+_P""=^@ZYXNTG^W?#5CI
M%S-?Z;]FCN/M$0N9,IY<A"-]&(%?-?Q,_:^_97\2_#OQ/I/A[X*?V5KU]IMQ
M;6%]_P (II4/V>=XV6.3>DI9=K$'<H)&,BE4IQJ8W$<U-S]Y[=-7^?Z&.!2Y
M*<K:WW^[\C\_:***^H/1"BBB@ HHHH **** "BBB@ HHHH **** /2OV9?\
MDY#X4?\ 8V:3_P"ED5?T"5_/W^S+_P G(?"C_L;-)_\ 2R*OZ!*^7SCXX>AP
M8G=!1117SYQA1110 4444 ?B+_P4;_Y/,^(7_<._]-UM7S77TI_P4;_Y/,^(
M7_<._P#3=;5\UU]_A?X%/T7Y'KT_@04445TF@4444 %%%% !1110 5^D'_!'
MGPR6OOB5XA>+Y4CL["*7ZF5W'_CL?Z5^;]?JY_P3EC7X8_L7^-/&MQ\BRW6H
M:H'Q@^7;VZJ/_'HW_.N#,*GL\)4EY?JOTN<>(BZG)27VI)?K^:/!/^"L7PS'
MACXW:+XOMX@EMXFT_;*P'6YMR$8G_MFT/Y&OJW_@EY\,_P#A"/V;8M=GBV7W
MBB^EOR67#"%#Y40^GR,X_P"NE<Y^TYX9N?VP?V)/ WBO1;<7GB/S-/O$CAY_
M?2L+:YCS_=5W)/\ USSVKVCQ+X\T_P" /B#X"?"W39$BAU6X;2]C=3:V]DZ#
M\3,T'UYKQ.><<*\$_CYG'Y+7_)+T?F85JGMX4Y=HMORY5;\C\GOVWO"Z^$?V
MK?B19(NV.;4S?+_V\(LY_60U+^Q'\'_^%T_M'>%=(GA\[2;"7^UM1';R("&V
MGV9_+0_[]>L?\%7/#/\ 8_[2MGJ:Q;(]7T.WF9P/O2(\D1_$*B?I7O\ _P $
MK_A@O@?X.^*_BA?6<]Q=:PSPVD=O"TLKVMMNW"-%!9F>7>NT9),:XKTJ&)]C
MERK=8JWS6B_S.O&2<HI+>=OQ5W^MCV[]O7X3P?&O]F_Q1;6 2[UKPVPU6U2+
MYG66%-TD>!SN:%WPOJRGTK\0Z_6C]@GQA\4M0^)WQ/LOB-X&\3Z)IWBBZDU^
MWN=8TBX@MXIB1&\&^1 .8O*"CTA-?GC^U9\(6^!_Q[\6^%4A:+3HKHW.G94@
M&UE^>(#UVAMA/JAKGR^^'JO#R=^9*7SM:2_KLV71?NRI[\C_  ?]?>S];OV;
M_ ^C_$K]B7P1X7U^T6]T?5/#D=M<0MUVD'# ]F!PP/4$ ]J_(']H#X(ZQ^SW
M\6-5\':N&E%M();.\VX6[MF)\N4?4#!'9E8=J_36'QYK'PO_ ."9?AKQ7H%Q
M]FU?2='TRY@<C*DB\ARK#NK E2.X)%9WQZ\"Z'_P4$_9=T?X@>#84_X3'2HF
MGM[8,/,$B@?:;!SZDC*$XR0AX#FHP]66&QDZ[^#G:EY:W3_K_(Y<')QH04MI
M:+U27YW_  \C+_X*P_\ )N/@7_L/P?\ I'/7YC?#WP5?_$CQUH'A;2UW7^L7
ML-E%\I(4NX7<<=E!+'T -?IS_P %8@5_9R\# C!_M^#_ -(YZ\/_ ."3_P '
M_P#A*OBUK/CV]@W6/AFU\BT9E.#=S@KD'H=L0DR/^FBFNG+ZBHX>I5EM%M_E
MI\WH)3=/"0:WM9>MS]%_$_P:\.>(/@???"*(QQ:;_82Z9!%D,\**FR&7![AT
M# ^JU^!WB#0;[POKVI:-J<!MM1T^YDM+F%NJ2QL5=?P(-?J?X;^(OQ3D_P""
MAFI:Q<> O%\?P\O8CX72\ET.Z6VC@C):.YW[-NTS[VWDXV2DU\S?\%0_@]_P
MK[]H!?$]G!Y>E>+K;[9N4 *+N/"3J/<CRW/J9#7'@)2I5HN;O[57^>K^^VK^
M1TX=<G-A_P"6S7W)/\?P5Q?V _V+K']H*\OO&'C02+X&TJ;R%M8Y#$=0N  S
M*7&"L:J1N*D$E@ 1@U]#>-/^"D_PF^ ][+X4^%GP_AUS3K"0PO/ILD6F6#D=
M3$RQNTG.?F*@'&06!!.G^SRMU/\ \$L]7C\.[CJ_]C:T&%L"9#)YT^X#'.[R
M\8_"OS3^#'PY_P"%O?%3PQX,_M#^R?[;O4L_MWD>=Y.[^+9N7=]-P^M=LH?7
M,55I5'[L+*W1[Z_AH<\>1TYUZST3?R2/T>N/VFOV7_VN_ VLCXD:/;^$M:L;
M-IFDU!$2]4  YL[J,;I6#$8CP"V.8V&:^ O@"NGI^U%\/%TI[B72QXOT\6CW
MB*DS0_;$V&15) ;;C(!(SG!K[2_X<W_]5>_\MG_[KKP;5_V>(_V8_P!MOX4^
M#D\2#Q0S:OH]\]V++[)L9[P#RRGF2= @.<_Q=*TR^>%AB%&A-ZVTUM^);E'V
M,XQ=]&S] OVQ/VUO^&3=4\,6?_"&_P#"5?VU#/-O_M3['Y/EL@QCR9-V=_MC
M%?G1^V-^V?\ \-9VOA6'_A#_ /A%?[#>Y?=_:?VSS_-$0Q_J8]N/+]\Y[8K]
M%_VQ/CI\&/@_JGAB#XJ_#W_A-KF^AG>PD_L6RU#[.JL@<9N'4KDLO"YSCGI7
MYT?MB?&[X.?&*W\*1_"CX?\ _"$RV#W)U!O[&L]/^TAQ%Y8_T=VW[=K_ 'L8
MW<=37EY;3C+V<O9-N[][IN^GX&V'2C)-*VCU^7Z_J?I=^P=X/3P_^R%X#L+B
M(,-0LI;V56'#K<2R2#/_  !U%?D!\5O@_?\ @GX^Z_\ #FT@>2\AUHZ=8QM]
MZ59) +<_\"1XS^-?L#XT^(5O^S#\._@=H;82TN-5TSPS<9.-L1M71G/^ZRHQ
M^E<#\2/V9AXB_P""@W@#QVMFK:/_ &5+J=\WEY4W=H5CB)/3=F:V(_ZY'TJZ
M%?V>.G7E\$G+_P E][\M%ZG#0JNGAY=W%27JVU^>K/:/&/PCM;']EC6?AQIZ
MCR+?PI+I-N3W9;8HK'W+ &OR"_87_P"3M/AK_P!A(_\ HJ2OUX^'?QGA^(7Q
MV^*W@>,J]KX4ATZ$<Y#R2I*TWY'8I]UK\K/V8_#?_"&_M]>'M QC^R_$UW9#
M/I'YR#^5&72G[6IS[S2E]]W?\44X\F"JTWO%/\8_\#\3[_\ VNOV]/\ AE;Q
M]I7AK_A!O^$H^W::NH_:O[7^R;,RR1[-OD29_P!7G.1UZ<5^>7[7O[77_#66
MM^%+S_A$_P#A%?[%CFAV?VC]L\[S&0YSY4>W&SWSFOT-_:Z_:$^!7PC\?:5I
M?Q1^&G_"::W<::MS;WO]@V%_Y=N99%$>^XD5A\RN=H&/FSU)K\\OVO?C+\)O
MC!K?A2?X5>!O^$)MK&.9+^/^R+33_M#,R%#BW=@V K<MC&>.M;Y/3@Z]"?LG
M?F^*^G7I^!V1BH[1MHOGHOSW/UC_ &F/@!IG[2'P<O\ PI>[(-0""ZTN^89-
MK=JIV-_NG)5A_=8]\5^1G[+?A?5/!/[9G@/0=:LY+#5M-\1);75M*/FCD4D$
M>X]".".17Z=?MD_M W_[-VG_  S\50*]QI<FN"SU6S3&9[1[=RX&?XE*JZ^Z
M@=":Y[XK_L^Z7\1?CE\'_CWX&:&]A.H6;:J]J,K=VC@"&Z&.K+E5;OM*]-AK
MBR^M+#RO+X).WI+3\_ZV9YLI/ZE*E+K!M?<TU_7ZGD?_  4 ^+'_  HW]K?X
M1>.?[*_MO^Q]*GE^P?:/L_G;FECQYFQMN-^?NGI7TW\(_P!J3_A:G[,^L?%S
M_A&?[+_L^UU"Y_L?[?YWF?959MOG>4N-VWKL.,]Z^(_^"OO_ "5CP-_V!)/_
M $>U>R?LC?\ *,_QA_V#-?\ _1<M9*G%Y:JC6J;_ /2F>A4IQE7PZ:^)P3].
M4^'_ -K[]JK_ (:L\6:%K?\ PB__  B_]EV36?D?VA]L\S,A?=N\J/'7&,'Z
MUX%117UE&C"A!4Z:LO\ /4Z HHHK4 HHHH **** "BBB@ K]NO\ @G)_R9G\
M/?\ N(_^G&YK\1:_;K_@G)_R9G\/?^XC_P"G&YKQ,W_@+U_1G+B/@1]*4445
M\D><%%%% !1110!\1?\ !7+_ )-O\-_]C9;?^D=Y7Y'5^N/_  5R_P"3;_#?
M_8V6W_I'>5^1U?997_NR]6>EA_@"BBBO6.D**** "BBB@ HHHH **** "BBB
M@ K]N_%GQZ_X9M_8Y\%>-O["_P"$B\C2=)MOL/VO[+N\R%%W;_+?&/3;S7XB
M5^W?BSXA>!/AA^QSX*UWXC>&O^$M\,1Z3I,4FF_8(+W=(T*!&\N=E0X/.2<C
MM7CYK_!@O[\?GOI\]CSZR3Q%--7TE^A\0_M&?\%+/^%__![7? O_  KG^P?[
M4\G_ (F']N?:?*\N9)?]7]F3.=F/O#&<^U>P?\$\_CEI/QU^%.L? ;Q^5U"2
MWL7AL%G8YN]/(PT0.?OPDC:1R%VX^X37C_[1G[47[-_Q$^#VN^'_  %\(_\
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M@I;6^F>)8HY)9+.SA%NMW(@W26T\ ^6.XYR''WBPR65E8?EU7Z8?\$=SJ?\
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M_95X]WYW]J_;/-W(4V[?(CV]<YR:_1+]L;XV?!_X/?\ "*_\+6\!?\)O]O\
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MA3M6]K63=-I+3>+[_P!?F:02IU7[3=NZ?Z?UVOU=OD3_ ()<M"_[6):WC>*
MZ/>F..1P[*N4P"P R0.^!GT%<O\ \%)O^3PO&?\ UQL/_2.&NR_X)FZ'?>&/
MVQ+S1]3MVM-2T_3=0M;FW?!,<J.BNIQQP01Q7U/^TG^T_P#LY?#?XPZUX?\
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MM7S77Z#A?X%/T7Y'LT_@7H%%%%=1I8**** L%%%% 6"BBB@+!7ZNZHR_"/\
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M.W'3<7/N:_+RBM*N%<JKK49\LGOU3^7<E491OR2LGK8_3OXF_![]E?\ 9/\
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MP7\2K#XD:5;[=(\3_N;[8/ECOD7K_P!M(QGZQN>]>Y_LC?\ *,_Q?_V#-?\
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MH"XRBGT4!<913Z* N,HI]% 7&44^B@+C**?10%QE%/HH"XRBGT4!<97[=?\
M!.3_ ),S^'O_ '$?_3C<U^)%?MQ_P3E_Y,S^'O\ W$/_ $XW->'G'\"/K^C.
M7$_ O4^DZ***^0/-"BBB@ HHHH ^(O\ @KE_R;?X;_[&RV_]([ROR.K]<O\
M@KA_R;?X;_[&RV_]([ROR0K[/*O]V7JST\/\ RBGT5[!TW&44^B@+C**?10%
MQE%/HH"XRBGT4!<913Z* N,HI]% 7&44^B@+C**?10%QE%/HH"XRBGT4!<91
M3Z* N,HI]% 7&44^B@+C**?10%QE%/HH"XRBGT4!<913Z* N,HI]% 7&44^B
M@+C**?10%QE%/HH"XRBGT4!<913Z* N,K[=_X)&_\G(>)/\ L4[G_P!++.OB
M6OMS_@D?_P G(>)/^Q3N?_2RSKAQW^[3]#*K\#/UOHHHKX(\@**** "BBB@
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M%%%%@N%%%%%@N%%%%%@N%%%%%@N%%%%%@N%%%%%@N%%%%%@N%?MQ_P $Y?\
MDS/X>_\ <0_].-S7XCU^W'_!.7_DS/X>_P#<0_\ 3C<UX6<?P(^OZ,Y<3\"]
M3Z3HHHKY \T**** "BBB@#XC_P""N'_)M_AO_L;+;_TCO*_)"OUO_P""N'_)
MM_AO_L;+;_TCO*_)"OM,J_W9>K/3P_P!1117L6.FX44446"X44446"X44446
M"X44446"X44446"X44446"X44446"X44446"X44446"X44446"X44446"X44
M446"X44446"X44446"X44446"X44446"X44446"X44446"X44446"X44446"
MX44446"X44446"X44446"X5]N?\ !(__ ).0\2?]BG<_^EEG7Q'7VY_P2/\
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M+>S7/"0QYPB@8'')QDDDDUT2J576=*G:UD[OS;7E?;RM\Q1E.;GT2=O71/\
M"_Y:&=\2/A3XO^$'B Z+XR\/WOA_4=NY8[I/EE7^]&XRLB]MRDC/%>S^%?BA
M\8K7]B_Q/X?TW1],G^$T>HBSOM9D\O[7;RR212&%1YH8JS,AW>4V-Y^88X]
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MV_DKV^?Y7,O6O^"B_P 4+5TL_ -OH'PR\/0,PMM)T+2+9T5,\!VEC8%O4JJ
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MQE2P&'537TI^WWHM[XD^(/P2TC3H?M&H7_@G2K6VAW*OF2O+(J+EB ,D@9)
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MQG&1E6 (R""/4$&M/6/B=XO\0>+O^$IU#Q-JUUXD\SS5U1[R3[1&V<C8X.4
M[!< =L5]3?$[6G_:;_8FA^)?B)(Y/'W@35X]#NM8V8DU&SDV;!(1U8-,AR>Z
MN>-YJY5*U&TJEFFTM+Z7=EUUUMT7<:DXR49=>OG:Y\H^"/ /B/XE>((=$\+:
M)>Z]JLW*VMC"9&"Y +-CA5&1EC@#/)KV75OV ?C_ *+I<VH7'PYNY((DWLMI
M?6ES,1[11S,['V"DUZ=XY\4:C^R?^R7\-M'\$S/H_B;XD6KZWK7B&T/EW7D
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M(QT)!=*I6Q'OTK<KVO>[^?2_31F<Y584O:-=+V\K77K_ %KU.?F_9S^(EO\
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M;K ("?E:4%]V0.OEAQZ$U\GT5FL.X<KIRLTE%Z732VTNMKOKU-'%\TI1>_\
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MC6>ZB<,XC*_>BW+PV!U.-P 9OH_X^_LWZC^UUXLF^+WP4OM/\66OB"."34M
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M9$8CN%)([UK*48+FD[(<I*.LG8\NHKTWXL?LT_$WX'V\%QXV\(7NC6<S;$O
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M**+ %%=OX<^"OC7Q=X#U'QGHN@S:EX=L+Z'39[BWEC:07,K(L<2P[O,<L94
MVJ?O?6O3K'_@G_\ '_4-+COXOAU=+!(@D"3:A9Q38(SS$\P<'V*Y]JQE6I0^
M*27S^9'/':Y\]45I^)/#.K^#M;NM'UW3+O1]5M6V3V5]"T4L9QGE6 (R"#[@
M@UH> ?ASXG^*7B*'0O">AWFOZK(-PM[.(L57(!=ST102,LQ &1DUJG%KF3T+
MDU'66ASE%>^>)/V#OCSX3T:?5+_X=WKVD*[W^PW=M>2@>HBAE=S^"UYQXO\
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MQ<RMS7T,NBO=;/\ 8=^-]\FM21^ [B.'1Y)(KR>>_M(8E9!E]CO*%D"]V0L
M01G((K&^%O[)OQ9^-'A^37?!_@RZU71U=HQ>/<06T<C+PPC,TB>9@Y!VYP1C
MK4*O1:<E-65NJZ[??T$YQ6[\OGV/+--TV\UK4;73]/M)[^_NI5@M[6VC:26:
M1B J(J@EF)(  Y)-3:YH.I^&=6N=+UC3KO2=3M6V3V5] T,T38SAT8!E."."
M*]-^"'A?5_!G[4WP[T77M-NM(U:S\5:;'<65Y$8Y8V^TQGE3SR""#W!!%>N?
MM#?LZ_$?XY_M8_%,^!_"=YKD-MJFV:Z#1P6Z-Y49V&:5E3=@@[=V<'.*B=>,
M:D(W7+)2=_1Q_/F$Y*+:EI:WXW_R/D>MJ/P3XBF\+2^)H] U23PW#*()-86S
MD-FDA( 0S;=@;)'!.>172_%GX"^/_@;?6UIXY\,W>@O= F"61DEAEQU"RQLR
M,1QD!LC(R.:]1T?XG?%[_ABG6?#=KHVER_".+5197.L-L%Y#.TL=QY 'FABI
M=E;=Y1^\1N["I55R*=)IJZ6^FKMOW[>96O-'L_R\NY\WT5Z+I?[//Q%USPGX
M;\2Z9X5N]3TCQ'=R6.E26+QSRW,T>_>HA1C(H7RW)9E PI.<5W^I?L _'_2]
M*FU&;X=73V\49D9+>_M)YB ,\1),78_[(4GVJI5J5-VG)+YBYXWM<^>Z*FO+
M.XTZ\GM+N"2UNH':*6"9"CQNIPRLIY!!!!!KV/PK^QG\:/&O@F+Q;HW@&_O-
M"FA-Q#-YT,<LT>,AHX7<2N".1M4[LC&<U4JD(1YYM)=QN2B[,\6HJ:\L[C3[
MR>UNH)+:Z@=HI89D*/&ZG#*RGD$$$$&M_P"'7PY\0_%CQC8>%?"FG_VKKU_Y
MGV:T\^.'?LC:1OGD95&%1CR1T]:TTM?IN-M15V4M=\'Z]X7M=-N=9T34M(M]
M3@%U8S7UI)"EW"0")(BP =""/F7(Y%8]?H7^VE^S'\2]:^$GPCO;+PWYUMX)
M\%)!K[_;[9?L3Q11F08,@,F C?ZO<#CC/%?"W@/X>>)?B?XAAT/PIHE[K^K2
MC<+:RB+E5R 78]%4$C+,0!GDUR8?$0KQDTUHY+?HFTG\TKD1DG!3>WZVU1SM
M%>^>)?V#_CSX3T6?5;_X=WKVD*[G%C=VUY*!ZB*&5W/X+Q7@C*58@C!'!!K:
M%2G5O[.2?H[E)J2NA****UL,****+ %%%%%@"BBBBP!11118 HHHHL 44_RZ
M/+I@,HI_ET>70 ROIC]@GP3X?U[XK:YXI\3VJZAI'@?0KKQ&;)UW+-+#MV C
M'(7);ZJO7FOFKRZ]M_9$^-]E\!_BTFI:Y;->>%=7LY='UJ!06/V67&7"CJ5*
MJ<=2-P')K&LIRI35/XFG;UMI^)C65X:JZTNNZOJOFKG&_%[XY>,OCAXPN?$/
MBG6;F[F>9I;:T65A;V2D\)!'G"   <<G&22237V)^QY^T-XF^(7P*^-/@;Q3
MJ$^NOI/@_4+W3-0O6,MQ%"8766%I&^9ER8RH)XP1T"@>9>+O^">GB[7M0.K_
M  >U'2?B5X&OI"]E?V>J6\4UO&>=EPLC* ZYVG:2?ER54_*/?O@'\!O#WP!^
M$?QMT:^\5:7XA^)UYX/OI=1L=(E\Z'2[589 L3/@?O&9@S X^ZN!@;F\C$U,
M,\)*G%=-(]4_3=6Z^5RN:,JU)Q:?O1U6WQ+[K[)'@OP'_P"3!?VB/^OS2O\
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M;AP01@\8.5)!]4_83\-Z)<>+_'OQ-\1V$&JV_@#0Y]?@TTQA8Y+H;FC;:!M
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MC3%3W7S(^?0N.]?-OB#XH>+_ !5XN/BG5?$VJ7OB+S/-34WNW$\39R/+8'Y
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M^V]\<M8UGXF:Q\-M"N)- ^'?A&4Z+8Z!8$PV[&'Y'>15^^2X;&[(  QR6)\
M\!^++[X>^-M!\3Z;@WVCWT-]"K9VLT;A@I]CC!]C7UY\8/V>K3]L#7KKXI?
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M)\4?B]X/\)S.T=OK&J6]I.ZMAEB9QYA!]=N['OBM_P#:FC_XR4^*'_8R7_\
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MH;C!'_/-17A_[07@7X:Z-XD\)>!_A+<7/C#7+>$6FK:Y;2F2#5KZ1P%6W3)
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M_P"W;WY?_ __ "56.2BG)J+_ .7>GK_+]R_%(\-HI_ET>77L'0,HI_ET>70
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M$YP!Q@DD];\>/&WAWQU_P4(^%TOA^_MM8DT[4=#T[4]5M,>5=WD=T-[J1PV
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M\01:)X5T2\UW5)!N%O9Q[BJY +L>B*"1EF( SR:],\7_ +$_QK\"Z#/K&K^
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M+8&2!WJ3X>?LA?%WXJ>'8]>\,^";J]TB3_574]Q!:K*/[R":1"Z^Z@BO9?\
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MXXF=7B+9**55U*CCYL^N<8UJ\Z3KQ2M9M+K:U][[^5O*_4FK*I1BV[-K\/\
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MM/VK-7N?B;\%=2T_5+S5PMSK/A&ZNX[>_LKIN'(#D*58AB2Q )!*E@<#X_\
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MCQ^T!\,O^QGTS_TKBK]R*^8S?XX>AP8C=!1117@'(%%%% !1110!^.'_  4
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M6)&.-V&( 4M\=>71Y=9QPW+34.9W3;3ZZMO7OO9]]] 4.7EY=TK?+3_(^H_
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M*K",N5R29'/':YX]Y='EUT?C3P/K/P\\47_AWQ!9_P!GZQ8.$N+;S4EV,5#
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MKYMEMYQ!#6\C?P[BSX)_YZ<9*A6\BC%RP24>^OIS:^O^2L9/2-+LK?\ I/\
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M\Z]N^'7Q6T;X;_'[XF:5XK25_!GBFZU'2-6,():%'GD"R@ 9.W+ XYPQ(R0
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MNW+?3\?O.\G\->#O'WQHFTGP[J$?@[PA>731VEYJ\C.L*!>&8DY&YAP&/&X
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M444 %%%% 'S#_P %"%W?!C1?^Q@A_P#2:YK\^?+K]"O^"@*[O@WHW_8?A_\
M2>YK\_\ RZ^BP/\ !.VE\)5\NCRZM>71Y==]S4J^71Y=6O+H\NBX%7RZ/+JU
MY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY=
M'ET7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY='E
MT7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7
M J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J
M^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^71Y=6O+H\NBX%7RZ/+JUY='ET7 J^7
M1Y=6O+H\NBX%7RZ^G?\ @GNNWXSZU_V )O\ TIMJ^;/+KZ:_X)_+M^,FL_\
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MIHHHKYTX@HHHH **** "OA#]O!=WQ>TC_L!0_P#I1<5]WU\+?MU+N^+>D?\
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M>55GRZ/+HN!6\JOHC]AM-OQ9U8_]02;_ -'V]> >77T+^Q"NWXK:M_V!9?\
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C4U% $.PT;#4U% $.PT;#4U% $.PT;#4U% $.PT5-10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pgen-20201231_g10.jpg
<TEXT>
begin 644 pgen-20201231_g10.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (@ KH# 2(  A$! Q$!_\0
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MG[=TV1IM-M)'.YWB1F;U)49KY]_X*&?\F<_$;_KC:?\ I;!7O^C_ /()LO\
MK@G_ *"*WJ2<Z492U=W^2*DVXIO^MBY1117(9A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !15/6-8L?#^EW6I:G=PV&GVL;33W5PX2.)
M,EF8\ "OE5O'WQ*_;!O+FS^'5[-\.?A-'*T$WC/:?[3U<*<,+)"/W2=O,//<
M'JM:PIN>NR74I1N>U?%K]I+X:_ ]47QEXLLM+O),>7I\>ZXO),]"((PSX/\
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M7O\ H_\ R";+_K@G_H(KHE_ CZO\D7]E?/\ 0N4445SD!1110 4444 %%%%
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M*&?\F<_$;_KC:?\ I;!7O^C_ /()LO\ K@G_ *"*\ _X*&?\F<_$;_KC:?\
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M\T\Q_P!QNT_^*JE/\)_BM-_S(&/^XS:?_%UTQQ6&6\J?_@:_^3*52']W[_\
M@GE5YJFKMG=HFS_M[0_TK#O+R^;.[3MG_;=371Z?=:IXB\'2^*X[+3;'PY'=
MRV+ZEJFMVMC")XV*.F9W3D,"/0]LTOA7P;K_ ,2[BY@\*)H'B6>W4//%H_BC
M3KQHE)P"PCF)4$]S7IT\7AH_%."_[?7_ ,D;*I!;M??_ ,$X.YFG8G=;[?\
M@8-9TS,>JX_&O9IOV8?BM-G_ (I''_<3M/\ X[523]E'XK2?\RIC_N(VG_QV
MN^&9X%;UX?\ @2_S-E7I?S+[T?47[&__ "1.S_Z_)_YBO<:\J_9I\$ZU\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ+8_9+ZTWPNT;,H9E*N 2"K'ISBI?V'?^31?A/\ ]@"W_E0![C1110 4444
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MPWD1SRND.02/D5>..E=WX8^%'A7P;8>(K+1]+^QVWB&\N+_4X_M$K_:)Y_\
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MG[*&A:EX=^$%K9:MIUUI=XMU,QM[R!H9 "1@[6 .*]CK\*S>2EF%=Q=US/\
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M YYJ*']E'QCX-^$?P7\-VL=OX@UO1_',?B;Q%<VDJ0PQ^89Y)W3S"A=5:4*
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M7_HA*ZVOR27Q,^=>X4445(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#':J2?LH_%:3_F5,?]Q&T_^.UZ,,SP*WKP_P# E_F;*O2_F7WH^HOV-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\%^IYGXL^ZU>.^(O]8?K7L7BS[K5X[XB_P!8?K4YA\0JVY_05\(_^24>"_\
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M .24>"_^P)9?^B$KK:_))?$SYU[A1114B"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W_ &A'\#3?"W4=+^(ES):^
M'=8E@TL/;QRR7'VF:54M_($2L_FB4HR,JG:RAN@->D5X=^UYX+\3^*OASHFJ
M>#]/.M:YX3\16'B6/1EE$;:C';LWF0*QXW%'8KG^)1UZ4 >O>&='?P_X=TW3
M)-2O=8>SMXX#J&I%#<W&U0/,E**JESC)PH&>PKSGX#Z=X(74OB1K7@S5[[5)
M=7\47,NMQWT;1FSU")(X)841HD95 B4_-NSG(8@BO+9/^"EWP4L56QU.X\3:
M3XN(VGPC=^&;X:F)O^>.P1;"^?E^_C/>NP_9%\/^(H]#\<>,O$NB7OA>Z\;^
M)+C7;;0=2(^TV-L4CBA651]R1EB#E>JE\'D&@#/_ ."AG_)G/Q&_ZXVG_I;!
M7O\ H_\ R";+_K@G_H(KP#_@H9_R9S\1O^N-I_Z6P5[_ */_ ,@FR_ZX)_Z"
M*Z)?P(^K_)%_97S_ $+E%%%<Y 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?.'[8LU] ? DFF0QW&H+?3F&*0X5F\M>#R.V>XKZ/KYP_;%FOH#X$DTR
M&.XU!;Z<PQ2'"LWEKP>1VSW%>_D/_(QI_P#;V^WPL[,'_&C\_P CPB;6OB*1
M\V@Z>/\ MHO_ ,>K,O-5\<MGS=&L5^CC_P".UIS:U\12/FT'3Q_VT7_X]69>
M:KXY;/FZ-8K]''_QVOU*"U^&G]__  3WEZ(Y^_OO$K9\[3[9/]UA_P#%USMY
M-?L3YL$:_0__ %ZZ*_OO$K9\[3[9/]UA_P#%USMY-?L3YL$:_0__ %Z]BCZ1
M^7_#G1'Y%CP66/C70MPQ_IT/_H8K]4Z_*SP66/C70MPQ_IT/_H8K]4Z_/N,_
MCH>DOT/(S/>'S"BBBOS<\0**** /B;_@IE_QZ_![_L9)/_1!KY/U3_5M7UA_
MP4R_X]?@]_V,DG_H@U\GZI_JVK]?X5_Y%TO\3/I,O_@OU/,_%GW6KQWQ%_K#
M]:]B\6?=:O'?$7^L/UJ<P^(5;<_H*^$?_)*/!?\ V!++_P!$)76UR7PC_P"2
M4>"_^P)9?^B$KK:_))?$SYU[A1114B"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *XSXL6OC^[\+HGPVO\ P_IWB'[0
MA:;Q+;33VWDX;< L3JV_.W!SC /%=G7&?%BZ\?VGA='^&UAX?U'Q#]H0-#XE
MN9H+;R<-N(:)&;?G;@8Q@GF@#QTZ+^UT@++XH^$$C#D(^C:D%8^A(GR!]*[[
M]G7XP:K\6/#.M0^)M'MM!\9>&M5FT/7+&QN#/;"YC"L)(7(!,<B.C@$9 ;!)
MQD^?3:Q^U]+"Z0>&?@[;S,,)+-JVINB'U91""1[ BO0?V=/@]JGPD\+ZQ)XE
MUF#Q!XS\2:I+K>NZA:0>3;O=2!5V0IU$:(B(N>2%R<9Q0!Q?_!0S_DSGXC?]
M<;3_ -+8*]_T?_D$V7_7!/\ T$5X!_P4,_Y,Y^(W_7&T_P#2V"O?]'_Y!-E_
MUP3_ -!%=$OX$?5_DB_LKY_H7****YR HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^</VQ9KZ ^!)-,ACN-06^G,,4APK-Y:\'D=L]Q7T?7SI^UY<7%
MK<> 9;2U^VW*7\YCM_,$?F'RUXW'@5[V1?\ (PI_]O?^DL[,)_&C\_R/!)M:
M^(I'S:#IX_[:+_\ 'JS+S5?'+9\W1K%?HX_^.UU$WB+Q00<^$-O_ '$XO\*R
M;[7/$+9W^&-G_<0C/]*_3X-W^"'WK_Y(]U7[+^OF<;?WWB5L^=I]LG^ZP_\
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M;0_A[XXN? 7B..]BO$U"VN9[;[1&@8-;M+ PDC5BP)90WW1\I[>Q5X_^U/\
MM(:5^RU\+&\8ZII5QK32WD6G6=C!,D EN) Y022N=L:81LN0<>AH ^/&\(O\
M,O\ 1_C?XT_:(^'2(=K>)]-\=76L>'I,L$5C=0Q>9!N)X6>),=V/6OL_]G3P
MIX=\,^!Y9?"WQ(U[XHZ/J%R;F+6M=\1?VVP.U4,<4XX"#;G:.C%O6OBRX_:X
ML_CE&P\??M)^&?A+X8N ROX9^'L<TVI/$V"%FU.:+Y'7D$P1A2.]?5?[&ND_
M!'1/AK?V?P*OH-2\/1WY_M"\CN)IY)KSRTW-(\O)<IL/ "], 4 4/^"AG_)G
M/Q&_ZXVG_I;!7O\ H_\ R";+_K@G_H(KP#_@H9_R9S\1O^N-I_Z6P5[_ */_
M ,@FR_ZX)_Z"*Z)?P(^K_)%_97S_ $+E%%%<Y 4444 %%%% !1110 4444 %
M%9EYXGT?3]<L=&NM6L;;6+]'DM-/FN42XN%3&]HXR=SA<C) .,C-:= !169K
MGBC1O#/V+^V-6L=*^W7"VEK]NN4A^T3MG;%'N(W.<'"C).#6G0 4444 %?.G
M[7EQ<6MQX!EM+7[;<I?SF.W\P1^8?+7C<>!7T77SI^UY<7%K<> 9;2U^VW*7
M\YCM_,$?F'RUXW'@5[V1_P#(PI_]O?\ I+.S"?QH_/\ (\9F\1>*"#GPAM_[
MB<7^%9-]KGB%L[_#&S_N(1G^E:TWB+Q00<^$-O\ W$XO\*R;[7/$+9W^&-G_
M '$(S_2OTJG'7X(_^!?_ &Q[:7DOO_X)S.I:EJK[O,T;R_\ MZ0_TKEK^XN6
M)WVOE_\ ;0&NIU+4M5?=YFC>7_V](?Z5RU_<7+$[[7R_^V@->[AUY+[_ /@G
M5#T'^"R3XUT+*X_TZ'O_ +8K]4Z_*SP62?&NA97'^G0]_P#;%?JG7P7&?QT/
M27Z'DYGO#YA1117YN>(%%%% 'Q-_P4R_X]?@]_V,DG_H@U\GZI_JVKZP_P""
MF7_'K\'O^QDD_P#1!KY/U3_5M7Z_PK_R+I?XF?29?_!?J>9^+/NM7COB+_6'
MZU[%XL^ZU>.^(O\ 6'ZU.8?$*MN?T%?"/_DE'@O_ + EE_Z(2NMKDOA'_P D
MH\%_]@2R_P#1"5UM?DDOB9\Z]PHHHJ1!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %,FACN(S'*BR(>JN 0?PI]% %/
M^QM/_P"?&V_[\K_A4]O:PVJE8(HX5)R5C4*,_A4M% 'SI_P4,_Y,Y^(W_7&T
M_P#2V"O?]'_Y!-E_UP3_ -!%> ?\%#/^3.?B-_UQM/\ TM@KW_1_^039?]<$
M_P#0171+^!'U?Y(O[*^?Z'R]_P %!+?5&\(^"+J\LM;U/X76FM^=XXL?#[R+
M<2:?Y;!2XB(=H%<[I IZ 'L*[#]DWPM\%;'0]2\0? W5TG\+:H(Q/I5AJ4LU
MG;3KN)<6\K%K>9E90RD+D*AVYY/:_&'XMZK\)?[)O(/A[XE\;Z+<&1+ZX\*P
M+=W5BPV^63:[A)*C9?+)DKLY!S7B'[.7@_4?$?[3_CKXKZ1X!U;X8^"=6T>W
MTU]/URQ&GW>L7R2LS7C6@.8PJG:&< ON)ZYKG(/F#]D[3?V/]:\"Z1I_Q'B\
M.7'Q,N]9N[>6*_-R+AY7O'6%3M^7D% .V,5]B_ME3KXC\+^"_@Y8-)%<?$+5
MX=+F^SL5:+3(,3WC!NW[M%0'_II7DO[)?QTO/@7\%;#P=XE^$7Q:?5[*_OWD
M:P\$7L\++)=2.A5PHR"K UU_BKX-Z_\ M(?M2:SKUYK'CCX<>'O!ND6^F:)J
MFC(MA-?7%QF6[9&N('#(H\J,L@P2I&>* .H_87U&Y\/_  [UWX5:K=FZUKX;
MZO/H!=QM:6S!WVDH7^Z860 ^JFN?_P""E'A.T\>?!OP7X:OBRV>L>.-)L)F4
MD%5D\U"1CTSG\*J_#_X*^(OV=?VN[+4++5O&7Q \,^/-&>UUC6]<"WDMG>VI
M!MS-+#"B1QM$S*I<<D8R>E=O^VIX7UGQ5X3^&\.BZ1?:Q+:>/M&O+B.PMGG:
M&!'<O*X0':BY&6/ SR: *G[)_P 7FM?V>M6M_&M\J:Y\-);O0_$,TC$D&S!Q
M*S-U+Q!'S[UX#^R/I.M77[947COQ*THU[Q[X+N/$4MO(Y86T$E]MMH5] L*Q
MC'%='^TQ\$/'^I?M$RZ#X0TV\F\ ?%I+&/Q;?0PR-!IPLGS,69?E0SPK''N8
MC=R,-7L*^"]2T_\ ;DT;5+31;R/PQ:_#XZ<FH):O]DCE%X2L/F ; ^W!VYSC
MG% %'4OVLO&GB;5O$W_"J/@W=_$;P[X<NY-/O=:F\06^F"XN8CB:.TB=':?;
MS\Q* D$#)K3US]M#PW'\$O"GCWPYHFI>)-1\5WJ:5HWAF-D@NY;XEE>"1B2L
M8C*-O?Y@N,\UY9\%/''B[]D;0/$7PUUWX3>/?&%U#K-]J&BZUX7TO[?9:I#<
MSM(GF3A@MNX+D,),8 S[5S<7P!^(OPC^#OP<\7-X8NO$/B?PEXMO?%&M^&='
ME6>X2"^\WSHX5W;9I(@ZX52<G.,Y)H Z-OB%XO\ &7[;7P>M/&OPZO/ &L66
MCZN^W^T8M1LKE'$6##<QA=S#;\RLBD9'4$&OH;X2_'3_ (6EI?CZ\_L3^S/^
M$5UN^T;9]K\W[5]G_P"6F=B[-W]WYL>IKQ&U\5>*?C-^UI\*_%L/PQ\7^%O!
MVEZ=JMM_:?B+3VM96E=8O]9!RT"\84R%2Y#87 R<GP3XC\;? /Q)\8_!4_PH
M\8>*[WQ)X@O=9\/ZGH=B'TRYBNER%GNV8);LK9W!N0,8#'B@!/BY\6O^%Y?"
M/]G;QO\ V5_8G]K>/=/D^P_:/M'E8\]<>9L3=T_NBO9?%'[17B.]^(GB#P9\
M,OAZ?'NH^&TC.M7E[K*:59V\LB;TMXY#'*9)BO)7:JKD985\]>'OAKXQA_9=
M_9JTJ?PGK4.KZ3XPLKK4M/-A*9K&-6GW/*NW*(-P^9@!R/6F^,OA59?"W]H+
MXF:OXT^&_P 3?&?ASQ9>QZOI6L_#S4-3812>4%EM[BVLKF,J0R_*[*<@XR !
M0![-<?ML6&H?#CP?K/ASPC?:IXL\4:S)X=M/#-]=QV7V?4(2?M$<]PP945-K
M'<JMNXV@YKVGX;^(/%OB#1[B7QEX2@\'ZI%.T2VMKJR:E#-&.DB2B.,X/HR*
M1CI7S)J'@WP)H/P#TG3KG]G/QQ>^!]8U6?4;W1C--J&NZ;/D&*\>/[0]P'<Y
MSY<A>/N.37??L6VGCJU\(>)SXH'BJ+PW)JS-X5M?'3!M:@L-H^6Y.2_W]VT2
M,6"XS0!]%5\Z?M>7%Q:W'@&6TM?MMRE_.8[?S!'YA\M>-QX%?1=?.G[7EQ<6
MMQX!EM+7[;<I?SF.W\P1^8?+7C<>!7O9'_R,*?\ V]_Z2SLPG\:/S_(\9F\1
M>*"#GPAM_P"XG%_A63?:YXA;._PQL_[B$9_I6M-XB\4$'/A#;_W$XO\ "LF^
MUSQ"V=_AC9_W$(S_ $K]*IQU^"/_ (%_]L>VEY+[_P#@G,ZEJ6JON\S1O+_[
M>D/]*Y:_N+EB=]KY?_;0&NIU+4M5?=YFC>7_ -O2'^E<M?W%RQ.^U\O_ +:
MU[N'7DOO_P""=4/0?X+)/C70LKC_ $Z'O_MBOU3K\K/!9)\:Z%E<?Z=#W_VQ
M7ZIU\%QG\=#TE^AY.9[P^84445^;GB!1110!\3?\%,O^/7X/?]C))_Z(-?)^
MJ?ZMJ_1+]J[]F.Z_:6TGPO;67B[_ (0^[T&_:_BNO[-%]O8H4QL,B 8SG)S]
M*^?I?^"9?C"88?X[Y'_8GP__ "37Z#D>=83+\&Z-9OF;;T1[.$Q5.C3Y9;GQ
M%XL^ZU>.^(O]8?K7Z5W?_!*;7K[/G_&[?_W*<8_E=5CW'_!'>XNSF7XQ[_\
MN5P/Y7=/%9Q@Z[O&3^YA4Q-.3T9][_"/_DE'@O\ [ EE_P"B$KK:R?".@_\
M"*^$]%T7S_M7]FV4-GY^S9YGEQJF[;DXSMSC)QGK6M7Y_+5MGCA1114B"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_K/B'5-!L-<TZ]US2PC7^FV]U&]S:AQE#+&#N0-VR!FMJ@ KYT_:\N+BUN/
M,MI:_;;E+^<QV_F"/S#Y:\;CP*^BZ^</VQ=0FTL^!+NWM)+^>&^G9+:/.Z0^
M6HP, _R[5[V1*^84U:_Q?^DL[,)_&C\_R/'9O$7B@@Y\(;?^XG%_A63?:YXA
M;._PQL_[B$9_I2S?$G7&'/@K4%_&3_XU69>>/-8ESN\)WT?U+_\ QNOT^%"=
M_P"%'_P+_P"V/=47_*OO_P""9>I:EJK[O,T;R_\ MZ0_TKEK^XN6)WVOE_\
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M';:ZE<:G EM<$=1'(6VMT[$U#X=^,7@+QAJB:;H/C?PYK>HN"R6>G:M;W$S
M<DA$<D@?2N?VD+VNC+ZIB.5S]G*RW=G96W^XZ^BN#O/C[\,=/NIK6Z^(_A*V
MN87,<L,VN6J.C X*LIDR"#V-:=]\5O!.EZ#9:Y>^,- M-$O3MM=2GU.!+:<C
MJ$D+;6/!Z&CVD/YD-X+%1M>E+7;1Z^AU-%<?X=^,7@'Q?JB:;H7CCPWK>HR
MLEGIVK6]Q,P')(1')./I5.\^/GPQTV[FM;OXC>$K6ZA<QRPS:Y:HZ,#@JRF3
M((/8T>TA:_,A_4<4Y<GLI7[<KO\ D=Y7#?';/_"C_B'CK_PCNH_^DTE:%]\5
MO!.EZ!9Z[>>,- M-$O&VVVI3ZG EM.1V20MM8\'H>U<;XX^)'@[XJ?#_ ,7^
M%?"'C'PWXC\1:IHE]:V>FZ=K-M+--(\#JH $GJ1R>!W(H]I"]KHGZIB>5S]G
M*RW=G96W^X^ &\3?"/XJ_LE?#3P)\-]+LM>^.T<.EBQD\/Z0POM*NHWC,MS/
M<+&/+C4!MQ9N>.#@D?>6D_%KQ!%^TQ#\+[J&QETJ+PA#K4EYL?[4UR9VB8;M
M^W9A<XVYR>O:L+]GGXG>"/A=\#? OA'Q3X[\):-XDT32+>PU'3YO$%D7MYXT
M"O&Q64C(((X)K@OCAXBU3X<_'3PS\=O!I\-^./"VIZ"_ANZM9/%%CI8W"9I8
MYX;BX<12 $E2@;=W[4>TA_,AO!8J-KTI:[:/7T-[QA\6_'WCZU_:*\)Z$GAN
MRG\(HEM8SZC;7#K+;R67FS"79*"7^8A2H '&0:SOV$[CXHZ5^RKX9O=3M_#6
MO:3'X=@?PWI6CI-:WLC!6PEU/-(T?/RC<B@#DX/2N>_9KN;OQEXR^.G_  D7
MB#P3;Z[X\,;:=9^'?$=MJ2A/L?E$ (_F,8^C,44,02HP17*^!?&VNVO[*_B/
MX':MXA\)?#'Q1H.A_P!BZ7XE;QOI\HO9E=E)$4<OFVX** 2^&'F'CBCVD+7Y
MD/ZCBN;D]E*_;E=_R/59/CY\8/AK\4O ^D_$BR^'UWH'BW43I*VOA6YNCJ&D
MW#1L\?FM*=LZ84J2J)R<].O >#[;XTM^W]\2QI^H^ T<:/I1OFN;"]8-IWFR
M>6L0$PQ<8W;F8E,X(4=*\\M_ EI#-\#_ !'IWP@\ _"K0- UJVFU3Q>_B71V
MGU+;$ZN8;B)\SQ[OF8O)YA)'[O@FO8CXVNM)_;*U'Q7\/#X8^*6F>,-'L=*N
M(-)\7:?!<Z8;>5B\K1/(6E78Y;$8)^7%'M(7M=$_4\3RN?LY66[L]+;_ '%_
MQM\9O%'A/Q=^T;>^"?!_A%_$7@ZUTV]6ZDTUQ=:K!Y DF2YE216D94W>6> N
M.0:[+XA?M.WRZ'\%1X#ATW4=9^)&H6ZP"_CDDABLA%YMU+A'4AE7A23C)Y!K
ME? _B3P=X:_:2^.>I^*/&'A&QT+Q$MA;6WVKQ%8[IO+MO*G1HO.WH0<J0ZK[
M5YM^RK\-[GX6>/O^$G^(OB3PY;?#KPI:W6A^ -;FUVS>VO8)[EY7D0B4A65-
ML>#AL \4>TA_,AO!8J-KTI:[:/7T/2I/VEOB5\13XTUOX<IX#TWPOX:O;FPM
MX/%4T[WNMR6Y(F,9BD1;92054LLA)Y( K*^*WQDA^+/PI^#_ ,0M*TJ?_B9/
M+<C2]^Z1)-@5X\J#D@@\@=J\?\'^#/#'@?QKXH\,Z%\&_A+^T3;ZMJUUJFBZ
MK;Z]HG]HQQS-O-O<I<AI&"$G#1A@%XVUZ-\</B3X/\&^#?AS86LW@K2-5T2:
M8WWA?POJ5O\ 9M/D*@-$H0+M )(R47)!XKW<CK4HX^G*4E;WMW9?"^IV83!8
MKZPH>RE?M9]F<W-\2=<8<^"M07\9/_C59EYX\UB7.[PG?1_4O_\ &Z@O/C]%
M#I,.IS:0D&F3MMBO9+T"&0^BN4P3]#65;_'>R\07:VMA:6]Y=2?=AMKY9'/T
M4+DU^H1E14E'DC=_WU_\D>XL'7Y7/V+LMWKI;?[B._\ $]_/G?H=S%_O;O\
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MPY_9-^%/PE\3Q>(?"GA7^RM8B1HTN?[1NYL*PPPVR2LO(]J]=KSSXB?&*T\
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M_%[09-9\+^%_[1TU;F:S:?\ M"&+$L3%9%VR%3PP(SC![$U:NOV9_BM<D_\
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M^&8_@[_T2?P/_P"$Y9__ !NB^&[2^]?Y![GF>:?\/(/V=/\ HH?_ )1-1_\
MD>C_ (>0?LZ?]%#_ /*)J/\ \CUZ7_PS'\'?^B3^!_\ PG+/_P"-T?\ #,?P
M=_Z)/X'_ /"<L_\ XW1?#=I?>O\ (/<\SS3_ (>0?LZ?]%#_ /*)J/\ \CT?
M\/(/V=/^BA_^434?_D>O2_\ AF/X._\ 1)_ _P#X3EG_ /&Z/^&8_@[_ -$G
M\#_^$Y9__&Z+X;M+[U_D'N>9YI_P\@_9T_Z*'_Y1-1_^1Z/^'D'[.G_10_\
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MZ?\ 10__ "B:C_\ (]'_  \@_9T_Z*'_ .434?\ Y'KTO_AF/X._]$G\#_\
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MY/-!8]+HKS2/_A<7[GS/^$'_ .0&?,V_;/\ D+]MO_3K]?WE$7_"XOW/F?\
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MIG[0<_QM@U:6&!M0N/">L>&+!+.[1;AXOLXF@2.56; P0>6..,Y'W_=?:?\
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M1;VCK)=2NR0H)9!L5RZ@AR#CBO;* /FC_@I!_P F7_$/_N'?^G&UKTS]F/\
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MINM6UQ/+MO[=VVQHY9L*K,<#@ GM7T)^S'_R;9\)_P#L4M)_](XJ\T_X=O\
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M#I(-"+KGJ#_J2#7W5\%/'ES\2/AUINN7?A+4O \TI>+^P]5A,,]NJ,4&5(&
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M8/7@]/6N?M/ ,=Q\4KKPH;MO]'LUU%IMG!B9]H4<_>S^'\J[K]F[_DB7A?\
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MVB_ VM#VBE?4]@E^)&D1^%UUL-(T+-L$.!YF_P#NXS^O3%<)^SYK%EHOA_\
MX1N64_:EGFN5E8!4<.Y? YZ@?RIL_P +]67P!'$$W7ZW!N#:@C.TJ!CW/&:I
M?#?X?ZM)K7VF\M9]/MXT=2TT91F+*5P <'OU]J\^-/"QPU6$9Z7O]U[?F_4Q
MY::IR28FK>,]-?XT6'B1#,]E9V$FFL @RY9]V\<]/UK?^.VO:?JW@&\T&*<M
M<:M ACD0!E1=ZL&//?'2N$N_AKX@@U@V2Z;/*-V!.B$QD>N[H/Q-='\0/AQJ
ML,6G36<,FH+';1P2+"NYE91CA1V^E=7+AHUJ$E/6.VO;5?B:6AS0:>QW7A+Q
M[I5QX/6Z>1H5T^%(YD8#=D  8 ZY(XKSWX8^,]/\/^*O%$ESY@@U[4S>1R;1
M^Y!& K#/ZBKOAOX9ZK-X.U59HVMKJYV-#;R?*3M)//IG/>N6TCX<:_J&JI;/
MIMS:J&P\TT91%'<ACP?PK.E2PB5>'/H]]>FC_,F,:?O*^YT?QR\46/B*WL]%
MM79I+'48+R2<#*'RR24'//7KTKYY_P""D_B*T\4?#?P#?V1;RFU"Y4JXPRL(
MTR#7MGBOX;ZUI>K2);V-SJ%LQS'-"ADR/]K&<'ZUYI^U1^S;XV\??"'08= L
M([[4;"_FO+BR:XCB=8FB5<AG8*2-F2,YYKT<!+"X>KAI>T5HM]?YEK?\/0WH
M^SA*#OM^I^;B?>7ZU^N_Q&UBTU3X>>$="1V%W;)I]](P7*@(BG9UZG/X5^:6
MG?LY_$'4/%%AH,>A*NI7DHBBC>]@QGW8/@ 5^EGB[X;:WI[V30V<M\OV6&-S
M;*9-KK&JL,#ME>M?0YU4HNOAVYJZYFOPM^OW';BI1YX:[7/5U^)&D-X9.MEY
M%A!V>3@&3?\ W<9KSKX%>*+'PUITGA^Z9A)<7LUS'<8PG[QMP4^GUJPOPPU9
MOA^8MA%_]H^T"U) .W;MQ]>^/PKG?"OPUUK5M6CCN;*YT^W4YDFFC,>![9QD
M_2OBJ=+"*A5I\^C??M>WYOU/*C&GR2C<T_B5XRT_7/&GA:YM_,:#0+]KF1MH
M_?97;A>?U-=]XS\=:6O@F6=)&E&I6\D,"J/FRRE26';&>:\FUCX<Z_8ZM);)
MIEQ<J7PDT*%T8=B6' _&NH\2?#+58?!^EB%&NKJU#F6WCY(W$'@#KC':KJ4\
M+:A'GT6VO35_F.4:?N*^QK? _P 1:?IO@2QT*6;9/I-L1)(X"JZ@DEASVSTK
MG=#\9Z;#\9-6\1.9ELM0LXK%0R %"ASO//0_F*G^'_PYU6>+4I;R&73UEMI(
M(Q,I5F9ACH>0*YRU^&_B";6!9MIL\8WX,[)^[ ]=W0UHHX:5:O)S^+?7N[O\
M45:'--WW.M_: UFRUC2+?0(I6-TEU!>/(J[D54;=MZ]37=1?$C2)/#+:V6D6
M%3L,. 9-_P#=QFO-?B1\/M6CUHW5G:SZA;RJHW0H7*D* 00.G3]:N0_##5F\
M 21;"M^UP+A;4D E0I&/KSG!KE=/"RPU*$IZ7_.U_P EZ&?+3=.*;*_P-\4V
M/ANUNM$NF8/>:A/=QW&,(/,8$(>>/KTJ+XG>,;#7O%WA>6W\PPZ#J0NY7VC]
M]@8*KS^IK*\+_#76M6U:..XL;G3[=6S)/-&4P/;.,GZ5!K7PYU^QU:2W33;B
MY0O\DT*%T89X)8=/QKT.7#/%RK<_O-/KWNG^!M:'M'*^IZYXL\>:5'X+>[21
MI5U"%XH44?-DJ0<CMC/-<]\"M?L-+\"V/A^6?;<:5 Q>1P%5UW%BPY[9Z5F^
M(?ACJL/@S3%A1KF[MC(\MO'R1N(/&.I&.WK4'P^^'.JSC4);R"73DDMI($$R
ME69F&.AYQ7G*GA5A)P4].:_W72_!F/+3]FU?J0:3XTTV+XS:EXD8S+97EA'I
MZJR %2K@[SST/IUK3_:$U:RUGPZGA^*8_:VN(+HNJ[D548-C.>I%<C!\-_$$
MFL?8SILZ?/@SLG[H#UW=#6_\2/A[JT6K+=65M-J-O)&BEH5+LK*H7!4<XXSG
MWKMMAXXJE44]8I6U_EM;^NIK[BJ1E?;]-CO]/^*VC7N@W&IOYD!MR ]NP!<D
M]-OJ/?\ .N!^%OBJPLO'_BN\N6:%?$-U#+"& Q$40KM8Y[YZU5TWX3ZS<>&[
MJZ>%X;LX,5HYVLX[Y'8^@-9_AGX;:WJNK113V-S86ZL#)/-&4P/;.,GZ5C"C
M@Z=.M&,]'H]?1_FOT(4::4DF:WQ4\86&O>)_#!MO,,6@ZJE[+)M&)=N057G]
M37H7B;X@:3#X/-\CO,E]&T4,:CY]Q!!R.V.]>1:Y\.=?L-7EMX]-N;J-G_=S
M0H71AG@EAT_&NHU[X8ZK#X)TU8D:XO+9I));>/D@/C@8ZD;1T]:52EA7&A#G
MT7GZO\PE&G:*N7_@)KEAI/@6Q\.2SXN=+AD9Y' 59%WLQ8<]MW2L+3_&FFQ_
M&F]\3,9A8W.FII@4H-RE9 WF'GI[=?Y5-\/?ASJL\E]->P3:=$]M+ GG*59F
M92O0\X&<USL?PW\0OK'V/^S9U^?'GE#Y6/7?T-;<N'E7KR<]9+77N[O\?N*M
M!SF[[G7?M#:M9:YX8;PW#,?M4TD-R95 9$57#@'GDD#MZUW5K\2-(N?#,FM%
MI(X8VV/"0#('[+C/?UKS;XD?#S58=4CN;*VGU&!XHT)A0NRE4"\@9/\ #G\:
MM67PQU9_ -S&T;)?R3K<):LP4E54C!YZG<>#Z"N1T\++"TH.>E[_ 'VO^2,^
M6FZ<4W_3W*WP4\5V'AN35=+NV93JFKW%_%/@!$\TKA&YXQCKTY[4WQQXOL)/
MBWX;UR#S)X-"CNH)4  \TRIMRIST'OUK'\-?#;7-5U:**>PN;&!6!DGFC*!1
MGG&<9/TIFO?#G7K#6)H(]-N;N-G/ES0H75ESP21T_&O0Y<,\5*HY^]).^O=6
M?X&UH>T<KZL]6\2?$_1[7PY'<Q&2Y:^C98XE #+Q@[O3!_SWK _9YU.STWP/
MIWA8S%K_ $])"69=JRJTC/E>>VX9%<WKGPIUG3]"L9XH'O)\,9[>([FBR>
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M^@BN*7\"/J_R1E]E?/\ 0N4445SD!1110 4444 %%%% !1110 4444 %%%%
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MK7Q0_9!M/$5]XQ^'OA/0M6U&&+3OAWI>D9U"%DO!B'SS=#9.N-S[;<!?;.:
M/OCXG?M%?#[X/ZM8Z3XHUV2WU>]B>XATW3]/NM1NC$GWI6AMHI'6,?WV 7WI
MOB3]I'X:>#M'\.:MKGBVSTK2_$4,D^F7MVDD<,R)'YC$N5PF%[/M)/ R>*\&
M^--UI'@_XH77C[P?\6O#'@OXG:3X8ACU;0/&!4V.JV/,D(<LZ21_,#^\B+<X
M##FN?\5>-(_V@/%7[('BO7O#T5@VL:A>7TFE7&94BD6V;:PW*-PRH=21T(/O
M0![7I_[='P+U30-3U>#X@VBV^G3+;W%M/9W4-YYC#*K':O$)Y<CIL1LU+XV^
M.WA3X@?LYZ]XX\$?%*'POI$<94>+K;26U!M.=74,'LW7>6&0"C*"-V<5Q-GX
M<TJ;_@I%J.I2Z=:RZA'X#BDCNI(5:2-OM.S<K$94[25R.QQ7AGQ 18/A#^VK
M!&HCA3Q+&RQJ,*"8X"2![GK0!]E^.OV@O ?P0\,^'I_'7C".*XU*&-+9DLY9
M;K4&V#=(EK CR8/4[4PN<<5TOPR^*GA3XR>%8O$G@W68=<T:25X?M$2/&4D7
M[R.CJK(PR,JP!&>E?+FF^)M+\"?MP:)J7CG4;/2-)U#X=VUIX:O=5D2*$7"R
M*US''(V KE=N1G)%?5G@?QIX5\=Z=>:EX1U?3-<L%NY()[S29DFB:X4+O!=,
MAF *@\GT[4 ?*O[4UO\ &_X3VVFZ]H7QZU"*RUKQ+9Z5%I;^%]*9+.&YFV?+
M(T)9R@/&[DXY->V:+>WW[.W@W6]>^+_QB/B?2UDC,>I:OI=GIHM>H\M%MD7S
M6<D8&"Q(  YKB/V]/^2>>!?^QXT7_P!*16Y^US\7+KX4:+X(_L_2M#GU+7/$
M5MI=KK7B:(OIVB2/DB[FP5(QC"X=,E@-U '7_"C]I#X<_'235K7P3XF74;_3
M5#7=G/9SV=U K?=<P7$:.5_V@NW/&:^=?B3\2=>3]GWPSJ^D_%C4/&=Q<?$6
MTL'UZRL&T1_(^WB-[)HTVED3!0L>''/2JGPNUC4+[]O^^M]5\?\ AWQ[JUMX
M)FAN[CPWI@L4MO\ 2$989E%S/N<9R,L" >G.:\UL?^3-?"7_ &5M?_3PU 'Z
M64444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X5\?OV
M</$'QF\1:=J>C_%GQ7\/XK6U^SO9:#<O'%,=[-YC!77YOFQGT KW6D(W @]*
MN$Y4WS1&FT[H_-6_^!/@[X4^%=8\3_\ #6/C#1=%?5Y+2]N].><BYU#_ ):<
M1,3*_'S, >G)K[>_9NTNUTGX.Z"ECXYO_B/9S*]Q#XCU*9I9KE7<L,EB3\N=
MN#R,8KY7\._LOS_#[XB6%CXX\<^"]1\ >%)=1U'PSX;U"Z6*>>YNF9E-VKC&
MU2QY!;H,"OH[]D'X=S?"WX#Z%H%QJVFZU/')<3O<Z1/YUJ#),[[(VP,JN[;^
M%>AB9*4/BO\ =_D;3=UN<W_P4,_Y,Y^(W_7&T_\ 2V"O?]'_ .039?\ 7!/_
M $$5X!_P4,_Y,Y^(W_7&T_\ 2V"O?]'_ .039?\ 7!/_ $$5R2_@1]7^2,_L
MKY_H7****YR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.N?\
M@34/^O>3_P!!-7JHZY_R!-0_Z]Y/_035P^)#6Y\:>%_^3@_"O_7Z?Y-7VNZK
M(K*RAE88*L,@CTKXH\+_ /)P?A7_ *_3_)J^V:^LXC^.A_@_5GH8S>/I^IQ/
MAWX'_#GPAX@?7=!\ >%]$UN0L7U+3M&MK>Y8L<L3(B!CGOS7#ZO\"]5\5?M7
M:/\ $W67TL^'O#>AR6&BV\+.UV;J9\S23 IM"A0 NUSU.0*]NHKY \XY[QI\
M._"OQ'T^&Q\6^&='\464,GFQVVM6$5Y&C]-RK(K 'W%-\5?#?PEXZT.#1?$G
MA;1?$&C6Y4PZ?JNGPW-O'M&%VQNI48' P.*Z.B@#AO%?PSL9/A#X@\%>$]-T
MOP_;7FEW%C9VMK MM:0M)&RCY(UPJY/.U?PKFO@S^SSX>\!^#? QU[PSX;U'
MQUX=TJ#3SXAAL(Y;A6C3:?*N'C$H7KCIUZ5Z]10!F/X7T:3Q%'K[Z38MKL=N
M;5-4:V0W20D[C&)<;@A/.W.,US$GP'^&<VJ:EJ4GP[\)OJ.I@B^O&T2V,UWD
M@GS7V9?D _,3T%=U10!ROBSX4^"?'TUA+XG\':!XCEL/^/235M+@NFM_^N9D
M4[.G;%:E[X3T/4K[2KV[T;3[J\TEBVGW$UK&\EF2NTF%B,QDKQ\N..*UJ* ,
MQ?"^C)XB?7UTFQ77GMQ:-J@MD^U&$-N$1EQNV9YVYQGFLZX^&OA&\M-;M9_"
MNBSVVN2B;589-.A9-0D  #SJ5Q*V .7R>!7244 <[XL^'/A/Q]HT.D>)_"^C
M>(])A96BL-6T^*Z@0@8!6.12H('3 K0\.^&M(\(Z1!I6A:58Z+I=N-L-CIUN
MEO!&/140!1^ K2HH S->\+Z-XJMX+?6])L=8@MYTNH8K^V2=8YD.4D4." ZG
MD,.0>E'B/PSH_C#1KG2->TFQUO2;E=L]AJ5LEQ!*/1HW!5A]16G10!ROACX4
M^"?!,MO)X=\':!H$EM"]O ^EZ7!;&*)V#.BE$&U6(!('!(!-2+\,?!RZ-#I
M\)Z&-)AN_P"T([ :;#Y"7._?YZQ[=HDW_-O SGG.:Z:B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF,5#XP7^U?\ @I-\/QIK*\FE>";]M5:( F-))@(5D],D$C/I0![%^SQ\:O\
MA?7@&X\2_P!C?V%Y.JWNF?9?M7VC/V>9H]^[8GWMN<8XSC)IWP0^,W_"Y(?%
M\G]C_P!D?\(_K]UH>/M7G^?Y) \W[B[<Y^[SCU-?)W['/P[^,7B'X6ZO>^#O
MC#IO@_0V\3ZN(]*NO!\>HNC"[?<?.:Y0D$\XV\>]>J?\$_;/4M.\)_$VUUC4
MDUC58?&^I)=:A';"V6XD!7<XB#,$!_NY./6@#ZIHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **KZAJ%KI-A<WU]<PV5E
M:Q--/<W$@CCBC4$L[,>%4 $DG@ 5GR>,-!AM](N'UO34@UB18M-E:[C"WKLI
M=5A.<2$JK, N<@$]!0!L45!>WD.GV<]U</Y=O!&TLCX)VJHR3@<G@5Q]Y\9/
M#%DNF$MK%P=3=UM%L]!O[EI0JJS.!' Q$8#K^\.$R0,YXH [>BFHP=589 89
M&X$'\CTJAH/B"P\3:<M]IL_VFU9V02;&3YE8JPPP!X(- &C16'X/\9Z7X\T8
M:KH[74E@TCQI)=V,]H7VG!95F1&9"1PX!5AR"1S6Y0 457U#4+72;&XO;VYA
ML[.VC::>XN'"1Q(HRS,QX50 22>!BL3PK\1O#/CNVMKOPSK=IXDTZX#F+4M'
MD^V63%&VLOVB/=$&!XVEL]>* .CHK.TWQ!8:Q>ZC:6D_G7&G2B"Z38R^6Y4,
M!DC!X(/&:=HNK'6K(W/V*[L%\QT2.]C$<C*"0'VY) ;&0&PV.H% #?$7AW3/
M%V@W^BZS8PZEI5_"UO=6EPNY)8V&"I%> :'^PWX?\-B+3],^)?Q1L?",,FZ'
MPG;^*7CT^*/M"K*@G$7^P)L5]!:;KFFZQ+>16&H6M]+93&WNDMIED,$HY,;@
M$[6&1P>>:NDA02>!0!XY\4/V5_"?Q+\0:?XEM]2\0>"/&%C;K9Q>)?"6I&SO
MGMQ_RQE9E=)D_P"NBL?0U8^$_P"S'X6^%/B:\\4G4=>\9^-+J'[-)XF\6Z@;
MZ^6#.?)C.U4B3/\ #&BY[YKU33]0M=6LXKNRN8;RTE&Z.>WD#HX]0P."*BBU
MJSFU:?3$FW7T$:S21;6^5&) .<8['O0!XYX^_9)\,>,/'%WXRT/Q'XL^&WBB
M_54U+4?!>IBS.HA1A?M$3QR1.1V;8&]ZZ3X-_L]^$_@C_:EWI!U+5_$.KLK:
MIXDU^]>]U._*\+YLS?PCLJA5'I7H5UJME8W5K;7-Y;V]S=L5MX9955YF R0@
M)RQ YXJKIOBK1=:CLGT_5["^2]1I+5K:Y203JIPS(5)W '@D=* .8^#7P=T;
MX'>$9O#NA7-_=V4NH76HM)J,B/)YD\AD< HBC:"3CC..I-.^%GP@T;X1Q^(T
MT>YOKD:]J\^M7/VZ1'V33$%E3:BX08X!R?<UUFK:S9Z%:BYOIO(A,BQ!MK-\
MS'"C ![FH[?Q!876N76D13[M1M8DFFAV,-J-G:<XP<X/0T :-%5K?4[.[DN4
M@NX)GMFV3K'(K&)L9PP!^4X[&N1TWXX?#[7+74+C1_&FAZ['ITJ07G]CW\=Z
MUM([;%6182Q0EN.0* .WHJ*ZNH;&VEN+B6.WMXE+R2RL%1% R22>  .]1MJ5
MHNG_ &\W4(L?*\[[49!Y7EXSOW9QMQSGIB@"S152;5K&VTM]3FO;>+34A^T-
M>/*HA6+&[>7)QMQSG.,50\(^-O#WQ T9-7\+Z]IGB327=HUO](O([J!F7[RB
M2-BI([C- &U1110 452N-:L[75+7399MM[=*[PQ;6.X+]XYQ@8]S5#Q?XX\.
M?#W2#JOBGQ!I?AK2]ZQ?;M8O8[2#>WW5WR,%R>PS0!N45SD/Q(\)7'B2R\/1
M>*=%DU^^MOMMKI2:A";JXMR-WG1Q;MS)CG< 1CO46J?%3P7H?A^'7M1\7Z#I
M^AS3FUCU.ZU.".V>8,4,:RLP4ON!7:#G((H ZBBFQR+-&KHRNC#<K*<@@]"#
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,#X@:#<^*O ?B31;-XXKO4M-N;.%YB0BO
M)$R*6(!(&6&< _2O%+?]FWQ#'=6$!UNSBTO0KI3X>\HN)=-@DCD\_: @&Y7>
M-(QG&R%22"37T510!\?2?LC>(;CP[-;2>$/AXJ27"&?PX+RX;3;V06[Q'4YG
M-IG[6&8,%,3'Y?\ 79^8=S;_ +,#23Z;?W]AX=O-8T^RN;:VOI8=\T#21P*G
MER-%N4#RYNAX#]\FOHBB@#X_@_9"\56NJ>-;FX70_$<6K7$=P;;5;^)+;6U6
M<2&"_2+2Q+M"\*TT]YC  4 FOH+X0?#M_ WPNL/"VJ66F!(TECEL;',EFL;L
MQ\I0Z+E K;<%1QVKOJ* /F*;]D.TTWP?;6NF>%_!]UJ%C8VMM%I]Q&8+&Y59
M6>Z@=D@8QQS$J698V+E%#JP&*AL/V.X;VSL&US1_#,]Q9Q6L=E:1[Y;?2XEN
M'>>UMRT0Q$8G,7"IO7Y655XKZCHH \RTOX6WFD_ W4O EJ]E:2/875A8BWRM
MO;1N'6%0-GRJH91@*0,=#7 ^)/V9]8;PNEK;:I!XRU!XU;4D\5RI##JY!0?9
MIOLUL$6#8N,B$D[5W*^2:^BZ* /F&;]DV>Y?4=5T_2/#/@O7[Z![19="8L;&
MU-JL0M(9?L\>(MZD[?+5>=Q0G*GO/V;_ (3:S\&?AK=:)=Q64=^9Y)H;2UO8
M9+-"1\NW[/I]DD88C+!8"<DDLY->Q44 ?/\ \&O@Y\2/A/KFKZI?:QX6\3OK
M4<<E_';VMSIDCW0DYGDD+W F;RSMW".('8ORC)(A^,'[.>K_ !&^-WA[Q8);
M6\T2UA6WGAN+FWBFMDRWF>4)-/N782*Q#K'/;;AD,6!KZ&HH ^?K7X ZGIO[
M,-U\-]-\.^#M,OV+H+&".*33KA3-N\QA-8R1K(RX)WVTP5AT?K6E\$?AAXI^
M#_A?1K:_BTN^-II\=G=QVMVY\B-&=CY*QVD:R$ J BQQ \X"\ ^WT4 >7>/O
M#OB?XH?"^QGT^UM_#'C*-TO+2&]N6*6TGS(0\B1EO]6['&W[V >E>?W/[->O
MV^A^)=,MSH.J:9M@BT?1[YWAMKFW\P37%M=E(6V(\FX?*L@(P67J*^D:* /G
M#PU^RW-8:;;S7-CX?T[5[: 1::NG[Y(M#1IB[PVC-&A5%! #*L9;&"JBN@_9
MW^">I?"C4M=NK[1O#6B"^2.,KX=FDD^V2(S$W4^Z"+$LFX%A\YSU=NM>WT4
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pgen-20201231_g11.jpg
<TEXT>
begin 644 pgen-20201231_g11.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'O ]P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1US7=0/B?38]3T8^(+R2<@D;U\HR,2 Z'(4<?+T%??'Q'^-/@GX1SZ)#XO\
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M&-KGU/\ %#]L#X/?!OQ -"\7>.+/3=7QE[.&">[DB]I!!&_EGV?!QS5WP?\
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METYZLZ2-(H)[E N>IR:U?A-IOPR^"?Q0L_'/A/X!_M%6-_:V1LEL9/#"2VK
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M2\)375_U\@]FC[Q_X;,^#O\ T.'_ )3+S_XS1_PV9\'?^AP_\IEY_P#&:_,
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M/A5_T.5G_P!^IO\ XBC_ (:H^%7_ $.5G_WZF_\ B*_*VBCZE#NP]FC]4O\
MAJCX5?\ 0Y6?_?J;_P"(H_X:H^%7_0Y6?_?J;_XBORMHH^I0[L/9H_5+_AJC
MX5?]#E9_]^IO_B*/^&J/A5_T.5G_ -^IO_B*_*VBCZE#NP]FC]4O^&J/A5_T
M.5G_ -^IO_B*/^&J/A5_T.5G_P!^IO\ XBORMJ>WT^[O%9K:SN+E5^\T,+.!
M]2!2^IT^[#V:/U+_ .&J/A5_T.5G_P!^IO\ XBC_ (:H^%7_ $.5G_WZF_\
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M/A5_T.5G_P!^IO\ XBC_ (:H^%7_ $.5G_WZF_\ B*_*VBCZE#NP]FC]4O\
MAJCX5?\ 0Y6?_?J;_P"(H_X:H^%7_0Y6?_?J;_XBORMI51FSM5FVC)V@G ]3
M[4?4H=V'LT?JC_PU1\*O^ARL_P#OU-_\11_PU1\*O^ARL_\ OU-_\17Y7*K/
MG:K-@9.T$X'K]*2CZE#NP]FC]4O^&J/A5_T.5G_WZF_^(H_X:H^%7_0Y6?\
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M5'PJ_P"ARL_^_4W_ ,11_P -4?"K_H<K/_OU-_\ $5^5M%'U*'=A[-'ZI?\
M#5'PJ_Z'*S_[]3?_ !%'_#5'PJ_Z'*S_ ._4W_Q%?E;11]2AW8>S1^J7_#5'
MPJ_Z'*S_ ._4W_Q%'_#5'PJ_Z'*S_P"_4W_Q%?E;11]2AW8>S1^J7_#5'PJ_
MZ'*S_P"_4W_Q%'_#5'PJ_P"ARL_^_4W_ ,17Y6T4?4H=V'LT?JE_PU1\*O\
MH<K/_OU-_P#$4?\ #5'PJ_Z'*S_[]3?_ !%?E;11]2AW8>S1^J7_  U1\*O^
MARL_^_4W_P 11_PU1\*O^ARL_P#OU-_\17Y6T4?4H=V'LT?JE_PU1\*O^ARL
M_P#OU-_\11_PU1\*O^ARL_\ OU-_\17Y6T4?4H=V'LT?JE_PU1\*O^ARL_\
MOU-_\11_PU1\*O\ H<K/_OU-_P#$5^5M%'U*'=A[-'ZI?\-4?"K_ *'*S_[]
M3?\ Q%7-&_:0^&WB#5K/3-/\5VMS?7DJP00K'*"\C$*J@E,<D@5^4->@?L_?
M\EN\"_\ 89M/_1JU,L'!)N[%[-'ZT4445Y!@?G[_ ,%#_P#DK7AS_L!C_P!*
M):^6:^IO^"A__)6O#G_8#'_I1+7SGX=\&:SXJ5VTNS\]%D6#>\T<2M*P)6-2
M[ ,Y .%&3QTKZ"@[4HW.J/PHQ:*62-H9'C=2CHQ5E88((."#^-)706%%%% !
M116I:^%]5OO#=_K\%FTFCV$\=M<W09=L<DGW%(SDYQV% &71110 5^J'[*?_
M ";QX$_[!J?S-?E?7ZH?LI_\F\>!/^P:G\S7!C/X:]3*IL>L4445XQSA7YG?
MMM?\G#:]_P!<;7_TGCK],:_,[]MK_DX;7O\ KC:_^D\==^#_ (C]#6GN>/77
MB:ZN_"FG^'3'#'IUG<RWG[M2'FFD !>0YY(50HX&!GUKK_A]\5G\-I!!J"12
M0Z;I.I66GR?9_-?=<*"(9 3@Q;MQQCC<WK7G5%>NXIJQT6.KA^(EUIT$$&E:
M9IVC6ZWD-_/':)(?M,D3;HQ(SNS;%.2$4@<YZU27QI?QZAXCO%2$3:]%)%=?
M*<('E64E.>#N48ZU@T4<J ZRX^(US=W4VHS:1I,VOS1&*36)(&:=LKM,A0MY
M?F%>-^S/?KS5;_A/]637-.U6(P17-E8QZ:JB/='+ D?EE)%)(8,O##OGM7.4
M4<J"QT,_B^,VJ6EIX?TC3[(W"W,\$,4C_:67.U7=W9P@R?E4J.:O2?$[45M3
M96EG96&G+ID^DQ6<*R,D,4T@DD92SEMY<9R20/2N0HHY4%CH-3\92WWAT:):
MZ=9:5IS7*WDT=F)/W\P38';>[8PN>%P.36SI]K;M\&=5N#X'FN[E=355\9!_
MW=JN%_T8KZGKG_:KAJ[>PNK)?@[JEL_C>ZM;]M25D\'JK>1=+A?]))Z;AR/^
M TFK6L(XBBBBK&%=CIG@G2F\%V/B35_$#:=#>7\EA':V]D9Y<IM)D/SJ-@#C
M/?T!KCJV+KQ(]UX1TS03;JL=C=S78G#'<YDV94CMC9U]ZEWZ =-JWPK72[[Q
M%I"ZU'>:_H=LUY/;V]N3;R1J5W!)2V=X#*<%<=1GBGVOPOTY?%FF>%=3\2KI
MOB"\DAAE7[&9+6UDDQB*27>#N&0#A2H/&>]49_B7-/XL\3ZZ=.C5]=LYK-X!
M*<0B3;\RMCDC;^M7;/XI68\4:9XHU+PS!J?B*S>*5YFNWCM[J2/&V22$*?GP
M!G# $\X[5G[Y.HR\^&^EZ)X=MM8UCQ(UK'<:C<Z=';VUB9I<PN%:4Y=0$YSU
MSV -4O%WPWNO!^BWU]=7D<TEKJLFEF&-#A]L:R"4,>Q##C%4_$WC67Q-H=EI
MKVB6ZVMY=W@D5RQ8SOO*XQP%Z9[UKZQ\3HO$\FL0ZSHOVG3=0NTOEM[>[,,E
MO,(Q&2LFULJR@9!7L""*:YQZF_I?@_3_  9H?C&:]N1=WR:'87=K*-/CG$7V
MDY*A9&P&Y"[AR!R/2L>T^%VG+XNTWPIJ?B9=-\0W<L4,J_8S):VLLF,122[P
M=PS@X4J#QGO6;JWQ(N=73Q(DEC#%'J]M;6<:1.P%I% <QJN>6. !D_6M&S^*
MEF/%6F^*=1\,P:GXBLY(I7F:[>.WN9(\8DDA"GY\#G# $\X[4K3%J9MUX%M-
M"L_MFNZK)96\]S-;V<=I:>?-<+$Y1Y=I=55-P(&6R2#Q6WX/T'PVFD_$4RZB
M=6BL]'2>TO(;#[N94^8"1E*/SM.,C&<$UBW'CZWUJQ%CKVC_ -HVT-U-<V;V
M]T;>>W$KEWBW[&#)N)(!7().#5:'QI!8KXFAL=%M[&SUJQ6P%O',["W575]V
MYLEV.WG.!SVZ4_>:'J:#?#%U^(6C^%?[27?J,$,XN_).(_,A\W!7/..G6NE\
M(^!;7PWXP\*1#4=.U;5=8LGN%T_4-,-Q:P1O"YS+EQE_E^7;G&03CI7.6WQ.
M6*ZT_5IM'2X\2:?9BS@U W++$0$,:2/#M^9U0XR& )P2*@L?B5/9>+/#FN_8
M(Y)=&L5LEA:4@3;8FCWDXX)W9P/2DU-Z!J7(_AOI<.E^%KO4?$GV2X\2;OLU
MK#8F7R#YIC!E.\80L!]W)QVXJC>> 8?#=B;KQ+J;Z:)+J:UMX;.V^TRR^4VV
M24@NH5 >!SDX.!5*^\:27T?A-3:(G_"/H$3#D^?B8R\\?+R<<9KJY?$6E>/=
M+E.MSZ=',M]/<0VMS=2VCVR2MN95F6.198R<G;M5@<X/-/WEN&IROC_P:O@;
M7(+"/4X=8BFLX+R.[MT*HRRH&  //&:YNNO^*OBBQ\6>*TN-,C1+"UL[>QB,
M:%$81(%+*K<@$CC//K7(5<;V5QH*Z/X;_P#)0O#'_84M?_1RUSE='\-_^2A>
M&/\ L*6O_HY:);,#[I_;]_Y)'I__ &$5_P#0&K\\Z_0S]OW_ ))'I_\ V$5_
M] :OSSKEPG\)&=/X0HHHKL- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *]2TG4(+'X(Z6T^M:MHX_X2*<AM)7<SXA'WOWJ8]NOT
MKRVM&3Q!>S>'+?0F9/[.@NFO$78-_FLNTDMZ8[5,E>P'<^(I-&\36^K^/=0L
M;DVMQ>QZ;9Z;;S+$\LBQ O-/(%."0N2%7DFNE^'NA^&](\<_##6=+@U":/6#
M<M+;7=PH-O+'\H"NJ?.N#UP,Y[5Y3H?BR^T&SO+&-+6]TV\*M/8WT(EA=E^Z
M^,@JP_O*0:UY_BQXAGU+P_>[[.%] #IIL,%HB10*QR5V#@CZ\^]9N+M9?UH3
M8[+0_"\OQ$\*^&-)75;K3M)DUZ_"6<TJ20VD:1[W=254ES@\L<?2L*X\&^'+
MZPN9;6[M]+N(9(S;PMKEO?->QLX4KMC *28.X8RO:N6L?&VLZ98Z?:6=W]E3
M3[V34+>2- '69QAB3W4CC:>*GN_'VHW%K);6]IIFEPS3)<7"Z=9K#]H=&W+O
M.3\H89VC"Y[4^62>@[,Z_P 2^ _"J>*/%_AS15U19]$MIKF+4+RX1A.T2AGC
M:((-HP2 P;.>U4OB_=6%QI?@#[/826Y_X1^%F+W1DRGFO\OW1CG)S[]*YA_'
M&K2:]K&LM)#]OU:*6&[;RAM99%VOM7^'C\JHZQKUYKT.F17C(R:=:+96^Q N
M(E8L ?4Y8\TU%W5PL>M_$K2]*U;7M=UF_CODTG0;#3X4T^&[W--)-$@159EQ
M"@Y+$ Y^IJ/X5>']._X23PQXFT<7%K;7$MY87%C=2"5HIEMV<,D@ W(5]0"#
MZUY[_P +$UIM8O-0E>VN&O;>.UN[6:W#6]Q&BA55X^AP%!R,$$9!%20?$K6[
M/4M-N[0VEDNFK(MI9V]L%MHO,7:[;,\L1U9B3TYJ>67+RBL['9'PW:>(/!/@
M:XU*>:'2])\.7FH7*VP!FD5;C 1,\ DD<GH.:S/"_A'PKXMLTU(_;]$M(+Z*
MPO89+E9@OGY6&9)-@^Z^-RD<@Y!KF++Q]K6GKHRV]Q&D>DVTEG!&8597AD;<
M\<JGB12>QJ#6/%U[J^FQZ:L-GIFFI+Y_V/38/)C:7H';DEF Z9/';%/ED/4[
M9O@G<1^#+EGDE_X32&](&D@?*UFLHA:4=\^801_L@FJ5GX%T.^^(^L^'X;FX
MEL=-L+AC<+(NZ6YAA+.0<8V>8",>@ZU03XR>+8_&47BD:F/[;BL1IRSF)2OD
M"/R]NWIG!//KS7,Z%KE]X;U6#4M/G,-Y"25D8!PV>&# \,""00>N:$IZW8:G
M9_#?P#I?B[2M'N+^>XBDO/$-KI4GDL !#(C,[ $'YAM&/Y4MGX7\,^*M<UO0
MM$AU*RO+.*ZEL[Z]N%D6Y\C<666,(/+W!3@@G!QG-5/#GQ,FT_Q/X:NKFUM[
M'1M)U%=0^P:/;B)2^>7P3\SXX&3@#@8JIJWQ)U._DUDP0V-B^J-(MU>6MHL5
MS<1,Y.QW'3(QNV@9[YHM*X:EGP_H/AU?AC>>*-6BU"[O4U2.PMK.VG6&)U:)
MG)=RK%<;>W7I[UKV_P .-%O=&B\6+/?0>&1I\][/8[E:[66*1(S"CX"E6:1"
M)"O SD$BL?1/B"NA_#>[\.1VD-W+=:K'>RPWL"RVSQ+$R@'D,&#,""N/K5%O
MB/KO]J6]ZLT$2V]L;*.QCMU%HMNWWH?)^Z4;.3G))YSFBTKNP:F_X>\(>%?%
M%E9ZO)=77AO2X=3BL-4CN9Q.J+*&,<D<NP$#*[6W*<9R,\BNA\,Z/:^$=4^(
M-E>^'KJU!\,3RI$VJ+*KQG'S1S)'B1&X(8#C!_#SN?QU?3)9P"RTN'3;64SK
MI<-F!:R2$8+R(22YP< D\=L4^?XAZS--=,&MH8[C3#H_V>& +%#:DY\N-<_+
MR2<Y)R30XR8K,T/A8VV\\3E>/^*>U# _[9'BNENOAWX37QAHGA.U&JM?ZGIE
MO<MJ,EP@2WN)8=X41[/G3/4E@<'CI7FFC:[=Z#)>/9LBM=VLME+O0-F*1=K
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M_P (GK?_ $";W_OPW^%'_")ZW_T";W_OPW^%?<'_  ]0_9H_Z'^;_P $=_\
M_&:/^'J'[-'_ $/\W_@CO_\ XS1]>?\ *'M/(^'_ /A$];_Z!-[_ -^&_P *
M/^$3UO\ Z!-[_P!^&_PK[@_X>H?LT?\ 0_S?^".__P#C-'_#U#]FC_H?YO\
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M5^*W_0FWW_?2?_%4?\,J_%;_ *$V^_[Z3_XJOIW_ (>H?LT?]#_-_P""._\
M_C-'_#U#]FC_ *'^;_P1W_\ \9H^NS[(/:,^8O\ AE7XK?\ 0FWW_?2?_%4?
M\,J_%;_H3;[_ +Z3_P"*KZ=_X>H?LT?]#_-_X([_ /\ C-'_  ]0_9H_Z'^;
M_P $=_\ _&:/KL^R#VC/F+_AE7XK?]";??\ ?2?_ !5'_#*OQ6_Z$V^_[Z3_
M .*KZ=_X>H?LT?\ 0_S?^".__P#C-'_#U#]FC_H?YO\ P1W_ /\ &:/KL^R#
MVC/F+_AE7XK?]";??]])_P#%4?\ #*OQ6_Z$V^_[Z3_XJOIW_AZA^S1_T/\
M-_X([_\ ^,T?\/4/V:/^A_F_\$=__P#&:/KL^R#VC/F+_AE7XK?]";??]])_
M\51_PRK\5O\ H3;[_OI/_BJ^G?\ AZA^S1_T/\W_ (([_P#^,T?\/4/V:/\
MH?YO_!'?_P#QFCZ[/L@]HSYB_P"&5?BM_P!";??]])_\51_PRK\5O^A-OO\
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M*W_0FWW_ 'TG_P 51_PRK\5O^A-OO^^D_P#BJ^G?^'J'[-'_ $/\W_@CO_\
MXS1_P]0_9H_Z'^;_ ,$=_P#_ !FCZ[/L@]HSYB_X95^*W_0FWW_?2?\ Q5'_
M  RK\5O^A-OO^^D_^*KZ=_X>H?LT?]#_ #?^".__ /C-'_#U#]FC_H?YO_!'
M?_\ QFCZ[/L@]HSYB_X95^*W_0FWW_?2?_%4?\,J_%;_ *$V^_[Z3_XJOIW_
M (>H?LT?]#_-_P""._\ _C-'_#U#]FC_ *'^;_P1W_\ \9H^NS[(/:,^8O\
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M*>A_^"Z'_P")KI:* .:_X5EX/_Z%/0__  70_P#Q-'_"LO!__0IZ'_X+H?\
MXFNEHH YK_A67@__ *%/0_\ P70__$T?\*R\'_\ 0IZ'_P""Z'_XFNEHH YK
M_A67@_\ Z%/0_P#P70__ !-'_"LO!_\ T*>A_P#@NA_^)KI:* .:_P"%9>#_
M /H4]#_\%T/_ ,31_P *R\'_ /0IZ'_X+H?_ (FNEHH YK_A67@__H4]#_\
M!=#_ /$T?\*R\'_]"GH?_@NA_P#B:Z6B@#FO^%9>#_\ H4]#_P#!=#_\31_P
MK+P?_P!"GH?_ (+H?_B:Z6B@#FO^%9>#_P#H4]#_ /!=#_\ $T?\*R\'_P#0
MIZ'_ ."Z'_XFNEHH YK_ (5EX/\ ^A3T/_P70_\ Q-'_  K+P?\ ]"GH?_@N
MA_\ B:Z6B@#FO^%9>#_^A3T/_P %T/\ \31_PK+P?_T*>A_^"Z'_ .)KI:*
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M@'@73_A=\3/"UCXD\+:7X:US0[Y-]O>VEA"R..A'W<@@\$'!'>M__A67@_\
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MTM% '-?\*R\'_P#0IZ'_ ."Z'_XFC_A67@__ *%/0_\ P70__$UTM% '-?\
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M,WC;XR?%P6>K^+?#Z^#=4FT_2+'0?$.E:796J1@^7->07?SW*R8#YX7!(![
M _37_A67@_\ Z%/0_P#P70__ !-6-/\  ?AG2;R.[L?#NDV5U&<I/;V,4;KD
M8X8+D<$U\+^+OBU\2?B7XZ^"WP^\>^.KKX&6VN^$I-;U;5=$N;>"74M1CD*?
M9X+K<\:*4"S84D$2 <\8\EU[XR?$71?A_P#M"V>A?&S6?%LN@^+O#>E:+XJC
MN5/EQ2NRR*OE_(>0$?:-KF,GO0!^K]%<W\.O"%QX#\%Z9H5UX@U7Q3<V:,)=
M8UJ42W=RS,6+.P '\6  ,  #M724 ?G[_P %#_\ DK7AS_L!C_THEKY9K[I_
M;(_9_P#'?Q:^(>BZIX6T9-2L;;2Q;2R->0P[9/.D;&'8$\,.>E>"?\,6_&'_
M *%:'_P9VO\ \<KW*%2"II.2.F,E9:GB-%>W?\,6_&'_ *%:'_P9VO\ \<H_
MX8M^,/\ T*T/_@SM?_CE;^UI_P R^\OF7<\1HKV[_ABWXP_]"M#_ .#.U_\
MCE'_  Q;\8?^A6A_\&=K_P#'*/:T_P"9?>',NYXC17MW_#%OQA_Z%:'_ ,&=
MK_\ '*/^&+?C#_T*T/\ X,[7_P".4>UI_P R^\.9=SQ&BO;O^&+?C#_T*T/_
M (,[7_XY1_PQ;\8?^A6A_P#!G:__ !RCVM/^9?>',NYXC7ZH?LI_\F\>!/\
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M*KD/^&9_A!_T2OP7_P"$_:?_ !NC_AF;X0?]$K\%_P#A/VG_ ,;J_P!WW?\
M7S'[IU__  G'AS_H8-+_ / V/_XJC_A./#G_ $,&E_\ @;'_ /%5R'_#,WP@
M_P"B5^"__"?M/_C='_#,WP@_Z)7X+_\ "?M/_C='[ON_Z^8>Z<=<?L\?LXWG
MBB7Q%<^$? ]UK4UP;N2\N%@D9Y2<ER&)!.>>E=QX[T;X6_$_PV- \61^&/$&
MBJ5*V5_)!)&A' *@GY2!T(Q4'_#,WP@_Z)7X+_\ "?M/_C='_#,WP@_Z)7X+
M_P#"?M/_ (W1^[[O^OF'NF=X/\"_"7X5C4KOP#8>#_"^JW5F+7SK%H85<("8
MPX4\@,<GN:Y[]E_X>^'O@)X"O+'4?%NAZOXJUK4;C6-<U2WN(XTN;J5RQV M
MD(HPH!]#ZUV7_#,WP@_Z)7X+_P#"?M/_ (W1_P ,S?"#_HE?@O\ \)^T_P#C
M='[ON_Z^8>Z<UX^^"/P!^*GB277_ !=X?\(>(-:E18GO;Z6)Y"J_=&=W05)J
M'P7^ 6K>"=.\'WOA[P;=>&M-D::STV8PM';NQRS)DY4GO@\UT/\ PS-\(/\
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MJ%CIS7B7&FS+&S2"+(W94@C/.,5@^(?@GKOC/2_%E]KFMV4GBC6-+_LJT%O
MZV.GP[P^T L7<LP!9SCH  *Z23POXM\2_#_6_#NO/HMI)=6)L[:?36FD4$IM
M+.' _(4 <_J^H:MX3_9COM8@US4KO6/[#%^-1NW66=96B5B5^7'!)P,5G>$_
M'%EX/\&W'BF>[\>^(%MM.AN;R'5[&>-%0[=\D?FQ1JQ7))"DG .!7=>)/A[<
MZU\&KCP7%>0Q7<FDKIRW;H3'O6,+N*@YQD=,U+X)TOQ7#IJZ5XI@T&73H[-;
M9?[->9VDPH4[A(H&TC/<]: $UWXN:#HNK>'M/61[^36K>2_CEM2ICALXX][W
M4C$C$8! !&22P %<CK7[2EKX?\(+XOO/!WB%?",S1K:ZHD43-*)'"1R&'S/,
MCC;((9E'!!. :C^&O[-&F^![7Q9;:CJMQK\&L1OIUDLZA3INEG)2SC/]U69C
MN[X7^Z*SO$WP7^(/B'X9I\/AXLTFUT:V2""+5EL7-Y/;Q.I6*1-VQ254*77.
M<9"@F@"UH?Q>N=#^(GC*PUJ:ZO[)O$NGZ)ID,2)BV:>'.3T.W=R>I]*ZWQ9\
M;O#_ ()U_6-+U5+N)M+TR/4Y)HXPXD5Y?*2*-0=S2%B %QSGK7-ZQ\![_4-5
M\5:I;ZS;P:A?:W9:[IC/;ETMYK9 JK*-PW*W.=I!P:9K/P&U'Q\WB#5/%&K6
MMGK^H6]K!9MI$3-#8&WE\Z.0>9S*QDP2#@8&,=Z -2\^.TNBZYX=T?6_!6NZ
M1>^(KAK;3/,-O)&[K&9-LCI(1$V!T;]<5YCX#^*7B76?#7P[UGQ-K>L^'GE\
M2W]G/!"EE<1:C$KS[4G<<Q1QA,93YB5'4'->AZK\-O'OC+Q9X+U77]>T6TLO
M#>H&]>QTNUE/V\^6R;F9VS'@MD*,\]6.*SK?]G2Y;PIX2T.[U:WFATC6KS4K
MHK"P\^*=ICY:\_*P$PY.>E &Y#\?K/\ LVQUZ[\.:Q8>#;Z5([;Q#.L?E%7;
M:DKQ!_-CB8XP[*!@@G .:I+^TC9S+XFNX/"FO2Z)X9U&73=7U1DA6.%X]I9X
MU,FZ50'!.P$CTSQ4;_!_Q7J?@^R\!:IKNFR^#;58;=KN"V==0N;6(KL@8$^6
MAPJJT@SD#(4$U=A^"]]'\-_'_AIM4MS<>)K^]NXK@0ML@$X4!67.3C;VH ]5
M@FCN88YHG$D4BAT=3D,",@BO&/B9_P G+_!G_<U?_P!)#7K^C6+:7H]C9LXD
M:W@CA+*, E5 S^E>0?$S_DY?X,_[FK_^DAK6G\3]'^3*CN>UT445D2%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 45^:7_!7C7-2T?7?A\+#4+JR#VUQN%O,T>[YUZX-?G?
M_P )QXC_ .@_J?\ X&2?XU[%#+W6IJIS6OY'3&CS1O<_H]HK^<+_ (3CQ'_T
M']3_ / R3_&D/CGQ$H).OZF!_P!?DG_Q5;_V2_Y_P_X)?U?S/Z/J*_F_3Q]K
M\F2OB+46QR=M[(<?^/41^/M?ESL\1:B^/[M[(?\ V:C^R7_/^'_!#ZOYG]#?
MQ)\&CXA>!=9\.&[^P#48/)^T"/S/+Y!SMR,]/6OE0_\ !..,G/\ PGC?^"G_
M .W5^1S>/M?5MA\1ZB&_NF]DS_Z%3O\ A._$(8*?$&I!CT'VV3/_ *%6T,OJ
M4U:-3\"E1:V9^M__  [CC_Z'QO\ P4__ &ZOJSX;^#_^%?\ @71/#@N_MW]F
M6RV_VGR_+\S'?;DX^F37\\@\=>(68@>(-2)7J/MDG'_CU#^._$,:Y;Q#J2CU
M:]D'_LU$\OJ5%:53\ =%O=G]']%?S?GQYX@5-Y\0ZD$_O?;9,?\ H5!\>>(
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MP<_Z$U?_  8W?_QVC_AC/X.?]":O_@QN_P#X[1:E_,_N_P""'N]SVJBO%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#X(_P""E'PDT_XM>)/!\$OQ)\$>";JPM)6:U\5:HUI+*COPZ*$;*Y4C/'2O
MB[_AC?3O^B_?![_PHI/_ (Q7ZNVMK#=?M?ZX)H8Y@/!5B0)%#8_TVZ]:]@_L
MBQ_Y\K?_ +]+_A7K0QDZ$(P7Z?Y'2JK@DC\0O^&-]._Z+]\'O_"BD_\ C%'_
M  QOIW_1?O@]_P"%%)_\8K]O?[(L?^?*W_[]+_A1_9%C_P ^5O\ ]^E_PJ_[
M2J?U;_(?MV?B%_PQOIW_ $7[X/?^%%)_\8H_X8WT[_HOWP>_\**3_P",5^WO
M]D6/_/E;_P#?I?\ "C^R+'_GRM_^_2_X4?VE4_JW^0>W9^(7_#&^G?\ 1?O@
M]_X44G_QBC_AC?3O^B_?![_PHI/_ (Q7[>_V18_\^5O_ -^E_P */[(L?^?*
MW_[]+_A1_:53^K?Y![=GXA?\,;Z=_P!%^^#W_A12?_&*/^&-]._Z+]\'O_"B
MD_\ C%?M[_9%C_SY6_\ WZ7_  H_LBQ_Y\K?_OTO^%']I5/ZM_D'MV?B%_PQ
MOIW_ $7[X/?^%%)_\8H_X8WT[_HOWP>_\**3_P",5^WO]D6/_/E;_P#?I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3?"?Q7\:^(M4L-2;1S'HM]J#60LYA:Q+#&&9=PF-SYCRC;DIY0SS@#%>I_\
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MBU9(5T>0?M??\D+U/_L(:=_Z6PU[17B_[7W_ "0O4_\ L(:=_P"EL->T4/\
MAQ]7^@?904445B2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B_C/P3\
M1M-^-D_C?P79>%]4M+O08-(FM]>U.YLY(WCGFEW+Y5M*&!$H')'2K7]K?'O_
M *%3X<_^%/?_ /ROKUZBMO:=TF5S>1Y#_:WQ[_Z%3X<_^%/?_P#ROH_M;X]_
M]"I\.?\ PI[_ /\ E?7KU%+VB_E7X_YA?R/(?[6^/?\ T*GPY_\ "GO_ /Y7
MT?VM\>_^A4^'/_A3W_\ \KZ]>HH]HOY5^/\ F%_(\A_M;X]_]"I\.?\ PI[_
M /\ E?1_:WQ[_P"A4^'/_A3W_P#\KZ]>HH]HOY5^/^87\CR'^UOCW_T*GPY_
M\*>__P#E?1_:WQ[_ .A4^'/_ (4]_P#_ "OKUZBCVB_E7X_YA?R/(?[6^/?_
M $*GPY_\*>__ /E?1_:WQ[_Z%3X<_P#A3W__ ,KZ]>HH]HOY5^/^87\CR'^U
MOCW_ -"I\.?_  I[_P#^5]']K?'O_H5/AS_X4]__ /*^O7J*/:+^5?C_ )A?
MR/(?[6^/?_0J?#G_ ,*>_P#_ )7T?VM\>_\ H5/AS_X4]_\ _*^O7J*/:+^5
M?C_F%_(^=_B7X/\ C=\5O"K>&]1T3X?Z78W%W:S37=KX@OII42*=)3M1K%0Q
M(3 RP'-?1%%%*4^9)6L)NX4445F(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBOD71?^"B7A[6?VHG^$<?AUEL3?2:;%XD74 4>=0>/)\H84L"H.\]
MN.:UA2G4OR*]AJ+>Q]=4445D(**** "BBO)?VH/CU_PS?\)[OQK_ &%_PD7V
M>YBM_L/VO[+NWDC._8^,8Z;:J,7.2C'=C2N[(]:HKXD\"_\ !3".Z\1Z!8?$
M;X3^(?AMIFO,J:;K-U(\]M-N( ?+P193D?,F_&0>G-?;*.LB*Z,&5AD,IR"/
M6M*E*=)VFAN+CN.HHKP72_VIO[2_:SU#X)_\(QY?V33C?_VY_:&=V$1]GD>5
MQ]_&=_;I41A*=^7IJ))L]ZHHHJ!!17@O[-W[4W_#0GBCQYH__",?V!_PBU[]
MC\[^T/M/VGYF7=M\I-GW>F6Z]:]ZJYPE3?++<;36C"BBBH$%%%% !1110 44
M44 %%%% !1110 4455U34K;1M-NK^]F6WM+6)III7. B*"6)^@% %JBOF3X'
M_ME7OQPT/X@>)=.\!-I_A#PQ',;;5;C5"7U)T5F"K'Y " J,D[VV[AP:K>$?
MVU-2\:_LIZU\9M,^'OFR:7=2Q2Z!_;/)AC*[Y1-Y'4!L[=G;K70\/43LUV73
MJ7RL^I**\^^ OQBT_P"/7PJT/QMIUL;&/48R9;)I1*UM(K%6C+ #)!'7 X(X
M%>;^%_VN)/'7[37B+X2>'O"(OK?0;=Y+SQ#-J?EQK(JCY!$(6X+LJ[M_J<<8
M,*E-N2MMN+E9]$T5\Y? ?]KY_BI\7/%7PR\4^#F\">,-#RR6K:D+Q+Q%/S,C
M>5&>A5AP<J<\8Q7T)J5Y_9^GW5T(I+@P1-+Y40R[[03M4=R<8I3IRIOEDA--
M:,LT5X5^RC^U%_PU!H/B/43X0O\ PBVCW_V$Q7DWFB7@G(;8F'&,,F#M)')K
MW6E.$J<G&6X--.S"BO'?VI?VCK#]F'X:GQ5>://KTTEPMK;6$,PA$DC9/S2%
M6VC /(4_2MC]GOXL:M\:OAG9>*M9\&ZAX%N[F1E72M19V<QC!656:.,LC Y!
MVX/O3]G+D]I;0+.USTJBBBLQ!17FO[17QD/P"^$>M^-QH%SXE_LT(?[/M9/+
M+;F"[F?:VQ%SDMM. .E:WP9^) ^+_P +?#GC(:3<Z&-8M1<_V?=G,D/)&,X&
M0<9!P,@@X&:ODER\]M-AV=KG:4445 @HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7^#?Q<\<ZI^QI\?];O/&GB&[UG3+UDL=1GU6=[BT7CB*0ON0?[I%<[I/A?\
M:%\6?LE1_&.?X[Z[80:)92W5EHUO/,)+JWCD.YY[A909')#8$BOP ,@<5Z;\
M*?V5_BCX:_91^-O@W4O#'V;Q)XCNVETNR_M"U;[0IQSO64HG_ F%>P>'_@GX
MTL?^">TGPSGT;9XV/AVYL!I?VJ$_OGD<JGFA_+Y##G=CGK7=*K"+?+;62[;6
M-7)+;N?&W[5WC'Q3\</V0_A!\0M:\1W*3FZETN_TV)2D%Y<!CMNBJL%#!4QC
M;_$<$=*]#_:$'Q!_9[^ OP0TNW^*7B75+[4=;6:?4XKZXM97MY(XV6V;$S%D
M0< %L<]!5OQG^R+\6M6_8E\ > ;7PGYOBW2]<DO+S3_[1M!Y41WX;S#+L/4<
M!B?:OH']JO\ 9=USX^? 'PKHFD74&F^+_#8M[NT6Z?\ =-,D(1XV9<@'K@X(
MR!VYI^VIQ<(W7+S/_@!S+1'*?\%-_'OB;P#X \ 7'ACQ%JWARXN?$203RZ3?
M2VKRQ^4YV,8V!9<@<'BO.?V\?CAXR\#_ !-^'>BZCXC\5^#OAC>6,<][JWA&
M?R;ZYF/W\2G'*#:=N[!#$D'BC4?@)^TU^U)XD\$:5\8])T'PCX2\,7"7,EU8
MSQ237S* "VV.:3]XP&/^6:C<3CM7T/\ M.6WQ5U.6'1?#OPC\)_%3P%<6ICN
MM.U34E@O!-@A7!FVQHJ\8*EF/JF*Q@X4G"#LVKWU77SVN2K1LCQ[Q7XPO]"_
M8%\5^(?"OQMUOXAS+(IL_$>\V=]9+YB#R&93YPD /S&1LG/  -8GC;]JGQWX
M)_9A^"?AWPI>SZC\2_'=J(8]8U)S<2QC?L:3=)D-(6=0"V<#)YQ5;P7^Q#\0
M_!/['?Q+\-#3K:;QEXNNH+F#PY9WJ&.RCC;Y8_/D<*6P3GYB,*OS,<UVGC+]
MB;Q)\1OV8_A=IT-S'X4^*G@FU#6;RS*T:R;MS1-)'N Y"D,I(R.<U=Z"?O--
M<WZ>72X>[?YG$_$KX1_M&_LJ>!Y_B?9?';4O'LNFE)]7T#5DEDM?*)'F>7YT
MK@J"?X5C.WD8/%1_MJ?M(>*/%/[/'P7\=>!==U?PC=>(KW,L>FWTMMN<*5:-
MRC#>@D4XW<$5H>,/ /[8_P"TEX?B^'OCG2O#'@GPM*Z+J6MV<\9FO(T()RL<
M\I.[&=JI&">#@9%=1^UI^R/XDU;X3_"#P3\,-";6;+PGJ"-/NNX+=EC"_-*?
M-=02S%F(7/)Z4XR@IP]HTY7>UK6MUZ#NKJYX_P#M Q_M!?LJS>"?B;J_QJU'
MQ1<ZU?QP7^@[&CT^W=DWF)8?,,3IA67<$0@X(]:_3/1]075])LKY4,:W4"3A
M"<E0RAL?K7RU_P %$O@=XV^.WPZ\):7X'T3^V[ZQUQ;RXB^UP6^R(1.N[,KH
M#RPX!)YZ5]/>&+.;3_#>DVMPGEW$%I#%(F0=K*@!&1P>17%6FJE*$M.;7;\#
M.3NDS3HHHKA,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \3^)W[%_P;^,GC"Z\4^,/!W]KZ]=)'
M'+=_VG>0;E10BC9%,JC"@#@5RG_#MW]G3_HG?_E;U'_Y(KZ7HK=5ZL593?WL
MKFEW/FC_ (=N_LZ?]$[_ /*WJ/\ \D4?\.W?V=/^B=_^5O4?_DBOI>BG]8K?
MSO[V'-+N?-'_  [=_9T_Z)W_ .5O4?\ Y(H_X=N_LZ?]$[_\K>H__)%?2]%'
MUBM_._O8<TNY\T?\.W?V=/\ HG?_ )6]1_\ DBC_ (=N_LZ?]$[_ /*WJ/\
M\D5]+T4?6*W\[^]AS2[GS1_P[=_9T_Z)W_Y6]1_^2*/^';O[.G_1._\ RMZC
M_P#)%?2]%'UBM_._O8<TNY\T?\.W?V=/^B=_^5O4?_DBC_AV[^SI_P!$[_\
M*WJ/_P D5]+T4?6*W\[^]AS2[GS1_P .W?V=/^B=_P#E;U'_ .2*/^';O[.G
M_1.__*WJ/_R17TO11]8K?SO[V'-+N?-'_#MW]G3_ *)W_P"5O4?_ )(H_P"'
M;O[.G_1._P#RMZC_ /)%?2]%'UBM_._O8<TNY\T?\.W?V=/^B=_^5O4?_DBC
M_AV[^SI_T3O_ ,K>H_\ R17TO11]8K?SO[V'-+N?-'_#MW]G3_HG?_E;U'_Y
M(H_X=N_LZ?\ 1.__ "MZC_\ )%?2]%'UBM_._O8<TNY\T?\ #MW]G3_HG?\
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M72_\.W?V=/\ HG?_ )6]1_\ DBOI>BF\36?VW]X^>7<^:/\ AV[^SI_T3O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@E=?]_F_QK.HH T?^$DU7_H)77_?YO\ &C_A)-5_Z"5U_P!_F_QK.HH T?\
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M[_-_C1_PDFJ_]!*Z_P"_S?XUG44 :/\ PDFJ_P#02NO^_P W^-'_  DFJ_\
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M_P G!3_]@JU_G)7._"7P1HVN?#K6_$&I:?#-9:1=2G5[FXB=I%MC;GR5M2I
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MVEI*=,C8)/.J,1D\X)Z<&OSE^)^DZ?H/Q$\1Z?I;HUA;W\\421QLBQ 2,/+
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M1_Z _AK_ ,"%_P#BZ\B_X=/_ +-O_0H:A_X.[O\ ^.4?\.G_ -FW_H4-0_\
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M_#7_ ($+_P#%T?\ "F_@C_T!_#7_ ($+_P#%UY%_PZ?_ &;?^A0U#_P=W?\
M\<H_X=/_ +-O_0H:A_X.[O\ ^.4>TGW8<S[GKO\ PIOX(_\ 0'\-?^!"_P#Q
M='_"F_@C_P! ?PU_X$+_ /%UY%_PZ?\ V;?^A0U#_P '=W_\<KR#X\?L@_LA
M?L]ZCX<T_7_A_P"+]6U'Q TJV%GX?N;V]FD,8!8;%E!Z'MFCVD^[#F?<^O/^
M%-_!'_H#^&O_  (7_P"+J:S^$_P7T^[@NK?2_#D-Q"ZR1R+<KE6!R"/G]17R
M;\$?V+_V-/V@;74SX3T'6#J&E2"+4=(U+4;^TOK)ST$L,C@C//(R..M>G_\
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M_:_A#_G]T3_O[#_C1_:_A#_G]T3_ +^P_P"-?,G_  Z?_9M_Z%#4/_!W=_\
MQRC_ (=/_LV_]"AJ'_@[N_\ XY1=@?3?]K^$/^?W1/\ O[#_ (T?VOX0_P"?
MW1/^_L/^-?,G_#I_]FW_ *%#4/\ P=W?_P <H_X=/_LV_P#0H:A_X.[O_P".
M478'TW_:_A#_ )_=$_[^P_XT?VOX0_Y_=$_[^P_XU\R?\.G_ -FW_H4-0_\
M!W=__'*/^'3_ .S;_P!"AJ'_ (.[O_XY1=@?3?\ :_A#_G]T3_O[#_C1_:_A
M#_G]T3_O[#_C7S)_PZ?_ &;?^A0U#_P=W?\ \<H_X=/_ +-O_0H:A_X.[O\
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M_P!FW_H4-0_\'=W_ /'*+L#Z;_M?PA_S^Z)_W]A_QH_M?PA_S^Z)_P!_8?\
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M_M?PA_S^Z)_W]A_QKYD_X=/_ +-O_0H:A_X.[O\ ^.4?\.G_ -FW_H4-0_\
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M<UU7PI_:^^*GB;X2_!GP?X4L-%\1?%+Q9;WQ_MOQ)+)'8+:6<A0W4@C.^1F
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M 21'NK8)''L:O5XYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC_(ON1IR1['VO^SQ^W=\<?''QO\ !>@ZUXW:\TG4-2B@N;?^S;1/,0GE=RQ
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M_P#(='_"D_'W_1>/%W_@KTC_ .0Z]EHH]I+R^Y?Y!S,\:_X4GX^_Z+QXN_\
M!7I'_P AT?\ "D_'W_1>/%W_ (*](_\ D.O9:*/:2\ON7^0<S/&O^%)^/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY7?0XJ[3:L%%%%>,<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF\F!81)@_>5D"XY+=*K]]>W,'O=Q/^&5O"O_ $,7C[_PM]5_^2*/^&5O"O\
MT,7C[_PM]5_^2*WO%VJ:WJ'COPKH>FZY)HEK?6%U=SRV<,,S.R>5L ,J,-OS
MGH.?6J&F_%+5-"O+_P -ZO9MX@\36U\+2T&FHL/VZ-HEE$K!FVQ[48!SG&<8
M'.*GFJM74@O+N4/^&5O"O_0Q>/O_  M]5_\ DBC_ (96\*_]#%X^_P#"WU7_
M .2*V[7XWV%UK6CZ,-)OHM8O;F:TFLYWAC:U>+&\%B^USA@P"%B5Y%4M*_:.
M\+ZMX@@L(9$^QW-V;&WO?MENQEF!(_U D,JJ2I 8K]<4[UN[#WBC_P ,K>%?
M^AB\??\ A;ZK_P#)%'_#*WA7_H8O'W_A;ZK_ /)%7OBIXOU31_'7AG2+75=4
MTNPO;6[FG;1M+%_<,\>S8-OE2[5^8\[?QJ[9_&33+2;7K2ZCU"2/P_!$;N]N
M(XXYI9) -BBW&V0%RP .P*2<=J.:K9-,+R[F)_PRMX5_Z&+Q]_X6^J__ "11
M_P ,K>%?^AB\??\ A;ZK_P#)%=/<?%231M-NKS7_  SJNBJ@C-NCF*8W3.VU
M(D\MR!(21\K8QUSC-<MXN^-6J:;<Q:4^AWOAG5EDM;B1[[R9H'M7F*-M='8;
M@ <CM0I5GU_$/>[CO^&5O"O_ $,7C[_PM]5_^2*/^&5O"O\ T,7C[_PM]5_^
M2*V%^-L>[2;D^&-7&AZO>)8V&JCRBDCMNVLT>_>B':<,1W' KF/#_P ;-1MP
M;KQ2EUI<<6HZG"EO!%!.+J.%U6./*MD."X Q]XGG IWK=P]XO_\ #*WA7_H8
MO'W_ (6^J_\ R11_PRMX5_Z&+Q]_X6^J_P#R16MJ?QR@\.V=\VN>&M7TW4+>
M.&>/3AY4TMS%)((U:,JY4D,0&4D$?3FNC\)>//\ A(]6U+2+W2+O0]7L525[
M6Z:-]\3YV2*Z,5(X((Z@BI<JJ5[BO(\"^/?P7T[X6_#F;Q)H'BCQQ#JMGJ%@
M(FN/&&I3QX:[B1@T;S%6!5B,$=Z^J*\7_:^_Y(7J?_80T[_TMAKVBIG)RIQ;
M[O\ 0&[I7"BBBL" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9T[_D\
M#7?^Q)L?_2VZKT[Q5X;C\5:2;)[R[T^19$FANK&7RY8I%.58=B/56!!!((KY
MH^+W[0W@C]G?]JNYU'QQJ,^FVNI^#[2"U:"TDN-SI>7)8$("1P1UJ;_AYK\
M/^AHO_\ P3W/_P 17:Z-67+*$6U9=#7ED[-(]>OO@3I'B'S3XDU"^\1?:I!+
M?1W0CCCO-J;(E=8T4!8^64+CYCN.2 1))\&]UF]D/%FN_8+JW2UO[>26.3[7
M&J[!EF0E"4PK%,;AUYYKQW_AYK\ /^AHO_\ P3W/_P 11_P\U^ '_0T7_P#X
M)[G_ .(I^QQ/\C^X.6IV/=_$OPY;5]5T74M+UJ[\/WFE6\MK"UM%#*IB<)E2
MLB-TV+@BJ0^#]C#;1S6^JZA#X@CNWOO[=+1O</*ZA7W*5V%"H"[-N %&,8KQ
M7_AYK\ /^AHO_P#P3W/_ ,11_P /-?@!_P!#1?\ _@GN?_B*7L,3_(_N#DGV
M/8[CX*6%Y:V]O<:M?3J=074[]Y(X&>^N%8,CLWEYC*E0!Y6WY>.E7=#^%D7A
MW5(7L=:U"#2()FGATA!$(E9B25,FSS"F22$+8Z>E>'_\/-?@!_T-%_\ ^">Y
M_P#B*/\ AYK\ /\ H:+_ /\ !/<__$4>QQ.W(_N#EGV/>O%W@&;Q'K^E:W8Z
M[=Z%J6GQ30));PPRJZ2;=P99$;^Z,$8K-U;X.6/B76)=0US4[S5)&LC91C9#
M"80Q5F97C0,3O16 8D*1P.:\7_X>:_ #_H:+_P#\$]S_ /$4?\/-?@!_T-%_
M_P"">Y_^(H5#$K:#^X.6?8]MG^%1UC3;JSU[Q+J^N+(L8@>4Q0FU9&W)(@C1
M09 <?,V<].G%9MQ\#+?6-6;5-=\2ZOK=Z8XH/WX@CB$<<AD"B-(P.22&/4CT
MKR3_ (>:_ #_ *&B_P#_  3W/_Q%'_#S7X ?]#1?_P#@GN?_ (BCV.)6T']P
M<L^QZ\OP1@\S1X#XEUDZ)H]ZE]8Z2&B$4;J6VHS[-[H-QPK-QQSQ5B[^".@Z
MA&L=S/>2QK/>7 7S%4A[AE=F!"Y!1D4J>W?->,_\/-?@!_T-%_\ ^">Y_P#B
M*/\ AYK\ /\ H:+_ /\ !/<__$4>QQ/\C^X.6IV/9IO@W;ZIYLVM:[J6LZ@P
MAC2\F$2/%%'()!&H1 O+#YF(R?45U%MX3M;7Q=>^(EEF-W=VL=H\9(\L*C$@
M@8SGGUKYQ_X>:_ #_H:+_P#\$]S_ /$4?\/-?@!_T-%__P"">Y_^(I/#XE_8
M?W!R3['H/[7W_)"]3_["&G?^EL->T5\,?'#]NKX/?%_P%_PB7AG7KR\US4=2
MT]+:"339XE8B[B8Y9E ' /4U]SU%2G.G"*FK:O\ 0F47%*Z"BBBN8@**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pgen-20201231_g12.jpg
<TEXT>
begin 644 pgen-20201231_g12.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &_ ;P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BDS10 M%)10 M%%)0 M%)10
M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7XW_ /"!UW_Y"KTO;1MH]T-#S3_AH7PM_P! OQO_ .$#KO\ \A4?\-#>%O\
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MBEJCH****YC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%M[291MBC4*H(/H/J*\!^#=^;744C;*E7P0>O6O;-<?['KVEW0Z>:%S[$?\
MUA7YI@*DJ&:T[O1NWWZ'W->"JX*6FJU^X^OM'N/M%BCYSQ7RU^VUJ+/9>&M/
M'*S7YE/K\B$?^SU]'>"KP7.BQMG/RU\J?MB73W/CCPG9]4"S2GZ[E']*^_S*
M7)AJC\CY#!1YJ\4=U\(8?L7P_=\8R#_*LGX4WDD_C;5-I^3SP/\ QT5T/A&/
M^S_AJAZ$QDU@_ V RZQ?SL.6N&/ZFODN'8\V*YNT7^+1]'FCMAVN[7X(Y/\
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MO+>3RXUZMM0%C] ":IR?$SPY'XH\/^'CJ.-8UZSFO].MO(D_?P1!#(^[;M7
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MX@?$:VT6S=IM%T3]_<,QSYLF25W>I9\L?7!KZ,\%Z3]ELQ*P^=AF@#IZ***
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M^*-!M?"OAO6X->UB;5+)I&TX>=!"B3J[;Y1\N<*1@$_A7NWQ0_8T^$LE]?\
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MLBO./8%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS3RGNQZ>P':NZ>&A*UM+%N"/HS]IK]MZ^^.4T.E>'M#72-!MY?-2:\ >YF8
M@,<<(.3\H)]R:^?[B_OM68/>W,EPW^VW ^@Z"H;>S6/&!5Z&'VK>$%35D6E8
M@CMZM1P>U6(X:L1P^U: 01V]3K#QTJQ'#[5.(?EHU*U)/!UOYGB9!CHG'YBO
MT*^!<)L? ]S-G;D?TKX*^']OYGB)N.Z#]37Z!_#N+^S_ (8NYXW*Q_2OR+B2
MHWCFOY5^A]/ET?W'J_U/A+]I*^34/C-+$H^:"VC5CCJ69F_K7.6]O^['%7?B
MI<'5/C/X@<\B*2.(?@@/]:FM[5B@ 6OT3*8<F HKR7XJYX6*ES5Y>K*JV_M5
MJQGN--N%GM)Y+69>1)"Y5OS%6EL9/[M+]E*]5->H<NIWOAOX[:OI(2'5HEU2
MWZ>8,),/QZ'\?SKP[Q]XJD^,7Q@EN[;S&L49+*SC<8*H#\QQZEBQ_*NEU:.5
M;*<PC,WEML'^U@X_6O)O!>I/X;O1)(#;WL#$[9!@AOQJZ48\]SYS.)RC348K
M<^CM1UB75OBWX!\.V:G[-HEQ#=NJXQB(A_Y(!_P*OTA^&_B:S\06:&!]DX'S
M0/\ >'N/45^6'P'\66>G^,+W6M:$K?; ((KO[PC&[+$CK@D*,C^[7W3X0U!4
MM[:\LKA71@'CFA?((]017%BUSRMV-,MHNG1YI;RU_P CZF63I3]]</X1\=QZ
MLJVU\RQ77 67H'^OH?TKL-V#7EM-:,](M!J7=5825(KU($]%1AJ<&H =1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )TKYJ_:>_:>C^'L4_ACPQ<)-XFD7;<72C<M@I'Y&0CM_#U/85M
M?M1?M#0_"70CH^DR*WBK4(\Q #(M(SD>:WOP0H]1GH.?SRO+YYI)[R\G9W9F
MEEFF;))/)8D]37?AZ'-[\MC:$;ZLFO+]YGGO+RX9W8M)+/,V223DLQ/4UYKX
MJ\<S:LSVE@S0V71I.C2_X"J'BKQ9+X@G,$!:/3T/"]Y#_>/]!63##[5ZQOJ+
M##TJ]#![4L,/2KT,/M0&HV*'VJW'#[5)'#ZU:CA]J U(HX?:K$</M4T<53I%
M1J&I"D-2^7\AJ=8?:GM'B,\5))L?#&U,FNL<<&0 ?@*^][1?[/\ A5".FZ+/
MYU\/?"&U\S5D.,[I"?UQ_2ON#QA(--^&UNO3$()_[YS7XKG<_:8ZIY:?DCZ_
M QM1CZ_\$_/&Z;^U/B)XCN7(<M?R 'V#8'Z 5VUC8HRKQ7G_ (5C-UJ-Y<9R
M9+AWS]6)KT2R+QX[BOU_#P]G0A!=$E^!\I5ES3<N[-"/2U8=*=)HJL.E6[.X
M# 9X-:T*JZUJ9GFGC*W70]%O;]AD6\9?'J>P_/%<!86,>KZ'INFR11W45J'N
M;EV4$M<S$$\^RJH_&O>]>\-VGB#39K*]@6XMI1AXSD9P<CD>X!K L? ]IHMJ
M+:TB*0J2WS$L23W)/6FI631P5</*M6A-OW8WT\SB=-TE+6-$1 BJ,!0. *]'
M^'/Q+U+X>W06,FZTMVS+9L>/=D/\+?H>]9=SH_D\JO%9LEN5SQ19-69W^1]J
M>$?%FG^*M,BU#3;@30-P>S(W=6'8U[!X/\8?:$2SO9/F&%CF8]?8_P"-?G1X
M'\;ZCX!UE;VR;?$V!<6K'Y)E]#Z'T/:OK[P7XNLO%NCV^IZ?*6ADZJ?O1L.J
MM[BN&K3Y?0SE$^C1)V/6GJ]<AX3\1?;H4M9F)G481O[P]*Z99JXFC NK)4BO
M5-9*E5J@"TK4_(JLKU*K4 2T4T-3J "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH :*XCXP_%+3_ (1>![[7KXK)(@\NTMB<
M&><@[4'MQDGL :[9V$:EF.T 9)/05^:W[57QF;XK?$.:WLIR_A[2&:VLU4_+
M*P/[R;_@1''^R%]3710I>UG9[%QCS,\Q\6>+-3\<>)+_ %S5[AKK4+V0RR.>
MG/10.P P .P KR3QMXH.I3-I]H_^BQG]XR_\M&';Z"MKQMX@.EV0L[=L7=P"
M,CJB=S]3TKA[&P+8R*]WX=$=6HVVMRV,"M6WLF..*OV6E]/EK9M],Z<4$F1#
M9-Q5N.U9>U;D6F^U3KI_M2N!BQPX[5;CBJ\UCCM3%AV]:>I6I''%4ZQT](ZF
M6.C4-2-8Z)%_=GZ595*AO!M@;Z4@U-GX:Z)XMU34@/#EY9VDF_\ =_:X2X8Y
M]O>O6?BMXP^.'@?PBJ>*[/0-5TED6*2XLU99(MPP> %^7)ZX-97[.\\5KK%D
M[N$ =22?PKV']K37K9_AU?PK(LH, &T>I88K\=K8N-?,7&<$TY)6MJTWW/JJ
M=)QH7BW=)_D?)G@;0S%:1_05W,.GLO;BL3P2Y6RCR.PKN+55<5^N/8^3,N.U
M*]L5<@9XB.XK4%FK#I3&LBO:IN Z"0.!4C0*W2JZQE.15B&3CFD!0NK$,.E<
M[J&G;22!7:2*&%9MY:A@>*: X6:WP3Q74?#+XA77P\UY9LM+ILY"W=N.<K_?
M4?WA^O2L^^L]K$XXK(N(<56DE9@?=^@ZS#?6MM?6<ZRP3()(I4/#*>0:]0T?
M5QJ-JKDCS5X<?UKXB_9Y^(S:7J \,WTG^BW#%K-V/W).I3Z-U'O]:^I]!U1K
M2X0@_*>"*\VI#E=C&2/2HYO>K"29K'BN <$'(/(-6XYJY[&=C45ZD5ZHQS58
M1Z0BXK5(K545JF5J@">BFJU.H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***2@#P/\ ;"^+A^''PSDT^QG\O6M<W6D.W[T<./WK^W!"
M@^KY'2OS>N+I+.WEGE.(XU+L?I7L7[5GQ+;XD?%_5'AF\S2]+)T^S"G*E4)#
MN/\ >?<<^F*^=_'-\?+M].0\R_O9?]T'@?B>?PKWL/3]G37=G5%<J.79Y=:U
M*:\F'S2-D+_='8?@*Z+3=,X'RU!H^G9V\5VNEZ7P.*V;&5[+3/E'%;%OIG3B
MM>RTOIQ6O#I>%'%9\P'/)IN.U.^PX[5TW]G_ .S4<EEM[47 Y:2S]JHS6^WM
M73W%KUXK+NK?KQ5HK4QU2I56G[,,13E6J ;MJ.YA\R(BK%% %+2?%VI>%9E-
MM#YFW@,#6CXG^(&M_$.U@L+B$P6X<-)DY+8Z"B&U21AD9K9T^PBCP0*\7^Q\
M'&LL0H>\G?KN=7UJMR>SYM"[X<L?LUJB^U=/;*1BLRU4*HQQ6O;]J]1G&:%O
M(> :N; ZU1AJY"^VLP(9;?&34#1[>16F0&7FJTL>* *ZMN%1S+N6GNNTY%-9
MN* ,:^M]P-<]=0[2176W2@@UA:A#R3BJ0'/[GM9DEB<QR(P977@J0<@BOL7X
M2^.E\;>$[6]9A]LC_<W2CM(.I^A&#^-?']S'7H'P#\8'PWXT6PF?;9ZF!"V3
MPLHSL;^:_C45(\T1-71]PZ#J'G0>6QRR\C)[5MQS>]<#HU\89E(/U%=?#.&P
M0>.U>8T8&U%-5R*:L6*6KL,U3J!K*U3*U4(I:M(]207%:I%-55:IU:H EHI
M:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KS_XZ^.A\-_A3
MXBUU9-ES#;&*UYP?.D^2/'(Z,P/'. :[_)XKY#_X*$^,FL_#7AOPS#+AKVX>
M]N$4\[(P%3(]"SM_WQ6M&//442HJ[/B&/,TVYV)).69CG\:X&28ZUK5S==59
M\)[*.!^E=AK%R;'P_>S*<.R^4A]VX_QKG?#MF#LXKZ$ZF=)HNG?=XKN])TOY
M5XK+\/Z?NV\5Z)H^EY4<5A)B*]GI7 XK2CTW Z5NVNEX7[M638[5Z5E<@YB2
MRVCI5*XM?:NHN+7 -9-U#C-4BSEKJ#&:QKR/K737L?6L^#0[S6IBEI"7 ^](
M>%7ZFMHC1R,J[7-(JEFPH)/H!7KWA?X(S:Q,&9);YA][R_DB7ZL>OZ5ZQH7P
M-M-/1?-:&W]4M4R?^^C6PSY7@T+4;I5,5C.RL,AMA /XFIF\*ZN/^7&3\U_Q
MK[.L_A+IZJ"MA).?[TS'!_E5O_A4]GM_Y!EJ/]ZEJ!\60^'-3A4%K*3\,'^5
M7H8);? EB>,]?F4BOKJZ^#]G(IQI]N#_ -,W*USFJ?!L*I\I)XO;(D6DTP/G
MVV;I6G;OTKLM:^&5S9LQ%N) .K0_*W_?-<G/I<UHQ ^<#J,88?A6;5MP+4+U
M95JRHIL=:M1S].:SL2:224V1JK+-[TXR;JFP#9*K/\N:G9JJRM3U AFYK)OE
MW*:T)).M9]TWRF@#$NEK.,KVTR31,4DC8,K#J&!R#^=:=QUK+N*LK4^V? /B
M=?$_AG3-40@&XA#.!V<<,/P8&O2-/O!)"N.W%?+_ .S-XA-QH6HZ4[$M:3B5
M ?[CC_XI3^=?1&CW1*[,9_S_ /KKS:D>5M&$D==#-FKL,M8-O/[UI039Q6#1
M!M0S5>ADK%ADJ_#)4,#41JGC:J4;YJPC4B"VK5)4"-4JFH =1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )7YP_MT>(FUCXY3V +F/2K*"VVL?EW
M,OFDC\) /PK]'CTK\FOC[K":Y\:_&5W&YDC?5)D5CZ*VP?HM=V#C>;9K3W/*
MO&LNVQTZUSS)(92/8# _F:L^&[7[O%9OC!S)KEG%U6. $?4L?\!71^&8?N5Z
MS-CT3PW8YV<5ZAH>E[HU.*X;PQ"/DKU30@HA KEDR66%T\(O2J]Q;A<\5NL!
MLQ6?=+UK)".<NX>M85XO6NEO>]5;'3WENX4BA-S?3,%@@ S@GHQ'<^@_&MXJ
MY2,C3/";7UQ%]HCD=Y2!%:1C]Y)GIGT'ZU[AX/\ A#';0PS:NB_+@II\/$:?
M[Q'4^W\ZZ;P#\/8?"\*SSC[5K$P_>3'G9GJJ_P!37I%AI:P .^&E_0?2NC2*
M*V,*P\-A8D38MO HPL:+C'X=JU[?28;?[D8!]3UK66'VJ18:S=0GF,W[*?2F
MM9^U:_D^U'V>E[47,8C6?M5>2R'I70M;U#):TU40^8Y*]T6&\4B:)9!_M#FN
M!\6_"BSU:-G@!2;'!Z'\#_C7L4UKQTK.NK3KQ6RDF5<^-_%G@^\\/W#+<1D#
M.!*!C\#7,><8FVMP:^Q?$OAFUUJV>&YB#J1C..17S/\ $CP!<>$[DR*I>Q8_
M*_78>WX5+CV&<NEU[U,MS[U@_:C&VTGFI4O/>HL!M>=GO4$TG!JDMUQUIDEU
M\M385ATLM4+B3BEFGJE--181!<-FLVX[U;F>J,S4RM3T/]GW6#IWQ %N6 2\
MMWB.>[###'Y&OK/2;K:PR37P_P##O4&T[Q]H,ZMM_P!+1"?]ECM/Z$U]GZ;-
M\P!Y_P :Y:RUN92W.TMYNE:=M-TYKG;6?IVS6I;R]*XVB-3H89:OP25B6TW2
MM*&2LB39ADJY&U95O)6A"U22RXC585JJ(U6$:H$3T4U:=0 4444 %%%% !11
M10 4444 %%%% !1110 4444 ,/W:_'3Q?J0UCQEK5^%V"ZOIIPOIND)Q^M?L
M6?NU^,5]G^T)\]?-;^=>E@?BD;4^IR7B!MWBR?N D8_\=%=GX9_@KA]:;_BJ
M[K/^Q_Z"*[3PT_W*]&1J>N>&V"[:]'T>?:@&:\N\/S<+7?:;<?*.:YI$'7K/
MN7K5:XD&*J1W7R]:BNKH*I). .:BP%2]N%CRQ ;^ZI[G_"O6OA#X-&FV?]NW
MREKZZ&80PY1#W^K?RQZUYAX'T4^+O%%M!(";5#YDO_7,=1^)P/QKZ>T.V6XN
M-^T"&#A5 XW8_H*[8KEB:;(V-+L/)7S)!^]8?]\CTK4CCID2U;C7I7+.1FV+
M#;F3Z5;6U4=>:FCCVJ!4JK7#*HS.Y6-H.WY5&8<=JT OM221U*FQ7,\PU&\/
MM6@8Q4;15:F.YE20=:H7%O[5NR1^U4YX:ZH5"TSEKRUSGBN1\4>'[?6K&:UN
M8UDC=2,,*]!NH?:L'4+?KQ7H)W1LCX<^(GA6X\':U):.&,39>"0_Q+Z'W'^!
M[UR4>H=LU]7_ !J\#CQ5X;G\E,WUN#+ V.2P_A_$<?EZ5\97ET89N> W;T/>
ME;4#IEO_ 'IS7V[O7+QZA_M586^SWI<H&W)=9[U!)-[UG?:L]Z:UQ[U-@+$D
MO6JDTG6D>:JTDG7F@"SI,QCUO3G4X9;F,@_\#%?;VFW&V93Z-G]:^%;%R=4L
ML=?/CQ]=PK[7T^8Y7)YS7-6Z$2.VM+C(4^PK8M9LXKE[&;Y5K;LYNG-<31D=
M';2]*U;>3I7/VTE:]K)TK)DFU ]:,#]*QH6Z5I6[=*A@:<;=*L1M5.)N*M(>
ME0R"RIJ2H4-2KTJ0%HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;VK\;_
M !AI_P#8WB[6K#=O^RWLT&[UVN1G]*_9"OR5^/FCQZ%\:?&=G$I6-=4G90QR
M<,Y8?^A5Z."?O21M3W/%/$$FWQ5,>S)&1_WR*Z[PY/\ <KD/&&8];M),\/#M
M_)C_ (UM^'KG[O->FS4]@T*Z&%YKN--NOE'->7:'=?=YKM=-O/E'-8- =O%=
M<=:H:Q?%O*MU/S3-S_NCD_T'XU2AON.M5+>X^VZY.V<K;Q+'UZ,Q+'] GYFB
M,?>0(]P^#U@-/T2\U)E'F3OY:>NU>WXL?TKWG1+7['8PQ'E@,L?5CR:\C\#6
MZPV/A[3\8W@2NO8X^8_J:]EM3TKHEL-FE"M7(EJG&ZHN6( JS#=)T )KSY7,
M6:J#-2JM5K>=6 '2KBUP2NC-BJM#+Q3Z7;69)#Y-,:.K.VF,*:D.Y1D3-5)T
MV]:T)!Z51N%ZUTP92,FZ4<UAW\?6MN\7O6/</NW*>2*]:GL;Q.1U: -N!&1T
M-?"7Q[\.GPIXXU&)%V03G[5%CIS]X?GG\Q7WMJJ]:^4/VP-'5;71=54 -O:W
M<CK@@X_+8/SK8L^;H-1]ZNQ7V<<UQD-\4D9<\J<5IV]]TYK:432QU4=Y[U*+
MC/>L"&ZZ<U;CN/>L6B6:;3^]123>]5?.IC3>]1J2:&D;IM<TZ-.6:YC _P"^
MQ7VCILVZ11GJW]:^./A[;F^\=:)$,<7*R'/3"Y8_RKZXTN;#+SSBN:IT(D=I
M8R_*HSZ5N6<O2N7LI/N\UOV<G2N-F1TEK)P*U[62L"S?@5L6K=*R8F;L#=*T
M;=NE9%NW2M*W;I6(C6@:K<9JA;M5Z.I(+,9J9:KQFK"U #J*** "BBB@ HHH
MH **** "BBB@ HHHH **** $'%?FU^W/X=.C?':ZO0K"/5;.WN@2N%W*OE$#
MU_U8/XU^DU?'/_!1#P:;K0?#'B>&(DVL\EC<, 3\K@/'GL "C_\ ?0KJPLN6
MJO,TI_$?GGX\C/V6SN /]7(4)QV(_P#K?K3- O/N\UL>(K/^T-%NX0,OLWI_
MO+R/Y5Q6AWV-O->XSIU/8-%O.%YKL].OOE'.:\KT:_\ N\UV6FW_ ,HYK-HD
M[V/4/DZU/X3/VB34IMV2UT5_!445R\=]\G6NA^'\@DL;TYR?MDF?R6B*LRM3
MZE\#R%O$5A&3D1V /T/2O4_MR6JC/+MT6O$/!FL1V?BBS9V&UM-R/<@]*]&L
MKYKJ4R.<LWZ>U; =?;S-,VYFR:V+7J*YVPEZ5O6;]*YZBT(D:\':K\+<#-9U
MNW2K\?:O*J&#+BTZF1GBGURL@*C:I*8>:$!7D[U2N.]7IN]4)VX-=%/<M&3>
M=ZYZ\;RY,]L\UT%X:Y[4F^4U[%'8WB8FK?=-?.O[65L)OA7+* -T4PD+'T#I
M_P#%5]$ZHP:'=[5\^?M52!?A%?AC@LK8_P"_D7^!K<L_/R:\\N_G7/\ &?\
M&M*UO.G-<G>7.-5N!G^/^E:=E<9QS77;W4;=#L+>ZZ<U?CN*YRUGX%:4,W%8
M21#-@34C3526;BD:;WK @],^!]F;KQA)=$92U@8]/XF(4?UKZ8TMMS#->%?
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M88HP^^%W4-E"1@Y! /%?:U)BIMI)/[2L-OX?[KNO78^$_P!@W]FWXE_"_P
M?$WX0?%CPXDOP^OI95TJ^&H02I=1RAHIU5(Y&>-74(XW*I!9NYKS[P?^S3^U
M9^Q-K&L:?\#YM!^)?@+4+EKB+1]<DCADA8@#>ZO+#M? "DQRX;:"5' 'Z6M^
M5+5.[E>_2S\["TU5M+W]&?G=^SS^S9^T#XL_;*M/CU\7]&\.^$WAMI+:;2]/
MNQ([C[*T$?EI&\R@#()+2YX.*]$^$7[/?C[PO_P47^*OQ1U/11;>!M;T<6FG
MZI]K@<SR[;(;?*5S(N/(DY90./<5]F;1UI?Y52ERM-+9-?)[DM<R=^K7X'YJ
M_P#!0K]AOXD?$3XA7_BSX/:7'JMOXMM(;7Q-I(O+>U+36\B/#<#SG13D(BG!
MW J>#O-?>GP9\+WW@OX0^"O#^IJB:CI>BV=C<K&VY1+' B. W<94\UVW2CBI
MC[D.1;7N.7O34WNE8\A_:1M?BS+X#@G^#5YI$'BRSOH[B2UUM UO?6P5P\&2
M/E8L4((*_=QN&:^%/C%\$?VR?VTH]%\)?$CPSX2^'?A6QO!>275G=1NDC@%
MY5+FXD=E5WVK\BG=R1P1^HQ%,9#GVH25[O7KJ7S.VFFECX>_:V_8)O\ XA?!
M'X;Z/\.-0CMO%?PY@2'2GOG\L7<2I&&4N!A)"T2."?ESD' .1Y1XH_9S_:E_
M;,\0>$=%^..D^'_ O@70+H7-T=+N(I)K\X"LP6.>;]X5!4$F-5#L<'I7Z:M'
M4;)5QE[S;UUO9]^Y%M$EI96OUMV/A?\ ;*_9%\?^(/BMX)^,?P7-B_C+PQ#%
M:MH]Y(L27,<3,8]C,0I^5W1E9ERI&"".>1\#?LR_';]H?]HCPK\3_C_IVB>$
MM.\)%'L/#^DS++YTJ/YB$!)9@JE\,S-(2=@4* <C]$VCJ)H:</<:EO9MKRON
M-VDK;723\TMD?G_^T3^R_P#&+P5^T\OQV^!=MI>O:I?6XM]2T'4IDB#L(A$Q
M^=XU:-E1#Q(K!ER,@\3_ +/O[+WQ:\8?M(CX\?'-=*T;7+2V-OIGAW29!((#
MY;1 L59U"!7<@"1V+/DD8P?O1H/:HFM_:G#W+>5[>5^PY>_?I>U_.W<QYK-)
MHGCD3<C@JRGH0>HK\Y=!_9B_:0_8Y^('B:Y^!MGH7COP;KLWF+I>K3I&T !)
MC\Q9)H<.@9EW)(0P&6 X _2YK>F-;TK:\R=GMZKS+O>/*_7YGP+\"_V3_BUX
M\_:,M/CA\>9]+L-5TZ/9IOAW39%D$+!65 Q0LJHF]F #NQ8Y)&.>F\8?L^>/
M-4_X*+>#OB?:Z&)? MAI9@N=5^V0#RY/LUS'M\HOYA^:1.0I'/7@U]I?9_:D
M^S_YQ5Q:BX\NEKV^>Y#C=2OU5GZ'P+^U-^SG\9;']JCPW\;?A!HVE^)[ZTLU
MMY=/U"YCB$<@CEB8NLDD09&CD'W7# YXJU^UG\ ?B]\<+?\ 9]U2+PY9WVOZ
M'<_:O$T=C>00P6<CM:L^SS9 74&.3A2QX[YK[P^S_P"<4OV>IC[JBNSNO\BG
MJ[]U9^A\W?MQ?LZ:O^TE\"KKPSX?NH;;7+6]AU&SCN7*13O&'4Q,V#C*R-@]
M-P7.!R/CCXJ?L^_M>_&[X)Z-X)UKP-X7T71/"YM_L6DZ;>6L-SJ#HAB60MY[
MQ+L1G)&Z(')PI. /U;6WIZV]3RKWNS:?S&YOW>Z37R/D?]J+]B^;]I3X#>$=
M$CNX-#\;^&[2(V-Q<?-#O\E$E@D9,D*Q1?F7."@."*\R\,:M^WSX=T>U\*?\
M(7X/U%+9!:IXIU"[@DF91PLK;;H;B!CDP9/<$U^A2P>U2K#5-W;?=W:Z7,XI
M1BEV5D_(_/;XF?LD_%/]H[]I#X7I\5='AU3X<^&]!AAUK5+74(H8M0OS#ON3
M''$Z3('F\M,A$PL>1CBNP^-?_!+?X/:C\*/$\/P]\$?V7XV^Q.^DW!UF\<?:
M%PRH1-.T>'QLRPP-V>,9K[>6,5(L?X5$DI)I:7UT]2E)\RD];6WVT/S@\2?L
MW?'+QQ_P3ETSX7:KX//_  GNBZM%%;Z>^JV3&:QCD+1OYHF\L;5?9M+@XCZ<
MBO7OB;^R/J_Q3_8!\.?#74=.AA\>:#H=G)8P--&1#J,$0!B\P'9AAOC+9V_/
MG.!FOL54IZQT2]Y27\S3?JE8F/NN+[)_B>#?L3:'\2/"W[/?ASPY\4]%;1O$
M^AAM.16O(+HSVL>/(<O"[KD(0F"<_N\]Z]\6.G*M/VTYR<FY=63%**LMCX?T
MW]F_XAV__!3S4?BT^@8^'TVGB)-7^VV_^L_L](=OD^9YOWU(SLQWS7W!QNI*
M7;\U0M(J/1*WZE/63EWM^5AU%%%, HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DVTM% $;+3&2IZ;M
MH K-'3&2K16FE* *ICIC1^U6S'3/+JP*ICIODBK>PTA2E<"IY-)Y-6_+]J39
M[4P*ODTODU9V>U+Y?M0!7\H4Y8_:I_+]J78:5P(1'3Q'4HCIPCI@1*E/6.I0
ME.5:@!BI3U6G;:6@!-HI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"DVBEHH ;MI&6GT4 1[:394M)M% $7ET>7[5+M%&T4 1>7[4>74NT4;10!'M
MI=M244 ,V^U+MIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pgen-20201231_g13.jpg
<TEXT>
begin 644 pgen-20201231_g13.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!,17AI9@  34T *@    @  @$2  ,
M   !  $  (=I  0    !    )@       J "  0    !   &CJ #  0    !
M   #)0    #_X0DA:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP
M86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y
M9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM
M<'1K/2)835 @0V]R92 U+C0N,"(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B+SX@/"]R9&8Z4D1&/B \+W@Z
M>&UP;65T83X@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD
M/2)W(C\^ /_M #A0:&]T;W-H;W @,RXP #A"24T$!        #A"24T$)0
M    $-0=C-F/ +($Z8 )F.SX0G[_X@T824-#7U!23T9)3$4  0$   T(87!P
M; (0  !M;G1R4D="(%A96B 'Y  !  @ "0 & !UA8W-P05!03     !!4%!,
M                        ]M8  0    #3+6%P<&P
M                                             !%D97-C   !4
M &)D<V-M   !M    >YC<')T   #I    "-W='!T   #R    !1R6%E:   #
MW    !1G6%E:   #\    !1B6%E:   $!    !1R5%)#   $&   " QA87)G
M   ,)    "!V8V=T   ,1    #!N9&EN   ,=    #YC:&%D   ,M    "QM
M;6]D   ,X    "AB5%)#   $&   " QG5%)#   $&   " QA86)G   ,)
M "!A86=G   ,)    "!D97-C          A$:7-P;&%Y
M
M                                ;6QU8P         F    #&AR2%(
M   6   !V&MO2U(    6   !V&YB3D\    6   !V&ED       6   !V&AU
M2%4    6   !V&-S0UH    6   !V&1A1$L    6   !V&YL3DP    6   !
MV&9I1DD    6   !V&ET250    6   !V&5S15,    6   !V')O4D\    6
M   !V&9R0T$    6   !V&%R       6   !V'5K54$    6   !V&AE24P
M   6   !V'IH5%<    6   !V'9I5DX    6   !V'-K4TL    6   !V'IH
M0TX    6   !V')U4E4    6   !V&5N1T(    6   !V&9R1E(    6   !
MV&US       6   !V&AI24X    6   !V'1H5$@    6   !V&-A15,    6
M   !V&5N054    6   !V&5S6$P    6   !V&1E1$4    6   !V&5N55,
M   6   !V'!T0E(    6   !V'!L4$P    6   !V&5L1U(    6   !V'-V
M4T4    6   !V'1R5%(    6   !V'!T4%0    6   !V&IA2E     6   !
MV !$ $4 3 !, "  4  R #< ,0 T $@  '1E>'0     0V]P>7)I9VAT($%P
M<&QE($EN8RXL(#(P,C   %A96B        #SV  !     18(6%E:(
M &82   TH    A1865H@        ;!8  +SH   .\UA96B         DK@
M#G@  ,(F8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ V #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M       #     F9F  #RIP  #5D  !/0   *6W9C9W0          0 !
M      $    !          $    !          $  &YD:6X         -@
MI0   %8   !4    G8   "5    .    4$   %1   (S,P ",S,  C,S
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_]#^_B@#^8[]B7]K
M_P#X."/V\_V8OAG^U?\ "#0O^".?ASX=?%7_ (3/_A'M&^)&F_MJZ/XTL_\
MA!OB#XK^&VK?VSIWACQ3XPT.W^T:YX/U.ZT[[#XBU'S=)GL9[G[)>2SV-K^D
M9SE/ F1YEB<KQ<^+JF(POL?:3P\LGG1?MZ%+$0Y)5*5&;M"K%2O3C::DES)*
M1]9C\#PUEV+JX.O+/)U:/L^:5)X"5-^TI0JQY7*%.3M&HD[Q7O72NM9?56?^
M#E+^[_P0Z_\ -]/_ (Y7E_\ &N_^JT_\P9Q_\8K_ -5!_P"8X,_\'*7]W_@A
MU_YOI_\ '*/^-=_]5I_Y@P_XQ7_JH/\ S'!G_@Y2_N_\$.O_ #?3_P".4?\
M&N_^JT_\P8?\8K_U4'_F.#/_  <I?W?^"'7_ )OI_P#'*/\ C7?_ %6G_F##
M_C%?^J@_\QP9_P"#E+^[_P $.O\ S?3_ ..4?\:[_P"JT_\ ,&'_ !BO_50?
M^8X,_P#!RE_=_P""'7_F^G_QRC_C7?\ U6G_ )@P_P",5_ZJ#_S'!G_@Y2_N
M_P#!#K_S?3_XY1_QKO\ ZK3_ ,P8?\8K_P!5!_YC@S_P<I?W?^"'7_F^G_QR
MC_C7?_5:?^8,/^,5_P"J@_\ ,<&?^#E+^[_P0Z_\WT_^.4?\:[_ZK3_S!A_Q
MBO\ U4'_ )C@S_P<I?W?^"'7_F^G_P <H_XUW_U6G_F##_C%?^J@_P#,<&?^
M#E+^[_P0Z_\ -]/_ (Y1_P :[_ZK3_S!A_QBO_50?^8X,_\ !RE_=_X(=?\
MF^G_ ,<H_P"-=_\ 5:?^8,/^,5_ZJ#_S'!G_ (.4O[O_  0Z_P#-]/\ XY1_
MQKO_ *K3_P P8?\ &*_]5!_YC@S_ ,'*7]W_ ((=?^;Z?_'*/^-=_P#5:?\
MF##_ (Q7_JH/_,<&?^#E+^[_ ,$.O_-]/_CE'_&N_P#JM/\ S!A_QBO_ %4'
M_F.#/_!RE_=_X(=?^;Z?_'*/^-=_]5I_Y@P_XQ7_ *J#_P QP9_X.4O[O_!#
MK_S?3_XY1_QKO_JM/_,&'_&*_P#50?\ F.#/_!RE_=_X(=?^;Z?_ !RC_C7?
M_5:?^8,/^,5_ZJ#_ ,QP9_X.4O[O_!#K_P WT_\ CE'_ !KO_JM/_,&'_&*_
M]5!_YC@S_P '*7]W_@AU_P";Z?\ QRC_ (UW_P!5I_Y@P_XQ7_JH/_,<&?\
M@Y2_N_\ !#K_ ,WT_P#CE'_&N_\ JM/_ #!A_P 8K_U4'_F.#/\ P<I?W?\
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M/_,<&?\ @Y2_N_\ !#K_ ,WT_P#CE'_&N_\ JM/_ #!A_P 8K_U4'_F.#/\
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M?W?^"'7_ )OI_P#'*/\ C7?_ %6G_F##_C%?^J@_\QP9_P"#E+^[_P $.O\
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M_!#K_P WT_\ CE'_ !KO_JM/_,&'_&*_]5!_YC@S_P '*7]W_@AU_P";Z?\
MQRC_ (UW_P!5I_Y@P_XQ7_JH/_,<&?\ @Y2_N_\ !#K_ ,WT_P#CE'_&N_\
MJM/_ #!A_P 8K_U4'_F.#/\ P<I?W?\ @AU_YOI_\<H_XUW_ -5I_P"8,/\
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M^G_QRC_C7?\ U6G_ )@P_P",5_ZJ#_S'!G_@Y2_N_P#!#K_S?3_XY1_QKO\
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M_P"8,/\ C%?^J@_\QP9_X.4O[O\ P0Z_\WT_^.4?\:[_ .JT_P#,&'_&*_\
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MS_P<I?W?^"'7_F^G_P <H_XUW_U6G_F##_C%?^J@_P#,<&?^#E+^[_P0Z_\
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M?_5:?^8,/^,5_P"J@_\ ,<&?^#E+^[_P0Z_\WT_^.4?\:[_ZK3_S!A_QBO\
MU4'_ )C@S_P<I?W?^"'7_F^G_P <H_XUW_U6G_F##_C%?^J@_P#,<&?^#E+^
M[_P0Z_\ -]/_ (Y1_P :[_ZK3_S!A_QBO_50?^8X,_\ !RE_=_X(=?\ F^G_
M ,<H_P"-=_\ 5:?^8,/^,5_ZJ#_S'!G_ (.4O[O_  0Z_P#-]/\ XY1_QKO_
M *K3_P P8?\ &*_]5!_YC@S_ ,'*7]W_ ((=?^;Z?_'*/^-=_P#5:?\ F##_
M (Q7_JH/_,<&?^#E+^[_ ,$.O_-]/_CE'_&N_P#JM/\ S!A_QBO_ %4'_F.#
M/_!RE_=_X(=?^;Z?_'*/^-=_]5I_Y@P_XQ7_ *J#_P QP9_X.4O[O_!#K_S?
M3_XY1_QKO_JM/_,&'_&*_P#50?\ F.#/_!RE_=_X(=?^;Z?_ !RC_C7?_5:?
M^8,/^,5_ZJ#_ ,QP9_X.4O[O_!#K_P WT_\ CE'_ !KO_JM/_,&'_&*_]5!_
MYC@S_P '*7]W_@AU_P";Z?\ QRC_ (UW_P!5I_Y@P_XQ7_JH/_,<&?\ @Y2_
MN_\ !#K_ ,WT_P#CE'_&N_\ JM/_ #!A_P 8K_U4'_F.#/\ P<I?W?\ @AU_
MYOI_\<H_XUW_ -5I_P"8,/\ C%?^J@_\QP9_X.4O[O\ P0Z_\WT_^.4?\:[_
M .JT_P#,&'_&*_\ 50?^8X,_\'*7]W_@AU_YOI_\<H_XUW_U6G_F##_C%?\
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M=?\ F^G_ ,<H_P"-=_\ 5:?^8,/^,5_ZJ#_S'!G_ (.4O[O_  0Z_P#-]/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#\.?^#;G_E"Y^QG_ -W$_P#K5WQTK[3Q#_Y+#-_^
MZ?\ ^JO GT'%/_(^QW_<K_ZAX<_<:OBSY\__T_[^* /PY_X-N?\ E"Y^QG_W
M<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M\DN:7PQY7S2?DM6_DOON-1DVDDVWHDEJWY);F-X-^(?@#XBV,^I_#[QSX/\
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MS X.:^ I4:U>7)1I5*T_Y*4)5)?^ Q4G^'WZ<OST(3J.T(2F^T(N3^Y)]O\
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M  ^Z_O.<)TWRSA*$NTXN+];-1?X?=]K_ #WO^#L7]HCXM^*_V\?A]^S1IOQ
MUNW^$'@SX(>"-9M?A]I>O7-EX6OOB#XU\4>-(];\2>(M/MKI++4=<&FV.A:'
M!+JB2_V-IVGR)8QV;ZEJKZA^Y>&6 PE+),1F4\/"6*J8RM!UY4U*K&A1I4G"
MG3D]8QYG.;47'GE)7;Y8<OWG"^'I0P-3$NFG5E6FG-Q7,H0A!Q46U=*[E+3=
MN]](H_K"_P""+W[#'Q>_X)P_LJ^,O@W\??C]X4^-NIZU\9M3\<>&O$N@>(O$
MVI^'_"_AG4? 'P\\/1>"K.X\9+;3V0L=>\,Z_J45CI\4.GO#JD5ZD,-Y>7L$
M7YEQ;G.$S_,Z6+P6!J8*,<)&C4ISITXSJU(U\14]LU2T?-3J0C>5Y+D:;:46
M?+YOC:.88F%;#T)4$J*A*+C!.4E4J2YWR63O&<4V]=+:VN?L):W=I?0K<65U
M;WENQ95GM9H[B%BIVL%EB9D)5AM8!B01@XZ5\LTXNS33[-6?XGDV:W_R_K^N
MY676-(>[_L]=4TYK\.T7V);VV-WYB EX_LPE\[>JJ2R;-RA22.*?)*W-RRY=
M[\KM]^P[/L[>@S6M<T7PWI=YKGB+6-+T#1=/C$VH:QK6H6FE:78PEU02WFH7
MTUO:6T9=U0233(I=E7)8@40A.I)0A&4YR=HQA%RDWV45=MZ=%]^H).32BG)O
M9)7;]$M_Z[&#X*^(WP]^).G3ZO\ #KQWX-\?:3;3_9;G5/!7B?1/%6G6]R5W
MBWGO="OK^VBG*?-Y,DJR;?F"XY:ZM"O0DHUZ-6C)JZC5ISIR:[I3C%V\_P M
M>:ITZE-VJ0G!O93BXO\ %+\OO/X=?^"^/[ G_!5GX\?\%0/#WQ2_9XTGXA^-
M_AC?:!\+;7]GWQ#X*^)&G^&--^"&KZ/I&F67BF'4Y[SQ/H<OP\OY/'UIK/C:
M7QA)'96%_8ZUIZV^LW=]I-U8:;^Q<$YWPS@N'*N%S!T*.(53$RQL*V'E4EC(
M3E)TW"U.?MDJ+C1]E?FC*$GRJ,E*7V61X_*Z&6RI8ATH55*I[>,Z;DZT9-N-
MO=?M$H<L.5-V:U2NF?W'^ ;#Q3I7@3P5I?CG5K77_&VF^$O#EAXQUVRC,-EK
M7BFST>SM_$.K6D)B@,5KJ6K1W=Y;QF"$I%,JF*/!1?QVM*G*M5E1BX4I5:DJ
M4'JX4W-N$6];N,6D]>G4^,FXN<W!.,'*3A%[QBW[J>^J5EO]YBZI\8_A%HGB
M6'P7K7Q3^'&D>,;AUCM_">J>./#-AXEG=V"(D.A7>IPZI([N0BJEJQ9B ,DA
M:N.%Q4Z;K1PV(E26KJQHU'326[<U'ET\Y?E8I4JKCSJG4</YU"3C_P"!)6_'
M]>7T>N<S,Z;6-)MKE;*XU33K>\8QJMI->VT5RS2X\I5@>5929"P\L!<ON&W.
M:I0DU=1DUW46UIY[#L^S^XY+6_BM\+O#7B/3_!WB/XD^ = \7:M@Z5X6UOQC
MX>TKQ'J>X*5_L_0[[4;?4[W<'0C[-;29#*>=P-:0P^(J4W5A0K3I1^*I"E.5
M./K-1<5\VO78I4ZDHN<:<Y07Q349.*]7RM+[U^IWU8D!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?AS_P;<_\ *%S]C/\ [N)_]:N^.E?:>(?_
M "6&;_\ =/\ _57@3Z#BG_D?8[_N5_\ 4/#G[C5\6?/G_]7^_B@#\.?^#;G_
M )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W
M&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MO!O_ &7#XU?^GRPKG\2?^2HK_P#8)@__ $T1Q/\ \C27_7BC^3.W_P""_O\
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MD>+J97@<NJ5:&&K3IUZF$]A1HJLIOV[I0_Y?R4K\U24J?M)WM-KWY76XAR_
M5I82AAYSITIRC4E1Y(04^9\_(G_$?-\4VX\TKM72O+*_X(J?MK_M7_\ !+3_
M (*3:-_P3;_:/O/$T/PJ\=_&6W_9_P#&GP@U?54U70_AM\6_'.LZ?I/@+XG_
M  \N+EVMK#2-?U[4M"?5KK1+RU\/>,/ WB@^+);75=2T_P .W$%\7Y/EG$G#
M\N(<O5-XFCA'CJ6*A'DGB,+1C*5?#XA+5SI0C4Y>>\Z5:E[).,93C)YQ@\+F
M>7/,<.H^UA1]O"K%6E4I05YTZB2NY12E:_,XSCRWBG+F]&_X/"_^3X?V9/\
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MF(RBI!RJRQ%7][%V@O8TY:\K5[34+Q=_M:KJ?(W_  ;;_P#!./Q9\0D\8?\
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MX-J#CXW#>4T<1&6.Q4%4A"?)0IS5X.44G.I.+LII-J,4WRW4FTVHGY3?#O\
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MD>74,=5Q.9XFFI4Y8FJZ%&>L;N7M)3FM%-1YE"*;Y>92;3M$^#_AW_P:??\
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M_'A/_4#"GF<0?\C?&>M#_P!1J1_'G\'/^5J75_\ M)E\=/\ U,_B%7ZIB_\
MDV<?^Q!@O_2:!];5_P"297_8MH_^FX&]_P '5_\ REE\+?\ 9M_P4_\ 4O\
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M. .23T ]3TZ?7\JYS,_R]_VB]8U?_@N)_P %[!X&\,ZA>:I\+/&OQKTWX/\
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M,:<)2]YRJ2<%>$4*& R#"U9.M)0G+G;JR@ZE6<8V4*4(J%W;:*UW<FXIN/\
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MR=>+O_7@6M?TKHJ_\G77_851_P#5- NI_P E:O\ K[3_ /4*)_-Q_P $G?\
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M_)89O_W3_P#U5X$^@XI_Y'V._P"Y7_U#PY^XU?%GSY__UO[^* /PY_X-N?\
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M[Q9;^K9(NCKXYV\U##6^Z[Z=>AW\7?P\#_CK_P#I-+_,]M_X/+_^1'_X)_\
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M #/U._X-T_\ E#/^Q7_V!_C1_P"M'_&&OFN._P#DK,X_Z^87_P!0<*>9G_\
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MWROYYX:_\E/3\\%B_P#TF']?\,CY[AC_ )&D?^O%;\H_U_PQS7_!IK;PP_\
M!+/5Y(D"O=_M2_%RXN&'629?"_PRM%=O4BWMH(^_RQ@=@%T\36WQ*D^F785+
MTYZ[_-O^F5Q1_P C-?\ 8-2_]*J?U_PY_-[^T?''%_P=8>'5C144_P#!1[]E
M:0A0 #)-K/P?EE<@8^:25WD<]6=F8Y))K[[ ._AE/_L19DON^M)?@CZ##_\
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M &5P_.E7G'VD,-7BU?W?;8AU'&DOBYK3J*#:LG9RT3O'["_X/"_^3X?V9/\
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M#/,M3E'EPLH^VF]5#VTU?FMLX0M/JUS7L[-'SY_P:]_\%*OV;_V*O'G[1/P
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M &+<#_ZL<>;\2_\ (XP?_8/A_P#U*KGY'_\ !G]_RD2^/O\ V9;XU_\ 5Y?
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MRK&"YFC++@['9?NLP;V?$)M<(4?/$9>GYKV<G^:3Z_K'LXB?_"-3\ZF&3_\
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M.;K036SI6>\".&:L*V6U<+SI5*=2K&45\2IUE>-3T<G-)VT<;.VA_6S\.?\
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M4I<WUJ_+[2#CS6^JJ]KWM=7VNKW/Z//^"NW_ "B[_;__ .S3/C?_ .H)K%?
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MN[<T^6%91\VU1=EI=[7T1\WPS4C#-(*3M[2C5IQN[>]93MYMJ#TT_27YX_\
M!M;_ ,%3/V)/@'^P#XJ^ W[1?Q_^'_P,\=_"KXJ>._&$5C\2=;M_#T7B[P5X
MR@TC5['4O!DMQSXGU2UU:'7-,O\ PSHZ7GB&$VUE<QZ=-;:E;NOO>(/#><8W
M/*>-P&!Q&-H8G#4*7-AZ;J>RK4>>#C5M_#BX\DE4G:#YFG).+._B++,;7Q\:
M^'H5*T*M*G"].+ERSA=-3T]U6LU)OEUL[->]^/O_  3"\56O[9__  <GZ?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M94VG;ZNU=^S5_72VC/W7^('_  =??\$I/BKX%\8?#/XB?LW_ +:7B[P'X_\
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M1G9/=>WU_F6C/H'+..2RHY8I_P SQ.*<+_X/JJ?_ )/Z7M<_J!_8U_X.(_\
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M=\KS'(\TS'$?6*D\OIR]G&GRPJXEJT6VGKA[W?-Y_FH_ _C_ /;W_P"",/Q
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MK7X/?LU6K>!_#?PT\8>#_%OAO1_#&BW?[1KZ+:Z?;CP9IVBQVAMQ#;Z;)*(
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M;V%KODU_#H?OM_Q%^?\ !-7_ *(A^W)_X;7X!_\ T2M?$_\ $+.(?^@S)O\
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M[_\ 3[RZWE]+&6<<MI4<L<_YHXG%1C?_  /"R?RY_F].7^BO_@GO_P %P_\
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M *-DH)K3KK<Z<NP.<9=AGAJ:RVI%U)U.:=7%*5YJ*:LJ"6G+W^X]B_X*M_\
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MLOING#V:4*N)::<G*[<J&^MM%]]SY7_;C_X* ?\ !&3]N?\ ;1TO]M3QI/\
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MO_T^\NMY?2QEG'+:5'+'/^:.)Q48W_P/"R?RY_F].7^BO_@GO_P7#_X(3_\
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M<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "@ H
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M]8^(?^A]G/\ X<\;_P#+P_M+,?\ H/QO_A57_P#E@?\ #L+_ ()J_P#2//\
M8;_\1,^ ?_S T?ZQ\0_]#[.?_#GC?_EX?VEF/_0?C?\ PJK_ /RP/^'87_!-
M7_I'G^PW_P"(F? /_P"8&C_6/B'_ *'V<_\ ASQO_P O#^TLQ_Z#\;_X55__
M )8'_#L+_@FK_P!(\_V&_P#Q$SX!_P#S T?ZQ\0_]#[.?_#GC?\ Y>']I9C_
M -!^-_\ "JO_ /+ _P"'87_!-7_I'G^PW_XB9\ __F!H_P!8^(?^A]G/_ASQ
MO_R\/[2S'_H/QO\ X55__E@?\.PO^":O_2//]AO_ ,1,^ ?_ ,P-'^L?$/\
MT/LY_P##GC?_ )>']I9C_P!!^-_\*J__ ,L#_AV%_P $U?\ I'G^PW_XB9\
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M'B,ZS/$34Y8NM2Y8\O+AZDZ$'JW=QIRBG+6W,];)+1)<WOW_  ["_P"":O\
MTCS_ &&__$3/@'_\P-<7^L?$/_0^SG_PYXW_ .7F']I9C_T'XW_PJK__ "P/
M^'87_!-7_I'G^PW_ .(F? /_ .8&C_6/B'_H?9S_ .'/&_\ R\/[2S'_ *#\
M;_X55_\ Y8'_  ["_P"":O\ TCS_ &&__$3/@'_\P-'^L?$/_0^SG_PYXW_Y
M>']I9C_T'XW_ ,*J_P#\L#_AV%_P35_Z1Y_L-_\ B)GP#_\ F!H_UCXA_P"A
M]G/_ (<\;_\ +P_M+,?^@_&_^%5?_P"6!_P["_X)J_\ 2//]AO\ \1,^ ?\
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MYXW_ .7A_:68_P#0?C?_  JK_P#RP/\ AV%_P35_Z1Y_L-_^(F? /_Y@:/\
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MUCXA_P"A]G/_ (<\;_\ +P_M+,?^@_&_^%5?_P"6!_P["_X)J_\ 2//]AO\
M\1,^ ?\ \P-'^L?$/_0^SG_PYXW_ .7A_:68_P#0?C?_  JK_P#RP/\ AV%_
MP35_Z1Y_L-_^(F? /_Y@:/\ 6/B'_H?9S_X<\;_\O#^TLQ_Z#\;_ .%5?_Y8
M'_#L+_@FK_TCS_8;_P#$3/@'_P#,#1_K'Q#_ -#[.?\ PYXW_P"7A_:68_\
M0?C?_"JO_P#+ _X=A?\ !-7_ *1Y_L-_^(F? /\ ^8&C_6/B'_H?9S_X<\;_
M /+P_M+,?^@_&_\ A57_ /E@?\.PO^":O_2//]AO_P 1,^ ?_P P-'^L?$/_
M $/LY_\ #GC?_EX?VEF/_0?C?_"JO_\ + _X=A?\$U?^D>?[#?\ XB9\ _\
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M#?\ XB9\ _\ Y@:/]8^(?^A]G/\ X<\;_P#+P_M+,?\ H/QO_A57_P#E@?\
M#L+_ ()J_P#2//\ 8;_\1,^ ?_S T?ZQ\0_]#[.?_#GC?_EX?VEF/_0?C?\
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MU?\ I'G^PW_XB9\ _P#Y@:/]8^(?^A]G/_ASQO\ \O#^TLQ_Z#\;_P"%5?\
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M^-_\*J__ ,L#_AV%_P $U?\ I'G^PW_XB9\ _P#Y@:/]8^(?^A]G/_ASQO\
M\O#^TLQ_Z#\;_P"%5?\ ^6!_P["_X)J_](\_V&__ !$SX!__ # T?ZQ\0_\
M0^SG_P .>-_^7A_:68_]!^-_\*J__P L#_AV%_P35_Z1Y_L-_P#B)GP#_P#F
M!H_UCXA_Z'V<_P#ASQO_ ,O#^TLQ_P"@_&_^%5?_ .6!_P .PO\ @FK_ -(\
M_P!AO_Q$SX!__,#1_K'Q#_T/LY_\.>-_^7A_:68_]!^-_P#"JO\ _+ _X=A?
M\$U?^D>?[#?_ (B9\ __ )@:/]8^(?\ H?9S_P"'/&__ "\/[2S'_H/QO_A5
M7_\ E@?\.PO^":O_ $CS_8;_ /$3/@'_ /,#1_K'Q#_T/LY_\.>-_P#EX?VE
MF/\ T'XW_P *J_\ \L#_ (=A?\$U?^D>?[#?_B)GP#_^8&C_ %CXA_Z'V<_^
M'/&__+P_M+,?^@_&_P#A57_^6!_P["_X)J_](\_V&_\ Q$SX!_\ S T?ZQ\0
M_P#0^SG_ ,.>-_\ EX?VEF/_ $'XW_PJK_\ RP/^'87_  35_P"D>?[#?_B)
MGP#_ /F!H_UCXA_Z'V<_^'/&_P#R\/[2S'_H/QO_ (55_P#Y8'_#L+_@FK_T
MCS_8;_\ $3/@'_\ ,#1_K'Q#_P!#[.?_  YXW_Y>']I9C_T'XW_PJK__ "P/
M^'87_!-7_I'G^PW_ .(F? /_ .8&C_6/B'_H?9S_ .'/&_\ R\/[2S'_ *#\
M;_X55_\ Y8'_  ["_P"":O\ TCS_ &&__$3/@'_\P-'^L?$/_0^SG_PYXW_Y
M>']I9C_T'XW_ ,*J_P#\L#_AV%_P35_Z1Y_L-_\ B)GP#_\ F!H_UCXA_P"A
M]G/_ (<\;_\ +P_M+,?^@_&_^%5?_P"6!_P["_X)J_\ 2//]AO\ \1,^ ?\
M\P-'^L?$/_0^SG_PYXW_ .7A_:68_P#0?C?_  JK_P#RP/\ AV%_P35_Z1Y_
ML-_^(F? /_Y@:/\ 6/B'_H?9S_X<\;_\O#^TLQ_Z#\;_ .%5?_Y8'_#L+_@F
MK_TCS_8;_P#$3/@'_P#,#1_K'Q#_ -#[.?\ PYXW_P"7A_:68_\ 0?C?_"JO
M_P#+ _X=A?\ !-7_ *1Y_L-_^(F? /\ ^8&C_6/B'_H?9S_X<\;_ /+P_M+,
M?^@_&_\ A57_ /E@?\.PO^":O_2//]AO_P 1,^ ?_P P-'^L?$/_ $/LY_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@#\.?^#;G_E"Y^QG_ -W$_P#K5WQTK[3Q#_Y+#-_^Z?\ ^JO
MGT'%/_(^QW_<K_ZAX<_<:OBSY\__TO[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=
M*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]PW_ ('6_P#E8?\ $0C^QA_T3+]I[_PC?A5_\^6C_4W-/^?^ _\ !M?_ .9
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MM_\ *QW_ !$(_L8?]$R_:>_\(WX5?_/EH_U-S3_G_@/_  ;7_P#F0/[ Q?\
MS]PW_@=;_P"5A_Q$(_L8?]$R_:>_\(WX5?\ SY:/]3<T_P"?^ _\&U__ )D#
M^P,7_P _<-_X'6_^5A_Q$(_L8?\ 1,OVGO\ PC?A5_\ /EH_U-S3_G_@/_!M
M?_YD#^P,7_S]PW_@=;_Y6'_$0C^QA_T3+]I[_P (WX5?_/EH_P!3<T_Y_P"
M_P#!M?\ ^9 _L#%_\_<-_P"!UO\ Y6'_ !$(_L8?]$R_:>_\(WX5?_/EH_U-
MS3_G_@/_  ;7_P#F0/[ Q?\ S]PW_@=;_P"5A_Q$(_L8?]$R_:>_\(WX5?\
MSY:/]3<T_P"?^ _\&U__ )D#^P,7_P _<-_X'6_^5A_Q$(_L8?\ 1,OVGO\
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MUO\ Y6'_ !$(_L8?]$R_:>_\(WX5?_/EH_U-S3_G_@/_  ;7_P#F0/[ Q?\
MS]PW_@=;_P"5A_Q$(_L8?]$R_:>_\(WX5?\ SY:/]3<T_P"?^ _\&U__ )D#
M^P,7_P _<-_X'6_^5A_Q$(_L8?\ 1,OVGO\ PC?A5_\ /EH_U-S3_G_@/_!M
M?_YD#^P,7_S]PW_@=;_Y6'_$0C^QA_T3+]I[_P (WX5?_/EH_P!3<T_Y_P"
M_P#!M?\ ^9 _L#%_\_<-_P"!UO\ Y6'_ !$(_L8?]$R_:>_\(WX5?_/EH_U-
MS3_G_@/_  ;7_P#F0/[ Q?\ S]PW_@=;_P"5A_Q$(_L8?]$R_:>_\(WX5?\
MSY:/]3<T_P"?^ _\&U__ )D#^P,7_P _<-_X'6_^5A_Q$(_L8?\ 1,OVGO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS_P;<_\
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M_L_"U>J=P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!^U?_  05_P"3Y+G_ +(UX\_]+_#5?,<7?\B?_N;H?^DU3Q\\
M_P!R_P"XU/\ *9_:+7Y<?'A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?AS_P;<_\H7/V,_\ NXG_ -:N^.E?:>(?_)89O_W3_P#U5X$^@XI_
MY'V._P"Y7_U#PY^XU?%GSY__U?[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\
M0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _#G_ (-N?^4+G[&?_=Q/_K5WQTK[3Q#_ .2PS?\ [I__ *J\"?0<
M4_\ (^QW_<K_ .H>'/W&KXL^?/_6_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK
M[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQYI*/-)[1C?XI-)VBKMV=MKQ3E&-N:2CS.RNTKO>RVN_):^NJ,NJ&% !0 4
M% !0!N0^%_$]SX?OO%MMX:\17/A/2[VWTW5/%5OH6JS^&=,U*[\O[)IVH^((
MK5M(L+^[\V+[-975W%<S^9%Y,3^8FZ74IJ:INI!5))RC3<XJI**WE&'Q.*L[
MR2LNMK$N<5)0<HJ<E=1;7,TMVENUZ+2W4PZHHMZ>]Q'?V$EI&);N.]M'M8B,
MB6Y2XB:WC*[DW!Y@B$;TR&QO3.ZD]G?;EE?TMJ^NR\OO%*UG?:SOZ6U[_E]Y
M^BG_  4L^)/[9OQ-^)WPYU3]M;X4:!\)/&^F^ [[3_!ND>'M*.E6VJ^%7\07
M%Q=:E<1'QSX[\V>/5WFM1)]OLL1J%^QM@3OXV1T,LP^'KQRO$3Q-*592JSG)
M2<:G(DHJU.E9<JO\,O57:EY^6TL'3IU%@ZLJL'-<[D[VERK1>Y#IKL_D?-_[
M'WQ(\+?!_P#:E^ GQ.\;R-!X0\%_$OP_J_B.[6 W)T[2C))97.K>0L4S2C1Q
M=C562.&:4K9MY,32[%;MS*A4Q67XS#TM:M;#SA35[7E\2C?^]R\N\=]9+>/1
MC*<JN%KTX?'.G)16UWO;Y[=/5;G,_M$_#OQ9\+/C/X^\)^,H;C^TFUZ_U_3=
M6EECNK3Q9X9\0W4NK>'?&>BZG \MGK.A^)M*N[;4]/U6QN+BVN$G:,RK<PW$
M27@J]/$86C5I_#R*$H[.E4@N6I2G&R<)TY)QE%K2UU=.)>'J0JT82@].51:M
M9QE%6E!K=2BU9IJ-NVJ/HS]G""X^'7[,/[7WQ7\6_:=-\%_%#X5R?L^?#N.X
MV)#X^^)6N^*_#6L74>B6LDHDU2W\ Z/I-SK.O:K;VUQ9:++-9V4UY;ZC>PV[
M\>-_?8_+</3]ZKA\0L;7M_RYH4Z=6"YWJHNM*7+"+UDDVHM1;.?$-5,3A:4+
M.=.K[:HUJZ5-0DO>[>U;Y8WLW9M;2<O4O!GP]\3?\%"?@%X&\,>"K9=>_:J_
M9OO_  _\/[^WGGM+.[\=?LV>)=6BTOPGXFN[RZ^SQW]Y\'/$FHQZ%K=U/.UU
M;^#M1T^[O9FAL[=5YZE:GDV,K5*KY,OQRG63U:HXZG'FJTTE?E6*IQYHV5G4
MBU'6_-E.<<!7G*7NX;$*4U;:&(BKRBDKV]JOA5M9IVO>2/3_  IJ7P6\<_MX
M?LN_LHI?V'BK]F/]G?4;WX?Z':7&R3PY\3OBQ;Z)K&O^*O%%W97MQ;6.K1_$
M3XQVUCH-A'J#VZ:IX=@T?1;J5K!QNYZD<71RC,<QM*GF&-BJU1J_M,/AW.$(
M4XM)R7L<*W-VOR3YIQM)7,IJM# XK%6<<377-O[U*E=1A%-+1TZ3<G:]I7=T
MV>&7WQH\"WWQ_F^(DOQL_;M3XYGQTVGQ6EO\*_A0=4M?$@UW[#%X!L_#R?M
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M7/\ \H#^P,3_ ,_J'WU/_E8?\1#/[-'_ $1;XV_EX(_^:BC_ %*QO_0=@O\
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M_G]0^^I_\K#_ (B&?V:/^B+?&W\O!'_S44?ZE8W_ *#L%_Y<_P#R@/[ Q/\
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MA_Q$,_LT?]$6^-OY>"/_ )J*/]2L;_T'8+_RY_\ E ?V!B?^?U#[ZG_RL/\
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MJ*/]2L;_ -!V"_\ +G_Y0']@8G_G]0^^I_\ *P_XB&?V:/\ HBWQM_+P1_\
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M/_R@/[ Q/_/ZA]]3_P"5A_Q$,_LT?]$6^-OY>"/_ )J*/]2L;_T'8+_RY_\
ME ?V!B?^?U#[ZG_RL/\ B(9_9H_Z(M\;?R\$?_-11_J5C?\ H.P7_ES_ /*
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M_E8?\1#/[-'_ $1;XV_EX(_^:BC_ %*QO_0=@O\ RY_^4!_8&)_Y_4/OJ?\
MRL/^(AG]FC_HBWQM_+P1_P#-11_J5C?^@[!?^7/_ ,H#^P,3_P _J'WU/_E8
M?\1#/[-'_1%OC;^7@C_YJ*/]2L;_ -!V"_\ +G_Y0']@8G_G]0^^I_\ *P_X
MB&?V:/\ HBWQM_+P1_\ -11_J5C?^@[!?^7/_P H#^P,3_S^H??4_P#E8?\
M$0S^S1_T1;XV_EX(_P#FHH_U*QO_ $'8+_RY_P#E ?V!B?\ G]0^^I_\K#_B
M(9_9H_Z(M\;?R\$?_-11_J5C?^@[!?\ ES_\H#^P,3_S^H??4_\ E8?\1#/[
M-'_1%OC;^7@C_P":BC_4K&_]!V"_\N?_ )0']@8G_G]0^^I_\K#_ (B&?V:/
M^B+?&W\O!'_S44?ZE8W_ *#L%_Y<_P#R@/[ Q/\ S^H??4_^5A_Q$,_LT?\
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M7/\ \H#^P,3_ ,_J'WU/_E8?\1#/[-'_ $1;XV_EX(_^:BC_ %*QO_0=@O\
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M_G]0^^I_\K#_ (B&?V:/^B+?&W\O!'_S44?ZE8W_ *#L%_Y<_P#R@/[ Q/\
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MA_Q$,_LT?]$6^-OY>"/_ )J*/]2L;_T'8+_RY_\ E ?V!B?^?U#[ZG_RL/\
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M'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@
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M'<_ 7_PX>@?_ "71_8F;_P#0MQG_ ()J?_*P^HXW_H%K_P#@J0?\/(/V"_\
MH[GX"_\ AP] _P#DNC^Q,W_Z%N,_\$U/_E8?4<;_ - M?_P5(/\ AY!^P7_T
M=S\!?_#AZ!_\ET?V)F__ $+<9_X)J?\ RL/J.-_Z!:__ (*D'_#R#]@O_H[G
MX"_^'#T#_P"2Z/[$S?\ Z%N,_P#!-3_Y6'U'&_\ 0+7_ /!4@_X>0?L%_P#1
MW/P%_P##AZ!_\ET?V)F__0MQG_@FI_\ *P^HXW_H%K_^"I!_P\@_8+_Z.Y^
MO_AP] _^2Z/[$S?_ *%N,_\ !-3_ .5A]1QO_0+7_P#!4@_X>0?L%_\ 1W/P
M%_\ #AZ!_P#)=']B9O\ ]"W&?^":G_RL/J.-_P"@6O\ ^"I!_P /(/V"_P#H
M[GX"_P#AP] _^2Z/[$S?_H6XS_P34_\ E8?4<;_T"U__  5(/^'D'[!?_1W/
MP%_\.'H'_P ET?V)F_\ T+<9_P"":G_RL/J.-_Z!:_\ X*D'_#R#]@O_ *.Y
M^ O_ (</0/\ Y+H_L3-_^A;C/_!-3_Y6'U'&_P#0+7_\%2#_ (>0?L%_]'<_
M 7_PX>@?_)=']B9O_P!"W&?^":G_ ,K#ZCC?^@6O_P""I'N/P?\ VB/@7^T#
M;Z]=_!+XL>!?BG;>%I["U\13^"/$%AKT>BW&JQ7,VFPZBUC+*+:2]BLKN2V6
M0J94MY2N=AV\N)P6+P;@L5AJV'=1-P56$H<ZCI)QYE&]FU>RZ]/M95:%:AR^
MVI3I<]W'GBX\R6CM?L_+[]#V6N4Q"@ H * "@#^-G_@X#_Y/5\%?]F[^"O\
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M_P#IF1XF3?[_ $_\%7_TAG\/=?JA]F% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 ?W&?\$3/^4>WPN_[&CXF?^IQK%?E?%G_
M ".Z_P#UYPG_ *C4SXS.?]_J?X*7_I"/UDKYL\H* "@ H * "@ H * "@ H
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MK<YN[7V=(Z)76ENEVY>V>$?B#X:_:%^-/_!.+]H+5?'&F:K^T"OQR^%WP?\
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M_P!><3_Z9D>)DW^_T_\ !5_](9_#W7ZH?9A0 4 % !0 4 % !0 4 % !0 4
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M)W?2UV7.<().<HQ4I**<FE>4MHJ_5]%K?Y)Q])U_]F7]HGPIX4F\<^)?@?\
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M]Q?6*'M/9>VI^TO;DYES7M>W+O=+7?Y*UCZC\:_L=>,/#G[$_P *_CLOP?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _N,_X(F?\ */;X7?\ 8T?$S_U.-8K\KXL_Y'=?_KSA/_4:
MF?&9S_O]3_!2_P#2$?K)7S9Y04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MBHN-DG'0QQ-)X>%.I0J5(U76ITI3E.<U*-67++FA)RBVF^:-E&S2M9)<W(_
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M9UHQBY[J/LH-+MLTG;=IR?O2D?G57M'>% !0 4 ?M7_P05_Y/DN?^R->//\
MTO\ #5?,<7?\B?\ [FZ'_I-4\?//]R_[C4_RF?NS_P %N?\ E'W\1O\ L</A
MK_ZEMC7R7"?_ ".J/_7G$_\ IF1XF3?[_3_P5?\ TAG\/=?JA]F% !0 4 %
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MZH\5_O& _P"OU3_TS+^O^'-SXUW<NA?L+_LCZ/\ #:7[!\._&]S\5M0^.?\
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MQ?5Q3_ P*LH* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /[C/^")G_ "CV^%W_ &-'Q,_]3C6*_*^+/^1W
M7_Z\X3_U&IGQF<_[_4_P4O\ TA'ZR5\V>4% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^'/_!MS_RA<_8S_P"[B?\ UJ[XZ5]IXA_\EAF__=/_ /57
M@3Z#BG_D?8[_ +E?_4/#G[C5\6?/G__2_OXH _#G_@VY_P"4+G[&?_=Q/_K5
MWQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H
M * "@ H * "@ H * "@ H * "@#XB_X*3_\ )@_[6_\ V0SQU_Z:9:];(O\
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M4DFMT[-V:OJF[KRN<S5E!0 4 % ']3/_  ;D_P#(H?M9?]C7\)/_ $R>-Z^
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MWAG4/"WA/PC\/O _A"\T?QEILNC>)DN?!W@KPEX?\+3:GJVDSSZ=+XB?2/\
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M>4Y-RDUWD_NN=2/VE/CJ/BC)\:A\1]6'Q4E\/GPK)XS_ +.\._V@WAX^%8_
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MIK9Q:LXR5])1=UTM<Z'XB_'KXM_%;1M+\->.?%_V[PMHM[/JFE^#] \-^$/
M7@RUU>ZB-O<:T/!OP\\/^%?"TVNRVS/:MKESH\NK_9'EM1>BWEDC>:.$PV'G
M*I1I<M22495)U*M>JXK50]K7J5:B@GKR)J%]=TB*6'I4FY0B^:2LYRG.I-I:
M\O/4<I<M];7M?O;W=[7OVH?CSXE\'7O@'6/'YD\,:IHFC>&M9BT_PEX"T'7?
M$'ASP\+0:)H'B;QIH'A32O&_B?1=/%C8^3I?B'Q'J=BWV.U,\$A@BVYPR_!T
MZL:T*"]I&4YP<JM:<(3J7YYTZ,ZDZ-.;YI>]3IP?O.S5VR8X6A&:J1I^\G*2
MO.<HQE+>482DXQ;O]E7ZW;;YO-;WXA>--1\!Z!\,+[Q!=7'@#PMXAU[Q9X?\
M,O!8+9Z7XB\3VVGVFOZK#<QV::E+-J=MI.G0S175_<6L:VL9MK>!VD+[JC25
M:>(4$JU2$*<ZEY7E"GS.$6KN*Y7*5K*+=];Z&JIP52551_>2C&$I:W<8MN*W
MMHY/9==^A7\#^-_%GPU\8>'/'_@36[CPWXR\(:K;ZYX:U^TALKBYTG5K3)MK
MV"#4;6]L99(BS%4NK2XA.?FB-.K2IUZ52C5@JE*K%PJ0;:4HO=-Q<6ODU^83
MA"K"5.:YH35I1UU7R::]4[K=7-8_%3XA'P-K_P ,SXIO?^$#\4^+K'Q[XA\-
M?9M,^QZIXPTV"\MK#79[C[!_:,=S;6^H7L206U[;V++<.9+5G6-E7L*/M85_
M9KVU.G*C"I>5XTI-.4$N;ELVEJU)]GN+V5/GC4Y??C#V<9:W4'KR]GJNJOZ&
M?9^/_&5AX$\0_#&SU^ZM_ /BS7-!\2^(_#*P6#6>JZ]X8AU&WT#4IKF2U;48
MIM,@U?4HX8[6^M[:07;FY@G98F1NE2=:%=P3K4XSA"IK>,*G+SQ2^&TG&+NU
M=6TM=C=.#G&HXWG!2C&6NBE;F7;6RW7W6)_&_P 2/'?Q(US3_$OCCQ-?^(-?
MTG0_#GAK3-5FCLK&ZL=#\(Z;;:1X:T^W.DVM@B+HVFV=K:VESL:](@26>YFN
M-TK*E1I4(RA1IJG"4ZE244VU*=23E4;YW+XY-MJ]M;:W]TA2A3BXPBHQ<I2:
M[RD[R;NY7NV]W]_V?5O$7[7'[1OBS1-;T#7_ (GWE[;^)]&C\.^*M8A\,>!-
M+\;^+=!CBB@;1_%_Q*TCPK8?$?Q;I]S!!#!J%MXC\5ZG'JD$:PZD+N+*-SPR
M[!4YPG##Q3IRYZ<74K2I4YWOS4\/.H\/3DFVXN%*'(W>-MS&.$P\9*2IKW9<
MT8\TW3A+76%)_NX-7;7+%6>JLU<QOAW^TO\ &_X4:#:>&OA_XV@T#2=-U:_U
M[1O,\%_#W7]6\.:YJ<,,%_K'A/Q)XG\):UXF\(ZI=1V]OOOO#&L:1<K)!%/'
M*DZ*]57P.$Q,W4K4>><HQA.U:O3C4A%W4:L*=2%.JE?:I&2\G:Q53#4:LG*I
M!R;2B_?FE)+92BI*,EK]I2]%J<'!\2O'EOX/\6> (_%&HGP?XZ\1Z+XN\8:+
M.MI=+XA\3>'AJ0T;6M0U"ZMIM7-[9?VQJ9W0ZA%'<O>2R7L5S($=-G0HNI3J
MNG'VE&$Z=*?O+DISMSPC%/EL^6.Z;5K+^[?LJ?/&IRI3A%P@U=<L7:\4KI6T
M7V?NTY>\\$?M+?&_X=^&;3P7X8\;Q-X1TW4+C5=&\,^+/!W@#XD:)X=U.[D\
MZ\O_  MIWQ)\*>+;?PI=7LY^TWTWAI=)>\NC]KNC+<DRMC5P.$K5'5J4?WLH
M\DJE.K6H3G%*R526'JTG445I'VBERK1;V(J8:A5DYR@^=I)RA.=.4DME)TY1
M<TNTO33[6-:?'KXRV?Q7M_CI'\1_$MS\7[34%U2U\?ZK<6^MZ[!>QVOV"!X_
M[;MM1L!;VEAML+&P-C_9]A9)%:65K;6\,")<L)AGAWA'0I_5G'E="-X0:YN;
M[#4KN7O-WYI/5MW;E7L*/LG1]G%4FK.$5RQ:O?:-G=O5O=O5M[G*^$_B!XS\
M"^.-(^)7A'7[K0_'>@Z\OB?1_$EM!83W=CKZ7+WBZG%;WMG=:<\PNG>;RY[&
M6VW-@P% $K2I2I5:4J-2"G1G#V<J;<DG"W+RW3YK6TO>_GU*G3A.#IRC>$H\
MKB[ZQ[:-/\?O.7O;RYU&\O-0O9FN+W4+NYO[VX<(KW%W>SR7-U.RQA8U::>6
M21EC544MA%5<+6B2222LDDDNR222UN]$DM7]Y:5DDMEHBM0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MH2YHP:ERV<;*2=G[VR/KSXB?"7XJ?M5?M$_L5_#OXQ?M!>)/&^K?&_\ 9J\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#^XS_@B9_RCV^%W_8T?$S_ -3C6*_*
M^+/^1W7_ .O.$_\ 4:F?&9S_ +_4_P %+_TA'ZR5\V>4% !0 4 % !0 4 %
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M)_Z)?X7_ /#G_#S_ .:2O>_UIR3_ *":O_A/6_\ E9Z?]LX#_G[+_P %5/\
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ME@/^@;&?=0_^7A_;^&_Y\U_NI_\ RP/^(>;]J/\ Z+)\ O\ P8_$3_Y@:/\
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M&C_7+ ?] V,^ZA_\O#^W\-_SYK_=3_\ E@?\0\W[4?\ T63X!?\ @Q^(G_S
MT?ZY8#_H&QGW4/\ Y>']OX;_ )\U_NI__+ _XAYOVH_^BR? +_P8_$3_ .8&
MC_7+ ?\ 0-C/NH?_ "\/[?PW_/FO]U/_ .6!_P 0\W[4?_19/@%_X,?B)_\
M,#1_KE@/^@;&?=0_^7A_;^&_Y\U_NI__ "P/^(>;]J/_ *+)\ O_  8_$3_Y
M@:/]<L!_T#8S[J'_ ,O#^W\-_P ^:_W4_P#Y8'_$/-^U'_T63X!?^#'XB?\
MS T?ZY8#_H&QGW4/_EX?V_AO^?-?[J?_ ,L#_B'F_:C_ .BR? +_ ,&/Q$_^
M8&C_ %RP'_0-C/NH?_+P_M_#?\^:_P!U/_Y8'_$/-^U'_P!%D^ 7_@Q^(G_S
M T?ZY8#_ *!L9]U#_P"7A_;^&_Y\U_NI_P#RP/\ B'F_:C_Z+)\ O_!C\1/_
M )@:/]<L!_T#8S[J'_R\/[?PW_/FO]U/_P"6!_Q#S?M1_P#19/@%_P"#'XB?
M_,#1_KE@/^@;&?=0_P#EX?V_AO\ GS7^ZG_\L#_B'F_:C_Z+)\ O_!C\1/\
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M_;V,_DP__@NI_P#+ _XA]/V+?^B@_M+?^%O\,_\ YSM'^N6:?\^,!_X*K_\
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M_B'T_8M_Z*#^TM_X6_PS_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+J?\
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M1_KEFG_/C ?^"J__ ,UA_;V,_DP__@NI_P#+ _XA]/V+?^B@_M+?^%O\,_\
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M_;V,_DP__@NI_P#+ _XA]/V+?^B@_M+?^%O\,_\ YSM'^N6:?\^,!_X*K_\
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M_B'T_8M_Z*#^TM_X6_PS_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+J?\
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M1_KEFG_/C ?^"J__ ,UA_;V,_DP__@NI_P#+ _XA]/V+?^B@_M+?^%O\,_\
MYSM'^N6:?\^,!_X*K_\ S6']O8S^3#_^"ZG_ ,L#_B'T_8M_Z*#^TM_X6_PS
M_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+J?\ RP/^(?3]BW_HH/[2W_A;
M_#/_ .<[1_KEFG_/C ?^"J__ ,UA_;V,_DP__@NI_P#+ _XA]/V+?^B@_M+?
M^%O\,_\ YSM'^N6:?\^,!_X*K_\ S6']O8S^3#_^"ZG_ ,L#_B'T_8M_Z*#^
MTM_X6_PS_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+J?\ RP/^(?3]BW_H
MH/[2W_A;_#/_ .<[1_KEFG_/C ?^"J__ ,UA_;V,_DP__@NI_P#+ _XA]/V+
M?^B@_M+?^%O\,_\ YSM'^N6:?\^,!_X*K_\ S6']O8S^3#_^"ZG_ ,L#_B'T
M_8M_Z*#^TM_X6_PS_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+J?\ RP/^
M(?3]BW_HH/[2W_A;_#/_ .<[1_KEFG_/C ?^"J__ ,UA_;V,_DP__@NI_P#+
M _XA]/V+?^B@_M+?^%O\,_\ YSM'^N6:?\^,!_X*K_\ S6']O8S^3#_^"ZG_
M ,L#_B'T_8M_Z*#^TM_X6_PS_P#G.T?ZY9I_SXP'_@JO_P#-8?V]C/Y,/_X+
MJ?\ RP/^(?3]BW_HH/[2W_A;_#/_ .<[1_KEFG_/C ?^"J__ ,UA_;V,_DP_
M_@NI_P#+ _XA]/V+?^B@_M+?^%O\,_\ YSM'^N6:?\^,!_X*K_\ S6']O8S^
M3#_^"ZG_ ,L/U/\ V7_V;/ G[)?P=T'X)?#?4O%6K>$_#M_KFH65]XSO]*U/
M7Y)]?U2YU>]6ZN]&T3P]I\D<=S=2);+%I<#)"$61I7!D;Y_,,?6S+%3Q=>-.
M-2<:<7&DI1@E3A&G&RE.I*]HIN\M[VLE8\W$XFIBZSK5%%2DHIJ":C[JLK)N
M3UM=Z[O2ZMR_0=<1SA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS
M_P &W/\ RA<_8S_[N)_]:N^.E?:>(?\ R6&;_P#=/_\ 57@3Z#BG_D?8[_N5
M_P#4/#G[C5\6?/G_U?[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W
M_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H *
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M .=)0 ?\15'_  0Z_P"CM_$7_B-_[3'_ ,Z2@ _XBJ/^"'7_ $=OXB_\1O\
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M\1O_ &F/_G24 '_$51_P0Z_Z.W\1?^(W_M,?_.DH /\ B*H_X(=?]';^(O\
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MBJ/^"'7_ $=OXB_\1O\ VF/_ )TE !_Q%4?\$.O^CM_$7_B-_P"TQ_\ .DH
M/^(JC_@AU_T=OXB_\1O_ &F/_G24 '_$51_P0Z_Z.W\1?^(W_M,?_.DH /\
MB*H_X(=?]';^(O\ Q&_]IC_YTE !_P 15'_!#K_H[?Q%_P"(W_M,?_.DH /^
M(JC_ ((=?]';^(O_ !&_]IC_ .=)0 ?\15'_  0Z_P"CM_$7_B-_[3'_ ,Z2
M@ _XBJ/^"'7_ $=OXB_\1O\ VF/_ )TE !_Q%4?\$.O^CM_$7_B-_P"TQ_\
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M?_P2 _Z1V_LN_P#AN-._^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\
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M';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?_P $@/\
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M* #_ (<7_P#!(#_I';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\
M'* #_AQ?_P $@/\ I';^R[_X;C3O_CE !_PXO_X) ?\ 2.W]EW_PW&G?_'*
M#_AQ?_P2 _Z1V_LN_P#AN-._^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_A
MQ?\ \$@/^D=O[+O_ (;C3O\ XY0 ?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_
M (<7_P#!(#_I';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #
M_AQ?_P $@/\ I';^R[_X;C3O_CE !_PXO_X) ?\ 2.W]EW_PW&G?_'* #_AQ
M?_P2 _Z1V_LN_P#AN-._^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\
M\$@/^D=O[+O_ (;C3O\ XY0 ?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7
M_P#!(#_I';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?
M_P $@/\ I';^R[_X;C3O_CE !_PXO_X) ?\ 2.W]EW_PW&G?_'* #_AQ?_P2
M _Z1V_LN_P#AN-._^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\ \$@/
M^D=O[+O_ (;C3O\ XY0 ?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7_P#!
M(#_I';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?_P $
M@/\ I';^R[_X;C3O_CE !_PXO_X) ?\ 2.W]EW_PW&G?_'* #_AQ?_P2 _Z1
MV_LN_P#AN-._^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\ \$@/^D=O
M[+O_ (;C3O\ XY0 ?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7_P#!(#_I
M';^R[_X;C3O_ (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?_P $@/\
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M^.4 '_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\ \$@/^D=O[+O_ (;C3O\
MXY0 ?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7_P#!(#_I';^R[_X;C3O_
M (Y0 ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?_P $@/\ I';^R[_X;C3O
M_CE !_PXO_X) ?\ 2.W]EW_PW&G?_'* #_AQ?_P2 _Z1V_LN_P#AN-._^.4
M'_#B_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\ \$@/^D=O[+O_ (;C3O\ XY0
M?\.+_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7_P#!(#_I';^R[_X;C3O_ (Y0
M ?\ #B__ () ?]([?V7?_#<:=_\ '* #_AQ?_P $@/\ I';^R[_X;C3O_CE
M!_PXO_X) ?\ 2.W]EW_PW&G?_'* #_AQ?_P2 _Z1V_LN_P#AN-._^.4 '_#B
M_P#X) ?]([?V7?\ PW&G?_'* #_AQ?\ \$@/^D=O[+O_ (;C3O\ XY0 ?\.+
M_P#@D!_TCM_9=_\ #<:=_P#'* #_ (<7_P#!(#_I';^R[_X;C3O_ (Y0 ?\
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M_B"=%O\ 6-:N/*LK&WL?%]UJD,HAN?#_ (XT(+:HUD\TX!V'_!#[]O[]K?\
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M>*/%TMG8V5M%8V<'B;4+:TM[>$0H@!_950 4 % !0 4 % !0 4 % !0 4 %
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M_P#2Z1\SQ!\>%_PU?SIG]*]?#'SH4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MU.32O"6E)I0NTTFZ-D ?VA_LC?LU> /V//V:/@I^S+\,=.ATWP9\&OA_X?\
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MOB+X.^*6MW^O>+9+73Y=:U2#P7JNOKH>E^'+2>;65O-36!KR_M+/3]-6:\N
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M(4 +NH!_%-^SS^T1\,/^"Z__  45\"_MY_MH?'_X ?LU_L&_L6>.+B/]CO\
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M]9\%?VH;N31M>7X=0^(_!]C8V5QK/V@ _MWH * "@ H * "@ H * "@ H *
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M*$OB(^*O[/\ LTK7CZO0!Z=^VC\#OAE^T7_P7<_X(%_"KXQ>$M#\>_#K5OV
MOA/K7B'P9XHTJRUWPSXF3PA-\;/%ECH_B+0]2BN-.UG1+O4M&M$U+2]0M[BQ
MO[7S+:[MY[>22%P#^ZKPYX;\.^#O#^B>$_".@Z+X6\*^&M*L-"\.>&O#FEV.
MA^'] T32K:*RTS1]$T;3(+73M*TK3K."&TL-/L;:"TL[:**"WBCB1$H VJ "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#G_@VY_Y0N?L9_\ =Q/_
M *U=\=*^T\0_^2PS?_NG_P#JKP)]!Q3_ ,C['?\ <K_ZAX<_<:OBSY\__]'^
M_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^Q
MW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * /B+_@I/
M_P F#_M;_P#9#/'7_IIEKULB_P"1SEG_ &&4/_2SLR__ 'W"_P#7Z'YG^?97
M[$?>!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?U,_P#!N3_R*'[67_8U_"3_
M -,GC>O@.-OXN7?]>L1_Z72/F>(/CPO^&K^=,_I7KX8^="@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * *UU>V=BD3WMW;6:3W,%G ]U
M/%;I-=W4BPVMK$TKH)+FYE98H($)EFD94C5G(6FDY:)-M)O17LEJWZ):L:3>
MR;ZZ:Z+=_+^MCX"O_P#@FO\  77?^"AFC_\ !2WQ9XB^*OC+X\^$/A9)\(_A
MOX6\2>(_#EQ\(?A=X<NK:]M=3U'P-X3LO!UAKEGXEU=-7UU]1U?6/%VM^8^N
MZ@(+>")-.BT]"/T&H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#X@_;>_X)P_L9_P#!1OPO
MX(\&?ME?!W_A</AKX<:[J7B7P9IW_"?_ !/\ _V/K6KV,.FZC>B\^&'C7P5?
MW_VBRMXH?L^IW5[:Q;/,A@CE9W8 ^9/V;_\ @@K_ ,$C/V3?'^G?%+X)?L4?
M#S2O'VB7MEJ?A_Q)XX\2?$OXR7GAK5=.F\^QUCPQ#\9O''C^S\-ZS9S!9;?5
M]#MK#489%5X[D,JF@#](OC=\"?@W^TG\-O$/P?\ CW\,_!OQ<^&/BN!(-?\
M!/CO0K'Q!H5_Y+^9:W/V2]CD^RZC83A;G3=4LV@U'3;M([NPNK:YC29 #\EM
M-_X-O/\ @BCI7@SQCX#L_P!A3P9_87CN\TJ]UZ[NOB3\<]0\6POH^HP:K9VO
MAOQ]?_%*Y\=^"],DO;6W?4='\'>(]!TK6(8UM-6LKVS)MV /3?\ @K\OQP^&
MW_!,'XP?!S]BKX!^-/C1\4?'G@#3OV<OACX!\&^'6\<MX7\.^*M,_P"$3U'Q
M/KT6O2WL3Z+X1\&Q7\BZAX@;4(9]8&DPZC]H^U2R, >J_P#!)C]A?P]_P3M_
M8*^ '[-.FZ=:6GBW0O!VG>(_BYJ%NJF37?B_XJM+?6/B!J,TX:1IXK?7+B?2
M=-+2ND.E:=8V\.V&)$4 ]:_;3_8$_9,_X*&_#K0?A-^V!\*W^+?P_P##/BF'
MQIHOA]?'?Q)\!):>);>PO-,AU&34?AEXP\&:O>".RO[N);.^U"XL-TOG&U,\
M<;J ?F=:?\&OO_!#2QNK:]M?V(A'<V=Q#=6[G]HW]K.0)/;R++$YCE^/$D4@
M61%)22.2-L;71E)5@#[J_;)_X)1_\$]_^"@/_"*3?M<?LS>#_BSJW@C3HM&\
M,>*3K/C7P/XWTS1(&9XM"'CKX<>*/!_C"\T*.5Y+A-%O];N=,6YEEN5M!/+)
M(X!ZG^Q]^P;^R%^P)X"OOAI^R%\"?!OP4\*ZO>1:AK_]@_VMJ_B3Q3?6_P!H
M%G=^+_&_BK4M>\;>+KC3X[JXM]-E\2>(=4?3;25K2Q^S6V(E /KF@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (YHHYX98)5WQ31O%*
MF67='(I1UW*0PRK$94AAU!! - 'R'^QQ^P3^R?\ L ^#O&?@#]DGX5#X3^$O
MB%XWN_B-XOTD>-?B)XW_ +6\97]C::;=:Q]N^(_BWQ?J5CYME86L(T_3;RST
MN/RO,CLDD=VH ^P* /CCXR?L _LD_M ?M(? G]KCXN?"<>+/V@_V:"A^"?C_
M /X3CXC:&?!934[G64(\+^'/%VC^#/$.-2N[BX_XJKP]KF=_DD&!4C4 ^KO$
M7AW0/%V@ZSX6\5Z)I/B7PSXBTR]T77_#VO:?::MHNMZ1J5O)::AI>JZ7?PW%
MEJ&GWUK++;W=G=036]Q#(\<L;HS+0!^.6C_\&[?_  1=T/XJCXR:?^P3\+#X
MO75Y-<32]0\0?$[6/AE%?2,'V0_!;5_'5[\'8M.B<!K;1H_ 2:/:D VUC'C"
M@'ZC?&/]G[X(?M!_"S6/@A\;?A5X%^)_PCUZQMM.U/X>^,/#FFZOX7DMK$(-
M--MIEQ"8=.N=*:.*71[[3A:WND3PPW&FSVL\,4B 'Y/:;_P;>?\ !%'2O!GC
M'P'9_L*>#/["\=WFE7NO7=U\2?CGJ'BV%]'U&#5;.U\-^/K_ .*5SX[\%Z9)
M>VMN^HZ/X.\1Z#I6L0QK::M97MF3;L ?<^L_\$Z?V./$'[0_[/\ ^U;JWP?%
MW\>_V7/AS:?"7X%>._\ A/?B;!_P@_P_LK?Q!:VN@?\ ",V_C.#P?XD\J#Q3
MKL?]J>+?#^OZRWV_<^HL]M:-  ?;5 !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % 'X<_\&W/_*%S]C/_ +N)_P#6KOCI7VGB'_R6&;_]T_\ ]5>!
M/H.*?^1]CO\ N5_]0\.?N-7Q9\^?_]+^_B@#\.?^#;G_ )0N?L9_]W$_^M7?
M'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@
MH * "@ H * "@ H * "@ H * /B+_@I/_P F#_M;_P#9#/'7_IIEKULB_P"1
MSEG_ &&4/_2SLR__ 'W"_P#7Z'YG^?97[$?>!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?U,_P#!N3_R*'[67_8U_"3_ -,GC>O@.-OXN7?]>L1_Z72/F>(/
MCPO^&K^=,_I7KX8^="@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MX:_Y[?\ !&/_ ,!OVX/_ )+H_P",$[<6_?DX?\8U_P!3S_RP#;_P<-?\]O\
M@C'_ . W[<'_ ,ET?\8)VXM^_)P_XQK_ *GG_E@&W_@X:_Y[?\$8_P#P&_;@
M_P#DNC_C!.W%OWY.'_&-?]3S_P L V_\'#7_ #V_X(Q_^ W[<'_R71_Q@G;B
MW[\G#_C&O^IY_P"6 ;?^#AK_ )[?\$8__ ;]N#_Y+H_XP3MQ;]^3A_QC7_4\
M_P#+ -O_  <-?\]O^",?_@-^W!_\ET?\8)VXM^_)P_XQK_J>?^6 ;?\ @X:_
MY[?\$8__  &_;@_^2Z/^,$[<6_?DX?\ &-?]3S_RP#;_ ,'#7_/;_@C'_P"
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_X-N?^
M4+G[&?\ W<3_ .M7?'2OM/$/_DL,W_[I_P#ZJ\"?0<4_\C['?]RO_J'AS]QJ
M^+/GS__3_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP
M)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@ H *
M"@#PS]IKX.3?M"_L_?%_X'V_B&+PG/\ %+P'K_@N+Q+-I3:Y%H;ZU9O:KJ,F
MD)J&DOJ*6Q;>;1=2LC*!M%S%]ZNS 8I8+&X7%N#JK#UH5734N1SY'?EY^67+
M?ORRMV_FVP]7V%>E6Y>;V<U/EO;FMTO:5ON9_.]_Q#C>)?\ H[[0_P#PQ-__
M //BK[/_ %VI_P#0LG_X6Q_^9#W_ /6&/_0(_P#P=_\ < _XAQO$O_1WVA_^
M&)O_ /Y\5'^NU/\ Z%D__"V/_P R!_K#'_H$?_@[_P"X!_Q#C>)?^COM#_\
M#$W_ /\ /BH_UVI_]"R?_A;'_P"9 _UAC_T"/_P=_P#< _XAQO$O_1WVA_\
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MBW+?_4.D?KA7R1X84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS_ ,&W
M/_*%S]C/_NXG_P!:N^.E?:>(?_)89O\ ]T__ -5>!/H.*?\ D?8[_N5_]0\.
M?N-7Q9\^?__4_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I_
M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9W\4Q:O,1;Z%/X>^)VI0:_<_Z-HLNH7!\N@#XB_;T_X*:>#?"?AW_@G+X^^
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_
M +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GS_]7^_B@#\.?^#;G_ )0N?L9_
M]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _SC?VKO^3H/VB_^RY?%;_U.==K]MP'^X8'_ + L)_ZCTS] PG^ZX;_L
M'H_^FXG@-=9T!0!_4)_P;B_\@_\ ; _Z_/@/_P"B?C#7P7&V^6^F,_\ =4^:
MX@WPGI7_ /<1_397PA\X% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@_WVA_V+<M_]0Z1^N%?)'AA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^
M'/\ P;<_\H7/V,_^[B?_ %J[XZ5]IXA_\EAF_P#W3_\ U5X$^@XI_P"1]CO^
MY7_U#PY^XU?%GSY__];^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#
M-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M 4 % 'XM?\$FO^2[?\%BO^TFOQ$_]5C\-*^SXK_W#@[_ +)BA_ZG8X^@SO\
MW7(/^Q/3_P#4BN?M+7QA\^<5\1?AM\._C!X*\0?#7XL>!/!_Q-^'?BRTCL/%
M/@3Q_P"&M'\8>#_$=C#=6]]%9Z[X:\06=_H^K6L5[:6MY'!?VD\27-M!.JK+
M"CJ ?./@C_@GE^P1\,_$NF>,_AU^Q1^RAX#\7Z+/'=:/XH\'_L]_"CPWX@TJ
MYA=9(KC3M8TCPK:7]G/%(BO'+;W$3HZJRL"H*@'T'\3OA/\ "[XV>"=6^&OQ
MD^''@7XK_#O7_L?]N> _B/X3T+QMX.UC^S[R#4+#^U/#7B2QU'1K_P"PW]M;
M7MI]JLY?LUW;PW$.R:)'0 \@^$?[$?[&OP \6'Q[\"_V4/V<?@UXX.F7FB'Q
MC\+?@I\.? /B@Z-J+P2:AI)U[PMX=TO5#IU]):VKW=E]I^S7#V\#2QL8D- '
MN>B^ _ _AOQ'XP\8>'O!WA?0O%OQ"NM'OO'OB?1]!TO3?$'C:]\/:1;Z!H-Y
MXLUBSM8=0\0W6BZ%:VNBZ5/JT]W+I^E6T&GVCQ6L21( <O\ &#X&?!7]H7PD
MG@'X]?"+X9_&KP-'J]AX@C\&_%?P-X9^(7A>/7M*6X33-:CT'Q7INJZ6FK:<
MEW=)8ZBML+NT6YN!!*@FD# 'F/PD_8A_8S^ ?BY?'_P-_9._9O\ @YXZ33;W
M1T\9?"[X)_#CP%XI32=2\K^T=,77_"_AS3-4&GWWV>#[99BZ%O<^3%YR/Y:"
M@#Z"UCPEX6\0ZEX<UC7O#>@ZWJ_@[4Y]:\):IJVD:?J.H^%]8NM-O-'N=5\/
M7MW;S7.C:C<:3J%_I<][ITEM<RZ?>W5G)*UO<RHP!MSP0W,,MM<PQ7%O/&\,
M\$\:2PS0R*4DBEBD#))'(C%'C=65U)4@@D4 ?,7A7]B#]C+P-XB\2>+_  7^
MR9^S;X1\5^,K+6--\7>)?#7P0^&VB:[XGT_Q"LZ:_8Z_JVF^&[:^U>TUM+FY
M35;:_GFAU!+B9;M)5E=6 /5X_@Q\'XC\*S%\*_AW&?@9:FQ^"IC\%^'4/PBL
MCX<'@XVGPS*Z<#X%MCX25?#!@\,G3(O^$?4:.4.G@6Z@'(_&3]EC]F7]HFZT
M"^^/W[//P2^-U[X4^T?\(Q>?%GX6^"?B'=>'?M;PR70T2X\6:)JTNEBXDMX'
MG%DT0D>*)W!9%- 'L6B>']"\,Z)IOAKPYHNDZ!X=T:P@TO2-!T;3K33-&TO3
M+6)8+;3M/TRRA@LK.QMX5$4-K;P101Q@(D:K\M 'S[H?[%G['OACXCW?QB\-
M_LK?LZ:!\6;^XN[J^^)NC?!;X<Z9X]O+G4$$=]<7/BZS\.1:[//>( EU+)?,
M\ZC;*S# H ]"@^ _P0M?"_PZ\$6WP>^&%OX,^#^NZ'XH^$_A.#P'X7B\-_#+
MQ+X9^U#PYX@\ :(FE+IO@_6] %]>C1M4\/VVG7NF?;+K['/%Y\N\ Z:;X=^
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MU**/4-#UFT6+4=*O8TNK&Y@G57H ZJ@ H _(_P#X(P?\FO\ QD_[/R_;O_\
M6F?']?6\9_\ (TP?_8@X?_\ 53A3W.(/]]H?]BW+?_4.D?KA7R1X84 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 ?AS_P &W/\ RA<_8S_[N)_]:N^.E?:>
M(?\ R6&;_P#=/_\ 57@3Z#BG_D?8[_N5_P#4/#G[C5\6?/G_U_[^* /PY_X-
MN?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX
M<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?V%_PA*>,$"JJ^,?%W]I_P!I?\)8226L/L?V  "Y^TDP>#G>=O.'AKX;ZO\
M5_;?\OO;<_M?9?\ 3JER\OL_[U^;I;WO-S#,'CW2;I>R]ESKX^?FY^7_ *=P
MM;E\[WZ6/TQKPCS@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _%K_@DU_P EV_X+%?\ :37XB?\ JL?AI7V?%?\
MN'!W_9,4/_4[''T&=_[KD'_8GI_^I%<_:6OC#Y\* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H _(__ ((P?\FO_&3_ +/R_;O_ /6F?']?
M6\9_\C3!_P#8@X?_ /53A3W.(/\ ?:'_ &+<M_\ 4.D?KA7R1X84 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?AS_P;<_\H7/V,_\ NXG_ -:N^.E?:>(?
M_)89O_W3_P#U5X$^@XI_Y'V._P"Y7_U#PY^XU?%GSY__T/[^* /PY_X-N?\
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M *!:G_A37_\ EC_/[P_XB<?^"PO_ $<!X(_\,-\&?_F,I?\ $..$?^@#$?\
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M%A?^C@/!'_AAO@S_ /,91_Q#CA'_ * ,1_X7XO\ ^6!_JGD?_0-4_P#"FO\
M_+ _XB<?^"PO_1P'@C_PPWP9_P#F,H_XAQPC_P! &(_\+\7_ /+ _P!4\C_Z
M!JG_ (4U_P#Y8'_$3C_P6%_Z. \$?^&&^#/_ ,QE'_$..$?^@#$?^%^+_P#E
M@?ZIY'_T#5/_  IK_P#RP/\ B)Q_X+"_]' >"/\ PPWP9_\ F,H_XAQPC_T
M8C_POQ?_ ,L#_5/(_P#H&J?^%-?_ .6!_P 1./\ P6%_Z. \$?\ AAO@S_\
M,91_Q#CA'_H Q'_A?B__ )8'^J>1_P#0-4_\*:__ ,L#_B)Q_P""PO\ T<!X
M(_\ ##?!G_YC*/\ B''"/_0!B/\ POQ?_P L#_5/(_\ H&J?^%-?_P"6!_Q$
MX_\ !87_ *. \$?^&&^#/_S&4?\ $..$?^@#$?\ A?B__E@?ZIY'_P! U3_P
MIK__ "P/^(G'_@L+_P!' >"/_##?!G_YC*/^(<<(_P#0!B/_  OQ?_RP/]4\
MC_Z!JG_A37_^6!_Q$X_\%A?^C@/!'_AAO@S_ /,91_Q#CA'_ * ,1_X7XO\
M^6!_JGD?_0-4_P#"FO\ _+ _XB<?^"PO_1P'@C_PPWP9_P#F,H_XAQPC_P!
M&(_\+\7_ /+ _P!4\C_Z!JG_ (4U_P#Y8'_$3C_P6%_Z. \$?^&&^#/_ ,QE
M'_$..$?^@#$?^%^+_P#E@?ZIY'_T#5/_  IK_P#RP/\ B)Q_X+"_]' >"/\
MPPWP9_\ F,H_XAQPC_T 8C_POQ?_ ,L#_5/(_P#H&J?^%-?_ .6']!7_  ;J
M?\%=_P!NO_@H5^U9\9_A;^U+\3O#WC;P7X-_9[U+Q]H.G:1\-? 7@RXM?%%O
M\1_AYX=AO9-1\*:%I-[<PII.OZK ;*XEEM6>X2<QB:")Z^#\0.%,DR'+,%B<
MKPU6A6K8]4*DIXFM63I_5ZU2RC5E))\T(OF6O36_N_-<3Y+EV68/#U<'1E3J
M5,3[.4I5:E2\/95)6M.4DO>BG=)/IK=\O]B-?DI\0% !0 4 % !0 4 % !0
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MC0H4(4G4]JXQH4HTHWJ.$'*ZBMU?NVW:/W#7B'G!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0!^'/_  ;<_P#*%S]C/_NXG_UJ[XZ5]IXA_P#)89O_ -T_
M_P!5>!/H.*?^1]CO^Y7_ -0\.?N-7Q9\^?_1_OXH _#G_@VY_P"4+G[&?_=Q
M/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I_
M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GS_]+^_B@#\.?^#;G_ )0N?L9_]W$_
M^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#Y1_;Q_Y,<_;-_[-1_:)_\
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M:I_HA5^!GYF% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % 'X<_P#!MS_RA<_8S_[N)_\ 6KOCI7VGB'_R
M6&;_ /=/_P#57@3Z#BG_ )'V._[E?_4/#G[C5\6?/G__T_[^* /PY_X-N?\
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M8FCA,=E6/BJN!<Y+"U/:7DZ-3FO"UKP<6HSB]7&4I*ZM ^R?B%^V1_P;P_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_X-
MN?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX
M<_<:OBSY\__4_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I_
M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H ^4?V\?^3'/VS?^S4?VB?_ %4/C"O3R7_D<Y3_ -C/ ?\
MJ52.S+O^1A@?^PS#?^GJ9_C*U_7SW?JS]T"D 4 % 'MFC?LV_'_Q%\%/$W[2
M.@_!_P >ZM\ O!NMQ^&O%GQ?L=#FG\!^'M?EEL8(](U37 PAMKYY]3TZ(0,,
M^9>VJ\>:N_AGF67T\;2RZIC*$,?6A[2EA)3_ 'U2&KYHP[6C)[_9>UCFEC,+
M#$0PDJ]..(J+FA1<E[22[J.[6CV3VW1XG7<=)Z[\$O@#\;_VD_&\/PU_9_\
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?AS_P;<_\ *%S]C/\ [N)_]:N^.E?:>(?_ "6&;_\ =/\
M_57@3Z#BG_D?8[_N5_\ 4/#G[C5\6?/G_]7^_B@#\.?^#;G_ )0N?L9_]W$_
M^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#Y1_;Q_Y,<_;-_[-1_:)_\
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MM3<XT:U18G#VOR1J4I\W.YZ6E%QA;F;E%\L(_<O_  5(_8'_ &GOVV?VT/\
M@F#^RKI'[1/Q"^-/B/XE_LC67C&;QM\:M,^'\&F_!_P=:1Z!?>,_$,\?PH^'
MO@:YU^%8?LBSWWB.'6_%'B37GT33[_Q+#'<R7MOXG#&>Y;DV4<29E/+\/@X8
M?-'25#!2Q#>+J^^J5-?6L175.S;LJ;C3IT^>2INW*>=D^9X/ 8+-<7+#4L.J
M>,E%0H.I>O.]H17M:E3DLW\,&H0BVXP=K2X.T_X(J_\ !(#XT_$7Q7^Q=^RM
M_P %0/B#XE_;_P##%OK.FVFC^/O"%BWP(\5>-_!]O)<>+/#>BZEHWPRT6*[:
M$VU[#-#X7^+'C;6/#JV6HW,^E^(GTJ\LFZ)<9<6X.A2S?,^&J%+(JCA)SHU)
M?7:=&L[4JDXSQ,VKW33J86A&=XV<5*,C7^WL[P].&.QN54XY;/EE>E)_6(0J
M:0D^:I*VNOOTJ:=XJ\>:,I?.W_!.7_@B3\&/VD/AA_P4'UG]LWXX>/?V5_&G
M["_CZT\%^+-=L9/"%U\//"L&EV?B6Z\;ZOXXTO7O#DVM:Q!I8\.R?V8FC>)O
M"[3I/'YHDD=(U]#B'C/&9?B<ACD^#P^9T,[H>VI0DJRQ%5SE35&%*4*BA!R=
M1*7-3J6<=+J[.O-,^Q&%K99' 4*>+IYA3<XQ:G[2;;@J<:<HR487YM7*-2W2
M]G(P/^"@O_!)?]BOX;_L">#_ /@HS_P3I_:O^(7[0/P,;XB6?PS\=Z?\7M'T
M[3/$*:OJ>J7&A07^@16'@'X;:IH=QI&N0066K^%O%7AA[RYL-2@UNPUE(+46
M6H:9#Q5G&(SVKP]Q!E=# X[V$J]&6$E*5.T(\[C4<J^)C44X<THU*57E4H\C
MBV^:+RO.L?5S&>69G@Z>'Q#INK3E1;<5&*YG&3=2JIW6TX25I1<7'6YYK_P;
M?? WPS\;?^"K?P8N/&%G;ZEH7P4\*^/_ (]G3KM(9+:ZUOP'I=K8>%)I(I5;
MS'T;Q3XDT?Q';;,,MYHUM(<HKHW3XAXVI@^&,7&E)QGC:M# N2W4*TG.JE_C
MITI4WJM)O?>._%&(GA\GKJFVI8B=/#76ZC4;<UI?XH1E'SYK:7N?HE_P1^_:
M*\6?M6_\')/Q9^.7B_69M:N?%=A^TW8^'I'=S;:=X%\,7FG^'/ VD:; SNMI
M867AG3=/(MXML;7<]Y=D>==3._SO%>7TLK\/<'@J4%#V<LOE4[RKU$ZE:<G9
M7DZDFKM?"DM;'DYWA88/AFA0IQ4>3ZNY6ZSE[TY-Z7;DY/\ !7W-/_@E[J5C
M^UE\1/\ @M1_P27\8W,*:?\ M&Z]\?\ XN_"*ZO)\KH_Q4\ ?%/5+5%LK9A$
M(UNKFX\-ZKJES%=0S-9Z/);C<DC.D<20EE>&X-XIHJ\L!2P&%Q44OCP];"PE
M>3]Z]DJD(IPM>=[O7E,X4L'3R/.:>^%CAJ-96^*C4I*]^KMK&*:WDGI8\Y_9
M;\,S_P#!-O\ X((_MO\ [1?B[3SX?^//[;?Q%US]DWX;I>1"TUVW\(>&K_5_
MA[XEN-.$R1W4*)K,?Q,O-8LU_=S0^%]*N7#E(]O3F=5<1<<9-E]*7M<#DU"G
MF>(<7>#JU(PQ%-2TDM8_5U"7O6=62TNW+;&3_M3B++\+!\U# 4HXVKUBYSM4
M@GLF^5TE%_WG\.KBS_@B3?0?M??\$Q?^"I?_  3I^)$\FM^&_"'PQ3]HKX+P
M7]ZSMX)\2V46IWFHW>A+.'CTVVL_&GAWP?X@V0>7#)?ZKK#3Q.-2N ]<9QEE
M/$O#6?X;W*E7$?4,99?QJ;<8Q52UN=NA4K4]=5&$$K\J0L_7U'-LHS.DN652
MM]6KM+^)%V24GK=NG*<=EI%:Z(_E$A?S88I,8,D<;X]-ZAL=_7U_.OU'^OZV
M_+[C[):Z]_Z\OR^XDH * "@#^M;_ (,^_P#D^[]I#_LTG5__ %<7PCK\K\6?
M^1+EW_8T7_J)B3XOC?\ Y%^$_P"PS_W#5/\ 1"K\#/S,* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /P
MY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_
M *AX<_<:OBSY\__6_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_
M +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M)5</Q1CL,LKQ%##4</:G2JXSGIOGITW=2454E-MI+:$>;E2<H\TY'QE\!O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'X<_\ !MS_ ,H7/V,_^[B?_6KOCI7VGB'_ ,EAF_\ W3__
M %5X$^@XI_Y'V._[E?\ U#PY^XU?%GSY_]?^_B@#\.?^#;G_ )0N?L9_]W$_
M^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#Y1_;Q_Y,<_;-_[-1_:)_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#G_@VY_Y0N?L9_\
M=Q/_ *U=\=*^T\0_^2PS?_NG_P#JKP)]!Q3_ ,C['?\ <K_ZAX<_<:OBSY\_
M_]#^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/
M_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M\ZRC^WN-/^AIP'_X=,)_\UA_:.?_ /0;PU_X74?_ )>'_#O'_@B5_P!&P?\
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M ,$2O^C8/^"]?_B.6J?_ #K*/[>XT_Z&G ?_ (=,)_\ -8?VCG__ $&\-?\
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M-=^&/"]W+JFEGPOH\;75O_:-M!_:4%C<Q0RZI:S+\QQ=5XGS3)W7S/$\.8G
MY?BJ%2;R;&4L16IUL0JF'I*HJ56LE&?/-I2Y&^1M-\LHR\C/)YQC, ZN+K93
M6PV%K4YR> KPK5(U*O-2@I<M2I9/FD[/EO9M/W6I?UI5^6'Q84 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?AS_P;<_\H7/V,_\ NXG_ -:N^.E?:>(?_)89O_W3_P#U5X$^@XI_Y'V.
M_P"Y7_U#PY^XU?%GSY__T?[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\
MDL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7 ]*^PRK_DCN+O\ L,X;_P#3^//>P7_(@SO_ +",J_\ 3F(/V?KX\\$* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /PY_P"#;G_E"Y^QG_W<3_ZU=\=*^T\0_P#DL,W_ .Z?_P"JO GT
M'%/_ "/L=_W*_P#J'AS]QJ^+/GS_TO[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=
M*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4Y2Y-;6E963O?1\KT\K'+1PF)Q$I1H4*M64+\ZA%OEMWZ)Z/S?W%WQ#^T/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^'/_!MS_RA<_8S_P"[B?\ UJ[XZ5]IXA_\EAF__=/_ /57
M@3Z#BG_D?8[_ +E?_4/#G[C5\6?/G__3_OXH _#G_@VY_P"4+G[&?_=Q/_K5
MWQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'GO8+_D09W_V$95_Z<Q!^T%?'G@A0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^'/_!MS_RA<_8S_P"[
MB?\ UJ[XZ5]IXA_\EAF__=/_ /57@3Z#BG_D?8[_ +E?_4/#G[C5\6?/G__4
M_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/
ML=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MH*^//!"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#\.?^#;G_E"Y^QG_ -W$_P#K5WQTK[3Q#_Y+#-_^
MZ?\ ^JO GT'%/_(^QW_<K_ZAX<_<:OBSY\__U?[^* /PY_X-N?\ E"Y^QG_W
M<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /R _X+Y?\HA/VW?^R>>%
M?_5J^ :^MX$_Y*[(_P#L+E_Z8JGN<-?\CW+?^PC_ -LF?J_X3!7PKX95@59?
M#^C!E(P01IUL""#@@@\$$<>U?*U/XD_\<O\ TIGBS^.7^*7YG05!(4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^,'[70/_#Y_P#X(]M@
MX/PL_P""C0!QP2/A;\+"0#T) 921GC<,XR*^PRK_ )([B[_L,X;_ /3^//>P
M7_(@SO\ [",J_P#3F(/V?KX\\$* "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MGQ6>9IC:$L-B<2JE&;C*4%0PU.[@^:+YJ>'IST>NDM>M]C]-Z^</)"@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/
M_(^QW_<K_P"H>'/W&KXL^?/_U_[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\
M0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_X-N?^4+G[&?\
MW<3_ .M7?'2OM/$/_DL,W_[I_P#ZJ\"?0<4_\C['?]RO_J'AS]QJ^+/GS__0
M_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/
ML=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
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M/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_P"%=_\
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M3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
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M/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_P"%=_\
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M3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
M[Q/_ ,+?T?Q=XB^$W_"._%GP%K7_  M'P_X \[_A.]=^'?\ 9NOW7_";:/X)
M^SW'_"7:GX:_M.R\-^1-_;,MEY3["IEN8TOK'M<!C:7U2=*GBO:86O#ZM4KV
M]A#$<U->QG6NO91J\CJ:<G-<)83%0]KSX;$0]A*$*W-1JQ]C*I_#C5O%>SE4
M^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_ [Q/_P +?T?Q=XB^$W_"._%GP%K7
M_"T?#_@#SO\ A.]=^'?]FZ_=?\)MH_@G[/<?\)=J?AK^T[+PWY$W]LRV7E/L
M*F6YC2^L>UP&-I?5)TJ>*]IA:\/JU2O;V$,1S4U[&=:Z]E&KR.IIR<UPEA,5
M#VO/AL1#V$H0K<U&K'V,JG\.-6\5[.53[$9\KE]F]P\._M._LU^+O^%=_P#"
M)_M"_ [Q/_PM_1_%WB+X3?\ "._%GP%K7_"T?#_@#SO^$[UWX=_V;K]U_P )
MMH_@G[/<?\)=J?AK^T[+PWY$W]LRV7E/L*F6YC2^L>UP&-I?5)TJ>*]IA:\/
MJU2O;V$,1S4U[&=:Z]E&KR.IIR<UPEA,5#VO/AL1#V$H0K<U&K'V,JG\.-6\
M5[.53[$9\KE]F]P\._M._LU^+O\ A7?_  B?[0OP.\3_ /"W]'\7>(OA-_PC
MOQ9\!:U_PM'P_P" /._X3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3
M?VS+9>4^PJ9;F-+ZQ[7 8VE]4G2IXKVF%KP^K5*]O80Q'-37L9UKKV4:O(ZF
MG)S7"6$Q4/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7X
MN_X5W_PB?[0OP.\3_P#"W]'\7>(OA-_PCOQ9\!:U_P +1\/^ /._X3O7?AW_
M &;K]U_PFVC^"?L]Q_PEVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7 8VE]4G2
MIXKVF%KP^K5*]O80Q'-37L9UKKV4:O(ZFG)S7"6$Q4/:\^&Q$/82A"MS4:L?
M8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_X5W_PB?[0OP.\3_\ "W]'\7>(
MOA-_PCOQ9\!:U_PM'P_X \[_ (3O7?AW_9NOW7_";:/X)^SW'_"7:GX:_M.R
M\-^1-_;,MEY3["IEN8TOK'M<!C:7U2=*GBO:86O#ZM4KV]A#$<U->QG6NO91
MJ\CJ:<G-<)83%0]KSX;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3
MO[-?B[_A7?\ PB?[0OP.\3_\+?T?Q=XB^$W_  COQ9\!:U_PM'P_X \[_A.]
M=^'?]FZ_=?\ ";:/X)^SW'_"7:GX:_M.R\-^1-_;,MEY3["IEN8TOK'M<!C:
M7U2=*GBO:86O#ZM4KV]A#$<U->QG6NO91J\CJ:<G-<)83%0]KSX;$0]A*$*W
M-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_ (5W_P (G^T+\#O$_P#P
MM_1_%WB+X3?\([\6? 6M?\+1\/\ @#SO^$[UWX=_V;K]U_PFVC^"?L]Q_P )
M=J?AK^T[+PWY$W]LRV7E/L*F6YC2^L>UP&-I?5)TJ>*]IA:\/JU2O;V$,1S4
MU[&=:Z]E&KR.IIR<UPEA,5#VO/AL1#V$H0K<U&K'V,JG\.-6\5[.53[$9\KE
M]F]P\._M._LU^+O^%=_\(G^T+\#O$_\ PM_1_%WB+X3?\([\6? 6M?\ "T?#
M_@#SO^$[UWX=_P!FZ_=?\)MH_@G[/<?\)=J?AK^T[+PWY$W]LRV7E/L*F6YC
M2^L>UP&-I?5)TJ>*]IA:\/JU2O;V$,1S4U[&=:Z]E&KR.IIR<UPEA,5#VO/A
ML1#V$H0K<U&K'V,JG\.-6\5[.53[$9\KE]F]P\._M._LU^+O^%=_\(G^T+\#
MO$__  M_1_%WB+X3?\([\6? 6M?\+1\/^ /._P"$[UWX=_V;K]U_PFVC^"?L
M]Q_PEVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7 8VE]4G2IXKVF%KP^K5*]O8
M0Q'-37L9UKKV4:O(ZFG)S7"6$Q4/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L
M1GRN7V;W#P[^T[^S7XN_X5W_ ,(G^T+\#O$__"W]'\7>(OA-_P ([\6? 6M?
M\+1\/^ /._X3O7?AW_9NOW7_  FVC^"?L]Q_PEVI^&O[3LO#?D3?VS+9>4^P
MJ9;F-+ZQ[7 8VE]4G2IXKVF%KP^K5*]O80Q'-37L9UKKV4:O(ZFG)S7"6$Q4
M/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_P"%=_\
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M3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
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M/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_P"%=_\
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M3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
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M/:\^&Q$/82A"MS4:L?8RJ?PXU;Q7LY5/L1GRN7V;W#P[^T[^S7XN_P"%=_\
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M3O7?AW_9NOW7_";:/X)^SW'_  EVI^&O[3LO#?D3?VS+9>4^PJ9;F-+ZQ[7
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M;$0]A*$*W-1JQ]C*I_#C5O%>SE4^Q&?*Y?9O</#O[3O[-?B[_A7?_")_M"_
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M25/[$I\SC]FU@\._LQ?LU^$?^%=_\(G^SU\#O#'_  J#1_%WAWX3?\([\)O
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M1_X5W_PB?[/7P.\,?\*@T?Q=X=^$W_"._";P%HO_  J[P_X_\[_A.]"^'?\
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MLQ?LU^$?^%=_\(G^SU\#O#'_  J#1_%WAWX3?\([\)O 6B_\*N\/^/\ SO\
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M\SC]FU@\._LQ?LU^$?\ A7?_  B?[/7P.\,?\*@T?Q=X=^$W_"._";P%HO\
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MA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\,?\
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M_:\^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_P"%=_\
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M)_L]? [PQ_PJ#1_%WAWX3?\ "._";P%HO_"KO#_C_P [_A.]"^'?]FZ!:_\
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M#O[,7[-?A'_A7?\ PB?[/7P.\,?\*@T?Q=X=^$W_  COPF\!:+_PJ[P_X_\
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MQ*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_PJ#1_%WAWX3?\([\)O 6B_\
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M/#O[,7[-?A'_ (5W_P (G^SU\#O#'_"H-'\7>'?A-_PCOPF\!:+_ ,*N\/\
MC_SO^$[T+X=_V;H%K_PA.C^-OM%Q_P )=IGAK^S++Q)Y\W]LQ7OFOO*F99C5
M^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M@EB\5/VO/B<
M1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=_\(G^SU\#O
M#'_"H-'\7>'?A-_PCOPF\!:+_P *N\/^/_._X3O0OAW_ &;H%K_PA.C^-OM%
MQ_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83
MQ'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2
MGS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\,?\ "H-'\7>'?A-_PCOPF\!:+_PJ
M[P_X_P#._P"$[T+X=_V;H%K_ ,(3H_C;[1<?\)=IGAK^S++Q)Y\W]LQ7OFOO
M*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M@EB\5
M/VO/B<1/V\H3K<U:K+VTJ?\ #E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?\
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M_L]? [PQ_P *@T?Q=X=^$W_"._";P%HO_"KO#_C_ ,[_ (3O0OAW_9N@6O\
MPA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'XVK];G2J8KVF*K
MS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA.MS5JLO;2I_P .
M56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=_P#")_L]? [PQ_PJ#1_%WAWX3?\
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MG$3]O*$ZW-6JR]M*G_#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]?
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MJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\
M#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?\ PB?[/7P.\,?\*@T?Q=X=^$W_
M  COPF\!:+_PJ[P_X_\ ._X3O0OAW_9N@6O_  A.C^-OM%Q_PEVF>&O[,LO$
MGGS?VS%>^:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO
M.Z>G)RV"6+Q4_:\^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^
MS7X1_P"%=_\ ")_L]? [PQ_PJ#1_%WAWX3?\([\)O 6B_P#"KO#_ (_\[_A.
M]"^'?]FZ!:_\(3H_C;[1<?\ "7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C
M:OUN=*IBO:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$Z
MW-6JR]M*G_#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_PJ#1
M_%WAWX3?\([\)O 6B_\ "KO#_C_SO^$[T+X=_P!FZ!:_\(3H_C;[1<?\)=IG
MAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:
M=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU
M@\._LQ?LU^$?^%=_\(G^SU\#O#'_  J#1_%WAWX3?\([\)O 6B_\*N\/^/\
MSO\ A.]"^'?]FZ!:_P#"$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?
MK'M<?C:OUN=*IBO:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$
M3]O*$ZW-6JR]M*G_  Y5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_ ,(G^SU\
M#O#'_"H-'\7>'?A-_P ([\)O 6B_\*N\/^/_ #O^$[T+X=_V;H%K_P (3H_C
M;[1<?\)=IGAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A
M;V$\1S5'[:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25
M/[$I\SC]FU@\._LQ?LU^$?\ A7?_  B?[/7P.\,?\*@T?Q=X=^$W_"._";P%
MHO\ PJ[P_P"/_._X3O0OAW_9N@6O_"$Z/XV^T7'_  EVF>&O[,LO$GGS?VS%
M>^:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV
M"6+Q4_:\^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5
MW_PB?[/7P.\,?\*@T?Q=X=^$W_"._";P%HO_  J[P_X_\[_A.]"^'?\ 9N@6
MO_"$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8
MJO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#
ME5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_P *@T?Q=X=^$W_"
M._";P%HO_"KO#_C_ ,[_ (3O0OAW_9N@6O\ PA.C^-OM%Q_PEVF>&O[,LO$G
MGS?VS%>^:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.
MZ>G)RV"6+Q4_:\^)Q$_;RA.MS5JLO;2I_P .56\G[25/[$I\SC]FU@\._LQ?
MLU^$?^%=_P#")_L]? [PQ_PJ#1_%WAWX3?\ "._";P%HO_"KO#_C_P [_A.]
M"^'?]FZ!:_\ "$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:
MOUN=*IBO:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW
M-6JR]M*G_#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_ (5W_P (G^SU\#O#'_"H
M-'\7>'?A-_PCOPF\!:+_ ,*N\/\ C_SO^$[T+X=_V;H%K_PA.C^-OM%Q_P )
M=IGAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5
M'[:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC
M]FU@\._LQ?LU^$?^%=_\(G^SU\#O#'_"H-'\7>'?A-_PCOPF\!:+_P *N\/^
M/_._X3O0OAW_ &;H%K_PA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7
MZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q
M$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\
M,?\ "H-'\7>'?A-_PCOPF\!:+_PJ[P_X_P#._P"$[T+X=_V;H%K_ ,(3H_C;
M[1<?\)=IGAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;
MV$\1S5'[:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\ #E5O)^TE
M3^Q*?,X_9M8/#O[,7[-?A'_A7?\ PB?[/7P.\,?\*@T?Q=X=^$W_  COPF\!
M:+_PJ[P_X_\ ._X3O0OAW_9N@6O_  A.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>
M^:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"
M6+Q4_:\^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_P"%
M=_\ ")_L]? [PQ_PJ#1_%WAWX3?\([\)O 6B_P#"KO#_ (_\[_A.]"^'?]FZ
M!:_\(3H_C;[1<?\ "7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IB
MO:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*
MG_#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_PJ#1_%WAWX3?
M\([\)O 6B_\ "KO#_C_SO^$[T+X=_P!FZ!:_\(3H_C;[1<?\)=IGAK^S++Q)
MY\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KS
MNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?L
MU^$?^%=_\(G^SU\#O#'_  J#1_%WAWX3?\([\)O 6B_\*N\/^/\ SO\ A.]"
M^'?]FZ!:_P#"$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:O
MUN=*IBO:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-
M6JR]M*G_  Y5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_ ,(G^SU\#O#'_"H-
M'\7>'?A-_P ([\)O 6B_\*N\/^/_ #O^$[T+X=_V;H%K_P (3H_C;[1<?\)=
MIGAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'
M[:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]
MFU@\._LQ?LU^$?\ A7?_  B?[/7P.\,?\*@T?Q=X=^$W_"._";P%HO\ PJ[P
M_P"/_._X3O0OAW_9N@6O_"$Z/XV^T7'_  EVF>&O[,LO$GGS?VS%>^:^\J9E
MF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\
M^)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7
MP.\,?\*@T?Q=X=^$W_"._";P%HO_  J[P_X_\[_A.]"^'?\ 9N@6O_"$Z/XV
M^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS4H6
M]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#E5O)^TE3
M^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_P *@T?Q=X=^$W_"._";P%HO
M_"KO#_C_ ,[_ (3O0OAW_9N@6O\ PA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^
M:^\J9EF-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6
M+Q4_:\^)Q$_;RA.MS5JLO;2I_P .56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=
M_P#")_L]? [PQ_PJ#1_%WAWX3?\ "._";P%HO_"KO#_C_P [_A.]"^'?]FZ!
M:_\ "$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO
M:8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G
M_#E5O)^TE3^Q*?,X_9M8/#O[,7[-?A'_ (5W_P (G^SU\#O#'_"H-'\7>'?A
M-_PCOPF\!:+_ ,*N\/\ C_SO^$[T+X=_V;H%K_PA.C^-OM%Q_P )=IGAK^S+
M+Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E
M*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._L
MQ?LU^$?^%=_\(G^SU\#O#'_"H-'\7>'?A-_PCOPF\!:+_P *N\/^/_._X3O0
MOAW_ &;H%K_PA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'XVK
M];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA.MS
M5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\,?\ "H-'
M\7>'?A-_PCOPF\!:+_PJ[P_X_P#._P"$[T+X=_V;H%K_ ,(3H_C;[1<?\)=I
MGAK^S++Q)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[
M:=&R]E*KSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\ #E5O)^TE3^Q*?,X_
M9M8/#O[,7[-?A'_A7?\ PB?[/7P.\,?\*@T?Q=X=^$W_  COPF\!:+_PJ[P_
MX_\ ._X3O0OAW_9N@6O_  A.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF
M-7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^
M)Q$_;RA.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_P"%=_\ ")_L
M]? [PQ_PJ#1_%WAWX3?\([\)O 6B_P#"KO#_ (_\[_A.]"^'?]FZ!:_\(3H_
MC;[1<?\ "7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS
M4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#E5O)^
MTE3^Q*?,X_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_PJ#1_%WAWX3?\([\)O 6
MB_\ "KO#_C_SO^$[T+X=_P!FZ!:_\(3H_C;[1<?\)=IGAK^S++Q)Y\W]LQ7O
MFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M@E
MB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=_
M\(G^SU\#O#'_  J#1_%WAWX3?\([\)O 6B_\*N\/^/\ SO\ A.]"^'?]FZ!:
M_P#"$Z/XV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:
M8JO/ZS4H6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_
M  Y5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_ ,(G^SU\#O#'_"H-'\7>'?A-
M_P ([\)O 6B_\*N\/^/_ #O^$[T+X=_V;H%K_P (3H_C;[1<?\)=IGAK^S++
MQ)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*
MKSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ
M?LU^$?\ A7?_  B?[/7P.\,?\*@T?Q=X=^$W_"._";P%HO\ PJ[P_P"/_._X
M3O0OAW_9N@6O_"$Z/XV^T7'_  EVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'
MXVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA
M.MS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\,?\*@
MT?Q=X=^$W_"._";P%HO_  J[P_X_\[_A.]"^'?\ 9N@6O_"$Z/XV^T7'_"7:
M9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS4H6]A/$<U1^
MVG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#E5O)^TE3^Q*?,X_9
MM8/#O[,7[-?A'_A7?_")_L]? [PQ_P *@T?Q=X=^$W_"._";P%HO_"KO#_C_
M ,[_ (3O0OAW_9N@6O\ PA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-
M7ZQ[7'XVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)
MQ$_;RA.MS5JLO;2I_P .56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=_P#")_L]
M? [PQ_PJ#1_%WAWX3?\ "._";P%HO_"KO#_C_P [_A.]"^'?]FZ!:_\ "$Z/
MXV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS4
MH6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#E5O)^T
ME3^Q*?,X_9M8/#O[,7[-?A'_ (5W_P (G^SU\#O#'_"H-'\7>'?A-_PCOPF\
M!:+_ ,*N\/\ C_SO^$[T+X=_V;H%K_PA.C^-OM%Q_P )=IGAK^S++Q)Y\W]L
MQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<
MM@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?LU^$?^
M%=_\(G^SU\#O#'_"H-'\7>'?A-_PCOPF\!:+_P *N\/^/_._X3O0OAW_ &;H
M%K_PA.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'XVK];G2J8KV
MF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA.MS5JLO;2I_
MPY5;R?M)4_L2GS./V;6#P[^S%^S7X1_X5W_PB?[/7P.\,?\ "H-'\7>'?A-_
MPCOPF\!:+_PJ[P_X_P#._P"$[T+X=_V;H%K_ ,(3H_C;[1<?\)=IGAK^S++Q
M)Y\W]LQ7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*K
MSNGIR<M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\ #E5O)^TE3^Q*?,X_9M8/#O[,
M7[-?A'_A7?\ PB?[/7P.\,?\*@T?Q=X=^$W_  COPF\!:+_PJ[P_X_\ ._X3
MO0OAW_9N@6O_  A.C^-OM%Q_PEVF>&O[,LO$GGS?VS%>^:^\J9EF-7ZQ[7'X
MVK];G2J8KVF*KS^LU*%O83Q'-4?MIT;+V4JO.Z>G)RV"6+Q4_:\^)Q$_;RA.
MMS5JLO;2I_PY5;R?M)4_L2GS./V;6#P[^S%^S7X1_P"%=_\ ")_L]? [PQ_P
MJ#1_%WAWX3?\([\)O 6B_P#"KO#_ (_\[_A.]"^'?]FZ!:_\(3H_C;[1<?\
M"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS4H6]A/$<
MU1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_#E5O)^TE3^Q*?,
MX_9M8/#O[,7[-?A'_A7?_")_L]? [PQ_PJ#1_%WAWX3?\([\)O 6B_\ "KO#
M_C_SO^$[T+X=_P!FZ!:_\(3H_C;[1<?\)=IGAK^S++Q)Y\W]LQ7OFOO*F99C
M5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M@EB\5/VO/B
M<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?LU^$?^%=_\(G^SU\#
MO#'_  J#1_%WAWX3?\([\)O 6B_\*N\/^/\ SO\ A.]"^'?]FZ!:_P#"$Z/X
MV^T7'_"7:9X:_LRR\2>?-_;,5[YK[RIF68U?K'M<?C:OUN=*IBO:8JO/ZS4H
M6]A/$<U1^VG1LO92J\[IZ<G+8)8O%3]KSXG$3]O*$ZW-6JR]M*G_  Y5;R?M
M)4_L2GS./V;6#P[^S%^S7X1_X5W_ ,(G^SU\#O#'_"H-'\7>'?A-_P ([\)O
M 6B_\*N\/^/_ #O^$[T+X=_V;H%K_P (3H_C;[1<?\)=IGAK^S++Q)Y\W]LQ
M7OFOO*F99C5^L>UQ^-J_6YTJF*]IBJ\_K-2A;V$\1S5'[:=&R]E*KSNGIR<M
M@EB\5/VO/B<1/V\H3K<U:K+VTJ?\.56\G[25/[$I\SC]FU@\._LQ?LU^$?\
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M25/[$I\SC]FU@\._LQ?LU^$?^%=_\(G^SU\#O#'_  J#1_%WAWX3?\([\)O
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_X-N?^4+G[
M&?\ W<3_ .M7?'2OM/$/_DL,W_[I_P#ZJ\"?0<4_\C['?]RO_J'AS]QJ^+/G
MS__4_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q
M3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H \<_:'^-W@[]FOX$_%_P#: ^($_D>#?@W\.O%OQ%U\+*D4]Y9>
M%=%O-6&E6)<,)-4UF>VATG2;=5>2ZU*]M+:&-Y9D1NO X.KF&-PN!H*]7%XB
MEAZ?5*56:AS/;W8WYI.^D8MNUF;8>C/$5Z-"'QUJD*<>R<Y6N_)7N_)7Z'^>
M5^RE_P '//\ P4./[6GP9OOVEOC)X6UC]FG6/BQHMA\6/!UG\)OA7H,&C_#C
MQ-JITG5KS3_$FC^#;#Q<A\"6&IKXBT]V\0"ZU.30(;/5KNZM[R]$_P"Z9GX<
MY$LKQ:R_#5HYA#"SEAJKQ&(GSUZ4>>,73G5=)^W<?9OW+1]I>*32Y?O<5PW@
M/JE98>E)8E4FZ4_:U7S5(JZ3BYN'[QKE>EES75K(_P!)6.2.6-)8G26*5%DC
MDC97CDC=0R.CJ2KHZD,K*2K*002"#7X U;1Z-:-/H?G@^@ H * "@ H * "@
M#^0+_@OG_P %^_C!^R!\8Y/V)/V('T33?C5I&D>';_XN?%[4O#EAXSU+P)J_
MBVSL=>\,> / /A77['4?"^H>*;OPW?Z/K.N:QKVC^)=.M;+Q'8:-IFF)K\5_
M>Z5^I\$\$83-<)_;&<\[P<IU%AL+&HZ,:\*3<*M>O5@XU(TE4C.$8TYTY.5.
M4W)024_J\CR*CBZ/US&\SHMR5*E&3@IJ#Y9SJ2C:2CS)QBHRB[Q;;LE&7X6Z
MY_P5I_X.&/V#?&'@#XG_ +3FM_&W2_#'CVX&K:3X._:9^">C:;\//B'96XM;
MS4?#]N!X2\-:IX=NX[62WDO=.\(ZYX6\2Z1;W,4SQVD-R!/]E#AC@3.Z5?#9
M;'"2JT5RRK9?C)RKT&[J-1IU:L:D;[2J0JTYO1/5<OMK*\AQT:E+#1HN5/24
M\-5;G3;O9MN4E+7K*,XNUKNS/[__ /@GQ^VCX'_X*!_LC_"+]JCP+ITN@6WQ
M!TB[@\3>$+F[2]N_!7CSPWJ-UX?\:>%9[M$A:\M]-U[3[N31=2EM;&76?#MS
MH^M-860U%;:+\0SS*:V1YIB\MKR4Y8>:]G52:5:C4BJE&JET<J<ESQ3:A-2A
MS2Y7*7PN/P<\#BJN%F[NFURR6TX27-"7DW%JZUM*ZN[7/M"O).,* /XE/^#@
MW_@LE_P4(_8._;QTCX(_LP?&?2/ 'PVN?@%\/?',^AWOPK^%?C*:3Q-KWB3Q
M]8:I?G5_&?@S7]75+BTT33(ELX[]+*'[.9(8(Y9IW?\ 7^!N$LBSO)9XS,<+
M.MB%CJ]%3CB,127LX4Z$HQY:56$='.3O:[OJW9*/V60Y1@,=@95L32<ZBKU(
M756K#W8QIM*T)16\GK:_I9<W]KVF3R7.FZ?<S$&6XLK2>4@!09)8(Y'(48 !
M9B0 ,#H,8%?D,E:4ET3:^YGQSW?JR[2$% !0 4 % !0 4 % !0 4 ?PA_P#!
M [_@I)^W3^TO_P %5_$_P7^//[3'Q)^)_P ++7P!\==3M_!'B:\TV?1(;_PY
MK6E0Z'=1Q6VG6\R2Z9%-+';$385'92&!-?M'&W#^39?PS2QF"R[#X;$RKX*+
MK4U)3<:D).:UFU:32;T^X^USS+\%A\KA6H8:G3JN=!.<;WM*+<EVU:/[O*_%
MSXH* "@ H * "@#^*/\ X.?_ /@H-^VC^Q[^TW^SCX/_ &9/VB?B%\&?#/BO
MX$:EXE\1:-X.N["VM-7UV+X@:_I<>IW8N["[=KE-/M;>U4JZH(HE&P'+-^N^
M'.191FV7YA5S' 4,74I8R%.G.JI-P@Z,9.*Y91T<FWK^%O>^QX;P&#Q>&Q$\
M3AX5I0KJ,7.]U'D3MIYZ_P!,_KX_9TU_6?%?[/GP)\4^(M0GU;Q!XE^#?PPU
M_7=5NBIN=3UG6?!.AZCJ>H7)150SWM[<3W,Q157S)&VJ 0%_+<?"%/'8RG3B
MHPIXO$0A%;1A"M.,8KR222/E,1%1KUXQ5HQK5(Q2Z)3:2^21[)7(8A0 4 %
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M7K0H\OLXSYI6LH^[&3C\48NR7*[1YGS?T3U\(> % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MF<CP'U['TXSC>C0_?5E):-0=HTVGOSS:3BWK#GWL?CI_P13T3]L:]_X)1?\
M!1']N[X]?M,_M+>-]6\?_L]_M ^'?V;XO'_QN^*'B=?">C?"GX;>-[G7/BKX
M277O$]^FD>(=2^(MN-!T3Q#IOV76]%D^'FH26%Y%#K#O+]5QA/*8\2Y'DV!R
M_+Z,,/C<%/'^PP>&I>UGB<114,-5]G3]Z$*'OSIRYHR]O:4;Q][U<Z>$698'
M!8?#8:FJ=:C+$.G1I1YI5*D4J4^6"O%4_><7=/GU7NG\ZO["7[4'_!:?]K7X
M@>)_V2_V4OVI_P!ICQSXT^,^A6]QXFU/Q-\<O&U[=>"?!7@FXFU/5-?M?B-X
MQ\1ZA<_"71Y;G4+*QUW7_"]]HNO>(IIM&\'VMUJ+ZVFA:I]]G>6\(970I9IF
M>6Y?1HX2;5.%+!48JO6K)1C3EAZ2BL5)*,I0A5YJ=-*=5I<KG#Z+&X;)\)3C
MBL5A<-3A2E[JC1IKGG+X8NG"'[V22;C&2DHKFDU[MS2\=_&+_@K=_P $1?VU
M].TOXG?&3XC0?$K38=!\?ZAH/B'XH^*_BA\&?CQX#UJZN89)=7M=7U3[)XM\
M/ZS<:7K7AZ[U&XM-,\6>'-;TW4)=*O="\0:7:WT$4,)PMQAD\I8;!X=4&YT8
MSIX:EAL7@J\4G:+A"].<5*,U%.5*I&2YE*$FHS"CE6=8-RIT8>SDY04HTXTZ
MU"I%=&H^[**<9):PDFN93BW$^F_BE\"?^"]__!0[]GWQ[_P5$\9>/_B GP=L
MM"\3_%/PIX%TGXOZQ\.3;_#3PM)?W>KZU\&/@OI&H6MC8^%_#VE:1>7UA=7K
M6'BWQQINF)KFFW'C?4]2MM1U3SL-C>",AQU'AREAZ#Q;G3PU6O/"0Q">(JV4
M88O%SBY.<Y247%7HT7+D?LE%J/-2K9%E]>GEL*=-UG*-*=1T55_>2LE&M6:O
MS-M)V;A!Z.,$GR_LY_P:L?\ !2S]HO\ :1U#XY?LA_M$?$;Q-\7T^&'@+1?B
MI\)O&7CG5;OQ#XVT;PY%XBL_"/BSP?JWBG4YKG6?$.C6][KWA6]\,#5[F[O=
M"C.K:9#>/I#:1I^E?)^)7#V R]8/-,!0IX7ZS6GAL31HP5.C*IR.K3JPIQM&
M$Y*-55.1*,[1E92YY3\CB?+L/A_88K#TXTO:SE2JP@E&#ER\T9J"TC)I24N7
M26CLGS.7\QWP2_;X_P""N/B?]IWQ%\(OV9_VI/VJ_B-\5_B_K/CKX2^#O!EY
M\6O&?CR58==U2XEOKKPOIWCSQ'JGAOPEK&CZ1I-S<0>/$BTN[\"Z1%J>NV6N
M: +-]4M/T/%Y)PM3RREB\QRW+</A<+3H8JM5CA:5"[C!**J2H0C4JPG.:3HV
M:K3Y8N$[\DOHJN RJ.%A6Q.&PU*E2C3JSFJ4(7LM%-PC&<HRDU>'O<[LG&7P
MR^N?VHOV(O\ @OU_P3:\*C]LGXA?'3XY)I6G:EH<_CKXD?#;]J3QE\1-3\*7
M=YJ-K;Z.GQ4LI==-QJN@7VKW4&D75Q?6?B?P9/=WD6E:S<F+5K2"]\O+<XX'
MX@J_V30P.#4I1FJ%#$9;1P\:J46Y+#2C'W:D8)R23I5;)RAK&1S8;&Y%F,_J
MD*%'F:?LZ=3"PIJ:2U]D^5VDHZK6,]+Q6C9_8E_P04_X*IZW_P %/?V6_$-[
M\5HM+MOVDO@'KND>#_C')H6F+I&B>*]/\2VVIWWP^^(VGZ; 7L=)E\5V6B:_
MINN:19/%:6_B;POK=]ING:3H6J:-IMK^5<:\-0X<S*$<,Y/+\;"5;"<\N:=-
MTVHU\/*32<_9.<)1F[MTZM-2E*<9RE\EGF61RW$Q5)MX>O%SH\SO*/*TITV]
MWRMIQ;N^623;DI2E_G:_LJ>-OVQ/"_[;6M>%?V$=;\1Z#^TA\:_$_P 0/@AX
M2O/"']BVWB5[#Q[K\L>MQZ5X@UV(VG@QXK+3C?7OCF*[TFZ\(:99WVNQ:YHZ
M6<NH0?N^9T<IJ9-3JYU"$\OP=+#XRJJO.Z?-1I_N^:$-:MY2Y51:FJLG&#A.
MZB??8FGA)X*$L<HRP]&%.M-2ORWA#W;J.L]7I#7F=DT[\LOM/]J[PW_P6A_X
M(U?'CX:>//C!^T;\7M#\<?$&*\\7>$?B#HOQR\5?%CP)\0;GPU-8P>(_#_BR
MV\575WI/BRZT7^U]+37_  SXW\/7UE-::MI]W#%>6ES;W*^3EE3A'BW!8FAA
M<OPLJ5"U*K0G@Z6%KT%43]G4I.DHRI*?++V=2C--.,D[-.$>/"RR?.*%6G1P
M]+DIVA*#H0I3IJ7PRAR6<$[/EE![JUU:Q_>^O_!4[P/X,_X)%^$?^"H/Q1T&
M&&'4_@%X/\>W_@#0;YHDUKXM>)C8>$[7X>:!?W,-U/;66J_$^[&AQ:I/9WLN
MBZ&9]:O[6XBTZZ6OQ/\ U;K5>**O#F&G=QQU6A&O./P8:G>H\1.*W<<.O:.*
M<5.=HIQYD?#_ -F3GFL\MIRNU7G34VMJ4;R]I)*VJI+FM?66BM<_B#\)?$;_
M (+G?\%]?BW\1M=^$WQ!\?6/@'PD]J-9\-^#OB9JWP+_ &;/AG:ZC)<3Z#X8
MCL[37+2'Q3XGGBCFE2YU%/&OCVZLXOMNJWT6DP6S1?L-7#\&\$86A3Q5"C.O
M53Y:E7#PQN88EQ5IU/>@_94KV5H^PH)Z1A*2D?9SIY+D5*G&K3@ZD[VE.FJV
M(J6^*6S48WTLG"%]%9W-WP)^W-_P6&_X(*?M0^%_A?\ M7:S\1?'?PVU%=/U
MW6O@_P#$_P ?W7Q3^'GQ#^'=U?)9ZIKOP;\>W>IZX/"GB"S6WN8[2YT#4+./
M3->B@MO'/A;4+5Y--N(K9+PIQMEU7$Y7&A0Q,+PCBL-06&KT*ZC>,,90C%>U
MIRTOSQ;E"_L:L6N<F>"RG/,-*KA8TZ=17C&K3@J52G45[*M37+S1>_O1;E'6
M$HOWH_V6?\%)O^"N7P^_9#_X)I>'_P!N/X1?V?XYU;X_Z'X&L/V7=.UNUGET
MC6?%?Q1\+W7B_0]1\8V6G7T5S;:9X0\)Z;KOB'Q)I2:A;3SZIHD?A!M1T^_U
M6*\M_P FX?X7Q&:\0SR;%<U"."G6EF4H-*=.EAJBI5%2<HR3G5JRA3IRY9)1
MG[7EG&#1\CE^55,7F+P56\%0E-XEQWC"E+EDH-JUYR:C%M.RES)22:E_%#^S
M9^S_ /\ !>'_ (+'7WB_]ICP'\<_C#J?A_1?%VH1V?Q#\;?'[Q)\)?A_:>,%
MC6[OO#?PA\,Z'?V^GZ1'I$-U#%/!X%\+Z9X8T1[B.QN;ZTOI9(*_7LPQW!7"
M<:675\%A54E27-0HX&EBL0Z6RJ8NK-.4G-JZ]M.52:7,H<EC['$5\CRA0PU2
MA2YG!>Y"A&M4Y-DZLY)N3E_?ES/>S33/SN_X*4>(/^"@NF_%[PM\ O\ @HUK
M'C;7/C%^SAX0/@7PSJ/Q"O[#Q/XFO? 6M:Q?>)]*U!OB19RWMQ\3]'U"ZO[N
MXT;QAJ6M:]?R6Q;2;C4@^EM86'O</4\BEA:N.R"-*&$S"JJU2-"+ITXUX05.
M45AVHK#3BDE.E&,(W]Y12DI2]#+HX!TI5\OC"-'$3YY*FG&*G%<K7LVDJ;22
M3@HQ75)WN?W9?\%/?^"LVJ?\$O?^"9_[(4?PIMM'U+]IGX^_!?X=>'_A&GB'
M37U?P_X1T/PK\-O TWCWXCZOIWFP6VI3^'H_$&@:5X:T6^F%IJ'B+7[/4;ZS
MU?1- UO2KK\7X<X8CQ)Q#FGUESCE^"Q=>IBG3ERU*LZF(K>PP\)<LN7VCISE
M4FK.-.$DFISA*/Q.6Y6LSS+%^U;6'H5JDJO+I*3E4J<E-/IS<LG)ZM1C96;3
M/YX_V?\ _@E]_P %^_\ @I1\-]'_ &Q]5_:T\4^#[#QM#-XX^%LGQS_:6^,G
MA+Q-XITO4VEN;#7_ (=^$? /A[Q5I'P_\+:LC2-X5AN8O NF3Z5-I]]H.FKX
M6OK#4G^[QW$? _#^(GE,,JIUG0?L<3]3R_"5:=.4=)0KUJ\Z<\15@TE4M[:7
M,I*I/VD7"7O5\SR++JCP:PD9NF_9U/8X>C*,6M'&<JDE*I-/2>LFGS*3YD?5
M7_!*+_@KE^W?^Q-^WCI?_!,?_@J'XC\9^+='\0^/+'X5V?B'XL:K=>./B?\
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M^"M7PD\5> /@I^T[\:?%'P:^!%Q>)K6J_$7]H3Q+X-T[Q!XL\8&YUN/P=?\
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M44VVELFVTG<^]X=PF%K9:ZE;#8>K/VU9<]2C2G*R4++FE&4K+HK^E]>7UO\
MX.M?VIOVG/@3^V;^SQX;^"'[1OQX^#?AW5OV8K/7-5T'X5?%[X@_#S1=3UI_
MBK\2+!]7U#2_"/B+1K&]U1K&QL[)K^Y@ENS:6EM;F4PP1(G+X9Y;EV-RK,*F
M,P&"Q=2&8<D9XG"4,1.,/JU%\D958.48W;?*G:[;LKW,.&,+AJ^%Q$J^'H5I
M1Q%E*K2IU&E[.#LG.,FE=WLG]]WR_FWX_P#V=O\ @OE^U/\ LB2_\%-O'WQH
M^,WB;X/Z!X4G\?Z%IL?QRUKPMXQM?AEX.AEM;OXG^$/A)X7N](T?2O#MA8:=
M?:U<:K!%IGBK7M)M+OQJ;#6+#4(]<U#WZ&.X'RW-/]7:.#PD,5.K["I.6#A5
MI/$U-5AZN*JJ<Y5')J"C>5*$W[)2BU[./HPQ&187%_V="C1C6E/DE)T8R@ZD
MW_"G5E>3DVTN76$6U#2W(?L-_P $)/V^OVT_^"@7[$__  4(_8=\1_%OQ#XJ
M_:%\#_LX>)C^RW\;?$OC/5=(^(FDWWQ$\'^+_ ^C:?XA^(]A$?%#2>!_'*^%
M=;T'Q]>7FJ>,-.77;V.74IK;1=#BM?E>-,CRC(\XR+.*>%IT\!7S"G_:6#IT
MH3P\HX>M1K3=/#R_=I5J'M83PZ2I2Y%:W-/F\G.\#@\!C<!C8THPP\\1'ZS1
MC!.FU3G";<:=^6TX<T94URP?*O=]YH_E<_9,_9L_;3^,'_!063]G?]GGXG:I
MX+_;&C\9?&K1I?B7:?%GQ3X'U-?$W@?1_&MW\4;\_%/0V/B=I->T[1O$]M<:
M@I>X\1#49(-0)AU&X:OTO-,PR?"9$L=C\-&ME+I8.2P[PM*M'V=:5)89?5I_
MN_<<Z;4=J?+>/PH^GQ6(P=+ >WQ%)3PG)1?LW2A-<LW!4E[)^Y[K<;+11M=;
M)2_<W_@X8^//[<'[)/C_ /X)[_![3?VJ/C_X \:^'O\ @G=\%M-^,DGPR^/?
MQ0T33/&7Q>\/:UXN\+^./&>KZAHOB+1I?%VMZQJVB3-<>+=:MY=:UFWBMI[V
M7=A$^+X#P.3YI0SW%3RW UZ4\\Q4L+]8P.'J2I86<*=2C1BI1DJ4(1GI2@^2
M+NE?3E\3(,/@L53QU66%P]6#Q]5TO:4*4G"DXPE",5.,N6*4OA6B\_L_V>_&
M+Q;XKT[_ ()8?%/QWI_B;Q#8^.+'_@G_ .-_%MEXRL]:U*U\5V?BNU_9TU/6
M+;Q-:^(8;E=7M_$-OJZ)JL&M17BZE%J2+?1W(N565?R7"TJ<N(\/1E3@Z+SN
MC2=)PBZ;IO'1BZ;@TXN#C[K@X\O+I9IV/D*4(O,Z<'&+@\="#@TG%Q>(2Y7%
MZ.-M+/2VA_*9_P &OO[9'[2'CGQ7^WYXI^.GQR^/'Q_TOX4?L\>'?'VA>&/B
M7\5O'WQ&2"]T;4O%FHWD?AZS\7:]KD.G:IJ]OIR:>;BQ@BGG#112&1%1*_3/
M$?*<OH4LDIX+!X+!2Q..J49U,/A:.'NI1I1C[1TU%RC!RYK-V6^GVOI^),)A
MJ<<#&C0H8=U:\H2E3I4Z>C4$G)PC&ZC=O5Z=+7][\3/ _P 5?^"HG_!:C]I_
MX@_\(U^U4=/^+!TS5_'O@7X2ZY^T+>?!#PO-:VVI!--^&?P!\)-JUAHEUKNF
M6M\!9V<7D:E<:=9WOB#Q9XBGO#J&JW'U];"\-\(9=A_:Y9SX9RC0K8N. CC*
MBDX^]B,=5Y924)..NT5)J%*"7+"/LU*669-AJ?/A.:E=4YU8X>-:5[:U*\M9
M*+LW]I)OEC!W2C_9]_P16TG_ (*J>"_V#OC@G_!1;6O$MK+H>D^,+7]GVT^)
M]UK%U^TOH6EZ!HOB6W\17WC[Q3<WTM_<^&SK-OI\GPQEUV:\\9"SM]3U$:H?
M!MQX'2OR3BZ?#5;.L(\@A!J<J3QSPZBLOG.<Z;IJA2Y4E/D<OK"@H4N;E2@J
MJK'R.;O+*F/H?4%%J4H>W]G98>3E*-E"-E[UK^TLHQNTN524N;\0?^#5+]JO
M]J'XZ?MY_'#PI\;OVD?CW\8_"^F_LB^+_$.G>&_BI\8?B'\0M T_7[;XR_ _
M3;?7++1_%WB/6=/M-7@T[5=3L(=2@MXKR*RU&^M4F$%Y<(_V7B7EF6X+)L%4
MP>7X+"5)9I3A*IAL)0P\Y0>$Q<G!RI04G%RC&3BW:\8NS:N>SQ/A<-0P-&5'
M#4*,GBX1<J5&G3DX^QKOE;A&+:ND[-VND]++F9_P68_X+<?MD?M$?M@>)/\
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M_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H *
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MXM)';(^-WP)P?J,G''<],U^O>*O_ "),!_V-8?\ J)BS['BS_<</_P!A<?\
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M\4/%7Q,U'PQJ5AK<'@"R\;VO@O3]$\%:EJNFW-S;P>(M8?PW<Z[K'AZ5DO\
M1["P\/7EW$B:W;;O:\+<LQV&IYECZ]*I0PV+CAZ6'52,H.NZ3JRG6C&48WIP
MYU"-1>[*4JB5N1\W=PKA<12CB:]2$Z=*LJ<::DG'VC@YN4TG:\5S**DM&W):
MVN=K_P %-?AWXQ^%?_!K9_P3V\&>/K:]LO%%MX_^!.O7=AJ*B._TW3_&OA7X
MW^-O#^F7<'W[6XTWP[XATJQELYPES9M;_9;N..YAE1<>':]'$^)&=UJ#C*DZ
M6.@I1UC*5*>%I5))Z74JD)2YEI*]U=-,SRZI"KQ-C9TW>+A72:V;@Z4&UY.4
M6T?KW_P:OZ38:=_P26\&7EG:P6]QKWQO^-6JZK+#&J27U_#KMCH<=U=.H!FG
M33-&TZR61RS"VL[>$$)$BK\OXDRE+BBLFVU#!X.,;](NGSV79<TY/U;?5GE<
M3-O-:B?2C12].6_YM_TS^9E;6&S_ .#K@PP(L:/_ ,%#GNF5%509KZ1KZX<A
M0 6DN+B61V^\[LSL2S$M^A7;\,KO_H1V^2E9?@CZ*]^%_P#N1M]SM^G]6/\
M2>K^?S\]/YAO^#M3_E%UX7_[.Q^$_P#Z@WQ<K]$\,?\ DI)?]BW%?^G,.?1\
M+_\ (S?_ &#5?_2J9PO_  :C_M4? /Q%^PA/^RY8^*_#/A_X]_#'XH?$+Q'X
MF\":CJ-AIOB?QEX<\9:A9ZQHWC_0M/GNA=>(=+M+>:+P?JMS8123:)<^'[*'
M5;>TM]3T6YU+?Q,RW&T\[_M&5*I/!8G#T*=*M&+E3I5*4>2="4DK0DVG5BI-
M<RFW'FY9*.G%&%KQQWUEQE*A5ITXQFDW&$H)ITV[6BW;G5[7YKIOWE'\E/\
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MY)>?_8!C_P#W9/0_^#P+_E(;^S__ -F8^#__ %>'QYKG\*O^1)C_ /L:S_\
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MO9XK%)QYEO?V>'552[.M3>FYW\*X3VN*JXN4;QP\.2FW_P _:NEU_AIJ:?\
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MOS<_X,_O^4B7Q]_[,M\:_P#J\O@!7T'BK_R(L!_V-J7_ *AXP]#BS_D7T/\
ML,A_Z9KGS3_P3H^(W@#_ ()[?\' >N3?M97\7A'1/!?QX_:6^%6M^/O&$/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MU/\ @G)X/_96\&?L[S_\%*?V$+W4_"W[/OAWX+S>)H?VI_@3%87=_HGPYL_
M\FNQ:>_Q$:XCM)[BU.H)9O<M,D+"!IRX+U\=6R?/ZN8U<<N'LZ4:F-J8I4WE
MN,NHSKNMR7]A:Z3Y;]]3QJF#S">)GB/[.QR4Z\JW+]6KW2E4Y^6_LUKK:]ON
M/P:_X(K?LI?L0?\ !*W]I+XD?'7QI_P61_X)Q?%O3O'/P/UGX2VWA_PO\?\
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MPF+4XTU%7]O.>#Y9U)2U7LX0C"-H^^TYRB&=X_FJ>TR3'<O-^Z4*-;F4;?\
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MQ>VFD^(M77P_IVD6VHW,EKX3.MP:=KEI\IQ1GG%6>X:67X3AG.L!@:C7M^;
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M2</JU>4ZDELYR5**LF[J"22>K<FH\OSQ_P %>OV,OV)/^"EW[8NC_M.>$?\
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MLO9NZM=W]3Q<IAC\NQ;Q,\LQ]5.E.GRQP]:+O-Q=[NDUIR]ON.P_X)*?$O\
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MG=)<G+>71+.\=[5<F2X_V/*^;FH5E5<OLVM2<(Q76ZDWTY;,_J!_X)#^/O\
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M]1WA3_@HI_P2U\#>%O#7@KPE^WO^PCH7A7P?H&C>%O#.B6'[6'P$CL='\/\
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M.2:]YVZWW/:S/%XW'X*.$CE&84W&5*7/*A5:_=Q:V5%/7S>GF?9G_!;CPO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\
MR\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8
M_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_
M (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC
M_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY
M/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#
M_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7
M_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^
M>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_
M - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#
M_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+SB_%/_!GK^PS
M=SVC>"OVE_VL/#]LD4@OH?%-[\'_ !A/<3EP8I+2XTGX8^"([.)(\K)#+;7S
MR.1(L\2@QMK3\5<Z2?M<ORN;OHZ<<7327FI8JM=^:<?3K*X<68U7Y\/A9=N3
MVL/OYISO\FOF=58?\&@'_!...QLX]3^._P"VU=ZDEK;IJ%W8>/?@3IUC=7RP
MH+NXL]/N/V>=4N+"UFG$DMO9SZGJ,UK"R027UXZ-</G+Q3S^[Y<%DZC=\JE1
MQDFHWT3DLPBFTMVHQN]>57M&7Q7F%W:C@TKZ)PKMI=$VJR3?FDK]EL6O^(0/
M_@FK_P!%O_;D_P##E? /_P"AJI?\13XA_P"@/)O_  GQO_SR%_K7F/\ SYP7
M_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^
M>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_
M - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#
M_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_
M -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\
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MY\X+_P %U_\ Y>'_ !"!_P#!-7_HM_[<G_ARO@'_ /0U4?\ $4^(?^@/)O\
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MG_ARO@'_ /0U4?\ $4^(?^@/)O\ PGQO_P \@_UKS'_GS@O_  77_P#EX?\
M$('_ ,$U?^BW_MR?^'*^ ?\ ]#51_P 13XA_Z \F_P#"?&__ #R#_6O,?^?.
M"_\ !=?_ .7A_P 0@?\ P35_Z+?^W)_X<KX!_P#T-5'_ !%/B'_H#R;_ ,)\
M;_\ /(/]:\Q_Y\X+_P %U_\ Y>'_ !"!_P#!-7_HM_[<G_ARO@'_ /0U4?\
M$4^(?^@/)O\ PGQO_P \@_UKS'_GS@O_  77_P#EYQ'BC_@ST_8=N[NW?P7^
MTU^U;H%@MMMNK;Q1<_"'Q?=S7?FR'S[>]TKX;>"8;:V\DQ1_99+"[E\U))OM
MFR18(MJ?BKG*3]KE^63E?1TUBZ:MV:>*K-N]]>:/:VC<M(<68Q+W\-AI.^CA
M[6"MZ2G/7S3^2M>79P_\&@7_  3;$40G^.7[<$DXC0320_$7X#0122A0)'BA
M?]G"X>&-WRR1//.T:D(TLA!=L7XI\0=,'DUNEZ&-?X_VBK_<O1;&?^M>8_\
M/G!?^"Z__P O)/\ B$#_ .":O_1;_P!N3_PY7P#_ /H:J/\ B*?$/_0'DW_A
M/C?_ )Y!_K7F/_/G!?\ @NO_ /+P_P"(0/\ X)J_]%O_ &Y/_#E? /\ ^AJH
M_P"(I\0_] >3?^$^-_\ GD'^M>8_\^<%_P""Z_\ \O#_ (A _P#@FK_T6_\
M;D_\.5\ _P#Z&JC_ (BGQ#_T!Y-_X3XW_P">0?ZUYC_SYP7_ (+K_P#R\/\
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M_P">0?ZUYC_SYP7_ (+K_P#R\/\ B$#_ .":O_1;_P!N3_PY7P#_ /H:J/\
MB*?$/_0'DW_A/C?_ )Y!_K7F/_/G!?\ @NO_ /+P_P"(0/\ X)J_]%O_ &Y/
M_#E? /\ ^AJH_P"(I\0_] >3?^$^-_\ GD'^M>8_\^<%_P""Z_\ \O#_ (A
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M  Y7P#_^AJJ/^(I\0_\ 0'DW_A/C?_GD3_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
MSYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$
M^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XB
MGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_P
MY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
MSYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$
M^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XB
MGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_P
MY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
MSYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$
M^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XB
MGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_P
MY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
MSYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$
M^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XB
MGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_P
MY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
MSYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$
M^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XB
MGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_P
MY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\
M@FK_ -%O_;D_\.5\ _\ Z&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+
MK_\ R\/^(0/_ ()J_P#1;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'
M^M>8_P#/G!?^"Z__ ,O#_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0
M'DW_ (3XW_YY!_K7F/\ SYP7_@NO_P#+P_XA _\ @FK_ -%O_;D_\.5\ _\
MZ&JC_B*?$/\ T!Y-_P"$^-_^>0?ZUYC_ ,^<%_X+K_\ R\/^(0/_ ()J_P#1
M;_VY/_#E? /_ .AJH_XBGQ#_ - >3?\ A/C?_GD'^M>8_P#/G!?^"Z__ ,O#
M_B$#_P"":O\ T6_]N3_PY7P#_P#H:J/^(I\0_P#0'DW_ (3XW_YY!_K7F/\
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MI<&89WB\RHQH5Z>'C"%6-5.E&K&7-&$X)-SJS7+:H^E[I6:]Y2_:NOD#QPH
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#G_@VY_P"4+G[&
M?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GS
M_]'^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/
M_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#\.?^#;G_E"Y^QG_ -W$_P#K5WQTK[3Q#_Y+#-_^
MZ?\ ^JO GT'%/_(^QW_<K_ZAX<_<:OBSY\__TO[^* /PY_X-N?\ E"Y^QG_W
M<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M)Z(?\-M_MG_]'<_M/?\ A_?BK_\ -71_965_]"W ?^$E#_Y6'U+"?] N&_\
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M (24/_E8?4L)_P! N&_\)Z(?\-M_MG_]'<_M/?\ A_?BK_\ -71_965_]"W
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS_P;<_\ *%S]C/\ [N)_]:N^.E?:
M>(?_ "6&;_\ =/\ _57@3Z#BG_D?8[_N5_\ 4/#G[C5\6?/G_]/^_B@#\.?^
M#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H
M>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MG$^./_4"^%M?F?&/_(TH_P#8#2_]/XD^0SW_ 'V/_7BG_P"E5#]Q:^3/&"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@#\.?^#;G_E"Y^QG_ -W$_P#K5WQT
MK[3Q#_Y+#-_^Z?\ ^JO GT'%/_(^QW_<K_ZAX<_<:OBSY\__U/[^* /PY_X-
MN?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX
M<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /X9_P#@M5_RD4^-
M'_8%^%/_ *JGP;7ZSPO_ ,B/!_X\5_ZD5#[3)O\ D7TO\57_ -.2/RGKWSU
MH #^O^?I_/\ *C^OZW_+[P/M']L199=+_96U#0I//^%$W[,/P\T[P!+:?\@B
MW\4:8^I)\9--PO[N+Q-%\3)=:O-?BE$=[+;WFDW)1[*6SF?S,L^+,5)6Q']H
M5Y5D_B]G+E^JR_Z]_5U%0LY)6DGJY''A-)8I2O[7ZS4E.]K\C_@O3[+I**6N
MZ>SN1_L]2S67[.?[9%_XF;;\.+KP1X%TS0$U"-YM)N_CVGQ T*]\#KI$3-]G
ME\46/A&#QS-<ND<LD'AZ>_2\\NVND\UXRTL;ED:;?UB-:M*?*[26"]A)5>=[
M^S=1TDEHG/E<;M/E6(UQ&#4?XGM)N5KW5'DDIWLOA<G#JO>V3LW'Z0M?V?O!
M?QOUSX:_MC6^@:-X=_9V/@?6/B%^T[X>\/6]GHN@>"?'_P $(M,L/&OP[T;3
M;"W@M-%7XUWC^%M0\%:7!;16P?QSJ,-DHL])FN(.%XRIA(U\L=2<\=[:-' 3
MFY3G6H8OFE1KSG)R<_JD54C5D[/]S%N[FD<_UB="-3".4I8CG5/#2D[RG3JJ
M\)MVO+V*4E-Z_ KWYKG/^&?$/PHM_@YXL_:F\0PZ%X#\??&;X^^,O!FGQ^%/
MV;OAY\9_"?P;\.:-H>D^)-/\,>&O 'C+Q_X$\">%KSQ+#K+Q6&KZKHOBR[N-
M+\,7,.EPZ;='4;ZZNI3Q#Q5/+Z?/5H83!4JLI5,=7PM3%3E.5.52I6HT:U::
MIN%VHRII2J)RYHJ,(N4:KJQPL6YPHT(2:EB*E&=64I.+E*I"$Y2Y+;)Q5Y];
M1Y?2OA(?@'\4_BM^S'XGO/ .M^-]1O/&'Q=\.^+?%6I?L\>!/@7\+/BQX6\+
M?!CQ)K4ND7'AKPO\1/B/X2O?B1X5UA].EFUOP[H'A^PM;/4[">]TYM:TZVN9
M<<2L9A\-F%-5H4E&GA9TH1QM;%XG#5*F+IQYN>I1H550J14ER3J2E)QDE)0D
MXF=7V]*EB(*:@E"E*,%B*E>I3E*M&/,I3ITY>SFN;24Y.Z=M&^7SKP3\8=(O
M?V:OVHOC9/\ !'X$'Q=H7Q,^ /@?X5V3?"_PQ<^'/A9HVH:3\1(LZ5IUW8RS
M>*+V+2]/9+F^\:WFNSZ_K9L]>\4?VW-IUI;)M5PTUC\!A5B\9[*>&QM;$OZQ
M4]IB9QG2?O25E23E+:C[/DA>$.7F9K.B_K&&H^VK<DJ=:=5^TES597@]7]A7
M>U/E26D;7;CWOP?\-^%?C#X&^#/QO\:^!OA[-XVU"V_;-^%_B?\ L;P)X6\.
M^'?%UI\._P!F^[\<^!_%&K^#=#TJQ\'VWC#0-4U:XCAUK0]"TEYA::7>R1'4
M[)+M\,74J86MB<)2K5_9+^RL33YJU2<Z3KX^-&M3A5E*59TZD8ZQG.5KM+W7
MRD592HSK483J*"^J5(<TYR=-U,1RS2FVY\C27NR<]WLFCY\^,?CB7]E[5/A[
M\+_AEX'^%4FA+\*/A9\1?$OBGQY\,O!7Q*UGXLZO\1? ^F>*-7OM3USQGHFJ
M7&E^$[2?4IM#T32O EQX96RMM-:2XO[O5S<7M=N%I+'QK8BO5Q'.\3B*%.G2
MKUJ$,-"A6G3C&,*52"E4:BISE64[R?PJ'+&6]*G]:52I5G44E5J0C&%2=-4U
M";BDE"24GI=N=[W6FCB?;OB6Y\&^ O$_[3_B/1?@MX/\*Z1/_P $U_V</&/_
M  J9M,DL?"]EXGU_Q+\+[\?V]86SVM_K<-MK4]O?:M'JEV=6\00VOV76[][F
MXN+BO)@JM6&7PEBJM22SS'4_K+DG4=.$*R?([2C!N*M#ECR0O>"2TCR14JD<
M/'VTI/Z_7C[6]Y.,?:[-JT;Q5E9>[]E:)'PAJ?B>Y^)O[*WB+XU>(/#WP]L_
MB?\ !3]H#X7>'/#/BKPQ\-/ 7A)-6\-^/M"\=:Y=:#XN\+>'/#VF^"/%5EHN
ML>$--NM'DUKPU=79MI[[2]6GU73[D6Z>S"FJ&8TL+"==X?%X/$5)TJE>M5Y:
ME"I1@ITZE2HZU-SA5:ER5$KVE#E<3LC#V6)C1C*HZ5:A4E*,JDY6E"5-<T9.
M3G%M3:ERR[.*BT:7_!2#QGK_ (I_:%LK/67T5H-)^$'P)N+$:5X1\(>&YA+K
MGP:\#:EJ/VN[\-:%I%YJD1NW8V-OJL][;Z-;8T_18M.T]4M5C)*4*>";CSWE
MBL8GS5:E32&)JQC95)247;=Q47-^].\O>DLNA&-!M<VM2JM9SDK*I.UE*4DO
M.V^[YG>1\!UZYWA0 4 ?V5_\&_\ _P F3>,?^SB?''_J!?"VOS/C'_D:4?\
ML!I?^G\2?(9[_OL?^O%/_P!*J'[BU\F>,% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % 'X<_\&W/_*%S]C/_ +N)_P#6KOCI7VGB'_R6&;_]T_\ ]5>!/H.*
M?^1]CO\ N5_]0\.?N-7Q9\^?_]7^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM
M/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_X-N?^4+G[&?\
MW<3_ .M7?'2OM/$/_DL,W_[I_P#ZJ\"?0<4_\C['?]RO_J'AS]QJ^+/GS__6
M_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/
ML=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _AG_
M ."U7_*13XT?]@7X4_\ JJ?!M?K/"_\ R(\'_CQ7_J14/M,F_P"1?2_Q5?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'X<_\ !MS_ ,H7/V,_^[B?
M_6KOCI7VGB'_ ,EAF_\ W3__ %5X$^@XI_Y'V._[E?\ U#PY^XU?%GSY_]?^
M_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^Q
MW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^&?\
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M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
MP7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!
M,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I
M_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#
M_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_
M ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\
M)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"A
ME3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS
M_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O_G?4
M?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X=G3O
M_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUCQ'_X
M=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S_HUC
MQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1&'@S
M_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!_P 1
M&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_ .6!
M_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\ P7+_
M .6!_P 1&'@S_HUCQ'_X=G3O_G?4?ZDS_P"AE3_\)JG_ ,L#_5^I_P!!,/\
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M/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H *
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M,?\ \TE'^I^<?]0O_A1$/[#QO_3G_P &R_\ E8?\/\/V#_\ GG\</_#8Q_\
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M  ^?PQ_^:BC^S,R_Z%^._P#"2O\ _*P^J8O_ *!L1_X)J?\ RL/^&R?V0?\
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M?O.]W)>1V'CW]I3Q[\1/^%\?VYI_A:W_ .&A_B'X4^)GC?\ LS3]3M_L&O\
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M+_TFN?SY5]B>^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M;=\%?_5=>':_%LV_Y&F8_P#8=B__ $_,^!QW^^8K_L(K?^ER/JNO/.4* "@
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MTYT:G+S*-3D?/'1-Q<)3B[-I-737GKR^"5UG0% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '](G_!NG_R4
M3]IC_L2_ 7_I\UROBN-?]VP'_7^O_P"FZ9\]Q!_#PW^.I_Z3$_JLK\\/F H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#\.?^#;G_ )0N?L9_]W$_
M^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?/_TO[^
M* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?
M]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "@ H * /YM?\
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MN7GK4:LZ&+J>RDIXBM1E&DK.:A!TXWDH\R4FHN4K.5EIK8\+^&?QG\)?#/\
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MTMVOOM_7]=Q@!() ) &XD<@#U)'0<]>GYF@?]?U_7Y#WBDC*^:CQ[^5+HRY
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MJ#E'E;3:M)M6N5_'6H77BO\ 9J\70?M43?!K7_&'P^\"^"K']F;XQ>!OB%X
M\3_&3Q7J3:GI%G:_#;QK'X+\1:KKWB7P-H?@>3697OOB%X>TO5?"NH:5IVFV
MVNO']GL***5/'4_[.6*A2K5JKQ^%K4*U/"TH\LV\12=:FH4ZTZJBE&A.4:D9
M.;6C"G:.)C]5]LH3G-XBE.G4A2CO>I!S22J2GRZ0E)2C=OK(_,&O=/4/]$7]
MA7_DRK]DG_LV[X*_^JZ\.U^+YM_R-,Q_[#L5_P"GZA\#CO\ ?,5_V$5O_2Y'
MU77GG*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_#/_P %
MJO\ E(I\:/\ L"_"G_U5/@VOUGA?_D1X/_'BO_4BH?:9-_R+Z7^*K_Z<D?E,
M54L&*@LH(5B!N .,@'J <#(!YP,YQ7OGJ %4,6"@,P 9@!N(&< GJ0,G )XR
M<8S0 @C0!@$4!R2X"C#D]2W]XGN3DGOV"N[\]-M?ZM_78"-;>"/ 2&%,,'&V
M)%PPX##;QN ) /!Y^H8N^[^\"15500JJH))(4  ECEB0,9).23W//.<T@&F*
M)D$1BC,8Z1E%*#'3"$!>#[<>V0:=WO=W]?Z_KT 58XU3RUC18\$;%50F#U&T
M87![CO[]:+OSOZ@*8T9/+9%,> NPJ"FT=!M/RX&!@=/RI7>_4!B00QX\N&)-
MI)79&B8+<,1M'!8  X/..<\;7=]W]X \$$C;WAB=QC#O&C-[?,1D8[8)_"B[
M[O[P)"JDJ2H)4DJ2 2I(P2IZ@D'!(QP<'KAD!&\$,I#2112,OW6>-'*]^"W(
MYYX_H*=VMF_OM_7]=P)-J[@VT;@"H; W!3@D ]0"0"1G!P.N*7]?U_7Y@-$<
M:D$(@*[@I"J" QW. 0,C<WS-CJ>3NZJ?U_7]:?,#I_!OBO5_ ?BK1/&?ATZ<
MFN:!?P:A8G5='TK7M,G>'<&M=4T76K._TK5M.N8I)K>\T_4;2XM;FWFEBDBP
M^:BK3C6ISI5.9PFK/EG*$O6,H-2C)-)J2=TUUU)G%3C*$KVDK.S<7KU4HV::
MW33NO*Q[G'^TC'H/_"1ZE\,_@A\%OA%XU\5:1JVA:G\0? NG^/Y?$EGI7B*S
MGT[Q+:^%;/QA\0O%/A3P,=>TZZO-.O)_!OAO0KFWTZ\N;#3)=/M)!&O+]2YO
M9QKXK%XFE3E&:HUIT53E*#4J;J.EAZ56KR22DO:U9IR5W%MG/]6ORJI6K581
M::A-PY;Q:<7)PIPE.S2?ORFF]='J?-'^?\]?Y_G7:=1_0;^SA_R@4_;$_P"R
MWK_Z>?V<J^.Q_P#R5V5_]@GZ8X\#$?\ (\PO_7I?^DUS^?*OL3WPH * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H [_ $;XG^-/#_PZ
M\=_"G2M3AM_ _P 2M7\&:YXPTI]-TZ>?4M2\ 7&JW7A:>'5)[634].6PGUK4
M7E@T^ZMH;X3(MZLR0QJN4J%.=:CB)1O5H1JPI2O)<L:R2J+E347=16LD[=+7
M9G*E"52G5:?/24U!W=DJEE*ZV=^5:N]NF[<> K4T.[\*?$KQCX*\-_$?PEX<
MU.&RT'XL^'=,\*>.K233M/O)-6T/1_$6G>*M/M(+N[MI[K2WAUS2K&Z:ZTR2
MUN98XFMI97MI9(7RG1IU)T*DX\T\-4E4HOFDN6<X2IR;2TE>$I*TE)*][7LS
M.=*%25.<DW*E)SAJU:3BX-M;/W9-:W[K:\>$K4T"@ H * "@ H * "@ H *
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M%3$4*<U/$WA.O3A)7Q%1J\92C)76JONM5;>7V&4U:4,!14ZM.+YJNDJD(O\
MB2W3;:^:7=71^8O_  SA^T'_ -$.^+O_ (;GQ=_\J:]WZWA/^@O"_P#A31_^
M6'I?6</_ ,_Z/_@VF'_#.'[0?_1#OB[_ .&Y\7?_ "IH^MX3_H+PO_A31_\
ME@?6</\ \_Z/_@VF'_#.'[0?_1#OB[_X;GQ=_P#*FCZWA/\ H+PO_A31_P#E
M@?6</_S_ */_ (-IA_PSA^T'_P!$.^+O_AN?%W_RIH^MX3_H+PO_ (4T?_E@
M?6</_P _Z/\ X-IA_P ,X?M!_P#1#OB[_P"&Y\7?_*FCZWA/^@O"_P#A31_^
M6!]9P_\ S_H_^#:8?\,X?M!_]$.^+O\ X;GQ=_\ *FCZWA/^@O"_^%-'_P"6
M!]9P_P#S_H_^#:8?\,X?M!_]$.^+O_AN?%W_ ,J:/K>$_P"@O"_^%-'_ .6!
M]9P__/\ H_\ @VF'_#.'[0?_ $0[XN_^&Y\7?_*FCZWA/^@O"_\ A31_^6!]
M9P__ #_H_P#@VF'_  SA^T'_ -$.^+O_ (;GQ=_\J:/K>$_Z"\+_ .%-'_Y8
M'UG#_P#/^C_X-IA_PSA^T'_T0[XN_P#AN?%W_P J:/K>$_Z"\+_X4T?_ )8'
MUG#_ //^C_X-IA_PSA^T'_T0[XN_^&Y\7?\ RIH^MX3_ *"\+_X4T?\ Y8'U
MG#_\_P"C_P"#:8?\,X?M!_\ 1#OB[_X;GQ=_\J:/K>$_Z"\+_P"%-'_Y8'UG
M#_\ /^C_ .#:8?\ #.'[0?\ T0[XN_\ AN?%W_RIH^MX3_H+PO\ X4T?_E@?
M6</_ ,_Z/_@VF'_#.'[0?_1#OB[_ .&Y\7?_ "IH^MX3_H+PO_A31_\ E@?6
M</\ \_Z/_@VF'_#.'[0?_1#OB[_X;GQ=_P#*FCZWA/\ H+PO_A31_P#E@?6<
M/_S_ */_ (-IA_PSA^T'_P!$.^+O_AN?%W_RIH^MX3_H+PO_ (4T?_E@?6</
M_P _Z/\ X-IA_P ,X?M!_P#1#OB[_P"&Y\7?_*FCZWA/^@O"_P#A31_^6!]9
MP_\ S_H_^#:9^[_[/GPP^)6G?\$//VM_!%_\//'-EXSU/XTQ7&F>$[KPEK\'
MB34K5]7_ &>G%WI^B2:<NI7MH$L[UGN[6VFMXUL;TO*!97/D?(XZO0?%>65%
M7HNG'"VE456#IQ=L;I*IS<J?O+1RO[R[I'AUZE-YUA9JI!P5)7FIQ<5[M;>6
MB7S[WUO8_"#_ (9P_:#_ .B'?%W_ ,-SXN_^5-?7?6\)_P!!>%_\*:/_ ,L/
M<^LX?_G_ $?_  ;3#_AG#]H/_HAWQ=_\-SXN_P#E31];PG_07A?_  IH_P#R
MP/K.'_Y_T?\ P;3#_AG#]H/_ *(=\7?_  W/B[_Y4T?6\)_T%X7_ ,*:/_RP
M/K.'_P"?]'_P;3#_ (9P_:#_ .B'?%W_ ,-SXN_^5-'UO"?]!>%_\*:/_P L
M#ZSA_P#G_1_\&TP_X9P_:#_Z(=\7?_#<^+O_ )4T?6\)_P!!>%_\*:/_ ,L#
MZSA_^?\ 1_\ !M,/^&</V@_^B'?%W_PW/B[_ .5-'UO"?]!>%_\ "FC_ /+
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M?]'_ ,&TP_X9P_:#_P"B'?%W_P -SXN_^5-'UO"?]!>%_P#"FC_\L#ZSA_\
MG_1_\&TP_P"&</V@_P#HAWQ=_P##<^+O_E31];PG_07A?_"FC_\ + ^LX?\
MY_T?_!M,/^&</V@_^B'?%W_PW/B[_P"5-'UO"?\ 07A?_"FC_P#+ ^LX?_G_
M $?_  ;3#_AG#]H/_HAWQ=_\-SXN_P#E31];PG_07A?_  IH_P#RP/K.'_Y_
MT?\ P;3#_AG#]H/_ *(=\7?_  W/B[_Y4T?6\)_T%X7_ ,*:/_RP/K.'_P"?
M]'_P;3#_ (9P_:#_ .B'?%W_ ,-SXN_^5-'UO"?]!>%_\*:/_P L#ZSA_P#G
M_1_\&TP_X9P_:#_Z(=\7?_#<^+O_ )4T?6\)_P!!>%_\*:/_ ,L#ZSA_^?\
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M  ;3#_AG#]H/_HAWQ=_\-SXN_P#E31];PG_07A?_  IH_P#RP/K.'_Y_T?\
MP;3#_AG#]H/_ *(=\7?_  W/B[_Y4T?6\)_T%X7_ ,*:/_RP/K.'_P"?]'_P
M;3#_ (9P_:#_ .B'?%W_ ,-SXN_^5-'UO"?]!>%_\*:/_P L#ZSA_P#G_1_\
M&TP_X9P_:#_Z(=\7?_#<^+O_ )4T?6\)_P!!>%_\*:/_ ,L#ZSA_^?\ 1_\
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M&</V@_\ HAWQ=_\ #<^+O_E31];PG_07A?\ PIH__+ ^LX?_ )_T?_!M,/\
MAG#]H/\ Z(=\7?\ PW/B[_Y4T?6\)_T%X7_PIH__ "P/K.'_ .?]'_P;3#_A
MG#]H/_HAWQ=_\-SXN_\ E31];PG_ $%X7_PIH_\ RP/K.'_Y_P!'_P &TP_X
M9P_:#_Z(=\7?_#<^+O\ Y4T?6\)_T%X7_P *:/\ \L#ZSA_^?]'_ ,&TP_X9
MP_:#_P"B'?%W_P -SXN_^5-'UO"?]!>%_P#"FC_\L#ZSA_\ G_1_\&TP_P"&
M</V@_P#HAWQ=_P##<^+O_E31];PG_07A?_"FC_\ + ^LX?\ Y_T?_!M,/^&<
M/V@_^B'?%W_PW/B[_P"5-'UO"?\ 07A?_"FC_P#+ ^LX?_G_ $?_  ;3#_AG
M#]H/_HAWQ=_\-SXN_P#E31];PG_07A?_  IH_P#RP/K.'_Y_T?\ P;3#_AG#
M]H/_ *(=\7?_  W/B[_Y4T?6\)_T%X7_ ,*:/_RP/K.'_P"?]'_P;3#_ (9P
M_:#_ .B'?%W_ ,-SXN_^5-'UO"?]!>%_\*:/_P L#ZSA_P#G_1_\&TP_X9P_
M:#_Z(=\7?_#<^+O_ )4T?6\)_P!!>%_\*:/_ ,L#ZSA_^?\ 1_\ !M,/^&</
MV@_^B'?%W_PW/B[_ .5-'UO"?]!>%_\ "FC_ /+ ^LX?_G_1_P#!M,/^&</V
M@_\ HAWQ=_\ #<^+O_E31];PG_07A?\ PIH__+ ^LX?_ )_T?_!M,/\ AG#]
MH/\ Z(=\7?\ PW/B[_Y4T?6\)_T%X7_PIH__ "P/K.'_ .?]'_P;3#_AG#]H
M/_HAWQ=_\-SXN_\ E31];PG_ $%X7_PIH_\ RP/K.'_Y_P!'_P &TP_X9P_:
M#_Z(=\7?_#<^+O\ Y4T?6\)_T%X7_P *:/\ \L#ZSA_^?]'_ ,&TP_X9P_:#
M_P"B'?%W_P -SXN_^5-'UO"?]!>%_P#"FC_\L#ZSA_\ G_1_\&TP_P"&</V@
M_P#HAWQ=_P##<^+O_E31];PG_07A?_"FC_\ + ^LX?\ Y_T?_!M,/^&</V@_
M^B'?%W_PW/B[_P"5-'UO"?\ 07A?_"FC_P#+ ^LX?_G_ $?_  ;3#_AG#]H/
M_HAWQ=_\-SXN_P#E31];PG_07A?_  IH_P#RP/K.'_Y_T?\ P;3#_AG#]H/_
M *(=\7?_  W/B[_Y4T?6\)_T%X7_ ,*:/_RP/K.'_P"?]'_P;3#_ (9P_:#_
M .B'?%W_ ,-SXN_^5-'UO"?]!>%_\*:/_P L#ZSA_P#G_1_\&TP_X9P_:#_Z
M(=\7?_#<^+O_ )4T?6\)_P!!>%_\*:/_ ,L#ZSA_^?\ 1_\ !M,/^&</V@_^
MB'?%W_PW/B[_ .5-'UO"?]!>%_\ "FC_ /+ ^LX?_G_1_P#!M,/^&</V@_\
MHAWQ=_\ #<^+O_E31];PG_07A?\ PIH__+ ^LX?_ )_T?_!M,/\ AG#]H/\
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M4A.TZEU"<96]V._+M?I?S/Z=:^!/FPH * "@ H * "@ H * "@ H * "@ H
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M_H&G_P"#(_\ RL/^&2_^">'_ $F^_P"";?\ X?7X5?\ ST*/]=<-_P! %?\
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ML/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\
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M\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4
M'_#WC_@E1_TDF_82_P#$L/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU
M !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4 '_#WC_@E1_TDF_82_P#$L/@9_P#-
MM0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\
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ML/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\
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M\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4
M'_#WC_@E1_TDF_82_P#$L/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU
M !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4 '_#WC_@E1_TDF_82_P#$L/@9_P#-
MM0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\
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ML/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\
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M\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4
M'_#WC_@E1_TDF_82_P#$L/@9_P#-M0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU
M !_P]X_X)4?]))OV$O\ Q+#X&?\ S;4 '_#WC_@E1_TDF_82_P#$L/@9_P#-
MM0 ?\/>/^"5'_22;]A+_ ,2P^!G_ ,VU !_P]X_X)4?]))OV$O\ Q+#X&?\
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M]&V^//\ Q(GXZ?\ S=4 '_$*%_P1)_Z-M\>?^)$_'3_YNJ #_B%"_P"")/\
MT;;X\_\ $B?CI_\ -U0 ?\0H7_!$G_HVWQY_XD3\=/\ YNJ #_B%"_X(D_\
M1MOCS_Q(GXZ?_-U0 ?\ $*%_P1)_Z-M\>?\ B1/QT_\ FZH /^(4+_@B3_T;
M;X\_\2)^.G_S=4 '_$*%_P $2?\ HVWQY_XD3\=/_FZH /\ B%"_X(D_]&V^
M//\ Q(GXZ?\ S=4 '_$*%_P1)_Z-M\>?^)$_'3_YNJ #_B%"_P"")/\ T;;X
M\_\ $B?CI_\ -U0 ?\0H7_!$G_HVWQY_XD3\=/\ YNJ #_B%"_X(D_\ 1MOC
MS_Q(GXZ?_-U0 ?\ $*%_P1)_Z-M\>?\ B1/QT_\ FZH /^(4+_@B3_T;;X\_
M\2)^.G_S=4 '_$*%_P $2?\ HVWQY_XD3\=/_FZH /\ B%"_X(D_]&V^//\
MQ(GXZ?\ S=4 '_$*%_P1)_Z-M\>?^)$_'3_YNJ #_B%"_P"")/\ T;;X\_\
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M=4 '_$*%_P $2?\ HVWQY_XD3\=/_FZH /\ B%"_X(D_]&V^//\ Q(GXZ?\
MS=4 '_$*%_P1)_Z-M\>?^)$_'3_YNJ #_B%"_P"")/\ T;;X\_\ $B?CI_\
M-U0 ?\0H7_!$G_HVWQY_XD3\=/\ YNJ #_B%"_X(D_\ 1MOCS_Q(GXZ?_-U0
M ?\ $*%_P1)_Z-M\>?\ B1/QT_\ FZH /^(4+_@B3_T;;X\_\2)^.G_S=4 '
M_$*%_P $2?\ HVWQY_XD3\=/_FZH /\ B%"_X(D_]&V^//\ Q(GXZ?\ S=4
M'_$*%_P1)_Z-M\>?^)$_'3_YNJ #_B%"_P"")/\ T;;X\_\ $B?CI_\ -U0
M?\0H7_!$G_HVWQY_XD3\=/\ YNJ #_B%"_X(D_\ 1MOCS_Q(GXZ?_-U0 ?\
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MZ-M\>?\ B1/QT_\ FZH /^(4+_@B3_T;;X\_\2)^.G_S=4 '_$*%_P $2?\
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MXD3\=/\ YNJ #_B%"_X(D_\ 1MOCS_Q(GXZ?_-U0 ?\ $*%_P1)_Z-M\>?\
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MNJ #_B%"_P"")/\ T;;X\_\ $B?CI_\ -U0 ?\0H7_!$G_HVWQY_XD3\=/\
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M4 '_ !"A?\$2?^C;?'G_ (D3\=/_ )NJ #_B%"_X(D_]&V^//_$B?CI_\W5
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M?\$2?^C;?'G_ (D3\=/_ )NJ #_B%"_X(D_]&V^//_$B?CI_\W5 !_Q"A?\
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M[K8F[TZLJ"7]H5O^P:CT_OU3XCM_^/B#_KM%_P"ABO4.Q[/T9_IU5^#GYP%
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % '\RO_!V[_RAT\<?]E\^ G_J475
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MAX<_<:OBSY\__]#^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\
MNG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /YLO^#HSX5?&?XL?L$?!ZQ^!WP4^+7Q[\5>#_VRO@IX_P!2\"_!
MCX?^*?B/XQ;PWX8TOQQ<ZGJ*Z%X1TG6-1AL8GDM;274I[5;&VN;VTCN)D,R!
MP#XA_;)_;1_X*7?\%??V<=<_X)]?LH_\$I/VO?V4K#XWCPUX&^-G[0?[:'A.
M\^$7@[P+\+1J>FW6OMHD>LZ=ID_B"?58M-_L_6%T==5U5-$GOK6P\/7%YJ$$
M]J =G^W1_P $W_VI/V#_ (J?\$EOVYOV*/A'JG[86D_\$S_V?-/_ &9?BO\
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M4O!&DZ)HFE6M[X3TVVU/6/[+>3PJ+^35&TN313IGBNX,6HPZEHITNZ /J?\
MX-YOV/OVI/AA%^W/^W-^V3\/M0^#/QI_X*'?'Q/BM:?!76F9?$?P^\!Z3<^*
MM4T4^)[1G,^E:SK=]XXU&)="U*&WUC2]*T+3)=4L]-O]1NM+L@#^DF@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * /R6_X+6?\ !//XA_\ !3[]ACQ%^RI\,/'_ (-^&OBO6?B-\.O&
ML'BCQW::W>^'X+3P7JMQJ-U:20Z!:WFH?:KL2HELXMY8596\X;2* /R-U3_@
MB)_P6&_:R\(>&?V<_P#@HI_P5P\.>*_V.-(3PI:>)OA+^SI\&O#/@'Q%X]\.
M^$)K Z?X/UOQ)I/@7X=2-I<EKIT$/VS79?%L<%XEMJDVAZC=6<08 _1[_@HM
M_P $3_A5^U[\ _V8/ G[/7CW5_V/_C1^P@-%F_8S^+?@*VGN!\,HO#FGZ%9Z
M=X8U2T@O;+4[[0YCX6\.W0U.UU%-:TK5=.35XSJ?VG5--U0 _+'XJ?\ !!;_
M (*U_M7?$G]DGXS_ +;/_!4?X>_'KQ5^R_\ M$?#WXC:-\/;3X6#P#\,+'P%
MX3\0:'XCUR]TBW\"^$O"T>L?%7Q!-H5MIG]K:]X8B2+2\PS>(958Q4 =G_P=
MA_#'P+^T?\)OV!_V5O"UK<ZA^V?\<_VN]%\+?LTQZ3<0I>:-X=U;2)-!^+NO
M>)ECN%U*'P':6^K>$;C59[&VFD75+'2[DNEKI]^& /Z/_P!C3]F#P-^Q?^RS
M\"OV6OAS"B>%/@I\.] \%VUVL,4$VMZG9V_VCQ'XFOEACB1]4\4^([G5?$.J
M3E%>?4-3N9G^=VV@'\Z/_!9/_@B1_P %,?\ @J%^U!X:^(FA?MD_LZ^$/V;_
M (/:CHFK? ;X"^.? _BW7M#T76K6WT^YUWQ+\1O"MQX<\4>"OB'XAUO6+>YM
MKB77[34=);PJMKX>&D0V<NJ1WX!]1>$/^"5O_!0?]I[]DO\ :O\ V.?^"N'[
M;?PR_:'^&?QG\(_#S1_@I?\ P$^#G@SX4ZK\$?$W@77KCQ);>)4M?#7PW^'.
MGZ]:V^KZ9X+DLO#VH)>:>]CHM_IF;&WU)W4 ^&[;_@WQ_P""EG[1&E_ ?]FK
M_@HC_P %2M/^.'[ W[//B;PWXB\,_"/X?_#V'P]\1_&%OX% T[PGH?B[QK/X
M;T?5[P1^&Y]0T5-=\3>*O'FI>'(+N0Z'"]T8K^W /[ K6UM[*VMK*TB2"UM(
M(;6V@C&(X;>WC6*&)!SA(XT5%&> O>@">@ H * "@ H * "@ H * "@ H *
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M>XTZZTZ>![2XL9X(9K2:)X)(D>-D4 ]^H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H _#G_ (-N?^4+G[&?_=Q/_K5WQTK[3Q#_ .2PS?\ [I__
M *J\"?0<4_\ (^QW_<K_ .H>'/W&KXL^?/_1_OXH _#G_@VY_P"4+G[&?_=Q
M/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH *
M"@ H * "@ H * "@ H * "@ H * "@ H _FU_P"#C3_DGO[*O_8_?$G_ -1?
M0J^XX)_C9C_UYH?^G)GT/#_\3$_X*?\ Z5(_E9K] /IPH * "@ H * "@ H
M* "@ H * "@":W_X^(/^NT7_ *&*!/9^C/\ 3JK\'/S@* "@ H * "@ H *
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M_P _J_WT_P#Y6'_$0Q^U1_T1_P#9^_\ !3\1O_GBT?ZFY=_T$XW_ ,#H?_*
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M_?\ @I^(W_SQ:/\ 4W+O^@G&_P#@=#_Y0']@8;_G]7^^G_\ *P_XB&/VJ/\
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M_P"?U?[Z?_RL/^(AC]JC_HC_ .S]_P""GXC?_/%H_P!3<N_Z"<;_ .!T/_E
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M]"O&?^"9!_P^?_X)5?\ 1^'[.O\ X7$'_P 8H_U-XK_Z)_-/_"6H'^K^=_\
M0KQG_@F0?\/G_P#@E5_T?A^SK_X7$'_QBC_4WBO_ *)_-/\ PEJ!_J_G?_0K
MQG_@F0?\/G_^"57_ $?A^SK_ .%Q!_\ &*/]3>*_^B?S3_PEJ!_J_G?_ $*\
M9_X)D'_#Y_\ X)5?]'X?LZ_^%Q!_\8H_U-XK_P"B?S3_ ,):@?ZOYW_T*\9_
MX)D'_#Y__@E5_P!'X?LZ_P#A<0?_ !BC_4WBO_HG\T_\):@?ZOYW_P!"O&?^
M"9' ZS_P5*_X(L^(_''A?XF^(?VI_P!C?7OB3X(M;VQ\%_$'69_"VJ>./"%E
MJ*RIJ%IX7\67VCSZ]H%K?I<3I>V^E7]I%=+/*)DD$KJQ_J;Q7_T3^:?^$M0/
M]7\[_P"A7C/_  3([[_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,@_X?/_\ !*K_ */P_9U_\+B#_P",4?ZF\5_]$_FG_A+4
M#_5_._\ H5XS_P $R#_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,@_X?/_\ !*K_ */P_9U_\+B#_P",4?ZF\5_]$_FG_A+4
M#_5_._\ H5XS_P $R#_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,@_X?/_\ !*K_ */P_9U_\+B#_P",4?ZF\5_]$_FG_A+4
M#_5_._\ H5XS_P $R#_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,@_X?/_\ !*K_ */P_9U_\+B#_P",4?ZF\5_]$_FG_A+4
M#_5_._\ H5XS_P $R#_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,@_X?/_\ !*K_ */P_9U_\+B#_P",4?ZF\5_]$_FG_A+4
M#_5_._\ H5XS_P $R#_A\_\ \$JO^C\/V=?_  N(/_C%'^IO%?\ T3^:?^$M
M0/\ 5_._^A7C/_!,C]!_A]\0?!7Q7\#^%/B5\./$VD^,O 7CG0M.\3^$/%>A
M7(O-&\0^']7MTN],U;3+I<"XLKVVD2:"4#YT8'CFOG\1AZ^%KU<-B:4Z&(H5
M)4JU&HN6=.I!N,X3CTE%JS71^IY=6E4H5)T:T)4ZM*<H5(25I0G%VE%KHT[I
M_P# .QK$S"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#G_@VY_P"4+G[&?_=Q
M/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GS_]+^
M_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^Q
MW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@#^;7_
M (.-/^2>_LJ_]C]\2?\ U%]"K[C@G^-F/_7FA_Z<F?0\/_Q,3_@I_P#I4C^5
MFOT ^G"@ H * "@ H * "@ H * "@ H * )K?_CX@_Z[1?\ H8H$]GZ,_P!.
MJOP<_. H * "@ H * "@ H * "@ H * "@ H _SN?VZ?^3U?VMO^SDOC9_ZL
M;Q%7[3E7_(JRS_L PO\ Z9B??8'_ '/"_P#8/1_](B?*M=YU';^/?ASXQ^&.
MK:5HGC?2/[%U/6_"7A7QUIEM]OTW4?M/A;QKI$&N^&=3\[2[R]@A_M+2KF&Z
M^Q3RQ7]GO\F^M;:X5HERHUJ5>,ITI<\85:E&3M)6J49.%2-I)/W9)JZT>Z;6
MLHIU(54W!W49R@W9KWH.TEK9Z-6OL^E[W.(K4L* "@ H * .VUCX=^,- \$>
M#/B-JVD?9?!OQ!U#Q1I?A'6/M^FS_P!K7W@R738/$D'V"WNYM3L?[.EU?3U\
MS4;.SAN_/S8O<K%,R90K4YU:M&,KU:"IRJQM)<JK<WLW=I1ES<LOA<K6UL1&
MI"52=-/WZ:BYJST4U>.NSND]K^?:/$UJ6%  3@$GH.30!V_C7X<^,OAV/"9\
M8:1_9 \<>#](\>^&#]OTR_\ [3\*:Z]RFEZI_P 2V[N_L?VI[.Y'V*_^SZA#
MY?\ I%K$&0ME2K4ZWM/9RYO959T:FDERU(6YHZJ-[<RU5XZZ-V;E$*L*G/R.
M_LYNG+1JTH[K5*_RNNS.(K4L* .T\!?#WQ=\3M?E\,>"-*_MG6X=!\2^)I++
M[=IVG;=$\(:#?^)O$-[]IU2[LK4_V?HFEWUY]G$S75UY/V>S@N+J2*%LJU:G
M0A[2K+DASTX7M*7O59QIP5HIOWIRBK[*]VTKN,5*D*<>:;Y5S1C>S>LGRQ6B
M;U;[6[V.)5E=5=3E74,IY&589!P<$9!'49]<5J6:NBZ/J/B'6='\/Z/;_:]7
MU_5M-T32;3S88/M6J:O>P:?I]MY]S)#;0_:+RXAB\ZXFB@BW^9-+%&KO2E)0
MC*<G:,(RG)ZZ1BG)O2[=DF[)7>RN*4E&,I/:*<GZ)7??IY?>>F^(/@-\4?"V
M@?$3Q+KWA^SL-)^%/Q('PE\=N_B?PI-?:-X]/VX'1X=(M]<EU?6;=#IMXLFN
M:'8:EH$3Q!)-41Y8%EYX8O#SG1IPFY2Q%#ZS1_=U+3H^[[_.XJ,'[R]R;C/7
MX=3*.(I2E2C%MNM3]K3]V5G"U[MM63LUI)J7D[>[X_72;!0 4 >C_!S0M5\4
M_%_X3^&-!\5/X$USQ)\3? 'A_1?',4UQ;2^"]7UKQ9I&FZ9XNCN;2[T^[MY/
M#5[<P:TD]K?V-S"UD)(+RUE5)TPQ,XT\-B*DZ:JPA0K3G2:356,:<G*FTU)/
MVB3A9QDGS6:=VC.M)1I59./.HTYR<'KSI1;<;6=^9*VSWV>Q]*_\%!OA-\0_
M@K^T5<^"/BA^T%??M->*D\"^$]8?XHZCJ6L:K=2Z;J,VM)9>'6N]=\2^+-0*
M:*UK<2)$=7:&,7^8K6#<Y?BR?$T<7@E6P^#6 INK4C["*A%<T>6\[0I4E[UU
M]B^F[T.; 585J'/##K#1YY+V:2CJK7EHHK73ITZ:<WQ'7J':% !0 4 % '?_
M  P^&'C3XQ^-=+^'OP^TRUU?Q5K-OK-Y965]K>A>'++[)X>T34?$>M7=WK?B
M74M(T/3K;3]$TG4+^>?4-1MHO+MF1&:9D1\:]>EAJ4JU:3A3BX*4E"<W><XT
MX)0IQE.3E.48I1B]];6N14J0I0<YMJ*LG92D[R:BDE%.3;DTE9?=8['Q3^SM
M\4?"G@K4?B/+:>$/%'@71M2TW2-?\4_#3XG?#3XK:/X;U'62RZ/;^);KX:^+
M/%2^'O[5D4PZ=+K(L8;R<K!;R/,Z(V=/&8>I55#FJ4ZTHRE"G7P^(PTIQA\3
MIK$4J7M.7KR<S6[MN9PQ%*<U3]^$Y)N,*E.I3<DMW'G4>:W6U[=;;GA]=1N%
M '8^%? /BSQM8>-=3\,Z7_:5E\//"5SXY\7S?;=/M/[)\+VFI:9I%QJ?EWUU
M;2WWEZAK&G6_V/3DN[]_M'FI;&&*:6+.I5ITG2C4ERNO55&EI)\U1Q<E'1/E
MO&+=Y6CING92B=2$'!2=G4GR0T;O+E<K:)VTBWK9>>J..K0L* "@ H * "@#
M^RO_ (-__P#DR;QC_P!G$^./_4"^%M?F?&/_ "-*/_8#2_\ 3^)/D,]_WV/_
M %XI_P#I50_<6ODSQ@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M^>?_ ('(/^$.\(_]"MX<_P#!'IO_ ,8H]K5_Y^U/_ Y?_+ ]I4_GG_X'(/\
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M +'&8?\ J34.W/?^1SFG_8?BO_3TC]%J^=/*"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M<G_!OO\ L71NCCX@_M*Y1E<9\;?#0C*G(R!\'@2,CG!'U'6C_7+-/^?& _\
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M&G3A=J"4/:151I:R=2/O2NK12BSC/ O@;]FF#XL?'WP%\%_&?P+\2^*M6N_
M5]^S=JW[0FEGQ/\ "34-&OX(M9\>_"]-7\<^'[/1K7X@6M[<V_AC0/&_C#P_
MIVGZG8Z1J?V/4='U/6+.YEUK5<>\/@ZN*I8NG3BJRQT<$_9XI3B^2CB.2C.4
MW0:3J3HTJC<7)7C.,;1N<\3[&A.M&M&*YUB50]VLFM(5.6$[^SLN:4(RE/5:
M/E:EG_L^^+O&/PW;_@H#X9U[X4?"WPAXB\/?!CQYJVM^"->^$W@_7T\*Z_:_
M$?X>:7>>"T'BZP\1ZC)X)T\EFM?"-[JNJ>'VN%@U1([B<17CUC:5*NLFJ0Q&
M(J0GBZ,(5H8FK'VD'AZS55^SG3C[9]:L5&>\79-J)7A"I]0E&K5FI5H1C.-6
M<7*/LJKY_=:2F^L_CMI=6/S,N9VNKBXN7CMXFN)I9VBM+>&TM8FF=I#';6EN
MD=O:VZ%BL-O B0PQA8XD5%5:]Q*R2NW;2[=V_-MZM]V]SU$K)+73375_-]60
MT % !0 4 % ']E?_  ;_ /\ R9-XQ_[.)\<?^H%\+:_,^,?^1I1_[ :7_I_$
MGR&>_P"^Q_Z\4_\ TJH?N+7R9XP4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y\_\ !63_ )1B_M_?]FA_'[_U
M6WB&OH>$O^2HX>_['.7?^I5(]7(O^1SE?_8?A?\ T]$^L?@3_P D0^#?_9*O
MAY_ZB.CUX^,_WS%_]A-?_P!.S.#$?[Q7_P"OU7_TMGJM<QB?F7I_[4?[8?Q2
M_:,_:I^$'P&^"W[--[X-_9?^(?@#X=ZCXH^+?QV^*7A+Q3XKO_&GP>\!_%F;
M4+/PUX/_ &?O'>CZ;9V$7C;^Q($F\47,]W+IIO)H[-+A(4 /</@9^U=/X_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\J[SJ/K'XB?M+>$/BM:Z#<^.?V<_ FI^,?#OPQ\%?"ZP\:67Q"^,.D7+:;X
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M .G9G!B/]XK_ /7ZK_Z6SU6N8Q/S!_8E_P"3S_\ @K;_ -G.? C_ -8W^!-
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M ?C%\0;7Q?X-U7P]XKM5L-8$VDP^'M*D%])8>?90W:W0:"WO+H(I>1'0 _&
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MXK_T](_1:OG3R@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_P"#;G_E"Y^Q
MG_W<3_ZU=\=*^T\0_P#DL,W_ .Z?_P"JO GT'%/_ "/L=_W*_P#J'AS]QJ^+
M/GS_U?[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0
M<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H _SO/VYXY)/VT_VMFC1W4_M)_&T;D4LN5^(_B-6&1D95@58=F!!
MP1BOVK*4_P"RLLT?^X87I_TYC_7_  Y]]@?]SPO_ &#T?_2(GROY$_\ SQE_
M[]M7?:79_<=0>1/_ ,\9?^_;46EV?W 'D3_\\9?^_;46EV?W 'D3_P#/&7_O
MVU%I=G]P!Y$__/&7_OVU%I=G]P!Y$_\ SQE_[]M1:79_< >1/_SQE_[]M1:7
M9_< >1/_ ,\9?^_;46EV?W 'D3_\\9?^_;46EV?W 'D3_P#/&7_OVU%I=G]P
M!Y$__/&7_OVU%I=G]P!Y$_\ SQE_[]M1:79_< >1/_SQE_[]M1:79_< >1/_
M ,\9?^_;46EV?W 'D3_\\9?^_;46EV?W 'D3_P#/&7_OVU%I=G]P!Y$__/&7
M_OVU%I=G]P!Y$_\ SQE_[]M1:79_< >1/_SQE_[]M1:79_< >1/_ ,\9?^_;
M46EV?W 'D3_\\9?^_;46EV?W >C_  <U?7_"OQ@^$WBCP[X1N/''B'PW\3OA
M_P"(- \$QVUU/)XRUO1?%NCZEI'A.."SM;Z[F?Q)J%M;Z,D-K97ES(UZ$@M;
MB5DB;'$TU4PV)A4FZ5.>'KPG5=DJ4)4IQE4;;27LXMSNVE[NK6K,ZT5*E5C*
M7)&5.<93T]Q.+3EK9>ZM=7;36Q],?\%"/BG\5?C7^T9<^./B[^S]J'[-OC)_
M GA/1W^&5]IFMZ;<1Z5ILVM/I_B%K;7M"\.W^W6&N[F-)/[-6!Q8$17$Q5PG
M!DN&H87 JCA<6L?25:K+ZQ%PFN:7+>G>$YQ]RR>]_>U2T<N;+Z5*CAE"E66(
MASS?M4TTV[7C[KDO=]>NM_L_$'D3_P#/&7_OVU>K:79_<=H>1/\ \\9?^_;4
M6EV?W 'D3_\ /&7_ +]M1:79_< >1/\ \\9?^_;46EV?W 'D3_\ /&7_ +]M
M1:79_< >1/\ \\9?^_;46EV?W 'D3_\ /&7_ +]M1:79_< >1/\ \\9?^_;4
M6EV?W 'D3_\ /&7_ +]M1:79_< >1/\ \\9?^_;46EV?W 'D3_\ /&7_ +]M
M1:79_< >1/\ \\9?^_;46EV?W 'D3_\ /&7_ +]M1:79_< >1/\ \\9?^_;4
M6EV?W 'D3_\ /&7_ +]M1:79_< >1/\ \\9?^_;46EV?W ?V3?\ !O\ \?L4
M>,U/#)^T5XW#J>&4GP#\*V 8=02K*P!QE6!Z$%OS+C)-9I1O_P! -+R_Y?XG
M^O\ ASY#/?\ ?8_]>(?^E5/Z_P"&/W%KY,\8* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\^?^"LG_ "C%_;^_
M[-#^/W_JMO$-?0\)?\E1P]_V.<N_]2J1ZN1?\CG*_P#L/PO_ *>B?6/P)_Y(
MA\&_^R5?#S_U$='KQ\9_OF+_ .PFO_Z=F<&(_P!XK_\ 7ZK_ .EL]5KF,3XT
M\4?L#_LX^*?B1\2?BRT?QW\(>.?C!JFB:W\3+[X3_M>_M=?!31?&6L>'/"NC
M>"-&U36/!WP?^.?@;P9)J%GX4\/Z/HGVN'0()[BUL8VNWGG>664 ]F^"_P"S
MW\&/V>-!UGP[\&_A_HO@BR\3:W/XF\6WUHU_JGB7QMXHNK>&UN?%/COQEKUY
MJGB[QSXHN;6WM[>Y\1^+=<UG6YX((HI;YDC15 /"OAG_ ,$]_P!FSX-MX;A^
M&$W[1W@S0_"&K/K/ASP3I'[;?[:R_#33+F75[C7I[./X77'[05S\.IM!NM5N
M[JYN_#%UX8G\-W:W%Q;7.E2VDTD# 'T=-\'?AO/\8K#X_2^&HW^+FE_#;5?A
M%8^+_P"T]:$L'P[UOQ-I'C'5/#@T==2'AZ1+KQ)H.E:D=2ETA]9B:T%M!J45
ME-<6TH!C?'?X ?"O]I7P$/AK\8=#U?7O"<7B?PCXULX_#WC?QY\./$&E>+?
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M7_J&:97M<7?\E3Q#_P!CC,/_ %)J'H9[_P CG-/^P_%?^GI'Z+5\Z>4% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!^'/\ P;<_\H7/V,_^[B?_ %J[XZ5]IXA_
M\EAF_P#W3_\ U5X$^@XI_P"1]CO^Y7_U#PY^XU?%GSY__];^_B@#\.?^#;G_
M )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W
M&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /)]3^ OP,
MUK4;[6-9^"_PGU;5M4O+G4-3U34_AUX/O]1U&_O)GN+N^OKZZT::YN[RZGDD
MGN;FXEDFGF=Y)'9V9JZ8XS%QBHQQ6)C&*48QC7JJ,4M$DE-)))622LME<U5:
MLDDJM5)*R2J2LDMDET2[(H_\,Y?L]?\ 1!_@S_X:_P $?_**G]>QO_09BO\
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MV-_Z#,5_X45O_E@>WK_\_JO_ (,D'_#.7[/7_1!_@S_X:_P1_P#**CZ]C?\
MH,Q7_A16_P#E@>WK_P#/ZK_X,D'_  SE^SU_T0?X,_\ AK_!'_RBH^O8W_H,
MQ7_A16_^6![>O_S^J_\ @R0?\,Y?L]?]$'^#/_AK_!'_ ,HJ/KV-_P"@S%?^
M%%;_ .6![>O_ ,_JO_@R0?\ #.7[/7_1!_@S_P"&O\$?_**CZ]C?^@S%?^%%
M;_Y8'MZ__/ZK_P"#)!_PSE^SU_T0?X,_^&O\$?\ RBH^O8W_ *#,5_X45O\
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M%_\ 837_ /3LS@Q'^\5_^OU7_P!+9ZK7,8A0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'FWQE_Y)!\5O^R;>.?\ U&-4KHPG^]8;_L(H_P#IR)K0
M_CT?^OM/_P!+1\9?\$B?^47O[ W_ &:K\&O_ %#-,KVN+O\ DJ>(?^QQF'_J
M34/0SW_D<YI_V'XK_P!/2/T6KYT\H* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M#\.?^#;G_E"Y^QG_ -W$_P#K5WQTK[3Q#_Y+#-_^Z?\ ^JO GT'%/_(^QW_<
MK_ZAX<_<:OBSY\__U_[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W
M_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H *
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MY!!Z$'N"*^*/ %H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M(_)/_"G.O_GD']J8+_H0Y;_X,S'_ .;@_P"'?/[6O_27W]M3_P -_P#LE?\
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MC,5B,7.,83Q%:I6E&-^52J2<FES7=KO2[OZGN=<)S!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?AS_P &W/\ RA<_8S_[N)_]:N^.E?:>(?\ R6&;_P#=/_\
M57@3Z#BG_D?8[_N5_P#4/#G[C5\6?/G_T/[^* /PY_X-N?\ E"Y^QG_W<3_Z
MU=\=*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M<^5E&46XR3C).S35FFMTT[6?R^ZQLU(@H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M_#G_ (-N?^4+G[&?_=Q/_K5WQTK[3Q#_ .2PS?\ [I__ *J\"?0<4_\ (^QW
M_<K_ .H>'/W&KXL^?/_1_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2
MPS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MC3A"3712Y4N:W1O5;:7M'Z/KA.<* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * / /VL/^36?VE?\
ML@'QD_\ 5=>(Z[,N_P"1A@?^PS#?^GJ9OA?]YP__ %_H_P#IR)_G(/\ ?;_>
M;^=?MKW?JS]!&T@'Q_ZR/_?7_P!"%-;KU0'^FIX<_P"1>T+_ + VE_\ I#!7
MX1/XY?XI?F?G#W?JS9J1!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS_P;<_\
MH7/V,_\ NXG_ -:N^.E?:>(?_)89O_W3_P#U5X$^@XI_Y'V._P"Y7_U#PY^X
MU?%GSY__T_[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ
M\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P"C5_VC_P#PQ_Q,_P#F7I?VGEO_ $,,#_X5T/\ Y8'UW"?]!6&_\**(^/\
M8V_:\#H3^RO^T> '7)/P/^)G R/^I8'\_P J:S3++K_A0P.Z_P"8NA_\L#Z[
MA/\ H*PW_@^E_P #\_N/]$;0(Y(M"T6*5'CEBTG38Y(Y%*21R)9PJZ.C89'1
M@596&5(P<$5^+3^*7^)_F? O=^K-:I$% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP
M)]!Q3_R/L=_W*_\ J'AS]QJ^+/GS_]7^_B@#\.?^#;G_ )0N?L9_]W$_^M7?
M'2OM/$/_ )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;V$\='#WP,:NS3JJI[2R:LYJER:-J7(G(YI\495#$O#N=6T9^SEB%3OAU/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^'/\
MP;<_\H7/V,_^[B?_ %J[XZ5]IXA_\EAF_P#W3_\ U5X$^@XI_P"1]CO^Y7_U
M#PY^XU?%GSY__];^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\
MNG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % 'X<_\&W/_*%S]C/_ +N)_P#6KOCI7VGB'_R6&;_]T_\ ]5>!/H.*?^1]
MCO\ N5_]0\.?N-7Q9\^?_]?^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_
M )+#-_\ NG_^JO GT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'X<_P#!MS_RA<_8S_[N)_\ 6KOCI7VGB'_R6&;_ /=/_P#57@3Z
M#BG_ )'V._[E?_4/#G[C5\6?/G__T/[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=
M*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQYWF\,HR?&YM&$<2L+34HTU5C&-2<JE.E&/M$I6M*HI244Y<J=NASYACHX'
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MJ+Y5%MI)-Q]&MFM.EE']JV3B\-"M"FW;FJ324:5_^OCY792:2;MHSZF^!O\
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M>J/HT[ZK5/5-=2*F 4 % '^IA_P;/_\ *'#]F3_L8OCY_P"K\^)%?S1XC_\
M)79E_P!>LO\ _5?A3\BXK_Y'F*_P8;_U'I'[T5\,?.!0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?AS_ ,&W
M/_*%S]C/_NXG_P!:N^.E?:>(?_)89O\ ]T__ -5>!/H.*?\ D?8[_N5_]0\.
M?N-7Q9\^?__1_OXH _#G_@VY_P"4+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I_
M_JKP)]!Q3_R/L=_W*_\ J'AS]QJ^+/GPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /YA?^#M/_E%[X2_[.T^%'_J!?&"OTGPK_P"2
MFJ_]BK%_^G<*?6<&_P#(WE_V!UO_ $NB?YL-?T.?J@4 % '[J?\ !MG_ ,IB
MOV8?^P+\9_\ U4WBNOA_$7_DD\P_Z^83_P!2:1\]Q3_R),7ZT?\ T] _:?\
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M)%?S1XC_ /)79E_UZR__ -5^%/R+BO\ Y'F*_P &&_\ 4>D?O17PQ\X% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^'/_!MS_P H7/V,_P#NXG_UJ[XZ5]IXA_\ )89O_P!T_P#]5>!/H.*?
M^1]CO^Y7_P!0\.?N-7Q9\^?_TO[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\
M0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?D7%?_(\Q7^##?\ J/2/WHKX8^<"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]9<R_P"B4S+_ ,..4_\ S6']K8O_ *$F,_\ "K!?_+ _X=P?LF?]):_V8/\
MPPW[9_\ \X2C_67,O^B4S+_PXY3_ /-8?VMB_P#H28S_ ,*L%_\ + _X=P?L
MF?\ 26O]F#_PPW[9_P#\X2C_ %ES+_HE,R_\..4__-8?VMB_^A)C/_"K!?\
MRP/^'<'[)G_26O\ 9@_\,-^V?_\ .$H_UES+_HE,R_\ #CE/_P UA_:V+_Z$
MF,_\*L%_\L#_ (=P?LF?]):_V8/_  PW[9__ ,X2C_67,O\ HE,R_P##CE/_
M ,UA_:V+_P"A)C/_  JP7_RP/^'<'[)G_26O]F#_ ,,-^V?_ /.$H_UES+_H
ME,R_\..4_P#S6']K8O\ Z$F,_P#"K!?_ "P/^'<'[)G_ $EK_9@_\,-^V?\
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M*56=.<N2$/8\W-2E*%G.E.VSLM5JV?MC7QIX 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'X<_\ !MS_ ,H7
M/V,_^[B?_6KOCI7VGB'_ ,EAF_\ W3__ %5X$^@XI_Y'V._[E?\ U#PY^XU?
M%GSY_]3^_B@#\.?^#;G_ )0N?L9_]W$_^M7?'2OM/$/_ )+#-_\ NG_^JO G
MT'%/_(^QW_<K_P"H>'/W&KXL^?"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H _'G]NPD?\%-?^")N"1_Q=K]MD<<<']C[Q8"/H02#Z
MCCO7UF2?\DYQE_V!Y-_ZN<,>YEW_ "*<_P#^O.7_ /J= _8:ODSPPH * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /QV_X)(_\CA_P5M_[2\_M
M)_I\*?V?*^LXI_@\*_\ 9*X#_P!2\>>WG/\ "R7_ +$V'_\ 3^*/V)KY,\0*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_2]+\%>._$/P8^-N@?#CXC:CK>KZ?HFD6?PP^(VL?#NR\$_$J?4;[4[5[-/
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'X<_P#!MS_RA<_8S_[N)_\ 6KOCI7VGB'_R6&;_ /=/_P#57@3Z
M#BG_ )'V._[E?_4/#G[C5\6?/G__UO[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=
M*^T\0_\ DL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /PY_P"#;G_E
M"Y^QG_W<3_ZU=\=*^T\0_P#DL,W_ .Z?_P"JO GT'%/_ "/L=_W*_P#J'AS]
MQJ^+/GS_U_[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\ DL,W_P"Z?_ZJ
M\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#\>/V[?^4FO_!$W_LK?[;'_ *Q_XLKZS)/^2<XR
M_P"P/)O_ %<X8]S+O^13G_\ UYR__P!3H'[#U\F>&% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!^.W_  21_P"1P_X*V_\ :7G]I/\ ]53^
MSW7UG%/\'A7_ +)7 ?\ J7CSV\Y_A9+_ -B;#_\ I_%'[$U\F>(% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!^'/_!MS_P H7/V,_P#NXG_UJ[XZ5]IXA_\ )89O_P!T_P#]5>!/H.*?^1]C
MO^Y7_P!0\.?N-7Q9\^?_T/[^* /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\
MDL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\
M\K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9
M'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8
M?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_
M^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J
M_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\
M+FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^
M*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_T
MC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_
M (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=
M*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+
M_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A
M/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_ %0J_P#1
M1<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B)_\ +FC_
M %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X+(_^*]/B
M)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*Z'_TC._X
M+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\ \K#_ (?*
MZ'_TC._X+(_^*]/B)_\ +FC_ %0J_P#11<(_^)#A/_E8?V'+_H:9'_X=*/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /PY_X-N?\ E"Y^QG_W<3_ZU=\=*^T\0_\
MDL,W_P"Z?_ZJ\"?0<4_\C['?]RO_ *AX<_<:OBSY\__1_OXH _#G_@VY_P"4
M+G[&?_=Q/_K5WQTK[3Q#_P"2PS?_ +I__JKP)]!Q3_R/L=_W*_\ J'AS]QJ^
M+/GPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\
M6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P
M_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\
M[[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB
M_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_
M^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4I
MP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\
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M?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\
MK+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!
M_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\
M#D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A
M_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\
M[N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM
M_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\
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MZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\
M6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P
M_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\
M[[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB
M_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_
M^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4I
MP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\
MU2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY
M_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11
M_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\
M5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_
M/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_
M\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!
M<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]
M?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\
MK+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!
M_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\
M#D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A
M_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\
M[N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM
M_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\
M^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#
M_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J
M2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8
M/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_
M %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#O
ML/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_
M .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X
M8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!
M?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5
M*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_
M -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^
MN?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q4
M4?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\_
M_%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q
M/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%Q
MO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_
MP7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"L
MO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_
M *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .
M0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_
M  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#N
MX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_
M .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X
M;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_
M /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)
MP_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_
MZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\
M6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P
M_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\
M[[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB
M_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_
M^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4I
MP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\
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M?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\
MK+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!
M_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\
M#D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A
M_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\
M[N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM
M_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\
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MZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\
M6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P
M_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\
M[[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB
M_P#OL/\ 6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_
M^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4I
MP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\
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M?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A_P .0?\
MK+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\ [N'_  Y!
M_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM_P#NX?\
M#D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\ ^&W_ .[A
M_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\ [[#_ %@_ZDG#_P#X;?\
M[N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\ 6#_J2</_ /AM
M_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P_P!8/^I)P_\
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MZDG#_P#X;?\ [N'_  Y!_P"LO7_!<;_Q/S_\5%'^N?\ U2G!?_AB_P#OL/\
M6#_J2</_ /AM_P#NX?\ #D'_ *R]?\%QO_$_/_Q44?ZY_P#5*<%_^&+_ .^P
M_P!8/^I)P_\ ^&W_ .[A_P .0?\ K+U_P7&_\3\__%11_KG_ -4IP7_X8O\
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M=22O&FF[R?O7:LM(_55>6<9__]/^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
@H * "@ H * "@ H * "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pgen-20201231_g14.jpg
<TEXT>
begin 644 pgen-20201231_g14.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Q ]@# 2(  A$! Q$!_\0
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MH_X;/^,/_0WC_P %EG_\9H^IU.Z#V;/T_HK\P/\ AL_XP_\ 0WC_ ,%EG_\
M&:/^&S_C#_T-X_\ !99__&:/J=3N@]FS]/Z*_,#_ (;/^,/_ $-X_P#!99__
M !FC_AL_XP_]#>/_  66?_QFCZG4[H/9L_3^BOS _P"&S_C#_P!#>/\ P66?
M_P 9H_X;/^,/_0WC_P %EG_\9H^IU.Z#V;/T_HK\P/\ AL_XP_\ 0WC_ ,%E
MG_\ &:/^&S_C#_T-X_\ !99__&:/J=3N@]FS]/Z*_,#_ (;/^,/_ $-X_P#!
M99__ !FC_AL_XP_]#>/_  66?_QFCZG4[H/9L_3^BOS _P"&S_C#_P!#>/\
MP66?_P 9H_X;/^,/_0WC_P %EG_\9H^IU.Z#V;/T_HK\P/\ AL_XP_\ 0WC_
M ,%EG_\ &:/^&S_C#_T-X_\ !99__&:/J=3N@]FS]/Z*_,#_ (;/^,/_ $-X
M_P#!99__ !FC_AL_XP_]#>/_  66?_QFCZG4[H/9L_3^BOS _P"&S_C#_P!#
M>/\ P66?_P 9H_X;/^,/_0WC_P %EG_\9H^IU.Z#V;/T_HK\P/\ AL_XP_\
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MS_C#_P!#>/\ P66?_P 9H_X;/^,/_0WC_P %EG_\9H^IU.Z#V;/T_HK\P/\
MAL_XP_\ 0WC_ ,%EG_\ &:/^&S_C#_T-X_\ !99__&:/J=3N@]FS]/Z*_,#_
M (;/^,/_ $-X_P#!99__ !FC_AL_XP_]#>/_  66?_QFCZG4[H/9L_3^BOS
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /S'_ &Y)-O[1VMC_ *=+/_T2*\$\
MZO;OV[;CR_VE-='_ $YV?_HD5\__ &NOHZ/\./H=<=D:7G4>=6;]KH^UUL4:
M7G4>=6;]KH^UT :7G4>=6;]KH^UT :7G4>=6;]KH^UT :7G4>=6;]KH^UT :
M]O#/=LRP0R3%1DB-"V/RIDF^&1DD1HW7@JP((_"OOK]CNRTOX,?L\3>-]?\
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M3_\ TICK]C*\C&_%$PJ;H****\TQ"BBB@ HHHH **** "BBB@ HHHH ****
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MPO)/$<FNAMFH->-?Y4G E,GF<>VZOVG^'M_X?^-G@GX?_$2X"3SV=J;V"9B
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M0]ZN6OBB_L89(;>^N((I!AXXY656^H!K3_X43\5/^B9>-/\ PG;S_P"-T?\
M"B?BI_T3+QI_X3MY_P#&Z/<[H+(P6U)F;+,2?4U+:ZW<64JRV]Q)!(IR&C8J
M0?7(K9_X43\5/^B9>-/_  G;S_XW1_PHGXJ?]$R\:?\ A.WG_P ;H]SN%D9-
MYXAN]2E,EW=S7,AZM,Y8_J:K?VA[UO\ _"B?BI_T3+QI_P"$[>?_ !NC_A1/
MQ4_Z)EXT_P#"=O/_ (W1[G<+(PUU62,865E'^R2*&U:5AAI78>[$UN?\*)^*
MG_1,O&G_ (3MY_\ &Z/^%$_%3_HF7C3_ ,)V\_\ C='N=QV1@?VA[T\:M(J%
M!*X3^[N./RK<_P"%$_%3_HF7C3_PG;S_ .-T?\*)^*G_ $3+QI_X3MY_\;H]
MSN%D8<>JR19V2LG^Z2*;_:!SG<<UO?\ "B?BI_T3+QI_X3MY_P#&Z/\ A1/Q
M4_Z)EXT_\)V\_P#C='N=Q61AOJTDB@/*[ = S$XI%U)D;*N5/J#BMW_A1/Q4
M_P"B9>-/_"=O/_C='_"B?BI_T3+QI_X3MY_\;H]SN%D9MUXJU&^ACAN-0N9X
MHQA$DE9E7MP":J)JCQME)&0^JG!K=_X43\5/^B9>-/\ PG;S_P"-T?\ "B?B
MI_T3+QI_X3MY_P#&Z/<[H+(P6U)G8LSEB>I)R:%U$J00Q!]16]_PHGXJ?]$R
M\:?^$[>?_&Z/^%$_%3_HF7C3_P )V\_^-T>YW"R,UO%6HR6:VC:A=-:KTA,S
M;!^&<5474F5MP<AO4'FMW_A1/Q4_Z)EXT_\ "=O/_C='_"B?BI_T3+QI_P"$
M[>?_ !NCW.Z"R,)]4>1LO(SGU8Y-+_:TACV&5RG]W<<?E6Y_PHGXJ?\ 1,O&
MG_A.WG_QNC_A1/Q4_P"B9>-/_"=O/_C='N=PLC#CU22%P\<C1N.C*2#4EWKU
MS?W#3W-S+<3-R9)7+,?Q-;'_  HGXJ?]$R\:?^$[>?\ QNC_ (43\5/^B9>-
M/_"=O/\ XW1[G<+(PY-5DEQOE9\=-Q)J:'Q%=VT$D,-W-%#)P\:2$*WU&:UO
M^%$_%3_HF7C3_P )V\_^-T?\*)^*G_1,O&G_ (3MY_\ &Z/<[H+(P_[6DVE?
M-;:>2N3@TU=29&#*Y4CH1P:WO^%$_%3_ *)EXT_\)V\_^-T?\*)^*G_1,O&G
M_A.WG_QNCW.X61D7?B"[U H;FZFN"BA%\URVU1T R>E1-JTDBA6E=E'0,20*
MW/\ A1/Q4_Z)EXT_\)V\_P#C='_"B?BI_P!$R\:?^$[>?_&Z/<[H+(PH]4>)
MMR2,C>JD@U->>(+O496ENKJ:YD;JTSEB?S-:_P#PHGXJ?]$R\:?^$[>?_&Z/
M^%$_%3_HF7C3_P )V\_^-T>YW061A)J;QME'9#ZJ<&AM2:1BS.68]23DUN_\
M*)^*G_1,O&G_ (3MY_\ &Z/^%$_%3_HF7C3_ ,)V\_\ C='N=PLC#;5I'4*T
MKLHZ*22!3/[0]ZW_ /A1/Q4_Z)EXT_\ "=O/_C='_"B?BI_T3+QI_P"$[>?_
M !NCW.X61@?VA[T?VA[UO_\ "B?BI_T3+QI_X3MY_P#&Z/\ A1/Q4_Z)EXT_
M\)V\_P#C='N=QV1@?VA[T?VA[UO_ /"B?BI_T3+QI_X3MY_\;H_X43\5/^B9
M>-/_  G;S_XW1[G<+(P/[0]Z/[0]ZW_^%$_%3_HF7C3_ ,)V\_\ C='_  HG
MXJ?]$R\:?^$[>?\ QNCW.X61@?VA[T?VA[UO_P#"B?BI_P!$R\:?^$[>?_&Z
M/^%$_%3_ *)EXT_\)V\_^-T>YW"R,#^T/>C^T/>M_P#X43\5/^B9>-/_  G;
MS_XW1_PHGXJ?]$R\:?\ A.WG_P ;H]SN%D=3^S7?%_VBOA:N>OBG2Q_Y-Q5^
M\]?AG^SG\&/B3I?[07PRO;_X>>+K&QMO$^F33W5SH-W'%#&MU&6=W:,!5 !)
M). !7[F5X.8VYXV.6MN@HHHKR#G"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH X3XWV>J7WPQUI-'C>:]5%E\F(9=U5U9@H[G /'?&*^*+'XA7.H
M:EI%CH]PXUF;4TLHWY 20[=@^N2?ICFOT2KXL^.7@:W^&_[:'P<\5VT*6^@^
M(+^:VN+>-<)]O,;*'(Z?,&0_5&/>NW#R6L7ZFL'T/M"$.L*"0Y<*-Q]\<T^B
MBN(R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***\W^+'QZ\-_!O7O!FD:[#J$MUXKOSI]BUE"KHD@
MV\R$NN%^<<@$^U5&+D[10TF]$>D4445(@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***I:SK5AX=TJZU/5+R#3M.M8S+/=74@CCB0=69CP!]: +M%4=
M#US3O$NDVNJ:3?6^I:;=()(+NUD$D4JG^)6'!'TKS_X2_'O2OB]XF\9:+I^D
M:OIL_AF]^Q3RZC;^7'.>?FC.>1P>N#T/>K49--VV'9GIU%%%0(**** "BBB@
M HHHH **\T_:.^+D_P #/@[X@\:VVG1ZK<:9&KI:2R&-7)8+R0"0.:Z[P'XD
M;QEX'\/:^\(MGU33[>^:%3D1F2-7*@]\;L5?(^7GZ#L[7-VBBBH$%%%% !11
M7B/[//[1<WQR\6?$[1Y=$325\'ZP-,CE6<R&Y4F0;B,#:<QGCGJ/2K4)2BY+
M9#LVKGMU%%%0(**** "BBB@ HHHH **** "BN.^+OQ,LO@]\.]8\7:A87NIV
MFFQB1[73X_,F?+!?E'U/)/05:\,?$+2_$?P[T_QI*9-&T>ZL%U%SJ@$#6T17
M<3+DX7 Z\XXJN65N:V@[/<Z>BL_P_P"(=+\5Z/:ZMHVH6VJZ9=+O@O+.598I
M!D@E6!P>01^%:%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYM_;XLVL?@G8>,H#LO/!GB'3-=B?86.%N%B<<=MLI)_W:^DJ\&_;JC:;
M]E+Q]&J&1F@M@$ R6S=0\#WK>A_%CZE1^)'MVDZE;ZQI=G?VLJSVMU"DT4J'
M*NK*""#Z$&K=?*'_  3Q^*DOB;X.6GA+55N8]5\/J(86N+66$36Q)V%6< -L
M.4^4]%4]Z^KZFI!TYN+Z!)<KL%%%%9$A117*?$+Q_:> =+2>91-=3$K!!G&X
MCJ2?09%-)MV0'5T5X#'\?]0^VC*QE 1^[\L;6]0#U_6O:?#/B"#Q-H\-]!\H
M;ATSG:PZBKE"4=QM-&K11168@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "LKQ9X@B\)^%=9UR>)IH=,LIKUXT^\ZQH7('N0M:M1W%O'=020S1K
M-#(I1XY%!5E(P00>H(IK?4#\O_@__P %3/'/BOXX:1I>NZ-I9\*ZSJ$=BEI:
MQ,L]L)'"1L'R=Q!(SG@C.,5^HE?/G@G]A'X._#_XE+XWT?PXT6K13-<6\,MR
M\EO;R'/S)&3@8SQZ=L5]!UUXF=&<DZ,;&M1Q;]U!7QG^WQ_R53]G/_L9W_G#
M7V97QA^W]-';_$_]G6661(HD\32%I)&"JH_<\DGH*,)_&7S_ "8J?Q'V?7SU
M\0[S]HWQ1XSU6P\#6GA7P=X7LG\NWU76BUW=7QP"76-?E1#R/FPP]Z]NM_&&
M@W4Z00ZWITTSG:L<=W&S,?0 'DU\?Z%XL\=?M4?'_P")/A2/XD:E\./#/@VZ
M-I#IGAT1PZA=<E3,\KJ2%R.G(!(QCJ9HQ=W)I67<(K=GH?[-7[0/C;Q1\3/&
M/PL^)VF:9:>,O#<<=PM]HY;[/>P/T8*W(/(/;@]!7GOC+]JWXLW7[1WCCX1^
M!?#^G:KJT8@&D7=TI2WL$V[IY[E@<L.5V@#KV/2N0_93TVRT;]O3XB:?8^-=
M2\?Q6NBQPMK>JW8NKB1U*!D:0  [#\O'I7H?P$ _X;\^/!QS_9UG_,5V2A"$
MY2Y;^ZG\]#5I)MVZ'9>+?C9X^_9V_9LF\2_$VTTO7O'JWGV"TM]%)6UNI9'(
M@R2 0,<M@=NV>/(/C-\6/VI_@O\ #>'Q[K.H>"WTN>2$7-A:6,C/IPDQCD\N
M 3SSD=LUZ#_P4IO+6/\ 9Y@LKN)HUOM<LH4U0E@FFMO)^T,5Y^49X[YKRJ]T
M7Q)^T-IFC^!?'?Q^^'-]X'@N(7G70IXX]1U54P41U9QL)[[<_0FBC&/*JDDK
M-N^G3R"-K<S1]'ZS\<-6^"/[-<7COXE2:?J^NI C"'0PT<5[+*?W,<>X9!8$
M9..QXKS&\\=?M76/@F3XBR:5X)_L^.T_M!_!NR;[2MN!O(\[/^M"=LX_E3_^
M"E'A6=_V8+/^S5N5TO1-4LIKE+4%FCMERF_/^SD<^]+X1_9/T#Q]X&LM:T[X
MZ_$74-#OK-6,D/B-7AV,@W*?EP  2"#TZ&HIJFJ:J2MJWTO\O(E<MN9GT'\#
M_BWIOQR^%^A>--*B:VM]2AWO;2-N:"0'#QD]R"#S7%_M3_'S4_@EX>\/V?AK
M2(=;\9>*-172]'M;IBL D.-TDA!SM4$<#KGK72_L[_"OPM\&OA;IOAKP=J<F
ML:#')+/%>R7*3F5G<ECO3Y2,YZ5\\?\ !1J^B^W?!ZP_M&+PM>OX@:XMO%EX
M&-OIC(@/S <-N.W(/85A2A"=?E2]W4F*3G9;'/?&CXL?M1_ N;PL-:UWP3>6
MGB+4%TZ.\@L)!'9SOC:KC&2F3PW)]:]^^.'Q^U3]GOX2Z%>:QI]MXC^(&K21
M:;9:7IY:.&[OF')4GD1@\GOCTKPS1O"NL_M(>/?!Y^)WQF^'^N:-X?O5O;/0
M?"-U&)M1N4/RO)E]PZ [5!'IZU9_X*7:(TLGPBUJ^U#4-*\.66O^3J&I:>VQ
M['S H68/_">#S[5U<L)U(4Y)7UO9?<:63:3-CQM\4/VFO@?X5D^(/B^P\&>(
MO#5KY<VK:#I*RQ7-E 2 QBE8X8KGG=G\>M=-^T]^U9?_  R^#/@;Q_X.ABU"
MRU[4+3?')"9'>VD&YD09'SXR![UD:O\ L6^&O$OA"ZGU+XX>/]1\+WD!,\MS
MXC22TEA/.68KM*_7BN,_;5\%Z1\._P!GGX/>&M N'N]%TWQ!I\%I<22B5I(P
M<AMPX;.>HXI05&I."M=W[6T$N631I_$+XX?M/>$_!]W\56\)>%=,\$6JBZ?P
MM=22OJB69;[\S !1)M()"GC/W>"*]Q\3_M0>'/#/[.%M\7Y8)9M,N[&*YM;!
M6Q)--)PD ..I;(SCMFK_ .U4H;]F_P"(H(R/[%GX/^[7QG\5M"OM8_X);_#B
MYM?M+6VF_8[N\6U&66$2N&?VVY!S4TXPK*+:M[UM.PDE)+3J>PS>.OVKH_!+
M?$7^RO!*:>MI_:'_  AK),;G[/C?@S9_UNSMG'\JR?VD/BQXH^/G[$USXV\!
M/I6G^'+[2KA_$5GJ89[F.-1M:*%E&W>&!Y.!BMCP3^RGH/Q \!Z?KFF?'7XB
MW^BWMDKF2'Q&K0A"@W(?EP, D$'IT-:'COX.^&OA+^P7X_\ "G@?49-<T;^R
MKR>&\DN4N#*['+G>@VXR#T]*I2IJ<;)7372P_=NO4R?V!;3XR1_#7P#-K%]X
M8E^&+:.?LEO;QR#45Y/E[CC;USGD\5Z)^S#\;-?^+/CCXO:9K,-E%;>&M=6P
ML?LD.QO**M]\Y.XY7K[U9_8=U6SNOV4_ADD5U#)(-,\DHK@G>C-N7'J*\R_8
M9C:7XD?M'(K;&;Q.H#>A*R\U%2TG5;6J_P Q2UYB:Z_:"^,'Q\^(WBSP]\$;
M3P]I7AKPQ<?8KSQ-KP>0W-P"=R1(!T&".1[YZ"O</@/K_P 3M4TG5K+XI^']
M-TG6]/N5B@O]'F+VFHQ%<^8BD[E(/!!Q]!7SU_P3G\1:?H:_%#P/J5Q'9>*K
M#Q-<SS6=RP2:6-F.'"DY8#'7MD>M?6WAOQ[X=\87^K66AZU9:O<Z3*L-\EG,
M)1;R,-P1B.,X[9X[UGB+0;IQCHNO7^F3/1\J11^+7BB\\$_#'Q1K^GK&U]IN
MG374(F&4WJA(R.XS7R9\+OCS^TI^T?\ #G2=;\":!X:\.V]O %N]7\1;U&J7
M0)WBVC4,%B P-S=\X/6OIO\ :*_Y(1X]_P"P-=?^BS7CW_!//XG^%M?_ &7?
M#&EV>LVIU'P_;20ZG;22!'MCYCON8$_=VL#NZ44[1HN?+=W''2%['1?LK_M*
M:Q\:-'\5:/XIT*'1_B#X3N6M-2TVU<B*9N=CQ[B2 2,')(S@YP:Y?4KK]K?Q
M!;76N6,7@7PG!'ODMO#MR)+J>1!G"S3#*ASC^#CGM7GG[,OBJ/4_C]^TW\5-
M$CDU'PW$/+MI(Q\EQ+"F3M]<^6>1V(/>E^"T/C']ISX4WWQ4\9?'C7O!NGM-
M-C3?"ES#86NFQ1D_+*Y4DMC')P<8Y-;RIJ$Y2226F^NK6Q3BDVSI'_:^\<^,
MOV0->^)'AS1]/TWQIX9OS;ZSILR&6 )$X\XH-V0-IXR3C!KZ'\)_&72?$?P+
ML?B4TL<6F3:/_:<K9PJ%4)D7/LP9?PKY<_X)K:+8>*/@K\3-*GN&U?3+_7;J
MW:YN/G:XC=,;VR.2P.?J:\#/C[6?!/P9\7_LNH\S>+9O%R:'IT8.YWT^=][-
MZ 8 _P"_E5+#PG.5.*M9_@_\AN";<5T/:?B-\4O%_P :O^"=?C3QGXNM[6T?
M5+AY-.AMHBF+,3JL>[DY.0PS[5]$1_%[1_@5^R3X;\::V&DL].\.6!2WC(#W
M$K01A(E)X!9B!DUPW[8_@ZR^'O["NN>&M/55L]*TVVM(]JXW;&0%L>I.2?<U
MQ7[6^CWVI?\ !/KPA=6D4MQ#IMEHM[=11+G,*1Q[F/L,YJ4H55%;)R?Z"TE;
MM<V-+\9?M<^,_"4/CK2],\#Z587,/VVT\+70E>YEMR-R!Y.SE<8&1G/\/2O4
MO@7^TM<?'3X*ZKXGTCPXQ\8Z3YMI>>&C.$(O4'$8=NBL>A/3D'IFNW\"_%/P
MGJWPBTGQ?;:U81^'5TZ.9[MIT6.$",;E8YPK+@@@]Q7QC^S#XZU#X8_ C]HG
MXS:78?:=/U'6[K4-%AE0B.4(SXD(Z[<R+D_[)]*CE56,O=2::M\^@K<R>AZ=
MXJUS]KGP_P"&;[QI-_P@*0V,#7DOA6"*9V,2C<4\XG)? (P& SWKV#X6_M&:
M/X\_9TM?BQJ$8TG3TT^6\OX=VX0-%N$B@]QE<CV(KYFA\'^(_'W[-,WQ7\>?
MM$>); :EIDMXUKH=W#8Z:A*L%MM@3+'(VD#!)SQ5#X,:+J'B'_@E?XAL=,22
M6\DL+\K%$,M(%<LR@>X!K25*$HZVNI):*Q3BFOF=?X#^-?[3WQF\/M\2?"'A
MOPC:>"Y9))-.\/:E)*+V^MT8C(D P&." <@$YXQC.=_P3/UJ?Q)XJ^/>JW6G
M3:1=7GB&&>;3YSF2V=C<%HV.!DJ21T[5[+^R'\3_  K/^R;X/UDZM8Z?INDZ
M:MOJ$DTZHMI)'D.)"3\I.,\]=PKQ_P#X)M^(+'Q9XT_:"UG3)OM.G7_B2.YM
MIMI7S(V:X*M@\C((/-$G^[JQ4;6LOQ!_#)6/N.OD+5?V@OB[\<_BEXM\)?!"
MST#3=!\*S?8M1\3Z^'D\VYR08X8P.Q5AR#]TG(R ?KJ52\;JIVL00#Z5\6?\
M$]?$%CX=\0?&'P+JMQ'9^*K7Q3<W3VMR1'-<1.S .H)RPXS_ ,#'K7)12Y)S
MM=JQE'9L]O\ A?XN^,4?@WQ9'X^\':;-XJT<9TQ]%NPMKK0*$J$WG,9##:=V
M!\PXKRGQ/K7[7.A^&[WQE)_P@,,=E UY)X5ABFD8QJ-Q3SB<E\ C 8#/>O7_
M (N?M":-X0^%_P 1=>\+W]AXCUGPC9&6XL[>7S4@F928UE*GCH21G( /2OF?
M3_"/B/XB?LUR?%CQY^T1XETU=1TV6\>UT*[AL--BRK 6^P(2QR-I P2<C%;4
MXW]^44DW;9_@7'NT?1/@']H1_B=^RZ_Q1TRSCLK_ /LJYN6LY"72*XA#!E]U
MW+D>Q%>$?"7]H#]I+]I3X;:7JW@70?#?A^.VB*7NN>( ZIJ5R&;*VL:AML87
M:"Q'WLX/!%2?L@_\HYM6_P"O'5?Y-77_ /!.#XF>&-<_9>\.Z):ZQ;'5O#Z7
M$>I6DCA'M\SR2!R#_ 5<?-TZ^E7*$:2J.,;VE;\QM**=EU.K_95_:2UKXQ1>
M+O#7C'1(-$^(7A&Y^S:C8VC$0S@[MDD>XD@';@Y)'((X.!SFHW7[6OBB.ZUG
M3HO W@VV1G>UT"\$EU<2(,[5FE&55CP?DXY[5P'[-GB:#Q%^U9^TG\3=#5]1
M\-6UM':Q30C*7$T4:9V?WL^0W([$'N*K_ T^,_VK/AGJ?Q0\7_'/7/!.F_:9
MT72?"=S#86^FQ1G.)I&4DG!!R<'&,DTY4U&3DDDM-];-K8.6S;/?_P!E']HB
MY^/GPRO]8U[3(="\0Z+?S:;JUI Q:))8P"67))"D'ID\J>:\B\-_'KX[_M-:
MAKNK_!VT\+^'? .EWSV5IJGB 22S:H\>"S* #M1@1V! 8<DYQR__  3NL3K'
MP<^-5II>IS:F;G6KN.VU*5M\EQNC8)*Q[LV0Q/J:[7_@F9XRT=_V=%\-27,-
MGKV@:A=0ZE83NJ31'?NWLI.0,'&3W4CM14IQI.I*,;V:^5PE%1YFD=;XX^-'
MQ/\  O[*/B_Q?XL\-:9H/CS1/,A$,;_:;*Y 90EP@W9VL&/RL<Y4Y]*P?VC=
M?^(OCK]BFV\0>')M#M4U+PH;_P 1I>QOEK:2QWRK;@9 ;+'&?SK6_;(\<>'_
M !Y^R#\3KKP[J]IK5K9J;*>>RE$D:S(\99-PX) 9>GK5O5;66^_X)YO;PKOE
MD^'"(J^I.GBLX62C/EL^;_(E=';J>8?L!V?QL7X0>!IOM_A4_#5M.N_LMOY4
MIU!6WS>66. I_>]>?N^]>L_L8_M :]\;_"/B:Q\90VMKXW\+:O)IFJ06:%$X
M)V/C/&2LB_\  />HO^"?NK6=S^R+\.(X[F)I5@N+<Q[QN$BW$I*X]<<X]#FO
M$OBIXRMOV,OVQO$/BZZ4P^$O'WARXN65>%_M&W3<%51_$S+&/K.U7./MJE2%
MO>Z?)_Y%-<TI*VI[I\,/COXD^)_[4_Q%\):?%9GP!X/LXK:6Z6/,LFH.02-^
M>  )5QCK&?6OH6OF;_@GW\/;SPI\!8O$NLKN\2^-KV;Q%J$K+ASYK$QCZ%?G
M'_70U],UQU^6-1QCLM#*=KV04445SD!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%9^OZ]I_A?1;S5M5NH[+3K.,RSW$IPJ*.YH M7=Y!86TEQ<S);P1C<\DC
M!54>I)KX/_X* ?'Z3QI\+XO#GPTURPU!+F[$>I,EVMO(Y4JT4<1?&[)RV0>-
M@(-4OVM/VL/#OQ:\%MX.\/ZU=Z!--.KLTEH\YO,9VQ%(2649VL3TP1ZU\-^&
M]2U#3?$VGQQ1Z7J%Y$I:XO->^>&V"'RUQD$QQ@X 11N8+CUKV,+A6OWD]UT.
MFG3^TS2\(_%;4_A]XRFOM'-_?>*;&7:6&HR0:?&Z@[F*AN8TS@9R6(S[5]XV
M_P#P4"US1=+TN.YT#1_$6I+;&6]M+'4Q'<L%')16&&.0QP.PKX?\3V?A[Q9I
MH.C>,-+M/$UQ;&"[@30Y(/M;!N90R%@3M5U#8&.,]<UA>"?%FH^&;R:P\'Z/
MI.G7DF;6\US6H [!6ZL\DFX98$X"KP,8[FO0J485M6M3:45(_8SX0_M&>%OB
MUX<CU2&XATB1EWM;W5S&<#'7>#CUZX/%>F66I6FI1F2TNH;I <%H9 X_2OQP
ML=2\/WC3#POKW@BZ\7WS?97T6\TB6"&Z3:P^63<5W87A@N26Y'IZ9\-_CAJ_
M@74AK>@W.D_9;"Y>34O#\>NS![9,>5L1)U V;@&ZDD=.M>74P>[BS!T^Q^IE
M?-7[4$-Y;^*M*NF#FP>SV)C)4.KL6^G#+7-^%/VW-9U31K75KGPQH^I:0T\<
M-SJ6D:U&T=IN7_EHK<[LYX'H:]+^)7Q0T+Q/\-["^TYXM0GO;R*VAMD42^87
M)$B@]&7;NRP.![5S1ISI35T9J+B]3P:TU(&//45],? !+AO"=S/*&6&6X_=!
MNX"@$C\>/PKS_P"$?P7T7QGI,.O7-G=:=ITDS&"Q=L.P!*G=R< ,"  >V<U]
M#Z?I]OI5G#:6D*P6\*[4C08 %%::?NH)/H6****Y#,**** "BBB@"&\NX;"U
MFN;B18H(4,DDC=%4#)->1WG[0EM+?2PZ=8[X8S@2SL1O^@'2J/[4WQ9T[P+X
M031#<J-7U@A(X01N6$$%GQZ< >_->!Z'>R:LL;V5K+YDQ 2-03GC_/%==.E>
M/-(TC'2[/LSP5XPMO&FD"\@0Q.K;)(V_A;'\JZ"N'^$7A>Z\->%U^W)Y=W<M
MYKQ_W!C 'U[_ (UW%<TK)Z$/?0****D04444 %%%% !1110 4444 %%%% !7
MFOQL_9U\"_M"6.EVGC?2I-3BTR5YK4PW4MNT;, &YC8$@@#@^E>E45492@^:
M+LQIM:H^<_"__!/_ ."O@_Q%INN:7X?OX=1T^=+FWD?6+IPLBG()4R8//8UM
M?$W]B_X4?%KQ?+XGUS09XM;G %S=:;?36AN0!C]X(V&X].>O'6O<J*U]O5OS
M<SOZE<\M[GEWP[_9G^'/PH\6-XC\)^'8]%U-K!--+6\KB,PKTRF=I8D<MC)[
MFMOP[\'/"OA7XC>(O'6FV$D/B37XHX=0N3<.RR*GW<(3M7IV KMJ*AU)N]V3
MS,^3/^"BECXEU#X<^%8+#3-4U?P7_;44GBJST>,R7$EFI4@ #YMN0V<>V2.M
M>*_%3Q3^RIXN^&VI:/X'^&YU;QA=6QAT^QT/P]-;WL-P5Q&7D"#;AL9Y.<'K
M7Z.$!@01D&J\.FVEO)YD5K#')_>2, _GBNFGB.2*C9Z=G;[S2,[)(\I_9O\
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MVXP<_<W\CV/'M7KGC[X$^"_B7X:T/0-=TDRZ3HMQ#<V%O;SO (7B&(\;",@
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MP3H%OX2_X1>+1[*/PY]F-I_9:PJ+?R2,%-F,8Q6W15RJU)VYI-V&Y-[L^=M
M_8!^"?AW6AJ,'A:6X57,D=C>7\\]I$QSDK"S%<\\9'&.,5ZU\+_A/X9^#O@F
MV\)^%K%K+0K=I&2WFF><_.26RSDDY)[FNOHHE5J3TE)L')O=GSQ<?L!_!&Z\
M52ZZ_A']Y-.;F6Q6\F%D\A(.3 &V$?[.,>U>H?#SX,>$?A7J_B34O#&F?V;<
M>()X[B_597:-FC4JFQ"<( &(PH KMZ*)5JDE:4FP<F]V%>)_%[]CGX6?&SQ
M->\1:"\>N[-C:EIMU):S2 8QO*$!^!C+9(%>V45,)RIN\'9B3:U1YU\-_P!G
MOX?_  H\%W_A7PYX<M;;1=1#"_BFS,UYN!!\YWR7X)')[UYWH/[ /P2\.ZX-
M2@\+27"I(98[&\OYYK2-SGD0LQ7OQD<8&,5]$T5:K5%=J3U'S2[GC6M_";P[
M\&_V:_%OA3PA82V>D0:5?216[323ON=&+?,Y+'D],U\Z_LM?L>_#+XV?LO\
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M3[*%;>RM(4MX(4^ZD:*%51[  "K5%%<QF%%%% !1110 4444 %%%% !1110
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MC0ZQ']D34)(6-S)<N5!2)A]SR\_?[FOJW]EO]F2U^".CW&M:Y/\ \)!\1]:
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M>UUO2_->#[5:/N3>IPR_45#C*-TUL*S1T%%%%2(**** "BBB@ HHHH ****
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MHUUX?UOP_:_#E-?F_M"PNK0M>N!Y?F['Z#(QCTQ7T1^P\C2?L1>#4499M,O
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M0[(!\D"D%E]<'U%0W'2Q)R/@7PO-'X;FOK<7 %PS>3+,PVG)(:91C=M;&W/
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MKWA_3?%6CW6E:Q86^IZ;=(8I[6ZC#QR*1@@@UH44; ?-=W_P3M^!5WJAO?\
MA$I(%+!FM(+Z9+=L'O&&P:][\(^#M#\!:#:Z)X=TJUT;2;8;8;.SC$<:?@._
MO6S16LJM2HK2DV4Y-[LXI?@[X57XKM\2!IQ'BYK'^SC>^8V/(R/EVYQV'-'Q
M*^#OA7XMMH+>)].-^VAWR:C8XD9/+G7!#<'GH.#7:T5//*Z=]A784445 CQ/
MQ1^QK\)?%_Q$'C;4/"Z_V^;A+N62">2*.>56#!Y(U(5CD \CM7<W7PA\+W?Q
M3L_B))8,?%=I9/I\5X)6 $+=04S@GWQFNSHK1U)O=E<S[G%_$SX/^%OB];Z/
M!XHT]K^/2;Z/4;3;*T>R9#E6^4\CV/!J]\0OAKX9^*WAN;0?%FC6NMZ5*0Q@
MNDSM8=&4]5(]17345/-)6L]A79\[^&_V!?@KX9UBWU*+PS-?RV\@E@AU*_FN
M88F!R"L;L5&#7T. %  & *6BJG4G4^-W!R;W..^*7PB\)_&CPT=!\8:1%J^G
M"02HLA*M%(!@.C Y4X)Y'K7#_"O]CWX6_!WQ$NOZ!H,DNM1KLAO]3NI+R6 =
M,1M(3MX/:O::*%4G&/*GH/F=K7.,O/A#X7OOBE8?$2:P8^*[&R>PAO!*P A?
MJ"F<$]><9&:3XG?!_P +?&"RTJU\4Z>U_#IE['J%J%E:,I,ARIRIY'MT-=I1
M2YY73OL*[.:^('PX\-?%3PW/H/BO1[76]*F(+6]TFX!AT93U5AZBO&_#O[ ?
MP5\.:O!J$?AF:_>WD$L,&HW\UQ!&P.1MC=BHP?:OHFBJC5J05HR:0U)K9G%^
M,O@_X6\>^*/"OB'6=/-QJOAFY-UIDRRL@BD(QR <,.G!]*3XG?!WPK\8+?1H
M?%.G'4(](ODU&S D9-DR?=;@\_2NUHJ5.2M9["NPILD:RQLCJ'1AAE89!![&
MG45 CY__ .&#_@I_PETGB#_A$$\Z2?[0]C]ID^Q-)G.3;[MAY[8Q7IWPT^$7
MA7X0V>J6GA73%TNWU*]DU"YC1B09GZD9Z#T X%=E16LJM22M*393DWNSS&Z_
M9M^'MY\8(?B?+H$;^,8E 6]WMMW!=H?9G;N XW8S7:>,O!NB?$#PW?:!XBTV
M#5M(O4\N>UN5W(P_H0>01R*VJ*ESD[-O85V?/?A_]@GX*>'+748(?"ANTO;:
M2T)OKN6X,$;C#"'>Q\O([K@UZ3K?P3\(>(?A2/AQ>Z:7\)+:I9K9K*RL(TQM
MPX.<C YSFN[HJI5:DG=R8^9OJ<9XI^$/A?QE\,SX U6P,_A@VD=E]E65E(BC
M " ,#D$!1S[5<U/X9^&=;\ IX*U+28-0\,K:1V(L+D;T\I%"H.><@ <]>*Z>
MBIYI=Q79\]^'OV"?@IX;M]0AA\*&[6\MI+4_;[N6X,$;C#"'>Q\LD=UP:]*U
MCX)^$-<^%*_#B\TSS/"2VJ6:V8E8$1IC:-P.<\=:[JBJE5J2=W)CYF^IX#XL
M_83^"WC36K35-0\(QQW,$4<++9SR01W"QJ%3S40@.0% R>>*]=C\ ^'X/!!\
M(6^EP6GAPVAL1I]NNR-82NTJ .G!KH:*4JDY)*4F[ Y-[LXSPO\ "'POX/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML92_V9*W5_H2W^[1UUS(\-O+)'&9G5"RQJ<%B!P/QKY5U'Q!^UIXA6XUK2M
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M=7T)FVI,,8B8'K\Q"D\'E3TJ.X_Y2AV_OX*7_P!"EIG[90'_  TW^S*<<_\
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M"".VZ,9&./O5#H^MZO\ "?2;)?M&DW>EZ#'&S23R[9=S*3*Z8X^0NP)[X!K
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M SZ7&KQS L$5$96=B?K]X^AQ4OB#1Y;N\FU&":WA2X+RRZE)=!)/G?C:>F<
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M3'J=O\1OVW_!OPQ^)GB'P-JFF:K/KFFV<-Q:06<:RR:G-*RA;>! =Q?YLDG
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M#G[46A_&;X1>)/B!I^D:A8:=H=S=6TUK=%#+(8(DD8KM)&"' &3U!KS+3?\
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MXD260+9F& J(=G3)\MF[9(JU0BYMR222OOH];;CY5?4^D_A3^UKIOCKXB+X
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MK"6BRR:=>Q[%MK@V32QW8W,568?>)PPRI.#@<BI?#OCZ/3?&$&FW5M"+*>_
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MF4_@HKSN;]CKQ7\/O%VNZM\'?B?<^!M+UNZ:]O/#]U8I=6:S,26>,$_(#GH
M,  9(  ^JJ*?MZEV[[_H/G=[GE7P/^%?C'X?'5KWQK\1[_Q_J>H")0)[9+>W
MM A;B)%]=W)/H*]5HHK*4G-W9+=]3QSX-_L_'X3_ !3^*?B\ZQ_:*^-;VWNU
MM?)V&U\L294G)W9,A_*NG^-WP9\/?'SX=ZAX/\2QR&QNBLD=Q 0LUO*ARDB$
MC@@_F"1T-=Y15.I-R4[Z_P"0^9WN?*=A^S3\=]+T^WT.W_:'NAHD(6)+F31H
MGOA$!@#>Q.3CN3GWKT7XB? _Q;X@\#^$M.\+?$[6/#?B/P[&$&L/&LXU']WL
M;[1&>&W$;L\XYKV>BK=>;:>GW(?,SYO\!_LJ^(9/BMHWQ#^*7C^7QWK>@I(F
MC6<-FMK:6;. &DV@DLQ_F <\ 5X+\0O@ZOQG_P""BWBK3X=?U#PMK.E^%+?5
M-*UC36Q):W220JK%?XU*R.I4D9#5^A5<C:_"GPM8_$R\^($&E)'XNO+$:;/J
M(D?<]N&5@FW.WJJ\XS\HK6&)E%N3[612J-:GA/@;]CK7[SXH:%X[^+?Q&N_B
M-J7AXE]'L3:I;VUM+D$2E5ZL",]!R%))QBNT_:*_9=L/CIJ'AWQ%I^O7G@WQ
MSX=DWZ9X@T]0TB*2"8W7(WKP< GC<W!#$'W"BLO;U.92OM_6Q//*]SY0L_V,
M?%/C[6M%N?C/\4[[XAZ1H]P+JWT&.RCM;6648PTI7&[N,8Z$\C)KTOX^?L^?
M\+J\1?#35$U@:4/!VOPZR8O)W_:%1E;RP<C;]P#/O7LE%#KU&U*^P<[O<\^^
M/WPK;XV?!_Q-X)2_&EOK%N(5NVCWB,AU8$KGD?+C\:XWQ1^S[XFF^$_P^\->
M$/B+J'@_7/!]A;V46I6L"R0WHCMEA(FB8X(.T,.N.:]SHJ8U)122]1*31\W>
M!?V5?$5Q\5M$^(7Q3\?R^.]9\/I(NC64-FMK:6;. &DV@DLQ_F%.> *T?C=^
MRH_Q ^(EA\1_!?B^]^'OQ M+;[$^I6<*RQ7D'.$FC. W4<G/"J,< CZ HJO;
MU.;FOY?TA\[O<\ ^'/P0^*^G>.--U[QQ\9KKQ#I^GN730]/TV.UM[@F-DS*P
M^8XW9QTR!TKW^BBLYS<W=DMW"BBBH$%%%% !1110 4444 %%%>>?&'XK)\,]
M(C:WMA?:I<9\F!CA0!U9CZ>@[U48N3LA[GH=>*_M ?M1^'O@C';:5;P2^*?'
M6I,(=+\+Z9\]S/(>%WXSY:?[1]\9KYI^,W[6'Q+N=(ETS0+VSTF2Z'EF\AM]
ML\!(Y4;B0.H ?^M>S_LA_LJ6GPFL6\<>*7DUWXEZY&)KS4K]C)+:JP!\I2V<
M-_>;J>G0<]?L8TH\]7[C3E45>1S/P[_8VU+XG>+?^%F_'^[37_%-U&!;^&K9
ML:?IL.,B C/SE22>#C/))S7UGI.D6.A6$5CIMG!86<0VQV]M&(T4>P'%7**Y
MZE253<B4G+<*Y+Q%\)O!_BR:>;5_#]E?33C$DDD?S-CID]>,G'UKK:*S3:V)
M/EGXG?L+Z'KUM;P^$)K70;>+<4L[N#SX8F8_?7^+ R?D)(Z>E>+_ !&_9B\8
M?#_0XYYM&T'7--ANA/<R+8R,LK%U8O*B,?DW*@!4 KGIC-?H=2,H=2K ,K#!
M!&0:ZHXFI'?4T51H_)N?1/MWB5V-N^G>7<L[6=O?E95C9"LIB9UQLP02&Z$@
MC-:FE>&6L/"^EW[?;;B2;4?)BCF8/)*(0AN9G*862( ^7M[N01ZU^D/BWP3X
M5FTJ^GO]"LK@21&-U6)4:;<-HCR/[W"U\ZVW[*D_Q LI;74&M=*TW1Y'L-/L
M+8%0D1&^0AU/+%W/S<_=%=D<3&2UT-543/D6Z^'OA'Q%X>NEUL:I9O<3R6-G
M+'NBM[AC\\8P@8[8P0,,<9;O7B_B#P[-X2V26>ED:J[+9F%;22*.+8IP8_XI
M'(9=TAP-Q]J^P_B9^SOXK^&^CQ:>\$::?<.+<ZA8W,T<2QMDL6B 8 Y&>HQG
MKVKR_5-2N9KJ'08=1O-(M[81VBV=U=V\GVJ,-M=[1Y 68D;20Q!YS7;3J7U3
MNC6,NQY+X7^)NK>'VLGUK4;F&S9&5(888Y9D6, 27&" 47(V;N6YXR:BU#1_
M#]YHO]LW^J77BNZF;RK66WMWB*@=F9E PQ;'/(QFNPUCX3P75YXDCT72]5U&
M[MT9KNWO;:-2%#A@5E+$E\=5'  X&>OEGV[6/#$]W?WUZ=/\NXW+:QQ,@<+&
M/*BC#\]3SQVR:Z(VEK$M:['16OB3Q1X(U2>Y%W!::"DLEND$$2O!+,P!6*-7
M&6/.,].#6C<2>'_%$B>)=;U36-<(MR=/LDT\QD[@0Y\E0$7!&S/''-4K7Q!I
MOCJXN-5OY]2U+4F3[+'8S6D9$D6P,Q3<P5#_  EE&XFN:,&I:#<0^(+B9O#F
MG21O]DM896(.Q\(,,/WC$ABS=L4[7\F!?_M34+.XN-8G$EGH-NZ#[#<QEX3)
MN_VO];(<<XZ!B.@J]J$4/C:*PU34];N)1)<+Y>EV%DT,<I!(5&"@!<'&-Q]Z
MH?VE'\1C82:H^L7\MQ(?)TL2QY;&/,"9("YR1D+DU](?LK_LB^(O&/Q!TS7]
M2MKS2_#MNT<\D%Q&RQ>2K$K$K'[['.&XXYZ5$YQIQYI:";45=D/[*?[.>I^-
M/BE9)J,!DT;3%1KS@,/*(R(S(1ST X/)8]A7Z;>$?!.A^!=--CH6G0Z=;,Q=
MEB!RS'N2>35_2=%T_0;,6NFV4%C;CGR[>,(N?7 [U=KYZM7E6=^AQ2FY,***
M*YB HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_B!\
M6/!WPIM;*X\8>)--\.07LIAMY-1N%B$K 9(&?0$9],BFDY.R0'645#9WD&HV
M<-U:S1W%M,@DBFB8,KJ1D,".H(K"\._$;PQXNUS6]&T;7++4M5T6;R-1L[>4
M-):OS\KCL<@C\#19@='1112 **** "BBB@ HHHH **** "BBO-_"_P =M!\6
M?&3Q3\-[.WO%UKP[:Q7=U/(@$#JY  0YR2,C.0!5*+E=KH.QZ117'Z1\7/".
MO?$#5?!%AK=O<^*-+B6:\TY2=\2G')[=QQVR*["DTX[H HHHI""BBFI(DF=C
M*VTX.TYQ0 ZBN/U#XN>$=+^(MAX$NM;MX?%=] ;FWTUB?,>,9Y].Q^N#784V
MFMQA1112$%%%% !1110 445PGQL^,&C? CX<ZEXSU^*ZGTVQ,:O'9H'E8NP5
M0 2!U/<U48N345NQ[Z([NBLWPWKUMXI\.Z7K5F'%IJ-K%>0^8,-LD0.N1V."
M*TJG804444 %%%% !1110 45@>.O'6A?#7PO?>(O$FHQ:5HUDH:>ZFSM7) '
M3DDD@8]ZO>'?$.G>+-!L-:TBZCOM,OX5N+:YB.5DC895A^%.SM?H/S-&BBBD
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX8(/0<'(S7F?_!,;[&OPS\=(-HUI?%%U_:(_CWY^7=WZ9_6JWQZ2.]_X*(_
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MYKTG]H+]I#3_ ('-H.DVVBWOBOQCXAE:#2/#^G$"6X8=68G[J#(R>>M>+_\
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M'!4XS7I'BCXU:?\ "O\ 9;M/B/I_AU4TZWT2UOK?0X'$:QK(B%8@P& %W@9
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M16?B+4?!GC3P\Y;3==TU0[1@D$J\9(##(R.1W['%<#>?L%Q^)O$7ASQ3XO\
MB7X@\6>+]'U&*\&IWL2+$84Y^SQVZG;$"V&+#).!7U=14QQ%2*Y4Q*<DK(\E
M_:*_9O\ #O[1OAFRT_5KF[TC5--G%UIFM:<VVXLY1W'J#W'L""",UX_KW_!/
MM/B%X=O;7XA_%'Q'XZU;[,;?3+Z_0)#IN3S*D"MAY,<;F:OKJBB&(J4TE%[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 54U;5;70M*O=2OIA;V5G"]Q/,P.$C12S,<>@!-
M6ZHZ[HMIXDT34-)OX_-L;^WDM9XP<;HW4JPS[@FFM]0/CCX;_P#!4CP'\0OB
MW:>$#X?U32M.U"Z%G8ZS<2(0\C'">9&.4#' &"QY&1UQ]JU\%?"__@E/HG@'
MXR6/BJ]\82ZOX?TR\%[9:2;/RY2ZMNC627><A2 <A1NP.E?>M=>)]AS+V&QK
M4Y+^X%?&'[?TT=O\3_V=9976*-?$TA9W. !^YY)K[/KX?_X*0>&]/\9>,O@)
MH>JPFXTW4/$$UM<1*Y0O&PA##(Y''<48/^,K^?Y,*?Q'V1_PF6@;L?VWI^<X
M_P"/I/\ &OC[_@F"RR>'?B\RD,K>,K@A@<@C8O-=Q_P[5_9_W9_X0^Y^G]K7
M7_QRN _X)8Z?!H_@WXJV%JGEVMKXMF@B0DG:BQJJC)Z\ 5JE35"IR-O;=6_5
ME>[R.Q[#^RWXP\#>+=>^*"^#_!D?A2XTW7FM-2F4J3?S $^;QT[\5@Z[^VA>
MZIXJ\0Z/\,OAAK_Q,MO#LQM]3U33I8X;995^]'$QR97']T#)[<<UR_[ LR6_
MB+X_RR,$C3Q=(S,QP  C$FO+?V3_ (K?$#X7^%_&">$?A1JWQ'\(:GXAO9=&
MUBPN8879Q(599T)+*,@?.?RK1T8\\W:]K;OOYCY5=GT;^S+^UQ=?M):KJ$5O
M\.]:\/:59!TDU6\D1H1.I : XP0_/2OFO]G7]HBS^#_CSXU:)8>&M:\;^,=6
M\5RS66@:%;&25HD4AI7;&U$!(!)]>E?2O[%OP5\3_";P;XFU+QG';V7B7Q9K
M$NLW6F6KB2.RW#"Q[UX8XY../<UY]^P'I]K_ ,+ ^/\ ??9H?MO_  E30?:=
M@\SR\,VS=UVYYQTS1^ZC[7E5XJW7S#W5S6V/4OV>_P!K#3?C=XDUSPGJ?AO5
M/ WC?1E$EUH6L "0QG^-&XW 9&>!U!Z<UYI\"R5_;^^.Q W'^R[/ ]>5J&>"
M.W_X*C6LD:A'G\'.92/X\8 S^0_*I_@1_P I /CK_P!@NS_]"6ERQBIN*LG%
M/\4*R2=NQ[%^SU^T=IWQ\'BNWBTBZ\/ZMX;U)].O-/O'5I,C.'&.QP?RJ6X_
M:&L!^T=;?"*STBZO=1_LPZG>:@CJ(;1>JJP/)+#'YBO M6FA_9N_X* ?VI/*
M++PG\2M,=KF5@?+2\A!8LS=!]TG_ (%6Q^PGITWQ$\3_ !0^-FH)F7Q3JTEG
MIC;B0ME"V!MST!..GI6<J,$G42]VRMZO_+43BM9=#ZXU"\73[&YNF4LL,;2%
M5ZD*"<?I7R5H/_!0VR\>:.L?@;X;^)/&7BQ9)OM.AZ:H8644;[%DGFP57?C*
M@ GM7U7XD_Y%W5/^O67_ - -?*?_  3%CTU?@+K#VR6HU!O$-[]K:(+YIPP\
MOS,<],XSVZ5E2C#V<IR5[6_4F-N5MH]5_9V_:DT+]H)M;TV/2M2\+^+-#<1Z
MGX?U>+9<6^3@-[C.1V/J*\PU;_@H1I?]N>(O#'ASP%KWBKQOINJRZ=;Z!IH$
MDES'&N7N25#;(QTZ$YK$\+(G_#T'Q4=)*?9/^$7C.I>2>/.PN-V._3K4O[!N
MBV)^+7[0FK&TB.IKXD^RBZV_.(CO8IGTW &NATJ4>:;CI9.WJ7RQ5V>M>,OV
MLM"^&?P@\-^,O&.AZOHFL:\H2T\)_9R^HO<$X,(0@8(XY;'4=SBN!D_;PN_!
MM]93?$KX0>+_ (?>&KZ988=>O8A+!$6^[YP !C^G)]JP_CRT,W_!0CX(0ZP8
MQ8+IUP]@LA^4W.YL$ \;LXQWZ5ZW^W!_9W_#*?Q'_M/RQ%_9C>5YF,^;N'E[
M<_Q;L8J5"FG!.-^;SVUMH*T=$UN=E\7OCIX4^"OPSG\<Z]>-)HP2,V_V-?,>
MZ:09C6,="6]20,<DU\E?';]LZZ\2? GQ=I_BWX5^+/ 6F^(=*F@T?6-2MB]O
M/(RYC20@ QEATSD>^.:X7XG_ &G_ (4;^Q_9^*,KILFHVYO/.8C) 7RPV?\
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MOZ)!JFJZ#*9M-N)V8_9W/5@H.TGZ@UUM:2JWI1I+I<;E[JB9OB3_ )%W5/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pgen-20201231_g15.jpg
<TEXT>
begin 644 pgen-20201231_g15.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &G T(# 2(  A$! Q$!_\0
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M 8 CIW H ]6_X333_P#II^:__%4?\)II_P#TT_-?_BJ\]V4;* /0O^$TT_\
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M_P#II^:__%4?\)II_P#TT_-?_BJ\]V4;* /0O^$TT_\ Z:?FO_Q5'_"::?\
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MM]J (ME&RI=OM1M]J (ME&RI=OM1M]J (ME&RI=OM1M]J (ME&RI=OM1M]J
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M_P 3 >\4'_QVE]5K_P H>SEV/J?;[4;?:OEM?^"B_P .W (\/^)2#_TR@_\
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M')+L?1&WVHV^U?/*?MR^!Y!E=%UXC_KG#_\ '*D'[;W@EO\ F"Z]_P!^X?\
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M/VA+OPGI7PLM;71HI)? NI7.H)-).<7OG,"R%=OR8 (SD]<UDU6=_P#@>?\
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M415&68DR8  Y)[5PWA_X9_#_ ,6>'];UW1OVDKW4M%T/G5+^"^!BLQZR$R#
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MV_\ B:],_P"&-[K_ **OXK_[Z/\ \<H_X8WNO^BK^*_^^C_\<H^M5/\ G]^
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MC_AC>Z_Z*OXK_P"^C_\ '*/K$_\ G[^ <[_F.+7_ ()D^$E_YG/Q'_X"V_\
M\33U_P""9OA-?^9R\1_^ MO_ /$UV/\ PQO=?]%7\5_]]'_XY1_PQO=?]%7\
M5_\ ?1_^.4OK$O\ G[^ <[_F.27_ ()I^%%_YG#Q%_X#0?\ Q-/'_!-CPJ/^
M9P\1?^ T'_Q-=5_PQO=?]%7\5_\ ?1_^.4?\,;W7_15_%?\ WT?_ (Y1[>7_
M #]_ 7,_YCF%_P"";OA5?^9O\0_^ T'_ ,34B_\ !./PLO\ S-WB'_P&@_\
MB:Z/_AC>Z_Z*OXK_ .^C_P#'*/\ AC>Z_P"BK^*_^^C_ /'*7MI?\_?P#F?\
MQSZ_\$Z?"Z_\S;X@_P# :#_XFI%_X)W>&%_YFSQ!_P" T'_Q-;G_  QO=?\
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M5?Q7_P!]'_XY1_PQO=?]%7\5_P#?1_\ CE+VG_3W\!7\R-?V$_#R]/$FM_\
M@/#_ (4]?V&?#Z_\S)K7_?B+_"E_X8WNO^BK^*_^^C_\<H_X8WNO^BK^*_\
MOH__ !RCVG_3S\ OYCU_8>T!?^9CUK_OQ%_A3U_8CT%?^9BUK_OQ%_A4/_#&
M]U_T5?Q7_P!]'_XY1_PQO=?]%7\5_P#?1_\ CE+G_P"GGX!?S+*_L4Z$O_,P
MZS_WXB_PJ1?V+M#7_F8-8_[\1?X52_X8WNO^BK^*_P#OH_\ QRC_ (8WNO\
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M6UD3R2[GUW9^#?A=H>E_ +3]-^'6E:[8^.O$NH65YJGB""5=1>Q2]:&*,A9
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M$$'!% 'QI<Z#XW^/_P"PQXZ\1I:WFH^(_']S_P )#9^'WN2PCL5GB,5G""<
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MA?X5O)#_ &+/!]EU>]8C-O?38-LN[L%& W_74?W:UITY56U%;:E1BY;'&?M
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M6)J/@/PSK%Y)>:AX:T:_O),;[B[TV&65\# RS(2<  <GM70[*-E--K8#E?\
MA6'@S_H3O#O_ (*+?_XBC_A6'@S_ *$[P[_X*+?_ .(KJME&RGS2[CNSE?\
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M-E $.VC;4VRC90!#MHVU-LHV4 0[:-M3;*-E $.VC;4VRC90!#MHVU-LHV4
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M\2+CQSXCATZ77;EX9+@6UKY4$S1!54L@8YR%4'GG%?0 _P""HGQW4 "\\-
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MV^U $.RC94VWVHV^U $.RC94VWVHV^U $.RC94VWVHV^U $.RC94VWVHV^U
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M0U>VB$T4RL'N$F+^7* S'.QCTXSP#\4-;Q2,6:)&8]RH)H:&-E"M&I5>@*C
MH]@W)RYM;]NW3<.5WO<_2_XJ>/\ PW\?M-^.WPM\'Z]H]WK[6.AQZ5//>16U
MOJSV0 N%CFD8(2IX&3@^N.:YG7OB)XI\,^,_AU\.?AI<>$?%VN>'? )T7Q/I
MNK7T TV]WLK2VGFO(B.R8!^5QU/O7Y\-&CKM959?0C(I#"C($**4'\..*B.$
M45:^GZVL+V=M#Z^_;4\=:5'\*OA1\-8(/#-AXAT$W>H:OI?@\[]-TQYB/+MU
M?>^YP,ECN/)Z\BOD2FJJHH"@*/0#%.KJITU3CRHN,>56"OVW_P""<:Y_8U\
M?6^_]+)J_$BOVZ_X)P+G]C7P!_V_?^EL]>9FG\%>OZ,PK_"?2.RC94NRC97R
MYP$6RC94NRC90!%LHV5+LHV4 1;*-E2[*-E $6RC94NRC90!%LHV5+LHV4 1
M;*-E2[*-E $6RC94NRC90!%LHV5+LHV4 1;*-E2[*-E $6RC94NRC90!%LHV
M5+LHV4 1;*-E2[*-E $6RC94NRC90!%LHV5+LHV4 1;*-E2[*-E $6RC94NR
MC90!%LHV5+LHV4 1;*-E2[*-E $6RC94NRC90!%LHV5+LHV4 1;*-E2[*-E
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M)8AM<RT^79?K<$YW5SYMK]O?^";JY_8U\ ?]OW_I;/7XA5^W_P#P3=_Y,T\
M?]OO_I;/7-FG\%>OZ,BO\)]+;*-E/HKY<X!FRC93Z* &;*-E/HH 9LHV4^B@
M!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93Z*
M &;*-E/HH 9LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93Z* &;*-E/H
MH 9LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^
MB@!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93Z* &;*-E/HH 9LHV4^B@!FRC93
MZ* &;*-E/HH 9LHV4^B@!FRC93Z* &;**?10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7D?[65QX9M?V=?'$GC+3K_5_#/V-1>V.ES"*YF0R
MH J.2 #N*]37KE>$?MT?\FG_ !#_ .O2'_TIBK:BKU(KS14?B1\?_P##&?@7
M_HV?XK?^%3I__P ET?\ #&?@7_HV?XK?^%3I_P#\EU^F]%=7UVK_ $W_ )FG
MM)'YD?\ #&?@7_HV?XK?^%3I_P#\ET?\,9^!?^C9_BM_X5.G_P#R77Z;T4?7
M:O\ 3?\ F'M)'YD?\,9^!?\ HV?XK?\ A4Z?_P#)='_#&?@7_HV?XK?^%3I_
M_P EU]??M-'7-!TBY\0Z1+XELC9QP7$FM6&I[;'2XHY@TLDMFK[K@; Q8&-\
MKW7'%UOCKJTGQLM_AK'IMB]Y?!=6M-26<^2^C^7\\A'7[0)/D"="&#] 16RQ
M%9QYD_Q?^97/*UT?&G_#&?@7_HV?XK?^%3I__P ET?\ #&?@7_HV?XK?^%3I
M_P#\EU]<^&KK5_"_[06DZ7>7'B32M)U33KV..'7M3_M"+5[F-T</"%=UMBD>
M]MOR;E; 3Y.(4TG4/&7Q"^,C2>+=?T>;0[BS&ER6>J2I;V7^@QRDFWW>4ZER
M2P=2"":?UBKWZ7W?>W<.>7<^3/\ AC/P+_T;/\5O_"IT_P#^2Z/^&,_ O_1L
M_P 5O_"IT_\ ^2Z^K?"OQ]\:>,O!ZZEI.DZ0MQHWAJRUO6EU$RH;F6>%IA#;
MA?N#9&QWOD9=1MX)K;TO]H*YU3Q]H]C-;6FA>']4M+6YTY]5BG675%FMO./V
M>91Y(=#E3"WSML)& 10\177_  [_ ,PYIGQO_P ,9^!?^C9_BM_X5.G_ /R7
M1_PQGX%_Z-G^*W_A4Z?_ /)=?7_P<_:'U3XG>)]+A;2$.BZS:3WEM+:6=VKZ
M>$*F-+F61!$YD1L@QGAE(^8?-7O%9SQ5:F[2_-_YB<Y1W/S(_P"&,_ O_1L_
MQ6_\*G3_ /Y+H_X8S\"_]&S_ !6_\*G3_P#Y+K]-Z*CZ[5_IO_,7M)'YD?\
M#&?@7_HV?XK?^%3I_P#\EU];_L=ZQH>F^#]9^'.B>#=>\#KX(NDM9M+\0W4-
MS< W*FZ!\R*1PP(ESUXR!7T!7@WP-_Y.(_:*_P"PQI'_ *:H*4JTJ\)*?37=
M]TN_F)R<D[GO-%%%<!D%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,0IZ9%>[6MPEY:PSQ\QRHKKGT(R*RG&:UD2T^I+11161(5X-\#?^3B/VBO\
ML,:1_P"FJ"O>:\&^!O\ R<1^T5_V&-(_]-4%;T_AGZ?JBELSWFBBBL"0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\(_;H_Y-/^(?\
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M/QMXD^(OCO7;2?4M<\.>-;Y=&$ES(L-@P<NTD<:L%+L6 )8'(45X?\._V?\
MPCXP_8@^+'Q#U>&]N_$^@ZI??V/,;R18M/\ +E1OW48.T%R[;B02>,8Q3^JP
MYG%RVLMN_P Q^S5[7/UW_M:Q_M'^S_MMO]OV[_LOFKYNWUVYSCWK ^*?Q M/
MA3\.?$?C"_MIKRST2QEOI;>WQYDBHN2JY(&3[FOS5^('PGT?X6_#?]FCXL:/
M=:J_Q%UW7-,.J>(+O4)9;B\6= [(^YB H V@ #Y20<U]X?MC_P#)J_Q4[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?#NPT%H?".NRS3:A8F[F8RO*07/F%]ZYVCH1C'%,_P"%?_%'_HK,/_A,0?\
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M:^L].U6RM;#4["PUB[MK?48K>/RX?M$<<H$K*@"[FY( R3BO;J* /,9OV</
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M"?=8[&&X>JMD'N*3P_\  OP1X7^+'B+XE:;H<=MXT\06\=KJ.I>;(QEC0*
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M.?3D4E3R&'J#ZBH%_:<^(+==2M/_  "2CV,A6/M6BOC"/]I;X@NP U&U8DX
M%DF36EJ7QZ^)NAWGV74Y8["ZVA_)N-/5'VGH<&E[*06/KVBOCQ/VCO'AZZC:
M_P#@&E3)^T5XZ;KJ%K_X!I2]FPL?7M%?)"_M#>.&ZZA:_P#@(E:6F_&GXAZM
M!>S6MS;2Q647GW#?9HQL3.,\]>3VI<C$?4M%?*B?'WQHW6_MO_ 1*F3X\>,V
MZWUO_P" J4N5@?4M%?+Z_'3QB>M];_\ @*E3)\</%[=;VW_\!5I<K$?35%?-
M:_&SQ<W6]M__  &6IE^-'BP];RW_ / 9:5@N?1U%>8?"?Q=XB\7ZA=R:A<1O
M86Z $)"J[I#T&1Z $_E7I](84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Y3IW_)T6N?]BC9?^EES7JU>4Z=_R=%KG_8HV7_I9<UI#:7H
M-'JU%%%9B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\ _;F^-?_"C?V<?$NJVT_DZWJ4?]DZ9@_-Y
M\P*[Q_N)O?\ X"*]_K\A?^"KWQQC\:?&;3? 5E=HVF>$X-]RJN,->S %L^Z1
M[![%FKNP='VU9)[+5FM*/-)(^(U&U0.M*M1?:(O^>J?]]"E6XB_YZI_WT*^R
M/3)UJ=*J+<1?\]4_[Z%3I<1?\]4_[Z%)@;&@+:-KFF+J'_(/-W"+G_KEO7?_
M ..YKZ?_ &B)/%<7[>B1Z(;I=3AU33H_#26.?EL=L7DBW X\O;G./E^]FOD^
M.XB_YZ)_WT*[_2_CQX]TC1X-*LO'&K6MA;V[6<$4=WAH8&SNB1_OHAR?E5@.
M:YYP;ES+LU]Y#3O<^JOC;H/@+1-#^.GC^T\%Z3XJU&S^( TRTFN9)_LUO')#
MNE)2)U##S P';<PYXP>@C\.Z!\*;7X^6>@^'-/M]/NO &EZ\^D7_ )LQM&G*
M/):N?,#&)22P!PPSR:^9O G[2>I_#OX'ZWX&T"XN]+U75-<BU636+>Y3:85B
M*- R,#NW-AL^PKD]-^+WB[3?$VI^(K;Q;J,>O:HC17^H&YWRW:,0664MD.IP
M.",<5Q^PG:S>B_X'^1ERO8^H/@;\%/"'Q*^%O@#5M6TF2XGN=3\07=Q8V-U+
M&+];6W\V&T12Q"*3W4;B 1GO5O\ 9L^%?@7XZZ5X;\0ZWX,T_1#'XN_L66ST
M^2XCM-4MY+664Q[6D+>9$RKEE8<#D9KY6M?BEXGM(M-CM_$]];1Z;?2:G8K!
M<>6+:Z<Y>:/;C:S=\5KS?''QS>:QIFJR^--3.HZ6\DEC<+<!#;.^=[(%  9L
MG+8R<TY4:CO:6_\ P0<7W/H?PG\)]"^-7@^'6O#7P_T?3=;M/'#:1'ID5]<0
MV=S8>0\I6X=G9\H(B2R8+#(QR*]"^!O@/PI%XF^#/C70H=+74IO%.IZ/<W.A
MV]U;V=S&EI*RD1W!+94@KN'##WKXNT'XH>)O#=K';:3XGO\ 38([]=46.UN2
M@%V 0)^/X\$C/H370S?M ?$*]FTJ:;QUJS2:5*T]@5N0OV61E96>,  *2K,#
MC^\:B5&I*Z3T)<6=O\*?!VB:IH?QB\6ZMIT>N7/A6S-Q9:7<.X@>26Y:,S2A
M"&98QS@$#)&36MX5TCPWK/PO^(?Q(F\#V$=[HB:?9VFBH]Q_9\9F)5[YT+[R
M/EX7?L#'\*\7\->.-8\(ZM+J>B:W<:5J$R212W%M-M:1'^^KCHRMW!!%;D/Q
MB\8IK]QK8\6ZC_:UQ;"RFNC<9,EN  (64_*4 '"XP*N4)-NS_K0;3/I^P^%O
M@'3_ (;7WQ!NO!-E+=W'@B/6U\.7-Q<"WM;K[48!,@WAQ'(,,%+'H<'FMOX.
M:!H?AKXM?#;6=%T&QT^3Q7X$O[^ZLT\UXXKA(I%8P;G)42;1E23WQBOD6Z^*
M/BC5)M7FO/$]_<R:O EKJ#2W.?M,*$%(W']Q<#"C &*EL_B9XEL;[0[RW\2W
MT%WH<1@TN:.XP]E&<Y2,]EY/'O6#HS::;W_R(Y6?4W[-?P[\%_$CX>V6N^(/
M"]G=A]<U%)+&UGN(;8QPZ<9414$AQ\ZYW=>>N.*Q/!/@'P=\0M-^$GB*;PM8
MZ.-:\93:%J&G6,LPM[BW #H#O<L& .W((SUZUX39_&CQI9^8+?Q=J%LLDSW#
MK!,(U,CQ^4[X4 99/E)]*SK?QEJT.CV6DQZS<QZ9971OK:U2;:D%P>#*F.C\
M#FDZ4[MW_K4?*^Y]'?"_X'>&?&D7BJTU*P>P$?CNST.VOE=T>"W:2020H2<%
MB%5<D$@D5N_#_P  _"7XA_$74_!U[9PV=_;ZDPL(-$M+Z&4I#O\ ,M;J28E2
M7"##C!W$XXQ7SMKGQE\:>*M.:PUCQAJ6HV33+<-;S7/R&53N63 Q\X/.[KFI
M[SXR>,]46-;KQ?J4NR>.Y#"YVL94^Y(S+@LR]BQ-0Z<W?47*^Y[-J6M6>N?L
ME^*9;/PI9>&$C\86\1%AYWES81\ ^8S?,@^4D'GC(S2> ] T+P5X9^$&M'PM
M;>*=3\4ZS*+B:Z>;-N(IEC2&$1L '&?,)(.<#C&:\=U[XM^+O%VEG3-:\4WV
MIZ:THG-G/,#$9 2=^T #=EB<]R33_"_Q0\4>#;,VFA^)K[2;4R&;R;:?:JR%
M=I=?[K$<9&#BCV<K6\PL['T!\;-!T;P_)\2?'$^B6_B'5IO&DNDJE^7-M91!
M!)N*(RDO(?E!)P,''-3:_P"!?AYX7U\Z<-,L]/U_7+33;[3;+Q!]IDTZT:5-
MTMF7C8.CLV I?. PSCK7@>G_ !2\4:?J.IW]MXFO8KS5'$E_+YP;[4X.0T@.
M0Q!Y!QD5=T_XO>,-.N+N>W\6:BDUY<B\N':XWF2<# E.[.' XR.:CV<DK7)Y
M6?3.F?!OP]H]UX5M_$OA2$W,6CZ[>7^DF_FDA\ZWDS&BN'^Z!P"N,CDY-9GP
MZ^%OA+XA>&?#'BF?P]9Z;)+:ZP]U9V\LPLI'MPIA>0;FD"C> P0Y.![U\]Q_
M$_Q1B$?\)/J!\F*>",M<DE8YCF9<GLYY;UKJ/A9\9KCP$T]I>R7E_I#6-U9V
MT-K=B&6P>< // 2" YQ@YZ@FLW3G;?4FS-3XE0^%Y&\&:7H]GIMAJ<ENG]MW
M.F1SB#SWDV_NS,>5"\G QGO7H=Q\//"]S\5/&7P^7PU'I^GZ/I,\\&M^;+]K
MC>*(.MQ*Q;84D)QC:!@C%>4>._BA;>+O"GAOP_!'>30:/YSG4M9NEN+V=I#D
MJ6 ^6->R\\DFLVY^)7B74M(.EW7B.^N-.,20-;O/D-&GW48]2H[ G%'+*P]3
MTSXM:JEQ\(?A+&--L(FFTNY82QQL'BVW!&$)8@!NIR#DGM75W'B;1_ _A_X)
M>)+\ZC-?:9I,T]K:62(J3,)FPLDI;*J3U 4Y&:^?+OQ%>ZG8V%G=ZA)<VFGH
MT=I#))E8%8[F5!V!/-6+OQ#>ZI9V%I>:A)<VUA&8;2&23*P(3DJ@[#/-+V>B
M0K'TWI.H:+JD/P1OM9$]I?W$M[<64MNX2VBN&NBT:RC&[RRY4':PXKGOB*+U
MOA?9M?+)8^=XEU ^*O[/B#;+K=^Z#KD J%SM#$#J>M>'S>);^\L].M)]2FEM
M=-#"RA:3Y;?+;CL],GGZUL6OQ$\16^J7^HQ^(+Q;[4!B\F\W)N!Q_K >&Z#J
M.U1[-IW)L>[?!OPVW@76=*\0Z7J\]_#J/A?4KZR6Z@\LVWE%0%V[V7!(SP:T
M+S3],UOX1>.?&.FR1:?I7B6.Q>YA"EA97B38N$VKR5RP<8'1J^?V^(?B&>^-
MX^OWC71MFL_,\[&(&&&C ' 4]P!45CXDU"QT>\TFVU*:#2[QE:XLTDQ%*5QM
M++W(P/RJ73;=[BL=/X?\#OXFU==,TG6H[JPV?:-0O6CEM[>TB4\R2[P,X'3W
MX'->J>(/&%GXT\$_%#4=%+-;Q'3+$3-_K9K./*%W/7#, 3]1FO$]!\9:OX;@
MNH=*U::PANMOVB.)AMEV]-P(.<9-7;?Q]KL.HM?Q:U/%>/";=Y8V5=\9Y*,
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M&(;Y<CFOSF_X>F_'S_H(^'?_  3C_P"+KKHX.KB(\\+6-(TY35T?M!17XO\
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M3^SO#EAX;@DQ/J#^?. >D*'@?BV/^^37,9&P/VL/!##.S5?_  $'_P 52_\
M#5O@G^YJO_@(/_BJ^'O'6L76@^%[B]LF1+E9(D5I$#@;I%4G'?@U7U+6=4\,
MZQ8P7=S'J-CJ'F11R^0(I()EC+C(7AE.#VR*JR)NS[L'[57@H_P:I_X"#_XJ
MG#]J7P6W\&J?^ H_^*KXB\)WVH>)O!NDWSW@M+VYA6626*!6!/.0%;@4WX<Z
MEJGB#1HM2U#4%FWR31>0ELD:C9(RALCGHOZTK!=GW$O[4'@UNB:G_P" H_\
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M^B_^"FQ_^(H_X69\&_\ HB^B_P#@IL?_ (FO%**TYI=PYI=SVO\ X69\&_\
MHC&B_P#@IL?_ (FG?\+,^#G_ $1G1?\ P4V/_P 37B5.HYI=Q<TNY[7_ ,+.
M^#O_ $1G1O\ P56/_P 33O\ A9WP?_Z(WHW_ (*K+_XFO$JYSQ;JU[%J&B:/
MI\_V2?4Y7#W04,T42+N8J#QN/ &>F:7-+N/FEW/I(?$_X0?]$<T?_P %5E_\
M32_\+/\ A#_T1W1__!79?_$U\R7&HWOAGQAI=E)?3ZAINIQ382ZVM)#)&N[*
ML ,@CL>]+I7Q*M]2M=*O'TJ^M-/U*;[/;W4Q3:9#G (!R 2" W3BCFEW#FEW
M/IL?%#X1?]$>TC_P5V7_ ,33O^%H?"/_ *(_I/\ X*[+_P")KY9T?Q=J6HZ'
MXIGOX)+1-/FN8TN;5HR\:H.%"G(+C^\>#5[3_&RS6\<%C97VMW%O9175S)F-
M&4,N5!)(!D(YVK1S/N'-+N?37_"T/A)_T2#2?_!99?\ Q-.'Q0^$W_1(=)'_
M '#++_XFOF&'XG6VHWD4&E:7>ZJ)+#^T/,B*(JQY(P=Q&&RI&/6KLWCV'^PX
M-8M=.N;NPEM3=>9YD<6%'5 &8%G&#P/2ES/N'-(^DQ\4/A/U_P"%1:5_X++/
M_P")IP^*'PH_Z))I7_@ML_\ XFOE_0=<;6/B)<-;W,LFFS:+;W,,+,=H+.?F
MV]CBM>Q\7?VI>3QV&EW=[9P77V26]C9 @<?>(4D,RJ>"0/SHYGW#FD?1?_"T
M/A3_ -$ETK_P6V?_ ,33O^%H?"O_ *)/I?\ X+;/_P")KYG;XD6BV4FI#3[Q
M]#CN?LK:FNW9NW;2X3.XH&XW8J+_ (6I;*NHSOI%^NF:?>BPGU#,90.6V[@N
M[<5!(SQQFCF?<.:1]/CXH?"S_HE&E_\ @NL__B:=_P +/^%O_1*=,_\ !=:?
M_$U\P6_BS59O%?BG39;5DT_3[9)(YH7C\R(-&S%^3\Q.,@8X[U2T'XJ)+IYB
M@TS5]9-CIT=_<WLIA1BC#<,@$ OC/"CM2YGW#F9]7#XG_"__ *)5IG_@NM/_
M (FG#XG?##_HEFF_^"^T_P#B:^>M/\:6.IZU8Z?;)+(;S3O[3BGP GE[@ ".
MN>:SK'XI6&I+I\=E93SWEZDLJVSRQQ>7'&Y0N[LP4988 ZG-',^XN:1],#XG
M?#'_ *);IO\ X+[3_P")I_\ PLSX9]/^%7::/^X?:?\ Q-?+^G_%JRU^.XAT
M73+[5+VW@DEN[6(QJUJ5)78Q+8+$@X"DY S4GPY\3"W^$EAKFL74SI%;RSW$
M\Q+R;0[=>Y.,#%',^X[R/IX?$SX:=OA?IW_@!:?_ !-/'Q,^&O\ T3'3A_VX
M6O\ \37RA-XTOK[XB>$5FL;_ $339K*ZNW^T2IY<R>7N&X*Q^91S@],UOV?Q
M.M9[?2KV73+ZTT?5)_L]IJ,NS:S'.PL@.Y%?!P2*.9]PO(^DO^%E_#;_ *)E
MI_\ X 6O_P 33O\ A97PX_Z)II__ ( VO_Q-?+>H?$M-6\$ZIJ]I:ZI8:;%'
M(5U2U:!I4*2!2-C$[&/. XZ9Z5;N/BK'8W6L6R:)J=_%HEM%/>WJ-$%VL@;(
M!8%FP<D =C2N^X79]-CXE?#G_HFNG_\ @#:__$TX?$KX==OAM8?^ -K_ /$U
M\S:M\7K#3H-3NK73;S4[+34MVNKF%XXU3SL&, .P+<,"<=,UT.M^+HM!_LJ!
M[.>ZU/5)/*MK" J69MNYB6)VA5'5B<47?<.9GO2_$GX=_P#1-[#_ , ;7_XF
MG_\ "R/A[_T3FQ'_ &Y6W^%?*GC[XC7+?#WQ@=.MKK3-<TH""YC>1!);;\%9
M58$A@5/!7GGVJ_XVOM1\*_!Z^NM,>YTG4XXX_+DN+G[5(C,ZC<78MG.?PS1=
MA=GT]_PLCX??]$ZL?_ *V_PIW_"R/A__ -$[L?\ P"MO\*^6-*^)EW#\+;B_
MOE$GBBQD_LJ6V[RWQ(5,#T;*M],T?#&\U77O ,E_XD\1Z@EY87-U%<W5J\<2
ME8VY)&P\  XHNPNSZI'Q(\ _]$]LO_ .V_PIW_"R/ 7_ $3ZS_\  .V_PKX]
MA\5>([3PAX>UK4-6OH=(U75'DF=/+:^BLV!%ND8V_,3@,V%+8;BNI^']QJOC
M30;BXD\0WD>G+J4GV2XC\D7<ML!PDQVD(P;/8-@#..:+L+L^F_\ A9'@/_HG
M]G_X"6_^%.'Q(\"?]"#9_P#@);_X5\I^'_B)J-K\/=1U">5M9NVU2;3=#FD4
M+)J&7V0L0  >=V6 P0A-;/P2UC6=:\'7#Z_?_P!IZG;:E=6DEQM"@^6^W
MXXXHNPNSZ4'Q(\"_]"%9_P#@);_X4Y?B1X'_ .A#M!_VZ6_^%>$Z]XRCT76-
M.T:VL+C5M7OHY)H[6V9$VQ)]YV9R !D@#U)JAX7\2'XIZ#]KLI-4\,BWOGMK
MB%A$+@M&<,A;#!1D]1SQ0%V?0W_"R?!'_0B6O_@+;_X4[_A9/@G_ *$6U_\
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MI?[6FC?&#4OA5X$FTSQ$E[IOBK1+B'Q!<W%LT^KS1RQQ[M05$&[:IVQE68@
M;LGFOU\.<GK7B8[G]Q35GJ<M6^EQS,%4DG '))KX+^+_ (R/CKXA:MJ2/NM%
MD^S6W_7). ?Q.3^-?;_B32I]<T#4-.@NWT^6ZA:$72)O:/<,$@9'.,UX,O['
M%FHP/%5UC_KR7_XJO,1RL^4/%N@OXF\/S:?%.MM)(\;B1U+*-KAN0#WQ4$_A
MB[UG5;:^U6[@86:2?9;:UC9461U*F1BQ)) / Z<FOKC_ (8[L_\ H:;K_P
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M6&X1[2"@?^\,\=/6ON3_ (4!X?\ ^?O4O^^T_P#B:=_PH/0.]YJ1_P"VB?\
MQ- 6/F[PSIUUHVFQ64T.FV]M;JL=M#ID;HB(!T(<G]*\JO\ ]FW[1:^)5M=>
M-K<7UTEQI4PA.=,42-(47G)!9VZ8[5]S?\*"\/\ _/WJ7_?:?_$TO_"A- _Y
M^]2_[[3_ .)HT#4^1+CX2P0Q^$WTU[/[1X?M39+#J-MY]M<Q,!O#+U#9&X,.
MA]:74/A?/J,VCZDSZ)'JVFSRLL$>F 6,L,@ ,3QYR2  0_7/;%?77_"A- _Y
M^]2_[[3_ .)I?^%"Z!_S]:C_ -]I_P#$T!J?'_B'X0KXRM=&MM8.DK:V>I->
M3VFGV)@BEC,901@AL[AG.\^G2HM0^&/B/4]#N=#O];TC6=.5#%876I6#M?V?
M]U_.5QND48PV!]T$YK[%_P"%#:!_S]:C_P!]I_\ $TO_  H?0?\ GZU'_OM/
M_B:- /GW1]/.DZ38V+7,MXUM D)N)SF27:H&YO<XS5U>E>Z_\*'T'_GZU'_O
MM/\ XFC_ (43H/\ S]:C_P!]I_\ $TPL>%T5[K_PHG0?^?K4?^^T_P#B:/\
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M/%/[4EWX;?4)?)M%U:]-L;A_[J![D;C]*36O@[?^&_$^E^'-6_:FNM-\0:H
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M_OF;_P"/U]+;J-U'MZG])!S,^:?^&3_'_P#T7OQ)_P!\S?\ Q^C_ (9/\?\
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MQ_\ ]%[\2?\ ?,W_ ,?KZ6W4;J/;U/Z2#F9\T_\ #)_C_P#Z+WXD_P"^9O\
MX_1_PR?X_P#^B]^)/^^9O_C]?2VZC=1[>I_20<S/FG_AD_Q__P!%[\2?]\S?
M_'Z/^&3_ !__ -%[\2?]\S?_ !^OI;=1NH]O4_I(.9GS3_PR?\0/^B]^)/\
MOF;_ ./UD:'^S_XB\37^JV6C_M*ZIJMYI,PM]0@LIWF>TE(R$E"W!V-CL<&O
MJQFRK \C!S]*^2/V1_$&C6_[0GQPLM$\*:[X;T;6;NQOM*-YX=N=/M7CM[5(
M9R&>-5#&5B0"<MRPSS1[>I_20<S&VGP9U+4+/3;NV_:BO;BVU.];3K*:*\++
M<W2E@T$9%S\T@*,"HY&T\<5TG_#)_P 0/^B]^)/^^9O_ (_7(>&?@7>^'_VL
MOB9JFD65[-I>BZ9)XC\):;=PE=-AUS4(BET\3$!2Q,*\9^7SGZ9KPSX2_$;X
M_P!OX%^)UUXEN/'&K:DOA]7FT=4U&*]@U W4:O+:S26@CB54:3=%;&3Y1E,X
MR#V]3^D@YF?47_#)_P 0/^B]^)/^^9O_ (_7C7CK]D?XE:Y\5$T^VUJ\\3I#
M;Q2/XJU=GA2'.?D#%F9BOHI[]JR_@Y)\:?B%IWPO\.^)/$OQ"T&QNO%FN6^H
M:G US#=G34LH)K42SSPJX0R%U621%;DJ,$<?H<K%45<D[0!ECDGW-5'$U(N_
MZ IM'(_"3P3K7P_\)PZ7KOBR\\77:X/VJ\0#RAC[BG[Q7W8D_P J[7=[U#NH
MW5S-N3NR";=[T;O>H=U&ZD!-N]Z*AW44 0[Z-]1;J-U $N^C?46ZC=0!\E?\
M%3''_#)EYDX_XGFG_P#H;5^.OFI_?7\Z_HJ\3>%=#\::6=,\0Z-8:[IK.LAL
M]2MDN(2Z_=;8X(R.Q[5R7_#._P */^B9>$/_  1VW_Q%>QA<='#T^1QOJ=-.
MJH*UC\$=%\2:CX:OQ?:/JUWI%Z%*"ZL+IX)=IZKN0@X/<5;NO'?B&]URWUJX
M\2:K<:S; "#4I=0E:YB S@)*6W*.3T/>OWC_ .&=_A1_T3+PA_X([;_XBC_A
MG?X4?]$R\(?^".V_^(KK_M2G_(:?6%V/P<N/'GB&\UR#6KCQ+JL^LVZ[(=2D
MU"5KF)1G 24MN4<G@'N:CTWQGK>BQJFG:_J6GHMP+M5M+Z2("< @2@*P^?!(
MW=<$\U^\_P#PSO\ "C_HF7A#_P $=M_\11_PSO\ "C_HF7A#_P $=M_\11_:
ME/\ D#ZPNQ^#M]X]\1:EK%IJUYXFU:[U6SQ]FOY]1E>X@P<CRY"VY.23P1UJ
M2\^(WBC4+Y+V[\5ZU=7J0O;+<S:G,\BQ/]^,,7R$;NO0]Z_=[_AG?X4?]$R\
M(?\ @CMO_B*/^&=_A1_T3+PA_P"".V_^(I?VI3_D#ZQ'L?@I:^*]6L8;&&UU
MN^MH;"8W-G'#>2(MM*>LD0#?(Y_O+@U%J^O7WB#4)+[5=2N=4OI  ]U>W#32
MM@8&78DG ]Z_?#_AG?X4?]$R\(?^".V_^(H_X9W^%'_1,O"'_@CMO_B*?]J4
M]^0/K"['X>_ 61/^%[?#?#+_ ,C+IO?_ *>HZ_H,F?\ ?/\ [Q_G7GEC\!?A
MCI=];WEG\.O"MI>6\BS0W$&C6Z21.I!5E8)D$$ @CH17=[L\GDUYF,Q2Q+32
MM8PJ5%4M8EWTJS,O1B/H:AW4;J\\Q)A,P)(8@GWKQO\ :4\:>%O@;X)USXNZ
MAIMK-XLTO3'TK2KR09F=YFRD"GLID 9L#HA]*]>W5XI^U3^SSX=_:!\#^7XE
MO]6@M=!@NM0M[73[@11R3B([6D!4[L 8'^\:UI<G.N?8J-KJX?L:?M!G]HCX
M%Z3K]W.A\1V9.GZU''A0+E!]_:.BNI5A]2.U>X;Z^5_V"?V??#WPK^$_AWQG
MHNH:LU]XRT"QO=3L[FX#VOG-&'WHF/E(+,!ST-?4>ZKQ"@JLE3V'.W,[$_G-
MMQN./3-(TA>,HS$HPP1GM4.ZC=7.0><>-O$7A#]E?X&:SJUCIEKHWASP_:RS
M6VFVHV(\SL2L:CNTDK\]\L37"_L-_M+7/[2'P;74-8GC/BW2+EK/5HX_E!))
M:*4*.@9./JAKLOV@/V?O#W[1WA.S\/>)[_5;32;6Y^VF'2YQ%YT@4A?,R#D+
MDD#U->'_ /!/+]GCP[X!^&?A_P")&E7^K+K/B;2BFHV<MP&M),3.%8)MR"NW
M@Y[GUKMC&E]7DW\5_P"OU-5R\C[GV*TI;J2?J:%E*\@D?0U#NHW5Q&1-YS;L
M[CGUS7DG[2_B[PI\+?A_<_$_Q'IEKJ&K>$XII-"DN.9([R9/*58_1FR 3C.T
M-7JNZO(/VEOV>?#O[17@^#3O$U_JUM8:3YU_%;:;<"))9A&=K294[MHS@?[1
MK6GR\ZY]BHVOJ9?[%/[14G[17P/L-:U"=#XHTZ0V&M1Q_*//'*RA1T5T((]P
M1VKWGSFP1N./K7R7_P $_?V??#WPT^%'ASQYI%_JO]I^,-!M;C5+.>X#6K2'
MY@Z)MRI!) YZ$U]7;JO$*"JR5/8<[<SL2[Z-]1;J-U<Y!+OHWU%NHW4 2[Z-
M]1;J-U $N^C?46ZC=0!+OHWU%NHW4 2[Z-]1;J-U $N^C?46ZC=0!+OHWU%N
MHW4 2[Z-]1;J-U $N^C?46ZC=0!+OHWU%NHW4 2[Z-]1;J-U $N^C?46ZC=0
M!+OHWU%NHW4 2[Z-]1;J-U $N^C?46ZC=0!+OHWU%NHW4 2[Z-]1;J-U $N^
MC?46ZC=0!+OHWU%NHW4 2[Z-]1;J-U $N^C?46ZC=0!+OHWU%NHW4 2[Z-]1
M;J-U $N^C?46ZC=0!+OHWU%NHW4 2[Z-]1;J-U $N^C?46ZC=0!+OHWU%NHW
M4 2[Z-]1;J-U $N^C?46ZC=0!+OIS3,W!8D>YJ#=1NH F\PXQGCTS2^>_'SM
M^=0;J-U $YF9LY8G\:;OJ+=1NH EWT;ZBW4;J )=]&^HMU&Z@"7?146ZB@"'
M=1NJ'=1NH FW4;JAW4;J )MU&ZH=U&Z@";=1NJ'=1NH FW4;JAW4;J )MU&Z
MH=U&Z@";=1NJ'=1NH FW4;JAW4;J )MU&ZH=U?G=^W?^V%\5O@?\?7\,>#?$
M%MINBC2+.[\B73H)SYDF_>=SJ3SM'&:Z*%"6(GR0W+C%S=D?HONKSK]H3XI:
M!\(/@_XE\0^)+E[>P^RR64:Q(7DEGF1DCC4=R2?P )K\IO\ AY!^T#_T.%E_
MX);3_P"-UR7Q3_;)^+'QJ\'S^%O&.O6>JZ)-+'.T"Z5;Q,)$.5971 RD<]#T
M)KTZ>655).;5OZ\C>-"5]3]3/V%OBGX?^)/[-?@ZTT2X>2[\,Z;:Z)J<$R;&
MAN8H5!^JL.58=17O^ZOPD^#O[5GQ+^ >A7NC^!]9M-)L;VX^U7 DTV"=Y)-H
M4$NZDX & .E=[_P\@_:!_P"APLO_  2VG_QNJJY;4E4<H-6?]=ARH2;;1^SV
MZC=7XP_\/(/V@?\ H<++_P $MI_\;H_X>0?M _\ 0X67_@EM/_C=9?V76[K\
M?\B?J\C]=?BA\3-!^#_@'6/%WB:Y:TT;38MTKQH7=F8[41%'5F8@ >]>&_\
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MC=0!-NHW5#NHW4 3;J-U0[J-U $VZC=4.ZC=0!-NHW5#NHW4 3;J-U0[J-U
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MXOT3QSX?\32>'M/35-4TS3H;H"*!NIBN7C$,Y7N(V/0BI5>#Z];"YT>"[?\
M.:3:!CCZ5]2W?[ NO03'38?B#X5NO$\OA\>);/PZOGK=75KY>]N2NU&'0!C\
MV">G-8GPX_8H\2?$#PKX4U6X\3:/X;O?%RO)X>TF^M[F:6^5> SR11M' &/"
MF0C/6CZQ2M?F#GCW/G7:/3WI=H]*]Z\(_LBZQJ7A\ZSXQ\7:#\-+&77)/#EE
M_;HEE>\OHW*2HBQ*<(K J7;"Y%4O&7[)OBOP#X3^)6M:W?6%K)X$U6VTJ]L4
M#N]RTX5HY8GQC85=6YYJO;4[VN/F5[7/$Z*^EF_86\1VOBC7--O_ !;HUAI6
MA^'[/Q%J.LFUN9DAAN2PBC$,:-([?(V=HP!7S]XLT.+PSXEU+28-6L==@M)C
M%'J>FN6MKI>")(R0#@@]",@Y!Y%.-2%32+!23V/8?V%?^3NOAG_U_P O_I--
M7[5;O>OQ4_87_P"3N/AG_P!?\O\ Z335^TN^OG<T_BQ]/U9Q8CXD3;O>C=[U
M#OHWUXQS$V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[
MZ-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-]
M$V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[W
MHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]
M0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-
M] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V
M[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW
M>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[Z-] $V[WHW>]0[
MZ-] $V[WHJ'?10!%OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OH
MWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N
M]Z-WO0!-OK\F?^"G!S^U))_V +#_ -J5^L&[WKX3^.G[/>I?M1?'[QY>V/A_
M39CX7DL]#DN+SQ%-8M-_HR3JPC2VD' F()W=NE>E@)JG5<Y;6_R-Z+Y979^=
M&BS6%OK-A+JUM->Z6DZ-=VUM+Y4LL08;U1\':Q&<'!P:^CI/VB/A[\-/@YXQ
M\#?"ZP\97D?BN>WDN!XPN+<VVG1Q2"0+!'"3N9B,%VP> >M>L?\ #MKQ#_T+
MN@_^%G=?_(-'_#MKQ#_T+N@_^%G=?_(->W/%8>I;F?X_\$ZG4@]V8WBS]M+X
M7^(+[XG^);;PKXLM_&7C[PFV@7AEGMVL;.40A%\M00S(Q )8\C;POS'$FF_M
MJ?"O3?$W@#QP?"7BNX\<^!_"L>@Z>IGMUT^ZF$)C+S#)=54LQ!7)(;D#%:O_
M  [9\1?]"[H/_A9W7_R#2M_P37\1JV#X;T('T/C*Z_\ D&L.?"6M?\?EW[$W
MIGCFH?'SX<_%+X/^$/#OQ-T7Q1)XC\(+>Q:?<^'9X$MKZ.=S(%G\SYH]K;>4
M!R ?6N[^%O[8WPT\/1?!K6O%7A7Q1=^+OAS8RZ5 -*N+<6,\+@CSB'(<R*#]
MS@$DG=P*ZG_AVKXE)('AK0R1U_XK*Z_^0*/^':OB3<1_PC6AY'4?\)E=?_(-
M4ZN%DK7T]>^_7S#FIO2YXE_PT!X,\1? 'Q%\/?$>DZXEVOBJZ\4Z'=Z:8#$\
MDH;$%V'.0G/)3)YXZ<^O_$C]O/P9XV\ ^/M,M;'QM:W7BGPRFBP:#-<6_P#8
M>CRJ@7=;Q*P.&.27(W8& .>+J_\ !-?Q&V<>&]"..N/&5U_\@T+_ ,$U_$;=
M/#FA'Z>,KK_Y!I.IA).[?X_\$+TSB?\ ALKPG_PT%H'C[^Q-:_LO3_ Y\+R6
MVV'SVN# T?F+\^WR\GN<^U.\'?MG:*_PC\#^&/$.L_$WPKJ?A*T-@C> =6BM
MK75;<'*"<.P*.  N]0QQD^U=G_P[:\0_]"[H/_A9W7_R#2_\.U_$>[;_ ,(Y
MH6[T_P"$RNO_ )!H]IA++7\5_GYA>F>4Z#^T9\.O&'PWT3PG\4=(\7W7_"-^
M)+G7]*O]#NX)I[A9I#(\%TTV,G)YD7D]<"MW4OVS?"GQ47XOZ=\2?#>MQZ)X
MVO[+4+1?#=Q%]HM/LJJD<+F7 (947+CD$M@=,=S_ ,.V/$?/_%.:%QU_XK*Z
MX_\ )&D_X=M>(?\ H7=!_P#"SNO_ )!I^UPM[W_'SOW[CYJ9S=[^V5X#U3X^
M1_$"W7X@^#H;71=-TVU'A^YM6E/V<MYL$\<I\N:%P5 8X(VD[1GCYL^.GQ$L
M/BU\7O%'B_2]$C\.Z?JUUY\.FQX_=+M RVT ;FQN..,DU];_ /#MKQ#_ -"[
MH/\ X6=U_P#(-'_#MKQ#_P!"[H/_ (6=U_\ (-53KX:F[Q?2VZ_S!2A'8\!_
M89./VMOAI_U_R_\ I--7[0[Z_.SPG^RWJO[,7Q%\!^.[WPWI)C3Q%9:4C6WB
MB>Z>-[MS '\MK1 P =C]X<@5^AS?*Q&>AKRLPJ1JSC..UCGK-2::)=]&^H=W
MO1N]Z\HYR;?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T
M;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@
M";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1
MOJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=
M[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O
M>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";
M?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ
M'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T;O>@";?1OJ'=[T
M;O>@";?14.[WHH AW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J
M)=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7=7CWP4;_B[WQ_
M_P"QEL?_ $UV]>N;J\?^"K?\7<^/O_8RV/\ Z:[>MH?#/T_5%+9GLNZC=46Z
MC=6))B_$*\FL_A_XHN+>1X9X=*NI(Y(VPR,(6(8'L0:^)_A?\6/%?AOX7?\
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MF66&58R<E"\;*2I/.TDCVK=8F*E=[7;_ ,B^=7/FOXB7MUXV^!_PRD\->/\
MQ1XC^*FMZ=9P^'QH][+:1S2*P-Q>W$"X^10"':7(^4 <DUF?M:?&[4['Q5;Z
M!/XBUKP\/",VF&=M.M;J)=:NY)(S<.98TV^3'&&Q&6R[/P#@5]&^)/V8/A;X
MMNK"YU+P?;M-I]BFFVK6MS<6HAMD)*Q*(I% 4$GZYYKLM8\!Z!X@\(V/A?4=
M/^UZ!9-;M;V4DTFU# P:$[MVXE2JGDG..<T1Q%.+B[7M?MU#GBK&S#KEEJUK
M+-97,<H:W\\1AMLB(Z%D+(?F3(Z!@#7B7[.[W/Q _9;TO2]1\072:QK-KJ-N
ME\]ZWVP'SY561&+;R4^7D'C KTOPU\/K#PWXJ\7>)!--?:SXFN(Y;RXG"@K'
M&FR*! H^XHW=>26))JIH?P<\%>&;SP[=Z9X?M[2Y\.QW$.E2+)(QM$G8M,%R
MQSN)/7/7C%<JE&,6EY/\'^IG=)6/ O@_\1M=^*FL_"'PE>ZG>0:IX3AU"[\6
M>7.RM--9N;2%)B#EE=SYF&X;;DYKZRM[R&\A2>WGCN8'&5EAD#HWT8<&N4T#
MX4^$_#?B3Q+KNDZ#;VFL^)?^0M=1ERUWP1@@D@#D_= ]:T?!_A'1OA_X:L?#
MWA[3X]*T6Q4I;6<)8K&"Q8@%B3U)/)[TZTX3=XJW]:A)I[&]NHW5%NHW5SD'
MD/[4K?\ %'^"?^Q\\/\ _I6*]ED;]XWUKQ7]J1O^*0\$_P#8^>'_ /TK%>RR
M-^\;ZUM+^''Y_H6_A0_=1NJ+=1NK$@EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=
M1NH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@
M"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U
M&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JB
MW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1N
MH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7
M=1NJ+=1NH EW4;JBW4;J )=U&ZHMU&Z@"7=1NJ+=1NH EW4;JBW4;J )=U%1
M;J* (MU&ZH=U&Z@";=1NJ'=1NH FW4;JAW4;J )MU&ZH=U&Z@";=1NJ'=1NH
M FW4;JAW4;J )MU&ZH=U&Z@";=1NJ'=1NH FW5X_\%V_XNY\?/\ L9;'_P!-
MEO7K6ZOFSP_\8_#'PE^,WQIMO%$FJ6,FI:[9W5HUOHUY=)-&NGP(6#Q1,O#
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M\*M:\&M>6<#^'-9OY=/U#49)"C63^2TD3 ="&9"O/J*\%\6>)/V>/&7CB_\
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M?D.R_E/ISP+XF_X3'P9HFN_Z+G4+1+@_8;D7$&6'/ER ?.OH<"MS=7@7A?\
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M_A!KW^]^@_\ BJ** #_A!KW^]^@_^*H_X0:]_O?H/_BJ** #_A!KW^]^@_\
MBJ/^$&O?[WZ#_P"*HHH /^$&O?[WZ#_XJC_A!KW^]^@_^*HHH /^$&O?[WZ#
M_P"*H_X0:]_O?H/_ (JBB@ _X0:]_O?H/_BJ/^$&O?[WZ#_XJBB@ _X0:]_O
M?H/_ (JC_A!KW^]^@_\ BJ** #_A!KW^]^@_^*H_X0:]_O?H/_BJ** #_A!K
MW^]^@_\ BJ/^$&O?[WZ#_P"*HHH /^$&O?[WZ#_XJC_A!KW^]^@_^*HHH /^
M$&O?[WZ#_P"*H_X0:]_O?H/_ (JBB@ _X0:]_O?H/_BJ/^$&O?[WZ#_XJBB@
M _X0:]_O?H/_ (JC_A!KW^]^@_\ BJ** #_A!KW^]^@_^*H_X0:]_O?H/_BJ
M** #_A!KW^]^@_\ BJ/^$&O?[WZ#_P"*HHH /^$&O?[WZ#_XJC_A!KW^]^@_
M^*HHH /^$&O?[WZ#_P"*H_X0:]_O?H/_ (JBB@ _X0:]_O?H/_BJ/^$&O?[W
MZ#_XJBB@ _X0:]_O?H/_ (JC_A!KW^]^@_\ BJ** #_A!KW^]^@_^*H_X0:]
M_O?H/_BJ** #_A!KW^]^@_\ BJ/^$&O?[WZ#_P"*HHH /^$&O?[WZ#_XJC_A
M!KW^]^@_^*HHH /^$&O?[WZ#_P"*H_X0:]_O?H/_ (JBB@ _X0:]_O?H/_BJ
M/^$&O?[WZ#_XJBB@ _X0:]_O?H/_ (JC_A!KW^]^@_\ BJ** #_A!KW^]^@_
M^*H_X0:]_O?H/_BJ** #_A!KW^]^@_\ BJ/^$&O?[WZ#_P"*HHH /^$&O?[W
MZ#_XJC_A!KW^]^@_^*HHH /^$&O?[WZ#_P"*H_X0:]_O?H/_ (JBB@ _X0:]
M_O?H/_BJ/^$&O?[WZ#_XJBB@ _X0:]_O?H/_ (JC_A!KW^]^@_\ BJ** #_A
M!KW^]^@_^*H_X0:]_O?H/_BJ** #_A!KW^]^@_\ BJ/^$&O?[WZ#_P"*HHH
G/^$&O?[WZ#_XJC_A!KW^]^@_^*HHH /^$&O?[WZ#_P"*HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pgen-20201231_g16.jpg
<TEXT>
begin 644 pgen-20201231_g16.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $L BT# 2(  A$! Q$!_\0
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M2M[41[U(#*&^7/>JE5;1<:2.?/PW\.&/:NA6J(PS]VM#3_ .AVT<D4&G0J'
M&-OI726MF\T3<A O9OZ5<M]/VL2SY7&0*Y74E>]S:-*/5&.O@;1)F20:7;M*
MN5;(/-5?^%=Z-%J",+"!01@_)79V:11R+E"Q;CKTIU[;<!U'0XP*/:/N7R1[
M'(W/@/1C8B'^RX2B/GY5Q4W_  KS0H-0@ECTR,*T1!..,UU<.UHI+>3*/(OR
M/UY]Z2.$7UH87D*R0GD =<4_:-JQNJ:L<]9?"WP]<"1WTZ,*5QR",5)9^ =%
MAC0KIL)\ML9Q[\9KJHX]L)PYE##.!U^E4+'SX_MJI,#D[E1AR*PYI=RHP[(Q
M-=^&.B7:7%O>6D47GKE?+0?SK)7X>:-9V21-8Q9B7 8KC/M7H*E+FWA9QN(_
MB;K6:L)^S:@L:"5U.?FYQ]*.:7<U4%V/.[GP#I<ETH;3K=?7:*N0^!=*6&<'
M2[=V(  VXKJ;R&*XA(CW&9%#'*_F*79)';Q%'#,PS@\_A6O.XCY%V.,?P-HD
MC"6XTN.27@;67@53O_ N@2:@H_L:W1@OWMISS781VT]V'>X"H_(^7IQTK/DL
M]EY(QF9F '0Y'X5:D[7N1.GY'+7OP]T"WF@=M.A*?[N<UD6OP]\/VSR^7I\&
MR0LVUEQC-=_<1JK;Y4+E!G@U091=1LP15CVG.>HK:,W8Y90C;8\]_P"%=^'U
MM%*:+:RQGJ2,XK*U[X2^"=?L6L-8\/P2V4PQNC)22%O[\;=C_.O1O,06Z[64
MHW1<8/XU7NK-;E4**,].E=$,1.#YHLX*M"-322NC\^?C?^SS>?!?54N&=M8\
M*WIS8ZM&I"_]<Y<?<<>G>O/?[!LV PI_,U^IE_HMAJ6AW6E:M9KJ6A7R^7>6
M$I&UU]1_=8=F'-?$O[07[-.I?!>0Z_HKW&M> 9WVQW>W,E@YZ13X_1NA^M?6
MX/&QQ$;2T9\7C,!.A+FBO=/"?[#M-Q&UO^^C5G2])MX?$6B;5)#W\"L">H+B
MK4>V10RL"&&014EFH'B#0/\ L(V__H8KU#R#^F+3XQ'86R*,*L2@#\!5JH+/
M_CT@_P"N:_RJ>@#^5J;_ %TG^\?YTRGS?ZZ3_>/\Z90 4[FD^[6EX?\ #VI>
M*M:LM(TBRFU'5+V00V]K NYY')P !0!%INFW.KWUO965M)>7EPXCA@@0N\C$
MX"JHY))K]%/V6_\ @G[9^%[>R\6?%&TCOM7.);7PV^&AMNZM<8^^_P#L=!WS
MV]6_9+_8]TC]GW2;;7-8AAU7XAW"9GO,!X]-5A_JH>VX#[S]>PXKZ?33U?!;
MYG/)S7BXC%M^[3V/I<#EZTJ5E\O\S)ALY[R*-?)"A1M"JNU54#@*.P&!Q6U'
M8"%5*],8Z5>M[=(8^ !QGCBIEC#?Q?=ZY]J\C?<^IB^B5D.AMPJ@D]JD611'
MEAU_A]ZKW%TL:A%Z>_/?I5&[U+R5!4;N.0*B4DMS2,',DU"\5&;'7&<5F1W^
MYEWMZDX/!]*Q]0U*62?&1MZX(.:HM<2*#@?+G.YN?K7)*H>O2P_NZG1-JHZ*
M,MNY^E9-]KPC;:#YC8X7/ _&LTM/=< ,S=E/2I5L6ACRXV/G R.*Q<VSKA1A
M%ZF==75U>3YQM!'"J,8X]>O3TI/L):,2,68]QGW]ZN[D\AOFPV#GGGW_ *U!
M8W"7UN2-TS _,%'3TK+5GH1CI=*R(!:F2,.K[4SQCTI_]BLP#JWS*/E8\'\?
M:MNRT^2./REA"H1C;CI_D4^/2[B:Z90<!3]X'-'*]S)UDF]2C8Z?O8[ANYZX
M]*O/8K" Q*G;ANE3MI!MHR$FD+D8"@\U%;Z0)(U:>ZN'E/WE5B,$=L"GR]SE
ME.,O>OH5)H89.2 %8]3QGBL>YMT#D0!Y)3T"*2/;FNOTSP_"L0W0;I.K;CN/
MYU/<::RR*%! Z?+Q@5?+S="5B(0E9:GG?V.\96:2U#D=#OQC].M9$VG7,GS_
M &>/?T9=V:]2FT?+GRUXQDY&/PK(DTL+O"KM<GEMO-+E:-XXF/1'E6IZ6%63
M*L@'&U1G->?_ !(^%>A_%SPZ--\261?RTQ:ZA&!]IM3V*MW7U4\&O>-3TWRT
M*A=V[@<=S7/W&BR[O)=%&T'D#J/05I&4Z<N:+LS2HJ6(I\E2-TS\I/C=\ ]?
M^">M".]3[=HUP3]CU2%3Y4H_NG^ZX[J?UKRROV0\2>#=*\3:#>:'K5C%J.E7
MJ[9[27HW.0RGJKCC##FOSE_:4_9EU/X(ZHNH6?F:CX0O9"MGJ&,F-NODRXZ.
M/R(&17UF"QRK)0G\7YGY=F^2O!R=6CK#\CPBBBBO7/D@K]JO^"*W_)J_B?\
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M^(_Y]:9_8]K)$08E&WV%$I2Z%1E3MM<SO^$NDFCPXSZXZ_C39/$$\A79OV'
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MRYC?+9SVSUY_G1S/<3C#9'=-K>]FW,6]NF*DCUY5.)F:0#!^\>.#Z5QGVZ3
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M77WI,_.N)L&HJ->/HSZFHHHKZ(^!"BBB@!*_/CX@ ?\ #2'Q@9G 5=2L>/\
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M\ZE3YI$DUXOFA,,01@MZ5B74C-'-&JD,O0CTJK<:AYT+Q$,AZ@H3FBVNC?.
M-L8P <G!:M(KN>Q"G[,K7&GQO!$YEDZ<\?Q5SNHQ[;QUQYD:CG/0^U=+JT<T
M438.V/. 6XP:Q)IXH;8AU4LO ;<:Z8[G;%KE,ZW^P::RFYB",P)15&6'IUJI
M>W6MW5O#Y0C2U#?)(Y^8<U2U'5!YJD_.V< ]2*222698Q-<-",Y"^V:[H19D
MQBS7%C<%;BY:1=V<8Z5.TLL=U&8G::(-WXP.]5-2U&SM9BJ2_:7V\\>]0_V^
M?,:'8JQ8R/K6O(^I%S=^UJ;I-ZOCD[ :=8WD31W4D*2C:^=N*R5UE-T,H088
M=3_A4FF:S&LEX@5P6'/8?A3Y">:^C)M5U)F:0+NC=P"-U4Y=0EMUM47=)N_B
M'0TFHWGES1G&\MQLSV]<U!<:E"TF$384Z#.:N,;!H:C:\8[9+<H[D$G'8&H9
M]6)M 8H1'(OWB_0U2-S!,%<E@ ,;3VIE^))/*@CD4KG,B]>*2BVSGJ2[ VMR
M-Y :W(=L@+V^M(NHR"XA$D09CG/-13+)/,I PJ+@&J\E\L<P7B:/!RO0Y^M7
MRG/>YUMGJ"18?&PN=AW<T:E>>6&C&<L,@J.*P;.X>:WP596S][.:EOKS[.H;
M?SC'-<TEJ;1M8L6]Q.K,$;;O&"?2M.QLU:W*-AU/?UKF[;5-TBAQM+'M73PR
M*MOF-@>U38M'+ZMI*?OH8XTC(;+2#J:Y?7%\D:>%0LIO+<9S_P!-%KT74=/D
MN%#$;=W]T?>KF/%^E)]ELX@N&6ZMV)SZ2K7;@Y?OHW9Q8S^!+T/T>MO^/6+_
M '!_*IJAMO\ CUB_W!_*IJ_35L?D+W/E?18XS(3$BI"H"11@<*@ "J![ "N\
MTNW:.)2.1TXKC_"UON52Q^0\"N_LX5$8PN0#FOCHW;NS](K>XK(T(65"JG@^
MYJS+'^[(]JAC4'DBII-RQG(XQQS78GH>1+<P+^39&_ R*\XU:X,D;X^_+)CJ
M/I7>ZY(T:-G@=ZX6.(W%Y:+G/)8=!WXKSZSZ'T>#7*N9G0^'[)X;./?M&%Z@
M9..M= L8MXLG:._I4>GPI#'L7!*\=><U-,ADF"D?*O'MG_ZU33@TM3EJ5'4F
M[E9KC:PW*VYN!QC-4W=I6=@N-IP0>U79]ID49P5/''ZUF75T%,AW?*#TQCFM
M&S:FK[(Q=<O$1=A^]UR1Z5Y5XH\0-=-+;PDA1_RTZX]A[UT'C'Q$8%F(Y8?*
M&[$UQEGIZ^8)Y,.X&0.HY(R?K7,]6>]3M3C=DNAV(C9II$V9)(W'GOR:UOMD
M,*_>VL><]CVK,O+YHU 0Y4'G'&:Y/7O$/D1R9FV C(R/UY^M3MJR.5U'=FMX
MC\60VL;@%4)&!DC%>6ZUXT:\=X8LE1P2?N_7%9>M:Y-K,CI#_JL8+]CTYKFK
MB)GD(1R>QSG_ #V-/E<M6=*<::LMS:75%M&,TLAD8#G)S@>E13^*C)(P@CRO
M4G^G2LZ#3"S+YG +<\^GO6BS6EB25(R/O,?4U?+;8B5;78RY]:OI,*>?Y_YQ
M_.B'6KA1MCW<#C;SG\:?)J5G)-(\DZ 9Z-C\#5BSU;3X^LD9W=" N.G?GVI<
MK&ZJL+'J5Y#\Y1MG7.W_ .M5V'Q4HDPYV\X.0>*MK>6LH"J5V=F4@#%9%]IZ
M21G# CCJ,\'_ /52:LB(U-3H['7(KL$;U+D9 P,'K[5UOA_6FAAQOW("1C.2
MOH#[?XUXI+!<Z<ZLC97J#R1^M=%X?\2$JN3Y<F>3G (]#4[:FTK35F>RZAJ%
MKJ$/RKDXP5QSSZ_G7FVO+)IET);==D>>5QG<<=OI[5NZ?J331H,[#W_PJSJF
MFVE] -R[?0\@]_\ ZU9O78FG:D[&7X?\4%U4/EDQC</I786M\K;>0!TW Y/M
MQ7GDVAR6TF^(>^X\^_2M'2]6>U=8'SCISV_Q]:$['1))NZ/2%N%:/'RR*17,
M:[I\-PKEE 7'3 (SCZ5I07BS6^=OS8VC_ U%(PFB",O/M@YQ5-*1A!\KNCSC
M4+5K4X #'J-O../2OMS]@V9YOA-JZN00FMS*H'0#R(#C\R:^0->TP+&[!<YX
M]37UY^P2NWX4ZV,8QKLWX_N+>O1RN_M_DSPN)6I8&_FCZ9HHHK[ _)PHHHH
M2OSZ^(<;K^T1\7G7:Q.IV.%SS_QX0U^@M?G[\01C]HCXN9.S.J66/?\ XE\-
M>%G#MAOF>_DO^\_(JQH^WYS@8J=55H_EPR]S[U$T<QC) P*19'\O;LPHY)%?
M 6N?I,(FGI\@9HQNWHO !%=IH\:3*D0C#IN!QMZ5R.AVT;1E^0^>AYS78Z!'
M))<*JOY,@Y^HKSL0^5'1)V5CN=*TB-8MQQCJ$JU-<)9H7?:HZ58M76VMP ,L
M>N:HWCI)&V] WIFN%:GC7E4F[[%+4+A=R2!^&'-<UK&J"&.0EB>.W:M#5+@J
MOECA0.U<C<)]M9XO,\IU'&1]ZNFFENSV*%%)7*=K?3W%\(U!^;^7<UUUO8QV
M\,9*_,!D$G/-9/A_2U%R6E(SMX]C71ZI<0P0@$X'8CO5N2N;R>JB<SXAF%Y\
MI<AE&=O;(K@[R\FD7RIYMLGM71^)]8^5Q'QN'WFZUPMBLVH7,LTK?+&<*>N1
MZUW4XZ7*)U$C22K"%<J?GF/455N&^SR>;*YE4=R>GTK=NO+L=/15PZM\Q]#7
M+W$YNBL?R[03P#7; SG)11EZQKS,\7E+YGEG[O\ C55?$5R;I#';*K9^\3G%
M6VM$DWARL>6ST[?6L^X:TL6)$Z%>AV\UUJ%SAEB>1V+3^)+N-U:2-68-]ZGQ
M^+I_M#AI,*>2NW'-9ZWEEYR;7'EGG+9-1OJ=HA\PE2['!4C)K3V9S?65>]S6
MD\2/)M.(VV]65NE06=T^V68SXSR._P"%9$VIV<*OL.W(YX[41ZK!"@8C"XST
MXH5/R)EBN;J='%KG[H[LKVSCDTW^VAR@DRY&"J]1[5C1303(SHV')W<GC\*:
M[-Y7F;MN>XK2-/E,O:WTN=-)K#0QHW/E_=ZY.:EF\BZCS&=CE<\'J:Y"WN':
M$EG))Z^M323%0LT3EH\9(SBN:::9M!JYVF@ZDS6X0@I*#R*OW6Z9 .')/W<<
MI7":7J*_:$E5\!3\QS776&HE]SQOO+'!SZ5S2CU.ZDT4[BX>W<Y^8J<\=JW_
M  [?#5(0SDA%;%<_J$9MV\QOE20'<*?X9E*7D<$;?N2<G%9V+J:,](CM9KA4
M /"-QQVKG?'&FF6W@#1>9MNX69AP0/,7I7:V:G;L5QT'S=ZPO$V%@A09):XB
MR??>*>&_C17F>9BKNC._8^Y[;_CUB_W!_*IJAM_^/>+_ '!_*IJ_55L?DSW/
MG#PO;O':H, G_9KM]/QA>"![=N]<WX?P(U(''2NJM5"].A[^F:^0IGZ'B)7N
M6D8*P.<\4R2Z+2;%&>?6K$RG<NU03CK4?$75-ISU'>NL\M-/4YCQ06:U=E&#
MTZ9KD+-DCU9 5SA54'MT_P#KUU_B0YAF/]T9PU<)+M@U LV&78#M)X/'%>=6
MWT/I\(DZ5CNH[HK""J^9(PSMZ<]L59A+*JMEMV<E2.]9MGCR0^[$I4?A["M.
M14X#CKQ51V.*I%)V*MS]UG+'/:N0\3:@;2U!##+M@\]!6WJEX;==H<$]/\*\
MY\7ZD-R@E@$!(XZG^O>LVSU,+3NU<XGQ#,^J:Q# A_=H2SL<\<9.?\]Z?YS6
MJC^ L.-W;_(JOI-PDDUU+U=CC\/2IM0YC7#90<GMG_"LTKG?4G[W*86M:@+6
M!V8[-@X/YUY%K6M2:U=2*TVRV4D !L;^@S^GZUU/C[5'DC%L&;+'GG^$'D5Y
MU=2)+-Y9.(H_F<CKGLOM]:N,;NX^;DCH3+,+J(<^7;=%7/WJK7.L06<86+D8
MP%!YJGJ&K?,(8%P3TR,#&/\ #BL2ZO%LLRR/O=N.3UK90.?F1H3:Q=7'W0(U
MYR3_ "'YUGWUU%)-FYNSG/"JV,"L&^UZ63<(F,:GC( S6!+J3+NSR<YW.>:T
M5,QE6478[RU\36%G&$AB60G@G86/US31JJ:@Y(LF;YN%C3!S_G^5<+_:4ZK\
MIXQG,:@C!J_8^(;E6"K+&6'.U@0?_P!=5[,Y_;7>AUUK=1><J0W,]B_/[HDC
MUXP1_G-;-M?74,+$R+=87YH1P_3M[UQ?]I6VJ,$N4/FC@ L<D^QJ/^UI]-F\
MN0^=;9X]1[Y_.I]FC2-1O9GIECJ$&J6[%3N4#[DN R^V,>U9-]8_9V,D!P5^
M\O&1_D9KFDU!XY!=6TBNK !MW?\ ^OQ72Z;JB:I:[@NX8P4'7WY[US2A;H=<
M9G2^$]<\[".Q+*,G<>>..:[VSU!)V4%0R]\\X->+QW'V"Z5XSCY@=IZ8KT#2
M;A+J.,[@"1U7@?E_C7++35'1&SW9W-Q)!)"PP06Y/'M7&ZM&+2X\R-B5%:19
MK:,N)&9"#\K9/Y?Y[5SFK:GW4D9SC=_A^7YU#9UTJ=]4=9H.H+,%0R=N,GK^
ME=$^>&+MEO[I_P \5YAX9U,+*-S8;I\P./TKO8[X&,$,RX^8X/&*I,BI%QE9
M$>K6JR1\Y!(^\/:OJ_\ 87A,'POUM&SG^W)>O_7""OE5IEF5OXCT(48SQTKZ
MX_8N9&^&^L%/^@Q)D>A\B"O5RW_>/DSY?B"3^HV?='T%1117UQ^8!1110 5^
M?GQ AE_X:(^+S1OLSJ=EG=T(_L^'I7Z!U\ ^/\?\-"?%G<@8-JMD!R?^?"&O
MG\Z=L-\SW\E_WGY?JA\<?[DHS=JJM;M'&RYW!NE:#1HL>1T9<8I$@V[3][<N
M,5^>\S/TF'Q#M#NF2WB0(ZR[MB_+G->A^$5$T*N\>)U^4LPYZUPOA]GT^1@T
M;36XRQ8'++^%=QX;O$N6(M[O[W/E.A5A^8KBKOFT.BJKQT.V6-F7 Y-4]2C,
M>U=G./6K%K%+''N=]S$YXJ.XCD59&ED\QB?EXQ@>E<L%W/'B[3.2UF46Z/(P
MQVKEI9OM;_:$7 C[=*Z/Q PEGCC3YGW#(]J6UT=3NV8^9LUIS):'T$&E%7)-
M%FAE@1R,[ARRCI5'Q)J M5D(D0J!QQTI/+G\.:IYK;GTQOO!1DQ-ZX[BL3QM
M>6_]GW4L4JN9!N&16L(INYG:\N9'G.L:XVI7DD0YC3AB#P*V=(MSI5G%(W^D
M(5SC'W1Z5B>'[=+K4A =JO("?F& :T]<U@Z78&U(PZY!(YR.PKU*<6.<N57,
M;4M6CCU!H8BP#Y*JQSBHXXXX[<2N@WYW,W3(K"FO!<S%R%613E?6DU#Q"MOI
MK1,P,A7!![ UZ,*/<\FKB$9&O:LTEP#&Q2V=BVQ>K$>E9TETSR;A9X1QD$=O
MKFJG@OP?XO\ BWKUSI?A2VM/(LGQ+?7;[4C)K6D_9Y^,&N:])9GQ-X::!3M\
M[<P5 .-IKU80A&.IX\Y3F[Q*Z7#7"!PNQ!P?[U4KF_,,#*T;2,#PW&:B^(6@
M^-?@7=6R^)-&;5],F7*:EHZM(F1V9>M>7WW[0&BM#FXBDMWSDK/$Z%?8\=:U
MC2YOA.&4Y+='J$FL0_9UR&CDZ<BHI-0^T*R)(A&,5Y7'\=O#]W"&*3^4#EI%
M@<HH]VQ@5H1_$;P[JMOYNG7T9_O;G&16OL7'<GVAZ-8W\D>=S[U4X/M6W!??
M:KH6D4-Q=W3KF.WM8C(_U*@=*X?2;G[#I,ESC[4L@SB,Y9O3:.]?1'P[\.:G
MX"@U.W>ROM"\2ZGX?N-0MKZX0HR,N"B(>S$=J2I.1U4[5-8RL>7W$CV+2QSH
M\5Q& 7B92K#V(-3PQJL:$Y(;EE5N!FDN-;N-=L;&_O\ <^IW$7^D2-R7?OFL
MBSO!;W'DLI&.3DUYU6FD['53G*]F:3967='E V<;:Z[0;[S;6-0^V7&#M'6N
M;\LF%9B,K(ORXZ5+X9O@K,I?+ Y!]*XY1OHSU*;M)'67^GHRH9+@S;N3'@\5
M5\.WD4.I2!#\H. N*MSR7,:1&W/F;@2S-SCV%8&DRG^TF0H8Y"_?'-<O*SMG
M(]MTN\;R&D W#%96O6[7$%I.\H4?:HB%Z?\ +0<5=\/W<?E@'HH&%/\ 6JOB
M)O.%NRE=OVF(LI[?.*>'TKQ]3BQ7^[S]#[NM_P#CWB_W1_*I:BM_^/>+_='\
MJEK]26Q^0O<\(T%?W:[?K761+M56![\UQ^AS^6JJ6^;L,=:Z^U=F10PY/ KX
M^E(_0,5>Y?CP[+@Y_I4D]OO5LC/&:2U78QSC XJW(IVG'2N]:GB2ERRT///$
MVX;@/3&/48K@&F2XN(#CY2@S]0<5ZSKUF)HWR#7E-]:O:W"!=K#SG!]>><5Y
MM>-M3[# SC.G;J=EI]Q''#&7.T;=PYXZ9J_)-]HW$#@?Y_QK(L;A8X_F3>,8
M*@>W2K\,R3+A5V@+P#]*B+TLC*I'6YRWB:X:%67<' &2<<]*\J\0Z@9EF<-M
M53M.>,?YS7IOC7'V1^QP>W/?'^?I7C.J7&=/E9OF;'&X\COUK.6Y[.$MRW,W
M2FD^SE W48^;@?@:35-0FCM6!Z8_B;.!3--N 8QT4_SJAX@<-;D*,=SGIVHA
M=HUD_?V/./$VH&:]E<L2,'G/'U_+%<C<R^5;D[L'EL]<L?PK8\03!99%8M\S
M?PX_/_/I7'ZA=?,@W?*3Q@\8YYKHA'L8U):E>XN#:K),YS,>@'7I7+ZAJF^7
M]XS,Q.0HJ;7-2,DFTMQ]W]/_ *U8:1^=(')Y)!W=1W]^*ZXQT/*K5+>ZBU)Y
MC3!923QGD]NM)<0J5(0-N.#A0>?\_P!:LZ9(+FY8L05C&.1CD_\ ZJF\Z.21
MMNYGD?:BC@?4T''?J<Y<-+:R;=I##M^-0FZ>4_-C>!D8ZG'':M2\LS)>&(]%
M.2W49JA>2)#((XTR5_B')_'VK969$I-#K:Z#+\LC$+C R,CWK>T_4!>1>3.0
MQX97Z>PKCI)&A8%VPW88QFM*SN67:T<F  &'../2IE$N-1G5Z?=&WNS%(<!S
MD'MFNHAM?[(:.=!N@D(5L<X)YS^A_.N%DN R12J,'A@>H'-=''JS+8JC$[&Q
M[XKFFM#TZ<G+6YT.I(NU)U;=@\]./\16_P"";\_*C2#8.G.<5SCLLUCN4[2P
M!&WKR/2I_"=XT=U@'.W[V,#O7!*-M#OC>QZS'$9E"Y.T?PXX_&L+7+([6PQ9
M<]>N*T[-GEC(SLXYXP<^YS]*I:L&>(AE9_0J,$=ZY6M3LHR<7N<_I^1)Z$'E
MEY-=WIV^:W4,WYG)Z5YS#)Y-\3OXQQN'_P!?FN[TFX_T?:K;<CA<T;;G36\C
M0NFFA1V#*J$8P<@U]@?L.R>9\,=:.<_\3N4?^0(*^.;RZ'DN)!GN,+7V!^PC
M)YGPMUSYE;&N2CY1Q_Q[V]>QEO\ O"]&?(<1-O!?-'TG1117UQ^7A1110 G\
M5? WCR&6;]H+XN$ !$U6R SWS80U]\=S7P;XUC\[X^_%T*2&75K-O;C3X:^>
MSMVPOS1[^2NV)^7ZHA.6CP<&11PC'%6?,3[.A/W\'*C-1&'=W^;UJ>X8V]OD
MQ*T>.6!^8?A7YYU9^DTUJ:OANUDC0$0_,XSDGK7H6EVPECV2P*DB_P 7K7+^
M&T2.&W<L'ROWAT-=K9,L8)0[B>Q[5Y-63YAUY.UD7M(D,T<L3Q[&1L8]J;J#
M$J1M/ J[8LD,P=U #\&H-:D2,X3@,.,U<=CQXR_>;'G^K[I+R-T :16QCVK;
MT.W;Y1(P9F//M6/>;%U2*0X;G! S71Z/L-QUQ63=SVZTFJ0Z^AC.0PS[5XOX
M^TYC/* 3$A/ 4]17MNH;48 ^YS7DWQ.F^0S1%<+QCO7?A_>8\+)M:GG-Y')'
M?6\5F 953<9,_<^OK7.^)M2NO,-O,AC<+DONX/TKJ+1GC\V7RR\CCKZ9KB?&
MEY+)>?8;*S>\U1AM2-,LH;MDU[=.-M2,1+F7*BA]LN)MT0@+;>K8'\Z@CTW4
M=6G"R,D$?\2JH8[?KVKU?P;^SH+G25O_ !QJ\D%]. 8K.Q.PK_O'O4FI?#I?
M"<A.CR-/#&?]9,,\>A]:[/;*QYL</*9SOP_T^?P[I]YI_A_,"7#;KJX;@D]L
MGTYKM=/U)]!C>W:VAEGD \M@YW*?7_\ 77*V4>O7C2K8VC.'.UC&VT?4^U;W
MA_X<RS2>9XGO9KB5CE+>UD*@#T+=36,JVNYV4\,UI8KZY\3;B%ELI]1AOYL[
MVA \T+CL<]#638Z7X3\30S/>Z#IOB2:9M[0+;*IC;T_#WKV'P_X=T3P_"$TK
M1+:V#G)DF7>[>N2>M5/$7@W0=2CNKB6R;2;C);[5IK>6Q^HK)8A)^ZRI86,O
MLGGL8CT)396_AK1(]/\ NFQN-.C(9?0C'/XUYCXT^!_PU\::W;:I=>%6\-:G
M"PDVZ4#':R8Z*R#WKU2T\+JT9NGN+[5"[@1S.YR?J.U;5C\'[V]:1M2U*:WM
MV^86T)RV#[FNJ.*G%74C"IE\);H\@UOPFRV,<Z6T,-G&1Y<EHNWRR.G3H14N
MG^+/%5IJ$.IW7BC4=>*)L1=4G,V%_NIZ"O5+_P#9RFD4G2/%-S9#.XVEPFY)
M/8^F:\>^)7P_\8?#&1KS488[[12?DGL/F$!QDEA]*[*>,4ERR9XU;!^S=XG2
MZA!8>.K>^UK2)(M/U>%,W6DSY19#W>(8KRW6%>UOED(  ^]\V0*U-+\8P6LF
MG:DJI.1ARK @L/0^M9WB"^M[ZZNKJ.%;:"Y8O'"AR5SV-;\BW,:<GS6.DTN;
M[19PR#(^IXJ.WN/(UA BY4@YP*P?#=\ILT0\,3A5)JXMP\.LP@*1\V!@\9KB
MG&YZ<97W/3+&_E%N%,7L&%<[N,>O$%B\I8851Q6K#O:Q ,F>[ =16+)MM]8M
MI(6+L6!.1FN%[GIIJQ[!X;AB^S@E\D8SS3O%UG#+%9J!L7[5"P(8\_..*/#<
M<4<>^-"KL01WJ3Q(7'D-)!D^?"%4,1CYQSBLZ#_VB/J88K_=Y^A]V6__ ![Q
M?[H_E4M16_\ Q[Q?[H_E4M?J2V/R%[GSSH,WF,N3G'1A7:64@\L<;N:\RT.4
MQX8D;3WSS7=:?J 503D<^O2OAJ,K;GZ7BJ3:NCJK7+2 'IZBM#C:1R3BLZSF
MW(CKCT/.:T>9,$#MDUZ\7H?+5/B,?58?E8;<5Y+XPMC;S2.JGY2'!^AKV:^R
MT9X^:O,_'5C)Y?FA,D=1ZCO7-7CS(]_*ZGO<K,.QU 2,JJ,E@#D#I6_I<YD\
MQ%"[>OUZYP:\WM;Y[6<1N2 C;<]!Z?C77V^HA4CD3Y5ZY'I7FQG9GT%>GI9%
M;QI"S6%S@ R!3COZ\UX'=EIH)UR JL<MWSS7OOB.=Y[=B(SL9>>E>"W ,>J7
M4$JLG)X/-7/4WP=U%IF!I]SLRG0J,9_QJ35V'V<CC'UQC_(K(OI)--U"0\E=
MW&3Q[5;N+H3Q$GTST_SZ5--]#IJ1>YY/XI!BN'8G)W9Y.>>.*X36+C:P&?D
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MA5>,]LG_ !]Z^V_^">K%OA#KN<9&OS#C_KWMZ^#]2F"9P6R>?7M^G4U]U_\
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M[/,FWH?_ *U21Z>S,,*1D_>ZY_SBM>8Y^6Q7CA"-PPSC.,\DU>MX&EVEAC)
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M.79AC&/2KE)KH-7Z'E>M>#S97T%I;W >68G$7ICWK'F\'ZMYDB?:E**<N%Y
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M?+L+9<YVQ*,GZ"K5?HY^4'\K4W^ND_WC_.F4^;_72?[Q_G3*!!2AB/I249H
MWO"OBO5O!>O6NL:)?S:=J-L_F17$+;6!]/<'H0>#WK]!/V;_ -JK2?B:UOIN
MHO#I'BSA6LV8)!>D8^:!CT8_\\C_ ,!ST'YP!NPXJ2&9X9%DC=HW!RI4D$'U
MS7)B,+#$1M+?N>G@\?5PDO=^'L?N7X>\<#Y=SX(XP>#[@UZ)H7B1+QAEQCK]
M*_)/X-?MH:EH*V^D^-C<:E:H%2+6(?FNH@. )03^^4#N2''J>E?:O@/XS:?J
MVDV]_8:A;ZEI[\+=6\FZ//\ =/=6_P!E@#7RM?"U,.[M:=S[K#XJAC(7@]>Q
M]HV.H),HP1T[&KWG<\GGTKPCPO\ $I9]C&7*XXYYKT+3?%\-U(%+C/4\UA&I
MW.2KA^5G;*0>2<GIZYJ&ZC#1@C.>M9]OK$<R\'C'&35E;Z-AG((KI5FCEY7%
ME*ZC#+Z'^=9%Q"S$@_\ ?7%;5Q(K+E1[U1:,2;\9RO<Y_*N:4+O0[J<[(Y^[
MMQM;)XQZ=:P;BUC)(Z'O@XZ5U%]&8P0PQ["L.X7<IR=RYYKF<3MA45CEM2LV
M168>_P#GVK NX]ZOD$$<<>M=9J&88SD?*3U]JY>\P))$P&&/TK+5'7"5SA?$
M/R.X/W3P6(KSS6%5F+ D@<\+CW_SFO1_$ ^5B>!C&#G\Q7FVOR"WF8G"MG!'
M0&A^Z>C3DK'-W  7*YR>O'^>E9]TA520W'/N1_G%%YJ212, <'EB&]:Q;[Q
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M?VG/^B;#_P 'VF?_ "31_P .M?VG/^B;#_P?:9_\DU^_E% 'X!_\.M?VG/\
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MT74$R_\ "N?M]W)_8_[R']YY7D/MV8V_ZI/];U&>?K[]H+]N_2?V<_BCX?\
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MY1.3GY *Q_B]^S#\,?CSJ6GW_CGPK#KE]IZ&.WN/M,]NX0G=L8PNA=<Y(#9
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M9Y'\6?V4_A5\<-8MM5\:^#[;6=3MT$27BSS6TI0=%=H70N!DX#9QDXJS\/\
M]F;X9?"GQE/XJ\(^$;70=<GLAILD]G+*L9@&SY?*W^6"3&A+!=Q())))SZE[
MT8]ZI5)J/*I.PW)O1L\;^)'[(GPB^+7C!/%'BOP5::IKH"![P3SP&7;@+YJQ
M.JR8  ^<'@ =!BNAU;X">!=>^*VE?$B]T%9O&>E0"VL]3^U3KY48#C;Y0<1G
MB1^2I/S>PKT/BCO0JDTDN9Z;>0.3?7R^78\U^+/[.?PW^.BP?\)OX3L]<FMQ
MMBNF+PW"+G.T31,K[<\[=V/:J_PE_9G^&?P+N;BY\$>$+/1+N>/R9+P/)/<-
M&2"4\V5F<*2JDJ#@D#TKU*E H52:7*F[=A.3:M<\[^'7P'\"_"GQ)XEU[PMH
M7]EZOXDG^TZK<?:IY?M$F]WSMD=E3YI'.$ '/TI?!_P'\"^!/B!XA\<:%H8L
M?$_B#/\ :=^+J=_M&6#G]V[E%RP!^517H6VDVG-',[WOY?(3;=_/<\;\5?LA
M_"'QI\0H_'&L>"K2Z\3I,EQ]N2>>$/*A!5WC218W;('+*<XYS7LO%%*:ERDT
MDWHMAMWU9XY\3?V1_A+\8O%D?B3Q?X+M=6UM553>+//;M*%P%\P12*),  ?.
M#P .E;OB'X > O%7Q&\/^.]4T!;GQ5H$2P:;?BZGC^SHI8JOEJXC;!=OO*>M
M>B\9H^E5[2:25WIMY#<F]WY?+L<[XX\!Z!\2O#-WX>\3Z5;:WHMX LUG=IN5
ML'(([@@@$,""",@UXU#_ ,$__@#;Z+<Z4GPZM/LUQ*LSLU]=M/E<X"S&7S%7
MGE58*>,@X%?1'UI*(U)P^%M>@N:25DSB_B#\(_"'Q4\)IX:\6:!::YHJ[2EM
M=*28BHVAD<$,C $C<I!P3SS7,?"7]E?X5_ O5+C4O!'A"WT?49XC"]XUQ/<S
M>62"55YG<J#@9 (S@5ZYZTG%'/*S2>CW\_4+NR78\\^$OP'\#? NPU2T\#Z&
M-$M]3N!=7:+=3S^9(!@']Z[;>.PP/:D^&OP'\"_"'6O$FJ>$="&DW_B*<7.J
M3"ZGF^T2!G8'$CL$YE<X4 ?-["O1,C=BCO1SR;;;>N@.[OYGA/CC]B/X(?$C
MQ%/KFN^ +&;4YG,DTUG<7%F)7)R6=8)$5F)Y)()/>O0-"^#?@CPQX#G\$Z9X
M6TRS\*7"/'/I*VX,,P< ,9 <[R0!EFR>!SQ7;<8HYH<Y-<K>@.4G9MZH^>;/
M]@#X V-GJ5M%\.;,QZ@@28R7MW(Z@,&_=NTI:(Y YC*G&1T)%>W^%_#.F^"_
M#NEZ!HUM]BTG3+6.SM+?>S^5#&H1%W,2QPH R23ZFM<T"G*I.:M)MKU!MO<=
M1114""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "BBB@ HHH
,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pgen-20201231_g17.jpg
<TEXT>
begin 644 pgen-20201231_g17.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %_ ^@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ]+_ &8_^3D_A/\ ]C;I/_I9%11^S'_R<G\)_P#L;=)_]+(J
M*\;'_%$PJ;H\^U7_ )"EY_UV?_T(U5JUJO\ R%+S_KL__H1JK7L+8W"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJ_#C5IKG7OAWH?Q/U3Q%_:NI:7\0[.Z_L%+2.RCM0;)E$I5V6*+*N^XLTY
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ME[55;3O_ $@C>^I\WT445Z)H%%%% !1110 4444 ';-%.4?NW/N*;0 4444
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M$=6^)?C^#59?'7@#PEH6F:LOAW2?$$,Z&^OKBX@%C+>6ZN0J-$G*G<!(I)8
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M!<JN$0+U)/JP[?6N>EB*DYJ_W"4FV?/]%%%>J:A1110 4444 %%%% !1110
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MQR>8BBTL8$ALY'$<BJS[EPB^6H4+'\45TTY.:NU8I.X444JUH,%%/ H44M-
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M!G!D?U/95ZL>.!DC])->\6>&/V6_"#_!GX(JBZZHVZYXH(5Y4G(PQ+8PT_\
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M^K?N!T/PE^UI^Q?XN_9;U[SK@-KG@R[DVZ?X@MX\(V>1',!GRY,=LX;&5)Y
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MPE\'^+/AKX#N/$?A#0M<N[CXHW]A/-J>F0W#RVJ^&KF98&9U):,2JL@0_*'
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MZ %6_P" 5^3U?N^2T?JV IX;FYN1<MWY;?AH>%4J^WFZEK7"BBBO<,PHHHH
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MAW6+[2M2MI++4;&=[:YMYEP\4B,596'8@@BJ=?>'C!1110 4444 >E_LQ_\
M)R?PG_[&W2?_ $LBHH_9C_Y.3^$__8VZ3_Z6145XV/\ BB85-T>?:K_R%+S_
M *[/_P"A&JM6M5_Y"EY_UV?_ -"-5:]A;&X4444P"I;>W:=@ ,TR-#(X KU'
MX8_#^7Q!>Q 1[@3Z5E4J*G'F8%#P;\.+O7)D"Q,03Z5]'>#_ ( V>DZ4VIZU
M/;Z;81#,EU>2+%&GU9B!6AXD\2>%_P!G'P[;27ULFJ^)KJ/?9Z0C;3C_ )Z2
MG^!,_BW0=R/G^^N/'W[1FLK>ZK=N]BKXA3:4M(!_=AB'4^_7U-?&XO,IU&U3
M=D6HZ79]$>$?$7PI\3>,K;PCHVH/J6H7"2%+J.W*VI**6*AVP6) .,#''6L_
MXT?!FWTVSDG@C!7&00*=\(_V7K;PK?6?B"^9EFLV$JWMW+Y21GIG&0!UQSGK
M7JOQOU2UT_PX;9W5I%3KGKQ7G87%5765G=$NU]#\Y_$6G&QO'3&,&L9>2!75
M>.+A)]2E*=,URR_>%?HE-MQ5Q'??#OPL=<U"*/;G)K[9^&_[-7]H:&E[]E$D
M>=IP1NS@'I^-?*?P/U"WL]4A:9E501DFOT/\'^-+^U\-6O\ 8\=K>1!=_DR@
MC=GT85^><5XO-</0OE48RJ76DKI6Z]M>VIO1]DY6K-I>1Y1XA_9NLKA&1(@D
MH'*,N#^5>#_$+]G6YTT2/' V![5][Z7\0M)\0R+8:W8OH]ZQVHMT08W/^Q*.
MA]CBH_%7@](;=W>,WECCYB1F2(>I]1[U\!E7'=2GB8X'-J3H57M?6,O26WZ=
M+MG54P;Y?:49<T?Q7R/R-\2^"[G1YG5XV7!]*Y62,QL017Z%_&+X'VM]927=
MFBNC#<"M?$_CKPG)H=](C+C!K]PP>.CB8Z'G'$T4,-IQ17K %%%% !1110 4
M"BE6@!ZTM I5JD,6E%%.%6,44]12**=6@PIRK2*M.JR@I<4 4\+56&-VTNWV
MIV*6J M!?^*;U4_]-;?_ -J5SM=*H_XI?5S_ --;;_VI7-5QU/B9G+<****S
M)/UA_9[^(7_"R/@[X5\0M)YE]%"+.]/?SH_D8GZX5O\ @=?5/P_U?<D?S>E?
ME_\ \$\?B (]1\2^![F7$=W$-2M%/]],)*!]5*'_ ( :_0KX>ZL8V6-CRIP:
M^4Q-/V=1Q.>2LST?XQ^$[3Q=X5O+2[B$UI>6[V\Z$9RCJ58?D37X*:_\+=?T
MSXH:CX$L=,N]5UVWOY+&&SM(6DFG8,0I55!)R,'Z&OZ%%C&L:&\9Y^6N*^"_
MPV\,>'_%OBW7[?0;.'Q3>3QI=ZOY>9Y8A& B;C]T +R%QG )R16F%Q'L+Z7N
M$9<I^>/P,_X)%^,?%MO;ZG\2=<B\&V<@#_V78JMU?$$9P[9\N,_BY'<"OLGP
M+_P3/^ ?@J&/SO"DWB6Z7&;G7+V24DCU1"L?_CM?4U%.>*JU.MO0ER;/(8OV
M0?@C#'L7X4^$=O\ M:1"Q_,KFN9\5?L _ 'Q=;M'<?#?3;!R,"72GELV7W'E
M,HS]0:^A**Q52:U4F3=GYM?&'_@CKI-U!/>?#+QA<6%S@LFE^(5$L+''W1/&
MH9?Q1OK7YZ?&/X"^._@'X@_LCQOX>NM'F8GR+AAOMKD#^**5<JX]@<CN!7]&
M%<W\0OASX:^*WA6\\-^+-&M=<T:Z&)+6Z3(![,IZJP[,I!'8UVTL;.&D]4:*
MHUN?S9T5]8?MO_L*ZO\ LPZQ_;VAM<:U\.KZ;9;WKC=-82'I!/@8Y_ADX#=#
M@]?D^O<A.-2/-'8W3OJ@HHHJQA1110![!^SCXF%KKU[X>G?]QJD>^$$\"= 2
M!_P)=P^H%?:?A'4O[>\(QI(=US9G[/)GJ<#Y3^(Q^5?FMI6I7&C:G:7]J_EW
M-K*LT;>C*01_*ONKX8^-H+BXMK^UBDGL=:M0XAA&YEDZX_ [E->=B8:\QG)=
M2#XJ>'_M5FTRK\PX)]Q6?\-;YIM(WJ<7-FVXKW('4?E7HNM6$NKP2PO 4>3A
M(5^9B>P^OTK3^&_[-?B31)OML<$DFH7,@8VV/W<"^C'^)O7L*\R;Y48GK>F>
M']6^-'PIN/"SV7V"UO#%-;ZKJ&5\B5&#)+'&/F;N.< @GFN%\3?L7?#WP[XX
MTO4O&6G3>*XVDCBNF>>2VC8=,[8V![^OI7U5I>G1>%[.RN/$&H165W(B@6_+
M2R-CHD8RS'Z"K7B;P;K'Q3L190Z:V@V#$;]3U8#[05_Z9VZG(/O(R_2L%4E'
MX78F[(M$_8W^!.GV,/V+X6^%YH"@9)+BP2X8J1P=TFXG\33M6_8M^!>MV[PW
M/PK\-(K<%K6Q6W;\&CVD?@:])DO].^'_ (>TNVO+N1T#0V$!*%YKB5OE5551
MRQP2<#  8G !(Z"E[2IO=A=GQ!\3/^"2?PB\60S2>%;S5_!-\V2@AG-Y; ^\
M<IWX^D@KX%_:*_X)^?%3]GJ&YU6>P3Q3X6ARS:UHH9UA7UFB(WQ^YP5']ZOW
M9IK*LBE64,K#!4C((KIIXRK3W=T6IM'\R-%?K#^W#_P35T[Q=8ZCX[^$NG1Z
M=XBC#7%]X;ME"P7XZLUNO1)?]@?*W;#?>_*&>"2UFDAFC:*:-BCQNI#*P.""
M#T(->Y1K1K1O$WC)2&4445N4%%%% !0**5: '+78?"?XF:K\(?'NE^*-'<BX
MLY/WD.<+/$>'C;V(_(X/:N0%?3G[&?[$/B']J;7&U&[DFT+P%8R[+W5]GSSN
M,$P6X/#/CJQX3/.3A3%24(P;GL)VMJ?K!\%_B3H_QP^%]AJ>F3K<6MY )823
M\R-_$C#LP.01ZBN9U:SET#5BP!5=U=AI/P7\.? 'POI4?@72UTK1=,79>6T9
M+M*AZSNQ.6<'EB>H)] *N^-M'BU:S%Y!@B1=W'K7RDK7?+L<9=T.^B\5:%]B
MF8>:HS&WO7CV@_L3? GQE?:O#K_P\LI-=6=IYYX[JYA,RNQ/F )( #G(.!C@
M>M=!X6U>71]0\IB5VFNYU[4X])N--\46[JLL,@AGAW &>-R R*.[="!Z@4XS
ME#X78=VMCYY\<?\ !);X/>(;>0^'[W7_  E=')0P78NH1[%)06(^CBOCGXX?
M\$P?BM\*;>XU+P\L'Q"T2(%BVDH4O44=VMV)+?\ ;-F/M7[/]:6NRGCJU-[W
M]2U4DC^:2:&2WFDAEC:*:-BCQR*59&!P00>00>QIM?N!^UI^PCX-_:4T^XU6
MSCA\,^/40F#6K>/"7) X2Z0?ZQ3TW_?7L2!M/XT?$GX9^(_A%XTU+PIXKTV3
M2M:T]]LL+\JZG[LB-T=&'(8<$5]%AL5#$+31]CJA-2.7VTNWVIV*6N\V+5FO
M_$JUK_KV7_T='7.UTUF/^)1KA_Z=5_\ 1T=<S7)4^(REN%%%%9$A1110 444
M4 ?0?[#'[/7_  T5\?=(TB^@,OAK2_\ B9ZP2/E:!&&(C_UT<JOKM+'M7VE\
M?O%$OQ\^,4D.DW:KX:\-EM.TV%1^ZD<'$TPQZLH4'^Z@]:S/V6=#'[,?["NJ
M^-V7[/XP^(4XBL7(Q(D+;HX,>RIYTP/^V*J_"GP+<Z?;PSZ5(L@ !-M*V#_P
M%C_(_G7PF>XN[]FM4CV\IP_M:OM&[6V/1?!=C>>$6ABO8#$&^X_56^AKTZQD
ML9R)85^RS'G?!\N?JO0U0T[4H)]/73]:LFBWC[LPP<^H/K]*R[W2[KP\QFMW
M:]T[J)%Y9!Z,/ZU^=RFXOF6J_%'Z53IQE'EDK2_!G<W4-OK%@UIJ<2W-N>1*
MG!0]F]5/O7(ZAI=YX1D$CN;K36/R72C[OH'';Z]#5C2?$2R!2K_K6_!K]O;S
M1PR,IBG4YC/0<XZ>A_I6O-3K*[=GW,5&KAW9*Z['/V?CRQ74[>R2=7NE!>10
M?NJ1P#_/_P#77(?&IK/3=:TC7M*F2'5+A72=5P=ZKC#,/QQ[X'I3?CQ8Z7:W
M.D7]D5AU&;>',)P6C4#!./0G /X=J\GDD>5]\CM(_3<[%C^9KX+.\VG1]I@9
MQ3DFFI)[;-/UMH>Y@<)"IR8J-UO==^GW&QK_ (QU;Q-!;07]P'@MR6CB1< ,
M>I/J:QJ**^!K5JF(FZE65WW9]!&$::Y8JR"BBBL2PHHHH T='\2:MX?68:9J
M-Q8B88<0MC/O['W%=Q\%OL%QJUU#=S1)=R,'4SN 9![$]3G)]>:\VI"H;J,U
MZN"S"I@ZT*DO>4=DWIKV['+6P\:L)1CHWU/HSX@>)M.CNM-T 7R1O/)EXD.0
M0!\H<C[H)Z#OBM33=+6V5-ZXST4#D_05XO\ "*QLM0\22P7+1I*T8,?FL!NY
M^8#/4]*]BO\ QAHWAZ\&CV$]O+JIC+D!@5B4==Q'?OMZU^JY=CECJ?UNM:*;
MLE?\/-]3Y/$47AK8:E=O=_YFO?7T&@JLLZ^?>N,0VR'D#^@]37+W$,FI71O]
M6G7CA5)PD8]%'^2:KPSW.H7#O;1M<3R'+W4PX/T'^14DJZ;IDWF:I>?:KH=(
M8_G8?@.!7J3J>T_PF=.E[+_%^/R,3Q1:7&KVYM](@$,)'S73I\Q_W0>GU->(
MS-J'P)\>:7XZM)9'O-.FW2QLQ)N86XDA/KN7/T.#VKZ)N/&$\T)ATS2UA4C
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M444 %%%% !3E[4T4]: '4X4VGUHA@*>*:M/6K10]:!13EK1%(6E%)3P*M#%
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M+#(NY'4Y!% B6OF/]NS]DVT_:4^&LEYI5O''X]T.)YM*N0 &N5'S-:.>ZO\
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MW;-_[,:^MR2K#VZ4#XG/*52*C*?<_+:BBBOTX^5"BBB@#TO]F/\ Y.3^$_\
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MOM&X$^HKRO1/ /B+PJT$D&KWL$*R"2:UMV*(^.HZ_KBNQA\37D>%?4+FW?\
MZ;J"/SQ7[7ERA1HJ%2C[-I+MJ?&8E5JD[PJ*2.A.FQ+UBF/TCJK<YA0^5IDT
MI_VV5!_6JZZ]K>T-%=03+V+0@_R(J&Z\8:[;1G?96<P^CK_4UZKE2\U\CC4*
MWD_G_P ,>7_$[4I5M91-I!08.3'*&_F!7/ZU<1P_\$T?BS+AD6;5"JAQ@Y-U
M:K_2K'Q5^(-R]K*)M+1>#DI-_BM8'QXU!="_X)?V[$?9W\1:VI",>6S=22#_
M ,=@!KZK(TI5ERN_R/C,]YDHIJVO>Y^8E%%%?IY\H%%%% 'I?[,?_)R?PG_[
M&W2?_2R*BC]F/_DY/X3_ /8VZ3_Z6145XV/^*)A4W1Y]JO\ R%+S_KL__H1J
MK5K5?^0I>?\ 79__ $(U5KV%L;A1113 ]"_9_P#",?C;XO>'-/N$\RRCN/M=
MR,<>5"ID8'V.W'XU^DOA6U;4+AIY!F21R[?4G-?#_P"Q7IHF\<>)=0/6ST9T
M7CO)-&G\BWYU^@'@&SW"+BOR3B>LZN8QH](I?>]?\CZK+H\F%<^[_(]%\.Z#
MF-#MKPK]N3XN:E\._".D> _"7F-XW\:2?9(/LYQ+#;%@C,OHTC,(P>PWGM7U
M9X=LT^S(,<XKX<LIE^*?_!2+Q=J=Y^^L/ ]I]DLT8<))&BQ*1[^9+,WU KEH
M8>$I+R.*M6DDSWK]E_\ 9^TK]GCP-!I=M'%<:]=JLFKZHJ_-/+C[BGM$G11]
M2>37TGH<A: <]:X?2KB.15Y!KM-%D"J #7M'E&LUN\E4M3C>W@;GM6W%(,!A
M6%X@OD6)RQP*8K(^8?VFO!FG^/\ PK=:7K-N+FUFZ?WHV[.A[,#T->#?L&?$
M[4_AO\2M3^ WBJZ,]G.9+KP[<2'A9 "[1+GHLB N%[.K#^*OI'XG7!U-F1?]
M6M?#_P"TQY_P[\7^ _B+IQ\C4=%U2/,B]2$82J#_ -\N/HU(I=C]*]:TO:K
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MH+E-2AC AD\YE"-$2>5<#&SOFK52I?;\!W9\"@T[-1TNZNZYJ:@/_%'ZV/\
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M4M?UZ_FU36-1G:XNKRX;+RR,<DGT]@.   .*]3"8=R:J2V-81ZLRJ***]PZ
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MQ=U:*%(P3]6EE_*M?PZJ_&+XX^$?#!T]O*N+]9[H;@0((OWLF?8A-O\ P*O
M?^"H'Q-7X@?M3ZKIUO-YMCX9M8='CP?E\Q09)?Q#R,I_W*_1<@HWES[V/S/.
M*G-6C"UK:GR11117WAX84444 >E_LQ_\G)_"?_L;=)_]+(J*/V8_^3D_A/\
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MEFW_ !*=;_Z]5_\ 1T=<W7)4^(REN%%%%9$A1110 4444 ?JC\.?$7_#2G[
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M^$__ &-ND_\ I9%17C8_XHF%3='GVJ_\A2\_Z[/_ .A&JM6M5_Y"EY_UV?\
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ME[S3LW_F1RO4_7CX@?L*_!OP;X@U2R;X+ZG=^$=/\+_VJ/$NF:[>2WUYJ:W
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MEGZR-S]WEOA:BBOT&E2C1BH0V/G0HHHK4 HHHH **** /2_V8_\ DY/X3_\
M8VZ3_P"ED5%'[,?_ "<G\)_^QMTG_P!+(J*\;'_%$PJ;H\^U7_D*7G_79_\
MT(U5JUJO_(4O/^NS_P#H1JK7L+8W"BBBF 4444 6H9.E:MG<;<<U@JVVKD,V
M*RG&Y2=CMM#URZTFZCNK*ZFLKE?NS6\C1N/Q!S7K6A_M$^-K)%2;5TU1!VU*
MVCG/_?1&[]:\"M;O;CFM>UO\8YKQ<5@J.(_BP4O57.RG6G3^%V/I.V_:5UZ4
M#S=,T5SZBWD7]!)5IOVB/$<@_<0Z39-_?AL59OS<M7SQ;:GTYK1AU7_:KPWD
M^$B[QIK[CM^MU9+63/6M;^)FO>)E"ZIK-W>Q]H7D(C'T087]*PY-8X^]Q7%#
M5C_>IDFK'^]6T<(HZ15D9^UON=/=:MUYK%O=4SGFL:?5,Y^;-9EUJ1.>:[:>
M',I5"W?7^<\US]]=[L\TRZOLYYK)N+G.>:]6G2L<TI#;J;-9TK[C3YI<U!7H
M1C8YV[A1115B"BBB@ HHHH **** "G TVB@"0&EJ,-3]U.X#MU.IE%5<8^EW
M4S=2YJKC';J7(IM%.X%E6_XE=X/]N/\ ]FK.J\I_XE]T/]J/_P!FJC63W$%%
M%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4X&FT4 2 TM1AJ=NIW ?
MNIU,HJKC'T9--W4N:JXQVZER*;13N!:MV_T._P#^N0_]#6LVKT)Q:WG_ %S'
M_H:U1K.6X@HHHJ1!1110 4444 %%%% !1110!V?PG^,7C#X(^+(/$?@S6[C1
M=3CP',1S'.F<^7*A^5U/HP]Q@\U^A'@O]K[X*?MA:;9Z%\9M,A\ >.D016_B
M:S?RK=V[8F.3&/\ IG-N3T;)K\Q**Y:^&IXA6FAJ\7S1=F?JO\1OV8?B3X#B
MBO- D7QWX2=1(M[I&#<B+J,P@G=D?Q1EAWP*X=?C"$C-DQ:VDMQL-O("C1XX
MVE3R/QKY$^!_[7GQ3_9[E2/PEXFF72E;<VC:@/M%DWK^[8_)GU0J?>OL#1?^
M"B'P8^.5O%9?''X8+I^H[=G]N:.IF"GINR"L\8]@7Z5\CC,A<DW3ZGL87-:V
M':YU=(]1M?BA;:;X2MH%E VQ9//?&36O_P )?%:>%[.W>0&7R]S\\[FRQ'ZU
MS>E_!;X+_&)8IOA9\;K5)/E9-(U65)9">R^6YCF SZAJ=XK_ &1?C1IBO_9W
M]B^(HL?*UK?&%V_X#*H _P"^J^9Q&5U8W]WR/?PV=T6TINVMW<]+L_$4$7@"
MQC9UR;<$\^N3_6J.O^((I=!LW9AYC0(3SWVBO+=6^'/QDTG2H;&7P#JTI6-8
MRUJT<ZC@#JCFJ&K>'?BI-"L*?#OQ,510HQ8.> ,5QU<#5M:W1'?1S6AS*7,M
MVSZ"\,:]:V_ANUC#+@VZ'KWP<URZ^+85AU:U:0;8Y Z#/3<#G]1^M>9>&?"?
MQBGL8K9?A[KL;(#&#<1+",9R.78>M;6E_LR?&S7;FZ:;2M-T2.<J/,O]20D
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MLT[@.I<FF;J7=3N,G5O]"G'^TG]:J58#?Z-*/=?ZU7J1!1110 4444 %%%%
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M 4444 %%%% !1110 4444 %%%% !DT;C110!(K?N7'N/ZU'2Y^4BDH ****
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M%+S_ *[/_P"A&JM6M5_Y"EY_UV?_ -"-5:]A;&X4444P"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /2_V8_\ DY/X3_\ 8VZ3_P"ED5%'[,?_ "<G\)_^QMTG_P!+(J*\;'_%
M$PJ;H\^U7_D*7G_79_\ T(U5JUJO_(4O/^NS_P#H1JK7L+8W"BBBF 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!Z7^S'_ ,G)_"?_ +&W2?\ TLBHH_9C_P"3D_A/_P!C;I/_
M *6145XV/^*)A4W1Y]JO_(4O/^NS_P#H1JK5K5?^0I>?]=G_ /0C56O86QN%
M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#TO]F/\ Y.3^$_\ V-ND_P#I9%11^S'_ ,G)
6_"?_ +&W2?\ TLBHKQL?\43"INC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pgen-20201231_g18.jpg
<TEXT>
begin 644 pgen-20201231_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /+?VK?VV/V4_V'O ]O\0_VK?CAHO@S3+VX,&FC49'DN=0F&,Q6MK"KSW3@
M$$I$CL 02*\WUG_@KU^PQX)\$2?$7XQ>./%?PXT?['+<V=_\4OAEKWAF'452
M-I EI+J=E!'=3.BDI!$S2OQA#D9_*7]BWQYJ/_!2#_@[;^)^M?M$,-5TWX"#
MQ-9_#O0+UO-M-.;1[^+2H9(XVRH<R32WF<9$Q#C!1<?MI^U3^S3\+/VQ?V=_
M%_[,OQIT5;[PWXST.?3M07RU,D!=?DN(BP(2:)]LL;X^5XU;M0!Z!17P;^TM
M_P %1_BGJG_!6SP3_P $@OV3O^$;TK7[[PU<:_\ $3Q]XHTB74H]&MUM);F"
MSM;..XM_,N'5(F:1Y-B)<*0CD'',_L9_\%D_B]^TU\'?VJOAIXE\,>$-%^.O
M[+5YK5GJTD.G74N@:\+%[U([N.V-RL\*/)831O%]H<Q[HW#MNV  _1BBOP[A
M_P"#@C_@K!XT_P""1-[_ ,%6/#GPP^!&C:3X5^(D>@ZUH<^F:M<3:S&\T$(:
M%?M@%JJ-/&"6DD:3+$"(1CSO3/VCO^"ZW[>?[.OCC]D+X[>-/A+\+K;X/_M1
M"SE3PA:O?76O:/97"Z<XN9+\O' TIBU&.41+;[4V-$S.2)0 ?KQ17YH?M[?\
M%;/VX_V;_P#@LW\+/^"8OP.\"?"S6M(^*WA6TU73]7\3Z=J,%UI;33:E;L))
M8;LI.L;:>9L+$A=7\KY3^]K8_P""?G_!5_\ :<\3?\%1?BU_P2-_;T\.^"IO
M''@G3!K/A'QC\/M.NK*RUJR:&VN1"]M<SSLDOV>\BD!$F (Y4;)4.P!^B]%?
MC3^TC_P7]_;W^&'[$^H_\%"!\&/#'P[MM(^-4GA"W^!OQ3\$7]IK&L:8B(SW
M<-^U]&995W@,8[01Q.)%/F>7E_9/^"T__!:K]HC_ ()__L0_!;]MO]F;P%X)
MU/3OBI)9+<:!XXTR\GEM5O--:_B=)K6[@ *JI1E*')(((Q@@'Z+?$WXD^!O@
MW\.-?^+GQ.\1P:/X;\+Z-<ZMK^K7(8QV=G;Q-+-,P4%B%1&; !)QP">*X[]D
M/]L/]G?]NWX&Z;^T;^RY\05\2^$M4GGM[?4/L,]JZS0N8Y8I(;A$DC96'1E&
M00PRI!/Q_P#$G]H[_@KU)X$_:2^)WQ]_9.^#VA_!?1O@5J7B3X<:;K\DFLW&
MJRQVK3R:1K%NEW$2TMJ)HYPL:Q1.R+&]RH<O\N_!C_@MSK7[*'_!O[\.?VPO
MAI^RS\.? 4GB7XP3>#8-'\%>%[K_ (1_PU;O<7<L^IM9"Z$MQ)Y=O*?+^T)Y
MDTJY8#((!^U]%?#W@/\ X*>ZY\/OV3OBW^W3\8?BAX ^)WP<\&^"M.USX?>.
M_ACILVGMXBED-TD^G7-O<7-P;2^2X6S@,98!3.C,$+-%'\T^(/\ @O%^V'^S
MU^PS\!_^"JG[2/A#P!J'PN^,OCZ31->\ ^&-!O(-4\+V,C7S6MS!?R7DB7LH
M@L)9)8WMXP[,J(8L%B ?KO17YJ_\%!?^"O'[8O[-/_!5?X(_L)?LY_#_ .&'
MBWPY\:M M+[3+WQ%%?VMS:/--<P[FNX;AXVB_<K-N%L6VDH%9L,=/_@E%_P5
M3_:Q_:-_X*'?M"?\$X_VR/#7@63Q#\(IFN]'\3> -/N[.VN[5;E(71X;F>9L
MXG@=3N!&75MV U 'Z+T5X+_P4T_;R\$_\$U?V*_&?[7OC;0GU<>';6*+1]"B
MG\IM4U&XE6&VM]^#L4R."[X)6-78!B,'XFUC_@M?^U5^R?X?_9$^//[9MCX
MUOX??M5Z=;SZG#X0\.WFFW/@62[ALKBT=9IKRX6^A$5\GFADCDS#(R$Y$8 /
MO7]IW]NW]EO]C_5?#_ACX[?$P6&N^+!='PQX:TW3+G4-2U-;:%IKB2*UM8Y)
M/+CC5F>5@(U Y8$@5M?LK?M7_L__ +;'P0TC]HS]F/XB0>*/!^MF9;#58;6:
MW)>*1HY(WBG1)8G5U(*NH/0]""?QJ_X*9Z9^TOJ7_!V#^SEH-EXR\"MJMS\.
MB_@DZAX9O9M/M-->3Q$IBOX!>AKJX(6<-)$\*$&+]W\C;_VNL=#^$O[-?PCN
MXO!G@C1_"WA/PQIMU?'2/#NE0V=K:PH'GE,<,*JBDG>QP!DDD\F@#$^/G[6W
M[.G[,4FCV'QL^*-EI.I^([DV_AKP];V\U]JVM3 9:.RT^U22ZNV ZB&)\9&<
M9J/XM?M<? 3X"?!:W^/WQN\83^%/#MY<P6MDNMZ/=0W]U=3OL@M(K'RC=2W,
MC?<MTB,K<_)P<?@W_P $Y/\ @IA^TCX<T/\ :)_X.&OC#^Q_#\7X7\<6WA*[
MU)_B$MA=^ M"+6\@L],M7LIA- /MUFLA$D1_=ACG?,]>I?\ !83]N+PG^W%^
MW3_P3%UGX/ZQ>M\.O'/Q'T/Q7!;7"B.5[B?7]-M/+G0%E$UOY=Q$<%@&DE +
M @T ?LE^S[^UW\ /VGM0\3>'_A#XUEN-;\%:DEAXP\,ZOI%UIFJZ)<.F^-;F
MRO(XIXED3YHY"FR102C, :WOC=\;OAW^SM\-=3^+WQ7O=2M/#VBVLESJU]IG
MAZ^U-K2WCC:22:2*RAED6)$1F:0KM4#DC(K\A_A)\4_$OP^_X/0?BEX"T*>5
M--\>?#2SL=<MX_\ 5R^1X;TV\BE<="RM:A0QY D8#AC7ZJ?MOJK_ +%OQ>1U
M!!^%_B $$<$?V=/0!S/[%7_!3+]AK_@HDOB(_L:_'ZQ\:MX4-L/$$,&E7MG)
M9BX\SR24NX(F96\F0;E! *$$@TG[:O\ P4T_88_X)V#P\/VROC_9>"F\5_:?
M[ BGTJ]O'NQ;^7YQ"6D$K(J^=&,L "6P"<''XL^!4'_!"7_@XR\(^(5_XE?P
M;_:;\/6@G/W+6T_M0QB3/\"?9M519.@\NVN,<!N9O^#K6(_%[]EK3_VP+X>9
M:^(/CJGA3P(S<A= T>PU2$S+_P!?.HR:C.'7B6W^QGD(IH _>WX+_&CP!^T#
M\.M-^+'PNNM3N=!UBVCN-+O-4\/7VF-=021I)',D5[#%(T;(ZLK[=K9X)P<=
M57YN?ML_\%8+K_@EG_P2Z_9XO_AWX)TWQ+\2?B5X7\.Z!X"T?6IG2QCE_LZV
M,UY=>6RN\,6^)2B,K,TR#<HW,.J\*?\ !3_XU_L^?\%=?#O_  2:_;)N_"GB
M.;XB^ (O$?P]^(/A/P_<:1_I/^F"6PN[6:ZN5(9K"Z\N5)%QB)&1F<N #[YH
MK\B? G_!93_@J=\<_P!J']K7]DKX3> O@=!=_L\6&KW>G>+]4TC5HUN8K*>9
M%1[1;V4RS3+&%&)(TC.YV,F%B:WX4_X+*?M??M>?\&Z'Q"_X*%_#)O"_@7XH
M^#QJ.F:]?6NF33VH-N8MUQ8Q22DPS-%<PE3(TJ(X<X; 4 'Z5_';]J3X$?LU
M_!?6/VA_C!XZ^P^#/#TDB:YKNFZ9=:G'8F.9H)3(EE%*ZB.5621BN(V4ABI!
MJQ^S?^TA\%?VNO@KH?[1/[.WCB/Q)X,\21S/HFMQ64]NMRL4\EO(1'<1QR+B
M6*1?F49VY&003^07[.]Q^TAK'_!I=XZ\4_%?QWX7U;PSJ7P5UZ?P[%9Z->)K
M*3MJEZUQ)?W<UW)'=,[EF!2&(C/S%CS7BW[,O_!5[]NO_@DU_P $3_V3OCWX
M<\ ?#/5?A)J_BK5M U#0;]+Z;7M2B.J:G<RW*W"21P6G^KGC2/9,08TD9F$A
MBC /Z'J\M_:L_;7_ &5/V'_ T'Q%_:L^-^B^#-,O+@P:<-1D>2YU"88S%;6T
M*O/=.,@E(D=@",BO3[>>&Z@2ZMY \<B!HW4\,I&017X%_L4?$2]_X*5?\':G
MQ)\1_M!9U/2_@1%XEM?AUX>U(;[;3CI%]%I<+QQ-PLADFFO,XR)B&&"BX /U
M>UK_ (*\_L,>"?!$GQ%^,/CCQ7\.-&%G+<V>H?%+X8Z]X9@U%4C:0):2ZG90
M1W4SHI*01,TS\80Y&?IFO/\ ]JC]FGX5_MB_L[^+_P!F7XTZ(M]X;\9:)/IV
MH)L4R0;U^2XB+ A)HGVRQOCY7C5NU?&O[9__  59_:;_ &8/^"TOP*_X)WZ!
MX2\":GX!^,.GVUU=:G>:5>KK&F[IKJ&5$E6[\F3YK975C",!RI!V[F /T*HK
M\\_^"=__  57_:?_ &J_^"I7[1__  3\^*OACP%;:3\&X[D>'O$/A_1;V"XO
M'6]2"-KB.:]E4C8X+*A3+#@@' ^=_@=_P6V_X*O_ +3WA3]LFS^'O@7X#Z1>
M?LK1W=S)X@N]'U<IJ45HVK;X%M#>OF6=-,9DE,JI"5*LDOFAH@#]E**_$SQ[
M_P '!G_!32\_X)%>#_\ @JYX"^$?P:T;2+7Q=%X=\7>'M5@U*]GURZ$\D,EQ
M:;)XUL;?*J!'(T\F2YWA442>Z?\ !83_ (+?_M$?L*_LK_L\?M8_LX?#_P #
M:GI?QLM[26[T7QAI]Y<RV2W-C#>1M%/;7<*G"RE""AR0&!'2@#]/Z\-^$?\
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M*B\$DDG .#CV^O-OC^_P1^#UE?\ [;OQ8LO(?X5> ]>GGUF)-TMMI#I!=WR
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MZP_X+):1X%^'D/CJ.Z9M4\,7.CW\NDSP?\)5)H2I$%O5FA<(8IB[22 LCKM
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM0N9?M"-]K$$-K''+'EI)A(S;PL154>3YH_:P_X(^?\ !4;XO?\ ! _]FO\
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MU;PC'\1_ VIZ!?6^H-;2W>F"\M9;<N?LT\L+.GF;P%E93@#/6OQSG_X);_\
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MT%XZO?AEIG@1-2TWP)JGB^]N]+M+F?1='NW>*WFE9(_WUS.RJH 02%5"J
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MQ?XZ\9VOA6P\10*#-H\,MM=74]Q#N! E,=J8E;&4,V]<,@-?._[0?[2/Q?\
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M /SS_P""@W_!".T_:8^'7[,>E_LR?'E? 'B3]E.2QC^'^H:_HG]J6UY:VRV
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M^_PAEA_L"9YKQI'A0:RWG*8[Z=0C,I5EC;<0K(_Z>44 ?FG>_P#!OSXWO/\
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M(-DDL;H2-T<S@,A(=?%=#_X(^^//C!^V)\%OVO?VYOC;X?\ %ES\ /"D&F^
M_#OA+PW/8V][J<9!&L7KW%S,WF;ECD6WC 59(D8R. 5;[PHH ^%(_P#@CO\
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ME6(16(48(.37[35^"7_!.S_E<3_:!_[!WB'_ - L* /J3X0?\%A_VF_V2O\
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M,X*>6)"& /M/PM^U[^RKXX^*TWP+\&?M'>"-5\96\MQ%+X8T_P 3VLU]YMN
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M.=[%D_:S7-<T7PSHMYXD\2:O;:?IVGVLES?W][.L4-M#&I9Y9'8A415!8L2
M "37Y3?#/]J__@G!^UG_ ,%#$_X*H?'W]L;X6R6_@72V\)_LV_"JU\<Z?=:[
M/YLKI-K<VFQS-<"]O)9C%;6I0/'#Y;RHDIQ& >J_&;_@H3\7/CO_ ,%O--_X
M)%_ _P"*E_X!T#PI\/+CQ)\1?%/A^PL9]6N[][:.:UL8&OK>XA@A2.YMIG;R
MB[ERF54'?A_\$F/^"LO[5_[??[#7Q2TW1/!OASQ+^T'\*/%Q\)B6Z/V#2=5>
M>7RK/6;M(N8(4 N);B*$986<GD@-(D:^!_ CX:>*?AK_ ,'F7Q1U+Q1#(EMX
MN^%#:SH%Q/Q]JM6TW38"4SU"36UQ%Q_SQ/I5#_@T7\(7_@2X_;*_:'\7WD.G
M>$[_ .(]I8IJ]]*(K:)M-.JW-V[2,0JJD5_ S,2 H.2: $L?V]?^"Y?_  3=
M_P""PGP<_9'_ ."@?QQ\(_%_P-\=M:L[#31X8\-6MG%8+=70M&D@:*V@GB>U
ME>-W64RH\)SG>Q9/JCXS?\%"?BY\=_\ @MYIO_!(OX'_ !4O_ .@>%/AY<>)
M/B+XI\/V%C/JUW?O;1S6MC U];W$,$*1W-M,[>47<N4RJ@[_ "KX9_M7_P#!
M.#]K/_@H8G_!5#X^_MC?"V2W\"Z6WA/]FWX56OCG3[K79_-E=)M;FTV.9K@7
MMY+,8K:U*!XX?+>5$E.(_//@1\-/%/PU_P"#S+XHZEXHAD2V\7?"AM9T"XGX
M^U6K:;IL!*9ZA)K:XBX_YXGTH ^L_P#@@7_P5%^('_!2'X!>-O#WQX>PF^)'
MPC\9R^'/$^IZ9:+;PZS!\_V74/)7Y8'D\J9'1?DW0EE"A@B_>=?BI_P9]_#3
MQ3I7B+]K[XQW=I(-$\0?%&PTC3;@J=DES8OJDUP >APFHVV?]X5^U= !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $=Y:Q7]G+8SO(
MJ31LCM#,T;@$8)5T(93Z,I!'4$&OE/2_^"(W_!.#0/V@M8_:N\-?"GQEI/Q)
MU^:YEUCQMH_QK\6VFHW1N/\ 7!IH=45MK8 VC"@*H &T8^L** /)_P!FC]AK
M]D[]CZ;6=1_9W^"NF:!JGB2X,_B3Q%+-/?:OK$A8L6N]0NY);JZ.XEOWLK?,
MQ/4DGR_]K7_@B_\ \$]_VU/CWI7[47QG^$>HP?$'2DBC7Q9X3\57^BWMU'$N
MV-)I+*:,N53Y!)Q($ 4.%  ^J** /#_CU_P3?_8I_:7_ &6[3]C+XP_ 72M2
M^'>FB)M'T2*26!]-FC#;+B">-UFCG^>3=*'WOYDF\N)'#4OV-?\ @F3^QK^P
M?X$O_A]\ /A?*MKJU@+#5+KQ+J]SJ]Q<V0W8LR]X\FRV 9O]'C"Q9))4DDGW
MVB@#Y!_9Q_X(3_\ !,[]D_XU3_'+X'? V^TJ^DU1-3MM#E\6ZC/HUI>HVZ.Y
MCL))V@,D;?-$75O)8 Q;"JD=Z_\ P2X_8A?]LR3_ (*#'X6:N/C!*AC?QBOQ
M UP-Y1@^SF$6PO?LPB\KY!$(M@'10>:^@:* /EOX9?\ !&'_ ()S?!O3/BCI
M'PT^"NNZ5!\:=/ELOBD(OBCXD=O$,,CRO)YSOJ#,&8SS@R(5<K/*N[;(P-OP
MS_P1\_X)Z^"_V/=:_8&\*_ ZZM?A'XBUNTU76/!L_C'5KN&>XM[VWO5Q)<W4
MDL2--:Q%TC=5< @CYC7TS10!\S>&/^"1/[#7ACQ'X*U1?AWJ^I:1\--6EU3X
M;^#-<\5W][H7A>]D<N9[.PFE:)&1B3$&#+!G$(C &-']O3_@E9^Q#_P4HM-!
M/[5_PD;5M3\+2L_AWQ#I6JW&GZC8!F5F1)[=U9D)4'8^Y0PW !N:^B** / M
M1_X)B_L6:W^R7J'[$.O?"[4;SX=:W<K<^(M-D\9:LEYK=PK1MYU[?QW2W=TY
M,40/F2L"L4:8V(BCO?V8?V7O@E^QO\&-*_9[_9V\+WFB>#]#\P:/H]WX@OM2
M%FKL79(Y;Z::54W$D)OVJ2< 9->@44 <+^TG^S9\'?VNO@QK7[/?Q^\.WNK^
M$/$4*PZWI5CX@OM,-Y$KA_*>:QFAF\LE1N0/M<95@02*^6/A7_P;?_\ !%[X
M*?$[PY\9/AI^Q@FG^(_">NVFLZ!?R?$#Q#<+;7MM,DT$IBGU!XI-LB*VQU96
MQA@02*^X:* /(OVA/V(/@#^TGX_\,_&'QKI.K:7XW\'0W-OX9\<>$M>N=*U:
MQMKE#'/;"XMG5GA=6;,;[E!.Y0K?-6.W_!-7]BI?V.)?V K#X,?V=\)KF#R;
M_P +Z+XAU'3VOE,HED-Q=VMQ'<SM(XS*SRL9<D/N!(KW6B@#X>^%?_!M_P#\
M$7O@I\3O#GQD^&G[&":?XC\)Z[::SH%_)\0/$-PMM>VTR302F*?4'BDVR(K;
M'5E;&&!!(KZ$_:$_8@^ /[2?C_PS\8?&NDZMI?C?P=#<V_AGQQX2UZYTK5K&
MVN4,<]L+BV=6>%U9LQON4$[E"M\U>NT4 <+^S=^S/\#/V0_@_I7P&_9S^'5E
MX7\*Z,K_ &/3+(NY9W8M)-++(S23RNQ+/+(S.Q.237=444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_P I!/'_ /V(
MFE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]77PQ=O#>G+$LVH7[3W,L6EWDWG$>:R63VMS(7.Z7RVR2[\\W^V?_P %I_\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M??@[^SK?V7BOPO=27.@ZCJ?Q%\0ZI':3/#)"9!;WU_- S".5PK,A*DAEPP!
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%%
M&/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_
MP@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__
M  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'
M_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I
M'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-
M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O,_VH/VH/!G[,G@R#5M6LI]8\0:Q/]C\*>%-.&Z\UB\; 6*-0"0H++N?!
M"@C@L55C]J#]J#P9^S)X,@U;5K*?6/$&L3_8_"GA33ANO-8O&P%BC4 D*"R[
MGP0H(X+%5;C/V7_V7_&=MXSG_:I_:IO8-8^)^L0;+2TC.ZS\*V;9Q96@R0&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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MX4N+OP?KGQ5TW5OBEJ091;VVB:1NU1;:3)W-]JOK6PMMJ@Y227. #79_M?\
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M=*\+\ _\I!/'_P#V(FE?^C&KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3>'_  7X=OO%WBO5X+#3-,M9+F_O;E]L<$2*69V/8  FOBKX2?L=?"W_ (*
M_&7Q5^VQ\=/AC/!X5\2B*V\&Z#+?W5M-J-O!&D*ZI<&.160ND2JD:%5VC)#<
M._CYQ0GC*<*%/XF[_))Z_BC]"\/LTP_#V,Q&9XI/V4:?)I:[E*46HJ[5W:+>
M^B5W8_*JOH[_ ())_P#*0;X?_P#<5_\ 33>5^CG_  Z3_P""?/\ T;__ .77
MJW_R572?"3_@G=^QU\"OB%I_Q4^%?P?_ +*U[2_-^P7_ /PD&H3^5YL3PO\
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M .Q$TK_T8U>Z5X7X!_Y2">/_ /L1-*_]&-7NE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>*_\%$?BW\0O
M@5^QUXP^*GPK\0?V5KVE_P!G_8+_ .R13^5YNH6T+_),CHV8Y'7E3C.1@@&L
MZM2-&E*I+9)O[CKP&#JYACJ6%IM*5248J^UY-)7M=VN]=&>U45^*O_#VS_@H
M-_T<!_Y:FD__ "+1_P /;/\ @H-_T<!_Y:FD_P#R+7B_ZQ8+^67W+_,_2?\
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MX9_$.XAU#^S_ /BI+KP=-;Z7;!-0MI<RSRE2@;9L7Y3EW4=\U]P^%_AW\/\
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M?P7DSO*99(A*@E9C(AN 5VE%V_47B#_@J%_P3.\7>(/B!^SQXL_:1\)7FO\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
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MNP^?*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M **** /"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*03Q__P!B)I7_ *,:O=*
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M ,I!/'__ &(FE?\ HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRC(HU)8R2A*WNOI?J@\4JN%H\/TI8BE[1>UC9<SCKR3U=E=K?16]1G_"X/\
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MIC*491I4TTZD$TU!)IINZ:>Z#_@DG_RD&^'_ /W%?_33>5^U5?F!_P $[O\
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M\IPV7N51-SJR^*<M92\KZ))=(Q2BNB"BBBO,/4"BBB@ HHHH **** "BBB@
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MOQOT[]MGQQ9_$?QMHVHZPO@O3S<WFGZ:T,3QF4^6 A/! W9/?(KZ.^Q>-_\
MH-V7_@,?\:\C\ _\I!/'_P#V(FE?^C&KW2@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>
M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>
M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>
M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>
M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>
M-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBB@#@_BW\3K3X%?#W4/BI\5/'=EI6@Z7Y7V^_P#[+FG\KS94
MA3Y(5=VS)(B\*<9R< $UXK_P]?\ V+_^CF[+_P (O5__ )%K8_X*V?\ */GX
M@?\ <*_].UG7XJUX&:YKB,#B%3II--7UOW?FNQ^L<"<"91Q/E$\5BIU(RC4<
M?=<4K*,7UC)WO)]3]DO^'K_[%_\ T<W9?^$7J_\ \BU[5\)/B=:?'7X>Z?\
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M[+_P&/\ C1]B\;_]!NR_\!C_ (UL45P'H&/]B\;_ /0;LO\ P&/^-'V+QO\
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M^'NG_"OX5^'_ .RM!TOS?L%A]KEG\KS97F?YYG=VS)([<L<9P,  5IE658C
MXAU*C335M+]UY+L<O'?'>4<3Y1#"X6%2,HU%+WE%*RC)=)2=[R70Z.BBBO?/
MR<*\5^+?_!.[]CKXZ_$+4/BI\5/@_P#VKKVJ>5]OO_\ A(-0@\WRHDA3Y(;A
M$7$<:+PHSC)R237M5%9U*5*M'EJ137FKG7@\?CLOJNIA:LJ<FK7C)Q=M[733
MM=+3R/G'_ATG_P $^?\ HW__ ,NO5O\ Y*KI/A)_P3N_8Z^!7Q"T_P"*GPK^
M#_\ 96O:7YOV"_\ ^$@U"?RO-B>%_DFN'1LQR.O*G&<C! ->U45E'!X2,E*-
M.*:\D=U7B+B"O2E3J8RK*,DTTZDVFGHTTW9IK=!11172>,%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 45\,?M9?\%Y?V9OV>?&UY\-_AOX3U#XAZKILS0ZC<Z9?1VNGQ2J<-&MPRN9
M6!X)1"GHQ.0)OV1_^"[?[,W[1_C>S^&?Q \+:A\/M:U.=8=,EU2]CN=/N)6.
M%B-PJH8W8X WHJDG&[) /U#X+XI67_7?JDO9VO?2]N_+?FMUVV/E5QOPH\P^
MI?6X^TO:VMK]N:W+?IOOH?<-%%%?+GU04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17F7[57[7?P-_
M8U^&[?$WXX^*#9VTDABT[3[2/S;S49@,^5!%D;CCDDD*H(+,HKX93_@Y3^%Q
M\3?9'_99U\:-YF/MX\1P&ZV>OD>5LS[>;^-?193PGQ%GE!U\%AW."ZZ)?)R:
MO\KGSF;\7<-Y%B%0QV)C";Z:M_-13M\['Z9T5YM^RY^UE\$/VQ/AK'\4?@=X
MI^WV0E\F_LKB/RKO3Y\9,,\63L;'(()5ARK,.:])KP\3AL1@Z\J->+C.+LTU
M9I^:/<PV)P^,H1KT)J4)*Z:=TUY,****Q-PHHHH **** "BBOG/]N#]JGQOX
M(U/2/V5?V7[6'5/C%X\C9=(C?#0>';'D2ZM=\$)&@#; 1\SCHVW8W9@,#7S'
M%*A2W>K;T44M7*3Z)+5OL<688_#Y;A77K;+1):N3>BC%=92>B7<Y7]KCXP?$
M/]J#XM3?\$\_V5_$,MA,UNLGQA\>V?*^&M,?K91,.#>SKE0O55)_VVC^D/@W
M\'OA[\ OAGH_PA^%?AZ+2]"T.T6WL;6/DX'+.[=7D9B69SRS,2>M<K^R/^RM
MX(_9'^$L/P[\+W4VI:E=W#7_ (I\2WV6N]<U*3F:ZF8DDDG@ D[5 &2<D^H5
MW9ICJ$J<<%@_X$'>^SJ2V<Y+\(K[,=-W)O@RK 8B-26.QO\ 'FK6W5..ZIQ_
M.4OM2UV44BBBBO%/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\'>;%KL7[4.G^$_.M_OOI>M0FTO[? ^\)(U3Y>A*+Z CZF_X*1?%WQ9\ ?\
M@GS\;_C9X"NY+?7?"OPHU_4]$NHL[K>\AT^9X9>/[D@5O^ ]J $B_P""AW[(
ML_C@^!X?BA.P'BS_ (18^)!X<U#^P?[<W;/[,_M?R/L/VGS/W/E^=GSOW/\
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M;8_:$\0C/P[_ ."=WQ'N=W^K_P"$EO+31\_7S6;;57]K[P'\1M#\4:1^V/\
M CP/>#QGX,@:/6M-3&WQ%HF=T]FX7EG49>,X)!!P"0F/7?A'\?- ^-_PYTKX
MI?#S1KJ]TG5[82V\JNF4.</&X!^5T8%6'8J:^TQ&%Q$Z:KJI92W48I<K[:\V
MG5?\ _!Y8[)8+GI8*Z_OU).W_@'LSRS_ (6O_P %-O%'_("_9.\!>%MWW?\
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M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%
M[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]
M"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H
M7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
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MFQ16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM8FYL45C_P#"2ZO_ -"A>_\
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M_P#?2UB;FQ16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\
MT*%[_P!]+1_PDNK_ /0H7O\ WTM &3\>OC+X4_9Y^#/B7XV^-BYTSPSI,M]<
M11$;YBH^2),\;G<JBYXRPS7\^G[67_!0#]IG]L+QM>>)/B1\1-0MM*DF8Z=X
M5TR]DBT^PBS\J+$I =@.LCY=NYQ@#]E_^"LNGZ[\0/\ @GA\3_#D&DR6#+I%
MO>FYNKE(TVVMY!=,F21RRPE .K%@!R:_G]K]]\'LJRZK@:^.G!2K*?*FU?EC
MRIZ=FVW=^1_/GC-FV94L=0P$)N-%PYFD[<TG)K7NDDK+S/<?V1O^"A/[3'['
M?C>R\0_#_P"(&H7NBQSJ=3\)ZG?22V%]%GYD,;$B)R,XD0!E/J,J?Z"O@E\7
M/"OQZ^$7ASXS>"9';2_$ND07]HLOWXQ(H)C?'1T;*-[J:_F$K]F/V+?A;_P5
MS^"/[+7@KPI\,=7^%QTJ/1Q=6.@^.-%OUN;)+AWN/)EDMF!+ RG(P"OW>U=/
MBKD&5UJ-#%1E"E6<FFY>[SJU];)W:=M7T>^QS>$O$&:T:]?"RC4JT5%-*/O<
MDKVTNU9-7NEU6VY^AE%?),/QI_X+!>'1G7_V1?A=XDQU_P"$=\87%EN^GVH-
MC\:G_P"&X/V\= _Y'S_@E+XHC5>&E\._$+3]2W>X5$4_@:_%_P#5W&R_AU*4
MO2M23^Z4T_P/VW_6/!1_B4ZL?6C5:^^,&OQ/J^J?B'Q%X?\ ".B77B;Q7KMG
MIFFV,)FO=0U"Y2&"WC'5W=R%11ZD@5\M/_P5,U301CXA?\$]_P!H71MH_>7*
M^ OM-LO_ &UCDY_*OSK_ ."QG_!1_6_VL/&VG?"#P#;^(- \%Z':QSZCHNM6
M3V=S>:B_S;YXFYVQH4"*>,LS<[ACV<@X$SC.<SCAZD>2&\IZ222[6=FWLM3Q
M.(>/LER7*YXFG+VE3:,-8MM][I-);MV/T[3_ (*T?\$Z'\3?\(D/VJ= ^U>9
ML\TV]T+7/_7R8O)Q_M;\>]>_Z%KVA^*-&MO$7AG6K34=/O85EL[ZPN5FAGC(
MR'1T)5E/8@D5_+-7Z)?\$!OVP_'_ (-^-=S^R=JUW=:IX<\26%S>:'IS2Y^P
M7\*F60Q9^ZDD2REU'!9%8<[L_:<5>%6&RG)YXW 5I2=-<THSMJENTTE:RUL[
MW74^)X3\6<5F^<T\#F%&,54?+&4+Z2>R:;=[O2ZM9]#]DJ*Q_P#A)=7_ .A0
MO?\ OI:/^$EU?_H4+W_OI:_%#]P-BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W
M_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?
M^^EK#^)'QN\,_"#P1J/Q(^)L7]B:'I-N9M0U*_N$2.)>@]RQ) 51EF)  )(%
M5"$ZLU""NWHDM6V^B(J5(4H.<VDEJV]$EW;.MU/4]-T73;C6=9U""TL[2!YK
MJZNI5CCAC4%F=V8@*H ))/  S7QMXI^+7QD_X*=>(KWX3_LO:]J/A#X)V5R]
MIXQ^*T*&*\\2%3B2QTD,,K$>5>X(QU'0;)<G[+\;O^"JFJVWB#QWX3U_P=^S
MM#.L^G>&TD-MJ?CO:P*373 AH+(D JB\N,$'.UT^O_"\=EX(\.67A#P=\,FT
MO2M-MDM]/TZPBCBAMXE&%1$7 4 =A7TO+A^'-96GB^VCC2]>DJB[:Q@][RTC
M\SS8CB32-X83OJI5O3K&F^^DIK:T=91_!7X)?"[]GCX<:=\)_@[X0M=$T+3(
M]MO:6R\NQ^]+(Q^:21CRSL2S'J:ZNL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EKYRK5JUZKJ5).4F[MMW;;ZMGTM*E2H4HTZ45&,59)*R26R2Z(V*R?&_
M@/P3\2_#%UX+^(GA'3=<TB]39=Z9JUDEQ!,/]I'!!]N.*;_PDNK_ /0H7O\
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MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
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M%S_@HG^UU^S]\2?B1\"/$'P\\ ? O6[CQGK-GXON;)KS5O$WDK%I]G;):3S
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MS;5[-Z^85\J7Y/\ P3Z_:..L)^X^#?Q2U<"]4<0^%M?DZ2>D=O<8Y[*1_"J
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MHXB/_3MWDO6#2J+U<;>94.(L%3DJ>-C+#R_Z>)*+]*B;IOT4K^2/IZBOQO\
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MW3VVHZ=>PF.6WE4X9&4]"#7]25>3?M!?L*_LD?M3WR:M\>/@9H^NW\<8C75
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M7_X*S?"OQR[6G[+_ , /BK\5Y&)$-]X8\&30Z?GUDN;KR_+7W*&D_P"%G?\
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MFESYCACPIR[A_-(XZM7=:4-8KEY4GW>LKM=-E?6P4445^6GZN%%%% !1110
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M"D]DK'\<<;XS&OBC%TI-PC"I+EBFTEK\26R<OB;6[=S].?\ @GE_P59_;O\
MCIH,?[(O@[0-#\5_$&X#-HGCKQ?J?E1V%@B_O9+M%&^\DC^4J5^=LDL'VG/W
M!^SY_P $[_!?@'QPGQ^_:)\:7OQ7^*<F&;Q;XFC!@TPYSY>GVG,=HBD_*0"P
MYVE Q6OS _X(%?"_Q5XR_;ULO'VDVLO]F>#] O[K5KD ^6//@>UBB)Z;F:4L
M!W$3'^$U^Y5?BWB/4H9'GD\'ED8THU(J53D5I-R;O%O=1LD^6/+%WNTS]O\
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M+J%9(IHG!5D=6!#*02"#P0<5/133:=T)I-69\2WMOXV_X)*>/GU;2K>^UO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ+5/V"/@UJ^IW.K7/BKQNLEU.\TBQ>+[E5#,Q8@ '@9/ [4 0> ?^4@GC_\
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M#7S5XN_9D^+/['&KS_$;]D:UOO$G@B69I_$7PFFOG$D(/+SZ9)R5?N82#NY
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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MH$D/7A6YP3WU.'\=3PCKJS79;M=_^!N:RPE54^<_1.BBBO".4**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5.0:YKX;^ YOB#XMT_0+C6;?2-/NM2MK2^U_4$?['IPF?8LDSJ#L7KUQT/(
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M2+C+U"BBBN8@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***S_%GBSPUX%\-7WC'QCK=MINEZ;;-<7]_=RA(X8U&2S$_Y/2FDV[(-P\6>
M+/#7@7PU?>,?&.MVVFZ7IMLUQ?W]W*$CAC49+,3_ )/2CPGXL\->.O#5CXQ\
M':W;:EI>I6RW%A?VDH>.:-AD,I'^1TK\@/\ @HI_P43\2_M<>)7\"^!9KG3?
MA_IMSFSLVRDFJR*>+F<>G=(S]WJ?F^Z?\$[/^"B?B7]D?Q*G@7QU-<ZE\/\
M4KG-Y9KEY-*D8\W, ].[QC[W4?-][Z;_ %9Q?U#VM_WF_+Y?Y_\ #';]2J>R
MYNO8_8^BL_PGXL\->.O#5CXQ\':W;:EI>I6RW%A?VDH>.:-AD,I'^1TK0KYE
MIIV9Q;!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ))/  H FHKXJC_X*\W9_9M_X>$S?L^I%^S@?$2V:^-G\2R?VZ=)-\+ :_\
MV3]CVBQ^T'?L^T^?]F_?^7G]U7K_ .TO^VUIGP?^)OPU_9V^$GA*U\;_ !*^
M+4UU)X1T-M;^QV$&FVD(GO-5O+M(IC#:QQL@79%(\TDB(B\LZ 'NU%>(_LN_
MMDVOQS^*OQ&_9J^(G@V#PG\4/A5>V2>*_#EKJQO[2XLKV#S['4K*Y:&%I[>5
M-RG=$CQ2Q21LO"N_MU !1110!X7X!_Y2">/_ /L1-*_]&-7NE>%^ ?\ E()X
M_P#^Q$TK_P!&-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRW2>TN8'#)-$ZAE=2.""""#W!JQ7 TTS(**** "BBB@ HHHH **** "BBB@
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M%M,T4\3RME'4D,I^7J""* .=\ _\I!/'_P#V(FE?^C&KW2OF7X)?&/X8>/\
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M!J#_ +ZH_P"$Q\,?]!J#_OJ@#2HK-_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH
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M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
MY\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B
M@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"
M'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.
MT_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&
M'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG:]OY-#^#>E>+_B5J4;;6L_ GA:XN@K=LR.$CQW+!B *V/ ?_!.C]CSP'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7YQ_\ !3__ ()@?9_[1_:2_9M\/?N_GN?%
M/A:RB^YW>[MD';J7C'3EEXR!^CE%=N Q]?+JZJ4WZKHT:TJLZ,^:)^<?_!,#
M_@F!]H_L[]I+]I+P]^[^2Y\+>%KV+[_=+NY0]NA2,]>&;C /Z.4448_'U\QK
MNI4?HNB05:LZT^:04445Q&04444 %%%% !1110 4444 ?+__  43_P""=GAK
M]KCPT_CCP/#;:;\0--ML65ZV$CU2-1Q;3GU[)(?N]#\O0_X)V?\ !.SPU^R/
MX:3QQXXAMM2^(&I6V+V]7#QZ7&PYMH#Z]GD'WN@^7K]045W_ -IXWZE]5YO<
M_K2_;R-?;U/9\E] HHHK@,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOQ,MH;?7/%_Q!@,,N\36GC"4.W! !+JW'/2N3_X<A?LF_P#11OBG_P"%L?\
MXU0!]C45\<_\.0OV3?\ HHWQ3_\ "V/_ ,:KS'X[?\$FOV<OA[\2/AIX6T/Q
M[\1GMO%7B=[#4FNO%[.Z1"$N#&1&-K9'4@T ?HI17QS_ ,.0OV3?^BC?%/\
M\+8__&J/^'(7[)O_ $4;XI_^%L?_ (U0!]C45\<_\.0OV3?^BC?%/_PMC_\
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MI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J /L:BOCG_ (<A?LF_]%&^*?\
MX6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J /L:BOSK^.W_!)K]G+X>_$CX:>%M#\
M>_$9[;Q5XG>PU)KKQ>SND0A+@QD1C:V1U(->G?\ #D+]DW_HHWQ3_P#"V/\
M\:H ^QJ*^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J
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M9R^'OQ(^&GA;0_'OQ&>V\5>)WL-2:Z\7L[I$(2X,9$8VMD=2#0!^BE%?'/\
MPY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\ C5 'V-17QS_PY"_9
M-_Z*-\4__"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU0!]C45\<_\.0OV3?\
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M_"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU0!]C45\<_\.0OV3?\ HHWQ3_\
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M3FMHKJ="R1DD') Y(XKH?"6C2^'/"FF>'IYED>PT^&W>1!@.4C521['%:%%
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MOP[UZQ\??!/Q-+)'/IFJN%27[+(Y#(UO<H(SDC:7CBW_ ";Q7"_$SXR>,/\
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M5F"6UB0"S%]+DAC@AEFP@,RF4I&[[)P#S[]J#]L/_@FQ\4O%/QY^!'_!3O\
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M.-%C-A\,?CW\-O!UYXD^UZ0!MAL=9TVQCGO+>2*/$8E$4B%<(6<)YS@'W?\
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M110 4444 %%%% !4<=Y:37$EI%=1M+#CS8E<%DR,C(ZC(]:^<OV[OC1\9/\
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M(\4MKG@NTU/Q1X>F!U!/">M:I#:WNIV+ 9AEC2'5("QR8A;^=D;EQ\Z>)?\
M@D3\!O\ @DQ\=/A'^V;_ ,$[G\3^$HY_B;X?\&?%_P -7?BN]U&S\5:1KNH0
MZ2+FX6ZDD;[1#>WEK.I0J@PYV#&: ,+]EC]CO]G/_@J]_P $VO ?[6/[,WQ$
MUSX6?M(:9HJVVM?%SP[JL]MKD'C&U15U"'6]K!K^*6Y!=XYU+&"6/R]BL%KW
M?_@E7^VGXW_;P^$OQ)_8K_X*$_"W3++XU?"BY/A;XS>%;JS1K#7[.YB<0:E%
M$1L>VNX0^0HV'[RA8Y8Q7 _%3]A/]KW_ ()Z_MQ^)?V[_P#@EIX<T[QMX/\
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M=W[$@CR[6!Y;IQU,=NX')% '97%W:6FS[5<QQ>;((X_,<+O<]%&>I/I7P_\
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MP4(M-=F9[B*XT]X)UBN7A^SER8<Q1DLL( .T_P""KW['/Q:TKQ]X5_X*:?\
M!/NT6U_:(\#7%KI!T..)OLGQ&T2XN$271-05,#"AC*EPQ @$;,S(J++#]A>"
MM.\6^-/ 6D7GQZ\#^'[77A+%?W6BZ;=MJ%IIMTC[XECGEBC,[Q$*1-Y4?SKN
M55P*VO"FAOX9\+Z;X;DU*:];3["&V:\N#^\G,:!?,;_:;&3[FK] !117Q_\
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M]^-5A\ /!%I\0]=T*:\TH^)-+TW5[B&8)_9L%[>Q6GVU\CF*)YT>3IMC#N2
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M#7QW3PY?M%?W6A0:'=:K:Q)<Q@&"TO\ =I@DD!# 3M!N)W @'J__  4J\?\
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M97N8X-+CL[JZO+:*2:"-KMS)OAW,66-7DP\CHH!Y)^QY\4/VN?\ @HK^T)X
M_:>\!Z1>?"[]F#X:0W7_  A-KKNGLFM_%6:6PELDU!X'(-CIB)*TL ?,DK!'
M(PP\K[ZIL444$2PPQJB(H5$48"@= !V%.H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBL+XH?$?PE\'?AKXA^+?C[4C9Z%X6T*[UC6KL(6,-I;0O-
M-)M')VHC' ZXH W:^8_AG_P50^ WC_\ X*#>+O\ @G9K&AZSX<\4:-9BY\&Z
MSKEH\&G^-EB4C45TV1U43/9SK)#(JELM#,5SY4FWS']G_P#X*F?MG>*?VGO
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M (57JOC_ /8YO3Y8^&_B+[9X1B;C=X6U5I;O3@B_PQ6\HO\ 34']W2@3UKY
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M:^,GQ9\%? ?X2>*?C;\1K][;0/!WAZ\UK6YX8C))':6T+S2E4'+ML1L*.6.
M.37R#^S?_P %/?VT_%O[5G@KX*_MA_\ !,;7/@]X0^+BWZ_"WQ?=>-;34YFN
MK:RFOQ9:I;0+_H%Q+:6\\JQLVY6C,>'*NR '0_$O_@H1^UO_ ,*VU?\ ::_9
M8_8>TWXL?#'0O$.KZ5=6VC_$-[?Q5J,>F7\]A>7EEIQL'@F19[6Y\N#[5YTR
M*C!59_+&-'^W7^SC^V#\ OAQ_P %4?V6/%LE_HWPV\4-;>.;:[@\B_TK0[X1
MVNM6=]$2?(-INL]3D )5AI2,C.K*6\2^#7[0FL_\$6?^"C_C']CO]JB_;3_V
M>?C_ .-K[Q;\#?B)>MLT_P .ZY?2F?4-!NI6^6"-IW9HRQ"KN5SGSI#%VNO_
M +$VD_LI?\%B--\9_"'087^$?[8/A?7]!^-'@15Q8#7+33YKZ+5%C7 'VF!;
MJ&3&!OFD8Y,PV@'TG_P5,^)/AKX1?L _$KX@^,8+R73+'2(%O8=/M_.N)$EN
MX(=D29^>0^9A5[L0*\L_8A\$_MX?M0_M+0?\%&/VOQ??"KPW;>%[[1/A5\ K
M<HUW:Z9>RVTTVH:]*0<WLIM+9EMDVBW$:J3N\Q6^D?V:OAY\0/ ?[/GA;X6_
M&W5;37M:\-62:;-J^\S'4H[.4QV=]+O5<7$L,4$\@ PDSN%)"ACZ%0 44$A0
M68@ #DFOD[]N+]O#]JSX4?%B/]G']@C]A>\^-WCJP\-P>(O%PN_%MKH6EZ%I
ML\T\-JC75QQ-=W#VMP$@7!"QF1CMP" >O_M)?M#:M\'M5\%?#7X?>%--U[QS
M\1]>N-*\(Z3K.MMIUENM[&XO[FXN+A()Y$BC@MGXCBD=I'B7"JS2)X#\/O\
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M-GPN_:RMLQV5EK/_  A'C=Q]W^R-:F@BMIV'0F'5HM-^=N(H;F[;(!;//_\
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M#=6<TML@6&ZB^UPL5)PRD\*-AD ,7XG_ /!5#]I_P!^S[HW[>_A7]@^+QU\
M=8TJ/6I-0\&>/3-XMT[0I!YD>K2Z3+91PR(82LC017;/$K$NP"OLZNU_:A^!
MWQDUKX(_\%+OV:O'MKK_ ( \7S'P)XJU.VR@2TU2>-=/>XC(#)<6^L1VUIY;
M@&(:K<DU\X?\$TOVA]=_X)6_M/ZE_P $2_VT=3.G>%KG5;J__96^(.K2;;+7
MM$N)VD70WG?@7<#R>6B,<L28Q@&V$NQ\,O\ @GGIW[,G_!0KXS?L.?#6:XTO
MX"_M1?"#5_&FFZ'IIVKX,\46-Y86-Y-9*.+=6&I6MQ&5QMDAC10%@3 !]*?\
M%;/C]HG[-O[)EE\3-:\&:[XD-K\4?!LEEX<\+V!NM2U:Y@U^QO(K2UB!&^61
MK8(H_P!KMU&%_P $]_@M^W/XE^+OBC]O+]O3Q7#X;\0^.?#EIHWASX'>'9TF
MTWP=I$$\EQ"MU<XS>:D6FD\R52$7S'5=RE%B^E/AC8^.[SX8^%9/C?8Z1)XQ
MM]&LY/$1TK,MI%JOV<+<M;,ZJWE^8TH5BJG8W(&2*Z2@ HH)"C+$ >IKXM_;
M._X*0_ME_#;XO>)OA3^P1_P3@U;XY+\-+:VG^*&M2>,;;18+*:>VCO(],L5E
M5Y+^]-I-#.RQ*=BSPKM=I0H /<OVA/VB_'7@GXG>&OV<O@)X'\/^(OB+XL\/
M:MKNGV7BOQ)+I6FVFF:=)9PW%Q-/!:W4I;S]1LXTB2(E]\C;E$9SX;\#_P#@
MIYX,^.?[0.N_\$R/V_/V<+CX0?%;6-%N%L?"6LZNFJ:%XXTJ2.1)9-*U%8XA
M=*T8DW0O''( '7!:.4)Y9_P4?\2?''XQ_L\?L\_\%QO^">_A+4=9\1_#'2#X
MEOOA],A6Y\0^#]9M+=]4TUT3=NN(EAB<* VUHY'0,ZHK:/[7_@?]FC_@OI_P
M34TO]JK]C3XB1VOQ \$!O%'PD\7VTBP:KX5\16BK.VG76#NMR[1I'(A)7/DS
MKO"1L0#ZK_8-\5>(KGX'/\&_'^L37_BOX3ZU<>"O$=Y=/NGO#9+&;*^E/_/2
M[TZ6PO6]#=D=J^)?B'XR_;'_ &X_CM^T%_P3U_8O\,7/@;PEJ_Q+NK?XU?'_
M %JQ#P:;9MI.G6,NDZ+%D?:]1EBMVWR,0ELD@.0[1LOU?^Q%'\2_BM_P@O[<
M=Q8V.G:?\:O@'X;U3Q_H3%XI;3Q D$-Q;2Q1;2#OM[^Z@F9F#*+"S4!ADK]'
MVEE9V$;16-I%"KRO(ZQ1A0SLQ9F..I+$DGJ22: *7@WPXW@_PAI7A)]=O]4.
MEZ;!9G4]4E5[J[\J-4\Z9E55:1]NYB% +$X Z5I45YW^U=^T7H7[*/P"U_X[
M:[X2UCQ#_9)M;;3?#GAZW\V^UC4;RZALK&Q@4\&6>ZN((5)X!D!/ - 'HA(4
M%F(  Y)KYD_83_X*G? G]NOXG_$?X(^&-!UGPKXQ^'>MRJWASQ1:/;7.LZ$S
MXLM?M$D5&DL[E&1U.,IYB9^62-WY;]B7_@H1^U[\6OVF]0_9)_;S_P""?EU\
M$_$E_P"#;CQ7X'N[3QK;:_IVLZ;!<V]M=6[7%N@1+J![RVW("<K+N*H-AD/^
M"I'_  3[^(/QVE\-?MG_ +%.M6WA;]I'X0H]QX#UE\);^(K'EI_#VH\@26EP
MI=5W$>4[DAD#N2 >E?M 8^"W[5/PT_:3@'E:5XFD_P"%=>.)!P@2\E\[1;J0
M]_*U$-91C^]KK'MQRG_!6[X_Z/\ LU_L^^$?B?J?P[U_Q=<6WQ<\.?V1X5\*
MV7VG4M7ODN3/!:V\7\4CO"%']T$MSMP>=_9]_;+^ '_!8/\ 8SUWX7+KX\!?
M$C4;&]T/Q;\/]4N437O!/B2T 9I!;OMD8VMTL5Q%-L"DQID*P9%^JO UKXKU
M+P-X<O?BSH^DIXH@TVVFUB+3',]K:ZB;?;<?9I)%5B@9Y45RJL4;D#)% 'S9
M_P $\?@=^V[<_$CQA^W!^WKXUM](\7_$;1-/TS2_@WX;F272?!6D6DUS/:V\
MMQC=>WX:[G,LX(3=*ZJ&4)L^L**"0.IH *^;_P#@HI_P4P^$?_!-C1?!7BWX
MP>"O$>JZ'XE\3QV/B+5M TV2XC\+:6<))K%YL1MMM'<2VD)!(9C<C9O9=C>:
M?MD?\%,OVR_AG\6O%_@']AG_ ()K:S\;=(^%0MS\4O$;>,K;1XX+B6TBOO[.
MTV*1'DU"Z6TG@F<1J=AE2/:SN!7TW\.O%7PE_;._9AT#XB3>$X=5\%_%7P#9
MZB=(UVR1Q=Z7J5FDP@N(SE2&BFVLG(Y(H W?$&B?#?X__".^\-ZDUCXB\(>-
MO#DMM<-;3K+;:GIMY;E6VNA(>.2&0X8'!5L@UP'[#/CSQ5XI^ L'@7XEZM)>
M^,OASJESX-\8W<_^MO+W3R(X[YQ_#]LM3:WZCLEZG3I7Q=^SYX_\1?\ !"G]
MI73?V$OVA_%US<_LN_$?5I1^S]\2-;NRR>"-1D+2-X6U&XD/R0'YVM9G/3@D
MCS/(^U_AEX$FC_:1U_\ :#^%WB;1M3\!_$?PE8R:JUC?>9OUJQD:"&^A* I,
MMQ92)#))OX&F6P4,&8@ ^$?$OB;]L;_@H%\2_CC_ ,$]OV1O#MY\//A]<_%+
M7;'XX?'W5+0'9;N([671M"ASBXO9((@LMP<);ASD>849OU T/3)-%T2ST:75
M;J^:TM8X6O;YU:>X*J%\R0J%!=L9)  R3@#I4MG8V.G0FWT^SB@C:625DAC"
M@N[EW; [L[,Q/4EB3R:EH *I>)/$6C>$/#M_XL\1WZ6NG:792W=_=2?=AAC0
MN[G'8*I/X5P'[7?[3&C?LE? ;5_C3J'@C6?%5W:W-GI^@^$_#D(DO]<U2]N8
MK2RL8 > \L\T2ECPBEG/"FO ?V/?VVOVH/VE?C)XM_8D_P""A_\ P3[G^#GB
M#4/ D^OZ$EKXTM]>TS7]$::.SNXOM-LJHEQ"]U;HZ DD3!L(-N\ POC)_P %
M5_VH/@%\$/#O[</C3]@<>(/@'K^C6FMW^M^ _'AU#Q-X:TBYC6:*_OM+ELH8
M9$\J2-Y%M[J00?/N=D7S#W^G?'OX0^-/C'\'?V]_@!X\L?$'PZ^,>CCP/K6N
M:>Y\F1V>:[T2XES@QM%=C4-/,; .L^KJC!2I ^:?^"3W[3OB;]A3XNWW_!"'
M_@H!JB6^J^&1)'^SWXUUO"6?CSPH[L+:R5W^1KJ%#Y0B!.50Q 9AS(_X#_\
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MWQ:U?Q[H7B*\\8^-?AYX@U=&\(>*K:YOFN]1TJVTQ$_T3S?.G^S_ +R5EE9
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M]2M[.SM(6ENKNZF6.*&-1EG=F("J ,DDX%6*^*_^"N'Q_P#AE^SMX_\ V?\
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MWO/M4L2QF3[5=.4M;&$><A:6XD10I=OF"/CVFB@#R+]D']F#0OV??V9/AO\
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MZC%>SZ?/#IMVEO<O"RV\\D/F+&Y!VL5R-P!P<9&<8R*_,!+'Q]_P;W?M%?\
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M2WUK\$_#NJV"2ZW8:!YF+>+4+W<PD1,,((D562-EWN 5MK?Z[CC2)!%$@55
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M[1^B_L1_'#QMJNM?LK?$[6#!\$/B+X@N/.E\"ZW,Q=_#VI3X %M,Y:2WF8
MELY'FM'^G5<#^U#^S-\&/VQ/@+XE_9N_: \'0ZYX4\4Z<UKJ=E( '3HR31-C
M,<T;A9(Y!RKHI'2@"O\ MA>*K;P+^R1\4O&]Z5$.C?#G7+Z4OT"PV$TAS[86
MOCO]A_X;_MN_MS_$_P"%W[8?[0UOKGP9^$/PLM1-\'/@^VU-<\03MITNGG6=
M>8@_9U:VN)UBLDPRB8EFXW2^V_\ !+/X ?MG_L__ +-5C\,/VS?CO%XU?1FN
M-.\(13Z4BZC%HB3,++^U;GS'%U?"W$:OY>U$Y5FN&'G'Z=H I>'/#GA[P=X>
ML/"7A+0K/2]*TNSBM-,TS3K9(+>TMXT"1PQ1H L:*JA550    ,"KM%% !11
M10 5\K?M_?'/1?'B:W_P3/\ !'P"\5>-O&?Q0\ 75KYB^%I/^$9T/3[Q9K0W
MVI:A(%@2*+#OY,1DG<HB(FZ1#7U310!@>$_AMX5\*66@+'I=O=:AX<T#^Q].
MUJZMD:[2T80>;&)<;E61K:W=U!"LT,9(.Q<;]%% !1110 5\$?MC?\$_OVL?
MA'^W?#_P56_X)BS>'[_QIK&BPZ)\9/A)XIU-K'3_ !YI\(589HKH*RVM_$B1
MHDCC9B-#G'F1S_>]% 'S;\(/AO\ %;X_?M+>%_VR/CY^S6WPLU7P=X UGPO9
M^']0\26.J7^H'4[K3IYGEEL'>$6T(TX")3(S.UW*S1P^6OF?0WA_P_H/A+0+
M'PKX5T2TTS2],LXK33=-T^V6&"TMXT"1Q1QH J(J@*JJ    !@5<HH ****
M"O/_ -IC]E7]G7]LCX67/P4_:@^$&C>-?#%U,D[:7K-ON$4RY"S1.I#PR@,P
M$D;*X#,,X)!] HH ^'_C#_P34_9/^%GPO^%/[#O[('P'T?PGILWQN\/>-]5M
M-)CDD>&ST:\BO[F^NIY6>64N+>&Q5Y'9MUW&H^525^TY/#GAZ;Q##XNET*S;
M5;>REL[?4VMD-Q%;R/&\D*R8W!&>*)F4'!,:DC*C%VB@ HHHH YOXQ?#L_%W
MX6:_\+&\4ZAHD/B+2Y=.O-4TB0)=V]O,OES&!SGRI3&SA),'8Q5\';@_GO\
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MR@ \U@]Q-]$4 5](TC2?#^DVN@:#IEO96-C;I;V5E:0K'%;Q(H5(T10 JJH
M"@8   JQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !116?XL\6>&O OAJ^\8^,=;MM-TO3;9KB_O[N4)'#&
MHR68G_)Z4TFW9!N:%%9_A/Q9X:\=>&K'QCX.UNVU+2]2MEN+"_M)0\<T;#(9
M2/\ (Z5H4--.S#8****0!1110 4444 %%%% !114&IZGINBZ;<:QK&H06EI:
M0/-=75S*(XX8U!9G=F("J "23P ,T 3T57TK5=+U[2[;7-#U*WO;*]MTGL[R
MTF62*>)U#)(CJ2&5E((8$@@@BK% !1110 4444 %%%% !1110 4444 %%%%
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MW]W_  3N];^/7P0\-Z/<Z_KGQ>\-6UG9PM+<SOK<&$11DGALGZ#D]!7Y._\
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M/XJ?\%</V1_A5\;/AY\"KA?&6NZE\4_#$^O>!M3\,>#KF\L-8M([-;M/LLH
M-[))&\01+99B&F3?Y8W%?SC_ ."?_P >?^"9W[/7P?\ %7_!.'_@K3X.GT?X
MR^!_%VMZ;JVA>(-)U:\'CZSO=1N+FUN;*"V5TO/M"W*QK$JEI<*X5A)FO>OC
M#XP^"_PP_P""O?\ P3Z^'-OI6@?#>/1/A;XXMAX EU>!6\-)<:/9"TT]P&"H
MW[MXD X9HF"%@ 2 ?8O[%W_!0[X1_ML>)_B#\-_#/P]\<>!_&GPOU2TL_&O@
M;XC:'%8:IIZW<336=P4AFFC:&>-'9&60DA>57*Y][K\V_P!E#]HGX$>#_P#@
MM]^W9XJUOXK:$EGIWP^\!ZA>26]^DS^1IVD7CWSJD19Y# C+YBH&9<@$9(%?
M:?['G[9?[.G[>GP,T_\ :-_9;^("^(_">HW,]M%>FRFMI(IX7V2Q20SHDD;J
M<'#*,AE895@2 ?!O_!Q-\'OA5XI^,?[%>K>(/AWHUU>>(_VN_"?A_7[R73HS
M-J.E3S8FL9WQNE@<*H,;$J<=*^KOC9_P4B_97_9 _:)\%?L2:[X&\90:_P"*
M-$O+GPII_A;P#<26,D5G;^:;:V\M5%Q(04C6*U678TBA_+ 9E^4_^#BOXO\
MPI\&_%_]B33_ !9\2="TVXT?]L/PEK6K6][JL4<EEIL$V9KR568&.! REI&
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M_!UK=?$SP_'+'X6T])(Y-9@#*PMHP007X(/:NI_X7#\(_P#HJ7AS_P 'EO\
M_%UXI\'/^"?O[&.O?"'PKKFL?L[^'KB[O?#=C/=7$D#[I9'MT9F/S=223^-=
M)_P[H_8@_P"C:_#?_?A__BJ_0Z;QOLU:,=N[_P C^0L53X<^M5+U*M[O[$._
M_7P]'_X7#\(_^BI>'/\ P>6__P 74^G?$_X::Q?1:9I/Q#T*ZN9FVPV]MJT+
MO(?155B2?I7F/_#NC]B#_HVOPW_WX?\ ^*K4\%_L.?LE?#KQ58^-_!'P'T+3
M=6TV<36%_;0L)(7 (W*2W7DUHGC+ZJ-O5_Y'+4I\/*#Y*E6]M+PA:_2_[QZ'
MJU?DS^V)^T_^S5^SM_P6N\2Z)_P6)^%L&I?"3Q=X'T2T_9U\7>,_#XU3PMH,
MR12#6(Y(9$>*&[GN)%#W)0O'#%$KLD4@-?K-7R/\6/VH?V$OVA_C3\6?^"<W
M[=EEX%6VT.^T[^R-(^("10V6OV=SI-I=^9;S71$<EY!-+/E86$L2>1( -VZN
MD\8ZC]AK]D+X0?L[?$KXA_%K]FGQ)87GPR^)VG:#?^$[#2-;-[I^F&W2\2:'
M3\,\<5BPEBFCCB;RU>:8(J*%%?&W[>/QX^&7A3_@OWX4^#'[6OPI'Q6\(^(_
MV=)+?X1?#<Z?;:I"_BN75)/._P!#N2+>&YGM8FC^USE$2+ ,BJ7QQ7_!/WX<
M?$[]A[QA^W'X=_X)4^(=6^(/P-\*> #J7P>TZ2_?5]/@\="QFFFTS3)B66]$
M;[5E6,LQ;[/%(S2*6/B^BWO[!W[>G_!&#P+;?##]IVRL?VSO#NO+XPTN1;A[
MOQYJGQ#AD)F66V16OKB.<HL:2A6A@CCMG)5+;: #],/V#OC9X7_9'\/_  U_
MX)=?'+7?$.H_&:T\&R:W+H^C^&-6U*PT[29K^8PQKJ?D& VMF)([ 322+_Q[
MH, LJU\T_M6_LK_LV?$K_@YD^$_@CQ[\"O"NK:+XC_9YUC6/$&D7NB0O:ZEJ
M*7]WMO)XBNR:<9_UK OP.?E&+7_!,7_@KW\!O%/BOQ;JG[=]QJ/AC]L+4;NR
M\)^(?A++X3N8=0,5EO6QT[1XCN$T4TT]S=NS2#;+>2LY6WCAD&9^V/XC_9+^
M)_\ P<V?!SX?_&G5OA]XCTBW_9YU?3M3TCQ/)97EI%J)O;UX[>6.?<BSX5B(
MV ?VY% &Q_P2]\2^*_A5_P %T/VE_P!BG]FSQQJNM_LY^%_!MCJC:-/J\VHZ
M=X/\42FRWZ=9S2L_D!_,ORULK!5:$K@&#;7W?^WM\3OCS\'_ -D'QYX[_9>^
M%.J>-?B';Z')#X.T#1X(Y)I+Z4B*.?;(RJR0E_/921N6(J.6 KN/A5\%_@[\
M"/#'_"$? _X3^&?!NB^<TW]D>%-!M].M?,( +^5;HB;C@9.,\"N:_:I_;"_9
MN_8D^'EE\6?VIOB?;^$/#5_K]KHL.M7MC<S0)>7&_P I96@C?R$.QLRR;8UQ
M\SKD9 /S<_X(L_"S_@C?XK_:OGU#X>?LN_%'X5_M0_#VQGO-<\'_ !M\0ZL^
MKE;B(P3ZG%%<7+V]TL@G.9%C5E,VX(BLC'U+]@_3_AY_P53_ &J/VL_C)^U%
MX$TKQKX;\#?%.Z^$_P .-!\06B75IH>GZ9"!>W%HCC$,]Y/,LSW"XEQ'$H8+
M&H'>^+="^!7[=/\ P4U_9]_:L_93\7Z)XL@^#>G^)I/&OQ'\(7L=WITUE?:<
M]G:Z(;V M#=3&XG:Z\A6<P)!(S^49XO,X3_@G?=_#[_@F'^TQ^U]\#/VEO&V
MD>#-%\1?%>]^+O@G6]?O4M+75M#U2%#<_9F<@2M9S0>1*BY=2\1QB5"P!\Q?
M\/+_ -I#4O\ @DM8?LL)\7-8?XDWG[8(_9JD^(B7I75FT\70<ZCYW7[2;!DM
MC/\ ?WN9<^9\P^H/VVK3X=_\$M?VP?V2/B'^RWX&TCP5X:^(WQ,A^$_Q \->
M'[)+:TURTU&(+I]S<H@ DN+2XC+I<-F3;-,K,5D85\GV_P#P3M^/^A?\$E=%
M_;(O?A3K \;:=^V4O[2E_P"!CIS?VJ-&-V(WM/( W"86*1WAAQO&TIMW_)7U
MC^WQ_P (1_P4K_;2_8^^%7[-GC?2?&.A> _B1#\7/'.O>'KV.[L](TW3XE?3
MA/+&2J/>7#F.*(G<XCE;;MC8@ _1:BBB@ HHHH **** "BBB@ HHHH ****
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M\/V]IJD%PZ74\BQ+-Y:L=PB#M+@@@^7@\&M/_AUE_P $]?\ HT_PI_X#R?\
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M.X2>UGCMWW1R(P96'S]00#^%<[I\-6TJUK_X(?\ RPZ%4XGOK2HV_P"OD_\
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MJJ@!1["J>F>"/!>BZ[=>*-&\(:7::G?Y^W:C;:?''/<9.3OD50S\\\DUJ44
M4'\*>%Y?$2>+Y?#=@VK1P&"/5&LT-RD1SE!)C<%Y/&<<U?KQ[]I3]NC]GW]D
M_P"('PZ^%_QBU+7+;6?BIXPL?#/@U+'PQ>7%M<ZA=2^7'')=K']FA(Y8J\@?
M8I948"O8: "JVKZ/I'B#39M&U[2[:]L[A-EQ:7<"RQ2KZ,K AA[$59HH AT[
M3M/TBQBTS2;"&UMH$"06]O$$2-1T557  ]A46J:!H6MR6TVM:+:7CV5P)[-[
MJV60P2CI(A8':P_O#!KE_P!H/]H/X0_LL?"/5?CK\=_%IT/PMHLEK'J.I+IU
MQ=M&]Q<Q6L"+#;1R2R,\\\485$8Y<<8R:\2O/^"QW[ ^G?$'3?A+J'C7Q_!X
MJUFPDOM(\,S? OQ@NH7UJF=\\-N=*\R6-<'+JI48.30!]054TC0-"\/QS0Z#
MHMI8I<7#3SI9VRQ"25OO2,% RQ[L>37 _LU_M;_ 3]KK1->U_P" OBV^U.+P
MOK[:)XA@U3PSJ&DW.GWZP0SF"6WU"""96\J>%\[,8<<]<>DT %%()(S(8A(I
M=5!9<\@'.#C\#^1I: "BO(?$G[<?[/\ X5_;"\-_L*:KJ>MI\1/%6BW>K:58
MMX:O$LWL[>+S))1>21K;RX'RE8G=E;A@M>G^*/$FG^$=!N?$FJV]_+;VB!Y8
M]+TJXOKAAD#Y(+9'ED//1%)QD] : +]%?*?A;_@MI_P37\:>#=5^)/ASXX:]
M-X9T*[EM==\42?"KQ-%I>F3Q%1)%<WDFG+!;NA9=RR.I7(SBOI+X=_$;P#\7
M? ^E_$WX6>--+\1>'=;LTNM'UO1;Y+FUO(&^[)'+&2KJ?4'M0!M444ADC$@B
M,BAV4E5SR0,9./Q'YB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** /'?
MC]_P3^_8W_:@UD>)?CA\!-'UC5-H63589)K*[E & ))K62.20 < ,QQVK5_9
M]_8T_9>_97BF'P"^"^C^'9KE/+N+^%'GNY4SG8UQ.SRLN>=I;&>U>FT5WRS7
M-)X3ZK*O-TOY.:7+_P" WM^!Y\<IRJ&,^MQP\%5_GY(\W_@5K_B%%%%<!Z 4
M444 %%%% "21QS1M%+&K(RD,K#((/4$57O-&T?4((;6_TJVGBMY4DMXYH%98
MG7[K*"/E([$=*LT4 0#3--$TUR-/@$EQM^T2>4-TNW[NXX^;';/2JNA>$?"?
MA>6ZG\,^&-.TY[Z;S;U["RCA-Q)_?<H!O;D\G)YK1HH S+[P7X.U/4YM:U+P
MGIEQ>7%DUG<7<]A&\LMNWWH68C+1G)RA.#GI5J\T?2-1@AMM0TJVGCMY4D@C
MF@5EC=?NLH(X([$<BK-% $45C907,M[!9Q)-<;?/E2,!I-HPNX]3@<#/2OCO
M_@L]^Q-\:/VQ_P!B_4OV<_V4?A_X437/$?C'2=9U;4-9U4:9 OV&^@NV>1HH
M)7FDD\K8#MXSDG@ _9-% %'PW?:WJ6@VM_XCT)=,OY80UU8+=B<0/W42* '^
MN!]*O444 %%%% &<?"/A,^)!XR/AC3CJX@\D:J;*/[2(_P"YYN-VWVSBKEU8
MV5\J+?6<4PBE66,2QAMCJ<JPST(/(/45+10!0\0^%/"_BZUCL?%?ANPU."&9
M9HH=1LTG1)!G#@." PR<$<\U=FAAN87M[B)9(Y%*NCKD,#P00>HIU% %/0?#
MOA_PKI<>A^%]"L]-LH<^59V%JD,29.3A$  R23P.]7*** "BBB@#._X1#PG_
M ,))_P )E_PB^G?VOY/E?VK]BC^T^7_<\W&[;[9Q6C110!0\1^%/"_C"P&E>
M+O#=AJEJLHD6VU&S2>,..C;7!&1DX->0_P#!0;X ?'3]I/\ 95UOX/?LU_%;
M2O!WB6[NK&:WN-<T^2?3M1MX+F.:;3+M8661;6ZC0P2F,[O*D=<,&*GVVB@#
MXBO_ -FS]N;]K/P7J?P0_:[_ &3?V:/!WA_7-.FTWQ-XJ\,ZQ=^(;^>VE39*
M;"SNM,MDMY"I;9--/)Y3%',,NS:>I\1_ '_@H3\<?VE+[X:_''6_A)IW[,NA
M>)-)UGPS8>&H-2D\4ZXM@8KBWT^_>=_LT< O88I960,94A$6-LLA7ZTHH **
M** "BBB@#,O?!/@S4M4FUO4?"6F7%[<V36=Q>3V$;RRV[?>A9RN6C.3E"<'/
M2KEYIFFZCITFCZAI\$]I-$8I;6:)6C>,C!0J1@KCC!XJ>B@"KHVB:-X<TN'1
M/#VD6MA96Z[;>SLK=8HHAG.%10 HR2>!WJU110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>pgen-20201231_g2.jpg
<TEXT>
begin 644 pgen-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )?!5@# 2(  A$! Q$!_\0
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M9/L7VS?Y>?*^S?+NV[L\[>]?<-%%<U6O.M;GZ&<IN6X4445SD!1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **2D#J>A!H =117GGQ\^);_"3X/\
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M\8_#OQ>\(7?QN\0:78_#W6K_ $JRU*S &HWLD181FXN01(8QY6=H8,?,8%B
MH'UK!\!&A_:BN/C!_;@99?#8\/\ ]C_9>1^^63S?.W_[.-NSOG-4O@[^SFWP
MIO\ XM7+:^-3'CS7+O60HL_*^Q>>7/EYWMYFW?\ >^7..@K)8B$865METZ]>
MG87.DON/E_Q=^TQ\0[W_ ()L>'?B/%X@FL/&<FH+93:I:JJ/*J74L.2,8RR(
MN>.3D\5Z=^UM\7?&'@+XR?LQ:3H&NW&F:=XFU\6NL6\07;>1?:+!-KY!XVS2
M#C'WC70Z?^Q)8?\ #(*? O5/$\UW''(\\>N6UH(660W37"'RB[ @$[2-W(S@
M@XQ@+^P[XH\3>)OAUXF\>?%V^\6:[X,UBUO[3=I<<-N+>%UD,"(CC#R-'%NE
M8L2$ QWJ_:8>][K1RZ;W6@^:&_J85FWQ*^/?[1'QQ^'MI\3]6\%^&/#MQ9RP
M2:0@%Z#-!\L:2D_NX@RNQ"X8EA\P Q63\,?VLO&OAG]AGXA^,O$MRFM^,_!F
MLW'AR*_D D%S-O@6*5QA<A#<CKRPCR>3BOI#X8_ 1OAU\:OBEX_.N#4!XVDL
MG&GBU\O[']GC9,>9O/F;MV?NKC'>N5^'_P"QSHGAOX+_ !"^''B#56\1Z7XR
MUJ[UBXE6V%NUNTPBV*@+/\T;0HP8_P 0S@5#K47I+9<O3[Q<T=GY?\$^?_BI
MI/Q9_9[^!^A_'+_A<?B77_$@_L^YUGP_J4Z2:1-'.8P\,,&T"/!91N4;L;B-
MI.0>/?A_K?C+_@H?X?BLOB!X@T&?6O!)U:WOK3R3-80M-/\ Z)'N0CR\J6Y!
M.7/.,"O18/V&?&'B'1] \%^.?C)>^)OA9H,L)M/#,&D0VDDT4&!##/<*2TB*
MH ((/0$;2 1W?QT_9=UOX@?%3PY\1O ?CV3X>^+M)TTZ,UR--2^BDM"[N%$3
ML%!!D?USD=, UM[>G%VYE=WUM]W0KG5]SQCXB^"O$7C?_@HI/HF@>,+SP=-)
M\/X_MFK6,2/=M +D;DB9LA'9]GSX) #8Y.:W/V<_C9XO^'.B_M&>'?&^N77C
M8_"AVNK+5+Q]]S=VQAN'2.0X!+8MP26)YD89PH->Y6/P!>U_:<E^+KZ]YID\
M,KX>.D_9,'(F63SO-W_[.-NSOUJGX#_9EL/"OCCXT:YJFIKKUA\2WA%UI<EK
MY:6\*1S1M$6W-YFX3MDX7ITK&5>G*')+6R73K?7\"7.+5GY'Q5:_&+XCZK\*
M[#XGZ'XW^*&N_%2X>.Z7PS;^'KIO#,L+7 W0)&MOY; 1$_O!)D[2 <D5]!?M
M&?$+XAZA\</@IX,\(^(YO!J^-]+ODOFDAWM:XC21I%0D?OD42!<\!B,C@8T?
M"?[*/Q;^&MI;^&?!?Q\NM%\ 6LC?9-,N/#EK=W=O"S%FC6XDYZEMIQA<CCBO
M4/'WP#;QQ\>/AE\1SKOV4>#([V,Z<UIO-Y]HB,>?,#@)MSG[IS[5I.M1Y[JU
MM?RT6W^8W.-]#RGXV6-AX!T'P-X*\4?'WQOH\XM'A6W\-PO-KNMR*Q<3-)''
M+, JJ5.  <')[5Y7\)_C]XU_X4G^TSH[>*M<U>X\ 6ZSZ!K^N0-;ZHL4L<QC
M69)$5]Z^0"2XR2Y[8%?1OQ>_9OUSQ9\9-"^*7@?QE%X1\6Z?IKZ/.;[31?VU
MQ:LSL!Y9=-K!G)R#S@?CY+XX_9FN/@3\"_VF/$=]XSO?&6H^,]'^TW$]_;)%
M+')%%-N)*':0S3-@!5"J%4 XS13J4I046[MM=.M]>G;S",HM)=?^">??$KQ%
M\8/ _P"SQX+_ &BF^*^J76HO'IUW<>%8XQ%I3VL^P"(Q\EGP5W2.23ER-O%>
MW?$CXK>)_AK^U9\)[VZU:X_X5IX^L'TM]/G(\BRU':&B?=C 9]T2A<C/[PC-
M>7?"7]C?Q'\8/@G\)K?Q%\5]5OOA?_9^GZS+X0N+*-G,ACW^0+D$-Y(+X56#
M;5  Z CT?_@IE9Z(/V6[J:\E-IJ]IJEDV@- H\[[;YF D?(.?*\[[O("DX.,
M54I4Y5(TM'>ZT6R>WW#;3DHFW^R/\1O$OQI\;?%SQK=ZO<7/@<:XVC^&;'<&
M@$-N,27$;  ,),QGC.#O&37TO7EO[,'PK7X*_ /P5X1:)8;VRT])+X*20;N7
M,L_)Y(\QW SV &!TKU*O+KRC*H^7;_(YYM.6@4445@0%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11575-2
MM]'TV[O[M_*M;6%YY7_NHJEF/Y T;@6J*SO#VN6WB?0K#5[+S/L=] EQ"9%V
ML4894D=L@@_C5;6?%VG:%KFB:1=._P!OUB22.TBC3=N,:;W)] %YS5<KO8=G
ML;5%%%2(**Q+/QAIVJ:7!J.F&75;26X-L)+.,N P8JQ/3Y5(()]JVZ;BX[CM
M8****0@HHHH ***2@!:*3-+0 4444 %%%% !1110 4444 %%%<IXL^+7@?P'
M>1VGB;QEX?\ #MW(N](-6U2"UD9?[P61P2/>FDY:(9U=%9/A_P 6Z)XLA,VB
M:O8ZO"(XY?-L;A)D*2+NC8,I((8<@]Q6M0TUHQ!1112 **** "BBH;6\@OH1
M-;3QW$1) DB<,N0<$9'O0!-1110 4444 %%%% !1110 4444 %%%% !1110
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MC+PY60YN2L3M(*C:;WJC->*G):L?6O%5AH-C)>ZE?6VG648^:XNYEBC7ZLQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&?FVDC]0*^+O@+J'GZ?<6I/5"!^%?"<34VN2JOZL_P#@GUN1SNI4V?5WPO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9!=, N#W..*_)SX>^$?$7QD_:4\61ZC8SQK?:Q-<:O+-$5\JUBF.(N1_%M1
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M>=B,-2E5AB)+WHO^OQ.FG5FH2IIZ,^@****]$Y@HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\/?'[PYK.U;D3:;*?^>@WI^8Y_2ORP\(_$3Q+HMG$L6H><B@?).@<5Z=X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(S!5+,0
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M:G(OFR0W5W%/);'(+21QYW#.3D-R.W-6-%\26WC7P[-I&NZEJ^N7K_,$TD1
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MWB4O)+*P5$4#)))X  [U\K:U_P %"_!&G:7(88S)J2HJ&/<6C2X9-PC8X'?
MSG'(KQ+X?Z]\2?V^/B%-9ZYJ$WA_X:Z8R27]GI<A17(R/(+8!=G^;G) 7]?5
M_M"G-J-'WF_D<GU>4=9Z(^@/$7Q,\1_M.WUWX5^%<LFF>#()C;ZSXXF0B.<#
MA[>S7K)GHS\#MWY]2\&_L_\ A+P;IL-K%;37LL8&ZXNI6+.1W(&!^E=OX<\-
MZ9X1T.RT;1K&'3=+LXEAM[6W0*D:@8  %:5:_5*=27M*R4I>?3T(]M**Y8.R
M([>WBM84AAC6*)!M5$& !Z 5)117<8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %)MI:* &>6*4*!3JY#QY\3-(\!V$DUY<1B1>-I/?TXY)]A7-6K4L/!U*KLC
M:E2G6ER4U=G57-U#9PF6>18HUZLQP*\O\<_M">'O".^%9A<7(_Y9K\S?]\CI
M^)%?.GQ"^.VN^-KB2.SEDL;+D @XD8?A]T>P_.O.8[4NQ9LLQY+$Y)KXW%9W
M5J>[07*N_7_)'U6&R>G!<U=W?;H9GQ'_ &]OCA/XVU'2=$^&8ET*.],%OJ1+
MDO#NP),!MN<<]*ZO5/&7B+6I&^U:O<NI/W4?8OY"J<=F<58CLO:O$Q&(^L--
MK5=;MW^]GL4,.J%U%Z/TT^XXKQ1'!#JWA^^OKV]CD6]^S1+"2R2O*A4+*/[O
M&<]B!6_]A]:F\4136>BM/;WUKICQS0LUS>+F,)YBAE/H6!*@^I%;+6/S'"X&
M>AK*4KPC\U^OZFD5:4OD_P!/T.9U&:WT73KK4+R;[/:6L3333-DA$49)_(5/
MX(O=7\/Z'8"V\0ZC=ML\U;N65E>0.2XR,\<,!CMBK/BRSU/^P;A=(M+2]OG:
M-!!?'$3(7 ?=Z_+N('<UL?8%3Y5&%' X[5TP?N>K_+_AS"7Q^B_/_AOZN>3?
M'H_&#Q@U]J>B?%K5?#6C0:2\5QI-NSJEQM5RY;:P!W*=IR#TK@?^">.C^-7T
M3POK-K\:-3\)>$;#7O-N?"J1R&VNT1T:5"X?:/,'!RN*^DY=/62-E=0R,,%6
M&00>H-4K71+72[?R+.UAM(,Y\J",(N3U.!7MT,?5I4O9Q^6QY-;!4JE3G9^A
M.EZY9:U;I-:7"2HXRI5@<_3'6KV:^#/"?C;6_ ]TLNF7;+#G+VTAW1O^'8^X
MYKZ=^&'QTTSQJJ6=T?L6IXP8)#RWNI_B'MU^M>]ALQC4]VKHSQ<1@73]Z&J/
M5Z2F*X90RME3R"*=NKV+H\NPNVC%&:6BP@HHHI@%%%% !1110 4444 %%%%
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M>H$6:*:IIU( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN;7&65V"Y<_[1R.G7UXK9\.#0O"&GM=^(;E=0E",8(HY&W2.1M4KCJ<=68\
MX%<7\5/A_KEQXFM1:0R-;7"JT=FSDBV3H-V3GUY[XKN+CX:K;:7IUM=7UH]_
MO#2PC)D5%4*V.V,CZG/M7GSE%Q4I3WZ+H=$4[M);$_A#Q1I\-T;RSM6S,JL(
M=Q\J(AN<@\X]O4 YXKJM6NM:N+6&^B\R]\N<,=T&YE#9^95YP,@'/M6SX$\%
MZ0NGPM;+BZ49>4G/EN<Y##IT/3WKM/A79CQ!J.N:?=/&RV<VUHTCV-(HX_J#
M^-<#_>5+01T?#'WC&NO#MM=:5-'>W:(9D,6^(!I'<J0<#MCOGI67I^@WGPY\
M&1-KUN]_'RT%U:C<K(<;=S'[OS''OGVKT'Q)X9L/"/Q.\'22Z?;PZ)>1-!,7
M;:J2-+]]A[@KR?[M>C?''^Q9/AW)X?AN+8ZAJS1O;".3?Y7EN&7A>BY ![^Q
MKHAA%R3]I*R7Y_UH9RK>]'E6YXUH?PM74KRZU>]TH:=J,["&)B#EXM@Y=3Q]
M[H>P%<?H>@M=^(+J\N=2ANK:QN K6:Q#&]00&; Y'M7N]YXT/@CPA9Q^*="U
M6#6X+=(\^298[MCP")%SM#=<'!KF-+^%FM:?;ZYXBFLX+7^TYFNAH\R%##$H
M)&YL_*QP?EYI5,.TK0U:7W!&HK^\>)>-[J2XU.%KVSMXK9F*FX@A*OG/)/."
M=N>,=A7+ZU;W\.J7#V2W5O#!('M+?(=6@[Y?CAL=#SR:]9TO2[C4%_MV^CM[
MI-LD<-HJ%T0D_,Y!(R0.G;!KA=7L3#>01VP4W#2 >2Y)09)VL!GU)&1ZD5A3
MJ6M%FLH]3CKCP'XOU"TU*T,L%C!)(SV;M."A975TRRYPV0PY]:EM_A7J]QK&
ME:EJ_B*&'5;> Q7%HB;VEAW$A@?NXYX)/.:=H,^M:CI]SIZ;KFUNMUK'$D9C
MV2%B58'J2"._J:M)X5\275AH<M_<V^F7UG(]O<+)<DRW<1.53_: ( 'H.0:[
M7.4;JZ7R\CGY4];-G-Z?X-\&Z7HPCO?$4LEM%=E[:YC 0BX.?W+!<[ 1WSCK
M7V;_ ,$[]2\-:3=>)M#TH7/VF0[QYLF]4VD[TS@'.6R,YX%?(GB#X;^&M&M]
M8EU3Q*L5M<7@FE2U4'RI#)D(<DX&05SZ&OH7]B/Q!X4T#XT3V>G17\TE]!L\
MZ64-$CL%$;#V(!7CH2*]#"5K8B$^9O7KMKI^ISUH?NY*W0_1.BBBOT ^="BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *.M:K%HNFSWDQ 6-> 3C)["OA+X
MI>.I_B%XJGG,I>Q@=EA'9CW?\>WL!7NG[4WQ ;3M-30[27;-<90[3R!CYS^1
M"_\  C7S5I-ENV\5^>YQC'B*_LH_##3Y]7^A]OE6%5&C[66\OR+5C8%L<5T%
MGIO3BI]-TW('RUTMEIG3Y:\3V9ZKJ&5;Z;QTJ]'I^W'%;L.G<=*\U^/7QX\-
M_ #PZEWJO^G:S=*?L&CPL!+.1_$Q_@C!ZM^ J/8RG)1@KMB]LHKFD]#MI)+'
M1;&6_P!3N[?3K" 9ENKJ01QH/=CQ7E[?MW_"[3_&VC>&-&-WX@EO[V*SDU.)
M1#9V^]@H;<WS. 2.@'UKXI6;XP?MP>/#8V$$NH0Q-_Q[1L8=,TU">"YZ9^N6
M-?;'P9_X);^"/"=E;:EXWU2Y\7Z[&1(+:W8V]C$PY "@[GP>Y/;I7T%#*'[-
M\\K2:TMT??SL>%BLPYG:*T/H^;6+F//W(5'!SQ^IJI_PD)+;1?P;O[OG)G^=
M<=XT_9]O/%&J-))>W!BSPGF-C\JSK?\ 9+M54%G?=Z[C7Q4>#,[FN:MFTE+^
M[%V_]*7Y'.\PH]*/X_\  /3(]8O%&X.'7UQD5B^./CIX6^%NGV-[XTU"'2+"
M\N5LXKAE+ R$$\@#(  .3VKC_P#AG75M"83:3J][9R)ROES-C\J\F_:!_9/\
M9?'ZQTJVO_$9MKK2%D^R^;"##*SXR9 .<X &X=J]++<CXAR_%P5;&JM0UYKK
MWMG:V_6WVOD9U,5AZD7:#C+\#ZSB73/%&BP:MH]Y;:GIUP-T5W9RK+$_T9>*
MYV[T\PN<"ORVTGQ'\:?V#_'BVDJS:?;S-EK&9C/I6IH.NWMGW&&%?HG^S_\
MM&>%?VEO#+WVD?\ $NUZT4'4=#F<&6W)XWH?XXR>C=NAK[F5&SO$F%1VLSK)
M+4.O2L74M)$BGBNTFLMO:LZZM-P/%:1C=68<UGH>7W^FF-CQ69#)/IMY#=6T
MC07,+B2.13@JP.0:[W6-/&"0*Y&_M2K'BL'!Q9O&5SZP^&/CJ+QSX7M[T82Y
M7]U<1 _<D'7\#U'UKL5>ODKX*^,&\)^-(K>:0K8:D1;RY/"OGY&_/CZ&OJZ.
M3/L:]JA5YH:GD5Z7)+0M@TX&H%>I%:NU,XVB4-3JC!IZFM40Q:***8@HHHH
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M'3FMJUFW 5QM&9T=O-FKT;5AVLU:D,F16;)-&-JEJK&U65-2(=1112 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\S_V^_A3J^E_$=M3DF6XT'6B[[<@LC'!QCJ"&!^HK],*^*_\
M@HSX1\076AZ5KNFQ^?IB;;:[Y^YR6Y]B.F.^:\?-(<U%32UBU\NAVX25IN+Z
MH^!_!^GZ#X%N-+G@DA:ZFN9/)N+MB8T(Z@^Y("Y[9[UVNAM-X^-X8;&VM-6
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M?)YMC=0)+"^,90@$?0UH5^FQ:DDT?+/1V"BBBF(**** "BBB@ HHHH ****
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M=.:U[:3IS7.V<F0*V+63I6+)-J-JM1M5"%NE7(VJ"2S12+2U(!1110 4444
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M10 4444 %%%% !115#7=<L/#.CWNK:K=Q6&G6<33W%S,VU(T49))HV ^ O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%%=YR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** &$4QA4K4PBH:+17=:@DCS5QES43I6$
MHFD64'2LN^T6RO,^=:0R$]25&:W'CJ!X_:N.I34E:2N=,)N.J9Q=WX!T.X8L
MU@H/?;67-\+_  \3G["OY#_"O09(:KR0UYDL#AW_ ,NU]QW1Q59?;?WG#Q_#
M_1K?'EV@7\JMQ^'[.W $=N@_#-=,UO4+6XJ%A*4/ABE\BWB*DOBDS$^Q!>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J*
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M?]]/_C3ES_SS7_OI_P#&M'[+_G-*+6@"DK'_ )YK_P!]O_C4R.?^>:_]]/\
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MEI-P]:-P]:HD6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH
M6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHH 6BBB@ HHHH 2O@3]MC]OC4_ ?BB
M]\ ?#F6*+4[+]WJ>M,H?R)".8HATW#N3T/%??$TGDV\DF,[5+8^@K^>_Q+J5
MQK'B76+^[E::ZNKZ>:61CDLS2,23^)KZ7(\'3Q-64ZJNHVT\W_PQV8>FIMM]
M#L[[]HSXHZC<O/<>/-;>5CDD7)'Z"H/^%_\ Q+_Z'K6__ IJR?AM\-=?^+/B
MVT\.>'+)KS4+@Y]$C0=78]@*^TO#?_!.'PS9V,8\2>+;JZU$C]XNG1#RU;N
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M_P#@4U'_  O[XE?]#UK?_@6U??G_  ZP\"?]#/JW_?*T?\.L/ G_ $,VK?\
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M $/6M_\ @6U'_"__ (E?]#UK?_@6U??W_#JOP+U_X2C5<?[BTO\ PZK\"?\
M0T:K_P!\BC^ULN[?^2A[>C_2/@#_ (7_ /$K_H>M;_\  MJ/^%__ !*_Z'K6
M_P#P+:OT _X=4^!/^AHU7_OE:/\ AU3X$_Z&C5?^^5H_M;+NW_DH>WH_TC\_
M_P#A?_Q*_P"AZUO_ ,"VH_X7_P#$K_H>M;_\"VK] /\ AU3X$_Z&C5?^^5I?
M^'5'@7_H:-5_[Y6E_:V7=O\ R4/;T?Z1^?W_  O_ .)7_0]:W_X%M1_PO[XE
M_P#0]:W_ .!35^@#?\$I_ VTX\4:J#V^5:\$_:(_X)T^(_A1H-UXB\+7Y\3Z
M/:J7N(-FVXB0=6QW ]JWHYCE]:2A&R;[JQ4:M*3LCR7P'^V1\7OA[JT-[:>,
M+S48D(+V6I-YT,H'8@\CZBOU?_9A_:)TG]I+X;Q>(+&+[%J=N_V;4M.+9-O,
M #QZJPY!_P *_#>ONK_@DSK%Q#\3_'.EAV^RW&D17+1YXWI,%!QZXD-89Q@:
M,L/*M&-I1[$8BG%P<DM4?IY7/^/O'.D_#7P9J_BC7;@6NE:7;M<3R=\#HH'<
MDX 'J1705\??\%1M6N+']F^WM(79([[6[6*;:<;D4.^T^V57\J^'PM%8BO"D
M]FSSH1YI*)\8?&K]OKXG?%/7+AM'U:;PCX?#G[-86!"R;,\&1^I;Z<5Y/_PO
M_P")?_0]:W_X%-7 U[]^SO\ L@^(?CE9MK=U<KX?\*H^S[?,N6G8=1&O?ZU^
MF2IX3!4KRBHQ7E_5SV+0IK5:'G__  O_ .)7_0]:W_X%M1_PO_XE?]#UK?\
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MS_A?_P 2O^AZUO\ \"VH_P"%_P#Q*_Z'K6__  +:ON5?^":GP]/_ #,>L?\
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MUSX!_P"AFU;_ +Y6C^ULN[?^2A[:B?!7_"__ (E?]#UK?_@6U'_"_P#XE?\
M0]:W_P"!;5][_P##K?P#_P!#/JW_ 'RM)_PZX\!?]#-JW_?*T_[6RWM_Y*'M
MZ/\ 2/@G_A?_ ,2O^AZUO_P+:O8?V4[OXI_'SXNZ;HA\;ZZNBVI%WJEP+IL)
M IY7/JQX_&OI?_AUOX"_Z&;5O^^5KWK]GO\ 9Q\,_LX^']1T[09)KRXU"82W
M-]<@>8P ^5/H.?SKDQ6;8/V,E07O/;0SG7I\KY5J>J\?*JYVHH1=QR< 8%9G
MBG03XI\,:KHHO9M.-_;M"MW;N5DA8CY74^H.*U*-N:^'4G%W1YY^+OQ*\?\
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M^AZUO_P+:OOP?\$K_ A_YF?5O^^5H_X=7>!/^AGU;_OE:7]K9=V_\E#VU$^
M_P#A?_Q*_P"AZUO_ ,"VH_X7_P#$K_H>M;_\"VK[]'_!*WP(?^9GU;_OE:7_
M (=6^!/^AGU;_OE:/[6R[M_Y*'MZ/](^ ?\ A?\ \2O^AZUO_P "VH_X7_\
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M?_Q*_P"AZUO_ ,"VK[7'_!.GX<G_ )F'6O\ OE:</^"<OPZ/3Q#K/_?*U/\
M:V7=O_)1>WH_TCXF_P"%_P#Q*_Z'K6__  +:C_A?_P 2O^AZUO\ \"VK[<'_
M  3C^')_YF'6O^^5IW_#M_X=?]#%K/\ WRM+^ULN[?\ DH>WH_TCXA_X7_\
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MQXFU8#M\JU]-EN98:G1]GB5JMG:^AVT:T(QM,^"?^&@/B3_T/.M?^!34?\-
M?$G_ *'C6O\ P*:OO;_AUKX#_P"AFU;_ +Y6C_AUGX#_ .AGU;_OE:]7^U,M
M[?\ DIO[>C_2/@G_ (: ^)7_ $/.M?\ @4U)_P +_P#B5_T/.M?^!35][_\
M#K/P'_T,^K?]\K1_PZS\!_\ 0SZM_P!\K1_:F6]O_)1>WI?TCX'/[0'Q)_Z'
MK6__  *:D_X: ^)7_0\ZW_X%M7WW_P .L? ?_0SZM_WRM'_#K'P'_P!#/JW_
M 'RM/^U<M[?^2A[>B? G_"__ (E?]#UK?_@6U'_"_P#XE?\ 0]:W_P"!;5]]
M_P##K'P'_P!#/JW_ 'RM'_#K#P)_T,^K?]\K3_M;+NW_ )*'MJ)\"?\ "_\
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MB@!-M.HI=M "4H6EI0* $IVVEHQ0 4H6EI: $I:7;2T (%I:*4"@!*<%I:*
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M>'?%VA^,+62YT+6+'6;>-S&\EC.LH1AV.#P:UL5FTUHR0I0M+BBD 44M*!0
MF*=110 4N* M.H 2EHI=M "4NVEHH *6@+3J $"U^1__  4X_P"3G9/^P/:_
M^S5^N-?D=_P4X_Y.=D_[ ]K_ .S5]'D/^]_)_H=>%^,S_P#@FO\ \G7Z+_V#
M+[_T6*_82OQ[_P"":_\ R=?HO_8,OO\ T6*_82JS_P#WM?X5^;#%?&%%%%?-
M'(07O_'C/_US;^5?ST:C_P A*]_Z^)?_ $,U_0O>_P#'C/\ ]<V_E7\]&H_\
MA*]_Z^)?_0S7VG#G_+WY?J>AA/M'Z3_\$WUW?L]:O_V,4W_HF.OJ98Z^7?\
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ME]4SSBN^]@,#H .U8RK7HJGUO_2_-DN7NV"BEVTZN4S$"TM%+B@!*7;2XI:
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M3TNRU+R&WQ?;+=9?+;U7<#BG+%KF:5[:ZWUUMM]PW4U/RG\'V=Y-^R#\3O\
MA$;;5T\)+\28Y-4M[<.+TZ*!\P_O9QY>?;.:^L_@/J'[+-_\3O#J_#"QMXO%
MT=C*;22SAG39'L&X3$_+NQG[WO7U/I^AZ;I:7*6.G6MFETYDG2"%465CP68
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M>V&J^&;W[3 ##&TDD,H_A;8K$'OBM9X.I'F:U2_0ITY*Y]?LP526(51R68X
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M)Q1&A.4I0ZH%%MM'VW2U\V+^W)X7OO /PO\ %>F:-?7EIXXUS^P%@=@DEA<
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MI3@KR5B7%K<Z#;3J*6LB1*6EVTM !112[: $IP%%+0 4444 %?D7_P %./\
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MS?\ HZ2O=J\)_87_ .32_AM_V#F_]'25[M7QV,_WFI_B?YG!4^-GX,_M"?\
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M5^._ACQ5\3?&7A=?'EE=:Y+X\N+XR0Z])XEBAMDE$F!;FS8C"_P[37U;\/\
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M_P ,?"_C;6)=.UWX?7&K0SZY>&X-KJ&\1K/N;IAB6/U]J\C^'OBK7? WPO\
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ML8([6VA48"1HH51^0%7<GD"C;4RJ.45![+]0<FU8\UT/X ^&=%^(7Q$\6O\
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MWDN+*Z7>R$P,H.<LA '4XKE/CC^VE86/[.<'Q,^%FHV6J)_;UMI-Q_:,##R
MY;S%>,D%6  //K7.Z-X+_P"$@_;(^"?B73/ -[H/@NS\#2I%:7ECMCTN0R3[
M(7'*I( W3K\U>)_$3X,^+)OA!\:M)LO!^J,M]\5H+ZSLX;-OWUIE]TJ*!S'S
MU'%=<*-%R5]]/3>UC51C='V[\)_VJOAM\:?%%[X;\+ZZUSK5I!]H:WN+=X?.
MB& 9(BP&]1GJ.QKEM=_;Z^"7AW5=7L;GQ1+*=+WK/=6]G));M(O6-) -K/[
MURGQ&^%6H:E^VAX*NM&T>;3='D\!:CI4VK6EN4@MI7CD2)68# (W# ^E?/\
M/;>.?!?[(_B;X!7'P+UC4/$]K%.AURSM5DLIU,I<7:R=6DQP .>E1"A1FTUU
MMI=:;W$H19]A>,/VS_A5X#N=!@UK6+JVEUW2$US3U6RD<S6[9VX 'WS@X7K7
M2^$/VDOASXV^%][\0M/\2V\?A2P9DO+R[!A-LZXRDBMR&Y&!WR*^;?AU\,]<
M_P"&IOV?]3U/PU=MI>D_#=;:YNKFU)BM;L1L C$C"R GH>>:X.X_9Q\;>+?A
M+\>-'T;PW-#<1?$M=?L-'NHS!%JUI$ 3''GAE;J,<$BE["CHKVV_.PN6.Q]8
M?#']L;X5_%SQ9!X;\/ZU<G5[D,;6*]LI8!= #)\MF #<<\5!XP_;8^#_ (&\
M9W'AG5/$S?;[67R+R>VM9)K:TDS@K+*H*J1WR>*S?A#\>]0^)7C/1]&_X49X
MA\)1V]NZ7&L:E910PZ:P7A8FQEE)X^7VXKXBD_9_^(7PUG\7>!M6T_XD7PU;
M4KB2,>%K6WGTS5(9')$DLC\JQ!YSTIT\/2E)J6GE=#4(MZZ'Z._%;]H;P#\%
M?#NF:WXGUV.*TU3']GQVBFXEO 0&S$B9+#!!R/45YE\$?VKA\<?VD/$_A;P_
M<VM[X&L?#UOJ5K-Y#1W2W+,JR))NZ8)(VXXKRSQQ\%_$?P!\2_ CQQIOA75?
MB3X=\%Z%+HM]I11)=0M&D+.DRQ@E69=^SC_GF/:MO]F>+Q'XH_;0^(OCW4/A
MUJ?@+1-8\.6Z6J7]L(C,RN@WN5&T2, 25ZCO4JC35.4EKIOIW[;BY8\K9[+\
M8/B#K6D_&_X2>#M \26>DRZO/=7NIZ?<VC2M?64,>7".!A".>N,_A7/Z9_P4
M"^".K:IIUC#XFF22^NS9+)+92K%%+OV 2.1A-QZ9ZCFL+XJ:#XBO_P!LJT\1
MVFC7T^E^&OASJ4EM>1P,T4EY*S*(4;H9",?+UYKQ./X#:UIW["_P?\(P^$KL
MZ_KGBZPO-<C6T/VB%6N9)&DFXRH5 BDGH,4X4J4HQYO+\;_\ %&-E<^_?&7B
MFQ\!^%-8\1:KYJZ9I-K)>7301F1UC0;F(4<G !/%<5??M'^!-/T/X?ZK_:4U
MU!X[FBAT&&U@:2:Z,BA@=@&5 !&XGIWKT?6--M]<T^^TZ[026EY#);S*>C(Z
ME6'Y&OB/]AW]G#Q7X3\5:CXD^(4-Q)!X$^U^&_!UC<(?D@$KO+<H#UWA@JMW
M&?05RTX4Y0E*3U7X_P!,B*33;/1_AW^TY;6?BSQ;<^+?%L&H^&M3\;?\(GX:
M%KI\D?V*X13OAF?&""2N'Z$@\U[#%\;?"4WQ+USP*FH,=<T/3UU/5&\L_9K*
M%NGF2_=5B.=I.<<U\;:'\"_%&N?\$^_%"S:)?6GCI/$MYXOL;&6!A<_:([O>
M@"=<M&IP.^17=Z?^R[XP;]B_XAZ?+,UQ\7_B!;MJ^L7#MM>6=BKBTSV C!CQ
MTRQKJG2HWO>VMORU]"W&)ZIX1_;>^#OC;QO:^%M+\4;]0O)?L]G<36TD=K=R
M9QLBE8!6)[8/->K?$3Q]H_PL\$:SXL\0326^BZ1;FYNY(HS(RH"!PHY/45\,
M7UAXN_:,\&_##X5:1\&]3^'\?AK4+"ZU;7M6M4@@LEML;_LS#EV<CMU[^M?2
MW[='_)HGQ5YX_L63G_@2UE4HPC.,5U?>_P#5R912:11\*_MX?!CQAXHTK0;#
MQ/)'=:H4CM+BZM)(K>21L8B$K#;OR<8SUKH/BY^UI\,_@CXABT'Q-K4O]M/&
M)GL=/M9+J6",]'D" [ ?>OC*_;Q=^T%^SS\,_@_H/P;U'0=10Z;=-XHF@1-.
MMX(]KFYBE'):11DCK\QZU)\<_@OX^^'/[27C[Q4@\>W.B^*A%+9:GX'MH;F1
M\(%:WN%DY4 CC'&*Z5AJ7/9NV^EU_7_#%^SC>Q]G>+?VLOA?X+\&>&/%E_XC
M23P[XCD>+3K^UC:5'94+LIVCY2 I&#WXZU3D_;!^&RZSI&E+>:E-?ZA9VU\8
M8--FD:TBN,>2;@!?W1;(X;'45\HV_P"S=K'A#P/^SI86V@>(;ZWD^(J:[JMA
MK%NDDFG1/M#^:(\JJ';N.?[QK>_:Q^&_B"']H>'Q=\(M/\8Z/\3&FL89I;:R
M)T;58!@,SRYVKL4 ,&X...14*A1<E&_?\Q<D;V/9]'_:"/A+XQ?''_A-?&^G
M'P7X0ALIH[%+)XY=.$JCAI,8D+D@ #/)%8?[0W[<&G^#_P!GO4_&G@:.Y&NK
MJ%OI]I!K6ES1()'*NV]2%P##O(;.,X]:X'Q%\*6\0?%+]J<>,?"'B#4_"NN6
MNCB$Z/:EIKEXT4F2VSPYC<;C]*\VNOAW\5KS]BOXP^%;JV\2>*-"BU;34\'K
MJUDZZG/;+<QM*3$<NJ@ 8!Z8;'%:0HTFXR?]WTV7],I1C=-^1]AZI^V=\-/"
MWPX\(^*M=UB:W_X22U%Q96$=G(UW,!\KL( "X4,#R16K)^UK\,E^#M[\3HM>
M-SX4L9DM[J6&!VFMY6<($>+&Y6RPX([U\H_M4?!/QQI?QL\)?$O38?%DFA?\
M(U!I<LO@V".;4-.F0<KY3\;&W9)'.<URVK_L]^)+?]CCXP:I8Z-XTO/$'C#4
M;"0Z5KUM%]LF$,ZG[0(HNA96.<@'Y*E8>A*,9<V[7Y[?(7)%I.Y]H_"_]L3X
M5_&#QO\ \(GX9\0-<ZT\!N;>*>VDA6Y0#+&)F #X'7'H:R_&W[=/P=\!>+KK
MP[J/B22>^LY?)O);&TEN(+1QU621%*J1WYKS7QA\,=2M_P!I#]E_4=*\-W%O
M8:5HMW::A=VEJ5CLP;0!%D(&%^8G /?-<-\%=<\7?LG^&=?^&FO? [7/&^IS
M:M<W-MK6D6J3VNKI*Y96FD;[IQQSG%0J%*6L==-KKNUO\OQ%RQZ'U;\3/VG?
MAS\)?#>BZWK^OJ+;6HQ+ID-G$T\]XA4-NCC4%B,$<XK=^$7QJ\'_ !Q\.R:S
MX/U5=2MH9?(N(V0QS6\G79)&P#*<>HKXW_;$^$7CC5/BW\/_ (JZ5IGBFST:
MWT(6%U9^%(H9M3T>4DN L;94J=^TE>Z_2O1?V#?A#?>%[[QMX[U%/&%G>^(I
M(H7A\710PS7(CR5N-D9X;YBO(_.HE1I*CSIZ_P!:"<8\E[ZGU[1117GF(444
M4 %%%% !1110 4444 %%%% !1110 4444 ?B?^W+_P G6?$#_KZC_P#1*5[-
M_P $G_\ DM7B_P#[ '_MQ'7C/[<O_)UGQ _Z^H__ $2E>S?\$G_^2U>+_P#L
M ?\ MQ'7Z1B?^13_ -NK]#UI_P #Y'ZE5\9?\%4_^3?=&_[#\'_HJ6OLVOC+
M_@JG_P F^Z-_V'X/_14M?%99_OE+U//H_P 1'Y7Z7_R%+'_KXC_]#%?OW'_Q
M[V__ %QC_P#0!7X":9_R%+'_ *^(_P#T,5^_D(_T>W_ZXQ_^@"OH>(_^77S_
M $.K%_9%I0O?MVQ7!?'CX=ZM\5OA#XD\)Z%KTGAG5M2@6.#4XB08R'5BI(Y
M8 J2.<&HOV?/AOK'PB^#_A[PEK_B"3Q/JVGQNLVI2ECNW.6" MR54$*"><"O
MC^6/)S7UOM^IP65KW/0Z^7O%G[77C*Q^,7C?P1X2^$U]XU3PB8&O[FQO$1]D
ML>]2$/?[PQ_LU]15\,>%_CQX,^ O[:'[0]WXSU.72X]2&EK9[+=Y&F:.$EPN
MT'D;E_.M\/!3YO=YFEM\UV+@KWTN?1?PR_:@\"_$?X9'QK)J*^&[*WO/[-U"
MVUAA#+8WF<>3)GN21CUKT*]\;^'],URVT6ZUBSM]6N;1[^&SDE DDMT!+R@=
MU&#D^U?G'XN\!>(_B%^S'\?/B';^&KZRTWQ3XRM/$6EZ7)"5N#9P2_/,8^OS
M!B?^ FO1+7XAZ3^T-^U'I'BKP5%=ZCH'AGX:ZA9:E?R6KQQPSR1R;8LL.6^;
M&/8UT2PL=7'97^6BT_&Q;IK5H^RM#^*W@SQ-:W=SI7BG2K^VM+9;RYFAND*0
MPMG;(YS\H.#C/I530_C;\/O$EYIUKIGC/1;^XU"X-K:Q6]VCM+*.2B@'DXYK
M\[])^%YMO^";/@S6=#T*>2.^UFWO/&"Z<A^UWVGQ7$JE6QR548^7I6Y=:Y\%
MO$_[67[/5S\'- _LZ&#4RFHW%M926\!^3]W&VX<R+\V3UYYI_5(>]9O2_P"'
M?U#V:/JSX6_MA^%/&5UXUA\2W6G>"SX?\13Z!!_:%\@-Z8V(\Q0<8!Q^%=/\
M0_CU%X'^+?PL\&0:<NIP^.9;A$U&*<;;=8TWA@/X@<]J^"/AAX@^!7AWQ-\?
MH_B[X<DU+5KOQ/J2Z?--923"2+S9/W4# 867=SGKROI72?"#P_XI\/ZM^QK9
M^)H+JWU!;O6I+:&\!,D%LP8VZOGD?*1@'MBM)86G%MVT_P#M6]"G35_Z['Z
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MHV]5.1Z8K!U+X3^'?"O[+G[,7CC3-)^S^,[SQ/I4MWK2[C=R^8SEE=^NT;4
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MQ]X;UKPR_B.PUW3[O041I'U*&Y1H%4=27!P,>]9-O\:O =YX4O?$T'BW29M
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M"N!@<8.1[&E]4C?KZ==[![-'Z!^(OB1X6\(_V4=:\0:?IBZJQ2Q:ZN%1;@@
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M>STNQTV&2&SL;6TAD.9([>!8U?/'S #G\:M;32A: (+2RMK"V6VM;:&VME!
M@AC5(P#U&T#&*@M_#^E6IA,.E6,)A<R1&.U13&QZLN!P?<5?5?04JJ6IW8&>
MWAW2'R&TC3VS)YQW6D9S)_?/'WO?K5J:PMKJXAN)[:&:X@R89I(U9XL]=I(R
MOX58V[:*+L"K-I-A=7D=Y/86L]Y']RXD@1I%],,1D5;Y8Y-+BEI 4[C1=.NK
MA[B?3K.>XD0Q/-+;HSLA&"I8C)&.U"Z/I\<EM)'I]JDEJNRW=8%#0KTPAQ\H
M]A5W;2T[L"C)H.F3+=+)IMG(MT0UPK6Z$3$="_'S$>]0:QX8T[6K&]MY8!;2
MW5JUFUY: 17,<;#&$D RN.H]"!6MSZ48HNP/D2?]@2\\0W-OIGBSXL:YXF\%
MPW<=T^CSVL23W>QMR)/< ;G /K7UE=:18W]K':W5C;75K'C9!/"KHN!@8!'&
M!5K%+6DZLZEN9[%.3EN5;C2[&\LUL[BRMI[-<;;>2%6C&.F%(QQ3GT^TDNH;
MI[2!KJ%2D4[1*7C4]0K8R!["K.TTNVLR1K('4JP#*1@JPR#7$?%#X4:=\0?A
M/XN\$68M] @\06$UE)<6ELH"&12I<J,;CS7=44XR<7=#V.)^$OPOL/A9X!\,
M>'D\C4+S1=/CT\:HUNJ32*BXSGJ,^F:ZV_TJRU:-([ZRM[V-#N5;F)9 I]1D
M<5:VTM#DY.["_48L*+$(@BB+;L\L*-NWIC'I5:PT73M)61;'3[6R67_6"WA6
M/?\ 7 YJY2@5(BA#X?TNW^S"+3+.+[*S/!LMT'DLWWBG'RD]R*L6NF6ECY_V
M:T@MQ.QDE\J)5\QCU9L#DGU-6:*=V!3T_1=.TEI&L;"ULFD.7-O"L9;ZX'-2
M76GVE^T+7-K#<M"_F1&:,.8V'1ER.#[BK.*7% %*/1=/CCND6PM42[):X585
M F)ZEQCYOQI6T33I+>V@:PM6@M65X(S"I6)AT*#'RD=L5=HHNP*<>C:?"+L)
M8VR"\)-SMA4>>2,'?Q\W!/6FMH>FO:V]JVGVK6UNP:&$PJ4B(Z%5Q@$>U7J*
M+L"G>:-I^H7$,]U8VUS/"<Q230J[)_NDCC\*?/IEG=7<%U-:02W4&?*FDC5G
MCSUVL1D?A5C(Y&>:6C4"M;Z;:6MS<7$%K##<7!!FECC"O(0, L0,G'O4=CHN
MG:;-+-9V%K:S2_ZR2"%49_J0.:NT4 5[[3K35(1#>6L-W$&#B.>,.NX=#@CJ
M*6]L;;4K=K>[MXKJ!OO13('4_4'BIZ*0%6/2K*&Q^Q)9VZ6>-OV=8E$>#VVX
MQBO-?C_\![#XV?!/7?AW;7,?ANTU,1@3VMLI6+;(K\(,#G;^M>J4549.+4EN
MAWMJ8/A+P?8^$]'TVUB@@>[M;.&S>]6%5DF$:*N6(YYV],UI7VCV&J21/>6-
MM=O"<QM/"KE#Z@D<?A5RBE=WN(K76F6=]-;RW-I!<2V[;X7EC5FC;U4D<'W%
M-.DV+7,]P;*W-Q<((YI?*7?(HZ*QQDCV-6Z* *NG:79:/;^186<%E!DMY5O$
ML:Y/4X QFF6FBZ=874MS:V%K;7$O^LFAA57?ZD#)J[11< HHHI >4_M5_P#)
MN/Q$_P"P//\ RK\+D^ZOTK]T?VJ_^3<?B)_V!Y_Y5^%R?=7Z5]YP[_ GZ_H>
MEA?A9^V/["__ ":7\-O^P<W_ *.DKW:O"?V%_P#DTOX;?]@YO_1TE>[5\=C/
M]YJ?XG^9P5/C9^#/[0G_ "7KXB_]A^\_]&M7VI_P2?\ ^0!\3?\ KYL?_09*
M^*_VA/\ DO7Q%_[#]Y_Z-:OM3_@D_P#\@'XF_P#7S8_^@R5]YF?_ "+'Z1_-
M'IUOX/W'WI2XI=M+7YP>2)BEHI0M %>]T^UU2$0WMI;WL(.1'<Q+(N?HP-36
MUO%90I#;PQV\,?W(X4"*OT X%2*I/04;3Z8H K6^F65I=2W5O8VMO=3?ZR>*
M!4D?_>8#)H72K%=0-\MC:K?%=INQ HEQZ;\9Q^-6MM+3 @M["ULY)I+>U@MY
M)FWRO%&JF1O[S$#YC[FK _3I2[:6D!5L-)L=*\S[#8VMD9#F0VT"Q[S[[0,T
MS^P=,^S_ &?^S++[/YGG>3]F39YG]_;C&[WZU>"TM.[ K7VEV6JPK%?6=M?1
MJ=RI<PK( ?4!@:LJJI&(U15C"[0BJ H7TQTQ2XI0*0%33]'L-*:0V-A:V+2<
MNUM L9;Z[0,TS_A']*^S"W_LNQ^S^;YWD_9DV>9G._;C&[/?K5^E4%LX&:=V
M!%-:P7$T,LL$<LL)+12.@9HR1@E2>A(XXI+NQM]1MVM[NWAN[=OO0W$8=#]0
M1BI]M+2 BM;6"QMT@MH([>!!A8H4"*OT X%,OM/M-4M_(O;6"\@R&\NXB61<
MCH<$=:L4H% %!O#^ER)<(VEV3)<A1.IMTQ*!T#C'S8[9J9M*LI)+5WLK=WM?
M^/=FB4F'C'R<?+QZ5;VX'M13NP*EQH^GWETMU<6%K/<JI19I859PIZ@,1G'M
M4MG9V^GVT=O:6\5K;QC"0PH$11Z #@5,!3L4 4[;1K"SO)KR"PM8+N88EN(H
M561_]Y@,FBZT33;ZZCNKG3[2YN8_N330*SK]&(R*NT478%>^L;75+=K>]MH;
MR!CDQ7$8="1[$8JNWAW2G6=6TNR*SHL4P-NG[Q%^ZK<<@=@:T=M+1=@4[K1[
M"^M([6YL;:XM8\;(9859%QTPI&!BF-X?TMH[J-M,LS'=8^T(;=,38Z;QCYL>
M]7Z7;1=@4K71=/L[HW-O86L%RRA#-'"JN5'0;@,X]JFM=-M+*2XDM[6&"2X;
M?,\<84RMZL0.3]:LT47 I:?HNGZ4\KV5A:V;RG,C6\*H7^N!S4E_IMIJMOY%
M[:PWD.X-Y=Q&'7(Z'!'6K-% %9]-M)+Z*]>UA:\B4I'<-&#(BGJ V,@'THM]
M-L[.2XDM[2""2Y;?.T<84RMZL0/F/N:LTF1R,\T@,V'PSH]OY1BTJQB,4GG1
M[+9!L?\ OC X;WZU-'HNGQ+=JEC;(MX2UR%A4><3U+\?-G/>KM%.[ I2Z)IT
MVGI826%K)8J %M6A4Q#'3"XQ2S:-I]S8I936-M+9IC;;O"IC7'3"D8&*N447
M8%6_TNRU6%8KVSM[R)6W*EQ$KJ".A (ZTMKIMG8RSRVUI!;RSD-*\4:J9"!@
M%B!R<>M6:*0%&ST/3=-N)+BTT^UM9Y/ORPP*C-]2!DU+::;::>T[6MK#;-._
MF2F&,(9&_O-@<GW-6:*=P*=CHVGZ6TQLK&VM#,=TA@A5-Y]6P.?QJ/\ X1W2
MO[/-C_9EG]B+^8;;[.GE[LYW;<8SGG-:%%%V!5CTNRANYKJ.SMTNIE"2S+$H
M>11T#-C) ]Z\S^-7P(7XH^%K'3-#\2:AX#O-/G-Q;7&BA5B8G[R2PD;9%/7!
M[UZM151DXNZ&FUJ?/7P+_9*7X7?$"[\>^)O%UYXX\7R6/]FVUU<6\=M#9VV[
M<4BB3@9/4^Y]:^A:**<ZDJCO)@VY:L*_(O\ X*<?\G.R?]@>U_\ 9J_72OR+
M_P""G'_)SLG_ &![7_V:O?R'_>_D_P!#JPOQF?\ \$U_^3K]%_[!E]_Z+%?L
M)7X]_P#!-?\ Y.OT7_L&7W_HL5^PE5G_ /O:_P *_-ABOC"BBBOFCD(+W_CQ
MG_ZYM_*OYZ-1_P"0E>_]?$O_ *&:_H7O?^/&?_KFW\J_GHU'_D)7O_7Q+_Z&
M:^TX<_Y>_+]3T,)]H_4'_@ES_P D!UW_ +&"7_T3'7V%7Q[_ ,$N?^2 Z[_V
M,$O_ *)CK[$VU\_FG^^U?4Y:W\1G.?$/QM8_#7P+K_BO4XYYM/T:SDO)H[9-
M\CJHSA1ZFN2_9Q^/VC_M*?#6+QEHFGWFEVQNI;.2UO@-Z2)@G!'####D>]>F
MW%O%=V\L$\23P2J4DBD4,KJ1@@@]01570]!TSPWIL6G:/IUKI.GQ9\NULH5B
MB3)R<*HQR:\^\>1JVIEI8O5\I_MX^*I=:T_P5\'M-UZ+P[J/CF_S>ZG)/Y(L
M]/@^>20MD8W,% YYP17U=7S[XA_9#T+XH_'#Q/XY^)D-AXPTJXLK?3M"T65)
M FGQ)EI&8Y&79B3QQR:UP\H0GSSZ?G_6I4+)W9YE\._BI>>.OV ?B-IVH:CY
M_BGP;I.H^'M0N(9]S,T",(I@X/.Z/:0P/)!KA_A;^T1\9_@K^S3X!\9ZMX'T
MR_\ A7I]G;6]U<M?L^K/"S[1=%3P 2W .3T]:]I;]BNW\+ZM\2[7P'?:?X9\
M&>-O#!TB70O+D9;:^ 94N5.3\NUCD=>:XO2_V%?B1??#WP_\,O$WQ@CU'X86
M1A:[TJTT_9<S!&W^0LI_Y99 QGD?A7>IT'>[5F[ZW[:[=3:\#RS]HCQ!IU[J
MW[6MYH^GKI]XOAW0;M=7M[F59KA)I(F&5SA>".E,^)&J7\6L_&\>&])LX?$,
M7PPT66\UB>[F662U>&#S\#.!($'RD=2!ZFO?OB/^Q/J'C/4/C9+8>(;'3[3Q
M]I.EZ78PO"[?81:,AR^/O A,#%7-4_8ZU74-<^)5^OB2R1?%G@FS\*0H87S;
MR0Q)&9F]5)0G YYIQKTDEKV_]M_R8*4?Z^1QGP#^.WCWX;>%?V=]'\;V>D_\
M(?XQLCIEOJEO)(\\,HC5K/S78XW2*<-[YKVWX _&S6OC=XN^(]W#96D/@'0]
M5.C:+>QAO/OI8ABXD)/&P-@#'K7C7[77P_A\#_L/^$_AY.SZOXNMIM*T?0)K
M!"KOJ*,JB1.ZKM#Y]C7TM\"_A59_!/X2>&/!=GM;^R[15N)AUFN&^::0GN6<
ML:YJSIN#FEJVU^-[_H1*UKGROXF\0>/=*_X*7(RG34T"W\,^=(DES)M&DJ09
MI=@X^T!]V!C[H%6U_;(^,&M^ ]2^,'A_X<Z1<?!VPDEDVW-Z4U6YM(G*R7"K
M]T 8)Q[&O<M0_9_GU/\ :B'Q3N-1MI=(;PP_AZ726C;S'+/N+[NFW'&.M>-O
M^PMXYT_PWJ7PVT/XMOIWP9U">1Y-%>P#WT,$C;GMTFZ;"21^-:QJ49*/-;1+
MO\]NI5XNUSZFT7X@Z/KOPYL_'$$KKH-SI8U<2,OS+ 8O-.1ZA<\>U?"GQ>_:
M*^-'QB_9;\>^-K+P-IFF?"O5-/N(;*YCOV358H0^P71 X*@@Y P?RK[UTCP3
MH^B>![3PC;6@&@VVGKI:6S'.;<1^7M)]U_G7R!JW[!_Q*B^&NO?"W0?C#':?
M#"Y67[#I=UIV^YC#-O$#R@_ZK<3D#DUCAY4HR;EW6]]OEU(AR]2#Q=^V-??!
M?P'\'/ OA]-%;Q3JWA2RU*XU7Q3>F"QM(#$ ID?JSN5;\JDTO_@H)JFJ? CX
MJZTFGZ')X\\!I;RO]@N3<Z7?132JBS1.,$CE@1G@XKL/B9^P]-XNTWX>:KHN
MO:98^-_">APZ#)<:KIBWVGW\"(!\\+]"#N(/7YJX7X]? 6_^#?[#_P 6EU>\
MTG6_$.I10O)<:+HL5A&D8N(R(E5!EE!R>>F:Z8_5I\JMJW^OY6+]QV[FV_[6
MGQF^'UGX)\9?$CP!HFG?#GQ)<6EFTNFW;27MBTX'ER2*>,'.=H[<=:YGP?\
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M9]'LT@>11_K9<9ED/NSEC^-<E:--0YX[M_D]_P OQ,Y*-KH\3\=?MD:QX?\
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M2VWC*;QVR.E.S8&W2[:<%]*.:0!11@FG;3Z4 (!2TN#Z48/I0 4#-*%_&G4
M)BBN1T_XL^%-4^)FJ?#ZUUB*7Q=IMFE_=:: =\<+XPV<8/WEX_VA77A:;36X
M!2A:7%%( HI<5RWC#XJ>$/A[J&E6'B3Q%I^BWNJR>5907DZQO.V0,*#UY('U
M--)R=D!U(6G444@,/PWX(T#P?-J<VB:1::7+J=P;N]>UC"&XF/61\=6]ZW**
M*;;>K ****0!1110 445@^$_'?A_QTNI-H&K6VJKIMW)879MGW>3<(</&WHP
M[BG9[@;U%%>;>+_VC/ASX%TGQ#J.L>*;*VM?#]W#8ZH58NUI/*<1QN%!()Y_
M(TXQ<M(JX[-['I-%0VEU%?6L-S;R++!,BR1R+T92,@CZ@U-4B"L;0_!NA^&=
M0U:_TK2K6PO=6G%S?W$$85[F4# =S_$<>M;-%.[ ****0!116%XX\;:+\-_"
M6J>)O$5ZFG:+IL)GNKJ0$B-<@9P.3R0/QII-NR W:*X[P_\ %_P=XIU#0[#2
M_$%G=7^MZ8-9T^U5\27%F>DRJ>=O-=C0TX[H HHHI %%%% !7Y%_\%./^3G9
M/^P/:_\ LU?KI7Y%_P#!3C_DYV3_ + ]K_[-7T>0_P"]_)_H=>%^,S_^":__
M "=?HO\ V#+[_P!%BOV$K\>_^":__)U^B_\ 8,OO_18K]A*K/_\ >U_A7YL,
M5\84445\T<A!>_\ 'C/_ -<V_E7\]&H_\A*]_P"OB7_T,U_0O>_\>,__ %S;
M^5?ST:C_ ,A*]_Z^)?\ T,U]IPY_R]^7ZGH83[1^H?\ P2U_Y(%KW_8P2_\
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M!XHU'PW?OK4=\VY$2_=RS21@$<#. #Z5T?6(4XJ2=]M.VC+YTDF?,.I?#5/
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M"OR+_P""G'_)SLG_ &![7_V:OUTK\B_^"G'_ "<[)_V![7_V:OH\A_WOY/\
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M2?\ ^2U>+_\ L ?^W$=>,_MR_P#)UGQ _P"OJ/\ ]$I7LW_!)_\ Y+5XO_[
M'_MQ'7Z1B?\ D4_]NK]#UI_P/D?J57QE_P %4_\ DWW1O^P_!_Z*EK[-KXR_
MX*I_\F^Z-_V'X/\ T5+7Q66?[Y2]3SZ/\1'Y7Z7_ ,A2Q_Z^(_\ T,5_0/9_
M\>-M_P!<4_\ 017\_&E_\A2Q_P"OB/\ ]#%?T$60_P!!M?\ KBG_ *"*^AXC
M_P"77S_0ZL7]DEI=M+17Q9YX44M+B@!,4ZBB@ I0*7;2T )2T4H7UH 2G8HH
MH *6C;3J $VTM%+B@!*7;2XQ2T )2T44 %%%% !1110 4444 %%%% !1110
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MH6EQ10 =*6BE H 3;3L444 %+BC;3J $VTM%% !1110 4444 %%%% !1110
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M;-U.5:",@CO\HKZ'B/\ Y=?/]#JQ?V2Q2[:6BOBSSPHI0,TN* $VTZBB@ H
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MI7_04LO_  (3_&OY_/[8U#_H(7?_ ($/_C2?VQJ'_00N_P#O^_\ C1_JXO\
MG[^'_!#ZKYG] O\ PD&D_P#04LO_  (3_&E_X2'2O^@I9?\ @0G^-?S\_P!L
M:A_S_P!W_P!_W_QH_MC4/^?^[_[_ +_XT?ZN+_G[^'_!#ZKYG] W_"0Z5_T%
M++_P(3_&E'B'2?\ H*67_@0G^-?S\?VQJ'_/_=_]_P!_\:/[8U#_ )_[O_O^
M_P#C1_JXO^?OX?\ !#ZKYG] _P#PD6D_]!2R_P# A/\ &E_X2+2?^@I9?^!"
M?XU_/O\ VQJ'_/\ W?\ W_?_ !H_MC4/^?\ N_\ O^_^-'^KB_Y^_A_P0^J^
M9_00/$>D?]!2R_\  A/\:7_A)-)_Z"EG_P"!"?XU_/M_;&H?\_\ =_\ ?]_\
M:/[8U#_G_N_^_P"_^-'^KB_Y^_A_P0^J^9_03_PDFD_]!2S_ / A/\:/^$DT
MG_H*6?\ X$)_C7\^W]L:A_S_ -W_ -_W_P :/[8U#_G_ +O_ +_O_C1_JXO^
M?OX?\$/JOF?T$_\ "2:3_P!!2S_\"$_QH_X232?^@I9_^!"?XU_/M_;&H?\
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MW_W_ '_QH_MC4/\ G_N_^_[_ .-'^KB_Y^_A_P $/JOF?T$_\))I/_04L_\
MP(3_ !H_X232?^@I9_\ @0G^-?S[?VQJ'_/_ '?_ '_?_&C^V-0_Y_[O_O\
MO_C1_JXO^?OX?\$/JOF?T$_\))I/_04L_P#P(3_&C_A)-)_Z"EG_ .!"?XU_
M/M_;&H?\_P#=_P#?]_\ &C^V-0_Y_P"[_P"_[_XT?ZN+_G[^'_!#ZKYG]!/_
M  DFD_\ 04L__ A/\:/^$DTG_H*6?_@0G^-?S[?VQJ'_ #_W?_?]_P#&C^V-
M0_Y_[O\ [_O_ (T?ZN+_ )^_A_P0^J^9_02?$FD#DZI9 ?\ 7PG^->%?M'?M
MG>"/@AX:O!::I:ZYXI>-EL]-LY1)B0CAI".%45^-?]KW_P#S_P!U_P!_W_QJ
MJS%V+,2S'JS')-;4N'J<9J52=UVM8J.%2>K-#Q%K]]XJU[4=9U.9KC4-0G>Y
MGE;JSL23_.OLS_@D^I/QH\8-CY1H !/_ &\1_P"%?$7H.YX%?JE_P31_9[U7
MX9^"]7\:^(K22PU3Q(L<=I9S*5DBM$R0S ]"[-G'HJ^M>EF]2%+!3B^NB-J[
M4:;1]J5\9?\ !5)3_P ,^:.<<#7[?/\ W[EK[-KQG]KKX*S_ !Z^!>N>&;$J
M-80I?:=O.%-Q$=RJ3V##<O\ P*O@<#4C1Q5.<]DSRZ;49IL_#_\ 2OU*_8M_
M;>\.>+/!>E^#O&^JQ:1XGTV);:&[O&VQ7L:C"'>> X& 0>M?F#K&CWWA_5+K
M3-4LYM/U&UD,4]K<(4DC<'!!!JG@5^DXS!TL=3Y)_)GKU*:J*S/Z"H_$FD31
MAX]6L9$;D,MRA!_6I!KVE?\ 04LO_ A/\:_G[75+Z-0JWUTJCH%G8#^=._MC
M4/\ H(7?_?\ ?_&OG/\ 5Q?\_?P_X)R?5?,_H#_X2#2O^@G9?^!"?XT?\)!I
M7_03LO\ P(3_ !K^?S^V-0_Z"%W_ .!#_P"-']L:A_T$+O\ \"'_ ,:/]7%_
MS]_#_@A]5\S^@/\ X2#2O^@I9?\ @0G^-._X2'2O^@I9?^!"?XU_/S_;&H?\
M_P#=_P#?]_\ &C^V-0_Y_P"[_P"_[_XT?ZN+_G[^'_!#ZKYG] W_  D.E?\
M04LO_ A/\:/^$ATK_H*67_@0G^-?S\_VQJ'_ #_W?_?]_P#&C^V-0_Y_[O\
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MW_W_ '_QH_MC4/\ G_N_^_[_ .-'^KB_Y^_A_P $/JOF?T$_\))I/_04L_\
MP(3_ !H_X232?^@I9_\ @0G^-?S[?VQJ'_/_ '?_ '_?_&C^V-0_Y_[O_O\
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M$_QH_P"$DTG_ *"EG_X$)_C7\^W]L:A_S_W?_?\ ?_&C^V-0_P"?^[_[_O\
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MC4/^?^[_ ._[_P"-'^KB_P"?OX?\$/JOF?T$_P#"2:3_ -!2S_\  A/\:/\
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M_03_ ,))I/\ T%+/_P "$_QH_P"$DTG_ *"EG_X$)_C7\^W]L:A_S_W?_?\
M?_&C^V-0_P"?^[_[_O\ XT?ZN+_G[^'_  0^J^9_03_PDFD_]!2S_P# A/\
M&C_A)-)_Z"EG_P"!"?XU_/M_;&H?\_\ =_\ ?]_\:/[8U#_G_N_^_P"_^-'^
MKB_Y^_A_P0^J^9_03_PDFD_]!2S_ / A/\:/^$DTG_H*6?\ X$)_C7\^W]L:
MA_S_ -W_ -_W_P :/[8U#_G_ +O_ +_O_C1_JXO^?OX?\$/JOF?T$_\ "2:3
M_P!!2S_\"$_QH_X232?^@I9_^!"?XU_/M_;&H?\ /_=_]_W_ ,:/[8U#_G_N
M_P#O^_\ C1_JXO\ G[^'_!#ZKYG]!/\ PDFD_P#04L__  (3_&C_ (232?\
MH*6?_@0G^-?S[?VQJ'_/_=_]_P!_\:/[8U#_ )_[O_O^_P#C1_JXO^?OX?\
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M_&OIBBCZ_B_^?LOO8>TGW/F?_AW3\#?^A9N/_ Z7_&C_ (=T_ W_ *%FX_\
M Z7_ !KZ8HH^OXO_ )^R^]A[2?<^9_\ AW3\#?\ H6;C_P #I?\ &C_AW3\#
M?^A9N/\ P.E_QKZ8HH^OXO\ Y^R^]A[2?<^9_P#AW3\#?^A9N/\ P.E_QH_X
M=T_ W_H6;C_P.E_QKZ8HH^OXO_G[+[V'M)]SYG_X=T_ W_H6;C_P.E_QH_X=
MT_ W_H6;C_P.E_QKZ8HH^OXO_G[+[V'M)]SYG_X=T_ W_H6;C_P.E_QH_P"'
M=/P-_P"A9N/_  .E_P :^F**/K^+_P"?LOO8>TGW/F?_ (=T_ W_ *%FX_\
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MNGX&_P#0LW'_ ('2_P"-?3%%'U_%_P#/V7WL/:3[GS/_ ,.Z?@;_ -"S<?\
M@=+_ (T?\.Z?@;_T+-Q_X'2_XU],44?7\7_S]E][#VD^Y\S_ /#NGX&_]"S<
M?^!TO^-'_#NGX&_]"S<?^!TO^-?3%%'U_%_\_9?>P]I/N?,__#NGX&_]"S<?
M^!TO^-'_  [I^!O_ $+-Q_X'2_XU],44?7\7_P _9?>P]I/N?,__  [I^!O_
M $+-Q_X'2_XT?\.Z?@;_ -"S<?\ @=+_ (U],44?7\7_ ,_9?>P]I/N?,_\
MP[I^!O\ T+-Q_P"!TO\ C1_P[I^!O_0LW'_@=+_C7TQ11]?Q?_/V7WL/:3[G
MS/\ \.Z?@;_T+-Q_X'2_XT?\.Z?@;_T+-Q_X'2_XU],44?7\7_S]E][#VD^Y
M\S_\.Z?@;_T+-Q_X'2_XT?\ #NGX&_\ 0LW'_@=+_C7TQ11]?Q?_ #]E][#V
MD^Y\S_\ #NGX&_\ 0LW'_@=+_C1_P[I^!O\ T+-Q_P"!TO\ C7TQ11]?Q?\
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M'2_XT?\ #NGX&_\ 0LW'_@=+_C7TQ11]?Q?_ #]E][#VD^Y\S_\ #NGX&_\
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>pgen-20201231_g3.jpg
<TEXT>
begin 644 pgen-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,A!O\# 2(  A$! Q$!_\0
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M^-<W11]7H_R+[D'MJO\ ,_O.D_X61XJ_Z&+4O_ EO\:/^%D>*O\ H8M2_P#
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M  LCQ5_T,6I?^!+?XUS=%'U>C_(ON0>VJ_S/[SI/^%D>*O\ H8M2_P# EO\
M&C_A9'BK_H8M2_\  EO\:YNBCZO1_D7W(/;5?YG]YTZ?$7Q0R2$^(-1)4#!^
MT-QS]:9_PLCQ5_T,6I?^!+?XU@1_ZN7Z#^=153P]&R]Q?<A^VJ_S/[SI/^%D
M>*O^ABU+_P "6_QH_P"%D>*O^ABU+_P);_&N;HJ?J]'^1?<A>VJ_S/[SI/\
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MWG2?\+(\5?\ 0Q:E_P"!+?XT?\+(\5?]#%J7_@2W^-<W11]7H_R+[D'MJO\
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MA?\ GU'[E_D'M)_S,]&_X:0^*G_10_$G_@QE_P :/^&D/BI_T4/Q)_X,9?\
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MJ?\ 10_$G_@QE_QH_P"&D/BI_P!%#\2?^#&7_&O.:*/J6%_Y]1^Y?Y![2?\
M,ST;_AI#XJ?]%#\2?^#&7_&C_AI#XJ?]%#\2?^#&7_&O.:*/J6%_Y]1^Y?Y!
M[2?\S/1O^&D/BI_T4/Q)_P"#&7_&C_AI#XJ?]%#\2?\ @QE_QKSFBCZEA?\
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M^BA^)/\ P8R_XUYS11]2PO\ SZC]R_R#VD_YF>C?\-(?%3_HH?B3_P &,O\
MC1_PTA\5/^BA^)/_  8R_P"-><T4?4L+_P ^H_<O\@]I/^9GHW_#2'Q4_P"B
MA^)/_!C+_C1_PTA\5/\ HH?B3_P8R_XUYS11]2PO_/J/W+_(/:3_ )F>C?\
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M4_Z*'XD_\&,O^-><T5I]2PO_ #ZC]R_R'[2?\S/1O^&D/BI_T4/Q)_X,9?\
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M=7EC<!E=-/F*L#T((7D5FKI]W)??8EM9VO=Q3[,L3&7<.J[,9S[8KZW^-O\
MPL3_ (1OX>?\(/\ V_Y']CI]J_L;S-N[9'MW[.^,XS[USG@NXNOAG^S[XA\>
M[&;QMJE^UI]OO%WS0D2[&^\.#PYY[XST H ^<M2\/ZKHJHVHZ7?:>KG"M=VS
MQ!CZ#<!FGZ=X:UC6(3-I^D:A?PAMIDM;2250?3*J1FOHO]FOQIJOQ6U#7_!G
MC"^F\0Z9>V+2H;]O->)P0,JQR1US[$5M_"72/$,G[,_B;3_"EQ+!KB:S)';3
M0W*V[_+)%NQ(Q 'R@]^>E 'RCJ&EWND7'D7]G<6,^-WE74+1/CUPP!Q4VH>'
M]5TF".>_TN^L89#A)+JV>)6.,X!8 'BOHC]H&[GTSX9>"?#_ (MNH]0\?13"
M:64$221PDGAY.Y/ X/)'XUZ]\8K=/B'I?B?P*VTWT&BV^LV&1SO5W##\U0?\
M"- 'PKINCZAK,K1:?876H2J-S):0/*RCU(4' J"XMIK.XD@N(9+>>-MKQ2H4
M=2.H(/(-?5W[-MN/A[X/\.7DB>5JGC+6%@CW<,+6-68D>Q(_\>KPOX^?\EF\
M7_\ 80?^E ' 4444 %%%% !1110 4444 %%%% $L?^KE^@_G452Q_P"KE^@_
MG454]D,****D04444 %%%% !1110 444J_>% %^;P]JUM>PV<VE7T5Y,,Q6T
MELZRR ]"JD9/X"H;S2[W3KS[)=V=Q:77'^CSPLDG/3Y2,\U]B_$GG]J7X99Y
M_P!"3_T)ZQ_C=86_Q&GTKQ;I\0_M'PYKJZ/JJ+U"><OEN1Z9(_[['I0!\L_\
M(WK']H?V?_9&H?;]N_[)]ED\[;Z[,;L>^*=J'AC6M)MS/?Z-J-C #@RW5I)$
MGYLH%?9<7_)ZDG_8$'_H)KR7X7_&;Q/)\9DT'6-3N->T+4]1>PFL=1?SD"LY
M52N[.W!(X'4#% '@UCI-]JOFBQL;J],*[Y/LT+2;%_O-M!P/<U#:VL]]<);V
MT$ES<2'"0PH7=CZ!1R:^M/A9X6M/!7Q=^,>C6"^796^EL88QT16&\*/8;L?A
M7-^!W3X4_LS:CXVTM(T\3:Q>-:0WS*&>!!*4PN1QPKM]2/0"@#YWU+1-2T5D
M74=.O-/9^5%W;O$6^FX#-+'H>IS:>^H1Z;>26$>=]VENYA7'7+@;1CZUN:Y\
M3/%GC#1X]&U?6;K6;;SQ-&EV?-D$G0!7(W8YZ9Q7UWX>O-+\,W'ASX*7:Q-'
M?>'I3>_]?,GS8S[XE/XK0!\8VO@_7[ZWCN+70=4N;>0;DFAL971AZA@N"/I2
M7'A'7K1X4GT+5('F?RXEELI5,C==J@KR?8<U]!?LRZUXGT?XU'P;J&LZA)IN
MF0W,"Z?+.QA780%(3.!Z_C7-^%?''B'Q%^T9HNGZIK=_J%C;>(G,-M<W#/''
MAW4;5)P,#B@#Q&[M)]/N)+>Z@EM;B,X>&="CJ?0J>15ZX\*ZW:VANI]%U*"U
M W&XDLY%CQZ[BN,5]7>$_"^F:C^T=\3/$6IVRWB>'X_M$,,@!42,I.['<@(<
M?7Z5Y?\ #/\ : \9:M\6M+?5-8FO=-U.[6WN--D.;81N<;4CZ+CCD#Z]30!X
MQINDW^LS-%I]C=:A*J[C':0-*P7U(4'CWI+?2[V\OOL5O9W$][N*_9HH6:7(
MZC8!G(^E?8O@+0;/X<?M!?$V/2H5BMH-'%[% HPJ%MDA4#L,DX%5=#T*TOOV
MAO!WCW1T_P")-XIL9+@[>1'<"/#J??C\P: /CV:&2WE>*6-HI4)5D=2K*1U!
M!Z&F5T7Q&_Y*!XE_["5Q_P"C&KG: "BBB@ HHHH **** "N7^.7_ ";WXI_[
M".G?^AO745R_QR_Y-[\4_P#81T[_ -#>NO"?QX>II3^-'QK1117VIZ@4444
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M\OAQ_P!BE;?^E5W7G->C?&3_ (\OAQ_V*5M_Z57=9R^)"ZGG-%%%:#"BBB@
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M=3$P2$%#D#.=K#CBM/Q1\9O"OAGXY:-X_P##ER-1MK^S\K6+.!&1XR0 ?O
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M-')M:T^;8Y7;NZ$ \=:\"HI+#QC=)[JW]>8N1'J?[4WC'2OB!^T1X^\1:'J
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M]X.\TRZA>%';<B#=Y7R D;R-N<<9K[ _:P\5?#C]H*;3=-T?]H#POX:\!Z!
M$TCPS!H=\55@FW<Y"@,V!M'&%!]SGX"HJYT>>:GS-6]/\AN-W>X4445T%A11
M10 4444 %>C?&3_CR^''_8I6W_I5=UYS7HWQD_X\OAQ_V*5M_P"E5W6<OB0N
MIYS1116@PHHHH **** /K+]@7XT>$O@X_P 49?%'B&/P]-JGA][73I&64M)<
M<[0IC4E3G'/%?,&N>*M=\62PS:]K>I:W/$NV.34[R2Y9 >H4NQ('TK,HK*-.
M,9RGU9/*KMGU9^W#\7/!7Q7\%_!"Q\,:U;ZW=^'_  Z++4HXXG4VTWE0#82Z
MC)RC=,CBN]\7?%KX2?$CX,_LP^"-5\7V]K;^'I8?^$E7[/-_H420KN4X3DL5
MVC;GKFOA:BL?J\>6,4WI?\?^')Y%9+L?;?QV_P""B6MR_'+4M1\$Z3X0U7PU
MID\<6DZA?Z"DMV\2 9997PZ MNQP,#%3_M1:G\!?VE/C#8>*A\48_#+:KX?0
M7<T>FS3QP:A$5"K<+L!VM&Q7*9YB]Z^':*4<+"%G#1K0/9I6L?:VK?&7P%\$
M/V0_%?PHT'XBR_%;6_$TP$3V]I-!8Z5"&0L%$W(SLSM'=L\8YW?VAM8^#G[2
MOP[^#]I_PNG0_"M]X6T%+*\MM0TF[N&\UHH RY10!M,1!ZYKX,HH^K)-24G>
M][Z==.PO9J][FQXPT33O#?B?4=,TC7+?Q+IMK+Y<&K6D+PQ72X'SJC_,H]CZ
M5[Q\*_AK\&1J/@_Q8?CNWA&]LVM[G4M.OM'G%]#.A5I%@EARI0G(5CSCJ*^;
MZ*Z)0<E;FM]Q;5UN?1?[=G[0F@?M&?&>+6_#%M-'HVG6$>G175S&$ENRK,QD
M8=<9; SS@#ITKYTHHHIP5.*A'9#2Y59!1116@PHHHH *^Z/^"0__ "7[Q3_V
M+K_^E$-?"]?='_!(?_DOWBG_ +%U_P#THAKCQG^[S]#*I\#/A>BBBNPU"BBB
M@#]#/^".O_(_?$;_ +!EK_Z-:OTK^(?_ "(?B#_KQF_] -?FI_P1U_Y'[XC?
M]@RU_P#1K5^C'QH\167A'X2^+]:U(R+86.F3SSM"F]P@0DD#N<=J^1S"[Q+M
MY?D>?65ZEC\S(_\ 5K]*6N 7]H/X=JH'V_5NG_0/_P#LJ7_AH3X=_P#/_JW_
M (+_ /[*N'V5;_GW+_P%_P"17U:IY?>O\SOJ*X'_ (:$^'?_ #_ZM_X+_P#[
M*C_AH3X=_P#/_JW_ (+_ /[*CV5;_GW+_P !?^0?5JGE]Z_S.^HK@?\ AH3X
M=_\ /_JW_@O_ /LJ/^&A/AW_ ,_^K?\ @O\ _LJ/95O^?<O_  %_Y!]6J>7W
MK_,[ZBN!_P"&A/AW_P _^K?^"_\ ^RH_X:$^'?\ S_ZM_P""_P#^RH]E6_Y]
MR_\  7_D'U:IY?>O\SOJ*X'_ (:$^'?_ #_ZM_X+_P#[*C_AH3X=_P#/_JW_
M (+_ /[*CV5;_GW+_P !?^0?5JGE]Z_S.^HK@?\ AH3X=_\ /_JW_@O_ /LJ
M/^&A/AW_ ,_^K?\ @O\ _LJ/95O^?<O_  %_Y!]6J>7WK_,[ZBN!_P"&A/AW
M_P _^K?^"_\ ^RH_X:$^'?\ S_ZM_P""_P#^RH]E6_Y]R_\  7_D'U:IY?>O
M\SOJ*X'_ (:$^'?_ #_ZM_X+_P#[*C_AH3X=_P#/_JW_ (+_ /[*CV5;_GW+
M_P !?^0?5JGE]Z_S.^HK@?\ AH3X=_\ /_JW_@O_ /LJ/^&A/AW_ ,_^K?\
M@O\ _LJ/95O^?<O_  %_Y!]6J>7WK_,[ZBN!_P"&A/AW_P _^K?^"_\ ^RH_
MX:$^'?\ S_ZM_P""_P#^RH]E6_Y]R_\  7_D'U:IY?>O\SOJ*X'_ (:$^'?_
M #_ZM_X+_P#[*C_AH3X=_P#/_JW_ (+_ /[*CV5;_GW+_P !?^0?5JGE]Z_S
M.^HK@?\ AH3X=_\ /_JW_@O_ /LJ/^&A/AW_ ,_^K?\ @O\ _LJ/95O^?<O_
M  %_Y!]6J>7WK_,[ZBF_!'Q!X6^/GQ&L/!?AW4[R'5KR*:6-KRS*1XCC+MDY
M/937TS_PP[X@_P"@[9?]\M7/4FZ3Y9Q:?^%_Y$.C..CM]Z_S/FBBOI?_ (8=
M\0?]!VR_[Y:C_AAWQ!_T';+_ +Y:L_;Q[/[G_D+V4NZ^]?YGS117TO\ \,.^
M(/\ H.V7_?+4?\,.^(/^@[9?]\M1[>/9_<_\@]E+NOO7^9\T45]+_P###OB#
M_H.V7_?+4?\ ##OB#_H.V7_?+4>WCV?W/_(/92[K[U_F?-%%?2__  P[X@_Z
M#ME_WRU'_##OB#_H.V7_ 'RU'MX]G]S_ ,@]E+NOO7^9\T45]+_\,.^(/^@[
M9?\ ?+4?\,.^(/\ H.V7_?+4>WCV?W/_ "#V4NZ^]?YGS117TO\ \,.^(/\
MH.V7_?+4?\,.^(/^@[9?]\M1[>/9_<_\@]E+NOO7^9\T45]+_P###OB#_H.V
M7_?+4?\ ##OB#_H.V7_?+4>WCV?W/_(/92[K[U_F?-%%?2__  P[X@_Z#ME_
MWRU'_##OB#_H.V7_ 'RU'MX]G]S_ ,@]E+NOO7^9\T45]+_\,.^(/^@[9?\
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M?\,.^(/^@[9?]\M1[>/9_<_\@]E+NOO7^9\T45]+_P###OB#_H.V7_?+4?\
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MW_X#+_(/=_F7WH^ **^__P#AT=XC_P"A\TW_ ,!7_P :/^'1WB/_ *'S3?\
MP%?_ !H_M7"]W_X#+_(/=_F7WH^ **^__P#AT=XC_P"A\TW_ ,!7_P :/^'1
MWB/_ *'S3?\ P%?_ !H_M7"]W_X#+_(/=_F7WH^ **^__P#AT=XC_P"A\TW_
M ,!7_P :/^'1WB/_ *'S3?\ P%?_ !H_M7"]W_X#+_(/=_F7WH^ **^__P#A
MT=XC_P"A\TW_ ,!7_P :/^'1WB/_ *'S3?\ P%?_ !H_M7"]W_X#+_(/=_F7
MWH^ **^__P#AT=XC_P"A\TW_ ,!7_P :/^'1WB/_ *'S3?\ P%?_ !H_M7"]
MW_X#+_(/=_F7WH^ **^__P#AT=XC_P"A\TW_ ,!7_P :/^'1WB/_ *'S3?\
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M]#W8_P#@&_\ C1_PZVUC_H>['_P#?_&J_M7"]W_X#+_(?N_S+[T?#%%?<_\
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M1WB/_H?--_\  5_\:/[5PO=_^ R_R#W?YE]Z/@"BOO\ _P"'1WB/_H?--_\
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M . K_P"-'_#H[Q'_ -#YIO\ X"O_ (T?VKA>[_\  9?Y![O\R^]'P!17W_\
M\.CO$?\ T/FF_P#@*_\ C1_PZ.\1_P#0^:;_ . K_P"-']JX7N__  &7^0>[
M_,OO1\ 45]__ /#H[Q'_ -#YIO\ X"O_ (T?\.CO$?\ T/FF_P#@*_\ C1_:
MN%[O_P !E_D'N_S+[T? %%??_P#PZ.\1_P#0^:;_ . K_P"-'_#H[Q'_ -#Y
MIO\ X"O_ (T?VKA>[_\  9?Y![O\R^]'P!17W_\ \.CO$?\ T/FF_P#@*_\
MC1_PZ.\1_P#0^:;_ . K_P"-']JX7N__  &7^0>[_,OO1\ 45]__ /#H[Q'_
M -#YIO\ X"O_ (T?\.CO$?\ T/FF_P#@*_\ C1_:N%[O_P !E_D'N_S+[T?
M%%??_P#PZ.\1_P#0^:;_ . K_P"-'_#H[Q'_ -#YIO\ X"O_ (T?VKA>[_\
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MT9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H *='_K%^M-S2QG]XOUH X/4/\ D(7/_75OYFJ]3ZBP_M"YY'^M;^9J
MON'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %H
MI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'
MJ* %HI-P]11N'J* %HI-P]11N'J* .O\+_\ ()/_ %U/\A6K65X7(_LD\_\
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MN\.^'OV)/A%H?BF&%] \77-YH%UYJJ5W3W%R$+9X^\ ,_2O*OV!?A/J'P/\
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M$$'YL$@;1@XK<\*_$*[U3Q9-X8U[0'\.ZX+3^T((TO%O(+BWWA&9955<,KD
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M3+\/\@_L'+/^?"/5_P#AHSQ#_P! [2_^_<G_ ,72_P##1GB'_H':7_W[D_\
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M%P:I_P ^&G_]^W_^*KA**K^V\Q_Y_,7]E8+_ )]([W_A;VJ?\^&G_P#?I_\
MXJE'Q=U3_GPT_P#[]M_\57"4Y>E-9WF/_/YD?V5@O^?2.Y_X6YJ?_/AI_P#W
M[;_XJG?\+;U3_GPT_P#[]M_\57"4^G_;>8_\_F+^R\%_SZ1W'_"V]3_Y\=/_
M ._;?_%4?\+;U/\ Y\=/_P"_;?\ Q5</11_;68_\_F+^R\%_SZ1W2_%[50,"
MSL /:-__ (JG?\+>U;_GTL?^^'_^*KA%IU5_;68_\_F+^R\%_P ^T=S_ ,+>
MU;_GTL?^^'_^*I?^%N:M_P ^EC_WP_\ \57"TZC^VLQ_Y_,7]EX/_GVCN/\
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MXK^.WAN^\'_&CQQHNIZJ^N:A8ZQ<P3ZE)]^Z<2',C>YZFO/P[ESN[O\ /S_
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MG_?!JP(Z*E^QW'_/"3_O@T?8Y_\ GA)_WP:D"-:6I5LY_P#GA)_WP:7['/\
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M2R5^UU?+9I_'7I_F<%?X@HHHKR#F"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5?\
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M1_YYVW_?L_\ Q5'_  GFH_\ /.V_[]G_ .*KG** .C_X3S4?^>=M_P!^S_\
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M%-7B8O\ WW[OT.6I_%^X_"3_ (2'2?\ H6;7_P "9?\ &C_A(=)_Z%FU_P#
MF7_&N?HKZ?E1WG0?\)#I/_0LVO\ X$R_XT?\)#I/_0LVO_@3+_C7/T4<J Z#
M_A(=)_Z%FU_\"9?\:/\ A(=)_P"A9M?_  )E_P :Y^BCE0'0?\)#I/\ T+-K
M_P"!,O\ C1_PD.D_]"S:_P#@3+_C7/T4<J Z#_A(=)_Z%FU_\"9?\:/^$ATG
M_H6;7_P)E_QKGZ*.5 =!_P )#I/_ $+-K_X$R_XT?\)#I/\ T+-K_P"!,O\
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M,ZW_ -#7=?\ @+%_A1_PC.M_]#7=?^ L7^%=/11S,+G,?\(SK?\ T-=U_P"
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MGP[H&JNMUM\27*85<_Z-&<\_2G5N^&?NWG^ZO\Z.9A<J?\([J_\ T,]U_P"
MT7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\
M]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=
M#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([
MJ_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P"
MT7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\
M]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=
M#11S,+G/?\([J_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([
MJ_\ T,]U_P" T7^%'_".ZO\ ]#/=?^ T7^%=#11S,+G/?\([J_\ T,]U_P"
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M?]!ZX_[\1T?V+J7_ $'KC_OQ'6S11S,+F-_8NI?]!ZX_[\1T?V+J7_0>N/\
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M_P"@]<?]^(Z/[%U+_H/7'_?B.MFBCF87,;^Q=2_Z#UQ_WXCH_L74O^@]<?\
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M *&>Z_\  :+_  H_X1W5_P#H9[K_ ,!HO\*Z&BCF87.>_P"$=U?_ *&>Z_\
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M$=?^1^^(W_8,M?\ T:U?=_[7G_)KWQ2_[%Z\_P#135Y&+_WW[OT.>I_%^X_
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MBB@#(\5?\@67_>7^=<'7>>*O^0++_O+_ #K@Z "BBB@ HHHH **** "BBB@
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M ,]7_P"^C5?\1!7_ $"_^3__ &HO]2W_ -!'_DO_ -L?87]ES_[/YT?V7/\
M[/YU\?\ G2?\]'_[Z-*LTG_/1_\ OHU2\0$_^87_ ,G_ /M1?ZF/_H(_\E_^
MV/K_ /LN?_9_.C^RY_\ 9_.OD(3R?\]'_P"^C3_/D_YZ/_WT:K_7Y?\ 0-_Y
M/_\ :B_U-?\ T$?^2_\ VQ]=?V7/_L_G1_9<_P#L_G7R,)I,?ZQ_^^C2^?+_
M ,]'_P"^C5?Z^K_H&_\ )_\ [4G_ %.?_/\ _P#)?_MCZX_LN?\ V?SH_LN?
M_9_.ODKSY?\ GH__ 'T:<L\N/]8__?1JO]?%_P! W_D__P!J+_4]_P#/_P#\
ME_\ MCZS_LN?_9_.E73)U8'Y>OK7R=YTG_/1_P#OHT[SI/\ GH__ 'T:O_7I
M?] W_DW_ -J3_J@_^?\ _P"2_P#VQ]#7G@G4YKJ:11#M=V89D/0GZ5%_P@NJ
M>D'_ '\/^%> +-)_ST?_ +Z-.\Z3_GH__?1I_P"O*_Z!O_)O_M2?]47_ ,__
M /R7_P"V/??^$%U3T@_[^'_"C_A!=4](/^_A_P *\$\Z3_GH_P#WT:>LTG'[
MQ_\ OHU7^O"_Z!__ ";_ .U%_JD_^?\ _P"2_P#VQ[Q_P@NJ>D'_ '\/^%'_
M  @NJ>D'_?P_X5X5YTG_ #T?_OHT[SI/^>C?]]&J_P!=E_T#_P#DW_VHO]4W
M_P __P#R7_@GN?\ P@NJ>D'_ '\/^%'_  @NJ>D'_?P_X5X<LTG_ #T;_OHT
MJS29_P!8W_?1JO\ 75?] _\ Y-_]J3_JJ_\ G]_Y+_P3W#_A!=4](/\ OX?\
M*/\ A!=4](/^_A_PKQ)9I/\ GHW_ 'T:<LTF?]8W_?1I_P"NB_Z!_P#R;_[4
M7^JK_P"?W_DO_!/:_P#A!=4](/\ OX?\*/\ A!=4](/^_A_PKQ=9I/\ GHW_
M 'T:=YTG_/1O^^C3_P!<U_T#_P#DW_VI/^JS_P"?W_DO_!/9O^$%U3T@_P"_
MA_PH_P"$%U3T@_[^'_"O&_-?^^W_ 'T:<LTG]]O^^C5?ZY+_ *!__)O_ +47
M^J[_ .?W_DO_  3V+_A!=4](/^_A_P */^$%U3T@_P"_A_PKQ]97S]]O^^C3
MO-?^^W_?1I_ZY+_GQ_Y-_P#:B_U8?_/[_P E_P"">O?\(+JGI!_W\/\ A1_P
M@NJ>D'_?P_X5Y'YK_P!]O^^C2^=)_P ]&_[Z-/\ UQ7_ #X_\F_^U)_U9?\
MS^_\E_X)ZW_P@NJ>D'_?P_X4?\(+JGI!_P!_#_A7DJS2?WV_,TY97S]]O^^C
M3_UP7_/C_P F_P#M1?ZM/_G]_P"2_P#!/6/^$%U3T@_[^'_"C_A!=4](/^_A
M_P *\I\U_P"^W_?1I5E?^^WYFC_7!?\ /C_R;_[47^K;_P"?W_DO_!/5?^$%
MU3T@_P"_A_PH_P"$%U3T@_[^'_"O*_,?^^WYFCS7_OM_WT:?^N"_Y\?^3?\
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MO_G[^'_!/>_[+G_V?SH_LN?_ &?SKP;S'_OM^9H\Q_[[?F:?^MR_Y\?^3?\
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M%\%I2^_),G3'%>K4YTGS[=+*[.B5];GVG^T?H7B+X8?\$^7\,Z3JMU\8+&[
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MDNTD?30KA(D;R]R-YASC#=JV?B=H-YXH^''B?1]/19+^_P!.FMX$=PBEV4@
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M_P#A._$'_05G_)?\*/\ A._$'_05G_)?\*/> Q/)D_YYM_WR:/)D_P">;?\
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M_P#H$P_FW^-'_"NO#?\ T"8?S;_&CW0T.@\Z/_GHG_?0H\Z/_GHG_?0KG_\
MA77AO_H$P_FW^-'_  KKPW_T"8?S;_&CW0T.@\Z/_GHG_?0H\Z/_ )Z)_P!]
M"N?_ .%=>&_^@3#^;?XT?\*Z\-_] F'\V_QH]T-#H/.C_P">B?\ ?0H\Z/\
MYZ)_WT*Y_P#X5UX;_P"@3#^;?XT?\*Z\-_\ 0)A_-O\ &CW0T.@\Z/\ YZ)_
MWT*/.C_YZ)_WT*Y__A77AO\ Z!,/YM_C1_PKKPW_ - F'\V_QH]T-#H/.C_Y
MZ)_WT*/.C_YZ)_WT*Y__ (5UX;_Z!,/YM_C1_P *Z\-_] F'\V_QH]T-#H/.
MC_YZ)_WT*/.C_P">B?\ ?0KG_P#A77AO_H$P_FW^-'_"NO#?_0)A_-O\:/=#
M0Z#SH_\ GHG_ 'T*/.C_ .>B?]]"N?\ ^%=>&_\ H$P_FW^-'_"NO#?_ $"8
M?S;_ !H]T-#H/.C_ .>B?]]"CSH_^>B?]]"N?_X5UX;_ .@3#^;?XT?\*Z\-
M_P#0)A_-O\:/=#0Z#SH_^>B?]]"CSH_^>B?]]"N?_P"%=>&_^@3#^;?XT?\
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M_P :/^$-T3_H&P_FW^-'NAH:_F)_?7\Q1YB?WU_,5D?\(;HG_0-A_-O\:/\
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M#\/?] F#\V_QH]T-#;\Z/_GHO_?0H\Z/_GHO_?0K$_X0/P]_T"8/S;_&C_A
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MTSP+X??2[1FTJ$L8\DY;U/O1H&ATGG1_\]%_[Z%'G1_\]%_[Z%8G_"!^'O\
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M1D="/2O,_BMX<US1OBIX4^)&D:#)XN@TC3[O2[O2+>1%NX8YY(F^TVHD(1G
MC*LI92R-P<C![;X<>-?#7C_19M8\-%526<B]ADMFMKF&Y  9+B)@'24#:"&&
M<8ZC!J)17+S(5M+HZB>>.U@DFF=8H8U+O(YP%4#))/IBL[PQXHTCQIH-GK>@
MZE:ZQI%XGF6]]9RB2*5<D95AP1D$?A7GG[26L72^ [?PMI<ACUKQA?1:!:LG
MWXTE)^T3 #G]W"LKY[;:P/V?])MOA+X\\:_"FUBDMM(LVBUS08V'R+9SC9)$
MA/4)*C?]]>]"IW@Y=?T"VESW26188GD<X1%+$^P&:Q_!OC#2O'_AC3_$&B7#
M76E7R&2"9XVC+*&*GY6 (Y!ZBO(],U[XA_%70=:\7>&_$.FZ/I,5W>6FE:'<
MV*S0WT5O+)"TEQ-G>AE9'(\LC:NSJ<UP7PY^+@^&O[+_ ,(K&75M'\-:IXB$
MEFNJZS<)'9Z>%,LDTI+E0Y&-J*2 S,N>,@W[%V\[_P"8^70^LZ*\"^&GQMBN
MOBQ8^"T^(>A?$ZSU2PFO(=1TB2V,]E+"5W1S+;L5V,K95B <J1SD8Y_P'XT^
M+WCOX/WOCU_$NCZ9)8?;);33(M.62/4$@EDXN'/S1[@FW]WC YR32]C);O\
MIARL^G:AO;R#3;.>[NI5@MH$:6660X5% R6)] *\AU7XN:MXPT_X<:?X1$6D
MZKXVTX:M]MO8O.&FV@A25V"='D_>*B@G&>3D<5/I>O>*?!'Q.T7P=XJUF'Q9
MI/B:VNWL=1:SCM;B">!$9X)$C^5T>-G96 !!1@<Y%1[-]1<IZEH^L6/B#2K3
M4]-NX;_3[R)9[>ZMW#QRQL,JRD=00>M0:;XDTK6=1U2PL-0M[R]TN58+ZWAD
M#/;2,@=5<#[I*L&P>Q%>,? _Q)!\*_"GQ \*^(+E8+/P#>7%Q'*1TTJ16N8#
M[[5+I_P "N,T'QU+\(_ASX435M8TCP;XM^)>IWFN:EK.O31QPZ>)%,QX=@KR
M1Q>1"B$XR 3D @Z>QU:7R_/\A\I]645X1\)OC4FL?%&Y\$+X[T3XDV\NEG5;
M76='DMS) 4D"203K Q0?>1D; )RP.<9I_P"SSXE^(7Q/\(:3XV\0:W;6UC*)
MXX]#L;*/%VL<CQB625OF1F93A4P  N<DFHE2E%-L7*T>Z45X1\"?'WB/XJ7
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M_A8_@W_H.C_OS)_\32_\+&\'?]!T?]^9/_B:?]JY?_T$0_\  H_YB_L[&_\
M/F7_ ("_\C<IT?\ K%^M8/\ PL7P=_T'!_WYD_\ B:5?B-X/5@?[<'_?F3_X
MFC^U<O\ ^@B'_@4?\P_L[&_\^9?^ O\ R.?U#_D(7/\ UU;^9JO5^?7?!-Q-
M)*?$3@NQ8@0OW.?[E,_M;P3_ -#')_WX?_XBG_:F _Z"(?\ @4?\P_L_&?\
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M_M+ _P#/^'_@2_S#ZCB_^?4O_ 7_ )&;16G]I\(?]!^3_ORW_P 31]H\(?\
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M?\^I?<S8\+_\@D_]=3_(5JUC:=XA\+Z;:^0FLEQN+9:)L_\ H-6?^$N\-?\
M06_\A/\ _$T?VC@O^?T?_ E_F'U+%?\ /J7W,T**S_\ A+O#7_06_P#(3_\
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MOW172OXKC\N0?9F^XW\8]/I7!#Q$FT?Z.W_?0_PHLPL;%%8__"2)_P ^[?\
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M_P!]4?VXO_/%O^^J+,1IT5F#7%/_ "Q;_OJE_MM?^>+?]]468S2HK-_MM?\
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MJM>F_M/7-I>?M&?$N>Q;=:R:_>-&WJ/-/->95[<7S13[G4M5<****H9]3_\
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M>UM!\QGZ!)J,VCVKZM:VUCJ+)F:WLYC+%&WH'*J3^0K0HHK$D**** "BBB@
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MS,2#LR=@(')(X%=='$\A^56([X&:\&OKF:"T_9V2*:2-)985D5'*AQ_9Q.&
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MT#4=3UJPE#Z/K4+Q^5;A7W1APS;LA2Z\#HPKY@HK/V%/MUO\R>1?J?7WP?\
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M'_@F5_R>%X5_Z\]0_P#262OVNKY;-/XZ]/\ ,X*_Q!1117D',%%%% !1110
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M ($A?ZV99_,_N9\^T5]!_P##/OA;_H*ZK_WU'_\ &Z/^&??"W_05U3_OJ/\
M^-U?^H^<_P D?_ D+_6O+/YG]S/GY>E+7T#_ ,,_^%O^@KJG_?4?_P ;H_X9
M_P#"W_05U3_OJ/\ ^-U7^H^<_P D?_ D'^M>6?S/[F?/ZTZO?_\ A0/A;_H*
MZI_WU'_\;H_X4#X7_P"@KJG_ 'U'_P#&ZT7!.<?R1_\  D3_ *U99_,_N9X"
MM+7OW_"@O"__ $%=4_[ZC_\ C='_  H/PO\ ]!35/^^H_P#XW6BX*S?^6/\
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M^LV7?S/[CP]:6O8)/A?X-AD>-M9U(,I*D87J/^V=-_X5GX+_ .@SJ7_?(_\
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MKPI_R$)/^N9_F*B_LF+^^_YC_"M/0;%+:Z=U9B=N.<4A'\XM%:__  A^O?\
M0$U#_P !7_PH_P"$/U[_ * FH?\ @*_^%?>W1[!D45K_ /"'Z]_T!-0_\!7_
M ,*/^$/U[_H":A_X"O\ X470'WK_ ,$=?^1^^(W_ &#+7_T:U?=_[7G_ ":]
M\4O^Q>O/_135\._\$A-%U#2O'GQ$-[8W-H&TVV"F>)DS^];ID5]W?M1:->^(
MOV=?B-I>FVTE[J%YH=U!;V\*[GDD:,A5 [DDU\OBW_ME_3]#@J?Q3^?BBO7/
M^&2OC!_T(&M?^ YH_P"&2OC!_P!"!K7_ (#FOI/:T_YE]YV\R[GD=%>N?\,E
M?&#_ *$#6O\ P'-'_#)7Q@_Z$#6O_ <T>UI_S+[PYEW/(Z*]<_X9*^,'_0@:
MU_X#FC_ADKXP?]"!K7_@.:/:T_YE]X<R[GD=%>N?\,E?&#_H0-:_\!S1_P ,
ME?&#_H0-:_\  <T>UI_S+[PYEW/(Z*]<_P"&2OC!_P!"!K7_ (#FC_ADKXP?
M]"!K7_@.:/:T_P"9?>',NYY'17KG_#)7Q@_Z$#6O_ <T?\,E?&#_ *$#6O\
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M?_ 27_XFCEEV"S.FK'O_  AH^J>)=*\075C'-K.E1S165VQ;="LH D &<?,
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M?Q$.GMKVGM<SZ>[26ES!<RVT\)8;6"RQ.K@,.JYP<#(X%._X6-H?_/:Y_P#
M27_XFC_A8VA_\]KG_P !)?\ XFJO4O?4/>+MAX/T?3/$-WKMM8K'J]W;16<]
MWN8O)#$6,:G)[;FYZ\\TFF^#=$T>;7)+3388VURX-UJ6X%Q=2F-8BSAB1RB(
MN.F!5/\ X6-H?_/:Y_\  27_ .)H_P"%C:'_ ,]KG_P$E_\ B:GWPU,;P_\
M ?P-X7U:WU#3M$:.:U8O;0S7MQ/;6S$]88))&BB(Y"E%&T$@8!Q75:;X5TG2
M-<UC6;.R2#4]7,)OKE2=T_E)LCSDX^53CC%9W_"QM#_Y[7/_ ("2_P#Q-'_"
MQM#_ .>US_X"2_\ Q--\\M[AJS-\6?!/P7XXUI]6UG1?M-])$L,[QW4T"W4:
MGY4G2-U691DC$@88)'3BN5^*'P-M=0^%^D^#O!NCZ;8:7:Z]::BVG-\EL(A=
M^?< *01@[G.S&.<<"N\_X6-H?_/:Y_\  27_ .)H_P"%C:'_ ,]KG_P$E_\
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M$E_^)H_X6-H?_/:Y_P# 27_XFCEEV"S.FHKF?^%C:'_SVN?_  $E_P#B:/\
MA8VA_P#/:Y_\!)?_ (FCEEV"S+_BK_D"R_[R_P ZX.MKQ%X]TB\TN2*%[IW+
M [1:2_\ Q-<C_P )):?\\[O_ ,!)?_B:.678+,U**R_^$DM/^>=W_P" DO\
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M"2__ !-'_"26G_/.[_\  27_ .)HY9=@LS4HK+_X22T_YYW?_@)+_P#$T?\
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M'_";:3_STN?_  $E_P#B:.5]@LS>HK!_X3;2?^>ES_X"2_\ Q-'_  FVD_\
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MMV__ #SN_P#P$E_^)H_MNW_YYW?_ ("2_P#Q-'++L%F7Z*H?VW;_ //.[_\
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M$E_^)H_X3;2?^>ES_P" DO\ \31ROL%F;U%8/_";:3_STN?_  $E_P#B:/\
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MW;_\\[O_ ,!)?_B:.678+,OUW.E?\@FR_P"N7]37F_\ ;=O_ ,\[O_P$E_\
MB:ZW3_&>EPZ=:QNURKHF&'V27@Y/^S1ROL%F=+16#_PFVD_\]+G_ ,!)?_B:
M/^$VTG_GI<_^ DO_ ,31ROL%F;U%8/\ PFVD_P#/2Y_\!)?_ (FC_A-M)_YZ
M7/\ X"2__$T<K[!9F]16#_PFVD_\]+G_ ,!)?_B:/^$VTG_GI<_^ DO_ ,31
MROL%F;U%8/\ PFVD_P#/2Y_\!)?_ (FC_A-M)_YZ7/\ X"2__$T<K[!9F]16
M#_PFVD_\]+G_ ,!)?_B:/^$VTG_GI<_^ DO_ ,31ROL%F;U%8/\ PFVD_P#/
M2Y_\!)?_ (FC_A-M)_YZ7/\ X"2__$T<K[!9F]16#_PFVD_\]+G_ ,!)?_B:
M/^$VTG_GI<_^ DO_ ,31ROL%F;U%8/\ PFVD_P#/2Y_\!)?_ (FC_A-M)_YZ
M7/\ X"2__$T<K[!9F]16#_PFVD_\]+G_ ,!)?_B:/^$VTG_GI<_^ DO_ ,31
MROL%F;U%8/\ PFVD_P#/2Y_\!)?_ (FC_A-M)_YZ7/\ X"2__$T<K[!9F]16
M#_PFVD_\]+G_ ,!)?_B:/^$VTG_GI<_^ DO_ ,31ROL%F;U7M)_US?2N3_X3
M;2?^>ES_ . DO_Q-:OASQ7IVH:@+:&28S.IVA[>1 <#)Y*@4<K[ =91114B"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKX\_X>J? W
M_GKXB_\ !8/_ (NC_AZI\#?^>OB+_P %@_\ BZZ_JE?^1FGLY]C[#HKX\_X>
MJ? W_GKXB_\ !8/_ (NC_AZI\#?^>OB+_P %@_\ BZ/JE?\ D8>SGV/L.BOG
MSX'_ +<GPS_:#\;_ /"*^$WU=M5^RR7?^FV0BCV(5#?-N//S#M7H7Q2^-6A_
M".;3DUN.X(OUD,+0*&^YMW ^GWU_.N6K&5#^(FODQ<DKV/0:*\$_X;.\"_\
M/.__ ._0_P :/^&SO O_ #SO_P#OT/\ &N;V\.S_ / 7_D7[*7E]Z_S/>Z*\
M$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SW
MNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![
M*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?
M^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]
MO#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/
M\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \
M[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[
MP+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\
M&C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_
M /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_
M #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\
M$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SW
MNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![
M*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?
M^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]
MO#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/
M\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \
M[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[
MP+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\
M&C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_
M /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_
M #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\
M$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SW
MNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![
M*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?
M^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \[_\ []#_ !H]
MO#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[P+_SSO\ _OT/
M\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\ &C_AL[P+_P \
M[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_ /[]#_&C_AL[
MP+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!/^&SO O_ #SO_P#OT/\
M&C_AL[P+_P \[_\ []#_ !H]O#L__ 7_ )![*7E]Z_S/>Z*\$_X;.\"_\\[_
M /[]#_&C_AL[P+_SSO\ _OT/\:/;P[/_ ,!?^0>REY?>O\SWNBO!3^V9X&7&
M8[\9Y'[H=/SI/^&SO O_ #SO_P#OT/\ &CV\.S_\!?\ D'LI>7WK_,][HKP3
M_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_QH]O#L_\ P%_Y![*7E]Z_S/>Z
M*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO_P#OT/\ &CV\.S_\!?\ D'LI
M>7WK_,][HKP3_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_QH]O#L_\ P%_Y
M![*7E]Z_S/>Z*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO_P#OT/\ &CV\
M.S_\!?\ D'LI>7WK_,][HKP3_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_Q
MH]O#L_\ P%_Y![*7E]Z_S/>Z*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO
M_P#OT/\ &CV\.S_\!?\ D'LI>7WK_,][HKP3_AL[P+_SSO\ _OT/\:/^&SO
MO_/._P#^_0_QH]O#L_\ P%_Y![*7E]Z_S/>Z*\$_X;.\"_\ /.__ ._0_P :
M/^&SO O_ #SO_P#OT/\ &CV\.S_\!?\ D'LI>7WK_,][HKP3_AL[P+_SSO\
M_OT/\:/^&SO O_/._P#^_0_QH]O#L_\ P%_Y![*7E]Z_S/>Z*\$_X;.\"_\
M/.__ ._0_P :/^&SO O_ #SO_P#OT/\ &CV\.S_\!?\ D'LI>7WK_,][HKP3
M_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_QH]O#L_\ P%_Y![*7E]Z_S/>Z
M*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO_P#OT/\ &CV\.S_\!?\ D'LI
M>7WK_,][HKP3_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_QH]O#L_\ P%_Y
M![*7E]Z_S/>Z*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO_P#OT/\ &CV\
M.S_\!?\ D'LI>7WK_,][HKP3_AL[P+_SSO\ _OT/\:/^&SO O_/._P#^_0_Q
MH]O#L_\ P%_Y![*7E]Z_S/>Z*\$_X;.\"_\ /.__ ._0_P :/^&SO O_ #SO
M_P#OT/\ &CV\.S_\!?\ D'LI>7WK_,][HKP3_AL[P+_SSO\ _OT/\:Y?QS_P
M46^%/P[U\Z-K3:K%??9X+K;%:[U\N:)98SG/78Z_2KA4]H[0BV_\,O\ (:HS
MEM;[U_F?4=%?'G_#U#X)_P#/?6?_  "_^RH_X>H?!/\ Y[ZS_P" 7_V5;\M3
M^27_ (#+_(KZO4[?BO\ ,^PZ*^//^'J'P3_Y[ZS_ . 7_P!E1_P]0^"?_/?6
M?_ +_P"RHY:G\DO_  &7^0?5ZG;\5_F?8=%?'G_#U#X)_P#/?6?_  "_^RH_
MX>H?!/\ Y[ZS_P" 7_V5'+4_DE_X#+_(/J]3M^*_S/L.BOCS_AZA\$_^>^L_
M^ 7_ -E1_P /4/@G_P ]]9_\ O\ [*CEJ?R2_P# 9?Y!]7J=OQ7^9]AT5\>?
M\/4/@G_SWUG_ , O_LJ/^'J'P3_Y[ZS_ . 7_P!E1RU/Y)?^ R_R#ZO4[?BO
M\S[#HKX\_P"'J'P3_P">^L_^ 7_V5'_#U#X)_P#/?6?_  "_^RHY:G\DO_ 9
M?Y!]7J=OQ7^9]AT5\>?\/4/@G_SWUG_P"_\ LJ/^'J'P3_Y[ZS_X!?\ V5'+
M4_DE_P" R_R#ZO4[?BO\S[#HKX\_X>H?!/\ Y[ZS_P" 7_V5'_#U#X)_\]]9
M_P# +_[*CEJ?R2_\!E_D'U>IV_%?YGV'17QY_P /4/@G_P ]]9_\ O\ [*C_
M (>H?!/_ )[ZS_X!?_94<M3^27_@,O\ (/J]3M^*_P S[#HKX\_X>H?!/_GO
MK/\ X!?_ &5'_#U#X)_\]]9_\ O_ +*CEJ?R2_\  9?Y!]7J=OQ7^9]AT5\>
M?\/4/@G_ ,]]9_\  +_[*C_AZA\$_P#GOK/_ (!?_94<M3^27_@,O\@^KU.W
MXK_,^PZ*^//^'J'P3_Y[ZS_X!?\ V5:NG_\ !2KX0ZEX?U?6H)-6-AI3V\=T
MS6F&!F+B/ SS_JV^E+EJ+[$O_ 9?Y!]7J=OQ7^9]745\>?\ #U#X)_\ /?6?
M_ +_ .RH_P"'J'P3_P">^L_^ 7_V5/EJ?R2_\!E_D'U>IV_%?YGV'17QY_P]
M0^"?_/?6?_ +_P"RH_X>H?!/_GOK/_@%_P#94<M3^27_ (#+_(/J]3M^*_S/
ML.BOCS_AZA\$_P#GOK/_ (!?_94?\/4/@G_SWUG_ , O_LJ.6I_)+_P&7^0?
M5ZG;\5_F?8=%?'G_  ]0^"?_ #WUG_P"_P#LJ/\ AZA\$_\ GOK/_@%_]E1R
MU/Y)?^ R_P @^KU.WXK_ #/L.BOCS_AZA\$_^>^L_P#@%_\ 94?\/4/@G_SW
MUG_P"_\ LJ.6I_)+_P !E_D'U>IV_%?YGV'17QY_P]0^"?\ SWUG_P  O_LJ
M/^'J'P3_ .>^L_\ @%_]E1RU/Y)?^ R_R#ZO4[?BO\S[#HKX\_X>H?!/_GOK
M/_@%_P#94?\ #U#X)_\ /?6?_ +_ .RHY:G\DO\ P&7^0?5ZG;\5_F?8=%?'
MG_#U#X)_\]]9_P# +_[*C_AZA\$_^>^L_P#@%_\ 94<M3^27_@,O\@^KU.WX
MK_,^PZ*^//\ AZA\$_\ GOK/_@%_]E1_P]0^"?\ SWUG_P  O_LJ.6I_)+_P
M&7^0?5ZG;\5_F?8=%?'G_#U#X)_\]]9_\ O_ +*C_AZA\$_^>^L_^ 7_ -E1
MRU/Y)?\ @,O\@^KU.WXK_,^PZ*^//^'J'P3_ .>^L_\ @%_]E1_P]0^"?_/?
M6?\ P"_^RHY:G\DO_ 9?Y!]7J=OQ7^9]AT5\>?\ #U#X)_\ /?6?_ +_ .RJ
M:R_X*B_!?4+RWM89M8,UQ*L* V6!N8@#^+U-+EJ?R2_\!E_D'U>IV_%?YGU[
M17R7KW_!37X.^&]<O])OI-72]L9WMYE6SW .IP0#GGD50_X>H?!/_GOK/_@%
M_P#94<M3^27_ (#+_(/J]3M^*_S/L.BOCS_AZA\$_P#GOK/_ (!?_94?\/4/
M@G_SWUG_ , O_LJ?+4_DE_X#+_(/J]3M^*_S/L.BOCS_ (>H?!/_ )[ZS_X!
M?_94?\/4/@G_ ,]]9_\  +_[*CEJ?R2_\!E_D'U>IV_%?YGV'17QY_P]0^"?
M_/?6?_ +_P"RH_X>H?!/_GOK/_@%_P#94<M3^27_ (#+_(/J]3M^*_S/L.BO
MCS_AZA\$_P#GOK/_ (!?_94?\/4/@G_SWUG_ , O_LJ.6I_)+_P&7^0?5ZG;
M\5_F?8=%?'G_  ]0^"?_ #WUG_P"_P#LJ/\ AZA\$_\ GOK/_@%_]E1RU/Y)
M?^ R_P @^KU.WXK_ #/L.BOCS_AZA\$_^>^L_P#@%_\ 94?\/4/@G_SWUG_P
M"_\ LJ.6I_)+_P !E_D'U>IV_%?YGV'17QY_P]0^"?\ SWUG_P  O_LJ/^'J
M'P3_ .>^L_\ @%_]E1RU/Y)?^ R_R#ZO4[?BO\S[#HKX\_X>H?!/_GOK/_@%
M_P#94?\ #U#X)_\ /?6?_ +_ .RHY:G\DO\ P&7^0?5ZG;\5_F?8=%?'G_#U
M#X)_\]]9_P# +_[*C_AZA\$_^>^L_P#@%_\ 94<M3^27_@,O\@^KU.WXK_,^
MPZ*^//\ AZA\$_\ GOK/_@%_]E1_P]0^"?\ SWUG_P  O_LJ.6I_)+_P&7^0
M?5ZG;\5_F?8=%?'G_#U#X)_\]]9_\ O_ +*C_AZA\$_^>^L_^ 7_ -E1RU/Y
M)?\ @,O\@^KU.WXK_,^PZ*^4;C_@I5\(;;PO9>('DU8:;>7<UE$PM/F,L2([
M@C/ Q*G/N:RO^'J'P3_Y[ZS_ . 7_P!E2Y:G\DO_  &7^0?5ZG;\5_F?8=%?
M'G_#U#X)_P#/?6?_  "_^RH_X>H?!/\ Y[ZS_P" 7_V5/EJ?R2_\!E_D'U>I
MV_%?YGV'17QY_P /4/@G_P ]]9_\ O\ [*C_ (>H?!/_ )[ZS_X!?_94<M3^
M27_@,O\ (/J]3M^*_P S[#HKX\_X>H?!/_GOK/\ X!?_ &5'_#U#X)_\]]9_
M\ O_ +*CEJ?R2_\  9?Y!]7J=OQ7^9]AT5\>?\/4/@G_ ,]]9_\  +_[*C_A
MZA\$_P#GOK/_ (!?_94<M3^27_@,O\@^KU.WXK_,^PZ*^//^'J'P3_Y[ZS_X
M!?\ V5'_  ]0^"?_ #WUG_P"_P#LJ.6I_)+_ ,!E_D'U>IV_%?YGV'17QY_P
M]0^"?_/?6?\ P"_^RH_X>H?!/_GOK/\ X!?_ &5'+4_DE_X#+_(/J]3M^*_S
M/L.BOCS_ (>H?!/_ )[ZS_X!?_94?\/4/@G_ ,]]9_\  +_[*CEJ?R2_\!E_
MD'U>IV_%?YGV'17QY_P]0^"?_/?6?_ +_P"RH_X>H?!/_GOK/_@%_P#94<M3
M^27_ (#+_(/J]3M^*_S/L.BOCS_AZA\$_P#GOK/_ (!?_94?\/4/@G_SWUG_
M , O_LJ.6I_)+_P&7^0?5ZG;\5_F?8=%?'G_  ]0^"?_ #WUG_P"_P#LJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^=_VP/^2T-_V ]&_P#3=;U]$5\[_M@?\EH;_L!Z-_Z;
MK>O8RO\ C/T_5'3A_B/%:***^H.\**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O1O!?_ "1+XG_]?>B_^AW=><UZ-X+_ .2)?$__
M *^]%_\ 0[NHGM\U^:$]CSFBBBK&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6IX3_Y&S0_^PA;_P#HU:RZU/"?_(V:'_V$+?\
M]&K2>P&[\9O^2N^-/^PQ=?\ HPUQU=C\9O\ DKOC3_L,77_HPUQU*/PH2V"B
MBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'HN
ML_\ )O?A3_L9-3_])[.O.J]%UG_DWOPI_P!C)J?_ *3V=>=5$-OO$@HHHJQA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z-^SW_R
M52R_[!VJ?^FZYKSFO1OV>_\ DJEE_P!@[5/_ $W7-><UFOC?HOU%U"BBBM!A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^['[!'
M_)H_PX_[!P_]":OPGK]V/V"/^31_AQ_V#A_Z$U>-FG\)>IS8CX3\)Z0^_2EI
M#T->R=)^GW[/=Y^T-H'P/\,V]U?_  NL=/EM8;C0I/&SD7\5N 3 X", P4,2
MA;Y@&ZXXK\\/B]:ZS8_%+Q7#XAU6WUS75U*?[;J5I*)(KF;>2TB,.JD]*^N-
M0\6? +XJ^"? '_">?#_XIZSKVA:!;:4VI:=9JD<Z(N1@B0!E!)"G .W&:^.?
MB%#H5MXZUZ+PS9:AIWAZ.\D6PM-5&+N&$,=JRC)PX'7GK7GX:-IR;5F_+_@F
M,-V?4_\ P2E_Y.G/_8"O/_0HJ^VOV\O^/CP1_NWO\X*^)?\ @E+_ ,G3G_L!
M7G_H45?;7[>7_'QX(_W;W^<%>+F?\?Y'+7^,^4****\DYPHHHH **** /:-,
M^!OAN'X9Z!XQ\1^,Y]$M]7E,*11:8;@(^YP 6#],(3D@"I;C]F6[L_BEH7A:
M;6XWTS6H7N;35K>'=N15+<H2.>G?H>M=[J$?A1_V6?A^?%TNK1Z>MXQ0:0D;
M2,^9N&WD87&>G/2H_ OQ<B^*?[1'@U-/L7TW1-)M9K6S@E;=(5$1&YO0X &/
M;J: .2A_9R\/Z]K6O>'_  YXY:_\3Z2)/,L+S3&MT<HVU@K[CGGT!KC?AI\%
MK[QY#JVI7VH0>'O#VD,5OM3N@2$8=54#[Q''<#FOHSP_<:'?>*OBO)X+TK^S
M/B'9O<@W%].UPMP/,.]XUR-F6'3&!E>O2O/]%\W5/V,]>2U9GO8=3:34$P2Y
M_?*QW?FI/TH Y&R^!&C>-=$U2[\!>,1XCOM-0S3Z==V#6<K(!U3).[^7O5/X
M>_!?2?%'PUUCQEKOB6?0;'3+K[--'%IYN6_@ . P.<N!C%=1^Q?;S1_$;5-1
M.4T^TTV0W,I'R $C )Z#H3^%:F@W$=U^RO\ $Z:''E2:V73'3:9H2* .#U[X
M&VT_@JZ\5^#/$L7BO2;+_C]C-NUM<V_N8R3QCGKGVK,\0_"1-#^#OA[QR-4:
M=M5N# ;$P!1%]_G?NY^YZ#K7H7[+T;Z=X+^)FJWO[G1O[+:%I9#B,RE6P/<\
MC\Q2^.HVN/V._ LD0\R.'42)&7D)S..?3GB@#SRQ^$L=Y\%+WQ\=49'M[S[+
M]@\@$-R!NW[O?IBM33?@;9:7X*L?%'CCQ*OA6QU+!L;>.T:ZN9AUW>6",#&#
MWX/.*ZS35-K^Q=J9F!C$^KGR]W&_YEZ?D?RJ[^V0KW4?@*^M1OT5]-9;>2/F
M/<=AP"/5=OY4 <)9_#7X>7&K063?$IY3>21I9FUT>20G>0 )1N'EMN.,'MS5
MSXJ_!OPA\+;B]TRZ\;W=SK\5N)X;'^QV"2EL[09 Y"YQ^%>:^"?^1S\/_P#8
M0M__ $:M>K?MC?\ ):9_^O"W_P#9J /#Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K4\+Z+_PD?B32]*\WR/MMS';^;MW;-S 9QWQ6773?#'_D
MH_A?_L)0?^AB@#V"Z_9A\//XRO/!MAX],GBR&'SDL[K3&BBD^4/CS Y'W3GC
M)X-<5I/P/FNO OC?7;[4&LK[PQ<&WDL5A#B5@0#\^X8'/H:]M^)WC_P/\+/C
MMJ_B2>UUK5/%T-LB16F(DLE+0JH8/G=G8<'(/4URW@77+GQ-^S]\8M7O"OVJ
M^NQ<2;>@+%3@>PZ?A0!\UHK2,JH-SL0 /4GH*]Q^(G[,,_@7X<GQ(FM?VA?6
MP@:_TY;<+]F60=2VXDX) Z#.:Y/]GOP:/&_Q8T.SE0/9V\GVRYW?=\N/YL'V
M) 'XU]/^%=//BKQY\0[34?%?AG5-,\30&&VT_3M46XN8MBE 3'@<A>3@G!%
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M_$;X+3>#?#=EXHT?5[?Q+X5O&\N+4+=2C(W/RR(<[3D$=3R.<5W?Q1_Y-/\
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M[OO7+?LJ_ 2/]I3XP6O@B76W\/)/9SW7VZ.V%P1Y8!V["Z]<]<U]"?!GY?\
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MA%?NBNNE-RG--Z)Z?<C2+NV+111726%:GA/_ )&S0_\ L(6__HU:RZU/"?\
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M>_"G_8R:G_Z3V=>=5Z+K/_)O?A3_ +&34_\ TGLZ\ZJ(;?>)!1115C"BBB@
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M!,365G=AMWVN7:J,ZGN@"*H/?!/>G*4_;J,7==?+L%WSI(^4****[34****
M"BBB@#T;]GO_ )*I9?\ 8.U3_P!-US7G->C?L]_\E4LO^P=JG_INN:\YK-?&
M_1?J+J%%%%:#"BBB@ HHHH ^L=(_8[\ Z;\"_ 7Q(\=_%F[\)VWBV0P06\/A
MYKQ(I-S@!G648&U,EB !3YO^"?\ J>E?M+>%OA?J?BJ'^Q_$UG-J&F^)+&U\
MT20I&[C,1=<-\@!&[&&!!->V>,(_AFW[ ?P"D^*$_B:/1XKQW@C\,Q02232
MSY23S2,(5W<J<YQ53X,_M-1_M)_M\?#6XTS29-"\,:#IMWIVEV4TF^4QBVE)
MDD(X#'@8'0*.3UKQ_;5K2DGHN;MTVL<W-+5^I\C>&O@*GB#]J%/A"=;:"-M?
MGT3^U_LP8XC=U\WRMW?9]W=WZU2^+'P-N_AW\?=2^%^FWK:]>P:C'IUM<>3Y
M37#R%0OR9.#EAQDU]A>!_&_P:F_;T33+/X5ZO:^,_P#A+[N(:^_B>5X/M(DE
MWS?9MF-I(8[,\9]JV?!/PVA\9?\ !4#Q_P"(M2\J+1/!K/K5S<7+!(4D$2K#
MN8\+AF,F?^F1K3ZS*,KR5DHWZ;E<[6_8\&_:N_8/D_9M\ V/BC3O%_\ PF%N
M+\:=JBQV0@6QE*!E!(D8G)..0.H]:Y?X5_LI:7K_ ,$Y_BS\0_'2> ?!379L
M;&2'3GO[J[F#;3MB5E^7(<=2?D;C'-?:'@'X>W_Q8^&/Q^\'ZW\0? GC6^\5
MW$^OZ39^%-?349K67JH90JE1E(EW#-?*7[._[8FE_#?X=R_"?XI^![?QS\/C
M=M(L+ ">S9G)?:K##@,68#*D$GGM4PJUIP<4[R35]MO+H)2DU9;HY7P+^S3X
M6^)W[17A_P"'?A3XD0Z[H&L6K72>(+?3F66#;&SF*2W9AM<%<$;N^?:I/BM\
M$?@M\-Y/%.DVWQEU;5/%NBO/:KI3^$9HHIKJ-BIB\_S"J@L"-W([U]6^"/V>
M?"7P,_;K^$.H>![FZ'ASQ7I-UJEOI]\Q:6T!@8A03\VTAAPW(.17S1^UIXR^
M$=Y\0/B1IFE?#75=.\:C7+I'\02^(Y)H&F%PWF2?9BFT!L-A<\9]JN%:52HE
M%NUEV[]?^ -2<FK'SYX-T&U\4>*M,TJ^UJR\.V=W,(YM5U$D6]JO4NY )QQ^
MHKZ=\+_L6>"/BYX5\677PK^,"^+O$/ARW-U<:7>Z')8)*@!R8Y&<EAP0#MP2
M1G&:^3K-HDNX&GB:>!74R1(VTNH/*@]LC/-?I'^QCX@^''Q7\._$KP#\*/#&
MJ_";Q5J6E&1]:N;[^UMT/W"ADD4&,98< =R0<@5MBISIQYXM_A;Y]?N*J-Q5
MT?FN5*L0PVL#@@]C15G4[%]*U*\L9)%EDM9Y(&D0Y5BK%21['%5J[34****
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M2V5B49)8X2LTA5=H+MN(/'H!7GM% !1110 4444 %%%% !1110 5\[_M@?\
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M/6OE?_AI#XC_ /0S3?\ ?F+_ .)H_P"&D/B/_P!#--_WYB_^)KE_LW%]H_\
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M3?\ ?F+_ .)H_LW%]H_^!/\ ^1#ZM#^;\/\ @GU1N'K1N'K7RO\ \-(?$?\
MZ&:;_OS%_P#$T?\ #2'Q'_Z&:;_OS%_\31_9N+[1_P# G_\ (A]6A_-^'_!/
MJC</6C</6OE?_AI#XC_]#--_WYB_^)H_X:0^(_\ T,TW_?F+_P")H_LW%]H_
M^!/_ .1#ZM#^;\/^"?5&X>M&X>M?*_\ PTA\1_\ H9IO^_,7_P 31_PTA\1_
M^AFF_P"_,7_Q-']FXOM'_P "?_R(?5H?S?A_P3ZHW#UHW#UKY7_X:0^(_P#T
M,TW_ 'YB_P#B:/\ AI#XC_\ 0S3?]^8O_B:/[-Q?:/\ X$__ )$/JT/YOP_X
M)]4;AZT;AZU\K_\ #2'Q'_Z&:;_OS%_\31_PTA\1_P#H9IO^_,7_ ,31_9N+
M[1_\"?\ \B'U:'\WX?\ !/JC</6C</6OE?\ X:0^(_\ T,TW_?F+_P")H_X:
M0^(__0S3?]^8O_B:/[-Q?:/_ ($__D0^K0_F_#_@GU1N'K1N'K7RO_PTA\1_
M^AFF_P"_,7_Q-'_#2'Q'_P"AFF_[\Q?_ !-']FXOM'_P)_\ R(?5H?S?A_P3
MZHW#UHW#UKZ&_P"";$4/QB^ VKZUXRMK?7]4A\17%I'=7,*[EB6WMF"< < N
MQ_&OJ_\ X5'X,_Z%O3_^_(KRJL:]*;@XK3S?_P B<\H4XNSD_N_X)^96X>M&
MX>M?IK_PJ/P9_P!"WI__ 'Y%'_"H_!G_ $+>G_\ ?D5ES5OY5][_ /D2>6E_
M,_N_X)^96X>M&X>M?IK_ ,*C\&?]"WI__?D4?\*C\&?]"WI__?D4<U;^5?>_
M_D0Y:7\S^[_@GYE;AZT;AZU^FO\ PJ/P9_T+>G_]^11_PJ/P9_T+>G_]^11S
M5OY5][_^1#EI?S/[O^"?F5N'K1N'K7Z:_P#"H_!G_0MZ?_WY%'_"H_!G_0MZ
M?_WY%'-6_E7WO_Y$.6E_,_N_X)^96X>M&X>M?IK_ ,*C\&?]"WI__?D4?\*C
M\&?]"WI__?D4<U;^5?>__D0Y:7\S^[_@GYE;AZT;AZU^FO\ PJ/P9_T+>G_]
M^11_PJ/P9_T+>G_]^11S5OY5][_^1#EI?S/[O^"?F5N'K1N'K7Z:_P#"H_!G
M_0MZ?_WY%'_"H_!G_0MZ?_WY%'-6_E7WO_Y$.6E_,_N_X)^96X>M&X>M?IK_
M ,*C\&?]"WI__?D4?\*C\&?]"WI__?D4<U;^5?>__D0Y:7\S^[_@GYE;AZT;
MAZU^FO\ PJ/P9_T+>G_]^11_PJ/P9_T+>G_]^11S5OY5][_^1#EI?S/[O^"?
MF5N'K1N'K7Z:_P#"H_!G_0MZ?_WY%'_"H_!G_0MZ?_WY%'-6_E7WO_Y$.6E_
M,_N_X)^96X>M&X>M?IK_ ,*C\&?]"WI__?D4?\*C\&?]"WI__?D4<U;^5?>_
M_D0Y:7\S^[_@GYE;AZT;AZU^FO\ PJ/P9_T+>G_]^11_PJ/P9_T+>G_]^11S
M5OY5][_^1#EI?S/[O^"?F5N'K1N'K7Z:_P#"H_!G_0MZ?_WY%'_"H_!G_0MZ
M?_WY%'-6_E7WO_Y$.6E_,_N_X)^96X>M&X>M?IK_ ,*C\&?]"WI__?D4?\*C
M\&?]"WI__?D4<U;^5?>__D0Y:7\S^[_@GYE;AZT;AZU^FO\ PJ/P9_T+>G_]
M^11_PJ/P9_T+>G_]^11S5OY5][_^1#EI?S/[O^"?F5N'K1N'K7Z:_P#"H_!G
M_0MZ?_WY%'_"H_!G_0MZ?_WY%'-6_E7WO_Y$.6E_,_N_X)^96X>M&X>M?IK_
M ,*C\&?]"WI__?D4?\*C\&?]"WI__?D4<U;^5?>__D0Y:7\S^[_@GYG3,/W?
M/\ _F:CW#UK]"?$WP[\,V>J&.'0[&./8IVB$>]97_""^'O\ H#67_?E:;E6;
M^%?>_P#Y$=J7\S^[_@GP7N'K1N'K7WI_P@OA[_H#67_?E:/^$%\/?] :R_[\
MK2YJW\J^]_\ R(N6E_,_N_X)\%[AZT;AZU]Z?\(+X>_Z UE_WY6C_A!?#W_0
M&LO^_*T<U;^5?>__ )$.6E_,_N_X)\%[AZT;AZU]Z?\ ""^'O^@-9?\ ?E:/
M^$%\/?\ 0&LO^_*T<U;^5?>__D0Y:7\S^[_@GP7N'K1N'K7WI_P@OA[_ * U
ME_WY6C_A!?#W_0&LO^_*T<U;^5?>_P#Y$.6E_,_N_P""?!>X>M&X>M?>G_""
M^'O^@-9?]^5H_P"$%\/?] :R_P"_*T<U;^5?>_\ Y$.6E_,_N_X)\%[AZT;A
MZU]Z?\(+X>_Z UE_WY6C_A!?#W_0&LO^_*T<U;^5?>__ )$.6E_,_N_X)\%[
MAZT;AZU]Z?\ ""^'O^@-9?\ ?E:/^$%\/?\ 0&LO^_*T<U;^5?>__D0Y:7\S
M^[_@GP7N'K1N'K7WI_P@OA[_ * UE_WY6C_A!?#W_0&LO^_*T<U;^5?>_P#Y
M$.6E_,_N_P""?!>X>M&X>M?>G_""^'O^@-9?]^5H_P"$%\/?] :R_P"_*T<U
M;^5?>_\ Y$.6E_,_N_X)\%[AZT;AZU]Z?\(+X>_Z UE_WY6C_A!?#W_0&LO^
M_*T<U;^5?>__ )$.6E_,_N_X)\%[AZT;AZU]Z?\ ""^'O^@-9?\ ?E:/^$%\
M/?\ 0&LO^_*T<U;^5?>__D0Y:7\S^[_@GP7N'K1N'K7WI_P@OA[_ * UE_WY
M6C_A!?#W_0&LO^_*T<U;^5?>_P#Y$.6E_,_N_P""?!>X>M&X>M?>G_""^'O^
M@-9?]^5H_P"$%\/?] :R_P"_*T<U;^5?>_\ Y$.6E_,_N_X)\%[AZT;AZU]Z
M?\(+X>_Z UE_WY6C_A!?#W_0&LO^_*T<U;^5?>__ )$.6E_,_N_X)\%[AZT;
MAZU]Z?\ ""^'O^@-9?\ ?E:/^$%\/?\ 0&LO^_*T<U;^5?>__D0Y:7\S^[_@
MGP7N'K1N'K7WI_P@OA[_ * UE_WY6C_A!?#W_0&LO^_*T<U;^5?>_P#Y$.6E
M_,_N_P""?!>X>M?.W[8#J/C0V2!_Q(]&[_\ 4.MZ_7W_ (07P]_T!K+_ +\K
M6S<?!KP+K/D75_X2TB]N6@C4S3VB.Q 0 #)'0  #V%=N$Q57#3<W!/3^;_[4
MUIRI0=[O[O\ @G\_WF+_ 'A^='F+_>'YU^_?_"A?AS_T)&A?^ ,?^%'_  H7
MX<_]"1H7_@#'_A7K?VO4_P"?2_\  O\ [4Z/;4N[^[_@GX">8O\ >'YT>8O]
MX?G7[]_\*%^'/_0D:%_X Q_X4?\ "A?AS_T)&A?^ ,?^%']KU/\ GTO_  +_
M .U#VU+N_N_X)^ GF+_>'YT>8O\ >'YU^_?_  H7X<_]"1H7_@#'_A1_PH7X
M<_\ 0D:%_P" ,?\ A1_:]3_GTO\ P+_[4/;4N[^[_@GX">8O]X?G1YB_WA^=
M?OW_ ,*%^'/_ $)&A?\ @#'_ (4?\*%^'/\ T)&A?^ ,?^%']KU/^?2_\"_^
MU#VU+N_N_P""?@)YB_WA^='F+_>'YU^_?_"A?AS_ -"1H7_@#'_A1_PH7X<_
M]"1H7_@#'_A1_:]3_GTO_ O_ +4/;4N[^[_@GX">8O\ >'YT>8O]X?G7[]_\
M*%^'/_0D:%_X Q_X4?\ "A?AS_T)&A?^ ,?^%']KU/\ GTO_  +_ .U#VU+N
M_N_X)^ GF+_>'YT>8O\ >'YU^_?_  H7X<_]"1H7_@#'_A1_PH7X<_\ 0D:%
M_P" ,?\ A1_:]3_GTO\ P+_[4/;4N[^[_@GX">8O]X?G1YB_WA^=?OW_ ,*%
M^'/_ $)&A?\ @#'_ (4?\*%^'/\ T)&A?^ ,?^%']KU/^?2_\"_^U#VU+N_N
M_P""?@)YB_WA^='F+_>'YU^_?_"A?AS_ -"1H7_@#'_A1_PH7X<_]"1H7_@#
M'_A1_:]3_GTO_ O_ +4/;4N[^[_@GX">8O\ >'YT>8O]X?G7[]_\*%^'/_0D
M:%_X Q_X4?\ "A?AS_T)&A?^ ,?^%']KU/\ GTO_  +_ .U#VU+N_N_X)^ G
MF+_>'YT>8O\ >'YU^_?_  H7X<_]"1H7_@#'_A1_PH7X<_\ 0D:%_P" ,?\
MA1_:]3_GTO\ P+_[4/;4N[^[_@GX">8O]X?G7H_@MU_X4C\3SN'_ !]Z+W_V
M[NOVT_X4+\.?^A(T+_P!C_PJOK'P9\":?H-U';>$='ACFDB\Q$LT"OC=MR,<
MXR<>F34RS:HU;V2_\"_^U%[:EW?W?\$_ SS%_O#\Z/,7^\/SK]QO^%0>!O\
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MWA^=?N-_PJ#P-_T*&B_^ ,?^%'_"H/ W_0H:+_X Q_X4?VO4_P"?2_\  O\
M[4/;4N[^[_@GX<^8O]X?G1YB_P!X?G7[C?\ "H/ W_0H:+_X Q_X4?\ "H/
MW_0H:+_X Q_X4?VO4_Y]+_P+_P"U#VU+N_N_X)^'/F+_ 'A^='F+_>'YU^XW
M_"H/ W_0H:+_ . ,?^%'_"H/ W_0H:+_ . ,?^%']KU/^?2_\"_^U#VU+N_N
M_P""?ASYB_WA^='F+_>'YU^XW_"H/ W_ $*&B_\ @#'_ (4?\*@\#?\ 0H:+
M_P" ,?\ A1_:]3_GTO\ P+_[4/;4N[^[_@GX<^8O]X?G6KX3D7_A+-#^8?\
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MYB_WA^=?O5XG^#O@:UTVRMHO"6CK;B61Q#]C38&(4%@,8!( Y]A7-_\ "H/
MW_0H:+_X Q_X5,<VJ+_ETO\ P+_[42K4N[^[_@GX<^8O]X?G1YB_WA^=?N-_
MPJ#P-_T*&B_^ ,?^%'_"H/ W_0H:+_X Q_X57]KU/^?2_P# O_M1^VI=W]W_
M  3\.?,7^\/SH\Q?[P_.OW&_X5!X&_Z%#1?_  !C_P */^%0>!O^A0T7_P
M8_\ "C^UZG_/I?\ @7_VH>VI=W]W_!/PY\Q?[P_.CS%_O#\Z_<;_ (5!X&_Z
M%#1?_ &/_"C_ (5!X&_Z%#1?_ &/_"C^UZG_ #Z7_@7_ -J'MJ7=_=_P3\.?
M,7^\/SH\Q?[P_.OW&_X5!X&_Z%#1?_ &/_"C_A4'@;_H4-%_\ 8_\*/[7J?\
M^E_X%_\ :A[:EW?W?\$_#GS%_O#\Z/,7^\/SK]QO^%0>!O\ H4-%_P# &/\
MPH_X5!X&_P"A0T7_ , 8_P#"C^UZG_/I?^!?_:A[:EW?W?\ !/PY\Q?[P_.C
MS%_O#\Z_<;_A4'@;_H4-%_\  &/_  H_X5!X&_Z%#1?_  !C_P */[7J?\^E
M_P"!?_:A[:EW?W?\$_#GS%_O#\Z/,7^\/SK]QO\ A4'@;_H4-%_\ 8_\*/\
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MX Q_X4?VO4_Y]+_P+_[4/;4N[^[_ ()^ GF+_>'YT>8O]X?G7[]_\*%^'/\
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MB_WA^=?OW_PH7X<_]"1H7_@#'_A1_P *%^'/_0D:%_X Q_X4?VO4_P"?2_\
M O\ [4/;4N[^[_@GX">8O]X?G1YB_P!X?G7[]_\ "A?AS_T)&A?^ ,?^%'_"
MA?AS_P!"1H7_ ( Q_P"%']KU/^?2_P# O_M0]M2[O[O^"?@)YB_WA^='F+_>
M'YU^_?\ PH7X<_\ 0D:%_P" ,?\ A1_PH7X<_P#0D:%_X Q_X4?VO4_Y]+_P
M+_[4/;4N[^[_ ()^ GF+_>'YT>8O]X?G7[]_\*%^'/\ T)&A?^ ,?^%'_"A?
MAS_T)&A?^ ,?^%']KU/^?2_\"_\ M0]M2[O[O^"?@)YB_P!X?G7[L_L#G/[(
M_P .,<_\2X?^A-71?\*%^'/_ $)&A?\ @#'_ (5Z9X;T/3_#NB6FGZ79PZ?8
MPQA8K>W0(B#'0 <"N3$8Z>*BH2A;YW_1&%:I"<;1O]W_  3^;JK^B^'=6\3W
M3VFC:7>ZO=+&TK06%L\[A!U8J@)"C(R>@JA77_##XN>+?@OK]QKG@S67T35)
M[22REN$ACE+0N063$BL.2JG.,C'!KZZ5[>[N=>O0^QM1F^!_QB\"_#R3QSX'
M^+VJZYHGAZUTLZCI6BOY$Z(H(VD$JRC)"L,97&:^+/B-8:+I?CS7[/PY::E8
M:#!>R1V-KK$?EWD4(;Y5F7LX'4>M?H5\-=:^)&@^!? &A^(_VH[3P%XEUW2[
M>30?"\FA6MP$MG4+:+),5!4N  ,@GW)S7P)\9(?$UO\ %CQ=#XTN/M?BR/5+
MA-4G 4"2X#D.PV@+@GG@ 5P89^\U?3U?ZI?@90W9]+?\$I?^3IS_ -@*\_\
M0HJV/^"NW_)RGAW_ +%.V_\ 2N\K'_X)2_\ )TY_[ 5Y_P"A15L?\%=O^3E/
M#O\ V*=M_P"E=Y63_P!^7H3_ ,O?D?$%%%%>L= 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Z]?\$C?^39]=_[&JZ_]);2
MOMNOB3_@D;_R;/KO_8U77_I+:5]MU\7C/]XGZGF5/C84445QF04444 %%%%
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M]J8#_H(A_P"!1_S-_J&+_P"?,O\ P%_Y&Q16/_PGO@__ *&?3_\ OZ/\:/\
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M_A_X$O\ ,/J.*_Y]2_\  7_D4:*O?:/"7_0WV/YK_P#%4?:/"7_0WV/YK_\
M%4?VE@?^?\/_  )?YA]1Q7_/J7_@+_R*-%7_ #O"?_0W67YK_P#%4>=X3_Z&
MZR_-?_BJ?]I8'_G_  _\"7^8?4<5_P ^I?\ @+_R*%%7_.\)_P#0W67YK_\
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M^@K[/AG'5:.+CAK^Y.^G9VO?\#YK.\+"IAW7M[T?RV./6DI5I*_73X ****
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MV<3X-^%\'AC7KKQ#J.L:AXH\37, M&U;5/*5X[<'<(8XXD2.-=W)VH"QY8G
MJ#P?\)U\#ZQK$NF^(]4&@ZE<7-X?#TJ6[6T$\[;Y7C?RO.&7+MM,A4%S@8QC
MO:*7/(+L\U@^ N@P?"W1_ XO-1^SZ/,+K3M4694O+6X5W=)E95"[E+L,%=I!
M((()!NZ3\*[B :E-K'C+Q%K^IW=HUC'J$TT5J]I$Q!/DI;1QQJ^X ^9MW' !
M. !7>T4_:2[A=GG/A_X/RV?B;3-=\1>,-:\9WFDHXTU=4CM88[5W7:\H6WAC
M#N5^7<^[ )QC)SZ-114RDY;@%%%%2(**** "BBB@ HHHH **** .'\7_ /(8
M/_7-?ZUB5M^+_P#D,'_KFO\ 6L2@ HHHH **** "BBB@ JMJFGIJVEWEC*S)
M%=020.R8W!74J2,]\&K-% &/X/\ #5KX'\):3H-K)-<V>EVD=K'), TCHBA0
M6V@ D@=A7FW[-?P[/@W0_$.KSV-UIEQX@U:>\BL;U6$UI:AV$,1!Y4?>;;VW
MU[#16G.[-=QW/ ?A?\(=8_XK:]C\0>(_!<VJ>)=5>>"V2+9>0-<$Q3*L\;["
M4)Q)%M)!')P,>DZA\(= NO!VD>';-;C28=&=9]+O+.4BXLIU# 2J[9W,=[;M
MV0P9@P()%=K152JRD[C<FSF?#/A'4M&OY+S5/%VL>))3'Y<:7BV\$,8)R3Y=
MO'&K,>/F8$CH",FMS5K2XO\ 3;BWM;^;2[F1"L=Y!'&[PG^\JR*R$_[RD5:H
MK-R;=Q'FGAKX.ZGX:\7:EXA3X@Z[>76J20/J$,]EIPCN1$I5%.VV!088_<()
M]:[GQ1H,'BKPYJFC7,DD-OJ%M):R20XWJKJ5)7((SSW%:5%-S<G=A=GF5K\%
M9Y-!MO#^L>.-?USPU#!':G2I([2U2:)%"JDDEO!'(RX&"I;##[P-=/XF^'^F
M^)H_#<3M)8PZ#J$&HVL5H%5-T0(1""#\F#T&#QUKIJ*;J2;N%V<!JWPE:X\0
M:OJFC>*M:\+C6=C:G:Z9Y!2Y=5V^8&DC9XG*X4M$RG@'J,UEQ_LY^&4^$]A\
M.S<ZE)H%G?\ V]&><&=F^TM<!#)C. SXW?>P <YYKU.BG[2?<?,S@M%^$_V3
M7-+U/6O$^L>*FT?<=+AU3R EHS*4,G[J-#+)L)4/*68 G!^8Y=?_  LECU[4
MM6\.>*=6\(S:HXFOX+"&UGAN)@H42[+B*0(^U0"4QNP,YP*[NBE[25PYF<CX
MF^&MGXH\%P>'KG4]3#6\L-S;ZJ;CS+R*XBD$D<P=P0S!U!PP*]L8XJOK7PR/
MB#3M(:]\1:DWB/29'ELO$<,=O#=1E^&!1(Q"RE?E*,A4X!(R,UVU%)3DA79R
MNE^";ZVLM3BU/Q=KNM7-[%Y NY)(K5K=<'!B2W2-$<$D[]NX\ D@ #/T?X7S
M0>(--UC7_%>K^+;G2U8:>FHQ6T,=L[+M>3;!%'O<K\NY]V 3C&37=44<["["
MBBBH$%%%% !1110 5M^*?#/_  FO@.;2%8)<F&.6W9NF]0"!^/3\:Q*["S8Q
MVMJRG!$2<_\  17-B</3Q=">'K*\9)I^C-Z%:>'JQK4W:47=?(^/;RSGT^ZF
MMKF)H+B%BDD;C!4CM4-?6'BSP#X?\=8DU&W:WO@,"\M_E8_7U_&N*_X9OTC)
M_P"*CN0/^N"U_.^.X!S6C6<<*E4AT=TG\T[:^ES]DPO%V JTTZ[<)=59M?)H
M\$HKWK_AF_2/^ACN?^_"T?\ #-^D?]#'<_\ ?A:\_P#U'SW_ )\K_P "C_F=
MG^M.5?\ /Q_^ R_R/!:*]Z_X9OTC_H8[G_OPM'_#-^D?]#'<_P#?A:/]1\]_
MY\K_ ,"C_F'^M.5?\_'_ . R_P CP6E6O>?^&;](_P"ACN?^_"TH_9PT@?\
M,QW/_?A:K_4?/?\ GRO_  */^8O]:<J_Y^/_ ,!E_D>#T5[S_P ,XZ3_ -#%
M<?\ ?A:/^&<=)_Z&*X_[\+1_J/GO_/E?^!1_S#_6G*O^?C_\!E_D>#4Y:]W_
M .&<=)_Z&*X_[\+0/V<])'_,Q7'_ 'X6G_J1GO\ SY7_ (%'_,3XIRK_ )^/
M_P !E_D>$TY>E>Z_\,YZ3_T,5Q_WX6E_X9TTG_H8KC_OPM/_ %(SS_GRO_ H
M_P"8O]:,J_Y^/_P&7^1X33Z]S_X9UTG_ *&*X_[\+2_\,[:3_P!#%<?]^%JO
M]2<\_P"?*_\  H_YB_UHRK_GX_\ P&7^1X717NG_  SMI/\ T,5Q_P!^%H_X
M9WTG_H8KC_ORM5_J3GG_ #Y7_@4?\R?]:,K_ .?C_P# 9?Y'AJ]*6O<O^&=]
M)_Z&*X_[\+1_PSSI/_0PW'_?A:?^I6=_\^5_X%'_ ##_ %GRO_GX_P#P&7^1
MX<M+7N/_  SSI/\ T,-Q_P!^5I?^&>M)_P"AAN/^_*T_]2\[_P"?*_\  H_Y
MD_ZSY7_S\_\ )7_D>'4ZO;_^&>])_P"AAN/^_*TRX^ >C6L)EE\1W"1@@%C"
MO>J_U+SO_GRO_ H_YB_UFRO_ )^?^2O_ "/$Z5:]A_X4QX;_ .AIF_[\"C_A
M3/AO_H:9O^_ JO\ 4O._^?*_\"C_ )B_UFRO_GY_Y*_\CR"BO8/^%,^&_P#H
M:9O^_ H_X4SX;_Z&F;_OP*?^IF=?\^E_X%'_ ##_ %FRO_GY_P"2O_(\AHKU
M_P#X4WX<_P"AIF_[\"C_ (4WX;_Z&F;_ +\"J_U-SK_GTO\ P*/^9/\ K+EG
M_/S\'_D>1+TI:]=_X4[X<_Z&F;_OP*/^%.^'/^AIF_[\"G_J;G7_ #Z7_@4?
M\Q?ZRY9_S\_!_P"1Y%3Z]:_X4[X;_P"AHF_[\"E_X4_X<_Z&B;_OP*?^IN=?
M\^E_X%'_ #)_UDRS_GY^#_R/)*5:]:_X4_X<_P"AHE_[\"E'P@\.?]#1+_WX
M%5_J=G/_ #Z7_@4?\Q?ZR99_S\_!_P"1Y+3EZ5ZS_P *A\.?]#1+_P!^11_P
MJ+PY_P!#/+_WX%5_J?G/_/I?^!1_S%_K)EO_ #\_!_Y'D]/KU;_A4?AS_H9Y
M?^_ I?\ A4GAW_H9Y?\ OR*K_4_.?^?2_P# H_YB_P!8\M_Y^?@_\CRBG+TK
MU7_A4GAS_H9Y?^_(I?\ A4OAW_H9Y?\ OR*K_5#./^?2_P# H_YD_P"L>6_\
M_/P?^1Y317JW_"IO#O\ T,\O_?D4?\*F\._]#/+_ -^11_JAG'_/I?\ @4?\
MQ?ZQ9;_S\_!_Y'EE%>J?\*G\._\ 0SR_]^11_P *G\._]#-+_P!^15?ZHYQ_
MSZ7_ (%'_,7^L67?\_/P?^1Y:M+7J0^%/AT?\S-)_P!^13E^%/AUF 'B64DG
M _<BJ_U2SC_GTO\ P*/^8?ZQ9=_S\_!_Y'EM%>P_\*/TQ>#KD_\ WY6D_P"%
M'Z7_ -!V;_OTM'^J6;_\^E_X%'_,G_6'+O\ GY^#_P CR%:6O7O^%(Z7_P!!
MV?\ []+2_P#"D=+_ .@Y/_WZ6J_U3S?_ )]+_P "C_F'^L.7?\_/P?\ D>04
MY>E>N_\ "D=+_P"@Y-_WZ6C_ (4GIG_0<F_[]+5?ZIYO_P ^E_X%'_,G_6#+
MOY_P?^1Y'2K7KG_"D],_Z#DW_?I:/^%*:9_T')O^_2U7^JF;?\^E_P"!1_S#
M_6#+OY_P?^1Y)3EKUK_A2NF?]!R;_OTM*/@KI@_YCDW_ 'Z6G_JIFW_/I?\
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M_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\
MQ-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69
MTM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PL
MCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6
M/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#X
MFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO
M_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?
M#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*
M^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<
MU_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_
M -!6/_OA_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA
M_P#XFC_A9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A
M9'AO_H*Q_P#?#_\ Q-'*^P69TM%<U_PLCPW_ -!6/_OA_P#XFC_A9'AO_H*Q
M_P#?#_\ Q-'*^P69F>+_ /D,'_KFO]:Q*/$_C71+K5"\5\)$V*-RQ/CO_LUD
M_P#"6:3_ ,_?_D)__B:.5]@LS6HK)_X2S2?^?O\ \A/_ /$T?\)9I/\ S]_^
M0G_^)HY7V"S-:BLG_A+-)_Y^_P#R$_\ \31_PEFD_P#/W_Y"?_XFCE?8+,UJ
M*R?^$LTG_G[_ /(3_P#Q-'_"6:3_ ,_?_D)__B:.5]@LS6HK)_X2S2?^?O\
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M*R?^$LTG_G[_ /(3_P#Q-'_"6:3_ ,_?_D)__B:.5]@LS6HK)_X2S2?^?O\
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M^&_PIT7B/35E0FZ  8'[C>OTHY7V"S/5)/\ 6-]:;6*_CC068D:E'C/]UO\
M"F_\)QH7_02C_P"^6_PHY7V"S-RBL/\ X3C0O^@E'_WRW^%'_"<:%_T$H_\
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M=10 W:O]T?E1M7^Z/RIU% #=J_W1^5&U?[H_*G44 -VK_='Y4;5_NC\J=10
MW:O]T?E1M7^Z/RIU% #=J_W1^5&U?[H_*G44 -VK_='Y4;5_NC\J=10 W:O]
MT?E1M7^Z/RIU% #=J_W1^5&U?[H_*G44 -\M?[H_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:?W5_
M*CRT_NK^5.HH ;Y:?W5_*CRT_NK^5.HH ;Y:_P!T?E1Y:_W1^5.HH ;Y:_W1
M^5'EK_='Y4ZB@!OEK_='Y4>6O]T?E3J* &^6O]T?E1Y:_P!T?E3J* &^6O\
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MEK_='Y4>6O\ ='Y4ZB@!OEK_ '1^5'EK_='Y4ZB@!OEK_='Y4>6O]T?E3J*
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M/_C->Q_9=;NOQ_R.GZO(_;NBOQ$_X>4?M#_]#U%_X);#_P",T?\ #RC]H?\
MZ'J+_P $MA_\9H_LNMW7X_Y!]7D?MW44US#;X\V5(L]-[ 9_.OS;_P""?_[8
MOQ:^.7Q\_P"$;\:>)TU;1O[)N;G[,NG6L'[Q6CVMNCC5N,GC..:^K_VS)Y+7
MX3P2PR-%(-0B =#@X(;O7FXFA4P\N1VN9./)*TCW'^T[/_G[@_[^+_C1_:=G
M_P _<'_?Q?\ &ORO_MO4/^?ZX_[^M_C1_;>H?\_UQ_W];_&N']]Y?B5^Z\S]
M4/[3L_\ G[@_[^+_ (T?VG9_\_<'_?Q?\:_*_P#MO4/^?ZX_[^M_C1_;>H?\
M_P!<?]_6_P :/WWE^(?NO,_5#^T[/_G[@_[^+_C1_:=G_P _<'_?Q?\ &ORO
M_MO4/^?ZX_[^M_C1_;>H?\_UQ_W];_&C]]Y?B'[KS/U0_M.S_P"?N#_OXO\
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M/^_B_P"-']IV?_/W!_W\7_&ORO\ [;U#_G^N/^_K?XT?VWJ'_/\ 7'_?UO\
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MT[/_ )^X/^_B_P"-']IV?_/W!_W\7_&ORO\ [;U#_G^N/^_K?XT?VWJ'_/\
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M_OZW^-'[[R_$/W7F?JA_:=G_ ,_<'_?Q?\:/[3L_^?N#_OXO^-?E?_;>H?\
M/]<?]_6_QH_MO4/^?ZX_[^M_C1^^\OQ#]UYGZH?VG9_\_<'_ '\7_&C^T[/_
M )^X/^_B_P"-?E?_ &WJ'_/]<?\ ?UO\:/[;U#_G^N/^_K?XT?OO+\0_=>9^
MJ']IV?\ S]P?]_%_QH_M.S_Y^X/^_B_XU^5_]MZA_P _UQ_W];_&C^V]0_Y_
MKC_OZW^-'[[R_$/W7F?JA_:=G_S]P?\ ?Q?\:/[3L_\ G[@_[^+_ (U^5_\
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MI]V?T;_VA:_\_,/_ '\'^-']H6O_ #\P_P#?P?XU_.1_PFWB'_H.ZE_X%/\
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M\"G_ ,:/^$V\0_\ 0=U+_P "G_QH_LG$?SK[G_F'U>GW9_1O_:%K_P _,/\
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M&6@H^MZBR-J%N"K73D$>8O'6M#XK>,->@^*7C&./6M0CC36KU51;EP% G<
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M .-'_";>(?\ H.ZE_P"!3_XT?V3B/YU]S_S#ZO3[L_HW_M"U_P"?F'_OX/\
M&C^T+7_GYA_[^#_&OYR/^$V\0_\ 0=U+_P "G_QH_P"$V\0_]!W4O_ I_P#&
MC^R<1_.ON?\ F'U>GW9_1O\ VA:_\_,/_?P?XT?VA:_\_,/_ '\'^-?SD?\
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MC[X4VMG<>,?"&K>&8+QVCMY-2MS$)64 D+GJ0"*7/&_+?4+K8XNBM_P7\/\
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M\+2:'--*NGZ?]FN/.A:/:_R\#/7H>10!Y!1110 4444 %%%% !1110 4444
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M -+35,?[%^L#.2NML,_BE:G[2.IW/PS\%>!O!OAVXFTO3VLS=7+6KF-YW^4
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M_P")5H\*\(((R07 [;FRWXBO!*0=*6O5A!4XJ$=D="7*K(****L85Z-\#_\
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M[./Q9^%O@=]</Q"F^)OPHU&^BO&U*WOFGC64L5BDD0LP R^T.C%<GD#(J_\
MM"?$;]F_]H7XRWWBK4/$'B?0DU/2($:\T_2BZVM[&V#YL3 &4,A RI&"M9'C
M;]H3X<?#S]EF]^"WPSU/7/%_]M:BM_J6O:Q9FRCA4/&QCBA8D@GRD'IRQSG
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M7HW@_P#Y(I\2/^NVF?\ I17G-1'>7K^B$NH44458PHHHH *[#X-?\E=\%?\
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MKAO2O$/V'?\ BS_PB^,'QQF54N])TW^QM$>1>MW+U9?4@[,BN:_8K_:&\'?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** /1O!_\ R13XD?\ 7;3/_2BO.:]&\'_\D4^)'_7;3/\
MTHKSFHCO+U_1"74****L84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ;?@?\ Y';P_P#]A&W_ /1JUH?%O_DJWC3_ +#=[_Z4/6?X
M'_Y';P__ -A&W_\ 1JUH?%O_ )*MXT_[#=[_ .E#UG]OY"ZG*4445H,****
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M_ <4?\,+1?\ 0TO_ . XKZMHH]C_ 'G]X>T_NH^4O^&%HO\ H:7_ / <4?\
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MH/11]8Q'_/U_A_D'UJ?9?<?GQ_PZ,T7_ **!J'_@&G^-'_#HS1?^B@:A_P"
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M?6,1_P _7^'^0?6I]E]Q\/?\.N- _P"AXU+_ ,!(_P#&C_AUQH'_ $/&I?\
M@)'_ (U]PT4?6,1_S]?X?Y!]:GV7W'P]_P .N- _Z'C4O_ 2/_&C_AUQH'_0
M\:E_X"1_XU]PT4?6,1_S]?X?Y!]:GV7W'P]_PZXT#_H>-2_\!(_\:/\ AUQH
M'_0\:E_X"1_XU]PT4?6,1_S]?X?Y!]:GV7W'P]_PZXT#_H>-2_\  2/_ !H_
MX=<:!_T/&I?^ D?^-?<-%'UC$?\ /U_A_D'UJ?9?<?#W_#KC0/\ H>-2_P#
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M  Z,T7_HH&H?^ :?XU^@5G_QXVO_ %R7^52TE7Q"5E5?X?Y!]9GV7W'Y\?\
M#HS1?^B@:A_X!I_C1_PZ,T7_ **!J'_@&G^-?H/11]8Q'_/U_A_D'UJ?9?<?
MGQ_PZ,T7_HH&H?\ @&G^-'_#HS1?^B@:A_X!I_C7Z#T4?6,1_P _7^'^0?6I
M]E]Q^?'_  Z,T7_HH&H?^ :?XT?\.C-%_P"B@:A_X!I_C7Z#T4?6,1_S]?X?
MY!]:GV7W'Y\?\.C-%_Z*!J'_ (!I_C1_PZ,T7_HH&H?^ :?XU^@]%'UC$?\
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M(_\ &ON&BCZQB/\ GZ_P_P @^M3[+[CX>_X=<:!_T/&I?^ D?^-'_#KC0/\
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M>BCZQB/^?K_#_(/K4^R^X_/C_AT9HO\ T4#4/_ -/\:/^'1FB_\ 10-0_P#
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M_P"A15]3_P#!7S_DWWPI_P!C/%_Z27-<E;_?X?UW,Y?QD?DC1117O'6%%%%
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M;\/:CX4UFZMWN[.WU"2"5;N-"!)LD@D=-R;ERA(8!@<8YK/;XP2WTE[/X?\
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M9"1)'&)94:9D((;RPV&^7KQ1X@^.OAC0/ NB^+R]U>Z)JUW%9PR6L),JR/O
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ML^:,UXR/VCM8/_,&T[\W_P :/^&CM8_Z VG?F_\ C3_UVR7_ )^/_P !8O\
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MNS_S!]._[Y-*/BY=_P#0'T__ +Y-/_6?+?YW]S%_8.._E7WH?N'K1N'K2?\
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M[+D_>R?>7^(^M<LT\O\ ST?_ +Z-'*%CL:*XSSY?^>C_ /?1IRSR_P#/1_\
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MSG'-%%  0&ZC-%<AXX^)$'@G5="TM-%U37]4UIYDM+/2_LX8^5'YCLS3S1(
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MXY61/[R_G2^8G]Y?SK[%^T1_\^EO_P!^Q1]HC_Y]+?\ []BM%X>S_P"@I?\
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M]X?G7U?]I3_GUM_^_='VE/\ GUM_^_=6N!9K_F)_\E_^V)_UOC_SX_\ )O\
M[4^4UD7'WA^=.61?[P_.OJK[4G_/M;_]\4?:D_Y]K?\ [XJO]1Y_]!'_ )+_
M /;$_P"MT?\ GQ_Y-_\ :GRNLBY^\/SJ19%Q]X?G7U)]J3_GVM_^^*CNKX0V
MD\JVMN6C0L,Q\57^I$_^@C_R7_[8G_6R/_/C_P F_P" ?,0D7^\/SIZNO]X?
MG7NO_":7'_/C8_\ ?H_XT?\ ":7'_/C8_P#?H_XU?^I,O^@C_P E_P#MB?\
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M;_@'C^]?[P_.A77/WA^=>P?\)M<_\^=E_P!^S_C1_P )M<_\^=E_W[/^-/\
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ME_S_ /\ R7_@A_K''_GU^/\ P#RO</44X,N.H_.O4O\ A-[K_GSL_P#OV?\
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M+F"YR?V>7_GD_P#WR:46\N/]6_\ WR:ZO-&:.8+G)_9Y?^>3_P#?)H^SR_\
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M.Y^9M%?IE_PYJMO^BM2_^$Z/_DJC_AS5;?\ 16I?_"='_P E4?VAAOYOP?\
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M  *>C_AW'\"/^A2;_P "GH_M2CV8?6(GX@T5^WW_  [C^!'_ $*3?^!3T?\
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M_P#J8-=_\#?_ +&C_A!_^I@UW_P-_P#L:++N!TE%<W_P@_\ U,&N_P#@;_\
M8T?\(/\ ]3!KO_@;_P#8T67<#I**YO\ X0?_ *F#7?\ P-_^QH_X0?\ ZF#7
M?_ W_P"QHLNX'245S?\ P@__ %,&N_\ @;_]C1_P@_\ U,&N_P#@;_\ 8T67
M<#I**YO_ (0?_J8-=_\  W_[&C_A!_\ J8-=_P# W_[&BR[@=)17-_\ "#_]
M3!KO_@;_ /8T?\(/_P!3!KO_ (&__8T67<#I**YO_A!_^I@UW_P-_P#L:/\
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M M455_X5W#_T'-;_ / S_P"QH_X5W#_T'-;_ / S_P"QHLNX%JBJO_"NX?\
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M#DZ*ZS_A4.E_]!/6/_ P_P"%'_"H=+_Z">L?^!A_PHLNX')T5UG_  J'2_\
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M#DZ*ZS_A4.E_]!/6/_ P_P"%'_"H=+_Z">L?^!A_PHLNX')T5UG_  J'2_\
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M5O\ ]"O-_P!_E_QH]M_=?W![/^\CZMHKY2_X;JM_^A7F_P"_R_XT?\-U6_\
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M-U6__0KS?]_E_P :/;?W7]P>S_O(^K:*^4O^&ZK?_H5YO^_R_P"-'_#=5O\
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M/JVBOE0_MT6X0-_PB\V"<?ZY?\:;_P -U6__ $*\W_?Y?\:/;/\ D?W![/\
MO(^K:*^4O^&ZK?\ Z%>;_O\ +_C1_P -U6__ $*\W_?Y?\:/;?W7]P>S_O(^
MK:*^4O\ ANJW_P"A7F_[_+_C1_PW5;_]"O-_W^7_ !H]M_=?W![/^\CZMHKY
M2_X;JM_^A7F_[_+_ (T?\-U6_P#T*\W_ '^7_&CVW]U_<'L_[R/JVBOE+_AN
MJW_Z%>;_ +_+_C1_PW5;_P#0KS?]_E_QH]M_=?W![/\ O(^K:*^4O^&ZK?\
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MOJ7_ ('1?X4?\/C=%_Z)OJ7_ ('1?X4?5\3_ ,^G^'^8?5I^7WGZ-45^<O\
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M^?3_  _S#ZM/R^\_1JBOSE_X?&Z+_P!$WU+_ ,#HO\*/^'QNB_\ 1-]2_P#
MZ+_"CZOB?^?3_#_,/JT_+[S]&J*_.7_A\;HO_1-]2_\  Z+_  H_X?&Z+_T3
M?4O_  .B_P */J^)_P"?3_#_ ##ZM/R^\_1JBOSE_P"'QNB_]$WU+_P.B_PH
M_P"'QNB_]$WU+_P.B_PH^KXG_GT_P_S#ZM/R^\_1JBOSE_X?&Z+_ -$WU+_P
M.B_PH_X?&Z+_ -$WU+_P.B_PH^KXG_GT_P /\P^K3\OO/T:HK\Y?^'QNB_\
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MG_GT_P /\P^K3\OO/T:HK\Y?^'QNB_\ 1-]2_P# Z+_"C_A\;HO_ $3?4O\
MP.B_PH^KXG_GT_P_S#ZM/R^\_1JBO@32?^"KVE:MX/\ $'B!? %_%%H[6ZO
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M/R^\_1JBOSE_X?&Z+_T3?4O_  .B_P */^'QNB_]$WU+_P #HO\ "CZOB?\
MGT_P_P P^K3\OO/T:HK\Y?\ A\;HO_1-]2_\#HO\*^K?V4/VEK?]J3P)J'B>
MUT2;08+6^:Q^SSRB1V955BV1QCYA^53*E6@KSIM+Y?YD3HR@N9GX*4445]X>
M@%%%% 'V/_P2E_Y.G/\ V KS_P!"BK]%/VU/^210_P#81A_DU?G7_P $I?\
MDZ<_]@*\_P#0HJ_13]M3_DD4/_81A_DU?*YG_'^1Y]?XSX6HHHKR3G"BBB@
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M .B!7G%>C_'K_D;M(_[%_3?_ $0*\XK.G\"$M@HHHK084444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >C>#_\ DBGQ(_Z[:9_Z45YS
M7HW@_P#Y(I\2/^NVF?\ I17G-1'>7K^B$NH44458PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH V_ _\ R.WA_P#["-O_ .C5K0^+
M?_)5O&G_ &&[W_TH>L_P/_R.WA__ +"-O_Z-6M#XM_\ )5O&G_8;O?\ TH>L
M_M_(74Y2BBBM!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5^NG_  2,_P"3>M?_ .Q@F_\ 145?D77ZZ?\ !(S_ )-ZU_\ [&";
M_P!%15Y>9?[N_5&%;X#\BZ**1ONFO4-R>]LKG39(X[RVFLY)(UFC6XC:,O&>
MC@,!E3V(X-2ZAH^H:1Y/V_3[NP\]/,B^U6[Q>8O]Y=P&X>XK]1]$\2_#_P".
M/PE\(:/JGC7X;MID?AS1+2QL-:O(K?5K74K61/M/F;AO6,QHX4=#GT.:\]_X
M*&>(+;7_ (*V5UJ7B7PWXDN;GQC-/X3DT*>.5H=#^SLOEL4 SB0*#U&=HR:\
MZ.*<IJ#C;^O0Q52[M8\V_P""4O\ R=.?^P%>?^A15^BG[:G_ "2*'_L(P_R:
MOSK_ ."4O_)TY_[ 5Y_Z%%7Z*?MJ?\DBA_[",/\ )J\;,_X_R.6O\9\+4445
MY)SA1110 4444 >^^ ?"?@[3?V>=2\;ZWX6C\1ZC:ZC]G"27TUN"A:-0,H<<
M;B>E:GB+X/\ @^^F^&/B31[";3]'\2WL,%WH\\[.%!/.UR=V#@@\^AXJ[\/-
M<A\.?LBZS?W&D6.N11ZO@V6I(7A?+Q#) (/&<CW%</H?Q:UKXG?%SP$FH+;6
M6G:?J$$=GIUC'L@@&X X&22< =30!Z3=>"?AI<?'"Z^&J^ F@'E#;JUIJ=P\
MD9,*R;C&Q*@#.,DGZ5PGP_\ @3H]]XF\<76OW\S^%/"4D@EDMF DN2H+!0>W
MRCG'4G QV]SF^)4LW[1GB'P'J!BM["_M$AL[VWC6*YAD,"MCS1ACG)QGH0*X
M'X0Z"]OH/Q9^%=S.J^(I7DDM?.D"M<_)A2#WY52?]Z@#EOA_:_"_XQ>))?"T
M/@ZX\)75RCFPU*WU*6X<LH) ='RH)'89],CK4OPC^$^@VD/Q1'BW18]<N_"L
M9:*,W,L*L465B,HPX;8.N<4S]G?X3>)/#?Q+AU_Q'I-UX?T?14DFN+O48V@3
M(4@!2P^<>XR,5V/PKU<^/H?CW?Z9#+<_VG#(;6*-"SR;HY@@"CDD\<>] '&>
M"_"7@#X\6.IZ9H>@3>"_%5I;M<VJ17SW4%R!_"?,YS],=<\UDZ9\.=#?]F?7
MO$USIW_%1V>J"U2[\UP57S(U*[=VT_>;MGFNJ_9Q\$ZM\*]2U?QWXNL;CP]I
M&GV,D:+J$9AEGD;'RJC8;MQQR34GP_CD^)'[-GCC0-%3[3KPU,W_ /9X(\QH
MR\;@J._"L/J,4 <=\(_ .@>)?A!\0]:U+3Q<ZGI:*;.X,KKY64ST5@#SZ@U=
MT;X<^%?AW\(].\<^,]/F\07VL/LT[1DN&@BVD$AW=?FZ*6XZ @8)-=#X%T+4
M/AA^SKX_G\3VDNBRZPRP65K>J8II6V[>$;YNY/(Z U8\8Z+>?&+]G#P/-X7A
M?5;[P\JVU[I]O\TR[8]A(0<D_*" .2&S0!YG)X^^&T<B7,7PQ:621-LME-K4
MX@B(/#1N/G)(/(;C@8KT7XY:3\.OA7_8MO:_#J"]DU:P-R)FU>Z0P,< 8&3N
MQG/..E>$^)?A_P"(O!UC97>N:/=:3%>EU@6\3RY&*XW?(?F'4=0,]J]I_;&_
MY"'@7_L#_P!5H ^=J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M2W027$*-]UG53]"14=36?_'Y;_\ 75?_ $(4 ?5OBSP/\,O"_P 2_"W@N7P)
MYRZY;1'^TH=3N!)#)(S("(RQ!&0#G/?I6'X;^!'AK3?&/Q2T74;<ZO#HFF_:
MM/EEF=7C)C9E+;" 2..O''2NF_:(^+,WPS\<:#+8>'M&O-5&D(\&JWL#/<6^
M6=<(=P&.IY'<US7[,^K:GXRF^*M_>22:AJVH:4[.RKEY)&5P %'X  >PH ^9
MQEL #)/0#O7UA'^S[X1F^&SZ)'9_\7%70UU;[09I,Y+9V;-VW.!MQM[YKR7X
M5_!/Q)JGQ)\.V.M^'=3TRP>X$LTE]:20*T<?SL 6 YP,?C7M>G_%3X?-^T2^
ML)J7B0ZS/)_8P1XH!8 9" 9!W[=P'/K0!P_[/NE^ ?B;JP\/ZE\/X([JST\S
M3:B-5N2UQ(FU23&" NXDG@\52^'5EX%^)WQ=TGP\G@.'1K&-[H7(CU2XF^T[
M4.S.2"N"N>#SFN^^%/@O_A _VHO&.F)'LM6L)KFVXX\J1E90/IDK_P !KS+]
MF/\ Y.*M?]^\_P#07H R?B/K'@V+5-;\,:+\.[?3M1AO'L;?4EU>XD8,LA0-
MY;?+SCH3QFNJ\<>$? 7P%T_2-,UOP[)XU\47MNMU=>;?R6L%NIR,+Y?).0>N
M>F<C(%87Q,^)VGCQQK%HO@KP_9RVFLL[:G:P.+M_+GR26+8RV.>.]=M^T]X%
MUCXBZ]HGC#PIIUSXATG4;"-/,TV-K@HX)."%!(&".>F0: .4^)?PM\-W'P_T
M#X@^#XKBQTF_N%MKS2[B0R?9W+;?E8\D9!ZYZ@^U=_X_\(_#3P+\1O"WA(_#
MT:@NLP1.]W#J=R)8R[LF5CW$-C;GJ*Q_B%'_ ,*S_9[\+>"-3=8_$=]?I>S6
M:N':!/,W?-Z?PCZYKU3XA_%B7P+\;O!>DW4=JVB:AI\:3220+YL+O(Z"19/O
M # R,XQGO0!Y5X2^!?A>W_:.UKPC?0MK.B6M@UW##),RLI.TA69""2,GTZBN
M)_:&^&VD^$]:T+4_"MJT/AW7K-)K2+>SA9. R L2>05/)ZDUZ[\,?!=WX'_:
ML\2V=S--=I<:?-=07%PY=Y(W*D98]2#D?A5CX!VNE_%?X>6>G:S)F?P9K1O(
M]PSF$EG56_V3EQ_P 4 96O? WP5X=^$.O+)I9F\6Z/I<-S=7QN)04FD&X#9N
MV\#VKY0KZIT+Q:_CKX?_ !VUMFW1W,P\KG($:J%0#VP!^=?*U !1110 4444
M %%%% !1110 4444 2M_Q[Q_4U%4K?\ 'O']3455+<84445(@HHHH **** "
MBBB@ KN_@9X;TWQ?\6/#NCZO;?;--NI76: NR;P(G8<J01R!T/:N$KT[]F?_
M )+IX3_Z[R?^B9* /2_AO\*?!.H?&#XD:;K.DB;0M%+M;P&XE40J),9W!@QP
M/4FJ/AOX&Z)9_M*'PMJ=H=0\,W-M)?62F9P)(BN4^=2"<'(Z]JZCP@,_%#X\
M CC[)<_^A&N@_9DUBW^)6B>&-0GD!\0>$UDT^=F/SRVTB?(Q/4X( _[ZH \R
M^&_@/P?_ ,(G\4-<UCPXFM?\(]>.+2W>[FA 0,XV;D;V')!/%0>&? _@;X[>
M&]:7PQHDW@_Q9I=N;E+-;Q[JWND^K_-G( [8+#K73_#;3KO5OAG\<K.QMIKR
M[FO9$BM[>,O([;GX51R3]*J?L]^%]2^#.F>*/'/C"TFT*R2P:TMK6]3RI[F0
ML&PJ-AARH R.=WH* .)T_P  Z#-^R_J/BR33\^((=4-NMYYKY$>5^7;NV]SV
MS6QJ_@#P=\$_ >@:CXLT27Q7XFUR/SDTYKQ[:"VC !.63YLC<!WR>PQFK.F$
MR?L7:P<<MK;']4K=^/WAS4OC)X-\%>+?"5I-KEK%9?9KFVLE\V:!_E."BY;(
M.X' XP* /$-6M]#\>^,-&LO"&B7.A?V@\=O)9S7!N$25F S&Q^8J <_-SP:]
MR^,WP9\#Z;X%U:_\(:=C4O"U]%%JH-Q*YGCV*7!RQ ^^#D <JPK$_9X^%.K>
M#?'3^)_%NESZ5I^BZ;)J2K< "3."H.W.5( ?AL'I79?!?Q1X \5>*/%FAZ;?
M>([N]\712O<)K44"PLV'8E?+.<X9NO84 <Y\/M-^&_C?X>^+_$K_  UM[-]!
MCWK;+K-TXF^3=@MD;?R-8WP:\.^"?BYXO\1%_!L6D:?9:(TT5C'J,\P$X?\
MUN\D'."!MZ<5K?"/19_#GP?^-.E7*E9[(O ^>N5C(S^/7\:ROV-_^1D\8_\
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MK/71VM]QI&5Y,Y.BBBNXU"FR?ZMOI3J;)_JV^E 'I/QZ_P"1NTC_ +%_3?\
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M  !@ 5QVI:E>:UJ%S?ZA=SW]]<R-+/=74K2RRNQRS.[$EF)Y))R:K44**6R
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MBBB@#;\#_P#([>'_ /L(V_\ Z-6M#XM_\E6\:?\ 8;O?_2AZS_ __([>'_\
ML(V__HU:T/BW_P E6\:?]AN]_P#2AZS^W\A=3E****T&%%%% !1110!KKXR\
M0+X9;PX->U0>'6E\]M'%[+]C,F0=YAW;-V0.<9X%4=-U.\T74+>_T^[N+"^M
MI!+!=6LK12Q.#D,CJ05(/0@YJM12L@-'5/$NL:YK;:SJ6K7VH:PSK*VHW=R\
MMRSKC:QD8EB1@8.<C K9D^+'CB:^O[U_&GB-[W4(%M;RY;5[@RW,(! CE;?E
MT ) 5B1S7*T4N5=@+&FZE>:+J%O?:==SV%];N)(+JUE:*6)AT974@J1Z@UU%
MK\9/B!8ZI>:E;>//%%OJ5[M-U>0ZU<I-/M 5?,</N;   R3@ "N/HH<4]T!J
MW?BW7=0\0+KUUK>I7.NK(LHU2:\D>Z#KRK"4MOW#L<Y%=/-\?OBC<1/%+\2_
M&4L4BE'1_$%X592,$$&3D$5P=%#C%[H5D%=7>?%KQUJ.A_V+=^-O$EUHWE^5
M_9TVKW#VVP=%\HOMQ[8Q7*44VD]QA1113 **** "BBB@ K]=/^"1G_)O6O\
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MO^$HUG_H+7W_ ($/_C1_PE&L_P#06OO_  (?_&C^R:_\Z^Y_YA]7I]V?=/\
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MN?\ ORW^%']E7W_/E<_]^6_PKX6_X2C6?^@M??\ @0_^-'_"4:S_ -!:^_\
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MH_\ @))_A7WSY:_W1^5'EK_='Y4OWWE^(?NO,^!O^$3US_H"ZC_X"2?X4?\
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M)KG_ .(K^@*S@C^PVW[M?]4IZ>U2^1'_ '%_*ICFF)BK<L?Q%]8I]F?S\?\
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M$/K%/LS^?C_A4?CS_H1O$W_@FN?_ (BC_A4?CS_H1O$W_@FN?_B*_H'\B/\
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M@WXL_P#7;2__ $&ZK](J^/Q_^\R^7Y(\VM\;"BBBO/,0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Y3QQ_K+3Z-7+UU'CC_66GT:N7H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "NHT?\ Y!,/^\W\ZY>NJT.-I=-@51DEF_G0!9HKF_&'Q.\/>!9#;7#OJ.I
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MEG_\B+_5C-?^?7_DT?\ ,]9HKR?_ (:.?_H6;?\ \"O_ +72C]HQS_S+-O\
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M_C=/_6[)O^?W_DLO\A?ZNYG_ ,^__)H_YE^BJ'_"Z[;_ *%2Q_[^C_XW2_\
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M8K8_\RM9?]_!_P#&Z?\ K7E'_/[_ ,EE_D'^K^8_\^_QC_F3T5#_ ,+@MO\
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M/'_\^_Q7^9W%%<1_PN3_ *@4/_?_ /\ L*/^%R?]0*'_ +__ /V%/_6;*O\
MG[_Y++_(/[#Q_P#S[_%?YG;T5Q(^,F?^8%#_ -__ /["C_A<7_4"A_[_ '_V
M%/\ UERO_G[_ .2R_P A?V'C_P#GW^*_S.VHKBO^%P_]0.'_ +_?_84H^,'_
M % X?^_W_P!A3_UDRO\ Y^_^2R_R#^Q,?_)^*_S.THKC/^%O_P#4#A_[_?\
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M175R SG:\JKN;.!U)I<L.1M;W7ZA96/HMIHXV 9U4GH&(%.9@JY)P/4U\[_
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M%%2P%6EI%I:0"K3J:M.H *1:6D6F M%%%(!U+24M !2M24K4 )1110 4444
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MX0AFN)K2SFTYEO8O-D+[&N!-M959FQ^Z!QCGCGT>BLU)I-=Q7.>^(GA,^/?
M/B+PT+K["=7L)K'[5Y?F>5YB%=VW(W8SG&1]:TO#^EG0]#T[3O-\XV=O'!YF
MW;NV*%SC)QG'2K]%',[<O0/(\OTWX5^(_".L^(G\)^*;+3=(UV]?49[74-)-
MU/;3N )&@E$R  X! D20 ^HXJEI?P!;2_A#XT\#GQ'/>OXCNKRZ;5;JW#2HU
MP5)+J& =L@DD;0<\ 5Z[16GM9]_Z0^9G":I\+SJ7B+X=ZI_:7E_\(BLRF+R,
M_:O,MA!UW?)C&[HWI[U5U;X9ZS9^/M0\6>$M?M='O-6MHK;4[74M/:]MY_*S
MY<J!9HF20!B,Y*D=5KT6BI]I+^OO%=GFOPU^#LWP_P#%7C77+GQ%=:]=>)S;
M23/>1!7CDBB9&.0=NTEN%55"@ #/6MSX2^ 3\+_A[I/A@WW]I&Q\[_2A#Y6_
M?,\GW=S8QOQU/3-==11*I*6[_I#<FSSBW^&FN^$=8UBZ\%>(;'2['5[Q]0NM
M+UC3&O8([A\>9)"8YH73>1N92S+G) &3GM/#]CJ6GV)35=5_M>\9RYF%ND"(
M#T1$7HH[;BS>I-:=%*4W+<5[A1114""BBB@ HHHH *ZG28;>^\/M8WD8EL[D
M/'*A]#7+5U&C_P#()A_WF_G4RBIQ<9*Z949.+4HNS1X%X\^#.L^%+J2:R@DU
M/22<QSPKN9%]' Y&/7I7 _99_P#GC)_WP:^RX;J6'[CD#T[5-_:D_P#L_E7Y
M'C?#G"UJSJ86NZ<7TMS6]'=:>M_4_0\+QGB*5-0KTE-KK>WWZ,^+OLL__/&3
M_O@T?99_^>,G_?!K[1_M2?\ V?RH_M2?_9_*N'_B&D?^@O\ \D_^W.O_ %W?
M_0/_ .3?_:GQ=]EG_P">,G_?!I5M9_\ GC)_WP:^T/[4G_V?RH_M2?\ V?RH
M_P"(:Q_Z"_\ R3_[</\ 7=_] _\ Y-_]J?&'V6;_ )XR?]\&C[+-_P \9/\
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M ?L\O_/*3_ODT[[/+_SRD_[Y->^?\)UJO]Z'_OW_ /7H_P"$ZU7^]#_W[_\
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M_@ID_P#CM'_#G'7?^BFZ?_X*9/\ X[1]>PW\_P"?^0>UAW/,/^"4O_)TY_[
M5Y_Z%%7U/_P5\_Y-]\*?]C/%_P"DES6G^R+_ ,$]=3_9F^+7_"8W?C.TUZ'^
MSYK+[+#8M"V7*'=N+GIM].]=;_P42^!?BW]H#X2^'] \'6<-WJ%KK:7THGE\
MM5B6"9#S@\YD7]:\FI7ISQD*D7H<TI1=5-,_%&BOJG_AV?\ '/\ Z ^F_P#@
M8?\ XBC_ (=G_'/_ * ^F_\ @8?_ (BO;^LT?YT=?/'N?*U%?5/_  [/^.?_
M $!]-_\  P__ !%'_#L_XY_] ?3?_ P__$4?6:/\Z#GCW/E:BOJG_AV?\<_^
M@/IO_@8?_B*/^'9_QS_Z ^F_^!A_^(H^LT?YT'/'N?*U%?5/_#L_XY_] ?3?
M_ P__$4?\.S_ (Y_] ?3?_ P_P#Q%'UFC_.@YX]SY6HKZI_X=G_'/_H#Z;_X
M&'_XBC_AV?\ '/\ Z ^F_P#@8?\ XBCZS1_G0<\>Y\K45]4_\.S_ (Y_] ?3
M?_ P_P#Q%'_#L_XY_P#0'TW_ ,##_P#$4?6:/\Z#GCW/E:BOJG_AV?\ '/\
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MKO\ X#Q__'*/^$VD_P"A:UW_ ,!X_P#XY1RL#IJ*YG_A-I/^A:UW_P !X_\
MXY1_PFTG_0M:[_X#Q_\ QRCE8'345S/_  FTG_0M:[_X#Q__ !RC_A-I/^A:
MUW_P'C_^.4<K Z:BN9_X3:3_ *%K7?\ P'C_ /CE'_";2?\ 0M:[_P" \?\
M\<HY6!TU%<S_ ,)M)_T+6N_^ \?_ ,<H_P"$VD_Z%K7?_ >/_P".4<K Z:BN
M9_X3:3_H6M=_\!X__CE'_";2?]"UKO\ X#Q__'*.5@=-17,_\)M)_P!"UKO_
M (#Q_P#QRC_A-I/^A:UW_P !X_\ XY1RL#IJ*YG_ (3:3_H6M=_\!X__ (Y1
M_P )M)_T+6N_^ \?_P <HY6!TU%<S_PFTG_0M:[_ . \?_QRC_A-I/\ H6M=
M_P# >/\ ^.4<K Z:BN9_X3:3_H6M=_\  >/_ ..4?\)M)_T+6N_^ \?_ ,<H
MY6!TU%<S_P )M)_T+6N_^ \?_P <H_X3:3_H6M=_\!X__CE'*P.FHKF?^$VD
M_P"A:UW_ ,!X_P#XY1_PFTG_ $+6N_\ @/'_ /'*.5@=-17,_P#";2?]"UKO
M_@/'_P#'*/\ A-I/^A:UW_P'C_\ CE'*P.FHKF?^$VD_Z%K7?_ >/_XY1_PF
MTG_0M:[_ . \?_QRCE8'345S/_";2?\ 0M:[_P" \?\ \<H_X3:3_H6M=_\
M >/_ ..4<K Z:BN9_P"$VD_Z%K7?_ >/_P".4?\ ";2?]"UKO_@/'_\ '*.5
M@1>./]9:?1JY>M+Q'KEWJS0&'PYK0V YW01C_P!GK%\S4O\ H7M7_P"_*?\
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M!8HJOYFI?]"]J_\ WY3_ .+H\S4O^A>U?_ORG_Q='*P+%%5_,U+_ *%[5_\
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M ,!H_P#XY1_PD4__ $+NN?\ @-'_ /'*.5A8V**Q_P#A(I_^A=US_P !H_\
MXY1_PD4__0NZY_X#1_\ QRCE86-BBL?_ (2*?_H7=<_\!H__ (Y1_P )%/\
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M$BG_ .A=US_P&C_^.4<K"QL45C_\)%/_ -"[KG_@-'_\<H_X2*?_ *%W7/\
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M;%%8_P#PD4__ $+NN?\ @-'_ /'*/^$BG_Z%W7/_  &C_P#CE'*PL;%%8_\
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M /BZ.5A86BD\G5/^A>U?_OS'_P#%T>3JG_0O:O\ ]^8__BZ.5A86BD\G5/\
MH7M7_P"_,?\ \71Y.J?]"]J__?F/_P"+HY6%A:*3R=4_Z%[5_P#OS'_\71Y.
MJ?\ 0O:O_P!^8_\ XNCE86%HI/)U3_H7M7_[\Q__ !='DZI_T+VK_P#?F/\
M^+HY6%B:U_X^8O\ ?'\Z] E_UC_4UYY#'J<<T;'P]J^%8$_N8_7_ *Z5U3^(
MYV=C_P ([KG)S_Q[1_\ QRCE86->BL?_ (2*?_H7=<_\!H__ (Y1_P )%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>pgen-20201231_g4.jpg
<TEXT>
begin 644 pgen-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,B!Q4# 2(  A$! Q$!_\0
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M?\)-H_\ T%;+_P "$_QHLP-.BLS_ (2?1_\ H+6/_@2G^-)_PE&C?]!:Q_\
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M$_\ 0WZ#_P"#*'_XJD_X6QX)_P"APT'_ ,&</_Q5'++L%F=717*?\+9\$?\
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M!_Z'?P[_ .#6#_XNCEEV"S.QHKCO^%S> /\ H>/#G_@U@_\ BZ3_ (7-\/\
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M .#*'_XJCE?8#J:*Y?\ X6GX,_Z&W0__  8P_P#Q5'_"TO!G_0VZ'_X,8?\
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M_A//#7_0PZ7_ .!L?_Q5'_">>&O^AATO_P #(_\ XJBS[ ;M%87_  G?AO\
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MZV_[^K_C1_;%A_S^V_\ W]7_ !H N454_M:Q_P"?VW_[^K_C1_:UE_S^6_\
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MY%/6&/\ YYI_WR*%IZT *L,?'[M?^^13_)C_ .>:_P#?(H7M3J %$,?]Q?\
MOD5(L2?W%_[Y%-J1: &-#'_<7_OD4QH8\_ZM/^^14S4QNM $+019_P!6G_?(
MIC6\7_/)/^^14S=::U $!MH<_P"JC_[Y%1M:P_\ /&/_ +X%6&ZTQNM $#6L
M'_/&/_O@4QK.#_GA'_WP*L-3&I@5VL[?_GA%_P!\"HVL;;_GWB_[X%6FIC4
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M-%_\%T/_ ,36_11S2[A=F'_PK[PK_P!"QHO_ (+H?_B:3_A7OA3_ *%?1?\
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MOHG_ (+H?_B:7_A7OA3_ *%?1?\ P70__$UT%%'-+N%V8*_#WPIC_D5]%_\
M!=#_ /$TO_"O?"G_ $*^B_\ @NA_^)K?7I11S2[A=F!_PKWPK_T+&B_^"Z'_
M .)I5^'_ (6S_P BQHO_ (+H?_B:WJ5>M'-+N%V87_"O_"W_ $+.B_\ @NA_
M^)I?^%?^%O\ H6=&_P#!?#_\36]11S2[A=F&O@#PM_T+.C?^"^'_ .)I?^$!
M\+_]"UHW_@OA_P#B:W5I:.9]PNS!_P"$!\+_ /0M:/\ ^"^'_P")I_\ P@/A
M?_H6M'_\%\/_ ,36W3J.9]P,+_A O#'_ $+6C_\ @OA_^)I?^$#\,?\ 0MZ/
M_P""^'_XFMRBCF?<#$7P'X9_Z%O1_P#P7P__ !-._P"$$\,_]"WH_P#X 0__
M !-;:TM',^X79A_\(+X:_P"A<TC_ , (O_B:?_P@OAK_ *%S2/\ P B_^)K9
MI]',^X79A_\ ""^&O^A<TC_P B_^)I?^$&\-?]"[I/\ X 1?_$UMT4<S[A=F
M*O@?PW_T+VD_^ ,7_P 33O\ A!_#?_0O:3_X Q?_ !-;*TM',^X79B_\(1X<
M_P"A>TG_ , 8O_B:/^$)\.?]"]I/_@#%_P#$UM44N9]P,C_A"?#G_0OZ3_X
MQ?\ Q-+_ ,(5X=_Z%_2O_ &+_P")K9HI\S[@8W_"%^'?^@!I7_@%%_\ $TJ^
M"_#W_0 TO_P"B_\ B:V*5:.9]P,C_A#/#W_0 TO_ , HO_B:7_A#?#__ $ =
M+_\  *+_ .)K8HHYGW$9/_"&^'_^@#I?_@%%_P#$TO\ PAWA_P#Z 6E_^ 47
M_P 36O12YGW&9'_"':!_T M+_P# *+_XFG+X/T#_ * 6F?\ @''_ /$UJTJT
M<S[@97_"'Z#_ - /3/\ P#C_ /B:7_A$=!_Z >F_^ <?_P 36M11S/N!D_\
M"(Z%_P! /3?_  #C_P#B:7_A$M"_Z FF_P#@''_\36K11S/N!F_\(GH7_0$T
MW_P#C_\ B:/^$3T/_H"Z;_X"1_\ Q-:M%%V!E?\ "*Z'_P! 73O_  $C_P#B
M:/\ A%=$_P"@+IW_ ("1_P#Q-:M%%V(S5\*Z)C_D#:=_X"1_X4O_  BNB?\
M0&T__P !(_\ "M->E%%V!F?\(OHO_0'T_P#\!8_\*/\ A%]%_P"@/I__ ("Q
M_P"%:=%%V!G+X8T;_H$:?_X"Q_X4O_",:-_T"-/_ / 6/_"M%:=1=@9O_",Z
M-_T"+#_P%C_PH_X1K1_^@38?^ J?X5I4478&=_PC>D?] FQ_\!D_PI1X<TC_
M *!5C_X#)_A6A11=@4?^$<TC_H%6/_@,G^%'_".Z3_T"K'_P&3_"M&BB[ S_
M /A'M)_Z!=E_X#)_A1_PC^E?] NR_P# 9/\ "M"BB[ S_P#A']*_Z!EE_P"
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M6FMUH 9_%11_%10 QNM)_%2MUI/XJ $;K36IS=::U #&H:AJ&H ;W%%'<44
M5E\[[8V77R=O"]\\5/5"-K;^VI5!?[5Y8W?W=O'_ -:K],!R]*6D7I2T@"G4
MVG4 %.6FTY: %HHHH =2TE+0 JTM(M+0 4Y:;3EH 6BBB@!]%%% "K2TBTM
M!3EZ4VG+TH 6E7K24J]: '4444 *M+2+2T %/IE/H *5:2E6@!U%%% #EZ44
M+THH *5>M)2KUH =1110 Y:6D6EH *=3:=0 4444 .6EI%I: "GTRGT %%%%
M "K2TBTM !1110 ^BBB@ I5I*5: '4444 .HHHH *5:2E6@!U%%% !1110 ^
MBBB@ HHHH <O2BA>E% !1110 JTZFK3J "BBB@ HHHH ?1110 4444 %.IM.
MH **** "BBB@ HHHH ?1110 4444 %%%% !1110 ^BBB@ HHHH **** "BBB
M@!5I:1:6@ HHHH **** "BBB@ HHHH **** "E7K24J]: '4444 36]T]K]P
M_+_<['_"M>WNDN%^4X8=5[BL*E5FC8.IVL.AH Z*BJMG>"X4!AM?]#]*M4 %
M%%% !1110 4444 %%%% !7D7PY\(Z_XD^(.I^/\ QA;RZ;=1>;IVAZ.9<BSM
M<X:1]IP7D(S[#'MC0C^(NJ>(_C0?"^@+ ^B:+;F77;R1-W[YQ^Z@C((PP^\>
MO%>FUIK!6[CV"N(^+WQ:T3X-^#;G7]:ER%^2VM$(\RZE(X11_,]AS70>+/%.
MF^"O#NH:YK%RMIIUC$9II6]!V'J2> .Y-?E1\=_C7JGQO\<7&L7A>'38B8M.
ML"WRV\.>./[S=6/<^P K:A1]K+78J,>8S/BI\6-?^+_BNXUS7;EI'8D6]JI/
ME6T>>$0?S/4FN/W4S=1NKW%:*LCJ'[J-U,W4;J=P'[J-U,W4;J+@/W4;J9NH
MW47 ?NHW4S=1NHN _=1NIFZC=1<!^ZC=3-U&ZBX#]U&ZF;J-U%P'[J-U,W4;
MJ+@/W5W7P=^,NO\ P7\60ZQHTS- Q"WE@['RKJ/NK#U]&Z@UP6ZC=2:4E9@?
MI]I6M:+\4/"-OXR\*/YEC./]*M./,M9/XE8=L?\ U^E5:^'OV=_CI?\ P/\
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MGL^67^(MQQ_.KE9$7V;_ (2B?%Z[77DC=:?PJOR_-_+\ZUZ; <O2EI%Z4M(
MIU-IU !3EIM.6@!:*** '4M)2T *M+2+2T %.6FTY: %HHHH ?1110 JTM(M
M+0 4Y>E-IR]* %I5ZTE*O6@!U%%% "K2TBTM !3Z93Z "E6DI5H =1110 Y>
ME%"]** "E7K24J]: '4444 .6EI%I: "G4VG4 %%%% #EI:1:6@ I],I] !1
M110 JTM(M+0 4444 /HHHH *5:2E6@!U%%% #J*** "E6DI5H =1110 4444
M /HHHH **** '+THH7I10 4444 *M.IJTZ@ HHHH **** 'T444 %%%% !3J
M;3J "BBB@ HHHH **** 'T444 %%%% !1110 4444 /HHHH **** "BBB@ H
MHHH 5:6D6EH **** "BBB@ HHHH **** "BBB@ I5ZTE*O6@!U%%% !1110
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M0FO)UA0NQPJ[F(&2> .I-:*]Z^;_ -O8%?@;; \'_A(--_\ 1U?23?ZQOK0
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M** 'T444 %%%% !1110 4444 *M+2+2T %%%% !1110 4444 %%%% !1110
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MCV_UC?6OGG]NS3+S5_@S%!86=Q?3?\)!I[^7:Q-*VT3<G"@G ]:^AF^^WUH
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M?\-E?"#_ *!/B?\ [\1__'J^#,BC(H^J4@]G$^]/^&S/A /^83XG_P"_$?\
M\>H_X;,^$'_0)\3_ /?B/_X]7P7D49%'U2D'LXGWI_PV9\(/^@3XG_[\1_\
MQZE_X;.^$'_0)\3_ /?B/_X]7P5D49%'U2D'LXGWK_PV=\(?^@3XG_[\1_\
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M!7B;_P !HO\ X]7P#D49%'U2D'LXGW__ ,-O_"C_ *!?B;_P&B_^/4?\-O\
MPH_Z!?B;_P !HO\ X]7P!D49%'U2D'LXGW__ ,-O_"C_ *!?B;_P&B_^/4?\
M-P?"C_H%^)O_  &B_P#CU? &11D4?5*0>SB??_\ PW!\*/\ H%^)O_ :+_X]
M1_PW!\*/^@7XF_\  :+_ ./5\ 9%&11]4I![.)^@'_#<7PH_Z!?B;_P&B_\
MCU'_  W%\*/^@7XF_P# :+_X]7Y_Y%&11]4I![.)^@'_  W%\*/^@7XF_P#
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MPJ_Z!?B7_P !8O\ X]1_PW/\*O\ H%^)?_ 6+_X]7Y^9%&11]4I![.)^@?\
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M5?SK2DC:)B&%-KC,S/\ L$GJOYT?8)/5?SK0HH S_L$GJOYT[[#)ZK^=7J*
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M6\RCS* +/F>]'F>]5O,H\R@"SYGO7Z#_ +%OBC_A+/V=;_1G??<^'-0;8O\
M=AD^=?\ QXRU^=_F5]=_\$Y=>9?'7B_0'DQ#J&D^<L>?O21N #_WRS5S8A<U
M-D36A]4+7#?#_7;^;QAXVT/4KI[I[&\CGM&<]+>5 0H]E((KN0I4D'J.#66M
MWHMEXF6US:PZ]?0&0*$Q--%'U.['(7/3/>O)B]&K&!M4^F4^H$2+7E/Q$^'N
MM^(?CQ\+_$]C;QR:1H0O!?2M*JM'YD95,*3ELD]J]66I* )-QYY^]R?>G+3*
M>M $@8G&3G;ROM]*>*C6I%Z4 21LRYP2,]<&I$8J<@X/J*B2I%H DR6R2<FG
MQL5Y!(/M4:T]: )%8A0H.%SG Z4]6*Y ) /6HU[4^@"1:DW%NI)QP*C6GK0!
M*C%<8./I3E8KC:=N!@8XXIB]J=0!(K%6RI(/M3UJ.I%H ^;=-\!_%3X$^,O&
MMUX(T71?'7A?Q/JTVN?8[R_-C?6EQ(JATWE2CI\HQGGCMWLS?#OXE?&SQIX4
MU3XAV.C>$/"_AN]75+?0],NFO+J[NE&$,LNT*J*><+U-?1+4QNM #=Q#9!P?
M44TL1G!QNY/O]:5NM-:@!NXJQP2/I49ZT]NM,;K0 DC%FRQ)/J:8S$KM/*_W
M3TIS4QJ $D9FY8EC[FHVI[4QJ &GO3&Z4\]Z8W2@!K=*93VZ4R@!M-IU-H 9
M2'O2TA[T -IE/IE "-3&I[4QJ &M3:<U-H :W6FMUIS=::W6@!G\5%'\5% #
M&ZTG\5*W6D_BH 1NM-:G-UIK4 ,:AJ&H:@!O<44=Q10!Q]DVB?\ "TK\12W1
MU_["OFQMGR1%\F"/?[OZUV-<[;2:Q_PG%TDFF6Z:&+8&+4!CS7D^7*'V^]^0
MKHJN70;'+VI],7M3Z@05+452T %4_B-\2-(^ ?@D^)=81;K5[K,>EZ:3@RR8
M^\?11D$GL/<BN@T&WM@]QJ&H2+#INGQ-<W$C\*%49Y_+]*_.7X^?&2\^-7Q$
MO];ED9=-C8P:=;$\10 _+QZM]X_6NK#TO:RUV1<8\S,7X@?$77?B=XFN==\0
MWS7E],<*#PD2=D1>BJ/2N;W^]5O,]Z/,]Z]M:*R.HL[_ 'HW^]5O,]Z/,]Z=
MP+._WKZ%T/2-+_9]^&$/B37M/M]2\=^)K=AI.FWB;DL;5@09W4_Q-V'_ ->N
M$_9O\"6GCOXE0/JP'_"/Z-"^JZDS=/)B&[:?J0!BMK6)O&7QR\5>*/B?I%O!
M>QZ%<QRKIY(=XK=3^["Q?Q(JJ,_6L)RN^5[=?\B7V/'&D+,Q/!)R>U)O]Z^A
M?%7A71_VDO#-UXS\%6D6G>-K&/?KGAJ'@7  YN(%[^ZBOG-F:-F5@593@JPP
M0?0UI&?-ZC3N3[_>C?[U6\SWH\SWJ[C+._WHW^]5O,]Z/,]Z+@6=_O1O]ZK>
M9[T>9[T7 L[_ 'HW^]5O,]Z/,]Z+@6=_O1O]ZK>9[T>9[T7 L[_>C?[U6\SW
MH\SWHN!9W^]&_P!ZK>9[T>9[T7 L[_>C?[U6\SWH\SWHN!9W^]&_WJMYGO1Y
MGO1<"SO]Z-_O5;S/>CS/>BX%G?[T;_>JWF>]'F>]%P+._P!Z-_O5;S/>CS/>
MBX%G?[T;_>JWF>]'F>]%P+._WKTGX'?'C7O@?XF2^TZ0W.E3,!?:6[?N[A.Y
M']UP.C?GD5Y;YGO1YGO2DE)68;G[ >%?%>C_ !"\*V'B?P_<"YTN^3<.S1MT
M9&'9@<@CU%:2U^?/[&'QV?X;^/$\-ZI<'_A&=>D$+JY^6WN#@)*/0'A6]L'M
M7Z%W$!MIGC/8\'U%>#6I^RE;H<DH\K(Z***P)%6I;>%KB4(O?J?2HE[UXQ^U
MU\:W^#GPU%AI=QY/B?7]T-NZGYK>$#]Y+['!"CW;/\-7"+G)10TKNQY-^UQ^
MU7)'<7G@+P3>F&&$M#JNJ0-AG;HT,;#H!T9A]!WKXTW^]5VF+,26R3R23R:3
MS/>O?IP5./+$ZXI15D6=_O1O]Z]4^''P#N/$7A\>+/%NKP^#/!8/RZA>#,MU
M[01]7/OTK;N/BG\(_ K&V\*?#T^*9$./[4\2W#8<C^)8DZ#V-'M-;15PYNQX
MAO\ >NV^&7PC\1_%>\NH]&AACM+-0]WJ%Y*(K>W4]-SGC)P>*J^/OB!)\4M9
MT\V_AW2]#F4"W2WTF$HLK,>,CN>:]+^.VIP_"?P+HOPATJ9?M<074?$MQ"?]
M==NH*PD]U1<<?3WI2G+1+=BN;.C_ ++VC^&?#^J>+?&7BB'5/#6G;0T?A5Q<
MRR.W&&/\ SW-8>H?"WP+\1O">KZO\,K_ %*#5=&@-U>:#K!5I)(!]Z2)UZD=
MQ5G]CE'CUSQ?>ZK<&V\#0Z+,FML^3$58808[OG)'>NU^!>I_!P^,KS2_!\FN
M6/B34+"XTZPN-:=?LUT\B%0"%'RD]@:PE*46];V^XF[1\F^9[T;_ 'I^L:;=
M:#JU[IMZGDWEI,\$T?\ =92015/S/>NRYH6=_O1O]ZK>9[T>9[T7 L[_ 'HW
M^]5O,]Z/,]Z+@6=_O1O]ZK>9[T>9[T7 L[_>C?[U6\SWH\SWHN!9W^]&_P!Z
MK>9[T>9[T7 L[_>C?[U6\SWH\SWHN!9W^]&_WJMYGO1YGO1<"SO]Z-_O5;S/
M>CS/>BX%G?[T;_>JWF>]'F>]%P+._P!Z-_O5;S/>CS/>BX%G?[T;_>JWF>]'
MF>]%P+._WHW^]5O,]Z/,]Z+@6=_O2K(RL&5L,IR"#@@^M5?,]Z/,]Z+@?=7[
M(?[5<NO36G@+QI=^;=L!'I6J3-\TA[0R'N?[K=^A[5]=R1F-BIZBOQ=ANGMY
MHY8I&BEC8.DB'#*P.00>Q!K]0/V5?C5_PNKX8QR7TN_Q)HY6UU#UDX^27'HP
M'YAJ\G%45'WXF$XVU1[!1117GF(4444 %%%% "-3:<U-H **** "BBB@ HHH
MH **** $:DI6I* '4444 (U-IS4V@ HHHH **** "BBB@ HHHH **** "FTZ
MFT %%%% !1110 4444 %%%% !1110 4444 %,I],H UM,DW1$$DD>OY?X5=K
M)TML7&,]1_G^5:U !1110!S?@OP+I?@=-9&F&5_[6U*;5+EIGWDS2D;L<<+Q
MP.U=)7D7[*_VN3X/V=Q>^?\ :+F^O)C]IW;\&X<#[W., 5ZY5S34FF-[GY#_
M +8FN/K7[2GC>1CE(+F.U09Z*D2#^>X_C7CD*O<2I%$IDD=@JJO)))P *[C]
MHJ^^V?'KX@2YS_Q.[I/^^9"O]*O?LNZ3;Z_^T)X"L[I/,@.JQ2LC<AMAW@'V
MRM>Q%\L%Y(Z%HC[#^%_['OPY^#GPY'C#XP/!>7HA6>YAO786MED<1!%YD?L<
MYR> .YCM=<_9'^+T[>';?3=,\/7<Q*6]XMBVF%F[%90 ,YZ*_7TK,_X*@>(K
MN#2_!.B([I8SS374JC[KLH"KGZ;B?QKX!\S/45S4XNHN>4G<A+FU;/=?@3^S
MG<?&[XO:MX;L[U[?P[I%Q+]LU10&;R5E9$"=B[A>#T')]C]7^,[3]ES]G"9/
M#>M^'K'6-92-'EAFLCJ-R >C.[_*A/7;D<$8&,4G_!,O28+?X3^(]051]HN]
M5*.W?"1J /U-?G_\1_$%WXF^('B35KYVDO+S49YI6;KDR$X_#I^%/6I-Q;T0
M_B=C]"V_9Y^!?[4?@2XU;X=Q6N@W\>8TN--B,!MY<<)/;\#!X[ D<@U\>_!G
MX3QW'[3&D> O&%EYBV^I26M_:!B%D,8/&1R5. <CJ"/6O5O^"9NMW4'Q;\2:
M8CM]DNM(\Z1/X=\<JA3]<2-77>+;&"P_X*7:2T*A3=?9YY,=W^S;<_D@I)R@
MY0OT%LVCU7X^?L6^!?$?PZUAO!7AVTT;Q58Q>?:?8<J)F4;C"RYP2Z\ GH2#
MTS7PW^RWX3TOQK\>O#&AZ_8)?Z;/-()[2?.UMJ$X8?4=*^^]0^-2>!OVQO\
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M;K7DW[,?Q8U7XL_#F:X\101VWBK1=2N-$UB.%=L9N82,LH[ JRGZ[J]9;K0
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M8=01T-?K%\ ?B#_PM/X)^&=?DD\R^6'['>-U/G1_*V?K@'\:_(O[3[U]]_\
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MC''/!+-U_A!KCOA#^U5\1O@E:_8?#>MYTK<6_LV^C$\"D]2H/*Y]C7:^+/\
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M* !@#I3O#_@O0O"^IZUJ.DZ7!87VM3K<ZC/%G==2J,!VR>H!QQB@#QSX@?\
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M6VY_#% ',?L7Z/?-X#\4^,+^TDL&\:^);[Q!;6TH*NEM*P$>Y>Q.&/N"IKZ
M;K3MH4!5 50,  8 'I36ZT -:F-3VIC4 -:F-3VIC4 -/>F-TIY[TQNE #6Z
M4RGMTIE #:;3J;0 RD/>EI#WH ;3*?3* $:F-3VIC4 -:FTYJ;0 UNM-;K3F
MZTUNM #/XJ*/XJ* &-UI/XJ5NM)_%0 C=::U.;K36H 8U#4-0U #>XHH[BB@
M#D;.WU%?B=?3/XDAFTLV2JF@@_O(7^3]Z1Z'G_ONNOK@M/;0_P#A<FIB+2+J
M/Q!_9R^;JC ^3)%^[P@[9^[_ -\FN]K2?3T&QR]J?3%[4^LQ!5[3<?VC:9Z>
M<F?^^A5&K$,AAECD'5&#?D<T ? ?[?-PZ_M1>*%;HL%D%^GV6(_SS7SU]I]Z
M^F/^"E>BOHW[0%KJBK_H^L:/;SB3L70O&P_!50_\"%?*=FT^H74-K;1M/<3.
M(XXHQEG8G  'J37KTY>XCHB]#4^U>]>A?#?X%>.OBM^\T#0IY+ ?ZS4;G]S:
MQCU:1L#%>D6OP]\"_LOZ5:ZM\3H8_%GQ"N(EGLO!<,G[FS!&5:[8=_\ 9]JR
MO^$P^*W[6UOXAM].UNVLX=%MOM5MX-TV3[*LT0/S+!$N-Y5>3GK0ZCZ;!S&B
M_P"S;X0\)LJ>-OC#X<TJ["Y>QTP->2CVRO%1?\(+^SVAVM\5=?9AP2FB<'Z<
M]*YOX5_!KP[\9/AWJ.EZ!>SV/Q:TN62<Z3>L$CU& #F.('I(N#D'FL>YU#X>
MS?!F\T75]+O/#/Q0T&Z81S*C,NI*S8:.8'_5LG;Z>]3S/NQ?,^E_&F@_!F+]
MF[P%;:AXT\1-X;34KQK&_M-,4RS2'&]70YV@=CWKR&/1?V;K=@\GC3QK=(O)
MA72XT+?CVK,^*-Y]E_8\^#L0^87&I:E,6/;# 8_2OGO[;[T1VW!'T['\6/@9
MX'8R>&OAK?>)[]/N7/BB]S!GU\I:X_XD?M0>./B39'3)[^/1M '":/H\8MK8
M#L"J_>^IKQ+[;[T?;?>K2C>XS9^T^]'VGWK&^V^]'VWWK3F'<V?M/O6YX#U:
M/3?'7AN[F.(8-3M9'.<842J2?RKBOMOO2&\W @\BES ?17[:UC<:/^T?XKDN
M$*0WSQW=M*1A98WC4AE/<5M^,FE\/?L0^!K.^C:"XU;Q)<WMLC\,T(CQOP><
M$C&:X[PW^V9XNTKPWI^BZUI'A[QI!IR"*RN/$.GK<3VZ#HH<\D#T->?_ !3^
M-7B;XR:]#JGB6]29K>+R+2UMXQ%;VD7:.)!PHX'Y5DKZ)]"=3V[4IO\ C 71
MVS_S/K#_ ,E)J;?RAOV"]*?@JGC*<,?3,8QGZUXE-\8=7N/A';?#IDMO[#M]
M7.LK($_?><8FCP6_NX9JZ'X3_M*Z_P#"CP_J/A^+3='\1>'[Z=;I]-UNU$\2
M3+TD7/0T:_C<9ZO\)=<N])_8O^--Q8W,EK(^H:7;M)"VTF.254=<^A5B#[&N
M&^ ?PHT[XD1>+-9\0:Q<Z+X2\,6*WNIR6$7F7,P8D+'&I^7)P>6X'''IQB_'
M36U\$>-/"R6]A%IGBN_AU"\6&'9Y3Q2>8JQ <*N0./08IOP?^.WB'X)ZY>W^
MA?9+F"_@^RWVGZA")K>[BY^5U/ID_F?6C6SMNPU/J+P;??#F[_9E^.'_  K[
M3_$]I;1V5K]JE\130R"5@[["@B& PY)^HK@/V--:M=>\4>)_AGJDJIIOCC29
M;&-I/NQWD:EX7^H^8_55KC_$W[8GB[Q'X/USPG%IF@Z+X9U6V^SOIFE6*P1Q
M'<&,@QR7.T#)[5Y'X7\87_@_Q)I>NZ7-Y&HZ;=1W=O)U D1@RY'<9'([BDD[
M-/J(^E_BQ:S_  1_9C\+^ [Y&L]?\5:A-K6L0X_>1V\+>7#&?J0&'_ J]*_:
ME\1?"O1=<\(6_B[PEX@UB/\ X1ZT.FW.G:FMO:^1MZ(A&,[LYQ7R)\9OC?KW
MQT\;2^)_$1@6\:".VCAME*QQ1IG"J#[LQ^IKK?!G[6GB;POX.LO"VJ:1H/C'
M1+ %;&'Q!9+.]JI(^1'ZA>.E*ST?4#W#P3\9O"OQ:_: ^!.EZ3H5]I.F^'7D
MLH7U2Y6XDF!!,8+ <A2O&?:OG7XI7.LGXQ>*1>_:?[?.KW'F ;O.\SS#T[YK
M.^(/QRU_XA>*-,UR6/3]#N-*55T^+0[5;6.V"MO!4+U.[G)KTJ7]NKQK+B].
MA^%O^$H$0B_X27^RD-]P,;]W3?C^*FKQU2#8W/A7(S?LA?&W>#YJ:CI[2!NH
MY()/XU9_9UDF/[-OQ^FT?)UM;&Q!:$?O!:%Y?/VXYQM#;L>BUX[\*_VAO$?P
MIOM=EM8K#6[+7D*ZGIVL0":"Z.XMN9?[V23FI-#_ &DO%7A7XH7_ (X\/C3]
M#O;Y?*GTZSM56QDAP!Y1BZ%?E!]<C-#OJ!ZM^P3=7'_"^XW0XT9=+NVU9F_U
M(MMG)D[8SCK[U=^'6N7&E?L<_&J?3;F6U$FL:?;[XVPQBDF"LI([%20?8UYU
MXO\ VO?%7B/PSJ&@Z5I/A_P;8:FNS4#X>L%MI;M>Z,XYVGNHXKAM'^+^KZ'\
M+_$?@.!+8Z/KMS;75S(RYE5H6#*%/8$@9^GO0[R=WY?@!F6>IS:?=0W-K,]M
M<0N)(Y86*LC Y!!'0@UZ#XB_:2^(WBK0[C2-3\4W4]C<J$N%54C>X4=I)%4,
MX_WB:\@^V^]'VWWK71[E&S]I]Z/M/O6-]M]Z/MOO5<P7-G[3[T?:?>L;[;[T
M?;?>CF"YL_:?>C[3[UC?;?>C[;[T<P7-G[3[U]N_\$P)GD\0?$=?^68L+0].
M^^:O@G[;[U^A/_!+G0W7PO\ $'Q ZLJ3W$%BC'HVQ2QQ]"]85I?NV3+8^U**
M**\HP.!_:*D>/]G?XBO']\:3+C ]J_'@7/ YK]IOB1H/_"5?"WQEH^W<UYI5
MPBJ.I;RS@?GBOQ!^U/%\D@V2+\K*>H(X(KT,-*R:-8&U'<CS$R>-PS^=>^?M
MJ3,OQ8TTJ?\ 1#H&GFVQ]W9Y(Z>V<U\T&\R,9KZ1^/)_X61\ _A=\2;+]])I
MUI_PB^L;>3%-"28F;_?4G]*Z)2]Y,N^IX1]I]Z[GX*_#>\^,'Q&TKPW;-Y4$
MK^;>7)^[;VR?-)(Q] N?Q(KD/A_X(\0_%+Q/;>'_  SITFJ:I<9(BCP JCJS
M,>%4>IK[+^'G[//BSP'\$O&.C>$K_P /:_\ $G7KR+3KXZ1JT4SZ=IA'[PDY
M&UM^0P],8Z4IU%%6OJ#D2VOC'1=8\6:Y\4Y[=1\./AM;C2?"VGR?<O+P#;&0
M.YW?,3]*^-_$GBJ^\6>(-1UK4YS<7]_.]Q/(>[,<G\*]4_:B\=:5HMOH'PF\
M)W<5SX;\)QXNKNW;*7VH,/WLN>X!^45X!]M]Z5/17$C9^T^]>_? :X_XL/\
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MU+1-,2.YVMC(5S]S\*)>\M@>IP_Q8T[3?#?Q0\6:3H[9TNRU2XM[;!R%19"
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MYJ;0 4444 %%%% !1110 4444 %%%% !3:=3: "BBB@ HHHH **** "BBB@
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M>F-TH :W2F4]NE,H ;3:=3: &4A[TM(>] #:93Z90 C4QJ>U,:@!K4VG-3:
M&MUIK=:<W6FMUH 9_%11_%10 QNM)_%2MUI/XJ $;K36IS=::U #&H:AJ&H
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MKC5];N9=Q:UMU^2$)@X#-)@<]F%<'KP7X2_M?:)K;,+;0?B%I[:7>.QPBW\
MW1,3ZL@QGT2K_P"S# WCGQ1\0_BQ=(3_ ,)%J9T_2RXY73[0F),>FY@Q/KM4
MT ;OC3XP>)]2^(EUX!^&NBV.KZWIT"7&KZKJT[1V.G!_]6AV L\AZ[1T%5_#
MOQ@\:>$/B1HG@OXGZ-I5L?$&^/1_$&@S.UI/.@RT#I(-R.1C;USG%>4?"7PK
MXR\0?&SXYVVC>/Y/"%[#K\,MQ;)IL-PUQ&T(\N3,@R %PO'%>EZA^SCXL\6>
M(O"FH^*_BC>:Y:^'=6AUBWM4TN"WS-'G&749P02/QH ]_7M7D'Q ^,?B%OB(
M/A[\.M$L]<\406JWVIWNISF*QTR%CA/,*@LTC=0@YP<U[ .U?'W@7POXO\0?
MM/?'6TT7QW)X.OUO+"X>--.AN6NK<PL(F_>#(" @<<?.* /4-+^,7COX?_$#
MP]X7^*>C:,EGXCE-KIGB+P]-(;7[4!D02QR#<A8?=.>2<5Y_^VQ-X^75/ J6
MD6@GP^WBBQ_LYI991<-=;6($P VB/.>5YZ5VNO?LU>,/'-[X>/BOXKWNM:?H
MVKVVL16J:3;P%IH7W+\ZC('4?C4/[9G_ !X_"K_L=K'_ -!>@#D_VJ;KXTK^
MSUXT/B*U\&Q:4;<"\;3;BY:<1F6,#8&4 DGKGM7KWP8O?B3:^$8)_%MKX;CT
M:#1(Y;#^R9IFG9EB4J) Z@ ;1SCO5+]M;_DU_P"(?_7G'_Z415Z!X>_Y)+IW
M_8!C_P#284 <I\$?C8WCKX"P?$3Q.EKI,<:7<UX;?/E11P2."PR2?NIFN.\-
M_%#XY?%K15\6>"?"_A?1?"MUF33+;Q-<3?;KZ'/$A\OY8MV. <\8->7>#X[F
M;_@F;XA6T!:3[#J3,%&?W8NG,G_C@:OK+X.WEGJ'PE\$W&GLC63Z)9>5Y9!
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MK36ZT ,_BHH_BHH 8W6D_BI6ZTG\5 "-UIK4YNM-:@!C4-0U#4 -[BBCN**
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M7'U85\@^=7<I75S4N^=1YU4O.H\ZJN,N^=1YU4O.H\ZBX%WSJ/.JEYU'G47
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M":/_ ..T?\.<?"/_ $6F^_\ !-'_ /':^XZ5>M',PN?#G_#G'PC_ -%IO_\
MP2Q__':/^'./A'_HM-__ ."6/_X[7W+11S,+GPU_PYQ\(_\ 1:;_ /\ !-'_
M /':/^'-_A+_ *+3?_\ @FC_ /CM?<RTM',PN?#'_#F_PE_T6F__ /!-'_\
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M8O\ X[1_PYB\,_\ 19-0_P#!+%_\=K] Z*.9A<_/S_AS%X9_Z+)J'_@EB_\
MCM'_  YB\,_]%DU#_P $L7_QVOT#HHYF%S\_?^',/AG_ *+'J/\ X)8O_CM'
M_#F'PS_T6/4?_!+%_P#':_06BCF87/SZ_P"',/AG_HL>H_\ @EB_^.T?\.8?
M#/\ T6/4?_!+%_\ ':_06BCF87/SZ_X<P>&O^BQZC_X)8O\ X[1_PY@\-?\
M18]1_P#!+%_\=K]!UZ44<S"Y^?'_  Y@\-?]%CU'_P $L7_QVC_AS!X:_P"B
MQZC_ ."6+_X[7Z#T4<S"Y^?'_#E_PU_T6/4?_!+%_P#':7_AR_X:_P"BQZC_
M ."6+_X[7Z#K3J.9A<_/F'_@C#X765&E^,&I21@Y9%T>)21W /FG%>I>!?\
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MM(M+0 4Y:;3EH 6BBB@!]%%% "K2TBTM !3EZ4VG+TH 6E7K24J]: '4444
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MJX0<]V[F@!MK:"W^8\O^@]A5BBB@ HHHH **** "BBB@ HHHH **** "N/\
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M^-._M:P_Y_[7_O\ K_C19@7:D6J/]K6'_/\ VO\ W_7_ !J1=6L/^?\ M?\
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M+3\'?]#/I?\ X$K2Y9=@LSJ**YC_ (6EX/\ ^AGTO_P)6C_A:/@__H9]+_\
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M5IU9/_"5:-_T%;/_ +_+3O\ A*-&_P"@K9_]_EHLP-2BLS_A)]'_ .@I:?\
M?Y:7_A)M(_Z"EI_W^6BS TJ*S?\ A)=(_P"@G:?]_EI?^$DTG_H)VO\ W]%%
MF!HT5G_\)%I7_02M?^_HH_X2+2O^@E:_]_119C-.BL__ (2#2_\ H)6O_?T4
MO_"0:7_T$;7_ +^BBS$7Z*H_V]IG_01M?^_HH_MW3?\ H(6W_?T468%ZBJ7]
MN:;_ -!"V_[^BC^V].[7]M_W]7_&BS NT52_MK3O^?\ MO\ OZO^-*-9T_\
MY_K?_OZ/\:+,"_15/^V+#_G^M_\ OZO^-']L6'_/[;_]_119@7**J?VM8_\
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M<HH I?V+I_\ SXV__?I?\*/[%T__ )\;;_OTO^%7:* */]AZ=_SX6W_?I?\
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M&1_PB.A_] >Q_P# =/\ "C_A#]"_Z UA_P" R?X5KT478&1_PB&A?] >P_\
M 9/\*/\ A#]"_P"@-8?^ R?X5KT478&/_P (?H7_ $!K#_P&3_"C_A#M!_Z
MUA_X#)_A6Q11=@8__"&Z#_T!K#_P&3_"D_X0W0?^@+I__@,G^%;-%%V!C?\
M"&Z#_P! 73__  &3_"C_ (0S0/\ H":?_P" R?X5LT478&-_PA>@?] 33_\
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M/_@%'_A1_P *V\)_]"SI/_@%'_\ $UTE%',^X7.;_P"%:^$O^A9TC_P"C_\
MB:3_ (5KX2_Z%C2/_ */_P")KI:*.9]P.:_X5GX1_P"A8TC_ , H_P#XFC_A
M6?A'_H6-(_\  &/_ .)KI:*.9]PN<S_PK/PC_P!"QH__ ( Q_P#Q-'_"LO"'
M_0KZ/_X Q_\ Q-=-11S/N!S/_"L?"'_0KZ/_ . ,?_Q-)_PK#P?_ -"OH_\
MX Q__$UT]%',^X7.9_X5CX0_Z%?1_P#P!B_^)H_X5GX1_P"A7T?_ , 8_P#X
MFNFHHYGW YK_ (5GX1_Z%C2/_ &/_P")H_X5GX1_Z%C2/_ &/_XFNEHHYGW
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M%_\ H7=+_P# ./\ PH_X5]X8_P"A>TO_ ,!(_P#"N@HI<S[B.?\ ^%?^&/\
MH7M+_P# 2/\ PI?^%?\ AC_H7M+_ / 2/_"M^BGS/N,P/^%?^&?^A>TS_P !
M(_\ "C_A ?#/_0OZ9_X"1_X5OT4<S[B,'_A ?#7_ $+^F?\ @)'_ (4?\('X
M:_Z &F?^ D?^%;U%+F?<#!_X0/PU_P! #3?_  $C_P *7_A _#?_ $ --_\
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M\*U**+L#+_X1?1O^@59_]^%_PH_X1?1_^@79_P#?A?\ "M2BB[ S/^$8T?\
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M4@ 4  8%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAFLQ_P!PI?\ XY3:?1S,+B?V_P".C_S-%I_X*5_^+I?[;\=?]#5:#_N$)_\
M%U(M24<S"Y!_;'CO_H;+3_P4)_\ %T?VKX\/_,VVG_@G3_XY5JGK3YF%RG_:
M7CT_\S?:#_N#I_\ '*/M_CX_\SC:#_N#)_\ '*OK4B]*.9_T@N9JWGC]O^9R
MM?\ P2I_\<I?M'Q /_,Z6H_[@J?_ !RM1*D6CF?])!<Q_-^()_YG:U'_ '!(
M_P#XY2[OB$?^9XM1_P!P./\ ^.5M+3UHYG_207,+'Q#/_,\VO_@CC_\ CE+Y
M?Q$_Z'NU_P#!%'_\<K?7M3Z.=_TD%SGOL_Q$/_,^VH_[@4?_ ,<H^R_$4_\
M,_6W_@AB_P#CE=*M/6CG?])!<YC[#\1O^B@6O_@@B_\ CE']G_$C_HH5K_X3
M\7_QRNK7M3J.=_TD%SDO[+^)'_11+7_PGXO_ (Y2_P!D_$D_\U%MO_">B_\
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M5Z'_ ,):U_\ BZ;Y/QF_Z+!#_P"$M:__ !==FW6BCVLO+[E_D',SBFA^,_\
MT6&'_P )6U_^*IK1?&C_ *+##_X2MK_\57:MUIK4_:R[+[E_D',SB3'\:?\
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M_P ^+_\ ?2_XT?\ ")ZO_P ^+_\ ?2_XT>VEV7W+_(.9_P!)'C'_  CGQ_\
M^C@8_P#PBK'_ .*I/^$;_: _Z."C_P#")L?_ (JO:O\ A$]7_P"?%_\ OI?\
M:/\ A$]7_P"?%_\ OI?\:/;2[+_P%?Y!S/\ I(\4_P"$9_:!/_-PD?\ X1%A
M_P#%4?\ "+_M _\ 1PJ?^$18?_%5[8OA35O^?)_^^E_QI?\ A%=6_P"?)_\
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MJ?\ SYM_WTO^-'_"-:G_ ,^;?]]+_C1[:79?<O\ (.9_TCQD>%?CS_T7V/\
M\(NR_P#BZ/\ A%?CS_T7V/\ \(NR_P#BZ]H_X1O4_P#GT;_OI?\ &E_X1O4_
M^?1O^^E_QH]M+LON7^0<S_I'C'_"+?'?_HO<?_A&67_Q=.'A;X[?]%ZC_P#"
M,LO_ (NO9?\ A&]3_P"?1O\ OI?\:/\ A'=27DVC_F#_ %H]M+LON7^0<S_I
M'C@\+_'7O\>(S_W)ME_\72_\(O\ '3_HN\?_ (1ME_\ %UZ[)I-[#]ZUE'T0
MG^50?9Y1P8GS_NFCVTNR^Y?Y!S,\K_X1;XY_]%VC_P#"-LO_ (NE'A?XY?\
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M_0\Q_P#@FA_^*KIEC?/W&_(T_P I_P"XWY4<[_I(+G,"Q\<_]#Q&?^X/%_\
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MZ4<S J>9KG_08C_\!%_QI?-UO_H+Q_\ @(O^-6MI]*-I]*5Q%;SM;_Z"R?\
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M)X5T7PE8=$GO%-Y=?[W\,8/L5;ZFO"->_;H^/'B.X\ZZ^)>L0-G.VP,=HO\
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MR_\ 15_&O_@_NO\ XY1_PU)\9?\ HJ_C7_P?W7_QRIM8_94^+OA_PB?$^H>
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M_=?_ !RO+MU&ZCV=/^5!RKL>H_\ #4GQE_Z*OXU_\']U_P#'*/\ AJ3XR_\
M15_&O_@_NO\ XY7EVZC=1[.G_*@Y5V/4?^&I/C+_ -%7\:_^#^Z_^.4?\-2?
M&7_HJ_C7_P ']U_\<KR[=1NH]G3_ )4'*NQZC_PU)\9?^BK^-?\ P?W7_P <
MH_X:D^,O_15_&O\ X/[K_P".5Y=NHW4>SI_RH.5=CU'_ (:D^,O_ $5?QK_X
M/[K_ ..4?\-2?&7_ **OXU_\']U_\<KR[=1NH]G3_E0<J['J/_#4GQE_Z*OX
MU_\ !_=?_'*FM/VK_C19R%X_BKXP8XQB;6KB0?DSD5Y1NHW4>SI_RK[A<J['
MT/X7_;_^/?A.1#!\0KV_C!RT6J00W88>A,B%A^!!KZ*^&7_!775XIHK;XC^"
M;/5+7@-?^'V,,RCU\J1BK'Z.OTK\[MU&ZL)X6A4WBB73A+='[Z?![X\?#S]H
M#2C>^!?$<%_.BAI]+G/E7<&>SQM\P[\\CCK7=21M&Q5E*L.H-?SQ^&_$VK>#
M];M=8T+4KG2-5M6#PWEG*8Y$/L1V]NAK]3OV,?\ @H59?&":Q\"_$N2WTSQ>
M^V&PUE<)#J+= CCHDI_)NV#P?"Q.7RI+GIZK\3DJ47'6)]GTY:=- ]O(4<8(
M_6FK7D',+1110 Y>E%"]** %7K4>K:EI_AW2+G5M:U"VTC2[9#)->7DHCC10
M,DDDXKSW]H#]H3PE^S/X';Q#XHF\Z]F#)IVCPD>?>2@= .RCC+'@#WP*_'#]
MHC]JCQU^TIX@>\\2:@UOI".3::%:.RVEN,\?+_&W3YFR?I7H8;!SQ&NT>YM3
MI.>O0_0/XR?\%5O /@BXN-.^'^BS^.+^/*_VE,_V:Q#>JL07D'T4 ]FKY.\;
M_P#!3OXZ^+97%AK6F^%+9N/(T?3XR<?[\WF-GW!%?)NZM*P\-ZQJEC<7MEI5
M[=V5NI::YAMW>.,#J68# _&OH*>#P])?#?U.R-*$>AZ=??M?_&W4%D$OQ3\5
M('.3Y&IRQ?EL(Q^%4/\ AJ3XR_\ 15_&O_@_NO\ XY70_ /X8>'O'7PE^-FN
M:Q:/<:CX9T6WO-,D25D$4CS%6) ^]QZUX]I7AS5]<M[F?3=+O-0AM@&GDM;=
MY1$#T+;0<#ZUO%4KM<JT\B_=['H'_#4GQE_Z*OXU_P#!_=?_ !RC_AJ3XR_]
M%7\:_P#@_NO_ (Y7EYRI((P1P0:3=6GLZ?\ *BN5=CU'_AJ3XR_]%7\:_P#@
M_NO_ (Y1_P -2?&7_HJ_C7_P?W7_ ,<KR[=1NH]G3_E0<J['J/\ PU)\9?\
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M_P!*M5S_ *>W3VJ]9ZB=PCG/)^Z_K[&@#2HHHH **** "BBB@ HHHH ****
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M_!/?QOXKMI[F'7?B+XL_LN;4HP0PMDCW2.7'W=S&=,\<MQ6+\&89/AO^P?\
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M\4::+HV.3G$;Y# 9[$D# K#V4DE;O>R9/+H:GB#XU6/[0'B#X8?"KP_X5M/
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MS!1Y@H =13?,%'F"@!U%-\P4>8* '44WS!1Y@H =13?,%'F"@!U%-\P4>8*
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M'[6(<9\PVV_S=N.?N=.>G->>_"OX.^,_C;XB?0_!.A7&NZC'$9I5B94CAC!
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MG<=F0>/[H]Z\Q_:(B/Q(^)GPV^%T9+6EU>'7]95>UG;<JK?[\G3W2I?BL?\
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M>G7MOJ%I)]RXM)EEC;Z,I(-37E[;:=;/<W=Q#:6\8R\T\@1%^K$X%?-/P_\
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MVD5W%*H1ECZ(=AZ  ?-7<^)?^3XO!'_8JW__ *$: /?Z1NE+2-TH ;3*?3*
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M8"KO^4]@AKQ#]G;X-VOB[PY!XI\.?'/0_AQXWLKJ1)M/U6[DL)4A&TI)',"
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M?M77?Q@L;'P?X6T>'P/\+=';_B6>&K(X#$=)9V'^LD/7G./?K2YG)Z/7OV]
MNV8O[47Q\G_:"^*EYKT4']G:!:1KI^BZ:HPMK9QC$:@>I')]S7D6_P!ZA\SV
MH\SVKIC)15D:IV5D3;_>OLC_ ()\^+M4\#^"?VB]>T6Y-GJMCX-66VN%&3$_
MG$!A[C.1[XKXQ\SVKU'X.?'FZ^#_ (6^)&BV^D0ZDGC/1AH\DTDQ0VH$F_S
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MT9'JTG@;2H-0CTMD6Z>XNDA"LX)4#=UX%>7ZN?\ B;W_ /U\2?\ H9K]-_\
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M4^LB21:\D_:J\#W?C+X.ZC<Z2"/$'A^6/7=,=1EA-;G>0/7*AN.Y KUM:DH
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M;QC"I&H 4#\!0!B?%VUUR^^%?BRV\-%EU^73)TLC&VU_-*' 4]FZX]\5\W?
M?XW?!GX??"SP_H4&B-)X\MK:.&^\-KHCR:M<7^ ) Q,?)9\G<6Q@CITKZ_7M
M2K#&)-XC4/\ WMHS^= 'SM^P;'<Q_"GQ&;VQ;3+I_%6IR263$$V[-,6,9(X.
MW....*M?L-QM'\+_ !2&4J?^$OU3[PQ_&@KZ$C4*#@ <YX%/C4+D* HZ\#%
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MW_Q-'_"O_%G_ $+6L_\ @!-_\35*:6S'[1=C)W&C<:UO^%?^+/\ H6M9_P#
M";_XFC_A7_BS_H6M9_\  ";_ .)I^T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-:W_"O_ !9_T+6L_P#@
M!-_\31_PK_Q9_P!"UK/_ ( 3?_$T>T7</:>1D[C1N-=SX3_9Z^*7CJ41Z!X
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M^E $E%1_:(_7]*/M$?K^E $E%1_:(_7]*/M$?K^E #VI%IC7">OZ4+,GK^E
M$M%1^<GK^E'G)Z_I0 ]J;2-,GK3?.7UH ?13/.7UH\Y?6@!]%,\Y?6CSE]:
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MC3XGZ9:6 AL[F2WAOQ;W$<L:#"ME3@@Y!&.U3.FX0IQDKVW$U913/AS]I/\
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MLN=+5,S4?=N?"UPTOVB;[3Y@N=[>;YV=^_/S;L\YSG.>]1Y%>S?MCVW@F/\
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MMT^F4^LB21:DJ-:DH ?3UIE/6@!ZU(O2HUJ1>E #TJ1:C2I%H >M/6F+3UH
M>O:GTQ>U/H D6GK3%IZT 2+VIU-7M5?5IGM=)OYHSMDCMY'1L9PP0D'\Q0!=
MJ1:\<_9,\=:Y\2/@7H7B#Q'?'4M7N)KI);DQ)&6"3NB_*BA1A0!P.U>QK0 -
M3&ZT]J8W6@!C=::U.;K36H 8W6F-UIE]=1V%G<W4I(BMXFF<@9.U5)/Z"N<^
M&_Q"TCXK>"]-\5:"\SZ3J"%X&N(S&Y )'*GIR* .D:F-3VIC4 -:F-3VIC4
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M_OV*/^$XU?\ Y[1_]^Q7YB_\/:OC9_T"_!?_ (++G_Y)H_X>U?&S_H%^"_\
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M7\OO#V$S]0QXRU3_ )ZQ_P#?L4?\)EJG_/6/_OV*_+S_ (>U?&S_ *!?@O\
M\%ES_P#)-'_#VKXV?] OP7_X++G_ .2:/[-K^7WA["9^H@\9:I_SUC_[]BE_
MX3#4_P#GK'_W[%?EU_P]J^-G_0+\%_\ @LN?_DFC_A[5\;/^@7X+_P#!9<__
M "31_9M?R^\/83/U%_X3#4_^>L?_ '[%*OC#4_\ GK'_ -^Q7Y<_\/:OC9_T
M"_!?_@LN?_DFC_A[5\;/^@7X+_\ !9<__)-']FU_+[P]A,_4?_A+]3_YZ1_]
M^Q1_PE^I_P#/2/\ []BORX_X>U?&S_H%^"__  67/_R31_P]J^-G_0+\%_\
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MH[S_ ..4?\-+?%[_ **KXW_\*.\_^.4?V5/^9!]7?<_?+SM<_P">2_\ CO\
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MH ^BF_.O%OVB/B5XBT"_\(>!O!,L%MXQ\874EO;WUQ'YB6%M$F^>XV]V52,
M_P"UZ5[);6XL[2"W5BZQ(L89NIP,9/Y5\Y_'B_B\%_M.?!3Q9JCK!H4@U#1I
M;N0@1P3S1$1;B?N[B<9]%- &1\7/AC\4?A_\,_%&JZ3\2=2\=P/I=TFJZ-XF
M2(1M"T3!Y+9D53$R#+!22#C&:['X8:E<Z-^Q?X7O[&9K>[M?!-O-#,O5'6T!
M5A[@UTG[2WC?1/ OP5\62ZU?QV9O]+N;.SB/,EQ+)$RJL:CENN21P "37)>
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MQ9\2/C!>_#?P9K?_  BMAHEG#>Z_KT4*R7(:;)AMX WR@D DM@XP16#XFO\
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M0]>U.IJ]J=61(J]:DJ->M24 %7--L)]2N$M[=-\C?D!ZGVJK'&TTBQHI9V.
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MKO<7=1NI**]*YN:/A_P_JGBS6;32-%T^XU75+MQ'!9VD1DED8] %')K5\?\
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MQNM '"_$WX*>"_B_#;+XJT.+4)K7/V>[C=H;B'/4)*A#@'T!K)^''[.7P_\
MA/K$VK>']%<:M*GEG4-0NYKVX5>ZI),S,H/< BO3FIC4 -:L#QMX(T+XB>';
MO0?$>FPZKI5T,26\XR,CHP/56!Y!'(K?:F-0!Y%X8_93^&?A%KJ2ST*>ZEGM
M)+'S=3U">\>*&12CK$978QY5B,K@UW&G^ ]$TGP%;^#;6T9/#MOIZZ7':F5F
M(MPFP)O)W'Y>,YS71MTIC=* ,;PGX5TSP+X7TSP]HMN;72=-A%O;0L[.40=!
MN8DGKU)JC>_#_0M0\=:;XQGLR_B'3K66RMKKS6 2*3[Z[,[3GU(R*Z5NE,H
MP?''@G1OB-X5U'PWXALQ?Z/J"".XM]Y0L P8$,I!!! ((.>*?X1\)Z5X%\,Z
M;X?T.U%EI.G0B"VMPQ;8@]2>2<Y))Y))-;--H X_XB_"?PI\5]/@L_%.CPZG
M';OYD$I+1S0MZI(I#+^!KD/"_P"RK\-/!^M6NKVFB7-YJ%HRO;R:IJ5Q>B%E
MZ,BRNP4CU%>N4C=* &GO3*?3* $:F-3VIC4 -:FTYJ;0 UNM-;K3FZTUNM #
M/XJ*/XJ* &-UHH;K10 UNM-:G-UIK4 ,/WA0U!^\*&H ;1110!YYIMGIR_'+
M5;E/%<\^IMIBJ_ALD^7 G[K]\!ZG _[[->B5PUA,A^+VI1_\(IY#C3U)\28_
MU_\ J_W/X?\ LE=S6D^GH4QZ]J=35[4ZLR15ZU)4:]:D[4 ,\1>-M+^$?P]\
M2_$'6R!I^AVKRHAZRS8PB+ZDL5 'JPK\-/B%X]U?XG>-M:\5Z[,;C5M6N6N9
MV)R%R>$'^RHPH]A7Z)_\%8?B-)X:^&?@#X=VLFQM7FDU?4%!Y*18$:M[%Y"?
MK%7YB><:^CR^ERT_:=6=M&-E<[#P7\+_ !E\2/M'_"*>%=8\2?9L&;^R[&2X
M\O/3=L4XKH/AM^SK\1/BQXFNM#\/^%[Z2[LGV7TEU&8(;(CKYTCX"8]#SQTK
MZD\%V/Q#^(?[*'PYTS]G_6CI^IZ7>7!\4:=IU\MI>M<LV8YY#D%HMN/:N]_:
MWT3XP?%3P'H^F>!?%^G^*5T72XX/&6@^&+Q!=2Z@!^\D=4P9E((&,D9!-;O$
M2YN71?IZ^I?.[V/!_P#A&?@7^R_B3Q)>Q?&KXA0\C1]+D*:)9R>DLV,S$'L!
MCL0*\Q^*G[2GQ&_: NK;19[AK71E81V'A;P_"8;2,=%58DY<^[9-=)X%_8VU
MB/1$\4_%;7+3X5>$0=V[5>=0NEZXAM\[B3V)XKZ+_9L\;> ])U/5[GX5^'4\
M*?#_ ,*1?:_$GQ*\0QK/J=S&.D%N"-L;R$8 '.#ZXI2G&/O?$UUZ?UZ:A=+7
M<R-2_9I^,2?L!VN@OX;U9]6C\1'56TA9=URMD8L ^5NW=?X,9]J^:_A3^T_\
M0?@:;C0#(NL>'"QCO?"OB*$SVC]F4QORA]UP:]<TO_@I#XK3]J2;Q]=O<#P9
M<XTU]#1SB.PW<./^FH^_N]>*]'_:0\4> ;[Q+86OQA\.IK?A;Q'"+_PS\4_"
MT2PWLENV,+<H!ME>/.&'7@>M1%SC[E6*:>O]>A.JTDMSR8> O@=^TXIE\#ZJ
MGP@\?2C)\-:Y+NTJ\E/\-O<?\LR3T5O4 #O7B?C_ /9Y^(OPS\70>&M=\)ZC
M#JMTVVTCMXC.EWZ&%TR)!]#7?_$']C3Q#8Z.?%'PTUBS^*O@UB"+S1#F[M\]
M!-;YW*1ZCBOJW]F71?C+\-OA-XC\->,O&UCX:U_6M,:/P/H>O7T;7UO=%"=Z
MALF(%3M )X)Z5;K>S5X2NNSW_P _O*YN573/SR\:?#7Q;\-Y[>'Q7X8U;PW+
M<+NA35;.2W,@'4KO S7-[J^X?BQ9>// /['_ (HT/X\:P-1\67^LV\OA>QU"
M]6[O[?;_ *^3=DLL9'')QS7PMYQKJI5'43;+C*Y8W4;JK^<:/.-;%EC=1NIU
MO8W]Y9W-W;V5S/:6V#/<10LT<.3@;V PN3TSUJKYQHN(L;J-U5_.-;_C3P/X
MC^'>I6NG^)=)GT>]NK2*_@AN-I,EO(,QR#:3P0#[T7Z 9&ZC=5?SC1YQH&6-
MU&ZJ_G&CSC0!8W4;JK^<:LBSO6T\WXM+@V"R>2;KR6\H28SLWXQNQSC.:+B$
MW4;JK^<QP ,GZ58U"SO=)NFMKZTGL;E0"T%U$T3@$9!*L 1D$'\:+@&ZC=5?
MSC1YQH&6-U&ZJ_G&CSC0!8W4;JK^<:]=^&7[-NN_%X+'X:\4^#[F_P#L3ZA-
MILVJ/'<V\*+ND:13%@%1R0":F4U%7DQ-VW/*MU&ZO;/AU^Q_XW^,%QK4/@75
M_"OBY]'M4N[O^S-48[0Y<(@WQ+ESY;<?3GFO'M#T'4_$7B2QT#3[22?5[VZ6
MSAM=I#F5FVA2.W/7TP:2J1E=)["3N5-U&ZN[^.7P-\6_L[^,(O#/C**SAU66
MU2\5;&X\]/+8D#+8'.5/%>>><:J,E)73T&G?5%C=1NJOYQH\XTQGM7[)_P ?
M;W]G7XTZ+XGBD?\ LF1Q9ZM;@\36CL-^1ZKPP]"HK]TQ<6U];V]]8S+<6-Y$
MMQ!-&<JZ, 01[$$'\:_G",Q(P>E?M=_P3O\ B=+\4/V4]!6[E\[4O#LTFD3,
M3EBB',9/U0K^5>)F5*Z55>AR5X_:/HZBBBO!.0?&ID95'4G%?F!_P5:^/C^(
MO'FF?"S2KAAI/AY5N]1"'Y9KQU^4'U\M#^!=O2OT^DU&#1;"^U.Z.+:QMY+F
M4^BHI8G\@:_GB^)'C6Z^(GQ"\2>)[R8SW&K:A/>-(3U#.2OZ8KULNIJ51S?0
MZ*,;NYBY-&35;>:-YKZ.YW%G)HR:;I]E>:M?06-A:SWU[<.(X;:VC:221CV5
M5!)/TKZ9TO\ 9Q\(_ G3;;Q%\?=5D@U"1!-9?#O1I0VIW.=VTW+C*P1G'UYK
M.510WW);2*W[3;?\6+_9KP?^95N/_2MZX+X-_M(>-/@FT]IH]Y'J'AR\^6_\
M.ZK&+C3[M.ZM$W )&1N7!YZUZI>?M6_#GXQ06WA/XE_#2VT3PAIZFU\/:AX4
M=DO=!@/\.&.)US\Q!P22?K7&_$G]DK6=%\/S>,/AWJ]O\4O "#>^K:*";BS&
M =MU;_?C.#UP1Q7-!I1]G55ORW(6UI'J7@'P#X _:*\6:7J?P2U^;X-?%<2B
M3_A%[R>0V3[>9);*Y0;EVJ&?RF'0$  #-=U\7-2^%_Q\^%/Q 597\:^/OA_X
M>&HS_$6"U73QJ4XD2+RS&HS*@!^^_)QD9ZUX-_P3I;=^V1\/>_SWO_I%/5C]
MFUO^+1_M.<_\RC_[=)64X\L]]K6^;[DM6>^Q\XY-&35;>:-YKTKFY9R:,FJV
M\UL>'?".N^+EU%M$TF\U5=-MFO+PVL9?[/".LCXZ*/6E>V[$4,FC)JO&6E95
M0%F8@*!W)Z5J>*_"^M^!=6DTOQ#I=WHVI1QK*]I>1F.0(PRK8/8BB_2XRGDT
M9-=7\7_A'XE^!OC:;PIXKBMX-8A@AN&6UG\Z/9(@=<-@<X//O7%+-N&5;</4
M&DI*2NF(M9-&35;>:-YJKC+.31DU5\PCDG]:]+TW]FOXLZQH\&JV/P[\1W>F
MSQ">*YBL797C(R&'<@BI<E'=BT1Y]DT9-,OK2ZTN\GL[VVFL[N!S'+;W$;1R
M1L.JLK $'V-0[S3N,LY-&35;>:-YIW LY-&35;>:0S!2 6P3TYZT7 M9-&35
M;>:-YHN!9R:,FJV\UU/@7X7^,?B?+=Q>$?#6I>(Y+-0]PNGPF0Q*3@%L=,FD
MY):MB.?R:,FNQUKX&?$;PZNKMJ?@G7+%='MTN]0,UHP%K"^[;))Z*=C<_P"R
M?2N>;P?X@7PFOBAM&OE\.-<?9!JIA;[.9L9\L/TW>U)23V8:&?DT9-5MYHWF
MJN,LY-&35;>:-YHN!9R:_1C_ ()+?'F6WUK6_A'JMPS6EXCZIH^]LB.5<>?$
M/]X8D ']USWK\WMYKO/@-\1YOA-\9_!?BZ*5HUTG5()YMIY:#<%F3_@4;.OX
MUS8BFJU-P(G'FBT?T)$;20>M%2W&UI-Z$,C@,".A!J*OCSS HHHH **** $:
MFTYJ;0 4444 %%%% !1110 4444 (U(M*U(M #J*** $:FTYJ;0 4444 %%%
M% !1110 4444 %%%% !3:=3: "BBB@ HHHH **** "BBB@ HHHH **** "G6
MZ>9(!C.>.??_ #^E-J[I<>79NR_S_P _SH TAQQ2T44 %%%% !7">(OBIX<\
M"?$3PIX,OH9[+4/%1N387"0!;62:)0[QL^1B1@<@8.<?3/=UYA^T)\%S\;/!
MEE86>I_V#XATG4[;6-'UA8]YL[F%P0VW(W J74C/<'M6E/E<K3V&K7U/3Z^'
M?^"K/[.K?%CX&IXST>R-QXD\&,URWE+EYM/;_7K[[,+(/0*^.6K[?B#K&@D8
M,X W,!@$]S3+JWCNK>2*6-98G4H\;C(=2,$$=P12A)PDI(<7RNZ/Y=MU&ZOI
MC]O[]EZ3]F?XVW<6G6[+X-UXM?Z-(%.R)2<R6^?5">!_=*U\RY%>W&:DKH[H
MRYE>X[=1NIN11D57,5\QVZC=3<BC(HY@^8[=1NIN11D4<P?,=NHW4W(HR*.8
M/F.W4;J;D49%','S';J-U-R*,BCF#YCMU&ZFY%&11S!\QVZC=3<BC(HY@^8[
M=1NIN11D4<P?,=NHW4W(HR*.8/F.W4;C3<BOK;_@G'^RZ/C_ /&)=<URV)\#
M>$V2^U%Y!\EQ,#F&WSWR1N8?W5/J*F4U%79,I<JO<^]_V!_@:W[/?[-%M>ZE
M;&W\7>-BM_=JZXDAM\?N8CW&$.<>LAKVU?O5=US6&UK4GGQLA7Y(8QP%0=!B
MO,/BY\6%^&<>@6=EI_\ ;?B+7M0CL-/TM7V-+DCS)">RHN23TZ#O7B^]5GIN
MSAUDSF_AQH>L^+OCMXS\>:Y8W>F6.G1#PYH-K=HT9>!6#S7&T]G?&T^@/K7M
MBTQ<]^OUS3UHG/G=Q-W'T^F4^LQ$BUPOB[XK#PI\4_!'@W^S/M1\3"X/VWS]
MGV?RD+?<VG=G'J,>]=TM>"_%[_DZ;X(?[NH_^B30!] T]:\O^+7QH_X5]JFC
M>'-%T2X\5>--:#M8:/;N$41K]Z:9SPD8]>^#CI7&ZK\?/B'\+A;:G\3OA]8Z
M=X5DE6*XUCP[J+7@L=YPK3(R@[<D D>OY@'T*M2+TKR_XO?&)OA7'X.U 6,.
MHZ!K6K0Z=>7RRX^RI*#Y<JXX8%L#\16E\=OBHGP4^%^L>*VM%U&XLS'';V18
MK]HE>145 1SW)X[*: /04J1:Y/X9^/+/XB_#O0/%L.VWM-3L4O'7=E83M_>+
MGOM8,,_[-8'P5^,3?%/X?W_C"^L(M#TB.\NH[:1Y21);0N5\YR?NY*L?3 S0
M!Z<M/6OGW1_CI\2_B59-KWP[^'%A>^$6=A:WWB#5#9SWZ*2#)#$JG )!QN(S
M7H/P6^,%I\7M%U!SIUQH.O:1=MI^KZ+>$&6SN%&2,CAE/9AP<'TH ]$7M3Z^
M9K3]JKQ1XP\8>)O!?@GP/;ZWXLTC4Y+9OM=VT-C!:I@":>7!(9FR JYZ5[YX
M'U#7M5\+:?=>)]*M]$UYU/VNQM9_.BB8,0-K]P0 ?QH Z%:>M>8?&+XU+\,[
MG0]#TK19_%'C/Q!(T>EZ+;N(]P7EY97/W(U'4^Q K"\-_%+XLZ9XJTK3_'7P
MRL[;2=4N%MH]5\,:BUZMDS?=-RC*"%[%EX'>@#W!>U.KR'XJ_':Y\(^+M.\#
M^$/#DOC+QW?0?:Q8+*(;:SMP<>=<2_P@GH.IR*Y>;]HCQW\,]7TF/XN> ;'0
M- U*Y2R3Q!X?U%KRVMIG.(UG#JK*"3C=TS0!]$U(M><_&KXO1_"/P[IMS;Z9
M)X@UO6=0ATG2-+@D"?:KF7.P%SPJ  DM]/6LSP/XQ^+\GBRSL/&?P_T2RT6[
M5O\ B9Z#K#7!M& R!,DBJ2#TRN: /4KB^MK6X@@FN(HIK@E88W<!I"!DA0>N
M!Z5(W6OCG]I35OB0O[2WP>^S>&/#\HM=4U+_ (1XR:HZF^!AC#&X^3]SA<$8
MW9)(KW'4?BQX@^&OPI\0^,OB=H6G:/)I0WI9:#?-=BX4X5%#,JX=F(&,<=:
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MHHH **** "BBB@ HHHH 1J1:5J1: '4444 (U-IS4V@ HHHH **** "BBB@
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M?PKX8@C\.:%;P#*^1!\NY0.N]]S?B*_1G4OA_P"!8?#5_P#')_BIX=BUJ_\
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M>M&X>M',P'9-&33=P]:-P]:.9@.R:,FF[AZT;AZT<S =DT9--W#UHW#UHYF
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M1110 4444 %%%% "-2+2M2+0 ZBBB@!&IM.:FT %%%% !1110 4444 %%%%
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M!M,I],H 1J8U/:F-0 UJ;3FIM #6ZTUNM.;K36ZT ,_BHH_BHH 8W6BANM%
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M,S_ #_HB7A7_ , X_P#XFCVWD'-+N?@#YS>U'G-[5^_W_#,_P _Z(EX5_P#
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M^ '_ $13PI_X!1__ !-'MO(.:7<_G\\YO:CSF]J_H$_X9?\ @!_T17PI_P"
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M7Q[_ -"9XC_\%5Q_\17](W_"17__ #U7_O@4?\)%?_\ /5?^^!1[60'\W/\
MPJ7Q[_T)GB/_ ,%5Q_\ $4?\*E\>_P#0F>(__!5<?_$5_2-_PD5__P ]5_[X
M%.7Q%??\]5_[X%'M9 ?S;_\ "I?'O_0F>(__  57'_Q%'_"I?'O_ $)GB/\
M\%5Q_P#$5_21_P )#??\]5_[X%+_ ,)!??\ /5?^^!1[60'\VW_"I?'O_0F>
M(_\ P57'_P 11_PJ7Q[_ -"9XC_\%5Q_\17])7_"07W_ #T7_O@4?\)!??\
M/1?^^!1[60'\VO\ PJ7Q[_T)GB/_ ,%5Q_\ $4?\*E\>_P#0F>(__!5<?_$5
M_25_PD%]_P ]%_[X%*->O?\ GHO_ 'P*/:R _FT_X5+X]_Z$SQ'_ ."JX_\
MB*/^%2^/?^A,\1_^"JX_^(K^DS^WKW_GJO\ WP*/[>O?^>J_]\"CVL@/YL_^
M%2^/?^A,\1_^"JX_^(H_X5+X]_Z$SQ'_ ."JX_\ B*_I,_MZ]_YZK_WP*4:]
M>_\ /1?^^!1[60'\V7_"I?'O_0F>(_\ P57'_P 11_PJ7Q[_ -"9XC_\%5Q_
M\17])W]N7G_/1?\ OD4?VY>?\]%_[Y%'M9 ?S8_\*E\>_P#0F>(__!5<?_$4
M?\*E\>_]"9XC_P#!5<?_ !%?TG?VY>?\]%_[Y%']N7G_ #T7_OD4>UD!_-C_
M ,*E\>_]"9XC_P#!5<?_ !%'_"I?'O\ T)GB/_P57'_Q%?TH?VY>?\]%_P"^
M11_;EY_ST7_OD4>UD!_-?_PJ7Q[_ -"9XC_\%5Q_\11_PJ7Q[_T)GB/_ ,%5
MQ_\ $5_2A_;EY_ST7_OD4?VY>?\ /1?^^11[60'\U_\ PJ7Q[_T)GB/_ ,%5
MQ_\ $4?\*E\>_P#0F>(__!5<?_$5_2BNM7?_ #T7_OD4O]M7?_/1?^^11[60
M'\U\7PA\?S2)''X*\2,[':JC2KCDG_@%>L?#_P#8!^/WQ&FC73_AYJ=C XR+
MK5MMG%^<A'\J_?C^VKO_ )Z#_OD5#+J%Q-PTK8] <4>UD!^<'P)_X(SVMC<6
M^I_%SQ9]L5<.="\/DJ&/7;).PSUX(5>>S"OT6\ _#_PQ\*O"]MX;\&Z%9^'=
M$MQ\EK9Q[03W9CU9CW9B2>YIVYO[S?G2JS?WC^=9N3EN!LT5D;V_O'\Z-[?W
MC^=2!KT5D;V_O'\Z-[?WC^= &O162&;/4_G2[CZF@#5HK*W'U-&X^IH U&IM
M9NX^IHW'U- &E16;N/J:7<?4T :-%4-Q]:-Q]: +]%4-Q]:-Q]: +]%4-Q]:
M-Q]: +S4BU2W'UI58^M %ZBJ6X^M&X^M %QJ;57<?6C<?6@"U157<?6C<?6@
M"U157<?6C<?6@"U15<$XI<T 3T5!FC- $]%09HS0!/3:BS1F@"6BHLT9H EH
MJ+FHY+B.'AY%4^A/- %FBJL4DMSQ!;RR_P"UMVK^9K1@T>XD&9Y5A']V/EOS
M-,"NS!< ]3T7N?P_"K-OILMP<R9AC[+_ !'_  K1MK&&T7$:<]V/+'\:GH C
MA@2W0)&H5?:I***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M27_[+_@>3XGV'C_2+:[\+^)(9Q-=S:%<M:Q:D!_!<QK\LBD\G@$GJ34WQD^-
MFH?!W4M+GF\#:[XC\,31N;[5M#B%P]BP8!=T ^=E()Y7I@5ZK16OM&VN?6Q5
M^YR7PQ^*?AKXP>%HO$/A74/[0TQY&A9VB>)XY%^]&RL 0P/!%=;59=/@AM98
M+>-;5)-Q/D*$(+=6&._?->#^&OV??B3\/=?T]_#GQLUG4O#,4Z&XT7Q591:A
M(\(/*1W/RNG' X/:A1C*^MO4-&>^S6\5PI66))5]'4&H?[-@R"HDCQT$<C*!
M^ .*XCXO_$?Q%\-['3KO0OA_JWCV*:1UNX]'GB6:U4 %6V.09,G(PO3'TJ+X
M/_&0_%J'4O,\$^+?!=QI[(DMOXJTT6AD+ G,1#L'''7Z>M+DER\_05G:YW8L
M9%8D7EQC.=ORD?3[M2+#*O\ R\,W^\J_T%>4Z]^UM\(/"WB2_P! UCQ[I.EZ
MM8S-!<V]V[1^5(O522,9_&O0+OQUX>T_PB/%5WK=C9^&S EU_:UQ<+';")\;
M7,C$ *=PP<]Q0X35KK<+/L:LEO,^-MTT?^ZB_P!16?>:+>W2D+KE[;^\*0@_
MJAKE_#/[0/PS\::]::)X?\?>'-=U>ZW>18Z;J<-Q*^U2S85&)X52?PJI\6OV
MCOAY\#KFSMO&?B#^RKN\C,MO;QVD]Q+(H.TD+$C'&>*/9SORVU'RN]K&Q=_#
MB2^SY_B?6W!ZKYR ?D$Q66WP1TXY_P")OJ6?K%_\16E\)OBWHGQF\-SZ[H$.
MI0Z?'=-:@ZG8R6CR%55MZHX!*$.,''4'TKRZX\:?M&^,M:EM]"\ >%_ NBQW
M#)_:'B;56O+B>)6QOCBMQ\A8#(#],U2IR;:>ENX<K.^_X4C8#_F,:E^<7_Q%
M8>B^#?!_B36-1TK2/&S:GJ.G!&O+6TN8)7MPQ(7>%4XR5;KZ5UOQ;^$NE?&;
MPW%H.MWVJV>FBX6>:/2;U[5KA1G]W(R\E#GD#'UIWPR^#'@GX-Z;)9>#?#=C
MH4<P7SY+>/\ >SD=#)(<LY]V)I>[RW;U#2Q\ZZ_\'?C+X^\<:CI.C:A'\._!
MME<&'^W+QX[V_OT&#OAB50B Y_C/KW%>X1_ FT\F!9M>U*:6(+^\98L[@,;A
M\G!Z_G7I]%$JG,DDDK W<\T/P1MO^@_J8_[]?_$4G_"D+?\ Z&'5!_WZ_P#B
M*],HK.Y)YE_PH^'_ *&+5!^$7_Q%)_PH^+_H9-4_*+_XFO3J*+L#S'_A2"=O
M$VJ_E%_\32?\*/';Q1JP_"+_ .)KT^BB[&>8?\*0]/%.K?\ ?,7_ ,32?\*/
M;_H:]6_[YB_^)KU"BGS,1Y=_PH]_^AMU?_OF+_XFD_X4=)_T-VK_ /?,7_Q-
M>I44<S&>6?\ "CI>WC#5_P#OF+_XFD_X4=/_ -#EK _X!%_\37JE%',P/*O^
M%&W'_0Z:Q_WQ%_\ $TG_  HVZ_Z';6/^^(O_ (FO5J*.9@>4_P#"C;O_ *'?
M61_P"+_XFD_X4;>]O'.LC_MG%_\ $UZO11S,#R?_ (4;?=O'6M?]^XO_ (FC
M_A1NH?\ 0^:T/^V<7_Q->L44^9A<\F_X4;J/_0_:U_W[A_\ B:3_ (47J7;Q
M_K8_[9P__$UZU11S,+GDG_"B]4_Z*#K?_?J'_P")I/\ A1>J_P#10]<_[]0_
M_$UZY11S,+GD?_"B]7_Z*)KG_?J'_P")I/\ A1>L?]%&UP?]LH?_ (FO7:*.
M9A<\A_X47K7_ $4C7?\ OU#_ /$TG_"B];_Z*3KH_P"V4/\ \37K]%'._P"D
M@N>/_P#"B=<_Z*7KP_[8P_X4?\*+U[_HINO?]^8?\*]@HHYW_207/'?^%$Z_
M_P!%.U[_ +\0_P"%(?@/K_\ T4[7O^_$/^%>QT4<[_I(+GC?_"AO$'_13]>_
M[\0_X4A^ OB'_HJ&O#_MW@_PKV6BGSO^D@N>,?\ "@_$/_14M>_\!H/_ (FD
M_P"%!>(O^BI:[_X#0?X5[111SO\ I(+GBW_"@?$7_14]=_\  6#_  I/^% >
M(O\ HJ>N_P#@+!_\37M5%'M'_2079XI_PS_XC_Z*IKG_ ("6_P#\33?^&??$
MG_15==_\!+?_ .)KVVBCVDOZ2"[/$3^SWXE_Z*MKH_[<[?\ ^)II_9Z\3'_F
MJ^N?^ 5O_P#$U[A11[27])#YF>&_\,[^)O\ HK&N?^ 5O_\ $TG_  SOXG_Z
M*SKG_@#;_P"%>YT4_:2\ON0<S/##^SOXG_Z*UKG_ ( VW_Q--_X9U\4?]%;U
MS_P MO\ XFO=:*/:2\ON0<S/"/\ AG/Q3_T5S7/_   MO_B:/^&<O%/_ $5W
M7/\ P7VW_P 37N]%'M)>7W(.9G@W_#.'BK_HKVN?^"^V_P#B:3_AF_Q7_P!%
M?US_ ,%UK_\ $U[U11[27E]R#F9X)_PS=XL_Z+!KG_@NM?\ XFD/[-OBS_HL
M&N?^"VU_^)KWRBCVDO+[D',SP'_AFOQ9_P!%AUS_ ,%MK_\ $TG_  S3XM_Z
M+%KG_@LM?_B:]_HH]I+R^Y?Y!S,^?_\ AFGQ=V^,FN?^"RU_^)IO_#,_B_\
MZ++KG_@KM/\ XFOH*BCVLO+[E_D',SY\_P"&9?%__19=<_\ !7:?_$TA_9E\
M8'_FL^N#_N%6G_Q-?0E%'M9>7W+_ "#F9\]?\,Q^,/\ HL^N?^"JT_\ B:3_
M (9C\9=OC3K@_P"X3:?_ !-?0U%/VLO+[E_D',SYW/[,/C,_\UJUS_P4V?\
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M>BCVT_+[E_D',SYI_P"&7/B5_P!'":__ ."&P_\ B:7_ (9=^)7_ $<)K_\
MX(;#_P")KZ5HH]M/R^Y?Y!S,^:_^&7OB3_T<'KW_ ((;#_XFE_X9?^)'_1P.
MO_\ @BL/_B:^DZ*/;3\ON7^0<S/FX?LP_$C_ *.!U[_P16'_ ,32_P##,7Q'
M_P"C@->_\$5A_P#$U](44>VEY?<O\@YF?./_  S)\1_^B_Z]_P""*Q_^)I1^
MS+\1A_S7W7C_ -P.Q_\ B:^C:*/;2\ON7^0<S/G3_AF?XC?]%\U[_P $=C_\
M32_\,T_$7_HO>N_^".Q_^)KZ*HH]M+R^Y?Y"YF?.W_#-7Q$_Z+UKO_@CL?\
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MSG_"*77_ $&[K_OU%_\ $TH\*W/_ $&KH_\ ;*+_ .)KHJ*+@<__ ,(O<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWR?$_P#T-]]_W[C_ /B:UZ91S,+F3Y7B?_H;[_\ []Q__$TGD^)\?\CA?_\
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M)O\ H?-<_P#(7_Q-:U/HYY!=F-_9_B;_ *'W7/\ R%_\31_9WB;_ *'W7/\
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M&FZK_P!#/JG_ )#_ /B:/[.U7_H9]4_\A_\ Q-:=%',PN9O]GZK_ -#-J?\
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MDDLAPJ*!DDFIV8*I). .237QA^TI\=W\9:A/X9T.?;H-L^VXFC/_ !]R _\
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M']FWG_/I<?\ ?IO\* (5Z458&FW>/^/2?_OTW^%+_9MW_P ^D_\ WZ;_  H
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M0!#3EJ3['<?\\)?^^#2K9S_\\)/^^#0!'14OV.?_ )X2?]\&C['/_P \)/\
MO@T 14J]:D^QS_\ /"3_ +X-*+2?/^HD_P"^#0 RBI?LL_\ SQD_[X-'V6?_
M )XR?]\&@"*BI?LL_P#SQD_[X-'V6?\ YXR?]\&@!E%2_99_^>,G_?!H^RS_
M //&3_O@T 145+]EG_YXR?\ ?!H^RS_\\9/^^#0 Q:6I%M9_^>,G_?!I?LLW
M_/&3_O@T 144]H)%ZQN/JIIE !2K24JT .HHHH **** !>M.IJ]:=0 4444
M%%* 6. ,FIX]/N).D38]^* *]+5T:/<G^%1_P*E_L6Y_V/\ OJ@"G15[^Q[C
M_8_[ZH_L>X_V/^^J *-%7O['N/\ 8_[ZH_L>X_V/^^J *-%7O['N/]C_ +ZH
M_L>X_P!C_OJ@"C2K5W^Q[C_8_P"^J%T>X_V/^^J *E%7?[(N/]C\Z/[(N/\
M8_.@"E15W^R+C_8_.C^R+C_8_.@"E15W^R+C_8_.C^R+C_8_.@"E15W^R+C_
M &/SH_LBX_V/SH J+THJX-)N/]G\Z/[)G_V?SH IT5<_LF?_ &?SH_LF?_9_
M.@"G15S^R9_]G\Z/[)G_ -G\Z *=%7/[)G_V?SH_LF?_ &?SH IT5<_LF?\
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M+AU_3K>>Q<326MWI]V )K2XC.UXG [@]^X(-6OA'&D/PN\%I&BQHNC66%0
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M<TYOV?9-95V\+>*]%\0L!E;9)A',?P-/]UU7X![I!_PT]\2?^AA7_P  ;?\
M^-T?\-/?$G_H85_\ ;?_ .-UP/B;PCK7@Z\-KK.FW&GRYP/.0A6]U/0CZ5C;
MO>M/9TWLD.R/5_\ AI[XD_\ 0PK_ . -O_\ &Z/^&GOB3_T,*_\ @#;_ /QN
MO*-WO1N]Z/9P[(=EV/5_^&GOB3_T,*_^ -O_ /&Z/^&GOB3_ -#"O_@#;_\
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M_P"-T?\ #3WQ)_Z&%?\ P!M__C=>4;O>C=[T>SAV0[+L>K_\-/?$G_H85_\
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MG]T^_JIHM:3Z,.IP\FZ*1D=61U.&5A@@^E-\RO6OB1I]A\3/!8^(VAVZ6M_
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M[0:ZWXW:C=>*/C!XMNH(I;D"^:,>4A;:%PH''^[7#R6-]#&SR6=Q&BC)9HF
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M\1:GX6_8ZTC4M'O[C3-0BT?3/+NK5RDBY6('!'L:Q_V5?BC_ ,+Y\!Z]X/\
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M_P!L[P_9^*KCX3:-J"R-87_BR&VN%C<HS1L,,NX<C()'XUB?$J?XC_&CQ/\
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MO(P<=02*[SXY_#_Q79?$3PG\5/ >GQ:UKFAV\VGZAHDDXA;4+&0@LL;'@.&
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MFE7GC#P;X?L[B,PW%_I>G32W6T\,8@[;5;&<9R!7NJ]*<M '-_#'X=Z7\*/
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MC6+>'9I'B-?ML+K]T3# F7ZYPV/1A7Z*+TKA?CM\'[3X[?#*^\-RM'!JL/\
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MXT4$)K^J0>78V;?WH83RQ'J?3KVKY]UC7+G7=5N]1NW5[JZE::5D4("S')(
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MF4>90!9\VCS:K>91YE %GS:/-JMYE'F4 6?-H\VJWF4>90!9\VCS:K>91YE
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M6FJ6%KJ5JQR8+N%94/\ P%@15/PWX%\-^#U8:#X?TO1 XPW]G64<&1Z'8HH
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MZ4V@!&IC4]J8U #&I*5J2@!M-;K3J:W6@!G\5)2_Q4E #:2EI* &TUJ=36H
M;_%0U'\5#4 -_BH;I1_%0W2@#.C^V_VU+NAB%AY8VRC[Y;C@^W6K]94<=O\
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M98+>WC'+N3Q]!W)Z  FOT]^&/PPT[]GGX;P^%;!TN-?O@L^LZ@G5Y"/N#_9
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MJ*** "BBB@ HHHH *5:2E6@!U%%% !1110 4444 %%%% #EZ44+THH ****
M"BBB@ HHHH **** "BBB@ IRTVG+0 M%%% !1110 5/:0&>4 #CN?2F10M,<
M >U;%K;+:Q[1RQY)]: )541J%'04ZBB@ HHHH **** "BBB@ KFM4\"66H>,
MM+\31S2V6I62-#(T& +F$@_NY/4 \BNEHIIM; 5K34K2_EN([:ZAN)+=_+F2
M-PQC;&=K =#@]#5FN"U;P'?:?XWM?$OAF:&UEN'6+5K.;(BN8O\ GIQTD'8]
MZ[SVIM+H,^-_VO?V)X?'0O?&?@*U2W\2<RWNE1@*E_ZN@Z"7VZ-]>OYRW=O/
M874UM<PR6]S"YCDAE4JZ,#@@@\@@U^\5?/?[2G['7AGX[6TVJ60CT#Q@J_)J
M4*?)<'LLZC[W^\/F'OC%;TZMM)%*7<_)S?1OKJOB=\)_%7P=\0R:/XJTJ;3[
M@,1%-C=!<*/XHWZ,/U'>N/W>]=E[[&A-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-
MOHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU#N]Z-WO0!-OHWU
M#N]Z[GX3_!GQ=\:M>32_"VER7>& GO'!6WMAZR/T'TZGTH;MJP.5TW3[O6=0
MM["PMI;R]N9!%#;P(7DD<G 55'))K]#OV;_V5],^!-C:>+O&T,6I>.I5\RST
MW(>+3LCJ3T,GJW0=%[D]7\'/@/X._9ILQ)9B/Q+XX=-L^L3H-MN2.5B'\(^G
M)[GM737=Y/J%Q)<7$C2S2'+,U<=2KS:1,W+L2ZAJ$^J7<ES<OYDKG)/8>P]J
MYOQ5XF.AQPVUI%]LU>[.RUM1W/=F]%'<T[Q%XHM_#ZP0B-[S4+@[8+*'EW]_
M8#U-:ZV\3SQW+0(+A5VB0J"R@]1GTK%:6;1/J2:?]H%G +LQM=;!YIB!";L<
MXSVJVM1I4BU AZT]:8M/6@!]2+UJ.I%ZT /6I5ZU$M2KUH =3UIE/6@!ZU(O
M2HUJ1>E #TJ1:C2I%H >M/7I3%IZ]* 'KVI],7M3Z )5Z4Y::O2G+0!)3Z93
MZ 'KUIZTQ>M/6@ :HZD:HZ &MUIK4YNM-:@!C=:93VZTR@!C=::U.;K36H :
MU1MUJ1JC;K0 UJ:U.:FM0 QJ:>U.:FGM0 VF4^F4 -I.U+2=J &-TIM.;I3:
M $:F-3VIC4 ,:DI6I* &TUNM.IK=: &?Q4E+_%24 -I*6DH ;36IU-:@!O\
M%0U'\5#4 -_BH;I1_%0W2@"BOE?VI)B%A+LYF[$<<?Y]*N5"/-^U-EE\G;PO
M?-34P'4M)2T@!>M.IJ]:=0 4Y>E-IR]* %HHHH ?1110 JTM(M+0 4^F4^@
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M:93ZFXB5*D6HTJ1:0#UIZTQ:>M #ZD7K4=2+UH >M2KUJ):E7K0 ZGK3*>M
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M'M7^E85[\/M+U*3?=27EPWK)=.?ZUJ:%XCTOQ-:R7.DW\&HV\<AB:6W<.H<
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ME_X5]I__ #\7?_?P?X5T]%%P.8_X5_8?\_%W_P!_!_\ $TO_  @-C_S\W?\
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M*MMO^@UJW_?V/_XBNVHHYF!PY^%5J?\ F-ZO_P!_8_\ XBD_X5/:?]!O6/\
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M7_@8O_Q%>ET4<["[/,O^%#Z=_P!#'XC_ / U?_B*3_A0VG?]#)XC_P# U?\
MXBO3J*.=A<\P_P"%!Z=_T,OB3_P.7_XBD_X4'IO_ $,OB7_P.7_XBO4**.>0
M79Y?_P *#T[_ *&;Q-_X'+_\11_PH+3O^AF\3?\ @<O_ ,17J%%'/(+L\O\
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M9_X,$_\ C=>JT4^>079Y3_PSY9?]#AXL_P#!@G_QNC_AGNR_Z'#Q9_X,$_\
MC=>K44<\@NSRC_AGNS_Z'+Q;_P"#!/\ XW1_PSW9_P#0Y>+O_!BG_P ;KU>B
MESR"[/*/^&>[3_H<_%W_ (,4_P#C=)_PSU:?]#IXN_\ !BG_ ,;KUBBG[207
M9Y/_ ,,\VG_0Z>+_ /P8I_\ &Z3_ (9YM/\ H=?&'_@Q3_XW7K-%'M)=PNSR
M;_AGBT_Z';QA_P"#)/\ XW1_PSQ:?]#MXQ_\&2?_ !NO6:*/:2"[/)_^&>;7
M_H=O&'_@R3_XW1_PSU:_]#KXP_\ !DG_ ,;KUBBCVDNX79Y1_P ,]VO_ $.O
MC#_P8I_\;I?^&?;7_H=?%_\ X,4_^-UZM11[2079Y2/V?;4?\SIXO_\ !BG_
M ,;I?^&?[7_H=/%W_@Q3_P"-UZK11SR"[/*_^% VO_0Y^+O_  8I_P#&Z7_A
M0-K_ -#GXN_\&*?_ !NO4Z*.>079Y;_PH*U_Z'+Q=_X,4_\ C='_  H.U_Z'
M+Q;_ .#%/_C=>I44N>079Y=_PH6V_P"AR\6_^#%/_C=+_P *%M?^AQ\6?^#%
M?_C=>H44<\@NSR__ (4/:_\ 0X>+/_!BO_QNE_X41;?]#AXL_P#!@O\ \;KT
M^BCGD%V>8_\ "B;;_H</%?\ X,%_^-TO_"BK;_H;_%?_ (,%_P#C=>FT4<\@
MNSS+_A1=M_T-_BK_ ,&"_P#QNE_X4;;?]#?XJ_\ !@O_ ,17IE%'/(+L\T_X
M4=;?]#=XJ_\ !@O_ ,13O^%'VW_0V^*?_!@O_P 17I-%'/(+GFW_  I"V_Z&
MWQ3_ .#!?_B*/^%(VW_0V>*/_ ]?_B*])HHYY!<\W_X4C;?]#9XH_P# ]?\
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MC_XBC_A4\'_0R>(?_ T?_$5W=%',PNSA?^%3P?\ 0Q^(/_ T?_$4O_"J8/\
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M:*+L#G_^$-A_Z".H?]__ /ZU'_"'P_\ 00U#_O\ _P#UJZ"BB[$8'_"'P_\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>pgen-20201231_g5.jpg
<TEXT>
begin 644 pgen-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &C XP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBOSG_:S^*OC3PW^T#XJT[2?%^O:7I\/V
M7RK2RU.>&),VD+':BL ,DDG ZDFMZ-)UI<J948\SL?HQ17Y%?\+R^(O_ $/W
MBC_P<W/_ ,71_P +R^(O_0_>*/\ P<W/_P 777]2EW-/9ON?KK17Y%?\+R^(
MO_0_>*/_  <W/_Q='_"\OB+_ -#]XH_\'-S_ /%T?4I=P]F^Y^NM%?D5_P +
MR^(O_0_>*/\ P<W/_P 71_PO+XB_]#]XH_\ !S<__%T?4I=P]F^Y^NM%?D5_
MPO+XB_\ 0_>*/_!S<_\ Q='_  O+XB_]#]XH_P#!S<__ !='U*7</9ON?KK1
M7Y%?\+R^(O\ T/WBC_P<W/\ \71_PO+XB_\ 0_>*/_!S<_\ Q='U*7</9ON?
MKK17Y%?\+R^(O_0_>*/_  <W/_Q='_"\OB+_ -#]XH_\'-S_ /%T?4I=P]F^
MY^NM%?D5_P +R^(O_0_>*/\ P<W/_P 71_PO+XB_]#]XH_\ !S<__%T?4I=P
M]F^Y^NM%?D5_PO+XB_\ 0_>*/_!S<_\ Q='_  O+XB_]#]XH_P#!S<__ !='
MU*7</9ON?KK17Y%?\+R^(O\ T/WBC_P<W/\ \71_PO+XB_\ 0_>*/_!S<_\
MQ='U*7</9ON?KK17Y%?\+R^(O_0_>*/_  <W/_Q='_"\OB+_ -#]XH_\'-S_
M /%T?4I=P]F^Y^NM%?D5_P +R^(O_0_>*/\ P<W/_P 71_PO+XB_]#]XH_\
M!S<__%T?4I=P]F^Y^NM%?D5_PO+XB_\ 0_>*/_!S<_\ Q='_  O+XB_]#]XH
M_P#!S<__ !='U*7</9ON?KK17Y%?\+R^(O\ T/WBC_P<W/\ \71_PO+XB_\
M0_>*/_!S<_\ Q='U*7</9ON?KK17Y%?\+R^(O_0_>*/_  <W/_Q='_"\OB+_
M -#]XH_\'-S_ /%T?4I=P]F^Y^NM%?D5_P +R^(O_0_>*/\ P<W/_P 71_PO
M+XB_]#]XH_\ !S<__%T?4I=P]F^Y^NM%?D5_PO+XB_\ 0_>*/_!S<_\ Q='_
M  O+XB_]#]XH_P#!S<__ !='U*7</9ON?KK17Y%?\+R^(O\ T/WBC_P<W/\
M\71_PO+XB_\ 0_>*/_!S<_\ Q='U*7</9ON?KK17Y%?\+R^(O_0_>*/_  <W
M/_Q='_"\OB+_ -#]XH_\'-S_ /%T?4I=P]F^Y^NM%?D5_P +R^(O_0_>*/\
MP<W/_P 71_PO+XB_]#]XH_\ !S<__%T?4I=P]F^Y^NM%?D5_PO+XB_\ 0_>*
M/_!S<_\ Q='_  O+XB_]#]XH_P#!S<__ !='U*7</9ON?KK17Y%?\+R^(O\
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M^([7Q%I\-U;2I-#*BR)(AR&4C((/H0:52E*GJ]A.+B;%%%%8DA1110 4444
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M4X/WK ?^DL%?#7]J?[5<C_:?^U1_:?\ M5K2H.G'EW'&-E8Z[^U/]JC^U/\
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MV@TXQ^7]KG'V?,EHS^7E2<[O,R[?/C: _9:.[_K3_,.4]\K*MO%&F7GB:_\
M#\-SOU>PMH+RYM_+8;(9FE6)MQ&TY,,HP"2-O(&1GRO23XU^+6I>+=1TWQQ>
M^"K'2M5N-(TJQT^PL[F*8V^$>:[\^)W<--O&R)X?W:@9W'<,J[\/^)?$7[3'
MBZTTOQ1)X7M%\+Z,][>Z;:P27LCBXU#8L7VA)8D0_.6W([<* 1R:2IK6[_K0
M7*>_45Y_\$?$VK^(_!US%KUVFI:OI&J7NCSZ@D*P_;/L\[QK.47Y59U568*
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MT9_T3P_^#O3O_DBOV[HH_M.M_*OQ_P P]O+L?B)_P[I_:,_Z)X?_  =Z=_\
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MOY5^/^8>WEV/Q$_X=T_M&?\ 1/#_ .#O3O\ Y(H_X=T_M&?]$\/_ (.]._\
MDBOV[HH_M.M_*OQ_S#V\NQ^(G_#NG]HS_HGA_P#!WIW_ ,D4?\.Z?VC/^B>'
M_P '>G?_ "17[=T4?VG6_E7X_P"8>WEV/Q$_X=T_M&?]$\/_ (.]._\ DBC_
M (=T_M&?]$\/_@[T[_Y(K]NZ*/[3K?RK\?\ ,/;R['XB?\.Z?VC/^B>'_P '
M>G?_ "11_P .Z?VC/^B>'_P=Z=_\D5^W=%']IUOY5^/^8>WEV/Q$_P"'=/[1
MG_1/#_X.]._^2*/^'=/[1G_1/#_X.]._^2*_;NBC^TZW\J_'_,/;R['XB?\
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MA_\ !WIW_P D4?\ #NG]HS_HGA_\'>G?_)%?MW11_:=;^5?C_F'MY=C\1/\
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MO([,SGD*%5?/M)_9/&B_!35O!%MXMG36KB_AU&P\3&S#364MMY*V1\MI#O\
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M1H5DDEN)3A9&54V9;.X+Z!_PT)X6_P"@5XX_\('7?_D*C_AH3PM_T"O''_A
MZ[_\A52=16M'\'WN/WNQSOC[1_$^B_$GX8>)M,\(:GXJL]&TC4K&_M])N;*.
M:&286GEG%S<0JP_<R9VL<8]Z[K_A/-;_ .$6_M7_ (5SXF^W_:/)_L/[1I?V
MS9C/F[OMOD;.V/-W?[-8_P#PT)X6_P"@5XX_\('7?_D*C_AH3PM_T"O''_A
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M&"R(DK(X![J0"#V(!ZBOHCQ=\"_ WCKX9V?P^UK05NO!]G';Q0:9'<S0K&D
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M=PR"4DR*PF9RRL2?E)([8KE]-_9+^%^EV>DV*Z)J%[I&DRK/8Z-J>OZC>Z;
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MG8^-6C:XN;/R4FCDF601F(N_RC?MP6(('IQ7N?[?W@W4-2^"]KXUT&,MXC\
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M<VEZ+&T,%K$9"WE^8?F?<4Y)],5]^_!?X/:/X7T.TBLK.&TMH5 CAA0*JCV
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MCL . *Z9%"J *6EI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@T*_ATL+'.Z*([J1&A9MH7*B9CNW# P0/?ZF<)4Y.,MT)IQ=F%%%%0(****
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MT.M6HD0[9%^_'Z>X]J\R4.4AJQNK)4@:J:R5(LE9DEL-2U LE2*U(!]%)2T
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M0UC4[O4YX+9=V(8GNI9#%'\QRJ%0>^<"E6K0JN^NC?XA*2EJ>5_\$W/^3-_
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M+?*$'S%OEQGBL+PM^TA\/_%_BC3O#EGJ]W8ZWJ5L;S3[+6](O=+>^A'\5O\
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M_.X*2E)7,?\ 8)\/7^M>#_%7Q=U^!HO$'Q'U:75 LHR\%BC%+:(,>2H&X@\
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M>^%EN-7M+-7&R 3FY$#LJ#8'>V/7.W@ 3[>-KQ>NG?MY>8N==#YU^*'P^O\
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MW8KH=>^'OP6^(GQA_9WT_P""^@^'O$@MU\_Q##9V45U;KI:QQ@MJ2E2!.<N
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M$8XXX@V<HL1SQR&4-73*NG.Z:M>_6]NW;R_X!?.K[Z'S;\#;G_AH[X??%_\
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MUH1UG6O45H1UF2RU'TJ9>E0Q_=%3+TJ1"T444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 0]*^#_V_OA*VF>(-/\ '=A!_HNH 6E\47A)E'R,?]Y01]4]Z^\#7,_$7P18
M?$CP7JWAS4E!M;^$Q[\9,;]4<>ZL ?PK:C4]G-2*B^5W/Q3\;:2;RR6[B7,]
MOR<=U[US^CWF57FO8?'G@O4?A_XKU/P_JT/EWEE*T3C'RN.S#U!&"/8UX[KF
MF-X?U(^7G[),=T9_NGNM>]YHZCK]/N,XK76=[>6*>(XEA<2+]0<UQ^E7V[;\
MU=1#)OCZTQGT]X7U*'6-*@N5.Z&ZBY'L1R/PK9\(ZL^GW4FGS-B2%OE)_B7M
M7C?P7\4K#)+HEP^,DR6Q/_CR_P!?SKU+7+&5HX]0M,_:;<?,%_B7_P"M3B[H
M#VS0=6RJ_-7<:5JF-IW<U\_>$/%R7T*$/AQ]Y<]*]*T?70<?/^M4![%9ZN"H
MS^E:<6H;N_%>;V.L@J/F_6MRVU?I\]92IQD2XH[FVOAN )Z\5;:X]ZXB/5O]
MK]:UK35UN(_O#<O!%<L\/U1FXFS+<<=:SKJZX/-59K[K\U95YJ/RGYJTIT;:
MLI1%U"\QGFN0UB_QNYJWJ>I 9^:N,U743,[*'51U+,<!1ZFNLT"^UI=+T:YO
MW.3&2D2_WI#P!7YJ?M&^,O\ A*/'=VJ2>9# ?)4YR#MSD_BV:^L/V@OBU#X;
M\(RRV\NQ0'@L5)YDD(^>;'HHZ>Y%?GY=7,FI7<D[DEG.>:WI1N[]C2*UN);+
MN?-;UF,;:S;6WVXXK5MUQBM9LMFI"V*L"; J@LFVN@\%>'W\2ZPB,#]DA(:9
MOY+^-<LC)GJ7P>\/FQL7U*=<3W7"9ZK'_P#7KW/P["6.\C@<"N'T&SW&.*-<
M 8 4= *],TFV$*HB]!7)-D,Z735Z5U&GKR*Y_38^G%=-I\?(KDD9F_8KTKHK
M$'BL*Q3[M=!8KTK!D&Q9CI6S;]JRK->E:]NO2L&2:=KU%:$=4;4=*O1U!)9C
MZ"IEZ5%'TJ4=*D0M%%%( HHHH **** "BBB@ HHHH ***P/$OQ \+^#+K3[;
MQ!XDTC0KC49/)LH=2OHK=[E\@;8P[ N<D#"Y/(II-Z(#?HHHI %%8WC/6Y?#
M7@_7=7@C26;3[">[2.3.UFCC9@#CL2*\'_9Y\?\ QB^/'P>\.^._^$E\#Z'_
M &NDK_V?_P (G>7'E;)7CQYG]J)NSLS]T=:UC3<HN=[(JVESZ1HKG=0\9Z/X
M-M])MO%?B71=.U.\0HC7$Z62W<J(&E,,<DA; Y;;N8J.I/6JW@[XL>"/B)=7
M%MX4\9>'_$UQ;H))H='U2"[>)2<!F$;D@9XR:CE=KVT%9G5T5\PV'[0U[X?_
M &POB1X6\7^+].T7X?:+H%E=VJ:HUM:007$IA!)G8*Q+%V 5G(YX%?0WA7QC
MH'CK25U3PWKFF^(=,9VC%[I5W'<PEE^\H="5R.XS5SIRA9OK^HW%HV**X;3/
MCM\-=:UZ+0].^(?A6_UJ64P1Z;:ZW;27+R#.4$:N6+<'C&>*U?$?Q*\(^#KP
MV>O^*M%T.[%LUZ;?4M1AMY!;J<-+M=@=@/!;H#WJ.65[6%9G245SW@[XB>%/
MB);7%QX4\3Z-XFM[9Q'/+H]_%=I$Q&0K&-B%)'.#65XF^-_PY\%:Q)I/B'Q_
MX7T'58PK/8ZGK-M;3J&&5)1W# $$$<<T<LKVMJ%F=M17-^,/B5X0^'L-I-XJ
M\5:)X9ANRRV\FL:C#:+,0 2$,C#=@$9QZBM+P_XETCQ=HUOJ^AZK9:UI-P"8
M;[3[A)X)0"02LB$J<$$<'J#2Y7:]M -*BOE3]KC]KSPYX1^ _B34?AI\4O"T
MOC6![<6<>G:G97UQS/&LFV$EPWR%\_*<#)XQFOI?PO>S:CX9TB[N7\RXGLX9
M9'P!N9D!)P.!R:TE3E&*F^HW%I79J45YCX!\;>(?$GB3Q9K5UKW@74OAC;_+
MI-]H%Y)/=1M&/W_VR4MY*[2#PG3OTYT+?]H'X77=[8V<'Q)\(S7=^4%I;QZ[
M:M)<%FVJ(U$F7RW QG)XI>SE>R0K,[ZBJ>L:Q8>']+NM3U2^MM-TVTC::XO+
MR58H88U&6=W8@*H'4DXJE<>,_#]GX6'B:?7=-@\-F!;H:Q)=QK9^2P!63SB=
MFP@C#9P<BHLQ&S17EGQ%^(&MW%YX6T_X=>)? +ZCJ#)J-S!XBOW9Y])QEY[1
M(&RY[AS\F!R:[K1?&?A_Q)X;'B'2==TW5- */(-5LKN.:U*H2';S5)7"E6!.
M>-ISTJG%I)CL;-%<_'\0O"LWA ^*X_$NCR>%@AE.N+?Q&R"!MI;S]VS 8$9S
MUXJMX-^*O@KXBS7,/A3QAH/B>:U57GCT;4X+MHE)(!<1L=H)!QGTI<LM[!9G
M4T5SOB#XC>$_"5\;+7/%&BZ->+:O?&WU#4(8)!;J<--M=@?+!ZMT'K2>#?B1
MX2^(L-U+X4\4Z+XGBM65;A]&U"&[6$L"5#F-CM)P<9ZX-'+*U[:!9G1T5R7C
M#XN>!?A[>P6?BKQIX>\,W<\?FQ6^L:K!:22)DC<JR."1D$9'I6AJGCWPSH?A
M^TUW4?$6DZ?HEWY8M]2NKZ*.VF\P9CV2LP5MP^[@\]J.678+,W:*Y+P_\7?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*3I4M,<4
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M% !1110 4444 %%%% !1110 4UNE.I#TH KR+5*\MX[J&2&:-98I%*O&XRK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &,*KR+5HU#(M,"E(E9]Q%UK5=:J31U0'G'Q(^%?
MAOXF:?\ 9->TY+AE&(KI/EGB_P!U_P"AR*^/?BA^QYXC\*O-=^'6_P"$ATP<
MA%&VY0>Z=&^J_E7WQ<0FLZ:&NBG6E3VV-5)H_)C4M&EM)I+6]M6BD7AX9XR&
M'U!KFKSP;9R,6@,EF_7]T?E_(U^JOC;X9^'?'$136M(M[UL8$Q7;(OT8<UX+
MXO\ V--+N&>30-7FL6/2"\7S$'MN&#^>:]".(C+?0U4T?"<F@ZO9_P"IGCN%
M[9)4U UUJEOQ+8R_51N'Z5]*^(OV7/'&BEFAL8=4C&<-9S*QQZ[6P:X#5OAU
MXCT>1DO-#U"W*C<=]LX 'UQ73&49;,M6/(FUR1?O6TB_5#5=]?Y^XW_?)KT6
M;394Y>-@/]H57^Q#^XOY"M"CSYM5GD'R0RGZ(:5;;5;SB.RFQZL,?SKTF'39
M&^Y&Q^@K;T_P/K6H.%@TN[D)&1B%L?GBD!Y-;^#-3O&'G2QVZ_4L:W=/\ 64
M!#3[[M_^FAPOY"O9M*^"GB&[VF:V2S7OY\@ST]!FNRTCX&VMKAK^Z>X;ND0V
M+^?6H<XH5T>)Z=HI^2&W@_W4C7^@KO\ P]\+KRZ*RWO^B1==N,N?P[5[#I?A
M&QTA=MI:QP_[0'S'\:TX]-]JSE5["YCE-'\+VNDPB.UA">KGEC]36];:;TXK
M8AT[_9J_;Z>>.*P<B+F?:V&".*V+.PQCBK5O8XQQ6K:V)XXK-R)(;2SSVK<M
M;3&.*+6SQCBM>UM3QQ639(^SM>E;%K;].*CM;<C'%:MK;G(XK)LDGM8.!6I;
MQ5#!#TK1MX3Z5DQ$]O%TK0C3BH88ZMHM0221K5A14<:U,*D0M%%%( HHHH *
M*** "BBB@ HHHH **** "BBL#Q+\0/"_@RZT^V\0>)-(T*XU&3R;*'4KZ*W>
MY?(&V,.P+G) PN3R*:3>B WZ***0!117QS\6OVZ-3^''[66E_#^'2;"?P!;S
MV.G:_KDL,OF6=Y=*[1*)@XC0!=C;64DA)<$8XUITI56U'H5&+EL?8U%>/?M>
M>/M>^%_[./C;Q1X8OO[,UW3K:.2UNO)CE\MC-&I.R164\,1R#UJU\,_CYX-U
MSP_X1TS5?'WAN3QMJ&G637&EMJELE[)<RP(Y7[.&#!F+9"A1UX%'LY.'.M@Y
M7:YZO17FGQB\8>)O"NI>"XO#^M^!]'AU+5H[.]C\8W<L$MU&Q7]U8A"-]P1N
MPK9!..*\SN/C!XS7]M+Q5X"M]9M8_#5GX$;6;2QOH(UMX[WS442RRJOF[,,<
MC=C&3C-.-*4E=>H*+9]+T5\K^./VR)/@I^SSIGC+Q7J/@/QMXNO)RD.G>#-=
M,=E>Q>>8S);O())'$8QOPI 8$9%>W^&/CI\.?&>H66G:'X^\+ZQJEYN$%CI^
MM6UQ-*RKO=51'+,57DX' YHE1G%7MI_D#BUJ=S161KGB_0O#-WIEKK&M:=I5
MUJDXMK"&^NXX7NYCC$<2L07;D?*N3S7C_P"T-^UMX;^ 'B?P7H=V^E:A>Z[J
MT%C?0S:S%:R:3:R''VR5"K'RQSRVQ3@_,*F%.51VBA)-Z(]WHK#T+QQX<\4>
M'6U_1O$&EZOH2AV;5+&]CGM0$SO)E5BORX.>>,<UC^%?C9\//'6K+I7AOQ[X
M8\0ZFR-(MEI6L6]S,57[S!$<M@=SBIY9:Z;!9G:44G3DU\J_M<?M>>'/"/P'
M\2:C\-/BEX6E\:P/;BSCT[4[*^N.9XUDVPDN&^0OGY3@9/&,U=.G*K)1CU'&
M+D[(^JZ*YNU\76&B^ ;'Q#XDU:STNR6RAGN]1U"9+>!"RKEF=B%4%F]AS2>#
M?B9X0^(J73^%/%>B>)TM"HN&T;48;L0EL[=_EL=N<'&>N#4<KWL(Z6BN!OOV
M@/A=IEK;W-Y\2?"-I;W#2)#-/KMJB2-&=L@4F3!*D@$#H3S7F7[<'QB\0?"S
M]FR[\9> ];BLM1:ZLA;:E!%#=1O#+( 2HD5T8,IX.#UR*N%*4Y*-K7&HMNQ]
M%T5@>(O''A_P/H,.J^*-?TSP]I[E(_MNK7D=K"9&&0N]R%R<'C/8UA:E\<O
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M\2DX#,(W) SQDUU=9M.+LR0HHHI %%%% !1110 4444 %%%% !1110 4444
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MVN0M%'AQJ'E1R"??][S&?Y=V<X;'3BO4;K]CSP9<>%?BAX;34]=MM'^(5_\
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M6.6,.H<*2 P##."1GN:KE=N;H.VES>HHHJ1!17%^(/%/C#3OB+X>T?2_ _\
M:_A6]CD;4O$W]K0P?V:P#;5^S,-\VXA1E2,;O:NTIM6L,****0@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%4_EFG".D(A$8]*>L=3".G!*0$2QU($IX6EH 0+3J**0!1110 4444 %%%%
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M-A;:Z9\P;E/8CL:['5/V7?%'Q$M?"6C?$WXECQEX5\.W2WQT^VT,6-QJTT;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>pgen-20201231_g6.jpg
<TEXT>
begin 644 pgen-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (J!*H# 2(  A$! Q$!_\0
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MC_X%R?XUDT4 :W_"7:[_ -!K4?\ P*D_QH_X2[7?^@UJ/_@5)_C6310!K?\
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M7:R3);I-=RB-&D<X5,GN3T%+VU9.UV'-(^5?^';^@?\ 12_%GY1_XT?\.WM
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ME\)6^L:)H21N/',?A">+4)"V5W[7F381SZ _C5*6(;LG_3'[YQ?_  [<\/\
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MZ*+L+LD^U3?\]9/^^C1]IF_YZO\ ]]&HZ*+L+LD^T2_\]7_[Z-'VB7_GJ_\
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MT9-%%%V%V%%%%%V%V%%%%(04444 %%%% !1110 4444 %%%% !1110 4444
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M:9D0C<=\ISP.U=[\/_ARFM?M&^&;O7?#37EG8_#NP6&:_LBT,-R& (RPVB0
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M$(.[(QR<Y],?X:?#6XUS6/V:;3Q%X8N+RPL=#U(7D.H63M%!(#F,2AAA3D#
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M^BO^+O\ O_<__':/^%P>(_\ HK_B[_O_ '/_ ,=KR&BCDCV"R/7O^%P>(_\
MHK_B[_O_ '/_ ,=H_P"%P>(_^BO^+O\ O_<__':\AHHY(]@LCU[_ (7!XC_Z
M*_XN_P"_]S_\=H_X7!XC_P"BO^+O^_\ <_\ QVO(:] UKX):_H7P@T+XBW#V
MC:/JUVUI';1R$W,.-^R21,?*DABE"MGGRVI.,%N+0WO^%P>(_P#HK_B[_O\
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MAHHY(]AV1Z1K'QN\<VLR+I_Q,\57T17+/)J%Q$0<],>8<U0_X7O\2?\ H?\
MQ-_X-[C_ .+KAJ*?+'L%D>M6_P 8O$[P1M+\7/%T4I4%D%S<L%/<9\WFI/\
MA<'B/_HK_B[_ +_W/_QVO(:*7)'L%D>O?\+@\1_]%?\ %W_?^Y_^.T?\+@\1
M_P#17_%W_?\ N?\ X[7D-%')'L%D>O?\+@\1_P#17_%W_?\ N?\ X[1_PN#Q
M'_T5_P 7?]_[G_X[7D-%')'L%D>O?\+@\1_]%?\ %W_?^Y_^.T?\+@\1_P#1
M7_%W_?\ N?\ X[7D-%')'L%D>O?\+@\1_P#17_%W_?\ N?\ X[1_PN#Q'_T5
M_P 7?]_[G_X[7D-%')'L%D>O?\+@\1_]%?\ %W_?^Y_^.T?\+@\1_P#17_%W
M_?\ N?\ X[7D-%')'L%D>O?\+@\1_P#17_%W_?\ N?\ X[1_PN#Q'_T5_P 7
M?]_[G_X[7D-%')'L%D>O?\+@\1_]%?\ %W_?^Y_^.T?\+@\1_P#17_%W_?\
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M8Q?_ !5*-&*M=ARG6_M*^,M(\?\ Q:O==T6\.HVUU8V ENF1E:6X6TA29FW
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MX1?5(M:BMHX+BWU"&(Q">&:))8V*$DJ=KC(R<'/->? ;B!6R:DKHH**Z3_A
M[WC_ $_2?_!C%_\ %4?\('>_\_\ I/\ X,8O_BJ+@<W172?\('>_\_\ I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .!#_P"-&H!_PC>K_P#0*O?_  '?_"C_ (1O5_\ H%7O_@._^%'_  DFK_\
M04O?_ A_\:/^$DU?_H*7O_@0_P#C1J ?\(WJ_P#T"KW_ ,!W_P */^$;U?\
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M ,"'_P :6H!_PC>K_P#0*O?_  '?_"C_ (1O5_\ H%7O_@._^%'_  DFK_\
M04O?_ A_\:/^$DU?_H*7O_@0_P#C1J ?\(WJ_P#T"KW_ ,!W_P */^$;U?\
MZ!5[_P" [_X4?\))J_\ T%+W_P "'_QH_P"$DU?_ *"E[_X$/_C1J ?\(WJ_
M_0*O?_ =_P#"C_A&]7_Z!5[_ . [_P"%'_"2:O\ ]!2]_P# A_\ &C_A)-7_
M .@I>_\ @0_^-&H!_P (WJ__ $"KW_P'?_"C_A&]7_Z!5[_X#O\ X4?\))J_
M_04O?_ A_P#&C_A)-7_Z"E[_ .!#_P"-&H!_PC>K_P#0*O?_  '?_"C_ (1O
M5_\ H%7O_@._^%'_  DFK_\ 04O?_ A_\:W?"MGXG\737*V6I70BM4$D\TEQ
M)M0%@J\#))+$# !I2DHJ[+C&4WRQ5V87_"-ZO_T"KW_P'?\ PH_X1O5_^@5>
M_P#@._\ A7K>J?"'Q'81WZ#Q9^^TZ-)+F62[/DONX98BK,[E&(5LJ,9[5YAJ
M]_X@T/4KFPO-1O([FW<HZBY8C/US65.M"K\#N:U</5H_Q(V*?_"-ZO\ ] J]
M_P# =_\ "C_A&]7_ .@5>_\ @._^%'_"2:O_ -!2]_\  A_\:DM]>UJZN(X8
MM2O7ED8(BBX?DDX ZUL8$?\ PC>K_P#0*O?_  '?_"C_ (1O5_\ H%7O_@._
M^%=_;^"/$0M0]WX@FAG>X^S+$MT?W9'#/(6880-A=PSSFN8\2+X@\,W0AGUF
M><$LHDAN9"NY3AAS@\'VK&-:$WRQ>IM*C4@N:2T,?_A&]7_Z!5[_ . [_P"%
M'_"-ZO\ ] J]_P# =_\ "C_A)-7_ .@I>_\ @0_^-'_"2:O_ -!2]_\  A_\
M:VU, _X1O5_^@5>_^ [_ .%'_"-ZO_T"KW_P'?\ PH_X235_^@I>_P#@0_\
MC1_PDFK_ /04O?\ P(?_ !HU /\ A&]7_P"@5>_^ [_X5!>:7>Z>JM=6=Q;*
MQPIFB9 ?ID5/_P ))J__ $%+W_P(?_&H+S5+W4%5;J[GN54Y432,P'TR:8%6
MBBB@ K<M(/[/TS<V1<78S_NQ9_\ 9B/R'O5+1=.&H7F),K;1*99F'9!_4\ >
MYK0O+@W5P\K#;N/"CHHZ #V P*WI1N[]C2*ZE1^M0OWJ9^M0OWK60V0-WJ%O
MO5,W>HUC>:5416=V.U549))Z "N66YFQE%;7B#P/XC\)PV\VMZ!JFCQ7'^ID
MO[.2!9/]TNHS^%8M1>^P@HKHM2^'?B71_!>D^+;W1KJV\-ZM+)!8ZE(N(KAX
MR0ZJ?4$'\JYVBZ>P!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBKNJ:'J.B310ZCI]U82RH)8X[J%HV=#T8!@,@^M=#X:^$?C3QAXH'AS2/#&I
MW>NFW:[&G_9V28PJ,E]K8^7'>E=+4#D:*5E*,5888'!%)3 ***T] \+ZSXJN
MS:Z)I-]K%R!DPV%L\[@>N%!- &915VXT74;/53ID]A=0:D)!$;.2%EF#G@+L
M(SGGIBC6-#U'P_>&SU33[K3;M0&-O>0M%( >AVL <4 4J*Z"Z^'GBJRT]K^X
M\,ZQ!8JGF&ZEL)5B"]=VXKC'O7/TKWV **[BT^!_CZ^^&]U\0(/"FI/X,MCB
M76O)Q /F"9!/)&XA<@$ \5P]":>P!1113 **** "BBNW\._!'QYXN\#:MXST
M?PKJ5_X6TH,UYJT<7[B(*,M\QZ[0<G&<=Z3:6X'$45V_BSX(^// G@[2/%7B
M'PKJ6C^'M6(6RO[N+8DQ*[EP#R,J"1D#(Z5Q%":>P!1717OP\\2:=X(T[QA<
MZ/<P^&-0N'M+35&7]S-,F=R*?48/Y&N=HO?8 HHHI@%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4J_>I*5?O4 3+4Z=J@6IT[5O M$R=:M
M6EP]K<1S)@LAR W0^H/L1Q^-54ZU,E=435%;7=/2QO \'-I<+YL)]%/53[@Y
M'X5G5U,-O_:VGRZ?UG7,UKQSO ^9/^! ?F!ZURU<52/)*QC)684445F2?9>N
M:IX3\*_ WPS;^(KGPO)IFI> 2UOX>CTI3K$NJO-.L%V+A8@44,JDL9>50KM.
M:Y=OV5?#\OAW1)6N-:T;64U[1])U:RU"ZLY)C'?$CS%@B+/;,N,A9LE@1T((
MKYS\0>+-6\40Z3%JEXUVFDV2:=9*RJ/)MU9F5!@<@%V.3SS7<:A^TQ\2-4L[
M6UN?$9>.WN[6_#BT@626XMO]1-+($W2NG0%R>.N:YO9SC\+)L^AZI;_LP^"/
M%VJ6*^&-:\06^FVGB34-!U:35(H7FD2UM9+MI[=4P 6CBD4(Q/S;>>HKDO"_
M@/X2^*-+\<>)UD\8VGAOPW8V<PL6EM7NY[B:Y,)3S @0)@JV[;D888/%>?:;
M\:/&NBLC6&OW-G(FM'Q"LD(56%^5*&;..I4D%?ND$\5)XF^-GC'Q?'JT6HZG
M%]GU6W@M;NWM;*"VBDBAE,L:[(T4##DMD $D\YI\L^X69Z[KG[,_A+1/ T33
M^)O(\67&A6VNVL<FHVC+<O.4>.QCM ?/:0QN,2?=+@C:!@UVOA']FGP)X?\
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M"W@B\KS0J( ,Q_*5QM()R#DU@>.OB!K?Q(UA-3UVX@GNHXE@3[-:0VT:("2
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M9\N;5-(9KH2;[B28EFEC.2T<>S&&ST9\]:YSQ9XXD\06-M801&UL89))?+!
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M-UJ/29M+D^VRK/)$J,I61(6=97!SC"F-LYQTKF]J^Y',>"?\,T>$O^?C4_\
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M -_D_P#B*/\ AFCPE_S\:G_W^3_XBO5Z*.>7<+L\H_X9H\)?\_&I_P#?Y/\
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MNDQ@!CG^(8]N+\-^']/\#_L-_$;0O$;37^DZ/\4;>SU(Z:ZK)/#%Y22^2S9
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M>(-2T&+PA:"_UB^D6[U$6YMPS[3M568 E5& !Q7SIXQ_9J^%?BWP#\+/B/\
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M?U]P<R/@FBNX^"OAS0O%GQ*TC2O$=CXAU32YV</8>%;=9M0N6"$I'$K<?,P
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MO_R6E_\ B:GEEV%9G>45P?\ PO3P/_T&_P#R6E_^)H_X7IX'_P"@W_Y+2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *[\*_]"WI?_@*O^%+VR[!S'Q+17VU_P *[\*_]"WI?_@*O^%'_"N_"O\
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MPH_X5WX5_P"A;TO_ ,!5_P *[/;+L>?S'RGI?Q%GM(UCNK&"Z0-O+Q_N99'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM<$<'')]ZJUZN"A*GAX1GNE]WE\MCCKR4JDG$Z[X=6\8OKK4#$DTMB%=4D)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR+[2I])LM>UAM#AO;J-MD5PLL<3B0 94*TBCGK@XS@UERTB=#T+_ (:HLO\
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M"A_\36A'^T%+-8F_7P;>M;*2OG>>,9'7'R^_:O%_ >GPQK<ZO.AGBM=T;*I
M\K<C8D.1Q[>XJ$_$74H[N-X,)#$ D2N=SK& 1MW]><GGU-5'#TE%2GU-J>&H
MQIQJ5Y-<VR7YGK[_ +4EI&Q5_#=PK#@JUT 1_P".TW_AJBR_Z%V?_P "A_\
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MZ%V?_P "A_\ $T?\-467_0NS_P#@4/\ XFOGBBCV4.P<J/H?_AJBR_Z%V?\
M\"A_\32_\-467_0NS_\ @4/_ (FOG>NK\#V$*^?JLR&:.U)1E4C]UN1L2'/3
MV]Q6U'"QK34$=>$PKQ=:-).U^O9=7\D>UQ_M"O-9M?)X.O&MU.TS>>.HZ_P\
M]15)_P!J2TC8J_ANX5AP5:Z (_\ ':\=;X@:A'=(T'R0Q82-7.YU09^7?UYR
M>?>K/B:.VU;0[758XYXY%54:660.LK$G*YQG</?L*Z983#R@W1DVUO?KZ?\
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M9(W>H6^]5F90IROW&Y7Z56;[U.0"4445(@HHHH **** "BBB@ HHHH ****
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MB7_"I?&?_0L:G_X#-_A1_P *E\9_]"QJ?_@,W^%"I074.5')T5UG_"I?&?\
MT+&I_P#@,W^%'_"I?&?_ $+&I_\ @,W^%=',NY1R=%=9_P *E\9_]"QJ?_@,
MW^%'_"I?&?\ T+&I_P#@,W^%',NX')UTO@W5+:WF>SNU;9*2R,KA06VD;6R.
M0?Y_6I_^%2^,_P#H6-3_ / 9O\*/^%2^,_\ H6-3_P# 9O\ "M:5;V,U-=#J
MPN)EA:T:T.GXDDGPZN9+XI%,J0[1)^\(+(F,G<5RH(],^E)XHU"TL='M-,L9
M)'#Q*9TD8$(RLV. .&(P?QIZ?#/QW';O;IH&L+ YRT2PN%/U'2H?^%2^,_\
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ML:G_ . S?X5F:[X-USPO%%+JVDW>G1S,5C:XB*!B.H&:5T<QC4444P"BBB@
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M !J*XO[F\51/<2SA>0)'+8_.H** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *FLO^/VW_ZZ+_.H:FLO^/VW_P"NB_SJH_$BH[H[AOO&N9\4
M?\?L/_7/^IKIF^\:YGQ1_P ?L/\ US_J:^@QO\%_(]"M\#,>BBBOG3S0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ZSP_P#\@F'ZM_,UHUG>'_\ D$P_5OYFM&OJJ/\
M"CZ(]6'PHYCQ-_R$4_ZY#^9K)K6\3?\ (13_ *Y#^9K)KY[$_P :1Y]7XV%%
M%%<QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!1110 4444 %*HW<4E*OWJ $HJ25<J''T/UJ.@ HHHH **** "BBB@ HHHH
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MK]U_KV/XC^54UI<94HHHJ1!1110 4444 %%%% !1110 4444 %%%% !1110
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M3:T=0A\^W2Y'++B.7_V4_B./PK.K)JSL2%%%%(04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%6M)LVU#5;.U5=[3S)&%SC)+ 8S^-
M&OIOP\\3ZSIZWUCH&HW=FP)6>&V9E8#J0<<US[HT;LCJ4=3@JPP0?2OTLM85
MT^V@MH4$$5O&L21IP$"@  5\2_M,Z2NE?%[5BD"P1W217("8PVY!EL#ID@UE
M&IS.P'EE%%%:@%%%% !1110 4444 %%%% !1110 4444 .3K4R]JA3K4R]JN
M)2)D[5=M56X62UD.U)N Q_A?^$_GQ^-4D[5,M="5U8M&9)&T<C(XVLIP0>QI
M*UM:@\Z**_7DR?NYAZ2 =?Q'/U!K)KE:L[,S"BBBD(**** "BBB@ HHHH **
M** "BBB@ HHHH *M76J7%Y#'%*^53T_B/J:JT52E**:3W*4FM$%%%%22=S\%
M_B"/AGX_L=:>*62-0T+FWF\J1 W&Y2?ER/1L@C.:_0_X3_M0V.O(YBNUG6'F
MX39MEA]3/ .5'_36/*=^*_+>NN\)^)M3TS5[#5]&O)+'Q+IS;H)8S@W"XQM]
MVQE<<[@<=N>.OAHU7S=3.<.8_;3P#\1K36K>*?3KS[*\AQ]GN"&BD/\ L..#
M^%=W'>0Z3IM\=/L(=+N[MPT\B#:IXP6],X]AUK\GOAG^U!<V9>Y$<HAQOO8;
M2+S9+?\ O-+;#'G1?]-8L2)_&&X8^A>'_P!M;0_#%AK%YJ7BJWO[:1<P06]S
M+>S9SD+#"P 'UD*@=\]*\65*496:.5Q:T/N+7O&>F^'[>-3()922(SM+&1O1
M$'+G]*^8_B%^V#X3MO&UEX;O?$\.FRW,X@NKM"TT=@I_BN98\[!VV19;GYF7
MFOASXQ?MB^*?B=-=VNGRS>'=%GRDB0S%KNZ3TFGX.W_IF@5?8UX@NI1JH"@@
M>@Q7;3PZ>M1FT*/\Q^AOQ6_9K\9>![Z]\<:)=V_Q&\%:L?M1U;1P)2B=060%
MCM']Y2P]<5P>A_$!;2W%O81)<VTK%;G3[Y!+;S+R 57JIYZC!'.#7A'[/_[4
MWQ%^ .O1?\(/J<\UK<2CS?#UPC7%I=D]O*!RK'^\F&K[9M=3^"O[5MU%!<2V
MWP:^,4R;Y;..99+*>;^ZS#"%SW7*N.AW'(KU\/C944J55<T5U6Z]4>55P/)4
M=2.[/"O!=Y8Z/XB\1>.[JWCAL/"-D][#$Q)5[USY=K&"<Y/F-NYSPA]*^5KZ
M^FU*^N+NYD,MQ/(TLCMU9F.2?S-?7OQ6B\ _!OX3^(_ 7B+7K?Q5XZO;J25X
M/#<PGM[>1?E@>:8C:-H!.Q<M\Y!Q7QW3E5]O4E46VR]%_5SUJ*TO8****9N%
M%%% !2K]ZDI5^]0!,M3K]VH%J=?NUO$M%NS9/,:.4XAE78_MZ'\#@UE75N]I
M<20R##H=IK07[U2ZI";NQCNP,R0XAE]Q_ W]/P%%2.G,.2ZF-1116!F%%%%
M!2QQM+(J(I=V.%51DDGL*2O6/V8=)35/BYI[R0K,EG#+<_-C"L%PK8[X)%)N
MRN!Q&I_#SQ/HVGM?7V@:C:6:@%IYK9E5<],G'%<]7Z77-NFH6T]K.OGPW$;1
M21MR'##!!_.OS=UFR.FZQ?6C+L,$[Q%<YQM8C&?PJ(3Y@*=%%%: %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<.8G!T,17G5A)4FDU&2DW=VO9.ZUZ-+KU1\?4445]&?*A1110 4444 %%%%
M!1110 4444 %%%% !1110 58L]/GOFQ"F1W8\ ?C5G1]).H2;GRL"GD^OL*Z
MJ.-(8PD:A$7HHKT</A'57-+1'33I<VKV,:W\+QK@SS,Q]$&!^=6UT"Q7K$S?
M5S6A17K1P]*.T3K5."Z%#^PK#_G@?^^S1_85A_SP/_?9J_15^QI?RK[A\D>Q
M0_L*P_YX'_OLT?V%8?\ / _]]FK]%'L:7\J^X.2/8H?V%8?\\#_WV:/["L/^
M>!_[[-:7DR"(2F*01$[1)L.TGTSTS3*/8TOY5]P<D>Q0_L*P_P">!_[[-']A
M6'_/ _\ ?9J_11[&E_*ON#DCV*']A6'_ #P/_?9H_L*P_P">!_[[-7Z*/8TO
MY5]P<D>Q0_L*P_YX'_OLT?V%8?\ / _]]FK]%'L:7\J^X.2/8H?V%8?\\#_W
MV:/["L/^>!_[[-7ZDAMYKEBL,,D[ ;BL2%R!ZX Z4>QI?RK[@Y(]C,_L*P_Y
MX'_OLT?V%8?\\#_WV:OU)-;S6LFR>&2"3&=DJ%&P>AP11[&E_*ON#DCV,S^P
MK#_G@?\ OLT?V%8?\\#_ -]FK]%'L:7\J^X.2/8H?V%8?\\#_P!]FC^PK#_G
M@?\ OLUM0:1J%UI]Q?PV%U-86Q59[N.!FAA)^Z'<#:I/;)YJFK!LX(..#BCV
M-+^5?<')'L4?["L/^>!_[[-']A6'_/ _]]FK]%'L:7\J^X.2/8H?V%8?\\#_
M -]FC^PK#_G@?^^S6U?:/J&EQVTE[875E'=1^=;O<P/&)H_[Z%@-R^XXJI1[
M&E_*ON#DAV*']A6'_/ _]]FC^PK#_G@?^^S5^BCV-+^5?<')'L4/["L/^>!_
M[[-']A6'_/ _]]FK]%'L:7\J^X.2/8H?V%8?\\#_ -]F@Z#8?\\6'_ S5^BC
MV-+^5?<')'L9$WAFV<?NW>,^_(K(OM%N+$%B/,C_ +Z?UKKJ*PJ8.E-:*S(E
M1C+;0X*BM_6M%55:XMUQCEXQ_,5@5X56E*C+ED<$HN#LPHHHK$@**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /;/V2-/:Y^)TUSY>
MY+:PE8M_=+%5'X\FOL2OF/\ 8RM0;KQ7=9^988(L>Q9C_P"RU[/H/C!-2^+'
MBK05?<MA9VKA<]'YW\?\"6N2IK)B9VM%%<%\</%C^#?A[<:A$Q2<W5O&A!Y_
MU@9O_'5-9I7=A'&_M<:/]N^'-C?A,M8WRY;T5U(_F!7Q]7W5\?GAU+X+:_.C
M PR0PSQMV(+J1_.OA6NFE\(T%%%%;#"BBB@ JSINFW.K7T5I:1&:XE.%4?S]
MA[U6KW7]EOP=9:UXF$^KCRK.<^4CM_$ "6 ]N *F4N57"]C'\._ =-2C07FJ
MR+*Q&1:6^]1[99AG\J^MOV<_V>M,EMX=!>Z2:]9E0321%&A0Y+2,A//U!(Z"
MOH_P/^Q+I6L:+#K%QJEQ:7,RB6&WMD79$I&5W9Y)QUZ5Y%XGU*;X6_%BVT22
M58]5T^XC'F1=)89. 0/0@]/45QNHYZ)[$WN>Z>(_V0-'\#^%+K4_#]]=2WT$
M)E*W;!DFVC)' ^4U\?:I'8_%+3IUMAB:UGCN;>90"\>[*2*#U&X;>G]T5[!X
MP_;PU74/AS?:3I^DSG5)87@%W/&4CAR"N]B>#QSQ7@7AGP]X@^"T_A'4M3MP
MVAW5PDMQ=K\RK(#E4<] ,'.>^31&+M[[U+46E=GK7AW]EKQ;H&EKKE_H0.GK
M'YC*KJ\RKUW%.O3\:\G^.WPELOB;H<S::T*^(--B\^TF;K<19 :W9OJ04)Z'
M(Z&OT?M_C]X-L?ARVHWVI0P110;W,AXQCD ]Z_.'P+JUUXLU#Q7JZQO;Z9<2
MSBTC88PKR;E4?08_$U*YK.;TL8S;C!R['Q-)#);3/%*C1R(Q5D88*D'!!'KF
MGKVKT#X\6=K;_%;Q/]C_ -4+ULXZ;\#?_P"/[J\_7M7HTY<RN:0ES*Y,G:IT
MJ!.U3I77$W1*E:&G-'(TEK.VVWNE\IV/13_"WX''X9K/2IATKI24E9FAB7EK
M+8W4MO,A2:)BC*>Q!J*ND\1VYO\ 3X-349ECQ;7/KD#Y'/U48^JUS=>9*+BV
MF<S5G8T/#^AW'B+5H+"WP'D/+'HBCJQ^@KZ#\-_"/3M)MX4FTB*1VP3-J";W
M?WVGA1[ 5YW^SS?66G^/8I[U0\:JK$-TVAQN_I7[(? #X:^"/&/A.+6Y]+LM
M0O;P%BTT8<1+G 10>G%<=:IR;[$MVU/C3PU\/-%D6P@UB&+2K>9T1M4L8L-"
M#P-R9VE?<8Q7K?Q,^"T?P5\+QZBEZNK:'(PCDG9 KQEONEL<%3TS61^V1:Z7
M\(O%VEV.EJL-EK4$K?95.1$Z$ [1V!##CUKS_P".O[1TGC#X66OPZTI'N]1V
MV\5_<$Y6$1[689_O;@![<UG&,I-=F"39!JMY=^,-.T?3=*G6&^U"66SFN?X_
M)B (;/KM8+GV%;_@_P#9"\7:I;C4=/TZ.;3@V5ENI@CSXZE0>H]S7CTGBR/P
MS;^&;2Q:675;!9+B>0*=DD<H&2#^' ]C7Z0_!'X_>&-:\!Z<9KR*%D@5/]GA
M<?G4R4H+W5<'=;'Q=X[\#:/J%C<^%==M6@AG<6US;LH$EO(>%E4=G4D$'N,@
M\&OBSXK? O5OAFLEZLO]IZ.DYMI+I$*M!)D@+*O.,X.&!(..N>*^ROCOXZA^
M*W[44L7A9OM&G010PW%Q%RCR(Q+-GV&%S7)^*KR#5H?%'AW5A&DTEO=07:G[
MJMM,BM^#!6%;14H;#M8^%:*/X0:*Z@"BBB@ HKKK/X6ZY=:+;:DZ06BWBA[.
MWN)-LUTI)4-&F.02, G&>U>E^+_@;X7^'[6^AW^H:IK?B:.*-M7FTL1K:Z=*
MZAO*0,"TQ3*AFRHSD#IFLG5@G:XN9'@U%>L:M^S+XRTC2_MLW]EH\@,EOITF
MI0I?SQ<XD%N6W $#(!P?:O*98G@D>.1&CD0E61A@J1U!'8U49QEK%W!-/8;1
M115C/2_V?_%5WX;\?6L.FZ5;:CJ6I,MG%)<,P\A6;YV&/8?D*]3_ &HOC$(1
M-X+T6?+'_D)W$9_$0@_JWX#UKP[X=^+T\!WU[K<*A]6CMVAL PR(Y'&TRG_=
M7./<BN6N+B6ZN))YI&EFD8N\CG)9B<DD^M9\MY7 CHHHK0 K8\-*\-T;R"[B
MMKN KY"S(&61B<;2"".F>HQ6/7H'@7PEJ,LVBZ@TEK)I,E['N_>JQB<DA2P_
MA.1W]16=24(KW]F)J;7N;GK_ (;\%OK5I+K-[:(=>&PO=^63&$  \J('.TI@
M?,>O(XP*])\!Z#--J3-Y\CG&77?D,<8&0>#BO>_V=?#/A7QK'HVD:G) ;>-
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M9MU3X8MI-S)?7GB>'7UU!9%$2HFS,17[VX[.O3FO49/VT]'D_:X3XQ?\(OJ
MTY='_LS^ROM$?G[O)\O?O^[C//TIU*>+LU&3TYK;:[<OZ@XU-D^_Z6,;XE?
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M>*]4T&#P;XEDT2]CTB%)3<J@4!8@03YC.PP>@ Z5\WW\>FQ^+9$T>6>?2%U
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M)%:2"-P#D$<_+N'![5PG[:'Q@L?BQ\6M!T[PJ[74&EPRI=W4(+*2[+\HQUP
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M>!]-5-!U1X;6-&,0N@LDLBG!50#DC Q@>];U(TE:'\S_ *]2(IRB^?H?0?\
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M[@9]1CM7GOBOX#ZO\/=#34M9+1BY!D%Q+EBF[.$8<G@YZ=^E3RJ/VK+MYO\
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MZ;YHK:_XN[_$I1C'5"LRHK,QVJHR2>PKC=3O3?WCR?P]%'M5S6-:-[^YARL
M/)[M637DXS$*H^2&R..M4YO=6P4445YIS!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]E?LFQ,OPKD8CB34)2OX*HKXUK[E_9GM
M8[/X/Z$T?6:6:5S_ +1D(_D!6-7X0/FO]H378K[XU:O<0X=+.6*#(/WC&J@_
MJ#7U_P"(+I=<^'>IW-N=ZWFD221[>^Z$D5\(?$2SEL/'GB*WF+&5+^<$OU/S
MDY-?</PST]HOA1X>L[DLQ;2E5]W7#(>/R-3/1(1^?M%2WD2P7D\:G*H[*#[
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M4EO=7,133S;6\0@%Q*HW"1P#CY!QD<8%8_OI7UTTUM9_(:;249?/M\R[\'?
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M>-6^(WQ2\5^)V&!JNI3W2+_=1G)1?P7 _"N0KVJ<>6"CV1HM@HHHK084444
M%.BF>%P\;LC#NIQ3:*>VJ&:]OXFN(\"5%F'J>#5M?%,>.;=L^S?_ %JYVBNJ
M.*K1TYC559KJ=%_PE,7_ #[O_P!]#_"C_A*8O^?=_P#OH?X5SM%7]<K=_P $
M/VT^YT7_  E,7_/N_P#WT/\ "C_A*8O^?=_^^A_A7.T4?7*W?\$'MI]SHO\
MA*8O^?=_^^A_A1_PE,7_ #[O_P!]#_"N=HH^N5N_X(/;3[G1?\)3%_S[O_WT
M/\*/^$IB_P"?=_\ OH?X5SM%'URMW_!![:?<Z+_A*8O^?=_^^A_A1_PE,7_/
MN_\ WT/\*YVBCZY6[_@@]M/N=%_PE,7_ #[O_P!]#_"C_A*8O^?=_P#OH?X5
MSM%'URMW_!![:?<Z+_A*8O\ GW?_ +Z'^%!\4Q8XMWS_ +P_PKG:*/KE;O\
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MJ5/B9$IRENPHHHK S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]S94$%O@_P"$>@^'?$GB"PO/AWH>L^#O#'P];Q)K.O7FG[C=:E<6@N8_)ER
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MIE[5<2D6K95+%W_U<8WM[CT_$\50GF:XF>5SEF.35F[D\J!(1]YOG?\ H/\
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M'A5] .@J&BBLB0HHHH **** "I;.TGU"[AM;:%[BYG=8HH8U+,[,<!0!U))
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\)#JO\ 9\3B2.T^VR^4CA]X8)NP"&^;..O/6E7QYXF6SO;,>(M6%I?.\EU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 Y#CDTTDL23UHHH **** "BBB@ HHHH **** "BBB@#N/
MC9 +;XF:O&-(CT(*MO\ Z!$R,L?[B,\%/EY^]Q_>]:X>NT^,<UK<?$;57LKR
M]O[8K!MN-0W^>W[B/.[> W!R!D= *XNJENQO<****D04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2K]ZDHH 5FW,32444
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M278H45?_ +!O_P#GW;\Q_C1_8-__ ,^[?F/\:/8U/Y7]P<DNQ0HJ_P#V#?\
M_/NWYC_&C^P;_P#Y]V_,?XT>QJ?RO[@Y)=BA15_^P;__ )]V_,?XT?V#?_\
M/NWYC_&CV-3^5_<')+L4**O_ -@W_P#S[M^8_P :/[!O_P#GW;\Q_C1[&I_*
M_N#DEV*%%7_[!O\ _GW;\Q_C1_8-_P#\^[?F/\:/8U/Y7]P<DNQ0HJ__ &#?
M_P#/NWYC_&C^P;[_ )]V_,4>QJ?RO[@Y)=BA14UQ8W%K_K860>I'%0UDTXNS
M1.JW.]\,_;_^%.^-O)6U.G_;]-^T-)N\X-BXV;,<8^]G/MCO7!5V6@V]N_PO
M\62OI<]Q<I>V CU!,>7; B?<K?-U? QP?N'IWXVF]D 4445(@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [[X[&];XJ:
MR=1N[6^O-MOOGLT*1-_H\>, LQX& >>H-<#7;_&FW2T^)6K11Z.N@HJP8T]"
MA$68(SU3Y>?O<?WO6N(JI?$QO<****D04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110  %B .377Z5IB:?"I*@SL
M,LWI["N8T\ WUN&Z;Q_.NV;J:]? 4T[S>Z.S#Q6LA****]D[">WL+N\5FM[2
MXN%7[S0PNX'U(!Q4%?;G['^I0:;^SM*;GQIJ?@**Y^(^G6YU72XB[2%H1B"0
M[AMC<@ L<@<94BM&X^"?@'7M=\?>-_B!X<GL[RY\=SZ+/H.GK>3#3(0BL'C%
ME&299=VY6<",]NM>7+'*$Y0E';MU_K^MT<[K)-IH^$J*^W_AM^S'\./$&G^
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MO9 0"P&W)&2!GW%1IX'\1R003IX?U1X;B3R89%LI"LDF2-BG;RV01@<\&BS
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MH/J*]!^+&EV6FV^AFTM(+4R6^YS#$J;CQR<#F@#SRBNG\)V<%Q:SF6".4A\
MN@/;WK0UC3[6+2[ETMH48)D,L8!'Z4 <113I.&&/0?RIT0!CFR,X7C_OH4P(
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>pgen-20201231_g7.jpg
<TEXT>
begin 644 pgen-20201231_g7.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *>!QL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *L6/_'TGX_R-5ZL6/\ Q])^/\C0!K44
M44 %%%% !1110 4444 %%%% &#1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[M(+G!?#?XF:IXXO+VUU/P/KWA*6VC5_,U2-?)ER<;4=3R1P>E)XD^/7P_\
M!_BF;P[K?B>TTO6(41Y(+H.BJ'&5^<KLY'/6N^JAJ_A_2_$$/DZIIMGJ4/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %6+'_CZ3\?Y&J]6+'_CZ3\?Y&@#6HHHH **** "BBB@ HHHH **** ,
M&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJAK^N
M6?AC0[_5]1D:&PL8'N;B18V<I&@+,=J@DX /05YAX*^+7B_XE>)[&;1/!$NE
M>!=S&?6-?D,%Q<KM.TP0#) W;3N;((S]TU<8.2;Z#L]STOQ%XHTCPCIDFHZW
MJ=II-C']ZXO)EB3/IDGD^PY-9/P]^)GA[XI:7=:EX;O'O["WN6M3<- \2NP
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M&N[6]3? P8D!H9U^6125/(QT/7&:] J91<79BV"BBBI$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYZGNJF2L[7$%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *L6/_'TGX_R-5ZL6/\ Q])^/\C0!K4444 %%%% !1110 44
M44 %%%% &#1110 4444 %%%% !1110 4444 %%%% !7'?%3Q?K?@WPR)_#GA
MRY\3ZW=3K:6EI#@1I(V<23-D;8QCD_09&<CF/B]\7=0T/5K7P3X)LEUGQ_J4
M?F1Q.#]GTZ G!N;AN@4=E[G\ WI.@V^H6>AV$&JWD>H:G' B7-W%%Y2S2!0&
M<)GY03DXK3EY;2D5:VK.4^$G@OQ#X3T>\G\5^(Y_$/B#5)OM5V<XM;9MH'E6
MZ8^5  ![XS@5W5%%3*3D[L6X444$X&3P*D05P_Q4^-'A3X-Z/]N\2:DL$CJ3
M;V,.'N;@CLB9Z=MQPH[D5X9^T)^V[I?@O[3H7@5H-:UQ<QRZD?GM+4]]O:5Q
M[?*#U)P5KXCU";6O'FLW&M:_?W%[=W+;Y+FX;=(_L/0>@Z =!7K83+ZF(:NM
M#IIT939ZM\9OVM_&GQDN+C2]*:3P[X<?*_8;.3][,O3]]*,$@_W1A><'/6O)
M]/\ #,<6'NCYC?W!]T?XUK6MI%9Q[(4"+W]3]:FK[G"Y=2PZU5W_ %]YZU.A
M&"$55C4*JA5'0 8%+117K'2%%%% !1110 4444 %?2'[.OAG0H_!LWB&]TR.
M^U 7AMQ))R8UP#E1T!]Z^;Z^G_@'_P D@G_["3?^@BO(S23CA]';5''BF_9G
MJXLX[Q#+83?:%')B;B1?P[U4Z,01AAU!ZBLF.1X9%DC=HW7HRG!K9AUR&]41
MZC'A^@NHA\P^H[U\A=H^;G03UB,HJS/I[QQ^=$RW-N>1+'SCZCM57KTJTT]4
M<<HN+LS.\0?\@M_]Y?YURU=3X@_Y!;_[Z_SKEJTB;0V"BBBJ+"BBB@#$\2>#
M=+\50[;VW F PMQ'Q(OX]_H:\=\5_"W5/#N^>!?M]D.?,B'S*/\ :7_"O?:*
M[:&+J8?1.Z['71Q52CHM4?)]%>_>+/A?I?B/?/ HT^^;),D2_(Y_VE_PKQ_Q
M-X(U?PG)_IUJP@8_)<(,QM^/;\:^CH8RE7T3L^Q[M'$TZVBT?8P:***[3K"H
M+JRAO8]LT8<=CW'T-3T4FE)68M]S#MK;5O"FIPZIH5]<6EY;MOBN+60QS1GV
M(_I7U?\  O\ ;S>-H-&^)*;AD(FO6T6"/^N\:C_QY!_P'J:^;*S]2T6#4,MC
MRYO[ZCK]?6O!QF54ZRO!:_UL<E3#QEL?KEI&L6/B#3;?4-,O(-0L+A=\-S;2
M"2.1?4,.#5NORD^$OQP\8_ '6M^F7!N=)E?-QI=PQ:VG'<C^X^/XASP,Y'%?
MH?\ !7]H/PK\<-+\W2+C[+JT2;KK2+D@3P^I']],_P 0]1G!XKX?$8.IAV[K
M0\FI3E!ZGIE%%%<)B-EC$T;QMNVL"IVL5//H1R/PKQ?P1X,\9_!OQI::#I1E
M\4_#;4)',7VNX'VO0VP6V[F.9(21@#J,^OW_ &JBKC)Q37<=PHKQOXJZYXV^
M%GBO_A-;)Y_$W@5H4AU?08XU\_3T7.;JWQC<.264_GC!3UO3=0BU;3;6^M_,
M\BYB6:/S8VC?:P!&58 J<'H1D42BTD^X6ZEFBBBH$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 58L?^/I/Q_D:KU8L?^/I/Q_D: -:
MBBB@ HHHH **** "BBB@ HHHH P:*** "BBB@ HHHH **** "BBB@ KSWQI\
M8K3PWXXT'P=I>GS>(O$FI2J\]E:.%^PVF?GN)6/"@#HIQN_+/5WGB[1=/\26
M'A^YU.WAUN_BDFM;%GQ+*B?>('MS]<-CH<9OA'X9Z#X*UK7]7TVVD.J:Y<FZ
MO;RXE,LK'L@9N0@[+T&?I6D;+62&K=3I!:P+=-<B&,7+((VFVC>5!)"D]< D
MG'N:EHHK,0445SGQ ^(.A_#'PO=:_P"(;Q;/3[<8]7E<_=1%_B8]A]2< $TT
MFW9 :FO:]IWAC1[K5=6O8=/TZU0R37-PX5$4>I_IW)Q7Y^_M'?MB:I\4)+CP
MUX-,^E^&6)CEN!E+F_'0@]TC/]WJ1][KM'#_ !V_:'\1_M!:[]G ?3?#=N^Z
MUTM'^4=O-E(^\^/P7.!W)XW3=+ATV/Y?FE/WI".?P]J^IR_*G4?/4_K_ ()Z
M%'#N6K*>E>'DMMLMP!)+U"]57_$UM4F11D5]M3I0HQY8(]:,5%60M%)D49%:
ME"T4F11D4 +129%&10 M%)D49% "T4F11D4 +7T_\ _^203_ /82;_T$5\OY
M%?4'P#_Y)!/_ -A)O_017C9M_N_S1QXO^&=I1117R9XQ/8W]QITN^WD*'NO5
M3]16Q#?66JG$F+"Z/\7_ "S?_"L"DI6ZDRBI*S+OBJSFL]-;S4PI=<..5//8
MUR%:_B+Q-<Z#X?E8*MU!YD8-O-RI!/8]JR=-O]-\1KG3IO(NNK64YPW_  $]
MZTBVE[QC[!I7B)13I(WAD*2(R..JL*;6IB%%%.2-I&PHR: &U)#;O/\ ='']
MX]*MPZ>%P9#N/]WM5L #@# J7("""S2'D_.WJ:DN+>*\@>">))H7&&CD7*G\
M*DHJ+O<9Y-XR^!=O>>9=:!(+6;J;.0_(?]T]OI7C6K:+?:#>-:W]M):S+_#(
M,9]P>XKZWFNTAX^\W]T5A:]I=GXFMOL^HVZ7$/\ "".5^AZBO9PV8U*?NU-5
M^)Z5''3AI/5?B?+%%>D^*/@S?61>?1BVH0#DPD?O5']:\XFC>WD:.5&CD4X9
M6!!!]"*^CI5J=97@[GMTZL*JO!C:*3(HR*V-1LT,=Q&8Y$#H>H-8]JVJ^"=8
MMM:T&]N+*[M7\R*XMW*R1'^HQP?4$@\5M9%&17-7P\,1&TEJ9S@IK4^TOV:_
MVQ].^)AM?#GBUH=)\4MB.&X'R6]^W0 ?W)#_ '>A/W>NT?3E?CIJV@[F-Q9C
M;(.3&O'XCWKZP_9>_;-:%K3PC\0[OY<B&RUZ=N5[!+@GMV$A_P"!?WJ^!Q^6
MSP\KQ6G];'CUJ#@]#[;HI%8,H92"",@CO2UX)QA7GOQD^(>M_##2]/UZRT(:
MWX?MYS_;9A<_:;:W(QYL2=&"GELGH/0EE]"I&59%964,K#!4C((]*J+2=VKC
M10\.^(=.\6:)9:QI%Y'?Z;>1B6"XA.5=3_(]B#R""#6A7#WDO@W]G_P+<W26
MBZ%X<@N/-E6TA>14>60 L0,D#<P]@  ,  5V=G>0:A:0W5K-'<6TR+)%-$P9
M'4C(8$<$$=Z&NJV EHHHJ1!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY=KZB^ 8Q\'Y3ZZFW_H(KQLV_P!W7JCCQ3_=G:4445\E<\<****+@<Y\0?\
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M)JC>$X1=)=2ONEDMS'(VPL>6VF%OF.3AAZ5YO\)OAWXG_:^OO$/BKQ/XQO\
M3+*WN?L]O;69)1&(W;$7("HBLHZ9.[).<D@'US\:[CQI:_#G4I/A_"DWB<-&
M(%81DA=XWE1)\A(7/7W[XJS\(9_%MS\.M&D\<Q)#XI9'^V)&$ _UC;,A/E!V
M;,X[YKP?XQ^%_$OPE_9*UC2=0\4W6LW]M?Q"#4ED=)?(-PFQ"22PP,\9(&<
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M"^(/&'@C6+^6_MM+'F0^=(7\EUD,;JA/.T\''3CW- 'U_1110 4444 %%%%
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M\11[K";$P&6M9>)%^GJ/I5L@J<$8/H:SO<X90<'9A1113("BBF22K$N6.!0
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MW!AUSSVKWF;4M&\0?LE>,-1\.^$O^$/TZ[TZ^DCT[R%B9\*5\TA0,[@HYYX
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MS>P/W6/H03]T5^E%?F>)HNA4<>AX52/([!5'7M#L?$VBWVDZG;I=Z?>PM!/
M_1T88(_^O5ZBN4S/*O@#H_B?P5I>L>#-?AN+G3M NA!HVLRE<7EDPW1KUSNC
M'RG@#H!TKU6N3^*WB;6O!OP_UG7- TN+6=1T^'[0+.9RH>-2#)C R2$W$#N1
MBM3P?XLT_P =>%M+\0:5+YVGZC MQ$QZ@$<J?1@<@CL0:TE>7OE/74V****S
M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZR.&NY.6;A<_J:VZ_1\NPRH4D_Z_IGN4*:C$****]8Z HHHH **** "BBB@
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M'"@;?DQQ7T]XH_:&\$^"_%]GX<UC49+*]N;/[>LLD)\E(MKMEG['$;<?0=Z
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M/#OB+3?%FAV6L:1=QWVFWD8E@N(\X=3]>0>Q!Y!!!H T:*1F6-2S$*JC)8G
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M>:F6C8J<6#8R#CUKT/P]\;_!_B+X>2^-X]3^Q>'(6=)+J^0Q%64X(V]222,
M9)R .: .\HKP"P_;B^%M]JR61O=1M8W<(+RXLRL/..202P'/4KVKV^^\1:9I
MN@RZU=7]O#I$<'VEKUI!Y0BQG?NZ$$=,=<T 7+FYBL[>6XGD6&")#)))(<*J
M@9))[ "L7P?X]\._$"RFN_#FL6NL6T,GE226K[@C8S@^G%>&>(/VROAGXHT?
M7M#MM0O();FPN(8+JZM#'!(YB8*,YR,G ^8#K6!_P3P_Y)_XI_["B_\ HI:
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M-\3Z7X\\.Z9XETM':TOX/,@DGA,<NPGH0>0,CZ'@C(P:YWXZ>#==^(7PWO\
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M=K8:%,  -SG\*I? []G?Q#\,?C1XQ\7ZG?Z9<:;K"W*V\5I)(TR^9<+*-X9
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M"?F(+')8_>(' Q7R3\._A[XB^('[0'C]?">OGPYXATRYOKZTNB6".1=!#&Q
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M3VH \1_8@M4T?XT_$?3+7*6<$;QI'G/"7)5?R!/YT?LC_P#)TWQ-_P"N=_\
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MGC**;;8:E=7;31_:%7<CG<,ON3!1B>#M^7)!'N?PI_9S\1>!?VAO%GCR^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVVBN0^$OQ#C^*WP]TCQ3%82Z8FH+(?LLS;RA21D/S8&02N0<#@BNOH ****
M"BBB@ HHHH **** "BBO#OC?^T5>?"7XC>$?#5OHL&HQ:T4\VXEG9&C#2^7\
MH /3KS0![C1110 4444 %%%% !17AWB#]HJ\T7]H[2_AHFBP2V=TL>^_:=A(
MI>,OD+C&!C%>XT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !117C/PJ_:2MOBC\4O$W@R+P_<Z<^C"8B\DF#B413+$0R;1L)+9
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M<'FNB^/WPQ^%?Q<\77L-_P",K3PIXYTN*.*:22=(\J5#Q[XY"H?"N/F1@1D
MG@  'H_P97XIV<^M67Q)?2KU(?*:PU+2\ 39W^8I7"D;<)C*+]X\GMZ=7R/^
MQ3\1_$^J^+/%?@[5-:?Q-HVE1L]KJ3R&4 K+Y8V.>2CK\P!Z!>,9-?7% 'QA
MIO[4?Q4\1?$#Q=X-\.:+9ZYJZW\T&FL(A''9PQRNKR2$L >-@!8@9]20#GZ-
M^U=\6_!?C+5_!?B?0(/$'BEML%C:11*C)<-M*$^5P\95MW'/3Y@,XL?LC_\
M)TWQ-_ZYW_\ Z71U-XF_Y2':5_VQ_P#2$T +:_M%_%_X5_%/0M&^)UG9_P!G
M:J\>Z&&*+,<;OLWQR1G!*GJK$\#W!KWOXW:W\4+6;1M,^&VCV=S+>^:;S5+Y
ME\NT"[=HP2!D[CV;H<"O _V[/^2G?#7_ (%_Z.CKH?VOOBWXET#X@>$_!.E:
M^_A#2=3CCFO=:B)1T629HB=X(*JBJ6."#SUH QO$GQT^,OP!\8>'X_B-)I&L
MZ)JC')LXU!"*RB0HRJA#J'4_,"#D?4=W^U7^T!XA^"?B3P9'I(MY-.O3++?0
MR1!GE1'CRJL3\I*LPS[U\O?M1>'-%\,7WA^UTWXBZA\0+]DGEO'O;\7:VV?+
MV%2"0I?YB1DGY5)[9]8_X*%?\C-\/_\ KG<_^AQ4 'C[X^_'_P $V5CXQU70
M;'1/#%Y.JPV$L4<A4,"RI+\WFJ2H/)V\]@<"O:/BM\;M1TO]FV#XA^&UBMKV
M[ALYHTN$\Q8_-= ZD=R,L,^U9?[= '_"@[KCIJ%M_P"A&N&\9V,U[_P3[TWR
M4:0PV5I*P49.T7*Y/X Y^@- 'M'PS^(VL>*/V>+;QE?M"VM/IEU=,R1[8R\9
MD"_+GI\@KE_V2_C+XE^,'@WQ!J7B V]S>65X(8%MHA""OEAL'\3UKS;X7_M"
M>"/#/[)Z:/?ZNBZ[#8W=A_9<:$SO([R;,#^Z0ZG=G Y[C%1?L2ZY-X7^!OQ'
MUFW@^U3Z?)+=QP?\]&CMMX7\2,4 =+-J'[4/B6UN-7M;;0_#4.&>'29%C:8J
M.0/F#_,?]IEY["NC_9J^/NH_''P!XF76K>WAUG2$"326JE8YHY$?8VTDX;*.
M#CC@8QT'AGPOUN7XS:)K_BCX@_&S5/#/V.X8#2;'4!:[4"AA(L><$$LR@*I)
MVXR2<5K_ /!/W_D"_%+_ *][+_T&ZH U/^"<O_'EX]_ZZ6/\IZ^O=;_Y M__
M ->\G_H)KY"_X)R_\>7CW_KI8_RGKZ]UO_D"W_\ U[R?^@F@#\YOV7/%'Q*T
M^W\2Z+\--$AOM1OC;S7.H7)7R[1(_, 'SD)N8OQDG[IPIZCZ)_9F_:&\7^+_
M (A:WX"\>V\*:W8I(Z31Q+&X>-@LD3!?E/7(8>AZY%<E_P $Y?\ CR\>_P#7
M2Q_E/4'PQ '[>_BS Q_Q]_\ H"4 >J_$;4_CSKGCK4]-\$6&DZ%X=LM@AU34
M"K-=DHK,1G=P"2.$['FN9^"GQ\\=I\;+OX7?$:*RN-4"OY-Y9H$(=8O. .W"
MLC1Y(^4$<9]N&U[XA:_\7/VBO$?@_6/B'=?#KPUI4EQ! EG<_93<>4X3:7W#
M+."S_,2,#@5RWP=M=+L?VWM,M]&\17/BO3H7N$CUB\F\Z2X(TZ0-E_X@K;E!
M'&%&,CF@#TOQU^U!X^\._'SQ'X)T/2+?7\;;72K!8<,)VCC8.[9R5 ,A/('J
M0!D9VE?M%?%OX:?%W0O#OQ.LK/[#J\D2^7#'&/*21]@D1XR0=K9R#DX!]0:I
M:!_RD2O?^NDW_IO-3?MM@?\ "Z/AD<<_)_Z4K0!ZK^U5^T1?_!FQTG2O#UK#
M=^)-6+&(S*76",$#=L'WF8G"CIP>O0_.W[0GBCXT0_#:'2OB5I%LVF:A<13V
M^H6ZQAH)5#'RG\LX!()X('0X)P:ZS]MIIO"_QP^'?BJZA>;2;>*$[<95F@N3
M)(OU*NE:?[97QT\$^-/A79:)X?UR#6;^ZO(KK;:9811J&R9#_"<L!M//M0!9
M^)/_ "8%HG_7GI__ *.2K/AKQ[JGPU_83T77='%N;Z',:_:HA*F'OG5LJ>#P
M35;XD_\ )@6B?]>>G_\ HY*Q=;_Y1VZ7_P!=%_\ 3@] 'H=_\=?$]A^Q_8?$
M"!K./Q#(50L+<>2!]K,7"9P/D%<$GQ]^/'C[P&OB?PKH%M9:'IMKNO=0>*)G
MNY(US,\:.>4!!X13T(SG@0ZW_P H[=+_ .NB_P#IP>O6_P!GD!OV/]-!&1_9
M>H?^C9Z +W[.O[0$GQ0^$^J>(M=ACM[_ $-I$OS;+A9%2,2"15)XRN1C/53T
M!%>2Z/\ &;XZ?%KPYX@\;>$/[%TCPWI<LBII\L8>>98T#L%+*VY@I&3E 2<"
MJ?[%=_'I7P1^*%[-8G4X;=7F>R7.;A5MF)CXY^8#'XUX]\([J1O!VHZ9;?%Z
MT\"V6IRR+?:-<0S?<("[E<*02RX!PP.!@T ?57[)/Q6^('Q@M]6UGQ)-ILV@
MPDVL/V:(1S+<C8Q! _AV..?7\:^B)F>.&1D3S'5253.-QQP,UYE^SGX3\)>"
M?AK;Z7X0UVW\1V8F>6YU&WE5O.G; 8D*3LX"@+V"CKU/;^-M<F\+^#=>UFW@
M^U3Z?83W<<'_ #T:.-G"_B1B@#YSFU#]J'Q+:W&KVMMH?AJ'#/#I,BQM,5'(
M'S!_F/\ M,O/85U'[,'[0NI_&;P3X@EU>VMXM<T/;YDENI6.9'1S&Q7)P<QN
M#CC@8QT'@_POUN7XS:)K_BCX@_&S5/#/V.X8#2;'4!:[4"AA(L><$$LR@*I)
MVXR2<5K_ /!/W_D"_%+_ *][+_T&ZH 7X;_M.?&CXL:7=Z-X7T2QU/7XY3--
MJC1)%#:VY4!5PS!=Y8,>2>!P#R1W_P"S/^T-XO\ %WQ"UOP#X]MH4UNRCD=)
MHXEC97C8+)$P7Y3UR&'H>N17)_\ !.7_ (\O'O\ UTL?Y3U!\,0!^WOXLP,?
M\??_ * E '2_&#]HSQWJ7QB/PW^%UG;/J%N?+N+N:-9"T@4.X&_Y41!D$D$D
M@X[9\.^+'B3QWK'QI\"6/Q#TJ'3M>TVYMXA-;@".ZB:X#+(,$J>XRI[8P"#7
M8^#?%%A\'_VV/&,_BN==/M+^:\1+NXX2)9G6:)B1T4J N>V[GO5#]I+XF^'O
MB1^T'X$/AR_74[;3IK:WENH1^Z:0W(;"-_$ ".1QS0!]]U\X_M6?M >(?@EX
MD\&)I(MWTZ],LM]#)$&>5$>/*JQ/RDJS#/O7T=7Q/_P4*_Y&;X?_ /7.Y_\
M0XJ /4O@/XZ^+GB3Q!J/B#Q_IT6C>!;C3);VR&R)/)8.A4$ ^;CRS(?G'.,U
MR'A[XS?&+]H/6-;N?ALNC^'?#>FR^5'<:HFYYSR0"2C_ #$8. H"Y )[GZ4^
M(FE7.N?#[Q-IEB&^V7FEW5M!MP#YCQ,JX_$BOS]_9N\#^$?&%GK&G^)/'^I^
M"-6MKC*6D=\EG%,FT GY^K@J01UQCWH ^J/V:_C]K/Q(U;Q#X0\7V,-CXNT%
MV$QMQA)560QOD9(#*VT'!P=P(KSC7/VC/BA\4OBMJWACX46=FEAI32*UQ/&C
M&94;:TC/)\JJS<*H&??KCN?V=OA1\./!_C_6]4\)>-Y_%^M_8_)NLW<<Z(DD
MBL6+(N&8M&/XCCGBO$_V1/'.C_!WXG>.M#\97T6C74Q\G[5?-L42PRN'0MT!
M.[/H=OTH S/"_B3Q-XF_;+\+S^,-*71_$<$T=K=VZ#"ED@8!UY(PPP>"0<Y!
MP:]Y^)_QU\4^%/VG/"7@>PDM5T'4OLGVA)( TA\R5U;#9XX KQS_ (3S1_B-
M^W1H.L:%.UWIOVB.WCN"I42E(&5F7/.W.<'OBM7]J+5(O!?[7/@/Q#J6Z'2H
M8K&>2?82 B7$@D/'4J.<#GD>M 'KG[7WQJ\2_!G0_#ESX;DM8Y;ZXECF-S")
M?E55(QD\<FM_XX_'H?!OX5Z;KIMH[_7-36..TMG)6,R,FYG;'.U1V')) R,Y
M'S?^W#\8_"?Q$M_#6E>&]436)+&26XN+BV!,*AU4*H;NW!/'2NA_;JT:]N?A
MK\-M4BC=K&T1X)V4957DBB*9]/\ 5O0!O>%?&7[2LD6B^);S2=/U/0KUX7DT
MU8HEF6!R/GVJ0X^4YZDC.2.#78?'S]H#7_#'CK1OAYX"L+:_\7:EL9YKH9CM
MPQ.T8R!G +$DX5>QSQT&C_M2_#;_ (1#1[YO$=L+BXBAC&F0Y>Y21@%\LQCD
M8/&3QQG/2OF7]I;0;:U_:X@F\2ZG?:#H&JQVS+JEFVUX(_)$196P< 2*=WH"
M?44 >E7WQN^*OP%\=>']/^*3Z1K>@:RQ07VF)M,.&4.P(1<E-RDJ5Y!X-=3^
MTW\?O$?P^\5^&O!?A)+&VUG6PC'4M1&8H \OEIC/RCY@Q+-D #IS7G6K?L^?
M!R\GTY-4^,E[JQFE1+>#^U[>Y=R[  (%5B,G SC%>K_M$>!?A?\ $W4K#P_X
ML\1V_ASQ/;6GVFQN7N%A?R69EP3)\LB[HV^7.X8)&,G(!L?"6W^,^E^++BS^
M(-UHFL:$]HTD6H:6 K1SAD"QXVH2"I<_<(^4<CH?6-2N&M-/NIT +Q1,Z[NF
M0":^,/V8?&'B+P?\?;SX;0^*?^$S\*1Q2JETDGFPQ[(PZO&23L&?D*@E<D]<
M U]E:W_R!;__ *]Y/_030!\7?#?]ICXT_%W3[K0_"^DV%[KL<AGGU9HDCAM8
M,*%7#';N+!NN21T'!([G]G?]H[Q?K?Q1O_AS\1+:"/7$$@@FCC6-Q+&-SQL%
M^5@4#,&']WOD8\H_8;^+OA;X<WWBC3?$FIQZ0=3%O);W-QQ"3'Y@96;^$_."
M,\'!YS@'2^'NKP?%O]NRX\2:#NFT>W>2=KA%(!BBM!;A_H[[>O9Z .F^)G[4
MWC[PM\;_ !/X,T.PM]6^Y9Z3:I;YD6X=(B'8YRV,N<=,D9X%>C:#\5_&WPI^
M".N^)OBY:*=?M;YHK*TC:%3<(R1^4FZ'<H^<R9/4!3D<5Y+H(S_P42O,C_EI
M-_Z;S7J'[=NAWNL? SSK1))(]/U."[N @SB+;)'D^P:13^M 'GVD_$S]I#QS
MX2E\;Z+::3:Z$1)-!8K!'YDL2YR45\LPX('S G' .17L'[./[1$'QF\#ZGJ&
MJ0PZ9JNBX&HK$3Y6PJ669<\@'8_RY.-A]17._!/]H[P!H7P#T%]1\0V5G>Z/
MIRVUQIKR@73/&NW"1GYGW8!!&1\W)'->0_L=>"-7UCX7_%R^M8)(H]7TY],L
M=O DF\F;(7_=,D8!_P!H^E '0Z3\>_C-\>O$6LO\,K&PTK0-/<(LEXD99@2=
MN]I,C>P&=JC"],]SZU!\:O$?P_\ @3?>*_B1HJ6'B*QG>T6QA^1;N3<%C((+
M !N22"1A21Z5XG^P_P#%[PKX#\+^)- \2ZM:Z#>_;A=HU^_E"12BHR@GC<I3
MIU^;V..O_:N\56'QC_9QN-<\)3RZCI>F:W&;B98RH945T9@",E0TJ'..V>E
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MYOCV:P\/QM<'3]-:ZFBD<%@TDN %/KM7I7:? /[3I,7CERC6]U;Z?N"R)RK
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MG^!I9V.HUSP1?:3F2(&ZM^OR_>'X5SO\Z]6TGQ EQ:I+!-'?6CC*NK9X^O\
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MH **** "BBB@ HHH+!023@#J: "BJ]CJ5IJD1EL[J&[C!VEX) X!],@]:L4
M%%%5=/U:QU59&LKRWO%C;:YMY5<*?0X/!H M4444 %%%% !154:M8MJ!L!>6
MYOE7<;;S5\T#&<[<YQ5J@ HHHH **** "BJ5GKFFZA<R6]KJ%K<W$>=\4,RN
MZX.#D Y'-$^N:;:WR64VH6L-Y)C9;R3*LC9Z84G)S0!=HHHH **** "BBB@
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M_P#^N=S_ .AQ5]KU\1?M^W'VS6_AQ/L,?FP3OL;JN6A.#7V[0 4444 %%%%
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M+FOMJO'/CU^SA9_';4O#]W<ZW/I!TGS!MB@$OFAV0]V&"-GOUH \%\>?#?\
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M?'?B37-)%GHNI+=K:7(N89/-WW22+\JN6&5!/S 5]0444 >??M"?\D.\=?\
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MQRM>EA<9]7;YE=,Z*%7V;=S\SMU*"6( &37OOQ4_9)USPJ)M0\,N^OZ6N6,
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M8FVC&X[=^<9XZ5V_AW_D5=,_W#_,TW5=!TS5MK3*UN^<GRFVAJOKY4-K#!
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M2KLC!@"<$,I[FNCKPGPS\==%\'?LQZ3X[FT&WTFS,;Q6VB:8 D?F>>Z*B''
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M(Z M]>U;O[.G[24WQDU+6?#^MZ*-!\3:2N^:"-F*.H?8_##*,K$ J2>O7K@
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M7()&T?AD5]?PS)<1)+&P>-U#*R]"#R#0 ZBBB@ HHHH **** "BBB@ HHHH
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MNZJTI<%A[@)C_@5?75>'CL5-2]E!V[G%6J-/E0V.-(8DBB18XD&U410%4>@
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M76>K^&-!_LS49-5BMFF^V7$N8VCE8KB21AU5><9XKHOBI_R8/H7_ &#],_\
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MQ5Z/^UO\0O">M?LV7AT_5;&]&K/:C3%@=69BLR.Q"]5PBN#QQG!QFO2_BI\
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M7%A ]KJGEEDA;[0S-,/7:K1MCZ>M=IXV_9?\<^-O#:)XG^,\6HZ&CK=JUW:
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M]JTZYDLK@_>:/E7]G7HP^M>C>&_BK:WC);:VBZ;=,=JW*DFWD/N?X#['CWH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K-7PSI":RVKKI5BNK,,&_%L@G(QC'F8W=..O2M*B@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *L6/\ Q])^/\C5>K%C_P ?2?C_ "- &M1110 4444
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M* /5Z*** "BBB@ HHHH **** "BBOE/]M3XK>+/AUKW@F#PWK=QI,5T)WG6
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MSU.WGCN>:\]^-7B#X<?%J]T=?A;X0U2P\775SF>&WMA''(I4\"-'8;]V#N4
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MO+A#HD:GR),*4R3OQ_%G[O:O2/#OAV]\4?L0P:580/<7UQX>?R8$&6D8$L%
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M'DN9MZGS8RA97!=MZ,''!]#FNX^/T;?\-N?#L[6P7TPCCTN7S6E_P464G1?
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MB@ J.2VBFDCD>)'DC^XS*"5^A[5)10 5#]CMS<"X,$9G'278-W3'7KTJ:B@
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MV.#^5:]CJ%[HERS6\K6\@/SH>5;ZCH:S=!TZT\/:E=W4$+#[3"8GB)R@ZD$
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M)Y)I**0@HJ*ZNX+&W:>YE2"%>KR' KA->^)#R;H=(3REZ&ZE7YC_ +J]OJ:
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M?C6K1',1+#^Z>M2VM\T<@R2&'K7JGQ,_9[\3?#GS;R%/[?T)>?MUHA\R(?\
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MH **Y#QY\7/"'PRN-.A\3ZW#I,NH%A;+(CMOVXR3M4[0-PY; YKKZ "BBB@
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MM/U'8CW'%9K6H!W1_*?[IZ5]#0S"%2T:VC[]#./N[%^Q<1H-S59N-0#1!16
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M(5F9@.N%('0G.<;'P6_:2T/XQ:E?Z,+"\\/^([$%YM*U ?/M! 8J>,[6(!!
M(]*^0_V:?^%EZEXX\93^![G1+?7'.^__ +8R7*F5B=GRDXW_ 'O^ U[?\-?@
M#\3K?]H:T^(_B^[T(';(+P:<[9ES;F%0$V 9^Z22>Q/M0!R.@?\ *1*]_P"N
MDW_IO-&@?\I$KW_KI-_Z;S1H'_*1*]_ZZ3?^F\T:!_RD2O?^NDW_ *;S0!]D
M>(=7'A_0-3U1H)+I;&VEN3!#]^38A;:ON<8'UK\^?"_[3U]I/[06L>,+BTUR
M\TF[$JIH?VEBT8*@*"I^7Y<9Z=Z_16OBSX:R+'^WUXH5V"LYNU4'N?*4X'X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M58L?^/I/Q_D:KU8L?^/I/Q_D: -:BBB@ HHHH **** "BBB@ HHHH P:***
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MH]RMI^FVVEVXAM85ACZG;U)]2>YJS114EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JQ8_\?2?C_(U
M7JQ8_P#'TGX_R- &M1110 4444 %%%% !1110 4444 8-%%% !1110 4444
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M=']UI%]9\D_N=0E/X?.6Z4_:89]&A?N_,_*4Z'>C_EGG_@8_QI/[%O?^>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5BQ_X^D_'^1JO5BQ_X^D_'^1H UJ*** "BBB@
M HHHH **** "BBB@#!HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?V2O"]A+HUQ<:==-@Q/=0_:[N4G'+"6,,,^ZG'I4QA1DW92?H)*+[GTS\/\
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MH.T6^8<XQAMN?*/[$_PE\*>*O%_C+4=5TK[5>>&]4M9=*D^T2I]G823,#A7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *L6/_'TGX_R-5ZL6/\ Q])^/\C0!K4444 %%%% !1110 4444 %%%%
M&#15O^S9?[R?F?\ "C^S9?[R?F?\* *E%6_[-E_O)^9_PH_LV7^\GYG_  H
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M\*/[-E_O)^9_PH J45;_ +-E_O)^9_PH_LV7^\GYG_"@"I15O^S9?[R?F?\
M"C^S9?[R?F?\* *E%6_[-E_O)^9_PH_LV7^\GYG_  H J45;_LV7^\GYG_"C
M^S9?[R?F?\* *E%6_P"S9?[R?F?\*/[-E_O)^9_PH J45;_LV7^\GYG_  H_
MLV7^\GYG_"@"I15O^S9?[R?F?\*/[-E_O)^9_P * *E%6_[-E_O)^9_PH_LV
M7^\GYG_"@"I15O\ LV7^\GYG_"C^S9?[R?F?\* *E%6_[-E_O)^9_P */[-E
M_O)^9_PH J45;_LV7^\GYG_"C^S9?[R?F?\ "@"I15O^S9?[R?F?\*/[-E_O
M)^9_PH J45;_ +-E_O)^9_PH_LV7^\GYG_"@"I15O^S9?[R?F?\ "C^S9?[R
M?F?\* *E%6_[-E_O)^9_PH_LV7^\GYG_  H J45;_LV7^\GYG_"C^S9?[R?F
M?\* *E%6_P"S9?[R?F?\*/[-E_O)^9_PH J45;_LV7^\GYG_  H_LV7^\GYG
M_"@"I15O^S9?[R?F?\*/[-E_O)^9_P * *E%6_[-E_O)^9_PH_LV7^\GYG_"
M@"I15O\ LV7^\GYG_"C^S9?[R?F?\* *E%6_[-E_O)^9_P */[-E_O)^9_PH
M J45;_LV7^\GYG_"C^S9?[R?F?\ "@"I15O^S9?[R?F?\*/[-E_O)^9_PH J
M45;_ +-E_O)^9_PH_LV7^\GYG_"@"I15O^S9?[R?F?\ "C^S9?[R?F?\* *E
M%6_[-E_O)^9_PH_LV7^\GYG_  H J45;_LV7^\GYG_"C^S9?[R?F?\* *E%6
M_P"S9?[R?F?\*/[-E_O)^9_PH J45;_LV7^\GYG_  H_LV7^\GYG_"@"I15O
M^S9?[R?F?\*/[-E_O)^9_P * *E%6_[-E_O)^9_PH_LV7^\GYG_"@"I15O\
MLV7^\GYG_"C^S9?[R?F?\* *E%6_[-E_O)^9_P */[-E_O)^9_PH J45;_LV
M7^\GYG_"C^S9?[R?F?\ "@"I15O^S9?[R?F?\*/[-E_O)^9_PH J45;_ +-E
M_O)^9_PH_LV7^\GYG_"@"I15O^S9?[R?F?\ "C^S9?[R?F?\* *E%6_[-E_O
M)^9_PH_LV7^\GYG_  H J45;_LV7^\GYG_"C^S9?[R?F?\* *E%6_P"S9?[R
M?F?\*/[-E_O)^9_PH J45;_LV7^\GYG_  H_LV7^\GYG_"@"I15O^S9?[R?F
M?\*/[-E_O)^9_P * *E%6_[-E_O)^9_PH_LV7^\GYG_"@"I15O\ LV7^\GYG
M_"C^S9?[R?F?\* *E%6_[-E_O)^9_P */[-E_O)^9_PH J45;_LV7^\GYG_"
MC^S9?[R?F?\ "@"I15O^S9?[R?F?\*/[-E_O)^9_PH J45;_ +-E_O)^9_PH
M_LV7^\GYG_"@"I15O^S9?[R?F?\ "C^S9?[R?F?\* *E%6_[-E_O)^9_PH_L
MV7^\GYG_  H J45;_LV7^\GYG_"C^S9?[R?F?\* *E%6_P"S9?[R?F?\*/[-
ME_O)^9_PH J45;_LV7^\GYG_  H_LV7^\GYG_"@"I15O^S9?[R?F?\*/[-E_
MO)^9_P * *E%6_[-E_O)^9_PH_LV7^\GYG_"@"I15O\ LV7^\GYG_"C^S9?[
MR?F?\* *E%6_[-E_O)^9_P */[-E_O)^9_PH J45;_LV7^\GYG_"C^S9?[R?
MF?\ "@"I15O^S9?[R?F?\*/[-E_O)^9_PH J45;_ +-E_O)^9_PH_LV7^\GY
MG_"@"I15O^S9?[R?F?\ "C^S9?[R?F?\* *E%6_[-E_O)^9_PH_LV7^\GYG_
M  H J45;_LV7^\GYG_"C^S9?[R?F?\* *E%6_P"S9?[R?F?\*/[-E_O)^9_P
MH J45;_LV7^\GYG_  H_LV7^\GYG_"@"I15O^S9?[R?F?\*/[-E_O)^9_P *
M *E%6_[-E_O)^9_PH_LV7^\GYG_"@"I15O\ LV7^\GYG_"C^S9?[R?F?\* *
ME%6_[-E_O)^9_P */[-E_O)^9_PH J45;_LV7^\GYG_"C^S9?[R?F?\ "@"I
M15O^S9?[R?F?\*/[-E_O)^9_PH J45;_ +-E_O)^9_PH_LV7^\GYG_"@"I15
MO^S9?[R?F?\ "C^S9?[R?F?\* *E%6_[-E_O)^9_PH_LV7^\GYG_  H J45;
M_LV7^\GYG_"C^S9?[R?F?\* *E%6_P"S9?[R?F?\*/[-E_O)^9_PH J45;_L
MV7^\GYG_  H_LV7^\GYG_"@"I15O^S9?[R?F?\*/[-E_O)^9_P * *E%6_[-
ME_O)^9_PH_LV7^\GYG_"@"I15O\ LV7^\GYG_"C^S9?[R?F?\* *E%6_[-E_
MO)^9_P */[-E_O)^9_PH J45;_LV7^\GYG_"C^S9?[R?F?\ "@"I15O^S9?[
MR?F?\*/[-E_O)^9_PH J45;_ +-E_O)^9_PH_LV7^\GYG_"@"I5BQ_X^D_'^
M1I_]FR_WD_,_X5+;6,D,RNQ4@>A/I0!>HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>pgen-20201231_g8.jpg
<TEXT>
begin 644 pgen-20201231_g8.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" -?!Y$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOCGX(_%+XN>!/V"_'6K:WHNF_P#")Z5IEA'X5;4+.&X@O(I;UH[D2Q[CO&'
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M%Z_I%O)@27%O+#="(GOMRA*CU'/H#TK(_P""QG_(C_#;_L(W?_HJ.O _B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F#0/VX;+7OVM9?@:OA&
MXANH[NYM?[:-\I0F&VDG+>5LSR(]OWN,YKM?VL?VEK;]E?X=:=XLNM!E\11W
MFJQZ6+6&Y%N5+PS2[]Q5L@>21C'\7M7PO\/?^4P-U_V%]4_]-<]>X_\ !7C_
M )-L\-?]C;;?^D=[7K2P]-5Z4+:-*YT<BYHKN>F_$+]L)_"?[).D_&NP\,+<
M_P!H"V9-'N+S;L$LNSF4)SCK]VM#X?\ [54_C#]D.]^-EQX;C@EM;&_O3HL5
MZ=K_ &:61-OG%.-WEYSL.,]#7S!\8_\ E$KX-_ZY:?\ ^E)KD;'5_B3IO_!,
M?PE#X&TZ.]T*ZCUR/Q/*Z1L8++[3-\P+,"#][[H)XZ52P].4-M>>WR'R)KYG
MVY^R#^U!_P -6?#_ %;Q/_PC7_"+_8-4;3?LOV_[9OVQ12;]WE1X_P!;C&#]
MWKS7NM?D7^P#X^^+W@?X>^.;WPUIUNWPXT^TU?4[S498HW,6I1:;OA4Y8.1E
M(,@*0<GGK77?"7]M']I[]HO3DT#P!I&G76N6%W]HU;7%M($B@M9"B1)MD8*,
M%9F.,NP^Z!L.9K8)^TER-**\]A2I:NVQ^HU%?*O[;'[9Z_LJ^'-)TC2[:WU[
MQWJT!D@2Z)6&WB7Y3<RHN"0S@A4!&2K<_+@_.NA_M6_M?>!=,B\>^,?A\^L^
M!%47-U;R::EJ\=N1DN"G[R, $'?(K 8R>*YJ>$J5(<^B3VN]_0A4W)7/TTKS
M/X[?M%>!OV<_#*:SXSU7[-YQ*VFGVRB2[O&&,B*/(SC(RQ(49&2,C/S+_P $
M]OVO/B!^TEXW\8:=XPGL);+3;&.YM5M+1865FE*G)!YXKYMG\/W?[>'_  4"
MUO1]=O9U\*Z/=7,9AC<YCTZTD\L)'_=,KD$GL96/85K3PG+4E&L](J[L4J?O
M-2Z'JNM?\%DK*'4F72?A7/=Z>K'$M[KBP2N.<?(L#A3T_B;T]Z^B?V;_ /@H
M!\-_VB=4AT&$W/A;Q7+Q#I.JE<7) R1#*IVN0/X3M8X.%(&:]J\+_!WP-X*\
M/QZ'HGA+1].TJ.+R?LT5E&0ZXQ\Y()<G)R6))R<DYKRB+]@SX06?QHT_XCV7
MAU=/O;+]\FCVI$>G?:@P9+D0@?*RX^Z"$S@[<C)4IX62:4'%]'>XKTVMK'T/
M7QM^T-_P4H\.? /XO7W@5O"=UXA?3UA^V7UO?+$L3NH<H$*'<55E/4<DCC%?
M5/Q \:Z?\./ ^O>*=5;9IVCV4U]/@X++&A;:/<XP!W)%?B1X9^#/BC]ICP;\
M;/C%<RR/=Z*W]J/&J_+=32RF6X4>BQ0AVQ[H.E5@Z%.I>=7X5I\V.E!2NY;'
M[FZ7J=KK6F6FHV,RW-E=PI<03(<K)&ZAE8>Q!!KY\_; _;(L_P!DK_A$OM?A
M:?Q+_P )!]KV^3>K;^3Y'DYSE&W;O/'IC;[URO\ P3)^,?\ PLW]F^ST2[F\
MS5_",W]E2ACEC;XW6S?0(3&/^N)KPK_@LQ_S2#_N,?\ MC4T<.OK7L:BTU_(
M48?O.5G=>$_^"O'PYU;5+>VU[PGK^@VTI57O(VBNDA)ZLR@JQ4>J@GT6ON;1
MM8L?$6DV6J:9=PW^G7L*7%M=6[AXYHW4,KJ1U!!!!]Z_'[]J3X[? #XA? 7P
M[H7@KPE';>/;46BR:K;Z1'9>6$CQ,'D7#2ACG ((S\W&.?T4_83T/6?#O[)?
MPYL=?BF@U%;*67R[@$.L,EQ+) "#T_=/'@=A@5IBL/"G352,7%WM9_F54@DK
MI6/>:^-/VDO^"D&G?LZ_%K5/ UQX%NM<EL8H)3>Q:DL*OYD2R8VF-L8W8Z]J
M^RZ^</VY_ /AB\_9Q^)7B"?PYI,^O1Z42FJ26,372E2H4B4KN&!P.>E<>']F
MZB5173,X6YK21X5X1_X*XZ3XK\5Z+HB?#2]MFU*]ALQ,VKHPC,DBINQY/.-V
M<5^@E?GM_P $G? /ACQ+\$_$6IZOX<TG5=2M?$SB"\OK&*::(+;6S*$=E)7#
M$D8/!.:_0FM<9&E"IR4XVL.HHIVB@HHHKA,@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)N85)_C)"-MZD1GTK[X_9U_9;\#?LR^'9=/\*V4DNH70'V[6;XA[NZ(Z L
MJ#LB@ =>3DGR+]J3_@G7X7_:!\4MXPT/6Y?!/B^9E>[NHK?[1;W950%9H]Z%
M).%^=6YQRI/-13J48NI2NU&77T%&45>/1F%_P5>\4^&[']G>WT+4)[>3Q%?:
MI;S:9:D@S+LW>9,!U"A"R%O5P.]>.>/-,U+2?^"0OA:'5 ZSR7,-Q$LG402:
MA))#^!C9"/8BNR^%O_!)NSM/%4&M?$[QM)XN@A<.=+LXGC6XQT$LSN7*^JJ
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MMFYAN/,_L[['Y.Q67&/-DW9W=<CI5TZD(X:=-O5M%1DN1H^B****X3$****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#\IK74+7X?_ /!7>6ZUFXCL+:35YE\ZY;8F;K366+D^K3(!]17LO_!7
M[Q)IL/P1\(^'WO(AK%QXBCOX[/>/,,$=M<(\FWKM#2H,^IKTG]K_ /8'\/\
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MIKOV*YXN:F?GEXJ^'NG?L9_M*_#SQ/JN@P^(/A_JMM;:M!;ZA"MPGE21*+A
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M$%VD!V1VNJV)FM)E>.]2&4*2$=?F5U[9&>H-6J,^91DFK_J/E=[-'T+17/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M['KE%>&>)OVW_@=X/U>PTO5OB#8VU]>Q0SQQK;7$H1)55D,K)&1"2K*<2%2
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M!^#W@"SNKG7_ !M:Z<MMJ5QI,D+6UP\WVF!@LRK$L9=E4D NJE.>&KN_AO\
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M)- XM;HUJ*P?''CC1?AOX5U#Q)XBNVL-%T]!)=72P23>4A8+N*QJS8!(R<8
MR3@ FMJWN([J".:&1989%#I(ARK*1D$'N"*BSM<1)17SW^T)XPT+XC?!OQ7<
MZ)\6-4^'-EX6U=;;5_$NBV-Q(T,L3*LEN-H5I!ND0$Q,0",$D!EKN/&'QY\
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M7B+P]J?Q'\#F.]L[RZ,EYHVIMY+1#>X57(:-E82JNY6&1G.:P?B!\1O^$_\
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MQB*-47[J@ ?A3J\DYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQ^RK\)/"_P[_9X\):3I6C6<,6J:/;W>IL8P[7TTT*M(TS$9?.\C!X"X4
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M^./C5X[;3+>7Q/>>.]7L%U&1=\L5O'*"(T)'R L[%MOWOESG: -#PR;WP_\
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MZL26_!ZW\9:;X?\ CEIGPQB\.6VLV/Q!NDTVU\0K,NFPQM%:R2KM@^<9WR,
MO&YO2O>?A3\-=,^#_P /]'\'Z-/=W.F:6CQPRWSJ\S!I&<[BJJ#RYZ*.,4>
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M9R.99I7)9F/Y#)P!FM:M:,E)KKY?K<J4D[V.[KY0^#W_ "(_[4__ &-NN_\
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M]"N71,]WHKYGC_:W\6^![[3Y?C!\'-3^&?AJ^G2U3Q%%K5MJUI;2.0$^U&$
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MO-%=PHRN\6Y"T1"G#K\PS7-?M3>._B)HO[4WP=30?A?_ ,)'%IMQJ,FC2?\
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M]JPZCF(*NV7S8@%^;)^7J,>]:_C[QYH7PP\&ZKXI\2WZ:9HFF0F>YN7!.T9
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MJ&NF^,WQTTKX*Z/I FTW4/$?B/6I3:Z-X<T>+S;S4)57<VU?X41?F=SPH]R
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MAE(Z$X Z,X[_ )K\>WS%RL]-T'Q%I7BK2X]2T34[/6-.D9T2\L+A)X69&*.
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M!I=EK%]JUOIMI!JE\D<=W?10*L]PL>1&LC@;F"[FP"3C<<=:OUBZGOJ:Z6_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %> ?MZ_\ )H_Q%_Z](?\
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M:Z;X:^!_A=K_ ,>/"VF^'OCE\4/BQK.AR-K067Q%'J^CV6Q2@:XE\K8"X=D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-9VOB?5)9M<O@6L]"TN!KJ_N0.I2)><>YQ7C7_#S;P/_ -$X^*!'K_PC+?\
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M!_"+P1X:N$"7.CZ)96$JJ<C?% B-SWY4UV-6MB HHHI@%%%% !1110 4444
M%%%% 'SI_P % ?&&H>#_ -EGQ8^F7$MG>:D8-*6ZA8J\*SRJC,#Z[21^->J_
M"/P#H'PA^%F@>'=#M8-.TC3+&,?NU"!B$!>1O5F.22?6O#O^"E7_ ":WJ/\
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M!FM_[=;C9F>(;R OSCYB>@'K7PM\:[7Q+XT\(^")O L7C75-?M]-N5UG4K^
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M^ ?7Y.3BH;/\/NW\C[6U;Q!8Z-INHWMQ.IBT^!KBX6,[G1%4L3M'/05#X?\
M%>F^)="TW5[2?;9ZC&)+?SOW;.#T&T]_:OA#PKI.JZ=X_P#%]KI5AXEUZ]NM
M.UDW>J7D5Q:WMHS(QC2Y4GRIQNP(R@SR*K^-M#NUTS2$\8Z/XQO&;P;:P^$%
MTL3YM]6 ;S/-VGY9=_E'<W&T&M_[ IW4/:ZNSVUMY1O\]6O=N[$?VA/5\O\
M5^]OZ9^A,EW!"P5YHT8G:%9@"3Z?6IJ^"OB-\+/$_BB#XAZKK5EX@N/$^C^%
M]'FTZ2RFE2,ZBJGS6B53AW! W?CZU]N>#)KNX\'Z')?^9]N>QA:?S1A_,,8W
M9'KG->)C<!#"4X3A4YF]_+1/35W6OEJCNH8AUIRBXVM_FU^ALT445XQVGRE_
MP40^'VFR? _4/B=8QKIOC?P*\6L:9K%LH2X&R15>$N.2C*QR#7T?X!\1/XO\
M"^'==DC$4FIZ=;WK1CHIDB5R/UKQG_@H)_R9G\5_^P0?_1J5Z=\#_P#DB_@+
M_L V'_I.E 'S]^WA8MXR\3? KP%>2L/#GB+Q<G]JVO\ #=Q01^:L3#NI8#/T
MKZAU6]L_!GA6\O$MO+L-*LWF%O;H!B.)"VU0/9< 5\T_MA?\ER_9H_[&N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP?XD274973^R;L[2!_SQ>CD8>T1@_P#!,[_DRKX=?]<;C_TIDKZAKX6_8/\
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MD'8?)'P)_P"3\_C[_P!>&F?^@M7UO7R1\"?^3\_C[_UX:9_Z"U?6] !1110
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M'QB_Z%KP/_X 7G_R71_9N([+[P]A,_7>BOR(_P"'O'QB_P"A:\#_ /@!>?\
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MX'_\ +S_ .2Z/[-Q'9?>'L)GZ[T5^1'_  ]X^,7_ $+7@?\ \ +S_P"2Z/\
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M "71_9N([+[P]A,_7>BOR(_X>\?&+_H6O __ ( 7G_R71_P]X^,7_0M>!_\
MP O/_DNC^S<1V7WA["9^N]%?D1_P]X^,7_0M>!__   O/_DNC_A[Q\8O^A:\
M#_\ @!>?_)=']FXCLOO#V$S]=Z*_(C_A[Q\8O^A:\#_^ %Y_\ET?\/>/C%_T
M+7@?_P  +S_Y+H_LW$=E]X>PF?KO17Y$?\/>/C%_T+7@?_P O/\ Y+H_X>\?
M&+_H6O __@!>?_)=']FXCLOO#V$S]=Z*_(C_ (>\?&+_ *%KP/\ ^ %Y_P#)
M='_#WCXQ?]"UX'_\ +S_ .2Z/[-Q'9?>'L)GZ[T5^1'_  ]X^,7_ $+7@?\
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M<1V7WA["9^N]%?D1_P />/C%_P!"UX'_ / "\_\ DNC_ (>\?&+_ *%KP/\
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M 7G_ ,ET?\/>/C%_T+7@?_P O/\ Y+H_LW$=E]X>PF?KO17Y$?\ #WCXQ?\
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MG_R71_9N([+[P]A,_7>BOR(_X>\?&+_H6O __@!>?_)='_#WCXQ?]"UX'_\
M "\_^2Z/[-Q'9?>'L)GZ[T5^1'_#WCXQ?]"UX'_\ +S_ .2Z/^'O'QB_Z%KP
M/_X 7G_R71_9N([+[P]A,_7>BOR(_P"'O'QB_P"A:\#_ /@!>?\ R71_P]X^
M,7_0M>!__ "\_P#DNC^S<1V7WA["9^N]%?D1_P />/C%_P!"UX'_ / "\_\
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M!Z52L?%?Q#T=H+34;30?%[WERUI9ZG;W(L@\Z_?C*'.57G##&0*X6QDU/6/
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M6=D_DU=?@S2$XU%S0=T%%%%8%A7A7BC_ )&74_\ KN?Y"O=:\*\4?\C+J?\
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MGF5?O2N2<10KU:1B  #6+_P33D$/[$OP^D;[JP7+'\+B6O"_ 'B;P!\1M/\
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M@BG_ /"M= _Y]&/_  ,U\;?LD_'3Q!\!]1T#X0_%;4EO=#O((X_"WB^4X1I
MHWZ?<-T5U.0C$\@ 5U7_  5*\0_$3PU^SQ#>^!+RZTZP6_0:]>6+[9H[0C V
MGJ 7*@XH<F@Y5V.J^,7BB[TWXC6/PY^&NGZ0WB233Y=5UG6M6)GM]"LU'RR-
M$,[I')^53U )KX#^.7_!0OQYX-\56FB^$?%'A77['38UGN-<L=+\D:HV2&AD
MC;[F-I!"^HK<_9B\1>(?!OPSGT+XC3ZKX1L_%DUUJ]MJ3!TUW7UMX\I:([ L
M%W!3\P QD#K5?X#_ +1%A^T!XB;2/L&A^%=9\.7#:YI]EJNEQ7$.I["JO#)+
MA?*=@1U!&:GF;6C'RKL?HO\ !W4-$^+GP8\(^.ETR&TFURTBN)8;:;?'&[<.
MJGTR#]*]&_X5KH'_ #ZM_P!]FOS7^/'[6#?L:_$C4_#WPI_LV_M]=ABUC5?"
MUX&>U\/7[ -*(3P,2 ABJ\ G/?%???[+OQP7]HOX'^&_'@T]M*EU*)A-:DDA
M)48H^T]UR"0?2GS.]KBY5V/"OA7X;T^X_P""@WQQL9(<V[>'-*.W/KBOI^;X
M?Z)96\\\5J1(L3XRY/52/ZU\Z?"/_E(M\;_^Q<TG^5?5VI?\@^Z_ZY-_(T78
M<J['R1_P3S\(Z9K'[.TBW4&\)XBU0KAB#_Q\,/Y5]0:?X)T_1;AKC3E:UN&7
M87^_\OI@U\\?\$W_ /DWFX_[&+5/_2EZ^IZ+L=EN?GE_P4$_8#\;?M!?$O1?
M%?@:73)//MELM1M[M_L_EN#\MSQ]\X)]Z^A_A_\ L9^&M#M]%O?%^JZIX_\
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M^S[7R_[OD+C^57:]2TWP[X?U+]F_Q!KHT98O$6E:S:6@U3[1(S2QRY+*8\[
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M/+?8WF&-@N&['..>U?!UQ8ZQH<VB:@G@\V>M:3<L-9O8662UO0,*Z2J?XR&
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M]*%KZ:T7_D#V'_7"/_T$5\R_\%*O^36]1_["^G?^E"U]-:+_ ,@>P_ZX1_\
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MX8?Q5=7>N?#?Q->6ZF"VFN 3+ CL/DF5SQ@@D$D5ZQ_P3._Y,J^'7_7&X_\
M2F2O=/B=\*?"GQC\+3^'O&&BVVMZ7+R(YU^:-L8#QN/F1AV92#0!^5OB:_\
M$7P.\,Z!\ _B3\04N?%6N:@U]K7B*>V;4SH6D.I!ABF=2Y:<XY! 2NQL=/\
M&W[.OQ>U*PG\=Z;X!^#NC6RZGHNA>'WB:\U1GCV6B"/8996DDY8,Q_E6Q\3_
M -E%OAW^U3H/AT_$OQ1I7A+XA:'<:%#JU[LOIK=D8.M@)Y@=BLHRIZY&*X3X
M>_!S2-7_ &E_&WPDU7P;XOU"?3]/86_Q&U.\=]9M/(4-$\+-^Z17QM3;SR*
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M!_\ R1?P%_V ;'_TG2O,?^"@G_)F?Q7_ .P0?_1J5Z=\#_\ DB_@+_L V/\
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M!/;:7H&I++&H5U \O<07D< E@HXVC.>M?!.!C&./2D"*,84#\*IX97TEII^
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M)QO&GB!\[M;U Y# _P"DOT+[R.O]X;OK22>,M?E#A]:OV#[]P-PW.]@S]^Y
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M ,)MXAX_XGFH'!!&;E^H38._]SY?I35'%*/(FK6MO_\ :A[+"VM[27_@*_\
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MM-<3.L<<:#+.Q.  /4DU^FOPL_X(KZEKVBZ5J?C#QXND/<P)/-I]C9>9)&6
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M\M #J\*\4?\ (RZG_P!=S_(5[K7A7BC_ )&74_\ KN?Y"M(;F-38S*TO"_\
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M"J&NZ]IWAC1[S5M7OK?3-,LXFFN;R[D$<42 9+,QX KY._X3#]LS_H1_ /\
MX,9/\*XOX0:3X_\ VY/&5[<?%W^S(OAOX)U.2S.@Z(SFSUO4XS\QD<G,L4/'
M^R2V!D;JENVPTKGJ?_#8'B;XI74\/P.^%NI^.]-C?RO^$JUB<:3I)8$[C$9!
MOF Z$ *>>G3,[^+OVLK)6N9/ 'PXU&(#<+&SUFYCG/?;O<;,]L],U]*6=G!I
M]K#:VL$=M;0H(XH84")&H& JJ.  .,"O,K_]H"R6\UC^Q/"/BCQ;I.C7$EKJ
M.LZ):P26T$L?^M1%DF26X9#D,+>.7# K]X$5-N[*]$<-X/\ VS--B\5V?A'X
MJ^$M4^#_ (JO"$M(];=9].O&SC;!>I^[8YXYVCD $DXKKOVO=0MM+_9?^*,]
MW,MO%_PC]Y'O<X&YHF51]22!^-=+K_AOP/\ M&?#&.VU*UL_%?@_7+9+B%F!
MVNC#*2(>&1QG@C#*?0U\4Z;\$O%6M?'?2_V>/B7\0+_4?ACH]L/$'AZQ:$"7
M7[6.4;;2YN,Y;R".4P<JI/"X =VMQ6OL?6/[(>FW>C_LP_#&SOK=[6[AT&U$
MD,@PRG8#S^!KO_B!&\W@/Q)&BEG;3;E54=R8FP*V[>WCM;>."%%BAC4(B*,!
M5 P /;%/90ZE6 92,$'H:LD^7?\ @F7*C_L6^ $5LO"MU%(O0HXN9,J1V(KZ
MCKXSU+X3?&']DWQ=XAUGX+:79_$'X?ZY=R:E<^";^Z^S7-E=R'+FUE(VB-CS
MM/3I[U'_ ,-4?M1]?^&4)_\ PI[?_P")H ^E?C1\&_#WQU\!W?A?Q%%((9&6
M:VO+=MEQ97"',<\+]5=3S[\CH:^3_BM\*?CI+X9M?!/BW1[CXN>%K6<30>)?
M"NLC1M<9$&(UN48A)#U)*DY.#6W_ ,-4_M1?]&H7'_A3V_\ \31_PU5^U%_T
M:A<?^%1;_P#Q- &1\/?"WQSC\/0^#O!?P[7P;I*RF\B\6?$S6%UF]M)B1EH8
M$W<@ [<X&37TK\ _V?\ 1_@/H%_#;7UUX@\1ZO<&]UOQ'J1W7>I7!ZNY[ =E
M' %>!?\ #57[4/\ T:?<?^%1;_\ Q-'_  U5^U!W_90N?_"HM_\ XF@#[/HK
MXQ_X:J_:?_Z-0NO_  I[?_XFC_AJK]I[_HU"Z_\ "GM__B: /LZLWQ)XDTKP
M?H5]K6N:A;Z5I-C$9KF\NY!'%$@ZEF/2OD3_ (:J_:=_Z-0N_P#PIK?_ .)K
M ^$Q\4_\%!/%C:[\3/#\?AGX9^#;U[1?"$-X;F+5=50_.\\J@++'$,#:/E);
M&2-^9;ML-(]+3]K;QG\5I7_X4C\)]0\7Z*'*+XK\0W(TG39,=6A60>9,O;@*
M0>W%3R>,OVL-)4W5Q\.OAYKT2\_8-+UN>WN'[X#S#8/3GN1VKZ5M;6&RMHK>
MWB2"WA01QQ1*%1% P% '  '&!65XT\8Z1\/?">K>)=>O$L-&TNV>ZNKA_P"%
M%&3@=R>@ Y)( Y-+E?5COV1X[\-?VO-#\3>+[?P3XW\/ZK\+/'MQ_P >^B^(
ME BO?^O6Y7]W,,\#H2> #7OE>=_%#X3^$/VCOANND>)M-^TZ??0K=6DY 2YL
MI&3*31.,[)%SV)!Y!R"0?D3PQ\>OVE?#?B?5O@'H_A+2?%OC3PW"%C\<:Q?&
M&.2R8C[/=2P$;I?E*AF5C\PPWS9)$VG9AHU='HWP<9;K_@HA\<YH#YT,>@Z5
M!)(G*I(!DH3Z^U?6.H*6L+E5!+&)@ ._!KQ[]F/]G<? C0-:N]6U:3Q)XX\3
MW?\ :?B'6Y!C[3<'/RH/X47<0H]*]IJR3Y5_X)NS1O\ L_W\*NIF@\2ZK'-'
MGYHW^TL=K#L>1^=?55?(7C+X+_%3]G?XD^(?'GP-M;#Q/X<\13?;M<\ ZC-]
MGS=8P9K23HC/U8'T_++_ .&J?VH_^C4+C'_8SV__ ,30!]-^-O@SX/\ B'J4
M&HZYHT-UJ$,?E+=J2DOEYSL+#DKGG!KGO^&7_AU_T!&_\")/\:\&_P"&J?VH
MO^C4+C_PJ+?_ .)I?^&JOVH?^C3[C_PJ+?\ ^)H ]X_X9?\ AU_T!&_\")/\
M:/\ AE_X=?\ 0$;_ ,")/\:\'_X:J_:A_P"C3[C_ ,*BW_\ B:7_ (:J_:?_
M .C4+K_PI[?_ .)H ]W_ .&7OAUWT1C_ -O$G^-+_P ,O_#K_H"-_P"!$G^-
M>#_\-5?M/?\ 1J%U_P"%/;__ !-+_P -5?M._P#1J%W_ .%/;_\ Q- 'M&N?
ML^?"CPOH]YJVKV4.F:99Q--<7EU>M'%"@&2S,6P!7S;_ ,)!X?\ BE=3P_ [
MX(ZKX[TV-_*_X2K6+]M)TDL"=QB,GSS =" %//3IFW\*9O%O_!03Q8VK?$GP
M_'X5^&'@V]:U;PE!>?:8]7U5#\QGE7"R11#;\H^4EL9;+8^YK.S@T^UAM;6"
M.VMH4$<4,*!$C4# 55'  '&!4:RVV*T6Y\)S_ GXU6\4DUQ\(_ASJML0<Z=:
M^(;R.9U/\!>3Y#QP<\5ZU\-_VM- \-ZQI/@#XB>"-0^".MNJV^FV>J%)-+N,
M<".WO(P(VP>.0HY !).*]7\>?&"+P9XPT;PK8^%]<\7>(-4L[C4$LM$-FAAM
MX7B1Y)'NKB%0"TR  $D\\<4_6_">C_'KX=W>B^// ]U9:;>EDET?76MI)TQ]
MV57MII51N<JRON'M2L^C'IU1YK_P4(N(X?V-/BD)'5#+I@BC!/+.94 4>I->
MJ_!>WDM?@]X&AFC:*6/0[%'C88*D0("#7P]:_!/Q?KGQ\T#]GCXC^.;C4/AC
MH,7_  DWAZ*2+_2M<@BD CM9Y\_,8"6RN.57/W=H'Z)JH10J@*H&  .!5IW1
M+5CY,_;8OH]#^*_[-^L7@:/3(/&)@FN<?)$TL)2/<>P+<9-?6=<1\:/@[X;^
M/'P]U+P=XIMWGTR]"L)(6V2P2*0R2QM_"RL 0:^<8OA_^V%\-88O#_A7QGX'
M\;>'[.,16>J>*+>:'4"@Z"7R\JQ P-W?%,1]BUYS\3O"^W_B<VJ<CY;E%'4=
MG_"O O+_ &XO^>GPF_.Z_P#B:;);_MOS(4D/PE>-AAE;[401Z'Y::=G<F2YE
M8[W/I2UX/J>G_MA:3?/:S6_PF#*-PVK, 0?3(S5;/[7O_/#X3_E+_A73<YN4
M^@HY9+>:.>)MLT3!T;W%>\:%JL>M:3;7D9R)$!(]&[C\Z^!<_M>_\\/A/^4O
M^%='X2O/VSV66RL&^$\(7]YL8SC.>N HK.>J-(:,^N/BYX"7XI?##Q1X1:Z%
MB-:T^:Q^U&,2>5YB%=^T\$C.:_([]E/]C/P=>?MB:WX=T[XG6VH77@*_MKVU
M46ZG^T]C S*N3CY&^4XSUK[;\O\ ;B_O_";\[K_XFL>P\$?MA:5?_;K'1?@G
M9WO/^DV]I.DG/7Y@F>>]8FY]MCC@<"EKX[\O]N+_ )Z?";\[K_XFCR_VXO\
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MC[P_'K^-14CU)DNIDT445B2%%%% !1110 4444 %%%% !1110 4444 %%%%
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MS1G:\<BE64^A!Y!K].-QXQP%X ' 'TKYN_;&\'63:+I7BB&&.+4%N/L=Q(H
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M&4WB?X*^!;_Q?X!\?:!'*+.\TJ74(HH)"1+:R.H()5PPSU(Q5+_A*?'R\?\
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M<DUVE !7A7BC_D9=3_Z[G^0KW6O"O%'_ ",NI_\ 7<_R%:0W,:FQF5I>%_\
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M110 4444 %?,_P ;/A7XR^''Q.;XU?".Q35M7F@6W\5^#VD\M=>MHQA)8CC
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M<RJ ?8"I]Y%:,[[XK?M+?#7X+6LK^*?%FGVM\O":3;RB>_F;. J6Z9<DGC.
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M$'KTKQ\.DZBN<\/B/FVBDR-V.A].]+7N'4;?@O4(--\36<]P_EP_,A<]%R"
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MM/\ VC/B+)XH@U26?0I?"7_"<_\ "(&P6!ENV60?)*7W8#(>JXYKW?4/V?\
MP%J?B+3=<GT"%K_3TACBVNRQL(1B+>@.URG8L#BM%?@]X.6#R1H5KY?]K#7=
MN#_Q_#I/_O5S2S#+%%*-#I;9?/6^KZWT>MNB-8X?%<UY5.O]?\,>8_L@ZUXG
MUG2?'W_"1Z^NO?9/%-_:6S%</$B2$%>OW<]!V%?0-<QX0^&OAWP'J6NWVA:>
MNGSZY=F^O_+=MLLY&"^TG )[XZUT]>#CJ\,3B)5::LG;2R73LM#T*$)4Z:A)
MW:"BBJUKJ5I>7%Q!;W,4TUNVR:.-P6C;&<,.QK@-RS1110 4444 %%%% !11
M10 4444 %%%% 'X>_P#!2#_D]#XB?]P[_P!-UK7S37TM_P %(/\ D]#XB?\
M<._]-UK7S37W&'_@P]%^1ZL/A04445T%A1110 4444 *JM(RHBEG8A54=23T
M%?>'PF^">@_#_P .68GTVVOM<EB5[N\N8A(V\C)1-V=JC...N*^&M%!;6M.
MZFZB_P#0Q7Z82?>->=C)-))&-1]!JX5 B@*B]%48 _"BBBO+,!<\$=CP1ZUQ
MGCSX1^&OB'I,]G>Z9;07;J1!?V\2QRPOV;( R,]0>M=E2K]X?6G&3B[H+VV/
MS/UC2[C0]6O=-NEVW-G,\$@_VE)!_E52NQ^,D1A^+'BY3U_M*4_F<UQU?1Q=
MTF=BV"BBBF,**** "BBB@ HHHH **** "BNHT'X<ZOKT*S*BVT+#*M-G+#U
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M3PTL[II33Q*ED65AL;>QRLA.X@J"<J*]A^,%WX(T?X=Z/+I4LXO+F>(:K<Q
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M,?N[E93&??=NQCWKI? >AW'A<WD\Y74/$^I (T%NVY;>,'(3=]>6;IP,5O\
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M.<'':OU/_P"%G?'SP'\26;QCX+TS6/AS#9KYVH>&6:6Z$S.%W^6Q!PN<LH'
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M+73[5(YY8-/33(C#&ECN!AC=.A=1P6ZFO2*\T]0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\/\ &G_(VZG_ +X_E7N%>'^-/^1MU/\
MWQ_*M*>YC4V1CTE+25N8'KWPS_Y%.W_WW_G75URGPS_Y%.W_ -]_YUU=<TMS
MKCL@HHHJ2BGK 9M)O0H)8P/@#J3M-?EM_P $R?V9;_X>^*/'7QJ^(>BWF@6N
MBQ7*Z;'J=NT,@7#/-<!6 . @*Y[[CBOU5KYO_P""BFJ7FC?L<_$6ZL9V@F6U
MB4L/XD,T8=#[,I(/L: .!\$Z/^TM\?\ 0+?QM:?%32_ 7AO7&DN=-T:#1%EN
M;:U+$1;Y&ZL5 8_45\N?L_\ [0WQ.^*EQ^T9X7\=>+[GQ)8Z'X;OH88Y$"1[
MXY&C\P*.A(6N<\-?M>_MD_$7P7IUUX0\/6=AX>\H6UA)96$5N9E10N(1+(#)
MT_@!'85QG[!@U*[\2?M :=KCQV/BG5/#5U";74I4M99;MY&+)B0K\Q)/% 'P
M]17M(_8U^,!&1X1'_@SL_P#X]3O^&,OC%_T* _\ !G9__'J /%**]SA_8@^-
ML]C%?)X'E^Q2S?9XKDZA:".23^ZK&7#'Z4V\_8C^->GWT]G=^!YK2[A.)(+B
M_M(W7/()4RYP>QZ&@#]8/^"17_)HEA_V$[K_ -#K[7KY(_X)A> -?^&_[,-G
MH_B.P&GZBNHW+F$3QRC:7X.Y&8?K7UO0 4444 %%%% !1110 4444 %%%% '
MX>_\%(/^3T/B)_W#O_3=:U\TU]+?\%(/^3T/B)_W#O\ TW6M?--?<8?^##T7
MY'JP^%!111706%%%% !77_"KX<W?Q1\96NC6[&&WQYUW<@?ZF$'YC]3T'N:Y
M"O7/V=/%$^C>(KVS:>WL]'9!J&I7#@"5XX,E85;/ =V0$#DUG4;46UN*6VA]
M)_%ZTA\$_ 77;'14^Q6UI8+:PJO54+*K<^I!.3ZDUXM^QCI"3^+O$&HD#=:V
M2PI[%WY_1:]-^/WC"&^^%OBC36*6EWR@5V!\WRY8=X7W_>#\C7G'[%U\L?B+
MQ/9':&ELXI1SR=KD' _X%7G036'F_P"NABK\C/JZBBHVN85N%@,T8G9=RQ%Q
MO('4@=2/>O/,22OFS]M+25;3/"VJ #S$FFM6/?:5##]0?SKZ3KYR_;2OU3P_
MX7LLKODNIIL=\*@'Y?-73A_XJ+A\1U?[+<[:S\%8+6^"W5M'<W%H(Y!D&(X^
M0^WS'\Z^;OCI\)W^%/B[R+?=)HE\&FL)6ZA<_-&3ZJ?S!!KV[]F/Q=;:'\+T
MM9&2XG:^FE$*, T:&2&/+?C(#^%<+^U#XJNKZ[MK".6WN-'NIGNT0X:6SNHB
MT$\8;LI(5L'U%==/FC7E;9FD;\S/!HV"MD]*T;?4(8L;MWY5F45ZT*CAL="D
MT=39Z]:>8B9DW,0!\OK751SQVL)DFD6*-1RS' KRZ.0Q2(XZJ01^%37NH7&H
M2;YY2_HO8?05Z]#,G2B^97?0Z85W%:G4ZOXZ"[H]/3)Z>=(./P'^-<G<W4UY
M*9)Y6ED/\3'-145YV(Q57$N]1_+H8SJ2J?$PK[M_X)^2>,O$G@W7-%GBC;P5
M#-BTNYLF6.=N9(XAT*]"2?NL>.IKX09MJD^@K]9/A+>VWP0_9G\*/IMO%-J,
M]E MLC#Y7N9E\QI&]0,D^^ *\O$4HUH<DHWN_P 3BKU'".G4]NT7X3V\=LN;
M<R$K@M,2Q;\36;XK^$-O-!+L1[68@_O(N#^(Z'\:\CTWX=^(/'ROJFK:K?ZA
M=O\ ,9'G8!?95!PH]@*[#X:^-=;\%^++3PGX@O9M3T74'\BVENW+R6DQ'R@.
M>2C'C!Z$C%<M3#^ZXJ2E;=6_(\M2=[ESX*Z&WA_6O$C:C9[=0L5VV\VX%9H2
MFXNHZKD@J0>?EKL?AWX97Q)(^HWI\ZZNCYCNW/7M]!TKC?C%XZ3X026WB4V$
MFH0),+6YMH6"NT3YR1G@D$ X/O7!1_MC>$_!*QKH$-_XD,J"5+:&/R6M\_\
M+.5GX##_ &<\8-?/UY4<->$6EI<W^HXJK%8E4VX-VO;2]D[>1UW[7GP)GU[P
MU8ZMH47FZSHSM*MNO!N(6 WH/]H8##UP1WKY[\ ?':?PK:M;&1[>9!L>-\JR
MGT(/(KU4_MK:/XRO8;'Q!HVH>%K*9PCW\C+<QQJ>I8(,CZX->CZGX9\*_%35
MH;V32M)U/2+2/;;WCP1N)U YD+XY7' R<<$UYJPL<;+VE&=GU/L,KSZ66T/J
M&-H<]/=:V:ONMFFKZ^39\H7DNL_';Q(-/TN&6:%G'VN\5<QV\>?F);IG&<+U
M)KZ-OKP^']%M+"TM)[)(D2VC:9!MC10 #N&1G %;<'QB^&WA'&EZ9#/=6\+;
M6;1[$?9U/<@Y4-]1FNQTG4/#7Q(T>>ZT*\CO8X_EG@="DL1/9T/(_D:[XY/&
ME"];FN^MM/N.'-L^GF<XQA!0IPVCOONV]-?EH><V'@"YU&U:X(>1NI9CDUR'
MB31WT]G5OO+SG^E>S:-XH/@D76CW*AK>12UL[<E0/O)GVX(]OI7EOCC5X[Z:
M5T_BR!^->3B*'L)<CW/'A)RU/!/C]9Q7WP=\4K-MQ';"9&;LZNI!_P ^M?!Z
M_=%?7_[5_CJ#1/!(\.12@ZCJ[*7C!Y2W4Y+'TW$ #Z&OD!>E?8Y)"4<,W+9O
M0Z:>Q>M[A(QSG\JU;;5[>/&=W_?-8/\ #3U[5]93K2I['3&3CL=YI-W'>Q^9
M%G;G'(Q4FH^(+73\IN\Z;_GFAZ?4UQ<>H3PVIMXWV1DDG;P3^-1+VKU_[1E&
MFHP6O<Z?;M*R-/4-:NM2.'?9%VC3@?CZU3I@[4^O/<Y5'S3=V87<G=CZT=>N
M#H7AZ'35^6\U$+<7/JL(_P!6GX_>/X4NA6D,UT]Q=_\ 'A9H;BX]U'1?JQP/
MQKFM6U.;6=2N+VX_ULSEB!T4=@/8# _"N.O/[",YOH5:]+_9GU"VTSX_>!;B
M[*K -21-S= S*54_F17FE/@N);6XBG@D:&>)Q)'(IP58'((]P17&827,FC]6
M_&?_ !4'Q?-K=N&M[&UAB@C/1 R[F/U)/Z"O1_$7A70;?18;6VVWFIRIG[/"
M/N#'5ST4?K[5\K_"OXW:;\=['29?[0@TCXCV426MW93\+J" X$L1[L,DE>W/
M;!KZCU#Q3H7PGT6UDODFU#4;K/V>SA(,TY'WG8G[JYZL?H*Y:RE[B@W==$>*
MXN+:D9'AGP[K'@OP_<6LX6XT\7RWZ1QEO]'&"LF/4$')Z=":Y&WNHM(^+^N/
M?* +F<743'H\;*-I'Y$?A786O[1US&R/J7@C9I[<.UK=[Y57UVLH!^F15GQ5
MX'T+QMX?M==TB8WFD;6EMYH7\JYM/[Z G@@$'*-T[4HSE3D_;QMS=2=]CJO'
M'C+0[CPND<21K(J8)'>N2^#]S_9?P]UF^F_=VEYJ$D\.<\HJ*I8#T)4].N*X
MJ\\(Z3H.D?VMK^H:S=Z5&%_<O$L0E9CPF0<L3_='/6KFF?&JV74(&NO"=Y)H
M5J%%M;V\J)M Z$IC! [+GZTE0Y:;C3]Y7_I!?74Q/&DAN/&7AF2ZQ]BDL6EA
M] [2LS_CRM>ZV,/A[_A#B6V>?M]JXKQ)X7T7XI>'1J_AZ>2XL/.9PD:A;K3[
MC^(;#U![I^(S7F]Q;7VD_P"A7_C30].A"Y+7DQAE"YQGRVP?UQ1)1Q$(KFY7
M'=!U.W^$<RVWQ&\2M;'%D=/ FQTW>8-GX_>_6OAO_@H%XFMM>^.$%E;.';2M
M.2&8CM([%]OU *_G7NGQ!_:T\"_!7PO>:/X,OD\7>)[@[I+F,[H?,Q@/(XXV
MKV1<_7J:^ -:UJ^\1ZQ>ZKJ=R]YJ%[,T]Q/(>7=CDFMHQO4=3Y'?AZ;3YF4J
M[72?CM\2?"^APZ7HWCWQ)I6FVL92WL[/4I8XHEY.%4' &3VKBJ*U<5+='?ZG
MV[^VK\=?&NCZ)\"W\-_$#6+.2Z\%03:BVF:JX,MP=FYI=C<OR<[N>M?'/BGQ
MAKWCG5!J7B/6K_7M1\L1?:]1N&FEV#.%W,2<#)X]ZQE14SM4+DY.!UIU8TJ,
M:2LB(Q446M+U:XT'5+/4[5MEU93)<Q-Z,C!A^HK];/%7Q ^*^O?#GPY-X,TN
M&_\ $.HZ7!/<:A>7$TL4<LD(.(H4;]XP#\DC;GM7Y$$9&#TK](/V&OVI(O$7
M@=/ .HV[S^(]"L)I[498C4+>+Y@A^8*& (7D-P >,5YV94VXQJ15[&->.BDN
MA\ >/?!>N?#WQ9?Z'XCM)+/5X6WRI(,%MWS!Q['-<_7WQ\3?V/\ X@?'C4]8
M\?\ C+5M-\-ZI);^79Z3;IF&WCBC9XX,_>(5>7<XQO'TKXM\.?"_QAXOLC=Z
M)X9U/5;8*6\RU@+@@=2O=OPS790Q,*D+N2NM_4TA44EN<S7I7[-OB.P\(_&_
MPGK.J6$.HV-G=@O%=)NA#,"J,_I\Q&">^*;\(?V>_&OQPNKZ#PM8P2/9G9(;
MR<0 R=HP3_%['%?</_!/7P?_ &%X)\9:%KVDQ6.LV^HO:ZA9:A&F[(PN9%93
M\H.W:_*J3R,-N&6+Q$*=.2W>V_<52:46CV;]J"'1-=_9E\7W=[*1IG]DO<P2
M%TD.\#,8##Y)#N8+D;)!GD'%?C>N=HSUQ7U-^V-^T+XHU;6M8^%<+:?I_AC2
M[E8YX=/MO)DN)$)8)*=Q&%8D[1QGU %?+51E]&5*E>7VM2:,7&.O4%ZU<ANH
MX^N?RJG17KQDX['2G8VX=8MX^N__ +YJ_#XDLH\9,G_?%<K179#&U8;6-55D
MCT71=>M=2N##"7WA=WS+@8J_J.K6NE1[[F4)Z(.6;Z"O--/U*?2Y7EMV"2,N
MS<1G ]J@FFDN)&DE=I)&ZLQR37IQS>4:5N6\OP.A8EJ-K:G0:OXTNK[=':@V
ML/3<#\Y_'M^%<ZS%F))))ZD]:**\2M7J5Y<U1W.24Y3=Y,OZ3;6K74,VJ?;(
MM*\P)+/:PAV[$J,D#.,G&:^K_@;^SKX@U[4-?M6DM;KX57RM);ZA&2QNHY@!
M&T'.591MWANC1@')%> >$=#\0:G'H'AR[TN:?P[K6HQBWWAHXQ-(0GFK(O\
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MAZU(O:HUJ1>U:HL>E:^AB*S\_5;E0]O8@.$/_+24_<3\^3["LF-2S!5!9CP
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MQ@@E5SD^N[@<5@7WP=U[X:WRVUAK,EYX>\YWN-'U",2#:V3OC;'R8&U%08
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M'A)/!3"["&3RODZ=<58M99?A[\%81JI,,TCS7LMD9%1E:0YC3)XSG;QGJ:\
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M-Y_QYS_]<V_E4U0WG_'G/_US;^5 'Q;_ ,$]?AMX1\6?!OQ'=:UX5T75KO\
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M^@W4SMXIOV9!J/\ 9,:[Y+>U)!/[TC:V.U?-/@CPEX'^(WP=T'Q_\5OB%?\
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MK/2O@;\-8O@[\'_"'@N)ED.C:=%;32)]V2;&97'LTA=OQKNJ**TVT("BBB@
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MC<>Q7\27*QM#IL+;H;3.]AT>4_>/X=/PK&HR222<D\DT5Q;ZF04444 %%%%
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M:>\ _!FW\7_"GXCWLG@CQ1%XCU"Y6/7(F@AN(996*LKL-H&/4C/45YY\8O\
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MKC./?ZU-]T>F/T]S[T@'3CWY_F: /)/%?P_G\/[[FT4W>G]3QF2(>_J*Y=9
M5&S&#]W'IZU]"=L#Y@?7O[GVKA/%GPWCOFDO=("Q7+<O;]$E^GI6T9]S"5/J
MCS?S/;.>![T>9Z<]OK231O;S20S(T,T9VO&XPP]OI[UL>&?"-[XHFW1G[-8@
MXDN67_QU!W/O6GJ9)-[&=I^GSZQ>K:V=O]HN#UQT7ZGL*]4\*> [/P]MN;I4
MN]0ZF3'RQ^RC^M;>BZ'9>';,6UC"(U_CD/+,?4GN:O=.G!'K_#[_ %K&4KZ(
MZ(P2U9+YG;&#U/M1YGM_];ZU$#T ^O/\S1]!G///?W-9FA*LFYNF,]*DJ"/E
M\YX/Z_\ UJGH **** "F20I-M\Q%?:P9=PS@CH1[T^B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _#W_@I!_R>A\1/^X=_Z;K6OFFOI;_@I!_R>A\1
M/^X=_P"FZUKYIK[C#_P8>B_(]6'PH****Z"PHHHH **** "BBB@#Z_\ V/=8
M?5OA_J^CW&6@LKPJF?[DJ9*_F#^=?*_B7P_+H_B[4]$ _>P7SVBC'^WM7^E?
M6_[)/A-]#^&LFK2EM^LW)F5>PCCRBG\3NKSOQK\-9KS]JZQM5 ^RZE/'JV[:
M,"-1F08^J$?C7GTYJ-:9BG:3/1_V@IG\"_ "/2+3Y/,6VTPLO&$ RWY[<?C7
MQ=7WA^T?X5D\7?"?6!"6$^GXU%%7HWEYW _\!)_*O@[KS5X1IP?>Y5/86BBB
MNTT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+3EZ4U:<
MO2M%L4B7^&GKVIG\-/7M6JV*)X87N)DBC&YW(4"DURZ22X2VA.;>U'EJ?[S?
MQ-^)_E5F*3^SK&6[Z329B@]O[S?@./QK$K.I*^A,F%%%%9$A1110 4444 %%
M%% $MG,MO>VTSKO2*9)&7U"L"1^E>H:/\7]*T_XD:SKO]A+;P:A?7]S'JUJ"
M-6LA<"0*\1,GE;X]X8?*#D<.."/*J*F45+<5KGT-X+_:,TCPG]K@N+OQ'K;-
M+93+KFI1B2^F6!7!MF"7*$0Y<$!Y)1Q\RMP!P'C[XH6'C#P3I>C6^G2V-Q:S
MQ3/@*( %^U95 #D#_2%Q[*?:O.**S5**=T+E2"BBBMB@HHHH **** "F3(9(
M70<%E(_2GT4 >QW7[037?B[5+N32X&\.SV]PL>EQV<$)N)GM/(5[IT ,O!8$
ML20KMCDFNVLOVH-$L2A_M'QA=^;KC:MLO(X)(]-A:VDA-K; 2AMO[S 96BP%
M4J%(Y^9J*P=&#Z$<J/=;S]IJ\CT75-,TN\UZPMGTNWL=-7[6,VDBZ@]S++N4
MC#O'(R%U 8[B#\IJ_K7[0WA_6OM%O8MXE\'1O.;A=0T(0BY*_;+F<P$>8H\M
MA<*3AL;XQE6'3Y[HH]C#L'*CU+7OB+X<\8>//B;J6I+JUCI'BQF>!X;>&XN8
M3]KBG7S$,B(<B,@[6ZG@5;U/XWVEGH:Z)H=C=SZ3#]CLS!K#*XU&RAAN$=+@
M*>&9I\J%)\L(NULJ"?(J*KV<=A\J/?&_:2T;2->U"YT?PFEU8:[J#7&M0ZPS
M-,]KY'V9+:-HY%5@(FF.9%(+NIVC:#7A-\MJM[<+8M,UB)&%N;D 2F/)V[P"
M1NQC.#C-0T548*&PTD@HHHJQA1110 4444 %%%% !1110 4444 %=?\ "WQE
M:^!O$\M_=K=QI/8W%DM]INW[98-(FT7$&X@>8O3JO#-AE.".0HI-<RLP/H;P
M;^T=H_A>.XM[F;Q!K3"ZM[I=6U*-9+N\6*#R_(EV7*8B!SM$C3C#-N5N*A\*
M_M%:+H^D65C/::M9)';+!.-.6/\ >*(8T*(WF*T8RF0P/&!E77*'Y_HK'V,"
M.5"*-J@'TI:**W+"BBB@ HHHH D6GK3%IZUJBAZ_>J1?NU&OWJLV=NUW,D2\
M%CRWH.Y_*MD464D_LW3)+G.)[C,,/J%_C;^GXFL.KFK7JWEX3'Q;QCRXE]%'
M?\>OXU3KFD^9W(84445(@HHHH **** "OJ7]BS7I7M/$NC.2T$#Q7D?H"V58
M?C@5\M5]9?L;>$WL_#>M>(Y"V+^86D2]ML?+'Z[FQ^%<N)M[)W(G\)\]?%[0
M?^$7^)GB;3E&$CO))(^,?*_SC]&KZH\5>=\-?V7?L]OE+F/2XK<L!C:TQ&\_
M^/FO-OVA/AS<:Q\>?#R08\OQ%Y*;L#Y6C(63/K\H!KWWXO>$#XR^&6NZ-;EE
MD^S>9!M'5HOF4?0[<?C7-4J*2IW,Y/X3\]1P *6D4Y I:],W"BBB@ HHHH ^
MQ?V)/VH=&\/6:_"?XF7 /@R]N1+HVK7'S#1;IC]TD_=A<GGLI)[$D?5'Q%\*
MZ7X4\4_V?J^@PZM?S+OM[A48-.IZ/N3A@/4_G7Y(D!@01D&OL?\ 9=_;?_X1
MOP_#\.OBA>WDWAA4\G2/$\*>=>:&>BA@<^; ./EY*@=QC'FXBC-*4J/7?_-?
MK_F9<D>:[5T?8_C'Q,G@WX=VMS=B.P@:!5M])TY"SO(QPL*[1DL3@G ]?3->
M-V%_XJALVN/%WPR37O+O/)2]TV=(Q)& 65BI(W8XC)(!)!.*]#MO#>M>%]/T
M_P 5->Q>/M2UE52P\2Z9*SZ5'"A.QXX\D1LX(WIDY8-\V.*Z&'Q]XG\'7%K)
MXPTVQU'0Y''FM!:B*6WR?]8N.&QG)!_.L/8SJ4[4VGIIZ]TMTUKU,(UZ5.'+
M:]W\[=O1Z?=L<DWCZW\3:;9>186MCIBS-:2VMPJ[H-O_ "R,9  S@G&,]ZZZ
M);#PB0_AB"S::XMU+?9+/8XR>A.?_K<5E_M-: GA'1[GQ786,=_#$L;3P1Y/
MVF(L#O &,.HQA^2!D=*BT'Q1!X%T/3$TG2VU+7-9B%U;K>S;TBA;D%V')QG
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M^-/_ &,%A_2OBZOTT_X)K_!ZS_:$_90^,7P]U"?[+#J=Y"T-R!DPS*F4?'<
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M\%R;;/RAY2XM21A>Q!YSZ\U4_8)GENOV./A1)-(TD@T=1O<YX#L!^E;?C?\
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M* /P]_X*0?\ )Z'Q$_[AW_INM:^::^EO^"D'_)Z'Q$_[AW_INM:^::^XP_\
M!AZ+\CU8?"@HHHKH+"BBB@ HHHH **** .C\/?$CQ5X3MOLVC^(-0T^VSD0P
MS'8#[*>!5F;XL>,+CQ%;:_)K]T^LVT)MH;PA=Z1G.5Z8YR>U<G14\L=["LCJ
M=<^*GC'Q+:/:ZGXEU&[MI/OPM,0C>Q QD>U<M11322V&%%%%, HHHH ****
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M(@E5UV_,I!(*CIFM;QAXLUR*]^*JZ9XCA\)75QXGTN+[5*6MEN8WM(VDMUN
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MO8\^HKHO%?PZ\3^!H8)=?T.ZTR":1HHYI KQM(OWH]Z%EWCNI.[VJ[K'P?\
M'&@:?)?:AX6U"UMHVC25Y$7]PTG^K$P!)AW=!Y@7GCK3YH]PNCD**]=^('[,
M7C3PCXQNM$TK1[_Q##;6EI=27EO''B,30"4[]KL$"G>NYB =A/2N+M?A5XRO
MO#G]OV_AG49M'\AKH72Q?>A4X:94SO:,'JX4J.>>#4JI!JZ8<R.6HKMM*^"/
MC_7-+T_4['PCJ=QI^HHLEC<[%5+M26 \DL1YA)5AM3)XZ<BLGPS\/?$WC)KX
M:+HEW?BQ*K=N (TMV)*JKNY558D$!2<G!XXJN:/<+HY^BNLL_A+XUU!M8%OX
M6U1_[&F:WU+= 4%E(J,[+,6QL(5&//I[BK>C_ [XA>(+&UN]-\':M?0W4(N(
M!#"#))"3@2B/._RS_?*[?>ESQ[A='$45[+X=_9SNM2\*^ _$5]-J@TWQ.^HJ
MR:/917EQ +>,/$R1><ID#C<6Z; I)SP#P>C?"OQAXBT)=:TSPW?WVENLLD5Q
M"@/G)'GS&C3.Z0+@Y* @8/H:2J1?4.9'+45V&@?!WQQXIT2TUC2/"NI7^DWC
M.EK>Q1@17#*Q5DC)(WN&4C8N6XZ5R<=K/-=):QP2R73R"%8%0F1I"=H0+C);
M/&.N>*OF3V8R.BNOU7X0^,]!N=/AU3P]=Z<;Z]73H9)]GEBY) \IV5B$<9R5
M8@\'C@U?^.GPP3X,_$;4_"?VFYO'TXF.6ZNHXHQ*P)!= COA#CC<0WJ!4\\6
MTDQ71P-%=Q;_  ,^(5W9_:H/!VJS0BW^UL(X@9(X"AD$KQYWHFP;MS #&/49
M3P3\&_%GC@Z/=6>AW[:+J-TD":A'$&RGF*DDD:$AI53=R5! P<D8.#GCO<+H
MXBBNM^('PVU7P+XLN-(:UNKJUDU"YL=,O/)P-0\FX: M& 3D[UP5!R"0.XJ3
M3_@WXYU6YU"WM/"NHS3:?=M87*[%79<C.8 20'D&#E$RWM3YHVO<+HXZBNVM
MO@A\0+NXU:"/P?JHDTF5(-1\V$1K92/'YBK,S$",E.1N(].O%9=I\.?%-]XF
MO/#L&@7SZY9*SW5B8]KVZ* 6>0DA44 @[B0#D8/(HYH]PNCG:*ZBX^%OC"U\
M26>@2>&M1&LWL8FM;58=QGB(SYB,,JR=<N#M&#DC!J'4_ASXJT?6M.T>[\/W
M\>IZD%-C;QQ>:;O)P/)*963GCY2<'KBCFCW"Z.=HKTG4O@3X@\.?#7Q%XKU^
MUN=';2[ZRLX+:2-9([HSM*KD2JQ4-&8AE>3\XSCC.#X9^%'C+QEHYU;1/#=]
MJ.DK<&U:_C"K;K, I\LR,0H;#+@$Y.>,TN>-KW"Z.4HKH='^'?BCQ!JVI:98
M:#>SW^F;OM\+((OLF&V'S2Y"Q_-\OS$9/ J[I_PA\<:MX@U30[+PIJMSK&EQ
MK-?6<<!WVT;%0LC]@AW+A\[<,#G'-/FCW"Z.1HK4\2>%]7\'Z@MCK6GS:;=M
M$LZ1S $/&WW75@2K*<'#*2.#Z593P'XDFUS1]%CT.]DU?688KC3;(1_O+R.4
M$Q/&.X8 X/L?2GS+>X7,*BO2?$'P,\0P0P7GA_1/$&J:2NFV][>WU]IRVB6\
MDD32L,^8RF+:I*2$C>.P.!6;I/P-^(6O65K=Z;X.U:]ANH1<PB&(&1X3TE\O
M.\1G^^5V^]3[2-KW"Z.(HKKOB1X#C^']OX3E6_:_77?#]MKIS%L\CS2X\H<G
M=C9][C.>E=@?V=WC\1>'O#DOB[2U\3ZG<Z3#+HS12)+%'?HCQ2Q.1MG5$D4O
MMQM)[CFE[2*5[A='D-%=M!\'_%6N7.J2>'-!U+6])M;VXM(;Y( GVGRF;.Q2
M?G;:NXK'N(S67X3^'/BCQU'-+X?T*\U2&&18I)HE"QB1ONQ[W(4N>R [CZ57
M-'N%T<[173:)\,?%WB1=2;3/#FHW2:9.MK?R>3L2SE;=A)F; C/R-]['(Q5Z
MU^&.HV3^)X?$%AK&DW6CZ:EZL<-B)E:262-(!*^\!(9/,XE7?DE0 <Y!S1[A
M='%T5UOBCX1^-?!%C<7OB#POJ6D6MM,+>XDNH@OD2$L%610<IG:V"P ;'!-3
MZ?\ !7Q]JUK9SV7A#5;F.\C$UNL<(,DD9!(D\O.\(0"0Y 4^O(HYXVO<+HXN
MBD!# $<BEJAA1110 4444 2+3UIBU/:QB23+\1J-S'V%:E$L[_9;/8/]9<<M
M[)V'XUGU)<3M<3-(W&X\#T'85'6;=R0HHHI %%%% !1110 4444 %%%% !11
M72^ ? US\0=6U#3[6[ALY++2;W5F>968,EM"TK(,?Q,%P#TR>:3:2NP.:HKU
M+X4_ J;XE:5I^J2:S'IUC=WFHV(58#)*LEKIS7V[&0-K !.N023S1J7[.OB^
M/POX%U32=)O=<NO$^F3ZD;&RC262W6.9TP CEG!15<G QNQU%1[2"=F_Z_I$
M\RV/+:*[+3/@SXYUIKQ;#PO?79M+EK*7R]A'VA1EHD.[$C@=53<1D>HJ]I_P
M7UB!==N?%<T?@;3=#FCM;^?5XG,PN73>EM% HWR2E?FVC 5>6(I\\>X[H\_H
MKJ?$GA/1=,T.WU71?&-AK\;S>1+8M;2V=["V&(<POD-'@??5C@D @5K>,O@G
MXA\#_#+P=XXU'R/[+\3>9Y,$;9FM<?-%YR_P^:F9$]5&:.9:>871P%%>M6OP
M 74+K1=(M/%MI+XLUCP^GB*TT=["5(VA:!K@Q&XR5#B-'/*[21C(S7&_"[P;
M:_$GQIH_AR76ET*;5KB&TM+F2S>X1II75$5@A!5?FR6YQCI2]I&S?8+HY>BM
M;Q;H]EX=\07NFV.J?VQ#:R-"UW]E:V!=6*L C$G (ZYYK7U+X2>-='T675[[
MPQJ%KIT,23S2R1C=#&^-DDD8.^-3D?,Z@<CU%5S+0+G)45U+_"OQC'X=.O-X
M:U :2+?[6;CRQD0$X$Q3.\1Y_C*[><YQ7H/B#]FF\L/!-CK.CW]UKNJ7HT/[
M/I,%F-\CZA:2W&T$,?\ 5^5MSCD$DXQ4NI%;L.9'BM%:?B/PSJWA#5I-,UJP
MFTV_1$D:";&=K*&5@02""""""0<UF5IOJAA1110 4444 %%%% !1110 4444
M %%%% ']+%%%%?GYXX4444 %%%% !7SO^T[\5/%4GB+P[\'OAC.EM\0/%<;S
MW&K-RNA::A ENV']XG*I_M ]]N?HBOF']F.$>-/VAOVA/'MV?.NX->C\)6GI
M!;V<2[U7_?=E8^ZU$NQ2[GJ?P1_9[\'? 70VL_#MAYNJ7/SZCKU]B74-1E)W
M-)-,?F;+9.W[H)X%=CXP\7:=X%\/W.M:JM\;"V ,IT_3[B^E4$_>\J!'D('4
MD+@#). ,UM5@^/?^1%\1?]@VY_\ 1356RT%N]3/FLO!_QT^'-H]W8V?BCPCK
MUG'=PQWUL3'/#(@:-]DBAE.&!!(#*?0U\Y>#_P"UOV+?BQH'@6^U*ZU;X*>+
M[G[#X=NM0F,DOA_4""4LF<\M#)T3/0^F&+>U_LM_\FU?"O\ [%?3?_2:.N?_
M &V/!D7C;]EWXA0L&6ZTS39-:M)H^)(I[0?:%9#V/[LKQV8CO4/;FZE+>Q[A
M17)?"'Q=)X_^%'@SQ/,5,^LZ+9ZA)L&!OE@1V ';ECQ76UH0?D9_P6V_Y'CX
M>_\ 7E-_Z'7YE5^FO_!;;_D>/A[_ ->4W_H=?F50!]H_$C_E&-\,O^QGN_Y&
MOBZOM'XD?\HQOAE_V,]W_(U\74 ?KS_P1+_Y)[X__P"O^+_T"OTOK\T/^")?
M_)/?'_\ U_Q?^@5^E] !1110 4444 %%%% !1110 4444 %%%% 'S'_P44_Y
M-OE_[#FF?^E*U]+VO_'K#_N+_*OFC_@HI_R;?+_V'-,_]*5KZ7M?^/6'_<7^
M5>C4_P!SI?XI?^VF:^-DM%%%><:!1110 4444 >&?ME?M)/^RO\ !>Y\:PZ.
MNMW/VN*RAM7E\M=SY^9CCH IK\H->_X*A>,I/C\GQ3\/^'['2;Z;15T6]TZ9
MS-#<HKLZ/G ((+?I7[2_%+X5>%OC-X/NO"_C'2(M:T2X*O);2DK\RG(8,""I
M'J#7PK^QC^PQ\$OB?\([S5O$G@J'4M0CU[4K19GN95(BBN'2->&'10!0!\E?
MLU_\%-M=^ ]KXI^T^%+;Q%JOBG7I-<U*^DN#%NDDP&"J!@=*_;GPQKB>)O#>
MEZM'&84OK:.Y$;')7>H;'ZU^=/C3]BOX-Z!^WA\+/!-EX-@B\,ZEX<O]1NK#
M[1*5EN(F8QN26SQ@<9P:_22UM8;&VBM[>)88(E"1QH,*J@8  ],4 2T45\?:
MM\0_BM\<?VFOB'\./!GC2W^'.D^!K:S=KB/3H[R;47N%+9;S 0BKC&!S0!]@
MT5\R_P#"C/VA/^CA?_+;M/\ XFJ]U\'_ (]64UO#<?M'0P2W#;(4D\/6:M(P
M&<*"O)QZ4 ?45%?,O_"C?VA/^CA?_+;M/_B:/^%&_M"?]'"_^6W:?_$T ?35
M%?$7QXU+X]_LM_#V;XC7OQ<M?&MGIEU D^@WNAP6\5U')($(\R-0RGG((-?:
M.CZA_:VD6-]L\O[3 DVS.=NY0<?K0!<HHHH **** /E;7?\ E(UX:_[$NY_]
M'+7U37RMKO\ RD:\-?\ 8EW/_HY:^J:]+&;4O\"_4SAU]0HHHKS30*9-_J9/
M]T_RI],F_P!3)_NG^5-;B>QYL._U/\ZZ+P;_ ,?%U_NBN='?ZG^==%X-_P"/
MBZ_W17L5_P"&SQ</_$B=51117C'MA1110 4444 %%%% !7R1X\N-9_;#^,&M
M_#?2M0NM(^#_ (1F%MXKU'3YC'+K=Z5!.GQN.1&G23'/4'JIKZ4^)'B=O!/P
M[\4>(E"EM(TJZU !^F8H6DY]OEKR;]A7PBGA7]EOP1*S--?ZY;-KM]<R??GG
MNF,Q=O4[61?HHJ):OE*6BN>P>"_ _A_X=>';70O#&CV>A:/;#$5G8PB-!ZL0
M.K''+'))Y)-8?BSXT>$_!>M/I%_>7UUJL<*W$]EH^DW>IRVT3$A9)EMHI#"A
MVMAI-H.TX/!KN*^9/!WC;4O _P 8/C#;^&?"NI_$^SO-4CU"YO\ 0);:)M/O
M!:PQ-I\SW4T2.46)''E.[+YA5D4@;FW8%J>A?$SX/_#G]JKP'8SWHM]4MYHU
MN=(\2Z3(HNK1LY66WG7E<,,E>A(Y'%<9^S3\3O%>D^,-?^"WQ.O%U#QOX<MU
MO=-UP\?V]I3,52YQ_P ]$.$?W/<AB=_]D-H)OA7>W*WUO/J5[KVIWNIZ=;I)
M&ND7DUR\DMB4D574Q%L'<HR26 PPKC_VL(AX,^,G[/?Q"M<0WL?BQ/"MS)VD
MMM0C="K^H4QDC/ +9J>TA_W3Z=KX8_X)IC_BI?VCL<_\5]=]?]XU]SU\,?\
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MY)8R*6!'[LD=,UAZQ\,]13Q4-"\.P:GXHN18P7LBP:1<02QB2-78&)QNVKO
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MV.#^ GAG4_!?P/\  'A_6;;['J^EZ#8V5Y;^8LGE31P(CKN4E3A@1D$@]C7
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MP9_[$[5OYO7UW0 5\<_LY_\ *0#]I?\ Z]-'_P#135]C5\<_LY_\I /VE_\
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M1HKMKY+$M^Z6X9 C2@?WBBJN?0"J%+V-W=OK<.4^K_"GBS1O!VD_L[Z3K/Q
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MDB@EFU+4H[A0L5I-:&?$'EJ5#-(H2(Q!D!PM=3X?\::#X@C^&7P^L?%]K?\
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M/WI&^OIVKTZ@ HHHH **** "BBB@ HHHH **** "BBB@#YC_ ."BG_)M\O\
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MY6=2@G53DCH<U^^5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&Q4J2I[':S#([$CO6)JWP]\*Z]-I\VI^&M'U&73CNLI+NPBE:V.0<QEE.SD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **\F_:<^.@_9T^&0\:RZ=_:EE;ZC:V]Y;J<2&"20
M([1\@;P#D \'&#C.1Z!X.\8:-\0/"^F>(_#]_%JFBZE MQ:W<)RLB']00<@@
M\@@@@$5?)+EY[:#MI<V:*\F\4?%K5]$_:3\#_#V"VLGT77-&O]1N9Y$<W"20
M% @1@X4*=QSE2?0BO6:4HN-K]0"BBBI$%%%% !1110 445Y+X+\-_&&Q^-WB
MS4_$WBW0]1^&-Q%C1-%M;/9=VSY3!=_+!X ?.9)-Q(("=!2C>^HSUJBBBI$%
M%%>/_M=>/M>^%_[.?C7Q1X9OO[,UW3K:.2UNO)CE\MC-&I.R164\,1R#UJHQ
M<Y**ZC6KL>P453T:XDNM'L9Y6WRR01N[8QDE02:N5(@HHHH **** "BBB@ H
MHHH **** "BBO"=-^)GB2X_;5UCP%)J6[PG;^"X=6CT_R(AMNFNO+,GF;=Y^
M7C:6V^V:N,7*]N@TKGNU%%%0(**\3^,WQ%\0^$_CG\$?#VE:A]ET?Q'J&H0:
MI;>1&_VA(K7S(QN92R8;GY2,]\BM+P7X;^,-C\;O%FI^)O%NAZC\,;B+&B:+
M:V>R[MGRF"[^6#P ^<R2;B00$Z#7V?N\S?2_XV*MI<]:HHHK(D**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _-+_@JO\6O
M''P[^)'@BU\*>,O$'AFVN-)EDFAT?5)[1)7$Q 9A&X!..,FNY_X)0_$CQ;\1
MO"_Q$E\6>*=:\3RVMY9K;OK.H37;0ADE+!#(S;0<#..N!7T]\8OV6OAA\?M4
MT_4O'GAC^W;VPA-O;2?;[JWV1EMQ&(94!Y[D$UH?!O\ 9Y^'_P"S_9ZG:^ =
M _L&#4Y$DNU^VW%SYC("%.9I'(P&/3'6O2EB*3PWLDO>[_,UYER<O4]&HHHK
MS3(**** "BBB@#X;^-OQ9\4_!?\ ;*\7>)_#7P_F^($=I\/[634;:#4DLWM+
M=;N1FF&4=I " "JJ2 2>@-:LFJ?%K]NGX=:/IT_@_2/AO\+]<>WO-1U3_A((
M]4O-1LU</Y,"Q1KY3%E"MYF"N"",@J>]T-5D_P""@GBQ64,K?#VS!4C((^VO
M7*J&_8;^+#$E8?@+XTOA@EB(_"VJ/DXQT6VF(]E0_P!T+\_J\RLE&/OI*V__
M  U^QT=K+4[+]K#X[7OPG7P=X*\-:WH7A'7_ !5++#%XA\131Q6.CVD* RSD
M2$*[_,JHC<%CSGH?)F\/^"K&-M4TK]N#5(_%F-ZW&H>,M.NM+\WJ2;!B$V9_
M@W<5Z/\ M=_"J76/$7@7XFVW@FT^)5IX7:>WU?PM<6D=V][I\X7=);Q2 J\T
M3*'5>"W(S7FUS\=/V/FA:UTOX6Z3KOBK 5?"=A\.Q_:1D[Q;7MU3<._SXXXS
M2I+]W'D3?>R3^^__  P1V5CTCP/\<IOC=^RY\3GU*XTN[\1>'['5-'U.[T.=
M9["[D2V9DN+=P3F.1&5AZ'<.U<-XB\2ZOX5_8 ^#][HFJWNCWC?\(Y UQ87#
MP2&-Y8E="R$':P)!'0@X->D>&O#=QHO[*7CJ^U#X<>'/A?JNJ:/J5S+H7AVV
MCB$<7D2"$3E%4-,$QN]/;E1Y+\0/^4>7P=_ZZ^&?_1T-$>7FLEIS(2M?3N>X
M_M+?%7Q=H&L>#/AU\.?LL'COQI/.EOJE]'YD&EVL"!Y[DI@AV ("J>">N>AY
MP?L@^,+6%M4M/VBOB7_PEY!<7-S>Q2Z5YIZG^SRFP)_L;L"M']I[PGXLT/QK
MX!^+W@K19O%&H^#VNK;4_#]J<7%_I]P@63R1@[I$*AE3J>V>ARQ_P43^$5U:
MFWT]_$FI^*]N!X1M?#]T=3\SO%M*>7N'?]YCWK**J<D?8J_?2_W^5OD)7LN4
MH_L:^*OB/K?C[XW:=\3+YYM=TC4;"V^RPW$CV4/^C,#);(Q(C24*LN% Y?D#
MH/+/V2?#'Q;_ &G/A#:7'BKXI>*?"WA&PN;FUM9]"OBNL:O()W=II;V0.ZQI
MN$2HO41G.,#/HO[%?B'Q)XK^*W[06K>+-'_X1[7+K5--EDTDN':TC-JQAB=A
MP7$7EAO]K/ Z5TW_  3K15_9'\'D* 6N-1)P.I^WSC-:U)>S4VDK^[^3V*EI
M?Y&/X&N/&?[//[2/AGX:ZQXYU7Q]X&\8Z==S:3<^)I5FU.QO+8;Y$:< &5&C
M(^\.O0+M.[8\<>,/'GQN^,VO_#+X?^(AX&\/>%H;=O$OB:&V6>^DGG4O':6H
M<;4.P;FDY()&.F&3X]_\G>_LS?\ 7;Q!_P"D"UB^);[7OV4OCIXU\<S^'=3\
M2_"WQM]FN]1N]%C-S<Z'>PQ^6TDD(^9H77!++G;MQ@<!H7O6E9<S7XWM]]B=
M]>I?OOV7/B)\/;.36OAQ\</'&K^);=?,72_'NHKJNFWV.?)92BF'<>-ZDD9_
M&NC_ &AOV@-;^"OP5\/ZK=6>D:3X[\03VFE00:E>A=-L+V9,RR33G ,,05R6
MXSM'K7,ZI^WYX(\5Z?+IWPBL]6^)_C>9=EIHUCI5U!'$YX#W$LL:+'$I^\V>
MW;J-/]J#X2>)OBS\(_!^L/X;T?7?&OA>\M=<N/"\Y$]AJ#+&5NK,&12&#!F"
MLR]57IFDE+GC[=6U]'_PP:W7.>50:#X-U*%-5US]M[4CXN9=\DND^,].M=*6
M7'\-B/EV _PY&?:O7_V5?CM>?$2]\6>"==\3:'XU\0>%9(2OB?P[+$]IJUG,
MI,4Q6-F6.8%662,< XQD&O'_ /A>?[(%G;+;:Q\+-(T/Q9L^;PE>_#P#4A+V
MB %N8RQ/ ^?'N*]N_99T6.XTW7/%"_![0?A':ZC<>7I-G9Z;#9ZG/8J 5>]6
M-1L9FRPCS\O0YP&:ZWP/GB_*]E]W]6'+;5'9?M!?%Z'X&?";7/%[V@U"ZM$2
M*RL=^S[3=2.(X8\]@789/8 FO(M'_9=^(GC[3X->^(_QQ\=:3XIN )FTOP/J
M*:9IEAD B 1A&\[8>-['+8YSU/IG[4'PEOOC3\&-:\.Z1/':Z\K0W^ERS,5C
M%U!(LL88CHK%=I/;=GM7F>D_M_\ @/PUIT.G?%:VUCX:>.(5$5WH>H:/=2B2
M4 !GMY(HW62)C]ULC(([<G&FI>S_ '2O*^O5^7ZDQO;W=S6^"OCSQUX#^,%[
M\&_B5K,/BNY?33K'ASQ4L*V\U_:JX22&>->!+&2/F'WE!)R:\>^$-I\6_CS\
M2OC+X7/Q#UOPIX T7QEJ"2:I87!DU.8LX6.QM99-PMH8E3?E!P90 ,$X]2^$
MD7B#X]?'U?B_J/A[4?"7@_0])ET?PW9ZO#Y%[J#3.&FNWB(RD9555 >OWJF_
M8L11?_'I@H#'XG:N"V.3@0X_F:U;4%)I*]E\F5M=]3E]2TOQG^R3\5/APL?Q
M(\1^/?A[XOUA?#^H6/C2[6]O+2ZE4F":&XVJV-RL"N,8XP205^O:^:_VW/\
MCS^"G_93M#_]"EKZ4KFJOFA&;W=S.6J3/ ?B)XFUCX._M&>%-=O-5OI_A_XV
M1?#MW:7%P[VVF:H,M:31H25C$PW1-M !8*3S5O\ :R^(>K>'_".C>"?"5Z]E
MX[\>7ZZ'I-Q"2)+.-L&YO!M(8"&+)W Y5F0UWGQJ^%UC\9OA?X@\(7[^2NHV
MY$%TOWK:X4AX9E]TD56_"OGK]DG1/'/Q6^(>J?%'XJ:>+'6O#5K_ ,(;I-GR
M5$L)Q?W@R,;I9!M##L&7D &M(<KBJC^S^/;_ (/DBE:W-V.P^.=]JW@+Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI6FD#2+'G:K$  L!DXK'^/UK#8_M(?LS6UM#';V\.I:K''#$H5$46& J@<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7A/Q*\)?%OP?\ $:Y\<?#34+?Q7IFH
M6T<.J>!O$6HRQ0[XP=LUA*=R6[L" RE0C<L<G&/=J*N,N5W&G8^6-;\4?M-_
M%[3[CPU:_#31_@W:WL;0W7B34_$4&L2PQ-PWV>* #]Y@G&_CW'6O?OA=\.]+
M^$OP\\/^#M&\PZ;HUFEI$\N-\FT?,[8 &YFRQP!RQKJ:*J53F7*E9>0VPHHH
MK(D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDKF.-V5&D902$
M7&6]AD@?G3Z* /$?V7_AGXA\)Z?XO\6^-[067CCQIK,VIW]KYR3&SMU/EVMK
MO1F5A'&,_*3]\C)Q7MU%%7.3G+F8V[ZA1114""BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **_*?_@L1_R5+P!_V!IO_1YKT+_@C?\ \BC\3O\ K^L?
M_1<U>@\);#^WYOE\S7D]WFN?HM1117GF04444 %%%% 'BGAKXB>(=0_:X\:>
M"[C4/,\,Z=X9L=0M;'R8QY<\DKJ[[PN\Y"C@L0,<"O:Z^<?!O_)^OQ%_[$W3
M/_1\E>P_%OX@0?"KX8^*/&%Q";B+1=.FO?)&?WC(A*I[9; SVS714C[T5%;I
M?D7):I(ZVBOD;X?_ +'NC_'+PCIGC7X[WFI>/_%&N6\>H"P?4;FTT_24D7>D
M%M#"Z;=JL Q).2">N2;.AZ'JG[)/QR\%>%],\0:GK7PJ\<S3Z?;:3K%P]U+H
ME^B&2,02MEO)<#;L).#ELGK5>RB[QC*[7EI\G_P!\JV3U/K"BOA'_A5^M?&#
M]NCXV>'O^$DU#P_X(^RZ-<Z[%H\YM[O4&6S58+?S5^9(COE9]O4*%[Y%[X]_
ML^^&OV/?!]K\6/A"^I>#KK0=2LWU?3H]2N;FTU6SDF6*2.:.5WR?W@(/;!Q\
MVUA7L(W4.;5VZ=^X^1:*^K/N"BOGG]I#QSXJUGQMX!^$G@?5Y?#6J>,/M%WJ
M'B*&,--I^G0(&D,(/ ED+!%;JO7@D$9G_#N_X/I$UU#!XCM_%3#<?%L?B&[&
MJ>;_ ,]M^_R]^><^7C/:LU3BHISE:_E?_(GE5KMGTS17R!^Q7X=\3^$?CE^T
M!H_B_6V\2:U9W>D1'5I$"/=PBVD\B1P /G,7E[NOS;N3U/UO?WL6FV-S=SMM
M@MXVED;T5023^0J*E/V<N5.^WXJXI+E=BQ17QA\)_@FO[:'AL?$[XQZAJFKZ
M%K<TLN@^";>_FM-.T^T21DB=UB96DF8+NWY'#?0+Q'[7G[+:_!/X6I?_  WU
MW4],\#-J>GQ:QX/OKZ6[LU7[5$8I[8RLS1N)-H89^96/3;@]$:$'/V;GKZ:?
M??\ 0OD5^6^I^@U%?&W[;VF>)]<^/7[.^F>#]7&@:]?76L6L6J[ [6D<EO"L
MTJ*>KK$9"O\ M =.M=#XD_X)[_#I= O]1T&Z\2:=\14MWDM?&K:]>2:B;H*=
MLDA\S:V6QD*H)'0CK4>R@HQE.5K^7G;N+E5DVSZHHKY,T/\ :F\06/[!NC_$
MZ6&/6/&L]LFEPK(@1;C4#<FT5V48ZN-Y P#@@8'31T;]@7P5XGLX-5^+=]K7
MQ-\<3#SKG6-0U:Y@2"0G<R6T4,B+%$K?=7!QCC P O8J%_:.VMN^WW"Y;?$;
M/Q8\4:UIO[9'P-T6TU>_M=&U&PUI[W3H;ETM[EHX%,9DC!VN5/(+ X[5]$U\
M//\ ##7OA5^V[\$])N/$]_XH\)BQUEM%?69/.OK/-M^]MWEZRQKB-D9OF =E
M)(45]PTZ\5%0MKI^K'+2U@HKY:\2VVN?M1_'3QAX'/B35?#'PS\$+;6VIP:'
M/]FN=;OIHS(8GG4[E@1" R#&XM]"LU]^P'X$\*6<FH_":[UCX8>-(5WVNLZ=
MJMS.DCCD)<132.LD1/WEP,_I2]G"-E.5F_+\_P"F+E75GT_17SW^T-\0_'?@
M?X9^!?"VDZC8P_$WQE?VGA\:Q#;L;6UF:/=<W21G/"A6*J>FX'M6/#_P3Q^$
M]U:BZUS_ (2/Q#XP9"9/&%[K]W_:1E/_ "U!601@@G@%"/7-)4XI<TY6OV5_
M\@Y5:[9].45\Z?LW>*/%/A?X@^.O@WXQUV?Q7<^&8K?4-&UZ\!-U=Z=.&"K<
M-_'+&R[2_5LY[5\__L>_LI:3\=/A;-J_Q.U#4O$7A:'5=0M]#\+1WTMK96ZB
MY<RSOY+(SRM*7 +'A1W&W;?L$E)SEHK?.X^7>[/T+HKX0T;X8^(O!'[1VI?L
M]>$?&.L:1\+=6T:+Q+*BW;/?:7;*[PR6=G.Y+1I)(8LGE@H..26.I\;OV>_"
M/[(ND:+\5/A:FI>&-6TW6K&#5+5=3N;F#6+6>=8I8YTFD;<?GW @C!R>N"'[
M"-U'FU>VGY]OQ'RJ]K[GVW17Q]^VEH/BGQ1\?OV>]*\':O\ \(_KEW-K<*ZL
M(A(UE"UM$LTJJ>"XB+[>1\VVNI'_  3Q^$$L:W=Y#XCU#Q4!N_X2RY\179U/
MS?\ GMO$@CWYR?N8R>E1[.$8QE.6_EYV[D\JLFV?2[?=/TKP/]AWQ+J_BW]G
MO3M1US5;W6=0;4]2C:[U"X>>4JMY*J*7<DX"@ #/  %9W[-/BKQ7X7^('CSX
M->,];N/%5WX7BMK_ $;Q!>#_ $F]TZ<':)V_BDC8;2YY;D]J\B^%?QFG^ ?_
M  3RU+QA9+"^IV^IZC;V(N 6C$\NI2QH[ <E5W;B!U"XK547RN"U;<;?.Y7+
MT]#[KHK\RM+\1_L;^([*#4OBE\3=9^)7C>0>9=:]J$>N0%)#R5@CBC58XU/W
M5P< #Z5[!^R)^T%X9NOC)J'PN\(?$+4?B3X*N-,;4]'N]:BN%OM+DC<++9/)
M-&C31E6#HW\(4K[T3PLHQ;5].ZLOE_2!TVE<^U:*^(OB1XQO_P#@GWXLU>31
M-(;6_AKXU,LVBZ)%+'&-)UT\F%02-MK*,,<9V%3@#^+WS]FWX*7GPI\.ZGJ_
MB>\76?B-XIN!J7B35A@AY\82"/@8AB4E47IU( ! &,Z*C'GOH]O/OZ6)<;*]
MSU/7-<L/#.BWVK:K=Q6&FV,#W-S=3-M2*-%+,S'T !-?,.B?$CXW_M/*^J_#
ME]-^$_PWE)%AXCURP^W:MJ2C.)X;5B(TB/;S.2,$$YP.@_X*"3RP_LK>*5#M
M%:37.GPWLBL5Q;M>PB3)'08.#[&OH#1[.STW2;*TTZ..'3[>!(K:.$ (L:J
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MP]C")+NXC_WXH%=T_P"! 5B_M??$7Q%X+^'>DZ)X-G6S\8>,]9MO#6F7K?\
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M"^E7VN:/_P (]K%Q;)+=Z5]J2Y^R2D M%YJ *^T\;AP<5X+\ _\ DZ_]I/\
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M9_%K2/ WCKP1X4O[:^FU'Q=<7%M8RV\:-%&T,7FN927! *]-H;GTZUPOPO\
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MV%W$T@DB8++)#8X\R:)"<EU/W03@8(KZ;M;E+RUAN(PXCF19%$D;1M@C(RK
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MW%%1S>YR"OI8^??@7X3U2Q^/7[0]WJFD7MII6L:GIIL[FZMGCAO(ULMCF)R
M' /RDJ3@\5Y_X#UCXB?L86<_@?4/AYX@^)?PUMKB:7P]K7@Z 7FH6T,DC/\
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MF-P& R$/;*MQUK["KF/B9\.=#^+?@76/"/B.V^U:1JD!AF52 Z'JLB$@X=6
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MQYX9\/ZO?::OBV_$\VC6<ZJUR0L9\UX^"4^3<">,@$<X->.?M$?\G-?LV?\
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MVZ?P':ZT\>@2R[MQ)MMN0"WS85P 1@8'%?2,$,=K#'##&L4,:A$CC4*JJ!@
M = !4591DE9W?>UA2:)****YB HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF/B5\2_#?PA\&WWBKQ;J7]D
MZ#9%!<7?D2S;-[JB_)&K,<LP' /6FDY.R Z>BO'?A+^UY\)?CIXHD\.^"/%G
M]MZQ';-=M;?V;=V^(E*JS;I8D7@NO&<\U[%3E&4':2LQM-;A117A'PF_Y.H^
M._\ UQT'_P!)9:<8\R;[?YI!8]WHJAK^O:=X6T2_UC5[V'3M+L87N+J[N'"Q
MPQJ,LS$]  *^>(?V]O!<I-__ ,(7\1E\'#Y_^$T/A:8Z1Y7_ #U\P$R;,=_+
M_"G&G.?PJX)-['TM17G_ (\^.7A7P#\)9/B1-=-J_A54MY5NM+:.3S(YI4B1
MU+.J[09 22PP >XQ7EDG[>W@'[;/<6WAWQOJ/@VWF:&?QW9>'Y)=!BVL5=S<
M [B@;C<$(Y';FG&E4DKQ0^5L^DZ*Y;QQ\4/"OPW\#W'B_P 1ZW:Z;X<AB64W
M[-N1U;&P(%R7+9& H).>*\1M?V]O!D<UO<:[X*^(GA#PU<.JQ>*M?\-O!I3!
MB C>:&8A6R,$J!SSBB-*<U>*!1;V/I>BOF[XE?M(:-XT_9'UWQWX?\-^)M<T
MG6K34-,AM]-L4N+B' G@:XE5)"JP!HRQ<,<*0<<XKQ2Z^)B^-O\ @G0MB_A?
MQ)X<7P_IWANS-YK^G_9;?4 +FU'G6C[CYL7R9W\<,O'-:QP\I+736PU%GWY1
M7S?KO[>?P^T'4FDDT7QA=>#TN/LLGCRTT*230$?>4/\ I.<NNX;=R*P.1@D<
MUZWK'Q:T70_&W@_PY/'=.?%<4[Z7JD*H]E(\48D,1D#9#M&2Z_+A@C<Y&*R=
M*<=T+E9VM%<7\3OBMH_PIL]#DU.&[O;K6]5M]&TZPT]$>>XN)FPH4.RKM4!F
M8DC"J3Z ]I6=G:Y(45Y-\6OVF?"'PCUF#0)X-9\5>+KB'[1%X8\*Z>^H:BT6
M<>88UP$7/0NRY[9P:3X0_M+>&?B]K=WH":5XA\'>*[6 7;^'?%VF-I]^UN6V
MB9$)(=,\95CCC.,UI[.?+S6T'9VN>M45PG@?XR:%XXU;QCI21W6BZMX3O#:Z
MI8ZLL<4L:%-\=P-KL##(F61\\@'(!!%3_"?XK:9\9/#,OB+1+'4K;16NY;>R
MO-0A6)=0C1MOVF !BQA8YVEPK'!.T#!,N$EN@LSM**X_Q5\4-,\'^.O!WA:_
MM;[[3XJDN8+&\BC4VR2PQ&4QRL6#*S(&VX4@[3DBD^*GQ2TGX1^&8M8U2"\O
MWN;R#3K+3=-1)+N^N9G"QPPHS*&8\MRP 56).!2Y9.RMN%CL:*\6\7V/A+QI
M^TUX-LKW_A($\8>$=&N?$-FMI,L>GO#</]F9)AG+/E20!@8!RQ'%=U\*/B=I
M?Q@\#V?B?2+>]LK6XEG@:TU&-8[B"6&9XI$D568 AT;HQ[54H-),+'7T5Q'A
M7XO:'XPU[QI86*W*6?A.Y%G?ZS.(TL6G$>^6..3?DF$8$F5 4G&3@X\DU+]N
M[P6LTTWA[P?\0/'.@6[LD_B3PSX<DN=,BVL0Y\YF7<JX)+*",#C-.-*<G9(?
M*SZ2HKGO /C_ ,/?%#PGI_B;PMJL&LZ'?IYEO=P9PW.""" 58$$%6 ((((!I
MOQ!^(7A[X5^$=0\3^*M4AT?1+%0T]U-DXR0%55 )9B2 % ))/%1RN_+;47D=
M'17S?IO[=?@UKJ&3Q!X.^(/@C0)W6.'Q-XE\-R6VEN6.$/G*S;58D89@ ,\D
M5ZI\0OC)H?PSN/"S:S#>_P!C^(+Q;"/7;9$DL;.5QF'[0^_<BRL0JN%9=Q&X
MJ"";=*<79H?*SO**X?5/B[I%A\5])^'EO:7^J>(+VRDU*X-BD;0Z;:J0JRW+
M,ZE0[G:@4,Q(/  S7EVL?MS^ =/U?5]"T_2/%7BCQ9IFIW>F2^&O#NE?;M0;
M[.X22X"(^U82Q&UG96//R\41I3EL@Y6SZ)HKR/X0_M/>#_C!KEUX>M[?6O"W
MB^UB^T3>&?%6G/8:@L6<>8(VR'7_ '6..^,BG_%_]IKPA\'=8L] NX=8\3>+
MKR(W%MX8\+Z>]_J,D0.#)Y:X"KG."[+G!QG!P>SGS<MM1<KO8]9HKYPT_P#;
MN\!3:MH^B:IH?B[PMXJU34[338/#GB+2/L-_BXD\N.XV.^UH0P^8HS,/[M=3
M\7/VLO ?P3\8/X9\3/J$>K-ID6IVD-I;B9K[S)V@2W@16WO,64G;MV@<EJ?L
M:E[<NH^5]CV:BO'?A-^U!X?^*GB9_#4_ASQ9X$\2F!KNWTCQII#:=/>0*0'E
MA^9E<*2 1G/4XP,UC^//VRO!W@/QUJGAIO#_ (P\0#16C76]9T#0Y+S3](9U
M# 7$BG((4ACM5NN.H(![&I?EMJ'*]CWJBOGOXI>'/ 6J?M)?!7Q)JL_B8^*+
MQ+RWT)=/N!'I^V.!IW-S&^&&5) V#). XP!CJ/C%^T[X2^#>MV/A^YM-;\5^
M+KV+[1;^&?"NGM?ZBT(.#*8P0%7KRS#.#C.#1[-NRCJV'+V/7**\A^$/[3_A
M+XP>(+SPY#9ZYX3\76D(N9?#7BS3FT^_\D_\M5C)(9<]=I..^,BL3X@?MG>
M_AWXVU[P==V6O:KXNTR>VMH="T:P%W>:DTT'G@VT2ON953[S/L / S2]E4YN
M6VH<KV/>:*\P^#?[0GA_XS7&IZ?:Z7KWA;Q%IBI+>>'?%6G-8:A#$Y(CE,9)
M#(VTX96/;.,BO3ZB47%VDA;!1114B"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSDU#K151R_O7#F5[^96^)WAW3;/X&^*]$BLH(])A\/75I'9H@$2Q+;,H0+T
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M=B< #H *L^ _ 6A_#+PM9^'/#=F^GZ+9[A;VK7$LXB#,6*JTC,P4$G"YP!P
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M[&.W50%VN"$"@   =,8KI;BWBNH)()XTFAD4H\<BAE92,$$'J".U>$Q?L(?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7.^,/A_H'CXZ(=>L/MQT74H=8L/WTD?DW<081R?(PW8W-\K94YY!KHJ
M*:;6J *QK'P?HNF>*-5\16FFP6VMZK#!;WUY&,/<)#O\H/V)7S' .,X(&<
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M $>:-0&[]OO21Z_#BY_].,5='NR@K*VC*TL9E[\=/BU\7O$>L6GP/\,>&?\
MA&M&NY+";Q;XVGN%M+^XC.V6.UBM_P!XRJW'FGY200.E9/A_]I7XM:/\?/A[
M\*_B#X'T?1;[7'O'N-;TN26XL+^"*U>16M&9@T3K(F'20.=K*>-P-8GPK^.>
MA_L9^&I/AE\7+34O"]MI=]=MH_BA;":\L-9MI9Y)D?S(48K/\Y#QD<8!S\V!
M!J_QM_X79^UA\!;KP[X=U:+P1:W.KFU\1:G9-:KJ4QT]]QMXY )/*52H,C*
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M^-MHVGKD5Q/POO+OP]X:^+WQC\>^$-5L=*\9WD$R>%5TTW=_'IL,*VR-<6Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_V#/_:J5[I12C4Y>738%+8YME6/X=%54*JZ5@*!@ >37R+X;\.^)+?]EO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT=M17S3)^UQXF\>7EXWP9^$.J?$_0K.=K:7Q!/J]OH]C/(IPWV9YP3.H/!8
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M*I.6'5A756=TE]9P7,88)-&LBANN",C/YT[.UP)J***0!1110 4444 %%%%
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M:GP_9!=DTLLJ?,JS96,)@[N#U"Y]*_8R\0^'KSX$Z;X<T?1QX8U7PJ&T?7-
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MZS<RVFJ>*I9H=,=H6\AY(U#%&E^ZK-D!5SEB0 *^;/CQX3MOV>OVD/AC\0?
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M1MZ#;GO6$HPG&,E:-[][:6]7U)LFK['/_M\?\FB_$;_KSA_]*(JZGQE\8?\
MA6=Y\)]%_LC^TO\ A+]0CTCS_M/E?9/]',GF;=C;_NXVY7KUKQK]ICP?XX\&
M?L3_ !2M?'?Q!_X6+J4J12P:A_8L&E^3%YT \KRX20WS!FW'GYL=JW?VAO\
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MYNW'S?,R_+R<8-,_;JT"T\3#X(:=?0QSVMQ\1=,CE21=P9"LNY3[$#!KZ/\
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M_A$:-I'BK7H--6&?4\M9V,IE*WSD0\_NXO,\H#HP^?->0:C\4]8^+WP9\ _
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M>E7T+07-G=('CEC88*L#U%:-%3S.R78#YFD_8)\)PQ'3M-^(/Q-T3PI@Q_\
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M;<@\@BO=J*%5J*/*GH',]@HHHK(D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /BG]O3]M;QQ^RWXS\,:1X4TKP_J%MJFGR74S:Q;SRNK+(5
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M/2+7ZW8W:W+V.ST7X[?''X\POK7P>\%^%]#\$^8RV6N?$*>Z5]60''FPV]N
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M$ R@[5. ?O"M_P"/7QH\;>'?B!X/^'/PST;1=0\8^(H+F_\ MWB225-.L[6
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M'Q3K-CXNOO!6K)I:>*M.A6&/4T:,/ET4E%E3[KA3@' Z@DYW[>W_ "0_3_\
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MY)/0")G#<_2L^5MZ:B.OHKSG]HXY_9Y^)I'(_P"$8U+_ -)9*Y?X%_$#PO\
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M?3_#/C?PYXBOT4NUKI.K6]U*JCJ2L;D@5U]#3CHP"BN+U'XV?#S1_$#:#?\
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M/A!8:9XT\*^*+QM3U?P1J5X+&:*^8 //:7##8N_ +!^F. >-IS\VTK2:6O\
MP0OYZG.?MB_L@^ T^"WB[Q5X*T>S^'_B31](N9C<>'H%LX;RU$;&>VGBB 1U
MD3(R1D$*<X!!YW]J_3=3UK]E/]GG3]%OWTK5[O7_  W!9WT8):WF:T=4D '.
M58@_A6K\;-!_:7_:4^&/B/P_+X-TGX6Z/)8RF32EUJ'4M3U:51NCMUF39##$
M[ !BQ!QQT)![OXJ?!_Q=XD^%/P!T;3M(^T:EX7\1^'[_ %>'[3"OV:"VB*SO
MN9P'VGLA8GL#6D9N*ASR3:?>_0:=K79T^B?L5_!?2?"/]@W'@#1]:,D96YU;
M5;5+C4;F0_?E:Z(\P.QRV59<$G %>2?L^_$K4/@S^RO\7HII[C6C\+=9UG1]
M,:^?<SPVX5K>-F&> 9 OL!@8 %?95?/OP)^"NIZ;HOQPT3QMHX@TKQAXQU:]
M@B,\<GVK3[F.-%?Y&.S< W#888Y KFC4YHOVCOJB4]-3'^ _[*7@G5/!.D^,
M_B'I%C\2?'OB2SAU+5-9\21)?KOE0.(H4<&-(T#;5"J. .V .S\-_LL^%?A[
M\5[+QKX#DE\$0M')#J_A_2%":;JJE"(R\'W8VC;#!D [CN:\W\,Z3^T#^S/I
M-MX1\/>%=-^-W@NQ7R-'N&UB'1]3L[=>$AN#*#'($&%#(,D+SC@#L_AOI/QM
M\>?$;3_&'CZ6S^'?AG3H94MO ND7BWTMU(Z[?,O;@*$8+U58^X[<[KFYW<N=
M6]?PM_P- =^Y\\?%WXA:;\1/VIO%ECXX^'/Q"^)_@SP0]O9Z5X?\)Z*;_3A>
M/$))KB\7>@:3YPJ*V1M!XYYS_B9JGP_\1:,;OP7^S%\7OAUXWT\-/HOB'PWX
M#33Y+6Y ^0R"&4"2,GY65@V59L8.#7T;\2/A7\0/ GQ8O_BC\)$TW5[K6K:*
MV\2>$=7G-M%J/DC$,\$X!$4X7Y/F^4@Y/(K U;5_VF?C5 /#Z>#=,^!.DW!V
M:AK\FO1:QJ(B)&?L:P *CX!&Y^F[(((!K>-16BX[)=[>NG]7*OL5/C%\4O'7
MB;X%_"'1D^V^ _%_Q(U*QT75;DQ/:W6EJ\;/=&(. T<AV,$SS\W'."/1O#O[
M%_P2\-^%X]"C^&OAZ_@6/RWO-2L8[F\D)'+&X<&0,>N0PQVQ6K\=?@1;_&CX
M7V_ALZS>:;KFERP7^C>(<[KBTOH!^ZN#C&XDYW8QD,<8."/-K7XE?M2:!;)H
M=_\ !KPYXIU2-1%_PE6G^*8K33Y#CB1K:1?.]V QDYP *YTW*%J;MKKK8G=:
M''_!/X5I\'_V\O$6@V6J7FHZ$/ <<NE07\S3RV%L;U0+82-\S(KB3;N)(5E7
M)VU]ER_ZM_H:^2O@!\$?B[X9_:L\2?$/XDW5CK"ZWX96W>^TME2SM+CST*V4
M,;/YI1(XPV\H 2QR2<D_6LO^K?Z&HQ#O-:WT0I;GP=^P/^RSX/\ &OP;T7QO
MX\L8?&UU-+>0:3IVKXN;'2[9;J4,B0-E"[R!W9F!/*@8P<]K^U)\ _#/P7\%
MW?QD^%NF6?@#QGX16.\(T6-;2SU&U$BB:VG@0!&5E)Z $D 9]/./V+;7XR_#
MO]GW1?$G@+3],^(_AK5KB]EG\):C?#3KRSN$NY8B]K<L#&8W5 S)(.&&5/S-
M7JOB/P#\:?VK&L-$^(OAW3/A1\-([F.XU30[754U34]6\IPZ0F:-1%'"64$X
M^;Y1U[=E24E7<G/W;]_PL:._->^A-^T!K5S\<?''PA^%46H7FA>&/&=E<:[K
MOV2413W5G#$CBS#@Y"N7P^WG ],UZ%JG[&/P0U;PHWA]_AEX=M[,Q"$7-I8I
M#>*!T87*@2[O]HN2>^:E_:"^!^J?$:#PQK_@K6(?#'C_ ,(W#7.B7MPA:U=7
M4++:SJO/DR* #MY& 0#T/$2?$_\ :AU.W.B6_P $_#NC:LR>5_PE-UXKBFTU
M'Q@S"U1?/VYY"Y)]<US)RE&/LY6MYV^?F1K969-^RVUSKWAOXC_"7QS*/&]I
MX+UMM%2ZUR%+C[?8,BRP+.K9#LH."2.RUS?[''PK\%67Q ^,^HV_A#08-0T7
MQU>6NF7<>F0++8PB&,>7 X7,:89OE4@?,?6O:OV??@O_ ,*5\&W5I?:HWB#Q
M1K%[+JVO:U(@0WM[+@NP4?=08"JO8#MFL+]G'X=>(? 7B+XP76NZ?]A@U_QC
M<ZKIK>=')Y]J\<:K)A&)7)4_*V#QTHE47[SE>]O^"%]['R7I_P 2]!^)WQB\
M;>,OB-\'_B3\7(--UBZT?P[9Z/X:_M/0M/M(7\LD(TBJ\[LI9RRG'R_@_P"(
MGB;0K.YL?%OP@_9N^+7P[^(NDRQR6=SI_@DV5A>Q!P9;6\BADVO$Z@@D(6!"
MD'@@_0FK?#OXI? 3Q_XG\2?"C2--\=>$O$UVVJ:CX-U"_73[FVOV $DUI<,#
M&%DP&97Z$<=:2U3]HCXV:_I,6N:39? SP?9W45U?QZ?J\>J:QJ'EMN$*31CR
MHXGX#<;N/X@2IZ?:1NI*UO7\+?\  +OU.%_;*\*WWQ:^,W[->B6VH:AX9?6I
M-56ZGMMT5U!;M;0-<1J<91S%YB9(X+<CBO6O%7[$?P8UCX<W_ABT^'FA:9NM
M'AM]2M+)%OX7VD)(+@CS&8'!^9B#CG(JW\7/AQXB\4?M'? SQ1IFG?:="\-2
MZPVJW?GQI]F$]HL<7R,P9]S CY <=\"O;9 6C8#J17+*M*,8*#M;_-D.3LK'
MSK^RA)9_'K]D7P.WC[3;/Q=B&2WG37;:.\6:2VGD@21ED#!GQ&/F/.23G)KG
M?^"=_P /_"VF_ ^P\26GAK2+7Q%+?ZI:OJ\-A$EV\(O9 (S,%WE $4;<X^4>
M@KO_ -C/X<^(OA1^SGX;\+^*M._LO7;.6]:>U\^.;8)+N:1/GC9E.4=3P>,\
M\U)^Q[\._$/PL^!UAX?\4:?_ &9J\6HZA.]OYT<V$ENY9(SNC9EY5E/7(SS@
MU522M447I?\ S!O=(\D^ /CR?X7_ +(WQ;\6VL(GN]&UWQ'>P1L"5,B3.4R/
M3=C/MFNH_9[_ &2O MQX#TOQ=X]T73_B/X[\36D.J:OK7B2%-0W22HK[(ED!
M1$0,%7:HX [8 Z#]G3X+ZCH?P9\9>#_'6D"VAUS7-8DDM#/'+YMG<RMM;=&S
M ;D;IG([@&N)\(Z?^T-^S1I,/@W1?!NF_&WP;8+Y&B7RZW#H^HVEL.$AN?.4
MH^P84%!T R?X5N4N9S4)6=^]KKU'?>QQWQR_9I\-_"+XZ?!3Q/X)5O#NBZIX
MVLX=0\-6K%;%[K9(8[F*+.V-@@D0A0 05P!@Y]5UK_E(-X:_[)[=_P#I<E>>
M^*OA3^T!\6OBM\*?''B^PTG2M(T#Q+!<CPEHUXDO]GVNTF6ZN9W91-*"J(%B
M#  D@#+9]FU3X=>(;C]L31/'$>G[O"]MX.N-*EO_ #HQMNFNED6/R]V\Y4$[
M@N/?-.4M$I2N[,+]V>M>(O#NE>*]%NM)UO3+/6-+N5VSV.H6Z3P2@$$!D<%6
M&0#R.U?*O[!?@[PEX6_9X3QK#X6TB+7[>XU@2:K;V$*7KPQW<W[KS@H;;M10
M%SC  [5]=MRI'M7B?['_ ,-]?^&'P+LO#GBK3AINJIJ&H326IFCF'ERW4LB'
M=&S*<HP.,\9P>:Y8RM2DK]5^I"?NL\O_ &6_@AX8^.?@V#XS_$_3+/Q]XM\6
MF6XCCUN%+NTTRT$K+%:P0OF-0H7.<;LL>>N6?'+X7Z%^RWXJ\*_%GX:V*>$T
MFUNST?Q'H.E*(K#4[.XD$0)@!"))&Q!4J!RQSZUIZ'X%^,O[+%QJ.C_#GPWI
M_P 5_AM<7,MUIFA76KII>I:.TCEFA6:4&-X 22H^]R>F,M?L/AM\4_VA?''A
MO7/BUI&F>!?!7AV\34[/P58WZZC<WE\F?*EN[A5$9C3.51.IZCH:ZN9\[FY>
MYVOT[6+OK>^AQ7B+X,Z-\8?^"AVN)XFMEU7P[H_A2QOI=(N#NM;NX\UTA\Z/
M.)%7=(P5@1G&>,@_8/AWPWI'A'1[?2-"TJRT72K8$06.G6Z6\$0)+$*B *N2
M2>!U)KR;PU\._$.G_M<>-/&EQI_E^&=1\,V&GVM]YT9\R>.5V=-@;>,!AR5
M.>#7M=<U:;ERJ^B2)DSX\_;P^(%W_P )1\/?AJ=-\7:QX;U[[5?^(=.\#VAN
M-3O;2 *%MU 92(G=_P!X00=H]^>'U'5O@AJ?AMM#D_8R^)D5H8O*\ZV^'J0W
M8 [BY282[O\ :WY]Z^F_VA/@SK'Q%_X1KQ/X,U:#0?B'X2N7N]&O+Q"]K,LB
M[9K6X ^;RI5 !*\C (KA+GXI?M0ZE"VCV7P/\.Z/JA C'B6_\617&FAAUD^S
M1J)]IYPN<COFNFG-<D5'IOK;_ARD]%8E_9"O-<\>?"'Q/X1\=^'/%":)8WL^
MEZ</'FFO:W]_I,B QK<!LB1E#-&64D$*O0U\\W.I>)-(^)1_8XM_%]K%X5O+
MPR1>(#>,VH6VBM&TQTC!_P"6Q V!B3^[<#;@A1]91Z'\4?A5\ ;JRTV_N?BI
M\3Y_,=;V]E@MH$N9F)+X=E"V\.>$&6(7  !PO)VO[%.C_P#"A[CPG=:I))X^
MNKS_ (2";QP%_P!,77-V\7:L,,%5R5"@CY,CJ2:(U(1E*3>C>GKW_K<$U>YR
M_P"W)\/X].^$?P=\&>#Y4\+1Q>.-'TW2Y[<[?L/[N9(W4D\E3AN>21W)KU3P
MG^QG\&?"GA]-+;X?:)KTK FXU37K*._OKF0_?E>>52VYB23M( )X &!7@7[3
MUOX[^(/P$^#NC?$/3Y/!OC.X^(6EZ7=W>G7$,RLQ$R+>6Y1VVA@0X5]K*P(Q
M@ GU#_A/OVFO L2:)=?"G0?B=/$/+3Q5I7B2'2HIE'"R36LREE<C!81G;G.W
MC%)J?LU&,NKZV_$-;63,;X5^&T_9I_:J7X7^'+JX;X=>+=$GUO3]%GN#,-(O
M(9<2B(L2RQ.IS@D_-]*S/@[\+=%_:H^(?CGXF?$NU7Q3:Z1XAO/#_ASP[J!\
MRPTZVMF"-(T!^5I9&R6W@] <=,>D? WX)^+['XB:U\5/BIJFG:CX]U*S72[3
M3]&5OL&CV ??Y,3. SLS?,S'OD D<US.M?"WXJ? /XC>)O%GP@L-,\:>%?%%
MXVIZOX(U*\%C-%?, 'GM+AAL7?@%@_3' /&TYTVU&7O66OYZ_J%_/4YS]L7]
MD'P&GP6\7>*O!6CV?P_\2:/I%S,;CP] MG#>6HC8SVT\40".LB9&2,@A3G (
M/._M7Z;J>M?LI_L\Z?HM^^E:O=Z_X;@L[Z,$M;S-:.J2 #G*L0?PK5^-F@_M
M+_M*?#'Q'X?E\&Z3\+='DL93)I2ZU#J6IZM*HW1VZS)LAAB=@ Q8@XXZ$@]W
M\5/@_P"+O$GPI^ .C:=I'VC4O"_B/P_?ZO#]IA7[-!;1%9WW,X#[3V0L3V!J
MXS<5#GDFT^]^@T[6NSI]$_8K^"^D^$?[!N/ &CZT9(RMSJVJVJ7&HW,A^_*U
MT1Y@=CELJRX). *\=^!?AGQ1XP_9+^,7PFT;6;AM6\-ZQK/A'1[Z^FP_DH%,
M4;2#.!MD*9_A!P, #'VC7S5\*_A=\3O!'A'XXKHZ:?X>\4:]XVU'6_#]QJNR
MZMIK>3R3&SK$Y*!PC+S\RYR5['GA4E*+YI=4]25)]3@?V9M/^#%WXL\':#+X
M'N/A'\9O"5L8Y-)F1K"XU-1%LE<S(0M_"Q7?EB6.S.-N=WHG@W_D_;XC?]B9
MI?\ Z/DKFH?"WQF^/GQ5^'.H^/OAWI7PTT7P/J!U>34(=:BU&YU*<(4$4 C_
M -5$QP763D@+R2,5Z3X:^'?B'3_VN/&GC2XT_P OPSJ/AFPT^UOO.C/F3QRN
MSIL#;Q@,.2H!SP:TJ25Y-O5KO?KW&SRKX*_#;0OVJ/'7C7XH?$>TC\5V^F:_
M>:!X=\/:F!-8:9;6[!&<P9*/+(?F8N#T&.V)_P!J#X!^&?@[X+O/C#\+M*L_
M /C/P?&M[_Q(H%M;74;57'G6UQ F(V5E).<;LJ.:W=8^&?Q2^ OQ"\2^*?A+
MIVG>./"?B:[;4M4\$ZE?"PG@OF&'FL[A@8U$A +*_<<9_ASO$'@WXT_M3"ST
M#X@^%].^$OPW6XCFUC28-8CU34M76-@ZP"6)1''"64;OXN.XS5<SYU-2]WM?
MIVL.^M[Z')?M>:#<_&KXM?LQZ=IVIWOAZ/Q#_:CS75D^RYBM9+6!YT1AG:S0
M^8F[MNS7L'BK]B/X,:Q\.;_PQ:?#S0M,W6CPV^I6EDBW\+[2$D%P1YC,#@_,
MQ!QSD5/\5?ACKVO?M#? CQ%HVEK)X<\+-JXU*=)8HUM%FLUBA 0L&8%ACY <
M8YP*]QD!:-@.I%8RK2C&"@[6_P V2Y.RL>'_ +$?C;4_B!^R[X$U;6;J:^U-
M;:6RGNKAMTDI@GD@#,W4DB,9)Y)Y/-<M^U3'J/Q0^*7PR^"Z:K=:+X:\4"^U
M'Q!-92^3-=VEM&I%JK^DC-A@.=H].#UO[&/PY\1?"?\ 9U\->&/%6G_V5KEG
M->M/:^?'-L$EW-(GSQLRG*.IX/&>>:L_M&? [5?BE'X:\1^#];B\-?$3PE=/
M>:'J5S'OMVWKLEMYU )\J1< D D8Z'D$YHQKR:>EW;] TYF-N/V,_@?=>%SH
M#?"_PVED8O)\^.Q1;L#U^TC]]N_VM^?>O*_V*?A_<?"WXI?M >%[G6KOQ!_9
M^I:9'#J%^Y>=X#:,T*R-_$R1E$)[[<\=*WA\4?VI+ZU.C1_!'PWINKE?+_X2
M>Z\512:6'_YZ?94'G[?1=V:D_9(^"OC[X3^,OB_>^.[O^V;KQ%J-G>PZV&C5
M;]_(;SBD2L6B1'<HJL%^51@8J[RC3FISO?SOU0];.[/'_P#@GW^S+X4\<?!V
MP\:^/=-M_&DTES>6NC:=K40N++3+5;B0.L<#@H7>7S'9R#_"!C!SW]Y\/="_
M9[_;6^&K>!M.C\-Z+\0-.U/3]6T;346&RDEM8A/%,(A\JL-V/E  &<8W-GTS
M]C'X<^(OA/\ LZ^&O#'BK3_[*URSFO6GM?/CFV"2[FD3YXV93E'4\'C//-)\
M7/AQXB\4?M'? SQ1IFG?:="\-2ZPVJW?GQI]F$]HL<7R,P9]S CY <=\"JE6
M<JT[RTU].MAN5Y/70\YD\#V?[5G[3/CRP\=%]1\"?#B6SL]-\+F5DMKJ]EA,
MLEW<Q@CS"H;8@/RX)XP6W=W\2?V0?AUJWAZXNO"7AW3?A[XLL8))=+U[PS:1
MV$MO-M./,$0 FC/1D<$%2PXSFLWXH?!SQ]X-^+EU\6/@])IEWJVJ6L=IXD\*
MZS,T-MJZQ#$,L4@XCG4?("V%P>?X@W.^*]6_::^-WAZ^\,P> -'^#%C>P/;W
MNM7FOPZQ>&)E(86J0!55R.,N1C.05(!I7E+E<)V2MUV[Z=1:Z69TG_!/=3'^
MQ_\ #U3U6&Z'_DW-4?\ P4.1I/V/?'Z(0&9;( L0!G[=!U)Z5TO[&WP\\0?"
MG]FWP9X5\4Z?_9>O:?%.MS:>='-Y9:XD=?GC9E/RL#P3UKF?^"B2[OV._B"#
MT*60_P#)V"H33Q5U_-^HOM_,T_AG^QI\-/#.@1S>)O#6F>/_ !9?*MQJWB#Q
M/:QZA/=W# %V7S0PC7/"J@ "@9R<D^?WW@/3_P!D[]I3X>OX#WZ3X*^(EY<:
M5K'A>.4FUCNUBWPW4$;']V>-K;> H  Y K<TO5OVB?@KI%IX>L_ VF?&W1;:
M-8M.UJ'7H=&U!;< ;$NTF4H\BCY=\9^8 $C)-:7PY^#WQ#\>?%[3/BG\8)=+
MT^ZT.WFA\-^$=%D,\.FF90LLT\Q \R8K\OR_+P"/07S25Y3G=._7?MIT'KU9
MX5\7?B%IOQ$_:F\66/CCX<_$+XG^#/!#V]GI7A_PGHIO].%X\0DFN+Q=Z!I/
MG"HK9&T'CGG/^)FJ?#_Q%HQN_!?[,7Q>^'7C?3PT^B^(?#?@--/DM;D#Y#((
M90)(R?E96#95FQ@X-?1OQ(^%?Q \"?%B_P#BC\)$TW5[K6K:*V\2>$=7G-M%
MJ/DC$,\$X!$4X7Y/F^4@Y/(K U;5_P!IGXU0#P^G@W3/@3I-P=FH:_)KT6L:
MB(B1G[&L "H^ 1N?INR"" :UC45HN.R7>WKI_5QWV/.OVG+/7?CQX$_9DM/$
M%K?^%-<\1:]!%J]L$DL[BV+VS"Z0*V&3*^8 #V/>O4/VC/V8=//[.FO>%?A1
MX.TG2KB:6SGN]*TM$L7UFWMY [6\DRKN9F4-AG.23R>3GI_C=\,/$7B?QE\#
M[G1[:;5[/POXA6\U2\N+B)9$@%L\?FMN*[V+$9" G)SC%=Q\9?\ A847A%;K
MX:'29O$-I<QW#:?K"D17\"Y\RW60$>4[#&'((!&#@'(P]JUR*+M_P_4GFVL>
M,?LRW'P1\7>/+C6? WAN;X;>/],TXV&L>#9+=M*F2,LI#SVBX28J>DN"1Y@W
M8.T+-^S_ &ESJ'Q6_:>M;*Y-G>3>((8X;A>L3FQ4*_0]"0>G:F?#GP9\4/BE
M^T-HWQ0^(/@C3_AE:>&M*N=,LM+@U6+4KS4'GQN:6:+Y!$@R57 8,3U!S72_
M"GX9^,O"_CCX]ZD88=%D\3:M'=:!J%P8[F-L6BQB5HD?=A7'*MM)Q3FTN;7H
MNM^JZ]1OJ?.WP"\$_"KPG-X3^&'Q1\%3?#WXP:1J(NK'Q.2]NVOW"REO,MM3
M3#2K(&VF)V'W]JC</E]0_;O^&_A+4M.^'^M7?A?1;K6;WQOHMA=:C-I\+W$]
MLTK!H7D*[FC(X*$X([5C^-_"?[0/[06G:!\._&_P_P##_AK2['5+6^U/QW:Z
MS'<)<+;R!]]E:@>;#(^, OP S [<UZ_^U5\.O$/Q(\.^!K7PYI_]HSZ;XQTK
M5;M?.CB\NUAD+2R9=E!P#]T9)[ UHY_O8R<M>NMU_3[#O[R=SSS]L[Q /@G\
M(/"O@OX?Z/>^'[;Q/KD>ER6G@7346]CM&#RW(LX4"KYSA2 1C[Y/O7F.CZI\
M$M%\+QZ$G[&OQ.N[9(O*-U>_#V.>\?CEFN&E,FX]<AACMBOK+]H#X-CXU^!8
M],M=5DT#Q!IMY#JVB:S"@=K*^A),4A4_>7DJR]PQKR__ (6C^U!I=LNC3_!'
MP[K>JJGE_P#"3V7BR*#36?M*;61?/VCJ5SD]L5-.:=-);]=;"B]#)_8IU[6K
M/4O&_A"+PAX\\-?#NQ\F\\,Q^/-,EMKFT1P1-9I(S,'C1@I0;BP5B#G&:\W_
M ."??[,OA3QQ\';#QKX]TVW\:327-Y:Z-IVM1"XLM,M5N) ZQP."A=Y?,=G(
M/\(&,'/U7\#?!7CSPQH&K7OQ&\6+XE\4:S=&\FMK)2FG:8NT*MM:JPW; !RS
M<L>3SDMS_P"QC\.?$7PG_9U\->&/%6G_ -E:Y9S7K3VOGQS;!)=S2)\\;,IR
MCJ>#QGGFE.K:,^5ZMK\G<'+1V/,[SX>Z%^SW^VM\-6\#:='X;T7X@:=J>GZM
MHVFHL-E)+:Q">*81#Y58;L?*  ,XQN;-A_!]E^U=^TEX^TWQJ\NH> OAW+9V
M-CX8%PR6UY?2Q&62ZN47!?;D(JL2O7_:SZ'\7/AQXB\4?M'? SQ1IFG?:="\
M-2ZPVJW?GQI]F$]HL<7R,P9]S CY <=\"L7XF?!KQYX/^*VH_%;X076FW&L:
MM;0VWB'PGK1,=KJZPC$4L<R\Q3JI*@GY3GG'(84T[._O6W\[_P"07\]38\=?
ML8?"3Q?H)M-.\':7X-U:']Y8:[X7M(]/OK*8#Y)4DB"EBIP<-D']:X+]LSQQ
MXF^%OP4\#>$+'5/$6LZUXBU&UT+4-5\/V@DUBYMUB+7,EO&N )Y F!@C&\XZ
M9JWJGBW]ISXK:?+X=L_AOI/P;^U+Y=QXJOO$<&K201GAC;00*")<9VES@>H/
M(]%^+7P%E^)GPCT?PS_PDU[!XIT%[6^TCQ5,JO<1ZA;K\EQ(H&&W'=O&.0Y]
MJF,G"4?:RNK][BV:NSY@T?5/@EHOA>/0D_8U^)UW;)%Y1NKWX>QSWC\<LUPT
MIDW'KD,,=L5Z=^Q'KVM6>K^-?"$7A#QYX:^'=B8+SPS'X\TR6VN;1'!$UFDC
M,P>-&"E!N+!6(.<9K4_X6C^U!I=LNC3_  1\.ZWJJIY?_"3V7BR*#36?M*;6
M1?/VCJ5SD]L5Z=\"?!?COPMH>J7WQ&\6+XE\4:Q=F\FMK)2FG:8NT*MM:JPW
M; !RS<L>3SDM=2?N-/KYW&WH>FT445YQD%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !2,NY2.F1BEHH \V_9V^#G_"@_A'HW@?\ M?\ MW^SI+E_M_V;[/YG
MFW$DV/+WOC'F;?O'.,\9Q7I-%%5*3DW)[L;=]0HHHJ1!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >:_&[X-_\ "Y(?!4?]
ML?V1_P (WXGL?$F?LWG_ &C[.7/D_?79NW??YQC[IKTJBBJ<FTD^@PHHHJ1!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'[1'P?_P"%
M]_!WQ!X$_M?^PO[6$(_M#[-]H\KRYXY?]7O3=GR\?>&,Y]J]'HJHR<6I+=#V
MU&0Q^3#''G.U0N?7 I]%%2(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>pgen-20201231_g9.jpg
<TEXT>
begin 644 pgen-20201231_g9.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &] ;P# 2(  A$! Q$!_\0
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MZ/=[AH>E[J,^U>:?\,P_!W_HE'@C_P )VS_^-TG_  S#\'?^B4>"/_"=L_\
MXW1[O<-#TS=[4;O:O,_^&8?@[_T2CP1_X3MG_P#&Z9)^S3\&H5RWPJ\#@?\
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M)(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8\;_ /@9H7_RSH_X6QXJ'_-&/&__ (&:%_\ +.KBY1=U_6E@E>5[]6W]]O\
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M'5-C#UXXH ZW2;Y;^QBF4YR*R_$WCOP_X.M_-UK6+/35[+<3!7;C.%7JQQV
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MGQ-:7'AN/^TY8+@-''<1%@P!Y/RD$\<]JZO4=:UCQ_XR-]K%K;V=VN!)#"&
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M\<U3K)61'<>]6XYJR,S15JE5ZI1R9J=6H MJU/!JLKU,K5 $E%(#2T %%%%
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M;44U6XY,UC0S=*NPS4M2#35JF1JI1R9JPC5(%M6J2JR-4RM4 /HHHH ****
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M5.C53C:K"M60BRIIU1JU24 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCVK9M/X:Q9#-FUK2@^]6;;_=K2@^]63$:=OVJ]'5&W[5>CJ"">.IUJ".IUJ
M'4444 %%%% !1110 4444 %%%% !1110 4444 %(U+2-0!\F_MY?"$^(_"MI
MXUT^+=?:./)O0O5[9CPW_ &/Y.?2OS]O[*/4+26VE&8Y%P?;WK]I=4TVVU;3
M[FQO($N;.ZB:&:&0961&!#*?8@FORI^/_P (KGX-_$6^T9@[Z;)_I&GW#?\
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MU!&O%64%0R":.I5Z5&M2U(!1110 4444 %%%% !1110 4444 %%%% !1110
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MHI]-6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5&PJ2FL*
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M\<-6XH:BY(D,-788:6&&K<<=3<!8XZL(M(BU,JTB!46IU6FJM2+TJ %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K>WD.G6<]U<2+%;PH
MTLDC=%51DD_0"OE]?^"GW[,LD@0?$Q02<<Z'J8'YFVQ^-?0_Q"_Y$/Q'_P!@
MZX_]%-7Y'_\ !.UOV=X_V?\ XA/\:AX&:_\ [0<P#Q +8ZF;;[.F?LN[]_\
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MYFEO=YKV6NOFNA^ROB_Q-HO@;P_>Z[XAU2ST71K-/,N+Z^F6**-<@#+$XY)
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M1(P'&?-;'$=?<G@?]EOX=_M!_LQ?!.T^)7A9];?1?"]@+6&2\NK1K=I+6 2
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MC9A_=4YX!K\P?BM>?![Q#\$='/PQ^%GBC3/$6DM;_P#"3>*]3N)9;9&*%#&
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M_4N6LG+O;\K"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4FVEHH 8RTQDJ:DVT 5C'3"E6F6F
ME: *ICIICJUY=-\N@"KY?M3?+'I5KRZ38:JX%7R11Y(JUL-)L]J+@5O)%+Y8
M]*L[#1L-%P(/+]J<(ZF$=.$=,"'R_P :<$J81TX)4 1+'3U2I%6G;: &!:?M
MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3;2;:=10
MS;[4FPU)10!%MHVU+10!%MI=AJ2B@!FWVI=M.HH 3;2T44 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>pgen-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pgen="http://www.dna.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pgen-20201231.xsd" xlink:type="simple"/>
    <context id="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61afe01c77bd4075ac870cbeb744df69_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4338078300e342f196795af559ba89f6_I20210215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2021-02-15</instant>
        </period>
    </context>
    <context id="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2d32b7d02bc4077abe174a0c01bf2da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4535941e16234d449e24cbb104b312eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if90df5438bc447dc89f799623be8dd72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d688646c4e54b0b9ff3d9d869a84f8d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia49fe028d6f84a65a5e7dc2e03d52395_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa378b75eb8240abb90e3c3a90199627_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia63f92b55b3047a6985c52240063ce82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2563c9235194a59932361f4fd160992_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i39c945d017804d08b6055d50caecddfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id1416fdd04854b98b98cc981399bba77_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f67f091705d4ed88119185ea9668127_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i17726fa9a8714d378f70b578726ea61b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifaf2a0142d19421f844e564b6e81c75e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i53867cd3f9c14cdebf63cdf61a3ccdc6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i867e347749054e8a8f0790f939874f83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia53c6ab11e9c492084aefb26999ce44a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib4c80061711f435bbcfbfe956b9bc43c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia2d62e92e6fa4e01ac83a1dcdafa12a1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i44c47c15a0a441909e132dd1581ceaec_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3ee3c718a7f048cfb2836108df24bc3d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0e53100af51f408a935d99fdc04896b2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4e07b0b288a443e6a8678c87bf210341_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iba5ee3e148774f35bb26b15071f0a9c9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4b48ec0589f54ea18ed709e5622f1f36_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic58e0c90d812453b961a416919b494e7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6edb27434f8c42f4b2dafbfd636c960d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic9ac13fe6c894e4d8bb963cd6fcd7ba1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7328bdd74884f999183a972e9e74902_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i526adef7e72140d5b11b92f77958580e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7dafd01f416a4fecabcd3625798ec85e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i25d775ca87aa45c7b569ef0164d07e18_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i62afd0579ab049588695814b856db8fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib00106458d554c29aab7306c704ec827_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e57cab296f149399d486ae6ead87efa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i190b69f516da44baba7e77735b9083e9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46f4056c01d04eeb92c3e2110de99905_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04a7a2917a5840d1828b5b69ba7afea7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice0df81f9c8d4e7097109272f7381494_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1053dfe438874cc9b2cd88769aca7327_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64c7b560b46b448dab6e990b87500645_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75596e499ae443c3adaaf6abf5854f90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ce876c2b26448c6b08a1b65b0889bf7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5f5c113267a4a07b0fd84856590b114_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2fae6176c89149ef8b0e8046c310748e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i762149a5fcb747d7b935b70a375b135b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5035cb92632a453d81e2f99ab37a6a4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife91272387c04b268c5f208e51e80445_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc0677b8b8ac4e0194068bb8d9fa9a09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i17f6c337649843ef9b6c799eb5e89d84_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:ProductsandServicesRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e8cb877d0184774ae2285744aa4fce4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6a4041a8bb484da3b179334191b0137d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8952cdcb9a6e414eb3558452807047c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3ad6258403540099941f2a068f4043d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ba88e8a7dd14e0e90467b7df8a754de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie518adbaa2914c83a75398892dc33f68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i027d6d87c78e4317a791117a2393e261_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d3ba94d22bb43898d8e8b5658bd229f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91fece37ad5247789405374ea393337a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84a4580dd157421b961abbc9269d361d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36032ed843b643ee8327a678783a2ac2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i486b675333cb4c5b91c24f42597dc946_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BreedingAndProductionAnimalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0750ead12ac4214b42916e3ed24bdfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BreedingAndProductionAnimalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a5e98f13a3a461ca2c7fbf143a0e4cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pgen:ComputerHardwareandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ab8005306a844bda35c05aa23ceb1a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pgen:ComputerHardwareandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic649546dedd34f7e81b3041baaf93e20_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id068240ac9514712ac2777d3f353304d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i321fedbbadb34d4087e52ceb65be7798_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11e11947645549f79ae1c1b067e15412_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaea8840b9e7545d180e072548e790580_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a99bff0ee894d4ebc0529513dfabc6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b61e5b1fd0b43908fdd386d73838549_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if71c2fc0f42a444597ac62521827f72b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1657211515ac4efba0ceb6486e26a0fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie92ebbe68805472d805003395a5e5588_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:MBPTitanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8a892879d07044f58213c5a70dccecdb_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ie5536916a8c741d08eecaed7c735bd94_I20200102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-02</instant>
        </period>
    </context>
    <context id="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pgen:OkanaganOxitecFineChemicalsAndAgBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87b81adc30c64968b22a72162d34e9c2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1656e2b95eb4e86b30c7f13bec36e35_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i21471e6197b5427aa9b34d6b3debcbe4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b06f8ff3659402fb91abb688b2698ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3da9f131522486b89e80d1abf10d1c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85eefc0df3064556bd575eced34b22d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3ea4810310f41c692ba79c0e33d366e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i76f58f326e0648ddba9b773ece024426_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf18b6a46ee942b59306c66d27119d0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ca877cac87e47049f837bf9595be757_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie008c068818d4427824c7865a4533062_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib6652a9a128043e1991ddf1ffe2cf37e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:RelatedPartiesAggregatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i54ddb7daeedd421691d65e569834db38_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pgen:OxitecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:EnviroFlightLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pgen:TSBiotechnologyAndEnviroFlightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib745c0a5e3374688a77e7b600fc20292_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i000d1fd7f4c64d64832e5ec0e8209d77_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i0ab86611cff54ee49aacd99b0b4f6651_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i6a0d69f64390425490a158f5ad474449_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i1c882e708e9042fab6cf9bdb465e7487_I20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-03-31</instant>
        </period>
    </context>
    <context id="id6ad8e1a4d324efba50a474ce9400787_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i9a9baf13b1f64feeacf1476a168dca43_I20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-03-31</instant>
        </period>
    </context>
    <context id="i417eb3d3304845829b5d8b4c5c5ba767_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9405291ea07342cfb48d39ff6203c28c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84f4ceddf2d74e208b2f43425f7a604c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="ifcde56c84e2945f99d5ff518fcea780f_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i02736ce52d7d455880b3764529cb4205_D20151201-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i6ed29543f11f4730be40ffd5240b7e9d_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i2af9e206e25f49e585e8fac9b7a42c1f_D20151201-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AllInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i3dd86fd0107044a1afd4581beb90db93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22bc12535b5845a98af2708db090b1cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b676559c5894899a277cab47b7d3686_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pgen:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b58e935da8149088da93a6187e4101f_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i08141bec58644c55a3f1a64ad4aba2ca_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i37eae9042f0b4b7991fad96ce5cd70f8_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i38614b5cdd4748fe900bdb143da08bc2_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ia18b9f13ca97407987783276b9377121_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ifac2f1a572c141fc8915df3c7e0d761b_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="ia04474b4f60340a5bfef5669908aca1b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ea41f0f9f8340a5ac240c128def61b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iebbb27ff74fa4587a1663d2f6c036f55_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib3fe0767e9cf4dcd85529165525f8758_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2655f8d02da8422ba8e92858830a2d09_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9caeeb9311142fcad4dc58cba84fe45_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1a58ef1f100e41ec83f7fadf1f120f61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3225f360239c4da99ac5a0f30e582367_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie6b7ccf82abb46088675f71ca095ea7d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i61c5e81e3c27464cb9bb433ba78dd8ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0a5d57f00774002911cf03b4ecb5d06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c6a3055772b4276a974fbd3f46d80af_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonT1DPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i657bccd941e9476e84df5f1bb47c01ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dd6ae11540d4a89bdea2402ffd96b43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i271b77f3585b428ab9b387bac0632795_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5465b8e9f47c478a9888a2bf4f068315_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13a7a75f53fb43bd8a86301d20bd199f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i615893ff388945289ba1d816cb0d5415_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i826d35e5de9342c1ac0b82187aa61817_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb0b6fb6681044eeb9ccb81e27858225_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5d3047a704254986b92408ff7382d63c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia38b8c82221e4b158e81089d5dec6cc4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8bc53c28fbc7455ea6911f3515a2093c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2da118b80dc492fa5a08a890cbbb15a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb26c32900c24b22b16c104fc410013d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a7cf1aab2104d78877dc52205013114_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia89a9eb5dec3401bb6b1302d72d9b091_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76d02ad8dbd04496a07bb96530bd6fe0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5fbcf7e50ae94bdb84158a09d5e84357_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i802c849fe1f7499fa51a352c7c1b630c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia75a4228d5b9446f82180329f657e205_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iebf2e5287fca469988ba7db1017cc983_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d624d8cf2ba4c258b6200df93fe4dff_D20110101-20110131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-01-31</endDate>
        </period>
    </context>
    <context id="i4c23dc33d54d41fbb6d5de96a2aa6645_D20120101-20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="i8df2f4bdfd5a4853b136cd50ea2e2827_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i9edf0818b0a147da90be9143a66128d0_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i2b584f29328e4ebf97207baf9e676a54_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:ReacquiredInProcessResearchDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i3e6a0b31f0c84cbea171358d7cdb8c59_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:TransitionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i390dbfc7bee54d449d2489dfabeb4caa_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">pgen:TransitionServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ife505a4aa67447108ab17810720818e9_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i6ac36b06d9ed4949b460f25d930f6824_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ib33d19e6739641da9b757a245fd3ec93_I20150301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-01</instant>
        </period>
    </context>
    <context id="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia684f990dec54beeb358abe6adf669ab_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:AresTradingS.A.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i507644cf395a4e4eb490f23ed7a3fb54_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="ibc9c931963d5454d95e8956328330cee_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i659785a3f54a436ebb55a8cdf1f7716e_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ib7fde582b25949f282255f9473749cb4_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:GentenTherapeuticsCRSBioAndRelieveGeneticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ife64afba6e6c4c7f9966578282bdffdf_D20150101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i59907113dd1d4344981247aabca5ca34_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ib7c97ac54869431f9460b1de625fdd9c_D20121001-20121031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-10-01</startDate>
            <endDate>2012-10-31</endDate>
        </period>
    </context>
    <context id="i1461c02f7c1144288c060625dfec3d80_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i07cadd8e29a94d468d706d75d4fa4499_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib8dfaf8751c2466e8b7d83681e50ce63_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i119157bf1fca4e4597d6d2074e4b318c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i768914f9023446359debd6de8db387bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0886f93ed7be4cb289c37677075c1648_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:PrepaidProductAndServiceRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24eba9045a464d27b051cf73783cbc93_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:PrepaidProductAndServiceRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51f077edbb924395b6f3b5746a7091b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:DeferredRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e4b2e1046db40339eccf1d387df8274_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:DeferredRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i762e74716595460bbc13425c76eaa2db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a8f257af9be4b51bb429c76d609121d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e4a4131130d462a9487459be4d56bd7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OragenicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9eb44801a44b4a62ad0fdbd70e99dccd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4820c653de64b4b8753948eb803072b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb4353ff9fff4974bf8fc31f026182f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8484095ee2884725be04bc8135beae81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dece6850a884e9aaa7eb9648a40bb74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34fe2362ff8a42598a97fb6bdba06548_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:IntrexonEnergyPartnersIILLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i066d432119f04600ad1a8035bcb6cf5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6512fb771f0b42ee964e35ec040d3d77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id87b208d51a248b49c170094f36869ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dd853c6b5c544c1a4eb81cd5293cada_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7d34d40eae14e879388b762c83dc166_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie65a1530d1d0476ca8be03ad2268129a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestStartUpEntitiesAggregatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23f70a5b8fd749b8b7137c61cfab72a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5561d3f0a6bc49eabcffabca3089383f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie98da80d8ac14d7791e297eacb592f73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:OtherCollaborationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6774b04fc34844d7bb0f5cabaee47b02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i559d7af0e8444c759749c165c72c4dd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08d7c23fc413485dac1d297dad0adfd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0d533c22a81455786266a631fcc3c93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0efc7bf936b3476083f68d4965ac2088_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i625594ecb5a643c1be9c45946c3fe6bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if05375e0f8b94091a3e217e403a5e204_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e5f8179595b4e5ba09bd4c1c6d600b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd472d7ad35f4a15b21d2195d5808bb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcfedad06ddd479bba91d37f6def04da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f1c801fb36143c49fd0b608bcfa5b48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia61312b716ae4e47b5211d08c39bc9a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i897525fafdb1444eb6402bf2a7754355_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida01d18612bb4a56b451ba944d2f4a9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6fff13a081c481cb9e48baa81cacfaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7aae1a7de0b42298d4467fd3ec004af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia72f10ede16740f6939170db24c97f9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id33a83c66e5e4d04930c270f49fcf9fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9143d9e97c0c469295ecf8f8e86bf4b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a32497816a24b0e98bfe2b91cdb5f5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03f0abd7a34b402a805fc120d404fcab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2add7e1ec07f40dbb767635c38522992_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pgen:OtherFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2add8a116b4448d19d15dd64d77975a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9829035a8a2f448e9920c55d9173e8fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i27aebe7d32b349b39eabbc338188b25c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i400855cb5a3d4e6582b7e57125c949fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ided6796ecfc64dfd806da8fc7d8e889f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaff95dd2e5e6493cab06cdbfe40f221f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88fed49ad0634fc1978b61d0cad74161_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:SuppliesEmbryosAndOtherProductionMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f1e8bcd17ae4fc0b556dc1a59ce8c5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:SuppliesEmbryosAndOtherProductionMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e13e1046d1a4e8d8a5d3ce4b8599cde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:WorkInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i148174464dab4df3b6cc16ca4f94f20c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:WorkInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9cbec292daaf4a33adb6add3983c2aca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:LivestockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id66643537bcc4586b5c8295486ad53db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:LivestockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i917953d1a25e429ca029530f8e586cc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:FeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa8e97e073a840e3a917dd25f9403665_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">pgen:FeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i827c577308054c018d5e48fada14ff8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6fc55d839644cba90653e38f783a62e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f3d42982abc4d50a68c8e28b6a8c52b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id59cb5726db6446eb9557596ccf3c7f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia7e33c160a5e4e85abbb9e977904ab51_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if23ada0abe5047e9816a9b05e4ac3a06_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia2462eb080f5476ba12592a72425bb0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:FirstNationalBankofOmahaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebe34c2e16ef4ced904a0a453bb78be8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:FirstNationalBankofOmahaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7417cafe9a0140cdb536d3070b429916_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ExemplarGeneticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie20ccfa747e64113890f0974c9cb925e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic1adbe486ee94be59a3ea92894502ff4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i933e7cc3ab3e474b9117c918400f0682_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1b7410140b740b2845853aabed50d7d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i792bcba573ad43159c20ae7da25f6f15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pgen:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifac99bde42eb4b6eba9f0cd1ac7f2e1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pgen:OtherLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17202f32a1d645efbfd56a212e966489_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ibf57ef00bf69495496f71af763419a23_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea183b22e6204e749452fefc61666933_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:A3.5ConvertibleNotesDue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i300109a3973b48cfaf6c87f24830c1e8_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i5dcdccfde7b24e57841cf202a0c22c5e_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ifbf7a9ed58fa4c19bfac3158a4004562_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:ActoBioNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcc2b6cdd3fa4b82a31d23fe1ca4681d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddfb43cef36f48d58869fc13628164ec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c1c0bfc1a8642e5b23938f795103bcb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:PrecigenActioBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i09db21ffd978403fb95c9f969486cebe_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:MerckConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i998ab898facc4cc6929d5d5803057739_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pgen:MerckConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="id1f9a8543e394b0089b989601e44377b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33041383733943a0bdbb0c01bba1ae14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pgen:AmericanStateBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:TransOvaGeneticsLcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebbd89e79742463bb7bb2c8072e4d28d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27fa0174f15049ad925a5c7467f8806f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7249ffe7fdf04fc58a2bebc05c00ac77_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i86b9331a29684594bdc6ff0bcff164e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib75f9587ce8b496db2609e0682fcb9b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd35f7da52004f518b3b73faaa279403_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id2e86fa379664890bce6f8505ae63863_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if94e6997c4484c4fb71d5424d9a823e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f6024ac23c341aab2161aee0517820f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2140f32269b445a7a78f85b8ded04f8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i06c2f36dc30c4039a45bf45425bd3b3c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i846cd2227b1f4f05943d3faf0edb56d7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dc0ff9076414c038f13048e82021a34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pgen:GeneratedAfter2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0274c8f694d3486099220e08fbba1fc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc450189ce644024ba68868dd2551779_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ForeignSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:TSBiotechnologyHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i9db2284265074c3289f29fb1232d187f_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i9ae95dbfa1fb42c993e1fed2a97942b1_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AffiliatesOfThirdSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i938616e63e9046f9b8b561f8f75cd7c5_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i5155424e1c244be3a4c16ac6cae35737_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ic3792a1ad213496a8d41cfdce5e38535_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i184114ce7b3f42b58ddf4c429939454e_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ie79bf4a7c0c64ef68087d0bb20da73a2_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pgen:AquaBountyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="icf7bc616c8ee45679cdc730430d0f09a_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:AquaBountyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="icf169456400e4ce8aeed85e7ca335ce6_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pgen:AquaBountyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i8d40ed18f6934798ba07115922d698e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb78e848d959475a8e60240fef86d616_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i258e6ee1096c48f3bafa2a89b56d3570_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7408085271934977bcbe87b303ee566b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i507bf64ce91c4dbe855ace68943a9ff1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0809b9c1122b4425b82973aa53316a00_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if630c00264644a5f934f6c52739e171f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id2b4d072e6db4429be9358d98ef2695d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e6fd3bf62174baf8ea4e643cd5ee2a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7bc9ff4a3e6143fe87ea8e2e89c9f0d2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pgen:CostOfServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8b1be10c992143819d5ff797b4bdd3b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb66d1f63fcb401b899173c39dea5ef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie12981139b134339950cececc0d8cefd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i793cc475e5a349a38e9012cbdf287644_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7db0821a8b444dd48ee9d160de991bf8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b44220e572445a7aaaedaab0fba9599_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib33202a64c764d2294be298ec498bf0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dd4e1dad5ab4578a892678be6523d79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id04130b19133407c8ffb14a7cdb84896_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2008PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1db41e22786f4f8e803bd5da7ae7655b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2013PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dfda69a28ff4552bd02d489a6714039_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlan2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3ec59376227463da776d509a74f26c7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i59afefa3805d493fad5e5f44d615e29c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i523c931240534675a00b833db69b7b7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b3bd75c2af44de39219feee8729308e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i661dc00e8d3e4137b45d1081c39df7fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7c5460f623b41c18486f8f337c91484_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7451bc6286184839ac5a35196b93e9b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i10990e5b1d6d46afa61c13573d2718f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a89d08d41a54d1186a979123197a002_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff9359d1e8b446cb97de06dd3a3d784c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i02779a4a24e94615abd773c870dd6261_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iffd402c659aa49ba8a4130d86b580fa0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f91c9052bd04dc58720b0900b461cbd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i371617dbee39477bb1cb5742a03f41fe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pgen:ExercisePriceAxis">pgen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3a9238cdda843cd8e2b1cdc9a3927be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id39bd16d2b0240b687313c2d206093e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pgen:PrecigenStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic42f0609642c4f08b491b5e9e5e122cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10782278c1794d1c8b675aaa49765ed4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc52713e7d8949749938bc75522e6d98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87018f1bd95f4a4f8cd3775dc1bdc558_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4889fe27e2cc4966b4f58c1e494a13ed_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i53aa5fac20ac403b9bce2f3bbe67a3a5_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27caa5d0d3674cb8873fa0e6c545b8cc_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a3e7401f5244362a8da8bdd6081990c_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id45a0b9d2a934bb4b5153625e67c9998_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0854d2b69b794445a113081a1772158a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf63e5924ca540d89aef4d0830021e64_D20201201-20201201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="i590473c574a14f01bc57d3d29295299d_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i5e90193768804ac2897e65914b465074_D20190320-20190320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-20</startDate>
            <endDate>2019-03-20</endDate>
        </period>
    </context>
    <context id="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-20</instant>
        </period>
    </context>
    <context id="if53067c947c6445b99c0734630919c2f_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:XYLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:LicensingAndPatentInfringementSuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i162c6a00ebd8403087aaba03e9e7257d_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:SecuritiesAndExchangeCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pgen:MethaneBioconversionPlatformDisclosuresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i163004d1571347a9896c92d4b1ec572f_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pgen:HarvestIntrexonEnterpriseFundILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2615524a66c943229cbd226d85d96e2a_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pgen:ExotechADSkincareAndThriveAgrobioticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ifb40c1f06726442485a1ee1321b1baa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ExecutiveChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib672478b9e8e43829ba3dd9807ad3e12_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i555d23957e82412498d8f685f322401f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:ThirdSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib87f8cebc3d94d3a9961d37fd3d97771_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:AffiliatesOfThirdSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pgen:SeriesAPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="i599bfce00a9945d9b726ceb46d1b4829_D20171001-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pgen:SeriesAPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i0670171b99994e70abea87f63ac354ea_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pgen:ZiopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i70be85e7d3844aaca71c406b666d60d6_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89a435ac6ca244c79163f5df75db8e16_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ic063de9522b3438b84804a067d67c361_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e54f6e16a9443f0a47fc8c8084f977e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:CastleCreekBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:CollaborationandlicensingagreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pgen:VariousECCAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3f3e239ae20c45c7b7aaf57a9b6cf875_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b50be6f05c0474e83a58face9d3645c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c1e80d080904677b59656be2a1b40b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4f71aeaa143c4b289ab59dfbe54174aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib379ad98b2cb45daaf83b5b7a21cc98e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7adb4d0947454afaa177f45a75cc9d60_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i27fb0d7ad0b6498ea08417bed7233684_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2017226d1f364332a399d4d0f2c037e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie0ee46d4ad6348e8955c1243244ba4e8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ife7c17ddfd9e4cfe8f7cfcc1d3d89d94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc1d30c65b074157a537d57ad73c2775_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2c9e1d13159420db631b851192aed69_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8404b30334554a8282ddc4963025afb9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if11002969f3e4f0b9cad7acc95c9688d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i816e511c14e944e784ccf02ef49dcfc1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6adeb8393ffb4cd9af54545b7f666403_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i416c63b209e448e4a1691314a0e720fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2de8331b876d4b82921c05eee138928f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6840d803ae85450585357ec60a8ed876_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f84542b3ea54137a7e7be5308c1f271_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49361cac902b4125a327a91917c78be8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if87036dbc7d542818b7d1e05ad396f7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3efccfc60d644e148ff53a1aea8fb101_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic65e43c5c8a9408d98dae73506aec312_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i142de93e903443e4ab31cfa896a0f6c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb84bd71d814449b98a10354224cd024_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia05ba222657c4da3a7946904d64b7cda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45928d9759c446fd8135abd8ae21531c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4c851ce2bf04d2d8ee0ae2363c3095c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6efc76794cd4f70892c233dfb405b21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec754f7c8fe345e9a691b4617bc583a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1856a6ee6ec445a2a3d19b2ec22d5c69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6153d68f9fcc4906bd9e9cd50a4813d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ab2a93de6ee44cf97247286fbd7e13b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04441decbc7f413abc71cd43fc461da1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d4ba24eafed49019e6ec63aabe7a182_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1adcf1f7e2814c5a98b167b18ede27d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57be64036b41497caa88c720697751d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74c2727e865d423586be763a463a4aeb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idadd9097495e4bc7a7045a8c4457de90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifafa1b4c69804dfd96a439a35168dfc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d3a6d84abe14c848540902462585373_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3b2a762b98949cc80b92e79db724b1c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc7bed861874412b9f1e982a3d5b7883_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib7b5d19dccb34749ad0bdd8bddb68e52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic62d85ceb878414ab0381b19dae2d6e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia50dbf2c0e31425c97e6391b41ca69ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i163a14083d2840e7b31ad5dfcf65b399_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i736231a7920a4f7da29a6de5b917aa57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icfdd8a57941e4059a00f31f76dafd79e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie213b50bea4c453b9fc821145579a6d8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2eda440ff9e84b8aab723bc6229cafb9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa651b05eb6d42d7956529f80d128fb4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9ada1cfca67342dbb51b59cb99e04067_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if943aa72ff3a4b8ba9787819a93ee378_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4927248b8114f8fa633cd593f9b134d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:PGENTherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67ad89a96f44459196c39386869a91e4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ActoBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8b87aa4811c44854b9ddc4b70159d6f6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:TransOvaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2f203cb6a2c84a37a5bda3f93b68e7a3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:HumanBiotherapeuticsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pgen:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8d70b9845a5b44eb94cdadc203be4f74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27fd320c35794ded9d690fc67a61ee36_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd6609bfdc1f48b586a5b70a92a8e8ff_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:OperatingSegmentsAndCorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib4962cdf48204222844e9ce74fd74c3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic93fa25606544244a088b1c2b2a76bc8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f9dcf0952c04e27a75572dcc547c1e7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:EliminationsAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5e2c484ec2494489bb341fdba607cadb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71de56fffeb14a6988696974ced53186_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i714a0770b5544bb98754740acc834259_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pgen:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">pgen:CorporateAndReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i133129ec5f3246d683d35411173d33aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13c8be8caa2f46178129d4ec229adbb2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9b2874d2bdd4deb9104cb8ea4baf8de_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8166ea8ff5b14ea1a56f75013f866d68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb6c9fa8b50d4640b4010be6ab64cc36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4a62b5534d74990aab59d86bee4c7e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d1a0c4bdf624f5a9be5028ebfc27876_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e7a12392b3748ccb33c84786aaae792_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i564e1936099a4468b2f386769723ec16_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356090</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="board_seat">
        <measure>pgen:board_seat</measure>
    </unit>
    <unit id="quarterly_installment">
        <measure>pgen:quarterly_installment</measure>
    </unit>
    <unit id="product">
        <measure>pgen:product</measure>
    </unit>
    <unit id="target">
        <measure>pgen:target</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>pgen:reporting_unit</measure>
    </unit>
    <unit id="day">
        <measure>pgen:day</measure>
    </unit>
    <unit id="claim">
        <measure>pgen:claim</measure>
    </unit>
    <unit id="relatedparty">
        <measure>pgen:relatedParty</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl8zLTEtMS0xLTA_cd4aee4c-e29a-4e38-8085-a57ce1cce2ef">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl80LTEtMS0xLTA_ad637d8c-2b1e-4eb4-b9b7-c47954e3967d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl81LTEtMS0xLTA_bcea5a34-20fd-4d8d-a43e-4bfb2620e002">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF80L2ZyYWc6MjBiM2RjY2E2ZGViNDY2ZmJiOTdlODMyZDE0Y2Q4NjAvdGFibGU6MTM4MjI0NmE0Y2FlNGVhY2FiZWE4MzllM2M1ZTYyMTYvdGFibGVyYW5nZToxMzgyMjQ2YTRjYWU0ZWFjYWJlYTgzOWUzYzVlNjIxNl82LTEtMS0xLTA_dea48d14-3b21-44a9-b5c7-277138da5892">0001356090</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="iba5ee3e148774f35bb26b15071f0a9c9_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMC0xLTEtMTAyOTE_98b5dcf3-d951-4783-922d-2c0ea94a8c36">us-gaap:AccountingStandardsUpdate201409Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic649546dedd34f7e81b3041baaf93e20_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i321fedbbadb34d4087e52ceb65be7798_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <pgen:ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination
      contextRef="i5155424e1c244be3a4c16ac6cae35737_D20180701-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzY1OTcwNjk3NzUxMzU_d9e7d0e6-80ed-4f13-b999-56a720a01b9a">P5D</pgen:ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="id45a0b9d2a934bb4b5153625e67c9998_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM0NA_ddde4444-f884-4ed7-beb8-9b358f73343e">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <dei:DocumentType
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YzcyMDNiYmZjNzc3NDFlYjhkOTc2NmQ0MDcwNzU1NTQvdGFibGVyYW5nZTpjNzIwM2JiZmM3Nzc0MWViOGQ5NzY2ZDQwNzA3NTU1NF8wLTItMS0xLTA_9e7196c8-189d-4040-8015-7f4a2b3a3501">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODE2NWY3NzBjZGFkNDBlNDhiNDhiOGY1YTE3MzlmYzEvdGFibGVyYW5nZTo4MTY1Zjc3MGNkYWQ0MGU0OGI0OGI4ZjVhMTczOWZjMV8wLTAtMS0xLTA_2fc8709c-be72-4a92-a889-4ff86336b081">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8xMTM_f0cd3672-8cc1-4dc7-9b44-dada0b3abb80">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8xMTM_23df9167-e62d-4437-a176-b9e645245f16">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6OWU2Y2QxZDA5NjNkNGZlMDk2ODZjZGNkZTU5MjJjOGQvdGFibGVyYW5nZTo5ZTZjZDFkMDk2M2Q0ZmUwOTY4NmNkY2RlNTkyMmM4ZF8wLTAtMS0xLTA_5c90e610-0ba4-44a4-a097-c247ffb453ac">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc5_d39e7210-f35d-42df-9381-c8bc1d125e00">001-36042</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgw_0439e67f-2386-41e1-8e6b-678d0a9d4618">PRECIGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8wLTEtMS0xLTA_a2eaea02-6fb8-4565-8680-f75823b224e8">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8wLTQtMS0xLTA_77806bf8-4b33-481e-ba46-ef14c4334616">26-0084895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF8zLTEtMS0xLTA_683108f1-010e-4add-843b-95358491f930">20374 Seneca Meadows Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTEtMS0xLTA_f6945d02-d572-4c18-bf48-899ea611a6e1">Germantown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTItMS0xLTA_e62d086f-c6d4-411f-8767-d08f1f01b3c8">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6YThkZGVjZGE0OGQxNGYzNDhhZWZjNTQ1YjE5NDk3YTgvdGFibGVyYW5nZTphOGRkZWNkYTQ4ZDE0ZjM0OGFlZmM1NDViMTk0OTdhOF80LTQtMS0xLTA_1f3dce2a-2a70-452d-99f4-c5a79ec999ce">20876</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgx_9c5108fe-8009-49e7-8852-b93c982c5476">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc1_5b3dc564-3466-4ef5-ac41-40d8aaa0b861">556-9900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTAtMS0xLTA_c79c43dc-2e37-4d75-88dc-ed3f6b4978cc">Common Stock, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTItMS0xLTA_c31289d0-6ad2-43c4-afac-f67ded6056e8">PGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6NDcxNzM2ZTI3N2NlNGYxYWFjN2JmOWI5ZWVlZTA2ZjEvdGFibGVyYW5nZTo0NzE3MzZlMjc3Y2U0ZjFhYWM3YmY5YjllZWVlMDZmMV8xLTQtMS0xLTA_59831f58-460b-459e-8331-bbe92b98c1e3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgy_7d66eefe-86c2-40ea-b612-56792aa0de2d">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTgz_25a51a63-5208-46e8-9346-a3784b7f8161">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc3_090701b1-6114-42ff-ad3c-c1c2410a9e70">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc4_b52f5e9b-9d1a-4e51-a1d0-e40a7e917e38">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl8wLTQtMS0xLTMzNTU_0a18a5e2-72d8-40a2-a777-679736979e2a">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl8yLTYtMS0xLTA_981178fc-a9ce-4953-9fb7-1db835b76a39">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGFibGU6ODY3ZTg2N2ExYzFiNDA2NWFhN2EzZjZlMTFmMTk5MjIvdGFibGVyYW5nZTo4NjdlODY3YTFjMWI0MDY1YWE3YTNmNmUxMWYxOTkyMl80LTYtMS0xLTEwMzk3_ac0d0583-ad64-468f-9a35-529f6514b4e5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF82NTk3MDY5NzcwNjEy_1a5a823f-1fb7-4ac6-be93-c457b60f05b0">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTg0_0b7179c1-6445-450f-ae9f-e31fe16e6bf7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i61afe01c77bd4075ac870cbeb744df69_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yNTEz_a539b7c1-6f83-4c9b-a540-359483f766d6"
      unitRef="usd">435100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4338078300e342f196795af559ba89f6_I20210215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yNTI4_2300f6ba-689a-4f4a-a4fb-fe3d625aff0a"
      unitRef="shares">205661239</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xL2ZyYWc6ODFhNTdkMTY1N2VlNDQ1OWIyYmMzMmQ0NzNjNDQ0N2QvdGV4dHJlZ2lvbjo4MWE1N2QxNjU3ZWU0NDU5YjJiYzMyZDQ3M2M0NDQ3ZF8yOTc2_63672a67-fdea-4d17-a40c-44bff77d0bad">Portions of the registrant's Definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2020.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzMtMS0xLTEtMA_9bc925aa-3bea-479b-a607-22dd4159dd12"
      unitRef="usd">51792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzMtMy0xLTEtMA_300f002f-c2fd-4ec7-9f0f-49095dd44984"
      unitRef="usd">65793000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzUtMS0xLTEtMA_ece3fc47-2a27-4570-9ff8-8ff86c657190"
      unitRef="usd">48325000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzUtMy0xLTEtMA_2645f9fb-726f-4df4-b339-71f4ca83001a"
      unitRef="usd">9260000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjE1YzdhODkwNjYyODQxZTRhNzRiYzM1NDY3MmMyNWU3XzQzOTgwNDY1MTExODg_7b80dcb5-1d98-4382-9421-72e459f64728"
      unitRef="usd">4825000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMC0xLTEtMC90ZXh0cmVnaW9uOjE1YzdhODkwNjYyODQxZTRhNzRiYzM1NDY3MmMyNWU3XzQzOTgwNDY1MTExOTE_766bb8ba-2f89-4264-b2a1-666e50afbca9"
      unitRef="usd">5201000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMS0xLTEtMA_f6cba48a-2f99-49a4-8fe8-ed4beb18989c"
      unitRef="usd">16487000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzgtMy0xLTEtMA_884c2b7c-93bf-436a-a665-7beccb13ea6b"
      unitRef="usd">20650000</us-gaap:AccountsReceivableNetCurrent>
    <pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMC0xLTEtMC90ZXh0cmVnaW9uOjQwZjljYTkwNWVlNTQwMzI5MTYwZDA4NWMxMTc1MTEzXzQzOTgwNDY1MTExODM_fc0e7a17-d8b5-4443-a85a-6a75665b89d2"
      unitRef="usd">1509000</pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent>
    <pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMC0xLTEtMC90ZXh0cmVnaW9uOjQwZjljYTkwNWVlNTQwMzI5MTYwZDA4NWMxMTc1MTEzXzQzOTgwNDY1MTExOTA_9d84e3a8-5d3e-4a40-a602-01c1f9abb68a"
      unitRef="usd">2312000</pgen:RelatedPartyReceivableAllowanceforCreditLossCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMS0xLTEtMA_08738b18-102c-4438-8270-4df754be3ee2"
      unitRef="usd">19000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzktMy0xLTEtMA_3c5af274-cc51-4f22-bba1-bcb207c023e4"
      unitRef="usd">600000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEwLTEtMS0xLTA_a5fbe770-3ccc-44de-bfae-65bd6bb4d530"
      unitRef="usd">3689000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEwLTMtMS0xLTA_3b488125-2373-42cf-b6e3-b6ae2c53d0c8"
      unitRef="usd">2942000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzExLTEtMS0xLTA_531e2aa0-cb1a-4988-b0c3-d0ab738afbef"
      unitRef="usd">232000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzExLTMtMS0xLTA_124e4ab0-ea4d-499d-aac3-a180afe392ac"
      unitRef="usd">2030000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEyLTEtMS0xLTA_d98c7546-ab3a-4b74-b3ae-b66a28d52a13"
      unitRef="usd">11359000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEyLTMtMS0xLTA_13abc31d-62b4-4e4e-9b5b-37631da03838"
      unitRef="usd">16097000</us-gaap:InventoryGross>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEzLTEtMS0xLTA_36592e16-6c38-412a-a9f4-7f3228a16cb7"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzEzLTMtMS0xLTA_6af24414-69b5-457c-9457-248f38f8b1b7"
      unitRef="usd">5827000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE0LTEtMS0xLTA_9f21ec58-a4b4-4954-a48a-7468ea9d42bc"
      unitRef="usd">9853000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE0LTMtMS0xLTA_538f57c8-8441-4d49-82b1-f811ab8ad261"
      unitRef="usd">111444000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE1LTEtMS0xLTA_62002a39-cefc-4b59-9663-5451bb1fac53"
      unitRef="usd">148948000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE1LTMtMS0xLTA_0e6189d2-f37e-48b4-a3bf-44c34b7d4e57"
      unitRef="usd">234643000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE4LTEtMS0xLTA_e2a6ac94-9a17-4d3b-b87b-cea84417f368"
      unitRef="usd">34924000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE4LTMtMS0xLTA_2911289a-bbf4-4e35-98c4-83210e9f0cd5"
      unitRef="usd">43952000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE5LTEtMS0xLTA_601a5416-364f-4e56-85ab-6c7f593a6b24"
      unitRef="usd">65396000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzE5LTMtMS0xLTA_5bdd5813-6389-4448-aa5e-61959153801b"
      unitRef="usd">68346000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIwLTEtMS0xLTA_bb7cba7c-74c6-49aa-8aeb-384fd071a7b8"
      unitRef="usd">54363000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIwLTMtMS0xLTA_7e9e3a3a-b73e-4b3b-9287-3c6dea76cf39"
      unitRef="usd">54119000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIxLTEtMS0xLTA_454ab537-eeab-4b02-9b36-2b13cae6c528"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIxLTMtMS0xLTA_5647282a-03a4-4aa9-b4e4-919024f09627"
      unitRef="usd">1461000</us-gaap:EquityMethodInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIyLTEtMS0xLTA_d377ae82-18c2-42ed-84fd-38c9460a0441"
      unitRef="usd">9353000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIyLTMtMS0xLTA_fdeccf00-8153-4926-9fc1-27bee92e6b54"
      unitRef="usd">11803000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIzLTEtMS0xLTA_68694fbe-bf3b-43c7-b68b-da4b05bb8d0e"
      unitRef="usd">1603000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzIzLTMtMS0xLTA_965445b4-a3f2-42f6-a3c1-7508696bbb36"
      unitRef="usd">1349000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI0LTEtMS0xLTA_07320d0e-247b-41ce-b15c-15845388275e"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI0LTMtMS0xLTA_7e497a0a-eaf3-471e-998c-6d6e3512a7db"
      unitRef="usd">40090000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI1LTEtMS0xLTA_4db5ba68-bfcb-4bfd-bc96-f0efabc83342"
      unitRef="usd">314587000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTpkMjhiM2E5NmEzM2M0MjVlYjI3ZjdmNTBhMGM5NjZjNS90YWJsZXJhbmdlOmQyOGIzYTk2YTMzYzQyNWViMjdmN2Y1MGEwYzk2NmM1XzI1LTMtMS0xLTA_5bdc533f-926b-4e0f-b409-630dd502f9cd"
      unitRef="usd">455763000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMtMS0xLTEtMA_9c0a30ba-450a-4b48-82f0-be8c91966b52"
      unitRef="usd">4598000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMtMy0xLTEtMA_07efa1e6-5cc0-475d-9f5d-7b972b133c2f"
      unitRef="usd">5528000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzQtMS0xLTEtMA_3e69f1f0-e3b0-411a-8664-118bf3538fec"
      unitRef="usd">8097000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzQtMy0xLTEtMA_ee7eb570-6703-4b5c-b7aa-142403dfad46"
      unitRef="usd">13198000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzUtMS0xLTEtMA_6f8d8269-0f7b-4975-8562-0d4c694293bb"
      unitRef="usd">9549000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzUtMy0xLTEtMA_198f6fd6-dc99-44d0-ae3b-11fa91c08aa1"
      unitRef="usd">11674000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI5N2Q5NzUxODljNjQ2YzZiZjczOGY0M2YwMDFmNTIzXzQzOTgwNDY1MTEyNDg_425a350c-c8d9-49e9-8a2f-b8762152f9f9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4535941e16234d449e24cbb104b312eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMC0xLTEtMC90ZXh0cmVnaW9uOmI5N2Q5NzUxODljNjQ2YzZiZjczOGY0M2YwMDFmNTIzXzQzOTgwNDY1MTEyNTc_b2acff20-a50a-43db-8bbc-a62e5925fb85"
      unitRef="usd">877000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMS0xLTEtMA_a1227f38-04e8-4e41-a2be-f4cbb417e66d"
      unitRef="usd">2800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzYtMy0xLTEtMA_ac40d7a7-515f-4b88-a437-5ace1b5ef444"
      unitRef="usd">5697000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzctMS0xLTEtMA_07ec0c6a-75cd-41d3-8326-b256b64e0d2c"
      unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzctMy0xLTEtMA_1a2c96e5-ee46-4f86-989d-952aa52700e2"
      unitRef="usd">1922000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmE3ZDg4ZDJjM2U5NzQ0MjRhZjA2YzZhYzM5ZTA3MmVhXzQzOTgwNDY1MTEyNjU_629c12a5-7539-4b1d-b3a8-054b8c1280d5"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i4535941e16234d449e24cbb104b312eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMC0xLTEtMC90ZXh0cmVnaW9uOmE3ZDg4ZDJjM2U5NzQ0MjRhZjA2YzZhYzM5ZTA3MmVhXzQzOTgwNDY1MTEyNjk_a9ddea4a-e95d-4321-96a9-e4d5a2d627cb"
      unitRef="usd">31211000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMS0xLTEtMA_b911815b-282b-4ede-a940-955d5fe52edb"
      unitRef="usd">360000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzgtMy0xLTEtMA_56b24d3b-bc52-45a8-9f6e-01ade336dad3"
      unitRef="usd">31670000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEwLTEtMS0xLTA_56b408f6-d92a-4764-bb34-95a4d54bf6ee"
      unitRef="usd">2657000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEwLTMtMS0xLTA_419547ba-ccd2-485e-86c5-59ebe8829ee8"
      unitRef="usd">2634000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzExLTEtMS0xLTA_ce561204-cc1c-418f-841c-a00ebe0d57f6"
      unitRef="usd">19000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzExLTMtMS0xLTA_a3dc0318-e86b-41de-8db0-a8dedc98b92d"
      unitRef="usd">51000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEyLTEtMS0xLTA_8ef4d4c4-96f0-4a5b-ab60-abebb6c0e9bc"
      unitRef="usd">14047000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEyLTMtMS0xLTA_e16d94cf-3d8f-46b8-8585-dd59ab49850f"
      unitRef="usd">50538000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEzLTEtMS0xLTA_bfa5b578-96d0-4e42-b34b-764cdfb39078"
      unitRef="usd">42127000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzEzLTMtMS0xLTA_5bdc7626-ce01-4fca-ae55-18751fcbd410"
      unitRef="usd">122912000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDZiOTlhZGMxYzM0ZDBlOWMxNjRmYjVmNjJmN2FmZF80Mzk4MDQ2NTExMzE0_6a874d18-67c8-44f8-aa17-6bc26aa708d0"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4535941e16234d449e24cbb104b312eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTAtMS0xLTAvdGV4dHJlZ2lvbjoyZDZiOTlhZGMxYzM0ZDBlOWMxNjRmYjVmNjJmN2FmZF80Mzk4MDQ2NTExMzIz_5267f2a3-3205-4e7e-93a5-a888218139f1"
      unitRef="usd">25000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTEtMS0xLTA_3538e522-480c-41bd-89ae-a124d2cf1541"
      unitRef="usd">171522000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE0LTMtMS0xLTA_4b4ed052-574f-4750-bd53-ec9464abb29d"
      unitRef="usd">186321000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if2d32b7d02bc4077abe174a0c01bf2da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZmE5ZWY2NWZjN2M0MWJkODVhOTAyNGMyY2QxNDA2ZF80Mzk4MDQ2NTExMjc5_6c962a0c-e327-4e68-9cab-390556574928"
      unitRef="usd">21205000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4535941e16234d449e24cbb104b312eb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZmE5ZWY2NWZjN2M0MWJkODVhOTAyNGMyY2QxNDA2ZF80Mzk4MDQ2NTExMjg4_664b55e8-bcc2-41c0-af92-8155dd1e8f1e"
      unitRef="usd">30182000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTEtMS0xLTA_9f699316-76b3-4eb5-8f55-64b7713bc5a3"
      unitRef="usd">23023000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE2LTMtMS0xLTA_52b4bd80-ebd0-4041-bc10-2311ec9d2e5d"
      unitRef="usd">48136000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE3LTEtMS0xLTA_5cb415c4-406d-46c0-bf0b-80369a199088"
      unitRef="usd">7744000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE3LTMtMS0xLTA_50b0f981-7b73-4eec-b28d-82027cd76164"
      unitRef="usd">10119000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE4LTEtMS0xLTA_44ac06df-b7de-49ee-ab7f-cdb4395d4b8d"
      unitRef="usd">2897000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE4LTMtMS0xLTA_d1a3beb3-3717-43bb-9bcc-dc565c567978"
      unitRef="usd">2834000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE5LTEtMS0xLTA_5634eb7d-025d-404f-8e38-3f0480c693bf"
      unitRef="usd">100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzE5LTMtMS0xLTA_0b6f5386-e07a-4c35-b6a2-2f06e617318b"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIwLTEtMS0xLTA_9f213629-21fb-4c82-888d-2f48bba71b72"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIwLTMtMS0xLTA_b05184cb-5e97-48a4-81c9-bb19685367e9"
      unitRef="usd">13730000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIxLTEtMS0xLTA_bb76f7e6-a840-444c-bea6-bc7ed5410562"
      unitRef="usd">247413000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIxLTMtMS0xLTA_73e86458-4a32-4d49-b4cf-9639dc56d7a2"
      unitRef="usd">384052000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIyLTEtMS0xLTA_976ea59b-dde1-4879-8efa-435d77e29d24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzIyLTMtMS0xLTA_05048050-8627-441c-bf8a-2052b3931940"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDM2_5b6f68a9-7148-4a19-a6bf-cb4243ffd87e"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDM2_cf6df0cc-4781-41e1-babb-857c3e94aace"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDYz_1a016d14-2893-418f-ab4a-8116b549b6c3"
      unitRef="shares">187663207</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDYz_f796ec2a-1dfc-4e0d-9385-1fa3b72f8387"
      unitRef="shares">187663207</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDc4_97aeb52f-8fec-46f3-8342-5a0823aaffe4"
      unitRef="shares">163274880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTAtMS0xLTAvdGV4dHJlZ2lvbjo4NmQzZGYxYWJjYmY0ZWIzODIzMDU2ZmE0ZWVkNDEzM180Mzk4MDQ2NTExNDc4_adfaaa25-9a00-47fe-9c6a-8300684c67e3"
      unitRef="shares">163274880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTEtMS0xLTA_350d3254-d381-418b-9a52-ff359fd6830a"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI0LTMtMS0xLTA_df00da76-534a-4e40-b66d-ab2c06fbc061"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI1LTEtMS0xLTA_51cdf9e0-cb11-4b53-b6d5-7de1045c611a"
      unitRef="usd">1886567000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI1LTMtMS0xLTA_584dd2de-732d-4b3b-9adb-00dc9c15c310"
      unitRef="usd">1752048000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI2LTEtMS0xLTA_717b0803-b483-4a2b-8a1a-161c564645de"
      unitRef="usd">-1823390000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI2LTMtMS0xLTA_0cbafbb3-328b-464b-ab11-973208b7bdf9"
      unitRef="usd">-1652869000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI3LTEtMS0xLTA_b3054236-80ac-49fb-9bbf-28bbdea7e4fa"
      unitRef="usd">3997000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI3LTMtMS0xLTA_cc3955bc-cc00-4662-859d-f1b43ddb62ef"
      unitRef="usd">-27468000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI4LTEtMS0xLTA_87c10b6b-fc74-48d5-8ff3-d31be065a78b"
      unitRef="usd">67174000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzI4LTMtMS0xLTA_7806294f-04f2-4328-93db-ed74a21d1a33"
      unitRef="usd">71711000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMxLTEtMS0xLTA_e8d756c5-5f30-47e2-a0f0-2b5bedd992fa"
      unitRef="usd">314587000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDAvZnJhZzo3NmMxM2NmZjNlMGU0YjIyYjI1OTQzMmNmMzk1ZjBiYS90YWJsZTphMDhmNGU1ZjhhMTM0MjlhOTNiZDY4MzM3ZjNmMWRhYy90YWJsZXJhbmdlOmEwOGY0ZTVmOGExMzQyOWE5M2JkNjgzMzdmM2YxZGFjXzMxLTMtMS0xLTA_d48cba7b-fb11-49ef-8ccf-b658bf3ff823"
      unitRef="usd">455763000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if90df5438bc447dc89f799623be8dd72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyNzA_bcee0023-0e8b-4a53-8ceb-dc461ad0d9d0"
      unitRef="usd">3053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d688646c4e54b0b9ff3d9d869a84f8d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyNzk_2161fa36-5797-4159-8a17-fdb069c8ac27"
      unitRef="usd">11832000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49fe028d6f84a65a5e7dc2e03d52395_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMC0xLTEtMC90ZXh0cmVnaW9uOmZjZmUzMDA1YmVjNzQyOWFiNzQ4MmNhY2MyMzllMmM5XzQzOTgwNDY1MTEyODk_a5701fb6-5038-400d-95f9-9db572cbd632"
      unitRef="usd">55573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa378b75eb8240abb90e3c3a90199627_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMS0xLTEtMA_9102896b-4ced-4a24-be29-8c3301cb1048"
      unitRef="usd">21208000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia63f92b55b3047a6985c52240063ce82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItMy0xLTEtMA_7ff6ece3-3f3d-4dee-886c-58dda9a17faa"
      unitRef="usd">14059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2563c9235194a59932361f4fd160992_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzItNS0xLTEtMA_0477a057-ff6c-4c3d-8da3-0b9d52c52873"
      unitRef="usd">69540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39c945d017804d08b6055d50caecddfc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtMS0xLTEtMA_c9dd6065-1c79-4e09-800d-7c074e74f262"
      unitRef="usd">24349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtMy0xLTEtMA_475eee3c-04d7-4c3e-9912-b2e4593c9274"
      unitRef="usd">23780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1416fdd04854b98b98cc981399bba77_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMtNS0xLTEtMA_806509ba-e6fa-45f4-857c-aafa2a8f1eb8"
      unitRef="usd">28486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtMS0xLTEtMA_509675ca-272e-43ab-b308-eae40e345267"
      unitRef="usd">56899000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtMy0xLTEtMA_0408a9f7-2957-4a6d-8731-f20ee74ac6c3"
      unitRef="usd">51803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f67f091705d4ed88119185ea9668127_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzQtNS0xLTEtMA_69f6a5d5-af9b-469e-92f2-b57ace7ca965"
      unitRef="usd">52419000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17726fa9a8714d378f70b578726ea61b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtMS0xLTEtMA_0607ee0e-8be1-420f-bbee-01a2a3231cd9"
      unitRef="usd">722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaf2a0142d19421f844e564b6e81c75e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtMy0xLTEtMA_098c82a8-a5ef-4dda-b79b-29e184620cbf"
      unitRef="usd">1080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53867cd3f9c14cdebf63cdf61a3ccdc6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzUtNS0xLTEtMA_b5657232-bf74-4bcc-9321-0cad0e6e3822"
      unitRef="usd">733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtMS0xLTEtMA_19b99410-92ce-464d-86df-a7a02e786734"
      unitRef="usd">103178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtMy0xLTEtMA_eba8edf2-6172-42a9-8cd1-0e8760c23689"
      unitRef="usd">90722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzYtNS0xLTEtMA_68d231a2-ae0d-4ae4-82c3-5fd27d1f07ab"
      unitRef="usd">151178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i39c945d017804d08b6055d50caecddfc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtMS0xLTEtMA_fc406c0c-63fe-4945-9bb1-d23dc0fac9e7"
      unitRef="usd">28550000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i54a1071be9d142908bc11711cd5bf021_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtMy0xLTEtMA_f6838e0f-27dd-4a84-8e9a-ad94644371ce"
      unitRef="usd">31930000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id1416fdd04854b98b98cc981399bba77_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzgtNS0xLTEtMA_ec1d33a0-934a-48a7-9e9b-bcedc12105c8"
      unitRef="usd">35087000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idfb6e680c4914a2bb9675f09ecf89708_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktMS0xLTEtMA_567ff732-a96b-48f9-95d8-d4674d888692"
      unitRef="usd">26963000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia3aaf2cdc3b4482e82a7919f03f8bec4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktMy0xLTEtMA_97cad642-ce4f-4026-8c82-784a405f79ec"
      unitRef="usd">29471000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5f67f091705d4ed88119185ea9668127_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzktNS0xLTEtMA_03426578-70ed-44e7-815f-9dca90c6f7a1"
      unitRef="usd">27589000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTEtMS0xLTA_4ee8d78d-5104-4db4-85a9-30a957feaa7b"
      unitRef="usd">41644000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTMtMS0xLTA_82d55c9c-4f0f-4e79-b5da-9eba352f961f"
      unitRef="usd">66666000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEwLTUtMS0xLTA_d8bc8107-1977-44b4-a848-e53711519c1b"
      unitRef="usd">333007000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTEtMS0xLTA_3b445914-c897-42d0-8e08-5ef3dbfe1af0"
      unitRef="usd">91704000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTMtMS0xLTA_b7833d00-c159-489a-85fb-5b861c8d6c3c"
      unitRef="usd">98634000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzExLTUtMS0xLTA_80992873-3f48-4775-a34b-0854103caf46"
      unitRef="usd">125162000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTEtMS0xLTA_1861d83c-1690-469f-955b-22821d0d29bb"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTMtMS0xLTA_baf162c0-c474-47c6-9527-2cf8cfa5a41c"
      unitRef="usd">29820000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEyLTUtMS0xLTA_692f8e5e-4ba0-42a6-80e8-9ecd8989ae46"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTEtMS0xLTY0NA_70ce0585-792d-48fb-96be-c73d330a91af"
      unitRef="usd">920000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTMtMS0xLTY0NA_0eb04f47-bddd-47ff-9aeb-b1bce1398a0e"
      unitRef="usd">990000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTUtMS0xLTY0NA_1ab14c2d-4e10-4ee1-bcd6-2425c0227c24"
      unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OperatingExpenses
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTEtMS0xLTA_76e9a80d-a39b-4bf9-8e7f-38034aca52af"
      unitRef="usd">189781000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTMtMS0xLTA_f85a7595-83d3-4eb5-96f1-243dc1c881ec"
      unitRef="usd">257511000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzEzLTUtMS0xLTA_0b4336d5-a9a0-4930-ac95-6d4709e1018e"
      unitRef="usd">520845000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTEtMS0xLTA_9f6bfbf5-b5dc-4c0a-8e52-a57b29cd5509"
      unitRef="usd">-86603000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTMtMS0xLTA_a7851457-e1d1-489b-babf-0ce15272f961"
      unitRef="usd">-166789000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE0LTUtMS0xLTA_eb8ccd04-fd06-4a81-9b6b-cb93361c8824"
      unitRef="usd">-369667000</us-gaap:OperatingIncomeLoss>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTEtMS0xLTA_b9c27c35-d306-4ad6-ae7d-682bb5b69463"
      unitRef="usd">0</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTMtMS0xLTA_05fccedf-68ec-4515-9896-9bb0b17f7681"
      unitRef="usd">8291000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE2LTUtMS0xLTA_74dfc3f8-b90b-4505-9a7b-845d9f19c3c4"
      unitRef="usd">-28273000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <us-gaap:InterestExpense
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTEtMS0xLTA_fa24aa64-db33-4941-b1a0-7a3a58bd96c6"
      unitRef="usd">18400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTMtMS0xLTA_97664556-6491-4ddb-b8df-ae1c7e1515fb"
      unitRef="usd">17666000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE3LTUtMS0xLTA_bc6905f3-061a-442d-9f2e-513f71c0fba6"
      unitRef="usd">8473000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTEtMS0xLTA_2e032ecd-31d6-4d9a-be44-398c83a2f911"
      unitRef="usd">2451000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTMtMS0xLTA_0d821615-1862-4488-bc89-beff0e4bc9fb"
      unitRef="usd">3871000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE4LTUtMS0xLTA_d7abdf6b-5c9e-4231-aa58-ed67a171e49f"
      unitRef="usd">19017000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTEtMS0xLTA_b0b7294d-573a-4974-a5ba-82ab72a51ccf"
      unitRef="usd">-165000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTMtMS0xLTA_58f9642f-f5ab-46f7-a40a-f192df945c75"
      unitRef="usd">3445000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzE5LTUtMS0xLTA_6805b18e-8b46-46b8-b4ca-ab150912f6da"
      unitRef="usd">470000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTEtMS0xLTA_5be7ac78-efeb-43f1-ab2e-7a80d449ab20"
      unitRef="usd">-16114000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTMtMS0xLTA_aaeed121-a5a6-4bf0-bf97-7626715e2d0d"
      unitRef="usd">-2059000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIwLTUtMS0xLTA_2a291d57-6548-4d68-b005-a9935deffdce"
      unitRef="usd">-17259000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTEtMS0xLTA_2f7b6728-07d2-4fed-bab4-800a4656383f"
      unitRef="usd">-1138000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTMtMS0xLTA_5d16426c-e105-4a21-ac08-4cb5d446ebcf"
      unitRef="usd">-2416000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIxLTUtMS0xLTA_51c4a3cf-3a98-4141-a6c6-516829b248f8"
      unitRef="usd">-8986000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTEtMS0xLTA_3d57007e-f00f-449a-98f1-0c869aef4cc3"
      unitRef="usd">-103855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTMtMS0xLTA_98716638-719a-423c-bc4f-ccb253ef1699"
      unitRef="usd">-171264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIyLTUtMS0xLTA_834c11bc-a0f0-45d6-9332-bbcaab27c495"
      unitRef="usd">-395912000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTEtMS0xLTA_b081cc0f-b408-4d2b-ac9b-1563ad848286"
      unitRef="usd">-82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTMtMS0xLTA_43a82ae0-4754-4568-8629-be2bc01ee8ef"
      unitRef="usd">-930000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzIzLTUtMS0xLTA_827a539c-fb6c-4387-a499-c5087f355482"
      unitRef="usd">-15425000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTEtMS0xLTA_898363e8-f6cc-43a5-bccc-b602b1e964f4"
      unitRef="usd">-103773000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTMtMS0xLTA_141bb8db-ba21-4813-b54a-98b06e83142f"
      unitRef="usd">-170334000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI0LTUtMS0xLTA_eb665e04-d562-4f78-9869-cf7219ee0304"
      unitRef="usd">-380487000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTEtMS0xLTA_e323b9a1-27e1-405f-8322-f7a9914c67fc"
      unitRef="usd">-66748000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTMtMS0xLTA_7537f139-eaf3-4779-8d14-7372633017d4"
      unitRef="usd">-153582000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI1LTUtMS0xLTA_c163ff95-67d6-4246-8221-abe5add31e0c"
      unitRef="usd">-134219000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTEtMS0xLTA_85e33e47-77fb-4c79-9a16-57d355a9d298"
      unitRef="usd">-170521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTMtMS0xLTA_1a82963d-fb8b-4fa7-864f-f0793f927f6c"
      unitRef="usd">-323916000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI2LTUtMS0xLTA_68f04d59-bec6-4c96-9724-1d7d27dbfe36"
      unitRef="usd">-514706000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTEtMS0xLTA_5a157744-a737-451e-a62c-5d358bb2c423"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTMtMS0xLTA_2c56e110-5ea5-4ca3-a6f5-543fae01ecb9"
      unitRef="usd">-1592000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI3LTUtMS0xLTA_17d72d8a-3e30-4fa8-9f1c-aabf9b8e4869"
      unitRef="usd">-5370000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTEtMS0xLTA_35556c4c-3f78-4da9-91dd-9d98b4c68968"
      unitRef="usd">-170521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTMtMS0xLTA_76670388-60ec-4047-b095-78d515b3776e"
      unitRef="usd">-322324000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzI4LTUtMS0xLTA_bb869e6c-d8cd-4792-bdb9-0b2e38d22833"
      unitRef="usd">-509336000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTEtMS0xLTA_b206a290-1f7a-4683-bb0d-72a8f98d0989"
      unitRef="usd">-103773000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTMtMS0xLTA_ed30d60e-efec-42fa-a93b-efc7daa8d8ac"
      unitRef="usd">-168742000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMxLTUtMS0xLTA_6f7d3951-86ba-4058-baa6-bdf3510cb8d5"
      unitRef="usd">-375117000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTEtMS0xLTA_42d45cd8-9487-4809-959a-dc864a992b1c"
      unitRef="usd">-66748000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTMtMS0xLTA_7a2563fe-09ce-4da1-b6fa-88eb7e64e468"
      unitRef="usd">-153582000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMyLTUtMS0xLTA_e07d3bb8-1f2d-4230-9d70-307c92ac22c0"
      unitRef="usd">-134219000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTEtMS0xLTA_396b4a22-6ad4-47df-8d5d-b637b2546ab3"
      unitRef="usd">-170521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTMtMS0xLTA_45bab461-b07e-4425-ba0b-5ccef2dfee41"
      unitRef="usd">-322324000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzMzLTUtMS0xLTA_60038c1a-2dbb-471c-b906-40e0d2c71ca3"
      unitRef="usd">-509336000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTEtMS0xLTA_27de82f7-ad1b-4bf9-abf0-364c5a89d819"
      unitRef="usdPerShare">-0.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTMtMS0xLTA_bf106a81-3521-413d-a1d2-6319985192fb"
      unitRef="usdPerShare">-1.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM1LTUtMS0xLTA_58dc8483-1e43-40db-9615-f26fcd80910d"
      unitRef="usdPerShare">-2.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTEtMS0xLTA_59076b00-2366-41f7-9356-525feac6e7c9"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTMtMS0xLTA_c571a521-2a9d-4b84-b1ba-0dd23a152dee"
      unitRef="usdPerShare">-1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM2LTUtMS0xLTA_62d1ea4c-bae7-40bf-ae04-9909b37fb3dd"
      unitRef="usdPerShare">-1.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTEtMS0xLTA_a4d8b2a2-a385-4df5-b437-28965c0663fb"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTMtMS0xLTA_b076eedc-e909-44f6-9a5f-d08d9ef2c976"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM3LTUtMS0xLTA_290ff555-eda5-40eb-a9b2-1949657093f5"
      unitRef="usdPerShare">-3.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTEtMS0xLTA_092e4812-fa90-4e07-a790-6faa19328968"
      unitRef="shares">167065539</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTMtMS0xLTA_0b80049e-f2c5-45cb-83cf-52e26f311170"
      unitRef="shares">154138774</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMDYvZnJhZzo4ODczNmIxZmZiMDM0MDZhYTk3NDk4ZjlkNDMwZGZiMS90YWJsZTowZWY1YzQ2MmE3Y2U0Yzk2OTkxYzk1MmE4NzVkMTUzYy90YWJsZXJhbmdlOjBlZjVjNDYyYTdjZTRjOTY5OTFjOTUyYTg3NWQxNTNjXzM4LTUtMS0xLTA_8a184fef-458d-4ef8-b0d4-031348c49256"
      unitRef="shares">129521731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtMS0xLTEtMA_bb75a0af-abab-4789-9541-2678b7f268ab"
      unitRef="usd">-170521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtMy0xLTEtMA_9b4bcff3-f390-43c2-90c5-764cf44cb6e5"
      unitRef="usd">-323916000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzEtNS0xLTEtMA_03160038-27fd-4e42-84d7-3d4396d1f66f"
      unitRef="usd">-514706000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtMS0xLTEtMA_8dab26a1-bee1-4589-9c05-857dc028f432"
      unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtMy0xLTEtMA_e0e39d48-d3e1-4d47-ac94-0f0d6d38b128"
      unitRef="usd">68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzMtNS0xLTEtMA_a7f0b39b-98f4-4308-bdae-3f21e454f055"
      unitRef="usd">-59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtMS0xLTEtMA_6af7e283-b139-4c75-ad10-e47a1023d058"
      unitRef="usd">4502000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtMy0xLTEtMA_2d140392-8b86-45b2-9df1-0e413a341241"
      unitRef="usd">1087000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzQtNS0xLTEtMA_9aaa260a-e834-466c-ae2c-efc5bf688f19"
      unitRef="usd">-13073000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMS0xLTEtNjU2_7eaa80ef-bbda-46d2-a902-ed135433f653"
      unitRef="usd">-26957000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMy0xLTEtNjU2_eb0ccb00-5e68-4cbd-aaba-0d61fb761b3c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtNS0xLTEtNjU2_32d17a32-6386-4165-94d8-d7b2079e738c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMS0xLTEtMA_04714076-e27e-45b6-9f40-a7be2fcad3e1"
      unitRef="usd">-139056000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtMy0xLTEtMA_08438683-0278-4190-abf2-7e593defe2c0"
      unitRef="usd">-322761000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzUtNS0xLTEtMA_991cc544-9ff4-4cfa-b423-a8109b977c1e"
      unitRef="usd">-527838000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtMS0xLTEtMA_6d7fccbc-7e03-4e72-838c-383df7d70244"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtMy0xLTEtMA_d049a804-0b5f-456f-8092-3d59e5e0614a"
      unitRef="usd">-1581000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzYtNS0xLTEtMA_924f4633-fd25-477e-82b9-d9644c4690ee"
      unitRef="usd">-5548000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctMS0xLTEtMA_6235efb5-4043-4184-ac2b-02a9fc104afd"
      unitRef="usd">-139056000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctMy0xLTEtMA_96b28480-caee-49e9-8649-6b4fe950a00d"
      unitRef="usd">-321180000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTIvZnJhZzo5OWM1ZTE3NDcxMGY0N2MwYTNmYTZmZmE3YTY0NTZkOS90YWJsZTpiYWNlOGViZTBhNzE0YjQwYWQyNTcxNGZjODEyZWI4OS90YWJsZXJhbmdlOmJhY2U4ZWJlMGE3MTRiNDBhZDI1NzE0ZmM4MTJlYjg5XzctNS0xLTEtMA_30c0c1c6-2b98-4d3f-880f-824947225fc5"
      unitRef="usd">-522290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia53c6ab11e9c492084aefb26999ce44a_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMS0xLTEtMA_fe1d885e-2217-440c-bf29-0dd8833ee738"
      unitRef="shares">122087040</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia53c6ab11e9c492084aefb26999ce44a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMy0xLTEtMA_7af36ddf-6020-4eb6-8da3-5adc217f87a0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4c80061711f435bbcfbfe956b9bc43c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItNS0xLTEtMA_6a74913f-1008-4bac-8a0c-2cae528067e9"
      unitRef="usd">1397005000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2d62e92e6fa4e01ac83a1dcdafa12a1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItNy0xLTEtMA_5c25a292-2dc2-48c1-b170-995399241b5a"
      unitRef="usd">-15554000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44c47c15a0a441909e132dd1581ceaec_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItOS0xLTEtMA_d94dc0d8-582e-4e77-be2f-a5c7b2b79a37"
      unitRef="usd">-847820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ee3c718a7f048cfb2836108df24bc3d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTEtMS0xLTA_b0477d6d-c162-4d6c-9626-586b76844f26"
      unitRef="usd">533631000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e53100af51f408a935d99fdc04896b2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTMtMS0xLTA_ed7ed26d-75f9-455a-8b1f-b86d6bcb3d23"
      unitRef="usd">12914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzItMTUtMS0xLTA_9ae8abf0-9c49-431b-b8a4-533a87d3b872"
      unitRef="usd">546545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b48ec0589f54ea18ed709e5622f1f36_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtNy0xLTEtMA_9b668684-6c06-4459-be1f-0ab4f880445c"
      unitRef="usd">-104000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic58e0c90d812453b961a416919b494e7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtOS0xLTEtMA_49b078f1-ed5f-4014-800a-f3478421d761"
      unitRef="usd">26611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6edb27434f8c42f4b2dafbfd636c960d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMTEtMS0xLTA_548fafe0-22d6-4017-8d38-68cbfca210fa"
      unitRef="usd">26507000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9ac13fe6c894e4d8bb963cd6fcd7ba1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzMtMTUtMS0xLTA_5cafb66a-9849-4146-a45a-2fed1491fd91"
      unitRef="usd">26507000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtNS0xLTEtMA_9cfd0b83-f8be-4728-b6fc-64a83af24fbe"
      unitRef="usd">36174000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTEtMS0xLTA_be236414-6b83-4b83-b6d7-c11ce885116f"
      unitRef="usd">36174000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTMtMS0xLTA_b8f12678-d101-4aa0-ae14-e38f1645c8cf"
      unitRef="usd">122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzQtMTUtMS0xLTA_abae2ac7-b271-4b70-b722-c44779985608"
      unitRef="usd">36296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards
      contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMS0xLTEtMA_07a51e26-aac1-40ed-b152-91a56d5fb383"
      unitRef="shares">70159</pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtNS0xLTEtMA_5a6af045-666f-4a36-bd26-d78e1f44979d"
      unitRef="usd">297000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTEtMS0xLTA_727cdb5f-0a3d-499b-82d5-036296cdf334"
      unitRef="usd">297000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTMtMS0xLTA_5635b339-4595-4f58-8b52-4f6a1a3f1b8a"
      unitRef="usd">2039000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzUtMTUtMS0xLTA_6b4c8bcc-bb8d-423e-a6aa-c1fe9a6862f3"
      unitRef="usd">2336000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMS0xLTEtMA_d22863c4-5a2c-4e3c-a84f-e1db91d9ab03"
      unitRef="shares">909980</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtNS0xLTEtMA_ba729e93-d657-42fa-8cf7-8398ea4061de"
      unitRef="usd">10695000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTEtMS0xLTA_2d7dd8cf-9559-4ab4-8fbb-b25a72005617"
      unitRef="usd">10695000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTMtMS0xLTA_98ea265d-a081-4c6d-9466-4ffcf931a2c5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzYtMTUtMS0xLTA_7a5e4b52-96b8-4969-8e3f-45daecee40d5"
      unitRef="usd">10695000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMS0xLTEtMA_7f8f0ffd-10e8-4bb3-8c00-5ef1bc2e221c"
      unitRef="shares">6900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctNS0xLTEtMA_931a0085-bbb1-4fd4-bb74-684869e893b2"
      unitRef="usd">82374000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTEtMS0xLTA_211c9869-5e19-4afa-ab75-592bcc06aa03"
      unitRef="usd">82374000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTMtMS0xLTA_aee39b4c-42d4-4012-8ef6-76142d6d1aca"
      unitRef="usd">5616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzctMTUtMS0xLTA_84480e96-84ca-4950-97a4-f1cc4340208e"
      unitRef="usd">87990000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtNS0xLTEtMA_0610a1d8-f5d3-4a71-82b3-b24077de314e"
      unitRef="usd">36868000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTEtMS0xLTA_5e0fddde-bd37-4180-8a71-248000fc8c3b"
      unitRef="usd">36868000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTMtMS0xLTA_3c4f5309-269c-4c55-9d86-e8ec0508899b"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzgtMTUtMS0xLTA_7870e5fc-bc17-4d2d-92b9-bc5cba813ce1"
      unitRef="usd">36868000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <pgen:OwnshareLendingArrangementSharesIssued1
      contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzktMS0xLTEtMA_cb036f51-cba6-4848-b5a6-aeb13ffc5081"
      unitRef="shares">7479431</pgen:OwnshareLendingArrangementSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ic53db3859f9b43b99d0a36885b204830_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTEtMS0xLTA_02a38483-64c8-46de-b5d0-de152c1cbc7c"
      unitRef="shares">22573856</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTUtMS0xLTA_fadaa66a-2a83-4e62-a3ec-01b3a594a624"
      unitRef="usd">159323000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTExLTEtMS0w_58ad1efe-527f-441d-8bf4-212e1af5cd8e"
      unitRef="usd">159323000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTEzLTEtMS0w_e550afb2-f992-4fa5-a330-97c513d0abdb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEwLTE1LTEtMS0w_9cfb494f-d27f-4b2f-9f7e-8e3614e02d5e"
      unitRef="usd">159323000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i51c9bd8f347a4b46a9c071451c8a7dc7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTUtMS0xLTA_743cab46-0d62-4c34-8675-9175f0e8c7bb"
      unitRef="usd">-724000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTExLTEtMS0w_609f0b43-ac43-40b2-8a5f-50205e6cbe5c"
      unitRef="usd">-724000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTEzLTEtMS0w_c9b09048-5f30-40a9-9e3c-f301c3a6521c"
      unitRef="usd">724000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzExLTE1LTEtMS0w_f46eb72f-500c-4424-942d-96fac7754e20"
      unitRef="usd">0</pgen:Adjustmentsfornoncontrollinginterests>
    <us-gaap:ProfitLoss
      contextRef="ie7328bdd74884f999183a972e9e74902_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTktMS0xLTA_7e96abbe-b641-4d98-812a-2ace3e0b35b5"
      unitRef="usd">-509336000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTExLTEtMS0w_3408f308-86dc-4d7d-b113-750fc91b799b"
      unitRef="usd">-509336000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTEzLTEtMS0w_9c483546-d83e-48e0-aa79-2de24739efbc"
      unitRef="usd">-5370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEyLTE1LTEtMS0w_78a55a1c-3cf9-475e-af68-ee4b2f2b373b"
      unitRef="usd">-514706000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i526adef7e72140d5b11b92f77958580e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTctMS0xLTA_5c28705f-37e5-431b-b9c4-98b96b2eae28"
      unitRef="usd">-12954000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6056963afdf140daa754e1e2f7642e0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTExLTEtMS0w_24ccfd24-65ca-4c6d-b922-81c2e6e487ae"
      unitRef="usd">-12954000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bed80c5df194534bf45b0e8dd755dbb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTEzLTEtMS0w_67e40284-f75e-485f-9d54-79222a96db4c"
      unitRef="usd">-178000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzEzLTE1LTEtMS0w_405d2852-ad7a-40c7-af36-f351b3e87405"
      unitRef="usd">-13132000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTEtMS0xLTA_5223ad68-d0b8-4fea-8ac2-6ffbd72bf5aa"
      unitRef="shares">160020466</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTMtMS0xLTA_3a3311e9-18d2-4941-ae24-e61841619e1d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25d775ca87aa45c7b569ef0164d07e18_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTUtMS0xLTA_d242ee72-ae6e-4347-a387-8c005edfc022"
      unitRef="usd">1722012000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62afd0579ab049588695814b856db8fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTctMS0xLTA_6d3e356d-8247-49c8-9daf-ab3202213753"
      unitRef="usd">-28612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib00106458d554c29aab7306c704ec827_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTktMS0xLTA_7af6b318-83ff-4af3-bcc5-8cdc173f346a"
      unitRef="usd">-1330545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e57cab296f149399d486ae6ead87efa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTExLTEtMS0w_adb6c75f-1416-4c8b-a20b-e687752263e4"
      unitRef="usd">362855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTEzLTEtMS0w_c7958b4b-5b5a-49e7-8164-506a27a4ec2c"
      unitRef="usd">15867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZToyYWQ1N2M2MzZkZTE0OTQ1OGVkMjRiM2IzNDNkM2NjNi90YWJsZXJhbmdlOjJhZDU3YzYzNmRlMTQ5NDU4ZWQyNGIzYjM0M2QzY2M2XzE0LTE1LTEtMS0w_fdb7efdb-22e6-40a2-baf4-86cfc43fbea8"
      unitRef="usd">378722000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMS0xLTEtMA_5223ad68-d0b8-4fea-8ac2-6ffbd72bf5aa"
      unitRef="shares">160020466</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dafd01f416a4fecabcd3625798ec85e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMy0xLTEtMA_3a3311e9-18d2-4941-ae24-e61841619e1d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25d775ca87aa45c7b569ef0164d07e18_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItNS0xLTEtMA_d242ee72-ae6e-4347-a387-8c005edfc022"
      unitRef="usd">1722012000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62afd0579ab049588695814b856db8fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItNy0xLTEtMA_6d3e356d-8247-49c8-9daf-ab3202213753"
      unitRef="usd">-28612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib00106458d554c29aab7306c704ec827_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItOS0xLTEtMA_7af6b318-83ff-4af3-bcc5-8cdc173f346a"
      unitRef="usd">-1330545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e57cab296f149399d486ae6ead87efa_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTEtMS0xLTA_adb6c75f-1416-4c8b-a20b-e687752263e4"
      unitRef="usd">362855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbfe1f43fc4b41eaad08b27677ba50fb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTMtMS0xLTA_c7958b4b-5b5a-49e7-8164-506a27a4ec2c"
      unitRef="usd">15867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzItMTUtMS0xLTA_fdb7efdb-22e6-40a2-baf4-86cfc43fbea8"
      unitRef="usd">378722000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtNS0xLTEtMA_3aec5cb6-2a7a-4a28-9b5f-75768b0e9c1f"
      unitRef="usd">18881000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTEtMS0xLTA_1efcc494-befd-485a-9c7a-f15c132f34ef"
      unitRef="usd">18881000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTMtMS0xLTA_5b9208f7-660b-4d21-a7b7-36ad9a632718"
      unitRef="usd">69000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzMtMTUtMS0xLTA_75eb29fb-afdc-46b2-b030-16a66bc7ea17"
      unitRef="usd">18950000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards
      contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMS0xLTEtMA_bd4232f8-e3f1-4322-af28-3223eedf6c72"
      unitRef="shares">1028144</pgen:StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtNS0xLTEtMA_b9f8fe20-60d6-4381-933d-7bbdb566a31d"
      unitRef="usd">63000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTEtMS0xLTA_e8f3814b-8c9f-4a7f-ac82-0bd9a0bc8018"
      unitRef="usd">63000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTMtMS0xLTA_5a433f48-7341-4991-b6b6-69ef2564fced"
      unitRef="usd">250000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzQtMTUtMS0xLTA_84fd22e0-d402-4cf3-af42-b07deb6d58d5"
      unitRef="usd">313000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <pgen:StockIssuedDuringThePeriodSharesAccruedCompensation
      contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMS0xLTEtMA_36d6cba8-6bdf-4fd4-901d-56fad81e064e"
      unitRef="shares">150908</pgen:StockIssuedDuringThePeriodSharesAccruedCompensation>
    <pgen:StockIssuedDuringThePeriodValueAccruedCompensation
      contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtNS0xLTEtMA_137c4261-505d-44ad-8d38-f9fe866cb7de"
      unitRef="usd">1102000</pgen:StockIssuedDuringThePeriodValueAccruedCompensation>
    <pgen:StockIssuedDuringThePeriodValueAccruedCompensation
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMTEtMS0xLTA_9bd62362-2ed9-4c9c-95d9-a077b9f0944d"
      unitRef="usd">1102000</pgen:StockIssuedDuringThePeriodValueAccruedCompensation>
    <pgen:StockIssuedDuringThePeriodValueAccruedCompensation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzUtMTUtMS0xLTA_e2105326-3358-4588-be80-381d76fda2b7"
      unitRef="usd">1102000</pgen:StockIssuedDuringThePeriodValueAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i42e54a23ae1b4f7297867650594b415c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMS0xLTEtMA_438e8540-ffb2-4480-953a-4207b548a3ef"
      unitRef="shares">2075362</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtNS0xLTEtMA_8ebd929b-73e3-43dc-a167-220779049fc2"
      unitRef="usd">10446000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMTEtMS0xLTA_b3b86656-f3d4-4a24-a330-29c0c818960a"
      unitRef="usd">10446000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzYtMTUtMS0xLTA_009b51c3-d54e-482e-9f19-778b525d6b87"
      unitRef="usd">10446000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzctMTMtMS0xLTA_f07fc04f-b8bd-49e2-a5fb-1ff0f8b29d75"
      unitRef="usd">6611000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzctMTUtMS0xLTA_5aea7780-6939-4db8-8e9e-0f1623352a1e"
      unitRef="usd">6611000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="ia966260303844c8cb44e155e9b3d72ef_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtNS0xLTEtMA_99e163d1-553b-4be6-9e05-6504488de3ca"
      unitRef="usd">-456000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTEtMS0xLTA_4b1aa850-67c5-49a4-aa8a-2b53ddb5f00f"
      unitRef="usd">-456000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTMtMS0xLTA_af34d568-f0df-4f83-87d1-0afcc6300089"
      unitRef="usd">456000</pgen:Adjustmentsfornoncontrollinginterests>
    <pgen:Adjustmentsfornoncontrollinginterests
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzgtMTUtMS0xLTA_67211ce1-d797-4ff1-8c5e-bdaa3d332086"
      unitRef="usd">0</pgen:Adjustmentsfornoncontrollinginterests>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzktMTMtMS0xLTA_af3bcd03-8f02-45e0-809e-12fe0c8bac7b"
      unitRef="usd">21672000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzktMTUtMS0xLTA_27e0c0c2-8bbc-418f-af96-b2419e323104"
      unitRef="usd">21672000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="i46f4056c01d04eeb92c3e2110de99905_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTktMS0xLTA_010c9c07-0fcf-48c2-a937-e7cd74e8c044"
      unitRef="usd">-322324000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTExLTEtMS0w_94f27f17-f2ac-4341-9bdd-ebc715692d8b"
      unitRef="usd">-322324000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTEzLTEtMS0w_0ef17039-6d16-4993-9855-0076a1eb889e"
      unitRef="usd">-1592000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEwLTE1LTEtMS0w_5268a78d-0f39-4120-b7ca-07b05afb0e2c"
      unitRef="usd">-323916000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i04a7a2917a5840d1828b5b69ba7afea7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTctMS0xLTA_c03199aa-91ff-4984-9195-404c8acdf003"
      unitRef="usd">1144000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f59de9e4c60433c8c9f49a58cbdbba0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTExLTEtMS0w_b830b7e7-83f1-4f31-80e8-b0415cb7634d"
      unitRef="usd">1144000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iddf6e9f41ffb4a5c813f79ab7a68cc2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTEzLTEtMS0w_9a25b663-b571-4e57-9a3c-7a1ce93b160b"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzExLTE1LTEtMS0w_c1db7540-1ba4-4c8e-90aa-45af3442c8ed"
      unitRef="usd">1155000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTEtMS0xLTA_75c99fba-eaaa-4f32-99f8-37d2bac4ad44"
      unitRef="shares">163274880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTMtMS0xLTA_9508c173-c367-412e-a85a-d202623435fa"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1053dfe438874cc9b2cd88769aca7327_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTUtMS0xLTA_8ea268a2-b328-42e7-8c91-946d43231e82"
      unitRef="usd">1752048000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64c7b560b46b448dab6e990b87500645_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTctMS0xLTA_e69d3a8d-0a74-405e-a704-e40d4e724781"
      unitRef="usd">-27468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75596e499ae443c3adaaf6abf5854f90_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTktMS0xLTA_59dee6e8-1610-4a51-bbfc-2bbaa38f5b59"
      unitRef="usd">-1652869000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTExLTEtMS0w_e29ac137-62e6-40cb-9689-f16eb5236a5c"
      unitRef="usd">71711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ce876c2b26448c6b08a1b65b0889bf7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTEzLTEtMS0w_4da91bea-f740-431d-9f59-f67ac44d1c41"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTplY2JjOWI0NTZlYTY0NGFhYjIxMGMxNTljMmVmZWM5NS90YWJsZXJhbmdlOmVjYmM5YjQ1NmVhNjQ0YWFiMjEwYzE1OWMyZWZlYzk1XzEyLTE1LTEtMS0w_3a984046-0f79-4540-a787-d5aedcc58474"
      unitRef="usd">71711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMS0xLTEtNjgx_75c99fba-eaaa-4f32-99f8-37d2bac4ad44"
      unitRef="shares">163274880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice0df81f9c8d4e7097109272f7381494_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMy0xLTEtNjgx_9508c173-c367-412e-a85a-d202623435fa"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1053dfe438874cc9b2cd88769aca7327_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItNS0xLTEtNjgx_8ea268a2-b328-42e7-8c91-946d43231e82"
      unitRef="usd">1752048000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64c7b560b46b448dab6e990b87500645_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItNy0xLTEtNjgx_e69d3a8d-0a74-405e-a704-e40d4e724781"
      unitRef="usd">-27468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75596e499ae443c3adaaf6abf5854f90_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItOS0xLTEtNjgx_59dee6e8-1610-4a51-bbfc-2bbaa38f5b59"
      unitRef="usd">-1652869000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d8aa8400b4d4ddfa3f6f72849e7a6f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzItMTEtMS0xLTY4MQ_e29ac137-62e6-40cb-9689-f16eb5236a5c"
      unitRef="usd">71711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzMtNS0xLTEtNjgx_ad1409c6-4892-4bcd-a0d9-123d0b3574a9"
      unitRef="usd">18366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzMtMTEtMS0xLTY4MQ_3b6c44f0-1299-40b6-bcab-3a9d54ffa5ff"
      unitRef="usd">18366000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <pgen:StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtMS0xLTEtNjgx_1d18e814-0d23-47e9-a296-05075e90cf6e"
      unitRef="shares">877249</pgen:StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtNS0xLTEtNjgx_de55d652-85cc-4b50-81cd-76880d05f8fd"
      unitRef="usd">117000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzQtMTEtMS0xLTY4MQ_0bd07244-1b34-43d0-a16a-d642481e0729"
      unitRef="usd">117000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised>
    <pgen:StockIssuedDuringThePeriodSharesAccruedCompensation
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtMS0xLTEtNjgx_f3adc0e9-1cf2-4726-acf4-be2ce404bfee"
      unitRef="shares">1955405</pgen:StockIssuedDuringThePeriodSharesAccruedCompensation>
    <pgen:StockIssuedDuringThePeriodValueAccruedCompensation
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtNS0xLTEtNjgx_69b2da99-c527-463f-a3dd-4f134da3b708"
      unitRef="usd">5100000</pgen:StockIssuedDuringThePeriodValueAccruedCompensation>
    <pgen:StockIssuedDuringThePeriodValueAccruedCompensation
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzUtMTEtMS0xLTY4MQ_4231aa37-14a4-4998-81bb-87bdc6b731cd"
      unitRef="usd">5100000</pgen:StockIssuedDuringThePeriodValueAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtMS0xLTEtNjgx_6276dcae-d31c-4301-9b1c-c17646c564d5"
      unitRef="shares">413911</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtNS0xLTEtNjgx_32030566-eb2d-4f79-a7d6-578c28f5092b"
      unitRef="usd">1006000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzYtMTEtMS0xLTY4MQ_a8703fc1-f10b-499a-bc65-bb714ebfbc4c"
      unitRef="usd">1006000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctMS0xLTEtNjgx_a76e5d57-6536-4d89-98df-f7576edc4d19"
      unitRef="shares">5972696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctNS0xLTEtNjgx_f37fe3f6-3130-4292-a969-f60f03fd37d7"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzctMTEtMS0xLTY4MQ_e1544346-1916-4b7b-a8b8-5bfc647a2ab2"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtMS0xLTEtMjQ2MQ_43299bb6-8808-4c0a-9a3a-6db6840b22a6"
      unitRef="shares">13051802</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtNS0xLTEtMjQ2MQ_fd026b24-d585-4295-877b-f6b931be1540"
      unitRef="usd">56827000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzgtMTEtMS0xLTI0NjE_6a8d76f6-5cf6-4dd9-944c-d0eec432ec17"
      unitRef="usd">56827000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues
      contextRef="i3c64edb04574493ca7acd0737007b7db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMS0xLTEtMzc2Mw_43a26baa-ae6d-4218-9422-2103b0137fa3"
      unitRef="shares">2117264</pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues>
    <pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues
      contextRef="i0a935b4c7f274d6790b182e0f03da520_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktNS0xLTEtMzc2Mw_60c8ba36-d5cb-4a75-a7d7-edfb8516b4f6"
      unitRef="usd">18103000</pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues>
    <pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMTEtMS0xLTM3NjM_c299aff2-794b-429a-a1ab-f15b738565bc"
      unitRef="usd">18103000</pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="ia5f5c113267a4a07b0fd84856590b114_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEwLTktMS0xLTY4MQ_2fb9966b-470f-4331-906d-b6ec29c800b9"
      unitRef="usd">-170521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEwLTExLTEtMS02ODE_1133f9d5-0aa7-496a-917d-a1b4b45374be"
      unitRef="usd">-170521000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktNy0xLTEtNjk1_a5a8f32f-bf27-4969-bf7e-69d95e11b9e9"
      unitRef="usd">-26957000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzktMTEtMS0xLTY5NQ_eeee55a8-ef6a-4253-a9ee-d4fef8ff78c1"
      unitRef="usd">-26957000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i320abf3f730f4e47b929d267fb5ec306_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzExLTctMS0xLTY4MQ_00ac8df9-93ff-47e0-a336-f963b6f6d054"
      unitRef="usd">4508000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia4a4983ed2fa431b96b6718a99c020d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzExLTExLTEtMS02ODE_a7f65673-a0a3-4fce-8554-14518d035dda"
      unitRef="usd">4508000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2fae6176c89149ef8b0e8046c310748e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTEtMS0xLTY4MQ_83c7c163-1834-4afd-bd84-b58d5664d1bf"
      unitRef="shares">187663207</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fae6176c89149ef8b0e8046c310748e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTMtMS0xLTY4MQ_92233e14-5d8c-44de-bffe-ec74bec93f10"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i762149a5fcb747d7b935b70a375b135b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTUtMS0xLTY4MQ_7836bbb6-170d-48e6-996e-4d94e3d6f58b"
      unitRef="usd">1886567000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5035cb92632a453d81e2f99ab37a6a4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTctMS0xLTY4MQ_3242a1ef-b9bb-436c-b549-635e2903a2a7"
      unitRef="usd">3997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife91272387c04b268c5f208e51e80445_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTktMS0xLTY4MQ_4ef69ebc-3540-4b85-b5e6-499bbd717b9a"
      unitRef="usd">-1823390000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc0677b8b8ac4e0194068bb8d9fa9a09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTUvZnJhZzoyNGZiMGRlYThiNDI0ZTJkODM2NWU5N2E1MmE4YWViNC90YWJsZTpiMmQzNzVjMTk3NmQ0NDhjYjcyNmZhMDk5NDI0YzE5MC90YWJsZXJhbmdlOmIyZDM3NWMxOTc2ZDQ0OGNiNzI2ZmEwOTk0MjRjMTkwXzEyLTExLTEtMS02ODE_ea390b9c-02dc-4b56-8270-fe14af1a4a30"
      unitRef="usd">67174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItMS0xLTEtMA_ca84e3ce-a184-4c8c-8a6d-2ff2c3e370a2"
      unitRef="usd">-170521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItMy0xLTEtMA_5aa1988d-6286-4582-8bbe-35e283ce7cc7"
      unitRef="usd">-323916000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzItNS0xLTEtMA_6c68c640-1450-492c-8162-55f1f9350a8a"
      unitRef="usd">-514706000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtMS0xLTEtMA_738735b1-15ac-461f-89ee-9005947b2c9e"
      unitRef="usd">17516000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtMy0xLTEtMA_f99a6b1a-6b14-492f-af6c-b27e0e9d33dd"
      unitRef="usd">24896000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzQtNS0xLTEtMA_749c11ef-7abd-47d5-89fd-f84e07644aff"
      unitRef="usd">33112000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtMS0xLTEtMA_1eda414d-b034-4d2e-9f42-71d00ba6b899"
      unitRef="usd">-4442000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtMy0xLTEtMA_7abaed70-f83d-44c5-926b-075ca397e351"
      unitRef="usd">-3071000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzUtNS0xLTEtMA_adc7d188-8fd1-4aac-88b5-a2a4918c433c"
      unitRef="usd">-20928000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtMS0xLTEtMA_7787acfa-d5d1-42d2-ae79-166c76c04d1e"
      unitRef="usd">9635000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtMy0xLTEtMA_564dc141-9a90-42a0-bc88-a5479710ea94"
      unitRef="usd">87862000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzYtNS0xLTEtMA_4ebe229d-1761-4a49-bdbe-224e673a9b3c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMS0xLTEtNzIx_76cbe2ff-c59b-42b0-b0e8-8bba881d6841"
      unitRef="usd">13326000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMy0xLTEtNzIx_9b28b803-0acb-4607-bf1e-ee9c78449ac1"
      unitRef="usd">32627000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctNS0xLTEtNzIx_23f3d7eb-c60b-41fc-b4ad-8fd253bda068"
      unitRef="usd">60504000</us-gaap:OtherAssetImpairmentCharges>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMS0xLTEtNzIx_756e1614-9461-4891-ab94-aad7aa3c3297"
      unitRef="usd">672000</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMy0xLTEtNzIx_5baeeff0-17e5-44ee-a792-17a4f9780d05"
      unitRef="usd">0</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtNS0xLTEtNzIx_547a03e7-28ed-4015-aad4-5e219563eac3"
      unitRef="usd">0</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMS0xLTEtNzIx_c6cc5b82-2c4f-4bc1-8928-b15cc4bcca2e"
      unitRef="usd">-26957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMy0xLTEtNzIx_102dff72-fef3-401d-9752-265720cefc34"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktNS0xLTEtNzIx_a951ad51-efae-45c9-ba30-90e8485159b5"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMS0xLTEtMA_a68ab8ca-3ad2-44e5-bd21-b86f76a3203d"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctMy0xLTEtMA_54cc3553-d4b1-42b6-979c-05087464240f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzctNS0xLTEtMA_638d9978-577c-4098-95d5-c405420ea01a"
      unitRef="usd">236748000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTEtMS0xLTM3NzU_6261a33b-e1aa-4ba8-a57e-abaf46255c12"
      unitRef="usd">-11436000</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTMtMS0xLTM3NzU_d2436c2f-32b8-40b3-99ea-ee1058d172fe"
      unitRef="usd">0</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzExLTUtMS0xLTM3NzU_383cf479-9eff-4902-a495-56499b7a0bda"
      unitRef="usd">0</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMS0xLTEtMA_14e3ad15-bae7-443b-860d-918ecb3c0c0d"
      unitRef="usd">-106000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtMy0xLTEtMA_ab9a7ba8-4292-49ee-9676-defbd2fa7fc7"
      unitRef="usd">7833000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzgtNS0xLTEtMA_7cd6ca45-6f2d-4e01-b3f2-e94fe36002aa"
      unitRef="usd">-30200000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:NoncashDividendIncome
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMS0xLTEtMA_2686f84f-9bb7-4658-9ddf-2f2552e0c2ef"
      unitRef="usd">0</pgen:NoncashDividendIncome>
    <pgen:NoncashDividendIncome
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktMy0xLTEtMA_6aa5ea4d-40ef-4ac9-b08c-fb7386beb7a5"
      unitRef="usd">48000</pgen:NoncashDividendIncome>
    <pgen:NoncashDividendIncome
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzktNS0xLTEtMA_61557047-5442-462f-8ae6-9eca8f7a86c3"
      unitRef="usd">14841000</pgen:NoncashDividendIncome>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTEtMS0xLTA_82b71461-9ea2-4e99-a41b-9b97eb00dd5a"
      unitRef="usd">699000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTMtMS0xLTA_c8f4f293-c113-4c29-9e13-e0a910a311de"
      unitRef="usd">1005000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEwLTUtMS0xLTA_102060ca-18af-4c27-92ff-8b878b609107"
      unitRef="usd">771000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTEtMS0xLTA_0722e750-f6d7-4163-a1ef-c0ff61070b6d"
      unitRef="usd">-1176000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTMtMS0xLTA_a1d365b1-f27d-44c9-9677-2ce83efbd4e1"
      unitRef="usd">-6730000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEyLTUtMS0xLTA_7f630503-6806-4d7d-9135-ff56e06e7cee"
      unitRef="usd">-11608000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTEtMS0xLTA_3f75c36b-6515-40af-8c1c-1aec1fdc3207"
      unitRef="usd">18366000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTMtMS0xLTA_6966ca76-b907-43be-8b25-b725ef8e9fb8"
      unitRef="usd">18950000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzEzLTUtMS0xLTA_acdf7ae5-e3ef-4479-9a1f-e318c2eb6ded"
      unitRef="usd">36296000</us-gaap:ShareBasedCompensation>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTEtMS0xLTA_408bf1e4-ccf3-4845-aaa8-bb979dc51bac"
      unitRef="usd">1006000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTMtMS0xLTA_c03c3d9d-d1b3-4872-9f6c-632214b3cda0"
      unitRef="usd">10446000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE0LTUtMS0xLTA_a63b1b84-4952-4cf4-b0c9-a1fdfb4f026f"
      unitRef="usd">10695000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTEtMS0xLTA_95259375-2e69-44e0-ac34-01974451956f"
      unitRef="usd">899000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTMtMS0xLTA_af40236f-c6b5-47c4-bea6-37efa351d7f1"
      unitRef="usd">3242000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE2LTUtMS0xLTA_281008f9-6986-49c9-8b2c-9f851cffb0de"
      unitRef="usd">1779000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTEtMS0xLTA_8ba3ab2c-efbb-4272-b5b3-e27328042689"
      unitRef="usd">10587000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTMtMS0xLTA_19cdfd4e-a9c3-48cf-b1e3-8733c20bd71f"
      unitRef="usd">9459000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE3LTUtMS0xLTA_4fc84b43-dc42-464b-8240-96dcdaa09705"
      unitRef="usd">4378000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTEtMS0xLTA_4f979a02-8e30-4d35-b88c-39f1b6a11c00"
      unitRef="usd">-156000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTMtMS0xLTA_1d1ce9dd-cfe1-4823-a0a6-2ce15ed798cb"
      unitRef="usd">-3674000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE4LTUtMS0xLTA_14ffe700-eed3-4975-8ca8-a6e2c2eda0db"
      unitRef="usd">-21278000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTEtMS0xLTA_32998071-d709-4a5d-927d-ad9bc0716387"
      unitRef="usd">-226000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTMtMS0xLTA_06704ef0-f43a-488a-8f20-172ad3800742"
      unitRef="usd">-837000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzE5LTUtMS0xLTA_fd07cbb8-8a51-479a-87b4-3ef43f874831"
      unitRef="usd">-1093000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTEtMS0xLTA_7a2779ad-69c5-4204-87dc-18e575e0ceaa"
      unitRef="usd">-2214000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTMtMS0xLTA_d8d8a62c-bcc2-48bb-adab-20faef552e40"
      unitRef="usd">262000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIyLTUtMS0xLTA_3c0734fe-6820-40db-8cdb-f93fd7ad41ef"
      unitRef="usd">2698000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTEtMS0xLTA_92b92d97-a7f8-4acc-8a3f-96b95e9ff1d6"
      unitRef="usd">-258000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTMtMS0xLTA_34369bb2-aba2-4d20-868b-37638925c357"
      unitRef="usd">-967000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzIzLTUtMS0xLTA_36a52b53-2c8b-4f2c-b365-d5eac3214f9b"
      unitRef="usd">-11003000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTEtMS0xLTA_c69736a7-5f55-45a7-8ee8-d95245afcb13"
      unitRef="usd">-1853000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTMtMS0xLTA_4f4005f5-17d6-474f-b858-5f6f9a8cc357"
      unitRef="usd">656000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI1LTUtMS0xLTA_c1309498-9a9b-496d-9740-68009dfd8d94"
      unitRef="usd">542000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTEtMS0xLTA_71f3c917-04a9-4e4c-b4cd-50dea06d1684"
      unitRef="usd">-2511000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTMtMS0xLTA_c52a7dd0-b84f-4c26-b98b-9a1b3d0a1349"
      unitRef="usd">-4100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI2LTUtMS0xLTA_683b679c-4b35-4f85-b430-babde58689a8"
      unitRef="usd">478000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTEtMS0xLTA_98e70a7e-3e25-4ad6-a7f1-c6e40fc8c2d5"
      unitRef="usd">812000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTMtMS0xLTA_a6db5edb-5afd-44bf-9d33-61e84660efd3"
      unitRef="usd">2262000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI3LTUtMS0xLTA_d5b5697f-66c3-4246-9c1a-935e8938d084"
      unitRef="usd">-1006000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTEtMS0xLTA_e9e8151e-86b7-458d-9d9a-dcaf46862c5b"
      unitRef="usd">142000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTMtMS0xLTA_b799bc29-82dd-4a14-89c7-85d02fa008b8"
      unitRef="usd">-333000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI4LTUtMS0xLTA_c5d34ba3-3031-4b5b-90fa-e40f5e81850f"
      unitRef="usd">-652000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTEtMS0xLTA_1e4393f0-f809-4258-ba48-fa2b031fa805"
      unitRef="usd">-1097000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTMtMS0xLTA_fc0c0512-7a31-44bf-be3a-46df0c205184"
      unitRef="usd">-5349000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzI5LTUtMS0xLTA_96491556-6c7f-4140-9949-8fe5e1a84ef7"
      unitRef="usd">4680000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTEtMS0xLTA_b4e1a9b0-53da-4733-91ad-d34446bd7fd6"
      unitRef="usd">-789000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTMtMS0xLTA_22f114c3-6b90-4c9b-9434-239f69697882"
      unitRef="usd">5186000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMwLTUtMS0xLTA_d6a51073-639c-43fb-8618-4f89968407bc"
      unitRef="usd">4385000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTEtMS0xLTA_99b7f831-d2f8-4666-bce6-dd100fea85af"
      unitRef="usd">-2682000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTMtMS0xLTA_a5f94e0f-32ae-44e4-a536-1c623b91c223"
      unitRef="usd">-5516000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMxLTUtMS0xLTA_26ead79f-be6f-4ad8-9bb0-4f393dc1daf6"
      unitRef="usd">356000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTEtMS0xLTA_374d5892-f5a1-4fa6-8021-cc59cce2d05a"
      unitRef="usd">-21045000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTMtMS0xLTA_fee981ac-5f00-4a9c-a5ee-d4dfcc770384"
      unitRef="usd">7423000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzMyLTUtMS0xLTA_63d8d517-561e-443f-b662-77805914fc1b"
      unitRef="usd">-38578000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <pgen:IncreaseDecreaseInLeaseLiabilities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTEtMS0xLTA_b66ebad7-af6e-4cf9-9943-dd8aaff76241"
      unitRef="usd">-887000</pgen:IncreaseDecreaseInLeaseLiabilities>
    <pgen:IncreaseDecreaseInLeaseLiabilities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTMtMS0xLTA_6c9e69ce-0550-4897-9801-8e9a1da9719f"
      unitRef="usd">-995000</pgen:IncreaseDecreaseInLeaseLiabilities>
    <pgen:IncreaseDecreaseInLeaseLiabilities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM0LTUtMS0xLTA_e29e95b0-8889-40d4-9e91-d2c4273360f6"
      unitRef="usd">0</pgen:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTEtMS0xLTA_fe841cb4-89ec-46e0-bce0-d5ccb4f53eb2"
      unitRef="usd">-33000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTMtMS0xLTA_c26c78c4-58ec-4061-856e-1db815d34e4a"
      unitRef="usd">45000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM1LTUtMS0xLTA_7e401375-0649-4c95-9df7-9110dd6461b1"
      unitRef="usd">-52000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTEtMS0xLTA_f5dc836d-7342-4bb7-a8e2-9f0a1f2f9112"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTMtMS0xLTA_027661da-57bd-49c2-8557-a5b5f0258b87"
      unitRef="usd">-585000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM2LTUtMS0xLTA_872146c0-dbc6-4854-aa6b-cd1ccd397177"
      unitRef="usd">281000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTEtMS0xLTA_efd7f07e-0097-495d-8f36-40901566475e"
      unitRef="usd">-77021000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTMtMS0xLTA_a9493389-4223-4973-aeb9-8dff20e4f015"
      unitRef="usd">-135927000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTozYmM5NjA5YmYwOWE0YWUzODlmZjc0NjFmODNmYWNjOS90YWJsZXJhbmdlOjNiYzk2MDliZjA5YTRhZTM4OWZmNzQ2MWY4M2ZhY2M5XzM3LTUtMS0xLTA_ef6e1279-5b3d-4351-ba9c-eb9aa4bcb7ce"
      unitRef="usd">-124240000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItMS0xLTEtMA_1ab2ab96-96b4-46bb-8696-a310aee4fc10"
      unitRef="usd">171360000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItMy0xLTEtMA_1369ddfd-2e96-43ce-8976-2fb70e93a081"
      unitRef="usd">55073000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzItNS0xLTEtMA_61882b83-f132-4b4e-8523-6bf2d6812560"
      unitRef="usd">178681000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtMS0xLTEtMA_9d19f202-7a84-43c1-a3e1-8c746b57aff5"
      unitRef="usd">133000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtMy0xLTEtMA_3d2b47c0-eef4-4655-ae82-58163fd96403"
      unitRef="usd">166495000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMtNS0xLTEtMA_98e4e451-b601-43e9-8320-339dd554d13e"
      unitRef="usd">65975000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtMS0xLTEtMA_9ca54d85-dc6d-4983-8086-125f208f9fd7"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtMy0xLTEtMA_37992cd0-f7be-4110-884b-61e76de1f0a0"
      unitRef="usd">23456000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzUtNS0xLTEtMA_88c3a11e-0f17-4984-920c-690c8ada5e6e"
      unitRef="usd">217000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtMS0xLTEtMA_78aba40c-e2e3-420d-a133-c0c89f346ce8"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtMy0xLTEtMA_e8a69a6b-bad6-4626-b8ff-99c57abe316c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzYtNS0xLTEtMA_d8ad73dc-a174-41de-8a1c-6e93f12a1c8d"
      unitRef="usd">920000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctMS0xLTEtMA_fb5b5bfe-1c2f-4c09-a43e-ac1d1380508d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctMy0xLTEtMA_95bb1228-74ef-4a21-b9e1-8df33c3b496e"
      unitRef="usd">3713000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzctNS0xLTEtMA_5a1f91c3-1d20-4bc2-a704-98c5427f72b8"
      unitRef="usd">16582000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtMS0xLTEtMA_f350f4a8-ef14-4a60-99a3-71f7027dfa52"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtMy0xLTEtMA_722014ed-dea1-4f98-b73b-5d17ffac538f"
      unitRef="usd">7244000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzgtNS0xLTEtMA_e7969c7e-5251-47ec-9b3c-5362985d54b9"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktMS0xLTEtMA_ea0b6329-fd79-44a2-8012-de625a8f9d51"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktMy0xLTEtMA_63b4da53-4f61-4e9b-ae39-e2a12220c47e"
      unitRef="usd">125000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzktNS0xLTEtMA_032f06af-7cce-46be-aca4-40c0053e3220"
      unitRef="usd">2598000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <pgen:CashInflowsOutflowsInAssetAcquisition
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTEtMS0xLTA_6f6951e7-a20a-40ee-b420-d1a7bc4898ad"
      unitRef="usd">0</pgen:CashInflowsOutflowsInAssetAcquisition>
    <pgen:CashInflowsOutflowsInAssetAcquisition
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTMtMS0xLTA_05f22a87-c9cd-4be0-9674-388195796648"
      unitRef="usd">0</pgen:CashInflowsOutflowsInAssetAcquisition>
    <pgen:CashInflowsOutflowsInAssetAcquisition
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEwLTUtMS0xLTA_0f0b3c18-ffc7-4177-98dc-39433aadb099"
      unitRef="usd">15500000</pgen:CashInflowsOutflowsInAssetAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTEtMS0xLTA_0da44c02-a245-4d13-b528-c1a597d5c1b5"
      unitRef="usd">7527000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTMtMS0xLTA_13ccfd82-7ede-4e59-adf1-b7f213fe87bf"
      unitRef="usd">37883000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzExLTUtMS0xLTA_934eb80f-5078-4c6a-89c4-1f18a111d1c6"
      unitRef="usd">41587000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTEtMS0xLTA_810b56e1-c744-408d-ac47-bd91d59eceff"
      unitRef="usd">6484000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTMtMS0xLTA_bafd4fd6-41d5-4973-8fdf-12eef6d00a5d"
      unitRef="usd">688000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEyLTUtMS0xLTA_59e7027e-1175-4e04-aa10-df7df2846deb"
      unitRef="usd">2267000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTEtMS0xLTczMA_6a51fc70-9c33-4930-89de-1df22dc1b450"
      unitRef="usd">64240000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTMtMS0xLTczMA_f8ff5269-a029-4d66-9812-50230f9684ee"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzEzLTUtMS0xLTczMA_bcb88c0d-5afa-404e-ba8e-94f180526776"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTEtMS0xLTA_7e6084f6-c4b8-4031-bb0a-1cff71a83cff"
      unitRef="usd">2942000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTMtMS0xLTA_9256ef47-5813-43b1-b804-207961bf44be"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE0LTUtMS0xLTA_7d050d7a-ac08-4586-907d-b54a23dc2191"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTEtMS0xLTA_2c3fc4fe-5bea-418a-90c4-ea16dafc3c21"
      unitRef="usd">27779000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTMtMS0xLTA_d78b680e-4053-46a5-8d51-d121734845bd"
      unitRef="usd">86851000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE1LTUtMS0xLTA_1b9e07af-dcda-40d6-b0b7-4c418edddf3a"
      unitRef="usd">-151213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTEtMS0xLTA_6e40247b-a29e-4962-9636-34b8c485dedd"
      unitRef="usd">35000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTMtMS0xLTA_2e86b0f5-fb4c-4040-ab24-30255db4d7d4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE3LTUtMS0xLTA_2fc10fba-39ab-47f7-96ed-ff5a8b81b61d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTEtMS0xLTA_b2002f17-39e4-4abf-a0c5-59e629d2e006"
      unitRef="usd">0</pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet>
    <pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTMtMS0xLTA_791298ed-61b3-4115-96bc-7888c4c7b1a2"
      unitRef="usd">6611000</pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet>
    <pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzE4LTUtMS0xLTA_20d7ea15-1b67-494a-838a-895deea536de"
      unitRef="usd">87990000</pgen:ProceedsfromIssuanceofCommonStockandWarrantsNet>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTEtMS0xLTA_e497d4c6-1e07-4189-9e18-29f668b26ebd"
      unitRef="usd">10005000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTMtMS0xLTA_213b9e19-b4f3-451c-9bae-ab0b975a960a"
      unitRef="usd">11757000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIwLTUtMS0xLTA_1c43bf81-cc61-4041-81c1-0fe5fe4c6b79"
      unitRef="usd">4561000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTEtMS0xLTA_1a1f2857-b466-4214-a9bc-b08ec4fff057"
      unitRef="usd">11927000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTMtMS0xLTA_937c13d1-4cb4-4a1e-a8e2-7a225bc5348d"
      unitRef="usd">10301000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIxLTUtMS0xLTA_7a1a39ec-65ad-4a41-8c26-9e4e22729e2a"
      unitRef="usd">4328000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTEtMS0xLTA_18c86698-fcd3-4d44-841f-cc717c80f96e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTMtMS0xLTA_ccd3d7d3-2548-41c4-a290-cda45c974000"
      unitRef="usd">376000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIyLTUtMS0xLTA_704c2b09-085b-422b-893f-b61beebe0c23"
      unitRef="usd">219859000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTEtMS0xLTA_835223a2-dbc7-40e6-90cc-4e47986d5f62"
      unitRef="usd">490000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTMtMS0xLTA_9b9b1f8d-e6ff-432e-81e6-818010229cae"
      unitRef="usd">618000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzIzLTUtMS0xLTA_56e62d3a-61ea-4aec-aa07-cba5ac49d1dd"
      unitRef="usd">623000</us-gaap:RepaymentsOfLongTermDebt>
    <pgen:ProceedsfromStockOptionsandWarrantsExercised
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTEtMS0xLTA_eba9fd2e-1c83-4b6f-adad-bbefc7cab190"
      unitRef="usd">117000</pgen:ProceedsfromStockOptionsandWarrantsExercised>
    <pgen:ProceedsfromStockOptionsandWarrantsExercised
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTMtMS0xLTA_e319bf25-5af3-45f2-af0b-dab25b1bcf33"
      unitRef="usd">313000</pgen:ProceedsfromStockOptionsandWarrantsExercised>
    <pgen:ProceedsfromStockOptionsandWarrantsExercised
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI1LTUtMS0xLTA_8ece16ab-d689-4a52-b390-ed488fb3bc4b"
      unitRef="usd">2336000</pgen:ProceedsfromStockOptionsandWarrantsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTEtMS0xLTA_24f48b5f-e91d-4b08-b630-4ad4124f1c3e"
      unitRef="usd">32705000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTMtMS0xLTA_cbcaaaf5-4d99-42b5-b6b2-2bca2a02635f"
      unitRef="usd">8138000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI3LTUtMS0xLTA_1809f371-06ae-4f3c-96b6-5174bbbd98f5"
      unitRef="usd">309795000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTEtMS0xLTA_b58ddf14-636a-4a32-93ee-7ad7b0dd8dde"
      unitRef="usd">353000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTMtMS0xLTA_0dd66e14-608d-47f9-abe0-46a40f9c6655"
      unitRef="usd">-810000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI4LTUtMS0xLTA_61a1f37a-e9db-447c-8b23-3aa9860c3024"
      unitRef="usd">295000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTEtMS0xLTA_1b6860cc-7626-4159-9fb7-49995e311cb9"
      unitRef="usd">-16184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTMtMS0xLTA_7d42ca14-d08d-48ff-9562-d48380904243"
      unitRef="usd">-41748000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzI5LTUtMS0xLTA_04779040-d04d-414c-96e0-2ac48f308df2"
      unitRef="usd">34637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTEtMS0xLTA_7c7e7c44-3dcc-47ed-bbcb-dba2cc525e75"
      unitRef="usd">68434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTMtMS0xLTA_40ca2e43-007c-44cc-b83d-fcc7d77eba1f"
      unitRef="usd">110182000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMxLTUtMS0xLTA_ac819100-d7e1-42f8-8266-851c34e3b2bb"
      unitRef="usd">75545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTEtMS0xLTA_4d194d61-4dc8-4d28-91cc-ef103be30397"
      unitRef="usd">52250000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTMtMS0xLTA_68a918a3-634d-4c23-bb76-c8942bae6f87"
      unitRef="usd">68434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo5ZmU1OGM2NDU1MDY0YzEwYmE0ZjFlZDhmMzBhNTg5Yy90YWJsZXJhbmdlOjlmZTU4YzY0NTUwNjRjMTBiYTRmMWVkOGYzMGE1ODljXzMyLTUtMS0xLTA_88a3117a-8711-44a6-b144-75bc8a2c2f8e"
      unitRef="usd">110182000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItMS0xLTEtMA_02dbfc9c-4fbd-4f01-918a-051e4620f35f"
      unitRef="usd">7202000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItMy0xLTEtMA_8721155e-dca8-4d16-9a8c-95638622a1cf"
      unitRef="usd">3751000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzItNS0xLTEtMA_c3222a34-ef77-498b-9700-f65b74b71dc1"
      unitRef="usd">3868000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtMS0xLTEtMA_a5417225-37b0-42ce-9521-00f17efeb383"
      unitRef="usd">48000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtMy0xLTEtMA_c80ae8e0-a5b3-46a7-9682-491aeeffe692"
      unitRef="usd">50000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzMtNS0xLTEtMA_e78137ec-35f1-4fb2-9814-ca882e1065f6"
      unitRef="usd">216000</us-gaap:IncomeTaxesPaid>
    <pgen:StockReceivedAsConsiderationForCollaborationAgreements
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtMS0xLTEtMA_5108f355-b8d3-48a9-9ecf-050475d388ca"
      unitRef="usd">0</pgen:StockReceivedAsConsiderationForCollaborationAgreements>
    <pgen:StockReceivedAsConsiderationForCollaborationAgreements
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtMy0xLTEtMA_3137fc98-a30a-419a-93b1-db8a175363f3"
      unitRef="usd">4530000</pgen:StockReceivedAsConsiderationForCollaborationAgreements>
    <pgen:StockReceivedAsConsiderationForCollaborationAgreements
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzUtNS0xLTEtMA_9f11115e-4fd7-4ba2-b47f-9d6e3e73e391"
      unitRef="usd">0</pgen:StockReceivedAsConsiderationForCollaborationAgreements>
    <pgen:StockIssuedIntangibleAssets
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTEtMS0xLTA_e82bb58a-a92e-44c3-ab44-cdd452fc36ed"
      unitRef="usd">0</pgen:StockIssuedIntangibleAssets>
    <pgen:StockIssuedIntangibleAssets
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTMtMS0xLTA_adc6ef49-2651-4b02-9f69-8c3b44230b14"
      unitRef="usd">0</pgen:StockIssuedIntangibleAssets>
    <pgen:StockIssuedIntangibleAssets
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzExLTUtMS0xLTA_d68f560e-2868-4a60-9fca-b198698bc149"
      unitRef="usd">159323000</pgen:StockIssuedIntangibleAssets>
    <us-gaap:StockIssued1
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTEtMS0xLTI0NzE_b18580a3-71b5-4dfb-b04e-b87414f7031c"
      unitRef="usd">56827000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTMtMS0xLTI0NzE_78c73979-3197-4893-b54d-393ce8584a50"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTUtMS0xLTI0NzE_ae4e03f8-b946-42bf-8f85-a3064b9c19b1"
      unitRef="usd">0</us-gaap:StockIssued1>
    <pgen:StockIssuedSettlementAgreement
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTEtMS0xLTM3ODI_bc9e85ec-ac59-47bf-b688-73b849548d29"
      unitRef="usd">18103000</pgen:StockIssuedSettlementAgreement>
    <pgen:StockIssuedSettlementAgreement
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTMtMS0xLTM3ODI_8718eb54-39d6-4e2e-bc37-4b2604a5b9d9"
      unitRef="usd">0</pgen:StockIssuedSettlementAgreement>
    <pgen:StockIssuedSettlementAgreement
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE0LTUtMS0xLTM3ODI_36dda342-33d4-4a51-ab5c-401fdde66fb0"
      unitRef="usd">0</pgen:StockIssuedSettlementAgreement>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTEtMS0xLTA_1adf077b-466c-4cf2-b6b3-715c8d94dde8"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTMtMS0xLTA_23e77173-2cb5-4328-84f4-1e00f5af5980"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzEzLTUtMS0xLTA_181df834-557f-42fc-87fd-b7855f4a0a3a"
      unitRef="usd">30000000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <pgen:AccruedCompensationPaidinEquityAwards
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTEtMS0xLTc0Mg_8ce5966b-089f-47e8-ac39-31b4d16d54d1"
      unitRef="usd">5100000</pgen:AccruedCompensationPaidinEquityAwards>
    <pgen:AccruedCompensationPaidinEquityAwards
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTMtMS0xLTc0Mg_8d11f795-613a-4819-a8ae-2c5155a0a908"
      unitRef="usd">1102000</pgen:AccruedCompensationPaidinEquityAwards>
    <pgen:AccruedCompensationPaidinEquityAwards
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTUtMS0xLTc0Mg_8ee896d7-5c11-4ddd-813e-0e4991f43bef"
      unitRef="usd">0</pgen:AccruedCompensationPaidinEquityAwards>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTEtMS0xLTA_0a775eb7-3a59-4574-a95b-8d83bca69ae0"
      unitRef="usd">277000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTMtMS0xLTA_afc733ca-d0a3-48d0-9ec7-188fe51f1858"
      unitRef="usd">694000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzE5LTUtMS0xLTA_4545b030-f23d-43b7-b7ef-4c4c5e9706f4"
      unitRef="usd">2267000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTEtMS0xLTA_15d15a9d-8307-4481-ac4c-e2a5fd855f1b"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTMtMS0xLTA_1df90459-e462-4525-a75f-a1d540ae0e22"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzIwLTUtMS0xLTA_cc1c6af8-1ed3-42d1-829a-d68b8b3548fb"
      unitRef="usd">234000</us-gaap:LiabilitiesAssumed1>
    <pgen:SaleOfAssetsIncludedInReceivables
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTEtMS0xLTM3ODg_954347c6-82db-453e-8be4-2fc5ef372d98"
      unitRef="usd">4227000</pgen:SaleOfAssetsIncludedInReceivables>
    <pgen:SaleOfAssetsIncludedInReceivables
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTMtMS0xLTM3ODg_e29de67a-3041-4d0b-9f79-34b2092ef0c6"
      unitRef="usd">0</pgen:SaleOfAssetsIncludedInReceivables>
    <pgen:SaleOfAssetsIncludedInReceivables
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZTo1NWEwMGEwZGMzOTk0YmNhYjEyMWY4ZjMxZjBjZDg2NC90YWJsZXJhbmdlOjU1YTAwYTBkYzM5OTRiY2FiMTIxZjhmMzFmMGNkODY0XzI0LTUtMS0xLTM3ODg_29225496-2d47-41b5-a25e-83987a2c2313"
      unitRef="usd">0</pgen:SaleOfAssetsIncludedInReceivables>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzEtMS0xLTEtMA_7a4a7c05-6d00-466d-b421-365cd0be6c99"
      unitRef="usd">51792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzEtMy0xLTEtMA_32d7cc98-28fa-4963-ac82-29567a1ea141"
      unitRef="usd">65793000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzMtMS0xLTEtMA_89266eb8-8942-4ab2-b22b-75eec23f0f8e"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzMtMy0xLTEtMA_7ab31f8c-1a77-4469-9f9f-1e281cff87c2"
      unitRef="usd">2223000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzQtMS0xLTEtMA_122d22bc-278e-468d-8775-980f7c04b91b"
      unitRef="usd">458000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzQtMy0xLTEtMA_dc774d6c-2a24-4f80-a656-334b4f060fde"
      unitRef="usd">418000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzUtMS0xLTEtMA_6030dfa0-ad1b-4489-af45-42813c6fbf05"
      unitRef="usd">52250000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMTgvZnJhZzo2ZDQ3ZjBmOTJhNGQ0NDNiODU3MzQ4MzE4MzkzOTkyMC90YWJsZToxNGMxNDlhMjM2MWM0YzI1OTJiMGRkMGUyYmQ3NDY2OS90YWJsZXJhbmdlOjE0YzE0OWEyMzYxYzRjMjU5MmIwZGQwZTJiZDc0NjY5XzUtMy0xLTEtMA_fc1ae7cd-6261-4f63-89df-3663c5ab423e"
      unitRef="usd">68434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzk0NDQ_4b616906-c39b-467b-895a-3dde72c18a7d">Organization and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trans Ova Genetics, L.C. ("Trans Ova") and Progentus, L.C. ("Progentus"), providers of reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and has substantially completed the wind down by December 31, 2020. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty resulting in a loss on deconsolidation of $2,648, which is included in other income, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. After deconsolidating the entity in April 2019, Precigen held its AquaBounty equity securities, which was an equity method investment that the Company accounted for using the fair value option, until October 2019 when the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party, for $21,587, resulting in the recognition of a realized gain of $7,348 which is included in unrealized and realized appreciation in fair value of equity securities and preferred stock, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 14 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company." &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that existing liquid assets as of December&#160;31, 2020, along with the net proceeds from the underwritten public offering in January 2021 (Note 23), will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators' product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December&#160;31, 2020, the Company incurred a net loss of $170,521 and, as of December&#160;31, 2020, had an accumulated deficit of $1,823,390. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, reduce uses of cash for operating and investing activities for non-healthcare functions, obtain regulatory approval of its product candidates, successfully commercialize its product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the original issuance of the Company's financial statements for the year ended December 31, 2018, the Company's resources of cash, cash equivalents, and short-term investments were not sufficient to fund the Company's planned operations through one year after the date the 2018 consolidated financial statements were originally issued and accordingly, there was substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern did not include cash sources outside of the Company's direct control that management expected to be available within the twelve months following the original issuance of the 2018 consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of the original issuance of the 2018 consolidated financial statements, the Company could not ensure that it would be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it was able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, was dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that were favorable to the Company. Should the Company not have been able to secure additional funding through these means, the Company could have had to engage in any or all of the following activities: (i) shift internal investments from subsidiaries and platforms whose potential for value creation was longer-term to near-term opportunities; (ii) sell certain of its operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. The 2018 consolidated financial statements were prepared on a going concern basis and did not include any adjustments to the amounts and classification of assets and liabilities that may have been necessary in the event the Company could no longer continue as a going concern.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzMzNzE_ba90c4d3-cf6e-455e-8104-7d81c58ff7f8"
      unitRef="usd">-2648000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzQyNzc_da1c9b75-0e6e-4531-b4dd-881cf196456e"
      unitRef="usd">21587000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i9d3080218ae0483fa5b7e0fe4a5fd372_D20191001-20191031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzQzMzI_c00f3c48-54a5-4489-a8d2-f827416c8295"
      unitRef="usd">7348000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <us-gaap:NetIncomeLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzYxNTU_35556c4c-3f78-4da9-91dd-9d98b4c68968"
      unitRef="usd">-170521000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjQvZnJhZzo2MDYyZWNlOTk4MzU0MmMzYTI4MGIyMjRlMDEyMWM3MS90ZXh0cmVnaW9uOjYwNjJlY2U5OTgzNTQyYzNhMjgwYjIyNGUwMTIxYzcxXzYyMDM_717b0803-b483-4a2b-8a1a-161c564645de"
      unitRef="usd">-1823390000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjQ0_c4e98b72-d59d-4792-81a3-dfb75619b53f">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 has had and continues to have an extensive impact on the global health and economic environments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second half of March 2020, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March 2020, ActoBio temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and the study is recruiting patients again. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. The temporary suspension of the PRGN-3005 trial was not related to safety issues in the studies, and in May 2020, recruitment resumed in the PRGN-3005 Phase 1 trial. Furthermore, uncertainty regarding the duration and severity of the ongoing pandemic may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 3 for further discussion of the impact of COVID-19 on MBP Titan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and licensing revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product and service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; in vitro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December&#160;31, 2020 and 2019, the Company had research and development commitments with third parties that had not yet been incurred totaling $12,054 and $14,664, respectively. The commitments are generally cancellable by the Company at any time upon written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December&#160;31, 2020 and 2019, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $30,164 and $47,238, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard&#160;&amp;amp; Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 18 for additional discussion of certain equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December&#160;31, 2020, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its investments in each of its joint ventures ("JVs") and in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Notes 4 and 17 and to certain of the Company's JVs in Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company determined that certain of its collaborators and JVs were VIEs. It also determined Harvest was a VIE as of December 31, 2019. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December&#160;31, 2020 and 2019, were $0 and $1,461, respectively, which represents the Company's maximum risk of loss related to the identified VIEs. See Note 5 for discussion of the Company's future funding commitments for its significant JVs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Company applies FASB Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including accounts receivable. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity in the allowance for credit losses for the years ended December&#160;31, 2020, 2019, and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#x2013;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Breeding stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#x2013;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8"&gt;one&lt;/span&gt; to fourteen years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets.&#160;The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 3 and 11 for additional discussion regarding goodwill impairment charges recorded in the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e"&gt;three&lt;/span&gt; to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 3 and 10 for additional discussion of impairment of long-lived assets for the three years ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 12 for the further discussion of the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises. There was no impact from GILTI to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59%&#x2013;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58%&#x2013;64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55%&#x2013;59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#x2013;10.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%&#x2013;1.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53%&#x2013;2.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33%&#x2013;3.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. As of December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) Trans Ova; and (iv) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. See Note 20 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 20 for further discussion of the Company's segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU 2018-17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis, and there was no material impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model for receivables to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2020-06"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021. Early adoption is permitted but no earlier than annual periods beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzA1_79f78e73-c0be-4a15-bb6b-bbd7463c4fa6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzEx_200108a3-a2db-4d5d-b8c6-73d8ce6f4693">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and licensing revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product and service revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; in vitro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <pgen:CollaborationAgreementTerminationNoticePeriod
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MDA_0de35b66-3913-436b-be1d-fc8432b9dc1d">P90D</pgen:CollaborationAgreementTerminationNoticePeriod>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="i17f6c337649843ef9b6c799eb5e89d84_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzkw_103ed3e5-6ed0-4dc1-8070-f245992e2d44">30 days</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDAz_9036b768-83a4-4079-b5a1-b77420d7ac7e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in &lt;/span&gt;&lt;/div&gt;research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE2ODQx_a025ca0a-ebf1-429c-ad95-5c021b81fb7b"
      unitRef="usd">12054000</pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred>
    <pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE2ODQ4_c8f4dde2-fc2e-47f0-a343-e92aa5555099"
      unitRef="usd">14664000</pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc3_59a2e9a4-8ed2-485f-a10e-b3b2ada243cc">Cash and Cash EquivalentsAll highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <pgen:HighlyLiquidInvestmentMaximumMaturityPeriod
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3MDQx_0c241872-c3c1-4a42-ae28-3df629e6dab2">P3M</pgen:HighlyLiquidInvestmentMaximumMaturityPeriod>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3NTIw_0fd4d58e-48d3-4e5e-ab09-ed1f5d11eb83"
      unitRef="usd">30164000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzE3NTI3_a3120486-a9c3-417d-bf30-e87acc9275e9"
      unitRef="usd">47238000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzc3_f593718d-7044-40d9-a12c-9ec55dcc54f3">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard&#160;&amp;amp; Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <pgen:EquitySecuritiesPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjYw_46bf401a-40ed-4d45-9deb-411c830951fb">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 18 for additional discussion of certain equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.&lt;/span&gt;&lt;/div&gt;</pgen:EquitySecuritiesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjUw_7189e78f-f34e-462e-8428-6bf878717231">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQ2_b457f886-5b32-4a77-af89-4313f892c782">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December&#160;31, 2020, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc5_4e043626-f4a4-489d-936e-334b6b2023f2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its investments in each of its joint ventures ("JVs") and in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Notes 4 and 17 and to certain of the Company's JVs in Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDA4_41427a8e-e997-47fc-afb7-6ca9bc3fb326">Variable Interest EntitiesThe Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MjM4_9b189323-0ee7-428d-8bff-d338248fae71"
      unitRef="usd">0</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI1MjQ1_091c0bc5-a1e9-437a-ab58-5dce979e32c7"
      unitRef="usd">1461000</us-gaap:VariableInterestEntityEntityMaximumLossExposureAmount>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQw_5cda666c-4b3e-4b07-8640-29553be1efaa">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Company applies FASB Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including accounts receivable. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjY4_6410bf32-ecf7-44a3-8a84-8a82c34ba1af">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity in the allowance for credit losses for the years ended December&#160;31, 2020, 2019, and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write offs of accounts receivable, net of recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtMS0xLTEtMA_c6d05399-fe8c-4609-b7bc-6eeb50b32da0"
      unitRef="usd">7513000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtMy0xLTEtMA_66e838ea-b7e2-46a5-8c87-5a543c5d1429"
      unitRef="usd">4991000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i6a4041a8bb484da3b179334191b0137d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzEtNS0xLTEtMA_09e09e5f-b272-4ee7-b32a-7d0f3024cc11"
      unitRef="usd">4631000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItMS0xLTEtMA_9725deff-551b-4f15-bdd8-2e97fa4f6785"
      unitRef="usd">899000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItMy0xLTEtMA_38251d48-95f7-4e6c-9dfc-ee441b77af3b"
      unitRef="usd">3384000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzItNS0xLTEtMA_65d87677-25ec-474b-ba88-5a7895b70453"
      unitRef="usd">1627000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtMS0xLTEtMA_3497d1bb-6a74-41b8-9ff3-16791634f7a1"
      unitRef="usd">2078000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtMy0xLTEtMA_86074990-4d35-4730-ad9f-ce93bd932470"
      unitRef="usd">862000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i3ac66f310c0b46028445485d22eb5a44_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzMtNS0xLTEtMA_517c9d77-a162-4209-b9d1-8600b438482a"
      unitRef="usd">1267000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i8952cdcb9a6e414eb3558452807047c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtMS0xLTEtMA_217623f5-a2cc-4326-b9d2-ec7d8322bdf3"
      unitRef="usd">6334000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtMy0xLTEtMA_9104b2d0-e126-4fa9-9256-96e91a776c2e"
      unitRef="usd">7513000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo1ODI3M2RmNGEyNjY0YTk0OTE2NWNlMTViZjUxZGUyZC90YWJsZXJhbmdlOjU4MjczZGY0YTI2NjRhOTQ5MTY1Y2UxNWJmNTFkZTJkXzQtNS0xLTEtMA_32df0423-f218-4c61-9ad9-b3d502963415"
      unitRef="usd">4991000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQx_3c4e209b-e26c-4f81-9047-183c554e0ee0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzAx_9576fc40-259e-40e2-bc61-cf274b590356">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#x2013;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Breeding stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#x2013;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8"&gt;one&lt;/span&gt; to fourteen years</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pgen:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjMx_6876822c-0e99-4984-9739-f0c6ebaa350a">The estimated useful lives of these assets from continuing operations are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#x2013;15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#x2013;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Breeding stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#x2013;4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#x2013;7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8"&gt;one&lt;/span&gt; to fourteen years.</pgen:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib3ad6258403540099941f2a068f4043d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliODNlNjk0YTlmNTRkYjk4ODhkNWY2MjFiMTI0YzMxXzQzOTgwNDY1MTExMTM_77ffa09b-6457-4bea-9d72-30f4a016bd61">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6ba88e8a7dd14e0e90467b7df8a754de_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliODNlNjk0YTlmNTRkYjk4ODhkNWY2MjFiMTI0YzMxXzQzOTgwNDY1MTExMTg_dfc79ff4-534a-4d28-a195-ed44793930f2">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie518adbaa2914c83a75398892dc33f68_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzItMS0xLTEtMC90ZXh0cmVnaW9uOjU1NTBmMWU3NWFlNzQ4YWRiOTdlYjNlZDVhMTk0NmM5XzQzOTgwNDY1MTExMjE_59e6dd39-4dfa-4bb8-9bc4-743d79f94d94">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i027d6d87c78e4317a791117a2393e261_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzItMS0xLTEtMC90ZXh0cmVnaW9uOjU1NTBmMWU3NWFlNzQ4YWRiOTdlYjNlZDVhMTk0NmM5XzQzOTgwNDY1MTExMjY_b8192658-2305-4445-9b0d-3cc340430649">P23Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d3ba94d22bb43898d8e8b5658bd229f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmE1ODZjODFhODNmNzQ2YmNhYTcxN2U1MjQ4YzU5ZjQ0XzQzOTgwNDY1MTExMTI_9a3d5bf3-2ba4-4b17-841e-19a51675d840">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i91fece37ad5247789405374ea393337a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzMtMS0xLTEtMC90ZXh0cmVnaW9uOmE1ODZjODFhODNmNzQ2YmNhYTcxN2U1MjQ4YzU5ZjQ0XzQzOTgwNDY1MTExMTY_5b335309-87db-47e6-9f0c-4c62b1eacb37">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i84a4580dd157421b961abbc9269d361d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJjZTE3OTJiMjIyNDQ5Mjg4OTJmNWU3NmUxOGIzMTdlXzQzOTgwNDY1MTExMTI_3e3c06dd-6923-4087-8224-f41837a68673">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i36032ed843b643ee8327a678783a2ac2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmJjZTE3OTJiMjIyNDQ5Mjg4OTJmNWU3NmUxOGIzMTdlXzQzOTgwNDY1MTExMTY_77fe126b-44dd-4906-a074-49e91b1cf852">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i486b675333cb4c5b91c24f42597dc946_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJjYzdmODU1MjgwMTQ2NzQ4MjM3NzA3ZDk4MGQwMDQ3XzQzOTgwNDY1MTExMTI_6315b056-e52f-48e5-b010-c1220dce88e9">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie0750ead12ac4214b42916e3ed24bdfe_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjJjYzdmODU1MjgwMTQ2NzQ4MjM3NzA3ZDk4MGQwMDQ3XzQzOTgwNDY1MTExMTY_5671e4ee-6af5-4cf0-9eb0-98fa36d2d708">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8a5e98f13a3a461ca2c7fbf143a0e4cb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmM2NjZlYmNjZTY2ZTQ2N2NiMzRhY2RhYzVmMDY0NzU3XzQzOTgwNDY1MTExMTI_970b40d3-4bf9-4db6-9ac6-e2b8a6bf76e8">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3ab8005306a844bda35c05aa23ceb1a6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTo2OTYxZWRhNWVlZWM0YTE0YjVkZTI3NTc3NTY0NWNmMi90YWJsZXJhbmdlOjY5NjFlZGE1ZWVlYzRhMTRiNWRlMjc1Nzc1NjQ1Y2YyXzYtMS0xLTEtMC90ZXh0cmVnaW9uOmM2NjZlYmNjZTY2ZTQ2N2NiMzRhY2RhYzVmMDY0NzU3XzQzOTgwNDY1MTExMTY_b134dbec-af49-46e0-a1c0-316d7cc2bca1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id068240ac9514712ac2777d3f353304d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjEy_5968307d-5f67-4df8-82b9-a1123e7d833c">P14Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjkx_ed87f4b1-4898-4083-b495-fa1379b85ea1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets.&#160;The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjg2_5cd7f939-ce38-4cdf-87b4-1ad82d196b0a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzMw_e4f49f07-f28e-4ffe-aa3b-425010607434">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e"&gt;three&lt;/span&gt; to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i11e11947645549f79ae1c1b067e15412_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjE4_949335dc-8b5e-4ca6-b501-6da4e4e791d0">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzMx_03281ae7-3e46-4d13-93de-0aa8c3b7de08">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDMy_1d37d6a8-02e3-4ad4-820a-b5a51c6613f0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzM0Nzc2_99b5b2fc-d809-4717-9302-53ce58d51f0e"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzI4_3deca997-d840-4159-969b-89edafeaede1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzkz_2957d5dc-f6f6-4049-92a0-1ba41a1e13a5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDE3_127f4db8-98ba-4b0c-8bb0-ef2c545c944c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59%&#x2013;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58%&#x2013;64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55%&#x2013;59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#x2013;10.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%&#x2013;1.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53%&#x2013;2.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33%&#x2013;3.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzQxMjE4_e1dd957f-47ed-433f-b063-3ac27aaf0fb8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzQ5_d41ffca3-79bb-4788-96fe-a0d4388ff2ee">The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59%&#x2013;90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58%&#x2013;64%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55%&#x2013;59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#x2013;10.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%&#x2013;1.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53%&#x2013;2.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33%&#x2013;3.06%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItMS0xLTEtMA_17a7d72a-e0ae-43a3-a496-4b57449473ed"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItMy0xLTEtMA_51745177-a930-476e-acc2-d87835d85119"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzItNS0xLTEtMA_5d2233eb-fadb-4c08-956d-13f52c470e78"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjdjN2E4MzllM2NiNTQ2Mzk5Nzg5ZjMxNTRjYTIzOTZjXzQzOTgwNDY1MTExMzI_b3b4199f-00da-4841-bbb4-641add517a41"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMS0xLTEtMC90ZXh0cmVnaW9uOjdjN2E4MzllM2NiNTQ2Mzk5Nzg5ZjMxNTRjYTIzOTZjXzQzOTgwNDY1MTExMzg_7c464798-a8fc-49d8-9f01-3ba207bf6106"
      unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjMzMjFkMzBiZGU2ZDRkODhiMzYzMzZjODc2NjVhOWExXzQzOTgwNDY1MTExMzI_194b1e43-58ce-4d4f-840e-440f12921511"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtMy0xLTEtMC90ZXh0cmVnaW9uOjMzMjFkMzBiZGU2ZDRkODhiMzYzMzZjODc2NjVhOWExXzQzOTgwNDY1MTExMzg_6dfd8684-d19b-453e-b4a1-0a2a2339cc7a"
      unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjJhYTU0MmUxOTExNzRhYzE5MDQ3ZWFiMzJmZjMzNzI0XzQzOTgwNDY1MTExMzI_44714a02-c80a-494a-9d4a-cc535e341c55"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjJhYTU0MmUxOTExNzRhYzE5MDQ3ZWFiMzJmZjMzNzI0XzQzOTgwNDY1MTExMzg_6a020b7e-8172-4ced-8d3e-8517eb4e21fd"
      unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2a99bff0ee894d4ebc0529513dfabc6f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjI2M2JkNGYyM2YyMTQ5M2NhZmUzYzQ1NDJlMjg1NzAzXzQzOTgwNDY1MTExNDI_e2104200-0549-4423-81b1-aea05db30950">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5b61e5b1fd0b43908fdd386d73838549_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjI2M2JkNGYyM2YyMTQ5M2NhZmUzYzQ1NDJlMjg1NzAzXzQzOTgwNDY1MTExNTA_47d81402-e6fc-4c5e-9217-e1dcee4d4dc3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtMy0xLTEtMA_b3111627-b476-4474-8a0c-e2ae75a7f180">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzQtNS0xLTEtMA_9ca3324a-49a7-403c-a031-cb6ca1767454">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNGUyNDdlZmI3YTQwMjY4N2Y0NDE4NTY0ODg0NThjXzQzOTgwNDY1MTExNDY_a4657105-d00b-4333-8c08-5c3686b675f2"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNGUyNDdlZmI3YTQwMjY4N2Y0NDE4NTY0ODg0NThjXzQzOTgwNDY1MTExNTQ_82f9b230-257b-482c-b2dc-db098a3952f1"
      unitRef="number">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjY3YTBiMWZjNjljYjQ2NTZhZDAzYmU5MmY5ZTZkOTAyXzQzOTgwNDY1MTExNDY_e75690be-113e-4afe-b492-d65e89272dd9"
      unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjY3YTBiMWZjNjljYjQ2NTZhZDAzYmU5MmY5ZTZkOTAyXzQzOTgwNDY1MTExNTQ_27142f14-5d8c-489c-8749-02213cff8a98"
      unitRef="number">0.0258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtNS0xLTEtMC90ZXh0cmVnaW9uOjU5YjhiNmJlYmVlNTQ1MTNhMDQwMDhhMmMxNDVmYTU0XzQzOTgwNDY1MTExNDY_10db9821-646b-42c2-9ff6-3dfd5c599aed"
      unitRef="number">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90YWJsZTpiZjA5OGY4YzIzOGM0YzQyODM2MWQwN2YyMjhkMjZhNC90YWJsZXJhbmdlOmJmMDk4ZjhjMjM4YzRjNDI4MzYxZDA3ZjIyOGQyNmE0XzUtNS0xLTEtMC90ZXh0cmVnaW9uOjU5YjhiNmJlYmVlNTQ1MTNhMDQwMDhhMmMxNDVmYTU0XzQzOTgwNDY1MTExNTQ_22188a77-96eb-468e-bd82-aa47a9ec3138"
      unitRef="number">0.0306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjU2_9cb0ee4e-8366-4708-ae15-df4103840b9a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMzM1_30f68441-3dbf-4157-b7f7-4d038bea41fc">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. As of December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) Trans Ova; and (iv) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. See Note 20 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 20 for further discussion of the Company's segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxMjc0_a90f448b-b26b-44b3-8741-cde3acb3c4fa">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzUxNDA1_4f7ca151-6223-41ae-869e-426bc8f4e3d5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU 2018-17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis, and there was no material impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model for receivables to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity's Own Equity (Subtopic 815-40)&#x2014;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2020-06"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021. Early adoption is permitted but no earlier than annual periods beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzUzNjg_1cc9d764-6a74-4398-aee5-d76736ba2a81">Discontinued Operations&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MBP Titan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially complete by December 31, 2020, with the final disposition of certain property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the facility operating lease occurring in January 2021. See Note 23 for further discussion of the facility operating lease. This discontinuation of operations represented the continuation of a strategic shift, that the Company commenced as part of the Transactions defined and discussed below, to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners and Intrexon Energy Partners II, including the associated deferred revenue remaining under each collaboration agreement (Notes 5 and 6), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying consolidated financial statements for all periods presented as a result of the Company's continuing involvement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale or abandonment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale or abandonment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the financial results of discontinued operations of MBP Titan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. Immediately prior to the reclassification, the Company evaluated goodwill, long-lived assets, and the equity method investment included in the Transactions for impairment. The Company recorded an impairment charge of $79,396, including $58,042 and $21,354 related to goodwill and other long-lived assets, respectively, at the Okanagan, Oxitec, Fine Chemicals, and AgBio reporting units. Additionally, the Company recorded a $10,283 impairment charge for the write down of the equity method investment and related intangible assets included in the EnviroFlight Sale. These impairment charges are included in loss from discontinued operations in the accompanying consolidated statement of operations for the year ended December, 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes deferred revenue, current, from related parties of $1,243.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes deferred revenue, net of current portion, from related parties of $6,836.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the financial results of discontinued operations related to the Transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on release of cumulative foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenues recognized from related parties of $436.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenue recognized from related parties of $3,042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes the impairment charge of $89,679 related to the Transactions discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenue recognized from related parties of $4,665.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aedes Aegypti&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on release of cumulative foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized and realized depreciation on equity securities and preferred stock, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of EnviroFlight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in EnviroFlight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also see Note 14 below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for its investment in EnviroFlight using the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for certain equity securities held in one of its collaborators using the fair value option, and the collaborator was considered an equity method investment through September 30, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where applicable, the notes to the accompanying consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Out-of-Period Adjustment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's financial position or results of operations for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzY1OTcwNjk3ODg3MDc_c0d5e9f2-91ec-4b4d-a38a-c466cb5ec6b9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale or abandonment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale or abandonment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the financial results of discontinued operations of MBP Titan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes deferred revenue, current, from related parties of $1,243.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes deferred revenue, net of current portion, from related parties of $6,836.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the financial results of discontinued operations related to the Transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on release of cumulative foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenues recognized from related parties of $436.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenue recognized from related parties of $3,042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes the impairment charge of $89,679 related to the Transactions discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TS Biotechnology Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EnviroFlight Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,622)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106,492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes revenue recognized from related parties of $4,665.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aedes Aegypti&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on release of cumulative foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized and realized depreciation on equity securities and preferred stock, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of EnviroFlight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in EnviroFlight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzUtMS0xLTEtNjQ2OQ_b5522f36-67d8-415b-aedf-4e1afa8fa16b"
      unitRef="usd">586000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzUtMy0xLTEtNjQ2OQ_1a03aa64-8fe4-4a64-a022-70b517490e83"
      unitRef="usd">17017000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzctMS0xLTEtNjQ2OQ_79db8a84-ef01-49fd-9668-b460bebfeecd"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzctMy0xLTEtNjQ2OQ_f6ee2f34-b7e8-48fd-a859-c70bb39bb5d6"
      unitRef="usd">9635000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzktMS0xLTEtNjQ2OQ_efaf5011-7ed1-4a98-ad75-71bde048c671"
      unitRef="usd">9131000</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzktMy0xLTEtNjQ2OQ_fd6497b2-96cc-4722-b69f-239c3a142043"
      unitRef="usd">13425000</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzEwLTEtMS0xLTExNTcw_825caff5-08ab-4c9d-8aa6-74b476c68fd6"
      unitRef="usd">136000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzEwLTMtMS0xLTExNTcw_43ceae79-0de7-4e58-aa1f-e0fd67395216"
      unitRef="usd">636000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzExLTEtMS0xLTY0Njk_b69b42ac-df87-48ce-aea4-960536e168c2"
      unitRef="usd">9853000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzExLTMtMS0xLTY0Njk_a28dbd53-78bb-4b6b-9268-e920c86d74be"
      unitRef="usd">40713000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE0LTEtMS0xLTY0Njk_62950e8d-471e-48ce-b1ab-8d85d891ed8c"
      unitRef="usd">1890000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE0LTMtMS0xLTY0Njk_a4a51bcc-7e21-4745-81fc-9f2fd1d464f2"
      unitRef="usd">1548000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE1LTEtMS0xLTY0Njk_e669065a-798b-4d34-8d70-072d2cd5a677"
      unitRef="usd">619000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE1LTMtMS0xLTY0Njk_a4024b39-65a2-415d-8b17-806611b410e1"
      unitRef="usd">1657000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE3LTEtMS0xLTY0Njk_c7702df6-93be-44bc-87e8-471b496d1b2d"
      unitRef="usd">11538000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE3LTMtMS0xLTY0Njk_c9c29774-0e8c-44bc-a2cd-cafbcca0e72a"
      unitRef="usd">13730000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE5LTEtMS0xLTY0Njk_dd679729-4caf-4c47-996b-6d4374caf486"
      unitRef="usd">14047000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i1657211515ac4efba0ceb6486e26a0fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0MTk3ODM1NTlmNTk0NzVmOTI1ZWFiMGQwNDI5NTU1Yy90YWJsZXJhbmdlOjQxOTc4MzU1OWY1OTQ3NWY5MjVlYWIwZDA0Mjk1NTVjXzE5LTMtMS0xLTY0Njk_25b17b52-edf2-495f-a3b4-c754bec0dcf1"
      unitRef="usd">16935000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtMS0xLTEtNjUwNg_e670922d-8991-45b6-a313-9c2788c85917"
      unitRef="usd">40692000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtMy0xLTEtNjUwNg_f0e9b1f5-c662-4c7c-9591-d19200473026"
      unitRef="usd">37423000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzMtNS0xLTEtNjUwNg_691d1d95-9232-4de4-88c5-1240df691649"
      unitRef="usd">33830000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtMS0xLTEtNjUwNg_2f147fd2-9c29-40dd-8174-3b46eda05bb1"
      unitRef="usd">-40692000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtMy0xLTEtNjUwNg_b5ec775e-b911-4584-ac7e-ad70a7ee2fa8"
      unitRef="usd">-37423000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzQtNS0xLTEtNjUwNg_253b2a03-7328-481d-97e6-2118b3d5cf88"
      unitRef="usd">-33830000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktMS0xLTEtNjUwNg_c5d7e8ed-6ed0-4785-a988-f58d40faa54f"
      unitRef="usd">-40692000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktMy0xLTEtNjUwNg_10afd061-3ba8-4ccb-b2ee-902100441791"
      unitRef="usd">-37423000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzktNS0xLTEtNjUwNg_c3cc51ed-2744-4987-b13b-59dfba825e89"
      unitRef="usd">-33830000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTEtMS0xLTY1MDY_35464bd9-4dca-49e3-b1c9-2d5d3f1aa024"
      unitRef="usd">-40692000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTMtMS0xLTY1MDY_858902f8-c911-4d39-b981-a792e98c3963"
      unitRef="usd">-37423000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo1YWEyNjQ2NDhkYTk0ZTU4YWUzMWYxYTE5NWU1MjRiOC90YWJsZXJhbmdlOjVhYTI2NDY0OGRhOTRlNThhZTMxZjFhMTk1ZTUyNGI4XzExLTUtMS0xLTY1MDY_30dcd668-bc81-4ec5-bef8-608dde3d56c9"
      unitRef="usd">-33830000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MzExNDg_113e89d0-8fc4-4127-a0f2-edef17650bc2"
      unitRef="usd">9635000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MzExNTg_4b236ea2-63de-470a-9a6b-09e4888be3c1"
      unitRef="usd">12406000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtMS0xLTEtMTAwODA_a68d3c87-312b-4826-bf59-c1e1ec43f763"
      unitRef="usd">2474000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtMy0xLTEtMTAwODA_73658f77-ffc0-40be-8dbb-8c7183f5b595"
      unitRef="usd">3647000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzMtNS0xLTEtMTAwODA_edc3e045-8d6c-4b6e-8ac8-7c96d339ee35"
      unitRef="usd">3493000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtMS0xLTEtMTAwODA_83f1fd4f-ff14-433b-a41c-4602ddc7a37e"
      unitRef="usd">9635000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtMy0xLTEtMTAwODA_d0a6b7f1-b85c-442a-b0a7-8c146a13298f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzQtNS0xLTEtMTAwODA_075b83d0-2e8a-42f3-bb85-8c21c45a7b19"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtMS0xLTEtMTAwODA_74dd5a83-5b79-42bf-a678-6f1de5fbacb0"
      unitRef="usd">12406000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtMy0xLTEtMTAwODA_02636f38-4617-40d6-9d57-f788663af3f6"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzUtNS0xLTEtMTAwODA_68ebd66b-d49f-4825-a5e8-cb5943d99bd2"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ShareBasedCompensation
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTEtMS0xLTEwMDgw_45dbdff0-35cd-45ef-bd85-268950b3bb91"
      unitRef="usd">-34000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTMtMS0xLTEwMDgw_93a6615b-3bae-495c-9102-65c48a7e7871"
      unitRef="usd">1345000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzEwLTUtMS0xLTEwMDgw_542aa32a-c343-44a7-9dac-741fec5052c2"
      unitRef="usd">1870000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTEtMS0xLTEwMDgw_e2805fbb-5d84-4f5a-af99-04e621b4e5fa"
      unitRef="usd">88000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iee18ecba2bc9456e9963b9859b0de407_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTMtMS0xLTEwMDgw_5dbce272-4022-42d3-982d-8c7cefd28ff8"
      unitRef="usd">2114000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie92ebbe68805472d805003395a5e5588_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTowNDZlZWMzODVjNGQ0MjgxYjBjMzRmMGI5ODE3YjkyMS90YWJsZXJhbmdlOjA0NmVlYzM4NWM0ZDQyODFiMGMzNGYwYjk4MTdiOTIxXzE0LTUtMS0xLTEwMDgw_8a2587f9-c23c-4746-8fcf-f4b0d65ae183"
      unitRef="usd">3558000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i8a892879d07044f58213c5a70dccecdb_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM2Mw_9d47d207-7827-407f-9a5a-ea5379999c8b"
      unitRef="usd">53000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ie5536916a8c741d08eecaed7c735bd94_I20200102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzE3MTE_50e437ed-f9dc-4ca3-a9d4-1a392f972f73"
      unitRef="usd">12200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MDE_9e3be7d2-b7bc-4786-a05c-e1f17c499451"
      unitRef="usd">79396000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MTU_46b5aad5-e99f-4472-a8f6-20579df61092"
      unitRef="usd">58042000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i3b28493ba5d84b4b91c9f4fb9047e96e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI2MjI_d6ae38c6-8139-4126-8c65-50da54fb2394"
      unitRef="usd">21354000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i87b81adc30c64968b22a72162d34e9c2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzI3OTM_1222abdd-e0b9-4db4-8b36-d46b0a9894f9"
      unitRef="usd">10283000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="ib1656e2b95eb4e86b30c7f13bec36e35_D20200101-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTk0NDY_3dd433e8-8395-442f-9b23-fa2c8a01cee6"
      unitRef="usd">-26957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtMS0xLTEtMA_1069d7ee-8477-4ba0-98a7-1d8143c25f33"
      unitRef="usd">2223000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtMy0xLTEtMA_268171ad-b799-4725-93ab-808eb2257bc8"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzMtNS0xLTEtMA_d585c3f4-129c-4768-8f3c-5b552932ab0c"
      unitRef="usd">2223000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtMS0xLTEtMA_0cfbe85a-939a-48a3-85cb-80a2daeeb009"
      unitRef="usd">9698000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtMy0xLTEtMA_680ec9a9-fefb-43a1-991f-539f64761cff"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzQtNS0xLTEtMA_2f16da96-e780-4ba1-98d3-51bc6f053451"
      unitRef="usd">9698000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtMS0xLTEtMA_88802fe6-7a6b-4cae-9243-2dbdd0331474"
      unitRef="usd">51975000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtMy0xLTEtMA_4bd6abbf-7706-404b-bccf-cfcb55751967"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzUtNS0xLTEtMA_2b8dd491-29f6-41db-b7f6-70089e15bbd3"
      unitRef="usd">51975000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtMS0xLTEtMA_5ad6aa66-286a-4dbe-8ecb-2b743cf17e00"
      unitRef="usd">20891000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtMy0xLTEtMA_7adcc202-93bd-4408-a6c4-9bf1f250d39a"
      unitRef="usd">4383000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzYtNS0xLTEtMA_af3ded6c-984f-4f7a-96a3-d5ed0c1eb247"
      unitRef="usd">25274000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzctMy0xLTEtMA_e4778527-7fcb-4268-8936-cbab018fc014"
      unitRef="usd">7817000</pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzctNS0xLTEtMA_9d1d1b50-6bdb-413a-8743-3ed732660bfd"
      unitRef="usd">7817000</pgen:DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktMS0xLTEtMA_284cf8e3-91e8-4026-80ed-0cb720413b8e"
      unitRef="usd">13622000</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktMy0xLTEtMA_b35c9daa-5220-495e-91b9-01325d27ec85"
      unitRef="usd">0</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzktNS0xLTEtMA_33a819d3-a140-4cc1-903e-fcc84dc55ad8"
      unitRef="usd">13622000</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTEtMS0xLTA_fcecb608-e465-4fd0-81d8-0714624c4fb1"
      unitRef="usd">212000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTMtMS0xLTA_3e6654a4-6537-4a35-b897-6f8895cd6069"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEwLTUtMS0xLTA_a406107e-2786-48ec-8776-f6b650940b42"
      unitRef="usd">212000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTEtMS0xLTA_ddac7efe-c713-4d60-ac41-1f7b05907659"
      unitRef="usd">98621000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTMtMS0xLTA_8cc62a56-c1f8-4f1f-9789-1ed54bf95643"
      unitRef="usd">12200000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzExLTUtMS0xLTA_53284801-6aa7-4a57-bc9d-646ceedb6d83"
      unitRef="usd">110821000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTEtMS0xLTA_b1bf8083-753c-4ba4-9369-0c1448365db8"
      unitRef="usd">8723000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTMtMS0xLTA_2d6ea7e5-f0ac-402f-af1c-3b6d50591b82"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzEzLTUtMS0xLTA_78eeab4f-f944-402f-82d6-0d36fbd77008"
      unitRef="usd">8723000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTEtMS0xLTA_b1081731-98a0-410d-baf7-1bad67dd1028"
      unitRef="usd">2459000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTMtMS0xLTA_e5833bcd-a834-47c9-9b22-463e7b4e9823"
      unitRef="usd">0</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE0LTUtMS0xLTA_6d56927c-bf65-4f04-a11f-61743026fccd"
      unitRef="usd">2459000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTEtMS0xLTA_7f100272-fe4f-4d6e-9b93-dc6d3f36faef"
      unitRef="usd">3058000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTMtMS0xLTA_46e78319-ece6-4098-a67d-ef8e501d9b77"
      unitRef="usd">41000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE1LTUtMS0xLTA_34799c58-33c0-48f3-94be-6d301de4aa7e"
      unitRef="usd">3099000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTEtMS0xLTA_66d432c0-37be-4db3-bc0c-9fad2cc0cc56"
      unitRef="usd">19410000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTMtMS0xLTA_c55b00a2-75c6-4ff4-b1f2-893eee4b7af2"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE2LTUtMS0xLTA_24f6f171-18df-4cd3-80fa-79599b5114a3"
      unitRef="usd">19410000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTEtMS0xLTA_654587c2-ca40-4a85-81fc-51ef5aed3360"
      unitRef="usd">12623000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTMtMS0xLTA_3f6df299-aeac-46cf-87a2-1b23eea585c7"
      unitRef="usd">0</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent>
    <pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE3LTUtMS0xLTA_ce455bcc-7f1c-47db-a665-14046d78e28c"
      unitRef="usd">12623000</pgen:DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTEtMS0xLTA_928f319c-1b1c-4ff8-a899-20d041666eb4"
      unitRef="usd">1019000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTMtMS0xLTA_e0afa688-cda8-40a8-a09d-e7b0309f5707"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE4LTUtMS0xLTA_47962867-e2f8-4410-a15d-85467e1aec18"
      unitRef="usd">1019000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i21471e6197b5427aa9b34d6b3debcbe4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTEtMS0xLTA_fa731729-12a0-46d9-84c8-0ae9d7ae573a"
      unitRef="usd">47292000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i2b06f8ff3659402fb91abb688b2698ef_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTMtMS0xLTA_1a13b36c-1b9c-43c4-ac12-499070e542c7"
      unitRef="usd">41000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ia3da9f131522486b89e80d1abf10d1c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo0YmFiODhjYWJhNWE0MjhkOGY2ZDVjZDc3ODU2OWFlYS90YWJsZXJhbmdlOjRiYWI4OGNhYmE1YTQyOGQ4ZjZkNWNkNzc4NTY5YWVhXzE5LTUtMS0xLTA_051393b8-0a25-4b9a-baa6-cf252a2b7781"
      unitRef="usd">47333000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="i85eefc0df3064556bd575eced34b22d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM1NjM_b568a260-1f25-4667-b83b-e73c47ea3ed0"
      unitRef="usd">1243000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent
      contextRef="i85eefc0df3064556bd575eced34b22d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM2NDI_ccecf7de-77e4-4537-b5d2-1adeaf333591"
      unitRef="usd">6836000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItMS0xLTEtMA_46c31076-ba39-42b0-b769-afddd707086c"
      unitRef="usd">1294000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItMy0xLTEtMA_a68ca088-f47d-471e-ad84-669100d1a4f1"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzItNS0xLTEtMA_45493750-8b5c-4733-a3d5-587197b73260"
      unitRef="usd">1294000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtMS0xLTEtMA_41bd62bd-7ab0-4a25-8330-191e9a4c9e97"
      unitRef="usd">896000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtMy0xLTEtMA_38fe144e-6dd0-4b16-ad2c-cf677a1c58a1"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzMtNS0xLTEtMA_453a1c5b-124f-4a08-b8f0-f41a9ba0e3a2"
      unitRef="usd">896000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtMS0xLTEtMA_eede913a-bb73-4298-83b9-7956118652b1"
      unitRef="usd">398000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtMy0xLTEtMA_10f49833-c0db-4572-aa26-f0efc91ca5b3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzQtNS0xLTEtMA_f59cdfb0-d469-4890-b592-afa8d22bc51d"
      unitRef="usd">398000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMS0xLTEtMTAzNg_6c2b9cf1-71b4-46f7-9bb8-4f7885f84182"
      unitRef="usd">633000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMy0xLTEtMTAzNg_59d67b04-bd8f-4b6d-a9df-732124dc7af9"
      unitRef="usd">39000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtNS0xLTEtMTAzNg_ecc90129-b73b-44a9-9e3c-f98fc822d5fa"
      unitRef="usd">672000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMS0xLTEtMTAzNg_fbe79ab6-df6e-4820-986d-69a0a4133ab1"
      unitRef="usd">-26957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMy0xLTEtMTAzNg_14de6909-1e14-47d5-8fe6-a0a1048c7e3f"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtNS0xLTEtMTAzNg_93c35bc5-68f8-4f6f-81c5-b31ef6391dc1"
      unitRef="usd">-26957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMS0xLTEtMA_afa71fbe-a097-4bc5-9cc2-78e5513b735f"
      unitRef="usd">129000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtMy0xLTEtMA_d53ff244-036f-4f48-9fc0-e3ae6b53955f"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzUtNS0xLTEtMA_95ce8ac5-1972-4b2b-9442-c52be33cd7bc"
      unitRef="usd">129000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtMy0xLTEtMA_28a6c60c-c110-4a22-8902-a61e502c44e8"
      unitRef="usd">-38000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzYtNS0xLTEtMA_06f996da-4250-4b76-9ab2-790362d8f178"
      unitRef="usd">-38000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctMS0xLTEtMA_ee1cdf3e-cb7a-486d-aac5-86450c047d16"
      unitRef="usd">-26055000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctMy0xLTEtMA_509571cc-7735-4544-9efd-e433bc7665e6"
      unitRef="usd">1000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzctNS0xLTEtMA_7a4c9e72-42b2-46c6-9b39-f943664687f2"
      unitRef="usd">-26054000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtMS0xLTEtMA_00045c1b-c082-4e11-aa9c-4ef4996ce565"
      unitRef="usd">2000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtMy0xLTEtMA_c27a7d1b-c94e-41d9-b835-a8b3052e39fa"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzgtNS0xLTEtMA_0185db6e-cfb3-4e6d-9382-a28eb5f35b28"
      unitRef="usd">2000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktMS0xLTEtMA_ab8c23cc-5b57-49e9-8881-401a4c80b508"
      unitRef="usd">-26057000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktMy0xLTEtMA_e195f0c8-b0f2-45c3-b750-5513e4d68c41"
      unitRef="usd">1000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ifd7b148d9b934a37973766102d67c3be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NmMyZTE5YWMyOTY0Zjg3YmJlYjY5MDhiMWVkYWMyMC90YWJsZXJhbmdlOjY2YzJlMTlhYzI5NjRmODdiYmViNjkwOGIxZWRhYzIwXzktNS0xLTEtMA_bf03e4cc-74e3-41bd-b7ed-97a6de345c77"
      unitRef="usd">-26056000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if3ea4810310f41c692ba79c0e33d366e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM3ODA_9629c1cd-0518-4a0e-a1e5-c8d5b71312a4"
      unitRef="usd">436000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItMS0xLTEtMA_bf28db07-5a06-45c8-951b-d7b06d2f0a8b"
      unitRef="usd">12307000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItMy0xLTEtMA_fb459ae7-9a15-49d3-a07f-9069b301e357"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzItNS0xLTEtMA_d896ba19-26ff-46f9-a9dc-098464ca7f6f"
      unitRef="usd">12307000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtMS0xLTEtMA_c1e9b226-eb7d-49da-96f5-e049fb11299b"
      unitRef="usd">116091000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtMy0xLTEtMA_e9bf3684-d664-46c0-a362-1c98815e6b43"
      unitRef="usd">10794000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzMtNS0xLTEtMA_b0dd2e60-7d76-4a44-a7d6-b1a3398a76b1"
      unitRef="usd">126885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtMS0xLTEtMA_c89eb886-91a4-4b11-b27c-5bd0f21bc932"
      unitRef="usd">-103784000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtMy0xLTEtMA_dae736de-ce08-4fad-b51c-e1c032320ab9"
      unitRef="usd">-10794000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzQtNS0xLTEtMA_56584439-a8ab-467f-b1df-78e20d4e5cd0"
      unitRef="usd">-114578000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtMS0xLTEtMA_96e47cdd-933b-4019-99d5-eb77f1fb38bc"
      unitRef="usd">272000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtMy0xLTEtMA_735460b6-1710-41fd-9360-66e72cfe8c27"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzUtNS0xLTEtMA_34b133ab-88b1-4753-890f-21bd610c56c1"
      unitRef="usd">272000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzYtMy0xLTEtMA_605a1539-7e2c-4d95-ab34-9ba7f5ea1b53"
      unitRef="usd">-4314000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzYtNS0xLTEtMA_6c1cede6-ada4-4f1a-8ab5-f0b03ef4941c"
      unitRef="usd">-4314000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctMS0xLTEtMA_2c62f679-59e3-4b9a-a82d-cc1db21de911"
      unitRef="usd">-104056000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctMy0xLTEtMA_b75146cb-cea2-48f3-97f1-886782939a1a"
      unitRef="usd">-15108000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzctNS0xLTEtMA_2fcad9f2-2fc9-4eae-b146-d02d51471197"
      unitRef="usd">-119164000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtMS0xLTEtMA_ef4e5bf3-e625-4aad-ba4d-205501e0588e"
      unitRef="usd">-3005000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtMy0xLTEtMA_3b9b8aa3-adae-451d-a884-2c4c5619c4da"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzgtNS0xLTEtMA_e1c1464b-5e93-412a-ad74-c7ea193d487c"
      unitRef="usd">-3005000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i674a96c0ae1749c38268be2fb3e982fe_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktMS0xLTEtMA_b79c00a3-f585-49ec-8e7c-41f2a2b90e0a"
      unitRef="usd">-101051000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktMy0xLTEtMA_2de219b0-e4c9-47e0-b3fe-7b078cce3a14"
      unitRef="usd">-15108000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="id2fc4d8930bc4b389ca7dc875e3cc0d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNWJhNTk5MDllMzI0NDNjYjI4MmUwYTE4MGI0NTBiOC90YWJsZXJhbmdlOmE1YmE1OTkwOWUzMjQ0M2NiMjgyZTBhMTgwYjQ1MGI4XzktNS0xLTEtMA_aac5f600-14af-4fae-a07c-a0909c9de78f"
      unitRef="usd">-116159000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="idf18b6a46ee942b59306c66d27119d0e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzM5MjE_4eb87f3b-32ff-4ae8-b07c-abc6e721ea32"
      unitRef="usd">3042000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTcxNzM_010869da-6462-48b2-bd24-b5499d465960"
      unitRef="usd">89679000</us-gaap:AssetImpairmentCharges>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItMS0xLTEtMA_b5fefc2a-f5af-44fe-b8ff-39e2b2072826"
      unitRef="usd">9396000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItMy0xLTEtMA_6d9a3071-278c-4d92-8794-d85bdec2e67a"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzItNS0xLTEtMA_d791f6ed-ce7c-4e35-b9b2-1ca5f5473615"
      unitRef="usd">9396000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtMS0xLTEtMA_c99a5111-0fd9-4233-bff8-ce36af0dcd59"
      unitRef="usd">111039000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtMy0xLTEtMA_0cf54347-7b58-4de0-9f1c-eccae90b64f6"
      unitRef="usd">470000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzMtNS0xLTEtMA_6419cb81-ff82-4ae7-8a79-8775e71a29ef"
      unitRef="usd">111509000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtMS0xLTEtMA_f51b8b4c-70e3-4310-8540-bd948995f7c1"
      unitRef="usd">-101643000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtMy0xLTEtMA_292988bb-c4c0-4e1b-b68f-1bac1353962d"
      unitRef="usd">-470000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzQtNS0xLTEtMA_0ae1fb2e-331c-4422-b4e0-b3dd3261a990"
      unitRef="usd">-102113000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtMS0xLTEtMA_559f3846-8539-4c2c-951b-aa0163fe28c5"
      unitRef="usd">1757000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtMy0xLTEtMA_6382f130-0502-4415-b9ad-008ce5c06a47"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzUtNS0xLTEtMA_b9cd8750-18fa-46a4-bdb8-96ba3f01fd49"
      unitRef="usd">1757000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzYtMy0xLTEtMA_cf837f95-6807-43d2-a11b-0ea79477d151"
      unitRef="usd">-2622000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzYtNS0xLTEtMA_f54613d9-f219-438d-9ca2-efab7065ea65"
      unitRef="usd">-2622000</pgen:DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctMS0xLTEtMA_77d19c2d-0753-418a-b4d2-6f0aeea9e328"
      unitRef="usd">-103400000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctMy0xLTEtMA_40e28cef-f2ef-43b8-aafa-1d679a5e8890"
      unitRef="usd">-3092000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzctNS0xLTEtMA_230cd18f-ca51-415f-a434-a38481dace72"
      unitRef="usd">-106492000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtMS0xLTEtMA_4d112e48-811d-4785-9906-e7d63c79295f"
      unitRef="usd">-6103000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtMy0xLTEtMA_757a111e-d657-4487-8683-39572c1ca383"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzgtNS0xLTEtMA_9ebd977e-4d44-4021-a025-a0cd7a431b12"
      unitRef="usd">-6103000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ie008c068818d4427824c7865a4533062_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktMS0xLTEtMA_f767298f-ea61-4e67-8afa-98e3c8d600ac"
      unitRef="usd">-97297000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktMy0xLTEtMA_15ea213e-8713-43cd-8b75-8493a1cf99ba"
      unitRef="usd">-3092000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i293514e6bbf4454794fe0e3960988a6f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTphNzI2NjAyMmM3NDI0YTBlYjk2OTdkMTAzOTQ4NDM3Yy90YWJsZXJhbmdlOmE3MjY2MDIyYzc0MjRhMGViOTY5N2QxMDM5NDg0MzdjXzktNS0xLTEtMA_a6ed9fc4-ec46-4968-a389-5a67b7da4cc9"
      unitRef="usd">-100389000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ib6652a9a128043e1991ddf1ffe2cf37e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzMDM_3934cf93-2b24-4989-ac28-9ee1602afac4"
      unitRef="usd">4665000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:AssetImpairmentCharges
      contextRef="i54ddb7daeedd421691d65e569834db38_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzNDA_f873c505-9547-43a6-a82d-de63a4023409"
      unitRef="usd">60504000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i54ddb7daeedd421691d65e569834db38_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTc2OTg_d802672f-9f8b-4197-8b7e-40541730e877"
      unitRef="usd">-5057000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtMS0xLTEtMA_c977994e-e388-49d7-9b08-4de0f1f67246"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtMy0xLTEtMA_26dc27e0-7273-495c-8bf3-ec58b23ece07"
      unitRef="usd">5107000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzMtNS0xLTEtMA_5f2ddb3f-c303-4522-ac10-e8a2297178b2"
      unitRef="usd">9007000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtMS0xLTEtMA_a3082e75-75ad-4e02-9bb5-9bee4d822ae2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtMy0xLTEtMA_aa92d677-8dba-418f-ae5b-51e9fbef4024"
      unitRef="usd">58042000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzQtNS0xLTEtMA_8e08ce6b-c1c1-4ff8-be8a-048e842da9a6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMS0xLTEtMTEwMQ_65e6dc51-9d3d-4669-abb5-e125178e2c16"
      unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMy0xLTEtMTEwMQ_29b7264d-df62-4ade-9732-7211be294764"
      unitRef="usd">31637000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtNS0xLTEtMTEwMQ_229af8f1-b4fe-4fa9-9ed7-82a23234f984"
      unitRef="usd">60504000</us-gaap:OtherAssetImpairmentCharges>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMS0xLTEtMTEwMQ_bf04e295-db32-4428-991c-cc092eb535ee"
      unitRef="usd">672000</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMy0xLTEtMTEwMQ_1558e3bd-9eca-42a3-8ade-b41c3ea668e7"
      unitRef="usd">0</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtNS0xLTEtMTEwMQ_7b67f99d-61d4-4351-bcfb-532e55c2f30c"
      unitRef="usd">0</pgen:DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMS0xLTEtMTEwMQ_d0b1806f-21ea-4182-b54f-5a1518640866"
      unitRef="usd">-26957000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMy0xLTEtMTEwMQ_263a70ec-aa1f-4e7c-9bf0-9ac166918ad1"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctNS0xLTEtMTEwMQ_93cf1e73-8498-49fd-9c62-0b8fa8e755ca"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMS0xLTEtMA_b2b5a89b-ea24-4bfd-97d3-41e34282856e"
      unitRef="usd">-106000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtMy0xLTEtMA_28584e9c-5b33-490f-ae78-2612ba6ef15a"
      unitRef="usd">-458000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzUtNS0xLTEtMA_ae9ba72e-8db1-4a2d-9032-05d7db66f045"
      unitRef="usd">-1927000</pgen:EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMS0xLTEtMA_c7ee251b-2acf-4399-aa01-4d91ef4d309e"
      unitRef="usd">-38000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtMy0xLTEtMA_ab304029-2df6-4044-b61f-073ad57059e4"
      unitRef="usd">-4314000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzYtNS0xLTEtMA_9b370ed2-9314-4822-a5b8-f708a12fcf4c"
      unitRef="usd">-2622000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMS0xLTEtMA_1f69d442-6c0b-4194-9e53-3d6736063f30"
      unitRef="usd">-1346000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctMy0xLTEtMA_e6e373b6-3a78-48b1-a170-46d5e095a0ae"
      unitRef="usd">2507000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzctNS0xLTEtMA_0a8ec396-1f64-4762-bba9-ca250d24ec95"
      unitRef="usd">3872000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtMS0xLTEtMA_7fb5f144-400f-4eaf-bb0a-936e20dec647"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtMy0xLTEtMA_387714dd-358d-474c-9f7d-2af4ccac69a0"
      unitRef="usd">-2710000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzgtNS0xLTEtMA_de5802f9-8969-49e5-9180-88045f0194e0"
      unitRef="usd">-5703000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i818efb75b9ce41b5a5a856f739968fc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTEtMS0xLTA_d0cf9a54-e530-4eaf-b588-f6fa0843a083"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i76f58f326e0648ddba9b773ece024426_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTMtMS0xLTA_4e3b664a-8975-47bc-a159-bea8de145d19"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i625f5d947f4a4ca5b985dc43e1a27a5a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzEwLTUtMS0xLTA_318dbdb3-b6ee-4159-b864-5277df739fe2"
      unitRef="usd">12250000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTEtMS0xLTA_c596ea2c-1e56-4693-87a4-deb9ede802ef"
      unitRef="usd">382000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ca877cac87e47049f837bf9595be757_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTMtMS0xLTA_2649de86-f75b-4434-a417-1a95538da24c"
      unitRef="usd">23326000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5b369de9672e4e4da1b5e8fac8ab5109_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZToxNzk0ZmY3ZDI1NDA0MjZiYWM2YTYyZWFkMTgzZDc1YS90YWJsZXJhbmdlOjE3OTRmZjdkMjU0MDQyNmJhYzZhNjJlYWQxODNkNzVhXzExLTUtMS0xLTA_60b97d27-3469-4c9e-9849-a3d694c95485"
      unitRef="usd">21191000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:AssetsCurrent
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzItMy0xLTEtMA_26062af7-b09a-4766-ba34-375ec6c63570"
      unitRef="usd">703000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzMtMy0xLTEtMA_c0f6e587-5355-4a01-aa8b-5c85906b30d3"
      unitRef="usd">30549000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzQtMy0xLTEtMA_149445f8-e5d0-4b64-b2b4-d9f277452c32"
      unitRef="usd">31252000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzUtMy0xLTEtMA_befcd584-4352-443b-b308-5b7ab3f5772c"
      unitRef="usd">2352000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzYtMy0xLTEtMA_51e4efca-a6ec-4c3b-aab5-41a07e93ccc4"
      unitRef="usd">88000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzctMy0xLTEtMA_177e6c55-ce39-4025-b7f4-26e864893ba5"
      unitRef="usd">2440000</us-gaap:Liabilities>
    <pgen:EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet
      contextRef="ibeef9924e4a74f15b13a46b3493cc9b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo2NjRlMGI2Y2RmOTI0MDJlOTI0OGRiYTAxZmRkYTQyYy90YWJsZXJhbmdlOjY2NGUwYjZjZGY5MjQwMmU5MjQ4ZGJhMDFmZGRhNDJjXzgtMy0xLTEtMA_4f41886b-42f5-4a86-a128-cdc8756e60c5"
      unitRef="usd">28812000</pgen:EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet>
    <us-gaap:Revenues
      contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItMS0xLTEtMA_75f63c57-70f0-46c2-9ae8-65ebc40a3755"
      unitRef="usd">16000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItMy0xLTEtMA_c366c5b3-a0c7-45e5-adb6-b9e8a7b330da"
      unitRef="usd">510000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzItNS0xLTEtMA_345e4e7d-f2b2-4636-9e94-be46076ae71a"
      unitRef="usd">268000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtMS0xLTEtMA_7cacd978-1004-4800-95ad-21db27d78053"
      unitRef="usd">92000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtMy0xLTEtMA_ac9f4ad8-c9f2-4b58-98ca-1750668a98f7"
      unitRef="usd">9159000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzMtNS0xLTEtMA_462b6fac-5c31-4657-8866-0cc4ce3b2673"
      unitRef="usd">12709000</us-gaap:OperatingExpenses>
    <us-gaap:GrossProfit
      contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtMS0xLTEtMA_db6ecfd0-b186-4e9f-8560-c1ed7efa2ed7"
      unitRef="usd">-76000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtMy0xLTEtMA_f04d1713-8489-4f99-a0ab-b4a8268074ed"
      unitRef="usd">-8649000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzQtNS0xLTEtMA_1e904c10-952d-4812-9f8c-35716cee46a2"
      unitRef="usd">-12441000</us-gaap:GrossProfit>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtMS0xLTEtMA_b70495f1-cf2f-4820-92dc-7d1b32f6ab72"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtMy0xLTEtMA_a204d9c2-17ec-45e9-a1d9-c7d784e489dc"
      unitRef="usd">21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzUtNS0xLTEtMA_08b9ef06-1372-498c-a2b3-ce70543ea4d4"
      unitRef="usd">39000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i62973e5b158441e1a528e26cd26a53cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtMS0xLTEtMA_a2402c2d-8d94-4fdb-8a36-3dfd5a623839"
      unitRef="usd">-76000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ide20c612b5ac42b0b7a4cc60e92d8691_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtMy0xLTEtMA_264249a9-b72a-4232-bdd8-70034e1da718"
      unitRef="usd">-8628000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9a7b1647f20470f95a5ab335b5dd845_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90YWJsZTo3YWRkMzYzMDVkOGY0ZDU3OWEwOGFlOGViZmM0MzY2MC90YWJsZXJhbmdlOjdhZGQzNjMwNWQ4ZjRkNTc5YTA4YWU4ZWJmYzQzNjYwXzYtNS0xLTEtMA_b9c27439-609b-44f7-89da-b939dc4ac42e"
      unitRef="usd">-12402000</us-gaap:ProfitLoss>
    <us-gaap:DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax
      contextRef="i6de7e2318c7849acbfae44a9cac32cb7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzMvZnJhZzo2MmZhNDViZjk1Y2E0ZDVjYmFhN2I1ZTEyYjUxMWVmZS90ZXh0cmVnaW9uOjYyZmE0NWJmOTVjYTRkNWNiYWE3YjVlMTJiNTExZWZlXzQzOTgwNDY1MTkxMjI_efe7c57f-7807-4b73-ab1d-3877fce3a6a9"
      unitRef="usd">-26572000</us-gaap:DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzQzMDY_da7c2a2f-48cd-419d-a662-71f00d931457">Mergers and Acquisitions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Acquisition of Certain Harvest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc. ("CRS Bio"); Genten Therapeutics, Inc. ("Genten Therapeutics"); and Relieve Genetics, Inc. ("Relieve Genetics") (collectively the "Harvest entities"). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303, and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original ECCs and therefore wrote off deferred revenue of $10,078 in September 2018 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 12 for additional discussion of the convertible promissory notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1
      contextRef="ib745c0a5e3374688a77e7b600fc20292_D20180901-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzE2NA_820dab3d-86a3-4581-9bbf-fdbacc401c50"
      unitRef="usd">30000000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <pgen:CashInflowsOutflowsInAssetAcquisition
      contextRef="i000d1fd7f4c64d64832e5ec0e8209d77_D20180901-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzQ1Mw_68ffe9f5-2a1f-4685-aa6e-41db89f9bb93"
      unitRef="usd">15500000</pgen:CashInflowsOutflowsInAssetAcquisition>
    <us-gaap:EquityMethodInvestments
      contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzY3MQ_220d3e16-4da5-4d7b-801f-fe72bc319888"
      unitRef="usd">4303000</us-gaap:EquityMethodInvestments>
    <pgen:RelatedPartyOwnershipInterest
      contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0Xzc5MA_9aa64fd8-3970-48c6-8726-e56f29823884"
      unitRef="number">1</pgen:RelatedPartyOwnershipInterest>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0ab86611cff54ee49aacd99b0b4f6651_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzEyNjA_2090ed29-1566-40d6-a3d8-64b418d413c2"
      unitRef="usd">10078000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i6a0d69f64390425490a158f5ad474449_D20180901-20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzYvZnJhZzowMjU1NWJhMTlhMjk0MDAwOTZlMDc0YmU4OGYyZjBhNC90ZXh0cmVnaW9uOjAyNTU1YmExOWEyOTQwMDA5NmUwNzRiZTg4ZjJmMGE0XzEzNDE_9bc9f998-48c6-456d-86f7-2626ddff131b"
      unitRef="usd">8721000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY5MTc_0242447e-4cfc-4310-ad4c-17b0bfbe2446">Investments in Joint Ventures&lt;div style="margin-bottom:11pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon Energy Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a JV formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investment in Intrexon Energy Partners was $(425) and $(423) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 3 for additional discussion regarding the Company's investment in Intrexon Energy Partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon Energy Partners II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a JV formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investment in Intrexon Energy Partners II was $(435) and $(435) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 3 and 17 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon T1D Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a JV formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provided the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Precigen committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Precigen common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue in November 2018 as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3Xzc3NQ_f47f13fe-67a0-48ba-bef6-00a937653e8c"
      unitRef="usd">25000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1c882e708e9042fab6cf9bdb465e7487_I20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3Xzc5Ng_e35b90be-fb3a-4a30-95bf-b75a7a1e02eb"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="id6ad8e1a4d324efba50a474ce9400787_D20140301-20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzkxMQ_125798c8-38cb-418a-bd58-57052e6f778a"
      unitRef="usd">25000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9a9baf13b1f64feeacf1476a168dca43_I20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEwMTU_7c90be19-38b8-421d-9773-313bed59299f"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="i1c882e708e9042fab6cf9bdb465e7487_I20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEwOTQ_2834e348-1607-4672-b97a-d95f800d874e"
      unitRef="usd">25000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="i9a9baf13b1f64feeacf1476a168dca43_I20140331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzEyOTY_f88b7b0e-747d-4604-bc52-c2adf478c76d"
      unitRef="usd">25000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment
      contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE0ODY_a7619b0a-7951-4869-8171-729610a1a921"
      unitRef="usd">4225000</pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment>
    <pgen:NumberofSeatsonGoverningBoard
      contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE1NzY_d536c9b3-b908-4a31-98f4-649234a8eff6"
      unitRef="board_seat">5</pgen:NumberofSeatsonGoverningBoard>
    <pgen:NumberofSeatsonGoverningBoardInternallySelected
      contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE1ODg_c7a57313-b622-4755-af91-f18867602e4d"
      unitRef="board_seat">2</pgen:NumberofSeatsonGoverningBoardInternallySelected>
    <pgen:NumberofSeatsonGoverningBoardExternallySelected
      contextRef="i417eb3d3304845829b5d8b4c5c5ba767_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE2NzE_a101bc80-9cf0-4d75-aefd-752a5f4f0390"
      unitRef="board_seat">3</pgen:NumberofSeatsonGoverningBoardExternallySelected>
    <us-gaap:EquityMethodInvestments
      contextRef="i9405291ea07342cfb48d39ff6203c28c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE5OTE_150d89af-63d7-4c53-926d-9a7eb8c7f147"
      unitRef="usd">-425000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i84f4ceddf2d74e208b2f43425f7a604c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzE5OTg_b3197267-ece1-4c9a-a67d-4822852161f1"
      unitRef="usd">-423000</us-gaap:EquityMethodInvestments>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzI5NjY_4b12f32d-421d-4120-9542-524174f67364"
      unitRef="usd">18000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzI5ODc_a556e5ea-2f5e-4e12-8e6e-a4bad0c9bd2b"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i02736ce52d7d455880b3764529cb4205_D20151201-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMxMDc_7b4096db-baa2-49f5-964a-8e3a39ed169a"
      unitRef="usd">18000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6ed29543f11f4730be40ffd5240b7e9d_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMyMTQ_fcf57029-b314-43c5-a0b2-26c485653c57"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i2af9e206e25f49e585e8fac9b7a42c1f_D20151201-20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzMzMDk_cc5ea3e2-51f7-417f-8ede-8de289305e55"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM0MjU_bfb1f899-ada1-4518-8887-1ef0e254615b"
      unitRef="usd">10000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="i6ed29543f11f4730be40ffd5240b7e9d_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM2MzI_5d65a812-d70a-4412-ad96-01c195890ddb"
      unitRef="usd">10000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment
      contextRef="i3dd86fd0107044a1afd4581beb90db93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM4Mjk_5c0689ff-0d76-4db3-b444-5c3f38a678fa"
      unitRef="usd">10000000</pgen:JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment>
    <pgen:NumberofSeatsonGoverningBoard
      contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM5MjU_a9d7213a-b15a-43f8-951e-adcd756f9c3f"
      unitRef="board_seat">5</pgen:NumberofSeatsonGoverningBoard>
    <pgen:NumberofSeatsonGoverningBoardInternallySelected
      contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzM5Mzc_df54a692-0024-4727-9d41-e5c3831c918b"
      unitRef="board_seat">1</pgen:NumberofSeatsonGoverningBoardInternallySelected>
    <pgen:NumberofSeatsonGoverningBoardExternallySelected
      contextRef="ifcde56c84e2945f99d5ff518fcea780f_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQwMjE_ac97a734-d3e9-4152-83bd-81aa208d9cb1"
      unitRef="board_seat">4</pgen:NumberofSeatsonGoverningBoardExternallySelected>
    <us-gaap:EquityMethodInvestments
      contextRef="i22bc12535b5845a98af2708db090b1cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQzNTE_5849ad1e-28c9-4836-afd4-7887c39e633d"
      unitRef="usd">-435000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0b676559c5894899a277cab47b7d3686_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzQzNTg_233fa4d3-8d7a-47ae-a3e9-615f572a258b"
      unitRef="usd">-435000</us-gaap:EquityMethodInvestments>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i8b58e935da8149088da93a6187e4101f_D20160301-20160331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUyNTE_2164ce54-9e89-4264-8410-a3131c108f40"
      unitRef="usd">10000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUyNzI_084bcf65-a136-46fc-9dcc-403df802645f"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="i37eae9042f0b4b7991fad96ce5cd70f8_D20160301-20160331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzUzODQ_7764deb7-d6eb-4c9b-af21-69f9fccbcf41"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i38614b5cdd4748fe900bdb143da08bc2_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU0ODU_453f0c06-2829-41ae-958b-64bb2e71901c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU1NDc_68a008a2-2cf5-4450-9e62-b0ad3f3c685c"
      unitRef="usd">5000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:JointVentureAdditionalCapitalContributionsCommitted
      contextRef="i38614b5cdd4748fe900bdb143da08bc2_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU3NDE_ecef400d-db4d-45e6-8061-06a18c690680"
      unitRef="usd">5000000</pgen:JointVentureAdditionalCapitalContributionsCommitted>
    <pgen:NumberofSeatsonGoverningBoardInternallySelected
      contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU4MjQ_b229a7f2-7eec-4735-b4cc-3db9d2b08fdd"
      unitRef="board_seat">2</pgen:NumberofSeatsonGoverningBoardInternallySelected>
    <pgen:NumberofSeatsonGoverningBoardExternallySelected
      contextRef="i08141bec58644c55a3f1a64ad4aba2ca_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzU4NjQ_3183fdca-6d80-45fb-a5cb-0a485ee2eece"
      unitRef="board_seat">3</pgen:NumberofSeatsonGoverningBoardExternallySelected>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYwNTY_c69eac3f-825a-46f5-b970-5f0528ab4c69"
      unitRef="shares">1933737</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYxMDE_8ab74f19-ca9d-4d6e-856e-73f55e5d91cc"
      unitRef="usd">18970000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzYyMzE_29c2ee40-4de0-4176-9bab-b6ea7f21d7a1"
      unitRef="number">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY3MDE_f7c6fd6b-4e16-463d-addc-9014eeadc7e8"
      unitRef="usd">8517000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ia18b9f13ca97407987783276b9377121_D20181101-20181130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMzkvZnJhZzoxZGZiNWUzZTQ5ZGM0ZDZkODYwZjk3NDNmMmNhNTNhNy90ZXh0cmVnaW9uOjFkZmI1ZTNlNDlkYzRkNmQ4NjBmOTc0M2YyY2E1M2E3XzY3OTI_7ee043a2-6158-499f-a026-81a62e0a19e0"
      unitRef="usd">10453000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzY1OTcwNjk4NTEwMTA_b21dfbe5-c616-4db2-9f3e-a1c15fb54cde">Collaboration and Licensing Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZIOPHARM Oncology, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ares Trading S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oragenics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon T1D Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners II, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Castle Creek Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Harvest start-up entities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;For the years ended December&#160;31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December&#160;31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Collaboration and licensing revenues recognized for the years ended December&#160;31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ZIOPHARM Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January&#160;2011, the Company entered into an ECC with ZIOPHARM Oncology, Inc. ("ZIOPHARM"), a related party at the time. Pursuant to the&#160;ECC,&#160;ZIOPHARM received a license to the Company's technology platform within the field&#160;of&#160;oncology as defined more specifically in the agreement. The Company received upfront consideration upon execution of the ECC in the form of ZIOPHARM common shares valued at $17,457, shares of ZIOPHARM common stock valued at $18,330 as consideration upon achievement of a milestone in 2012, and reimbursements for research and development services performed during the ECC. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a wholly owned subsidiary of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modified the scope of the ECC &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in connection with the Merck Agreement and provided that the Company would pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement. See discussion of the Merck Agreement below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company amended the ECC and a prior ECC that was mutually terminated in December 2017 to reduce the rate of royalty that the Company was entitled to receive on certain products commercialized pursuant to the agreements. As consideration for execution of the amendments, ZIOPHARM issued the Company shares of ZIOPHARM's Series 1 Preferred Stock. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. See Note 18 for additional discussion of the terms of the preferred stock and the accounting treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license agreement (the "ZIOPHARM License Agreement") with ZIOPHARM, which terminated and replaced the terms of the original ZIOPHARM ECC, including the amendments thereto.&#160;Pursuant to the terms of the ZIOPHARM License Agreement, the Company granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i)&#160;products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii)&#160;chimeric antigen receptor ("CAR") products directed to (a)&#160;CD19 for the treatment of cancer (the "CD19 Products"), and (b)&#160;a second target, subject to the rights of the Company to pursue such target under the Merck Agreement, and (iii)&#160;T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. ZIOPHARM will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. ZIOPHARM is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products, and after a two-year period, the TCR Products. The Company also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. ZIOPHARM is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. ZIOPHARM and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with ZIOPHARM responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the ZIOPHARM License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that ZIOPHARM will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration of the licenses and other rights granted by the Company, ZIOPHARM will pay the Company an annual license fee of $100 and agreed to reimburse the Company $1,000, paid in four quarterly installments, with respect to historical Gorilla IL-12 Products (the "historical Gorilla reimbursements"). ZIOPHARM will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed programs in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed programs, up to an aggregate of $210,000. In addition, ZIOPHARM will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. ZIOPHARM will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. ZIOPHARM will also pay the Company 20% of any sublicensing income received by ZIOPHARM relating to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reacquired rights to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to ZIOPHARM. The Company will pay ZIOPHARM royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000. The Company also received from ZIOPHARM reimbursement of costs incurred to transition the necessary knowledge and materials for ZIOPHARM programs for a period of one year from the effective date (the "Transition Services").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As between the parties, the Company agreed to perform all of the obligations of ZIOPHARM under the Merck Agreement, other than an obligation of exclusivity thereunder and ZIOPHARM will remain responsible for all payments owed under the Merck Agreement&lt;/span&gt;&lt;span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with respect to CD19 and the other target under the Merck Agreement as a result of ZIOPHARM's, its affiliates' or its sublicensees' exploitation of CAR products. Further, the Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to ZIOPHARM for such products. The ZIOPHARM License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the later to occur of (i)&#160;the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, ZIOPHARM may terminate the ZIOPHARM License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the ZIOPHARM License Agreement following notice of a material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the ZIOPHARM License Agreement, the 2016 Securities Issuance Agreement between the Company and ZIOPHARM was terminated as of the effective date of the ZIOPHARM License Agreement, all of the benefits, rights, obligations and liabilities thereunder immediately ceased and terminated and the Company returned to ZIOPHARM all of the preferred stock owned by the Company as of the Effective Date, which was valued at $158,376. See Note 18 for additional discussion of the preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the execution of the ZIOPHARM License Agreement, the Company had $51,084 of deferred revenue remaining from the original ECC, which was related to the Company's obligations to perform under that agreement. Replacement of the original ECC with the ZIOPHARM License Agreement was a contract modification under ASC 606 that represented the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which were limited to the Transition Services, were distinct from those under the ECC. Therefore, the Company reviewed the various forms of consideration in the ZIOPHARM License Agreement to determine the transaction price. As the Company's obligations under the ZIOPHARM License Agreement were only related to the Transition Services and no other obligations under the ECC remained, a portion of the previously deferred revenue from the ECC was relieved, which the Company determined to be $49,329, and the remaining $1,755 was included in the transaction price. The initial annual license payment of $100 was also included in the transaction price. The remaining annual license payments and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of ZIOPHARM products developed pursuant to the ZIOPHARM License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price of $1,855 as it performed the Transition Services required under the ZIOPHARM License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also reviewed the consideration paid and potential consideration to be paid to ZIOPHARM as part of the ZIOPHARM License Agreement, which included the $158,376 of ZIOPHARM preferred stock returned by the Company and potential royalty payments to ZIOPHARM from sales of the Company's CAR products. The Company determined the exchange of its investment in ZIOPHARM preferred stock for certain CAR rights previously licensed under the ECC (i.e., in-process research and development) and the relief of performance obligations to ZIOPHARM under the ECC constituted an exchange for distinct goods and services. Therefore, the Company wrote off the $49,329 of relieved deferred revenue and recorded an expense of $109,047 for the reacquired in-process research and development. Potential royalty payments to ZIOPHARM will be expensed as incurred as they relate to distinct goods or services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Gorilla Program represented a separate collaboration agreement under the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASC 808") and was not included in the accounting for the ZIOPHARM License Agreement under ASC 606. The Company recognized $500 of the historical Gorilla reimbursements on the contract modification date and recognized the remaining amounts when receipt became probable. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck Licensing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company received $10,000 in equal quarterly installments over two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a Securities Purchase, Assignment and Assumption Agreement (the "Merck Purchase Agreement") with Ares Trading pursuant to which the Company reacquired Ares Trading's development and commercialization rights under the Merck Agreement. As consideration for the reacquisition of the Merck Agreement, the Company issued Ares Trading 20,640,119 shares of Precigen common stock valued at $140,353 and agreed to pay Ares Trading a royalty of 10% of the net sales derived from two CAR products specified in the Merck Purchase Agreement. By reacquiring the rights previously licensed to Ares Trading, the Company is relieved of its obligations under the Merck Agreement and therefore wrote off deferred revenue of $31,826. The remaining value acquired of $108,527 was considered in-process research and development related to the reacquired rights under the Merck Agreement and expensed immediately. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;potential future royalty payments to Ares Trading do not represent consideration paid to a customer and will be recorded when the payments are probable. See Note 12 for additional discussion of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Oragenics Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, the Company entered into an ECC with Oragenics, a related party at the time. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $5,000 convertible promissory note, which was subsequently converted to shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale (Note 3). The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. In July 2020, the Company and Oragenics mutually agreed to terminate the ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the ECC totaling $2,823. Following the termination of the ECC, Oragenics is no longer a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon T1D Partners Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000. The Company received reimbursement of research and development services provided pursuant to the ECC agreement. In November 2018, the Company completed an asset acquisition with the T1D Investors, resulting in the Company owning 100% of the membership interest of Intrexon T1D Partners including all rights under the ECC (Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genten Therapeutics, CRS Bio, and Relieve Genetics Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into three separate ECCs with Genten Therapeutics, CRS Bio, and Relieve Genetics, all affiliates of Harvest and related parties. The total upfront consideration received for the three collaborations was $10,933, which mostly consisted of equity interests in these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests in these entities, including all rights under the ECCs (Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon Energy Partners Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a JV between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March&#160;2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company. The ECC is not active while the IEP Investors evaluate the status of the project and their desired future development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intrexon Energy Partners II Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company. The ECC is not active while the IEPII Investors evaluate the status of the project and their desired future development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exotech Bio, AD Skincare, and Thrive Agrobiotics Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015 and 2016, the Company entered into three separate ECCs with Exotech Bio, Inc. ("Exotech Bio"), AD Skincare, Inc. ("AD Skincare"), and Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), all affiliates of Harvest and related parties at the time. The total upfront consideration received for the three collaborations was $11,000, which consisted of equity interests in each of these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In conjunction with a settlement agreement with Harvest (Note 17), these ECCs were terminated in December 2020, and the previously licensed technology rights reverted to the Company pursuant to the ECCs. The Company wrote off the remaining balance of deferred revenue associated with these ECCs totaling $6,993 as an offset to the loss recognized on the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Castle Creek Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October&#160;2012, the Company entered into an ECC (the "2012 Castle Creek ECC") with Castle Creek Biosciences, Inc. ("Castle Creek", formerly known as Fibrocell Science, Inc.). Castle Creek was a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until it was acquired in December 2019 by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical"), a privately held company focused on developing medicine for rare genetic disorders. Pursuant to the 2012 Castle Creek ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The Company received (i) upfront consideration upon execution of the ECC in the form of Castle Creek common stock valued at $7,576, (ii) shares of Castle Creek common stock valued at $7,612 as consideration for a 2013 amendment which expanded the field of use defined in the agreement, (iii) sublicensing fees totaling $3,750 in the form of cash in 2019, and (iv) reimbursements for research and development services performed during the ECC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company and Castle Creek terminated the 2012 Castle Creek ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates, FCX-007 and FCX-013, pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Castle Creek ECC. As Retained Products, Castle Creek retains a license under the 2012 Castle Creek ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Castle Creek ECC for so long as Castle Creek continues to pursue such development and commercialization. No further licenses to the Company's technology within the field of use are provided to Castle Creek. On a quarterly basis, Castle Creek will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each Retained Product from the 2012 Castle Creek ECC, as defined in the agreement. Additionally, the Termination Agreement provides for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract, and the remaining deferred revenue from the 2012 Castle Creek ECC is being recognized prospectively as the manufacturing activities are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2015, the Company entered into a second ECC with Castle Creek (the "2015 Castle Creek ECC"). Pursuant to the ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Castle Creek mutually agreed to terminate the 2015 Castle Creek ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Castle Creek ECC totaling $10,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid product and service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized under collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December&#160;31, 2020 and 2019, as well as the estimated remaining performance period as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Performance Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oragenics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners II, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Castle Creek Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Harvest start-up entities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTg1_928eb972-73bc-4249-94eb-fb568b76d342">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ZIOPHARM Oncology, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ares Trading S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oragenics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon T1D Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners II, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Castle Creek Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Harvest start-up entities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;For the years ended December&#160;31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December&#160;31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Collaboration and licensing revenues recognized for the years ended December&#160;31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia04474b4f60340a5bfef5669908aca1b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItMS0xLTEtMA_1ef031fd-0b86-450a-8a17-a984bf8da236"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ea41f0f9f8340a5ac240c128def61b7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItMy0xLTEtMA_039192a6-20cd-47d4-9dce-0b761ceb3895"
      unitRef="usd">2171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebbb27ff74fa4587a1663d2f6c036f55_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzItNS0xLTEtMA_cb1f5582-46f6-40c7-9915-3a276bafb459"
      unitRef="usd">16298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3fe0767e9cf4dcd85529165525f8758_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtMS0xLTEtMA_98a33017-2be5-4832-aa9d-7d5efe374d15"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2655f8d02da8422ba8e92858830a2d09_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtMy0xLTEtMA_32ebc089-7215-4f9c-9f62-e7725bec6ad3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9caeeb9311142fcad4dc58cba84fe45_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzMtNS0xLTEtMA_45a25464-326c-4ee3-87bf-f58850a748ae"
      unitRef="usd">11175000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a58ef1f100e41ec83f7fadf1f120f61_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtMS0xLTEtMA_7d0f6bac-d449-48bf-9a71-be0038ed4b71"
      unitRef="usd">3053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3225f360239c4da99ac5a0f30e582367_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtMy0xLTEtMA_11495355-2ed3-44a6-a5f9-e11f170a7e99"
      unitRef="usd">-564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6b7ccf82abb46088675f71ca095ea7d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzQtNS0xLTEtMA_b7e9c21d-d284-467f-b743-e0e92223732e"
      unitRef="usd">1353000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61c5e81e3c27464cb9bb433ba78dd8ac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtMS0xLTEtMA_ad22d417-a419-44fa-98fa-8904412881fe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0a5d57f00774002911cf03b4ecb5d06_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtMy0xLTEtMA_4e2e6d2e-061c-4f0f-9dae-0405126c7fde"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6a3055772b4276a974fbd3f46d80af_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzUtNS0xLTEtMA_5c56ac74-d848-43ef-95ea-a851500cf6cf"
      unitRef="usd">2502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i657bccd941e9476e84df5f1bb47c01ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtMS0xLTEtMA_75fb64c0-043d-4df4-8720-e0c6cb71644f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dd6ae11540d4a89bdea2402ffd96b43_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtMy0xLTEtMA_482c5726-4786-4dbc-a8b4-a03984ac1069"
      unitRef="usd">2596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i271b77f3585b428ab9b387bac0632795_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzYtNS0xLTEtMA_dde240aa-ff46-413e-9dfc-f009686eb8a8"
      unitRef="usd">6929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5465b8e9f47c478a9888a2bf4f068315_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctMS0xLTEtMA_85d3a45f-8802-4889-8b9f-c2a1e32e6f14"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a7a75f53fb43bd8a86301d20bd199f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctMy0xLTEtMA_08f49d71-9a48-4c57-bb51-4d5d51a9c152"
      unitRef="usd">1217000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i615893ff388945289ba1d816cb0d5415_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzctNS0xLTEtMA_af21dd89-9bf2-4b20-a82c-f5169d8f0eba"
      unitRef="usd">2998000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i826d35e5de9342c1ac0b82187aa61817_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtMS0xLTEtMA_333c9f97-e7cf-419b-9db9-f80469e74797"
      unitRef="usd">17810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtMy0xLTEtMA_9c80c8c2-72c8-4349-9536-78ffbdebc65c"
      unitRef="usd">3713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb0b6fb6681044eeb9ccb81e27858225_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzgtNS0xLTEtMA_25d08b17-87f3-4102-8c7f-df8f162b9ebf"
      unitRef="usd">1394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d3047a704254986b92408ff7382d63c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTEtMS0xLTA_bc16644b-8c90-4507-a3fe-030f91e263b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia38b8c82221e4b158e81089d5dec6cc4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTMtMS0xLTA_cf59ea7d-204d-4b1b-b72c-8125aeabb5e0"
      unitRef="usd">4862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bc53c28fbc7455ea6911f3515a2093c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzExLTUtMS0xLTA_f784fdb4-cee7-43ce-b24f-368be3914dd6"
      unitRef="usd">14447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2da118b80dc492fa5a08a890cbbb15a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTEtMS0xLTA_ac343ae6-5f20-47a8-a3c9-48526cc5ad63"
      unitRef="usd">145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb26c32900c24b22b16c104fc410013d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTMtMS0xLTA_b08eaefb-503b-4a48-931e-e854f7ac869c"
      unitRef="usd">64000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a7cf1aab2104d78877dc52205013114_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEyLTUtMS0xLTA_fee6833f-b4df-44fc-a959-4ae802c99a0c"
      unitRef="usd">12444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia89a9eb5dec3401bb6b1302d72d9b091_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTEtMS0xLTA_52722686-2110-4041-9d34-ff949f5f4175"
      unitRef="usd">21208000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d02ad8dbd04496a07bb96530bd6fe0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTMtMS0xLTA_09e0a436-f827-44e9-a499-5c8eab7d9763"
      unitRef="usd">14059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fbcf7e50ae94bdb84158a09d5e84357_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTo3ODRiZDBjZGE2ZTU0NjcwOGNiNzQ5YWRiZDliN2YwMy90YWJsZXJhbmdlOjc4NGJkMGNkYTZlNTQ2NzA4Y2I3NDlhZGJkOWI3ZjAzXzEzLTUtMS0xLTA_6609a6f3-7a76-4f60-9175-d592e33e9a7c"
      unitRef="usd">69540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i802c849fe1f7499fa51a352c7c1b630c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MTI_e3baaa79-204f-43e7-b6b1-c2fed00e488c"
      unitRef="usd">20205000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia75a4228d5b9446f82180329f657e205_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MTc_ed761bf8-47e2-4a02-8db6-4223d0588199"
      unitRef="usd">7505000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iebf2e5287fca469988ba7db1017cc983_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1OTQ2MjI_896b3f03-0b39-4c82-9a71-b1a91eff4b15"
      unitRef="usd">39446000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i3d624d8cf2ba4c258b6200df93fe4dff_D20110101-20110131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI5ODk_6e6b9fa4-3f95-4cee-a176-64e48eba9c85"
      unitRef="usd">17457000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i4c23dc33d54d41fbb6d5de96a2aa6645_D20120101-20121231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM3MzE_af5e08bf-83bd-4f92-a55f-52b7711353c0"
      unitRef="usd">18330000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborationArrangementPercentOfCollaborationPayments
      contextRef="i8df2f4bdfd5a4853b136cd50ea2e2827_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQ2MTI_a440ea02-2a67-43f0-b933-25878a7e2b53"
      unitRef="number">0.50</pgen:CollaborationArrangementPercentOfCollaborationPayments>
    <pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible
      contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzg4Njc_9d248c86-cd92-4e1d-8a21-2392b3dd9537"
      unitRef="number">0.80</pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible>
    <pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived
      contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzg5MDk_ec6a4d57-6354-4156-ba2c-db245e264d9a"
      unitRef="number">0.80</pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived>
    <pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzkwMzA_2a202ed2-4970-4e3a-add8-487ce8374aa2"
      unitRef="number">0.20</pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible>
    <pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzkwNzI_b9b8761c-71f8-42d9-b554-4935da097602"
      unitRef="number">0.20</pgen:LicensingAgreementPercentageofOperatingProfitstoBeReceived>
    <pgen:LicenseAgreementAnnualFee
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0MDg_34eec396-4d97-44bd-8380-819db4c15759"
      unitRef="usd">100000</pgen:LicenseAgreementAnnualFee>
    <pgen:LicensingAgreementReimbursementofHistoricalCosts
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0NDc_8d93c6e7-0fbc-4278-b89a-4f6187a97b2c"
      unitRef="usd">1000000</pgen:LicensingAgreementReimbursementofHistoricalCosts>
    <pgen:LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk0NTk_28a0110e-e885-4bf3-be63-b6dfe3d53087"
      unitRef="quarterly_installment">4</pgen:LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments>
    <pgen:MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct
      contextRef="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk3ODc_0bb312e0-c6f4-4460-a1d9-32820acbbadc"
      unitRef="usd">52500000</pgen:MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct>
    <pgen:LicenseAgreementNumberofExclusivelyLicensedProducts
      contextRef="i7ea016b8ea6f476f9b5d2c6938a43d59_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk4MDI_2483eb7c-6c34-4e27-8986-c3eb41de11ec"
      unitRef="product">4</pgen:LicenseAgreementNumberofExclusivelyLicensedProducts>
    <pgen:MilestonePaymentsRequiredUponSuccessfulAchievementAggregated
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0Xzk4NTg_d3d4bfea-1916-4d2e-a42e-8018d4f2b1fb"
      unitRef="usd">210000000</pgen:MilestonePaymentsRequiredUponSuccessfulAchievementAggregated>
    <pgen:LicenseAgreementRoyaltyDueAggregated
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwMjYz_8f7e6815-4f47-422c-8df1-8bff5a113e5b"
      unitRef="usd">100000000</pgen:LicenseAgreementRoyaltyDueAggregated>
    <pgen:LicenseAgreementPercentageofSublicensingIncome
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwMzE5_c4385d17-f15a-4fd0-b72e-5c2d3f21eb52"
      unitRef="number">0.20</pgen:LicenseAgreementPercentageofSublicensingIncome>
    <pgen:LicenseAgreementRoyaltyDueAggregated
      contextRef="ia1872e456f884a09bd2becb67a926a2c_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEwODQw_c1446f5a-f98b-45ea-9043-293b58e75e6e"
      unitRef="usd">50000000</pgen:LicenseAgreementRoyaltyDueAggregated>
    <pgen:TransitionPeriodDuringWhichCostsWillBeReimbursed
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzExMDA2_b45da37f-8f38-4d79-ac20-67675a779275">P1Y</pgen:TransitionPeriodDuringWhichCostsWillBeReimbursed>
    <pgen:LicenseAgreementTerminationPeriodFollowingTriggeringEvent
      contextRef="i899454939ed242799bd5a3e8c38117ed_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzExODk3_7fb0c568-ffb6-471a-aa0f-89267281b26c">P12Y</pgen:LicenseAgreementTerminationPeriodFollowingTriggeringEvent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEyNjU2_14daef21-d09d-4826-b7e0-52d987d1f0d3"
      unitRef="usd">158376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9edf0818b0a147da90be9143a66128d0_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEyNzk2_c3686f26-0f09-4287-bdf7-695e98728d61"
      unitRef="usd">51084000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2b584f29328e4ebf97207baf9e676a54_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNjk1_707add9d-d53a-4891-8bd1-9c85558d1e9b"
      unitRef="usd">49329000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3e6a0b31f0c84cbea171358d7cdb8c59_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNzE3_9d823a85-03c7-4dd9-af58-ae0516868fb4"
      unitRef="usd">1755000</us-gaap:ContractWithCustomerLiability>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzEzNzk3_5c2b24c5-04d6-4dcb-9a0c-099313643cbd"
      unitRef="usd">100000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i390dbfc7bee54d449d2489dfabeb4caa_I20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE0MzEx_0d3b48fa-5d7f-41c8-9649-639616001307"
      unitRef="usd">1855000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i891d9ddf65eb401aa3bc6668ab5b90b1_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE0NTYz_14daef21-d09d-4826-b7e0-52d987d1f0d3"
      unitRef="usd">158376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2b584f29328e4ebf97207baf9e676a54_I20180930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1MDQ4_707add9d-d53a-4891-8bd1-9c85558d1e9b"
      unitRef="usd">49329000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ife505a4aa67447108ab17810720818e9_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1MTA3_191b4128-d736-457d-afe3-5fc0723fdb8c"
      unitRef="usd">109047000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie810160caf2b4c6c8fa5088912ae9065_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE1NTU5_f28e936a-2711-4c35-be0d-f04e41cfa9c5"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MjI3_87f9274f-ce24-406e-b478-fa459f336060"
      unitRef="usd">115000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:PaymentsToRelatedParties
      contextRef="i6ac36b06d9ed4949b460f25d930f6824_D20150301-20150331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MjY1_a9f976e3-ddfc-41a4-b820-5a5a394edf4b"
      unitRef="usd">57500000</pgen:PaymentsToRelatedParties>
    <pgen:CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired
      contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2MzY4_5e1acff5-bd34-4372-b396-768a1a49f11e"
      unitRef="target">2</pgen:CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib33d19e6739641da9b757a245fd3ec93_I20150301"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2NDE3_6cc91bf7-87c5-47dc-a91d-55feef0681ba"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <pgen:CollaborativeArrangementConsiderationReceivableCollectionPeriod
      contextRef="iefb7a70b457a47f4b3380e98a286d965_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2NDU3_eedecd1c-3ed5-4970-ac4b-6dd1ab1ee420">P2Y</pgen:CollaborativeArrangementConsiderationReceivableCollectionPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2ODMz_19c1b713-6553-467d-9b8d-2b610a124f69"
      unitRef="shares">20640119</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2ODc4_002efc34-6cd5-4e83-9c17-6a26a32712ed"
      unitRef="usd">140353000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <pgen:RoyaltyPercentageToBePaidtoOtherParty
      contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE2OTI1_20a30c5f-ea0b-4513-82b6-363cf547482f"
      unitRef="number">0.10</pgen:RoyaltyPercentageToBePaidtoOtherParty>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia684f990dec54beeb358abe6adf669ab_I20181130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE3MTk0_4ad6b819-9eaa-4342-8b5e-27447f126a0a"
      unitRef="usd">31826000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i7d3afdf0cf3b443489354e0a5ceaabea_D20181201-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE3MjMw_ae8d8af4-36e9-40b1-bcee-266c8d401f7c"
      unitRef="usd">108527000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <pgen:CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
      contextRef="i507644cf395a4e4eb490f23ed7a3fb54_D20150601-20150630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE4MDMy_943009ba-1cd5-4f55-83ff-db5f70b81147"
      unitRef="usd">5000000</pgen:CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ibc9c931963d5454d95e8956328330cee_D20200701-20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NDcxMjA_6a38d4d0-5f28-4fab-a094-c336fba0a298"
      unitRef="usd">2823000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i8b58e935da8149088da93a6187e4101f_D20160301-20160331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzE5OTY2_c96f0348-8cf0-4948-bb1d-d8425e5ecbba"
      unitRef="usd">10000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:RelatedPartyOwnershipInterest
      contextRef="ifac2f1a572c141fc8915df3c7e0d761b_I20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIwMTk5_eb62f3de-06da-4f37-b080-0a2d47429b7f"
      unitRef="number">1</pgen:RelatedPartyOwnershipInterest>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i659785a3f54a436ebb55a8cdf1f7716e_D20160101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NzA3NTE_32b24d38-4c2a-457c-9d61-4d6ed6abc4be"
      unitRef="usd">10933000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:RelatedPartyOwnershipInterest
      contextRef="ib7fde582b25949f282255f9473749cb4_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIxMTU5_a6ce38ef-5189-4764-ac75-1db09f0ec4f8"
      unitRef="number">1</pgen:RelatedPartyOwnershipInterest>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIzNTIz_3b2b539b-7744-4b6f-9df5-8c5b85e696fe"
      unitRef="usd">25000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborationAgreementTerminationNoticePeriod
      contextRef="i8a2c558866a54bf5989407e67ebe1943_D20140301-20140331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzIzOTM0_8cca5c03-8399-4b48-9bf7-908749316dba">P90D</pgen:CollaborationAgreementTerminationNoticePeriod>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI0NTcx_ac32fcf5-79d5-4dcc-91ad-1ad534dd4c6e"
      unitRef="usd">18000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborationAgreementTerminationNoticePeriod
      contextRef="ic75bad3fcc5f49f19aaaf592be963c8f_D20151201-20151231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI0OTcz_c1d48c44-344c-43cc-962f-2cf35dd08367">P90D</pgen:CollaborationAgreementTerminationNoticePeriod>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="ife64afba6e6c4c7f9966578282bdffdf_D20150101-20161231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1ODgwMzU_246084f8-09db-42fc-b67c-3a433272fb6b"
      unitRef="usd">11000000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i59907113dd1d4344981247aabca5ca34_I20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1ODg5MTA_824783d9-6016-4645-8ad1-a535d113ba41"
      unitRef="usd">6993000</us-gaap:ContractWithCustomerLiability>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="ib7c97ac54869431f9460b1de625fdd9c_D20121001-20121031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzI4MzUw_67e59eac-6215-465c-9867-590d86f439ee"
      unitRef="usd">7576000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborativeArrangementConsiderationReceivedValue
      contextRef="i1461c02f7c1144288c060625dfec3d80_D20130101-20131231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NDc0MjQ_c35cf329-abc7-40ef-b7e8-d519d4d85863"
      unitRef="usd">7612000</pgen:CollaborativeArrangementConsiderationReceivedValue>
    <pgen:CollaborativeArrangementConsiderationReceivedCash
      contextRef="ib52392fdc095449b805cedc12dc9b680_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzMwMjg0_2c8c9c87-0b46-4ae3-819a-435b55afa567"
      unitRef="usd">3750000</pgen:CollaborativeArrangementConsiderationReceivedCash>
    <pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
      contextRef="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5NTQ_81f0c524-084c-4df7-9487-2057e75e1c2f"
      unitRef="number">0.07</pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne>
    <pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
      contextRef="i07cadd8e29a94d468d706d75d4fa4499_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5Nzc_6cd784f1-ed04-4db3-b6c2-1695fe086f67"
      unitRef="usd">25000000</pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo>
    <pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
      contextRef="ic16cca3f2b904e4399cc8f4daf9b0791_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Nzc5ODU_e0829782-9855-4d5e-8206-3d1db9069d99"
      unitRef="number">0.14</pgen:CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo>
    <pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
      contextRef="i07cadd8e29a94d468d706d75d4fa4499_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1NzgwMDg_545b3ad3-ed9c-4c2b-a1b9-0bb1f0f7f4d7"
      unitRef="usd">25000000</pgen:CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib8dfaf8751c2466e8b7d83681e50ce63_D20200201-20200229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzQzOTgwNDY1Njk1OTc_68c7740c-bfc5-4092-a3a1-c8dc06f630b5"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTc1_5f4204c4-c51c-4481-a87b-561a3c78c1db">Deferred revenue consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid product and service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i119157bf1fca4e4597d6d2074e4b318c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzItMS0xLTEtMA_ee1adc54-373d-44f7-8f6e-da8e0920c5c2"
      unitRef="usd">23420000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i768914f9023446359debd6de8db387bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzItMy0xLTEtMA_9982d9cf-74c3-4724-a75c-3987cb41d7af"
      unitRef="usd">50593000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0886f93ed7be4cb289c37677075c1648_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzMtMS0xLTEtMA_34c2f83d-24b7-4cb1-8167-a1fc200c1aaa"
      unitRef="usd">2126000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i24eba9045a464d27b051cf73783cbc93_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzMtMy0xLTEtMA_44511e5f-80e9-4207-8321-914b104ff232"
      unitRef="usd">2805000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i51f077edbb924395b6f3b5746a7091b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzQtMS0xLTEtMA_84e25c50-81bc-4cdf-9407-bf40ae53ffab"
      unitRef="usd">277000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3e4b2e1046db40339eccf1d387df8274_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzQtMy0xLTEtMA_7df5fc39-f634-4656-8c35-333ab8532cfb"
      unitRef="usd">435000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzUtMS0xLTEtMA_000bc118-7fc4-4070-85e7-69c72639dde1"
      unitRef="usd">25823000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzUtMy0xLTEtMA_ec40e4b0-56bf-4fe6-b77d-03d9eee24db3"
      unitRef="usd">53833000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzYtMS0xLTEtMA_449a5fb0-15cf-41dd-ad70-1a4eb8509566"
      unitRef="usd">2800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzYtMy0xLTEtMA_2d84556c-f18a-4097-abc5-429c98678657"
      unitRef="usd">5697000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzctMS0xLTEtMA_7a7dfa08-0a35-4a8b-bcfe-fb2c737651ba"
      unitRef="usd">23023000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzctMy0xLTEtMA_66810b74-8d8d-4a70-ada2-71fc00af475a"
      unitRef="usd">48136000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzgtMS0xLTEtMA_2418ed7a-b9ea-4f43-b448-8d50d41af5c0"
      unitRef="usd">25823000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTplNzcxMDQzYTA5ZDE0YWRhYmMwMzM2Njc4MGI0ZmYxNy90YWJsZXJhbmdlOmU3NzEwNDNhMDlkMTRhZGFiYzAzMzY2NzgwYjRmZjE3XzgtMy0xLTEtMA_52196f5e-0480-4102-9c02-6c72185fd009"
      unitRef="usd">53833000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90ZXh0cmVnaW9uOjUxZjZkZTg5NmNiYjRhNTViZGE2NjE5M2NhNTQyODg0XzM0NTg3_2627eb42-01f6-43d3-81b5-11aecd03265e">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December&#160;31, 2020 and 2019, as well as the estimated remaining performance period as of December&#160;31, 2020.&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Performance Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Oragenics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intrexon Energy Partners II, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Castle Creek Biosciences, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Harvest start-up entities (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i762e74716595460bbc13425c76eaa2db_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtMS0xLTEtMA_686369ca-66ae-4b08-a336-077845d616ab">P0Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i8a8f257af9be4b51bb429c76d609121d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtMy0xLTEtMA_f8decd20-dc67-4660-bc43-0c50eb8603b4"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6e4a4131130d462a9487459be4d56bd7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzMtNS0xLTEtMA_25eb0053-531b-4802-81c7-c3468f758609"
      unitRef="usd">2864000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i9eb44801a44b4a62ad0fdbd70e99dccd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtMS0xLTEtMA_d4487ac5-0f5b-4e72-bc80-1f3b0c2172d5">P3Y2M12D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic4820c653de64b4b8753948eb803072b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtMy0xLTEtMA_4c8a7a63-59a3-4934-a154-e9f036ab48c4"
      unitRef="usd">8362000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="idb4353ff9fff4974bf8fc31f026182f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzQtNS0xLTEtMA_45b3045a-3444-415a-86e4-a4f1441cd9d7"
      unitRef="usd">8362000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i8484095ee2884725be04bc8135beae81_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtMS0xLTEtMA_a91facc7-f39a-4fb5-bd9f-96fdfb1c5a8c">P3Y10M24D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6dece6850a884e9aaa7eb9648a40bb74_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtMy0xLTEtMA_6e85761b-3e6b-4a0c-a18d-e4a06c95201c"
      unitRef="usd">12843000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i34fe2362ff8a42598a97fb6bdba06548_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzUtNS0xLTEtMA_6f9266e9-687e-478f-ada9-79b7301d7fa5"
      unitRef="usd">12843000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i066d432119f04600ad1a8035bcb6cf5e_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtMS0xLTEtMA_358ec8af-e65b-4bc2-b622-d130d425622f">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6512fb771f0b42ee964e35ec040d3d77_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtMy0xLTEtMA_cb86d1cd-e11a-470b-95ea-2c5ff8f29545"
      unitRef="usd">379000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id87b208d51a248b49c170094f36869ec_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzYtNS0xLTEtMA_86dd6b49-1d1f-4d4f-a0ef-765ce3d50d6b"
      unitRef="usd">17697000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i1dd853c6b5c544c1a4eb81cd5293cada_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctMS0xLTEtMA_b92e4ab0-73d7-4af6-8278-8ff05891f1ee">P0Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic7d34d40eae14e879388b762c83dc166_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctMy0xLTEtMA_500bcf70-a43e-4415-838b-a842f868a7bf"
      unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie65a1530d1d0476ca8be03ad2268129a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzctNS0xLTEtMA_b84ebfcd-6343-4361-9d81-faed63f29a13"
      unitRef="usd">6993000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i23f70a5b8fd749b8b7137c61cfab72a9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtMS0xLTEtMA_552a47d1-09e3-433b-bfae-c9a82079f63e">P2Y2M12D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5561d3f0a6bc49eabcffabca3089383f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtMy0xLTEtMA_a2a7b271-d3ea-414b-8447-c628273d432c"
      unitRef="usd">1836000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie98da80d8ac14d7791e297eacb592f73_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzgtNS0xLTEtMA_6ba77858-fbee-481c-a559-593d5af7030f"
      unitRef="usd">1834000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6774b04fc34844d7bb0f5cabaee47b02_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzktMy0xLTEtMA_0152d8f6-8f08-406c-8255-23d3feb3f6d4"
      unitRef="usd">23420000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i559d7af0e8444c759749c165c72c4dd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDIvZnJhZzo1MWY2ZGU4OTZjYmI0YTU1YmRhNjYxOTNjYTU0Mjg4NC90YWJsZTpkMDNiMThkM2QzYjE0ZWI4YTZhMDIzYTEwMWM4OTg5MS90YWJsZXJhbmdlOmQwM2IxOGQzZDNiMTRlYjhhNmEwMjNhMTAxYzg5ODkxXzktNS0xLTEtMA_62faf5ea-43ac-4cfd-a1bf-76190142599d"
      unitRef="usd">50593000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90ZXh0cmVnaW9uOmNiZmFhYmMxMTg5MTRmNzQ5NmZjODQ1Yzg2NzdkMTc5XzE1MTg_f328fefa-15fd-4914-8084-28e95f5a258c">Short-term Investments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 2 and 8 for further discussion on the Company's method for determining the fair value of its assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, all of the available-for-sale investments were due within one year based on their contractual maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and are not significant as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90ZXh0cmVnaW9uOmNiZmFhYmMxMTg5MTRmNzQ5NmZjODQ1Yzg2NzdkMTc5XzE1MTU_63acb84d-4dfd-4870-a44e-150d6fe5c967">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2020:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtMS0xLTEtMA_345a1738-f952-439b-a5a9-a70a02252441"
      unitRef="usd">48048000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtMy0xLTEtMA_d40a1124-c65c-4cc2-a5a0-83879380468c"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtNS0xLTEtMA_7c332f63-2369-4513-ad0b-9c0494f21a80"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzEtNy0xLTEtMA_20ed3f9c-61ad-4c2f-a517-1a9bfe1341be"
      unitRef="usd">48061000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItMS0xLTEtMA_ee7fdf81-9064-4f67-9bb3-7d1405067a4c"
      unitRef="usd">264000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItMy0xLTEtMA_eaf9038e-6cc7-4744-b878-a6ffeee28d62"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItNS0xLTEtMA_334bffc9-041a-415c-ae5f-8657c58a47f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0d533c22a81455786266a631fcc3c93_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzItNy0xLTEtMA_50ffc2bb-8b26-487b-a310-e85780572b5e"
      unitRef="usd">264000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtMS0xLTEtMA_d3f2edde-9240-4fb7-8946-0499d085714d"
      unitRef="usd">48312000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtMy0xLTEtMA_32bff181-20ec-46e1-9031-4feefc9d3b75"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtNS0xLTEtMA_6a33ed3b-7a88-479e-a187-f4ad7d0520d8"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo3NDk3MTg2ZGIzY2M0ZmQxYjU3MGQ4YWViMmQ1NGNmNC90YWJsZXJhbmdlOjc0OTcxODZkYjNjYzRmZDFiNTcwZDhhZWIyZDU0Y2Y0XzMtNy0xLTEtMA_c926ca82-6954-43c2-836f-e6e057ce69cd"
      unitRef="usd">48325000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtMS0xLTEtMA_86c7662a-72c3-4b4a-9c07-b853f693346f"
      unitRef="usd">8989000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtMy0xLTEtMA_dd0c85b5-41bc-44a9-b413-7a39547bdad1"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtNS0xLTEtMA_582b8594-918d-4e7c-8191-c040939461ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzEtNy0xLTEtMA_590fa3eb-4c97-442f-bde5-36dd0ba91667"
      unitRef="usd">8996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItMS0xLTEtMA_c1f3fa51-2e95-448b-8294-9555ba21f0b6"
      unitRef="usd">264000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItMy0xLTEtMA_5a7957c8-562d-49bf-8260-142a18dfb2f0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItNS0xLTEtMA_7002684e-1983-49a9-b944-d685c22ecacc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i625594ecb5a643c1be9c45946c3fe6bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzItNy0xLTEtMA_93d831a6-11b2-48c4-bd64-bf0313c7b37d"
      unitRef="usd">264000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtMS0xLTEtMA_a0cbd669-7e8e-4b17-aa96-04d07d22312c"
      unitRef="usd">9253000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtMy0xLTEtMA_dcca9203-7116-4930-ab27-e74f81cc8f1e"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtNS0xLTEtMA_6fe5065f-8393-4020-b112-70dfce25f74a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDUvZnJhZzpjYmZhYWJjMTE4OTE0Zjc0OTZmYzg0NWM4Njc3ZDE3OS90YWJsZTo4MjA0YjFjYzc1Mzg0ZjI4YjEwMDYwOTE0Y2U1ZTA3Yy90YWJsZXJhbmdlOjgyMDRiMWNjNzUzODRmMjhiMTAwNjA5MTRjZTVlMDdjXzMtNy0xLTEtMA_6cfae6a9-60b5-4299-a305-efc20e1a240b"
      unitRef="usd">9260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MDk_99bbf5ff-1eb3-41b6-983a-5ac6cd530acb">Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. During 2019, the Company's equity securities of AquaBounty (Note 1) and preferred stock owned in one of its collaborators (Note 18) were classified as Level 3 within the fair value hierarchy prior to disposition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the Level 3 investments during the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained interest in deconsolidated subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend income from investments in preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds to be received from preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculated fair value of the Convertible Notes (Note 12) was approximately $165,000 and $126,000 as of December&#160;31, 2020 and 2019, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $168,147 and $157,560 as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company's contingent consideration liability, which was $585 as of December&#160;31, 2019, was reduced to $0 as the period for potential payment of this contingent consideration expired without payment in June 2020. The contingent consideration liability was remeasured to fair value at each reporting date until the contingency was resolved, and those changes in fair value were recognized in earnings. The changes in the fair value of the Level 3 liability during the years ended December&#160;31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration recognized in selling, general, and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 10 and 11 for discussion of non-recurring fair value estimates used in calculating impairment charges recorded during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MDM_44245595-b218-4dca-9a74-7d18a3102a02">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if05375e0f8b94091a3e217e403a5e204_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItMS0xLTEtMA_1617313b-cb9c-4afd-b96a-a2486a7db120"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e5f8179595b4e5ba09bd4c1c6d600b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItMy0xLTEtMA_ddec1fd6-2592-44a8-a9dd-89529dae22d5"
      unitRef="usd">48061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd472d7ad35f4a15b21d2195d5808bb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItNS0xLTEtMA_e4f4a42e-3446-43b2-a088-5051fe54b2b4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08d7c23fc413485dac1d297dad0adfd2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzItNy0xLTEtMA_e90f7486-d505-4b8a-8c26-d9294c465cf2"
      unitRef="usd">48061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibcfedad06ddd479bba91d37f6def04da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtMS0xLTEtMA_ce8f38ff-b3f6-4e8f-b607-b20c6f91f236"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4f1c801fb36143c49fd0b608bcfa5b48_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtMy0xLTEtMA_957a3e9f-48de-4ce1-a9a7-de8ef7572288"
      unitRef="usd">264000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia61312b716ae4e47b5211d08c39bc9a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtNS0xLTEtMA_16dcd630-4f71-430c-aea0-f96c8c228c5b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i897525fafdb1444eb6402bf2a7754355_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzQtNy0xLTEtMA_148a6eb4-57a4-48a5-b0bd-c5869004d750"
      unitRef="usd">264000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ida01d18612bb4a56b451ba944d2f4a9e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtMS0xLTEtMA_f8ecee8b-047c-47bd-b141-093c411098c8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6fff13a081c481cb9e48baa81cacfaa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtMy0xLTEtMA_af9f07a8-d6fc-483f-97f8-03fb914f84dc"
      unitRef="usd">48325000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtNS0xLTEtMA_2943bc94-0bea-44c4-8a1e-4b3342d0b8ea"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpjYzc4YzZiZWZjNTM0NWYzOTJkMGNjNWE0ZTViMTNlOS90YWJsZXJhbmdlOmNjNzhjNmJlZmM1MzQ1ZjM5MmQwY2M1YTRlNWIxM2U5XzUtNy0xLTEtMA_1f549760-aa32-4e69-af6b-00c0acc5ec7d"
      unitRef="usd">48325000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic7aae1a7de0b42298d4467fd3ec004af_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItMS0xLTEtMA_29c497e4-6b24-4c18-ae4f-2e7b7e160072"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia72f10ede16740f6939170db24c97f9d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItMy0xLTEtMA_954dfd2f-387b-4abd-8157-c52adf938366"
      unitRef="usd">8996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id33a83c66e5e4d04930c270f49fcf9fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItNS0xLTEtMA_d886f178-96a1-4db1-9345-816e40a3a2d6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0efc7bf936b3476083f68d4965ac2088_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzItNy0xLTEtMA_a559aa06-7fd9-4b97-ac4b-40f694edbf1a"
      unitRef="usd">8996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9143d9e97c0c469295ecf8f8e86bf4b2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtMS0xLTEtMA_b31a3a0c-25b8-4c6f-9074-4d2ba80ef3e4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a32497816a24b0e98bfe2b91cdb5f5b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtMy0xLTEtMA_9a0b8533-3b76-4f9f-8163-0ae84d003e44"
      unitRef="usd">264000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03f0abd7a34b402a805fc120d404fcab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtNS0xLTEtMA_0f7cf90c-787c-4467-953e-d8780740c125"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2add7e1ec07f40dbb767635c38522992_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzQtNy0xLTEtMA_fd9fb7fa-fa82-4e7d-9cd9-393da3796710"
      unitRef="usd">264000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2add8a116b4448d19d15dd64d77975a5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtMS0xLTEtMA_0f12a3f0-abb3-41e3-aa10-74584602d75e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9829035a8a2f448e9920c55d9173e8fa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtMy0xLTEtMA_62ff97fa-3a9d-4cd5-8fe8-1cef182971ff"
      unitRef="usd">9260000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtNS0xLTEtMA_82cc5aea-ddfe-43ea-a9b5-caca587f6382"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTo2MTZiN2U0ZTQ1OGI0MTJkYmViNmJlMDEzODQzNmUwZC90YWJsZXJhbmdlOjYxNmI3ZTRlNDU4YjQxMmRiZWI2YmUwMTM4NDM2ZTBkXzUtNy0xLTEtMA_66399f1c-7963-42b9-95b6-4bc52ca38652"
      unitRef="usd">9260000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzM0MTE_7cb1f302-363c-4c14-b36b-f4d0ad6b5a2a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the Level 3 investments during the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retained interest in deconsolidated subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend income from investments in preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds to be received from preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i27aebe7d32b349b39eabbc338188b25c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzEtMy0xLTEtMA_dd3790ef-b287-4721-9c65-595e5f87f25a"
      unitRef="usd">191000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <pgen:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzUtMy0xLTEtMA_790d7c3d-fd2c-476c-8118-486a7930f748"
      unitRef="usd">14239000</pgen:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary>
    <pgen:NoncashDividendIncome
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzYtMy0xLTEtMA_541c44fc-9519-48a0-a7b3-75d5e3fccdad"
      unitRef="usd">48000</pgen:NoncashDividendIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzctMy0xLTEtMA_6eb534fe-a28b-4333-a301-e7fc754cee06"
      unitRef="usd">7446000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzktMy0xLTEtMA_b9900648-9f99-4ec6-b106-776051bd561b"
      unitRef="usd">21587000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <pgen:PreferredStockReceivables
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzEwLTMtMS0xLTA_ec8e0c16-b21d-4b50-a566-5d3230b404b3"
      unitRef="usd">337000</pgen:PreferredStockReceivables>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZTpiN2Y4MTAxYjZjN2Q0NGYxODE3MmMxOWVjNjZiMGJmOS90YWJsZXJhbmdlOmI3ZjgxMDFiNmM3ZDQ0ZjE4MTcyYzE5ZWM2NmIwYmY5XzExLTMtMS0xLTA_d39ad3a3-86e6-4feb-8469-de321617e736"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzIxNjQ_899d763e-8c26-4025-af4a-e255a1b11f2d"
      unitRef="usd">165000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ided6796ecfc64dfd806da8fc7d8e889f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzIxNzE_ead318d3-4887-461f-824f-f2725218d599"
      unitRef="usd">126000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebt
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI2NTA_49dc7cfd-7243-4ca4-ab35-f54ab5558d2f"
      unitRef="usd">168147000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ided6796ecfc64dfd806da8fc7d8e889f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI2NTc_a3a14832-a04f-4585-984f-eeefe9ca0bdf"
      unitRef="usd">157560000</us-gaap:ConvertibleDebt>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzQzOTgwNDY1MTUxMDA_19167995-9590-41e1-8dbc-959b7087d173"
      unitRef="usd">585000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzI3OTU_4d4ae252-a16e-4b0d-a410-a978023bf0c4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90ZXh0cmVnaW9uOmI1MjY3MTk5MzA0NjQxNmI5YjE1MWUwOTgzZjQzMzZlXzY1OTcwNjk3NzMzMjQ_ef8f9ffe-c897-4716-aaa7-25d19636f30c">The changes in the fair value of the Level 3 liability during the years ended December&#160;31, 2020 and 2019 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration recognized in selling, general, and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzEtMS0xLTEtMTM5NQ_1169f95d-7613-45be-8457-eef02a8e653b"
      unitRef="usd">585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i27aebe7d32b349b39eabbc338188b25c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzEtMy0xLTEtMTM5NQ_20f5ffaa-34cb-4c66-924c-ca40c5b114f8"
      unitRef="usd">585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaff95dd2e5e6493cab06cdbfe40f221f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzUtMS0xLTEtMTM5NQ_1ef905fa-0d4a-47c3-a3d6-9dd2675fb51b"
      unitRef="usd">585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i9d0968ba139544f5890a7b58950634c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzUtMy0xLTEtMTM5NQ_28613fae-4af0-4bec-8250-19993cac2ab2"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0b2ef97b451e4b288b2e62ae5801f30b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzExLTEtMS0xLTEzOTU_478e87ce-9b2a-42d2-b8b3-28f5edeef84b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i088a49fa06f042b3b7d0a766cbe4ba16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNDgvZnJhZzpiNTI2NzE5OTMwNDY0MTZiOWIxNTFlMDk4M2Y0MzM2ZS90YWJsZToxY2JjYWU0YmFmMWQ0OWZhYjM4NTUyNDdjMGI0ZmY5My90YWJsZXJhbmdlOjFjYmNhZTRiYWYxZDQ5ZmFiMzg1NTI0N2MwYjRmZjkzXzExLTMtMS0xLTEzOTU_deb726f8-29a7-4098-80a8-333157324a54"
      unitRef="usd">585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90ZXh0cmVnaW9uOjk3OTI2NTFkZjBjODQ3MzQ4ODRkNzY5NTRlN2FhOTJmXzk0_0c240aec-cf4e-4a95-832a-25b7f180d22c">Inventory&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies, embryos and other production materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Feed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90ZXh0cmVnaW9uOjk3OTI2NTFkZjBjODQ3MzQ4ODRkNzY5NTRlN2FhOTJmXzg0_a5cacfc3-a054-4c4d-b43a-4c62c600c9e2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies, embryos and other production materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Feed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryGross
      contextRef="i88fed49ad0634fc1978b61d0cad74161_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzItMS0xLTEtMA_2d3868a1-f077-4d7d-abc7-9dc8f509f8d6"
      unitRef="usd">2060000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i5f1e8bcd17ae4fc0b556dc1a59ce8c5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzItMy0xLTEtMA_f450b133-7a52-4c59-a1ff-28731a76533d"
      unitRef="usd">2282000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i1e13e1046d1a4e8d8a5d3ce4b8599cde_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzMtMS0xLTEtMA_9442e998-9b87-4ec2-97ed-4802d5d36049"
      unitRef="usd">2348000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i148174464dab4df3b6cc16ca4f94f20c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzMtMy0xLTEtMA_227ff454-3e47-4326-b477-f82e9d70f57d"
      unitRef="usd">3702000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i9cbec292daaf4a33adb6add3983c2aca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzQtMS0xLTEtMA_a2500011-3f50-48cb-a8cd-2960b1af7921"
      unitRef="usd">5047000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="id66643537bcc4586b5c8295486ad53db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzQtMy0xLTEtMA_55630679-d376-4351-85d1-9804757c9bcb"
      unitRef="usd">7553000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i917953d1a25e429ca029530f8e586cc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzUtMS0xLTEtMA_b2dcf670-1d76-43c0-bb4b-8cba9501bd65"
      unitRef="usd">1904000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ifa8e97e073a840e3a917dd25f9403665_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzUtMy0xLTEtMA_18eb6a5a-aba6-4799-add1-d4722decb570"
      unitRef="usd">2560000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzYtMS0xLTEtMA_83650940-c7cf-4e0f-bbef-fb8ea4ae9fc6"
      unitRef="usd">11359000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTQvZnJhZzo5NzkyNjUxZGYwYzg0NzM0ODg0ZDc2OTU0ZTdhYTkyZi90YWJsZTo1ZjlmNWZhYzkwODU0OGM3YmQwNjM4MzA1ODdiNTNjYy90YWJsZXJhbmdlOjVmOWY1ZmFjOTA4NTQ4YzdiZDA2MzgzMDU4N2I1M2NjXzYtMy0xLTEtMA_56340b23-2f3c-4ea2-be15-33133b14be6f"
      unitRef="usd">16097000</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzYyMg_896adc31-e7bb-448b-89ac-aed2e586d106">Property, Plant and Equipment, Net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Breeding stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction and other assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $7,449, $8,222 and $8,946 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company recorded impairment losses of $920, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, primarily related to right-of-use assets at certain of the Company's leased locations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company recorded impairment losses of $448, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, related to the impairment of property, plant and equipment in conjunction with the closing of two of its operating units during the third quarter of 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzYxOA_6c8d9e7a-54e8-40d5-bbf7-5bceb752d625">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Breeding stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction and other assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:LandAndLandImprovements
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzItMS0xLTEtMA_eabd4650-0977-4011-90f2-f06f55f231f3"
      unitRef="usd">9844000</us-gaap:LandAndLandImprovements>
    <us-gaap:LandAndLandImprovements
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzItMy0xLTEtMA_5c28011a-b7b7-4288-8ff1-9c6edc6b4f59"
      unitRef="usd">9814000</us-gaap:LandAndLandImprovements>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzMtMS0xLTEtMA_84b8c064-723b-4b72-87d9-7d80d8ab9a89"
      unitRef="usd">12088000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzMtMy0xLTEtMA_e4f3d7c6-1f6b-4bfe-b716-2af20953269f"
      unitRef="usd">11765000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzQtMS0xLTEtMA_3f864806-0a6c-49bc-bd34-9e612269c74b"
      unitRef="usd">1228000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzQtMy0xLTEtMA_7cb7d87f-7d23-4e73-b1f0-a61be663170b"
      unitRef="usd">1025000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzUtMS0xLTEtMA_24ff058d-35c6-41b6-8306-e6ea6de01df9"
      unitRef="usd">31150000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzUtMy0xLTEtMA_e15a6e4c-71e9-4db9-a182-2065218a876f"
      unitRef="usd">33707000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzYtMS0xLTEtMA_55f76c56-5f9f-426c-b28e-8f10f855224b"
      unitRef="usd">6260000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzYtMy0xLTEtMA_9a4318ea-fa2b-42de-84ff-2ceee594c995"
      unitRef="usd">6607000</us-gaap:LeaseholdImprovementsGross>
    <pgen:BreedingandProductionAnimalsGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzctMS0xLTEtMA_128e7bd8-36b9-447e-8de1-5e28c22ce6bd"
      unitRef="usd">868000</pgen:BreedingandProductionAnimalsGross>
    <pgen:BreedingandProductionAnimalsGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzctMy0xLTEtMA_146fb098-bfbe-4ee0-bc5b-0df802c26a04"
      unitRef="usd">5191000</pgen:BreedingandProductionAnimalsGross>
    <pgen:ComputerHardwareandSoftware
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzgtMS0xLTEtMA_07f0e2ba-b12a-498a-a42b-59b0ec8b3a81"
      unitRef="usd">5684000</pgen:ComputerHardwareandSoftware>
    <pgen:ComputerHardwareandSoftware
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzgtMy0xLTEtMA_f9adbdf6-72f3-4022-8f6f-d7dedcbb2073"
      unitRef="usd">6877000</pgen:ComputerHardwareandSoftware>
    <us-gaap:ConstructionInProgressGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEwLTEtMS0xLTA_5352eb34-70b7-4e5d-8b2b-c83f9173856e"
      unitRef="usd">2754000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEwLTMtMS0xLTA_9724eb60-7269-4656-b8f1-18ab8f7c5ecb"
      unitRef="usd">5229000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzExLTEtMS0xLTA_8d1339cb-b3f7-4456-9bbb-d7268a6ba7de"
      unitRef="usd">69876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzExLTMtMS0xLTA_d7519be1-f5ff-46fe-b2af-eb58d4749978"
      unitRef="usd">80215000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEyLTEtMS0xLTA_9a6a3862-e907-46ea-9254-c8e0b43760b0"
      unitRef="usd">34952000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEyLTMtMS0xLTA_b0a5f9ef-ed86-4797-95a0-9fb6288d1ac1"
      unitRef="usd">36263000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEzLTEtMS0xLTA_2d4eb57d-2230-46ab-874d-67ddd36049ea"
      unitRef="usd">34924000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90YWJsZTowY2I1NDIwNTFiNDg0MzcwOGZiMTkxY2Y0ZWQzOTI3YS90YWJsZXJhbmdlOjBjYjU0MjA1MWI0ODQzNzA4ZmIxOTFjZjRlZDM5MjdhXzEzLTMtMS0xLTA_be8eeabc-5e01-44f6-9dfb-4db57965b648"
      unitRef="usd">43952000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5NzY_5e7d3748-92a2-40e3-9b12-5869f5e772d0"
      unitRef="usd">7449000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5ODE_1e2a657f-1557-46dd-8547-7320e25aab9e"
      unitRef="usd">8222000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTE5ODk_7fc415bb-0bc8-4c14-b4df-519829c6f296"
      unitRef="usd">8946000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzc2OTY1ODEzOTY3NDI_929668f5-d28d-46b7-8868-3a5e1678ca20"
      unitRef="usd">920000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQzOTgwNDY1MTIyMzQ_15c2be63-7411-430b-8daa-5c01774713c4"
      unitRef="usd">448000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <pgen:NumberOfReportingUnitsClosed
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNTcvZnJhZzoxNmZjNzNiMmZlYzM0MDlkYTI5NDI4ZmE2MmRiYzFkYy90ZXh0cmVnaW9uOjE2ZmM3M2IyZmVjMzQwOWRhMjk0MjhmYTYyZGJjMWRjXzQ2OQ_4db7ad21-282c-4c5e-a364-d56a7d88f69c"
      unitRef="reporting_unit">2</pgen:NumberOfReportingUnitsClosed>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDM_31535fcd-ee06-4a38-bf35-5158589fd597">Goodwill and Intangible Assets, Net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $43,643 of cumulative impairment losses as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2019, during the Company's annual goodwill impairment test, the Company determined it was more-likely-than-not that the fair value of the Trans Ova reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the Trans Ova reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $29,642 goodwill impairment charge for the excess carrying value. Additionally, the Company recorded $178 of goodwill impairment in conjunction with the closing of two of its reporting units during the third quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 20 for information regarding goodwill by reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following as of December&#160;31, 2020:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents, developed technologies and know-how&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following as of December&#160;31, 2019:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents, developed technologies and know-how&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the year ended December 31, 2018, the Company recorded a $16,027 loss related to the abandonment of certain developed technologies that the Company ceased using in the fourth quarter of 2018. The Company does not expect to use these technologies as a defensive asset or market them for sale in the future. Because these technologies were used in combination with other technologies, the identifiable cash flows did not result in an impairment loss; however, because the Company made a decision to abandon the assets, it recorded the charge to research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $7,593, $7,920 and $11,666 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDU_bebf475d-53a9-4fab-a86e-c519e1194367">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzEtMS0xLTEtMA_599250d8-880c-4349-9511-f21cc43d4195"
      unitRef="usd">54119000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i018f1b16362d4eb49b749a30dbdaaa5c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzEtMy0xLTEtMA_1506750b-676a-47dd-b1e8-90a65daed31f"
      unitRef="usd">83992000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzMtMS0xLTEtMA_a48a6503-d8ff-4626-ae26-4143fc215c3b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzMtMy0xLTEtMA_bf62d2d4-06ef-4c62-814d-36d9ccce307e"
      unitRef="usd">29820000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i867e347749054e8a8f0790f939874f83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzQtMS0xLTEtMA_cdb1840a-3ff5-4903-bf0c-c8cbfe232ac2"
      unitRef="usd">244000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i5295e599fcaa4928a3aea11647f89945_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzQtMy0xLTEtMA_20c852d7-7f4c-48eb-a295-2aa644d50317"
      unitRef="usd">-53000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i8952cdcb9a6e414eb3558452807047c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzUtMS0xLTEtMA_9a0b7bdf-6907-4c3b-a188-dec5278799b1"
      unitRef="usd">54363000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9e8cb877d0184774ae2285744aa4fce4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo4MjljNDlkZDJmZTU0MDE5ODEwMmJhZTRmYzRiM2MzYS90YWJsZXJhbmdlOjgyOWM0OWRkMmZlNTQwMTk4MTAyYmFlNGZjNGIzYzNhXzUtMy0xLTEtMA_1e78b675-4a71-4e85-a55d-5d6d448affc6"
      unitRef="usd">54119000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE1Nw_91dfa908-9d30-4476-bf35-3af17410ba36"
      unitRef="usd">43643000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE1Nw_9ea69d35-c99e-4faa-b674-42bc6cc03b78"
      unitRef="usd">43643000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzQzOTgwNDY1MTMyNjc_080de05b-a154-4165-a925-98f3362db10f"
      unitRef="usd">29642000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzQzOTgwNDY1MTMyNzE_e6a96ee1-1056-471a-96bb-d4050b0104b1"
      unitRef="usd">178000</us-gaap:GoodwillImpairmentLoss>
    <pgen:NumberOfReportingUnitsClosed
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzg1OQ_b428303e-46aa-4cfb-9606-5a987fd11514"
      unitRef="reporting_unit">2</pgen:NumberOfReportingUnitsClosed>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxMzQ_0283b9b2-30c5-4239-8423-e7e7c865eb4a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following as of December&#160;31, 2020:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents, developed technologies and know-how&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following as of December&#160;31, 2019:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents, developed technologies and know-how&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i827c577308054c018d5e48fada14ff8b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtMS0xLTEtMA_71c97422-4459-468f-a9af-9f37b19231b6">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtMy0xLTEtMA_def113cd-58e0-4740-9f81-7d797095ee8d"
      unitRef="usd">96927000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtNS0xLTEtMA_150992f6-3762-40f5-a829-d3ac216e30f2"
      unitRef="usd">34412000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f46f4ce4f5d4e4fab326620d2b600b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzEtNy0xLTEtMA_05063f03-ea5e-46ed-8aa7-4bee0476792a"
      unitRef="usd">62515000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia6fc55d839644cba90653e38f783a62e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItMS0xLTEtMA_bbe4abb7-badd-4d3e-a18a-04815efb7564">P6Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItMy0xLTEtMA_2b6b3635-778e-4bf9-aabe-2030ce36a475"
      unitRef="usd">10850000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItNS0xLTEtMA_3f505d48-b95a-4cde-be13-f86f1a4670f3"
      unitRef="usd">9340000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ied6ba1ca069a426ca9cfb32e3b7ab3c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzItNy0xLTEtMA_2c732b08-997b-453a-9e50-047fd2855f0d"
      unitRef="usd">1510000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1f3d42982abc4d50a68c8e28b6a8c52b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtMS0xLTEtMA_81ee7adc-7630-499a-8241-d1ee0a8feac3">P8Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtMy0xLTEtMA_380cc879-9c29-406b-81db-75db1f048d30"
      unitRef="usd">5900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtNS0xLTEtMA_de8f334d-ee41-40f3-a7a6-49fde9810627"
      unitRef="usd">4529000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3d8e3f82f07e47e68f0a8616dce7bb5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzMtNy0xLTEtMA_cf8352b8-b91e-4f43-b984-991a7a3a3e53"
      unitRef="usd">1371000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtMy0xLTEtMA_69d400dc-260d-4fd0-be53-f2243392bd16"
      unitRef="usd">113677000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtNS0xLTEtMA_aee79093-8664-4be0-a7df-de971c88bb4b"
      unitRef="usd">48281000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTo1MmYwMjM4ZWFiYjc0NGIxODQwMWMzMWNhNDIzODcwNC90YWJsZXJhbmdlOjUyZjAyMzhlYWJiNzQ0YjE4NDAxYzMxY2E0MjM4NzA0XzUtNy0xLTEtMA_cba2bcdf-4029-40ea-9405-69f62863aaaa"
      unitRef="usd">65396000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtMS0xLTEtMA_e8804e6b-4174-4ed4-8b00-0faece147aea"
      unitRef="usd">90659000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtMy0xLTEtMA_4f95fc26-7e55-4b60-a9ab-b766fdb1d379"
      unitRef="usd">26619000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id59cb5726db6446eb9557596ccf3c7f9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzEtNS0xLTEtMA_5442f952-f773-47a6-9687-53d4e4733700"
      unitRef="usd">64040000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItMS0xLTEtMA_ebc96679-c702-43d9-af7e-bf178c8e1cbf"
      unitRef="usd">10700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItMy0xLTEtMA_7fd3f94f-1f1b-499d-aade-91dc18dae349"
      unitRef="usd">8440000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia7e33c160a5e4e85abbb9e977904ab51_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzItNS0xLTEtMA_a301b727-32af-4510-931a-62b9ee76826c"
      unitRef="usd">2260000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtMS0xLTEtMA_759c88f3-1cfa-46c2-8465-96cf33c853cc"
      unitRef="usd">5900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtMy0xLTEtMA_1900da34-4de1-4276-b234-b9a429494177"
      unitRef="usd">3854000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic5d76c7ffee04f1cbcd2c3731d0e77bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzMtNS0xLTEtMA_87a3d364-2dea-4b8b-911e-44c58a4988b6"
      unitRef="usd">2046000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtMS0xLTEtMA_86f1d5bc-dbef-4fc4-a807-a3fe5097736a"
      unitRef="usd">107259000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtMy0xLTEtMA_d27ead5a-c65c-4965-a0a2-c518f7492124"
      unitRef="usd">38913000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTowNTRmMTMzMzNmM2E0OGZjYmVjOTdmNDVmNWYwZWQzZS90YWJsZXJhbmdlOjA1NGYxMzMzM2YzYTQ4ZmNiZWM5N2Y0NWY1ZjBlZDNlXzUtNS0xLTEtMA_d5b28d1b-e110-463a-9f8b-51e0b7b7f3a7"
      unitRef="usd">68346000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if23ada0abe5047e9816a9b05e4ac3a06_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzExNTE_8537c3fa-f2ce-4b8d-a5e7-c54ae3db478a"
      unitRef="usd">-16027000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5NTg_e8b49f10-b769-4d85-9371-9dc5f4a0fe0a"
      unitRef="usd">7593000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5NjI_3a609555-f07a-4241-8c1e-8d07bd7ff1fd"
      unitRef="usd">7920000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzE5Njk_d6962e64-2949-4d9f-b91f-38ee851b7e77"
      unitRef="usd">11666000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90ZXh0cmVnaW9uOjFkMDBkM2YwOWY2MzRkZWZhMDE1ZThjZGMyNzczN2EyXzIxNDY_627c13d9-f2be-4813-8f0b-f5b9c5200263">Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzAtMS0xLTEtMA_9533809b-e658-41e3-b24d-fb2a4af139bc"
      unitRef="usd">7704000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzEtMS0xLTEtMA_32417b44-e867-4faf-b93b-716b1b8c3847"
      unitRef="usd">6908000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzItMS0xLTEtMA_30b302d0-03bb-4b12-9706-608beda551d3"
      unitRef="usd">5742000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzMtMS0xLTEtMA_705763b4-2afa-4f84-a361-fe5430b82316"
      unitRef="usd">5432000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzQtMS0xLTEtMA_c7b8f16c-1b0c-4a92-b2c3-6b762ac23b5c"
      unitRef="usd">5419000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzUtMS0xLTEtMA_f1ef4644-a851-4652-865a-a66f3f8af712"
      unitRef="usd">34191000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjAvZnJhZzoxZDAwZDNmMDlmNjM0ZGVmYTAxNWU4Y2RjMjc3MzdhMi90YWJsZTplNzJmMmM3ODM1YTc0N2VlOTZmM2QzZTczZjczNmI3Ni90YWJsZXJhbmdlOmU3MmYyYzc4MzVhNzQ3ZWU5NmYzZDNlNzNmNzM2Yjc2XzYtMS0xLTEtMA_13520983-caab-41fb-975c-e09647338919"
      unitRef="usd">65396000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODY_6f0fdfd2-6f16-46dd-98f8-52c948ac18cd">Lines of Credit and Long-Term Debt&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on April 1, 2021. The line of credit bears interest at the greater of the U.S. Prime Rate or 3.00%, and the actual rate was 3.25% as of December&#160;31, 2020. As of December&#160;31, 2020, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $5,000 as of December&#160;31, 2020. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2021. The line of credit bears interest at 4.00% per annum. As of December&#160;31, 2020, there was no outstanding balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Precigen Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Upon the occurrence of specified corporate events as defined in the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December&#160;31, 2020. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount (Note 13). As of December&#160;31, 2020, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $168,147. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02%. As of December&#160;31, 2020, the unamortized long-term debt discount and debt issuance costs totaled $31,853.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of interest expense related to the Convertible Notes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest of $3,500 is included in other accrued liabilities on the accompanying consolidated balance sheet as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ActoBio Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 4). The ActoBio Notes, which accrued interest at 3.0% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued 6,293,402 shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $616, $921, and $290 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Precigen and PGEN Therapeutics Convertible Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, in conjunction with the Merck Purchase Agreement (Note 6), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note had a maturity date of June 28, 2021 although it automatically converted to Precigen common stock on the first trading day following the second anniversary of issuance, which is December 2020, if not otherwise converted prior to that date. In October 2020, pursuant to the terms of the Merck Note, Ares Trading voluntarily elected to convert the entire $25,000 outstanding into 6,758,400 shares of Precigen common stock. The shares are restricted from resale by Ares Trading for a period of 180 days from the date of issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $3,655 as of December&#160;31, 2020. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of long-term debt as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc2_f57678f2-d9fd-48db-84e1-e63ee41c05b8"
      unitRef="usd">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iebe34c2e16ef4ced904a0a453bb78be8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI2Nw_f8ff3655-f557-41d7-bb21-2d524f03a242"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI5NQ_03dc1fb3-9444-4dad-bbd4-57df4d680cce"
      unitRef="number">0.0325</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCredit
      contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM1NA_ddc16188-7d06-45f0-9e49-1b88507b6f61"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ia2462eb080f5476ba12592a72425bb0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzUwMw_c66f18d5-4e03-4dc8-9da5-14a8b9b6a398"
      unitRef="usd">5000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzgyNQ_80480286-00b3-4ef0-8529-843ef5b251cf"
      unitRef="usd">700000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0OQ_7026d556-2315-4ef1-adfa-2c1d6378e059"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCredit
      contextRef="i7417cafe9a0140cdb536d3070b429916_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzEwMDk_7a8e7672-e99a-4b07-82a1-da46bf052637"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODg_1b9bec01-f097-445c-8fb2-8702877d4be8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="ie20ccfa747e64113890f0974c9cb925e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzItMS0xLTEtMA_bb72a31c-0d6e-470b-8ee5-a87a74bcaea1"
      unitRef="usd">168147000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic1adbe486ee94be59a3ea92894502ff4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzItMy0xLTEtMA_b2f975cf-0dcb-43f0-8944-4af3462b3e69"
      unitRef="usd">213771000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i933e7cc3ab3e474b9117c918400f0682_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzMtMS0xLTEtMA_c974279a-7532-48cc-9795-ac9aba16dbb2"
      unitRef="usd">3655000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia1b7410140b740b2845853aabed50d7d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzMtMy0xLTEtMA_957283b7-6923-4798-aeac-c8828655b229"
      unitRef="usd">4089000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i792bcba573ad43159c20ae7da25f6f15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzQtMS0xLTEtMA_ee6577d3-984c-4077-a2c4-0e01c0786c25"
      unitRef="usd">80000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifac99bde42eb4b6eba9f0cd1ac7f2e1b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzQtMy0xLTEtMA_9a9d3da0-2660-4d88-a7ae-3ef524ad22d6"
      unitRef="usd">131000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzUtMS0xLTEtMA_c01e9f6c-e0da-4020-8c11-70222846b5c6"
      unitRef="usd">171882000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzUtMy0xLTEtMA_fa26016a-094e-4cde-81cf-0a0eb45790b9"
      unitRef="usd">217991000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzYtMS0xLTEtMA_981ac02c-aa1c-42bc-9c17-de489506686e"
      unitRef="usd">360000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzYtMy0xLTEtMA_cdf87677-d0f2-4686-a5f8-bf1ae7371e6d"
      unitRef="usd">31670000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzctMS0xLTEtMA_c9b9d2ad-cf30-4792-aa89-33d964611430"
      unitRef="usd">171522000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTozNDNlZTcwOWY5MGM0N2Y3YjZhZjZlZGRiNmY4ZjAxZC90YWJsZXJhbmdlOjM0M2VlNzA5ZjkwYzQ3ZjdiNmFmNmVkZGI2ZjhmMDFkXzctMy0xLTEtMA_d4706b88-5f56-4990-811b-43783b14daeb"
      unitRef="usd">186321000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzEzOTA_2019a9a2-01f1-42a2-ae6c-99b657fbf454"
      unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE3Mzc_e986a6ad-5e6c-45f5-a655-b060e1719221"
      unitRef="usd">193958000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE4MDQ_8df972cb-ebb0-48e1-97e0-9caa7039fd95"
      unitRef="usd">6042000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzE5MDY_db9b9db5-95e4-4bfc-aa36-bfb0bb246cc3"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzIzMDU_e161b96a-0c59-4486-a0e2-59127a0c00d6"
      unitRef="number">58.6622</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <pgen:ConvertibleDebtPrincipalAmountInitialConversionRate
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzIzNDQ_4f5de2c1-b891-40b8-b364-3aad6c6fa637"
      unitRef="usd">1000</pgen:ConvertibleDebtPrincipalAmountInitialConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzI0NDU_ab43cf98-17a0-4102-9b07-33fc01eda153"
      unitRef="usdPerShare">17.05</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMyMTk_f0cb27e0-1e15-447f-b225-3de627d9f62c"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMyODA_7e80859c-43df-4e88-a874-84e23b761762"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i43f5fd8d2e8c4afba347048ed65c2ff2_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzMzODI_708fe7bb-ef2b-4fe5-a041-cd2a7139b1ad"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM0NTI_f5061769-dcc9-4265-acaf-aff308bf67a2"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM0ODU_6cd11aed-2eac-4d51-8313-d4dca01251c8"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ibf57ef00bf69495496f71af763419a23_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzM2MTU_27a3125a-a9d0-4e4e-8748-702a82ea923c"
      unitRef="number">0.98</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzODI_051c3e21-a0ee-4252-9beb-4b998761cd07"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:ConvertibleDebt
      contextRef="ieed5ad89bf7c4f28ab282ab7e0df1e84_I20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU0NTg_516a7575-b449-4b7a-98c3-5d20531acb10"
      unitRef="usd">143723000</us-gaap:ConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU1MzM_80c2154b-d131-422d-8fa6-b282e8b31a03"
      unitRef="usd">50235000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i17202f32a1d645efbfd56a212e966489_D20180701-20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzU1ODc_af0602c3-27ee-48fa-943b-5212a8b3bc36"
      unitRef="usd">13367000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYwMDE_cfe20fd8-cb75-4425-aaf6-7b198541a78f"
      unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebt
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYwNDk_49dc7cfd-7243-4ca4-ab35-f54ab5558d2f"
      unitRef="usd">168147000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYxODk_50ac8a04-33e8-4831-a5d7-fb96553b4e75"
      unitRef="number">0.1102</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i400855cb5a3d4e6582b7e57125c949fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYyNzU_10853c45-9f33-45ed-9b20-cbfd98ecf6e9"
      unitRef="usd">31853000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0ODE_bfb28e09-8ad4-4d6d-9b5b-fbabaaa77c9e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of interest expense related to the Convertible Notes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItMS0xLTEtMA_f92a03b4-0d24-4bd6-9eec-4f32c8c42302"
      unitRef="usd">7000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItMy0xLTEtMA_2338e7e1-67af-4d1e-ba94-f1c8cfa14320"
      unitRef="usd">7000000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzItNS0xLTEtMA_c322df41-2827-49c3-a2c0-3273bf9f1c0d"
      unitRef="usd">3462000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts
      contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtMS0xLTEtMA_1841017d-11b0-4562-8549-30b88fe46da3"
      unitRef="usd">10587000</pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts>
    <pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts
      contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtMy0xLTEtMA_a9b95906-6ce3-45ea-95b7-b42d4ad4bdf2"
      unitRef="usd">9459000</pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts>
    <pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts
      contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzMtNS0xLTEtMA_79579241-102e-4eb3-8b3f-9cfe11c8b7c1"
      unitRef="usd">4378000</pgen:InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtMS0xLTEtMA_ed2efd14-05d7-46dc-aa13-dfe4afe7713e"
      unitRef="usd">17587000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iea183b22e6204e749452fefc61666933_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtMy0xLTEtMA_d80784ee-37ff-46c4-8c09-ab2d11ba6f6f"
      unitRef="usd">16459000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i262b7d274e6544f8bc0db9d2e9901a90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZTplOTdiYjE0MWJjNmQ0MDZiOGJlMjhmN2UwM2Q5NDQ2YS90YWJsZXJhbmdlOmU5N2JiMTQxYmM2ZDQwNmI4YmUyOGY3ZTAzZDk0NDZhXzQtNS0xLTEtMA_c0294868-bac6-4f43-a9a8-65f415d0bd49"
      unitRef="usd">7840000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzYzODY_a8d69c5e-b2fe-4a7b-9c49-dc83b52a863a"
      unitRef="usd">3500000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i300109a3973b48cfaf6c87f24830c1e8_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzY1NDc_deb5d86b-5193-4bba-ae66-1612abb254f0"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5dcdccfde7b24e57841cf202a0c22c5e_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzY3Njg_4220ce2f-82d0-4ce1-8853-c7ccb8733ab2"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ifbf7a9ed58fa4c19bfac3158a4004562_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MTU_94aee9c0-3523-47b9-94e1-295929b0f1b3"
      unitRef="shares">6293402</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InterestExpense
      contextRef="ibcc2b6cdd3fa4b82a31d23fe1ca4681d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc0MzA_01b8b472-d365-4872-bf24-61d0f4d616f4"
      unitRef="usd">616000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iddfb43cef36f48d58869fc13628164ec_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc0Mzc_32ba2a60-992b-404b-9dd9-25da6d5ef03e"
      unitRef="usd">921000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7c1c0bfc1a8642e5b23938f795103bcb_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjUzMjY_75e6bbb7-c250-4a03-b5d4-39fd979dc059"
      unitRef="usd">290000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i09db21ffd978403fb95c9f969486cebe_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzc3NjA_f06d22aa-9a71-4dcd-a27d-b74d04d54782"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i09db21ffd978403fb95c9f969486cebe_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MjY_0f0e93e0-ed1f-4a2f-a1e7-7eac87d5afca"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i998ab898facc4cc6929d5d5803057739_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4MzU_1d025269-08c1-448f-9e4b-761b34ea4625"
      unitRef="shares">6758400</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <pgen:DebtInstrumentResaleRestrictionPeriod
      contextRef="i998ab898facc4cc6929d5d5803057739_D20201001-20201031"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzQzOTgwNDY1MjM4NTM_d47998af-987c-45e8-bfc7-3ab0579e7f7e">P180D</pgen:DebtInstrumentResaleRestrictionPeriod>
    <us-gaap:LongTermDebt
      contextRef="id1f9a8543e394b0089b989601e44377b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkyMjE_8cb7bcc2-9668-49d8-a430-d65437a291ad"
      unitRef="usd">3655000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="i33041383733943a0bdbb0c01bba1ae14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkyNzM_3d85d756-9f8a-4053-94dd-817fb9df2741"
      unitRef="usd">39000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id1f9a8543e394b0089b989601e44377b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0XzkzMDQ_075cca64-3f9f-4b83-ba10-fe15151c41b4"
      unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90ZXh0cmVnaW9uOmJjMjQ0MzFmNmNmMjRlNThhODVlOWNmMTgyNzVmNzU0Xzk0OTY_89cd6991-2271-4011-b258-b978b17e4058">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of long-term debt as of December&#160;31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzAtMS0xLTEtMA_8faaea40-d676-41b6-b659-33ea1b0f7dfc"
      unitRef="usd">360000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzEtMS0xLTEtMA_86b78876-1dfb-432b-9267-7955bd92d067"
      unitRef="usd">397000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzItMS0xLTEtMA_f3d35aad-fd53-4a4d-a8c4-1eeba4793755"
      unitRef="usd">200360000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzMtMS0xLTEtMA_9b45eb64-36b5-4c89-92c4-933d88d4535c"
      unitRef="usd">374000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzQtMS0xLTEtMA_28e3f082-0c1f-4f14-a52a-fb715fb22cdf"
      unitRef="usd">389000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzUtMS0xLTEtMA_71c18a67-7dc2-4ef4-8b9c-8247cf7be5e9"
      unitRef="usd">1855000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjMvZnJhZzpiYzI0NDMxZjZjZjI0ZTU4YTg1ZTljZjE4Mjc1Zjc1NC90YWJsZToxNzg2NTRlYzViN2I0ZGZmYjBmMzNhOTdlNjhjYWMyNy90YWJsZXJhbmdlOjE3ODY1NGVjNWI3YjRkZmZiMGYzM2E5N2U2OGNhYzI3XzYtMS0xLTEtMA_4ff40e50-a95d-4ccf-938b-e40ef0f11898"
      unitRef="usd">203735000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU3OTQ_0a050296-7489-450b-9892-f5ac1b5514d0">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss from continuing operations before income taxes are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax benefit from continuing operations are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit from continuing operations for the years ended December&#160;31, 2020, 2019 and 2018 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computed statutory income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and provincial income tax benefit, net of federal income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and internal restructuring transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reacquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States-foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December&#160;31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities and investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating, capital loss, and interest expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December&#160;31, 2020, 2019 and 2018 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in valuation allowance as a result of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mergers and acquisitions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of AquaBounty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of deferred taxes for subsidiaries included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations treated as asset sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations related to MBP Titan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption of ASC 606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity component of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section&#160;382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December&#160;31, 2020, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December&#160;31, 2020, approximately $42,100 of the Company's domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $756,200 available to offset future taxable income, including approximately $503,500 generated after 2017, United States capital loss carryforwards of approximately $211,500, and federal and state research and development tax credits of approximately $10,200, prior to consideration of annual limitations that may be imposed under Section&#160;382. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. The Company's foreign subsidiaries included in continuing operations have foreign loss carryforwards of approximately $82,300, most of which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $21,200. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries do not have material unrecognized tax benefits as of December&#160;31, 2020. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MjM_0193e5c4-1379-46e1-bd7f-34fd3b2d400a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss from continuing operations before income taxes are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(167,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iebbd89e79742463bb7bb2c8072e4d28d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItMS0xLTEtMA_5a459034-4c9b-4b35-bdee-d90ba4447475"
      unitRef="usd">-97313000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i27fa0174f15049ad925a5c7467f8806f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItMy0xLTEtMA_c96f0de9-3822-4da5-9f27-b2e3dae7e316"
      unitRef="usd">-167990000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7249ffe7fdf04fc58a2bebc05c00ac77_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzItNS0xLTEtMA_a50548ff-9409-43c5-aaab-abd9026f5a17"
      unitRef="usd">-394580000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i86b9331a29684594bdc6ff0bcff164e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtMS0xLTEtMA_362d9279-1275-470c-80ec-bd51d8742d7e"
      unitRef="usd">-6542000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib75f9587ce8b496db2609e0682fcb9b5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtMy0xLTEtMA_e1455b5c-67c9-4dd9-9c88-2dd4eb043c83"
      unitRef="usd">-3274000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifd35f7da52004f518b3b73faaa279403_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzMtNS0xLTEtMA_50e4ea91-2c6b-4f7b-8691-c23324c6caf2"
      unitRef="usd">-1332000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtMS0xLTEtMA_71376b21-ab61-4f4d-befb-f181eaf9450a"
      unitRef="usd">-103855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtMy0xLTEtMA_3961ec10-4b4d-4f8b-be63-e220d1cb3ca7"
      unitRef="usd">-171264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTowMzIyNWRjMDBiOGI0NTdlYjY0Y2EyMGViMDAwNTY4OS90YWJsZXJhbmdlOjAzMjI1ZGMwMGI4YjQ1N2ViNjRjYTIwZWIwMDA1Njg5XzQtNS0xLTEtMA_6969727e-89ef-4521-9efd-a1eed58fdb73"
      unitRef="usd">-395912000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU3OTg_945143f9-6f3a-4331-bf03-1b73f65249c4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax benefit from continuing operations are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtMS0xLTEtMA_a913fe56-f690-473c-88e7-e3f3803b2a6e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtMy0xLTEtMA_9935fc62-80be-4c96-b135-ad9c12132043"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzMtNS0xLTEtMA_41f82a44-3a55-488a-a49f-3a10b893c4c9"
      unitRef="usd">-31000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtMS0xLTEtMA_b2c3e85f-91b5-4d08-ae55-80f6a6acf333"
      unitRef="usd">37000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtMy0xLTEtMA_b2a7f9e6-8b86-4429-93c4-f0344492a3d4"
      unitRef="usd">-561000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzQtNS0xLTEtMA_f8efd96f-c4af-4680-8615-3bd345c76ce7"
      unitRef="usd">-11855000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtMS0xLTEtMA_fa4fb136-1032-4307-9f15-214c3d81fc9a"
      unitRef="usd">74000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtMy0xLTEtMA_175002a8-55a9-40f4-a4bf-a2a462709b7e"
      unitRef="usd">34000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzYtNS0xLTEtMA_5c1dc206-fe0f-40a2-b002-3ef61777d0e9"
      unitRef="usd">68000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctMS0xLTEtMA_578621d8-eae1-4d01-bc48-b76fbdd36d32"
      unitRef="usd">-204000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctMy0xLTEtMA_4b34ad3e-8ca1-4450-bf14-5bf3588c75ee"
      unitRef="usd">-230000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzctNS0xLTEtMA_e3b2d59a-1f76-4ded-afcb-52823f9018d2"
      unitRef="usd">635000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktMS0xLTEtMA_fba5009a-5812-464e-839a-8f932d637c77"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktMy0xLTEtMA_632b2fca-c3a7-4003-94f9-ada636a55282"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzktNS0xLTEtMA_f066df36-b605-4083-9084-6e3a44790c26"
      unitRef="usd">113000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTEtMS0xLTA_6f5b7cee-4c44-4c0a-93dd-0ddabb378836"
      unitRef="usd">11000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTMtMS0xLTA_3fd216a0-49e9-4183-9b1f-c18f2f71fc94"
      unitRef="usd">-173000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzEwLTUtMS0xLTA_8bcbe859-5e88-4509-a54a-9f4166549d9b"
      unitRef="usd">-4355000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTEtMS0xLTA_242e0590-a5e1-4c1d-8861-11220bba0563"
      unitRef="usd">-82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTMtMS0xLTA_597e105b-f76a-44a6-947a-6079935fe39c"
      unitRef="usd">-930000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTplNmY0ZmZhMzYwMzc0MDlkOWE0N2I0NDc2MTg2OWJmYi90YWJsZXJhbmdlOmU2ZjRmZmEzNjAzNzQwOWQ5YTQ3YjQ0NzYxODY5YmZiXzExLTUtMS0xLTA_6c9e5d2d-2a4b-4001-a50b-eee0ecc94923"
      unitRef="usd">-15425000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MTc_b1f661bc-bcc5-4a12-9cb6-9a6ed6f9781d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit from continuing operations for the years ended December&#160;31, 2020, 2019 and 2018 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computed statutory income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and provincial income tax benefit, net of federal income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition and internal restructuring transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reacquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States-foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtMS0xLTEtMA_0caf630f-b2d8-461f-80b1-feb100d1ca11"
      unitRef="usd">-21810000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtMy0xLTEtMA_bb310613-e5e5-4ae8-a5d2-e86e5c6f361f"
      unitRef="usd">-35965000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEtNS0xLTEtMA_29d62a35-45d0-4c78-8c0c-f97b59464d81"
      unitRef="usd">-83141000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItMS0xLTEtMA_424d0f10-f43c-46a3-a971-be5394ed0411"
      unitRef="usd">-5167000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItMy0xLTEtMA_0864fbf4-88ac-421d-85e8-f74ab536e1b6"
      unitRef="usd">-5494000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzItNS0xLTEtMA_07b524ba-eebf-488e-8118-474eaa0d2342"
      unitRef="usd">-21717000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtMS0xLTEtMA_545594a6-68d7-47f4-a3c9-012fe50d61ff"
      unitRef="usd">5709000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtMy0xLTEtMA_3ad4ac48-086e-4389-adb6-fc6b456aa391"
      unitRef="usd">10303000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzMtNS0xLTEtMA_1d730c51-7fd1-4ace-830d-c905a0c91917"
      unitRef="usd">4696000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtMS0xLTEtMA_b903692b-32ff-4655-a7c6-4d82b3f00b45"
      unitRef="usd">728000</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtMy0xLTEtMA_84300b45-e1e1-4bd9-b556-fb43cc6a89db"
      unitRef="usd">595000</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzQtNS0xLTEtMA_63388795-7e30-4011-8b6f-530a5999f610"
      unitRef="usd">294000</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtMS0xLTEtMA_23491dfe-0ac6-4816-b664-7b76e308d840"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtMy0xLTEtMA_489d497d-4cd0-40d3-8238-c9b9ef3d6303"
      unitRef="usd">273000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzYtNS0xLTEtMA_ea924e65-8424-43e9-aa6e-16eacadf5c35"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctMS0xLTEtMA_8449d7ee-165e-4109-9696-05c2cec4a6c6"
      unitRef="usd">524000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctMy0xLTEtMA_e1f2bce4-6da7-4bf5-a8e2-e2dad24409b6"
      unitRef="usd">1772000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzctNS0xLTEtMA_ea7a2962-e863-4c37-87fc-780bba598bce"
      unitRef="usd">185000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtMS0xLTEtMA_32af91aa-5936-4b8c-8b6d-ff724bc0cfee"
      unitRef="usd">0</pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts>
    <pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtMy0xLTEtMA_143887bb-e60c-4890-98f6-49d924468bb2"
      unitRef="usd">260000</pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts>
    <pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzgtNS0xLTEtMA_1024f096-f617-4777-9133-259d9031dc57"
      unitRef="usd">52000</pgen:EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTEtMS0xLTA_2dc851e3-f343-4594-aaba-1701962f2429"
      unitRef="usd">0</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTMtMS0xLTA_9b6b203c-b4f3-4eb8-a637-8976e66be6d7"
      unitRef="usd">0</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount>
    <pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzExLTUtMS0xLTA_38fdd769-b96b-4f57-ba7c-95c355c32640"
      unitRef="usd">2696000</pgen:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount>
    <pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTEtMS0xLTA_e4722f34-c3eb-4752-8f21-d1e7b5ccf1db"
      unitRef="usd">0</pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount>
    <pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTMtMS0xLTA_8898af44-31bf-48be-ad86-7d7f37c40208"
      unitRef="usd">0</pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount>
    <pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEyLTUtMS0xLTA_4cce247f-98fd-4825-b8d5-2de82c238479"
      unitRef="usd">8666000</pgen:EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTEtMS0xLTA_fab8f4da-413d-46d1-8792-a06c867ca41b"
      unitRef="usd">-21000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTMtMS0xLTA_69d49fc8-08b8-409a-9357-93616cee3bcc"
      unitRef="usd">-76000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzEzLTUtMS0xLTA_98b6e65e-e7d9-44cb-85ce-8323fb52738a"
      unitRef="usd">215000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTEtMS0xLTA_66491972-f38d-4d7e-af2a-9aef9dfe8ddc"
      unitRef="usd">-306000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTMtMS0xLTA_eac65a08-d5fb-4b7a-96dd-ef145a14c76e"
      unitRef="usd">-72000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE0LTUtMS0xLTA_af4bad47-7511-4907-842f-58b8dd9d2f4e"
      unitRef="usd">-3517000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTEtMS0xLTA_98f70e76-9d9a-432a-bf2e-6dd289cb508c"
      unitRef="usd">-21391000</pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance>
    <pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTMtMS0xLTA_df8b88b3-e188-4a47-bc2e-34d2ec0f857c"
      unitRef="usd">-31948000</pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance>
    <pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE1LTUtMS0xLTA_7b0236a9-2f49-4103-a5a9-b7c6e9880f50"
      unitRef="usd">-91941000</pgen:IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTEtMS0xLTA_1f90910e-d8a3-4f62-a409-ca3788c3d106"
      unitRef="usd">21309000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTMtMS0xLTA_07d3230d-d3d5-4f94-83f6-266e9a3ba894"
      unitRef="usd">31018000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE2LTUtMS0xLTA_b9195b7c-6454-460b-88a4-1ee2d65cfd9e"
      unitRef="usd">76516000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTEtMS0xLTA_3921ea67-1cd6-4564-8a3c-d8d1df05cff6"
      unitRef="usd">-82000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTMtMS0xLTA_c5d51f6f-bdf0-44dd-a935-2b30c88a68bc"
      unitRef="usd">-930000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTpjY2M4YTVlZTVhMjA0YjBmYmVkZWRhMWMwYWU5NzNhNC90YWJsZXJhbmdlOmNjYzhhNWVlNWEyMDRiMGZiZWRlZGExYzBhZTk3M2E0XzE3LTUtMS0xLTA_8c876023-ec6c-491b-b494-9cf18e87a9cf"
      unitRef="usd">-15425000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MTU_f2f86172-5312-48c7-ac56-aea9ec53c8f4">&lt;div style="margin-bottom:11pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December&#160;31, 2020 and 2019, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities and investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating, capital loss, and interest expense carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzItMS0xLTEtMA_5b3d4253-6641-4760-877f-3084f61ba996"
      unitRef="usd">1816000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzItMy0xLTEtMA_a3f16896-6d76-44b2-a7b2-eeaee147ca96"
      unitRef="usd">2140000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzMtMS0xLTEtMA_25b58700-83ad-407e-9c53-4a1c58c4fa6c"
      unitRef="usd">289000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzMtMy0xLTEtMA_d3edfe43-544d-4899-b65d-7c76d26f3cbb"
      unitRef="usd">415000</us-gaap:DeferredTaxAssetsInventory>
    <pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzQtMS0xLTEtMA_ca4d6f75-431a-4ab6-a464-90213ebc1927"
      unitRef="usd">570000</pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption>
    <pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzQtMy0xLTEtMA_013e2e9c-854a-4b11-83f8-edc45f3b36b8"
      unitRef="usd">11933000</pgen:DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzUtMS0xLTEtMA_eddf1b06-4e5c-4fe5-8fc8-940f36905cb0"
      unitRef="usd">1882000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzUtMy0xLTEtMA_1a4d21c6-17be-4667-be07-be64b19d8f13"
      unitRef="usd">1830000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzYtMS0xLTEtMA_fef933bd-d72b-462c-9b94-20974186d333"
      unitRef="usd">74981000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzYtMy0xLTEtMA_15222a33-fd76-4124-9635-ebae648863e6"
      unitRef="usd">85308000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzctMS0xLTEtMA_dd243756-2953-448d-981b-30db0ba50ed4"
      unitRef="usd">1834000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzctMy0xLTEtMA_4c2c3584-595c-4d06-aa88-0e53f5f0e8d0"
      unitRef="usd">3385000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <pgen:DeferredTaxAssetsLeaseLiabilities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzgtMS0xLTEtMA_6e83e7c5-7a98-498a-9cdb-a473a94fe5ef"
      unitRef="usd">6140000</pgen:DeferredTaxAssetsLeaseLiabilities>
    <pgen:DeferredTaxAssetsLeaseLiabilities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzgtMy0xLTEtMA_41ce0cc8-00a4-4b69-bf2d-2c7e8605cd93"
      unitRef="usd">10035000</pgen:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzktMS0xLTEtMA_284e70f3-1c92-410f-97cc-d7948ff1017d"
      unitRef="usd">16402000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzktMy0xLTEtMA_1834385d-09bc-4905-b1a9-2b8c3ded4e37"
      unitRef="usd">19389000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEwLTEtMS0xLTA_eff5ad04-e291-4a9d-9ff8-a0c33df10cda"
      unitRef="usd">7423000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEwLTMtMS0xLTA_dce2f97b-20c0-45e2-9ca7-a2ac7fe091b8"
      unitRef="usd">14876000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzExLTEtMS0xLTA_a6720e63-ba66-4173-a331-72151f1dfd34"
      unitRef="usd">10210000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzExLTMtMS0xLTA_ad2343c4-c37a-4a9b-92d5-69a9ca181102"
      unitRef="usd">9686000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEyLTEtMS0xLTA_6b91054f-c70f-4699-aa69-ccfd270b945e"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries>
    <us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEyLTMtMS0xLTA_d7f3e0cd-6fae-451e-9651-ae368eeb1fc5"
      unitRef="usd">8592000</us-gaap:DeferredTaxAssetsInvestmentInSubsidiaries>
    <pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEzLTEtMS0xLTA_229ee362-8af9-41a5-bffd-3cd9bfe8dde7"
      unitRef="usd">275519000</pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards>
    <pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzEzLTMtMS0xLTA_1963c657-f72f-40b2-9a75-ea496a5f8696"
      unitRef="usd">196663000</pgen:DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE0LTEtMS0xLTA_57001b41-e313-41ed-86c1-7a443987b165"
      unitRef="usd">397066000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE0LTMtMS0xLTA_e5b18e3f-02e3-464b-8a48-b7f557fa6ebb"
      unitRef="usd">364252000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE1LTEtMS0xLTA_20ed4a2d-d961-47c4-81b7-60e8197e20c6"
      unitRef="usd">387348000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE1LTMtMS0xLTA_4f5f52b6-5a1b-4b96-97c5-f8d892d7ccea"
      unitRef="usd">349008000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE2LTEtMS0xLTA_0e531a61-416d-4df0-8a60-aec69d47ce62"
      unitRef="usd">9718000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE2LTMtMS0xLTA_3effbaa1-11f1-455d-beac-bf87bd7fb304"
      unitRef="usd">15244000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE5LTEtMS0xLTA_46d89263-0887-4154-bf45-60c338dda704"
      unitRef="usd">5011000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzE5LTMtMS0xLTA_87c4f449-3a06-44e7-b7fc-e11b71375e47"
      unitRef="usd">8091000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIxLTEtMS0xLTA_2d412ae0-8830-4455-887b-7ec78cab9198"
      unitRef="usd">7604000</pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt>
    <pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIxLTMtMS0xLTA_52a4870e-7011-4e1f-9b8c-5d5732880bd6"
      unitRef="usd">9987000</pgen:DeferredTaxLiabilitiesEquityComponentofLongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIyLTEtMS0xLTA_ba783f5b-d8b4-48ee-89ca-7c80144cb6a1"
      unitRef="usd">12615000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIyLTMtMS0xLTA_faf6e88a-c0b7-45c6-910a-62a11ec39ac1"
      unitRef="usd">18078000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIzLTEtMS0xLTA_52080663-a049-4133-ab74-2dcd81fa4ba1"
      unitRef="usd">2897000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo0MGJkZDBhYzkzYzI0YzIzYTAxNzg3YmFjMGMwMDhjNi90YWJsZXJhbmdlOjQwYmRkMGFjOTNjMjRjMjNhMDE3ODdiYWMwYzAwOGM2XzIzLTMtMS0xLTA_bd7d8d6b-20fe-4634-aeb9-200a64b335d1"
      unitRef="usd">2834000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzU4MDQ_2f2417eb-4bce-4f73-907e-da6f3e8d87d1">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December&#160;31, 2020, 2019 and 2018 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in valuation allowance as a result of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mergers and acquisitions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of AquaBounty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Establishment of deferred taxes for subsidiaries included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations treated as asset sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations related to MBP Titan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adoption of ASC 606&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity component of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in deferred state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtMS0xLTEtMA_993d59d5-3d45-4b2f-98b4-0d3cc84c0d58"
      unitRef="usd">349008000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtMy0xLTEtMA_16166d60-5400-444c-8706-169d7e57981d"
      unitRef="usd">292217000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4e07b0b288a443e6a8678c87bf210341_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEtNS0xLTEtMA_3f9d48c6-7827-4b00-931a-429b95d48881"
      unitRef="usd">211078000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtMS0xLTEtMA_6dd1ffaf-5f85-4c84-9f79-54d785634414"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtMy0xLTEtMA_763bcced-2997-44b5-b38e-6d8223de0c57"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzMtNS0xLTEtMA_7666c15b-68d3-4fac-bf10-4c99a6d383af"
      unitRef="usd">418000</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet>
    <pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtMS0xLTEtMA_558790ff-cf60-4190-8ee9-751c0a2cd22c"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation>
    <pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtMy0xLTEtMA_d55090c5-7894-430c-9981-c9e972805c4e"
      unitRef="usd">-3504000</pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation>
    <pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzQtNS0xLTEtMA_c18d63fa-7c2b-4513-8e58-cff869405f77"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetDeconsolidation>
    <pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtMS0xLTEtMA_142c15de-262a-4e10-a916-ded4c47d909c"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtMy0xLTEtMA_1c0b8d28-6c91-467d-b3c4-effb76ae64da"
      unitRef="usd">8592000</pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzUtNS0xLTEtMA_b2885b19-a5b0-404e-931f-6cbefad08afa"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtMS0xLTEtMA_63229744-43a1-4980-aa84-944f3638925a"
      unitRef="usd">21309000</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtMy0xLTEtMA_a62dafc9-57c9-461b-8e1c-6bfa6dae02ab"
      unitRef="usd">31018000</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzYtNS0xLTEtMA_7ccdfdca-a429-45f8-af82-cef264b4ee7f"
      unitRef="usd">98549000</pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctMS0xLTEtMA_8c97a03d-3818-4c7d-a2f5-48a5df669a75"
      unitRef="usd">7977000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctMy0xLTEtMA_01af1545-6be7-4ef0-b721-d47b0a0de263"
      unitRef="usd">10585000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzctNS0xLTEtMA_a8e53641-b0ed-4cec-a319-184354e03d57"
      unitRef="usd">3832000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMS0xLTEtMTIxNDE_711ffbca-34c5-41d7-a2a3-9583e4b90e12"
      unitRef="usd">8019000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMy0xLTEtMTIxNDE_c8e12696-b186-4734-8ae8-38fcd2e6e6b8"
      unitRef="usd">9663000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtNS0xLTEtMTIxNDE_b4382c15-6b8d-4393-9afb-87bbe263519d"
      unitRef="usd">8735000</pgen:ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="id2e86fa379664890bce6f8505ae63863_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMS0xLTEtMA_863f97ca-7f02-45d4-b64f-a9982c6fc102"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="if94e6997c4484c4fb71d5424d9a823e7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtMy0xLTEtMA_1604bd68-3bbe-4196-a36c-6b2db0d56983"
      unitRef="usd">512000</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="i2f6024ac23c341aab2161aee0517820f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzgtNS0xLTEtMA_571e430d-decb-40cf-8732-73b762320cc1"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="i2140f32269b445a7a78f85b8ded04f8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktMS0xLTEtMA_63d0f720-71d4-4d8a-bcc5-0c2b0689c003"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="i06c2f36dc30c4039a45bf45425bd3b3c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktMy0xLTEtMA_1c0ed883-d5f0-45b5-be45-bdfc88ef2317"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple
      contextRef="i846cd2227b1f4f05943d3faf0edb56d7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzktNS0xLTEtMA_d148899a-a2c9-4f5d-a833-558131b826d7"
      unitRef="usd">-7477000</pgen:ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTEtMS0xLTA_be852aff-3ae5-4828-ae77-9398fc924241"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTMtMS0xLTA_62caf22c-0850-477e-994a-4d37ad7511a8"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEyLTUtMS0xLTA_6f75166c-467a-4e5b-b72d-427b5c41695a"
      unitRef="usd">-13367000</pgen:ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTEtMS0xLTA_6ca4d4f0-7849-46a3-a0b4-ebb1e948e60b"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTMtMS0xLTA_9572db7a-fa92-483a-a5a6-383902961ea6"
      unitRef="usd">0</pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzEzLTUtMS0xLTA_7745f52d-cbe8-4e99-afc4-47b2f0ed0142"
      unitRef="usd">-8666000</pgen:ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTEtMS0xLTA_a577fa8a-adb1-482e-9008-5c93c82eba81"
      unitRef="usd">1035000</pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTMtMS0xLTA_6d7442e2-7809-4138-a92b-8976d08de732"
      unitRef="usd">-75000</pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment>
    <pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE1LTUtMS0xLTA_4e208476-70ea-4fe8-9053-2bc7d234c6c7"
      unitRef="usd">-885000</pgen:ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTEtMS0xLTA_e7d82f3f-1f6b-41fc-a1c8-9a4b849a3c23"
      unitRef="usd">387348000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTMtMS0xLTA_b60fbbe4-be2f-4d6e-9fdc-a911bf948c3e"
      unitRef="usd">349008000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i190b69f516da44baba7e77735b9083e9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90YWJsZTo2ZjM0MDljZDY4ZjU0OTU1ODY2ZDYyZDk1OWFmZTJlNC90YWJsZXJhbmdlOjZmMzQwOWNkNjhmNTQ5NTU4NjZkNjJkOTU5YWZlMmU0XzE2LTUtMS0xLTA_f06968b6-47f5-4005-8b3b-c6fc58ee492d"
      unitRef="usd">292217000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <pgen:OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness
      contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzIzNjQ_106ea097-cee7-4a61-a015-51c3946fd506"
      unitRef="usd">42100000</pgen:OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI3MDI_508ea15c-2a5c-49e3-9bcc-82b7f72c1253"
      unitRef="usd">756200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0dc0ff9076414c038f13048e82021a34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI3NzI_3cc908b0-3d33-4b42-94b0-e4ca4841d28a"
      unitRef="usd">503500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI4NTU_c1068d61-3361-4c3d-b200-c76866e9f755"
      unitRef="usd">211500000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ia3bd6ffd74b747f4a6e079c55fe037f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzI5MzU_6cc46dab-f812-4eb8-b90b-f280e4533f90"
      unitRef="usd">10200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0274c8f694d3486099220e08fbba1fc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzMyOTI_3c9fa2cc-1bd4-4859-90b9-fc0ba81f780e"
      unitRef="usd">82300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="icc450189ce644024ba68868dd2551779_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNjYvZnJhZzoyZTE4OGUwZmJiZGY0ZjJhOTM0NmQ1MzEwN2RlZjI4OC90ZXh0cmVnaW9uOjJlMTg4ZTBmYmJkZjRmMmE5MzQ2ZDUzMTA3ZGVmMjg4XzM0NTM_52cced54-c778-48a1-98da-d0411e55cb74"
      unitRef="usd">21200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQ0MzI_a407d3ed-4d63-42ca-9310-9df1f4d70b5b">Shareholders' Equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuances of Precigen Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, Precigen closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374, after deducting underwriting discounts of $3,688 and offering expenses of $188, all of which were capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 12, 17, and 23 for discussion regarding additional issuances of Precigen common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Lending Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the offering of the Convertible Notes (Note 12), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzY1OTcwNjk3NzUxMzU_d9e7d0e6-80ed-4f13-b999-56a720a01b9a"&gt;five&lt;/span&gt; business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuances of AquaBounty Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Precigen purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316, including $3,077 from Precigen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Components of Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) on foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQzOTgwNDY1MTU4NTI_f7529ae2-9f1a-4980-a488-8476481d1753"
      unitRef="shares">5972696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic71559913e3449d9b0624deef119e5d2_D20200131-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQzOTgwNDY1MTU4NjM_4e4c957e-3404-4274-9195-c7dd4d952e04"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzExOQ_e8d63711-5d85-4df9-8015-53a3e7d03d74"
      unitRef="shares">6900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9ae95dbfa1fb42c993e1fed2a97942b1_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzE2MA_987dd5e0-f411-4963-8c8b-a5550a0d41d1"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI2Nw_56967a15-a120-4ac9-961e-6aa99cd39c4c"
      unitRef="usd">82374000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMxMw_069cf137-99bc-4688-aa96-d2e5a0d8f09b"
      unitRef="usd">3688000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9db2284265074c3289f29fb1232d187f_D20180101-20180131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzM0MQ_4a587558-d7ff-4545-8848-fb38811be21a"
      unitRef="usd">188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OwnshareLendingArrangementSharesIssued
      contextRef="i938616e63e9046f9b8b561f8f75cd7c5_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzg1Ng_639f2c7f-6d56-43f6-a397-4391bc08df05"
      unitRef="shares">7479431</us-gaap:OwnshareLendingArrangementSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i938616e63e9046f9b8b561f8f75cd7c5_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzE2OTQ_309caafe-5069-4b68-bf94-0a5ee8358df2"
      unitRef="usdPerShare">13.37</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic3792a1ad213496a8d41cfdce5e38535_D20190301-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI2ODI_8e60d74a-66cb-428b-a3f1-8a35a0867fa3"
      unitRef="usd">6611000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i184114ce7b3f42b58ddf4c429939454e_D20180101-20180131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzI5ODE_8306f168-3477-4611-beee-c8c4298c29a6"
      unitRef="usd">10616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="ie79bf4a7c0c64ef68087d0bb20da73a2_D20180101-20180131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMwNzU_1cf05bd5-4301-4ea4-b1e4-f02c699c10fa"
      unitRef="usd">5000000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised
      contextRef="icf7bc616c8ee45679cdc730430d0f09a_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMyNTI_1064190b-763e-4028-a225-32656872e348"
      unitRef="usd">4316000</pgen:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised>
    <us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
      contextRef="icf169456400e4ce8aeed85e7ca335ce6_D20181001-20181031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzMyNjY_a32491b3-bbc3-45e7-8dde-cd671acdf99d"
      unitRef="usd">3077000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzQ0MjA_671d76fd-1a14-4409-86d6-5caa91348da8">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) on foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d40ed18f6934798ba07115922d698e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzItMS0xLTEtMA_2bff1576-c62c-4061-b275-0fe0a63d4427"
      unitRef="usd">13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb78e848d959475a8e60240fef86d616_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzItMy0xLTEtMA_2f25f975-2a67-4827-9669-43d188586bf4"
      unitRef="usd">7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i258e6ee1096c48f3bafa2a89b56d3570_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzMtMS0xLTEtMA_461f5ef0-7eb4-4c65-afb4-f6001aace1c5"
      unitRef="usd">3984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7408085271934977bcbe87b303ee566b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzMtMy0xLTEtMA_56c20b6b-13ab-4967-b35f-d8e93dc826e2"
      unitRef="usd">-27475000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5035cb92632a453d81e2f99ab37a6a4d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzQtMS0xLTEtMA_0c050b4e-d75d-4af9-973f-8eb39ee4b13a"
      unitRef="usd">3997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64c7b560b46b448dab6e990b87500645_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90YWJsZTpkODc1ZjFiM2NiMDY0YjY5YTAwYWRhNTkxYWQwOWVlZC90YWJsZXJhbmdlOmQ4NzVmMWIzY2IwNjRiNjlhMDBhZGE1OTFhZDA5ZWVkXzQtMy0xLTEtMA_087a0064-8cf7-4bf8-93bb-9a3fd6b7ad66"
      unitRef="usd">-27468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMjA_e1929a82-e39f-4941-91f9-5f0097700d6d">Share-Based Payments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Precigen Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December&#160;31, 2020, there were 185,078 stock options outstanding under the 2008 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December&#160;31, 2020, there were 27,000,000 shares authorized for issuance under the 2013 Plan, of which 10,225,570 stock options and 1,176,629 RSUs were outstanding and 7,055,010 shares were available for grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December&#160;31, 2020, there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 845,248 stock options and 551,083 RSUs were outstanding and 2,432,624 shares were available for grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,382,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(929,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,093,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,236,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,371,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,693,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(976,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,453,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,437,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation costs related to unvested awards as of December&#160;31, 2020 were $13,842, and are expected to be recognized over a weighted-average period of approximately 2.75 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of options granted during 2020, 2019 and 2018 was $2.98, $3.79 and $7.94, respectively. The aggregate intrinsic value of options exercised during 2020, 2019 and 2018 was $51, $66 and $356, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information about stock options outstanding as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,259,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,437,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information about stock options outstanding as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,585,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,264,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,159,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,157,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,802,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation costs related to unvested RSU awards as of December&#160;31, 2020 were $4,188 and are expected to be recognized over a weighted-average period of approximately 0.75 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Precigen currently uses authorized and unissued shares to satisfy share award exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Executive Chairman ("Executive Chairman"), who previously served as the Company's Chief Executive Officer ("CEO") until January 1, 2020, and as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month through March 2019 and based on the volume weighted average of the price of Precigen common stock over the 30 day period ending on the last calendar day of each month thereafter, and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Precigen and the Executive Chairman pursuant to the terms of the 2013 Plan. The RSU Agreement expired March 31, 2020. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $454, $1,868, and $1,956 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman. The new arrangement consists of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully &lt;/span&gt;&lt;/div&gt;vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250. The compensation arrangement begins in calendar year 2021, and the foregoing elements were prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. The terms of the equity awards granted to the Executive Chairman are pursuant to the 2019 Plan.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTY_853a3d63-35ae-4746-8e06-d2a04561c5b7">Stock-based compensation costs included in the consolidated statements of operations are presented below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i507bf64ce91c4dbe855ace68943a9ff1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItMS0xLTEtMA_044d83c5-3796-4ecc-a8d7-767727b8fb85"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0809b9c1122b4425b82973aa53316a00_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItMy0xLTEtMA_4e592c2e-ab5f-4098-b650-290ceeb9057f"
      unitRef="usd">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if630c00264644a5f934f6c52739e171f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzItNS0xLTEtMA_958ba80d-f776-4315-a303-5570b43912a9"
      unitRef="usd">78000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2b4d072e6db4429be9358d98ef2695d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtMS0xLTEtMA_897f3b82-adb8-4c0b-a233-425457956a34"
      unitRef="usd">134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8e6fd3bf62174baf8ea4e643cd5ee2a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtMy0xLTEtMA_8a348c6a-20c4-462a-a4af-5e2b256c5a72"
      unitRef="usd">220000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bc9ff4a3e6143fe87ea8e2e89c9f0d2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzMtNS0xLTEtMA_e3c17f2f-a1d3-4d4a-b70a-eaa4d2ed709c"
      unitRef="usd">237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b1be10c992143819d5ff797b4bdd3b5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtMS0xLTEtMA_2ec5c74e-f101-4f65-9875-5fa896b5f9c6"
      unitRef="usd">1815000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb66d1f63fcb401b899173c39dea5ef6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtMy0xLTEtMA_49c9c123-9b6e-4711-9a7c-10a6e86ba0e1"
      unitRef="usd">3478000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie12981139b134339950cececc0d8cefd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzQtNS0xLTEtMA_f43bb2df-48e4-4349-8174-1338f1db3c76"
      unitRef="usd">5017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i793cc475e5a349a38e9012cbdf287644_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtMS0xLTEtMA_5781753e-5f52-4296-a6be-83b08be97c50"
      unitRef="usd">17787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7db0821a8b444dd48ee9d160de991bf8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtMy0xLTEtMA_6ec97d86-490f-43f0-a004-9822edd60a59"
      unitRef="usd">11380000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b44220e572445a7aaaedaab0fba9599_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzUtNS0xLTEtMA_1b5125bb-29cb-45be-a487-f638ea865f36"
      unitRef="usd">25222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib33202a64c764d2294be298ec498bf0e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtMS0xLTEtMA_5b2af002-1b56-4d68-9867-e79fb3ae03ad"
      unitRef="usd">-1380000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3dd4e1dad5ab4578a892678be6523d79_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtMy0xLTEtMA_f3df47e8-bb18-415d-a7b0-38319a11a316"
      unitRef="usd">3852000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id04130b19133407c8ffb14a7cdb84896_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzYtNS0xLTEtMA_3d016b3e-3b86-477f-84e9-d2497948e180"
      unitRef="usd">5742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctMS0xLTEtMA_b366b899-4893-4dc2-a366-b1d702242dba"
      unitRef="usd">18366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctMy0xLTEtMA_ed784d5b-d9d0-4ec7-9e14-b6af7bcbd79e"
      unitRef="usd">18950000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTphYzM4MTkzNjE4MGQ0YTJhYjg3NGFiOTA1Zjk0NmY1Yi90YWJsZXJhbmdlOmFjMzgxOTM2MTgwZDRhMmFiODc0YWI5MDVmOTQ2ZjViXzctNS0xLTEtMA_67d93494-7f48-44ca-a0a8-fa8debcd82c6"
      unitRef="usd">36296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzgyNg_413902ea-9e8b-46ed-a869-caa41a0a521d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6231e1a761dd4e3cad5a9888fdcef4bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1Xzg5Nw_79469737-ca9a-42e4-99d5-83f05c8bcac3"
      unitRef="shares">185078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxODI_f87719f3-4fb2-41ff-8501-b214ba0847b2"
      unitRef="shares">27000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzEzNTA_cd2d3f63-2b0f-4c94-8983-6dcd7f019388"
      unitRef="shares">10225570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzEzNzE_40fdac22-ce34-4c9d-b9f8-9424cf1c6f69"
      unitRef="shares">1176629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1db41e22786f4f8e803bd5da7ae7655b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE0MDA_d967f5d9-beb5-4cc7-a567-60257e6680f2"
      unitRef="shares">7055010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE4MDU_2f320281-7872-43ef-a171-29b5daabde37"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxNDE_ca2a8f29-cdd0-4220-a3ec-1f4bb86c87a9"
      unitRef="shares">845248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTYxNjU_0c2fa17a-29fd-468a-9350-fc5856144558"
      unitRef="shares">551083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0dfda69a28ff4552bd02d489a6714039_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzE5MDA_b2229464-c5fe-4beb-a504-63a9119ea1f4"
      unitRef="shares">2432624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzY1OTcwNjk3NzU0MDk_08a9cb76-cabd-4924-a4b6-55bbfdb07620">ten-year</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzIzMTI_4cc47823-fc59-4c2e-9a60-e59fdaca78a8">ten</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzIzMzU_bf3d5161-b148-4d1d-96e5-be50c5b72c9a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMDk_0d899db7-a49b-4737-8b16-b2c80dad5ab0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,382,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,470,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(929,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(785,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,093,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,236,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,371,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,693,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,061)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(976,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,453,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,437,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id3ec59376227463da776d509a74f26c7_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtMS0xLTEtMA_ad071af7-3d83-4281-98e5-46f37dab76d3"
      unitRef="shares">11382747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id3ec59376227463da776d509a74f26c7_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtMy0xLTEtMA_0eab2524-5f5e-4aba-bc49-7d63f9aba421"
      unitRef="usdPerShare">28.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEtNS0xLTEtMA_e4282566-2bd9-4052-a6c2-9e25d128bdbc">P7Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzItMS0xLTEtMA_a05b5191-5e72-4751-bd3f-aac7144ee34a"
      unitRef="shares">1470339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzItMy0xLTEtMA_456be612-1941-4b18-9d4f-35aa69acced6"
      unitRef="usdPerShare">14.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzQtMS0xLTEtMA_3a14f26d-07f7-4285-840e-9a0f105955ce"
      unitRef="shares">45159</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzQtMy0xLTEtMA_8e24db03-00f8-4d4d-abc9-24343845ce24"
      unitRef="usdPerShare">6.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzUtMS0xLTEtMA_4722c311-70e0-4d96-9b68-b9671efe9de4"
      unitRef="shares">929596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzUtMy0xLTEtMA_ef0348b9-1dcb-4876-afc6-da928e8134ea"
      unitRef="usdPerShare">21.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzYtMS0xLTEtMA_54a1d435-d8bf-4180-b49b-bbab2dfd35c8"
      unitRef="shares">785268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzYtMy0xLTEtMA_09c8bffa-64d5-4348-a1b8-316c8a2e9440"
      unitRef="usdPerShare">26.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctMS0xLTEtMA_1796de51-e71d-49e4-a2ad-3a4cd3adb86f"
      unitRef="shares">11093063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctMy0xLTEtMA_fc04f34b-cd3b-4e2b-93ff-c0d528bb2d86"
      unitRef="usdPerShare">27.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzctNS0xLTEtMA_ea905e48-f1b7-42f2-86f2-03af1235e4f8">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzgtMS0xLTEtMA_86a38a9d-9e97-4d84-b102-fb19e3342b74"
      unitRef="shares">1556575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzgtMy0xLTEtMA_9d948b85-e886-4d20-9a12-affe6466b6e3"
      unitRef="usdPerShare">6.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzktMS0xLTEtMA_5bcef2b8-7483-44d2-9806-80ffd69672d0"
      unitRef="shares">19887</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzktMy0xLTEtMA_f8713253-615d-4d42-abc1-ca113df8c644"
      unitRef="usdPerShare">3.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEwLTEtMS0xLTA_88464658-292f-41a9-9943-1517f2a8b799"
      unitRef="shares">1236326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEwLTMtMS0xLTA_93601681-3faf-4938-a08f-533bee7fafa5"
      unitRef="usdPerShare">24.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzExLTEtMS0xLTA_d3829b25-6881-46db-aa3d-1c9effb02a47"
      unitRef="shares">2371143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzExLTMtMS0xLTA_c6721ffd-331d-45a3-b85c-87eb8434c20a"
      unitRef="usdPerShare">38.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTEtMS0xLTA_3c1fa560-87cf-426b-89b6-d2862904dcd5"
      unitRef="shares">9022282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTMtMS0xLTA_10a8cb7e-5533-4da8-b42b-e1af56318c74"
      unitRef="usdPerShare">21.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEyLTUtMS0xLTA_9ae62756-e609-4e33-ab4f-21ffce6f4761">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEzLTEtMS0xLTA_e3fbed7c-3698-459a-91e6-363073a27704"
      unitRef="shares">5693498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzEzLTMtMS0xLTA_e5b4f4ca-e2fd-4833-8959-80dd5dc3374c"
      unitRef="usdPerShare">10.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE0LTEtMS0xLTA_983e660e-2678-4c46-a2c1-be5571a0975f"
      unitRef="shares">30061</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE0LTMtMS0xLTA_6d165e7a-9c52-453e-9501-4de4a56ccd93"
      unitRef="usdPerShare">3.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE1LTEtMS0xLTA_a7085b9a-f0a9-46e8-a881-605452700dc1"
      unitRef="shares">976324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE1LTMtMS0xLTA_53934c61-b4c0-4ac4-9370-baa5a2ba6ec8"
      unitRef="usdPerShare">15.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE2LTEtMS0xLTA_d181f0ab-bb0a-4f9d-bb42-52cd535703b8"
      unitRef="shares">2453499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE2LTMtMS0xLTA_c70ee6a9-5ddd-4d30-a4d7-b5a0135be19b"
      unitRef="usdPerShare">26.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTEtMS0xLTA_0c97482e-17a4-433f-a15e-239c730c9d7a"
      unitRef="shares">11255896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTMtMS0xLTA_902010b4-3342-4468-abc0-482980a41de9"
      unitRef="usdPerShare">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE3LTUtMS0xLTA_78f2efeb-1777-4862-a030-f31fa5105496">P7Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTEtMS0xLTA_307bec45-d59a-42ed-8115-54c27cc68eb6"
      unitRef="shares">5437667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTMtMS0xLTA_a01b1deb-c7bc-4125-8b7d-5e72beffb684"
      unitRef="usdPerShare">19.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTo0NDIzMmQzNjllZGU0MzIxOTFmODJkNzRhM2UxOTlhMy90YWJsZXJhbmdlOjQ0MjMyZDM2OWVkZTQzMjE5MWY4MmQ3NGEzZTE5OWEzXzE4LTUtMS0xLTA_d5dec43f-e4a4-4ef1-88bf-7827fab53157">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI0ODE_ad964341-e0a7-4325-ab91-67d1e16d9c1a"
      unitRef="usd">13842000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibd0bbb1eee4b42d0aa919cb62a3b9507_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI1Njc_4cdaa388-3e27-4ec9-b890-c7ab0911461d">P2Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2NTg_340a0560-64df-4fb3-b433-2dc328fabc8a"
      unitRef="usdPerShare">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2NjI_2a256675-f3f7-414d-9fd3-b4306af27d2b"
      unitRef="usdPerShare">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI2Njk_1ac874b3-6540-4bdb-805d-e8ac6d0f5700"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3NjM_fd8cc3e6-7aa1-453c-9094-6e088d39f1f7"
      unitRef="usd">51000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3Njc_72a27a96-5df4-4875-8646-f752cc1b7dd0"
      unitRef="usd">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzI3NzQ_16a6df2b-04ad-4b54-9353-4d053a77c4cb"
      unitRef="usd">356000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTM_ff1620d5-fc6f-4687-a530-7cd541734b19">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information about stock options outstanding as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,259,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,261,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,028,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,437,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information about stock options outstanding as of December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise&#160;Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,612,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,585,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,264,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMC0xLTEtMA_64581347-98e0-438d-9c56-62ab144559f5"
      unitRef="usdPerShare">1.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMi0xLTEtMA_f77acc18-95de-4106-b1c6-3c1e6e3c80fa"
      unitRef="usdPerShare">5.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItNC0xLTEtMA_321961d8-9ced-4bec-b342-f3d0fde7d655"
      unitRef="shares">3259685</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItNi0xLTEtMA_9270202c-a9b1-4936-875d-a32c68aba692"
      unitRef="usdPerShare">4.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItOC0xLTEtMA_1def582a-2349-4b9f-b6d2-4a1205fe6afc">P8Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTAtMS0xLTA_bc6b55b8-c23f-4cec-a134-e428dd876c3d"
      unitRef="usd">18157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTItMS0xLTA_2cd000d1-bafa-4253-8e21-cab897ef24db"
      unitRef="shares">1271310</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTQtMS0xLTA_0c450353-146e-4da8-ac87-e9c0d9a1af1e"
      unitRef="usdPerShare">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i717551b5c24c429c9a30be4e9873e51a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTYtMS0xLTA_bd29fc97-362f-4560-9b68-fbbfeeb115f3">P8Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8bbc252e9b194ed498e4fd1ac301b96e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzItMTgtMS0xLTA_37acbbf2-9548-4c9a-89d3-f4078a8aca7f"
      unitRef="usd">9018000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMC0xLTEtMA_7be89c09-4472-4c34-9f48-f61ca4a51609"
      unitRef="usdPerShare">6.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMi0xLTEtMA_15b267bf-e0ae-4c82-a33a-4c637a6d9db7"
      unitRef="usdPerShare">15.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtNC0xLTEtMA_bfd1ac66-050d-4cfa-aeff-c6b4c0345ee9"
      unitRef="shares">2261216</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtNi0xLTEtMA_19993252-d674-44f7-93d8-428b2cc2097a"
      unitRef="usdPerShare">11.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtOC0xLTEtMA_aaa8c596-b101-403a-8b71-0c5dfc79f08c">P8Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTAtMS0xLTA_2358c55c-f40f-43f7-abc3-c790ffc5024b"
      unitRef="usd">1325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTItMS0xLTA_2a700251-bb92-49b9-8c47-dc9b95831e01"
      unitRef="shares">345788</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTQtMS0xLTA_5af7f639-301d-4f55-872f-f4d6e0bd7551"
      unitRef="usdPerShare">9.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i72e3eae62693434e8547ea56b69a0aba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTYtMS0xLTA_51061ebc-5d83-462f-822c-31e220a33833">P4Y9M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8b3bd75c2af44de39219feee8729308e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzMtMTgtMS0xLTA_92de3d05-739a-4bb4-b386-9b9bae2a8600"
      unitRef="usd">689000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMC0xLTEtMA_70be1292-ff1d-41b5-b7a4-008eb04f373c"
      unitRef="usdPerShare">15.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMi0xLTEtMTcwMA_ff7df371-11b9-4e31-b0de-1a5bb6ebf824"
      unitRef="usdPerShare">20.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtNC0xLTEtMA_f8cc158c-626b-4f20-9a03-516e1ba46dbb"
      unitRef="shares">3028309</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtNi0xLTEtMA_53a83f37-3404-4f91-a521-c1043bfc7207"
      unitRef="usdPerShare">18.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtOC0xLTEtMA_7b150a62-e420-4dee-b55b-db30722e6f2f">P7Y4M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTAtMS0xLTA_2af1e4e9-099d-4752-a53f-bbf030c6df2a"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTItMS0xLTA_a8743b2b-19a2-406c-bf9a-01adc92d3dbc"
      unitRef="shares">1216258</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTQtMS0xLTA_9816e64c-ff46-40c6-bd11-b9d912925357"
      unitRef="usdPerShare">19.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ibaf0aff3149642e4883c5589733f0003_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTYtMS0xLTA_c7f1f92e-6591-4e28-ad00-db73d29b12ba">P5Y7M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i661dc00e8d3e4137b45d1081c39df7fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzQtMTgtMS0xLTA_4cea8974-6511-4d4f-9c7d-626e867b0e5d"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMC0xLTEtMA_458661e9-78f4-47cb-8a90-e6819674183f"
      unitRef="usdPerShare">21.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMi0xLTEtMA_438ad919-68c4-4245-bf3b-c160f1597f45"
      unitRef="usdPerShare">36.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtNC0xLTEtMA_1715dc16-01c8-464f-bd58-71a93d876894"
      unitRef="shares">2303371</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtNi0xLTEtMA_f66294b4-3927-4bc8-96e7-b1406b4e2665"
      unitRef="usdPerShare">26.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtOC0xLTEtMA_54e659ba-c627-4504-8d0b-0c848a1df81c">P4Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTAtMS0xLTA_66ad208e-cd03-4eba-9d40-7d1f69d0da05"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTItMS0xLTA_9d300989-c83c-41a4-b053-4dc0a39114de"
      unitRef="shares">2200996</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTQtMS0xLTA_ca5c0005-187f-48a0-a16d-1122388d9aab"
      unitRef="usdPerShare">26.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i8690a18310fc4cf48763ea7c4c9eff81_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTYtMS0xLTA_28e8cfc6-8f56-474e-a000-4195a2341c57">P4Y2M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia7c5460f623b41c18486f8f337c91484_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzUtMTgtMS0xLTA_6e29f2db-d79b-4c36-a6a2-ef33e96c5290"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMC0xLTEtMA_2ea02c56-693a-4271-b5fd-b4c47cdc3ca3"
      unitRef="usdPerShare">37.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMi0xLTEtMA_a0b74e2f-9f2a-4b8d-ae23-8a915879ddd1"
      unitRef="usdPerShare">47.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtNC0xLTEtMA_70b1cf8d-efe9-4f58-9cc9-b44775ff12b6"
      unitRef="shares">403315</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtNi0xLTEtMA_65430317-d1d7-4472-be47-1f26e72cb774"
      unitRef="usdPerShare">42.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtOC0xLTEtMA_38c05950-8dca-411b-9ff0-4e6d5ab86265">P4Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTAtMS0xLTA_a1a5f32a-0479-405d-96f9-f25dcb74603c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTItMS0xLTA_ff40702b-8a41-4020-bbf9-fa054ebc278a"
      unitRef="shares">403315</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTQtMS0xLTA_93ecc817-edda-465e-9449-8ab37f4ee0a9"
      unitRef="usdPerShare">42.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i14ff499386fa4ad0ae7a01e536126f0f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTYtMS0xLTA_0442accb-072a-4113-a04d-395b0bd61f42">P4Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7451bc6286184839ac5a35196b93e9b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzYtMTgtMS0xLTA_0ae5674f-2827-40e7-a2ad-63a1b0f7ea28"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctNC0xLTEtMA_b9675b11-e063-4425-b967-6accb3a4bd5e"
      unitRef="shares">11255896</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctNi0xLTEtMA_6e5fc448-8efb-46b4-bec3-eae24380228d"
      unitRef="usdPerShare">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctOC0xLTEtMA_c1f03ad3-72f0-4774-91cb-85498345b393">P7Y3M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTAtMS0xLTA_463bd404-d76d-4bd8-82f5-0fb78e488fb9"
      unitRef="usd">19482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTItMS0xLTA_42992251-3800-4d19-957d-7a54202e7c2f"
      unitRef="shares">5437667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTQtMS0xLTA_88687913-cb8b-410a-a093-175ca3080402"
      unitRef="usdPerShare">19.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTYtMS0xLTA_353671dc-d4a0-4f58-9e4a-b416776ccdc5">P5Y7M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpiMGYwZDk4ZWVkNDg0NWNmYTAwYTBkNWMyMjkzNWI0Ny90YWJsZXJhbmdlOmIwZjBkOThlZWQ0ODQ1Y2ZhMDBhMGQ1YzIyOTM1YjQ3XzctMTgtMS0xLTA_0ba23820-0451-407f-9783-479421136f9b"
      unitRef="usd">9707000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMC0xLTEtMA_077869b0-2b96-49a5-8174-38641573368b"
      unitRef="usdPerShare">3.17</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMi0xLTEtMA_cd936058-70a1-4e38-a724-380fb1b1abc9"
      unitRef="usdPerShare">8.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItNC0xLTEtMA_87dd945b-b239-49c0-9b11-4db812da91ed"
      unitRef="shares">1612219</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItNi0xLTEtMA_77bf6e5d-b42e-4b36-b777-c70d35424436"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItOC0xLTEtMA_c0462ce6-9f84-417a-af2c-512df306c520">P8Y29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTAtMS0xLTA_ac8d004a-bb20-4dd0-a451-2ee070749abe"
      unitRef="usd">473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTItMS0xLTA_bed6c5db-a38e-4269-ada8-9f3a36461eb7"
      unitRef="shares">585144</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTQtMS0xLTA_24fee8d1-b926-4a5b-8c14-277f54632e3a"
      unitRef="usdPerShare">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9de199605ca243d6a2e6f2230b57e1f7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTYtMS0xLTA_2f26cd09-3064-4dca-ab43-58b4c9267f0c">P5Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i10990e5b1d6d46afa61c13573d2718f4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzItMTgtMS0xLTA_98dbd3ce-7999-4fbb-979c-8dfadbe25b00"
      unitRef="usd">194000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMC0xLTEtMA_1661c376-151d-42d4-8503-8b3bb1f725a9"
      unitRef="usdPerShare">8.77</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMi0xLTEtMA_fb681298-14ba-4c60-a267-63ebd64b5fdb"
      unitRef="usdPerShare">20.68</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtNC0xLTEtMA_4209b15e-5b94-4edf-9f34-ac8c84e76fec"
      unitRef="shares">1278121</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtNi0xLTEtMA_8627ad12-8bcb-40dc-9273-3867afa24863"
      unitRef="usdPerShare">15.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtOC0xLTEtMA_15876988-5dd4-4bc4-a103-eef50523f624">P6Y6M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTAtMS0xLTA_3be24d5e-fd94-4ed6-b226-7fded2956550"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTItMS0xLTA_845facb4-8326-4f12-ab03-c89b1874ba0b"
      unitRef="shares">753064</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTQtMS0xLTA_a22287fa-4e6c-4396-8bce-824b64e4abfc"
      unitRef="usdPerShare">15.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0a89d08d41a54d1186a979123197a002_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTYtMS0xLTA_9b8e9ff4-86df-4a45-9971-d13b9dd53153">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iff9359d1e8b446cb97de06dd3a3d784c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzMtMTgtMS0xLTA_68b5c107-ef11-4cb2-80d4-368354e040c9"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMC0xLTEtMA_5dcc6399-e8fb-436c-b809-9198a70db3e8"
      unitRef="usdPerShare">20.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMC0xLTEtMA_9f9588c0-3ddc-41c6-bce0-5dc9519dd81e"
      unitRef="usdPerShare">20.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtNC0xLTEtMA_31f73026-cba0-4066-bb48-37840d498319"
      unitRef="shares">1646500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtNi0xLTEtMA_ac67eb54-01e5-4531-acf8-bc2dabb1c371"
      unitRef="usdPerShare">20.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtOC0xLTEtMA_be1337c0-6a44-4f89-9dfe-1c4e7c4a86ae">P6Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTAtMS0xLTA_56adab87-1e8e-4d32-8c17-175001b79595"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTItMS0xLTA_fa3f5030-89ec-4840-9a48-946e4b2d46a1"
      unitRef="shares">892000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTQtMS0xLTA_539fcdd7-6d79-435b-9a83-31632be7e126"
      unitRef="usdPerShare">20.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i02779a4a24e94615abd773c870dd6261_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTYtMS0xLTA_abaafafc-6749-4d88-9abb-375b4ae757b5">P6Y7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iffd402c659aa49ba8a4130d86b580fa0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzQtMTgtMS0xLTA_8daba2e9-cbd7-4047-bc52-9e29412f643e"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMC0xLTEtMA_aebf93d5-eece-4214-bb11-20c98fdf5ac9"
      unitRef="usdPerShare">21.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMi0xLTEtMA_97f175c6-be5c-427d-a140-b1ebd45e9f24"
      unitRef="usdPerShare">29.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtNC0xLTEtMA_5a8b13af-9851-4033-92fd-41dc4bc7c6e8"
      unitRef="shares">1976645</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtNi0xLTEtMA_6dd1886e-a658-41a6-82d4-7b49da392529"
      unitRef="usdPerShare">23.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtOC0xLTEtMA_ca937bdd-13bf-4e08-a389-b163e82270d5">P6Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTAtMS0xLTA_42c80521-07b4-4bd8-afd8-e6d3bbd5a02b"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTItMS0xLTA_dc7aae06-bb8c-4397-9802-f1fb40d4f21e"
      unitRef="shares">1585940</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTQtMS0xLTA_a98346e2-5475-4e0e-826f-8bdd4d0c4660"
      unitRef="usdPerShare">23.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4641cf4346ac4f34aa07c5e1b5beff39_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTYtMS0xLTA_1e4a1937-bc5a-42ec-976d-c5f0a91bda81">P5Y9M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i5f91c9052bd04dc58720b0900b461cbd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzUtMTgtMS0xLTA_2959d08a-1f00-4c58-b0f3-cc9563c0e324"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMC0xLTEtMA_a360695d-1fc0-44be-ab6a-14ddbf2b7dab"
      unitRef="usdPerShare">29.56</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMi0xLTEtMA_2575b6d8-c2f0-4828-8b53-ea8c0d547b1c"
      unitRef="usdPerShare">65.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtNC0xLTEtMA_33b858ff-d934-48bf-8e36-320366cb65d2"
      unitRef="shares">2508797</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtNi0xLTEtMA_67756dcd-43e4-4b08-bd2b-648eb0c73280"
      unitRef="usdPerShare">34.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtOC0xLTEtMA_bd2809d1-ee7a-4e8d-9263-9a6f4216f63a">P4Y4M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTAtMS0xLTA_4d9e8566-ed9f-43df-b091-64f3c8925bc5"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTItMS0xLTA_ee8b5ae6-89c4-4fa0-8bea-616549cad969"
      unitRef="shares">2448046</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTQtMS0xLTA_1b0b6c49-39e2-4c87-893d-d01451fbc3a3"
      unitRef="usdPerShare">34.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4edffa3c58344b1fab15b7265abf4faa_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTYtMS0xLTA_8a5474cb-0d1f-4e3c-a0d1-661337f77d98">P4Y3M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i371617dbee39477bb1cb5742a03f41fe_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzYtMTgtMS0xLTA_d5523d4b-fbfe-4fdc-a866-a3171eb53810"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctNC0xLTEtMA_e609655b-80d1-44ab-a87e-d4ccbaf5a33b"
      unitRef="shares">9022282</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctNi0xLTEtMA_0695cfe2-1ea7-43b1-96bd-35327153f05d"
      unitRef="usdPerShare">21.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctOC0xLTEtMA_096baac3-3631-4ee1-b9ef-4830b3124811">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTAtMS0xLTA_d7c9486d-9a79-450e-882f-ea7c8a57b95c"
      unitRef="usd">473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTItMS0xLTA_2bc24dc6-bca0-41ba-a474-8e03294b5d4b"
      unitRef="shares">6264194</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTQtMS0xLTA_ff4129dc-48d1-40eb-952f-99f95a75c640"
      unitRef="usdPerShare">24.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTYtMS0xLTA_6f9c0e90-1b89-4493-9a93-08d309b7ab36">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTowODkwMTRmOTA0ZTg0ZGFiOGU3YTQ4YWEwNGU5ZWY2Ni90YWJsZXJhbmdlOjA4OTAxNGY5MDRlODRkYWI4ZTdhNDhhYTA0ZTllZjY2XzctMTgtMS0xLTA_0b9b3f30-ca1c-4269-acbe-d69deaf0d3b5"
      unitRef="usd">194000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzUwMTg_7f896e78-9d5e-4cb5-92dc-f68b9b322299">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,278,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,159,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,157,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,802,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id3ec59376227463da776d509a74f26c7_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMS0xLTEtMTcxMw_3f2ceed3-2e69-4fe4-8465-a6c169e38dfb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id3ec59376227463da776d509a74f26c7_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMy0xLTEtMTcxMw_b3d69197-ef41-4d46-be1d-162f93c18322"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ic5db9674c53c4097ad5e3b0525665ed0_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtNS0xLTEtMTcxMw_8f4cf2b7-5d0f-4c19-b7f0-371595bb3486">P0Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMS0xLTEtMTcxMw_74935450-afff-400d-b8c7-d7a58558aa5b"
      unitRef="shares">1069126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMy0xLTEtMTcxMw_a7740db7-bb58-40ab-88e2-8c64a9d1acae"
      unitRef="usdPerShare">13.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMS0xLTEtMTcxMw_6873f230-ad4c-4b3b-8d1a-57365a7c925c"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMy0xLTEtMTcxMw_844fe9cb-8ce7-42fc-9999-ce65af980003"
      unitRef="usdPerShare">15.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMS0xLTEtMTcxMw_f20f50e1-c213-42c8-a420-db9f5f71123d"
      unitRef="shares">73785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMy0xLTEtMTcxMw_7001d795-88a2-4d0d-a50b-725866ebbfb1"
      unitRef="usdPerShare">13.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMS0xLTEtMA_24ab316a-9b95-4bb5-a481-dde757a82d92"
      unitRef="shares">970341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4bbcb1ed88ef4a9699e6fb9221b4c65d_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtMy0xLTEtMA_a2cc4a15-b16c-4087-8d26-c41c9684c5f5"
      unitRef="usdPerShare">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iaea8840b9e7545d180e072548e790580_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzEtNS0xLTEtMA_0143bb34-775a-431e-9126-a556487ec5c2">P1Y5M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMS0xLTEtMA_85ac3dbc-7eed-4b85-b027-32649796d523"
      unitRef="shares">2278460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzItMy0xLTEtMA_70dd1986-c60f-49d2-ab57-c4f542bb7cfd"
      unitRef="usdPerShare">6.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMS0xLTEtMA_5ec425aa-0313-4717-9a4e-c9d30f847c32"
      unitRef="shares">1159165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzMtMy0xLTEtMA_0a737018-3078-4bc1-b2e0-c712bb312841"
      unitRef="usdPerShare">8.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMS0xLTEtMA_d978a58f-9101-4444-815e-7a8ceec7d90e"
      unitRef="shares">307654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzQtMy0xLTEtMA_2adff320-3dfe-4ccd-89f0-4c2f2ddd12b4"
      unitRef="usdPerShare">8.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtMS0xLTEtMA_1b321767-5bd1-4c09-bb24-0a48edd774d3"
      unitRef="shares">1781982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i59afefa3805d493fad5e5f44d615e29c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtMy0xLTEtMA_c5df6fc6-502e-474e-a84d-777f3bbccb56"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i128047ea0e4641fdac891f53d5a3aaf9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzUtNS0xLTEtMA_9932a4f4-5672-4740-9b3c-ceb1fafeec02">P1Y2M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzYtMS0xLTEtMA_5d18a009-5f82-4bab-9826-c211e3a887c0"
      unitRef="shares">3157390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzYtMy0xLTEtMA_5439cfdd-74ce-44db-8d42-3632bebab1bb"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzctMS0xLTEtMA_36f3b477-23eb-430c-96d5-7f2d14db6088"
      unitRef="shares">2802593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzctMy0xLTEtMA_cefa6dcb-4c4f-46fc-b28b-f6c011580c00"
      unitRef="usdPerShare">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzgtMS0xLTEtMA_a0f2baf6-164e-42a8-a884-5a25cf0ea1f6"
      unitRef="shares">409067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzgtMy0xLTEtMA_8bcb00ca-1f25-483f-b243-bcef0ad0023f"
      unitRef="usdPerShare">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktMS0xLTEtMA_f48aa38c-8013-4afd-a8a1-a03fadb25f5a"
      unitRef="shares">1727712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i523c931240534675a00b833db69b7b7f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktMy0xLTEtMA_444b4840-4141-433e-bd8e-e076bb1a2099"
      unitRef="usdPerShare">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90YWJsZTpkM2FlYzk2ZDU3YzQ0OWMxYmRhNTMzNGE1ZGUzMzlhOC90YWJsZXJhbmdlOmQzYWVjOTZkNTdjNDQ5YzFiZGE1MzM0YTVkZTMzOWE4XzktNS0xLTEtMA_e2b92e21-0d15-4486-a423-16d22e165f6c">P0Y5M1D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id3a9238cdda843cd8e2b1cdc9a3927be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzMzOTc_20d82d72-d09e-4108-a4bd-d1b17dd0af88"
      unitRef="usd">4188000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id39bd16d2b0240b687313c2d206093e5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzM0ODI_6c044122-5f75-4e2e-a6d1-3fea99e35661">P0Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <pgen:CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense
      contextRef="ic42f0609642c4f08b491b5e9e5e122cc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzM3NTI_0aa29dc4-e5ae-40c2-a7f8-91360cdc4447"
      unitRef="usd">200000</pgen:CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense>
    <pgen:LockupPeriodOnRestrictedStockUnitShares
      contextRef="i10782278c1794d1c8b675aaa49765ed4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzY1OTcwNjk3NzU0MTA_f6e1709e-5a40-49bf-b335-8156146248dd">P3Y</pgen:LockupPeriodOnRestrictedStockUnitShares>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="icc52713e7d8949749938bc75522e6d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NDA_ac334b75-b0b9-447a-97bb-172829b656cf"
      unitRef="usd">454000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="i87018f1bd95f4a4f8cd3775dc1bdc558_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NDQ_7b10d31b-aa58-4fac-8dcd-0950aa998d6a"
      unitRef="usd">1868000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense
      contextRef="i4889fe27e2cc4966b4f58c1e494a13ed_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQ5NTI_aceb5c65-e532-4f58-a10a-c3e2cf1a68d6"
      unitRef="usd">1956000</pgen:SharesIssuedDuringPeriodValueIssuedForServicesExpense>
    <pgen:CompensationArrangementWithIndividualAnnualCashRetainer
      contextRef="i53aa5fac20ac403b9bce2f3bbe67a3a5_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgwODk_7c009ff6-cef7-4995-a9ab-427e17975510"
      unitRef="usd">100000</pgen:CompensationArrangementWithIndividualAnnualCashRetainer>
    <pgen:CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue
      contextRef="i27caa5d0d3674cb8873fa0e6c545b8cc_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgwOTg_4c6113dc-5ea8-45f0-bee4-22d19b4663c2"
      unitRef="usd">250000</pgen:CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue>
    <pgen:CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue
      contextRef="i1a3e7401f5244362a8da8bdd6081990c_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzUvZnJhZzo0MDQ2MzBmM2ZmOWU0Y2Q5YTFmNzRiZjhiYmZmYTk0NS90ZXh0cmVnaW9uOjQwNDYzMGYzZmY5ZTRjZDlhMWY3NGJmOGJiZmZhOTQ1XzQzOTgwNDY1MTgxMDc_3f6cb14a-cfe2-481d-bf2f-2f83f26ff815"
      unitRef="usd">250000</pgen:CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODA_ad3e6dd6-64da-4222-9761-354bde7c6160">Operating Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM0NA_ddde4444-f884-4ed7-beb8-9b358f73343e"&gt;one&lt;/span&gt; to nine years, some of which may include options to extend the lease and some of which may include options to terminate the lease within one year. The Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases in continuing operations was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flow information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets added in exchange for new lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i0854d2b69b794445a113081a1772158a_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM1MA_c78bf1b4-57fa-41b8-ae26-e72d8fd61bea">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <pgen:LesseeOperatingLeaseTerminationPeriod
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzQ3Ng_4c1a8450-4254-4164-a9f4-959f458d5cd3">P1Y</pgen:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODE_c9b79972-f08d-4b9c-ae1b-aee4edfea29f">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases in continuing operations was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flow information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets added in exchange for new lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzItMS0xLTEtMA_9e3dc14c-79ae-42d4-ad10-0ea75027a9b1"
      unitRef="usd">3578000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzItMy0xLTEtMA_039131d9-4e1b-42e1-92dc-c71385cbb0c5"
      unitRef="usd">3821000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzMtMS0xLTEtMA_38c82878-3b0a-4a01-a760-d0dc3c459b85"
      unitRef="usd">1763000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzMtMy0xLTEtMTAwMTA_e2fe4a3b-010b-48dc-9282-a46651bd6b85"
      unitRef="usd">2042000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzQtMS0xLTEtMA_6e4d1bb4-94cb-4742-91c6-55bb9bec18ea"
      unitRef="usd">842000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzQtMy0xLTEtMA_508ea5f7-d928-41c9-b321-8fe6d3759fcb"
      unitRef="usd">845000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzUtMS0xLTEtMA_bacbe7bb-8d67-4678-a539-488e3a075410"
      unitRef="usd">6183000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTo0Y2M4YTJlMDQ3MGE0OWZiOTFlMGM2OThkMTFkZTRmNC90YWJsZXJhbmdlOjRjYzhhMmUwNDcwYTQ5ZmI5MWUwYzY5OGQxMWRlNGY0XzUtMy0xLTEtMA_184dd92e-36aa-4f25-b035-05c36abd0731"
      unitRef="usd">6708000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzEzODI_3ff32045-4dc0-4fa0-9518-2e0d9eb50ef2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzAtMS0xLTEtMA_eb071ebc-1972-49c9-b104-034ec967289a"
      unitRef="usd">3608000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzEtMS0xLTEtMA_cb5b86a5-af13-4f0a-ba91-25135cb1e67b"
      unitRef="usd">3392000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzItMS0xLTEtMA_d09c79d7-bae9-4a14-a8d9-115b98206fd7"
      unitRef="usd">2087000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzMtMS0xLTEtMA_b3180856-edc1-4996-85f4-9068424a447c"
      unitRef="usd">1841000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzQtMS0xLTEtMA_dc22fc5f-84f4-4f11-aa1d-27a151a5734e"
      unitRef="usd">1116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzUtMS0xLTEtMA_2fee591c-28c9-49fd-8657-81ce4fcbc6ca"
      unitRef="usd">867000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzYtMS0xLTEtMA_865a40c9-a2c8-4c99-935c-00f007358625"
      unitRef="usd">12911000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzctMS0xLTEtMA_cdc43fcb-1218-4435-9ae6-a3a2f84af445"
      unitRef="usd">2510000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzgtMS0xLTEtMA_e32a4472-a957-4e37-b150-6d8a66af19e5"
      unitRef="usd">10401000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzktMS0xLTEtMA_e3733666-ec63-4554-a89d-f2d8621cb2f6"
      unitRef="usd">2657000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzEwLTEtMS0xLTA_56ba858e-c455-4c83-8e41-8b97f37dd3c5"
      unitRef="usd">7744000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpjOTFhMTJjMGY5NDI0NDAxYjNhNDVhMWZhODUxNjM4Yi90YWJsZXJhbmdlOmM5MWExMmMwZjk0MjQ0MDFiM2E0NWExZmE4NTE2MzhiXzExLTEtMS0xLTA_f1561b3b-782c-420a-aeba-e8e0af255cc2"
      unitRef="usd">10401000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzItMS0xLTEtMA_8f14fde6-b984-459c-bbda-ad3136032d59">P4Y2M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzItMy0xLTEtMA_9331d247-d1ab-4757-8313-533d9c770440">P4Y9M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzMtMS0xLTEtMA_b29a4ec8-8ef9-4d2d-943d-47357d8785d9"
      unitRef="number">0.1027</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpmZmNiZTEzODg5MmU0NTljYWViZWZjN2U0Mzc5MTBmNS90YWJsZXJhbmdlOmZmY2JlMTM4ODkyZTQ1OWNhZWJlZmM3ZTQzNzkxMGY1XzMtMy0xLTEtMA_b37da50e-8b23-4963-b60f-18eb0d8187f9"
      unitRef="number">0.1032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzMtMS0xLTEtMA_2f9cf619-a75d-455c-b118-f2140d294d3c"
      unitRef="usd">4012000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzMtMy0xLTEtMA_35a6d447-e068-40be-a867-2bf3c5a7c6d6"
      unitRef="usd">3877000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzQtMS0xLTEtMA_2aa33b23-0eed-40ec-8080-8cf47bb08747"
      unitRef="usd">417000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90YWJsZTpkNzZiYmRiM2ZhOGI0ZWI3ODJhOWFiNDQ5YTkwMDcxMC90YWJsZXJhbmdlOmQ3NmJiZGIzZmE4YjRlYjc4MmE5YWI0NDlhOTAwNzEwXzQtMy0xLTEtMA_0ba62d4a-8180-44aa-89be-158633452d72"
      unitRef="usd">1137000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzEwMDc3_458f2f78-3743-4a12-8b44-8e1dd2eccdac">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2020, Trans Ova settled one of two patent infringement lawsuits brought by XY, LLC ("XY"). The lawsuit, originally filed in 2012, was tried and appealed between 2016 and 2020. On December 1, 2020, the parties reached a settlement resolving all remaining disputes. As part of that settlement, Trans Ova remitted to XY a settlement payment, which, in addition to all the other monies Trans Ova had previously paid XY, constituted full payment and satisfaction of the judgment, including pre-judgment interest, post-judgment interest, costs, and all past, current and future royalty obligations under the judgment. In exchange, XY released and forever discharged Trans Ova from all obligations arising out of the judgment. In addition, XY dismissed with prejudice its pending appeal. On January 8, 2021, the parties filed a stipulation of case termination with the district court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The second patent infringement lawsuit brought on by XY was filed in December 2016. On March 20, 2019, the United States District Court for the District of Colorado entered judgment under Rule 54(b) as to ten of the twelve counts of the operative complaint, dismissed those patent counts from the case, and stayed the remaining two counts of patent infringement pending XY's appeal of the Rule 54(b) judgment. While XY's appeal was pending, one of the two patents remaining in the case was separately invalidated in a different district court proceeding, which XY did not appeal. As to the ten dismissed counts in the suit XY brought against Trans Ova, XY appealed dismissal of only four of them, each alleging patent infringement. On July 31, 2020, the United States Court of Appeals for the Federal Circuit reversed the district court's dismissal of those four patent counts and remanded the case for further proceedings. The Court is assessing next steps of the case, including an amended scheduling order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While this patent infringement lawsuit is pending, Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of district court and appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company's disclosures regarding its methane bioconversion platform. The Company produced documents to, and met with, the staff of the SEC and voluntarily cooperated with the SEC investigation. In September 2020, the Company reached a final settlement with the SEC regarding the matter. Under the terms of the settlement, the Company, without admitting or denying the allegations of the SEC, consented to the entry of an administrative order requiring that the Company: (i) cease and desist from committing or causing any violations and future violations under Section 13(a) of the Securities Exchange Act of 1934, as amended, and Rules 13a-11 and 12b-20 promulgated thereunder; and (ii) pay a $2,500 civil money penalty to the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, three purported shareholder class action lawsuits, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Abadilla v. Precigen, Inc., F/K/A Intrexon Corp., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chen v. Precigen, Inc. F/K/A Intrexon Corp., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Seppen v. Precigen, Inc. F/K/A Intrexon Corp., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, were filed in the U.S. District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims track the allegations in the SEC's administrative order described above. The plaintiffs seek compensatory damages, interest, and an award of reasonable attorneys' fees and costs and have filed motions to consolidate these claims. In December 2020, a derivative shareholder action, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. The complaint names as defendants current directors and certain officers. The plaintiff's claims track the allegations in the SEC's administrative order described above. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 10, 2020, the Company received a notice of arbitration from Harvest pursuant to the Collaboration Investment Opportunity Agreement dated March 13, 2015. In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued 2,117,264 shares of its common stock to Harvest valued at $18,103 in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Exotech Bio, and AD Skincare, which the Company had $6,993 of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $326 prior to the settlement agreement; (iii) the commitment of Harvest to take reasonable commercial efforts to transfer its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid, resulting in a loss on the settlement agreement of $11,436 which is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2020. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including the IEP Investors and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of December 31, 2020 and 2019. These disagreements and disputes result in management distraction and may result in litigation, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company's business or operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December&#160;31, 2020, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="idf63e5924ca540d89aef4d0830021e64_D20201201-20201201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxNzM_21a35cb8-7163-496a-af18-9997b1a0ed54"
      unitRef="claim">1</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i590473c574a14f01bc57d3d29295299d_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxODI_8a76ca23-8944-4ef9-a2b3-be6d1b6241ef"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzYxMTY_0fd916a1-0ede-4afe-95d9-b5219ff9dc13"
      unitRef="claim">10</us-gaap:LossContingencyClaimsDismissedNumber>
    <pgen:LossContingenciesTotalClaimsNumber
      contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzYxMzg_4178017b-6ebf-4d09-baef-74e6af514d01"
      unitRef="claim">12</pgen:LossContingenciesTotalClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgwOTc_0988d278-5a05-46e6-a032-ed1b33d26c08"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <pgen:LossContingencyClaimsInvalidatedNumber
      contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMDU_a2f5ca20-6bee-43dd-9170-41f297dcf1a7"
      unitRef="claim">1</pgen:LossContingencyClaimsInvalidatedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMTM_50fba674-af6e-49f9-859d-bca935c7be27"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i5e90193768804ac2897e65914b465074_D20190320-20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgwODM_262f9538-a65f-4aa9-9fe3-be9cbf777670"
      unitRef="claim">10</us-gaap:LossContingencyClaimsDismissedNumber>
    <pgen:LossContingencyAppealedClaimsDismissed
      contextRef="i5c86ba033a9b4c4c8e0d55ff85e8f9ca_I20190320"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMjE_0d2b556d-026f-4afe-8716-b4565305a6cf"
      unitRef="claim">4</pgen:LossContingencyAppealedClaimsDismissed>
    <pgen:LossContingencyReversedClaimsDismissedNumber
      contextRef="if53067c947c6445b99c0734630919c2f_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzY1OTcwNjk4MTgxMzE_9c3b350b-34e9-43ac-a4e3-6de20b0854bb"
      unitRef="claim">4</pgen:LossContingencyReversedClaimsDismissedNumber>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i162c6a00ebd8403087aaba03e9e7257d_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1MjY4MTk_e79a7be9-e61a-4dc6-8892-d543895c2598"
      unitRef="usd">2500000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i163004d1571347a9896c92d4b1ec572f_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1MjY5MTU_407f6376-1ab6-4380-9d76-93b040d9bf53"
      unitRef="claim">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues
      contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI0NjA_b592c1dc-cb32-47d0-9889-d3ae8adc45a7"
      unitRef="shares">2117264</pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues>
    <pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues
      contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI0OTI_f4f778ff-0b37-48a6-b983-abbc908079b9"
      unitRef="usd">18103000</pgen:StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i59907113dd1d4344981247aabca5ca34_I20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI1OTQ_824783d9-6016-4645-8ad1-a535d113ba41"
      unitRef="usd">6993000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EquityMethodInvestments
      contextRef="i2615524a66c943229cbd226d85d96e2a_I20201130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI3MzE_42bd017a-57e3-4e7d-87cb-0b10bd85ff03"
      unitRef="usd">326000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3e4cefb4227c4ffc9b86f9a6c230e6dc_D20201201-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODcvZnJhZzoyZTE2Y2Q3ODhkYjg0OGYzYTEzZWE4MzY5ODU1OWVkYi90ZXh0cmVnaW9uOjJlMTZjZDc4OGRiODQ4ZjNhMTNlYTgzNjk4NTU5ZWRiXzQzOTgwNDY1NTI4NTk_40e4f89d-a1d1-41cc-a061-be4cfa74cb74"
      unitRef="usd">-11436000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzY1OTcwNjk3OTI5ODU_87c1d258-503e-43e5-8e66-72920f3cc17c">Related Party Transactions&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Security and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximated $800 per month. In 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month and issued to Third Security at the end of the month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services were provided. For the years ended December&#160;31, 2019 and 2018, the Company issued 1,606,062 shares and 696,033 shares, respectively, with values of $8,233 and $8,324, respectively, to Third Security as payment for services rendered pursuant to the Services Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf prior to and after the expiration of the Services Agreement under a separate agreement. The total expenses incurred by the Company under these arrangements were $159, $26, and $47 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $83, $89, and $89 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note 15 regarding compensation arrangements between the Company and its Executive Chairman.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Equity Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Equity Facility, the Company could, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). In conjunction with the Company's July 2018 registered underwritten public offering of Convertible Notes (Note 12), the Preferred Stock Equity Facility was terminated. No shares of Series A Preferred Stock had been issued under the Preferred Stock Equity Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes 1, 3, and 14 regarding additional transactions with affiliates of Third Security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transactions with ECC Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM previously acquired through collaborations. In conjunction with the ZIOPHARM License Agreement in October 2018 (Note 6), the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the year ended December 31, 2018, the Company recognized $14,793 of dividend income in the accompanying consolidated statement of operations. Following the transaction in October 2018, ZIOPHARM is no longer a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Castle Creek, and warrants to purchase shares of Castle Creek common stock previously acquired through collaborations and other transactions. As a result of the acquisition of Castle Creek by Castle Creek Pharmaceutical in December 2019, the Company received $1,280 in December 2019 for its shares of Castle Creek common stock and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The $3,311 is included in receivables on the accompanying consolidated balance sheet as of December&#160;31, 2019. The Company recognized a total gain of $3,222 on the change in fair value of these instruments, which is included in total other expense, net, in the accompanying consolidated statement of operations for the year ended December 31, 2019. Subsequent to the acquisition by Castle Creek Pharmaceutical, Castle Creek is no longer a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2018, the Company mutually terminated ECC agreements with three separate related parties which resulted in the recognition of the remaining deferred revenue associated with these ECCs totaling $11,877.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pgen:RelatedPartyOwnershipInterest
      contextRef="ifb40c1f06726442485a1ee1321b1baa6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIxMA_76dca096-0fb5-43b7-a8c8-7bc8e3ba1781"
      unitRef="number">1</pgen:RelatedPartyOwnershipInterest>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="ib672478b9e8e43829ba3dd9807ad3e12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzE0MDM_75497651-63ad-40fc-b79c-988265bcbc33"
      unitRef="usd">800000</us-gaap:ProfessionalAndContractServicesExpense>
    <pgen:CommonStockCalculationPeriod
      contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzY1OTcwNjk3OTI5NTI_cf867d39-d44b-4f11-8c61-140036c2330e">P30D</pgen:CommonStockCalculationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIzODA_9e139204-8d1d-48f8-8a25-a16a5e47c1c2"
      unitRef="shares">1606062</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzIzOTU_48d2ffdf-e44b-4d45-b781-4e3ee99e0758"
      unitRef="shares">696033</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI0Mzk_6cc99970-ae4d-441c-b2e8-f0bba0981ecd"
      unitRef="usd">8233000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI0NDc_d21b3671-8607-4d04-a1cf-c67b9c1d54ad"
      unitRef="usd">8324000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NTk_6c3a20ff-4e04-4139-b67b-921b76cb2789"
      unitRef="usd">159000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NjM_6999262b-3106-415f-9833-0d16bd68c269"
      unitRef="usd">26000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzI4NzE_e080e86b-3943-4c76-a771-eace3e6611ed"
      unitRef="usd">47000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:SubleaseIncome
      contextRef="i944eb05698ac46f595fb49e6348b4555_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MDM_4f8d8987-974b-4606-b4d2-7f204431e5b5"
      unitRef="usd">83000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i555d23957e82412498d8f685f322401f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MDg_025eef88-b1ac-43dd-ac75-a467df392cbd"
      unitRef="usd">89000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue
      contextRef="i98d45710dcbf4fa690f77a1d7ff87197_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1MzY1MTc_84d5d37f-97c4-49cd-871f-72f8c9548a7c"
      unitRef="usd">89000</us-gaap:OperatingLeasesIncomeStatementSubleaseRevenue>
    <pgen:ConvertiblePreferredStockAmountAuthorized
      contextRef="ib87f8cebc3d94d3a9961d37fd3d97771_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzMzNzA_3941684e-e733-4f1f-ae55-31d20694804b"
      unitRef="usd">100000000</pgen:ConvertiblePreferredStockAmountAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i599bfce00a9945d9b726ceb46d1b4829_D20171001-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzM2MjM_7dc0838f-3793-41eb-82bd-90858aed07d5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pgen:NoncashDividendIncome
      contextRef="i0670171b99994e70abea87f63ac354ea_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzU0MTg_23233ef6-4289-4db9-bca0-979d6e649754"
      unitRef="usd">14793000</pgen:NoncashDividendIncome>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i70be85e7d3844aaca71c406b666d60d6_D20191201-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzcxNzI_30426a5b-baf4-4bc2-b45f-d46d05299841"
      unitRef="usd">1280000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i89a435ac6ca244c79163f5df75db8e16_D20200101-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzcyMzg_0624c9b6-23f6-4281-a134-264848e894b2"
      unitRef="usd">-3311000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic063de9522b3438b84804a067d67c361_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1Mzc0MjE_d10daa8a-8f05-492c-8661-1ad4749c5a6f"
      unitRef="usd">3311000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i1e54f6e16a9443f0a47fc8c8084f977e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzc1MDc_bcfce0c4-5903-4658-8bf2-bac4112d9bcd"
      unitRef="usd">3222000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <pgen:NumberOfRelatedPartiesWithTerminatedAgreements
      contextRef="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzQzOTgwNDY1Mzc3MTY_be50a0c3-0a44-4d5b-9ca2-f4250123df5e"
      unitRef="relatedparty">3</pgen:NumberOfRelatedPartiesWithTerminatedAgreements>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic159581ac2ca410d9e3b9a4af1197197_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTAvZnJhZzo1ZmZiYTQ5ZjRjODM0ZjRlOGMyM2FmNGUyMWMxMzFiYS90ZXh0cmVnaW9uOjVmZmJhNDlmNGM4MzRmNGU4YzIzYWY0ZTIxYzEzMWJhXzgwODQ_1f0fe52f-af5d-4078-bf37-db5d74f25320"
      unitRef="usd">11877000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM0Ng_82d7cc53-93d2-4d13-a6b9-4806ddabda87">Net Loss per Share&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Historical net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,065,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,138,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,521,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities as of December&#160;31, 2020, 2019, and 2018, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,732,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,323,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,955,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,093,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,849,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,260,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,152,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM0OA_08e90cd4-2b94-4b48-9f54-7a2543a79884">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Historical net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(375,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,065,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,138,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,521,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtMS0xLTEtMA_b1400f56-e09b-41e7-8770-dacc69fd6003"
      unitRef="usd">-103773000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtMy0xLTEtMA_9dd64c9e-4aa8-4e6c-8db2-4b394eb7a802"
      unitRef="usd">-168742000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzMtNS0xLTEtMA_3fce35f9-5d9d-4ed8-b60f-77b855d3514b"
      unitRef="usd">-375117000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtMS0xLTEtMA_cdc12911-e812-456e-8fc9-be02a9f5a509"
      unitRef="usd">-66748000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtMy0xLTEtMA_8ec48dd0-7024-4dc7-9011-d9f32e4e0b7b"
      unitRef="usd">-153582000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzQtNS0xLTEtMA_fb7ace54-bdf6-4920-ab72-72dabca9127e"
      unitRef="usd">-134219000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtMS0xLTEtMA_0ab1be1e-50ae-48ee-bf0e-5da5f27d2620"
      unitRef="usd">-170521000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtMy0xLTEtMA_77db2edd-2ebd-4d02-a68f-ff1de72109a5"
      unitRef="usd">-322324000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzUtNS0xLTEtMA_c062ff8a-1b0c-42ff-aa5a-10a11ca6d134"
      unitRef="usd">-509336000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctMS0xLTEtMA_df60ff1e-2c01-4bd2-92d0-ed302bed3ae6"
      unitRef="shares">167065539</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctMy0xLTEtMA_b60169f8-e34b-46b2-8ff1-fd7fac0ceb04"
      unitRef="shares">154138774</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzctNS0xLTEtMA_25002fea-aa4a-44b2-a54b-6222b4bdae33"
      unitRef="shares">129521731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktMS0xLTEtMA_4569b10c-1d67-4976-b20b-d84667da1f25"
      unitRef="usdPerShare">-0.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktMy0xLTEtMA_53c4a1a9-e3fa-48aa-ad9c-5e556203fc0a"
      unitRef="usdPerShare">-1.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzktNS0xLTEtMA_f44ff83e-1398-4b0f-b39d-c5d3fc8ec0d2"
      unitRef="usdPerShare">-2.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTEtMS0xLTA_f6ed29ef-633d-46d1-ab2c-d99d0c7da69e"
      unitRef="usdPerShare">-0.40</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTMtMS0xLTA_c4a5b6a7-f4e0-4f32-8f0b-34a0450fd99d"
      unitRef="usdPerShare">-1.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzEwLTUtMS0xLTA_ed638410-162f-4f7a-bfe7-448569e06ad7"
      unitRef="usdPerShare">-1.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTEtMS0xLTA_0a6a0710-bf46-4eac-ba05-4117f8f841d1"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTMtMS0xLTA_fee5bcc3-e979-4473-8251-b48a5ecd956c"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTozODk5ZDY0MTM2MTI0NDA3YjI3N2YwNmEyYWVmZTdhMC90YWJsZXJhbmdlOjM4OTlkNjQxMzYxMjQ0MDdiMjc3ZjA2YTJhZWZlN2EwXzExLTUtMS0xLTA_a404e5eb-c566-4f36-9269-94531a897100"
      unitRef="usdPerShare">-3.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90ZXh0cmVnaW9uOjEwNmRkYWY4NjI3MjQyODE5Y2EzMGFjMTAxYTJiMjQ2XzM2NA_2ce05e3c-65b9-4f2a-b79e-013a3b3d0ae4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities as of December&#160;31, 2020, 2019, and 2018, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,732,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,323,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,955,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,255,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,022,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,093,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,849,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,260,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,152,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3f3e239ae20c45c7b7aaf57a9b6cf875_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItMS0xLTEtMA_e2567761-d4ae-4209-a809-cd37e605839a"
      unitRef="shares">11732440</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b50be6f05c0474e83a58face9d3645c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItMy0xLTEtMA_3befa157-0a21-4a8f-a5cf-87d279267646"
      unitRef="shares">21323068</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c1e80d080904677b59656be2a1b40b2_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzItNS0xLTEtMA_7ab311a4-3565-4462-9ebc-265317b862ca"
      unitRef="shares">18955668</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f71aeaa143c4b289ab59dfbe54174aa_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtMS0xLTEtMA_308df600-4ded-4432-9038-37894077a762"
      unitRef="shares">11255896</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib379ad98b2cb45daaf83b5b7a21cc98e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtMy0xLTEtMA_0f3cc204-ddec-41db-a25d-412011b07a96"
      unitRef="shares">9022282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7adb4d0947454afaa177f45a75cc9d60_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzMtNS0xLTEtMA_55382cc5-9208-4f3c-a3d0-890bd0197253"
      unitRef="shares">11093063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i27fb0d7ad0b6498ea08417bed7233684_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtMS0xLTEtMA_c6dd9b65-7b7a-42cf-9030-a6772db46d64"
      unitRef="shares">1727712</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2017226d1f364332a399d4d0f2c037e2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtMy0xLTEtMA_88a80284-501a-474d-b804-c6d59491bb4f"
      unitRef="shares">1781982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie0ee46d4ad6348e8955c1243244ba4e8_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzQtNS0xLTEtMA_be1589d0-1ca6-43e7-b79a-20c307d8e120"
      unitRef="shares">970341</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife7c17ddfd9e4cfe8f7cfcc1d3d89d94_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtMS0xLTEtMA_0c5b0a49-a0f3-42a9-9f6a-8470854ad8a1"
      unitRef="shares">133264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc1d30c65b074157a537d57ad73c2775_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtMy0xLTEtMA_48c1f48b-74cb-493c-ba7c-5b94914763a7"
      unitRef="shares">133264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2c9e1d13159420db631b851192aed69_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzUtNS0xLTEtMA_eb8f8d2a-0a15-4e19-b06d-3eafca3076e3"
      unitRef="shares">133264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtMS0xLTEtMA_427196c7-fd52-45a7-9e82-2227a70a6b51"
      unitRef="shares">24849312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtMy0xLTEtMA_6ccc89f6-face-45a3-8b6d-b4e804973ab1"
      unitRef="shares">32260596</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTMvZnJhZzoxMDZkZGFmODYyNzI0MjgxOWNhMzBhYzEwMWEyYjI0Ni90YWJsZTpiZjc4YTU0OTQ1NDA0MmJjYWJiNWJhNWMwYmE4YWZjZi90YWJsZXJhbmdlOmJmNzhhNTQ5NDU0MDQyYmNhYmI1YmE1YzBiYThhZmNmXzYtNS0xLTEtMA_1403d502-a7e2-4c08-8387-ae29dc9e2127"
      unitRef="shares">31152336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTY_84ffd0d2-3e2d-4506-87ec-5e9413096606">Segments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company realigned its business in April 2019, and as a result, its CODM began regularly reviewing disaggregated financial information for various operating segments. The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise.&#160;The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the year ended December 31, 2020, the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. The Company also excluded noncash losses associated with settlement agreements. Segment Adjusted EBITDA for the years ended December 31, 2019 and 2018, were not impacted by these changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results.&#160;The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment.&#160;Corporate expenses are not allocated to the segments and are managed at a consolidated level.&#160;The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed.&#160;The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December&#160;31, 2020. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which in 2020 and 2019 included the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Castle Creek (Note 6). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reallocations from changes to reporting units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles total segment revenues from reportable segments to total consolidated revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenues from reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues, including from other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remove cash paid for capital expenditures and investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add recognition of previously deferred revenue associated with upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reacquisition of in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment related to accrued bonuses paid in equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated net loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company had $5,908 and $6,724, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $595, $1,401, and $6,255 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTQ_82e675f9-ec37-45c9-8875-d084a09cfed6">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information by reportable segment was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reallocations from changes to reporting units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PGEN Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ActoBio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Trans Ova&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Human Biotherapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Goodwill
      contextRef="i8404b30334554a8282ddc4963025afb9_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMS0xLTEtMA_876a4e0b-4761-441b-be6c-87b8949050ae"
      unitRef="usd">15232000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if11002969f3e4f0b9cad7acc95c9688d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMy0xLTEtMA_e6aa2ca0-5b56-4d6a-a48c-6d4afa67b0f4"
      unitRef="usd">1788000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i816e511c14e944e784ccf02ef49dcfc1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItNy0xLTEtMA_182d20a1-dfd3-4bb4-92f3-28438aea252d"
      unitRef="usd">46236000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6adeb8393ffb4cd9af54545b7f666403_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItOS0xLTEtMjExNA_f0f7bf32-1024-44a2-8a66-50dfc5293041"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i416c63b209e448e4a1691314a0e720fc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItOS0xLTEtMA_2e2299e1-8749-4e7f-91f6-85b89df00fcb"
      unitRef="usd">20736000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2de8331b876d4b82921c05eee138928f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzItMTEtMS0xLTA_8eb70488-373d-46b5-a675-6e469df30d0f"
      unitRef="usd">83992000</us-gaap:Goodwill>
    <us-gaap:GoodwillTransfers
      contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMS0xLTEtMA_1d4f7cff-d727-466e-b47e-c6dc932fabd8"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMy0xLTEtMA_77a37129-4c62-4211-b42f-99fb00dd7de4"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtNy0xLTEtMA_a3717ad2-da7c-43ab-82fc-b970b0201957"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtOS0xLTEtMjExNA_746a0dc9-eab5-4078-bff1-af48ac8edf68"
      unitRef="usd">482000</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtOS0xLTEtMA_0025137f-20fe-4c85-bf62-8de8537ffdcc"
      unitRef="usd">-482000</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzMtMTEtMS0xLTA_969aed6b-6c2c-4702-b781-f6d89bbe287c"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMS0xLTEtMA_6cc370f3-087d-4705-bc51-c903d0d15fe1"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMy0xLTEtMA_68e4c07f-7b34-4917-89dc-7621fae9aec8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtNy0xLTEtMA_06c18b64-f4fd-4893-8335-96247c81d106"
      unitRef="usd">29642000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtOS0xLTEtMjExNA_5f452505-1dcc-47db-a022-a1f80a79c103"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtOS0xLTEtMA_a852a676-b17a-426f-a80e-968eaeb632e8"
      unitRef="usd">178000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzQtMTEtMS0xLTA_530fce25-691c-4f55-8f8d-08a58347b8bf"
      unitRef="usd">29820000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMS0xLTEtMA_5ad1bfc2-8456-461c-a6c1-6e1dc661dffd"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMy0xLTEtMA_139b5a68-660c-467d-8f04-f517a91d8894"
      unitRef="usd">-53000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtNy0xLTEtMA_38597be2-8627-448f-9197-4c35934dcf5e"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtOS0xLTEtMjExNA_ddf175a0-4f11-4d64-8c9a-31989008c5b1"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtOS0xLTEtMA_d9ed2c0f-aef4-46d6-b56c-6ff9c4c8db6d"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzUtMTEtMS0xLTA_8b55caa3-ae3c-4cf7-906b-39815afb3229"
      unitRef="usd">-53000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i7f84542b3ea54137a7e7be5308c1f271_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMS0xLTEtMA_ffa7b89c-a730-40eb-9982-3cae30a44b3c"
      unitRef="usd">15232000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i49361cac902b4125a327a91917c78be8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMy0xLTEtMA_5e466d5d-0569-4223-a881-bdba3e319034"
      unitRef="usd">1735000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if87036dbc7d542818b7d1e05ad396f7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtNy0xLTEtMA_f5f07d0c-b19c-43d3-9b48-a810e0d55be5"
      unitRef="usd">16594000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3efccfc60d644e148ff53a1aea8fb101_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtOS0xLTEtMjExNA_a58402a3-0859-4333-b972-c2f551d710bc"
      unitRef="usd">482000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic65e43c5c8a9408d98dae73506aec312_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtOS0xLTEtMA_6ee71cbb-786f-4441-a1d0-8668b6af3982"
      unitRef="usd">20076000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i142de93e903443e4ab31cfa896a0f6c4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzYtMTEtMS0xLTA_aec6ccda-5031-40ca-a531-357759ba0e00"
      unitRef="usd">54119000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMS0xLTEtMA_460c5568-d043-4671-91a7-fbbfbf641431"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMy0xLTEtMA_b49ecfbb-7289-4f25-8639-093befbc521b"
      unitRef="usd">244000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktNy0xLTEtMA_629a2740-e98a-4792-8e49-760333afa5a1"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktOS0xLTEtMjExNA_82366c4e-2225-4a71-98a8-b4cccf641d8e"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktOS0xLTEtMA_b3f0c704-ba5c-40c6-922a-e3d3f975270f"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzktMTEtMS0xLTA_8b9a6788-d168-419a-86d4-9eb0a71bdcfc"
      unitRef="usd">244000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ia05ba222657c4da3a7946904d64b7cda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTEtMS0xLTA_aab2c48d-523a-4a37-a7c1-85a4628e2d26"
      unitRef="usd">15232000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i45928d9759c446fd8135abd8ae21531c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTMtMS0xLTA_9e1bb648-f445-4a89-8f53-4a4f63024b2b"
      unitRef="usd">1979000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic4c851ce2bf04d2d8ee0ae2363c3095c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTctMS0xLTA_c6d0c973-d6c4-4cc6-90df-f5e76da99bbd"
      unitRef="usd">16594000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if6efc76794cd4f70892c233dfb405b21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTktMS0xLTIxMTQ_e95e7867-1476-482b-98e9-9e02559a94f8"
      unitRef="usd">482000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iec754f7c8fe345e9a691b4617bc583a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTktMS0xLTA_cb08bb9e-b8ad-4ff8-b209-e65e147fc6a5"
      unitRef="usd">20076000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1856a6ee6ec445a2a3d19b2ec22d5c69_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZToxZTA0YmVkZWRkYTE0NWJhOWVkY2ZhMDcwNmU2MTQxZC90YWJsZXJhbmdlOjFlMDRiZWRlZGRhMTQ1YmE5ZWRjZmEwNzA2ZTYxNDFkXzEwLTExLTEtMS0w_902ffa46-7a8d-4382-a9d0-8e8dde38d08a"
      unitRef="usd">54363000</us-gaap:Goodwill>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMS0xLTEtMA_db7749d9-6ce5-4d30-a957-90813c3dee7e"
      unitRef="usd">776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMy0xLTEtMA_9b5220db-2bf6-4ff4-aebb-54ecb8911169"
      unitRef="usd">3053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItNy0xLTEtMA_0c610d13-2385-4a2e-8118-27d1c2230db9"
      unitRef="usd">71186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItOS0xLTEtMjEzMQ_208b88c3-cb7b-48c1-bf47-0661568aecfc"
      unitRef="usd">17810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItOS0xLTEtMA_8ab3617f-bedd-446f-a531-119a71eb4410"
      unitRef="usd">10299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzItMTEtMS0xLTA_4b25f295-843a-4297-a68f-1f425004a237"
      unitRef="usd">103124000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i6153d68f9fcc4906bd9e9cd50a4813d6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMS0xLTEtMA_87df99a6-17a0-4e62-ba66-680a0b580446"
      unitRef="usd">5006000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ab2a93de6ee44cf97247286fbd7e13b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMy0xLTEtMA_82721c36-e4d7-4aa5-a617-f48076e32409"
      unitRef="usd">-3000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04441decbc7f413abc71cd43fc461da1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtNy0xLTEtMA_141fae14-b366-436b-bab9-2d6dcbe10d3b"
      unitRef="usd">340000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d4ba24eafed49019e6ec63aabe7a182_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtOS0xLTEtMjEzMQ_31b66241-f2a5-4659-9156-198e82b0f058"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1adcf1f7e2814c5a98b167b18ede27d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtOS0xLTEtMA_3025143a-27b5-42c6-874d-5c2974723b33"
      unitRef="usd">281000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57be64036b41497caa88c720697751d4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzMtMTEtMS0xLTA_377a902d-70f5-45af-bd81-30c3968e9b34"
      unitRef="usd">5624000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4198bf6d0ee54ee08f65f72c1bc10f37_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMS0xLTEtMA_817521dd-d2a4-469a-9370-2e579b617984"
      unitRef="usd">5782000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7b4d7a15f68406a8eb2aa3b847a4815_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMy0xLTEtMA_162755cd-778f-47bf-8dca-1dc7e3375e4d"
      unitRef="usd">3050000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83f8768c6659485e9a282f66acec95f0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtNy0xLTEtMA_8a155fef-b3e4-415b-beb4-aed18c577bbe"
      unitRef="usd">71526000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb84bd71d814449b98a10354224cd024_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtOS0xLTEtMjEzMQ_6f156b0c-decf-4561-b5d1-fd0dae92c65f"
      unitRef="usd">17810000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90a47d7236aa4aa9bf29fc31df5ebcae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtOS0xLTEtMA_4b0e7cc2-caad-48bd-90fd-6269ef4bc02f"
      unitRef="usd">10580000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzQtMTEtMS0xLTA_926bd9a5-8338-4039-a3fd-2679f384df1f"
      unitRef="usd">108748000</us-gaap:Revenues>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i74c2727e865d423586be763a463a4aeb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMS0xLTEtMA_c9c686ac-3f05-4a32-bce2-d9793c4d63ff"
      unitRef="usd">-25611000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="idadd9097495e4bc7a7045a8c4457de90_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMy0xLTEtMA_65fad4e5-2429-4404-82d0-4e17b89f891c"
      unitRef="usd">-7861000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="ifafa1b4c69804dfd96a439a35168dfc0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtNy0xLTEtMA_4cdca778-07f0-4aa5-bbe8-d9d8c8b84909"
      unitRef="usd">2624000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i3d3a6d84abe14c848540902462585373_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtOS0xLTEtMjEzMQ_24657508-632a-45df-a653-cef3f453a51e"
      unitRef="usd">-2139000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtOS0xLTEtMA_891033cb-7a33-4ceb-8678-541da5e3b4cb"
      unitRef="usd">4274000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo5OTgxMDM3ZTA4YjM0N2U2ODY0MDFiOGU4ODhmNGYxOC90YWJsZXJhbmdlOjk5ODEwMzdlMDhiMzQ3ZTY4NjQwMWI4ZTg4OGY0ZjE4XzYtMTEtMS0xLTA_6c6d1b29-46e4-4182-acdb-8f907ad109eb"
      unitRef="usd">-28713000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMS0xLTEtMA_b8c0b7aa-d9ec-4c0e-9e3d-1d1d29fb2fdd"
      unitRef="usd">2227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMy0xLTEtMA_9a6c683b-68a5-46b5-8f28-0c47d0a6c89f"
      unitRef="usd">-364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItNy0xLTEtMA_00f0e0ec-0440-481c-b7c6-bfc0aa0cbb24"
      unitRef="usd">68672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItOS0xLTEtMjE0Ng_4f922186-ea81-429c-b326-eff607c86730"
      unitRef="usd">3713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItOS0xLTEtMA_082eb1ee-8ed8-419a-af8f-3dced4a0a3df"
      unitRef="usd">12514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzItMTEtMS0xLTA_46553483-a2f3-4720-81c7-6916aa0828e7"
      unitRef="usd">86762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia3b2a762b98949cc80b92e79db724b1c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMS0xLTEtMA_17bdbdee-81f7-4347-a62d-43ca9ceb6658"
      unitRef="usd">11341000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc7bed861874412b9f1e982a3d5b7883_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMy0xLTEtMA_4322c66e-377d-4ced-a778-61653e307299"
      unitRef="usd">498000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7b5d19dccb34749ad0bdd8bddb68e52_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtNy0xLTEtMA_bf4334b9-2ce5-41bc-ad5c-49150e2c1acb"
      unitRef="usd">1361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic62d85ceb878414ab0381b19dae2d6e9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtOS0xLTEtMjE0Ng_c0cdd07b-0eb3-4fb6-b335-f0c23923259e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia50dbf2c0e31425c97e6391b41ca69ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtOS0xLTEtMA_0d2ef95e-0f52-49fe-b2a0-f151afd96422"
      unitRef="usd">1270000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzMtMTEtMS0xLTA_c23d1f9a-992e-4663-81c6-c91cf16adc7a"
      unitRef="usd">14470000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6b8cdaa4edf4feb8836cbc73e4095c7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMS0xLTEtMA_b621e97a-5b2e-4e82-8d7e-1953a2bed513"
      unitRef="usd">13568000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59e12b992e454f1c8320786f7fcdb74f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMy0xLTEtMA_9f3b8a81-7e94-43bf-921f-afe8e8d1b7f6"
      unitRef="usd">134000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6840d803ae85450585357ec60a8ed876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtNy0xLTEtMA_dbb0fef1-df28-4f24-9a43-0aebfacf87c9"
      unitRef="usd">70033000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30579e6277e34fcab7a39f1c4b82532c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtOS0xLTEtMjE0Ng_8a6d25d8-869b-497f-a5a2-babbd0db8678"
      unitRef="usd">3713000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1df9a023b9954b1c9ea3dcd6d528e91d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtOS0xLTEtMA_676344af-6179-4c28-be6e-96c4b55027a8"
      unitRef="usd">13784000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzQtMTEtMS0xLTA_563dbfe6-1c80-4aa4-b446-03a8ec678cf8"
      unitRef="usd">101232000</us-gaap:Revenues>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i163a14083d2840e7b31ad5dfcf65b399_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMS0xLTEtMA_1892aadb-42a5-4008-9e19-99272a561982"
      unitRef="usd">-30164000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i736231a7920a4f7da29a6de5b917aa57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMy0xLTEtMA_44260a92-2899-42f6-af91-f171068aba67"
      unitRef="usd">-13662000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i4c8af51757604f2888eb3d26248d34ff_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtNy0xLTEtMA_35ae4a4e-c6c7-48e6-a65d-39ff280b60b4"
      unitRef="usd">-6337000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="icfdd8a57941e4059a00f31f76dafd79e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtOS0xLTEtMjE0Ng_d5853d92-0aa9-410e-8187-2682c01d4bab"
      unitRef="usd">-1051000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtOS0xLTEtMA_3eaf5bdf-3165-4aef-b628-e3cceaad68b7"
      unitRef="usd">-4901000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTpkOWQ1ZTIwZmI5NmQ0YjRlOWVlMDFhY2IwM2Y3NTEyOC90YWJsZXJhbmdlOmQ5ZDVlMjBmYjk2ZDRiNGU5ZWUwMWFjYjAzZjc1MTI4XzYtMTEtMS0xLTA_fa9c8ff8-b6c9-4c96-822b-d7d77d4c6f3a"
      unitRef="usd">-56115000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMS0xLTEtMA_75ace042-1636-4827-a412-96b8b533abdd"
      unitRef="usd">29021000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMy0xLTEtMA_892d9cb7-4929-445f-be4c-f8cfe1f4310a"
      unitRef="usd">6684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItNy0xLTEtMA_6b42d826-fb84-465e-89fa-8015c9ee5900"
      unitRef="usd">75178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItOS0xLTEtMjE2MQ_57a001b2-a883-43e4-899e-d871f4790221"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItOS0xLTEtMA_438c0527-94a6-4b73-b88c-3439dbe2a262"
      unitRef="usd">30213000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzItMTEtMS0xLTA_4a4f7b9d-f5c6-43de-8d20-5b54578bf212"
      unitRef="usd">141096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ie213b50bea4c453b9fc821145579a6d8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMS0xLTEtMA_a6c97f61-55d5-4ae6-9a9f-b4fe20167ad6"
      unitRef="usd">617000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2eda440ff9e84b8aab723bc6229cafb9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMy0xLTEtMA_097fb054-50b4-4d24-9057-0c20116a274a"
      unitRef="usd">840000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa651b05eb6d42d7956529f80d128fb4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtNy0xLTEtMA_f4d8f10b-95b0-4cd9-8cb9-7ac10f608370"
      unitRef="usd">558000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ada1cfca67342dbb51b59cb99e04067_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtOS0xLTEtMjE2MQ_61114d2d-dc25-4dcb-9b85-2d0c48922621"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if943aa72ff3a4b8ba9787819a93ee378_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtOS0xLTEtMA_4c7e3b88-7895-4a13-9009-6592430afc28"
      unitRef="usd">255000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzMtMTEtMS0xLTA_0027dfc7-3559-4968-a9ab-17756f9f8839"
      unitRef="usd">2270000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45fab86640804eebb69e48a3328ee0da_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMS0xLTEtMA_c3352b14-468e-4c32-a4b3-8687a827a654"
      unitRef="usd">29638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b1ee44af5b843c5a39a4562d6c4bf85_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMy0xLTEtMA_c9844665-f622-4d8f-ad9d-a6607482895f"
      unitRef="usd">7524000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0080f2f69e14454fa7363472c5d1d038_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtNy0xLTEtMA_246d1864-60d4-4652-83ae-53cb02fbdd5f"
      unitRef="usd">75736000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i092abaa40b2f4de59a37d96e019fefa9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtOS0xLTEtMjE2MQ_3b1be7f1-fb7a-4e5a-bb73-00aa9977ea92"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia49447d0847941cb8500f29ce34bf906_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtOS0xLTEtMA_b3158340-6731-4aa5-b7b0-184a7724b68d"
      unitRef="usd">30468000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzQtMTEtMS0xLTA_8da398f4-8bf2-4dce-9579-9fe413fe081a"
      unitRef="usd">143366000</us-gaap:Revenues>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="ia4927248b8114f8fa633cd593f9b134d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMS0xLTEtMA_1779f91a-0539-4b9c-b321-bcf6176abb8d"
      unitRef="usd">-32832000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i67ad89a96f44459196c39386869a91e4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMy0xLTEtMA_650521fe-4246-4166-9732-2bab415b93f0"
      unitRef="usd">-12797000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i8b87aa4811c44854b9ddc4b70159d6f6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtNy0xLTEtMA_50d0f094-e7c4-4b67-a49e-2382d8859cd7"
      unitRef="usd">-5730000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i2f203cb6a2c84a37a5bda3f93b68e7a3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtOS0xLTEtMjE2MQ_cd92a4c5-6c51-4be7-a622-53c40395d37b"
      unitRef="usd">0</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtOS0xLTEtMA_9f3bf82c-d6da-4060-a540-2797df00ffa1"
      unitRef="usd">-10708000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo3ODg5MDRiNjA4MDQ0NTczYmVhNTAxZGVhMjg1MjBjOS90YWJsZXJhbmdlOjc4ODkwNGI2MDgwNDQ1NzNiZWE1MDFkZWEyODUyMGM5XzYtMTEtMS0xLTA_23c9135c-6808-499c-9173-c29bd31a5375"
      unitRef="usd">-62067000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzM0MTU_c0a0b9fd-5d7e-42c3-84a1-f46550ec5751">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles total segment revenues from reportable segments to total consolidated revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenues from reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues, including from other operating segments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consolidated revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment Adjusted EBITDA for reportable segments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All Other Segment Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remove cash paid for capital expenditures and investments in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add recognition of previously deferred revenue associated with upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reacquisition of in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustment related to accrued bonuses paid in equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net loss of affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consolidated net loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItMS0xLTEtMA_5d546549-87cb-4b78-a011-ee29ce46af64"
      unitRef="usd">98168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItMy0xLTEtMA_ae8fb1d3-3843-4c22-a93b-cb7d5cedb0de"
      unitRef="usd">87448000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzItNS0xLTEtMA_9a385f0b-3866-45f2-8efb-59d2485740b1"
      unitRef="usd">112898000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d70b9845a5b44eb94cdadc203be4f74_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtMS0xLTEtMA_af301417-5180-4f2e-b136-20b40be43864"
      unitRef="usd">10634000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27fd320c35794ded9d690fc67a61ee36_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtMy0xLTEtMA_dfd539f1-3caa-4c18-955f-c34f086ebd08"
      unitRef="usd">17964000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd6609bfdc1f48b586a5b70a92a8e8ff_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzMtNS0xLTEtMA_91da869f-c10d-4c5b-91df-f1b02e597c30"
      unitRef="usd">40841000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4962cdf48204222844e9ce74fd74c3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtMS0xLTEtMA_c0ac12ff-8f15-467b-a3bd-f68715312459"
      unitRef="usd">-5624000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic93fa25606544244a088b1c2b2a76bc8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtMy0xLTEtMA_70495894-9e2a-4de2-8e89-01dc02fdd329"
      unitRef="usd">-14690000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f9dcf0952c04e27a75572dcc547c1e7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzQtNS0xLTEtMA_539704c7-255a-4e01-8cd6-73b37918b13b"
      unitRef="usd">-2561000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtMS0xLTEtMA_5c071077-5eaf-4538-998f-6059f3ffa956"
      unitRef="usd">103178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtMy0xLTEtMA_9cda1038-940c-47cd-bf16-3d86ab5be427"
      unitRef="usd">90722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2MzZiZjJlMmY2NGY0MTkyYjYwMGZlOWQ1ZTI0NDlkYS90YWJsZXJhbmdlOjYzNmJmMmUyZjY0ZjQxOTJiNjAwZmU5ZDVlMjQ0OWRhXzUtNS0xLTEtMA_e389f3bb-8f3f-4e2a-95b7-91d668dcb742"
      unitRef="usd">151178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="if735649b0eea4bdf9f11f744e5c88fde_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItMS0xLTEtMA_832cdc3a-d8dc-4f68-a3e5-dd9e547004bb"
      unitRef="usd">-32987000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i3f082d7aa2214556b2adde8d4175a6a9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItMy0xLTEtMA_11db10a5-b545-4131-9899-38bb39138b36"
      unitRef="usd">-51214000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="ibabe827116f34842b8aa68bc363aa892_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzItNS0xLTEtMA_003390eb-5805-465c-8797-69a6d23d46ed"
      unitRef="usd">-51359000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="id2880dafa664482fa9e45d1be0a122ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtMS0xLTEtMA_25e63e31-06c4-42e8-9f86-e34841849df5"
      unitRef="usd">4274000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i5dceb5c6a8924410bcb2fa8cbcb78395_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtMy0xLTEtMA_fdb7ba83-d40f-4929-b0a0-730e2aff00b4"
      unitRef="usd">-4901000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates
      contextRef="i0a6cb33f90db4c209fdbf8e715a608b8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzMtNS0xLTEtMA_a8337878-cd84-4a05-87cc-2f3daad03d36"
      unitRef="usd">-10708000</pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates>
    <pgen:CapitalExpendituresAndInvestmentsinAffiliates
      contextRef="i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtMS0xLTEtMA_72ca49f4-5529-4875-a8ff-0369c33075e4"
      unitRef="usd">6970000</pgen:CapitalExpendituresAndInvestmentsinAffiliates>
    <pgen:CapitalExpendituresAndInvestmentsinAffiliates
      contextRef="i400e4392bba74e7b9bb28ba96bada78e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtMy0xLTEtMA_fdcd9574-7181-4c3d-87b6-8b3cc0c26880"
      unitRef="usd">12512000</pgen:CapitalExpendituresAndInvestmentsinAffiliates>
    <pgen:CapitalExpendituresAndInvestmentsinAffiliates
      contextRef="ie899dcdca5994b48a3a6b8a07148c1be_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzQtNS0xLTEtMA_05470cbb-7353-4f61-8c26-7feeafccdec3"
      unitRef="usd">15276000</pgen:CapitalExpendituresAndInvestmentsinAffiliates>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i5e2c484ec2494489bb341fdba607cadb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtMS0xLTEtMA_55b8ae6b-5477-4e77-915b-91ac72689877"
      unitRef="usd">25005000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i71de56fffeb14a6988696974ced53186_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtMy0xLTEtMA_48ba4145-9d0b-43e8-94f4-ab347c9f1f59"
      unitRef="usd">14721000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i714a0770b5544bb98754740acc834259_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzUtNS0xLTEtMA_239554be-4a65-4f7d-9954-985fbe046b26"
      unitRef="usd">33204000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InterestExpense
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctMS0xLTEtMA_ae069b32-f5eb-4f82-974d-aaefdfdfa0f0"
      unitRef="usd">18400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctMy0xLTEtMA_c5134473-7c3e-4fd1-9ce2-d19122f56fb5"
      unitRef="usd">17666000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzctNS0xLTEtMA_48783402-f47c-41d0-a9eb-c107ad6dcc8b"
      unitRef="usd">8473000</us-gaap:InterestExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtMS0xLTEtMA_e88e7d33-18ce-4994-8fa7-22bdc6d5d76e"
      unitRef="usd">15042000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtMy0xLTEtMA_7375de71-4f1e-4100-869d-5806be7deb87"
      unitRef="usd">16142000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzgtNS0xLTEtMA_d02c146b-9559-4951-8c80-9916317b52ea"
      unitRef="usd">20612000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktMS0xLTEtMA_81fb0f98-4d04-4303-a788-3c739f76d3ce"
      unitRef="usd">920000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktMy0xLTEtMA_b37342de-80b8-4f0c-a1d5-963b6a9d3c01"
      unitRef="usd">30810000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzktNS0xLTEtMA_2deacb4a-e5bf-48d1-9197-0c3a2ad346fe"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTEtMS0xLTA_2c08456e-16d4-493b-babd-ee6c4b17eb44"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTMtMS0xLTA_d46cdf9e-5671-48ec-8bd1-342157d6a1c6"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEwLTUtMS0xLTA_2825e40a-7d1b-4e0b-8e98-76ea79a343b6"
      unitRef="usd">236748000</us-gaap:ResearchAndDevelopmentInProcess>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTEtMS0xLTM4NDk_e2f89ab3-500e-4827-b3a1-5c37bcb746ad"
      unitRef="usd">-11436000</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTMtMS0xLTM4NDk_523ef463-4aef-47f4-bf19-56b7407ebd55"
      unitRef="usd">0</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <pgen:GainLossRelatedToNoncashLitigationSettlement
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTUtMS0xLTM4NDk_d918dbc1-2a66-485f-91fb-19ab5e3095d4"
      unitRef="usd">0</pgen:GainLossRelatedToNoncashLitigationSettlement>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTEtMS0xLTA_4d068fb5-c98a-4907-8e1b-55f9fdd3ae6e"
      unitRef="usd">19746000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTMtMS0xLTA_9d19546d-3aaf-470d-9933-7a32f3b5ce74"
      unitRef="usd">15098000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzExLTUtMS0xLTA_80f4a2e9-4a64-40d6-992e-7d425d604236"
      unitRef="usd">30554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pgen:AdjustmentForBonusesPaidInEquityAwards
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTEtMS0xLTIxNzA_687c5e63-8283-4167-ada6-a06b580a3e8b"
      unitRef="usd">2833000</pgen:AdjustmentForBonusesPaidInEquityAwards>
    <pgen:AdjustmentForBonusesPaidInEquityAwards
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTMtMS0xLTIxNzA_8244a322-3ff5-4cbc-a7a0-485c0958033f"
      unitRef="usd">0</pgen:AdjustmentForBonusesPaidInEquityAwards>
    <pgen:AdjustmentForBonusesPaidInEquityAwards
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTUtMS0xLTIxNzA_355a7664-5373-4cd6-b17c-8c6f111a8cf5"
      unitRef="usd">0</pgen:AdjustmentForBonusesPaidInEquityAwards>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTEtMS0xLTA_30d35d67-cebb-4515-a715-5af5f18a1c47"
      unitRef="usd">-1138000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTMtMS0xLTA_092c7c6e-45b8-4458-9bc2-09474cea5fc5"
      unitRef="usd">-2416000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEyLTUtMS0xLTA_09a7c49a-4ae0-44f4-84be-54eb10412619"
      unitRef="usd">-8986000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i98209d97da634f4b9b2fd73d1d447f39_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTEtMS0xLTA_d9c7925e-34f9-4ca4-887b-6b44c3db3ec5"
      unitRef="usd">11000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9d6317e321384aff9fd999a306d6fc6f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTMtMS0xLTA_4076a635-b4f1-4cb5-b353-b851dc0de576"
      unitRef="usd">67000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1027610b08bc4e779c00b9b4d5e18e90_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzEzLTUtMS0xLTA_99913ad7-f8dd-42b3-aa4c-8e0eb040cbb2"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i133129ec5f3246d683d35411173d33aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTEtMS0xLTA_6a63e3cc-1801-4ddf-b4f4-811ab9019323"
      unitRef="usd">-37566000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i13c8be8caa2f46178129d4ec229adbb2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTMtMS0xLTA_6b068164-f27a-4fd4-9f3d-f719b270cc26"
      unitRef="usd">-46011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id9b2874d2bdd4deb9104cb8ea4baf8de_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE0LTUtMS0xLTA_6977f0a5-67fe-401a-9d68-ae82d327db66"
      unitRef="usd">-74609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i57be64036b41497caa88c720697751d4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTEtMS0xLTA_995098ab-524c-4989-95c8-23c0f24f9b7b"
      unitRef="usd">-5713000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9c047e9cfcfa41ad9f80dc883cf77e37_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTMtMS0xLTA_9068db8c-49d9-4b1c-b6a3-5d925feac087"
      unitRef="usd">-14306000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib641dafc945b4e3791db22c632cf45e7_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE1LTUtMS0xLTA_c29f486b-518e-4246-8a45-1d7dac22eeb5"
      unitRef="usd">-2343000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTEtMS0xLTA_fa4dd1f8-99fe-4fdc-aef5-62ac305ff197"
      unitRef="usd">-103855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTMtMS0xLTA_9eb105a7-a5e1-4f6a-9401-eed93d67b1fd"
      unitRef="usd">-171264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90YWJsZTo2ZWIzMWVjZTI3ZDY0ZTJjYmVjOWFmYzFiZWQxNDljZi90YWJsZXJhbmdlOjZlYjMxZWNlMjdkNjRlMmNiZWM5YWZjMWJlZDE0OWNmXzE2LTUtMS0xLTA_f038644e-4f21-47c7-8f3f-d56c8c22feb8"
      unitRef="usd">-395912000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets
      contextRef="i8166ea8ff5b14ea1a56f75013f866d68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMxNjA_f6c2bd85-d368-4fc8-ba37-49da05b9674f"
      unitRef="usd">5908000</pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets>
    <pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets
      contextRef="ibb6c9fa8b50d4640b4010be6ab64cc36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMxNjc_a8eb3934-34cd-409d-87b9-f01102c35308"
      unitRef="usd">6724000</pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets>
    <us-gaap:Revenues
      contextRef="id4a62b5534d74990aab59d86bee4c7e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNTI_dcf5c392-e415-4474-a013-9b5ef3991f5f"
      unitRef="usd">595000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d1a0c4bdf624f5a9be5028ebfc27876_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNTY_613613b9-ac29-4da7-8b3d-e3a0316d493e"
      unitRef="usd">1401000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e7a12392b3748ccb33c84786aaae792_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTYvZnJhZzplNzdiZThiMWQxOWY0NTYwYmNmODYzMmQxYmVmMDBjYi90ZXh0cmVnaW9uOmU3N2JlOGIxZDE5ZjQ1NjBiY2Y4NjMyZDFiZWYwMGNiXzMzNjQ_aaccf619-29fc-488d-805e-cff98266be76"
      unitRef="usd">6255000</us-gaap:Revenues>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90ZXh0cmVnaW9uOmFmNDIyZDcxYTEwYzQ4MDU5ZTM1OTdkNDlkODVlZDk5XzEwODY_6a0e2f27-7900-4e89-b80f-eb5b0bb5ef0e">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:20pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90ZXh0cmVnaW9uOmFmNDIyZDcxYTEwYzQ4MDU5ZTM1OTdkNDlkODVlZDk5XzEwOTc_710baea1-5068-430d-ba98-dba751eec8de">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:20pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Precigen per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItMS0xLTEtMA_863c5d58-13b0-439a-8f25-a9b73f7eec12"
      unitRef="usd">29838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItMy0xLTEtMA_b6f2c6b1-ba99-4113-9c85-6c2ae8d0cc2f"
      unitRef="usd">30424000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItNS0xLTEtMA_f37b20fb-3cf1-430f-9adb-2c09a4ae5a13"
      unitRef="usd">23583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzItNy0xLTEtMA_217a241a-a419-488e-9ce8-2d11f85ce23f"
      unitRef="usd">19333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtMS0xLTEtMA_712577b0-289b-4308-bd52-c215a044e603"
      unitRef="usd">-16600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtMy0xLTEtMA_fe8516c2-b57d-4fb1-bd7b-a90723e231da"
      unitRef="usd">-11830000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtNS0xLTEtMA_073e7f2a-8180-4920-ad41-11f7a024a4ec"
      unitRef="usd">-23006000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzMtNy0xLTEtMA_d6200738-635d-456d-af6d-af7758d13ee4"
      unitRef="usd">-35167000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtMS0xLTEtMA_f6c9d01e-59dc-4df1-91a4-843ce10f03f0"
      unitRef="usd">-20846000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtMy0xLTEtMA_48c49972-163c-475d-8294-51366c3b6b08"
      unitRef="usd">-15709000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtNS0xLTEtMA_a68de76d-d241-4aea-9668-aeba318b3bfb"
      unitRef="usd">-27536000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzQtNy0xLTEtMA_2b367a15-7534-4a00-a529-50cd67630879"
      unitRef="usd">-39682000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtMS0xLTEtMA_ca97d6c4-143e-4ea1-a15d-e4813b3ad2fe"
      unitRef="usd">-55998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtMy0xLTEtMA_0bddbab4-cfa8-4465-a418-f15559e2fc6d"
      unitRef="usd">-43354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtNS0xLTEtMA_7b223c98-a02a-455d-a065-95a431b252fd"
      unitRef="usd">-29508000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzUtNy0xLTEtMA_bec5c6e8-1b52-43af-ae27-d6dc08277690"
      unitRef="usd">-41661000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtMS0xLTEtMA_f99efede-65c6-4109-8b3d-2228f5f123aa"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtMy0xLTEtMA_5db781f3-d4c4-4a27-9970-11e07c4a85df"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtNS0xLTEtMA_08bc89d5-5a85-4f74-8d0b-b389731105e4"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzYtNy0xLTEtMA_e20e173c-2c3c-4bf1-bd49-a30dc6099eb1"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i9185a52cd32f4937b7dbee6052b12ec6_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctMS0xLTEtMA_82245c8b-0517-44a3-80ad-ebdef8943e7e"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i746812701b0146bdadf37bf89cc04de0_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctMy0xLTEtMA_a0c17ca1-a53e-49b4-8835-b4e0623b2424"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idbd74c417cb0493f8b8e5830950ef16b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctNS0xLTEtMA_3b3b6fd6-266e-48bd-b295-237f034a4f36"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTo3ZTQzNGRjODEwYzc0ODRlYjM0MGRiNzdmOGE3N2JlMy90YWJsZXJhbmdlOjdlNDM0ZGM4MTBjNzQ4NGViMzQwZGI3N2Y4YTc3YmUzXzctNy0xLTEtMA_6171f7d2-a388-4103-95e5-d81169308e5a"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItMS0xLTEtMA_6e135b59-99c5-4f51-a759-78150e5a70b6"
      unitRef="usd">22585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItMy0xLTEtMA_08a4f570-c567-4db7-8de5-d49aebf3c11a"
      unitRef="usd">32836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItNS0xLTEtMA_72c946c6-91ca-47d2-b952-513fdf44d889"
      unitRef="usd">18299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzItNy0xLTEtMA_ec4ddac4-f403-474a-8c85-e331bc6d1703"
      unitRef="usd">17002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtMS0xLTEtMA_9966c64b-e1b6-40f0-912a-d2a640591431"
      unitRef="usd">-41855000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtMy0xLTEtMA_6b4adced-3d79-4164-af5a-f50e376c35d7"
      unitRef="usd">-21508000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtNS0xLTEtMA_d6b49e6b-572c-4303-b611-fb62b932712d"
      unitRef="usd">-34702000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzMtNy0xLTEtMA_9f9b93a0-6eb6-4b91-9e4e-f40b9d07cb63"
      unitRef="usd">-68724000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtMS0xLTEtMA_2635eae6-cb50-4e19-a221-db03b8872301"
      unitRef="usd">-44539000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtMy0xLTEtMA_1708b554-0ea6-45cf-9a4a-fb47cf71a46c"
      unitRef="usd">-22440000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtNS0xLTEtMA_45257e0e-c089-46c8-937b-1888606db3b9"
      unitRef="usd">-39119000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzQtNy0xLTEtMA_14905d32-0417-421d-bdbf-531931261cb8"
      unitRef="usd">-64236000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtMS0xLTEtMA_0b2086aa-77c3-41e3-b04a-e71ee2f1b52c"
      unitRef="usd">-60709000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtMy0xLTEtMA_18ec40c3-ef01-45b2-87b9-1e27d07edcce"
      unitRef="usd">-38766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtNS0xLTEtMA_5f47fc9a-c0cd-4eb1-8dff-07579e1ecd15"
      unitRef="usd">-53634000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzUtNy0xLTEtMA_0c616586-bd82-4ff4-a600-b2adfb0828f5"
      unitRef="usd">-169215000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtMS0xLTEtMA_99515707-922f-4231-8b87-275e3d886dc6"
      unitRef="usdPerShare">-0.28</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtMy0xLTEtMA_c4deb10f-d7ed-451f-a4a5-56ee8e7a2637"
      unitRef="usdPerShare">-0.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtNS0xLTEtMA_c361bb69-83fc-4b84-afaa-579ac9020237"
      unitRef="usdPerShare">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzYtNy0xLTEtMA_76df87df-be4b-44af-b774-95d863199641"
      unitRef="usdPerShare">-0.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib6f9be5c0ff745da804817e2a0e3426d_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctMS0xLTEtMA_6c091756-3a35-4b80-8d0c-6cacd77fb475"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ib01d8e29be4d4b3b93b6fdc809b81285_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctMy0xLTEtMA_a08b0b56-1cf7-4871-9809-786e82ed8f40"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctNS0xLTEtMA_3d33914a-018d-4ebf-8de0-f39a0684dc12"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i564e1936099a4468b2f386769723ec16_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xOTkvZnJhZzphZjQyMmQ3MWExMGM0ODA1OWUzNTk3ZDQ5ZDg1ZWQ5OS90YWJsZTowZDk2MTc4MGQxMGM0MzQ0YjE4YWIyNTkyY2I1ZjQ0OS90YWJsZXJhbmdlOjBkOTYxNzgwZDEwYzQzNDRiMThhYjI1OTJjYjVmNDQ5XzctNy0xLTEtMA_9b768b1c-98dd-41de-97b2-e0d05e1d2855"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzM3MA_2869fcdc-d388-4986-82c4-d153bf7543e7">Defined Contribution PlansThe Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $873, $1,186 and $1,392 for the years ended December 31, 2020, 2019 and 2018, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMyMQ_e56dbd49-6e29-46f7-ac73-bc817cf05a18"
      unitRef="usd">873000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMyNQ_860af679-8745-4f70-80bb-46b1c62a89a1"
      unitRef="usd">1186000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDIvZnJhZzo5ZmVkOGM4ZmZkOWQ0YTQwYmUyOGNlOTVkYTk3MjRhYS90ZXh0cmVnaW9uOjlmZWQ4YzhmZmQ5ZDRhNDBiZTI4Y2U5NWRhOTcyNGFhXzMzMg_99423a6e-6836-4195-b7f5-3f12e6cda670"
      unitRef="usd">1392000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzU0OA_a7177bc7-62c5-44a3-9f0e-c829b69b492b">Subsequent Events&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of approximately $121,200, after deducting underwriting discounts and estimated capitalizable offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility which were originally due to expire in July 2025. The Company will record the impact of this termination as discontinued operations in the Company's consolidated financial statements during the first quarter of 2021. As of December 31, 2020, the right-of-use asset related to the lease was $9,131 and the lease liability was $13,428, which are included in current assets held for sale or abandonment and current liabilities held for sale or abandonment, respectively, in the consolidated balance sheet. Following January 2021, the Company has no further payment obligations under the lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQ4MTk_d10889dc-2f7d-48ed-972a-7f7eead1010e"
      unitRef="shares">17250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib4ab914c752c49be915c5d9265eab46b_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQ4MzE_9ecda68e-e355-4282-8628-34732bd4c7ff"
      unitRef="usd">121200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQzNzM_71772ee5-d75b-4d4c-989a-cba256541b80"
      unitRef="usd">9131000</pgen:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset>
    <pgen:DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent
      contextRef="if71c2fc0f42a444597ac62521827f72b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8yMDUvZnJhZzo4NzZmNTE3MzNiMGY0NTIwYmQzODUwYTAwYTg2MDNmOS90ZXh0cmVnaW9uOjg3NmY1MTczM2IwZjQ1MjBiZDM4NTBhMDBhODYwM2Y5XzQzOTgwNDY1MTQzODQ_6632db69-fd4b-4d86-90f1-74e59bbdfda5"
      unitRef="usd">13428000</pgen:DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164022843816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 15, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRECIGEN, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0084895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20374 Seneca Meadows Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Germantown,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">556-9900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PGEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,661,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant's Definitive Proxy Statement for its 2021 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December&#160;31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001356090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163928333864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,792<span></span>
</td>
<td class="nump">$ 65,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">9,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade, less allowance for credit losses of $4,825 and $5,201 as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">16,487<span></span>
</td>
<td class="nump">20,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related parties, less allowance for credit losses of $1,509 and $2,312 as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Notes</a></td>
<td class="nump">3,689<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">11,359<span></span>
</td>
<td class="nump">16,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">5,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets held for sale or abandonment</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="nump">111,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">148,948<span></span>
</td>
<td class="nump">234,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">34,924<span></span>
</td>
<td class="nump">43,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">65,396<span></span>
</td>
<td class="nump">68,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">54,363<span></span>
</td>
<td class="nump">54,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">9,353<span></span>
</td>
<td class="nump">11,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets held for sale or abandonment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,090<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">314,587<span></span>
</td>
<td class="nump">455,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,598<span></span>
</td>
<td class="nump">5,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">8,097<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">9,549<span></span>
</td>
<td class="nump">11,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, including $0 and $877 from related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Lines of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, including $0 and $31,211 to related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">31,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payables</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities held for sale or abandonment</a></td>
<td class="nump">14,047<span></span>
</td>
<td class="nump">50,538<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,127<span></span>
</td>
<td class="nump">122,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion, including $0 and $25,000 to related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">171,522<span></span>
</td>
<td class="nump">186,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion, including $21,205 and $30,182 from related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">23,023<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">7,744<span></span>
</td>
<td class="nump">10,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Long-term liabilities held for sale or abandonment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">247,413<span></span>
</td>
<td class="nump">384,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, no par value, 400,000,000 shares authorized as of December&#160;31, 2020 and 2019; and 187,663,207 shares and 163,274,880 shares issued and outstanding as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,886,567<span></span>
</td>
<td class="nump">1,752,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,823,390)<span></span>
</td>
<td class="num">(1,652,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="num">(27,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">67,174<span></span>
</td>
<td class="nump">71,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 314,587<span></span>
</td>
<td class="nump">$ 455,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917823880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 4,825<span></span>
</td>
<td class="nump">$ 5,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent', window );">Related party receivable, allowance for credit loss, current</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, including $0 and $31,211 to related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">31,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">171,522<span></span>
</td>
<td class="nump">186,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">$ 23,023<span></span>
</td>
<td class="nump">$ 48,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">187,663,207<span></span>
</td>
<td class="nump">163,274,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">187,663,207<span></span>
</td>
<td class="nump">163,274,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember', window );">Related Parties, Aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, including $0 and $31,211 to related parties as of December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">$ 21,205<span></span>
</td>
<td class="nump">$ 30,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Receivable, Allowance for Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920904616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 103,178<span></span>
</td>
<td class="nump">$ 90,722<span></span>
</td>
<td class="nump">$ 151,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other noncurrent assets</a></td>
<td class="nump">13,326<span></span>
</td>
<td class="nump">32,627<span></span>
</td>
<td class="nump">60,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Expense, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
<td class="num">(30,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(6,730)<span></span>
</td>
<td class="num">(11,608)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(103,855)<span></span>
</td>
<td class="num">(171,264)<span></span>
</td>
<td class="num">(395,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="nump">15,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of income tax benefit</a></td>
<td class="num">(66,748)<span></span>
</td>
<td class="num">(153,582)<span></span>
</td>
<td class="num">(134,219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(170,521)<span></span>
</td>
<td class="num">(323,916)<span></span>
</td>
<td class="num">(514,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to the noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Precigen</a></td>
<td class="num">(170,521)<span></span>
</td>
<td class="num">(322,324)<span></span>
</td>
<td class="num">(509,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts Attributable to Precigen</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations attributable to Precigen</a></td>
<td class="num">(103,773)<span></span>
</td>
<td class="num">(168,742)<span></span>
</td>
<td class="num">(375,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations attributable to Precigen</a></td>
<td class="num">(66,748)<span></span>
</td>
<td class="num">(153,582)<span></span>
</td>
<td class="num">(134,219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Precigen</a></td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="num">$ (322,324)<span></span>
</td>
<td class="num">$ (509,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (2.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">(0.40)<span></span>
</td>
<td class="num">(1.00)<span></span>
</td>
<td class="num">(1.03)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">167,065,539<span></span>
</td>
<td class="nump">154,138,774<span></span>
</td>
<td class="nump">129,521,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 21,208<span></span>
</td>
<td class="nump">$ 14,059<span></span>
</td>
<td class="nump">$ 69,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">103,178<span></span>
</td>
<td class="nump">90,722<span></span>
</td>
<td class="nump">151,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">41,644<span></span>
</td>
<td class="nump">66,666<span></span>
</td>
<td class="nump">333,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">91,704<span></span>
</td>
<td class="nump">98,634<span></span>
</td>
<td class="nump">125,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other noncurrent assets</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">189,781<span></span>
</td>
<td class="nump">257,511<span></span>
</td>
<td class="nump">520,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(86,603)<span></span>
</td>
<td class="num">(166,789)<span></span>
</td>
<td class="num">(369,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Expense, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,291<span></span>
</td>
<td class="num">(28,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,400)<span></span>
</td>
<td class="num">(17,666)<span></span>
</td>
<td class="num">(8,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest and dividend income</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">19,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(165)<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(16,114)<span></span>
</td>
<td class="num">(2,059)<span></span>
</td>
<td class="num">(17,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(2,416)<span></span>
</td>
<td class="num">(8,986)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(103,855)<span></span>
</td>
<td class="num">(171,264)<span></span>
</td>
<td class="num">(395,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="nump">15,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(103,773)<span></span>
</td>
<td class="num">(170,334)<span></span>
</td>
<td class="num">(380,487)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="nump">69,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">24,349<span></span>
</td>
<td class="nump">23,780<span></span>
</td>
<td class="nump">28,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product and services</a></td>
<td class="nump">28,550<span></span>
</td>
<td class="nump">31,930<span></span>
</td>
<td class="nump">35,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">56,899<span></span>
</td>
<td class="nump">51,803<span></span>
</td>
<td class="nump">52,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product and services</a></td>
<td class="nump">26,963<span></span>
</td>
<td class="nump">29,471<span></span>
</td>
<td class="nump">27,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163918607368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 103,178<span></span>
</td>
<td class="nump">$ 90,722<span></span>
</td>
<td class="nump">$ 151,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="nump">69,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">103,178<span></span>
</td>
<td class="nump">90,722<span></span>
</td>
<td class="nump">151,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="nump">69,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations | Collaboration and licensing agreements | Related Parties, Aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,053<span></span>
</td>
<td class="nump">$ 11,832<span></span>
</td>
<td class="nump">$ 55,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925316792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="num">$ (323,916)<span></span>
</td>
<td class="num">$ (514,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Gain (loss) on foreign currency translation adjustments</a></td>
<td class="nump">4,502<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="num">(13,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Release of cumulative foreign currency translation adjustments to net loss from discontinued operations</a></td>
<td class="nump">26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(139,056)<span></span>
</td>
<td class="num">(322,761)<span></span>
</td>
<td class="num">(527,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to the noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">5,548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Precigen</a></td>
<td class="num">$ (139,056)<span></span>
</td>
<td class="num">$ (321,180)<span></span>
</td>
<td class="num">$ (522,290)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920412664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' and Total Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect of adoption of ASC 606</div></th>
<th class="th"><div>Total Precigen Shareholders' Equity</div></th>
<th class="th">
<div>Total Precigen Shareholders' Equity </div>
<div>Cumulative effect of adoption of ASC 606</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income (Loss) </div>
<div>Cumulative effect of adoption of ASC 606</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative effect of adoption of ASC 606</div>
</th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 546,545<span></span>
</td>
<td class="nump">$ 26,507<span></span>
</td>
<td class="nump">$ 533,631<span></span>
</td>
<td class="nump">$ 26,507<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,397,005<span></span>
</td>
<td class="num">$ (15,554)<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
<td class="num">$ (847,820)<span></span>
</td>
<td class="nump">$ 26,611<span></span>
</td>
<td class="nump">$ 12,914<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,087,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">36,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as payment for services</a></td>
<td class="nump">10,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as payment for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants issued in public or private offerings, net of issuance costs</a></td>
<td class="nump">87,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares and warrants issued in public or private offerings, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt, net of issuance costs and deferred taxes</a></td>
<td class="nump">36,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OwnshareLendingArrangementSharesIssued1', window );">Shares issued pursuant to share lending agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,479,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="nump">159,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for reacquired in-process research and development, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,573,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_Adjustmentsfornoncontrollinginterests', window );">Adjustments for noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(514,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(509,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(509,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Release of cumulative translation adjustment to loss from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(13,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">378,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,722,012<span></span>
</td>
<td class="num">(28,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330,545)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,020,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants</a></td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringThePeriodValueAccruedCompensation', window );">Shares issued for accrued compensation</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation', window );">Shares issued for accrued compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as payment for services</a></td>
<td class="nump">10,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as payment for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants issued in public or private offerings, net of issuance costs</a></td>
<td class="nump">6,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_Adjustmentsfornoncontrollinginterests', window );">Adjustments for noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of subsidiary</a></td>
<td class="num">(21,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(323,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Release of cumulative translation adjustment to loss from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 71,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,752,048<span></span>
</td>
<td class="num">(27,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,652,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="nump">163,274,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,274,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards', window );">Shares issued upon vesting of restricted stock units and for exercises of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringThePeriodValueAccruedCompensation', window );">Shares issued for accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation', window );">Shares issued for accrued compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as payment for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares and warrants issued in public or private offerings, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares and warrants issued in public or private offerings, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,972,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued upon conversion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of long-term debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,051,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues', window );">Shares issued in conjunction with settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues', window );">Stock issued in conjunction with settlement agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,117,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Release of cumulative translation adjustment to loss from discontinued operations</a></td>
<td class="nump">$ 26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,886,567<span></span>
</td>
<td class="nump">$ 3,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,823,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">187,663,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,663,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_Adjustmentsfornoncontrollinginterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in noncontrolling interest balance because of current period activity, including business combinations and subsidiary equity issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_Adjustmentsfornoncontrollinginterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_OwnshareLendingArrangementSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_OwnshareLendingArrangementSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringThePeriodSharesAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringThePeriodSharesAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringThePeriodValueAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringThePeriodValueAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920899912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="num">$ (323,916)<span></span>
</td>
<td class="num">$ (514,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">17,516<span></span>
</td>
<td class="nump">24,896<span></span>
</td>
<td class="nump">33,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on abandonment and disposals of assets, net</a></td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">20,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other noncurrent assets</a></td>
<td class="nump">13,326<span></span>
</td>
<td class="nump">32,627<span></span>
</td>
<td class="nump">60,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal', window );">Gain on sale of discontinued operations</a></td>
<td class="num">(672)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="nump">26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_GainLossRelatedToNoncashLitigationSettlement', window );">Loss on settlement agreement</a></td>
<td class="nump">11,436<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(7,833)<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NoncashDividendIncome', window );">Noncash dividend income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(14,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discounts on investments, net</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">11,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">18,366<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
<td class="nump">36,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense', window );">Shares issued as payment for services</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">10,446<span></span>
</td>
<td class="nump">10,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of deferred financing costs</a></td>
<td class="nump">10,587<span></span>
</td>
<td class="nump">9,459<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(3,674)<span></span>
</td>
<td class="num">(21,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other noncash items</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">837<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivablesAbstract', window );"><strong>Receivables:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="num">(2,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Related parties</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="nump">11,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2,511<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(812)<span></span>
</td>
<td class="num">(2,262)<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(5,349)<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(789)<span></span>
</td>
<td class="nump">5,186<span></span>
</td>
<td class="nump">4,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="num">(2,682)<span></span>
</td>
<td class="num">(5,516)<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(21,045)<span></span>
</td>
<td class="nump">7,423<span></span>
</td>
<td class="num">(38,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">(995)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payables</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(585)<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,021)<span></span>
</td>
<td class="num">(135,927)<span></span>
</td>
<td class="num">(124,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(171,360)<span></span>
</td>
<td class="num">(55,073)<span></span>
</td>
<td class="num">(178,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">166,495<span></span>
</td>
<td class="nump">65,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,456<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Investments in affiliates</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,713)<span></span>
</td>
<td class="num">(16,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash from deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,244)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of investment in affiliate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CashInflowsOutflowsInAssetAcquisition', window );">Cash received in asset acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(7,527)<span></span>
</td>
<td class="num">(37,883)<span></span>
</td>
<td class="num">(41,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Proceeds from sale of assets</a></td>
<td class="nump">6,484<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of discontinued operations, net of cash sold</a></td>
<td class="nump">64,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from repayment of notes receivable</a></td>
<td class="nump">2,942<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">27,779<span></span>
</td>
<td class="nump">86,851<span></span>
</td>
<td class="num">(151,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of shares in a private placement</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet', window );">Proceeds from issuance of shares and warrants in public offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,611<span></span>
</td>
<td class="nump">87,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Advances from lines of credit</a></td>
<td class="nump">10,005<span></span>
</td>
<td class="nump">11,757<span></span>
</td>
<td class="nump">4,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of advances from lines of credit</a></td>
<td class="num">(11,927)<span></span>
</td>
<td class="num">(10,301)<span></span>
</td>
<td class="num">(4,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">219,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments of long-term debt</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ProceedsfromStockOptionsandWarrantsExercised', window );">Proceeds from stock option and warrant exercises</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">2,336<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">32,705<span></span>
</td>
<td class="nump">8,138<span></span>
</td>
<td class="nump">309,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">353<span></span>
</td>
<td class="num">(810)<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(16,184)<span></span>
</td>
<td class="num">(41,748)<span></span>
</td>
<td class="nump">34,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of year</a></td>
<td class="nump">68,434<span></span>
</td>
<td class="nump">110,182<span></span>
</td>
<td class="nump">75,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of year</a></td>
<td class="nump">52,250<span></span>
</td>
<td class="nump">68,434<span></span>
</td>
<td class="nump">110,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">7,202<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="nump">3,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Significant noncash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockReceivedAsConsiderationForCollaborationAgreements', window );">Fair value of stock received as consideration for collaboration agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedIntangibleAssets', window );">Fair value of stock issued for reacquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Fair value of stock issued upon conversion of long-term debt</a></td>
<td class="nump">56,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedSettlementAgreement', window );">Fair value of stock issued in conjunction with settlement agreement</a></td>
<td class="nump">18,103<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1', window );">Long-term debt issued to a related party in an asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_AccruedCompensationPaidinEquityAwards', window );">Accrued compensation paid in equity awards</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and other accrued liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Purchases of equipment financed through debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SaleOfAssetsIncludedInReceivables', window );">Sales of assets included in receivables</a></td>
<td class="nump">$ 4,227<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_AccruedCompensationPaidinEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation Paid in Equity Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_AccruedCompensationPaidinEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CashInflowsOutflowsInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflows (outflows) related to an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CashInflowsOutflowsInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_GainLossRelatedToNoncashLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Noncash Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_GainLossRelatedToNoncashLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NoncashDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income included in net income that results in no cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NoncashDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity (in exchange for shares of common stock) and from issuance of rights to purchase common shares at a predetermined price (usually issued together with corporate debt), net of capitalized issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ProceedsfromStockOptionsandWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received (i) from exercise of stock options granted under share-based compensation arrangement and (ii) from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ProceedsfromStockOptionsandWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_SaleOfAssetsIncludedInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Assets Included In Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_SaleOfAssetsIncludedInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense recognized for consideration of services paid in the form of stock. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued to acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued, Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockReceivedAsConsiderationForCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock received from collaborative partners as consideration for collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockReceivedAsConsiderationForCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164023999960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,792<span></span>
</td>
<td class="nump">$ 65,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents included in current assets held for sale or abandonment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 52,250<span></span>
</td>
<td class="nump">$ 68,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915769336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen, Inc. ("Precigen"), a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PGEN Therapeutics, Inc. ("PGEN Therapeutics") is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. PGEN Therapeutics is a wholly owned subsidiary of Precigen with primary operations in Maryland.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen ActoBio, Inc. ("ActoBio") is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exemplar Genetics, LLC, doing business as Precigen Exemplar ("Exemplar"), is committed to enabling the study of life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova Genetics, L.C. ("Trans Ova") and Progentus, L.C. ("Progentus"), providers of reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, Texas, Washington, and Wisconsin.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform assets to a wholly owned subsidiary, MBP Titan LLC ("MBP Titan"). MBP Titan's proprietary technology is designed to convert natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, the operation transferred to MBP Titan was an operating division within Precigen. Beginning in the second quarter of 2020, the Company suspended MBP Titan's operations and began the process to wind down MBP Titan's activities and has substantially completed the wind down by December 31, 2020. With the exception of certain assets and obligations with which the Company has a continuing involvement after the wind down, MBP Titan has been presented as discontinued operations for all periods presented. See Note 3 for further discussion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty resulting in a loss on deconsolidation of $2,648, which is included in other income, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. After deconsolidating the entity in April 2019, Precigen held its AquaBounty equity securities, which was an equity method investment that the Company accounted for using the fair value option, until October 2019 when the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party, for $21,587, resulting in the recognition of a realized gain of $7,348 which is included in unrealized and realized appreciation in fair value of equity securities and preferred stock, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, Precigen completed the sale of the majority of its non-healthcare assets and operations to an affiliate of Third Security, which are presented as discontinued operations for all periods presented. See Notes 3 and 14 for further discussion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company." </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that existing liquid assets as of December&#160;31, 2020, along with the net proceeds from the underwritten public offering in January 2021 (Note 23), will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators' product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December&#160;31, 2020, the Company incurred a net loss of $170,521 and, as of December&#160;31, 2020, had an accumulated deficit of $1,823,390. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, reduce uses of cash for operating and investing activities for non-healthcare functions, obtain regulatory approval of its product candidates, successfully commercialize its product candidates, generate revenue, meet its obligations and, ultimately, attain profitable operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the original issuance of the Company's financial statements for the year ended December 31, 2018, the Company's resources of cash, cash equivalents, and short-term investments were not sufficient to fund the Company's planned operations through one year after the date the 2018 consolidated financial statements were originally issued and accordingly, there was substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern did not include cash sources outside of the Company's direct control that management expected to be available within the twelve months following the original issuance of the 2018 consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of the original issuance of the 2018 consolidated financial statements, the Company could not ensure that it would be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it was able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, was dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that were favorable to the Company. Should the Company not have been able to secure additional funding through these means, the Company could have had to engage in any or all of the following activities: (i) shift internal investments from subsidiaries and platforms whose potential for value creation was longer-term to near-term opportunities; (ii) sell certain of its operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. The 2018 consolidated financial statements were prepared on a going concern basis and did not include any adjustments to the amounts and classification of assets and liabilities that may have been necessary in the event the Company could no longer continue as a going concern.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917064952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 has had and continues to have an extensive impact on the global health and economic environments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second half of March 2020, the Company's healthcare business began to experience delays to certain of its clinical trials as a result of COVID-19. For example, starting in March 2020, ActoBio temporarily suspended the last cohort of the Phase 1b/2a clinical trial for AG019 as a proactive measure to protect the welfare and safety of patients, caregivers, clinical site staff, its employees, and contractors. The temporary suspension of the AG019 trial was voluntary and was not related to any patient safety issues in the study. The voluntary suspension of the AG019 trial was lifted in June 2020, and the study is recruiting patients again. Additionally, from April to May 2020, enrollment of new patients in the Company's PRGN-3005 </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 trial was temporarily suspended due to a mandated hold on certain early and late-stage clinical trials at the Fred Hutchinson Cancer Research Center in Seattle that was instituted in light of the COVID-19 pandemic. The temporary suspension of the PRGN-3005 trial was not related to safety issues in the studies, and in May 2020, recruitment resumed in the PRGN-3005 Phase 1 trial. Furthermore, uncertainty regarding the duration and severity of the ongoing pandemic may adversely impact the Company's clinical as well as preclinical pipeline candidates in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of COVID-19 on these and other aspects of its business, including Trans Ova and Exemplar. Given the dynamic nature of these circumstances, the full impact of the COVID-19 pandemic on the Company's ongoing business, results of operations, and overall financial performance in future periods cannot be reasonably estimated at this time, and it could have a material adverse effect on the Company's results of operations, cash flows, and financial position, including resulting impairments to goodwill and long-lived assets and additional credit losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for further discussion of the impact of COVID-19 on MBP Titan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product and service revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December&#160;31, 2020 and 2019, the Company had research and development commitments with third parties that had not yet been incurred totaling $12,054 and $14,664, respectively. The commitments are generally cancellable by the Company at any time upon written notice.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December&#160;31, 2020 and 2019, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $30,164 and $47,238, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard&#160;&amp; Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 18 for additional discussion of certain equity securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets and liabilities;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December&#160;31, 2020, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its investments in each of its joint ventures ("JVs") and in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Notes 4 and 17 and to certain of the Company's JVs in Note 5.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company determined that certain of its collaborators and JVs were VIEs. It also determined Harvest was a VIE as of December 31, 2019. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December&#160;31, 2020 and 2019, were $0 and $1,461, respectively, which represents the Company's maximum risk of loss related to the identified VIEs. See Note 5 for discussion of the Company's future funding commitments for its significant JVs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company applies FASB Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including accounts receivable. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity in the allowance for credit losses for the years ended December&#160;31, 2020, 2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#8211;15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;23</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#8211;4</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">one</span> to fourteen years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets.&#160;The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 11 for additional discussion regarding goodwill impairment charges recorded in the years ended December 31, 2020 and 2019.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e">three</span> to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 10 for additional discussion of impairment of long-lived assets for the three years ended December 31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for the further discussion of the Convertible Notes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises. There was no impact from GILTI to the accompanying consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59%&#8211;90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58%&#8211;64%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%&#8211;59%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#8211;10.00</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%&#8211;1.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53%&#8211;2.58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33%&#8211;3.06%</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. As of December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) Trans Ova; and (iv) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. See Note 20 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 20 for further discussion of the Company's segments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model for receivables to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2020-06"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021. Early adoption is permitted but no earlier than annual periods beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917141752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MBP Titan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of market uncertainty driven by the COVID-19 pandemic and the state of the energy sector raising significant challenges for the strategic alternatives pursued by MBP Titan, beginning in the second quarter of 2020 and throughout the remainder of 2020, the Company suspended MBP Titan's operations, preserved certain of MBP Titan's intellectual property, terminated all of its personnel, and undertook steps to dispose of its other assets and obligations. The wind down of MBP Titan's activities was substantially complete by December 31, 2020, with the final disposition of certain property and equipment </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the facility operating lease occurring in January 2021. See Note 23 for further discussion of the facility operating lease. This discontinuation of operations represented the continuation of a strategic shift, that the Company commenced as part of the Transactions defined and discussed below, to becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and expenses related to the discontinued operations of MBP Titan are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the wind down of MBP Titan, certain assets and contractual obligations which were previously managed by MBP Titan continue to be managed at the Precigen corporate level. These remaining assets and contractual obligations include the Company's equity interest in and collaboration agreements with Intrexon Energy Partners and Intrexon Energy Partners II, including the associated deferred revenue remaining under each collaboration agreement (Notes 5 and 6), as well as the associated intellectual property developed by MBP Titan to date. These assets, liabilities, and related historical revenue and equity losses are included in the Company's operating results from continuing operations in the accompanying consolidated financial statements for all periods presented as a result of the Company's continuing involvement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale or abandonment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale or abandonment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of discontinued operations of MBP Titan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with TS Biotechnology Holdings, LLC and Darling Ingredients, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's non-healthcare assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities that were directly related to the subsidiaries sold:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intrexon Produce Holdings, Inc., the parent company of two companies focused on the development and sale of non-browning apples, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc.;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intrexon UK Holdings, Inc., the parent company of Oxitec Limited and its subsidiaries, which focused on biological insect solutions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ILH Holdings, Inc., a company focused on the production of certain fine chemicals focused primarily on microbial production of therapeutic compounds; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Blue Marble AgBio LLC which was formed in January 2020 and included certain agriculture biotechnology assets and operations that were previously an operating division within Precigen.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions".</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represented a strategic shift of the Company towards the Company becoming a primarily healthcare company advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. Immediately prior to the reclassification, the Company evaluated goodwill, long-lived assets, and the equity method investment included in the Transactions for impairment. The Company recorded an impairment charge of $79,396, including $58,042 and $21,354 related to goodwill and other long-lived assets, respectively, at the Okanagan, Oxitec, Fine Chemicals, and AgBio reporting units. Additionally, the Company recorded a $10,283 impairment charge for the write down of the equity method investment and related intangible assets included in the EnviroFlight Sale. These impairment charges are included in loss from discontinued operations in the accompanying consolidated statement of operations for the year ended December, 31, 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the TS Biotechnology Sale in January 2020, the cumulative foreign currency translation losses totaling $26,957 were released to earnings and included in loss from discontinued operations. See further discussion below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, current, from related parties of $1,243.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, net of current portion, from related parties of $6,836.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial results of discontinued operations related to the Transactions:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,057)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,056)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenues recognized from related parties of $436.</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,794)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,056)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,164)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,051)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,108)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,159)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $3,042.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes the impairment charge of $89,679 related to the Transactions discussed above.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,643)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,092)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,092)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $4,665.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aedes Aegypti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized and realized depreciation on equity securities and preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also see Note 14 below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for its investment in EnviroFlight using the equity method of accounting. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for certain equity securities held in one of its collaborators using the fair value option, and the collaborator was considered an equity method investment through September 30, 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,628)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,402)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where applicable, the notes to the accompanying consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Out-of-Period Adjustment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recorded an out-of-period adjustment of $26,572 to loss from discontinued operations which relates to the effect of cumulative foreign translation losses associated with the entities sold in the TS Biotechnology Sale. This charge, which is entirely noncash, should have been recorded in the year ended December 31, 2019 as an additional impairment charge included in loss from discontinued operations. There was no impact to net loss from continuing operations, cash and short-term investments, cash flows, or Segment Adjusted EBITDA. The error also had no impact on the cash consideration received upon closing of the TS Biotechnology Sale nor the representations and warranties made by the Company in the transaction. The Company evaluated the effects of this out-of-period adjustment, both qualitatively and quantitatively, and concluded that this adjustment was not material to the Company's financial position or results of operations for the years ended December 31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917060632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_MergersandAcquisitionsAbstract', window );"><strong>Mergers and Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Mergers and Acquisitions</a></td>
<td class="text">Mergers and Acquisitions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisition of Certain Harvest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc. ("CRS Bio"); Genten Therapeutics, Inc. ("Genten Therapeutics"); and Relieve Genetics, Inc. ("Relieve Genetics") (collectively the "Harvest entities"). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303, and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original ECCs and therefore wrote off deferred revenue of $10,078 in September 2018 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for additional discussion of the convertible promissory notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_MergersandAcquisitionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mergers and Acquisitions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_MergersandAcquisitionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915712760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Joint Ventures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Joint Ventures</a></td>
<td class="text">Investments in Joint Ventures<div style="margin-bottom:11pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a JV formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Intrexon Energy Partners was $(425) and $(423) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for additional discussion regarding the Company's investment in Intrexon Energy Partners.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners II</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a JV formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of December&#160;31, 2020, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in Intrexon Energy Partners II was $(435) and $(435) as of December&#160;31, 2020 and 2019, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 3 and 17 for additional discussion regarding the Company's investment in Intrexon Energy Partners II.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon T1D Partners</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a JV formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provided the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Precigen committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Precigen common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue in November 2018 as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915605528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Collaboration and Licensing Revenue</a></td>
<td class="text">Collaboration and Licensing Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaborations and licensing agreements may provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ares Trading S.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon T1D Partners, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the years ended December&#160;31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December&#160;31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Collaboration and licensing revenues recognized for the years ended December&#160;31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZIOPHARM Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January&#160;2011, the Company entered into an ECC with ZIOPHARM Oncology, Inc. ("ZIOPHARM"), a related party at the time. Pursuant to the&#160;ECC,&#160;ZIOPHARM received a license to the Company's technology platform within the field&#160;of&#160;oncology as defined more specifically in the agreement. The Company received upfront consideration upon execution of the ECC in the form of ZIOPHARM common shares valued at $17,457, shares of ZIOPHARM common stock valued at $18,330 as consideration upon achievement of a milestone in 2012, and reimbursements for research and development services performed during the ECC. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a wholly owned subsidiary of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modified the scope of the ECC </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the Merck Agreement and provided that the Company would pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement. See discussion of the Merck Agreement below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company amended the ECC and a prior ECC that was mutually terminated in December 2017 to reduce the rate of royalty that the Company was entitled to receive on certain products commercialized pursuant to the agreements. As consideration for execution of the amendments, ZIOPHARM issued the Company shares of ZIOPHARM's Series 1 Preferred Stock. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. See Note 18 for additional discussion of the terms of the preferred stock and the accounting treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license agreement (the "ZIOPHARM License Agreement") with ZIOPHARM, which terminated and replaced the terms of the original ZIOPHARM ECC, including the amendments thereto.&#160;Pursuant to the terms of the ZIOPHARM License Agreement, the Company granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i)&#160;products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii)&#160;chimeric antigen receptor ("CAR") products directed to (a)&#160;CD19 for the treatment of cancer (the "CD19 Products"), and (b)&#160;a second target, subject to the rights of the Company to pursue such target under the Merck Agreement, and (iii)&#160;T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sleeping Beauty </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of cancer and in the HPV Field. ZIOPHARM will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. ZIOPHARM is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products, and after a two-year period, the TCR Products. The Company also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. ZIOPHARM is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. ZIOPHARM and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with ZIOPHARM responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the ZIOPHARM License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that ZIOPHARM will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the licenses and other rights granted by the Company, ZIOPHARM will pay the Company an annual license fee of $100 and agreed to reimburse the Company $1,000, paid in four quarterly installments, with respect to historical Gorilla IL-12 Products (the "historical Gorilla reimbursements"). ZIOPHARM will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed programs in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed programs, up to an aggregate of $210,000. In addition, ZIOPHARM will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. ZIOPHARM will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. ZIOPHARM will also pay the Company 20% of any sublicensing income received by ZIOPHARM relating to the licensed products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reacquired rights to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to ZIOPHARM. The Company will pay ZIOPHARM royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000. The Company also received from ZIOPHARM reimbursement of costs incurred to transition the necessary knowledge and materials for ZIOPHARM programs for a period of one year from the effective date (the "Transition Services").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As between the parties, the Company agreed to perform all of the obligations of ZIOPHARM under the Merck Agreement, other than an obligation of exclusivity thereunder and ZIOPHARM will remain responsible for all payments owed under the Merck Agreement</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to CD19 and the other target under the Merck Agreement as a result of ZIOPHARM's, its affiliates' or its sublicensees' exploitation of CAR products. Further, the Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to ZIOPHARM for such products. The ZIOPHARM License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the later to occur of (i)&#160;the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, ZIOPHARM may terminate the ZIOPHARM License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the ZIOPHARM License Agreement following notice of a material breach.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the ZIOPHARM License Agreement, the 2016 Securities Issuance Agreement between the Company and ZIOPHARM was terminated as of the effective date of the ZIOPHARM License Agreement, all of the benefits, rights, obligations and liabilities thereunder immediately ceased and terminated and the Company returned to ZIOPHARM all of the preferred stock owned by the Company as of the Effective Date, which was valued at $158,376. See Note 18 for additional discussion of the preferred stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the execution of the ZIOPHARM License Agreement, the Company had $51,084 of deferred revenue remaining from the original ECC, which was related to the Company's obligations to perform under that agreement. Replacement of the original ECC with the ZIOPHARM License Agreement was a contract modification under ASC 606 that represented the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which were limited to the Transition Services, were distinct from those under the ECC. Therefore, the Company reviewed the various forms of consideration in the ZIOPHARM License Agreement to determine the transaction price. As the Company's obligations under the ZIOPHARM License Agreement were only related to the Transition Services and no other obligations under the ECC remained, a portion of the previously deferred revenue from the ECC was relieved, which the Company determined to be $49,329, and the remaining $1,755 was included in the transaction price. The initial annual license payment of $100 was also included in the transaction price. The remaining annual license payments and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being received. Royalty payments from sales of ZIOPHARM products developed pursuant to the ZIOPHARM License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price of $1,855 as it performed the Transition Services required under the ZIOPHARM License Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reviewed the consideration paid and potential consideration to be paid to ZIOPHARM as part of the ZIOPHARM License Agreement, which included the $158,376 of ZIOPHARM preferred stock returned by the Company and potential royalty payments to ZIOPHARM from sales of the Company's CAR products. The Company determined the exchange of its investment in ZIOPHARM preferred stock for certain CAR rights previously licensed under the ECC (i.e., in-process research and development) and the relief of performance obligations to ZIOPHARM under the ECC constituted an exchange for distinct goods and services. Therefore, the Company wrote off the $49,329 of relieved deferred revenue and recorded an expense of $109,047 for the reacquired in-process research and development. Potential royalty payments to ZIOPHARM will be expensed as incurred as they relate to distinct goods or services. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Gorilla Program represented a separate collaboration agreement under the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 808") and was not included in the accounting for the ZIOPHARM License Agreement under ASC 606. The Company recognized $500 of the historical Gorilla reimbursements on the contract modification date and recognized the remaining amounts when receipt became probable. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck Licensing Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company received $10,000 in equal quarterly installments over two years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a Securities Purchase, Assignment and Assumption Agreement (the "Merck Purchase Agreement") with Ares Trading pursuant to which the Company reacquired Ares Trading's development and commercialization rights under the Merck Agreement. As consideration for the reacquisition of the Merck Agreement, the Company issued Ares Trading 20,640,119 shares of Precigen common stock valued at $140,353 and agreed to pay Ares Trading a royalty of 10% of the net sales derived from two CAR products specified in the Merck Purchase Agreement. By reacquiring the rights previously licensed to Ares Trading, the Company is relieved of its obligations under the Merck Agreement and therefore wrote off deferred revenue of $31,826. The remaining value acquired of $108,527 was considered in-process research and development related to the reacquired rights under the Merck Agreement and expensed immediately. The </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential future royalty payments to Ares Trading do not represent consideration paid to a customer and will be recorded when the payments are probable. See Note 12 for additional discussion of this transaction.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oragenics Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, the Company entered into an ECC with Oragenics, a related party at the time. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $5,000 convertible promissory note, which was subsequently converted to shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale (Note 3). The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. In July 2020, the Company and Oragenics mutually agreed to terminate the ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the ECC totaling $2,823. Following the termination of the ECC, Oragenics is no longer a related party.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon T1D Partners Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000. The Company received reimbursement of research and development services provided pursuant to the ECC agreement. In November 2018, the Company completed an asset acquisition with the T1D Investors, resulting in the Company owning 100% of the membership interest of Intrexon T1D Partners including all rights under the ECC (Note 5).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genten Therapeutics, CRS Bio, and Relieve Genetics Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into three separate ECCs with Genten Therapeutics, CRS Bio, and Relieve Genetics, all affiliates of Harvest and related parties. The total upfront consideration received for the three collaborations was $10,933, which mostly consisted of equity interests in these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests in these entities, including all rights under the ECCs (Note 4).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a JV between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March&#160;2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company. The ECC is not active while the IEP Investors evaluate the status of the project and their desired future development activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intrexon Energy Partners II Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company. The ECC is not active while the IEPII Investors evaluate the status of the project and their desired future development activities.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exotech Bio, AD Skincare, and Thrive Agrobiotics Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 and 2016, the Company entered into three separate ECCs with Exotech Bio, Inc. ("Exotech Bio"), AD Skincare, Inc. ("AD Skincare"), and Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), all affiliates of Harvest and related parties at the time. The total upfront consideration received for the three collaborations was $11,000, which consisted of equity interests in each of these entities. The Company also received reimbursements for research and development services provided pursuant to the ECCs. In conjunction with a settlement agreement with Harvest (Note 17), these ECCs were terminated in December 2020, and the previously licensed technology rights reverted to the Company pursuant to the ECCs. The Company wrote off the remaining balance of deferred revenue associated with these ECCs totaling $6,993 as an offset to the loss recognized on the settlement agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Castle Creek Collaborations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2012, the Company entered into an ECC (the "2012 Castle Creek ECC") with Castle Creek Biosciences, Inc. ("Castle Creek", formerly known as Fibrocell Science, Inc.). Castle Creek was a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until it was acquired in December 2019 by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek Pharmaceutical"), a privately held company focused on developing medicine for rare genetic disorders. Pursuant to the 2012 Castle Creek ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. The Company received (i) upfront consideration upon execution of the ECC in the form of Castle Creek common stock valued at $7,576, (ii) shares of Castle Creek common stock valued at $7,612 as consideration for a 2013 amendment which expanded the field of use defined in the agreement, (iii) sublicensing fees totaling $3,750 in the form of cash in 2019, and (iv) reimbursements for research and development services performed during the ECC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company and Castle Creek terminated the 2012 Castle Creek ECC by mutual agreement ("Termination Agreement") with the parties agreeing that the two drug product candidates, FCX-007 and FCX-013, pursuant to the ECC would be treated as "Retained Products" under the terms of the 2012 Castle Creek ECC. As Retained Products, Castle Creek retains a license under the 2012 Castle Creek ECC to continue to develop and commercialize the Retained Products within the field of use of the 2012 Castle Creek ECC for so long as Castle Creek continues to pursue such development and commercialization. No further licenses to the Company's technology within the field of use are provided to Castle Creek. On a quarterly basis, Castle Creek will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each Retained Product from the 2012 Castle Creek ECC, as defined in the agreement. Additionally, the Termination Agreement provides for the Company to perform certain drug product manufacturing activities related to the Retained Products. The Termination Agreement was accounted for as a new contract, and the remaining deferred revenue from the 2012 Castle Creek ECC is being recognized prospectively as the manufacturing activities are performed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2015, the Company entered into a second ECC with Castle Creek (the "2015 Castle Creek ECC"). Pursuant to the ECC, at the transaction effective date, Castle Creek received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. In February 2020, the Company and Castle Creek mutually agreed to terminate the 2015 Castle Creek ECC, and accordingly, the Company recognized the remaining balance of deferred revenue associated with the 2015 Castle Creek ECC totaling $10,000.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consisted of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid product and service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under collaboration and licensing agreements as services are performed. Certain of the arrangements are not active while the other party evaluates the status of the project and its desired future development activities. The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December&#160;31, 2020 and 2019, as well as the estimated remaining performance period as of December&#160;31, 2020.</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Performance Period (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917244536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 2 and 8 for further discussion on the Company's method for determining the fair value of its assets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, all of the available-for-sale investments were due within one year based on their contractual maturities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and are not significant as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917137528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. During 2019, the Company's equity securities of AquaBounty (Note 1) and preferred stock owned in one of its collaborators (Note 18) were classified as Level 3 within the fair value hierarchy prior to disposition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Level 3 investments during the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained interest in deconsolidated subsidiary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend income from investments in preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds to be received from preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculated fair value of the Convertible Notes (Note 12) was approximately $165,000 and $126,000 as of December&#160;31, 2020 and 2019, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $168,147 and $157,560 as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company's contingent consideration liability, which was $585 as of December&#160;31, 2019, was reduced to $0 as the period for potential payment of this contingent consideration expired without payment in June 2020. The contingent consideration liability was remeasured to fair value at each reporting date until the contingency was resolved, and those changes in fair value were recognized in earnings. The changes in the fair value of the Level 3 liability during the years ended December&#160;31, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration recognized in selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 10 and 11 for discussion of non-recurring fair value estimates used in calculating impairment charges recorded during the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163916981016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies, embryos and other production materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915840088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">Property, Plant and Equipment, Net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction and other assets in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $7,449, $8,222 and $8,946 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company recorded impairment losses of $920, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, primarily related to right-of-use assets at certain of the Company's leased locations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recorded impairment losses of $448, which is included in impairment of other noncurrent assets on the accompanying consolidated statement of operations, related to the impairment of property, plant and equipment in conjunction with the closing of two of its operating units during the third quarter of 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917183144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $43,643 of cumulative impairment losses as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2019, during the Company's annual goodwill impairment test, the Company determined it was more-likely-than-not that the fair value of the Trans Ova reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the Trans Ova reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $29,642 goodwill impairment charge for the excess carrying value. Additionally, the Company recorded $178 of goodwill impairment in conjunction with the closing of two of its reporting units during the third quarter of 2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20 for information regarding goodwill by reportable segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,281)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2019:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,619)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,913)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, the Company recorded a $16,027 loss related to the abandonment of certain developed technologies that the Company ceased using in the fourth quarter of 2018. The Company does not expect to use these technologies as a defensive asset or market them for sale in the future. Because these technologies were used in combination with other technologies, the identifiable cash flows did not result in an impairment loss; however, because the Company made a decision to abandon the assets, it recorded the charge to research and development expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $7,593, $7,920 and $11,666 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917073624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Lines of Credit and Long-Term Debt</a></td>
<td class="text">Lines of Credit and Long-Term Debt<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on April 1, 2021. The line of credit bears interest at the greater of the U.S. Prime Rate or 3.00%, and the actual rate was 3.25% as of December&#160;31, 2020. As of December&#160;31, 2020, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount and was $5,000 as of December&#160;31, 2020. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2021. The line of credit bears interest at 4.00% per annum. As of December&#160;31, 2020, there was no outstanding balance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Precigen Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023 and are repayable in cash, unless earlier repurchased or converted. Upon conversion by the holders, the Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon the occurrence of specified corporate events as defined in the Indenture.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December&#160;31, 2020. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount (Note 13). As of December&#160;31, 2020, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $168,147. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02%. As of December&#160;31, 2020, the unamortized long-term debt discount and debt issuance costs totaled $31,853.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of interest expense related to the Convertible Notes were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest of $3,500 is included in other accrued liabilities on the accompanying consolidated balance sheet as of December&#160;31, 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ActoBio Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 4). The ActoBio Notes, which accrued interest at 3.0% compounded annually ("accrued PIK interest"), matured in September 2020. The Company issued 6,293,402 shares of Precigen common stock upon conversion of the outstanding principal balance and accrued PIK interest at maturity. Interest expense was $616, $921, and $290 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Precigen and PGEN Therapeutics Convertible Note</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, in conjunction with the Merck Purchase Agreement (Note 6), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note had a maturity date of June 28, 2021 although it automatically converted to Precigen common stock on the first trading day following the second anniversary of issuance, which is December 2020, if not otherwise converted prior to that date. In October 2020, pursuant to the terms of the Merck Note, Ares Trading voluntarily elected to convert the entire $25,000 outstanding into 6,758,400 shares of Precigen common stock. The shares are restricted from resale by Ares Trading for a period of 180 days from the date of issuance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Payable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $3,655 as of December&#160;31, 2020. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Maturities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of long-term debt as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915710520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from continuing operations before income taxes are presented below:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,313)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394,580)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395,912)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax benefit from continuing operations are presented below:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit from continuing operations for the years ended December&#160;31, 2020, 2019 and 2018 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed statutory income tax benefit from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,965)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and provincial income tax benefit, net of federal income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and internal restructuring transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States-foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,948)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,941)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities and investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating, capital loss, and interest expense carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities included in continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,834)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December&#160;31, 2020, 2019 and 2018 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance as a result of</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of AquaBounty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of deferred taxes for subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations treated as asset sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations related to MBP Titan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 842</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 606</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section&#160;382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December&#160;31, 2020, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December&#160;31, 2020, approximately $42,100 of the Company's domestic net operating losses were inherited via acquisition and are limited based on the value of the target at the time of the transaction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $756,200 available to offset future taxable income, including approximately $503,500 generated after 2017, United States capital loss carryforwards of approximately $211,500, and federal and state research and development tax credits of approximately $10,200, prior to consideration of annual limitations that may be imposed under Section&#160;382. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized beginning in 2024. The Company's foreign subsidiaries included in continuing operations have foreign loss carryforwards of approximately $82,300, most of which do not expire.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $21,200. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries do not have material unrecognized tax benefits as of December&#160;31, 2020. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917092760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Precigen Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Precigen closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374, after deducting underwriting discounts of $3,688 and offering expenses of $188, all of which were capitalized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 12, 17, and 23 for discussion regarding additional issuances of Precigen common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Lending Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the offering of the Convertible Notes (Note 12), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xNzIvZnJhZzoyMGI3MmY4NDg1MDM0OWJkOTE0NTY4MmVjZDUyMTUyMC90ZXh0cmVnaW9uOjIwYjcyZjg0ODUwMzQ5YmQ5MTQ1NjgyZWNkNTIxNTIwXzY1OTcwNjk3NzUxMzU_d9e7d0e6-80ed-4f13-b999-56a720a01b9a">five</span> business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of AquaBounty Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Precigen purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316, including $3,077 from Precigen.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) on foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,468)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 for further discussion of the release of cumulative losses on foreign currency translation adjustments upon the closing of the TS Biotechnology Sale.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915842744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Precigen Stock Option Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December&#160;31, 2020, there were 185,078 stock options outstanding under the 2008 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December&#160;31, 2020, there were 27,000,000 shares authorized for issuance under the 2013 Plan, of which 10,225,570 stock options and 1,176,629 RSUs were outstanding and 7,055,010 shares were available for grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December&#160;31, 2020, there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 845,248 stock options and 551,083 RSUs were outstanding and 2,432,624 shares were available for grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,382,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.32</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(929,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,093,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,371,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(976,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,437,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation costs related to unvested awards as of December&#160;31, 2020 were $13,842, and are expected to be recognized over a weighted-average period of approximately 2.75 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during 2020, 2019 and 2018 was $2.98, $3.79 and $7.94, respectively. The aggregate intrinsic value of options exercised during 2020, 2019 and 2018 was $51, $66 and $356, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,259,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,437,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,159,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,802,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation costs related to unvested RSU awards as of December&#160;31, 2020 were $4,188 and are expected to be recognized over a weighted-average period of approximately 0.75 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen currently uses authorized and unissued shares to satisfy share award exercises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Executive Chairman ("Executive Chairman"), who previously served as the Company's Chief Executive Officer ("CEO") until January 1, 2020, and as an employee and executive officer until September 24, 2020, received a base salary of $200 per month through March 31, 2020, payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month through March 2019 and based on the volume weighted average of the price of Precigen common stock over the 30 day period ending on the last calendar day of each month thereafter, and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Precigen and the Executive Chairman pursuant to the terms of the 2013 Plan. The RSU Agreement expired March 31, 2020. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $454, $1,868, and $1,956 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company's board of directors, upon the recommendation of the compensation committee of the board, approved a new compensation arrangement for the Executive Chairman. The new arrangement consists of (i) an annual retainer of $100 payable in cash or, at the Executive Chairman's election, shares of Precigen common stock; (ii) an annual grant of fully </span></div>vested stock options having a grant date fair value of $250; and (iii) an annual grant of RSUs having a grant date fair value of $250. The compensation arrangement begins in calendar year 2021, and the foregoing elements were prorated for the nine months of 2020 not covered by the Executive Chairman's previous compensation arrangement discussed above. The terms of the equity awards granted to the Executive Chairman are pursuant to the 2019 Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915604408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short-term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. All other leases have remaining terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xODEvZnJhZzo2NGY2ZjRhOWFiODE0ODhiOTQ4MzM5M2QwNWM0NDc0My90ZXh0cmVnaW9uOjY0ZjZmNGE5YWI4MTQ4OGI5NDgzMzkzZDA1YzQ0NzQzXzM0NA_ddde4444-f884-4ed7-beb8-9b358f73343e">one</span> to nine years, some of which may include options to extend the lease and some of which may include options to terminate the lease within one year. The Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases in continuing operations was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.81</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets added in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924169192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2020, Trans Ova settled one of two patent infringement lawsuits brought by XY, LLC ("XY"). The lawsuit, originally filed in 2012, was tried and appealed between 2016 and 2020. On December 1, 2020, the parties reached a settlement resolving all remaining disputes. As part of that settlement, Trans Ova remitted to XY a settlement payment, which, in addition to all the other monies Trans Ova had previously paid XY, constituted full payment and satisfaction of the judgment, including pre-judgment interest, post-judgment interest, costs, and all past, current and future royalty obligations under the judgment. In exchange, XY released and forever discharged Trans Ova from all obligations arising out of the judgment. In addition, XY dismissed with prejudice its pending appeal. On January 8, 2021, the parties filed a stipulation of case termination with the district court.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second patent infringement lawsuit brought on by XY was filed in December 2016. On March 20, 2019, the United States District Court for the District of Colorado entered judgment under Rule 54(b) as to ten of the twelve counts of the operative complaint, dismissed those patent counts from the case, and stayed the remaining two counts of patent infringement pending XY's appeal of the Rule 54(b) judgment. While XY's appeal was pending, one of the two patents remaining in the case was separately invalidated in a different district court proceeding, which XY did not appeal. As to the ten dismissed counts in the suit XY brought against Trans Ova, XY appealed dismissal of only four of them, each alleging patent infringement. On July 31, 2020, the United States Court of Appeals for the Federal Circuit reversed the district court's dismissal of those four patent counts and remanded the case for further proceedings. The Court is assessing next steps of the case, including an amended scheduling order.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While this patent infringement lawsuit is pending, Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of district court and appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company's disclosures regarding its methane bioconversion platform. The Company produced documents to, and met with, the staff of the SEC and voluntarily cooperated with the SEC investigation. In September 2020, the Company reached a final settlement with the SEC regarding the matter. Under the terms of the settlement, the Company, without admitting or denying the allegations of the SEC, consented to the entry of an administrative order requiring that the Company: (i) cease and desist from committing or causing any violations and future violations under Section 13(a) of the Securities Exchange Act of 1934, as amended, and Rules 13a-11 and 12b-20 promulgated thereunder; and (ii) pay a $2,500 civil money penalty to the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, three purported shareholder class action lawsuits, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abadilla v. Precigen, Inc., F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chen v. Precigen, Inc. F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seppen v. Precigen, Inc. F/K/A Intrexon Corp., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, were filed in the U.S. District Court for the Northern District of California on behalf of certain purchasers of the Company's common stock. The complaints name as defendants the Company and certain of its current and former officers. The plaintiffs' claims track the allegations in the SEC's administrative order described above. The plaintiffs seek compensatory damages, interest, and an award of reasonable attorneys' fees and costs and have filed motions to consolidate these claims. In December 2020, a derivative shareholder action, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed in the Circuit Court for Fairfax County in Virginia on behalf of Precigen, Inc. The complaint names as defendants current directors and certain officers. The plaintiff's claims track the allegations in the SEC's administrative order described above. The plaintiff seeks damages, forfeiture of benefits received by defendants, and an award of reasonable attorneys' fees and costs. The Company intends to defend the lawsuits vigorously; however, there can be no assurances regarding the ultimate outcome of these lawsuits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 10, 2020, the Company received a notice of arbitration from Harvest pursuant to the Collaboration Investment Opportunity Agreement dated March 13, 2015. In December 2020, the Company entered into an agreement with Harvest to resolve matters related to the parties' contractual and equity relationships and to settle all claims made in connection with the notice of arbitration noted above. Pursuant to the settlement agreement, the Company issued 2,117,264 shares of its common stock to Harvest valued at $18,103 in consideration of (i) the termination of the ECC agreements with Thrive Agrobiotics, Exotech Bio, and AD Skincare, which the Company had $6,993 of deferred revenue remaining related to these ECCs prior to the settlement agreement; (ii) the return of the Company's ownership interest in these Harvest start-up entities that had a total value of $326 prior to the settlement agreement; (iii) the commitment of Harvest to take reasonable commercial efforts to transfer its membership interests in Intrexon Energy Partners II; and (iv) mutual irrevocable and unconditional releases of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims. The Company wrote off the investment balances and netted the deferred revenue balances associated with the eliminated service obligation against the consideration paid, resulting in a loss on the settlement agreement of $11,436 which is included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2020. Outstanding receivables from these Harvest start-up entities related to research and development services performed by the Company under the ECC agreements, which had been fully reserved in 2019, were also forgiven as part of the settlement agreement and written off by the Company. Following the settlement agreement, these Harvest start-up entities are no longer related parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, certain strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including the IEP Investors and the IEPII Investors. While the Company believes it is entitled to payment for work performed per its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of December 31, 2020 and 2019. These disagreements and disputes result in management distraction and may result in litigation, unfavorable settlements, or concessions by the Company, or adverse regulatory action, any of which could harm the Company's business or operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of its business, the Company is involved in litigation or legal matters, including governmental investigations. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December&#160;31, 2020, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924329768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Security and Affiliates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Executive Chairman is also the Senior Managing Director and Chairman of Third Security and owns 100% of the equity interests of Third Security. Through December 2019, the Company was party to a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximated $800 per month. In 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month and issued to Third Security at the end of the month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services were provided. For the years ended December&#160;31, 2019 and 2018, the Company issued 1,606,062 shares and 696,033 shares, respectively, with values of $8,233 and $8,324, respectively, to Third Security as payment for services rendered pursuant to the Services Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of the Services Agreement, the Company entered into a new agreement with Third Security under which the Company reimburses Third Security for certain tax-related services performed by Third Security as requested by the Company. The Company also reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf prior to and after the expiration of the Services Agreement under a separate agreement. The total expenses incurred by the Company under these arrangements were $159, $26, and $47 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $83, $89, and $89 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note 15 regarding compensation arrangements between the Company and its Executive Chairman.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Equity Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Equity Facility, the Company could, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). In conjunction with the Company's July 2018 registered underwritten public offering of Convertible Notes (Note 12), the Preferred Stock Equity Facility was terminated. No shares of Series A Preferred Stock had been issued under the Preferred Stock Equity Facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 1, 3, and 14 regarding additional transactions with affiliates of Third Security.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with ECC Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborators in which the Company holds more than a de minimis equity interest, including interests received as upfront or milestone payments through collaborations, are considered related parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM previously acquired through collaborations. In conjunction with the ZIOPHARM License Agreement in October 2018 (Note 6), the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the year ended December 31, 2018, the Company recognized $14,793 of dividend income in the accompanying consolidated statement of operations. Following the transaction in October 2018, ZIOPHARM is no longer a related party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), a convertible note, common shares of Castle Creek, and warrants to purchase shares of Castle Creek common stock previously acquired through collaborations and other transactions. As a result of the acquisition of Castle Creek by Castle Creek Pharmaceutical in December 2019, the Company received $1,280 in December 2019 for its shares of Castle Creek common stock and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The $3,311 is included in receivables on the accompanying consolidated balance sheet as of December&#160;31, 2019. The Company recognized a total gain of $3,222 on the change in fair value of these instruments, which is included in total other expense, net, in the accompanying consolidated statement of operations for the year ended December 31, 2019. Subsequent to the acquisition by Castle Creek Pharmaceutical, Castle Creek is no longer a related party.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company mutually terminated ECC agreements with three separate related parties which resulted in the recognition of the remaining deferred revenue associated with these ECCs totaling $11,877.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924169192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,324)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,065,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,138,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen per share, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities as of December&#160;31, 2020, 2019, and 2018, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,732,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,323,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,955,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,093,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,849,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,260,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,152,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915856840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realigned its business in April 2019, and as a result, its CODM began regularly reviewing disaggregated financial information for various operating segments. The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise.&#160;The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) loss on impairment of goodwill and other noncurrent assets, (viii) equity in net loss of affiliates, and (ix) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. For the year ended December 31, 2020, the Company modified the current period definition of Segment Adjusted EBITDA to exclude adjustments recorded to reverse the difference of bonuses accrued as of December 31, 2019 compared to the value of equity awards granted, as the Company determined in March 2020 that those accrued bonuses would be paid through the grant of equity awards instead of cash. The Company also excluded noncash losses associated with settlement agreements. Segment Adjusted EBITDA for the years ended December 31, 2019 and 2018, were not impacted by these changes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results.&#160;The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment.&#160;Corporate expenses are not allocated to the segments and are managed at a consolidated level.&#160;The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed.&#160;The Company's segment presentation excludes amounts related to the businesses included in the Transactions and the operations of MBP Titan which are reported as discontinued operations (Note 3).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics, (ii) ActoBio, (iii) Trans Ova, and (iv) the Human Biotherapeutics division. These identified reportable segments met the quantitative thresholds to be reported separately for the year ended December&#160;31, 2020. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. The Company's Human Biotherapeutics division is an operating division within Precigen which in 2020 and 2019 included the Company's majority-owned subsidiary, Triple-Gene LLC, and its collaborations with Castle Creek (Note 6). The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to be reported separately.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information by reportable segment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reallocations from changes to reporting units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,861)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles total segment revenues from reportable segments to total consolidated revenues:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues from reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues, including from other operating segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,214)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Segment Adjusted EBITDA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remove cash paid for capital expenditures and investments in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add recognition of previously deferred revenue associated with upfront and milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquisition of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment related to accrued bonuses paid in equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395,912)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had $5,908 and $6,724, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $595, $1,401, and $6,255 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924180520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:20pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915756888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Defined Contribution Plans</a></td>
<td class="text">Defined Contribution PlansThe Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $873, $1,186 and $1,392 for the years ended December 31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925466200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company closed a public offering of 17,250,000 shares of its common stock, resulting in net proceeds of approximately $121,200, after deducting underwriting discounts and estimated capitalizable offering expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company executed termination and recapture agreements with the landlord of the leased facility used in MBP Titan's operations, thereby relieving the Company of all of its obligations related to the facility which were originally due to expire in July 2025. The Company will record the impact of this termination as discontinued operations in the Company's consolidated financial statements during the first quarter of 2021. As of December 31, 2020, the right-of-use asset related to the lease was $9,131 and the lease liability was $13,428, which are included in current assets held for sale or abandonment and current liabilities held for sale or abandonment, respectively, in the consolidated balance sheet. Following January 2021, the Company has no further payment obligations under the lease.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924131528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements reflect the operations of Precigen and its subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and licensing revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i)&#160;upfront payments upon consummation of the agreement; (ii)&#160;reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii)&#160;milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv)&#160;royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product and service revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Exemplar also generates product and service revenues through the development and sale of genetically engineered miniature swine models. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, contract research organizations and consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in </span></div>research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsAll highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard&#160;&amp; Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesPolicyTextBlock', window );">Equity Securities</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. See Notes 3 and 18 for additional discussion of certain equity securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets and liabilities;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tr><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.267%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December&#160;31, 2020, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its investments in each of its joint ventures ("JVs") and in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Notes 4 and 17 and to certain of the Company's JVs in Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest EntitiesThe Company identifies entities that (i)&#160;do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii)&#160;in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii)&#160;have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivables</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Company applies FASB Accounting Standards Update ("ASU") 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"). This ASU replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including accounts receivable. The amendment requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due, which were not considered under the previous accounting guidance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through sales of products and services by Trans Ova and Exemplar in the normal course of business. The Company's expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' accounts receivables. The Company's monitoring activities include timely account reconciliation, routine follow-up </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on past due accounts, and consideration of customers' financial condition, as well as macroeconomic conditions. Past due status is determined based upon contractual terms. Balances are written off at the point when collection attempts have been exhausted.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are used to determine the loss allowance, which is based on assessment of anticipated payment and other historical, current, and future information that is reasonably available.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#8211;15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;23</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#8211;4</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr></table></div>Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">one</span> to fourteen years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets.&#160;The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company may elect to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the quantitative goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the quantitative goodwill impairment test is performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzMzMjEy_3cea6c4c-4d45-46a9-bbf7-183ee039ea9e">three</span> to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Notes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt was the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represented the value of the conversion option and was calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt issuance costs related to the Convertible Notes were also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital were recorded as reduction of the original value assigned to the conversion option.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.</span></div>The Company accounts for the minimum tax on global intangible low-taxed income ("GILTI") as a period charge in the period in which the tax arises.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Through 2019, since Precigen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on a blended approach that utilized the volatility of Precigen's common stock and the volatility of peer public entities that were similar in size and industry. Beginning in 2020, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of Precigen's common stock. For any stock options where sufficient history is not available for the expected term, expected volatility is based on the blended approach discussed above. Precigen estimates the expected term of options based on previous history of exercises unless certain terms of the stock option require a different expected term that more appropriately reflects the estimated life of the stock option. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59%&#8211;90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58%&#8211;64%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%&#8211;59%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#8211;10.00</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%&#8211;1.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53%&#8211;2.58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33%&#8211;3.06%</span></div></td></tr></table>Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's chief operating decision maker ("CODM") regularly reviews disaggregated financial information for various operating segments. As of December&#160;31, 2020, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) Trans Ova; and (iv) the Human Biotherapeutics division, which is an operating division of Precigen. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of PGEN Therapeutics, ActoBio, and Trans Ova. See Note 20 for a description of the Human Biotherapeutics division. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, loss on settlement agreement, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. See Note 20 for further discussion of the Company's segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIE. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The Company adopted this standard effective January 1, 2020, on a prospective basis, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The Company adopted this standard effective January 1, 2020, and there was no impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, which modifies the impairment model for receivables to utilize an expected loss methodology in place of the previous incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted this standard effective January 1, 2020, and there was no material impact to the accompanying consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40)&#8212;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2020-06"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The provisions of ASU 2020-06 simplify accounting for convertible instruments by removing major separation models required under current U.S. GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The amendments in ASU 2020-06 are effective for annual periods beginning after December 15, 2021. Early adoption is permitted but no earlier than annual periods beginning after December 15, 2020. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). The provisions of ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740 and clarifying certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. An entity that elects early adoption must adopt all the amendments in the same period. Most amendments within this ASU are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquitySecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquitySecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925414536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text">The estimated useful lives of these assets from continuing operations are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#8211;15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#8211;23</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#8211;4</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#8211;7</span></div></td></tr></table>Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUyMTBiMGM3ZmM4NDQyOWY5MTVlYWY3M2QwOTQ2OTQ4L3NlYzplMjEwYjBjN2ZjODQ0MjlmOTE1ZWFmNzNkMDk0Njk0OF8xMjcvZnJhZzpmODVjNTdkZWJkOTY0MTM0YWViZmYwZTdhODEyMDg2Yy90ZXh0cmVnaW9uOmY4NWM1N2RlYmQ5NjQxMzRhZWJmZjBlN2E4MTIwODZjXzI3NjA2_e3681c3b-2ac4-4666-9ce6-2bea04dccec8">one</span> to fourteen years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used in Option Pricing Model</a></td>
<td class="text">The assumptions used in the Black-Scholes option pricing model for the years ended December&#160;31, 2020, 2019 and 2018 are set forth in the table below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59%&#8211;90%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58%&#8211;64%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%&#8211;59%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#8211;10.00</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%&#8211;1.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53%&#8211;2.58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33%&#8211;3.06%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts Receivable, Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity in the allowance for credit losses for the years ended December&#160;31, 2020, 2019, and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write offs of accounts receivable, net of recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property plant and equipment used in the normal conduct of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915777976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for abandonment for MBP Titan as of December 31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale or abandonment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale or abandonment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,935&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of discontinued operations of MBP Titan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,423)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,830)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes a goodwill impairment charge of $9,635 and an impairment charge on property, plant and equipment and ROU Assets of $12,406 recorded in 2020 in conjunction with the suspension of MBP Titan's operations discussed above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations for MBP Titan that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions as of December 31, 2019 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current (1)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, current, from related parties of $1,243.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes deferred revenue, net of current portion, from related parties of $6,836.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial results of discontinued operations related to the Transactions:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,054)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,057)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,056)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenues recognized from related parties of $436.</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,784)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,794)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,578)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,056)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,164)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,051)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,108)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,159)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $3,042.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes the impairment charge of $89,679 related to the Transactions discussed above.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TS Biotechnology Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EnviroFlight Sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,643)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,622)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,092)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,297)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,092)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes revenue recognized from related parties of $4,665.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aedes Aegypti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations for the Transactions that are included in the accompanying consolidated statements of cash flows.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on release of cumulative foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized and realized depreciation on equity securities and preferred stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in EnviroFlight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,440&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,649)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,628)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,402)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925431816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summarized Collaboration and Licensing Revenues</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZIOPHARM Oncology, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ares Trading S.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon T1D Partners, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">For the years ended December&#160;31, 2019 and 2018, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the year ended December&#160;31, 2018, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics and CRS Bio.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Collaboration and licensing revenues recognized for the years ended December&#160;31, 2020, 2019 and 2018, include the recognition of $20,205, $7,505, and $39,446, respectively, associated with upfront and milestone payments which were previously deferred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Deferred Revenue</a></td>
<td class="text">Deferred revenue consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and licensing agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid product and service revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Summary of Deferred Revenue by Collaborator</a></td>
<td class="text">The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December&#160;31, 2020 and 2019, as well as the estimated remaining performance period as of December&#160;31, 2020.<div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Performance Period (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oragenics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrexon Energy Partners II, LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Castle Creek Biosciences, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvest start-up entities (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">As of December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Exotech Bio, and AD Skincare.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915615896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments</a></td>
<td class="text">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December&#160;31, 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,253&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924424488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:40.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States government debt securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the Level 3 investments during the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained interest in deconsolidated subsidiary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend income from investments in preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds to be received from preferred stock</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">The changes in the fair value of the Level 3 liability during the years ended December&#160;31, 2020 and 2019 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration recognized in selling, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917071864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies, embryos and other production materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917238968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consist of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breeding stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction and other assets in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,952&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917298136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill for the years ended December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2020:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Useful Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,412)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,281)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following as of December&#160;31, 2019:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, developed technologies and know-how</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,619)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,913)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense</a></td>
<td class="text">Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923259864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,882&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,321&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of interest expense related to the Convertible Notes were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of long-term debt as of December&#160;31, 2020 are as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925495992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from continuing operations before income taxes are presented below:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,313)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394,580)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395,912)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Benefit</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax benefit from continuing operations are presented below:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,355)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit from continuing operations for the years ended December&#160;31, 2020, 2019 and 2018 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% to loss before income taxes as a result of the following:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computed statutory income tax benefit from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,965)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and provincial income tax benefit, net of federal income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible officer compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and internal restructuring transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States-foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,948)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,941)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:11pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December&#160;31, 2020 and 2019, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities and investments in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating, capital loss, and interest expense carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities included in continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,834)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December&#160;31, 2020, 2019 and 2018 was as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance as a result of</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mergers and acquisitions, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of AquaBounty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,504)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Establishment of deferred taxes for subsidiaries included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations treated as asset sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations related to MBP Titan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 842</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASC 606</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred state tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation allowance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915647656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) on foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,475)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,468)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925305624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">Stock-based compensation costs included in the consolidated statements of operations are presented below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,382,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.32</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(929,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,093,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,371,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(976,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,437,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Information About Stock Options Outstanding</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,259,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.76</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,437,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,707&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information about stock options outstanding as of December&#160;31, 2019:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise&#160;Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,264,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU activity was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,278,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,159,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,802,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917094440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs were as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases in continuing operations was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.81</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets added in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, maturities of lease liabilities, excluding short-term and variable leases, for continuing operations were as follows:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924480840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share:</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,324)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,065,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,138,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,521,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations attributable to Precigen per share, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.02)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities as of December&#160;31, 2020, 2019, and 2018, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,732,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,323,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,955,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,255,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,022,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,093,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,849,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,260,596&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,152,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915831624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Information by Reportable Segment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information by reportable segment was as follows:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2018</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reallocations from changes to reporting units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,186&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,861)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PGEN Therapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ActoBio</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trans Ova</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Human Biotherapeutics</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from external customers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles total segment revenues from reportable segments to total consolidated revenues:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues from reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues, including from other operating segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:</span></div><div style="margin-bottom:5pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Adjusted EBITDA for reportable segments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,214)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Segment Adjusted EBITDA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remove cash paid for capital expenditures and investments in affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add recognition of previously deferred revenue associated with upfront and milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,612)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reacquisition of in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236,748)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on settlement agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,436)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment related to accrued bonuses paid in equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net loss of affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated corporate costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395,912)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917280456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,006)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:20pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2020, the Company recorded a loss on settlement agreement related to Harvest (Note 17).</span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,855)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,709)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Precigen per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163922957416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Deconsolidation, loss, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="nump">$ 21,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">23,456<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net</a></td>
<td class="nump">$ 7,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
<td class="num">(30,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Precigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,661)<span></span>
</td>
<td class="num">$ (29,508)<span></span>
</td>
<td class="num">$ (43,354)<span></span>
</td>
<td class="num">$ (55,998)<span></span>
</td>
<td class="num">$ (169,215)<span></span>
</td>
<td class="num">$ (53,634)<span></span>
</td>
<td class="num">$ (38,766)<span></span>
</td>
<td class="num">$ (60,709)<span></span>
</td>
<td class="num">(170,521)<span></span>
</td>
<td class="num">(322,324)<span></span>
</td>
<td class="num">$ (509,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,823,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,652,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,823,390)<span></span>
</td>
<td class="num">$ (1,652,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163928287576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementTerminationNoticePeriod', window );">Required notice period for voluntary termination of collaborative agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred', window );">Research and development commitments with third parties not incurred</a></td>
<td class="nump">$ 12,054<span></span>
</td>
<td class="nump">$ 14,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod', window );">Maturity period of highly liquid investment</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalent investments in highly liquid money market accounts</a></td>
<td class="nump">$ 30,164<span></span>
</td>
<td class="nump">47,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount', window );">Maximum risk of loss related to the identified VIEs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Expected useful life of intangible asset</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Expected useful life of intangible asset</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Precigen Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pgen_ProductsandServicesRevenuesMember', window );">Products and services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Product and service revenues, standard payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member', window );">3.5% Convertible Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborationAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborationAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_HighlyLiquidInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original maturity period for highly liquid investments to be considered cash equivalent, maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_HighlyLiquidInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of commitments related to research and development arrangements with third parties which has not yet been incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5747-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_ProductsandServicesRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_ProductsandServicesRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163928203496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_AccountsReceivableAllowanceForCreditLossLineItems', window );"><strong>Accounts Receivable, Allowance For Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Charged to operating expenses</a></td>
<td class="nump">$ 899<span></span>
</td>
<td class="nump">$ 3,242<span></span>
</td>
<td class="nump">$ 1,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_AccountsReceivableAllowanceForCreditLossLineItems', window );"><strong>Accounts Receivable, Allowance For Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
<td class="nump">4,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Charged to operating expenses</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write offs of accounts receivable, net of recoveries</a></td>
<td class="num">(2,078)<span></span>
</td>
<td class="num">(862)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 6,334<span></span>
</td>
<td class="nump">$ 7,513<span></span>
</td>
<td class="nump">$ 4,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_AccountsReceivableAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Credit Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_AccountsReceivableAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163918703656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings and building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Breeding stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings and building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">23 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Breeding stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment, useful life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BreedingAndProductionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BreedingAndProductionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pgen_ComputerHardwareandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pgen_ComputerHardwareandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925129384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Precigen Stock Option Plans<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.58%<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164045750728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details) - Discontinued Operations, Disposed of by Means Other than Sale, Abandonment - MBP Titan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 17,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">9,131<span></span>
</td>
<td class="nump">13,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale or abandonment</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="nump">40,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">11,538<span></span>
</td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale or abandonment</a></td>
<td class="nump">$ 14,047<span></span>
</td>
<td class="nump">$ 16,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Discontinued Operations, Operating Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924904312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Financial Results for MBP Titan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,748)<span></span>
</td>
<td class="num">$ (153,582)<span></span>
</td>
<td class="num">$ (134,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember', window );">MBP Titan | Discontinued Operations, Disposed of by Means Other than Sale, Abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,692<span></span>
</td>
<td class="nump">37,423<span></span>
</td>
<td class="nump">33,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,692)<span></span>
</td>
<td class="num">(37,423)<span></span>
</td>
<td class="num">(33,830)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,692)<span></span>
</td>
<td class="num">(37,423)<span></span>
</td>
<td class="num">(33,830)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,692)<span></span>
</td>
<td class="num">(37,423)<span></span>
</td>
<td class="num">(33,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,406<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163922360504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,516<span></span>
</td>
<td class="nump">$ 24,896<span></span>
</td>
<td class="nump">$ 33,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
<td class="nump">36,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,527)<span></span>
</td>
<td class="num">(37,883)<span></span>
</td>
<td class="num">(41,587)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember', window );">Discontinued Operations, Disposed of by Means Other than Sale, Abandonment | MBP Titan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="nump">3,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,406<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88)<span></span>
</td>
<td class="num">$ (2,114)<span></span>
</td>
<td class="num">$ (3,558)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920573896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 9,635<span></span>
</td>
<td class="nump">$ 87,862<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember', window );">TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration</a></td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="nump">$ 26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax', window );">Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember', window );">EnviroFlight Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember', window );">EnviroFlight Sale | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment charge on write down of investment in affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember', window );">TS Biotechnology Holdings LLC and Enviro Flight LLC | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pgen_OkanaganOxitecFineChemicalsAndAgBioMember', window );">Okanagan, Oxitec, Fine Chemicals, And AgBio | TS Biotechnology Holdings LLC and Enviro Flight LLC | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of an increase (decrease) to a gain (loss) previously reported in discontinued operations in a prior period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1020-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=121548190&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pgen_OkanaganOxitecFineChemicalsAndAgBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pgen_OkanaganOxitecFineChemicalsAndAgBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163918839496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments', window );">Investments in affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember', window );">TS Biotechnology Sale | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember', window );">TS Biotechnology Sale | Discontinued Operations, Held-for-sale | Related Parties, Aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember', window );">EnviroFlight Sale | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments', window );">Investments in affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale or abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Discontinued Operations, Operating Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920064808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,957)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,748)<span></span>
</td>
<td class="num">(153,582)<span></span>
</td>
<td class="num">(134,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on abandonment and disposals of assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">20,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">12,307<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="nump">126,885<span></span>
</td>
<td class="nump">111,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="num">(114,578)<span></span>
</td>
<td class="num">(102,113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="num">(1,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(4,314)<span></span>
</td>
<td class="num">(2,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,054)<span></span>
</td>
<td class="num">(119,164)<span></span>
</td>
<td class="num">(106,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">6,103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,056)<span></span>
</td>
<td class="num">(116,159)<span></span>
</td>
<td class="num">(100,389)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember', window );">TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">12,307<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896<span></span>
</td>
<td class="nump">116,091<span></span>
</td>
<td class="nump">111,039<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="num">(103,784)<span></span>
</td>
<td class="num">(101,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="num">$ (26,957)<span></span>
</td>
<td class="num">(26,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="num">(1,757)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,055)<span></span>
</td>
<td class="num">(104,056)<span></span>
</td>
<td class="num">(103,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">6,103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,057)<span></span>
</td>
<td class="num">(101,051)<span></span>
</td>
<td class="num">(97,297)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember', window );">EnviroFlight Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,794<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,794)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(4,314)<span></span>
</td>
<td class="num">(2,622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(15,108)<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(15,108)<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember', window );">TS Biotechnology Holdings LLC and Enviro Flight LLC | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,957)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember', window );">TS Biotechnology Holdings LLC and Enviro Flight LLC | Discontinued Operations, Disposed of by Sale | Oxitec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on abandonment and disposals of assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember', window );">Related Parties, Aggregated | TS Biotechnology Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
<td class="nump">$ 3,042<span></span>
</td>
<td class="nump">$ 4,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Income (Loss) from Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pgen_OxitecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pgen_OxitecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_RelatedPartiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163918693832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,516<span></span>
</td>
<td class="nump">$ 24,896<span></span>
</td>
<td class="nump">$ 33,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,326<span></span>
</td>
<td class="nump">32,627<span></span>
</td>
<td class="nump">60,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal', window );">Gain on sale of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized depreciation on equity securities and preferred stock, net</a></td>
<td class="num">$ (7,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="num">(7,833)<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of EnviroFlight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">11,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
<td class="nump">36,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="num">(3,674)<span></span>
</td>
<td class="num">(21,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Investments in EnviroFlight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,713)<span></span>
</td>
<td class="num">(16,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,527)<span></span>
</td>
<td class="num">(37,883)<span></span>
</td>
<td class="num">(41,587)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember', window );">TS Biotechnology Holdings LLC and Enviro Flight LLC | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,107<span></span>
</td>
<td class="nump">9,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,637<span></span>
</td>
<td class="nump">60,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal', window );">Gain on sale of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation', window );">Unrealized and realized depreciation on equity securities and preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">3,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,710)<span></span>
</td>
<td class="num">(5,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(23,326)<span></span>
</td>
<td class="num">(21,191)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember', window );">EnviroFlight Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Loss on release of cumulative foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of EnviroFlight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">4,314<span></span>
</td>
<td class="nump">2,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Investments in EnviroFlight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">$ (12,250)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925340392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 148,948<span></span>
</td>
<td class="nump">$ 234,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">314,587<span></span>
</td>
<td class="nump">455,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">42,127<span></span>
</td>
<td class="nump">122,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">247,413<span></span>
</td>
<td class="nump">384,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(170,521)<span></span>
</td>
<td class="num">(323,916)<span></span>
</td>
<td class="num">$ (514,706)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | EnviroFlight Sale | Discontinued Operations, Held-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet', window );">Net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | EnviroFlight Sale | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Operating loss</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(8,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (8,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees | TS Biotechnology and EnviroFlight | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,402)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Summarized Financial Information, Assets Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_EnviroFlightLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyAndEnviroFlightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_TSBiotechnologyAndEnviroFlightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920301304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1', window );">Long-term debt issued to a related party in an asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CashInflowsOutflowsInAssetAcquisition', window );">Cash received in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,823<span></span>
</td>
<td class="nump">53,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 236,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember', window );">Harvest Intrexon Enterprise Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CashInflowsOutflowsInAssetAcquisition', window );">Cash received in asset acquisition</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_PrecigenActioBioIncMember', window );">Precigen ActoBio, Inc. | Harvest Intrexon Enterprise Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1', window );">Long-term debt issued to a related party in an asset acquisition</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member', window );">CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in affiliates</a></td>
<td class="nump">$ 4,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RelatedPartyOwnershipInterest', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 10,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="nump">$ 8,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CashInflowsOutflowsInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflows (outflows) related to an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CashInflowsOutflowsInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_RelatedPartyOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_RelatedPartyOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_PrecigenActioBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_PrecigenActioBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164022870296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>board_seat</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,461,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment', window );">Additional capital contributions committed, remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoard', window );">Total number of seats on the joint venture's governing board | board_seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardInternallySelected', window );">Total number of seats on the joint venture's governing board, internally selected | board_seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardExternallySelected', window );">Total number of seats on the joint venture's governing board, externally selected | board_seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Intrexon Energy Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Capital contribution</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember', window );">Other accrued liabilities | Intrexon Energy Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (425,000)<span></span>
</td>
<td class="num">$ (423,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of consideration received by the entity for collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_JointVentureAdditionalCapitalContributionsCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional capital contributions to the joint venture for which the entity is committed, maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_JointVentureAdditionalCapitalContributionsCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount of additional capital contributions to the joint venture for which the entity is committed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of seats on the governing board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardExternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board, externally selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardExternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardInternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board selected internally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardInternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments In Joint Venture [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ScheduleOfInvestmentsInJointVentureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919060104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>board_seat</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,461,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment', window );">Additional capital contributions committed, remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoard', window );">Total number of seats on the joint venture's governing board | board_seat</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardInternallySelected', window );">Total number of seats on the joint venture's governing board, internally selected | board_seat</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardExternallySelected', window );">Total number of seats on the joint venture's governing board, externally selected | board_seat</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Intrexon Energy Partners II, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Capital contribution</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AllInvestorsMember', window );">All Investors | Intrexon Energy Partners II, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Capital contribution</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember', window );">Other accrued liabilities | Intrexon Energy Partners II, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (435,000)<span></span>
</td>
<td class="num">$ (435,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of consideration received by the entity for collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_JointVentureAdditionalCapitalContributionsCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional capital contributions to the joint venture for which the entity is committed, maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_JointVentureAdditionalCapitalContributionsCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount of additional capital contributions to the joint venture for which the entity is committed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of seats on the governing board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardExternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board, externally selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardExternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardInternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board selected internally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardInternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments In Joint Venture [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ScheduleOfInvestmentsInJointVentureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AllInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AllInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pgen_OtherAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163929297832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($) </div>
<div>board_seat</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,323,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,823,000<span></span>
</td>
<td class="nump">$ 53,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 236,748,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="nump">$ 50,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember', window );">Intrexon T1D Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardInternallySelected', window );">Total number of seats on the joint venture's governing board, internally selected | board_seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberofSeatsonGoverningBoardExternallySelected', window );">Total number of seats on the joint venture's governing board, externally selected | board_seat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for reacquired in-process research and development, shares | shares</a></td>
<td class="nump">1,933,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="nump">$ 18,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">8,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="nump">$ 10,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Intrexon T1D Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Membership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_JointVentureAdditionalCapitalContributionsCommitted', window );">Maximum additional capital contributions committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember', window );">Intrexon T1D Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems', window );"><strong>Schedule Of Investments In Joint Venture [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of consideration received by the entity for collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_JointVentureAdditionalCapitalContributionsCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional capital contributions to the joint venture for which the entity is committed, maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_JointVentureAdditionalCapitalContributionsCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardExternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board, externally selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardExternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberofSeatsonGoverningBoardInternallySelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seats on the governing board selected internally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberofSeatsonGoverningBoardInternallySelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ScheduleOfInvestmentsInJointVentureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments In Joint Venture [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ScheduleOfInvestmentsInJointVentureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919431848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,333<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
<td class="nump">$ 29,838<span></span>
</td>
<td class="nump">$ 17,002<span></span>
</td>
<td class="nump">$ 18,299<span></span>
</td>
<td class="nump">$ 32,836<span></span>
</td>
<td class="nump">$ 22,585<span></span>
</td>
<td class="nump">$ 103,178<span></span>
</td>
<td class="nump">$ 90,722<span></span>
</td>
<td class="nump">$ 151,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="nump">69,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,205<span></span>
</td>
<td class="nump">7,505<span></span>
</td>
<td class="nump">39,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">16,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member', window );">Ares Trading S.A. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="num">(564)<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember', window );">Intrexon T1D Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">6,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,810<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember', window );">Harvest Start-Up Entities | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,862<span></span>
</td>
<td class="nump">14,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OtherMember', window );">Other revenues | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 12,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OragenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OragenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163901928760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>quarterly_installment </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,325,000<span></span>
</td>
<td class="nump">$ 9,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,823,000<span></span>
</td>
<td class="nump">53,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 236,748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,333,000<span></span>
</td>
<td class="nump">$ 23,583,000<span></span>
</td>
<td class="nump">$ 30,424,000<span></span>
</td>
<td class="nump">$ 29,838,000<span></span>
</td>
<td class="nump">17,002,000<span></span>
</td>
<td class="nump">$ 18,299,000<span></span>
</td>
<td class="nump">$ 32,836,000<span></span>
</td>
<td class="nump">$ 22,585,000<span></span>
</td>
<td class="nump">$ 103,178,000<span></span>
</td>
<td class="nump">90,722,000<span></span>
</td>
<td class="nump">151,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementTerminationNoticePeriod', window );">Required notice period for voluntary termination of collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member', window );">Licensing agreement between ZIOPHARM and Precigen 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible', window );">License agreement, percentage of development costs for which responsible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived', window );">License agreement, percentage of operating profits to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementAnnualFee', window );">License agreement, annual fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicensingAgreementReimbursementofHistoricalCosts', window );">License agreement, reimbursement of historical costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments', window );">License agreement, reimbursement of historical costs, number of quarterly installments | quarterly_installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated', window );">Milestone payments required upon successful achievement, aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementRoyaltyDueAggregated', window );">License agreement, royalty due, aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementPercentageofSublicensingIncome', window );">License agreement, percentage of sublicensing income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed', window );">Transition period during which costs will be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent', window );">License agreement, termination, period following triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="nump">50,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,208,000<span></span>
</td>
<td class="nump">14,059,000<span></span>
</td>
<td class="nump">69,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,205,000<span></span>
</td>
<td class="nump">7,505,000<span></span>
</td>
<td class="nump">39,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing agreement between ZIOPHARM and Precigen 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct', window );">Milestone payments required upon successful achievement, per product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts', window );">License agreement, number of exclusively licensed products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Licensing agreement between ZIOPHARM and Precigen 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible', window );">License agreement, percentage of development costs for which responsible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived', window );">License agreement, percentage of operating profits to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LicenseAgreementRoyaltyDueAggregated', window );">License agreement, royalty due, aggregated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,457,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,171,000<span></span>
</td>
<td class="nump">16,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements | Reacquired in-process research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements | Transition services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member', window );">Ares Trading S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for reacquired in-process research and development, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,640,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RoyaltyPercentageToBePaidtoOtherParty', window );">Royalty percentage to be paid to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member', window );">Ares Trading S.A. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,826,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired', window );">Collaborative agreement, consideration receivable, minimum targets required | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod', window );">Collaborative agreement, consideration receivable, collection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member', window );">Ares Trading S.A. | ZIOPHARM Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationArrangementPercentOfCollaborationPayments', window );">Collaboration agreement, percent of collaboration payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member', window );">Ares Trading S.A. | ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_PaymentsToRelatedParties', window );">Payments to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,053,000<span></span>
</td>
<td class="num">(564,000)<span></span>
</td>
<td class="nump">1,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote', window );">Collaborative agreement, consideration received, value of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="nump">$ 2,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember', window );">Intrexon T1D Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,596,000<span></span>
</td>
<td class="nump">6,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementTerminationNoticePeriod', window );">Required notice period for voluntary termination of collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,217,000<span></span>
</td>
<td class="nump">2,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementTerminationNoticePeriod', window );">Required notice period for voluntary termination of collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,576,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,810,000<span></span>
</td>
<td class="nump">3,713,000<span></span>
</td>
<td class="nump">$ 1,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedCash', window );">Collaborative agreement, consideration received, cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne', window );">Royalty rate as a percentage of net sales, tier 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo', window );">Level of net sales at which royalty rate changes to tier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo', window );">Royalty rate as a percentage of net sales, tier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember', window );">Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member', window );">CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. | Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborativeArrangementConsiderationReceivedValue', window );">Collaborative agreement, consideration received, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember', window );">Intrexon T1D Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Reacquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shares issued for reacquired in-process research and development, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,933,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Shares issued for reacquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RelatedPartyOwnershipInterest', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember', window );">Genten Therapeutics, CRS Bio, and Relieve Genetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RelatedPartyOwnershipInterest', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CollaborationAgreementsLineItems', window );"><strong>Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborationAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborationAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborationArrangementPercentOfCollaborationPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborationArrangementPercentOfCollaborationPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which the consideration is owed to the entity under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Consideration Received Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of consideration received by the entity for collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementAnnualFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual licensing fee due under licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementAnnualFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementNumberofExclusivelyLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exclusively licensed products under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementNumberofExclusivelyLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of development costs for which an entity is responsible under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementPercentageofSublicensingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Sublicensing Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementPercentageofSublicensingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments in which historical costs will be reimbursed under licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementRoyaltyDueAggregated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty amount due under licensing agreement, aggregated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementRoyaltyDueAggregated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period following a triggering event after which a licensing agreement will be terminated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of operating profits to be received by an entity under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LicensingAgreementReimbursementofHistoricalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of historical costs to which an entity is entitled under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LicensingAgreementReimbursementofHistoricalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Required Upon Successful Achievement Aggregated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of potential future milestone payments to be received under agreement per product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_PaymentsToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflows for payments made to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_PaymentsToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_RelatedPartyOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_RelatedPartyOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_RoyaltyPercentageToBePaidtoOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage royalty payable to another party as defined in applicable agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_RoyaltyPercentageToBePaidtoOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period following the effective date of the licensing agreement during which costs incurred to transition knowledge and materials will be reimbursed by third party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=pgen_ReacquiredInProcessResearchDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=pgen_ReacquiredInProcessResearchDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=pgen_TransitionServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=pgen_TransitionServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OragenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OragenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163922163144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 25,823<span></span>
</td>
<td class="nump">$ 53,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">23,023<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pgen_PrepaidProductAndServiceRevenuesMember', window );">Prepaid product and service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pgen_DeferredRevenueOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 23,420<span></span>
</td>
<td class="nump">$ 50,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_PrepaidProductAndServiceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_PrepaidProductAndServiceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_DeferredRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_DeferredRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923916200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 23,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc. | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 8,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 12,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc. | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember', window );">Harvest Start-Up Entities | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember', window );">Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember', window );">Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember', window );">Other | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember', window );">Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Average Remaining Performance Period (Years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember', window );">Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Upfront and Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems', window );"><strong>Summary of Deferred Revenue by Collaborator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_SummaryofDeferredRevenuebyCollaboratorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of deferred revenue disclosure which includes the collaborator and the corresponding amount that comprise the balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_SummaryofDeferredRevenuebyCollaboratorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OragenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OragenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924764744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and Milestone Payments<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 50,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OragenicsMember', window );">Oragenics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember', window );">Intrexon Energy Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">8,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember', window );">Intrexon Energy Partners II, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">12,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">17,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember', window );">Harvest Start-Up Entities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue</a></td>
<td class="nump">$ 1,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OragenicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OragenicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_HarvestStartUpEntitiesAggregatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_OtherCollaborationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925265704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 48,312<span></span>
</td>
<td class="nump">$ 9,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair&#160;Value</a></td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">9,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">United States government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">48,048<span></span>
</td>
<td class="nump">8,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair&#160;Value</a></td>
<td class="nump">48,061<span></span>
</td>
<td class="nump">8,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair&#160;Value</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164099740376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 48,325<span></span>
</td>
<td class="nump">$ 9,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">United States government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">48,061<span></span>
</td>
<td class="nump">8,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pgen_OtherFinancialAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in&#160;Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in&#160;Active Markets (Level 1) | United States government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in&#160;Active Markets (Level 1) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">9,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | United States government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">48,061<span></span>
</td>
<td class="nump">8,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | United States government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pgen_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pgen_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164033196392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Level 3 Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NoncashDividendIncome', window );">Dividend income from investments in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 14,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="num">$ (21,587)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,456)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary', window );">Retained interest in deconsolidated subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NoncashDividendIncome', window );">Dividend income from investments in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_PreferredStockReceivables', window );">Proceeds to be received from preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Increase Due to Deconsolidation of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NoncashDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income included in net income that results in no cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NoncashDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_PreferredStockReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables from conversion of preferred stock to cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_PreferredStockReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164022830264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of financial liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member', window );">3.5% Convertible Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value of convertible debt</a></td>
<td class="nump">$ 168,147<span></span>
</td>
<td class="nump">$ 157,560<span></span>
</td>
<td class="nump">$ 143,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163928254968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in Fair Value Level 3 Liability (Details) - Significant Unobservable Inputs (Level&#160;3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 585<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of contingent consideration recognized in selling, general, and administrative expenses</a></td>
<td class="num">(585)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925416392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">$ 11,359<span></span>
</td>
<td class="nump">$ 16,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_SuppliesEmbryosAndOtherProductionMaterialsMember', window );">Supplies, embryos and other production materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_WorkInProcessMember', window );">Work in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">2,348<span></span>
</td>
<td class="nump">3,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_LivestockMember', window );">Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">5,047<span></span>
</td>
<td class="nump">7,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_FeedMember', window );">Feed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">$ 1,904<span></span>
</td>
<td class="nump">$ 2,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_SuppliesEmbryosAndOtherProductionMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pgen_SuppliesEmbryosAndOtherProductionMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_WorkInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pgen_WorkInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pgen_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=pgen_FeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=pgen_FeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924635480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Land and land improvements</a></td>
<td class="nump">$ 9,844<span></span>
</td>
<td class="nump">$ 9,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and building improvements</a></td>
<td class="nump">12,088<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">31,150<span></span>
</td>
<td class="nump">33,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">6,260<span></span>
</td>
<td class="nump">6,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_BreedingandProductionAnimalsGross', window );">Breeding stock</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">5,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ComputerHardwareandSoftware', window );">Computer hardware and software</a></td>
<td class="nump">5,684<span></span>
</td>
<td class="nump">6,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction and other assets in progress</a></td>
<td class="nump">2,754<span></span>
</td>
<td class="nump">5,229<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">69,876<span></span>
</td>
<td class="nump">80,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(34,952)<span></span>
</td>
<td class="num">(36,263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 34,924<span></span>
</td>
<td class="nump">$ 43,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_BreedingandProductionAnimalsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of animals maintained to create offspring or to produce goods to be sold for profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_BreedingandProductionAnimalsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ComputerHardwareandSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and amortization of computer hardware and purchased software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ComputerHardwareandSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924751896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,449<span></span>
</td>
<td class="nump">$ 8,222<span></span>
</td>
<td class="nump">$ 8,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets held-for-use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberOfReportingUnitsClosed', window );">Number of reporting units closed | reporting_unit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberOfReportingUnitsClosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reporting Units Closed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberOfReportingUnitsClosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923843000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">$ (178)<span></span>
</td>
<td class="num">(9,635)<span></span>
</td>
<td class="num">$ (87,862)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">End of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,363<span></span>
</td>
<td class="nump">54,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,119<span></span>
</td>
<td class="nump">83,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,820)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">End of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,363<span></span>
</td>
<td class="nump">$ 54,119<span></span>
</td>
<td class="nump">$ 83,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923470552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,643<span></span>
</td>
<td class="nump">$ 43,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberOfReportingUnitsClosed', window );">Number of reporting units closed | reporting_unit</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on abandonment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="nump">20,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,593<span></span>
</td>
<td class="nump">7,920<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember', window );">Trans Ova</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Patents, developed technologies and know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on abandonment of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberOfReportingUnitsClosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reporting Units Closed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberOfReportingUnitsClosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919089048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 113,677<span></span>
</td>
<td class="nump">$ 107,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(48,281)<span></span>
</td>
<td class="num">(38,913)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net, total</a></td>
<td class="nump">65,396<span></span>
</td>
<td class="nump">68,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Patents, developed technologies and know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">96,927<span></span>
</td>
<td class="nump">90,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(34,412)<span></span>
</td>
<td class="num">(26,619)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net, total</a></td>
<td class="nump">62,515<span></span>
</td>
<td class="nump">64,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">10,850<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,340)<span></span>
</td>
<td class="num">(8,440)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net, total</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,529)<span></span>
</td>
<td class="num">(3,854)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net, total</a></td>
<td class="nump">$ 1,371<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Years) | Patents, developed technologies and know-how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (Years)</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Years) | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (Years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Years) | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (Years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924993544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 7,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">6,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">5,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">5,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">5,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">34,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net, total</a></td>
<td class="nump">$ 65,396<span></span>
</td>
<td class="nump">$ 68,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917614712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Trans Ova Genetics, LC | First National Bank of Omaha</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of credit facility, interest rate at period end</a></td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit facility, current borrowing capacity</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Exemplar Genetics, LLC | American State Bank</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Trans Ova Genetics, LC | First National Bank of Omaha</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_TransOvaGeneticsLcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_TransOvaGeneticsLcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pgen_FirstNationalBankofOmahaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pgen_FirstNationalBankofOmahaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_ExemplarGeneticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_ExemplarGeneticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pgen_AmericanStateBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pgen_AmericanStateBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163922986904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 171,882<span></span>
</td>
<td class="nump">$ 217,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">31,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
<td class="nump">171,522<span></span>
</td>
<td class="nump">186,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">168,147<span></span>
</td>
<td class="nump">213,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">3,655<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=pgen_OtherLongTermDebtMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=pgen_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=pgen_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917901752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 376,000<span></span>
</td>
<td class="nump">$ 219,859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt, net of issuance costs and deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,000)<span></span>
</td>
<td class="num">(3,674,000)<span></span>
</td>
<td class="num">(21,278,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,882,000<span></span>
</td>
<td class="nump">217,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,147,000<span></span>
</td>
<td class="nump">213,771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Precigen ActoBio, Inc. | Harvest Intrexon Enterprise Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 616,000<span></span>
</td>
<td class="nump">921,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes payable to banks | Trans Ova Genetics, LC | American State Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member', window );">3.5% Convertible Notes Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.6622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate', window );">Principal amount used in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,723,000<span></span>
</td>
<td class="nump">$ 168,147,000<span></span>
</td>
<td class="nump">$ 157,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt, net of issuance costs and deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Convertible notes, unamortized discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,853,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member', window );">3.5% Convertible Notes Due 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Common stock price trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Common stock price consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common share price over conversion price for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member', window );">3.5% Convertible Notes Due 2023 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Common stock price trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Common stock price consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_MerckConvertibleNoteMember', window );">Merck Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock issued upon conversion of long-term debt (in shares) | shares</a></td>
<td class="nump">6,758,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DebtInstrumentResaleRestrictionPeriod', window );">Debt instrument, resale restriction days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pgen_ActoBioNotesMember', window );">ActoBio Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock issued upon conversion of long-term debt (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,293,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember', window );">Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ConvertibleDebtPrincipalAmountInitialConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount in principal used in the initial conversion rate of the Convertible Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ConvertibleDebtPrincipalAmountInitialConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DebtInstrumentResaleRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Resale Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DebtInstrumentResaleRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_PrecigenActioBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_PrecigenActioBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pgen_HarvestIntrexonEnterpriseFundILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pgen_HarvestIntrexonEnterpriseFundILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_TransOvaGeneticsLcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_TransOvaGeneticsLcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pgen_AmericanStateBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pgen_AmericanStateBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_MerckConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_MerckConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_ActoBioNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_ActoBioNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_HarvestIntrexonEnterpriseFundILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915928232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt - Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Cash interest expense</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts', window );">Non-cash interest expense</a></td>
<td class="nump">10,587<span></span>
</td>
<td class="nump">9,459<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 17,587<span></span>
</td>
<td class="nump">$ 16,459<span></span>
</td>
<td class="nump">$ 7,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments and amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pgen_A3.5ConvertibleNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915950520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">200,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,855<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 203,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164056700424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">$ (103,855)<span></span>
</td>
<td class="num">$ (171,264)<span></span>
</td>
<td class="num">$ (395,912)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(97,313)<span></span>
</td>
<td class="num">(167,990)<span></span>
</td>
<td class="num">(394,580)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">$ (6,542)<span></span>
</td>
<td class="num">$ (3,274)<span></span>
</td>
<td class="num">$ (1,332)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924415848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>United States federal income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(561)<span></span>
</td>
<td class="num">(11,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="num">(4,355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit from continuing operations</a></td>
<td class="num">$ (82)<span></span>
</td>
<td class="num">$ (930)<span></span>
</td>
<td class="num">$ (15,425)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924454024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed statutory income tax benefit from continuing operations</a></td>
<td class="num">$ (21,810)<span></span>
</td>
<td class="num">$ (35,965)<span></span>
</td>
<td class="num">$ (83,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and provincial income tax benefit, net of federal income taxes</a></td>
<td class="num">(5,167)<span></span>
</td>
<td class="num">(5,494)<span></span>
</td>
<td class="num">(21,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible stock based compensation</a></td>
<td class="nump">5,709<span></span>
</td>
<td class="nump">10,303<span></span>
</td>
<td class="nump">4,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation', window );">Nondeductible officer compensation</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax incentives</a></td>
<td class="num">(524)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts', window );">Acquisition and internal restructuring transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount', window );">Reacquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount', window );">Change in deferred state tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">United States-foreign rate differential</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(3,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance', window );">Income tax reconciliation income tax benefit before valuation allowance, total</a></td>
<td class="num">(21,391)<span></span>
</td>
<td class="num">(31,948)<span></span>
</td>
<td class="num">(91,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance for deferred tax assets</a></td>
<td class="nump">21,309<span></span>
</td>
<td class="nump">31,018<span></span>
</td>
<td class="nump">76,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit from continuing operations</a></td>
<td class="num">$ (82)<span></span>
</td>
<td class="num">$ (930)<span></span>
</td>
<td class="num">$ (15,425)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to adjustments for acquisition-related transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic deferred state income tax rates, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible officers' compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible reacquired in-process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164099723720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 1,816<span></span>
</td>
<td class="nump">$ 2,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption', window );">Equity securities and investments in affiliates</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">11,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">74,981<span></span>
</td>
<td class="nump">85,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,834<span></span>
</td>
<td class="nump">3,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">6,140<span></span>
</td>
<td class="nump">10,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">16,402<span></span>
</td>
<td class="nump">19,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">7,423<span></span>
</td>
<td class="nump">14,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">10,210<span></span>
</td>
<td class="nump">9,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries', window );">Investments in subsidiaries included in discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards', window );">Net operating, capital loss, and interest expense carryforwards</a></td>
<td class="nump">275,519<span></span>
</td>
<td class="nump">196,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">397,066<span></span>
</td>
<td class="nump">364,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="nump">387,348<span></span>
</td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">$ 292,217<span></span>
</td>
<td class="nump">$ 211,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">9,718<span></span>
</td>
<td class="nump">15,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="nump">5,011<span></span>
</td>
<td class="nump">8,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt', window );">Long-term debt</a></td>
<td class="nump">7,604<span></span>
</td>
<td class="nump">9,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">12,615<span></span>
</td>
<td class="nump">18,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities included in continuing operations</a></td>
<td class="num">$ (2,897)<span></span>
</td>
<td class="num">$ (2,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments and investments accounted for under the fair value option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax assets attributable to deductible operating loss carryforwards, capital loss carryforwards, and interest expense carryforwards, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from equity component of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the entity's investment in its wholly-owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925377448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of year</a></td>
<td class="nump">$ 349,008<span></span>
</td>
<td class="nump">$ 292,217<span></span>
</td>
<td class="nump">$ 211,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet', window );">Mergers and acquisitions, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation', window );">Deconsolidation of AquaBounty</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,504)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations', window );">Establishment of deferred taxes for subsidiaries included in discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,592<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations', window );">Current year continuing operations</a></td>
<td class="nump">21,309<span></span>
</td>
<td class="nump">31,018<span></span>
</td>
<td class="nump">98,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales', window );">Discontinued operations treated as asset sales</a></td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">10,585<span></span>
</td>
<td class="nump">3,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations', window );">Discontinued operations related to MBP Titan</a></td>
<td class="nump">8,019<span></span>
</td>
<td class="nump">9,663<span></span>
</td>
<td class="nump">8,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt', window );">Equity component of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate', window );">Change in deferred state tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="nump">387,348<span></span>
</td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">292,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple', window );">Adoption of new accounting pronouncements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple', window );">Adoption of new accounting pronouncements</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,477)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the valuation allowance for deferred tax assets as a result of current year operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the valuation allowance for deferred tax assets as a result of mergers and acquisitions, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in valuation allowance for deferred tax assets as a result of the change in deferred state tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in valuation allowance for deferred tax assets as a result of the equity component of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the valuation allowance for deferred tax assets as a result of foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the valuation allowance for deferred tax assets resulting from the adoption of a recently issued accounting pronouncement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Discontinued Operations Treated As Asset Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Assets, Establishment Of Deferred Taxes For Subsidiaries Included In Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925355512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">$ 10,210<span></span>
</td>
<td class="nump">$ 9,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,823,390)<span></span>
</td>
<td class="num">$ (1,652,869)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_ForeignSubsidiariesMember', window );">Foreign Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness', window );">Net operating losses inherited via acquisition</a></td>
<td class="nump">42,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">756,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Deferred tax assets, capital loss carryforwards</a></td>
<td class="nump">211,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">82,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=pgen_GeneratedAfter2017Member', window );">Generated after 2017 | Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 503,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, acquired in acquisition of a business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_ForeignSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_ForeignSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=pgen_GeneratedAfter2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=pgen_GeneratedAfter2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163918826280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in public or private offerings, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued in public or private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,374<span></span>
</td>
<td class="nump">$ 6,611<span></span>
</td>
<td class="nump">$ 87,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Capitalized offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OwnshareLendingArrangementSharesIssued', window );">Shares issued in share lending agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,479,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination', window );">Share lending agreement, length of time for shares to be returned upon termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised', window );">Proceeds from shares issued for exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 2,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_TSBiotechnologyHoldingsLLCMember', window );">TS Biotechnology Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in public or private offerings, net of issuance costs, shares</a></td>
<td class="nump">5,972,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued in public or private offering</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember', window );">Affiliates of Third Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in public or private offerings, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_AquaBountyMember', window );">AquaBounty Technologies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued in public or private offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised', window );">Proceeds from shares issued for exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pgen_AquaBountyMember', window );">AquaBounty Technologies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent', window );">Additional investment in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Lending Agreement, Length Of Time For Shares To Be Returned Upon Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4M<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591554-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnshareLendingArrangementSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=7656903&amp;loc=SL6757479-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnshareLendingArrangementSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_TSBiotechnologyHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_TSBiotechnologyHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_AquaBountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_AquaBountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pgen_AquaBountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pgen_AquaBountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163928123976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Precigen shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,711<span></span>
</td>
<td class="nump">$ 378,722<span></span>
</td>
<td class="nump">$ 546,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gain on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Precigen shareholders' equity</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Income (loss) on foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Precigen shareholders' equity</a></td>
<td class="nump">3,984<span></span>
</td>
<td class="num">(27,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Precigen shareholders' equity</a></td>
<td class="nump">$ 3,997<span></span>
</td>
<td class="num">$ (27,468)<span></span>
</td>
<td class="num">$ (28,612)<span></span>
</td>
<td class="num">$ (15,554)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925265416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">$ 18,366<span></span>
</td>
<td class="nump">$ 18,950<span></span>
</td>
<td class="nump">$ 36,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pgen_CostOfProductsMember', window );">Cost of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pgen_CostOfServicesMember', window );">Cost of services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">5,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="nump">17,787<span></span>
</td>
<td class="nump">11,380<span></span>
</td>
<td class="nump">25,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation cost</a></td>
<td class="num">$ (1,380)<span></span>
</td>
<td class="nump">$ 3,852<span></span>
</td>
<td class="nump">$ 5,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pgen_CostOfProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pgen_CostOfProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pgen_CostOfServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pgen_CostOfServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917970232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense', window );">Shares issued as payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="nump">$ 10,446<span></span>
</td>
<td class="nump">$ 10,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pgen_ExecutiveChairmanMember', window );">Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LockupPeriodOnRestrictedStockUnitShares', window );">Lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CompensationArrangementWithIndividualAnnualCashRetainer', window );">Compensation arrangement with individual, annual cash retainer</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Precigen Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,255,896<span></span>
</td>
<td class="nump">9,022,282<span></span>
</td>
<td class="nump">11,093,063<span></span>
</td>
<td class="nump">11,382,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,712<span></span>
</td>
<td class="nump">1,781,982<span></span>
</td>
<td class="nump">970,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs related to unvested stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="nump">$ 7.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2008PlanMember', window );">Precigen Stock Option Plan 2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available to grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2013PlanMember', window );">Precigen Stock Option Plan 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available to grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,055,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,225,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of authorized awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2019PlanMember', window );">Precigen Stock Option Plan 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available to grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of authorized awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ExecutiveChairmanMember', window );">Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense', window );">Shares issued as payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="nump">$ 1,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue', window );">Compensation arrangement with individual, annual stock option grant, grant date fair value</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Precigen Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten-year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue', window );">Compensation arrangement with individual, annual RSU grant, grant date fair value</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Precigen Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to restricted stock unit awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of monthly expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CompensationArrangementWithIndividualAnnualCashRetainer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation Arrangement With Individual, Annual Cash Retainer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CompensationArrangementWithIndividualAnnualCashRetainer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation Arrangement With Individual, Annual RSU Grant, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation Arrangement With Individual, Annual Stock Option Grant, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LockupPeriodOnRestrictedStockUnitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time during which issued shares are subject to a lock-up on resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LockupPeriodOnRestrictedStockUnitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense recognized for consideration of services paid in the form of stock. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pgen_ExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pgen_ExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2008PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2008PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2013PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2013PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlan2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919782728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock Option Activity (Details) - Precigen Stock Option Plans - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances at beginning of period (in shares)</a></td>
<td class="nump">9,022,282<span></span>
</td>
<td class="nump">11,093,063<span></span>
</td>
<td class="nump">11,382,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">5,693,498<span></span>
</td>
<td class="nump">1,556,575<span></span>
</td>
<td class="nump">1,470,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(30,061)<span></span>
</td>
<td class="num">(19,887)<span></span>
</td>
<td class="num">(45,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(976,324)<span></span>
</td>
<td class="num">(1,236,326)<span></span>
</td>
<td class="num">(929,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(2,453,499)<span></span>
</td>
<td class="num">(2,371,143)<span></span>
</td>
<td class="num">(785,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances at period end (in shares)</a></td>
<td class="nump">11,255,896<span></span>
</td>
<td class="nump">9,022,282<span></span>
</td>
<td class="nump">11,093,063<span></span>
</td>
<td class="nump">11,382,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price (usd per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balances at beginning of period (in usd per share)</a></td>
<td class="nump">$ 21.94<span></span>
</td>
<td class="nump">$ 27.95<span></span>
</td>
<td class="nump">$ 28.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">10.03<span></span>
</td>
<td class="nump">6.52<span></span>
</td>
<td class="nump">14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="num">(3.88)<span></span>
</td>
<td class="num">(3.17)<span></span>
</td>
<td class="num">(6.59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="num">(15.47)<span></span>
</td>
<td class="num">(24.92)<span></span>
</td>
<td class="num">(21.48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in usd per share)</a></td>
<td class="num">(26.53)<span></span>
</td>
<td class="num">(38.53)<span></span>
</td>
<td class="num">(26.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balances at period end (in usd per share)</a></td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="nump">21.94<span></span>
</td>
<td class="nump">$ 27.95<span></span>
</td>
<td class="nump">$ 28.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at period end (in shares)</a></td>
<td class="nump">5,437,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 19.61<span></span>
</td>
<td class="nump">$ 24.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balances at period end, weighted average remaining contractual period</a></td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">7 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at period end, weighted average remaining contractual period</a></td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924525688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Information About Stock Options Outstanding (Details) - Precigen Stock Option Plans - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">11,255,896<span></span>
</td>
<td class="nump">9,022,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="nump">$ 21.94<span></span>
</td>
<td class="nump">$ 27.95<span></span>
</td>
<td class="nump">$ 28.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 19,482<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">5,437,667<span></span>
</td>
<td class="nump">6,264,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 19.61<span></span>
</td>
<td class="nump">$ 24.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 9,707<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Price range 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options, exercise price range, lower limit (in usd per share)</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options, exercise price range, upper limit (in usd per share)</a></td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">3,259,685<span></span>
</td>
<td class="nump">1,612,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 4.63<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">8 years 11 months 1 day<span></span>
</td>
<td class="text">8 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 18,157<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">1,271,310<span></span>
</td>
<td class="nump">585,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">8 years 8 months 23 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 9,018<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Price range 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options, exercise price range, lower limit (in usd per share)</a></td>
<td class="nump">$ 6.06<span></span>
</td>
<td class="nump">$ 8.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options, exercise price range, upper limit (in usd per share)</a></td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="nump">$ 20.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">2,261,216<span></span>
</td>
<td class="nump">1,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 11.01<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">8 years 2 months 23 days<span></span>
</td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">345,788<span></span>
</td>
<td class="nump">753,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 9.09<span></span>
</td>
<td class="nump">$ 15.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">4 years 9 months 3 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Price range 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options, exercise price range, lower limit (in usd per share)</a></td>
<td class="nump">$ 15.80<span></span>
</td>
<td class="nump">$ 20.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options, exercise price range, upper limit (in usd per share)</a></td>
<td class="nump">$ 20.94<span></span>
</td>
<td class="nump">$ 20.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">3,028,309<span></span>
</td>
<td class="nump">1,646,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 18.85<span></span>
</td>
<td class="nump">$ 20.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">7 years 4 months 17 days<span></span>
</td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">1,216,258<span></span>
</td>
<td class="nump">892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 19.82<span></span>
</td>
<td class="nump">$ 20.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Price range 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options, exercise price range, lower limit (in usd per share)</a></td>
<td class="nump">$ 21.13<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options, exercise price range, upper limit (in usd per share)</a></td>
<td class="nump">$ 36.84<span></span>
</td>
<td class="nump">$ 29.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">2,303,371<span></span>
</td>
<td class="nump">1,976,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 26.33<span></span>
</td>
<td class="nump">$ 23.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">2,200,996<span></span>
</td>
<td class="nump">1,585,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 26.52<span></span>
</td>
<td class="nump">$ 23.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember', window );">Price range 5</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock options, exercise price range, lower limit (in usd per share)</a></td>
<td class="nump">$ 37.88<span></span>
</td>
<td class="nump">$ 29.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock options, exercise price range, upper limit (in usd per share)</a></td>
<td class="nump">$ 47.35<span></span>
</td>
<td class="nump">$ 65.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options (in shares)</a></td>
<td class="nump">403,315<span></span>
</td>
<td class="nump">2,508,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 42.26<span></span>
</td>
<td class="nump">$ 34.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining life (in years)</a></td>
<td class="text">4 years 3 days<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">403,315<span></span>
</td>
<td class="nump">2,448,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in usd per share)</a></td>
<td class="nump">$ 42.26<span></span>
</td>
<td class="nump">$ 34.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining life (in years)</a></td>
<td class="text">4 years 3 days<span></span>
</td>
<td class="text">4 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ExercisePriceAxis=pgen_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ExercisePriceAxis=pgen_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ExercisePriceAxis=pgen_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ExercisePriceAxis=pgen_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ExercisePriceAxis=pgen_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ExercisePriceAxis=pgen_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ExercisePriceAxis=pgen_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ExercisePriceAxis=pgen_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ExercisePriceAxis=pgen_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ExercisePriceAxis=pgen_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925276664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - Precigen Stock Option Plans - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balances at beginning of period (in shares)</a></td>
<td class="nump">1,781,982<span></span>
</td>
<td class="nump">970,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,157,390<span></span>
</td>
<td class="nump">2,278,460<span></span>
</td>
<td class="nump">1,069,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,802,593)<span></span>
</td>
<td class="num">(1,159,165)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(409,067)<span></span>
</td>
<td class="num">(307,654)<span></span>
</td>
<td class="num">(73,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balances at period end (in shares)</a></td>
<td class="nump">1,727,712<span></span>
</td>
<td class="nump">1,781,982<span></span>
</td>
<td class="nump">970,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balances at beginning of period (in usd per share)</a></td>
<td class="nump">$ 8.71<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share)</a></td>
<td class="nump">3.09<span></span>
</td>
<td class="nump">6.59<span></span>
</td>
<td class="nump">13.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share)</a></td>
<td class="num">(3.99)<span></span>
</td>
<td class="num">(8.74)<span></span>
</td>
<td class="num">(15.82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share)</a></td>
<td class="num">(8.59)<span></span>
</td>
<td class="num">(8.99)<span></span>
</td>
<td class="num">(13.47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balances at period end (in usd per share)</a></td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="nump">$ 8.71<span></span>
</td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Balances at period end, weighted average remaining contractual period</a></td>
<td class="text">5 months 1 day<span></span>
</td>
<td class="text">1 year 2 months 26 days<span></span>
</td>
<td class="text">1 year 5 months 4 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pgen_PrecigenStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923966120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LesseeOperatingLeaseTerminationPeriod', window );">Termination period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924938712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 3,578<span></span>
</td>
<td class="nump">$ 3,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease costs</a></td>
<td class="nump">$ 6,183<span></span>
</td>
<td class="nump">$ 6,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163925374136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 3,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">3,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">12,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(2,510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">10,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">$ 2,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">$ 7,744<span></span>
</td>
<td class="nump">$ 10,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915643816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">4 years 2 months 15 days<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">10.27%<span></span>
</td>
<td class="nump">10.32%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917182104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flows Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="nump">$ 3,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets added in exchange for new lease liabilities</a></td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">$ 1,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919353720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 20, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in affiliates | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember', window );">Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in affiliates | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_XYLLCMember', window );">XY, LLC | Licensing and patent infringement suit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled, number</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LossContingenciesTotalClaimsNumber', window );">Total claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Claims dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Claims pending resolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LossContingencyClaimsInvalidatedNumber', window );">Loss contingency, claims invalidated number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LossContingencyAppealedClaimsDismissed', window );">Loss contingency, appealed claims dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LossContingencyReversedClaimsDismissedNumber', window );">Loss contingency, reversed claims dismissed number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_SecuritiesAndExchangeCommissionMember', window );">Securities And Exchange Commission | Methane Bioconversion Platform Disclosures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pgen_HarvestIntrexonEnterpriseFundILPMember', window );">Harvest Intrexon Enterprise Fund I, LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues', window );">Stock issued in conjunction with settlement agreement, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,117,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues', window );">Shares issued in conjunction with settlement agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss on settlement agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LossContingenciesTotalClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LossContingenciesTotalClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LossContingencyAppealedClaimsDismissed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Appealed Claims Dismissed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LossContingencyAppealedClaimsDismissed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LossContingencyClaimsInvalidatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Invalidated Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LossContingencyClaimsInvalidatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LossContingencyReversedClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reversed Claims Dismissed Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LossContingencyReversedClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_XYLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_XYLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pgen_LicensingAndPatentInfringementSuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pgen_LicensingAndPatentInfringementSuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_SecuritiesAndExchangeCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_SecuritiesAndExchangeCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pgen_MethaneBioconversionPlatformDisclosuresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pgen_MethaneBioconversionPlatformDisclosuresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pgen_HarvestIntrexonEnterpriseFundILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pgen_HarvestIntrexonEnterpriseFundILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919709432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>relatedParty </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,446,000<span></span>
</td>
<td class="nump">$ 10,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NoncashDividendIncome', window );">Dividend income from investments in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">14,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,456,000<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
<td class="nump">2,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ThirdSecurityMember', window );">Third Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Expense for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CommonStockCalculationPeriod', window );">Common stock calculation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued as payment for services, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606,062<span></span>
</td>
<td class="nump">696,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued as payment for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,233,000<span></span>
</td>
<td class="nump">$ 8,324,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue', window );">Sublease rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember', window );">Affiliates of Third Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_CastleCreekBiosciencesIncMember', window );">Castle Creek Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sales of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Proceeds from Convertible Preferred Shares and convertible note</a></td>
<td class="nump">$ 3,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Changes in fair value, gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Third Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Expense for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pgen_SeriesAPreferredSharesMember', window );">Series A Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pgen_SeriesAPreferredSharesMember', window );">Series A Preferred Shares | Affiliates of Third Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_ConvertiblePreferredStockAmountAuthorized', window );">Convertible preferred stock, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_ThirdSecurityMember', window );">Third Security | Executive Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_RelatedPartyOwnershipInterest', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pgen_ZiopharmMember', window );">ZIOPHARM Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NoncashDividendIncome', window );">Dividend income from investments in preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pgen_CollaborationandlicensingagreementsMember', window );">Collaboration and licensing agreements | Various ECC Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NumberOfRelatedPartiesWithTerminatedAgreements', window );">Number of related parties with terminated agreements | relatedParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from previously deferred balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CommonStockCalculationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Calculation Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CommonStockCalculationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_ConvertiblePreferredStockAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum value of preferred shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_ConvertiblePreferredStockAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NoncashDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income included in net income that results in no cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NoncashDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NumberOfRelatedPartiesWithTerminatedAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Related Parties With Terminated Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NumberOfRelatedPartiesWithTerminatedAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_RelatedPartyOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_RelatedPartyOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized for the period under subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577943&amp;loc=d3e41620-112719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ThirdSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ThirdSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_AffiliatesOfThirdSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_CastleCreekBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_CastleCreekBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pgen_SeriesAPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pgen_SeriesAPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_ThirdSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_ThirdSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pgen_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pgen_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_CollaborationandlicensingagreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_CollaborationandlicensingagreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_VariousECCAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_VariousECCAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919709080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations attributable to Precigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103,773)<span></span>
</td>
<td class="num">$ (168,742)<span></span>
</td>
<td class="num">$ (375,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations attributable to Precigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,748)<span></span>
</td>
<td class="num">(153,582)<span></span>
</td>
<td class="num">(134,219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Precigen</a></td>
<td class="num">$ (41,661)<span></span>
</td>
<td class="num">$ (29,508)<span></span>
</td>
<td class="num">$ (43,354)<span></span>
</td>
<td class="num">$ (55,998)<span></span>
</td>
<td class="num">$ (169,215)<span></span>
</td>
<td class="num">$ (53,634)<span></span>
</td>
<td class="num">$ (38,766)<span></span>
</td>
<td class="num">$ (60,709)<span></span>
</td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="num">$ (322,324)<span></span>
</td>
<td class="num">$ (509,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,065,539<span></span>
</td>
<td class="nump">154,138,774<span></span>
</td>
<td class="nump">129,521,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (2.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40)<span></span>
</td>
<td class="num">(1.00)<span></span>
</td>
<td class="num">(1.03)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924720904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">24,849,312<span></span>
</td>
<td class="nump">32,260,596<span></span>
</td>
<td class="nump">31,152,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">11,732,440<span></span>
</td>
<td class="nump">21,323,068<span></span>
</td>
<td class="nump">18,955,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">11,255,896<span></span>
</td>
<td class="nump">9,022,282<span></span>
</td>
<td class="nump">11,093,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,727,712<span></span>
</td>
<td class="nump">1,781,982<span></span>
</td>
<td class="nump">970,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">133,264<span></span>
</td>
<td class="nump">133,264<span></span>
</td>
<td class="nump">133,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163922880824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Information by Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 54,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,363<span></span>
</td>
<td class="nump">$ 54,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,635)<span></span>
</td>
<td class="num">(87,862)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="nump">19,333<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
<td class="nump">$ 29,838<span></span>
</td>
<td class="nump">17,002<span></span>
</td>
<td class="nump">$ 18,299<span></span>
</td>
<td class="nump">$ 32,836<span></span>
</td>
<td class="nump">$ 22,585<span></span>
</td>
<td class="nump">103,178<span></span>
</td>
<td class="nump">90,722<span></span>
</td>
<td class="nump">151,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,713)<span></span>
</td>
<td class="num">(56,115)<span></span>
</td>
<td class="num">(62,067)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_PGENTherapeuticsSegmentMember', window );">PGEN Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,611)<span></span>
</td>
<td class="num">(30,164)<span></span>
</td>
<td class="num">(32,832)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ActoBioMember', window );">ActoBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,861)<span></span>
</td>
<td class="num">(13,662)<span></span>
</td>
<td class="num">(12,797)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember', window );">Trans Ova</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
<td class="num">(6,337)<span></span>
</td>
<td class="num">(5,730)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_HumanBiotherapeuticsSegmentMember', window );">Human Biotherapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,139)<span></span>
</td>
<td class="num">(1,051)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,274<span></span>
</td>
<td class="num">(4,901)<span></span>
</td>
<td class="num">(10,708)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">54,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,363<span></span>
</td>
<td class="nump">54,119<span></span>
</td>
<td class="nump">83,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,124<span></span>
</td>
<td class="nump">86,762<span></span>
</td>
<td class="nump">141,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,748<span></span>
</td>
<td class="nump">101,232<span></span>
</td>
<td class="nump">143,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | PGEN Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,232<span></span>
</td>
<td class="nump">15,232<span></span>
</td>
<td class="nump">15,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="nump">2,227<span></span>
</td>
<td class="nump">29,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,782<span></span>
</td>
<td class="nump">13,568<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | ActoBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="nump">6,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Trans Ova</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">16,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,594<span></span>
</td>
<td class="nump">16,594<span></span>
</td>
<td class="nump">46,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,186<span></span>
</td>
<td class="nump">68,672<span></span>
</td>
<td class="nump">75,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,526<span></span>
</td>
<td class="nump">70,033<span></span>
</td>
<td class="nump">75,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | Human Biotherapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,810<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,810<span></span>
</td>
<td class="nump">3,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 20,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,076<span></span>
</td>
<td class="nump">20,076<span></span>
</td>
<td class="nump">20,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Reallocations from changes to reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from external customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,299<span></span>
</td>
<td class="nump">12,514<span></span>
</td>
<td class="nump">30,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,580<span></span>
</td>
<td class="nump">13,784<span></span>
</td>
<td class="nump">30,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,624<span></span>
</td>
<td class="nump">14,470<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues | PGEN Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,006<span></span>
</td>
<td class="nump">11,341<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues | ActoBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues | Trans Ova</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues | Human Biotherapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment revenues | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 1,270<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Adjusted EBITDA defined as net income (loss) before (i) interest expense, (ii) income tax expense/benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) write-off of reacquired in-process research and development, (vii) equity in net income (loss) of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_PGENTherapeuticsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_PGENTherapeuticsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ActoBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_ActoBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_TransOvaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_HumanBiotherapeuticsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_HumanBiotherapeuticsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163919799304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 19,333<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
<td class="nump">$ 29,838<span></span>
</td>
<td class="nump">$ 17,002<span></span>
</td>
<td class="nump">$ 18,299<span></span>
</td>
<td class="nump">$ 32,836<span></span>
</td>
<td class="nump">$ 22,585<span></span>
</td>
<td class="nump">$ 103,178<span></span>
</td>
<td class="nump">$ 90,722<span></span>
</td>
<td class="nump">$ 151,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=pgen_OperatingSegmentsAndCorporateNonSegmentMember', window );">Other revenues, including from other operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,634<span></span>
</td>
<td class="nump">17,964<span></span>
</td>
<td class="nump">40,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=pgen_EliminationsAndReconcilingItemsMember', window );">Elimination of intersegment revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,624)<span></span>
</td>
<td class="num">(14,690)<span></span>
</td>
<td class="num">(2,561)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember', window );">Total segment revenues from reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,168<span></span>
</td>
<td class="nump">$ 87,448<span></span>
</td>
<td class="nump">$ 112,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=pgen_OperatingSegmentsAndCorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=pgen_OperatingSegmentsAndCorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=pgen_EliminationsAndReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=pgen_EliminationsAndReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163920087416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="num">$ (28,713)<span></span>
</td>
<td class="num">$ (56,115)<span></span>
</td>
<td class="num">$ (62,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(17,516)<span></span>
</td>
<td class="num">(24,896)<span></span>
</td>
<td class="num">(33,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_GainLossRelatedToNoncashLitigationSettlement', window );">Loss on settlement agreement</a></td>
<td class="num">(11,436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="num">(18,366)<span></span>
</td>
<td class="num">(18,950)<span></span>
</td>
<td class="num">(36,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="num">(1,176)<span></span>
</td>
<td class="num">(6,730)<span></span>
</td>
<td class="num">(11,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(837)<span></span>
</td>
<td class="num">(1,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(103,855)<span></span>
</td>
<td class="num">(171,264)<span></span>
</td>
<td class="num">(395,912)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_CapitalExpendituresAndInvestmentsinAffiliates', window );">Remove cash paid for capital expenditures and investments in affiliates</a></td>
<td class="nump">6,970<span></span>
</td>
<td class="nump">12,512<span></span>
</td>
<td class="nump">15,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=pgen_CorporateAndReconcilingItemsMember', window );">Other expenses:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,400)<span></span>
</td>
<td class="num">(17,666)<span></span>
</td>
<td class="num">(8,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(15,042)<span></span>
</td>
<td class="num">(16,142)<span></span>
</td>
<td class="num">(20,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="num">(920)<span></span>
</td>
<td class="num">(30,810)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Reacquisition of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(236,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_GainLossRelatedToNoncashLitigationSettlement', window );">Loss on settlement agreement</a></td>
<td class="num">(11,436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="num">(19,746)<span></span>
</td>
<td class="num">(15,098)<span></span>
</td>
<td class="num">(30,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_AdjustmentForBonusesPaidInEquityAwards', window );">Adjustment related to accrued bonuses paid in equity awards</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net loss of affiliates</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="num">(2,416)<span></span>
</td>
<td class="num">(8,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Unallocated corporate costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(37,566)<span></span>
</td>
<td class="num">(46,011)<span></span>
</td>
<td class="num">(74,609)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">(5,713)<span></span>
</td>
<td class="num">(14,306)<span></span>
</td>
<td class="num">(2,343)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember', window );">Reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="num">(32,987)<span></span>
</td>
<td class="num">(51,214)<span></span>
</td>
<td class="num">(51,359)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates', window );">Segment Adjusted EBITDA</a></td>
<td class="nump">4,274<span></span>
</td>
<td class="num">(4,901)<span></span>
</td>
<td class="num">(10,708)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pgen_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Add recognition of previously deferred revenue associated with upfront and milestone payments</a></td>
<td class="nump">$ 25,005<span></span>
</td>
<td class="nump">$ 14,721<span></span>
</td>
<td class="nump">$ 33,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_AdjustmentForBonusesPaidInEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment For Bonuses Paid In Equity Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_AdjustmentForBonusesPaidInEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_CapitalExpendituresAndInvestmentsinAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Expenditures and Investments in Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_CapitalExpendituresAndInvestmentsinAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_GainLossRelatedToNoncashLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Noncash Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_GainLossRelatedToNoncashLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Adjusted EBITDA defined as net income (loss) before (i) interest expense, (ii) income tax expense/benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) write-off of reacquired in-process research and development, (vii) equity in net income (loss) of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=pgen_CorporateAndReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=pgen_CorporateAndReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pgen_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pgen_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pgen_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163917777912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Additional Information (Details) - Non-US - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 5,908<span></span>
</td>
<td class="nump">$ 6,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Lived Assets, Including Property, Plant, and Equipment and Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163924053064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 19,333<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
<td class="nump">$ 29,838<span></span>
</td>
<td class="nump">$ 17,002<span></span>
</td>
<td class="nump">$ 18,299<span></span>
</td>
<td class="nump">$ 32,836<span></span>
</td>
<td class="nump">$ 22,585<span></span>
</td>
<td class="nump">$ 103,178<span></span>
</td>
<td class="nump">$ 90,722<span></span>
</td>
<td class="nump">$ 151,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(35,167)<span></span>
</td>
<td class="num">(23,006)<span></span>
</td>
<td class="num">(11,830)<span></span>
</td>
<td class="num">(16,600)<span></span>
</td>
<td class="num">(68,724)<span></span>
</td>
<td class="num">(34,702)<span></span>
</td>
<td class="num">(21,508)<span></span>
</td>
<td class="num">(41,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(39,682)<span></span>
</td>
<td class="num">(27,536)<span></span>
</td>
<td class="num">(15,709)<span></span>
</td>
<td class="num">(20,846)<span></span>
</td>
<td class="num">(64,236)<span></span>
</td>
<td class="num">(39,119)<span></span>
</td>
<td class="num">(22,440)<span></span>
</td>
<td class="num">(44,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Precigen</a></td>
<td class="num">$ (41,661)<span></span>
</td>
<td class="num">$ (29,508)<span></span>
</td>
<td class="num">$ (43,354)<span></span>
</td>
<td class="num">$ (55,998)<span></span>
</td>
<td class="num">$ (169,215)<span></span>
</td>
<td class="num">$ (53,634)<span></span>
</td>
<td class="num">$ (38,766)<span></span>
</td>
<td class="num">$ (60,709)<span></span>
</td>
<td class="num">$ (170,521)<span></span>
</td>
<td class="num">$ (322,324)<span></span>
</td>
<td class="num">$ (509,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (2.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to Precigen per share, basic and diluted (in usd per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (3.93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163915599656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plans, cost recognized</a></td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">$ 1,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140163923359752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued in public or private offering (estimated)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,374<span></span>
</td>
<td class="nump">$ 6,611<span></span>
</td>
<td class="nump">$ 87,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember', window );">Discontinued Operations, Disposed of by Means Other than Sale, Abandonment | MBP Titan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the period (in shares)</a></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued in public or private offering (estimated)</a></td>
<td class="nump">$ 121,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Operating Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pgen_MBPTitanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140164017949416">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2014-09 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>151
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_ ^CX,0:N"<>!%_IO6-BAS*3\M&>C*.+EF<9\82'QD(P^'OB0YXD%@EX_%N
MMG;OM(;[QUOT:S=X&,R,:3Z4R7<1F?BB==HB$9^S/#%W<O4[+P;4LWBA3+3[
M):O-LSW:(F&NC4P+8V"0BFSSSYX+1^P9G'H'#&AA0%\9^-T#!D%A$#0UZ!8&
M7>>9S5"<'T;,L,MS)5=$V:<!S1XX9SIK&+[(;-RG1L%= 7;F<BB?N"(3"#%I
MDV_3$7GW]CUY2T1&;D220&3T><? >^S3G;# _+C!I <P?4IN9&9B3:ZRB$<O
M 3I <,>2;EE^I"CBB(?')/"/"/6H5T%HB)M?\]DQ\7O.W*\P'^'F?^09O-VK
M>ON+T00[GP<.+T!]_O=@IHV">?\/ MG=078=9/>0@V28PVHTY'Z]Y%41P\U]
MK_T98=';L>@U8S'(LIPEY(XOI3)5=' <HW*.T.GOZ/2;T9EP)61D9R.!15+I
MGQJD8O[]].9-S1PXV7$[01&'N5*6VK70(7CJ!V<*Y8>CM=L^;0<^PNMTQ^NT
MX412#,3=:?/A,.)8<Y9H+(YG.TYG*,Y59H19@ZL23F[S=,95%1<<P_/\=M#W
MNA3AXWNE:'I-&-WQA;!K&-QUR]+*N-4 3>ZNAN-/5[='9'P[/,:X[0FZWX3;
M. NE@K@Q&\(C,C4PL8A49"CSS*@U_$?5A''TAP%&DI8D:1.2]^R9C".8;F(N
M0L<4"7 -).VW/>^T>WK6PQB6&NT'31@.HDAQK8^V!^0+/$>^9M6^PR&I%YQT
MR91G/&3D!HHTN=*0>M7CBJTQSF42\'$9?\UY:,\@YO=RE57RQ>$^<2BL,@/&
M1QB],COXN*R_IK>;DQ,EGT065OL4Q[P98=3*3.'C O^:VD1J [+\EU@>7B@X
M(O5.3_H8MS)3^#6IPC&#HOXP%1P@\+#,X)>IP<?U_(NTJ6H2RPS3X1J07J_?
M/COSL!SJEXG!QU7]7AC("7).?/IN]AZ65I@K\%8E+1QI*-,4U&=J9/AX1&ZE
M79?D@25H(4++A$%QG8=L&HEL0:;K=":3*GXU !-($AB3,CU07,"W/B)7SV',
M,JC[#Z6N&J#;P70T^!/C5&8#VB@;?(?=7_LQ [V!2#(-TRPB8ZWSZGE6@_F#
M:XQ;F0=HHSSP(!/(F[ S=F6(JMP5U2#=2HQ0*?*TD<AO"\A-<>;F%LAI7DT,
M1ZQQ5:GOM)&^CS/#U68_;\M9MJ5:R0Q'K&%6RCMM).\N=&0(66<A5:5*U. ,
MPI #! !$&S",72GP%-?G@MTT94E"/N8:;NOJ..(X=?4V+96>XB)=,+I*N5K8
MJ?4)$$P,^2==LJS:<?]O*T!+R:>X4(^'UW=DD$?"0.$P,(9#HG:%XW7"%I7,
M<+R:O6902GS0:$\PC4'%,$_5P-1Y*BB5/FBT$9CDLT2$X![)JI;@J$#I.13;
M)GRZ[ :]8R@9GJI>7XIZT$C47R;6:<R@P")?<P-ARUQ*?"<RHMWE]U6=G>(M
M_3UZU.OU^SX-S@Y0W.O#X(J\W>SJO=T2K.R9W=G-.6A6=4E:@SJQ>BPS;>L2
M$W.B=KO$7S49\;G(A--&J'J?UYLBV.VXYS"A!7"Q3:IM!^6&<Z?M .5<%\LD
M@NQ#X)"(5YS5EK/MWD'Y8LAX/-Z0$/IE2X;8]2)52FSCAZQB[N BNP?CT3&9
MYF%,EHZ>WM%;"9C7,T[FH'L1G($>V-$5]82 J$) RZK"QEUHUQZVSP(EGWHD
M8NMJO\PW?9"U[8-PVS4$3X7<UIB__.SWO=^VS3]LCQR4.33 ,]X 1A2Y41U2
MC1J VE5:)LV@8<]LOQ-T#1<K,T -6%V#LDR80</66<&JZ* =YH7#7?_ 6)6)
M,FB4*(= 3 &I,<R39_*95\LL#N5YGA_T^MY9I;\Z>PUUFP/=APE-0ML[V?36
M=U=W'S\&KN7?*1_??#FY83:%:I+P.9AZQR<00;7Y&+$Y,7+IVO,S:8Q,W6',
M&:QR^P#<GTMIMB?V!;M/0I?_ 5!+ P04    " #Y@6%2EHT6_10(   =)
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;+6:;6_;.!+'OPKA"^ZV@%.+
M#WIJDP#;%+M;H+L;--V[U[1$QT(ET2O127.?_H:R8MKB@UU<^Z:QW2'UYY S
MOQG:5T^R^]*OA5#H:U.W_?5LK=3FS6+1%VO1\/ZUW(@6_F<ENX8K>-L]+/I-
M)W@Y#&KJ!8FB9-'PJIW=7 V?W74W5W*KZJH5=QWJMTW#N^=WHI9/US,\>_G@
M4_6P5OJ#Q<W5AC^(>Z'^VMQU\&ZQGZ6L&M'VE6Q1)U;7LY_QFUN6Z@&#Q;\K
M\=0?O$9Z*4LIO^@W'\KK6:05B5H42D_!X<^CN!5UK6<"'7^/D\[VS]0##U^_
MS/[+L'A8S)+WXE;6_ZE*M;Z>93-4BA7?UNJ3?/I-C N*]7R%K/OA7_0TVD8S
M5&Q[)9MQ,"AHJG;WEW\='7$P #// #(.(.<.H., .BQTIVQ8UGNN^,U5)Y]0
MIZUA-OUB\,TP&E93M7H;[U4'_UO!.'5S*]M>UE7)E2C1.U[SMA#H7D_7HTOT
MU_U[]-/%*W2!JA9]7LMMS]NROUHH>+(>ORC&I[S;/85XGO)>%*\1Q7-$(A(Y
MAM^>/1SGQ\,7L-[]HLE^T628C_H6O>TZT2K$^Q[6&9B0[B>DPX3,-R'OUPA<
M@PK]0OR]K1YY#4]PNFHW53I,I:/L\2;&:4ZN%H^''K&MDCC-Z=[J2"?;ZV1!
MG?=KV:E+);H&-O11]*KQB=S-DQP\GF64Q!.1ME5.DLBM,=YKC(.;\TD4 MRW
MK$5H9Y+];$EPQ9\[7HHY@LEZQ&M(6L,!A_2'BDZ4E4*UA$/0([E"%VR>D7C8
MQHMX#D<-SH?^'$Z?:):B^^<_<!*]?3G%@YT^CW/(9OU&#.FH?G;Y,K&\A!.6
MI1-?VE8D2F*/,]/]\M/@\C^)>HCL#>]4)?HS'8'G<93O'$'F%)/OY8C4=D0^
M\8)MDD0>'V1['V1!'_PAU?0H[>1DUK-HDDT%V48D9\2M*-\KRH.*_E1KT;D4
MY?;#Z#0Q.&PBZG$1C@P&HJ"D#Y .6B4[Y[Z-8X\V#M-XZBJ761+EJ4?; :)P
M4-M=)S:\*I'X"L6+/J/ZQ$F?#\?)#E6DV$JO#JLX(SZI!BR8A$%P1!:T%G4Y
MQ%@/.$#PER]!NVQUVG5J)W9"S6(ZU6Y;88P98Q[UAF(XC+'/4O$:J@X_'4>9
MU!; LIQE4Z&V':$L81Z*88,Q'.;870=U;*>>YV@#%8L:#H2F[D8[=HY:X?:N
MC2O*<L*FJAWLHWGLB7ELN(;C$R&F>/M0 =A&U_J%QG86C&F>3(4ZS#+PKT>H
M028.,_-7*<NGJJZ=TFQ,Q8PFUA%UF>&#;'\LS> ,AWGVP50MNB3EJU555]R3
MW[$-DVBJTX$DEF"/3$,<'$;.T U=RM7EMA>A.++ADE,[W&TKC+/(%T0&0O@,
M"H74V:2!=&ZI<UA!5+G%$<,C$N;1'[(M_K]<2FP:37??8<*B*/? E!A@D3"P
M=GG4[UEBPX=B%ELEH<..Q7&:>+:>'/0_YS5 $#M+""!=&H;:*@,0$@;(ST4A
MMSHV-_Q95_#.Q=M08'$^18?#*HY)YEFX 0<)@P,$=ENHAPO9Z%J"[ZX2@!Y+
MT8I5Y=DN&PC985DS*K:M,,6Y3[+!!@EC8PS34;AWQT:I-A+RF$T+-8<5QDGJ
MJ1^( 0<)@^.]6 DX6"4T E!-;J'OJMJBWI95^X N=HW"19:F:-7)!FR.6I/O
MU6,01Q^515;D._B4^"I58O!$PGCZ".^'9>QZ*J>^TU!RF$ !ZZD_B($2"4/I
M)>@WLAN./<BL9?NPNPXHQ5*YM@MV@&",E/QA^^7JPBR/.(S@P/H2M4$@"2/0
MY1+!@=FGPLS1A"6QE1%<5M039=2@D8;1>-C3/[]D6O=-DZ,AF^8"ATWLJ7^H
M 2 - ]#!EV_F-[7AAUG$IDYVF,513#UIEQI$TG G=]P+G3@/U.[(&,'$TNIH
MW C)L2>TZ<'U8YB['R=Q#'W%D(6.C[<KODD\CZ+H!\8W=?2**8Z)==_IL,L2
M2GQGT2"?AI%O0^D,[Q!(>]%X%TBC.<[(#X46M6L'0B,RK;4=9BS#U-/P45-B
MT'")\7&:\WP^<FJWBXDT9=.FVF&%(V]#2$W)0<\L.13_>C)*7:6!5<<YK;Q9
MVY0&-%P:[,HX ]Q36ATU@%7%.(P\2*2F2J#A*N&C2^&W)V\;V)9X1UM+4]]-
M)C5,IV&F[Q+W*?<ZT,Q2AJV(L^UHQB+?91 S$&=AB-_*IJG&BPR=)VYEJR#S
MB+;P* [/I[_M?=-O>"&N9QO(-J)[%+,;Y/JJ[3M,=+QF4Q4P'.PZ[]>\$VM9
MEZ+K_S7<UZGGT,2&U>S$K2LX$ZJW7LGB"Z0NJ=,S>N2U3O;0T&O"#93KM0#P
M]U:M95?]%[+&6?G[[? *9^D\22AP(=U/I#_6'Z5LGF7[^:N^UZW:<$N]5;V"
M%QHJWXD5S"XBIJ$5-#GVL2DQV(G6OH2&!A  L:4OXR^K%A5\4T&L.46Z:)XE
M<3+-MB[#-"81\Q1P[."KSI.M_K;9[G!=0F]?N/LQ9C/U$G!/:6YYU669Q"1+
M/!1C!L L#.!#K<,7&\,%!02+_KW$H]"5B6P$^DE_1_?*N0H;KS2WT.:PNH2S
MF_A\;2C,3GS+.N3<_F1\CV)MPB8I3J<E@\,,K+"G(&2&Q"Q,8@L00_"=+3ZU
MOIAWWMTY[)QW=XN#WV[H'\[\SKN'JNVA#UW!P.AU"GO6[7Z+LGNCY&;X.<=2
M*B6;X>5:<)"M#>#_5U*JES?Z%R+[7P3=_ ]02P,$%     @ ^8%A4BD1/SX!
M!   T@X  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6S-5UUOHT84_2LC
M&E6)Y T,V("WCJ7$4=65MI*5[+8/51_&<&U0!L:=&>Q-?WWO ,8.8,?>JE+S
M$#/#_3CG<B^'F6R%?%$)@";?,IZK.RO1>OW1ME640,;4K5A#CG>60F9,XU*N
M;+66P.+2*>.VZSB^G;$TMZ:3<F\NIQ-1:)[F,)=$%5G&Y.L#<+&]LZBUVWA*
M5XDV&_9TLF8K> ;]=3V7N+*;*'&:0:Y2D1,)RSOKGGZ<T< XE!:_I;!5!]?$
M4%D(\6(6G^([RS&(@$.D30B&/QN8 ><F$N+XJPYJ-3F-X^'U+OK/)7DDLV *
M9H+_GL8ZN;-"B\2P9 773V+["]2$1B9>)+@J_Y-M;>M8)"J4%EGMC BR-*]^
MV;>Z$ <.='C$P:T=W',=O-K!*XE6R$I:CTRSZ42*+9'&&J.9B[(VI3>R27/S
M&)^UQ+LI^NGI3.1*\#1F&F+RP#C+(R#/)IPBUW,F(=<)Z#1B_(9\(%^?'\GU
MU0VY(FE.OB2B4"R/U<36B,3$LZ,ZZT.5U3V2]1&B6^+1 7$=U^EQGYWM3L=O
MW6WDWQ3!;8K@EO&\(_&>@)?\D:]^)5\DRQ6KNNR/SVA*/FG(U)\G$GE-(J],
M-#R2Z#Z*1)%C:25$D&[8@L. ,(ZS5-8=IY)$$N)4$RZ4&F #2/,$^@I<)0K*
M1&96-]-AZ(XF]N:PC%VC$9:L,7K#8=AP&)[DL"O6NBS6OR=29?,/,-*1,VX1
MZ1JY'G7[B8P:(J.31&85)K(6LGS68FGF'W S1EH;R OHPSOJ0@D=IX6W:S3R
MQT$_7K_!ZU^*EXM\]4&#S!#Y0@]P*B->Q&F^(E<.P=$D5S@E+J5$"Z2T?VXI
M*,*4B8"C!-D"Y(\_4-_Y:3>2I:\9K@&ZJ364[UK^VE<.O\/4\]O5Z+&A?N#T
MER-HRA&<+,?G%G<.2NWZ;%>C/L!!M]\".G+=%N8>L]#WW"/#$S:@PS-!7]AU
M86>27<]QO1;HKM4PI)[?CWG<8!Z?[CN190@4I2AZ&1"5H"A@]Q0Z$3+]&U%?
MHQ94NS=]R,>=0@Z=^J^%_AS+-PRHLU<YYW(.J5+%^_CKR&\[(?"Q%YR@1:#/
M%.V"81@>8W"@T_1R!OA=IC3.JIGX]VC0\VGTF+Y#8Z^TU#U+/>;56VA [E<K
M"2NS=T)?Z5Y@J???2CG=ZR ]+83?J1]UU,,A;0]"CTD8'%$/NI<[>K'>_0_T
M@W:ELE..K@F*/SWR*J9[/:6G!?5[%81V]:P#N6OBCHZ_Q_::1\\5O4N[+N@*
M"'6=]@=CCYGGT+#]I64?'#C,:>]7)E=IKK""2_1S;@-\8K(Z0%4++=;E&60A
M-)YHRLL$#YT@C0'>7PJA=PMSK&F.L=-_ %!+ P04    " #Y@6%2RE%+/S8)
M  #'+P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;,U::V_;.!;]*X0Q
M'UH@C<67'D42H$VZV ([LT$SW?FL6'0L5!8]$IUT%OOCEY04TR8O&>>QP/9#
MX\?AM<XE>>[AE<X>9/>C7PFAT,]UT_;GLY52FX_S>;]8B779G\J-:/4W2]FM
M2Z7?=G?S?M.)LAH&K9LY29)TOB[K=G9Q-GQVW5V<R:UJZE9<=ZC?KM=E]]=G
MT<B'\QF>/7[PK;Y;*?/!_.)L4]Z)&Z&^;ZX[_6Z^BU+5:]'VM6Q1)Y;GLT_X
MXU7*S( !\:]://1[KY&A<BOE#_/F:W4^2\P5B48LE E1ZC_WXE(TC8FDK^//
M*>AL]YMFX/[KQ^A_&\AK,K=E+RYE\T==J=7Y+)^A2BS+;:.^R8>_BXD0-_$6
MLNF'_]'#A$UF:+'ME5Q/@_45K.MV_%O^G!*Q-P"G@0%D&D#< 2PP@$X#Z+$#
MV#1@2/5\I#+DX:I4Y<59)Q]09] ZFGDQ)',8K>G7K9GW&]7I;VL]3EU<RK:7
M35V52E3H1ND_>E)5C^02_7,CNM),3H\^H.\W5^C=+^_1+ZANT>\KN>W+MNK/
MYDI?@XDT7TR_]WG\/1+X/4S0K[)5JQY]:2M1'0:8ZXO?,2"/##Z3:,0KL3A%
M%)\@DI $N*#+HX?C AA^=?SP/,*&[N:##O%H(-XW<2_:K>@CH=@N%!M"L6>%
M&E,ZCLR&D48:[B]P0G&F&=SOI\Z'%4E&R"'J"@C&\7ZP@\OGN\OGT4Q,RZ^]
M0U]^:I7KHSE)=T'3:$Z^KC=EW9DE;E;XG9350]TT4(;&..D^]91R)S\^*,_R
MU,V/CTK@U&0[%MDS6$BU$AUJ9;O8=IWYK.Q[H<!IS[PKP922U&'EHS2&9 XK
M'Y4F/&$PLWS'+(]/^L!EFO 3])M0D4DO=D&+:+J^M[HB-O6_M<)IT4+VS4:7
MRD4]:!QZ5PG[[KU1N:7.,;HOFZTP619_;FOU%^J%SG*M:M$/L?20I=!9KY!6
MZL6/$]2Z5SPFOO"2]0$G;MY]4)93ZJ0=B$2U\ 56%$YL'4BB2?HR\M.\-074
MR'ZH >5R63<Z)["*3"$/:>',Y07!THPF#C,X6IH$= 3OE3@<I?8/0V;9R35:
MZ-)3MULC*M)6MUNA_9/0U!=R+9 J?P;88F@2:<Y=50"!&28I<QD#0%KP I,
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MC\MB1*^?E> <%.TLHVZ"(6":9\Q;/@"09L;P!A)L;0J.^Y1#[@'%>QY[P"V
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MN6HK,7BVN&8/DBW-*C=C4BV&YG:AEGW,M8%Z/V=,;A^T@^+?A\$_4$L#!!0
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M"+PF9628E/4#[QHK0 MP26R.A7V$"&*^(WF3O<$7^4Z3!:+I"3E 3YXQ6R#
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MC(L&P-]W3=._O-%?,/\$QX?_ 5!+ P04    " #Y@6%25R:L@YH"  #9!@
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MEOCM 6D"\'PMA'Y;F/;6?\VR/U!+ P04    " #Y@6%2O46#(_8.  !W*
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6R]6FN/'+>Q_2O$($ D8'96
MNRO;LB,)V)4=QX$?0B3'N CR@=/-GJ'5W1R3[)D=__J<4V2_9A_1O5?)%VFG
MNTD6JTZ=.L7NEP?G/X2M,5'=-G4;7BVV,>Z^.C\/Q=8T.JS<SK2X4SG?Z(B?
M?G,>=M[H4@8U]?GELV>?GS?:MHO7+^7:6__ZI>MB;5OSUJO0-8WVQQM3N\.K
MQ<6BO_ WN]E&7CA__7*G-^:=B3_OWGK\.A]F*6UCVF!=J[RI7BVN+[ZZ><[G
MY8&_6W,(D[\5=[)V[@-_?%>^6CRC0:8V1>0,&O_MS1M3UYP(9OR6YUP,2W+@
M].]^]C_+WK&7M0[FC:M_L67<OEJ\6*C25+JKX]_<X2\F[^<SSE>X.LB_ZI"?
M?;9011>B:_)@6-#8-OVO;[,?/F; 91YP*7:GA<3*KW74KU]Z=U">3V,V_B%;
ME=$PSK8,RKOH<==B7'S]D]_HUOZNDXO:4MWH8(-RE7KK33!ME#LOSR/6XHCS
M(L][D^:]?&#>BTOU@VOC-JAOVM*4\PG.8>1@Z65OZ<WEHS-^;8J5NKI8JLMG
ME\\>F>]JV/F5S'?U$3M?JC>N#:ZVY>B(Z?[ICS_;5K>%U;5ZAXL&P(Q!_>-Z
M':('M/[YB$7/!XN>BT7//WDL/L6\_%'8C8$SOFOAZB>+_L+BZ5)I]7?K-[:U
M6A7.[YS/?L,\6H4C(FVB+=3:NMIMCGBFV>GV"##'+994MBU &<&V&U4YP%IA
M/0O_E384;F_\4>PJ8+DMX.$000@I8VVT)JCHE"[W\+]16$FUYC8J6&;\$![^
M2I,@P[M:>S[H]2Z/CMIO0'$<W+@058>?;90!MI4(ZG5M5+'5=6W:#0996-@T
M7>O.7%O(KN"%+CJY:&BY\Z7Q89DGJ81G.MD3MFK"2KW]]IL?U7LQPW1P3QA=
M>WIG\32Y$KD"#T13/NX:^'FWU6"E0H;C>N_QY"8Z^F,<-7%2)]'9,>;"N-$4
MVS9%<_3? V[KM_P?<5IRS&'KZOJHW*&%;T*W#K:TJ"(9Q8+3A+:=MXW<V.5-
MBU4_X%*--5?CT]=%=#?6#3')OU,D=AAHC*=+-*9TF-5$3EO4.DCN-+;P;FW.
M6!/*NP$!ZK8Z*M.*@\PM'!M"GX"U8\A*4UL),&;+^S]K7&FK8P[?Z +QUB=P
M ZKPQG;-2GUS:YH=L^1;P"%!\_OOWRQ5Z;CVFF" O4J'<=IAR)-%_R>9 68!
M>XV-!"V0(CON\1=B5XIQM:W,6=R"!*)I>7?;->"% 3BXY;K-5@:59@^QL"/#
M<N@/0/Z[ ^Q1_],A-3"J(0_%SAN$::/(8=H76R0V/)I\%8S?V\(09T$="'3\
M/[,,,2V[HD\*YD(:Z4B6"<C@ITWRCJ;/00N6F*#CQ1Q((BS>9]<>S,+DY1V]
MV]5,8W'[IXK==^Z@5^J]IWD_[?4T<JLW!/!P"Q!.%<PQ6[OQB>$* P</["V3
MD09XTSL$^QA2W]*#X.ZZ*^FWWJLR>WX^*-1-"3SV&P'UM3=&9A5O$L7YT93V
M"-K]?B '/;+[-QH0<AZ!7XHGED-*XR\;@NN\7:KWYE9CE5]TV,+@R I%,WXA
MET)(M@!^)9R#7?Z$?%_#.I$4%U\NQR!$.K(RWF?[@+EH!0/XA]XB-*:DT!@D
M>RNTC'60TY+IR)!(V0SL!1-3$7L(!-C$S5OUWA+>2$3$:OB]>+H:;_YQOO"$
MI &QT@2[:5,:)CNB:IDH()N-IAMQHW$(P5[7G1 3O=.%Q%' \297&TA_J2I#
MD/O\;%&2ZJ7:0NS.4V*-6@"^U(GVP%JU_1WYOX-+*PB#/'D%;$#3%A](]-XB
M@6#1G4 P/X?HSZ*!IT<_'31!UC\)?):0"^)YXLB.BF8%WH.APCNX+,1DX*!2
M_=9I#[,94\K*M/2;7$I#!_.I7F?NG\"2KEH;\$7/* 4Y$S:"'E# $>/9R(F>
MX<@MS)^CBS6\-L*CF&^<9'U44+^FH9-Z!;P"J&/B2W-;F-W(9#ZB%^LQ)TD(
MUMMDDR7##EM;;&=;I2U4=K"D[9*;]J[>B\I5NJ*+9B9-X<JQ:X.TV24U"?-U
M5G8R'7Y/?$;29!;ABG5E& >MU#MCU(\N&G4E3U6=%_;@3)W43K!?AN$U,J!6
M+^YD;C'(>*QZC>C>N*Z-1_#"E-'Z@C_<3PJWEU"B4&DUQ8RPI BC3(\6T]E6
M:I[QT@]HS%.@"V1!HK^1XL'( YA!T,[DK&V(:5)Z\D<=2OT;6@G>!9-],'&E
M?FKSQK[L-S;9P@@.^+P#+/W!L^C"[QT"7"#X51(LDH%P*TPR%%FC>UH'Z0%U
MZQ&T?5\)&28JN0Y;\6QB,WU$CVYT-   7COMRZ16,&-TO8[3!7H"5HCZ.(E%
M:1Z*1K(M9Z.&24$:@NF C.8_7"X_?XXP)\3:D(M1VE8J+KCB&K.$U(W+WKLT
M2&+)-696A+YWX^PGL.3((Z2$2DE_DG(77Z[4M63"S,[L1,R8@9$B>(++K4&-
M9-68>,'\UG$(F BE*PHPTS8SK^7[K"V.^]V;$,5RB>\T>[G=3A*/VTA"GO<K
M;;U0/>DT]6MX#-;UC$LKL:A)7D-R&R$\K-'(UD4:3%9Z  .'GHEPA6G1C@&4
M:$ ]Q$$DIAR1GG!<3NI$ZF+R0WGL#9>CV>A@&S0*K,$[YF0FR:!K<]?(/O>@
MR$&VR?GMU/<LQ8!>5:%, 1"<X?W68F/O4C2.RUR%YU<33WA3"Y9VJ!UXD#[_
MP^7%\K,77RSGT.Y=LFEM[P^.UBR-)2JR31C_8GGU_,7]$._:X7%Z;?RQDT8M
MN1G/32-=W456%FRFUS1DG?].QH#2_JK;CEJEKUPSNIX6O&DL&_VKH\=[M=6Z
M]FR+W<=M00DYK6ZC21\1U>1E3O&IJE5 N:(=%\\?K%K#?J45B.'$P5,%3,LP
MW-@V5=TA9MQ;$-<L,LY7"_6]1:1+NHDS?RN]VQMTWL:SXVWU)@5NC483/57?
MDMZB$O')6D8/OI1DOZ,S 'B6C#''@9HD=:#D5.5=(U<?+4AV! &FO%!/I,I?
M7CTE=; WJVMWF#%:KD",ASCL-"11U>@;(4T2_ 8ST AT<DI4YOCCHM3BB;^K
MX2!O@':@LOBH!T^@@YW]C.3&7W(H""!!W>O<_.1'01.X+P[JF3H)"B2Z!?Q#
M/J"1_J*@E$L3<S_SR;&?:X@.*',PT\^K=ROU[?7U6_8'[R>^LR(K?P4YIXZC
M[22@;/)L^(";MK%R/N:P!)4*\UHPFRB ,*0XIMIAHPY)<,:12P57U\>S= (U
M=-W<Z4G'GK42.L*V%%\FM<_M4BXU+M4G+)TLHJ/Z6H#8@9(^&-92ZOFRT[DS
M1_>"+MTDH<(FR C]TFCTP<*$@H-ISYDY8MA8TBOTK'1.TN-D&]!"DE#A[0'J
MH2NHZ*NN'K:[G.UU=C+7 .(5=91@/O/6F/' Q9K'IJB8?[S70]=E*;L@$);_
MAI3OA28TG1F4>$(=SYO4QN7QP@MK'O[V1,@DDZ.<:$(N5ZPP0_F>\&QBZ&@#
M]YAO@V;7X%HI,1FQ+=^5L)!W/D&K/TM:J:\[WRN3AXO&:1,&U'1"@%J8)VE%
M%,V++YXM/P.7R ' @]RUU2(UX,BNZ5+5+@WZ41O3),L7EU?+JR_134WHTMQ"
MC8RD0Z;$JKF*MF:3#GL*';:J G&%&5OU91'_ S)&.NNJZWL#,55GE3#?J#"A
M9^GFHP,6L,X.;5;-1:HNH^FD!S6WJ&\Q,>5P=(>@HO1\E\O[.J34H@+A(0&;
M<DWAA3BEZYXU4@+D@7!L97DBJE@&SE"3FCXOTI%#+^&Z73[33Y"8<SC^]MJ&
M>S=&%<1#X6&'6,<E.^ZG&*HLGB=!Z2923*& X\>()<*@9)9?8^?-QT[$!!85
M1",KW%J:9V\V1(OSO=K4TV.?D\Q=3G@B-?&Y,>0!R$-#\JFA&9W=\!6L!'?2
MK@MD*"@;/$M:T%$,Q)2536?O(Q96ZN==EG/03AM+)P\%\8Y&OI="/D+4O3C%
M!<(D(!I"L4P!(93A.,Z;:#=LG8\)06,WP^-93]H %KN*J2DM3H;"?"5"NIT+
MM/Y<RK79Z/&P0B0 _Z#1'T&?8D?ON/HHKLNZ>];@LKP8:=(FIS<H_-T:!6'M
MNGAB]7WY("PPX^54PT%"]9$OY^0  B-*0W_Q3/G_,BE4:"FNS3U%"LP0KBY"
M>-X#C=3:#6< HAJ;4WY,]JVQ[%Y#3Q"*^=A-RNO!U#P13^^ *T>%UY/_@^#\
MN$"A4B87(RN&H?_/.>=4C.)5)[^9-I"YQ0.H&0>YP3USN]A^YHL)<B<$1P2G
M/2>,PAD0*K]+?/(I72:509*G>KOD<4(OG;%*:PXHM06,R6_N!C$A+Y0VWO2[
MX.YEGM&*W PZGENLB800?9<03R6-[2;!U!C=]N_E*MDL\93W63J@1IQT!!*.
MXINU*+5!$C@YCO9-F*G1.50?JP%RBI)L37R_)NAX,$:&W8KG9T':.HK7T3C:
M.Y8C43ZC]$T63M]F+%$JHVRDAB!.<%[FWI.K8JZ&AO24>/=T(771N6^/P=35
M(]I[J,M9;O+<O<TP2(<_DS=5J:/J[Q[OGOC< 6+R+ K1]C[WZBAO,2W3PDO+
MST"E:87V*KT'G/)<DX70YM[U/'TV:LU^E)PVF,?PGR1_QMG=?),I*=CD)>*&
M30:/!UO!;G[QDI153R9C6?]*/;%/@1);1>D3O%#!I,A(9S#OM'DDDM_0A'QF
MNT-?FNB<44_G*?QP0?*,^$JGIZF&26+J_,/M=BAN72O6_ G6T!Q&\R331X4R
M,T:\SI,*GBGU,V"*+'3&4>1>>)5ZLJ_6&'8F1U'#2>X<Z,)^T!!:&(+*(;V)
M)B[*/=_(3]_508V4N/(GN?3$[D<;2" U<K\'U=24Z7)45UBA=Z0N4OKC<2W?
M<N%AL)?D>I9S^5L ^<KJY-,#F,MLRJ3ROZGD_[8'2C1S4B#3)Q2_=CUN<CJ@
M9^W:OIGD%P"BG^_IDJ8=4:Z;QTFRM(9"D0<A/>/MTXGNW>+3G]0_IAGN^^CH
M?/(Q&(3H1CYY(VEA ^F[L.'J\%7==?J8;'P\?9+W@^8G/T"]J3#TV>J+SQ;I
M#4'_([J=?%JV=C&Z1OZ$KH:6YP.X7SDD5/[!!89O#5__"U!+ P04    " #Y
M@6%2W\0+_WLI  "PA   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6S=
M/=N.VT:6OT+T9G=L0-WNB^TXCF/ [L0S'B03;^QDL%CL R66),842V&1+?=\
M_9YKU2F2:K<'LR\+S,3=:K+JU+E?2R\.OOL8ML[UQ:==TX;O3K9]OW_^Z%%8
M;=VN#&=^[UKXR]IWN[*'7[O-H[#O7%G12[OFT>7Y^=-'N[)N3UZ^H,_>=2]?
M^*%OZM:]ZXHP['9E=_O:-?[PW<G%B7[P2[W9]OC!HY<O]N7&O7?]K_MW'?SV
M**Y2U3O7AMJW1>?6WYV\NGC^^C$^3P_\5KM#,#\7>)*E]Q_QE[?5=R?G")!K
MW*K'%4KXY\9=NZ;!A0",/V3-D[@EOFA_UM7?T-GA+,LRN&O?_+VN^NUW)\].
MBLJMRZ'I?_&'OS@YSQ-<;^6;0/\M#OSLXZN38C6$WN_D98!@5[?\;_E)\&!>
M>'9^Y(5+>>&2X.:-",KOR[Y\^:+SAZ+#IV$U_(&.2F\#<'6+1'G?=_#7&M[K
M7[YG8A1^7;RO-VV]KE=EVQ>O5BL_M'W=;HIWOJE7M0LO'O6P'[[U:"5KO^:U
M+X^L?7%9_.3;?AN*']K*5?D"CP#0".VE0OOZ\LX5OW>KL^+J8E%<GE^>W['>
M53S]%:UW=62]F6,6__UJ&?H.N.5_[MC@<=S@,6WP^/\$O7>NC>+Z/.S+E?ON
M!.0QN.[&G7S!AL6[KFY7];Z!'^'I:]\&^$M5DK!\V#H0F)7?[<OV%M]:Q3^[
MJEC7;0FOEDT1>O@ 9+0/**$H:D4/KX+.Z&@A6OI=YU;UQH$(ME51PZ-A6(:Z
MJLL.P#@K7C5-4;>]ZV0[VGC )?%Y($4;RA4OMBUO7+%TL)1K:I &A.:L^*4.
M'_GA7]N5ZWI013T>\/KGW]Y^?WKQ#;R&KU;T"!P$T## GWO/ZY6PVJ<>]0S\
M4@,(< A  9YCT_@EG'+KRJ;?TNL.WO>[>E6X]J;N?$MG/P/L[>"G%6*JYE<#
M/EG!#LT:<?!3V:VVQ+8+^O,UG_5/019?E1V<; A XQ#@B!N "@!TGP"3-:SL
M0-4TY2U!+6?$91&;*V ,H'(#J *2 "+@?T"- 'J)""M8."M C<&"Y0Y(OD#*
M=;W :X%[M>K]Z]H70-:][X!$S2W0*X 1 !$FT)LR](#&K>]H??SH'6#8%1?+
M1Y?E")P"[$;QZL_G0 6":]]Y5L3%SI5A@$/#@>##7EGGX)HUX@*1'<JUZXF7
M]\!-B.E%@8C:P/L=_JQ;A;IW>*+U>D$H =@;?^L</*,T1XGV'9 *65L/IT<C
M$R-G86 9^ / ?.,;8$9\%I?"3UK? WX;$@6 'EE6X%.(ZQ"0PY05^J&ZY8W3
M8I_?N*G7N ,L\M>A=4(>$@E=$_8!0%;=4!,E%4E%N0'V ,&JJAKEIFR:VT6Q
M[ORN>+4'@B+0/Y6WLJ)K.]\TR,<(2 MV-*XC\"=>???+G_]V>G5^_D0I;L"=
M9YAJ( J78+-:5AY;WU0H7\K%KNP:QBUB]!2HN'%3GF;F>-/! G\9^M6V!G74
M%M<E"GSQ"V@_8N%KAWH$X7[ORKYO8.\MO(K@P0M]W0^"T0:-M2(^Z@DX9>5
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M2?6AJWA^P8"@PI#J6I72@5XSG1FB%3F<N?&81$"5?@::",2UH3SOAKKT>>"
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MIX(E[B#Z0!CZ0(0$ZGL]>7F:)]6YN?E%<H1:OW.;JH 8_DF%-YO5FI;[K7/
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M,P5],#N4:S"U_**^WH?IX= R3[ONI]T I]T0)/^UMCZR_:4%< :KSRK>"H0
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MP(O]B-ENVM1=:6XSK@'-MT9CS*TZ7&]]BHX@%KSWLPKK9'O=()G%+#>?":>
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M6Q<<3Q.W?HB[)Q0B1X$WG73)L[F]WK<DW1@H2J:!B+T(YAN.O! Y^G5KBVP
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M6%$#O%^4 (.YH0G:'Z*^^D]02P,$%     @ ^8%A4D54^S9R!   ; H  !D
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MV<5-Z*Z=M((/@3C^Q&ZXH@WP-3V&O#X:UO7>K1=J)C'FFQ%5:H0GA4?6WT]
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MK)I@QK]6.047 @77 .%4S8N$VIUM)O/G>MV-2XG$><][AJ>1FQ<4G?>\9^;
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M#H85O([2M?GK.+QA#LX?,7FDL?8\7NP0CJ^,7!EM)7^#G[#@&(&D7R40&>C
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MU?'CX[J_<Y_A_9?+1VX/4E.!]VB:3)?S2;\YCA-OFG #[XS'^SP,*_R $I8
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M<VAE970R,2YX;6RM6FN3V[85_2L856Z\,XR6$O5T;,^L7XW3V-Z)U^UD.OT
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MJ.SG5/:B+DK^A&E9U  =_KE1$KT=+<#S50&;N0LZH/VF[>5_ %!+ P04
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M;WG5N=!Q CR'KVU"C^J3XMP8 8>1/& "TB@/4A21(&&?5#N+SN]C'JH4)$3
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M91:B/8?7:V5LP^IZDU+9KLGI_FWY04F-AT%EWZT[,7S1U9WKX(FZBWFH8*8
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MZ46/Z' 5# .K*G_]6BF+ESG_6.#M&;2;@-]SA2$W ^>@O8]?_P-02P,$%
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M"3K]W0)'&+J<.UBC)C]4&)2\CQ6[M7RS-YE/]LV-->AY_H2BH*HJJD,:34?
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MAA5>>&R\ /976KO=Q!^P?S.>_P-02P,$%     @ ^8%A4N[Q@P1@#@  MR4
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M1L%GEA;@^]J D<8/=,#X6ZTW_P902P,$%     @ ^8%A4L@;@ 'P"   *1D
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULK5G;;N0V$OT5HN%@9P"Y
MKQZ['=@&/)X),D$F,>PD"^QB']@2U<T=2E1(RNW>K]]3)*66^N)Q@GEQZT(6
MZW+J5)5\M=;FBUT)X=ASH4I[/5@Y5WT_&MET)0INA[H2)=[DVA3<X=8L1[8R
M@F=^4Z%&T_'X?%1P60YNKORS>W-SI6NG9"GN#;-U47"S>2^47E\/)H/FP8-<
MKAP]&-U<57PI'H7[O;HWN!NU4C)9B-)*73(C\NO![>3[]V>TWB_X0XJU[5PS
MLF2A]1>Z^91=#\:DD% B=22!X^=)W FE2!#4^#/*'+1'TL;N=2/]!V\[;%EP
M*^ZT^J?,W.IZ,!^P3.2\5NY!KW\4T9YW)"_5ROJ_;!W6SK XK:W31=P,#0I9
MAE_^'/W0V3 ?']DPC1NF7N]PD-?R W?\YLKH-3.T&M+HPIOJ=T,Y65)0'IW!
M6XE][N9!*.Y$QNZY<1OVF^&EY=Y?]FKD()]6C=(HZWV0-3TB:S)EGW7I5I9]
M+#.1]06,H%BKW;31[OWT18D?1#IDLTG"IN/I^ 5YL];:F9<W^\O6LG_?+JPS
MN/O/"^><M>><^7/.OHE7_ZXL]MM*FHP]BK0V$N]XF;';/)=*8@.]%>Q.%Q4O
M-_] 2)ZQC#* W:VX!)Y+)BWCRFKFL/!1E%(;]IF7?"G+)?L@#?(&3TAHNT/G
MA\[4:^@R&8^_H_<D3/Q9TSM9.F&$=79_WQ#W1M?+%4.(1;$0!B&>7"9^>U2:
MK;EEE;?::<:QUSS)%(;=+HT0( ;'W@SV'P[>(H7<:E?1JC:VYM@#6>N53/<7
M&/TD =N^"B0I%<:!WFA%+BS1$5<)4V))/[DL>9E*NN09$E02BLC/2? -I!$'
M5I4VCME&VQ)66PL6)'6:M]V#::]TA\(V9+\CNTR,VJ[U.-6R%." *:0'B _,
M'8VCP&*;%:TBR:X7R.<0(YTB3Y#;<R$0!0EU2G\F%0(*:%XKM3E]0GRQTJXX
M(DV/[X$;N10EE"@*G X&2[]@(W>,5U#C618>SB?S\9A5L*,@RABR3R4A8!X0
M4-8>$A"W%=R31VJF7*5UR WB9?@Z*)@J;<G2RL#"!I+;1.C)B5LF[Q#FC&]H
MM># AE<J!,':.KAB%_DA8(*"',[H67+Y#2QYTJHN!%O[TH+'_ DQ7;8V_25#
MGR)D9N-3,A2>ESHC[4G" 3?X [C" AYCA+0181T"J63*%VH+)"AI1)M#0X:2
MZ9=N!#>$*$JL-M4#HT\NO8.W46^P'UT^2<['Y\GX?-JXCE:?7^+1;!8?)>@+
M;"5\95>;)*3K$U=U</3)/)EB+>W#Y6QZMKO^0%2)<C:>7"AO6O,,F6"@59='
M#J<@&:_0[,1L8^*YDC$5HU\/I6W7 <(3)V6<S\ 2O0UO.>\0N=6>$0*M=049
M(8L%%!9[M8*,:WC-\>=3$ZM,:S  0IE.D-P<<)(!QX?4Q^O.D<-NV0GEY75*
MH&$\U?EI!;"B%87/T/AAARRQUFQ38@OOA5AQE1/X"6K:1YGG+L+\-4Z/;N,P
M&F4&YF^]',QPVG%U0)>^R5%,(%9N4*"77D;,B9/).W#!R?0\%(23LPMO]U>2
M8SK>2Y$N= ^XV=;(1TYZ-B[MUR/X(??V[X$^"+-R64JL\-@6IK"-X[Q4])[&
M1+5[;[<!">L\//TV:*ZTR8+9?52F>$Y@BRJ39W4A0LK.X*SY9736_/*;..L1
M-<P[Z1?MB.;P>LF-ISX<3.$-4.E%;R'<6H@>[%XLR^#]7]$RQ5[FXL641I7,
MA<?2HZ?GCZ%C^H&GZ-YP\6;PE15-EX.FC#<MWX'V[,U@YT';'P[>=AN)KYS6
MMR75M4)8<Z,+YC"A>2JD7Y1$<H[5* SD*?&<JMIZ[%7DWR10NW^'P4PU''I,
MQX35%:TY07.9C-$OP$"0H6I+!'):4D:S!Y$A<7U%VC7%]XAAU<XK<L$G:E3*
M_]9E&!);]&YA_5.-\PA4!!IDDP^C3_DUM'4 2 48RY3R"P=1-<VQO43!=9(4
M(LQ9]B9 ;_HV>8W#?5M >8;NTE$]_45W&HAC!K$5!SD19J-_ZM<&.*1(T!0I
M-0OI-SGK) K/,NE\[\M<=P@),-R.'8=Z_;WU'^_N_$!#9F"@5GRAP5+:$,D>
MJ&,KK3*++@1TBDX2D,?@3=.P+###[$P;";&)JKW.VPD$G", Q(QJ5UT!NF Y
M$$LA%5[K4C15'UZ/@TG:JD5JPR$XO&FL(:<IF%6PHD_(*Z%:<$[V$4FF=1/<
M!Q89#=?]Z].O]S_>/GQ&71-/4M<6X.,I+#1^,CFDVG$0M\)^!O&CA'5*G^R1
MU3S"\_QMLL/4KC9E:'];81R)&\E_UP8:!:E6HZBFJ:GW2R5OZX9 MGA^1L/I
MVNZU4X _U*;IH(CZC_20\UV%4XTR]C\:,"9GR<7EC"1GDKI2HNY09^(D QW#
MME '2O"6S$(7Y/#C_83=NA*MI_N=72</=AV:;/T%B)::*8W"0LU&%SB;X["Y
M[7'(80@=61'A!,B25>V*4A.C-E-!2R9WW&+88W=P_)>0]FM?!IWO%-#NIBLJ
MT8<W](>,UV.V,QMWR63(;JUWD:V5:S%!HJQL>KG>\8!7[_X>6A8\%:C-&%XH
M*"]\7V@YX6223.?CO=6^]? %[16VDT%;DHFM(S4TLV0VF9#LGWA9T\1/_4K;
MU;P4PK9QVH_BEN*:1&NHCC88H<N K.9T&W?XA5%/JI:VZ:N/Y\*"HY-+"0#T
MC3@D\-XDU\=Q)PL;3RQ]C^_=,9U.VU%]1>T6J92CBPJ36PR[[PK1N]:>E9-8
M%'8,B5[V.(IM>H(.P=> OY?BO7;SV-R*:EDO+$U VSFPB]*749GT7[Y,#Y$%
M]YFNJ%T-)MYTN@1?55L&M4T=P/UVPMDI6]&M(>%$^XTG!K [/AE!G_A)EZQ!
M*;)=E-3.6:M3Z<4VI0?1@S(V!(@VG4PFR?SB8GCHX^JH\_FZ$&;I/]+3]XNZ
M=.%+=ONT_3_ ;?C\O5T>_HGPF9LE8(-9),?6\?#BW8"9\&$^W#A=^8_A"^V<
M+OSE2G"4=%J ][E&?L4;.J#][\C-_P%02P,$%     @ ^8%A4O_YNO,.!
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MGZ.@>($3Q<Q3 1V5('J#8*H$!FG(D'@<^"<@"5S'L[;,L"V.?1[&3A D=A+
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MW#4#)W,49L#(YP(4>3QU J%3;]Y'$-I38+QDLCV(?1\A1TQ>2/J[OMV%WE=
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M7=X\N@"=6G-YZ,/AU>3[*]J9)7]E;JQF]E/L.#M^R+ZVWV]WR^U7\'>R7FK
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M<&@VO#Q/P'6[HS/(-G%>UY9X^N.QYG6++@#X^\9:.AA!H%_@B]]02P,$%
M  @ ^8%A4O.B^J?. P  ;P@  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&ULI5;?;]LV$/Y7#D*!OKB6+"=K6M@&XK3%6B! T'3;P[ 'BCI91"A2X8\H
MWE^_.\IRG&$)-NS%%LF[[[[[[D[4:K#NSK>( 1X[;?PZ:T/H/^:YERUVPL]M
MCX9.&NLZ$6CI=KGO'8HZ.74Z+XOBI[P3RF2;5=J[<9N5C4$K@S<.?.PZX?9;
MU'989XMLVOBN=FW@C7RSZL4.;S'\TM\X6N5'E%IU:+RR!APVZ^QR\7%[QO;)
MX%>%@S]Y!LZDLO:.%U_K=58P(=0H R,(^GO *]2:@8C&_0$S.X9DQ]/G"?U+
MRIURJ83'*ZM_4W5HU]E%!C4V(NKPW0X_XR&?<\:35OOT"\-H6W[(0$8?;'=P
M)@:=,N._>#SH<.)P4;S@4!X<RL1[#)18?A)!;%;.#N#8FM#X(:6:O(F<,ER4
MV^#H5)%?V-S&RN-]1!/@\P/]^E4>")8/<WF V(X0Y0L0BQ*NK0FMA\^FQOHY
M0$Y\CJ3*B=2V?!7Q$\HY+!<S*(NR> 5O>4QRF?"6_S9)^/VR\L%12_SQ"OS9
M$?XLP9_]'PW_(P1\-?!-F$B#PBJ0%J%%N+)=+\P>I+8>:Q#0QTHK";9IT"FS
MHP=8O)^5Y\6L* KPK7#H>5,1HK1=1W- +27O9C10GAJ7?90!0]/?.RL1ZV0N
M>EH]*FIZU'MXLZ#X-.4S$$U 1TU?1YE<(Q7<#4ZE1:V\M)&Y"U,#^I#\:Y"B
M5T%H]:>H-#Y1Q4=ZL7CT\]=3Q4>4D6$H,O6_&&>9 C@DX! =@M@YQ"ZI-JC0
M)G=-)MJZFK-):Q2L6".DTBKL(?**,K_>WL /HF?>4N(]NH3O$P6'U9ZB:(4/
MS/>4%$ND]22LI1KL1D>V3TD'FQR.\896R18& @7KU(X2T:1L'9$M20I%!T3G
M6]1)A/,Y_#B)-RB*1@ES0@RK:%N&,3?EGTOCQT(8JDDD(D]),?Y)$F^Y(XRW
M6M6)<4,(1BJAJ4-H8]2SCF[*O5'.![BG,G$/4&BNU1PN4\/0Q&)7T?XTM6,1
M';\3W]GF'<E-S#RUV=\$2G6!@5B_^3!;+!>IM$\'6HGJ("";+):SL_)B=E!3
M),VDCO582QF=XPE*@3RTJ"DK2S>0X+YS("H"MZ9+-A1FLI^"*'S=*0U-C^D>
MT?O9I.<S%2M!G2<1TAMY#E^LIFN/)7RYPUO*S%AHHN.F@U[L$\/3KDIS]B3+
M_)]>6OG))="AVZ6KCFM,(SG>!\?=XVUZ.5XB3^;C57PM''6HIV -N1;S]^?9
M6,II$6R?KI3*!KJ@TF-+7P3HV(#.&VO#M.  QV^,S5]02P,$%     @ ^8%A
M4C[,O-O3,0  _:T  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULW7UI
M;QQ'LN!?*?!A9BB@V2*;NBP?@$1)M@;V6"O*?E@L]D-U53:[K.JJ=AVD.+_^
MQ9D964>3M/T6#PL8%KN[*C,R,B(R[OSFIFX^MUOGNN3+KJS:;X^V7;=_^?AQ
MFVW=+FV7]=Y5\,NF;G9I!Q^;J\?MOG%I3B_MRL>KT]-GCW=I41U]]PU]]Z'Y
M[INZ[\JB<A^:I.UWN[2Y?>W*^N;;H[,C_>)C<;7M\(O'WWVS3Z_<I>M^V7]H
MX--C/TI>[%S5%G65-&[S[=&KLY>O5R_P!7KBU\+=M.;O!)>RKNO/^.%]_NW1
M*4+D2I=U.$0*_UR["U>6.!+ \;L,>N3GQ!?MWSKZ.UH\+&:=MNZB+O^SR+OM
MMT<OCI+<;=*^[#[6-S\X6=!3'"^KRY;^G]SPLT^?'"59WW;U3EX&"'9%Q?^F
M7P01YH47IS,OK.2%%<'-$Q&4;](N_>Z;IKY)&GP:1L,_:*GT-@!75+@KEUT#
MOQ;P7O?=)>]&4F^2R^*J*C9%EE9=\BK+ZK[JBNHJ^5"715:X-CG6OQY]\[B#
MJ7& QYE,\YJG6<U,<[9*?JJK;MLF;ZO<Y?$ CP%F#_A* 7^].CCB&Y<MD_.S
M1;(Z79T>&._<(^*<QCN?&6]JQ?_GU;KM&B"<_WM@@B=^@B<TP9.9"3XT1945
M^Q+&!61?U%4+T^0ITN84/O_P8,FGK0-BS^K=/JUN<3V9_]GER::H4G@U+9.V
M@R^ P;H6V0O9).G@56#XA@:BH3\T+BNN'+!/E2<%/-KVZ[;(B[0!!"V35V69
M%%7G&IF.)NYQ2'P><%>U:<:#;=-KEZP=#.7* B@9H5D>P.M3C]>G!U'QT5V[
MJG?)1Y?50,!S^'SP((3'"UE6P]__VR&N^-&;+2P%,<)<ZIJD7G<@!EO$=]<
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M@$"#DZ3I=& Z]0#"^TGQ5UT8#;C8[5G4==/28$9=#;)J4WPA)<[:- @DF3*
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M9R7KEI1=59S(FS@/ Y4;IF4F\ ;&H )$4.9/2DJ)%Y:XUAP-7P(,C+GI2RX
M\-T_*"S!I]/!)UM]5O*$N&,5.3Y#9\QAK.1_@T[4)C\2V>_0AR=9*4_^_A\O
M5F=G7Y\]35[W!;O :;UK^10_?BZ/K\Z3=WU3D7>7>;#XP@ZG,WGBN:$)_>ZK
MY'7C7$B"3E;RPQ,2=GV'TARTP)M41FWK34<?PJAUY0YQ1<CR/3N<F_LSXPI
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M?'@S,74MK,:AKJZN%V^U!9M+/5-Q;S\)T>CQ;E+>1>H&.T0J1!:#$>3"(AE
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M*4L49@GR888U[V#"R"P^0+:.S.0I8"-GQF#RQG''MFCPP>ZP_OC_U?Y%*#F
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MA^=W_BU?OTI71D<C2KV/BSG)LQ% YZUP$F..4_D&SQ-GT"=*9NA&G._S':1
M)_F)+ID-SW@0I3]^)"[9YZ876LZ9." 0,1ZMVQ3&]GQK!VA<9X9 XTX4VL$O
M$]<L_W?S[51DYS&5:+U)N_2[;ZC%Q84K2PH35=VW1U@9[K_%A$OL#_+RU>KH
M,;P9'O_NFWUZY7Y*FRL,?)9N Z^>+I\_/>(VI?H!=!$<$HN!NGI'?VX=:IOX
M /R^J8&XY0-.@!8:@??=?P%02P,$%     @ ^8%A4H6K!P9@!     H  !D
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M+GF<\HHFX/E"(&]L.K1!]PG][-]02P,$%     @ ^8%A4AWO=7[%!0  G0\
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MFT;'3T\",&V7;Q>D-[ZSKC5QG_;3DA]&-$Z!]W.M:;]P#OJG=O$=4$L#!!0
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MQQM>+?#BQC%0++D%RF0^M7LJ&(O$E=FV6?A:,_.\R4J*.':=G8:]W@ K268
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M@[=[]UGB<PJ4%<#U0N))U RL@_:!-OT'4$L#!!0    ( /F!85)($P2-A0(
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MQJ9)&E @ Q>)3:3'968QBV*6YEL)T] G'(014))&B5/MP.J-%IO?((BV@H*
M,  ,3F,O(DT^O\NKL"P/+7B*R($W2+PX3(YA*!TPE!Z-^ .J9M4W@F+]:;$0
MMNCL8NF>;+X7T*RLF]IJ-(:KX[N\SU[D$S- XBN HYD81X[GH,.[RL&GJJ$]
M.=L*YJWL"<$$YMYB\97QU:IYI:U(-CW4)96/ \ KI5I)M1]P9I_AJ3#X(S/2
MT=HH=^$/+8!&J:7IM.%"-L@&;'_V%O@W&QTU-.B-5*_OS#H (@3$@S6Q@5]2
MQSMYY 4Q,L !EURU4O(9PNN]S-KLX;%.6'W'D@_)Y($_3^@W+FQ>!%X6X,7/
MDB+4 SGD370 Y5?;>%36^^B'K)HL\3*_8('O17[$8B\MTC<KY6)1EXCPWJHL
MS%E2)"PL8O:Y7?%:M91N4/))RNJE;IHAY<(L&L;WX""NRJ4UNA+/8**574CF
MPBP,@7,R*G14GV5$_4$.QUV5W_I:UZX)P_(:9*8ZN ,!-0K:]LJB2'$HZ7JU
M4FJ ;5 D]5D20@=.D@B3=7<*SY<"<%&'-'O+(*%UT<V2=T^$+FK=')MH&\T!
MCF_7Y5Z:ION@/EVLF<\N6&<*/ ";$$78G:4GP'3"_@:D*@>#:>2G],55Q(0"
M31&/"IJ/)"SB'(."!GBS5?.9-[T+'2? <_C:)O2@/BG.M19P&,D#)B"-\B!#
M 0Y2]BC-*#K_WPR9#0R9_=<,.3 Z,>.5,X+B>%OS.=C1U./MTO$-J.B2G<+2
MKZVZ1K1$/F""3;" '= (-S8[5*V%)94QIY(^S58?\F335Q:$AZJV=K:]K<UK
M;BT\6]>Y7G.8WF6PCR,:7.T'7O9SL^@;'&A*1\H_,6*K%+\A^,E'M7D&&HGW
MPKQ@,7#X"7EC7ID6)7+-6N$2$2EK6MN:P!@.OJ"*A*])YJ/(>D44L3M%EIE7
MCZT:CK2BA0+B7))AXSRD_Q%M:P!:2SUKQ;/8*_* Y0E@F8,'2M6+?6?22O0)
M7I0G[%: Y/:^IM8<4)QONP40X>D($0:I%_M0HH"4'0<J<$'7"Y8!N!$+8B_/
MTN,\5F)9#;6Q81CXK/#2/+7.W'&2[N>ZKFJNWD*APJ'"H0'/.V#8TDA2A.QG
M*@CN8_?DL9*O:LI.*GS>EARQ(1/?R4*TCURI5\3]A:L*&9XE2&K0?I&"EJ)U
M<H_!-D*?[H.XHC3V0K#G+<CRC/TZPB91CHX^SM&M%9Z/.)&.8Q(+E*><@0C"
M.-['Z6[,[+'^5"Y.>SW@( $? 0:>7P1H_[NG4]C88H\YND0O]6.(+O)LS)@]
MK(#!@>4 <K(1+=^7HU3CO;S(3M:C*#[&;?G ;?EQ;G-7&Y3^6T\/Z3M&94?E
MT8W,F5[Q4EQ,[#% /8O)Y17UE)3.+[59PD BKO=4B=]V3K6NR._M&5^X/D!K
M]O,8^,# <_%4=YU586'W0T@V6 2E%2&R,:,1&(DBC^976:J85L*-3@X5RC=]
MXQ>AGH1RY,>W78EV%?IMX8_IX$N-NI9-73G1$'+UK>?71+ROPTPJZ'2TV3Q_
M0DLQ;VJ]W/16NV$0KB'_G42R>=J<EZS?QJ.YWQ446!\7]@YD;!<#AU*C8R,)
MN##-&RB(<WZ6$3$F(&H<Q*/PH 0E&BL!_?R7ZSOV"(+K*/>!@L)R5NYEH/.K
M2JX&ES[<L#S>&I4$V_';>:F?_A"I*3@^0RJOR]QPXG97)7M\\\/2 ,6'VO#W
M-X93VQENC\&E#47YZCK99HW%ZM^]*Q^H=53&IAE:XFE.C?&!?$"R[6;"FIW'
M<F*,L68[=X$MX9UN/.G@!L2Z:\'A[7"I>N7N$K?3W8WL%ZZ0F9HU8H&E_H<L
MF3#E;CG=@Y$K>[,XE\;(U@Z7@N.L0Q/P?2&EV3S0!L-5\^5_ %!+ P04
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M$I%4G"F1UY<I^/SI#'P"A(*_URP7BE ,+:GTU+M9<:73N-3)/:&3 ^:,RK4
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MD:LS9,(I'?'7;*=EPH]-PJ4E=1I)_3KF,O'3Q25U"D?Q\.13IW747[6=1'X
M>Q+F_J"3#;2R/??'5)?4J1H]0Q-+G<C1 =O8 /9UF&ZGCC30R3K1.;:\I$[1
MZ!G:5NKDC [8N :PP[,#ZG20!GK7GO-?+B]3IV7I&7K8U*E:.F /&\ .RTSJ
MY# --+&NR/G9^C)U6I:>H:--#\9T W:T 6SL^0.(#T:_%<A5.^!6J)W>=E/@
M_FX_1+_I1L=N>S>!?V1RQ6N%2BB,:7(Y,4HHNZ%VM]!BTPZ2GX76HFHOU\!R
MD':#>5X(H?<+ZZ#_:6'^'U!+ P04    " #Y@6%2%W(!;8L#   \#@  &0
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MR##7EH*8OV>\0\8LD_'C[XHTJ->TP-/G5_9?7? FF$>B\$ZP[[30ZU'0#Z#
M)=DR_2!VOV$5D',P%TRY7]A5MG$ ^59I459@XT%)^>&?O%1"G "27@L@K0#I
M6\!M"R"K -FU@$X%Z#AE#J$X'69$D_%0BAU(:VW8[(,3TZ%-^)3;O"^T-&^I
MP>GQXI!O$$M8T!6G2YH3KF&2YV++->4KF M&<XH*;N#$>*+,3MG8U"GXIK
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M?)Z4GRF^()FR!CB^E=*\-.P;I7F3+OX!4$L#!!0    ( /F!85+PXVX#[@,
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M0TC3;D8 *)ITA0=L*_$RL>)*PNHZ^K;*ZUM3]&H2J&@BH:5F.LV+7"^=<!8
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MA*#G,R:C-!,O /UI.4//G[U SU!:H(\;OA, %Z<3";.BN$WB9@8NZAD@ S.
MT3N8@(V -R4L,=A?VNWI8_:S1]Y/+ XFL)SMFI*'-;T@5H_O8_D247R"B(.G
M)D)V\R7;@KDS:#ZSF\]8_/!VXAC,YT\V-[Y]\73ST#*7M-T?M/)'!_R]3O[9
M/82WY)!+8;?$:<90 5D_XZ)ZJJYC%<D[ ;L(PI'7&ZE8UYDSE2D3EL&X[6#<
M:C#N(#FH'G$:U3D9-D>4\U*F7ZL'II6JW065.U5C;L]QX&'_=')[N" ZBKCA
MM(=:Z"A*,28MZHB1US+RK(RN\FV4EG4V6*$UY\D^S3)3S'H&*N'Q$&<UQC_
M3'WJ]=CJH# (?=)CJZ,<,U._9>I_ U,N-ZQ$!<32KBS5LT@()DW9:^9K(\&4
MDOX:ZBC D*#'2D?YCN>X9F9!RRRP,OLC4A%?(!'!M@!NR6%)X6U),7$+M/&,
M_:"W%',=Y/1HV1!'E,*64FBE]%9M[$HZ90QJF6(5[_)=%BD9A$#/@6 I4+UV
M\3V2952(K-F6;<(P$0ZUD1)_ZO66::ZC^HQMB"/&TY;QU,KX4P&Z-$N_PI*I
MQ-+>)(<I!_XQJ-[R'@D&Y*NT5L$!LV(P&0D"P1)_/E$9T52)I]HF'@?4[6_C
MJ1[Q3C_>=<PX""GM39..HE"4!J8*.YUF<JR3-:\G <*^K0(0(8=*Q2@#')T7
M#OK$#"@_H/WU-_KRG7" V8$:Q%9F2[5\8R75$Q3S'/H742\]NU/7S,@+ZV,)
MJ:\1,\&FGL9,AU&?'%2C8V:D8T8>J9U-A*8%$&-(1G?]FMS0(7IH84]C8T!1
M/W#[; PP@DDPM%"=+,'47DX.9#?$X:.Q1Q]+*7,#9$P#W-]2)ACVO7! ".!.
MVV"[N#EJ'+9MX[!M&P?VT#@8";J&A.#U"^#<!*-!&&HL#3@7>V$PP++3.]@N
M> ;ZK1,$/VRYVG; _N8>+:&86A0C[F0']G^_@,6=5L!VL?#+*BO61<!Q:3T>
M<*<$L%T*:$WI&YXE,#$"O7U[>="AHJ9%54__13]KF;ORC:>_?YE)5R&)O4)^
M<Z="](+63U &B(>=OL0UH*:.,Q &I"N,Q%X8G]RHS(A>P#0F.L0+';??@U@]
M'?/HRB"QE\'O;D.(7LDT6CJ$8I]J*Z3#+%T(Z4HBL9?$'^A#B*&HZ8V( =57
M+U;(,:^N,!)[8?QE*9/H1<[4C1A@&FT;Y)AV5RF)O5+^+QW)C.B-OMYL&$"N
M%_;GP.!I2H823U>_B?V[P?<H<J+W^6-,78V6#B.>GE -GQ;"8$#ND4X($+L0
M>+(>)X_V_W,#9$P"K$6I >8%#AV@TDD$8I<(/Z9<B=[+CVFHY1X#BNC?@19&
M',93/$"R$QC$_H'@Z#N\DBT_3^703E90Y_>K'-J) FH7!;\L,],G5W[:57YJ
MK_S?]]&"&FIZ+_/-#1B7XGXK;$ 1GPSD$7KP??ZG-L*-M\"230R0,7&<?C8Q
MP3 A7G^A)@>'<SDKU]4QJH!<OBMD?:;3/FV/:E]7!Y2]YS/\:E$?N'9NZO/?
M=U&Y3@N!,K8"E\[+ $I161^IUC>2;ZLCP!LN)<^KRPV+$E8J /R^XM#A-#?J
M!>W!]OE_4$L#!!0    ( /F!85*21"!3'@4  %(6   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8R+GAM;-6846^C.!#'OXH5[<.NE#38$"!5&JD)N[>5MKM5
MT[U[.-T##4YB+> L-DDKW8>_,5!( G8C[4JGOK3@>&;^,S:_ 4_V//LA-I1*
M])3$J;CJ;:3<7@Z'8KFA22@N^):F\,N*9TDHX39;#\4VHV%4&"7QD%B6.TQ"
MEO:FDV+L+IM.>"YCEM*[#(D\2<+L>49COK_JX=[+P#U;;Z0:&$XGVW!-%U1^
MW]YE<#>LO40LH:E@/$4975WUKO%E8!<&Q8P_&=V+@VND4GGD_(>ZN8FN>I92
M1&.ZE,I%"/]V=$[C6'D"'3\KI[TZIC(\O'[Q_JE('I)Y# 6=\_@O%LG-5<_O
MH8BNPCR6]WS_F58)C92_)8]%\1?MJ[E6#RUS(7E2&8."A*7E__"I*L2! 78U
M!J0R(*<&CL; K@SL<PV<RL I*E.F4M0A"&4XG61\CS(U&[RIBZ*8A36DSU*U
M[@N9P:\,[.0T8&+)4\G2G$;HVY9FH5H.@09H4>X$Q%?H$TO#=,G"&*D8"'8;
M^O@S9_(9W5*YX1&Z27=42-@.4L#U,LXC\,92I//^/J R9+'X '&^+P+T_MT'
M]$X9/&QX+L(T$I.AA.R4QN&RRF169D(TF6"";B'61J"/*80_=C"$LM2U(2^U
MF1&CQX N+Y"-^XA8Q.H0-#_;'(\[S(/SS7U#-G:]TG;AS];X@W7A"44+&4JJ
M5JJ/9F$,RPI#!6"@ZN@ZBIA:(;72L'0Q%WE&!7I\5K=;+F#\CXSG6]&OEIFE
M:^TB__T%%* ;B";^,>AW:OU.H=_1Z)_G60:R42@$E9W[H[3W"GO%N]T4._[8
M@>+M#E>M/8W8CNO8];0C>:-:WL@H[X%+J(Y>7&GM'D2UL3/RO1-Q[6G.:.2Y
M&G%N+<X]JW8Q"Q]9#$M,.S6Z[> $DU.)[5F8D#$FW1*]6J)W1OU>$>BU0A/'
M<[!]HK ]S?8=:Z11Z-<*?:/"K_"0P!/1*<QO11Q@#R+B$V4=\VQBC[%[/"_P
M6WMT,,*.9[G=*8SK%,;&%'34[J.O'/"0"AZS"/CP\ANE"%A?//*J#[P,"O0O
M0';',OXI5GT5+<*8PIB&!'WTF<;1 -K&  A"#2S 5M.VK#=),WS0>/&O\6Q>
M.3C<+9ZE(0$F35QBWL:PTJ^')NU'R!HY8TWPI@=A^U<H.:_,CS%)=$\N;GH'
M/J]YF/DRK[P< <;61F]: S;W!BCY8'FF@G8#\'U-_(;^V(S_<]@ZQVVN$\>Q
M-+$;K&,SUQ4U#>O=073?U_42W* :FUG]?X&N! L,@A/@S.(5W#7<QN,WB3O2
M )M8QA6YISL*03J[9V5Z]$IQTA'G'7-&6+,[20-A8H9PE3$4@C[!I[30Z&N#
M>$Q.]77,P2,-,$E#:V*F=2-0]^I!VJ@>>*WJ=4SR71W/2<-S8N;Y-[FA61^E
M5'9*:]/<.A76GG+PTG2LJJ$],=/>]*9&VJ__'>7JF.2[1 -BTC0"8FX$OQ%+
M#PLT8US2Y2;E,5\_%P@X8M5OPQ1I&@UQWR:FFG9%S.W*@*F =#0K5[<GFE9%
MS*WJ+ 0%I/WE %]FENX!;AH+,7\1O,J7H')P_&T#;P::I]1N.H)M[@A&=@1V
MF_>V)EN[P;UMQKT!#$%EZIWD:9V^BPP/#ML2FJV+0TN!ECQ/97FV5(_6!Z/7
MQ7'@R?@,7P;E\6;CICQMO0VS-8/='=,5N+0N/*!*5AY@EC>2;XLCO4<N)4^*
MRPT-(YJI"?#[B@,9JAL5H#Y&GOX'4$L#!!0    ( /F!85*HR((K, 0  +,/
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+U7;8_B-A#^*Q:Z2G?2
M[B9.(+!70%I>KH>TJR+HM1^J?O F [$NB7.V WM2?WS'(20LA$#5[B$$L3W/
MS#QC>R;3WPKY584 FKS$4:(&K5#K]*-E*3^$F*D[D4*"*RLA8Z9Q*->62B6P
M( ?%D>78MF?%C">M83^?F\MA7V0ZX@G,)5%9'#/Y?021V Y:M+6?6/!UJ,V$
M->RG; U+T%_2N<2156H)> R)XB(A$E:#U@/].'5L \@E?N>P50?/Q%!Y%N*K
M&<R"0<LV'D$$OC8J&/YM8 Q19#2A']\*I:W2I@$>/N^U?\K)(YEGIF LHC]X
MH,-!J]<B :Q8%NF%V'Z&@E#'Z/-%I/)?LBUD[1;Q,Z5%7(#1@Y@GNW_V4@3B
M (!ZZ@%. 7". =X9@%L W&- ^PR@70#:UP(Z!2"G;NVXYX&;,,V&?2FV1!II
MU&8>\NCG:(P73\Q!66J)JQQQ>O@$<@U2$98$Y,'_EG'%S08J<DL>E,*#>C!)
MQ(J,06H\?N0SDQM0FDP3C6N@R/L)X$*D/B#RRW)"WK_[0-X1E/PM%)E"]:IO
M:738F+7\PKG1SCGGC'.4/(E$APJM!!#4X,<7\$Z# @LC58;+V8=KY#1J7$)Z
M1US[AC@V[=4YU R?@(]P:N".70.?7 VG]S7PZ?7P7D,PW/+LN+D^]XR^4:9P
M1JE79^3/1YPC,PVQ^JO!1KNTT<YMM,_8>!3)^E:#C/'V/VO"E<H@(%H0AFDJ
M8AH'*9/ZNSEI#+_YF665/W5[M+/8S2V:1+H9XEYL#K?AHL3T5,*U\5-*O2+;
M*<EV&LF.F0J1E@^8.X.<T35T=CJ]!CH7)::G$K33.4?'*^EXC71FB4D16%6T
MRLFL5CSBN&5UF6#L761Q*D';'JUWL5NZV&UT<0(KD!*#+6$#209UGG5/[#J=
MGN,>>7<JU7%[KEOO7J]TK]?HW@+8Z_3+D]M4"M]<.@D*F/3#/'4'Z'XD4A/K
M.@J]BR?^HL3T5,)QO6Z[5\_POF1XW\AP7T=FB9;P@B2QH(!,)5= /F7(;'9#
M'N<-B83:5:6SWRQ=T8-Z2O__.SPJE':ONX#4J;QQ&KV9HR=\#0ERUF+$Q0T&
M&HO W^2_Q[VJ$O3MR@2MZ@3]X85B5)CTKLORM$KS]$*>7RQ)N1D_DU_PUH)Y
M40+)4L@T]]5^R=SM!41XEHP45$M-,:OR,_7>;F>J%$N;<^R_*0.C0M?A16B[
M]IDT2JL\2IL3Z:_;!-]R0YZB!WA(T)]:X\U*J&W?V?9/34&ITAYMSGM7%)Y1
MH>)54K#M[IF,ZU2)T+%_1%49%68._>MUG>.*;!TT)['I-DQ7J(@OLD3O7KS+
MV;+S?,C[K:/Y,7:DN_ZQ4K-K9Y^87'/L62)8H4K[KHO73^XZQ-U BS1O@9Z%
MQH8J?PRQJP9I!'!])83>#XR!LD\?_@-02P,$%     @ ^8%A4J!:BY@D!
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M9SP.0<2_+1U0WX\CB3S^3(-VLC9C8O[S/OK'I/.B,T\DHH/0_]6;\^55Q^Z
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M___YW."LI_?^A1)P.@EZ-IC"HJ1YW"&UYKMQ$&=%%!.6)VTNB0\XGP3#\DG
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M[$.LNK!4$T$+?>:OJ) W"#U,Y"4/F J0ZVM*Q6ZBKA'-M7'Z%U!+ P04
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MQM^(QS+[#U;YO7X#C!92\20WUBU(HG3S&;[F0I0,4+#' .4&Z(T!)'L,<&Z
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M_?[T#XZX]G/A,U-K+C1)(<&PX*J/FT,5)_"B863N3KU+:? ,[2XW^-4"R@[
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MSO'C"*0QP.=3(?33PAR_B\^M_E]02P,$%     @ ^8%A4DTQL.M !   2A@
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M-F4QN"X66JS=['<FM!:Y.UQ1,J?2!ICK"V'>0,J%'2=7/Q^,_P=02P,$%
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MO>]BAU#Y6)\OC-QD<^M"&IR"L\<U7H5 60%\OY32[!?V@/)R-?H'4$L#!!0
M   ( /F!85+QC' U^@(  &((   9    >&PO=V]R:W-H965T<R]S:&5E=#<U
M+GAM;,U674_;,!3]*U;&)I!8\]6D'6LK02LT)D"(#O8P[<%-;EIKCMW93@O_
M?M=NR *4#M[VDMC..=?GWG-E9["6ZI=> !AR5W*AA]["F.61[^ML 275';D$
M@5\*J4IJ<*KFOEXJH+DCE=R/@B#U2\J$-QJXM2LU&LC*<";@2A%=E255]R?
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MID:=>XYF5;,4Z$3<85)JS64&0V:X:6PI@8M1,B$T<X>H 2,FDE+X"?RZ4T(
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M(9.49TC 8F1]QY<3'!A!&?&+PEJV[I$I9<[YLQG<Q"/+,1D!@T@9"Z(O*Y@
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M;?,J,[MU2II/E#LBEC23B,%"RYR+4+N(ZM2O!HKGY<$YYTH?P^5MHK^40)@
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M, @Z?DJ9\(9]=S97P[[,#6<"YHKH/$VI>AT#E]N!U_1V!_=LDQA[X _[&=W
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M3#?M1!@#_7W#N3H,S +MWX#9?U!+ P04    " #Y@6%296$>NW,$   >%
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MRH^[NASZUG;]@_5Y3;7=P6$(T8[4-AR*8]@E=N,= 5^QUVORK39&$8QVU;?
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M$/XKIP@DD+;FI6\#M96VE<&DP:9MP ?$!S>YMM9B.]ANNTG\>,Y.FA9HPT!
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M15&K3WIUV2^5"ZL*WZ-,E*6.QT_GU&.B=A?H?*J472]<VU-WK:-O4$L#!!0
M   ( /F!85)QX.I,[@(  ,X)   9    >&PO=V]R:W-H965T<R]S:&5E=#@U
M+GAM;+5674_;,!3]*U;$ TA XJ1-4M16&JVF(<&&^-@>ICVXS6T3D=B9[;;P
M[W?MAO0K+4R(E\2.[SD^]\2^=G<AY)-* 31Y+G*N>DZJ=7GANFJ<0L'4N2B!
MX\A$R()I[,JIJTH)++&@(G=]SPO=@F7<Z7?MMUO9[XJ9SC,.MY*H65$P^7()
MN5CT'.J\?KC+IJDV']Q^MV13N ?]6-Y*[+DU2Y(5P%4F.)$PZ3E?Z,6 M@S
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M5Z\MM09=L[6^"N+C,"3$XBL#8.*&X\V;T$<;6>T>FOV.-JO7HK@S>?9BBQC
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M=.+3I=I@U#\(1GV#4=^-T7?M-2_];G5- M?^T3<$]=]!4)TH(7ENUGR[WM<
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M,D0^EH"3O1DU.I[MC$9Q!]VE"I.P0^Y0^32FL9L\:LFC4?*OPN1:C4F_PA*
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M>('5,@6E#*4SM$X\>A[OK&3ID/B#-8/Z!SQ_? /<L&H-II'!1A*DW&^%S2Z
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M+0C+[5-)5J+D^M6F([BH8XB8>G/'[VD9XSE1$K9*PE$E7Y0FFYRI/70-;71
M=:92T@SIJOA #X/NLU$L8T0R6& \S4NH"*:^9$S!/FC&2WB'IB>KW;!6F_#B
M!@P1T3QV>_K':$[T1ZW^:%3_N@2QH-QD%6K$5(DVJB8:N.%BSXE[BH8H#SNX
MEY#)$!5'<S^VRXI;6?'X ;5'!FF80C0L$<A!I6" 422G5HGQP*TP#GM58CT$
M86<>S7L*AR@O\ER[0.QT+=+Y+8F2YI5$+=#=ZAX],DVXM?\YPP-7M983A194
M' 1>3Z&-*_3F9R0>30%X/#FA0NI7.);%0? F/W/!=U--90&9NK'6S(9T+-<N
M0Q(+9(H]+PC/B'([4>YXQNT)W]&J?+R5&JA!FIJ"@R"(U*K)O:SI(B2Q0*91
M$ 1G)'6S /9&)<&L"Y,LA\G0%)/T%=*,<)4WG3S[%P9&4UZMPCQ+"GGSOK8A
M:AKVT\P&BJ)SA[ ;2?!OS2046OC(--*0GB9]Z/G]<<2&LXPMB077FUM.Y743
M"1X?26XS<6A[^,,:1;X[,LCA;D+ P1\<$''7K_%XPS[VE\,%CJ2IF3I,SSI(
MP>$YI>:PV6?^RVW8 IGC?AL>Y3D5UC5B/-Z)^X$(G&!LP[I.B.,_& BWZS_N
M>/_Y7X%HN,.10%R&)!;(-/3#?D[,CBZBA9G S85>H<K=^O[6KK8_&MQ65^7>
M^@I?)_75OZ.I?XFX(Q*N* KE= N4SE4(22?KRWW]HL6ANNYNA(;+<_6XIR2C
MT@#@\ZT0^NW%?$'[$\OR/U!+ P04    " #Y@6%2M$ [)G$#  !"#   &0
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MDR ! ^D&6R0)'A^8HQ*N-M#.I<!S^_-5(V6<K!#)WB-K[ROT+?$90%L\) &
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M3ZO74JLO>;(KW[M\2O(\V98?USQ<\K00$+\_)TE^^%(8:%X.OOX_4$L#!!0
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MC@T6SD!<"EEDC;#R(&-Y_4E^-8&X$E!$S0*X$< = >P,"-B-@-T5L <$G$;
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MC=H#\U'+NMO6$RTJU^&V0IM^Z8:EN:% V@"SOQ-"GR>6P-]YD[]02P,$%
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MAZK4.V^9JK^ZUMO.[1L[KH[\,SW/Z_'[3Z:^#.ZPV! F=:?76M*[BO5YBGK
MUH;BE9U1*Z[TQ+/+0M])($R ?K_F7!T,LT%[RZ5_ 5!+ P04    " #Y@6%2
MW"\U1@<#  !H"0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&ULG99=
M;YLP%(;_BH5ZT4IIP88 J9)(;:)IDU(MZL=V,>W"29S@U6!FFZ3]][,-)6F!
MI-I-P,;O><XYP:\9[KAXE@DA"KRD+),C)U$JOW9=N4Q(BN45STFFGZRY2+'2
M0[%Q92X(7EE1RESD>:&;8IHYXZ&=FXOQD!>*T8S,!9!%FF+Q>DL8WXT<Z+Q-
MW---HLR$.Q[F>$,>B'K*YT*/W#K*BJ8DDY1G0)#UR+F!UQ/H&X%=\8.2G3RX
M!Z:4!>?/9O!M-7(\DQ%A9*E,"*PO6S(AC)E(.H^_55"G9AKAX?U;]"^V>%W,
M DLRX>PG7:EDY,0.6)$U+IBZY[NOI"JH;^(M.9/V%^RJM9X#EH54/*W$.H.4
M9N45OU2-.!# H$. *@'ZK,"O!+9S;IF9+6N*%1X/!=\!85;K:.;&]L:J=34T
M,W_C@Q+Z*=4Z-?Z>$X$5S39@1G0W)+@$=U@5@BJJ!WQ=3H,9Q0O*RLGS*5&8
M,GFAUSX]3,'YV04X S0#CPDO),Y6<N@JG9H!N,LJC=LR#=21QI0LKX />P!Y
MR&N13SXMAX/W<E<WI.X*JKN";#R_(]Z,2$E(#WSH3J_NPVL/S/&K?IU5#TP+
M G[=+*02^IW\?83NUW3?TH,.NNX!;&MAJ8JLRFS/[=@/O7CH;EM80<T*3K%0
M&ZM4A8<L?X#:6?V:U3_%\MM8_08+>7'4S@IK5GB*%;2QP@8+Q@%L9T4U*SK%
MZK>QHB8+PK"=%=>L^"CK,2':K=>*B#9BW"#&84<C!S5P<!S(%69MK$&S.C2
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MB2D:7%/SF>8!:":H*]]#*XW4D3[,Z<T$XQ)H?ZTU[B>N+;M7>/H74$L#!!0
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MV:"L YZOI30[PR;H_P32?U!+ P04    " #Y@6%2L0@9D_0$  #]$@  &@
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MH4LN(0A+W([?Q=38GAG-N0YBJ=-:-_F:4Z6F>/Q.RD8J]22^,^X[^IS7#(@
MQ6P-LI)K6C[:7#NN"]#7+8??\J*32F:)6V9OJ+)%#(JN4>P)EO9*&*8VBFN&
MKE/8E@74ESM7W'N]Y'LUDZ023.(6S*61P2."[$DAG:$F0\[\G8K\<\".FVAO
MI1%=*Y9=G:+\/ )+WWHPF9.ZS!*,AV30\AZ02FN)6VN7N?,WDF[K]DB]Z<0C
M[+<TG:126W*$V@*A-W%I:"QQKWO8\GA[IV[[80A.G6LN-+P;*[#SSX8 H_)O
M+?F-D9OL(/X@#1SKL\N(T9 I.P&>KR3TGL6-/=N77[RF_P)02P,$%     @
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MHR2F,B<POT^$F;6KEUS!Z@;]_#]02P,$%     @ ^8%A4BF%R0FS!   ^1,
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MLMMM[';[V?T+IDW<MS&PL>OB4Y6G ,P*'%/SP R21HACG\*N 9CC!($F[0:
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M:1C1O 3(YVO&Q.&FW*#YVC?^#U!+ P04    " #Y@6%2)UD'[GL#   [#@
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M'[0T3YG!Z<6?IK6^"*5 325XV!-)P6]@)32M-".<?P<YXXVU!CS0HI%,,ZK
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M[<QT5-IYF DC3HYJ=4?J!@W6FH=V,MO60#^O&K]?F1I^S:&=.;F2"_"BT>2
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M2!BT5C,#>YB6K=,GS)1]J83>)9JGXB7DNHA*HEOTF&7$U )3-&/-!V4J<YV
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MR+SB,N^D>\.<S5I&2AYE=2%G[MMG['=><)4+UI:C]0!C !@?#)"]N>(>Y A
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MY2:N-ZF>WK*KHNGXFMONHVO J^9S;YF/B60R)+;)9ZUGC[(H6KXSE_ZH14/
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M+GAM;%!+ 0(4 Q0    ( /F!85+&J%7![@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /F!85*97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ ^8%A4K2B=1F4!@  'AH  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /F!85*6C1;]% @
M !TD   8              " @=<.  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " #Y@6%2*1$_/@$$  #2#@  &               @($A
M%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ^8%A4LI1
M2S\V"0  QR\  !@              ("!6!L  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( /F!85(4A_3L00,  $H,   8
M  " @<0D  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #Y
M@6%2*[IO;K$#  "E"P  &               @($[*   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ ^8%A4K?!K6,;"@  O3<  !@
M         ("!(BP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( /F!85+W??O$^ T  (Y#   8              " @7,V  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #Y@6%25R:L@YH"  #9!@
M&               @(&A1   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ ^8%A4KU%@R/V#@  =R@  !D              ("!<4<  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #Y@6%2W\0+_WLI
M  "PA   &0              @(&>5@  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( /F!85()]_C441(  )0Z   9              "
M@5"   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ^8%A
M4D54^S9R!   ; H  !D              ("!V)(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " #Y@6%2K XB&K$(   ((0  &0
M        @(&!EP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( /F!85+F:?1CL1T  +IL   9              " @6F@  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ^8%A4O#&[K;H P  TPD
M !D              ("!4;X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " #Y@6%2LT7"A%<'   [%   &0              @(%PP@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /F!85(B@1/Z
M= (  #0%   9              " @?[)  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ ^8%A4@3H '0!!   G@D  !D
M ("!J<P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #Y
M@6%2*H#N\3X&  #K#@  &0              @('AT   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /F!85+Q1>>-5PX  -\F   9
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M970R-2YX;6Q02P$"% ,4    " #Y@6%2[O&#!& .  "W)0  &0
M    @($V"@$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M /F!85+(&X !\ @  "D9   9              " @<T8 0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ ^8%A4O_YNO,.!   GPD  !D
M             ("!]"$! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " #Y@6%2HWI0\9@+  #J'P  &0              @($Y)@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /F!85)WPW.!BP0
M '8+   9              " @0@R 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ ^8%A4M._,$F0 @  S 4  !D              ("!
MRC8! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #Y@6%2
M\Z+ZI\X#  !O"   &0              @(&1.0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( /F!85(^S+S;TS$  /VM   9
M      " @98] 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ ^8%A4H6K!P9@!     H  !D              ("!H&\! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #Y@6%2<Z8O4_D)  !.'P
M&0              @($W= $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( /F!85(=[W5^Q04  )T/   9              " @6=^ 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ^8%A4L,;'(L$
M P  =@<  !D              ("!8X0! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " #Y@6%2@II7,Z8$  "L#0  &0
M@(&>AP$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /F!
M85)($P2-A0(  #\%   9              " @7N, 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ ^8%A4JB8+5T= P  G 8  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( /F!85+FKB!*, <  ,<3   9
M  " @2BF 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M^8%A4L7;\*+4 P  (PD  !D              ("!CZT! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " #Y@6%29SQ'54($  !Y"@  &0
M            @(&:L0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( /F!85*Z/>BY/P<  .@2   9              " @1.V 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ ^8%A4A^;;J>@!
M7PL  !D              ("!B;T! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " #Y@6%2&1U#)4D$  "?#P  &0              @(%@
MP@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /F!85(K
M.H%(O@0  &01   9              " @>#& 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ ^8%A4LF87H5, P  '0H  !D
M     ("!U<L! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M" #Y@6%2&9[;_A4$  !F&   &0              @(%8SP$ >&PO=V]R:W-H
M965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( /F!85(7<@%MBP,  #P.   9
M              " @:33 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L!
M A0#%     @ ^8%A4EH*(H!Q P  GPH  !D              ("!9M<! 'AL
M+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #Y@6%2\.-N ^X#
M   Z#@  &0              @($.VP$ >&PO=V]R:W-H965T<R]S:&5E=#4V
M+GAM;%!+ 0(4 Q0    ( /F!85()4'"Y6@0  )X/   9              "
M@3/? 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ^8%A
M4ITL$A="!0  5!D  !D              ("!Q.,! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " #Y@6%25"%T1B &  !((0  &0
M        @($]Z0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( /F!85):]+,"IP<  ,,J   9              " @93O 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ ^8%A4E</T NH!@  Y!X
M !D              ("!<O<! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " #Y@6%2DD0@4QX%  !2%@  &0              @(%1_@$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( /F!85*HR((K
M, 0  +,/   9              " @:8# @!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ ^8%A4J!:BY@D!   ?A   !D
M ("!#0@" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #Y
M@6%2Z[,;Y4$$  #_$0  &0              @(%H# ( >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( /F!85) W]$-[P0  -D4   9
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M970W,"YX;6Q02P$"% ,4    " #Y@6%27_LQVE4#   3#0  &0
M    @('M,P( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M /F!85+KT*AV@0,  'H-   9              " @7DW @!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ ^8%A4DTQL.M !   2A@  !D
M             ("!,3L" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    " #Y@6%2+@?/R0($  !H#0  &0              @(&H/P( >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( /F!85+QC' U^@(
M &((   9              " @>%# @!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ ^8%A4D:R[DG[ @  1 <  !D              ("!
M$D<" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #Y@6%2
MW=^0B,L"  "'"0  &0              @(%$2@( >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( /F!85(DTRJ%@@,  ' +   9
M      " @49- @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ ^8%A4MK!SC;@ @  YP<  !D              ("!_U " 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " #Y@6%2E]7U1U0#   J"P
M&0              @($65 ( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+
M 0(4 Q0    ( /F!85)TPGW1L ,  !(,   9              " @:%7 @!X
M;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ ^8%A4F5A'KMS
M!   'A0  !D              ("!B%L" 'AL+W=O<FMS:&5E=',O<VAE970X
M,BYX;6Q02P$"% ,4    " #Y@6%2N0)-WK@"  "(!P  &0
M@($R8 ( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( /F!
M85(S8EHO*@,  ,$*   9              " @2%C @!X;"]W;W)K<VAE971S
M+W-H965T.#0N>&UL4$L! A0#%     @ ^8%A4G'@ZDSN @  S@D  !D
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M=#@Y+GAM;%!+ 0(4 Q0    ( /F!85+S5R[9+0,  .$*   9
M  " @5AZ @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @
M^8%A4O$-X+3G!   7A$  !D              ("!O'T" 'AL+W=O<FMS:&5E
M=',O<VAE970Y,2YX;6Q02P$"% ,4    " #Y@6%2KP.MH?@$  !E$@  &0
M            @(':@@( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4
M Q0    ( /F!85+3FYZLJ@0  &X1   9              " @0F( @!X;"]W
M;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ ^8%A4K1 .R9Q P
M0@P  !D              ("!ZHP" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX
M;6Q02P$"% ,4    " #Y@6%2RM43F*T$  "P$@  &0              @(&2
MD ( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( /F!85("
M7V1/(P,  /,*   9              " @7:5 @!X;"]W;W)K<VAE971S+W-H
M965T.38N>&UL4$L! A0#%     @ ^8%A4K&8:6:M P  R X  !D
M     ("!T)@" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4
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M,#$N>&UL4$L! A0#%     @ ^8%A4CFU)J9< @  _P8  !H
M ("!$K<" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @
M^8%A4E2;RV*1 @  \08  !H              ("!IKD" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#,N>&UL4$L! A0#%     @ ^8%A4MPO-48' P  : D  !H
M             ("!;[P" 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L!
M A0#%     @ ^8%A4HG)Q,LQ @  D04  !H              ("!KK\" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ ^8%A4MC=GQ6!
M @  $ 8  !H              ("!%\(" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,#8N>&UL4$L! A0#%     @ ^8%A4K$(&9/T!   _1(  !H
M ("!T,0" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @
M^8%A4OV-71G!!@  31\  !H              ("!_,D" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#@N>&UL4$L! A0#%     @ ^8%A4BF%R0FS!   ^1,  !H
M             ("!]= " 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L!
M A0#%     @ ^8%A4B=9!^Y[ P  .PX  !H              ("!X-4" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%     @ ^8%A4G%\?!J
M"0  (SP  !H              ("!D]D" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,3$N>&UL4$L! A0#%     @ ^8%A4A3KMDOZ P  "!   !H
M ("!2^," 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @
M^8%A4KR227ZT!@  <AT  !H              ("!?><" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,3,N>&UL4$L! A0#%     @ ^8%A4JD9A4-X @  4P8  !H
M             ("!:>X" 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&UL4$L!
M A0#%     @ ^8%A4I(J*6OU!   U!0  !H              ("!&?$" 'AL
M+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%     @ ^8%A4G&Y^OIK
M @  U04  !H              ("!1O8" 'AL+W=O<FMS:&5E=',O<VAE970Q
M,38N>&UL4$L! A0#%     @ ^8%A4AFUR4:& P  J0L  !H
M ("!Z?@" 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&UL4$L! A0#%     @
M^8%A4G%;:^[C 0  4P0  !H              ("!I_P" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,3@N>&UL4$L! A0#%     @ ^8%A4M)ME<E& @  8 L   T
M             ( !POX" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #Y@6%2
MEXJ[',     3 @  "P              @ $S 0, 7W)E;',O+G)E;'-02P$"
M% ,4    " #Y@6%2:MK6>/('  "G30  #P              @ $< @, >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ ^8%A4DE$#<=  P  044  !H
M         ( !.PH# 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ ^8%A4F:]5%&2 @  =T(  !,              ( !LPT# %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     'X ?@"\(@  =A #

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>542</ContextCount>
  <ElementCount>654</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>156</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - Consolidated Statements of Shareholders' and Total Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' and Total Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080009 - Statement - Consolidated Statements of Cash Flows (Reconciliation of Cash)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash</Role>
      <ShortName>Consolidated Statements of Cash Flows (Reconciliation of Cash)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210101003 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210201004 - Disclosure - Mergers and Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/MergersandAcquisitions</Role>
      <ShortName>Mergers and Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210221005 - Disclosure - Investments in Joint Ventures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InvestmentsinJointVentures</Role>
      <ShortName>Investments in Joint Ventures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210261006 - Disclosure - Collaboration and Licensing Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenue</Role>
      <ShortName>Collaboration and Licensing Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210331007 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210361008 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210421009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210451010 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210491011 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210551012 - Disclosure - Lines of Credit and Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebt</Role>
      <ShortName>Lines of Credit and Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210621013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210701014 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210741015 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210811016 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210881017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210901018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>210921019 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>210961020 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211021021 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>211051022 - Disclosure - Defined Contribution Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DefinedContributionPlans</Role>
      <ShortName>Defined Contribution Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>211071023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.dna.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230113002 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/DiscontinuedOperations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230273003 - Disclosure - Collaboration and Licensing Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueTables</Role>
      <ShortName>Collaboration and Licensing Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/CollaborationandLicensingRevenue</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230343004 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/ShorttermInvestments</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230373005 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230433006 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/Inventory</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230463007 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230503008 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230563009 - Disclosure - Lines of Credit and Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtTables</Role>
      <ShortName>Lines of Credit and Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/LinesofCreditandLongTermDebt</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230633010 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230713011 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/ShareholdersEquity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230753012 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/ShareBasedPayments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230823013 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/OperatingLeases</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>230933014 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/NetLossperShare</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>230973015 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/Segments</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231033016 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.dna.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240094005 - Disclosure - Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240124006 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails</Role>
      <ShortName>Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240134007 - Disclosure - Discontinued Operations - Summary of Financial Results for MBP Titan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails</Role>
      <ShortName>Discontinued Operations - Summary of Financial Results for MBP Titan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240144008 - Disclosure - Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails</Role>
      <ShortName>Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240154009 - Disclosure - Discontinued Operations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240164010 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails</Role>
      <ShortName>Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240174011 - Disclosure - Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails</Role>
      <ShortName>Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240184012 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails</Role>
      <ShortName>Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240194013 - Disclosure - Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240214014 - Disclosure - Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails</Role>
      <ShortName>Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240234015 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails</Role>
      <ShortName>Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240244016 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails</Role>
      <ShortName>Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240254017 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails</Role>
      <ShortName>Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240284018 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails</Role>
      <ShortName>Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240294019 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails</Role>
      <ShortName>Collaboration and Licensing Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240304020 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240314021 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails</Role>
      <ShortName>Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240324022 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails</Role>
      <ShortName>Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240354023 - Disclosure - Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails</Role>
      <ShortName>Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240384024 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240394025 - Disclosure - Fair Value Measurements - Summary of Level 3 Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Level 3 Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240404026 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240414027 - Disclosure - Fair Value Measurements - Change in Fair Value Level 3 Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Change in Fair Value Level 3 Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240444028 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240474029 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240484030 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240514031 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240524032 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240534033 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240544034 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240574035 - Disclosure - Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240584036 - Disclosure - Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails</Role>
      <ShortName>Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240594037 - Disclosure - Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240604038 - Disclosure - Lines of Credit and Long-Term Debt - Components of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails</Role>
      <ShortName>Lines of Credit and Long-Term Debt - Components of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240614039 - Disclosure - Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails</Role>
      <ShortName>Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240644040 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240654041 - Disclosure - Income Taxes - Components of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240664042 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240674043 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240684044 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Summary of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240694045 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240724046 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240734047 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240764048 - Disclosure - Share-Based Payments - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240774049 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240784050 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240794051 - Disclosure - Share-Based Payments - Summary of Information About Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails</Role>
      <ShortName>Share-Based Payments - Summary of Information About Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240804052 - Disclosure - Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240834053 - Disclosure - Operating Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>Operating Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240844054 - Disclosure - Operating Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Operating Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240854055 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240864056 - Disclosure - Operating Leases - Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails</Role>
      <ShortName>Operating Leases - Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240874057 - Disclosure - Operating Leases - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/OperatingLeasesOtherInformationDetails</Role>
      <ShortName>Operating Leases - Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240894058 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240914059 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240944060 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240954061 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails</Role>
      <ShortName>Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240984062 - Disclosure - Segments - Information by Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails</Role>
      <ShortName>Segments - Information by Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240994063 - Disclosure - Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails</Role>
      <ShortName>Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>241004064 - Disclosure - Segments - Reconciliation of Net Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Segments - Reconciliation of Net Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>241014065 - Disclosure - Segments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SegmentsAdditionalInformationDetails</Role>
      <ShortName>Segments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>241044066 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>241064067 - Disclosure - Defined Contribution Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>241084068 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dna.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.dna.com/role/SubsequentEvents</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="pgen-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - pgen-20201231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - pgen-20201231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pgen-20201231.htm">pgen-20201231.htm</File>
    <File>pgen-20201231.xsd</File>
    <File>pgen-20201231_cal.xml</File>
    <File>pgen-20201231_def.xml</File>
    <File>pgen-20201231_lab.xml</File>
    <File>pgen-20201231_pre.xml</File>
    <File>pgen-20201231xexx211.htm</File>
    <File>pgen-20201231xexx231.htm</File>
    <File>pgen-20201231xexx232.htm</File>
    <File>pgen-20201231xexx311.htm</File>
    <File>pgen-20201231xexx312.htm</File>
    <File>pgen-20201231xexx321.htm</File>
    <File>pgen-20201231xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pgen-20201231_g1.jpg</File>
    <File>pgen-20201231_g10.jpg</File>
    <File>pgen-20201231_g11.jpg</File>
    <File>pgen-20201231_g12.jpg</File>
    <File>pgen-20201231_g13.jpg</File>
    <File>pgen-20201231_g14.jpg</File>
    <File>pgen-20201231_g15.jpg</File>
    <File>pgen-20201231_g16.jpg</File>
    <File>pgen-20201231_g17.jpg</File>
    <File>pgen-20201231_g18.jpg</File>
    <File>pgen-20201231_g2.jpg</File>
    <File>pgen-20201231_g3.jpg</File>
    <File>pgen-20201231_g4.jpg</File>
    <File>pgen-20201231_g5.jpg</File>
    <File>pgen-20201231_g6.jpg</File>
    <File>pgen-20201231_g7.jpg</File>
    <File>pgen-20201231_g8.jpg</File>
    <File>pgen-20201231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>157
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pgen-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 43,
   "contextCount": 542,
   "dts": {
    "calculationLink": {
     "local": [
      "pgen-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pgen-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "pgen-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pgen-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pgen-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pgen-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 956,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://www.dna.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 9
   },
   "keyCustom": 112,
   "keyStandard": 542,
   "memberCustom": 78,
   "memberStandard": 58,
   "nsprefix": "pgen",
   "nsuri": "http://www.dna.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.dna.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.dna.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i523c931240534675a00b833db69b7b7f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794051 - Disclosure - Share-Based Payments - Summary of Information About Stock Options Outstanding (Details)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails",
     "shortName": "Share-Based Payments - Summary of Information About Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i523c931240534675a00b833db69b7b7f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i59afefa3805d493fad5e5f44d615e29c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804052 - Disclosure - Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
     "shortName": "Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pgen:LesseeOperatingLeaseTerminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834053 - Disclosure - Operating Leases - Additional Information (Details)",
     "role": "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails",
     "shortName": "Operating Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pgen:LesseeOperatingLeaseTerminationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844054 - Disclosure - Operating Leases - Components of Lease Costs (Details)",
     "role": "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails",
     "shortName": "Operating Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854055 - Disclosure - Operating Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864056 - Disclosure - Operating Leases - Lease Terms and Discount Rates (Details)",
     "role": "http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails",
     "shortName": "Operating Leases - Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874057 - Disclosure - Operating Leases - Other Information (Details)",
     "role": "http://www.dna.com/role/OperatingLeasesOtherInformationDetails",
     "shortName": "Operating Leases - Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i163004d1571347a9896c92d4b1ec572f_D20201001-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894058 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Details)",
     "role": "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i163004d1571347a9896c92d4b1ec572f_D20201001-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914059 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i944eb05698ac46f595fb49e6348b4555_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944060 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954061 - Disclosure - Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details)",
     "role": "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails",
     "shortName": "Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984062 - Disclosure - Segments - Information by Reportable Segment (Details)",
     "role": "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
     "shortName": "Segments - Information by Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i74c2727e865d423586be763a463a4aeb_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994063 - Disclosure - Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details)",
     "role": "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails",
     "shortName": "Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8d70b9845a5b44eb94cdadc203be4f74_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pgen:NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004064 - Disclosure - Segments - Reconciliation of Net Loss Before Income Taxes (Details)",
     "role": "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
     "shortName": "Segments - Reconciliation of Net Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8eef584cce6245a7ac9807ec45566a3a_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:CapitalExpendituresAndInvestmentsinAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8166ea8ff5b14ea1a56f75013f866d68_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014065 - Disclosure - Segments - Additional Information (Details)",
     "role": "http://www.dna.com/role/SegmentsAdditionalInformationDetails",
     "shortName": "Segments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8166ea8ff5b14ea1a56f75013f866d68_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pgen:LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044066 - Disclosure - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)",
     "role": "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails",
     "shortName": "Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064067 - Disclosure - Defined Contribution Plans - Additional Information (Details)",
     "role": "http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails",
     "shortName": "Defined Contribution Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i9db2284265074c3289f29fb1232d187f_D20180101-20180131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084068 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.dna.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if71c2fc0f42a444597ac62521827f72b_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210101003 - Disclosure - Discontinued Operations",
     "role": "http://www.dna.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210201004 - Disclosure - Mergers and Acquisitions",
     "role": "http://www.dna.com/role/MergersandAcquisitions",
     "shortName": "Mergers and Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210221005 - Disclosure - Investments in Joint Ventures",
     "role": "http://www.dna.com/role/InvestmentsinJointVentures",
     "shortName": "Investments in Joint Ventures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210261006 - Disclosure - Collaboration and Licensing Revenue",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenue",
     "shortName": "Collaboration and Licensing Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210331007 - Disclosure - Short-term Investments",
     "role": "http://www.dna.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210361008 - Disclosure - Fair Value Measurements",
     "role": "http://www.dna.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210421009 - Disclosure - Inventory",
     "role": "http://www.dna.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210451010 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.dna.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.dna.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210491011 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210551012 - Disclosure - Lines of Credit and Long-Term Debt",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebt",
     "shortName": "Lines of Credit and Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210621013 - Disclosure - Income Taxes",
     "role": "http://www.dna.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210701014 - Disclosure - Shareholders' Equity",
     "role": "http://www.dna.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210741015 - Disclosure - Share-Based Payments",
     "role": "http://www.dna.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210811016 - Disclosure - Operating Leases",
     "role": "http://www.dna.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210881017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.dna.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210901018 - Disclosure - Related Party Transactions",
     "role": "http://www.dna.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210921019 - Disclosure - Net Loss per Share",
     "role": "http://www.dna.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210961020 - Disclosure - Segments",
     "role": "http://www.dna.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211021021 - Disclosure - Quarterly Financial Information (Unaudited)",
     "role": "http://www.dna.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211051022 - Disclosure - Defined Contribution Plans",
     "role": "http://www.dna.com/role/DefinedContributionPlans",
     "shortName": "Defined Contribution Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211071023 - Disclosure - Subsequent Events",
     "role": "http://www.dna.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pgen:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pgen:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230113002 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230273003 - Disclosure - Collaboration and Licensing Revenue (Tables)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueTables",
     "shortName": "Collaboration and Licensing Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230343004 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.dna.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230373005 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.dna.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230433006 - Disclosure - Inventory (Tables)",
     "role": "http://www.dna.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.dna.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230463007 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.dna.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230503008 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230563009 - Disclosure - Lines of Credit and Long-Term Debt (Tables)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtTables",
     "shortName": "Lines of Credit and Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230633010 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.dna.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230713011 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.dna.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230753012 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230823013 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.dna.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230933014 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.dna.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230973015 - Disclosure - Segments (Tables)",
     "role": "http://www.dna.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231033016 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - Consolidated Statements of Operations (Parenthetical)",
     "role": "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
     "shortName": "Consolidated Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if90df5438bc447dc89f799623be8dd72_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i3b447b89e06347ad9f36601cc9f190ca_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pgen:CollaborationAgreementTerminationNoticePeriod",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:ResearchAndDevelopmentCommitmentsNotYetIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails",
     "shortName": "Summary of Significant Accounting Policies - Rollforward of Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i6a4041a8bb484da3b179334191b0137d_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib3ad6258403540099941f2a068f4043d_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib3ad6258403540099941f2a068f4043d_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094005 - Disclosure - Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details)",
     "role": "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if71c2fc0f42a444597ac62521827f72b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124006 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
     "shortName": "Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for MBP Titan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if71c2fc0f42a444597ac62521827f72b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134007 - Disclosure - Discontinued Operations - Summary of Financial Results for MBP Titan (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
     "shortName": "Discontinued Operations - Summary of Financial Results for MBP Titan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144008 - Disclosure - Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
     "shortName": "Discontinued Operations - Non-cash Items and Purchases of Property, Plant and Equipment for MBP Titan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if37f6425079b45c695c6c6eb8de34e5c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i0a60c6f608e44733aeaf3d64347034ca_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154009 - Disclosure - Discontinued Operations - Narrative (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
     "shortName": "Discontinued Operations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8a892879d07044f58213c5a70dccecdb_I20200131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164010 - Disclosure - Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
     "shortName": "Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities for TS Biotechnology and EnviroFlight (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia3da9f131522486b89e80d1abf10d1c4_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174011 - Disclosure - Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
     "shortName": "Discontinued Operations - Summary of Financial Results for TS Biotechnology and EnviroFlight (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ifd7b148d9b934a37973766102d67c3be_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184012 - Disclosure - Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
     "shortName": "Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows - TS Biotechnology and EnviroFlight (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i78d76ec04dae49099d97a2a44d97f432_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194013 - Disclosure - Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details)",
     "role": "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibeef9924e4a74f15b13a46b3493cc9b8_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214014 - Disclosure - Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details)",
     "role": "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
     "shortName": "Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i000d1fd7f4c64d64832e5ec0e8209d77_D20180901-20180930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:CashInflowsOutflowsInAssetAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234015 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)",
     "role": "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
     "shortName": "Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i1c882e708e9042fab6cf9bdb465e7487_I20140331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244016 - Disclosure - Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)",
     "role": "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
     "shortName": "Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ifcde56c84e2945f99d5ff518fcea780f_I20151231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i1a534fa963094fe1a659de5ddf688bb3_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254017 - Disclosure - Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)",
     "role": "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
     "shortName": "Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ifac2f1a572c141fc8915df3c7e0d761b_I20181130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ib6b5db75752746b88d0767bdebc0c827_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284018 - Disclosure - Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
     "shortName": "Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i5d3047a704254986b92408ff7382d63c_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294019 - Disclosure - Collaboration and Licensing Revenue - Additional Information (Details)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
     "shortName": "Collaboration and Licensing Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i899454939ed242799bd5a3e8c38117ed_D20181001-20181031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "pgen:LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304020 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i0886f93ed7be4cb289c37677075c1648_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i4e07b0b288a443e6a8678c87bf210341_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - Consolidated Statements of Shareholders' and Total Equity",
     "role": "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
     "shortName": "Consolidated Statements of Shareholders' and Total Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ic9ac13fe6c894e4d8bb963cd6fcd7ba1_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i559d7af0e8444c759749c165c72c4dd3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314021 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
     "shortName": "Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i6774b04fc34844d7bb0f5cabaee47b02_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i559d7af0e8444c759749c165c72c4dd3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324022 - Disclosure - Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details)",
     "role": "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
     "shortName": "Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354023 - Disclosure - Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details)",
     "role": "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails",
     "shortName": "Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384024 - Disclosure - Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i08d7c23fc413485dac1d297dad0adfd2_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "pgen:NoncashDividendIncome",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394025 - Disclosure - Fair Value Measurements - Summary of Level 3 Investments (Details)",
     "role": "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Level 3 Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i9d0968ba139544f5890a7b58950634c0_D20190101-20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i0b2ef97b451e4b288b2e62ae5801f30b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404026 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i0b2ef97b451e4b288b2e62ae5801f30b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i088a49fa06f042b3b7d0a766cbe4ba16_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414027 - Disclosure - Fair Value Measurements - Change in Fair Value Level 3 Liability (Details)",
     "role": "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
     "shortName": "Fair Value Measurements - Change in Fair Value Level 3 Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i27aebe7d32b349b39eabbc338188b25c_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444028 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "role": "http://www.dna.com/role/InventoryScheduleofInventoryDetails",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i88fed49ad0634fc1978b61d0cad74161_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InventoryGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandAndLandImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474029 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandAndLandImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484030 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Details)",
     "role": "http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails",
     "shortName": "Property, Plant and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514031 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i867e347749054e8a8f0790f939874f83_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524032 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534033 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544034 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details)",
     "role": "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia2462eb080f5476ba12592a72425bb0e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574035 - Disclosure - Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
     "shortName": "Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia2462eb080f5476ba12592a72425bb0e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584036 - Disclosure - Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
     "shortName": "Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i933e7cc3ab3e474b9117c918400f0682_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594037 - Disclosure - Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
     "shortName": "Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604038 - Disclosure - Lines of Credit and Long-Term Debt - Components of Interest Expense (Details)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
     "shortName": "Lines of Credit and Long-Term Debt - Components of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "if1c2e4d5e5f24f0bb24ad32c2d82c78a_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614039 - Disclosure - Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)",
     "role": "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails",
     "shortName": "Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644040 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "iebbd89e79742463bb7bb2c8072e4d28d_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080009 - Statement - Consolidated Statements of Cash Flows (Reconciliation of Cash)",
     "role": "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash",
     "shortName": "Consolidated Statements of Cash Flows (Reconciliation of Cash)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654041 - Disclosure - Income Taxes - Components of Income Tax Benefit (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664042 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674043 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684044 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails",
     "shortName": "Income Taxes - Summary of Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "pgen:ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ibdf3a1e21efd4c2a83272a3c28e9f405_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694045 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "icc450189ce644024ba68868dd2551779_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i9db2284265074c3289f29fb1232d187f_D20180101-20180131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724046 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "role": "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i9db2284265074c3289f29fb1232d187f_D20180101-20180131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "iff3ad1cbe4f94438bfc6c8e05f20b744_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734047 - Disclosure - Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity - Components of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i8d40ed18f6934798ba07115922d698e0_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764048 - Disclosure - Share-Based Payments - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Share-Based Payments - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i507bf64ce91c4dbe855ace68943a9ff1_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774049 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "ia282a6bdf4f94e0fa88158eed45e3d08_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i59afefa3805d493fad5e5f44d615e29c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784050 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Details)",
     "role": "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pgen-20201231.htm",
      "contextRef": "i279af4c8c630493ab9758ebd3252a95c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - pgen-20201231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - pgen-20201231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 156,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pgen_A3.5ConvertibleNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.5% Convertible Notes Due 2023 [Member]",
        "label": "3.5% Convertible Notes Due 2023 [Member]",
        "terseLabel": "3.5% Convertible Notes Due 2023"
       }
      }
     },
     "localname": "A3.5ConvertibleNotesDue2023Member",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AccountsReceivableAllowanceForCreditLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Credit Loss",
        "label": "Accounts Receivable, Allowance For Credit Loss [Line Items]",
        "terseLabel": "Accounts Receivable, Allowance For Credit Loss [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_AccountsReceivableAllowanceForCreditLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Credit Loss",
        "label": "Accounts Receivable, Allowance For Credit Loss [Table]",
        "terseLabel": "Accounts Receivable, Allowance For Credit Loss [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_AccruedCompensationPaidinEquityAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation Paid in Equity Awards",
        "label": "Accrued Compensation Paid in Equity Awards",
        "terseLabel": "Accrued compensation paid in equity awards"
       }
      }
     },
     "localname": "AccruedCompensationPaidinEquityAwards",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ActoBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ActoBio [Member]",
        "label": "ActoBio [Member]",
        "terseLabel": "ActoBio"
       }
      }
     },
     "localname": "ActoBioMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ActoBioNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ActoBio Notes",
        "label": "ActoBio Notes [Member]",
        "terseLabel": "ActoBio Notes"
       }
      }
     },
     "localname": "ActoBioNotesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AdjustmentForBonusesPaidInEquityAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment For Bonuses Paid In Equity Awards",
        "label": "Adjustment For Bonuses Paid In Equity Awards",
        "terseLabel": "Adjustment related to accrued bonuses paid in equity awards"
       }
      }
     },
     "localname": "AdjustmentForBonusesPaidInEquityAwards",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_Adjustmentsfornoncontrollinginterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in noncontrolling interest balance because of current period activity, including business combinations and subsidiary equity issuances.",
        "label": "Adjustments for noncontrolling interests",
        "terseLabel": "Adjustments for noncontrolling interests"
       }
      }
     },
     "localname": "Adjustmentsfornoncontrollinginterests",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_AffiliatesOfThirdSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Third Security, LLC",
        "label": "Affiliates Of Third Security [Member]",
        "terseLabel": "Affiliates of Third Security"
       }
      }
     },
     "localname": "AffiliatesOfThirdSecurityMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AllInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Investors of Entity [Member]",
        "label": "All Investors [Member]",
        "terseLabel": "All Investors"
       }
      }
     },
     "localname": "AllInvestorsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AmericanStateBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American State Bank [Member]",
        "label": "American State Bank [Member]",
        "terseLabel": "American State Bank"
       }
      }
     },
     "localname": "AmericanStateBankMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AquaBountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aqua Bounty Technologies, Inc.",
        "label": "Aqua Bounty [Member]",
        "terseLabel": "AquaBounty Technologies, Inc."
       }
      }
     },
     "localname": "AquaBountyMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_AresTradingS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares Trading S.A., a subsidiary of Merck Serono S.A. [Member]",
        "label": "Ares Trading S.A. [Member]",
        "terseLabel": "Ares Trading S.A."
       }
      }
     },
     "localname": "AresTradingS.A.Member",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_BreedingandProductionAnimalsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of animals maintained to create offspring or to produce goods to be sold for profit.",
        "label": "Breeding and Production Animals, Gross",
        "terseLabel": "Breeding stock"
       }
      }
     },
     "localname": "BreedingandProductionAnimalsGross",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. [Member]",
        "label": "CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. [Member]",
        "terseLabel": "CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc."
       }
      }
     },
     "localname": "CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_CapitalExpendituresAndInvestmentsinAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Expenditures and Investments in Affiliates",
        "label": "Capital Expenditures And Investments in Affiliates",
        "terseLabel": "Remove cash paid for capital expenditures and investments in affiliates"
       }
      }
     },
     "localname": "CapitalExpendituresAndInvestmentsinAffiliates",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CashInflowsOutflowsInAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflows (outflows) related to an asset acquisition.",
        "label": "Cash Inflows (Outflows) In Asset Acquisition",
        "terseLabel": "Cash received in asset acquisitions",
        "verboseLabel": "Cash received in asset acquisition"
       }
      }
     },
     "localname": "CashInflowsOutflowsInAssetAcquisition",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CastleCreekBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Castle Creek Biosciences, Inc.",
        "label": "Castle Creek Biosciences, Inc. [Member]",
        "terseLabel": "Castle Creek Biosciences, Inc."
       }
      }
     },
     "localname": "CastleCreekBiosciencesIncMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_CollaborationAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Termination Notice Period",
        "label": "Collaboration Agreement Termination Notice Period",
        "terseLabel": "Required notice period for voluntary termination of collaborative agreement"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationNoticePeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_CollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements [Line Items]",
        "label": "Collaboration Agreements [Line Items]",
        "terseLabel": "Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborationAgreementsLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_CollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements [Table]",
        "label": "Collaboration Agreements [Table]",
        "terseLabel": "Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "CollaborationAgreementsTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_CollaborationArrangementPercentOfCollaborationPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party.",
        "label": "Collaboration Arrangement, Percent Of Collaboration Payments",
        "terseLabel": "Collaboration agreement, percent of collaboration payments"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfCollaborationPayments",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_CollaborationandlicensingagreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees, milestone payments, and research services related to collaboration and licensing agreements.",
        "label": "Collaboration and licensing agreements [Member]",
        "terseLabel": "Collaboration and licensing agreements"
       }
      }
     },
     "localname": "CollaborationandlicensingagreementsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which the consideration is owed to the entity under a collaboration agreement.",
        "label": "Collaborative Arrangement, Consideration Receivable, Collection Period",
        "terseLabel": "Collaborative agreement, consideration receivable, collection period"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceivableCollectionPeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity.",
        "label": "Collaborative Arrangement, Consideration Receivable, Minimum Targets Required",
        "terseLabel": "Collaborative agreement, consideration receivable, minimum targets required"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_CollaborativeArrangementConsiderationReceivedCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Consideration Received Cash",
        "label": "Collaborative Arrangement Consideration Received Cash",
        "terseLabel": "Collaborative agreement, consideration received, cash"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceivedCash",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CollaborativeArrangementConsiderationReceivedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of consideration received by the entity for collaboration",
        "label": "Collaborative Arrangement Consideration Received Value",
        "terseLabel": "Collaborative agreement, consideration received, value"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceivedValue",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock.",
        "label": "Collaborative Arrangement Consideration Received Value Of Convertible Promissory Note",
        "terseLabel": "Collaborative agreement, consideration received, value of convertible promissory note"
       }
      }
     },
     "localname": "CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2.",
        "label": "Collaborative Arrangement Net Sales At Which Royalty Rate Changes To Tier Two",
        "terseLabel": "Level of net sales at which royalty rate changes to tier 2"
       }
      }
     },
     "localname": "CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1.",
        "label": "Collaborative Arrangement Royalties As Percentage Of Net Sales Tier One",
        "terseLabel": "Royalty rate as a percentage of net sales, tier 1"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2.",
        "label": "Collaborative Arrangement Royalties As Percentage Of Net Sales Tier Two",
        "terseLabel": "Royalty rate as a percentage of net sales, tier 2"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_CommonStockCalculationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Calculation Period",
        "label": "Common Stock Calculation Period",
        "terseLabel": "Common stock calculation period"
       }
      }
     },
     "localname": "CommonStockCalculationPeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of monthly expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals.",
        "label": "Compensation Arrangement With Individual, Allocated Share-Based Compensation Expense, Monthly Expense",
        "verboseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "CompensationArrangementWithIndividualAllocatedShareBasedCompensationExpenseMonthlyExpense",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CompensationArrangementWithIndividualAnnualCashRetainer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation Arrangement With Individual, Annual Cash Retainer",
        "label": "Compensation Arrangement With Individual, Annual Cash Retainer",
        "terseLabel": "Compensation arrangement with individual, annual cash retainer"
       }
      }
     },
     "localname": "CompensationArrangementWithIndividualAnnualCashRetainer",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation Arrangement With Individual, Annual RSU Grant, Grant Date Fair Value",
        "label": "Compensation Arrangement With Individual, Annual RSU Grant, Grant Date Fair Value",
        "terseLabel": "Compensation arrangement with individual, annual RSU grant, grant date fair value"
       }
      }
     },
     "localname": "CompensationArrangementWithIndividualAnnualRSUGrantGrantDateFairValue",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation Arrangement With Individual, Annual Stock Option Grant, Grant Date Fair Value",
        "label": "Compensation Arrangement With Individual, Annual Stock Option Grant, Grant Date Fair Value",
        "terseLabel": "Compensation arrangement with individual, annual stock option grant, grant date fair value"
       }
      }
     },
     "localname": "CompensationArrangementWithIndividualAnnualStockOptionGrantGrantDateFairValue",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ComputerHardwareandSoftware": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation and amortization of computer hardware and purchased software.",
        "label": "Computer Hardware and Software",
        "terseLabel": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerHardwareandSoftware",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ComputerHardwareandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications.",
        "label": "Computer Hardware and Software [Member]",
        "terseLabel": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerHardwareandSoftwareMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ConvertibleDebtPrincipalAmountInitialConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount in principal used in the initial conversion rate of the Convertible Notes.",
        "label": "Convertible Debt Principal Amount Initial Conversion Rate",
        "terseLabel": "Principal amount used in conversion"
       }
      }
     },
     "localname": "ConvertibleDebtPrincipalAmountInitialConversionRate",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ConvertiblePreferredStockAmountAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum value of preferred shares permitted to be issued.",
        "label": "Convertible Preferred Stock, Amount Authorized",
        "terseLabel": "Convertible preferred stock, amount authorized"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAmountAuthorized",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_CorporateAndReconcilingItemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate And Reconciling Items [Member]",
        "label": "Corporate And Reconciling Items [Member]",
        "terseLabel": "Other expenses:"
       }
      }
     },
     "localname": "CorporateAndReconcilingItemsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_CostOfProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Products [Member]",
        "label": "Cost Of Products [Member]",
        "terseLabel": "Cost of products"
       }
      }
     },
     "localname": "CostOfProductsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_CostOfServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Services [Member]",
        "label": "Cost Of Services [Member]",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CostOfServicesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_DebtInstrumentResaleRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Resale Restriction Period",
        "label": "Debt Instrument, Resale Restriction Period",
        "terseLabel": "Debt instrument, resale restriction days"
       }
      }
     },
     "localname": "DebtInstrumentResaleRestrictionPeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_DeferredRevenueOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other deferred revenue",
        "label": "Deferred Revenue Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredRevenueOtherMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments and investments accounted for under the fair value option.",
        "label": "Deferred Tax Asset Equity Method Investments and Investments Accounted For Under The Fair Value Option",
        "terseLabel": "Equity securities and investments in affiliates"
       }
      }
     },
     "localname": "DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax assets attributable to deductible operating loss carryforwards, capital loss carryforwards, and interest expense carryforwards, net.",
        "label": "Deferred Tax Assets, Operating, Capital Loss, And Interest Expense Carryforwards",
        "terseLabel": "Net operating, capital loss, and interest expense carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DeferredTaxLiabilitiesEquityComponentofLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from equity component of long-term debt.",
        "label": "Deferred Tax Liabilities, Equity Component of Long-Term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesEquityComponentofLongTermDebt",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Discontinued Operations, Operating Lease, Liability, Current",
        "label": "Disposal Group, Discontinued Operations, Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityCurrent",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent",
        "label": "Disposal Group, Discontinued Operations, Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "DisposalGroupDiscontinuedOperationsOperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal",
        "label": "Disposal Group, Including Discontinued Operation, Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightofUseAsset",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Equity Method Investments",
        "label": "Disposal Group, Including Discontinued Operations, Equity Method Investments",
        "terseLabel": "Investments in affiliates"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsEquityMethodInvestments",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Income (Loss) from Equity Method Investments",
        "label": "Disposal Group, Including Discontinued Operations, Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity in net loss of affiliates"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsIncomeLossfromEquityMethodInvestments",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operations, Operating Lease, Liability, Current",
        "label": "Disposal Group, Including Discontinued Operations, Operating Lease, Liability, Current",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationsOperatingLeaseLiabilityCurrent",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to adjustments for acquisition-related transaction costs.",
        "label": "Effective Income Tax Rate Reconciliation, Acquisition-related Transaction Costs",
        "terseLabel": "Acquisition and internal restructuring transaction costs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionrelatedTransactionCosts",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic deferred state income tax rates, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred State Tax Rate, Amount",
        "terseLabel": "Change in deferred state tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeinDeferredStateTaxRateAmount",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 11.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible officers' compensation costs.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Officers' Compensation",
        "terseLabel": "Nondeductible officer compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible reacquired in-process research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Reacquired In-process Research and Development, Amount",
        "terseLabel": "Reacquired in-process research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReacquiredInprocessResearchandDevelopmentAmount",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EliminationsAndReconcilingItemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminations And Reconciling Items [Member]",
        "label": "Eliminations And Reconciling Items [Member]",
        "terseLabel": "Elimination of intersegment revenues"
       }
      }
     },
     "localname": "EliminationsAndReconcilingItemsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_EnviroFlightLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EnviroFlight, LLC [Member]",
        "label": "EnviroFlight, LLC [Member]",
        "terseLabel": "EnviroFlight Sale"
       }
      }
     },
     "localname": "EnviroFlightLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Summarized Financial Information, Assets Liabilities, Net",
        "label": "Equity Method Investment, Summarized Financial Information, Assets Liabilities, Net",
        "totalLabel": "Net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_EquitySecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities [Policy Text Block]",
        "label": "Equity Securities [Policy Text Block]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesPolicyTextBlock",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pgen_EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amounts of gains and losses from fair value changes and disposition of equity securities and preferred stock included in earnings.",
        "label": "Equity Securities and Preferred Stock, Unrealized and Realized Appreciation (Depreciation)",
        "negatedLabel": "Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net",
        "negatedTerseLabel": "Unrealized and realized depreciation on equity securities and preferred stock, net",
        "terseLabel": "Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net"
       }
      }
     },
     "localname": "EquitySecuritiesandPreferredStockUnrealizedandRealizedAppreciationDepreciation",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ExecutiveChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman [Member]",
        "label": "Executive Chairman [Member]",
        "terseLabel": "Executive Chairman"
       }
      }
     },
     "localname": "ExecutiveChairmanMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExemplarGeneticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exemplar Genetics, LLC [Member]",
        "label": "Exemplar Genetics, LLC [Member]",
        "terseLabel": "Exemplar Genetics, LLC"
       }
      }
     },
     "localname": "ExemplarGeneticsLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price [Axis]",
        "label": "Exercise Price [Axis]",
        "terseLabel": "Exercise Price [Axis]"
       }
      }
     },
     "localname": "ExercisePriceAxis",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_ExercisePriceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price [Domain]",
        "label": "Exercise Price [Domain]",
        "terseLabel": "Exercise Price [Domain]"
       }
      }
     },
     "localname": "ExercisePriceDomain",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price five.",
        "label": "Exercise Price Five [Member]",
        "terseLabel": "Price range 5"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price four.",
        "label": "Exercise Price Four [Member]",
        "terseLabel": "Price range 4"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price one.",
        "label": "Exercise Price One [Member]",
        "terseLabel": "Price range 1"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price three.",
        "label": "Exercise Price Three [Member]",
        "terseLabel": "Price range 3"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price two.",
        "label": "Exercise Price Two [Member]",
        "terseLabel": "Price range 2"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ExotechADSkincareAndThriveAgrobioticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exotech, AD Skincare, and Thrive Agrobiotics",
        "label": "Exotech, AD Skincare, and Thrive Agrobiotics [Member]",
        "terseLabel": "Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc."
       }
      }
     },
     "localname": "ExotechADSkincareAndThriveAgrobioticsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Increase Due to Deconsolidation of Subsidiary",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Increase Due to Deconsolidation of Subsidiary",
        "terseLabel": "Retained interest in deconsolidated subsidiary"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisAssetIncreaseDuetoDeconsolidationofSubsidiary",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_FeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Feed [Member]",
        "label": "Feed [Member]",
        "terseLabel": "Feed"
       }
      }
     },
     "localname": "FeedMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_FirstNationalBankofOmahaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First National Bank of Omaha [Member]",
        "label": "First National Bank of Omaha [Member]",
        "terseLabel": "First National Bank of Omaha"
       }
      }
     },
     "localname": "FirstNationalBankofOmahaMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ForeignSubsidiariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Subsidiaries [Member]",
        "label": "Foreign Subsidiaries [Member]",
        "terseLabel": "Foreign Subsidiaries"
       }
      }
     },
     "localname": "ForeignSubsidiariesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_GainLossRelatedToNoncashLitigationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Noncash Litigation Settlement",
        "label": "Gain (Loss) Related to Noncash Litigation Settlement",
        "negatedTerseLabel": "Loss on settlement agreement",
        "terseLabel": "Loss on settlement agreement"
       }
      }
     },
     "localname": "GainLossRelatedToNoncashLitigationSettlement",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_GeneratedAfter2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generated After 2017 [Member]",
        "label": "Generated After 2017 [Member]",
        "terseLabel": "Generated after 2017"
       }
      }
     },
     "localname": "GeneratedAfter2017Member",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genten Therapeutics, CRS Bio, and Relieve Genetics",
        "label": "Genten Therapeutics, CRS Bio, and Relieve Genetics [Member]",
        "terseLabel": "Genten Therapeutics, CRS Bio, and Relieve Genetics"
       }
      }
     },
     "localname": "GentenTherapeuticsCRSBioAndRelieveGeneticsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_HarvestIntrexonEnterpriseFundILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvest Intrexon Enterprise Fund I, LP [Member]",
        "label": "Harvest Intrexon Enterprise Fund I, LP [Member]",
        "terseLabel": "Harvest Intrexon Enterprise Fund I, LP"
       }
      }
     },
     "localname": "HarvestIntrexonEnterpriseFundILPMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_HarvestStartUpEntitiesAggregatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvest Start-Up Entities, Aggregated [Member]",
        "label": "Harvest Start-Up Entities, Aggregated [Member]",
        "verboseLabel": "Harvest Start-Up Entities"
       }
      }
     },
     "localname": "HarvestStartUpEntitiesAggregatedMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_HighlyLiquidInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original maturity period for highly liquid investments to be considered cash equivalent, maximum",
        "label": "Highly Liquid Investment Maximum Maturity Period",
        "terseLabel": "Maturity period of highly liquid investment"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_HumanBiotherapeuticsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human Biotherapeutics Segment",
        "label": "Human Biotherapeutics Segment [Member]",
        "terseLabel": "Human Biotherapeutics"
       }
      }
     },
     "localname": "HumanBiotherapeuticsSegmentMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance",
        "totalLabel": "Income tax reconciliation income tax benefit before valuation allowance, total"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of operating lease liabilities.",
        "label": "Increase (Decrease) In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments and amortization expense attributable to debt issuance costs.",
        "label": "Interest Expense, Debt, Amortization of Debt Discount (Premium) and Debt Issuance Costs",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtAmortizationofDebtDiscountPremiumandDebtIssuanceCosts",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_IntrexonEnergyPartnersIILLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrexon Energy Partners II, LLC [Member]",
        "label": "Intrexon Energy Partners II, LLC [Member]",
        "terseLabel": "Intrexon Energy Partners II, LLC"
       }
      }
     },
     "localname": "IntrexonEnergyPartnersIILLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_IntrexonEnergyPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrexon Energy Partners, LLC",
        "label": "Intrexon Energy Partners [Member]",
        "terseLabel": "Intrexon Energy Partners, LLC"
       }
      }
     },
     "localname": "IntrexonEnergyPartnersMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_IntrexonT1DPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrexon T1D Partners, LLC [Member]",
        "label": "Intrexon T1D Partners, LLC [Member]",
        "terseLabel": "Intrexon T1D Partners, LLC"
       }
      }
     },
     "localname": "IntrexonT1DPartnersLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_JointVentureAdditionalCapitalContributionsCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional capital contributions to the joint venture for which the entity is committed, maximum.",
        "label": "Joint Venture Additional Capital Contributions Committed",
        "terseLabel": "Maximum additional capital contributions committed"
       }
      }
     },
     "localname": "JointVentureAdditionalCapitalContributionsCommitted",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amount of additional capital contributions to the joint venture for which the entity is committed.",
        "label": "Joint Venture Additional Capital Contributions Committed, Remaining Commitment",
        "terseLabel": "Additional capital contributions committed, remaining commitment"
       }
      }
     },
     "localname": "JointVentureAdditionalCapitalContributionsCommittedRemainingCommitment",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_LesseeOperatingLeaseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period",
        "label": "Lessee, Operating Lease, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_LicenseAgreementAnnualFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual licensing fee due under licensing agreement.",
        "label": "License Agreement, Annual Fee",
        "terseLabel": "License agreement, annual fee"
       }
      }
     },
     "localname": "LicenseAgreementAnnualFee",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_LicenseAgreementNumberofExclusivelyLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of exclusively licensed products under a licensing agreement.",
        "label": "License Agreement, Number of Exclusively Licensed Products",
        "terseLabel": "License agreement, number of exclusively licensed products"
       }
      }
     },
     "localname": "LicenseAgreementNumberofExclusivelyLicensedProducts",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of development costs for which an entity is responsible under a licensing agreement.",
        "label": "License Agreement, Percentage of Development Costs For Which Responsible",
        "terseLabel": "License agreement, percentage of development costs for which responsible"
       }
      }
     },
     "localname": "LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_LicenseAgreementPercentageofSublicensingIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Sublicensing Income",
        "label": "License Agreement, Percentage of Sublicensing Income",
        "terseLabel": "License agreement, percentage of sublicensing income"
       }
      }
     },
     "localname": "LicenseAgreementPercentageofSublicensingIncome",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of quarterly installments in which historical costs will be reimbursed under licensing agreement.",
        "label": "License Agreement, Reimbursement of Historical Costs, Number of Quarterly Installments",
        "terseLabel": "License agreement, reimbursement of historical costs, number of quarterly installments"
       }
      }
     },
     "localname": "LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_LicenseAgreementRoyaltyDueAggregated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty amount due under licensing agreement, aggregated.",
        "label": "License Agreement, Royalty Due, Aggregated",
        "terseLabel": "License agreement, royalty due, aggregated"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyDueAggregated",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period following a triggering event after which a licensing agreement will be terminated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "License Agreement, Termination, Period Following Triggering Event",
        "terseLabel": "License agreement, termination, period following triggering event"
       }
      }
     },
     "localname": "LicenseAgreementTerminationPeriodFollowingTriggeringEvent",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement Between ZIOPHARM Oncology, Inc. and Precigen, Inc. in 2018 [Member]",
        "label": "Licensing Agreement Between ZIOPHARM and Precigen 2018 [Member]",
        "terseLabel": "Licensing agreement between ZIOPHARM and Precigen 2018"
       }
      }
     },
     "localname": "LicensingAgreementBetweenZIOPHARMandPrecigen2018Member",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of operating profits to be received by an entity under a licensing agreement.",
        "label": "Licensing Agreement, Percentage of Operating Profits to Be Received",
        "terseLabel": "License agreement, percentage of operating profits to be received"
       }
      }
     },
     "localname": "LicensingAgreementPercentageofOperatingProfitstoBeReceived",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_LicensingAgreementReimbursementofHistoricalCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of historical costs to which an entity is entitled under a licensing agreement.",
        "label": "Licensing Agreement, Reimbursement of Historical Costs",
        "terseLabel": "License agreement, reimbursement of historical costs"
       }
      }
     },
     "localname": "LicensingAgreementReimbursementofHistoricalCosts",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_LicensingAndPatentInfringementSuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing And Patent Infringement Suit [Member]",
        "label": "Licensing And Patent Infringement Suit [Member]",
        "terseLabel": "Licensing and patent infringement suit"
       }
      }
     },
     "localname": "LicensingAndPatentInfringementSuitMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_LockupPeriodOnRestrictedStockUnitShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time during which issued shares are subject to a lock-up on resale.",
        "label": "Lockup Period On Restricted Stock Unit Shares",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockupPeriodOnRestrictedStockUnitShares",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Lived Assets, Including Property, Plant, and Equipment and Right Of Use Assets",
        "label": "Long-Lived Assets, Including Property, Plant, and Equipment and Right Of Use Assets",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "LongLivedAssetsIncludingPropertyPlantandEquipmentandRightOfUseAssets",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_LossContingenciesTotalClaimsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of claims.",
        "label": "Loss Contingencies, Total Claims, Number",
        "terseLabel": "Total claims"
       }
      }
     },
     "localname": "LossContingenciesTotalClaimsNumber",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_LossContingencyAppealedClaimsDismissed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Appealed Claims Dismissed",
        "label": "Loss Contingency, Appealed Claims Dismissed",
        "terseLabel": "Loss contingency, appealed claims dismissed"
       }
      }
     },
     "localname": "LossContingencyAppealedClaimsDismissed",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_LossContingencyClaimsInvalidatedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Invalidated Number",
        "label": "Loss Contingency, Claims Invalidated Number",
        "terseLabel": "Loss contingency, claims invalidated number"
       }
      }
     },
     "localname": "LossContingencyClaimsInvalidatedNumber",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_LossContingencyReversedClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reversed Claims Dismissed Number",
        "label": "Loss Contingency, Reversed Claims Dismissed Number",
        "terseLabel": "Loss contingency, reversed claims dismissed number"
       }
      }
     },
     "localname": "LossContingencyReversedClaimsDismissedNumber",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_MBPTitanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MBP Titan",
        "label": "MBP Titan [Member]",
        "terseLabel": "MBP Titan"
       }
      }
     },
     "localname": "MBPTitanMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_MerckConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Convertible Note [Member]",
        "label": "Merck Convertible Note [Member]",
        "terseLabel": "Merck Convertible Note"
       }
      }
     },
     "localname": "MerckConvertibleNoteMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_MergersandAcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mergers and Acquisitions [Abstract]",
        "label": "Mergers and Acquisitions [Abstract]",
        "terseLabel": "Mergers and Acquisitions [Abstract]"
       }
      }
     },
     "localname": "MergersandAcquisitionsAbstract",
     "nsuri": "http://www.dna.com/20201231",
     "xbrltype": "stringItemType"
    },
    "pgen_MethaneBioconversionPlatformDisclosuresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methane Bioconversion Platform Disclosures",
        "label": "Methane Bioconversion Platform Disclosures [Member]",
        "terseLabel": "Methane Bioconversion Platform Disclosures"
       }
      }
     },
     "localname": "MethaneBioconversionPlatformDisclosuresMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Required Upon Successful Achievement Aggregated",
        "label": "Milestone Payments Required Upon Successful Achievement Aggregated",
        "terseLabel": "Milestone payments required upon successful achievement, aggregated"
       }
      }
     },
     "localname": "MilestonePaymentsRequiredUponSuccessfulAchievementAggregated",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of potential future milestone payments to be received under agreement per product",
        "label": "Milestone Payments Required Upon Successful Achievement, Per Product",
        "terseLabel": "Milestone payments required upon successful achievement, per product"
       }
      }
     },
     "localname": "MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Adjusted EBITDA defined as net income (loss) before (i) interest expense, (ii) income tax expense/benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) write-off of reacquired in-process research and development, (vii) equity in net income (loss) of affiliates, and (viii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.",
        "label": "Net Income (Loss) Attributable to Parent, Adjusted EBITDA, Including Cash Paid for Capital Expenditures and Investments in Affiliates",
        "verboseLabel": "Segment Adjusted EBITDA"
       }
      }
     },
     "localname": "NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_NoncashDividendIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividend income included in net income that results in no cash flow.",
        "label": "Noncash Dividend Income",
        "negatedTerseLabel": "Noncash dividend income",
        "verboseLabel": "Dividend income from investments in preferred stock"
       }
      }
     },
     "localname": "NoncashDividendIncome",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_NumberOfRelatedPartiesWithTerminatedAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Related Parties With Terminated Agreements",
        "label": "Number Of Related Parties With Terminated Agreements",
        "terseLabel": "Number of related parties with terminated agreements"
       }
      }
     },
     "localname": "NumberOfRelatedPartiesWithTerminatedAgreements",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_NumberOfReportingUnitsClosed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Reporting Units Closed",
        "label": "Number Of Reporting Units Closed",
        "terseLabel": "Number of reporting units closed"
       }
      }
     },
     "localname": "NumberOfReportingUnitsClosed",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_NumberofSeatsonGoverningBoard": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of seats on the governing board.",
        "label": "Number of Seats on Governing Board",
        "terseLabel": "Total number of seats on the joint venture's governing board"
       }
      }
     },
     "localname": "NumberofSeatsonGoverningBoard",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_NumberofSeatsonGoverningBoardExternallySelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of seats on the governing board, externally selected.",
        "label": "Number of Seats on Governing Board, Externally Selected",
        "terseLabel": "Total number of seats on the joint venture's governing board, externally selected"
       }
      }
     },
     "localname": "NumberofSeatsonGoverningBoardExternallySelected",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_NumberofSeatsonGoverningBoardInternallySelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of seats on the governing board selected internally.",
        "label": "Number of Seats on Governing Board, Internally Selected",
        "terseLabel": "Total number of seats on the joint venture's governing board, internally selected"
       }
      }
     },
     "localname": "NumberofSeatsonGoverningBoardInternallySelected",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pgen_OkanaganOxitecFineChemicalsAndAgBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Okanagan, Oxitec, Fine Chemicals, And AgBio [Member]",
        "label": "Okanagan, Oxitec, Fine Chemicals, And AgBio [Member]",
        "terseLabel": "Okanagan, Oxitec, Fine Chemicals, And AgBio"
       }
      }
     },
     "localname": "OkanaganOxitecFineChemicalsAndAgBioMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, acquired in acquisition of a business.",
        "label": "Operating Loss Carryforwards Acquired In Acquisition Of Business",
        "terseLabel": "Net operating losses inherited via acquisition"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAcquiredInAcquisitionOfBusiness",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_OperatingSegmentsAndCorporateNonSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Segments And Corporate Non-Segment [Member]",
        "label": "Operating Segments And Corporate Non-Segment [Member]",
        "terseLabel": "Other revenues, including from other operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsAndCorporateNonSegmentMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OragenicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oragenics, Inc.",
        "label": "Oragenics [Member]",
        "terseLabel": "Oragenics, Inc."
       }
      }
     },
     "localname": "OragenicsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Significant Accounting Policies [Line Items]",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_OtherAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Liabilities [Member]",
        "label": "Other Accrued Liabilities [Member]",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OtherCollaborationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of other collaborations not separately disclosed",
        "label": "Other Collaborations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCollaborationsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OtherFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Assets [Member]",
        "label": "Other Financial Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFinancialAssetsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-Term Debt [Member]",
        "label": "Other Long-Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_OwnshareLendingArrangementSharesIssued1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.",
        "label": "Own-share Lending Arrangement, Shares, Issued1",
        "terseLabel": "Shares issued pursuant to share lending agreement, shares"
       }
      }
     },
     "localname": "OwnshareLendingArrangementSharesIssued1",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pgen_OxitecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxitec",
        "label": "Oxitec [Member]",
        "terseLabel": "Oxitec"
       }
      }
     },
     "localname": "OxitecMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PGENTherapeuticsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PGEN Therapeutics Segment [Member]",
        "label": "PGEN Therapeutics Segment [Member]",
        "terseLabel": "PGEN Therapeutics"
       }
      }
     },
     "localname": "PGENTherapeuticsSegmentMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PaymentsToRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflows for payments made to related parties.",
        "label": "Payments To Related Parties",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentsToRelatedParties",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_PrecigenActioBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precigen ActioBio Inc. [Member]",
        "label": "Precigen ActioBio Inc. [Member]",
        "terseLabel": "Precigen ActoBio, Inc."
       }
      }
     },
     "localname": "PrecigenActioBioIncMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PrecigenStockOptionPlan2008PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precigen Stock Option Plan 2008 Plan",
        "label": "Precigen Stock Option Plan 2008 Plan [Member]",
        "terseLabel": "Precigen Stock Option Plan 2008 Plan"
       }
      }
     },
     "localname": "PrecigenStockOptionPlan2008PlanMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PrecigenStockOptionPlan2013PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precigen Stock Option Plan 2013 Plan",
        "label": "Precigen Stock Option Plan 2013 Plan [Member]",
        "terseLabel": "Precigen Stock Option Plan 2013 Plan"
       }
      }
     },
     "localname": "PrecigenStockOptionPlan2013PlanMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PrecigenStockOptionPlan2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precigen Stock Option Plan 2019 Plan [Member]",
        "label": "Precigen Stock Option Plan 2019 Plan [Member]",
        "terseLabel": "Precigen Stock Option Plan 2019 Plan"
       }
      }
     },
     "localname": "PrecigenStockOptionPlan2019PlanMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PrecigenStockOptionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precigen Stock Option Plans",
        "label": "Precigen Stock Option Plans [Member]",
        "terseLabel": "Precigen Stock Option Plans"
       }
      }
     },
     "localname": "PrecigenStockOptionPlansMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_PreferredStockReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables from conversion of preferred stock to cash.",
        "label": "Preferred Stock Receivables",
        "negatedTerseLabel": "Proceeds to be received from preferred stock"
       }
      }
     },
     "localname": "PreferredStockReceivables",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_PrepaidProductAndServiceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Product And Service Revenues [Member]",
        "label": "Prepaid Product And Service Revenues [Member]",
        "terseLabel": "Prepaid product and service revenues"
       }
      }
     },
     "localname": "PrepaidProductAndServiceRevenuesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ProceedsfromIssuanceofCommonStockandWarrantsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity (in exchange for shares of common stock) and from issuance of rights to purchase common shares at a predetermined price (usually issued together with corporate debt), net of capitalized issuance costs.",
        "label": "Proceeds from Issuance of Common Stock and Warrants, Net",
        "terseLabel": "Proceeds from issuance of shares and warrants in public offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsfromIssuanceofCommonStockandWarrantsNet",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ProceedsfromStockOptionsandWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received (i) from exercise of stock options granted under share-based compensation arrangement and (ii) from holders exercising their stock warrants.",
        "label": "Proceeds from Stock Options and Warrants Exercised",
        "terseLabel": "Proceeds from stock option and warrant exercises"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsandWarrantsExercised",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ProductsandServicesRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from products and services sales.",
        "label": "Products and Services Revenues [Member]",
        "terseLabel": "Products and services revenues"
       }
      }
     },
     "localname": "ProductsandServicesRevenuesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ReacquiredInProcessResearchDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquired In-Process Research &amp; Development [Member]",
        "label": "Reacquired In-Process Research &amp; Development [Member]",
        "terseLabel": "Reacquired in-process research &amp; development"
       }
      }
     },
     "localname": "ReacquiredInProcessResearchDevelopmentMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_RelatedPartiesAggregatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Parties, Aggregated [Member]",
        "label": "Related Parties, Aggregated [Member]",
        "terseLabel": "Related Parties, Aggregated"
       }
      }
     },
     "localname": "RelatedPartiesAggregatedMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_RelatedPartyOwnershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in a related party.",
        "label": "Related Party Ownership Interest",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "RelatedPartyOwnershipInterest",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pgen_RelatedPartyReceivableAllowanceforCreditLossCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Receivable, Allowance for Credit Loss, Current",
        "label": "Related Party Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Related party receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "RelatedPartyReceivableAllowanceforCreditLossCurrent",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ReportableSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reportable Segments [Member]",
        "label": "Reportable Segments [Member]",
        "terseLabel": "Total segment revenues from reportable segments",
        "verboseLabel": "Reportable segments"
       }
      }
     },
     "localname": "ReportableSegmentsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ResearchAndDevelopmentCommitmentsNotYetIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of commitments related to research and development arrangements with third parties which has not yet been incurred.",
        "label": "Research And Development Commitments Not Yet Incurred",
        "terseLabel": "Research and development commitments with third parties not incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitmentsNotYetIncurred",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_RoyaltyPercentageToBePaidtoOtherParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage royalty payable to another party as defined in applicable agreement.",
        "label": "Royalty Percentage To Be Paid to Other Party",
        "terseLabel": "Royalty percentage to be paid to other party"
       }
      }
     },
     "localname": "RoyaltyPercentageToBePaidtoOtherParty",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pgen_SaleOfAssetsIncludedInReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Assets Included In Receivables",
        "label": "Sale of Assets Included In Receivables",
        "terseLabel": "Sales of assets included in receivables"
       }
      }
     },
     "localname": "SaleOfAssetsIncludedInReceivables",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ScheduleOfInvestmentsInJointVentureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Investments In Joint Venture [Line Items]",
        "label": "Schedule Of Investments In Joint Venture [Line Items]",
        "terseLabel": "Schedule Of Investments In Joint Venture [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsInJointVentureLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_ScheduleOfInvestmentsInJointVentureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Investments In Joint Venture [Table]",
        "label": "Schedule Of Investments In Joint Venture [Table]",
        "terseLabel": "Schedule Of Investments In Joint Venture [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsInJointVentureTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment used in the normal conduct of business.",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Estimated Useful Lives of Property, Plant and Equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pgen_SecuritiesAndExchangeCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities And Exchange Commission",
        "label": "Securities And Exchange Commission [Member]",
        "terseLabel": "Securities And Exchange Commission"
       }
      }
     },
     "localname": "SecuritiesAndExchangeCommissionMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_SeriesAPreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable preferred shares.",
        "label": "Series A Preferred Shares [Member]",
        "terseLabel": "Series A Preferred Shares"
       }
      }
     },
     "localname": "SeriesAPreferredSharesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Lending Agreement, Length Of Time For Shares To Be Returned Upon Termination",
        "label": "Share Lending Agreement, Length Of Time For Shares To Be Returned Upon Termination",
        "terseLabel": "Share lending agreement, length of time for shares to be returned upon termination"
       }
      }
     },
     "localname": "ShareLendingAgreementLengthOfTimeForSharesToBeReturnedUponTermination",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_SharesIssuedDuringPeriodValueIssuedForServicesExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense recognized for consideration of services paid in the form of stock. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Shares Issued During Period Value Issued For Services Expense",
        "terseLabel": "Shares issued as payment for services"
       }
      }
     },
     "localname": "SharesIssuedDuringPeriodValueIssuedForServicesExpense",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues",
        "label": "Stock Issued During Period In Conjunction With Settlement Agreement, Shares New Issues",
        "terseLabel": "Stock issued in conjunction with settlement agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodInConjunctionWithSettlementAgreementSharesNewIssues",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pgen_StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues",
        "label": "Stock Issued During Period In Conjunction With Settlement Agreement, Value, New Issues",
        "terseLabel": "Shares issued in conjunction with settlement agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodInConjunctionWithSettlementAgreementValueNewIssues",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options.",
        "label": "Stock Issued During Period, Shares, Stock Options Exercised and Restricted Stock Awards",
        "terseLabel": "Shares issued upon vesting of restricted stock units and for exercises of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRestrictedStockAwards",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pgen_StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards and exercises of stock options and warrants.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised and Restricted Stock Awards",
        "terseLabel": "Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedandRestrictedStockAwards",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Restricted Stock Awards Vested and Stock Options Exercised",
        "terseLabel": "Shares issued upon vesting of restricted stock units and for exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued related to Restricted Stock Awards vested during the period and as a result of the exercise of stock options and warrants.",
        "label": "Stock Issued During Period, Value, Restricted Stock Awards Vested and Stock Options and Warrants Exercised",
        "terseLabel": "Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants",
        "verboseLabel": "Proceeds from shares issued for exercises of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedDuringThePeriodSharesAccruedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for accrued compensation.",
        "label": "Stock Issued During The Period, Shares, Accrued Compensation",
        "terseLabel": "Shares issued for accrued compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesAccruedCompensation",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pgen_StockIssuedDuringThePeriodValueAccruedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for accrued compensation.",
        "label": "Stock Issued During The Period, Value, Accrued Compensation",
        "terseLabel": "Shares issued for accrued compensation"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueAccruedCompensation",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued to acquired intangible assets.",
        "label": "Stock Issued, Intangible Assets",
        "terseLabel": "Fair value of stock issued for reacquired in-process research and development"
       }
      }
     },
     "localname": "StockIssuedIntangibleAssets",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockIssuedSettlementAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued, Settlement Agreement",
        "label": "Stock Issued, Settlement Agreement",
        "terseLabel": "Fair value of stock issued in conjunction with settlement agreement"
       }
      }
     },
     "localname": "StockIssuedSettlementAgreement",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_StockReceivedAsConsiderationForCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock received from collaborative partners as consideration for collaboration agreements.",
        "label": "Stock Received As Consideration For Collaboration Agreements",
        "terseLabel": "Fair value of stock received as consideration for collaboration agreements"
       }
      }
     },
     "localname": "StockReceivedAsConsiderationForCollaborationAgreements",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_SummaryofDeferredRevenuebyCollaboratorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of deferred revenue disclosure which includes the collaborator and the corresponding amount that comprise the balance of deferred revenue as of the balance sheet date.",
        "label": "Summary of Deferred Revenue by Collaborator [Line Items]",
        "terseLabel": "Summary of Deferred Revenue by Collaborator [Line Items]"
       }
      }
     },
     "localname": "SummaryofDeferredRevenuebyCollaboratorLineItems",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_SummaryofDeferredRevenuebyCollaboratorTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the collaborator and the corresponding amount that comprise the balance of deferred revenue as of the balance sheet date.",
        "label": "Summary of Deferred Revenue by Collaborator [Table]",
        "terseLabel": "Summary of Deferred Revenue by Collaborator [Table]"
       }
      }
     },
     "localname": "SummaryofDeferredRevenuebyCollaboratorTable",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pgen_SuppliesEmbryosAndOtherProductionMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplies, Embryos And Other Production Materials [Member]",
        "label": "Supplies, Embryos And Other Production Materials [Member]",
        "terseLabel": "Supplies, embryos and other production materials"
       }
      }
     },
     "localname": "SuppliesEmbryosAndOtherProductionMaterialsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TSBiotechnologyAndEnviroFlightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TS Biotechnology and EnviroFlight",
        "label": "TS Biotechnology and EnviroFlight [Member]",
        "terseLabel": "TS Biotechnology and EnviroFlight"
       }
      }
     },
     "localname": "TSBiotechnologyAndEnviroFlightMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TS Biotechnology Holdings LLC And Enviro Flight LLC [Member]",
        "label": "TS Biotechnology Holdings LLC And Enviro Flight LLC [Member]",
        "terseLabel": "TS Biotechnology Holdings LLC and Enviro Flight LLC"
       }
      }
     },
     "localname": "TSBiotechnologyHoldingsLLCAndEnviroFlightLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TSBiotechnologyHoldingsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TS Biotechnology Holdings, LLC [Member]",
        "label": "TS Biotechnology Holdings, LLC [Member]",
        "terseLabel": "TS Biotechnology Sale"
       }
      }
     },
     "localname": "TSBiotechnologyHoldingsLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ThirdSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Security, LLC",
        "label": "Third Security [Member]",
        "terseLabel": "Third Security"
       }
      }
     },
     "localname": "ThirdSecurityMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TransOvaGeneticsLcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trans Ova Genetics LC [Member]",
        "label": "Trans Ova Genetics Lc [Member]",
        "terseLabel": "Trans Ova Genetics, LC"
       }
      }
     },
     "localname": "TransOvaGeneticsLcMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TransOvaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trans Ova Segment [Member]",
        "label": "Trans Ova Segment [Member]",
        "terseLabel": "Trans Ova"
       }
      }
     },
     "localname": "TransOvaSegmentMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period following the effective date of the licensing agreement during which costs incurred to transition knowledge and materials will be reimbursed by third party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Transition Period During Which Costs Will Be Reimbursed",
        "terseLabel": "Transition period during which costs will be reimbursed"
       }
      }
     },
     "localname": "TransitionPeriodDuringWhichCostsWillBeReimbursed",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pgen_TransitionServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Services [Member]",
        "label": "Transition Services [Member]",
        "terseLabel": "Transition services"
       }
      }
     },
     "localname": "TransitionServicesMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_UpfrontAndMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments received as collaboration for the entity's collaborations",
        "label": "Upfront And Milestone Payments [Member]",
        "verboseLabel": "Upfront and Milestone Payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the valuation allowance for deferred tax assets as a result of current year operations.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount Current Year Operations",
        "terseLabel": "Current year continuing operations"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the valuation allowance for deferred tax assets as a result of mergers and acquisitions, net.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount Mergers And Acquisitions Net",
        "terseLabel": "Mergers and acquisitions, net"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmountMergersAndAcquisitionsNet",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation allowance for deferred tax assets as a result of the change in deferred state tax rate.",
        "label": "Valuation Allowance, Deferred Tax Asset, Change In Deferred State Tax Rate",
        "terseLabel": "Change in deferred state tax rate"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInDeferredStateTaxRate",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation allowance for deferred tax assets as a result of the equity component of long-term debt.",
        "label": "Valuation Allowance, Deferred Tax Asset, Change In Equity Component of Long-Term Debt",
        "terseLabel": "Equity component of long-term debt"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInEquityComponentofLongTermDebt",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the valuation allowance for deferred tax assets as a result of foreign currency translation adjustments.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Foreign Currency Translation Adjustment",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the valuation allowance for deferred tax assets resulting from the adoption of a recently issued accounting pronouncement.",
        "label": "Valuation Allowance, Deferred Tax Asset, Change in Amount due to Adoption of Accounting Principle",
        "verboseLabel": "Adoption of new accounting pronouncements"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeinAmountduetoAdoptionofAccountingPrinciple",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetDeconsolidation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Deconsolidation",
        "label": "Valuation Allowance, Deferred Tax Asset, Deconsolidation",
        "terseLabel": "Deconsolidation of AquaBounty"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetDeconsolidation",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Assets, Discontinued Operations",
        "label": "Valuation Allowance, Deferred Tax Assets, Discontinued Operations",
        "terseLabel": "Discontinued operations related to MBP Titan"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Assets, Discontinued Operations Treated As Asset Sales",
        "label": "Valuation Allowance, Deferred Tax Assets, Discontinued Operations Treated As Asset Sales",
        "terseLabel": "Discontinued operations treated as asset sales"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Assets, Establishment Of Deferred Taxes For Subsidiaries Included In Discontinued Operations",
        "label": "Valuation Allowance, Deferred Tax Assets, Establishment Of Deferred Taxes For Subsidiaries Included In Discontinued Operations",
        "terseLabel": "Establishment of deferred taxes for subsidiaries included in discontinued operations"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetsEstablishmentOfDeferredTaxesForSubsidiariesIncludedInDiscontinuedOperations",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pgen_VariousECCAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various ECC Agreements",
        "label": "Various ECC Agreements [Member]",
        "terseLabel": "Various ECC Agreements"
       }
      }
     },
     "localname": "VariousECCAgreementsMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_WorkInProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work In Process [Member]",
        "label": "Work In Process [Member]",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "WorkInProcessMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_XYLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XY, LLC [Member]",
        "label": "XY, LLC [Member]",
        "terseLabel": "XY, LLC"
       }
      }
     },
     "localname": "XYLLCMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pgen_ZiopharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZIOPHARM Oncology, Inc.",
        "label": "Ziopharm [Member]",
        "terseLabel": "ZIOPHARM Oncology, Inc."
       }
      }
     },
     "localname": "ZiopharmMember",
     "nsuri": "http://www.dna.com/20201231",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r241",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r241",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r108",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r197",
      "r205",
      "r308",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect of adoption of ASC 606"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r197",
      "r205",
      "r308",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r197",
      "r205",
      "r308",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r456",
      "r458",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r679",
      "r752",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r456",
      "r458",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r679",
      "r752",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r274",
      "r434",
      "r438",
      "r680",
      "r751",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r274",
      "r434",
      "r438",
      "r680",
      "r751",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r444",
      "r456",
      "r458",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r679",
      "r752",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r444",
      "r456",
      "r458",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r679",
      "r752",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r275",
      "r276",
      "r434",
      "r439",
      "r754",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r434",
      "r439",
      "r754",
      "r784",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r280",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r655",
      "r657",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average Useful Life (Years)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Adoption of ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "verboseLabel": "Adoption of ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r534",
      "r535",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Cumulative effect of adoption of ASC 606 [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Losses"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r34",
      "r72",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade, less allowance for credit losses of $4,825 and $5,201 as of December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discounts on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r89",
      "r361"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r117",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r75",
      "r115",
      "r116",
      "r117",
      "r735",
      "r763",
      "r767"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r114",
      "r117",
      "r121",
      "r194",
      "r195",
      "r196",
      "r571",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r109",
      "r117",
      "r121",
      "r571",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Income (loss) on foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r73",
      "r502"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r532",
      "r533",
      "r534",
      "r535",
      "r682",
      "r683",
      "r684",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible debt, net of issuance costs and deferred taxes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r460",
      "r462",
      "r505",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r402",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Capitalized offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r237",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "All Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r462",
      "r492",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Stock-based compensation expense",
        "terseLabel": "Stock-based compensation cost"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r284",
      "r311",
      "r313",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r79",
      "r284",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for credit loss, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write offs of accounts receivable, net of recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r168",
      "r615"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r168",
      "r342",
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r168",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedTerseLabel": "Impairment losses",
        "verboseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r181",
      "r249",
      "r262",
      "r269",
      "r303",
      "r564",
      "r575",
      "r597",
      "r701",
      "r733"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r37",
      "r38",
      "r107",
      "r181",
      "r303",
      "r564",
      "r575",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r181",
      "r303",
      "r564",
      "r575",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets held for sale or abandonment"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r358",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets held for sale or abandonment"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r291",
      "r321"
     ],
     "calculation": {
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r289",
      "r292",
      "r321",
      "r708"
     ],
     "calculation": {
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Aggregate Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r463",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BreedingAndProductionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animals maintained to create offspring or to produce goods to be sold for profit.",
        "label": "Breeding and Production Animals [Member]",
        "terseLabel": "Breeding stock"
       }
      }
     },
     "localname": "BreedingAndProductionAnimalsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and building improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r41",
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and building improvements"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r553",
      "r554",
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of financial liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r85",
      "r170"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r171",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r162",
      "r170",
      "r176"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "totalLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r162",
      "r600"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Decrease in cash from deconsolidation of subsidiary"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Significant noncash activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r179",
      "r181",
      "r210",
      "r211",
      "r212",
      "r214",
      "r216",
      "r226",
      "r227",
      "r228",
      "r303",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration and licensing agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r101",
      "r376",
      "r711",
      "r739"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r69",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, no par value, 400,000,000 shares authorized as of December\u00a031, 2020 and 2019; and 187,663,207 shares and 163,274,880 shares issued and outstanding as of December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r442",
      "r443",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "Defined Contribution Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DefinedContributionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r124",
      "r126",
      "r127",
      "r139",
      "r718",
      "r747"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Precigen"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r124",
      "r126",
      "r138",
      "r562",
      "r563",
      "r583",
      "r717",
      "r746"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to the noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r124",
      "r126",
      "r137",
      "r561",
      "r583",
      "r716",
      "r745"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r231",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": {
     "auth_ref": [
      "r411",
      "r572",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase by the parent of an additional equity interest in a subsidiary during the period, thereby effecting a change in total (consolidated) equity attributable to the parent. The purchase of the additional equity interest represented by this element increases the parent's controlling interest in the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent",
        "terseLabel": "Additional investment in subsidiary"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r177",
      "r574",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction and other assets in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r413",
      "r414",
      "r435"
     ],
     "calculation": {
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r413",
      "r414",
      "r435"
     ],
     "calculation": {
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, including $0 and $877 from related parties as of December\u00a031, 2020 and 2019, respectively",
        "verboseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r413",
      "r414",
      "r435"
     ],
     "calculation": {
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion, including $21,205 and $30,182 from related parties as of December\u00a031, 2020 and 2019, respectively",
        "verboseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Add recognition of previously deferred revenue associated with upfront and milestone payments",
        "verboseLabel": "Revenue recognized from previously deferred balances"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r63",
      "r704",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Carrying value of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Unallocated corporate costs"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r143",
      "r680"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product and services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r529",
      "r538"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r189",
      "r529"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r529",
      "r538"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Common stock issued upon conversion of long-term debt (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Lines of Credit and Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r702",
      "r704",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r63",
      "r392",
      "r704",
      "r731"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r98",
      "r403",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Common stock price consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Percentage of common share price over conversion price for conversion"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Common stock price trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r614",
      "r616"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r97",
      "r396",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate on convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r99",
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt instrument, periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r99",
      "r186",
      "r403",
      "r407",
      "r408",
      "r409",
      "r613",
      "r614",
      "r616",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r393",
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Convertible notes, unamortized discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedLabel": "Deconsolidation, loss, amount"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r530",
      "r538"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r530",
      "r538"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r182",
      "r530",
      "r538",
      "r539",
      "r540"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r65",
      "r66",
      "r519",
      "r703",
      "r730"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r511",
      "r512"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementByTypeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "terseLabel": "Deferred Revenue Arrangement [Line Items]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]",
        "terseLabel": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]",
        "terseLabel": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r530",
      "r538"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Deferred tax assets, capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestmentInSubsidiaries": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the entity's investment in its wholly-owned subsidiaries.",
        "label": "Deferred Tax Assets, Investment in Subsidiaries",
        "terseLabel": "Investments in subsidiaries included in discontinued operations"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestmentInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r525",
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state research and development tax credits",
        "verboseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Valuation allowance at end of year",
        "periodStartLabel": "Valuation allowance at beginning of year",
        "terseLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r512",
      "r522"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities included in continuing operations"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plans, cost recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DefinedContributionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r168",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r168",
      "r244"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedTerseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summarized Collaboration and Licensing Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax": {
     "auth_ref": [
      "r12",
      "r13",
      "r18",
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of an increase (decrease) to a gain (loss) previously reported in discontinued operations in a prior period.",
        "label": "Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax",
        "negatedLabel": "Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, Net of Tax"
       }
      }
     },
     "localname": "DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r11",
      "r14"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "terseLabel": "Gain on sale of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r22",
      "r134",
      "r742"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r14",
      "r22",
      "r27",
      "r513",
      "r537",
      "r543"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "negatedTerseLabel": "Income tax expense"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by means of abandonment and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Abandonment"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleAbandonmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r3",
      "r8",
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]",
        "terseLabel": "Discontinued Operations, Held-for-sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r355",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets held for sale or abandonment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents included in current assets held for sale or abandonment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r358",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r355",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.",
        "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)",
        "negatedTerseLabel": "Loss on release of cumulative foreign currency translation adjustment",
        "terseLabel": "Loss on release of cumulative foreign currency translation adjustment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r358",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r358",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other expense, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r355",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r355",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r23",
      "r30"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r31",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Domestic"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r35",
      "r53",
      "r71",
      "r183",
      "r640"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Related parties, less allowance for credit losses of $1,509 and $2,312 as of December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r91",
      "r190",
      "r640"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party payables"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "totalLabel": "Net loss attributable to Precigen per share, basic and diluted (in usd per share)",
        "verboseLabel": "Net loss attributable to Precigen per share, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Historical net loss per share:",
        "verboseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognized over weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to restricted stock unit awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r225",
      "r308",
      "r402",
      "r410",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r758",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r30",
      "r181",
      "r303",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r30",
      "r181",
      "r303",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r30",
      "r181",
      "r303",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Impairment charge on write down of investment in affiliate"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Membership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r86",
      "r250",
      "r300"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investments in affiliates",
        "verboseLabel": "Investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Joint Ventures"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVentures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r86",
      "r161",
      "r177",
      "r302",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r298",
      "r748"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Changes in fair value, gain"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r719"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r591",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r588",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r589",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r445",
      "r446",
      "r451",
      "r453",
      "r589",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in\u00a0Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r445",
      "r446",
      "r451",
      "r453",
      "r589",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r589",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r591",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Change in fair value of contingent consideration recognized in selling, general, and administrative expenses"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.dna.com/role/FairValueMeasurementsChangeinFairValueLevel3LiabilityDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r177",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "United States federal income taxes:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Expected useful life of intangible asset",
        "verboseLabel": "Weighted Average Useful Life (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r343",
      "r345",
      "r349",
      "r352",
      "r681",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r349",
      "r685"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r343",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r349",
      "r681"
     ],
     "calculation": {
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, net, total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofDefiniteLivedIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign income taxes:"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on abandonment and disposals of assets, net",
        "negatedTerseLabel": "Loss on abandonment of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Loss on settlement agreement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r329",
      "r331",
      "r700"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r177",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r177",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r332",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r168",
      "r330",
      "r333",
      "r339"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment",
        "negatedNetLabel": "Impairments",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTransfers": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Transfers",
        "terseLabel": "Reallocations from changes to reporting units"
       }
      }
     },
     "localname": "GoodwillTransfers",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r141",
      "r181",
      "r249",
      "r261",
      "r265",
      "r268",
      "r271",
      "r303",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r168",
      "r357",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets held-for-use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r168",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of other noncurrent assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r354",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]",
        "terseLabel": "Amounts Attributable to Precigen"
       }
      }
     },
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r142",
      "r169",
      "r203",
      "r204",
      "r205",
      "r206",
      "r213",
      "r216",
      "r560"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss from continuing operations attributable to Precigen",
        "verboseLabel": "Net loss from continuing operations attributable to Precigen"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r249",
      "r261",
      "r265",
      "r268",
      "r271",
      "r698",
      "r713",
      "r721",
      "r749"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss from continuing operations before income taxes",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r181",
      "r198",
      "r249",
      "r261",
      "r265",
      "r268",
      "r271",
      "r303",
      "r561",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "verboseLabel": "Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r27",
      "r30",
      "r544",
      "r742"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations, net of income tax benefit"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r14",
      "r22",
      "r27",
      "r561"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "netLabel": "Net loss from discontinued operations attributable to Precigen",
        "totalLabel": "Income (loss) from discontinued operations",
        "verboseLabel": "Net loss from discontinued operations attributable to Precigen"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share",
        "verboseLabel": "Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r133",
      "r168",
      "r246",
      "r300",
      "r712",
      "r741"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in net loss of affiliates",
        "negatedTerseLabel": "Equity in net loss of EnviroFlight",
        "terseLabel": "Equity in net loss of affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r25",
      "r28",
      "r29",
      "r30",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r515",
      "r517",
      "r524",
      "r536",
      "r541",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r182",
      "r208",
      "r209",
      "r247",
      "r513",
      "r537",
      "r542",
      "r750"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit",
        "totalLabel": "Total income tax benefit from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails",
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r177",
      "r509",
      "r510",
      "r517",
      "r518",
      "r523",
      "r531",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "United States-foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Computed statutory income tax benefit from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Nondeductible stock based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State and provincial income tax benefit, net of federal income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "pgen_IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax incentives"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r164",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "negatedLabel": "Related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Receivables [Abstract]",
        "terseLabel": "Receivables:"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r341",
      "r347"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Patents, developed technologies and know-how"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r130",
      "r243",
      "r612",
      "r615",
      "r720"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r146",
      "r397"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Cash interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r159",
      "r163",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r710",
      "r740"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r241",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment revenues",
        "verboseLabel": "Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r106",
      "r177",
      "r222",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest and dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r297",
      "r699",
      "r724",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandAndLandImprovements": {
     "auth_ref": [
      "r42",
      "r55"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.",
        "label": "Land and Land Improvements",
        "terseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "LandAndLandImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land improvements"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r633",
      "r635"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r41",
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r94",
      "r181",
      "r263",
      "r303",
      "r565",
      "r575",
      "r576",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "pgen_EquityMethodInvestmentSummarizedFinancialInformationAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r78",
      "r181",
      "r303",
      "r597",
      "r705",
      "r737"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Purchases of equipment financed through debt"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r96",
      "r181",
      "r303",
      "r565",
      "r575",
      "r576",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r63",
      "r64",
      "r181",
      "r303",
      "r565",
      "r575",
      "r576",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities held for sale or abandonment"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r358",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities held for sale or abandonment"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r24",
      "r26",
      "r30",
      "r355",
      "r365"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Long-term liabilities held for sale or abandonment"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r63",
      "r704",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r92",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of credit facility, current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Line of credit facility, interest rate at period end"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r92",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r60",
      "r702"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Lines of credit"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r63",
      "r394",
      "r704",
      "r734"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, including $0 and $31,211 to related parties as of December\u00a031, 2020 and 2019, respectively",
        "verboseLabel": "Less current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r192",
      "r387"
     ],
     "calculation": {
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtScheduleofFutureMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion, including $0 and $25,000 to related parties as of December\u00a031, 2020 and 2019, respectively",
        "verboseLabel": "Long-term debt, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r99",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled, number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed, number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Claims pending resolution"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r31",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Mergers and Acquisitions"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/MergersandAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Cash equivalent investments in highly liquid money market accounts"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "Valuation Allowance"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r162",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r122",
      "r125",
      "r135",
      "r169",
      "r181",
      "r198",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r213",
      "r249",
      "r261",
      "r265",
      "r268",
      "r271",
      "r303",
      "r597",
      "r714",
      "r743"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Precigen",
        "verboseLabel": "Net loss attributable to Precigen"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails",
      "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r122",
      "r125",
      "r208",
      "r209",
      "r568",
      "r582"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to the noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r220",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r532",
      "r533",
      "r534",
      "r535",
      "r682",
      "r683",
      "r684",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Debt Assumed",
        "terseLabel": "Long-term debt issued to a related party in an asset acquisition"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r411",
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r410",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Expense, Net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r34",
      "r36",
      "r70",
      "r281",
      "r282",
      "r709"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Notes"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtComponentsofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes payable to banks"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r249",
      "r261",
      "r265",
      "r268",
      "r271"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating loss",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r625",
      "r635"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/OperatingLeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r621",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r632",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r631",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesLeaseTermsandDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesIncomeStatementSubleaseRevenue": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized for the period under subleasing arrangements.",
        "label": "Operating Leases, Income Statement, Sublease Revenue",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "OperatingLeasesIncomeStatementSubleaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r32",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r45",
      "r46",
      "r95"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r168",
      "r363"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment of other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r110",
      "r115",
      "r598",
      "r599",
      "r602"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Gain (loss) on foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r111",
      "r112",
      "r115"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "auth_ref": [
      "r115",
      "r118",
      "r119",
      "r120",
      "r601"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "negatedLabel": "Release of cumulative translation adjustment to loss from discontinued operations",
        "negatedTerseLabel": "Release of cumulative foreign currency translation adjustments to net loss from discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r123",
      "r126",
      "r129",
      "r136",
      "r402",
      "r603",
      "r608",
      "r609",
      "r715",
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other noncash items",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "verboseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OwnshareLendingArrangementSharesIssued": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in connection with an own-share lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing.",
        "label": "Own-share Lending Arrangement, Shares, Issued",
        "terseLabel": "Shares issued in share lending agreement, shares"
       }
      }
     },
     "localname": "OwnshareLendingArrangementSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Precigen Shareholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CommitmentsandContingenciesContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r152",
      "r155",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Proceeds from Convertible Preferred Shares and convertible note"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash received"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
        "label": "Payments to Acquire Interest in Joint Venture",
        "terseLabel": "Capital contribution"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedLabel": "Investments in affiliates",
        "negatedTerseLabel": "Investments in EnviroFlight"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment",
        "negatedTerseLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r463",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r37",
      "r83",
      "r84"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds from repayment of notes receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sale of discontinued operations, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r151",
      "r161"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of investment in affiliate"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of shares in a private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r157",
      "r187"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Advances from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r149",
      "r150",
      "r290"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "negatedTerseLabel": "Proceeds from sales of equity securities",
        "terseLabel": "Proceeds from sales of equity securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/FairValueMeasurementsSummaryofLevel3InvestmentsDetails",
      "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities.",
        "label": "Proceeds from Sale of Other Assets, Investing Activities",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.",
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Expense for services"
       }
      }
     },
     "localname": "ProfessionalAndContractServicesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r30",
      "r122",
      "r125",
      "r160",
      "r181",
      "r198",
      "r208",
      "r209",
      "r249",
      "r261",
      "r265",
      "r268",
      "r271",
      "r303",
      "r561",
      "r567",
      "r569",
      "r582",
      "r583",
      "r597",
      "r721"
     ],
     "calculation": {
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r89",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r88",
      "r360"
     ],
     "calculation": {
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r55",
      "r56",
      "r362",
      "r738"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r177",
      "r362",
      "r787",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r55",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r55",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r140",
      "r314"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for credit losses",
        "verboseLabel": "Charged to operating expenses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r283",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "auth_ref": [
      "r262",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r452",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r452",
      "r639",
      "r643",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/DiscontinuedOperationsCarryingValueofMajorClassesofAssetsandLiabilitiesforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLongTermDebtAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r637",
      "r638",
      "r640",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r158",
      "r187"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Repayments of advances from lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Payments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsNarrativeDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialResultsforTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Reacquisition of in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r508",
      "r799"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r177",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "negatedTerseLabel": "Reacquisition of in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r39",
      "r59",
      "r170",
      "r176",
      "r785"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlowsReconciliationofCash"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails",
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r74",
      "r410",
      "r502",
      "r736",
      "r762",
      "r767"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets",
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.dna.com/role/OrganizationandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r308",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r240",
      "r241",
      "r260",
      "r266",
      "r267",
      "r274",
      "r275",
      "r278",
      "r433",
      "r434",
      "r680"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenues from external customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedScheduleofQuarterlyFinancialInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r437",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Collaboration and Licensing Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Product and service revenues, standard payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Average Remaining Performance Period (Years)"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Summary of Deferred Revenue by Collaborator"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r131",
      "r181",
      "r240",
      "r241",
      "r260",
      "r266",
      "r267",
      "r274",
      "r275",
      "r278",
      "r303",
      "r597",
      "r721"
     ],
     "calculation": {
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofFinancialDataforEquityMethodInvestmentsIncludedinDiscontinuedOperationsDetails",
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r630",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating lease right-of-use assets added in exchange for new lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r117",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/MergersandAcquisitionsAssetAcquisitionofCertainHarvestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r99",
      "r186",
      "r403",
      "r407",
      "r408",
      "r409",
      "r613",
      "r614",
      "r616",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r25",
      "r28",
      "r29",
      "r30",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r462",
      "r491",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r462",
      "r491",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r343",
      "r348",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r343",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r337",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r337",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r47",
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/LinesofCreditandLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r89",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r184",
      "r641",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r249",
      "r252",
      "r264",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r249",
      "r252",
      "r264",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Information by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r463",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Information About Stock Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r469",
      "r481",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used in Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r102",
      "r179",
      "r226",
      "r227",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r6",
      "r7",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "verboseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r278",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r249",
      "r253",
      "r265",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]",
        "terseLabel": "Other expenses:"
       }
      }
     },
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r177",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/DiscontinuedOperationsNoncashItemsandPurchasesofPropertyPlantandEquipmentforMBPTitanDetails",
      "http://www.dna.com/role/DiscontinuedOperationsSummaryofSignificantNonCashItemsInvestmentsandPurchasesofPropertyPlantandEquipmentonCashFlowsTSBiotechnologyandEnviroFlightDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of equity grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "negatedTerseLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Balances at period end (in shares)",
        "periodStartLabel": "Balances at beginning of period (in shares)",
        "terseLabel": "Restricted stock units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balances at period end (in usd per share)",
        "periodStartLabel": "Balances at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Balances at period end, weighted average remaining contractual period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "negatedTerseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofRestrictedStockUnitActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of authorized awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Remaining shares available to grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r471",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balances at period end (in shares)",
        "periodStartLabel": "Balances at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balances at period end (in usd per share)",
        "periodStartLabel": "Balances at beginning of period (in usd per share)",
        "verboseLabel": "Options outstanding, weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails",
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, terms of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "negatedLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "negatedLabel": "Expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "negatedLabel": "Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r177",
      "r463",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Stock options, exercise price range, lower limit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Stock options, exercise price range, upper limit (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r488",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesSummaryofAssumptionsUsedinOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at period end, weighted average remaining contractual period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balances at period end, weighted average remaining contractual period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsSummaryofInformationAboutStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r61",
      "r706",
      "r707",
      "r732"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r626",
      "r635"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State income taxes:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesComponentsofIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r15",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r278",
      "r337",
      "r366",
      "r371",
      "r372",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.dna.com/role/SegmentsInformationbyReportableSegmentDetails",
      "http://www.dna.com/role/SegmentsReconciliationofNetLossBeforeIncomeTaxesDetails",
      "http://www.dna.com/role/SegmentsReconciliationofRevenuesfromReportableSegmentstoConsolidatedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r179",
      "r181",
      "r210",
      "r211",
      "r212",
      "r214",
      "r216",
      "r226",
      "r227",
      "r228",
      "r303",
      "r402",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r104",
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r209",
      "r225",
      "r308",
      "r402",
      "r410",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r758",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesRollforwardofAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r225",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Fair value of stock issued upon conversion of long-term debt"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r103",
      "r402",
      "r403",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued upon conversion of long-term debt, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Shares issued as payment for services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r68",
      "r69",
      "r402",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "netLabel": "Shares and warrants issued in public or private offerings, net of issuance costs, shares",
        "terseLabel": "Shares issued during the period (in shares)",
        "verboseLabel": "Shares issued in public or private offerings, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "verboseLabel": "Shares issued for reacquired in-process research and development, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r69",
      "r402",
      "r410",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareBasedPaymentsScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r104",
      "r402",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Shares issued upon conversion of long-term debt"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Shares issued as payment for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r68",
      "r69",
      "r402",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "netLabel": "Value of shares issued in public or private offering (estimated)",
        "terseLabel": "Value of shares issued in public or private offering",
        "verboseLabel": "Shares and warrants issued in public or private offerings, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityAdditionalInformationDetails",
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Shares issued for reacquired in-process research and development"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r69",
      "r76",
      "r77",
      "r181",
      "r285",
      "r303",
      "r597"
     ],
     "calculation": {
      "http://www.dna.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r181",
      "r194",
      "r195",
      "r196",
      "r199",
      "r207",
      "r303",
      "r308",
      "r410",
      "r499",
      "r500",
      "r501",
      "r534",
      "r535",
      "r558",
      "r559",
      "r581",
      "r597",
      "r603",
      "r604",
      "r609",
      "r759",
      "r760"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Precigen shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofShareholdersandTotalEquity",
      "http://www.dna.com/role/ShareholdersEquityComponentsofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r628",
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease rental income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r610",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r610",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r610",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r610",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r646",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information",
        "verboseLabel": "Supplemental Cash Flows Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.dna.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/GoodwillandIntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r532",
      "r533",
      "r534",
      "r535",
      "r682",
      "r683",
      "r684",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/IncomeTaxesSummaryofValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/CollaborationandLicensingRevenueAdditionalInformationDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummarizedCollaborationandLicensingRevenuesDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenueDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorCurrentYearDetails",
      "http://www.dna.com/role/CollaborationandLicensingRevenueSummaryofDeferredRevenuebyCollaboratorPriorYearDetails",
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/ConsolidatedStatementsofOperationsParenthetical",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonEnergyPartnersIIAdditionalInformationDetails",
      "http://www.dna.com/role/InvestmentsinJointVenturesIntrexonT1DPartnersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "United States government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/FairValueMeasurementsSummaryofPlacementintheFairValueHierarchyofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.dna.com/role/ShorttermInvestmentsSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).",
        "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount",
        "terseLabel": "Maximum risk of loss related to the identified VIEs"
       }
      }
     },
     "localname": "VariableInterestEntityEntityMaximumLossExposureAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r627",
      "r635"
     ],
     "calculation": {
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/OperatingLeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperSharePotentiallyDilutiveSecuritiesExcludedfromCalculationofNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/ConsolidatedStatementsofOperations",
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.dna.com/role/NetLossperShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e709-108580"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1020-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=121548190&loc=d3e32787-111569"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=7656903&loc=SL6757479-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5558-128473"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121577943&loc=d3e41620-112719"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r801": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r802": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r803": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r804": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r805": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r806": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r807": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r808": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>158
<FILENAME>0001356090-21-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001356090-21-000003-xbrl.zip
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M=FOL-L80.1,=NQAK)H)H4.(Q)JT]!(GI([BM(=H8(V$I>U^M5EDE\,J(S^$
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MD-L=NPZ>ND=5 04R40>QH*"*1H/)B?\H7B-5IK!YJ':?Y^VFSRNK4E'7F+$
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MQIJ9 JI5@^G>TNC:=-%5Z/9U*L&M324H$ZS/[,2:%&BY-I5L\"#N24Y@E!N
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M%?'GOLWN?T[I3O,P;V!EU5Y]>I]=#W0:04N\R"'9*MK<B1]:(;=&K3:" QZ
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M@T%65=]V96VD;\ !-F(SZ?BAX[&0QU$<B-B5+'$4**JNJ8-W[-JPL1^>R_R
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MG'M)Q$+.(F<3>@NL/3H]2N1D15/*/3 T@D@$@1^SR%<Q=R,W#0(NE(C]U-X
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M,ZPH<G*/R*%$Z -2B"A5'D/_1Q ["0N<,!%^Y/&X0X[UMBX>!"F<R ]XH%0
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MV U3Z;FV\##!72H)ADULIP*,V,!1R@LV@!%O!GA75&XO SCF))7"25F4^%$
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M70$TFW_.1IWC[XYT.'4X.*DGA7)YS^6AW6.^*WMQG+*>\'D8*Q'',; VT-6
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M-/IC4L'"JLT,DCZJ"GS]]O33= YYY#AAE(H>CX7JL=CW>G&:A#U')I'G)V'
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M2%NN,*RYP .NB*8&:/E?2!<H@*6A9TII^^R&*%7;4:$O:>DX)!%XPYG!Q+S
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M/U=W#DOG>O'--D":K94&SH<);I@:2H["3A(^7/[:M+WAG&+<:GQH/$-:BVE
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MG_INLK(]556/> 8.4;?$ -E8P5NPU^ &1-1K,V$6<$ALW]=*I7URZZ4!G.3
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MLI;Q"AR_57?VA'8_S[=_\$7D^?[%6>U1QA!.X,8LNO:Q+$@H7\L]\M!QHXK
M=;14W6*094$+\E8S?V.)-L^E8'0+?9J&413%OR ='[,^^WN3[9#IJEOFC9+6
M*0[5,S7<*0$X55DQ5CMS'V@9-AP3] ,[EM:V33QO8Q%-L*2:V]5L;3]+N^M1
M&[IUTG:*J]>FR"\6W%R/QC7#]90YM\QE5G :)EL#]E&OF!**KJ+U0%5'UZ,T
M!(^&WC[0I3%S$^^ 04[V)CH2R!922_P3 U6AY28SA;7YFMU?\GLE5< )5^[X
MNC?Y+_W33+YDH[K*5(PXJLC'R$R1AD..!(%B?H;^DH<Q]JL#X;AT/S4^2G3S
MY=)L2:+0 ^(YL;")$:K,ZHO9/),?!;,DKTA]S^L5KV9^WI7@]A(,P+G:>JC_
MG!?6L\?A7T@RE'DK6?XW&J:1$8<OJ6)M.SIP;*HV^1*HG**5FAMIJ&OA9QT4
M\-P+E)I)&@U-31=RXGF0FLHA':_27-?<KD_.U'X^DH2P/BF,*\ 9<*K"B !#
MAZ6ZK(UBGL57WK::%0R/L?:J&<[755Z3V['1/ 2XR_#GR;H#?)&SUYQ7$U3W
M^SQ?8:QLCI#!S%5*=-QPOE8<8N?=)XOF7!@?-5FUEEZ/RC(?O0%)G[3I6B^Y
MS;L" :]KY,KJ9D$R6T:;R3*77779>D$C';"NZT*X>RJ(>5J 8L&]?[.B(1^>
M\WEE)PUTRUJ*5/E!]+.2M,34S#LPR]7G].M.^BRMJKSCG<K8#)<6W7K?.2:&
M.#R,S)A)XW601"^7&TBY@  7@=ZZSM!_<&L>-S&,MV45F82 A<D-*5X[9#XS
MYQ1D%!UWM_T^R35^>HMK_'24?^39][_/-7ZT^ZZQSS<B*1;3C628764]1L*8
M;70[=JMWP:<K4 ZBJKW=13.$YK6;"9_[8.B#_SQX>!\,O0^&[H; O"66"!_4
MD,],<XH CU8SG[P^3M#026!N6V"11/!6QYK3KFS+]@)6<*V'>;^/94.3=VIY
MK.6<^@Z]L0T-#-V!U8DR1<$<I3#N0/DZ.4MZI5J'4<GB74@%Y@@68__@UCZ3
MEH23-I,Q.:M)55CLB/R=QUK#VQ*W(V_V63Y$7,EAH'<]Y63G;S 5F<"!K=,8
MKQ-[D!9X:X/8 3.KQ4>DOZ46*6SM;\F_E::6<$^T*.)-J'-8AZ@D68$P#2V?
M_OFK<SY1:Y\YP^5,2W-V.[YF#*>9$4FOBI44>X%Y-4\;LF5+K0'6BBV ((3,
MG#S$18X6NXL&[7C)))OQ$6?^^HY\"CY,0 =S.6YX2\CW9QQHXFY;POC*V61'
MT. C3H/.?U(:A</%%$3P!R+<[].B@F;G=VUT)P7*A6R PROY<"#_,H7__PJ"
M8R8MT=(XA@8D]3S *<IHQ]>9Y#)7XQ<7FY$%D1[$$:!1]+MQW[&V[?.IK5\'
M[7Y#OL43D*<S3@*VKN>%@CW[P$&_L.L<A$38FE!7Q'"U6O!E+-:O)<"A.'J:
MIQN),1*'3@L9K88(1_-.+1[*[.)\1A 3%JY^/6*,%B;]ME+.7A&%,:4A3#VA
M%;$>%R4G+K$.*3<RDW])S3V'PY;%HG70?JR#S_<%8N,OXVCH])'O5+7S"'V1
M$S@JQTZX9_,ZANMX*^]\ZY.8NO(.DAZ2S@N\-6O:C!<35!E*E<V+7Z8N'L#_
MC2"%1%"LQ<M53K[\%=]<,C26B0"3<.TB6]+0IY-YT3174D4F'QCP4PH L_45
MLHL#HA*G_1\EV<8EAW!,=T,#N^]E-RCYS"0HXJD-(]M2WV&V/ )^PK/5HI(V
M%A_&5C,XAYE'FKYH#R\E <"THG3"WHN4MU7F)\;(+%@5YCM/NV^,"0SK=N=4
MCM:,^Q" YV)$<">G]+2G5%RM;U(2HS<ZU3&'L1WFJ :!)Y3H'*LKH/5R]R&T
M31J01 T4FX#P4ZI.&5K6K6M-19'BA#'P1<@9WD"U@*(!(ORGH>YI;!N+2A-U
M;N'-J &IBNL+)%G"3DC:"]%?5FB82W\@1(#Y>75#FUX6==A&^'/Y!V;C:K&V
M<]*1VAHC_84\!D\_WVC)8K96D*'3LQ%2,IB!'1UOSRVS][GRFCRXK!_@"#RH
MF$'R =_[0F/_[]1X!PQ$R5B2CDDWJ*P0*>*!_TP4BT0@-]_JFKD<JX&]:8]A
M4:?@#397:1J%5A-H53SW7KI*[*C=J_K_U&0][1$2RX?S=?VBJ'?6IWCX'7=T
MDD&R$;.BLZ'\>SV>O#*3_ %P]^=&2W-> />YS.:0@4RIJ:2#",\HXZ[U+"F1
MWO#]'M1FGRWK!=G-:H^E1#>HQU(6.RZZ^-C[L]96'8_8X;,SOAO]L_-5FVB9
M,RLZWMDS]9& H]N<79Z"]D")@W5D'.S]=E7Q]RX%F80OL(BF@\TIQ*R@P>8+
M4<R6X;!D,TZ]E<V&V$M48_B1->M UY1L+G$FB4'M)>,39%ZN%)B>#)YKB;C_
M"-H*(K\G13M#;BGI.M8:<6]R716.!LA;[!;R#R4BO:CKQ4RZ.Y[+)]URQW(T
M/S%[VYQK'%MR[&@EVL^+&J%-W;$%VMN!=>D=:AK >>@1Q(9X _-(2-NS5=MQ
M06T(1%;X?$(*K,VU*(([QZW$$^/$%5Q Q[[J7P:[,KV"8MF 5SG<1!< #I>2
M*U00,N[(PRTJU,J6AG-Q!2.3OW,1DO#[@9BZ1,QI> -[_,P2P(92)9V'&(K
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M.)9+9T  9<B$L!:X+A8=+0PN&_LF.2DER;A$P('QC;AE%1:,6KJU)UUGI05
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M&TLR?HQ2RGT,O.M^8K/SO6B2DR,'0.BU@"IWG&@KLT;PI09X6<AE+KU;:W,
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MP:_."DK! #Y%+!9A0A?>3F\GV$;_Z)1H+*$M/P4U&J*J(M^&L^W5[HS :R*
M*;UM']_VH!FV[KI1?X;U+LN/KOF#SR]Q/['5R,NDBWARG(5]CM:W:\?#O#LN
MJ;<%IWNGPTSVBYS;%913:4FC>'&6>VFC==YW$JQ=F0^V/[TS-41UBM]A8_4*
M#9N9,4:CAVWLXDJJG5NHK;5T]A(QV.?X*#)Y\PAI+MRNX(J^)1%*!% !D&>%
ME#1;7=6M%#5?9?_(F@7/-;PZ-A62VFSQ.T+'V6AC]B.683TW*5F\H8M"QGX,
M\#?,SIAY.2I8S5W:=@Y=^CG=*R'.B8@ N\JA&WS>._U,8&T(H%L&!'4A+-<R
MLDBFNZ*!=6MIX"84/?R5E0&I@AH._.,8/1>IKR<:8F //VA/MO?FZ]8.D!OP
MKOO90&>/GA(Y<@YVE.YF45WE(1F"F@),70'086G*S=B!]IR%[I++Z4X(,?M[
M[S3GKQ&=C=#319,)]5$GG1EC[RP\*&PP.]1Y+JY*?5XJ'+J-D(#4>L.+K"N#
M5%0:%+"Q_)V/XV4D6J('#C\U7E#KTD,R0-(NN,G20!LY#;N;G$$I;>7C[Y?<
M1=A?$EVJ0EF?O.D8IA_7>F[U@<IX+ ]>2B*#5!'N^"L1L3(T2-G1ZT5G7H0G
M!JR%[I6WJ" %^6LJZE3^]07>_"I?"E3=P;?XY,Q".2-HVM"\CGNV6:4 +MU6
M>:,,X6,??17YX"$@- VVK5%:[\7 :E0!_&&4^N*&!Y9YK';H*\J9X#C/"#YY
MQP1@D[?=N<$LCU0>'<[7%D$TZ$F:>D]-@K,88CV\9"HF5&J^/#N\54+>* GV
MG05W7T2CAO?L$(WG:(?.>1&.@H')DP!QWN1U3<N:V_HXIR1 .P1J0O*/9JD0
MO/'!:"\ )S6RL+*>-=P6C\.$'&*;O'EY>/3CY&ORH I CO":EP*"Q;\/.Q)W
MC?7Q <M"5#7(==AKXGY]LT<#YLW$TZ>]8BO?UZ7!>_,!@WE<1UL!7L "P+30
M[$]_[=L"MA91B1SFWA6=UZU$=!9DW$@PS%&]( :6E7FB[8NQG;C/:MZ:U?SN
M/JMYG]7<29?QS9?E)'YB1=>/H!-U4;K6*;;//IE;A_Y#:+_!-I;HG'4162,3
M-3^U7MM;_=Z2?;?0(Z]?VA""*NBRBP7*QX.0HF4L$.D\PJDQK4R]!O%>-(>Y
M4\Y(=9JF(7))]G@V?Y]=XC'!,>::\&;Q/L]7^#L=QUS\9/1H7Q<M_H.>L*Q%
M17-O;G1Z%P>;--A4V?OQ3;$U#=W-_PR\8!+*#;K.0%'BX(P4%F^W*M]=Y<Y\
M!.CLW$!4(UU+QO?5]HO;A[ '$W:,YH[^=6+<DYT!(H_U(+;I8EP@VL-92:(<
M8NPYXUP,=LS.CY/-Q4)^+78@/-@/ 'R*K7"!@7#NC(TZ-#OBAX?V6K&OTZY[
MNR>C5VS5JYA%'KX(&>38;(:=+VT\Z3K+2(F6= C5AC!RH.1DLB_W3C_6WD=M
MTM6O#3>1.PV-O-<BNW K56!LG!-A#MNKNEY,T9%4=O^H;I= \Y$=+GRBQT?*
MLEX8YL6=VA!0P5 #3&5D1'B8_1VRX_8!GJ&MIO;UF[R5]N5A5&<_OKW3J'R4
M:ML%C(NL/7^$)=K-(>FGZ-;P6(EQ+]S4=!'X$KC)T'!#6VW)DUM>D013P@D\
M,[2(,2W,$7V[**4RA=M&>BTM(H&G<-D5"]SU13WO<'OOG"446ZA MN(_'NV2
MSNY!Q]-6=2.;N]MJW*F!Z.>Y5L(J";+^1(<L".K1FK1PYTH#:UH;#?Y,1C'?
M5<@^7W%NO+J<E?D%G85G>P=/>N=C]O\EKSR^@'_YMV<'!T^??SY6W'1Y]A_O
M/>&U$#A@;.4;:^1=F)0M(EQ8*;?8+;IADB&?FVY8EJ5==PLU;+,Y6WJCYHNS
M1;RY8F%+07/$MDETM[YJ#> ]^8%4WN2GN#%GC !DY=(7K/S3PZI8TC[^FI<7
M++])_SR_OTI_X%4BJU$#698808L_IE*9G+P^AJJ5OA!]4L>P^6QQ:2/(T&?+
M1&O_IY*E0WZ;SMG]UOZ16ZOYD$S[E(7244G7E^5,\VJ,7AC?)Y$(+NLJ%QL7
M^LB^:]=9+,X?CLY&?!SV/EWA7^+RC%?XA>Z_<'8ME.QK<C3-ZK!AP%&$II!X
MJ,]2:2\W"]4SP@B^UE#;\Y" '.8$4K4 B_;]8?UC#VN3K[(FAO5ODTNN3@];
M%:(+T:U0U"E44INXQCEG^_1*R.F8,O;)$+](BLXWZI>8DX&C'7Z0'J>A!P/_
MQ0=?X'Y*#@! 9OIR7YJF[#YR_^Y/W!^J^>@ M8+B4J!>L"@S\?"*2BC\(SMU
M&D%3./"&#X?^NP +2ZX1FE$VM0"LX[285!KT T?S'T[/5-)I:-'7C:K8UBYQ
M)M7E:=VV-S/+/N#<Z]#,DH-\9*!=<C:?GB&5&W;^<1=P+>Y/X1\J]P(^9?S$
M>5$Q%!&3M@A]P:WIC]C1M.<9\HV"6[#'.=$)P-+]WOZ!>\L[J@5$,(),.0WW
MXD\0.3IS7KCJM-T.#KT0#R7JWQ':.;Y!L$2W9GX43; 1-R@VY71M7>@F3I.
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MH[;;4=X2)X'.FD:3")M+[VU=H6'D'V/<EW1F+'!3AKIZ;_*K,L>*I3ZBS37
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M H1[RTR<4^A4KY7D\:1H.5C^)-=$W6')KJ]R]DSI?R6UF&A>X1_@ER\G@J!
M>TXU<U(-C\8I25FCM.X*+$X\A7?9A\E1IPF3_ZK/VQ TY$_P;RWNX5MS3!<!
M<O?@@&W/_>\FREZPUHU:9Q]F0G]&:XX@-1!\CC7ZYJJ>7&2%4I"*O3_A L9E
MMYRP)A>$=[C8XCFU@;7AX</#0-BD&I^.($GBCF.EBUQQ:$_](9XJJS/@M@-<
MVH,X/*NQFSYP%G=B;N]_[Z'(B?)1Q3(=T4 BOT=.@8=E;CM1@EVR<J=\;W*R
M%H92M#5C+KBM/QU8TV;Z_>ZCISTU20DHAFWKC68GC&NT)8]'2IVIGA$D&3,:
M=UR )LZ9-A88;KV[_,'<D$I;46S!)1G=+%=(-W)17W2+RWR-:&!3ET[,[J<G
M?6BJ3(QR^O*2;1[04&G9*IP-,.P@"RQ75NP!)K(@E;I4L2G5<"EVWV>H1RK_
M87?H#V.&&8S?K'OD?M.=8E]P#@Y$U-&T+'T!7HU<%X>DJDN]@(]PF1A\F0L'
MI0&NO8<Q-9,1N$U411P\?/1P\G7 V>5&("U@0.W_UVQ\B2_"0Z=9\+2G(7=\
MBLC0(_G[_C?T"C1KH]VY! ?+6MK'1D$AT<.=/^:0+"9I8F71-B-![3Z.R9J2
M" !P,R!ZUMR_V#C4-%C15W6#&GG757[T\(^"$BZZ2D#7'[$Z91SP1U7M+?/U
M5;U0?-==C=+P7#@L^J3(">BLU8^:I-PU;A/G.D$XR&.:Y&S;[$-YMTLO!U[)
M?IL4*PE)GAZ%!S]X8'Q)5&#(LC"O8S/)A& A#FEP0*SR1?RO3E\IM!D&:%5"
M*%#NL6W L1JSXN (1?\ICA44K=%?NWO(X ^_KM^-F_4<N@NX3 ;['/$Y=6&"
M%X:4.?U_[+UIDQM7DBWX5V#J?JTJF\@L+J*6DDV;I4A18G51Y)!LZ<U\BP0B
M,T,,1*!BR23JU[_KQY?K-R( )E5-)CB&+Z5B HCE+GY].7Y.<(VJPTX7_%P2
M7)E9\9&V5@3DRDG=4[6FYT5PT:1->/FR;:A.XX&=JU*87Y#KHC@V.<)X:67A
M4LV*'-VBO90<:%%?EVU3<\[PF>5<_^/?[G]][WL^"RA[;Z)&NB]O"K"N&N:!
MEI/A'N@?;C4W($(::@GQ5=+W@N*E@H&PZP:RP,(+9^^>J44).Z<6UQ@^%K>^
MT]@1B3-J]2Y5PHDT*NW:,Y ^F\*E).#"MRCI'-;4RV!GRDM*PSRKEYIY1,8X
M-QLJ0GE<I:^DH>$6-[7DQ9O7Q\K^WLK^PV-E_UC9OWL#_4/9.$/\.D=HTM#V
M33_YN:E6G"/]^]\?<RYA]!6R7UK/(X/&>9PW*,2^E@*J^W7R]]/%*PK2J\7?
M3A?_5;9O,Z042M'TH8N%8_#'%S3 :KW86GIW%=CU=^&*"-\>7^5E2\T#"-:"
M"^)MUWE#;AK.$BK1,IX@1#5%IPF$UTRF]YQ8HLCF/Y$OXG)V[7"%]$78Y;P)
M-C3L/0N")+=1L$0W,CK!D'?3GX_X:<M8%^3CB5VU@D#_?6*S<3X$4\B67N]
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M;QWEQC)]O;;9LOJX)WEAK1=818A!TRAJO"S,+DB3B5J2(7.XT2XR0,?BPJI
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MS6&L8-64[#%V%-)O8P@CR8NP91>O?GS^>HQF39G1T#A(CRS,'+)$UHV0L*P
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M-+S*C%!JEM/NT&.L\'I)/ 5.)#Y?]T+P$QO.V;6!*TO7:N9I:3 +G[5 4Z,
M!P*22H=X<I3:Y<P>%U(W1)TO/@#F8YEH5&A9-=M93W4B)A/X*0N<1C J7,L?
M_GY&OLHZF $0\RC=A@]6H"M,9U46W0$AD3"1:=GGF02$$EH0L_T@@1NS"FA
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MM4MX<YZF:G)6_0I_=*@9#SZ%Z9PG$I']*:TC]OIAD5T7\3WFA3(P!47%!&L
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M(IEXJV7!Q[D6H.=6PZ$7EWXKG.P*J=>S-R*OD99I?#'2JH^,K\;NX +H%M"
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M5[7C;3 <HOLE\^(['K%$_2,^UI[68I$O$Y)N]US.GR!EL7";\%](Q>%A&#@
MB.=0LXJ:]H!&+#2=P 32I)UYX)[@FS@[R1JRJLQX(>%0EDXV:_<@O_Q?7Z29
MKE)EL4B<&UB"KC_QY$)S3SYY8@ZXA.&"P;7LH]D7E9>Y8\A]B=8C;D*5AM6S
ML1.)BY;,C8)5PH]2K-)F6YS#>F+)4G;]S[H3PKQ/EYAUN $#PVO>8V6XY13\
M5V4OBNB^*>X]C?7S#05S^X+,Z3;N"^K/+:1_;PZ^2RO$U7?X)-OUD)/VMRC*
M-II\>YW;$!,M4L!HOF/63FS6^#G/*9MF:\!U-6H(A"[(\"*Q<?<F*D.?%P6W
M0MY8E,I6,;R RK9*0W7'"L=QT4[;7]4)XB?3Y9%3J-'V%U3P#*-QP;*U>QSZ
M(WKEB__\ZOX1O7)$KQRDQR<)K>"\K\BN)+9QY.8DN838C!%MQ(3B88@ZEQH9
MI]UJXN@=MHORC,H Y<5678C@AU;R3QN:,%I<Y4 CQLQ([5/<Z4 "P%^V9A5N
MU0I&6Q@O)LQHPH(B!Z;S6(/%;P?2^MGQ<,ZO3/DW'-N$8ELX@N08S:X'*IV:
M$LW2.35Z]:2[3E-&7%3?.OP_N1D(MK4N<"Z]"^$SB_HVPWE8R&!>AD9!TIOE
MP57P&I)\1M..FMHH*2ZDO^H>X[%DP%+?1L*37;',7C(.[8\19WSB#5"T?550
M#>LDK.Y-E5,[>+NB<@G>LFJ@VMOUH%6CQL9B!5%(;F<70HIQ[\ZBHX0>L@ T
MX.POT1.*DS(G1P\W(3;ENE7T_LV/%=H5:<X@!N[1D12&FI@.YSSA+GX%\@W!
MII"XJI-)J/KF$L(YGU^8'9N]/2:A&SK:TI0TV11YGPQ$D6XJC84P-%O+*,>0
MNJR%!"02[^YH!Y?N.4N%Z+62H.+ +?2XQQ1]TN?%_O&0_NDO.ZNH$!+(:ZM1
MWG")G>1Y8,B,Y<' 4 UAS!#C:J'[%7"F?;&CS"1M] Y<Q9%^*Y-60KUTM :4
MY"0"&FTC?/;J!Y[8L$&,W!RD"AV%E#&H(I/124?E["YKW2B.TIOC[TY''>,\
M6[DP&-WLU+AA)#GPZ6#)[I$=DVAEC0=I?OPS) .I[D:Y31HO&ZTN#I9N'"0J
M.?J)6(8YZYOA/*$>/5X=<L#%[K8C)N'CH8I$L]>5/#1S.W^$^(SZ1<PTZH]F
M"*%N;U71OXL=1NW931B8(RCI$\]].G4IWVS<L<=I^7C3,M1DA+NBJ'<TM['C
M$79,>UF(]$,(R0?NB4/<(J>4-!$?Y^J3;B'>)9+C3L@9/ .!LL0<)^<C2XZ-
M\]Q:I0C>4I%#YK6A@GW4Q@%9I3JW#AO9M,>I^IA3A011SPPI2F:^FT*)83R@
M5JF:FT3OI@]?RMO5P0,8F6=^%ODV87F-\682XW-69'QHOX=@-!O1PT90P6ZJ
M$:.Q88+FR"WF<A]&1Z:_%EHR2<^\Y\*6]4FB)7J1."PZ)$*?.PZE<"GK$F=P
M#W(H'2V1%?'-SH[(A(5D3,O)K_M[T6RHC5D0A:F"REJYC+D*9MT78XZVCF$C
MUC@'+%-+/^;X;*)'\"$0$:I)=E>+"^K'R5*\B(<C5=O1**O$!H@9!3,E0M9#
MQ[DTJ61148X3UG&5.NKI]CW<Q/2&H$YVG.):(^L=O]ZLJL2_2IE[2+FLQT@E
MR_KP;$;((X75:+RS0M;F*PPN$7#@*:8WZ ><Z3-S,&SP[C0RJSLUVBE# %(U
M&2P \C33(@/%Q+E,IWE=B*)&<*/#VL%5F!#:&;YPZ]/%:\+54'5=%KY7DI$'
M*='"%DQO.VQDHSF^OQ"_LNE8Y]6%$%[0MLV7;" (-I6KT0X[-[\QC!B7A?-+
M@TSY+X;_#BT3L.==#Q*I\'_E$6C_@3XKW("8KRGEELD(A><4-N[X?3M6?$C'
M^TDZ.%O!S';;.GPOC*Z -+=STZ'@,)E.%A4K-@XGCQ*\(DY0@.>&I(2<>TW=
MA,0;PKG#!&L9'N=YN :Y8UD(<*KR;;'SJ](A<[7M(H[1OLJ]-64AN&*%GH9_
M]6%QQ!X"(3H+5PXK(4S//U&#B-A"PA9U0!^*I:1.Z"M'E>QD7)Q(#*H"L3_!
MNS,XL,+#A:%8Z_P8^]Z:M.3;\ 1*2TU%$&913J**8DV$1 Q\W<#_P3PTBFR=
M89JW!EQAL9MYM 08LLY7=-VV7"JY;^0^JK9V,I=IFMA@1B^5<M ^FGT<P:>$
M#0#.U.M2EJD58L+?U_Y0'M=.]-E#5%:8SIR_D>2K9)7&'U9ATO2SS+DO)+[@
M_D#\3K*EJ[Q<=P*B<W--?:XU'5H16R6^1;$RP7FB(H.N/'5_$0.H--/3*Y,T
M\G]7(41\J9SZ9!K)Y^/IH6-B)3/@456C%Y6=C2L]/GMU\B8>,1FD)6[4@UX6
MCE',0,_1[,W#R\"3IL]KJ%^TK5'+;S8EKX7O&BUW0BLNA1VCLHP<E1$%;1)G
MX7_K/I+!6]00G8V3RY;6:^Q#9PG#HNB%AYZ8YHUAT&7-+7) #!+<)OA+O BQ
M=(]PG7UPG0='N,X1KG/W/N>(EL]E!IQ90ZM?9X;T,XP@GDG/%$=Y!4%XZ[PU
MP">?FG-1LOK=Y/<,R!^WC!>AR!%'+4D;44!&_P6+/S/WYQT[=0)NX(;4\X*Z
MR!;Y=3@^,<@8\[0JFP='.7A/XH9+7+]:$!6<&E@^U%?Q<!Z?[>8QNRX.<<*$
MO_O 0Z&GXZ&U%@P=?.V"HY?Q 8;^/3S_2<5$2!+[MQ\T\Q3TQSL(9^5[%LMH
M)HUYCRF/Z\+ MN-BH;87"MK96F+B6M)EQ) 9QH!+@XD05[QWL9%K&=^?,F3C
M(4*RH2U(0?5?79'<$Z/K,5U[X<G ?!??DP)VJ*M%][7<L6-Q@9O"RR/)DI@$
M('LOX<*/40>F;XS$;T/8*<!ITG]0S$&(>?'FP0DKJ_$;TDIP _]$WH_R5N=%
M?U,P8MY/1CE>;>YJO+V3G-0T]>6R5R8H(C2]5&9A"O+@3G,-3&2SUPUM[6;Y
MEN;YHAJ(8*$O1NFOS\[:[VEF574S]$=,N:NYZ;00;S<&PW=*\7I7I+?S@^L.
MG! *(58IYY4.LEE!MK*=2U=F42^]3+).QKPB77=J4GS#J"$YR9N!K,[R<VA*
M:HO84['H)+'FWVNVHAW>/8&<&I/V3I&"M@A1,UJX<A'&K(KA;;$N<VGGRH,Y
M0PF=@+58^7H&_G9%+*.D*:CDWMJYBX>.X3HPP4A)<J;>/W(VE?69ILT<%:XP
M@D>9B7RAH6&U31Y&6BV9Y]88Q;F1U!HI9T=1T>1X?I4KP/E7CJG6E#Q7V]Y&
M^. H+EF\"W&I('SZ'2)7VGM-=*_B=VN*+7816WF!1J('A%;\.0O$*844/ K!
M!!KQAI+(+?.VW<Y>XM#K?"_8\C*#<C$_><X$<7<[I\IL 3 9]G*F:N X2GA_
M%!#1!OT)YSE5,4.T3:2_/"5RI/LCDU--61;T@5.R[2\[D:/7/%PJIF>V+_*D
ML(*UMM#)FZ$2M9-=@LDM)/]3-R=YUS7+$JG\Z[(E,.)UP5G[BQ%N/5MTY"H:
MD7XLLZZDTI0(+.3*&T.P13*Y(IAQKN-%O^%[T79RFF$L,X"ID<*J:HV98 E?
M480HZ-4N+\'Q T6/M9:VH#I"]F8E,B1T;QHXO*X0GZ.E(#>1"^%.QI*1'-5.
M 4W?[RW<*1Y'C9//Q*HNAI8WY1P+QF<K79DV%)3OJ9,;&VFBG29GN^!F+4[5
M7GGNNFXVP68O7OWX_/5<^C]"388>SPN%-J"W1GSGM)U#:+(F"4(YQHC=CXJ[
M0K.-W7LY,)M%7W%SA89IDQ;]"ZX)179'M*%H\P8ZA,.:M0BHRO$-WN=+B'<
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M9*2XD#4STAS4+!W3@!_6:9>^0+XCZIF]9*1<^54X0@RKUS/DS94AS2Z]9\9
MS ;1<<-T<&+6*=&%+64CZZC#X_@JXF.F,WRVX&F>^[!+J,5O8>2TLYC5RJ><
MEJY:;Q7Z"YH#<(J'B6\D_UN\"W,%2PZ[X8Y52DP7JS] 9Y/9X1XF-)BM2D]I
MF/=!U0B:\3 ?NBEY4EQ(14J+!;FB/=OQ9MRW^:91G]*X.J+^2$F3J0U9#DG/
MM2A9&Q*2:]HD[""811KVX(E1 K+N;89I7FS,=1)T@WY^S7VW$@)($;C^Z(5
M85C7O33&S,S/C@VI&?)2(<?OH>[VYH2< P,RB-0F.KL/&^\RWU X.SHRKC,^
MSNPIJ1UO.SQ\M2>&4H\ #>',35<Q&G2KW8V&5?AWM\PWA7 ;[%X/VN;(#@1.
M<3-OU!.*MEMRHVK?<6P-D?LN3:H/=&3&],UTV9PN?AG614L9I'F=E%TH$E#6
M,':<;DM9A>456OK-IV4_P&-3$J\S7/@O87"H>[E'-P&_B=UT^CQ,U@!ZJG0_
M_:DXO3S-K(/ND0*@G[YYC!8DG=['CU^>_3GS7G)8V54A;-P#%68(*LK*I<8G
MK;<RYSF&+Q8L,3P#$:H3FGH^/;<_T(=6+P;@1>YB7VM_URW]Y\7C6647;A'H
M(A58QJ@H[FG%2C12;7"I&%7&Z>*I3(VM>)OG<!8T;5V$I[>N=(QB1>C.<*>.
M$JGWO_D^?M$OJ&4%46<>;O>-"-W44ID*1OLNX7,&#%\+RHWH@3;Y+6W>'9[Z
MB(4,:Y#@:7W)S\5T631V5@-P.F@184#-R1)GNE@B7:-"""TXM)E]*H>ZBU>B
M>T;1:=XNP2;8E_T@)L+ !EY+=LY6)V_+Q2D,APM;G-B&P9'<97GT% F5UQ,Z
MGXAMLI)5V [-MK#R+A\QHJGB-*32 \><8?-\&=[,R.1@6L-9;2Q?^-,EWBJ6
M>7F(Q<Y( W#%1.^WGS##27,@G?, G* 52L*J?LOMS=*)CLDH6=- NVR8_FM#
M!#F]#\D/?:],FI[)HH/#<.V[7L,P)2VO#^YQPW]'K'$$"NYL,4QXR'&<*:R4
M6J:Q_VB+A=5?U,NMG0N47^H6CX,?&7Y7EZ#"P.RYJ].S=PQ;:8VV8/:@"0&F
M>-&FE66'"CT3^QQX7Y0P>]<Z4T8I1G@[W&!0A3-YM16[*?W.:XH -A1F8UJ"
M$\!=SF4;Z1!.%Z_#4@>+2"9N""(PU]+N79](JC#/JI?W4]?+<T-<%Y58#-Z"
M@A0!FYC3/T6&+&HPEL@L$=D,S[J0%B8>VHYP"&^C!YS0H-@VMVA?7',]A.6I
M1C*0V.<QAYDDBO>ZZZ/9M*?Q_3 I\]0\Z),B^@T8+^GJS*BD3+O,#"?4*A3K
M%9U2NU>&.E$5UV#9J0Y\\ ; F=Q+9J81<QM/J*V]S8RR+59R\/DN.46.G4+?
MXG].==(MJ^.BO;&C;<P9R_GHP_7"W!1,SNP(C/+$@^9,7LFJ@Q.7TIU4Z>GD
M8AFGJNOS!UICI0<<2F0&@W/JN%VYYDON&#HSM84G33O8</C@26XBA-#2*SG4
ML7NJ&7IB#I(X5D1J#%J8MC]9*F\*M?0><CR%&;2/;+5JV/T^K"ZM(ZDK^KXR
M<0-S-7UNBS&<*21-)!F002(/67L5V EII( M[:#.[4;:-1/1!XS@>E.L2A-7
M(#,H>]/13EIW0!;%>S8@_U#8J;)V<I0/5Y]O1!D9=?UB7H9]=B3N-#WC2B=T
MX*W*."'M>I1,B ,%%+23[6Y"P("=M 1.VIK%IBG8(]/#WI+]M\>2_;%D?Y I
M3PD)IPEAIISC0Y+V/,[)HKXNVT:J#TKO):+2K!<]?R8RVLCD"J9'[ZSO-M-2
MF*2L8]+TP'.=OS$QZ%7^S[Q=4?Z-X,T$<I!WSE=E(^D,S]N7""B7]4ZS'3YZ
M0T'+XL5U+AS2:3R>D[Y967!16/QRR>)DBZI9RM&8:@'-3@F[ N58?%: R5D,
M>43D 4>1J[AG$EXI*8:3A0\!_8KEWT.XA"@C/"V_SM6P)L9]6@BR@GC5Q-%!
MU+&31+.!=YXG@^9ZUL^WLU6U5,Q5TR  ^"Z7PT;'Z7442A<<[9DKGXG+2+_Z
M\>494C#PB;#AVD+J6UKJM/P6/LZ(\[-4OK;H#7@LALM+&DDDJC($(&7$#&"<
MH]H,$V<F>WOW1DPS--:\?=.T;TU.NJ@[!1@8@ZURZ@\"H<#S(032,M.-MSXK
M?76"S'"2G!Y94SB=HYVWXI-P<\2=94LBX[1@?!Q-KTX822,=JE3B(ENC-S%.
M;-N&(%[] OT]SCHZ%Y, U\V[<AG^M^T5;^F11,$S+UHDF>4)AEEF4S &\':1
MG))N$V\RB&9\.AR?7S'NMV)LQC33,MW@BHX!QI683X:-AO3A#]PI5.4X[F%A
MR)305# Y3A8;U%/XU&K7?F#*C'"D$1\(23TB-Q^6]#] #CDNV9Y^&BSQ_#C>
MBOC@[L[&L[ECY*YGV.'9#+$8.P+,(F66F#!$O67)$W:?3.KKQ$S240XL7X*D
MA#'ZJ+94\1_@0V@2/8"8Y4#CDJ1V\::$:RR[4<NO9<*SM">X=<W NSI^970E
MGD6?7H07,A8%*2F(9238PD:*7>%*Y:;T43#'MSXWT2&ROB4MQ]TEH1*^WY(Z
M1_+KLC+Z$2D,]LI]K^BL5*X"CE7N++D.!R4;8)W-+YAIDW&_%D29_8Y/4SL@
M4U8>8]UM? KGQ,H7*]\_,]2<6S#9,UYWR2K&4P+N*>S<G(>L3T;;-29)'8\6
M5D*8F>!,&"&V])>O([K))"W9E=RI#V$$NB/4L"1\>404YUNV29>J^F/:!LX
MV;GK))DV[MW]/LXUIR97W%'8>2?*GD[VL+O3Z$AS7F@DNDJ'\ZE8OL>R+5\:
M[$V83^]_]\TWS,7.B7]L\Z>/Q=LDRB,&+((:* 4CPBT;"0=+K3ZJR@4?)"Q^
M\B6YB$36#/A5FB5BV&4&*'-X/0QWCJ:'Q^2F4#%?-&-5I6GL<*W>;) 4S2NV
MH#X#+_SNR)W6L*HQ3:P&,^*A;LQ]"ZL7)K':QB(9NTTH<932L%D5JTO8-W;]
M[<9@98K\Z]D8X!>%WFV::38F/ _S6?YT\O<>/QSJ<>GQEN>")X#8S?GPQT\
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M7GY)I%V1M6H8M3C&]CJNC_&OTD=WWFEB,_C #P$1 8#8(@4OY^!CV1=S9^-
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MI7Q5-%#A6C4,9'4_1J[PI2$A-:-XJZ\OGCW+'!,].[Q" \%4%YEW.)38XKI
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M*,D=034;4 L;MZOV2+KO#E*H!I/U=GZ[+KSBGFC:M6$)W@DT5F"MG+YRF^9
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M=6@*FQGK#.,G>CHJ,W#C>-GTJ%_!&X.?7%0F>NHEP^S&;/[,F>?*2T2S@+
MI68QA.O=0M91<R1]???TJ1Y-^8^B*<,Q72S$IRK 4@YFX)UCE*\'#'\PHO-
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M<E-'%&)$Y#4+@&P$^Z7<P]NV1AT8=F>:8EVC6E!-MO]+OK;=,B%G$1M!JJ)
M#%&>C\4:W%M%@6O8%/JR5"$B<7V?XZ]P>"J^\WR]!LU8&D7T1B)MKU!2DZHE
M%G=1PWM62A[!9WICRF:4K(582!4(<T$TH&+6.>AR@5O*&.Q/J";[GJ=1LM+#
M\BA&5U8&;&^-N)V-'] <<MDB%X;S7-@!U246R"2_P J(3>%-#9"IZ7Z#&235
M:[I#T)=..M>ZBY(_"G7PG[,](%$QG&+=(,([K-=+E<:ZMLQB'1K8P6_T"P;!
M/SC]H@MO8X6 $8[7ZUP>VOYU'1DQ 9/2BM .@G#0!+M6"3>"*DZ\\RQ))OPC
M48:,!RZ(N86(+X/6Q]+]V49SD<?2?=U+/FZB%33TN$[WAPX(*=B>VM8V=@[2
M'1>7U?-4T73&! U.(EZ2,1^M&5I0]"MAS!]S=Z3JI9/@V>$KDLE* 6G34\V+
MP-_W\!4W)O.G?3*_3^9WP*)M-)L(@-)_2.T7E1Z!BT5QJ[7TR:\W7C&MCGN0
M_2 93^/8YHY]OT%#$&[8G$P8[UUU>4N8*>&R.51ZTL)VO1,-FN[?2JVMYJRB
M3TI0H=<%8TWL>KWOBGJ*%@/F\AXS*5A/]>;* KF<L?J0KFN-)K0K\B87%I@6
MBQJ#KU%[),(WH)/"\H:-N34!,LA05^?2PF>IHB"*FR7:T""19BO6,P"[!]UU
M[STKQCR"YW%?""8)BTJ7631M+BT=WMNU2(0,[6EK0A M2L(E!JTYW4ADD[NY
M]"^I'!R1)2];MMKDQ6T;E9LW]VY>JM>45^/$'+H?==Y82W=CK%Y[1)9;G;CD
MV13((W:S[Q 1H9C 3N%>:DIJ!!_<N^$7>2-49G(.)=S\"(!=T922LJ9H?=$6
MB1)\+0)\7F.SI(6_4GI$ T76Q#C9#M&TX[?*4N7'E">Q-27D W,+$2XX3<-V
M9&L#EMKQ<,!O$B+BEKF,^@\QZ@2^%8<BW8/O4Y!BI6Z+,\MMAF2=J90!<[?C
ML *K[,Z.+H3F9'39#)"_%A0.HT"=E0V"WY9HF5Z;NGLNS->S!8#5<WC.JA$M
MH][#QE\S=!LB[<9J(Y^[=O DT?!I3#N1UH!/%DG,IYUZS0TVW"YDX!V9#'^?
M1O6X:I9*U21,[&@>#5$LUXB)U4O/G[<\[3PY3^66"'GL5N3:[-\\QGVUKS78
MT(Y,K0$_58._SE72*@L:VM7%:Q6Z4$$5YP6=]HQKAB^WBP9GIBZ=N@\X!"EJ
MIQ_)"Z"P#WL3HF#X4CC$2V&CT03@3D4W&.5?5R.33UN*GG8\3Y]36-9-7=K)
M%3O*E&@G,4+OQ?:IZ^X"<NM,L1G*NJ-%!>-8:^W=ZA2%',B#M,0I0K!?A,GU
MHO+X[X?+_+H#2<X[)@=_\M)NYB#H;!N#.%H6BH=.C1GM.:@%FFH<P9D+?)#;
MVE8B?;WH&S&11XQDRL6;-G:7H&IC!ZHJ4 -RX_!6^@>M!-LIQ*45U-?]#'*&
M=G,F?4CW1$L.D1N7B<XVH&"27TU+D4(KKF'&<S0JBKW,E_K V=M72X$#O:G'
MH @ ;45Q#=+)DL6[Q#Q_:_+*6F+X7@MI_EMKT$GO1>:F55S/)$$E,AS=G3@=
M>;.4ZFCJ(I @CW?7?'-#SE5L'3NXP0"3I<DG1:'0PC2:F8!WQGEN:T#B6LA*
MH<@(P_#91;G=5N!8A&P7@HQBZ-_S?A)=&&4>'8I<Z[XLYZM$D<:7.17/(RJ<
M83:FO8[,5CP],MC"!(=M-I3--Q-B8PJ8*2TS$Z<S5&R$IQ)!,-I%HDO**;#6
M%W+9I[?1S#WYRO,4[:!RDVBR+W1)H4T"2P3G7L-?KKIN.6(B:9;DUC>V\S.P
MG0TL84QZL'<Z0\@]K@Z3_%$EUZ939L''MJE"^/#?5+D!MRBA$)LA,*P6V/Z+
M=_S4>2^!J.!$"&#')84!S$5,%SN.P:BB2\7HRI+F6G&DVWD.CZ@J%HI@TO&8
MK$VC8N,&NVE/[E<3JGL5,ZFB/TMDVO-60P8B7R@QIVXL<V%@!;<V%',YEVQ7
MVKM2U\ ;I<U>'BL2F3_AU=73M<G3)G"(A PT,G,+FVU\C.Q,B"^[+F*&G. *
M?KR*P:UW:GF:MA+#'=N?@\&D\7:\42S-M.-&2BH_H57.L$8S51%,3V.>A\XS
M"?H$Y3A%W^2[B.Z(&169:@1&[A/Q<U7- 9#.;]O!^?Q9NRWE/#=.<_!&6E@^
M%0TOQTF2VSM,4BV8*2&QP%)2&C&R(K+B<73'N=UV %'9\A8I=H\2T79MDICG
M'B*I;K:%K^77(',O^A%^#S7"#^S7-1D(Y-I@QJ]8YU*=B0 ZI1OH8EM(XT:T
M2T#$U>C]Q-F'XYD>O(!JF:K8C+VZH69=[H=-V'C;?6=$UC#)Q48L#',+E:HK
M<IR,):!C8OI7;BC$=+'<'%9[":_HY>+!1D>K6.%=*>9ZNP5KCC -'V C(=VX
MKI[+<:Z%S.<:6\&Y\-UR0BHJNOE9/.YNNQ1-2Y534(%&O5LX0[<SUFFDD;2O
MA69LIHE@<Y/E7 *7"Y#!Y,9D;W?,;5-' 9?Y/%J;%M1%@O4)<!<V[/&RD69G
MHX6<74H*7$=\A6X7C>KLT+[5IUM>O9 < 0.OHB+)<3(/U=8R>)>2 9I41 FK
M%O]!MZWIU])3R&U#IE\E0,K(*8-TGMB2''#3@E6;UWQ#(:1'53,^7<.T$>'H
M#2N9?V( S784%Q!$&S+AL$17HCT7@5_Z'<&[;#^7*;[B3E8^M7KBIC/.S9Q@
MOH:W$QXT5&Y)!>YZ4A"5EN)9N\J3F M?]2O=)CVLW_%N=8Y,LJ_ IIY7#Z2#
M,SH%P#9U:X$&Q<EU$-@W]:A@$V=DLLU7YFZL5'J<G8(="B(9E+AF/&#OZFG#
M\G*3P=^Q?%<+IX[ERB%*3.SJ9B,>/?EFRI.;JE '&F(AZ_MJDYNJ3<[Z:I.^
MVJ0#][!CLA#D@*_\='&AS=QK-<A#WT1%[E:)73=#?F2<4:H"YLTXJEXP^BK&
MO9,HA83A6Y!QL]QS2!"DG9T2:NOAM!U#;MFX5(01NA+MT@'#/DKT)T];LPV.
MY:?3-XVK<BMK0\X23XQCY!^" #37W*'NX9#R=LEDRK)X$CWFP6WU05M>J':*
M'.-H%5W*9:+[ER@&\WM.-2$F$8/ONN*+QS6I;]N0+3,5PY[IH=NC.?QFPS46
M$H6@7)W%N>EUV9R2S=@\AN<KNFU&('HU-0(4,MN74)7H6+C^!XUG,;6RC?8O
MZY-LVWLV@Z,K>C4NX[72-#!IZ6LC$C*'&U_+C2[2 Z+=!B<9M34S)=-8(:53
MZJK=#*KT\=Q=RTJ&'X:#U.K[;G<!-0 GS<+N2+U\6PH(K9#-2DYIL37HGCE:
MF0D=-HJU'0@W758>Z7Z[".'@$A+=FUHH0S.9SPXN%&&R 4N=#PR#K62LQUNE
M3[!C''/ V4_6WG)H;JGJ"=NF5X5_8'S54Y9/+MP*!S>L3O%FMW>LX?,5MF#"
M<]A8<SNE;1S@Q7_5)1NF0H:+&W.+KE:15^NF4KR4"'8(1\ZPR%\OWG]\Q_D/
MW=1@T)#H[I!%Z-!_+8Z:F8GKEJFW%;+O*&?DCA1W9?/&<"*$+,!B(I81+J&O
MK870J M9P+DKN";D1_F&S9:&W,[ND,2/@1#$@8-XJNM0*4D;&>NDZY)XGC7;
MKK?I*ZDGW-YV^HEL*1[E+63T<LYBL&PQRHD@\:6^4%X)E(QB ,FAMVLH]ZWW
MA[K[J:C76@=ZM8 @1*ZOR$LPC6H(59!$IC!*[DX']&;CI)N,%;*=)!)=M5W0
M^?RJ@=Z1?M$Z7)>W:86]75"FJU/XL@5=15-#R!'742C=RH;#X>-\3MC3>%97
M25F2$@?FZYEMH2,$<O?+"&5!& (EQ&-@99ZL5I.7<$A-9*=]J>[U2Q =V)J$
M@!I9I 'PLSP[;&Z#U9.[F(X7$WTT2IK+*Y@+.KYX$_6,O=FD0>2$>MK8"?;"
M3C;"]Z^2LMF(:-DSIW/Z#Q-@PJW>7->/.G:1ITD>;BVTTI>$?J7ID6TM.!,]
M8RI<J!JZJFV(BFT2G!=C7P2/<"?BS2+LM-8-BVFT+F5BNU4=VW=YZ*@B*>P2
MHXVC794R5XS7\ZCO1I,"<L/U9,6R29TQFG+H)^WI!G:J8SGIC,\3WP #IHF&
M9V*[VK9L6'@IBLI%Y3-4;V_=0('VGQSH!ZLM[#SK?T;5?'GX6_09UH/=QEDL
M)<<LWWXH'ZZSI$PC:YWJZGH#CF2_@,J,ZG+BQJD@]\0IXF?;U@PL5Y_G*5QP
M5]IC;&\O, 4&!A:?PP.$UT,=!=U68Z^5#A\;H,DJX2I?U#X.A06:@4[+F]?G
M(LS2@0ZJ@(=BWNI_M%0YM#6"4_P%6X>=ZC$A,=PFES0^8$&?,6:8V\F/8XXD
MCG>[@''%RHX/91:#53/NH_6P*,2VQRY2.+<XF*'D5,X*=5YDNEG<]:5H-8N6
MUMZLFYG0(7FDLB.0X!EBHL@H<]-/X!?EVZH_78Z&9T"F4"&@ 2X'.]37F*A
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M%S,$W:#K++0M*3NT'C]JA]YS'LA>$"'^FEH;I>MR;PKA=3T"T*;!FCAM>!#
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M8]!1&;'4+?US9R9%8*$([)!?JN&%]1WDT]:9D=LPGOS^."G7==6+P .*@(6
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M^[HQ3W9;8V]=^[[]<;L)X%L =&2MDFWN3&)Q'(HJ@E3 I)NZV0M*)#PR!*&
M^,8D36H.F??V<VKGW4@*WV3S%S>IRYD>AW<+F2,Z!#LEF_J$63+_-+'L2K5,
MU68X;9.+2(#S9&@<(T43_;(**AYFNE!-<K*F^3\S96V,.3VU=#)@V^_1D<1U
M0=4>6P$QI#E+XAZWAGM%F+31;M-MCR.)4>.K!-BPPWRC]#J> $&UPD.T4A&W
MGNEDO*:/'F)=L]T'K]>B1T.;9TE%=-8!3Q.HTR$B5JIFYIB,<[.CX?SK-BGW
M?#R1CTP@S&F%-TE^*Q6>WQWX2L+Z8D@ZW<V7=0*V#T;E/<3\-D]/XFM)YC3>
MSE.<U;O8M/X >P-8(AKA<P8 QX \9E(E-]UH:S I2JP<:#\EW;X<?W 40Y,R
MWZ*!3*.OL+N"__&[8(4J>J9K9W2LC>.C-SH@4@J,)6Q.R!,M</R(7P=D3A."
MF[7S79-B7J]*0O\MOPNWYM13&,29K\58P2KVN^/!U$S6J14N;^(M6=&_#BX&
MP3_.S]]3TPDJ/I/[9G,(_UT&0+51"S,(*O;V=A,Y\%]%+A/NGQ$IY/TXJVE[
MF5L#A,W)P"8JYW \+IF7B O":B))%JUK,YZ795OKJ6T!YSGSK8=0#UGD1%RC
MVB,O=!U3G>GZI!M/X%TIITEEAA[-S"@\3IM@B'?766^22,A3^O39ID9XJSXP
M<R9A&34V\D2FA+2I%!JJ)M37XL;O9'U^*OR<Z/A:S14:FMQ =D3]9>-A&'P
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M;T'O!9,!Z_3M__X<9=$E:<9ORN"UT8&DLLZS*-V4"1'4JE(X W%2Z>]\(/N
MOO)N+3PH]SD4IP])D3L:IQ_AXECD:9I?HSJ(?2I$#A46A@ISCPJ%I4)NJ!#
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M53Y1PKG35;R6]3ZV_N;%.3J?XM:=QZD?LG0UK2^?";*X#%H^>Q&H6G!)8/1
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M!]SLE:D2J9CG+)LEND+FWVF9+F&&T-LBJX.<!9\"ISIE2NL Y\-W@G "C,5
ML5!F0;K=]/0*"^*W__8O#FZ8\KJK,\$E%$X[! &HJ\"T$&_BT]X8_?PE:BR(
M1U(_!'6IAPH0@X"9).=_G&>4QJ.<1 (!2'+'Q#7S<H4>>)]WPC 5F128*OV&
MEJ(E[.2\Y"YL$"^PJ: N\D4Q@H6I9DIF6;]Z*3Z[V[K)"!<R)ZSP/4V,H?!2
MA@=8SYNFC&RX"#O4)\3U_"2ZPWQ6EF$^8$7/HSF'Z7U7I&MR&7;*.0F8%%!
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MB(L1E]TS1+V1$1<C+D9<=MB9@>UT&RLM3T&J<EJ].B$<U0^KZF<-.6(S<(2
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MVS:X/# \JB#+\_U\GD?$Y@&;A'Z8"=%K#:VQD+R6]3-]5?\(R&":Y-/9PU^
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MB>G00'6T]&1E9'%!15:F:VTRZ="H/ FRM7:(-M)31,G9+$R#:RPO7])! CD
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M?)2,H,!#7E^836ZN=!_ (?9$^PGB%@^#<W+R91B&LYB%G$#R8:TX#>&]U3W
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M=<6?Q:D=39G+_<2$!)=%%IRM?#_G(MI6>X*1Q;MO# (<+Q7W[]6>\X?)H\A
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M\4>_K%0&(&\>R#[ACXIA]2*7.9[Q_2'K.>GJPGSAA2F]C9R-.6>10A!77$L
MD<IE7P2,".6-+6_EZFY9Q$*>J9@#>KZ8BY )6OB**,VY+;%>10Y()+CIR#$D
M+"E$IRCG*#+N(A4EMZ2:-8?P(Z)",Z$ADC%9"MP-8("O+--N%HO\/=X7JT+W
MBHM]<@!9T",NBL32X\774/8%A?"Z2_5B;8"9>P6_HB]LIVTKO@ #B]*#\AZT
M3.GH>UAS[_D7):ZHU\&(JBLS&DWI!C YEZF\?)P6M4CA1&?'"@^.67;/Z/!'
MH*,P476TNL,:!PIP,"],I;)6ER@]ZW<8@;!?[IC.8QM/C,31#4X4Q/<K*-1K
M!!JZIKQH<649/J*QFG:ZGL?B?7$Q!A&*$ QME0T*BZ/5MU*-3[&;Y?[APEO6
M>WF&(#/Y6%EL/_B*,%XBIJ/7GV==4[QX5H(OK7&XF-3O6+BD-ORA&0INUV:Y
MU]MES I:#2_Z%H6?V@'P)$RYG%9U>5D%JD$M$-/3A)!!Z=Y-Q+LJ'5TUN>]A
M[N7T)$(/HI<6QJQZ?"U.G'@2T5&_N,"'GPUY4?P8IOITL7"A IY@T_P06&$#
M?MZRU""(J+"4/%1S5?)E!PK)X_TB?-'R')7*, E'2X=LX 2+PXN57XJJ^A),
MCJ*9\/><C(.$MRBG4T"O4*R"U=\@@Z3N%((XA^>CY!XB(6J=("H[E);23OM2
MB3R2,GA18DO'>%22L?*, 5CAJQZKJ-)D$4N4;Z.R12G(EK)T8IP58(5><;I0
M+A(!'<1NJ"4408P&+B(Y25O^/4$+46 B:CY+D)MRYS4TDA*O2N(LV!I$-@D3
M%1L5133RIGX5.P>=("2MYJ=H8#B4=1!6OR(# FV[((+8;UG^)6[7X-;2YU',
MB0614B@O4R9*5#"M(W:1KOEK]0DE5$HLB\"$%HS\7-5%551*N8<%A/Y"85KP
M?+Z%S;_3WU.9%[58,3%U4>%J@3@H,QQ3Q+"R8IE$DXX7<PPA*#S&IV#.>:8
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M3X0FUJ3_3\?,UPM+V')U'>H9WYM'S:WFD+FI99L/(H!O.AH!EH( 3"/ NB'
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M&7PQT$P7: /NHY_VVD8/GE,AF51E%>,73"&2!O!^!M\#5!6FB2) 0V;H 4L
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M .'5L.C=_*,7-N5F30I::3WP\4)C7-G;'LC/::]384V0<9KY'LE\(WO-]%P
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M_ME*R^5<B#-)@E2*7T3$L-KWHGTIKK.-=^.;A!W>.M09SV/Z[N/XV7:?7P(
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MI:SIN\ZC'GO_:Z!D/L]BW9D>^X 7=,XP[ O98'>(7$G^-YL=4*KSLK%^JS>
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MF+3! .5>@UI.C=CY10-]2XGQW:[2GF;*Z0SJ^E5O:VQZ+#998P7<8<"I'7*
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M\\75HY$M)(XD//WZMWM+(&$&(Q"P)58^.$(2F]V]]O/TFE>1EF/@$JF5M$F
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MF0Z9KGV&.S+=TDPW-\J]+U9W4@&B"1&$M@Q\]!:(9XF;R)CAO!CEQ'8YWX"
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M9W *)DTWV(H3#(C=59KA11ZI2X@/B6[E1/?V5/9@U#D$'XI*1#B(I!D41@O
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M6RB+,1):-)YR&A:;A-8827;@O)8@+?,A$.5<3>K",W+347T7-2F(ZMM%]3Q
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MD6T:2HRQ$$Q,V1@QM32U\[*RCPMY&$-35^7A>6@JN^B<4@Z8*V0LDF+@> I
MJ.=.6N$4$UO;5-HN9QQ)>,W0C22,8D(Q;7@2)YZ5MVNS?)G9+9_?2>,B33F!
M9#J#$#2"\5E  6^B+LL0:ZDD'I8;#^\6M'Y&9-\<V=].D)VD)"Y[!MG:.C'3
MR:(&\UH)'23ED3@?,2_S(2"[+;T-$-XWAS<]@;<-V8LB3XC-P>U9!IMUJOV?
M%16)L"A;>7!O? ;F0FIR$S@IVU[A.!KV^S7QLE>0.4H/K[WSO<?L,+2*8MH8
M,?UTMT[N<5EP>74J8WF!YPK-G6:Y$Y+#,WZY,_[+HB-;"QY<$1B0J(H&'[@
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MVA;R;(#I'PC<M@(7^17%A&*ZCV-P!=EP> S>U3&XF/ F/'7.R&+GZB"AB$Q
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MAE!%F58><T>E]B)1K*,@V>? Q=>9]_J)MI6"[XB"URKV>4S21.<1$QPC[K0
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M>SN)7%J:*> ^SZ$5P"706@'!]EE 7<H"KQM0C [CJ-][,?*[I8?[FYF;#,+
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M4>P4YYGOOK/HM/+=K?+=Z1G?,1J4]T8CJI-%W$B&K-<442.D@L/,$DYV]J0
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MO%M)PJI\&OB8,3KI?<XD ?^NC0QV7)CY!:%D'FG?.<ZZ04L"</(<MJMC\XX
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M)W@K8 _,_9394X4J3%GQIKMI(#^'8:_R=[<2U"@O M/7C,SL-0]=F!R<HA=
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MAXT?H)Y).3OE$Z53Z=Y6!H*Q0A0N9'JVS#F57ZL6RCO8S8];O4@%+VQJ4&C
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MQ:9].*&I*[1VH9!^Z\(%F1\F0\&9D,5\[66 LEEGR\N(<V?R<YF#I;1%6(G
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MIV&>1HRY<1X[H'_G(9@W,0MB%IV$H!@2%X#K___^Q1_L(IZA94<5.0]W#?(
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MI70"=QI2PHM\GD4QF#8IR]V()W@YDU#86>Z(2';YC>RPW9!R__!YWXW<GU1
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MN91PLBSVPQR;RV86\[S<2NS LSQ$N^<\M_,DVGK:EYL(O+J1%:60W$)2DP2
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M,QP(3H'G01N&G>>.:>.M"EXK$9GW.-#B"ZX5$4YL',*D2F>)052FE+L\FMP
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MKE"- ),ZFBOX8ZL;^D/^:=A>;/1/NA>=_.YJ*F&^NA?5BS/#]O^1H8;D_%+
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M%8? J=-(.&4=2T(I6I639(^GP'G14?,DVI5*6.1K3(/KF_*S@E#<!)T5R?I
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M[]0VGM,[(]F#WKBFOAA.&MK;OP#\-#E)\RL\'?X*NQM55_L+T#%BWY,!?!L
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M,2RFIB'<Q94= 5WD"[^P :[G>D':U?>3::>BSVKAS?OQ3]N?5LIO1G_C:C5
M"9ODXUX'K)+SSO].0;U,,I4"M>!JX!4DO_JEO?P:;+^^W,FYG50/;HG:ZA8G
ML'JX"E31*SIVKKT;$PCO!4YBVJ_6VF*K5!\5$N1XDT+(RT+27%+4ZPVX+ UO
M!6&4E\^^I<+?U'TR*TKQO%-KL^/I!3S"+ZHORS2SI0M))",B259K*G6,0<@(
M.]1KU=>B,CJ*P,:C\;[_WVFONJ/Q_B!42J;Z)ZHK(/8IW-LI_/)/_:%__\U5
MS9M&U5P=O?N=@KHX/SKMGQ_!^T<'^_#LM_VC T_>7/PN3GX!E?+NI_/C%\NJ
M9O_Z^/1W^N;BY8>3/UY>PUJNX+OR^.+WJ^./KWIO3\_$VW?_NCCZY25!57-T
M\*8;K/+,YHQ&'PI!32AL6;)"T41( # NI'K6F8F^?40#-I6)E5K%Z"6.1G)*
M*F<H$<J6BL;TK!-!@5_"E4Q&4S IZPO)I-Z^E49=U82P9#2L-1=N_>EO@@PW
M(MSU+)#G#;1/ @7'BPK9=_YI1Z@ .B]KW?FP8>_A )32Y:22:>@970"X^(_1
M<'H&JGR",&/8!]D\O!J (!Q/'2BBGAU=PT%,AJ!I]D#?CU&[;H-VG1+2$PNR
M@2M1:FV5BLJ58"A[$ ^&U7Y;4_MMB>'DDTO+CRL(<C+ZU8XF]3]:EW@0W01N
M%F@YT >$8+^V6'G)CO>[FI%@'0^%+BTOA-2T,,ZE(@4'EK$@U$N29W\#=:Z"
M5L2<PT%V@J)/YQ(0%)#&<'0]M[%K+@&M7N/6T+F$6T&*&X+Q#9<"H*S^$*AM
MI+G1^+QWB2#DQ:N,;/8ZAP/_O//=L_K?S[[_1^<7=$D.,J8#^36=]/QX]K$U
M[^%74*B]BOU>!#P*'XD+WUE^X]GWG>]PE ,@FPJH(+,\:UB^@<O/OE\$1AG3
MS;#:-NP!QQMH"BH)7XI0"LU9E-&3"!=D@E+WP1YY[,H+X(7#04:J8+_G_QY6
M<U5:'/*$N>(W>G35+35@6I-DP2P%A5MJ65A;1M"ZP6G <<X9;*<@]^0ZKLCX
M?15#5P9&Y7-:4"CXTC)E/>]D [S!M:W'+#HFSB.86#8;74!.(Z!8- QZZ*_'
MQ]6K6'[Z7F7Y6:#!"]=#*>_!(L@N,(3VV7P$8N[/[<(M?1O$.EV6E/J4I(A1
M&(O-H8PC3J2RE#0/#_H\(;]^?M!#"M!];=*%-?_692#0>:1E(8*5\(=RA29
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M,T1:AXNHYK<%U/_;(,#/I)BMW"8;""9[83?2R]-#@6\^' $*!))0(E%3P,T
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M3/FVL:%EX%;(5&A-6"&T-@5.N2@\LS1R%LM$Q<[I^038FW*K+)B>DB<P+5P
M]51R0@,C+E!CTL[8>&0\WJJ0UTF8H&AA+#H]P? HG),4S X9)+7&4\DPL8*M
MF;RSX_"_#(?CY!O#4^(@Y(5DVCA+@Z:E=R1(07?&QB/C\):Q87'V70#=;5P"
M+>X8*:QF8&Q(6IJ@$XG.HCO!?'[I]RZL<7?F?&''DW[LO!C%^+[S4V\X]KTX
M\'%7D'&;XY.5@>.XT&BX8)Y:3QP 4*VL+4$PJ5U!QF.25&=M>X-S[DTRJHC*
MIT)0XPH3G"F2)J(T40EE%& 1M:?I?;4MVWD^'R"+.\FX82EX8J00!F?=^!@\
M9<$;5VJR,S<>&8O/S0WC-?':LT(QCSD6V#)?\K)0.B47HO.E]%ASI>A#RN/>
M<?@]<WARQ)7)E25(<B&P]MM[IVED2DO-V,[<>&0<WC(WF Q$.ZH*K1(')4Y8
MH;U*14@ZT9(Y$UW*E1IFM0SKP<8VFFD.L-AXLU!XS)_<'<)3B'+]TXYPL!'\
MK!U-BNEE)PXFO0D.'OJ.KM1![CQDLQ!7X$0HJXA@4AA=.L,$ =2BN&:AY+NR
MG<>BK5Y6FBIKK/VN\[0LA7"@I S!/MFJL#S%@G"2# "2DCNVBW$] ?ZV7#OM
M 7PR&H7#.6F 3;4)$GBX]%[LC,['QN1',R;W21HL (>;$Z& VW6% P.T ,-"
MVFB=DY$\^U'LZ?(A9?;O6/R^7<?.2^Z93LXK(66TI:$T<4FE9<14*GQG=3XF
M%O]]QN)):9&"$P40LBH$][%P3*2"E]I%;J@(H02S4^P)\9 "V7_Y,-<)3DW=
M1;,V5@NS8"D%Y$&"%X8E*RW15AOBG0,08G=C=AZ>W+ENVP_6<\%M+ N9&-@/
MRFJP'SRV$Y,,8*.T8!NBW/GL[H8[=_;#Y6+OX*XY,X1X)AQCCI:>$I&\@$=1
M'NY@.^RX^.MS\=Q <$1'&Y,K).&N$)@*9SB-1=12)&6]+HU_]N.:QF$[)O[+
M,#&WRB=JK6/ ND%IK53PDC$B@84I%3OKX+'Q=\LZB+'4G*?"B9"P.X\OK)&@
MI6W4A'EC+ '^I@RL@X?$X_<4BZA8U3QD,^%T.+']SG?L[HT8ZZW68V;JD>T<
M-AN&4QS0WJSYR0ZRNO\#^LN(>C"PK(D.7;M<$.I<Z2@G+"@6C"-FU]3Y<8GZ
MCVV#3#+%6*G+@E$*!AD1M#"!BR(E(TR225"%(__H'B/WE>]\?RSVC5W%.V&[
M$[;WWS&K#(39H(,+1 A36J*<,Z7DQ(4RQ5TVYZ,3MG.[F9A(K.!ED313@*NC
M*:PPII >[&FG@E&5]VN/R,^N9-\)VYVPW0G;V[*4DO-)14EL-,(%IP65VA(3
M9-2"2[5S8CPV83MW8I0E,;9,O%!6E85()2D,@-DB2,,BY]%8A4Y*LR?%9Y?'
M/!AAFUT@?Y]8^%'X;^C]^>/_A3^:A5_8T5EO4/T\ UZJ?[% X?8#I\]E(_-Z
M@Q 'DQ\*JK,,_LI<S/)(DGEVY=?_^<63*9]S@>?P\W#4F9S'SG6THW$GPAF%
MSD'T\<+%444PG.YU$)5U["#@7_1>9U2Q/?S7#\\&L(+022 "4"?V+="#17H;
M=ZY %'0VYYKV!B@=8N?T?-3[,W;V@?Q<;SB93:3Z1^?EA^$D^G.LC6Q>PD7L
M'W1>OX=OVU&L7NZT=W'3)NYM[2 JA[,-_ (OQP'L(X[L99SB#O(Z7[QZC4N?
M5W(^:MIE#XYV7[2O+)]XO^?C8(S#DNMK'B_<\QUIG9$5BF^N&K]>/S'_Z#!U
M_F>;]"/"O!8F19H4@.1D);5<,J\\=24GVV80WZB;URGD?_>LZ_5[D^M:<;^:
M'<ZC5\MO_WM._,5_!O8/,SUY]_N'M^_>OG][>B:/+XY[;][!=T[_TT-5??SN
MI3QBQ_!O6/?!&?GOQ]\^GIR>71T?O*&X[J/3PV[DSEJK#"8+)FP#K KT#Q:>
MI1AP"IS6H&:!3!A9#>KO;4415DDK&--!.B-$F;".F7!F4BE5A,??IVF\HXA/
MI C?C4&5U"5="+B50E@L:0H.(!AC/!"I-<6Y4FI/KB4(E"/;$$5TB47)M$K>
MBM(8K9U5P0$1*.^-YO<)X7=$\6E$\>ZPJTWI>"*\((Z;0GC-ZNF!U!H*V!ES
MR)_]R,T>,/8:JAC%\66$?_P9^]= (^/QT/?L!'12QA[32X E@TFF'="G $.&
M@]BYM-<7@ 0 GYSW !A=Q1&\!KJN-YR.^]=  RF.1C$L08[ZMX^G<+<]?Q,$
M^4;@ J 34&R_/[Q"W=T#^-093R]@;=>H85'I3N+H8MS\X\7P A9Y_;=QGKK7
M2V ZP$DM(;A%/&#/1C%61U?#/8!R@RF^-;R,]7?NAM2^* ;+3_RA-P%#R"\<
MG%I[<&\/3W[]Y_ZKH\X"%AK?91_E-[OMPT'G7W8PA=NM4!?(,,!=K8M%G V4
M'0!V389PD9V7+UY47#';[\D 5WMV71L WSUKWGGV/? 2\%8_L](E /?KCIU4
M- 2;>-[Y=3H:3Y%>X-'P:K4$^(&]ZF^S7P"8%X$W SRM(J-8?Z-%?FB=#/(Z
M.I?P@RAT\SI[@_S!U(O]4#UVF.K_UNL&?D=NA;,!]AX"%Z,LR)3<!SZNOS\C
MVN=H7,Q.9[:R1D8 ,8][H:9B>!7^B!^BGS80%9^%1]@L"Y<)+\^VZH<7%_#)
M\3E85./.G[8_Q6U/MM)9/)1,!.T3<U9X)K4K <F&9'B*(J2J01QM=!;%A)JM
M==;E61S\T*+T/^/^:&0'9_F,7K0/X55]1/_!O3QAI74H3P[>=\M8.C V1,&3
MD:"H8BPL5651"H"RT5GCM<Q=581<S8S?:^AB'<5,AO[])Q(,$ D/GO,@11 T
M.5=BH94I+;.V+.N1[ZPA&/9)(&=',-L2S!$_^OBR:Y.,!*<A:^Y"(9)AA94R
M%9(YI2CEDGL"!*/W.%_U,Z)H6R.1K#_O 9S$DT=2LBU4 W()K[@"RJ/8NW @
MHQMM#48[4!^8[(!W\/T #^D/+_-S0 ']";)YW $5CL0 5!BF(U3JM<A[#NJA
M<Y2_"[\@T9#'M;V;#BKZS$H%/WLU'/7#%2RY\^]:V&</SH*'8;\1QZ!NCN((
M*'_VRK/OJT?M(Z.<CBPZ*SJOG^^C9FJ_5FFGJ_,A2OGA%4K_\=3!4?5JK%,]
M]__]8O>KTYAQ7.B-_11]Z!T'V[]:U)<+GP3*SZX-^$!O!(J@-Y[@:O)IH!K)
M[^=M7 P#J)SJHT#R (3:VF(50]:@*9_& JRHU;M@SQ7ZK"Z'X^P>^2&K86"K
M?\#)3LZ;6$;KB[5;F<R_8MUXV)].-G]EV6G6<B;[C!N^$:KYN>!RZ<A:?YZ/
MFO5<VK-8N%&T[PN;8+D_V/Z5O1X_^_OB+F&+2Z=ZQP/9O/V4OIR#+M\"2-^:
M5WZ8 @F.\%.P'/M@UM(Y'Z'N^?]ZD5'BB <#6PO!3#)41IL4V/(&#&ZANPJ,
M$HPX($/\W[_;1[L)-.]1CC[F/507L(:UED12I:N==2D8*TMOA/"4V1(T5Z(*
M((8F4IIGC>T7PSYB!RZC"I93Y;@73 4=A>0I &;E*@GJ-S+;MS.@*B4VB$LZ
M;$DG9:UP.1K^V:NT06T%-3KC:CCMHX%TC6;-3'EL!'" KQS(UN41-(DEX4(*
MT@HMN:.\]$&2:%EDFE6Q9DEXA>'@+XL8[O#XYTU(;3AH(;5?86/PGY.T\(%?
M:U_(#*T5[,G!M<I?;86 (R>L &+'RM=$"F<X+\ *4]JJR)SDSWZ4JU#M_V0D
MUN_/_4HSVQ)Q5V-?IHA-26=XK?*MC(;7MI^#89FMUU'@\\[K&!ODTK)%EPDU
M(YH[A\F^H==B"F 5"+E<0E]SP)6!$YZ.!<[KP1'BOS/K70$JOIA.IMF^1V]6
M;Y ]%,#+30P*'ZV0&T<Q3'T=;((/X;%5IWV]AHWMN I+]G$%P^8".W#:/HXF
M%IX/,@">-QEGJPV.O@=H">-AEXN>D):/['EG?QG#(SVL.!5F4!+(8R9">N/Q
MM#Z-9I&K%N3?QD ;(Z0>VOEU5+LM.Z_1GEQT=L!Y#7T^*7S@XIIFQ H;B&!?
MY--V%D'RL')U^.G%M(*@E96*2[C%L]IRI\Z>OWA2< ,93"-Q'P_A?JC.QX,Q
M2ER7[:^A^04'YN5LQY4%C4O)Y^G]<#K(<'T""'&2F>CA\\6)GPQK^M4+K('_
M& VG9^>=7O99KS=[?OWEY?%"]'QOR0%X0^ YI2^\O<ZWBWH_^[%Q/-JYY8FG
M.W-VSHS5%4.T^<1>'2EH29S*R+[L6U\SU0)I#D<]("H@X=EOH&^T#H WEO6<
M[_&?HS@9/J_<FTO.U<5';U[UHCP] \6/"YU;M.C/A-\? S/NS4WUO48J%BY:
MM/KWD*J*ZM R>&\Y;AL?PE[C0,CGL" 1.]_UOJ^V,9.80([P3K/MN>/WU7D<
MOH:#AI,%X +&<_7W[YZ].GT-5X#RZ ,P^7C<.?QW05E];=7??ZT?#I]K,A)F
MS(Y'Y>T )/<>K*99CC_OY<@-+'G2@]_+@NER E_^[MF+_5?PH-F"0P_>FU0B
M\3M;?__% 34W_5:]O/RQ^>HJ!\1WKGX(& ^ Y%%0@=B)DWS6[^"WFJO.F5S+
M(1I\,PM/.*(IDF'^[F;$4/]F;[;UT\)'P">M#9^^6-APM71XL7VN(6)@J$8Q
M@SBLSVU\XR&LO%7A9PR!-CKO? HL#:KBL@=:Z<)V_NR-IK"$9__\]3_5K>,#
M !WCMV>:&H! CF3!<\>U(JW.8KZ&4?MW>N-\:M4+,VJHV+B'"*U6'2@9,_]U
MX.<[/V.L85%UGMLZ4>G^&0HW,8,7=E)#1]2TR"K+89(O+$(WQLS6"]77_1@O
M<9T_13L%2/4M!7PK@'1'&=6F]'P-;@CBODWC^)T,N$+G3G2/GZ\C0RU"FM'*
M%= Z('1,[(P9$XTO$80A-630 ^_:',B>\?[*-F;<U-Z*;0/)&37"+]0T%N8\
M?L/JG[=Q)_SR_TY[-6],Q['U>_V&_S(9QP2/G&0^VWS2B]*Z\@>W)60EJ[(/
M#^#^Y&I8Y/3#2Z"$8:@T6ONREF'M%^'+.Q+1&OT&/]W"KXBS)Z.IK\58K<R
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MF9@3BDNKL"%.W4X:"JP\%:Q\F68&FD<JO,# !US.R@X)9;E_Y!+'-@J6DG4
M*^IZU<_#O)@:A62*E9Y9*8O<T0B[B SY))V9Z'TB@6D5DJ:*W\X+BI4^H95>
M;/XP#R)Y9E"2C&<="HFT9P(QQJS3@E&?P$HY>_36/T<KG5,X86QLILX<8#/G
M;L_*KMYLP'?FYW\U,.M"8I9$2F(*N9.CSC*,EGFJHX'M5I0(2JT0^/LT3X)%
MY#PA&JGD 8&Q L8DHD+2>$4E,R%$4E6O:?KH@.^L%O+"\96"= 7IKFH$ ] %
MXEW,2;^<:9>\]#IBD2AVBM]!* O2O0S277#-Z#D&?P C(5U"/$6)G%(!819,
MC)'F<O^E%<&6]0W-AFN*=,\4AGI1\_QP.!A4M<K]P9F$X=5ZQ$<<.3(8^= _
MS'G4;P&Z9Q^ 5X/=+\U2)^NX0/A,$+XU358Y-U8D@' B/$ X"0'9 (R56!Z=
M%M@(*<=G!4^0AO4+0UF</*P">6\%\EZ:KA;(>R#D7;!6&C070GJ4B+:YQEYE
MN56!.#4^2_9J*12PUF5IYG62\?20]^H3LO[H]W90U?1Q!M):TCGJPM1:_9XO
MR/4 Y/+39$U9%9+%&F'+ *^L=LCY%%%RU"NFI""YY3=ERWAND<4:!0^+-=>%
MA!1K?K@U7_ 0*37)TX5TT &L&;PN&RQ%BB2/<>Y#*,":N5XFK$ZIEG,*D+VZ
MP]K+7&^B3G #W7NS9QSS'Z!7 ^@O3<\*C,\$XSO3I(QRHF-0%CD3P9U,G"''
MN094%SAP8I/P>%['O7,WH<4(L14P+6"Z..RX@.FL8'K!B04E1B81$>8:(TXP
M1<;#/](K2K1( 6,SKQ/EVH!IQ:A_JT2D;E+MK*D(\D3F+FL_3PG>CANOW$\-
M+HM"GS?WN2P W?@PD<B>R(39"TWU\5M[_=%8/CKFCE:=L5AOOVJ",F[H&'.G
MM*K57]4-<F1'A^>ZP@>#_EZ<5'6V1UGU>UBU>TR'H\-!O-QSY5RB^LFUZ\Z5
M<2=RP7^.1R,K!F\X6#;58'X\SIK:,<!4PELVTC?X[3"-#:#HVFWNL)]44A4=
MIPB3)!%G(7>O<@(18J,/F%$IXE5=NQ1<Q,;F[E:>6RR,A!V">D^CTRJ(<%77
M;G-:N:XQT8P[[&8!Q=/)BGN8ZO-9Q\F\,L%F(VPMO=RXZ>2B3U:E;3\$%&DG
M0)2J.V56=Q^,EWVE-G[9_/J#FZPO&Q_<T64=<T:6*]7LZOLG+;MRD^O<BG7\
M6'!'L"&.JD<X>\"#BX6:7[?[X<Z+O[M;Z>]&Y;Y?3M","H$W:A#72_M/B'<4
M%^V_!;M9/8M0X=D;)OLJP]5F?K<"WEWJ:(/^T=4(^6*)H:W"S=B=W./B#%NF
M-L'\.F/+/[:B'0S_>0^YN5^.V6N54;RRL(AXY,*:_:VO2J&O:!LNEK;ABT8J
M-C*"]=I^T@3^/BMG'CH^"Q&^N=%U4I)&Q161PHC<T=QYPC@57LEH+0UN.O@]
M%:&!6_'OP^'@!':#N;M2XZV&+*@/-0G@P+5:[>;F[C[<Q^G6WD>\_6.=;VUN
M[S;7UD^W-C\>-7\TX7H[HOGM:@#GRU&3KA]O?/YRNEU=XVMG:V]WM]6%S^RU
M=IN;J\=;ISMB8VW_^(I\C-222>,MDM)&Q!W6R#(F$59*<Q$DD;E('+_#MSH!
M14FO*.D]77!86YVH4+D=9.1.$.=RVI^206)#* GW.VD[C8-^J'J%/P!W7DM\
M^/G@Y2(^G#1,2J 8!2\5XE)BY#QG"'N!H],2,\>S K>FA/Z_15'3*VA7T.YI
MT$Y&;CEAA# <N*0V]VCF(D-?$-(%-8>CL )Y3P%YK:G\ A$=QH(AP8A#7&.*
M-/$*><:E3DH Z)FJ0D=>[YQ;4\![IFSU%[72]=YH$(_!/#_VXF#GI/&G'8S@
M%7B%?_SQX4%D]]>#4%NLNM'O,S'GR6!B.7?< CH%G * $H[&!.]#\?OJC5*7
MQ,$"3*6R7B"<!*!45!2(F<:().:PIT31()96V#LZ%[^O9(K?DP!XKBGV4K 0
M)5B9TTHP( % E3'#BKHY)!86 O DIC4EY^FU558" 3"6(6X81Y8(CJ))F$GK
MN/;@\^AE)FF-TL2+*<_9E(/C+(LL&GA4;A1W22?/2,)4$DT3+ER^IJ8\Q>6Y
M<"QK*B/&.4><P"L-/AJR/!'.B0\FJ/J9\ELXM;F-KC?6UQ_.V'\]#K5%I!L9
MN^::8R-BI%IS186+F /+(TSD7KV:%,9>;RRZ)%-G#8$A] HE9G+=@A/(!9.0
MD2DD1[RPVF?&;I[CI*8([)Z'[&!OCE(+;,'&HK'6JNB,Y-IR[-Q88+<P]CJ:
MUE1E9]1"2>(0BQ*<88L],'8=4(27TAL!\P>F1>BRYO/*8J_1.42QY7.Q;)XB
M!2Z7$E@O%49;HY*3+CA8!V+<!Z=0]AK:\A1EE\E0*:-!4JN(N-(I5VD;I(Q3
M#).@DA4UM.6W$&+_8(>C3FQ\&,2XW_B]W1_Z=H1U_YC$J]<68\=2!LXH(29A
M+C&V@5B-@:][)WT2L3#V>D/1):T^)G3TVB8498ZQ.T^1DY2B4!WO4@&O$T#1
MG'*K2F#NOHQ=$)J<4B1AQVF,0-8C$]%CC@,+ZMZ-:\I6_B3V<T'+O=,R$ \\
MG!#P>!5VR(AH$?4"&%JB1O!\1J5,C6)OQ5KG'4;7RE&L@R"6<NVX\41A;'AB
M4DL3Y]%*MQCR4QCR%"<',PX2I@Z10!+B@0,GQS$A)86/+.MN2 <;H9J'A&.)
MH\]DB?]G!W_'X2@77 ]&Z/"@$7NCJGRZ\0]RGY*MUQ]$)R%HP;QTP@O._5AH
M&78E00WSX%H62EYO)+JDR.@,C=PZC!0P/<1MDDA3I9%."0MM2"(Q/ENY0PF\
MG:>]J,!@6\#11L*C5H9I[92D7K/@B90ER[^&5C6E I,[**6LA\A91)P3@333
M#EG-:=)26^72O+/\2P"]AG8<I;!$,!Q(P%Q);[6+F-E J=2$&EO(>DV->8JL
M.PT$)X'7+1EGB#-)D F:P-J*03+PNBUA2RMRV9@2/W_F2N4[&U*_I3 Y9;#;
M6.%T"HH;!UR!,.4E\<DZ1:TIG+S>@'-)D%,(:KD*!&$3,^ PAQR #?+&:HJ5
M29(!)Z<E%?V9^[L+20)+V$KGN8D6&!Y8E[<,:Z#G+)7$EKJ:U@4QMQ2H-U4$
M!9:U;@EW2'.ND)<4W%Z6CQIS8LNRKI5B>3'E>=-RHX/5.&CK"0]*&1*I4=%Z
M)PQ-BA5:7E-3GLYK<58I+31*+H*/K8E'5@B#A&%!6*!##*>Q*3^ZK+1^(?1[
M-Q]X48N\L?_ 7 ,,1;K[Q>4(BG3W="J%4MQAGCSCP"N"<@XGX:VS,7+E,"T<
ML98;R_XT1\1$T*#S04C"&G$L/=)4"$09L/_H6)*!5TVJ.)US2]'2#Z& :@'5
M&QQO$Y1-. *D<J^$43GI10JOJ.<A%+9>5U"=9NLTV91SU3BS'G&? K+$Y8P7
M8C#)M04F+*T(O"SF%D5_>5"]W!?A%UT0SKX191![S\@[<89M[5Z(O=%[1/2+
M]4J8RGUY_J^_/#+R'>-Y'%8O*;0WQN+L6? ]J[S?)5F?->C]M,#\<"Q=?WOF
M3[OG.X<!7FSN#G+#AE58;Z[='U4:J1^/^Z/H=W/^_G(E.[^ZUOBV#Q^Q@WB1
MPU]-_@VM,:[])B^0"EPB)=AAKY('V*,F&0+FDQ0+V'!IN/Y)<K+GW<OJ.1;,
M->7<:L&H)^\VL=[+LU6U%5COK44W6NV%IAWLQ\K>/O[GL#TZ^1;]X:":0_CC
MI"/'YL#FQ;0Z',;1<*T]])W^\'!0H[83WR?8?@!XOKT+^+O7W/P(> PXO><Q
MX'P7,!:W *-;>YYMKWUD&]^NM)WHMMK;W4^YU\UQ,^/XYE?XGB^BU:V^G\#G
M:>LT[#<WO?CWZ4<"[_F9&-4I)HN( &SFAG"DL>8H=W 325@JM+_:=2(Z0;0-
MW"7+.!;8&1Z$<4$:J0-C[&K7B6^[?;"LJ@GRU.P]H)O"K[_X\HUZ)8W!T3(+
MSEDV'D&BR0UY2,ZMP?K&[@O9@N2+(6[NT/&AWX5O/OF?C$#GPU5UC_$=.QRV
M4SM6G2KLW[;=R:L> ;:A(7"4)[>^;'!3UG5V Y_Z@V_P]35KY/(2%O7]IP2F
MXS0'8PK9HG25#L0C&!@.,D7AC517%ZJQGGOC#+&"<H>5C7 5PF/2 2;'QP?T
M<;'=W&\\MS;R_>%HN0%[UW (='L0@;+D7^\ * ['/8[@+[GZ++].MCUHY!9$
MU29Z?85=7I)W=$MY?[=]W]KU1%QN>C+N ' C&OQZT"X/,N4)6PR0)GF"]UL'
M%J?SP9X-@H%;4;M.*AR_8T:4YB3E9NO1]F6.G3@6HP_$ZAF&_J\;_+;R 7!T
M'LU;%G4T/N<=I!J)[^>[2/7CY[R3E)&Y863^J';6MSPTJSL[@[AC1[$:CT_
M+L8TX:],,5ZBQ\K+M67_WFOG_G/?1E5WQYT^W%BOZF@7@%0WAN>L^NGTP5]U
M[/PMA<:Q#LI3ECPG#+S:8#T)U*A@ [;@=<SCO/&J;W?%\SO;&?.F^+L=MH<U
MBI(_S.\;1\G[K+6VS\#7H]N?UT^W:!-O=[\<;^U]9\W/7_C6C[_:S>X7TOK<
MZIY'UL^BY-6U_?'&VO;^UEYK;^OT:W=[[5.[M>F/MM=V=[=_K)]LKWW'6W0+
M@Z]X22"!"TL4TR@901%GQB$KK$%6@<-"*;@WG"RM<+V,N5X4K?32'** 7]W
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M8"K)$!/FP19*60<(_W))\3+JQ'1*R+$$E!)^0D[F]C,4>YD,293)>9>WU:A
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MUKH0HSKAT522JA#&6BP1^-,&<6<4LIX#1<KDEL?@$K'U(T9%;Z;HS12]F2>
M<4,X"R8:Y;'GTE CHD\ZZ:BE2]S1PBCK@."7]&8<(T ;L4=4.(VXEPD9K#AP
M2^JLAGV9Q?E)&):*^/K:KK",<J/ D["4.QR-=BE29X@/3B3A;K?=8J5/9*53
M 2B+G1:,(>:41!R\\^SR,81MU."Z8S!27K>*^&*A\W:26,+6!649=QQ30&>1
M/*$X<,R3MW=8:-E=G]-NI^(U."F?#.RN2N=R:"X5,H)%%+32L,MBF#Y1=M<W
M8+L4GDY%$CU6B>/@ ,:59,(S+2@UY@YF7*STB:ST8G=-P22GDH55HG-Q@PK(
M^& 0,RQ8IHQ4I.C-%+V95Q5'+L5I-X.TMH1(QSG7@9A 1 B2!Z6,$E84@E4'
MZ+ZD-X,3H19X,;+.,<1)9,A:@I'B0G.):5 BE@K?4N%;0/398L":&LR$U98F
M0-$(Y!9[(8(ABD6=;#G*JQ.27I!@25,RF00S:P+B/@BD4]2(^)@(S*DB*2VM
MF&4J<<'1@J,%1Y^\!X^VW"2+9<*<.N94P%9)Z5WDSA)9R&@]('0JVJ>I]\)&
MBT)($7$&KZQQ GGKK= J2:;GGK9>0+2 : '16[M-)V8#R9"9#.=,N^2EUQ&+
M1+%3G!<R6B<DG2*CDAF3B$?*2'#KJ3/(""<1=UY0;YF6@KXV,GJ#VLSDT5J'
M7; 47U/UF6X<[?9#XW 80V/4;\3A",QD%*])O:3J-Q-=@,9PMS\8H5$<=,>%
MF>W>W_#);B5;,Q&JJ89BV+"N_W=LM(=98 :^ @S^8-!/<3B$R;8=^*'ML]K,
ML'\XR H.66NF'> Z>: ;\(/O=P_LH*J[;_>&H\%A]27+C8&M] M&NS!LH3V(
M?M28E.CG953IS_QGK UQ<*8-T;!C68CN6!;B76/ML)*^R2"R7-WSA_QEO9/_
M&3;B?P[;HY.I@M-\P=7_'-K?8?7!'_[1@FLWR#\;MI>_(:8XR!([PU'?[S?Z
M1SUX#5_8[U4CUX91J:1I8!7:47\P//NX_F?C* YBPW<L#$AJ9Y&>X6206>.H
M/=J]2_4''@P&""8M)_/UA^W\X.\NJ^OD)9@AM=T[K,;ETB*<K 5.WRD!Z^7L
M$N\'L6/S0$W4<2:P/?7!B9GABX]8!Q9U.+K](U<6_'4Q@Q<R@4^(DRM#-O7O
M[N!"C&$G(C>(=A_9!+?[WG:.[,EPZ;?+3PF/>&54[SD@MS]^2D_V^.-9@)TQ
M+\L\C0"L<9#?!;=C:W,OC=U!I@/_U8Z48(>]2EYS3DTR1$2;% O8<&FX_JD
MTRJH */[W]_LPC[$A\R">EE+8G&?83P!-YC6%4@:LRL5HS5)8"JLYE@Y)\!-
MIHJS%)6B')_SQLEN>J4RDVIJI0LI$\6(D]6:"!UCX"+"3>F?:UF7$!-,T(5
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MKT^:F]^/FVNK/V&, :(,6(DP.,O7$J2#R[EQQBFL52"*+:V &<UB*]E$\H*
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MI]-4C@8.7JH*B%*&@<I9A[3B 4D50F 2<Q/MF,K1.4LGEJ:1!4P+F-8J$EC
M]"%@.L65HX[1.H]$Q 1QGB0R(;E<K"V4D<))KI=6.+O1+UY4,+U'#\F'M!]\
MTNY&T^YD(QX?Q-XP-H[LL/'?,UCJ@UIH/=!DIV]XX4WTX?VULLGN'+76MDAS
M\Z-HG6[]%%$%IKA&AEJ*.(X,&4<H$EJ:!']4-."E%;7,^?53]N69IILYSI73
M)F+)N++!)"8E)MZ;1 SV-D\WO!A/]R,1NDSW#=.]L?;Q)W@95@J5$!$B1QY#
M0%IPA12C.%)AK3-Q:44O4WH=8"OW>)89)U8PGJR1#!N>(H%O-B&*$)+4VCE6
MS;@^FW%=9GS^,[[_4R7/B7 .8><UXIYPY'A(2!"CJ?$R42/SC!M^_6@]#W_5
MH.XDVL&P$7LAAL99%ZSQ?LO(<B.C<_Z7F&J)Y+E<;@SB\"#ZW,2X<_+N5VWM
MJNU,O-QV=CC(!<1G3WKE01L7SYC?D=/>;>\$'M!G:E#)EMCVH.KKU^D/AW!;
M_?3<&^&5KN;G=[21_NCW=OZ 60BK5>+O_\5.^-0??!\N?H[^PZTD-T[?(H"'
M8"U;#*[]TX 52)T$"E0'P$6GD-92(V9%)%)I;REL@X9>5^98;ASMMOUNHYUS
MJGWGL%H1O>E% :MAG'H-'_.'@T'^W20+&]9%7E+6^_&BRJLP]X;,)+,Z21V.
MX#_G5P&OHP*XX7+C8 "S/P!3:%2]PN&MHWZC8INHG] AT+')5]A1PP/]M'!/
MDVZ3DP7\/\-&)^M$!%BU?GS95V&GQ#R5G<Z!P10[?>ANMGX"[_U)A*<N2H84
M)^ A,NR0#M8BX3%1BBO"/ </D5\OD7\A.YVRSGR%RU]W<&>36+@[^(Z]P]YX
M81ZU1[O5-7+?Z7P#N5?Z;8MW$ _RP5YOYV?^U95UC*W$L/%+K",L:,9LM(D%
MR6%18\;/U[&:K&-L&)Y>Q^NM3Y>(&5BSS^3L",QL&'N7:L3 A07+W$A?S^[G
M.]S.\ ,\00SG"QN_O85--[[\Y,$!B% 89$T],#,1D662HR"D54'K)(U?6AD=
M]:_S,ICZ=EZ6XX4&:R'/\K 1+O!QM-L>A,9_#NT@USW#^_-,7L'WWZ[TQ1XC
M?C45OVP4#]QOJ;Z-X<F3-X;_W.^'HW:GDQM#]$:VM]-VG3B&[AJVAM];/5_@
MVVNK1]MKK2XL[&YKKXFW/_\%BW/UN/7C.]^B7_>:>YXU3\-NLWUU@7^":_Z^
MWZ1;L+"W://TZ_[VC^W=YAI\Y^;NWO;GYDGKU)^VZ,>3?Y^N'[?6FC\9$4PD
M'U"$+1-QR[(P A/@>P@MM$E!&'6U-[P5E#BFB8=5QRELL][#PO/::2<5]?%J
MY^^SB:C \V(J&N.Y>&AS^%_?Q96[3I@9)1V)''-#M"5!26L$IRDY[_B3-Y/_
MYG=C..S$C70V(&][\7W_Z:)+7(F !+,&\60=LEI&Y,'SC808SJ2J?1OYS;S?
M[\*:CE7)9K7]V\&@(B"VVS\<\XB=,QNXO[]^YJD#6:[T,(:3)O3#^[:@%Z4#
M_1OM0'^/%M>+UL7Z7OV_7_'SO[4NWK]'P*W>Q(G*8%F:=S_5\[^:Q (3M7=:
MJ8")YDIQ&RG50G%N+4\^SB.QX(RZU2?D\T#N-DDBX'#MO19XT-MK_^IN;WX'
M;[HZACIJ=N&:FU^[6Z=?VTU@<]>3"';@.9H8/.C][(FW-K\<-3?W>7-S]62K
M^ZG3^@Q>^N?UTZW35DXBN*2R; P5.&BD-0:OFG&#C" $)4J\YRQPDE5:!5\F
MY-%UPPM62UA K8#:U5 @T8DX(IFL$AFY<8H;RW!PP5HK? 5JCSN9+:#V4%";
MTI446"J!'9)*6L15",B1J)'!5HI@8V D+:UHM@S@MRB@5A2CZL:*+XZCWEB-
MY@R J:6*+-,_@P6/VNJ$E<'),*,53YK-F+1V&@?]8(>[MX'FQ93\4:LB\X6
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M69]ZTILN&H]]C&'RQZF/CN\NO['=@YN=98/A'IB"($HHB7FB6FOPDP.5E.O
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ML]1YP$F.J^.;:)&!.4/2)$FU9!;^;VE%BF5FY"O@H3?TBGB=&FC$+(X&FE@
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MUX.)581I(IE?3QNG!UZ"0:6#0&"E,L MKY$)5B#"K7;&2<O,]93I9MR:0WM
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M]O@9(FA!NO\UL'!3^#<T?ZR/9[4];(..^/+UB(@6!'3]?^&R\=1&VL'I&R5
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MB60IJ&R]\5*Q;+*6(>H@Z_QNJA]B(.R>]JK?'B_*YF!0#LO+JM0V0HV^+]A
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MCT_!\0ORNM6,:Y=<F=GKET*U=SHANJ?2V?17_@X+M-Q2X@Y"0E(A@[=<">Y
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MPE8#)PZ_(IY%33D''KU#^\NT\<L%^8B>OAKW@OS&#;PV\+IX<]@#:.3(1)4
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M%QJLV*OT(&Z=(GQ_%9^7)<#F(2GQU<4WN$X_XS+]659IY2VD!S ,W]D[V!=
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MI\ID6/IWW"+XV_<'*"%)O;BO!.Y&[)\@C[4FT#2^ 36B5V6OAOUN)UY<?$Z
M.-=C(;D(5C .5 I06CI*O1$B>F6]]CHOK<>B"29X($R&V6 ";W'O/6,D424(
MZB^2E*^(*GJ,<."C3&L;C+6YE&VSL.S.Q3'G$^>&/C$*K6ITYN)7YWEYCNZ'
MSDU4QZH \$Q41Y(Y !AB4O8$E ?B4Q DN<1!&,JYB0C <ETNJ@+64V#OTR;H
M+G3&*Z$$SG5:<6U=AF""$A2L<-YJ:9*/@DONK Q+X[1J(DH>&7]F(DH"RU2X
M*(CF)8Y$:R"6E=+G$JP1(+VPHO0JY?)[9/<NH3KUI.R\U!K5,@#=;=Q_]U.F
MKKK_[F'I-A$ZWQ_:9B-T0 D?2QOVJ%4D:,NBEL6S)#1[;4HSL.QM:?;6AH=W
M>WMNAFWC:FM<;4UPT +@:!H<!-Q:SB4C:-:5MO#,$BMU)-I)0 I(.I2V\+(-
M0K>5T@TB+;UNV+C:&E=;$Z2UY  \#=(R1AEMF2#!&T^ 44<<M8(P+8,3U%"@
MO&K^JQ;58Z+QM36^MN7VM34!8H\.0-, ,2&%TBP&$L'1<>IV D<\,*6U"B$&
M634>7DR V.HI5(VS;9F1;IF<;4W W7* VTS G7=<&$X)!5ER7W0F5AM!0%O@
MC F5K5_;L&U-GX]I6P7K_7-42 G_&SM?-JX#-_Y=.*33.ZGH=./?>-MD:F,N
M [ZN)7+B<7_8*?>\&J0NWOPE_>NT$T>'$RZ<>7 \9SI]Q'F<WLGHYD>.W."@
MTZL7@\^K9_;]P867,?Y,2O7H\<[72SCS[^%@,IYC5$:('R3WF;B,PWWENJ?N
M;+CVS\NSQ"E>6=5;+LC-T\_YT:9?[P("77]04<>KDZ*VE;MP.&YIQM(Z'!1T
M_Y].XHQZ&G0.!H#;;)E,+FL1J05EP>SKM8V]P@ZM?F[]^Y]N92=1M%WDBN$J
MSZ'>@#FL=062:EE'I>0V\E+E&2#&X)DTU)@()A@/?NPWP6?0-"ABVN<<6( D
M&$2(*I@$OF0XN! 8SS&NW? [UJ8(@3N!#^+_"<]UI (T!V^X%/&>3/JH&+5W
MF% _Z7;[IR@Q6A7>MX8G1S@X?,FP521)F:#KMCJ]6H\ITW6^?X)2I]A@K7ZM
M>[3ZTY.^EAL6+GF30BK^]EH&"M9NH7YD7UW>M^LK,I8 K&C5LXM4Z_CC(4Z$
M124&<;&Z[GB87DT^_"MVAL===_:JTZNF7#TTQYTP1E!KU[FR!40O%_(=X^MZ
MA:]79'=]3:[;^L&Y5^DZN_':U]XJUIF^^>I]WWK_L7[]&II^"Q^K79=4K,A8
M];HTJ[*N9AWA:$7&6BKLK@H--/3:T"O2J[T=#7PC$^K_L_>N36TDR[KP7U%P
M]HX]$Z%BU?TRZX0C6,;V]KP#S-AX//"%J"O(%A)'%V/X]6]6=>N*L,W%MH!>
ML??8EEK=75693SZ9E9EU@VCU3[J4DBO7_N1FTF:)[:B5X9XZ3M*:RTKZAOCC
MHY^.N;C1PG2LE%/S+6/]<2'0;QMIV1'(G'2R3U!QTK);,+P/$9B+5M]R&VC]
MQ*/*EJEF"J:NEI9O"=A_RQ0\J:F<;#VUZKVGJ1RVB@@V<WH?<SK=T&O]T4FQ
M]<M!M(/AK\W<WF)NMXZ/!_'8CF)KNI'0*CL)#58V6-E@Y<.?TP8K?S!6WN2<
ML*>9SWGCP3^N=$T3(C%&8N$MY2Q(2Z-,E#+LA(HDJ9Q814R=6$5,<\+8?204
M],_WMC^>[^R_@?MOX</]8WSXZF5G[]4[=@#O<_#^Q?GNJW?B\/T!W>TL)11\
MV.+PF\^[KV LVV^Z>]MO/AZ\?\T/]\/)[O;)R4&Y7[=[^.& _G/Y>OZ$,:R4
MEL9A1)V1B!LKD":*(Z8E)T(Q)K7;>)8W >ZI>\]ZY&+>XF6^#OP_3\5O>2Y9
M@^T-MJ\;MC_.$\U^(+;/NE[X8!BLLT8*6X)X9!I913.VX^2((]9YL_%,;TK\
M&+']/CHV/NV22H*-P5$X$F3@TB8KB2<,2$&@BNA4SKZ^!B":[F4/'$;FNI=I
M%8+APB%'F0&*Z#$RN9D9#TX3&JPA,3?/:4M"VY28]<62[]*-_<=SK >2OG__
M-&L]H?,+9\?>"C^;_F(/!2)G3$LIEV04^6!N&A%W3"*GE$)>X< $IYPSN?%,
M;O(U9EK?]ZR*[^B,KRU6K*Q9O)7[U?0'>X3X,=\?#'-)?93(),T1)\HBFZA'
M OA58EAZ07'VU+#^$3WM&TK34)I[H3*YX+!IX;6>Z+-PR)[7 >-<(NUH[ID3
M,+*YO)#&B!56W%@7-YYQ=>?FJ ^5O32AHL<:*GJTW;=^))+,NF^Y&("L!(<L
MT^ (46F0#58#KV&622Y)=&KCF="B33A_8FC2T*J&5JUWI.AIM<?ZD0@Y:X]%
M>8I1!X*<H1)Q*QS2GG!$E4J"2T8CLXO=:9X(/#:AH@<;*GJB[:U^)(#,VEO1
M1*4/V""&)0=GS5MD'6=(:,<]8(I*V&< ,??32[XA-0VI^8FQHJ8#U7K@SZP#
ME='!!>8C4L88Q)-SR"CCD0[)!A>I<!CG_IX/QKW[IFSXI2Y_CRXI<M7X'E?>
M([;:!*P#)U;P0(B6%N0VPY!1%F/:Y+0_8(C:F<]I)Q(L#E,2$4$"XC1PI 5F
M2#OF'/!F*FS)>U3WU2+O9[40?H29Z0W.-CC;Y)>O,\[.LIZ2DYI0HQ'ASB+N
M)4:6YF-M671!<B=2<!O/*-Z4^H$#[5W.[7GT>W\I&29,(%$[SJ5W1H6(90C,
MLJ T]VN[]]>DB=\9#>;2Q#G%QA$1D7"&(QY#RKM^'%FOO>91R11]3A.G2K<)
MO:^S'];HZ)RG"@K74X';(4.3 /U0E']&!;2DR@9"P<?R#G$</#)4L5Q&K&RR
ME&O)J@.6Q2-6_+NY;FNK\BLWIVY%\YL\YD<( W-YS$1H)8W62(0 ',!Y,/\$
M,Q1C$EA0EB3EN0YB=LSZ]SQZY0D;Y'LQQ,OGA5S&03_8X4F3U+NNJCB?U,M<
MI#P 'T^AXN,2.4HE4BG$0(V00N"Y^-RC-<I/3/D?EXO>I.?> R;,TG,U%\EZ
MQY%F.?DL 6&W#NRSU^"Z:\6=Q6[CF1*LC>6=]V\;3%@73%A[#[U)//U>NC]+
M/+644JV2!2H@/>+,R.RL1Z0I=Y)';EWRQ477=V[AL,::W[CH:^BB-_FCWQT'
M9OFCQNEH4@(.($-"W'*!C%$$!<*<"4$P(EC.'Z6X\=$?F8_>)%.NAS+.DBFE
M=L(3K%!,N:.2=Q1I'#AB4C/!(^8XMVA;/R?])AV$'VTNSZKQ/;)<'JJ4L=Q2
M'@V71%@7E&)>*QR"I)(T.9,/&(G^FL^9%,%[R8Q!42<'W@&X"$YC@PPQVL)R
M.Q;U8Q2A)AWLWD3()".T]ABQ$,#!)%XB\"\Q M$R@@"UU"26=+ 5I0'W5"NP
M=CU&U^4>W]# XC&QZVN"X(%CZJ4PUG+CK+:<,!RT=$+C9/':!L&;/+4[P]1<
MGAHC23%,)?+.8L2Q!)AR7",&3A90;Z,9,:6=*9=M@>^K8=\Z%EH_,5#X4A3\
M-LC0Y*D]%.6?Y:E9+U5T@B-,HD!<,(*L3QJ("@W6N5PV1*[C*(]'\6]PCX>D
M\JN#X+?Q/YH\M4<( W-Y:BX2QA2X*M)RCGC2X.B&%!'Q/"K/K98VECPU\B-Z
M*#QA@WPOAKC)4WMHJCB?IR:D!=.K%2(QMXP+C.:&2/!/!>R;.&6$$?<6 E]C
MH_S$E/]QN>A-GMH]8,(L3RU9E@1F&&D3/>+@F"/@<!H!@XO<T=Q6!FBZ-K2-
M&P_]\6#"VGOH39[:]]+]69Z:8";Y$!2201G$F7"@^YHA1B2C+JI(J&Q<],9%
M;_+4'B,.S/+4K+,VV>215!QP(&@P_]8YQ)1PW$8EE!/91\>T\=$?F8_>Y*FM
MAS+.\M0TN.B61H,\8#/BF"ODO*#(1&HXH4ER%M?126]Z^SV)GE-<<N(39^ 7
M>IX8MQ8K+R)QPH$D,=/DJ3U@)'HWGV1DHTN&!8%B]/F "<*1RX>14NR-3B$)
MFQ-F*=F\>UR@:>[7-/=K@/9! 6V3S7E'H)UE2AB5B!(YAS,*#T"K K*$8^1(
M=(&+:%)NY4'-)G_H752;DJ0O[,B(9(@W6% 7, ]>:$6QPP9CQR4!9V!M=V2:
MI,D[H\%<TJ2PVA%F$S):$/#_&$.&IH X"9X[K[S,Y0&D;91L2_Z8>WP],5"X
MG@K<#AF:I,F'HOPS*B!#(%K+B*P4&E3>2J1S4W7EN F6&2IH]KG8IGK,73V?
M4N> 6]'\)FGR$<+ _"'EUC#E0D"$N81XQ#J?\FG (Y L:DH5#M6&C&P:!_S(
M#9G;&>(F:?*AJ>)\TB2G7L.*$X3!""/N NAB@O]$&9AS05A,W3KV#6B4OW'1
MFZ3)^\2$6=)D\,K:B',YHRX-OA1XZYBB1)++E8V)YOIKTLZG;QO^<[='&E1X
M2CYZDS;YO;1_KKV?T>"N18H$5R*S\]S93R:D@;'S@#V7$C=.>N.D-VF3CQ$'
M9FF3)')+P%'/^5D6<1H],DJ"$HB$K2$N6$UR>S]E&B_]D7GI3=KD>BCC+&V2
M&I$[L%I$$L:(PZHCAQ-#WALAF<>1Y4WT]7/3F_9^3Z*]7SZD+5D&8LDX=R19
M1X135 KK$D_6-FF3#QB)#A;2)IG$TH@ 0.0!B+B+R#H)N,1#<(DZ%:PKV3Q"
M/O!6;(\P;;(!V@9HF[3)=0;:6:X$%4HX&33R- '0:JJ1=H*A:+7'07#EB-]X
M)L4FOO.9R.O:\_*)5<BMW)-ABDBB@HN1&:Y4[BSFA.+48I8X27%M]V2:M,D[
MH\%\KTGFM- IH6 8!S1P">G()&(4,RF]DR)0H%UM@75;F3LG4J]Q/?L3 X7K
MJ<#MD*%)FWPHRC^7-JF4D,$'Q%G,.1I8(Q>H0Y+KZ+!7C&J\\8SQ3?YS?:ZF
MD<6][<C<AN8W:9./$ ;F>TT&T',3"(I1Y</7=$"&2H:,E8E3(I-D=N,9WV2Z
MZ6/Q(S=D;F>(F[3)AZ:*"VF3P40MI$0QF 1V.23DL"%@DA/SVE#A?--K\O$I
M_^-RT9NTR7O A%G:9(S:"1LETL;G7M 6(^VB19)(P8VWP<A<W=3F7+?QHZ;J
M3PP5UMY';](FOY?VS](FB<-.>FX0,Y$B[K4"'& !!4RX(,EY9EGEI#_FZ%SC
MI*^AD]ZD37YW')BE36HKN.+>(1Q(+FYD'EGX*Y(RGQ21E I&%R^=-5[Z(_/2
MF[3)]5#&6=ID$(*RP!U*+D6@Y &448/7;AE1)#K!-,'KZ*;/ITW^K+*&M;_'
M-V2"N_X +"2J)O<W!JL1^F/0L=8$FNH+1OVSW_):#?O=3IA^^9@ <77!I[$I
M H716 1N6+)!1)$X#Y*(2,TU)\6O0>2B22ZX(TSZ^>2"*+&10KA\8CQ!G%L'
M**DB"MQ[9Y.PC+F-9Z:-*6U33>\IO?S^=/,GUXS]9!!:E:SY4S'HQFTN[W&"
M'B@Z?Z'P]E80W61Y/!04GF5YY+1ZGR)%)%J%.',$&>D"8H)1101+( &E(?'=
MCRMY; A\DWO<ZZ ?!-RL#%X1JC%7T>*8JW]3L%X;D@0+8.VM3>M3\]MDF'QG
M")K+, $:Z*SU##')@ C&2) S,2&N&7:,4*X)R8VY"/X1);\-KVIXU?U73]^*
M3^4P8).6LY[X-9^6$Y0W7,N C,U'OHG<NT33A(!1>6V%<D"Q-IYQQ1H&U035
MFJ!:DPYT[U@T2P>BSE,>\KD'WF+$B;/(<L61CIA1PQU(AP,RU::2MTGCTS7L
MKV%_3RVJUN1E?2\8GN5EI<0)-2$?_ITW-W!TR B@A,8D(VP^F(;G=G9\4YL&
M@INPVE,)JS4Y8=\=@V8Y83(9CZ/!B#@-;BE8''!0X3]8!X:-4]8QF5OIT2:N
MUC"K-9J9GQ57:Q+IU@/!9HETV!G'$L/(6Y(/\9,&6>\B"M*$:!,.+)^A_IC<
MV)*"]Z]1%B3X,W0^/2M#RT+?Z8V+5'Z1"5BJJ94N))X,CSA9K8G0,>8C#UG
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M(6";\OXW;Q.MK]C=%N!@"^:W%3^?15_+HXNM.=GM S:V;.N\ADID*ZQLG94
M>I92>W8VZ'\&H1C%[D7K2P8C,.-"A@"'@2RZ?# D89X&BB4V+(J[&(SO)H#5
M3L'+_J#^*%]'GIZLX;WMUT?28\X)I4@D!; >:416!H)8BM:8R(24),.Z$LLX
MW<IK-MR<HGO!\K7#[C]!\#O'$4!Z/!@ >0!Y'@]SJ&H\.ND/BCYDC0&H'0['
M\(\JT)*5)LO/,%U4GU0H#DH5![X#OU_W8>^?Q%96 ]N[^)]AZ\7GZ,>CSB?X
M[ 3\(KA[ZY>-JQ]N_-ING9_T6V>#^*G3'P]AKN#QG_(4P8PLW/'Y22>FN?ON
MI00J.H#;/G^QM_$KS.>HTVW];GMC.[AHU6:N78$33'ZO%6OE+A_%Z7WZ]7VJ
MW[^-9Z,JFDCYY!:PGK%3WJGE  Q@F;KY$8!:-[&?GM.4(4IRZGG"VG%#G(@F
MB@C*X+^VNY$-:0569R!;OUU#:-]W1B>O@99^Z@3@G5O=;M]GAK :R%Y\SG^-
M._"6)]V+^E]/V12RW?W71]A::H+G* H+IA![BJQ*&AG") :^ QZJVGA&5QPS
MG,U9ZS3/)H@N.&W')ZT=._ GT\!TNW5F+S(/;75ZK33N=B]0S=IJ# "1FJ%'
M_Q3N!5K<]Q];Y["NK>$8[E5?.1R[#V!L,VK8+YI+@I6F5&E/E.&!>.UR<,5:
M;I04,?!O-9?G?;!UL;<@A'_ JXW/*MNVUWL#0X''9W'+[_P.5.%M'4-^8H)T
M0(!3G</S&3P;[^QO'249B<K42M@<VS N(<>8R'V!).&2<AW"QC.0FAA1-G)7
M+!\H\D<T/FN!1,",@H)NMC+@GE:ZV^J5@':6GYDD+0H08"#HM1]7'D/&L9!O
MEC'6=_M#<%@!A $()Q]V[1"D:V"SB]L*ML!=M"" JP0\ET$66%VX[Z=^%UY_
MROI:$]8'=\I?UX^[3N0+9\S7,5R>7W/%6)SNA;?,>-4+=K#R-<'-L6D4!Y4E
MR+^I9Z@X0+4)/AL/AF/;*^J4+QEEA[W0TM9,JEM%K%M9KEM;Q[!2&7#!_&2/
M:_IO,$0NCLXCC&8ZK,F#5]C$:Q^<_P&SREI_=FVO6NN%YV2RW1G 2RTB3'5E
M@KNW/N50Y.16]9CKX699F/<F0=V+V>WX<@V@D^^. UP(,#6,7;#UQ^T6C 26
MKUM;U'#: ?X"\E'&$RO;D7^Y9+4!BTH0ODC=< 1_E'A*?J\^K&AY_K":H<RC
MX:(;V50OJ"(LJJ - !HWAFGGE1"41AF,OIE-K=#J=9FC[?$ 1EU!6PGJ5A\#
M@Z]]@V%C+_\2N]M;1]8SQIW*;?V=06 <+3+*.404U=0X*:1/X#JNZ'36OM%:
MZ]RF,A$7C$C<\J1]8$J)X.$C+X3^2B.M;PI$-&)P2S'XZT@Y@@,C#EDK-.+)
M>J2##P@; 8S*&!UDV1#4\FH$H<*4FP@#U]JD2%7,YU@9*1U/ BA.Y(9;P(/P
ME4-H&V'XCL( '-KZZ(27 C@THRBO#;($6^09+%@B5H(T9&$P0EYET=D:92-2
MG/UL[\$HK YBMF?$(Z]R]M2&.00%)JE[L>[^\NO>O+-91K-H.ET_^_]@* ,8
M>C_J#X;MUOBL)CXYN'9ZFFE/497:S"_%B$]/.Z-1G)* <L-V%6JKW-D>#&7A
M-W;F2D[7X2IMJ5A&_O'\]=G4=X:5;?^E\VMVN6T/O/$NO.S(PO@'-W69!0,P
M 22AV'J.F3/.1YI[KD2I++.34)^IS3LV#-_992YO_-P.3][4+_V4E?ER;_\X
M7T]VX,^][8]'RL,LIR21CTF!'V,$LL8ZQ &*P<$$YD4P*/9*YWCF^GJ8WE8_
M4_+1-1(&XA^[L?RR_37G^-\@;0OB=IQWY//EQ<5N+>) ?J\L9!VXM+S8/#+4
M"LKIIA*@Q&?@%^5K?BL;+?!^_S[OA-')9%=S[H=U1@J>_<0ZX+WCT?4_64*A
M^1U<#V()@O=S<.DE$FQIRN;^>S*8O,\9N'+(@7?U$14'ZS?;/;<7PXU_+8X2
MAK@TJ]\X(=<//Z7O-OQJ%0!"^I5K\ML8S,\@7P6O8]?F75HG@PR0_Z<3*<$.
M>Y6\YIR:9(@ =U>Q@ V7ANLCM?%LOZ@=J,/__9=]L(/(N^G9<7S(8Z@68(5J
MK1TW^;]+(%D9/I>2)YY'1GC@07H=N2.)4^L]H2D'L";1S"J 4^VMMD[LIQRQ
ML34NYU# 4H3B)IR *@^D(("O(17W3FO%DL51>L&%T],P^OUS@A+]J?:+2\K7
M%_*^GCQ3V#\^XEX2PH)'H ?@#XJ$D8N1(TH#,8Y+R?*AHE1<90K_+H0>;/IJ
MH_[F[;O[EBEB650<DR0HYTQ2JX/5+@2)-3$&?S^9@K$TLO1%6?J\L^V/6)+>
M$0[^(_C\B&L2D$LT(9HT2U2FI(E8+4N5IW*MB^,B@.VPHJ1U##E[G=D=([.
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MPW[/NNY%ZZP_''9RP&N5S+EXT:\_Z.0D7/ K*T,PF),R%S/AOWH1W&HX]0G
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MV'G_[OS@\D#LO?KK\\[[-UUX)_S/Y>OY?D(&UL<3[I$RN>J*!HYL(!CA:)7
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M0->10S< ^OT!=$:KB>8!&'5$3%J+>#Y$SV$F$!8>/G$!*U@A %"%[YQ5L>8
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M[_J?T]VWRPS\\/2 _M[=V=_A>]L?+P[W_R)[[W=/#M__WH5Q,OCWY>[EQ\_
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MC63(29P0T='AH(E6J8(.MB9MA7X^=*P(M']KK'@]FX VP>(;!8M_PGDGCS8
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MN<[,G;9;.8"7@S[QN,2NKK*K*E S!HEA"R' Q:!"%4N NU8+-YR&%5Z"0SD
ML7O>&?@LLB7^-*S)_2)" AU;$-/*6;B1G"88MU3><.4EY\(9X[%B7#)LB/$T
M5<%P^.@V>R&KY/1-/9P& [\HK9<OCHQGC@GL$./1 ">S'ED.&"A#I-AA+;AS
MUTGKHL.8/<1LFTNA]=0N9X%+($4YX#LSM<,J,EZ)9V=8DIV'):#9 Z$!1S.>
M37W7RO^<!7(MF'/0@/R488YRC[LE$)K+(-<]N%AY.*.3SO"+P<7.G-<SMQUY
MDH/ DQWCS$?&HTX7GEYF:13]20^&<7Q1PN6@P?F.LR!LG(O-SJ9VB0'!LNP"
M_8:ONK <!5"&<;I!4#,OL''N0P1TR ']5M6D)=]PW/-QD/,C<YAX?L%* &(\
M\OW3DGRSQ+\F&Q[=W%MY_EWJL#,H=J?*J,P_GHA209GA9,<EWR-?W#D]LWX2
M$(<W!^2 80]SE'8ZC]F[K.]W[11NSDW[Y-[/^W#S7I[=<3>T8(*J&2BAV+QO
MT%_<";''@QCK/85*.,M\?>IWJMM-!Y+W&<I#%N8OCR%G]5?Q_G67Z]>]UIX?
M]>N(MVXO3-@@^MCY5.T9C-U9/_;L++BTW?G4&=9;""]RV;:O)JT6T+<OGM?5
MW!-!FMP5+@#AZ_?0V=AU.[[=REM *'6JD /0_SB<S%Y6")C:WM(M*KM6Y]=D
MX3ZV@^K'L""GH 2V%UNNTX=?9V.2;W0&,II?9H)>U:N S(:QSVRN[\=5]LBH
M7PDEW*;H8#4CPY%-:7YH^9)/_2[ IQW JL"+5H&ZR4[-; KFAE/V=][&L]%D
MBV%B^F<3/MG]2WFW<5XJ%^XZ&W'^I-*532 0D\VKC!A3J)C?"YQ[6+O<,N]"
MV9"W!2LH!KCI74QN7%C,(N[ TZM=O:P]8>):P3\&U<+VRMUZ&2BJJ&6E0(/X
M_\:=075?.YI_C=]:OW1^;?E2$9,G-<2,@)68^9+5,WDS;\?#RHI<M#YU^MW)
M?MIL1V_NTVI;Y6VL* YAO]A?IT.(?CPH93>M22YX:ZO"'O#X>#OOP-1FJA*%
M'/(:PCTL(J1\0*@#KR]+S^FX>UPUE@=$B.6A_RZ7_-*!49W9"UC*_[I!ACR1
MU$N+<71!<\RP5M9F-R&:J*A0H4Y*,W4."C:+20@WRI"?5/V][ _^@&7NOIW*
MR3H5 OYHGO77Y1[XF+O;!V3GPP%PK8]'41FKP+%$41*+>/ 2:6TH"H(S;82G
MPNAR\B^^>O)ORP-*=O-^>;S(S*!L.-=* ZKTH*Q#!JL;^0XY5P[S0(0BN=S#
M:".]H8$[$KU0X#M4"55XDE"%;^5$7!-#@1FH7(B7G2:C:DFL81SOCCA623(E
M$;%.@ON@,3(!_FF8PQP'X\#UVW@V.@$RM,)_& _R47"9R)_803SI=T-%[8:
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MI^5DZ)+<>C&9Q;#J=E5@I8K[P!7].4"VQ4>]@MIU9R!B)NKPA66K1136#.#
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MK,E*=.'*O1=_8MO!<\W;_Q[3'7JTAX\:"]R8!?;W>R_J_+5YFP^SPR/<G^>
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MJG';W/:]&>>Q2ZB\*\!JME0-Q\K,:^L9B=D@5,G<":PI5*JOS,IHI5/?\LE
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M#?[</!G7SO$!P2F>Z#W3?Y[S THGT814H'C(O*!S0KN<$^BL$N].?\FG<"!
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M:4M2DD>EK8>4DT_&\Q*-12-R5J;I4\N VS-]*I6DE2^"J8A(^I1PS&M=6%1
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M\!LMDUK7DOBT0"XFPZP*M:<J,; *M2NG-A=5@8?+"KF]1V "0;_DZL#+JQ,
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M0[W0@:@WZ%#4.ZHPFE<=#02Y/&*3]_Y1T52EX7'8S[V3UYU><#3\\&.=R&Z
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M#!V5A7$SU#'%M?>.,:^YTM):&Y6ACZMU6H;XLOGAX-A:[Y,D!E&3/.):PQ2
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M[%)'YL/?\(6_6J3[ 5/G4!CP%9K &X8MP\$LK4L\K+C$UF$!=1D9PJIJS&+
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M01>".-;5*Y#+B6TO'RG>HJLX!ZR-Y[LE ?]\ .-V85.=DU]^^']02P,$%
M  @ ^8%A4N[C-T471@  [@H# !4   !P9V5N+3(P,C Q,C,Q7V-A;"YX;6S=
MO5MW6SF2+OC>OR(GYW50B?NE5W>?Y;2=U9[E+'ML9]<Y3URX!"QV4:2*I)Q6
M__H);%(2)5$2R0V06ZZ5)=L2!7R(" 0B H&(?_M?W\\G/WV#^6(\F_[[S^PO
M].>?8!IG:3S]^N\___'E-V)__E__\2__\F__%R'_^]=/[W]Z,XN7YS!=_O1Z
M#GX)Z:<_Q\NSG_Z>8/&/G_)\=O[3WV?S?XR_>4+^H_NEU[.+J_GXZ]GR)TXY
MN__3^;\*Q:(2.9 $S!!)$Q OK"7 . N<>B&3^'^^_FL2D3EA/'%""R)#E,0F
MRDCDT1IK>!+4=8-.QM-__&OY$OP"?L+%31?=/__]Y[/E\N)??_GESS___,OW
M,)_\93;_^@NG5/QR_>F?UQ___N#S?XKNT\PY]TOWTYN/+L;;/HC#LE_^]^_O
M/\<S./=D/%TL_326"1;C?UUTWWP_BW[9T?Q97#\]^HGR+W+],5*^11@G@OWE
M^R+]_!__\M-/*W+,9Q/X!/FG\N<?G][=F3)-_5_B[/R7\K-?7L]0$C[ZKP5I
M]YO+JPOX]Y\7X_.+R<WWSN:0__WGBZ\PQ1DY97PUW_]]^\N_W$X=_21>3KJ5
MOL=_KX<HD^V- KXO89H@;0Z_Q\JFB]EDG(K(_NHGA1N?SP"6B\-6^MA@O5>^
M$\H;2I39KN>;S.*=#TV*@,WFU[\Y\0$FW7='EPORU?N+T>?E+/[C;#9)N/O?
M_O-RO+P:.9%5Q#U%J..)2'".X.]EHG*V.K/@@O!WJ;->2B>7V2]")YSK&7XI
M5/L%)LO%]7<Z.A+<MVM*/@YE1<K#%_=Z=GX^FW;C_I>?7,*'RV79A$6OC1R5
M01@PQ#+%B'2"$T<S(R99X84.J%)$BU4^@>GN<C=DY]4\_C2;(UU0.?_\TY]0
M5.E:3Z\ ^GE\(%1WM<3Z$[\L+L_/NS')> GGU[]?E'95N5C.VG!BQ7E<3%_1
M>)72N)#!3S[Z<7HW?>TOQDL_&0EKLJ<ND& 5$*E3(DY%3X3F+&LNO:.ZA5@\
M@F<7D> O4R1J<*":.'R"I1]/(;WU\RG*Y.)51 NGD!K2&\CC.%Z.DJ*&>XI'
MK*6<R*@3"3I($@3/4@C+6% M).-Y:+L(B7B90E*9+_74QRV.#\LSF*-^NYC#
M&4P7XV_P#FWG<W@_6RS^!LL/^8O_/N(T*Q>%(B*)0*2ABCCI$XDY>/#<>VU#
M$[6R'\Y=)$F^3$EJR;%Z8K58H*$WHB$%FZ-!+R@J(KT%XKAG^$]*M5::*L>:
M2$LW?9U%O+Z<S]%%'$G#T&V3D3AO4)U+H,1:CQL5#"03M>*AB35Y!\60+*L#
M>/Q E@^F<#5)_3B?7<!\>?41'93EJVDJ._2BQ 1P XVR N"21I)S1D194.(3
M.J7HQ@.3QA@GH 7/GP(U)$NJ@@A4HW\UB7@W18/^ZSA,8+4\!/+V>YQ<%AO_
MK[-9^G,\F8Q >)Z5=$0&I5&KJDP"@T@"!) LXA&.'FT#R=@%W)#,J H24IT?
MU23E9G:<("06#%$1!)IN.1!480$/VJ2883H!;:(G]N'XL<R="AP_B*[5N+JR
MT7Z'Y=D,O;EOL%@6=;08L2!$#-0325G&%4E/7#:1<. @30B)JB9;_A$\N_!<
MO1R>UZ!Z-1'H#.NUMIE-X]H^,>B-)81!'#4(Q7BT5+1-)$LME9>009L6 K 5
MS2[LUR^'_?TI7H_Y:(_@JJ=?WX-?P*="OP_YC\7J]!D)KK4+DA$F#*HD'25Q
M!DT2H-0*GT/PO(FJ?Q+5+L)@7I P5.- -:%X,UY<S!9^\M?Y[/("O>R5^8'?
MC;,I(KU$9WP%&FE^7XJ%LS9RY8@&+]&*1>8&;Y'#E#$%0FAJ8PN1Z8%Y%X&R
M+T>@CL6]:N+V?NS#>#)>CF&!/M&6")*DCAD7'-I#F1(I0D![US'".4TRI*2-
MH2UDZCE@%1<^$B%[5/*H[JDQ1'(KB)<I$33]1/ ,F($F@>H-#$.*MU25B?L[
MY%"Z5Y/X+>L)SCM/,VIV*=#G9Y(2:]#^2Q),\EDI%YH8W,])]6EC+DW%H"<7
MJDE#N68=KSP 7.3K3DM_A6GLQ%.IZ)5FQ#B&KKY%:%X%Q,<LDR8[%703M? $
MIB%%7)K*1RV^M#@HK\/(6F1#3? $V5B2L'Q"]94E?HG@J;:(L8F;]A!*A<NY
MV262^J._\F$"UPOTF47'K"6*XF:44B5B,QHH1E)TB%B,RC;)^-@.9Z!'Y"'2
ML.6JK2_]ZT6ESB\FLRN 3]!=_6U9*75"Q> 42:F[5&22!"H8>DC&"<F#5"PW
MB4\]AVR@IV<-":G+E<KQJQCGEULQ99Z!HR]%3+;H2H&@)&@728J2,9G <];$
ML'H:UD /T1IB4I$?%4VLZ7+NX_+OX^79Z\O%<G8.\VML5]?(G%$J)28(,S*B
M*Z R<0KEF%LD!;7<!FCB9NX";DB7'I7EI3IOZL7!+N'+;*WM/OKYYH*=B31D
M*@C/Y8K6X8D88HF6:"LU9\8XV<3N>AS2D*Y(*DM()3Y4M,.GL/B07\\AC9?7
M2"PPRDQ N30XOY16D""U(MJ5,%K(-K,FL?)M8(9T7U)9%GK3OIX4S*9?O\#\
M_ V$&R# L],Y G$H@.@6"D,L!T.$C%J%Z#(-;2*5#[$,Z9JDM@STI'RCV[,'
MAU;FWL88.0F"H3F<HR-.,C1U$%B&'"E53?)'GX8UI.N.VJ9G/7ZT"-I\R'O<
MS=R EN"-"!H]*8WT8(X22VTF,LC,:!9.ZB8!D)ZX=Y$R]S*E[)@<;2&&(YUD
M+MF&)+$RK0J!>#2D">=H,;&@F-)-[F@?O6NJ$@H-C$H16"!H_[D2J2JK4NAG
M*BZD"4)F(4\1"AU,E' OOC\A](<0O(G5M7%Q3;4(:  &W%.N^ ')$9N807>1
M6^]0ZZO(6QM>^V44G" (V$\ ^A/^..&<#7"69BX=HJ%&XH&O)*!C:")AU*.6
MC4EKU^BYZ$[X!AH$["4F+5A3+Z #&7#ZM'HY],5_WUAU2<&/)AFA@1$M'#H1
M4J(3X1TC*BD=J$#%EIK(RS.X!AK\ZR4G-5E1]RIA$\BMO'H+R0?5)=EK(H%[
MXC.H$G*R1M@4J6CBV3\.:: !OUY248D!K1W\S:S=G!WG-I*8H63,.4%\>>S(
MO0M&ZRR8<4?T\8>9,UU-/*JRX^0N_@9NIL$P13DQPB%5)$?O4"=#E,C.<$Y%
MCHVBQWVA#S3.6,O9.09#*[]$OO;/$IZ2J!@YZLGBGX%4!/=&1E&P.E,9M<E-
M?*(G'O'NOZ3R/&:*'[E"\B\6(V!.*$$S8?@_(G4H=28,)4G:K"%R*MM4^K@+
M8T@._N$\?_CV\&!2URS1T&4A?8((XV\E$0F-P>O%"3SIE4<<@2<T 33CQ(9H
M"&=1R S&:M=$23X%:DBN?CU1J,:&RJKMH'@K.A R&,M(3L"+*D:\DDJB E5,
ML\R$:)(K=CCD(04&*@K5<5A8UQN\W0&+C2V074XZTH1V)9H4DC(@P01%-$T"
M+4UGK&OG#6Z%-*0803V1J<2"B@4TX,*/T]OO%S!=P*MIVGC*>0U,J7*'% 2A
M7.MRJ<,0F$HD:>.MD?BCT,1$V0';D$(&]82D-E.J2<O?9LON7<+[F9]N/TI3
M""Y8E%\(*9:@AB/6H..JC;14!9FM:Y*<^BRR(44/ZDE*78;4S#/\#5>]/<.-
MR1PM6$>"RHA(6=1SD(!HGB&S7!Z(-BDK]12H(?G\]:2C&AOJO1,\F\V7Y=)M
MLTB$,-JC%BN/@=$@DIDK$IS*1 B>'(LZJS8U4+>!&5(N43U!Z$WV>A>=?G%6
MWI[A'^5!VS<_Z5ZC+5_[^?P*C>:N+.LH)F=HXD!DPG--EK**3C%*G!9)RYBY
M;E.F82=T0TH$JB<B]1ES3V;^[9?[]'J/_ZY9/QL5'&(^@^48)[F+HF<Q[;LC
MMZJL_03^:@7'/R_Q:[?_9_G&*>U=>?R142L2:A?<E6J1W]S)K.WOQ0AWCO?&
MBG)7JXBTS!";7"903LI2LLP(V_1*[!I)O<I([\[1PY@7@KX^\_.ON,@ 3"M0
M>!PH59+XDBIO#A0QD7JOHS)4-3F%G\ TI*AT/ZEXO&!2/T94K#R] !RF' %O
MX!M,9ET5Q_5:1P:XX+%D0K%DB>14$9_0[?0:3QK/A0#61#:>1#6D0'5=Z:C'
MC'J&.TPFI6(C3'&A$P3V*IV/I^/%LBS[&UQC$UQRD6Q79$>CD8  K1<*5^W1
MS1#4LS8O#G>#-Z0H=%V):<">BKF-B^6'7*I"=B4M8/YM'&'Q>39)HR"H]3$&
M AZ@)*VC*(.UA&JNP417$J/:I#,^!FE(4>>Z(E*)#=7+K]X>@*7P^4@!=T9K
M//-2A%*^*!"KT:61Z*5F&KEKE,J_'<Z0XLMUQ:$"^6M6\<[C]?S)6A6D)3D7
M!Q-D(-[+1%C",RX"\$95PVXA],_ON"[B7V)OJR([E\BU6Z_EYH;PXVS>R=)R
M.1^'RV6)W'Z9E92;DG(\ZS3ZN^D2YK!8CJ*UII3B(<@2].U9 &0,E,(4.GD9
M*)[\31Z#M%G.D"S[ Z7O8;+)R?E>L8CZYEJV7F3?MJAP4GM)120YF4BD05?%
M4TB$&DI=RCF[W.11Z#X@A^0K-)&WBCQJ)$7;=L2OD&=SN,F8A\7;[VBQ(C_&
M4S^_>H=D7#RR+;3UB6=-B7<"MX7*)8PM-#'>EMH\AG+1Q$QHN*9JJ=VW&$>>
MAR"B$81I8;OWF"7&STF@"I!&E*HV3?2V8!F2RA^*9#Z:#GX@"RM>]$]G=[%<
MNY ^9B7!(HA0"NIZ]!6<\9IH893SCD9EFL1"'T4T)-4^5+FJP\Y&!\-CO0.2
MC1(,9T2%$-"[*2$NEP*)(?# LW+4-[D$W G=D$))0Y6Z^FRNI]]@N:%BD[.)
M2RBO&BQN I?1_2W=2IB,I0Q/UH$VB5K>05'1B3:<9QFR1_]=R-(TSA"7&2-1
MXIYF2$\;FN0'/^9$G_:P/YS76[I='4+B-E*[F_?HD\PEX,LSN()5D*"!E\Z%
MG&4P1M(VZ7C[(MWS%"<O1&+:<JQ>>=IU7]./,/]\YN?PJU^,8[E]&D\NEY!&
M3)B0K8NE"%DJ)! H[2J6@E0Z19^],FV:)SV-J[V#BA/?F[/#,0K>QH#<(+F4
MS)8T"F(A6 +..3PP#;.\R<7%P8B'I)!K2MO^4;@:+#U)H.TQX-(&)7DR1 13
M+O4D^H:EIJCBD+GP(*)O4KFS O8A^6['D\KV;#Y"',#A>JDSAFA7S/;L/4'B
MX#D5E;0^J,19DP#<CG& W9=:,MO6_>L^0[R<=X^D_31]G*\+>G1-&/Z8SL%/
MQO\#"7_T:?W75Q<7<XCCCG]OX/;O(U=:,D!VQ)?,>YER)-ZC5\U\5,H&G^!^
MD_:'^74-< WI$*@C6=<;[=1,K-F^MK,#KXEA@S5*RE+Y094JH(H1:V(BEFE-
M.0AE6!/7]!Z.89GG546G!N4KLO\Z,+):V.921]8#"XPJDKI6N3Y:$IP DG*B
MUFKG0V@4$'L<U)#B8*WDHA)+ZC[C?7RQP$-6P3&T7!DN5B@@5FJ!RHMJI:+V
M,K=K=-HK3'^LQ*HV@E*1+4>\@CTH*0$]):,5FL&!E<[.B9;2K[X$B7UY3*2C
MMT>X\F^3C#*L>^YDC:;*&\)]0JF)"062\M)<!+3A@5HCFY2\.=H]]] O@IOO
MC_TC&,>1ILHZ"(&N->&O,(4\1C#9)4O1HDJBO&!G8(FGM.A'KB@U*;HVCPH>
MP3,H$W>P<MF/C?7+&&[$Z4N;7R%,)+HKAI]*YY3$->$I<@%!1.K;],5Z+M?E
MD-<XWV"Z>KR]K?SLV^]KWI<71/A?*BE>/L1$0Q;$>)71=&$E4= *XI(Q(%,2
M.31ZH[,WUB&= 'TEZ>';G;:LJ[^%;M+)*<\F0<R$EZ+G,EN)'J_M(N"9JLP8
M[NVF&VC[,\<3J^+: M*/[L=X5+W]K>WH7C6(6J^$<=SF[X3O8Z_T4OCN/;%1
M2AB;N\Q:9*.0DKC2N$D+]!NM9HRK)J9ZU2R2YPV/D3!9I%(\4<E21E&ZTKE.
M.$(=!0].H@=]A/NF;="&=*X<+AO[.P1[L>0D=Y=WK=-/<%&,5E2!^ O+JQ'8
M!-D:2AAW"N$;-"%+W0I% U-<.R-5$\NMV@J&=(_92O".Q>#3G7!5ZX?L,D7S
M<Z]A19%4;)?T&(37L_.+.9SA9\;?5N?28>3<=Y;^%.VUKDIVQ9U9UK<.ZWUV
MD-L?HD?S%/=;\B5U0:&5Z:TT1&D?/ LQ!M&DI'_E=52Y-]F"J=-PLSDJYW5Y
MUGCU9>ZG"W3="K)IZOZU$J5/$"=^L1AGW%'=3]-_7ZYNAXJ.?/7A];OK>^4_
M+F;3SWX"'^;OQ_^\+**$'[]YD*4<S5P9U,NVW 8X9HF5Z ((1YE*009HT]MK
M0#38TUIKZ^6=<LMMO4@:!H_VDM,F[\$9HYXY3IA7G$AFT'[1WI.<!:,(PKDV
MB9;[I;(?R[8;DI0>R*2ZM^!;"++K#OFK'T^[K.SY>%&J=5_."_%@/IZEVV>S
M'%).-A)0&:5?>R#>95I*,J>@,T,?J]U5>MNU#2EQ8TAB/32Q:KY?.K#?_'A2
M2(JK+&?!;0[=[;EQ@]XKZ2&Q1(+W2%V(&H\$6<38>^.DML*W*Q1780%#RD1Y
M"9+?5$ J5IEZE))X/GFA7&1$E29K$BPG@5F-^'(VRDJA=).B,D]@:KC<@P1'
M2E!,A%AJ/G'2O0CVN90?#-RX(*-TNLE)U]1%/&T$N)9$/BSD=3K6'V.[[@1:
MI53*E@!:FUH1&040Z[4G261C54XBMFF/W!/WH&XV3R"@U7E[[&AQ]Q;G;#9!
M3I7W!5]F2S]9O3NH&3!^8I9&,>-=U]6D$'4I.O[;9/9GU3K4MX,V(MDCJ.O=
M+9<)T,O^-L;1?KWZ8U%Z"]]D#[Q"W^/;JC&D$(PSCU96<IX1*1PCH=0/CCYE
M)M";X+E)0XW=(?9ZFW7M4:W;6*S4!L[['H?^VK'R,RR7DXXMJ+=, @N,&$^[
M:A*JU*L PBB><1S-4/#Q.8G:>]9!13(;"<Z=EU;-6%+S<GI>6NJ^@=6?[Z9/
M-D,)Z(0G"*6E@;7%([?$J^A(9$PYGP05;2J\[P=S4-9#8SD[ B/KM7(\+^;V
M_W14^Y!_&T_]-"(%2L7=1?>,=[%J/CGBGCL0,I#,J41TQA ;/"=)0Z9.Z,Q<
M$TV]*\ A!06/)%]->-=0C751FELB=/U?1B:HX*3.A/GD4,6&0*S,@GB3:?2*
M(O F!7]V@[=GP.T'55N]&5>O.]ON[4JW1;UOX]R+8@,@H;@3TFLF23*4$^D@
MD&"1;MPZ'4IQ!!V;7&;77LB>U;Y_"$$]J3 TU)/;DN_?CWT83[J$-)EI8KCO
M=,F(D^4-5 B!EK)V 9+*7K3I4[$GSB$UK3R9XJS'R9H)"M_&B]66>#.[#,M\
M.;GN,#XR5#G)$R.<BU(?SN,&,/C%*97P6XKI-D;>4Z"&U-_R2()4C4>]I:9%
M<9(HA+;..T(ME/J#4:"6I88$P5DT0IE\_ZW.8"K,V!_D!#TU6^O9@W 'S036
M60V;KM$HNA03J$RR W2L3:E+2#4CC%L\Y[U3C#>I)+X+N"%UY#R6V5:;9W6T
MW![6Y'4,$?&O?VF4H[,TI4BR,IWT.Q1\HPB/AB<5=,A![J34>L'8*9I+?R0E
M=CRNM0Z,E#CT*A)X;2$6PE@*&FBT)$4=2JMK30++KNP(;35*CF.M*HGO#'(G
MJ3OBX[43!DGZ,[&.,NON1!?O%@O< )MY?%TKY-6W2SK4NI/:=9V?E-%\C*5]
M9RG;*Y4VQ)4:"Y0[+0UJ7G2/=U)B!TV_DQ@=\2E:<]W5GDFM==8GB##^5C(B
M%J,<HG/!(1E43$0R$8D501$PV4O*( =]S$#N!K2=!$O\(*=B(XY5M-A7'L9C
M-5E,Y)!CSD2G\FJ#2005\7!.3/"4I=>I3=N?9W#M)$-'*P)W+$.]'JOJ'&OK
MN_HWX[+NZ1K8*%*EF%:&F%2NMX*DQ#I9BEN <2Q;9K3>Z=C:.OQ.G/]10NN5
MJ%PW\_^19N..)0=4*J)"$3\=RZTF?E$(-&:)G*5M:K[T[/K^@T6]:[&H7G?>
MM9_W8>WGC5?WXZMK2S8J;P*%R0D]/0U$>@.EX(0G/ @)1@JJV_1\?!K63I)C
M?A MTX!3U2O4%@UXMPJJ#<YP)@7Q(:':$PC,&Q=+Z2/JN9+:M*D<^BBBG63F
M1PE9U^5/0\?HXQQ0#:9KXVF-[M4TW2K*Q8AZ)CPWC"BA/8IVHL1+/$RIY2*9
MP!/W1TK:VP7N3H+F?C!!.P)G6S>DYVB$@Q>!>%H4J&*.!"89;@L97 R*!M<D
MN>7PAO2<_EC&407&'+EUI66:,T!H1@E8!06<[3I)^!23<X:Y5NDE=5I7\A\E
M7;T=WUJ'!5_%.+^$M!D"!V5-9E$1:9TED@(BXR&3; 1$+B7-L56=M-T0[B1:
M/TCTN2W[ZN6F(X[5Y?"=1.>;O.977<+"^?CR?+&Y$WA(+!GMB.:YE*2-D5BE
M'+%X,D?!0(JH6XC:87!WDKL?+3A]!,Y6D\)/L  <YJQDU,,WF,PN"IC.VGL5
M41FC)=CMFB]G?OKE;#Z[_'KVZ^5B/(7%XO7L/(RGW>+^/A\OEX!KS"-J6/%J
M*0$*!E<A-*Y"9^(C!..H\T8WN=*MO9"=)/<'"XF?5!@:'MMOSR\FLRN ]<ND
M3=7/':?614HL,ZXD11=R64NHX-JYS)%<32YD]@&YDRBJ'TL4FS&QSE7-0WCO
MRQ^;H+QBJ,QQX50J@:!<)E9+36+F7$$TW(G=[FV>GVLG ?E! O,MR%]-]5SW
M)RUU2L]+_&2=[D>%"S0PHJDWI59?IP8=X0K=FARY$+E)I&([G)VDY0?+.:_
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M,B1E":,E38YE1ZPTCF1(2BG)(CVYA;730H9TC?7"I+J^H!S]VFMQ2]W\: ]
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M0GQEX-+8BZ5U'O'L8N"_BO^\'"^Z1X]SZ"K=?IE[W";Q>I\L1IK2Y*!TON&
MEH8,BG@6&-$,?'+:^^QW:S94!\\0@C.GEKU3L;>U'MP>1(#%R*NHM>"HHH,I
M1(H:_R8823ZR9%G*ODV_]3UQ#B'8<VK9/ :+3V%9OCN_\.-YT>4EN00!)Z64
M4$&3+'E)AC:1N/(T4T6I(0)CR9S:GKR/>0@]W08NG]59?[RS?!OT3^#+$3 O
M=<TNYK,(BQM?KGO\^0TFLZZ-UCKIT5%IJ;",($MQ95'@+LS.D&*]F-(XE[E8
M[;"O '@('>A.+=&#%9#6:OH1XKZZSM\I9\TECGQUAR8CZZR6G";"'44:*U<*
M!2H@3CL'.6>:HSBBXCYL%;L(OOO!!?_TXG$\Y;YJ?C:>WKEO6W]RO36YM]X
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MO[[V%^.EGY34T96!NMFFXP[\$2O:TT5%#(=$I/*,A&PINNM.<AI8MCMF7]9
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MT=<#;QRPX>H37,SFRS+5^L=]'BWN-4$E,AVPFBI4O-O1N+R+_ ;32UB4??D
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M4I8@$T23#!81FC2<V"$?UNU;LR,Z=)%X QHL^W2>E^=, :.0M'O26,C(CL5
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MRHL\690R6;@^W$7C$E>0<R3"AE"[ Y&5@X(CD59DKM>Q(>AYUPA!O]TFP[J
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M];$,0O Z0XU $#:+I%V3[I$/@3IJSO2FC1:M#=;B\S^FPSF^*V4V$-GZ0AX
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MSS!7JXF3I<5R;9S"2XT(K74:O579D?=>S*-7VT^A\4PG%71H/--%?LT:S^C
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MT]AW3H$V=3SOJ[1\@?S<N%K#I.(\B90#%&,]*$9B=4R06*.T'K7AC+4R0?K
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MLHO2128@E+ PW0*],AF*%5'4.CW%-;&-[B!YMH8>BD/81FT-,BEO #J?0^M
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MIQEP58T^4AB$DLA?3.1)(IEL636L4_U<S&:'Q-Y/,9LN!#N@*B#KP'XN9G/
M5.JI',@F/#@@&N=2 M<I@LF(U>^FW3F7 "SE')C0&=M$HAP4?0^CF,T^V-M%
M_0=0V0)1"73UY%'5?C7.%?#"9C"V,!W( =)RO=NP8ZYLT4FG6U:VZ**0W93
M25)S9#1<-"J"2CZ!-UAO@6NA#^DY<K<61;Y7%FPOUMV6!%@6 G,T0E4[6203
M:BH1P4-#NXX+GJ'&6-AS"9/#<B_Z5.ENB^9<E#%< ^!S"9/M]-JY&L4F2ME+
M"9.L \')&33/9MG:R6L6P7+ZR5(**;:O(OED2IBT)4T77>R[A$EQT3*G T11
ML183P04F0992E(VJILTVXLV3+F'22<?;E##IHJ!]9S6_'H[),!B2(1#FH4RF
M*X*&EK8 DC6P0A+-4I5[!M@T_[BE,&\E%3.+VA&C8\I)A>PKIU S9KUAK'#V
M6%)QSU /_2+CZC)*2*M0" O:246K@'/@K*-% 2U&Q8(RI4F<V5/*%%XT;EM&
M6,\'QD=>3*8]U_": 47&O>?>@97:ZBB=8[Z)P&Z@..X(@2Z<O+?%XT;*:I!4
MNP3SVV2<SO$X%462J$#F(LAJ\[+V_BN **SC==4RI1UYKH \\^=A_FRHL@:F
M\!+/(+ D,W,"G#$T)"XE1.8X<):"YO0JW"YCWB=QGNGR,%TZJ:?!T<S;88C#
MT2(V]6+E"U)YK0(A"J9V&:V-A<@*!\VD\5(KJ523@J!WH3R39Q5YME1;@S+%
MUQ!=6P*#1,FDS9!-J)4G<P&GR%,T@NED&#+ZK3&7GK>N3G3:4'D-TERO@1IH
MVBIYS!*T3#0XH0S$2#\,)[>MR,Q]FV2$:QB>V;,&>SHIJDVZZ&W/>^FHUY3!
M2T_]S9C\]-/EB>AB%[[.?R3;GPPT)8R'G,A<4[KVJ$BIGI!RIP/G,IGU<O3[
M0O3,O0<R1W>L\ 8YHQ_P*Y)P9@,O@K"UG2.+)M54B RTK3LPL@B3@@S:J!;+
MW 6 9YZM6N,V4E&#G,_+G++SG*_9P&69G! %N*ZA3ID >7(X06+6J%"%J)H4
MCKN#Y)D\J\BSG=(:Y'[2V&>S]]-)S1;D7&0C2@96N*6!Z=IU.#M(P=F@<TPJ
MMJF?=87AF3FKF+.IHAJD=2[*,9%W,+D@\U*&YY0>2,Z]$%* Q43.@I6TA3I:
M(0U+&@O3ZO]G[\V:VTB2=<&_,C;O7B?VQ6SF04M5M\:J6KJ2ZK;-?:'%XB%A
MF@)T 5)5.K]^/,!5($AF(C,2(,2S2.)22 __OHQP]_ %F6RR#3THUC.S[MV3
MQH-S2^QR</S[@O/KQG'9:*&852"0&5!)9*#=,=662XD9$8(.;4J#KT5X9M&]
M596[P;2%,8/#W5/EZ=F(40;DD-FZ^9?6X)-WP"QRYQGR[)LT"WPNF]P+PP^1
M5H=2-KG=_ZX11%K6XG2626F7/T!<YYZQ8G.4U@&J&J1.R4%@O !+D26F64FQ
MB8/;6])CSS;N1;?%E+ WN GM)?!ECEL7D5MF).\@\WYRE!NS80CW!D!Y("PL
MNDAR[Q183_:4,D:"8RF#*]I&6:)WO$EPYV#8]TBN\^&3KP^"^R;=V^7Z!'E;
MKKZQNAHE&(O*TAHRH#)Y@XXXXUPH(&S05BN)/C9)"1A%^NF]M^8\&<++44!N
MD/$V465P*4H%8]?%=Z*VH??@LM-@Z/4/3B/:W(3*SSTX]FVV'B#!6M?:]:AQ
M[2+V<P^. Z;22%T,=N'! ?7@* R9X"%"\3K7&34:@J#CS*)Q18J44FA?O+QO
M^AY&#XZ]L+<'_&/WX-A>["]"\<)(,J.$J E19CV5.4&6TA4;;(II@Y#'V4.A
M%S*/]U#HH]:QFV5L]/;8:.AQ*:#%Y*6CC<+RQ$'):L][P<%;++*46NFO.N'>
MY6D_ 0U&5_H>.FL(IEPNN:9$BDBDC1YB(?$$9AZ52$ZJ-D/P?N[.&D.<AC$A
M;9!U_WBM=A<!GSMK#,.U=Y.$74#93V>-R-"KNH,&43=4+2%*G2!(8X*0*F4V
M]8YUP)TUVI*F#Q:3==;X)Y[FLEBN;GHVQ.!S%"Z XD:#\IS$-,Q#"2JFJ+,O
MH4F3]([R'60_C3[(=NJG,0R6%D."^[3]B"2/\5Z1 CCI(RH+43L$EDM*,GO,
MH4G5V)/ORS(ZCT8 Z-ZM:*R^+'_@\A,NZ]BP=6?_U?JS=FJ@<L\G#>MTTD6\
MC98D)<8DLDLL,4ZNK72<>ZV-M"S$%*0Z>5S0@=I;5\G<^L:BO,+E&7'LGV%9
M;XU^):;4XID!W6K&>7 +; 8M?@-*'07S5B1OI%+,"6\"2[0]<INUM27? V5?
M$89MSB_/5[,YKE:W'OC[=?(<,[Q82>]Z*=*"LMR!*TF1,Z5M-CE:S9N<YP\)
M-?0TJE>C8?7Y[?)=6)Y=?G'K.:\QGA$"YU_(;CN163CF44/,M'154P=BB1RL
MT=ISJY)J<QCUD''ZLV@TQFP>0ZV0&3L&6.=]O9F7T\5?J[?G9^N_W\PWW]H3
M+)Z59#D$8UDM%DO@HN1 ^DF!2XP8RF/[9/?''0$-&NEVLL2:U8GUV:>0++AD
M)2BWSN,(M5>P\$6JXHL.TZ7*[*%TH=G6,(;&1[QP7U/U/9[6W)JZ67U_^]><
M#O+/LZ]70\].;%)DOF4'*(,!Q40=).4-V,Q$XAZ3P&[]LQ]\S!% /+(N&P1:
M7Y%O5 <W_GMV]OG5^>IL\0675T7DWT]$T9&K0'L1DH1*.09>2@F&7&R>'4M:
M- F3/2C5$?!B?.TWZ%/R'E=('_CYQ3R_QF]XNEA/D;LYKY;D/M=BNX^?P_SC
M9W+>/WV^4M2KQ9<XFZ]=[7\O9V?D.;PMY<19-$'3 I*U$11'!+)R#""SVGGF
M+)=-4M3&7L@1$7"O&(_8)^5J/1_29\SGI_BV;%'9ZN7W6U]=W*%EHVU $A5S
MO6]/BJPMQSU(:YWFF#AKT\BIKZ!3E:\U8UI39/9=.+9:GMU:X':#[NYW$6L"
MP45.D5?HBBVT.I= 9:,@HJ OM6.&5"Z*Z%)\27+<HB!]M4F_H8+NZTJ]+7L6
M>T!Q1->MRGV?7%?I*1TDZW%;WHEG#XLT[?7XM- NFN(R,7-"U-X8"S'6/IY(
M_J@WDD-213NTEO/099KNP3+FGJOQ@R5,#SC&3@1]];[FJKV9IU_^0:M',@AQ
M&;[B^=DLU82E7\(\DZ\[^X;T8[SZYM5LJ"25L#H"F1",]F.GZC!T00YO4;:4
M8#/OEC8X0(CI[/:Q@5SL 841(\L99R>_XZ=PNK[>^7[Q?L3 )4_T:M@40$7R
M<$F2>H-?#VX54Q!;*D!75Z"L,/WR:?'MO^BC+_85^L?FEK+EL4=MOPQ5\XA!
MQ"K*A117=.\@Q_T&2&_8;S][6DMC, B+$34XX@EP1Q[-I1$I1PBB2I%U@<!9
M :N45MX5E<N6EA<'B.0]%D S(/LH;NPC_-T2TXS^\2*1WBZ.D:LIG5'E&*4F
MW==D*A\*+2TJX$:P[)3@)&RG _K>1TQW_ Y3^6)T?37(.[M]J?!Q&>:KD"Z/
MDML_69-6K:O_F01AZ+RG%0<(P0LZ^95AAI$Y&D2;L&M7$8_Z5&Z,6(,[H=OR
M7+Y 721JF6U_5Z3]I->W O$!K@Q H$%ZP!;)9)*(O'9XT!Y!F2@A)'I'-",I
MO3,BZ$;-G:?AQ"/)\_NC1!_%CVU(7.;KO9F?+?'OQ?S7>IW]=3E;X6_G\_SF
M]W>7IZ3R4F1/'B;*B[(X"RZH.@'8Z1@R^L)E)ZNBV_.FOYD;"LNBK4Z;#X^\
ME; RF_\_"]+B_Z1_UY*V77)G'_BT80FQ7<7<R'*55B0TNC:,Y<H4$YB706 T
M7%H=>3[I)O (VKPA!2X_?:]TJXDD-[6$MR8!#,A='O7YK1 ;JHH-C-$[S7)(
MDK&LO$DQ*30N*Q%#"$S(!S#>09(!6^Z-M?K#^,W;$OU^<U7KF951>0A1TB:1
MK(; 2@$,IOCB> J^6X9FGZ<.BRXO3NE;BUJ@\0U?+.DD_;2^G'U%9^DL7Q9N
MO,>$]./\/\/I.9YXPS1RU,"E5G66(9VG6G'ZPW#'F4V^A$Z+[/_LZ4Z:MMC_
M&%IN"T$#-WC[Q<QUEMT[\@7IZ_ )3WBTAMYS 07)55>1)?#:.3#&:4$'=92I
M2;I_9PF/C5%M(6K@VKP+W]=*^+BX3'VZRM'\42LG(153I,L@$ZE A9C J92A
MCA0KC&PSEYM,+.THW['RJ 4\8Z=-WQ;DQ@QX%;[.SNBOFNPYB^=K[_#5XLN7
MFC273WPF>SY@;>(=+"C!,T19)'B/PH?(1>'= J\[//S8N#()""-&W':5]SU6
M9<_FGRZ^4_5X(KER7!L',:($I4P&KW2"K% 9IXKGFU.XQ^/1%GF>J34.5",F
M=J^7\*_SJL5%^8#A;+68_V/Q#9=5O)>+L,PGY.^:K(N![&KQ46 &?(H"8E N
M>R^82MW2-!Y\S%%R8SS%CCT_\D')UJ<HD?CT^P<\Q50W0VZ=TED@2%;I&5*"
MR$LDC:0D=/ ^:3.<!'<?_//18J#R1QS9^+BLO_Y]1U9:-VDB6^!829UR 3HL
M Z"M<;/@0]#=CIR>#_[YB#)0^0T&-MY7M2BBB%G8!+H6M2FM&#AO"R2OBXHN
M,)DGG(0R89WH(7C5_=0_X@#&KHN_N$9/2K/DA 6ID(/R](?GZ,$REC-'(9SH
M=BO4]8FMJV<FW"::*/D0ZF=>+<[7%U[U)NTZBSI%97V.&KSF"53A=! F(G94
M)B$Y^FA2E]R53MGGVP28.C.E(<2+$54]<@G">_QZODR?PPI??%KB9<CY1Q$O
M[U:["#EV'4MGZ:8O:1D.Y&(J%/9&&965X5D8P%)W6D-GH\OD<:/(Q<A@:"<>
MK8!ESU1YH)9E3TSIH_RQ4U2VW\Y>)E&4["0/M'6B=V0]&Z' B> @"XVLI%#H
M7.YD@CSTE&D+3AJALFBAT@97@;?;+/^^N-6]E)%AE4O,4*?[5KG(HW91@M$J
M:0)%NVV)ZB,T^KI'H..S*4:%H,'LF&UR7<W0ZR!9R\36^T7;3X+K.!!VX,4
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M1<O"A;&BRQ5J;PMUJS3'9WB,I_P&'95OB;-Z,<__6LS#S7=NNVV7!.XB;LN
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ML\G1PE&QX'5FSG3:7QY]U'&2H(&:1\S.O]+$Z\N2WLOFX[<4<]. -,DHI2W
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M/)/:%A<8<TWJI@Z?KH]<]AT\6_L@VX"E?W[XQ^(;+N=5I!_/EZMK*BU<4-&
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M67J];. %N-9U^JQWX'/*H%((T67-GLL>#X5??:":^$K)R>B#EY)V;D&:L"%
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M'1%_/QDF)#-P_K.!S99;0QX"5]S2]5B[.+CL2#UG5X0QXD%+WIXL\&V(GK/
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M*L60Y(KN#FWT^NB9+IR\7>!B&+DGS7K,N=V :?A])5L^RN@%]ZQX4<WPX!E
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MI63Z\*9Y2+X+F%>=DNG%K;VQ^4-(W9S_P5F#'F$LP^^AA"P9"< LB4'DLJ0
ME6^3L59//253C^U]*%P[*'S?.=T$1*1V/G!.A%UOD='$EE G2TX'99,,VY[A
MCF#BKC><.HC4B^JSVB2KZ/GL*3P+/ (M)S.F7%$)@#BO*%&)*0I6"LL;%N&]
MBAN]$O4K9@OVUA]UP?3J"G-[,:I+?>8A5!ZJ,!>8=BJ!)"IZ0:2T9?^?5&67
M5&8V)2:@B_?Y!#G?OS"W.N/[$+?V57ZO5O1LFM[.YGA9H8;[-)O>S7/)&)PV
MMGC/K(PQTV6'F/)$"S":"8\76;=-;+U>^T2J,'NQ:38(C6L79=PJ$"T@MT(I
M&Y.E=.E2@_<<S^OI9I98)QQ^#UFK0@4C.N['[/*ZY\[]^C3=J0-:IQ*O=K:\
M@3R;P[J=\KO_NTFZ\+%7M4D)]CK@5MK/I8!"H&/2(4D:HLU2&6:9=,"U3&QG
MVN^QEPXP-8PFZX#2LE1>EJD@01'G4-8I]3I1H8W+;2JM&TX-.TW;KPW&,$$=
M.OBAJ G#B7>HO45(SK#$A85NNO'_&[Y[2^9I&[[[<+[VO?T TK/=2+57P'@P
MQ*52%YP"WC5&"^*C8LD(QED2G62TUVM?FH"UHWF;"?'W4J,?QSX@O.7E50JU
MW$L_I^-_01IE94RR2A0;!(B$$(E56I(H00=A@[.=W+W>]T$_F"](H@;@4[LV
MG&MRK&ODQ@@NE^61VZG8V[&SL[!8'71D*&@\ 9!B.!&I0B#>*$,L%ZJDZ9-)
M3<8X5L#^ N5O:(XV*(9=-3RB#EXIY@6,#,LF>J\)!X/?2&FF=L9($GC404:K
MO&I2I[.%X_3"TIR7#W6>'LB(!E?@.SB?0UP[7?AK- 0+]:?I[,]"GG^M?CZ2
M-')*0R8%+&(L%[81O%S84D1!];U=Y76$I0NXUR=!U5G6X Y<Y8ANAFR^_>7G
M/]'>BX:'$(Q"1I?NZBSQCI82B.,INIPSAS8)\(?AO#[1J<"6!G?35U@ /O 7
MRO [-.8FL_,"[L/TRWP68;$8*>NR51*%5R?T$EP.))0%JB9YJU/,,E';ILAO
M+Z[7)SXU&55Q&NK*\=R,9/T*DU46>O8)2>$7OSXB3WZN=.(W6"[7=8&C8"6+
MS@L2; KETM5(!$V)4=YP[65DMEM[5Y^WOAYY:<N0^Y*C*K2*E3\#:;TQSR\@
ME9UZ:*"M@&YL-5G2#DJB#R&U1R$'1KRB@F@CP!F@7JC4J'6L [S7(U\-V79?
MN/1Q#=VK>&JATF^S^9O9]&(!BQ)(_3!]_X^+\?+RK$RK7HPR==HR!&9$0,W)
MK4?-J211/AHEHF(V=NST[O2^UR,JK9AP7T[,\2[Z)C!?:JO6R/Z Y:_9[?#I
M**%U!@PL0:^1EIUI);0N2Z&<LDP8KH)M$H3LA.[UR%4[IMV7+'OTD+E"E*OK
M=PWX6C6B]C-EJ8D!R]#R=Q:-?NW0_*=E='W,/.H6TK03T>N3H#K,N2\UKJX^
M*C'X\?2B$&A=N(-TN)><?_\WT@/?/Y[Z^>4J[EH.5J+WL\F*@%?!KY%B(06+
M'P1/&CU.$8$$F=85PS9+YV@;N6MXIM-+;O6X]U.1@ :;,PX9',>8T1Y2)(#F
M)+JWNJPK38;H2)G3U ICVG1X/_-)X$>E7AKSZ=0=AJ6Z[LM\EB[B\O/\&\S_
M&D=8CRES@J'%( DSO,R@+%.HA+5$R" USSHIUR7HU:FV^"$ SVFB8R^&SRH2
MOG*A^16>4C%QA6A39]D%5.U>@YUHAF\V.)Y1][E>B<J#B0!5.<:8'%&9E7EG
MZ*)ZF@-R+FLP$31T<OR>(NOW=!L,Q/D^Q*W=;/#C'(\\72*H/\83-(UF4_CB
M+V]WPZ%_F!V7F;C25B'1ER2^^!@I.J%U]CSQ;J5IC[YJV++R2OR8-2-F@Z$J
M^SMA7;!,!(E6L2]##37+Q'H1RP#*$%#H;4Y-4EU/<I3 4*9 ?=8T'^[<!<RK
MGB30BUM[6\H/(77[20)*6L6E("P7)2; $VM*J)I%*AE72>@FF:BG/DF@'MO[
M4'BP20+"6>Y+AE0%C:!\J7$UP9-,:0B!4R\-[V0(/-E) GVHWFF20!^2-;CN
M=\[(U*4/2I) DR:2EGQW0#-6^61%0JB>-AF?]S2'D!["]8H$;MXNOE)-Z*I8
M*K(CG 57<D":!(YR*;AB6:%+0W,7E?T,!T@,&=*I0/R*%6Y[>V>[8'IU\R-Z
M,:K+&(%#J#S4_ @=>#:11^*3R"CDTJ\W#0CN37#>V*P;[GI\6O,CJC.^#W$'
M7.RFP&;N.%Y,#N\D60YK4Y+$<1 &K I2Y!8W_]->[-:+61T7N_6A=/76T\T@
MB]VS#:3V!OT301)*-Y$*K[D@(9&H)3.&62$C[63+/_ZN9\SD%M1LTDFZ:W")
M"-180VT9A,6)S)H37ZKL@\V9J8"NB&I2Z?#4Y\8<\\77H7:#(-W^M8*,)M1"
M0A5=)(D$!\2A=T-,B!*B8<8JVD(4GL,RQV/$H1[5=YK^M6?(G*6T>HR?W'*!
M*@R,V?O<.M-AND/?'@4#W$4F@J8Y2&>9<S;B16PB1>\.K^11IS<,,/<%-//>
M\T0"I$2D%K3L%,U$<R%L2#SJW.0[;3[WY>-L^O/C^"](ZQ&.U],]OLQG:$,M
M+[],_'3IIZF4L:Y:>_#77\<_?RT_YQ\+6/^E43#)YL0Y<<'',BL^$$=C)AP8
M?D\\>LY9)[NE!IHG6G371X+N6#J#<ZC=VHC%B$/BR1D@EI=V, 4*#7";B6*>
M>1F%]MM-#2]M1T@UX3B*MBVR48>$]$1TW*)81F/1-I-HI05F' DI.C!2\<3:
MY+:?>?GD,?+2FD]/H7SR.B/X.\Q^SOWYKW'TDW4VT'HGN$/\617*>4=\P/]5
M5'LT"IF#+#I(7*?XVDX4SRKJWH?UL]HLJ!QVO3K9;4B;E'X'4+4C[SO1#!]Z
MK\2M62M2#R<'-'*1F"%9E2HS:2GQ67BB-==&41LU=#%0GB+_]P3@!V5_#PHW
M,%,^S:8_-A'"8()D5 >B*1I+4O)(7*D+R!(5GF!.B="D9.86AF%C+96X,JM#
MTIV.1JW0RG]>^/D2YI/+W\93/XWC.]&#'U./?M02MN!T"ZYT?/)QX95#X&\%
M6$P )[WE8(63'&2P+'K DPCJM79\U/\@E:F_LC(."G#U>OX0G'CH*%O\L"XG
M,!H_*&0&Y\%YZD.@WE&##/'0D1_W#U69*QM+<9;W_ODCPI--< S!Y6-(L[T
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MMX3WYR\:MAO\-V?RSSQXER=PY>6>YXAB@L3#X]C-D QMN#4%Z'B@=1U*6*(
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M7+ZUPW:$5!KJ>WWI32^PKBCQ^-EK-@_DY@.3Q F[.=3BAZ(K%(#-"NRRCLQ
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MSOZ& E21TTO<,1IQ2][G[BH/-6%^_+(I>H:3*)?91W2)\N%'J(LGC(]#,U&
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MQ6;QUK"'9K'7(OBAJ2NS&T%^P3%?J1QY0^]]8,!3X'1ED=9C/ZT;5,.XPTZ
M0O?W;F,NC"ME,&EY;V<(KLS,VG;JTY3OOFP>$/FXF+B?[Q$?(0J-. FPK:_B
M<9O7V _0W;;G/:$+I #T':2O&MQ>\Q=&E#/8]JQ?ORIBBRTU8=WPQCGHY=@O
M8!3L$=L%5,!DPF9UL0OK8@Z685-I-B__,(L7N_=;4@"#M(L^+VQ9)5YM0N0:
M?^KQEZ.*I-,>2E]1_F6>ORP*W4P8/Y56%!OP>A87)B.WZG23WC&4%<Y#!./C
M"/>(3[''1+$V%GSD<IRM[9<A"17''M_V<Q>N]ODE%[\#@J?DA-BP7!_,ZZ51
M?\G:=](T5<UP^GG'?T@SV2A!)-B5?28'IXZ-2&-/4)9U1PLE++"J=]<;%MDZ
M]#:PE-P(O/#NW?:+VQ<R6\@U,$E\8@', >^Q-"S@9C#R>TO%S:_R)D/VTVO8
M)/62,^:[,@:_'YF%%N?F\>6-?$!O#.C8!ZC-7$8.40"\]%2/MQ!,'9O0A8==
M669%='',6=MK8-=GON!B99@X:#M5A*+HCX[*W1_XN_<F$2 K"^OV:EXY;GY@
MO<O(WF!V5O+T*>2-I]9%FZU,M5;,GSK3S?=S\M$]NUL!M\7Z/5N.7ZJ\U[OR
M7BWF=)C,-$?P]%@0+3\"TT'W79$:IH[/O9\?Z:&MXU9H4NR?:=/<+7*Z4"C
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M6.O6X?35G05R_BIN.>BHU[<OZ,A[.IVJ5VH+XF%&F+W>OF[1ZQ-M(+O-NK1
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MA:MC7U\PB=RY^%!T<-=C90%_5;6+@*J'TO7^ZAZF"M!<NWXU'4++[S<4 "J
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MB7&?8>@#6K3$4\$[7T,#PMZ-5K>&-S4I%R(SM<X0V7\1Z0AW8398ARRL!+[
M<G(UKI:=32#GE5+2]K/;UQX)--&*_REZ2\\ZYS%=1A:#FFV93""_8K7BE%,3
MU6TVK10V.94"S.54=17/=#^_?KTL5-'J<FZR2;;W=PHP23)(JOEB6:0NPLK[
M P]&!X:U753NQ%O]"W";!=$7(T>7O7X\VF@>=$SH;7*/^.+G^CZ[88$+YH)'
M+,Y9NP51@/@6Y6^;+OQ5X[7!P:\:-_;5(T@RSLN]F:#JQI&=OU-^O^644YW&
MQ)+VE8/1?#X<H=/OWPS,9MXL^+Z=42]:XNL<<[F(P]3.LA;;O#05<90_<H0
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M.BHX02D.93)D]2['1U'N(^3O=K;T'X3-[2MA3WY>XE<DDJ:^%A0\*>K<G_#
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M\(6Y&F+QJ4>'>\^/SS2\RY9O-7@1.I&?VO$Q[':.\/LY[)<03!<Z"]?WF?F
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M2?NO)U'?+!32&E;5P @6'2?0D^H8_^@+%CDU&(V\W]^+3J,[G:]Y8#6A_V]
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MTY2_EUJHO4FR[6_PE[B 1E/8+E:T.3 ,MVJDA0W[YK;\]V[QPS^P4/G[ :$
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M--FU0*(A!V1,?\P%%-?T<E(TGV'+L:RWI'%/3AM&F M8-@U!E\-9V:%K75R
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M\PRUA06UT\<!>9&ZWOV]?3XS8>+$K]HGNYY/9SIJ)R^T/W'I41)!"4TB!;B
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ME)5=:!::8=['3RHT:U\<WI%@@AVU' 9#M&4HR+("K'BRX(_4D;&.]LMQ <F
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M %4K%WS(_C%N0#'KDUL*J?1ZS[7[@.=9AEV7,*X%\]-KS/OU?@7YHN! "-N
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M:V?XTMH7>JU@[6BQX;Y%K(7%W9(8!K-73/GJ4;<S$YDJRKJ_DK(B"E8/PQO
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M?.MA:E5&TWICT@G@ZN;2LV(]OKP/#O'DXWJ$ZO(N'0014C!0:Q:G<"=V-E9
M?T I9Q*,+'+C;&%H@?5(QND_J;"Y(W5VGG6T5X)D@HQTX$W?\R:-ODWM$ 92
M98"N0]+J\FY<(;6R$S(ATZ;KE(D %[';RPZCQ/C3%&@7O6*$EC6"B#2%=O^7
MKOP/.Z"E-KI^HMXLNJ>&GYN? 1A\6TIR4#P!G!VB!! -3@ NCJRP<OCU7*4H
MDY^?N48949Q-XWN?>* H+$*56MMGJF[9__:"Z'VQG07'0PO\S*?B;2*XKQ1,
MAVCT#M5T>T^+(O69*C (]V./($L=\]]8$9Y/M#>Z% ?Z\EON@)CT//[H!/ 1
M*@L&7GUDA:&@N\1%26*A!%AJN[!CA/NGFO*?Y<%B9<\/&1->]<(KC_AAB:,M
M> ZDJPEB/UI+J6MB=V<*9S 7.[GST(&#%#"'75N8@T3W1:(D-$T@L]#(H.H!
MOOY=>_&]PS9=#/M]RU^=DJYQ F>QO=VKF>UQ'U9--S;ZW_C;KO(Y0T=[[!WJ
MOZ<O9F02FF16-C:H^)GEA4,-(E", NFJ 04249S+#A>K]29&A4W6K,R*_QW5
M:4V6C=H!,8)=S,F,E85_;+WK.Z$J"GG8MQJB\IO>C(8SK-N.&2A!;37$#X0$
M7?#>+LU$1"EJ"I U]$_;R2G;LQ]^[WL4<TW)Q>O<ZV>7);]U3X8*R)YNBM_;
M(D=27A\QC\$*36)SA'^D:>="A83DG7W]1 \]^3A8-YE>)"7&E=H[FM(0$(?8
MOJK](<='A"D"23N7[-(1?Q;&."N"Y*'TM!V+UF9X1BG:/0H=SA,OD7YI<&BE
M^[3(=J7FP;3-X[9 L'I$U.RT#OE;8:["WV'=,X[,0"=@Q+0$J3U 6YFTD4X^
M0S=8BC\Q:%CBL%)!;>W3U/'%<*YLH/S;,V%"W8MUH'&",9:B<&0!-Z88?S:4
MUF9--\*0M5/S;U9U%7[;7/B9L'3+\IF(Y\MKUZ=SQULWSD^5'FI /1OL"T>F
M6"LRM/+\!\E@A(>K-Z$:VK%Y&MGV#'ZZ[K^&>[K\\O2+Q(#QF"?CA;=?/U!L
M(42^>V+%$7>';Y>&CFW4""%ZS=IY!!O7DHB1/U0BT5*0FX+2 MMOW"?.2=WN
MXMMB6A<A132C2&,H0#F>R$S:'-]=S7QF;RNQ5J3J=E72BNVEZC-SP92>I403
M=\3O+,XOI,+08X%ZBM-?A"%PRO2]\V5C'])GMIWYX!^N>8:[TKM-L(=UM_SV
M4WE>J6![S'XW@3RV7,PG7T+H1JIYOD@MG=S0+B"AXC1OSZUKH:DW9]F4VOV9
MC^WLP6J54_<%_<S[*X7VRNM)^-<G #8<\PI",GXVOO7YH$=N0^71V4J*&[3*
M^ML-P<"12N+]TC_?S_WVOAFJ-5!7HJMG:760@6U:KTS]3,G5(P,GX^)+QU8(
M3^N"%?!??N<17&K_@4:9Y*W[??N>P96E"RJ!V"(B1+G=U/8FX#Y]8M4F?C<Z
MI3]-NNGE1_9<EV0036I&9RJ#*%_Q->&E^3P+L(#9 A0MW^U\JWZIK9Q-O_X_
MW>>MM+IM9TX 'KW =H((%9D/OTVR7TO!XC@&7,A-O]_'F?Q^DO]6<H>U;U'B
M<Y];OHD:XU3.\.0Z9#MDQ'^ST,<9E.8=2]/V7Z#:@JKP3NM&9."$A@X)U14?
MBE,E9:"X?$\ K+:VW]ZOU#<*O*\'?Y4J_;@1\?'SG68&L0\S@^5XL,F%$X"S
M+J5;-D4Q/&)O'SL5OY/=P(8+@6].T2"MFG=( ]M$/)7'I7.]K%2"E_(&1%>,
MWU\Y,C<VG T%U>J+[Y\ 7@TDRX(R^V J^X2=*GQ/+>EXI[A;XS:P#3WE&SS<
MF4M4HB]$55QR#D1<?="V58OI2+O->D3EW)/C@:>>_A_'4>S63U[ED>.:(#^1
M,YE +LW+(4<J%('6FNE+_1N:( \//^G#*U9DE37CO4_LBV]5=P6=;TM1(LJ#
M6!$,I-$XI#-]F?5G01Q@!\FXOM8OC^VN%COS?0LU>W[MCYCIR+[H* K9HHX0
MHYAW[4%(2E'EC3=S)RE9BQ,KMW>+RB[:C5NMWV KOV:_=JWD&H@4;[267!ZY
MY(%S/0&L[]$\O3N*'^2-HN;Q=_%K4B4V?W!"E+F0(OL6)V<H6<HZL,+SN?5<
MK$[$E1_M *W>$*F_0[VR."EA>_$4W4:+'%CJ&H4'Z;1R;>K@/R/-<8*T]\>G
MK:G/R%T=JR< 88U5;>8!S<#B= G6'UUK#QVKXF_,^DJL^G=>M+#\'OO3JS?
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M<UO:\R +1%TB[24KO<M.:YU6!*_EJ%6V>[[GM8G:9 G_]]06Q-;77E/WO/*
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MWH B"_#-EF>E#TP8%ZJAPO+GGE]E%.M0^8BE3M( E0S!<HA/UI)X4(LSD1R
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M@I)MY7K\<L=[:^Q$L+EMH+6F*TMTMV/T4)T^_2'K1+JQN-\-)G.VT "M@S3
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M'>-^\GFT7M==Q7KTE)Y0T<41$>\X[W=QDPT"8V46D%)5<7T+K\(2PW?)N[/
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MV/E0:=>O/H)5WT;C+YX4<W8+)ML_R36T9CW*7JV%SB;^6,%MU*LQW-[>UTZ
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MME3/KVBFHFWQ/0UPK<F\BD6'^[*_!_SWO2)8'SOTP3?P;%^T/ TPKPZ#6QR
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M'OV;*)>8_<1@8\? K^YA<]O<N&"3R*L24. "R?P[?O-IPL?)3N,INI5.X 8
M?/EP-[3,&]TJJ6?)3 .-9XGJ:B)Z]SU^/N8XN*P_?-7JD0H-4!IT2W0%P#82
MJP<["[TP #M#U/1LD- <RU0T'9'3N<(HF76&KKKNQU4$.-3<0NH6SVPHY8;E
ME)(;W&U^E&Z(D/OW27-U=L'-79?'"G<4B'Y_=3FN_]'?SJ$U*J\TA&ORU,PC
M%@I^="L>![R$D?$MO7:&\MR@8[?C .6 &B6:RWV@.XLDZB,R"03?<B:+[=G0
M_?,$4OY?"]\^Z(.7C<PCC_;OTP"((D^O8-RWQU2VD1$FK,1\#,.)Z7DU)1LQ
M(7(I.6G\DW?KL-MQXK*O/KU !P&+SL$4H2ZCV>.-=WV'#M]PWQK=#A7X:&)X
M<@I2<D#L)EAP5A"SL:N+3XN3VR9$6X"[DP4'*):G)^TW#I8@27LUO<<WUF$-
M1(7'E7CD^WU]-2ZAG)1<#>:]IHLQIZJI9^3ZH9)$P@(Z,I$G5>#:Z.7]*3\!
MJ/L# G_6%Z[S9T0?J8Y;958TYF'JV';[G3U>AXY:<3.LWB\&81R:(.>A/-6C
M(OC&Y#$/I\=,0SKW'CWX^$BS$W-?))R\I"J>-YX@F#(UZSXU-C^WO+%F.TW!
MOGU2)049ZOAAJ,FQE(),!I8L=G)NO:Z;-?)PNE@7QBT$ 02,KP5">4D6L*XC
M*N/H"C$13]1G9^T]G-Y0>?JP\JG#NW1QCS+5+^H[AKN4>2M*' W@? D2R0.U
MYB/P#4[Y=LW>+6K.^?[>?569X<R.%%;Q#S"'P,^RE<^^E\JV_.EEIM"8! 0N
M ;="7#H#RN_%.*U.UP9R[Q?Y39%A> WHWY>*0N6@1*2*>M^-P)1#MTDTKX_+
M"O?AAO5G:T]T&;W4<F)SR>+2V:Q8MX851LON/?FM/7D'WDH"L@,EAU<$Y\/V
M-J#SEY:6JMJ&CM;F.DJ,IAPWMQJK-OW06P<9+?FP?M.JI_#"8=16L:WB-J1+
M</<+U7@/3&;K,$GHQP5NQ3;>J!^R9V[,MI8'CC5F4FJ+;8,.W<9C)L3T/5Z'
M,9)Z5S)?P"Z",1#AOU<V%<$&2?^T'G?$9<]TT@#?4=1>R,_%1AJ $3MR:.!-
MRJ ![C6U.7X;KDI<AR71)YUXO!^""C9#?2[/ *VL2]-C\>+1.M[M7+,#P>3;
M=P>V\^0::OR.W F<,?? 'T&:_X&O?T #!)Y;.J'+1(@[]/N_>>Z^B.8THP&:
M[[]N"/X)(I),+UO1 .T7=-<3KN)"/J$6)ZD53:98OREGZ2(8#9 !,NR:Q3_;
MFCY0]Z14-M)U5#.*:'\BG*+>?X48;#'%'[H<,L^5 'YY?T+9O1519P$JZ?\-
M)#X#7<+6CES?)>L4!]<WS*F_C@/6?CIQ.1O+<B,MU.8Y?,N<)+2!YJC7I,]9
M;G!%9:#WW-DHV8*.B]_^T0V[13V3FJIP[EM:2_9;=39*-1F";W,CRQ' +0KW
M-A+>5E?5LH8)^P'4S9+N<L1'@WS3:EH<Y [*W[JW+WYIMI,Q2H&.&F])"3G4
MFQ:?%.>JYHN:51E=+:R,6*,!F-_ 9M!L*+(YZC6:056B=L,0G<XY8AL6658B
M\) A7?DS,WPMJ=_BQ&UAI867)8@^8!_!9+;EX2RPD1+,M;?B^NK+T>)^O^9%
M%=.5T,TC0J8N'M+!J.I%N-JUN^MB91?+_T02\W^Q]]YQ36WKNG!<*BB*B#2I
M00%I*M([41$041 $0H\(2!,1I!,2!>DE E*D12DB4B)=:4%:$ 2D]]Y[:"$A
M[8:U]MIG[7WWV6?O<_;YOG._^_V1'W..,4GF'._[/L_SCCG*DVU%X_0'G';G
M/0AZ;?* DP#P<E$HRG'B4H]+^;U+.$8MW:_WL&.C7SS<UK30?$V//L_<E7V2
M?RJTW9H]#^7;GOUAGUBAO8KG>)G'HZ$]Z#KA9UY""P!(D?,,?9,K$_0J=FUD
M,MQ3I&SU/,5HPGV[3NJ<+$\I\,:&+N!233ON%3F?)(M5&[FG=JYJ,9+3C2_I
MU-9)@0NYUON:U[S(L[$_>1L7F4Z06+90ZU?RD&%HCKW<GRH7SLEL%:SQDS$6
MMPJW&]D5)\8RF#KB^N?MAH%EV<5?7]4FG$%V@$2N5FX2TMF*H24X0[ ,%7!\
MY4DEB=7&D$\R;DN%/\X'^..LR.5V'T608KR0/'/\_&R%/)PM@.4=?G':==UR
MBK!;+%14>BR\SD5LU]<[L0-1PZ'\)GIHXE6,6T;YD(_K-.TI;? !CN\<#M22
MGD^?G )'# N8KF\PO[AX4Q?:H'EF6UOU.401>H=VG?_22&(N.6_JBI?K*8NG
MDSCQZ)Z&PJ&6J4T]C+?5N'@WCL N!?T<];D4T2CDZT)J]R"K/6F,Y[AG6:ZO
M.C#I'3L'9%$1GH$,N6)P*:@@J!'C0GQ>'/A>]6M.2]9%NR8![J2X8Y%!Z4,C
M?N1Q++)E$,1,X76P$JKNL>L6[BLD[=A)/Q61NO[0/Q_ J9?%0.B:AJ\=SUWF
MXT>8;^'J)JY\B7X5^2BB@<-M OS([$;O?/URIQ;;7L-'#89W8A_K 0\9VL-*
M3_-)I8MYS*\[86;RV]MA;>,!$!=YNX<?^W)%[^@D2CA,X%3@N ]X,207A7W"
M9/16(6J94-,KB+ET7<VA=&EU>Z_%*[ZG9A7'C.^A7,,:3M /" E88F?67]I-
MSY=U]I]?3>X\NULON@FYY3.*,6-J1#&-.<,$^M[W[ [YM4O.IQX+-N(IY>$1
M.98&7M!%;34P"N-"J_ Y4]%<FW>[FP]J<#MGV>&2MQ,@#A=.O[=U^?J$Y[7/
M;.7%;X.=[FWXDS>V,1.OJD2I@"M40"W>M9]S9D7]E!5;?/_28!(\=D]B?1;K
MY'H6;]4[PQX2D[(8^H+XX,;K3>?J"]]X%N24OV#:?F@3-/RZUKJV4B2BD:<\
MR%9:D/5\R.X]7:%9EH] !;Z8:XT\IV-)E^ILMS;7]6<W1R3N?\7:-[B>&1]U
M')0L W/H1@R>NU4?:(GX_@M/;%I\[P)GL[_]6B[QFA7T:.C]/L][OJAR%P.V
MF)F6WLC;N+2\[YS>/"\F18XD/]S+NM888"X8PBT=%^VCW!N]>15<E5!A"1X3
MDU7](-KW#D5?O0P76#+;[0HJ@-::^A]EI@)^KOY8[8,Q-1@WZB?QR'Q"OQ8^
M&.S$KKA*Y;J"OH=XK <BVW>T#@F6>('P\5\!T_-4P/G+=R:6]U\\VRJ[1054
MN8-V!0A@F@V^X4!G58 %/L\-I IC<I_@>LH8*S1.2W[5/=&J(, ?HWC,#7(+
MJMFCFS<=/JQI5Z'F1Z:?()\DY3>M;E_ESU&Y]&A57==9&R1+"V +,O>E3_D/
M^X##5?;M5L=I@>5+ F'7&N!G)U;4Q-^PA-G"2T9G*XRET0)DDC^X.X,-:_5R
M*@"TIL;7_41&1SVPVV0T^T+K^;'1ZV-N8W,#'6QSL\\MO!YM1GR:GP]0F\^=
M\MO]O/N1AJ.BQUGUK?1_^H!;T*-'OU$!QZ"&=;Q]3\I5P8;;!KY@O=MM-PO3
M/S6G\38!GM%K\@QF4 &-K36,5,#-KC#09C((/^^?U.0ZO#B]V5QHQ?B@&<:#
M,.R[\.IZTJGG*HSS@;<?S"MM?!/F[)2VL-M<4\4ZK73Z/,(6)+I_Y[XXIIXW
MGA06^V*%R]A 2_\+,X8_1GS]LQ'>2>8"CZ583*YQ2CFI=CZW=?M3(\_"N*+F
M."B?AYZD$ED_N7L9'T0AT&@@QLA2B\+ BUTU*?<WIP+HG<$5'?OOOX2,W (9
M23VJT\5_QPHT04KWH\XQNNK>@]S:"3)S.BYHKC-'KWP^BTZS_L+K:];?CT5)
M#M;@<[ OR\XEHH^]1YA+KK/<FS%?K#"5W*^@/PT&-7[A&ZT>7'*;+DA\E@LY
MJ>EI<R7M<=G>PAL(@4]^L%C[BV%<I"47%2#8&3^[V(((0K.H\&-];*;')KBW
M+KN+CZZPXW"XXJG/.\?RF<D+ACRVMCQGM?@)],'0&[,N-AIP@(_[JF%5[YX.
MJDPM/#?$M:S]\R^FAG8A?<>"MDDOD-6Q ]!3Y%22WA;1S*N7WU*X<4NG8M7X
M[?E&)O?8P.<"+V ;/JUCFC=0M06[R&!0L>M+KODVTW:IUX-2P:D&?6-'MB5N
M:GJ1LIRNNKO%Z5E)2W^S?19C^2H(953]46[>OF=]8KS';*]G7RKG9M&5JCV@
MH%]MD8_W-_007[M&L9H OORC^O'R&A>5%!7Y"Q?" <?*F^OY 6I/7O&?/EH3
M%3&/=H",_L*HKD,%O**?EJU:RC@?Q>TK46!-5+80!:U,7:=/XA2<FY*VYSF]
M,:MVF03=H@+6K6<BX:<=N#Q_*-WM.>+\SN1<ARB]FETCEIO7_5D8G3\["$SY
M0044=\9B80JT>& .DT6??\T)Y"Y<4\VDWP05O/(7X4G<*O8TAK0GNQTCY[A,
M:T,E=RHFY>%$WZ&57*"+GX)L.U_)"A6 6L$<(5Z@8.35N.MZ:[QG\Y_3Y9QD
M6:ZZG+]C7FF48CV,N9]N.)5VK9ZH&2&^7=,KT[2 #PUKJO6[&NZE]=,:BVU4
MCSMBM3<URI*+A^B^BI)_PX.X.2E)\9R9X.OI+"\T'3[25 (86LM*!+V6W67X
M: 0X?:2>;0\J' KM=V.BI4[P]]LD=5,S5C!J":WOD!E!/H___*\:XU7@RFF2
MKMYP$,5O5Y,YY9= "-TN3-&\WW:#DSY0G*NOW\D@YTIV"K%#U- CERLR2V]#
MS26S#*J>D\YA5E,B$)9]X?FXGAC\HK@2^DB>KN&'Y2Z/-8K6ZL^4/#:%M88(
MD8+?IOJ3%O T,;U,X2!7[%[('M'*+=@_<)F+?"H7)'T[)^W(SS@IMTGA/%1W
M"FF/G N:VU>A6<RR#$T^+[[IHW3/1ESS0,F=S"0@K3-,DY6^P-NP,0,I2@?E
M(D,376+?-?J/.S^G*/PPHV#B$;R]3B^,'I,_:JK!GOMQ_,?5HA<_XEZY?,P^
M./+SC)3VICF\4IB4B@@#K9974F+,4,035,#WJF70WOYS*B!+3$!4*S@[OGS5
M>7'C?5G&0Q0)G;<K1!/J#'[??E\>_CT)6'S%_Z,5<X-F\5'*%BU+^*FU:/7>
M M.8+K@,._\R^9%Y_&+E3_+D3Z;.*C]RJ5!CC=PO:7SKEJ0]D$2'N!C^Z_<G
M9<2RPX40&MO^92^Z"C^.1)+55H9V4RXA=HX9I8C9L8E\J4V>&3-S()1W9WEI
M<IOJGE"-%O*P4NO1C9_QSSG*K O=/9"'#,IV#DXI1$@U#J1SNK)W'^QQ?2I7
MZ(OIL!#?1N%^8CTRSI+?J]SRBG7]Q-KWWE7_(HD*>/,2,PWYE+"-6B=B _4X
M2:KE6U[I1Y+TL;C99Q^EK+J+OU !]>?I<,<[ D+I'S/7+\1&:SGT6:#E/Y&,
MZNSI[#4&&BLJS3*BB0(^!Z PX!&H+"A%L*K7FM+^E;=_^@@89#@$Y\+=(363
M(R@JS=AXS&:V,PO!BGLP0ETFZEE%;U#8O%KD=V,</Q7 "$O+I[O?YL[$'S$_
M$U7D^]A&UM7=I0VD.OA]>=];IOX1^\7 C;)'W1ILV\*9 B*>8O52L8$GI@9;
MX.?AUOFKJ/ J<!B,VPKSSFS<LB I-I26P#W^HERSY!8(1GQ1XK$)VB;')3%K
MR\0*?MS&1"\5G+KJR\E;:@!&)2XDUWS(R@M)*"KH[0<9$>"Q'1 F/68VSL*(
M$9>""C//PII] ZL.UCN(YR)'YA\"KMY\<40X@TXQ7\98/JH&DH,_U<@5@RZT
M*/R0:LV<8LJ-XF73\A(&G)E[:65K(U:J'U'M:C>>SO@QOQ;QF@J8RE93B^$%
M-O*=#KEOGV'<?U6 ]Z:(PVQ77QERO\.&EK?*0;D%4Y(B:XPN/CJ?B;@7'+;R
M _K]6D @AI9K@MNI #8U?B<T=YVPD]+NY]9]LX3ZB)X.M4>QBT_T)?):Z+\*
M[J/Z(#0&-H/RXO4R\;X)\+)? C+)?8N>C=ND_5,-"#LV(ONSQ!N-;[8': 'X
M (Y.@7C%JMDS0A_+&5%^P*>3"!FQ&JS@6>'>]-"&=A;/F9=R:N8^;W<V8/JD
MKGDKC(5$0X#@R-+.I$+CN!H'N;^58DLQ&@>OI:F&^D#K.":L]B<KIVUV+&9*
M"J,2*F*07E1 &$UQ[8:&_:LZC X_ST <!7>KC!)^<F[;B<"B0,VTP#6R(L^D
M"Q.=K]>6'952L@--\"#ZP"]VIP;G>?1#/;8B*K51S8X$$S+]A8)/UNEJQ?"@
M05(#S<'#(2=51+>>:U$ZMS1CS[R+8(I7D],[HCK[&MK>RN.A,,>U)H**SS'+
M.?GI3?:L4*F9]%(.FVR[D(=O92058(\\BA^<7@\-0NV^LI36K63'L=R\.6;V
M\,A7P6_*,4<46VW:CT)8?8CUDQQ4@$WRGAUVX*NG?)"G1#Q1L_^HH.W4+TO/
MY]I_TO/Z--H^A+TVY!B0.TA(PR4E;EF:=88H/GQ[-#M"DZ$DXX1 ,2J[#1_$
M_.)INMVZH_9XBUG^Q#ZX%KG;>5GS#%LYHEJH5&M1?HTR24<"3CLCPOE4!N'3
MPENVX-,V/Q]'E85+"H8,8?9_P/:3,8\2OQ&*S;8MH$;D:I6;CU[)AZ@!1^\<
M#=@LU0K*T*.;N:_\C$YKC#&^A]*-_.P;752CA1VX,GO)E*2R'J=ZKYJOKLYT
ML:C'QVR[UAR7B ^>)9]2QYO;IM@' @3N5?L_D]ES/Y]G>I+_YA=BVY?O8TJ\
MY0?!G ]^3.)B+&65$(6:Z.= $2%7+7RMWB]W#$'/+<U4DT9@3_;7(;@D+&0-
MD[4$821Q)<&4:WH7SEJ@1^1/5-XVTSASA/&2R8N(:U^_*1X#%JP]#=Y+J&W#
M7!:7<>:/\1"].&=_.O>UIB]]#A3LG$62)(>6):,\306V<ILY,R=/BR)VW;6,
M.J%OUFL"U^-?'.'7P!JWSVRVH,*57)N1K*O1TWH,R[8=9U_[>FV;>\8I9-H@
MKKRQSGF^Y-[L@_\!>Q#2K.]3)>466.TI[-\?3S'!H2&JZ0C=F(L>\VMS1>.U
M_3APJMH4BAU/)C[P,9^RS!JYW6BZI5QDW7-ES$Y*BNOQ8KM56L!L[,NHV%DD
M-^C)NE;3R"")!GKT5S[TRYHGR:T7J#-[V71./TT^H&Q] 9RCURSL>@$JED6%
M;@IL09KR.)JLA-]&8X8NP95.V-K$]11WI5_R6YS_#O(/LH(!A1OG=Q.EE9Z*
MKG(YSR:AME&8WJ*=ILZR=)6KM?/=\%25]F_PXVH"E"$K_J 6(//>J6CN!J1?
MSXG!=@E._O6*L+F+K^DWN15G-W<01:X@>RK@EW&2='R]]OMFQVF,R(*XN[&>
MY.V+ZL(3$MLO3.)N3VTU^YT_<IV6()OMN!%PXIP*_J#QWM#&\TM9+LC4'6*!
MJ]9)W3CHQ(Y_9=\W+/@%+5E958^\C9V(=\EVI F^=F7/^4[)KT.DSB&@;[C:
M7JT&VTZ_F&Y!VHIR9;5_>KA(OM [<"E)LE@.QAK<^NU+; [9"]'MC'&Y8EM;
M%3)QH4K;XB+"_9GXDHM:A\PJM[\)94ZRP 9['E4Q?5<Y\:+G1+<Q 8T_07C*
M7Y"ER6J\/KEQF09 ![[8E__1?C$+2)*:#26/GF(Q2<9H_>$8DN(!'J(%^S0Z
M:0N^X&?5PHOHZ<)#,60#)M)7-#$&\8=CM,Q2%A'$2$+3T.$:[MH:+!'>N !:
M>0V?[Z "QCS^>.))R-4 #N-=YTD00FAQJ,UN*05(XRU#6C)SU94RF_479Z@.
M)1%*5R-<8H8*^*$:I0S,06()B(-L(.$Y?)\7^(=CF&.W%@[&38!S4*S7K(?(
MEZF T!_P?IJ_M:=2 5^6_O)T=4<W E2*G6S'HW>8;,Y@ENW__4;0)R-#*)!F
M*B#9_[P72 <TO0/<NPW:7J "-I3^XH34FXE8(\EO4R1(C4.-Q0>F5 !3,A7P
MZ085D"1/!;AU_]7YX$(Z*_Q/S<MWV+H?:&EN6SAK/I3O=,&U&UORQ^!3O-X4
M9O)'%<X9Q"L0MKB<<Q8[D5@JPR'G_N.I8$6:_-G 3Z>C;AB?OW\G;>HYXKO3
M+O 5C/\GO S8,"&;LBUQ?)6E8?"!Z9USYJ(_8WG;YJXIJU=]%G./DVR9MX!V
M!C1^L6AX9?<XC7>W_PLY&S4P@I+Q^QH S^O8#B@B0M[O[C=UX45V$0LC/J<:
MZTR69*\\F:\Z>Z<^%+#XVK2K"H>Z^'D [L@4?0[N[#B8<:VF(ME5>\TNKJ6C
M@@IX;GT[_)C7HL! W0 >0KQ(NH+W^CPQM+0Z(UY*;"WG=1Q8KTAC$WE_RX;G
M;-O;?90+JL.NB=/8I#;#*.@>%2"S!_=";5F%=@?H,4,L-'1\!;8/!F<QF,D7
M!Z^<49:KD:P(9*G/IPF=L%S,_1+M'9L,:"7;!I()-)4UHHJ-&&VIX_[2>ZF>
M,2#[2\JYX;GDM! -3)8BJMB346W0N#2E\V"$NUT[R;9BGSE<P'/73N!8@/,W
MR@5*X^0IDD=/E^.'>]/.^Y<GO"+Y8Z1N3YTW.=\0-/P+V8$RVKH#\I9J\%>$
MRX",<BEC0*/FZ;WW!JNE%'3K[N01J!U6JPG?7R,YXP(R>A,X::<M9P%0BC\U
M<UVU;= >DI:A=M@_B"<V],@.!GMR@]AN<!YGYE[S?KC7.>B2YJ\=OVPQ$$G4
MAKKA3WW4^K :OR)U<2Y:N=D+=6FK5US@T;VLBL'1.Q;BP9@B*)*#"SF>&$>I
M?11*?F\0DYSBXEN(1KT]L"]82O$.VQTN6S>C&;YW$:#C[,O0SOJ")[JM/JB5
M'GEG.QE-$UQ!/U=N$J#,#O:,:&<+W6Y[RE=..9O1I^)-*LI4P''1'MO>+MQ^
MD 1_G2& 5VE9*$83(WR&]5V7:RK?WNPD.]I9(@Q8IK$+8\-VIKME+7MG-U5I
M)G;(]B]HB0N^^*4]BO3IEZGTT>*4*'1(Z8J1D,[;GZ$C2;()Z/5!U)Y78(4R
MO4B>>?JN,14@O02*GJQ("E8[N[P^[1IJG,A5D?^D[DZJX:D/0_ 2N8>W&XEY
MP9SS)0S(5!@OZ1P^E6CA\YZD7009N_16P"6UB2L.*>%@D[P^>YXQJ'K^WL=<
M_@1!^S$:9DT.<0UJ.5OZSX"3X'[9VARAT\]^:OHA5#$'#4Q8B7:,T+?F@ 1G
M9\;H KF!GQA75X83LR%"#&'O'HJ]K ><?@B^]V11HE5 C%-J\1-%K&1P8Y,
M#PN;=K;ARA"_O1M!AN<?\,@W %]26/!"[VD_AW_::-MS!%=X<Y;IN;N6-]1C
M5S^84X$G;;]/'Y(&1H%9]/L+A4551\?V!4[T1D09O=;7\.W"H**Y[.LG0_?]
M]I9-4<AKRSC!J;%.K3;0.*\)[FC?"RL@$YC-6$:D93N^Y.;ADE'N7K=G*6*4
M226]M:ZMDV7BKB>8SJ_H.*&>7US)[';A[+SELVT[UNQ5^82.]SE&\:_!9I$C
M3':5"F!U3CJHRWLVZ!>]V^7F)KWG;1,'MTK_% S7M?-EYY9H4#_3/V)6ZQD
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M9IC"6;Z9,7:]?>?0RUZ=(4>X6A2B2?\)TTI?S:[RXD-5"4^F;Z><S+E]]I*
M)$)M;(;TN<]E:0>[J@L8RBD.=J0]8P&(OJ*9X9@^%7!2WIKV7)Z@O^K5VLUV
M'[ML$&6=N0-?@'DLM^BN_UT<,/HS'-;^SR.P_PEX[+D!+ &N4P$T&C7:$C?
M(DG\<&PD&:&=9$BTQV%&]M=2SM?49MSRZ4I/'Z;PV*0A6FC$2SG)1 4("\]
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MGFNUFC"SE4_XUQ\NK.N9T9FUS]-^.WC!K:'LD.7PCJY;EV8WD2-E#RHBY"(
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MQV#+IB8NK=\UQ[>C)/4XZ>]XVF=&5NZ184?6DTIR#4:Z[/9I7H(-8#L(G9'
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MM&-A[;Q5?$_M(03'+X'G5,YJGCQM<CS,YN'2G;+^@K5!Y*-QH^\GM:Q<:@Z
M&1[@%;H<FF&=L/(AGCZ[KJ>@UZJ^8M..W:P$.D5\#SP:A7E27+*.N6X94%^(
M#D/2N*0!.#HZS;O8Q/0*-W! 'VU]VM3FI4N*SHOJZ/(YG>V-)UMB<]MG%O0C
MVDR&>RWV'&7/$$?[3QJ6O7$2AVP0N]KNB"^C\,+!:0?P]=PI?_/DC(F%D[(G
M<B(TQ%K;[9XQQ X%GD#]W$1 *G73L:!97"2VRQAK.U(>D\M8$.?TTZH(3R)P
M75/KM&F<0I%V.;OTK*)H>N;3@YP[*IU.J^:>SKN7<NQU#>Y!Q=9(8!IUH)^B
MCOI <";X=2QZ5CY$1=D%^!8NF!(2^GBFA_OM>X;VB]/G-4V4Z2[HWJ;G%$06
MP.V!(Y$4KJ-3,:4TT<Z,7 .N+1>]IW00X2/0KDM"\6KV;Y([UP)ZH[R+M!_+
M-9(?7ZLQVBP:(&&4XJ(RWSS-<5;;M%0S!IT407VN$X4-(K$#\#*.;\Y=>%IR
M-LU&:1Y8?S],SL%U*?^H?K&H9NCO5CJIB$*#GB!&Q2F<$A1F"#X;-"U&&2/J
MD9HHF#E?*PA9,MX+VO7$IL[9=&:EU[ OC]A3E[2^N% .+(M'ED8]78=WD1!-
M7.)+KB,2LUXY1%>2"[:C$S$M_7ZE4F[@@+<H38(RN-#ZV+T THYP^/%%Y1F'
M(NK+>@T]5H)RLAJ[?WM !6P-C"#!_4">;CC;E.V9^W140*EX^N=;J9_-^5]?
M%PK_I3Q#M">7TS ZY\HYLQA/1=OW;%[]9*;O3N)[W(T@K!$330.PE+-C%YM<
M0]:S\4^QA$LSOEG]+@WQ41VG;KVZJK1^)B ?0P6X=@VA;N+-,T=(^GCG,KSX
M_3A)W]Q&X52V]V^.LOZL5 S^?O18>DX24!Q0S&.1I=!2H^A;IKL/7E,P7$@2
MZ-%JE &O[)/.S5+N"6/@..XZFJX1=R*]+PH;6&@R?.\:K#%)HM'9B^6N=/GA
M\OWC; =HX@UXFZ@*B IXR'N4I@)'P1U(K-[F$%H73_:$S^IQ^P;5']R:N&F:
M3].\9<(,G EI9XUECKMKGKP2%<75J?!QI" W,_=2W:HS/IGHN9:E7W@ Y.R&
MY%E=I<%4"E0,+P"#BF(KI\?\!B)M!&[NRYUKSAF64RJ[\.@Y?R?LL='WN7-G
M]'1R1TCTM.L3?:2-V/W I(N39Y]8G]GGN^6VPIZ-+3+U^1KD?4S^[JZFF#-3
MD:$^+B9^;G-@(M@?3%?[J9P"]R5<T/"89%'C<P:>) 44^:A;A3_J+XM,K$BU
M%@+RY.>I&KW)/[K4\#5E-TND4\S-^^ZR8^YC&E_?_[5C ^V*GDH#;3\&_>'U
MP/^>%-98C.)/#>[:7Q68TNHIT]> OE_\?5,#X%GX89? *%2>ICM<*BFQ$^ Y
M2UC5WR@,"#&E;-2:+EM3:-F5>+_2S?]P2VJR**U9Y.$=IK2,&4(9'_P"%2>7
MU,@3;T,=M[2^H<Z2E&,4UJUPXX^KON@0G<LK7V<18LMT2OEMF5(S_A=O;QX/
MY=O^C4][H;0AZU1($2I;LDR;A#25$&(2A<0D.V.NTF(GA$+F(R3$),LDS&1/
MRAIC'XPUAAG+N)B9:WZ7S_VY[^_G_CWW\WV>?[[/'^/%>9F9ZSK/8WF_C_,X
MCE-ML()[0='+U3CRP,_O+TFEB:8\JK9\Z-A#-^=D#+Z!KB$RBRQ-JF(H#6$9
M(B. D//I=Z%"EHD/U$2/&1ZUYU:DI=_X*-[8N]E(F_@'#"_C45N 87DPHP!W
MMO*)=U*(,KG1<>:DEF?PMBV=MW<(\[RM!T^&F@@O12=2N,*4<_<6V,?)')MF
M/H*IH2_TEG(%_H@/A&U#+*U'W",L],5= ]NUZPG^'IO%'4M>S3XWK<G]\!H&
M;K9Y"ZY?D?/Z?EBHVH*VJN%RJU!0?"_#*1"E.F45GH]V,NBR[M%:]N(*22@M
MZ["_\O(=>"^] "%:T_!=UGGKSE^ELQ%XY4L'1&Y\_(&FZ'SQZ,C'+7,"<1I,
M5+UPCZ4I./;6V25].LT@\8^BK=>.S"K/6NVLTQ^43OIQ35(N*G-#L&M+]FOM
M]XT=Q39CE:N4_4_[L_8UVJ1@8U=<#?!$'"P@+XU_ VS5:=2JN>=-&G=7"V1
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MZ@V$MK$3!Q68LSF9?GR$T4<Q$Y?<[LK*#CNK4='K#[*7V_(0'C&#',LD? ?
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M/\_)([YN/=2KV=YFC4AQ[C,Q0/SYQ^EM:W[RRGJW##?EO7]="$#/?%_+315
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M\-A9-;0]-S-6I/#7]+4$1:,R$Q.;A1/Y4&O"J: .BJM.FCCSZM$]D$ E7GV
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M4^%3ZFL_$6Y[?Z_UH7F_UG9FK07-_]C0GP0P!KK4]%\$L(3C_1<!5 ,#_TD
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M0R7.@_8_^(@JF=*8O;BK6ZWB9THEK9YODYRH7^L"Q9TBMJ% V7)AT A24+E
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MB!<SK:S36+P;4"+XZ>,CQ737)4J0WC2Y/ALD5K[VQBS&HEZ QQJRQ9BSR>R
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M]W2F)BB0I"%;L:,8U)GPB#GJUW11\U+T,WB8T52M?9UALBEYSU.F3,JC6WN
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M/.[EYX'\:8AR0\(,DXS,),KJ85_(*I-Q>2GNHGZ0#66'DE* CPUIULB7$PG
M3A!CR5;36$F+M)>[O>>B:CZHD.?^@C=-+5<8WR(%C_>Q :&J%JJ&68&))B-^
M% SU!=_A3-X5>+)P^"ISYG10T0+/[/C'?3<#HSR'[,WB:22J<$A->>/>PT5F
M(ZL!L/QSBBV3;(>S$7FP$:W'@(MXGS;HU:',>T/$.X+*3X8-&>5F3,Z^91N+
MZGCPC<W/!*0+105);+]1OTID&)9;@0[E@_!"NI44"H-_$.NY?L)A_"$)MXI1
M4_-H/:+M2<FK\P#K@ =S[DS1N5R)T?LEH[O-(8Z.W"%^3D2WY4W]$_D!@C3L
M)W4KZLC,/55>R/@^+K+/0&_+6-,-NN$N,2V"(&;0[*E+XU]28BH0WG*>5JME
M1O@;N7>B F=:5[&;D]8C'KF^V]&;)]H=*%1LC9%J03 1=<NQS*@(.<0F)XQ^
M=;O0#8Q[G4U0*PM>O;&16QH;E;AI2R&FLV<HCO]W?-0QP&83MA=[<0UF!S]D
M!+K$$2Z#@8EF0W 1.Y9K6_,P,>32&#]ZWK,LDK"02!Q(^OJU1%[LAX3$U>2U
MM0"+[% FR1T5+M'"6!W^V5.VI#Q8,Q#A0FNB%W4_8FYL^+;H!69)J8W9]Z=E
M>PUO^*FWW\:5H'!J++SGR1>)9OBU<;.CE#<0Y:O#OLPU<4%6OQY>CKG)_6.7
M$76J ^IVF&>#_X!&,096X',>8 4+GJ.E9/ML#/2J=^>?+#QYZOW"G^:%RN,2
M4U&#G#S=GN0)L(U58\)(;LGVZ/MNDX:<,O_]*G)4W@QX#54^T&9#W6++AY4L
MF+-NE-+";"[X<WQ.&>!BF-(7[(NT\V>X 98_[VA\X_LR\_XRD;%UECK.HP$X
M#V?1^;1)F?E(5;YG=I]M@\M^D;[X!V<I/$M+?&>7<E%I_5X3?K4$<N*[N>%Q
MAHR]X/U->M-O(XZC"\W)6]=\/+%R$;RR+WH_9Q@,&O*GS@)GTX$[3/BN8\!C
MB8-=JSFX\5?,S_?]71WK8]Z@[8"1:B>'1=%(AJF9.%1_RC[JQP">9O88@*3"
MV9*R(B*(BK.;RF#>M2#Q.%),H<V4_J4JQP/678:Y!Y<'$ZC?TW/3N2_%,;ES
MQ$6IVA2MU86^D?<P.'(O"@N[P>'*+S[W %;1"3"GF"[,/?"A"BT?N3D%=20\
MAOB9=W>X >B%A:&W<O/N%DT3U49HEU*<G\KR3@G(''K?H&SB;J6]Z?@?Y^K<
M'N#D!8P+$>*,'I(["55DO:6>/*$>T]S"=WSK?A/+^  E&RK<!?PAVH:'UF!@
M;FS#OUQRSWJJQUJG=)MI^.O+E0?FL?BI[QG7\6 T30Q-.X?\4EC1[8--J2SI
M)IE;=ID->=279.@?NVMU' -851VQG.U]:-B5P#BCT4J$7 _S:,HEVMK^6Z]/
MGW&CO_6>JC)8PP,=A4"6X\2Q'\F2;]<R%/$V$HUCX8U 1<;)>^U6(@ZJM2TZ
M70OOHC]^3%@T;F0C6"4OFC7"LSTG$-:*):_';HKD]UBOPM0SH9U]=5+?0;R!
M<<W* 5&^F;0V;JDL.044SQ*I[X3M$Y]X;DG,#;'HAIK:I[^?+PXXFJ!8F_76
MHTO(=E1KT8CS):A[<?%T<1LA."O6[&WFHUKXIR8FHM.8.C4E))'W]"L^VUZ%
M>(YVW>OA[ M)'5NX;VNZ9\?QX]2&-CRQZ2+Q(=;Y)5DQ\'F[0BKNTU$%,KVF
M(<,ZS[DQYO-];&];PEKKU:V!55/VB6(SW]5)_LWB_2'U]:9C0'B$8E5J]KJ.
M2VV3FXP;V?K9.NQNKZ5NZ9E'L>?ES >!U9UA3R"\!,M 7(]!J(J[95[X0?=K
MN[M]9[Q_>&UM=6+AF45NS,&-PF.5M0G.OCG=QX"2ND_P*3!>"$C\ &]%$5[#
M5CN6$ SNN"GRA8%C@* [YH",YCWRJH4+*1T# DZ2O\1_)W_E4]S8W7]/_J*X
M,Z'5L*Z:P'_/\Q(E>?S-(.%AWDGRU^B?R5_??/^1N_K[+SCK&'!F&\N3,WLB
MK37(L17OA=,WU\>DV5H]?&*^LQCCY.#Q]>+'RW3G*5ZK%+R"@JX#I'_*'"_R
M].[)/J_:*X)=J*@. B,Y4)M&9]\WV#XF=M4X>')%+YCSR)[H S)_'34Q/\C*
M@SWCHB>JVN,H?G1V&"6HL5$Y47]8;G#C$9HX'ROB1VMROP8M?'V:?T3%]X%1
MEW@@( #=].H8$+9*4(4-?3L&+-T:A>$C-V".@B.4=6?%-V)W1G2J4VR&'..T
M,0N*O$TVZN[AIJY0<(.I4S35:)@74;/,."\BNE!4%8&G*ZY(&&J<$DM+\FZW
MK$I9+DEG061]MZ P*1FX9O4@Z!6(KB1AYH_=TP]!R+L*TA_9,A[-$I@'*@,#
MWJA*%^$5']8-56[*;&N-%5L[X,P'*XP[O.*3'IW_<37N_NUB-7MT0!3Q-GH;
MK^M'S^@V8<N_JSHVQK-C6*$Y^>/G[")@@Q7@WQZLCU6Q@B'!.,$(-.AUPDW5
MX%E]6S6Z=8O)-_*<-Q6>,%P9>WDO0JBN=OY949+NJ(=HLFM%15.*OXW?^#2K
M5X%2EZ9-T"%RN5O]/(;^-5D@,)2;L04IL-58V->-_-GB\*@64&X?9A2?K$2E
MFHJSL<:=PE-F>M7'C967SG,AE'^FQS78U4>:9TA+5H7WT>>)O,#E=HZXC4R"
M %%AB,@HNT(6Q,>['<U4HCGO+DX_ UR+G+E)W?M"O%#FL[V[_7;JX=V68\ 5
MB,DL@D'JM9S4Y34KLRK>7L7Q:LFRVGZH3^9'GKDR>LB8:));MVUWE^!XX8&[
MUIBE[<K[;N_(U*IZ*:EA<IB^;(M5!QS=8WC)^J>N_'K1Z$C.M\S+7;AP+[:8
MZK>7MY142F/Q13QJ&)YZ3&<[,B6,J&]/2BM9[2^=MCH<ZEDLO?\='//!\!+]
MF7VX]2!4QAW%C7"7BK 5PXI;08(:ZI82P6*NXU&>98<^'5F_Z"P'_(4&+P$
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M\3DW>SQ]H0N5L;E)9Z]J7JWFCC\3=-,]\D"&=CH;CR$(I1![VC]V5NCG^+R
MY#@/I%Z1#(3G:L$&9JQMP*0@\OKL.JA]O&-J=S&BJLA'!I7_H?*][F7PL\SW
M$E=T[@8J\YS)M<1?$A\3=89D[%"5J'R1W_"%AHBSUKMDTT,X7"N.41XJ>#N
ML1?<;7TD6[#U'=%292C+N>H:J2D+R\_G/WF?T>7C6[6V%3F,ALN3=6P'*F/
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M"^KS-<4KO]--/];S*554K,YVBJ6%)YD7F5FC6K$ .;B/N(W1/[((JD'O%#!
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MQ;,S<\*9T)+>MO$B:[BUV@36B5H,;](<5Z[J1?E#C+9K?FX9_4'2'D#6->F
MYPC:4!TJ7>,B[!K1NQ/*E1_6R)=E5++2*_#P642\PGW;DBT5,ZTEV?:S'U0_
M2*Z"R&)&[TIH5WR42,&$6*0KLW=JYSOV#+;VG'V]P8"O3.DOUA?5+5@PH*@#
MWK6)V0#3&>\6.D!U_.^M&J)W]+7H#M\"PR]%+4"/"+>V.!,6"X<:<\QYDYO@
M!#U<+*HK8-/^[]?>]>MW/9)1-0W IN:HQ;(M[W /@7Y6IY1Q[2^7>4=-*KE8
MG3Z5"+.SG^*\_RLF>.IQI'<H5:&0W&9;/N!Q6V/.? 3UXKSUV+CVBWB+VX'
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MO.$*.7M:W1]<!Y_$<3?*$*-(0<.-^K-L1A3(_=3N4>YZBGJI_>#-[XK=A9/
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MF0_0KOE<WS(@U7C5)U[84RS[<"IV1>*SXH,O,^\2.O5*WMYBT% Z(,J6BVR
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MP[A()5DI7&#^;XUK/GYN!M6HKTX7NN.$?&Z4_ZQ]XWGF"5.G@<L2NCPN$.1
M8>WU)KTGVB*E\!.WR@EBH9OMX]%;Y1_R+!Z^ 2PR7_K,)!-=!$-HN:N:YPKI
MF!J2L)M-S5Z\-]+VD%/Y^YG[%&'J6\)F*RC<;SXLLC@_878QJG*_TL;V,FSL
M<I!1G<3XE[J''[P"W_ZZ\_-X_:$_[?00D<-LY,1BFU,O%UXF6#J]*K.) <V6
MBB[X;"=-O?WA>;HA?Q9RW1BL*I-AEK>V[C"B@1UQ*AJ=[1YRD<9B%ZMHFUW
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M]OL8F<LW+MEC[=5T) O8-Z?G;>A"H@8@K!]3!$@<HS*-($(8*7%$OJ?NNX(
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M!0&Z<X$2J9#0W0#W)U%:0QY%4YJ6R9IG_3R+&WK>;IV=9W[->N&BNITZ/T6
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MT.SO<#DRPTY7/K+3.WXD.M>._B]U.."_U>%RT#/9P"U?R#G$OUP0JM%:K71
MP] .Y..Z*9GWB[$6S\CSUDC)83@W[1>(NUGI<8__#/HD[C7I?$;>;J::D]?3
MM^;VGS]>C)W5%6YZF'M1VE'MBIZ>:M>?K178S2Y762U.^?B&$_?OZ-]2!["X
MVR81[4B.Y#2"QC1KG(#/O3WMBL_5HC.O-J3VA"+M(S*8! 4E+J<+20XSJG4F
MZ%359CBP4BFL4<LN1SI[=O.LK8Y[X:3Z@'BUC."TYANOLXLPQ _V6PF1<4Y&
M8_4%^3RC"YZO_55=G*HS'=[[5,Q"8F G[*&^>"C+ZK1@92U"6B#&^F'FJ(H
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MC1]\DM V[,JTU_(\TDWF)*/FE,+S?C=>RD6\>5TZWN5'8N#SR+/W0C05EVW
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M#4O0#T2WO9'#2&4H/&I?/C3_1'^/ZEC,R:T':]\<K\1-N;(6EHF)B3ZU&F0
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M8ZFLOH]Y"SL.ZS^?@#_R+2B<SCW XU(65''?I3\_4CY_6\Y?X*?$[&5W^=Z
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M7PN+"[D!FC/;A7Q8<7R84?C=JZ3)7Y,!(,V2%XO=0+S*"9'H<W_SOE G>OW
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M\)YMEAO5$@^JL"4Z4R7X9R5&2Z'Z2\$QA4T+"%>]#<M[FW8!K0)XR'/ZS[3
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M?CS"G1*+KPC&_]-[U,2I"/86@3W:BM;7)B_?DNMKH3, %#[(^7]KTO>\_^2
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M_HZ^QI,O8G419= !U!EO4+00K*UICF-/]_(HK]B4"=6M*>!52C7\DJ&#X,G
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MG[85*_[T-<YHJ$C#V*:G< 0L,[YIBC3RD<Z$?HT%6^PJV+>0G3+6Q#]"ND*
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M>2$MD+6 <E#U9H=XF"Z(:%^(8P!8[)T#O5PM;WDX),G_>28S\@N'I.+:ZR3
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MP,'(BS_.A]R=6\Q@>[KP+49X1_^)/_UA]\E $4X2(@PJ[5_#A!'1R>V!+)'
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M;M#=D!;N8%U4DZ\9L_&!OOA"1H;7&U%*&Y1GDKH-+5);AQ [LNKA/%N-@Z=
MFI*7GYN'_ 5!EMXD"Z@!51M]# L/U=4D)<2[:XL6^(/O-I)4:JY,._=SI)$I
M:X[ 5P(++]I/&VA'H_"P.'METF[[!6WG$O_0 Y^QK'Y79;73\$>"O04"H":+
M%0#MA1&B L2DG;&!<? V1(3#M43O...N#-[Z"IS.]?8 -?ZUCWD=PM78^N"M
MX!:.(^.?':U;=.T?MRR[^OHB#[S-\B8R!S,G]^P/E!O,M%81)5N(#K/)&)Q'
MJYWFW&U2^NO*VFQ=OZUQ@O2;I3,SJ3G\/M>#CDNHJP^P!U14Q*+1EVVFVJ0Z
MV@<DXF53:IJX7[X__0N;[&^2@4@4*;T-%6</&%6TWV[;HMS%WPX=6.SK\/ 1
M[#6,?L'SXT'[JS$><BFLZ@"9341C$1W ..Z)MA+7'+Z&-WTWH[%J!?S@HT59
M!O4+8I^ Z_=(7(4#I2ZXY!'CF4G%%F^:'D'82&I3XP5M(YN^C,A7=P.2V2F$
MLM7G:V>"=1J- VX;EGD%.1_]P@G/N" %-M^X)^Z"4P%-XG%B45@4USHF/;SR
MYXQ26SKGE$M"(*E-JCF)]X1VT8,-X4!LJF'K@*>5_7E*# [%YU],20>3^ I#
M$'LY+FM<MJA,82>)ARP+1[2/?1%]B:C:H*NZP@5!\SE,;'R.I-+FHKD4[N/P
M&).2KV3[Q?W<T]@XVA\H]9Z%6.XD(Z6['\ZGW)O)*='YV62,;-KC*1@SO&YC
M-$'9O4]1PAVP80>2\7TM$F)<8]*JY,8LM4O?WEQKDEV+MU;=LXE@&T[^ CK>
M;$<"F:$1-+6"D,:VZ_54^T(_A5'5[U-ZH7Y*O6LMO/&'9,(Z@A(V'$B'9ZGW
M41057*;&3L(1RO*!8$5N;(]4ZA+(STL 0.@<^H2/*^UZK;'*]."NZ[!)])<,
MLXT#[&5/T:HX%0CG.M>7AR'63AI7D55Q^;D2"Q8#=ZK7'LE=SR](JZ8$V50<
MZ((;IVQDC7IM$WQ013[K#<EHAT':-9(,;A&]X9%+@5(-1QPH]S#I$P2?\"TZ
M^F+WIFQX1(;A[=XNOS2E6O8N%%LNG0D N&G&SEC7;/FO:IJOQ62BG7\6->3P
M;^='%B?.<5 +CXT^,<F_*(]ALCU2Q=PQCOVL)PS =T7Y%DH5*<R6XDP]01,>
MHNF$J*:&X$Y(Q[NN6UZX,M6^T.R"3YT>%'L><-(@L->BT.S=2'13=HN'\,S>
M*B(Q54--SGL^-0/>EV8"@^1NR[3#)V5P@U]!'/6?<8CC=L[[MSY:*6(_A:Z>
M'P2@DB4V!/$*KY)8 I.QRQOA)#\FGW1 -RO-9Y;-G#?; 9M/7W.I3M@\FW%3
M$;EV N'(!#B>E/@E!@ WCI@/L<09,P"LE C#)AN"]&+,U+?Y"XKWB *51+/G
MT%3LG"!2R9\YU]IC^E_8F:YA, .K;Q*<CGY0_SG!6<5UO=13;,QBT3-):;R.
MG'I05.7;@@C2LG%#M*"]#'N]ENI:T$[;8 C1C^:-I5W#9@=A4=%+(RK9FLMZ
M:._)E!XW/SYT7.NI(I90CJ-BUXYROG5=06$$=;6@0W">9@ZL&;^_C4D]Z1[&
MW/;IOOL[;<Z*]E-"^N^RBQQ/W;SXW,ZS)EQPV9P\[!QL]6O5(*Y.FE_L[!A-
MF[R[6T&OGN]8Y'VB,_#8"TXN <WGK3;AP"^9EL^TBMD[2^5CX#LCR\;O-(#Z
MR6#[>FKM]HDZC0MZ-AG\- >*RX 6772=1*6_%J>5,\<>#=J<C//["N$)%B:I
MT23HP)'\X;H$*2?5$K]CK?>>$2X^\CMIJA3J%2OR('J?@VQ$U$TD;K<%SG4-
M"DVQ>INQ<Y]^Y7"IBQS_09_;/?"U^C(+>QH#D/:DDMZEJ7[P'N3"[MHYJY$V
M=]M-%8-O!TOO?9UZ-Y;ZB*-)R\%D*L*1$_@P##I;(*/X).M!Y0;<==)EIQ[E
M%R*#4>\T=SG@-T9MK:Y#N](I!F1I"AJ??9H=8D1DQ]\W;<(%364&J?ILM$HG
M"K,4J[>*R@\@SP5?)$&^QCU?H2M^!RJ+WA!.TRHF5@-W\SU3?08%[^K[(XKH
M<C1ADE^G&>_T^JST09XNE_W MN!9IGM[W?&:+R:'BV?KX\M3IS74>R237&M&
MM;6.H3=&\!#68&-*#W&[BU_3L8&<'NZNO,FM\"/7PTNHZNFA1(MW(H!7UV26
MSG(TQ4(_JQ>J>=S,IM/K?X(5K^RFV+3\'-F?HHM0^/O(E7EHK$>4!U1TUG]M
MSEC)WW)@QYN:25F*W5/Z>,PB?Z;YL,##:$+/$0W<Q^#&?2#Y,DD:'H*#G6&V
MBB=76XUTO'TU'%[ WY=6E^)$"5LTH/Z!3%T92\DWZ3U)<'4_0%?4;U?=30HO
M(*^OSBVB<K?!3&_KUPY[#96C&,&*[E,:;M&[6E"UQA0%#$Y0\E+5.:M4T6BN
M:WLV+$R#!=QHHX+Z*Z##W"NS%\/=:A..F:CF(IHG.<_;J,U(QKHYL:%+?^B4
M#KP*X"#$4%WO]U4JA^F/U^G+N[>'7GP0EWUNGE:8'WE!HNER>4MCJF&GL,T[
ME"(<BACBOK#E55\;3?-KZ($^W8:_@57#.SQBA4#DAM<TP8#BU==8H'2:\/W"
MA;#%VH%7Q&LL[L_UY68+J6*T!\/:C@44Z^TONVG[G>5VSU*+PC:VK^AO78F)
MHUO.)S:Y ;-.9\L'D3]2UA'!O^*0GY;X*&;/]_.M_B0 K]4YB);?N=ZIXB7P
M-4W+*TE]@ 4 KF22%BB(DFE&J2L,UAX#_E"!L:]5?5-0^#'=1V;%1V7;GY^4
M+;08+<8O#59ZQKEL%ZQWR%O5-F+0L]0]F]X#HS*YE$=3-:Y,D*'E,[$,FX<'
M6@Q$D3QPOO  _N0 UWF"Z>RO0R?KRB?;_H-C#M@+4XQQ<'Z*6CM4;E@94;>B
M*WI_RKR)>M.(_'PA?$\P3/4Y=$5E)V+#]]-! 51-?#]]!W4@%_]Y;K(11&E#
M8>3IGR9@*R:VJ/M)YNT^9.^YM)JD Q/Q)@MS&XVIQ<?!,4RF;XX'A4.E*2&%
M%*\[Z)^#'ZTH;WI\1*^8U>K)8!2ZC^IR1D&:U1]PZ,@?Z4.4PES7-8!04>@
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MPOCZ*]1KL@Z\"VO'[)JH3>?5P?U!H7W6^\AI?!!D;$X)N+=*'_UOQK<ZE&B
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M)5R+(O%>1>Y><4/5FZ[,;VW0K>+C]S3 S\"]O_+4VJQC^]9';UP]=4^<!D!
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M*N!Y&';JAB(C#6B2'2_44'H2/H8G+13'@!A[Q[\L[GC>X[H C6?EJ&S^D?W
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MH_)2YG&B_/%EYY=,*6V+^_!L<#AN"T0$83*1G,$9'20%F[H3(W8A/P=JU5E
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M ?)C'X>OCT&]Y5X(:>!9N@:V^";_Q$O&/$GZUBXW=SBGM/.Q0*K0]D:;MXO
MJ[8A@QXEH VBVM1]9V>WKL7NR]8/I)NPVV45#VDR*7PJYS3#OH\0M] $)&ZX
MBS=;$*^</>58XX88JG<[8]3T3OY-[]VJBQ&]$A5$+C3H-55"F<[Q)Y8_$'9_
M>?)3#ZVR+XLB(D*;-!/*B*Z2+$D< 6'ZVSLH8PJ'G.=?W"@3<C!R+9YQ5WEC
M:WN3#A:;U5U'+SLL^C[G,3^9; )@J[;/9QCSYM^0#KJ%".!0UOC3S.I;I>[-
MKH0M-Z6[2$F&BWS2'-8IQ#>F*5UNOVH[E!-0Z&XY6/\?T]C;7]7;*T**LNFN
M%3MP$IO,%Y<Q^TH#L >S=V:K9@>#5= 4JT[N&[E+,,,O:4OY9C^J[JA>$*K+
M*GTZ,264JQ53Z.I3C+*K[ZOPRGM:F-A"MZ!<U7"D]ADR%[$!#9S<=QP!7W\4
MD$^<L!O_A*P-XS ^(9G<V<5Z4N+,BRSAI:L"\ L[>,G.IV1]S8!*/<S!DYQ.
MW*PF?_RP5#_55S"!;_1-IV?W3;4>,VN=TUCINQGN/TD$D\WQN<\9?H2W*W90
M4%9E<Y+9?S.=@)D?\*6)26&<X=@TG@2B2[TG=.%WMT)Z$2K;RCC(^U$E"I9!
M U#B580/+=SLK7NHPT =J1QFH/&?O#ABRL!_#TME(R/IG\Z5W8)-L5#BE6F
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M::<_.)XZ<[EF!%QYZXJJZM&$A;AQ)6'DH*< * @R_/4=I;??!/H5S8BH]F@
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MF2,/>-@\)T[<\$XUC1C:T>6BAXV4%,6OAQ0!^Z=PMOXP'J]+WA?$Y=1.J4'
MW0]?MR23[%WE^7@F!_9_:/2^EOKFQ#RLQZ2*IPMN@PPTMWTJ\]JH0TJ./_-D
ME=U7N(/7>D[7'E!MYY)07^C7UP:=H(<&055'"O-[<RY P@1Y"RRE<MQU_A#/
M'CRQ<< @\A9 7X6SO_ID=NA^=8KA.I=V6IF%GHJHHS(TD-W=^%&_.!0I'[]A
M"2X=1;-4R9$S1E&A"T41;(:?;NY^N[@Z&5O5[H6LCSKM["H;U*AM:(E>0!+F
MM GLC2'"WTY8Z E9?7AB'M##\Z#:9H@/,*\@=%9@[_RA/>Z"7+30(NR!!QQS
M(.ZEU?:=9/4V0Y&NH5D.7;6!0W\ZY_S9?[]1>7$JT+K!NVE!A.BH+@^]CL8L
M2 VT7PD2_H$&5 .'5#AUY56<FA1;/59JT^RN1E>B/,K=P+#AHD5[]E"CR%[*
M\"HE=I':,6FN'S=0G&US-YQC,?W*Y;.CW+=E-S%=V&)V!$1=8#8.OH<JH#K
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MB82*-7++177JR/OW'23O&JCR(@L!J5:0'<S1^#0Q %<YJ]*8\%;>G0FI,S9
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M >&Z&0 4^+TJ.^G9G_0>*QDF '[, $P[6$*H1P_"\2)REQ1!MPN8\.52*6*
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M'KGA077#>#&'[02G212A8HM->Q@ @E[1(+'EUE:=)SA-O"CO3PM:/>W +/0
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MDD,(GHU UJ4WA<3[@2ZIS<J+(4,Y+W0BW]Z[]/G*XH[/G]O-2=C^)^:=[@Q
M,/JP.G\KJ@YGP$%^><F-9H3[(E)CW%JN.%.>+ALE_'#7MXVEAE;V,=LZ1_FZ
MZF39A$TUSD[;TJZ%$;!\3]O.^)"F:RR$J8DA+Z,FY2\YE:B"#D>T%6EU86.W
M\/CP)EB_RF"*+*@[WC'>DU3HF)?R941/4,]L4&L D/NC[<W^_W03I@=.T.<E
M49TQ[#3= J;OT,N%EA=793(  8^DU14<X"3I=J:CEN]I#J7O#I^%GJ'Q;I7C
M,E#\C6"#Z?O5!)<BC_$Q %D>[#3Q,E3'+'6*22 \#Z9@AR1)US )*,C-V#
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M_F& LQTI--2$=M3^1 M<!-$%<GG5.3L&@+2#B0NN2DLNE9$E220]+.^%1PS
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M*+W.!3X=,C<F(UU9(4J(? ]G_<6ZQZUO?S=!_9\DFSV-Z'.4IYKU(&@73S,
M':2UT:TR$93#>=C0@1*:OPVSC6"JYDG)XI )1#HQA3YZW/^'T'> #\&&0LK'
MVJ+@LZSL=,0GU">FB >]/:$FG?!Y-AXZ(KG\+++A M/V*F[\Z!/E-/7_M)+_
M"]GOMO?,S_6BG/I?ZT4:O]:3OOU>;]KQ:ST*\(^ZT0W$RL2S85FC[92#9O#I
M553G+'6 ;"BH+NZE0J^3AV^J2:[&5538UH=+.#$MK3/OK]5X)++HO!.9.+9U
M1C)Z4_>@MT&\527E6E,Y/B,$0?.%SYRY,0&S]%VE[]L4RE,Y]6L1[UO*KTO
MK_6^Q[\6[M[\7MC;^8^X$>9/;Q&"5,,/L&]N,A%65O8H1+J*0HL/POK#^(!;
M=;C3C##<,J-6Z3?DU8R8 $MXZN<+Z^HP6C&/9VVE)+W.<-N"PJ6K!FF%3*,Z
M+$.O.[?=M"1=&2Y#:$OP_371&+.W?PG5^K]V8Y4_+00#:= SI5?G,P#39,E:
MU;+UI;XB#ZI1#VC^H P=$? AEZJT94+MF"84E_CVEPD]0A]D*Q]+CV6BU9OH
M5>@:J0%J2;&77@HU!]/\4YC6=P5CQ4,.BJ$+3<%_,.0^+R#R]Y#+__D;0YD7
M&MP>Q^2/)80&7/G^'Q!\)_5.5N:;?7^'KX?"<$9(LKD@.S.T:4#2$5=I@J@V
M>"!RV;CB) -P)PRT!3?/63E)CFG)*3 ?P4]__@QVV /0]@WM34!.!F"PA!ZM
M:67Y 9,-ZP(O6U!U&  G[*8>E[>?;PS3V@D8]A^>O_!03H[KS>>_QJC_HU]1
ME:#[ZNHL7@[T$?AJNCE9JXI >P4??^8%^=Z ;X"R=;>E-V4::G)-O/R9MR;(
M2KE_$,NVBJ8<V#KP7Q05(7^,HD)J9@"BK-/A?7=E:!QJ4(A5,3_9]@_YDWUV
M?0\>2&;F"P1%!*6G//[^76SG7_RKPPC:6FZ0>/DZ4V]4T9OJ^PEEZXB^0?I5
MCPRFZ?"&KT*Y(B"X?)N/),VCAE;B7W^MA1*1"R_+J\3LX226,&;<T@Z^;]K(
M !0;4&,69.G51/CTQESV0>KE*TY>A^JTZHP-K3Z6?K_0^*Y#1W?\3;YJZFD"
MX(S^_P502P,$%     @ ^8%A4C)R#US"O0  6^$  !4   !P9V5N+3(P,C Q
M,C,Q7V<Q,"YJ<&?L? DXE&_?]BTDZR!+B*F02LB>==J$Q)02$5-)]B1A,(R2
M?9E0%#&%R#K)5K:Q2T+VC"PSE)T9R[B9,?--__?]WN<[GO=Y_N^W/,][O,?Q
M?C?7<3A<]\U]7?=U_L[S_-V_:YC?F9. X(7SIN<!-C8V((7U!3!'@;, ^ZY=
MO[]9!P?KFW,/)R<'!R</%]?N/7P\?'R\/+R\_ +"@OP"0@*\O()B@D)[141%
M1?D@XOO$1/8)BXB*_/XC;.RL:S@XN3DYN47X>?E%_H\/9@,@M&?7@5W5[&R'
M@%U";.Q";,P6  H ;)QL?QS OQYLNUCWN)MK#S</+^N$"D%@%QL[^RX.]M]W
MS>H-9O4#'$*<P@=53^_>>_D6UR%O$;5'B6_VR)XI;12U["7+J=]^\)B;1TQ\
MGX2D_&&%(T>/:6AJ:9_4T3U[SNB\L8GIA2M7K:Y9VURW=;SC=-?9Q=7-YZ&O
MGS\R(##L27A$9%1T3%+RL^<IJ2]>IF5EY[S-S7N77_"AK+RBLNKCI^JFYI;6
MMO;/'5_Z^@<&AX:_CQ"(I*GIG[]F9N?F*:MKZQO437!K^_>XV !VMO]Y_,UQ
M";'&M8N#@YV#Z_>XV';Y_SY!B(/SH.INX=.7N6YY[SVD]FB/R)G$-Z6-W++J
MEF31VP]Z><3D-(CRE-]#^V-D_WL#>_Q_-;)_&]A?QD4 ^-C96 ^/70B  3M7
MLF*. '^G[8JHRR* R6<''L8.^GW 5R8-^<9_48T?*+P5>6 RT_A0O3\3B/2G
MB\'6>(=AY-=U3&"J8KU.-.>8!;9AT3+93IV()?A0?2MW7C%V@ZGMXVQ@.(7W
MW)"&4542KS?)U*GB6=U7[_<IVESWF]<_2UQ^M8:M>C@BZ:G59ZR703I_=T/^
MO/O,!'C$F?ZRI\5K>\J5";Q];XV?90*KW!^80 DW$W@=,Y[S:NZ\Y> 8PR1?
MBY3.J%2^;"3Z^:[(92/@/VQ6!HXVI61&JF^^F__][Z[4TO+^L1LG34BGU*Z_
M( .XYW;M$\)X#ZG.=%BD=1E*!S3?7\PQKDY EV_<S^,[_A0SIN!U8NV'3*%M
M4WIFC?S 6ZG,08H[-0ET)QM<1CF1.I645R\&!**"2E3D>LX<B%.?9 +(N*#A
M%^TT!V15VS0D KU+WXF$M%N>EUPS>G/],ZPVR;P&26?#G0&-:<KTDZ#BT;IO
M&AP?AW/D\X8WK+4#X[Z&K&GT)'$OB[M0<3;%.OG&3FC$*N*77JM'"6J0"7"G
M+ED5Y*6[DE>(U"?JV++YM.E-8<?^$^]N]*>V3E0XI.7:X0"4WM!N]( K8; %
M@BDJN%:?G)5:B?B,AZX)>,G^>@ES[8FIW]N)[*'Z4#3$.C9+](_FC[J?PUR6
M]+RUKME'-]@I-Q2FGQL\CX%&PXC2%(')^"PP;7=_25AF%,=K1>T/I9K+FNWT
M\^#I25QLVO5^NB,Q7KM%BW;A35W5M:3C&ZH=FU.&\Z>STY[5'QGM90(93.!$
MK</LPAIK.:747TYGS5$K=,3OVD"(L)L_5%"?"]KE368"+>).)9Y/!4(:'XS(
M2F??@XT?KJN:S&N'\-&1Y*@ANIY^]''EF_B^Y>'.FOZ9_1KJQH,V@L$))_.?
MZRF[U. 6[GO/8TYGQ2@*[XHY\OH_JT$R8)-OL*O.,"'\0GP>(Z71@0ED,X'/
MASL9'Q48CQ4;_KP["]& *:0GHIU03.#,3Y'+-Z8Y12Z?^KM-=%+FT$Z>;[Q*
M:]IR?"X(H3DH'5LJEEF@W3HXWEP_%)M@T'7)BY#=RCM,C&3<$$)3"C9EDZ9R
MGCV[5DV_M, $O*315H5U>%&&<^^ =5<QS0;Y/)"NUK[33F*AVHH#6_$+#QT'
MW3$TC#$3:"M@ N]+5UQ4Z )0^E-&OET5"?^U'7Q?A:B M?> 5[]=O WZ$J$*
MERDW$K5UPYM]^%.,C: !D4S MOY=_\-1<REXY?OWE3'=7PB:,5)(P4/G0V\>
M>]0 6#=#.4)4W9C ;D>*Q["#,&-L4-^T&%YD/\X$7.6XE$-,**5K%>?5,X,Y
M S6PE1OKB"#B,FQ9 T^_6UUP1R>N>,^5:XAQ3!?=J)/[^FQ*9B&]I^ =+AE!
M7<Z$U4WN1_^X@Z;$A..](ASJV=MWVF T(^/MJK2Z?/0T:RFJ!AL+T?$Q3$!]
M(48Q$M2FJ#/$AA_?HD"H7E3KEQJ)P>D]:Z7E"?Z>#I_62TCU(142Q/D+\5:N
M1B/;KQ[$/GGE5,US)*M43O$G$R#H$>O?D+-;FJ=ZFM,/FP>9(\ "C2!$BH$/
M'(KZD,#W>??/>WDR@P.,P8GRG\.+_3F@PZ_.)ACYA?W"\-(M41SU:>GW1MZ9
M@/C&;M4P3#%J+9@)<!ZGW!CJ:_0EBSIPB^1$C:L\B; \<1IZ=RYFX_V+_4Y.
M2RY7'B3TT!-B'A:8^IS1-OXAPTG)3:6(-Q)@T>77&?UOW5(Z?+T4@HO4PY8%
M3F_NKG)?39Z$+?W$,7H,(0,H32; 4UQA?F3>7[Q22#LJ"5IZ5O&>V-0F_R?K
M5T*8MWZ;4+)-;.S9Z! !#R;PZ37TIZO1#9RHA?D#/53D<8-S5)CID2+LGH4)
M\G,DW&BH%L,*T*[7SP9,>TW\W$HL7!I[].I>VWWUA.?%#M<(^QN-1"S_'NG\
M(QO[#/P_H \RY#\X83:5+#O/!.00(PC8MT]&(M8Z;$8BE_Y>XVK./#SH&P\C
M83#]YM_P%5F>=\^L!A<?_/Y]+F(_I=OM6:8LY;P..02VK" .6J-)\ BTT&)M
M,&EA3*412R"$O,TW&!"'$E*^_31IV+I>MD5Z5_7(4/$$$TCRP= 2;-$4J^T6
M[Y/^>]S-::7CK@:IF\/3P<+YO$K7.G'TO8_36V3D#5!'JQ@D572XTYB[+<W9
M/X**'EUWWK;.Z2#/D,JQ:W!5)N!= V<<RX>3L:3RB;4#CHPI+2S=_F&[:(3=
M%RQC-WY+[;D)VG^%"3P.L/J57UCI[Y(.6UJ"K!?I=7;^ZE[2<]ZINF(O@_4M
M0,8V]H$E>DI:[<V)8YVWMU/RBPG?FQ3B8W3O^EN<W64 \>@#K1NK6>&[)O:%
M_I$TKFCGJDMKK=E@MD6MR[-7NYITHB_!?1PR]!TD82*3^*4-)M A=>RI7<4F
M$V@\J?<R[[:_W1(3>!1VO5]=IA#35I?F-1))*A]A C'&T,V]Y;_UAB5\Q/CW
MN(XY,DBL8?C5$%].7ML@LJY26=.RFD.KT7HWQ!>]6$_0HH>!5V#<KFNK+:2Z
MDBTJ6+1"]*Q,Q(T$AUTV>WG'!360S--R\^<^S%#=-;QP5Y[DB^W^L.H'?NZ>
M/:DMFL?ZW#^RI,7TJYF6"?(5%7 #-& "CG+8[0/#'=MYVY6X(MAD+H*R0 YB
MM)G"UD_CDC?@&YX('!E'CWW+.!Q\&$$7GP_ QAHN6"> L3NWMH=+D67+%<B5
M*/P0M-CB%H6G<F9=E(QAF!H_9@*+W$Y,($NXFC!=+\2:E"-DQ,ZCX_CU,]9V
MB"0SDG-W75/,D7S!RT8BP#^YL:WET474&1=G2-H[WJP)[_NN.+&.WN(800]S
M,(%O1DBN/^U^: 8*;:"35!9QV-D;+ )^%?JGB*UE;T&4+Y>^!<OL>\LGV)B
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M%Q>Z5!M'Y93JEF3C.HM: TE[[+JJ,L:8@'_%,T\NMC#?A1M<C1-/\&7KF<?
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MD$5,SH(UHO*J@QY%\8+FB@RH_#_8>\^PIKIV73161)J"@( 0$10%$1&0GM@
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M]LS6^#_>A?SC!_+]/W'H^7]YY/S_)\S_6\*LBNR#5HLT4(6(J"BF-$E1_?9
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MJO0J2@Q,'W:Q@Z];I&DWRH4 A[!L@$2A$@BLQY_,7W Y,=$]N>8GQJEIKYA
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MK\SJ^"@'<,INK?RO=^')R]M?+'MMX_ZN;*,BI#&, 5,QHU$[[IL%J?<I5-5
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M^SP;<-2!,L>4(;51FJ;3T\8Q*X@7AP/4TV9!*]PD=]#PZB8)7:/.3._K #(
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MW19@^"C3FL>7'@228>M?:9.C361DQ#<(JDITV2R$,CGZ666)P3P->T(KK.+
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MFYUG1_[:Y7RU.N1%.!>:<^Y#V26>"&)RCUA;R""FX@PJ#7,8:]5$W(&]&>0
MJ0 =3:].0;GWK HNHB@0$423+W_X!PD^4]6N;K[[-WM>[+KX 5/]+$4)]HX,
MH7JW/Q8TF4MHKS!? $QZ5MBVLSP-D.+P'^>X:E(GF7WF=0<PQ)+)U4NR9#9[
MX.<L8X7FVF[/)1MK_=PO )><]QX8\CNY70#&MOP1[:BK)ILPYD3+3Q/8,5>3
MUU%QD@Y=83D!>/.5U'DVA)*@$P]K8)Y*?(M?LE9U9/S@I038\<E*Z_4CLK]*
MEEJ G))3W8G)*@7%"X#@?2SZ[)(I66F?-G$')'6]'H;3^)YH\!,D3@J*]2#N
M^Y6I^'ZR;0'K(R&JMC$F"S50PS=^TLQ@FX-YNZ8?L)M3HF%S&LZY!W4IZ#--
M!$5;&]M!+W/*&5DW^Q1KR)&M-I<4AP!7<'R,J6P?2DZK3R=I];O_ZGF97,@*
M0^ JYT'7@IBHXEJV3?U!OUUV^6H<V(*&%>RIUE"(X2^$D/E_<.@822V#QKFK
MS<%'6O#TCQ_W]P,IIKVV+2!;9*Y\UY)L;U93<^>T>OA2DIIH^-P1#_#T2H!;
MJ\JG%_'G8P,$ 0S6VTMKJF%.&\[[K!M"*\*+>^[Q1'JB9FTI<\"*5!W_2WSJ
M<1DDE,10C6D1 4;QVT%]M/S4O]AVWF4T2$%;"HTJ:)/?,UM^ ; DQY:UJPWH
MB3F2.BH<M3F#.K#&?.)2,0[)RJI=U=K5=\>KR66UQOIMDNPIBPE7A1 QK$@6
MYWQ2M%,]^N$@A\"KOT" -#&$S85F'?KU=2R?+[CEAZOEC %3VAWF$,'UW$(G
M!]2>E^7="T EC.&<X][?L)F>>W9M$KXV9/G!V2 -1'?U(#G\ K"]5.%6,./P
M\(BH%>#7#KZ#VQXH'QBNRY>FF58M*(-N46PPP%)[@V1QSSDP\5(S2GL6G9W[
MO<P=WXC5C^Y;U:P^;EOE)3K/;?8A&<E(Z1,09#%>AYS?&FN/[!XO4;MY7\L@
M!2*K GO>PRQX;Z#^W(+W R%ZW@"'BCIPT%\-1C9^%4E%]?]Z.$V<VPHAPS';
M/,<8)%++<SUFF/IH&BST2\"JZUU<G9K+/,PP$]])4H5$ (_$.R\ GS,.6OU(
MR@&1YX%]?S_Y5!JF"BN<U/H1.2'OE_7-O_N1*OS5VD'4)M"P#CPT0=4^3#]4
M'1L>,:XBK!?[ZG#^X+ "-M(F/AVDWX3[TNQ^$"@U:NJ:Q?;I*)SK;^3\V8R8
M:":IIY-EM!F'.I73S"^"]Z&=04<B*A> _&Y?S5IU;*6GCOJ^V;*0:-O03\U"
ME6 $X9'H8GW$%E&FX +0H1[7?]F5KN;]W:6L]S&J.B,@S8TMTLVI[OF3FD]N
M\!&!]\_=#*%&E ! 0!S3R;C:]A-R!$G>):%$0 =O,&687 45\/S7/BU+1U'B
M%=6Y3'&OY$*67&,"^.0"L  *6<"'CVT?#&/[GX_:?D]F1$E6_:.ZFY>5$'!&
M8Q^G0),&9)1,9)B<#IK$HA5H-\/?J39_ B>T>+>=+I;[0*ISB6^)$'*8)*]E
M7U.![!@$K^,PI%8?T?-;0B.I ;% H^R#.%OW#V:0:)1":TU^,",\5  /;&^@
MBG0=[UGCG\E[I+XGVB_C-5(D#T\Q0 +66)J*PFRQAWYW\7PLN*;Y'LHJ1@\=
M04<B74!=*9D7-J-/R;[^E!HA>_X)OA1!@) :!\AR7$*(OW8:;3-XD]8R!!$H
MF%N*DUU:JYLCA]##OTV/>-__RXV$T$@9*&2A/KJ%58*H5S\$[*QD(J64_TCB
MH^UDUP"'<0(-;V,^8P8A=8);B&^PD;39F]J/NM(R*!V,F:8EYL"Q#<4/OUZU
M%G3L&3D.V333JY=;24U_D^^\L17DCH!NH-N0 J2!\V0%>_SU+F,-,28H;+;O
M4)&>V:Z=QHX],>D8U[:_GU![*H03!.-WFG&]ZJV$3P6F#C#Q]Z#)K;*/;*-4
M=QCHVQ@;^-P>\V$&<[C/4^$.\&N.NNL9K+WE@BHC5FP)(SJX[#)QP2%#9>:#
MW@X@':&Z W:E:B3(%1N.3XS*\Z<]K3(M_YZJE1SV&B=6P!!D;"G@\4$_5@=M
M1E(?S]=V\ ?]APKR-47@@T#IU\Q&,]2O/0"30FWP?U?8 ._N?+1+U^T"_ISQ
M6ZW!]Z<UJ-QK?<L:MKNG"K>%6R1RMN"+,B\ UYL8;I5\VKHSG)!L<'M:(Q/^
M4?:LM1)S8C2W?:4,[)Q#T8J;EF%O&KL;/6S F2;)*!2A<'R]K>*N>\3LG40C
M:<A$"@H=(E<B?G,35>@-OT'BVOC>9^5I3]L4Y^Q\B]'_FDEJTM/SH3^+"H&8
MT;V%Q:@OC]'@;82K\>)Q3F1#\=6<WL]0.)8GQ7]!;31[\MK6D+[#GTOSBY0
M'[33?NX[DMAWW&J4PO-TRU>QEN-VHW?3*6]2BUV249I10RP:>P,CY&IFKXT.
M&S@']J<GJ+L6=*14*P"?[R@ -9</="(YCO)+U5P%,KT<V=QGM25MF=7>4&\2
MC"1+K&XY/\M56YV"_/K8DUU0X0UD:GEI[8/G[9"+KY;<7)BH,/71%;^?=,E*
MIXY!:@Y"-!HJ.[@>K$V;PAEJ*/+VDK*:Q>S'0V)I'U$/-V<^?!AM'=JQ0IKY
M\[$XA/83.TG8GFK3E".](]@.TVE4+]ZQ/V.;X?R/_">*'C'Y7-W[@PGTA7+B
M'PY,10(L4 .DMXLO-.^WQB=.+!I5_28*L4;8?CROHA;(4N^OY3;IQZ-U&=9-
M,A+C)<<)&$>LS2/%>&3&I(ENF/#S0F([6L>M5K 3$ME4DU%M,3NE76Q6\$;
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M>- S']KO$90W;SUM!J\B \8L9!:4JCT7FDN+PQ>:'XN;RDX.RB_Y*KT=AT?
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M5H;DI G3E>L\7%[#WX(>CDM=WYTBG<X9XB\ D4&!I690 0>W'069HNNWZBX
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M-=PM4ST2%1IUAYLK3XYQ.Z )52^L'K[8M&6LQ;MI9C7W&[7HK-"/7P6]?'8
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MB)I40#>*8BX/(0Z <-.YS+"?CZA G_,RK2&!?Q,^<Y"MLZZ= 3%%H*MT.*G
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M-I3R3 VQAT:TM\[_"SNRMBZ!YN\]!4KF1M&P9N@T4X'7VL5).)I43@6A#H]
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MC"+;XBCF#%0+@PMEOPG.75;9Q5D"H1OW,3&5(AU*WJO10.JV '4?DJ:K9U2
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MPSKM'D$D<ZS9RDAXZF'PR&H:BZXIDM89+4>9 !TZ ],(' ,QKIOCI^E1<HR
M?3I$.YT).&80S2?O+V1E!/<X:64D!/C_T#BP&\L$'&:-YSLMN+WM&A8'&,:=
M+]H*_"==<G0&-8FG!^CK0 X>V8&,8IHD.%I!2;&YU#33JN&*\IQE;?;A)7.E
M-U*Z+\JRWFVH-!?U,P$>J 0K&A?U)58ES334DSTS\"[EZL+1C!Z9GOVX[+H1
ML?G:3X5F&2\#S]B7ERW+'*9'!J"!<(]FG5;(480B"WK84WE]YYS-3*W7EJ^H
MOKYYN F/W+D.[</34^KU9V%/@9SUH+S;</OKU+393.MEW4F7%>(Q%W>@6M<Q
MXJZ92364/.(SM4W8XR?:LL=C$-R#EE'NKQ$:#K:SHG'@BL ZK9NK]"EMU\Q)
MY7[&Z$BZ2R&IXV9?O4[5#N/(D*:T(?W,C*GTK'/G][X[)T]%WJNK6<AX4GK!
M1$ IEU9/W!/7U,@D*:WFSUK&9(D.;"<JV0T(3<.+& +G2WRXWV]2RL7C"0?4
M\I,J%Y%<]+>GZ[G)X%F.R,H4/!,@\\M3AA\[F&<^"BI&E<^C$_$*,>K/ VRZ
M7X2_2%^@H?:MX9:0/G\0#]P>W] 1H2<)PVC';)N+!2RYK&VL+KPNU9H'U'0V
MGI?U+TUKA51[0:=DTY<AW%ZB3Z S$S@N0ZW\3WGMN4I9CSV^9ES)L6@X&"FS
M<.[W=JS_P!PX- ,7B;H'.@8/-R11Z\GYD>?XQ:AQO<1Q[?  \RJ+RY3C9Z.?
M58IW&+E:(R[08P/0TG#05;)(/@''354,T'<)/2+)&YIG'AXBN+KQ\J1<K'SU
M=7VH4PNJ*C":2"!A8NHM2:4CK=-"")5[J1*6L3\*%8X*2!"C3(E/6Y/"IS=*
MM=8IF6_M2*B6217KO@^U@_4:LQ-H8>?I^*=%B$VS+V*OM!CK8NVF8#,4$62!
M70=39>ZN9XQ$(3F6T\ 5R#326T<5[T*M^G2C%2?L#  V)00+X."8:IAED7HP
M?[TC$U!IT9XRTZ!D,4 3_V $>\<IKULR=>&:MV^=7B>U2Y,P3<+E?J67W*&V
MGAL[M^]!EO#:\)R_I-$F\%!G#> C9[JJ4D5]1K9OP1VAV9(W#4F#%.39GP:*
MCJ!136^M[2>WBKKF9XW&30,4"J\EW,L8,M6<^K9I+UGW8(^;$-@(BIJ2HJI_
M\I) /Z6IXU5/@#G'O"1,XHK7:0W7U^W]K7]*AK;6)H>4\ED@6L@[35AI'%6%
MA)Y%1VTY@?FDD>/>(/N!BNU3'!,EG;S*A4H^,X]-2GRG*T#MM[ 7J'7&(\?[
MWIKH/(GUR-T]>_W$6;&C2F^^GFQ\Z"'= *VDO].SQ=.59J*;09$,X,AI/5.M
MZ,/M)473GLE<=\R_)7-%W@Z=?>=G=3UC:<-/^PD3P(UJ.:+N6]F;_2 G;LL"
M[4A/9@+FYK#23,#H/> "!#=$9=M79 *ZNA"Z3,#G5O /'*IH?A,R:_(3W^K#
M8O48GM__YI7Z_TF& 2>+U;]$* PP5.$I321SLE*3#%?MYXI7Z2-MCKF.YLJZ
MI,7WDBJOY/7\,?$X?.+6^AYHF@-'RDEA40C[96))L3:DDO'U1-2%IR3;V(-&
MO.BM"8PCA7\U'KB[4<T$X,P9PBN&XCI'$T27&"9FGV:2P4?_;N:O_R3"\E%]
M2*H^$Q IE$V[AX.AOIQ&+71/,^@@JA7]!4O3&=@Q 3M+J&;,OEG^-FP#6.TQ
M*TI3_^O=>*/]F1V&D#6*' ?^NW_$=8H1FK;KQ 1,Y_VUA/7_;C3/9J]ZE^._
MS/PO,$-@B6S(6(HI2:D=Q@'=I#VF6A48N18:GJHL([/5;]!&N25>/SUM"N!)
MJMP7=0'NWUX:?H[@'\S2O>7J6^ YZI9P$#QPEX)Y5'K-PB/&*J.^[^7<@GLS
M2V4+_J&R_Y,/MG;_]5T]WD!&ZUL@7;468T3N7DQ9/#'0*GIYY'I=NJY?[9.(
MJZLM#]U>AD?)\GAPG-?W=0G(1W7-0'$4A5$F8,E[*'@^[Z,C5$MC##+>$N2A
MLYK*]5/G_)8L">JYUB!@Z8\8\R70 V=2LPGLT>8#.Z->Y-<T[?SZY(F&^L]A
M86.?Q9T?N;_0 @ >LZM=[VA]>RM@_=!M>%3WINDPS2'?:?SV]#(7G*R9<-XA
M<.R]HNV8:>.O]YMAEF:41*5&K/1/HW<#%;K<X"_E]>R2 3:2YP]T9SRZ"A"<
M%G:!1&$%TZ'B]TGSJ?VWGJK&5EA. AX?)#=R/->5\:)_@(4(?T]2:DLW2".
MXF0.A=N6Q=\L2[G:D.$TW2H=B"3PW"!)'J*?A;(9D47RWE'C=IJFQ =ST&9?
MAUWZ6ZQQDW[2SZ\>,RTA?.-=E8[[E-H<>7="> 6K2 )%U]_W3JK)=5A.]*[K
M@A88OMYQ?=(?[,$&-D,PCOP\XW_XYUS?0R>3V]YE^SJ[*DD19]3XOQ;:"B??
MF]?+9XCDQWD'J)P'.8[L*UT?FNO?=O;ZT=F=K/7[EN6K>7?->Q,.+[$C8DL6
MI.PVE 0U_N;GP;<FZHO5X^$.W!<BB\UY[KX)Y$KL?;V16'/J-\_F4W67?%:)
M, $M3OZ5C*:!JJ7[E7'T-^H/+:TS'B%?4FG\^$7$Q?'58,4P*&\R++)VMT;_
M^JJ'TDB) =SI3NUJ4'Y;SS&( ,*>Y)T1K)6"*1A8_Z 5_"LAE?#ZZ=V8N5W<
M##C1L!AA-L*067:<?,7(=G7U]+Z'SAES:K;X\$G\F(DV( QK]<CA"*C[ $=#
M<'1L/3=^75RS')JNF?6),E&?6ANA:U(G6972^8,=^;+*@)VT]C;(-Q":<\LP
MP!=0E>Y6[=Q_A?V@>H>\U)U^F\3D!V>*'[DHD-&Q#.!BH*AV[50\QO*1:EN-
MDRN,8G/ZF=[(0>-)0"]'F*7X@GP<]=4L^M@24C:^Q;&J_&Y)RY$QKP**2/OX
MBN]7M]%NA3LW(W>#/1I"?%Z0=EHD>"M_8S/Q=*T?W&UC?E)VG2)NC!6>Q_IH
M8;XT4D>SSAED"[Y$>>AUD4A2']NQDIK'OEG\\@.5YP?CAIO\@UY3W\RV#>@!
M9T'$1)Y1.-HVKF-?L22)*O"-+(5U=S$:/WN$@&$3[EC"J@S5<_!/^'RH)//^
M'-K.]=;LJ8E>+59,/&M60Y_N326\(TA#IT?PU9&BCCI?2?-I](+[F]@1RI7-
M0]G3'%+:7^<K1)OW=#[?S7,(X\DWN+R=1H?!"!T]*U/9%7&+4IT;0&&:,3D_
MS(+RBD*7OSTX-3R\-KR_FBBDMEO-+:@04_KXJT+A(<$$H",1(3K+^P0L 46*
MC<!4 TQ5O?$-893Q7Q/)R<>.G/6YVR1U-$@:&FA!#<5G2K1#=:79KE=6IANE
M7W6MNEBZ_+C8^(+LUA;1<>GCN$F!*2+U9\EJS/&0IT^O=O)=3EV^V#6;8QUO
M=]7>Y#ER9'KC\C9XG]-S>L^)-\0(CB.RQ+@"R(9%=Z)8?3[O\TC%#28@&FB_
MQS%VR4C(3N'_V*_[_#N'#(@ /D0S'D!J61)0A\?@D)L5=3_O])^H'JG4?7M!
M'KZ0[OSMMY.9F,!)J1?])2@H(H0E!FWPO0RA'2: AL&XY%11,OO=_()D#.DE
MY'5&I&4TF&HSS01L8-%$&!JUI8RXP.+E67\M?'NUO3)H38G?M2<P[J+D.U&5
M6!:_^5E(6F U 999AGW?WTTT!,?IYS!LJ4S :P@+/G\8W/IG#J$?X%XAP?.B
M&WK1^TZ$:?J1;#X4*1_'!/P.!8Y/RS !BS>I+$D;J?^7"965D8+<<=!O"'HW
MDH:68PQ3668NY[=DTTZM,P&[$!-*=0=N3]A B@G 6Z*8@.Z][>63_PMC, BD
MILTP 8G3PO7*4Y*#_I;1>\Z);9/% \[CU+ ]3ZOCF8JZ5L4WU>74SC;Z0:Y8
M&9VR?*,(Y:ICX=0AYC_JQ8#_?0-KU(>:R7&1&49Y*5%-@-$.#RVVTA^Z*#A?
M% H:E-'+/GG7_."[=?VO\Y61IP9QQQNB<J8Z1FY:&=W_OXC1!F0\G#!"TT U
MA^ DF("[J&8C2LCK$D8+!?=E;>KJ#SHZP?7C>$';#S/UR425.OGA DRL'C<3
M<%@M::4U^'!T*RR"(4?U_@C]7OAQ1=M:CS+@(\OQK4G$YL7F"=I]F8R1B9,K
MQU5RV>W$>?)ET8[]>:?ZGZ1+QB<1"G+J1<WIA;@*'%3?<":;)B\#&3M'0-%K
MZ.\S1Z^$9IF\ZIAN#Z0L68F9!?Y>*DA^N//I9,Z[2T9PT.KDO@VJY3(\MR,=
M3),'C@))\2YT] _&SWW+<:2[\P3BP]A.L%OM-B:X*$/18N.;;\5P BM9S_YY
MQ=LZVUA7]55,%.V/I4[U#Y](][P]<_RD8NS>@8LB!9@W!AR,,7N<U#EPC(SB
M0/VA<52$GKI4^X3MUR&N4-,^A[!BY$7.(PDI#55K4A(E>."$C349LYI?@G ?
M,)#9_>(9:-UVYAF]O"OJ;-UOP2#IBP^)8Q,E_GKZ5U9'W 8*$<5[R7&;ZT]Q
M8A5, !IRI (LZ3G<WJYO?-;MB^>5$N_C978)G]D4!$;8PLX+SS-$Z:4*Y!&B
MYBPH(DN&%(.M_ND]9=Y[M*=PU[<X+G=.@-,I;+6H#E78(:96:%&CXOVUQF'+
M0G@SK1$UOLM01MQF*7B0$/5"/1>!E_]T:DDA=VN]$5A#/L@J*_+6H\?Y>J["
M6R?R@NC9^9/.G!^^JEWIW[7BJ2,>(EK]RKCW<JG[[>]D08L'W\[91R*[P96B
M-$WV\%G]*]3+K,)5S9VF1[0%::<KSF1$C;[V33A[AZCP&#KI>?U8OI*X#^^Y
MU>8X\O1X&B7I,_TU4B);V.7!YLJ Z:.JJN&CW^6.71T#GXMT>M"H%PDV&Z5G
M,4Y[34M@Q<?@10XDG_<S3G5OQ.W-!AW&OKL>=K-[0#B=P'=I(GS=<NQ;RKC3
MQ?+*7K-_^3*9\#RNPK[=D,2-EZDF^+Z[34W;/R?'Z*U,^:9:$[;F,3XAX)<\
M<1VPY#C-CE3@CV>)?<0%@MR'7XNNMRI%P6,['F<-N\1^L%]JO]38*3OCCDF^
M74\9N#LVON!I)'23\W]_I?\_CTW@N--L*^00EH-:WO9]WZ=X=>QT8[LCGG'U
M,_]M#7:#;NA&\ I^/6P+,P8VHH:[$F \V0E'H=D3C\<ZBITJJ<\R#EDJ(>G+
MW5\>3KRH*5K/GBB:Z6BU'!>U(G&$T?1SSV$Y),*F5O;R)^[$=]^8N!P1Q%9V
M\PS25N_SEF85:N8MN+RF6IV%@H/-%F\1Z\02PR>^.V4+!/V]>PT/]1WAP9[5
M18$#7Q9["(I"03"BV_YE+^QI>KB>!IF_:4INL(+7W*JAS+2TXNU(59;VA&SZ
M<;(:."A(G.@@H]"'/$73HL<A?,F2K1!AA%$1O*C53B+T=_VC20N?6K6S'ZT/
M*IP_+<G3+:BO%CR2O0S^PM&AKTL))/<VF\.X#$KRVV9C-,'\DTP U.&3A8]>
M6\J133:Q_<2H)L5>X6T,\0 )W9:E18]?0W#E+$&\R4Y+3^R^Y=,_BFTJ>(L'
M;$HW/Q+:K)/RM9O407R.MYO?F+BT6)SF1RBQ:<FN<$)VZYBT[Z.3=%;9KE5$
MS4Y?JDZUW?1&-!:='N#BR)3K5#!+?#%49X>+P>%SD">1/T#DO06"\$)43^3G
MFDH2-E(J];G%D?.&"@E?(CU<4\<[9[8ZI>S[:SN:P!+.J"9]5ZJ'2&)=>TM+
M*H7#?/^F_,[RHH/>) ,"D ETG<KI8W!2AT<87'10BZ>_,U;36Z"X_0VE@'_]
MVIN)^?6-O<#)./WZP('9JF^PE0(_4.L6$S"F,>N.(8=00DFHN(!Y4\WX;[>=
M+20BC]6665,!!S(\V)*@W;@9E@#9\-RKID=X@[?D7=+VI?]:#M>,&YMN1HJ1
MC;/I::6W6E=\H0LF6LW.,;NY[C9-TES%P(D6O&4<4@/9&XR.JI=FZ?R'T,=3
M$]]3<0_B>#Z5G0XTZZX/A2;QJ;=^K,(MNQ=_1*(0]B,&9[VR^9#'(#0(2>$)
MF*/B@G>6)(;O'$C_N]%-E:O7-HCW<M]S\EV=V:(?H);C@9*()Z3I%MX0UMV_
M50!O<5 R)H"[V/0TY&&%G!FFDX\&,$FEVF19"F_,5Y-R*8W47M* ,=5\%L@)
M]VA"\CV3K<Z^:=[I8AQWVO7[F)^&]L5',36RCP^'JI+9&G%B##$J$ ^.8'!;
MNOGE+VX:>I3T% 1)3@T=#)MN8 AN+GS;W7-M>&*7C"@\/ZF]! -KF.JC/[C:
MW1K4@-U1<Q+KVL:$(U@U<,J=S$&/+V$"<HYCZG,G?Y?28!T]U1]#B^9*N&?L
MDTXS 3/OTSM:QRHLLCB_]B5^<,P?G]'-V\AUQMY J3W.3_XZ^_71AI5-W?[I
M;GW+;(0\JTM5$_*)#N3X1JPD%5="-6P9KO837Y,)\AGO5WP9TS^L<7SW2A97
M8LJSD4K_Z7+1&*PR-,N VK%O $^9=2E"A>8[=8EDSW8DF_JL_N8[\.)VIX)L
MF-K'ZWR/H"-@M^EG+N>I ?LW: _)@3'^EJM, #\\SGO/>6%\)HW(]L/]1^OC
ME2:.^8.%-!XJ!Z&7 SF1+:R'*GX <26E5L\S 1[+P(?/:*M?!/8KGW<V\$]9
M.0\4L><)>Q^KFECTFJLT %(-9S#B5/L6()!FE4NS&*DH0G-]>'%;-6'@\E[&
M1^<<CX#7PG?#'AMFO]Z$6"&_272T@H\@N'#T=P:RB*LC>N;Y8P_\.ESQ(76Q
MCK\BO,MZ5"HB3.4%$MNT_7;09OEX_C'+V:PTT@#E97]I/8NS4ILOCRN QT7R
MB:X_5 ?-(V86%E0@QH@#5-%0Z/[Q)0A/?5"^5F:@UEO51/HG2ZD2D8U1.8*[
MM?&EF1=M+L<K%$4_!9=..%EU7]U-F9EN 8TK42I(^XB;==250OA!R;&,)<<S
MR8K0>S&M!Q2LODDHS[G.'U.7JLZ#T!,#UN.0:E0ZN:AQ6J >5CSE]20]Q%&]
M>M#MJ.,U""SSX;.P5M\HR8.#V?P,$<8(Y,OOAI&G6*#GE"@9%S:%G_L\5&F:
M:WB_]/KU@7/7^77CB,_9!OIK,:/9E !J-2F?L-Z*%D*85<4M0F\ :N=$'W6F
ME8MKJ]^TVQ1RW>]L.'7S99#2NO&D*G3MQ%!6N\?JROZ-Y6D.!#\9U0P6"JCK
M@;:!^?/2YZ<(-[\&E8+>*0F@U7\L['9O+980;R+%:/?)(TW T>DVH 3-M<0+
M>9S,$5M*FQ2U',*X?ZTN-Q4KEK-Z'7%M[2'@_!$5"*6/'A6 2<))LP0TFK>Y
M\.,RKW1^[$=MSJR;5L_MG!,:J^Q5(GC\PHQ"3Y'+*:%]2#4$;P/5Q\%_ E1N
M(ISP30Q6;GI4QH9(.-]AT#I\MM!D$O5] &G'!)R%2>OU?O<&$:HJ9S.%ZUU+
M&*..F&B$]_&*)7Q(J.1-*.?HX[*:V$-L^GRCF:'CV,0!%-3R&,V#_LQ %OYR
M.7G)0)M$==)-M#1^171^&RSTY@CQI(-II]CZ0-ZCO<#5Z7U#N$B;GKPW"3C3
M&T^<D;GBHE;?5T%Y73AS=6(N\36FZ++I>BTV@=RQNC!KM2]!?=L4[!&EIY %
M'B*Z[MOBPOT7_=^:OWDU(O[+RB$L?#/S'<6JOU:Y.Y%0M5(5/U>U?>:Z#O"T
M(1XU+NE,3U%%GKM-"QPYG=.WFMCS,19V[GVI:O\U6%; \Z!DP2P%^TZQ7B\*
M2I#Q2^8DJ7?5:@8MUL(3F'V49J%$L:C8N(*US_H0G5&PZ_>4TZ;=,E]X\3--
MD)S#!#3I6[9HY+JV,P&D),UH"F3\/1, J<_,\F$"0/FAHSNE0!-ZS#8N!EQF
M&<60IF9R1"+\<GI5B0DEY_Q*ZG^_/9!UXF[EL[G"SAE*FP?QE*5CZI<T/.-R
MO0O]A[D+/1OGB8M&\:TA3UTB[]@-T:R@GO3\0#PT,O#+1.*&\=LY]6.BGR--
M. X]\@*CIRLM8[!*R,9:4*L^V\U!A/SL*4UX,>ACG\_ORKO*/L<.^=^9D Q/
MV.GP*O]$=:*,D:?#G/ ^11^H$+.?OR,\1PS4S+_2=HF-XZ:G-+2_YQZ*$497
M600S 7&XNQ/<Z-$MA$2?ID(<XV!UW[+]$5LE+._7NF?)PF@I#S8IB0MX45';
MC^L#U9EA*^:O<55I2?6F>,@H[.I(!>3H<JW!5_*2XK8N]]B=&N_EMYO*:JYU
M2GJ;4_482AT53Q9M9 +8&%S?W$JHX::DX3(WMA6&7%^^O-4+BMRHDH]MS*^Q
M7]P"/XS<5R L.0H%)DYQD1::05*>,M(_$?P?>HZFM:K_:MZ\W2'*Z6#M[BZ'
M7!0PR>!MQQ93!SX@3$GY80A-/"YZFA^A00:UB P7NGU:DMA>C J)Z3M8D& :
M\Y2@F/GV)RCX)=X\5<=TLH$)L/*4E!>DR S[3PO P0Z#_I"$\?4V9V7SR UO
MO:MQH(J,A%V_<D'Y,@;E\E$#JZE*% PMX$SUH%B3!RG7^RQ\'U9%#GVVO?^H
M)'Q+:1.C2X] N:&$$.)D^R0$=#94IJ,),RLX-T:UM*S?=[S5K #:O"K^,NLI
MH"-A:\FE:-\;?F:](_L+2X"<F^"4F=\^;3%XHYW+0_TY56J/[?;&W%YW>6TM
MHT+INE\4/9.F"L6#J4J3&2)]GS1'HDK7/>X#D:;'C%6WVSGPMW$T09!A%5E[
M%1KT84HVN7_?9E UST[\L+.5Y68IFF)"5J-6[Q]Q6$HW.+,-]999N1*"B  _
ML+U3E"H+,%12(*1/,0%A*)H<&=8$&F. >>$#IHRVX:A"O\?>R $>)J N]*V3
M__5O/_C%>YQ-'[?GP%Q@FQSEVP:>]!2D&G@5DTN#4WUG+SRI#K=H+\R7O>#1
M^ZW2;[#J'NQ'@R&#"T6:W>C%]\9@3T#C%$?TW)";JBWH["Z["W,4C].^C,Y2
M40J)'EWO1PXAN*3-9D>/.]25#Y40JH8G87>J;XF+'9!SD#;_S7=5?+]!91T,
MH!KTXG?"_$&\MY1+/K[R$,[Q=GY?=?)PV822$KFHU38\'Z[O :7A9I*L[6J7
M$:;[-I=QO*S;_SO((83#Q]2X%>>#W50Y)L!!HE->GNR@3K6?K!U,%$$C%]ND
MO>>4NQ]=.O+H$B8,]R#Q(@+"2DL<0HF4]#+;DPF(L+!;8UPE-:LY]3P:U3M:
M@-OYB6G8?B"S8M80I3BI\+Q6>4%<\>K!SQB2#99"]S_A)+\)F9ENZY5:SB[+
M[Z#[;+9GR=4-^W\;-I<V#K4+_%KA<C[N\OYS5*V17ZUE)!/P "*"[+*BN683
ML'5WV6/=5(=2$V%ZS>9%\#G=K)#(E^)2ST>/J9  ++;ZD7:*_HIQD@JE6%$G
M9B;-6X#N9*68M7'G,]_V+P]A?^9+K3N8*=&X(D,XHAE<U/X.!A=1J>7"EG>6
MEH%TS6<)5O\"8X.D/@6]IV$-^0)=LRHGE3_'(ZJ&S:N&-1^;^RRT3U<&)B!L
MR"T40^HE,K<C6;K[ND]>__K6Z,L/HFD'DB9R/C49'K[F"B-+"?0W\%,B@$=1
M'KBGN$/GZE!Q+HI#H$II;_=LF[B]V6'[ZN3S8]YO!=7O7VH\7-9[R8[FL7^<
MYCB$NP<!P-E'FI&P>/^&Q^;?>L#[QC^#K*2I,+5OG[>EV)7&L<_HGY@ MTD_
MPD(C\,ABNM&@!"R>IJ6Z1A198@+\!Q3D9+3<.CE*^3@[I6ORB85MS=JWZWL9
M #]5@6Y4DP4M9!8&H+(UBLJ(D45*\-_BLP44!+]]F#;WVNCX?6&T7>MPFNPC
M..8"O1YY'OZ-U9P$D=*+M>@8FOW,>I1VJGIO2!'<&'5B;]YUAWRJXZ169MUG
MPV.79A--9I2(FOO6\)0F"?MV?:5+)'1$O?JCM+/.MWJ%4B!GGW)[)WF"X8VN
M#(>"7]=U[7\R 16_J]N<K]_RA_#1Y$G9;98';CN^7JL@VEC? AT:E;LM7M4>
M5W^GT-V@,*Z=3RA#=G6\8=L90:E1[ONB%]*&5,/]Q-V!"%.CFW&2 ;@8O]-Q
M#VDF]6/3#J#7X9WN-@M< +#ZBR]^C8!AI42<5[8T58EREZJ$GS[BTEM ,R=/
M%D3INUK[^9YV1;:G^+_AE?.XP>W!II1A"SO,: 4?I0FRI(8YZ>= R4=R6GSI
MNYKPEM3  M<O25J[KIMSC_(^7T?>4RO:5.]YDG66'EMO2I:DN%*=\PW]@)$&
MRO 3@YIOOYVM@)X@]@B:RLQ<.&)X2EX^8V@J#+EIX8?,<CXC0V1X"))5\$"B
MY+XR7 852X%(5X)DOGU\F6W_4_-^JCGDY(OY(*1_Z9$P5*2K;I"8WDU453Y1
M;A8MQ.@%'J8%S#@'VI,21V(P?J>#O;>J)C).V25VJTV%&9V?;!)^3^ ',$99
M"4Z+GJ6&$#)56F2X2!6E\870)W[M[O6)G$HJ4ALI=>+CA6)*X<]>.)L0/??E
MJ2EV5$M2>!.8Y]R)X8?U2@7REK5KW$]N-=/ZLS4'CWUWB+F]$6R3\"Z?_\'
MJZGARI*1=VNEI7 F@,@&)![>5^Z9R8ZMQ;67F+2)Z@S1'D$6=27T#2;'M%^G
M M5:ER+=?@EPGI<?QEW;"KT4$'JB>_=&>_4-!3Q7UXUN26 )HI().'R,*DV
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ME^4:Z+=+AEJ<E35VOCMSJ'<42'5D<#(![SLN,@%-&<"_MCVNI DP 89)SYB
M\/-@ZB<:<L-F/W[7:BY_1W2C:.\EZC6R]SN=]==(S QZ3\J?GR;>](\-1[@A
M3<"M\XM JD;X7_LE=ZPK@K_B7LF8H7Q1R@9YP'E^CWDD2\8UCY!,Z'PZ' R>
M&29@MN#OANP).\G9OR#=Z'\Y&VB-WN0HWP3?0>&A5'E&M#0;$\#^Z*^]GO][
M,T7D_7\)SN0?YQ::[(:/[69_!O\]FD5_HMF _9>HC>9ER0G3-/] D0TN^8!M
M.XY#H2KDP'\Q ?F$^O*:>U^7>O3 ,WIZ]O<1?81.KLS]SO_&WGM'-=5N_:)1
M492N]"*H@"A5Z240 0$1 0'I302DQ(#T3D2D2 M%0 &)=) 2D5Y#+R*]AQZJ
MU 00 H3DQN^]YX[]OG[?N_<]]XQSSKAG_['&2-9:S_/,/G\S:V4^[WQT-AAT
M5%Y^"/DMD.]W(,60$,21-,2/4(TB GX />:""=S[$GDU+?Z\F)@P-+7RXQ&@
ML><Q-%10YUK2BECPP8>IGJIS(^<^L)^^[]4=#F3<2$D.KU?+A'TUF<$%WN9#
M^DVVW>UD>Y#?7XU1->)R&9;GU\=%NV7BN!\, .5<?')$>X16"EX6,<R8W46]
M[\3P6-WK=^UL\$P1@8D[,YEX9^F,Z\ZONWGK"'K(D'7!?&3-E4I[+_.M)/10
M&#]8RO)=\H5TRZ4ZNEE<P#V7T&;QUG?B+1_WE\]??YO7+YDJ-O] 44%O67\P
M?(GC:=0\!LS\!.>7;](:()]]8/*IK-Y4+A*B8"WXY<&F@02W/77UZQJE5F[6
MDLAFY&5Q4-B>PTN'@76I@RR#8+T1IQ+NF-M7K0R-T!%W-B\ .W@C71_,GS%*
MI\9B,/XFFP/WABQGS"9G3,0 U@:O%_O:TE;)@]I!OENAV<Q(FIVB)62%QJGP
MH<$PVJ=D/U4C@??[PV!1ERKP.];I_.^JM!F%M6$M\F#-T:QAWMIAZIW)QBF@
M@T=B>>4$5]^'@RV55II+,_$79%@GQAKY.WU.RWP@1=[OIRW;^9OSU&4[J0N[
M+CY[;C!SXQ;/>50-><+Z!$%8!;PXXV58$;$[I37FOC^<=^=KS@A_(2>/\K<E
MX--YC")WA,B=D=4B!;;UE.4..&>DFW6)<H#;@7A-Z8<H%\WRQDFISU_]/WWY
M-O_*)4V_EZ]5TKJ5<$<1;(=F[]'P,R[^*2>O]&!HV+]%E,R6/.7[ ]WB*F>3
MBGS_>Q'H.:VO1,";X+9#@:OS=?#'7D;IHI^.+)Y0+'O=YMFQZ^>ATN^%HD,_
M%"FCQ26KQ,S64?H?WZ""0F_9U*7?;HLW>QCA62B*[7"]QU>0-4NM!6J?I:W!
M6'Q"!?Q<CD*]T1HT0Z&ZOA\,"8O&VZH!?[*2C]46"T\9.4\2 2;I(A0.7FQ7
MUM>^XE)4M2NG>MZT750X:.W44K VG@5BB^%ORS79VGD;1A%%;/<\HG59%FOL
M+^IPD&5)8M[SB''@)UC.%AIW+R!P^L=OW&8W--!E@;FS?3>@9294PL8==U<\
M=B9T"A\NWJT70PO *=9[ E[$]5$YDQT,OWY6'=+!*058)?-UO4CF*N"LB?5\
MNY!:5F!OPCLBV[)](EYUF&G_XOUKJ8X@AC*JCSG=G6;T9B&,3K>C-@E<_H^1
M."A-*8?DH.5IC533.$>JW!>*XA'H_H! -5XM1W&!"+@J"5^H*:=6/E'2N% G
M-:B=.\L.#L^UI<#/%Q:>9Z62YKXVSF?.&8W9,Q\OMZ_P,[6GUTB:1_'.C$X_
M5AVF"MQDMMISE<X>,2@R8:[0#K]L:7^\_<$YM]O9.5\93.4LL=C/[R.X::'J
MW-AGF08Y]R6OJNWIK"@FM^$4#MN4 VNX.:\0 8A=0R<OZ^69?>FBJ9VP].O#
M@CLEPOM$0!D[XYYP<7;B^;9+=<[O,:O>CQ97.F0X*^P>X4S1D&<:%X7<]\$S
MB@8:&I>$,V/6W9UK-RCON.:5N RGOVMH&EC#RRUN0*PU@ENK>AQL\R(UWO.=
M0%I5JRQLNS^>[?KLGZSD_?R\UD7I7@=CW*(2SCG3OK+6MEXV>DFV/.5=#^/Q
MM-CUJCOY/G%GSR7Q\ >_DI&1:$/A1;"\8VFU81,+55_ >5]-"PN[K*+S5%&#
M9S=%)[=FOU:(4*RC%.#R6S^CDBHQ%O)O<I7.\:QG?*!8!9Z5^:&1)(1:R) (
M>]O8NA  53N1) *VC+=6]JH6O^U^Z+L;XX:<8BELY,$N=Y1AKU@R&S<)"C>.
M7UVZ4^83Q'KG'M\Y;MA8!1Z$&4Q6QTH<U+&U'#NE.@<XOW!&5^V1K2ZY=@(A
MJ_9+Z=)%#2(+=F]_OGUQK7)X$($8M:GX$K]R:SM7]:3D2QDYRG?UJLP/+6R=
M58;$871YUU;%P>"^SZ8$M2OW^>]5S,_LYZ/?RQ7QTUVN>;7\]AJ5WV@N[A--
M_CA\\HU=*\E5+4GUQZ-1X/3B:=K6X8:1@07YF$A6;7)7Z!@*Y0;F[=T:,< <
MM199S;QZSADL77QZ;L']D*E1G*T&IM4PL+]<%R$C<CU*C%DG7KWUNEZSWFN7
M?D?MN LA1HV\FF"TD,B3B!:IB'%UF%I->8J2[OIENNCF:V?K7G5U*I&;)'5V
M^DJ%XN5+?J!H(GT@7I\O>JX;)O?P5#8^R52Y'!*M*BJ;KG7>"DZV 48+R%^<
M@&^!NX:,A/#M1Z/#OFFKYP3Z;]9J4^!%Z@@3@ZEMON:+#K[9HNH.%^!>SE='
M^[<G$Q>O2-VB^-AYM70L=9F:ZH0$$KR]+$=B"@MQOALGJJI[PM;#SDF4X ]R
MI7KLXGZPQ]$QU>T2A&NISC2.M4YQ><+!D@6!58;T1H_6F1A88F9DIAFN?%>W
MCG=(@E+BU?,=CCWP!G<[[0J2F&A=O*A4UT*Y;:S>,_E'0<Z!/CX>]F<L7/?<
MFQ:J]ZP<Z#\P3#E&R]GLU75014G=V2;7VO=K:%7.' @44,\S6AM<9])UK$K1
M,R]N6$HFA\8!'^7>Y+FB5,9$+M]5!-'N^.I(8!X4%+X>ZWBLL"9489\K<+T"
M6"0(Z)YPJRAKDBXB NB]#0TP3KGB6X[=^R<[MV_N\ERK[&35:Y97L=73B5GS
M94>)1#X?V@(J,K;T0&\6/Q.L__&<-^NHU:F[6_XNS#=YH>H?P:5;XB!>BE0B
MARS 3BA,B("UY=R#IP%S)SZSVM88N';\K,,UZ-9Y]JQG>=M5.8%0:(OZ9R)@
MX.$&@0B0PHW/0:MV\/'R($*+ !'P22+09UR8'J?J3J!7(US1-"2\-K0\/$)V
MP'#J$I;'E\RA<Z2(P=:764=-S?6G4Z %GE'H&J\'$0!-Q8-E(P"#I&21H$^:
M,G'\E.",S?K'V<KR/_U[^'\UO$&LM5:0$E/2KQ^LA=D\CJH=J1R:!@]EGJ/H
MC"UL&$>:UT@(Y8<O_&F4_9\7+$&T<=(,B?S4!!L,>; 'B+1(?FT_._.=)]%B
M(98YXCR@/H(&?6DM*\$T\!).SY8V!D@G$:VG-2HN!.U+.N?TM?9;0;,:"U5T
M>F<NOT\6.&1P%82)=T3N7ZDE I"]!/&_6-#SQDL);8', Q!Q(=&6E>U%X]JO
MFKI223+;^LQ>.XR$)]'D@?4&3^:H5Y/ZME<U1CZ-<7]U-T7RS]H_>OB=[B&P
MG7UQVL?V>)'A*).-Y6\7TD.#WE1Q<HU(S AYS$CICKD;F:"W.P8>N+"],BH*
M42J[)<-/XZ# Y^VE.E!.PN'=.3/W^P.RVEW<EIMO.+EN4^5Y#;-POG/C U\(
M^]6L[68A$: H@#C!SRVJX7E2$*=D)<B=/6BT+S.LD7."ZXJYZ0\IV<#4#/OC
M@/*JVN!F02NV!R/11ST:W&7^&6I5+/G <Y@5U&([BJQ*UP07W.H;/YVI3>=N
M*2G](<KU>BMW# TMF?O-9''(RUII[;_1>&EJ$[<I9B<(KADSVV'Z\0;ICB<C
MPAQ%#^)Z@@7#TH.CSB0,,VJKXTREPE&#^Q"G5IVR],7-Y_/9L>_M^!^Y=,74
MO5./$G#G"X[P'Z2F ?_7;CM"*F:\2.&GA5PJDNIA)=U<M/Q6MX)W8$@E$> N
M20??H>/_AA=#.C-;X%Y:F)PV]G4C[)Q3GT$B>^UK S#2\F5:6&HJD;_AQ+H%
M1+.#M[6V<G-P@U#,.G[Y<;FH/>C*MYS$&/(9=I\=O1E_*6>00=FPQPS(>-2]
M(EXCE5TE]DIIP@K+QW>"=2_5SWV1[A6VWV1CX?H;.QCK")D7*_*6W6L[E.V-
M2<Q&S?)&IH;$+?NP4@JWJ?!6Z^UO&- O>&;)MUU1#+ 6CI3(FHMV]A/Z>B_L
M14@S>V)B./O=.L&[:8.]= .K1,#?N5&R.L[0#PV.%CLAURT;W1(I:8>A]"WH
MG>^>?]W#'MWJ^OI)U';SN70!Y68%Z@$17FRV5&U% ^K',<\ATQZ[7,C=1]G4
M4Q>IBL*BL[TROMT2ET;\G>P6#A)L"\W!&WYGIW,J(WW<:#:CO_+89$5YD:>,
MU^)D/.SRC1PT$0ZN&[4A;WQ#2E)9WI6'8W>>V$U5<$2]RMZ#^7+$>UIE=/U9
M5H-_MG.+5[-G2L>!7/-3D!M@E@K3$\H9K6V'XF7Z.V]*!9#;K\XNVG,DI(V+
MS<^%'L-C7D!*W(^*A[?8WLF:J(DQ.HO>MZ,>9CE#6R/=E)4B66W_C&1*?[.8
MN0%\8<K(G8M]:JHU;V-H M7*OWZ%MXT>)95>^E6-_LQ>?!/=(@O^,S>F9./$
M:$VCR&$+'9L:$R&ULR>YO0N<:;1,A<WW6XBER,3:NUG^76#0YVKQ,9AK5=UH
M8S/_.!?^B=[AP/62B7*R#>5MRG"";8<VQPD;6KAXN:PV'>5^5YLLFB&N2M^6
MYS*.SB$WO3G#Z^\R7?YSV#\&AS\9IL1'%8#]WPO!>.3QA7]/\)<)O)!G/&8>
M+BX:!BTF$987(<\&1,N+7P-'Y_<LK"V"3D#0;B>,R&DH!+3O.**]\,R/JYA!
M1\5_L"/0*7!F;O>E'A$PP3]^U&TI[]%WX:6HRX3O^ "RR@N?QD $'%!4$%P-
M+V'@%MI?9KP]>PP4V+!7E_>E9#T+.Q. $3GG<YJWV)/(KE!LG[22<Z\YU.E&
M[JJ9!3+X%#.BYKP-.EM0FND9Z'#GI1$/F6W_!LGVQ>!N(]N[#X;D!/QGG[Z\
M; @0=NMBE,79M4#F3PW;+IMM2-U*23/Q"$F]F&EG]Z;K$2+TG/594?+O=UM6
MHV5BMU^Z&Y8X<EW8;^!KN^+MNO?X1'X)5 TW27A2IF%4<C>>ZGQ]OZ#4-Z/*
M'?04*E\-4]GS<$A<YJ=JRN[JDTK3U1/./+L7E;$UU^^42?XP"JK#&9(!U+MS
M^NEJ@=_B&P3T,;2A]7P+<ENFNB/;%=T98\M#6\-J2;RO5R1">/;JAQ!581T
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M(:7_"3+^/4C_6R;_ELF_9?)_I$R2EXF UT\(WS'J'*[>)KM2L0N,%1N?3->
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M'+>[FX'CN=.D> QT9X\V;2N",P3>F/#V:_.-0L44+#3(&<2@.I:79=R?QEU
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M<_1XDQ&@,?JB>-@ 83!OTL38P;<M'Q&P9'9I*<:*73;;N9R/)R$M]GS =16
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M669582KY_GJX&0B6\B"I&A<5MPZ=L+.(U*\:1O!2"]X5C%AF<+J5';+I8I&
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M&55>AHJBB$:F3*_EO=:3TT%8JAGM,>GS!8=1/S+K=KO_H+4BIVK+9%ZV#+N
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ML8Y0IX,3?E.ZRJL1DNG;,]4)D#'(GU84^[^\;--A+WBD\%9-Q=8\)3HI^<L
M46=G2N1>N6V,].>(ZLGV+*OMX]S1@/ CGD??<Y_]"TW'UQY6 #SDNSE145,
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M<-KR^U(<J_?@.1@"D]]N#8$1- FBX6I9FNB!S+=EY5R'JPYO'&SB*X)3K%0
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MFOI\+G9#/?4[>\9Y*Y"#<4"SMA;DZ)JD:::'Z7@#-4=-==UOG1V0U<3;I?H
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MTYS S0HW>6DPD"\R?\R48._ G(\4V1A-AGRYT1DMG4$Y^?T-"HQ;"Q,M$M@
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M S[=O 9T&@Q+Y1"'^2 "SR[TE.^AZ+#6[WLGKP&M\;#@LCXPF*OI8'_=]!K
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M3Y?R&6B,6SH2JOT[8:4\5ATS\D[.\Q(A1P,,SR*?,:KXH%+J"_/J=0**)*]
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M"=4G>[R6/+X..[D*CB7RRVB*T7KFHMXQ!0-FJ&=DX3=]H]._9JB.5 8/7'C
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M3:.:\K3,%G]G20>A<?6'BI%V)H/=]EI>[R,2JR:G;]E-LB7I:3'HE/$X)'\
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M[K6[%L7])MW_RMM;(H]43^W48E;B$4:$[>MN-<7;LGMHT.Y^]DG&V<-DIDS
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MQSO[=TI\^_#7NTC$1OEOW7TF )!_0=AYL?Q;]X#09_<V -!_^[=.H(%P#0:
M_NMNH4%A?]?]M:R0 =0  \ "< *\P#5 &) @Q*<(J $W"!$; ": )6 '. %N
M@!?@"P0!X4 T\!!(!%*!/X <(!\H <J!:J >> 6T ]U 'S ,C /O@3E@&5@'
M-H$]  6< .=$1$041'1$S$2<1'Q$@D1B1+)$RD2:1#I$=XG,B>R(?B/R)/(C
M"B6*)HHC2B7*),HG*B6"$341=1#U$8T231$M$B&(=HB^$IT1DQ#3$K,0\Q!?
M)Y8B5B:^26Q(;$GL2.Q)'$@<21Q/_(3X&7$9<1UQ&W$?\3CQ'/$Z\1[Q,0E
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MPJV3 FD,C."0-L.]@"[WTSZA*W;BK)^ZM@R4(]J6[C4+@67=1J^P_J <>8V
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MCH5(/=(KQ7@JI'8PKXJ",_2(NWB0]BNHK,_X9MV(R6#MI*&#P>ZL4(-E59*
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M1B83='P#;A8^ZT'I?"/<<U&=DM*][=*W>)$^E8.#/B;,GE\'"INKS%GZAU3
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MF(3QLDY1M<X_[Y[MVY0&QD8?* /M%0 V1B<R'?\P<W1 0P9;/H_N'K#?[6=
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M3U#PK,Q]PA9(B@LH?[CVO5"'"[C<@IRQ#&<KO6%_07:Y@/S3M.?Z&>?8)<C
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M1 %SX<-LDI;%-W6.@=LU:7;??BTK]B[7<J#^GJHD0B%S87QU+F6CW-KK>8R
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MU-$+&?2CKI@2U)T#?-9=BA2]@"/_>RK^R/]O*OY^!O__H.)O%Q2PS_UA]U,
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MYF%OD9G>6-Y-+ Q6W;TV"5Z)X.:29_,/@X\F^4T=A P"[R\6 VT/#+(<,-
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M?@V4$.T=7$*8U:GACC3WSK.$8B#;D:6SEO,X*M%5SN]&F#))="<A63'^A6M
M3 G]K6 GW5/I8G:)OEMFF&I3HQ:7ZKGJ9WHT\,M ]K3-C.65,/LY[FM9?S4#
M3XJ$^CUV>FF4BWG(;QL;UY6^M[N]>],\^9#G3["S:62F5<I$?CO['A Y2P;.
M83L0HN.HX<Z\2PAQ5"_=:77"N\(\DC%1OM!8'1 EP4Y^UAD8B.F4_=1J.#:U
M8&HH!)2#F@W QVG)W--9N:NM8I&AXMF?K'0AR"+5[_* >GKE>F7M6E0$^L;_
MTXN,WO7)=38.7%$4.1#V\O%6%_$ ^B(8NPF87KRD(2*B9$5>#T\GM,$G".Y
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M$NYK'0W@[$G:)_Q)E!W[RQ#YOH88&I7&D*JM9@XP\*M];] 76)G/_68U +/
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MYM&(%&3LP6&%,Z+:7$""C/X'^BBJ#+I*T5W[A)[VJ<^4.%SY0BPYZ3G?^MG
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MOT7C#'U&+(%YXT;;\3Z^C^CX0#C(ME+ 7WDS/J5UL.GUDC;B/8RG:S?7%KD
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MH>J%[T_>N<+\%>S3E[J5 TZ7+J!"TP*GDM+L4]=8M8U;2-8MV?TSB$%--II
M2SXX@)^8V2JTHZO-!2"90BQ)'J2\$\2NG8"PV!V(V3#"CWN(SAO@JEBVB#HY
M@@LX.A,-8?W@(;I-B.4/+N!W+J -QT/6/\ ?-!#;NSR ?#'*0QMW'K@>Y70#
MO]\A^&RR9.%BB.WY(K9Y/WB1PT//(V,\!/T[YV,7[]V3NAP^9RX@(_9?D)7R
MSU0=VC\DS@6 G\PPI0,Y]D#ZR90UWGMN]3'R>?BI2^'!KH$3>'B2Q$',@FG^
M",Y#H9^S^&\SB]AM5NG_QT0\'#B"HNQ$I)R!!)STFN]7["N.Z&6#9KA6_>H>
M%W",4_(HD0.Y#Z8%G(-#'>&(R#$E]HM$'LT-@2S!>BY 1?J_!2/^[Q#GSUG\
MG,7/6?Q/G877,+ :S!*+8#QEU\!5P.U"T9P33-*?S$SPB95I9=WI:[3=%]_[
MCR[O:8]>FKJA!KM&%^G<Y0+\WV IEXS9[[YIOB\QB[M]7?V(1T?#9(W SGM#
MEXO+^[>MYXOTJY':P]E/\_B#JK^%[V)Q:<WS"UV>]Y*DU?VM0SUE/(_;9!BK
M]#*816+^TCO?<3.ZRR-0A>S_I SRO]:#CT)D2?)26D47=A(7L$%%[%3@]1W(
MT%@N0"XFD L(Y0+8=K.6?U*1/X >A V>E*UHBQLZ,,?M1>[P_]&X>,Z+(\C3
MYK01F@,[A_"2L'.5B82@GR!8";Z(KV$(ME:,0?-Y+B $R8ZRY )N%\,EQD9D
MOOS+G/Y1;VA=:TUCZJD@:=P4KC-SO5ZDYU=Z+RVO=SG>[H37<WT*WM/]C;$1
MUJ],I3++GM WOU(OFD$=62/[LFMGS*Z!D).1;?O/.,.0$V!?)) IV84XCO#*
MDV2$#+6HS^X3A7SADH,/:,-6T%BKAM&2X:(Q>9FSM)D83-('Y]MU@,F)*<NJ
M2VE&[XRVJI/P>,@-#,CH\KUEVW*T1"HCY8VBXI:ZCUZK4_ @ZMMZ2.*AF++H
MZ-O#G:";Z>GI2-TFC%_$@/-FT3Z'V#ZRDM?VO[F<L7^PP4^,Q\9O/"%6Z\P1
MV>JT$5B/..(O)&=A";&L8PD$<0'!7$##,!>@A"2KPEU@T/\:JON?_ #&\MP6
MD540PM#B IKCN8#12N8RQ(<*9&6>);!)7,".PPN#5PF(;Y&ON8!&"/MF![)A
MA.Y%1')'_F^Q@T#+;#.__>-O'^@*3TR3+46/-]1N=02)OFG_Y4BP9]BIWQ,&
MS-RO!RCZ+E<N8V^1S%F9A+?%E=D!GTIRUDL6EY LT1I& ;-_WY9EP0RA$I,1
M-<0XL->UD Z90W@:(YE"..4([>Y>[-0W[XE3TU$*ZX.R/"DIQ]U:3KJ9,@ZO
MK:MA8)W*NRJ*&NKQ;V8O-<)E6D'RE\\L653GHODL3(6_W?T6D.%4U6RZUX ?
M&\LB]GVH?5*[8O3Z_)5HI3(]PZXMO+/S5+!;!)NQB[CV7?JX(]VHL9#IU9'M
M.8VC D_YDI]&%W@S3OVH;ZJLJG#M\BA99E2EEI.FIBU/G-I\F*2U\69()QSR
M*"3YBFGQMX*C1C:YJ,*D!U@E\(4T1.9B@9*11G":J8;YI]94ISKVJ9V9%);D
MOC9G@*,P C\#';M.[UGGH\MVB-Q$,7G 1D-W.EM&(P19JM0^]YI.N# -MV8@
M3*^LF;M)Z1M4>Q-!-6NH==7G?1/7I.]9]/6"KM:/8=^YJEJ*6WKI;*G%5F&Y
M%31A1PG\$G6[J5;6C*QBJCVFG>ZTD!I<]>G8 [\NVZB"&[DCLRCSX3+%YBN]
M;CM7.M[Y]?7)IXVYRKV@;K[$ ^B(-H(PYPL$L ,4[J%L IBO;@_B56&*])8Z
M)W0B7H+,+'FF"E.@MJIWDN_89^9KTRYC$;^2S:<KU-**?-UD1@Q;)#!%SC-.
M+CA2ESTZ ?VJ6QFV4Z!$J=+&2MA-Z3ROG3<U[\WPKC Q- W*#4MTJ8ZC.!4K
M=\><,\XN#,B[)U^D*^TI+AY^##5HZM+G=[5H(3*B RY+*RE@OZ%BA?RFSXS@
M^SP1[ SJ-4GK+SCPAQ7[P>GE^IG[(_[^:IR>TG%S@?GHL;1O;DYF8OVUJ>W+
MLN$WGI3)^(9$WY[JR19)FNL7]U'SGG)3=3(+_?[TZTI2D1STDXEK15=)95YV
M$[YL:?^:]E<3D"[U2NAQB%@_9?VY.O^,KZ[^M:P$N<$=Q1;=9^\=NZ1VL\U+
M6A@=IHTCJK]EGZVL75+[UE(?<V\^6_$-Z1F13]?<0K P(:T$+7[7L"X]UT#N
M-,G4W+%5;*TC&S0 ZGMW83*@,37B<KW)]\=KL6V!23UM7 #MP\'/A!X*K99G
M^K3\E%@9+8.C^X K!W]E<@$/> $3F/%;L, ,([[^UQ!%/;&LT0_XL:]L/Z%U
M;*#'^G*$6\ T,8<<@@C/8GUFXV007NME$683X_NWMV?J%33#?T0R]&:$F)(]
M,JJWO]&0+UO<J6\71A^#]$[D2]"Z&[$]ZG%AW@&5H9A?%(8>JY\V#[&MJ\(W
MD$*C%.X27O9N^9D]*\+EI2[:9X"I=BCSTMXB.^5VH515)8NA(-B;X(1TO.BW
M--Q0AFGQ.?K J5J7UF5%LLHSW[&FRK0(E8W*4#^:P]Q5W]%\(.35C-B$&V$T
M#")XS]N/-M?MY8BGGX[^U4%_,7:MMJ" C5]U'51%QRS>&YQ]Z6IL5I^MM(G!
M4#.DBU;ON3F WU-^R)X9L&%\;_0XQA*3PO86Z!8_G+F8'U]G65_DI>YOEF%H
MTD>^T:LYI!G F/?7SEMCF&>U@&<3 W]EN=(045R -Y(/9D4+C/6@J\<2*/>9
M[B"=,F@@];&;"*$I&FOQBA<LMO>NAT7T&QCYBZ]?AML-8T_%W7[?G%[>U."+
MNV2G:(^L*5M36)<%7:T00X-FR?.6<S6D"J>&,O.!I/G8/+V^3)?48&OT0&;N
M@.I2/B-\Y^L(LW4V11"9(J-%$_^(Y8.YIG7,T#)=ECB_T"Q30%JEP"1Y0/G]
M(1R1_^M7 8=]Z*7TO&N\(*H^KOV=NZ $6L >88MR%G<0(*X-K]H768/M"(XW
MBK+4%78;,1,?2@?<VD6P^BZ390.A\_O8>Y^:G0?6P5K9=+XV1!)>N+6!!'*D
MO:)BHW$JYOS;7;K/P^/A4LR^ZP0<#9]WT<K70+ZQ9J36^>I;T%4T$702XI?:
MF>V:2^H2ZY^T-HUW.&$A46B-CN\83LPN05FT*J'OKDKX=/OK?7(M57]&7KXJ
M)O'](59BN+BQ45WBC5_>2E%15LO(C.KFF',$X3;K/CM3K793D-.7"CM) W=R
M 7%NRLQ6VB_@!+CN($ROR,_@&KY^A)@4QC[BC%$QIG5'7^-D%,CEYWF77$UO
MNM6HJ=<"T?%PNWCY/@K4]F#5?<FF?0Z.-0I)5T0#/8^1K<MTSEJLKQ625]8]
M\C.5]!Y$UBZ3DB_>*KO^J53-3DS5!54QLC:'-C]+ ?(;"#'K>Y"2+9*TEXL?
MIT$MHYLM(05+,FJTS#<43%B+3Y'WG$L5COYX]_F%YYX#F"*S A_K:=<5!Z>8
M[/.#UD>:A\7.Q9BN=C[P&6RWZRP?MA4[.Y!A8AM;G?OCPK*<KMS9LD]RHJA-
MM]YUE%I"AH>$9GGY=</KO5K!*;)/=_U5;9IQ[W?&W1;]]MU8? 1V'L$;F  4
M]*!EO69IS;8">V142!S):>:VR<AC+,ARME_!J9'TO37$8@0GH'(;1]?)_=)U
MQC_P]HO:_7<F&AE35<%]57Z2KPH@Y+MYCD,EJ]U)A2/ZE<=ZA9,\%<Q+.,?(
M9O/>BU'8G:1KRJ^MTB?/KRAJ#S\:(?OH]K+R*P;&4CF#D*,L.5K]W]G98>#C
M=1_&P*<17F ^F"W]_D@@%1\/LZE<A2N0-K-NWUY;-W^=QHB4)_U5G;&!2K#4
M(\]W)L3=I^MHB/08H54_?%WY^AQ65<-XDGRY<2<\X]L&QVDBVR+:T3;SG.DH
M*BY#<=QYR@JM&M'<OTHFJ^BJY.LP]6;7#S&"V)EPY>5U#% ,YD%WZ):6[#X>
M5-JAEEH'/T+/1_ZYY&58Y7QFGK1P6=PZYX=\<ZNX@Z2GX0M;E/*]\IH>#]J0
M%0/J[2YG.EB[Z92.-GCF.C-MEJ%8:<<:DQ=#7S223ZM7/3/TI([#TLN;;K7/
MA$2F8$)3OCJT&_#BFI?IJ\CJL5B0!AW2"3[4HDIU-@.*KDJ(3X0E(SKTY;B
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M1[GL'N3!'YP1WVTJM>-_A^WJ_]=O_QQ=$^L/6SP#KX&S9RTY^+!>LR/+<US
M]P^#7, FG NH;.'=O6S#!<BLA['[N8!5J<OL'FRR 90[\?^]+QPC_I.6XVHY
M]/5G:MA,B[I,JW&W_J&EC6"V[J6K\7Z&!\<RY-GZE1S*:41+XTUGD^NTGFWT
M@'B3G[+<:&!HZK3+*"E':QXDMXX/'?/0S*X>;:XE.$Q%< &N?%D]PC^A$#\B
MEQK9Q>PW);ZZDPR+0H,:-,QSQ>$0R;!/]QE!3&!0['C>'CABNN4K8J@T;-'Q
MTVA7[9>XK_K]5NEJZJ528(7>/#/]T2AC+6;9:&A2<VCH--W"*K6QK/3+^G%C
M\P.^!%EL=<5 Y<7__HGFU'<#,?J=X82M%F<_,E;(A6EIWMHP%F(IXOS#J8IS
M:4Q#F:"VGA=:2CF-<;[_@="\\^A((YLXZW#[X&W$3>#?^8CQ\G)4TU]VUPI*
M04-*924-61YT;;1>G[)J?8UJ@/6#P*2"['%GET&5:6?\#UR#C4!%R7S1OA#I
MFRGX8LZFWHP)/C'EC;\U1:XAI?K[K-2?B<:[GY]!_M@L8X3-Y#CLUF.K!P:V
MA#%>T55;*WY1'/>(0T4NX.1U9N;14Q:(64A;MF7CVX2]I7GU(>5,@2-+FO];
M\H;"BOTT-LZ]2TQ,S"F[RZ370&_'*]TA O,['%+;Y2.V[O=2CSDE>;9., %[
M&2ND#U*TMT;K])GV(*^:*8VO. :B6;?V''S<8IS->2P*C6+12A^"7#8M&+E*
M(U%_K50/?X>2CJ2A]VD-QWI\.G=!OFM+XO/7\'OML/,L()J9MO&GEKS%:$J&
MH\OJO&'W;3/U@% -^_OD/.MZO^]=H^OV&U\J;+N?,+_<4?&9Z!P2)FY$0,VT
M./MJJG22HPIU) 6I]-%IETP?*LBRGXR:66ZPM&O\PAD!"K <:7548'J+/%7!
M'XC+=R-,[LXY.7HVX>A>\=![(:H8,NG2CZ8"096BNF)FOEES_?@NV[Z'0IDF
MRWM_00?Q=YF&*^W2+SII@%GZ2>?3AK+OJQ['Q1+RO&,9 5E.HY,.%K+D54/,
M13-!"SM1C-<E(Z<'OB$*^*=YJ<T^Z:5 K].J!I(Q7X#X_6Z8*!L)HKEW"\8%
MQ@S#!:@?O_W%/*+8-U,(_+YB5C]R:LVN$558)TI7M'2'6BMG9EP<O6L'O9YH
M++:51O$WTZFPZ/2!Y[OLU8]0PY[)!E9CL47A0]6PRF2,8F"'FN.UZ62K9\M=
M&C87XA!G=,;0&Y4:: 3(T'Q^8\-Y,75]+M_9=&"\Y1)MOXM$>P!_X7:*UOL*
MD^O&KB0\/?KG+"T@H:$HRER/(!DS6"1++!EER5-\FP>P=;VP"%I05UY*I&A#
MB/Y&"&1AP\2RN?5=<5V#W3+*J0B4@K%&?Q^@]X=D$BNU5P.6T"#9&+LDI)3W
ME.-XLM4$:\HBX)-# 6*37,-G8S]],1'=KZ@\<\PS9T>D[_S]72Z S\?]9$O0
M47C, *$VR?U;.)KAR2[<DR E'$HB>OKT=>AZE.ZV-U6^'"6ZT5SV1C<^#2/=
M99D2.J'+_SHR=J8<1?ZF'BVZ:O\AH+FH+" X,*7W)@ZU=/%;)5&<@.LDSY)/
MVR2;]D5=5@X*)5P[0$J8NO3[X&YH5]D5!&A,:G+VE!RL7MN8FUAD!H:V(L*"
MI\BY)''],]%T#B0Q@_6,W6Q#?4<? ].=G%G*S <AYN[G^</6;X:?&N[L._I-
M'5S67G&21B2\+,7Y7?^F% X%;WG'#+OZGG'2UKBW^DZO0TG)X;!'_NW8=T)]
MB$%%ZU)^Q1I87@TV%YE7:2<J_?9!>Y2 ^9H;HB ",K2XYSL_G%\XM[DU8;!&
MEZ<$$P1C?N&0<KF 7UID*8(O[-ODV)4&O.'*CC0WE"=Y0%J$>07+D6:9U#/3
MR1B5ECLH9BR(]EH\/7%#(]G#EQP=@!AKN1/.$4_:5CX1XL/"*40]>_I'38@B
M55*_6<Q)I&1I96(18_2UH)%\R781J= \;E_ !813OI?*Z :S$2X\^#SL0#Q6
M]MIWLI7B*",P5]VFL+2?_6--8]"K>-'M*K..BCT):U>).1ONT#&]QXGSHTLP
M,IDSGA2V">ACQMA#XJZ*<J?;Z18NX'6@G[5DPT")C\.VDYO/A-!LF7A!GE]*
M6,W@+\:Z\Q<C[8)8=F9O;8)O:#O:I&13+_4C[N]4X*B#(B&7O*E?II^^1? N
MA2PJH+0?%/<7]<V[[145]'G7UT:Z<;8NH>;GP^L8M]B94'.*7G.AESLM;,.5
M2HHODB+N\2XV$FIHRF 8/\L10GX;HM<R"HX,;8Z"12"<FO_&C42'\)<8G?V2
MC7N$6HK(^K/1PT:EV"W R6B"S9:WGG:R?F4&<F.A6ET'DJQZ**7")8AXI,ZU
MJH(M:_T9_XG4O5J"1F8Z$8ZWQ\!HG&$.WQ6Z#+DL5Q?2+>G,Z!_EB(8?]41>
MVYEAEK:3?MD;YG'QS='U*V2CQ)H$XN@7>J9#>MYB5S7K'.5JU<V! J3!._A1
M1T)AKI%]A H?(T=*Q[9&& R2MZA6%;&5E2O*EC=.R5HH@ZNI(R4"9Y<Z96U6
MA5>GQAXZV)_+[=0=*:PFYF4B02@C ]\@G6L8SPXNX$\N0))E16"J'(6%GQV
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M%$4;;B><?]:BB&1=/PKKY+< 2H 93A-P<JL,)<5 0S>;@?(J=9\9A%4>K\V
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M'VQN;):UCC>OSN@0I)E;W=(76! *(;%-<]S&@0Y+W6-;=G'DB#(U'\8N/)C
M)Z/4-,[@QW:;?>]H]GDU9G\7G=#,F:CQGSI[\[VMJ\((,@%A$:>P/88X/?;:
M?ZY4Q!O=UV_1YS\3O2^I;5P@8W$FYUQ2BGUUGW=. RQ]/I+G!<P[/4E:H$4^
M8$'EZDY''A?PTFM",-&3YMX%2X@!,-%D5V"70,VUZ:74]U 3&BE)??""0V/:
M_.G-/7ZYZ:&EC5\37<SE<_(#,+'%;B4866N1K(@[&+Z]#WN71<<7E404^P-
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M\B?JZ)).]T?2]$[WW6=E^<FAJ7OS]-EM[+26,5/,D[;,\)F,$6!),8=I$UQ
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MAJ]L*+$:K)NU,F41D)Q]$)'G4-N,WZ\%L5K>CD*-F()T-)D_K1#%LF;:4+F
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MZVJZFW8,2G7H>EM>J$[#/-X*"ND_/WTAK.J[.?A9KN=18.%?]^K J*N54_/
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MOY6]-&H- 8+ZU7Q^8)>0L?]]_4F;NJDCT#R,H99?0;8?DM\'V/5U<7$3#/G
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M:- W$0+U'W1<BB!8N_VK)!D39WI.[SV;TW8WYG+\V?B.N.GC^P +T;^!<OL
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M)N)<9,_(?$G*QIH0QE& *UC1XTJU)^N=%(Q;#EO<*S(V3"N?)*HY4N_8!I*
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M->.38W5BZ-BN5/D#!WD'T^W4I%O*\%").FI]78JUUWAD#&HO,-.%$4#>H@Q
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M0J-CK#\!6"4244W;:LM?I?:T.0=7K$/GP,\,S^XO"EO_]6'2GYHC_05Y<3D
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MWS>W7[U5=CE)[JB;_GUM,2DK<R?_[]I#9BL/KO>W9&D%"F<JU^5ZF^?>DJB
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MZ(Y8Z@7I*_0+BS%(E]F)36TPWZI3)&2\P/]@=Z-&'.O2_;HP0G)?=5]0B;'
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M&L%IR C@J,0)<T&!O:@U.;Z=&KI'ZVL&>L6;(_"1-P=>851S0>_P%$7.*\,
MV)[NF:Y>XNJ8'!=D480<.(9$P&BCK&7,< OR[(^"?\^M"___#TA7%DO8;E;W
MPP :2GNPR!*_8@K,TV 4W>X(U4M$VG1A@2]1S.@XPH"J%IM8=@.HXG?+63])
MZI;2J3F0$QKD_TS=N]KB\?T3]BDNDH*B%_6X('(H(_+7467[(KB@J"CB; [T
M&/2VVF%(-$H -5NP.[79%H">V=<,9=30%EBKG+-#2%WL2N/!6+7;(31VXPPB
MK2/R#&G-_Y2_ZA6Z8MP"QCK.;!!/D+GPP>@M,,0%[7?D=20N<@)67]^S^66<
M<VB>%LZ(K*=!UN)07- A8H\&697QRO(^[/ *Y)C#IG\52[<(=<?OLH7!'6)-
M(TFKPA+:0=ZH"0DI]@O+Q!DE%UF7U,Y*<D%O,2Q13\[ACCD\<-J]E"5LP?@!
MV-'$9Y=IFVL_J -2B 1HS*YL347'7#+<E) RUX$29@E3U]TZMPLY@F A^;$#
MB0IY+]5K*R;UDO,&W]?5@G;G.'R!/,*VP$<Z9 [%$HEB&/*X/_.#'364HS,9
M O3->$,[+H@/%H,T")J%\2/PC+OO:EQ.<_[,$^."G,>J#"M4I<,AXE-^SS^=
M:*#QE*W6GW5E8]9:LS)QK&-,!H>-XTG,$E?O]5O,ZRSG(228 IXXQ0H8BSP>
MV2UU-(KBUJ+;E;T=C53$^JU2 \01-5WB8:/?@50ERGM:3]SZ_6"VAAD!)>0,
M],L)56$"_@!%.@#CE-"G*/]-P #>#3T"]47S T'4@7;,Q!6&VC#+DC9 P237
MPC6$@#]7=%N/T]0V7^$ N'/"MLF8(5&0Y4X'/VNN6)7TGV^M'FH=$EDNO5R^
M!\40I2G&0CW1@'X%XRO[%=1[_>!?0"!->DYQ+>TUTF6\51QPLXPRIL5F4'O=
M52G>SRJKFJ$%RZL'<HHN>54@"KN&)[Y,N!E[>A^,)_##+<(1?RD]@4PX_+L#
M'\43FK0@\'HH\S:GMU6<_81EP)2)''2=6:-3,61Q1G8C<(6*$?7AR-)*XX7F
M+,?5#+5+?357Q&25!@D%\G6)97[?_11DM&N9.<]EQ1M./%<Z^ E%@,;S.H.R
M"<A!.X@ ''.<,PXYC)HMA=1X1Q'<%6#HR"-TZ_8+4 H^V5"88C#E9$U"U34;
M(=7K0A6OI<)?P%%4B2WWR["C4^[.4^Z M^W0C&T#Z0.T!+6?,XVIGDF >J)
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MK)L_.)PE%M<]Z[4_V[Q<5U3";KVJ+4)OV:I@CV--TKVJXDBWZHBB6Y-T2"\
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MCQP1[2-M@37X^A"'W=V*W@5OQU58<[HHU@FP8C_?GD&6F0D9/^U3-NU2L"_
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MUQ2G&&L%Y"DG6_?OJ^F'#_+UP9%T!^@A>S+R-WJ[RV'"WKZRB<8L<XY,65/
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M4J%#-DN^-2UP=^"+[TH RH]CS=\9P35@IY%9S9MYK+CF,AH?,QB&=!)#--K
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MT^[D^V5F9OJIM 0./='^S35K])O+Y]'$Q8J@/'4+=;_ODTER !Q(4,?9=>Y
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M^>O')6PKK)(I_:E;=^XU&^"6'WUBKIU_*VW;M8:D,6QC( US=3CA9NO_:9]
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M>$5B]HK ,Z*T \F@N\*"$=A'W"P;/92-O?ZTYL]A1>]:33LBOT.8M;7U1$&
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M6]/KEM8LB\;IH%W,-7D.B;0AA9_2B)8M"=ZECPG=J9M_OC6KUTN1+EK3#*V
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ME^YLG6:@3(^_6'3CSCW:RE%;Q"HJ))ND)ZGNZ.M[N7-AJ0'&DCC&? #8\@C
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MK=35RCD"B;VT*GI6\_K9NY\&9/QA%;\+E@R('SYCJM@:8;VP)8M6_^-Y<G8
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MK!QM";;F^Y>;V^H;2;.S[F[N6,$N#98Z,$=-[$#2,P86Q8$4*K(L<RYRC#]
M]^%(\H<!3MUBM-JE!TTM=O%[ZJ)*#\3_NMSO=)]QW@,JBL,EESJ+.,U^(O*;
M.<5HYSM[H3;'+&S==/QAF8T&D_E'6K80A,DCK*#E&F2^8$5A '&2Y<O.[CJ)
M$9@Q%4,[.['_9EDR_&"S&%^&'[4Y-589N0B>C)5B:4QW_6K6YAQG#&9@EQO?
M?FOKG,G/O]_L7*SBK_;K\]%<^W\>ZWVM^W!9H%I,J]_'.YDH(VRL%:>J?C%=
MRCY73DQ K\BMQ>/.:NK=U:$*\^;@F(C(93H0_:[_CJ9 PTI\VKF*<:* .I3D
M,CD3CO=T4W:N(]3LJVB-V].\6H^,,"8S&.01DO,.7,\R1&WF/G@(2^U0HZ_T
M8D$L#3_AKTK"34DQ9>C=E9H!Z9$HS[9.FQ?+K9.1(TJVA!UL[?,%FQAU$1$8
MV.ML6.HY@^%GK79$KV)='/+CZ-72Q]WEURP&*\R<'AZ91XII^,HXNDR^\:Y5
MVVM6A%:%B@5ZMBK A*]9*+E;2E1W#*W+IJU@>:SSA*D4"]( D%9VDTWYZ'F4
M1V;"II]M&=7--#7=8<IAH6$#4CW_\%[I)8[3R^#29_>:;,1"]BAMOO:B1C4F
M,N<TSGA2R[V)CKWF@]:I2H-3*1E](V<+G!Z:!KBNAQNB40>H(X$(%+0RT# T
M)<PV*'\](/)[Y&7 DT&F\O6/"=JL!#\M$>V09HCT/-@;.[[82?5\2'%\75<\
MI0439C7MY;[.U+;(QM/^U2\#/68V]+56W]CI%*&VSWO3>Z,A/\XM+#4_QE6[
M9B_84QN9W"3;)1L[U*B<39C02K$]]*]IF^N,>/".,6+$_,I.:0R$(<:_[LXG
M+*?-X*B)$YX/%B&)IF"P=[JMT_#UM+=C#_[R4,WOPGL3^@/E"TU&/BBV+KYL
MPV>NT=,,AM7Z%:< Z5+[14SU@SF=G7[X]/UBIEZN9T:JC\+3WK!1%KF]H#.'
M:1?H7S =$)2KQ1&+G5ROV00WJ?+@KA%\#!![LU3O/) '^)4!9;2=0(%_ -M8
M498*8Y?9G!)I$NS<\MJ0&&!J-'7?)[\OHMW@/G52#?=:[V5 2F6?[X=G0[E2
M.D2GMU<@KCG:K:O;L8W)I</65Y+S-.1/#CLK1%W^X/B78X]^E11.*D?YCG^,
MY2^M2Y#&"ECNF=0[$PUB]6%1P4[5D1 1;"!X3HO6N5A P.BS7YJ*H@?@,\;7
M@ZDF"C?'C9&X#QOY)4GJ7Q<^WEFP?#T9.Y'7G)>%S ]D;X5V!U'_;BBBQ&['
M^2&4WM(KX;VW-1U\3AK697\9L=">PO$I68\J*5FK.'?DSK;JA)R?5VIK0;VS
MRS N_'L+%]%:T)2DVSS/#GZ+05(S *7@)UU*&^1FPE/3\RQ_=NX6R_;(P!.Y
M37_BQ=CII!EI_.P!1'=)8 QG&L<D6)[DB4:K1C%JC0CK%B.(1+W XQ$][Y :
M@<?32'ESJV2KFNI.5*&)N[!,;K4"WPO#Z*>^!^6W"'R>L$W]YSVYXM;*IA-H
MU"W2^:FUS@^=[[NN-T5[6MMH%+F=;Q:"=_I/IGK:'*&>W?H[O]FXPDPKN6CG
MXTY60^Q[(.G(D?43(";R-&(I8TF:(X;19_@E111(MS2P$7U.^0Z&.12*J->2
M/S,_=0#NR;][<Y"PN/1[);W<];*6Y168;+Q[>G];7?=MADNRP^JE50$HIN(^
M7I$@&^.VH1%5WZ:/O%VKGQX53YDAGM0ML.O,G-/-@CI]5/AV83:YRQ!SGFZ:
M1@T^@Z;0"'\8ZU"Y(.F!1WI/&D?\^MQTTI_1$AN61!! W:$M'[QX^_Z!0Q-]
M)J]\,_U^V7/LO;FQ,#S.=CI-]9QZPX8]/KX&'N'FZ"T0GEW1; >W#K5F!+W"
M'1\9WK52;]**E^VTU.])LQHJZGSEPV]@MG?+8U"%.%B^3;8=SZ$',S, X2.S
MA8!F["^F:H 8+=7T?%M3/4."]5O7K[4SON/JP7+1]U>FU4B?],XA I*5O*8_
M)XDNFVMD[JZ:SO<M:[9('$_MF:48)@V5-!$4PU]M?7 ?GVN,,5&O"7A)I(;J
M.XLGXN I^1W1M-FK>S%&GEYCC5LQCF$RGWFHO!W)!2G]S04]-N&"YG@"XW$J
M3Z*0 '>$=PYV\$+?$E.2@CW$RL:\U_A^V@_+/).#77][[>@:0A;]VW\-[?__
M?<W@W[1]R_\,W<:3N/XBR<6_ 4KT 2<@CQ= \;*7@98NJ:D(?I8-5>.$\22Z
M#7S<(T#7J?@* Y*@;>.IY=3%"")2+YR(63I#66;KSNG 1"W+ALN0LU<68?S5
MJ:>DBC7.R)C<M#76:$@SAY+<8S3NERI8%UFU7H.GN>)MI[-"RS[A+]%>5$NE
M!DP[X)W.1F>W^MG?""]O/FEMVW?-(?/6YZ#QL/8ZKV^KR>@:INT,%W0?%K?4
M0-A",O@HB_(S(\V] 1D+,0-= K,Z(M(8Y4FRGZ#(3^CFWKIYC-V,UZ[].$N<
M(3I)&Z0+<T%_8%0('NNFRJT-"(FQ*.IFR2ED?D=NB<U6O?ZJ2R%9MQ1>J)'@
M:BK;('==3!5#A,?1WWWS=7O2T\:H@5M'?.],_NPH?[*8K*YYNY*J.84_N9@W
MI30J4.27'/F;^-;+J@UX#MB_$FIMQP&K9N<;(Y@W)@XTXDH:X[..;J*;J::U
MU+$Y'+.SE5&30/;&BFS.QEYZG<#T8%BF-!HMG47ER]8L!P9)?N6"XE*.0L?*
M;!E:EM,1C_1L.)0IB9M <(UK&:YJ7=>Y,QJ7+J=:C+ 1EWH1[[CE5P05*(C.
M,;1+4X2*WYFJA;RO1#@6WET=DU"]>8DJ>6-)4B/P"?J&4VJM"\3/&%/ZSZ+Z
MZ0S5NY66;F,_8>].KJW93MDJ#@ZTL(FQ5S@C)8W8[F&KR"+IWI)3V!^USI>M
M)<N(K6_>Y:CYC&U!.H69_2ZXK)GN,8]]?+R1E)':)8'MN:,:*;V;?)@0)TWM
M(M';-O;[G*7Z\UY))ZEI#E]I37=-QM3%RR4PA%7O&?2??D,+6R=.=P8,.82:
M#@YI4I2)8D+6#E/R1A:NM[_0Z)'SJ3A[55)PU1TW&V%G@5GRPX+)RO6F''G[
M^7[BK=5VTS9>7LM?6EP'O[Y74P70=FUK.]YQ?HT==/N<=J"?U/3NZ]@68MYY
MN8E ZW3%YUN<<Y-]<:&ZM!P6&:Z9/&S;G$E;LY.!FT1C]'&J.Z=?OIKZ<N\O
MG$35ZEB>CYRUE'M^6*#YI<YU(Q6/3T.9N;=QMKIX&VDI) L*N&T(XC_MY-00
MQ]W6^+;ECA"<,9X?=HOPLDT]>:N3(=>]U$#NRTB7/343>V;=5!K0(EDR3E%Z
MG+@@T?O5&#GLRE*2K!P]'/401AG[!7T=.E43R;;O-;W4-2F7=62HIF=]=*_F
MD0\R-#K6.7V8T7+_@8]9M6=\]W2\LJ-F"%.TDK[GZ"AD8O@AL]>)I-A?B)R$
MQ^YGMWI+_H.^>4Y!,!&7U#=1?"Y=]E6 M4NB(31V9+\R F?JZE"A)WZ^G[\S
M:"O+($,X "'XH[_Q? VM)@6"(HNA8[K=1!(YIV/'%H^S"TU-,.9GUA<%)S$B
MRY"?R0F<BRSI2<YO&RM'"MV+2AU !GX#+!H)$?!"K.MY&;QF!#TI1Y+I?WF@
MP^U2_C7S*E2RR34.GPNO<(M@H _?L\Z!%XG*T\28FZ;J#K]F$^U=H@=$!"J%
M[7*DGJ$$7AE\+0SP>1U1^B1UPUJG5D?3!>5U8 G'0U&1'^5WH0+9."O;<$5]
M*YO,]>&U-%AWB3"$ZH9Q!<9I(BG-B-J:'F$;YN9$K&EL#T+T8$E &G$,@/3K
ME@A4LXRJ@"4O>D*B=B-]-(]>L[*;J,%1WLAU*E8R/=?,<*Q)NW^@)O#-AN'5
M3ITM>><8:KHD_"1>XLA=0B8?K;HI#"5M.KYBV%4(:&_TV%>H.ITX0[$(*B!N
MK9KWA.0H.A@Z6G?-Y)RW<]E@#*\FO%7JQW84>@;YGH2JC3KZ6\Z9M\1 H<Z2
M2A9BJVLLRU!&>/_B178R%H5-7S1N9Z=U22')QV*5OM2C)[L1)SC@C1^3B,]A
MD"6TM)YYULV9B.",DE.LP&"ZS75@D[ZS )W%B*T4;$.LIE1_[>JBI[?3_EGH
M/9=4\T'N*4YH2:W;+CTP$?U6>UKY?1N]EQ:2(E1 Z7&1FO*ZBE:]GF,XE55X
M=PK5D\(,[*&53Z8;\2>4U4[+7DS-49JID)KVCY$^4NPP<;'N>'V@P3]AGQFH
MI&CJ/,C\O*5''>-'YZT,])>DFPJR<5T:L1,/'C8_[E!9+HJB1>[V+#U&G.(<
MPYA-OYRJUDDQ0?28*@"6]'TJ"RMI'$R5/NE^;8KE7T%3 U\;;T1C-$^U?0LU
M+2( W_NL&^@N-R]XD 7S6F:(;N<CD_J=^]^E)#^)<W.I/%@437.%(*4@[86?
MP?[+D_"\4]Y*%.'K(L9J0BKV.2X3CL3IWLD4CZ;" (>*+:611OW)#M_+K?.-
MK=$00$E\]LV('O,9+S>@424-Q9W48 &65#WC\_;I+GF&0AH+SN&GEQ64>[".
M,61D93+@C!O3VBY?UVL:XYL;)JEY\#\0'__)3<PR2EP( KO,^7[?"CN,1-%6
M+8]MK8\3MBNM5:2MIE;Q@_8O%(F#>T=$3QW?5:P+VGC$V\=@)H02UE-H\FK>
M)3%<YY=7\S;.907M"Q]I77H\1/V%QT5B!5E&0-P1A#.+$#;E'Z'C5HX ,A4V
M4,,/O 2G(@0[-!DS&O'YS)Q(*B1I5BJ70$,(53]; 2>X]1/^_HB.<9TUUBE'
MR3G6PDYNG$97[]XXLFC1*;:42"Q-'ZH]/U:U_"A7Y1@\JX>&NMU5"T552^=J
M5X;;]9KIB-^P+_09U B0A-MKB+!?$J<(26^F>Y5;H@1:HKO?D91/52%,+K7Z
MC0A47EVSMKKT(>MQG@I/7ZEU:#'TF#9L$N2^1H(4HCLCKHV\E19 S1"Q*D<'
M<8:I45OU1[\O G5';HPB3ONI>C^A$CXJ0* S'_']3L](Z[#T*^LF+*#=[>GJ
MM;0+*G8,==[N_U61P&S!3*H,$8<EDN*1RHT&**4[X:H_$\Z/IQJXNQ#B:R1'
M2<KA66$54N\(^I.%?Q,LBW.U^!X35<W]5SQ6D4I.?=3LL\CRO:4%0\>S>'W+
M_!W4RS0<.@K2H-M.WV?6LHNYH "2)?,*W9<+ZA4YNSD/Z1D.EF$Y 4B\.95T
MC)E';W[*<GX9(&L$V-*/:*M5;8_(O4NBGBR%R0Y'^OO-A[\?IJ>\1*!SAWN$
M:2X:@1H1'S5DA#0EO2 JZ<&NMPC\=XJ$="\&O=H[S$%"SVHZTL=>4)%5#A5W
M#.[B#"JAA/K5;#]5^CCQ2>\R+KV\PDR]GF!-7,L]%_XTQ[!1L:DS^U&S/-0U
MK%6QM878#_\^R1&0.+*)[05+0GSD 4?Z@V$*5@P33ET2Q0BWT/5Z$"#TB75,
M^)&1.8[E#CQH?CB;Q@('_CV_":DO*Z!ZR@JF"3HE]!UBGPJ.&'N=/+?W8>/=
M^N[27ZO?^\5TT%4>E=[E#O@TQUJ=3;SEE? >FIJ 3N&J$&8#]NVO"+QS<%#5
MRU79JF;!C-)TYG3ANIE=S9@7'O:1%ET^74?0G>AM'5[T*#P*7Q\.*TG\"JEC
MW0:6&"(#L2=G.X+I8M0$EOA5L#0FX)VJ]@58;VZNH1"YMJ3G@E@W6.Q@E\_E
M_8:>J28=2X&!/=;S1^N%FPHJROY4<0?Z;<R;Z:1I9C&\B/[<\&R 6:Z>& 6:
M?BJL$-D,V;[OL>E=Z@15SKEO>US1;.])!4M<?IN'T.1(BR*#_N++U<Z#9E!K
MM>'-1E]XX=WY6T5N ;EJ0Z>LPE3VJX.X(&8"\.WH2NPXN0G&$LMP!P2CJ+MI
M74KTA&WAJNLT6!I92)L+ JQ8ORW#A+U8RHR9L9\ '*TZ#0E)X((:.ZY7PI 5
M2++PVJS\]"UD<ZQ2EE53@G4,8>#8X[=U+ (DWL"A>X+X9T)]]QU$/=&MLN\6
M^\!8^P,J;#(Y-/>WZYE[#M\+LI)R)412*+?K]6D&Y69HWV$SXJ<*N'45)%K@
MZK?6.]5%[N:HEWCU $L^9G;C% 'XT8]O$E:W-!K$0M)[U[_\VIK]\67LT%(]
MJ?5(]*E/2/G,VC%F"-4-K+@\4*NA'NI2+3RM8M?[L2FG)O^>B/MVY\%N+-Y;
MRG'O0D[%3-?25_'D)<ZISPVLRT I_3K3 6@]<ATY0@!/>K#"'5&,#!J&<XDN
MT5N2]"#)IXQU!S@63H6)4.B[5/*?&,<*=Q-R\ET@.%@=3Q6VI.J^"+_<[$T2
MW'82$?:80V=..D]':^K?O^<7-S3C*-"2K'_3D( 0B0^"]_ATDF!5=P+@:47R
MB9A&GZ3,6R$-GK^O#YWN:32V4(\7V4!%EIKEJ5D[5'\4,BM@YJ#,W?/FR8^<
M8G=5[)AI ]G?C_X%:. W9K%T&%@$W4[U[7]&3W%FD[%(;!*6O^L,>H BMMY4
M?!)PA/1DI.5S03W;1DYT"]S]B_2U%[*$L[%:],]Q.NXJ$>]\IKZJ1$>,Z'(&
M(Q:@\\];+0RVK5W^-W;N.ZJI=/\7?V8<1P4!!0$IDE%$.JCT(CGJ  )"I'<B
M*F) 0)H$",DH36I&JM(R2(G4*%40B!#*( +2!:0D"$B3A!*VI/TRYWR_OW;_
M.>O<^UWW>];=:['8B\7:*\]ZGM=^/Y]/LG<*T'87KS<*)7;9O"Q=NX5I?!QW
M[@91/+PO:\?'+BGWY8*-8Q[BPH3^M\F\0L><NJ#U4TICA09-X_;WNBM2C#%A
MOATVEMLN+GT.F#B@#VXIS^$SH^DX#H?LU.1V(VKFNC?DNUWR2_Y(V)U&'$8M
M4T+W8E3J*_Y<^'&3*;C0*7,ZUR3UFTGDY7*?*Q^5W-SB:&46N;]T=]@TESR_
M23!790E62=OYO%'+6SUF6S.1)E[_=+%]3KG3^.W+VPJZYSCB^J%VGQVM_)V"
M72--F%"T8V)X#]CF_RMM_K_I]S[]5[3YA2_/_C,O?X".9?!:K8R/V'89WFME
M<B'M)MA=!Y8J\=5[TI=4ZB;S*(7$AN$NK8NSGFB0F(??DW:6?F'_0<09'OMO
M\%'^_\1!B(P'M)<Y-YJ8$ES(3"<7LN:(#B'6T84X%D?G."M<R'[%._SE+MB6
M40_V,Y%32!G\[ /4+@_^NWX[R[]P_\EU41HQSOZ1 T+H:WM&\C&3_/N'?YE_
M+/33\9YZ=!6<"O_/NU 6LH&2[_D'+_]3N0--AM9_A-&^\S9IV>F;\RP57K*E
M0 +;92D!'1U_NW3DAXRG!3I'%\ZTD95XLVF01%K7B.-"=CB&>Z\06[\,\,8J
MR_O'R+-H!J;-D';EOP.E_XE%^=?O?OXW?8K9$+NP_ X>PRO%#G4(2;$. LL4
M.&!E),(R':G2)$H MLRPS@))SN2KUV,A;/_Q.69PAV1//,N,$.Y2D'T[>&G%
MI2MY\$OX17/&5K_([GS@I\I&\:NG'E>L7W!"-@U5]%H1SN:YN7ZIX,M8_-9;
M827L?G^F*8Q,5?94'NGT7%Y?L\G6TMOJ0%?W([(",V12B!$7/1#]W^_#YF>A
MP-G#$*%)6W?( PC[)<QW'G+J-ZC,8>@CUMH*=F*6-WV%^3"6]B*,M7$)NYMK
MP(7\P;MR*&K\7,CS YS3%)[COW$A0^5K)" #6K_'A< 28?_?TX3 L\"SP+/
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MT^]%JOI=*EOKRK@00?L ^0TY^+HY>@!V=YP761\0M8@8[']$UB6T(*V'I23
MBZQ3_XBLCH ?[I%H%2VP!2[DK\SB_RNS'OGR_F6%6PBH<^-E5BG*EWFQK[,
M/3=]P>,[L:7L^5TMS.N-0&"*Y)JO](R(3"3"*D<+ SP-3;5,-P@F?9/F1 ,"
M05[UL5.+'9MH)'\<%J!@U:CE4\,8)K#T[%OP=9FPUXK;NNQ<)UYF7<#T8X[_
M9V:M[](,R%#:2TU>9(7]/;*.M!Q\P1M[-2^S<"Q>9NVH_Y59!XFLT_JPE+:A
MOV?6<PIQO4]=.'P;>[\K<JEMJ]3KV1@OLWH6?-C^(>6W6DN56CBU-K&M,73I
M,6A#OI2ZEU++MX*\O(8CM^BVO,S*^Y7=4JC_>:R\;]H<3UMTV,(,VW$Z"1\6
M&'XW:9OK7;S,,OU'9M5.O-L\BNWX@Q=9E+F_1]8YFE@2;]'?DCFPOR+K8]M?
MD?55C$2+^<K19AK_%5G><:1:E1:SY7YVK>AF#O/]/VU0#B0($@0)@@1!@B!!
MD"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!
MD"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!
MD"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!
MD"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!
MD"!($"0($@0)@@1!@B!!D"!($"0($@0)@@1!@B!!D"!($"0($@0)@@3_S0DF
MM"@SM3@#F(-O .^P>=QOL(.&IT)IKI9TJR1:T'('B8_%3UG#Q4S!4F6<#7V+
M61JY9A^KSM+.Y2X<.9<#/_$)Y5Q7@3AF6--6=6K!(,L^6+JCN;/\T[J75W*F
M(G7,S3(B250?UIXE9U7$V'I1M5[BF#_2V-3G"1=-*-NPOVX97OY-N)K@4OQW
M>@)C2^F,5*CGX/.>]4^L8BXDVA^[R(]_C6=_AG/JPWK,]W''N) OK_JYD&]X
M+J2\Y<@Z'<["O9[;4^9"7J*"]R3;5+YO<T<X'(4#M&6.0!,7DJ&&Z<;N!<+V
MQ^9.*6\87N5"TL@Z7$@SEE-.D_\8^#^<3?OCQ]_X( H0\/!?>A BXP'M9<Z-
M)J8$%S+3R86L.:)#B'5T(8[%T3G."A>R7_$.?[D+MF74@_U,Y!12!C_[ +7+
M@]S1_TYK:QC,B =FYC<GB?/P+BYDZ@#U)XYI-$: I4\/Z'1'JY2=V,OR$!T*
MT/(L<<H^>G9,Z_E&X7!(;JACVII-:UU#G$[6'9.U=_.K2R<_J_W\N-7-XTR6
M#-ZNQ,%'>C#@H<Y2>MO3)/_QNY\B-#H=BZY 3_G\3I#I'7!XN^7(^_F*+7!<
M+^%"#AER(>U7<1M(VETF(POHI?C=9B#'C53N-4#%#$]YTW(I'M$_XV@+G5-E
MPZ&^_;#.'%CT?4.W^'=9DCE $OPA'=(\^N7CZ=JQZF]5F^J_\J;O+D;ZBX5R
M5R5)P$4OYGQMEF1%YRWY08^,\ 5QJU!W^8W/4;E[JE DJGAXD?G946#>J,S9
M<\7LEOVY%?C4&'KL3'5Z4F[\IN1BA'.PN\N?7(B9TY=4IV&G?+E$.V?9-&W'
MU&LS5V6+RI2^KEY55E1Z?_FGQP(8R%A=A%81O/#[_/[_6\D7?@[_,A=RD FT
M,W]!WTYGG&4_@?XZ@M%"2IK&!W#4T!ZC+7J>"Y<LWN60DNZOAVX>11UX9R0Z
ML1X*Y5^547Q+F^'@*M=RNEN+@&RK^AKZJ;B44F0"L0L;68(AM!L>C^E_@)^6
M&#1H?Q\J)L4OF9KLVY'^H,*CU4EW-$7.1B/FME7(ET4KVZ ;9O#5+</$5#7<
MQ(66@:0@NS(3*SX?H:S@,H4I<\/>;J6+22VN_KTFB-CF998H@2-XDAV-]IP7
M2N!"ZI8:Z8T6M!Z<_\]5Q8 !XSD@7X0D"1F=GG1-<NTW)3/F419D%T*\_T)]
MVJS%C$&'_G)LBT6QZ^<NC1ZDP)\B[ S=VX\TFNUID_<?I%48![UO0"3G57ST
M7]62#/7I+@ZH*[]2I=<J,A;$]%7^,W"HS$) 4LUN)X,VYIJOO7EW.B.C?DUA
M0&W\;2V,Q(4 \CT;1?-80 &ZCJ,E,5[2U/+5'OG1#UU[&]TY>ZSIK<4TZ2!J
MFQR1,A'/0E*<OPV=]NV+TO$8^?9E*%31[[[7.-H@N&C-TO..EFA#$OWHMF+5
MTZ5G+0TM&8OQ.8Q0&Z1#D8U2B6192!!!;O#$5,QH8;^:HR):#7;(4%"I6LS_
M6ZY;C:N5L-O'[/1 GS57\]5O$T8?B6<7^" <.=C\_!R@DLTZ(<L09+>$X![#
M:@]U1\F^@PI48WY 7Z)_V#^UV4&*Q5S,@8OXSIZE[\:584*Q$H &8FQ,3573
M\J)<;2I;I9"IEW92-@LYPX4@YOV%_ZQMR4)]Z.'7_Q2;2C2VTDTVEENG6,44
MR;C8>YZ2_K+I^W9U)@TW>4?/Y,"I1YGW+>7U$UNON=M7"#V\4#I<)R?:4M!
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M=*ABO9JWD<6VR;A/T$1.K\[#$G:;X\)R=^P_)@V*(]'<-Z<<%\+6<5S(3_W
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M9V2RE2V!,(KWJ-;&F2%#5<JSD'YXQY&R7_?Q,2&7] =M"LA)*OVZ<@L3@E[
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MS>Z-GBJR)) ,IZQ4UP2CUC'ZV/83._!IR3W.$6/>;G:<_;;M$F8$5M>8LAL
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MDDE+[#)3>'\CUL,G9#C?(5LYSRA)*JZ7EK&0V.7Y8)1B[K&:(NE;$ 3<6NF
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MJK!?\-;^U-6%[/5XYJ]H$[I.UP[@.:\J3B5T!$B@ENW?TH52Z@($C:G*L,-
M;?M^8V*H7G4H_MC7\;WFO=@ ]'FMR-RW,WP:%<C?9XU^GS+!EZ#Q"6Z7?NL;
M%])\=X,0N]^/I+S6O-=N6Z24EUJE_XH@92*2EF)O^U1A8"@SHVD1)INPM6X$
M_73KU<Z"Q=2 77G'$1-!MY:AG,?#%Y%F%MEF]];Q&MG;IV@6#(!7GK\!\(Q\
MNGB'^B2>4<PNY\BB'0%2);!&48]ND0BG^W9C##,])T(M$@*J6]0)J.W."$(<
M2Z[RWKY)>G#@(9RPJMKFN^9?70K>>E7?^[%_UP+^D1XNSV_;IWAK6[I1E4QY
M4/?U5H5]JE@F_YMVA?*TPL.C%4<&D/K:/G7?;U$,MBR^EL]??$GQ=!6)(]N4
MF&NN#OADG(Y4/?%95N+]Q73'^-:!]3PO6M\:?BJ)<88W7#:V7;M%"78?_P1Q
MRDCO7";!QT6:HP\\I4TSBNG9G9;PCNRPG)2JME2\J$K)A&5WQ1\(G[T;2'%'
M\7&,/.W.7MA3I$M_;Y)#W>.]OK[@U$-4/M*DYGE=+443G]BC)JZF0I)EQDTJ
MFD70A\4W\]*L,EWE%7PEI#_=]S=^-KCZ>Z'I<\+ZRFA'1TZ.!>+.=_?BHO)Q
MC6&ZBS;V%H)V&0XH%33R"%QB9[&N1M)=5-6F&6G H>H5&2&@YUQLJ=K3%R@B
MG*[:0. U$%1M?.D[CQZS[*Z'+N=(I6LYQNE=R !J /]:V)1_?O%7E]*4TBF.
M?7>+EJ#TAT)IC?0^^JO,^_*&303+$1\MVE:ZV>"D7H=U[MN0U1&;#(+$>X1<
M@=?3OL +=KFH"'IPT8=-A:TZ@F7KG#*RZVV;\]GIM(P2SD-2#2&%=!_.SYEV
MF8C%>IX*Z(P0VCA-)W;R,M[H,,I\NP/ZJ6%6+E)(9FVKIZJG!!7M_F0*=8%:
M,Y*RNYEZZ^VP?\OI4N<YW]>^.?K.?2\O,]N\317+TFTK\J^(]-%"7@'ORXD&
MA'X3_+?OA0(^LS:+=BXY%?(G=:U6Y>=N(2GRCV->O[]('HK5'[$AJ5*$'J[J
M#SH6:RT]M#38ZMN 3;TE8VDN4$#6L0<75V (M#--6!X?68'TGY4'Q5&F5,$D
M>E\70LSP"/WG9;*M4SL5)@343'<Y.D; D]3J$!M1JEI<R%%@CCPQ;NOB,Q7U
M^8*'B]OT9V)ZEAU%1K7]UCW/()9*V8UZI3KYZ))8XF4[^.1H\8K"^S2\2FN^
MN8:E;J^!)D7&4*4&38UU"7FPTZ0X)1Q=R&=;6D)[+YWUP&HPZT9DA;M+SUX;
MB6:W>0#0X!P1IT !):&N4S^?]!SE_(""]31R(!\#<LZ.MZFBGGU"64U0EAYA
M@P5&&>,NQ$[FZ\*N<KAWI%I2X?/="J;KD[JUDK^F?JQY#/6"*.A)"),.=3E.
MU&6=] E[21=)G.D1;"U*#+3-?Y$7_I17;TZF%_@:-N15CX6/V/KZ6+>T%J<U
ME*<MU>]F)4[ GL".H$UX5\@RMCT*H\HRF<"(H"_3=W&_H<\RBIQI<]%MYWSF
M?N1"[@[&/6Q.SA;Y:G0R=6#$K2Z^RTB^0&$I4RWT!)V(\Z^D,OTKHL32#]8:
M,P7<8#_33,1B#>WY-(CV1BZ9#VC=2R>S19&C>W^P,Y4G78PZ'D>8"*<]9003
MTK[8E757Z>JGMY;H^S2<*6E3O#]Z.THE[W24:'[_W(^8SW,TIP#@%\+&50HV
ME@NI?UA+%^_!"M2+CNS.^,YS(;QI@,Z@;8%PNA!E9FS+>35GLYTD,[,:,4\C
M/%$9GUTRL,@_<*,6=WWBQ>/I'B.Q454/2VVJ\IT6Q>[)4#<K1\D3%\ZWR":2
M;SCY["B_G#W??2/9L9Z@JCXHMLC/E'SMF_=\OB9O6T#IC=,(P=KC0H457Z9Y
MJ.AZA2TO&B.90_[6X\))>T7L+&R[&6F^&B%$N@,#SF7'<R'^L!C$)$=OK WV
M%?/S*W9VR(;_>'A(BG<7]@1:/93*%K*FIV3E1XGV-SRG"!U9:=Y\@C8K.5?H
M9[A?F@"-D;(>V=QU(O*J]G,4CGCGW9:KAKFB_5=T%<>SO!0T"599DB]*K&V"
MDM/S76IB]8,6TZSQ]8MY-X>V]##VMN+/6D1=VV]DS,KUH#HRFN[\,56_?*Y(
M;*0F^Z*-61GV!*S6>YT+X24.A;?N/0@4B?&,!NV!)>OCXW<0XC[')UE7Z8T]
MF\)H.0"+7#B8XK_9HD.+)^N?8K?ABTV+KX8>M6V?1_"O%)P<DJ$:2.6N6:S<
M>4SR^'#ALVA'8$FV8[NGO9F-VZC"//+6:\&L]Z5JE2,9>5/-C)%,LY(/A;VW
MUP-%MPP+KPK8Q*IY'_QV)<;7[LND?FV:OQ5B+EMCME]S<& 34#1] IO_HSF@
M:Y,?S=/W.,571GO"Z )F0.:8T4':0!&=CT/NY)QKI8G55R)0>/-1*:IQ7F,C
M5&0GZLHJY]N""3VNI,IW8LM5;-A?ZY=]5R>GR,^7X&>RQ*H-?DE1\-3@*Z^_
M]C&)8*5%.6AE[?3PQ:N11#.KC-N'YV:MS<UM=BY^G3^EZ-BW<'BH$UY@GA.8
MF.>H[-%?7%:79L5WP=TFK(D]B6V'8^<KIP@L85[=B6>>-J653IN.DI!X'*\6
M/H7"4B11\991"#+G^$>6,FWZW0AJCVI$)(2_<O6Q!2)@Q^Y).L;5N:[$EA92
M53&#UFVU8SN6!UR'JTGBE(&3..% 0>1NMNXBH.(>\8Q@Y5:O-%!ZIO$5N<.M
M9I&1FK=HXS.@23F;DT=18%FY9E8.7NQB.HS+Q/JD5?05%R_:$.0T]X.#>GM7
M1V][W1V!%< FN1#.D:B_;E3F368&6F>("[D?Y<BHH\.CUPW]CL[J J[R/; I
MUP7YF!9+:KZZ+=+_/B\5XS'':4+Q+?;%:!BMH3)%%N4@]:R%OQ1>8DF8NZ?O
M [CLDVVP;WL"H0=HG#/AUR^6A^8?6@^$V?;1,I$C&2$9RN-$_>!.^V@SN\:&
M[(MI93"D^)'(L6W#)+67--\C$LT!DZ,,W8B+R2Y#W4%E<DKI<+.U<_B+Z4NF
M8PB:N3J@G+TQQQ3!S.HC6")0#E\\%28!-)K2A7 J&-%)()[:71&Z@/OKYE0C
M.53G)VQ'0TLC\%RML&P.M4:!I7ZKMY0<F%US' UEJFJ8TP7CJ3B!M1Q$O.:&
MA<68X>PY"CI;I]>K$ZUCE:EH6Z1RO<SSCY<4^LD(Q_V._>;'=A?L3MR9>HS3
M(.@'QQ 4/BSU7ZP4T_EI6Z7F?%+R*6>3M"\$FSP11M+DAE659N[#9/\%A?>"
MEKIX6BAQPY)IA3["KL5ZXP18Q]A%&$.T%.U;%?."\UI.=32M@KK7"8W/42-4
MP;H0"6)"%:N2B!BT<9'3[&K*[=O>=R;VSEL\]%-5K?I0>O+,KX8:?4'K_O;/
M[+IOGG=J_OV#GJRAE7#<F<#XL9=MU]Y72A=)-7RWK9]^Z/CFS6W^.&)LIWF;
M3"S2]+B74EW9*#)2UT!>M[<D+%)^;V:+%4#!?7K+$53A&2A$JPQA?1/:E-%6
M^/:(65SI&N)(BPXU8$IXF<('$*X,[7P]\_$O 5#!D!G'ZS1.IEB%:-W%E5DU
MNA+@SX5TZQPUA(=5K1UYJ48*6QWM!_CC+VCTB0E'5UD%Q2F5&!X-],\W,V->
M<^RT,AJV$J*6F UHDN(*#\E<8UA(_.Z5*2,R:1ML@YFR)I=_KO';5LJ4S,AU
M;#RK-XHY4>3O%'65UV2H\8;Y@3-!.DBZWR_$.=++Q  D*C154TB:5X'> #3^
M0*#O-HVCC>GQ\Z0>PEA</"_/#JW.*DZH$0TM*E 6G4:ROP%G_ ZYX1UDI,?K
M+QVP_JB^$R#DXNN0S0F3H!78)[WW[I0XI73"RR0FT%XVQCI.1/SQXE*^DVV,
MO:Y]B273'Q44><VDV%O"+C!P:: F6<Y-ZL/YXX1#?#Z5F<HF*3YB;W,>FRL%
MPG/HBTMF9<$6F3U?2( ^B6/31PE@:O-&C]_/9AD3;<F([W)KV$\8C;_>%QAH
M.\F%/'4CK9]IY*1?Y]1@YUMA- <_6\Z12*8N8 .+U9XR*F%>9T6-:0T*L61Y
M+2FQ L!VZ$-C/8?OTC<[HQ!6VS<;1@FT'<PO'S6) O<:1_@MKW:ZL N*HKPK
MON;\W%CBCKG=[G9!YNP'I2BO 3T,W_FRQ)#%/IO*5;W(HX9R?6J(>RL#]N<J
M%ZR$S<H&A'%]=YZ[?* +,ZHJ+QV4L%\<M@D*2,N)TFNZ\V77YT)-+1+?!_O[
M?O%3VU^5-!?2;FXD]94+:3"J8+J@".T,&>VX &FT:OH"?D.5GM[A<8YNE5U6
MUZ@MR86028>!0^19I6$C*.#J8/*T15G@@\?!$?GATI'-NE-::-4HSS+8RLEO
MLO,8:"=<,<[>JO8/=JK\:CA&N$H_*#4M-F)LV0J5^ JIE,487K*QE]\X0U$O
M(3[_XAQJ&NUTK7\$,T!X31[*N#6>JI%IIFB7$P%WUOR>@;]H5,X;JS6VW8W$
ML_HIET$?YD+FG_WU9BSL.##8U0Q[@@Z_3:L>[(2):;D2I=%PP)FNW'V.S!&M
M7R1U]H8*6#%[$$=88:'E]\8?[KFT%1$GD3F.3T)@)U !;L,L/5X#X5&V1-?A
M_]+49J$F2VD.*3//E[CE92%PT%3H"7F8-"X^-BI<F/A'T;G1$^'Y>B-Y<GHF
MWMK(S)NOW\@_]WH:XW9S];UFMIQ^QCR^SF/0)Q19/%UW.TS"Y$80LF=;@R-X
M#3C ]$"?93>&<B%/H'6FG:<<NV&'VW1Y]!?$$[D0KZB?N1 J]HEAJ.\\(K[Y
M817%NN)>LW><5H)'#Z53^-1M\MNZ2P)G:IJ8*N$SC),-4>+QG]8K1-,[XGZ,
M0=ZBA9S/V-;K$;!*JO*PKNC5LX]O?>*;1B 9]+IS(9H943*GB#$5C^UH.Z/*
MUK$*U.(R$\$2$T*?O.Z:-;.&5Y,^9S0\HC$Y?!9,L;^>&H#=@Z8B1&!(]407
MHUCZBQ[.D94%Z"<NQ(:&V!"A2]V@"Y%AT3E='QJ#@=M_L_!SM<)3/'(C*5 Q
ME.RUMS1\G/\?(W=K1T3,"^1KA_VL6R(R :S.0K(@OU VI<3P;.V47J7OS?.K
M!?+B/PV7P1Y^>JY45]YO7]9_=O%#?;JW5(%[\N"](4)<B;SIVL<N1<J*PFB5
MN'_XO3''?HEZO8J9.9/)?1B/+YQ'(@V%FS_$.L:%,(CL>B[$%YJ /V%DL H]
MQ.N^L4\B''Z;.\XYC<KN;CM/5RO"TA88V!$,%*TQ;&A&96X>YRUZ=B6PW.5[
M?"MKE4S^N":YG "U2M,-8,T=2 (P!3K)09_QRF3**^LN+R <OKISVB13MQR8
MY(5@ID*7^8TB*V89/.W8LB-.'9^W.$3,HSQ N=B]5/H4X6^>K]MQW+ST].C+
MA8,GIF*B$$HIX_$4:$R;++8]F#3?1A+CR/J2CK3] NSWO#,2CK2N! +:YT2T
M AYA:[W)!NXF%@D[T*.FWLAJEZM4O,C@B6#S;/U$U$1/HT-@5*-]6Y+9X\D7
M3/,W&('Y9%4^5/D);X]R=+T2A9+RX8*:TDC9YF6FDF--753L3SO)<G*RT_F&
MV6=*K+20[:/Y&XHC]J]%5>D6=XND5NY0^+]6?O,'1!A+O.DD8]L/PGR@_"QU
M=D4]_DF; >#WLAI?O88XQ)$'.&M4/'GP"5;P&S%MT&X"(P P-FTG#L4:7K[;
ML'=ARNVK9&Q>Q-W6$V*S>K2&0I\M9.-Q5SF*E79?.37HS<?"A%B*M(/D8[)C
MH3NOFKL8<ZNU2@_Y?U'W7E%-INW?:&8<"R B(M*)#>F@0F@B><4!! 2D0R@9
M1*1$>@L8DG>D21^I2A4A! B]A9I('T! NM20("(]0<HC*7SQ6^M_LD_V6GOM
M@^\[S5I)[ESW]6O/78)&$F3@7Z82'+^.GDY?>^MIW=67IQ5/3X+Y695;EE:[
MP;)7OR60EQ("DFO2X1W@=6GV!3"KBFD<RIG_2. &PY0]0!9!WT!I31!OHYX!
M_%0,-[!+24G2-J#]Z+5=^H,^TPU_392*?#09;'8.H87&^HH7JDY4?K^[<>GA
M&3Q.0>A-Q_"KRTS&WW=;$?&U]B'N487.=HY*:GDPX>S;U::0TNDBDP'="D<'
MYZ.;XR2%JARSI9\+L3S@;:_F%]:BP1)RUBM:P2ZB;RRC*&)8C49RQKQ[4>@1
M*0OZI;\30W.J!N1MN\P$D:>6<=OWZ+A>\!GB'X[.MQK+F7JL0FWCY<5[/9(*
M]+];IE=H'%Y(*"8VTWU[AL.V^7<4@G8ODS<EQ6DZ69!$"V? F>PTD6;!NJ&.
M[W143L#!13(IUQ+ZBBG<PJ+!3EI6E7P(49N@&AHQ-4.F#^LI^[(Q#"X]X2J=
MZF;MJO4%=J?2>:$6IRO@'Z6Z]J0N6H,<IB<[8CON6 FVY>#]-'2Y&-I$WMK\
MM79(*]CB83Q"Z0)I5(Y;*+C8'KJB_$I'%7"CO^R9*XAO](V"7FF'N%7,>]KF
M7YH,7C^(L'R0/]'K+";)/\U4QVXTL:],*1SD#%LX\.3!S<:5G_[0F(_=0X7R
M38[>W1 .AWPWQR9@7W=9)LD\K6F4NN!F<WLU\004:CG759Q6)G3!+'K8.$M[
MB&:7V&K'A&CYE9W3;9"SB(^O-#)Q,M$?6+J[9N$YH($=?C[&3K &[M#._GC'
M<0FZ*!> 0'O(YFJCC HSA0 L78S"EX!CX=#"'H$ GH))8IHL@_F'/RP!ZM2D
MJ6]OE%HH)I:/)K^.[^R\4/!1JA#]/N=HYHY0J+TWKSMPE"].N=T\<BU#W%F,
M+Q[+*HC+QL45F79 -":[L1#N-^EAJ6E&,-7BK0./(\ G0VXV(=K+:O/AQ@%<
MRD[?OS7CGHY]F3R^[5[PYB$F#?IEU(B#K'U.G>W0@B:TG.5?'#KJ %RC^5I,
M;[<;KXR*,</HT%=!]RU[=>0S[P?XGD?V4V^V5LXDLV4V:'9.,&,L8'.(N?2=
MS3WF/!)42]M#W''T.@'AONTMYPOW*IBJ_Q:9K"(DK!4DLUQFDRYKZ1B/58#*
M%<8DI#_#6K_4G,ICK>_-@2T3PB2M;>>FN\>2O,92%#6>1,U%^;04FDB99OLP
MQX_$5X/#'!87 5^&'Z;3 ;,<"6W<C=6Y@IXD2@&%5#)HZS-$^0I* $BB\U@
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M1U)KYWCHM#*_5GZOCH,9_T"#I4ZV,$K)W/AVGW),\5I<=F.VS9%,OTUCF6R
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M-DPVW!M B[*'9C"T1#)L\,V0;S#%H^HZ;>NST8='9&.9GVY/Y_WTPNWR;ZS
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M]@5SIGA'("^Y]7JL5C<7A(9?+B9M-W1<HW2;Y8@SV+$7"SZXFGQ<L6?67]=
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MY(B(6/,PRXW''SL)#83NIJ9>7Y K/ (]M/MY8?%IY0=F>63>1K$W)-ME.'3
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M+JF'X/*9!#O0R'YR7$A93[$6Q<S,;FO,ZCK\"H:6LT3R7"\E*<3;_4+>;YD
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M=_2;+  G/7%D,IP%>/GU][YMZ=#!.Y/5QPR?.7AO9-G?@R\D'@-Y:"OMF+$
M<793H7DKU,3;+  Y&7$8M8*=A\59]33&DH]3]48<O^YR\4U8,T>1.#[DMT:Q
M6*/:KTI\-6'$Z]SX=:O;Q1]6;Y:<\FO W:XM+11\9*W>&/(Q:=JNUUSVJ1._
MZB!B["U_CUZ;_FU8YD0./\]X+R7H-LY%93FOQYI;U$6S7HPKZ+:1F9]_PVC:
M3.!NP :O0I-N8C22; B-17"'<L"@;2!QFB%EAHB.:!1="=+"D+:XEM7::T@]
MNB1?JP0,1<RX35!YO#&SL"P9;0>+[&ZI!@$_#F4^&,0QQ.=:7D^Y*OM09M-D
M5@_$A1/D46JP./&KJ$ ('UJE/<M9I3VJYF*[;@;D@BN\?B E9>-B-_)"L71@
MB+3?PL7A7#,_$4-W+>ET69>C*GUI/<TN:IW'QK5Y:#287 )V<E<@@EY\KV7)
M O#50RF"1.V7H4JPM58P]R8\5#'X=*CXN '6V>XTS1T%,VX7%523?T-DG-PH
MV0/^["88*CF$]9O!RSZ5]-WA:XS@*G%P?(4<6;-?^=HZW&R(CC()G"=O)?D5
M=Z&D8WRR-N?T;Z N-O>P6=1J01'ILM/&JG&$6G*>GK')YI1RM]20CU%]5G(%
M1";=6@9IX2K*3S,GCZRU OG9= 5Q<A7,I>XI2.?-:P(+APJ[)*\*8U_5:^;2
M1MNG9:):9GCK70JF7?6\O,3QQ!G S-J^&J@.W8'.YFD_O7>D\D===7#J3IXQ
M-S3Y?'RQ\)!=H/D9.YOR< FM>% 0WY,/)7E&]7^@A*#O&LWFLU%=*+-\4]D'
MPQ;J\!53?\@%OKD>_0N3M6HQ4FW=TP&Q^/'T>=%H$O1G6G!K4$#L[GD?LX%Z
M\P)7L_&J=R0-->;B>8\)D^J/NK%NWY0NYEM7^LKS7S]G&Y>X7?U6*+4QZ5'<
M[(H^=[:J9KO)?')8K)F75[_5=-I*=YZ&RSV>V/ \P5,9*5;Z<GYZSJ4[1XFU
M! ?/\ZZAZK0IBB U@9;GESNI3=9J,:?5%<_ -2F"D<Q+,,\VY"6\R+Y!!).7
M<H% TDUDLTV=9&O*9#?6]?8MFY67MLJ_$:H?/O#&^<TOIO)?DCMW_J387O4Y
M60>MK+4A=%@,"^",T?^Y0<?;T*[W)L0@P\MC_%:LD.1@[CD-D.?TQT%(EJ.1
MZTNF[(>\P#MWO:<':,D#H\H$=Q;@G!OP9W4A<A2U= AO<)P6VYZC@&-'?99'
M#URA%^!>LPJOU'C@#N1X;/8'6-ZC8:8H+*S52BEBOY5PG)%LYB82^W8+@</I
MV;G]V>?%7=CEJA5OHV^3:F&4SRQ_&1]D6MBWBK^,UK^!U<^:+S3S4!\OUA'#
M+Z@(%4+*A*3:N4-'N3:DA@H8*<@&4:O7L:&] >9U9DFZ3T/\CN[1[] <R<74
M][1W1U[:;(9WB49=(G)T*)Q'-$/)F9]8 *[=!D$C,B+>O?X:,=O@$Y6I0EG,
MG5OK7 ^]#!O?Y%JGU9NC8%?I=OA&3*[>J3<8D5M^B[/%HZVSDH[R\<(RO&&8
M]7*EXBXOC,YP45&MHL,]J=%\Y"VT='<:I3 K[TM>YSV4U<<@"V5]OF%7GH5B
MU2[(\SJC1S$Q^OF\!%FTB*U2;R/PLX8VD1WVW,]U _(M4#B:BF4N/W:W;MVA
M>0#C@6=DX;;/%/8X,]_AUL"1Z:*WH)<[%(U^[Q]CQSCDQ,9\:C$OJJ[]\\9N
M$>Z*"O'@AER;5D8A^6,ZF_.*2=@:^3X;&+&A8U:^[#D5%37?-*EQ4Q;18K87
MQU;,C&\7!7MLN:T4:Q<R^]^T@WB8K>%:?V+7%TI.7@%(@XE^<+W9YS=&JX*.
MDBW^F* >8'.^YQTV0X"!:2*T;S-'IQ.9;_/AV;9+?WQ_)3JL0.>IG&.@U]EA
M]HD"V@9EE05H$03=Q-%"*$<V=9DM9AGY5G+M!4JE"K-1D?P.0XOE0WGXHUMK
M;D'K(\JBCZUQTD4#' 9_DLZ)?%&).AEFRB]A??+DQB6;H4"GN)QR/>507<^1
MPV\'<;UAK8LISE+>:BF/:S(:2C<<*_#4K7V+1.;57\E.#.&.5^Q^65^9H6]A
M6 #,+18@-Q5,%V=?=Q]G0-G-W>]G7GJS  LO6 #NB[!;S'B'5@3-WW>+&3"$
M^"'_0_Z'_ _Y'_(_Y'_(_Y#_(?]#_H?\#_D?\C_D?\C_D/\A_T/^7RL?M8R@
M\VXQST)SF=/3O] 2WZ\ S_@91/:1=[2_[@5N>M+MW4B^PX+6#?45#Z\E<%U8
MUG/^*G+[=9W2I]>@J?+4;EK-R'W9G.RSB?R7[F%5F_M1TO#Z-W%EDVB9F<P/
M Q-UX^H7Z546%P=3BHIR!HS,#+VJI?7WO5.W0F="1A563\(/%B/^\]:G_K..
MF3X^AQQG :B+M"M'/Z^ 3HXT*F'CA;M)HL4ERTP@"Q"NW.)&4HU8C'!T*X2&
M--X>\F4!*C2IP9_AT<=U%T&[S7-R*PLU^@I*J<Y$C=3E=AXD'K.^F^GB/75G
M%3]LW;MDQWO2^N)BX;9=1FRZ>HUOZH:;Q$3U))P]C%QD1A@+L(3LX*+?OL$"
M[.C880^168@A!2;?@PUF2SL+,(BDBR@PS8!DMO W,#.0_IP%:'%@:Z68@L <
M=##NL0#$!_>/N$18 'T$^1GAP +10@?_P0(<+%%:6(#S<0CZ@"$3O03<XV0!
M(KBYUM4]&:KLAZ7B>V+F/U! ^_^\/_@O"F%WB3U8W7^K101NH7*Q #F(2V#R
MMPX6H$<,N!KJQ0(\(M ,?_ZAZ7^NIJK@V8:9O\(37I73/2?7"V^1NWZ]V7HL
MF04X(W%</'$/K,)^SJ%TR5<(^SG$2A_S?#H+( ,VA8=0)F:CFK.U^A[2\BC)
M1/,6=VO#"N; X"X!"+]/3@S#BS!4^N0*"945E M8M,V4I4AF<"P"?U>D::E)
MUOK+&S5L7W_S8PJW=PO1BW].L%O*,->HQ*0T6/ETIX3;'>5@M[*LQB>29D59
M&,-B0XFG1'T?G:VGI/SDJBI7)L&)W0>1G8S7B.55PM,M.@AQ#G%06$JHO*5P
M*#A'("<1V#HJK+XE')YJ1<QF(.DE8&(%X@GP4 T[5L?N0V0+D.DJR?SRA; ,
M3?B^ /"]NC0($\L"O'^FS3S#MGE=+4P1">I=%B"OB)%)(!_0V7V]^"%Q_4LW
M,X*V1;^._2[RXP;_S6ZP/\5KW0_7S5NQNTI>Q*)H82V'F]E.Q<L9F]$(EZ+E
MP_;DPHF. /1JD!G:0:XM+0\-M>KF[\G>R-^QMK7NO/2UBU)[QZN7!RUUSRM%
MXHQ*+V]L7)YD'>1F;&5<<G]!648E_EUXGF2UD(20)EZRT[*@6N^.XF!_0>.<
M4?[=?T5:-OE[V>,BMON*@3NS '\I-",9IJ#SV!$8E/D !J:0"'M7<ZGOE.FQ
M*X@8+#/KS8&!W<'J2< )IX2.&,!A\QSU$V6OIXGR>PX7S1ETLSJ<0.1,I[Y(
MU*3PP,V1.FJ_D>=<>7^E0.DRBY18F*-V5&(K%^TW!%%-&+%EW*J+X:H>S:D8
MEPH&NT!7&T?'2WA30"6HG@U5\\TISR=%P<RV8:HY"Y#NJAS=N:?FO[!4M+SC
M<\0A>20SDS'>,>[MX[;.^!"E>[U_'D&NKM=C <X>$?M:#%T^R+\@$SI"K],B
MB&-MJ-EAB9%Z8\'(*T-R>.O$#6"EC<L;B0C%F?(F-R=''^XT<K>?2II8]?)A
M ]C]%3;0A^0\F&=HZUTXZ'?)QEQL"(E/92SBS" ]NIZ.0!>U]'2EAUJ9YF80
M]1&WJ=K0G8;)]#??8/O4%,I6JP$-"IS(0$24L@UV+O,*S9CD%,\"5"HR]&?6
MA5F L$6*[*%M=:1>;WD@];*T.47_@T+IGL*&V[LTF1OG]\IC'$"^STT*0XS?
M#"&,<LVY=#,, R*@3_-7K;(\Q=9'%12DI_=KO=[:8P:I MX(<[3T\SI]"O(J
M? 2R-1F?@:_?\NZ-/WKHBIF=.4T#DCA:@!% H5UL5*R7._EPG_0T?4YP5/U*
MOJV=;F$/,=/6^M.T"EFCMXZHL"&U2(AJGKX!NO:U9"EGX=GZ']7U=9%^ZN=L
M(:G.HZU$1ZO>VI:N=#%+L:XB%5.4Y3VTM*&?5+!JG?B$OY?!A9HE%=-B+5,0
M^.GLG,23FBPG?1W]3GGG[:[QV^M9_O" (P>X.V6T#1$%%NY%O8=IDP2;MTXM
M@TZ0"_)F$[G&EX-L0*+D7>'LU.S4F<CYI*.6'4N;%2O\2&SA<KG+"%.DH;]J
MI<+YY1A:.\/20R!-N)$WS<_YL70OWF(D,RMKJ6O"5+$P(\4D#Q1@=',TN\[[
MRZ^^]A"4",1W5=\X"2,AY0,9Q[C(%-2D(.M1I5/)@OJ,0O:CKD13]R1"QW:H
M7F1":[".0\,@W:\ =JMMU!WEQJWV.8.:2-Z!4IAXL@-D^,,[S;;\*N"YT@W<
M6IQ!@=58%^8JY@]5XGJ1@]?@^U%9#*14J8]K/MO9,%+:T$TK.[C314KOSO'F
M'>TD6-P#MMGHJU:Y/MPHJ#(8_[1TNJ#!':M\G@0</TX2C $)KLZ<W8O>/<I6
M;@,*>(8JPN9:-R[3<VY1]N,W%;OCY;L0@JX[J\96KL*AT?S,8K^\L0F7*JUI
M%L!BJ&Q3O"[)HM7Z/H=6-HQTK:?GW,WF@8@!E%9,NF*JI"1:2*]=6J_+/,X(
M<GL?%W_6"R/\1D_%R,3^,M^5$UN;';Y321Y'FG*R]NPAF8FN!Y)W2.CF(UU;
M06-R8ELWE%/BE>Q>\9WB=[NE#DT9I+4<$8I!)+J*4"$<\ I'338</-DS9!61
M<JA5CAFWL7BXY>GEZ??K[JIY"TDDR]4^6U];("E%NB4-I1:[<<]NO23+*LOA
M^JZS#TIH"&5:H^6;56-C-:QC99@Z6&^7J*LXX((-U!WY@_%7J/1=RBA)L*/@
M+[+C-);BI#M4KT&Y]<G\$)073&YI9_*/* 9KB!B2JU^I*X-PGIN[T0Z#ZUL;
M[_QP0[L]C\=G3 ?P,C(??_%="G3G",\+6RS*BTQQNE>18AID>DU*QR3\0-6$
M<:!YE' S;"')!?>$G)(M[.NIB%&2]M&3?IUB.Y0G<SVGU-U-PP->MF YE:04
M+:S]).)<_"7)7DO[^((DEPR5E%?]!1F6[_B$'-/T^FQ9@%'Z95G\-M1KB(!=
ML0SIWM0XWH[@P6]=A@43HR+QL2'2(ESAT^=JR J1^8,;F^]K:_LWZPW*8!4Z
M^'<2#;4Q:X^$TPC!/ 8N%Y" 2EWG^+S?DVQ )H7M*13>V&181A?N(,-%SSC^
MSKU^/>TTSH#@-=1 PG.4L'>QY/2>4Y\,;GC(X;RBF5G,*@O V^=F_#WG"/Q^
M9JR%^4CJZ#%BS!/*4&?VFE*^L<-%F0K"T0G&C8X7KUB -XN"S 8%AG@-_<#\
M6P[MW[:]3^G=(\<Q$R>AQX"^ @-$W^Y)7>7J Q8 .OK'25_XNA_<;[RI?*_C
M@.$R5KJUC[!]>R'_)Q[ ]=> 50- < ZR;_O]B<GW?UIZS_@^<:PCWZ'T'=]&
M.RWM(\R.#?W))D,G/G<*"5W\W/>+Z#M11@58#:#E:./A:)-UOO4<\FX.>H>I
MJ?OKY=]./SQ^_4\-G4_4^3G,'#WHT;$WV35"[5XY7H,J:W&4K%#?T-_D_N_:
M_YT>)]^?.'%I]N7=IJ;E$*[<#HU:!B=P=(_Q':I8$7G6\K[HO21EX/M5!'31
MY-@0&^YAD_IY\A1D_LF%UH2/^RS VJ.?OOY[-DHB'B+)'DAZBL&X [.5< RQ
MLF.#C9F#[C_C8"#8047!"E*C%=C2@DA ,Y-Y#TNP?5QO_U]V)/[S':AV_ #/
M=H+QX/D<9A>!"H;KL,DT]![VXRQR[BEX;S&*F?5N5QU,_]V )L4"K!B!4S,8
M@,/G_^B7?G)#T&AAS#I-%B WY@0U-([Y)V&6V'>@JO 20;U/8O_N?CN4A.C$
MOIZM&H'&LF\[(P@]].':UHYZC:@S8P'877J4P+&S!;4/#$ $;D8(I@?L_VG(
MOH:=_+== I=CC\ZR )VIH9U@JOO,2<2>+<R?(-!#F'=YRP)\\U=@ 0R^T"X%
M'"W*,)ME$"O>H&*L^L*_8E,I.!)!DS.GYQO/:3->A/*Q *L8LGMH93,+L'VM
MB05(Y&<!,/Q<N$["/%27;HK8G4_L4P#0A6CE%*,)LT::)WFKS>YV^5?Y9Z5*
M:UM<*ST!#KD]A>.N 51MJP:GA%%(=4:'YO!FSQZ]BOKKQ,JHT>34;V\B/1]7
M27!%>9FN#7Y8S'I?L+Z8)]E6*#<_A.;O%NFLD9$([OB*L4H53X6\"4MOSE^?
MQK@,U^%*2[<<I^\,AO9"+V_LO=WE1$:$2E<-.?;+T74Y)S7M+\0J1Y5M6G6-
M6D6U&<TH1#P=+,/F)35/+VJX)[G1%LI?X2>-?JLH_ZA]P2^Z@%2P4F?;8V+=
M-,"\FF2%=]H<6\[^;)%Q0;VKQ&IQ8= L/W7<:T '5=S8;1[2:^49SK9]LY1=
MQ%D4+82T1;/TL;WKR/'"X>N6$T6IIZWGK\:J(_%,3[Z*J8G);S=7!?9'IOW"
M#WT0SIK>(] 5?H3%^V6&P\3 84-6M@?L2#&YLAZG@\Z+W4]IF)"R$CNR\D#B
MEQ(K\0>;*<_J#]WR]#<TA-TMUOT08TCJBZ\X6[?6#'2S@I FL>^"2U!.)0G(
M;65EN<H$?L5-"5A?5 K$AWAJU@_Y-JBYJ]D:& @&A0Q/JJ6X!9XC.-RX\<8G
MX0Z':G.6ETG-*N1&N,CSK 5Y#\V+>E(@#TLK70._U8W' N+A&3'%HD^''$3&
M]7#C%:X;BMG9XZ%:$>GK>4>058%QTP5T$Q#84$5PM"^D!>G@/LHF1KLKV8K/
MV XBFRE0VPD]DDO9KEN=K9:, E<;!AJ2L?JM >>I[H6K;P%D);<_JA>3[.UI
MU!;RULT9-X:XI=:,V7I@O=3MA&YG.]O)8?X'=6_^U%36OOVFVU94%$1 )H5N
M 9E!!60FK0A(Z"3,0X#0B (A8F2(! BD6QEDDD=&911#""% 1 C(%&1NH)F'
MR$P2 9D3%=A""*_/.7_ .?6M.J?>]^==>]>JN]9:U_6I>ZUKH[E34U_-G+#0
MJ#E'R,"-B&M<ZQ37#EE:JD*'['B,^# ?CEJL1'>>G[(1*2@!&/M#=N.:?/TR
MTV)E^J1_]2C6-K,Z6SG+]VWCO"3[?E41&CYME5.;5IMYR:U]/==IS!ZKB$DZ
MU:?QR@1I&Y5[<"=4-50;95U@M?]>Q5]YSHL4M?,Y$MQ.^\O[7(PJCL:23PUZ
MO1:)26!<Q<TUR[!H4IY=:)$74>99T:0.]JK>ZK;VYJ\M#=R6;"HZ(MI/V29O
MJ#[^EUSW]!L=8LG$!%)B7OY]4WT=M$-ZS+Z#PR[$YLIH.9LC$YB5-SKJAPV6
M6+6BAL"<* <VUA[3 ]W[)FKZ]T8)&N;>OP/, Z,UA%#/$>@\7PPP6%1(,EXZ
M L5OX2WNU1D+Z"P=F?7I@:)X;,'=]O7N)^MMQMI/B3A,AVOCXX(3);NR;#F:
MZ,/W"4Z3VM8O-'SCNKMQQKAFZ -31?N;\V(4V+G0%%EBX+O,<F>''"U6'YFL
MZ>B::=^I9I<:.*%&,G?%46YIO-*P6 @)R9JKJLU>M<9]3TL\ OD/I0K.<)>+
M.0H2>&V>WXO%39T#C4V!3I1MU,+I#]-S.X.O2CH9BF/:M# /RK:^G E5N;ZF
M]?W[)\OBEV;MLE/,O_%>(FJ<*&RU/NHR7<O9^I],TD&#LG+_!5(X$;;:Y#8J
MG:2O5'SZ14AX+=9ASP$S%TF]4EBW !NELQ:FFC@+R7H%4A[<[?8?+A7AG^@C
M92Z3LS'I(H54K0MQT2@27D60-K-I;%MT_'$M;3V3LU9RS.]:\OX?[N)FE8T@
MXIVC*:\W[;UZ':/+(>:;!A/=4/T)ZFFWW',A*>5=AGP/NGS:*VH9G9GWL*[Q
MQ6KKB2/0?6]Q/!S '-CB&.MW>#<*:'P1[F &MN0S)I1U>'RKV5LGE6_P>KU0
MG@=[Q?:OG=2TRGF]+I7[?$+6L;0X2)(Z![^: <\I$G_IV,&^*M% >7]WS0;R
M.'_3QH&B"LLOQC%0;=:;!Y6UZ8%6V&I[DN-9"38' ?NR5]2PL:*LVJ?6-6_S
ML+"H/\9W>>'\#UHH%!%\D-?@[E)81R  TFQ"!EH[O*?_$UUT$-H^7<M\O._7
M2L;_JZW7OYXL_#&HRNJ7-/358TL#X;=(QOF"P>"B&HJZLY'7=W6K0:<E.DE2
M&3NZ'C7[.?4.U*8= KD>G%6PJ4R%U[@BT !)P;KN,+<U0&/.HU/V;%';PJ6A
M"L!!T&/+L_QKY)5W1_A^X=-H=H'YI1C_%UJUSZI,C4H#93\VM18*J]:NN_L7
M+BN\D!.M6ASW,4@B]MH;.>88\!1ERD,>>0Q0^JXNI7@LIT..0!*AN'QC^X<5
MY],?:O6S(1#M&2^*7D76SF>LX/+A*_,K:X6*$YKF$OQ+P!0%92XS8BY/2Q%*
MKM62Q,)%@**NF!/)7?7I:^'&9_L_Y[K&8N\$T:/#VV5+*=AC]4]9= 93I;Y)
M5\O_S&-YO?%JZ0HE92/F;LQ@Z%*!,;8EW\F):5K>S8MSZUYH:4R1O?/L+JJ,
M[%(IU^=L9*0TG>EK;HE>6ZYUA AV7]"W<-NIYM)\"P!;CHK4>6XJ1\-A')D/
MM':@)Z:_#,,5GNG--.1.3Q]T[#6&Y33&-*'U^_3+!TJ\YE\WNM!#ZD'=+7K4
M$9H,),O-*46)=2/7,QVR"37[<W1RK"YW+6N ,D%V-G+,34\.=#G00J-4RA_7
M,(D-J\."7H7:S7][T6BN+OOL$N_:J6]-9MKS7]W'_M@-]>XZ;'J#F!^@ A@L
MJ?FK G#G@5X+P_'6P</376ZF/:"L^>M/O)26 OH]HC+"4Z$()*=PS\6*@.CX
M08>?/8@/1QX_WKM?2Q=X\ 6&?.Y-!^>_?SE_TNSFQ7/1;54=KP5/P?ZBWW\G
M;_Y8\_=;"-^^'ABY]O@>@3Y5]1V!-L2_]<B?4!18O_3>_];Z+7?EZY+WW2C6
M_^R^SK[PP<\!^X4DA4UL%*M(% A'\H82"/=HTNL,$$8,"&^+44JSYGG*@P$,
M&D5=K9L'5X^;ZJ,H'6AL!$9RY].OUL<'.I%W2P8K.<M?4P@USC:#>H%^3L7N
MM[ ^0]"13H-3QMKZ%SW3@RR_,;+WW@</Z)13C%1MQ:6'LAU2V:OC(^_U-9"#
MO6N;+:FB<OUEWH*!H@LZX$ />,(-\(6@9NO%DV#_WUB5*BSK!,'E =Q^Z@S_
M#R_?/X";_F1W+[ZIMW#TB]25)*TKZ3KB!'\+HF=\^NZ-7-/J'I])Y'JS04T%
MKR^T<[QC)DL3K%FMO=9*;YE049BK6V8(2<=E7TGO,'Y>I"EX6[K6=^$(E!-D
M_.YQ;I9 B/N9_<T_<4[0'X)#B)YQY[L"$]R$Q;U44V\BJO"WT1AYH(_38R!0
M&@N+?CQH9O%[$Z]EZ*FI))L@PC>)]NN.BEI'Z\BN1VH=MF1U&N3&M10T/]N9
MK!:,C./PVBJ2D,RE4ZXE9=WG\Y7[]2U=J!#L]WOY&(AX<N!(0_UD0T.!NB3Z
MUO5'H0F771&V6;#@S-%PUZ3 ?0WW(DN^V&&&CN",8 [\;N6'(WS.^ U 2Q2J
MMP+NO,MFLF@HID<@P[-ZQ<:(VZ!*<?(V>@1A=.054E35],?9>8NR^1/<L_,O
M=[_:L$-R'FEPV5\E$_MTSUB=ETZ;J[ 4N<>R*E&&%2RY#);<R[R8'@S3;ZAJ
MD'P5]\"A\DGG.%&V<(5>,O^?3$_%BIWT=/O'+LA]@L]TMTCRW7W1IZV8(] O
M?/!8JS\AR5QB]!M4H;OP,I!( Q2[)QG7N>9YHETFWF>LB_$R>9U(:>[F<F*E
MQUKD(:FJF1D95!@72I[2:[2B1%9[])AGX'>N!TX4&H@Z.!2HVL4AM+-0IKIE
M*TE.:S#=Y%23]M',L72'E(>?3!IL?W(@=CIF/!0CR[1U$\/R&\J_])96RE%O
M[$Q8K0PU8C86S'*>-O_&\4Y:D#2_R#]7#20$8+U!G^>-TWH0]<FF4-90G:>;
M-7N2V].Q?0+7[\+=B]W6"7I8/+KS8VNT(+JMK6.T!O.4)]X<OFE23FU!9+X%
M(H$&NQSE"/LP7UB!K<K&(2FPUM?A33+,KF29$P7/FLF+N-OR_5:6+'W.3$4U
M1-7*I55'WZ8-\IC.D?=KK(31VKRK5;J]+^']1AFG K[@X >A7>8@GE3G @AX
MNX[!<@_8*D]KS_Y\!.H\1<59=$5B29L%WXSS$=C!5W*>I-R _5E76?_$>R/D
MFN8OUZFY/@$LI#:2F2Y9G$"%IT]\=LX?-U(?#4G)2 Y$&(5:S)>6YDKP:GTL
M)_'\:HIL:)H6&0:#:,%T_*IJH0L;\X(]HTK!O\RK.-^>Z>V_!=IX-:"ZG*_R
MMG[2_ K.]H-4H?;[B6;=8K-#1AJ!?=;$D8E7?H-S[3$62:B<FUJ-'*0NFA$Z
M'S^F103AW_63[NBL<=*0HRGJK&I#'-LC]30]2U\V8VG%+M/'.$MU\!',+@X+
M;3)<U7OC%&S^3='864V=EIV_THN"#)3196!V05=&\WVB$*M%O^/= 32W'WH$
M>H*/Z1?HC.&CN&MP*2_^[P#/[-]IPM_\Z/OL-)G9:/*'O&89\#-_(!HMP33_
M27?60DF@-*G)O[K,]F5=<G5.0EWZ?G5GO=^X9S1+?2V=^!2R$] 81NSWV"N7
MGT:X1I).1L'#]UX\?9QFIDZ7!XL)P<CJ<1(T8_Q;5\KVE-/CW6RH4GYK7G:G
M0HUY,LM,:M?BL"Q&]0C4'LKM;V>8U_!H[3J_?%Q#&@'H*O[O+<-X@TH$;OX(
M9#^JUTE(,+\Q$K;>^LQ -KHEM;2:5+Z LBF>/0(]6(NY6-?X]GT+;M4YVS=G
M>-<P*=-+$^HJZ_;,/F7-RLE7QO;P36;NFY*9E#&'%<\7!25O[MXWNLL=;U"'
MY,6YTT\G2:6';5XYK)"S:WJHI;?])BLW[6\WP8 !PCO6]!)[.QDL:2['%TE@
M7THQ[OG;U(S3QBGP[9;=BZ_R>E/-"V+&,^1Q!MVY1?&F&I1&W<_[V\EW1RJQ
M>??1FP:;+HJ;^DS-$&S@6(?/.GONE*%+@8+O:;O<2:<)R [*BG1G+O16CN[S
MH:PYV_!$F&.JNK/&@4&_@8BE-*/:(7^1I!SM*S$]]?5&0TS&87K,3X$+HN @
M^,\X(38M :_&3I7R!# \UZ["2^/G @2&0 1GX<PL7IZWM)> ]V%YV;";1^B;
M&IN3MSP\2I(W(ZWHY'Y4N$@1=77,4DCD?DKJ@RKZ [TUQTPT:W7 /-#Y\[A;
M^34*I"1ZZM;C2.JT77H@+Z=E**FJ_,\U6";I OED+U[R-V67T_;I\SI]6ZMS
M)N#P_BW3:Z7SA#83A@(:08C_=M JLU94ATDRU96GW7\S/<2NM(5AGLY??%_-
M70NT0S"JH^YB3>(+AZS%;8)VOT\'!*7^2Z*2G-#&M%/0<OL^CF-6WSA'I]()
M]AB399OEWL=\1]^7_:J?EAZ"3SY)\CL</ZQZ5]<[4UFW\:>GX!\F0B=1;SM!
M7A=8X9I\*)*A2]0^XZOQKM2SN\;UH&C[)*.P[=- 1T^D_],=<)RY,,]T.4!K
M6X]V'EB'95BT9#W KHP]3'=[0WI)&<.N^ES#OAUIVN\R=%C*O+Q#@666]XBY
MY$Y0QHCF830HU".748]K_$\Q(LR5WY*4FHLPNB7RAF*X&L81PE:$FW[M M?D
M=*:=P)OSO-/PUO=/O-+IV$XBLH0Z"<=GJXI%4_#'V5$M5Z*];S7QSF8V1J(Z
M;O'T;LA6R,J3?<J1I*[N',-LP\L-;W/7 WP#G&BGSSU$,D5W<B5===[1H+;9
M@?D9F,*\3,_%T7?I^,'1Q))@B16'JZD+M>1-U(!^K^'\:+U'-Z\1O7F%YN<&
MI![H\NT!+Z[O(KDG36)UUQXGRFDV_S6O71P!-]W;%;I5^!M&]%GQ#<J) O"S
M;[TYWMQ/-J$AT\^3WGF]$$ME.UM<2NB\6XTS#GE8=[;-&:HL-13]Y_>\P/,P
M2;EW*14Y^EOJN%QGM$OQA>^?#;^N$I<%KN$QKB4,.3--P:!!)^;O>17 APV/
M9YSCR5->@Q-C% '=#X4WO"YW!UG9TDZZXZTR6^/#:%+"J3>F-'=Z:U]I8F>H
MEXQV]&O']$W$-1?0+S8=/M_] 55,*DSW4[$+7=N/&)C^NC5"_7%AM4.S>([6
MDA31QLA9G4>5S4C*438:O#@XF1>?_FAR2^USWE(35"L_T?PR_Q0/W@%/,V9N
M[%4&,A1:>(\3.'DZH#FTK.=T9J%<C@NCN:8F:6L^JN7&F)-QB$V4^)TOJ.#9
M6)O3TS7'79V"PZBLWU)3 M4=WZRK]EI/AY3,0*]P!HCO'.KS9NUHLID7+JM[
MIB<8P_I<-C8^T<C1A*;=Z)K;AW$,I77CA$TUC,'S&$E<E.UA)C^*B)-BTQ+Y
M]FPS1PON4NMN-Y4-O8A+LVEM',;WM\A/;G=(J>W:;%::6I1!":7N ?O:Q.B0
M75Y(_XUBZ44ERET5S>X4JL_J&%EF'%]-UK:QTK]$ZM?;YFK8YMK;YAHV8_7>
M;MZJ*+QROL"P6ZW?4@KE\>K*]_I6]9H@XK_T(]#4_*:I$!N>Z'U&H(P' TP6
M^!CT;M$YCP]4CI9B)U+HW81V7/PK]J70MB/0.;[RXI"X+4MNTY(U)I2L5WG]
M"'2S=GQ+ZP%F.VA+NW)D+_Y:5&"8QG!E'!4AZ)D^D!FK8--4;U6>IJ,.G%JV
M[ZM9/30NJ\U]_I].9##9)0MROHA[2%9,M<J:]56%!*_8NIX8KZC*J/G/T%\*
M-:ZIK0'O&2H#BW.A;8@SX%/X2SZ<(<EY' =I+C?*XDXPGWT[ HG.KPE3!U W
M7J$N).D,5E+,R=B["3!ZH<F%YG'D:/LJY]KX6V_7W;>5!HE4=;T)V9A16* (
M*H3\[VQEO[Q;:T3IIJ2:);.S0W3C.\<HROV+Y2W3@?ZL7@U,!**/.;]]>S8,
M _:C[,#/ $.=1:<8FGQ=8#[F(BI']H<A;#99=.+-9[ KY=KK="XBR"EZF\)L
MT:>F<ECV@O#G(3V=RC6!F/$L II/=&"XA7'WU#0N9D&<>-*1 !RC#(M=.Y!Q
M++ .EWWH%#BYZWPEIT&VN7EHSC6[.BNIMEAV/'!X-]7J?%'-H\S"X1"RT1?H
M1F;#PV^V#H4)!\9(T9]PH6S7+M%$) A09!$NFHT ^$+3Y.[&^D338/)'3WW2
M$>C9-^^3>%-N6BK>%L.20W=%23<[5ZSF(A/*YCM"@TCSWC;H1Y=#NLF(L*O?
M-.ZN.=37[9IW7R6I!<&PZ DB?)J^'65H,V#M'G)0!7-+BW%:=2A 60#Y^4E7
M,<Y21H-BRVBDTXQME)?<+J%ZH0N]G10C#:"#(EC"E3K=R#-,QA4 S6Z)K[]"
MYM)< 0]6T(^:>?/ :1O-%J53G@OP4@ #&]WYA5D;\.U'#16=ZS(L6H=?3_#\
MAK]J&G<,G9NP5'?V2:#$9TH$7^MT2H\SUC[_8[V%I"E5K?;I%#A]\F3C^B"9
MY71[0YC>DDWWA+.-'E'$93/B1H.WGH_2%LDODK#QBIO,>G]8^X/OS@8J2,>(
MX6]SLZLYWL?1-F:T!,:OZS'RO-M?<?%R!D H%8?V!").4$K13-ZITG11F<\(
M>#PTO20GLEUKHMPVWC>1=ICSG')1^TJ<FWVEL-%([*KRB<-F?]FUZT]&D)DK
MCJ^F+*?^Z1='D,=YYW?U40.W@@$*Q=(#2++/\Z0>/'>,KFWXDM8-%>H0R (%
MG"#%#G.-X>;[)3?9T*#7$\U&);@BB]'*:2CB6R^Q@XRK[YB7GK@;_6O:V[Z1
M55_HXV>7;JPMCRM5?F:M&&>J04AJHQEDX>Z2U4'X'/)KEMIX6@OCW;( ;292
M?CV3<K/O^M.EY^F9]W81]5+*50=UC>NAFS*M_D%PSG+.#WC8 ^RYH_WM"-'G
M#%7\"2 Y6IM"\ O[1__0MV-!0J"S=DJ[E? &Y3I=2"Z?11E+&&OGA8=C(M0W
MQC9*"H5/.B]^$31=O/BUPC+<)>P1T'?*2N=5NW@'Z_)W12/5;G5GHR7)(*/<
MY<B+Z'-OCT!(JF.A'?G9DW?A*$B!5L8[&R.#>TR7JBT2:S]A@T31(J=I_I#E
M*)9H)_R9@C#?J R@]1#.-$N6X\I_O#P6!A:-QTAY!2 OMW!)"7^98G6>OD!@
MSB$ A2[&K^_K:Y\O[T]I5VP^]$LN-XK%6(YWW"VS[X3I?696R@:GD,$LJ[ )
M:T0:_4"$KAX>:7+CS8-J""^$Z%)@G&X?YUY65J\3SVO*EV@TZCZ]"V/^L2]D
MQU5)*#Y\=@3R2Q5O*S0!7'W8K6D$"7-%%$.-W@J$LC46I "R<SU/JB-(Z.8P
MB[=<S)W<]3XSS3<VSDRC'H'NXXBW1W:""<%7$@V2[J%C88:31;MUQEC4W?NV
M0K>>EG(08B28B'0B#):"GB;2,-B^?+*4Y"#%7;< YNW5"0DN9]TJ,+*:N%Q\
MO-<!!CM-:]W4VIH_'QP\8<4?_2YRL"B5M $.V#M\N331;#Q_ YYLA[]D/!NZ
MYM_>RGT!9TLWW\A]UA"D;>9[< [95Z-'MC[ T8_')?]AFOTM6SOOPR$A.Z9_
M;0&Q5!M-KOFTLO0N+\VLM06]BHW![4;?57#%Y=F^<, &D0W4T_3K W>_UN>V
M<!80@M[<B>P"=FHX6Z@+'*]PFJ];S$?P=-JTI#H9US.ZQU#F^KPC4.QO445B
MTP%05MH)X,D*?%0O+WQLF<%L=L2P#J_/!NZ'V#QZI]]^,_G?RTLG[3K8U_25
MX\G)^6KJ$*>R\<=/BVJI)_M"PFO5OO9^J<N@_SNOA10C6U6Z0U+0[SO2N62=
M>/Y8W*==^S3=L:#G>0AS]?$CD$_::3</0'@Q&?#N**K=HB]Z@)^9*W!W208]
M0Q) Z4'[7J%J,JR9=\9EB+S& *$O04R\+D^K,1VSV0OPN >_7*L8$@OCY#FU
M>'K3"[U/#\8N*5!&R;*% [TW>R'ZVW(#,]FS0P7>V6HA%0]*UER:W_;%##H@
MN\4<(6M@OW#72.W&M?&W#UOO-?#-JE:1QX XWM!B0@<\.;+VPL,8*:#&C1<5
M&"//&"]^'F3P.V\A10\LM X^BS_&5NNL[OFA_/7=".?Y.-/$$\VY#RKL-0ZL
M"\]76I]*[O0A$G:3[$C]^E+;L%2UB>>7Z>;5!>HACHCVZ_7-@OJP%5A<8*:C
M0%/BP>B\77(ZQ9"VG*)4R%L^T ((!U)\)*]EH><LV*6HG2"\?03R]R'">0C1
M)-G.>9GDCNF'U'+S/.TJ[/'JEK&5MV/MI,_79B/V/TE%AIE+)R!:QBLJ_37\
M7@9JG%(]\+P=/+LNPN7N-G])B6@(VNI_U1J.ODF)@CG+?,FZENFS\8!L?U=G
M8TY_X-_-L$HBE*:"-E"6TWW*V_L0E78:]W,_FQ8;\QN@P%[H>(5W$AR?:+9=
MQ/&]R;TL@K1^UB#%]PTNHV/>E%L?B[<A5]63$%Z!LB)5>@W?O.[*>;ROH,MH
M!_G_?8.8[*QA*^J0^D ?"Y_NEFS)V,ULR/1<'4R%9"[U7\GD# P)EXXZ>#(A
MK:9S1F,%LOG-??I&"J9AT*YVQ^0:E'X8L["9<<K+__?_\]O'_U_]L^G_K_8Q
MY_]J'SOS^%)'H,M\[\-XG4/=8QW_@.>H!.81Z+#GV/<]VENSL9V<Q2/01CUW
MP?,P,^TOOB5):8$^M&G (HCCPP[SV^Z<'<SB'BPV#6C5Q_];H51H9L%QKLQ)
M6QG5W'S<3Z$EA'F@G*^XV3.BQ%^ZD%\>!-@*Q*]*JK&N#7E &.J]XY\;'J6.
MI'Q::!BZD@$M='X O<-N*?%Z^QYE]5RQIB#(J#[U,"-LLBG4!+%IRQ+]B_"#
MW1:F'3OE=;CU[0=>%]:17->_L*W/]BOCFZ@]Q<*IQSKVGZ>6K@6[>WO]'O:9
M?M*/J>6/V4P>4+2-[Q.>R1MPF-#B"NITY2R.G<9>$PF41+?'WC\9.AV:LG2!
M3=,PMVKY9] 5I6I2T\BX4BA[M0#VT'T\58_=4/&I9 R%1EMNE/#IQFJM][?%
MUHPQR0\%%_FV@!&/Z,R53R.PX5* +<O_&=^Y#*!"N(//B^D+YU?KD)I<\-/:
M;;F & 4K\?7P(Y (W5OZ2L&?<FXOSUXPTI=,H[5?+Z7:=;)\72 2:W?5QIR6
MC/ 22^K8\KZ4%?0M?18\%[F5$7Q;T\GI3;E#I27,\VV!6]O-WLT+'*/W1M%9
M]K>VH;)+YK&\A0]G53P/_T/PA2?>8(*%&9*HW+I4WE,XKZ=S6UIK.=/4GNUF
MKKKV%D>P:4QK*Y3Z+_^B*SY^?DRZ*QN>H/^1;T8LN1Y8CX 5Z=?T]]C*J"Y'
M5 K?O78^ECN8+9]%VEAM-@Y-QP8Z$B':4)1:VWA&;41I[E4RTK[+5XWN4I%)
M,0YC;_<K^,O1AXS#%O,;C;3]'U>-.7PO<CK,B;GFSG?BDML.%6^^XQ4E\@G$
M'QH.$"@X$^>Z<;X*Q_M$X"33-3O&8 1O'7&8APIBW=FHT)=K\7!BCMW&B'24
MKEET9D__T1C]R3[<6B$>%_F2 G-"V>=3)IU] C/+NWM',A4?KQFHEG6+>&[9
M?WJX NFR#UMR[D^_BJ=+3)!/'8&4B*TF0<J2,>@JE^U0"&?W+G-;BV]5" **
MN+X<T413Q=) XX5G^+/<ILYYM0F\!X88D+V-99]UM4CX05[<N@3.C*CH=$=P
M5(4GWH#)OU>W'T0?K)9N&&%%[=A>^F7U(%"Z0D]]X%;! TOCX)(EE0"KF,%*
MFY'0(%7-VP'U5X@E"[]F*ZLHH"!TZ0&2S'B*A,?#$8>E?!*T;B/+S<(UZ/Y#
ME'[KE&N/N21P<Y&0*M#AA7> 3P$J;$Q<%1[*73/S]N*=$2CR*G8CJQI*D("W
M!7<W@06]^YU^()=ZMJ2U>1Q<PY<C6U,#[!8 QOP1R,%6R>Y?-:<NEW9'\C.*
MJZCC%/,16=3?QK =4K*B3@G1!S^^%DI5D?DR&FCZH=HN"S42JPX+^T1TS+ZV
M] 2EKP9Q3+)'K:('73(@?5_HV -5'/7WO-LCC-_P4$"#2^QA_#86MND!!;QY
M<EV,RV.F& RJ<LICS?@T4%SK?1QXVK8@JJ/?)$>U;;H$9ENGF"H0+E7.T2>)
M&-^@Z[8V?A++)'6]:[BDJYE$3<O3=F%Y3P-CAG)KU9EV* HD3KU\M>RKWC"#
M+C6@'D9U)E\8H\#$'NV%+\$"L9K?6@SA3J,M#2G1QW:]@#Q"&=^MEH<OO A8
MD_$B#:-Z1Z"DF"M 442E6X"\Y 3?\H<3O(M#6Q& V\U@CA;&;1QO&Z-D+,W=
M3:YP7T!QARJ$WW_#I>XX\;Y=?KN58W[%C>&?0$ZPRUSK%EO)SZ%3K<ZE&O+Q
M7QV@92$-C)O]DE!UV,6) G1C<$E&9J:K7A&#(_&F-A"FO35#"V>:"I-L63]0
MOG5WB'M/X4RK?U$BYT/.PEG] @_.M]R!^6KV$>C$:B,SZ=O06125Z^%4.YQK
MY@&=U#_Y<JU[W8D[VN$?%8G9V'&76 T.G4C/!FN4K7,"C/N:?9]^LB,YM^>7
MV[#?+']7EEZ5LZJBA(3,_=L7LMSYYYIQUFKHP9WRBQ2KH%O0QKY]P\K:[#IZ
M;2:>P 9OS+#38O=_]@96>A2$:PDR.@G-*FSJ]M-1(-G3.RD7&<>),M0'B\QY
MK=8 2-%30^'!)5X?T5*15S(X6HZ=QLB<,L3<&L+RW:O82WK7:GGG [,T;U-"
MQTNK3?^SWTR&P'0AR)$)&QN(>@A)&F(?>#TKXP8Y,=5=^3364R[?^:'S1O[K
MZ?26V3VHFF&W%E4-\L_W^2:1IX=B!!_O[]=I4RJ"@:9%FH!*$V&RO]?S4W45
M#D2Z"*O["1\XK0O7O'?%/(Y MB]VO")65/]?-/;XND>@ML#6I<M%LN -82[Y
M".0,?XK>*?RA<B_D1?DXVN&=LNA2Z _-V_=F_Y@:9"4\CTOKDGW^]."<8-(8
M^:K2IM0@V5PU9A"A3?7'1 8]Q$8?OPP449#NIO8#%YG&44@WU&:TC(W6E(LA
M^?B]GYNN774<")F"G(9D*UPRK*LBVC>;.DZ1E/*")\(]+DG>):5TA%KQ,]<'
MM:C3T-'G!RI!C5O[4C'*N*3-(]"?HE-/VVVHF+%65D3,\%[.M#I2@VT2I,-Z
M.=HU]Y^7[SZV:0T6FQ>=&:Y\YP4/-ZN[@BI8$842'OA)1D1OE_^97M#8P%RN
M;<WM59GL52'%P<";0&+($:@_]\+CM3F/F8&=M?V-:'_M:N+L%%^?6_J"G2K>
M0;@@T/Y1HVN,2SA1UDH*UOL< B76P7G?[#1$8$4M2,XA+83B=@C2?/ P%OXS
M:J]^[[&]>-ET #/4PR/0DCGT*1V7E$$R?OG@!@%)C[0K78HT'^Q[4UJU9I4:
M^:)2B:@3-W"%M<4C*6_Z<=0<B*^<*(96I@M-2T!F>*!XCLF[C!%Z]<I"S8\A
M#*4<@8['",7,"?-N^')I%CSP1A>[Q7R(592TDWS6H--;3'_.H*OP?+KH^0"D
M&)I#B"K%(4]M+1(N5!;M1G/6>\DHU\:G+6M302E=/L%NS>2/A%J8]'X0DRRE
M:A=+<48.8ET;"VR4#ZAU#4:D_H"OZ&=4JY8'XB4M)<3$Y-VWT.[\"&4<Y+&-
MT1%(>68/H_..O RN(R?O1!V!DA=JGEBR;?/RO(_'#"S4'*^/3RVE-.J<_3%S
M3B+3J,BJ/.6*UR@FM>*_V:TV<LJSX3 7/[C:>:TOY<%N>.QB#KV',[LM%V6Y
M>5]R@-S<X !9I09%U?RA=+GLKME$Q&2G$8H7-: QOS>B5/L.H;2Y'?W;@?5_
M<[YJ?]B_&>:B?SL0=AC./B_XB!0'F*]Q8-CX@Q,4#OCDJN DKR@![V[P]R8"
MCRMR']DAB*WNUY'>K*;;4H9(\W.!%R[4HWRBEAXMWM]0^P0T6V2J_F!HI_;!
MBHPEDO,DR3CP1^US[/-1?=<R<]0SG3S2KB^OO)Y0_IOF.$?>L;'/W!A']?;E
M$X?N!Y1FV/1.&:ZCJS"Z-7_Q3=($IYA<>#?4EX2WX29L'J?A+7FTN$^M-84'
M;;+@YWPL=UKTC!NNY>X+UC#>,AS#JK1P;ABF*4.M(6.Y?5XNPC)5V9*?@US<
ME]6S5FY5G990';<A(<("V!>7(&M?2PLLC^MO];DN968^#%S:=#&OU)M3&X[]
MS2S(P2X5^1#&\UP-U5*:R^[X[1HPY' $>I*,EP8(Y:C'"C(Q5_AAT?[M%_SM
MWXYJ_]C\I=J+)$TQ%-P":R&!OI[7Y*%&ASK8#HGB2A=^1[_O2?Z5N_YQ.KF_
MJ[;FO>2JA5*72TJAE&CLI_)--4TSQ,M >Q(R;+0Q)<(?.KC0M-*T!/U'X?U;
MR?(KGT??9%;DM^2OP$[K7SS?DI4?D=,Q$-Y'SQHZP0<#3[D>NQ<.B6'>*:/:
M?Q/7%*1:_=+.N_-_F:1[&)H&ALV!NQ'O<#E=-8#95NI>@MZV^.ID+^O !K.I
M63J99YV]WALE[!%5K^Y"3![@GF]O1:FRJKG9U\4RWN21I&#IY6^(1HX9H8]#
M[%9&*%>S(-CJS$L*$0<7;T<W.SYJ2C'ZDWROA'VXXO<](GVNYMGA&\$)?B"P
MRMOK5I"*$9ONY7FP<E+X\!MT[@S;($Z_X ;X-$ZW;6C)AM5Z%LW<DTTM:&TW
M:A8J$8:*V@W_]X[)R0VDO*#?]V204="V_]CQY';6U;"W'U]%(UI455V+'42G
M)ZBU:^W7H.PL%#(PK&'V.[UF[W3'9/&M6#5GNOK;-,W5WJBON0!)(K, 'K"M
MQ"8-#,RV 3C,)N/BCY5ON<'WX@2)]S"N9+#\GSS \'WNLPD 9*/9AX+ AP&1
M#S&U:>?G-]_S_CASV3_-/A:68_\[T\Y6O\QF?EUI_=/S++41\DY2E5X!^-ZJ
ME9OQK@/YDEI+C%3-X\C9\CKL];V3D/SHBDTA>6OI ]FD0;"_=4W=+@K9S>Q2
MB&. #\FF&@=:N/I%6D)>=Z-*7,Q/@,;BT'/ML$T+Z$WN=C?C%,\@6<XIC2TZ
M7?6G_+D1;;UHWS]X(D5LLS_;7L\%[(GWR[_Q?\NH?W(52#(\_2K.U!E^W_CE
MVOMR" 3*)"&RY%VM^I"3@8^RC!R?A#K:VNK]0W(HE&07(SV?.Z^X2,$78EG"
M46;?2W*#@V&K^P?S'0<POO];GG>']TR>$X#F6&>T"XP.R6!_N#!R-B WSV,:
MF.DHO #<YXE"&:J*.&U];V$O=*YRR[<HSL$E]I4"_7^A+X^'+EY]1_9638U$
M'EYLO62O9K65"LDJTZ\:*2>J2*'U([0R0OKBY!$?)1TT<@WQM],#^>F9JX1/
MO2;>L+HI(ZQ"[4*R_YC@N&"RT2^1;;A9S+-.:OWSK(9SS1C6\!@ZTBQG8PD;
M$>YS_::&#=8WJ'QU5XMP&I-D\E*QONF8EMS]O\AXI(=:^Y9$3:)E+UX<=Q"J
ML:DB8V*VL95!9[]]BYP1';CDL[-<5<=0@7YKH?G1Z\M-#W;QO*&_\%)<ZJX$
MS[HS.A0V%D83CAD!T[4ST)5K-,EO\C\7N0*ABR?QI]@:5"/+\6Q9T7CS7]>,
MPY/X_U1"9J ^X67N&E[MW?7=(Y6.8GECQ:>,G#_<'\OT)580D3654!LM?X?8
M^_#HB/2LK88PVJF^JAMZ[)EL!9%9E_Q5)\KFY2)W2 %G)<I,AGQPAG_L\ U#
M+N9CC"B/_%P6<PHE58VW2?, XJBX(FCKL+E6!Y5OPHM-7Q6(,1?'MQ:!(G#B
M5#SUEWVEQG<6?NGKB-BZ&[NC?U3G<:XZ?^FK+1/LV@PO%<LZ.+9_<2W)H I)
M'WI/T;"4Z2_X%\N8^7P_Q;..PL:/]CX5@(,M*0Z!)?KY$:XU-E/H_NC*87[V
M^R/0?X\^KM>V[LNYCA16'QX3#"I\^1L^(R[HC_Q!_BN[(;3G/4>@7J^L(]!'
ME=7GIF>L^6E76W=6":OZ0RM]C,Z]]O]1QN^Q#?B4:U>,))?Y]Q$H2$-!')=P
M>W@+[WMP&3?47BA9.XF5LSW5;,M&#\GS#1ET[F[BV?%GTZ4UH??)"W-MI=.:
M]0XS4W-_O,A\8D4SN$IVP(8T.,8N4_R<RIV"DV,&<XG/DBDW&-(4B%KOU)71
MM<R&:]?RR;'!#OB7+_M@:@?5NUC)F<F^38T6_;J</[Z+V[Q/NS->>PB1<U,R
MCBF^'Z,U)7GY/5JNK"I;!D+;;_@CQJ.@,L[O5P,-9"9-:0SCK+I=?[T&/;2U
MX]HP/C'F->8=L=>Z*;I($XT9)4@WPWE'(%9]M\)3%WE9H)^BD\J'OL%#@ (6
M/%Z@!EBRM1P&I^'G<6!7+BT)JP$_#Q!MN(?[< QKSI\UF,K^C&V1T4REY\L^
M-7]9:'6Z\@\1V4)QL?@N(Y;O!J5?-('RC)Q(OO!=O3N,M;':0'LNN633[MJ$
M=HR/L_%959=4<PEYTZ"H[D1VT+];F)%"Q'7UFO0Z93[8;JPQ6^DJ! /72@2S
M"USXG$=[J[2I/D<AONATS*68?P4R/*G.F99;EU1LWF:T%?[*=/1JX)T<]W?'
M:US*?)#3.A7)JQFO397GP+Q@TY-!/)V+JFQRYLHU2AS%5BRQTT_RMP3[APZ[
MM:Q_BN]-P/PJ2,+=H?"L)L\5,JRFS3>S;%!2?;S3QK$FZ&OWC:5WGLSP20.'
MK.G'U5^]VQ=D #",F\:7<!FRY\'^]@GE";$J(C%_%S=-/%C,Z=K[X5B&"R68
MT*)X=KISD-_G@,=,X[8G/8,9!S?FT0.,V[#UA6=DY_%>3]0@)%XQM\:>T&A[
MS$&*0FYLF(Z;!G(1WME>NK$S'Z+>Q0R^"7V'R8I&EF T@K;UZ.MDQUE3 B^Y
M$WPIK#4NYCK@R!Z:LKU39 TX<SDL<JI  1_"]=XH* %ZVB)7.FBB;2RIB0U3
M'][7MN0HSI 0[GD/A,Z3?/K97'ERQTN$X] XO&4*]M,*FN>DQ\M*V]Q5NZOF
MI^O0Z4J#,,Y7W3=V]D7&,+-&VYSILF]#'N68&78'JN.W!%MBQ-/7J;+#77IK
ML!)UNT*U[L"2_ W6+7*#81U[6]A&:2QK.LV".\,I323A8X9KX>(QP^;'>?YQ
M,;(Q_>!:E;A:FOAG\Y\! M>:%?,W3Y@MVD$0AU,!75:FN11WZ&]FIRQT(9$\
MMJ%'.Q?8>*,HFIT:X]%?H ![WO=EVK:99VAC>]S(L6V2[,+P?5JVVD=_X'(Y
M+(!96HQH)ALW9S@UY!?+].D5WS<RD/GEL^W'!JL4EOK+<O'@+$A6.21?W6JL
M;$G-_0NU3^V :H,<ROFD\_$(U(64YJ8+1FW9T00K+I<GNO&*Y]K>^/.Z<5QI
MOG[1^;5P\PM!NK^/=HU7"\\A <2L?F'!0^1R,$8MZ<9'].B_E'&JIC#YU/BG
M?]_N!(9T]6?G.R-1_;6NUY<QEE%F(Q/)*25O^=69#<%.)=\='R<M-Q=DO$.@
MR57+]9U%4H"C_6'<$>@^_+@;+N-V"R\AWEQ#,#)-?L;705.FX;3/QIAG.J8B
M^Y("&LE:K65L4S^KIBGH.GM9(ND;8C!HCI\SHZ<V[E[GXSR62W84_2M%W9!^
MJD^L<DBZK]= )."KTEQ#UF:8^J/T;K8?1_F4PVNBAKD+9RBL<("Z5N^M6\05
M2FS6]S^0B1E#GF7P3J3=9]/.\]T."^EFQSKJC>-JC>=K2@-<".*^3/VS.M (
MEZW](>MH6[ALYBZO^;'?[CBL=Z6G"3)<]E7SN%L[K,#4_(9N;O*G6+*F;NQ]
M#;W\BN^.$U/3N[5)_\GH9I4254Z.5I&46C[6;VSD31F,>'L%1>F."@Q6<Q4V
MX12<,)O9L9"H(/S-"RZ0Q+1O)\28 5B>+=O_B4!RG?$+3Z@#<Q)5>#)WSZJH
MIY&<H >7PBD@:D:"Z'-7MMLCXRMI[OJ;DZ^H 2Y[CT=LHN(O.'RPJI.GG[G-
MV4FQC-1_"T1^?.82%UE%T\R2'B\P'@Y]E%Y./.4.TT4=5%LYM)=GDB$5.;44
M!TDUQZP[X\[*:E-?0@T'O+,H456]%+.(F%A EY?'$HUM#8!/F7SP9<,3L**G
M8@9;?V(8X>2Z%*2P&AVO 44/'CFM69=GVVD@ZQ^[W6R!(2&A+*B&.T\Y+:[9
MA!*8O>L(9#A'Y?7+J0;I5%R(T721$G<]_G)R5]PY^.._RI&X@(,='TCJ'V9Z
M:U9%>M$51"&7DKO3L6$YNBD-$>OV5&/IQL(^""YI_+XL9##P7!@G0O6K\I4W
M2QI&[JC*-&' GU?4[GWF"'1O:&IWAWY6U(N7TZ$PLZR38IS0\7?Y1_(SFJD:
MZP@$ FZYT59&ITJ:ZD9VH-:V[T=>3_C5HQ4CWUDTS!M8KM/B*,_^#2X?B].T
M@G&K:7W?)6V8U"T*2A[7#<'7-[I,KUA"="E)E269ZG]Z*3L,94$<(Y'3M06;
M43-DQW0@CPMO7Q 7: .M;)TX0@#XR0C_-^ %YRRA)QWHZ0&+\4U^C$$!L(#P
MK&BA56O3_LGFHK/SA/;1";P/:Y?1.";H6*2=QF7\P9.<J!#_'%F;[9ILQLB\
MYJSJ@[*G/.DRA9ZV(VU0[/(_.V<9EG4[\=0USLHZUAML![;;0<M?++M<4A\E
M0?1("96;J"Z+[ (CXY!@3TI[94N19N5 1)^6BE_&*/AW7-1N"F#)Z]FM!598
MX(OK7P'%W:!#"EZ&-11KW)IJBGBPL6VJ'\KMZ2B4KP$<>6F=8K6[N]F($J0B
M-U8VN_(!<[C+_SZ[ #:]M;9LXN\.D)]TLJYO7(+H37@^]G8IO2)!F2M/%G/
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MF&:'>0"14^ G4'G4$>57DXCHB7.LMA9U2#1FKZ$DQPMXS+!PKL2)N-%0.NR
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M\%Q26KE[Z'15U<.,&2Z5@[K*![D+?*>W)=+K]7_B!>43\OO_68=R(W9VCXN
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M@YXI\D%]5< :'W1494IPANK:@S#-IQ&LZ[CMBW1Y#/,ZYQ$?-+/P!/P+\"_
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M\M05%VQ391_XF[6Z]<6G_0A7-=<.<HX-D8DCG1["*R\5?E00OJH;&'$TX4?
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MID$/\SKD#=BD9CY(DC?H2#U,<2 !'70F9*F6O=@L?Q[;K(>?(<A7ER/O-%8
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MC.@;:^J [$>9L41A:NLQ^2;YF1+T*=H?&N>ESHK+UWB$"_"2_;P)W0TPT(K
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M#PE/OD5L"AR+R<448%C?A2! W8T/CE]>$H)BV\"\6\WQ?#L&>5MS'<I3+WF
M611$"$&7/OD*]O^!ILR)&CX3OA$#KJT2R!]"LQ,A0U,BZ/H:+:)1K;!'@JHY
M](9.!WKZI1C/'"W8[R($6=&Y)D(0/5A,"%(H^E>"P7^72_JGW'^1^_S#$H3E
M7 4<[WO&"Z:C$YJ/\4N%(._H* ;TL6[0'90\6\P=TTK%I9H>\RFI*"V!(>'M
MV533;<ZC@)AL6>Q*<R8:(3?0=_+E"9G&:L$;-IPO^QTGD!F2VD2+.DRAUUD1
M]?MKC4Q?%X)8-E7;$*FQ42%(XAD$: <O!LD)0?V0'#1=]Q<AR&V=O"W'A+!^
M?2( 0T0WE0E!12Q^/IKU3L3ADAW^(]&0?TK^+R<Y[3,ZGG8()<>&?Q <!C)9
MS#8J-)FTAYDO8<^&/#5U*[R1U*/<9@X>7AE8^W68T(W]\*[F?=USC<?7S$-_
M0\XVHZ7CJV*KW XF8$T4$N74;8A*25FABQ??]<JF65N4&_9O%WC"7$XZYRM]
MSC0AX$XZ/\W$[F^G.@04V8O<]H<+2FV?_A'S'?^@I/8#_Y]C[;Q5]%W,=S,X
M=5S0:\OT%50$2;NMG'?C)=;T<4&MHH?]B8E^) 3=%WW]8@;F']?\2)P*4R&G
MQ1P%.NFI>*Q?@=$ I#K,+*C52XX]\C*0PS=RX$)C20'%%RL!7Z=U0E/WEV."
M@8'*FXW<P]_:T;[DKF9BW3O7A) B6";R8RBV3\&EU-)^P%7T3TX-<8(_IE%)
MB'HS4I,8=LS%2"Q,\>/!L:H'D@.PL?GAJMJ%J F&CF/KWPL@.7X=B& >W-6B
M>@!(*4> ?5A!;2J7VY7@3\/2ZA=JA:  ./*,YSDIF8L<B:@&X@7P\D)8M!FJ
MQ[*W5YD,.:<?4OUK5X:.4SZ,X*TS_*KT8T6@^L?R^U%&X1D^/=WZL1]'1MHL
MB]4=0P>W%DH:RLT.#S,K>Q?,JN:HIG;^UZ^!['=HOOKZ62R("8\W/P.$FVJ@
M;A:C?Y<ZBH1<9:_%28UO= M!*Q#Q@*J0'"^1EY89;R)7\TN75ZV^5 GZ2B[/
M"$'%L#9%"1\;HLG4X%AW[IA+OE*.=<A0;$-16<K*)Z);:J/1[9E#Y>)YO%1!
M[]T\@O] ZI)SU;?&Y=[CQ%,G=Q%8\A2:/,I^=(;5^=B@:B7_KHI86[/&B^X5
M:GA^_156W!,T(^C0%!_GW%1#A(QM:V1'1W*"SWIZ1D)\:Q\S%J\6WBEWQ5U2
M':AH.-9G+T_ KKGD(5I@6N0'(8G-'[<"==ZUV_R!4T4TN_0H3/4L:7;+O0YR
MY7J\3U5W]W09FO&\K/75Y_KO1X]*_V'E@+GABLUIU$LK >+=^WF0HG%^E=OH
M9J#1E8% TR^_<5U+RZ=:< N<J>A/?XQ?YB1U/[NU7JF1N*_^>[KM8?\U&\=K
MR3A-O]8S>06-EEI=[_4F7]SM\ERNU+*V/)-.U>K:5H^@X;*G'@0],]^%<F#5
M/6++MC5NQ2\O&V!B(3)BK7"5)@#3F@[WFS*#W!6SBK]:/ZH^O)D;:A+(Z*KT
M"U?*>B3;)F/GH'K]B!?R%FL]7^E>;D;U8?-:JZTP71/S-7(OHTAL33_D[ME1
M^M!'XT3'S)/M=4LB=L4?<V\=;0ITOV!8G).=7M_$W!RX\P.2%?&.?B;"#_/@
M )2>(M8.G;:[WX:11>V@\^4[3]L%!^H_WHP.:,^QS'V#;+R0:_O>?'4*>M!K
MH@5_@E//,?J9^,<+B6YW%\U?3Y]-,3UWO'BA[&VL^&"^1KJ+MU)(R)M!1RCU
M!-U74;/G=C[U+%Y=R>5W9F^1?<B]!^O8(Q.!OC&_XVMIOM4;5;S#RG2C-LAC
M,L&E[['YR9C/;C3":&+ZAV;9$3 CM:@T0 D_U'BWZ!PARTLEX'U$6_.I(7$_
M?$#P\2MAX7&GT7_B?YN8 6I0=D>]]KM2ID=VYI8[FK=J2]_HGR&MB#MGOP_C
MZ+]9NYR[PU6NY#Y%\FW_W L.XN0B/M+O-7$09Y]S'V7E54C];T@UXL<@N0)R
MD E."27'DZ4(W9[P=EA/<VVDCT\T?M[K: U7,YY@9]7V8'ARJI[A:7OU\\92
M(.3*0)C$][DA0V4_4M/M*[=?/@<K;2[<++4A(HR=DAYG9&@:1?8:3&=H=3BE
M9\PH8!7>;Q(K+6S^P(J=KWM=D9]1O*;Q^H6#O5V#06;VI'<U&[J\PK9J+1 ?
MBE'K1M"E#B/E+8<(DVIP-I0"3: =--?Q$R@/A;WH+AH'LI;H54FFSLVJ@N'G
MOYJ$-OY5'?<MY*W'7^LF:KY0Q?A2EVNSI?:$(JU+^2ASM8-:'6#9-]6'2Z/L
MO4AY/7=7&O).'\890FE/O^8F:SN5VG7I3D0.1>)'1NL][B*CPY1C0>'F<BRI
M)-/ FTQ/*,4$SLG,IO3MOP',M:]'UT,)@B[6^S?8-PAY)4QV=%B@[E9V28!2
M&/G+QM<F,IH067KG9B+B5B\6%II_<BA;I\K% 5N,,;225U>1G2'=FISQ6V@,
M=TP8>GKT<'Z^];?+EFMZ;CI^^82D!V.1BZDFA%/_XMVYHOCS!"T$?>TB>0M!
MOK+,-/XOS4=&9U&B(S4;"&>7K1 $94#_Z$/31+]X_0@N+E(3L.]G._X3<94G
M8@J/:] ?3Z.#UK@&D#3:-IYT&7ZY%?[-^=X6/S5DC6]3_*!!GI<:0N9*_0@M
M\YBK* E6_%/:=';+*/H ,BQ?< 1E=OMVO\' IQZZ[D^UIW^6L3[QPKK+-&\T
M.[G<;>G/JJDA(2BRBB-RGA ?_N;WZ$[5XUAHA=O6',^?[ _O4Q.=IDNRTOCB
M4T=%#% U5PCJT,FE#HLX*Q'".H_^1@$CG+Z+L/DC$4;Z/UQWDD-$SZU >9)P
MWELS+'0.(Q#[2<0%+[1"-G20]T6PZD'0#V3^KX1]X&1""M# T2>"0VO[A*#/
M>'H?3WJ!S+N5%N FB!&I\F'FQQY"5&=!I(@-A$@!ETDB;GVI/A["LGHC!+$3
MS?#P[UPG(6A7]H]]B?ZIV3\U^Q]JEF8LPES@_9VL)$81+L[4I!(C:7IOOOLU
MXE6Y?ISAI0JIL=Y]/QT*;MFL3%:'D6&4& Z.VPZNU__^';Q&[EXS+'3$U16M
M]0$$P1 Y'RSJ["W'T3/RY+=&_)RJEBK^98./F^^:!#:IQX2@ZHZ;0E"IH>3$
MEL#J/(X?SR!O;*3U^W\?_/C_)E#_OSW+-OB/PNL,M C''  N<$/G!:!^<_T
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MTXK%^[5#X4_[EF0H%1;:+T)*[3J_G _0KJY8@;Z?T.#GY<X"01%15A$4<WU
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M3Q&7*FOO5AE,%'6O-)M#(W)&9YL3K754EUA1]* 6R%&4'_]%\T\ A:X?BZ&
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M(D/'*4!VN81K/'Z *:;5:[KJA"'B+IQ\5])Q#CH5^#Z1FD?;ASK&SN5 V:(
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M5-6?6*II.,"W56# #J\5844I($T@;7=$,XDRI<#V #3;!.!:=F\V'<BC+KQ
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MSA!S]'0%YELR?)PKZ)%B;@G*@PZ-?F9E\S*/BHB<=UZ3$.18JEII\6.0HDI
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MMW^/TPP#\6^);GLG0O)W>.+\/)Z9]_U /IZ! 4Y:+<N^ 6+ZW_ %59&!W*N
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M*,-+\('&\2?O)6\>&-2A,M:^:R/C!9V*\8+B(;,#_VNO]1_^KS1R3.(W,%]
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M(-XVYLAA\ !]?]+\ZR^8/M1?T+.H1Z9<,&<A +^<"^:;180[UU$\HP\NA5<
MJ-Y(-DIPO@AY8_$&F2U52^'-UP)E,@L9O_I4N]103*."CCEZ^,P<'77A97^D
MWZL^02I@>6K/(AD#BT+ TV7?)!AYW8EBVHN/7133EB)[]N(2EOBUE9%0 %OB
MY=FM+4Y&!M<A]8$*"E>?MO(4715.W.,'4@>'.EL6F]X =[O@)L8FHSIQ5L^F
MJ2 N._+Z]A19H:L1)1(X+$/LB+F53C-$X*&4I7YC?J<(_5Y[_AXT-P+;;:_/
M&IF@ZJ\%DAW3@1DUTUI*A; P7>I3K-UG(-+;.UC"B-MQT>C)B77H>2;(!3.;
M2U1(U!)? ;,#2KUAL0WD78XYW]A+]#^ (4K3RIDH<M:2V83;F.]5X Y1(0EU
MD>Y+-(T>&RHTDO^K@KRN2WX?U[UO4'AG=>,"]?&)3TCKX[\[3B#=*%5-/4N\
M +2'P-7+$7%&@1W?"XZ&\G;((T\ ^64(/8XRWYTV, [Y!\"]@HN[HD0!1\.#
M.!(:.$PYO(_6BE[9>UT>B/!UX9U0KCR11-ZB"AYG1%[&][)'BM!%QY!2?A3<
M>PU4-R1)-2RRCM3?#CPEWK[E*^384R#>WDHY/;Q81)*IP,47W&R9UO*]MK42
M$;9N'YX2T&.?/&W_..LO4<NE6O1[#G3LTB\=%X?)1_Q "$T9@2;Z)D6>100P
M+H/YHLFJ\9$<]DF06/MDC33@J4I^4)O"XPJ>8(;$9%#K;0OAAE:X\4 8:#WR
M*J,75=?4@Q?9@EX^0', _5T=MRG&!?E8Q$POBHTUW/!CS $Z/ECH#T[O$EOZ
MG\T +X6;. 9DPDKMZC[#IAE:T$NZ[@_V7!Z_M6M]ORP<@JJ5V)X-(N.),YVV
M'9<04'W BIS;7W :P) /WS,$&./DU 0B_@K]%L4)GZHE2K+]C=S.>*ZR0\TG
M;=DVT":G)#H:*&=>>6;W!!_5M+0:_<7U!Y! CB*.]H8OQ1[%]7!Q]I.$1Z-1
ME^HQ2= +:Q%&=A/H..VKC^SU6@MASK^E**?H==TVV%'&<7L'1YE,\]\?6^7O
M\T[1\(Z7<V\"?2__YV#&_^E@QO1_([R6F&3\0C\_W2"\XVH'*) QUE,-1D/Y
M.A93*I X9R[\9) P;:" M'MT=+2EE[.VN[\9>JU@;8UD=[W ,_1:<+!']8L5
M1;_$9#_;%WU2>HHI8>6*1G^D61A<RTPS''(/L+*O-9!N,#<<D$ZK-7++_J/U
M-S1=*7N;Q>9_@)='&4(L5PJUGXB9>8O_+IC(!'4E+M%K;K>C?AS_/&UX#T+,
MPWOBCGYE_8\BSP!BK-ZRC AGJ<P[+W!TR:J?5\CG9G[&T$.1W:(8@D/4,";H
M-1?9DPGB1#V#_-#5_Z?<?\K]I]S_Q^4VN))/+FMG1[B7;6!.,2YM$+)R0^ H
MK!<?A),N#(MP07DJA]P*:;0)/I(-("P0''5%J#,W#$0^&8OX]VQ^K2RW_>B6
MGOP6\5+/H,\L,ZS*0,4C)P!6FI_C->S[)&A+>:+"JC0'-IF9$Z9,SUG"6T![
M6'XFXS)BQE)C/;F#CZY!\:F?)L\VOB6A3B$\G:<X2]X&^'H%<=K\V=IZBRSH
M?N.]QS[I9K.N<$YI@02WH5;&6]X-O<-5K'6Q6$AKO4?F4GC8TAV]*EMY6\LR
MWG""4II-Q.-Z_'>J^A[@J3"[Q8B'=&+H*HRS3- J+_3_T 61BW@ZHX()BKH&
M)H] ZV:.+Z*B(( W_1++%$EKMZ<P0:\^VC!XK%DYG^YLL=S!33QP\PX3='Z5
M=ALUQ@8HL3P=?">8_KIHZ_/2T?E>%%'7EV%[Y9]2_RGU7RE5OP#!OS*SG4D<
M31;";5>15WJAY]M4*!#3V B4!>!+Y-0T_B0W\OIA4R+CL^CUP8F[;11X>TI[
M<4M!$F?/XJ^-$U4K6;M3O]:E?UALY+I9(*0>^UO!;XA0[7LSY:NJ/NA%'Z]<
M^)N!$C8)M[G,% D=7FDC;G-><0-:>7%N5BZVNEPU3'6W\;L7-7M*95VD\U]X
M !D#(5N;_M!3V#EF>:UQ%!H39-44[_T58<0P3+W"!+T=<6*"RBS1-K^QX&B$
MI7I< .CQ;>XM\%/(_A_:G$S0K#00RD*>5+2SMM+Q-W[6%U28H._;(^?U:;VH
MHY_*RLBS?$8Q_O^F'5?@E&R& 5NO+^WZHCH3-.EJ69TL09L69G1),D$;'W(^
M,6Z#CV@L4C/2[X.2[V%^Z.YMLVKWJ"![,T'WAV^V5\NS<(R%=-M^+U";QCJ?
M1E%? G)0GW_N4YG>.^;#Y6N]^B^.M\@BMFX,<&N=<;^9)L@$+;!4Z)8-,A!7
M3^%B&)U?8FPP04<5[S%W>B'[VOVH>1RCD#@Z[P74K8\R9_[[4.?_!TDJK+ I
MUB$IP?796;%0;(&G;6&L0$9;VI!8YKV5%)[6UMIRZ:R'H.O1N-=3[9>=?F?
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MA<J8O<&O+GCY$O.KQ'T>#<JIC1A95)Q =ZTI\XEQ6!1POAM0@4VD+2JE+)3
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MR>_1P.U0FI:SUZ+8N%PE\6]6]5V\J@EZA>6;622%[172O>+6EWI5O]PT.5?
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MT8?>*/GB>NU2Q2H-DBZX@9,(66XC&"9Y<4^>*"P.?> ^Z>XZX!97[$LC%H_
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M-Y,AQ\!ZQ0_%QS9_SPGQ-GSJNQKAJ/(.':]B'['3NNG*_0G-8&$>2?E3$;F
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M$C>@=HI.3(HLV$-A"+Y%MLB;0]E-XZ9I4L%R*'61*S#$5>79T:E,!<UH;27
M=4X*TD!BSO!2IV,%EJEP8E0G*L>$,QBEPGU+,W96/O;RXD$5PU/*2^,$S]?#
MC_7V8J@>@JEG>(VG]1,AUG5&G>?BKDZ?,?2S=? ;<,\+V>E2Z$GT*=EYF;A4
M-U4'4RP/>.KHYK-4;Q?S'/Q3J@H?3K6V*+#71I:Y\.,SDH%#.-BT^8V;=H3G
MMZ[%FMY/..4:DQ9R;0?C#KYVUB$>78MX\_8UZ_SY=[WF!H,!F8$0_U'2+L\&
M5^:YPA9?7WB+AROLF*]'7I%KS;U,V&6"A5MUH)X65_<BJ7[#-;J\,WKH1./(
M4"R4*[/Z'=^,&[_JPGX#?J,T!W\.WRU2!;[$\O!4^QU\:"]K#U!++[]S"_<C
M2B'U5!%B8F/H,M<I,][T,43K,F</N;97@%;PGW&(J3GO(/?VK>XXZ=7@KINT
MN<_,PH'$U\N_OU1^XATSSO BN!W?G#7%' K9K>M'4 MAZUV_X_JB[6&E5[?O
M:7D7A8RBYYRCQTF8Y%H/E46UNAO7UR>\PIP)D6.Y*24;'\CV;!YI59V'H[,4
MDQ'IUO#;$)/+_3UJ-XAZ03UDGEG^:I>"7LZ56#WXY,::_&N18]'?I:#,V!M<
M>;VS$XT;:1&]&H@\B()2Y/6T@:%'44WT@H/(R02U>B22L^AVY(''^*WD1YVS
MPUO]Q0FSN$DE&#CTJ=2ZF2_J1K8G#RZ.R >8XX,8CDHM>6D$"W='C\0\K%%]
M_1YGABOU:-&H5>#< 7$G].)Y;#3+-;W?^GVYUF).*"^VC $&?* JJG.0K;7,
M%!+.$VGO;Q+??]/KPG,3^N+H)E+0SO43/E5VI<[)\T5.KLS;=LUQGR_UGGPQ
MAK&N61Z4WZBTF YS/<VT+GPN1!#[#'%KFE<4SWW%/6LD2T882>TK7&3OT)A@
M M5TO^1ME2;3>MG07OS.*.GC%:+. ^"N,$@D!YSGK/H^1_T\)0HC BVT\F#<
M8V2_$Q#%*^*P^M13OWL8/3IB?Z]!Y(1C.]T4A47QOKA26LF=E-9G?&Q?SN[-
MV-;-XKBIO7;41<P __=R=^+.L4S#PF(#^-[;5'9:%S=<GSUUF*P7[![K4&\8
M"X.9S5X]6"JW-T"VVDMG5[L:C!AMGH8/@#C[-+A.1K66UU1_&KM.'N+V@,6M
MHI_Y-MR4Y^<1&?96O)3;6],_+@>\BQ(]H@I@^M&_]I SR6LSPCZ<3)=^W#H6
M[55QEMS.F\+JY8H"(*X.ZT*BA<^=69K[>/*9IILUSS[6%7O3+O!)*HYDX^3=
M/N<=L9HUWXY.)'K'6B<N%#T2EYCZ?7%TCW,O?#9?<*9)B8"A6[^J/&K>P/Y9
M(P7^CDYM+8Q"S*;>;6X-F+1\)NS\"N6Y4V84J=.P27)\=K#!JRXSCHO8S(7G
M>T=TFA?&C;O)XW).X(G+FZB<:G_1$6!K<;5IYL'I=1N:JVZ3*^//F9^Z%Y>H
M'_T*K%TS5^>[C-/-BXK#3F%AQ5P#GP=PU8PJ'06U4YY%=#8[:(KVJ,\$&J^!
MVGA0_?XN= 8Y];[$TNJDA<=>$J8$YNQTK[,5[SU1^VNCN-I R(S2"QNPC1$F
MO8UDM4:LAO""77"*P \TQ(^4\" SSIUTO@Z#T@+M'_+LG57D=RF)KJ+W 32&
MO4XK;[;B/K*=W5-!0,K1?"7["TY/&9N(TF[4 F6T61F^:<?CG)76GGK_8U4_
M&/<%8*__WC6 C&(O7;14FVIP?&T6#L-:6+F5'O0@>4#V<][];<F+"#N26"S(
M0@QE]DX'EN@B5 T]"+M]U-T2Q/V'?I:Q1WK'51=WX,TN5H9;.II8B;\C2EXC
M9%#J)]D%<D@IJ._Z8I[DH$+6K!K_:]X%X"3O/%>&[EF-O.';="#U%/\/^STD
MO)]92V7MB)EN"R!.Y2=R!QMV'B2W=OZVK)I?&^Q6:?ZY,5AWHNY4L?ZK30;,
MO,I(/>/!D.4@H+P<:GCNSL%6Y?LUC^IL7MA[O[P[M%_^^N.DK3&])/3W2"<&
MY]N\@+*IWH:>^5']#F87"0WPDB"#>.2(X)_BBM1=-2*3R0U<SI1U?EF__,&U
M , \5?TA$L_1ZF?8N-C$'N,313^$S=DIT%-Z#*=,B9!<N7RSDZ.KGS:Z@_6P
MZT/VZ_[!XBK]>:O,J-"PW;9XX_W<W0@RUEIN]_N%HL<?W8JC&#!%C\K*$-6X
MF,MGRI'&WD[^CD5P!5T-T>=,:!@J-MJZ\':>9^Y"T=6@V.2A61$86.4-<MON
MD981>Y*)L$_HG1_'D.?[@C7XT Q1$.]K/TJ6K^C/7';_,'L<2./_<(K7GR\R
M0%^K9BUM#E?\2+D?M>@UFBPGCW"S"$B>[Z8_#>7Y52H_V'_F8(G?#9BW@3<A
M^T$ ]FW@!XZ^&T'VB4?> SVWI/G*<'7] =/#R4T;"9\,&ST\"\SU=E$)5GV"
M.&Q $M:J>FT?VRK /6JF5FUS(^EW\!T6SQG\;3]TCD@1E.&8\*W &;[R%>'/
M@/:R$4+=!/!F68%=UR+@;R;.:=H*?]#**/J6ZC_PWV$;X/_]8>B_N(W6OQ#E
M?>/S*0C^0EU]JB/@SA\1F':*ZWK4@5SO&%)Z0!F-J,"6/&&3>0(\^YFK-?<D
MT %F@+67?&?E^%5E'(/DWZ4@MCFO#7>C^AUPWK.INXD\OA%DYM[Z]&M"(G[G
M*\:%EN32T*C^,E6-+W1'?)UZ6VWF)GE7'UE]_!RJK\'#^^!XW+%<.V/;J$?C
M1$R_L59D@V^^_T1>)=ZHSEW@];[^9-_0.,YHT<VDE</E?:6/O$X75 .#<V8S
M16S')^'L>R)GH2R@\)RBW&IVFZ+TOIF?E2\\+4*-L> ]8ST_(():6Y"=W#G'
MBNH/'VM27?D7VV.K/\X>X,=2:.(XFMM4!76S>EJ[3]-R,*'DR_ZS00YP:R)"
MWO:$QGKM;\^'E_TF.M)N]PUX)M$\TBL-QI*77M"8M+*>4JC,J1K3KL"QEX9>
M#S^,=>EFT;JU?S8Y\&0/O+PX#-FWIU$S>-123.)(0;?!:I"/+ODV7-(*E /-
MQ<G8'P:<GC.G,T4[V$&:;%R^*(SWA6%Q7><T7X[-Z@^2ZP?_M"X%[4*XX#^R
MEJI4^6LW/T'D]WW]I:>4NDR=DH)<SHL1_R1@J"?K+K1DAR0BH\ELCV[_T,@Q
MNJ>GF)&J_"%DT<<P88P@.YK'M9S]=*P5&0++2%NQMS<W&JWS.%YGY9UAV.OR
MU3OA,\%YQ&_).EGY5VQYG" +0X/?!"NE*@A!P,>Y*F+8(<F)R1XM$:J%%_';
M0?X!_C% R0&X>8,[Y,LNZ,T%JRX[LH1)"AA[S>DN.YYDVO?9TQ-G(CDV-GVC
M]YM+2U+C--JN.:FK!^3%S&&C/^%:!%_P&D?IG'E'"T'\7@\EDK[NE<64:VV&
M3\N]CQLB,\9N-60E&R8E?>F,+F\(ZKWL/U$<[D[0[(D-G4\&0WAK# 33;&LA
M+<!L"9,1#+H9T<?"H)47 0A;"LK2X\CTGX=G!8,!Y[G<#5XICFT2P^@DL#)[
M#B/'Z<&Z!;0WC\GY9C1K**8:QSCFSZCIEMR5?UG&B_64_XU04'>'=&^.KQ:>
M6Y<M4(,VCJ@$V$]YA[@9UFCG6Z/&!A3KK'&=% OC%;P)P4D>KF+L>C9.FZ ;
M[)U6I3Z)C7J<8MEK,$90^Q*E:@5-^CI_=?XPSXQ*4D-1I2!%6Z=&P(FM2B]@
M*K!]\^SE)$,L65L;,RH@4K_&UWRNBFB9O@4!8]HVM8GL$36 U'M580[]T])!
M&F-?0"F&]!8+9?A*#K5-7/$[T-$\::J5ZKI_(=-RDG'N.:<N[/AN5WBC,/Q4
M9_]4?HKE!![6VDVV"J[\PWRXO(8+O>I>6!>@GJG?E[P4TG"JYW!K=[LUP?,C
MQ Z?6/RS1_"8R5.RKO+<PXG'E>%LQ$^4"(6<J_:@:7L=*-7LS@EPJP4=S81S
MG5:_XWD&B"M%<!X_U5UHB,1P9&Z)].:Z?SC%GY 8\^USV&9*P&F.;D$&D4RY
M$W!((SZ_2Q>:O3%T?=<E2'I$#5"%&E#/TIK.T@IMBO_NM!GU0N+=_G'Z#=MA
MK.QDC!=6!5:\/-9PRINP6_GMHRDOM@+*HD0_'J[D/)%O%HM!1OL%VH-_>G*D
M;C WWV#X<HG]+P.)=:Y#_0JFD?#"HU%]G_:^XCNMS///4]%J7?[\9UQP%C2:
ME+/9WJ^0A6AYKVT8_QHO^(W?3MO!BV? ,<'?Q>_:$CLT)NGF.BN7M;-U"/Y<
ME=D\R!G9@:RW>1?A3N[FR^2T8EU<QT/V691]@8.S&C((Z52OP8317D[B,$[0
M\^,='2;[B4HW4?;N8][36HWE$X0 [ .Y4UM*4LB_E74X[T-?YBZV@6-FH,NM
M?C;;>S@?5KD^KU'5U^+MT6IX\A'IJJ+']4>26ZC^K5$>!CCQRI>'$3\@*]BS
M9"YN/[*=XY23:L6%Y_48 WP.OQ$H_ZSOZ<GWI8-56<ME*?:')LW3CCMW3:]C
MS=PGKFB!_4H%XZX3&^=T)TU%MN/*?+]B,=F:AW<LU2Z!^<'\# .+)[]%O:I^
M6&+IYIFGI]]7S1XT<%1];[L2&Q\;8.*5Z3=.<"L.=\LXPFM5869:.AHXP#S<
MBV > :V/\>#L+AN\WE8_+L"UZ;+HK-<ZG/:^)WP;07$K@.%)01S?+'M5D2Q_
M./<14AOQ&^M[D;I"&1&@<.QS.#&'QT7><RQEVHF2E.KSN:=5W\3^;?"1*BFT
M6M)R:R ,,\Q[#6V8_TR;IDW0PR('(*4VFN?]QFC#10N$@ H/-]]N;(?;$C0V
MJ_>&<5^^0ECFE65W;."90_5I87L]WC;5_G--G5%G8#,[_+:]]#&%9\8IRY:"
MHN+S@K4!BZU)E?4]:E]J+(_$R%<5W)VRA=<#9N< /8XXAL&2@6=(M$0AP-YJ
M/V2M/S\EJ\?L-;(DU2J6^POQRMJ/'P+:"O QJAH;-7C2Z8?+XPS;.(TJ1$9=
M;EUZ7VA"<D++\U.51DZJ,*RQ+YD><K3ER@/'FGWG%DLT!UK95@S/0HSM07QP
MWI%6W> K1U4>N>4U#<@^I'OF&75,XK.+,J(&"HS*6J8:\08.#H\,SFQ ,UA[
M>VP 33:)!IWI61.8\O.G\T0*;*A,ZHG)5%CG5E>M,)M!I>E1VZQ3,&NV_@3D
M*/G-B-H+MI"HW2^\[,)[2=DU3:]*?8*\OD"=Y1C$^^)4,+T^I.R7^V*=W4D^
M;0?-.XXJOBRN'_#TJG6:<;S]J.:;KN?'X&%6EVO-W9)HO^LET9Q2^_),Y^%Z
MC(EO;M>;PG3,00R$980CSR,48XU@!3=9',I*+I?$!#L5":X#.#Z71MF/L@?:
MN:1;]@=2->V_[^[VY(J/TZ;:>^2 AJBM7@P<^WJJAP?Y=+M<%4->M1&B';J!
M-!G,P8(5ZSL%Z!I/XL:EL3L_HH-I%^HO-)DW>4>&BKM"Q1GUSMXT6+[L<G1S
M!?87EYDA7T%%7^+O"X^X46S"1KWEM1 >CS9<DN*.EA^J&TVH-9\\\XVPK\C;
M"LLLAF>*+(2*DC$IZ">)U@>)##^"9@)F[^G86H&SH#QO$X7@C)B $QUS\+\!
M!8)<\8,>M:UI@.USL^'=!PM*W%27%3=(TW&RR)\R:E[S9?T1N4.O9;RVL_E)
MV4Q=Q?RZT0#1^ S_'#Z'73>>6I09O<Y31QW,.ISH>?M<G6-2@6&=B>[*RN+
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M[NDU?_*)QO4I0:<]E:3/AFI1Y@JAGRW1O>?1JV;05IRD'C?SJ:?E-CJ=2A'
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MNT*?J%BE$5(=X1[=T97_R/MYQ.?Q"<\RXY_5G,K=7N6%-CZ\NUZ"+"5>+VQ
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M9YM.=Z3B=O>\PJ,>%1GNIZ!*4U^L*YE3PA'@52U^ N#2A4 _@:O[;6LU^_&
M&!7&)+A&(1+1K4+=)).\G<M)W_W%VMMDZ*@IE86[^":#>&+1B]ZEP4*'Q=OU
M3I]PP[8UM DMABC)/A"5"K]SED-Q?(LL1P!52'X&1GF/=BRL_N81K0>MJDTP
M0FR^'CX\L\^)2'H32HK$Y7S;&8LF2PGP+139N^ZQO=GXU+L[?1ZP.WM2KG9F
M/.%6X[DP >?+LT-8Z_2C++8JN^:72_Q%RWG\!%C9[@$4:7_V%P8!.^Z!8.TJ
M2AP^ESE.V%[_AW1OUD4M,5^Q)]+.?$M-G)EQH3)@S)G_938?2JQG05?,!K6S
M'!(VOJ+.Z^Y1F#(0SO/J7K_(ZX4Z\!%M_ HSR 4:A@=0PU 'U5_ (B>-:V^L
M9BV>#(P64X@GZHL2*1VG+$AO@9!&V3^?X %.[X3+X2^F,595$=+WG_!E+0QB
MU)@VUUD1;:X_*GQM&4)_S3LFK=IR8D/1/B&K8-%;@3/W<^5..1\;D])/?7#C
M;UN\I/@<;_?CF[:0S&&Q_LV$LJ&QD]!J5+<IFALCW8MHCS%ROFAK2N:^ZGMW
MK#=8N/A<O+_!GIG$'E$);^D[)OC++RG,'AW'E[Z:MX?>!]4 .YOY, \77K<D
M*8)V[_N/@-)!.$I#F/G*V=-JW+!E^OB)KM$/U[>UI%F*#C\\1S'R')AQM.:9
M_B^ED%57$5<]]"Z*Q>#78>E4?#(ZP88S/MP[+Q, T+IYLN4B^,TEZZN0RXH.
MMB7&JF[#Z1>4&">RW<[1QK)E(S7^V=4UY"'GH3NWQPL><EI6Y8&;QU:V^_JH
M8V,T+^R0=@[MJA5EB<J,E68:/PFV+!(")"-\4^E\:E4Y:!IWK<7V#I$572MD
M;<S;;6Q(_V*^RH_]/-6]P;P_]!R<O)\<ZK^-WRR$H B3D*TM;G^%O!14\QQ9
MNXM^72[28@Z^L; ='TT[1$[=L#^@'/'L(5U.J$GKDG:LGK\EQWE?4ARP%MC1
MV"(L71;0*9N1>WN212_QB(J"Q-^G3:8DWKY(GWKPM"(4#4-A3"YS<0Q;9EE]
M>>YP4#1;38ISG85-KH6<Q^$[;Y/<!T^/@A'C+9(:R/)JC!;XO',3'M#G&76Q
MD0##3+56_X)P^]W(-FQ4.VIY']+]4=&$?GO7%+I:.,^MP]\EXH(QF)2JH#%W
MQ>E]^NJ\7[D'Z?CD2(OE#Q^M]?/N\KNEIVUK.1?2EZ%;,)S$#C&X+&HC1YOJ
M1ZN(?4<Z1;=(NZX/E[Q0>/B3:?@MR:L^P2>PV,V<.6S0C"Y&/W0J$P^XUG8-
MS=Z/HXD4N?_39E)$MI^'3S/8F6SC 2M018*\U=X%#ZCTC&S1@5%]/15+Y )-
M0L0"B21_^L"E4L>?Z,L["M54S,0B0.ZVI-M &@*N\\*7V7Z)<AVJ3T!4BSN=
MO7@^FZ;>]69_":O.S8\U,''1HYP)V'<G:;0?*T91(:+VE6$@\B7L8T\*L-DC
MI/JWN&)D[61JVY<,AS;L$,"0;YR"$CRZM!I[#KR.F^3B0([NP=Q1H4]XLQ\U
M5\9N3'=:,NA*?> !(+ZZQ2/J"&/=-_G4[DA(FA_CD_;,T:"#F3XH4XW0OAV.
MPA,)WYC9%W$ONDP\0+EKF#]C:' Z6TCV,=:[6_IYOK[579&"EZ=F)_C:LL)E
M23Y2!Z*.^X%\Z+SK?$G(5E==>?HV]] KX3+0Z;W]#] [@Y<%*L+@?,3FGJX/
MPI-();T8[8UYV "E-]]YEKLA-^G^XI,#>T D>=KKV%FD_E[Q1^P])%=>N7,>
M9^CME:WZNH<;6A"-LJOWP[V!F<2 9-7M7]-1B3@:M"M,;(\%06#98*!AFM58
M>U4%?^21SML&B6:.QN5P#PE:_8>%=UR\JLQT?;]?+E08\Y^1UJ '@=VV@.%2
M6_!SVTB1_+PJRX7^FY-F:>L'<@LS\FLHFQC,7:S;#$X8C8"?O2_M=F"JCZR=
M^EZ)X5%D_W%G!;)V(&_3=NITQCGE=M#N (K49IJ4T)(:Y?G<P!\DZ6$5%'LL
M-NLHDPG7W.>(76!MT?LH^TE(3)I)A/]Q[3<\0%S'YKEKQ3P5@KQ_-'I9&'G>
MR:Y/ZVS#ANSMGZU0TJT@3UY<O!+ HT6N&B;/]7M+:%&%>!</N%ZKRV]:A2Z&
M7<IJ3Y]@TF.I+KF>GV7%J_MLW$YKU%*B\SIA.I[!7L_KL0B-;&=4HOUJI>D
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MM1BKK5#V5M3;/.2K;LZWU('\$<]BG6_TY7OIRWW([. F>C4:=(H'Q.75\"7
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MIQF@8B11'-U;2; ?1$/OLN^M%=I;?9_Y\X+RU$ZMU8?$S<K7*J+#D7R1G5<
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MO*(Z%([RU;KJSCW'CE34I[J,'=@,[J*^YYLTHOJ+KX?VL9UB-1%1_0:MTE<
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M07:[+9E5EQ!VYNPSY2M OZS7%6#7=B+JC]>?R.$KP.]DL-H9:Y#$!:?*?8R
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MMI&/[# 4:X%ZX&0UQU?'[0E!#^L22?[<8<N??Q>*BW@+P48"KJK(<V1LHE.
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ML*BK,G%T?#799'%A^5$*:^G8H9TW@5PNL.&R:TJX&]C*B-:Z'DOY^7M=8V_
M*N6!3-&YFZ0E''*1KC4G L5L:FV^#(9= B2L#->+S:D,3.I):"?L0[X9_=$]
M$B.LY"0BJT6U'/X85Q[*FBR0>-JD$54PCRSDGS8NJ/F 'TBA0*D)1^,I8]HA
M65*JK7B/T186-WN(^PQJ)3EAK>%@RH_YT"N$P*T"J\@%*<$U,E: '9< 5D(O
M>LAF?O,,7F]@4:?6_.W?$X9?EJN@V8I$[PH:PBH&M;LEWB/.11I5S(ZR+]Y*
M7.PO<BJA:/U 3ANIS<N'#U'<B.[,*MAOR*]P2V.8L>"=DZZ(XWE$V#\7VUJ4
M)]@5;;V#)1F@&/_L&#X*X2XW]*%1S"0S55%E.:0G,IE 8Q.(2A-VN*FB\+F5
M,3Q7.]K+6@M#H%'?\'>Y03\8UW:,O7)& (L3N8GW:VG[[R\!;7%VR YA]^7:
MBTP?I5N.\4J#4,:%'A&19<E*K7<2^[]5WD',S#.%.H6?SFR;=N:G>DW"1?'U
MIM-(UQQ6N%1*9X]TD'A7Y;:$U5=@34NX5O@T= _SI.]'*3AFJ28GMKQ-,N<#
MDI((?E-.J)H>M7$Y2RF1L%"1E>UXZ=:2VG6O@W06C!TD@BX!G]*(ZE=V3A9X
MP0DURR'SR0"3DY9RN*3U;_]."2ALI2C;2Q4=NRGVQMBR].W%+OD<R;^^0+,Z
MVMVD]6M6RY%@,M0]O#4"RX^W6T9U0ZEAD-7PB*^#N83TM5>SL#Q5WU=?&_C<
MS R:Z! -&YD<,Q?Y8 @]$Y&%@+UB_!M.V6P@H1BK"<=$8>H7B F919W.W"8A
M=T"ER@U]EU7P<KYY<DY<*8D-KCA6;M>*1Q1C2ORQ6-$_TC]ZOVV/9P8MOK5N
MK0HTZ>MI_Z=-V2%^3N8"/KL?\*V3<3TSKRDE.U1;2;8Y;?'NE997@%_#0\,J
M2(\(@5TYN%!8S L]A8W1OPY)SQ(.-# ($D!TCQS@J7#^O$WN$A!2>,6*-*=Y
MF9[*ZDZ:]8/\00F6M8WVSYETAI>@PG<&YHO#F TLP]_\'QX'IUPKPH;Y>7R'
M.\WP!NG93XJEZWK7_F'.#U9E=WW[.J^B@JR%;EU,'*X@_=W]1G'>8@/L*U)A
M*NK0+@%%/.2/7O,F"F/;"0] &;E.U@JUK3_&^B>+P@3;LRR%4AW^E'\/Z \;
MX8Z0.6!-+<MHE>M._//UU0YK"*O>=T;AS_DTUX04^NT[N"6["H)D;EEGFFO"
M@4T?\":QZ/ RNOJW[M+)37/%)0/A:IQ.OY<5F2;FO<LO 1V*?U,+MV6_^OB[
MBXADV+=6?9UKJJ[YHE/Q_IWO*G"A'/@"+YV"8,&%E_!F:.WY:BNIK;_0X9^]
M^RX@[.5ZX.N74.!F61&AW=648:G7[@-E\"L*JI_^S2J>B-=*;^-KRQI3A7DV
MRB !@1"00&-C]' A7E@ZW#X1.J^U0I[[(L#]Q1]K0@\$YKY6%I\#";J9")5Y
MV_"J@,KX%GN5K$1M=3SQM:G$"O<3 QN9ZQ+*)O4/.O[:'[J3#;V-? 1M^1#>
MY_%1&&K2,%Y*FD52U0[-K3?F]&<.S$AJ>:V+O(;'L2E0YE@+9YT(_L(2@2MS
M_LKJ_-/E#LF%'ZW,]C)@O%[?\^C6U?QVHH_U>2S^0)9H:A_4LN,=KT5O._3.
M]W$%YT!60QYC)]Q@$5T7YF=:?Z=LQ[GFM;:JGP=^X7O-T/;6[J?@.\.VQAX?
MDX"-2(0@)&G39 8\>\+A&L?LZPFRU;83<N?N "JX_:$>?3W-&/.WW99C\BSF
MQ&7F+YZR*^95BC888R.,MJCL$(=V\=($[;'#_^RDXT?0>;T<<E'*;GDV,%!@
MD$VW(B<GM]K\#0&GI]DN?=3T+2MC31[H$J(NCC8\;#D#Q02#F$VVR'PG('YB
MPWLJ:;[WF&A8(PRU131YQUN!)T:XO8@" N7SMNB?"X20(5U[@5R/FN&X]7H
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MB[6]&?6S".@ 1X [;[;SZ>BV<-XBNK/)/2W7ZJ&#TK3\VN/GDK,BQ.7E5<[
MOZW@Y?V?M80=C+#-S1&^$PZX>WDJOI,_T3[91 /.$&:)>/7]TZ>@C1_[D[T$
M8=QT%Z;WA[*"LY^_,U=UCKAA[?O(<G=.E,&G.^PJ=-H5HZCP2P!.'QF^2%.I
M/LT(9;*Y-V Y_)F,IUN()V]&9HG(=/&9*(4S"^LIJ2O^E@]A]C/J+E[_]J)=
M*#X"0#-3:1H1V:/C/KF0T*\8UTJ?W:)^?I/(/U,H59CD53#_(\E[6H[3;/:W
MV>>/?L"*XG(CTAU3C&9GJ\^Q31B2\2\'8N82$.UH;7CR>^@+^5_:OKOO ^A6
MH\\ZH_^^W!;E;"_/]_KU#TSBF,"P=0YNEB+$X,+-$Z]377K*-J6H,^1<E\/!
M77W#ULEVYT8$?=/ZM-W[S0V)=PL^?K%F)RM26+NM^3QY!QV> RDQ&W8.A')/
ME0X8:CD\_O7S^#K'OVI,4:<,P7=BVYJK3F*+37M=VB,VXTFOZ0([0*4RNJ')
MASO3M;?1?O0HBVUU.@WYC3KP&VCXCORAP>GUHY$K?=ZJIL#J-#46FD<3SGVS
M(M8[T._5:0<=UZJM^/, TRG2M=K&:EQ\%LL?^\^:66639)Z4Z]'1/PRFJ'3Z
MGJ@SFRK\/W;ZI8_>\QGU";%CZMF4Q8%QMH9LQ\V$KRD.H)]D+E,O9HXL;!@W
MS>,3X.&ZHFIH7>VIY[?BU85^\LPSZ4&_ 7GA\I> D!RX/"$";S[3,5BPG6Y5
M=CPR*U(;4Y9M7,54*_= X44?($C#P^:MZ<9IYQ*!7R4U&"3Y"I9A@'\WI:Q0
ML"B*S0JQ^)2MH;' \6OV)^"]IU2F[S#B_8SUPQ>&UAV;$*-$TK)I]Q+.0)2U
MKQL!NLBI:36<5L(J[G=[=JG4=#V\+Y=X1[^2Y608[G@.1_8;7V1> G8=D1NT
M[/JKXCEK/?H8)6BD#4X_)W119'3/=I0H!PSU&96;W>&03E3G;\G;DY5[_=XC
M6VK_%?+'):"W@@EB38^O#VWQ]Q HPB !UMK.,CORSF*Y+WJT3SFU^K<EDM+/
MRD].EO2JT[>WG;!EN4_XJG4Z7C)?:=5-0$4XV/:SN[+/JCA:'&-?8TC+U"TW
M8?&GT;!$=DDB1OS;O_?#SK=TRNZ<:P::+_EK-ZK/GR6=( DKA:31''K3GG23
M++\"\XS^7=)(@'%_DP!:?T"KX[L-/=+)31 CV OF@2M5C^^[^=#?_(=T;LDL
M2@(=HCZ29ZOT^(.)3"!UZ&QI]\U#WAD?P,Z"?D;Z!MA^EM%FKN0D_L'V<M!G
MQB+E" 7F @VJEZ8'V-,O'J:I"6,N2-R+=EHD!)(-'"4",?0,L*[G4_83O*.N
MO&8"6;QW G,^955NQ/L+UOIF"UV48HGB*S8W%E  0H4Q'APMJC=<$;;K&K.@
M1DG##VWZ#&HY-TU&_$0 )S(P-GT+KK/=/F\P?C5L84C8O7\9KU7"]R"3[4[T
MZ">FA,#52P -41$G%VZ'-T6U/&$:H3'U SK6U@5[TB2VW=JFYUE<E5-\=Y+]
MFZ&UA=A^KZ'<W3AV/Z*]SJ>P'2^H@Q.,4[Z%$0\GW9L:K4M/7WNL[JL*%OJQ
M"5/1D.KQ+\+VK-(*KEP"L'=PE-T!V-&J<>G!N9B,M(&4/]$M. 7!N<6&_[J1
MBXOW@=_7@QDMNFYKH$_/F$' PV>5=4:PA*5OO1*H@*.<.<DNO2FPB_CL[QG3
M\,75YTG&GW19_MP06+O-SJ,8;*&6R6LH:2%]<F3_H(!O)JU6CL@LK#-Z3"NT
MTP.D;;&Y"M7VA(B)M>!DF9I%55)W;.- \?+9\E'I)8#P8'U2;HD><6=^[E>U
MQ3"FY YO MW+3Q]5*4=#K>/. \RW)A#]R-MA9VHF2OR!2"FN9WQ6&5Y+H.SC
M0QOL-?ZCG,JEW4UT@AW<1T5X:%Y;Y8;BN6WAAS</U?)9:NN7;^ML:YW'8/IZ
M*FB)3#B5I6BX$<SU:-#SF^P]?X&$MEVGO!3; "I<&M)];.7/T85I+_(6T7EY
MA'))E\N#$&-8]^1Z8-_ N%#B +T+YA*PG-=GWH"G_'DN*EIJ]!O/\"A+UZ-6
M[JY@ZM]OVU^F9WKHPY UEX">"L .XO;TL7[XAN[4%]E#:=93-?4[E)Y,F0SQ
M=,)"WL7?-(QV-OXQL??VMQ7-^)I^=#%Y9X4>J)[3YQAD_N99'BO)#E2[66Z#
MJ>_&"B]?D0H4KE_:Y>_E[/J2HBW'?6)$N++SZ]=C/A*+Q3(J^%@\O/WFE5ER
MLSU3T34:=^6MR=[CGN.S9_^U\!M4BSK7('I/(!USPE-!0NV5&2]S?L>/#^J_
M?S_#1J>EWK^IHN?1JSRE8%?>[I]<6Z7L9W31*J;,4X?.B0/1P98Z>9@;TN7#
M&Y&NA?+U1XXO8&<TZ2?ML6"N&N@'X$UWTKUYBWF(HO*C'D5-6U-X_SU.G92[
M=C2T\(3SEQ";&L'H=H<<%I=LH3$BYTH%];!3DN56I;[H\$'O4(%:&UDXY1TB
MY OA$L [? FX/ESI9[OK;07FNS!LOHCE6\8V5U<WU@OY'BL.!Y*H&+[VV?F4
MPFQ63J.)SBMN(+ZD%_@;J:Z@/G>=D%_<;7BU=UJK=P^M+@'Q8*=![B<G,)M(
M$,WH<0[[*Y?I\A\]>1J@,;=&]CM\AJI6'[SF335Q^ZH3-16S]4\G2DN_U%2"
M[J!D<5^,_V&#W57Z^2X@&Y> /[0ZB![0W3"O*N%66_F9<H#1>V&0^7,Q U3G
M^)*G&Z>5:+PNZ=;&N28L>W]E)$)9M)@@UVO]X-RAQ(.3T*2_--M9.OMOW7?A
MP_Y6^AGY3Y  P;\8,<T#&JNIH*R-0(E(_W&8;%'K=FN*B@:\=U^.K9"_,W=4
M3DVZ!>G;S2@BG_*!C&H6_19J[T#]TXKH19Y?,[\$;'I,UWZR-RE++D,.LPA[
M:1V!HY9J>W(^(.Y;$J@[K6EG$+R$NM_SEDMFFT[-(I]6H>F[[V[]6EVL)-&2
MT/KX& P7B:&.8(%9$-CN159OUYL6WX[1"\H/?K30Z!5+)]Q#I,?S6A/LS\W@
M7M/*PLMZ$(Q-!!2Z$G+F1L4OQ^H7HOP/9G=8=-TQUL.Z^ER(*(,OF^FEC[P$
ML"L[YP)O#F(*PM%]JLE=^LP,"1$9W%S+[X*V[76RY)7*H]$[?FMT$M%_]A"/
M$)-HS2[@'3."L!;NI'IUA,NRZR1GEYOL]D$7W:U#?KLPU;[I7(+*N8FS#9.R
MC]^R%;3+?.8]W.,ZT-F*S3I2>%X]-C7JT\>?R'OI_Y KI3:LQT#T^>H\"="$
MJZVKY-XUL$)V:B1I80"4*96NRN+D"JL% 7'UNX?X]MZE&K:N_4B$TG0+\+HU
MJS-+JEJ\=PJ&[?R7'UU0U3N%XZ_&SJJ>_27HT[;ZVA.F6,-J)7 DN%X\%,0%
MU\*#0V2XA4T:9FH^WPO4M9!/,?,QL^^]%WSM]S*=MBO@6G$;$V+6W!%%$D1%
MM/'B?-MQASU&/]U=2X\)R>KCKS,?<G,Z_::WGMI 4AT%<C\A4:GC#;?_CG/&
M9(B2+>HZYS\V9[7C2"RJO)MP)+V/WKZ..FFZ2'?_Z-9 FDYDNKO]HNIMT(,3
MXPQC;$G</J*NX9\=PL(;-%@A0]C';SPFD*]8N-F8AQR^:&IKM!!5TIE8/12#
MNG,F<-"E]7E9VG27B9\D-. +<P6#CT?(S0EOHB\2N4W&_1H-:MP7C9<S-XI<
M3:"]-K,SO3G<( :"B@R2<>M,O =,NQ#W?.GEQ!OHCXR/6N3._T*P<R/?MN*%
M4YB7"]@4A*5D6'Q\O<%4EP"G86B?M71$5_9]PDM,.YF>#TT2VMKE1XF%SNVW
MQ3Y@X=7*4OI(9+U@*((3KH,7#*Z]"F7C3$W#?Z%\D&(FHUW Z_KHKL*\5*(%
M  !A6M''BN/)NY;8I'/"@!QP<4@!(>)EV-IX[06/WDE ^%"B["7@UM9$KG)P
MC^<E@-;[0O*01&6&%X+\$2UHK<<=B;^= %AQ?>YB/UQR5E%R:%+YQ)R_P<W8
MA@H*3!THWXN_!*RT8\L*83D8G]2N*_S"Q&T(;A@K=3_GT9TQ"MWJ698(/,._
M;.%&POJY)@&Y[)T.RO*R^T:(Z>&8S+9.75G@ ,KN[89<N^M-)34Y$W()Z-#D
MU3JV"3[E@,7"DN$6C.BJ2T#9P:_!5:[5=_I]+ /PYS:1 1%$9H=U9290,+1B
M#F8N90M_6J5\GZEYZ '3QPU1@L-W:>?)]703$_?%]U^STO86*2XJ18Y1D>FF
M(<INRT@&N/1,;? E@+%VQM9&X+CZE&$RH?G/J?R.E6;?"!K2E7/-0G-B7\2'
M_C8AQQPIKH<CH=@R?+S^F^.+JSE^@+^XR+K:)U2\>41H7XS/$IF9!0QI&F,<
MO:$=OBYHV'+[%F6(DL=O%:'ABN3 2P#%DT;2M/$A%LY7I&NBL-/L8; 3RB]N
MK]UF/R8['A2:HI1=C$.=?(-&\BCK4Q"25DZCVH"P:,S"7NG*=%F[CQ<'3=T,
M%QFEG3&"@C"Q<G%%S"3I]A BK4<!Y$STK+!:655WN]I6XX9$P_*Z1;SDJ\"9
MT41-)FW.IN($[3]#-S0TY8G":\ _*))N$5;T$F#'TGZ078D2R550-^_W.>0W
M*QQ;^:_=K5.9"7#.% ..72/H8; 6+S*T0WZKT%$;0[ *7JS6CY\SR]+=!/=%
MGW59X_VZ9I$NJ(@ V:)E9U0W]04'I!5L]O$!:23*SM<IS2]HC]U;7J!E9]F&
MF ]9K;\(+@.?A)D3$BX!#Q\2]"\!ML>7 %)T>K.0YV]?G<5])*^V67OJ9B#P
M*OB.74C ):!R%^I:2W\;EFJ>-#@A3<LC+KN]^7]'?QK8"487$Y&KFRUL5Y2Z
M*$ (PG!F^#55QYC774Q-.DG.6;Z[22XOLQY]O^VJW']]-!7B/YW-0*ECJK#3
M[O7@N"/IH*(J/UXV4=;'</MY[VO)6URKN&&/R3A%#P,7;,G\< %S<I3P3[@@
M!AJ1NE1'&>,M3$]96]$MK$*G5++$R"@[<LUI\NF-O7;)P_JOJS+[4_C]+IM_
MVH[=2^?,7RX!8S^,#>(F+\#&SP*RVKNA<\B.=AJ$ "SB)[HP[?M(N7/=NWES
M54>.08$BZ=)<M^7'?FS_JK1_ IC2-VJ A >F']R4U4LV;1B4Y<KAXE,BI6@2
M9Y O,'W[[BVJ8'^QQRN!V=?*_7ZFJ\077,%*%G_1LY O)S4+,[E3EI],SOY6
MG"K%YDGM9\?1])B3AE%OK.G)T$4&ZTDO=6TZ!FMOED=3SO#U[76>!K[L($BY
M].;A _E]SD62J8Q!_/2FCS7719MW#(H+%O@$;_,>;K"L!^[VO'D49&=1S]#A
MT?"^H+E<&_CL,/JH'06L&0E'.F;I=[*2!*-AN\0GL.D<--7 O6H V;AV4E:>
M2K ,!HDSAO%"0Q"LF5\.RXCZ3GAM5-HMTSN4]3<RSOV=?0.6>D9F?W>]J(L_
MZ-WH2>B1:1ELY%/#AY0JA0C9Z21KWC+O7\(QQMH[;KM<V5(*AE'O.#N-*[WX
M7METI>(ZA WH6(5W*'*Y7Y?$A]%KA]UC!S5LL C&7.G*7'.Z8!E2<3Z!OH='
M ,>3XW6B6\'^RN*:70MW?J\%YR07<8'>I?%J3*$);/[%1Z)V$_/]Q7U])XVQ
M#V"7./FC?Z]0N>5S/0$\.9!S]FWSMZPO5(M0%%4Q3JMDCV@+]7G6DHX5<H7$
M&'+$]N;.((2(YK>[WMFRA(N5I5M$ZAQ,V??A<H*'J]WD?0OE6P)QO\@Y(P&Q
M!_17(K2Z R%9CZ]_[PUFL9@;=(-\W_JQ;3 WC)*43KQWUZ2C][&K1P]<(:\T
M%8C3JNG=L!\7TR=>MQDDOK\0W@&_-Y70/I<BD!G<_Z>[ KEKF7U#] 57CBVM
MG6'L&S;W1*<T=?Y#"1(=8M(<V O]8,U'""[:X@@+S\J=7[#0@WB_&+P7PI<0
MC>5['0%X>WRC95#O*CDBG!"/<*0,_V4D %;4VQ0[7>;WS?G,F&I#]\5NKL-'
M[N:!XM<EV3=_2UE[G-]ZA/P#Q90\G"\RGK[)VW[&);,+QNE=\/3I723 [WA!
MG&E;>PZMAGU$G,B?8;:-:?H:J;Z#WIL</S0L^(UNS4II4]>1B%MHRLXZ!Y%&
M09P7><ITB[RX@WGSSX(0W070L9JE^;,OC/&4E>R\H2.Y%2"\(#;+A20Q353Z
MKX?[)2"J35 _=_@DR/!0+4R]MN9GUIA_K,8&ISYY.\OZ4M7]>><<9C $5E/3
M70G1E6D!=_VMG^,$Q]BV7 ).F*H)> \<'7IU93%O&5:C?<Q9S$]"1Z_LH5??
MT8U+9C(^MO3K?7A.Y>$5Q%+FMV )CY(=J2:1D487N2Z^2%OI;&B&'^I.>6>@
MJER:Q(K84GWLQ.5-N170[S2Y&-"M&FTV%YE(QZ4HGAL$_.I(%$AY"@X667Q0
M%7W+U?MZ,N]AWD'GKR?Q(&.%M43+'/.SD :(!D/6ER/)Y*31?] >F_J9<&D@
M&ZRBDY6';49FB=T)G>B<TB0:(I+D(O(R;3V6S+<W6 .SM&CI4Z%?<Y'K[2:U
M;(QD(CJ^"5IVD['S;9PXUKH$C'^Q3_MZZT?07]\7QG1:;ZS)SX&;'#XS6/]S
MG1TFLQZ!8L?B.8NYA4>#/5S9'@FF$QYQ4B2L'(DJY.Q3-@7!WM'%+65\H^>D
M7W#.Z\0W:3!IT.SQ=@XL@33LJVB\;B*=6#>#%$[W[.E7YWYZ":A//1'+<,:(
M,Q#OX]LCX+3O[/JBQ+ O>C@4.-]Z4[XSI$J8_]OJA=G LJR(?P#3E,+=@J31
MY3G?V>W&W8ZF#ODGWZ;Y=2?0K7]B2NJE@/6A0#R(R1P&.$LYP<)DDL11EU9J
MIFOGL3YGY7[K?C*_5^:CWZJ[CV5 M>=W=A "%Y^(E+B#G1Z)5["YCHG"W"*(
M[_8(F26OEIWAS84?(L%>\52A\9.9#ZQ%FR%E&0%4HZ/["';2N/E^G+*'_4H[
M YP?#PW^_26Q-3OWNUJ<Z_GM1DU[,"\+9>A2/*:*)(B8RZ8FZ..?6.)DJXNV
M$UU..+SEZ@8=V9-K[]C;&]>%79NWW!OA!0ASX2W;NZ#HJW(93!(E!*XX]N[3
MFIN[I..\QUKT\D [NANJB:4YG8C-U5R/C]?*O50GC@;W"4*F43PD:N=R42(W
MU[3&.VJ^N5S.O!&\JZ3WQO718LVT1DU=&\V&?R\79IZTX(#8QL(=,--1^S7"
MS$_2?8)S.822P^;D2-6NV?;=-W9ONU'??O)BEDT@$.PL3HT824=\]OG4,B73
M:FUT(S77V<._WJ]<XF/,Z+4&3U@_>2M,D,B\)Y_:":02$_E@USU&^#WI/ 2>
M?F_WL6W>*VZ'SF->%-Q-QJU+HDI::?#Y4EJ'H'7VAJTK\+QQKE<,[=WUOTJE
M:JR>81'?=_.!X;E1!:.:^.]])_L31S9,SN:FW="(;"&"O5N)WMJL2_IZ ^M0
M]_O<-,26PL:/XPH=PO&Y#@QZ FO P?#24C'B#"[@U^?>KE^%)=Z;FVF#WY$G
MQ68+CX"7\T>=JQ%]) DW53O)/M&DV93>]1RL <!TR?D=<E;46N%<W_E@I^WV
M17QIBS;9XHA_R29N^X5E7*<)K*S[^_)QOPA=D%.13I:UF7G_@LQF.4.LO4/
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M^>486L2VJ?*JP#'( _9JQ$)<2[=N; 'VR6I7C7$1MEG!U8$*1DH"?LRUY.;
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M8 [O]6UAY >H[=4B;1_0T $AFE@U:R%9Z7:0$)O+ ,KN%!2U< 7"!<!Z&);
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MS&0UK.T.-QO-'TQ)'O[>>L;?(=N,;C)"8Z-)A.._E[,0BSDA>P+QQ.51F G
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M$#V+A"K=$J?V@1%%DE%'\L1A,A"106(W@)*2_5W(0*MY]/(DBYK4>X)_C]U
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MR'>N%ZPL?PWO6__ VO&8XC;%E64*;JH3]?FE1RG;&\R+WO6!TRA.0DJ3/^=
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MR !^V9L,--XB\502N^S$00<HD@&B=TS>,$E;L-,OIJCB^*S4Z\((%RJ;M<G
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M[O+\]J+F^.'REA"+@UD0[*<G&5:20_(_.B<CPC_XI%V""R[KM?0*PQU5,VR
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M60EKX]69QC??IZ7*"E\^PW_WM5>!%L&D4&_JER^72-8],G!RU=S.$9L 64,
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M&L;U*/UR7[SQ3P5]N%E'B&^7)V/E2*BI1HM9&W9?8@JZ&C\S3FM<CC]1.<.
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M?)M"O#5_FXIV*/:U2DGE]X*3XMXLWA' OLFN/CXFHE[85QG?WH+F&YEP?F9
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M.R\S]+D^"2.#JSK)#/:#VWVFKA!M!Z2"I2Z(1!&5,^&/XF3\A9=&;VXVBA=
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MTK>;[ZZ&A)B&H!DJOD[T4K9)"H)4KCX^!TAV-UP_P/ 8=1EN(VS!X\*<CY/
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M>6<R5MEG1P!N_K]>&KT[4F*C&]7PV1NMS7QX&Q#'T):,J+]FI(/NC$R\IM)
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M-PUN-]ZP\NSEVWLV7"J^\G[X6Q#=XQBN1S?8;^P-*3O2FQV^(D!+)@DABKV
MGR?+E1G\];5F=4GV!ZQJ:G7O'\QGNGT#W$W<67<:<;AT^9+29<!NY]D7$'#*
M/D-R"%K9W61,J/YCXF1TDI3C[N[G[5I4927/L*RFQME:!+@D4BA<<R 9U'QM
MI)3(Z.&55YD D]"15B5; ]0SHQDD2$WV$&\?'^]MC*+O@I00+=H!MR:(K_ 6
MR$"O=+F^5CDCE,.K"H?R9X-B"(''%G6*GZ49'ZBY69,N>YV2T;:_Z^LY8"[I
M\H%UTEB\CFK6\P2P.4B42(\SZERMI"7:Y4B4I;#E\!7E!\G$^1A=.C+>M*SU
M+;+APR:0$?,BD7D>$<G'3TC,6W6?A VUL^$GUA624P4XK1]D H*K42>57<\O
M34A#XE5)E]W_M3G$7!)7(F(N#UUY:0.K+7(.H"P;0=@:;:-1'TDH@0.]O4,[
M@E<!S*ACAJ>V_VF*3D35V[$JX^BIEJ_-PG)[ T?;X4%JG-RT !1KT5?B-5QU
MPH(VL&/FQ<$Y(+PR7<Z%?])@6)9SVY9M\*>@I]6V-_$'O#<>\.,>JNOOP4)?
MX AEN.8_NLRU+8.8Y#YL&-N'>;DHM)IMR<%>8KG#E*2Y+UD]W?'DZ+[9T@6(
MN?W2PE"QZBCRCZ87^+G2-5Q?&YI1&,]33Q]I@@[STJQ*?_0E0T=A^SEE/+Q]
MZ_? ;BD <[&VZ!PP#IYW+<1%@$/D,SC,4%0:<"^6H=SZ+Q%3G"E66.W38V]7
M>>LK1ED= 38H(DO.PLI]/-LGVKF@G(=W#;?0<SG 2M9A#TVV*DL9M]+CE\J7
MY8S'\I:OPW.F!LY2S>I)S2J;@@$E+XFW<)U9"V@&6*>%/-<Y(+1X96B_.VS)
M\_'USS?C*%]MWJ=M4NF\UZ'8AJ9KE)^'<!.0'2?^02)AC9J+]$].3&;4$RT?
MQO&'"/(7B"P]I]94=MJ=@4Y.'L95X9:082)-59$/&[]LE52)]%NQ[3WY,A-!
M:+$,BMLR,")=OH__<P[H:<O]^X(@+N3F25-_4U3L$)(YH"^# <\>*2MY3<PT
M([QT_:-X=8Y?YGJ-@L<L?Y1(^F)]^.48"N9:BD!W8ZU3?J),53-N9/E+WKH"
M/29D2ZAB$/EX9+LDH">^W.$SY4=;S4N*B_??;G>B%<A-BN,'Z@FA6N> %B59
M]!QZ,O0PDA",=6)DM.?*^%*PP=[3!76LMZCGI-5K=[4"S&LN'G[=/2FTJ)2T
M%CBXUMK,'M2J8%E>TSQ\0-L3HB/_ IVT:_[QWJP &X97.J8J=0X=3.(A^!?!
M<O3ZBTU_[[5/A(]X:7+Y".YM/[G-?N%S\/$+=7:*F,1C/Q$BB\!"FK0F2\IA
MTG?US2CT.!/NQUQLCWXRZ3(KOJE^X\2.=/E&SBD(Y<GW2V/#@O58!HE[#HTN
M.0?</9,^!U#=?5&D,SF[D+[?_*(99>TA0>?CMEK>\.I*0J!TX"W_A__XV?HT
MZ[$;NAJS174.H)W#7ZBO(;4X(<NCM4[9P!5?\ V_9H?>WL?DZD$F-Q94O<8\
M9XFL:EKK+Q0S#_7 +VZBNEG/FD#2\D3,/[[0E]R:QW\Z&),A"QW_]U5Z-U&]
M6I")TX61L0_;1&V^K/SJ4 ?/)'V+<X#=@XM/YQ*UZZ;>7%B\\D);_G"2,/ -
M8F8RZ<0%KY&_*G97X^P+T]2F6X[(<)S6NI=BEI]<0*HN)%7A'+ 5CD>WUA^0
MHHL<??WS\JVE53PN#&6YQ"A$%5XG47^3W&K!>QZ,5IX#B&QJ&L/KWBJ;XR?6
M:@'NTZ0Q"(_,M.2S893$J^JA Z8M.R^)."Z,&\M\A#S^%<[]1?+A&*'2=T,!
M0:*S+CPI/LUZ([V?%$&<@TSJ8-L0/59D.*(J'^X^M8,;@O<XRLC3Q-/3WS!
MY6??0(KHG _" 1*=U,Q>A:?O('V!YEHDLPWVNKC&NE=5E\=(3?ZA:+EN76)>
M?I8) JV;.BL$5^5,&?=>TV'!KZYV"SJE_V[Z<X4G;DW_P,?[X9+=]">C-BX(
M9B=6H?<#^ZA<B;>=&V=6BOB-R[_8;T0@_#C( _-B .R BFKFS[#W[!) )U'-
M2K7EWMA-OM>-\,ZXG[LI-$TC"L)G-_/KQ )YS0QBG[&]D266I7[>&M/0VV%:
M7Z=YP9==8$H:0K/MB$&A-^I"G+1XT8[I,NVWJ!>"9_QL\+U\K1;]=29'KUEQ
MI-!3=?@KO,#3>C-, <<#!^WFSU%,U][5[G,JO2A"3% L\':6@^+#&_1KKMA6
MDG[I"CZX$M]6QI>77)[LM@0:S6Z^"XD%<H*K&>('F O#B$,.9Y^:7SVU"P W
MQ'@,YI&#\R5\M)=E;J68[#7V#''$]S&?6,Y9TK;B?N[FZRDQ_S@UN'4AJ7^6
MI5(QRZ50FS6ZY3GV_OZBGL$NAV_0^FVJLWS0]1J+)T/G $!\K/4-XU/#"$(K
M>,(,2U=&H5ME]0S IIE@:IJ,0877\ZZ,>]VW+JN? ';5#HT '5;='/QN4<6B
M[%&QUPYC\/,;!1-DO.$RZ#I5@ZW5K[.A"=2?FE+I@"\'((*26_0+(1L%IN0+
M^ V34O'Y6+X2JLW1&KG!CM?L2+=9VRCGIPM*!XN'N3_;_;74X 5((-Q^&KJ%
MQC'?MB'@%^0V_*'G@,!"K<1W!^*LNR=$3WSXOZKT13",[#5FDP@BE:EYL<:0
M@5&O$[ZBHW?T</8<<"$I#Q+-)Z8,%3\'X#@=C"7\>=5\0EL1[+#(CI/@J93@
M=JBE:R#3QV_;'_<Y^0*O'1OE#W+HJK$ _K-B]&EM=M?3=.4L0@YR8N+QLN2E
M?CZB:\ )>7AS'+'VNM>!/G=5QK>*1=<D['^6^XK^ +M"HQ&X'(0=\.IZ]="Q
MPDPN\/#9EZ ]G[V+#9C3\*:_UFPBH6\@YHIF>:SQ^9TN\C\,C>PG[#[,S;[Y
MMD#O=X>J8CMNDZ\CI:',T[_*)J/;T.F)TN!C0K3Z"$7)[6&(?23)-_]L_Y8A
M5O)X'7G4C_JN+.55./A-O!VR-P+>R=+/_=</FN_*,\5SG%*LUH&[C/)ND<B3
MI2;O?YS'DW\.L ]7,F+?6HU;#5GSNN>EK0"F%XH),.,M]^&?8E!JJOL-@C2E
M'(,4P] KV8C9APUGD@N86,]H/OK;W1BNJI+@I@:3%A9OF/TKY^UPX$XV#S+1
MF,$IP\W5O+L"XD.O.'52M. :-"=^396PMG"J0[4&NCWL3+I.+S7H]$7D5+;Q
MC6J]GI[(\[:>*S0N/?<7:#)CV^II6E,AL4F^C*$RI_Z@C1]<+QM/U,X!J7<K
M'7XI)97"?W0*"9;17)'N0GUIO'2JN8Y@(-%L!%#W2TCL-QD9C/&/V(R*;^L[
M!%O=[)>ZHU@CQPUJK5.6QQY%5LY><PS@K\:[YO U?1-00Q1PI^].YS"9O!;_
MN.YV3X#'"%B67CP3^3=7Z4U3; &(FLB""VU'!3<#1JI<A+7"M[W 3!93QG^F
MM3C09F8(.>Y'>NW\"=/JV N<.X;G %LRC:$B;.3"H.T*LT$R9TP8[,ZFB?/^
ML81 Y8CX8E62/M_HQYHOUVXO)892Q*4<FXYAD\.W^(>L:_#*!Y6^+OLIZ1$M
M[DN13OGW?7(FHXNG\:9[<'=\[W)YGN-WPI"^0DS2KJ:U6\T%^HIF[^]4 &KG
MM&HICV<&CHH39F1$IF&?.@&V(B[M2T:_9 PUQ8VUG0&U1[>4W"8>^=H8C3&-
M3_WQ8;QE%FIG]XLV7.RSF-3=GZB'!.XY\&4U+#0()-N?-3BFE]JAD!'KX9$U
M.6TV/M69%/\]CK=%//%ZZ7P;HR^A0860A8723V!<OA(RS@':[Q4/1M@4S>(#
M+0(?(&,76@1 '\94Y;<NX"\?NMQV:/0JDDDQ*%%^9_81_3HN,3'C#N#RDPJ*
MV!VN<-U"T:_[0AWIZ%8DC7U*7B@^LJ.^.IVOSF/>3-K]=>Z48AB?IJNIM$P6
MK:TQYA[EE;@$TQG6027Y8J(D(13/#Z7XH^&7+8RT<\C.F4+8==H*O3SN;]X%
MO60/^('!H=AQ8S&RL;3K@^N^PC7NN8[7!..TW%WD1N. .T4Q42533&JNJOC(
MSENH*2?KCOK8PZJ.LN\IJU,V7:Z BVSZNY\ ;K4_BCX)3E:0*KF?G@2TS4,#
M/<\!(6.S3*Z-UUZ+3V/>"XR.M27+LU^<&=W84K\@13_?_N;*'3U,5LMR-8G!
MG@L8TBP.EQOUM*#&Z"1T!%"BT?45.K(+$?/\<<8M=5VZP@.)@D>=HHMFJ C0
MS1'AD>5&O/)93TKC):<"F9K[IT]OJCR>0KB[W<D!6.56$+Y@S;BW&'9GVVOZ
M+5;=.63J<FK;QM4]/D4=OM3A.PC*D4N!(G8%$I'Z ;T(!B([7F!^*ZD!RT@W
M/ATZ)LL2WSGJ%^82Y;;6::"F<@/SNVYZ+*,66ZYT;0Y( W\X%' 5%@&E,UY=
M,,5_FF#+RC?NOE-36P-0H&CJI@9L_110]AW[,$ZTQ^<B/XL3+0K,Q!*4VXJO
MT0[_Q!\_(SRG-@'I^8LJS'::5BHH)R7P57CP?7GM"2TIT7,II&J9^_5YE<C@
MH*#?X$VJ HIN^_/BT'/>(7 ']H@265&:,F;"=I]J=;.1)TQ\0I/R8Y8(5=@+
M\X^/!0W__N4,( J1AYI='^>UE2;G?7B20$<KHZ6U^OH6PSE :G1=,US/_'I;
M%&_[0I31[XF53@@7K.B9$[UU)U=2CLV0>)M9K\<NI\&VR9V[>T&_M^L*=T!2
ML#X#X]&-CI-/#2(QBW?J)CH-3N.E)>BD#L6T5?/E_=5^G6;T%CH9^JYL)F._
M.!-OO9[_$-O)AF>V7/'QL 0"CJ-FI1@_??19$)#)H.B7D:2"V<U35\+%7;#I
M.AT*/=E8I_Q4.>RM))D09FX CUV/8% :P]T4_+0?=C:RT2(W7=H4KWV8GU>9
M[6&G]*/=AC+]] '%6^.T(\$AHB1>M8./OD(N!1B.JDS5OY':58UT+ Y^FPS9
M+N>Q>86-M1,UZQ';]+^ KU 9: 2+M"-Y=++-"*&&J9WQ:[>3EWJK/JE0ID8(
MW)*\<:PB0D'#,TQVY>\"^& 0B(+;D-C^&<*\DLR$)R69_/.T%09RM0?'DZ.#
M<BI>W8+/W?FM,/9N[1S TJB;OZZ0?E83CK)J'.'11$BF<6\]8U!]S*#*Y$/#
MR>JM0VA:H%? ;OLAV!QOR2[];*Q]6SMCDW;ETK/-^1\+ BFQ=H(E;WQ,]G]_
MP4';)I3'@EV(6O./M7M,00T^B*^IQU]#?]<DW,VN1=33 $JE[M^7_8+;F(=^
M:+X!LVOCNX5L&_5UCI_88/2R@XJU_M*HN6SI0[W\\>8,!>7]>WP'>U.(:T3=
M, VBX,F[7:L,VF[S>,/[,;;F&;]]H*;K(#:X;2WNFHZ#G] 2Z>.HO.';_HGI
ML-=E/C\8E2C?4Z2]6BD0KO!<<3D0[ADF)#(&+T*I'7R5,U(M"[M<D9/>"C8>
M84I'"=#M'DPB7=>/3K^QK"FX$JZIKT.'$PZ"T&ODKYV $I1P3@'.:*=H;)C"
MU)..:I:/:=;V' *L2WR*A"P7[,YE&+0-I^$CPP5.6]$;=4W"'K[]N%CX"F0\
M]GVO2[C"-4 (EJPWR)#LA57<B+[7_E&VH>_C0/ZTNO*3F!]INMVBC/I#('''
M0G=<Z+R8M799>-[@MK$6CS.?> VEY24K@&O^]<6,D9$I6*H&#AQ*N@2+)ZY+
M0QQ2G@Y-3)CPWW[::MO:=<OY6\(PU7U.%%*"J.97^.>/R?3Z5?,)A]6!"57!
M+\:L,<L&O.^41B+13#/K26_9DE,^),N-,G]VN1'_M)CVV9/,3>E>2;OLA^7[
M,PD%]O5?P930JCCEW+/VFAHVO<E:+?M2KM5*IYN=.V)US]^68>MVPK(/FMG'
MJW:[K%=@R<]!MTE]87+=);/U#'6  O.M*P_6?<=">[%FI]W*"H/^3QQ<//M;
M?[$E+-5TNRHJ2_F<C':@VG68S=:33Z("KC>:;3VPVH7*"\^YD\KXN#/7%0W\
MY-*[RK=GJ8ER,U2CGBBF-=_&(]PZB'T859RTSB@VZ:/VP*)AW.UQ'W6EI,R9
MM!E!;0')L?9=+7_MI5!,Q[;E96.3EX)_:K6+NLS+W-\-%*T<$D*QG#O1"QM'
MT9XN*7T]>^5A')8Y #>6(X"!(4AP6,S3KU=X4B^%7@*?6"HV^%3MEKF+6-//
M'\1O%G+3VZ*\X% B TEX9.SIH%?!=K&<?\[S)ONEFIK*<!TIK<8K<YY'<QXO
M"[&,'":$H18PBRPO2X59NV<WLS2B).6W4I:WLEO/!;!N"EZ9IM,4'3)7'_ID
M)*\L9 ,Z(1 >,OYV?XKV?J>V10W^L($A>PSOI-\!PZ5Z)\F]F.5<S '<T2AG
M>2)>IDQ:5P=6<%6P<>T<*CU\Z+'B'SA]AW.GXL3/T SVJXT,FY3P^WE.[M,T
MHY4;198^+I53*JX5VY$AUV6<W]R-PSS!%\"]2O/*A;_5+_T9_AKYTP^IN&R/
MCPZMGG*OX2C27)B&S6KY3DRW36MQM>XJAOR2G#9G#J1Y167W4Y3O'5YA9F)V
M?J<MU9A^^$C4P?WFJ8&*,)-,8-X++4N/],;]XAVZ-06OV#8+[_8C!4^%CJVF
M?39=LZGDW6Q#[A3URRJ""_8K$9C^9F%'7^WEJ@*EV0FNYES[4<0$NUX23+>\
MMF!5DX*BK+B7L7TB.12^LUGRS(E"*CBA"TX#6+3A8V#DCU0TUJB&P(P>X8ZB
MQXRJRBJ&!C'J-<,NE0ZE#WW&XJDGP+YM2_I[?(@/OJ,:&,9*C047H-ZP=<RJ
M9OYX8_=RX9[Q=0E:_8^,2OLK0>8Z[8S<(K%5?HI'X=GQW!PN@M*/>7,]:3Q6
MIM)&+;;+/8IZ>6K&H-ZWU<N*?HW?8+$T\+OP/'O?60,]#6<?D-CT^KPIH-8\
M2EN/V^9)+RNVW[P/WHK;\[W<.=PH.N\$)&BA7H5,6PT(5@_E[+5_;UMF#A?Q
M4JU=>D?Q,;NQ>:PS9:0QZ:I:\;2&<$:(HKI)W;O'+2_V*?4<FOF'91H*MUUD
M+[FLI#%+%YT#BBD70VB"$C9T?YV^6Y<[80S:\;2 0"I>G -4*VN,:C(X2=T\
MOSM,7T .HCY3\,Q=ZRI!4?R!.9FZN')S(S<GG4I8KYZHA0^R)/S6K0=+IQ??
M'0MTZA+ AY#I^-CLQ!'0R;XQ*;EG$1/EC-%N_M.A)1E199:7GC<B\G'JH?C2
MM @CT_U+,:D>?PS^) Q8#E5"MNBB>8G*3E\WNM]^-)UT=/F_V'O/L*:Z;ETX
M2K-0I$L-2E-I(KU&5)J(-.E"'D5$:E2D!Z(B1+J @( 0.M)%>HUTD-X1I 24
M'I)0 X3D6SR/[WGW?I_OVN=<>Y]_Y_W!=;'&6IECSGN,.<8]YBI3[*;J'_ZS
MTG=5.X3@LU[1X>9T" ?)E#R;R7[.:%F6<A@'=NJ4HE@J<:= GJQ.H);?Q8O4
M>%ZH MW(N;/_!SU#S4I']N/"&3L9V>3$2#V91[&KCB<>JH^J>E@I<49]"/!X
MJ,1YV+*5U27>868>6L!3LH=<LO%J03!%L1)KOXT&KWE/]2<//]R*:IT+D!/7
MKB-)XW$DP0#FLI!QUYZ%_N1Q=T\2+8W'B_<5B0_^=^^3_?E.V7^N WTK?.ZF
M4$"BFL6(B4Q["B@[02Y+/B%M<'7$O!]<Y=7>SQ;0#W"5)8+#&^%RI(7^W;$1
MN5_H%/ZN\\'[SY5*^F!$7UA'_\$IHM?Q1\PIH+#B6D7EZK=;S6.R$4KZ-N!R
M-O-Y"HBDIK"P=$0-/_X,U[/?'SK1)^Y30!K@X^]O?400/-"[]HB+1V_Z)\^(
M$1!D_F3"%OFU.A_ ^A4IH/GC3_7DD. 44%H4$H&_"R'60LK$]ND^)QYJ: 9(
M44 MPP'JB 'M%C11%$RR >.W9Z-0V\QX'/ET!P7$J0TT+;#+"GERJ:2- OK7
M#F?^31FYI^0G?[,#EH9]GQ6/(I^Q)*#;P>RJG&FKY@=G5R:+J^SMGI<Z7KC?
M)KX<>6*V:;(CZ<BS6)GH@YDT67505'1COVD+5"4*&3.K"4,^9I[1LD.?N12I
MTG;4\H^\F;"."P;K.$8+;[?3TNII9/@<_[OTN0")J,.?X]+1GR'.3-17^WK-
M*: 3=!00NQX%Q& ]A]IP0A-/08CY1+\.J[:Q0(Q?V)3(K1K+BYJ.YQ1YLDQ%
M^8AR4.,Q#P/Z-8ZK-C\Z/DVL\C\RZOYY*NNU?7AUIRW772:7T(*+;OUU=%C3
MN4P2=R[Y)!/YRD>($Y2F"N^$(IXY;CNLV6L2&5+/DS6K-E?>4!-D'V.19D:]
M]8Z]FFT6J1R?-\_ +:%G.,+ANJG/^2Z^BSLBYEIPYU(&N;R0T^&'WJ&AMURM
M"%!LO\RD@$+S.'<3\7XO]('^GT "XX R>/N9$.C"MP][[W885@YA)QTOEE;)
M9[@VG2_>M_A(:GUQ_P\S*62 J#/W4ICL/:1^=4TD3B\Q=[@HA?UBJE*H;- L
M6*K[5?^SZS:H-.=#76_-6I%L0!>0#T)S2[!<&/GEI"@R%3"H1N$ALIC%F@*'
M?.WC9!\_OV?4L17%R_/>;Y[[N*%D&/IX5"5]'Q=9PZV&?L8,0<ON)-F,XG;A
M5H%Z_,.2.M0===XWOGYR\=A-D^ROX-P-QA>\T+\)C 'P(G8#<#E=T!11CHE$
M!R:9PBW32;:5HVG#4CPW1US*>V\:*KLH#-=;WTI[=]KP^Z2E9^":M2'I!F<"
M=[AO0(27'U_$FD7#8-+Y/ZY=<7-1^;Q\=];]^D9_"5U'/SUX#DT!?3V>%B;(
MCBAZU%PC!82F.MYB)515E&!UV,ZO6%8Q_*+#E<5?]@=;XH*N7?1CZ3K6NG=9
MS.4>[9I6>$3KI]SA%]TJ#PJ\8\U&)-U(GS;@'WY9S+\KJ/O<+.[TE,X]>N:=
MDS^* CH[U:)-E$+COE) W%"B;2H/&;MW1 0O0'DL2"X5(R0-QE=V&*S9VOT'
M"BB'#['KO:R@-4$9U_93%X(U.HN[FQK%R@E52-<*/Z&D\X\E(^A7J:.5I<VU
M.KBHF3O83FRC25(0A@65WPIPXFYCY+ZS[[4C1*YC'IW_XU2_X%CC$SP3LC\$
M;F+WI+N6!B8/V^.,@?#3+4#OOF0#T=)0W?)2D/X^U:W:)Q@L)+DQS7Z]"Q('
M3\\GV1)U"YT2O*K0IV4;;F_,F\58=T=<Z_V9$G*XWI,5X_MSR[;@\*[W.)DY
M"OG<$=]5N6>!*)-DNJC^!=Q-1::!<DO<L[9*=Y?=5JLB<S@TH0\N'DB1S[@@
MCC\G^!C.0P%E2&4 <2BGXWB;#;:,\L6$IXL)[D"-\?NL]/\ZFXMH[B$J44"W
MCM^\;]*/HH!8;87O9B;9M/5*+E500,U]1)7CLUK 6=/CLW<IH* 4/(+\=B8"
M"'X%4F21^MLU_1RKXZ5.W")1N?V[NCM*]]4&#'O9=.H^?%)U4SV1FIC=*[D
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M].?>#C,DVLVK&=RL&<#M- A:#L?1FW%:Q056'*'VH'WF/%E&X?)TT]2+C6T
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M$?6WJ97Y]YB]XCKB]MM&<(!?T*,6**#_$ ^V$?^BT5^B-F+$SQ<UI-'3GX3
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M"S+TQ=W+SV9;MS;?4C(SOT6?Y3ZP+=*@[&-O*K0XBBX1]!Z(VX&80![ 0@/
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M7<&M,Q!,KA-##N6\#>X,;@CYWVRNE#]0SX-=<7V2>Z]3<-3B^:EMN6W;59(
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M",>/J2#);*5XQ!O9>&>I$.7@#&,_/W9MYJ_10E.V;IZ@3ITNQ7[+@S9;VT=
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MVVY[::?_+?R_+00R0,;+"]-:JW^M)(^X_;62_-\1V*KAC=#S.#B" BJ-[Z"
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MCYRKQ/@+]VG$7/H>_O#B=Q5OVL9\Z.O&4_H\6D-TR'3EQU%YE:5V3QZ_[V#
M/%QTX=B/7!1E>'=ZSAA^BR@Z!PM3B$\($,>O<S=,9\@:_DBT#S8-__A>BN?R
M%0,57<')*HL/>3983V &-WJX+Z+?)E39RA/!^&\&#-X44!N_(#&O:&7L*1'^
M9._+I+9LZ-<?MC^N5^^SG>3+[MR_SAMKB:K(;<?>[6@S.Z F7QRK5U45E/_@
MX*H\MBH\5OPS1N;IHL4P+);W02F72QT$-&<^V"AT]$&=@UBYVKQDC/>OT\^=
MR$EV&JM2X,C@>214>/MB]'5#W8.EI/6*J!/+_ +XB*B@'3X(UI<FUKJBX7VL
M;@4]/3=KG>?\O?Q4W3ZE7N96D["P"FS ],W4*^T]RK_BBYS%Q\REOW'/]C,'
M3UT43'\DCER\$_GJI=P\M*SN!^GZ4?QV@Y01@6;(F;NW.-,MH=]WUH6N/\[L
MUL.I+H.$=]Y?2_3PXRUK3 S$@K89(59]_T)BTKP23%+TS)D.;I=0ZC/J\Q'3
M/L(A(OE/$'2J[)CD?L;IE51P57D-?MWKW(JQ>(QTN>Y$>=/S#I40-??Q</,K
M[^TX$F))X%6'%W%1)XD0 H\-,:^0= $?MY'K0YN'4?0XB^;P<?]2/FQ94QXD
M(O K[L?^!S<>M[O.:V)^G; +NMBER$4Z+LL'[Y05!I&T-?I4&(,W)(5Y Y:U
MVKN!,,="8@+YQKA1@H17TWF!&-#/HP$U9^TF,O-@(YCHU-$RPS^\,%1NS7[9
MU>'TP]+7;6]I0M1T55.WU^ZR>H56[7S2S2UM^*M(-E>B>T<>*3K>R>HU8AV.
MIX#(<:&[ECQ[$3LE[$=Y/.3+3-1 RM['4$!'8NSK7Q1P/&O6>L1G^^0@=!#3
M7S.[@.6TEU%MQO'-H 0/GGR)X[M#_Q;\J\#(+>/E14"&/ Z%KD H!*YY*?+?
M$=A"\#;H^0TX_!_1,WYGS;I@L9^)9(?O:(:&SW*[UAN)Y-F)9!=_G[:2:XSP
M>1&K50L_9:%J= W_-;*A(./]_?<CIM/H>_=-'+/\96JK<>%);8M!^+#VVO@4
M=^&XHYP(#[6&'@<&MC!6]C_\SOD4@\G<6QC$$?5."4FD0HHL;4D6.,IM9/;.
MU?C_VCOSF*;/,([_A$ -( C":N72<E44G),C(M()"!;!1N[#@8H5H=8B%@'!
M5B5R%(HB8B>.EJ-0 :%C'$KE*E <1@<([=9RTW#+4852*&U7=L3_ERR9F?\]
M>?-)GB=YWWR3;_+-\_;C,!Z2$.JI?JMA[J3MTF1I27&L9:NVJCOH*7V7K6Y.
M-"$:]EIBE+@T,AZ7[F209%PM%)5$"$&!*1??%7%HPJ'9)@9OZJS9R[Z.!-.]
M9_%)J!-5J9W4^J\*"_B#731QJ*'/?+,)LZ<6XLZ_>/+I?+AJXF.=K</.]@_*
M37QZ<M[]Z'ADO)LWU^X$X28=P9;%<S^Z<IZEY%]#E?'GXJX^4R[J,$U+2WL?
M +H]XX,4'."]PRI=,M(.$R.L<)5*+G;DHY2<"E9"I$G$M9(V9U.-@:Q3"=VV
M? '$XT/I<!-S%W]AP>)DJ:R/<DAH1FY_B;%HO<ZE0(5>;"E-=&.%S7[H_S9*
M&1* PY\CD4V5"IF)W*Q<R<DH9FK&^T8]\^1P8Q*26-I[8+_WN(NNW<'V*6D=
M G(XLVJ+P.K,<+;09]0\-78LL2*$JE/W:PI_8GEMP884&FD_:,VC^,<C<K^/
M.X_6]Q(7+E6-B#*Y^+V#:/!;LTZ29DX$5NMNW3'+[8A'03M9=T[PB[&7)XMY
M[)%5;$3OXDWXEAC&A .#[R!@^\.W.^[!C&+UYZ8ZF55TK"A,G<\D1+RB%\H!
M!&7RZX:]F1L+0Z=4;F#9C SD4D7P$CHTJ%5FP,5.]*UL<T.HV>:L69EZ@IPA
M]QE.18U@-L542G%$"3+D 'AXMOEPC5!E^33K:BR-5<D#D0"U)^?3-#1P,Q3T
M4W&VL&(T@MT-ZAHCZ'8SPJ87A*_#[QWC0.\[1EBRN-M:):M=*V4BS <+$*J9
MRFV;&'"FWI$#&$2C5\E,0$#HSJS7N'K.BF',&P\9)C>?%B5T4#H<F?R*])M!
M7N5HRT"X7[\-4@<=:KZDQ\VGS:SKSSTBVT6'FL:H6*HT/CCC3+R F75Q"XK6
MJO,JW?"44FJING.R/<^?<UIJ8X>.VC1]BQB;]QK+X_GN1NYGU:+\CIE4J:*/
MM..MI3]L' @O"VR5P?IMYB3F?;1J3NU\E&AK9>"=GG:#;+UT39 ::,@HEUY#
M9RQ0Q_W('VK4.\-JR40GBR1M<7IDN3CT8QO9[KI_ #>O)-.^YSCT:+]'[Q4*
M;. -( =4?9-952*!B"ZT&5$[)VQ.']/?UP1=#,)8_X)^7&40'-Q1<H'9$A@>
MET9V5BK/+[P=-7FYT4OBP!-C_7M(BYD,G-0;5CDEZZGE+EPX$7X5>GQ'E_;!
M A1(/>NA-(1-K:EG2"N>,,"1(_R %OXA.8 *1/O'OSBX=F5FHL,.&VJ@J5\V
M6=:IGVB/%N%=?I+YS'0KB9_(=ABK7LI;7+>.57=] 3_7 -Z.2G4Z<RMI;CIZ
MW[78>/#=S9Q/,EYM:3*_8#IGEH_/ICO7B^JKQ6AOJ(VAJB<$[L.M@X\QG, *
M>X ,5O@2M+<<$.BQ+&VMYT%8%Z,@G*L<J-M!8)N,,B1&&W Y4'*^*<M-*KB)
MGKBG>$Q&CL9"CSZ6 SCE(F=Q!2[V7 XIULW36U:K=L>I-R3L\0,T$VQ7-$B2
MSO5>[V\RH;3*EFD=+[.8[_Y4Q8:?_Y&2_K\.CKLPB< T?$RU2;:JL+CEGRI8
M@;)L.WID$:]P<<3B3V41$?B/XME)QF5NA?[7_0R!W5I2-2)L"V%,FP.?&D=*
MI@E"7T*;23FANX.ZVK.Y%:3HEI;8-1:Y)LZ1K1MO^!DOI<U2/PHMI,M_==,V
M])']$:C=7(+AO@%UH&]LIGMO:LDLB3!@\T-B7SE 38<O*D23?5KA"[+*Y !<
MAS#B\O=8_U)K[-:HRS3(8'*_C@+/^!SNY0O^!?\L\"(B3%G.^QU02P,$%
M  @ ^8%A4L_Y9M^XFP  YIT  !4   !P9V5N+3(P,C Q,C,Q7V<Q-BYJ<&><
MNG<X7-';-CHB2A!==)*,%H(@>@NB!]$[B1HFZD0O0PBBC1*]]SIZ[WUTT:.7
MP6BC=X/C][[?>[[SQ_?'.>?9:UW7WNM9>^]U7_LI][.N_?#O815 K"2G* ?
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MXT@U:\V!>.%@DIOLC<1B:VD'?>PK<5R)-#E97V6T_I5Y"?KE<5_.6H059[U
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M )B&4=M_WYK3)L;>(3+RV/HUPX%3_Z;Y^P7"J_9'%7'**\L\U2@3WT6_^TZ
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M[O 'P//Y2[7?IKW)!';B2=K7979P7L/;*-ZA ]Q#DP"[$NRH9\\^)';%WLS
MZG*_QC']JE/(%;IN%=&UI!E-_;/N037\%J3Y8ZO&&I'R2N=E.#'H(N4>M_P!
MP%*^#KVE*VL_"^UK%X)\/PR,NB):?W(5H%AW\IZ(V+XQ\KT1<RL<71OB9;W%
M,((RS7D ',E"KODAY)!_FRX/@-S')?_99:_0-%;K=WK/'%3"KK'M<R=+KE/
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M;O8 <(2P)V?5/0"@>NV+C(/YY9,Z\ UN\*;/"Z'AP)[0J,)GY%\<"P%XF5X
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MF.?Y:,*:,DCM]< QY_D"ZC&QVDA:9X33;+4R)QT+!B5CB7JCABD ")MR'>)
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M4+?_.@Z-2"-J1!%>#-5T<I;XL3400B$T"-^H2M200!\\6\:A.I*NUS\Z*HS
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M>M2ZG,R!I,:SXY%F#<DX\P(0*8+>+9W3N0_AW!O>M)#?XSJ+$L<?/7$]#_3
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M$<$B=W?.O0>[584"80+61[''(&]D0IL!:E301S@AEF"6$MPQ'J(P];.?=DK
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M"J?'&WDU-;_R/-X\,<Q<>7JFU95F[7>__<Q2 E,-A!IY5*L^FNJB5=BCKP2
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M,&HYDTI<$GEX=7O)RZQO4&CFYYON04)GXG+Z[REP/Q&\L:RN(.M3X$HY30T
M0BEFJ$Z1,805?KS"RT5</GA0?S9 8)8J:;1?\L:QT^[TLIS6<L<U/L48':98
MRUT^6TV%IX.;[>+NE)<GNP,H:\HFZ715YG;9="-$OZ/O<JIXA4S2>%/6R$1
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MWV [(=Y*<%/'K2::F!&?[;G__^7T?S,4%)Y^.I4L_S^"ZWCV_P!02P,$%
M  @ ^8%A4E;Q=/*<T   0^$  !4   !P9V5N+3(P,C Q,C,Q7V<Q-RYJ<&?D
MNV=84V&W)AQZ[[TC71"0)DB+B#21IM)+0) J(-4 @2!(;P(""D*4*M*D=T(O
M(KUW$IKTA!H@A.$],^=\Y[PSU\R<N:[OUWFRUZ^]\^R]UK/*?>^]GIO9FU4
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MLY> ;.J4'L>*%.)I,!K^5Q*2 MP?Z)$WE.P&L.<^#CVI$A6Y_GP#6%_',=P
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M28R;#,>KJ>U)/H9/<%T;C)IZF3?Z$_0?W.8]D_@+]NX!84]IVJX3OI;SGAL
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MQ]\SS4Z4&$'\7:[98MYJ?FY1;K"%K!'['>SSE:KR=67*%%KO?%\%*581I<J
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M[]<1T/6#$%;H[$OHW_J?-X :XDK.0)/L@A*">U77WS,:C DIKW5YKC9;CA'
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MXEPB[QYP59WDM!1&]GNL(GTE@'KBO]'VGE%-/='#;A0118JB="%2!*5*[T1
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M<@982:BS0/,_6,)9ZG4F&015)>D]JCG[I);5:<DV3XJS[/PY@ (]>3[AI;.
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M^1>G&QS-,SB'2Q&HE96USZD6N]>LH]+N,G-6E"\, WI?4SG)8IVB(T?/T:*
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M^')5[H8FJ9IBP83TM/AMKQ]X%1M)UZBZL +DPO\4<)^L[6D\.?E-\B%(-,N
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MFEH=X&Z=UI%(;N;V-: CJQXG?7OFPCE\+$-5.R[=0T$#Y@H5$5)XWCBF(.Q
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M1F\ <:+S8F2!V_?V[RW'*!B+VU2V3>JP7+'T3^9^]5?1L.M69BU4)_?IV1/
M%% &0Q_;H\9-!:P82LP^C--6O%G=CP =#W7 1OA+/8>ZRH2Z_&/4*@JIGU=*
M]SR6;"O-;:F!;.:G#JH46*$<H_NR?G$_?"W^[S[)EC%)I#3U52 90UF*RU4I
M*@W);5W(M<?RK2_88F,@15E'1GDP/R'0"#^J6_,#;P%=/M\GKN_P,G7/D5H0
MQ4H/0*I(6,R-HN567[$D'.8Q0V#&HRF!BAZ'GOPJV&Y[:5IGTV9[<(=!0C_?
MK>/J!)2E22TXZ=V<X8$>I1]LP=HCWL!D3L/2[8%MW'WTB\W%2-A/?X1JP7\(
M_(H:<E)S2HY[0-).&5"=R=I<\V EB^9-37SOSE&;E5?PHZW8HRSMCK$6/L(3
MG&*C'U:J/9.15-]F-A^11KR#6-5Q&$F]6I[,#AY31%3+,2'J2P18(XD5;WVD
M_'V[&2)1@J8;,W:#9B-$)H;S\W*:WVR"^*'+.4L/3#'@[A?2ZF;WP@<Z1ZK&
MN:*))SRI@#BJ!(="FW,=R'$$@=0TK\<+ U=M!NW8NNE77[%'*YI>\*^!TR+
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M-Z&/4#0955S*;%9+2;X=ZN4#@6S<X%+5W)^!*1>PTW9C?W+9 '6^'$/&>KU
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MR+G%O&)>P6?6<$@V#C$Q7;*N.AP0)TJRI+%Y#2#SA77MJ^C6?E'[24TG(3C
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M7I#.+A2Q6 D<%/XX(/FU$G6B@B/#)P#!\930 :B4^-0@5S%2[4V*:" M]/:
MI"H+Q%"?F_@'O?8TQSDI$M@]0A+@B+;.B9)F+94KM=?G2 I_^!:[(:%=\NJ@
M<+>/;?J/Q<N#F(HZ"6L6/6_1+BQF2/8YFOK7C^S-*R.E+D#0U[DQ-XYC?'O8
M^?9$U'YI*F8JI,B!-'\GXV68FJ5BH_C+-Z[='(T*"G%*J@#O _U7CDQ"Q6PQ
M41MQ:S^6'\$/3A#A4(ZFRKHKW2%OH928$R)[LAD"7QY?C?N\JX1H*;*4-U"\
M,T,W_UL/:FQI[-F/K]_2Y%_35!\ 1'MVFWHC6^Q_+MCIR=*U_>5LBYDWW3'Z
M^<O7._%79XV%!-, EMOEED>P$A/+6<\?/K&>I;$[LW=:P-3@K1( T1'U4N(O
M3TZ[Q"S31%7XHH4$JTH@#<WDQ&.Q:I.%8>;6EF=6J?8&/.Q!24,:@%M_U&R>
M./.S5]>G^JXKL46J]K^(H=%\W6]Q\]$2@O0:X'(X]PDZED/_4_+='H$,C?5G
MYJB8O6!Q^@/<SKL5?T8ER33= &M_ USY\0&G5-N&M4</7,2'&7RM#?1[J'CV
MB=G\QK6-L!Z*8TY8^7V@OM.-(9T-T"/_+,K86G-Y:OTBA_\N1H)V7 /:^:\!
M#D50K@")>&0J @)$\J"';CD:Z5W /3&?OI[:55'&'^Q)XV:N*A 9""+LLC'6
M!;4HT+7$-/%T[+15S%RF=H([Q7PF+E2ICP?"E@ 1O?*Z8B+,+]'ABP* Y*%#
M"7;9P-IH\29>V=M85I&IBZLMOY2K_K]KYO&AT9T-XEI23,>QM8KC.IKROF&*
M])8H)UC7Y3K*_K&W7@9-[$2J^]*R5,WT0RY=7-'T+5T0;V,F9W''ZNW#N>UZ
M-V-.<L]$-E;!(%EO[N(%Y;4<AP'T65 @<H0&;$$3IT:D#=N_?8$^.U<DY7$Z
MB ]BD_G:GYW;E-%H_'WVYDB\?Y5I\G>9!?_,C0JZ X7"VG40#E\#:%<*L,K(
MW5]+;-.Y^E,L7!MC?4?LLK$"A>>W1A[P3@&=!.9+.Q'5_.&RT7F#+A4!\DW1
M>$8UO47F"([("K>_/O?/,^-",G :&%!4+8P)DJPU?;I[4:MFJ9E5P0_G9Q1X
M$>.N?')&] E %'7Z\JL/5XFJI8%BJ5!1;M3Y@_\\,U!8+O1-Z@/Q7 [Z?<Y<
M&&LP@KH [1+!WXWXC#-D5^!*J63.0E]8)"2/FK#RQ5=T0+1!U;JX ?V=0MRC
M0P()N2U\N\FV4R!R+F,>_"&T;O1TM[[#C W)ECZBK'C+ (TC.@X\Y&8,=\?O
MR=H(Q^M HZ=S("!C7<QT_(O]_8K"AJL ,D[*5_5]U76WZ2NKV4Y--N=:[S:$
MW5!,I+04BMSLL'-5M67\U##UP-A)P? )A/M>9:7>N\"!@0C7UVQA:R%!:PIS
M>=1>I 5]NTW&_4.]6:-UDZSRV_$5#MEYJ%<X<8>QG0X/AE^ZV5-3AN>;A?T,
MU42[/5)XH;;IU</+.UB7:\!=?59<O.(<+O :\!I!?@U8&5B]!B1N'YV3TD&?
M832"<:8N)"#^7T^#ZML]'L0&)'4LE2QI;$%$9MN>0+3E1[V4Z\&TVOW./;Z;
MHRZD S3W;L4GW040O%K/$*RPOP*=,*Q0PS5@S2_DPS4@-"30TLV).2ULW\QN
M3E"BM2%ML*]G/UOEH-?$F?Z41B_^I-?*(4 \]@?6!PF9.; :V]?YMLGYKC83
MDXR:"D4#D6VUJT J=?;QDQG5B!# ^<-LCE 9PWE H#OD;OY4BQIR)!A(GG0-
MZ,H8DC0+R37L)4N;CJU_0OGL-U.UV"O=?LX5$IPUO@;FR*=_EH_YXC;'.0<*
M\BQFO!)XGX!<=P[;^/CJF,[3+.(!\=/(G0YD?F0Q?BF_@VD/DQ,)HQ*%10,I
M10_IP%47&165GN?: /?*D(X>Q%YNJ.9>;F/KY US7#V;XQFT'#6R<Y@1QRGA
MY*\!9O;7@#Q4A4)3Z=V;(Q6( .Z. D\"O :FF6\H9/!?"GGXGRN@MH%K0/ '
M[&R P)6.?/X@^T\HVQA_F8Y@CY5:-7PUP@ JBBGW825J>Z*,SEDE#FDQBVGW
M#-0B+7Y[:B<7Q$-X=O.%%(/C]BXM?3W9LRN=''("+Z2YLVPH9_:RMDLY6YC>
MO0]&8XW;G3]A]M"?=!PMWW.VT7IE+1<_U4@Q-Z\\CF/%[*IA/JLRI;(\'\]K
MB%LM$:D$Q"@Z?^B",6P%4&$>[.K5QS%+SADG?Q)7:'AS:OD;WBM,8E++\*5M
M]<0Q&R%#U]#M5PV[$NX29\K4X/0;9H_?59-E38<ZR>G$41\DD ]?9/.J[RQ=
MFF<VG\9XS=[KQPU;+\!LC7!#9,/X[4POB%:,)>*&X/LN(_ZXSZ-!&R 0K?T2
M[9BUL8AU7;3 BZ['W'4;P!1(?&S+A[87F-MI/]+3/D:JHI7H98 ,I\VOC+N.
M2,TI&<Q?-22&419ZL30RN>E!GSADD,=_=C[9VMMGKS<84&3HR@-;QK;%?O.?
MCLU EJS^&I:,>AG5-E][/,J(W&22L;8STPCTOCF)@&N 7DUFJ3^SUA3JJ-^+
MT> G!5]>GZ:-YJ3J X5 >6V%A;P$C0#MTB.#_@X5U1^G#Z.2W *5"S*'&[[.
M]_Q5%,[ZI=#UZ><:=ZEE7%N*A^9$F?.#]+- +MY'8!)%U]L5UP!P@N#3>>[U
M%Z^>!/)49!69;$N&UIY^&W;Q<6(?)AN,R2ONXY -JYC#)ATL.1G9/UPZ"M3B
MCO-U_F%(1_MQ:$MC\6:!E*<5&1ZQ&5_*EL^UC\?K6IL">X1B*C+TZS/-C'#-
M-TS#E>)8Z_)0WLWWQLKO+<4'BET#3B!F[X)?K'QM7__-,161P>>@7'Y*0:E,
MDYT#?C8^MR'!25&S_D3^]H5_E<;W0\-SH]K]T]8OM/I")O.SW&E.9#$J79\/
M>/)^<>54.+CM,M1V[^D];C+QH)3/3TH)DP:\_)[D;PO7 NL;/797.?<K]/(O
M][8WE*GS2_=_OE57M:P(=FIJG5MVCTIJO0_ZT?V4CV8SZX<\M1:@]%(VN6C'
MYU;-5E9^:,A%B2M54)_$*:J()_5C27YZW#]%_=Q_24[@H="7X>T^^@SJ]84+
MG.)'O-T\7:J\J\XDIVPQGMMF=<;A^1%="J)KJP\(@:+;Q?V1Q9(Z"\6]Z6>2
MRQ38JV[)UB]HA\=BJ=,?*!%V<QX"3%GIO85LJ]DI+S+P*+? PG8O5N\(1Y<=
MGD7\5$BQ"4HB>R  !^>AIC]SP12HI(FQ\JV![$-J1N/<#J0(-)<GEEJ4FBF*
MO%ZC^,VAIVHRS^?PHB#7I@!)O7+NRSOC,XLWHH!6BA&]YV!J7CO,-?HK]5P%
MN%E%J709HLN%QK>54V0Z#K+MZ1<!QRIKX=1@%L9J.R[VLT6%?X;4D2<NF/+O
M>_M/743K%VPU3<WX"1JP%@PPQNR%8FV#:B9M3:;]G,ZA@FQZC^*ZSHW/+M"/
M7&&=/5[QZ;22<N;XO&S2O6CT3.NEQF1^VE$Y[$$)S@*[BF0E8Y9I*8T^S=YR
MOGV/';^7?O;D!A*_2W_#5HI8'^FCB/<U2K:GCGWK9.EKPQ7CB=>/J>F?XN3Z
M!F +\%%W$O$TV3.@\!\>#[T8/K!#0.*-M%EBH?N_<*URJ7WV-!%6+PVF?^61
MW[7BSS?D2[!H(V"AG8Y>%Y57;+NJ!3BKX!ZYT*D7SIZ8[9;"KSE8G .0 ?\
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M[)!@99 VYC#R]&[2&)A8W&]X*+\\?W[CMX_$D$NE.+?"7"/Q/U5GNHSU8CE
M0<,<&S"HVN5S#2(V]1I >@+\= Y]5A/&2ZM!;PI)(HPM(8T6!E^D:3"YRS,T
M\WZ_5^)!/W_^B5FMOGV9)$ ";=-<CO61J_H+]QH)77H9KQG]OAG14)-8OE[S
M#A*[9>@JE^W]"<)CZ-J[,@^, U&5><Z32\ZCB*/X3O#2[+-SW64+97KM=RD5
M@M"9BD2 CYYY.MA9#(79,KYP=>21P]-]FTI8[2[MPX/Z3)>L^PN;@FU="ZV,
M%FM,)..S&JJ#QSQ#JR%:X\]&D*;G(JRJR6J+J@W:]'[#")1^&6RZZD;Y3U1
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M;;/^ZY%4$_2Q&(GP5,5YTT&F6X?NX&RFX9CU4RAW*W!XC0@<0 ]U$:NLKF8
M7N82;3A\+!HZVAW.?VJ!E-%@[2M@0=K!SZD0^$/R9#PWLYG0Z75:A5': O_'
M'QG%,4\Z$>YO,J@EF^?$0\5FT)0Q(;U[KXI48:=>YX8%4@LW5#"D2'INS>^!
M_>BA<J)&"BF C^?BDX]#T7$^>TB70%@KL53?\J&[]15UKBWWL+!B$%*H_F=1
M@E]0[SN8LB;5,>M0;'"T/&,GY\OX=#4D."S6;OOS+'^$DN!)A298CONBZG9G
M;FNU;IGFX)=84771-+[X:E&H]79/P)<^.?QV)DD2/C> ?N7_72I?>\VLRRL
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MI+;Z5N13FA)!!]2DTSJS .;7KF4%2C&(ZU@S_U!5LSBY+?/JU:L<L_KC%+L
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MW.E[Q"?<\J29D=RG>P6G<XIQNWVKJ\^:[CA@:_=/6)!! Q2+R(-1]K2M#&$
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MTSMU7!8K2Y(.2-5TT, #C8HH):AO;T^1.XY_3N7@6Q$@]9L(5X3>RU?&<)W
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M?"+&8N23-VUVZOCPLN& 9E_$Z*YZTUTMI][;Z8A\Z]_Q]+KT_T(;2F<=$0Z
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M"_ RM!<C!8W!?6$P-8U@ A8PW5/JD5V^.&84:7?Y\^^J0QK5&:74YV&12TS
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M: 4TXC$ZP.X816F 49@FF['%C"_'OS_/:P[R 4MTWYUZOE7TY6D GI-T&%8
MECQ/"Z 80%N@ :!1O\.@1ASLI31?^^C)5?IAE;""WO*A)BY!>60@\*))Y,K/
MO*,!E9LT,\^1ZL.>"*?O^%]^DR?]9^72E9A$8A\WGF9.<M-!9MU@N5_LZV/#
M5><C@X3#J8N,(Q^2)2ZFC$=%P:)Q8[/!;2^%Y6LAY>78,Y'M]<6TSNCP&&$7
M;#1N:^Q"UD>3UI>,NTF2VDERA , Y1HL HPA:7LZ)HLFUUB3]CV\&J\P/#K
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MZW&PHABK$ XWZX??_ S;7I)?'VUSMGA0QO32=;MT9L3U[$!;??*VOQ\6?^%
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M< 2@_$2N!-,D4$O/T.N(LN\53;!=R;86_*A_"X I)/'V/= 02H,?2$<K^6!
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MA?B_L??>44U]W[[H1D&DB4H'(0HH(")*E2(1%0$1:=*5J(!T4&E!8H(B1:J
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MEXTY33F2?J+>1"U;P']?-*]ES9GC'^.$GC\+JE'D%6('D*4[22?B]+!5)/<
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M7KW"8%C3^NY>F47U7P,L+*D9"<4G05^/1^H:XBLMD)++VVE)I!&;]&N@'W[
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MNMG ;]C72JR:7UW@QJD[-]($;"G'81-SL GN+GP?);C3ZX5N)A/@^=%V9#2
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M2\= .SX456XEU"!Q:A\=[;'!&* R 65H$P:VXU'X5*KBF4 W+A);V]AIQN4
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MEDO3I5<A/$CY!E_JW_XJ5^9:VKK+!-Q_^G\U7C26\5V8"#NSPCD/.X?JY"]
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M_G\1]U3\5T+:_\^NTW_KAA$"=[)Z#M 3VC@0YT?UA&C7P YZ*L8#:3N] B5
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M'7 M'@SQ*38-ECU5V^?A^T[V99BL]$LQ\].Z?!_+4][OS@#[&'LW2;:4-/!
M)6/X->,SKK:H'E^"E&6,(!7 1P3%9GJP86O"=V.LHSQQJ"=B94VH5VGFI5A0
MR6'.8VVC>6%Z\)U;M!%'P7CJ)51G"3T;H4,PB<5R_D0+!<PXSJ45B!FT-CPM
M\!T3GKJ2-4 I_^G(XU.VS]+8/XPO"%7/!'H3$]%L2"%]\FY*"/UY/7_<@XH'
M"W7BF @UE,#44G"2QV#S8,NCJJCT>[+P*XZKYZE@X)37F'P._XLZV,ZM9DS
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MH01SR \/ZA$6O&BFPB5P_5;V*GT?2"_W&*=/@TMB]@X#,4&-GO&7MLJ7G1F
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M1:[=/P!$/ CKD%MIXS;^:/:7DWLIV?]&>MV&<']@,>3G+THHB_BXLNQT#_R
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MU.O==?U'-!GV/(N';$3G<YUSP= \$)[?2[V0 E2'%0RA)M1/B)*I=_L)HS%
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M >!$$[N'?AOXA*[PLHOPY^9I[X^>3QSE7Z)XUVX[XR:\$G]!HFFZ8BUTW\Q
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M^@G*YVJ!9.J,U8-+%-?=OE.SSI#2!=\N72&/AWMT6R$&8Q4WI2J\<Z$Z7MB
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MBG'TL3-&US^ODM__DKPQ2^X]PIS\O',17#+TNZ%)BH0LV]_9WGU8QI@/%&>
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MB_Z\<3.J4N?4*379@;CXZU*!-6DU67';W@U50<.TC @ #&WU/2#\O%.UL+=
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MXQ&Z\TGVW:M;,OL>@F;VOOTK)<C\5"T3)FN2+O891];#I?R*L%:L<<YE5.M
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M6QLU_:O".PW\H 5YLO*O<N'WQ0,))$%B3RL\QND \&(F7&MZS0+P^S#A,2F
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MOYBQ^0IAY=;EQD\]G:+BV1_9A-K.M8;;F$3F977U\-XCPLE0<I!3V&8-(:I
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M8,4O2O0,/:W@@NM5<40R_?DM@'<:*M#9+*=PUN;C>HF7=$T:Z83#CZ>O$L9
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M'A)>1-%1Y)74ARYM)8%E;F!9S_*!D37=1*G$5<?3.I**L%!IHSTCV_C^MRU
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M%[^W;LO'+JLNRS:WN$]U"ZCJ!OHV0)DK:,U2!*>9KIQJ'/_T8OYQ@/VP$Z6
M$_%;>7\\N;3@2[:(R'27J-&U</3C:Z:HS#YSETA$^-9F#=!P3HTMTN<XB*04
MHJI^]Y!E0Q]2?K-5G.KA^Q \H>,]V;G?:L=T,D@7!K^2LB[35ST%AHZ51_F[
M+XCT[G=>4GN(15')<0B1H99PJI"](5W-=?C*B&[S1!N]NW:P/.V=<8ZTY<9X
M>_[6_2_FN'YX%6;%BV'IAY?A'L/:#)6W288^M #PL3CUT!\V?N.=C-G%'U,1
M&58UEXJ25?^RU"PR5+BFJFW^]NS2)LR=VX/B#]J$1>*K?G>DWO?0(/2/&DD
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MRNH7-$?H,Q 55&%!5*3JY[N&=+\?Z[95C[8'&[C:[+VK\CCDNDJF"D=^:_)
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MI,MS0W;J-'+155!+;8(ZT5T+&=75=:MYAY+40"68D)DQ)<"&I4H(F.@_JBY
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M/-U*QHBUCBT,:/L=2+Q]"V_>*.^XPGO<&Z1SZM"!=W:[B7P)84X4HIX=P.M
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MBQUK.7G[0)Z?GLX3[]-E3H\($_J7EE:X\A943ZZ<#U]"G/ER"\16V[?XD%E
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M+X1Y4[%W.%;%N2[M95477":]'>#:77M:GIBW@/8F(,D<90#&_L%[10Q[:RP
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M_#A?FNO"$FE([:F/;FQJIN:J^5RKE[:Z>*2/<$;E8^NX5E;2\KMS/T?)9&^
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MV2E.7KP*8>BP5GHQ+3+=1'EN/*N\^$6XDOJ^R7U?OM\U?%Z^>>&_5SF2S@B
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M(\/_Q;;4]-R.BHB)G%7Z)FOT[-Y(Q#OQ]R-O7DJGV/^__B@<X"&+!)-&"41
MLRLN@AI%<J1*V PE_"GN]0$RAHHP?:1<#:>PF]73<;++5ODJPNT:ZH4<NX E
M/.,2<Y)=D!#O[9E>M05*CJ&GBXK)_819.70\VOR)VS-S,7<#WG O^CVZQX<
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M^5W40RID]REMXJR9,_F_1H.&:Z()/T>/G?-B9EP9E8!WHP,H9#C[&:\:98K
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MX*!%+Z'H*ST*TIKN(HU</\"R."G D%X(R+]EJ@*UQ5<X9/74LOX!#R#C;*2
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M)"/AFZ[ADJQA<]GI&-;QY;Y7G9T-DS>_3T4HOJ^F4,A!VD71^S0"2_1&!A^
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M\]C'8')FO0<L9?P7H@#\FW#S2RK-+.T8-[BA&MMN$$_)I_Q-;1M!I;6"#_^
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M'DJ'Y"T[ZSCQ>_A$M?&"V<#"]=B916,!I8NO'E0DOY4^Q $3F3O)M;PL7%F
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M>\;ZW$PO?>F_>APF!Q!=:+P;)A>- BEJ[Z<V [*$(O3L$DPNCXU<+@KQI<<
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M]!]MM#Q3QX "ZN3"A8P$]LD,(5@%X-N38^H01GD]C.IK?#)'M(_B/O%UN.5
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M8@ MTQXL<*B<(A+*$2TE/R$Z@ ,)OM_+,-Y"1.YQS<V;8196M\.1AHA-UXG
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M<X=F)M<5(OJB9@[[65O%VE,FY(_8!99E7K!2RUNJ!/.P/^^"ZBH7V6-F64#
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MV:*#]P>%J-30K]S#WV,*]S+&N35F<]!?<N%R$6-?ALF.6QLMU9G+(6.)^26
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M,0:W]9XJMG\\9[=SP[SB#/R0VIONK]\J/V.6\A8/LUX>KYV[;Z',@"&'P-+
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M-"3./'2Q%'Q[!/3[I> ]OD2+4R1OBS45N<]5O^=/AY_J;G[7;.=[S%%WU+C
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MUE+ K]A]&"6+T+?K\/J6/LK5;NIILN%C XLUE%#U2#^QE_ , 'F=_U;:DO<
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M8S0RBF[02W][UWU\\P&?Z[']22SY[SJ#L?J@QOIJ8'6XB7QG!=,,O(%\5+F
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M[8VY<"_^,N[IEQBCW]LW?]&W^_^!%8PW]-,@H9_^:;D8,GG(ZF.LC$+0QZ
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M^[/C2YCF8\]R57_C8X7/E^Y;VEP'=497OU%$G=.*S>@5O018*$F\4P<LWZ[
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M)RDDEM0,HYN=:ZG"&<+LG#"7H=3>(>U1 9WI KT!L'I'I-.U29<[A_#1U^Y
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M3??$1XFUOH-[-V#"\$A2*ER8$(P -4)ZUJ7 7[T+$* @W5+.(IM _^8Q3EO
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M! .I^_KD1Z8VQE?B)$<B+F,34+GJ/>V.4FV54@82I?']=/T!; I!F!!2"VI
M:9/TVAYB;7HG'PI.#F?!P=(781*?';B07?EEL<_")&WBM7US5' TV0"WO%')
M/+YGFG?Y_D0 !1R18*!E<6<9+V&NX0!/JG$178.\E:.1Q9%<N>&/8ZE)^H[*
M/1(<J>^.5Z]9=;7+MXZ,4HG\F^_UN"^,/,B2F61$L4LL15@6( FPZRHVI:OC
M^TCR"R"B][A2:E&0T:DWC=Z%E+6(8II3]9%J*8-W*F<SZTCA0PIP :8.9YP$
MV$?(>8+)S,L\W!^2>IFE3N%-^0Y'#7T#];*&YHOL Y8=HZX_6@\ZATMX%O0
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M#?CBH")_)V,SZRN874-E4E3,-4D#34'X1O/]AE1([(?Q&-GO'%ZZ*MSD]V/
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M.W"4%1>SBJ"#KER3"X.B<J&=QQT3&IAKI3JGZ8>\2S6$ZZ[JZ3_HYLY@.#[
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MON?H?(\CKDR N(7!W<<* <<A[W.SVQ\>6NH8+U14U+@+_=2-!F1$"^729-\
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M$8O#*6A9T@^MLC1AS"SX,G4GD-49 3OS/A]F;+O%\Z7GRWL8/8787CTT@M/
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MPL"7*M"/NT'"[0O6#%Q5#F?=%47YV8.M"U,C&HA/*1KZ_LZ.+Y,3SR30!#<
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M)^O56.>;\/:7@OS,A/(_3@O8L+P@7#V70[4+@CAQ:MV6;$J..LQJ7V='V5?
M#&9.1\-TEO>GA>-YUN',DT\402EG+.@>;(8E,0ZNBLG.].4OSJL<G# ?I4A)
MHB!]</11[>F6$\V[J14\$>;7&9RF!901>D_F=HUQ)8LK>4MH_YLK66M,Y;R'
MEV-3SG#^#4!JN((5Y?1-QV'W!O <1O0W#].-GV:QK)%$0 Y0F9>$VL(\/Y))
M!HV9%@=#OKN^R7DG(K$*B2O&SO0B(IB7[X[K=1[J9%']JFOO(4]8KKX07XP/
MJ%.8V36,;V/!!: $PB\,([T"%.UUK)OWSQ-)7G454)Z UC(VVSBN1T&4.#T$
M5SA0R;Z0[/8<7YB4:(A\E_R0+,H)&;U>M+]O^YH +?)M<=[5GS/XU[2#::6(
M7G[]>V567;V9;'_D_X8-@]M*,3 )^S4)FJ4=%F1+3%CONIS-6X]RQ0["-INK
M]!K3)8JS:%P(<LEE'KQ";?PT-?E!7P[C+R/-@OJAF@!7GK9J1 [>6+$]6,GY
MD-A)3_U[SQH-E85#17.8([I(8TW^&FMHRY7B-QLK(ZP?SJ.U''/=SE"<9?Q5
M,\-?:OOOU-#*\/F?/"7T?X<P1Y&83),>8<MP&(+CJJ -Y*!4O=*5>0-@W$-L
M2@9M#NFH$FHM!(.,TA::.7\R6'2Y9]4B5VHB.D:I\,X8FWFNJ).Q0-?" 1=)
M?+7)0"P9#QP)^1U/K0(U:@17]OZN/55B"!+%&V%E^R2X+*$EW3/:@=\L0/UY
M"2 SNJWU</[]@MR[%]G:_DJ=\.#*>EH+IU>!!;K.DD]4]6@09?#[IW#*ZUY#
M+FJ8/MS3%]K4ER*^)(//+V*X/'@,0??=U0D"?<:I8%X[CPT 01&)9E+?DLY?
M-HX6O@0C(3_K6Q\.23]/'N5IR\- .DVUQ5EO %[-53OF$6$P7NIT"'NY4WN8
MC\&9,B- ))MQR_@+>O:/PMD:SKH2T:F@PX83.+K4PAJ&5J;N"M?,F<A;+#^E
MUU\]#JFJNAY &%VEK_2L8.)6=BP>8]MR4/\ZR*VG OFJ#+;A3M-)*3"^Y5'/
MZ3@_Z(L&' >#YX)ZDWH'>$03OW<8L)'LBB1C\S(['Z<D1/-.GE30=$WW:@"U
M^/<!,MV$/#QP:8]BV3Z+1]4TFN?;O\\9V6<WTWI^^53UO7YM99,D YTS9[W]
M[^/R*J!6H;X4@*X*T]NWN-%>$\'W7K)3>.6O:L4[0Z)N?C\(>PH3.WGN?^5/
M3W\/( 1S=69S3%>@&ENPYDOA%16U4P-U#=4U=!1:LNX;"Z5*#PGTM>C]G"_(
M*_(7S6!/L%Y-K6T5!6 0H#Y4Q=[E%H\C=1'C/M_G?BBAXH<W$H%]WRO12=]+
MM36,6#PSVL;>-9!X$.$,N2KQP)HVU=M,^+*)9<Y:$[!Y5Z+%73.N-\Z%L"K4
M8; =QP>_MS:U30F;&N\4C'6JF$R[ED6;ZUNT!;O)>5I&9A$/0S/G6CE.9$XV
MSI*22RES9S[C]I 5;540P8-P]QU+AFRW:P[Y@OVJAS5I7?Q--P"9)9?CR<.N
M=R41*<AZZX3I&MUO/ ,,5]D7G.\R)^9:55Q@$M@U)TWNQ,D!#L9W%8T><JOG
M3!L@X$2+OD!TTYW70#>;\GJR1-'2.;*3T]/*M-71D(,:=U;OM[=%>I' @H<#
MF.."N*]?( =%%6D!)WHK:<67=5[69>/=&IH9,Z4GUUGR23+.TRTNX]^]H(-/
MWT_OFY>=MG#X3&(+=508#2OM_LE#$[ \Q-P !K+6$G?;>D)&\-*EW98C:CDG
MQ![3$S!=YI;:E)U>:9IS$E!DM,Y; BS%'RFQ'[?/S]]E@_%:!7I^-9W;\S$D
MV$?Y7*WO=I.\>KR6-ZJ3MES31@L>@SW%N8#210NU&2U%RJP^^8?,AKR@>8$E
MB?.2()L7ZZW^-K]3]>- UYW;P&J_56=5I!^H>VD-55#SB=&L;Y[>8/LS2?I.
M*<;S!A _TY']"%MC0A-Y&B &MKB>;:EN2B)ZK+U5LV#T?FX ?6BF<MXSH"%2
MLK.KR-?@G--O6*)#P6'>G/E5O&2QJ01=6KGD:J[PO*KF]5BQA AU4*[76:7/
MUEDI+L3O'A216_L,3S>O^@1OK(&(W,(>1D*D,L]"X3Y,I/<+G)J*!I;$"[RV
ME@UN .S;;[B;6 83O@7=@[EA$='7/24K>Y+2DF8B='<<V>1&O0'G"(,IWFJ,
M8.=K%%A$7<Q[P/IXH^TYA6AY+EITR12+"&WA %?N6O"HC!\6Q*/=PUMN/U^_
M,&R'N37B)I YH>]FNCVA%I=/4J>LCT\VDC@^A]#* J!R_7?!Q_CE+UN?>QF_
M">'OSU1/%6P_@'WOJA>R#,I^<2&!'$5;E2TYG/6]'G=QI1Y+#:VQ+P$5G""L
M,.=]A]1@!8-U[>)!^%;N<L[GK1/$$ TI_CE6/,:>ON>K7W\N+#G7W2(+>0-(
M2."XO]OTBK=E.B[D!@#+P2(:LSDE;&!KP4JOO);>]1E%#%<UA^^"-@6I$A!%
MVNX"_:,(35S 3SC3R=53]8VQVA"JWSL4\M&Z.%^\B-):&KH4M4*Z:\(5@@>E
M^CZ^6BM/8S%\$/&P4T-?NU7VX9;B$TO_C8N6+XWO/*:_."B/!/ F3->27!7<
M ,!H;::@B0*C)2I%TLM2:X>%8NL;@+G G\ NPVW#<.>PUF])#]0143> =Y:4
M.\NL6,,XKP+Y*9EF1VY9]DC6UQSA5JQW(P-[XOWZ3Q!-^S_C;Q&-9_-?#F;,
M"Z$Z1/X;:^_UUE2TM?'&@J@TI4I7BB@!E-Y!5$! 0+K42"^A]XZ @%(%!)3>
MBX%$2N@0.M)[ J$3>DTH(4" XW[./W#.M_?%NEP7ZYESO//WSN<=8[5/!?35
MG7^$JRAM V./2?Z_#VWY__? (N27"MD$HCI;A0EJ/K:0=NL*.Q2#45+/Q[-H
M8<J>MMN'6JU-[V AER7R=M8$'NSYA=;8IQ@35"*QTI;&+W+N4VK26YU,<DNV
M0H-U]@09+Z\+3=]&=67#Q,>XI%FR ,.*O:Q!R8ORM7>* +>VI6PA<&?ORE+^
MUHL,4TJB+*.I>DXY@B18U$Z>*?")+63+YWZ=.C5\J "BA&N5<P0"5#<D)&"O
M89TO[A$@I@2=\FUZ<2A:,XN)&Y\'N:=&Q_CWF^XA8/_NS=9\@O2%EF_:\G"B
MS^\M%$/C:3@+XVUT4<I@E4)RA 2YQMRYYVTOJ*\--*O 2-P4=19BED7!_46[
M*;PN\=Q03]1)E959K0E1S_7&B4:5L/-9&"1#%+VL.N8/]H+CGD>I)KT;_#[_
MNLI/ASST,-(D<Z/$3,J@TOY*$%O7M2=V#7@_(1H3@.-3IQWKN 9(W0&]&<6D
MGSS'V*UP7I0).'_;/-AT[_^RA0BR\V/=Z.$'ZS;;Y_WL9%O1%['(I>R,1\0%
M,'0B:!'1-4]$YN;>SK)6QLU9L6^<&0PC6TDF7604O(HW#WM+?YIBK,EOY>FC
M9Z/,$U'GJ#%YRL#'5Q2C)#6']YP+783^G8F4+P%X=F3S>V@Q;Y'-MME\@,E^
M=\^/3S]\I-*?Y;>6'_Z_HRV4/OU6D;B5I![8NX+X5DW(Z#)(4@A :$0;Q#]*
MO#*-=F5FNPQA.JK\.?UI)3-E5LKN0XK-WNBY=_1*,+49".1K,-1LXWGT+B('
M.D@U(<D>X3V%4LJOT!"EA@_:LJE(X/_A6NWC_XK(*/AI;QC9':5W3XFL-2KI
M,T)#TT1O?]_?,?/R9UDK]O.Z!G0V&4,2!/,91XJ<[;+IHM0!?)\L_Q.HKDI0
M=9\--;-HWP8)&BU,<GPF,8N7T<'$WD]1 B(+%!08:SDJ]*=$,O@]WC=.P,D^
MNC@*Y-O9UF;=ZN5]V0E\OA1&I5JGNP\' ^5/4%I*063D5WI3SU^G-V=]5Q)*
MKM$;U(Q*:RR\8A=K7/57;X59RJ1.&&\>ID5*3(TD'F9_^-E<^\S?&1-KH&FF
M3A43*+O\(H:IR=@>2-+:9)&&COI*'Y*X;PXD=ZVQS3N,?T.9]TZ6Q+,"%]"Q
M/7TUEG!UH7G%V\"=T*&LK!>T\=[5]QO_XRM,#12T0E\&^[A9V;YL)S*+>&"J
M2>O:_ON]]@N>0069# 7R"TZ^666=:&M$-Q6ER9][I=W)5^B<5?"OT1<U[,R!
M^I/PG0KJ[0$M['AM8K%#755*]+9DDJ2-K^7FG:4R1!E:677\4;.L9EA^B(BM
MC*Q=X ?PJC]E>*Y]*\,X?TT%1\^B^H13FI58;>67>,$D5UK/U9SA&J!X%],)
M(JI9NFQ'^$XZN@-IW$#/0F\=1_9 %@L<0=@LHFE>7Y;(/>K$A% :@NS/'>MT
MC.YZD>BE>5K=#-96DCR!5M^:C)Y@DDJ*3J-M*^&2F\KQLN#6Z7826L^W"X)$
M0AG?P3FC6K&Q#!J&!;>GLH0[7TY?3MYL3*VCA;A$'R&IM!N^\CMU?0((&F",
M')2C?[C^6UNUQ ?3-5J*7M3_*]J@.ZKK/4!W:A+\)S:#&5]N9S\&I1I>'=.7
M3%R6X#>ESPV8+[2#I^YT0XGL2[.(X]"?L)-WQOMX027EX&[$C1T0F2^DIW(S
M(/]K3);B&;KWB>PL$3B6%XEH$;;KA$BSLP6^:Y@\*$8&JOQ6]PL2'-YB]HS;
MI/6^=4BWP;31L\@,9@KJ238OG[<[Y\-8U2+='Z'UCKU9$O?&ZV>*ZZ<$TM>W
M]=-MMH>(47"3.OA6M[_ 0^_&:>3?$LOBKPP-/&6B910P#=XN^GD)R)CQ17"*
M)5#194\_:1%=H>RR=Z[W)6JMD%0+J]$Y@@OV7W]K8DG\CY[4<6],7S'8XWF[
MWR<9]X:>D+(7^2[N;I1<0GH>N'U'W3J+/D;,-F+?+;!-' ("X%P!O#27BL%Z
M7R^O@M/L>[&H8[GTG(90E[XK>>S&D+\>=/8C81>HZ!0$"5 <7P'[8F]@QNLP
MH]J*%P6'L$GGP/;VFCORO]S+I82PBJ[!S+@ ==S]@R[_YB2S 8<U2QHQX[OW
M>X0"R W@#MFL'RM6 YWTM+LP?]:;P]^/502:.M3Q.T![[+E3K4@^IC[F\F-]
M_3L\05_4-25'W+)GL&S@09X2Y1#B[WD47GZ2&UZ-P-UF"(6KJ^*@ @^-U^/\
M[I93.5J=>X "?95[D%>/PR0*9TGV!6M<H4$M5/!@/8+^^FF'SZC95C4\:Q#D
ME9S']L6';>HDK4,^5FQ!6+<VPRFUX<& 0B9?;@AUB!:Z^7QR+N/7HD98@<;+
MA#>[B4\.D(6&P!AL0BR#?@3_/HB!,\(]^+3R]!1:9@63+*ZYN>GOI6O(:YWT
M_5MI,42G['\W9DN1\Z4>7Q?@CHILZ0WP!@)-BJ_'CG2DMF*)- -N*V*Q'3DV
MZNOW3,PIQP8>^+5API,_LL/3]LS=L F[Z9J1%L;S2EOBS/587(_KN]?SM$M6
MR6B$;+-UA7R7DZHF]4 %^@W,1(T+-53BEVVN;-KED4DM%& ;?3;H; XI4IQM
MN@:\.*K<^M 9U'#9S?[ @>FR)#K=Z6-K TLW-.G"( X3*>IX8K9Z*^F.\9:A
M?V\4_PF%F*GMFZ9T8\  ]WQVAKV(PV[NS;R^3Z^>*/0MV=)-^1JH3S0K+)]Y
MSM1DZ!09)PB^@,><*DL,&VJI\"=YC%)*C]N+=W9*I>1OIZ?AX9DTS:GIWC'R
M T^TOK2S=S1C!8=58%EZDJ"F1F((+"5!,_5BUV9+<+.5>U2QMMJIT&[(Y5YJ
MQS:NT&]U->$E]. OM4=\ULZ='B>#941TQ.JAJ6_R!SW]:GT_ZJG0BR^?E99C
M:89)?%JYL'RUR2$=>@5VR<8.[B\RN,0-W#2Y*__R<[EMN YKO'&7]M 7 5$;
M^Z(ZJ^V9]HL@.VFPH]OC;U]!/X9 YE,!Y!MGVGHBC<@77I<AV7D#BTI@.W1Q
M6E C,.B-II-6H4%&YR%8^'7Q:R$C!@")>9(KI;S1@0@[LZD]&<EZSHJD &SY
M[':J_^_+_#LZ-46# CDO26^\8Y3U6&C6ONA(1W4T#42-5W#7Q66>24T-/I;)
M9/_9!/3SO6U%3F.J2>098JT,.S(>[_W&^(]5U2(?TKBPNUH1Q_](/FW8H(5'
M(I#KE4%<0138$HS/MT#2%6"HCY.MG_OXR_I0ER<*,D^PC&0/AI=:5;,*4S&B
MQYI?$ X55&;I#T.LT%;4[RS%*=R8^?BDRC.)A?X&G6H5=LK:U? <T'A^O9UY
MTGGOQXE.KF&562$Q=Q9+DD97DG<+7-BK(KJK_-;'8[EU.ARRW3U?LOVA>_59
MMQ[T-<6&?K_CNV/ZR-&&DXJV;$!CMB*$AO>'_63PX>2E[ 11K]!AXI'C"7/
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M%Q4C_V?Y,._3^9=.8+8WU0'[EID;N8M('%>LF9*DC6629H6L_H9!<]+Z<LP
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MNG5.%>HLTK"41-^8OJ[Y=&7O6]S=;:J&QP(!MBW>C<SJ&(RO>65MS=3G%/J
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M]ZVRN&,CW(:<RA<?ZPQY-'JX,D(4G.O$C0 V>?<2571,@BNM5L49H1VK24)
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M,A\X/W520POMCZW;K]FK-O7$Z'YF@\+'5!FRQ[%"_6S'1+=Q45^3?11\ZD!
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MKF<Y;4#6IOM1B3UTHGM9\;L*+D?W]3&+F*AGJRG/5C//PBY<YX !_T'_[P>
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MQB=@L?N2^J;/;%NJ27I<91^B":;R/$X3T?U4P"'[YTB*C(.;!.9N<3"Y"BX
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M>S8,@9:*"\H5GRE^@>:<1'_A75G _'C'*-D"$;G)I@$NB!/NKCW*5009 ]%
M+?RHIA(7K_.-ZT]'A[5]1R8\"=V;X!!GZ#%Y-[FPK/[9-S#)<)**@7S0NP/?
MGCK?F,QU_C_,O6=4DT';-1I%146(*!TA*B J B)-:5$4 1&PTB$B4D*D*25
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M'>DN;U]?G3I!%EF3G[M])O%>3LI K.#9[4-/W;B;B9"PK1K,N+@)M@]#?^6
MK8S4%YN9><]=6'(2,R7WMVZXQ9VX(0=Z^[J=80+/(+N-CY<,Q17377D/8ZIU
M;5:DO-Q;#7ZU-P0>M?(E?OO=1EM264'D4D)IO'TZHO10\GCFSB)RRD/<8A_@
M/+I8E*B:*=,A> 6^ZX? W[+D"-QR2(+/*H=W@V)QEQ0X$:E7$VVA4O.29CNN
MQ__W08?LCCD@6)!V^*+5PMZ@]7B#$2UIC H\S.XFL(7HL]3 =M/"T0[':3>=
MB3]#G0+K54HY-C\6]+6_T0492E 0,/@0_#5I/>X*!BU2E: ]V-2AC:.'&BGC
MGJC?CF@-#)-_L6Q<!*F>*HZ:<^Y"8DQ7(F!4YR>4ZLAZ1;\".+(E^ S638?(
MJ_O;_:4L5BLR6ZK?X[K45R@*"'8&B2%4Z<[D93=E"&4%<E*U94,>"Y.X:'6K
MH 5^3G=C)HB434?G4DU:S:L+_^0$G=P=+T:T4^9I-VKHYZ85CR^S#U&Y4_8!
MIVC]3%N/;Y77AW8<<7W@NHN^SX%?N4M>0/'EOE@'AB2]>JH?'OX;*P][$DC?
M/ALWTU;R^LRHP7+F7?UIB&5?_U[GW;6)VF!Q;JUJ'2BU?:6.S/"(M/)(8(O0
M)X#'X(5;@4'"%O$;H]U87+S 4T,UFCTF6+>L7IC!!VFF[$RKA]4[3H-6%X//
MCC<'LM G]!RC71K/Z]NA$*%OAY_C, =3$XJ?W./P2J-G\\Y_\4?!CGBQ!:0
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M;?1%6TE]<K=K'*X>"B5:";3M ] H08*;2@0;1)^-](<*_,H1R?QEYH6=B2U
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MZ>K08114BQ>)B^(2W0BCWJ3N*;3F<*?;5T?I^+^\O70G-_G>4VB*P-66?OA
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MHJ;LENZJL"H;4N=?8W);]P2MWK$G9X\'0"07D4(-(RRNC_!&MR 5%49T=(#
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MA\Z%CE.]_DW+>F--[U)L*^/'U5[QE[";B?)T"?*#W"(D2?I8_5!E<.6T-.2
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MM,W.1]V==9-IOK?PHVK!L=RD47&78N_"A<.Z.DKMGD2/2#%<^V !4"%X\,T
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M=OD0(/]5=Y15[NR_[">@V9(]-=@)B&8)F6?> R6:0OXJSO-1.XFH/T4N&S-
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MT!S5);/(V+8;<%W<S&PV.SSE\9#ZD.>%,4DS(9$AM@&D&=8:(4R2VFA>-&!
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M5YL?;R>S)P9-&*/]8J/[CG/1.'9B[V91'CR&8):J4$0<@3(QN#'#-A?P/1.
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MB041]+>QE(?*-GDC8C%?D4Y3IX9CVL_Z1VS)C:Z+A) BB6PDD4RZO^Y &*T
M!8).ZWA+^CNKG_;/N!%GM;'K&T%B8:2)B"SQXP^G[&BY!H:J4M4D:0EH:V1M
M3>4FW]TY!S-]V,=(#T4Z?WF3(+/B!R6ZV<7)^WCM>75":K@B\@$;')0+:#8:
M17#[K#MDJ5B1@3XS#YSY('A-S:6"N-T%980WZ1EYVP0:C#.G_:S/G\!96R4W
M1^PPG]>6)Q9T!X%QVZ>'U.Q9%73, K\Y #T!72AK37^3NC'CIM#SI/<3..US
M^',_^P2\X/B2+=-0!4*3"#DHKP?T<M<LD>F*;^7^ENU-$>!;F8]I,RR&P.]?
MJG[TF?$TV;?0\1)QF1TU/V*8SB]'9@*!!.U@RM-23.Z?A=O#/FJ/^+=K:UOC
MEKC7OZL29EHJ%G]OYBUBHB;!K'''U$^?G\*U30*-?.374AMK&8OK-89YIJ3&
MHG<P(4B)XW?[V]QP%CVB^9N<>I*K2XQ,TY-^M<RW@SC/&])9G]/Z?E2PC2*9
M9];19R&NF0;,@+/"Q!62^$&=]$Q[%&VIL89B<O8&4WAH//[=J[U]8STW=%E8
MDBMFQ+\E"-<?9*XQ^F*BE(">%(+5S/J^HVO6U-L83L"?\2?4^G/U8&9B#(CH
MSL!6%]S*%QR6RR51]XR"[%K4Y0N"'C=S);)N3QMM[U5DMK"0P-K ,5D'.; +
M5Q!K!A"LN/7."KWK.3UIXA/(AW$?(A<6I$/6Q'I*$0RY%JAV18H!_H+<VQ3H
M&.+906 F1DQ6AS$@>%HP8%/ <U0XH_"9/8]V=I#<OL>>QI,1Y]^K=44DS/<V
MOHPU#)3T,BYGS5=:X_K^IX$U,:L/H%O,!@C2N@W383Q")1]N#4_>MOI6/\3X
MW*A(YU7HW)<_[;NA3 CI+Q0P,;L;.IM):$%*#$GL-P<:,$S)5\UK/17RJ]=T
MM)T-YA><FXQQ4C#6(=^@#AY%1M<<ZSX%;+["JTV@EZ?O)URYQ)!NY76-^;&S
MAN?VMO&W;ZFE9.2MHZ". ]@^1!^A1$K_OG![W+5FGJT[0[^LT/;^).?!A!],
MZ ?O;R\0R[VPC(WUW<#%B2)BO?4I&8Z!VY)QZLE-+X.IW"UL/YA*K&;G]&E>
MX+5H@IOO"85J(A,G)0(>I>A 38,>_Q8T^[\2SV\Z0+91(D<"W-!8S/]&)R]&
MVJ;25YR 1*!?3T!3,N03D&;T\9OBTT<7)@'SE4X.4CB[$53N]27;_Y-$?D\J
M\ 0D*'L"FE2@FE+VG"$[EUM/V7H4:D\6"NO,WCE</LJ*8-L$%X*)NNB_5WBW
MCV/_2=1]O[YQ$3@!4>G]3D#"=#8GH,K0?W5+#8_^2QD]/J@HZK<"8O5JUD0K
MQ+MNK@L5=C2+'@B;^(XD<[Q^:*B2$G*7>6[J2N65'?]UW14(6#; )Y\4FPQ:
M_TAZU&!WX6KD<V9-D*A$K,/FULT.+:/@7W03Q;U%3P?\/)W3T[9]W-D'+O[,
MP]-]>?8QECQR^H6.OT3&@E7KG*AP\MRCO&$#K1>#=]7SWW/Z29]SOZ/F7^"N
MZI 2_RY: W2O;T-;KAD&ROO0(/[P4*[X5\Z9MV!+O?YF]^5_5:<N<@(QFG]I
MS^N_W2D-L304?7F1_CD[<^['BR##AXN"HG/^2DJY8$6AI+6;LTYGI/5_3\H9
MBXE=ICDO5$AWYS.=N]*@?T[*74N.U.K:U,KV]D'1,W.'2N6.>//.>2%\;W M
MAFZ]PRMGG7-EXH^53I7>F["=.F:6LTW.AC6CL/DS"8LG( 8+@*\C !(I5WEE
MU+O$8F/S#::14F-8TG!XAR9CVCI^[WF)0M'+IM I^3D&Q/ 'S<I$^HLTH;->
M'QU;>>M?2;R,S7#,R'RR;2W]7242\BB%/5AI/R^_)KJ4_1MCP%E_^?-?BBQA
M"ODK1VM\*CY7'U?WL=X3 3D<98"J=0=D!]\ZRDCU3Z[P/\G6?P<R'M8$L9M:
ME1D/]@0ZN;M_J<]8IC0(I=TM$[._8QCP,< T/,EA<((I+"SLHR%-X=>,*O$/
M,^UU'_GY\<$"_P_FC6Q 2)O_D3>BB3P#0_U;WL@0RY[+O_)&0O\M;T3;>#/O
M:YOX;D?UEJIBSH*-_$!/0L&<=66_GGRN^])1FI#\%_W96'[#LVZTOJDV[V?K
M:;A78P-, ]4D>_4B'KINN+E=35QYN+EH,;[;^POTFU1BI2=J"0H=^3G3,>U6
MYO:EKL[P;BCWN!!HG^]NSRT&%,NJ63X;<ZH]??BO).Y-H\>N 56+KX*ZH:9[
M[,5Y1?,A60L"(^"K-7%JU2(?_2RUO$0.,>! ;)EE1L?,&IXO:O-+!I[Q_<MD
M><<8-=]D&72XQ6Q=M.3W$H649S[^ DL'G-4+VH>2PB&\FGN=K$EF?^U3=*,M
M[YHT#'NOET0V9.M79^$?2*N.S.:H7.6^91&;%#\FF5#0>[TF:?6@Z'KQ1KU/
MB,;]UMN18-$##C\W"95OHC\^KZ9(C/S(G^ZK?R#?4=O$*BW 0-IEW39T$>0>
MK2WAF_6WXQR9MZS-M+4\P_'+\UO/Y;LR#6MJ%SC*,'G<7S=8DD2.0Z14-;P\
M\N'5^)Y&O =MIY_ Z)_=F:Z4^0VWOI2Y,XW?U6OW4R>2[%$N F7C<;7CI?#I
M<\22KXMV=JP]M);=$C#EZB)WQTI]?:M4=[EFOG[YZH:JNJP!S[J%AZ8YW*OA
M0OPFV08UR6M\!34AY5^,D_2';\+']B].]0EVE&[*-;O(:%71&9?2W.2^U7EE
MDI6D@=/Z1*+#06):6%]*[%U0O?=,_ETZ9]K/LSSL1:]S^!+DYXWT93S]-*;P
MR,L4J6_ TT4P(]Q?->[^KN8H8;2G<&(MY6%APV! [-'+IMGC6_UF<4)M5?6M
M<<S+5N_3[A:,.7B:U8T,+2UM=1QKB8M67@@5C7''B(O.UN=+KYJ6RMFHZ#SE
M[#6HK7J*FF" FZF=&BRS\[(HQS51#=RQ)':C0T)F4*JJ6I5/8LA?' LO -]4
MZROA;'J1EY!]X/)0HFO#(?UGE/DO^_%,FN0@O:=?/TVQ[QUSZ8]8:E5^JZV"
M,5O/=E2F'2UZ&=O #M(W&:QG.E\/H3^P9MQ>41#@>7U''5^*3V<_\TB-RR!>
M)=>*X8ENE27.C./L\X!T[K]H7K-AN56)S<\N#&:AXZF+L1UYSY\-?>[]J>UJ
M.B/:?/9C@$+VA69Z>]=08HI7'8>@OQ ="JQX;C^_+C*_M:RU!'90YN;>_N5-
M1]XUH2^F/6<$QP-.C;/ /P=V%-XE.V\Q:XVA_V6L=[%9A)P;#[F(.'KQ:7R.
MR\3RGL08ST[^J5$GJ/E6\H##+?J6'#,LY<_6MF7"7+P\/6E+;\]97WJ9=J>C
MY0WCV2[&CX%COLJ2G_('Q"=\.>NJ=:E5#Z\^<3Q*5"JI,:0-W%0>??)&P]^%
M:>Y>V-O?L<I; LP7UFYZN+K5BOG6-]='KYTG#S\.&3N^AR_XFLAA/U+ZI9)\
M^>EL7I;"\:?G1H(L;@T]8@-("(7N&S!--+ !_-R\P!&;\M+<;#.S-RWJ^BHZ
M&)E]J;5K[TRU]"5TW",#G>T W?8#=;;AO5F+SR%;FZZXZL#Q<#.=-TXE:4)9
MOGL#,*C3 6]NDMIR7.ULAQ>?P<5&C35Z?B3'ZVASOX;H2<L7G_8F=N9F[GE*
M-'N$+\<]S?$P%3X]%.16%22\U-JKZA6Y+@AE0&_Z]>5\K>QY>"#O'@TJ*8#Y
M6JJADYXYTK[CD5BVZJHL-S )ELYXD1]38&&CZ^7RS,7-4^KHQY=P4^S:W1\E
M-4:O+HI^3?QO58IF_ZO^ @CQ_]\E !7_62IJ  B?@"C!R!NGT<Q  C7L>M"*
MXPGH6N\J>$#PD\?B<>_"NX:\V7^I1-_G?7TG 3)O'=WT>?A L2[M\%M8DL O
MW6N__WP?FY@@/;V?.-LIT")]W(>[&XV^>X?C6I$:+9]!ONBI57UX ?.1&&^-
M*VL=PZZ+1-/J@(]7:&Z$CY2:&RKVVSO7=_MF5IZ-\EQ%\_023IUY]"Q#((.5
MTHWDA0D&_QMN.RU&Q1_XR+_N_DUH+*'96]6M2TOD<)7+%!#[16:**TM*7-%P
M.]O;0MZDD<-L",C^TZ^)^JN*#/GPVQ_R4B_+\?" P-=Z-+Y84[/UO2PH;]KY
M6ZGYA._D<-%<D=?%OC/[9T)*;A4GO1WGL&>HN59XD6M40%HWVO#F&1.#X0VY
M_,2I*<NIFH_-5G=/W?R?(0#MO8IJ!M1&,[CZ;YM?RH'#](JCRND0U=@R:)ZA
MU1V> M]S)I;MGG(R_>=>]]-+L,>'9,AHT1L'7+Z#3][JP1K5NP0VP]TW9[<U
M/+F](89:MX)J:H*C)R88^+Q#9RYL+MX+CV:_4+)'$_*X;7137A=U[6""H4^&
MK[\ARL$Z/O*<3PG[9T/:\T1J^C5K(9COX_2K#];<1B^'#-WI'8B?+LI\5)6L
M:QXHYA<(!0Y?1NE$QB(^(EH"3%L;!,=,FL_FG<+M@HW$>'=XZ>&M/$[8,[-7
M!86,6IZ;QM/3LZL'P[,S5MTN'MP=&A?/:0H&,],^IE5A/Z,_J_6MNB5CAX'!
M0G*%.PTO:NJ .GS/F"%9HZ=PM*92\DE]9&4%TB@W)*9\S!T;W:S)96?>5ED[
M+C&S<###U\>]U'WZIL*!K-'EIVC[R=%L9"-Z,(;]^VS!-BMRK9X_9(IW>%97
M<XI]JR:08?WAIKNK6[F$?4_?B_"G7 *W<^V>OU\ C\RH%,X^KI:>M]^\X#;*
M9I]/2L@4W$>FNW'9&=<.>Y-5<KP\GKG0]HMJR+TJ;C0:<J>Y<U!4YCVK>U-2
MN+XV@EZ2#X'A?_:X;*V+V6"B=%CS>U[!GR;DNYW6U/"RS)]>0E8=A=#UD $=
M5/Z,<QU5<[-4,7&+:7E.2^"U,C_KZ0_N<F3KU20?B4W6AE=<,TZ:D[/KBPX(
MGNJC&XD)4A@<U(V2V+P2JIN&5='F-A$+J*1945\I'7%X+3MP1?89<3#!8YF[
MIH0[UMA_>*/NWFF4U';[C@>R5BY ,OOR?+'%[+6%RY-7GQG]9AM#@Q6\%LJ'
M]3<N&O_)\)X)L-!YYG(].IAS_(O)I=['DM*Z"G$%<U-Y[R841J;S%69;;ME;
M>W<DA40WGJZY*7IDH];"3&Q6); OM?Z6]8/RS_%OSBJ/S*S6^<I@)&IS.7<&
M-1Z1M(H=KMAQ7GGMN6[FE$O+I\:B-^HNW% SNNGFF++=SW@Q%FM\7D\7EC\#
MVU2QG.ET'45_N!EQ.T*+NFOW.FC@% &_%]B?(HS58]=2MS+&7N^("Z:*V6;?
M?Y,*3T X@1%T]4#"P8OLJ9B_$;,;J\M;@WYN/;)97I;L1KZT%GO-HNXK3?&#
M\Y+YALF_*D7]V;T9IW[0++1@".;?PX$<G(N K ;IQI=%E0%U+T\WSZ_A%N^S
M6Y([M*;9]]NW;<LTGSC@MR(R+;/5$ S'R>DXORX&M""0V3V9=8>$2(-,UTV:
M<Y)F-1S=FCT??M4_;V"R%>3RQU*T0#FY</L&4Z-SQ_^57K.5\O_U?RKY;^S_
MM$]'I??Z3U01*G@ZLB1J*?A_2C@K%28Q*]G;M4'ZEM@N1R422\\$A G!4 %4
MF,3[UQSS#NK^R*G3VU$N'&0/R%A".X(39B";-XD34CQ.&4$KZ:[N>=7)$P#3
MZC6[CZR=C+>7 B?SYZRZ_3S$V;I2VF^]2[[)+M.4%'I![1Z'N<:0-X9IM1(V
MH_[))7>5Y-A?6Q7^/$KF]:MBZ1\5ZJ0EYYD/L.?[B (R'"BV<3$@FK=O*MK&
M=#8EQ'OL!A;]@"2+[P'J_L(227&_V)G]VSGV?1!D/'B:Y3Z00^KLHBH!'Y@B
M8^5*8L2"5.X/O] Y"R/=L-2R3TI_*4SJO5';^?-2MNH1$C61=__'?-8+XC8^
M[W<\V@[\=L;W2^%?ZDVB>THA$&C8$!'T:^#L[6B[Q=TFM=S;JHDND8 5^0'"
M$1 CRP%T/0'U(7NG;"H\(.A3;>MX/[1Z#<.@/NS]A'A&XKN2FIK+C-6!6#VQ
MK8PD.?G=;P85@> A># *7+-AZ$]*FP'./VDT2=G9M$^:S,#OH:?,\9J'G5@6
MB@Q)L>?"/CB"4XNS>:1,[CA=]IP;]?Y/U'+:W1Y_<+A?T9!?LYG[$;:NV4>A
MA47\^*OJO0+;-6QMV4I"07DVO$U@R'W2O+XQ]66#3FY4A/D=VPNKCX&D8FAW
M*<5#D&_$%4=BA#+*/?60C]I:>>I0"[?;)<J&7+FWDS06LN:";1.B=AU%QNZS
MQ"5/P2-Z#6I(!REYJ[ZW6R2QSSAC(Z426BX\9C0=,#E0'O=A\L*;'@')/[BZ
ML^BKB;FBSQ"S/QAU>#ZT/GDG0I,%ZVD53FM%'V!W[/+ ZTN>V2"J"OP05Q^.
M<@P"]QP$&%"N4J6KE%^T%7D()ZC*O!TOI4S:QXW<[ Q<::U?9.D9<"'XQ;0)
MS7>^@+$$>ZL]^3,CL?&LA;SZG+LA,:7G^Q2-8"T!6CO9"2!8R"R  6YIXP@=
M4Y8_4A-TUN7<K>W"G%M1;$WE0W\/Y/?JOZ/#S5#GJ)?A]NV^@59DR6$S_+,)
MEXB_^8E9RQ\KRYT',\,R+.LF"8'4-X\F&G?042WW"/-BU(O6L05Z>F>QG>K>
M4==_96HEY_+D3=TAWPV:XB9_-JT]KE*_[8*D&6N[#4?A!I,\B;X=.@ZS7@$F
MIHTU43]_O"HYO,LM(MC3VF]XG/U[[ 3D?)6D3S"J2W_HP0B)S!NQ5-CEK]Z2
M:LZ?\XRO)7B0&>"_#8@+><19#:#NR*_]TWU_03V.#1JLQKFXQLT1]TQZ8:1\
MJ;-1<H)\C2X:XYYG*SFIGC^,O/+G:+LS$\)_3ZP\S"LOSOIA_Z[X>2FYI8!P
MC. XL:![>T:,H-TC->W1VZ90153XD(\0&Y<COW4MMT<[C#]_H][N?7>Q\,H2
M(_AGV_Z(*EO.GRRZ&F)<[6=>IKJL)DLKZ4&W+J3M2-#DW\D^WOH-,.F65$33
M8<<\'8'1-YM1T@SZ;=7/TI?\OE.!1/.3Y:BL:XE9SSXR5?1'HY\5UB/=^&K_
M6%@WMD[^L!UUAL)/E(H<U?1@7UM@KQHKEX>R+[P7=[LB#<K77AM<MMHIDD,#
MHC>*BA$7@)*R&]E??A P9_):*@X84KSRL)IRQ3%R^K<?+H?P+.*;6:*RO^TM
M2(XB!9V;)%OS+0!L1P"_,F,Z;_G[^ID@RH5@!!%]GQG/ LUH@"9 SWA0F:B=
M)R#.=/.6$1_TI36C^SO63DWB9JRYS_$RUTSOI1F^]E_-6$T8+_A95H*J6'Y^
MW.N^,DN=R.9I S\%1'J@EU7/?(5AF1$ZGK"7(ZOU;M<W8_3ITH6CX>V#OO%S
M/N6.[2>@FG/@ZJT"\E.@WTPWSL;[!,2CX6)O-\JO.B(F[EFD>NUW2OSW28U%
MU+18;S:[JA1Q @RF&+H%XNI2:>,K7#Y??QNQ]I13'D[(@N*?B/"LA]A\.MS0
M@.$'5 B^'_!ZL.M50%AY;]FTCB/KY=4J[10>E8;G]$>L&5G.K$V^N[7DBB$I
MI@^_41<A'MN7G+,OJTKAT%P5H=M72=;9#J,KQ/)"=X?1K??(-94\-1KIBQ;>
M-QH@TUC"80R5!G \B"$5Q&VZ[@N(Z9'4?GG 7+RWQ5RD;AM4=S<DU@%*='5,
M@;WMD*GMKC9:TD%Z.;P:2DRKS%\5U2S+3\$Y2;Q,[9U+UO%,7'OUNK7;:A3U
M7$5/%W<"ZH'2PW.>ZC9+"0)IA"[.24[IU!2#EZ](QUL\J<&8YS(WF][[P,L^
M51R> MK?+Y4KZ(OHQ2^\\[^[H/1.;8H&Y^=6D;<:K51@JF+%?)EQ,GZ]:>FB
M@9?O)ROS'O$=% +=%93S1/TX_+%DS\@)2"O,LJ9VTFQ1&NZ:]RI.' [QMZBP
M5:J0 63)O$!ZN[KRB(\'!SRL0[DG(9=E+]!&L6/B8'?N-K=VFK6#S$>%Y=_7
MVJ* "N)!/[ZW$\H&AQC.2/B4T+LQ?,.D_2JP)QRGS6##O<93:<TDQ?1S=3H_
M6-DO9V( T?C, LICX$>.'FW2D*I(KJ[_%ZC891^Q]Z8/AMT'N7F$#14.SC=(
ML<&;NVVO 3\^.T\B>8;+J*+.J M;^Y#:H'PXOLY1'/&IN;++U7^]J5GGGQJM
M :;;'=EOJ!R-$VZSAL3RBNO42N2W;]31B*<TF$M;LE6W9:=X#R#\R('ZMEO'
MGT?Q G45+C"[K$M-Q)^KFVP>+#?=JL[>F9&Y<U#VETA$_LZFL*!?5]!6$CFR
MH]NN6%#[(=5ZE,J8OUP]!>3S#"[3YV9BK\YM-#Z'VROL[\W0!O62U:E#6>HD
M[9YM;HH8D(D;$-,B"<85=);,SCG5,XE?GNW[3GL=_=:=GRPHEE9['+F?B7IS
MZMV""+WG[NK\+NB9245;C8T6J-+25%CQ1W69(+&)&H,0KAGSS:=X@QB]8JL?
MSXJ! *RFWAVM!5</_I"8M-6P^'<EIGG&$K#)W5$B>QYGVVX'Q W[-@W,@()A
MIM>[ B8*%#)QQQ"RY0J0&\N19"Q^]C.E5QC$XF6!JO'KVN: DP]$)BF>A!/0
M^=6Z(_V<DJDY)V7&%#W^U9>CA=%6D6;D#>;%G&"6UL#>35JR1#=I_72?#5C7
MS!5D@,!.L2#!G%S;^YB#/UNL7,Y)WWM^[6[:!N'14_4] ;^_)[ AKB7T^AYF
M<0227;*9Y]:2=*XO9)]['<544PJ9$*6Y&!!]<RRG7W_;%)TW11"=$<&@:CCS
M I_YD)]WN@7Y>W#DJO-8.<2OW+TBZ&!/C^GOM?;9AGZ>*8CY393ZWHC0XW@S
MT]V3BB,AZ@QWKW=>;W#+F<.WL.%1&[JEP!&!\/$;/*-G"/% [[K;FT0E,GB:
MAZ>>L.T^VZ/\LBTCB,6XELC[Y^C%GD)&J67 3'N@N+HK[%H/N]+CN$ZA.P,O
M+'.O<^=NGX"8P#L./W7RCKVU^TY C"A7Z.GA<YS=XD<H8Z->VK2R&=H;'[,?
M%I_Q]'3]J:MWCE3'PEKBYG-'V)0,!43-$H)(S;C>"+S559S4)0 IH6$\_K[.
MM>)&U'+T9:^0+H=+_C\X9A TQ\E;ZGP40U)D D+'[ZNU<]NU4?-'F7K$_1A+
MBYK ,!TQK2XJZ6<L >1 */-_@::PB1A4 ZP$#$U[A56<H_6D_;CW_-//KA:=
M;,^Y#;S>P.[U\CA/ .8WLN;544OF6UM;7@'U/6[F!-L<LC)\M,N6??3QS&3<
M]FBGZXT,6=IBT+=?BPH\'Q+9LF[3E3VC_L+6T,50:2EJ (D YIFQ=&YZD1TC
M*4&HKFGTE[P^D0L?FNUNONI&?!)&W0_2P6]/6S@K0L]\'=KG"Y)]!+P(%.BT
M^L''V13W_$E'TG"4L8YZ[: 3JI*V;+(#$[U 3U*OJ3>CRI T>]]N2HD+W;R1
MM6'8I;55&IM]G_E6:RT7LWG]JM\1G9R;O0?.+^X$Y'2LT9TA"Y_]+LA=3:S+
MV]4_<L_'NHP^*==^7]:9%<8 %:6H /TD#QRRFOS(9>$BD9J-UV.Y1[(9H!:I
MUP9=N7FY>H7/FZ[0T.* AM]\_)0?(!DIGD1,C!RL!4J*G[4E3KS+XS*H'>%4
MJC!W'Q))S&IEUE8JQ=)3^XXJ(A%72;M:*5V<7CJD&]2MG0G3\.]5;$*%YN#3
M*2^DLA8]DM297IB%HO^>]317Z\<9)'P&\HBCG8)2=?4N%CZMZGS+(?&/ X>D
MK0_;A5\V->'5+U @V3B##JD+@/+:E@HYCDTOHD>W\$GQH[[/G*"=,^4++:NS
M'W8V[ Z'1+]&A_SO2I^!HTY _]5-0^Q_40<4FOL<M61R G*O&-HOH+ D':5"
M>5#M3TX)%=;;@\QRBLI?\RJJ70A2P*UL2N;6Z38\ R![3VI)3QW)RU(FF!S*
M Z3YZK]?-QR<@$CK__,V O3OMQ%#M TG(,W_*/1Y[=\*??Y&"B$>#"'9 )$G
M),>H"O7VK[!"07Q0WMM^6D/0FNXET&$^11I(.H7&F 6Z454K7"!VDXG-T.SV
M0$W1STHS,[I$C;,7#DH6Y(CZD22VCIG("(IV@6;QGZ8W2)N!7*S/]RMA&_=
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MXFRY.^MR4/>^QE4/[L%CE4@,P= B;A,1K: XU RMFKZ >.OK^/!-I^&E[X>
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MT,<!KYN/E?5[EKK>O%S@3)05Q:L"?4,7A1Z<Q,9#C  ,3;I3>#RZ4P$\PKX
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M=>$:VO.G[5?>?R28)^R_NI]6Y&,ON;^[='G+IZA6MC2+2.@O](;*MQJA?&L
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M\UV/S<W5+"3W% 9]:-C$T8#=I;4F,@DG<*<__ZMK!K;M?W'ET^S%G-L!950
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MTA-6# K>>$@LL#GAK#3L5W0+8L=)NXXA6'%'IO#4XKH^Z'*B8X$W1 <89%T
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M.1"GHI,EI=7U<L4'].72I[3(6/0QAFI$X"!9T;?@!IX4F&.]6J52&>I6U/U
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MCOY.VUQU!_;8 FY'=NA]KAG>RNE+AMK1]DI-/]K0HDNG43LV8MSPC@($.U.
MKFE?97*U#7Q%==1+8GWF+.Y:0ND3#)M'H\A93/UOM:-ULD7+HZ'!I&RC(?NJ
M6+=E916:#*=<B;"]EYYF%6\58JZI"YAN9P^GCUY]LM7WM73.44V$IN\HTE1#
M^ =,LQRKLR&LW.XSG#S#'#63*QOI,1^WV+5 2NX%KQ(;4GV[#/ (\8$@3GS"
MG"GQA'S3(4/(>=N&!L,3>IZ?K6TTH2]Y].+BMVN*M??F+J]92?$3NUP2MS[F
M=:!]P.#3F$F$4I1,F4@"7#R6Y<#821=ZJE*'O';S:+^?T(ET1S1[J!>2V_"\
MBDA4/M3C>NU\K'Y9_$*<1_1G+3'6?<7#$WZ8V%;JG:&2@+<BX'XU:UOZL+S#
ML1JS]W5A*[!*Z--<F$'WN_RYRX6Q8\H=//!2]O4R5ZRR41AXPU (_VFPF2LN
MR"-74_S,27B-#*-&<1ABS33J#??$>MU77(I2;-_XRT<5*6;V,3-)XF?%W,^:
M:#/075 +9KQ\M+*XCG8V2EC(:5^#;W2C/#ZS/5,I5<5R0UVP1ZJ* :6XM[7!
M- UF@G%2;U#(LL#2R_<OB1JC>XQJ5]:[&X1N&/[647Q7/URCUZ:"8..KAPM)
MGVO34,4'SGEA,YIC3+JRR!T#N>99Y:4.S^X[OY3\SD^:]W.=;1[8*WK@_ &!
M6%B5=:QZ>X#*AEW&^D2<-R'<P*37%YC+<UL6L,GXS8IYT0PP=AZ.L/FT6'2$
M%@^B+*D$G&=EJ,=,44I7>MY.[%F3]571D]&[TZCEJ69UAEG(2^3T.PW>"KQ1
MWH1CN@1Y,JX'Y__!/^" 9GY2#>7)UP5)5B-S8Z8ZUN 1*JZM#$,:YYQ0-<C(
M\\[9L3T-PZC;#C/W'VEQ%M3,+4D &-VBLR9>$I(KV4$YVE:]V<^&/&LGG X%
MA56^S=VN_VU6RO*&A?DCC<A()O"S[#N#6^5Z!X5>4E)I*H<G*BTM.RWX;2]]
MX^<[<HQ1[=7>'COQQ-:<3=$T.#I( !.4^&$Y4TVWZ%IR30_NFO[5^XQ7@R\S
M-;??^*:T)#8=.8]TA1RH;D4@]R@ +SE!T^03\LF*XN#<(NQ'[G,JU>@W^_N*
MQ@JX+)>8N $B5UO#5]02%ZD&:564 GC"S^U.C0V1;^*H1-2J&+F;?G-'"K['
M00%JP(F/&Y2W25K#\7^?G5Q&^O":J9O ZOD@7E_4W9(P7'=3NFA]Z5NUSN*B
M\JBWI^/@=<5Y5T6F1TV29XILK49 ^D,*,9K&PPG>:U*JNN)IWJ3U]D]FMD@A
MTY6IF.0Y.3P]04ZV:0<AW505[22ARXZ[7_M@#%<(:X!,$HBV7M[')WPMYLC,
MH1]EPWL+G(SPQG:CZ7TN+1YAYP09MEZ,O]L)KE@@N8W5^A!5#]^1!S+B!8+"
M\YW062M)*EX+N \]1D^*G"?-Q\+<Z9Q8."^XRWT?5K8('(G933)5*ANWZ9!X
M@QNZWG5.PZT\DY\M_8(V=%<5!R'%D26I,5#/D)ICT7*2R:1(E/%P;L#+O:C+
M[\0^?\N#?7A3W>4UYZ+MMPQ]AD&T\)'/PIOTU70=?2,]8R1:E55Z";K[=+>/
MSTE4]54A<ISW\G84*G0A9)J@ >L,$'22 U5WKI_-X]J(@N93EFN*4F>=Z_KE
MXFN'76A%<_.RKV!>U<]VG=%GN3:B6/6"]MQ*DO&/WYJ6S;1S03%!84%#-A=+
M2&7(1\@3OFN&SP7-\7ZS 7G#VAJNZ_M/:42'OCJ899A9% ;U603E8BUQ4@-J
MHAC5#A,1)GQ,KHUZ>ZV+#%O1Q)S+0[G3;-,<90ST!A=NM.F,IN3VGK$/ )\*
MT)<9.$!!9]2]"1:! N.:PYM>;SJ=E03/VBP\O>AQW+J%-J&#&WX7;SNG?JP9
MNJ'7-'EJZ,D#_J35'=TO89)-)X]\ZP3FGW=M09Z2.R\0=:NH9N!Y&V_;2Q=;
M[!L5!4SOF6$' ;-!MK@OCP0?T<D>-AJL>RDN3E7(AB$=P:PK0=(-V-R("K\&
MT,1J_!5I,:R:LI&:L[R"I//@XR</3(/K[MMS0X]/:+$I60?@0.!ZV_D;<XZ/
M;@R8S[MS&VGKG>BG^3$Z63%M> +OTB5+#<.A%EKOHKEE%-E4'$0?^@/?WI_
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M@,X[WBE%.S.GPP>4^F2_LO1:62Y(S>[99-TK;9W345MLJX<VJ?9Y-BO*.(O
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M2FCM#-MSG9O?S.^];:0[HI-[$S$-0I]CU%!8FQ3'TM=^3$1<&W5_&;98&;O
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MNX7VF/9I5Y7E'!^S.3#2F:V%E-T4Z!I4RZX>V^&HSC[CT2SK1-S/^GQ8J-J
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M#/2XT4I43CSC) 4JZ$B2TU^!=Y"%TK4>U8*<B=Y42QD!=2>Z#U> Z%8TCH_
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M2^#_N\#_>#(&<F.2W':X^!8J5KJ69'>,!AVN#I4@\ZM2Q7J_@"01%"9/*UF
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M[*  P-3/-]+\24KT%YM_@<)02^S>TFGA,J7ZV#^*GDT6=BZ$]^_;4A7N2E:
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MREN?^<[RSLPUE_ CL4&T*F%'5N$M'\&+Y+*[7"RO;["^*.Z2B'(E)4 C1L_
MN94D?0H<$J$8)V=<!EEM!67/=R M?@I7::M7G;T>Q'GF48K*YW_9L@\<L6!6
M:#K^XXG4"#1R\V0^CI4D6$Q!8 ^@%K@=Z9 ,T]HE:C'L*[KV)/#YO2\=DIY<
M4P G+XUL\JW!(M:A]Y[JJ09JCC)^%]=QLG+W,S8ST[EKE+"_N1M1M%VL,VH@
MH<_=4?F=,W,JVW'@##P=A=<T:^D-.$G(N'KO<%5Y16F"W.UN$?X&2.!;!2,G
MO.)X6B[9.:@#QFY#>O_2_HG9#''Y?4B9B_W7$S>9-*LDW4/4].*R:UE\!\XX
M/_]:Z1%5M;Y\QE,44]XR6<ICL-9_2T/4.3MRU0=GHT^ZKV=NIF,OG*@DR=@Y
MX_HI0!">"]]&.^PSCT-0V(0;,.L-3@HZ\*;3<VSJ+#6F[EBI9DQDWN*D\,>[
ME?*+YNN+\3(MC:R?O1L$SI*R<!$P%LKUN.43BQ\>7G0_&C>T7?,+1\R.$T,8
MUSYI43-/>7./]Q7H;ZSVA85?@QP:ME5<VXE[/!6S?%!&%!N3_67(?,B)2[;/
M+&%V6JT-^4HU*)%48MR#&DN%,M7LRO;1KQ]4F&ZB0SC/3^ODCIZ?:F-;U#_^
MA:7)(/.Z!II[SK%-13BH'\H5=#3@",$PE/!@K&ED51(#]IH^,22W\<;9:TL6
M1::73G'EX.[+;RTZ^_BZ=V0@%O[)P=E,C#5B!])C<&K,M,NIQ>3AY:O AS?A
M3N\+UB,-1W?9WI T%!(_M_:!8W.6?)I4W5 K0'VL<L NZ&0(UR<E"W??%Q:^
M>5G>NJYN^\M]R!_V4D7:43?@#S=#P>X1,SV^_L!3Z*B3Q,78&XG;?%]+$TJO
M[25:GW*$%=DKMN HGF]4^@)E8;*S>+,.3^'$;==TA"UB7UIM[-9NTW.>VCNW
MCS@7V!EXALQ)N4K*Q9G4:+^@".!5$L>+.2U;^%?@(^J\W;8NW)^'Y:I8"GJ/
M!SF_&Z_.TZP7UZ9$62\4!0RXV[I:MU?(KIB5>+"IM>KV'8WPUUSBRZHY^.4L
MM\C>VZW0<R)KPL0/A.UKTPLP%[D6)UZ-/IK(Z.7<K(NW[F=&GS^L6+%W@3JZ
MV'ZH^$I99]MX&W 3^CD4-QU6PYTQ&S51S*.Y%YU<MO8N_JDVFV[I\J[=X6%<
M9^?\T.RNSGHZZH:+M6D5"S9Y%G>"[NCL35@^-!6%B_7+##<('7,P"Y1=GI,2
MXDQD:SXKP7ZY';9?9+68&(QW3B);!'4!.VJ/M65B9E6DT9X=_ *T;TT<WD++
MTM<XE8U/7NUX'ALGXDZ,I.9+ %;=D9;,)%W&ZFH_L= 'A7<6A?H/^P-IN&,Q
M+?<^1)Z^WF85U[ARH:G=,-)JR3&+S%SJ<JD,)HH+T7Z\S55MN;5EB^"UC\ 6
MP^C0W!RAV8H7^S1ENVD<FP"!"6=S'T^F[;;  X;X4:1 DOVXMDEQ=D6YJD8-
M;GM]R:EBIE/LS[V/5W<CN)#ELD_R?,J7ZCEK60<"^(HE/HM.1'SLY_D<N3>?
M8SLA36JC/]!3CCUN &[D\LD2[0B-7KU>$>2"F5[ISZ19^88W;).]HJ;HGAS^
M_N)=QIN0<P#IN!$EC>L1,-\-=HR])B+$*A0[,)8$7_:QY*!#BI7!+$;3NA@S
MMW&GCS3?1^D"AQK[]50YOO+5_<N(Q%>BB47K&WHBM"[%3GPZ!#.W=)UK?XO(
MJ<N<34,7<\[>$5#S$W" 8:RNU?123N+L18N^B8[J<LSJ*9JU]R2H/=]QX7ID
M+M^!3X-YJ5^,W"J]E-T[=:4Z1FMMY.YTGUUKR5*H@5_WO4DMQ,6-;G]7"=]B
M?FC<]C-_+9:3O7R?I/]X"<H&&X;<KV3O.AY&T7RI)BI&N9AC&C$UD)&T>$%R
ML<)X\-AH?IS<-%(KJ&UYY3A?E?EZLDA;[4'*W?X@R8NW<V=H^]Z5X3]&"7'Q
M%*Z--[=)2HF(ZCD=-]BV72*>MV)+:J7(N$ODZ&&\4V%79:'/CKF6NO*W6]QS
M93/81AH.!*:YF^; 3@BQA0J)7SG;)&$KLKRVS\A?X(VJ+W,COQ8=T@+GE 9"
M9?T>=<5G%"4=KRCLMCT2[A\6T!0N8AT3T,K]6+3C0=G=G5V.6?CB>C'%#U44
M[\T=V?E#QJ4Z_%U/7 &QR=*%H 5DK:V'YP=N0TADL&+OI*;#VA[^ 8YE[\9N
M7I]@6)0^1;6OS/]9 -N8\@5T0U5J6$QA66ME"V;J=E?O34FSL=AFT^IN3,/U
MUR6? B!5KXH\$*RC/N7-_&I?'5AN\YJQ/WWM&]__\"SSTI8/A<H1-0;K4/&6
MJAZX<H!4RN52THB+(QYMBK3$LV\J]<ZS"F2)9UEMQ[2FLY["C7R(#\&W%OGL
MUHK>M?Y>7Z=BT&,X94^95_F[J/18J]B,6YDW<$]#]+_ME'F>T;Z@;2BF!S\S
M#]T1(.%(5B/9-KP1?YLLA@YU*3Y>*G"D7[:F3?I4-  \O_<1QK,IT3 *?8LO
M0CAEV;>)>AF.%3A*+U\9.ZC9T?JQ)<[OR177R&LE7YR$['I4.6*/_'.K3O7?
MP]*BE2;X\O9$ZB3-L^Y?]OC<>L]X;&\RM];:MD!57[52-)1-1<Q!Y6 R<:ZC
M00#ZNJ*J7VSAE1WTZKMWXE:/OU[COW4)X;K[_+&6LQRIXU&' C@(L(>>\'VC
M\(LO'#"E?BKY&2.C.MYL2?$/]9MOVUA[>EZ]>_>B1[?,V^S>S?AV?V6.#I)B
M"S%-I&^M;?)^:>6J-CEE#]DW<]]-N^B+7[?$^[1K*#_W,U2+("@:$(R"5W7\
M+^ ]!U;FZB9#1OUG%B>B.6YQ?'WZ('AB^_632W%G/KII&-H"JJXJ_*0DZAO;
M<0]4SU2O#&K?27^J3+9)X@[9.-GH&Q#/V_I=.W8>CI:TI\B27OH3M+7+!YV4
M)%RS2;>6/W?LR_+VR1>-BKY05^+UY2NSD"UWBS3U>9G+BPV3&>L#=8>D&9O>
M[:%HO*%P?5IC99FIZGI;(OUFV&2.)[S3':ERSM0QE+;__,9K#5ZU?2+N]:C]
M16NZG#JX*/]SP+[YX#[RA9V]!)?#[RI&#R3=-C"7K(3D\G-?N>+#+YNRO(<_
MBV.B2G>1*8>4J#XH$\B&H^4"K^PJY&375S1]^80V#DI65ES+[CY[[3.O^ODX
MQWX/^ %C1YI "5K4EJR6Y.U0$?,Q8^E21PVT_;'^4^\+KH[N.@8IZ4]6V3$$
M9&@:=^B$;BBZ.4@T>7-11E,H4$JG I4VR,M[=>'-O2,>7Q:XW*78VCXTBY0;
MKR&V^'BA=?N<RF!\%DE)1^(VYTZ8GMTXK"//SQ[PLOR@#_/@\Q=/)FLS*BZ^
M3G^WM)-R(;&1)ZTLPR%9NFH?*E/(W=R$]U%EU,N8,]$:4U>9F,KN']JV7_W]
M70QT4="UV&?W<,MI$MOU!_4"IAV^@*LWC\Y6YX::NXL?>[*]VJ>?;]VAD:NS
M2GOF5H+)*;K8A#P@^.E;J9.<9E\F@;.ZH'GE\^<&R?JHW=LE=80R#_ Y\.^X
MJVE[E5E^/QU2W_RN)T J;XXFAE_K#NE"GFH\'(Z3"$+7W#]T/]&9:'.C6L,R
ML#+W:WR1B%19>LUFRWA(AGVQ'<8E/$!$(H3--*8N>X3E@F*I?7WB_G8.HW:O
MJY_)'^(%E:5,6R:V+X4I.17[.)['IS9GN[ZT%"M_Z:T\-VS67)!7%Q_.OW!>
MN(,_U-*>+,\:GQ:ORFYH_=>+^2X^%MK4PNO6,:BNUX[G/8M)J@'"18[&>XF$
M6S+*>XC0)(XHOT\-O?$.T3WA3IMB.O;Z\0ZQ62Q?%VIO3K@\-A5NH)Q72-6^
M+@BS>G1O%XT,L'[5+?/M;%D4+@!'R*J]TC/Z2KOD*EOZ3Q<?JWF/O%:3/#=G
MF#QN(R$4Z6:"T-<S6G&V:AXJDBQ)$ CJXC]81G/QIS$OOA/GZL"O]A;N\UUS
M!D?>"W[=%.G$,-0,?Q: S861)B4HTH@P,)OGSZ1#OM_P%9/W,XJGE=K"5]DD
M&BB(BV1F43H$N7.-L?L[8VI%$6S:4=< @D<&,88 WGCF%4^'!('LX_-MLX:%
MKFKN=,AY20JL%?Y9WI9"4B\ &M1)$;3[&",J&4S](C)H/(J-\-5]O:BE+TB*
MA:_JJ;5\<]WGH.3+*-9EX=_J[+ '@!_:W$!M0(/:GU**3Z:7FNL\![XSL2[P
ME= "! ?H$%R&$MA[GUN4H%';Z)"F7G#DHN83"K+!?[*= MFT0;9+WW7M^:'+
MA617#(;5)YCV3V49Q,>$7:!K08F@:U\9KK7G=AB^>R)'A[QX'+2-#KEY&[6"
M$\BE0U@.C+-N,L\"Z]]T:>*)-![>1N@J*ZCVAV\6*J7FFBF@Y$NHK<#K9>S&
M,N(:'1(20MCRI_!9 /=2A@[Y2TQ-F?U ^KC2,"WX&(F-&II AW0_]4-0I 50
M=(@*ST]/LJ"EG-^O;7]Z)I%E6M9H4D'=IHT7)+.)@XZ=6(.2[/@!6H!T-WE=
MF [ATE*!S6-7<*\ ;"6,5+6\-J]KBEH+E6$XQ4:-2 1 -3XD:C'0'9+TV[0@
M1P8+&!T,GI5CV8;Y85*Z&[167W$XJ%YO%L"_+\M 7V'XW$>'$#Q8HZO05*92
M%'F5#@$A*)-W2-QO@URAQBV;HV@!&;T SL\1!A;_+WH<H<,$M,"+H1+)<$36
MLG0MGX;MA$V3CWP= B@;ZAF(:)XV1J3]HLFB0QZ-%(#1<1DL,%VPH-&I8F*F
MW24PAETJ3+1 P1X4SML1+(H^V \M*'RU# )$&+4^2X> ?E2YK>;31C_2(0PE
M)-:-5<0E4.9 /B,*='X*[45$\:"H3*O8GZXLROL9B*Y+@L@NP(<.,7@N@#R=
M^< ?+&#C-#6 FH$R ,L& <SOGC7,)[M_9T(N1+)2-M5? /63 ZCIAE\\8$34
M?QT IANN_+QAM.6*93Q\."F10K,&K,> Z5Y% B'" !3!HDBCPN@0#BV5TW-@
M &8#/W0$6S[--Z!6)@'=4[K$*\R@^^]!P^KRP, )204AP](AX1DTKAVYC'@!
MJ&2 =NJ=UBE4^0IT@])$C0\&)6LL 3@7!R0H\Z?AN>I-(_I@Z- A9"*68G#W
MZ>2LCJTO@F'2[1LHT"0DR2P922'9TR'KBRA2GC=%[/W?Z#>!80;Y+5I''="=
MZ0W%EZ_!-@A@82P- X3K0/UP/PA^"^@ORHGA,ZLJ=-CD#WIM@K\!T]:N#ZQV
M#.NS@?I1$+/>%AJ)8;QJM@'@9 -;V8@@2VP'G>KY F+X!T$BC7.J$+R? %MO
M $O?H+XOAX;Y"$RO<!$M66F!&>] >"KS@>XL!!5,;B@&$A2Q3C-:H"BP%,K
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MEK]Y=W<%\][*]MA.Q7'UZ%<#,-S!RIIWZ #H&&]'VT3_VC'UDG>>8/K7TZ!
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M,%1_#Y)/Z+1=_5-5R:K[%[UMN&-6A6?U@/H]>7[GZ1" E61T3_07:HI=/S
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M<'3HYX!% _L/(79GUVM7_/DL]R\N75"7G"I?NH+N/[#/9B!L63H'(IS)0'@
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MFNUV@/'&T/*^&_^<6FQ1$07:_$A@4@Q/KJ"EC":1]8'6#)P$F7<503W!@2(
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M%>3 )+(Y16$U\K-]U&V5%Y'SHCX*DG\'\K<,ATX*C+,,EOA*V"DE'B:[C/G
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MO,V-\*65- "_CB!_AA/;U*%@8'(EP:V7NTUSPYD98-(7:AHTR '>LJV4RB_
MRX@+9%O$G\)=<<0VWW_A._R:!M._Y]L%E13<*./&P(L'Z&'40VJ"JAX-AK!
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M^IVCJK_2,/_/A/ZW_/^3Y0]&VE%> "B<"^ZIIRE&*K#(&TK &>1;7Z'%5,3
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MM'STJ54XNL[7RF9FO<G0R+HT%D254E>T5F<A#5!BUF3=>Z-X. <WWPMQ0.7
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M1J[X?,7KKZW62M_/KW&TB[X@+RGX&K6]:.N3Q"1A;U,3 %L:C)5RM;"_&#A
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M5]6;>/Y6!)5NDT*V"20*N/O_L/<>4$UMZ_YH4 05 4&0*E'I(J#2I$9%0$1
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M4%MQSW<ZQ.+S)];;7>KHE$934A >K$_0:[6QZ[#<B'#L?^33C2PW%+8,J/7
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M2LKB>UY!O264YI?4/"+[L@%V*_H-C["]#]#41K[-^.F><2N(SZDJM3KBJY;
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M>3-RQ^@'C78X#THV'3 /ID;W4-Y_7Z+P*#F,:#'1^M3R7C&C^&V$KWYL_F(
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M5G/^:[R,9"4,QD.*YZA_ZWJ\Q"?S9/70&X>01X\6I67'7V ./-9=WR46:LE
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M[>UXH8__I8._]"?&7]'MFZS:\QLG7,!<%!-?Y/=N]Q0,$^_HR&&]T)LY@(1
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MTF_J.GDDT*&3PL,Y9Y9[UMTWF*]ICY'MGGW 905)N8.?,G7QM%NOZZZ1NA?
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MPY=)7;CD>3HO-:]<]%:4 ^K898<P9^?!NJT$P0D\X0KLORZM(/?YJ1EC9VH
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M=I=.6FB;)-(D,('H&5$K#'4UDLH\3)B?5$=G$^2'@ J(=PRT;68 .$VX0&$
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MNH6P,"W#/.<EY+7:);#8C83XD5GE'7\QVT!/\F$ SVZ#O7!BV[<8( -Y5C$
M%G# MN$<DASCJ@H%>*$A"$N)@[@)Z\'ZN@O_!%@T%0;S0*R0.U4@ I.3#Z33
MOG()EL#)$KL0V'P-G!["4.&,(V(6!&>76V/%Z!E90Y#X'I(CD)]2U:$ 6\02
M%<8Q?I*5Q@"^*J4/5DKSLE*R>&&79ZN[!8Y<?@5KTV]9F_U_(0%MSJ.':6BR
M&'1A=AN&MA@)P3GZ0VOL&Y!TB!Q)YVA%SI-AC9.?NFI^(X6;BV%=81 SA-0I
M8P!U26"O#"W81DH*XL:R@?55L/5!5BKS?''"+<*(Q5?"4-,[>"P5[-6DE?U
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M0 &=:#BT@N)<_,&1*QE,UM"95S'3B^@5M48PU3IQV8DW+K^8,'/P' 0SO+6
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MW+TR(\^N/V(I&63HO\;G%&N:,#^%%W^W0.'%F/-.M8SFM!V%_A; (8U-AP.
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M0)@R0<F A?'@R!VI!"KL :)1Y9BY]7D,H$'+0 )O%6IDO; S-=W1F<BG;.!
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M:__+[HZNA:KHAK<<B A$G;\ .MA;U[53B[(.VS=^L:+,UC5&+"?/=9:W6>Q
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MWV"0Y/B9ND7.&B9,"EVOAO"#(WR#T5%SKZ#M#I:%_,) 8CS3#61A.>R92F,
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MPVN0&CA14->"^"^3CIOOP=S^3?DWY=^4?U/^3?DWY?\NRLWP&$T4SM8//=L
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M3(_1+(N;==3<Q ]]:Q^A8RH3Z"U(Q9>U2GO$NGJ<;MG34GW9PU#S92^+"*H
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MQ,WAV22<,F]^N2ZYW'"!!>^A(YP%"]/3#OLB2_+7D2CJF-V^_:A4K9S#LIC
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M\VP_5FKXP9V7I0<CUE+=OUK.^BG-WIMCLN7/M)2P?41P7[ 0V3IF7<("3?B
M]7KH?1:BLW<'\N3MH@A+[+;(25WX8M\8:3N"[)2P?Y%J 1A2SA WY%5NW_1[
M;^'E/KBK;C/)UJ6<\]UD0KIT0>@CK(R[ WL$Q=X(Q$G'>)>6W'0@4]-]$ZLJ
M_7>N0EFJ$EX'9LGD&:%>?=YY58>>WYCT5NBK[:-/@,5PA$"J[S"V^!X#% TW
M9L)8JP1V<NB1SD-?UFH_ST1A#^:*G8<//^?3*#"^]T2JJSCTSZJI=0Z*FP%Z
MB8MF@%:MAW";=OBW^+\^&O'5XY<N6^2M>%WY[L_Z'?</Z&AU\[0TI7I5G5)T
MA?S ^B20OK&G6A8_,.^5Y]9\LLK(E?TAMU3X$XBHFAL9NOJ;+$&H;A6SF[$%
M:N%$6?.T$OI(JKH=ZH"U1O(09A9)FJ.VWN,?MT"MD?U(B\]U!/;%J+: 7^'4
ME"$Q@:='Y">YPW-=Y-E-[5Q63]K@2%,06:\$\0X8U!]:%TH9Z:5SO$B[57:D
M5'#6;]8ZI<#,5TKZLY\=(C^X732NLWQKG\C6G" $1U>?32,Y2A/Y(C()C1Q7
M(Q8MR3VE^7)[SQ-E3$1H+"Q=M:<.SR5I'"0VH+?U*:6I%)?M+%H.U8#P#5>F
M.F5OEEQBM[0K#OM^LO<5W7\^Q(<VU3'0@"8BUC()^;2Z!DV*3[.Z=;6>0'5%
M]> 6M_)P=HK)$=>T*P^4'PI>V)*1?0]X[%^C\I#9UL"4A-:+Z:7Y;K-]PA[W
MM3UR!ES=(A8LA7TWGGV[WC;Z1)18JQMG>*T'WE7GO[;LVK4;;/P"#CZ(,O8B
M*8+<Q:6 6@).W,/I-+Y$]:>\CC9Q3.WI<YV""./86<5CEQ .^$*F9YDVR0!A
MS1CA)WV13?S#BCJ*!"BGAU7VX+4!Z4#WUE@.;^TCO0)WGP5QER#!L:KH< AW
M\>94( ';N@9O;9+YA M%RB.H%T>4WEV&]?P6^B9E>W.^0Q/[ .BAQ,Q*KWE=
MC".N"ZWHG0'<2$6!-JM;@ILTR64KO&?:Z9>%@O,9!]^20/$JCB5Z2(L/ [AK
M31&--[5PH]7MPHL)>IS!0WOXJ$K[$K@UID7$M;$A:*/&WCS/(0L <3<W^=(B
M&:"YM28!]*@->BD?ZT++TM.B<@.V<$IY,V9\6K*?*D5<4Q93L< U?MIW[3\K
ME)-N9?*,X[>)T"U26.ACKH?@8Y7H,&8:U$9=I/A%-IV".\D,JDZ9Y@];S$3F
MEL/=GS_@>^GM<EKNTA=1W[S[F;>[MNP\:#_H7NH,D,0*.E2X8H][K7'_AN?3
M&0K%+7?*P3@K(^F6\UYT^2SLV"AR9KL!@% 66U)6^%^0UL1G9XS%T8\*.@Z/
M\>[,<;HU]060$UCH(V!N5>YQ61(^5E$1^\J $I'JXY'[K4I9I5/B<_+T,U<V
MME>W&: [L G99ASK$VT&B)UJ$ECVWGZ*"VI<6U45&%%5(V-Y9;PA_([/S[=X
MN8*A^=?$RL].=? =%76!^P.Z(MM^3/_D7JMF@+QPF5L^=O221_MZS*^N1N5^
M-#LVU[_5)^YTU-?":FBU!MGWQI8UWIC]H](/MY&:OC!<Q4Z(#CB;/D!>KK;^
MU$>:N;"4F)>!2ZM?LSG!TXI>>84MW"R>82+M"K^6&2%Z#P7%"S37E:8YY_5Z
M5T!/+&T3"6LVWC()Q^>>V4:*Z<^%LI0X:O[6U/B)I,,68+*-:\/!QF&VP*L.
ML(""CN:L/>[X\OA\Q7AT7ESF?'?OF71+GDR_$SYA*^,XRU7J[7< EICZ@@%R
M/?&R.L(+Q<6/\?Z&DYDQJL^,W+]D$K=Z%QM//P)D;+L"$A18B[@DE!<H;_V]
MM*ZVXBE@IU1=[7&1+T+RF?=#0OS:W!J)=X:+J01S/84)JL/G85\$O_FC6<S:
M(_GVV#K? K"SLH^@LT!:(MB@7E/,LV@PT^V74:<"4ZEHZZ/2\HFCZ*^:F^8X
MSA4,>#/HL@07'4,H*C*/ZB-WBFA]HG[%/K?."PX#C+<+ 0D"9ER=)/W"><37
M',8.K%RQ.4'4/7,?Z3TS_\;?IE=C)NMY&=^&>AN4'76.3$]T4WRF=VI%_,*0
M4U U_WC\L_$ 0_X!OT@%/]%9EQFU1B'S<3/+&(>1I7T!_MT,N,_W@NSH=37V
M!YCEB9_7/G322YI>L_R$B./FO <@J[!!].8EK ;6&-ABFNO31 ;H+CV# <H^
MY-_F!IV];'^(]X8=YY\3<++K".!LZ:LB9!@!MG;H@[NI7/KP0G35]GG.;&F5
M"I5B9X>7O+\DWL8&X+^J;:ZOIE%^?V6 C@3S43U^H$S]?!$%0)$17%[):\W)
MU?^J\CO.K@MA"@WI<VU&EKE#5G7!]WU//OJLVT$<],2Q,4"SF)Y9[EBM7#\,
M3Z68H]O $WC19D-3^7.SY]K*Y:BB*J->(@0IH*E1LCY1/RN&;^LQ)\2_9XNG
M'B(85I(KCHN@^5=6\GL4I:K;PT4>^\3NA<K^OF%_[/GV*7KE)FZMD[+8#!97
M6P=-(8T6EI?%!%KZ/:J]?#W)/,IEDJ"6Q+X;;3XTIX>% @+#56L?<A^K#C?T
M,;E7:!PR. @\BUY=?-_V"%[D:._Q:$QR[\&T;V-W2<4Y88$OT['!*WX'A7<0
M(&#0#% A]3U'EZL-79_\*8QY7GH*S_/J]+KWS>^.],5[.6)4"DP32-W.!'1)
MM9#[1;J>#)"E,.S9VFDM(@-TOVLT2Q:9S&.D]_#>M:*L0X\QQR&S>3 !Q6 Y
MS[W4\ 9'M=10IC^9CWI8>HSD7WP?,73?/6;^M<]OMZSAGE7/H=#\[LKI.L]I
MS(*Q7&[M R]ZIQ8^'.VJ.(XC2C]'^:*9'V:_PEI8(1-KEL-_%:;TS28A%>5Z
MC-0>0+'!50JLDBAN!$3(C /D^ <@@YQSHRF:4BD;N)"E]KK,)C>1XP*K8H66
MDD/6I6],/%HAW8H8PVV' ]U!Q!(#)J[^\>KFP"FCAL'-[!5XH,B=W;(+AZ]_
MN]25&%J92$*,GR1TM/2-W=^9K6[1A3I0T-LCV=5[*8W%MAGG"-<I9?'G;)*.
M;KP,>-RA^:6$U+LH_$*[WE$MOV2/%_MD#W.%/@[FU+$@M0&V/N]15F1<R](I
M<JM2IP<66;;Y0D$P7+N?5VR93:01B?V>Z;(&'L?CX WT'W4G-5+6>U7\>UZE
M3OL_R/(3K\56H=T3HL'EBVORX!#O+>@+O5/DQH60;.,/IEX(@K]W\BC(YI=<
MXS%C(6Q, Q2>9P/$W*S^47FTTHM?]L6)WCWBY%>IUM-1QNZ=VD<%M7W:X0["
MKYV[Y6GRP)9,5O1WVA&FM=Q'N5/<8N8ITJ%J'*/&$3H00NH^5USEYROJJ:<Z
M3]](13VJ^0U[6[*3,-(T3(L.5D1QTS*=A]1H/AUVDW7T^AQ:Z+YI0LM A=4U
MFU>?7:6_=_RP[L*=?)+ YIYU=E\]I,$\B-C(_8W)7894!YVET\V]H>?*-$"*
M/5F/@V0*2NV&Y46DO3%(4FY6I#23\CXJ^.>%,9:E:2862SI/D:#7>V#V;CCY
M.,7-,D"[9S G("M5:0Q0'M^B&L^T$R[[Q/*_%LZLYPZ#;5BC^!@@YPPH3;BR
M V](7K2O).-;N;D\=[YWNKH43$SV?LM[<\9$*(JU\,O/FXKA4;0G%'!HL 02
MOKU6"R2CB]0C@X_9>;!7X\<C2D2?6A)G/!(Z/?2L?E^L(G[4N]GG0D*SDOJ;
M%*GR-&QD./9)(X<!WM?XHD =D[#<^QRM?B)1+MYZQSUX1R)NM V5L(] W2'C
M.Z#C'+<IB.>EW@H5YC':-BY)"U.SCSO%1W8%W81*P[;1P Z!21'+N=NQK"O6
MUC>086W7C<73."]B);TO7]!^RRDMZ8L5<UXH/!^$]?6JQ-S$)&[,E$8.XLH@
M7_;_U HZ1M?JA,2A3A)GJ@'_6XK/?=N&[+@2'7W.L=>S3'64B@PT&&R+,4 Q
M$'(,B:U#*-ERW700759AG!@PU3V<.A16?J86.XIE0G6_+[BCU#N?*%=W'DX"
M&4;FNFI>7G9W-CXZ'!#$3BW<FJ.,U!W!/?@6?)3^?9J%#/D:%/S;C&()E=IY
MH9@W>#U!J>-<UF/E:FVC6:U3B^FU-XMZ-,:I/?ZR]K -D=A2?*#(3/5"!IQR
M\NL,FYZN[5B"=&OZDXOI=1])ZCP%OER_+B7K)49O]T4[B0PQ0 ^X("WBZC2,
MGL+9Q(_NPO?<LX[:CY0GC:6"F_/GG9M#EZ_/.C_#'L[8[NNGJP=WZYTG0]I+
M'C,#%"5IF6?&?6=DW)-5YKW1D:LF!7&M+VKB$WH],<U@P> >, M=V@YE\@,%
M)P4Y!:E)IG2TG'2?OA4^QKZ:-'<\'N0R>N"AI^Y;TL'BW9Q CR?XK;RV^ZGI
MNNK;BF1LU#PM"^>!XU[6>NO$1X&FRY?Z<MTGCTDE]Z6>\TMWIF.YWG[Z"1-'
M/29#HJALC_)L5W G5!6CS!\FR%F\0R9O195$:9SN=G$!#UGWHYG^!U<$P>D"
MM'=,ZXG:R]P)]PZ6FE;]T929KTNN,K9E$72X5^ J2E+[;=V&X* JD&GQ;QD@
M[H; (F3[LJF0-V'HR=G!YT= XUWF8JUO8Y^V/>FWC+/5E(5U=_HJJ"_X:>*.
M( ?;IL4B=HS)564?/5KLE+X^@N=][V\<X]JOV+W0^DL'%(B?1E=MET%"<'=Q
M3#BLXQLHGD_1,@K=N)W6,!&#3)0\]GUQH=?VI/0Z'^(7_EEP,P/$T\2#.@V$
M!)' +U(%X!\]* 4_<B*O!=8D67&*W^?H?^TU,;A^XICA35IN)38"?0+;H$\*
M1,>*GZ+DQZU+&<5 F\@M8Y=N/A2W>5E[I"#M2P<Y9$9U62& <NVBN?V$W_*)
M$7.#1:USV8VL=_YYZ8P5\84!VM!&HNG-%QF@/36X 7&&FHP01H]Z[S! 9N+E
M5&:PD*AF0NA5"00#E&-5H2?/ '5:4?)I$>OHS?<KD.H-@9NOLZ-E]</_N08S
M.!MW4(>#E!#% )$M1&@G"9,"J>+2K]JX),^[!%0EK=J>4;@2NP3J\)K<Q]M2
MPEI'K&9X(/?Z6.%U;9BHX'/N 8V8[?GABA75E%WWU.YD/) 6HJ%#K>WX?G37
MNX^T&#9+"]GB#N?R>Z+C=K&I+M0^QGH#E2CIA5$7\0G7<5,CS; T.'^@0H#A
M6?2)%653_E>Y*_S5U8\-A1)')%^J',])>JC%OI$B;NGS:FFJ8GIE0W-7I'Y+
M;Y26RTS#??S!X_@L.2A3=J[- HSMH +DLQKB1$E3KD[%LP<7>"6UO7:-_">;
M*OOHTQ!N[R:YX)DL$7+X.X2Z3=BURONLVA*2ZSZK'X42/F'9:.^:E)%N1.FU
M$#^*@&$Z$<'96>2!CY$;61/]H&'%<WJC3Y,V<<>/V/2Z@?99CW.2/BH\T[:+
M4#//@'-SE:2$"0W>XY+_:60M=Z0+E%L@G? V:YA=S6/##.^I6Q7 /A"'25P5
M/TN)3]LW\YP1A[CM:R,GH.3I!.\LL5O7+T,?O+D3B0]NVP;A>V<^X>(;P-)?
M,2_01]5@0ODM8&$@>DX$RF/6+/^-Y_H524G0[62Z99?)ZS7-TL!9')4WG_@A
MF0(S: +"2$<KH8=$(H238^U</TV<9 W-<M#OO!G+N<$6,$]U1NRKH"Y1L+%;
M0CH>1"P'K=PV9;MY><( GN%6F7B;BI6>?_+DY3?E:T<X0LQ4I0[^[/3(&72T
M_L9KMV,[.8TZ#I23H=M9@/0'U"5\/L4Z,@)W8,FNIBXP2NCJQ]Z<8%N1EV9)
M 60+7TBU&],W!!Q0[D (,1 <Z\3?7U%#B'8E?V]23IJX,5[5'Q%K&Q+7$WIY
M<8&3.V".ZK7OA.2$SQS0.4\(*W9$<A!Z\PY-]=9^O!P\[%\1FQRS#LIY]'7Q
M)8A8CG9?\]GV ]8IYJU-NK#HZ3.#BKZ&QA9J*&FYJ!)166'L&YN'9L<>M7MF
M?_1IOVG5O_E[;8#D@+? G!Z%.7A4I^"KDAH;AQMB5)7SN40*#]D$AK)@!S&C
M@2WBD$&4%Q:ECZ?+_L2<%"==45<DZ+*VFA?"'+2??74-[Y*4:U2B_9+]K:W_
MZFJ"PR#&+GHY2,S;1;W,5BMW_3!AX<A8"$O7XL%8UE@\G@$ZT'0JN&>F'-.J
M3P$;4="Q#88%=A-F5>+"&,/CRJHQU0]21:KT6"0D6'&53XC$>3;!DB!%!HC3
MT=#796Y&S$*^+ZY!7W7/Q_VW:<&U]?PZ7OC=>W==9 )X!LID"X \4C<3#)W0
M,2>N%/"/!'G2[1="CET)G#CM,\/*UXV_AW#U,?QTPY#/X&_;;[0G?VK@H#L;
MX0S0]@4+)E?(QGZK^X^>*BHS0'[!!<W57X(-!RP'U VBM[CZ*H.9E*HYE.Q'
M/4V7:01^DY;4,N6]L*5/8K1%<@[Z9!?IUGV**NT9NU8C@0O8]2$IQE3@P"@;
M"OJ%JKFF*DWB]K""HKR7:SM \I-[-SLK*AZ*,VD2[J'<G6B!'"P.YEBBBS<"
M$/]<.^8HQI(_6@FEIFT,T+CY\;']T2]ZU+LXK6"],0 -!:9(]0AV06@$<<0[
MJ65UK4[IR,NU(X'8//\:__.W7JVL+"X5N[ ][<O&S;[&;3Q9I'^QQNSQWMX[
MO^^)[CP326^^P "=Q?;B "E%:J8F _2);Y$>SA<<'3R.V3!YS_QW+*2SJ.,[
M Y2PH0G_WW_W\_]>8_GG7UW<*F& Q"DT"\/;\NW_4<WH_T?M?W[L_[_1G.+(
M$/IENBP#5 :S9(#ZX7\PZE\>V0X!-ED=;RT'+$?"_J,=XO^P_1]2X/].VT0P
MZ6LG+\#LQ;&BCW8.JXDU(J.IB= 7X*V)JTQ-1?].CUI7A/4?]66*5.S\W]3)
MX9D0!FCN*9D!HCWW8H V/4<BVW"[,M.J3$.;6J>_UG4#P'1C!/>?PV,S#)!1
MB3O*GHGR2TC0?:YI!NBGP0@:,:>0?]Z0U^J_KZ[_F:?CT61K*^!1#O+C,CI:
M6!Q+Y.:NC"T\5!6C$>U:)X6JE@YPO<25F$4*B[5FL6LZ29&</D8Q2L3:3]@[
M03\XMOF+-<Y=-I%RG[Q@>YS<]2A4.WHSM_:5T?=]MLM- ,>LHT1S$S]%H 46
MG3)]&E\Q(30^/6B]\7Y(V)?%->Y05UR2WM.Y8SDA,%F4_8"<#H0":=/R3LU9
M%A<?+%$3>A]F-ISA.Y4M>USB]=Q\AT'G'GY)O8U[O*@M !VOQ^7>[^YT=$ -
M(N!N]X#N^RL* 3/WOS;J:-)^/:FX /?05XVLW@&'\M@PB5TC+J8TNY&B:M?8
MM:Q^@=-8CFA0^_JI90"W&:%%4]/)$?7+E6/FYM+,WT>'H D&Z- Q("&/J@:H
MY#DNC_BEINRD?[?Z6'4U9)A:")/V$VSF :(!\[_^V/ F _05!IF;09UG@%QT
M8'NF/D[W%=["722NV:NZR@;>]B&! 8_UP^@?)YT8(-RG&TSXHCO;MW< /K.S
MS;X;'/V3WMFR@P[4JG6F%NR%T84#OV(V#^)QZZN\Z!8H4H7^+'V'1@MM@F4G
MK+Z%^.U\FH_<R%GF_D^[A'Q^2)N9;DD!=R440 CY#4(,T"6+0#K]JS%5=2<,
MLG04BYX9E9W?._=/0Q^S0<OHO6. (K+(;C06M?7]_4-@\N T)P/T[FPC X2^
M@TU=RMF7YIZBK6K^0\C_2DB(&>3>#+L[NC(<]V)^H%2-ZZ []$$21UL\5+WW
M1&)<H]*\>%/E)AOU0@5L4Q5'9XTF8P$)-VI8L!P#A/=B(@/].NR S.YW)W[5
M(K/CKS[_WM#X:&%D<2YG7A%P=L<M>:"I;,P)<1@R0 9,2YS5P!:YET)=:(L[
M:?O07__96SFC#) _C; &J4MXC2.$9S/--X])!$29L^:4%Z!Q,<=^1FPJR4[X
MTUED!7U9CQG.(_ACZ!&I#-"71\;_)O)>5;1NP@YF6GQPOV#7G"YHI[@G#&.
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M7ANB^N9[*A9ZGNB63'VE.W XS>D21X[7(<=@*T%725'\NS]P(JF3+$UOV6&
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MDP:$*43+>$*X6D:17WUY]9!DZ.WZN",G'B0=%5,_.]]U0O PF^!"^03I8/6
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M]TVU:N!@MG*TO;"!6I?CD9#]UZR3PF1WOU#1;=[^\6/Z:$2QOU5Q5ZOF([F
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M WG!FA9Z:%=%37O]B88<5<C;!X%G%>Y75):][H%J+C?^Y\)/?@DS;C3PKZ_
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M&4J2 VT,"7?EF8"''X7S>4N9YI?VYK1WZS,;,Y4DI(UTR;]M(;ZX=$2DK.F
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MU;*J+]ALV'BH$48K*?P->9<!#%9,)-6\EGKF-_<1!>NW%MO\1N(*FD\?)3(
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MYN-]?=_,UL">8?8%R)%52&%$S9AG\/<]5&BJ?X5V29_LE%/A5G6'>HG<62O
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MB5T<F/9VK,$499+U[Y876EB_1H<L2><&;QL6W>7*>7BSLF]=4%40'8:\U^&
M9P!AM[L\.<,#N"H(G9$:_/*&$^C%9TEI9P2CF&-C%R('= ^I]B<P )7!1S(R
MJXYRA*0&'&>EA%:ZWR1J+\X;?R-<D:8L?>7[$#_VFV,L4WS&Z" NUU^:8HQ@
M(H,9XPMH8<K>S.=+"1>2*S_7/GS?YB/="Y\Y'2*Y*N?:ZJ 1%,BIK>NCM^A(
MD1FE]R"YZ5\]9X;).I?8/7/MZE@]1(V^\QQ>B=_]\ U@=$"J%PJ'"R+.$7NL
MG1Y#.:@FXYB@ "YVEX^O:=SX;E;AT(9NA7<F*7Q,FIS90I_BJKR;N/O@>8E+
M<+FOE+D3B)NZO);O[O^Y7,&5#*'KP3EW5N;@&,#%W'L(&S!&Y$X:4SC&&,"<
M3C\2["6G'H-5)^V9*P-8=^X/:<1L28XI,H#/HROTEYJ.)/KY>?>7?U8<.P>4
M+<D&0P[0^;PM2<)5Y#(\]CF!O&)?,A"-FL;FV'T/XE%TWGOK/D=%&*5,=<&.
MLX%ST'$B<DR"EJ+A./%6=.$*(:;!T*@?=Y50M#$2,RWU4ES\=67[P7;.CI1G
M7&\XX,_HBH4$3BH/CTF_;*5T*KEI#,J[J&:!83=PGOX0NE<RYX">"=9Z%;(W
MH-M>FO:> 3BC@V31$=+0RUT;PR<5JP0NA[06?M&1W,7EKB\N&1EGQ'N@;TK6
MZ921?L6)[2U7A]=C%0$9<A0]ZAD"ZBG4U0#'="_9UXDN8.AH6&0'7>+6$DNX
M(2^S>8NZXN81FR(%(RV3Q28PP:C"EP$'" <BA^ZB/!SOW<B/=G(\X21_5EY!
M[FOS(;0W[0/4&0/Q5B$-5!+<DH<.=O%8]4B'#"E*664,'JN!;;8'KZT5'W _
MVWQY'1L*8[?$2U!Y)XW[X XLYPDI(? \W&7RT,?C</'##*#G?,:/J,M*&0?T
MC=UL5JIK/O2]7O1A ,WP[VT3;O$$B<9RR\#"&@R?!DO&=]B"5^JR#T?+O;8K
MNP1.,C&]#A:L08O08C&.J'W>!>->#;+A]).$_O=$-MB!-I(-A-5I0%[;\:90
MA;Z8'J4]@.  UXZJ?X1^QP <8=%(9L0=BHEWGK^4)7&:7D8\>K=G67ICP46Q
M1^3QV\SGRFO ]W1+U?&U#L06F'N8 KHP!9P-QH?LJ%)=GKD&^OG]'[ME>(P*
M* A++7N1_8EM94]6I\Y#[DV4*IU),+(R?9FS[CLW_U35JK'*2%@/K++LB,C)
MV7H1 1VRA\^XGT&'A3 '\GS2M>1Y5I7+>\5B6UZQV@N?%2ORU5N"YB'8R#Q$
MOT8H9TXU,#<4,9=]^*&SNW?)U;!-_5V7A%O;.%]BKJS%^&[&1#\N=WM/5"?9
M$/5"*U4SR&;XF8)<F[:<N6)OJ]WG!EY9JE)&V=U9Q30L92ENY+1)6G-CC.@/
MT<,$ON7L<=5WT7R]KE0AF9(+_2UWCBV>UZ\7$"Y!E#8+9@BE=#_\D4/O6<%E
MGK)#KT'5UOL+[<[WXG*PMXZ;/2B>8MWO]WS\&4'X4)-WAW\;Y0S9DA1 RZ0Z
MY9#9C<G0+++OOD=S$D&-(0T\(W87+ $-XM3Y2/^@_<1P<I!VYPK",,]I2/G5
MOM)>3_;0)>GW3GS,K8M\ AX'T\2?QFF+= 2\HK?XAC1G8T5M$5ID%&'Z?H (
MV%OKW\D<&_EAD-$4V_3:S+7WIL6M!WMU5#R:K>>;#!(Y,AP7X/59GB*)(3,Q
MX8]^>P3A<=Z^4]2-LQFT-X"+M*XGF+0^IVKGM"YJR3EI03H#3GM7&!+>UI83
M^CYF::@AFHP5$))3IT9'_ 8@=OE>^LFY@>$G/_U<\F6YD$'E5J ;+L# 7B40
M3N/C"] =^+=K/CY)E(J-BWS5S*LR+]85BW!4ODZZB,N89'D)^37>T*!N>]?W
M-G&59+O\%+VR/8C2UF>(4WO*FF^V?'/I?EEFWE&LA<LGO$:H@+7[8"4+1=8)
MQWMZ \4Y/*\RM)SY7+]CF'/LO>F'3*Q4)Y\8<Q7B$-%N69S\"N]826BWYZAP
MV;I2#7ER4Y$TXK%/\$>5U%*4 (P >XK@F3! \M"[(8<0(EY:,4YJ3FT9HXUP
M(46=>T]^NW2O].@E\8-[6=&Q#.">[.Z%%#YR3/;8_%5RW*QA7]YT>8\GEF?0
M .[QJ<[FV$1EHZG!+M;)*A\R/ JW,;#2LRS_?+8:67L*.36'I3U!0]=/9J^;
MD7K!@*O+27MVDVX(>XLD7(9MJ7F U8 4EL8F2>.E%4&G8G7 <DL0&6\9 U9R
MD"GW?UL9N6O59>B-K\&<4Y:]3.+*C&;XR-FGKX-*F]]^(*@VWS3/=<O(+PO'
M#SE)+Q^[0>Q@?_GH9F>@*LO(M6M7]VP5+9G.6@A]&$J8*O_M!G[;(,2I_@#3
M&NMH[--O3B5J_6D^60S R=99P&Q>/8CVQ6KPXXB:R-0R=O):YCL.?\LF(7J%
MLW21II=9K^O+*1T?'_',?3\>%W"9_*"?Z$>HSS" V_.;VY:O8Q0654QU,"(*
MA9&3$NC<NR;:0K[-844H+A_DT% 5/6N:ABT>U5?&?<0_-%\?M:;HEMODJI'P
M=7,7=Y.^%!HQ+3PWY;B6^D11*8;+N?I8K'B?I\&HZ:4FKA4W^UMIG?P2O*,2
M=KWK[,]1!KUPQ:_?7>4'OQ'*1%^9'I",XF7R,N\O$O&=71)*>>^99>L ?^NC
M?IF\WL;MY&GH93:PG\6T%Z[$O,OGH7^>5U(;;#D/_T SV"3UR<X9RO_#W]7+
M+\[5'@X\=?(=^U!Q699+CYYR1N;HO-G%0,6X5:]7"7JZ>\)J2!GWZ,?Z*M5/
MQSFII9.2Q".*]?++O*UJ5($$L6,%/]X="*.+>1?K\^$:K2?+ _E>F_[V@O/J
M@>6-)P67"E@O1![GJ+PDN#SZ9E:K;.5*ZA/EF*C*BT-)I##BWD^>G+)?*;#A
M]+5*S#)\]&WE^C?)YZALW)Q*':EI>Z9UG5NWH[#C<)IFP)TC:QN?7E[='3]B
MX*D8;RC6H1AI-Q4;H2"G*A[_5:*_\%$,OTLU)"RUNZC*X$I4M-7IO*E@_8VC
MURW,>9DT^S8Z-GI&;4<,'CY:*IM]U58!,6V.<_8WL^_=: N=[2V2ZKCHW7O,
MP.O!ZI>3J@"_^!/-'9$7,0#6DE &4'@1S,"L!W))1$B<3/6H;+(8?88V.+ST
MQMQ.I4$H+[I$S+AWY?Z>UJ4WUB,:]O?6_3^X'4ZI+D+I O8% TK2:DTSK3TF
M%45?R@53AEA'Q5[3-E@XR'U"__5R3]8_UNJFP\F;,?/.DEEN8$TB>>%ORS,=
MC'O=UE^WY"VZ97RI")U1CW 24CTX>6C_!ZY:34WG*EZF#,ZPC==^$8/XOHU]
M&=5[W-(-LIAMF;]R'W3?VNS02UO8S@BYZ_/HK=&:0<* P]<[#P@%LN\E+^H5
M74U]HE2(%G 9XD317N4Y6\-3AJ<I(E.Q/E'SP]=OK_IH%?'GXZ5M&N0O;N=E
M^W_2<-@W4"(K!WM_ZZ%5[]4]TP.>BMTVE^TN$A\5(^5R+BP?D:5-BCZ>Q?&=
MB,';.=3GBCFI%=$3NQU\\LN]#28_/HY-[@ 13A$?5TF.A0PH20B\8W\W$ <I
M9.K47T,P@&CG:%3FZ)Q*[.CW4>,[7ESM'L.7NEI">N5?Z%J <,@)J0&Y &AQ
MT6'8FK?6@,2VL2!M%@JELBOM30!IYXVK?@5"8^5]3)7>K' ]TC0/CXU== ;U
M>K?9I*)[.7&^==Y//8%28-/25;I]1C7;NCE<"<6UKRDWQUGH7>3TGHW>>-=M
M-PF^5[J G9V+B:%T86.O3-(5QS6A%B,\V.N,G?H9FISCL V^U:B/V SK^9+^
M(?_F[85+;G9'XVE3+"Q$OK?_Q>K:25PQ"S4P0)@!#+S=I+]D(PD15X:9Z>>@
M' Q@X1N% 5S>XVOE1:G;>MU%QKX&@^3V9->.KYZ>2TY?CLBTP<T-) GYTPK"
M;I07):0F2AQ^;FG*%CO/X>F;T;02NCT:V:^6U"#+[\QO=DK?-6^C+>M6K/'5
MUNZ#>KV6 KH&X7[OA40AQ!/H"6E3$>/S??!"0Z.#=5*CRM-+L]KG=DN]WR_/
MRL+RPL5 AQP/MA3[YP62AE0BE$:/;6^T)UE:"+TA&#QHF"J,CF9_LRD^H*ZK
MPKNIH^C) +B=Z5*]4[V>'184Z][;3/9K)F5^8;\=>%(1UPRQ_K[SR!<N3#8P
MH'=T5CKBI7D,OT(=>CQ=(KS=?=^&3OAL6TKK'L[*5MPS+.UAVN-YK>_TAG"%
MH>'AEI+/1G-G'?J"@DHAB/Z2<*WCWI@F$M&&'-.8O!+J.N%*;,QV]A@]IG(E
M,[:%);ZGOZSUY)>JQ3VYLN95G1O"_CJ&E:4]Z"5<>^!\MT7X]=\>W?$\DK6Y
M-Y?\NG%H)4J)"8F7AIL.K-3M"^[/]CG>^YY)7&9+\,W^%(5HPSLFN@G++(X?
MJ"[DB F:,LZHFW[$._M*3V[2;?['OM.]9QHPH]>L=F62=GW2(YHU=<UO/\])
MD2>R.9<_.\\^/-V7MWO3Y F@?QM7U@OL%8Q](I64FG3:CZUE@+ 967EN E*,
MO+$P]#&$])WZ&KTX/.A*[X) Q5\+PNV-6<3B]4(0#FBR[C+JW("G)L<R_HRM
M\FL_Z?QDA3Z( T>K/R=?K*ZZS,Z1L+_]7)7OJU+# +;8R6AZX\YG$KJY/AW_
M=LG1;.*6G^A# WT#Z_T[3TH&\HE)H8I5>RDZ7P:*##2YR<\K>J17[D3WCT<_
MOQ2TQZ.9R&R5N,D].**GP5W)TU0[&:<LV5(S=5#O2(QU=+@%LX,5,2,4H9>G
ME^N\3<_ZM"#'*S=O.?"EPSWXP-4PJPB.C%BL2+8%)&),HWC 3:D4\1!_O2@[
M-)%UX^1&1$)9HEQ@9G?(2.N9,Q_&;Y5)GG+/JU-#<2,LB,V1ZUT9Y)"FE&,#
MZ\0C+ZV=DXL:V]6;M%WC5 \=TIC42'9\'G#2NZ?VL>R="9R@=Y!V06Q)577"
M)ZR+L-S\Y:9QGA7;#E[WIO[/5B*B042I)E&^ZNK*+@TK]+V!I"FET294%A9^
M_.ON%[=O/X#M1E6E9/3GS,,$*GURYH4\Z>\G8[AQ.*?N0_?S\HHB7MTI<C]C
M+>%XG/7PG4M*7[OT3L/]]D0_'\;+1IS>,#0V*R$:E<&SYD.[<&.-65<*QDZI
MWGE5[_9"="*LPYR  94\[@>V2F-5G[Q]5R^LCDWJ5R7V7S2J,+A8$[MDQ6LV
M;??<=8ZN1I2)@6>?NXF7MF_BN.Y@$CU$O]Z_[M%0>YU5:\U_D3:Y8$Y5QT>Y
MU&Z']BIR.%SM1->]%+"^,Y+8O:1Y<?W(Y+#2*UU^;<]NQ WB>G)9'ZS9_H3_
MU3K7J#47E1,>K N05YC']:,>X=/ORU/&YF1N)5_*,VG(EE<]D'= 9^_AH!0/
M$Y/S^O>?+$R2FXF[1-Q=G32\\(_Z[SYU_=";9%4F(+M/_9FK#*V1:>K4V;V?
MO-/PCI&(ARX<Z# -.[1W^)# VK$0BSZ)\DO#@B/98B\.G&W)<PNWS1^K^P*:
M9N;-GY];G.K]^>W%$TV)?SSG_\$ 1#%3;MW015@/<ET;?39GCKK/X$9JN-2Y
MGT\ 77Z [L3R_'X1NR;$OD\Q0O,B5)(T5D>Z+E9^A:O8_"+3P.Y(9;T37TZF
M5X^+J%F4A%;>1)/K;)P\:1YF \>+0L\QSWO%V1;*18<&?U\R^7$V)_DD<T8(
M'A7E^K'[;DB3_=%PUQ,*!]Z*^^;6%;V\#9AR0^2R@/TR>_=X#'@E"05/E7A9
M<H^,7IG1EWC5UK)H9* @JB]1EGDO]>M]ENL!LM[$(F%#;?)DPT?Z-TC!L!T#
MN&^[]5FW>;EK<]KRZ6H@"]\K/%+8.Z)IP,3..Z9!"!WJ=M,NMB,;9O#H1W5X
MM]P1/[:FU"1)ZP]2(GV89G08Z3'19IBJ3WQV\'S@67Q$@X!SZ+L;DD]/ , -
M)MO'Z5GV+M;!'?3W7IJTC?:HTYN6IH5?6A?=VY<;$F_YB+])SM5E.W7_R6(A
M,@K&I0']:.-4;AE#-4^?Z_\Z7>MX)W=49[\!K5?WA63,#2F6AA3)?NJ=+.0]
M<I!5K^>2SHV8)=_TD22%^X?J5MR-]AKM]4MN2PWF?=O-#@:7:_]Z)M)5"6$
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M++7^OZ.]C/'3#_>MJ C[2V[[8_S:BA\W#^SZ"$H5"@.ERI_! )ZX(XE*WQE
M+02>YQFE@B\9SCM>M3K3H^S_OFVI==3QT%PW1C>@F85*C*%O\4T.I%D'ZQG-
M#??.O'%JLNBEEOWS7J!@(*"O=[*;@?2H0LG)M(N4PY"U)BAERH1T%CH;B=QL
MR4/B? +$ U;:_]? TS;'8*'_@?X/]'^@_W>'KD2R+:1</M7E>; F3F]0'$L/
M,D'62>0A.P5,0&A]:!U&C^H"YW6W7HJR/%KP9(^'%EA&/0JXABOVQQRDX5X1
M5*C'?&=I3)X0ZN[XG0TTGAF#R>:=3!I(2QPRV']M&KVI-ZV7B!F%),B"0>4H
M!:TP#B=?V,!N[YJ'DEDE=C9\V9<",J%MI\< F,3!+$69;8,MQ[3&2"/+H9)0
M_VERR'(E]BEF@F< ^H,]DP&,BZ,F]'Y%*[6"^CE7HXC^@YI)VTS"0\K7M/;^
MDQ@((6P!M;ZG%TG@-B:@JQ$_9Z\.4-)6?Q?'0CM9F,ZEZ4%_4AY#WZ6_LT7\
MKY*HWOI][N_$_8>7__#R_P O?%,,H A9SP!X%]1@]7T]5+E<Y[WL!ETG"WL^
M)K6=>*#M^NG!I=EDFLG/>^2]U@N$+I8:)Y:-C%8MI'%:5[&%IQ90VIYEU8ZU
M4W<S@&"]2>PV5^7.,G 7%/U8#/E:@ 8#>"_<@".? /G'2VVSK(K1\?1K/EP,
MX"%2<@-9]!#:!FGXL=VHU4X/@$Z8D-?HS^ \R/'D6080FD;G@\1 ?UPDJM!9
M\Y#D</I3:B@#*,4DB%Y CL!:8Y9LC5>;B9PY9HO8V<E_S/WGO= _("TQE(@M
MDRD]6B,UD][7P !.(P_^!_'_7Q&CM<D*A.:FQT(9X:(+M?0CQ58:*ID7HI03
M'CQ]^\+5Y.542GT6>@1Y#+HL.WT55@\A^0]^+^/B/IN5Z!0:5W(:R>5_"W47
M"<40LJB>8 >K%X8D&((%>(/ISN%3Q $:J^AQL&I6PC( +E@9KSG2&0]-A(;2
M\XT+=EXT39B1%^C/8KA!5_]3#-!HS(]+1-G?6:.UI(*LZ_UD7><_$/\M(3YB
MZN B]^'D5 V#'OJ3 2A5-V#:1(^4)[;E0 [I/SJ(BH$*5PN2L5>)%@G'T4'4
M<YY"/ZP1]PE.E@>83Q^1C^/)U-1S7EOY]R"[JR 0^GDX8 G9=VINR73K]UC[
MV\QOOV6[-Q,%^D^1'->(8!**:4:MBWF_9@"[=W!#")E4']"05<(POQNRY3KG
M[W[T,V2;PX9*4=,Q>.A_HQ#P'\3_.R*NCV&ERA'?0%@"CMH8[.R:J?M0H_QA
MN$!W'M_4L):-\\NO-5.3Z3Z;5$FD"+(S%@^C\H E$)&/LH0_:?+(9Y\NB^\J
M2Y6[(ABG+3<=R!$+O!0% NX?W@G]IS.B1\)/,8 _@_2!=JK*SDF&D^AM;@V#
MO\H9NAKH:6(-F#\\;?-8.+3H(02L8+3^ _+?"L28 *O#")^;Y&#3UQ# GYTT
MH#QV]#\V+OGT6)S^J9I<2#B2C>KJ0U1OXJD=QW!A=Y=W3#:?MM:M%\MZVW+C
M_(U U1;TD(&;VS&6V$JDVLKMDIAV^"C:;"B#8L;EM_IG$%[Z3Q#^#^+_CR"F
M68&N8T;VLB!@:^P>#UAUHPLC$@?N>(9<+?(^G!5^1E#JR</:V:'JO-\--?]#
M:GHU+Q/VYO7^9HL&G;B'^CZVK>GWC)0OT5V=.(]T=ZN,:F8O&M6O#TS,-L<\
M0_%H[2'#C 8T_/PG#')W_W#U2&O.P)X*-SR;?X)9Z+.6SY'X@:!8V"Z$)S$=
MW0"/'%,FZD9]2%3VK49[^'!4MA5UV9_7OOE]>V!N;[P/,?LB6-HGT?GNYH]C
M@1]FWG='EQ5A!_U3I.(??EN(K/8Z77E)+FC-XRNZ Q,5[S( $4#<E V'G][@
MY-+*4(>-.BWFPD\W1L]$HH7UY\)7">$:JRYK#.#I=@';XPJMN'_N6=C+  B6
MV"T5'!OR.U: 'F<[T ;Y^Q+<;12=;8L!G*!,&%,.X1E MT'R="Z= 7 NE+W!
M1,9\%3J96C69\S_:6>V?/YH"2(4RLD4%CZ4][F8 Z\*?:,?0'3BRF",U*. T
M QAPE64 Y\K1W9)D*I+27@V+TQC"";.=3*U<._A_<U]3YI?$YNTVXS1+63N]
M/T]I_I\F_/_L)Y79Q0"F>#@I'=2%I+QLG:CTGAOFAXZ_WNK<DRSUFAC2L,+I
MS:_C^F E<U[[]M#PC44&X+T.^5;J@W2ZFAM:J< C2U,LJV4 G1R(/)5P>41U
M=EIH7EGBG(24[Z "KFY*-5&>+5W(.&'3*<!5M$S7AX6J6(E:EQH&T[\E W!)
MHPO9&V_S@0&9(,4 B@90](HI**AS!B".8@#''B,_#990MT&MI]$=T5WVYQ@
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MLB0M>VP7JF;40##T_7PIR\07K>=I9M7/4V;1S3W;+:*3^]U?4(&BZA9Z#UP
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M,@TL)U\A*/%T4+ZJ'%FF?[%>ESS05H&57R= E@C9H,X0X:A+PX[JTHZ5(2:
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M$6T)LC)/!Z%UJ1>@2X<VY66!HI VQKA*]6=C&<PFH+@5]'^.!_CKF@GC>XB
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MIM]!@VB'- '(B], DA.] =%) A"CQE^0<R&?  2K"2"%&)@QC0;12T*WF#0
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M85ZW&MP*@A:9 KS6-/COO ".\QUO96#T[&\WH/&NWF!/)("02)+_XP8E\8?
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M9/9 4X<G'R6K,EWZD,M$4!;@SL#<N]JF<*-@*HH4R?"C/>]E?27S:/(R+:4
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M\1PO_G<N]P2%P;8?>)TQ=_IJQ*5SFY3YH#'1]*%GNCNO-%Q5$=/^+4)\1]V
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M,BRK$),;@=\YG2VK(B9QQ*OO>NR3\J7MPK:-/Q@"]?LQA5XL4UA\7Q\R6&%
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MVR2WXL:0'"K$7D' POX6!ZA0E36.M.#-$*&A;K^@I.YU%(M&USAZ@T,:;_P
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M.2?B).:B0_9V*LNEV;,C LW,&H6*=EJ2&52:KDP@V+S9YOBK/2OS"!^ID'Z
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M]J!N\?M="#<Z7)=)PAK/,&2<]^2;7= O496@EPIJ\ @OVU4-TK)JS<A#)=%
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M(B:OA%NVC:$6T&U+D25NMS6=);[?ZBI=4#RSKK1J:\*H8 07UDJMO"/5NZ\
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MCD]D(R' QSN-Q[E:SFYTJ[ZWJ=_X9K_0P-3'=%V/<1T3JAP%HT?L9-3GK#.
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MEQ?3FKH#Q6>,Z6,^K?1[$\#+WC?I,2NE^SGGS!QOO-2- ?NV*3Y=G%CJWGI
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M;^CPL^9W'<AL&\3%X*+(XN6L+^,5N1^L%OMXZPP6J/3BEOTN)FRE6R<@GM;
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MQ9H1WBY;X/W:>5U;78UN1]'Z#P0A->T'8BM"9E<245<(3=/;AG"-XSP74I1
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MY6WR8PK^"'"::DK2S:GPLVIV3^FPT)-X'];4%GK^17LB,JN&9W+$MG*BP8R
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M)LAY<-Q^PO%IVFI ?.>6L4D-I7CAE(]?;$7>6(GMV&?JZZOG6Z'NB\@IAR-
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M)6#S630*,'OV[/IW9?1?A4> <DZN!?0YA!ZEU.<5$V7T"S(@Q@J:#N#!#TG
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M0S?[I]T"4^Q2-MQ(SWM,ZD4G!^!^^Q5O*C?O'-CW[4(<8TR(D[\2X(.?$.*
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M9G_;D<2*!T56)@<#/CL KS1SP"N+!GAIE32EYI"8JF!6G[J72"*ZQ%<)/9M
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M/U_P%<3NG2$(GDGKWO&EZ_]B[[V#FOK>O=$@4A0ATJ6K@"@("%*D)2+21$!
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M&ER5S<SQLJOW^!55=MI]?\.LX+M@4\'HV)9!]CFT17R6394H@/-ZP&1,Y7Z
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M1H;-YIBVHA-"$\T #LR+N:U.5J,P$ UC<RY.QFL>2OY]BB\IV1A>0*)7 OV
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M.:PMD'MMEUI'0%^VQ/$+8^KBH8ES4]X!4E5[8NV10NRDA,-<&8K<J/-FU90
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MB06M\!OXI$L+L&.Z1X^1%^&G 4R:4[9=O5DV+!E^.8(B@F2/[?7 /31 . W
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MABQ2+CU^-DD@(M5OM9##J6?K1SR*20'6M7%.I <6K^]DW;DH_$%)#<"W:I-
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M,,X-V'@0<W$*I3CD)8HV<:E>D,.&[&'RL((2/MLV]CRL&Y-C\-2@(N#>'\^
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MH&%50Y@&X![]_2"E2V2 .Y9/+"%,@F$D5#GVRTQO3K5U*;J6]=6I1F/E5X
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M3@H>87[8\)QDJ9^?(8]K!3'NIXP]01:[W+YK2;CI$^N?8G)9NZOJ,D _T(S
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MN[)$F##<Y?N#:UE&U'(TA2;TM@F [*F_$ (4F4JX"]FD9'6&@$RHW;JP6J=
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M6,\3VVD9I'Z+!O"]RYY+\<]I\^Q#FI]4(FD %-H%&"N[3+4[,*0!%H!TM^Z
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M:%!D83O].?ZFM);P^YZO]XWKJ8<T0)N^DH\*8BOW^,^4S,<WL:4GI1XG.S0
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M<6];4"P4)5(L'MYA-+83J]WJ1RH9M?;8"7&'C)V9M5/($7J=%ZA5!_BM5QQ
M U1&1!;!+H":/2%F;YKRW*B2X0L+YJ:38B8I'J>J^4$O :ZK&!:XM/;'*6@<
M!L>4/RU3];(D/$FXWC!+[9+47.33C0[!@#.=JU%KFB(4NS1LQ!H>!CF*&*]-
M6Z[2A68M>P=PUE;;[:L2[%-J< VL.GB>S>C<X77;%H)UQ<]&SC"V5^4)X9L9
M3!JKK32 BQ33IO9!?,E<0U7BJ+WII/F(*?\U":%UR4C9R?D';0 G"M>0I@2\
M'\2Z?3+ GA3V&2IQ._AN"OHGDU@(?,6@XL>6ZH<CWY[Q,3Y+# E&/*.J$BSB
M"=IMH!/JWI_93[L'&14%Y2:7\#4;!CO-7=ZZC@N2/WO>OW/[,_K+6*R"-P^\
MSX%O2*%[:<-?6("I$ETN9,BX%_<M>;4\_*BR0>',9#7,GPR!5MD-OO<J1YV$
M/I)B6OA]ADFI+M'_74?"<+X%\Q#C1.C5G3YNF FA8UT*AXAPX">PU8J$\>3D
MM.Y7]F_FWK1<.+.BJSXN&-N1*V_O'5=OA 6/]\VFIR2Y8>DP/3)#GL!4FNKP
M$A1Y=3 P$7?$--3KWHF>?J?75]A?HG]#T7PTP!I7+@U@$T&LHR.=%Y96)#U<
M<(7C)VA V]7&G$OS]Z-,OAA,?PN57VD9#971Q_-B:]UZ\K4(D_8('FX,,=#S
M$[53;N?GN<GJB]#>H*?K]O%KFP1?,@[88NTO?*-72KE-P/G7OFZA^\<]D^FV
M&-R']7,)#:5Z[MN": XWU8 (C'W-</&# ;'H/D^='+!8=WN ]Y*NQ*+Q.,*T
M?K"1DV)*>I/"F8;@@.SG16[7Z9JR59(.QB<G_21"KC.%JJ:0V D2X#@C;1O2
M/-9(V2:D3:I>[>B9"8^;B^Y[MXM^, NE',55>,"[T9P5FT"H6NL9N%0J:SP'
MR=:NKE]FLWC(*>#B$>;T\L?R2:]!=1D["QAFN( MQ8-DE$W1)]  K<:<[KP"
M12>#U6V>5N[#T_)BD%,LV+-'0D,65'8*$ ^@3R8W62BV$5KUP>NB"-Z5RP\"
MS_=(&+&*1F9+__IZY=Z&^H>%4!F2)JX#6:'87H<5E!%>P9RJ/P[)-\I=/D,5
MOC7X>ZO3-UZ]M+:2X?[UNZKL03M   G<X<".7XQZ@N&#E@#YK3H8A25,$W_I
M!,^_P_PPC($5:4V&"WWX\.R9 X)\ F*Q."N%"9L7!7*0()8-9<,*1*S3C[7O
M\T&S;\)2B84H7M?48?C%084#BT&RV9#'S^F)R2[A]=VL-?:X%^OJ_MA03:.#
M! H7@16KUZ1Q95S=,1A/;B):\KH]H@K+T@"N[IR"$3+G$U6_Q'+/WV!(BDDE
M@D,;%0D.:03##M )BG,1D,O!58FXG_N^1)^S0Z/G36N^]7.\O17':Y4FXI&J
M-7$:X&+/+&I_CPY^!@NNY+V@I])4&!T3/;R#I %R..\>0PE"6]I!/(T*[IB3
M]3Q8QIEU8,O3E%W-LX1C]1(7)HVN29TL%RPM_/V\#>_S7+,ZB)B'BQ]/:W=@
M1]XC3&<16+_!SPYC![S&P+=Z=E[\_J!]Q9#O;I?MB7MQQWPJ$2=@P!+J.)#[
M"5!$:M@R]9=24&/HP(J9=71^I=SMSX[^I\RC0E5 $I8EOZC?:8#C"NG:MS-H
M .-:ZT]U4<'7=J1\YY/S=-G23/4?_V!9#KO. W(%"D C*28D/SQ&A\"=P5I%
MT*I/604_XRB1/2(A57^LR3Q :CAFN]U7QQ]SDLH/S?HF,#^Y N3T1PFX^C4?
ML28]OS97'>YQL//^"*4:YP42&"2]Q], WV@ /GJV,'N:8%Z14> ;5?5E?(]J
M/R>4;(V=T$9=:7F,>WXJR/(U3+V:P-Z$F;@Q-FM*0MTEY+U4/'G*TX9[]#P7
MQHU=*.J9B%=1#+M@S7(48 <=D\'52(AXML,*8>=VG^9.9'&N#DX7:C___J;Q
MN[2@+S_]>IF@JV 0G.XHV133XL,T&0D",#W"30&HQ1N2KU+8VC'M+[(S'6BW
MU=TRL!DI12FM);7556[3635_YZ+2D7IC(G^U/MJ9!F#1C6&U"1PM \#G"B28
MS);\)D(O0;/:,A1)0X3H5A$&/#@2W 07Q)<_CO4&E[_0#U;\45CC.2-YXB/K
M<UO^F;B19[CH32"\*VEI6GP8%EA T28A%->4!-H:T9P:ZXFW?MI&SE^O >#O
MQ?FJ+HKIS2@5>L]@)@QQEF$[@19#EJ.*K"$!1M;O& ,]!EX;N&QZ.L:P:R^;
MP7]-E*N^;:YN%!Y7"'"0)#S-<G',6^[2>CN??L'-8.?>$?4SZGX[']DST[90
M9PXR-2] HZ^C\1'/ZKDDSTS+$EX.IQ!WQSCV7CWPY/3.P'D_-1<#T  5RPZ=
MGEZ2ZV>K+*2_BK;SUWY@<Z*:;R$[HDGUO.0[,&["H_Q5II=GAQ7<O.;.ZAW=
MNGG3]A6Y[E5["'<_DUY;7SB(&PZDR!-T"^D>9K@^@'$Y0/_STO3%6R\\66\V
MS54ZF<O*L7TQO76M'?*5]*# ;@GS%?%R<^T1)+@.?'2RAZU[1-B3P4)D9DR?
M; C%W,3+-('/&!:#.QYY;]>EJ5V+E[,S/'_[\]?\^=JYA&^ )+NWH>V8GP%:
MP!W1%AH@^V'H->/GJ< V5#SX5+T&=LH;JX2:J?,NTY64W$Z.Z0PIIXSQ>G1O
M,9^=U;UZ+$@YDN)68@4?%3F&K[>)Z?XXO:1<9:DD)F)7FONT9I>O&#QN3#5"
MS?8=/!>C ?I3J^DFC.C<A*G0 %]=3*CE#%GXL/;]G?CVS5=@=G63@IX"?8AD
M4/LKQ5YE07Y=]:\K'&BI9B1!HCUU(X]\G:*!9X_POUQT]F::_=@TFW,QUV6A
MVR'G0S!146T'V6\HUTCI^"%L/:BNHHSN25X@;'V^D84[F]40I?%;7&O'K ]2
M#T\R7VU#GJ9*&"BWH=S%#0?F0-NG*C1M2LFW9JI&7(\8"T-;VI"<FE<=*,KX
M1U5TNRT.?^5R<@.-TCG1Z2O@\<YSYN3OY]?/5YZZJG.?1$],V]%ECQIF8^_0
M$SC5^'@81Z&[B9OJ"]7?NF,IOK<G'5-53DOKKAW)#BBQ (=G<(\B/&2 2]1K
MO++Z)>,V[C;<"2M<-E+?[IHZ'1,.X%%[G"<>WA:4O+N6A<\S3NTRTFU>-K#K
MN%#KKCK5J?O>2NZ!PVW9[T)WF<M+U\\'^9@,]<W_'Q_+'7@F@3V,>5VEI-L[
MH$ Y+B[J^<IX=TBL)]HGW&&2!ABA/FH(JH[FA]V"2[G+]LRN\M5+2G(WE5P"
MNJ5X3RU<U'AZ0 .0YRR];88#JC*O:(]5J*8V%(PDB*)L$K,.#[O@\3/Z@C2M
M-@Q^@A&#7P]"NA<*>2I$"UQV<0S-JD$A05ZHB6XJ?T=S](PQ\Y0X15+JT<G=
M@($/E>^]6@0CLF-[,7=L!RMR#,QS/PEWQ=BE)_@1BPYJZI7)BB&%S8WL<1BZ
M8^)XZEG]OG?5_FI&7]C6+=4]QSP"1S_5%G:;5('=C'$0?6M'B*L+* '7.1NU
M4#?.'?SLA^4S?^3I[%-_:Z:O,*@^=*MM6I^O3)XK45]#7V,Y>:<:IG!U=0I3
MLWPC]7G_TQ5E,PA=$X\0XQUM0%YUM\P5Q$\CNF'HQ&[+N^]7?L2XE-DZO^;7
M>_?SZ/K1^T%CMS]?DG:3F]2WSP"+/X,9LD>TUU*%1Y)NJL?J%V6?Z:!.>$[N
MCYY9.; N*R5-T;-UPQ#I0C\7\36RJ.I#ZT^JXD3]&Z<O]3)N+Y9 9D 3O,0
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M?X"$ TG'QAY]<KY?I1JZ27ROGW@WY/'&BL8;RWD9"M?;&0^T(,@-Q=[IY[E
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MX_IZY?G([F1?368&TX;IO7-O-=MKV)GI&(@-=A++:N3>HEU3-[SV4]]3L[C
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M2W\^:DK6QS/$VSO$4>Z7U?3-JM-&_%VU5X]RK&DQ$U"++#]N-2V#*S#X.S3
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M"#'[8KO:D_$.PRONQ+Q[+.:K%E)96R6B\>2-PKT/YOZKE@JCD_DV7/T&$32
M"#?#7A@-<,R6<#ZU8]U>,Z,U<COD3%</=X;F_:U$T.;N,EAH U6 GLGK5T2O
M)^.8'SQ3+$&*$N(T.SAI $7%W[DK^T7JB3D\<T&GX2N:F?3(#O]!H%@0GG;R
M@["QH^Q=K;Y2:4SUT40_PIF"CQ1W/$]O6OZ4E9UAL57;^<HM.?FL.\^2(]6?
MGV+1@(S0 #/(8AJ U[8-0[P( >W?'L$BC]A299A;,.13RS3 OHFPL=P",O-
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M';"\0ZT\5DA*_^K]$7 U5#?<-=R,RABTOV:9=4-LM>S+P3G('',A>CQEE N
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M<+T7_98DI4+F!M*4<;L/G2SFHCRW\XJL? ?7C02+D\\X[-[N='F^HJEZE"E
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MJ\1'B)D*5Z"&>AYBU0@("L%MGM^8<K!_+"&O_;*,W5II7B!,*.P&ZLUWY"/
M;U(V?-W1FB]H5A/V;4N^</1$DNK5X6'=9SQ%%Z)YVT<?;1S=V8E.S!AR4E8F
MFYJ2!G\.-7Z]M$^J2$SGJ G3%\AMI)RAILWT]:;BPLUT&4WX"3W&W3O(*W@-
M2A;=W(T\1(=X@Z5OYZFJ!7@@*;ZV3,.$9/LM2=Y*7R:5V%'&];"3#XY18HU4
M1MUUZ.A@V3-1'$6'N,+X(T;2%S3$G*55/-<J)V9=MH8M,Q[U?Z1UMCW 0VC'
M1?0<BVCUY;L X=T,5@J'5GBH2;I=+4TY##VD-,+?('BJS&/"2'#^<^?/Q;XF
M<=,7T19G4C741!'+L4MWBU9_T2%3V!?\IEY8'M1Q"R"LEMR5LYSBF& S<(34
M$90R42)GO\_!L0%B6@Z@_4C<9&C74X$:J[L(BQ^+O8FAT8C[^B=@JQRII#Q/
MY&,L-)V:]-1]/:T6R[UT*.G:PS:-0G;84MFQ8)O;M2]8/TN>CM+> ]EV7\!<
M)=(A@?@"=C0S[02078\=0@]Z)00@GF9#Q;.Z/\8\3+BS=<3;U8LE0.T&2\R"
MEE(I ",J3,'JAKS.Y#@*MBQ8B(N/O_7D8_ZI]X7SIUB%V6>*!=$2J40-U[@P
M$25]Z"F>7<CA_/:[BUSGL4]49M-)N%]5_)%X1QGN25GR]R&GN!8F9T&)F"O5
M"7L;^67>L_.)7-A-J>K::1PS_5I64!ERUL75UC$]],*;I_<NG1%]QJT-U:1(
M$[T;EO"A6H<3=8%W'RT7Y)WXHN!<%+'[K>[;4D5L/L,OSTOT"/ZB':3PDUCJ
MQD000PW68B2=DN>>LCQ"E^1_+M A=M'*@5:77$:'7]:M*;4ZPB T<8ILH;_0
M!*%^25.]]OFO/E^;YX7H9>9\4]6?PH$]R_O>,RU99Q#K:E$2Q-RH*02N40&!
MOUG^UF!6Z'9QT,">J)>-53R;T[$)D#7L3]'1DR2SQNUGSJ?<^,L+ W4G]]E"
ML%=WU"K[Q^F06GT4O[.U:D7L+</+B'@+%W/>$V?(GI+\]YO5,7C>A=M[UGNZ
MCE.K<N/673>)!G2(PPK!IZ<%@YS*J/(_^FZ.=P8F0&.6;6!;9JD7U"ISGX )
MSG.VI2]Y=;Y03O4'TBYM36F05OSAT$L C*1RAW3V329B=S)F,<$U7LU*)PWA
M<8W6%CZKLT .'6Y=2O(*VK/: +E/X7><IN*TU(7:,F[?>=H0[#VZ>Y8P5#*D
MB68=II96@V41>Q;I@#7$/.?B8'#/,+^-M.RN^4(TW& R_ILZAA\Q64=(.D12
MI+&2>G/Q X.T\Y?)6W'4U"3N*."7QZO A3MRM!^C\J2MYX798Q%)L&*2ZZM/
M/^+C$CBCTM$.@_J/G_'&N)=%)EYI$E'0%E&)K.8 W30%J$_(R._>+NNHO)1&
ML,U:&&Q("(W[3CX=VJR,K515O:GK?P'2KS)!AT1@#]'X@-TZ43;@JWV:<W&2
M6"E<1*QAD&\^QC+D9JWZ\Z/(Z-O<;VK)3%6^_ U8)J"BH>63%2#;N 8HF'5;
M7U09E&G[,%AJG(^(9MLO>:#F:',>#"SA]U3>QX%2:9) ZE2B$9_^1+/@U)6N
MC2CI.Q8ZCYN_M!V3;AC8Z_Y#]2.[S:#$#/43WD$> 1WT_=A>%B3-2I9]08=P
M;F CM)CZ*D_F28==ZSVV9N]H^>CY$];RI/IS+,0\VRE"C1\FPK1:N*ISLWL"
MRXMP,[8RT.]E%T4ZG3K7+.XC]"I47EYK?NMS 5(5>).'U*KH5L*^<()/MA<3
MO)UR'=4>##:P?ISD>Q'AIML\$MM^M 'BTY@\U1X.RY^)"@;6_*#/T9Q3I:$U
ME7H/0X=NYYO91ZN41KQY:?=YYKI/LSC)QM#5=,^;8"GV4)$#O^!S;;?(_@"&
MI+ +NP:DDB2,^I%G7#QXAW>NAZ1$,%<CAM6DN_AM"XY?9U8SZXCZ!1$)F&<\
M1OQVQ&D9_'#\YX;LW[=:N]Z.G%D&/TZ#A^^,&']L__]\:5-V _=<=*W58SL_
MMU_0 LP9,U'OQ+4YK3&_C=SOLS+WNPB8U9,&$<'90MKB 7/?#U/>8] 5VPD+
MBVD=C_[\B_S319S%FSM9[.?%7AG+6L0$P,!4:QQ'XX!#(Y/82,\,(@S1%_EV
MO_99^ARTQ6Y)/$=_@X]')E!CZ9"@9TCQQ"F57\D^_AG:KAH7QBL"/VM_C:P8
M"C"U%\57G/RB]K8!)4W--UKM+PG%*BE6B#Q=/8U]@JY1USH,Q&W=):E$SA0'
M7R<6]05GSGOM)"4_?JFC.=WQ^LK+KT+15WZHF:D3,61I('@<)N*$D@#"J%CB
M:IWHT9[Q\HI>I:6TRV\OG2B[PW/$7EQ6"#&+ U!3-71(X=:O(>)ZC1M)Y2K@
M, G;9_ XWE1MJ%"YI*-IJ+I7B%/0N)L%.V<U1Y!E02B0:TJ(C<'$J2F9O.S)
M,>8%N?FL-$144I>F2VKS^O(GC\(*[L*]\H_5.)V%TUI7EMWA3_HI/$)UHDK4
MU*)$H^=)>V-:&L%QX>GNC3@\$6,X9_BHK37?Z,#VFPAOP@5KMMU#%.VO1&PC
M&X8%\?8U$1OM JU+R)$G'DZ;%#B@R7I%E\NEL7+"M?H<J@E]B'DB%V"K/Z?L
M=855[[P(8C<F:U. =YD/5FA6"QT\F1(V!0U-_$:3__X<Z3,./'/^(1=65BPL
MJFL@J]7KY1YV=C[/]$VYJ'L*K:U\F0Y9AD%K?KZ*-S:\-V!X6O@ ;WXWEYNT
M:RYF2&72OJ1^+)I?S2%L#YH5>'" HIIL^4V^^C+T[ Q3WM;PV'-<YP<#<$ )
MO$_LI4,($D#6Q$!1-AW"JC=1IF'%S55PT+W8X).V@<_LV7UHA""@NT2.!\QV
MU7**84R5DAKZDQJ\\83J<R'VB6A5.!Q='OQ^IHR<%:6G\K3H<G;SO)_#+[:/
MB#JRE8M1HPWWRB,D&['E3O&>"=*^6JD7L\(-TN>>U$=.G1<67),51M7!CFSB
M7[#E <J:, **OZ](N:*X7]&@T _1^6D=YA_[MDG@Q^I5XA";322T:*Y^[S$K
M-T+UL0]K:W(.T</<O6\IKV3[]U:7@X.HS5Y4BS4?*:.N'4IY5-!-L9KZH%18
M4D+<U>Q-#YH3U]?X_/@H]G6(@/!<WPMKCF9-FPN%DZO^U_EIK#!B1GT<C$\"
M"(HC+HIR]'PL*@@VZYXSG^ FL*8VSAA]_WFK/Q?I'6MC#JRMU\(*VG_A)L="
M.RA7NE%B +8AX4-1UZ7D"@.']#HVUW65$J&Q .W9:M7=N]BQW"R5%M<&W;.-
M28:>C)^*I!'QX_B(^/I1[BJ,45_,*/QV&>+(S1>2R_[)-9!QHMZ)RJWE)V@4
MIJB9NM.[E"K[)J%[6-]3H^#JK+[=DY7EWK?O8U"?^N_G(.^1KE<12RX#?FA4
MO!9?IYMX]9=B!#=2_LJ!>^*-RQD2,S]4<;\1I#+D16WQ2VG%=M$A;K)1@[!@
M%Z2JVQ3[T,\A:DP?#<[F(YL[,53RX&[APPL$DL/C;S6\,WCN:FE$XA1?D6TV
M(H_B;$;V10K:W?*Y$M;T_%!@<6#IVA-";!*\O;I?8FN>H27+.-*JBU/77VE\
M;&AI2B^(HF*?7#>I;F7QO59.)!9N85_UJ^^SVJ.XR]*/SPN]@#R6:I.M5@6&
M3($"..DL'6()7Q48LM+Q$4U6E'LICEGADCZMG9K>44IP7N=BN$*+H<<XO/<8
MV0&>C;S0KX1[;I:D4E%A1A(93=^I+S$XDJDB<^8-]IZ0]JC^MZ/+%A9;C49'
M$<&3']KKG8JR<I'VFF-#T5D/]E=\^K:G;"^$/S!:ZH?6W^ _YX/(-2<QP&D5
M HP/X;5ZI9ST2/F%W^'0M:WKW3*YKBN'(N^G1Y^KPX](^F@5K:?*/=!7E8B!
M*_S35,;AF-H<5HY'OOAZMT$V IJ7(C(!8T-@+5ST+A,K]XY=*UDSUB@Z<-B;
M%U)V8&_0S\D,0&'W"O(2P.2.'&4E,2T4]P.[]L\Z"!YP]^B0R5?FWK91WY@)
M KCC_S1AM G<4GO:3W2"E$C. :>O*;WBSLI;V9;H^Y8&<W5I3L6'!BUSWD?5
MZW[\.DV==!\L@[Z \E4:DIS]F=VXQTYN)(C&<KYXT+Q7)[_O1,.A7TSN+26M
M/JHXS7\4A/"*O'RBL&##1!N%':5! 8/KQ)5$W)UVA_3+Q[O3\5VY>:[2'0Y[
M5478W)-4'(X>Q9TJ 3(FEV#/)0@W@(@;$0W+3_LS[I@_+U60:Y%SW?YQ8"%:
M+GR<]K>3/Z7R,MRLGT>'U%S24EG:D>E]5BWVI2AN[530THW\SMQC%1\.' L^
M07A5LUAA5(4<*4WR,,?"8W<W_/.,5KLC;Z-X[]V VQJ=BDQH_0?SYZF9ATF&
M DKOR&4PO-[@-(W*SVGJ--T9^R_.SL<,$E0^J/88A?<4AGBK,4GRG1RU()L-
M[D6X';*WA*;19A,C^$BEO#$5?M\NRMW;4[*._:J\U4# 1W]]7BH[K1U]< K@
M)DK55+.PIJP:Y9M5VQ/:G] ABI]>]<^*.W2P3C3\Z)A9L35=,/^PR6-L?>&[
M\KI^6+V:5D;J,)I0G>HD\PF[4LX+2\;-J32.'BTEPB*+QCA'&N^5=>'2"Q!C
MGW\]284%\%*%+QU_T4LP4<4U&0%2>M]4*YE(*4.39S^XZH51[@6FQRAN/ZB.
MTGZEO^E9%[D)3N 55H#^6G/#IG):%>;%%I>Q3<K8(25H&):8 F;3%6@1!-JR
M<P,#7'IT_0/I4MW9MK.83(Z&Y>E(CIR/(4\4*OG.$RPHW6.KUF5$&#F)Y%;#
M4]ZU7-TV*<N\*&!E4)O0Y4/F=[[ ,@US+X/)C_<GWSQKZO3KZ561=V26^JR5
MQ#H^*5*[3@G00NPRGG&R$= X:E*DK@A[>FT<"1!:8R(W:SQLM)!7J*\\-6%U
M'HBAB:02.,EH8FN,UMG90RUN]MEVS451[&QCY*M41:0&M(X,6R*")NF0>IO\
MN1><87EW&]?@,&:*R8FV_8M39V5*:"M/?_%,!.QXF-65QP<7R0JW9P-B]?S0
M?%QCA9[<*,+[KOR%%.OJJ5(W]]V73Y[$<*06PY/DW8=V:)6%\@/S=(@MC D8
M(_MU]#>2XWP;RZ;<N =**&+6>[Z\ZA.X[PHK]!3U(K!B*RKV[42G9(!Y\4_;
MVFY$Q8U*DG0,Q16(%>\:M0%L:TO8F",ROK>:1Z=F"9^ Z']/%B:JL&[Z&TTJ
MEY%T#6"L0"SA"_)J'ZU=6&:<*ZCS;:Y;<20+ON<;F[# XN>+D:^BX8% !2FQ
MQN;@AGLR8G#]6H]](600>1R JY9T+-]AYUI6;ZB[6TIH#=@)4N_QT"\9H4-L
M^F=EC)*K>2\FG0HSKDJ\&0L696='5@O;60#FG@'@YNB.TBFARR_OXU:8V*?C
M3(Y1JA2VCY-8UZVJ27U5WI-OS\IHZ'GZ*350^-V/?C+_T')>TD<XML%?((71
M%_,H^JY(!1)WS8Y_?X#IA'WW(Z1DVZ<11_''@C^N-,U<D)C[<=UGNK]RU!)P
M($<2(^X:'*(F5VJZ<:TJ61Z8^D(:#7H/L8\(J=1ARFS69':>\#4L.Y[64D;D
MJL.'6TL"!I,'BO L0-!6W<Y[]-K@CP?)A"TKU!+N\Y=C_?V#(WFQNS=0S3:'
M:/+ >JVO0RCE_L3/(V-&).6P")W^LP>M.H<O!$76/=Z.WS=M>Q1W@N3]2SUG
MD=R2BQ3IOP=D3\R5WCE57'")$Y>N</Y&?)S+>OI!R)>C1R4"V_PO[=Z9AQ$_
MHA]0'2;\:T]&1SS<,0E])3YTT\7V!N?ZHHI<\G;DU:N9#]3=&SGNSO%-M91=
M'S3')E2$96;)K'PJ* U'G'*4>!%,$']D\BJPZ5CT,U-PHO)5V>TWQDFN^,5E
M[UHA'_9K* ]R;-6O'KF[X"80?L7RAG_7\:.2JQ]:#TSM2UA3MG\4=*'=&BZ!
MKA*B+HC'U4Y;_6AI1*GUTT[ ,3D UKRBW],LZ@2\93LRGT=G,+N4#'E0[M<^
M*#2IFTR<HQV2P@G!^46Y!K^"=;S!4PN1\$N2'C^^:1_WB QL\%'^#:;33CBB
M["<BD6!!AT1.=)WH]\QNLY Y\5U3W<B@+#*H[R?SD=/K6[<Y \R,B>OD<. -
M$:M7UE5Y?"K*H6['OD::'&?VZ*NKIKE9RE<:L68+=W)L51<4+)U0P*DSO*)A
M11*J']4J[LZEZ$]R7+**,%JO_EX>TF(XO=T^>_7"@^M6--M%9UD^8+U>5*/T
M*[;>HG>V2"GJ\YW!JE^-E]@/?GB5YWNZ^=M6G@+# _,=R(BR+S%O1ZR@\*PF
M^_/'=OH_CZ'ZH$<]C5BQG%;(:R3Q'07=^WY>/7;;4V).NH]6[ E"^HU2]26[
MG?C1T-CANQ%E X >07 U8//,)A?G$K^OS$9?EWFSN[U<U*@ LWCD*XHTI(F<
M,P*[7=[ER>:W*U3V:-5E^DB=Q[X0\:B:)OO[3<>V> /QHU&TC0THV(A)&;O6
M2(>^LXIE*S0)1(SY4\*ZC.7NA9[47W:CCU$/!W^I"+^7R^/^AC]<:4!LKW=?
MHO'TXYYR/#CW75;ZH5S9K:W74YF:->/]7 R1F\KA'2#">>M30-$4EP!B'-%R
MAZ2<ZC>99O>T=W B;E(>ZV$;R3LT=+3AJ=9Y:H:6).4J$>B@&)%8K/N>(B%D
M,Y4\VW@6L58(91JZ^K#2X[?/"B^]\E:70HO ^Y*XRHGOU=J&K07+*RRW-]+>
M1OB<Y;WXPER-CQ72_B5'LZ[']/KOF.AUU#(9[AO6U!$*R\SY0-MPV_JH:N9A
M^7B3QU4T)=^;X<R &:LVE[H>XU+?\.:_6ISIC;=2"9>Q57P-?F\;R6"2$$P1
M<Q7 FO>Z_!K(,-%]R8).R9O5^M:?N+J%ZS0"Q%:_F6M<(+%9 +BLH1*R6]@D
MG$/N \K\[,S=*XOH@<@W.RW+YCT)SX2?OTG!>6S&7+$M61L/N:C#*NV8^A%R
MC]5>2NZA^*9&EUG[^PM_%EOY_^='_%L3D6W'3!;1/YP^IY6S)_3E%^VJV9>]
M*J=#0B"&P@\466'<2T;_3:74&Y)L+1W"@:AH&!4@:66DYPQNA8G'6"EOBZ3&
MR,JQJL5\<KW)-?(([(:>MV\9Y@9,:TB0;.M$E4EF+Y J:<Y:KF43/_LX=+]?
M=IR.S _*8]I3QHDB-C6=*&]^8)XJ.:*IM\\O?*W]N0UD6<.2I% G"NOT],.P
M(7!7WMB65>5'W7%6MB' U9($C!YJX)PWKE3J?VJ;/+AQ>E-=K^]CB676TYEW
MAK476TWLSGRHT;^I$&EGTJRGM_=#.?0T;1CZQ3IL]\9\/ESMYM \^DC.Y!#\
ML\L07TJ ^_Y&,&7PW,&5CJ/$*!< OTE8"$H:3^P/+TS\P&^1_R1F<#B]NS_T
M5N=K\OT:W,+@97.>;/:L96N)W:NH[]7,U'0-R:>XHPO;Y2%'[\#[POG(#16'
M!K;C-6]/BTY5W94\/W_^.V$](U;7T)]KUQA5ASZ,MQ^Y",^]V5 TQJ(P.50_
M^(2O1-+H^TF1^QX$CAK-@[@/)5P6B[>J,T?GO0P%%$?J^J+J^K *>WXJVG5[
M<UFH<%FHON5L3CWUUP9SG:W?_D45_9 IW[&9L>&<JVBAQSD14*G*X\U4\/4N
MX%>"/&.+.G^E72G:M['#:*>*;)?KZJ9$?."E6?01YRLF(BPV!<DUKW<QKSWB
MFAHDU)UKYTE&(7C62C,2MM%4BX_HA7'/6>)_M+>!E?(US\='*.78"B'0IF L
MO_]7XH310'>=U@,JMMZ&1S:9+1/^Z)V!MNZU<TS?/ZZ@UE_%!H:(9-3"0JJ9
MJ.^0)Y *Q*%K=^Q>:5?WNY[;\HY6*]!2<_AXU'C ]*O7JW?O(A2$XR3$^\47
MRYPZ:F^6B1?HNXNU2!7&J ZW$L03UK!1*%624EI?_#B6R5Q?(L)S\TG"^TYH
M_H+74N#)NI*+=6+.F^(],.YJA=$%+?%B(BSP*8#4FQIZF:_/GJ.3]VZ/1MO3
MJ97(I\;--%0)U[N9C'<EK8,J+@M) +GMH)K7^_A-JO\DX&EOP^%4HJ8<G'''
MVEG!><NK0_SFV+!D3CP[,]N7&Q#Q'=9>QCY'.24]KY:,+!YT][WDRN@^L['G
M1,\;P9[7D!W?[C-+VEP6KWQOPV_*7H7XWHXP3KM2"-G,R)5S B]8]^P\(&=T
M[(OXS1L@_M?C 3>8%G4R%W4^[LF*ZDMB+,[![EK8E_%[00VA7+GR[B'PH^.?
M78K^;%IDF297?FL(_& <RB>-G'D-&7112]1F_^3ZNC"J*T#H_X.5&P0>%XU1
MQ!68OT8]HKPJ)G)]2,2\WO6D9)OF)X>@)XXE&!47J#[GRO>RQJIL;^9:/++]
M:\6_GF>2FUF22DLW;S!'AV7JV7JUN NVV3\.%7K^WMY<*.C JDWD6 GA5[;G
MK@+%NC3V>K'MN)7_Z+I.V8774?HMEK$_8S6X5E[9?.5-)/%/8$-06A05/)$E
M:IFR?';>M;#J[L&<A] G=P8VCF&3!5B"+6]F+E3$'WQ2L+T\>J;S1Z=:N8(8
M8SX]415+_D2-K739E41T;N .6RJM1#Q>IK[##>FBVGP_Z,%JCHG82H@5ZQXD
MR6PN?(XWTS-3:L_0$J8-6Q_[2J1H<0&IJ8-(*^+1/<R).&2_5^I1#C>/J'GM
MA6:F8JGT,FI<M3"MPS1_$5\ YAIOE$*9]0#_R7>F;!L:'^+6N8OO$P3F>F:K
M-<>L6.K&! R)= @A282D<=AGW7$GI&JG]D[FRX83U5UZMB70*)WEG*?\R5M4
ML$=-^N#M2E%L-3B$Z]1D574Y4D_V66I/QTC.*9%J4S6?X"R!1O7^F+I=)8H4
M];TMY@:P/CF1BP@T\T4PU2H<=%5Y[#4\S!4G]^, BU9H%7/_I/>ON12D5QDU
M91EU#-YO,1RK_YDP;MK]P77_>C*S@L<6\F,]3=C/K(8F31(?/4NZCLL=/MN\
M*53F^N%"T_Z!8AA[G_MK[$UNAPXH#]Z5BP<17_<$H?!-T!Y;BPO[QF/%7U?7
M$N>Y65JZN\8]]I(+V?]#1NY5A)QT_73,$T.S,=V=07GC@4[%8HG1TZ.2'!MN
MG\G!LW\?IPZRR&F1=$DWW%+]13M47VR%JX0'^PO-DP-;C2J-*V\+S8_I%7(^
M\)^,FOP(2M+\Z,&]RN/&R[RCTKG,]!:+2$5DJG168QR%ZW<;A!HN5$=M^&G_
MWPFWN8NJAW[1>XYW:G,=JQ?<N#4/XY YR>&1V90&O5$S*X3<_'&NZZGU3TWN
MSREY]7.V_>CQ-]#\:TF*I <46Y)AM(9"\E7=")XZ&DS6#*/(N<!O.T+JAYLM
M;A0(3#L)90NFILPGF#VCP-(!M/:7L*L=A0.FHUT_1I0_.:9"]M#\G0?[XV^F
M9DD5Q-R<]>8+/YWS0KA**@Q8(%I>HJ;0CBRA]O2#4Q7'FEMAI0D[V5NJ]0FN
M5%//4[IJJ=3Z=6&WT\@>R@32&C"9A 5!#Q5AF('TYIQ-?^6;434_Y='[OL9N
MO0H]H$4K(O@D]>Z2=JU1A&I^:EXE5)@_NEPE2G%^P,EB\=35.:RD,<4]=BAS
M47V.Q#;E_0TCA&K74L36::ETIG7+FLGLFY)Q\Q9]+!YZ/3IC7>0 2_A&5O^L
MQ8JG;MH/R98;9=VN$^6%20:6F7<U;EV<$3DJ'&HJ',3E;J/OA"W1+9CDX.N_
M"GP==V.G/ AO?=!]@[2/@R^-/R4Q\\N/#XA[^N)'KN]'UI1VEO:6G7&]53"\
MPS_)LIPV!3L"N*)9$7K7.VE\P%F;.$/^&O*8O0H;'6(X1X>8G]%<T]9L0!Q\
M&:,_W2,4)13%>E5]K]< MI6<:\,&X"V(U\O@.0#:I+)3"6[*Q;'\;)G]ZZMA
M^9=P+O=4]\]S4#DR%BQL@=.OU;S26"(TG(ASUTE<]<NGAO/B)Y?/>G>GE\>Z
M=I0'7;XX?(K3_WM@M#XN 26'="9Y$S#"-HB"1HO41=_<SF_".<HD3 6/_OL3
MG-_\K^N?*I5IC&I,T?CJ?3E;1I_2[JS1[AP,*LPFAZQS;R?U@,W /*4[Q0@_
MM,(@1F'PX[#CL",C,&?]C&?];C,,883LOS@9P0Q[MZSW;OF&JZ*K(B/,US4S
MUS4_<X"*&!V YE DZE!T ?3?[Z[12DYM)6>J"*H(,CK-_X5*G#$5BW](AXC0
MND;EC;@ J:OP#\^$VJXBT])BN+=F8H7]3K>(?EO7*RPQ]N"M9J+PDB26#Y(4
M](D.H2X)!BW->Q+&L^0&+W*U*X;E9U)^L/C2@K4.4<YT5#,C%3J0;!--Q4X)
MU_8J'(=HK(G:O2'UOGMANYG'1KY)C=4XN2L.B!1^.$2'. 'AVR9%+KYV>PWB
MH;6I@-B^]Z>UIF/;_*Q\-C^71X]P.K6_!?/3.076TRD!C/?AW[/<?U^U<*_2
MB:ZB$QU,F8SL^?>ZN/O_+)3X7]Z,FU3_8S5$S"23@$0 RRT#'A?%Q$.N;AW^
M<(N^9A?: ^\KNFSH"]H<!?EK*.]9H^NUN9TZ_^.Q]M\/G$_9B, <7@-OT!F(
MDMK!+*)W_0@/NKZ@WG3AY<+HZ S+SH!E.J=[C-YC_[CPTN::43'#7.,0ESPN
MK@5!<:W3O4_GE2*^BF2KX6-Y&SKOYM?F>31SA#2?SQV<JI:DG"02&C$'6R96
M>9U:_.U:3X;K/(BUO*KUZ^OY&6&O$_E:' !__1@K12ES(>D,J754L7O97B9]
M=)%O2:2W*B7/R^@$=O2+ZC;Q_-X/*5-^2P.^=Y8W18X,W<@O*XP;98LP>.8X
M5U 6J;_ONRYKON@Y/]*/ZQ=P[6.#MV@'Q<;1S[V]?=OKX)W$7:NW\6J&M>\4
MRQ)Q*Z1UG:12 >.7>W/]?X)3WJ1;"$K2$3](.]*?4[0,\XE*+XCU:F39;XY:
MPS[8_S0OXL0;>_:,S/NO#$:#"SH2O6&)F&AH/J8!^G/NII^; &"ZUM5CEY[Q
M*-U/%;)R\F[F4L=X_RNS30G_Y#H?^,F"3QZ#3>?()<8O'KBJ\6IFSV"CH$1#
M?) -OR \$7.P>8+#]%KL9X1)_;&DM 1A'O'=9*W-S]G#IK!]F;@N_',L4:?-
MBR_!)HP..;Q199.ME[%$7G4Z+1IZ>2R6#H$8VZ@@ZF@'O^[J DK3"LCSY;WW
M;H5@]2J"?L%*+S^A0Q+"\4Z'[VS'A:\HK0;"CE3*BK]:@G%5&J=IP,OZUO5*
MGV=NJK]TOYN[$OS9*5_2:J'$*Z_N^,/ CE=+3:F#EZ6-4W _$6C3GG<-Z>]\
MGMZP?Z:\ NR,F]E,T"$_0<>%19P](L(_T1_NJ7]T+U^W;FEL<$<,=^!J%\;I
MT-=OG38W$"JT@U@0V_<KQ4C-1-WB)RIWEU2^6#QK?Q))<Y@.K8XDRE(.I\^V
M?\=.FC7(R.H3Y)UV]C'['"#'697"R*V=RP_X8(I+@]7[: 0T+QWBF#V-J;7F
M*W=1%VOM77T]]+.1"RU7ZJI0._W>;(FK%C^P2D8" M-&J8!.I4-N79"2VY'#
MJL-J\LE[>.B0\J"JQ!NDI%2_1\4OWV[L\@J9]K7M<TSMCN[EQ-T?V(:/2U"X
M92<<O@U%N#A,GMQ!7B5=._^T^XAF^:,C7+<U6MJWB&HS'/X&.8B45;,HF0 #
M]0.OI4V]IAXYI@:<TY3B]4V808E3KG=J\0#^GBZ/ALL-3A<7%^67.&64O0N4
M.G)ZD<"2Q11=%%^E8I\M:-8I@AK_;'#H,[.^!,0LSA$O$DN 'DXE;@5M^&CH
MI)HW->< 479KOY:OL!RNKT=M;MD>>ZPZ6TSC!6(;:++=JYM07L0#*.M@VXD/
MZD8^K24/A)^X,BMG<U/$,BY*Y79LR*C4^=I9>,7>=TL?T,&>'>R3$SSK.\Z*
M]^*_:88.M)!I7MZHD+)<RAYP.1:ZMN186AJM9'YR\%S%6_9BEFL;V;V"&UE2
M1_1O_M?M4OVUWAE]//B?;ZUJ5J05(%JXF9ZKZKA79_EZ.L[9'Z+VR<)>TQ'B
M;.N94<2H%X1RE;+:^A)Z((U+C#U3&1^0OG0ES:PH;8Z_EPE?N.;*>';:]37C
M,*/DJCU$F;$ +-,9H309L:<?F<'2YCLX:/YA^KTR1]^2H6OA+.,#TCZ9@IE,
M"3@ZXIA<WOE[M?&_BA;&C7J655;! "%P^-U_NA=6) Y[6+>-)I&6NC'K"V:?
M2\VU.EKM6A$3FE1GBWO7JK)Z#Z2U'3ME7732]%:;NN(>S2M8K\\/WW^:RH58
MDIC??01V:[V3>$CI$2Z3-AS69YL?K?1[:;(F?8RN/Z3W0&J]G?R,#@FZO"AJ
M/UI!-+(,,^\>DD?7JF=?%2L+H[Z=@4D%TOJX+L3VX;5+H!9(E2-#3:)G!%5$
M!*YSW+:;^K+2">PG<8^W8VC<SD=^ OA:P>) 11L?G(R([5PR5U0&4:E^NVW9
MINM:TJG2RB+E\C=5>;G."$>W9',>JD=?J0A\'%V#YAX1RG48IT-"W%8PIXR^
MZ&8DX>LL=LT&5+$>VQOKB8,8U:KL+2*J#0WAHG3*LM(AX\)HBJ$L1<'H&]?.
M"6NP WX[#V8B":BA)M6T8<K>OUFV: (9XRS4P__. ONO+)HE+ST,R@"F.94B
M40\_L]6M_T$!FWA'@Z [CQ!QM#T$.J2^<[DR.,&J_1M4M2H35(1'TR$3[U @
M!?<_%'0(>PN1B?8<&X(F<L)HIS NT\)=*RB(3]NRWOO17BJ$ZV<L&0U;OTR1
MHD,"C.D0DB*>V(H&2R'J82,&5AX0J^AO8VCHREERZ@\W9UH >N(M'>) A^R<
M2&* .\T 9P,\A 9 -W0TSOPMR,_MV&R\QS;UCP]V]M(AH?>!/73(Y5NU6& _
ME [AO@H#F5AHCADA,"+K/_#0L"0//V/0#VAM-+$5"H'-AR-N@2-Y*CB>.H)"
M[OU7(7K%:YQ.WC!L^Q\W?#0"[$$,(!;DF7\9U3+&D /\(X<\>J'M[-SZYA]W
M;X"Y*'L%PU6X/UCB:0+>C":S847_NQ=0R#]>",1/Q#.<S4O,H.W1 YW=A?GI
M-@XB2Y":,*+LQ= A+U*'?%@4*[#MA/>C/:#';3I@%/DQ1IM6\_SM-MA$'.W?
MA?QIT[DI4(7&+!DW+T$3<&# </L# TIL@8&61"#^NR7+?UO"#5I2P+"DY(\E
M@;O22 @=DB+SWW&5@"&PB&>%@>Z*@ K)II80,4%*5A>5I1*;95J5F[ATG6S8
M,(WXIQ0%HNV$7N#T.E*=6%&[<[NL";$!O&C/\^IW/U7E.9USZ'51H"Z?U-,#
M'WW9;Y)SP,XR ?V)I1T4^@B<G>RW 9JSZB8-@-IF:.A&WWW'J'YN_3I]S$H>
M?W3.>5S'E3@V=2$_-J$[CQ27[.Y\+"R.U!.^DLKZ^>,]B-J>;WD>K5[3%=R;
MBFYNJRISYJJJKOR/%LZTW.VJ< "_7Q\=&W7[\4E/7\?#;VBW;;NS"E\Y]@'R
MM*4KKBS-BP!>BUJFSE+FF=+NSGY!B2.5B?&-1JSM$SAA -5=[ZLXO.VMOUX_
MDJ1RU.X^=>;8;H_D,A84H.Z']L&K02C+P P=LN^AS\.R'M1AH,SZ"%M>V"1W
M&/37I\5SZ/&K<HOP*1B45H,7I0FU2SJC.8O@F;9+GFF9%<^H@O+P+;]6]\ZW
MJ%.YE[)'+<=/UDUUO _OO1W#M-WH]@RE%15>$E2I*W#]@)H) 0K,2% D;43I
MD(YWDS *[UTTB9=Z0O:%$M?V(G[K6RKMB $=\OLP8]F.9=V;#F&-)^ W3B'
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M? X+/F<>,3K(+EW4<W2@KD>14[Z+X2P<1XLF'I&>IG(1$_&+HY+G]J@K\&?
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MV6Y+T$Z)R03:^C(@\<\60NN%S3ES+<94_TK]':O#W.P&3<6R&X 884%&9O1
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MBX)EXYUESRGPWYZA3=ENA.P02G;(^[\/'-MZ&XTH]Y_I,2LN]:L+;^*R?OS
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M%/ WI<@'4B5W"DB$D3R1)RA:NK;M]6-^JNTIX'T@Z8;@3?++'.76.JQA/Z/
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M@4(_],#O ;Z0&GAX;0I]"",Q/\/%Z5S\KD'DUMY')IGB'+% WE- >UJ/3SZ
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MB&_'KW=*%3@UV*^%:UZ)+UC@1W!3 21,#S,+).8_!6^*23!;=\BC"47%9#W
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M/$NWCA6=Z,;2C'!N192I4#=WTO%BR\'FMTF7(\7TYGSEF N9XC_787R'\_W
MJWZPV'S1!@RR<13_+,]>-TT5?>>!L/;A"_NMTA+H&.YF%8GN:6TKNI(=AT,/
M2_),B;PX?ZOOVE4&\?S:6ZT:X4<^Y"@2)I(J2PJVKB>Q=H,)TOI%%F9/TTUS
MP+5?32;7&7CZZ!D>VR.M*28D"4@\!(C,_;=7L#AK![N"LB^>_BW)O<M)W]T8
M+A:[%'P;P?[WC&)/ ;&60NEN)8*/QIY%3USPWW$UE;,>8$]<8/"3\LJ7?R)G
MK5-!TNK)P22> A:E&B>*3P'OPO6JI?=4DU(_OO)_W_&4@4?@1:FZ17R_"]'I
M"=J#ID#QZ.N;\YMPWU?%/IS4ZD;2O/$_PA4^H]O[& G:;0K0L9XY7JN>ZIJ)
MS\Q&1LQUO'?H Q"SO^EKD)[8>=P31!'*\6BHM6;F>G+P@ '/J\94(_L;I:_V
M>2K-%C%]"$ZJ9$-S>C<6/H5O$9Z9'N(;8NKQE4J\))Z.LFP/.A J:7.F*393
M2$1P'R9,J29R9[=;.0&4AS.^E/S\)FR\YEP,ZLO^VF<^#$5]$4G9)O9W^'N?
M4T*]TW@@O=5M3[N_I3%&"8E@P$,TJ?=.OK:XD"0-;!3,Q_&&MR&#Q\Q)359=
M0WV,$N<:2/.JY?,Q[;PA1L0V04=9EOD$Q8D*&LJ73RFD=#:R$2C)/!2IZ7K7
MII8SI1+_(6S"W[3^%=J)>)#(H_[2JUB=ZX%1,4?.,HB%@J=Q_*?;N<7$2(VG
ME$K5=(J>?>PWUN-E[9#9!6"B[4V*DUOY-"7LQ/W&V?Q#OA5\;6877K]^.RF>
MNO$BA($D8DEQQUU#[TE^K!\WO7V=79_]EW(3P8.'[>_(K\U11J&A8_E!#PT5
MDJ7B82&(Q_&*VF=EHR4)R!3(J66\)<#)KO_8<;L+XS5Y4=4IY"NVK221-,E'
M,@)0'V% O&Z_RZ%ANYM9"?P/IE-?ZXMH&F=$,+&VNKH!^5M,RJ$X5.\WFB;8
MJD8[><X&="'"SF3XFD2XW*[ :J7K9ZOV3X,$L%'[>-MX7:8*-_VP@MBOY!LA
M[VV+*(=>V[8H4C4)LV#4>8']3M(FDN$V_&.JU#V!H'"C%;=HDB=!&[_-ZQR@
MIKU2Y.[NY"_G*R6%JP].>;H9?YFAX9];,HFA)_1,+ L2R3&EUJ)-_E$"5>8Z
M51*?T#I,"S]Y/5[X[?V8J)U$V9/V^[:G8(L)5;_YDHXB@YF2)8=#5$AFO6&L
M59FHAR2AHB*LGKZSM(<%A_AW.@V@U]!+5PB;4I)5YY%NM(P'VUZHA(L3,E;G
M:T;A\=2;US0EU$GIT=_,S)>>LZ[IMC,&7EX**(UR6WT'N\'-H#0CT7&(ZT$Y
MY Q&0>.AKGWNH65S*<A@M"PVI0+H"JJU9D8@@T?(B*#>,\0K(.BB$R*09Z.C
M:=KE(Z8<>/+JJM.4=+HJ7KT(C&Z3/7L&T09["6=IRR5F66-$!=:;(I)OZ*J+
MG(/EKW?5'/#*!P&U1[0Y5SX)E/29"VTLE"0MWC.HR[T.8,JG=]L]Y[%S;BBL
MUM8EH?(?MCB3,AWJ(MVN"7(0 5>$/71%[_QK*EJ!WW'(''6*B/+[4P59LYD,
M*-#Y"?KP<R2,AV*_R!U%-<0),KR8$$>+Y<RYN'M0D4EX#=)>)0?^(.J,9V-@
M[#)[0V*O#6_J76^JW>7WDOL5$:-YE$HQ174K@SG:G;9YH'<O9UG\+>+;RN/F
MS[\C)R^[B%I\3ND!)L)J:#&XYL=#.%:&+Z-(:(P,NM7N4\K]OW"8ZXARH=GS
MOK");=N)8S5H]%@/>!K&[!=GXCO/WJ-=F))X/ZA [N?>L-RA&0KF"D+:=9LW
MC&Y7;$L[R%E/_ZKNO[%ORB",KC[(B-Y78_;NVNYNZB5GP7@C=X8=(YTG[9E*
MZ%NS>M-A77 *?S'E;=A&3[XL8ZFK33Z_'.V'R%KS=\YI6%?K&$B-$M,%YOS4
MRQ"3,U5"TOMU_C;A(]>9."S^!+1U6YE/@+-7@L1#[DT@#\/TBM,=:C6_14"3
M&/Z>>UHT/+HI.?/KV*S5:G2Q><)/TDW]4CZ.[')>2T!KQ1$%",8HD0LV;%>/
M%=?J:$+IEA1XA<P0L(NH8.6YIKG!]#!A_?[=LH^-)OT^Y9@V2:HC$1.Y-*ID
M<V6KSR%E<QMA8*<]/]5/K=GU&INO""%CWG^J4=:_*WJ ^+('B\N_-09V O-
MX3U!RX2E_%M-M,%1=YEBF=)&:<58UGOR9CN(3V?)E.LKS'T1-X+M/C:$NW&6
MY-/9#=Z]%G4*>,"Y CZSZ-?%4P"'+=3)^N?$IJCY]ALGJUB;CW=82D2$B:YS
M/WJ!MM1[3764;;P1+Y3N:8XZC,>Y*6.:XG&D%>'#M6,[A%K, ,WU@^2(7/QY
M*N1P8D;2DJQ[@.>/2\71)MTB@(Y(3;<A)2.@&U]]HHR&L1)>MV+(W]-R_:K(
M#;OI^EN"=_<J*K3P9G%^X#BN-K4<W#2-73T@6;LA&:VH\YJ'Z1?]J-ZZWDJ-
ML8MY?J9F_:+4=/N;-0QXEV\<_!G)VFEQH-+O2?:U&CL%I(HBF/[2)-QH@B02
M*2-CW W!'R?S>/M*=5:Z^G"7W# >FWNVT7BU@_?]L;1./P&G'JY1R_6+7TUW
MV29K[$661=-_[1?B3@'"'-KCGNY^;KQ[(R+K;(_3K,KU;!*^7WBE*YXZVO9^
M=+JK'7FSJ+P;E.JU:!3[=\H@6&FYAJNZ"=HQXZ U^ :Z1S4,Z?Y&23[H;D+F
M?R^Q1A:=?"Y3Y"B9TV40CM]#L=$FX%=##+_-N=3S9524FU5]JERIJHJ?<_E+
M-,F[)B"TX/<CS?.ED_VQRBRLRZ:0LKVXD3=4N>;N\[IAE?"4.I#R0,<-BT]3
M'RB;#Y_.6B:^<;GFGG)X^<MNYQ&U WZT"F&C@/OY2L*I!J\0SICST\^J8?*W
M>;68%B(O:5R]OV9UE>I T@"SIZ2P4UG9 PE>Y!1I_RV)%TF?^F8+$X/XLN_7
MP]871M9AM47_B&WP!7@,23#JWBB[VR\*;LNKM?- $/3.%$&0\[Y.R5A@[SEW
M$E6<9G1,@( HS7TY6<DM^J4;34/]6#_)0XVII2O7.,(!@+<  !/KHT:\49SE
M? _S@[X#RT;]+:F*&U41!7'VT]<"L:"G\H'BH+UQV_!03I(\CAE,GJUWH^IZ
MGE2\7FJGN_CT]I%'_[*M"VG><*)],03:U.5F%>?'7V'J5!_QM&: OU'NHZ">
MA([<B21K+[S6+)'JOJC7 BZ'6-E8"B?RTG[SS:BF;-%_9.X'6F)K3BK;Q"S6
MO"R9'><LOB;\3GB:T\<KDRJ7>/G1%JIQ=2[M65+4\RI* +E"ENQ.Z;PP(%8Q
MJ.+_=H#?P>+)/E,A[!&"J+STFQB#?\3QD4\"-#<=)0!$MP1A<"6Q[B$J.&DF
M2& =2#A/1@EXEW,I1]N]LS[U@\_O?LNH[G8V)/S*OQQ:>HFUJ*GE\D]DFTZ<
M><O+54!JQE%\".(I*#NAQU9H]!3@ +L <<UG TF-N6]7?FMB#!9KPCZQB@Z%
MSZWRKE$P<"@";YI>&2*;VV7+2U2'!ALVC-LW'S\.2)N)4,._GP&1 $Q.R,#5
M;D32G!3%M-X+"GMF[B[S2X4KX&HA44_GSB-5$0T6726W?D@M0R+H.G;*TC4+
M39RR&*R_8SEIV>_.I]?N]S/\=?+4FK[N4\VR[IR#Z%. \S;;&NT:*3DF\"OT
MY,NQE-IRK/ C^Q1)<BQ_\?G]$[?55KO9/1N[4\"3S(=I5NIQTK/XX_)?O?I"
M4YQS-F$8.+O'WD&]&K+<3%YW&53 G'C;W^P,6RVYWX+P.:25%D>[P=Y/G]."
M<DJ+HVN5SZA %]NZP7U&EREGQ#J*5V[[?W^1H<=@6_^=(:[=&3>/G*&K=@?V
M; 1T1?'^EXHQQ+!T<(*&18%SYM2Q3D$@\[>73A=G;H$KN!GA9:< ED4W6+0M
M4UPUGR;?R!,=EH>W)(,^HTE3_<SE(F^>ZE3=. +< 3]RAV[[?,*UW779_A%R
MC511:^^3IZ;;?]PN=W(QS%)Z08+%;9^\:A1C/K;MNQ&1&_Q+M/Y#4-GMYT<<
MD)0VB5&/$$F<NY5.LQ;G,-Q/K#8V^)J=W)&9HY"EHAM]L-%F=JD4G+?\C6!7
M<8&3G[//^H@RP]I3VM#1A[/TW%F0?8[PCG_K9DTH]56V!8#Z"W&3R)ITDPA.
M4C0,$\@:V\(W2+"HW'K5"&-+M<T^UG7Q7)!-C,.%LJ'(IK5VF+WFC\?E C'"
MH4 1H4\5<X0 ;0&51*D5XBD@0:E">>E:/GK'/,_(3@"M.ZVY,0EV'N("\KH$
MZ?:V7KR08]K(U_NC_RIJ2O;CJV[[XDTGI85VUX.RQ,KH;"09%02:VC8_&Q><
M48F9X!"B+AA=\MY]%:-A7.A"_O&ZH;$Y7M1D7=_+.N7,67-@QQ-VX.6I_]0L
MW^<:XK^7E/7$0O789I?I1F408=CP<=%KR83CQ^N292$P-(%@E&.?PWB_/F^P
M-!YF/3Z/S-CI)@79: C4P4NPV.:@G[&.5>U.LS)&<6"^E%B_[V"<55%+$ZW,
M^Q3@92H/85B?!"8%SO= ! SP*$&W?.&//]7>SZ1+5 V/BR]#.NR^J1=-74+\
M?SM ?*$Q_Z.=1U(8<1 >2O^#4%=W!:MX2>A7'_[AQQ IJ5- -Z]]8]7)W(G$
MLLP+]7SI__W5=J:.QDQ9(];W65:F+TK*7J24=*$W2B76GLQI+]>]_?,+%FN_
M'2 :'!_0F2?;H1:P>8R3Y:.TW[/QWC9$C_+K:7&Z1=^I_&41H[?3FXOQ#(L.
M+<YED#MCI3=G-LW?WYAG]84P44,H7P._&RX>PQ@H5MJC5L83OB<W'G!!I#Y_
M1,W.69C1?1%T\^D *5$L2%%]7/E7FB@N#HNYFA9#Q? R%PPK^9>8R('. VC(
M9[K]K5L^]?=6-+@)^7NA-7.MS0N(;AB3Q0:06W%;$*O\U7TQ6)=9J9JV_]@G
M0Y8K;.UE \-/UWE*R#PC2!4:T%L1NA#[?]A[[ZBFMJY?>","2CTJO44%!4%
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M29M.A/@C2(M9%167-2WG9:MH+H0"0<BYA+#97)OMG* F77F_@@(P+>Z9%U&
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MVJ.Y:!YCSI._F^YWD#X##:[H%41VJ4GW5ZKZ3;>$S+7>8+):;7FN@CLF&JN
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MB=Y-IUU\T-/ZE"&.+MG2*9ZS-JZ8_XTDQN(&!6BZ><*4I#!CRT)0O7E?#3*
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MC8<D*,2I5C:ON^5O?,ZN5; S/UPWYEF$5(JL[3G@-IM<71ES!,\-MACD3BI
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M?(7='G&8NNF6]6V.H7?A@VI'OXW[U+7WM17ZK)AM7\1_#PTW_+P"NR92["'
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M)8$D=LCLH1\(77V?3>:(>K'\F *@(CTK3)_/4P",Q7TT?IM: ,&^Q;L>^%(
M]/2ATZIHUHQ;.K;$XTE_J?9A)058-:( C-.ZY,/1PT/J0D*X)A=M' 4(?IR+
M0JZ208-W"L []UP*T*M?1B12@)'2HC!)!@F0:Q$<@-*J;?>PJ& (MA0_O;_N
M"=;'0(";@#(20"[_?%2O/YI(@#8GD#EVTRD E M%I?; &SU2C"; =R';.&\J
M"P4XI4\!CK%$DTB38'LZ@\G,J $H))$"/*/O(B/+H)N5U%EV%(;V P5(K^LE
MKJ,(2<OWLV;<;;%/QJ+W_>O!/&"4.M4,<O".DE%2T,T<D,,Y)RO\G2*:H+&.
M7MS=)A_ J%.^5T'E%P]^W=7JB=;1IH!,YZ?)J+)?3/?!6S&V?7!T)0U2@.>E
M46&238LH#%,H.8@+G8(B:4*P(9I@6L@W_15*/ELK!DI( UF4H ?';<A@&^#8
MT=C0_,.C9:@M" 4X84W';OVDEP(TGT7C3S50@,^V)$TITEG08 WE35(P:*OY
M(?LM!RCH@.<4("-WCWR5 LQYI&-#RP[II-!;7!2 KS3DEPXLM@>,T^3'*!Q[
MZ"<GU()$ 1+\FZ._7_,;_RCIS 50I,NU[7!0:=".9X+0 R8G2 I8G<>0D9?0
M&["(DUH$W1L"RT1(IQ^C^JS YF^D?H,A7I 5_CZEFG3Z,EAH_&?A!32V+!/4
MJ1%T:P#U2Q9J>/SAAL*6G8%N<X&I\>9'-"',D>!.0P'>M!>"1!U4(FM-M7M"
M+Z$L,]!M[F'HYCR*6INX%>J V2E];POT61VCZ(+=E6F"N1<%P/,,HZ@D#U^1
M.2*K#^D]78G$GVY+97>_=*6,8#8RC><=1F^N_90B-N%ZP.(TO;=+E>(DNO#'
MHT6,&5CQFZDR,)#LJ#I#,2;CJ#[7FV# ]X.-4;MQ/SLQ^"L?F4,U_Y!!+AT,
M85 \7U[ZLRH'LEW2*!CUT=16W@A3?,,/(8F)0P]85VWWR%"R@@$8PU![T*F3
MKA3@B!#52XU94?>XKK 13*IL\0*C4.P9*-5^A3NH!=52U(P>V!A+LD;=S8M@
M0#2_>0^ZCEQ' 9Z #=-JC&I.>$<M $/@B2[539G]VC),:5Y(QF^H/I0-!6C*
M^>7RG+?0I=M@,&,O@,+Q3A>V+]4L@'?9:V QCH%,EP]Z!Q3 J "#;E\B/ 55
MHX9IF6Y6E!>7RBB9W2:5 ESC>H["7@;Y800C)3 F$Z-;;0G<:)*FGS6[^[LZ
ME2XRNQJ5# *&'%8.1:6[,>Y]R)P&6MDT3+5TL" [-;CW$N@"AGQ47]<LC,1J
M2S[[BLPNF SR2;U 815!MAU&T<67UFFVH#ILAA0@,[EUFL"/IG:1C(K- YYZ
MT(5/NJC&%AAIJP2M;5$ P@U+L![R>;">G5_-I;X\C9?U >&!=I1JAU%6E"_=
MV \T-L.# ASPJL! $:N@"#!2F2D :'S?\&PTB<V6K&"3J\F_Q53>!<6D@[YQ
MPFF3&<#'?-ED'G(+.03-CIKQ0^%J=Y1^JFCQD_TVJ+MM& JK"B5,BI!D=D(/
M6=+$0%7P8)?S7'EMU'NZ3J6,S+,+\D]SH&8^@600;&\5%*_@4TP!Z(]3@/;5
M8='L- TO7SA)9CWZD&5*G )\"@+K ;5X@%IRQ3F0F4]1@,C1HGX8E0Q&DOF1
M<,@J>/%OLK0U]-*CO\F*?SDFFN!0!SW@K[>B $^/4OL_JD5UC'JDUNPFB9MJ
M51D\*^$O0M@!/\D:)&3_!12]YNEX)1\PT.@O4/4;$<U?%^9R> 6.I"I@3UB>
MI0"_1(#Q%>); ;;2:#N$<!D&.K!<4W# NGEMRY7@$ X[$*@'W?-4^%?M*I:H
MOO4Y"(E'A%JY15:T(^B:=#+/PB@YU)4;-=/YRS7F:+P2H06L6O=7U=GC^A^M
MTZAMM0?"^+6R""CV3CKI80+H4Y"1^E7Q3!O(Z5?)[J\+MK+0;D E9%O)!_VG
M\LLH3/HZ:LD#YTUF-OGEQ9_N01-NR*/QBH2Z?]&ICX/N6?S;/29_ATT):LGM
M+WX0 1A9P8JE./^J.(Z]9I[+(0'5'%P%>J*K#?W3$R :,W*"=!!.U$P;"B0+
M9G?_+-DK!88_&]6.T'#0#C35#G;-ZK]:DXHN^(.?T04B#^/Y"7(H&P=8SR=0
M@!1)M-CU@(\$!SU*1PVNY8J?P05V/.OJ0Q:RV%\"; E&5=-X!0(UO)BH/27O
M9T!L@QT71+Y?84<M-T%CM"=0?1.SZ21N4*T3-J^HP9\&OC(S7IT HY7]5\5A
M4(P.2#;VJXN<;3@?ICC/I3)-9@>QE25-]*]>A\+H_CN5()7*(075_)KJE+)6
ML)L*HJG#U 40M7E)!G]V07CV+]W*",:[('++^23_V6G!\2%8"@3):[ 7Z)^X
M@-<#W7)K&TTPD0<)90E@.D!-"9[GHYJ3J\$JLEO1/W'"C^.GG]5 ?D4J/_0%
M]"<_PZ<)$+5DJ+=7?H$JU7D4@,Q^B#YDG@)CM E#!5409M.K?^(.ZJ<\;SP5
M?<'AB#%HFASB>@)TBAMU1-XDF)J#BD@3P,&1%D[%^UT0[V_-H#%&$V 8=<U*
MD5@@5(/%]%$'/"K70(.SJ51;()5U"CCNW(0NW<6QD?]'N^8?TU85Q7%<H77(
MZ$B U+GY-G"(8XX,AK(9>:NF^^&"@$BK8/,6]R--B0%=&09<[EB%;C.Q3ITD
MSJT=8:)L+5WF$$36#MF,"4O)M'6;2BVXK1O0/0*UC_:]B^>^BM'__-,__./]
M<4_NO>?<<T_.]_/:)S7C##/W(HN&OQNEQ"7U!O XX4?^\HMB/Z79=8@00">0
MZ4GS(,4MH;F/@[I39!)@68429J5#N3<98[C2K)$)21O@9%(YSNIK $E['1"3
M+#813;@8^[1AP&;$+<L:(7@"2]KSH(V]E]! EPFW+)JWDAH>D$<4!3[^ 8HO
MWOLA2<6#8+PLC\C'+5PZ!$+[7X8 E)-[0#6^)3L1E>V]# [.&;'QA@\GF'$6
MT%H[-;/,"]*P&DT57 .=DKP+D5;+!%F=4]P\E\^!C*RWH5]+"68Y0!9E(*N)
M(_)(<C7#I8(KAE,#S _75,(I3A*B8U1+AY(WX[0A:N8A+V*ST=0Z)VNW@B9Z
M02F;(.>'[-U$A5OYG!XZ4' FMCE0G]9%WYH?5I\AOJ ')/Y.19+&J3]]:8;!
MUPZX6=<1XJN"^*K":3P]H_ XV4?$#P<D,B$A5,,OA/CK0*5=-^$^[C/B Y$O
M<;QX[,6%*)#;"36SD3CJ(([6 I:MIF?2/32[7 SX #0[I19ZRP(@W6)5CF.]
MA5-"W[3: 4.:*$'/<$JX:.NG';'A'5W'D OTVW\_\&-#*XZ7LP12LZC(PKM,
MF <:-KS0)P$M?GL-F/2B*9=?\1X<9QNT4:@401_0M4TD([SX&@ID?H9\4"SP
M&F(B@2QZ%A =(/VT%?!-$3/2X;FX,$>@_.^C&H!$!<T>)*8??<0"$ H)=8?"
M NPQKIX$3#7!:=OIZ2B4%$*1'YSL83*]U1F&36Q5AK+:M;0_S23B];VYN,I6
MG/(FNAV<QMC,VCJS>Q0^]ATH6%IC$1<0IA^BID/UXFZ>LZHX:),#^3)> /'R
M^?#Y7#ZS%+FOQ%X]U/VIKR19N,TK@/"/=46!O[TD47NI6:X7\F 1])ZV_7E.
M_\,FW/@SK'>+ZZ'$W(UF<;;MN6Q)?G0!-3L)K6,?).5SY("+.0%TY$."_FK;
M_GSD@*LY<0Z1,3-1B&ZW^\*0SLHO=-:D>Q-;_AH?-3Q5AQ\K\5S1E6U)/'3J
M1D=1Z8Z[@Q^H,YLSH@=/X\"EHG_^5/%OGV<DM9M4>869S<??+]A4\W7%QD?'
M5:FN6<U8D7G[A0QO,.%HSW'[&[M2UHR6E'^RN[]\E DZ=__DL"Q?4MS]Q)0Y
M9"C37HU*NW:^%8X^WK=UJKYD9-MDRZM/+AT+O\8\SWW_S5?J_C';RKJG\]QE
M%=W;TX._K)3<HD>DAU=UHK2&9";E^IT-VH^.5/_V4J5REW3/S:K!L_9]M=)5
MH51-_(6LG>'$[+9VY?S??_\__[E'-G?]#U!+ P04    " #Y@6%2GA->3?7P
M  !N!P$ %    '!G96XM,C R,#$R,S%?9S4N:G!G[+MG5%/=VC8:!04%1)!>
ME2(* H+22U2DB8"H]"8@74"D!0A$07J)@(""$*IT0D=Z[R"]A1J0WA)*"*2=
M/'M\[WZ_=^\SQM[?.>?'^;%G,L?(2-:ZUW67><WK7@M(,Z1EP/5G:IIJ@ L7
M+@"2R"\ :0Z@ J"X>/&O-WE0DM^7J"]=HJ2\=)6*ZC(U[55:6IJK-#1TUQBO
MTUUCN$9#<YWE.L,-)F9F9EIZ5C86)C9&)F:FOXQ<H""?0WGIRJ5+5YCH:.B8
M_H\'J17 0'TAFR*:X@(?X"+#!0J&"Z1. "\ <.'2A;\-P/\:%RZ2,5ZFHKYR
ME89\0/5UP,4+%!07*2G^0DW^-8#\.X"2X1+C+8G'EV_H65'QN3-)?HK+I.9_
M4M[&_'(4)?# ^D/0E:LLK&SL'(*WA>[<%7XH)2TC*R>O\E1535U#\]FKU_H&
MAD;&)C9O;>WL'1R=/#R]O'U OG[!GT-"P\(C(N,3OB8F)7_[GI*5G9/[,R^_
MH+"BLJJZIO9777U[1V=7=T]O7__8^,3DU/3,+ *YLOIG;7UC<VL;?7AT?((Y
MQ9Z=_^77!0#%A?\:_[=^,9#]NDA)24%)]9=?%R[Z_'4  ^6E6Q*7&1_K45FY
MW^"3_$3-]"0NL[SM"O^#ERAFZP^C5UD$'B(%T7^Y]C?/_CW'@OX?>?9WQ_[;
M+P2 EN(".7D4#  @@/ J*_(.X#_S_^N)WR 4$X6QXQV0*OK(JCVAKG-,<EX'
MQE)X;.!5.EN"])=R1&0K;;QFZ[9FR>:85V[_=SWH@_)S"=5 54C[(3:*!% Y
MC02B/#Q(@*Y1$H!F8$6<0+]XAP1H&QHF 5C-(2^3/73M<+#2*L,_AGAQ\?"6
M8R HFP2@D@'BS7E1C<U\), (806*YYHG ="> <_,.V:;-W9*F,^8_]F:^C\9
M>)G\'N-6=[[S;\)1G\B=5TK=#ZP?M8RS_*>+_[.%D[L^]/\!_Q_P_P'__T?P
M7M-@'FS/ZM"KE8V@>P>*+BL*#5HQ'[K92S8F2WGD&$JO2U8DMU$R4BM>=[*X
MIFF!W)T]AZHR&:9;,^FI O[UM("@=;OJIV !R"4:D%5&+9HU?"-)]H0FOW&S
M"N>0O:34!_UP%BT97O3#+?%*?Q$%F1C+IO(R],R H6"&%2C=SI=Y,[SJ9*/>
M3TGY>:,=1$ L?O6/P]NJH"4KJ@,WXPM<@+R49=A*<G@F=C"YPCR<R*5<#.81
M36=KE2'JIHA3_EH*EGZ'L7=%T5O4%!Q9#'KO^I<PKR[=<&O4+ ([H0P_>T)9
MM],9Q\6/ W2(V]JW$?V:N?%71%GN:T\VMMZY 5R@D.-"FY  EQKUBW;"NN4-
M"@KRPFU0^U7G^C6-_+$R3?JA=WF'& I[UGL$H#>^31IZVJ^]I,Z>;;9P#JFJ
MVWJMI_I60T^5"?#_=AJNP??RI)<0-MW\Q$82X#CR*N$9O)]^+A2EBM,#37J,
M[UJ>JU[R66X))P![I](W$@A9T"H#5LS'DVS<([_I:IN,!9PJKT.Q^-Z%'77R
MMUFMKH2L!EWL:PL)$B#$53& $ U!,B[4XM3WKI\<*;:<^)\2B,I[OC[D8^&_
MAGKPSL)RY/(2I2>FT=F\U.&JV=Y]GE8,;D*1 *T\?-C<%?I=79HM$@#A!_LZ
M?L8#=@='1:>-2<+=%YM8E\-VY_+!)MBP%2"UDTD^JCLSLW-]@\#MBN9[QN]
M-&9ZKWD6S-#E!&E3=/V\5,5#+LM!OC\DP.KH=&5@O\<9K(:WNVIX(>6(!-!2
MM3+(R1Y,?OH\9W(8N@>F@>_(KY?\=)!7SEVY\G#6_+:\R]>$1'WKAIF;"H][
M_#8XK(OU0ZEE;TXOP<I^5R)IFE[U)!EPF,\KWZ]M_%ZM_43M-CM2AO%,.'CP
M)C/[<&_+*PMQU*DJ5@+=@$D:>2A.B]5Z68;JF%G@Q'$_V];W+64P#RX2[2AC
MFQL-TTE\5MLD,-6Q/@F3"B 'VW"<!&!1E,')X&71=,.?Q&Z8F7N+JK$T39<L
M:O*5A_PTB ?(_/CZ.8Y8,EP@^D6)OY5<5$0JL,9$\J/Q9A;0Z?-($-L<MI"(
M.*31?%]WK>)AR&.KW@4VJI]R@%ISP<'Q,@]>NM:W]>FR5C$_4]2HX[ISOW_[
M 0!L:\+-:PCQ1/$%1R#B[G)J5^ULR]N$-JX9$J!4]&:"\IR'Q22.$\]<CEK:
M8T:S*'2;:Q&O3^.X?R3<_'UFWCX4.[36W1&;.@02@I( S@?AYQN= 2JFXXWF
M!5L&Y0NRE655:?$(V<1P58? U1\V@FT"HWN"<A_&MY8&Y5*]U5,7.SQ^+@[;
M^[B)ELPS/GPY-Q@B$-/69O"J]R;J,5P%W;)[A.9$#H>0 ,A;:-;0G/&J@-Z?
MJWLOM*I:%N;S=P<2>FY^>+3M;+_\;(DXSELMG5;@[(TY9"\%5GL)!$G>NGL5
MSJFI^$#X+CN1W])L"\)PCP1P'(#'6M(.EB=6N0D]]Y9C>\UP<"[:^9A<'-J7
MM)^-!3];S+S[,# 0*]->W]/)RVB\R<-;21R9/*"A%NV,X"$4&N%_/XD63NC;
ML\CTPG'AWU;6QOLJLO(+.!F%5]-HLGW:++HK@+N0DHMC+YX"5EN&O!.+RZRK
M3<&PV[@6[KC<OTF@ECKIP JM6A,GI_WP)KEKT ZF7\;&;E*V_NJUUS/B6.9\
MA;N"WWPUX_IQ7EAM>\58JOJ$*6>\_&PU_[%'KJ69L<7<@*.O&[^J5..FWNK[
M]_I?#ZF58CR!UXC<H.25YKK;4*3Y YRA7NSE.M#3T:[P-GW1>C6]R:]>PU)+
MQ(E7,MVZ"(7.(11.JQ'];*[KJLZY8-&";PR'L"*L@4J8DZ8AL\="U??M*/@1
M5CS_L;]47@28)L"+LX>YH\L]3TOR8NZD4<B]![4W_0V?)'S5KWK7L,!32P+0
MVJ!AQ,]+^$)C"'K["!Z^1(?71:6:A&FB+9(\2YXX7!IT]T5KUTL.9M:J#<H7
MT=HK&DX9D  ,>)TEE*YFHPY8LXCW.DU0M@'.L\6Y9Z[=9FBA81_?Y.=N20>*
MZO&;CA://[68JJ9S15]_6LL1,SZO<9WQ2>@''4E=GO7*7.$$MY0IG<ZNVKK1
M?R-MN>[D>K:M"5F#7)9[S<ZGI#8ZA]+_FH"]VDL(/Z!LJ=H(9E72GB;&:YM#
M]D1QCT#DVEO:DUCY505DW<9X)\G</Y.^O/>GZL6;Z+@_$G>#-($^38R)NHY]
M-"[O719[T7?Q"OE;S;>UJ0QJDM4F%(]KDT2P@]I7K"^;,7RY[W$,UR%D NV_
M$RFQP1WGSTV.+01^3=T2B^MR^:,1S77'O&'N5@2RXD'H:B0&CMA>TL+FHNR1
MZIUUQ6/CKR?V147%%$MEU!7?[?&XQS./[ G]7#\I)-,&D1M_$TN'>X)EF=II
MKXW)=&)139KJWW?DW6MQT ]]:?'F2>P'"AM"@G'A;X/ >C^:;TBB4&#O%_Q=
M;(!890GX\1@?6L [:PLL/UJHN'3?P.C'0!TZ/4OQK4UL]3U(^<RX,@L""^\D
M*HTUBN=;&DNMI<?Y,D)ESP*MN]8?%AW%18>H=?M/5Q!G>>YCQ3- .+4:;!A2
MR=YLVJ2?W:9N?,TVVL1WS$[R4B=$6H4$H'<?SCU [+S$>KB3V;_-Q!6.'-)Z
M.5D=Q>Z"O^WR1[C&0_%]H>]2LUETE=)3F"=1MKM:+=M_YT_$NA\OC-<A>X_Y
M]-+&[ARJ=GDM/2$;!$6>QC8+[ACJ77&M=KG<OFWJ_T&'FC 1GO&6D77CW36_
MC^#5%</=+B0)$&99%=:1QBA8WX*RC-S/[BI9K=#B_4WY)<F\Y",[M>+]A>!X
M23^;\,_I(4>WP4.82.512Z/ T70J JSYLM8*/7US8N$BJ%:OPC]-6L$Y@H=.
M,-K?ZIK)"PW[2\UN]X]&:.W=.BPKQ3\26?!R(U*67""A;E[&QL<E3RJ;8*$N
M8H):@-?2XVOR%V):&?>UN/9>7,B>ZTE\-OQB7;T;]I=7Q\ ];9P"%H)LAB'I
MV4 &<Z_'&Y7@.DE'6QSU\KJV_&)K+WDWS/+?ZU<\MLAA@!I@)U%1& \L5:FC
M(?'NV(GQS8D,!M--CH#.0]HB7LFU^7Y.B@^T5-S7F.LZ,.BQOH8P264^G.H[
MYT4F-%6(556JZ4BU*(](UY*+(.''EWO; (%,+\Y0ZJUMD4TW!.OR:0=]4+H<
M-F#EUZYX-6_H^7:?X&*BV_N#6WH<%6S?TWAI!5X%G7'J*JXTU6(&T#+M"[RM
M%JP\$JCU@L)Y"R-S>GJE']%9OW6%[[&[R[]]VS4-60!&XP)L^JNLAJJAR=4'
MLY-5P-F-Y]@<L*[S_2;0A"/?$J7KAV_&/OC?$O$-:@!7$)P9IQK L*H;3+Q&
M%J76,%HL<?J9!+;P$#05\&CAN4]HDC[_@'C9^XSW346%6"LD[\?SY%!/YBCD
M-+3YUH)9!W7+5-4 34]U]:];X D;SN[[T;H+!LM>#X4;"VI]BJ[9K'%"I/=7
M[MR,64\WN,+E7F#G+00 R,?[&T##&^5*L,HG]T[V>%^,BBU01KGE(YH:HS]_
M81/YJ-&KB#,<#[R/U4+M8'P(!8HB+@4S3B:UH5+A-JDZE9J:26/'OPO81==O
M.4Q\]!4X"N)DGB)7^:-&+=2T;KV\:W6&DR'D>MZ838"(?N@3T8RH84ABSX^,
M=$$2(,GE-$PYK+8Q*XL<I$+%!ZOJN]M+5$0>K%87W8J_^9N=-MV9U=K#0?\L
M1E>U17 7>YNL1=&.A0@F\EP7\P7+C(10@R6PFEY(4?:2QL<KEGSL?W#/QU*_
MOPV55#:T+DJ&("E*O-(EL?8X)>*@-T(Z#,TX8(1.CA3/-(U _#:^_B0G<9%9
M,%R8Q:!5<"GXJ;.8OG_-P0A3E?*COZ0?/ /B>#![T,%+_T[QUJH;Q>(062TR
M:G'<NU%GP^"U&,*&K*EP13;;BO3)M9X,QUA2M]@#/_JM)T)6TL3UX^F>76!N
M_I0WKWNSO_Q(S'PPLTSF9JO["-+TAV%M;)+VO%P<FA5Q!Z?J/[WW':72OG0E
MM3W]%DHO'G@-&TGE61-O]T7M-;\(O[*I\[W@4($@);3E0X@#O0F"49]_,%)G
M>_W@KY.M_OH*6$558A[ZESJ%?*KE;)8&*_.>W"<KR_-7W+Z69#5:NK,LBG*+
MM;R6K 16SZ/'I\3^U%IX@P':Y6=%G@6'W\F*!/RK*3+8+.J8TIRZHDN%G5,?
MVYB&('F3UD55M"NONKZM^!5^#WJU$K /Y=*N/) ,HTE"E&Q5]X$ZM-&3)\?B
M2$L&K(]:)<.*D5?,Q8 G:@E"ZX:Q&$!1-%VN9J^0XK(9][>I#?%"L&_LJL:D
M'6HXN-&V9!%A-/RAP -9M"!'&_D]4OPX/\N1%AIR4? +7+ &+M4IOEN[PHM]
M+8*,4!8!P?:"&+Q=5JO'F@<(60(X]6]L,V=S@>-'?_I:",5'%L&$3^@H8E@+
M!7E;8_8E 0:<@&7*$I"1TV4(G@\./',Q+;B#IPN$9/K4]*0[63"$K4([W3[7
M]\0H\T;M*1 9 G2T",!.#MD43LXI_WMJ.\+,AOT#M8I?BM79X8^Q<CE+6-87
M:)E/B/9M<;K-<169L-(_UT8YV;_$O:O@N1+T-/&BO0A[6#F[#X:J6_R<!T]/
M GS6WR W!OG$5FP7N1%=^D0"H"+)+<I:-6-\_%I][7!+AJ66V7&]R- _ %7_
M1Q-%//KX 30)P.>R[F?.O Z;X65KV?1' 8D,AC!\30ZQ[1\OP%5TEKQ*?.SV
M8/Q.L>X5$VSHL)8$-E5_["1&:U# S%'^7=+UW=;VLP]F.C[V0&D\5^QEN;G\
MMR$2/Y]NM[XVK'5TI%"XSP8/N@>V19NNJD<WNA6#("N>BYSEXU*SQT/BVI'=
M<B4"D??HAF'?XCW2G9T\T[0:9OE6>6P.)KVLOGCHP".+(4[BX60A_S8B4 QD
MH@"G/S":ZUKD$MQ;[6MU1+JE2.Q+BNPLT6%CISM-P#(&8SDC_5%\&F&WOD8'
MT6=>3GSV,J]H1D?L=A>3GE'\O]=0__=DQI( .'\G'MT]F]6OOR4PO(2;M?"9
MJWAS$B HU-(76$,/'9?MP4"(J7M%8ZUB3O!Q?$R!JR\K)@_W&N($J3:#8F#D
M3XXD0+4%"7!KW*:4.$$".$'W=#%%<<3QOWT$8O+_T'#[D$_1/VW9[5MQH\$'
M$A).@$')@0+5J--(JWC=BI)10/]/]_>Q'^,:7>>+,Y( ]ER1>,3?#11Q?%7*
MJAEB7/4X$5FFWSV@WW4N=N:]3KP+&G]2'<DI5%U56_Y]1O-7J VN4\V^W4J/
M*2%AF'D0T@;$>_%VBB/L5V#A+,!*.A/$"N&F3?^]9*=6KUTVNQ898!6YW<S&
MZ1(*NY""@F+V14*SBZ= -1)@&=8L/?9.&0C6'G5SRZIIGJ1)%4QLCTA1")N/
M2ABP:KLJ=U-B3X\X3 )0>D$^ FO@H<?<;@;C4@I%"]+G)\#*'.]9=DUFE5!]
MX4XQ]]Y3J;-10AYQDA<!V7N5Q%Q[.WT3'#:? $KH2!'',SEA-KI>FO1D=:VP
M!_?Y0F_+/7]^RUOH(\O+,*%/T1AXW9Y+(#\"_UZ^N01-\;@&:^\;7@6E[Z"$
M.#;&92*?1W^J_/40)A#SI<63=A4U_I<O?_.JH"#8HZ9)M"Q- 99#%EPD@(,H
MZ_+27A]:71LM.N\7& )?DJI<>OXH%O%6(=O>M=='/F&$A7+YHAJ$W,0MI]4/
M1RJ:0U;H+X$&.J#+0VIVC:'^ Q$R[:5=D04Q[-QJ[SG?]Q(@\O\=0'AAOW@*
M8V5U#2__9F .<8C(, :TY;V ?X,-\2TTP1:./T_&*;>?SW[66Z*.,\IQ2:8
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M&A0%_.])@!'G$_&.6IC#R$J"W!DP5Y]=_NO7]-7V":^[=[4\EN%S<ZN&49[
MJ!2A4$^E#T<:XZ]T61^HVTM ?_MXLUO+R=*,YTG]1F"S<,@86/"M$49.1RF:
MD*1])9AHAT:'OPQ.76!CZM?PG/#F#K#:.Y/MBT8-9JKL$I6"SGS<6;5G\\//
M\^!'J-LI>1<X'IS1+8W5Y<KYN[X^SP[-6=O;A>F?P2S!6F.[8'V43)>V%Y,;
M;;W2;]2J"/0N%+A1K4>(\KJRKWP)1#DD\FPOVW1MY@\LF7>L"/QNNB>HQ1;*
MOGWIBT:*XFAWA:>]UTS1B6"Y*0E0T1(RUTX"7,7?^GG_S;OC(H=P]R#ZI)Q@
M;,HI+\JR8)^0L)B?%8F4O'HGZ^/_F"(#8%6T3:<[_L5$(PT2>KFCQ(G%S[RT
M$!&:6<@IPJ29DW958X>R%/[M\D@^KE;:^U+?GU5";J.Z[W*,91=FB>YGF IJ
M;I@UO*7*RS9TY:[H?,ER^=.(J2WK6:'! T! AKC<7$6N# EP+7+-GEQ\]&C6
M3D0B;.\"ZG"CPT\<+^"#" N5\JR.V5<>>A<YOC6\/BP]+=$-V,[?2WK!M!%)
M C HB^Z8)+=!HFMD:NB720 ND*7JKR35<2F67S$&6KX\B^N(/P(ZCV<6]-B-
MV6S8K"=O[[FV;+Q9LQ]A,HS=KM_/Y>T^^.Q])=]<- ;SJ6C(ZUUE6>S*4Q8%
M'M7?[,G^RS_BZLHGIG-!>9H3)R4/31S]QC?I!8)_-P8M"/Y0#XYCP6?)R9Y]
MY[H 2Q9@2(TI"<PJ+U?UI=J="\AWXKVXEU,_(7ZBU;M?K<&X?;ZME1IJ=%#*
M'\W.E6S-_/JBIN+5(\BG9.*U\C$PH/G>)%' 45DAG<8HC[P$*O704FF)O_/6
M@E#0:GG$LUTD^OH\)Y73%Q%=6[0O\T#=B1*YI;[^/]KE,WN<4V 7"< 1>(\X
M;B&)MOS<R$DH0A)4=B%VC<2)BK#!P]V,&*+F;0,V3ZM>;DG9-OA$O\C/$%^K
MM2$FL[?+^]!.7:R/[AX["?"43-?+!SIDE1P)1"X J^P)-SI(@. F!1(@7@2S
M'[E/'"_!%Z%)@ >6;F(]*T)XA3Q,- F0!8*@?/(@AZJ\J'T8X@$Q DF6W8MI
M)$ ?,\Y'E1?AU9(8"%SG633_]Z\$K-J!".,A@TJ-#;SAL'\TRP3IJ(<X#)\+
MA9$ 5'X^)(" X=X"$\1QBJA/%G_?_'V]@0S_9/8."1#F21R%'>O2$Z\='Q U
MX'/U=_[+H?N8P]U OG\RJT>NT"U"-G SG1?/O;6$C[.L]23+*M,SPU6BU=[:
M#/[I/QK-)G*/X]0@HXI K,)XRQE?B^MF-DZG]A#>@^^8&RC'1ORC1?5_#&+@
MPJ@Z)LUMS1)Z%E:;;(.^\0\6H?\<0D)#%G1/?JF_A?>(_C^)^4]B_I.8_V&Q
M ?H)5F;?TT*%?X<-@#OS4$K[J26O<"N?'Z[BK-OP^7QU,7\"BN3LV@MD 0FQ
M%^ S\G>U)(L$)I/_@IP[0^XD#G7>_^]_&IEC.Y_CV=LE:HVM..@T\#-*Z."P
M^%ZT;?'F\I+!1$Y9V$#;@&_<W&\?"FBRW35=?J[J(HIA3\A'D4R\( H2LB<U
M3A6.%[I*)]19CK#*^J[&5J5 =,AY^5*C%M^OPVXD(FZ>AV74L@P_3X[Z.<%B
M#*\RU1;<LZF]4SBBY7[KJX1'!V>T2P]G('J8S7*.!&!KV7R* A)9:F'X@FP<
M9)650)U.10*T3QV1 (E2#1L^#99^XB_IZ)>A&/%@(HN#Y9R%#_[F]/WY@.S=
MAL"YBC'_=RZ+X,8S7&42[M=!W 1H3@7MFBL5,ARB^,H^0_OR2?K<Z['+F8X?
MBB_3"&O1%FZK]QN\^&5'&W.8N-%22Y2 C$0L0_"B;L"S5^H8$J!;_)Q!D9X$
M""G9( &$'96]]Q%XBI<;0436X=SMYIO3C7J%CU=T&9UKT$:+NBYOW^V.38D_
M& ABHXV7++6-^]88._C;]RJSX7 5;%;1H>62E!NE*:C&<ZI4'#GQ3O'YNPYM
M6]':^!KU <=K9/,*H(0#0*L,A;=(-7'IK]OH3X3^NHU>_==M=&W>?PA.X<O\
M&N<#<XI%P0EE6L00"OH$Q9V4,>5=K[45G>Q&_VTL(':%O<_J%WB,34-(D57H
MQYM9-%4'P<DMPIOG/HK89)O;^\[P^<3N";?$ >/V@MW1J_ZWZ?RTP9[9[D=,
M!^RZR2G ?YD.91+ ZS1CHDBF'<;BP'$:[JIX8U44V'&NW.3IMK_KQ4T'7ZNI
M]Z*Y5U-!\RU)":F/Z>/*T*RKHZNHC^%L=<G!JTWA#1 )YM)YN4:.H8L:3RI2
M'<4L!\6N78%4'5\%S"[)LOU+# ^7%,9V4'0ZT%:>*V3)P3)L'+S7XD(<G3R0
M,E\T3%X[._RNV-+H42N[T!UPR8MY'8+Z K;F@ET$\9( -*;#Q->CRY81/ +3
M)U!^LW$\>][,NW<#.:!"YYV8Y67Q!,%H"NX//NC8T,JOM@WXD13_].^J?&5O
MJ.6H,IEA\!T]!_FWR1^"]K[$/6WQTZ2_FKWM+/D<S@'J7VJOD>P_%/YF<V3K
MVL!:=EZ^''!E[P48B.Y%IZ=R#5/-[DM?!A%$-J 1/"*P;N7[M:C!EV<[- 3X
MJ_@'AY6>U$IA5ZDRI(Y9.X#78EA5C<VLC>ND\L0;!@?-8$#AL[1$)CWC5(;!
M!J3M"?.9!"X ]![K@XDT/:'EG]C-2I9MG<_)[%EF/8)/%>+W28"@3)#9TT5Z
M]%7U(W7%&K?;_O>O708NBQI/FHTX;'2JIZ0J>Z*\BSV;/!Y-J$'<O1AD95??
M4QW?;C%2YMKF.VHO+WN'%"%3I.JW>8=&KHI#D6,<QA<M.]7,/6-VA>**2UR%
MO"<[P9F+LU&09W!U8#'AT]D)VAJIJ(XS ]4;G1E,L8A;O!"&36K[A70ZYP>.
MF##7;>RB]RGF[Y)5WB']U7F92(A#B=WYTPNE4@T1U!8_GBTA+<:7]8D3A"PW
M&&<2-?5O>:Y\8F(BT/]ZT_-;!]:&!3N\U2?C3C!Z\)5E-LEQ+-RRJB9>:MME
M1?E=#O3YG>'< "#JL-/4*";;Z>-% J 5GE!]!=H)G[O8/@GT_XFE>CI@$X>9
MRVX]+[;9&0I(0S9(./_LE@B./!7Q+XM6AD#P-+R/11G5JIGTS-0>JS*KF$R5
M/.267B<25Q2T%!P0QGF)03D.V8(1NX ,FEDF5^85[Q:>L$Z1 BNLI^?>AT4F
M.ND\C_<O%S0W"P'S/<<E+L 5[Y*L[:0:'M&QK/'XK4Z#\[2OW::&7X[5>B]=
MV4NG<][]8[6705 XQ@T;9A7-F44DWSPR@T8TWW>P8)@2'!<O5M13&K0RAFFA
MDHH@%^8OL*4LSJ[:!/?2O@?)2J5$)45P<Z95,Z_#4"/I+"1 AF$L$/5I&G)V
M%8IUT*6!C(CT\&(?[;3@0PQW-_#%8'BYAPJJ.<\>/="U>#-ESBX.DKEEX#W-
M8YUVI")U]*SA\?S]V^%_/E[;O]+6(_X3K(2^U-)&'V'!&]_A"B^V $6:<D+D
M'ZR73'9US*7-U92NQ=$/JCWX?=_9@\AQHWWI^"JZAWA=_H $N$7>/.FN(-W.
M+X%620!J;O)^^J7(<A$B[IH6=N M!V/ 0KH7N=$]'3#&S71VR^L(AT7NAK$3
M9[:#6Z$;IR5V3^:^<^OE7+[X?C=?WW2#RN&=)2->"NT&5>1$5UK\0N%3=,,5
MK3(AUH[*O+\::IT_AU+;&S5N,:J%O(TWC=!A4=/7_OYNGV:3]U]%Y76:JK,Z
M*F ?Z%_^&XM31RM'H86081%5P]1.@<*5HU4QS[J)2YIU%;$.;[^9^-JSREPO
MHI_O2RMVA_KMMR 5IT@ ) MQDKQ%>*RXU1*R^X@=.+5DS-"WX=2&O6:UWS-'
M/I!*(S*-_PL8+R80FAUN>LXSZR2 O1<Z.529:QX+>8VZG)NY75/AQ%HSMHT(
M@<[L6SC7_8P4ET3X_E&)8/5@"V=[Y]I*B2["#JP:!+LA-0-YMM/IJG\U5/V:
MD KX<*J;=(<O%+1NY5HS?4-A\/F;6UXQZF)&S-0+0OB'0B$MF\RK4/Q-KR7B
MDUQ=!$W[H7S^&-Z5AHMN\>+T(_P0C-F"W!S!;K=([/C/'!?>O>O\=?"?G]0W
M]JPD[TF@>I9+ZW(W%Z70 4DAA4Y&TI@*@7CEL3F5EJ22M5MRG$M.*-_EE6QV
M383PKJ-,^=;$*YNXVS%O8Q)'/]K:RE'R?.;PT@B*[$-['9];AG@5#=@?EKKL
M_DP1:E4PMK&^1D_U17ZZFQ>E>X X[88PB^>@X%U:+=7.)M65VXM<DQ8(3MN6
MVEBU4-#'"'TM_NY.<$,XHWT(^^)#6]EG6;,L60@73^6UK&9OK!#:ILM"C%#0
M+ ]2,9A4GD8NT7$_=#2 V$<H#ZVWF^BFO5#X<W24$#M3VF-!/HH#%$@"=++$
M[R2G!(/ -XK-'.I%B7DN>=?9RM+]'01BI5^4)-I=\O[Q*?)EMI38:WCE^*!9
M*4;).G)%2C?&@GHLD+4/S>'&8#*T_&W9-&GJWN2^S>' YUZ&(HE;L6. 7CE*
M6H[58L@[M\\<P;,/E<6 ;YJ:.%R:X;>_^_)\%^PS;V?P&XD*P.Z^7<E]E3JI
M&B:RZZ_*9,B?@3="P2,: U: EQP1>6DK4'H!22<3_[D!SB?Q^0XS#S(,*1GZ
M6;K5W%,^I\XR>DT8_FZI@NW1(:%T,SN!K&78.A+@ZGB7'W#638I.!TBG52*:
M(UGV.F9\0"+T2_T;UWDJV1ZI>?Q30HXR-YY]HBJ&M3O]#D<@/-^$D#5UR\I=
M9.'.F\\9D=*<49Z/C[A09/JR?SNVU)?8/ZR7U5A_A$E"T85,P6R4]LOJN\X;
MD\XYL&XO7?2R=9ON5K"L(ZV75]2B;[6UR4JUD07L229H V.)A9?@E=%*[4XI
MW"&=-Y1^I;>3 #IU9M&*'X2U:=Y*7]$;6<W,>FB'T#99SAK.=H#+$WY4FRZX
M80*Q+@5.ALD<H9E>R"%E_ZB& A-CN[B2D<J&<L%O\9H"?Q+,/D-J#MJBHD1P
M#98L9DXLYQ\T17$S#GXAPS-QO#9*K;$+T2(-'\=<J/(%7F(\7/*+9N3,=Z&>
M68V6>H2*P&N.J/EY\1BKB5U1OB#_(17UBOJ)=[M)]G=9$6*B*Z#E>ZTQ%9(P
MI[V3@ZC%ZZC?)4ANA1=365IPEGZK4<7P/^D*4]2\:_%2MA3.%]G#J10Y='Y,
MH:WZ<=PQS+W8[)66$##[JC@-UM!X4KD'#OJ^!M6LPBG",4DQ*K*+^?KWJ7%_
M[&N<UZ&A$+83Z#6P)Z'@]N2)MH?QV/&58Q)@MTG*JG$BN\HNU"-\;^6:S9/^
MW,A\ &TYVY#9G7['EJT=J_R:TH H5? "[@%Q/!G"TWQYSEF^WPSKWV4H;3BN
M'6"%'"!;:7 3UF00B/75RXQ+U#?J%K0VNM_:1C$"L8,SM<0$7MNL'P?AR#*[
MWA>#3<5QXH3V;MEY]LR62;\3?B6[X>H_EG;W58N,NI5L==TVD^$M-._*]&<B
MX\R,.2C/P%S6B573UL:-B7%^?N'WGTNQ;+<,X]7ZN/A^O+6K@U,0QV'T@?R@
M]M-VQ.7,(G/G&EJ#\RG(M6V#]LX]NZZ. =>"RT]J%-OK^"F$(D-T7#P$,XKW
M_'D*5$%_8-6G[0[C>W0KWR_'D37Z[O#>P6[1>$Y MO<"#,&C.UL.6SF2/AUR
M FL2?BJSXV]-BSZ$L()^<O/K-5;B JHN(WR?H_9G:.T>OMDU_?@Q2>E3(49?
MW-7PE#X1HZ0<B52\@.YH@]SP&K)\.N)E;&H^=K$:$U=@9+9U6B8"T$]97)?]
M@U 1'ZKEO;^1LH%7P1F [Z.&UILN+;9XN?,$WPPS:!I_Z+R#4U)6P=^8;Z/I
MXJ1HHUTN6%X>PW@TU9EW]6/*=SSUE7B-RM"7DQT+MGQJSI/2?!B'W'P=A0>8
M1LOZZ^7CV1A&@BU45B&(':1]\"I:429=H-XJHP^CK8/3&84?B-YS90.4:WI0
MTC,JK[ Z@D.7EX/NJC&F5NFWW<8H%4:>^6 HL!$!I8%]&.4[Z.0(5S<$9\.9
M6'6,WUF.1'N"S)# 6.W50H4? )'1*DM$"S*P*2!C3F6%,_7U=.Y]1QE$.C3
MQA9RD\@FEA=RZTOZ1Y&TSH^2&B6":NY?LQ)W7T5I9T_?@2<?0]B<_WHDK5J]
M1*=<F]\2QH_BL[C]9?H#IRIL3X+^H4K:)Y3&0O1RNK,Z$D*F'S@-UD>_&1W6
MS8O57JY#^V,_C!$:)<12DF1L7Y<$4Z_>JCD$G[;_(.S?K9>L2=F$+7(5GRM'
M_FF^#39 P=L.Z#M*0 WZQ/[Q]?K8?A937U>!)-\KLQSJC)4-7#S,NH#TR5YG
M$J#:IX.>;L&Y;,'YU)!A4Y+:RWE(1K6YN7+\#[!-:?"ZHEZ9(K/])9W';<P_
M''^;=$GKBOCSDYV1QG["J8.EL::9#AQ+$6!3>YMLYUGBX,0M8S&7_4?:9\9\
M!N:Y&C?C+PQ33HH*83*P/L4@6$<SC[F6_OB))8,KL3?*"+6?FR>(F5@$%XB)
MCG*N]:AM?/C4!TC_[6*N.@.&^_.4J'Y0EL3"D99AQ)NH[C"X4XOU9*.VYY2)
M=M;<P(/Y?NE]B@$#Q.6U 6DF^P1S+]44P[<A3'H:%R/O9/R?3DK^]S</1=H#
M^<"BO^(/-5DURZ=%V>(IM_[\SAY]^Q@_<0SWR>%79$AQT):I5)9L'+5#[49[
M#C-ADUN3.3_-^O(/.9@2Z\76>G"M!BUA)VX1R:^J2_,@;JMW>1CKE2:+RR\9
M<X;ZB'PZ]9/8&@I0S\>ZZ4PR)*U,<LE0Q58?BJXG"[5!HZ?E/2T;RN(?NSNI
M4PS8? %>4T=JSV5D#TWL$+GP?$THF8AX\>MF73Z%3O28U(CLWZWJ&FU*3\YQ
MT^-?NLLZPX.O9E]LQ'5K2,&OS3A/_1BX//NAR1VO@C\WM$$.Z7D%\"TB3=UM
MV0M=T19/5>\,G:5XZJG:.3$?NN&93-MA<[ +)YS5O(WC>:&[U^MDZ:J;?TAL
M()HKX/<)V8HB),"5Y';@C:TG#T3,MH[XLDY$J[X []^I'G_:YZ&:?4C?)G/1
MF15:9X)+Q1BBW>)0*7\44^FB/7X:'<_%TX_G@F\L+\EHQX7\<7$J]*[[Y@+8
M8),[A9=#[)8N[1@NLJ*5DQ]^,&K+Y\]AC.M=XAF;P:S\*G,LK!C7XE&C>R:5
M^S.&%T@<VCZ'=WHW)6_X^)9R?UP5B-?=L1A A;T,ZEDQC)8:J&,6%;T!+N[)
M*K 3.F0^.HAJ9L6>+M-#=X^C7"QD2UV7D[0<]]80[*_S!R[SWMEH<@(+C#9:
MHI-V7J*:?N \4W<2S3TL@O<UK^]0"KP?G/\3"R@E]]59A87:)O([6&XCL)3&
MY*OX\5>[PS,)*G5H*G*2N;<9RB8:;0NUBZ311Z+-WJ9Y(WP;:'CE,G0@Q'#$
M,!W/CS+C84418M*:ZN=,$.U?.AAC&9@ 5']$1HNRJ@@Y<TKL"F59D2(7G]I\
MU 8#28!+M[%PCSR0H0K6-U?' ->9<);LS*[0W/\9W*+V@>K7*TN7!0W^\!1\
M%:'"4YP=E(TI33?EYC@\XZ^IKAGG6: MCPX.TNC5_5$NU_-\VH)%6-]0NG>Y
M1^=%QIF,'P\,)V9NA)4>[FH6;$K& 3L0=-$F'L\[J,%?WGXG_%[OV;((6!6?
M@W4!F4H/'D)I0"9C2@PP"4*!A6D!LQ&S1]!%G@?=[A9K*]#9@U?5A 0O.*7#
M6=W4DJYD@_CE]=7W28])@(LW\_$B1Q D60'2:2%+*^_%Y<T>\"W0?IF_??7'
M<@%5)J6A%Z^]27&AUA]?(YAS:.95O7%MR*N3!HPS(=-%6=(AX<:[<[OJO(J.
M "L15^'.]]O^!6U[;92&(PP: B]4 [TA;4K'0Q[F:-[(1GL?"I4\RV+OD=[7
M^2F/UG[ \[EHSU,(M&67WKSP6VG<?6IS-?;^#.9^HM#+:-M7'R;)K>G&FW_K
M7]+ZEJJ%\#<V'A-^-@MLI=^'=?DL<M?%+BIHX4 N!EYU(6R)AWVVAS!:M14N
MSS._C1T.$1,OH6=F(]ZV:CIBFYD9#DGI["-5"SQM' K<R@@%+4^[>P:R$\)!
MND(?Y8J.]8P9K4!'Q*=N#) 9>7*;IRH5&(@7P@*+0*N8"UC;5=W+%*R=T(L+
M2SOR N7!S<NBQ]W.KV*-WZKB8)V/J$*ESL4A-I<+;#SL/Z2[5'>ZT!;$RXA<
MI.[]\U[W62O6!37= :,&<UHA=:\X+LW*7XKX,H?P/=2N]*^*.>H=[+FWZRL$
MS_5Z5;*+M&T:QY, @V.2:^H=2^70+L=F*; A(:?1';G#&26R9_IL?+VZ,I7'
MVJRDJJ#JS2J/-1=7=/2-X%8,''L;GV+64F$9RM.7[=]=URB???%YZ.Z\\JJ8
M[U+EP,Z<VSO#4KP<EFJ9]W,@'_IV'9*>7CW+R8+OJW9!'UWG8,)]>_?PV7ZU
M!_RH3^I*]R]9[_!6P#JXG7"=K.I/&L<AR%ODMK>I)JID:2NI_M/-T >/713=
M-8P>O*V(GTN5ZRMQFLI[E2*\I1!XM>N97N(H6BV10A5'31P;SMOG84CH2B[)
MV.M)P%AY  9E90\/95N['Y_"K0CY5=K*T\0KW[ZTV;JYT=4$9PW1ON]FL/DR
MX)+T0I9R_QT, RT) ):"N5&6X<H<0ZCSG8ZI<I"D@VJ# \:TY!9#V#5F<%9N
MH!7L:_2/C8)<M&$[[Q70'#(3"REQ!+J@HDP?.W@>5 WQ[F?>L;:4,--LBY%;
M2(CU2-#=D?CPLF:L90V[R3-J#GQP>5@;^SU_RT3_=]C* <V,XYB1J>3C0JS=
M.F99)KXA:C E^G'%+/#]F^MRW;I!@2,F^804$L 1$KK$5EV43P*45R_(X856
MHE(5/)B4W[RZ]^"S6-=CJY%*9J/R!$NKF=F.G[-S"-.\9#=*9R;'>._"Z L)
M?<L^I:8K>>W *^!WJ%2L<W>]_(Z?R/-D7CO'M<\1-Q2,%-\54_=M^E)&MJ?I
ML_O/O2-01Q>?S.#GL6G(N2$/##\V"AUL%K(Z3>3'_IQ^J?K]/6H+/>_K71YP
M<?]F;.' -#L\NUG,T3LE#\]T8YG1PE3=\\NFS#1#<2';O?#X"EFJ^B_42N%4
M^? L17.4>.NB/-;>'H4S&3'8:<.XSW5=_LX].%+L2.8.'AG#,V_HR@;7.MP)
M=@5\MQC_9 3L[IOKNWAW9"^G:OR ."I\QJ!![778\?E=J&)%_(,N3\77EKKK
M^)<:XPCQP2-Z=K [VKL<IZ:*@K0F(<2^!]CGQ'CH3S>JTTY+E-2Y1#$W5;U\
M^C9@F/W>6.&G7V^^/#C4C4Q]J<L:B$ [U:>G%3G1(!MN>7CE(*1R*WO+ >XW
MM.\:6-9[\',%CV?@IGN %Q5OH&]T<;A%>,6(K0 9'<N:FFK*<[8-35Q6GI(
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M8M[=8B^;V$<"T'A:<FX1)<,Z$N9!%=UKI<BI$SH+S"&J=[38LC'),2WG123
M\%[1[Y$K<CN-$N2 !M*A?2(;=7,<^:9-T5I=M\L_N I^,7_HU _C+W_=:H<$
M_/8=TJT)"N-KGB(!^DK%;)W%=UYM0&9LB'JX;,AT*)P$R)612L-=VDI7;"+$
M$7E;0AHUD0L<G8*H>&Z;CFF.SR5"<_N2[1H'&1?<JUP0.H\5ZEI/20!*XN]F
M"JP'(9,W]'B.<+L;:^9[;B8_B1XG < >=[54)$(E_9D>&69T>5K2-7-@/9#T
MP>\4[R)%%7!"C\HE.?UUE35KW+SCFGW9OZVE005.C@L*3"0WUK8/SDB ;[E2
M)?6PVX&CAHL"HT!G^MDA1!O8=Y6&K5IN8]RS=V5<U/766\28:<GDP*7O-SS>
M.>H<W ,/I$L0Q<#":,)D\IX0.H@$>)S05E(,,L3QZHPJCU.>5B"ZXU*C4H,I
M&M]\6[UYR?NF*_?7VH+ 4<@EO,JJ.#20 AVR\5F]BS>L7OOK5*TR/4Z_@DUL
M:9#OM+<>M/S#Y4ZJ<1OEQ0M=+[&.*"&#6D)N0O<Y:P>V^1KHVI*ZB\*+D21G
M*1<_@X7R]*F^/Y]8)'O6[1??R[;);L9H=#,X%N6>+\X10PI$^&!_/>8DBF$;
M<+>P;NW2@=(HEY9@*3CM'"*K8QD7(79++<)WT4LTU!8</T?U^PJ"GKF_MN,8
MY;;7A%,&F;ZJUV48R "QF-I.B+FT?W_[Z?;K;[=$JYM?J ]JG, S6#&J6$/F
MD*G4:\$!SIGFYIQ]QS0N_GI1FO%/5E12F7^QX&@ WK[^( JVE?HS93JLM"Z/
M@\4##BX]4-23,A=Q[;H@8_Y8Q.2GRX(A1NK1$A0B<7-LS- IQ@_3ZH%1!5PX
MF#3X>2AF&$.T'TE$3NX362Q\[:YQ&'\^#*^<^=+_;3CCN!@^X]-N(8$6WX5F
M&H,@71;7JD?=DLYIYD35VY-9D_D,4E03[>*\V"9G@A<E#A/9^.%3,KPT8 DO
MM-CT"F6]W0&KR=903E<^(4NO9J+.@S>Y80 H(>1N/G]2JO6"D!3(N<T1V^++
M$Y>_1;=")>E4<\[3DK^5-%ULZ/RPS%27Z[F1O;M(4I\06:47J[:IC&?Y6^)[
M?I=8Y[61H^Y7V\H[VP6FL5VA0HOEY1I;1'$_+HFIL_>.UYBX?7I31)9B74G!
M$RY,"(8@N=UF['YKJ^R&]FN<&$[#7LZN-9R-G?U<KJ7TM?)HP;JGG"=W*+./
M@=DS9AU26%*=<QQ9],X,, ;NU"L1'C\N<7D)P%YJ*CD/20%G'R -X$5.T],\
MK&_JFW;]0G/S'A<LDC6D&?]E8Z$*S9#&O ]!/MTJ7 GQ.A[ZK[]^7=P_Q9$5
M4KK+/IC93IR3>.4Q6[6=MB(V@7A;E&-?SQE#U (\%FD96&:82SD_6AG>W5J%
M0DF JR5X(0B:OIW%A*:Z9"%M,6)Y=C6)_D[1TY$&)]="B>Y'N.)'.Q9MR["@
M0&JL/PJC2^$0R%T3UBYYMFB7X#GL0QOT\GEDN]V'_D[8UW@%Z[H &8P6UC)W
M=DM:),N)M5XM07C8)MO)CYCM_[-U)RWWW?HOD.R\^]?E'Y$(H\3;\YZ3U5G^
M2=LB"SRJR&^+O-B[/^NX*L[&A#J^)>;P<_;6A0GQG/R!4!%OR'1#9Q4PD:BU
M7_RO>10FQ:LV](Y$)V@HRS]M&A4\/Y>#UV=@=9&F;I&LO S\8S78[E4=CN?U
MR0A!A1*5,(8S?WSYT1V%H/W5$MYK@3>PADC1=+@S4EL$)TQGJI>LWZ1;I263
MZG7SQ:&=NG4=HD48J2;+##32L]@G'BR+!2ZJMW/H=M&0 '-A7;QT[XXSW>]9
M7$8-+@I,\3-$2]?GC\RIQX.LA'VCTJ^6KY8J46&X4<G18"T<_Z:!!2_:,+C$
MTW2M.0@SH(?*[5KK3?P99VN<8ZXFY7WS-!J<JT:]<[S1OO0Q\ )6Q!>^ !+I
M&'7PX3C><<]O]!@2_[%M5JK8X_*1G??J+Z[CX@ 5C#'6+=])GO#'3RT[1R:<
MJZ]P;I,<WI^F%N7FQ6-M9/4I897666HJ\"->L\[ZYOAG_:2D46428%U&RED4
MFJ L#J:"+B_&X(3!TI/57NB8-&B,B?2ONLK#EPY_OK]E^!;5TB^SUV9-S?/#
ML(ZXM$@W(24>A&F6&K$170$"G)*(@I4B'4P1+> ZXGY'8RS1"&XT$0C  R=%
M\>QN0J$N;VI07F.+FP88-\$J@U<7J=_$511]D%0)NM+'GV "8\F>%%-FPQ;2
MW7AJR;!]M%79YIS3)^">.Q$;HL^>EO@DWG?@VH/%RO.>AQGG_Q=S[QG55/2^
M"T8141&0)ITH19 J*+U$5)I4!4%J1'J-]!8(($6Z@(!TZ9W00B_2F_3>2>@]
M00R!A##\[MR[UJPULV;^]WZ8F0_O^7SV/N_S[.?99[_O+CC^:_%W+S;9_RXN
M=19;>5DA1A6>E-* !@>Z?7QQ2/_3*?KX*)=&BP-+&3',0MGR&-4V J>XC"3>
M&L++06^,M4C G.J(CQJ6B_;OE<$CBT5^+.45SY7$;:J262D;GO$-4?,.>H0.
MO5%?:$LCO;9;W=>/E_]+X04Z-%NKGVH1MD;9OQE>B>,Y?ANC+N!-B*':-L7H
M_HL66C6>.#K%Y_T5K,BQR=-95NGX1?481X)J(.@@I5XTSLDX#(9NUW,TQ=Y8
M%H\L-]U)D+BSF#-ZIO7V?!99_F^V$QX^VT2Z^$S<\\DS(]PDZ"E!@0P#SR9
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MM*BP0[BUE,RY4E*+>+9,.TDN: C)IZ]1#VS;*6$V8!*H81H[S908A=4DU16
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M F_/>>ET&GIB-0,_6XAC,Z$)#BN'G-"3YR)#,NRJ^[O@%]#'E]]GUM=A/5<
M1J_CKME4:#WQD6\[Q3ZS::-@XJ21"A<-2DUJ0E&/U"7>'*Z),)V@=;=8AA/-
MM[12SF35>N;]&+ [R:KG+4*S#P/90-,L:UH+=7&]A]M;QX.S8Z9/JQJOJ8Q
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M_.I8Q<I)B) 81/S9ULN9NW<;7^9(<*<^:W$ONTQ4 R=>=FXFF\\75>@C1WN
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MY.79W60Y^@V) <RX#T4[ZLUJB(MCK3XU9T=P"C2\U.?<.L9E/;UL@6TX76:
M#K+G8#OVX+=>),C94.)#G!,;26?3&V;Q1%J&$[.A%S'.3:ILX;:L:Y9+29(;
MJ<7KH\%$>ER&-W((3K,+7M#!>;Z+U9MD.:3IP?KF2:F*L!0YF!_5Z2\TYAI.
M^^4AK@"AC]56FJ7WSH6QSOS"AZ5X5?$2QOWQMJ2D4//&I.[N[CL#&T\OQQ\Y
M9[3ZS,XD;J](XLC68-_\^:HQXO!\8T64C(QG;:3^A+M,J^CQ@%/5B[KJWI&,
M+V4J3 [F/"*:=GSODC]<+/VLK4A!PM#OHCT$?;$?,!PV3>D,=7H^TXD%=0[Y
M!CU- KMM4J_J%/1%+%VH./,A4(/+#%EGS!4 ^:$]^)CX&/=J2,$#T5S3/"[+
M(NO2L4EOD\K@J#&M)-D/=/_&9K\ %4''=F12H.^@->.0Y=*+G:$/@S2X?]%T
M25=VG6?_W4H">F<Y.VW,LA40!V#DI\UR3WK<-%Z=J4Q8&ARX.6J!IR!N<VRN
MM>7ILU1D+#&BZ;1Q1DK54>\C$1DSX5< HX=Y\=6RD5TB+2"TCH:+E.7?/*TP
M$7X5)8DX5TI-N3TPC@=$B  Q7'^JO:R+6V*GZL!K1#AB7JVCN'ST5AF7;+M4
MD]_CWQ2Z%WU!@81A2?*69%],EMQSD:.=UW*>NV;Z$/HT'V:I4&HGNC=;B@VW
M^NN4=X]=O?] 7T9_TYBW[^:/4B5MYQ-P@-23,B@2?:R%:+KFCR2H3F/J I.3
M8 N_Q9@&EUDF1R?IY[R3QEM?8W+R+U-.?1EACEH++KL":PSO1O/*7,\_]4<*
M4)X$++^T^O"9[%;1*?VI:1HZM[,)U!T-[IM)!2>@E@TG9%B67Q_2U*?=<YQK
M,_"+C"X=+))U+_2"("$AA,?KPG1><)5)^0$X+N.7G^'Q(4W[@CK?>\ZJGR5F
MJL!'QMOIXWP#!<T]PDV_-\^!=[V\$2K^%,1%K ^OUP*0VL[A^V* >.]B]P:5
M5V+-@>16ZW]:]G1< 1B@)I??"1)(%A"+E_AJ1^ILJ./A.S.T7W?R@]PW+<?2
M25VB;:J.7[=O'9)%7/!TP.X0N-'8*T /0^KM[W7Z[#QM?FKZ5ID&(=-=VZZ)
M<3]Y96('?PG+\4>!YQF0QGH,A@[2%/\J0MS=(#QC@HA#)<$GJN3AE YZ:T8'
M C?F-P_7[IM'3'S\UEH[+9>P:]:8NXW%^6=27-:W6X^2VWFJHJ3<J&X..32%
M##?H"'SG&DRXQ5U7/WCG/)P=,;U@@WT.Z]""5UC4!*E]([(+_G$98+2* 2,$
MC*:RFE8,GL;-Q2W-CL5#6= .F;)C+58O)',P#T,^+9BFN=ZJ5F9#E-Z\KW:O
M,I;Q\VU]SKIG?']@Y%!A8/>\_&.AE%B&@8)H-@2P5FWXUW?5S7/?EO:6&\OU
MGFU\;&[7:I'%GV.;$#LLO'"!(O:AS@[%(.9M@GQ>+<^?E%5:*GP]NY%2=^+R
MY]?%$;P>9 ?'*5Z#*0KJW'P 0T=?:U )8N#FX8EKE?_ YG9L^Z9CGU\#_!60
MA'!_Y1E&*X(;?=BZ4H6*5#D02Q%FVP[%WM*.9/E]\'D1\5+R7;IKZM:+XWD@
MTC2-/<Y)5L;=M\"6-JV4 OA^!G[LMFBK DD1V,I8NP6!0J^!]-50C?JNBRGQ
ML)V;^'I;<T5YR)1A'")T;>&IYFE6>_2&74L6<,RJ^6J;2[O21HU*GU3/IP)<
MO.\_[X"_N<P5LX?-SV(K<7Z8H$/B -($IM6 ;O_F]#Q$Z<-S(QF?>*7G<XK@
MMWNK]Z#\%03%,8*G7_XYD6]<<!-1.24_SG<N\M_:MMSZ[VU;O,D.!]!9/4 V
M>8:=-C+T3&AJQ)[A9JX=<WK":\:)\G?5?XN\Z9H_K=O=YE;#Q/-&VTP5TYWJ
MV1*.[KU]KR]R!?B4107>-Z7"Z/<L^]^.[ 92_[-U?UD=U?*0MT<PY[XWWVT4
M%:!4F%4?M 8Z:,=YP[OA=7ZQ>&4BM3VH\APON[QHMKIIG7XPXH$=\8*709\C
M%ZG(<)"W8[4-I'4I!88]UO;W3E5R7WYK#[C99MIRF0CLRZJ#1!'LUZDHU82#
M\R;*-"/+#/?*[9WI3U\],Q2O3^&)"@!FWCA#%8AQ2DW]R$@ EU23<BTZ6 ?7
M\!#H"OMB<Z$S_&NEEC,+\MHFYW'GCZL(_MK&UNFW2[+0&AGLG5H!_D(>U?6B
MIKBL]Q&[A*HFMQL ?<G_WMGE-*NK/;B-%J=C6Z2 C'[LP/*^P;X9WUB8M+5W
M8L4=E;"D/BI0GN1D$B/JK(:>18)"_*EP_NMOT#')EPGY2R9#?@+7'L]Q4C7Z
ML$G9BNGW&BME9X%[+J\D7/BWYML9D"A!H/X,6'U\L.X$>50SIH/2'=<0S[_1
M6!T$KE5Q).P$QR5%T3[E8U,@K5;TJ_^?/'Q1<050OTPGLMJ"[AVUL70A[6UE
MZ5TF6E(UIJJ7GMHR-DMZLV48.2^5,=(_HG\4J+T#JX$$O&!S59I.UIAR5UNF
M,U>3/FJ&E?1]^I+K1KVLQ?'F-U_ X*\ 28[:XO#WGC&I;9%%F^_D8A]<1IWB
M=?"O_">3>Q=H?=IX511'DV0[F)[3I#4=]I.QB9)"Y]>/$;NPFM5#D&5A^./Q
MS[BB]UA>IB!E.Z<'( ":_$Y'GX/^+C"(2.>ECSQJ1OE9=UV Y\2$:4TB#PVO
M51O/@A5+)=ZD7ZMEZ1%)9J)^UQ6 %$J+_"EK C%'[GL@,(X'3:&-CEZC[A2G
M$U$JIE(&/_@IBP!@.\[P**MMR"9!@'V<!_9ZI/V_Q@!9;BPF5K/K9P?&J1<C
M8A_0B2ACEN_08=3O#7%5F0!.J6TY^]UE&:PR3K^@+\\HEG+9=#?US=9>E_(4
MHA2_++[PGF5+3:K0ZP;+*I#GUL:GV0\8EK7VKT0!$YMD?^Z)S<;V<6O[: GM
MZK:&JN;:N%#&/KF6<(X@D;AF,L#Z(]U7M8\:/RS,8O2.N+EJY=W^:^@WE1(.
M@_^#SRFO)_\/5!ZU(VX.BJ(_YD]PURK$<K]<4EBCMUR/N)# #N(>HX 1J[<)
M$NC%3ND7"XCRD2JK^J:ZW*+P_(E#3H?6CG@41-RZHT__,_D91Y/6@M':Y17@
M&\SB^ %!&OWDAU#%K%K=Y.FPE%7,H_<\W_B.XQ*5J*7CI?6F]GJ4,IN6P>.@
M_2,A43WE3*@AC!Q.H-7;M[?=SY7X6J[8/J_NK]HX#TQB@ PUC_9="_M6;^$.
M#5"?/@@A\?5SR_3I,%7/4W26.IX$EZ"2K'W_9Y1F58[Q8O50^Y\E-=K 1[U2
M\%PBDW\?B-(-= NG20'N=((X3*R^:QH_$C,J/IV:"K[!G79@ZFJ8/ #YJ:3L
M;)J&H5T;_4KD6[)E,.6:H!C)SAW&1LN\KVG.',2.]S\ZUW\@_3;@3'N.ZZ;"
MH\_T7@J2@A _/]7MMSMKLE1X.5SLZ\ML!%4D\UF46ZO2!?XULV!O<LX.C2UZ
M\*&B6\K\T;; NM-J 1GC]C)_.%JX(^L.06I&3,Y<<=+*$?+^@UHK6+>]<0I2
MH @0L$)MJ7+-B5<\$%]Y'C7K:.S.,W+L2[SM^)]]IO[O_\<++OXO@N1O O9H
M-DT7M\F=!/,L_-@!8*D6_=VO*>.'!MT[U^H1]5[X5_9HX_4=PL"P;^&A8HER
M*7&,_7DJC_6;-KS4\N7.M+G9>3&<="IM%&,R3MR]>WX#K*CA,AEQ(IW4?TC@
ML<\2:LWM]/%R3('SH..IXEN3.P^K:*I_/F^JF9PV9SPM,%X\I/\\LRX2FR^^
MV2<VHCH*[HGHMB=Q&TXZ08%;'Q-?3\U<8N]*2;*IGM(O$)ZBI>V3R4M7^Z*E
ME]O'D6;=4:!O%X$F+];]WKXFLA&>,.AA5NR>(<HCS7+K=KE6#Z5.L7"G"8($
MZS.E(.[Z0*6'=(SE@L(:^)JW[1)H>.$5P+2.,U@O/C7FFR.6M^MSE="4=NZ<
M;M#H0NTZ0G#,^?UE%!R-^2C=[<JX-9+KRXHM;Z^)L#?$:Y>2B8QH%&XCM)LF
M/_PHY>5LX&AJ%%1\WX!@\='#%+O\B&7$S'8N"KH\C+]U(O3R_&W$^60/.UL+
M>AG?X4X=W;&V'LH^C1W^]]-LH@7?1R1#8/2RN&A^&3B?J) ]FHDVKMG8.0[1
M3 XJ]BI5:4:WE<ME3"3&/Y]E%<5R5.=.^>W+:TN#$3>EI]4B T?%?C:%M8JJ
M#<]O)89\]BX\U[!<4DV?S&OHEYV6RC_+_\2_).;97D,L<H#Z;5AO-M6[R:Y9
MN/"//HFO(S*LDH.^^0@$?[^_"'JF^)2_Y^L</NQU$]\@E?H#;^SZN?[_QMQ[
M!C45O5^C4514E*: U"A5"8A*%9"H2!<0Z34J38@!D18@$*1*;P)*BU*D!@02
M>@\0D=Y[24*O"35 @.MO[IVY\\[]W[=\>>_]\'PY<V;.G'/6WFNMY]E[/UI0
ML XTJ'^3Z?NM7NX0:$%YE0C;(N:-NTSY_-7!RN0<UXIR-[2/Z:>+[_J%-^K2
M0<]EBLR]0#H<*Z\Z;*D312!#N8FB+(/+*>'/_O^]!H+ISU94#X0$B=$X _P,
MH/D9,X+PF^:GHJE;1RLG%WT@&]=S.W,0GRA#DL)XV+O%C^#Q>&5^5.L#<!3<
M=CY54<\K8RON\.J1.NWN^K)W<K @G:WW:.BF3.:.E3C!)U;&U2KGIV541+<U
MO^[+\MI#M>[7O:[;>\7>/608S\"J-VI\P_3S8<S?1OVFHFIWEI\Y8YW$&&9S
MA]]\@@G79OS=P?XE>0B);-R%C^8MG\7%#?A+WJD==L.=FRVES-&GA;<[[S*_
MT,U?B-EFV[4+A>V;W\T"^W!:;WJ/VN.X^?=5Z[2,T03&L0W#.:O$K/=58+.=
M5<UVL71KOD1^O(YAOB$TN/Q146ST#P,[H&-#/PW3*YKRS:(G'NB8_Z31"O1.
M?36[]"/T_<O"M(V%1JSK1'")%>AW;937XF_WR]ZC^3H6?R;$#F=)H_[(2K=[
MTMPF.[YV#)%(K@.S0U&M+>%WM;\5C)>=L(YE*OP/_OZ^'4ZE)RD%G@$N>T:Y
M<S^0:1'<>7<&<*D^N0Z#:;.8/=$"MQT-91Y[4ORP[<T%Y^FEO4&T@Y^M'O*2
M[EMZ&BY;IEI>*2Y511."Y6(S>\AF5E+[!&<OK3YWI^B>R $:&;KJ5.>>F;G'
M<74V65KB+=#1P1CX8*FJN*+'^9NK!6.<S JS?3[;Z+CV0-V* +M[4MGN8D71
M?/&['HL\=.=C>:/KK#T!TT=&Z-K=(@7/%;.*C::B[\(8F)&U8PZ#85ZWLB"F
M_MY0J]11['\W?0\"M:4LT?A/V4>D40(;X/$15\M#A7VO##..R5IZSG;)0 O/
M]1V*SRD'OGF+D;IU+'+,=&PIA%P_ V!.LOZ.@_ QDN^<>KI.^D=*$K=WW'C3
MB[VEV4C@"\CW6B51*;JMT%0)AI/H@Q;OA<W0BZA]?^3&E=NO#"N_#:G4Q3[P
MO+B68+F% S-34]OXF#!#" A!@OI<>H7KF4S$20[[SWG_^7L[6>?,/_E/,4I&
M#RWHO*I)?NJ [OD5#L+5"5 ZK4;/ % (#^U^%68P 7?$'@;+-[=HXPE8F4_H
MG.*-2 3MI '\=Q>_OEOPJ'&\8G' =3?SQ[/_>R'(DM4YZL(/FBHUCC1[T:$B
M)9*K)&"Q,O15RJK<R!4S6SOE*\9V;\[S;!INC.2K8":6%?@B5%S\6"BZD=(Q
MG/ L[5$$TS]P;'[._1.1O8::Z)M&0N]-5]<%G?O1SA$JHE!?B,D>O>]_4T_E
MSG][O)"AMAEQM5>K+N/OX/'S_;N6<YB=%WZ(SQH&,W!+/)W(Y[2^BS6@Q9@(
M(":YE0E DR%?&U6Z.$@3H="W*PD&XL@K7+\R:Q*Q_O&J?*YUUS+>B][<,++@
MX%1\<V2844]1>TX)#<4\T<)YVT=@?&:E]R0X'!X5)S*F )0LD&]3'!:^Q5\R
MM:%;Y+G&L[ZB :IU7QLK-O*&W=0SB?]_9-&-@13]UADQ,BJ8ZY\[]V,X P0=
MF-W@ORYP;,2K\#!M,Z'G*]LAG)3?[9ZTK2%4IROF][+H1YU/)4QNWK[AB<.D
M5F1\^-WLV_\#7O]O.9YIOV< 678&>*_+*J/!\9SA<]S)LOY1(.0^-53F5'@Z
M+4S Z#3QP)AV$XS3AI*0U]<*<FT7(LPE/::Y$V+^:E*A^%???OVNY7WTSOHH
M9@VBK&HQE-F31[N[2I/U"M;<[68]/H!VPW-#G:-OI.SZLI\!YB$IJ<I/='I?
M':I)31;B_K,((.#ACB:ND8YN3[K'U)'^_6&Y,48C:O1+>MB?Z-F8ML:CX8=F
M/Y02J1"GTA5Y\;QV)R&'V2DZ%+G$'?,$U-+ V07&8NZJ39N+?'RR?=%[S;%1
M-H%EW^XTL=9813(_>N5&Y*;2L-_,,@]O(]K50WR@4NS8F,U$T%80AKN=,#:<
M6$3U,:1.?F1;Z#!ICFGC=AA*C/TB:#'\^.N&M.^1H<:149^M /NV$O:SVZ1)
M_O&O&H7FD6JTMC>QWEN!NW5).NC0K$'FI,P-6UDW("T$E.I7E/B\\J>D#&OU
MMA>+*#FV%Z&],K/Y\29G1(.&WRO.4B;5:JM3S/9'#_'23>.SO*WV]<[C,S>B
MH;_T9-ZO\]>N&*GTJ+B.'-!'.^ZZHLP6XR6E4KS7_)B>.BOZV(T)O5&+1>D\
M *=_%)>M]\YMXN8_"LG)8VDI:,F=VD;FV(J'*7WKMSM,X'W6NV+I&U0/^M(W
MO[)+HIP!]HS-<SMV&*$!JB_7Q&Q6S$><!ZI3V5<L+R;XC"K<7H:9?S8;V1@H
M%9O,@4Y6:K;%?S#'6D3N%AW;+9:HF98QN&2(FH7(_[_4?]C(]!M;QW=I#E0"
M)17'M?5Y,^D MS]"4;D&RX_0RYX"E4*CBG#%K[9B7&E5> 94XS)Z>23QR@[^
M$TF$P\T>_NGOL39Y/]DA?^8,X.!HM%^JXNI3;C\A9'!N?G+2];S+EIF4G@GS
MIT:VQODD*OZT:11U=&=M47?,6(V:['HL2F759FAKN#F(^15"^H,=0HB[>LHS
M83K3!WYEL58^5E2MNL#HDK 7&B$%IFHJBA>]GT&.-V(^+&)V*IRW::WW:IU4
M7=)(_%5;XTL$)MI=Y\ 97K+(?N7^TOYS3=0$T.X8G-I@G*!D=3 913W&Y[BU
M9T:)\%5"\AV-HF)2&M_95,<0<C=N)9>KN, ;)$:"=LQ;WT7-;ZLN&HBU&:3%
MYGS[W*YKM@-AHA9:D)$T5IGV,P#NJ')??$=#BLDMF>_EC-9J?%'$#1O>!8U;
M/"0/T%IC(*0<21-]0D\T2CT#7.'8+Z$)FPWOERR>A'8< R<XG)-C'M9U-\[\
M7>HS[D5BU)HF9S\#?_M%D#<G5"F6Q:E%J@<S_%I7LF"BT\7"53Z4:Z\E_98^
M KU"K@AZ\/;G7TT4R]B..(XKBW=>C):THOJ0S8DB[<#Q65VJQ ^J3VO -.(,
MP(RSMV4;KEF!\KRIR,Y1OY%6=>GMHO,'8*JMIQY"B#S;AJ3>G6W5TKUI)I.?
MO=+ -[AU*4$ 53JMGLD<0+P?GYE0)6#[Z=(SM,07)/=>#*/&7"M5B]*N&YDA
MVC!\)P!RY02EV:A5^#JWQQ/*_7Z^XO)EW\TY *-KH-4> >6?BVO$A$;XB?&Z
M]LJ?)CCGG %L?!.<XQ:\D.#TNLW>Y,$W[=X#B1K/+!NBQ+<:,V\DF*- $A%[
M3..YK6< ;''P7+YV2.@/!P^S]HA?>Y6#]XLS.S$L:07W#ST_T#F,9=VZ:4IC
M1K*?=LO[+*,N(8P]*9IG -U0,RPU?"(C.GE[-3I"=.KD]RKP/4LRV"TR&.PF
M*[W;"BYG_.Y.T2?VAF/3=8_--:C!.9,.QF82XR^M7N@]FR^]<>7*.YQ(\.N&
M7/0KLG-38]@L$X().H>F(VYD6_&6OKV$\O(AV%8-;X@-M_^YL#C_=#U/AM['
M>E0!#M"MC"KA*$X_]O**2'=3<J?^)!^= 8B-&^!C&;@KT;TN;E66[V:2+O.8
MLGQB58:@@V#PQ"/#N.QG5>>?<0(.2LKWQ)F:9J_Z<:WI,6@Q7:#*CTQ (WK7
M;>4=GP9KQ+^0.>8$ EN_(4@\Q&I=9K_>,N@L$'&.(@.YH;E--=:J&DSYZR/H
M(!&9]]?602_N%6W\CG7S!L9M\U08H31P"H+36Y%#,':6$J88'XV)Z8"_X;BM
M.[?]F^8B Q[17ZI>-=2?-^YW/BBS!8W1S@ G/T>;1L#EDO =@F?S+#/U/NS^
M]LSQ"VH(Q<QTJB,U%O7>P6QY]F4"J&)0#%8E7XK76SX#5"1%-[+0WAX_6*E)
MG%[(]I[YW3?=F_L2MC@I]NK*>?GMZFNXZ-910U+,6"_^'S1/KSB &:21D14K
MA/3[$R#X1&=+@V7;0*MQ!\=]YUORF<6 9WSJ1N]:75<:61OMP503*R'JLT)D
MB_()Z@QP]?30&8$J]4(YM[37NBXR@4X@%F"K-&/=BB +B,S4]+%#-:)3VR=#
MG,) J Q5.G\Z CSW@\P>!R6D@]J85[G8L3DF^(6)57;*TU^2BM9A%IP:,X?O
MG@JF&4'6<61DDR<*F[O!X@ .0"A(%P?GK6AG-PLG.'7DED8;"4]KON,W-:!]
MFZ>;:(C]]Y<E3MEUVV*"9Z1/)T][_I$]_^KFTCK89L=O<JD]K-)O;WM_O<>C
MPG6B5 HUOF5!-L:#;R&>D4,CBJ2.(1PG4=@H#J-^+C*'/]OLA?ZI%FNQ[).%
MCU<$ YLXCVU6QCN-T*-^T-,7.P[0,X"QDCBUEHAV;3ZJW,A!$D[,C]D/L;R7
MZ&NT8H2=A;HB^%O'Z;U>J]++38<ONV^%-EYLX$>\/4G?/0,$'#&%UJF+C_92
MKLEXZ%F:%R>5MC,X:AI\?MSI;\=GM]]\6&&L=6SMURO;<(Z,:H-PFEM4U$))
M:*1&=8/;X*]I0JJ/[==Z\D--,\OO] I/ 6F!EN!6<-01/E20_ XA1"6)M.NR
M01QCFR6"3GMS(#G#^?I+"M@HS"?S"Q>4#CX"Z!\W%[<IO<_5/3IX/:J#$C"?
M%@&N*4MJ-3A'SF)UVY(IGCBT/O%7V-QDA"]0N>]M@G:"[J"R@%?YD_J%+M'M
M/\9W]JL!+''!^#L4AB8K62KL6/IT@$OG)R%=OV7VVB*[9\:-@3V8ZLBJ^>V=
M_.I@]BN++/C&B\8>CWL%L;ZFA7Z]-14QE 1#:ASYN*WBE&W8?>W]QMZ)I,%
M=,[;/"E-]BL!@F3%3[>G'O&$_)E#3*:2>OW][E%SR-;M&5<H]JV0#= 9@"66
M]>@Z(\A'6T;ZJSS^>DWC-]S5<X]ZYDF/>9G$H&URXX4^];O8!E7$FLX$\!'-
MD<I"@(0 ?X^D4F[@DG;&$<J#L%VT'YA#JFNB<.IOGT!(U?'BD[)8@9[^S^U>
M)26IQ)@O&QOK=3$A5G<I5[4<+BSI#11+?=M8L(\R#1!OV_UTC56M*S#6)2[
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MVX3CXH]@.L,2[+(1_Z(;PZC+V_##16<NZ4VC<:&T)2 _CY\[C]'!4?G%V ?
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MJAHD8N/8.<UL#%P>V(@U7;PUT3F+=N#J#P]WMA4ZF'+44EE%$ C@B\M6]\X
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MZ"@_\91\28CYM^&+%Q=$L]^'L]VTCASR>4\S7H%ZU<^NZCZ:.APDY09( ;\
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M]OF:.>RFEP6?6[^PN?I4]).I.KV'BF/I0_U/WB6>9%"ZU6FH>18-1+9L#$:
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M.J3.Q5TK73S(N ^#W&!)!$=9::6:[Q'\A2,L[,>4V*BDN:V;!>CB2N<+&V>
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M=1)%CLFI0>SR?EB8BU118?VP'D\YFY4./5V*D*J+<05JGE'<T5/*2+6:>,*
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M9YZ9J45/MV(8)_/Y].?^,B5R:-OGV?JP#_]'>]\=U.3WO1D;54%!>@E*%5!
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M&9J-B7UN&I?>FI'0&N"[D2[D8?M2V<TC[<_Q_";3A--][?(/IP#EO^RWQ"'
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M8RRWG<<@$X^H_((8[I=IORW[]PP+^5^R[!^&_=.N28"%FHH2/&H.  P0#\G
M\^%V\([0"!G RD%(YQ-))R#'X0,^QF3@8P^XLWRY[+V* 9)@H*I!!C1F],D
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M]'F20I4C2+1@PI@I%U65$P9T?,[ZNHM;X8I<_Z5B]\X:2++=$V"I3F&/#(3
MY]_L)1""QMQXB'KC4E6O[<U2Q_55,H-?]!ALS,D*,0(LXRUH9O2W7)@VJ14/
M/U"2W+NV2E)_2 8"R(#R?(?I6Q6)!OXO!H\#X&2 [?L@>#D/1C'HY&]3IE/%
MC[@V>>&+J$5;ZT$KD'D1L3/@\_X)DE!/)GS0$.=#4B+)P]MJ=\ 'YV:ER4 7
MN+.Y(1-9;$JZ]\.A&X[=4&,G(7RBT%L@PB!%^N( )8*Y!(KXTV0@)M!7\Y?
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M-7B9/&1EN!<.KBR4+)UX(Q?R8&98>#>M3# [[#/RN6-95J/NH83CK#"A("=
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MI<H2H.:J?D8;7NQ\6?'X5-F4>&JGHWWZY_>"K_ARXD/(@)_R^AI1<$%-Q8(
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M2;H!B-XV2@@V=-C5+%H_NAD[EH3V8; SYEJ+2@\]2+S;E5IBWM?9XW,Y14Q
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MTG6R[<H&JU]_&-P910\%,Q)EY]T0:+9<W$L;;D[M+&>+1^5GWRI?6SK+[UW
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MS>(7.L6]'"2*4VP5HL=S$)13TY&+&@M-UV_51C[>*3$]]7J#)EKZ9E^TZN.
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M8U@[$$^#[#7<BF\.56E05^GIJ2_AS@%BU8S+LC ,_8K+D<$QF:=W.^YW><U
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M*]+34AX+1?4,3MFYBX--3S$YIC1N6GQGS5F[\YD5J=9^FQQ=22D*L^%5PL[
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ME#^W-=K(<E'S];/]0O$[QEIV*/=-^0@"E><*&+U% MD_QM>)F(MJ)Y$67$3
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M$+'?!,R3S]FI<4'R?%AH\Z^(%'VQ\>NXM^0KA99#WL/]@$__JG;RU[LX^A
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M8\[6RW#6M/X_[OF[[R?NS*_=^XJ'KM0?A$GAJKNT&!K1>TK:IYK&<I(3Z\I
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MQ%48^@9G:!CQ_$U]1P"6 (+KIR])"Y;YJ!3)<4':?YL3!"=]39)%Q)P06=R
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M,QBEL&L *LCTLNZ8+U=O"7@-B%.4T$9;58-V;J(#KGCXJ2DL]R-< /5. ]U
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MR91/P<+V.<$RB#]^Y@ES/V,#AX%V@+PB?BENH";Z2XKV9+I:HMVZPP2J9/?
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M_WX?^4_:EI6?C[KN3%YX>]*'E2 A3&W(N^9G/E"N^[HVM;B4.T=JE,E;N4W
MU]Q@7"1>![B**\B?>^K8<&ZP;$D::YO+Y%QQL2_*)=8\+4).QEFD->RR:XD1
MIA-6(Y(T*[;_0;V/)^MCU ,$5"+:GP_NU:5CS(R(ARPM'NB0J>!*RXGK/V8M
MYIG'.(6TKD4_BJ:+(&7^<>>59(BJ, !;TE BJN4N0J17(SU#0?[>4L6@T:Q
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MAU">DYK;F$AULM0(#HU+0+1O?] 8(1DQLHLO:]*?Z7+8GS]LHA[D$KI('R_
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MD,=5'\T$WX#A^ \E]Z1Q5H)O?M8QI]IY(&MNWP07D'=R1.*AUOS=!*%(A6L
M[1$DA?D:8'&.(B1:U4P\U.R?:GQ27CJ$/[@KQ(OL=_B)A->*MX3!2>ZX4]8T
MM(Q!&ZF'0.'YI\^RZI?#%E$E6>4L,DFS'VNL7_]Z+4DR@P+"299#T/0V LDV
M8WW3+!@=A*)=K@^+4-< ^4D$ RQ!)7+I23+%%S\EQJ%7*1H]W N?6#F]^Z\
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MW=FS,A07Y<H(S[,3R;<7DS4_V'5*%9=U^+*E?$<[QV)&A2<%.4.(]MB(+E;
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M?%"CG#3]P%T^*;N UY4WN:IVWB__*"-62J)C^6WO:MJ(_$?W\@\?DE*S(WQ
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ML:V..DX)CLV98MA:@+56L=<  KTUHO=9L"@[X.QE9M2<OFV63>RP]-,\O\&
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M:*+F)W%:W@7]F_W.@LZ9)0F\P#BA2#GVQ$6B802%JL@2QTRZ#:IT7S39NJ(
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M8\,]S3)%SWG],$=9:1GT_1:0<PN0;E"/EJAYCFW.=_^;RH8R,&YJQ!@-F:[
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M\/VZ?W?]E-PP.%(!Q!<D^?80UM-.-[U@_)E?-J3/Y%?0'4/%E2^$"4K%Q;>
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M1C:P7;Y/:X05*?NMXL&U-\XCQ! -0EAC^T'<R)P=@KM:YZ3*'N=W\C-#]MA
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M7OW'J)X5FS&Q#72^AC(UGOJ05J<T),/GS&<?R,*>!%@&@1DC2OZ&)A2+M>!
M'>6]45@Z%IF$K=*+P0Z_/?(YH>B-ZO4U.)2S>Z=5Q5\K=$SG:XLQAP]:33JS
M-:L.X5 <!^Y4=)+MZY\WM^.)RG@<'_3-%MJW4\P*9H<OOX"T1^I,;![M\0;6
M;M9:7;[BM"5ZL=@2TJ=,<Y=P,'2A=;1U]O?F.P5RG:A_Y0;_;ZD())1CZ,L9
MXG9\>NZSL'-_ATN_EU+O],+.K@(>#PEN>H2K3*P><Y"B5G?Y4&3>8FF]9"Q-
MX'M>5FJW$;MCL1S-O:E' ?4X%!1_ N>]S(^V\:\OS%&5\CW5_:!2?@7:ODS]
M#5G MBR-AW[>2($A22AZ.5;"U6?+$LFH=?YE3&UNQ$7X?N7D_MNY\(&!@X1Z
M'*,8#[^!G(N88V LK6E:)B@W4U69YTW:Y;=NTD)$/QON5\#1+ZXBU/=O5)1U
M&18)6D! ,RYLN5XH7GJ&AW=C8H'<(H.P)DAI6Y9>@7Q;]%VBW%7)., RDUG4
M3.8@]\W]/_^J>_Y_++?S_P=02P,$%     @ ^8%A4A*^L_E4Y0$ =R0" !0
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M.NJ5>3%-6SNTGTYMQO[%(9=RGVQ#&ILN5OQSK>C. 7?F'%R&Z(#H@)_MM6_
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MNUV&AV<5G5[UI-44Z'#V@_^Z0W98A=UO9 "[\Y-!TL8M1S@(461L-S9_>[B
M9^"<%0'NJW:GF<#YF:;W*WE6J78B[\0@J+N\&J*0YP]C]2LHG@-OY1%#,'2U
MA=2-Y-NLN'V)N[<Y.)R+*C:*,Y7CQZDD^"PA!'O$OPRCRU,MA<4Y-_&O//L8
MCI_NHH&S/;9CZ->R7;[V(*.BBA04WQD^>VYKS71C5,Z7(#X0%C5T%41ANXR+
M<B]$)KY)L3BO=M T/U8("PN_T8B*[6>.U[(EF!=H:[#.;I?:]K>+) _3B7 0
M?ULJFZESHXJT0CQ40):L5 CU-(NE5SA,;H7'CF(%AT6WSZGWMV,Y2;N37T*O
M&5!.D$_@!^FO9[C%H$1[:L_X4QP3Y@+BA_=!B^;;DF W[1WI *OPW&T-YVTO
M3>:!?7)9H[%]/Z7<91N1S&;#G8OOM0\[;N@H36)O6XURF]Z.<B Q\Y#9G7I&
M52O# 321F:*OFA]8S_TJ</:VZ':SFQ7-8WBZ0ASH!M6L5($UA-=!<5#@&?=A
M3,5(W2DW9,#8LTV7G#4UPJ\=@TQ"#T3C(Z;@D$B!OQZ0H*^(P$GBR2S:Y>7J
M>>L3*,OA3TD;)/K 3M[(Z%+%4"F"/;>&Y>\'UOZ)?PR.?]TKIOVO2_T%,"K^
MP<8P'*)_&\_4CD3IS-3Q/$+IPE6ZATFO=CM5[_PLX\QA^<;S9KTWOV.X?KI@
M)?@5M2M/.\?R?Y]H^H.D6(UN#_93A"T_4/1E+2OWBC@U4'07,-5CUWS=Z] (
M=L=Q\EVW*O"H555;7S_L8,]MT;ZC=@,!(!17HR]52RM$F^N]:>UJWL#->O=-
MKQBD=DCS?G."JJ$DYP_F]?9YJ34IE#(R2NQY@8%W,TX(4XA?_4\5]PEY\:Z;
MSE,SB3-O\LS2/_/Y\O,E9Q)U2:M[S*$_$I,=*, E%<TW#-S='&2)M^V%OE^>
M%O?<E<A93.!_MAFBQ-Z^L*4QYOYCFZ+X(!;GJ)KGVT!Q,UQ8\+<*(QP[[,\J
M&*&VR&J50OO[3?>-'AJ8E,%-1#&N5=[UQL_G>.QE(WI/%M% PN[PCOIYK+9%
M@[EAN1_>]??OMEF/<;>XL9)G9*\;=UBRVKO$AUU%0@L\RPP%I\]Z4K2)9N3U
MV>"G]%UEI[G5.<&J*?65EZ6>!QODXP$\):Z5!X,J<K<!K6B $?HM@!3I<SBZ
M^B& >3P_3?^T+4$T4WB=E;,Q$!<?M!#G&O12'*1W>=56BB1)0O+@T4)Z1E36
M.6.%"ZB_NO^J:YXM/7UIJYU%+S9V61GM85<UOB-24%]7I+^L.[@Y/_)QO)G6
MA^1WC"3]M$-3)A?D.\H84E"L43WU;O=%R0\:E@'=<5F_3.C'W;[F1GNC#PR-
M685M6E$+N5,7>N"]4=>A7M4HUDQPJ,+>9,/@HM_G'RLN_AR_7KQ=&/"(/8RI
MX\O7BDQP\E=1U]QLL7EI' _1FSO8=_TCZSSWZ47#(_X_OS["DO#Y0 %H0.^8
MR+5S]HK>@&>N0A95'^62=Y,SUZH7T=CV3I-:C/>!-VT$YV3=\KT_MNF%];U)
MX^M)#,P,SK?D6U?UX;XY0]6'I('9R=(;--MV[BPCGX?E\J3)- V^WU5PXUW[
MEKYK?1'<./7!L$@T0-S&E;_\0=EH1EFU-2!LQZC5L4)7MD#?\%5[<Z,2(I?P
MX5YV@9>A3V@Z&GB<'88&]H(AVS+?2\A98WQ&D\4&6OU+#8PM^#]$WGI#5?IG
M2E6E!1+&Z<T3?>XN]C1B4R@JW?'3&>3J#+)AS*L]N73GV^)5M-$ U.I6\X3(
M_Y$N7''J@@\-!!G=15;M:I^_XBL.^/-=-A&>6L;+,;^E/30P QU3^5VS9N>G
MA/2]"2DU\&YC'"-G]' ]4;&/DF9KHIQ3^<YVI-WU!@>+),YVM@OR.:4=*X!]
M)XNI;N%\7&+H*]G=]>I=PQ_NQ<A>*Q2VV;WHO)8[Z;^"P)5II27>NP74JVJZ
M9:I-&DP<"-+@3>SV'3[)PEL3UF4VP?]^SAA19WS?&^C@98P*[L1I<@Q;!ITZ
MAJ316*?Q#Y-_FDTTZ'9T9C>ED>O]Y1Q%R+A%L(TGO#ZK;B1]K>"EKSHEQF .
MJ[C'FM+31M)B:/938) _]XYFA&$FT/%WK!]@MMJ O(^79JEGI6:M2WVX"P4K
MZ/O?Z;#6Z3<R9TBZ4L7H7+#;5Q8EF68\\"'1_FOU]]]/NVBG>9VL:4C@(#!W
M'/,'O8:H!S>?K>+^$C&W^>LQ!G$7XMP1J[?4J'>1,/Y= OJL<[ Y26+SN^L&
MAW/*Z_8*3[(T9P^S?WDLPI;11WCET%KV@2X"5W*FCF#(FKE]JDBW(O5M]H^F
MWV4G]WC)UN!D&%=/#6;#;I]XZ??JW>;DVE ?9.64V5RW3=M@I6=Q5515BZ<#
M:SF"F\LXD/<,(#\RQ(>TVZ1RVY19/KW6DHC]_AH[OH0 35PP._3133P:6-]I
M8T4#LZ)HX(8[)E!B-K<E#Q9V(+["\VFN9*(N6L8N4_.5S;-:9,O.8US*)1=R
M>=R7;"^W:"-FD>J(V2X&*I,F"=HI:L4R$VH[SJ^HDG%E"?NBTO4UQO@TX!3_
M_Z#NO8.:?+\^X2 H*KU)!Q4$E"9(;Q&5)B(@(AV4WI$>6D"0WE% Z=*+$&G2
M$WH1Z3W4T#L))032EN]OGW?W>6:?F=U]YYW9??_*3#)SW_=U<L[G?#[7?:YS
M!(<(@N#1' J,-.\=PKU);NPSKQ/ZSF&@5% 6KMOZ.EDH":]=EI=,%W+KP YY
MWDU@FI&<=QKLSQNSTH (%]??]X[/NO]+1_V]4<@**L?]*=> 2J 8T@#=[\+?
M:R[0B%J.DF0_H%])F[ TL0D6/8_D$& 'OW*WT 85H".0VJ$X"SO$D)5NRA_T
MYLC!GE!2[H/[\(,T<!]= [?R4H@B7\Q)XN=@;@515 76&1-P$)6A$7M $W S
MBHX/_Q,FMG;N,L-2)=^]_+NABX9J=WQG3:=U*H-_]F3G]Y+UW81&C_;'YZ:)
M+P'G,8)?,&XH[2[@'8GGY2"G-YK;=+^U6*\_"(<U;_MQ+2;(\#7&PN 3"&C.
MTGW-2F,G/R]9PJ#"&Y-??D4+>[_O35VH;H7<N-4#".!D6E^F #H0 ==PYM,)
MB07FIO..F93)\%W:J(SWLBZ?Z5D^#3_)NN8>XCZ!>X5I0UA\]C<U@/)-W?G[
MZF6':XQUAJ7<OO( *0]_7O_ N@ZYC0K(+HP(<%Z. #^>SAN?T&D9+\E&J_"5
MN-Z/_G;*WD7;1 0X76LA F)RF5OED;ZJ=5,*:L+=[QH,N&T3]Y'?6:#3KF%Y
MG1F  P$(_R@1X'!T#?-EU=3\YH3(H:BDK,)?,S5:K(#]F@.G;]K([<IAL>3I
M)A<W]#K&HF"7'M[C7>88R_K(5<CYA(YGM.4ASP(EUR3)*173EA2PCCFT7CNB
M@2!7.UG8/.I\4[. @VKKV4:JCX2UG:PWNF/8W4(TD E?PZZ!2H\14?!=I5+%
MOFA\4#>;-F<QB$?TW;ZQ_(5#AQR>GB,P5K=H/O.R96K?Q5OSQS<AVZ87.1^R
M;&BSA_H5R1TG(-\(CQR6*26UX7H=!LW3E97*JWU8RK1W/M5A3@]/OK6;Q6QX
M+#Z5:>>4E3RP8% 2!1D@N-*9CJ+K56H9Z'^9Y'_G^Y;00NOQM']@6US<CY%D
M3M><=84(F)=&Y,9)EDK438J<EFT%)6N4S4?EVRK>0':+!,/;JXB U9*>(VH<
MYUBEI#;=H#M3Y53?7 %6@4]5M#XS;_MQ<8C\2\&N5GVL;: XLK@.;IV1.EWP
MB$-3)-=MLX?U5#@Y1?Y@F(;3:59!?E58NB>#,ZVZT*POJ'A)]4'HJ@)B$N]'
M7DV>I'PC1,*^T-9PLI:VO.!!=/NU5I[_*WUU!5:7?J 95!"H/^X%N[TW P]*
M2_08=7K\$R#87Q/2[DK^$7[S-(^FQMO,N._9Q"9T$N)RBA50M6YJ3K6,)Y$9
M?$)+SNM]5N( 3RVNMJ+:")^4_NU)-;9@TL\;WU?^2X9GQYP$Q;Z:WJ6=P$W2
M^CPXJ'1W&LI:WQJZM+H*7W;I?,4EI56N3,;9)7M^%+.(\5W3OA9X#Y_EY>*I
MW3;IJL#IR*+BZ4F]EV[79..<1\K=:HN[#@C09T) >?&U8%:,Z[*VSZ3(V2TW
MX?%U92NW-H2!V1_> 1(3\L,MGO$J4!BZ%6.'( *H=OP[IJUA6BJ:778VMP)"
M\E(MM]7G0F]>1 W+# $")&T=" )C]4$OCUY73^V[>5.(JPQ5MOW1$"+CH-VF
M-LB191H.%,3T(!+C,B0N$R,.EVP:W#E[6E$7GL^ZK5TMGI%TD(6%C=QH]40'
MCQ%8YW @U!563GE7+-,?-#/[G(^%-T1K_;EH8;<7QK;G66]QM=F3[F0(MO/C
M&Z',)B.\6GYE:?$Q6892XM2*3J,X112L@W ?XR<:OS9)Z$'T&XUK5JR+,=G(
M\+B]T> !6&>%R.91'\<@*6CF8Q$NZ)]IJN>Z]?$+=UL;:P5I9-:3-$E&WK15
MS!^UJA0[-%,V3TWA6^5>? PJ@A@K;]RLSL8VTZJ]\AX"F#8UQ0POF42O&[Z/
MIDS1N-=9_BE%8Q_PTX(<<]X%HQ4J;D%N5CO]-'G.G\J;!FGDL9)1RC*(N#+I
M'XS=:CRW^>A!/47_@Z9?C1$4%17/.>AEHT/CMGCX23=)*]\'=R@ UW,Q)83.
M*_Z4GQ:B]*O*I->"$<>#1*O?1W%'.4M$E[ 71*SJ\'[89?1,#+1LJ(\W7E8>
M%ZV7[WWH8$>6_D0\+BFJZ-NGY1"GDUA33.H*,(J[;KI@-9=9>*E@Y;LR7:=N
M5](OLOB7961473+DD,E1\NW#Q)]&H##-^LFZ^5*(LT@!?9<[A:L&X^G=J>;C
M^9&87&HH!4X2>39A+O(ES]18]5(_)C+%[[X-M=2/!PFDE%_:1_B33<__YX@<
MHC@<LTIX%&B./.I89)MXB^)HH#->- W* -9V6EMBC9JIPVX[98T&.T!(,06K
M7DHWQEVK(&=&K3TFWS[<F/%0'1<_6LP*^2G#TM]K3SJUG0_EO2)WWD.\S3,)
M#?TCS>P&\M&REN/K>'O2@^9!E'2,1.Z-[=I=^").SC;SQMB#H2X7_85GG\YX
M/UG($ $=SSC3$5R?26G93>)H:2P6M'1PKK9?T$RCK-&V+CPJ#Z('^&E'R<<)
M7*@[F:M#;#/OQHX^3'K-%PE3_:5JXKBFW(&^FUA:R8;9>X[I(^]TF^WKW&$Z
MZ(F E1LO]10-D<FC^QM$4S18S%F\J\+0^OA2(9Q>T0X7(TJI,J@,].=XTR;!
M2/BX"""2U]B^71RB5)3?:J6'KX)R. BNTKF7+@K!'_379=#4<HL[^#8?1#&<
M6%G1@P!!CD-$P('>"I4@@A"]NC>_5V$B;#>,92HP26M._Y/4Q]]?&$)*7;B6
M/")!LC=I$ GBO_(YM[5$6N/M4;-EAP;?U]4FV:KSUA[J?232@H_)<H_>!TPS
M'V2C)G0P)@@3*H:GC2DC9M.^7_RXJ=Q<&RG?HGUX 6I/69 ?[4FWFT3NQZB/
MK;_PDU&Q!32,^I;,]'(QX,,.6_40+2Y6/3FBD\(X#3_ZX;&?8-^YN8AG+?*N
M/JRL'1SKU_QGQBW( Q]6XB0Q;FZ%H I3+=O=CF(@G(KG,59I5<\=K,K,2BZS
M?>M:B#Q<\+BK;X;MO'O(I!?(=)!AOR_L_<TRP30))7AT[),S?T?FT[DWY)]V
MH#*)JVI=B32@%/$BR '=!L68+;=0!4;N%TZ ]&<^3.Z4)MS'@H,(<!R)DJ.N
M+S4W4>8D%,D-.?^QQB\.]UA\HPLIX0ZIM');%9W31L<@CR*\<AG,G.3X\M#%
MFK*&!R";K]VZ!0,Z>W5)7=Q=L\E/N8-U5?RD^T;FMK0Q%UP1#9<]2U\E"L24
MG6,ZM9\,#J\$*50GEN71&.7#Q/=A=GBE/72.6WC?NR83$MYH-(KM B;\(_?P
M=%?L%-( O488:0YN-S&S9:<R/](WTUKUQ;Y\%(6^00KP/]K:%B"=^L]*F_ZO
MW=%@.N-\MJPQ<0BIVC 4%LYW*$Z]O"_PX!L60&6#D>Z^M$A4D"\&I6NJ.6EB
M%/IY<Q@X6FYM*Z]3)OY8B8MCVP++@:3-,.'()2*@R__Z8EO<Y==DDT53TR</
M-=^L#<^%>/0HL\B0,0SY^"NE.N7M2!F[Q#VC$)1YLW0S/5\UADEM!5!1LP'3
M/14>4V&Z=AO7@B]3$H3U)L;.J X_@_-]TPJ/H-9/-CS*)-R8 QZ&<U8<TL '
M5]-QCY;#_'^B)_R,H:7 VI^_<[\;=2RMX2<IE<_F]RPRS#GJY]D7'F] ]2]]
MB0"EJ:,-&3<GO>]$@-GP7T4E.Q\7-;8NMORX1W&WO:6]V2N.T*-H<EVM1=5=
M$?F$_,SF^$E3$;D8UUUIW8^-NP];2A=5.M=*BP\+O)DI_OW/304[OFR;94X?
MG%M*&C_&]FF_"0K90A8]%"CAKZ$Z53V/^)#X;*(()3PN6">ZX8"$:;C*R/<?
MELI>'C -+9AJ>BM\&>'14OAIKL&Q7LN0H@UULNIEJV.&?_;Q(2<\,/9@=S)O
M_$@SPJ=H5A/\J&/1W)Q:I"Y'/& 0<9RH#?,]-J-N/M S[U24/@E&2F&Q_WJP
MJ=V%]<;=RY85!2W1#I/W!;D'LAX!U-<#9Q 6UYV@4JU.+@Q:&01]5C>AP(HS
MJW9(GA+ECI(8QL"I; Z3V353TB7-\]?/!?T'/4XM_?F-!LM>XDO4"3_K^/H;
MTX$2IUT/2V$!^&4V<T)E[W>N\)\NXL%VN[K143)*K_*Z$4$#-E4YJ\@*)MV(
M0Y/JTRK/U1= -XSG3T>X]ZE<0JX;_6)E3U._'D,%(M(J.<')S!;[C+?=:DB7
M#[C$2JA');^#\%X674*.Q4HO?B4%%3TXK@G.[GMRQ[E:*$CK :.![M:_9*VX
MO553>'Z&9!H?B[5[DL.I#CE-%4[^W:+45RR-GLN]-<*U@""JC^?O:F<7)*3I
M),0A^NYAY@A]26&^"<.P/RV?;,R'QM*W ]Y59S=(QJLV*!CPQ67LUA]%GON#
M=YPUVAHX#OJ.F)%'& /!?LN;'>1D7/D-6HKQ$]KO!PKX8AYN/_[G0V"4E*]-
M4^N?[8HN(N"L W;*8VYB7E!,!/27Y 7/W" "1N-M%,=&H@CLW,FJ*E(Q- (^
M*JR,< %2]MZ_S)UR3<"3?2+@#]0*4ASH203<!U<3 >9#%N*ND!^#2K?\<S8M
MD)J3WHR+DZX0RZU*]TD]7]WFV"LL\FFR0U>([S[A#7Y\Z<L4[,U>_DCE;6SL
MKF9=:F)U\'M@;"XR":-ZWCYSX@H;JW6W:3Q&5RV+)YYS$-X('%@8&:SG=@9S
M#2'=5J=C5UD&@]*6/HI865PX.!,!0K$)6PXRYSI.9SG3N^Q[AJXNZT9YW^^H
MK^LE_5%5YNIFP\US*X^5XT:HZ_RL-548#3+>NU\:=%<H:J[Z-*Q$UC;63M;M
M";BMI;BTB" \GBN >!$FMST3--9B]@4_H]2ZI*>A_!C-WC2YT)V9# 7?.PT.
M&VY8E[K8;K7D^,H3TN%;VTXM%>DB604^VXRZ*O^QKJOUR>I6YS(=J+;WC2.;
M2Z&G<9U8GNUWQG5J$%_;<$SC0,<BE3R7'A+8+C<3:CW]NM(UB2+Y9J)S^<4\
M3)&&&V10H:OR4&-@,<SWMD!^H;)%%H$58R/=DPBO6+T3?:/-&S%CIO:V$6N3
MD;(N/,<N8[-R>'9@4<"$&F["\N'T)J!"H-P> A7*-KZ0\QUZ<U76>-5^TW#S
M:[]N2'@D.6D8/$2Q:\6M?3XW3/MG?5^L-PT#$6 ?]=1DZM&].5BQ6?,1>L<"
M".XG HZ]EAF"][*) $*ZFCD,J8T8Z;6XC>DY4O!><^(,>"X%X9Z[FZ/!/O3
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MTBR_]M.'-TL>5-T"I#*DN8['0VX$W?DB(F!&A0B8")LIV+4@)?!C9E:X6A#
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MJ  H*W9Q3"ZS"N%T5T1G8[O8J&&4:1D%%GTVOC0956\ )X/TU61Q@&1*TEX
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M<YC[')K"9+H>98-?Y<;N%'$CV2[-81(5-';27'V1#_[ ;Q^+QB^Q3O&B(KN
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M*ZZ0X-A1D]=B-:ZO,>;NZNR2\=OQ(#_H>VB#QYOO\S@]HW]W>@DEX+2<D\B
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MSEQK_:#>\3@KE<F'OYQJ'5%QV(YD(7+](2JZH:MO6B<>8TR6Y&^%P0P-!;G
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M]_K=UA]!'?"@%HK+E)\5(\1FYH1^++3UTR@)73"KEC\7^8$>X(G3%GJAPY^
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ME48::DMZX8X\I: 6^3IH]Z%-9!&F-E$[HLF::\+QK+_4SBDV-I6Y-748QDM
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MU/G^SS5G$$,)V-%?W%R-,B:IZ+?[PRBZ$*KEH7>7WS=#G"KVP]#G:EC@VC6
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MJVLQ1.W53,IACZSC%W.32&ZP8%\GF[O-O3GK>++RB?;;6"/4/A%R=!^&H3;
M<.1D6&3/-M?>]J-)<W=N_11&?/+V0H=D45$1&X=<";MDW>7@G5)-+Y08=*MA
MMDD5>\HE/&6H0'^V;Q(DC!U$5I#@)<'L[[0E-SYQ>6@0+;Q\G4Q&2E8'=G^W
MN=&O#!8/FKL&L+528CB1YBFI2,3][E\K_;^Z/XSUTT>_M'JBY%+]:3KUN!RG
MC[$M#$%8K5#MI"XP)$0))6M.CM?NJ_@J\VP\)Z?@B$@\N ,(B.A& !UA=*WL
MA9!4U6-$345H6F\7<>*K%LZ[@._W_P1D;.UV0<4QLRIHW[W^/.R!Z]T5C1K1
M5L,%GK3;:AM^!]&1'AW<FG3QBM:_=S?\S_==,> N LLDWN@7]-GD'EZT>!_'
M/OAFO?[?4F;D1]7G7+9&"D5$V\ 8.)T@X3Z6%M=S/I,,5G(:+YS?'Z#H77JX
MCB9YAN?OOY' 2$8$?2M)'C;GSXRS@*L2>PK9@'"FC<W#Q'X#4!CT$-/0SWK8
M YX[U)MM5<KA"?7T]G9"*[%ESJA35$E\#-WJ('S;1-R[!CC"F;&\JR/)A1#M
M#L]=5I]0^I4%_]X>O5924Z,OP=;(%R7%7/ .*G62OUY&&4&CUP!6H?9G$'IG
MCP68_=_%$5=W(>5#LH<Z\V_C]<.)[9<\8V>U,)S@&:C(:I:1/IH0OT"H<HF>
MN?RX*4Z[0XK*ID_NSP>XF>[X^$YJ,=0M,=%V^?Q)5"\=AZL"T$%U_]JEKG(E
MX,30]V.*P"5'HU3IYJI@H?77(3)#$_3O0CY^4 -9G&(*]W"8!WT$*LQY3 5>
M?+4)JE%L<8"S3>+ZO$ X:9!3#<)PPE_M70.<W.EY/\.<X"38\+,%-2W96>VV
MC 4V)CD>'S[Q/D@O('!3!1KH@7/&]G<%<4W"D&)87YY/2-SY,M/W&C6/?S:W
M_[R[\[&)."X7/5#Q_BHO2-8<2H-V2RS;;O9N+W<_O--HLF[[/%PJL)L]: N_
M133G4)%)8"!,9C_!5F%>=?6_0;^;(=QJ]OM)6$KZ:QT>S_3A=>BYM> /5WE\
M]_<I#OFKTKJH]D?+6!%DX>>$&&]-'J^FIL2H2+'OBF-YT%\0X:&[D!,NHFU_
M@8W#,%!=>&X95$7[-N0:T$W2E?TPZ[//7OYGUT?O?HDA.#_@\FC)'OH.NT&5
MKG+JJ._B8>C9[CFO .=,!:.]Q4.N;Y^C-@8&/I"PN=+?.J@UBO[/U:HB!*)M
M5O;E\&_NOQ1SY1/%EM0'[O.')L8W#3O@';!7]FA?Y$9FQ3OC!U?:^J0I/J0X
M@^\_[ 3G9 Q&"]X\/_QR:U=RXQK KBCM> VXC9>V+MEA]1XI:/!],?VHWE:/
MJL\E*< 29HH&LP3-W'AKEJM/>"/T[IO)QU.?G!4F*Y=C;42IYMZS?*2:4."G
M7I0SGI%70I-TLH8C\F&6NTRLV;M9()]#[M9B5?$3 $'BUBDBW'L+JHMLXS5I
MB%L+U:T-/Y)9[_MG<E^&A,V&R/2&43)QYMC9FZB@.B'/8D+N56.U-:OJ*U.-
M$?%@84=:R;CH9J2^.S&56<,+#[#*'/YCPVS[+0NH^D1IM>7D9C..XBAPWFJ)
M5>J]K-O;D;NJU"P_J'5SVI4F8*XB+-@5Y3 H$'V@96_6H)JJ)\I5O;A8OD'Z
MBVF#^RO1;[9U0( _;&\:]TH%,[/RMKI],EE]]F2U6M.=+B7>.*KO9)23)(3Z
M=87\*B @D $)OG/C&LJ4UU)[W9FPKW;5ZJL:QN6O ?QK+";9VL(>]Y>HV4*S
M^3#4^PQ%#BNU\>GH<8D 1T&WUK;980&_4"\5K$56U7..>>_B^;E!"B/I#V:#
MHHNTFH^+/;=^9&M/E,YN%NY[H*CI=N"L)]^FY"4N(1/"&4)\7U8PHG%V=][9
M>#8&RYQ65"N285&]V?+H_?W#&+P [^?#G\U/NYT??K!)L,K"6F;G)70%*U!%
M'X$7!%#_$!TPRKEE2IF=YO)\ 65[)YLY.-^=K'BRCJ56JC?(R3(KO!PV"Q..
MZ\MXDXD"1]QW-%7, 1)X#.G\0N9*75;_,*PX<+] UA]U(V[ ]]4H&,]RE7<*
MXH":8G@_R:OEFFXMA&=M7,'WCL3]XNCVO>6:DZA6567N%F)\]UF*'&&UJC'H
M497QLM-'']XS->B]ZEQ=HDAR)0JM%Y16&.$C6M[BXN-""_QOO+UG4%1=U_?9
MB.30DG.0($B6G!M$"2*"2$9 ).><&QI!<A(04%(+2)*<<\XB(!G)#9)3-Z%I
MZ&X8KON=9^JM9YZ:^YZJJ?FPOY[:9YV]UO^W]EE[[>TUNI!I<Z'93C['3CR4
MW3H:0N'(^.H6T*@=[,ZIJQ,1_*T60/-%2-,SD+AE0SB.C;((];!B;0TCD[[4
MGVPV4K2\\-!7Q=528/[UIHR.J=O]1.!=&%XK]^'7TI5,&=]G:IYM3 ]36F=[
MJGQ@P']V@)1!A6^"B-NO+:+:67BBQ1-4WC298I7U$?;DU"E*W;TIR]>&DR!:
MB$.PRAT)/;"$$WR0E[H%$-G%&=G:!/CVX?"W.?0PL+]+>1$JM_.-H/.UA1Q&
M%EO4L*?(H[(.C%&D3>IMO5@,=Q!L;X,E1W/K87Z)++"+UN!%/@X1OYG=69\8
MB .1K=J7!11TA*V,>5&E>K2T=Y?$7098OYXH_0;,VZU*LL4VMIO!+&@=)E'3
M,#0*HM1Y-?U+(^7OTU?R T* X([NUU#'I'YHXTY\?6/3_#>4-_*&L"5KM*%]
MAE8O*&TG[3-9Z"<B #XSZRM>W$/',T@BE*G^%O AA*EF]H),=N>-:5N>XZ<E
MT5("*TD-A>JN"I\;,H3^/SU2OJ/"7PDB!57_"%F1B_RDMW.X)&!'QUZUW1 S
MW *X1OL@2'JVZT<O -=6?;+GBKSPU=3RI4&$<LFB2@"SIY5G>30S;J(H3@4?
M*DD+6XEQ@D&B O'&X^!(8S!/X<*2D6:YQ9!PAG@,X^" F?L/J3 "P:4\Z:HB
M>6%$YN@ %!_8S\0BN^V?\M,I8]I2;ON,8YF5W6-DN9B .8Q<3H<@_[4%KQ-;
M?=3@&$BE&<&)X8GLZZLNSMU&?#\KB/81D.+W/JD.W*39ZV3 YE5@+.% (U1,
ML4.G_ER6B_NT0YUFFL:&V9)4J.AW&IEN6!LC ,G'_Y=%"CF'<(N75P!B."R
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MVW(_]@!DS[;X: >FVI#G;Z4TB=^UT>'D]J=B*]7:G@%3/R[S?NP3OMI3C6]
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M@V"Y'*]Q-Z6Z5P@VT].*C9SF32*^&XB)(Q1S^#AI^>O#.^BMX"6=O&!\^.5
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MT7*!*[TIX;6I=G@%<TLTF+-Z2V?0-&<9T7$1]^/%C\"\Y7(&K_ P43F*U$_
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M0!EJ<1=<11S=ORYOZ]BR S<*L%#0WY%_KOJ8OUL2-\E+\Z7VMX!J:-^1\.L
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MIMT5O,$]9C3#5^I)7$)*[P/&)T.)Q< RJ!CT<R=%YFK$?"Q&X(9M:FOU55(
M=9W9*2X-X2OCT*74>M+4IIK?=^(0NV0&Z06MQQ3H"G"VM":^%+[W-/DSPU'O
MR/6U80+&IAK%(QE>5-7;XN-413WJ'=N(*.QA<O>"2B@+YC0O:$L@YZ-"F)-8
MP.2_Y:40E&,-3(W5X4<Q<E")1_JPIO!DCG,!((^"ISUN_QHR&''27Q7U&UN\
MJ3.#$2XQ59,<$:@C414Y2.V*IV%[RK\6@H^B!45VD8@+D_>5#54..*:(KO7G
MZ;[FJN+YB2-/AF+.A4;XGV!$"#ZT8PLL$.S5PNV+V'QFJHO3KB*/M8Y@*I@%
MZ8*_5%^F;U3AX*0#\D%%.^&Q4<3K#RF!F8"KXO]66+>/";AOA>19H'@*)/Y3
MK2,BMO7,Z^KL+JWY=^IGD%@!GW@Q%T(/O3<F.&6_HYVD=6;E0Q4]J:]WS*=Z
MR+OCJE""NST1-JDP=,B_<:YD%&>F57/X(/4:UP14?0M( BO UCY<=\_ZQ E*
M+SAZ:4FWY.B4NS#;F!*DD-.3^O"IF5QVW;&7MW9$",$MX*.A5E 95J"]\A:P
M^#)%[@H:8.I8PLEL1?.W#(V/D;2@R'DV6BZ1\76;C'=%.'E>3LIYK8[9RA>R
M^ THA0US+>A$12 HMVE72$>8HQ<&]<8>$IP6A8P\*0N99:-<*!$H#=%+'KX%
M:"45!G/"A];I(D,H_;/Z3>9"YV,>U:,+Z],VT0K-J^.4-'JZ/Z3>W7L%H"'H
MF_AST <AQ017^;>]:)O9GFE(YLWE;RFPU]'@36O$4U+[A2^J38US-A$KN.F&
MXK7-^#(3:?_VKYV P"O@S+L0O;N$N((:K(-R1C%%O],&$VT.G8%R@DF"_]$\
M'=2("T)(L^.E4S4>B6OM$-(J.EXI[4_;,?3$IV!CZ! -FX@WV8[X<6 8F-8P
MGJCQP=DF@>+TYX+[</]I01Z+%@!\Q\QXY#;:%/Y$T&/"RCB/7*D!\R2T*>8I
M/+<!+6G. M*OZ6"L6TQX\L[']GT=9PW)K'OL.F+0W2/SO"L6"L!((.),X<CB
MJI&@KN>^_A5'JT](UVN?:.@G-SU>P,=AIC)W7:NVZ(M$,#DJAE0W/M(6<=#T
M[%3?^9?=FU8GT'HXF^9"4SZ:;@O 7AE#"J%R5QO=XJT/VW?.\DU@V.OF=R44
M9M'3Q0961X$*-0K![^SE%0(LD<;B#76KZ0?UWS\]697U!+Y,#)J?6XP*/S=[
MTSL!:ZN0)/+F::*-''+EI   = B4 /1#+TD-)^;7JGD^/&I/.Y*H>K"'3)6T
MKH_=?O363D[9?J3[J,WCV_WI$*H!N!_R-2JFH&^#'JS>],!\A2G+FH3Q2805
MK\C8\.G53NF@]!9H'=I8/01WTV\V2K;+,$DS5RKPPHMD^9:[[BI]#36Y6&%;
MSX@29XN0@@#+0^;)HWS<Q"E'=O"SKUI6T=&#Q\%/CMY@'OZS;TD#KV\EC_((
M]K'CGEZIS_P8?>IFH\_)%_OD(TL);E-55"?EOL$J [8%;)V)J5D<\_. T'S/
MH%=NU:#9 .1&%*P'_@V<7Y;XNT8/L@7A8>P[M=0,8_?[#/4HLK"2^HD:U,&_
M86EI-0?QF_&_"29N 7 =N0/!H/Y<O-_><YI'(:!Z(L&*&P>]%[_+U96.?U5\
MN)&8O.,RI8)TML@08*+=F:V9BE/7Y9>G?T Y@=J]$W^ W1#BBQ*?+.^..1][
M\ETA"0V:.?R;4XX?H<'CZD>Q!XIB8(K?G3+V<XRV'3XE)LIV[JY6P;+/U 3T
M*LG/+>/97@!V0UAN 2,@^ 0V[ ARKCNOK"\>+,0"5*^9KA@5IW7G;K=52>>+
MI;:^7M=O!:"BU&\!G^,U;@$65'=85'-PM']Z /DSWV>PQ@CL_]LV"VH:%0O.
M'F/[X_F;GFAIZQC]'=HQ?UKU^ALP&^3F[UJ(8L(UC7RB5K;4,4AP3R'E ]1E
M"_3B &2WQN9O/H$,AE<<["-I)7T9/55\IU\E1]LHQTA9QU/^441_V)'8-^>
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M=/^U=TF\4>74G10F];95B&G':4R["%@*6#;&/'RZP^-8@JN(HL:Q_?^XWPC
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M9W=B7-N&="G8OM8#LW*T-[9F;1>*-YX+.DDV-?Z8G0YB?MG*7= M(S\9";[
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MLNP%\RVC7$TN,4 N.#OLB7WO<H+_G:&W_(1VIPWU4T"J:T![SEAEB>>%;YK
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MYL98_62CKFHI1Y=&NA3V;VS'S*BPSF=O0-HER6<.$@< $(M+/XABO-:DQ#6
MCO7=-DI8[XUSO?GWPY+?K@1U0!<40IX\MTFZK9FR[NH;GAR;T3V$TEJBZG?-
M,1MP<?"YBW"YSZ#T:""VWH#%.JCP&E!S%NQ!9H=,C\R?,>UW)__N;[G3I[SX
MRHF1>8Z5YAZ!XM[=$B0TE!(_807 :2^7B#ZK+9NHW..=E$I<AL=+MM_KR7^R
M3/?%8ZMA]I,\J$VJF1Z;AYP;HH*H8!'0''#]N@E93FV=0.*TC.''63"WC0!M
M*R'ZU&KZ&K"2FU<"$<,$@!,/M5\V\MVIURJP^EAN]FW5*2A:N+)]2:RW@^(9
MIN5+RST@$TX"?84(]G\ D8K3H30>N$]/Y1#;*Q'Z0KF'V_9U:QS!*F64.C3'
MGWP *1IA12IOYX)DOPUMI\UU+-/*/1\US5;;E>=Y&F)W4_2;VB/7OQI&W\9J
MHP\ZKP%5)V>A$ ,4E&%I*]'P3-&NIKJ"^Z<8<S7GZJVGAB_'^#PU!S6/1:,L
M;TWB6? ]IH-!I3N'X#C4DNZ7-C^1O<4GM=KA7E1@QA4^QE89VK4_D8&7ML#W
M'H$CVO"2Z,6L[R*JOY7G^=_P#L/4#@FY! I(*9S/5\;P4I"GX_Z"^!Z?@U#X
MQP>5-!FZ7\S,M&HKE"H0U<H:C$/RG\,!1Q0 _)"E"#8,34Y!/;#B&\%,!AQ=
MMV!7#3+NII..37$E_6&2JBAC#7.?]HW>%<>0&&%J.EB5AXP;4W0S-)H.[]?6
MNAVLE@L*),JGY7F*3W^>K8+:?73!VB@(>Z8AM%I:$7R/AL*7KP'+:9E_*B,M
M:BQ*L9)S S\S3%2-'\Z@6,5&H@?Q[<+O=IZ"S)<82]R>!\@LB?TB!>IG#+M:
MW<<C%&_M ^\WXCFBNZ0OA'RD\IP/K!WS;"?G@0P'#(-BPR?PIL8G><TEF8Z&
M+U,UW9V$!'2*[A.>3[4ME4.[Q=$ZG:89GT\6"'6=M S']_9&)73A-[//WW,;
MMG4SL"E0E "T,4PKW7B!JQ)Y@S]&DH*F9"');69T=K5O6*3P3_6>*0VQ"["E
MQFBP@F;O7R57+1'AV)/:/T!T4K0J_=Y4">[9]8$\+\65\]]< \Q:%S.OT.3>
MQT#OS.X._%T>GV<U2]_K/?%#.W^INJAU,+<V N0?2V6P=M;?:AHO*1!B%&!V
M/!=:AM[I;(S]I'%"0X#*8)"71K8$5OM8-J!W4!.#=:4\J"X)J=FO;O4%:BX/
M&:(7^H(X5EF7F4XR9C>Z+TH++N5PCZ>6&S-T&B8L)_==RC5&;'KM!]6)<G6>
M8:"P=%ZL!VHIN/H>1 9-MOY58@N5H3^96TW8JU<<0=)'0B>T3\'MU_;)U\=H
M3^D/H"--0D/V9(PE<)BQ*\#P;:-.B@"\W&0S14V7GQ>BQDBV9N;^N/4HDKQ,
MQ?G2LU#&M2K@H;RHKIKF>=$XCAD#ZDI&[%H5@),742 XC</IF-E5)6Z45E/Y
M>W21D+JGSL?>TGA$Z!*Z"];P HG4>@YS$R/U+I4^=<!DX1Y?Q>[+/Y5(B71Z
M#\]Y5U9]#3#AE.B!J1/M!PN!-_/R3 &'\,_XVVAHUP 3200\O/XT# ,T6:C6
M]@0L->[:=[S)X?G@;T(P"&8]:W&!AL0[&"5[19B9-]1'ZZ8)W_[. 7S%<_]R
M9TB_)ETN'33D+PD.1"*ZBA98_>FP*J]^83PF!NV"%Z?56<)?H;G4W[1XDJ\!
M7DMIHIH"3U%5XT+-=R$*@08Q0P4=\JX+ ZD'W\SN;2@<MB8#-N1!KJ7XWXHW
M=Q7+<";YCDSP2+J%E727KUMH!-V&L=M ,-!1! DCZ"8G<_,7&I7G6UXB:$-!
M22'6XY*BH8:+S\=:DV!ZGD(_)H&$9'5#OW_?46D=8JN[U(,(3$*\T7RM3*41
MMB(_O'[,=+^K#'AT^,TVX.'OPL=RST$Q1,HZCBL2BM%6!&,=B:!"G( ^ZF;D
MV]KJFM&]6:EOI%3%YJS9%S#8L03!$D0'FU& W3GEJL&\K(L;,JB[E/>B-JV#
M?:?:?+HKM<(<3OT9(=F''[H&W,*!,.\4;^/4IAIM)9O2$]R=KM+R$AR>GYZ.
MWGIM!B:NS8+%=*[&3S; 9]FTY%JFEX;&)"BP:N]SS1ZOC!K>9Y]1>5'\*I^0
MB#L>P;W>,#1#]@P_F$Y^\_6Y%U'&Q7GB)X7@9IVK9H\,$@NPF?JPLZ4#SG8C
M(DV*Y-6BH90<^^]CP^[;CX4"?TF>!$&>7.J!H9V*9-< >R<N5+C]X8[L31W0
M!Q,"L6[TIQ+F&(I$#8N^3FL^6(PJP'NIPZH&XH:9#%H6#5L4:AHYOJ(3<[++
M&;H7M!;[,/T)'[,M@CF5;L5^=6H:2N$O;2^;U"6LA;2,_C'P-IVM!CSJX?'P
MYI>?3@ WL5IR/\'5Z.@EFD;:2R5+AQH@!3JQB3[J>P*;/2KZ;/NV5$)D6O:;
M5L/V&-G5UV0',R%6S5@N3-R*.@81+&F,TT2%!(^2G ]:/(^SC7"^W/[]JB*8
MFV9K\A/P'!YYK #5C\??)?3-J\[RG&1>8[<5+XNXT<'A-"A[-%;B%VM%:R_V
MZQH0$&895W*V[IS64G$Q?%L4!I=W0>G,$7;BJ=&(L%()$P]S4\F.9VM.RW28
M7B[.C> YQNZ'WMOBL0/8E0ZVQU?)_N(.IHK!C=;N^98[B9N_%LS7#&;M[,LX
MQ1_R6*W?W&"\W;!W6XH=_5)PU* 9-S!6<PHU33JM-W29!2'?T:1>P<@5MXZ'
MB<@P_4@76(L=230YMEN4;0G$U+373Q(1+!+T#@!\9-'8R7'/RUIFU?WSCF)U
M380D<3,QEL^PO+YV+*>E,=B+KKP2ZC\SY_QD]88#=/E''Q1IB;7X]4%2[>8U
M8(ZW6&>.G_8J%<]\X^'3Q,S :X"EDQ(#4 A+O *GP7&EH-(K5AKZTR .'4;1
M.K#R+MI\'?&WM6^JOD"E;JS(NY\556'],-)ZV.^7]-A%BW?( TEMD;XCG;AU
M_:3O3P4V=WW32NGYXBOXXBV]BOTGC4ZA-_21>V=!SL40%==LU5Q5-W"PF7HH
M9Q\-KK/2#F9#Y4;A>"P:PDYZHABB6 :-7)G8LZD</S&3&WBR9Z/''48J$%HL
MQ\*[Z\&,]D9]$F^QO0:P2G=8S;!W6_)H3#H42PJ&!$O+Z'.I.H=E./VN6E\D
MKD*W="F2+X+C4>S=<E>"75./>IR$NWI?5;>U5^2.M7'=URT%L(?X7<IAR7=0
MZKLN*U;DL[?HD^J_#KSG1EIJC"X^9=Q+5!*?DVR#\& _HZ>0>2'[\N(8+61E
M'#B\V^%.;?SS*,UL93>Z)UR"MV_&4'# W.0^^1KM@C#N9IBECB%:^XL)7'+0
M>D#1J>\,2V4):>CEJQK#66L9ZT$&'Z,P_""0#(- ++";H<\Q _L1R"+BN/6]
MA'2'O$15@;"SS_PWGW]X(3X='WO"WFI%!=;O9B/"2.4M']QD)]H:'*"J,,T6
M]J%[I()+O2=-"4NUN4@^5,3RR99/8X\3.+RK56*7J(>)DG&"(T"N;:M[C9IH
MT'-,2??W/(3[P^;&^=^&,N99$BIR2?YK?<%_( U@(P=-%AW:8F<U6Z2)-@4'
M;QB/2DI%/:;3ZXM7%V MUBTCF$#H^E HJ[I 2 W9:^@[1;]> WXK'5\#<C$C
MF,_,>.::-O8'JR:4"*=1]PLF0,9I+A;N5PRQ&<4SP\-6T5[!/XTS#,;?QF11
M[:Q#NKQ;M3-%/IC4[47+8HA@$E8S!P@@\P2>$:?2A#&,%8\M=*@Q8K.?+4X)
M?&.@X<%'Y/P*KF\1LO=R.27Z!@[R"QL+19:AH'<L[KSX0:+2S*$G1L*=IB2G
M7)ZXG"YG&!7QAPSHA%9=<3U''[2KCU?)]8=FO?+C73 4_DWPKN.QG'O\YRC9
MX5O1<_"N6400S@2]?Z ZSE>5J C\:+QF&[E@\Z5TC8@4V%0$^U_3I;\DB\I<
M[S#2';N"+#E],/(\B+Q1 7Y^VVR9%4G(835'O7?$!%CUEW#P6F)4M(528$=W
M3.O&]H_WN!<MS.8"UY8TVF@#/RD1NL7)R,R#TJ_"\23SCJ;.82M(5 J6HZJQ
M5N6G6EY/_%U][@,$QF[_%*Z!/@AQ@;R\O->68ZQT1C_%Q@;EO<GHP$#5IK3_
MXB&P:CVCS ZAY4?.3!%TYJ.P->$LNL\FEP#@UOK50$R#:PV R7JQBBFQ$G6Z
M?*XGVPBO\M-"Z707"#D[.]LD]K^@'YF[2KZ!>"N@@>!X8%6?Z><S)7[) XXP
MG)1_@Z% )N%XZ&6K/TE<5OT:3]3#&VL:$DCP>?4QVE)\<HVAF!K\_\S]C_[O
M!TEAEV]Y2]#K<TC#(%OX]B._J#X-[GJ31>E:FX>EIP3U&07%+<S8^I53GZM?
M)]&T(";MB<$$'YLX\7MW[<(UOM+!THF-EF&GG'E75?)/FZ4"D5)-M[)/?VU[
MZLTC;G9L*.V1W)(Y"%1BB[VTA1AC>.-+P';(C2!1[C%),B^0C@=I"K<@=_HK
MUV"6?"&&N(<? %O)2*"H_\#%-: UXT8&JST;<%*DRD)*P_3,G6:AJ=WEN9@,
M:7_"^U7J> OIO;)E5O^EKF8:;/P/X]Y\WJ@RA-NO;O/VM]_ZF7^Q[/)\HYXC
MG*R+AK%7V4#9\.Q_ #P9DN+N]BC(M*.]AG^S]!Y7T5[T&Y[ROBSW6ZU#- 2S
MD.?8@@*(TE68-<9HEKM\8@,$=K:I<F<\XJJG;""K;75J^"7KW.5]$(PGP1ZL
M2+?)0.P*L:?;=XH_GBN6?_Q*WC,R%VS>T];-FBQU_@OQ@^_7?K,@[G$=UNJ2
M7#2D%'T1U& VX%414][[D=NV9Z?&<_YL+OG@7Q .0-]5L/]]1[PDUCI_9D<Z
MWI':0;KY*3UUG=>A"6T"\;]SE6;8=PMDK#541#E;<$7NA8P,/%[QOQ.5J;%T
MZ9!7M6C+%KK0+LFDL7VZKL]MU-^FU=SGUKL D&B4RR<@?;6T]LI!U.ZBB%_7
ME^0O]IS6J83,=7Z9T:?J#(!7&>7^!7#<!ZSZRA#A=CI72^!N">A46_^W@XCP
MI)HG/\,OGB>!N3Z/667@@E@N5'0(GJQL2N* !4NDBU&/YFY\ P))UJ2.4F7>
M":_KJ[[J3,N.6<"$GT1C^2(CNU.\,0*CV_0U=0%:#+;A3X+5]3\RZM1*$*Q"
M*PY:+Z/#%H$8SVB*\(-CNM$:Y_HJ/<L5JJ_GOU;&%+3]8\U43GW!/Q='O>WI
MW3UD&'K/X$/1(=< ZNRKI&99[+8BI;W7U ,_[A%U%@$Z-39O^VR+:5*8>,\)
M[06%D_2L,"K)FN_;Y^J:E[&I3 !LWFDJAC[B?8MC--G6(NTD[]@)<S\S2$OW
ML"8F[OEA5U-2;#=N@RA/Q=RN^P" [3BUPH@&X;3M5E+V7'1;'-BTOM<4'%GS
MFYC3.VVV(8B&UQNBHT=J<%(;'155OZR><T5K)0TX0-M4OZ;1MZ[>4)\50>#E
M: $?6IB!)."=UL5;E=BT(O#%D2Z&I:+][*7R$$/-D7A-?XPT.I7TULLAUL>G
M0_00Z"1$\9)[LUE"W0JK*:D%?K]2*_"PHGK-P3.=N--Y>BO5$U6,GRY<0O^N
M^$,FA-P1.FF@B'$\XS:4&OIFZ.[T%MV>1\$TI^-#T\*U]=G#(H$_S+Y<C<.K
M6VZ8*%[E)U;K%=9:.KR*'98<C1/*K?(=K[H$.9D\-%8"+S4>SS, S'X@@ ?H
MFM.P25%%6_9[X []&$O0+'%BI[D&T4%.I[]6[0&^CN!DUC<9<PT(461H)@/;
MM7GZJ$<!&>DP:LD9=G4?1Y'N<@]:WXELMV$BVT+,CV:;]B#2>1";J\23'8H[
M6$W(?;K".&V'7 D2XD3C52-U&8#M[V?2GBMQMP#@I+:,ST 9[ 32+".T'/)D
M_.."/RB,/'5W?VZ&.6Z7X;W><O[=.X"/7.&35Y\,D1"OE9-&N=).,>)OUDE'
M5JXK2Y*1:/K3S&:LZO)W?_8%L(K>A+RF@X> L6EG@YEO-:2 FODSN3&:W#U*
M=DK]DGAZF\FK<RA,:K:D9<9#1EG=@\)^C5J#%<SW@Z@NDX2]/+>E8-NJ<J,S
MQ:Q);7][5J+Y >E8Q<]8GT_WB%M;N?TE!\">4YW0:J.N%NJKHLZS9+X@B0#_
M(2?[SB#EM;>Z=8"*FT*#[F.L8I'1,[Q25K,I*$^#8"H<2U3&UL@4#_H:T)4<
MLFN!,>N\\ J3D.MOHGC)S)$^HWS>%]7-:"T<]";XM9H;\6D;X,(%V=)F10N1
M1K-'0*1=5KQ/;C<:,O&<])7YWK#F^L''\)[]ZPILF=I*#J>*%5U>(@%;&;?4
M8Q=XBU8BY!Q$;@H7J)DZC'B%GKHX$$H_21S4 $YLSV9T#5'C(%@2#--E!QM;
M\\@75P3YMQEKA56SS[6S:@1RA*0/%%SC0!LZ(7A.K/<UX&Z@+KH> FR::N:W
M4/%X7W'U3:ML#JSY->[Y6TF.91&W-.\>P"D\&*@X">3P[[*42S%K3-)M''O=
M/-8UT4$?]]282E4(D<@UT*TC<Z->9YH0KY'^XQKPINX:</R<=D.Q8E;<OTN1
MYI.>9OHU@($5.KP,5[_Z] K>)G>H1C"YP;5T]E"7J!SR%C,&$<=:HT2I$$S]
M"D%E]B_Q6PFA&D=[34F2A^IMUX"9:T!G1J5.$!]F*A0'+9RU6C37$/KM'7^+
M?'35F4!M6<F@^\:5V(D1 GYC ?(,JX)R(9]QDJ[Q1)9,1!%J,A?GU_V%:@^L
M>"$45X5$K3JWM)>A-&"S5W[Z+^J2=C$<E+\6NV!N@LL%BV8Q%&1C44H*?*=A
MV##4T*>6&Q!A)+)4TQO5<#49#W)<[5WK?K2;4S>OPKDO'_7"/="2#S7 U>Y/
MAF9AXT,CNA54]+!!3JL#\L3@+KZW?:S6RP_G4G&_6[_(DV*VKP&5&U\@^IB.
M99= B#5%R$;-Y/OG%?.;F.X]B0\#4<JQM2O]L-@HF([CZL?_?_QZPY\9*[K2
M ENZB<2D%ZW,Y7.6C:WB>T=UY;C4G1G=N8@8/.WGUCO8OJ1W3"C:>POM7P.L
MH8K/AQ61C.7?WV]$:QI_@=J2R9;I99*RQ.FPQ"=O7@/^1=U#*KYC53'#[EPJ
M8%/:??)"19V<G4H3)Y<,U47E=6/B!#8X4FG?3.U7R]Y%'\R<+?LA.@_8P0WJ
M(5U>%R0.9C46I@6BKF'/(-.N6^FY31UXXED*W'U+89F52V41Z%Z:MU''-2!L
MU+]_B17BP1Y:*;?SM3G./BN*EH2+0KY23V3WMAKCJD\XX*#%X2!<^B*D:X 9
M&8-YU4R%GJC\D&;T2O-N0Z+V^=O&9=[Y/QB\W-=ZJ/')"AG]J2]F*/@$&@R]
M=P QR'Z^ZICL-(%(EBKB79XVT&/5;)M+$!R?,KK4 0-7_H0ARW%+6 V> <B%
M#CK^H)EOIDE^K%P6FOQ8]I-GD*UPMYJ<8?7_&H97=,T.!34:_1L,%Q&VA>E\
MB* IIOQW&%XUA>/#4JSH?%E"QV(/7F$DTCDQVJ=!;LQ:]M_;%^+*\PY(,A[N
M*S?R7R)8C BN ;?N1*9T+E'\*G9+$G@HFX;&6+W&%IDD=30S3)S8O\\>SRVK
M2-X20@Z>S]S[%0F6+V-@86OB)SPZ6I[,0.K #K?=<4K8E%+[9JG$G2O*G 9C
MI$?KK)=LC(:;6FOOI]L*+4J-?%GS8-_V"[4DCWRM(O,94U4785QK2*VM4JY:
MKWP9X[;/B22:#Q$=EG&W67C3232DD;%@*X-2Q.[)MY+)AX-69P%*,$B[V@?/
M_5[6Q[2GT:VL?SC@'_[00KR%YZ0JA;O8T!FO/P9/N?)'[N<;_-7;<NG_]<;9
M__,ML[OA^YI95=_W4";[M P(ZN8N3\1=,R) .E;FN, ^DYQ^>:AS%5NRG#V1
M78G_/2&\SU,V7CDZESRZ+M71K3-&M-G>4+@*D43/::&A,'E]E!;Q_OWX3C*:
MJ438SJEMG"1'7Q$L^'T<0G[*P@AH"4*\:;!2*I0]#;%%.=%=:HYGFA61;%HN
M@LT_]+0&*)HVJ2I%]RC",DA=_"DARA.-DMYUD[/:IU.D8ANM\]W7@-#EE1\W
M/8LSB'!*DS@2W]-(WI/,F^L:S.M1.N],KTBNRO$W,\+3;^'G1TMP0U2;KI5E
M B*FZTO%L;ZQ9TGS]X G_O;/:\\;O. _<UZ^?;!P,+X7H1^5-WD-(+\&V#=1
M=_E;I,,KU,93[I)&7H915+ W'$O.+V$5##6=C[4R=HN^?SV/S5QPDN'"QF=R
M0ZFFVDQH-ULH@++@D%9A%C:OT_1$&2DOH1<C^ X/JS5S&1BI@&IV:8;:&[V
MN.$3,K..I$4FF^KF:OM@J>P,;_;-!3)'K,M?PVU.N^&G#6+7 )$Q*J5K@$=]
M])I%QF>\(-@:%1E;';FBE6NUZ%#SR5G>O4;^X1FM3F<&,?[X@OO;_OMUEZM;
M+3]P.\&:7;,:&S4B(2;()4:'=%[=ZM%S(^-^TX&.Z+RSD-$:P0VY%)-=$9@T
MI2;(G?&R]&[]932&=@;K@DI8SZ@F,S#%SW_@M3KI/]E=&LQM5W@7\\EG0H'/
MI'Q*.*@KLMU<?<EET>H=JZI%-M&3+.S@D<X<[31HYTWK/!0<.--P1>99[Y_G
M4*QL4_7U.=$B#";K9W0Q-51M.G]A6_U#J/-WR]R!_=-L_#8O($ AY*6%4\F(
M8?CZI*=AJ_TZ;'GYD$S_!8^D]:3I(./CF>@\6A*'+"Q+]%E1RJ@\V-^XZNF0
M2Y7RXVO 9U%H?FD]8U9=T+O@I\ET6]QV O:4J:?BHDH,ODQ!L?$'#ZSR2PI?
M-'EGJHD2+<*G=XSHC/4@F]#:!?7A\2$039JNW5QX4.4$GDCP9/USVJWTK%N'
M^"V\\^;\PR+)'DG8R"^;QUPQ?1] RF,6Z4O$WLRRUX A599H>(D@^?I1ST@6
M[=L\5M6WV[N64T):K!T%)4]<62<:Y%^4\\J6V#JV8#:N 3=H5NJH'O&?'NAU
M.1\>G1F-3_24C+(%\DU6OH^@158(]^.R1DL*A4!!##3;<&^_6P'K7AULL7 1
M*/E2I,J[,#J T(?;VG9+(%V3-?HKSC<X ?^7)XK#AJJG50K+_"VU(9>AWHKZ
MB_FOYFTC^K<.4CX.Q0"W1>^V/#'8S%E%/[CS3)/U;61V;*+,N&U:%(!MO>X*
MVGW*=-\^YJI\%]K/'WT7.NL\L6$Z%7IP<B[N)<5))'@3HM82 BW(>UTW UJB
MNE^S0/XU /4B&/7DL@R_B1==,R<[N>K.^F#7D+;/*^]LG=%*OA1D;^]/WX(A
M)'1A3W!:1%E2HT\4GQT<'Y#;X\DJ?"_K?I)1[<==[ 44^HFW7P-DWTZDI@>B
M\9>O2"21(!+]'E)%GY5I3QPH=U)RB 0G,#*[CM\F>T0E6[<@@1@F+X8^PT2'
M6U5-I*>^&\.Q4BV9N^7IIT$_-F^V=)W(^X'6K@'WL"FO,.]R>/!PJ.35W$G<
M.^XKHLQ3VAD=L@<["I0C=X6WAW*J1&'ILMB90LU,G/2HB+ P\9SPV0WMID=#
M9];L)3YY[1G3&RKHQI'M9M%4<(8IWV\Q*>UR:4OWWR'SF#W+#+3>3OL81&XD
M"YTQH]?K9/U(Q>432CO+U7]U0SYYOY#'*&DAH/Q1@GKE1_D\E-?N#O(@5.1L
MTNZ2R'26:%9XV%OO]6NBZ#S40]!:!CM$&"/:H150/Q%(\LB5+<LEJ0:JDX+5
MJ7@]M?2U/Y2SH2:.&!4%YF:V?/#JT<-C#C0H?4,\W&[=Z33)Q3<)D?3@&I 8
MMK0M-_D\L6*Z9O!16IH/]*1HUR6<O3PM/=MV'$*WE;O _KVRX-M5NLHUX/E<
M(;MSQK/S#/-A#U'2[4<.%UU?9CU0?IO.U(QGK-]\PX_YK05>CGVTYC][?"E7
MFCJY5C+U L3I)$GB''+F=+6$O ;LZ',F:WE+:>3H',&S?H3FA5KN3)5M&&0/
MMB^^5BH1I#=V.H SSM"-WOY:GJY>JD@ZQ0/R&TN>KFF*TI;6JTD(C;+_@-W6
M94^EP!*[]$P]CZ\.4;AC6NDR#T<C4+<&,S)!BT+CPL(G)-,B3B7+XHAU;KT7
MYI6#(<'3L3&9F#@%P;%&#]0 2>>%<T;I9M_6&Y[QR8?%L5\>=3ESD?#.>S@-
M9+CO63Y!!W;A6=$VLHN?47(&6A&?WB1KY?\^31*X^U7SWD,!@EN3JH]OU:,*
M'.KQ%1AQ1**F8^*ICV=R /]>\?W#$J>]B0@!@3AOS]4X+:K.> 2+H;,7OAJ8
M?>#/9;^3 ]Y&+<['!?";?$LOMC;/Z)P2+33[M@18C3?SF<R1*BG4\I!8?/]%
MZ*W.P4W=3'R"&FIDDEK0_<#B@8-U[X;EZ&;PA+':JPN#A">L!0K:*LQ[E2+^
M&%1V]'H5W^-<1]@Y]WJAN9:>N=2DI/+ZBTJND7!!<\U$2=YX"M$_6_T1:IHE
M\27]<4E^C*EIT$Z5]YEDVS>#TX_>=(?BA7O,;)>7O%A5%WF5(G#NFDYLKNHI
MR%/Q8]^*B/^/#XK+!B=6'3O4WM[N^3URN)9HG='&?F1&$!1Y"VOTTX%74NNR
MZE)[Y&5OG,ZWC4TI.-)R#YDF=RFN5A,*DR/;.U$H6EWMNC,]_C-<4%SW;XJ=
M?U[Y.14!WEQQQM9Q&H,OOQ,('BL4FO(#<K5O>MVE,YXT(/I G@F+.K[XMX=O
MR$78.V?-R&L^LI.ST>TXE,"N&(^\I.'D;S5@ /C<->4GB+SI]BRNTG%4/2WJ
M%57=3N!LQC^C&0+2:L^COKC>/X]F>,P0""X%SN;^# >$,VL(+ZJ',Z"\R2UB
M 4)^5XZF?T#-=U+*N=*>+..DQ[/A@"$XS07_#>8(.=_6GV"N5-$GG+<1&_HO
M50'JDI5&]Y^.</]XL4:>N7P!.ROX=QST)D#JNZU808+:".](+<7SL<V_B<E5
M2#TQH:C(MY$^G/P _QM_MY* 1BK&K#&:1JSSD*6!$V!\>3%>^5+IELJIG/L'
M$5+*[PA-3[(%L2GXL^1_J">"9[L7A[QF]E"!7HN'PR*N.^&^'2PPV&9QCUMQ
M*U7>N(_^YC\@6B/S:2M6"Z43T7QKY/B =+;+VQN4'Q'&%><1L7J8YD9R3S;V
M?*IQ1(EEXP\EH.A'_G5?Q>I%2[!8_E:];54QK-8I*E9 QO"X1T%V2OV/S:^D
MZ3S//C]%J\M8!CPEBQ[,_4_*A^#%P<7QNH [2-$SF#V]UQ2KS_CXW_0;SXVY
M3))?,H49OTGEGU?_(7'Q/^Q;;V844KF?J2]SGV"<,G;QKY_TN0)D3&9E)A@'
MUP4RZ8!YDQG_T%R+]T0/'C56'57O'DE%SOFL +]>_/&TYDVW<KGNTI'4K$<!
MKRZBG_G]0TAR\]',W)" %C=EKX#?E,U-N#^%8W(X/T'S,^]FYZXCS[VE*-<I
MQN.\O_[^CRGKXBPCQ67IA=MW%#_GC2C=R#< D!*TWO@6H\X2IQ%;V,LK79Y_
MJVR,KPGX]P%WCX5_)FNL@F-7H_?%^7G\0ZHT50&T%--[ ZVU#]7L6'FFI3\B
M+)L$'/^6![G_;"C@E=2IYVG.[WOJQ-!&:Z6&YMJ=R;][F--,@PJ99VQM,OTF
M^XXTY3Z40&_D?VXY\#^V(GB+P /C,7BUHHE_!_B R7^1I(2W_Q/&)W=!J7\N
M ?* Z4W0$[O1I$Q?;M^7L D.:R.-4O#\ZP9CV_+48S1]9S/'5./M:G_!LMI*
M#%O$APN#W0JU-I%9(0+Y]^J#I;4\(1CG4[AZJ1QJ*'H#:[W<D$&)R!HH,3/I
M9[94<>$P"I__1?7\-OE>8*KKOM+-R5AGK9B<Z5W[PF1@B1W<P= G,>-#DJ>T
MJQ!:A[&O_F'?KXM PYU'RBV/%9TH9HYQ4AAK<)Y:-2)8LB!"5JU%.*>WU^;4
M<"UI;)TU&*JV0]&]2#:*OP\VTD.?5KF<ILE><-%$+/@6/=CM4^(XY3!2O3L(
M.Z^G)W9KR(!1W8\LTX8K8T?0$498N170$(5C4>/](V%1V@])#^,\>Q2%**<#
M! <'7\7X3#7.5DW^WJV3H*>:_1W7P:4JP-JWJ6$+S P_'0J!5JX7_3B7LN12
MF]A-6KO45=RZHS"$P<M/!:_#)O5ACH*:U-PY=6<EP3G(Z' ?@0$G"=FO#-MY
M[X<S= P4<US9N+%VT&R7]-;J'/O' EEG/0H(:,<A_&LE.^6V/_TX5_,H_%UY
MO4HLMS;LDG(XVMI*#?+XJD#8!69H*1AJ,M0>J4QP6;&_@U-\V>5=]? PJFR"
MI3QWLLN,^3+MT::YR1!/2;MK$SG%<-0U0,4R&CD4/J)=3?9.S/GJUKC*JN*!
MJ$M'^-P$CN\G>';$)3-6OM=(;&DFQNO*5_H(+HZA#_10)"T#A>(N7TSI!NAC
M]O-VS'/Y2JS +L^GLJ-P5(/3'HG$.DE< &5Q@@[*Y)ZHJ9?H^?WJWG5-#W>7
M>P[$EW+PI*IHEJ(;+8F"OX_9J1V!S"E^7RZMK9,^X^W_0!5VUP&?I& \UU;]
MBI!XQNY.!R))$!(%G7'9=*Q+'G,K=<%ZZ0=VCLVW.6['S15X+;86O$Q]^&9Z
M&6\ M\ZWW$P2FCRL:OR$V_0VO(@*KOC(*CO6,9NP,'[OU^5S7K[0U,SM)X!C
M1K[P&;IKP!SE>6&S!4)-$%^BQ"&P G\6 MID^B@[P-Z=F!P\7=H^/<]&P'?V
MW"\:C9<<89.]4F_R)AVN%.I;?DW5\'5-\V(R/1(%6J G9B;>\YWK<VM!4T]
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M2[6NR_'[:U@?MY\!-Y)19^RFXI8)LB_SJC?,K1FB?J8DBUO02]2-8?E0HJ%
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M 89!Q<9#1GGB@5[%G!-TS52E:CY ^?($+GB8V%@Q+;93?>SC]1PVB#X9_X0
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M(6:1$1?H WX)CT.U9V7LI<XH1'Y9<[,GM()W)(Y8^VV]"^=C7,0=Q,WGS5=
M#-N:#U3*,C 3N.R1,N3MGM;UZI=[JC[@TQ 5]"_$[<,^U\932/AU]OBB^(-N
M6;&YHLM:ZX:,H(,B379>SG =I[=PSZ6<PJ7/,FXFPM@/[Q+WDS<5D/OY,L%&
M LP:/8(.=XM";OM_,DC#1S=[)P1[GOWE'5^^4O',E?O]+$ZEO8I!X$7MR#LQ
MI^P@#I>P*3V\6S[3NBQLZ[8)Z"@MTB5\2;%=UU1C;<))^ W6<51(A%[^F(9H
M:^BI7///?_F#90QO>M2&7^X5,2]X7-;H6$,<&^0C$P3PD<A;4\YN\=I;3@&R
MJZ[Z1$5W&=SOMU5))@6)5XG[=SSE?[$.Z$W47S>WXT;]8;!P@!]($<:)B!!,
MT9OQ8;\'ZZJ.++.F\OVCG$*S:9OVN8/^?/-VW&]'Z0QGW/?)P$H!*!=#DFE8
M@K#!]5!LX6MVLI(;?V+VVQND#[XH_G/\2^G+[RD]5;Q=>+F9$7%B4^P-Y!89
M@!\31426H!U(6J)(Q3W'VPMV-I713XH[ND@G/$('R!3_V_YCIWL12F>0ENYI
MQM@I/?YR)RN8!XEI&Z* 2;SAE6WM:>TA_]8B%IHO,\0E.ZXQE#M[" MMX*U]
MAE6QCL)M;1N;^^LHC'Z+ .%JBD\G4OZQOD(C$0&KGRUY/U<C1BIW%<*<;/K8
MZ?YEJZEZ,_J?TJ%WE9O"55G2IN+_367!'[P/%M;:0']$53UX)/Q*UV5\)33R
M9%T3;\"=)*56,A2Z575*AW'%=6/(0"0Q!=+ZP4W'*."9,!EX*6 PI-O'.RHL
M?5=PL+*[B]L*.CB!_G&GMC"(>":RB9P"M4)8CI#,'9EXOQG=0=2T\_G8<HCI
MDH&R@5ZOYJBGBL"CM7C>_:H.2XO;"F9@EZ$7V?4).HEB1SZ([9/O.UHEU;10
M@L0D@<\.2^5>)/6U&1L2*"W!M_&SPWSDS>AU\/O)-X^B?\FM0(?K+?$QA-M;
M_KP'R%H1 ?Q''5W#J?J+RVHSI1\W/F[;;WD+AV8?0Z17/TEIT0_]K;4LZ.#_
MYO9Z](H7]=_=TBF!BQDW5<_FR<"9]]DE?"3&N@7,,I0S)L907E!!^VL*)<3W
MH48.Y]Q?_QR?B &?TPIZ8D_^&]+4$/O/?,M/G\"'8PJY$S%[9E_OO+P%<=^8
MC+0H1I4\T5!=C!H;-GH@NAUC$LCNZN>==/-O1:W-BA5]MQJ-W@31_A?>$R6O
MY(DNY%9[*<;;BRJZ1.(P6/U"4@-'NKTI3C.,>/.MYIOP07;,84)S"A6><C&R
MIOK$.+5ZP?8+FIZUHQOD?P5$V"SH<V;MO<F99?1&X"*'I8$>^DQ57.;S=D9C
M8!?5HX*S)6K-14G(Y>3[>!^?7X[QQ^Y!^<O"X#I$^LZ1S K73L:J/HFNLF(\
M/4'=H,K%HRY-_Q9<$8J?&"0#EXA:PF%FC$0E@_@SYM?!9$"(:*<C\?3O$&*P
MM$9-K ,K")-*\W1:B'1+<@Z:*UJL'^7U'Z+M??] #OIFSN3DN85!U="0.FMB
M^O\H7!F$^BJ>)1DT0KB5-+%4\%!D0SG?3GL*3D*B2ZI7$%)[P+AM 79[6U<>
M!H@TJ4C[=WD[MX'8A,(._;RWFLUOG#Q)\!@Z"1>X10&C^/:M$7!B&&04F5]/
M!_VHYR-UZ)]*1(KY&J&A;)M\\N-BG#<J",9_U-WEG_?N;A.@URSI<3+G](VW
M_O+& J\25]*-G>UJ!\Q3<4=G_OND%Q\>$SL?S6;?Z>S<Z?.6N4JQ!+Z(>$N(
M#JX&?Y9.NX+/1+!O5!?^FJ+C1+L%7[K_[J5J3'$EQ,&"M463P+Y% M76\5'B
M\POPSD^J'?NLBO?EVK4U^8,%TA55*>O\GJD#7@W-D(_'8'KBG0+;"M*M424]
M1'[W\*P=^\E<[ <57://BYX6AHB2M.WMAA(B%]$"IK Q9L[654* ?!4 =9QV
M]'L2W)"6F0%*%BV0DC"\)WJU$"L*#YCUJSV'Y,P-Q3O[/;^BC^I?]]\Y&QHO
M0=B IHQGT)J??RMIOD;VH>8\QF\$=/\YR><O8%-K$=:X&-U+N]/A?9QTBW)M
M@(W4;6!^%Z^<#A?1Q=;U'E<['BQH_38SYIQWF;?N*<NAHFCX6'FVX'^/=,N_
M-PEV/A>"_3DP=>/Y8BG'(859%25C I_N>;06EZ\?NQ06/Z6TO"*_E6:3&:"B
M/P9YXP=K.[TPC<]=BBKXO6!RNR.W%B/]Q?B6@.?NM&G5;:!_I<-WT< +JX:S
MA86":7VO+Z;A'T7]\%7FK:;;*_:J1WRCB4N3Z#6KVCJ.4G =_\<NNC!1@4HB
M*!WVARQGV;;ENE.A83L'2I5CLA9"G#,_+"=HL(1%OD3L5LNXOH'GL*T!CEDZ
M/F&H77"J$M@\UW NW2Q/WEJ1W^,PX,3DQ5GH$8)]G<Y^*2U,H:C$SZ& +_6@
M<5C5)CURH<;693F/4C&!]^"#84-Y0W#'QP9K,A!2#502#(>+Q+;]ATJLDU>,
M[SK-Q$7L]-]]GUJ&XW7U5\"[HAI"O1VX$*&E>67V<E8'Z"@-JVF\P+5\F@Q(
M"N";E4YJ=<$W--7S5O_!SN$2,NSBV:J#^K^)4EL:I=YX>YLJ+#?V?4S,IOV,
MDA^&H(4W(TC D2U)@D[Q]Y)D)@:$J;5,"]@\Y59"A4[H@8O>N\D_9VQ.'7."
MOHHX6]LSJU*)# F\O/Q+.0!XX3T>;K4DQG^@/5HXO@>M#4U/I>GGY7CU,=H.
MP+/@/,^2K/%EF/XU\R&BD1?*S\B=]K?0_K<DX46FUJ9'^L\9S6J^P-%U?A88
M&ISG4/V%#=F8:;.N KN)-O^QO!Z.:)<BC\R;3]LXA?(%CY0 1005GJ:%##!*
M>PS7RO[4S+'=$7DZV-[;V'G_8NB;I^^R&NS6;U&V^3.3^@HP)4NY84J62@^F
MTW"#*>HQ)?NUT??<$_9.(FNXWQ]K%H)I$6_'\$98O3:^NWS7':$$FZ>9G5,G
MYIK)"CW'Q/:YR$I"UGC=KW/]Y2YI;L.<ET!<9OC<)I)(#<8IQV-'%-O$9'GW
MSLD4)R\GI66L/*=0>E%6(QGX.Y^(V@OA$\;45Q3!X%'.S-]\SAXXQQPC9RVI
MBKO_,,0+"3+.&E0\NP\6M8$5JQ18Y/:@"&0@]+241&]+GS99_J=4Y+J0G$-G
M-_4V\X5]K\6) E]*/!C<!+ZPR<<=9T!:B-H_U>[X/GWVX_52U-UDSPJ;@Q_'
MR&?G$\$(,[&M+AM(]*(N3,>?DEH>:E?NPIX:<FCQ"P1?J?D=((?F%%G(*-IO
MP3F:@*?Y$6$6K:*DUZYG<3BE5V4-<:2*7C+PP6_ V1OWZQ;E_ZI;E$7M;;L[
M9^*')]I2I;%.&>B4-T.Q)HBR BH#O6^B_;L#I?O4]P<L8!I#]_E$"*KGBL&B
M]3!'*"R=3=H4_WU=H[.L/L9.[Y/P"F[ETXF7V &4''YDD9-XUQVZ[2J(?2I>
M/["&?MU_S\ET;<O\@SK@"J$G7E7AP=,\Q S6D@9)?157_ JZ]XF]S*X50KS>
MEJ/_W!YV4\ES,=*SI=#-(3C?^D;N] 7G_>-\[O)E:\Z-&)-#79HP/ W.$49)
M9,(*M;0LL=5S=55:Y)U%]^S73L9"COS/7V>]1[]6Y@8&_.FC/_C3IK6T&)!F
M[LYWP9W\^Y8M7/AW9NJJ';92CS9>Z-)$^+*<_3!87(M4>H:,OL(+(]C\,$F&
M"'52/R #/KV.<^\'W9#6F>=VA$0[;\-LL3X=Q^:WRK'R@Y8U43*5%:0!PGU/
M=;I:V:3OW4%H7@V?B:H-E8O#APW #!S2?5 *+T7]+'5LBI60L+#FG;166:WF
MND6YXL>-NSGF*_\>D6L+N2H3*=MLL%.]IE/V.3L6^2"B6:=*I,GQ1]3EI3J:
M1=CVC",&0F*YM%/6,;KCCN;JX)X^<;0+7=UY/C/CU5KWKL$S5\E'^2H%^O\A
M+N0A;"!39?Y*=OY\M2K7'5D(@H\NTT%*O3*F0+ ['FCK!N-_[*:W7L&7<K!>
MT<9C/.G'\*0=VY,^ZSR3O+?A'K+">L=?%RTMW3CX:[U'<-P-8];%Y5CGUCF3
M5B[6<)# T_VY^[IW@B1$/N/1*WH=WJ?58<"*DAJFXSX6W))(!,D@8]*U;,IM
MZ6FHKS[QLM(:Z,UY$>C:N29ST!%$!EY]EYY3=3Q"<B_8S7-HM:YI!E)7&"6?
ME:Q*\@*"]#&#A7Y6Z@ \MUEBZB?XO#D#T0C%Z:LFG@_ZS/;"I[)0O:81"?KJ
M$;D72R$$R7G'OE",#)>9,3PTLUXB%>;AS67UV>XV;S_.[X0EO<GBC;K$P>/M
M]U(=L,!#FKT]/_A*_%SG>N+(EI+;?#W(K.(.9;[%;%RL7Q<RC@PX%SZ?T)VH
MO8BJF>0O+H\W2#GJ>OE])DNA?3.=YPK V!+7;,&SMAW6BK7^0(2@^Y0=?-6R
MIK;8?LT,*U:J;3N_%/JF@KY*@;%N&P#AK5%"P8<[!JB]=I,SDQ>$!YF3QIOV
MPK1=$H3,>\!]5(@\L@"!,LO=H<" 6N+YE,+@,MKA<N+S2S), PSM_8) Q 55
M^>>0SU&*#G@$[CW>%N6G(7*FV#3MYOG^'GXYT=@Q0N&*H"@%7V8=_WE<+3Z+
M)GKF3&EF3?G:C3OZ0L#=Y7_:[CH\\6M[I@+@>#S;O)&1]51M2WL?,$0%'9>E
MN>MA\S)CXOPLG?-Z!58)+LL_O"/>UCT/ Q9)O$01&$#D+\/(XF+J#1VMRV7G
M->--^JS?S,CR6"">X(H0."_\A0:*0UX+'4=G@J^=+)V4HM'9CVMT%4YS>VG]
M=2[G\R?D^5GX;BF8V=SN/ +47[,SOZQ=DBB:J6$%Q'J$:+'<DFK^(W>$U,0+
M8:!Z>#//7W8*:Y'N$$Z[ZHCW[?L+;%-<^4*7.6?CXB8$UD7&UM/I06"XT%-\
MY.*.08MWGNOK/+4518UWZZKTO^LWFPRMHT36_.AP0F,.;B>^$ 06HI_6%'D]
MCL VSA9D*;C&D,AY?R[POCE4B>LT-0S 2H2DE3S&@Q9SP_S!8"9N;)'6N[5G
M;.:PN-46'L/]\W 2+0&!6\LM54,"(-2:C0U4 RA4 1EP3'2VK)6%O-V_4\7D
ML3,_=\]]P/OP?!:UJ]"2^D4PKNVIMR8Z/C,BSTJ?BO6EQ2U37D?4K=[;K5Q7
M^.?@&TXTO!5\1;SV)0K*/@=76<7I)ZV*P(TZ/04[AZH[@]184FHCXCIY#$:D
M=6GZ54!GX8<-E,2'F(ZPTCUF,ZV;7W/VKE=7'/"=NJXZ?>VJ=>ATY_9(9<D7
M3#I5"#N/HB1E4J^"; ==@;*NG90-W_5256:[*P\%01R"06[=L:I"5)("0DB.
M'KP,01)&5,)FF]_&LD<>@=CLXC%:S@YQU+3,E2V6-55*'AQ$^X5;Y^"9Z$<
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M&6=1 J$)D='!$]1ZY'E678SAG,T:>C)=F5FG9'INR5SD[[ZYE$W7)5_-X'V
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M2F1LC3J<4#EE";U_5ZK)I)"'(*; /#32$$F;BFLW>KXOWH$US;G,^EZ+'1\
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MKC@._"PS_ * 4+$2'>]J$4ZF&KVC>P'@5585Y>'1SKT 4%_"6%X 4F$;Q1>
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MJ 'O$+706MP8E;2Y>N=HX&'8.R\NUI5:_]4D"/!9C4M&2L$A=L^1<1.& UX
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M;9D*N2O1:Q> \/R,9FOGDS,2W<]*3W7X@3%F$GZ/(=BNM&K G</06<'C,PM
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M849%XIELH^;6Q- +,!_D,#JDJ?0K=BI8L!#;%""(QJ2=-AQ(#M]A,@W%#KV
M\YF69GGJC]DUSC\>VZNQQPCAI-T("1< 1MB!:.@%H*04FDD(0+>N8Y]BW+X>
MO67]]0"7UA=U;5JQSM=+X(YXT0TW98P2JH,Y/<-^I(-;\,EP""\12/P,<UZ9
M0N3W:=-/!POQRZ94N5.7=<P]O'<R=%#'*_HE;<I)FK6\H:.AP"UY 39XM,QU
M#U>)OXF+V!2LK/%N__[B-[V=$(M,T4YBA'N.G*8NK+3*_R'$0'.;TBA.BKVZ
MG_$,5DH[9YYH4.')FXZ+1<<=GO7QOG$_7W@KEB?SQ]?YD<<3[;NO7F?WN6HR
M)$=8]Y.XB61>\^X28O5042\>2FOV^+(Z(/X-A$[_T8J+B?X=(Z3V0!_X&[;L
MM_&\#J].D$OJLTU+9DZNDY$5R^C?_'/BOO"]ERY>T#L_2WN'1I1OY!?U2Z*_
M?EM#8(J&TD[RHP[?])WBYEU"/EG2X=E;_(BB.;WJ%X!H<JJ/I&$D2/W*Q>=2
M1O@:9&@,:-,9K(1Q>T-:)A82>\I6]R#>Q]WKHE.QR!-EUU"?]<(.GF%Y]<54
M$AS4""+(.\8C'31(K#"<$:S5]VG[":BI%[Y]8&7O/)$9$AH\LF=M6B8:5ZA\
MZL/!(ZN?5B)9DKAYZW]TZ_#_S03=J NF=XHG%WKK<-^6_(0#F;+Y'2?UGZW7
M?9L7'G=HU\E3G'(<P-#61ZP>7PA7T6GQ:\?7:NW#$C5P!V=I-_L$6OHU\U^B
M&*48SO/^%",N %@:] 4 I56EBS06L.R6VY)\PHD*WPYO/4NO#Y$>H=6(\^?G
M?]W'<&F+#!)(GT@L-%$FF#FA2"7-=J;N!]>L8I4 [T_K0^#]7<EV $M-@3]W
M,#10J<IPMNZ&S9#MPD'P#1V$R0%H*S;Y'$)@]>M+M]=_EE[7W''GRZ[71(\9
MLI9YBZS"J2 _63MWB:].IX@WVJ&5, ^SY7UF!,U&-UD'^@2[$X#>,RN:UK=L
MZ-_$7GMB2:4SFPS01@\%D6B)9+K;9"1F0'OI(/WFV*F6Q^LV$-\+@-O!"O:#
M6.2:05Y0V[=AE9/44J6ITP1U0Q6H%NGN2;W3A^/< [)FDB3B3BX  6E$)3T'
M&L+5A04E-,V@URM83^;#%K)^>==PB_("( @JC&C[ZK0T16)/.[@ ;*W'@=#O
M(3Z0_H?8*5P>Y'FXD.L)BG.=:%VP@D6MGN6JP06\C+$:Q$S(9B98!2D@06*%
MDN'94K_5>0(CP_.GCTE7P,YHEU90NK7=5=,'GTM(UVO53&4,92N'A=JR)V!O
M(!L?BYD(.LA?A*DK^IUZLXKI.<FV0R_6_$5I0F8$$L\8:%X2Y3 &*9JW2G!,
M9,?<.5GY] ) 6V+3\NVL47W41[S#?EM0-XX&P' X0JD&!1$K0:Y35Z+F'!F3
M#!81=HQ&(]UYSQL\*7)F] %"6>A?2PXC 04,++=%MR%T9,4I>L3VN*T9XS0$
M3#'NYVP*3ZK8PZ8Q9#+)7_[+(R+108$32DCU5*KN,[6O5_>!?83RZ#D@X$+D
MIQB3P:,-!!M&O+CU%>%R7='W<V_X5T)-+MHOZ2%6E)SN\6&?");L.46\\[Z^
M&QD'UWQ:N0+?;A0X'U&[)BLKI*0"Q)[U3A#3+@!/6XB9A(=(K:>:'F1AJ^Z)
MK?8D*_#&WM'MV,CEU5W#KMF/]63H9I%77<4_<%?&]HK'><DXCMQL6*A5KIOH
M#9<,I T;W:Z)V*A6JZM,+/L]>=YO-*2>OAOYX3>O7$(SC-4=>]Z:66WK^=*A
M/[S!<?E;XX (69\Y&%)%*?VLP=N#I3.WE* #M."'7D%(KS<^=90T+6R4K[V?
MT_@5A/='/'DW> ,7^H <TAW<S(*']!_8VW-OA&Z###;)<./Y5O0SJV")UP2'
MFE]IR[DDNJX-R*O.^;:W2EV[&'BBSTB$QV'=H').VO)6O$RN0.'[K>A+15YY
MC[Y\-\$;8QL5 J*M>R9!I"L3F"3255#,.>B5]^X*!)D$5=][="R-&FN@F7U1
M(?WR38"3!)@-MXJ_ V;$>4E$$Q30]5Z%5_8-*PO6<8[';AWRKVH=7E/$?:^9
M_<AQYC9\M 0B<4VAKI:!#3!<J2J_\KQLQ1RY22,_ZOSH_=SO[T1EJ+W+_/D'
M'#(1Z6P+9S-*X9XUW]DG&CU,?E:2/067PTFH#&H]W A%&0B](1@X!W]<P34R
M'RS70C?#>($Q^'$KR0UEPV]>Q7]1CF391TWFDSR=_^16 Q1"K 8]Y;X N$,2
M;6G2FHMYVUZ?HF375&T?_X&U?'"\<?_=&'.AX(+%8.@(_2Q'.?YIU+ \:6&!
M=,6&X-[+4SQ0'2*6H26!,GXQFR!_Y^_>SU=/]G+PJV&[3K73.2*%(:B*+BRP
M2-;3;3<WL5=P;[VA& 5$GPR>U\<P)V@+[;<N()HYS]\ _8L>I4NVW^;F'Z7L
M>#&E>==P!V:O?7W%2U =IX&D[::K,?"I\T3<C]>?%VF_53(J%IYHF:XC'$C[
MA#&<?&QXD3VA9HD^'_JO9YUM6,?*3TF0+U[C;KN*]Q,:1O%UO[/3*<:.-E":
MJ%THL4#[ZO[Z)1+;7A3=//B1IF.GG69(Z,Y7A+Q=9O;;7#(SS3RF3#]&<?\-
M#*]93''7#SW+W=JY6U&6N9^63N(F3<!:#F,QP/Z7N6^C;D#<PP*GK)O;Y\BE
M9_-:1^Y4BV%Z1=K3Y,L_7L?-^ <EGMMAR<XBTP17> %XDG,!^+[0,]SNEW(!
M8""O#R1<QX"B(<VPA@M :QTC=*4[#30Z2A,R,=Y5:=+?@#TLOS?F =1.2(T8
M50;G_\M@\JT@&#=B\O$%8$^\)7+1D0,O3/HFA!Z#,)_Z,4#Z_[6V#59.]>=Z
MY[',#0>K[.8'_PS&J<VDP=K>4$2=Z?6 :EN+U&]22C>4_W5,'][\']T-_6\3
M/976N0-%M\'7F4G7AJJ=Y-Z(=)'Z,+)%LOR(,JZ[TEQQT@>,_"3;W&%4X]79
M\G[-HVQ&X*^(0HYL))3-8XT>/5D#W3\#>I3OY30Z.IBNLBI:?(-<<U(@J,0/
MP=AAS]<%<?A!;>7%;NK@+7-E:.4/'>G,8J:]@+0?M"*,?>[ONKBQ37\_4-VD
M>N1Q(OO\H)77>NZ\-1%3? 7LA';JA\4*,<$V)7$)Y\V\DP6" X.=@ZR#B(PR
MP0B3&Z[:5LY_82]U4!GS,V MXD=M(8(%VK<:.<6(RZ&',GH$&5+OU 0SM(:@
M&R7=Q'?O\MWY(AX_/F5K6I#3^EW-YM<CZS<X"'8'QX:$<$C$*UX $A!>^QF&
M/R4*&="WCPH 3:.\@X.9K^-W6SWC4728D*DAH4:G1$V/#2$6AS(:EY#.NK=Y
M,ZYA1Q8\=S*N+NY8.R[S[#/:EFJ[\ER'GJ=EKTT(W9FVOP"D: :4@E71D4=O
MP7HA6'798M[1X!=?#$%99;$_K)2>?Q5SV0*X% !,?.U^& 13!>F*C#,D"HCI
M9KN*"L?\N/IX&;'-:FZ_&$L2#0L:-O\]\^L\SZ'OT[IQQ3[7995425\1P%C^
MZIW>'\F-&1^WW807L^'X$ )UYI#$P!;2*D>)0B++Q7W'SF3]](_S<0!I@1 Q
M_SDH>R;I>[T5UJ![VMP@F&%A/("_"GL0K9?]F%U*7Y=REGM7:?,E#+6,YM/%
MZ(9%'2'U\XD?&VF7/\:%UV7W,/;K/^,^#,6L97E,0JZT9_BY1$QP;*TWJPP?
MT8-!.,JZL'HG-O'RN.K*<;_2?81'1G .\C'_RONR-\KR^KIH&AH1<LXY3Z5I
M\^'ZT&8Z>.:WSQ>#>RCO-;1A&(?V31OU@K>9;XY*CVGVV_#G4K_N4]N!+AMG
M(NQTCKOLS_* ?7Q8-(ZV5\('0#":(:TUANN;24$:#R=!6[OC_RW Q6K<"C(T
MEB3@'J(^E1 <]@(E=7Y(#XR82!/SDX9?9?BH:@%)V+R]_4[*06VH#'G*9-5F
M8*X7?CF&S&XB&.4T9(^3"::G<#A],[(8@7@=Y](:'_[DM:L+_8UG99+)#1+<
MD_HAO2RD[^M,)"W;-;,-,W;$;W)$PO9W&D:I,)33>3<L[6\<K/C[^X=]FBUX
MZ"MW^V=DFE[)![&W#'YBJ0W#KYH4^ $T%F;E87J+J%4TZ]00Y< QV'AFX@+P
MX6=X UP!X7O6^?B;,*0%)OBGU#0(9SF8&2&Z5E4O:HR;WZCS&H@"+AXHC1S^
M@= ;:ZKW;#\PLEC]]-8UUV_T R ENTEP(ZA/J0^7CUW'"6P0'0>,YWN%EU:<
M'(<8,,.MBZQO#"UM&&K3T^FDQ@*N65",7JJVJ)9PY3ICSNY)/WQA::QE.VXQ
MLS&'DA/NF*V,]17IBM-S+TNHW]C?V*CFWU4="BLE_5BGV,(X$40KD8YIQ$^P
M\9. &\U3Q$COXUM',(Y;E6H$*:0A^69SUF])$[UB<V"]>K +%Z)\H9(Z-^70
MQ[MWVG^FEA.Y,)^CVGCOT?BM*]W@P3.H=TG =LCEV@-VZ_BP<>PJ>>_,;*#X
M4VC"RQ>VM8'A%D->#&<>;+O4CO><7]QAIE*X=#,HV?I36#QR_0U8#HTGL>6C
M/#G1N;G\ZX@%\YX?VG9?+#-OU@A\>)HS#-A^1Z&XJE;C*&=^W MWT@M<4\<5
M;J;%]7*G#6I?FR]MG''-X1;.D5S;/!3+CAY,-V!M&OMF=B715/[E):\JJQ\?
M4^.+]*6D48%Z)1U'-(3;WS7!2L4'0#)S% J9YQO"K.+NY=%7-?3*UW\.8RB[
M.2(<3<>>A*&\#1$TW!B$K2/O-6,^C[N\&^G7<);(J3^F7BK[(GSC"9SJU>WK
MQ4#$0).Z%+"/Q(H[&>AE1?_&Y9KC2JMP4W<PNXEE:0-G+V,+Q@5J,[H,!)(A
M-R1?(X,9^E@*GC 0UL:1?JP>14QH;'G];Y7TO7/3?#_Q^=6YCA7V>^4?4M54
M 6BUSUG\#J]K>%]8RU2#'Z#KXS?L(#R>B-76E,T/J*T.8^)#Y:1&/88/-G<:
M&ZC ;RY/<4]Q](/EB5]ZF0C/_KV;T,N&F2@JKWMW/R1(1ZMF(GE;;U<_^@Y
M@M;PJT2EHE201W/AN\!>>",Y>\Z&8 C*S:.O^7Q>4(&PBJG;=IGX!!?KO/#;
M&]EQ2A[<3-NR-"_?#XTBI Y8_>Z^9.3X"I; _47CM[*3SZ(N8RS3$CC7+[L_
MDQ$8%$;3#PC;L OZ&[WR#[#39L-E;D[Q>Y)$9II][MGO1PETXR]7NXG)ZRHU
M=^G*6NA9F&?]=+$O94 YQYCTFW=Z/6E2]P1.PE'4&YQHWS;DT*)-MUJI)XUQ
MUUS.\,80]K5\OY6\*/'X;VI-K]9HP4D?7 CIMY*TX11#L):(5S)+Z/P/W.2E
M6:8"&/P*.,)+4THMF'3&&9P++*4LQ4N2\/%C:R-G1E(Y274>)+$9GV"3ZZ25
MA[.^6ZPK:S9DM2POF)Q:%D<SQXN!\4:M%%.2A'!%9LQ>$)8_N&#W[>/RQ 6>
MPQF)R2NC8K<Z12G[&+XF\V_]2YHN/7M#E4:MX<0M, <FO@]VM<7GH0EZ&.93
M;[^7@UVT-GG.@WQ<SY'':1/0,$#EUP[G[NN#:F"X4*-HC?X\T[2J_2CMENAU
MJS=3[F]=@Z4GN$-,4*QW79(Y]0&=]0'#'I^#Q0Y*CGYI6R^=>0(+9T@B8<ZV
M:"-</]QI]A LO8 *)7[)I<<^9=V-R)T$V//O?J+B?]8^%2O4HM(/2^4=VLG<
M*.:Q^:U>_CDW B1E%VZ42E_R+='%?#53V,6MJGP4J.(3^_QE'0?2J8DIXUP&
MEB9=CBNO!3]H;\:P8]O8O#B/[R!<QCY/>.;CGE!6_WAO&O5 C8,Y">++_+J7
M!O-HC7]!^]J2;LT=TJ/IE;Z  'Y3.FK'QZ7N\Z^I6.Q$>Z6(604%3Z#'SC]#
M&[4F$[^V8\[BZPC, 5M7:^Q^X)[1<\T5/VKV:[[KDT[?G.C\PYZ:BM AP6^=
M_5^O@A6*NW)Q,F_U_E,$?30LFA<4\5YX^O=^WO4E-A\[VOPQXWP R_EX*A8=
MJN")P L 2Y0<3F/S$>)^E,QBW9^KGQ5'/61FVM\FFW]P616F?D!%]7.$YN,H
MLEQO=%E8@Q<X2: D^Q%-7.%&C_4021"CU#,5I]A11#]AM<_CO1&;;IDOHW[]
M-@/LYLAN7:#@56*[]F7<UN#>)E$4>;WP>K58T:. 55VMVL!>?P[Q'*6444U
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M05KV0K6A&TJE]$HU^JL<!O8+M025DO5]1/*ZV^R!S'9G1[Z7\LBTL<)3'0D
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MP>T[T82%PO-\RY'L(2DREBYW"W.KXJQU^.'1D)")=W3\Y@>[]6DF0VY+I^?
M#4AR<7-H3+</_C'TC1Q)(:SF*XGO>QWGA Q!MDUYW7V1>DL?;6IU61[>++E[
M%I4L'W0*^Z^8[)E'$H*6/D[IIHQVW_[P E_AS# GFV=P(,\A@1%9(\0BT\OP
M?=!6(T%G@RON=J.DYD8V8 /94<Q-6BJFZ:8(K[+U6E-J^])#?IA&15,'N?*F
MLI:6'ZP4DYNJF(K5HSN\W32MHB9]CJNZDK+7%K1R$ETLI*?+D@IK*1G'=/I.
M:=(='3!!V#*<#5KVG%Z(#S<\I0_[$%J>,23S;=-,WWW3P/7ATA< MCK95<6]
MID%L+>'4")CY7TH^X("F2D!=V-:F'XK:(W1KU;E_P@W98\4'8?EZ;&]6;G?W
MW6B"M4:T5#P?2S2E0+NJ4IE'VXL_7_Z:5?Z"BJ.=!M,8"*HX-?3.[J"@>OOB
MP6E9TY=9@G&UG5&C9Y )3X;$.Q\9P9\60==OI7UHLBEB([9HT^&VX"PXW;L8
M8NQACV8%[;5CM]0;9;\XU=9NL66$4=@?:BD8+YNLD^LMN0 F8!' 84T'O"N8
M"RV1FM]W?I3VYS=CI!C+.$6J6R*-!)_KAP=#/#15(7P1R)JH&5N/.3%<4!5T
MR,%N<R@/%X=8=I[Q67NQX%KX*A%A)E?28$&I[/PW=2/LVF>+3@LK&-EKS)U=
M 8YW!^%-"3=Q7G()(AA04MV+\&:>CVVPQ+#GLHTF7/FL^I_HLMZ3O VZ*.N!
MUIL2<#,*0LCTH1+H$BYC<9"S=5*T0!_*_J5A4F5(I.:CJJKX;575";.FO#0%
MT_Z?(3VIQXDG9%/>O-A_ 7@=U.>WE<:]]"LW4_)%([WXT.3LUR &J4/V=U'/
MVC=.A@PVIA!)FVZ#QL5,*V%^P\HOAZ82KN<Q:O.Y_Y173+_KFBYF\>'-&^H&
MV6_8"<')D)V?(4+ EH.7A1R8RB2(-_12F!EVFM>Q?*MKW(QI*>RE#^^9&>=9
MG7<>?,49P6#,8P61OGER6Y@AY0>R-Q'7AK\-UL*Q.?L$;T'9EW_1!T("&!)/
MS"3Y6;\,UXE2_(C]>F0MI22"K#T]YDNR^OY?QOT7< 3>EG -]W0KH5L(F<:_
M=VZ6X++<N7 W>T'@![10ZE,J?S3S$4^8\!_AN0BUD\#C_X;ZD,14^H3#CZGN
M+C:?TG7+TK^XNHH*1ZM' ^&@YST1#Q=]M8$IQN9=<WJYJ<%\QN;!&L;;MZN9
MEC(#-!ZX;!I07L](F8V,=28+. :,'ZH/K?*5))4_D <?U* -=G<:R],(DY45
M?=LG7#/.[L/[13B:WB5TZ&4Y/*U;RV\C(HT[Q79M=X#E<6_9>7EI9(FH=X)#
MV4-!Y(:DQ,]1561^I>IR>X]N=MTT3"_,[2V,K ]?KS'/'RCVV"$94UI.#QY,
M\7OY!$C>S;9\-S;*PY)16\G*(<S_#KB,"DZB1UV7L5K#KD7*/Z;^%MHP5D<_
M:.W_3E55RKIP>5BM7"HHT=1H\7+>*I<D]%(N]@^.AOEMZJMUUN;UMK?@3.'H
M#<3A!0":+I391JS#G4&MT:!!*"/XGLE3@M)G@\_P,J?>#^%BYITE]E*BV5:N
M%,/++(?WJZ>H9K/5AAS-W7UE?%/S$ETRQ&YU9ZC#>2]]^^8/$##4SMY,PP>!
M:=*&(.C4XK<O05BRQ)2;&*R8!9V>-HW >PD6R1*@6'M#E8;_OHYSE:8YWA_,
M@ Y-$D.OU6#8S.*M$LVD[L;Q[,:I3%[IGAZ>KJ:)R>$^2H2Y:OL^KCEGSOZ/
M\XG!I2.3(G4W((D$G<U5,IZ$;G=W-<PKCK\;"Z!L-&2OBKQ]+0M;I7T55Z(!
M>:5-CZ%):'%-H8GWALJ=FICN4N:_<,NQL3_?SG$^]%03DB'=:<W58DI$%S.3
M?JQ? ILAR] [Q1@^DT@+0\VRDT]%M (GKSC#11^_S_"_2<!.A.2YP8\HO'CE
MXH*3'"*B/B =#/]$2NT='%Z5Z-9/9Q!K=GXJP_[*#\$-'3/5]YBI%D"2-H];
MOO^1 C(/KRE/:_/C'C[$R"4<S1I/*R[=/[,.!-Y,H1$*UGE.MME58AD JD4Z
M# A;C;-&/_]MV((I3OKX_4CIGA42,6/GL5T\[ILFYL&G:&2J[T(_\G0)Z4QG
MO&G-:G+PLH=#]\YB\SJ[._9E:SK$KWHO-/WM_T+=?T4U]47MOW@0%*1*[T7I
M77H/ M)$I$B1&I5.A(A4(1 Z2"\""@(B"-(%Z1U"1T%Z+PF]20(2MA#"X7O>
MJ__5__>><6[.&#MW>^PD<Z_YS.<S]UIK5QZ)\]-I2W,E5%"3G5OVY3= #ME1
M!I!$>SK NQ1OB65&ME/W>5:IFGBCG)H:V^-TPI7$WC].:7;RV+Y+3!WRZHZ4
M3^FCBF;C=69!AS\BHF-R1_'VMP$US(#N;)LE&CCT,:K5_+Z772C5U'$Y=[?A
MYBI?0J&7N>UQ0,519&>]8$]G4M;)LP#>?HO T0(Z5K:APLR%M<][(QR#"5W^
M/'>D969*YD=']57\J2VA<]<U:+CC;LA4/@6882^P/Q<]QKSHVGC^R&;(%R9+
M+Q.FZ,"<R4B3K:>CF.P%>G,SD#E:5;\$&$"V.+<6_9Q5MO_JP;E<,4;?Z_AN
M2EI^@"B+)R*<:"L]\DO53/B/I<DO;0/]^76=2.X8[X!H;CJ@8TPGYT$F&0S=
MHL\XH__EQ$%OUM/9@?M7;.,=970A8'!A#!<'=GWE2L)5G1PJ5A]^7>A+,X"F
M%9:+R8BH" V.@!X,;N7_R&UNMHOYK]/R5?M-)VV'<( !BCMFT0:;'"L&5RN^
M-??#7K]N<&YT< H^.D=R:/R$"-TVHGG9W'$32->:/O501U-]:F@QTX36I4UL
M"<^H=?OST=Q)>T A\4C4014=._DI8YWIMU!CK=I*W#\#W-)ED2Q-Y"1>><(1
MZ[$=4V\%_Z]-EVHE_C]MNFZ_=Z\''W3'IMEP^\QJ? /RM8%<K,/::F*;$C;F
MV:2J6J6V/U<.*LB&=682XIJQ8I'^&B)6%D&H?SLG[\&7_J5 PESAB__.=8XM
M;(_76>;#;2X_@[GPMVL:6K"S<:_^WFQ6;XK6?EORGOKV,P>+U- _FFO^)?]'
M#Q"L@I2.3Q:?;,POX%3._Y?54W( 0H3W':_R-?J?ZIDYMKE$-HW.I/-.Q.J5
M[5!3WS:FII8QFO^E^[%O3LFNVJ'M2X<LH''A"##W(NH1O50,P)_CL\<SB_J3
M>+D7<NV[H<OW'F6)LLD&O> ?]G0F9X](3YB=]]DSS1!XG[+)S-D3)U3Q[O]1
MTZH+>Q;NT_F.Z_8,7KQ2:WLWL+XH,[WD=473DAH+QYV@.U2P<4/YW-_<^019
M[%8K=F$ =73PR]]+-D2$^9?'^LB'[IMB8BRT @^XL7_+.>("X<,T*]4U8&EK
MC1(\);:]LD[_9AT79WN<4*%=65S#Z(VP.9"4A4]GI#WK>(C(?CZMN!B\DWY?
MGNG<=WF Q14MIL'AXGTC;D UUF'-(?>(,<!OL8_ ,OU7="!3U/#)*%0X[P9)
M7-I='1$]'@ZI?HUSR\=[_4]4RX:@)WNN&[D5<,/R (5'V+,(Q$M#9INZI(O'
MF8H"V3-.RQP=%IEI9=]WS&HI([I92>^U0W$]C1.GXC9KLS%P4PO)F.R2N+35
M9XE#>@*I'AM0E;>O'QPO.-E&# S+3+0S3>*",(>?N"GN&2P;5R,_X"L%?6JV
MO'"P'XBBD*,M%:5_\MZ'?;X$-0QI3(=0P),K$-)>9.+S3)W*QKS:UR[%5QSA
M9#SE-X@HB^X\X(FPV)=P[8B[ L4[;$VS$L 8R0BYH^CSDAB\T5>WDNX1YWTO
M#R\V71B,O%1E]G/R<_8("?(4,IZ$V;X.FJ0);H#?KM>/3G9&5'RXFS=!1D>N
M>$'OE)?Q<.8*]!T6OMD4O6J-S>J59 #L22WC>ZRWWSGFZQN6"'7H&?>9)1&]
M5/.VJXPYZ$2I*:QQ=))Y',D]PTOQ#A+>C-QI,3S3V8AZP=1%_(GHQQ_L;/:W
MJ2C9M/3 8CE^KG8CHVG9($E:5X5 BVN]VLH-?H6;E3].**I1SO#E_1VNNPYA
MG<._GB60X&6PL.[HIF!==$@,@C2FC76;=FO/PO\C6_#  _8A0]3@VEL0?3K$
MH^S0N/ S2Q6W+2")4J>%6V#.>FTNY9RQ%A%N<AD9,P%FZ:W4FQHIDB79EX.\
MY.:\[*7EU5.Q=8U@G\L2,.<*G/4RSJ>3).#-\8H*I-'M/*2QS-UTA(-N0*WK
MPNS,5/>B+\D*<I90HL+W(KL=M@99\(+SY+'%/+C,,XI6#2/?U9PTDX\6<X!E
M)7[U.H28 O'(%I=X'Y5#=JN:B*<3U06N$J_^&*N^Z4?>?,;V;_D*]!Q!6DLE
M&W""-@74=#-5.52?2N+T8EB.56M;\6U^J_F!*[FN30M!*Q>V7_D]C&2Q%AEH
MR1C(]\/B1+0=0K,9<[!RK[%VZI2;U-[0RPGZ>0Q>+F;R:$W1C/KWNIBF5Q/N
M@A[908GICU^[\"#6'J\;@5'^8[\W>?C<J+;NL7K+K1E*:OUMI:%?3-PT>+GB
M@'N2I#8[?L(HUTIP3XN!)MM2=P*#R!L6VEFE47TE@38!]3F%'GGU'6O=Y!!^
M5S#C$#?FW6Z'2*::Y N^NA KTXLG;_^='!GO:7YQ?[+0>/DV;L\FMS-.51(E
M>8LP"@9/M-%#7SA]1GYUW[!Q2[L5+ASWV%D;E/(AY;O0?8;P^U)QF*-89AUN
M0/ *U .%MI96J$I]LP;<!WK]7P^.?ZAKAD<U\7?QFX4SY.OP=HCNMDNNG47!
M53!5B)ALID\M--%\WW.>V 31Q^AMZ%@^_]7T([<WTZ,W/3V[YC->\K>/452+
M/W+78[0&U:HFHL:"++V9LF13I"EF$$6N;S(*8MVY*32=X+MJ$Y[VL!QSTKW=
ME8^)JX[YFPP\9%L=)@S;/.O[&)N4 UI,\,[O[R"?K@LR8B8,!!I%$2;!A6L1
M6%,U>JT\*]:?+;J+/[TBTY6<0(-E\SN?B?N";R#6\@FWCT<_J$*QK*HL-ODW
MJ]]ML"DE?/H KVS%!<'&V@-GXPFW B!]*U28U:A(&==LP9AZ=G&=GEG]>;I"
MZZ: 0B0OU4>.4"+PYQ-KS2+A>C>%RFM+*U4J="K3(0^G:02R,,7<MUW3YH$0
M0^FMB0M]G3HKL6MKH1WP)9,H]'=NZZ.D ;6:9YVW0P3=%5;IZ]5O B?="[!H
M,-] T4#(0E*RR)+5'DY?,&M+2]@\P]SQI6JICN5KGD^S7E@'%#@#&X&4VCDO
M+JC8O441U5H_Y<.I8R#::C5UIY:WH)M'YG5WC%+_ ]Y<0.Y" ?!?ZR@MV[=8
MZ(QMLT)[/.%K;,&2QIT*='8$&*>EDM[5_"SXV>03Y?:-&M/D'^Y&D/U2!=N6
M3R6'8X$>(3=&&)=[9^S9VF9\1M3O+#_X6<V4Q3\%??VFZ YY2@GGAZ33_06C
M,+B@VUI FUS)3J E_IZ1QT;51\XZ#Q<^_D"&_AE3->]/9Y4>WEJ3>,/"E5WE
M^O=L21^#*&R6%NQTN(0+7T1;/.TF8?LW?9UV,)(H98_&!,*].4"NPP)CUQDG
MP*:E$]CKP-.!W-UR68D=E@Y/R*WHEH/*#!%N[H+9?ZL[(18*#3'P<H5H<5_$
M'61)BYXCA-]GIXN\-W=8^=;0(&@[^UP09P[HHQ QB!\#D76YHCH_HL6?ZC:V
M3LWU<U879S.ZL3GS2N9N/,<PDX- Y/5K1_.([CPBP'N]FGA'\QR)7)'(W+,I
M#UBY[W&SKZ5K"';1)E+&L]AVG7T"[8(]!.Y&3%:T3R+UK\VTR<<_HH>9/T7P
M\KG2&MP!"9++A((S?,N%B[^<^>-)A2$.J/)<C4K$6MZ"7.[RSQE[1AB#?'KE
MF.?/2H]"A,<(0QEYBB99S\  )DW9<J'EO[!"_W_"6OP_815K)W> "G,UCP;-
MZ(:#*0!8-S<5/X8-*="(FE_!ED18TO[:%O\Y82BB2%9FZ5,!&GCL(IA]+'@9
MUD;'L-NP(@/$.ZS-_+/I]B,(?7"C8MVG30B_H"GYF!_XII0\RW#1@G %FO)\
MI"TYQS6@,?%7/3X3S-1T81DC#@\*AI4,\DD+A8D?9C ^2W]O+%\ZMFQBEW]8
MB38,0G+_\(^K@JM<VS?$:X\*;N./\[SUT4&QJ$P+WW^IFBI.,2+2NO=:)2-6
MB?&2&,DGL[)'MS7$,W/*W0U+Z]-?'5?F?DD23[UI$KE(EY_C[9CV;*N5"J$Q
MV69>L+ISWOY>.2DKF&+1SMI68F<S,8RR0B6<ZF&9]@PNIY)DH[D*7KZ6'W,%
MJEL-;1/V^ PX/+S,KZN\>8\\L^'UM9&/TUUY%7R\;"!OX)CV!-IR^8E LY]/
M#J8#QK2 3RMTAKS&4S#8:,[GND*]FIIL.1G-FSVE>HUO?QIOFDEMDQ)+#^#H
M,?W9/:.+:,D^,KA89VMR3RI0ZSC)&T,($!&)H5U/@(VJS)8&G*QE1JP?Q<AS
MD>1MFTZTB;[R6,]$/FZFO:R:X7@Y8>GD<O\[.8NP!8^#W^W1]')6U[R+W2L0
MJ5>S>'+J%<AANA';V9>H\ 0K4%X&"8#U6,,;(91BOO&0NS"?==64RS;\:GLF
MG]D[!9"%O"5%YN#%5A.$'<[Q&P[]%B!C[-PT7L]-MA+_2^#HT?%Z&N.<0]KJ
ME@[7XUB_6I TJ)N$V&[:P?I+N833)0+R43I+IOEX-0$LX*9>.]9_!8H-3&K8
MDJ0!?CQ,[K60WT?:[F4N>A0WQOJGF0?9TMCF6^^#&0#=IX #)K\?K(I]/9:,
MUR8A\,S:00AJPSW]% _%QWEBQ1S4D%RG.R%@0!V5_"[[+%(N,63@,"N/<4J]
M[N^?!^8Y+XR?.:10SQ(G9\NJ??>#>Z%$(=P!DG:87_A9)IQR7\)"<&_#UX?E
M'-],XI@LB+X/L)($F2NGNDD:X&-^5L"74<E1_GG_[2T5!$ >3AZK:L!0BX;^
MANF>,P9_%]_2<L7\[,DO_98U@$,T9,6J<J*"^2-7B"</*MH,UF\E)LU[LMP6
M]RGF38CA>A47I%,8#MVCH=J1[V#$;&5\L6*ERLQQ8_P$=ELBV+K2^G.\>5TH
M-XH7!C10R>'G5+A4%)2[QMI^3X$MMQ]-H3H)WN(+532I9_ S,QDSO:P]R[=9
MAE^!*HESO =5C;[L7('H$!X&G,1]XS;NRO[1;0+9HU%?5CX'\+=D[JYG[[_X
M9X5^MFX^J.*?R<(K>[0X//" F\C3I;DA$J@5'='#"_*)?,'*:4F_I7CEU>I/
MDM)N)A^PU<Z[+MA%0XZ'Q3Q.MR;\GO2MY%\PE(3\/F(;,_GNS.+ ,#+)0QE-
M\II:^J:W.C7"$4(*T/19= A-G28SP+6P:K'W!BRQ'57G[V<>G!YKD,<B%A:;
M_'@%RN1XFIT7SP(1=N>)^JX77),NV\%I-'4>%SI])_)_EY.\#K,!!\V)#FD@
M!E<$#%0!\C31"M:$K%*MX@+LV&*^<<WW.Z*+E[DOV!W"'_R<9Q&[.'YR,WC1
M7A?KC7/ E/3]"ESL-4)4!ZCWS6"",U0-4)SZ=1<GM]Z\= '%V":C375?BBK+
M,;!O[3UVS-Q.<KL"41,4[. A&)HX51?)[DIFD\:F#.<<I.FJ1ME>9H@5O4V8
M=*KR-Z=TMXN*,BV))Z\1'J7U[)!WF528#D/7@-._*F'H4PPJ=KB#DW3+GUI'
M@IA^@_$N =B-.QN+1-2N1G;0 FD(>HF":F"@[T33(_F=JEUI0P$\)3U?G"7T
M6^>?;X(% BV=,>JW?1#1C7F\4^(2DKYVT%[+ZR1Y.EVOJR_AR<[ND"P45\X!
M/?XB$EHXE?9D944J.VUF>!%AS?PSO?EDX%"<- R!6E'X#DCKO<3<KIUD&C;0
MM/%H7*P\HWLKH''B.6H3<G"2?2Z)6@V#,WZ&*UQK++F;]7,,O,'58ZWA'=O*
M%K/QP\1^/@EJ] #_.[YMN9.C0RF,OS9@="&#-XC0:&HW9+>>\;G4O:#S2ZRH
MX$\W;CC1KHVDC#T\81 ;OJVBN1$Q[7X-"-L1GM4"ALQ]>:H8EY@JOK>>JJ*H
M3MH1:-&P7;R>:H)\W\LGYN1A>:""8V4W)14[@@&6*7,)>RAQO-[52:H.%5=
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MD:M:AAG1P<W@/A2"9A$P0"KKQ#@?#[D56R&=*$8U4M-DR;[&@NBC6+NX'YU
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MW2WW&Z1,[4K1%>@3_!/M=ENQWZ_*.RSY :![(0X8H+C?"6*E]]BN0 EPB*S
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MAX%!K*FOJLF%N],^UCZ&J9=!X^\\=7_Y'01V S/IRMX\S0Y_J'8_32&1[%Z
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MKP$D'A^@FI<?E5U#9$]#YF$,CM6[3$O?<"7BC(M2W3.KTH,Z3)G@N_=H/LS
M:J)$/OKMR-7W0 WW^.&53SOX@K(8?JU'7P& :2QJJ'$:'5PN)LP0!ZZ 1.ZY
M^1;:'<@LO=?S_F8IU\#(S;I:<%OL<"M5KD]Z-MCILN20P'B0IQ?CFT;C&OH8
M>PJ]\\H<!]:\Q35J%*5XTKA,HM!CC2X*)(Y\=L'RRWOY_ _3=5W579!&/QI@
MU9VHKG.5R7N9Z]JUT]U3^#J6?T+R:% H.7WTR?[)9T<2]JBO/#WLEU5P%[V[
M*X1))6G,\>!DC&7E@,*E4]^GF6/EYH]SS1<))G.PG/:H&P\LU!C,]-E =CN
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M%-78Z5_CL+T#<;9N2@2- Z4IT,/%'@XQR/?/-GV71XE=-U(K&N3>^@Q+[E]
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M88OP\Z<4R%*D[#1)[V2@C*69JIX@^LH)<KXPAUP!1O0;6C#+&V(=J&N6?RS
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M]?0[F[2P\&4?@F[8\!7@S\3R%>!Y28/]9DY\O=)MPM0: %>"BB^[ D1S-.O
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M]N'S?U?W_.3K4-F[&&*1[]HB;_DR7/R.RNKW?L*14?D:P0Q0"/DU>UR6A0H
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M'7]8.$JK9OBY2;CEOI%V+G %N$M^.29Z!1B:(O]A;#8"Q_P"$U\!IN5P)5>
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M."!4&^N8ZCU<?MQ6Q<UQ/0G\S:Y*Y27I/C&U#8BOR(MO2;P_:[MV(J-$PYE
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M=^']\P_QUK)E9."(4V26<$YQP<RNK;)8O4-!Y11W*YO5QO4L8W'H,,9F?R*
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M+LC@FH#.(%DV5T*FD<FW-+BV863%:*;G5@B_J9%QT\_-N[$_08YUI\H+H<W
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M/1?3WG6=3!&KNYS8&O$O*PYMLP?KDWU>X;@74#&_$@^BG'"$G"XU!'U<!NU
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MKGZV112%#9"<83]O4L86Z7_C/V9]'3T(#4U'C0;P++%\[2_@?J@RHR6$RR+
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MOG<MM"+$-45DN/G%U5Z^5U^^R#)H: ET^O7:3FW&-Z8/_7X:>UIZV@Q^!(R
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MZ*W1DT4%V8FV&% $@E;^#,"SCF!K-N'J$%"S_3XF[WG_4/49_*F#]J66/6<
M2V<O[=46^B4]ZM3,2'0Y7$,3.RNA+_ K;XO7K%,<%]<RN>XWU=Q/%B)=;2>;
M*0O]]DON\!+/(@_CT6]\U/F6'(6=1OI]-U0MEY4F*J[2:]TP%F"2\6W4U0L9
M(WXB\-D3T;@!^RY-T=2%L, '_J$?I'+9=._EY[8E(B1B$9]17J)-@<=?#T-V
MPI# +IE_J+;V D6:K)K4&>+3SNSB0(A?$!N5;M:Z4E\S)C6=QC8@A+5?7@99
M_E!6F(9*$E/P9P#,,S MBG6(P'>7\+*@D)B(LQ]7UX*\!%?+-PRT_+!A#U1[
M?C^714\[6?8\S#V=N97GDA>?;T32?4MU$;O?J$_-VX]("E5'/FW >*>+5:>Y
M8$]G)@A,.J;]$,$FTOQMA.QY*?;7;=)OAH7''\\]$KKRC;Z'3M?/RA]-1[3
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MSO?'7Q>AXC6C7W;S/EWH?3G@WWO1ZZ/\>Z'7_/M+:'&^KAPAZ,[$ 6WRCS-
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MT%S.NC2#]9I$;19MAC$ 2Y@!LK*&Q&<DW<=G>.U*34W4'9US#&QL>K<!F N
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M'VOO1K1C#WP>>L[A,_HH)LO^C:K2AO^I@K2CG;<%22U2A%2#=#B0,$G?5&4
MWQ[[J^S:?R6N""8%=6 0B<F[R[R,W\F]CFWG6(",3^&I?%#TC_#=Z+'0QH,9
MAM-X$GN#$T9F*X$K5^']8G;B[^3ISX?WXS@. )XH<SPH= YO$^+A?W4EH6RH
M8*DX_ETL_6.AV2PVG,685,NS&1CUQP;?\EMX];?.A0I2/TQVJ#Z_<N9_J[!I
M&_YBC]^$D=N.\0"4E?\++>3-W2I!5$*H$M3SO/T:9,U-3_3]^8J=7$T.53GU
MF<2,DFQS%DLJ>!':'O2\M_G(68YTZ9;-9?Y@!?$53B"*Q#Z(JI6=7V<Q'FEJ
MGN$;<AI\&L)DJ>?D.,+,#&*1]_J E;S,.N%J5W1K>2/KA^WA+(!X&YHY9FKW
M=/4N.L8M=^:)0,K$VO@$^WL?P$65I:RT.< X!9D<E__)RU8%63SU@3<^I]QJ
MJ(#HXYCADW>([H:SMTDN5-Z2:/%S;D2$WL-0P>A>8]>A567,49J%3JA"@+%8
MH77"MW1+"NIJ=;?2-Q< [B@:PKYWP&W2,#=Y +O=<D]T$]AQ(<VESV8C_^+G
MC08EE,C/-E/)]'UQ;)'VO%+FN3M[]-_=V-5G\VUARSAX8R\K="0;V9.496[Q
MN/Y5:#C%&Y=]/7.7DVL$Z]E&3'%TD\F?\  WY(EO?*&N=H?KDRW-+;>;Q&#?
MP_!:(,5'!8D"6Z_'R/)<&YGX;)I/L3?53EE&@T@-,T(INW.*N4$>CC^]<^N3
MW C0YZ4K_:7T=S_\])GH=VARY[OWP, _$]VQ]QIF<F)@UGMR_L'F+2$ZPD1)
MW-6X[PJ[CQ>?049O!1\T2QQFE/%(; PZ<AQ9H_O7&WZ#0V"&IS$![(02+":\
M%'&5*(M32I@75=&IK/@YI!OL2%E1Z3W&EV[YV.Q-,V<G)4M[IF;9BX\EBC;U
M9X =_A7N [KS"7(_U ((,XSP!A]L$3@+($OW:_4RUWUI\;K%*L[TTX]9?"G9
M[V^:XW';]<?@)@3YJB]Y3([=A&)9@3#7K':%!H_DG$\4XW,UXV+-5EU7:'UN
M+3<3W!DI<\>D=R" B>#I65,9G:"C_;31Y])>[Z>:ZGU]>?W$=N9G:VQ"F:5\
M_WD[HD@\H6C^/I$;5](*V<\3<<M9&4WJO\MZ<_[=%(>_ 1AL'' ;1^2Z@^M!
M94S3EU<G?!G1_R3Y2".8?<]*@^[F:1A,W!$+&@=A:YG6=\U7]=;<VG4AFDZ:
M:>/1;LD2O2\H[ ^%C]H.:/ &AXB+\SAS9%BMWAS[>C3-6B(Q\!LK>\<+.GG(
MK<^*E(8M_IQ:0"IADY+.6F/<.>-NMF!XC>]!+$P[-[%%'VC975/)F3#69FOF
MMS.JF'B1*O^ET-.![U8$CM:$P(XG,\1_BYL7E6T&6L<U!S"/V/3M4^<+13PU
M*Q;6Y%@)_OR-D!.6T#$Q^9;O@O&.-WP^*7 ?<XV.QM0V7;3? YHGC@2W0,J&
MZUKC^! !?+<O-=J2T79P60I1FC6_B#SWDV< &CC6R-N3Q(Y\"&4[*/JND[_.
MEE)_TR2_0V.J@T704OC'K4)-JB"^+['5H2IM& >YMA#2S8!>+NGR7[X)B&C1
M4G$9I<-QU(+WDJG7)34Y5*[(XFPT.'0>L:F'L\&6I\-6B#*>,_='.<D#.G_>
MCOIU8VVGAL:CZ?:VA9X>YYCBIW.0?/6'>'#!\5;J])!)>Q=4+[6/*X?'L\%]
MU+WYNLGF%.]A:9%)2TES@59%EQ;O1S:VEUY$T6%-&E;<AB!3D&%<>L9ITKPV
MY6X9*S&W[<UPDHZUQ&9,P,ZU)IR,M;::/Z.JX6!AP/A+9R!Q+])DE]&Z2K?O
M3Q8MZG,M&3VAY(!$R,LSMS96X,=&BJ@7T0WP54^[W=1;TVCUG8NQT!WMJLX9
M)0H#)R<Z#W!'$.[F<W]6B.#8N)ME4.R0R;2Z^V@,L&/\4YB_[_N^4B9*\#2+
M= LZ0XDS*TR8Z_+>5O"?_YB1M7*M\TU,3WO/X=4W;SZUQFIXDZ[)CQ: $3 S
M@K/_0C!N!I4Q,[E*$L*U9IWF?=/TCCC8*0K7>!7X(O>-)F_"J.M.+O1E4>E@
M72G]U"[B'7,W[M9"$_ *3!/;OJ>]J27R,5+6O&1H4C_(M%IO:5IZH/1N>Y)H
MXJ?\F_I?@]TJR"9ACE@HB,-;U@RW2(2*1B&M%"-6IJFTV6^>LM62VNJ5Q/"H
M9F<:0DG;==L4!256[:1!=_^K!U \_Q#^2,?ESDX#!?5U#Z,1I6*).]Z,?@=Q
M!*0S#CP7_1%F+/+. _H*;Z0:D8SB8^=Y^.!+>]<7=T#ZL(AJ8=/TB@OPI^"'
MPEKPR4VB7$U=3$YE14DJ:&IVJJ(R\1+@\,(M/83],55M[L%S@IT;+NC "\?]
M?OM3RW>CU>^'+K)&6_S6*09G@+>U$4"J?7L7PO,6T;%S;7GTOZUARJ7"S%FL
M<X33'F93"":>KVT5.>,[47YEGRR/F-\/?'4&(!\C9,TS=F]E7#1MR9[TSQ3*
M!N0E?!8NHBB\#S0%3\A/>GIQ'"]5YELJ?JG2EXP_,HO^I688.<YIS*G+:O0B
M:$65WY_SQ,K[7IO.4*G%=8@R!S/;N]B9[1=DW1Z _)CU0&6E1K1+88K;\UO9
MD;>.$LZ?#4G^[Q"%^W9= RFEBZL0T?#'F":0^5 O-A=E/^R@EV'#@JY(;$#O
M(13X#CYY$M6Y$UY^,OBD=F4N"$+58B295G!5F3-2!_5(8,>#I95^X0-@I3BZ
M%LB%B535V!?0SHM393#D^Y]-"_ZS<((#M57R;<%"X<4F,SJNL9*X;C;U6WD+
MGZBBI(CF^X= X@T,EG^_X+BW!7Y-P=?F_>4O*3IY-6$_T;'J#W]EG82#G=ZX
M:G)&PH9/>(@B_4IB,.50$/YJY@'$*1$%ZU/9*>L0D-D9/Q;F>''X^]TH[WYH
MX_$=B%)>UCFM!R*[O]H>X)IL/+ U82/+NNDSTF-HK5@:>BMNR2^R>!$NZ*]6
MJVDV_:;!&9-CCGVHJVJ#AQ3Q]8G\"NGFX)_4JAUE<BM^'DW9R:H>W1'.^QMR
M"RPHD2 #?%*3OXG>0!E[UV?W- V6+8?"+#JGFJ3+\Z1EAXTCGT4UD;&1\=K[
M!::<5ZUQUKD*J4D@M+.L5EV;#O(,<&?L<-4L9[$V0!27TT;DAUSR?'9SY]>-
M8JVHN3?M/IVQNE(6UQ\\6UH*VBW!S!U:A.\\P!VEYG+;0!0Z1\8M2+3H,X#4
M H8.]:'6#7^C!7(O,J 7ZQ>I.V_TK6KJ1;D5+\OO0-VB"IZWR>V"4=#0TZ*R
M,P 3\0XN^L_V#^O?]FP%.RK^W^O33:8BJZX4W.>(:Y=/K?//H*WU2J)TX=,K
M^-2.MDBL>0Y@ 5P8H\);3%*TI8!#2-?6RG>4G;_/KNFKV[WF*+H3>-\M[I8-
M(?[JE=640]?.N,:A" M,X<PW.6)/NG !5"TV7%.@IFSXT&;)NBI[+9V]QDC&
M3^0CZZ+>+?\,T#;#;J6L&I'6%">*.1C]6#HMU;M#?S0QH D<BV$U"A#6($('
M[L!D42M*=-H?ERKPW"%B&3?838J6)]MNRDV8!4!]E#X#@UT. FX,HCR2!7&G
MS2.0>(G.?EO9G6CYGITQU=\ZC9VR"4>Z([QRTQ9?NSC%--4RMW],DBAZMZ4R
MDE6N,Z5'X-=;#2N*+CQ*>!_X\*3MEUO<T3O"<TC_J.B6@T!@XPY%>55)1!.?
M9+Y(EK/US?B=;*96Q?P'M=E.Y\9U]_^M7AD?Q'>0*;WLAY#OZ5KZC$U%#'\$
MMF^+_*M%G;[X-#)&I2S?( 0K=I.EHHK+\@)1D)"$DT&8C.B= >P@.KF(_<B3
M2?CQ"H4((7J(JN$X@FTIWL<LS/?<CO1Y_E'S-3L']?0TE<CY>@$4;OC4_FY.
M2\(7<5^<9F0Q0VN?NDME4+1]LJ::&.AK>OCR[1RB)-ZSZEN:"@C7D^?U.G(&
MYOG+(%IOG0"65Z"?Z.:3:L9ULT[@VW.,01D4GZ!["RX+')?G+M1S:QW5'+3B
M/.)LJ\'A-T/DRBY7GG VAP.D;NJ#O?(N<?G3NNBWN/4F9,D-U13M(!GTS)9R
M!S X73,5T  <.GO%;"WI7KFG"V0V3O'W1P[;V==O<MTXR-(33F3/ -3:#8@]
M65L@02KTSRKT<AMV+03_^BLO[ZLOW(<ZOF> \3\!6+LS "R<8+K+M&)IH(^I
MQMSS'U%O="^9DFK1+0G2=RD&CPO._CHM_CAO\UZ,W<%<I)_/J>:9WGO$*16&
M#&X;6AYW\):0>*!S8T+V@PQY\%>>UJ=32E0QK1*KYJNXSR8FA(P)D]?)2CU-
MMF1#;GVC722Q<UM,&9'C=DSE/APOC BE7^_Q,NS#]LJYIJMV8O5Z3H<QSX3#
MA5#%2D^$_EN5BW\E_Z-XTC\J_:9AYKZ:TX\0/4X$")/*N(-4EWS[P\81%D?'
M3S7E3I8=]1ODF@?D&'Z8#YX"F[LQ.Y^LQ&$'I]SCYA"++J=U-L7S6-<,B5&1
M";V/)ARJ\OW87(Y(.=U%1:$?P!O$ YA@[H1<8)2X4YDBV]:QLE@.],4:;_7+
MAI<Q.Q*<&MV  -BJK_@YN[.!L^K,PP/1ES%X^%N8_U=UH9+:@9RA6^&4E/03
M[6M7^$WO]NI+&&"PM_$[^',F^!&[3>1=_A/T/CAI"+@Z$,#M#=+"S03;EC]0
M2W8J'QE9[==3HUB80CPS,;A T(69+32S.H_3-37#Q]* 9X ;D#, %UK<&SPG
MD)/AK05_A[BZ332_@]SG]%QR%'1PT>01/3":)UW++V5:C[.HE-E!;"J? 2ZM
M$MQ.GGH/3+;X(D<R,M;SV53<7'(3)MW8]FBR_>>NRCZEJ)\1&LT:)C+/S;(3
M94]389RHE0"^X 6$3@6.F!2[.EJ$'K]6'5W9!!7S!^4$Q)":JND^* !Q8CWB
M# 0Z+8)'GH[;G2:U@9=&F49CBZ:9<65A:P]&<V&<!'5L[SLXG33B,D%_&.GN
M*$/5RN<XH-&\F#990^^JXQD/  =[9Y'4S$"D&L1OD6GH?\U/RI:5R"M*AI@S
MGP%BLK3. (7KQF4Y6/@1FS3J>*NL9*S%R:^,0<\T]\7_2K 8W UD1],3VNJ!
M-Z);,>\]\_/6=TR0%>$*O'QHTP">LHB77%(1HK]>O 2] 7".@'*^9P^WID4S
M$T GYC!IPL_65EH7!=EY[]3.:EQO&/[E]\FN:86\*S/J/YBX*E?-FWS\G',A
M'6Y>"H;E_9&]TCW7&7QCO1F;84\(%+CU!7H442" =D!!6?*[:G55^<5%!CC5
MK\H8=44RR]H?HR3*WA-%B!E?$Y80K^;&(;5V./#X_7ZC]&^.D^4<4"W0/6X>
MO(G(4,F3?8^FGX WCA-"Y<8OAX3,> 1G"'(Y#@\@1*_KNI+91-!7M:\"K1%O
MO1"4[J?.S4JBP\S-B!LP\(,9[R (JY#1*W7G*SR.(7<]W[U#/+SXX]@BD,1-
ML,&B/TECJ AP'=S6EZLZY<GVGWBYM^\^E96MZI#I>Z8YLR'>?^XZ#33^:41_
MG0'8E1@)7=BVYB7","ZJ1<;1W)9IMB6 SDZA;!29Q:)I*5=?%?$FMQ) LX/:
M:V%(J1PL6L!<^;.]-626)1ZR.K'G"PQ;<!9>;H)LW2D3\5&?4:'^9!2U*$L'
MPYL7_; OAXA&5%1'+M8%?U&1-#73*FH-&BJY=OD-X@;&!AZ"8&7_A4<$EJ9Y
MKMOJ^4E?$ N,"A=XHD%1O@%.-CX#-,C#;;K%7KHBZ :P&:PA\G6&!]Y9G)[O
M?<)COGRYYF,U&8[P>WGR#=Q"-RG)_:>#*._<D^LP97QS4Z<_9':YO]3C/A?L
M$,  \Z!Z'^C= 11QQY1$-^X1:+'6)2>FQZ2R/%.E#-3:[L6!V1D--[ZV2M8Y
M.N4>3;X]<U;<MX]ST[>EN\DTB_O=5\;B2P<W!ZZ\VY_X2G,R"IV;)1"JSP#N
MX&_?U2),E_,5,,["@WI186N\,=:19@'K-.'^_*(^R]G_G8W"!O$U6/$(&!E>
MC@@EJ-M7IV/XJR>]LQHEM1?;YJF-6J\OR#5.M9(S' (N3+]:1]\@C2)HE>Y(
M% 69@F@)Z0([A;52\PI&]O=V#D'"CV1CUH)#"Q^ 2\%D>*DY[B94A!8&ETR0
MU<!?ZLQ@6EL:HX[7(XI(SJMR[-&&?Y3Y(;R>-SEC/KDZ4FPZW<N(++5RZY9Z
MK\J5G7X9MHT7.>CMRQA*;;2@= 1B'8@J7QP"FU2<'S3VQ47?6UL%)8;EWK]0
MTDII^EL=>NZ8ED_3D6*Q+W%$+=[[4:S[?JNW'OEBV5RO^N\.U/4VP.F(4KA9
M#3:+8!CP&\%+ET)@\DF9QO7HP\]"[*E3OU,4E]BX[$ZDB62U!.W<]8";>*?O
M:#Y"ZGS5R&XS6U_'HZ9;\M[*9 X20:4T-,< 1O#$2F:>B,A-V3>9X;?#_A:_
MJ)>!6MD46#1ZC\M?V.OV._7VBDAR_BAS%[C\#:XU@GC&ELK*,+)HLJJ;+5/T
M;M/\<J6L$L/@YYW'?G QD8 JYY "D\9[Z%\+^X5I:5;ZOQH,7#7E+E:E+YMZ
MJGS/GI);1FG)7B6WUV*JG3P'3]YO,!C!"Q@J7OAM8!N;++Z79CD4HY3FQ_7D
M6<8ECD -7EZ>3U?D> =L<]!O825SP(G.0ZSC*>KM&<#6Y.7<-L,CU3K4QWLW
M,J'A%#?XYBY_:%],.'@+KTG+6O6GLQA4T,E5_VY['/DM_Z7X<4T^ZX@M8J53
M0[KW&L%9 ^\9IY14N&H(&4F6:RZ'!%>#:#Z3=N2$X=?-J0O@#0KG,+9IO[^%
MP.[=B^TX' 4-.8M:O58$OW(3?NO_-N\P!B*%)B!/M&$R!%&H""&W)<4?N8-+
MT:G-]#M*E:-*7$WB2Y=Z2^YSJQ;:0*+$1V^^Q L^(@3CF56J<-%-\*N@@UX:
M;TEB0DU=-<5O#!J$K3^)24=LQ;XZH NQ*)YMA =5Z$U[J]>GJ"7 N:_/EJK-
MK\JU=4GG9',1G/Q&\_JM#ZES?OXCB/&OID3<H9A_7E[4AO]S*856;L+=/8N8
MM2:LLBH#6/GE?ZQ:!K]=<WG(_9#41KI3/$ T^;X"9L(A>W*93OQ:ZV&Y N)9
M5UW6RO:'83(G\@0ZDU$TWPHDI^Y]US>[PXM+?N/7"I0-N,BX"D O+=S8\$5V
M?MI9*=^6?\V6JW]T0'=G>=LYSJ>< ;PFS>>^U%6[9E!\V\H=5X75F&^?&'K3
MF83.,_:&Q8%2%M1K WG$OCY:9[\5+$PXR8W8;9.9.PEQ28?V-V7GY;.K8)G^
MN0'IOQ8*T?N^SPR_U(FH%FDD$>S6)Y*)TON;$&0X'Y+S#O]$5V[GHS9W\E9@
M \])[G& 3!K(?#I?VTV$IB=6-D0]2O7V+?J"W").U7L5,&6Z221V^"FL!Y;Z
M25Z#@O8,<)'[NTRPJ:/Q>/+E?VI5^M=R=7NNK5DS@)4P0:LO]_N31LAT;1ZL
M_$+8;_HK"N^:+HIL(]XCRE018076KX!0$Y?D3=)"4P_0^\OGHX4W4^\/&8^2
MS.A"8,KP[+6G,ZM)M'8_'M>0MPF+W>!^,Q>4+C&:+A$H9>XI2$&UC;!C,<C^
M 1TZ+<-A(MUG&>QN7T]D[[K=)U&":1/VRW<'!CL0DII'^G(J[?39V>6&5)W9
MWP!8.N[7 VA>I1"3<;.;E 7JV=/&=V0?1-#49%>44Q^TM__>>H^U)J,XC'&$
M^2\J0J7FQ3>GD5,$S\$F$FN(B:;HPLYOS-"MIWB$!K8#$+W=;G1\P4(!M_O^
M"%)4OZI%+#A!+8 WS;"HD&JH_P^2'$V0^U,UZBY@K4L@ZQE@1O[9U&A84^[J
M&:#<^EVN?0 M?O^']ZZ.33*1O> "30%PS-6SJLV=7;WBV5'_#^\?)Z9#@I@A
MIR4,NM)Q9VJJ_55,;YY5M\[76?N2=:8V5>V2'VK8.2CM_"L'7"?XDW^+Y^![
M.XA>P,Z:P4_\%P[C ]']K2I<+R15:V3O(XH.:EO;Y/Y9_3Y/B,I.^WLO5D9$
M1L>W*>^=A>8'D1%,*>HAFZG@JG!&?M;1BT+U?*='$(F(A;B!:DPHL P_3)1U
MG.N-KG["?7V3(3A:KYC*0U1"HDMA+C@F!/[^]XLM2^\";FZ8+D$5-ZN.%PN>
MN^Z/OP*M_&..EE!;AZRQAQ%6="*W+=W>L[:9@LOQS^T'W\0K+@\[.J%3.-SO
MNGX]TN\[RC(=*22J%LS:)PTDHYRM_3YD*TY_$-R7T0H7^7[\CW[ ?R4757.1
M$G;KD,Q0U$P>\]80]/"'ZDE9L5 B*]MMQKY-CYL)H9;"H&N3(II,&53!(1OT
MG77T>H=)QR09JI'TQ(_?5>XEWP28[MZ0?1SO/TC8(]KF<;T.:.#/Z.[76NFO
MX<T#ZS^/W[_DF5VH<O<?=T6].DV F;S&8CY ;7R<*1^46KP.V7I$IBSX],*>
M@R,PV+O_19VN2!5!?4[1K=5<NK\G-;>;OY3914=Q\N:UYC#L!]'!"MVRM,=?
MV&(D)Y_M7:VE/D#C'1/3YKJXZ<IJP;+'$3.N4MPIX]<B*KD*=&>_06?3*N2O
M3RVAGY\6UE(B9[U3FIH]/6^8KUIV.^;$3E-_-C.._D7!<\UW#\5]->Y[H5O3
MO))C9AROYP-NW;VR+4ZUV<#]*]*S-XQ[WY!,@9+,BLP\;T%E?L]1Q^X=M*AC
M@P'_]KFC<?1;5SC5T5K=^@'=H*.'Q<0"MJYNPN?3:;GQO=\1Q0V\XBIKEV$C
MT/@V=G'G7NLDZ*;7;_]"S19&R2<**W[\TK/W#E:2;,96%*06#' ">?>^=G/]
MCLST\'E.M2/U):B74\+B/C2I(V\])?*W%:6+"U\G798$<*0,+6#<D$O4PGL@
MBS?+@XSKPOE_8PV] &Z]RC-5G;-W.A>2=C5!*23#,X!4JL(\1=I.P.JC&2]G
MG,FY:S+'[[S\7VM _*]#?_].K]O_[ZN2C)TP+4(>%A1$8DLRQX=40#-68](R
M39(:/!49F?,E]BZ6PNSFNX'U 3=&%%3SG_ ,NM<8BRU_^O)23Q/XH17(=N1V
MX$%0]SIY9-\/\R!46,NPURE'H&_@IL=FH5E&-TXJ)-+9;%@LFUU:18HC63K%
MD&!;5!VZZ[CO@VSQU&C0P0;HAE 5SJ*1+LQ<=.##38\KTIA;LFT>5UW5ZW3.
M +0Q\[/'LO"P,P"!FILP.MCYIP?X#W( 9]XPJJ))]/OI#AQWN4M\2<GB#!#2
MCG<^9<<TPXF7H_^6^OF?CZ%K5$+'K=PDF#C:8HFCF&2U>'Y)AVBF,T!_#5']
M#%!O= 9HC?ZG7]!?,Z,+7IX!EAM/%DDO_^^-_@_?:.FT1$'ORBQPXQ#/):1\
ME'W"84,VRKI48Q%T#E4438B(B=]H[L'MPCUQAI:T"8HP44@G;B'/P!E]@;0J
MLYFPR,T-M#X#4!(#<"?*^9#3H.9[71AM/..GG>W2HU A?+N2 WG#Y!<V^V_T
M68L)2B#IR8J.[<.OI8D]R_G]%HH![1CF6NWY:=GF] N$]^T!MPA<&T;VLE=J
M#$DWXBX/1&&'7-59CT?[RMH@\=]U!I- :XNJNR)_&CK1!R;+'B<#IX&=B">I
MIT\06XA%'2?!HJ4FS- 9X,%*+?L9@)O98BM\61V>1_+H]Y8E*8EAIADWP"1V
M!5,@_I:'@9ZJ=UOYO[,PP(@E29][AXIS[P"#"Q]2X<X ;/#VR7/O@ 8FV('<
MV%)YN6(38RON*OIA$<1PSS/ -F87Q7I:4.JHW9S.@[N79@=_G3?NLZOM-9<:
M:5Q:)9-SY:%$CWRK[F;54EWJ?YSSG<0+X\?EMD0JS0RVL#V&Q$YJ+DUVQ\8]
M/"<04:HWXT]IW5^X7&^<SX+XB1QM(:<#:)6Z)=>?>=CNM,'7C]=78&Y9ZZ,5
MOO F)%V#UW%Y)'(U7;9J,+<(+X.MT5%2(9,=;\K@M@U6%XE+AY;B1EMUG-L@
MF,;)35=Y*^3$K'=XZY+);2XY@=@!!9&"EU6TI3#D%W ?B9/ .X>@6CWF3TS^
M:F+2E&4FLY]D:+O%JE6:\Z'K_J7 -H%DV08X]:3=HG2:P*@N.G2S>-Q,^-5D
MKWNVMM"AI0\JH- QZ,?FQNQ$B=_)U$G-S,R.YZA3#?K*W+JJ16IY>N(9@'<)
M14T:YKZ.=/>G,,1?(G%B@EJ4N(9D1$3\):[$Z:1/2"[T='&VU[L-4H1G<&_>
MQ*<XWCMJS< J*RA=BV[-"<[:U%!YB0SM[7#>WF/<LJ X [S:)H?)X KN):68
M?<M'=G_CE'HZ1%4N&%FR=%D_X.'X,DNW%S4.W*#-T1]-![F4JDEJ?,.,C'+[
M#:^!//]5_,/C]<;*;9'MSIH]\*"VN+S95GMN2$NGA%L:VN%H5/\T#\UC/R.1
MLM!4K5@[P?7)O1+ECN%UKU!;N1WSOJ4^^H5S_(NMAKS2,\"$U/R==*$@@T1_
M*@M*>*/;&>#*NY]&K$[CK[CY<@Y?2'+E1T&G]^G&SPT:@@@KG7;UO\B$&1Q@
MF9_8*/KYWE)TY>KH[;&?<DA&@N+<8E '&R,JZ;1 9KH2B"<^ )'VW;3O=C'H
M1UY-'(?MHU'(/=_)3)DH;L9N'X/U4W@3E]4)S[JYX(@[@AO>J(XJK#L ,<Q.
MF$B8*FC$7@.CIGN5Q\!],K^\5;"H4!A%'K1B@BF]&G:\.([&[$R7=]UG$2_]
M<M%O >F^/[>0WW0C+ %BWS&IS3]8W+<G],A@];OF]+DA(J%Y$'-34V5G-X9!
MD_*.K,@&VTG6IJNME;1=TO_[:N!1_1B0S+QM8\EHX,&WQW@8VN@<Z$O7]">A
M\L/>)'33U2AA:UO,DO[>CJ2>K(U]Q$)4)2JD]*D)9/#MFE/F&:"O)>"SYF&D
MSUB'=*R:#+=R?O##\(N9>\]9R'#GKJ7K+K/"]3&<.M(E78&@CD6%^3XY\*I^
M7<KLE*T,=Z9ONR,^7@QH[WWJ._I:"^/M;]>J*[8B[AC]Z]1*N[)O'SI];]5S
M:OP73@,XH:],>JY?PQT1PQ)PQ[L*9+%Y&[3D9NKASV$V8&,Y)I09;O5/ZR$B
MW_L".-:.]T0D,R<?-0D/VMQ1?,B9Y[$=<MP:1*W;C_PE+-E]U35K*&BB]@RP
M22-8>F#>[P8W\U1$;#BTC?E;C6G'^4WF^CD[RW.4,<X2A0DW%D 1H[KI+ -L
M?D:I#A/!33Z&_8A'RWD'K#);^N<?0DXA()'+%7K,/K79.XX78MV;K3@&^\6:
ME#0F:*B.E_Q>$RDA)..\6F8I]A\7XW5C^$,_:X2L@I*=E8!5/',()_1PZS-1
MZ>$^/54&&M?!I!P9NZZ!4A.&#_"0]+H\1!/(?/C'6*:6[\&W9Z-E#N5"@_V+
M'[)C.Q?+)\S%XS=/6TG,1+K5E&64*/_/ZI0)CTGI)WJAE4BNS,+UOC. O=U=
M^X^_<([E-8<+A\Z$*+J!HGSNT@^Q:V[Q>JINK'_7!L.D$*)4OG>349!6W]YD
M&EC_\[P\U*BKZG#AZZ'"4W)'QCW/I),+,*.A L-Y$T>!AC&;C4/F*I<-SSRR
M7=1= @+'W@:DF#9I/N8H+W>:U"==Y"^W6JWSIAB;3Q@<ZS9XGQ8G1R645[#A
M5'91-:?@\+''SBV;MM^W4Z[U:]^2EF3YK1:E/,RI]9-(R_^7"&(>I!>9>GI/
MH&KE<==-8S!%B2OP+O31-I@-;557':07?9EL[2#0^&)<Y?Q#UJ%8T#3ONI%T
MVOWO\;RB?(4B@E7]W2Y?S2%M#F@.7%W0-[I)WO"]JK9"LW?G &1/G>8*^GF:
M+-;\1C,QMJ=Q6O1%!R_/>RJZZ6<#9;5F.)0I#ARRYPC5-U(M_UZ#O=;.-Y']
M6OMZ&V^9R[ ('96SQOC'&/4,^^6G/E@C?;FY=RX[:I4=9*Q60^EU_G[/(4)(
MK7^Y:L>H??<II>4;P)J.G-I&00/+CT_4+^9N]/GK>#Q0+,R8ZP9JX-T]C_V)
MKF:2R+0I<DOTL]O3MQ:H"@*>NJ73BL1GW1:81[UT/P.0J7O-F8&;]=<DFD=L
MNIC2.#0X+B+3%XWNMF7Y&C:G7RL?4F(CP)LAUA\]%\OL[NR_#KDO<%/O>G\<
MV4U6FF0.8M?H5U0%^D) ZPR776JK5XK!KDZ!#]B3Q#WLPN<+<V7TBBR)X25+
M*YAZ%R65<L(TBCW-0:+&14F]UB?W^/0VS6I=@EF(^=W>T5:W&[,PSP=U9\6'
M%O+,)9_&,]:< 2R ]41]?&M0MO8"W0:";J+KM;,=9>*!=OQKVQ#M$LFB=JJ(
M+$Y-EC5H IX\S3%[[9 IT3>>K:[@E8]7^5IG[,6O.):+5WKH*F5.Z/!!!R]P
MO<W<-&:K$&14AT"PU8/@XK ME=N=16\DQYP\RY51W1;ALY1[\,"4Z>5WR\6C
M"LKS']N?SP]E?;CUSDK0]>@Z;?=-?L\2^LJ&>N3/8O-663]1I^WUO,$[.@^B
M$Z\?II*01X>;R_,&!J.)8#;'J?**-W5UOT2+-;)97CD_4K1GV]11U'O\$02Q
M'!PI4^'"^&9;U.C];<(\TIZQKJ^F]4FY@2-0W@"J+VX_S&2,OW-K1TC&N^WX
M## ]]8XH=6&4=.D^<9V\.I)Q(>W;8*&)8]E:6!?WT3GWJS\#O#NE+'1=&S%A
MSW-<,HM[O,CI?T6N\$',8DQ\0C(C@YYQ+,/[S4L# [+3TA<.>NOA@0_$WQ-Y
M<^U3TE.=X:C91Q7TVAXL<>V&K$;](#) 1'IVR@%+_\L(=;8[+JC'D8^^$R\;
M]*M-W]"A^%[V'K[P$2RR;"-[_U[/O<F76BPHE7 MX4MNYF($*!;%L3IHO#:A
M6I#^@L>TC3Z[OXC$_T8*L6QQ@3#8>,A%A;?.SS M/W*PL87]LO+=-R0JDV,T
MH%CQ"4,I[E;,]65"B@!Q'K+WQA76(VYE[SC3E@S^0?I5': D8N(=Y?.M; #&
M:^<R+_IHB4FX@^%Z;!A[4:QAE,36?JLW'78Y#"T(#=+$]20)Y+C_,+>[<+W!
MD8753B#A9PP/1Z+E94_,-06=# )W@RM,%F>=P55&VXPW(R0U_WREGC>ECA";
MF>7A+F[4Y$'L1^]:78"BG5.G3$K 8SMY G[)7'922QHMDX*"?+]W9Y'WPD7T
M _\6<KM],+)K;J;JZ$B3)"N95M1$Q>RE]$Y=$/>57,]"%7;O#! ()SH0$AP9
MYPEF,(EO'1'FWHDNKS_YA;5+7C\#7$!!<0CB#0J-RN'6N'GN"*9<H^NEO2^_
MKH(DJ"JG8!TL-#3[;5C3@>:!J"^C>Z,[4@D:ZIXP1M6 #VNS/[D;HJFI8_SR
MB9JC7,-DG=7/Z[X**H9@1]$BOPI)5P*Z-K_;&XK.1X<K<57_5(4F#)=^+KHZ
MSZC"^99>DP6P.RDCPDB^$7?R^6BX"IF![V8\_-.Z^](8CI3G)8IXKR0YWOW]
MZZ6Q]8DGB8NN%RZD49(%R@<P+LQ>Q[R 1P*O.KY&*[&"&%9=EL]QT>DR#N E
M$:%!023/L[PM:[U!W"-V1&IH6\-V597F*1VV^"LJP[7]PJ+&;R93/>!^E!OS
MI##NZ7^+(9$=&YT#_^YNVU_F*>#@#)+1-^R#>$]]MC=$9D0$X%1VS,\ZI*MA
M]-HWIWYU=2B5N23=IH^6P 98G@&\ SQRL%X6!"UIU&=X6^,AROP,\%Y*Y0SP
M]37F=%??A !2+ZN,\G8G\"9*57&"/_G;'_4C2JS+&/2,4O\R!"[S)_U<?+'\
M-&F_2YI/]8>%T>KNW(*$YIMWH?.7_2]DK>)6E%B+BDJ4.>L2OKQI?/OF1]C%
MZ':JHUD2U>TS@,"L^&FH=._I;<BQ/DMSN5#HV_Y@8HOO<^F&@3,  T8H63PR
M7?Y$CF@ZK."""S7 @S]N;1*[.$%/0S2Q'[L>5P0:4M=O,;CZC<IDDB;1K,/N
MIY ='7K2"(MTLD>W FNFY]"=!<>"3L82=AL"-P6C8. Y"9\&-SPSM1LY ]#+
M:$>3FTU-@[RPXXXWNI*=*"4%B+]IBK[O.8^MB<HWLK4%;RD8WSF6:8T3B+0L
M,E)G*"^2VIK9N?BD\,&KA:CA;<U76TCC'K"^779\0L*^B5/I3GG/\N><B,4(
M \?7R,W\;?3LAZ1YU.2#)6X 8>!0Y]S$<@A):@..9?GRG&9QCL/9ORYVQ0L"
M;"[[[HBHD-@\EYM\6\O\"Y4]O'(A=L<*NZN>B:LUNK*O\K4&;)8?:O1^16*8
M SJ.;3ZFFMJ5G:RP&^!*N5CXKW'?MGS1=7<YL9V5,:#MP'IP!'@C#61<.92+
M9WH'S9B1"+M%PE(5=%;)67UR61,ZJ)+,?<UY.',&L%R5714'QHBQC)[S7"1\
MCF5B=)/]M A/I]*_=S]W<(,7SY?"/S4PR5>T1I-(@A8X?OEJGEJGJI))&C.<
MX<.9HGD'%6@+M>T/OS7V;M+1W/:XM>Q'R5J>6?B@B%6!:@"'VD!D$\!-F*M[
ME663ZZ&XR+WC#]4)RK$D.[V$"7/XQ*EP:D!'C#&!KL&<>U#!V,<1&.R\B*ZH
MJJPPSOK2;N+:=76.G1VM#[IDPZ@P+A,O+V\V"^T".WH<^M_P'(-5#OO DQ)3
M#D:'+*X$](TBZ)5NP60<::@MJ AQFD-B3HYBF>3NE14Q-YSP8_2^;^R!8;,<
M^[/O,0RUX-QU_29@*!^N:9V-ZR95X](M0R-M.)=FQ+MM$S@MQAHJ'OH@.@AU
M:Q0E0X&;8L:I":ARP2>RP:YC"HXBK8I0\$+NQF$6S"NN,?K'C*GQO7??D3OL
ML(!3[VGJ,T#Q)!BHU37Y.J:E]=YI=XK3!%$G=]WI>4#KE\^YFC4GA^:I?&>
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MGUVGJGQP'^FJ&#*K7?OY[4^YGF5A8Q7)P LO32M:4!,UX&BCL@$%NFQ3_M(
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M/&O+./J;L[M8TQ5\>JQ_E1=*M03EV*F&DFK^FCS<?]F:JE<X6/*9)7W/?0[
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M)EZH!*EE4WO&?\G[]6MA:#9?-&QN(.6+34H?EZP\Z^;?F5&""OF*  $W>PW
M6"VO6B(A!$88#C)>"1=_*P:R%HF;/19_':'U=U+N[%-BR>YCX--@ 3QS.=30
M:!*BI(?FJ<B]HT>;QJ;)F,K/+BUR^NXQ.2<):!^TL0P(58$ZX9(QU*$2F)1F
M1;U1OL;+5_P""]'D$<@V_O]_>AUT/Z\!3D"Z7JXXM)A7 1G:^D.-%D]R;,LG
MT@-M0AD$5XR]YU>?1S<VW9\?4*;Q;F!!BQU =W6R7&1WE?:/L=6$TE1,[:_W
M>@5Y>37AJ>(BQ?(-TXFFJPEE#?V'2'5#R1I.+O;W]X&+]=$;8ON-\=> CL@
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M/=VZS8G7W?+6W_%3B<$8:?LBU6KG/=2*H HE'M;+S 6<).BAVS2EH1")N6N
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MSWE8_Q-=S?-C_ J'G3'9RW4E'PLF0ID2'D&9V2H6O(3/!*.#@.-:JW;=Q=>
MW^+]Q+9_,&;L5G (UJ1'8#6K7UE";7)=RE7V3,215$*3I$:F8#<"+PBOII>)
MDDG\E_J>QRJ_[[@2&2[CTM:4"!GF+4]EBJTI<6U0K$/.6SU]DQOF\#6L@U5
MX!<@O^M;(V+L9!E_.>/4!#M?+2K)@QW6?"#$E/.PZFF7):<%<3&C#.]J%1.G
MN:0G7CNT(_T\/QTOKB98 \\&((/-^4A@IS=^'J7R,]-/:MGN;ZV_)X63>&<$
MX&__LS*.V2R")Y8S.BQ4\"^^X0EF3<NHZ<5G2)W"DI]Y$M63/MFO?%Y3<B9V
M">A15CO",[QUJ8W6#WU0!2Z7IY_ZE; 04L<V+O+W_<2,G1 K_TC]>D4%KOAS
M )3Z[W$%F"TT-6B^,-^M$8BA."*Y!@1$\A_2;G<S783,5 A> S*;/R!>P(PX
M@HD0O)E#WWA86#SVF1LN)-YLTU!XQU4?[:Z&=G%(D;GT[D]S8HF$<;;F]V3W
M^P&E&0YTB#X7N-$Y 119!E85+7I1$KN1.-EA=Z^!.#LK+N"0(B7R4O V%_DG
M//"QF[/@9%R6@[N&S04[3ADO4$)@&/-1C<T#33(=]BJN806B:EO"1A):DFEV
M2[?6@,E^'*=*0:?PL*@F[("26I WW_2PG^;<]\B8R+DBT1IM12; '5KYD8"&
M.!4^_@;X$'H_9 DW,YZRY^-.)B0N>Z-DX%;7/M5/Z7ZO$T;UE?P^LGI\+UH!
MI/_D NS^3!/;J^3XH$;X1J'1)>(@1'N3$67F!GI1B$PSG+RPMI]:CU2<1BFF
MZ,#[UZ_\E/,ML.L;I:"SZ%;6XNZK++"(6%^1IV6V*V/UY4/H<^C ;N+T,+2F
M!]D0*W&2H$+4WLO;GM]W?Z,K&ON)HBV0(Q,D$!;\4H4.;)ZIV/OK\9]#ZNKW
MQBY_4RF4Z<CS P>Q=J5.JR&/%SKZ#372;S^*<SFN]LBY@6WWW(G[PZSTLIE'
MP^1G$46E-63ZGP.><[TM4Y (65RZ!JB<+>P%^V+R=3#PR'U0B-2VV#]$J$<]
MLU^'=OQ]/[8-6V-8B\^Y?#04]!-98[>C*)@Q0\M[_'B!VHF'VE*-(ZGB73V"
M>A8$X99@ (\51[VO;7^M0ZI= !02!=ALPD&SP4\F/92<4:?U=?^0OV;#W7Z.
M^DL^")^ENN9O'1+=<%HM@^E('>]W9<<R9X'![<;;3[QR@D"5"/N9_@&56S-$
M67SJ[475SC-D.6XFT#/\=H*^)(>Y\SJ/3\&[ZA^=K!X&^KY97 S8S>A@+U$$
M]V2V\B.S<?=>8JU'I@5JZN5Y?&+38/>7RCUJ9]">RKV<7B[QETL,6<2[5VS3
M2CD6[DYF?@F&U.MA%ZOUX&9\"!H,O^.6G11)L&:LO6AK:]%SAZV7PUR2'E@I
MD.MW\Y0\-[RWJ&"L/SA281\Z6Y=*V&\:MV;:5>:!Z,O)T["CLV)]VL@O&2YI
MKPI3'MOS*V-U\N(K58Q+JD9\9II[VSNN 9&!,W T>T;<\Y;DI05UBF.+.P^3
M!8$!'U<3]^U$T+D":& D0AC,Q8[I8?L2R%_D(NZ^&;YNM?RLD2^J@\-!R+U(
M4WZ%),ST%9YR]>K=9F=V5J(OZT'=H@I[#KCLK\>'S&.1WY;^3P&/>F ]!9R-
M': $W5;BA%)]7;['&]P_!K=V>'0K^H. _J"_81 8DF5_)*G"2;!#8&637"O=
MD)5)Q;O,_G_J&?0?)$ <DVOZ/:Q9+)T I3NT"O=/3T*>'&T<]W!Q*!YU)3=E
M"5''\8*Y?W7\7GUDX'4 +L/8[U5@EKOLV&JR3'Y-(O\L68J7@VC<=H=[RCLR
M$RP([;X&Y$7Z EVJ5%#G[C.O[3BG'Y9N633^8HC\1XI77P7)+!+1IABRQWV!
M9G%W#82E\BH"^(Y.KYX4,8[PD;O7SFZ>!>SYP.[4 >GPL&X_J\SH=^X@Z^=\
MB="/U(F*=XD!\#Q5#\.YEYO]"(JX5;*(PF[G5?8@P0.">>'<-R/_N\]#_\9<
M Y09B%8D4][S^5:8]<,N&,T2>\NBG[LNKDO^@*W?Y%-5/36))O3)IE*\!R-_
M].53:WP:^E6V7PHNI\*M;T$?IX?'=?^8KZ=.Z;/^\4KIE>^-]*;OL]S^YH&G
M1P\+V,K.DLWUCE2YPZA).&*MS@[G35;X&CK:X^)]9"!X=24=.EQ];(\7O>35
M>ON,K'R_;1&X SQ1 C(6]IK+RPX>W!+\'COF^#]N-@MP[A^-RT[JIA%X4HTA
M9G%5H=OO[E 6;9O-TAHS)H>/\'[PKGI![S50"='#C_RG 7\!^?@/S&8Y@<$E
M%*&]E5MO1\E*> LCP^5S-H_?2<8[S)IBYU$T_;WNS%I9.M-_PM A9%<@90&C
M(T*/3OH=LZ=$WM>\=P_M+-&0N:3^_'NMH)\+T-W^._;X6)W]2I]]Q9D;S:8Y
MCW5(W_A+!N>.3'G%7L2S#6U&?P W5H3LGY^9K==GUI\=CV\%^.9Q2Z<5YTP:
M+*L^R@F,WC<EJPE8L<=KN-\<=T-.(56JW$MYU+U+M%,@?P?FFGWWP$$H>/^
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M]F%LJ_'^XQ)?[,=MGSVO8+ZP_]5D&L)/NI5@'&2T'$S>LPBLG?:*C%U/J"U
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M.;HJ>T0D%Z3%DK5KWNT$\F- ^J 6?^^Q<BHM(2320FIZU4&_M..WU$,QPRM
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MSWF'/Q)9,3+R"(+._K%%2ILC.^7(HY$?S)RK% G[&H_(]* ]0^=FF&DP_IV
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MT!4YJ:?.@.;\^Z_ZB/_5\9]MBN;_2U9!@=(?9Y>8@.?FS^=_'>^'P0X$YJX
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MB_6("JAPEHCVOD+L#Q6)<Y-#SQ)G$_FA F^8OQ#(UUM(5[+BG=G?1&V"+B"
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ML$P73.WFQ 1LVTI=1M$?[^"G'/WO:$SNF\UQ4555DKU476]&JRET@%E5[*\
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M"=N-6@^&Z3MSO%1;+ ]N^@I^VU>Q!U-CF&8YJW%\7=+#4)0;IV5%X<DA=?8
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MSA6L\+A<?Y;M/'OE&X?B%4Z2[6-,U)>]/_-C5PY#=[:P?-#K>/)&S$34.1'
MC)M_C5F-L&)[]\;JQ[:'V0E-?'JN#[(9%#*Q0$:XA=-L3BPV%6!Z&3+4Y5//
M%]7GWVN)#/:CPJDOR4>D,R8MP=HO>-?U)V)%$<$-(,X]0F>U>=^HS^Q#'OFY
M04?PYB8 ?S FTD\[@UYKUT'?U*">WW2ZI<ZO6;2>)*[3S?)\NGGI0ZZ$!+KX
M(ND/(>T6$=!B>D($1.LO("R#R^0,E\^UCE40-;PDBT*_<:#1%GF<^CP1@.V1
MZUV$:MZXM Y"OI>2 ]Y;^*UXT:P\=8^PF '\V/0O7_*>"WVZD.$D H(;]XB
MVW!$0#?3R3609<1YX$>YJ__ZY<^Z=GB@D>)8L.WBB4=E#%]UB)#2R]&/\MX3
MB*>$OQ[CF41Q<A@N;3SAT#^_/S683^@G H [I0[S(UZ';7HASWEU5NVI\F,[
M)$17057!82C-+PN !L_"&C/*]0#PN5C&7FI,99_OO:^P8P,+V6K]\1L1K"BE
M:RY$ +T<ZSJ4"7^M&*?0YK%@-R*J0DG[,[4T=7P8\?GK8M F+TD7 H((D4IO
M3Q5J/:,*WT@\HQH;F'^ >/^T@ BP[*A?KJ[DHCL?$:N2UN^7NX%)^D3@]&,?
M\H-BC= ,E_X61 '1%[9MHL$@0MV51NW=UL43PIQI+K:WZ5P?6S=Z>G#P3T"M
M%FAL([#(UNG0<!$SX'1WG@V(KN*+90WHG1]O.('T/,X"T!W)7KN7<L"V VQ]
M:- 4A4%V+I#CW3%==NDSK!Z?ER)^_\:YH,(\;9)5!#^F'SD,6;XBR\ I+.JE
M8B/0H @Y)C_5<:'*01HO2D-C&]/'E>D]30TCC@'N577@_>[ CS1_UB2+A3Z9
ME1-"T4(S9.CWU2@ARO4SLR"\I"MCR"K77#+^UTB_TYWSWX4WJ*4LHP^)@"MX
MI<O-T^MM"V#&O48SX ;/GWBA=9,,L%;!RN<@U5<4_%%W3CG#&;I40N]_Z??_
M?"Z'9QHE7/43&I5Y8"5M9J)DN*4UEL,<=[:O4&<[,_>-\(0"<"AA;F 1I620
M]7EV-HZLL/ OBZ:'A*YPFK)>>@3!2Z2I+."O8P:&(/9CX530R217(B [L:D0
MKLY2*801&AM@]W\6S@L7&7H0#RV,OQC%%QYV(\:Z"1L$W0FT+X>]](7F06E$
M,P*+=2>LE[IYGJ6OF3 %09?06Q?#INU05'E[*Q% R_/ZTH5&^IK_W]YOSZ!W
MKELQZN%?BI;^L$9A:4_RA+'HGZ..6PA,W(;9X:TJ(@ 1V !M+^]T1_L_,TBU
M#/O!X"Y)%C[!]FULBD7W:T5"V7^X^-K=O<U/=J*8W^\QJ3Y33"NO1X_T1Q^D
M*A% +IB0 )IF7"[[<_5I'"1%=78S0D\IE3[5.[?P[[( \(IF%&MXP&!Z)32(
MP&>:7NX%;I\@:6&]F!&[5UY';5E>$R]S3>)1(@_%3]63L])?,MZ+)D"T=;"H
M&:57O&:$SK"HQ LFL9%H%LT[0>,&-,P/EVEN+.MVFU!)LS4' 9YVR5)]6&"6
M8X*W7SKI*9S'@0Z$G7QO9]?=2#?4>\PARV%UK I5QCXN?OMV@=6?N=A%'VD_
MJXL8E ;;.?#5I07.0Y*;N^<ER-T;R6"_Z_7RVD@!0' 6Y [@O;2B% (8L3E*
MG[TOE?(4=GSD\2\F#L&3I9R=KYX][TV;I/317C62I5CQ!^8F/"MXS4SR\9J7
MY\YGK',3,_YNXZA;%-)4'&OJ!J+>P-Q:Z_>4V&\M.(R4V_>QY)7WTN=T/W=2
M7*J$@(+D@3(Z6+!VTDJ0EK_LX0Z'S*&MHS6%KF?'<.RLWEIS^M2,&:PS% UO
MGWLWTW8I"Y:?,\HJ?S\3F;MZ?<"\4F^YEC3DZ[Z+LDPYCZ##/<:JXD/X)P35
M.YPT!MK"<3,L42';=MA(XY[_%'>'E?/V")-31_U/WA*QH8__T^4??^]U'LZB
M0#D'KX1I7U[8S!PS?[]VVXGD#/GX6;U2\]".NW1"Z#O)Z_'Z>B2')^\W*#B"
M=T1/4]$W&)&&XW>,=Z(W+5FV/B[KK^L'^NFE\>)\<[?6/9.W20>N$$2?W88N
MJ$$.2O<M7$7;.N]T;>-_I*F*KBV.OE3]-KH9\-7+9<X>+YW3S.&A;$TAZ+.H
M5(E9VV$J4"[T>X\%M_>T\SUYZ1H76R!?XI^  M$H0##5RA.[Y"IW1SAK8VJ[
M6]K(N_'@@S6#\?M(4<B.DLL+9'S#7KK>.VC)2T:AM!>Z$\6%EQJ8Y_B/V,W_
M:4C:]HZD5*QL& J$/T>T:IJ.#:+RX7;C]EKW56E%XN[=2_2X<XV]NV!+J4-S
M>T:RDO%\X[S>>>LN.W21,[VG8G4EJK/,K"T)S*:0US*363%PS,ZA<P)#C6**
M[815N7[$=XOH,YXE_R-B3)F KYG#IF:D',V!%Q_^E:/O0-UJ%'YSRT'A1=DE
MN;\J8;2C-S*P=_>56O MCH_+[QMB/OX)% :7.T6:"ML<MA-F8U_^V.*BY;_%
M_SF.DT(DFLXMU^(^?9=! 1?E^RPU310=0B%_!&$=T6C^MC:H?9IBPS/=0D/Z
M58+C:Z><VC0#SBBZGOD<5<I/$1\!;.7AF85^P)KA"=_Z0;KU81N/LM[C?A,]
M%#K09HUQ[WHSQPGTX4>*0FWAJ3_%\D"OW@ZF_DP;5J5LD2B(+.+8(6/_*U>L
M.M<OU+<K"7%OF!UEC7Y@P IZ6'T8 ;2%E!(KDIZV>U2QY9HWU^SD%CG:];OG
MM]+KX>[8UU4Q:K^8 1/0AL92S4;_ 5@+M!SO@EMZ/B*CA?8'JU6.5;[^57FK
MH?@LTMS"(X[I5H*B58ILGD;M^TO?_'N!Q,U;YOK)1-6>*QH2D1@RH\$:^4E;
M=#2K#EC?-;W;875ZDQ?DR1-OS!V/S493AQ:9F!C:G8"FH7;^BBMI+2RKU<E?
MP;TL<6(/XS)UMZ<?TGO07Q@9X(+RO)1:M1O&[L.>-]T\]F9 ]Y([1))\%!=\
M6SFU3>,I*;RD??;KI/Y[$^=%$EX+!5E'(YI&T>5?9JD47L7R1(-!=\7[^E@?
M[F?<!K<5,T=2K#;Q>3&I860"@%(O2SBJ&>&9G86]OE><'BS;YKVX5U=TYZKH
M-0-+&KOB!289([E"2$&J%NW^W')\7TC/O+QDJH?*Z+5(\EXXU>KU6?(!US=-
M#[$3M4M;O> 2#YQIKY5=HMC/&&72#T]R$L)H15^_OO8=0'WD_%JP]MOXV3<1
M+47[5W^QM1_'+**[<K=Q9+E>>0,3"\JUXY4:=D2 XKEBP0-Z/7B!R#'F],KO
M-WZ%W.ZQ7 #4Z^96"LS2(,.L,=X9VS=0KHI6#XX3B62QB.9ZO[^L2E+V^EJZ
MFU:B1Z]8.Z4*<_%JSDY/M^>Z!_#\ :[Z7-4\!#V/;G?(KTL[<G#4;2F3ZE">
MZGMGS3]RYUF!@F.7!!G#^XOO[B9BEM7C?AJ9MOJ>AIW'W-^='J7.$UQONX %
MNP83@S5HN#5RU<T_-A<*E1 $;#W-IIE2C!EOI0K;I'#F&PAD&W8@[-SBKFD*
M?0 U4&PA:C;>R&,:9,R=4.=44IWN4;VF\W;:IKE?%==J:F_D&9 EG(?<^*Z@
M&.B:]A#,L,,Q\B+=M[;1^5QTDXHZAFO"38/I%4*WJGK4T3$O!5($+[\9"B@V
MLKC"\I3?H_".HV2_2UU2\WD43\O9?*$KFIU=5("1[<T1U0V1O,U;'WK*>!W2
M=.3[<K_*Z4O(!+UQP-[L8(K*[G%GZ_ZNH1^J&=]%M>+XR=Q*ISI^12EBX"63
MK ND IO><4F.;OD)56-R2[]&<.0?&Q5M?7)EG^LV4GST/.KW_=@GDO)-WFQL
M3^ZXP^>Y*T$-MAOIY6^PXI\:9+TS34SFO=+U*W[71?>O5CUTK*FU"?9EB!S^
MF74:HG]%FEIM#=@&*F^"H_SF-GT&4BTR.AWNMW? 7:G:U*FG2)]24C%_*Z\7
M[+M+22[Y1Z(\?RN=<6E"2 :<U[MB%\ 1 O:-MV;X2MM,2LL;Q577DA1EG$$Q
M\)3K P1L@.5I@U&:V27Y1(6-,K9(5$!P1HJ5ZA+CDX.4VBWW]HV<J>X]TOEA
MI:F6L".$O0N937]]D7;4*-Z6:"ABV!1?H.H+9?_<V%[4\R[>/\OD--N%Y)<B
MGW5DH(]>:>ZY='>!$<ZAX7&QX2;M[$:=^T1I>5CV.=ET=J+YA_-L@%&Q\X\8
M55)H!5AXJ].,T7I,QI;_A#4RJ4SH.+H1;/C<M$\&XK3F.$6 U4G2RG16\_6
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M&9,;NOEZ(PF'$/5\^B.-H[BJT'@=-CY1*Q8%10<=I-%A=?RF?^W04CZAEPA
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M?O^+N^^*:NI[MPTBH-*D]R)5J2*]BT@3(=)+*"K2A4@/$(B*]"8@(" @74I
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M[L7W+!)?E8=8W\PE6^JY;<N213;REQ1%P/$]\8(7P(6#[UJ?/TQ\;B#F6Z)
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MLBB<((;<:,(<*FG8HTI!]A_>Q.^ZNMV #W"2#<0 [OVDDALR#T>3A;JWR>'
MZ$TL5$;!-]G-D:^-74+O,C<6[/ZY]M-]ID&G-T+O+KIV?.<>W5)5[,Q?M+98
MF.^V]Q MB%NL_9L@$;?HY68K41DZ^$YR FM=DTTF+0S^Z'L%H!6S65-6.#1(
M!=9\%"9+X!J\W:0C,'?317?7ALWK ;MQT[NHVM-QC.V*F'&\/JXTQSE+"&/;
MT2@&];)#.=1CNIXC A+_,OX5;&]\I5R1$L-!,+R#AW_1]T?7]P(C%EAPQP7;
MIJ:6M14A*[9T5JX2O>7A41R6#UZ&T2C!:>5 R0^K&7B9TW[JD*EHH8&W(<B^
M10U60FR%&G'N]*:=06V:F;,BXI8?M9D(#:Q-7[[,S;6[J2)L+4S4]GG+6$$:
M14)_$/&3OSE1C$3O?\V526X5C7USAG-<Q&KX*1^B4_MBR:UP&B40QV>(@@EW
M5/-(66&B<2)OA;J]ZR,=+VZE,WNDM(E7LTL.-R>9&@K,!A$ (Q/%HZ>X:$5K
MW*A66L?-=4@Z)[X[UC^\#,U[.KOZ0-$O3/@GE60O=-Y_"4SKW,85;]-\/8%=
M<[5ID@S3_SZM?_E/X@@OLWN_TDE!?$>P0(9AZ_@R9J_L]$3%H*D6](#BLW^H
MJ>AVO7!+$\GP@HC$M[&3%]4Z5P!+\F3.*8PKVC84*EF(YXDWFD17I6JH"!!&
M_^CKU2/A7:"D4/F%.8]O?KU&\3T+[%CQ. (GY)1 !X+=Z43-4LJP9?+E]Q%^
M[R2K\Z<+T2<XW+?67R4J",)U"OXZC@]O$\*<?)%6-NNV[$LK3#&^L%Z-J=1H
M2*1GM ?0JO67/WAS'6L-X+*=?$Q?-<?J3J*ZFSN"-E+0&]"4NSO(<-.10W)(
MU9%\7G4;-@']<:S* ;4<Q0.+\ *)?>L7CY2%;29]7%N%:%%2E2H_!..9F?DT
M1LKUF3@GLPNANM?<*?0*X!)KUN?!V(B9W0[X-&)MWG_Q*S=[2'OOM6;_,-=7
M?H/.@;BPEMTV+ER!D@;G^P6VR;!FOF 7Y\(!8,VCEYEHY4;A]_H><0^*.H+Y
M0<K/L'CEDG[[@C\O)\0L!PPX,CX2BQ2!?ZG9_U**B;<LN,7O>HI_,F@W*J6X
M2X:"?83:%:A&U^PS#J-U=MR6ZL<0#E'2'S<=90_3:'Q_,5C0D*Y=[J1UL*]#
MS;%_HW\$CRWP8N.^_MP^)\<E7>C3"YDJ3IN:!.4_O$E*S!YW'%H*%4: ^ED7
MPZ&2=J60LDUWAK6ZT3WN5.?9L$0R:ZSG=/?A&4(E?LF6%O?1]:MW.]46,J:N
MZHSIMJL]7]CMA_UV[]N%7[$O+>]E/^-E7DR_ B"R5VZ+#G^'<J#%R3:N .Q*
MSEC&;71LP[C/(*75+*C&C,RP*7#0^0G(FCO>14@R5+3QRQ>]%O:8(,$>3D:L
M8P\LE""7VH]H(Z_!7&8ENP;921EES"N7)=,0!A)R+!BM"Q^KB[%JS<G]QN@9
MZ;:.'+-EJAI49P/;ZV!B@: ?2/G78$U30,@QG!$#C)CJAF$^9Q(;LU+)PER"
MXH#7X#MW]G4V=LY1;IA!94!Q<?"[9_GZ""<7;A<EJMACH](ZV8Y^<RX>4=%B
ML>1(PQCG.I.6=Y#-NQJ31-+/[>4>F([R$05JXHJN)T$'HYF-= VF#XZJ]"'-
MX2RO1FNF;^F&!+F/EOHG9LY:Z",&!*BHV??CVNZZJ%+CR9;::5V GG!TM&EK
M?;V,6(+&W<2G+\89N[6AK1<W+A%&Z?!"O&AFB[@]6M3/>JQ%N&"+)"SS,M\A
M$7UF$M62T$WA3K#\*;SV\(XV-UV(SA/R!>#Y++YKT#O@"K![&^O5;2,Q$OQ@
M9B.8+\F,=3_Z"*XY]YL]H?6R3,&UY^#7K7[:Y('*OWN:'NG%:& $)QTV^],Q
MC%P+S2R5L6NDAIDA3#7&&8"E>V-+M3SL/;<*)ACM[V$&+!F&7RN!>K/(L[N0
M!9GYK%EI:+G]/(NW>S6*V35\J*\EY7-DL:<4_NXEW7$/-;Q59' LZ/CP=D:1
M8([M!!!R^S1QII=.I/F[JO-]7K<E;XH+$/''&/E>FJ);^4F$Y$^Y*>%>F*E>
M3DZ<9]-BN".V+;NDK1Y5/_ZZO6%\M7G,.SK$A_T*X-@3Y==]/R;<.X;$8:.#
MUM>;*_I<-;1<BI+<$*N9*9TT[8(!^J#T:+BK1HI:Z^_RC53EZD@N4<O> 5 >
MV'^07K6YCU/W0EURV4[L^%P*]I@2N-KT%,VLE8!L,P-[HWW/AEC!FMX^<VF=
M[,L\#=%L;)F&)^2*PLX5XF+L6I2M34R)6H)$)EI\2=-&)^^2Y_L'LHI^IBDI
M+\%F!OML&( <SNDGC:6NZ?:[;4EY\.[9_(?^6X<LG-+6ZP&K'I]S/(%J'TH@
M?5W@&3\]C+=EI$()KFK;N&'\\4L*@3$Y]!=L#7[A)?O*F_,I10],?5]**L+4
M"Z=N';9WX5_[44_!WK_NOB/RSLKN3;J-6W ]IJ7%".G]V]M(.#QS+CTKOA2T
M<>BD8\]KG<:GDQGYXE&S4@K%K6'E2A,G.&@;-B*E;(;NCV]Y@'W&Q8H+U,>*
M9B6=M-KJ(^#';*O)(L<:\?IQ2&W^EZ')RY\5<^R1NCJ_Y :EJ:-5."MQ7NCX
M.Y:X3PN+ECC&\>X7+J/Y$=+.83]2'VG0<,LFT6OD&5[XB3B^O\6PW&3;S1'X
M(J/7]Y01GF\#<=1)LFBOF4A 9?S6C'U78J88_^V3(R#FVR28'<)ZBMJ/+L2<
ME'JXGOPP7- 1#$W+-4GG2];7)@O][!CW?5GZSC>IJ$!8!VW4]$YM!9>3!%01
MY_JFR30);:WU?+P"#G8[YF_D>C,/$ZF\+_&;TS/^\Z,.XNFU)B 9WFG$&Q;B
M5V7-*]@3=(<<3M<M$O5,ZU6P[O.+N'=NAW+/OUT!"OSZM+)P&2@Q.&H_PE(K
M)*>I&N'#8:-X^ZU#I1A/&IB&E?HXJDPNP>NSQ) ];K:KSN;NI,#X;HM> 2X.
MO>#O5@ZK6FXPCEQV*UI+X:.X34;B-;YI,GB;K\VN*H!S$1MXK3;"?;(_!#"%
M2UG;@\'_[,P M75VX7^:YN9]9FB<Q$UJ\N7[]L2*]]!;'+#/Y@X8&0.U;L0E
MN>5O^+F)+IL/4G9.Y#J+(N^]Q.:ZT3RX=XW-JR48(,-A2NB2*ATD#YAUH?F/
MWK( 55JXB[S-3Y=ZV1PA\CWFPV^.4(M*G.VRLJ%_3C4FI=%'A$ZZI9@J4Y)Y
M]45!WEMQ"N)"X\-#:LML^YO?P)<2GO"X/'1%E)(J.JV-J9_C*%7&TC'4>U[2
M1,:#<'*;-Q$H3R]'E&E2I?HI4;["$%,4!Z5$*1MU2FQS2M9BGV:Q30FVC-0V
M[!8>EDGEUR8OU36(O-]SK> NLY6+B7S8"<K.](;=VE[@F123&A)_.N'#H3DG
MD36&F%Q)X8;7UO]@L9(A&@X6MNW/I@*W<6ZJ,#9/\+WR*#?7#7B;_R$W9:3?
M@X_T 3&,\;7@]^VHXB=B(PT[=<HE7%$JS%B!#,R44?I%5Y,ZQ.A9V#QZ$E[[
M0)I<<=IJX&"V%RRD)9LI[)]1E4_;V;8A(!P?E<6.*UA2)9_>!B[M\JSU&TZ(
M^T1;NU"JT?UM:G!.WYL4?4-^;Z9.5?3G4M]W&6I."SB4?=([GMYB4]M=6EAS
MO&;(\-3PY\^4-S_##NZO&/&4ZPBON>TVQ%#5(EQMJT7[4I<N03V?(8G"&<)L
MPA?'84$RKA8%NJ"-G8$:=S_-/_;4M6%FSF3IPRGI=6V?D,I_QWN18_CG.#JT
MFYTAUB8MUP;7W*^G]!I]&RY2>^OMVS&E!DX[7BX5^1MM.YDS\L223JKT+;=?
MH>:9NND@'Q6_2M6/2"G&/G'B-R_?04\4M;=D22/--=B8T2^F'=AW63K.EG5'
M\09H.*NYU"P'R'S,._:4FJ',4(\D"YOJ2<_PI$LIJ>])H(E\BV39[,(6H^>F
M[*B-\TA&]*Q?G0=_C;K[FP2/+P:-P78?#JD-3';LW$W[!^)?7^-<SRRED16N
MM6Q+<JC<A2 V*9);,Y9IL3J1XV8@QL?"RT+3$T%,0_A)--9*]Z0J7@>WBP6C
MS? " )7, E?94B?$*8U-QW@/IML9DL@3(2-5S#DTU/B9A'D%NOL=+]T^I<3_
MPU7%IH"^9$0@U8TQP4,J($.I4."V0FQ"\JOXC'W9 7F&::@-!M9SR84F.>T6
M-3+$"D87C%O8+$Q$1])"1DEG$@7X=E\\"Y/OHY9^] GD 3P?T1.-YXSU[<L;
M>9UI?1V3*G=PX=8A?<[*!0O))3A7_? 7;@); VI>WOQ9<@8T[VX)#E%0W>(V
MXRAW4L@.\Q$</XY5V'_6KF'F"IJV?'#CYT!F&5$G>\A"TY<DW^=CJZSW<_\C
M/^7FQ\*TE@R/NQ?#AZKC/PN?D.X.G1J_N2:'ZKQI[-4^@M)O7QMH,-SXMX5#
M1]0?LH3&6@27HXNE2_->%6T%B!7D2>^GC(E6S\TJZ0B7K$8)/YROH8OY3"5A
M-1P.I4.+,Q5T;UB2%L'Y&V\XC._R?=74YB,5HKH-6 HTEB'03XGEC!>$:$X(
MQ!LTN@H+QDU.6\T](,J))U[[S,AB\.L7.M<TT>,ML'+_6C#C@U# T'2_4+QB
M$-J54F.Y<4H:M*L.M+!!S!2-V?Q= /02)<R<\8DQ><8<\ZIV9-.WJ*+:;^%,
M^1%7@.IC7>KP+.[1_(=ET7RR]4R22C2D!J>95AP=2^XK40>ZXJ$V,A,YSG E
MK@KK)]^3^!3>_FF@&'CWY#!,B\OXU30"'*YTKP+2M1881*8Q(5V\9'VH]<KE
M4,I%?\3\OMQZ7"!"[!O'+ S1OJ8EY)@_9P4)1*N&M+'.7@&Z[(IP8LM=*7J%
M"Y9;#QX*!8_R70'<:@\2/L6ANJKP9:S2*Q]O[07+X'4PX#[*P/X /IO[(',^
M[(WM<^H(<=&5"^D+Z6\O]!C^,D&?0POL/?-)YXH (38,3-U 9F P0@)G9!4X
M^30!GJK_]=>/'1/F\KGW%N8W('PTR&(]%&4 -8T6ZDQ*3T-ZD\5 JJ[6P[,W
M;/6&DKL\>PS5M_$3C];]>KS<F9E7]0B!$\?#8=>-@42C-5,0I[+;EX5->K4]
MH[/F/QP26@ZBTS*<-&*-#[GYPR@#;F;7,,9B0<;8X7"\3MXFYUW,5)3;U$[]
MB.A@78:'PR?GT \)$T*Y9Y2KN?BJRI,*840P[;8-&X:R/](G0DPJ[16"=XPJ
M-= %^]QOM@9M5:=B)281=S;T=)$2O%\C3K6P8>!BP]TZR9V.#F33XUP*^J+U
MJ/?@]\?JCW^^5[TK^)BE1R61 K\"@,)B3BEMEPMCT> PWRPB($W_=^7V3U(K
M55-PMY9ZIL^SR4UC>P7&AZPL[P#<R1: K;+I@_BP-N71M\%"4.6)?2D]WF[6
MX*1R"^L%6_/HQ#Z^9/*:#ZM)[XE4>4+PI6%3+8JE$- +&86_:?[Y"Y]H@[+.
M2</TBO)>O9=3J2VVPPSWL::D7A8XHY3=M_4/@L?$4.,%D!AS0<C+!N%0NX0^
MHARC3T93FHPZM)MM_%6CP2(@7)2NS\31K#741<]=B^DN?"JMGNQB0/'\T!H6
M*^+-5L$ &>Q%9-.)EB]-4O9.UK9X6%T!G+<XO?8N^"<@!JQ+R;YB@P<8-IZ6
M*T!W,"66+&8E\Q\RB4 ""@V*D$H$F^70^1KV-T?#EEMX08Q@;YOP6(N];[IF
MGJ-X6$W#L;RHP_CJH2"UB%/ECP[DLU]O;L:94"-*K(KGFRFG3U09H0ZC^_C
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MID6GE+#Z^#'1L/2(TR(M7@)+]QPC>E)R$LPP!:5$@Q[8N0X] 85/2 U&]Z;
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M$0 M!O2$ >LS48M=@BEK;#P<[X'E[0Y6"D<A,O(A;=UJP#N63K(*\)CQ,IF
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MEOP3M= \IT'UW'V&QA80)UAV')6/9R7D [N=[#,P8_5BA]#1%]+/_NH7&OU
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MKJ"KHZ4NK82Q-G\X1]B1G6E8[L>91_F_+:@@N'2$?WTX63 /(=INB7%:P@I
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M<^_9OW->&<S?T16\>6^K,VZ\%P'!N7?NSCAV6 C($B<[J2!VI.JH+"+E6(^
M>5V1:@07=[8?]OLCS+V:\*[XT3U0UNT?WJCS@!S2]U@.D=K1.-2QRTP6&5.Q
MAWOR-1J%N^9%V H&U6U#4DIXS.T+FGR^KFAS+()G-GL6.4-ELL\A_4=K(31
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MB.;!5GRVBJLWTY_M+D+0ZLSS'<E5PB>,D.>#MH2Q]Q%.@D%T:]=+$4N=\\K
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M&R([OJL/I425]?"_O*#U2@D:1.%,:H<R>>F+8QC6!9C'YEE5*?&X]U=XN:3
MJ72704;WC!2O[FDQO<36IG88L2-FVP4$B+1!;+SQ/ AIJ_!.'J>8-1<H5X=$
M2E?5[1:N-SN@;X/:E_WXW<7?EG]_U8C>2EH*U..JC6>C_%A@A7:?UVA.%]ZR
M\-?3C0-5LKY[2ENA,Q=WKT)T,1 ;)X%VA[)-(2AP56WK2H*0!1$N=^OP]J8/
MGF@MQ0C=&QC$QWU\RR,G&"1>77L::!%(L=HZ?0B;: 19;.G21WT<OX9ZDU)0
M?_R!RY4[X:([B1V"W#UZBVCGA8@L(2#GV!>1YS!)E@Q<_ 5K9N$:D1DP,9=6
MZY1F?Y%T55';][<M;/DLK2"C_TAI/^1Y6?G,@@?J(+.3".E>5U-!_D7TB2Q&
MOAI%,2#5"/,Y(F_KCE#U\,<5+G]N/]*7SQ";8[PY;3ZC]H+O^)G+ H?7T'2.
M:[,!#CRC-XF?#)-<C?7.ID=D=];9?"J48,0YP,6&D\F=M"\C8LON#MZ[K(N#
MA$.JP9TLW-/D1X!] 1Q%-^%M?5#.VY,(N*B:NR8Z-NHKU[&J%)G\_HP+OK =
M50]?8@FB@CAE3T3O [P$SO8L);^=7,H/XI6<Q?4RKT"E*?G=Z%ZAB]M2"XUO
M_ 91+UR59I2LU:#)K10J*()B(Y!-W-L1_WLO'LFIX4WG6X-BET2M)>#=U%/P
MMXFA4!7]TI^4F7G5'Y_&W0N&)9M%"^W:/K5T9#PO@.4S7>_)+.D$,9Q)BNH!
M3N!,\=O7CN_:VFKPMS0KI93RO>S,,;EL]??1<B"/-V8(>8K1+%[^)#(=2HE/
M;*@AP<FGJ45/L/#@YP^ %^_JV ;A5/$D)'7QE)/*):20FKA,#;,O?JL-(VM(
M%1%MX?>S_>^6DVI3/Q>17?$#EGCG;75<=C@*/+Y;,\?9?DDZ$FFFEOF2D+;L
MGM+7-DUW:"MB&5O%?]D,"U]@<CF"AGM!HP78:CA1TD" \J;)[%GMV1J2?7U=
MV3U1)O!W!2&N[@LN5-!6-&'!G!#?D9'-#A3?7<+RSM5'>'<_TGBP]YOCR]"U
M)S$EH10VJXO9OJDS![-K"SMD#7U/@<?$TJ6:5CE@KHPL70]@\I"\A/KP1V]J
M!UXM&=?5C<O2KQK\<GWV[*I628&^WAWUJP$"&G;$"\D$(_WL4[K !('3J7@$
M/(KU],1!!1#M/>;1YK%:-G3YYQWHZ6AA=BN?F<_(-A#UOSIP F+$XRX'.>(I
M2^<%"Y#EB5%MGE)U,Y?]RRC@YLBSNJMY@@KU"?=<^S_<ZE8L4[7%9V_]6?IR
M(9X@OX@.0XDA6M</C250%^,F#:N>:.]*BZ;3D:YRJWC/QE1XVM_6&UXQP"0W
M[_3;2W@MU(*[H5<0>6U44/7I)$%=AG,JR>[&>']AFWZ:D")BO3TX_B76BO[*
MG=FH.DNQ'Q/9G;M!J%L F)!M1BP,I_S-J LC]\5GC2[9V\)MQA)M[=O<K.9L
MA1M!I9<3FNI3?#WY'%4L4GL&F!<ZU.Z<O*]ILI<W&L;5$FVZ);S>AUB\K9\6
M^EEY@X:^26'1<DS^"M%^MO\<L>Q'7X& (NAFGQ;=U8-SEBHE 0H=R3#,JN96
MPBJ:C:+RO/7"2?8NY8;MM]3T )A8$:RRLF=F.>U,781C4U,N<51TI/ D4T4<
M+TU+YB.L%$;7!FK8$@TZP:[C4K7BA5F:7]X?QK*E0FYJ-STI^GH&ONP>WLI$
MO-)"'-(ZR<+@DIOI"4TV&9V[7H/6[A*S3QO-JQ\QFZPB@]M83[T$_6B>:57B
ML6SO?>A%!=W6?;5^*HQ?O?U?K<3_@?][X,!!V)J%B7^?0\]:@?0@C!K7$QW2
MBFRUF8L7W5E=[G0Q VVSLB&%KVR;SM*(&<?V\WUPG"LJC6FP[\Z,3Y'%7D:-
MHCEKCN.9;,@RPQ2FF?GN'W.()#/B99[.SYT_Y:?QKUGF'WUP7_KIC4$!]H1=
M?4"?\+N#PCS<W/%I?0(&8^^/W7,%WZT#\:95]8!>=3>FWRPP2WM5X+0LUQYU
MHRSRW^T<]'_&TPK'V&F3?*=S(79.+6$ZX$RU*! 1/(W&94<@10L!;%>K?,V5
M4VWSJ5JN$ U?$^H>G#-*A<-;N)-#/&+(^2=[=SP<YC0Y/),^-+R?;<WY_]U&
MJ?]P U4?&I#0)B=+@]!3/.XG O ?V,58*FCO!MGP5)S\ I]PROJST+^ U*\>
M(@?\5.?AV;EC)II^J^K_7/83A8#C12.\66:6NK,8OHRI##%NS'-7CDF^0+[O
M255);&S:96A>OK%82<-WD=1XV-.&W4-A6=%;!J.0?63R%N0*Y:HZH107'Z7R
MV(/^2[3FZ*>6/2TTXEM(28#3Y[NSLL.F:OL/+390FKTNB4HSXJ=K"Q54N1-/
M[&]7<HY%*<^[.$"(6@WN A\EP"8--:/[[Q)\\Z_\:-^H=_G,J*MX-:M!9# \
M9S.[RJA'^CP"^A?Q0F$Y\B;Q^^@&:<:P\N4?T_74]3"=3K8ZV]Z7<EM"BRM5
M_N,!-YJZ[S0YV""SR6?VRI/&CMJC &T*!ZJ6&$Q:!Z9QNX"N+ L+(+C5*#O8
M="5>L;YIC/O%^*/ZWY:K.G&'UJ2#BYRMFKOQZ.K=,*SC NT,V0JX?Y0:7%'#
MKS=P$*BDJK>Z.FI>G>@4I;,:9XG,GC_+\H(/.6ME^3EV3+'69V/AR^&5J*/J
MG8OB:]DS&CUJ-R>0KHO@D"S:\17"1/$22XW]IL#UL%NCL",O.AX-.A7ZIQ*L
MMB4'BV^UG,G*V,6C!Y/&;7AE-,>MGTA;<(1;=_$J%33D>DQN.5Q3<[@[4_T0
MG_MA!7X()4>N6#0YC\I8?@-70L.11CAP'+3F0CS^Q+59M]QZ;H.5W^8!W9^7
MT3"52#Z0FB=G:A-FH"EI[,0='7 EP]'35]DU:%XN16O?_%S2X<6H=R<?&LQ:
M%Z*^Y#?81U^V[ ;34^@QVSFX2J+RDD!.B<O1E7J9JG4U^GIL^JCAZ#:;ED[F
MA(A%XC.&)I0VTSY#)VHRNVJ&S [8I)YF]H,YH[\(=UW\D38]P;N8@J9J\^.'
M6F+;,64#O)%R8=R'R?$&7U19<V@AS]8PG[(#J:#[AQR'[L5'3)I(UV-W6);H
MI)HJ:O#(.?C XR-\<M*FJ\RFXNLVC"^%4#:2FU51R7V1"JJA-:S] 211Z'<)
M&UX,)]KJC4213"*'Y+P^E*>NQ4\DURTHLTH'.5">TGV_2,A+L%R[*BC&2=&&
MXN"S(V7^=%:M*+?UKQ^GTM']DA6EK1'2N?$XWHI81NHM:*^ZJOEEC*FWQM*)
M:W/)CP:T^.;-J+;6R1LD!SY 018:[3LSV;G ]Y?*KTQ'X_&*1SI"HI["-<;?
MHB_K+7B_](B[=>LLZ28G*6YFMG7A98,KD1=R1<6D'(:MT_XZ=V74$EL[7,O+
M!-OU6G>SE]RQ4;C<_32&O^+A'@--W/B^ 5+E5'K)[H9"ZW;;5$66.O]0;A#>
M5T[8:@8^,U(Z&I);:*GW\^_GP<MIN;^G=1(*Y?C#I$0T,:YK1)6]&IFX*+Z"
M89N%9]>">XRX$'Q DCFAIP-R3K*VKO!".&2ZPKMI(^\.5Y:W<LJY^S17N_$+
M]ZNAJ*^H<X2"#^GQ[? 61UQX[#5[4N-@9LG/P42%9>%.,YU?0@].5KX.;>A/
MM\N9)6?LD:F@3U+FX]E&PU#54SESB>S[-\DZ3ZA+*IKJ(,IW6Y*RP#R=<ENN
MKL^>_[&;$W)6N6%QL_#38H"%"H1@! [Y8Y'[RXX*"HGO5+OU5,2(R^'7'_2,
MEAD5)*EN?>Y1$.(\W<& L*&8IZ$%U@F]QVP.KPM4U$1N',LC\KK4.('@)4PP
MZO:D,]%^*.Q)_9B,JS^!W=NWT)#KYD]Y8C^OU,B)K>(V%$+IP5:E)!%'<2]F
ML)W;&J9$SM"<<6^&0);VX05]N)-;[LKW:FSBMR%Q/;NS/:'\W7/U6VRFGBE1
M"\KQJ0'5^U)1@(86X(B7/H<:GDG=.L"!N7[Q:+?/V6I%=U;ESE4OP'SZ=AE3
M?#P;)'ETKT6+IEQD5A2.*^S>G=YMAU1))>22'P(VZ:EALJ[R-I7!#VOM#5=7
MF9Y,^$V(.6:*)-2#LU]>C>'+^G+MF&Y..\.R+CO;O1-90FI=F_6R[%FH2PG&
M9U]&HDZR]C&TI^2<$/\KU1/^LJ+L.IOL.TE7MH&;Q8M?(EKGM0?J&A.HH'-$
M0%T"[NO'$G' PG&FB<+6G\UJGVDT0 5ES78&J1[V'K_OW3#9PG%UFZ7\/?N-
M;E:Y9NO7ST'T") IW\Y&;#3:N4799%+6=L[9V-7(-+;B@"$\R[34[V9NZBO#
MLZ]!0Z SU@O51E'-ECATA( *(+NDZK;498GBC)JA@K2(YQ>I(-V6T4+:YYG8
M*)TI5RD_-R.7/>E0-'<A0'LZO+VQYL=//[<6NA=ORI&N+UZ),9(JD'B^12ML
MZ8.G-?Y2;L[9MUCKVKV@G-P_^N.X(HK<-T+6/N8%XOJ8]/&IG7/.>,O890&G
MB98B[8I[IAJ]5H)1LE9+9G\L:4$L!0&T6Y''ZHAGOY9$<@A-[>!+M>!(M8M?
M1GG-AG<.BBJN'.LGRC-()O7*/!_5,@_.0].9MNX;,=SHJ@U4+I5.W7\S"K,[
MMH@"HO':,>Y4T&(V2F)\>5@F;(+" XSURT7G:DIXQ(K:J[Q_R"8WTW>KAWOJ
MX2(+_L_0=/UBP5I[-O.F/S9RE],:B,5GO"E&)%EP75OK9J,#N,*$A4W\O:^"
M[G$-1L7X[>;-#F$+(CVJ6H;,)F7[61C7ZV?J2GTYPC(<:7[^G/MKUO3&L/[=
MV_L@=NBM]6PV-7G*:-\1IB-U%,5.EG^7\!BO^JIC>Z8N/T\AB]?BNDP$Z;>B
MX#GV#\S!E(OT*I\I??-BQML<^9-*2/DJ<8ZN)H=VH5[^"\PLE9B/,@'*JO*Z
M536C>7'\:O/GHF84[M%5EKQ^\]]H>?-_J+_P_W\DR9Y*=J.(LD:6;#-)MJ1)
MRLY4R#+6;(-!D7T9$4+(3I8)8V?&OJ3(GK&,L98E,V$,9L;'ZW.[O;^W[_?[
MV^>'SU]PGL]SKNMQW1_G7.=X_P(H/%(IA>1.N]/-3@"WK*3SE%U#A6FE](LX
MX9?=?4? ?C9X:' 5\^/1:Z-RN%MJ5\;N]K(=@Q=9.E"^%!.2P/C2=#=-L-??
M*C2_6*>LNVW&-?W'66+3=4M^"W;"6\'HLZ\Y.?S09J_+A^L?T*U"!5F^T;AR
MP6XC.&E+"A=!ZQSP_)]2&U)Z34C+[*,DL$+6V%S@0=)3A^U_R?FB",RK'0+*
MG6@>C]X!PG7T2!+OY?-*7*?>V\UB]/S5HP#+3</GM[11X5358UNJ\$28ZPZ0
MLK/$'#?5-ZL;3>?.8[,<+)VWE9_I!+LVBSQ]5/@=$3DX7Q,CQH?2IX6#E.%@
MRREJV&FT6,T%8:.5--8G-6^KILG(X/RZ/>'W'L2= )K2R"M)]^,3DF"U)<)]
M&5U_ZSVGJ6BJ\74V?7L4K;!-GR1Q ECN[^:*IC.<NE*J-*5-^T7YO.W""<#>
MVM4Z:][>05!"R,O"JQN%,(/&MX&/]:D7B9CR9042S)!2#BN<;=]>CZZ'LFD7
M'TZ1RET0Y55S7U.=W?.C%)GMHJ7)J.Q^?WR]:F<F1E [?Q[>H 6T#7;6O.]X
MI?9&TK4-1*V@MTWD(*.XPUN;_NZ0X.6\[9I%89C>--5T$0OX?6;#5JS'*BRZ
MTF.X]5R?M&QEO&;DM=W+W.U&7OW5_*[+@J8)Z-5-7U3KOZ:Q42V9D-3_&D3\
MH=QM'(03P.4_%=<L8&87-BZ(-RV42S&S_EH6NP-:*J,^)N+C$.8$_KT3P#E*
M/_V"K?=*8N%46.W2!**>(QTJ\>3R7R$G37/!Y9TD(&N8PPF BV)]E_2H05.^
M)!M2ZW*+33H[^67CTX>O^/"".I(+?3[[55P18>C^;D_<F9 G0  %>1QD+&L?
M7'_,\:/Q@[C,!?J1TK"_ZL.]:CE#U(*>?,8XY-_M.DK*S\-^_3&P<[OU\G0,
M7> $T*T7"/UUI%R-HI6? ,Z#/BUXYHA)9JPZK?;-_9WSR0W'#!(Q>>4N(,&Q
MROH<\^, \\;Z).D?IEM#GN3FM+N!B.)#4Y\SL_J,=W@6,?__#B54X9?-;]O2
MLAGW6P(YW6Z@LD&*K@N2E$X2;FAQ)!JA6P;7T*X;[6M?<G<R>"&\5].&L;F2
M;#084\/^O<.)45B1_798IR;]XA]2^T[4RVFJV%)G1G2O@%U[('DEHWH7HZ<W
MN*&RNVVZM9BR?EI8L7B:PNOJRJ-7<8?XI>E>+G[Z=WRM[0D@1O-9Q9\%<=)P
M#NN,_A==CY>-3;F&;4VOX+1[BJU?B \:[BC_2\]8 O_"]_@_=H5>QDALGIHY
M3]%=N?KM>UJOSZ2(/.@4,OG2+Y#7TG0'$"+] !Z@M%IA[8RBZR3(EQ_!H#<1
M&J32&/DV_F-3B'?UAODEYR-R#6>F>&/*;8N^=->!Y)0P_R]S;YH _Z0S:,DG
M &<P^QS5<0+$"]=9$BDD27::"]B[!FFMU?-TX5U>ZQ$<ZP(E$@6<OWWU]22P
MFB^@J(HG@/>\Y/93\D=:GP#&+E?Q2$*R%/]1OZVNMCBUTK\+])[^)=@)&G64
M7A[L7>ZJ&L3Q:9HWXS6ZSECL?G'.?*Q,S[[XRG3I= I]$/S/#<P6MF53>P(8
ME;93/O:F!/> 9"@U1$8](J91/FH_>]O:I-'8:OY9<7ULU0?C:TZ4'KM77&>%
M+FAW5H9DE5OVD>?B[<Q V *,'&7\F(<")'!UY7'#3P =O%D'T:!K%(\N8ROY
M2R< -QN(#YQ8?6 =&:#P-?DF.\]3A[V^I]M4,"W;%XPK)= C29>6+=I(9G5+
M; ;[@EI2PGI+TX_&9%=L1_4]+RO*__A:[O2ZIP;T(5@*T4;%N3=@\S9 SV!S
M1[BXPT*RR90\@BN0Y$.8*JZ"PK+ W30SY7'/?4/$[+O:K+E'-9K1.X%AMY@9
MPP&+@#MA[T[KZ#3Y)_$7)8>$?#RI',)FG67I"SP[B__A4NI"CA43?[1Y2=KP
M-M,\5BSJB$DK+MX#HNO9_WSU[TC=;]1('FZ7; T-#V-[<@(@8%K+_^2><X=
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M]?=8>;DC93^U9DGT^0]$LR<F^7]E/BNP*;T2%F[5&(T(.W:BC/>&L=]_ I<
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M+U$UE^=8N7BM2.;5J?*@C4)R0+_(/^2SK@X]OQJ2K_8G=W\"H4*A+4-BV+[
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M":9J]6R_ 5GFDB7C'_1N:KCA0%;H"<L5M?.X54-^P">GK'7,=9=<%<HET@G
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MS%D=EB[C+;W[8X8]L;U8@?K>SAV_X0 &!H_TB(^9/YW7ON.%<9R784%<05-
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M1.''/V^Y#?:&+"C:;&\"D7\*.FQJG'"@.VW-ZJU]42C98]LVHUL^[=Q$(0"
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M(G.>:HD_Z&R/4^=+T^'^KJ>G^UQ(S4S'U:?G3WNZI9[ :*]0_*@U&]@>2#L
MD<IC[<.5$7S.[\;RF'D5(TW]0U:EW+?YZTNA[K@$_$81-,Y)A!!<[?KBD%']
M..(FVC4O)%W?<8D$0QL_9FM:=_I?!&2V8$[A6UQ8@2COBTLYAR68Y!DH77Z"
MYZZMB-6K3VIO:C_*PHF35J7"L9ZX8'P =GUD?674BK%I97GU"N5\%ZZHG)?2
MI#[!$_[]]L"I_KI*G4E++?Z[7.9H^M7L>F8\2GS]_G90]&<MTM,A41EKR-/]
MXW>U'K:EY'Q,5G[LH^RY)2_8V&:(^>M@+)CI0@%TY(4*-!3-'6C,76PZ[#5&
MF3JT+'02MQG^I(C+>[7CI_#\%6W03!\-B'AMTQQZ?W#9'] )[LMFV2MX0?VT
M>;Y)\Q4[4N>-8Z@E?_RV)0V\EQ]+$^-U 6PZXN2" E]VG-FY*Q4EC\>@'82Z
M7B9_I/PCISCOS5.\PU'K/H*<K+7S$ROUN?J^3KTE0P#U;":C1HK<$_[M")Q)
MG4J%BH=ZR75[N^\P-6ZB% )!ND+""&G]S+5=,U:EW%;V3L'O)HJVLK7_1CX8
MMG3RF!K\+^Q*\O_4: JZ-2Z""228K)@6I;O&V/TU*4OI/1V%ZN#C@/-?>XEQ
M\B>F=_(>\7*E_G3]R180<U*+*N!'T,=QL)'8T::X_D+<T NZ451?TI40M&MH
MF9,+\TZ:M;?1^XL*QQ1Z?;QQ0D(^FF@Q9-4FCT[B^\HA8X8+3MXROSE2!WY'
M?=C?[B$9,,/GK>!<6'R9<%M'Z4>C#C.77J?+3C?%ES215RP:VSU.^("A<Y!L
M8TOC(K6/!E^*Q6<Z /7/Z??C*J1:))P9OWM@?RYL@FOP M< >P'-:\"L8\V7
M8-K['-/UVV2C-EA7_<7F0%\]$ L^'KEB;DT+]3&>,)](SC1-TL/S 9_(\KWY
MHWA_C""0P7W9 '9BX?-.DEP@*$Y.O@<PGK/P_3-&H&]AP"^QD*M<+#'R<O<U
MT[ []0A<OSLE:,>P;;<G<G:,ZOY9F)^Z0BC[RC@N2&(%I&!VM7S^[W9LI5,0
M?SMF+]7>MVBZ OU"G])$T-OM<>)N1.JKY&YFC_2X@PKR*6V#.058BW6HLT
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MH8Q@M]7>->ANOTG(,YD%T6(=4G?Z* \*N&?=2Q:;(=JD'2V=\0IVB5$J [O
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M2YXK:S'C@'KS#7=SZ;PS0*>Z&A &U0G7(29 RHG<*$)5F4+(C<:QWXYI.AT
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MNT2W)A)Y,.OXRN30SM29:_@,0-/=F-!G6!=EI*J.9PLNQ5L^)(GAHWDOQ<%
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MDZYS='_<B';+" D/])&L*E 7>,O<K/#;:=;"\WIBT'.'-_<<!3.V+TL@+<;
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M<S\"V\"#!-N/(\M+GH0BS?3:E+;1(Q[[X-$2$OUJ.1/6^:WO*"O,C>3VFKT
MF 7QKVH)>;E6X=\4R?/F[@,5,S(,E-@F#T-A$)$D#DQCBW01$;4*C'E<RIZ
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M.J[E>7W&6_"QD%LI-+#5'C0XJM: -[C!8DK2OK:V@=+?GC3T85:T8B/TSH!
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MB7FZD!M'P2#-=WI>I;6$==<;):86 F_M?6H:&#_[%UI09OB$<5$QM1(*V#-
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M-[+ECOC<957=KPGS3KDEQJQ'X:NBTLFQ!/%#;V*70.?L3_KG+TY%\FT]1)(
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M]_T^$%WV0U/W:_B-#X:JRS'K$)O#DDEY#)LC/S^Q'H\R)K[TJ3!L:'Z;>^M
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MC!P8\(+$/U.I<4+OWBN N+?6C5([.%^G,J8\6''(9.WOX%+8E3>.*ECF?W'
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MOMQ/!!UYD$Q-9#^)Q83O[%;^Q3U=-R)05KM/^89B^T1_??W1(<A2"A!VX*I
M,I!NC:HK$/1[$!KU/Q#)I@2%ML+Z%595'LCDO)FMS+=[[0DH%5M<%.Y;B<?G
M#.==#@=F@AQ6))[P;+GSN=.4TB0.F^5"[_O+K"]*.%NPP]B@;^9AZPH=?V;4
MCG0%Z].:IOJ$&I2Z,RO;%L5E!HWCDHW"7SMIKY21H4#J ]=/0#I/V*5-5X]O
M[]+M&)UYG.QOI;YP>/M:9/PE$!K?3"G>5P5[+4UE86,%_ 2U)U!A&]*\Q$&:
MX8M[S&U9(7T8G]8BD]GL+\\ O !*\4UNL0FSGH;LY34'>GS\8E4(F8H88"70
MR?WT>]C2<S=O-XD*A<$Y5'GRXY7:ZO62]O[VRW!\Q@5>X%V[CDXTHSW\O)Q]
M2N:=:C1.\YM2?>CB<DIOHZD7;96W##Z.O_C1O[#G9@57"%C@MXE&<&P@:7$5
M27M6!'*C8Z%9V66#&N$R^2G+CY%"_>< B!<7V]X"$[XR:Q%&L\G/-WKC5#.M
MT%S+WIG=HT%Y7"S8+Y.A7G(JS-,/Y]YE_F.TW$4AXTJ2FL$#"SMPM'W"I9NH
M&SP)=RD$F3,]S%\:>@<';ZAMOJH4-27J%X!A[.H:!!J_C/').C7:+%7TM?FK
M+2B59ZOCN6^ZWO5R,CX%-^35/G.;3B@7X(4P=F%86F7\L)CKCNS-:]&0EK>U
M+09]TRI7O(VI$MJ#KUUA OM&L3K.7]H7"^C0Y(B2>\W1#8\R@EB2PCLWEWY0
M9JS"AODRE'90G)A,[RI?O$ @5.VB;!U:\^(K$YWSWC6 &WCT7W;&_#%-_BFC
MGOI&3ST)G)-7EV(V:/[$Q6 7>KI4-5W<@6Z,J)<$=VF*$*JZ: >?V;I]*P[R
MFAK+;?W\USL:+ 6;IT@"^>X$_*_&;)517KAQ09JX+^/7'3=^@8M$(KHNA4=#
M?9P]H"?(R J<9-6-U$>*A(KFFE[;IT%!-^+<4;/7D507H"1PA<1(%>JIEK'=
MILD3'9V2_-331]] _''[9RU.NA4&5=LJ\W_B/-G8]>1!B^8%.@9'P/JS2??.
M 1\OJJW^JS)-P;/HUAL53L^W^;D)2K$!G%9.3Z04KI%H*Q%95U<*Z/H(SG9T
M?BFTV<7"R=;K2]+TCOS2([OR67Z/:R8/RF(17G'Y+FE,^O4A4BL?7F #A82^
M4=:]?/ -\(H!P%8 ?LQD%)>.'".%_QJM49]:Q.S@%N.#'+_I8RLT'17\=</&
MO=H,5W?W]DR]DQR$_ZX[83V&Y,P#V(A:^42=)>_85B\'#W^1JJ75&OT-AT0Z
MYFC3&+?CQTQW^VQ;/!1!3TS<M-ZNB\RZNEEEFO2Z?D+KH*3#T*A@K^V,60/Q
M%\S416-9+%Y_5O5,'#WM!63I5D%<)Q/G  &H A[3(T Y3S3I,7^A.OF/+:JA
M:=BU>:#KJBG_/[:HE#$CO<>/)_VNSNQ+8+X#/]7_AS6E_K]84VS?^UT.1]^]
MJ[0>5X_SAM.TJDAWSNZ%-[#KYQ+?;C_)T&,_,2_7OF8?FQCC<X6RBS6)0:]_
M6&%JQ$2L-J42]6LF9%&:<N8B_C2#L,Z*%I$'9^R=]*H+^D7&*?E1=Z,LOP&J
M:>0"*?UH>EP_F:N1'..7W'X@R L&UX@0B^/(0YO:KZ2SV8\N^TIN6=.H]_M6
M/6R\0SB,F^4?8#2FYAP0HBD#3LV^T>)OT:5YMS:^OY&@$[J'[C**DR/QOUFY
MNQZ[-=W?*^N1C%\_O'<A*DE6CDMM(&,"L!MX?3I8PBN>QVGOV[ =HQ'3#2/0
MJ84W0[?)#R,3G,//G_Y4OPZ5SP'12-J#JE@!!J^JJ]O>'*G-UA7</>IHOSS#
M7"M+9ZGRG%6=EPH39NC"V$SV#5,4'9@[=3OPKMSQB_%^(;U\R(I6DM)5,U,[
M)M]@#7&U%HM<T8$+<;,7ZED58<./D(:Z-W[7E:R7?$AFGN?VHN)@,B_5T>C[
MR]+/':A#VA<:SP+.)BV(5T@O=K/V)C\4[1YDYE>Y?D&3;PN&C#.C$1&_U34*
M(<]U&D8]#62'=48K7I2SJ_HWW[]R+TGWT3TV;3UUAK6OE1 ''8+L#+VM7O5$
M:.RX]V3>R8S(J4:G@]W(+M7[Z.0P3B%U[HU#3.OSC>BUR?5@)YOOR$_&NZ^Q
M,&[H Z)/_A.<,$( GQ8I7#?V]<LJ@58<1Z=W_")0KIUM"T.M24-46G0-MQN!
M<N7K%)H/WLE>>X:3.)+-KI*HU%<YR60(H8C:O5V^:NQNG,PAYY>M0_ X?(WW
M[L'YSG9[LVYK<A#\RX$.X=T+[.,"H'$6Z5TNCAOAIP-NR3'&TEW#TY@.?BI"
M+#RZW@K4C6%6?_E&QK8<@C%V?@R6R8R_S?2M@/^A<Y]ZL/C\M]R7W_('LH-^
M'=+<SJL1_O]SC3QB\>'!67VKVZDD<;B+6R=4OHIQBQU=!+\U/EAN,2Q>)A%Z
M[SGO2*#,%KT7\+L2SFH)@\YX2 C=BSK <8#2='XTALU[OA.)--6MM(!]E?@*
MO-TKLY!U^B;@@JCB)S7O_%: $PV06';R0*T?2/14%)?MLB[=X@WGQSQY-77_
ME#>@#X;O]]6)W(%A)2Z$1MFI$T1D'U@;@%HY=EKFW+>;SR)/]_BZIPIL3=H(
M#/]HP_:O^7-H73?Y\NK_FEL(-3JU@]"1/IR5!- 2KUCUVPF.>?E;SL^JZ#G;
M,<???*IC4-/%=81:/T"U8R(X@,P(WLVCDP*P\Y*:HK^<19U1?.T6DU*:JNWO
M[W.(TBV_J=A-)F D<C'?_&Q#;)+,A>=EUWG7;^;P8Q\@6HVV(!&>0M\24\"G
M M!G4U!G?U=QB&AO.OBG^H=@8PW?2:%5NDNAIT_$F.![#ZAWP;^3O(2X]3TK
M$;[G .NPX87'(HRX(,K"4QU(UU.B7*YE/W\L%L>PW&U]*UU@Z8>,TJ%7KF;1
M/1'Q^0?9$UNPZO4822FDG4!X^L3.)MC!-J?<F_4B'R4<WW,KOO$#W!1%EP;T
M_K/]ES0MZ583@2-J67+9E<^ROVH[2?-A6(;(;?\7PO;:&*Q$9VORH0\^K'@I
M?EIGR:3+_];7^EBIO6Y^_L:NF'[!Q!D3C48NQ<-MN&^)^P!_O\;-J>V/2F#W
M0S4-CN5&E$#\740]WJ\C@.,WB75-=@8,9RIN-IE(X/7Y/CL;2"BZWP'=Y=QP
MIS0L.36#&N%U>J3#X0SJSHL:T@\)E,C*^XXB90X2:;[V9]&49O;U_GTCCZM6
M8Y,H!>\*NXN/P^Q@T=GLQ$2\0Q<[M\3AH6]#>-'L9CH\O/_/KN<,-O8-9$&D
M2RSL>;#VM:-!'QW<?4)&)_\-XE^\>#M:.Q]<#@E#]:9.-18-3AJ]RK6ZXGYW
M:,K]>"9S25:7UR[*,+]H<Z-JBW:I/AX\I2GI=.**4\'&A\M8F"E&ED(^[IFD
M8Y<]W&NU9/-*&\YR/Z $2U1VQ6F7IG!459M(IB6B [ZKDP!!H7HG7%T+$$V*
M)RZQ+BAJR5^!+F]=\N2/(]9_\[JRP_K/(%3D[BR=<\!CVW*;<$W1L0!&\A2&
MK8Z18[XHS6NY1,++E=%)J6*URY_WP['T^R09U)>X#ZPE5',T0W=CD^O/9F?7
M#%+)#_]6Q6+XR%?0E4@"N /!2F ,-@H<5[ )KYWG.OC63S&42IO8_.+*?BTG
MES AI/'4D#R>AKPJ;Q.&W@N3;X%Q."+$QB?'+3K+QZQTA&]AV7?X'M16W_\1
M0L?Z)]DJ#:= L.W$T")8B$&M6EZL<T[&<M/3CM=F*[WNK&@_"KO=:Q;-3B'X
MRD$$X3W12E4"$>T$5B/#H'K\.!/#J8K)-8XW"R^BP4*E IYJ)F.K!V7%G(9C
MG_U(![S//CH+/(9R-1&1OLU9PSUJ-E2;(P,W_15179(>PK\IFOH:91]_E&-,
M8)1XE8!2[C$BSA-P"(XM<X$PJ :VI8J'=&_J*$NNZ]"]7'RU2+U__6N0Z1O+
MLR45=885WWEH\3*2U?$<<!7F/"O  1G2/3@'T$+*.G_F;*+/1E,::UJC%@<F
M_^@=/=5%*IK&I!Q<B?-U?)'A[#D=<?IK+*,'5@\+%_('/[N(+AL61[>W.GAR
MR#?KKE)9F->M+YSZ0;AAIW4D>#CB$,CVSP@D68Q@#7> %<W::+TSR"YQ^6TY
MV^S$5)#8%YYK;,S[P2TQ ;R)88%L=R$8\6VHB+\53BB#WSGQ@_X/EKQ,/RZK
M*P:\\;N4Y$LW]0O>0-7M++ITM$.QA&3?2+3N*7!*0.N]5Z#]&&Q\_]N#W 9^
ME,O]C?M7O"J^(9P2H U'J=^:MB:S#.:!2T@4+-K< -&&K^K49!J!\B[RT&+X
M+><E)ZLH-2TB<AIMYO+/ 8SI[MH\ .X#QIF]Y=#U'ARPVQP6 54GLQ"J0O<N
M:)%7&^^0:)P*37B<:0'%6IR6"O\7#6W.DX_1#NSP?%/S]F!EP<:XVQ/W &(7
MG-"/YK@%*UF>!J]OQ&G87RF:&P3GB,F> RCJ8T("-'P#7L);GLG6.;ONZ_\5
MU<X.4L(Q$X#+TA'UL<!%DT]U/+$4NLU@%9+CLEID_MAN\8-'B18/K^T+ PAK
M%(U5%,&0X6AD?5HO?.;H47T-83V0I'966V(U.^N8+?2[,'M=N^ECRI7?_3PU
M!G3!-W<*OX2)?;A&V;PW+8U2%<G 9P]C7^[/;F0#\= I1>[*$#4?;[I.;UC=
MS0:Z"&R7JV5,8].PQD5\,!,'L?1*V )^"M78RORE>7V3L1GY66\SD=I8*=N/
MV4_E5JM^?G>XDK8LR.NI+7,XD'9K:GG[[)VY?D8JRO'T$:S_5\ @_)!M GGP
M:00/)X,<EI%GP77_##T+U.F0,E$[,^> UU86YP!=@^?XJYGH<%SHZ0/T[."A
MS_KO.MW\#*[I0=>[]/%O/)XB0\\!+N< 7/<9/&U+TS4><QTA"TYOJVH?IH7X
M@A@VE:0=I&/4G36Z/RJ-Y8H+?ZR^IXYZ*<3O\C$Y,4[6"RI F$61&0A#T8M[
ML9ILHYYF?V<"!@L@95U*(,5$'Z^ZQIDL^\NZPJ\8!H\7W*D>'\\>@L[@GG .
MB!2(>H[D2*Q8'.:%N"SY\=EV<IM$A69^3)*(@4Z_DG'H3[C[85DP53W9RB$2
M0452&@N0(,JUGS2B@-$+\H0G)YDF#0L"R=V)6X[O\ ''#LT1G8]T[VJ^[5@7
M"NP&BWE^SM)<,"0WDA-=9-KB'Q(QIR:09*P)CJT0JCQ"$LF62C;';RTXFOM7
M;NP6CYNO_A;_96'W<?NZNYK, ^U1CZA!0GQO%5I\,2[Z0LP(0N3:T7M!."X;
MHSI\Z.KT^([@6T#?D^6?:6]W'P0R4 _$?)] UH1MDVDTBO1O4OJYAB7I,0OR
ME7NQ?(HWY(S3 (^? QQUG\%F,$ONRG-(?,R6CH"^([TM1*M3O>Q%I6'40#>&
M15.%:(.-[YP@[.:K3_EJ=3]M^\1NM->$3'I%)_,@G"?KSUUEE/#B97#_(@&&
MLUAZ%_:CD"B.'0[S_*KSE2.<I 7SD2IE_<8H(=1O+,3+_.= 8=U:.<Q*[=#J
M[ O)S]_9K83HUU&SX=O;2*<[6F/AG_@<=TM;W^?)P'I(+XAW:KJ9,59>X#K$
MB9%I4W4P+C?7@",S/;9UZ_?U7@^D,N=>=M86[\O;\^);1Z10?$4\/. J><+Z
M#K'D] '8AJ%^C[(J1/3WP27ODLVC1X,>;$?991'K)C/"]-<CMCHNJ34G3EGT
MP@1:/9;V(E2G@C1I(39/IA0DJ3^I#D>2]-43-@XYKER6#(SP2=8+V;\BY,HU
M["*$A76? QB@+RZD9B Q^QS0>?1TR]<Y/B@9I%I8/7]U+M*W?) U3OBE=*T[
M(>7]A?A5(-['*X$F$!)0 [Q)1( T21=/%3O5[>U;8 X,)VG+SUH]&\6V]E4N
M1O1".[5?'B:]R!D2SY_I^MI?9B;JK+]JTJ+3U$686D)US#\WL(DEL^&G\8A<
M#[Y<0GAP91%80]614^+-%D_0VDTY)KH<W//  'S%.2#>AEO=&8N)X&<D>N"'
MM4>\&#F)4;09YX!&2)+><\/:^D#Z7TO263.1[33NRL),$/QP+ Q YB4J2@([
M$;+$4P+<II7 ]DL5RL\6WW,'YN&WIGE)L8CU2\>5U-?Q:12B@-.T7L90. -9
MS&F!&Z]U#HC:]12(5+V5-GL@^=P 8>'_%GU7O2&%\U*;A>M04T>'H)3LC5+O
MF I,?F/5<?+NQM#R(B9:W7G)F87,*$ T!-)!HI\T*R;UVW\0^3X.>-JY-!&)
M64WH"@>$)/9?H?O'B3!4A7? #E8B\RS,K*SURS=//'0"X@C''D/5/R[Q&2YR
M+F<Z?%,8) _ 6$D&2\>M,*S ]6U%32D$WK@\W1Q29ACZ.OZY=HRFU?7/9L]W
MFYX'?E --O3&X<X!PD#0.: Z7_L<,-JWS=GAY\4E55"X-Y,4, ZO9R@\58,L
M8[,^<0M.U0VSZGV[[^;@3-'O+T] <=9'81BNRPV*W9&HZ%AF"Z\BZ9R5M$KF
MS1,[C]H%&'=)0$=::Q 6S&>(^UL0^J+V-MPU80@ ]#+T!8#87 _#:\+. 8=-
M9U^%OE+DS8-K N\!9<WR[ZS_#H31G)BO*:0NO'B=8B<8_T8L,]>0Z>AY\]2>
M[<BMW$&H!#&VD&1)],:> [C>Y6F-*61H-4>I!++H9'/Q\+H8TQ5?B0D)!H>>
M%2#DP!B:BSI/XVC-.%*A4,4%:30V$'H<_SPQOR9T(,W'P7ZE]-MIZ4->0N:;
M'])$43^Y@+X%VJM?&P:_W9[S")3>!0BD> O4484B>*!/JD?4:9?;GO$I/9^H
M?')"EV@5#2;N8@&1SG9D+HX/?X?<0C)?N/>RS9DW&T3U&W9C**%F!.!3Q*2\
M="29=<RS#03270NWQJ]VZ15L73L^MC4#92;=>,9EZLL;^!.NF'P83,PE9'1S
M#\+;D;1$7U>&C2.0/3 &ZNBF:KI@>:/[HA("]GGOG -2OZ(-?=V^D&D@&;V*
M-BP(01+3E/H;A%J\]HAMZW>"48PDKBK37,89\C1A3)J.$_O%/MXF%30-[&W6
M@G>J28<>):$*(?L=-9:.Z(;P#PM6[:_E&K,C#*V5&"I:W9(/*NS9^!W_%#?Z
MF?T5FVRISL4*H%E1UC3$R#P(Q[)#J&<;PY%-PNP&X@Y^L#O9D6,*X+"S:L]O
M)RN Q1S%W=M,YJ\_!]RAQ$^=)6\CSZ0>]Y]5J^L7$<\!QGB!3AC#O$X)Y'"O
MNX&[> ;'6[MI//G')VG^B<F9*0U-S&+2G&>%,YC\C!Y;=2HZ!3NQ_#QJO%:?
M 2+SJ@]A%L\!/14V2U3=KM&JE/FNME?AG^J_>)YR21I-Z@E!V!_82ZRP]P,]
M;Z.<]D^'T:Q+#KV,S-O<KNU5-.^4TMD3W2>]^>4)L;]&-AN5KNDFB;_+.5O)
MA?"_4_/(E@E&[?QUO'7Q^4BTT^2=)RR#2YRV>E0O1'KN <.<&G?XEIT%](@F
MSGCXLS_RTA'\]-E+72]^%W]([EOPZ).R?>8A[$Y%WVIGE]VC9R@3+Y_45D&L
MZ.RWFJU>1C9X=^]%FL/:,X:O04WP<1FOOSFIAF5[[K% C'U$1UU6]+^L0+CL
M+YL*3Y=W!3R\\IXW1N W)VP<1=X@OR04DZYG+.N$U%5]<F@'E9C;$!N-QW=:
M*Q2YV/4JGJF,:J??D_O^^N/%8R/94:)F/IP#2N+/1DBE8!@-8RH:^?L9T3B\
M!].X3I*$UQ/E3D7)3,/$ATBLQ,@%I].</43B&'%\ZP[PQB.8PWPF[I@PEGZP
M)P"U(F;AX]LOA*!-C_$"RP^"0T2K@RT6!SKE5RNNUK>(%.;)V>>SU&5^GCJP
MKLX<57;J!NO+QP^3!QC"SP'YZ1FGWD*;2#J2P%)#F&.YNM"RAJ@U\IVM+&=%
MWN?RN!?N]U@NNYD_&(M5KI^(=4K23*JZA&=$[3$1B]N1O/5E+1JR:E448'1O
M6E&!C"Z+:<4-DXA?=)]J60+>%-[G U19QR]1A=W"1Q">$4.>:'+?]2\^M<$Y
M'MI(<\VO.;C([-F(D:Z*FIVED36)G;>+XI\0/E8O&;@:)KT;\)FL8GZ4<&>%
M8C4;D1*J+&6\TISWILY;F&AV^B!@!%AG$N2)9($"\3;!!_1*.WUIW&DQ!2VZ
M?WERFC+1#RGD)!XO?G/DW$59!E.B0F'@/6X(!H>X,DKFUQ'HQ2EN65B!=%I:
MQ L="8(/#S>E ,*=Y#<[6C^KAY1YXK^1^[ZCJ':0^/HW6K$P+'^M<RF 2^8R
M:#P)-#Y%A:?I%"""]]"/C]XI\;N$7WM#^> L-N[2=C]J1?SM9B/0S:_%_W"\
M0F'LC2LU"4RL701&!7#CO7O]*3K+')>*DC Z!,80D2;%GYX1-CMC.L AKL\L
MG*\\>?^85!&W3^]90N4F/:6IB,^[/""8):4(MI6Q.N6W3%J\=XYV7434=5C(
M[[4I5822SBK/ 2L?SRZ*^4X.&K;QM4RHUUIXC$Q+GIU$W":$#FPN<!/"0\<>
MCGF5Y3>@)_]P_8IU%?Z$B_=-:,^T(\M_ME733\L?:PONWW[C;[&D@U/!]W:Z
M,A-KV\E7"&GADD&I^X9X@]45WZQ6098_MYMX;HD!@U3>W)7)C(7%V=2'-H8
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M]SOY,K5; *WUG8])9O/=<(G7]V@8KLV9/ "B?Z*0U.KF9&HB:G%0$\;FI(B
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M%,-KXV6,][A6)^E>C3Z+O_/5<7 ^9B=^_XO!@ &4!%O-)648-"O!8P^O+''
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M2E[8F/3+$F,NN4Q1=/:,#<%3'X-5"KB:>Y%4?10=T-N,II^B/0?-\TQ!NO9
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MU5=)7PUYJ5/Q\:%*M)HE!?,!HO5+-A=8(.VVPOA15@-J-VDVJ3H#ZQ7*OED
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M!5G/#9\F89LJ[VD,:4OQOJ&(=Z)<A4PG++5A"]ZY-0F\O*^C8DE51NNK;23
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MIEK%6ET\;D"BE)4":FQ,U=W\CSG&TA2>W!%X<"Q6.H^]0]2H2W%;C#=>%#!
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MY'O)']FR%38_0SSP;'E:YFL=B8[1U7J:>+JH0V2'7?;RZY*%N%TB*92B5LG
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M($#STA#.C0-P7.#:3;//:#LR]O61L]QG#F#,1@9^.[[&V_]DQ ZP]J*7(P?
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M+MP4G8MA=MOU(Q'*CY1<4S=61Y $$UONE[LJYV7^.8O?Z(XT[96X#U$8TJ%
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M<V.W3CZ@!02_*Q%/OV/7PFY&:.. .3*96>%HS57VD+CD*8O>)^4H>U2>\M.
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MSFW.VTC<UM]=24G;K*%G]A]LMSTOCH+I)JA+;$??$NW#NHUXDEB^W4+L=@?
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MB&"6$@)%F/HI92+!F=&NADEG<V/?K7"#/(S/PFIVCN(*K-'/K UQLB^G9P"
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MRT*YIXFW97$K%U/WKSAIEHS[#&<LAI2E"42,!I!@'L%$\$@@'G ?&Z6Y'2K
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M?_["8><.O^+J#Z[GBIUSVX=RE=/'918G812G*41AIFQ*X4,210QR+TE#0H.
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M<Q(^:7!MI1YRI&"(J84)[![;B6Q<1QC;&;!V:)VU4 V;FLX$M=-MS\:TO'4
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M -X"4*N=B8*W_-X6#6/]#/[E)@W[D!*0\QBV98I]3@(>R7D^)!!%<MI/8^5
M$82I%Q'DLX1NGLS_/SR4S_(\'G_\U-/W?_"39V;+S$CB&5E*;8J1/5A BPOX
M7B'SPP)TX( -.J 'CUX>]P "3Q$".XC:IT^!I);9+4SMZ<VGKKQ,#ZH%D&"I
MAUO"Y;BPZ[R> >=59&>BWO0E:V>B^ F#=8XB#C.'6[D_-7*24UV_+5MANK3'
M,2*I'V<"^I@0M?"7!@%!!.(P"EB**(^XU?[RV=[FMM#OF',K+=B(.S A]7FH
MS>8]9P"./!-=@9WU/&"$B4MF/M_AI%QII/M3]C*[Z1H^D;RT35.EVY9?M'LT
M<CU?<]GJW9)%@O(X#6 H%Q40,<DMQ(L"*")?$)]SCP6IW1+#N.\Y+@!:R;0)
MQO@7OBK;M%$-_J921\F/<I*Q-.O-Q\*&?%SA.U&B42$X;7J&L)06?%2Q*/M*
M+/0/K1[ZX$@KXCZHU1I#]\1ETODSD)@%)L<)S:8!9]E@WKQY^_9EYR1+O#!&
M/LL@$QZ"2 @!,Q\+R%,24"_V4H&,ZMZ9=3<_<^E$HI,W;]RDANE#;>!(YQ3
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MT"=)1C$4B31U$8TSB!-I _.09=3S/$&QT4:G7;=SX^8]P;7A=>3LUR:8SGP
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MUG20,$:OQ_3QIA_:0 WP1><>PNR_UZUGK.4Z=-#P&*Y81T-[HK6MEG\!MAH
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MQ8MUG1=<3M8T2$.BPY,$IQ!E'H(XB1A,>!9Y*$O2%)N')PT68VYL^HXWO5P
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MQ4Q@Q92Y/D6R"+T8158KRMU)/-[[4IV/5EX4VZG9EDE5>K9%49LBIQNM:I]
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MSIIB<'0H:WQACW.9@W)MIXNT-9_6]Y]U3M%N]:F[:3;3+XI() ,2P$1X J)
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MK*@=PCC14KKG0VBW>C:$Y>*R^=H]IELO&VISL% VO<9QA9_?2R&WJ\^9%,M
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MO\KJ\Y+$,J)$1-##H0Z.1Q1BG<.# Y;Z,95<FFU0.Y5J;KQ420RI%AFPCEJ
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MM!'E;T6VV8CU5RF7,@H2$N,(HC!4A.-)"7% /2A8D'I!BE' $QLZ=RW@W&:
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MA[O\Y;Z%E]KR(VWRS(=5'2*QSY[99<SL%B4B)A[UA81^BM5*C[(44N7MP31
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M8<W6"O^=[ Z7&99H.5U9F(X][6+"$I&C]8/M]7W/RNMW[X[\K..$U8?V=TV
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M,6<8(+"GB++EB%*P?[W/G_]-75W3@_KPFA4NW7D2$C!0K7WG3;[JW/DXT>Q
MCWKW9[X4?A"36'J0<X]")!():>2GT).QX#*(&25&JXU!4LR-)M3S%3CS.RZ
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M]-2G(O10" 7CB=K8H1CB5$J(J0A0&D:2>48>.]8]SXUIM.R [85?5%X 6GS
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M=:.<(9A@7Z!$1(G'+!,S.91N;AMP_5UL-1\5K;B*F:HP,IWVG-8Z ?UE-_7
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M[7@3/5&G<A>\VDO=2?5O/T1>ZJK"]TJUK"@V^<N732F6B*9>&,01E 3%$*&
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M4HXABK@'J<?4'R(-DR#EH30K_&O6W=S6RDI@<"2Q!<=>QM=@[7.*VLAKVDG
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M1*<LXS )111*+XEX9'4--P+@DP349HK?\\KDO%;(KUKDJXS=_VL<Z,VX?P1
M1UX 6HG!??OI+JI2]JQ:$1JY1REF:HF5R]7 M.M)EP1+/([7!=O7[18'+K+E
MAW69E2]_WZRVZY+D+Q^SE9KKRY1Y'@XQA6GL)_I.((4DX0AR/_$IICY.N%%R
MU;,]S(U]:B'!3DI0BVE&.^=Q["<8)^B,3266P!@SQD7E]]Q0M.10"/;7A\V/
M_U3OUKR@?CBF@_/M3C+Q+ZK53O'+#PXT;IG7*&O/N(W/X:[Z)B%)$A,/IHG
MZLB)?9@R$4#I^T& $/4)LPK#N5JBN9'%SKR3UV(N +.IWNANI S-9U/B/[9E
MS;)"XV*?-^MK.UC.RC(Z!]BI2>YJH::UUKG"\)4ASUG#P_CX._E5NW+=DCQ_
MD9M<EQ.IW 63./:B),#0HSY7!S^40DI%"L.42YI0QHEOE$#I8D]SXT]M!J\E
M!5U1!SECGH?7C!R=@#8RZ0W$RYK'+F+ADI_.=S8I[US4^9A/+K\PC"<^9NNL
M%)^S'X)_4KO!]8/VM:BRO14W3YN\S/ZGXJCF_N$P7I?RR$,L\F'D\T Q"8X@
M18& 7 HOI4G@)U%@PR17R#([KAD8.WW-<)@QST0@C\Q-M1:P4@/L]:@SE"ZJ
MVTZFC4U=E4:,KG8 JDN2NT:<26G0 6['1.FBR?^7NC=;CAQ'TH5?!7>GRDR8
MX0*2P'^GW&KR_%FI/)FJ;ANKBS"L$J=#00T9H4S-TQ^ 2^P+P  I'FNS+DE)
M$NX?2(<[X/YY3Q*;P](,'H8R02*&-$D41-HB0!PD!*9!%DG"$BHBIR37Z5>Y
MM Y#)V(OYZIWC<NDJUL<D7$GH1FEMN6MJUKLZUF\5;*TB6#<D-Y6WR67^8OI
MQ+BFR?U4E,U8YMCNWOS3+*!92$/*(,I,^UPL.224,Y@RSIBB**7*GJ36:>BI
MV8-.>+"1_F:+7OR3X;MK/HSZT//O6@FW[$R7B3EO1X:%>V#[,C&DG?)D!T)\
MM#Q:%^2]9=GV .U"%J[+$\?,TNVAZ5X6;Y\G]&D0]YB7XH?D-9M3F^G%LTP)
M)'18S&2HHV0>0I8R"9G@69K1D#$["MQ3 TS-XM<B@DY&EUYG1\"SL-=70C+T
M)MH.&KU:P!V!Q:7[VW7PC-7X;0>F&_#ERWM?_=Y.ZW^^U=N1^T;L\G9:ZMT&
M;V>NZQ?%]NY5_HGF9<T%JX/MU5/7N+S9A_E',=>/,7[X=[J4?^H0_6GU-$M#
MPFF:*4@1TI8QS+1E#%@"@TBF..)Q*E.KKIGCBSXUF[O>[WI92WL#GAI9W6+O
M$:??+J:?YJ0.O&IL$X9OJ[W-&@[8ZW%B<:/\#3#J@UI_L 7 UM;H!@-3&*L]
MUC\OO"_..Q+C3YW/G8X1I1]U!V7\6=G?F7D#"7H>CC55..]-\%!VOE?&-.@L
M))!)[<4C1"-($,,04Q2D&(<A)[%;KOJQ85R,T3B)Z:V4CN=9QQ"T/*BZ$I6A
M3Z#:&KNZ+]YJ^5C8^??N1TMG8/!Z9G1LG'$/@\YH>G#*<^[:'H'[=UE)?<>C
M27*6+W)>/#?T T]/>=,UX6NQ_$^Y_+RH4^[$# =)EF19#&/"D38"*894*@8Q
M,<$^C5-BQU_49_"I.9^=^'66O]@H8!K6=!HT%*++.LI[IJ5A/@:+8@GR5B>'
M>-AUJBRV$ :<@(&MT!I[TWMS2W:P)3S0T@,M/O@\/-@.&Q,#@C[2IL4W<YRL
MG?)"[;SJI=2>B.FG69@6FL<_#;IQ=HY^&S\?<WW7(VV^DE<]>4S*Q?IS\=5S
ML^<<G-TX<7WF>)LJ/;7=V7#I^XQ!ZB=G<90@EL0I%))1B!0W1.U! E,EB4Q4
M0BE+9\MB2>=VGNB%\9Q6GO6HPWV 7[N*/;I<ECE;+<W^O?GNOI62YWJZ-J5\
M-X"M*]%$6XGV6[X JTIL+CI-BM!K=M(PRW!$&$PQIX;I-($T4ES[#)0G@N&,
M"N:UJG5Z0</$9\@N$O&(^L#N@%4%YFAEET.$*9>&G%*9Y:G@Q?:V?FM&6U>P
M>/AB.@I^R2DSNR+:J6AW4JH/*[DN18[3,(YI("!7D8"(13&D3(10OUY9)@5)
MF%O1E<O@4XMCOAAF>_W!K'4 M1(WH%/C]:;;9+T!6@^;2N;K9\C.1 V%^\#V
M:@C(G:U8'^Q\FC2G\4>U;WV0V3=VO9[1MZ5$TT7U@VS^^WE1M\]]+.;Z&=7'
M_UZ9S>%B/O_45$_,TE@&*.0(*H%BB$R*+@V5:5.L"!8APL2M?L%Q_*G9O_>/
M)B2M^TINR_V_0".Y:U<*M[FP,W,#(CRPI5MW^/VMD_WW4T"#OXT*H-7!:\^+
M7NCY;8CA)L+(W3)ZX7/82J/?8Z[(USCHVGMXF,;V#]/NNO,S6?*\,G'9/V7^
M\&CX/71L2!_D=VD(P;7E[CH"K>C<-+ +9S3F-#6->A31LXR$TH$MY@S&*$(\
MXEF614XM>=] AZD9WRT5=*QL MZ\$$ NQ WXV:H$:*,3*#NE -]HU=[2(]MC
MY)?'(>UCNJ_$]/,_[C8)'VLD;D"'!6C! &LTP!8<P.#A.0_D;>;2>T+(R&J,
MGQGR-O-T-$7DC43I<7S\9SZ7U;)8R"ZH^2[U,E]*\==SL?BQXES'N6HUO^6/
MN7RIY?\FRY9R<48CF@1!E, 4IQ0BBE-(4RH@U;<Q% 0R9MSZ+/D:2::V)JYU
M 5V/7+WT-=J E58'5&M] -TH=%-O%S\W.CF<=5XUB1:GS&--S<!KTV96.CU
MIP@PFH"-*N!V>U;,GO2W<6?%X3AZK-D9JR;IR:3&F*/IYV*IA\OUJJY6RU4I
MP=/A9[4L #-^I2F/,1]7W8>-/I2R\31LOB>W@V<?:)\]A;YJ@/&.I'W@L',^
M[>6!/2-1.=?_^O"'7.B%=GZ[$+?"I*";K;VE?JW:BON. %M@&LB(<!@(P@QY
M2 BI4"DD-."IBK,T"YPVWYQ&G]I*UPI_ QX:\>OC.KJC@&-@YS07EB'94 @/
M'4QUX/ZQ!>ZN[%U[A"%(RGO!YC5N<1)@W(BC#S8'L4*OA_2S<7\4A?B9S^?;
M6]>28$$Y2F$<8P51&G#($LXA49B1, G3B#NUK3XRQM3L52>BFU$Z!IZ=Z;D2
MDH$-3"?=8!OW9]3W:2B.#3.J.3BCY_Y'?^[2?I^V=H*XE*+ZI,7Z0>=2&Y(_
MZ;(NK+Q3MR\TGYO=!#V6^<>VY#*7U2Q H?9D=.2>R,"TLDUTY!ZR!))((,51
MEF2Q4Q5C3SFF9B*,=%6]U#XUTINT5AV.Y(L7[:#6KJF;]>@[/W869@34![9"
MG0; ?%? B%FCWVEAL*\[96Z$OP%KQ: J2ECI>_P9K2L1]6G8^HHRJO&[$J]]
M WGMXWK&@/Q1BM5<WJD+26XUU<:]_+5\IS'XUXR+2 12,)B%40014=J(1H&"
M.$0!8CB(8NI$E-93CJD94;/YO6JVBLSW>]A,X]IN,7WGRS)B''X6AHX=6PT,
M^I;M36I=@%$&U-KX#"6OP]-K4-E3E''#R^OP.@@TKWQ<SR+DK:)GN=1A+*U6
MI11WB^_&:)=:##-Z]=>B8)4L:W:CSPMM-?0_:Y3R>5Z;C_=TSE?S^L?M\"LV
MS?PP1S .B"&J2QBD6"00I['2?X^3B#EU@1I2V*D9YPW#PDW#.UN!3E]@NHUW
M&M=&0CM;VTJ#6FNPJ_8-V%+<-I@<_YVQL_U3>1,&7B"F\1*X5Y6/,#M>J].'
ME'?<*O<1D#^HEA]CS'ZKV_%ZRG;/]ELQS_GK+,4\D5$8PLB0S2.J8L@(36%&
M0Q4JK&,#ZM2,UF+,J:TU.S7V6T*[+0LV8-M9=\\0#FRD3Z'7'?O<@$9D\'?[
MWT&\=P?,?)I.FV%'M8 ...P;,I=;>]>0%$^RR9ZH;K>*5N^+[_+9%/PO'C[6
M_=-,+Y]Y80QIM2[6RC -42A3J)0A?T8J@X3$'(HL8R@.,Y9*IZ.@JZ29F@UK
MU0"W)TJ!G0M,KI@H.RLW&OP#V[]&#W!R FC9%-AME!BDT,X+G)ZK4:X0:.S:
ME.NQ.U*IXN&A@VYK;+8<DU2B3"("*<E2B%B80BQ(!+FDV@^4,L%N#:M=!9B:
M.?VQ>GHRG5$+!;[-]26U0Y,OP/)1;I,__D<N2[-DUA=^RA=4._1TWL6JRT=J
MR&CD)FBER^V[=0A*]X/80;8B7+>6AYR]26T9#+JAW!?%-PCMWV@+N2]"/4-P
M7YO&7_*%O%,-L_U,($Q(F&(8$IE!)$,"211(&"1API$D68:PB^7<?OC4K**1
MK2;D:AHN%*MEM=11G\;7S6SM &AGDOK",K"Y^5(L'J"&_@ETV#0B^K,BQQ3W
M:2%VGC_JUW],L_TO^^@U/6J(-J=+GS<I,I\7_[O(%\M_Z)^UN6@ZJT1A(C@R
M2&&L/^=0Q9#&*8)Q*K$("<:QM.)L<1IU:M_Y^F#V3H$MR?7/H)8=M,+WZ'-C
M/1'GS<)@\(YUY/V&R#K4[0R!\$@U.MZ0=JN]<47L;)V-]</&JZEQU6^G?L;Y
MYG[^V5>Y?$^KQV]E\9(+*=Z]_E69?I5KLIQ;OLQ?FOQ%GF!"991 EG&ES3W7
M$3 B,22,,A4S*@7!+AR/]D,[V?R1Z!ZY%AVL3+V[#G6+-6T470OMYN8YS(.=
M$S@,N@.;? .LD1IT8AMN@=_^:E#^?8N=Z_8RS,[>HSMB/GU+A]%']3S=4=GW
M2WL\H8?7VFW>UQ0W3?']-_UNZ64B-O_M>J )R17B@39?$8$H8 '$,='_1\)(
M!;%"H1W3EOV04_-7UWRGM=0M.X?9N%L (WC]DX,G90>[A8/J'<R!394-CGVZ
MK-D!ZN"7>@=V+%+S:UY4-T?4":*S7JC=D\9S09TTV_$_W>YT,]A"YK/F..>]
M--PG\\\+(7_]__)UIG 88TX45#0TY]9A!IFB! 9ID"C,<*B458;-R1&F9HX;
M(4$K):C%!%I..XMQ&LCS%M<+/ ,;6&=DK+_YB]IO_+JJ<^PJR?_MH7CY=WUO
MX]/I'_9=N=//'>6#OZA6]WU?OK!O"EW=;^(;+9>O'PK#;C0C2H4I#A!$-#*4
M0DA!FNB?%$F%2%+&,^6TXW\XQ-0^Z%9"4(L(_FZ$=,R:/@*D7=!W'3P#?]".
MR/1(:SNEO-\LMH-11DY:.Z7E88[:R2NO/\O[1'E-B_W>=!=9+-\595G\-&1F
M5,^^_OM,<)&@D$O]O:>&FE,OYR0)!8P#D0I&8X(%Z7O6=VGPJ=F$+[MG@:H5
M_P;P1@' .@T ;U7H?TAX<6;<#Q%]XCWT(>/.T2+XM(:ZE1VLA0?O+T%]U?FC
M+69#G4]>'/_-SB]MD3EWOFG]C!X[2::,U7 RZL?)!7^]?7Z6="[%^SG-GZH/
M>?645Y44,XH2A%&D0Q46:_^&9 HRGE)(LD1Q$:. 4/NM)+LQ)V?73,$OWXA]
M V@K.."UY$!THCOL@%CB;[&GY!_5H:V7 ?3]-J"=S* 1&GP8#E"'/27_P(ZT
MJ>0#8+>])3>HSFXN63YJO-TE-]UVMI<<;[T^(+TOZ:(RIW/%PBPDGY?RJ9J%
M82H5RB+(-=H0:9<54L$0##C' 0^8#!/6-SP]-N#4#/AN2+8E,?B[=J1JH:\(
M7H^"[A[*7@OEJ(&M,XI7!;KGH!DJ[#TZYIL%P><0.!<2G[VO9RE!OLB7\HNA
MKOVLE[+%0\[F;9[MN]<_Z7\5I;9O577[*Z]F/%68B1C#6*9,Q\?F$#(,8FUZ
M*-=N))$)<:K0<AA[:E:H$1W6LH.-\%U..GL%M?R@5@#\;51PI2%PF!@[\S00
MW -;*J](NR?YNV/F-;_?8?AQ4_O=<3G(ZN_QB&N)M<Z,N4?21%029EFH(,>&
M5(L%%-)4^UJ*<"YC$441%_U(M:QEF)K-V^9S.O@0^U)GV<^(G9$;&.>!C=TV
MQ!<,WSA<6<X@#L.392_&&W%D.>-TFA_+_5%]CT;6[23OE Y?GXN*SO\HB]7S
MYP6?KTS9CZE<K0/>E11M[IO99N&Q$!E+H22*0)20%!+!$IB&:19&@E%E^ ;M
MDVK["N)D'T=(L;TW8X#Y1AOP*.<"*.V<&'90/3F ,KH0Q<*=?:3W9-F>G P_
M!0.;SDYJ4(M] ]:"@VW)P5KT39]<KQFYUR+I]VREIRPCG[-<A]CAF<N5S^MS
M_I)SN:A,8G#7]^6;U.^U-M\/LE#KM.%O9:'R9;4LWLGO;;^86193%6(4PDS$
M$J( ZZ Z10PF488B1F,41*G]F4QO.:;F;#::R$TCG;HS5:N*<8\V]0O/C39[
MC7A<#AOZSY[-B<XH<S+X&76K!+C=3,BWG0G95#I\VTS(.],E<<P)<3D1&F5B
M1CHENG^4CA^(V3JA"R";G,6V;95V7[J)7G]Y_^;K6.EJO,\?-?5__(C'3U=C
ML'LD=?WC>JQV=\M'6=YR7NKE<VNU;?/\5<8534,"$RD91(K%D(9(&!ZOF*0)
MPRFUVB6^/-34UJQ:6$ ;:;<# 0?3=QY;B^7&&V(#KR@-6*V@V[YXGPJ4\Z@Y
MK G>T!O)[%^!HIOQM@+FK'T^_X3Q3+"5)CM6UNX.-T-:E<O9#_UVU$;[#UD\
ME/3Y,>=T7A_H*"$ISV0",<$((D0YI$1'!E%"$V-;,Y%9T52<'65JYG-;/J<C
ML_-8GK>9WA :V%RZ@&/]95LI?V9'0M^_M1NA?]O?B3@_P"C?O)6.W>=N=_$U
M[*CW]-<>,_2C:<O]>?%!*EF6IO_!KV:SUS!>-9V[Y_/B)]5*SB+,D<(!AAD6
M9N=5",@,-U5$2$ R2CB)0W>*U&M$FIH-:40W_ 8OG:R =L+66[&B50HLZ2]
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M&C%R]HG,;G3M]<F]G?MC/,V&8\&0)GS26!R]I.GBN29CF$688YQ0 H44&**
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MDU;,)#TNM6K-46G3=W!9 "9!V>H'5EI!L-QHZ$(;[F62+6SQZ%,W1F@+6H7
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M3 ^,MN.@'G;KMUO.S;BR=AE-U??]HUSST#;%W#..M4M& PI%DJ40A8A!AK,
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ME(YZ*)(:\"#, BP#)*FP#GVVGSPU0]/(YN"5[L!D$3GT57Y@V]"(U2<+80<
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M_08 P]DKF^QN_6VPURT>WYOV>2:]:KY.V:+F3R^R;%*O:BZ(PB1=U5GE9=L
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M,#34K>DHUPJ"RF@#5HN\I4 W9.>RU:HF FPN:*C.70H0?,_^^77BK>=TZ+2
M>A(:U4"C6^LFWS29JV8-6<]I<W6C(FATK.>V^7NK)ECK^8:3ZE!Y\8:3.U+5
M1I."O/[DVF^WE/,Z VY9G)SBEV:*#^M_S:13_5V;#WXU7S>OZK[O@\_;5W7N
M0'-UMKC$]YCC%:8,A-9.4<M08_1P"[XW+_0W6BY?OTLN\Q>3IG+;]?O0"]#[
M4HI\:8H^6[*,&8T#D5&1P21)J5[ZD]B0]J8P#) @F.  !5;'IWT%F-KRWJH
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M ;<.-\>TO:;%S<[SQNMQ<TR-G28W1R_HX89\_"6?="Q0FD][F?/JRY?W[9I
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M.1C8+N[(O<G+!%N2@T9TT,@^&,@.B9:#@3U26J4_T-V2)'OA=C8ETNV)XR5
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M,_>X=&WKV<;<:!)_E/6?=],;SLWJ4_5=<EF^6N& &&5Y@CB"L1%"1XCJ:8+
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MSE+]IL=4QUB*0:S_K4,NR>(D5Z) 7J=9SG<WM+=^92U8T)_MYV(7('8C@7#
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MA@C/62$$22 N"(=(40P)%A3F62$C2=(($?=C,4Y=#BU@WS+:)L9.;:>/]G1
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M@1DS(E4RBDTV70XS3!-5*"H8<UJF\NYY:,M8*UO!REA@K?7.H7.'WFW+HQ-
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M8/[[Y[\V7U%_Z OD?_[K_U!+ P04    " #Y@6%2F.V[R5!0 0"7Q@\ %0
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M:8*TO,IJW9[$@0%9'R^/PN(JRFL,EF]FEQC\CS "\AJ]$1(8UQC@AT!L$IJ
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MYYV[,%LL1CQB]"MD)C&7T;G,1&(U4%*NGZ-+Z"VOX[X_3<ZP&8,Z<.I!\ W
MISM'*M'$\HZ/TPL_/R_CAZ1CJ31]X52P,B'&HK<I(]'(&3.6&96JY-%?H&G8
MZ[-U@-27"EI TT,!C9C3H$STA$='B10I$Y>"(8F[9$6*B;$J=;"/*!GV.FPE
MY!PD[@::1-\R<-=7?41EH"DY0Z@Q@DB-T8,76A(F!3<V./"5LP!WM#1R#-QS
M_+^GK!N RQ^SZ>P^%VO@WZXF$$H*HR/)&#*4J[F!!&HR+@?@#I3@EE8Q-Z]2
MULB923]0ZE</0]<=K5J>?X)X/>^JP_TT?;BAH[M@^;?I'/RD7/W&/WU<_WAR
MA<3&<:?"-W#W\R@FP9(69;AG2<=RD=#W@T!2$F4&0 SY86#W3.E2OW0-FXCJ
M&3&S-M37@,=U,W7B)GJ5&+LBA9QH,$B^$)$$Q0T!ZDRB)@7.JY0A/*!CV"Q5
M';3U(?+=$>-6B)FNFK;VA)DO2'[9#E;"V137R"6%&P!X$J-#ER#'4-(?EA06
M+<W,"ULE+_424</Z8;71U),R&C!&723[K+A&(K  /E,BDL)@EO.$P4FRQ-O$
M= *>39T^X"^3-:QG5A=</2JD 7@]SPB-!N,5)%\;83!T1C_6!2E(#,HGZTU&
M9!S5[1\V3U475/VHH8%P\BX0+O46*S_R=UA>S-*=45Z,C!48(CL@.J*\9#:E
MB28N%^V=LDI0<+P*MK:B;NB!:;V&E?WKHP&C=9^II^X+_U*:!:\G"W[V7V'Q
M]BLN4M3=>.KGWSJQ/CUI;N1Q#0N3'0EEX*",T1-;AA *FWD RP'CR?K0[)6G
M8=.T50$]G.Z;L;7(XGJO^ 6FD,?+D:,A,R,MR5WP9!40)R"3Y*ATEE(N794A
MTL_0,VQ'PRKP.TSFAP:LGX]H2/>9UCE*'FQDG41+$S9:)FH&IHFR-FCM<XA0
MI:UF'7:&;:)X=/-97>/-6,X;*;P9+^)*$)#NY' [C-A)I2W%$$Y#3"47!2AN
M=(ZHYU0JI5EV54K6=B%RV*Z,53':HW8:<%T_S&=Y-<!B!)%*8;4A(MNR9=A
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M#M1>&!<HI50@<=N@WALBN2L-?!4CT7D.2F8=H5(_P.][B.-.0-AYB.,N6FD
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M2,NX90H2.>.,*&8,M]D9Y=-^&'WUV5MAT?UX6.Q7*>UB;K7:GN(O0]0Q1$=
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M]R%?8"E-";H<6RI?,H:](A##:3(J":=IE1X$VQ*X'<R^MWQ[%?4T +OWL%@
MO"_3_AX98ILE,N**(9:R7"^.N*&C(6;"9Q.E]J'.&?T+-&T'KN\MP]Z7$AK
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M&;*O+T)UJ+W2X*5DX)U1,:B8==B'MFF,G@X2?-X;WY9H_&[&[#%-?#)></O
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M,12@*:8<."8XY("E.&VBWVL(18>!\OP-C*<0;W0(LPXVWZ %WFE9#LXDI5%
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MYG^NENEZ:TNKG2LU+,NFU'96!B$7!R(*';6,6:O4V#W?2C/O[<8I>NB1ENS
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MQ6V!PKO5J[#Y\/MZ]7F1,;_\\B_*BGZ]+6Q[D2X6G[>D-U]O9,DFF%22I(-
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MH0054]39E]"D7&-/^;I%W!A4[,4A<YB)ND7> ]0XD>0WWBM2&"?]164A:H?
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MF^\/'G\ ,$,_>;XNPE8@:JK[#C+Y7\)BO65F?_EERZ#UZCQL-ENOS!+:[&T
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M5^X?R!GL2\3](LMVMR)DRU>6WX[YQ,"2D/BZ1&K(*MF:7W\3K%6E6LXA#WA
M]71TR*6J$I'+@T0F,I'IA[W+W&_]T^K-/0H/Z^,JIP,K^$S[<<S96N$MR%B'
M6[)2LU.^-J8.-COR)YT=,G-XCN[PW33WW@>!#=0SM[%[OE4YUYX5IVLO4"E!
M14[<V.1(4*A8\#HS9P;9M6FZPS=KJ7TT$S:MR+OH#O_CU<+7#4?O".ZF#UJ2
M44I;@-F$U=M(=321!EV\C_7YOKD_9& :F_4\:?,40;2-!2962 ='XM,<707<
MS+.@E,N0?.T$88J&&,C\YIR+( $ZFX<\<)L89#W<4TT-B%%XVT,[<Y^+;S&D
M_[Y8TJJO5K]MU@FWV[>D,2+HPX_$X]GZTYT#7RF5Z&"OF>@4R%Z70)8[9(A1
MQMJ!)(@\[$74F%5[QM,^"E\?0_ISPVKG1^R:<?^.F\\4R]R4[+N2K-<6M#.)
M I1,[J(1Q 1ST22>>1XX@^>Q%>;USMO"91*IS@V-1WR!U[?]_U,6 HD9E@O9
M9Y$I?(U*0HC*R%)T$M(-@LAS*PVS+.PT/*+I9=L14+Z*/FNG]"7I9L?D6TQ(
M/\Z[EAP+P2,*63+($AT)S@GP+E-HX945T2A>\K!6N^/7[J_']YY:?P1/+530
M$<*JFF[8^PTWB?[SU="I]>HZ>%T(IH)TW$/AR8(JFM-!;!,4[R0K"37GP\H-
M]UN_OPZLTR*ME2KF1MOEE>[M.X KUL)[7)<[WM[+]?9\^_-Z\Z\/R_2!O,%/
M=:_54X%ICMD7#IG7IGP1/40? QBK=6VIH(H:-C'Z0$+Z:V$W ?Z.J9P^@'@W
MMW"7VS>?=G9]]9X"DK(\WYZO?\!K$[_P17%G P.3([FNS#GR3"@0T18]XUYI
M-O!!\_XT]->6:3+X-5=)'\B[W64O5JN+</8SXB(GR[7DB2(8"FF52=7E904T
M5S8K)VM%R%[&[6:)_E[N-#!;^PFT#UC<1?];7'Z,%_3A]2_K\L\E87ZS3.%L
M9X 702%#*PP$K&E.DP+X^F#.8N""18^6#<O5C%VYOY<!38S/A.+O ULXD+5?
M+^I]RKK\?Q=A0P2<?7FUVIZ'L[-+;S,1>KCA"HQRI?;;KA/?R=L,:*/C9(=5
M&19>3DA4?Q7&#<S:L90V-UB_292^Q<OKX3_(T?S](M4+XG)Q]H*T0C[IE9M
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M^TZ*I ?&D;115H?9IZ>,P/[9[P&?VM)Z-<R1/X\\YIP6PI,3G H%P(JPX%W
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M"15PPJ]"O\ELMG\$^MB2QWKS.8CE66H/L 1+:Z8:'$JR9)F!M]F#Q!P8]YS
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M>1;DKFW_GW[+N!NJ X%A6%EVX#UV6Z$W;C98XPR%?5'6TW4T#+R7"7CBA;Y
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M"L?AWN#XK'I\L@GCG?EJ \V[,]W.H,9"F/+88I5JF5)+Z50#Y[:HM "F*EZ
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M"=CGE!P!S.!?;?D=?VTQO5B!_(]<P'RWVO(T=(<,Q__?;'VS)-^)49^A7A1
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M79^^[/R6J?CU7U:Y;[RN_@M02P,$%     @ ^8%A4@RZLGTI!@  ,A<  !@
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M>GJ3L(!I:#4=_[['VX$3N<38M<A0"\UN^1YBLJG\3LZ/IU>+LY.S\6AQ-KM
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M,#(P,3(S,5]G,3(N:G!G4$L! A0#%     @ ^8%A4B86'"KB>P0 :E0' !4
M             ( !K'D, '!G96XM,C R,#$R,S%?9S$S+FIP9U!+ 0(4 Q0
M   ( /F!85("95D5V1H! (DQ 0 5              "  <'U$ !P9V5N+3(P
M,C Q,C,Q7V<Q-"YJ<&=02P$"% ,4    " #Y@6%2L!_7I#;,   \^0  %0
M            @ '-$!( <&=E;BTR,#(P,3(S,5]G,34N:G!G4$L! A0#%
M  @ ^8%A4L_Y9M^XFP  YIT  !4              ( !-MT2 '!G96XM,C R
M,#$R,S%?9S$V+FIP9U!+ 0(4 Q0    ( /F!85)6\73RG-   $/A   5
M          "  2%Y$P!P9V5N+3(P,C Q,C,Q7V<Q-RYJ<&=02P$"% ,4
M" #Y@6%2*;GSK6I- @#VW@( %0              @ 'P210 <&=E;BTR,#(P
M,3(S,5]G,3@N:G!G4$L! A0#%     @ ^8%A4B=Z(V=.U@$ P2," !0
M         ( !C9<6 '!G96XM,C R,#$R,S%?9S(N:G!G4$L! A0#%     @
M^8%A4A#%+!KX10( YFL# !0              ( !#6X8 '!G96XM,C R,#$R
M,S%?9S,N:G!G4$L! A0#%     @ ^8%A4H;QBXZSHP( (P8# !0
M     ( !-[0: '!G96XM,C R,#$R,S%?9S0N:G!G4$L! A0#%     @ ^8%A
M4IX37DWU\   ;@<! !0              ( !'%@= '!G96XM,C R,#$R,S%?
M9S4N:G!G4$L! A0#%     @ ^8%A4N]& :N].0$ MV4! !0
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M2P$"% ,4    " #Y@6%2X ZKT^ $  !&/   &               @ %Z!2D
M<&=E;BTR,#(P,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ ^8%A4N&[%'8K
M P  <P@  !@              ( !D HI '!G96XM,C R,#$R,S%X97AX,C,Q
M+FAT;5!+ 0(4 Q0    ( /F!85(M$1$\SP,  *4+   8              "
M ?$-*0!P9V5N+3(P,C Q,C,Q>&5X>#(S,BYH=&U02P$"% ,4    " #Y@6%2
ML"XK.C@(  !<)@  &               @ 'V$2D <&=E;BTR,#(P,3(S,7AE
M>'@S,3$N:'1M4$L! A0#%     @ ^8%A4G< ^1 K"   /B8  !@
M     ( !9!HI '!G96XM,C R,#$R,S%X97AX,S$R+FAT;5!+ 0(4 Q0    (
M /F!85(,NK)]*08  #(7   8              "  <4B*0!P9V5N+3(P,C Q
M,C,Q>&5X>#,R,2YH=&U02P$"% ,4    " #Y@6%2TN:UC1X&  !A%P  &
M            @ $D*2D <&=E;BTR,#(P,3(S,7AE>'@S,C(N:'1M4$L%!@
0   ? !\ (0@  '@O*0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
